1 0 0 9669632 -DOCSTART- -X- -X- O

1 0 7 9669632 Effects NNS B-NP O
2 8 10 9669632 of IN B-PP O
3 11 20 9669632 cisapride NN B-NP D020117
4 21 23 9669632 on IN B-PP O
5 24 32 9669632 symptoms NNS B-NP O
6 33 36 9669632 and CC O O
7 37 46 9669632 postcibal JJ B-NP O
8 47 52 9669632 small JJ I-NP O
9 52 53 9669632 - HYPH I-NP O
10 53 58 9669632 bowel NN I-NP O
11 59 64 9669632 motor NN I-NP O
12 65 73 9669632 function NN I-NP O
13 74 76 9669632 in IN B-PP O
14 77 85 9669632 patients NNS B-NP O
15 86 90 9669632 with IN B-PP O
16 91 100 9669632 irritable JJ B-NP D043183
17 101 106 9669632 bowel NN I-NP D043183
18 107 115 9669632 syndrome NN I-NP D043183
19 115 116 9669632 . . I-NP O
20 117 127 9669632 BACKGROUND NN I-NP O
21 127 128 9669632 : : O O
22 129 138 9669632 Irritable JJ B-NP D043183
23 139 144 9669632 bowel NN I-NP D043183
24 145 153 9669632 syndrome NN I-NP D043183
25 154 156 9669632 is VBZ B-VP O
26 157 158 9669632 a DT B-NP O
27 159 165 9669632 common JJ I-NP O
28 166 171 9669632 cause NN I-NP O
29 172 174 9669632 of IN B-PP O
30 175 184 9669632 abdominal JJ B-NP D015746
31 185 189 9669632 pain NN I-NP D015746
32 190 193 9669632 and CC I-NP O
33 194 204 9669632 discomfort NN I-NP O
34 205 208 9669632 and CC O O
35 209 212 9669632 may MD B-VP O
36 213 215 9669632 be VB I-VP O
37 216 223 9669632 related VBN I-VP O
38 224 226 9669632 to TO B-PP O
39 227 237 9669632 disordered VBN B-NP D005767
40 238 254 9669632 gastrointestinal JJ I-NP D005767
41 255 263 9669632 motility NN I-NP D005767
42 263 264 9669632 . . O O

1 265 268 9669632 Our PRP$ B-NP O
2 269 272 9669632 aim NN I-NP O
3 273 276 9669632 was VBD B-VP O
4 277 279 9669632 to TO B-VP O
5 280 286 9669632 assess VB I-VP O
6 287 290 9669632 the DT B-NP O
7 291 298 9669632 effects NNS I-NP O
8 299 301 9669632 of IN B-PP O
9 302 306 9669632 long JJ B-NP O
10 306 307 9669632 - HYPH I-NP O
11 307 311 9669632 term NN I-NP O
12 312 321 9669632 treatment NN I-NP O
13 322 326 9669632 with IN B-PP O
14 327 328 9669632 a DT B-NP O
15 329 339 9669632 prokinetic JJ I-NP O
16 340 345 9669632 agent NN I-NP O
17 345 346 9669632 , , O O
18 347 356 9669632 cisapride NN B-NP D020117
19 356 357 9669632 , , O O
20 358 360 9669632 on IN B-PP O
21 361 373 9669632 postprandial JJ B-NP O
22 374 381 9669632 jejunal JJ I-NP O
23 382 390 9669632 motility NN I-NP O
24 391 394 9669632 and CC I-NP O
25 395 403 9669632 symptoms NNS I-NP O
26 404 406 9669632 in IN B-PP O
27 407 410 9669632 the DT B-NP O
28 411 420 9669632 irritable JJ I-NP D043183
29 421 426 9669632 bowel NN I-NP D043183
30 427 435 9669632 syndrome NN I-NP D043183
31 436 437 9669632 ( ( O O
32 437 440 9669632 IBS NN B-NP D043183
33 440 441 9669632 ) ) O O
34 441 442 9669632 . . O O

1 443 450 9669632 METHODS NNS B-NP O
2 450 451 9669632 : : O O
3 452 458 9669632 Thirty CD B-NP O
4 458 459 9669632 - HYPH O O
5 459 464 9669632 eight CD B-NP O
6 465 473 9669632 patients NNS I-NP O
7 474 478 9669632 with IN B-PP O
8 479 482 9669632 IBS NN B-NP D043183
9 483 484 9669632 ( ( O O
10 484 496 9669632 constipation NN B-NP D003248
11 496 497 9669632 - HYPH B-NP O
12 497 508 9669632 predominant JJ I-NP O
13 508 509 9669632 , , I-NP O
14 510 511 9669632 n NN I-NP O
15 512 513 9669632 = SYM B-VP O
16 514 516 9669632 17 CD B-NP O
17 516 517 9669632 ; : O O
18 518 527 9669632 diarrhoea NN B-NP D003967
19 527 528 9669632 - HYPH B-NP O
20 528 539 9669632 predominant JJ I-NP O
21 539 540 9669632 , , I-NP O
22 541 542 9669632 n NN I-NP O
23 543 544 9669632 = SYM B-VP O
24 545 547 9669632 21 CD B-NP O
25 547 548 9669632 ) ) O O
26 549 558 9669632 underwent VBD B-VP O
27 559 561 9669632 24 CD B-NP O
28 561 562 9669632 - HYPH I-NP O
29 562 563 9669632 h NN I-NP O
30 564 574 9669632 ambulatory JJ I-NP O
31 575 582 9669632 jejunal JJ I-NP O
32 583 592 9669632 manometry NN I-NP O
33 593 599 9669632 before IN B-PP O
34 600 603 9669632 and CC I-PP O
35 604 609 9669632 after IN I-PP O
36 610 612 9669632 12 CD B-NP O
37 613 619 9669632 week's NNS I-NP O
38 620 629 9669632 treatment NN I-NP O
39 630 631 9669632 [ ( O O
40 631 640 9669632 cisapride NN B-NP D020117
41 640 641 9669632 , , O O
42 642 643 9669632 5 CD B-NP O
43 644 646 9669632 mg NN I-NP O
44 647 652 9669632 three CD B-NP O
45 653 658 9669632 times NNS I-NP O
46 659 664 9669632 daily JJ I-NP O
47 665 666 9669632 ( ( O O
48 666 667 9669632 n NN B-NP O
49 668 669 9669632 = SYM B-VP O
50 670 672 9669632 19 CD B-NP O
51 672 673 9669632 ) ) O O
52 674 676 9669632 or CC O O
53 677 684 9669632 placebo NN B-NP O
54 685 686 9669632 ( ( O O
55 686 687 9669632 n NN B-NP O
56 688 689 9669632 = SYM B-VP O
57 690 692 9669632 19 CD B-NP O
58 692 693 9669632 ) ) O O
59 693 694 9669632 ] ) O O
60 694 695 9669632 . . O O

1 696 703 9669632 RESULTS NNS B-NP O
2 703 704 9669632 : : O O
3 705 707 9669632 In IN B-PP O
4 708 717 9669632 diarrhoea NN B-NP D003967
5 717 718 9669632 - HYPH O O
6 718 729 9669632 predominant JJ B-NP O
7 730 738 9669632 patients NNS I-NP O
8 739 750 9669632 significant JJ B-NP O
9 751 762 9669632 differences NNS I-NP O
10 763 765 9669632 in IN B-PP O
11 766 777 9669632 contraction NN B-NP O
12 778 793 9669632 characteristics NNS I-NP O
13 794 798 9669632 were VBD B-VP O
14 799 807 9669632 observed VBN I-VP O
15 808 815 9669632 between IN B-PP O
16 816 819 9669632 the DT B-NP O
17 820 829 9669632 cisapride NN I-NP D020117
18 830 833 9669632 and CC I-NP O
19 834 841 9669632 placebo NN I-NP O
20 842 848 9669632 groups NNS I-NP O
21 848 849 9669632 . . O O

1 850 852 9669632 In IN B-PP O
2 853 862 9669632 cisapride NN B-NP D020117
3 862 863 9669632 - HYPH O O
4 863 870 9669632 treated VBN B-NP O
5 871 880 9669632 diarrhoea NN I-NP D003967
6 880 881 9669632 - HYPH O O
7 881 892 9669632 predominant JJ B-NP O
8 893 901 9669632 patients NNS I-NP O
9 902 905 9669632 the DT B-NP O
10 906 910 9669632 mean JJ I-NP O
11 911 922 9669632 contraction NN I-NP O
12 923 932 9669632 amplitude NN I-NP O
13 933 936 9669632 was VBD B-VP O
14 937 943 9669632 higher JJR B-ADJP O
15 944 945 9669632 ( ( O O
16 945 949 9669632 29.3 CD B-NP O
17 950 951 9669632 + SYM O O
18 951 952 9669632 / SYM O O
19 952 953 9669632 - SYM O O
20 954 957 9669632 3.2 CD B-NP O
21 958 964 9669632 versus IN B-PP O
22 965 969 9669632 24.9 CD B-NP O
23 970 971 9669632 + SYM O O
24 971 972 9669632 / SYM O O
25 972 973 9669632 - SYM O O
26 974 977 9669632 2.6 CD B-NP O
27 978 980 9669632 mm NN I-NP O
28 981 983 9669632 Hg NN I-NP O
29 983 984 9669632 , , O O
30 985 994 9669632 cisapride NN B-NP D020117
31 995 1001 9669632 versus CC O O
32 1002 1009 9669632 placebo NN B-NP O
33 1010 1011 9669632 ( ( O O
34 1011 1012 9669632 P NN B-NP O
35 1013 1014 9669632 < SYM O O
36 1015 1020 9669632 0.001 CD B-NP O
37 1020 1021 9669632 ) ) O O
38 1021 1022 9669632 ; : O O
39 1023 1035 9669632 pretreatment NN B-NP O
40 1035 1036 9669632 , , O O
41 1037 1041 9669632 25.7 CD B-NP O
42 1042 1043 9669632 + SYM O O
43 1043 1044 9669632 / SYM O O
44 1044 1045 9669632 - SYM O O
45 1046 1049 9669632 6.0 CD B-NP O
46 1050 1052 9669632 mm NN I-NP O
47 1053 1055 9669632 Hg NN I-NP O
48 1055 1056 9669632 ) ) O O
49 1056 1057 9669632 , , O O
50 1058 1061 9669632 the DT B-NP O
51 1062 1066 9669632 mean JJ I-NP O
52 1067 1078 9669632 contraction NN I-NP O
53 1079 1087 9669632 duration NN I-NP O
54 1088 1094 9669632 longer RB B-ADVP O
55 1095 1096 9669632 ( ( O O
56 1096 1099 9669632 3.4 CD B-NP O
57 1100 1101 9669632 + SYM O O
58 1101 1102 9669632 / SYM O O
59 1102 1103 9669632 - SYM O O
60 1104 1107 9669632 0.2 CD B-NP O
61 1108 1114 9669632 versus IN B-PP O
62 1115 1118 9669632 3.0 CD B-NP O
63 1119 1120 9669632 + SYM O O
64 1120 1121 9669632 / SYM O O
65 1121 1122 9669632 - SYM O O
66 1123 1126 9669632 0.2 CD B-NP O
67 1127 1130 9669632 sec NN I-NP O
68 1130 1131 9669632 , , O O
69 1132 1141 9669632 cisapride NN B-NP D020117
70 1142 1148 9669632 versus CC O O
71 1149 1156 9669632 placebo NN B-NP O
72 1157 1158 9669632 ( ( O O
73 1158 1159 9669632 P NN B-NP O
74 1160 1161 9669632 < SYM O O
75 1162 1167 9669632 0.001 CD B-NP O
76 1167 1168 9669632 ) ) O O
77 1168 1169 9669632 ; : O O
78 1170 1182 9669632 pretreatment NN B-NP O
79 1182 1183 9669632 , , O O
80 1184 1187 9669632 3.1 CD B-NP O
81 1188 1189 9669632 + SYM O O
82 1189 1190 9669632 / SYM O O
83 1190 1191 9669632 - SYM O O
84 1192 1195 9669632 0.5 CD B-NP O
85 1196 1199 9669632 sec NN I-NP O
86 1199 1200 9669632 ) ) O O
87 1200 1201 9669632 , , O O
88 1202 1205 9669632 and CC O O
89 1206 1209 9669632 the DT B-NP O
90 1210 1214 9669632 mean JJ I-NP O
91 1215 1226 9669632 contraction NN I-NP O
92 1227 1236 9669632 frequency NN I-NP O
93 1237 1242 9669632 lower JJR B-ADVP O
94 1243 1244 9669632 ( ( O O
95 1244 1247 9669632 2.0 CD B-NP O
96 1248 1249 9669632 + SYM O O
97 1249 1250 9669632 / SYM O O
98 1250 1251 9669632 - SYM O O
99 1252 1255 9669632 0.2 CD B-NP O
100 1256 1262 9669632 versus IN I-NP O
101 1263 1266 9669632 2.5 CD I-NP O
102 1267 1268 9669632 + SYM O O
103 1268 1269 9669632 / SYM O O
104 1269 1270 9669632 - SYM O O
105 1271 1274 9669632 0.4 CD B-NP O
106 1275 1279 9669632 cont NN I-NP O
107 1279 1280 9669632 . . O O
108 1280 1281 9669632 / SYM B-NP O
109 1281 1284 9669632 min NN I-NP O
110 1284 1285 9669632 , , O O
111 1286 1295 9669632 cisapride NN B-NP D020117
112 1296 1302 9669632 versus CC O O
113 1303 1310 9669632 placebo NN B-NP O
114 1311 1312 9669632 ( ( O O
115 1312 1313 9669632 P NN B-NP O
116 1314 1315 9669632 < SYM O O
117 1316 1321 9669632 0.001 CD B-NP O
118 1321 1322 9669632 ) ) O O
119 1322 1323 9669632 ; : O O
120 1324 1336 9669632 pretreatment NN B-NP O
121 1336 1337 9669632 , , O O
122 1338 1341 9669632 2.5 CD B-NP O
123 1342 1343 9669632 + SYM O O
124 1343 1344 9669632 / SYM O O
125 1344 1345 9669632 - SYM O O
126 1346 1349 9669632 1.1 CD B-NP O
127 1350 1354 9669632 cont NN I-NP O
128 1354 1355 9669632 . . O O
129 1355 1356 9669632 / SYM B-NP O
130 1356 1359 9669632 min NN I-NP O
131 1359 1360 9669632 ] ) O O
132 1361 1365 9669632 than IN B-PP O
133 1366 1374 9669632 patients NNS B-NP O
134 1375 1382 9669632 treated VBN B-VP O
135 1383 1387 9669632 with IN B-PP O
136 1388 1395 9669632 placebo NN B-NP O
137 1395 1396 9669632 . . O O

1 1397 1399 9669632 No DT B-NP O
2 1400 1411 9669632 significant JJ I-NP O
3 1412 1423 9669632 differences NNS I-NP O
4 1424 1426 9669632 in IN B-PP O
5 1427 1434 9669632 jejunal JJ B-NP O
6 1435 1443 9669632 motility NN I-NP O
7 1444 1448 9669632 were VBD B-VP O
8 1449 1454 9669632 found VBN I-VP O
9 1455 1457 9669632 in IN B-PP O
10 1458 1461 9669632 the DT B-NP O
11 1462 1474 9669632 constipation NN I-NP D003248
12 1474 1475 9669632 - HYPH B-NP O
13 1475 1486 9669632 predominant JJ I-NP O
14 1487 1490 9669632 IBS NNP I-NP D043183
15 1491 1496 9669632 group NN I-NP O
16 1496 1497 9669632 . . O O

1 1498 1506 9669632 Symptoms NNS B-NP O
2 1507 1511 9669632 were VBD B-VP O
3 1512 1520 9669632 assessed VBN I-VP O
4 1521 1523 9669632 by IN B-PP O
5 1524 1529 9669632 using VBG B-VP O
6 1530 1531 9669632 a DT B-NP O
7 1532 1538 9669632 visual JJ I-NP O
8 1539 1547 9669632 analogue NN I-NP O
9 1548 1553 9669632 scale NN I-NP O
10 1554 1560 9669632 before IN B-PP O
11 1561 1564 9669632 and CC I-PP O
12 1565 1570 9669632 after IN I-PP O
13 1571 1580 9669632 treatment NN B-NP O
14 1580 1581 9669632 . . O O

1 1582 1589 9669632 Symptom NN B-NP O
2 1590 1596 9669632 scores NNS I-NP O
3 1597 1605 9669632 relating VBG B-VP O
4 1606 1608 9669632 to TO B-PP O
5 1609 1612 9669632 the DT B-NP O
6 1613 1621 9669632 severity NN I-NP O
7 1622 1624 9669632 of IN B-PP O
8 1625 1637 9669632 constipation NN B-NP D003248
9 1638 1642 9669632 were VBD B-VP O
10 1643 1648 9669632 lower JJR B-ADJP O
11 1649 1651 9669632 in IN B-PP O
12 1652 1661 9669632 cisapride NN B-NP D020117
13 1661 1662 9669632 - HYPH O O
14 1662 1669 9669632 treated VBN B-NP O
15 1670 1682 9669632 constipation NN I-NP D003248
16 1682 1683 9669632 - HYPH B-NP O
17 1683 1694 9669632 predominant JJ I-NP O
18 1695 1698 9669632 IBS NN I-NP D043183
19 1699 1707 9669632 patients NNS I-NP O
20 1708 1709 9669632 [ ( O O
21 1709 1714 9669632 score NN B-NP O
22 1714 1715 9669632 , , O O
23 1716 1718 9669632 54 CD B-NP O
24 1719 1720 9669632 + SYM O O
25 1720 1721 9669632 / SYM O O
26 1721 1722 9669632 - SYM B-NP O
27 1723 1724 9669632 5 CD B-NP O
28 1725 1731 9669632 versus IN I-NP O
29 1732 1734 9669632 67 CD I-NP O
30 1735 1736 9669632 + SYM O O
31 1736 1737 9669632 / SYM O O
32 1737 1738 9669632 - SYM O O
33 1739 1741 9669632 14 CD B-NP O
34 1742 1744 9669632 mm NN I-NP O
35 1744 1745 9669632 , , O O
36 1746 1755 9669632 cisapride NN B-NP D020117
37 1756 1762 9669632 versus CC O O
38 1763 1770 9669632 placebo NN B-NP O
39 1771 1772 9669632 ( ( O O
40 1772 1773 9669632 P NN B-NP O
41 1774 1775 9669632 < SYM O O
42 1776 1780 9669632 0.05 CD B-NP O
43 1780 1781 9669632 ) ) O O
44 1781 1782 9669632 ; : O O
45 1783 1795 9669632 pretreatment NN B-NP O
46 1795 1796 9669632 , , O O
47 1797 1799 9669632 62 CD B-NP O
48 1800 1801 9669632 + SYM O O
49 1801 1802 9669632 / SYM O O
50 1802 1803 9669632 - SYM O O
51 1804 1806 9669632 19 CD B-NP O
52 1807 1809 9669632 mm NN I-NP O
53 1809 1810 9669632 ] ) O O
54 1810 1811 9669632 . . O O

1 1812 1821 9669632 Diarrhoea NN B-NP D003967
2 1821 1822 9669632 - HYPH I-NP O
3 1822 1833 9669632 predominant JJ I-NP O
4 1834 1837 9669632 IBS NN I-NP D043183
5 1838 1846 9669632 patients NNS I-NP O
6 1847 1850 9669632 had VBD B-VP O
7 1851 1852 9669632 a DT B-NP O
8 1853 1859 9669632 higher JJR I-NP O
9 1860 1864 9669632 pain NN I-NP D010146
10 1865 1870 9669632 score NN I-NP O
11 1871 1876 9669632 after IN B-PP O
12 1877 1886 9669632 cisapride NN B-NP D020117
13 1887 1894 9669632 therapy NN I-NP O
14 1895 1896 9669632 [ ( O O
15 1896 1901 9669632 score NN B-NP O
16 1901 1902 9669632 , , O O
17 1903 1905 9669632 55 CD B-NP O
18 1906 1907 9669632 + SYM O O
19 1907 1908 9669632 / SYM O O
20 1908 1909 9669632 - SYM O O
21 1910 1912 9669632 15 CD B-NP O
22 1913 1919 9669632 versus IN B-PP O
23 1920 1922 9669632 34 CD B-NP O
24 1923 1924 9669632 + SYM O O
25 1924 1925 9669632 / SYM O O
26 1925 1926 9669632 - SYM O O
27 1927 1929 9669632 12 CD B-NP O
28 1930 1932 9669632 mm NN I-NP O
29 1932 1933 9669632 , , O O
30 1934 1943 9669632 cisapride NN B-NP D020117
31 1944 1950 9669632 versus CC O O
32 1951 1958 9669632 placebo NN B-NP O
33 1959 1960 9669632 ( ( O O
34 1960 1961 9669632 P NN B-NP O
35 1962 1963 9669632 < SYM O O
36 1964 1968 9669632 0.05 CD B-NP O
37 1968 1969 9669632 ) ) O O
38 1969 1970 9669632 ; : O O
39 1971 1983 9669632 pretreatment NN B-NP O
40 1983 1984 9669632 , , O O
41 1985 1987 9669632 67 CD B-NP O
42 1988 1989 9669632 + SYM O O
43 1989 1990 9669632 / SYM O O
44 1990 1991 9669632 - SYM O O
45 1992 1994 9669632 19 CD B-NP O
46 1995 1997 9669632 mm NN I-NP O
47 1997 1998 9669632 ] ) O O
48 1998 1999 9669632 . . O O

1 2000 2010 9669632 CONCLUSION NN B-NP O
2 2010 2011 9669632 : : O O
3 2012 2021 9669632 Cisapride NN B-NP D020117
4 2022 2029 9669632 affects VBZ B-VP O
5 2030 2037 9669632 jejunal JJ B-NP O
6 2038 2049 9669632 contraction NN I-NP O
7 2050 2065 9669632 characteristics NNS I-NP O
8 2066 2069 9669632 and CC O O
9 2070 2074 9669632 some DT B-NP O
10 2075 2083 9669632 symptoms NNS I-NP O
11 2084 2086 9669632 in IN B-PP O
12 2087 2090 9669632 IBS NNP B-NP D043183
13 2090 2091 9669632 . . O O

1 0 0 19721134 -DOCSTART- -X- -X- O

1 0 3 19721134 The DT B-NP O
2 4 18 19721134 antiarrhythmic JJ I-NP O
3 19 25 19721134 effect NN I-NP O
4 26 29 19721134 and CC O O
5 30 38 19721134 possible JJ B-NP O
6 39 44 19721134 ionic JJ I-NP O
7 45 55 19721134 mechanisms NNS I-NP O
8 56 58 19721134 of IN B-PP O
9 59 70 19721134 pilocarpine NN B-NP D010862
10 71 73 19721134 on IN B-PP O
11 74 80 19721134 animal NN B-NP O
12 81 87 19721134 models NNS I-NP O
13 87 88 19721134 . . O O
14 89 93 19721134 This DT B-NP O
15 94 99 19721134 study NN I-NP O
16 100 103 19721134 was VBD B-VP O
17 104 112 19721134 designed VBN I-VP O
18 113 115 19721134 to TO B-VP O
19 116 124 19721134 evaluate VB I-VP O
20 125 128 19721134 the DT B-NP O
21 129 136 19721134 effects NNS I-NP O
22 137 139 19721134 of IN B-PP O
23 140 151 19721134 pilocarpine NN B-NP D010862
24 152 155 19721134 and CC O O
25 156 163 19721134 explore VB B-VP O
26 164 167 19721134 the DT B-NP O
27 168 178 19721134 underlying VBG I-NP O
28 179 184 19721134 ionic JJ I-NP O
29 185 194 19721134 mechanism NN I-NP O
30 194 195 19721134 , , O O
31 196 201 19721134 using VBG B-VP O
32 202 206 19721134 both CC O O
33 207 216 19721134 aconitine NN B-NP D000157
34 216 217 19721134 - HYPH B-NP O
35 217 224 19721134 induced VBN I-NP O
36 225 228 19721134 rat NN I-NP O
37 229 232 19721134 and CC I-NP O
38 233 240 19721134 ouabain NN I-NP D010042
39 240 241 19721134 - HYPH B-NP O
40 241 248 19721134 induced VBN I-NP O
41 249 255 19721134 guinea NN I-NP O
42 256 259 19721134 pig NN I-NP O
43 260 270 19721134 arrhythmia NN I-NP D001145
44 271 277 19721134 models NNS I-NP O
45 277 278 19721134 . . O O

1 279 287 19721134 Confocal JJ B-NP O
2 288 298 19721134 microscopy NN I-NP O
3 299 302 19721134 was VBD B-VP O
4 303 307 19721134 used VBN I-VP O
5 308 310 19721134 to TO B-VP O
6 311 318 19721134 measure VB I-VP O
7 319 332 19721134 intracellular JJ B-NP O
8 333 337 19721134 free JJ I-NP O
9 337 338 19721134 - HYPH I-NP O
10 338 345 19721134 calcium NN I-NP D002118
11 346 360 19721134 concentrations NNS I-NP O
12 361 362 19721134 ( ( O O
13 362 373 19721134 [Ca(2+)](i) LS O D002118
14 373 374 19721134 ) ) O O
15 375 377 19721134 in IN B-PP O
16 378 386 19721134 isolated VBN B-NP O
17 387 395 19721134 myocytes NNS I-NP O
18 395 396 19721134 . . O O

1 397 400 19721134 The DT B-NP O
2 401 408 19721134 current JJ I-NP O
3 409 413 19721134 data NNS I-NP O
4 414 420 19721134 showed VBD B-VP O
5 421 425 19721134 that IN B-SBAR O
6 426 437 19721134 pilocarpine NN B-NP D010862
7 438 451 19721134 significantly RB B-ADVP O
8 452 459 19721134 delayed VBD B-VP O
9 460 465 19721134 onset NN B-NP O
10 466 468 19721134 of IN B-PP O
11 469 480 19721134 arrhythmias NNS B-NP D001145
12 480 481 19721134 , , O O
13 482 491 19721134 decreased VBD B-VP O
14 492 495 19721134 the DT B-NP O
15 496 500 19721134 time NN I-NP O
16 501 507 19721134 course NN I-NP O
17 508 510 19721134 of IN B-PP O
18 511 522 19721134 ventricular JJ B-NP D017180
19 523 534 19721134 tachycardia NN I-NP D017180
20 535 538 19721134 and CC I-NP D017180
21 539 551 19721134 fibrillation NN I-NP D017180
22 551 552 19721134 , , O O
23 553 560 19721134 reduced VBD B-VP O
24 561 571 19721134 arrhythmia NN B-NP D001145
25 572 577 19721134 score NN I-NP O
26 577 578 19721134 , , O O
27 579 582 19721134 and CC O O
28 583 592 19721134 increased VBD B-VP O
29 593 596 19721134 the DT B-NP O
30 597 605 19721134 survival NN I-NP O
31 606 610 19721134 time NN I-NP O
32 611 613 19721134 of IN B-PP O
33 614 624 19721134 arrhythmic JJ B-NP D001145
34 625 629 19721134 rats NNS I-NP O
35 630 633 19721134 and CC O O
36 634 640 19721134 guinea NN B-NP O
37 641 645 19721134 pigs NNS I-NP O
38 645 646 19721134 . . O O

1 647 658 19721134 [Ca(2+)](i) LS B-NP D002118
2 659 667 19721134 overload NN I-NP O
3 668 675 19721134 induced VBN B-VP O
4 676 678 19721134 by IN B-PP O
5 679 688 19721134 aconitine NN B-NP D000157
6 689 691 19721134 or CC I-NP O
7 692 699 19721134 ouabain NN I-NP D010042
8 700 703 19721134 was VBD B-VP O
9 704 711 19721134 reduced VBN I-VP O
10 712 714 19721134 in IN B-PP O
11 715 723 19721134 isolated VBN B-NP O
12 724 732 19721134 myocytes NNS I-NP O
13 733 743 19721134 pretreated VBN B-VP O
14 744 748 19721134 with IN B-PP O
15 749 760 19721134 pilocarpine NN B-NP D010862
16 760 761 19721134 . . O O

1 762 770 19721134 Moreover RB B-ADVP O
2 770 771 19721134 , , O O
3 772 776 19721134 M(3) NN B-NP O
4 776 777 19721134 - HYPH B-NP O
5 777 787 19721134 muscarinic JJ I-NP O
6 788 801 19721134 acetylcholine NN I-NP D000109
7 802 810 19721134 receptor NN I-NP O
8 811 812 19721134 ( ( O O
9 812 817 19721134 mAChR NN B-NP O
10 817 818 19721134 ) ) O O
11 819 829 19721134 antagonist NN B-NP O
12 830 831 19721134 4 CD I-NP C042375
13 831 832 19721134 - HYPH I-NP C042375
14 832 836 19721134 DAMP NN I-NP C042375
15 837 838 19721134 ( ( O O
16 838 839 19721134 4 CD B-NP C042375
17 839 840 19721134 - HYPH I-NP C042375
18 840 855 19721134 diphenylacetoxy NN I-NP C042375
19 855 856 19721134 - HYPH B-NP C042375
20 856 857 19721134 N NN I-NP C042375
21 857 858 19721134 - HYPH B-NP C042375
22 858 874 19721134 methylpiperidine NN I-NP C042375
23 874 875 19721134 - HYPH I-NP C042375
24 875 885 19721134 methiodide NN I-NP C042375
25 885 886 19721134 ) ) O O
26 887 896 19721134 partially RB B-ADVP O
27 897 906 19721134 abolished VBD B-VP O
28 907 910 19721134 the DT B-NP O
29 911 921 19721134 beneficial JJ I-NP O
30 922 929 19721134 effects NNS I-NP O
31 930 932 19721134 of IN B-PP O
32 933 944 19721134 pilocarpine NN B-NP D010862
33 944 945 19721134 . . O O

1 946 951 19721134 These DT B-NP O
2 952 956 19721134 data NNS I-NP O
3 957 964 19721134 suggest VBP B-VP O
4 965 969 19721134 that IN B-SBAR O
5 970 981 19721134 pilocarpine NN B-NP D010862
6 982 990 19721134 produced VBD B-VP O
7 991 1005 19721134 antiarrhythmic JJ B-NP O
8 1006 1013 19721134 actions NNS I-NP O
9 1014 1016 19721134 on IN B-PP O
10 1017 1027 19721134 arrhythmic JJ B-NP D001145
11 1028 1031 19721134 rat NN I-NP O
12 1032 1035 19721134 and CC I-NP O
13 1036 1042 19721134 guinea NN I-NP O
14 1043 1046 19721134 pig NN I-NP O
15 1047 1053 19721134 models NNS I-NP O
16 1054 1061 19721134 induced VBN B-VP O
17 1062 1064 19721134 by IN B-PP O
18 1065 1074 19721134 aconitine NN B-NP D000157
19 1075 1077 19721134 or CC I-NP O
20 1078 1085 19721134 ouabain NN I-NP D010042
21 1086 1089 19721134 via IN B-PP O
22 1090 1101 19721134 stimulating VBG B-VP O
23 1102 1105 19721134 the DT B-NP O
24 1106 1113 19721134 cardiac JJ I-NP O
25 1114 1118 19721134 M(3) NN I-NP O
26 1118 1119 19721134 - HYPH B-NP O
27 1119 1124 19721134 mAChR NN I-NP O
28 1124 1125 19721134 . . O O

1 1126 1129 19721134 The DT B-NP O
2 1130 1139 19721134 mechanism NN I-NP O
3 1140 1143 19721134 may MD B-VP O
4 1144 1146 19721134 be VB I-VP O
5 1147 1154 19721134 related JJ B-ADJP O
6 1155 1157 19721134 to TO B-PP O
7 1158 1161 19721134 the DT B-NP O
8 1162 1173 19721134 improvement NN I-NP O
9 1174 1176 19721134 of IN B-PP O
10 1177 1183 19721134 Ca(2+) NN B-NP D002118
11 1184 1192 19721134 handling NN I-NP O
12 1192 1193 19721134 . . O O

1 0 0 9636837 -DOCSTART- -X- -X- O

1 0 11 9636837 Carboplatin NN B-NP D016190
2 12 17 9636837 toxic JJ I-NP O
3 18 25 9636837 effects NNS I-NP O
4 26 28 9636837 on IN B-PP O
5 29 32 9636837 the DT B-NP O
6 33 43 9636837 peripheral JJ I-NP O
7 44 51 9636837 nervous JJ I-NP O
8 52 58 9636837 system NN I-NP O
9 59 61 9636837 of IN B-PP O
10 62 65 9636837 the DT B-NP O
11 66 69 9636837 rat NN I-NP O
12 69 70 9636837 . . I-NP O
13 71 81 9636837 BACKGROUND NN I-NP O
14 81 82 9636837 : : O O
15 83 86 9636837 The DT B-NP O
16 87 91 9636837 most RBS I-NP O
17 92 100 9636837 striking JJ I-NP O
18 101 103 9636837 of IN B-PP O
19 104 117 9636837 carboplatin's NNS B-NP D016190
20 118 128 9636837 advantages NNS I-NP O
21 129 130 9636837 ( ( O O
22 130 135 9636837 CBDCA NN B-NP D016190
23 135 136 9636837 ) ) O O
24 137 141 9636837 over IN B-PP O
25 142 151 9636837 cisplatin NN B-NP D002945
26 152 153 9636837 ( ( O O
27 153 157 9636837 CDDP NN B-NP D002945
28 157 158 9636837 ) ) O O
29 159 161 9636837 is VBZ B-VP O
30 162 165 9636837 its PRP$ B-NP O
31 166 174 9636837 markedly RB I-NP O
32 175 182 9636837 reduced VBN I-NP O
33 183 187 9636837 rate NN I-NP O
34 188 190 9636837 of IN B-PP O
35 191 201 9636837 neurotoxic JJ B-NP D020258
36 202 209 9636837 effects NNS I-NP O
37 209 210 9636837 . . O O

1 211 218 9636837 However RB B-ADVP O
2 218 219 9636837 , , O O
3 220 223 9636837 the DT B-NP O
4 224 227 9636837 use NN I-NP O
5 228 230 9636837 of IN B-PP O
6 231 236 9636837 CBDCA NN B-NP D016190
7 237 243 9636837 higher JJR B-NP O
8 243 244 9636837 - HYPH I-NP O
9 244 253 9636837 intensity NN I-NP O
10 254 263 9636837 schedules NNS I-NP O
11 264 267 9636837 and CC O O
12 268 271 9636837 the DT B-NP O
13 272 283 9636837 association NN I-NP O
14 284 288 9636837 with IN B-PP O
15 289 294 9636837 other JJ B-NP O
16 295 305 9636837 neurotoxic JJ I-NP D020258
17 306 311 9636837 drugs NNS I-NP O
18 312 314 9636837 in IN B-PP O
19 315 331 9636837 polychemotherapy NN B-NP O
20 332 335 9636837 may MD B-VP O
21 336 341 9636837 cause VB I-VP O
22 342 346 9636837 some DT B-NP O
23 347 354 9636837 concern NN I-NP O
24 355 360 9636837 about IN B-PP O
25 361 364 9636837 its PRP$ B-NP O
26 365 371 9636837 safety NN I-NP O
27 372 376 9636837 with IN B-PP O
28 377 384 9636837 respect NN B-NP O
29 385 387 9636837 to TO B-PP O
30 388 398 9636837 peripheral JJ B-NP D010523
31 399 406 9636837 nervous JJ I-NP D010523
32 407 413 9636837 system NN I-NP D010523
33 414 420 9636837 damage NN I-NP D010523
34 420 421 9636837 . . O O

1 422 431 9636837 MATERIALS NNS B-NP O
2 432 435 9636837 AND CC I-NP O
3 436 443 9636837 METHODS NNS I-NP O
4 443 444 9636837 : : O O
5 445 448 9636837 Two CD B-NP O
6 449 458 9636837 different JJ I-NP O
7 459 468 9636837 schedules NNS I-NP O
8 469 471 9636837 of IN B-PP O
9 472 477 9636837 CBDCA NN B-NP D016190
10 478 492 9636837 administration NN I-NP O
11 493 494 9636837 ( ( O O
12 494 496 9636837 10 CD B-NP O
13 497 499 9636837 mg NN I-NP O
14 499 500 9636837 / SYM B-NP O
15 500 502 9636837 kg NN I-NP O
16 503 506 9636837 and CC O O
17 507 509 9636837 15 CD B-NP O
18 510 512 9636837 mg NN I-NP O
19 512 513 9636837 / SYM O O
20 513 515 9636837 kg NN B-NP O
21 516 519 9636837 i.p NN I-NP O
22 519 520 9636837 . . O O

1 521 526 9636837 twice RB B-NP O
2 527 528 9636837 a DT I-NP O
3 529 533 9636837 week NN I-NP O
4 534 537 9636837 for IN B-PP O
5 538 542 9636837 nine CD B-NP O
6 543 548 9636837 times NNS I-NP O
7 548 549 9636837 ) ) O O
8 550 554 9636837 were VBD B-VP O
9 555 564 9636837 evaluated VBN I-VP O
10 565 567 9636837 in IN B-PP O
11 568 574 9636837 Wistar NNP B-NP O
12 575 579 9636837 rats NNS I-NP O
13 579 580 9636837 . . O O

1 581 594 9636837 Neurotoxicity NN B-NP D020258
2 595 598 9636837 was VBD B-VP O
3 599 607 9636837 assessed VBN I-VP O
4 608 611 9636837 for IN B-PP O
5 612 622 9636837 behavioral NN B-NP O
6 623 624 9636837 ( ( O O
7 624 628 9636837 tail NN B-NP O
8 628 629 9636837 - HYPH B-NP O
9 629 634 9636837 flick NN I-NP O
10 635 639 9636837 test NN I-NP O
11 639 640 9636837 ) ) O O
12 640 641 9636837 , , O O
13 642 660 9636837 neurophysiological JJ B-ADJP O
14 661 662 9636837 ( ( O O
15 662 667 9636837 nerve NN B-NP O
16 668 678 9636837 conduction NN I-NP O
17 679 687 9636837 velocity NN I-NP O
18 688 690 9636837 in IN B-PP O
19 691 694 9636837 the DT B-NP O
20 695 699 9636837 tail NN I-NP O
21 700 705 9636837 nerve NN I-NP O
22 705 706 9636837 ) ) O O
23 706 707 9636837 , , O O
24 708 721 9636837 morphological JJ B-NP O
25 721 722 9636837 , , I-NP O
26 723 737 9636837 morphometrical JJ I-NP O
27 738 741 9636837 and CC I-NP O
28 742 752 9636837 analytical JJ I-NP O
29 753 760 9636837 effects NNS I-NP O
30 760 761 9636837 . . O O

1 762 769 9636837 RESULTS NNS B-NP O
2 769 770 9636837 : : O O
3 771 776 9636837 CBDCA NN B-NP D016190
4 777 791 9636837 administration NN I-NP O
5 792 799 9636837 induced VBD B-VP O
6 800 804 9636837 dose NN B-NP O
7 804 805 9636837 - HYPH B-NP O
8 805 814 9636837 dependent JJ I-NP O
9 815 825 9636837 peripheral JJ I-NP D010523
10 826 839 9636837 neurotoxicity NN I-NP D010523
11 839 840 9636837 . . O O

1 841 845 9636837 Pain NN B-NP D010146
2 846 856 9636837 perception NN I-NP O
3 857 860 9636837 and CC O O
4 861 866 9636837 nerve NN B-NP O
5 867 877 9636837 conduction NN I-NP O
6 878 886 9636837 velocity NN I-NP O
7 887 889 9636837 in IN B-PP O
8 890 893 9636837 the DT B-NP O
9 894 898 9636837 tail NN I-NP O
10 899 903 9636837 were VBD B-VP O
11 904 917 9636837 significantly RB B-ADJP O
12 918 926 9636837 impaired JJ I-ADJP O
13 926 927 9636837 , , O O
14 928 940 9636837 particularly RB B-ADVP O
15 941 946 9636837 after IN B-SBAR O
16 947 950 9636837 the DT B-NP O
17 951 955 9636837 high JJ I-NP O
18 955 956 9636837 - HYPH I-NP O
19 956 960 9636837 dose NN I-NP O
20 961 970 9636837 treatment NN I-NP O
21 970 971 9636837 . . O O

1 972 975 9636837 The DT B-NP O
2 976 982 9636837 dorsal JJ I-NP O
3 983 987 9636837 root NN I-NP O
4 988 995 9636837 ganglia NNS I-NP O
5 996 1003 9636837 sensory VBP B-VP O
6 1004 1011 9636837 neurons NNS B-NP O
7 1012 1015 9636837 and CC O O
8 1015 1016 9636837 , , O O
9 1017 1019 9636837 to TO B-PP O
10 1020 1021 9636837 a DT B-NP O
11 1022 1028 9636837 lesser JJR I-NP O
12 1029 1035 9636837 extent NN I-NP O
13 1035 1036 9636837 , , O O
14 1037 1046 9636837 satellite NN B-NP O
15 1047 1052 9636837 cells NNS I-NP O
16 1053 1059 9636837 showed VBD B-VP O
17 1060 1063 9636837 the DT B-NP O
18 1064 1068 9636837 same JJ I-NP O
19 1069 1076 9636837 changes NNS I-NP O
20 1077 1079 9636837 as IN B-PP O
21 1080 1085 9636837 those DT B-NP O
22 1086 1093 9636837 induced VBN B-VP O
23 1094 1096 9636837 by IN B-PP O
24 1097 1101 9636837 CDDP NN B-NP D002945
25 1101 1102 9636837 , , O O
26 1103 1109 9636837 mainly RB B-ADVP O
27 1110 1119 9636837 affecting VBG B-VP O
28 1120 1123 9636837 the DT B-NP O
29 1124 1131 9636837 nucleus NN I-NP O
30 1132 1135 9636837 and CC I-NP O
31 1136 1145 9636837 nucleolus NN I-NP O
32 1146 1148 9636837 of IN B-PP O
33 1149 1159 9636837 ganglionic JJ B-NP O
34 1160 1167 9636837 sensory JJ I-NP O
35 1168 1175 9636837 neurons NNS I-NP O
36 1175 1176 9636837 . . O O

1 1177 1185 9636837 Moreover RB B-ADVP O
2 1185 1186 9636837 , , O O
3 1187 1198 9636837 significant JJ B-NP O
4 1199 1206 9636837 amounts NNS I-NP O
5 1207 1209 9636837 of IN B-PP O
6 1210 1218 9636837 platinum NN B-NP D010984
7 1219 1223 9636837 were VBD B-VP O
8 1224 1232 9636837 detected VBN I-VP O
9 1233 1235 9636837 in IN B-PP O
10 1236 1239 9636837 the DT B-NP O
11 1240 1246 9636837 dorsal JJ I-NP O
12 1247 1251 9636837 root NN I-NP O
13 1252 1259 9636837 ganglia NNS I-NP O
14 1260 1263 9636837 and CC O O
15 1264 1270 9636837 kidney NN B-NP O
16 1271 1276 9636837 after IN B-PP O
17 1277 1282 9636837 CBDCA NN B-NP D016190
18 1283 1292 9636837 treatment NN I-NP O
19 1292 1293 9636837 . . O O

1 1294 1305 9636837 CONCLUSIONS NNS B-NP O
2 1305 1306 9636837 : : O O
3 1307 1312 9636837 CBDCA NN B-NP D016190
4 1313 1315 9636837 is VBZ B-VP O
5 1316 1326 9636837 neurotoxic JJ B-ADJP D020258
6 1327 1329 9636837 in IN B-PP O
7 1330 1333 9636837 our PRP$ B-NP O
8 1334 1339 9636837 model NN I-NP O
9 1339 1340 9636837 , , O O
10 1341 1344 9636837 and CC O O
11 1345 1348 9636837 the DT B-NP O
12 1349 1353 9636837 type NN I-NP O
13 1354 1356 9636837 of IN B-PP O
14 1357 1369 9636837 pathological JJ B-NP O
15 1370 1377 9636837 changes NNS I-NP O
16 1378 1380 9636837 it PRP B-NP O
17 1381 1388 9636837 induces VBZ B-VP O
18 1389 1392 9636837 are VBP B-VP O
19 1393 1395 9636837 so RB B-ADJP O
20 1396 1403 9636837 closely RB I-ADJP O
21 1404 1411 9636837 similar JJ I-ADJP O
22 1412 1414 9636837 to TO B-PP O
23 1415 1420 9636837 those DT B-NP O
24 1421 1427 9636837 caused VBN B-VP O
25 1428 1430 9636837 by IN B-PP O
26 1431 1435 9636837 CDDP NN B-NP D002945
27 1436 1440 9636837 that IN B-SBAR O
28 1441 1443 9636837 it PRP B-NP O
29 1444 1446 9636837 is VBZ B-VP O
30 1447 1455 9636837 probable JJ B-ADJP O
31 1456 1460 9636837 that IN B-SBAR O
32 1461 1474 9636837 neurotoxicity NN B-NP D020258
33 1475 1477 9636837 is VBZ B-VP O
34 1478 1485 9636837 induced VBN I-VP O
35 1486 1488 9636837 in IN B-PP O
36 1489 1492 9636837 the DT B-NP O
37 1493 1496 9636837 two CD I-NP O
38 1497 1502 9636837 drugs NNS I-NP O
39 1503 1505 9636837 by IN B-PP O
40 1506 1509 9636837 the DT B-NP O
41 1510 1514 9636837 same JJ I-NP O
42 1515 1524 9636837 mechanism NN I-NP O
43 1524 1525 9636837 . . O O

1 1526 1530 9636837 This DT B-NP O
2 1531 1536 9636837 model NN I-NP O
3 1537 1540 9636837 can MD B-VP O
4 1541 1543 9636837 be VB I-VP O
5 1544 1548 9636837 used VBN I-VP O
6 1549 1554 9636837 alone RB B-ADVP O
7 1555 1557 9636837 or CC O O
8 1558 1560 9636837 in IN B-PP O
9 1561 1572 9636837 combination NN B-NP O
10 1573 1577 9636837 with IN B-PP O
11 1578 1583 9636837 other JJ B-NP O
12 1584 1589 9636837 drugs NNS I-NP O
13 1590 1592 9636837 to TO B-VP O
14 1593 1600 9636837 explore VB I-VP O
15 1601 1604 9636837 the DT B-NP O
16 1605 1611 9636837 effect NN I-NP O
17 1612 1614 9636837 of IN B-PP O
18 1615 1620 9636837 CBDCA NN B-NP D016190
19 1621 1623 9636837 on IN B-PP O
20 1624 1627 9636837 the DT B-NP O
21 1628 1638 9636837 peripheral JJ I-NP O
22 1639 1646 9636837 nervous JJ I-NP O
23 1647 1653 9636837 system NN I-NP O
24 1653 1654 9636837 . . O O

1 0 0 19319147 -DOCSTART- -X- -X- O

1 0 5 19319147 Rapid JJ B-NP O
2 6 14 19319147 reversal NN I-NP O
3 15 17 19319147 of IN B-PP O
4 18 33 19319147 anticoagulation NN B-NP O
5 34 41 19319147 reduces VBZ B-VP O
6 42 52 19319147 hemorrhage NN B-NP D006470
7 53 59 19319147 volume NN I-NP O
8 60 62 19319147 in IN B-PP O
9 63 64 19319147 a DT B-NP O
10 65 70 19319147 mouse NN I-NP O
11 71 76 19319147 model NN I-NP O
12 77 79 19319147 of IN B-PP O
13 80 88 19319147 warfarin NN B-NP D014859
14 88 89 19319147 - HYPH O O
15 89 99 19319147 associated VBN B-VP O
16 100 113 19319147 intracerebral JJ B-NP D002543
17 114 124 19319147 hemorrhage NN I-NP D002543
18 124 125 19319147 . . B-NP O
19 126 134 19319147 Warfarin NN I-NP D014859
20 134 135 19319147 - HYPH O O
21 135 145 19319147 associated VBN B-VP O
22 146 159 19319147 intracerebral JJ B-NP D002543
23 160 170 19319147 hemorrhage NN I-NP D002543
24 171 172 19319147 ( ( O O
25 172 173 19319147 W NN B-NP O
26 173 174 19319147 - HYPH B-NP O
27 174 177 19319147 ICH NN I-NP D002543
28 177 178 19319147 ) ) O O
29 179 181 19319147 is VBZ B-VP O
30 182 183 19319147 a DT B-NP O
31 184 190 19319147 severe JJ I-NP O
32 191 195 19319147 type NN I-NP O
33 196 198 19319147 of IN B-PP O
34 199 205 19319147 stroke NN B-NP D020521
35 205 206 19319147 . . O O

1 207 212 19319147 There EX B-NP O
2 213 215 19319147 is VBZ B-VP O
3 216 218 19319147 no DT B-NP O
4 219 228 19319147 consensus NN I-NP O
5 229 231 19319147 on IN B-PP O
6 232 235 19319147 the DT B-NP O
7 236 243 19319147 optimal JJ I-NP O
8 244 253 19319147 treatment NN I-NP O
9 254 257 19319147 for IN B-PP O
10 258 259 19319147 W NN B-NP O
11 259 260 19319147 - HYPH I-NP O
12 260 263 19319147 ICH NN I-NP D002543
13 263 264 19319147 . . O O

1 265 270 19319147 Using VBG B-VP O
2 271 272 19319147 a DT B-NP O
3 273 278 19319147 mouse NN I-NP O
4 279 284 19319147 model NN I-NP O
5 284 285 19319147 , , O O
6 286 288 19319147 we PRP B-NP O
7 289 295 19319147 tested VBD B-VP O
8 296 303 19319147 whether IN B-SBAR O
9 304 307 19319147 the DT B-NP O
10 308 313 19319147 rapid JJ I-NP O
11 314 322 19319147 reversal NN I-NP O
12 323 325 19319147 of IN B-PP O
13 326 341 19319147 anticoagulation NN B-NP O
14 342 347 19319147 using VBG B-VP O
15 348 353 19319147 human JJ B-NP O
16 354 365 19319147 prothrombin NN I-NP C025667
17 366 373 19319147 complex NN I-NP C025667
18 374 385 19319147 concentrate NN I-NP C025667
19 386 387 19319147 ( ( O O
20 387 390 19319147 PCC NN B-NP C025667
21 390 391 19319147 ) ) O O
22 392 395 19319147 can MD B-VP O
23 396 402 19319147 reduce VB I-VP O
24 403 414 19319147 hemorrhagic JJ B-NP O
25 415 420 19319147 blood NN I-NP O
26 421 427 19319147 volume NN I-NP O
27 427 428 19319147 . . O O

1 429 433 19319147 Male JJ B-NP O
2 434 436 19319147 CD NN I-NP O
3 436 437 19319147 - HYPH B-NP O
4 437 438 19319147 1 CD I-NP O
5 439 443 19319147 mice NNS I-NP O
6 444 448 19319147 were VBD B-VP O
7 449 456 19319147 treated VBN I-VP O
8 457 461 19319147 with IN B-PP O
9 462 470 19319147 warfarin NN B-NP D014859
10 471 472 19319147 ( ( O O
11 472 473 19319147 2 CD B-NP O
12 474 476 19319147 mg NN I-NP O
13 476 477 19319147 / SYM B-NP O
14 477 479 19319147 kg NN I-NP O
15 480 484 19319147 over IN B-PP O
16 485 487 19319147 24 CD B-NP O
17 488 489 19319147 h NN I-NP O
18 489 490 19319147 ) ) O O
19 490 491 19319147 , , O O
20 492 501 19319147 resulting VBG B-VP O
21 502 504 19319147 in IN B-PP O
22 505 506 19319147 a DT O O
23 507 511 19319147 mean JJ O O
24 512 513 19319147 ( ( O O
25 513 514 19319147 + SYM O O
26 514 515 19319147 / SYM O O
27 515 516 19319147 - SYM B-NP O
28 516 519 19319147 s.d NN I-NP O
29 519 520 19319147 . . O O
30 520 521 19319147 ) ) O O
31 522 535 19319147 International NNP B-NP O
32 536 546 19319147 Normalized NNP I-NP O
33 547 552 19319147 Ratio NNP I-NP O
34 553 555 19319147 of IN B-PP O
35 556 560 19319147 3.5+ CD B-NP O
36 560 561 19319147 / SYM B-NP O
37 561 562 19319147 - SYM B-VP O
38 562 565 19319147 0.9 CD B-NP O
39 565 566 19319147 . . O O

1 567 572 19319147 First RB B-ADVP O
2 572 573 19319147 , , O O
3 574 576 19319147 we PRP B-NP O
4 577 583 19319147 showed VBD B-VP O
5 584 588 19319147 that IN B-SBAR O
6 589 591 19319147 an DT B-NP O
7 592 603 19319147 intravenous JJ I-NP O
8 604 618 19319147 administration NN I-NP O
9 619 621 19319147 of IN B-PP O
10 622 627 19319147 human JJ B-NP O
11 628 631 19319147 PCC NN I-NP C025667
12 632 639 19319147 rapidly RB B-ADVP O
13 640 648 19319147 reversed VBD B-VP O
14 649 664 19319147 anticoagulation NN B-NP O
15 665 667 19319147 in IN B-PP O
16 668 672 19319147 mice NNS B-NP O
17 672 673 19319147 . . O O

1 674 680 19319147 Second RB B-ADVP O
2 680 681 19319147 , , O O
3 682 683 19319147 a DT B-NP O
4 684 696 19319147 stereotactic JJ I-NP O
5 697 706 19319147 injection NN I-NP O
6 707 709 19319147 of IN B-PP O
7 710 721 19319147 collagenase NN B-NP O
8 722 725 19319147 was VBD B-VP O
9 726 738 19319147 administered VBN I-VP O
10 739 741 19319147 to TO I-VP O
11 742 748 19319147 induce VB I-VP O
12 749 759 19319147 hemorrhage NN B-NP D006470
13 760 762 19319147 in IN B-PP O
14 763 766 19319147 the DT B-NP O
15 767 772 19319147 right JJ I-NP O
16 773 781 19319147 striatum NN I-NP O
17 781 782 19319147 . . O O

1 783 788 19319147 Forty CD B-NP O
2 788 789 19319147 - HYPH I-NP O
3 789 793 19319147 five CD I-NP O
4 794 801 19319147 minutes NNS I-NP O
5 802 807 19319147 later RB B-ADVP O
6 807 808 19319147 , , O O
7 809 812 19319147 the DT B-NP O
8 813 820 19319147 animals NNS I-NP O
9 821 825 19319147 were VBD B-VP O
10 826 834 19319147 randomly RB I-VP O
11 835 842 19319147 treated VBN I-VP O
12 843 847 19319147 with IN B-PP O
13 848 851 19319147 PCC NN B-NP C025667
14 852 853 19319147 ( ( O O
15 853 856 19319147 100 CD B-NP O
16 857 858 19319147 U NN I-NP O
17 858 859 19319147 / SYM B-NP O
18 859 861 19319147 kg NN I-NP O
19 861 862 19319147 ) ) O O
20 863 865 19319147 or CC O O
21 866 872 19319147 saline NN B-NP O
22 873 876 19319147 i.v NN I-NP O
23 876 877 19319147 . . O O

1 878 879 19319147 ( ( O O
2 879 880 19319147 n NN B-NP O
3 880 881 19319147 = SYM B-VP O
4 881 883 19319147 12 CD B-NP O
5 884 887 19319147 per IN B-PP O
6 888 893 19319147 group NN B-NP O
7 893 894 19319147 ) ) O O
8 894 895 19319147 . . O O

1 896 902 19319147 Twenty CD B-NP O
2 902 903 19319147 - HYPH I-NP O
3 903 907 19319147 four CD I-NP O
4 908 913 19319147 hours NNS I-NP O
5 914 919 19319147 after IN B-PP O
6 920 930 19319147 hemorrhage NN B-NP D006470
7 931 940 19319147 induction NN I-NP O
8 940 941 19319147 , , O O
9 942 953 19319147 hemorrhagic JJ B-NP O
10 954 959 19319147 blood NN I-NP O
11 960 966 19319147 volume NN I-NP O
12 967 970 19319147 was VBD B-VP O
13 971 981 19319147 quantified VBN I-VP O
14 982 987 19319147 using VBG B-VP O
15 988 989 19319147 a DT B-NP O
16 990 1001 19319147 photometric JJ I-NP O
17 1002 1012 19319147 hemoglobin NN I-NP O
18 1013 1018 19319147 assay NN I-NP O
19 1018 1019 19319147 . . O O

1 1020 1023 19319147 The DT B-NP O
2 1024 1028 19319147 mean JJ I-NP O
3 1029 1040 19319147 hemorrhagic JJ I-NP O
4 1041 1046 19319147 blood NN I-NP O
5 1047 1053 19319147 volume NN I-NP O
6 1054 1057 19319147 was VBD B-VP O
7 1058 1065 19319147 reduced VBN I-VP O
8 1066 1068 19319147 in IN B-PP O
9 1069 1072 19319147 PCC NN B-NP C025667
10 1072 1073 19319147 - HYPH B-NP O
11 1073 1080 19319147 treated VBN I-NP O
12 1081 1088 19319147 animals NNS I-NP O
13 1089 1090 19319147 ( ( O O
14 1090 1094 19319147 6.5+ SYM O O
15 1094 1095 19319147 / SYM O O
16 1095 1096 19319147 - SYM O O
17 1096 1099 19319147 3.1 CD B-NP O
18 1100 1106 19319147 microL NN I-NP O
19 1106 1107 19319147 ) ) O O
20 1108 1116 19319147 compared VBN B-PP O
21 1117 1121 19319147 with IN B-PP O
22 1122 1128 19319147 saline JJ B-NP O
23 1129 1137 19319147 controls NNS I-NP O
24 1138 1139 19319147 ( ( O O
25 1139 1144 19319147 15.3+ SYM B-NP O
26 1144 1145 19319147 / SYM O O
27 1145 1146 19319147 - SYM O O
28 1146 1150 19319147 11.2 CD B-NP O
29 1151 1157 19319147 microL NN I-NP O
30 1157 1158 19319147 , , O O
31 1159 1160 19319147 P NN B-NP O
32 1160 1161 19319147 = SYM B-VP O
33 1161 1166 19319147 0.015 CD B-NP O
34 1166 1167 19319147 ) ) O O
35 1167 1168 19319147 . . O O

1 1169 1171 19319147 In IN B-PP O
2 1172 1175 19319147 the DT B-NP O
3 1176 1182 19319147 saline NN I-NP O
4 1183 1188 19319147 group NN I-NP O
5 1188 1189 19319147 , , O O
6 1190 1193 19319147 45% CD B-NP O
7 1194 1196 19319147 of IN B-PP O
8 1197 1200 19319147 the DT B-NP O
9 1201 1205 19319147 mice NNS I-NP O
10 1206 1215 19319147 developed VBD B-VP O
11 1216 1221 19319147 large JJ B-NP O
12 1222 1231 19319147 hematomas NNS I-NP D006406
13 1232 1233 19319147 ( ( O O
14 1233 1237 19319147 i.e. FW B-NP O
15 1237 1238 19319147 , , O O
16 1239 1240 19319147 > SYM B-NP O
17 1240 1242 19319147 15 CD I-NP O
18 1243 1249 19319147 microL NN I-NP O
19 1249 1250 19319147 ) ) O O
20 1250 1251 19319147 . . O O

1 1252 1254 19319147 In IN B-PP O
2 1255 1263 19319147 contrast NN B-NP O
3 1263 1264 19319147 , , O O
4 1265 1269 19319147 such JJ B-NP O
5 1270 1279 19319147 extensive JJ I-NP O
6 1280 1287 19319147 lesions NNS I-NP O
7 1288 1292 19319147 were VBD B-VP O
8 1293 1298 19319147 never RB I-VP O
9 1299 1304 19319147 found VBN I-VP O
10 1305 1307 19319147 in IN B-PP O
11 1308 1311 19319147 the DT B-NP O
12 1312 1315 19319147 PCC NN I-NP C025667
13 1316 1321 19319147 group NN I-NP O
14 1321 1322 19319147 . . O O

1 1323 1325 19319147 We PRP B-NP O
2 1326 1333 19319147 provide VBP B-VP O
3 1334 1346 19319147 experimental JJ B-NP O
4 1347 1351 19319147 data NNS I-NP O
5 1352 1362 19319147 suggesting VBG B-VP O
6 1363 1366 19319147 PCC NN B-NP C025667
7 1367 1369 19319147 to TO B-VP O
8 1370 1372 19319147 be VB I-VP O
9 1373 1375 19319147 an DT B-NP O
10 1376 1385 19319147 effective JJ I-NP O
11 1386 1391 19319147 acute JJ I-NP O
12 1392 1401 19319147 treatment NN I-NP O
13 1402 1405 19319147 for IN B-PP O
14 1406 1407 19319147 W NN B-NP O
15 1407 1408 19319147 - HYPH B-NP O
16 1408 1411 19319147 ICH NN I-NP D002543
17 1412 1414 19319147 in IN B-PP O
18 1415 1420 19319147 terms NNS B-NP O
19 1421 1423 19319147 of IN B-PP O
20 1424 1432 19319147 reducing VBG B-VP O
21 1433 1444 19319147 hemorrhagic JJ B-NP O
22 1445 1450 19319147 blood NN I-NP O
23 1451 1457 19319147 volume NN I-NP O
24 1457 1458 19319147 . . O O

1 1459 1465 19319147 Future JJ B-NP O
2 1466 1473 19319147 studies NNS I-NP O
3 1474 1477 19319147 are VBP B-VP O
4 1478 1484 19319147 needed VBN I-VP O
5 1485 1487 19319147 to TO B-VP O
6 1488 1494 19319147 assess VB I-VP O
7 1495 1498 19319147 the DT B-NP O
8 1499 1510 19319147 therapeutic JJ I-NP O
9 1511 1520 19319147 potential NN I-NP O
10 1521 1529 19319147 emerging VBG B-VP O
11 1530 1534 19319147 from IN B-PP O
12 1535 1538 19319147 our PRP$ B-NP O
13 1539 1546 19319147 finding NN I-NP O
14 1547 1550 19319147 for IN B-PP O
15 1551 1556 19319147 human JJ B-NP O
16 1557 1558 19319147 W NN I-NP O
17 1558 1559 19319147 - HYPH B-NP O
18 1559 1562 19319147 ICH NN I-NP D002543
19 1562 1563 19319147 . . O O

1 0 0 7282516 -DOCSTART- -X- -X- O

1 0 4 7282516 Dose NN B-NP O
2 4 5 7282516 - HYPH I-NP O
3 5 11 7282516 effect NN I-NP O
4 12 15 7282516 and CC I-NP O
5 16 25 7282516 structure NN I-NP O
6 25 26 7282516 - HYPH B-NP O
7 26 34 7282516 function NN I-NP O
8 35 48 7282516 relationships NNS I-NP O
9 49 51 7282516 in IN B-PP O
10 52 63 7282516 doxorubicin NN B-NP D004317
11 64 78 7282516 cardiomyopathy NN I-NP D009202
12 78 79 7282516 . . O O
13 80 83 7282516 The DT B-NP O
14 84 98 7282516 cardiomyopathy NN I-NP D009202
15 99 100 7282516 ( ( O O
16 100 102 7282516 CM NN B-NP D009202
17 102 103 7282516 ) ) O O
18 104 112 7282516 produced VBN B-VP O
19 113 115 7282516 by IN B-PP O
20 116 119 7282516 the DT B-NP O
21 120 130 7282516 anticancer JJ I-NP O
22 131 135 7282516 drug NN I-NP O
23 136 147 7282516 doxorubicin NN I-NP D004317
24 148 149 7282516 ( ( O O
25 149 152 7282516 DXR NN B-NP D004317
26 152 153 7282516 ) ) O O
27 154 155 7282516 ( ( O O
28 155 165 7282516 Adriamycin NN B-NP D004317
29 165 166 7282516 ) ) O O
30 167 175 7282516 provides VBZ B-VP O
31 176 177 7282516 a DT B-NP O
32 178 184 7282516 unique JJ I-NP O
33 185 196 7282516 opportunity NN I-NP O
34 197 199 7282516 to TO B-VP O
35 200 207 7282516 analyze VB I-VP O
36 208 212 7282516 dose NN B-NP O
37 212 213 7282516 - HYPH B-NP O
38 213 219 7282516 effect NN I-NP O
39 220 223 7282516 and CC I-NP O
40 224 233 7282516 structure NN I-NP O
41 233 234 7282516 - HYPH B-NP O
42 234 242 7282516 function NN I-NP O
43 243 256 7282516 relationships NNS I-NP O
44 257 263 7282516 during IN B-PP O
45 264 275 7282516 development NN B-NP O
46 276 278 7282516 of IN B-PP O
47 279 289 7282516 myocardial JJ B-NP D009202
48 290 297 7282516 disease NN I-NP D009202
49 297 298 7282516 . . O O

1 299 301 7282516 We PRP B-NP O
2 302 310 7282516 measured VBD B-VP O
3 311 314 7282516 the DT B-NP O
4 315 321 7282516 degree NN I-NP O
5 322 324 7282516 of IN B-PP O
6 325 336 7282516 morphologic JJ B-NP O
7 337 343 7282516 damage NN I-NP O
8 344 346 7282516 by IN B-PP O
9 347 362 7282516 ultrastructural JJ B-NP O
10 363 374 7282516 examination NN I-NP O
11 375 377 7282516 of IN B-PP O
12 378 392 7282516 endomyocardial JJ B-NP O
13 393 399 7282516 biopsy NN I-NP O
14 400 403 7282516 and CC O O
15 404 407 7282516 the DT B-NP O
16 408 414 7282516 degree NN I-NP O
17 415 417 7282516 of IN B-PP O
18 418 429 7282516 performance NN B-NP O
19 430 440 7282516 abnormally RB B-ADVP O
20 441 443 7282516 by IN B-PP O
21 444 449 7282516 right JJ B-NP O
22 450 455 7282516 heart NN I-NP O
23 456 471 7282516 catheterization NN I-NP O
24 472 474 7282516 in IN B-PP O
25 475 483 7282516 patients NNS B-NP O
26 484 493 7282516 receiving VBG B-VP O
27 494 497 7282516 DXR NN B-NP D004317
28 497 498 7282516 . . O O

1 499 510 7282516 Morphologic JJ B-NP O
2 511 517 7282516 damage NN I-NP O
3 518 521 7282516 was VBD B-VP O
4 522 530 7282516 variable JJ B-ADJP O
5 531 534 7282516 but CC O O
6 535 538 7282516 was VBD B-VP O
7 539 551 7282516 proportional JJ B-ADJP O
8 552 554 7282516 to TO B-PP O
9 555 558 7282516 the DT B-NP O
10 559 564 7282516 total JJ I-NP O
11 565 575 7282516 cumulative JJ I-NP O
12 576 579 7282516 DXR NN I-NP D004317
13 580 584 7282516 dose NN I-NP O
14 585 592 7282516 between IN B-PP O
15 593 596 7282516 100 CD B-NP O
16 597 600 7282516 and CC I-NP O
17 601 604 7282516 600 CD I-NP O
18 605 607 7282516 mg NN I-NP O
19 607 608 7282516 / SYM B-NP O
20 608 610 7282516 m2 NN I-NP O
21 610 611 7282516 . . O O

1 612 623 7282516 Performance NN B-NP O
2 624 637 7282516 abnormalities NNS I-NP O
3 638 648 7282516 correlated VBD B-VP O
4 649 655 7282516 weakly RB B-ADVP O
5 656 660 7282516 with IN B-PP O
6 661 665 7282516 dose NN B-NP O
7 665 666 7282516 , , O O
8 667 676 7282516 exhibited VBD B-VP O
9 677 678 7282516 a DT B-NP O
10 679 690 7282516 curvilinear JJ I-NP O
11 691 703 7282516 relationship NN I-NP O
12 703 704 7282516 , , O O
13 705 708 7282516 and CC O O
14 709 712 7282516 had VBD B-VP O
15 713 714 7282516 a DT B-NP O
16 715 716 7282516 " `` I-NP O
17 716 725 7282516 threshold NN I-NP O
18 725 726 7282516 " '' O O
19 727 730 7282516 for IN B-PP O
20 731 741 7282516 expression NN B-NP O
21 741 742 7282516 . . O O

1 743 758 7282516 Catheterization NN B-NP O
2 759 772 7282516 abnormalities NNS I-NP O
3 773 783 7282516 correlated VBD B-VP O
4 784 788 7282516 well RB B-ADVP O
5 789 793 7282516 with IN B-PP O
6 794 805 7282516 morphologic JJ B-NP O
7 806 812 7282516 damage NN I-NP O
8 813 814 7282516 ( ( O O
9 814 815 7282516 r NN B-NP O
10 816 817 7282516 = SYM B-VP O
11 818 822 7282516 0.57 CD B-NP O
12 823 825 7282516 to TO B-PP O
13 826 830 7282516 0.78 CD B-NP O
14 830 831 7282516 ) ) O O
15 832 834 7282516 in IN B-PP O
16 835 836 7282516 a DT B-NP O
17 837 845 7282516 subgroup NN I-NP O
18 846 848 7282516 of IN B-PP O
19 849 857 7282516 patients NNS B-NP O
20 858 860 7282516 in IN B-PP O
21 861 865 7282516 whom WP B-NP O
22 866 874 7282516 exercise NN B-NP O
23 875 887 7282516 hemodynamics NNS I-NP O
24 888 892 7282516 were VBD B-VP O
25 893 901 7282516 measured VBN I-VP O
26 901 902 7282516 , , O O
27 903 906 7282516 and CC O O
28 907 911 7282516 this DT B-NP O
29 912 924 7282516 relationship NN I-NP O
30 925 929 7282516 also RB B-ADVP O
31 930 939 7282516 exhibited VBD B-VP O
32 940 941 7282516 a DT B-NP O
33 942 953 7282516 curvilinear NN I-NP O
34 953 954 7282516 , , O O
35 955 964 7282516 threshold DT B-NP O
36 965 978 7282516 configuration NN I-NP O
37 978 979 7282516 . . O O

1 980 982 7282516 In IN B-PP O
2 983 986 7282516 DXR NN B-NP D004317
3 986 987 7282516 - HYPH B-NP O
4 987 989 7282516 CM NN I-NP D009202
5 990 1000 7282516 myocardial JJ I-NP D009202
6 1001 1007 7282516 damage NN I-NP D009202
7 1008 1010 7282516 is VBZ B-VP O
8 1011 1023 7282516 proportional JJ B-ADJP O
9 1024 1026 7282516 to TO B-PP O
10 1027 1030 7282516 the DT B-NP O
11 1031 1037 7282516 degree NN I-NP O
12 1038 1040 7282516 of IN B-PP O
13 1041 1050 7282516 cytotoxic JJ B-NP O
14 1051 1057 7282516 insult NN I-NP O
15 1058 1059 7282516 ( ( O O
16 1059 1062 7282516 DXR NN B-NP D004317
17 1063 1067 7282516 dose NN I-NP O
18 1067 1068 7282516 ) ) O O
19 1069 1074 7282516 while IN B-SBAR O
20 1075 1085 7282516 myocardial JJ B-NP O
21 1086 1094 7282516 function NN I-NP O
22 1095 1097 7282516 is VBZ B-VP O
23 1098 1107 7282516 preserved VBN I-VP O
24 1108 1113 7282516 until IN B-SBAR O
25 1114 1115 7282516 a DT B-NP O
26 1116 1124 7282516 critical JJ I-NP O
27 1125 1129 7282516 dose NN I-NP O
28 1130 1132 7282516 or CC I-NP O
29 1133 1139 7282516 degree NN I-NP O
30 1140 1142 7282516 of IN B-PP O
31 1143 1149 7282516 damage NN B-NP O
32 1150 1152 7282516 is VBZ B-VP O
33 1153 1160 7282516 reached VBN I-VP O
34 1160 1161 7282516 , , O O
35 1162 1167 7282516 after IN B-PP O
36 1168 1173 7282516 which WDT B-NP O
37 1174 1184 7282516 myocardial JJ B-NP O
38 1185 1196 7282516 performance NN I-NP O
39 1197 1209 7282516 deteriorates VBZ B-VP O
40 1210 1217 7282516 rapidly RB B-ADVP O
41 1217 1218 7282516 . . O O

1 0 0 1423339 -DOCSTART- -X- -X- O

1 0 8 1423339 Amnestic JJ B-NP D000647
2 9 17 1423339 syndrome NN I-NP D000647
3 18 28 1423339 associated VBN B-VP O
4 29 33 1423339 with IN B-PP O
5 34 45 1423339 propranolol NN B-NP D011433
6 46 54 1423339 toxicity NN I-NP D064420
7 54 55 1423339 : : O O
8 56 57 1423339 a DT B-NP O
9 58 62 1423339 case NN I-NP O
10 63 69 1423339 report NN I-NP O
11 69 70 1423339 . . O O
12 71 73 1423339 An DT B-NP O
13 74 81 1423339 elderly JJ I-NP O
14 82 87 1423339 woman NN I-NP O
15 88 97 1423339 developed VBD B-VP O
16 98 100 1423339 an DT B-NP O
17 101 110 1423339 Alzheimer NNP I-NP D000544
18 110 111 1423339 - HYPH I-NP O
19 111 115 1423339 like JJ I-NP O
20 116 124 1423339 subacute JJ I-NP O
21 125 133 1423339 dementia NN I-NP D003704
22 134 136 1423339 as IN B-PP O
23 137 138 1423339 a DT B-NP O
24 139 145 1423339 result NN I-NP O
25 146 148 1423339 of IN B-PP O
26 149 160 1423339 propranolol NN B-NP D011433
27 161 169 1423339 toxicity NN I-NP D064420
28 169 170 1423339 . . O O

1 171 179 1423339 Analysis NN B-NP O
2 180 182 1423339 of IN B-PP O
3 183 186 1423339 the DT B-NP O
4 187 201 1423339 manifestations NNS I-NP O
5 202 208 1423339 showed VBD B-VP O
6 209 213 1423339 that IN B-SBAR O
7 214 220 1423339 severe JJ B-NP O
8 221 231 1423339 impairment NN I-NP O
9 232 234 1423339 of IN B-PP O
10 235 241 1423339 memory NN B-NP O
11 242 251 1423339 accounted VBD B-VP O
12 252 255 1423339 for IN B-PP O
13 256 265 1423339 virtually RB B-NP O
14 266 269 1423339 all DT I-NP O
15 270 272 1423339 of IN B-PP O
16 273 276 1423339 the DT B-NP O
17 277 290 1423339 abnormalities NNS I-NP O
18 290 291 1423339 . . O O

1 292 297 1423339 There EX B-NP O
2 298 300 1423339 is VBZ B-VP O
3 301 309 1423339 evidence NN B-NP O
4 310 314 1423339 that IN B-SBAR O
5 315 323 1423339 cerebral JJ B-NP O
6 324 333 1423339 reactions NNS I-NP O
7 334 336 1423339 to TO B-PP O
8 337 341 1423339 drug NN B-NP O
9 342 350 1423339 toxicity NN I-NP D064420
10 351 354 1423339 can MD B-VP O
11 355 362 1423339 exhibit VB I-VP O
12 363 371 1423339 patterns NNS B-NP O
13 372 376 1423339 that WDT B-NP O
14 377 384 1423339 suggest VBP B-VP O
15 385 391 1423339 highly RB B-NP O
16 392 401 1423339 selective JJ I-NP O
17 402 413 1423339 involvement NN I-NP O
18 414 416 1423339 of IN B-PP O
19 417 427 1423339 functional JJ B-NP O
20 428 440 1423339 subdivisions NNS I-NP O
21 441 443 1423339 of IN B-PP O
22 444 447 1423339 the DT B-NP O
23 448 453 1423339 brain NN I-NP O
24 453 454 1423339 . . O O

1 0 0 1610717 -DOCSTART- -X- -X- O

1 0 7 1610717 Cocaine NN B-NP D003042
2 7 8 1610717 - HYPH B-NP O
3 8 15 1610717 induced VBN I-NP O
4 16 25 1610717 brainstem NN I-NP O
5 26 34 1610717 seizures NNS I-NP D012640
6 35 38 1610717 and CC O O
7 39 47 1610717 behavior NN B-NP O
8 47 48 1610717 . . I-NP O
9 49 50 1610717 A NN I-NP O
10 51 58 1610717 variety NN I-NP O
11 59 61 1610717 of IN B-PP O
12 62 70 1610717 abnormal JJ B-NP O
13 71 78 1610717 sensory NN I-NP O
14 78 79 1610717 / SYM B-VP O
15 79 84 1610717 motor NN B-NP O
16 85 94 1610717 behaviors NNS I-NP O
17 95 105 1610717 associated VBN B-VP O
18 106 110 1610717 with IN B-PP O
19 111 121 1610717 electrical JJ B-NP O
20 122 132 1610717 discharges NNS I-NP O
21 133 141 1610717 recorded VBN B-VP O
22 142 146 1610717 from IN B-PP O
23 147 150 1610717 the DT B-NP O
24 151 160 1610717 bilateral JJ I-NP O
25 161 170 1610717 brainstem NN I-NP O
26 171 175 1610717 were VBD B-VP O
27 176 183 1610717 induced VBN I-VP O
28 184 186 1610717 in IN B-PP O
29 187 192 1610717 adult JJ B-NP O
30 193 196 1610717 WKY NN I-NP O
31 197 201 1610717 rats NNS I-NP O
32 202 204 1610717 by IN B-PP O
33 205 215 1610717 mechanical JJ B-NP O
34 216 217 1610717 ( ( O O
35 217 226 1610717 electrode NN B-NP O
36 227 235 1610717 implants NNS I-NP O
37 235 236 1610717 ) ) O O
38 237 240 1610717 and CC O O
39 241 243 1610717 DC NN B-NP O
40 244 254 1610717 electrical JJ I-NP O
41 255 262 1610717 current JJ I-NP O
42 263 275 1610717 stimulations NNS I-NP O
43 276 279 1610717 and CC B-PP O
44 280 282 1610717 by IN B-PP O
45 283 288 1610717 acute JJ B-NP O
46 289 292 1610717 and CC I-NP O
47 293 300 1610717 chronic JJ I-NP O
48 301 315 1610717 administration NN I-NP O
49 316 318 1610717 of IN B-PP O
50 319 326 1610717 cocaine NN B-NP D003042
51 326 327 1610717 . . O O

1 328 331 1610717 The DT B-NP O
2 332 341 1610717 electrode NN I-NP O
3 342 349 1610717 implant NN I-NP O
4 350 360 1610717 implicated VBD B-VP O
5 361 364 1610717 one CD B-NP O
6 365 369 1610717 side NN I-NP O
7 370 372 1610717 or CC O O
8 373 376 1610717 the DT B-NP O
9 377 382 1610717 other JJ I-NP O
10 383 385 1610717 of IN B-PP O
11 386 389 1610717 the DT B-NP O
12 390 399 1610717 reticular JJ I-NP O
13 400 406 1610717 system NN I-NP O
14 407 409 1610717 of IN B-PP O
15 410 413 1610717 the DT B-NP O
16 414 423 1610717 brainstem NN I-NP O
17 424 427 1610717 but CC O O
18 428 436 1610717 subjects NNS B-NP O
19 437 441 1610717 were VBD B-VP O
20 442 445 1610717 not RB I-VP O
21 446 459 1610717 incapacitated VBN I-VP O
22 460 462 1610717 by IN B-PP O
23 463 466 1610717 the DT B-NP O
24 467 479 1610717 stimulations NNS I-NP O
25 479 480 1610717 . . O O

1 481 488 1610717 Cocaine NN B-NP D003042
2 489 490 1610717 ( ( O O
3 490 492 1610717 40 CD B-NP O
4 493 495 1610717 mg NN I-NP O
5 495 496 1610717 / SYM B-NP O
6 496 498 1610717 kg NN I-NP O
7 498 499 1610717 ) ) O O
8 500 503 1610717 was VBD B-VP O
9 504 512 1610717 injected VBN I-VP O
10 513 527 1610717 subcutaneously RB B-ADVP O
11 528 531 1610717 for IN B-PP O
12 532 534 1610717 an DT B-NP O
13 535 540 1610717 acute JJ I-NP O
14 541 551 1610717 experiment NN I-NP O
15 552 555 1610717 and CC I-NP O
16 556 566 1610717 subsequent JJ I-NP O
17 567 569 1610717 20 CD I-NP O
18 570 572 1610717 mg NN I-NP O
19 572 573 1610717 / SYM B-NP O
20 573 575 1610717 kg NN B-NP O
21 576 581 1610717 doses NNS I-NP O
22 582 587 1610717 twice RB B-ADVP O
23 588 593 1610717 daily RB I-ADVP O
24 594 597 1610717 for IN B-PP O
25 598 599 1610717 3 CD B-NP O
26 600 604 1610717 days NNS I-NP O
27 605 607 1610717 in IN B-PP O
28 608 609 1610717 a DT B-NP O
29 610 617 1610717 chronic JJ I-NP O
30 618 623 1610717 study NN I-NP O
31 623 624 1610717 . . O O

1 625 632 1610717 Cocaine NN B-NP D003042
2 633 642 1610717 generated VBD B-VP O
3 643 647 1610717 more RBR B-NP O
4 648 656 1610717 abnormal JJ I-NP O
5 657 666 1610717 behaviors NNS I-NP O
6 667 669 1610717 in IN B-PP O
7 670 673 1610717 the DT B-NP O
8 674 683 1610717 brainstem NN I-NP O
9 684 696 1610717 perturbation NN I-NP O
10 697 702 1610717 group NN I-NP O
11 702 703 1610717 , , O O
12 704 714 1610717 especially RB B-ADVP O
13 715 718 1610717 the DT B-NP O
14 719 731 1610717 electrically RB I-NP O
15 732 743 1610717 perturbated JJ I-NP O
16 744 752 1610717 subjects NNS I-NP O
17 752 753 1610717 . . O O

1 754 757 1610717 The DT B-NP O
2 758 766 1610717 abnormal JJ I-NP O
3 767 776 1610717 behaviors NNS I-NP O
4 777 781 1610717 were VBD B-VP O
5 782 789 1610717 yawning VBG I-VP O
6 789 790 1610717 , , O O
7 791 802 1610717 retrocollis NN B-NP O
8 802 803 1610717 , , O O
9 804 817 1610717 hyperactivity NN B-NP D006948
10 817 818 1610717 , , O O
11 819 835 1610717 hypersensitivity NN B-NP D004342
12 835 836 1610717 , , O O
13 837 838 1610717 " `` O O
14 838 845 1610717 beating VBG B-VP O
15 846 850 1610717 drum NN B-NP O
16 850 851 1610717 " '' B-NP O
17 852 860 1610717 behavior NN I-NP O
18 860 861 1610717 , , O O
19 862 871 1610717 squealing NN B-NP O
20 871 872 1610717 , , O O
21 873 877 1610717 head NN B-NP O
22 878 885 1610717 bobbing NN I-NP O
23 885 886 1610717 , , O O
24 887 895 1610717 circling NN B-NP O
25 895 896 1610717 , , O O
26 897 905 1610717 sniffing NN B-NP O
27 905 906 1610717 , , O O
28 907 915 1610717 abnormal JJ B-NP O
29 916 925 1610717 posturing NN I-NP O
30 925 926 1610717 , , O O
31 927 930 1610717 and CC O O
32 931 937 1610717 facial JJ B-NP O
33 938 947 1610717 twitching NN I-NP O
34 947 948 1610717 . . O O

1 949 955 1610717 Shifts NNS B-NP O
2 956 958 1610717 in IN B-PP O
3 959 962 1610717 the DT B-NP O
4 963 968 1610717 power NN I-NP O
5 969 978 1610717 frequency NN I-NP O
6 979 986 1610717 spectra NNS I-NP O
7 987 989 1610717 of IN B-PP O
8 990 993 1610717 the DT B-NP O
9 994 1003 1610717 discharge NN I-NP O
10 1004 1012 1610717 patterns NNS I-NP O
11 1013 1017 1610717 were VBD B-VP O
12 1018 1023 1610717 noted VBN I-VP O
13 1024 1031 1610717 between IN B-PP O
14 1032 1037 1610717 quiet JJ B-ADJP O
15 1038 1041 1610717 and CC O O
16 1042 1048 1610717 pacing VBG B-VP O
17 1049 1059 1610717 behavioral JJ B-NP O
18 1060 1066 1610717 states NNS I-NP O
19 1066 1067 1610717 . . O O

1 1068 1084 1610717 Hypersensitivity NN B-NP D004342
2 1085 1087 1610717 to TO B-PP O
3 1088 1095 1610717 various JJ B-NP O
4 1096 1104 1610717 auditory NN I-NP O
5 1104 1105 1610717 , , O O
6 1106 1113 1610717 tactile NN B-NP O
7 1113 1114 1610717 , , O O
8 1115 1118 1610717 and CC O O
9 1119 1125 1610717 visual JJ B-NP O
10 1126 1137 1610717 stimulation NN I-NP O
11 1138 1141 1610717 was VBD B-VP O
12 1142 1149 1610717 present JJ B-ADJP O
13 1150 1153 1610717 and CC O O
14 1154 1160 1610717 shifts NNS B-NP O
15 1161 1163 1610717 in IN B-PP O
16 1164 1167 1610717 the DT B-NP O
17 1168 1177 1610717 brainstem NN I-NP O
18 1178 1185 1610717 ambient NN I-NP O
19 1186 1191 1610717 power NN I-NP O
20 1192 1200 1610717 spectral JJ I-NP O
21 1201 1210 1610717 frequency NN I-NP O
22 1211 1219 1610717 occurred VBD B-VP O
23 1220 1222 1610717 in IN B-PP O
24 1223 1231 1610717 response NN B-NP O
25 1232 1234 1610717 to TO B-PP O
26 1235 1242 1610717 tactile JJ B-NP O
27 1243 1254 1610717 stimulation NN I-NP O
28 1254 1255 1610717 . . O O

1 1256 1261 1610717 These DT B-NP O
2 1262 1270 1610717 findings NNS I-NP O
3 1271 1278 1610717 suggest VBP B-VP O
4 1279 1283 1610717 that IN B-SBAR O
5 1284 1287 1610717 the DT B-NP O
6 1288 1297 1610717 brainstem NN I-NP O
7 1298 1307 1610717 generates VBZ B-VP O
8 1308 1311 1610717 and CC I-VP O
9 1312 1322 1610717 propagates VBZ I-VP O
10 1323 1335 1610717 pathological JJ B-NP O
11 1336 1346 1610717 discharges NNS I-NP O
12 1347 1351 1610717 that WDT B-NP O
13 1352 1355 1610717 can MD B-VP O
14 1356 1358 1610717 be VB I-VP O
15 1359 1367 1610717 elicited VBN I-VP O
16 1368 1370 1610717 by IN B-PP O
17 1371 1381 1610717 mechanical JJ B-NP O
18 1382 1385 1610717 and CC I-NP O
19 1386 1388 1610717 DC NN I-NP O
20 1389 1399 1610717 electrical JJ I-NP O
21 1400 1412 1610717 perturbation NN I-NP O
22 1412 1413 1610717 . . O O

1 1414 1421 1610717 Cocaine NN B-NP D003042
2 1422 1425 1610717 was VBD B-VP O
3 1426 1431 1610717 found VBN I-VP O
4 1432 1434 1610717 to TO I-VP O
5 1435 1443 1610717 activate VB I-VP O
6 1444 1447 1610717 the DT B-NP O
7 1448 1457 1610717 discharge NN I-NP O
8 1458 1464 1610717 system NN I-NP O
9 1465 1468 1610717 and CC O O
10 1469 1473 1610717 thus RB B-VP O
11 1474 1480 1610717 induce VBP I-VP O
12 1481 1489 1610717 abnormal JJ B-NP O
13 1490 1499 1610717 behaviors NNS I-NP O
14 1500 1504 1610717 that WDT B-NP O
15 1505 1508 1610717 are VBP B-VP O
16 1509 1518 1610717 generated VBN I-VP O
17 1519 1521 1610717 at IN B-PP O
18 1522 1525 1610717 the DT B-NP O
19 1526 1535 1610717 discharge NN I-NP O
20 1536 1540 1610717 site NN I-NP O
21 1541 1544 1610717 and CC B-PP O
22 1545 1547 1610717 at IN B-PP O
23 1548 1555 1610717 distant JJ B-NP O
24 1556 1561 1610717 sites NNS I-NP O
25 1562 1564 1610717 to TO B-PP O
26 1565 1570 1610717 which WDT B-NP O
27 1571 1574 1610717 the DT B-NP O
28 1575 1584 1610717 discharge NN I-NP O
29 1585 1595 1610717 propagates NNS I-NP O
30 1595 1596 1610717 . . O O

1 1597 1606 1610717 Cognitive JJ B-NP O
2 1607 1616 1610717 functions NNS I-NP O
3 1617 1620 1610717 may MD B-VP O
4 1621 1625 1610717 also RB I-VP O
5 1626 1628 1610717 be VB I-VP O
6 1629 1637 1610717 involved VBN I-VP O
7 1638 1643 1610717 since IN B-PP O
8 1644 1656 1610717 dopaminergic JJ B-NP O
9 1657 1660 1610717 and CC I-NP O
10 1661 1673 1610717 serotonergic JJ I-NP O
11 1674 1682 1610717 cellular JJ I-NP O
12 1683 1691 1610717 elements NNS I-NP O
13 1692 1694 1610717 at IN B-PP O
14 1695 1698 1610717 the DT B-NP O
15 1699 1708 1610717 brainstem NN I-NP O
16 1709 1714 1610717 level NN I-NP O
17 1715 1718 1610717 are VBP B-VP O
18 1719 1723 1610717 also RB I-VP O
19 1724 1734 1610717 implicated VBN I-VP O
20 1734 1735 1610717 . . O O

1 0 0 19940105 -DOCSTART- -X- -X- O

1 0 12 19940105 Metabotropic JJ B-NP O
2 13 22 19940105 glutamate NN I-NP D018698
3 23 24 19940105 7 CD I-NP O
4 25 33 19940105 receptor NN I-NP O
5 34 41 19940105 subtype NN I-NP O
6 42 51 19940105 modulates VBZ B-VP O
7 52 57 19940105 motor NN B-NP O
8 58 66 19940105 symptoms NNS I-NP O
9 67 69 19940105 in IN B-PP O
10 70 76 19940105 rodent NN B-NP O
11 77 83 19940105 models NNS I-NP O
12 84 86 19940105 of IN B-PP O
13 87 98 19940105 Parkinson's NNS B-NP D010300
14 99 106 19940105 disease NN I-NP D010300
15 106 107 19940105 . . O O
16 108 120 19940105 Metabotropic JJ B-NP O
17 121 130 19940105 glutamate NN I-NP D018698
18 131 132 19940105 ( ( O O
19 132 136 19940105 mGlu NN B-NP O
20 136 137 19940105 ) ) O O
21 138 147 19940105 receptors NNS B-NP O
22 148 156 19940105 modulate VBP B-VP O
23 157 165 19940105 synaptic JJ B-NP O
24 166 178 19940105 transmission NN I-NP O
25 179 181 19940105 in IN B-PP O
26 182 185 19940105 the DT B-NP O
27 186 193 19940105 central JJ I-NP O
28 194 201 19940105 nervous JJ I-NP O
29 202 208 19940105 system NN I-NP O
30 209 212 19940105 and CC O O
31 213 222 19940105 represent VBP B-VP O
32 223 232 19940105 promising JJ B-NP O
33 233 244 19940105 therapeutic JJ I-NP O
34 245 252 19940105 targets NNS I-NP O
35 253 256 19940105 for IN B-PP O
36 257 268 19940105 symptomatic JJ B-NP O
37 269 278 19940105 treatment NN I-NP O
38 279 281 19940105 of IN B-PP O
39 282 293 19940105 Parkinson's NNS B-NP D010300
40 294 301 19940105 disease NN B-NP D010300
41 302 303 19940105 ( ( O O
42 303 305 19940105 PD NN B-NP D010300
43 305 306 19940105 ) ) O O
44 306 307 19940105 . . O O

1 308 313 19940105 Among IN B-PP O
2 314 317 19940105 the DT B-NP O
3 318 323 19940105 eight CD I-NP O
4 324 328 19940105 mGlu NN I-NP O
5 329 337 19940105 receptor NN I-NP O
6 338 346 19940105 subtypes NNS I-NP O
7 346 347 19940105 , , O O
8 348 353 19940105 mGlu7 NN B-NP O
9 354 362 19940105 receptor NN I-NP O
10 363 365 19940105 is VBZ B-VP O
11 366 377 19940105 prominently RB I-VP O
12 378 387 19940105 expressed VBN I-VP O
13 388 390 19940105 in IN B-PP O
14 391 394 19940105 the DT B-NP O
15 395 400 19940105 basal JJ I-NP O
16 401 408 19940105 ganglia NNS I-NP O
17 408 409 19940105 , , O O
18 410 413 19940105 but CC O O
19 414 417 19940105 its PRP$ B-NP O
20 418 422 19940105 role NN I-NP O
21 423 425 19940105 in IN B-PP O
22 426 435 19940105 restoring VBG B-VP O
23 436 441 19940105 motor NN B-NP O
24 442 450 19940105 function NN I-NP O
25 451 453 19940105 in IN B-PP O
26 454 460 19940105 animal NN B-NP O
27 461 467 19940105 models NNS I-NP O
28 468 470 19940105 of IN B-PP O
29 471 473 19940105 PD NN B-NP D010300
30 474 476 19940105 is VBZ B-VP O
31 477 480 19940105 not RB I-VP O
32 481 486 19940105 known VBN I-VP O
33 486 487 19940105 . . O O

1 488 491 19940105 The DT B-NP O
2 492 499 19940105 effects NNS I-NP O
3 500 502 19940105 of IN B-PP O
4 503 507 19940105 N,N' NN B-NP C507346
5 507 508 19940105 - HYPH B-NP C507346
6 508 526 19940105 dibenzhydrylethane NN I-NP C507346
7 526 527 19940105 - HYPH B-NP C507346
8 527 530 19940105 1,2 CD I-NP C507346
9 530 531 19940105 - HYPH I-NP C507346
10 531 538 19940105 diamine NN I-NP C507346
11 539 554 19940105 dihydrochloride NN I-NP C507346
12 555 556 19940105 ( ( O O
13 556 562 19940105 AMN082 NN B-NP C507346
14 562 563 19940105 ) ) O O
15 563 564 19940105 , , O O
16 565 568 19940105 the DT B-NP O
17 569 574 19940105 first JJ I-NP O
18 575 584 19940105 selective JJ I-NP O
19 585 595 19940105 allosteric JJ I-NP O
20 596 605 19940105 activator NN I-NP O
21 606 608 19940105 of IN B-PP O
22 609 614 19940105 mGlu7 NN B-NP O
23 615 624 19940105 receptors NNS I-NP O
24 624 625 19940105 , , O O
25 626 630 19940105 were VBD B-VP O
26 631 635 19940105 thus RB I-VP O
27 636 642 19940105 tested VBN I-VP O
28 643 645 19940105 in IN B-PP O
29 646 655 19940105 different JJ B-NP O
30 656 662 19940105 rodent NN I-NP O
31 663 669 19940105 models NNS I-NP O
32 670 672 19940105 of IN B-PP O
33 673 675 19940105 PD NN B-NP D010300
34 675 676 19940105 . . O O

1 677 681 19940105 Here RB B-ADVP O
2 681 682 19940105 , , O O
3 683 685 19940105 we PRP B-NP O
4 686 690 19940105 show VBP B-VP O
5 691 695 19940105 that IN B-SBAR O
6 696 700 19940105 oral JJ B-NP O
7 701 702 19940105 ( ( O O
8 702 703 19940105 5 CD B-NP O
9 704 706 19940105 mg NN I-NP O
10 706 707 19940105 / SYM B-NP O
11 707 709 19940105 kg NN I-NP O
12 709 710 19940105 ) ) O O
13 711 713 19940105 or CC O O
14 714 727 19940105 intrastriatal JJ B-NP O
15 728 742 19940105 administration NN I-NP O
16 743 744 19940105 ( ( O O
17 744 747 19940105 0.1 CD B-NP O
18 748 751 19940105 and CC I-NP O
19 752 755 19940105 0.5 CD I-NP O
20 756 760 19940105 nmol NN I-NP O
21 760 761 19940105 ) ) O O
22 762 764 19940105 of IN B-PP O
23 765 771 19940105 AMN082 NN B-NP C507346
24 772 780 19940105 reverses VBZ B-VP O
25 781 792 19940105 haloperidol NN B-NP D006220
26 792 793 19940105 - HYPH B-NP O
27 793 800 19940105 induced VBN I-NP O
28 801 810 19940105 catalepsy NN I-NP D002375
29 811 813 19940105 in IN B-PP O
30 814 818 19940105 rats NNS B-NP O
31 818 819 19940105 . . O O

1 820 826 19940105 AMN082 NN B-NP C507346
2 827 828 19940105 ( ( O O
3 828 831 19940105 2.5 CD B-NP O
4 832 835 19940105 and CC I-NP O
5 836 837 19940105 5 CD I-NP O
6 838 840 19940105 mg NN I-NP O
7 840 841 19940105 / SYM B-NP O
8 841 843 19940105 kg NN I-NP O
9 843 844 19940105 ) ) O O
10 845 852 19940105 reduces VBZ B-VP O
11 853 864 19940105 apomorphine NN B-NP D001058
12 864 865 19940105 - HYPH B-NP O
13 865 872 19940105 induced VBN I-NP O
14 873 882 19940105 rotations NNS I-NP O
15 883 885 19940105 in IN B-PP O
16 886 896 19940105 unilateral JJ B-NP O
17 897 898 19940105 6 CD I-NP D016627
18 898 899 19940105 - HYPH I-NP D016627
19 899 914 19940105 hydroxydopamine NN I-NP D016627
20 915 917 19940105 (6 CD I-NP D016627
21 917 918 19940105 - HYPH I-NP D016627
22 918 923 19940105 OHDA) NN I-NP D016627
23 923 924 19940105 - HYPH B-NP O
24 924 932 19940105 lesioned VBN I-NP O
25 933 937 19940105 rats NNS I-NP O
26 937 938 19940105 . . O O

1 939 941 19940105 In IN B-PP O
2 942 943 19940105 a DT B-NP O
3 944 948 19940105 more RBR I-NP O
4 949 956 19940105 complex JJ I-NP O
5 957 961 19940105 task NN I-NP O
6 962 970 19940105 commonly RB B-VP O
7 971 975 19940105 used VBN I-VP O
8 976 978 19940105 to TO B-VP O
9 979 987 19940105 evaluate VB I-VP O
10 988 993 19940105 major JJ B-NP O
11 994 1002 19940105 akinetic JJ I-NP D018476
12 1003 1011 19940105 symptoms NNS I-NP O
13 1012 1014 19940105 of IN B-PP O
14 1015 1017 19940105 PD NN B-NP D010300
15 1018 1026 19940105 patients NNS I-NP O
16 1026 1027 19940105 , , O O
17 1028 1029 19940105 5 CD B-NP O
18 1030 1032 19940105 mg NN I-NP O
19 1032 1033 19940105 / SYM B-NP O
20 1033 1035 19940105 kg NN I-NP O
21 1036 1042 19940105 AMN082 NN I-NP C507346
22 1043 1051 19940105 reverses VBZ B-VP O
23 1052 1055 19940105 the DT B-NP O
24 1056 1065 19940105 increased VBN I-NP O
25 1066 1074 19940105 reaction NN I-NP O
26 1075 1079 19940105 time NN I-NP O
27 1080 1082 19940105 to TO B-VP O
28 1083 1090 19940105 respond VB I-VP O
29 1091 1093 19940105 to TO B-PP O
30 1094 1095 19940105 a DT B-NP O
31 1096 1099 19940105 cue NN I-NP O
32 1100 1102 19940105 of IN B-PP O
33 1103 1112 19940105 bilateral JJ B-NP O
34 1113 1114 19940105 6 CD I-NP D016627
35 1114 1115 19940105 - HYPH I-NP D016627
36 1115 1119 19940105 OHDA NN I-NP D016627
37 1119 1120 19940105 - HYPH I-NP O
38 1120 1128 19940105 lesioned VBN I-NP O
39 1129 1133 19940105 rats NNS I-NP O
40 1133 1134 19940105 . . O O

1 1135 1137 19940105 In IN B-PP O
2 1138 1146 19940105 addition NN B-NP O
3 1146 1147 19940105 , , O O
4 1148 1154 19940105 AMN082 NN B-NP C507346
5 1155 1162 19940105 reduces VBZ B-VP O
6 1163 1166 19940105 the DT B-NP O
7 1167 1175 19940105 duration NN I-NP O
8 1176 1178 19940105 of IN B-PP O
9 1179 1190 19940105 haloperidol NN B-NP D006220
10 1190 1191 19940105 - HYPH B-NP O
11 1191 1198 19940105 induced VBN I-NP O
12 1199 1208 19940105 catalepsy NN I-NP D002375
13 1209 1211 19940105 in IN B-PP O
14 1212 1213 19940105 a DT B-NP O
15 1214 1219 19940105 mGlu7 NN I-NP O
16 1220 1228 19940105 receptor NN I-NP O
17 1228 1229 19940105 - HYPH B-NP O
18 1229 1238 19940105 dependent JJ I-NP O
19 1239 1245 19940105 manner NN I-NP O
20 1246 1248 19940105 in IN B-PP O
21 1249 1253 19940105 wild JJ B-NP O
22 1253 1254 19940105 - HYPH I-NP O
23 1254 1258 19940105 type NN I-NP O
24 1259 1262 19940105 but CC B-NP O
25 1263 1266 19940105 not RB I-NP O
26 1267 1272 19940105 mGlu7 NN B-NP O
27 1273 1281 19940105 receptor NN I-NP O
28 1282 1290 19940105 knockout NN I-NP O
29 1291 1295 19940105 mice NNS I-NP O
30 1295 1296 19940105 . . O O

1 1297 1303 19940105 Higher JJR B-NP O
2 1304 1309 19940105 doses NNS I-NP O
3 1310 1312 19940105 of IN B-PP O
4 1313 1319 19940105 AMN082 NN B-NP C507346
5 1320 1321 19940105 ( ( O O
6 1321 1323 19940105 10 CD B-NP O
7 1324 1327 19940105 and CC I-NP O
8 1328 1330 19940105 20 CD I-NP O
9 1331 1333 19940105 mg NN I-NP O
10 1333 1334 19940105 / SYM O O
11 1334 1336 19940105 kg NN B-NP O
12 1337 1340 19940105 p.o NN I-NP O
13 1340 1341 19940105 . . O O
14 1341 1342 19940105 ) ) O O
15 1343 1347 19940105 have VBP B-VP O
16 1348 1350 19940105 no DT B-NP O
17 1351 1357 19940105 effect NN I-NP O
18 1358 1360 19940105 on IN B-PP O
19 1361 1364 19940105 the DT B-NP O
20 1365 1369 19940105 same JJ I-NP O
21 1370 1376 19940105 models NNS I-NP O
22 1377 1379 19940105 of IN B-PP O
23 1380 1382 19940105 PD NN B-NP D010300
24 1382 1383 19940105 . . O O

1 1384 1391 19940105 Overall RB B-ADVP O
2 1392 1397 19940105 these DT B-NP O
3 1398 1406 19940105 findings NNS I-NP O
4 1407 1414 19940105 suggest VBP B-VP O
5 1415 1419 19940105 that IN B-SBAR O
6 1420 1425 19940105 mGlu7 NN B-NP O
7 1426 1434 19940105 receptor NN I-NP O
8 1435 1445 19940105 activation NN I-NP O
9 1446 1449 19940105 can MD B-VP O
10 1450 1457 19940105 reverse VB I-VP O
11 1458 1463 19940105 motor NN B-NP O
12 1464 1475 19940105 dysfunction NN I-NP O
13 1476 1486 19940105 associated VBN B-VP O
14 1487 1491 19940105 with IN B-PP O
15 1492 1499 19940105 reduced VBN B-NP O
16 1500 1508 19940105 dopamine NN I-NP D004298
17 1509 1517 19940105 activity NN I-NP O
18 1517 1518 19940105 . . O O

1 1519 1528 19940105 Selective JJ B-NP O
2 1529 1536 19940105 ligands NNS I-NP O
3 1537 1539 19940105 of IN B-PP O
4 1540 1545 19940105 mGlu7 NN B-NP O
5 1546 1554 19940105 receptor NN I-NP O
6 1555 1563 19940105 subtypes NNS I-NP O
7 1564 1567 19940105 may MD B-VP O
8 1568 1572 19940105 thus RB I-VP O
9 1573 1575 19940105 be VB I-VP O
10 1576 1586 19940105 considered VBN I-VP O
11 1587 1589 19940105 as IN B-PP O
12 1590 1599 19940105 promising JJ B-NP O
13 1600 1609 19940105 compounds NNS I-NP O
14 1610 1613 19940105 for IN B-PP O
15 1614 1617 19940105 the DT B-NP O
16 1618 1629 19940105 development NN I-NP O
17 1630 1632 19940105 of IN B-PP O
18 1633 1649 19940105 antiparkinsonian JJ B-NP O
19 1650 1661 19940105 therapeutic JJ I-NP O
20 1662 1672 19940105 strategies NNS I-NP O
21 1672 1673 19940105 . . O O

1 0 0 1711760 -DOCSTART- -X- -X- O

1 0 7 1711760 Delayed VBN B-NP O
2 8 19 1711760 institution NN I-NP O
3 20 22 1711760 of IN B-PP O
4 23 35 1711760 hypertension NN B-NP D006973
5 36 42 1711760 during IN B-PP O
6 43 48 1711760 focal JJ B-NP O
7 49 57 1711760 cerebral JJ I-NP D002545
8 58 66 1711760 ischemia NN I-NP D002545
9 66 67 1711760 : : O O
10 68 74 1711760 effect NN B-NP O
11 75 77 1711760 on IN B-PP O
12 78 83 1711760 brain NN B-NP D001929
13 84 89 1711760 edema NN I-NP D001929
14 89 90 1711760 . . O O
15 91 94 1711760 The DT B-NP O
16 95 101 1711760 effect NN I-NP O
17 102 104 1711760 of IN B-PP O
18 105 112 1711760 induced VBN B-NP O
19 113 125 1711760 hypertension NN I-NP D006973
20 126 136 1711760 instituted VBN B-VP O
21 137 142 1711760 after IN B-PP O
22 143 144 1711760 a DT B-NP O
23 145 146 1711760 2 CD I-NP O
24 146 147 1711760 - HYPH I-NP O
25 147 148 1711760 h NN I-NP O
26 149 154 1711760 delay NN I-NP O
27 155 164 1711760 following VBG B-PP O
28 165 171 1711760 middle JJ B-NP D020244
29 172 180 1711760 cerebral JJ I-NP D020244
30 181 187 1711760 artery NN I-NP D020244
31 188 197 1711760 occlusion NN I-NP D020244
32 198 199 1711760 ( ( O O
33 199 203 1711760 MCAO NN B-NP D020244
34 203 204 1711760 ) ) O O
35 205 207 1711760 on IN B-PP O
36 208 213 1711760 brain NN B-NP D001929
37 214 219 1711760 edema NN I-NP D001929
38 220 229 1711760 formation NN I-NP O
39 230 233 1711760 and CC O O
40 234 247 1711760 histochemical JJ B-NP O
41 248 254 1711760 injury NN I-NP O
42 255 258 1711760 was VBD B-VP O
43 259 266 1711760 studied VBN I-VP O
44 266 267 1711760 . . O O

1 268 273 1711760 Under IN B-PP O
2 274 284 1711760 isoflurane NN B-NP D007530
3 285 295 1711760 anesthesia NN I-NP O
4 295 296 1711760 , , O O
5 297 300 1711760 the DT B-NP O
6 301 304 1711760 MCA NNP I-NP O
7 305 307 1711760 of IN B-PP O
8 308 310 1711760 14 CD B-NP O
9 311 324 1711760 spontaneously RB I-NP O
10 325 337 1711760 hypertensive JJ I-NP D006973
11 338 342 1711760 rats NNS I-NP O
12 343 346 1711760 was VBD B-VP O
13 347 355 1711760 occluded VBN I-VP O
14 355 356 1711760 . . O O

1 357 359 1711760 In IN B-PP O
2 360 363 1711760 the DT B-NP O
3 364 371 1711760 control NN I-NP O
4 372 377 1711760 group NN I-NP O
5 378 379 1711760 ( ( O O
6 379 380 1711760 n NN B-NP O
7 381 382 1711760 = SYM B-VP O
8 383 384 1711760 7 CD B-NP O
9 384 385 1711760 ) ) O O
10 385 386 1711760 , , O O
11 387 390 1711760 the DT B-NP O
12 391 395 1711760 mean JJ I-NP O
13 396 404 1711760 arterial JJ I-NP O
14 405 413 1711760 pressure NN I-NP O
15 414 415 1711760 ( ( O O
16 415 418 1711760 MAP NN B-NP O
17 418 419 1711760 ) ) O O
18 420 423 1711760 was VBD B-VP O
19 424 427 1711760 not RB I-VP O
20 428 439 1711760 manipulated VBN I-VP O
21 439 440 1711760 . . O O

1 441 443 1711760 In IN B-PP O
2 444 447 1711760 the DT B-NP O
3 448 460 1711760 hypertensive JJ I-NP D006973
4 461 466 1711760 group NN I-NP O
5 467 468 1711760 ( ( O O
6 468 469 1711760 n NN B-NP O
7 470 471 1711760 = SYM B-VP O
8 472 473 1711760 7 CD B-NP O
9 473 474 1711760 ) ) O O
10 474 475 1711760 , , O O
11 476 479 1711760 the DT B-NP O
12 480 483 1711760 MAP NN I-NP O
13 484 487 1711760 was VBD B-VP O
14 488 496 1711760 elevated VBN I-VP O
15 497 499 1711760 by IN B-PP O
16 500 502 1711760 25 CD B-NP O
17 502 503 1711760 - HYPH I-NP O
18 503 505 1711760 30 CD I-NP O
19 506 508 1711760 mm NN I-NP O
20 509 511 1711760 Hg NN I-NP O
21 512 521 1711760 beginning VBG B-VP O
22 522 523 1711760 2 CD B-NP O
23 524 525 1711760 h NN I-NP O
24 526 531 1711760 after IN B-PP O
25 532 536 1711760 MCAO NN B-NP D020244
26 536 537 1711760 . . O O

1 538 542 1711760 Four CD B-NP O
2 543 548 1711760 hours NNS I-NP O
3 549 554 1711760 after IN B-PP O
4 555 559 1711760 MCAO NN B-NP D020244
5 559 560 1711760 , , O O
6 561 564 1711760 the DT B-NP O
7 565 569 1711760 rats NNS I-NP O
8 570 574 1711760 were VBD B-VP O
9 575 581 1711760 killed VBN I-VP O
10 582 585 1711760 and CC O O
11 586 589 1711760 the DT B-NP O
12 590 596 1711760 brains NNS I-NP O
13 597 606 1711760 harvested VBD B-VP O
14 606 607 1711760 . . O O

1 608 611 1711760 The DT B-NP O
2 612 618 1711760 brains NNS I-NP O
3 619 623 1711760 were VBD B-VP O
4 624 633 1711760 sectioned VBN I-VP O
5 634 639 1711760 along IN B-PP O
6 640 647 1711760 coronal JJ B-NP O
7 648 654 1711760 planes NNS I-NP O
8 655 663 1711760 spanning VBG B-VP O
9 664 667 1711760 the DT B-NP O
10 668 680 1711760 distribution NN I-NP O
11 681 683 1711760 of IN B-PP O
12 684 692 1711760 ischemia NN B-NP D007511
13 693 701 1711760 produced VBN B-VP O
14 702 704 1711760 by IN B-PP O
15 705 709 1711760 MCAO NN B-NP D020244
16 709 710 1711760 . . O O

1 711 719 1711760 Specific JJ B-NP O
2 720 727 1711760 gravity NN I-NP O
3 728 729 1711760 ( ( O O
4 729 731 1711760 SG NN B-NP O
5 731 732 1711760 ) ) O O
6 733 736 1711760 was VBD B-VP O
7 737 747 1711760 determined VBN I-VP O
8 748 750 1711760 in IN B-PP O
9 751 754 1711760 the DT B-NP O
10 755 764 1711760 subcortex NN I-NP O
11 765 768 1711760 and CC O O
12 769 771 1711760 in IN B-PP O
13 772 775 1711760 two CD B-NP O
14 776 781 1711760 sites NNS I-NP O
15 782 784 1711760 in IN B-PP O
16 785 788 1711760 the DT B-NP O
17 789 795 1711760 cortex NN I-NP O
18 796 797 1711760 ( ( O O
19 797 801 1711760 core NN B-NP O
20 802 805 1711760 and CC O O
21 806 815 1711760 periphery NN B-NP O
22 816 818 1711760 of IN B-PP O
23 819 822 1711760 the DT B-NP O
24 823 831 1711760 ischemic JJ I-NP D007511
25 832 841 1711760 territory NN I-NP O
26 841 842 1711760 ) ) O O
27 842 843 1711760 . . O O

1 844 847 1711760 The DT B-NP O
2 848 854 1711760 extent NN I-NP O
3 855 857 1711760 of IN B-PP O
4 858 866 1711760 neuronal JJ B-NP D009410
5 867 873 1711760 injury NN I-NP D009410
6 874 877 1711760 was VBD B-VP O
7 878 888 1711760 determined VBN I-VP O
8 889 891 1711760 by IN B-PP O
9 892 897 1711760 2,3,5 NN B-NP C009591
10 897 898 1711760 - HYPH I-NP C009591
11 898 918 1711760 triphenyltetrazolium NN I-NP C009591
12 919 927 1711760 staining NN I-NP O
13 927 928 1711760 . . O O

1 929 931 1711760 In IN B-PP O
2 932 935 1711760 the DT B-NP O
3 936 944 1711760 ischemic JJ I-NP D007511
4 945 949 1711760 core NN I-NP O
5 949 950 1711760 , , O O
6 951 956 1711760 there EX B-NP O
7 957 960 1711760 was VBD B-VP O
8 961 963 1711760 no DT B-NP O
9 964 974 1711760 difference NN I-NP O
10 975 977 1711760 in IN B-PP O
11 978 980 1711760 SG NN B-NP O
12 981 983 1711760 in IN B-PP O
13 984 987 1711760 the DT B-NP O
14 988 997 1711760 subcortex NN I-NP O
15 998 1001 1711760 and CC I-NP O
16 1002 1008 1711760 cortex NN I-NP O
17 1009 1011 1711760 in IN B-PP O
18 1012 1015 1711760 the DT B-NP O
19 1016 1019 1711760 two CD I-NP O
20 1020 1026 1711760 groups NNS I-NP O
21 1026 1027 1711760 . . O O

1 1028 1030 1711760 In IN B-PP O
2 1031 1034 1711760 the DT B-NP O
3 1035 1044 1711760 periphery NN I-NP O
4 1045 1047 1711760 of IN B-PP O
5 1048 1051 1711760 the DT B-NP O
6 1052 1060 1711760 ischemic JJ I-NP D007511
7 1061 1070 1711760 territory NN I-NP O
8 1070 1071 1711760 , , O O
9 1072 1074 1711760 SG NN B-NP O
10 1075 1077 1711760 in IN B-PP O
11 1078 1081 1711760 the DT B-NP O
12 1082 1088 1711760 cortex NN I-NP O
13 1089 1092 1711760 was VBD B-VP O
14 1093 1100 1711760 greater JJR B-ADJP O
15 1101 1102 1711760 ( ( O O
16 1102 1106 1711760 less JJR B-NP O
17 1107 1112 1711760 edema NN I-NP D004487
18 1113 1125 1711760 accumulation NN I-NP O
19 1125 1126 1711760 ) ) O O
20 1127 1129 1711760 in IN B-PP O
21 1130 1133 1711760 the DT B-NP O
22 1134 1146 1711760 hypertensive JJ I-NP D006973
23 1147 1152 1711760 group NN I-NP O
24 1153 1154 1711760 ( ( O O
25 1154 1159 1711760 1.041 CD B-NP O
26 1160 1161 1711760 + SYM O O
27 1161 1162 1711760 / SYM O O
28 1162 1163 1711760 - SYM O O
29 1164 1169 1711760 0.001 CD B-NP O
30 1170 1172 1711760 vs IN I-NP O
31 1173 1178 1711760 1.039 CD I-NP O
32 1179 1180 1711760 + SYM O O
33 1180 1181 1711760 / SYM O O
34 1181 1182 1711760 - SYM O O
35 1183 1188 1711760 0.001 CD B-NP O
36 1188 1189 1711760 , , O O
37 1190 1191 1711760 P NN B-NP O
38 1192 1196 1711760 less JJR B-ADJP O
39 1197 1201 1711760 than IN B-PP O
40 1202 1206 1711760 0.05 CD B-NP O
41 1206 1207 1711760 ) ) O O
42 1207 1208 1711760 . . O O

1 1209 1212 1711760 The DT B-NP O
2 1213 1217 1711760 area NN I-NP O
3 1218 1220 1711760 of IN B-PP O
4 1221 1234 1711760 histochemical JJ B-NP O
5 1235 1241 1711760 injury NN I-NP O
6 1242 1243 1711760 ( ( O O
7 1243 1245 1711760 as IN B-PP O
8 1246 1247 1711760 a DT B-NP O
9 1248 1255 1711760 percent NN I-NP O
10 1256 1258 1711760 of IN B-PP O
11 1259 1262 1711760 the DT B-NP O
12 1263 1268 1711760 cross AFX I-NP O
13 1268 1269 1711760 - HYPH I-NP O
14 1269 1278 1711760 sectional JJ I-NP O
15 1279 1283 1711760 area NN I-NP O
16 1284 1286 1711760 of IN B-PP O
17 1287 1290 1711760 the DT B-NP O
18 1291 1301 1711760 hemisphere NN I-NP O
19 1301 1302 1711760 ) ) O O
20 1303 1306 1711760 was VBD B-VP O
21 1307 1311 1711760 less JJR B-ADJP O
22 1312 1314 1711760 in IN B-PP O
23 1315 1318 1711760 the DT B-NP O
24 1319 1331 1711760 hypertensive JJ I-NP D006973
25 1332 1337 1711760 group NN I-NP O
26 1338 1339 1711760 ( ( O O
27 1339 1341 1711760 33 CD B-NP O
28 1342 1343 1711760 + SYM O O
29 1343 1344 1711760 / SYM O O
30 1344 1345 1711760 - SYM O O
31 1346 1348 1711760 3% CD B-NP O
32 1349 1351 1711760 vs IN I-NP O
33 1352 1354 1711760 21 CD I-NP O
34 1355 1356 1711760 + SYM O O
35 1356 1357 1711760 / SYM O O
36 1357 1358 1711760 - SYM O O
37 1359 1361 1711760 2% NN B-NP O
38 1361 1362 1711760 , , O O
39 1363 1364 1711760 P NN B-NP O
40 1365 1369 1711760 less JJR B-ADJP O
41 1370 1374 1711760 than IN B-PP O
42 1375 1379 1711760 0.05 CD B-NP O
43 1379 1380 1711760 ) ) O O
44 1380 1381 1711760 . . O O

1 1382 1385 1711760 The DT B-NP O
2 1386 1390 1711760 data NNS I-NP O
3 1391 1399 1711760 indicate VBP B-VP O
4 1400 1404 1711760 that IN B-SBAR O
5 1405 1418 1711760 phenylephrine NN B-NP D010656
6 1418 1419 1711760 - HYPH B-NP O
7 1419 1426 1711760 induced VBN I-NP O
8 1427 1439 1711760 hypertension NN I-NP D006973
9 1440 1450 1711760 instituted VBN B-VP O
10 1451 1452 1711760 2 CD B-NP O
11 1453 1454 1711760 h NN I-NP O
12 1455 1460 1711760 after IN B-SBAR O
13 1461 1465 1711760 MCAO NN B-NP D020244
14 1466 1470 1711760 does VBZ B-VP O
15 1471 1474 1711760 not RB I-VP O
16 1475 1484 1711760 aggravate VB I-VP O
17 1485 1490 1711760 edema NN B-NP D004487
18 1491 1493 1711760 in IN B-PP O
19 1494 1497 1711760 the DT B-NP O
20 1498 1506 1711760 ischemic JJ I-NP D007511
21 1507 1511 1711760 core NN I-NP O
22 1511 1512 1711760 , , O O
23 1513 1517 1711760 that IN B-SBAR O
24 1518 1520 1711760 it PRP B-NP O
25 1521 1529 1711760 improves VBZ B-VP O
26 1530 1535 1711760 edema NN B-NP D004487
27 1536 1538 1711760 in IN B-PP O
28 1539 1542 1711760 the DT B-NP O
29 1543 1552 1711760 periphery NN I-NP O
30 1553 1555 1711760 of IN B-PP O
31 1556 1559 1711760 the DT B-NP O
32 1560 1568 1711760 ischemic JJ I-NP D007511
33 1569 1578 1711760 territory NN I-NP O
34 1578 1579 1711760 , , O O
35 1580 1583 1711760 and CC O O
36 1584 1588 1711760 that IN B-SBAR O
37 1589 1591 1711760 it PRP B-NP O
38 1592 1599 1711760 reduces VBZ B-VP O
39 1600 1603 1711760 the DT B-NP O
40 1604 1608 1711760 area NN I-NP O
41 1609 1611 1711760 of IN B-PP O
42 1612 1625 1711760 histochemical JJ B-NP O
43 1626 1634 1711760 neuronal JJ I-NP D009410
44 1635 1646 1711760 dysfunction NN I-NP D009410
45 1646 1647 1711760 . . O O

1 0 0 8586822 -DOCSTART- -X- -X- O

1 0 12 8586822 Contribution NN B-NP O
2 13 15 8586822 of IN B-PP O
3 16 19 8586822 the DT B-NP O
4 20 31 8586822 sympathetic JJ I-NP O
5 32 39 8586822 nervous JJ I-NP O
6 40 46 8586822 system NN I-NP O
7 47 49 8586822 to TO B-PP O
8 50 54 8586822 salt NN B-NP O
9 54 55 8586822 - HYPH B-NP O
10 55 66 8586822 sensitivity NN I-NP O
11 67 69 8586822 in IN B-PP O
12 70 78 8586822 lifetime NN B-NP O
13 79 88 8586822 captopril NN I-NP D002216
14 88 89 8586822 - HYPH O O
15 89 96 8586822 treated VBN B-VP O
16 97 110 8586822 spontaneously RB B-NP O
17 111 123 8586822 hypertensive JJ I-NP D006973
18 124 128 8586822 rats NNS I-NP O
19 128 129 8586822 . . O O
20 130 139 8586822 OBJECTIVE NN B-NP O
21 139 140 8586822 : : O O
22 141 143 8586822 To TO B-VP O
23 144 148 8586822 test VB I-VP O
24 149 152 8586822 the DT B-NP O
25 153 163 8586822 hypothesis NN I-NP O
26 164 168 8586822 that IN B-NP O
27 168 169 8586822 , , O O
28 170 172 8586822 in IN B-PP O
29 173 181 8586822 lifetime NN B-NP O
30 182 191 8586822 captopril NN I-NP D002216
31 191 192 8586822 - HYPH O O
32 192 199 8586822 treated VBN B-VP O
33 200 213 8586822 spontaneously RB B-NP O
34 214 226 8586822 hypertensive JJ I-NP D006973
35 227 231 8586822 rats NNS I-NP O
36 232 233 8586822 ( ( O O
37 233 236 8586822 SHR NN B-NP O
38 236 237 8586822 ) ) O O
39 237 238 8586822 , , O O
40 239 242 8586822 the DT B-NP O
41 243 254 8586822 sympathetic JJ I-NP O
42 255 262 8586822 nervous JJ I-NP O
43 263 269 8586822 system NN I-NP O
44 270 281 8586822 contributes VBZ B-VP O
45 282 293 8586822 importantly RB B-ADVP O
46 294 296 8586822 to TO B-PP O
47 297 300 8586822 the DT B-NP O
48 301 313 8586822 hypertensive JJ I-NP D006973
49 314 320 8586822 effect NN I-NP O
50 321 323 8586822 of IN B-PP O
51 324 331 8586822 dietary JJ B-NP D017673
52 332 338 8586822 sodium NN I-NP D017673
53 339 347 8586822 chloride NN I-NP D017673
54 348 363 8586822 supplementation NN I-NP O
55 363 364 8586822 . . O O

1 365 372 8586822 METHODS NNS B-NP O
2 372 373 8586822 : : O O
3 374 378 8586822 Male JJ B-NP O
4 379 382 8586822 SHR NN I-NP O
5 383 384 8586822 ( ( O O
6 384 388 8586822 aged JJ B-NP O
7 389 390 8586822 6 CD I-NP O
8 391 396 8586822 weeks NNS I-NP O
9 396 397 8586822 ) ) O O
10 398 402 8586822 that WDT B-NP O
11 403 406 8586822 had VBD B-VP O
12 407 411 8586822 been VBN I-VP O
13 412 419 8586822 treated VBN I-VP O
14 420 424 8586822 from IN B-PP O
15 425 435 8586822 conception NN B-NP O
16 436 442 8586822 onward RB B-ADVP O
17 443 447 8586822 with IN B-PP O
18 448 454 8586822 either CC O O
19 455 464 8586822 captopril NN B-NP D002216
20 465 467 8586822 or CC I-NP O
21 468 475 8586822 vehicle NN I-NP O
22 476 484 8586822 remained VBD B-VP O
23 485 487 8586822 on IN B-PP O
24 488 489 8586822 a DT B-NP O
25 490 495 8586822 basal JJ I-NP O
26 496 502 8586822 sodium NN I-NP D012965
27 503 511 8586822 chloride NN I-NP D012965
28 512 516 8586822 diet NN I-NP O
29 517 519 8586822 or CC O O
30 520 524 8586822 were VBD B-VP O
31 525 528 8586822 fed VBN I-VP O
32 529 530 8586822 a DT B-NP O
33 531 535 8586822 high JJ I-NP O
34 536 542 8586822 sodium NN I-NP D012965
35 543 551 8586822 chloride NN I-NP D012965
36 552 556 8586822 diet NN I-NP O
37 556 557 8586822 . . O O

1 558 563 8586822 After IN B-PP O
2 564 565 8586822 2 CD B-NP O
3 566 571 8586822 weeks NNS I-NP O
4 571 572 8586822 , , O O
5 573 576 8586822 the DT B-NP O
6 577 581 8586822 rats NNS I-NP O
7 582 586 8586822 were VBD B-VP O
8 587 596 8586822 subjected VBN I-VP O
9 597 599 8586822 to TO B-PP O
10 600 610 8586822 ganglionic JJ B-NP O
11 611 619 8586822 blockade NN I-NP O
12 620 623 8586822 and CC O O
13 624 625 8586822 2 CD B-NP O
14 626 630 8586822 days NNS I-NP O
15 631 636 8586822 later RB B-ADVP O
16 636 637 8586822 , , O O
17 638 640 8586822 an DT B-NP O
18 641 649 8586822 infusion NN I-NP O
19 650 652 8586822 of IN B-PP O
20 653 662 8586822 clonidine NN B-NP D003000
21 662 663 8586822 . . O O

1 664 671 8586822 RESULTS NNS B-NP O
2 671 672 8586822 : : O O
3 673 681 8586822 Lifetime NN B-NP O
4 682 691 8586822 captopril NN I-NP D002216
5 692 701 8586822 treatment NN I-NP O
6 702 715 8586822 significantly RB B-ADVP O
7 716 723 8586822 lowered VBD B-VP O
8 724 728 8586822 mean JJ B-NP O
9 729 737 8586822 arterial JJ I-NP O
10 738 746 8586822 pressure NN I-NP O
11 747 749 8586822 in IN B-PP O
12 750 754 8586822 both DT B-NP O
13 755 761 8586822 groups NNS I-NP O
14 761 762 8586822 . . O O

1 763 774 8586822 Intravenous JJ B-NP O
2 775 783 8586822 infusion NN I-NP O
3 784 786 8586822 of IN B-PP O
4 787 790 8586822 the DT B-NP O
5 791 801 8586822 ganglionic JJ I-NP O
6 802 809 8586822 blocker NN I-NP O
7 810 823 8586822 hexamethonium NN I-NP D018738
8 824 832 8586822 resulted VBD B-VP O
9 833 835 8586822 in IN B-PP O
10 836 837 8586822 a DT B-NP O
11 838 843 8586822 rapid JJ I-NP O
12 844 851 8586822 decline NN I-NP O
13 852 854 8586822 in IN B-PP O
14 855 858 8586822 MAP NN B-NP O
15 859 863 8586822 that WDT B-NP O
16 864 874 8586822 eliminated VBD B-VP O
17 875 878 8586822 the DT B-NP O
18 879 886 8586822 dietary JJ I-NP D017673
19 887 893 8586822 sodium NN I-NP D017673
20 894 902 8586822 chloride NN I-NP D017673
21 902 903 8586822 - HYPH B-NP O
22 903 910 8586822 induced VBN I-NP O
23 911 919 8586822 increase NN I-NP D006973
24 920 922 8586822 in IN B-PP D006973
25 923 926 8586822 MAP NN B-NP D006973
26 927 929 8586822 in IN B-PP O
27 930 934 8586822 both DT B-NP O
28 935 941 8586822 groups NNS I-NP O
29 941 942 8586822 . . O O

1 943 951 8586822 Infusion NN B-NP O
2 952 954 8586822 of IN B-PP O
3 955 958 8586822 the DT B-NP O
4 959 966 8586822 central JJ I-NP O
5 967 974 8586822 nervous JJ I-NP O
6 975 981 8586822 system NN I-NP O
7 982 988 8586822 alpha2 NN I-NP D058647
8 988 989 8586822 - HYPH B-NP D058647
9 989 999 8586822 adrenergic JJ I-NP D058647
10 1000 1008 8586822 receptor NN I-NP D058647
11 1009 1016 8586822 agonist NN I-NP D058647
12 1017 1026 8586822 clonidine NN I-NP D003000
13 1027 1031 8586822 also RB B-ADVP O
14 1032 1040 8586822 resulted VBD B-VP O
15 1041 1043 8586822 in IN B-PP O
16 1044 1045 8586822 a DT B-NP O
17 1046 1053 8586822 greater JJR I-NP O
18 1054 1063 8586822 reduction NN I-NP O
19 1064 1066 8586822 in IN B-PP O
20 1067 1070 8586822 MAP NN B-NP O
21 1071 1073 8586822 in IN B-PP O
22 1074 1078 8586822 both DT B-NP O
23 1079 1085 8586822 groups NNS I-NP O
24 1086 1088 8586822 of IN B-PP O
25 1089 1092 8586822 SHR NN B-NP O
26 1093 1097 8586822 that WDT B-NP O
27 1098 1102 8586822 were VBD B-VP O
28 1103 1106 8586822 fed VBN I-VP O
29 1107 1110 8586822 the DT B-NP O
30 1111 1115 8586822 high JJ I-NP O
31 1116 1117 8586822 ( ( O O
32 1117 1125 8586822 compared VBN B-PP O
33 1126 1130 8586822 with IN B-PP O
34 1131 1134 8586822 the DT B-NP O
35 1135 1140 8586822 basal JJ I-NP O
36 1140 1141 8586822 ) ) I-NP O
37 1142 1148 8586822 sodium NN I-NP D012965
38 1149 1157 8586822 chloride NN I-NP D012965
39 1158 1162 8586822 diet NN I-NP O
40 1162 1163 8586822 . . O O

1 1164 1175 8586822 CONCLUSIONS NNS B-NP O
2 1175 1176 8586822 : : O O
3 1177 1179 8586822 In IN B-PP O
4 1180 1184 8586822 both CC O O
5 1185 1193 8586822 lifetime NN B-NP O
6 1194 1203 8586822 captopril NN I-NP D002216
7 1203 1204 8586822 - HYPH B-VP O
8 1204 1211 8586822 treated VBN I-VP O
9 1212 1215 8586822 and CC O O
10 1216 1223 8586822 control NN B-NP O
11 1224 1227 8586822 SHR NN I-NP O
12 1227 1228 8586822 , , O O
13 1229 1232 8586822 the DT B-NP O
14 1233 1244 8586822 sympathetic JJ I-NP O
15 1245 1252 8586822 nervous JJ I-NP O
16 1253 1259 8586822 system NN I-NP O
17 1260 1271 8586822 contributes VBZ B-VP O
18 1272 1274 8586822 to TO B-PP O
19 1275 1278 8586822 the DT B-NP O
20 1279 1286 8586822 pressor NN I-NP O
21 1287 1294 8586822 effects NNS I-NP O
22 1295 1297 8586822 of IN B-PP O
23 1298 1299 8586822 a DT B-NP O
24 1300 1304 8586822 high JJ I-NP O
25 1305 1311 8586822 sodium NN I-NP D012965
26 1312 1320 8586822 chloride NN I-NP D012965
27 1321 1325 8586822 diet NN I-NP O
28 1325 1326 8586822 . . O O

1 0 0 12851669 -DOCSTART- -X- -X- O

1 0 8 12851669 Absolute JJ B-NP O
2 9 12 12851669 and CC I-NP O
3 13 25 12851669 attributable JJ I-NP O
4 26 30 12851669 risk NN I-NP O
5 31 33 12851669 of IN B-PP O
6 34 40 12851669 venous JJ B-NP D054556
7 41 56 12851669 thromboembolism NN I-NP D054556
8 57 59 12851669 in IN B-PP O
9 60 65 12851669 women NNS B-NP O
10 66 68 12851669 on IN B-PP O
11 69 77 12851669 combined VBN B-NP O
12 78 89 12851669 cyproterone NN I-NP D017373
13 90 97 12851669 acetate NN I-NP D017373
14 98 101 12851669 and CC I-NP O
15 102 118 12851669 ethinylestradiol NN I-NP D004997
16 118 119 12851669 . . I-NP O
17 120 129 12851669 OBJECTIVE NN I-NP O
18 129 130 12851669 : : O O
19 131 133 12851669 To TO B-VP O
20 134 141 12851669 achieve VB I-VP O
21 142 150 12851669 absolute JJ B-NP O
22 151 155 12851669 risk NN I-NP O
23 156 165 12851669 estimates NNS I-NP O
24 166 168 12851669 of IN B-PP O
25 169 175 12851669 venous JJ B-NP D054556
26 176 191 12851669 thromboembolism NN I-NP D054556
27 192 193 12851669 ( ( O O
28 193 196 12851669 VTE NN B-NP D054556
29 196 197 12851669 ) ) O O
30 198 203 12851669 among IN B-PP O
31 204 209 12851669 women NNS B-NP O
32 210 212 12851669 on IN B-PP O
33 213 224 12851669 cyproterone NN B-NP D017373
34 225 232 12851669 acetate NN I-NP D017373
35 233 237 12851669 plus CC O O
36 238 254 12851669 ethinylestradiol NN B-NP D004997
37 255 256 12851669 ( ( O O
38 256 259 12851669 CPA NN B-NP D017373
39 259 260 12851669 / SYM O O
40 260 262 12851669 EE NN B-NP D004997
41 262 263 12851669 ) ) O O
42 263 264 12851669 , , O O
43 265 268 12851669 and CC O O
44 269 274 12851669 among IN B-PP O
45 275 280 12851669 women NNS B-NP O
46 281 283 12851669 on IN B-PP O
47 284 292 12851669 combined JJ B-NP D003277
48 293 297 12851669 oral JJ I-NP D003277
49 298 312 12851669 contraceptives NNS I-NP D003277
50 313 314 12851669 ( ( O O
51 314 318 12851669 COCs NNS B-NP D003277
52 318 319 12851669 ) ) O O
53 319 320 12851669 . . O O

1 321 328 12851669 METHODS NNS B-NP O
2 328 329 12851669 : : O O
3 330 334 12851669 From IN B-PP O
4 335 338 12851669 the DT B-NP O
5 339 345 12851669 Danish NNP I-NP O
6 346 354 12851669 National NNP I-NP O
7 355 363 12851669 Register NNP I-NP O
8 364 366 12851669 of IN B-PP O
9 367 375 12851669 Patients NNP B-NP O
10 376 377 12851669 ( ( O O
11 377 380 12851669 NRP NN B-NP O
12 380 381 12851669 ) ) O O
13 381 382 12851669 , , O O
14 383 387 12851669 1996 CD B-NP O
15 388 390 12851669 to TO B-PP O
16 391 395 12851669 1998 CD B-NP O
17 395 396 12851669 , , O O
18 397 400 12851669 the DT B-NP O
19 401 408 12851669 records NNS I-NP O
20 409 411 12851669 of IN B-PP O
21 412 415 12851669 1.1 CD B-NP O
22 416 423 12851669 million CD I-NP O
23 424 430 12851669 Danish JJ I-NP O
24 431 436 12851669 women NNS I-NP O
25 436 437 12851669 , , O O
26 438 442 12851669 ages NNS B-NP O
27 443 445 12851669 15 CD B-NP O
28 446 448 12851669 to TO I-NP O
29 449 451 12851669 44 CD I-NP O
30 452 457 12851669 years NNS I-NP O
31 457 458 12851669 , , O O
32 459 463 12851669 were VBD B-VP O
33 464 472 12851669 searched VBN I-VP O
34 473 476 12851669 for IN B-PP O
35 477 485 12851669 evidence NN B-NP O
36 486 488 12851669 of IN B-PP O
37 489 492 12851669 VTE NN B-NP D054556
38 492 493 12851669 . . O O

1 494 497 12851669 COC NN B-NP D003277
2 498 501 12851669 use NN I-NP O
3 502 505 12851669 was VBD B-VP O
4 506 517 12851669 ascertained VBN I-VP O
5 518 525 12851669 through IN B-PP O
6 526 532 12851669 mailed JJ B-NP O
7 533 547 12851669 questionnaires NNS I-NP O
8 547 548 12851669 . . O O

1 549 554 12851669 Sales NNS B-NP O
2 555 565 12851669 statistics NNS I-NP O
3 566 568 12851669 of IN B-PP O
4 569 573 12851669 COCs NNS B-NP D003277
5 574 577 12851669 and CC O O
6 578 581 12851669 CPA NN B-NP D017373
7 581 582 12851669 / SYM I-NP O
8 582 584 12851669 EE NN I-NP D004997
9 585 589 12851669 were VBD B-VP O
10 590 598 12851669 provided VBN I-VP O
11 599 606 12851669 through IN B-PP O
12 607 613 12851669 Danish NNP B-NP O
13 614 618 12851669 Drug NNP I-NP O
14 619 629 12851669 Statistics NNPS I-NP O
15 629 630 12851669 . . O O

1 631 638 12851669 RESULTS NNS B-NP O
2 638 639 12851669 : : O O
3 640 646 12851669 During IN B-PP O
4 647 650 12851669 the DT B-NP O
5 651 655 12851669 time NN I-NP O
6 656 661 12851669 frame NN I-NP O
7 662 664 12851669 of IN B-PP O
8 665 668 12851669 the DT B-NP O
9 669 674 12851669 study NN I-NP O
10 674 675 12851669 , , O O
11 676 679 12851669 330 CD B-NP O
12 680 685 12851669 women NNS I-NP O
13 686 690 12851669 were VBD B-VP O
14 691 696 12851669 found VBN I-VP O
15 697 699 12851669 to TO I-VP O
16 700 704 12851669 have VB I-VP O
17 705 708 12851669 had VBN I-VP O
18 709 712 12851669 VTE NNP B-NP D054556
19 713 718 12851669 while IN B-SBAR O
20 719 721 12851669 on IN B-PP O
21 722 726 12851669 COCs NNS B-NP D003277
22 726 727 12851669 . . O O

1 728 730 12851669 Of IN B-PP O
2 731 736 12851669 these DT B-NP O
3 737 742 12851669 women NNS I-NP O
4 742 743 12851669 , , O O
5 744 746 12851669 67 CD B-NP O
6 747 751 12851669 were VBD B-VP O
7 752 754 12851669 on IN B-PP O
8 755 769 12851669 levonorgestrel NN B-NP D016912
9 769 770 12851669 - HYPH O O
10 770 780 12851669 containing VBG B-VP O
11 781 785 12851669 COCs NNS B-NP D003277
12 785 786 12851669 . . O O

1 787 793 12851669 Eleven CD B-NP O
2 794 798 12851669 were VBD B-VP O
3 799 801 12851669 on IN B-PP O
4 802 805 12851669 CPA NN B-NP D017373
5 805 806 12851669 / SYM B-NP O
6 806 808 12851669 EE NN I-NP D004997
7 808 809 12851669 . . O O

1 810 813 12851669 The DT B-NP O
2 814 827 12851669 corresponding VBG I-NP O
3 828 836 12851669 absolute JJ I-NP O
4 837 841 12851669 risk NN I-NP O
5 842 844 12851669 of IN B-PP O
6 845 848 12851669 VTE NN B-NP D054556
7 849 852 12851669 was VBD B-VP O
8 853 856 12851669 3.4 CD B-NP O
9 857 858 12851669 ( ( O O
10 858 863 12851669 range NN B-NP O
11 863 864 12851669 , , O O
12 865 868 12851669 3.1 CD B-NP O
13 868 869 12851669 - HYPH I-NP O
14 869 872 12851669 3.8 CD I-NP O
15 872 873 12851669 ) ) O O
16 874 877 12851669 per IN B-PP O
17 878 880 12851669 10 CD B-NP O
18 881 884 12851669 000 CD I-NP O
19 885 890 12851669 women NNS I-NP O
20 891 896 12851669 years NNS I-NP O
21 897 902 12851669 among IN B-PP O
22 903 906 12851669 the DT B-NP O
23 907 912 12851669 women NNS I-NP O
24 913 915 12851669 on IN B-PP O
25 916 920 12851669 COCs NNS B-NP D003277
26 920 921 12851669 , , O O
27 922 925 12851669 4.2 CD B-NP O
28 926 927 12851669 ( ( O O
29 927 932 12851669 range NN B-NP O
30 932 933 12851669 , , O O
31 934 937 12851669 3.2 CD B-NP O
32 937 938 12851669 - HYPH I-NP O
33 938 941 12851669 5.2 CD I-NP O
34 941 942 12851669 ) ) O O
35 943 946 12851669 per IN B-PP O
36 947 949 12851669 10 CD B-NP O
37 950 953 12851669 000 CD I-NP O
38 954 959 12851669 women NNS I-NP O
39 960 965 12851669 years NNS I-NP O
40 966 971 12851669 among IN B-PP O
41 972 977 12851669 women NNS B-NP O
42 978 980 12851669 on IN B-PP O
43 981 995 12851669 levonorgestrel NN B-NP D016912
44 995 996 12851669 - HYPH O O
45 996 1006 12851669 containing VBG B-VP O
46 1007 1011 12851669 COCs NNS B-NP D003277
47 1011 1012 12851669 , , O O
48 1013 1016 12851669 and CC O O
49 1017 1020 12851669 3.1 CD B-NP O
50 1021 1022 12851669 ( ( O O
51 1022 1027 12851669 range NN B-NP O
52 1027 1028 12851669 , , O O
53 1029 1032 12851669 1.3 CD B-NP O
54 1032 1033 12851669 - HYPH I-NP O
55 1033 1036 12851669 4.9 CD I-NP O
56 1036 1037 12851669 ) ) O O
57 1038 1041 12851669 per IN B-PP O
58 1042 1044 12851669 10 CD B-NP O
59 1045 1048 12851669 000 CD I-NP O
60 1049 1054 12851669 women NNS I-NP O
61 1055 1060 12851669 years NNS I-NP O
62 1061 1066 12851669 among IN B-PP O
63 1067 1070 12851669 the DT B-NP O
64 1071 1076 12851669 women NNS I-NP O
65 1077 1079 12851669 on IN B-PP O
66 1080 1083 12851669 CPA NN B-NP D017373
67 1083 1084 12851669 / SYM I-NP O
68 1084 1086 12851669 EE NN I-NP D004997
69 1086 1087 12851669 . . O O

1 1088 1098 12851669 CONCLUSION NN B-NP O
2 1098 1099 12851669 : : O O
3 1100 1103 12851669 Our PRP$ B-NP O
4 1104 1111 12851669 results NNS I-NP O
5 1112 1119 12851669 suggest VBP B-VP O
6 1120 1123 12851669 the DT B-NP O
7 1124 1132 12851669 absolute JJ I-NP O
8 1133 1137 12851669 risk NN I-NP O
9 1138 1140 12851669 of IN B-PP O
10 1141 1144 12851669 VTE NN B-NP D054556
11 1145 1150 12851669 among IN B-PP O
12 1151 1157 12851669 Danish JJ B-NP O
13 1158 1163 12851669 women NNS I-NP O
14 1164 1166 12851669 on IN B-PP O
15 1167 1171 12851669 COCs NNS B-NP D003277
16 1172 1174 12851669 is VBZ B-VP O
17 1175 1182 12851669 similar JJ B-ADJP O
18 1183 1185 12851669 to TO B-PP O
19 1186 1190 12851669 that DT B-NP O
20 1191 1196 12851669 among IN B-PP O
21 1197 1202 12851669 women NNS B-NP O
22 1203 1209 12851669 taking VBG B-VP O
23 1210 1213 12851669 CPA NN B-NP D017373
24 1213 1214 12851669 / SYM I-NP O
25 1214 1216 12851669 EE NN I-NP D004997
26 1216 1217 12851669 . . O O

1 0 0 10193809 -DOCSTART- -X- -X- O

1 0 5 10193809 Urine NN B-NP O
2 6 7 10193809 N NN I-NP O
3 7 8 10193809 - HYPH B-NP O
4 8 14 10193809 acetyl NN I-NP O
5 14 15 10193809 - HYPH O O
6 15 19 10193809 beta SYM B-NP O
7 19 20 10193809 - HYPH B-NP O
8 20 21 10193809 D NN I-NP O
9 21 22 10193809 - HYPH B-NP O
10 22 37 10193809 glucosaminidase NN I-NP O
11 37 38 10193809 - HYPH B-NP O
12 38 39 10193809 - : O O
13 39 40 10193809 a DT B-NP O
14 41 47 10193809 marker NN I-NP O
15 48 50 10193809 of IN B-PP O
16 51 58 10193809 tubular JJ B-NP O
17 59 65 10193809 damage NN I-NP O
18 65 66 10193809 ? . O O
19 67 77 10193809 BACKGROUND NN B-NP O
20 77 78 10193809 : : O O
21 79 87 10193809 Although IN B-SBAR O
22 88 90 10193809 an DT B-NP O
23 91 100 10193809 indicator NN I-NP O
24 101 103 10193809 of IN B-PP O
25 104 109 10193809 renal JJ B-NP D005198
26 110 117 10193809 tubular JJ I-NP D005198
27 118 129 10193809 dysfunction NN I-NP D005198
28 129 130 10193809 , , O O
29 131 133 10193809 an DT B-NP O
30 134 143 10193809 increased VBN I-NP O
31 144 151 10193809 urinary JJ I-NP O
32 152 153 10193809 N NN I-NP O
33 153 154 10193809 - HYPH B-NP O
34 154 160 10193809 acetyl NN I-NP O
35 160 161 10193809 - HYPH O O
36 161 165 10193809 beta SYM B-NP O
37 165 166 10193809 - HYPH B-NP O
38 166 167 10193809 D NN I-NP O
39 167 168 10193809 - HYPH O O
40 168 183 10193809 glucosaminidase NN B-NP O
41 184 185 10193809 ( ( O O
42 185 188 10193809 NAG NN B-NP O
43 188 189 10193809 ) ) O O
44 190 198 10193809 activity NN B-NP O
45 199 204 10193809 might MD B-VP O
46 205 212 10193809 reflect VB I-VP O
47 213 222 10193809 increased VBN B-NP O
48 223 232 10193809 lysosomal JJ I-NP O
49 233 241 10193809 activity NN I-NP O
50 242 244 10193809 in IN B-PP O
51 245 250 10193809 renal JJ B-NP O
52 251 258 10193809 tubular JJ I-NP O
53 259 264 10193809 cells NNS I-NP O
54 264 265 10193809 . . O O

1 266 273 10193809 METHODS NNS B-NP O
2 273 274 10193809 : : O O
3 275 284 10193809 Puromycin NN B-NP D011692
4 285 300 10193809 aminonucleoside NN I-NP D011692
5 301 302 10193809 ( ( O O
6 302 305 10193809 PAN NN B-NP D011692
7 305 306 10193809 ) ) O O
8 307 310 10193809 was VBD B-VP O
9 311 323 10193809 administered VBN I-VP O
10 324 326 10193809 to TO B-PP O
11 327 334 10193809 Sprague NNP B-NP O
12 335 341 10193809 Dawley NNP I-NP O
13 342 346 10193809 rats NNS I-NP O
14 347 349 10193809 to TO B-VP O
15 350 356 10193809 induce VB I-VP O
16 357 368 10193809 proteinuria NN B-NP D011507
17 368 369 10193809 . . O O

1 370 375 10193809 Total JJ B-NP O
2 376 383 10193809 protein NN I-NP O
3 383 384 10193809 , , O O
4 385 392 10193809 albumin NN B-NP O
5 392 393 10193809 , , O O
6 394 397 10193809 NAG NN B-NP O
7 398 406 10193809 activity NN I-NP O
8 407 410 10193809 and CC O O
9 411 418 10193809 protein NN B-NP O
10 419 434 10193809 electrophoretic JJ I-NP O
11 435 442 10193809 pattern NN I-NP O
12 443 447 10193809 were VBD B-VP O
13 448 456 10193809 assessed VBN I-VP O
14 457 459 10193809 in IN B-PP O
15 460 465 10193809 daily JJ B-NP O
16 466 471 10193809 urine NN I-NP O
17 472 479 10193809 samples NNS I-NP O
18 480 483 10193809 for IN B-PP O
19 484 486 10193809 33 CD B-NP O
20 487 491 10193809 days NNS I-NP O
21 491 492 10193809 . . O O

1 493 496 10193809 The DT B-NP O
2 497 510 10193809 morphological JJ I-NP O
3 511 521 10193809 appearance NN I-NP O
4 522 524 10193809 of IN B-PP O
5 525 528 10193809 the DT B-NP O
6 529 536 10193809 kidneys NNS I-NP O
7 537 540 10193809 was VBD B-VP O
8 541 549 10193809 examined VBN I-VP O
9 550 552 10193809 on IN B-PP O
10 553 557 10193809 days NNS B-NP O
11 558 563 10193809 three CD B-NP O
12 563 564 10193809 , , I-NP O
13 565 569 10193809 four CD I-NP O
14 569 570 10193809 , , I-NP O
15 571 574 10193809 six CD I-NP O
16 574 575 10193809 , , I-NP O
17 576 581 10193809 eight CD I-NP O
18 582 585 10193809 and CC I-NP O
19 586 592 10193809 thirty CD I-NP O
20 593 598 10193809 three CD I-NP O
21 599 602 10193809 and CC O O
22 603 606 10193809 the DT B-NP O
23 607 610 10193809 NAG NN I-NP O
24 611 620 10193809 isoenzyme NN I-NP O
25 621 629 10193809 patterns NNS I-NP O
26 630 632 10193809 on IN B-PP O
27 633 637 10193809 days NNS B-NP O
28 638 642 10193809 zero CD I-NP O
29 642 643 10193809 , , I-NP O
30 644 648 10193809 four CD I-NP O
31 648 649 10193809 , , I-NP O
32 650 655 10193809 eight CD I-NP O
33 656 659 10193809 and CC I-NP O
34 660 666 10193809 thirty CD I-NP O
35 667 672 10193809 three CD I-NP O
36 672 673 10193809 . . O O

1 674 681 10193809 RESULTS NNS B-NP O
2 681 682 10193809 : : O O
3 683 692 10193809 Following VBG B-VP O
4 693 704 10193809 intravenous JJ B-NP O
5 705 708 10193809 PAN NN I-NP D011692
6 709 714 10193809 urine NN I-NP O
7 715 721 10193809 volume NN I-NP O
8 722 725 10193809 and CC O O
9 726 731 10193809 urine NN B-NP O
10 732 735 10193809 NAG NN I-NP O
11 736 744 10193809 activity NN I-NP O
12 745 754 10193809 increased VBD B-VP O
13 755 768 10193809 significantly RB B-ADVP O
14 769 771 10193809 by IN B-PP O
15 772 775 10193809 day NN B-NP O
16 776 779 10193809 two CD I-NP O
17 779 780 10193809 , , O O
18 781 784 10193809 but CC O O
19 785 793 10193809 returned VBD B-VP O
20 794 796 10193809 to TO B-PP O
21 797 803 10193809 normal JJ B-NP O
22 804 806 10193809 by IN B-PP O
23 807 810 10193809 day NN B-NP O
24 811 815 10193809 four CD I-NP O
25 815 816 10193809 . . O O

1 817 822 10193809 After IN B-SBAR O
2 823 826 10193809 day NN B-NP O
3 827 831 10193809 four CD I-NP O
4 832 835 10193809 all DT B-NP O
5 836 843 10193809 treated VBN I-NP O
6 844 851 10193809 animals NNS I-NP O
7 852 861 10193809 exhibited VBD B-VP O
8 862 863 10193809 a DT B-NP O
9 864 870 10193809 marked JJ I-NP O
10 871 875 10193809 rise NN I-NP O
11 876 878 10193809 in IN B-PP O
12 879 884 10193809 urine NN B-NP O
13 885 892 10193809 albumin NN I-NP O
14 892 893 10193809 , , O O
15 894 899 10193809 total JJ B-NP O
16 900 907 10193809 protein NN I-NP O
17 908 917 10193809 excretion NN I-NP O
18 918 921 10193809 and CC O O
19 922 925 10193809 NAG NN B-NP O
20 926 934 10193809 activity NN I-NP O
21 934 935 10193809 . . O O

1 936 951 10193809 Electrophoresis NN B-NP O
2 952 958 10193809 showed VBD B-VP O
3 959 960 10193809 a DT B-NP O
4 961 972 10193809 generalised VBN I-NP O
5 973 981 10193809 increase NN I-NP O
6 982 984 10193809 in IN B-PP O
7 985 991 10193809 middle JJ B-NP O
8 992 995 10193809 and CC I-NP O
9 996 1000 10193809 high JJ I-NP O
10 1001 1010 10193809 molecular JJ I-NP O
11 1011 1017 10193809 weight NN I-NP O
12 1018 1023 10193809 urine NN I-NP O
13 1024 1032 10193809 proteins NNS I-NP O
14 1033 1037 10193809 from IN B-PP O
15 1038 1041 10193809 day NN B-NP O
16 1042 1046 10193809 four CD B-NP O
17 1047 1054 10193809 onwards NNS I-NP O
18 1054 1055 10193809 . . O O

1 1056 1063 10193809 Protein NN B-NP O
2 1064 1072 10193809 droplets NNS I-NP O
3 1073 1078 10193809 first RB B-ADVP O
4 1079 1087 10193809 appeared VBD B-VP O
5 1088 1097 10193809 prominent JJ B-ADJP O
6 1098 1100 10193809 in IN B-PP O
7 1101 1108 10193809 tubular JJ B-NP O
8 1109 1114 10193809 cells NNS I-NP O
9 1115 1117 10193809 on IN B-PP O
10 1118 1121 10193809 day NN B-NP O
11 1122 1126 10193809 four CD I-NP O
12 1126 1127 10193809 . . O O

1 1128 1132 10193809 Peak JJ B-NP O
2 1133 1138 10193809 urine NN I-NP O
3 1139 1142 10193809 NAG NN I-NP O
4 1143 1151 10193809 activity NN I-NP O
5 1152 1155 10193809 and CC O O
6 1156 1157 10193809 a DT B-NP O
7 1158 1164 10193809 change NN I-NP O
8 1165 1167 10193809 in IN B-PP O
9 1168 1171 10193809 NAG NN B-NP O
10 1172 1181 10193809 isoenzyme NN I-NP O
11 1182 1189 10193809 pattern NN I-NP O
12 1190 1199 10193809 coincided VBD B-VP O
13 1200 1204 10193809 with IN B-PP O
14 1205 1209 10193809 both CC O O
15 1210 1213 10193809 the DT B-NP O
16 1214 1218 10193809 peak JJ I-NP O
17 1219 1230 10193809 proteinuria NN I-NP D011507
18 1231 1234 10193809 and CC O O
19 1235 1238 10193809 the DT B-NP O
20 1239 1248 10193809 reduction NN I-NP O
21 1249 1251 10193809 in IN B-PP O
22 1252 1265 10193809 intracellular JJ B-NP O
23 1266 1273 10193809 protein NN I-NP O
24 1274 1277 10193809 and CC I-NP O
25 1278 1281 10193809 NAG NN I-NP O
26 1282 1290 10193809 droplets NNS I-NP O
27 1291 1292 10193809 ( ( O O
28 1292 1295 10193809 day NN B-NP O
29 1296 1299 10193809 six CD B-NP O
30 1300 1307 10193809 onwards NNS I-NP O
31 1307 1308 10193809 ) ) O O
32 1308 1309 10193809 . . O O

1 1310 1321 10193809 CONCLUSIONS NNS B-NP O
2 1321 1322 10193809 : : O O
3 1323 1327 10193809 This DT B-NP O
4 1328 1334 10193809 animal NN I-NP O
5 1335 1340 10193809 model NN I-NP O
6 1341 1353 10193809 demonstrates VBZ B-VP O
7 1354 1358 10193809 that IN B-SBAR O
8 1359 1361 10193809 an DT B-NP O
9 1362 1370 10193809 increase NN I-NP O
10 1371 1373 10193809 in IN B-PP O
11 1374 1383 10193809 lysosomal JJ B-NP O
12 1384 1392 10193809 turnover NN I-NP O
13 1393 1396 10193809 and CC O O
14 1397 1402 10193809 hence RB B-ADVP O
15 1403 1408 10193809 urine NN B-NP O
16 1409 1412 10193809 NAG NN I-NP O
17 1413 1421 10193809 activity NN I-NP O
18 1421 1422 10193809 , , O O
19 1423 1429 10193809 occurs VBZ B-VP O
20 1430 1434 10193809 when WRB B-ADVP O
21 1435 1444 10193809 increased VBN B-NP O
22 1445 1452 10193809 protein NN I-NP O
23 1453 1455 10193809 is VBZ B-VP O
24 1456 1465 10193809 presented VBN I-VP O
25 1466 1468 10193809 to TO B-PP O
26 1469 1472 10193809 the DT B-NP O
27 1473 1480 10193809 tubular JJ I-NP O
28 1481 1486 10193809 cells NNS I-NP O
29 1486 1487 10193809 . . O O

1 1488 1493 10193809 Urine NN B-NP O
2 1494 1497 10193809 NAG NN I-NP O
3 1498 1506 10193809 activity NN I-NP O
4 1507 1509 10193809 is VBZ B-VP O
5 1510 1514 10193809 thus RB B-ADVP O
6 1515 1516 10193809 a DT B-NP O
7 1517 1524 10193809 measure NN I-NP O
8 1525 1527 10193809 of IN B-PP O
9 1528 1535 10193809 altered VBN B-NP O
10 1536 1544 10193809 function NN I-NP O
11 1545 1547 10193809 in IN B-PP O
12 1548 1551 10193809 the DT B-NP O
13 1552 1557 10193809 renal JJ I-NP O
14 1558 1565 10193809 tubules NNS I-NP O
15 1566 1569 10193809 and CC O O
16 1570 1573 10193809 not RB O O
17 1574 1580 10193809 simply RB B-ADVP O
18 1581 1583 10193809 an DT B-NP O
19 1584 1593 10193809 indicator NN I-NP O
20 1594 1596 10193809 of IN B-PP O
21 1597 1603 10193809 damage NN B-NP O
22 1603 1604 10193809 . . O O

1 0 0 12231232 -DOCSTART- -X- -X- O

1 0 3 12231232 The DT B-NP O
2 4 12 12231232 striatum NN I-NP O
3 13 15 12231232 as IN B-PP O
4 16 17 12231232 a DT B-NP O
5 18 24 12231232 target NN I-NP O
6 25 28 12231232 for IN B-PP O
7 29 33 12231232 anti AFX B-NP O
8 33 34 12231232 - HYPH I-NP O
9 34 39 12231232 rigor JJ I-NP O
10 40 47 12231232 effects NNS I-NP O
11 48 50 12231232 of IN B-PP O
12 51 53 12231232 an DT B-NP O
13 54 64 12231232 antagonist NN I-NP O
14 65 67 12231232 of IN B-PP O
15 68 74 12231232 mGluR1 NN B-NP O
16 74 75 12231232 , , O O
17 76 79 12231232 but CC B-CONJP O
18 80 83 12231232 not RB I-CONJP O
19 84 86 12231232 an DT B-NP O
20 87 94 12231232 agonist NN I-NP O
21 95 97 12231232 of IN B-PP O
22 98 103 12231232 group NN B-NP O
23 104 106 12231232 II CD I-NP O
24 107 119 12231232 metabotropic JJ I-NP O
25 120 129 12231232 glutamate NN I-NP D018698
26 130 139 12231232 receptors NNS I-NP O
27 139 140 12231232 . . O O
28 141 144 12231232 The DT B-NP O
29 145 148 12231232 aim NN I-NP O
30 149 151 12231232 of IN B-PP O
31 152 155 12231232 the DT B-NP O
32 156 163 12231232 present JJ I-NP O
33 164 169 12231232 study NN I-NP O
34 170 173 12231232 was VBD B-VP O
35 174 176 12231232 to TO B-VP O
36 177 181 12231232 find VB I-VP O
37 182 185 12231232 out RP B-PRT O
38 186 193 12231232 whether IN B-SBAR O
39 194 197 12231232 the DT B-NP O
40 198 210 12231232 metabotropic JJ I-NP O
41 211 219 12231232 receptor NN I-NP O
42 220 221 12231232 1 CD I-NP O
43 222 223 12231232 ( ( O O
44 223 229 12231232 mGluR1 NN B-NP O
45 229 230 12231232 ) ) O O
46 231 234 12231232 and CC O O
47 235 240 12231232 group NN B-NP O
48 241 243 12231232 II CD I-NP O
49 244 250 12231232 mGluRs NNS I-NP O
50 250 251 12231232 , , O O
51 252 261 12231232 localized VBN B-VP O
52 262 264 12231232 in IN B-PP O
53 265 268 12231232 the DT B-NP O
54 269 277 12231232 striatum NN I-NP O
55 277 278 12231232 , , O O
56 279 282 12231232 are VBP B-VP O
57 283 291 12231232 involved VBN I-VP O
58 292 294 12231232 in IN B-PP O
59 295 311 12231232 antiparkinsonian JJ B-NP O
60 311 312 12231232 - HYPH I-NP O
61 312 316 12231232 like JJ I-NP O
62 317 324 12231232 effects NNS I-NP O
63 325 327 12231232 in IN B-PP O
64 328 332 12231232 rats NNS B-NP O
65 332 333 12231232 . . O O

1 334 345 12231232 Haloperidol NN B-NP D006220
2 346 347 12231232 ( ( O O
3 347 348 12231232 1 CD B-NP O
4 349 351 12231232 mg NN I-NP O
5 351 352 12231232 / SYM B-NP O
6 352 354 12231232 kg NN I-NP O
7 355 357 12231232 ip NN I-NP O
8 357 358 12231232 ) ) O O
9 359 366 12231232 induced VBD B-VP O
10 367 379 12231232 parkinsonian NN B-NP D010300
11 379 380 12231232 - HYPH B-NP O
12 380 384 12231232 like JJ I-NP O
13 385 391 12231232 muscle NN I-NP D009127
14 392 400 12231232 rigidity NN I-NP D009127
15 400 401 12231232 , , O O
16 402 410 12231232 measured VBN B-VP O
17 411 413 12231232 as IN B-PP O
18 414 416 12231232 an DT B-NP O
19 417 426 12231232 increased VBN I-NP O
20 427 437 12231232 resistance NN I-NP O
21 438 440 12231232 of IN B-PP O
22 441 442 12231232 a DT B-NP O
23 443 448 12231232 rat's NNS I-NP O
24 449 453 12231232 hind VBP B-VP O
25 454 458 12231232 foot NN B-NP O
26 459 461 12231232 to TO B-PP O
27 462 469 12231232 passive JJ B-NP O
28 470 477 12231232 flexion NN I-NP O
29 478 481 12231232 and CC I-NP O
30 482 491 12231232 extension NN I-NP O
31 492 494 12231232 at IN B-PP O
32 495 498 12231232 the DT B-NP O
33 499 504 12231232 ankle NN I-NP O
34 505 510 12231232 joint NN I-NP O
35 510 511 12231232 . . O O

1 512 516 12231232 (RS) NN B-NP C095756
2 516 517 12231232 - HYPH B-NP C095756
3 517 518 12231232 1 CD I-NP C095756
4 518 519 12231232 - HYPH I-NP C095756
5 519 529 12231232 aminoindan NN I-NP C095756
6 529 530 12231232 - HYPH B-NP C095756
7 530 533 12231232 1,5 CD I-NP C095756
8 533 534 12231232 - HYPH I-NP C095756
9 534 546 12231232 dicarboxylic JJ I-NP C095756
10 547 551 12231232 acid NN I-NP C095756
11 552 553 12231232 ( ( O O
12 553 557 12231232 AIDA NN B-NP C095756
13 557 558 12231232 ; : O O
14 559 562 12231232 0.5 CD B-NP O
15 562 563 12231232 - HYPH I-NP O
16 563 565 12231232 15 CD I-NP O
17 566 572 12231232 microg NN I-NP O
18 572 573 12231232 / SYM I-NP O
19 573 576 12231232 0.5 CD I-NP O
20 577 583 12231232 microl NN I-NP O
21 583 584 12231232 ) ) O O
22 584 585 12231232 , , O O
23 586 587 12231232 a DT B-NP O
24 588 594 12231232 potent JJ I-NP O
25 595 598 12231232 and CC I-NP O
26 599 608 12231232 selective JJ I-NP O
27 609 615 12231232 mGluR1 NN I-NP O
28 616 626 12231232 antagonist NN I-NP O
29 626 627 12231232 , , O O
30 628 630 12231232 or CC O O
31 631 638 12231232 (2R,4R) NN B-NP C097299
32 638 639 12231232 - HYPH B-NP C097299
33 639 640 12231232 4 CD I-NP C097299
34 640 641 12231232 - HYPH I-NP C097299
35 641 657 12231232 aminopyrrolidine NN I-NP C097299
36 657 658 12231232 - HYPH B-NP C097299
37 658 661 12231232 2,4 CD I-NP C097299
38 661 662 12231232 - HYPH I-NP C097299
39 662 675 12231232 dicarboxylate NN I-NP C097299
40 676 677 12231232 ( ( O O
41 677 682 12231232 2R,4R NN B-NP C097299
42 682 683 12231232 - HYPH B-NP C097299
43 683 687 12231232 APDC NN I-NP C097299
44 687 688 12231232 ; : O O
45 689 692 12231232 7.5 CD B-NP O
46 692 693 12231232 - HYPH I-NP O
47 693 695 12231232 15 CD I-NP O
48 696 702 12231232 microg NN I-NP O
49 702 703 12231232 / SYM I-NP O
50 703 706 12231232 0.5 CD I-NP O
51 707 713 12231232 microl NN I-NP O
52 713 714 12231232 ) ) O O
53 714 715 12231232 , , O O
54 716 717 12231232 a DT B-NP O
55 718 727 12231232 selective JJ I-NP O
56 728 733 12231232 group NN I-NP O
57 734 736 12231232 II CD I-NP O
58 737 744 12231232 agonist NN I-NP O
59 744 745 12231232 , , O O
60 746 749 12231232 was VBD B-VP O
61 750 758 12231232 injected VBN I-VP O
62 759 770 12231232 bilaterally RB B-ADVP O
63 771 775 12231232 into IN B-PP O
64 776 779 12231232 the DT B-NP O
65 780 788 12231232 striatum NN I-NP O
66 789 791 12231232 of IN B-PP O
67 792 803 12231232 haloperidol NN B-NP D006220
68 803 804 12231232 - HYPH B-NP O
69 804 811 12231232 treated VBN I-NP O
70 812 819 12231232 animals NNS I-NP O
71 819 820 12231232 . . O O

1 821 825 12231232 AIDA NN B-NP C095756
2 826 828 12231232 in IN B-PP O
3 829 834 12231232 doses NNS B-NP O
4 835 837 12231232 of IN B-PP O
5 838 841 12231232 7.5 CD B-NP O
6 841 842 12231232 - HYPH I-NP O
7 842 844 12231232 15 CD I-NP O
8 845 851 12231232 microg NN I-NP O
9 851 852 12231232 / SYM I-NP O
10 852 855 12231232 0.5 CD I-NP O
11 856 862 12231232 microl NN I-NP O
12 863 873 12231232 diminished VBD B-VP O
13 874 877 12231232 the DT B-NP O
14 878 889 12231232 haloperidol NN I-NP D006220
15 889 890 12231232 - HYPH B-NP O
16 890 897 12231232 induced VBN I-NP O
17 898 904 12231232 muscle NN I-NP D009127
18 905 913 12231232 rigidity NN I-NP D009127
19 913 914 12231232 . . O O

1 915 917 12231232 In IN B-PP O
2 918 926 12231232 contrast NN B-NP O
3 926 927 12231232 , , O O
4 928 933 12231232 2R,4R NN B-NP C097299
5 933 934 12231232 - HYPH B-NP C097299
6 934 938 12231232 APDC NN I-NP C097299
7 939 949 12231232 injections NNS I-NP O
8 950 954 12231232 were VBD B-VP O
9 955 966 12231232 ineffective JJ B-ADJP O
10 966 967 12231232 . . O O

1 968 971 12231232 The DT B-NP O
2 972 979 12231232 present JJ I-NP O
3 980 987 12231232 results NNS I-NP O
4 988 991 12231232 may MD B-VP O
5 992 999 12231232 suggest VB I-VP O
6 1000 1004 12231232 that IN B-SBAR O
7 1005 1008 12231232 the DT B-NP O
8 1009 1017 12231232 blockade NN I-NP O
9 1018 1020 12231232 of IN B-PP O
10 1021 1029 12231232 striatal JJ B-NP O
11 1030 1036 12231232 mGluR1 NN I-NP O
12 1036 1037 12231232 , , O O
13 1038 1041 12231232 but CC B-CONJP O
14 1042 1045 12231232 not RB I-CONJP O
15 1046 1049 12231232 the DT B-NP O
16 1050 1061 12231232 stimulation NN I-NP O
17 1062 1064 12231232 of IN B-PP O
18 1065 1070 12231232 group NN B-NP O
19 1071 1073 12231232 II CD I-NP O
20 1074 1080 12231232 mGluRs NNS I-NP O
21 1080 1081 12231232 , , O O
22 1082 1085 12231232 may MD B-VP O
23 1086 1096 12231232 ameliorate VB I-VP O
24 1097 1109 12231232 parkinsonian JJ B-NP D010300
25 1110 1116 12231232 muscle NN I-NP D009127
26 1117 1125 12231232 rigidity NN I-NP D009127
27 1125 1126 12231232 . . O O

1 0 0 9209318 -DOCSTART- -X- -X- O

1 0 8 9209318 Lifetime NN B-NP O
2 9 18 9209318 treatment NN I-NP O
3 19 21 9209318 of IN B-PP O
4 22 26 9209318 mice NNS B-NP O
5 27 31 9209318 with IN B-PP O
6 32 46 9209318 azidothymidine NN B-NP D015215
7 47 48 9209318 ( ( O O
8 48 51 9209318 AZT NN B-NP D015215
9 51 52 9209318 ) ) O O
10 53 61 9209318 produces VBZ B-VP O
11 62 76 9209318 myelodysplasia NN B-NP D009190
12 76 77 9209318 . . O O
13 78 81 9209318 AZT NNP B-NP D015215
14 82 85 9209318 has VBZ B-VP O
15 86 93 9209318 induced VBN I-VP O
16 94 95 9209318 a DT B-NP O
17 96 106 9209318 macrocytic JJ I-NP D000748
18 107 113 9209318 anemia NN I-NP D000748
19 114 116 9209318 in IN B-PP O
20 117 121 9209318 AIDS NN B-NP D000163
21 122 130 9209318 patients NNS I-NP O
22 131 133 9209318 on IN B-PP O
23 134 138 9209318 long JJ B-NP O
24 139 143 9209318 term NN I-NP O
25 144 147 9209318 AZT NN I-NP D015215
26 148 155 9209318 therapy NN I-NP O
27 155 156 9209318 . . O O

1 157 159 9209318 It PRP B-NP O
2 160 162 9209318 is VBZ B-VP O
3 163 172 9209318 generally RB I-VP O
4 173 180 9209318 assumed VBN I-VP O
5 181 185 9209318 that IN B-SBAR O
6 186 189 9209318 DNA NN B-NP O
7 190 200 9209318 elongation NN I-NP O
8 201 203 9209318 is VBZ B-VP O
9 204 211 9209318 stopped VBN I-VP O
10 212 214 9209318 by IN B-PP O
11 215 218 9209318 the DT B-NP O
12 219 228 9209318 insertion NN I-NP O
13 229 231 9209318 of IN B-PP O
14 232 235 9209318 AZT NNP B-NP D015215
15 236 240 9209318 into IN B-PP O
16 241 244 9209318 the DT B-NP O
17 245 250 9209318 chain NN I-NP O
18 251 253 9209318 in IN B-PP O
19 254 259 9209318 place NN B-NP O
20 260 262 9209318 of IN B-PP O
21 263 272 9209318 thymidine NN B-NP D013936
22 273 277 9209318 thus RB B-ADVP O
23 278 288 9209318 preventing VBG B-VP O
24 289 292 9209318 the DT B-NP O
25 293 302 9209318 phosphate NN I-NP D010710
26 303 311 9209318 hydroxyl NN I-NP O
27 312 320 9209318 linkages NNS I-NP O
28 321 324 9209318 and CC O O
29 325 334 9209318 therefore RB B-VP O
30 335 345 9209318 suppresses VBZ I-VP O
31 346 357 9209318 hemopoietic JJ B-NP O
32 358 368 9209318 progenitor NN I-NP O
33 369 373 9209318 cell NN I-NP O
34 374 387 9209318 proliferation NN I-NP O
35 388 390 9209318 in IN B-PP O
36 391 393 9209318 an DT B-NP O
37 394 399 9209318 early JJ I-NP O
38 400 405 9209318 stage NN I-NP O
39 406 408 9209318 of IN B-PP O
40 409 424 9209318 differentiation NN B-NP O
41 424 425 9209318 . . O O

1 426 429 9209318 CBA NN B-NP O
2 429 430 9209318 / SYM I-NP O
3 430 432 9209318 Ca NN I-NP O
4 433 437 9209318 male JJ I-NP O
5 438 442 9209318 mice NNS I-NP O
6 443 450 9209318 started VBN B-VP O
7 451 453 9209318 on IN B-PP O
8 454 457 9209318 AZT NNP B-NP D015215
9 458 462 9209318 0.75 CD I-NP O
10 463 465 9209318 mg NN I-NP O
11 465 466 9209318 / SYM B-NP O
12 466 468 9209318 ml NN I-NP O
13 469 472 9209318 H2O NN I-NP O
14 473 475 9209318 at IN B-PP O
15 476 478 9209318 84 CD B-NP O
16 479 483 9209318 days NNS I-NP O
17 484 486 9209318 of IN B-PP O
18 487 490 9209318 age NN B-NP O
19 491 494 9209318 and CC O O
20 495 499 9209318 kept VBD B-VP O
21 500 502 9209318 on IN B-PP O
22 503 505 9209318 it PRP B-NP O
23 506 509 9209318 for IN B-PP O
24 510 513 9209318 687 CD B-NP O
25 514 518 9209318 days NNS I-NP O
26 519 523 9209318 when WRB B-ADVP O
27 524 530 9209318 dosage NN B-NP O
28 531 538 9209318 reduced VBD B-VP O
29 539 541 9209318 to TO B-PP O
30 542 545 9209318 0.5 CD B-NP O
31 546 548 9209318 mg NN I-NP O
32 548 549 9209318 / SYM B-NP O
33 549 551 9209318 ml NN I-NP O
34 552 555 9209318 H2O NN I-NP O
35 556 559 9209318 for IN B-PP O
36 560 561 9209318 a DT B-NP O
37 562 567 9209318 group NN I-NP O
38 567 568 9209318 , , O O
39 569 576 9209318 another DT B-NP O
40 577 582 9209318 group NN I-NP O
41 583 590 9209318 removed VBN B-VP O
42 591 595 9209318 from IN B-PP O
43 596 599 9209318 AZT NNP B-NP D015215
44 600 602 9209318 to TO B-VP O
45 603 606 9209318 see VB I-VP O
46 607 615 9209318 recovery NN B-NP O
47 615 616 9209318 , , O O
48 617 620 9209318 and CC O O
49 621 626 9209318 third JJ B-NP O
50 627 632 9209318 group NN I-NP O
51 633 641 9209318 remained VBD B-VP O
52 642 644 9209318 on IN B-PP O
53 645 649 9209318 0.75 CD B-NP O
54 650 652 9209318 mg NN I-NP O
55 652 653 9209318 . . O O

1 654 656 9209318 At IN B-PP O
2 657 660 9209318 687 CD B-NP O
3 661 665 9209318 days NNS I-NP O
4 666 670 9209318 mice NNS I-NP O
5 671 675 9209318 that WDT B-NP O
6 676 679 9209318 had VBD B-VP O
7 680 684 9209318 been VBN I-VP O
8 685 687 9209318 on IN B-PP O
9 688 692 9209318 0.75 CD B-NP O
10 693 695 9209318 mg NN I-NP O
11 696 699 9209318 had VBD B-VP O
12 700 707 9209318 average JJ B-NP O
13 708 716 9209318 platelet NN I-NP O
14 717 723 9209318 counts NNS I-NP O
15 724 726 9209318 of IN B-PP O
16 727 730 9209318 2.5 CD B-NP O
17 731 732 9209318 x SYM I-NP O
18 733 738 9209318 10(6) CD I-NP O
19 738 739 9209318 . . O O

1 740 752 9209318 Histological JJ B-NP O
2 753 764 9209318 examination NN I-NP O
3 765 767 9209318 on IN B-PP O
4 768 769 9209318 9 CD B-NP O
5 770 772 9209318 of IN B-PP O
6 773 775 9209318 10 CD B-NP O
7 776 780 9209318 mice NNS I-NP O
8 781 785 9209318 with IN B-PP O
9 786 790 9209318 such JJ B-NP O
10 791 807 9209318 thrombocytopenia NN I-NP D013921
11 808 814 9209318 showed VBD B-VP O
12 815 822 9209318 changes NNS B-NP O
13 823 833 9209318 compatible JJ B-ADJP O
14 834 838 9209318 with IN B-PP O
15 839 854 9209318 myelodysplastic JJ B-NP D009190
16 855 863 9209318 syndrome NN I-NP D009190
17 864 865 9209318 ( ( O O
18 865 868 9209318 MDS NN B-NP D009190
19 868 869 9209318 ) ) O O
20 869 870 9209318 . . O O

1 871 872 9209318 A DT B-NP O
2 873 880 9209318 variety NN I-NP O
3 881 883 9209318 of IN B-PP O
4 884 896 9209318 histological JJ B-NP O
5 897 905 9209318 patterns NNS I-NP O
6 906 909 9209318 was VBD B-VP O
7 910 918 9209318 observed VBN I-VP O
8 918 919 9209318 . . O O

1 920 925 9209318 There EX B-NP O
2 926 930 9209318 were VBD B-VP O
3 931 934 9209318 two CD B-NP O
4 935 940 9209318 cases NNS I-NP O
5 941 943 9209318 of IN B-PP O
6 944 956 9209318 hypocellular JJ B-NP O
7 957 971 9209318 myelodysplasia NN I-NP D009190
8 971 972 9209318 , , O O
9 973 976 9209318 two CD B-NP O
10 977 982 9209318 cases NNS I-NP O
11 983 985 9209318 of IN B-PP O
12 986 1000 9209318 hypersegmented JJ B-NP O
13 1001 1016 9209318 myelodysplastic JJ I-NP D009190
14 1017 1031 9209318 granulocytosis NN I-NP O
15 1031 1032 9209318 , , O O
16 1033 1036 9209318 two CD B-NP O
17 1037 1042 9209318 cases NNS I-NP O
18 1043 1045 9209318 of IN B-PP O
19 1046 1059 9209318 hypercellular JJ B-NP O
20 1060 1066 9209318 marrow NN I-NP O
21 1067 1071 9209318 with IN B-PP O
22 1072 1080 9209318 abnormal JJ B-NP O
23 1081 1095 9209318 megakaryocytes NNS I-NP O
24 1096 1100 9209318 with IN B-PP O
25 1101 1108 9209318 bizarre JJ B-NP O
26 1109 1115 9209318 nuclei NNS I-NP O
27 1115 1116 9209318 , , O O
28 1117 1120 9209318 one CD B-NP O
29 1121 1125 9209318 case NN I-NP O
30 1126 1128 9209318 of IN B-PP O
31 1129 1143 9209318 megakaryocytic JJ B-NP O
32 1144 1152 9209318 myelosis NN I-NP O
33 1153 1163 9209318 associated VBN B-VP O
34 1164 1168 9209318 with IN B-PP O
35 1169 1170 9209318 a DT B-NP O
36 1171 1183 9209318 hyperplastic JJ I-NP D001855
37 1184 1190 9209318 marrow NN I-NP D001855
38 1190 1191 9209318 , , O O
39 1192 1207 9209318 dysmyelopoiesis NN B-NP D009190
40 1208 1211 9209318 and CC O O
41 1212 1213 9209318 a DT B-NP O
42 1214 1226 9209318 hypocellular JJ I-NP D001855
43 1227 1233 9209318 marrow NN I-NP D001855
44 1234 1237 9209318 and CC O O
45 1238 1241 9209318 two CD B-NP O
46 1242 1247 9209318 cases NNS I-NP O
47 1248 1250 9209318 of IN B-PP O
48 1251 1265 9209318 myelodysplasia NN B-NP D009190
49 1266 1270 9209318 with IN B-PP O
50 1271 1288 9209318 dyserythropoiesis NN B-NP -1
51 1288 1289 9209318 , , O O
52 1290 1303 9209318 hemosiderosis NN B-NP D006486
53 1304 1307 9209318 and CC O O
54 1308 1309 9209318 a DT B-NP O
55 1310 1322 9209318 hypocellular JJ I-NP D001855
56 1323 1329 9209318 marrow NN I-NP D001855
57 1329 1330 9209318 . . O O

1 1331 1336 9209318 Above IN B-PP O
2 1337 1346 9209318 mentioned VBN B-NP O
3 1347 1350 9209318 AZT NNP I-NP D015215
4 1351 1364 9209318 incorporation NN I-NP O
5 1365 1368 9209318 may MD B-VP O
6 1369 1373 9209318 have VB I-VP O
7 1374 1381 9209318 induced VBN I-VP O
8 1382 1384 9209318 an DT B-NP O
9 1385 1396 9209318 ineffective JJ I-NP O
10 1397 1408 9209318 hemopoiesis NN I-NP O
11 1409 1411 9209318 in IN B-PP O
12 1412 1415 9209318 the DT B-NP O
13 1416 1425 9209318 primitive JJ I-NP O
14 1426 1437 9209318 hemopoietic JJ I-NP O
15 1438 1448 9209318 progenitor NN I-NP O
16 1449 1454 9209318 cells NNS I-NP O
17 1454 1455 9209318 , , O O
18 1456 1461 9209318 which WDT B-NP O
19 1462 1464 9209318 is VBZ B-VP O
20 1465 1470 9209318 known VBN I-VP O
21 1471 1473 9209318 to TO I-VP O
22 1474 1476 9209318 be VB I-VP O
23 1477 1481 9209318 seen VBN I-VP O
24 1482 1490 9209318 commonly RB B-ADVP O
25 1491 1493 9209318 in IN B-PP O
26 1494 1497 9209318 the DT B-NP O
27 1498 1513 9209318 myelodysplastic JJ I-NP D009190
28 1514 1522 9209318 syndrome NN I-NP D009190
29 1522 1523 9209318 . . O O

1 0 0 15580403 -DOCSTART- -X- -X- O

1 0 8 15580403 Adequate JJ B-NP O
2 9 15 15580403 timing NN I-NP O
3 16 18 15580403 of IN B-PP O
4 19 28 15580403 ribavirin NN B-NP D012254
5 29 38 15580403 reduction NN I-NP O
6 39 41 15580403 in IN B-PP O
7 42 50 15580403 patients NNS B-NP O
8 51 55 15580403 with IN B-PP O
9 56 65 15580403 hemolysis NN B-NP D006461
10 66 72 15580403 during IN B-PP O
11 73 84 15580403 combination NN B-NP O
12 85 92 15580403 therapy NN I-NP O
13 93 95 15580403 of IN B-PP O
14 96 106 15580403 interferon NN B-NP D007372
15 107 110 15580403 and CC I-NP O
16 111 120 15580403 ribavirin NN I-NP D012254
17 121 124 15580403 for IN B-PP O
18 125 132 15580403 chronic JJ B-NP D019698
19 133 142 15580403 hepatitis NN I-NP D019698
20 143 144 15580403 C NN I-NP D019698
21 144 145 15580403 . . I-NP O
22 146 156 15580403 BACKGROUND NN I-NP O
23 156 157 15580403 : : O O
24 158 167 15580403 Hemolytic JJ B-NP D000743
25 168 174 15580403 anemia NN I-NP D000743
26 175 177 15580403 is VBZ B-VP O
27 178 181 15580403 one CD B-NP O
28 182 184 15580403 of IN B-PP O
29 185 188 15580403 the DT B-NP O
30 189 194 15580403 major JJ I-NP O
31 195 202 15580403 adverse JJ I-NP O
32 203 209 15580403 events NNS I-NP O
33 210 212 15580403 of IN B-PP O
34 213 216 15580403 the DT B-NP O
35 217 228 15580403 combination NN I-NP O
36 229 236 15580403 therapy NN I-NP O
37 237 239 15580403 of IN B-PP O
38 240 250 15580403 interferon NN B-NP D007372
39 251 254 15580403 and CC I-NP O
40 255 264 15580403 ribavirin NN I-NP D012254
41 264 265 15580403 . . O O

1 266 273 15580403 Because IN B-PP O
2 274 276 15580403 of IN I-PP O
3 277 286 15580403 ribavirin NN B-NP D012254
4 286 287 15580403 - HYPH O O
5 287 294 15580403 related VBN B-NP O
6 295 304 15580403 hemolytic JJ I-NP D000743
7 305 311 15580403 anemia NN I-NP D000743
8 311 312 15580403 , , O O
9 313 317 15580403 dose NN B-NP O
10 318 327 15580403 reduction NN I-NP O
11 328 330 15580403 is VBZ B-VP O
12 331 332 15580403 a DT B-NP O
13 333 339 15580403 common JJ I-NP O
14 340 345 15580403 event NN I-NP O
15 346 348 15580403 in IN B-PP O
16 349 353 15580403 this DT B-NP O
17 354 361 15580403 therapy NN I-NP O
18 361 362 15580403 . . O O

1 363 365 15580403 In IN B-PP O
2 366 370 15580403 this DT B-NP O
3 371 379 15580403 clinical JJ I-NP O
4 380 393 15580403 retrospective JJ I-NP O
5 394 400 15580403 cohort JJ I-NP O
6 401 406 15580403 study NN I-NP O
7 407 409 15580403 we PRP B-NP O
8 410 414 15580403 have VBP B-VP O
9 415 423 15580403 examined VBN I-VP O
10 424 427 15580403 the DT B-NP O
11 428 436 15580403 suitable JJ I-NP O
12 437 443 15580403 timing NN I-NP O
13 444 446 15580403 of IN B-PP O
14 447 456 15580403 ribavirin NN B-NP D012254
15 457 466 15580403 reduction NN I-NP O
16 467 469 15580403 in IN B-PP O
17 470 478 15580403 patients NNS B-NP O
18 479 483 15580403 with IN B-PP O
19 484 493 15580403 hemolysis NN B-NP D006461
20 494 500 15580403 during IN B-PP O
21 501 512 15580403 combination NN B-NP O
22 513 520 15580403 therapy NN I-NP O
23 520 521 15580403 . . O O

1 522 529 15580403 METHODS NNS B-NP O
2 529 530 15580403 : : O O
3 531 537 15580403 Thirty CD B-NP O
4 537 538 15580403 - HYPH I-NP O
5 538 543 15580403 seven CD I-NP O
6 544 546 15580403 of IN B-PP O
7 547 550 15580403 160 CD B-NP O
8 551 559 15580403 patients NNS I-NP O
9 560 563 15580403 who WP B-NP O
10 564 567 15580403 had VBD B-VP O
11 568 571 15580403 HCV NN B-NP O
12 571 572 15580403 - HYPH B-NP O
13 572 580 15580403 genotype NN I-NP O
14 581 583 15580403 1b NN I-NP O
15 583 584 15580403 , , O O
16 585 588 15580403 had VBD B-VP O
17 589 593 15580403 high JJ B-NP O
18 594 599 15580403 virus NN I-NP O
19 600 604 15580403 load NN I-NP O
20 604 605 15580403 , , O O
21 606 609 15580403 and CC O O
22 610 618 15580403 received VBD B-VP O
23 619 621 15580403 24 CD B-NP O
24 621 622 15580403 - HYPH I-NP O
25 622 626 15580403 week NN I-NP O
26 627 638 15580403 combination NN I-NP O
27 639 646 15580403 therapy NN I-NP O
28 647 656 15580403 developed VBD B-VP O
29 657 663 15580403 anemia NN B-NP D000740
30 664 668 15580403 with IN B-PP O
31 669 679 15580403 hemoglobin NN B-NP O
32 680 685 15580403 level NN I-NP O
33 686 687 15580403 < SYM B-NP O
34 687 689 15580403 10 CD B-NP O
35 690 691 15580403 g NN I-NP O
36 691 692 15580403 / SYM B-NP O
37 692 694 15580403 dl NN B-NP O
38 695 697 15580403 or CC I-NP O
39 698 704 15580403 anemia NN I-NP D000740
40 704 705 15580403 - HYPH B-NP O
41 705 712 15580403 related VBN I-NP O
42 713 718 15580403 signs NNS I-NP O
43 719 725 15580403 during IN B-PP O
44 726 733 15580403 therapy NN B-NP O
45 733 734 15580403 . . O O

1 735 740 15580403 After IN B-PP O
2 741 745 15580403 that DT B-NP O
3 745 746 15580403 , , O O
4 747 752 15580403 these DT B-NP O
5 753 755 15580403 37 CD I-NP O
6 756 764 15580403 patients NNS I-NP O
7 765 769 15580403 were VBD B-VP O
8 770 777 15580403 reduced VBN I-VP O
9 778 781 15580403 one CD B-NP O
10 782 788 15580403 tablet NN I-NP O
11 789 791 15580403 of IN B-PP O
12 792 801 15580403 ribavirin NN B-NP D012254
13 802 803 15580403 ( ( O O
14 803 806 15580403 200 CD B-NP O
15 807 809 15580403 mg NN I-NP O
16 809 810 15580403 ) ) O O
17 811 814 15580403 per IN B-PP O
18 815 818 15580403 day NN B-NP O
19 818 819 15580403 . . O O

1 820 825 15580403 After IN B-PP O
2 826 835 15580403 reduction NN B-NP O
3 836 838 15580403 of IN B-PP O
4 839 848 15580403 ribavirin NN B-NP D012254
5 848 849 15580403 , , O O
6 850 852 15580403 27 CD B-NP O
7 853 855 15580403 of IN B-PP O
8 856 858 15580403 37 CD B-NP O
9 859 867 15580403 patients NNS I-NP O
10 868 873 15580403 could MD B-VP O
11 874 882 15580403 continue VB I-VP O
12 883 894 15580403 combination NN B-NP O
13 895 902 15580403 therapy NN I-NP O
14 903 906 15580403 for IN B-PP O
15 907 908 15580403 a DT B-NP O
16 909 914 15580403 total NN I-NP O
17 915 917 15580403 of IN B-PP O
18 918 920 15580403 24 CD B-NP O
19 921 926 15580403 weeks NNS I-NP O
20 927 928 15580403 ( ( O O
21 928 933 15580403 group NN B-NP O
22 934 935 15580403 A NN I-NP O
23 935 936 15580403 ) ) O O
24 936 937 15580403 . . O O

1 938 945 15580403 However RB B-ADVP O
2 945 946 15580403 , , O O
3 947 949 15580403 10 CD B-NP O
4 950 952 15580403 of IN B-PP O
5 953 955 15580403 37 CD B-NP O
6 956 964 15580403 patients NNS I-NP O
7 965 969 15580403 with IN B-PP O
8 970 979 15580403 reduction NN B-NP O
9 980 982 15580403 of IN B-PP O
10 983 992 15580403 ribavirin NN B-NP D012254
11 993 998 15580403 could MD B-VP O
12 999 1002 15580403 not RB I-VP O
13 1003 1011 15580403 continue VB I-VP O
14 1012 1023 15580403 combination NN B-NP O
15 1024 1031 15580403 therapy NN I-NP O
16 1032 1039 15580403 because IN B-SBAR O
17 1040 1045 15580403 their PRP$ B-NP O
18 1046 1047 15580403 < SYM I-NP O
19 1047 1050 15580403 8.5 CD I-NP O
20 1051 1052 15580403 g NN I-NP O
21 1052 1053 15580403 / SYM B-NP O
22 1053 1055 15580403 dl NN I-NP O
23 1056 1066 15580403 hemoglobin NN I-NP O
24 1067 1073 15580403 values NNS I-NP O
25 1074 1083 15580403 decreased VBD B-VP O
26 1084 1086 15580403 to TO B-PP O
27 1087 1089 15580403 or CC O O
28 1090 1096 15580403 anemia NN B-NP D000740
29 1096 1097 15580403 - HYPH O O
30 1097 1104 15580403 related VBN B-NP O
31 1105 1111 15580403 severe JJ I-NP O
32 1112 1116 15580403 side NN I-NP O
33 1117 1124 15580403 effects NNS I-NP O
34 1125 1133 15580403 occurred VBD B-VP O
35 1134 1135 15580403 ( ( O O
36 1135 1140 15580403 group NN B-NP O
37 1141 1142 15580403 B NN I-NP O
38 1142 1143 15580403 ) ) O O
39 1143 1144 15580403 . . O O

1 1145 1147 15580403 We PRP B-NP O
2 1148 1156 15580403 assessed VBD B-VP O
3 1157 1160 15580403 the DT B-NP O
4 1161 1166 15580403 final JJ I-NP O
5 1167 1175 15580403 efficacy NN I-NP O
6 1176 1179 15580403 and CC I-NP O
7 1180 1186 15580403 safety NN I-NP O
8 1187 1192 15580403 after IN B-PP O
9 1193 1202 15580403 reduction NN B-NP O
10 1203 1205 15580403 of IN B-PP O
11 1206 1215 15580403 ribavirin NN B-NP D012254
12 1216 1218 15580403 in IN B-PP O
13 1219 1225 15580403 groups NNS B-NP O
14 1226 1227 15580403 A NN I-NP O
15 1228 1231 15580403 and CC I-NP O
16 1232 1233 15580403 B NN I-NP O
17 1233 1234 15580403 . . O O

1 1235 1242 15580403 RESULTS NNS B-NP O
2 1242 1243 15580403 : : O O
3 1244 1245 15580403 A DT B-NP O
4 1246 1255 15580403 sustained JJ I-NP O
5 1256 1267 15580403 virological JJ I-NP O
6 1268 1276 15580403 response NN I-NP O
7 1277 1278 15580403 ( ( O O
8 1278 1281 15580403 SVR NN B-NP O
9 1281 1282 15580403 ) ) O O
10 1283 1286 15580403 was VBD B-VP O
11 1287 1292 15580403 29.6% CD B-NP O
12 1293 1294 15580403 ( ( O O
13 1294 1295 15580403 8 CD B-NP O
14 1295 1296 15580403 / SYM I-NP O
15 1296 1298 15580403 27 CD I-NP O
16 1298 1299 15580403 ) ) O O
17 1300 1302 15580403 in IN B-PP O
18 1303 1308 15580403 group NN B-NP O
19 1309 1310 15580403 A NN I-NP O
20 1311 1314 15580403 and CC O O
21 1315 1318 15580403 10% CD B-NP O
22 1319 1320 15580403 ( ( O O
23 1320 1321 15580403 1 CD B-NP O
24 1321 1322 15580403 / SYM B-NP O
25 1322 1324 15580403 10 CD I-NP O
26 1324 1325 15580403 ) ) O O
27 1326 1328 15580403 in IN B-PP O
28 1329 1334 15580403 group NN B-NP O
29 1335 1336 15580403 B NN I-NP O
30 1336 1337 15580403 , , O O
31 1338 1350 15580403 respectively RB B-ADVP O
32 1350 1351 15580403 . . O O

1 1352 1353 15580403 A DT B-NP O
2 1354 1359 15580403 34.4% NN I-NP O
3 1360 1361 15580403 ( ( O O
4 1361 1363 15580403 12 CD B-NP O
5 1363 1364 15580403 / SYM O O
6 1364 1366 15580403 27 CD B-NP O
7 1366 1367 15580403 ) ) O O
8 1368 1370 15580403 of IN B-PP O
9 1371 1374 15580403 SVR NN B-NP O
10 1375 1376 15580403 + CC O O
11 1377 1387 15580403 biological JJ B-NP O
12 1388 1396 15580403 response NN I-NP O
13 1397 1399 15580403 in IN B-PP O
14 1400 1405 15580403 group NN B-NP O
15 1406 1407 15580403 A NN I-NP O
16 1408 1411 15580403 was VBD B-VP O
17 1412 1418 15580403 higher JJR B-ADJP O
18 1419 1423 15580403 than IN B-PP O
19 1424 1427 15580403 10% CD B-NP O
20 1428 1429 15580403 ( ( O O
21 1429 1430 15580403 1 CD B-NP O
22 1430 1431 15580403 / SYM B-NP O
23 1431 1433 15580403 10 CD I-NP O
24 1433 1434 15580403 ) ) O O
25 1435 1437 15580403 in IN B-PP O
26 1438 1443 15580403 group NN B-NP O
27 1444 1445 15580403 B NN I-NP O
28 1446 1447 15580403 ( ( O O
29 1448 1449 15580403 P NN B-NP O
30 1450 1451 15580403 = SYM B-VP O
31 1452 1457 15580403 0.051 CD B-NP O
32 1457 1458 15580403 ) ) O O
33 1458 1459 15580403 , , O O
34 1460 1464 15580403 with IN B-PP O
35 1465 1471 15580403 slight JJ B-NP O
36 1472 1484 15580403 significance NN I-NP O
37 1484 1485 15580403 . . O O

1 1486 1490 15580403 With IN B-PP O
2 1491 1498 15580403 respect NN B-NP O
3 1499 1501 15580403 to TO B-PP O
4 1502 1512 15580403 hemoglobin NN B-NP O
5 1513 1518 15580403 level NN I-NP O
6 1519 1521 15580403 at IN B-PP O
7 1522 1525 15580403 the DT B-NP O
8 1526 1530 15580403 time NN I-NP O
9 1531 1533 15580403 of IN B-PP O
10 1534 1543 15580403 ribavirin NN B-NP D012254
11 1544 1553 15580403 reduction NN I-NP O
12 1553 1554 15580403 , , O O
13 1555 1556 15580403 a DT B-NP O
14 1557 1561 15580403 rate NN I-NP O
15 1562 1564 15580403 of IN B-PP O
16 1565 1577 15580403 continuation NN B-NP O
17 1578 1580 15580403 of IN B-PP O
18 1581 1588 15580403 therapy NN B-NP O
19 1589 1591 15580403 in IN B-PP O
20 1592 1600 15580403 patients NNS B-NP O
21 1601 1605 15580403 with IN B-PP O
22 1606 1607 15580403 > SYM B-NP O
23 1608 1610 15580403 or CC O O
24 1611 1612 15580403 = SYM B-NP O
25 1612 1614 15580403 10 CD I-NP O
26 1615 1616 15580403 g NN I-NP O
27 1616 1617 15580403 / SYM I-NP O
28 1617 1619 15580403 dl NN I-NP O
29 1620 1630 15580403 hemoglobin NN I-NP O
30 1631 1634 15580403 was VBD B-VP O
31 1635 1641 15580403 higher JJR B-ADJP O
32 1642 1646 15580403 than IN B-PP O
33 1647 1651 15580403 that DT B-NP O
34 1652 1654 15580403 in IN B-PP O
35 1655 1663 15580403 patients NNS B-NP O
36 1664 1668 15580403 with IN B-PP O
37 1669 1670 15580403 < SYM B-NP O
38 1670 1672 15580403 10 CD I-NP O
39 1673 1674 15580403 g NN I-NP O
40 1674 1675 15580403 / SYM B-NP O
41 1675 1677 15580403 dl NN B-NP O
42 1678 1679 15580403 ( ( O O
43 1680 1681 15580403 P NN B-NP O
44 1682 1683 15580403 = SYM B-VP O
45 1684 1689 15580403 0.036 CD B-NP O
46 1689 1690 15580403 ) ) O O
47 1690 1691 15580403 . . O O

1 1692 1703 15580403 CONCLUSIONS NNS B-NP O
2 1703 1704 15580403 : : O O
3 1705 1714 15580403 Reduction NN B-NP O
4 1715 1717 15580403 of IN B-PP O
5 1718 1727 15580403 ribavirin NN B-NP D012254
6 1728 1730 15580403 at IN B-PP O
7 1731 1741 15580403 hemoglobin NN B-NP O
8 1742 1747 15580403 level NN I-NP O
9 1748 1749 15580403 > SYM B-VP O
10 1750 1752 15580403 or CC O O
11 1753 1754 15580403 = SYM B-NP O
12 1754 1756 15580403 10 CD B-NP O
13 1757 1758 15580403 g NN I-NP O
14 1758 1759 15580403 / SYM B-NP O
15 1759 1761 15580403 dl NN I-NP O
16 1762 1764 15580403 is VBZ B-VP O
17 1765 1773 15580403 suitable JJ B-ADJP O
18 1774 1776 15580403 in IN B-PP O
19 1777 1782 15580403 terms NNS B-NP O
20 1783 1785 15580403 of IN B-PP O
21 1786 1794 15580403 efficacy NN B-NP O
22 1795 1798 15580403 and CC I-NP O
23 1799 1803 15580403 side NN I-NP O
24 1804 1811 15580403 effects NNS I-NP O
25 1811 1812 15580403 . . O O

1 0 0 15673851 -DOCSTART- -X- -X- O

1 0 3 15673851 The DT B-NP O
2 4 14 15673851 activation NN I-NP O
3 15 17 15673851 of IN B-PP O
4 18 24 15673851 spinal JJ B-NP O
5 25 26 15673851 N NN I-NP D016202
6 26 27 15673851 - HYPH B-NP D016202
7 27 33 15673851 methyl NN I-NP D016202
8 33 34 15673851 - HYPH B-NP D016202
9 34 35 15673851 D NN I-NP D016202
10 35 36 15673851 - HYPH B-NP D016202
11 36 45 15673851 aspartate NN I-NP D016202
12 46 55 15673851 receptors NNS I-NP O
13 56 59 15673851 may MD B-VP O
14 60 70 15673851 contribute VB I-VP O
15 71 73 15673851 to TO B-PP O
16 74 86 15673851 degeneration NN B-NP O
17 87 89 15673851 of IN B-PP O
18 90 96 15673851 spinal JJ B-NP O
19 97 102 15673851 motor NN I-NP O
20 103 110 15673851 neurons NNS I-NP O
21 111 118 15673851 induced VBN B-VP O
22 119 121 15673851 by IN B-PP O
23 122 131 15673851 neuraxial JJ B-NP O
24 132 140 15673851 morphine NN I-NP D009020
25 141 146 15673851 after IN B-PP O
26 147 148 15673851 a DT B-NP O
27 149 161 15673851 noninjurious JJ I-NP O
28 162 170 15673851 interval NN I-NP O
29 171 173 15673851 of IN B-PP O
30 174 180 15673851 spinal JJ B-NP D020760
31 181 185 15673851 cord NN I-NP D020760
32 186 194 15673851 ischemia NN I-NP D020760
33 194 195 15673851 . . O O
34 196 198 15673851 We PRP B-NP O
35 199 211 15673851 investigated VBD B-VP O
36 212 215 15673851 the DT B-NP O
37 216 228 15673851 relationship NN I-NP O
38 229 236 15673851 between IN B-PP O
39 237 240 15673851 the DT B-NP O
40 241 253 15673851 degeneration NN I-NP O
41 254 256 15673851 of IN B-PP O
42 257 263 15673851 spinal JJ B-NP O
43 264 269 15673851 motor NN I-NP O
44 270 277 15673851 neurons NNS I-NP O
45 278 281 15673851 and CC O O
46 282 292 15673851 activation NN B-NP O
47 293 295 15673851 of IN B-PP O
48 296 297 15673851 N NN B-NP D016202
49 297 298 15673851 - HYPH B-NP D016202
50 298 304 15673851 methyl NN I-NP D016202
51 304 305 15673851 - HYPH B-NP D016202
52 305 306 15673851 d NN I-NP D016202
53 306 307 15673851 - HYPH O D016202
54 307 316 15673851 aspartate NN B-NP D016202
55 317 318 15673851 ( ( O O
56 318 322 15673851 NMDA NN B-NP D016202
57 322 323 15673851 ) ) O O
58 324 333 15673851 receptors NNS B-NP O
59 334 339 15673851 after IN B-PP O
60 340 349 15673851 neuraxial JJ B-NP O
61 350 358 15673851 morphine NN I-NP D009020
62 359 368 15673851 following VBG B-PP O
63 369 370 15673851 a DT B-NP O
64 371 383 15673851 noninjurious JJ I-NP O
65 384 392 15673851 interval NN I-NP O
66 393 395 15673851 of IN B-PP O
67 396 402 15673851 aortic JJ B-NP D001157
68 403 412 15673851 occlusion NN I-NP D001157
69 413 415 15673851 in IN B-PP O
70 416 420 15673851 rats NNS B-NP O
71 420 421 15673851 . . O O

1 422 428 15673851 Spinal JJ B-NP D020760
2 429 433 15673851 cord NN I-NP D020760
3 434 442 15673851 ischemia NN I-NP D020760
4 443 446 15673851 was VBD B-VP O
5 447 454 15673851 induced VBN I-VP O
6 455 457 15673851 by IN B-PP O
7 458 464 15673851 aortic JJ B-NP D001157
8 465 474 15673851 occlusion NN I-NP D001157
9 475 478 15673851 for IN B-PP O
10 479 480 15673851 6 CD B-NP O
11 481 484 15673851 min NN I-NP O
12 485 489 15673851 with IN B-PP O
13 490 491 15673851 a DT B-NP O
14 492 499 15673851 balloon NN I-NP O
15 500 508 15673851 catheter NN I-NP O
16 508 509 15673851 . . O O

1 510 512 15673851 In IN B-PP O
2 513 514 15673851 a DT B-NP O
3 515 528 15673851 microdialysis NN I-NP O
4 529 534 15673851 study NN I-NP O
5 534 535 15673851 , , O O
6 536 538 15673851 10 CD B-NP O
7 539 542 15673851 muL NN I-NP O
8 543 545 15673851 of IN B-PP O
9 546 552 15673851 saline NN B-NP O
10 553 554 15673851 ( ( O O
11 554 559 15673851 group NN B-NP O
12 560 561 15673851 C NN I-NP O
13 561 562 15673851 ; : O O
14 563 564 15673851 n NN B-NP O
15 565 566 15673851 = SYM B-VP O
16 567 568 15673851 8 CD B-NP O
17 568 569 15673851 ) ) O O
18 570 572 15673851 or CC O O
19 573 575 15673851 30 CD B-NP O
20 576 579 15673851 mug NN I-NP O
21 580 582 15673851 of IN B-PP O
22 583 591 15673851 morphine NN B-NP D009020
23 592 593 15673851 ( ( O O
24 593 598 15673851 group NN B-NP O
25 599 600 15673851 M NN I-NP O
26 600 601 15673851 ; : O O
27 602 603 15673851 n NN B-NP O
28 604 605 15673851 = SYM B-VP O
29 606 607 15673851 8 CD B-NP O
30 607 608 15673851 ) ) O O
31 609 612 15673851 was VBD B-VP O
32 613 621 15673851 injected VBN I-VP O
33 622 635 15673851 intrathecally RB B-ADVP O
34 636 637 15673851 ( ( O O
35 637 639 15673851 IT RB B-ADVP O
36 639 640 15673851 ) ) O O
37 641 644 15673851 0.5 CD B-NP O
38 645 646 15673851 h NN I-NP O
39 647 652 15673851 after IN B-PP O
40 653 659 15673851 reflow NN B-NP O
41 659 660 15673851 , , O O
42 661 664 15673851 and CC O O
43 665 667 15673851 30 CD B-NP O
44 668 671 15673851 mug NN I-NP O
45 672 674 15673851 of IN B-PP O
46 675 683 15673851 morphine NN B-NP D009020
47 684 685 15673851 ( ( O O
48 685 690 15673851 group NN B-NP O
49 691 693 15673851 SM NN I-NP O
50 693 694 15673851 ; : O O
51 695 696 15673851 n NN B-NP O
52 697 698 15673851 = SYM B-VP O
53 699 700 15673851 8 CD B-NP O
54 700 701 15673851 ) ) O O
55 702 704 15673851 or CC O O
56 705 707 15673851 10 CD B-NP O
57 708 711 15673851 muL NN I-NP O
58 712 714 15673851 of IN B-PP O
59 715 721 15673851 saline NN B-NP O
60 722 723 15673851 ( ( O O
61 723 728 15673851 group NN B-NP O
62 729 731 15673851 SC NN I-NP O
63 731 732 15673851 ; : O O
64 733 734 15673851 n NN B-NP O
65 735 736 15673851 = SYM B-VP O
66 737 738 15673851 8 CD B-NP O
67 738 739 15673851 ) ) O O
68 740 743 15673851 was VBD B-VP O
69 744 752 15673851 injected VBN I-VP O
70 753 755 15673851 IT IN B-PP O
71 756 759 15673851 0.5 CD B-NP O
72 760 761 15673851 h NN I-NP O
73 762 767 15673851 after IN B-PP O
74 768 772 15673851 sham NN B-NP O
75 773 782 15673851 operation NN I-NP O
76 782 783 15673851 . . O O

1 784 797 15673851 Microdialysis NN B-NP O
2 798 805 15673851 samples NNS I-NP O
3 806 810 15673851 were VBD B-VP O
4 811 820 15673851 collected VBN I-VP O
5 821 832 15673851 preischemia NN B-NP O
6 832 833 15673851 , , O O
7 834 840 15673851 before IN B-PP O
8 841 843 15673851 IT NN B-NP O
9 844 853 15673851 injection NN I-NP O
10 853 854 15673851 , , O O
11 855 858 15673851 and CC O O
12 859 861 15673851 at IN B-PP O
13 862 863 15673851 2 CD B-NP O
14 863 864 15673851 , , I-NP O
15 865 866 15673851 4 CD I-NP O
16 866 867 15673851 , , I-NP O
17 868 869 15673851 8 CD I-NP O
18 869 870 15673851 , , I-NP O
19 871 873 15673851 24 CD I-NP O
20 873 874 15673851 , , O O
21 875 878 15673851 and CC O O
22 879 881 15673851 48 CD B-NP O
23 882 883 15673851 h NN I-NP O
24 884 886 15673851 of IN B-PP O
25 887 898 15673851 reperfusion NN B-NP O
26 899 900 15673851 ( ( O O
27 900 905 15673851 after IN B-PP O
28 906 908 15673851 IT NN B-NP O
29 909 918 15673851 injection NN I-NP O
30 918 919 15673851 ) ) O O
31 919 920 15673851 . . O O

1 921 927 15673851 Second RB B-ADVP O
2 927 928 15673851 , , O O
3 929 931 15673851 we PRP B-NP O
4 932 944 15673851 investigated VBD B-VP O
5 945 948 15673851 the DT B-NP O
6 949 955 15673851 effect NN I-NP O
7 956 958 15673851 of IN B-PP O
8 959 961 15673851 IT NN B-NP O
9 962 964 15673851 MK NN I-NP D016291
10 964 965 15673851 - HYPH O D016291
11 965 968 15673851 801 CD B-NP D016291
12 969 970 15673851 ( ( O O
13 970 972 15673851 30 CD B-NP O
14 973 976 15673851 mug NN I-NP O
15 976 977 15673851 ) ) O O
16 978 980 15673851 on IN B-PP O
17 981 984 15673851 the DT B-NP O
18 985 1000 15673851 histopathologic JJ I-NP O
19 1001 1008 15673851 changes NNS I-NP O
20 1009 1011 15673851 in IN B-PP O
21 1012 1015 15673851 the DT B-NP O
22 1016 1022 15673851 spinal JJ I-NP O
23 1023 1027 15673851 cord NN I-NP O
24 1028 1033 15673851 after IN B-PP O
25 1034 1042 15673851 morphine NN B-NP D009020
26 1042 1043 15673851 - HYPH B-NP O
27 1043 1050 15673851 induced VBN I-NP O
28 1051 1058 15673851 spastic JJ I-NP D020336
29 1059 1070 15673851 paraparesis NN I-NP D020336
30 1070 1071 15673851 . . O O

1 1072 1077 15673851 After IN B-PP O
2 1078 1080 15673851 IT PRP B-NP O
3 1081 1089 15673851 morphine NN I-NP D009020
4 1089 1090 15673851 , , O O
5 1091 1094 15673851 the DT B-NP O
6 1095 1108 15673851 cerebrospinal JJ I-NP O
7 1109 1114 15673851 fluid NN I-NP O
8 1115 1116 15673851 ( ( O O
9 1116 1119 15673851 CSF NN B-NP O
10 1119 1120 15673851 ) ) O O
11 1121 1130 15673851 glutamate NN B-NP D018698
12 1131 1144 15673851 concentration NN I-NP O
13 1145 1148 15673851 was VBD B-VP O
14 1149 1158 15673851 increased VBN I-VP O
15 1159 1161 15673851 in IN B-PP O
16 1162 1167 15673851 group NN B-NP O
17 1168 1169 15673851 M NN I-NP O
18 1170 1178 15673851 relative JJ B-ADJP O
19 1179 1181 15673851 to TO B-PP O
20 1182 1186 15673851 both CC O O
21 1187 1195 15673851 baseline NN B-NP O
22 1196 1199 15673851 and CC O O
23 1200 1205 15673851 group NN B-NP O
24 1206 1207 15673851 C NN I-NP O
25 1208 1209 15673851 ( ( O O
26 1209 1210 15673851 P NN B-NP O
27 1211 1212 15673851 < SYM O O
28 1213 1217 15673851 0.05 CD B-NP O
29 1217 1218 15673851 ) ) O O
30 1218 1219 15673851 . . O O

1 1220 1224 15673851 This DT B-NP O
2 1225 1233 15673851 increase NN I-NP O
3 1234 1243 15673851 persisted VBD B-VP O
4 1244 1247 15673851 for IN B-PP O
5 1248 1249 15673851 8 CD B-NP O
6 1250 1253 15673851 hrs NNS I-NP O
7 1253 1254 15673851 . . O O

1 1255 1257 15673851 IT NN B-NP O
2 1258 1260 15673851 MK NN I-NP D016291
3 1260 1261 15673851 - HYPH O D016291
4 1261 1264 15673851 801 CD B-NP D016291
5 1265 1278 15673851 significantly RB B-ADVP O
6 1279 1286 15673851 reduced VBD B-VP O
7 1287 1290 15673851 the DT B-NP O
8 1291 1297 15673851 number NN I-NP O
9 1298 1300 15673851 of IN B-PP O
10 1301 1305 15673851 dark NN B-NP O
11 1305 1306 15673851 - HYPH O O
12 1306 1313 15673851 stained VBN B-VP O
13 1314 1319 15673851 alpha SYM B-NP O
14 1319 1320 15673851 - HYPH B-VP O
15 1320 1331 15673851 motoneurons NNS B-NP O
16 1332 1337 15673851 after IN B-PP O
17 1338 1346 15673851 morphine NN B-NP D009020
18 1346 1347 15673851 - HYPH B-NP O
19 1347 1354 15673851 induced VBN I-NP O
20 1355 1362 15673851 spastic JJ I-NP D020336
21 1363 1374 15673851 paraparesis NN I-NP D020336
22 1375 1383 15673851 compared VBN B-PP O
23 1384 1388 15673851 with IN B-PP O
24 1389 1392 15673851 the DT B-NP O
25 1393 1399 15673851 saline NN I-NP O
26 1400 1405 15673851 group NN I-NP O
27 1405 1406 15673851 . . O O

1 1407 1412 15673851 These DT B-NP O
2 1413 1417 15673851 data NNS I-NP O
3 1418 1426 15673851 indicate VBP B-VP O
4 1427 1431 15673851 that IN B-SBAR O
5 1432 1434 15673851 IT NN B-NP O
6 1435 1443 15673851 morphine NN I-NP D009020
7 1444 1451 15673851 induces VBZ B-VP O
8 1452 1459 15673851 spastic JJ B-NP D020336
9 1460 1471 15673851 paraparesis NN I-NP D020336
10 1472 1476 15673851 with IN B-PP O
11 1477 1478 15673851 a DT B-NP O
12 1479 1490 15673851 concomitant JJ I-NP O
13 1491 1499 15673851 increase NN I-NP O
14 1500 1502 15673851 in IN B-PP O
15 1503 1506 15673851 CSF NN B-NP O
16 1507 1516 15673851 glutamate NN I-NP D018698
17 1516 1517 15673851 , , O O
18 1518 1523 15673851 which WDT B-NP O
19 1524 1526 15673851 is VBZ B-VP O
20 1527 1535 15673851 involved VBN I-VP O
21 1536 1538 15673851 in IN B-PP O
22 1539 1543 15673851 NMDA NN B-NP D016202
23 1544 1552 15673851 receptor NN I-NP O
24 1553 1563 15673851 activation NN I-NP O
25 1563 1564 15673851 . . O O

1 1565 1567 15673851 We PRP B-NP O
2 1568 1575 15673851 suggest VBP B-VP O
3 1576 1580 15673851 that IN B-SBAR O
4 1581 1588 15673851 opioids NNS B-NP O
5 1589 1592 15673851 may MD B-VP O
6 1593 1595 15673851 be VB I-VP O
7 1596 1606 15673851 neurotoxic JJ B-ADJP D020258
8 1607 1609 15673851 in IN B-PP O
9 1610 1613 15673851 the DT B-NP O
10 1614 1621 15673851 setting NN I-NP O
11 1622 1624 15673851 of IN B-PP O
12 1625 1631 15673851 spinal JJ B-NP D020760
13 1632 1636 15673851 cord NN I-NP D020760
14 1637 1645 15673851 ischemia NN I-NP D020760
15 1646 1649 15673851 via IN B-PP O
16 1650 1654 15673851 NMDA NN B-NP D016202
17 1655 1663 15673851 receptor NN I-NP O
18 1664 1674 15673851 activation NN I-NP O
19 1674 1675 15673851 . . O O

1 0 0 982002 -DOCSTART- -X- -X- O

1 0 5 982002 Acute JJ B-NP D058186
2 6 11 982002 renal JJ I-NP D058186
3 12 19 982002 failure NN I-NP D058186
4 20 30 982002 subsequent JJ B-ADJP O
5 31 33 982002 to TO B-PP O
6 34 37 982002 the DT B-NP O
7 38 52 982002 administration NN I-NP O
8 53 55 982002 of IN B-PP O
9 56 66 982002 rifampicin NN B-NP D012293
10 66 67 982002 . . O O

1 68 69 982002 A DT B-NP O
2 70 76 982002 follow VB B-VP O
3 76 77 982002 - HYPH O O
4 77 79 982002 up RP B-PRT O
5 80 85 982002 study NN B-NP O
6 86 88 982002 of IN B-PP O
7 89 94 982002 cases NNS B-NP O
8 95 103 982002 reported VBN B-VP O
9 104 111 982002 earlier RBR B-ADVP O
10 111 112 982002 . . O O
11 113 114 982002 A DT B-NP O
12 115 123 982002 clinical JJ I-NP O
13 124 136 982002 presentation NN I-NP O
14 137 139 982002 is VBZ B-VP O
15 140 144 982002 made VBN I-VP O
16 145 147 982002 of IN B-PP O
17 148 149 982002 a DT B-NP O
18 150 151 982002 2 CD I-NP O
19 151 152 982002 - HYPH I-NP O
20 152 153 982002 3 CD I-NP O
21 154 158 982002 year NN I-NP O
22 159 165 982002 follow VB B-VP O
23 165 166 982002 - HYPH O O
24 166 168 982002 up RP B-PRT O
25 169 171 982002 of IN B-PP O
26 172 175 982002 six CD B-NP O
27 176 181 982002 cases NNS I-NP O
28 182 184 982002 of IN B-PP O
29 185 190 982002 acute JJ B-NP D058186
30 191 196 982002 renal JJ I-NP D058186
31 197 204 982002 failure NN I-NP D058186
32 205 209 982002 that WDT B-NP O
33 210 214 982002 have VBP B-VP O
34 215 219 982002 been VBN I-VP O
35 220 228 982002 reported VBN I-VP O
36 229 236 982002 earlier RBR B-ADVP O
37 236 237 982002 . . O O

1 238 241 982002 The DT B-NP O
2 242 250 982002 patients NNS I-NP O
3 251 254 982002 had VBD B-VP O
4 255 264 982002 developed VBN I-VP O
5 265 274 982002 transient JJ B-NP O
6 275 280 982002 renal JJ I-NP D051437
7 281 288 982002 failure NN I-NP D051437
8 289 294 982002 after IN B-PP O
9 295 298 982002 the DT B-NP O
10 299 311 982002 intermittent JJ I-NP O
11 312 326 982002 administration NN I-NP O
12 327 329 982002 of IN B-PP O
13 330 340 982002 rifampicin NN B-NP D012293
14 340 341 982002 . . O O

1 342 345 982002 The DT B-NP O
2 346 351 982002 stage NN I-NP O
3 352 354 982002 of IN B-PP O
4 355 359 982002 olig NN B-NP O
5 359 360 982002 - HYPH B-NP O
6 360 366 982002 anuria NN I-NP D001002
7 367 373 982002 lasted VBN B-VP O
8 374 377 982002 for IN B-PP O
9 378 379 982002 1 CD B-NP O
10 379 380 982002 - HYPH I-NP O
11 380 381 982002 3 CD I-NP O
12 382 387 982002 weeks NNS I-NP O
13 387 388 982002 , , O O
14 389 392 982002 and CC O O
15 393 397 982002 five CD B-NP O
16 398 400 982002 of IN B-PP O
17 401 404 982002 the DT B-NP O
18 405 413 982002 patients NNS I-NP O
19 414 418 982002 were VBD B-VP O
20 419 426 982002 treated VBN I-VP O
21 427 429 982002 by IN B-PP O
22 430 442 982002 hemodialysis NN B-NP O
23 442 443 982002 . . O O

1 444 447 982002 Two CD B-NP O
2 448 450 982002 of IN B-PP O
3 451 454 982002 the DT B-NP O
4 455 463 982002 patients NNS I-NP O
5 464 468 982002 died VBD B-VP O
6 469 472 982002 due JJ B-ADJP O
7 473 475 982002 to TO B-PP O
8 476 485 982002 unrelated JJ B-NP O
9 486 492 982002 causes NNS I-NP O
10 493 499 982002 during IN B-PP O
11 500 503 982002 the DT B-NP O
12 504 510 982002 follow VB I-NP O
13 510 511 982002 - HYPH B-VP O
14 511 513 982002 up RP B-PRT O
15 514 520 982002 period NN B-NP O
16 520 521 982002 . . O O

1 522 525 982002 The DT B-NP O
2 526 530 982002 four CD I-NP O
3 531 539 982002 patients NNS I-NP O
4 540 542 982002 re AFX O O
5 542 543 982002 - HYPH O O
6 543 551 982002 examined VBN B-VP O
7 552 556 982002 were VBD B-VP O
8 557 567 982002 clinically RB I-VP O
9 568 573 982002 cured VBN I-VP O
10 573 574 982002 . . O O

1 575 585 982002 Pathologic JJ B-NP O
2 586 594 982002 findings NNS I-NP O
3 595 597 982002 by IN B-PP O
4 598 603 982002 light NN B-NP O
5 604 614 982002 microscopy NN I-NP O
6 615 618 982002 and CC O O
7 619 637 982002 immunofluorescence NN B-NP O
8 638 640 982002 at IN B-PP O
9 641 647 982002 biopsy NN B-NP O
10 648 652 982002 were VBD B-VP O
11 653 659 982002 scarce JJ B-ADJP O
12 659 660 982002 . . O O

1 661 668 982002 Nothing NN B-NP O
2 669 677 982002 abnormal JJ I-NP O
3 678 681 982002 was VBD B-VP O
4 682 686 982002 seen VBN I-VP O
5 687 689 982002 by IN B-PP O
6 690 698 982002 electron NN B-NP O
7 699 709 982002 microscopy NN I-NP O
8 710 712 982002 in IN B-PP O
9 713 716 982002 two CD B-NP O
10 717 719 982002 of IN B-PP O
11 720 723 982002 the DT B-NP O
12 724 729 982002 cases NNS I-NP O
13 730 737 982002 studied VBN B-VP O
14 737 738 982002 . . O O

1 739 744 982002 Renal JJ B-NP O
2 745 753 982002 function NN I-NP O
3 754 757 982002 was VBD B-VP O
4 758 764 982002 normal JJ B-ADJP O
5 764 765 982002 . . O O

1 766 768 982002 In IN B-PP O
2 769 774 982002 three CD B-NP O
3 775 780 982002 cases NNS I-NP O
4 781 784 982002 the DT B-NP O
5 785 794 982002 excretion NN I-NP O
6 795 797 982002 at IN B-PP O
7 798 802 982002 131I NN B-NP O
8 802 803 982002 - HYPH B-NP O
9 803 811 982002 hippuran NN I-NP O
10 812 822 982002 renography NN I-NP O
11 823 826 982002 was VBD B-VP O
12 827 835 982002 slightly RB I-VP O
13 836 842 982002 slowed VBN I-VP O
14 842 843 982002 . . O O

1 844 852 982002 Although IN B-SBAR O
2 853 855 982002 in IN B-PP O
3 856 859 982002 the DT B-NP O
4 860 865 982002 acute JJ I-NP O
5 866 871 982002 stage NN I-NP O
6 872 875 982002 the DT B-NP O
7 876 881 982002 renal JJ I-NP D007674
8 882 889 982002 lesions NNS I-NP D007674
9 890 904 982002 histologically RB B-ADVP O
10 905 913 982002 appeared VBD B-VP O
11 914 919 982002 toxic JJ B-NP O
12 919 920 982002 , , I-NP O
13 921 929 982002 evidence NN I-NP O
14 930 940 982002 suggestive JJ I-NP O
15 941 943 982002 of IN B-PP O
16 944 946 982002 an DT B-NP O
17 947 960 982002 immunological JJ I-NP O
18 961 970 982002 mechanism NN I-NP O
19 971 977 982002 cannot MD B-VP O
20 978 980 982002 be VB I-VP O
21 981 989 982002 excluded VBN I-VP O
22 989 990 982002 . . O O

1 0 0 1504402 -DOCSTART- -X- -X- O

1 0 16 1504402 Hypersensitivity NN B-NP D004342
2 17 23 1504402 immune JJ I-NP O
3 24 32 1504402 reaction NN I-NP O
4 33 35 1504402 as IN B-PP O
5 36 37 1504402 a DT B-NP O
6 38 47 1504402 mechanism NN I-NP O
7 48 51 1504402 for IN B-PP O
8 52 61 1504402 dilevalol NN B-NP D007741
9 61 62 1504402 - HYPH B-NP O
10 62 72 1504402 associated VBN I-NP O
11 73 82 1504402 hepatitis NN I-NP D056486
12 82 83 1504402 . . I-NP O
13 84 93 1504402 OBJECTIVE NN I-NP O
14 93 94 1504402 : : O O
15 95 97 1504402 To TO B-VP O
16 98 104 1504402 assess VB I-VP O
17 105 115 1504402 lymphocyte NN B-NP O
18 116 126 1504402 reactivity NN I-NP O
19 127 129 1504402 to TO B-PP O
20 130 139 1504402 dilevalol NN B-NP D007741
21 140 143 1504402 and CC B-PP O
22 144 146 1504402 to TO B-PP O
23 147 152 1504402 serum NN B-NP O
24 153 163 1504402 containing VBG B-VP O
25 164 172 1504402 putative JJ B-NP O
26 173 175 1504402 ex FW I-NP O
27 176 180 1504402 vivo FW I-NP O
28 181 190 1504402 dilevalol NN I-NP D007741
29 191 199 1504402 antigens NNS I-NP O
30 200 202 1504402 or CC I-NP O
31 203 214 1504402 metabolites NNS I-NP O
32 215 217 1504402 in IN B-PP O
33 218 219 1504402 a DT B-NP O
34 220 224 1504402 case NN I-NP O
35 225 227 1504402 of IN B-PP O
36 228 237 1504402 dilevalol NN B-NP D007741
37 237 238 1504402 - HYPH O O
38 238 245 1504402 induced VBN B-NP O
39 246 251 1504402 liver NN I-NP D056486
40 252 258 1504402 injury NN I-NP D056486
41 258 259 1504402 . . O O

1 260 267 1504402 PATIENT NN B-NP O
2 267 268 1504402 : : O O
3 269 270 1504402 A DT B-NP O
4 271 273 1504402 58 CD I-NP O
5 273 274 1504402 - HYPH I-NP O
6 274 278 1504402 year NN I-NP O
7 278 279 1504402 - HYPH O O
8 279 282 1504402 old JJ B-NP O
9 283 288 1504402 woman NN I-NP O
10 289 293 1504402 with IN B-PP O
11 294 295 1504402 a DT B-NP O
12 296 304 1504402 clinical JJ I-NP O
13 305 314 1504402 diagnosis NN I-NP O
14 315 317 1504402 of IN B-PP O
15 318 327 1504402 dilevalol NN B-NP D007741
16 327 328 1504402 - HYPH O O
17 328 335 1504402 induced VBN B-NP O
18 336 341 1504402 liver NN I-NP D056486
19 342 348 1504402 injury NN I-NP D056486
20 348 349 1504402 . . O O

1 350 357 1504402 METHODS NNS B-NP O
2 357 358 1504402 : : O O
3 359 369 1504402 Peripheral JJ B-NP O
4 370 375 1504402 blood NN I-NP O
5 376 387 1504402 mononuclear JJ I-NP O
6 388 393 1504402 cells NNS I-NP O
7 394 403 1504402 collected VBN B-VP O
8 404 408 1504402 from IN B-PP O
9 409 412 1504402 the DT B-NP O
10 413 420 1504402 patient NN I-NP O
11 421 425 1504402 were VBD B-VP O
12 426 434 1504402 cultured VBN I-VP O
13 435 437 1504402 in IN B-PP O
14 438 441 1504402 the DT B-NP O
15 442 450 1504402 presence NN I-NP O
16 451 453 1504402 of IN B-PP O
17 454 455 1504402 a DT B-NP O
18 456 464 1504402 solution NN I-NP O
19 465 467 1504402 of IN B-PP O
20 468 477 1504402 dilevalol NN B-NP D007741
21 478 481 1504402 and CC O O
22 482 486 1504402 also RB B-ADVP O
23 487 491 1504402 with IN B-PP O
24 492 496 1504402 sera NNS B-NP O
25 497 506 1504402 collected VBN B-VP O
26 507 511 1504402 from IN B-PP O
27 512 513 1504402 a DT B-NP O
28 514 523 1504402 volunteer NN I-NP O
29 524 530 1504402 before IN B-PP O
30 531 534 1504402 and CC I-PP O
31 535 540 1504402 after IN I-PP O
32 541 550 1504402 dilevalol NN B-NP D007741
33 551 557 1504402 intake NN I-NP O
34 557 558 1504402 . . O O

1 559 560 1504402 A DT B-NP O
2 561 568 1504402 similar JJ I-NP O
3 569 577 1504402 protocol NN I-NP O
4 578 581 1504402 was VBD B-VP O
5 582 591 1504402 performed VBN I-VP O
6 592 596 1504402 with IN B-PP O
7 597 608 1504402 lymphocytes NNS B-NP O
8 609 613 1504402 from IN B-PP O
9 614 615 1504402 a DT B-NP O
10 616 623 1504402 healthy JJ I-NP O
11 624 631 1504402 subject NN I-NP O
12 631 632 1504402 . . O O

1 633 640 1504402 RESULTS NNS B-NP O
2 640 641 1504402 : : O O
3 642 644 1504402 No DT B-NP O
4 645 655 1504402 lymphocyte NN I-NP O
5 656 669 1504402 proliferation NN I-NP O
6 670 673 1504402 was VBD B-VP O
7 674 682 1504402 observed VBN I-VP O
8 683 689 1504402 either CC O O
9 690 692 1504402 in IN B-PP O
10 693 696 1504402 the DT B-NP O
11 697 704 1504402 patient NN I-NP O
12 705 707 1504402 or CC B-PP O
13 708 710 1504402 in IN B-PP O
14 711 714 1504402 the DT B-NP O
15 715 722 1504402 healthy JJ I-NP O
16 723 732 1504402 volunteer NN I-NP O
17 733 735 1504402 in IN B-PP O
18 736 739 1504402 the DT I-PP O
19 740 748 1504402 presence NN I-PP O
20 749 751 1504402 of IN I-PP O
21 752 761 1504402 dilevalol NN B-NP D007741
22 762 771 1504402 solutions NNS I-NP O
23 771 772 1504402 . . O O

1 773 774 1504402 A DT B-NP O
2 775 786 1504402 significant JJ I-NP O
3 787 800 1504402 proliferative JJ I-NP O
4 801 809 1504402 response NN I-NP O
5 810 812 1504402 to TO B-PP O
6 813 818 1504402 serum NN B-NP O
7 819 828 1504402 collected VBN B-VP O
8 829 834 1504402 after IN B-PP O
9 835 844 1504402 dilevalol NN B-NP D007741
10 845 851 1504402 intake NN I-NP O
11 852 855 1504402 was VBD B-VP O
12 856 864 1504402 observed VBN I-VP O
13 865 867 1504402 in IN B-PP O
14 868 871 1504402 the DT B-NP O
15 872 876 1504402 case NN I-NP O
16 877 879 1504402 of IN B-PP O
17 880 883 1504402 the DT B-NP O
18 884 891 1504402 patient NN I-NP O
19 892 900 1504402 compared VBN B-PP O
20 901 905 1504402 with IN B-PP O
21 906 909 1504402 the DT B-NP O
22 910 923 1504402 proliferative JJ I-NP O
23 924 932 1504402 response NN I-NP O
24 933 935 1504402 to TO B-PP O
25 936 939 1504402 the DT B-NP O
26 940 945 1504402 serum NN I-NP O
27 946 955 1504402 collected VBN B-VP O
28 956 962 1504402 before IN B-PP O
29 963 966 1504402 the DT B-NP O
30 967 971 1504402 drug NN I-NP O
31 972 978 1504402 intake NN I-NP O
32 978 979 1504402 . . O O

1 980 982 1504402 No DT B-NP O
2 983 993 1504402 reactivity NN I-NP O
3 994 997 1504402 was VBD B-VP O
4 998 1003 1504402 found VBN I-VP O
5 1004 1008 1504402 when WRB B-ADVP O
6 1009 1020 1504402 lymphocytes NNS B-NP O
7 1021 1025 1504402 from IN B-PP O
8 1026 1029 1504402 the DT B-NP O
9 1030 1037 1504402 healthy JJ I-NP O
10 1038 1045 1504402 subject NN I-NP O
11 1046 1050 1504402 were VBD B-VP O
12 1051 1057 1504402 tested VBN I-VP O
13 1058 1063 1504402 under IN B-PP O
14 1064 1071 1504402 similar JJ B-NP O
15 1072 1082 1504402 conditions NNS I-NP O
16 1082 1083 1504402 . . O O

1 1084 1095 1504402 CONCLUSIONS NNS B-NP O
2 1095 1096 1504402 : : O O
3 1097 1100 1504402 The DT B-NP O
4 1101 1112 1504402 methodology NN I-NP O
5 1113 1117 1504402 used VBN B-VP O
6 1118 1125 1504402 allowed VBD B-VP O
7 1126 1129 1504402 the DT B-NP O
8 1130 1139 1504402 detection NN I-NP O
9 1140 1142 1504402 of IN B-PP O
10 1143 1153 1504402 lymphocyte NN B-NP O
11 1154 1167 1504402 sensitization NN I-NP O
12 1168 1170 1504402 to TO B-PP O
13 1171 1175 1504402 sera NNS B-NP O
14 1176 1186 1504402 containing VBG B-VP O
15 1187 1189 1504402 ex FW B-ADVP O
16 1190 1194 1504402 vivo FW B-ADVP O
17 1194 1195 1504402 - HYPH I-ADVP O
18 1195 1203 1504402 prepared VBN B-NP O
19 1204 1213 1504402 dilevalol NN I-NP D007741
20 1214 1222 1504402 antigens NNS I-NP O
21 1222 1223 1504402 , , O O
22 1224 1234 1504402 suggesting VBG B-VP O
23 1235 1238 1504402 the DT B-NP O
24 1239 1250 1504402 involvement NN I-NP O
25 1251 1253 1504402 of IN B-PP O
26 1254 1256 1504402 an DT B-NP O
27 1257 1268 1504402 immunologic JJ I-NP O
28 1269 1278 1504402 mechanism NN I-NP O
29 1279 1281 1504402 in IN B-PP O
30 1282 1291 1504402 dilevalol NN B-NP D007741
31 1291 1292 1504402 - HYPH O O
32 1292 1299 1504402 induced VBN B-NP O
33 1300 1305 1504402 liver NN I-NP D056486
34 1306 1312 1504402 injury NN I-NP D056486
35 1312 1313 1504402 . . O O

1 0 0 16174948 -DOCSTART- -X- -X- O

1 0 7 16174948 Absence NN B-NP O
2 8 10 16174948 of IN B-PP O
3 11 16 16174948 acute JJ B-NP O
4 17 25 16174948 cerebral JJ I-NP O
5 26 42 16174948 vasoconstriction NN I-NP O
6 43 48 16174948 after IN B-PP O
7 49 56 16174948 cocaine NN B-NP D003042
8 56 57 16174948 - HYPH O O
9 57 67 16174948 associated VBN B-NP O
10 68 80 16174948 subarachnoid JJ I-NP D013345
11 81 91 16174948 hemorrhage NN I-NP D013345
12 91 92 16174948 . . I-NP O
13 93 105 16174948 INTRODUCTION NN I-NP O
14 105 106 16174948 : : O O
15 107 114 16174948 Cocaine NN B-NP D003042
16 115 118 16174948 use NN I-NP O
17 119 122 16174948 has VBZ B-VP O
18 123 127 16174948 been VBN I-VP O
19 128 138 16174948 associated VBN I-VP O
20 139 143 16174948 with IN B-PP O
21 144 157 16174948 neurovascular JJ B-NP D013901
22 158 171 16174948 complications NNS I-NP D013901
23 171 172 16174948 , , O O
24 173 182 16174948 including VBG B-PP O
25 183 191 16174948 arterial JJ B-NP O
26 192 208 16174948 vasoconstriction NN I-NP O
27 209 212 16174948 and CC I-NP O
28 213 223 16174948 vasculitis NN I-NP D014657
29 223 224 16174948 . . O O

1 225 232 16174948 However RB B-ADVP O
2 232 233 16174948 , , O O
3 234 239 16174948 there EX B-NP O
4 240 243 16174948 are VBP B-VP O
5 244 247 16174948 few JJ B-NP O
6 248 255 16174948 studies NNS I-NP O
7 256 258 16174948 of IN B-PP O
8 259 271 16174948 angiographic JJ B-NP O
9 272 279 16174948 effects NNS I-NP O
10 280 282 16174948 of IN B-PP O
11 283 290 16174948 cocaine NN B-NP D003042
12 291 293 16174948 on IN B-PP O
13 294 299 16174948 human JJ B-NP O
14 300 308 16174948 cerebral JJ I-NP O
15 309 317 16174948 arteries NNS I-NP O
16 317 318 16174948 . . O O

1 319 330 16174948 Information NN B-NP O
2 331 333 16174948 on IN B-PP O
3 334 339 16174948 these DT B-NP O
4 340 347 16174948 effects NNS I-NP O
5 348 353 16174948 could MD B-VP O
6 354 356 16174948 be VB I-VP O
7 357 365 16174948 obtained VBN I-VP O
8 366 370 16174948 from IN B-PP O
9 371 381 16174948 angiograms NNS B-NP O
10 382 384 16174948 of IN B-PP O
11 385 393 16174948 patients NNS B-NP O
12 394 398 16174948 with IN B-PP O
13 399 406 16174948 cocaine NN B-NP D003042
14 406 407 16174948 - HYPH B-NP O
15 407 417 16174948 associated VBN I-NP O
16 418 430 16174948 subarachnoid NN I-NP D013345
17 431 441 16174948 hemorrhage NN I-NP D013345
18 442 443 16174948 ( ( O O
19 443 446 16174948 SAH NN B-NP D013345
20 446 447 16174948 ) ) O O
21 448 451 16174948 who WP B-NP O
22 452 461 16174948 underwent VBD B-VP O
23 462 473 16174948 angiography NN B-NP O
24 474 481 16174948 shortly RB B-ADVP O
25 482 487 16174948 after IN B-PP O
26 488 495 16174948 cocaine NN B-NP D003042
27 496 499 16174948 use NN I-NP O
28 499 500 16174948 . . O O

1 501 508 16174948 METHODS NNS B-NP O
2 508 509 16174948 : : O O
3 510 512 16174948 We PRP B-NP O
4 513 521 16174948 screened VBD B-VP O
5 522 530 16174948 patients NNS B-NP O
6 531 535 16174948 with IN B-PP O
7 536 539 16174948 SAH NN B-NP D013345
8 540 555 16174948 retrospectively RB B-ADVP O
9 556 559 16174948 and CC O O
10 560 570 16174948 identified VBD B-VP O
11 571 576 16174948 those DT B-NP O
12 577 581 16174948 with IN B-PP O
13 582 590 16174948 positive JJ B-NP O
14 591 596 16174948 urine NN I-NP O
15 597 607 16174948 toxicology NN I-NP O
16 608 611 16174948 for IN B-PP O
17 612 619 16174948 cocaine NN B-NP D003042
18 620 622 16174948 or CC O O
19 623 626 16174948 its PRP$ B-NP O
20 627 638 16174948 metabolites NNS I-NP O
21 638 639 16174948 . . O O

1 640 652 16174948 Quantitative JJ B-NP O
2 653 661 16174948 arterial JJ I-NP O
3 662 670 16174948 diameter NN I-NP O
4 671 683 16174948 measurements NNS I-NP O
5 684 688 16174948 from IN B-PP O
6 689 699 16174948 angiograms NNS B-NP O
7 700 702 16174948 of IN B-PP O
8 703 708 16174948 these DT B-NP O
9 709 717 16174948 patients NNS I-NP O
10 718 722 16174948 were VBD B-VP O
11 723 731 16174948 compared VBN I-VP O
12 732 734 16174948 to TO B-PP O
13 735 747 16174948 measurements NNS B-NP O
14 748 752 16174948 from IN B-PP O
15 753 760 16174948 control NN B-NP O
16 761 769 16174948 patients NNS I-NP O
17 770 774 16174948 with IN B-PP O
18 775 778 16174948 SAH NN B-NP D013345
19 779 782 16174948 who WP B-NP O
20 783 787 16174948 were VBD B-VP O
21 788 795 16174948 matched VBN I-VP O
22 796 799 16174948 for IN B-PP O
23 800 807 16174948 factors NNS B-NP O
24 808 813 16174948 known VBN B-VP O
25 814 816 16174948 to TO I-VP O
26 817 826 16174948 influence VB I-VP O
27 827 835 16174948 arterial JJ B-NP O
28 836 844 16174948 diameter NN I-NP O
29 844 845 16174948 . . O O

1 846 857 16174948 Qualitative JJ B-NP O
2 858 869 16174948 comparisons NNS I-NP O
3 870 872 16174948 of IN B-PP O
4 873 878 16174948 small JJ B-NP O
5 879 885 16174948 artery NN I-NP O
6 886 893 16174948 changes NNS I-NP O
7 894 898 16174948 also RB B-ADVP O
8 899 903 16174948 were VBD B-VP O
9 904 908 16174948 made VBN I-VP O
10 908 909 16174948 . . O O

1 910 917 16174948 RESULTS NNS B-NP O
2 917 918 16174948 : : O O
3 919 927 16174948 Thirteen CD B-NP O
4 928 936 16174948 patients NNS I-NP O
5 937 941 16174948 with IN B-PP O
6 942 950 16174948 positive JJ B-NP O
7 951 958 16174948 cocaine NN I-NP D003042
8 959 969 16174948 toxicology NN I-NP O
9 970 974 16174948 were VBD B-VP O
10 975 983 16174948 compared VBN I-VP O
11 984 986 16174948 to TO B-PP O
12 987 989 16174948 26 CD B-NP O
13 990 998 16174948 controls NNS I-NP O
14 998 999 16174948 . . O O

1 1000 1005 16174948 There EX B-NP O
2 1006 1010 16174948 were VBD B-VP O
3 1011 1013 16174948 no DT B-NP O
4 1014 1025 16174948 significant JJ I-NP O
5 1026 1037 16174948 differences NNS I-NP O
6 1038 1045 16174948 between IN B-PP O
7 1046 1052 16174948 groups NNS B-NP O
8 1053 1055 16174948 in IN B-PP O
9 1056 1059 16174948 the DT B-NP O
10 1060 1064 16174948 mean JJ I-NP O
11 1065 1074 16174948 diameters NNS I-NP O
12 1075 1077 16174948 of IN B-PP O
13 1078 1081 16174948 the DT B-NP O
14 1082 1092 16174948 intradural JJ I-NP O
15 1093 1101 16174948 internal JJ I-NP O
16 1102 1109 16174948 carotid NN I-NP O
17 1109 1110 16174948 , , O O
18 1111 1121 16174948 sphenoidal JJ B-NP O
19 1122 1129 16174948 segment NN I-NP O
20 1130 1132 16174948 of IN B-PP O
21 1133 1136 16174948 the DT B-NP O
22 1137 1143 16174948 middle JJ I-NP O
23 1144 1152 16174948 cerebral NN I-NP O
24 1152 1153 16174948 , , O O
25 1154 1170 16174948 precommunicating VBG B-VP O
26 1171 1178 16174948 segment NN B-NP O
27 1179 1181 16174948 of IN B-PP O
28 1182 1185 16174948 the DT B-NP O
29 1186 1194 16174948 anterior JJ I-NP O
30 1195 1203 16174948 cerebral NN I-NP O
31 1203 1204 16174948 , , O O
32 1205 1207 16174948 or CC O O
33 1208 1215 16174948 basilar JJ B-NP O
34 1216 1224 16174948 arteries NNS I-NP O
35 1225 1226 16174948 ( ( O O
36 1226 1227 16174948 p NN B-NP O
37 1228 1235 16174948 greater JJR B-ADJP O
38 1236 1240 16174948 than IN B-PP O
39 1241 1245 16174948 0.05 CD B-NP O
40 1246 1249 16174948 for IN B-PP O
41 1250 1253 16174948 all DT B-NP O
42 1254 1265 16174948 comparisons NNS I-NP O
43 1265 1266 16174948 , , O O
44 1267 1275 16174948 unpaired JJ B-NP O
45 1276 1277 16174948 t NN I-NP O
46 1277 1278 16174948 - HYPH B-NP O
47 1278 1283 16174948 tests NNS I-NP O
48 1283 1284 16174948 ) ) O O
49 1284 1285 16174948 . . O O

1 1286 1291 16174948 There EX B-NP O
2 1292 1296 16174948 also RB B-ADVP O
3 1297 1301 16174948 were VBD B-VP O
4 1302 1304 16174948 no DT B-NP O
5 1305 1316 16174948 significant JJ I-NP O
6 1317 1328 16174948 differences NNS I-NP O
7 1329 1336 16174948 between IN B-PP O
8 1337 1343 16174948 groups NNS B-NP O
9 1344 1348 16174948 when WRB B-ADVP O
10 1349 1359 16174948 expressing VBG B-VP O
11 1360 1369 16174948 diameters NNS B-NP O
12 1370 1372 16174948 as IN B-PP O
13 1373 1376 16174948 the DT B-NP O
14 1377 1380 16174948 sum NN I-NP O
15 1381 1383 16174948 of IN B-PP O
16 1384 1387 16174948 the DT B-NP O
17 1388 1404 16174948 precommunicating VBG I-NP O
18 1405 1412 16174948 segment NN I-NP O
19 1413 1415 16174948 of IN B-PP O
20 1416 1419 16174948 the DT B-NP O
21 1420 1428 16174948 anterior JJ I-NP O
22 1429 1437 16174948 cerebral JJ I-NP O
23 1438 1439 16174948 + JJ I-NP O
24 1440 1450 16174948 sphenoidal JJ I-NP O
25 1451 1458 16174948 segment NN I-NP O
26 1459 1461 16174948 of IN B-PP O
27 1462 1465 16174948 the DT B-NP O
28 1466 1472 16174948 middle JJ I-NP O
29 1473 1481 16174948 cerebral JJ I-NP O
30 1482 1483 16174948 + SYM I-NP O
31 1484 1496 16174948 supraclinoid JJ I-NP O
32 1497 1505 16174948 internal JJ I-NP O
33 1506 1513 16174948 carotid NN I-NP O
34 1514 1520 16174948 artery NN I-NP O
35 1521 1522 16174948 + CC O O
36 1523 1530 16174948 basilar JJ B-NP O
37 1531 1537 16174948 artery NN I-NP O
38 1538 1545 16174948 divided VBN B-VP O
39 1546 1548 16174948 by IN B-PP O
40 1549 1552 16174948 the DT B-NP O
41 1553 1561 16174948 diameter NN I-NP O
42 1562 1564 16174948 of IN B-PP O
43 1565 1568 16174948 the DT B-NP O
44 1569 1576 16174948 petrous JJ I-NP O
45 1577 1585 16174948 internal JJ I-NP O
46 1586 1593 16174948 carotid NN I-NP O
47 1594 1600 16174948 artery NN I-NP O
48 1601 1602 16174948 ( ( O O
49 1602 1603 16174948 p NN B-NP O
50 1604 1611 16174948 greater JJR B-ADJP O
51 1612 1616 16174948 than IN B-PP O
52 1617 1621 16174948 0.05 CD B-NP O
53 1621 1622 16174948 , , O O
54 1623 1631 16174948 unpaired JJ B-NP O
55 1632 1633 16174948 t NN I-NP O
56 1633 1634 16174948 - HYPH B-NP O
57 1634 1639 16174948 tests NNS I-NP O
58 1639 1640 16174948 ) ) O O
59 1640 1641 16174948 . . O O

1 1642 1653 16174948 Qualitative JJ B-NP O
2 1654 1665 16174948 assessments NNS I-NP O
3 1666 1672 16174948 showed VBD B-VP O
4 1673 1676 16174948 two CD B-NP O
5 1677 1685 16174948 arterial JJ I-NP O
6 1686 1700 16174948 irregularities NNS I-NP O
7 1701 1703 16174948 in IN B-PP O
8 1704 1707 16174948 the DT B-NP O
9 1708 1714 16174948 distal JJ I-NP O
10 1715 1726 16174948 vasculature NN I-NP O
11 1727 1729 16174948 in IN B-PP O
12 1730 1734 16174948 each DT B-NP O
13 1735 1740 16174948 group NN I-NP O
14 1740 1741 16174948 . . O O

1 1742 1752 16174948 CONCLUSION NN B-NP O
2 1752 1753 16174948 : : O O
3 1754 1756 16174948 No DT B-NP O
4 1757 1769 16174948 quantitative JJ I-NP O
5 1770 1778 16174948 evidence NN I-NP O
6 1779 1782 16174948 for IN B-PP O
7 1783 1792 16174948 narrowing NN B-NP O
8 1793 1795 16174948 of IN B-PP O
9 1796 1801 16174948 large JJ B-NP O
10 1802 1810 16174948 cerebral JJ I-NP O
11 1811 1819 16174948 arteries NNS I-NP O
12 1820 1822 16174948 or CC O O
13 1823 1834 16174948 qualitative JJ B-NP O
14 1835 1847 16174948 angiographic JJ I-NP O
15 1848 1856 16174948 evidence NN I-NP O
16 1857 1860 16174948 for IN B-PP O
17 1861 1867 16174948 distal JJ B-NP O
18 1868 1877 16174948 narrowing NN I-NP O
19 1878 1880 16174948 or CC I-NP O
20 1881 1891 16174948 vasculitis NN I-NP D014657
21 1892 1897 16174948 could MD B-VP O
22 1898 1900 16174948 be VB I-VP O
23 1901 1906 16174948 found VBN I-VP O
24 1907 1909 16174948 in IN B-PP O
25 1910 1918 16174948 patients NNS B-NP O
26 1919 1922 16174948 who WP B-NP O
27 1923 1932 16174948 underwent VBD B-VP O
28 1933 1944 16174948 angiography NN B-NP O
29 1945 1950 16174948 after IN B-PP O
30 1951 1961 16174948 aneurysmal JJ B-NP D017542
31 1962 1965 16174948 SAH NN I-NP D013345
32 1966 1976 16174948 associated VBN B-VP O
33 1977 1981 16174948 with IN B-PP O
34 1982 1989 16174948 cocaine NN B-NP D003042
35 1990 1993 16174948 use NN I-NP O
36 1993 1994 16174948 . . O O

1 0 0 2466960 -DOCSTART- -X- -X- O

1 0 10 2466960 Continuous JJ B-NP O
2 11 21 2466960 ambulatory JJ I-NP O
3 22 25 2466960 ECG NN I-NP O
4 26 36 2466960 monitoring VBG B-VP O
5 37 43 2466960 during IN B-PP O
6 44 56 2466960 fluorouracil NN B-NP D005472
7 57 64 2466960 therapy NN I-NP O
8 64 65 2466960 : : O O
9 66 67 2466960 a DT B-NP O
10 68 79 2466960 prospective JJ I-NP O
11 80 85 2466960 study NN I-NP O
12 85 86 2466960 . . O O
13 87 95 2466960 Although IN B-SBAR O
14 96 101 2466960 there EX B-NP O
15 102 106 2466960 have VBP B-VP O
16 107 111 2466960 been VBN I-VP O
17 112 121 2466960 anecdotal JJ B-NP O
18 122 129 2466960 reports NNS I-NP O
19 130 132 2466960 of IN B-PP O
20 133 140 2466960 cardiac JJ B-NP D066126
21 141 149 2466960 toxicity NN I-NP D066126
22 150 160 2466960 associated VBN B-VP O
23 161 165 2466960 with IN B-PP O
24 166 178 2466960 fluorouracil NN B-NP D005472
25 179 180 2466960 ( ( O O
26 180 181 2466960 5 CD B-NP D005472
27 181 182 2466960 - HYPH I-NP D005472
28 182 184 2466960 FU NN I-NP D005472
29 184 185 2466960 ) ) O O
30 186 193 2466960 therapy NN B-NP O
31 193 194 2466960 , , O O
32 195 199 2466960 this DT B-NP O
33 200 210 2466960 phenomenon NN I-NP O
34 211 214 2466960 has VBZ B-VP O
35 215 218 2466960 not RB I-VP O
36 219 223 2466960 been VBN I-VP O
37 224 231 2466960 studied VBN I-VP O
38 232 234 2466960 in IN B-PP O
39 235 236 2466960 a DT B-NP O
40 237 247 2466960 systematic JJ I-NP O
41 248 255 2466960 fashion NN I-NP O
42 255 256 2466960 . . O O

1 257 259 2466960 We PRP B-NP O
2 260 273 2466960 prospectively RB B-ADVP O
3 274 283 2466960 performed VBD B-VP O
4 284 294 2466960 continuous JJ B-NP O
5 295 305 2466960 ambulatory JJ I-NP O
6 306 309 2466960 ECG NN I-NP O
7 310 320 2466960 monitoring VBG B-VP O
8 321 323 2466960 on IN B-PP O
9 324 326 2466960 25 CD B-NP O
10 327 335 2466960 patients NNS I-NP O
11 336 346 2466960 undergoing VBG B-VP O
12 347 348 2466960 5 CD B-NP D005472
13 348 349 2466960 - HYPH I-NP D005472
14 349 351 2466960 FU NN I-NP D005472
15 352 360 2466960 infusion NN I-NP O
16 361 364 2466960 for IN B-PP O
17 365 374 2466960 treatment NN B-NP O
18 375 377 2466960 of IN B-PP O
19 378 383 2466960 solid JJ B-NP O
20 384 390 2466960 tumors NNS I-NP D009369
21 391 393 2466960 in IN B-SBAR O
22 394 399 2466960 order NN O O
23 400 402 2466960 to TO B-VP O
24 403 409 2466960 assess VB I-VP O
25 410 413 2466960 the DT B-NP O
26 414 423 2466960 incidence NN I-NP O
27 424 426 2466960 of IN B-PP O
28 427 435 2466960 ischemic JJ B-NP D007511
29 436 438 2466960 ST NN I-NP O
30 439 446 2466960 changes NNS I-NP O
31 446 447 2466960 . . O O

1 448 456 2466960 Patients NNS B-NP O
2 457 461 2466960 were VBD B-VP O
3 462 471 2466960 monitored VBN I-VP O
4 472 475 2466960 for IN B-PP O
5 476 478 2466960 23 CD B-NP O
6 479 480 2466960 + SYM O O
7 480 481 2466960 / SYM O O
8 481 482 2466960 - SYM O O
9 483 484 2466960 4 CD B-NP O
10 485 490 2466960 hours NNS I-NP O
11 491 497 2466960 before IN B-PP O
12 498 499 2466960 5 CD B-NP D005472
13 499 500 2466960 - HYPH I-NP D005472
14 500 502 2466960 FU NN I-NP D005472
15 503 511 2466960 infusion NN I-NP O
16 511 512 2466960 , , O O
17 513 516 2466960 and CC O O
18 517 519 2466960 98 CD B-NP O
19 520 521 2466960 + SYM O O
20 521 522 2466960 / SYM B-NP O
21 522 523 2466960 - SYM B-PP O
22 524 525 2466960 9 CD B-NP O
23 526 531 2466960 hours NNS I-NP O
24 532 538 2466960 during IN B-PP O
25 539 540 2466960 5 CD B-NP D005472
26 540 541 2466960 - HYPH I-NP D005472
27 541 543 2466960 FU NN I-NP D005472
28 544 552 2466960 infusion NN I-NP O
29 552 553 2466960 . . O O

1 554 561 2466960 Anginal JJ B-NP D000787
2 562 570 2466960 episodes NNS I-NP O
3 571 575 2466960 were VBD B-VP O
4 576 580 2466960 rare JJ B-ADJP O
5 580 581 2466960 : : O O
6 582 586 2466960 only RB B-NP O
7 587 590 2466960 one CD I-NP O
8 591 598 2466960 patient NN I-NP O
9 599 602 2466960 had VBD B-VP O
10 603 609 2466960 angina NN B-NP D000787
11 610 611 2466960 ( ( O O
12 611 617 2466960 during IN B-PP O
13 618 619 2466960 5 CD B-NP D005472
14 619 620 2466960 - HYPH I-NP D005472
15 620 622 2466960 FU NN I-NP D005472
16 623 631 2466960 infusion NN I-NP O
17 631 632 2466960 ) ) O O
18 632 633 2466960 . . O O

1 634 641 2466960 However RB B-ADVP O
2 641 642 2466960 , , O O
3 643 655 2466960 asymptomatic JJ B-NP O
4 656 658 2466960 ST NN I-NP O
5 659 666 2466960 changes NNS I-NP O
6 667 668 2466960 ( ( O O
7 668 675 2466960 greater JJR B-ADJP O
8 676 680 2466960 than IN B-PP O
9 681 683 2466960 or CC O O
10 684 689 2466960 equal JJ B-ADJP O
11 690 692 2466960 to TO B-PP O
12 693 694 2466960 1 CD B-NP O
13 695 697 2466960 mm NN I-NP O
14 698 700 2466960 ST NN I-NP O
15 701 710 2466960 deviation NN I-NP O
16 710 711 2466960 ) ) O O
17 712 716 2466960 were VBD B-VP O
18 717 723 2466960 common JJ B-ADJP O
19 723 724 2466960 : : O O
20 725 728 2466960 six CD B-NP O
21 729 731 2466960 of IN B-PP O
22 732 734 2466960 25 CD B-NP O
23 735 743 2466960 patients NNS I-NP O
24 744 745 2466960 ( ( O O
25 745 748 2466960 24% NN B-NP O
26 748 749 2466960 ) ) O O
27 750 753 2466960 had VBD B-VP O
28 754 756 2466960 ST JJ B-NP O
29 757 764 2466960 changes NNS I-NP O
30 765 771 2466960 before IN B-PP O
31 772 773 2466960 5 CD B-NP D005472
32 773 774 2466960 - HYPH I-NP D005472
33 774 776 2466960 FU NN I-NP D005472
34 777 785 2466960 infusion NN I-NP O
35 786 787 2466960 v NN I-NP O
36 788 790 2466960 17 CD I-NP O
37 791 792 2466960 ( ( O O
38 792 795 2466960 68% CD B-NP O
39 795 796 2466960 ) ) O O
40 797 803 2466960 during IN B-PP O
41 804 805 2466960 5 CD B-NP D005472
42 805 806 2466960 - HYPH I-NP D005472
43 806 808 2466960 FU NN I-NP D005472
44 809 817 2466960 infusion NN I-NP O
45 818 819 2466960 ( ( O O
46 819 820 2466960 P NN B-NP O
47 821 825 2466960 less JJR B-ADJP O
48 826 830 2466960 than IN B-PP O
49 831 835 2466960 .002 CD B-NP O
50 835 836 2466960 ) ) O O
51 836 837 2466960 . . O O

1 838 841 2466960 The DT B-NP O
2 842 851 2466960 incidence NN I-NP O
3 852 854 2466960 of IN B-PP O
4 855 863 2466960 ischemic JJ B-NP D007511
5 864 872 2466960 episodes NNS I-NP O
6 873 876 2466960 per IN B-PP O
7 877 884 2466960 patient NN B-NP O
8 885 888 2466960 per IN B-PP O
9 889 893 2466960 hour NN B-NP O
10 894 897 2466960 was VBD B-VP O
11 898 902 2466960 0.05 CD B-NP O
12 903 904 2466960 + SYM O O
13 904 905 2466960 / SYM O O
14 905 906 2466960 - SYM O O
15 907 911 2466960 0.02 CD B-NP O
16 912 917 2466960 prior RB B-ADVP O
17 918 920 2466960 to TO B-PP O
18 921 922 2466960 5 CD B-NP D005472
19 922 923 2466960 - HYPH I-NP D005472
20 923 925 2466960 FU NN I-NP D005472
21 926 934 2466960 infusion NN I-NP O
22 935 936 2466960 v IN B-PP O
23 937 941 2466960 0.13 CD B-NP O
24 942 943 2466960 + SYM O O
25 943 944 2466960 / SYM O O
26 944 945 2466960 - SYM O O
27 946 950 2466960 0.03 CD B-NP O
28 951 957 2466960 during IN B-PP O
29 958 959 2466960 5 CD B-NP D005472
30 959 960 2466960 - HYPH I-NP D005472
31 960 962 2466960 FU NN I-NP D005472
32 963 971 2466960 infusion NN I-NP O
33 972 973 2466960 ( ( O O
34 973 974 2466960 P NN B-NP O
35 975 979 2466960 less JJR B-ADJP O
36 980 984 2466960 than IN B-PP O
37 985 989 2466960 .001 CD B-NP O
38 989 990 2466960 ) ) O O
39 990 991 2466960 ; : O O
40 992 995 2466960 the DT B-NP O
41 996 1004 2466960 duration NN I-NP O
42 1005 1007 2466960 of IN B-PP O
43 1008 1011 2466960 ECG NN B-NP O
44 1012 1019 2466960 changes NNS I-NP O
45 1020 1023 2466960 was VBD B-VP O
46 1024 1027 2466960 0.6 CD B-NP O
47 1028 1029 2466960 + SYM O O
48 1029 1030 2466960 / SYM O O
49 1030 1031 2466960 - SYM B-NP O
50 1032 1035 2466960 0.3 CD B-NP O
51 1036 1043 2466960 minutes NNS I-NP O
52 1044 1047 2466960 per IN B-PP O
53 1048 1055 2466960 patient NN B-NP O
54 1056 1059 2466960 per IN B-PP O
55 1060 1064 2466960 hour NN B-NP O
56 1065 1071 2466960 before IN B-PP O
57 1072 1073 2466960 5 CD B-NP D005472
58 1073 1074 2466960 - HYPH I-NP D005472
59 1074 1076 2466960 FU NN I-NP D005472
60 1077 1078 2466960 v SYM B-NP O
61 1079 1082 2466960 1.9 CD I-NP O
62 1083 1084 2466960 + SYM B-NP O
63 1084 1085 2466960 / SYM B-NP O
64 1085 1086 2466960 - SYM B-VP O
65 1087 1090 2466960 0.5 CD B-NP O
66 1091 1098 2466960 minutes NNS I-NP O
67 1099 1102 2466960 per IN B-PP O
68 1103 1110 2466960 patient NN B-NP O
69 1111 1114 2466960 per IN B-PP O
70 1115 1119 2466960 hour NN B-NP O
71 1120 1126 2466960 during IN B-PP O
72 1127 1128 2466960 5 CD B-NP D005472
73 1128 1129 2466960 - HYPH I-NP D005472
74 1129 1131 2466960 FU NN I-NP D005472
75 1132 1133 2466960 ( ( O O
76 1133 1134 2466960 P NN B-NP O
77 1135 1139 2466960 less JJR B-ADJP O
78 1140 1144 2466960 than IN B-PP O
79 1145 1148 2466960 .01 CD B-NP O
80 1148 1149 2466960 ) ) O O
81 1149 1150 2466960 . . O O

1 1151 1154 2466960 ECG NN B-NP O
2 1155 1162 2466960 changes NNS I-NP O
3 1163 1167 2466960 were VBD B-VP O
4 1168 1172 2466960 more RBR B-ADJP O
5 1173 1179 2466960 common JJ I-ADJP O
6 1180 1185 2466960 among IN B-PP O
7 1186 1194 2466960 patients NNS B-NP O
8 1195 1199 2466960 with IN B-PP O
9 1200 1205 2466960 known JJ B-NP O
10 1206 1214 2466960 coronary JJ I-NP D003324
11 1215 1221 2466960 artery NN I-NP D003324
12 1222 1229 2466960 disease NN I-NP D003324
13 1229 1230 2466960 . . O O

1 1231 1236 2466960 There EX B-NP O
2 1237 1241 2466960 were VBD B-VP O
3 1242 1245 2466960 two CD B-NP O
4 1246 1251 2466960 cases NNS I-NP O
5 1252 1254 2466960 of IN B-PP O
6 1255 1261 2466960 sudden JJ B-NP D003645
7 1262 1267 2466960 death NN I-NP D003645
8 1267 1268 2466960 , , O O
9 1269 1273 2466960 both DT B-NP O
10 1274 1276 2466960 of IN B-PP O
11 1277 1282 2466960 which WDT B-NP O
12 1283 1291 2466960 occurred VBD B-VP O
13 1292 1294 2466960 at IN B-PP O
14 1295 1298 2466960 the DT B-NP O
15 1299 1302 2466960 end NN I-NP O
16 1303 1305 2466960 of IN B-PP O
17 1306 1309 2466960 the DT B-NP O
18 1310 1322 2466960 chemotherapy NN I-NP O
19 1323 1329 2466960 course NN I-NP O
20 1329 1330 2466960 . . O O

1 1331 1333 2466960 We PRP B-NP O
2 1334 1342 2466960 conclude VBP B-VP O
3 1343 1347 2466960 that IN B-SBAR O
4 1348 1349 2466960 5 CD B-NP D005472
5 1349 1350 2466960 - HYPH I-NP D005472
6 1350 1352 2466960 FU NN I-NP D005472
7 1353 1361 2466960 infusion NN I-NP O
8 1362 1364 2466960 is VBZ B-VP O
9 1365 1375 2466960 associated VBN I-VP O
10 1376 1380 2466960 with IN B-PP O
11 1381 1382 2466960 a DT B-NP O
12 1383 1394 2466960 significant JJ I-NP O
13 1395 1403 2466960 increase NN I-NP O
14 1404 1406 2466960 in IN B-PP O
15 1407 1413 2466960 silent JJ B-NP O
16 1414 1416 2466960 ST NN I-NP O
17 1417 1424 2466960 segment NN I-NP O
18 1425 1434 2466960 deviation NN I-NP O
19 1435 1445 2466960 suggestive JJ B-ADJP O
20 1446 1448 2466960 of IN B-PP O
21 1449 1457 2466960 ischemia NN B-NP D007511
22 1457 1458 2466960 , , O O
23 1459 1471 2466960 particularly RB B-ADVP O
24 1472 1477 2466960 among IN B-PP O
25 1478 1486 2466960 patients NNS B-NP O
26 1487 1491 2466960 with IN B-PP O
27 1492 1500 2466960 coronary JJ B-NP D003324
28 1501 1507 2466960 artery NN I-NP D003324
29 1508 1515 2466960 disease NN I-NP D003324
30 1515 1516 2466960 . . O O

1 1517 1520 2466960 The DT B-NP O
2 1521 1530 2466960 mechanism NN I-NP O
3 1531 1534 2466960 and CC O O
4 1535 1543 2466960 clinical JJ B-NP O
5 1544 1556 2466960 significance NN I-NP O
6 1557 1559 2466960 of IN B-PP O
7 1560 1565 2466960 these DT B-NP O
8 1566 1569 2466960 ECG NN I-NP O
9 1570 1577 2466960 changes NNS I-NP O
10 1578 1584 2466960 remain VBP B-VP O
11 1585 1587 2466960 to TO I-VP O
12 1588 1590 2466960 be VB I-VP O
13 1591 1601 2466960 determined VBN I-VP O
14 1601 1602 2466960 . . O O

1 0 0 1928887 -DOCSTART- -X- -X- O

1 0 8 1928887 Naloxone NN B-NP D009270
2 9 17 1928887 reversal NN I-NP O
3 18 20 1928887 of IN B-PP O
4 21 32 1928887 hypotension NN B-NP D007022
5 33 36 1928887 due JJ B-ADJP O
6 37 39 1928887 to TO B-VP O
7 40 49 1928887 captopril VB I-VP D002216
8 50 58 1928887 overdose NN B-NP D062787
9 58 59 1928887 . . O O
10 60 63 1928887 The DT B-NP O
11 64 75 1928887 hemodynamic JJ I-NP O
12 76 83 1928887 effects NNS I-NP O
13 84 86 1928887 of IN B-PP O
14 87 96 1928887 captopril NN B-NP D002216
15 97 100 1928887 and CC O O
16 101 106 1928887 other JJ B-NP O
17 107 118 1928887 angiotensin NN I-NP D000806
18 118 119 1928887 - HYPH B-NP D000806
19 119 129 1928887 converting VBG B-VP D000806
20 130 136 1928887 enzyme NN B-NP D000806
21 137 147 1928887 inhibitors NNS I-NP D000806
22 148 151 1928887 may MD B-VP O
23 152 154 1928887 be VB I-VP O
24 155 163 1928887 mediated VBN I-VP O
25 164 166 1928887 by IN B-PP O
26 167 170 1928887 the DT B-NP O
27 171 181 1928887 endogenous JJ I-NP O
28 182 188 1928887 opioid JJ I-NP O
29 189 195 1928887 system NN I-NP O
30 195 196 1928887 . . O O

1 197 200 1928887 The DT B-NP O
2 201 207 1928887 opioid JJ I-NP O
3 208 218 1928887 antagonist NN I-NP O
4 219 227 1928887 naloxone NN I-NP D009270
5 228 231 1928887 has VBZ B-VP O
6 232 236 1928887 been VBN I-VP O
7 237 242 1928887 shown VBN I-VP O
8 243 245 1928887 to TO I-VP O
9 246 251 1928887 block VB I-VP O
10 252 254 1928887 or CC I-VP O
11 255 262 1928887 reverse VB I-VP O
12 263 266 1928887 the DT B-NP O
13 267 278 1928887 hypotensive JJ I-NP D007022
14 279 286 1928887 actions NNS I-NP O
15 287 289 1928887 of IN B-PP O
16 290 299 1928887 captopril NN B-NP D002216
17 299 300 1928887 . . O O

1 301 303 1928887 We PRP B-NP O
2 304 310 1928887 report VBP B-VP O
3 311 312 1928887 a DT B-NP O
4 313 317 1928887 case NN I-NP O
5 318 320 1928887 of IN B-PP O
6 321 323 1928887 an DT B-NP O
7 324 335 1928887 intentional JJ I-NP O
8 336 345 1928887 captopril NN I-NP D002216
9 346 354 1928887 overdose NN I-NP D062787
10 354 355 1928887 , , O O
11 356 366 1928887 manifested VBN B-VP O
12 367 369 1928887 by IN B-PP O
13 370 376 1928887 marked JJ B-NP O
14 377 388 1928887 hypotension NN I-NP D007022
15 388 389 1928887 , , O O
16 390 394 1928887 that WDT B-NP O
17 395 403 1928887 resolved VBD B-VP O
18 404 412 1928887 promptly RB B-ADVP O
19 413 417 1928887 with IN B-PP O
20 418 421 1928887 the DT B-NP O
21 422 436 1928887 administration NN I-NP O
22 437 439 1928887 of IN B-PP O
23 440 448 1928887 naloxone NN B-NP D009270
24 448 449 1928887 . . O O

1 450 452 1928887 To TO B-PP O
2 453 456 1928887 our PRP$ B-NP O
3 457 466 1928887 knowledge NN I-NP O
4 466 467 1928887 , , O O
5 468 472 1928887 this DT B-NP O
6 473 475 1928887 is VBZ B-VP O
7 476 479 1928887 the DT B-NP O
8 480 485 1928887 first JJ I-NP O
9 486 494 1928887 reported VBN I-NP O
10 495 499 1928887 case NN I-NP O
11 500 502 1928887 of IN B-PP O
12 503 512 1928887 captopril NN B-NP D002216
13 512 513 1928887 - HYPH B-NP O
14 513 520 1928887 induced VBN I-NP O
15 521 532 1928887 hypotension NN I-NP D007022
16 533 540 1928887 treated VBN B-VP O
17 541 545 1928887 with IN B-PP O
18 546 554 1928887 naloxone NN B-NP D009270
19 554 555 1928887 . . O O

1 556 559 1928887 Our PRP$ B-NP O
2 560 570 1928887 experience NN I-NP O
3 571 583 1928887 demonstrates VBZ B-VP O
4 584 585 1928887 a DT B-NP O
5 586 594 1928887 possible JJ I-NP O
6 595 599 1928887 role NN I-NP O
7 600 602 1928887 of IN B-PP O
8 603 611 1928887 naloxone NN B-NP D009270
9 612 614 1928887 in IN B-PP O
10 615 618 1928887 the DT B-NP O
11 619 627 1928887 reversal NN I-NP O
12 628 630 1928887 of IN B-PP O
13 631 642 1928887 hypotension NN B-NP D007022
14 643 652 1928887 resulting VBG B-VP O
15 653 657 1928887 from IN B-PP O
16 658 667 1928887 captopril NN B-NP D002216
17 667 668 1928887 . . O O

1 0 0 2886572 -DOCSTART- -X- -X- O

1 0 8 2886572 Enhanced VBN B-NP O
2 9 17 2886572 stimulus NN I-NP O
3 17 18 2886572 - HYPH O O
4 18 25 2886572 induced VBN B-NP O
5 26 42 2886572 neurotransmitter NN I-NP O
6 43 51 2886572 overflow NN I-NP O
7 52 54 2886572 in IN B-PP O
8 55 66 2886572 epinephrine NN B-NP D004837
9 66 67 2886572 - HYPH B-NP O
10 67 74 2886572 induced VBN I-NP O
11 75 87 2886572 hypertensive JJ I-NP D006973
12 88 92 2886572 rats NNS I-NP O
13 93 95 2886572 is VBZ B-VP O
14 96 99 2886572 not RB I-VP O
15 100 108 2886572 mediated VBN I-VP O
16 109 111 2886572 by IN B-PP O
17 112 125 2886572 prejunctional JJ B-NP O
18 126 130 2886572 beta SYM I-NP O
19 130 131 2886572 - HYPH I-NP O
20 131 143 2886572 adrenoceptor NN I-NP O
21 144 154 2886572 activation NN I-NP O
22 154 155 2886572 . . O O
23 156 159 2886572 The DT B-NP O
24 160 167 2886572 present JJ I-NP O
25 168 173 2886572 study NN I-NP O
26 174 182 2886572 examines VBZ B-VP O
27 183 186 2886572 the DT B-NP O
28 187 193 2886572 effect NN I-NP O
29 194 196 2886572 of IN B-PP O
30 197 198 2886572 6 CD B-NP O
31 198 199 2886572 - HYPH I-NP O
32 199 202 2886572 day NN I-NP O
33 203 214 2886572 epinephrine NN I-NP D004837
34 215 224 2886572 treatment NN I-NP O
35 225 226 2886572 ( ( O O
36 226 229 2886572 100 CD B-NP O
37 230 240 2886572 micrograms NNS I-NP O
38 240 241 2886572 / SYM B-NP O
39 241 243 2886572 kg NN I-NP O
40 244 247 2886572 per IN B-PP O
41 248 249 2886572 h NN B-NP O
42 249 250 2886572 , , O O
43 251 254 2886572 s.c NN B-NP O
44 254 255 2886572 . . O O
45 255 256 2886572 ) ) O O
46 257 259 2886572 on IN B-PP O
47 260 268 2886572 stimulus NN B-NP O
48 268 269 2886572 - HYPH O O
49 269 276 2886572 induced VBN B-VP O
50 277 278 2886572 ( ( O O
51 278 279 2886572 1 CD B-NP O
52 280 282 2886572 Hz NN I-NP O
53 282 283 2886572 ) ) O O
54 284 294 2886572 endogenous JJ B-NP O
55 295 311 2886572 neurotransmitter NN I-NP O
56 312 320 2886572 overflow NN I-NP O
57 321 325 2886572 from IN B-PP O
58 326 329 2886572 the DT B-NP O
59 330 338 2886572 isolated VBN I-NP O
60 339 347 2886572 perfused VBN I-NP O
61 348 354 2886572 kidney NN I-NP O
62 355 357 2886572 of IN B-PP O
63 358 365 2886572 vehicle NN B-NP O
64 365 366 2886572 - HYPH B-NP O
65 367 370 2886572 and CC I-NP O
66 371 382 2886572 epinephrine NN I-NP D004837
67 382 383 2886572 - HYPH O O
68 383 390 2886572 treated VBN B-NP O
69 391 395 2886572 rats NNS I-NP O
70 395 396 2886572 . . O O

1 397 402 2886572 Renal JJ B-NP O
2 403 416 2886572 catecholamine NN I-NP D002395
3 417 423 2886572 stores NNS I-NP O
4 424 427 2886572 and CC I-NP O
5 428 436 2886572 stimulus NN I-NP O
6 436 437 2886572 - HYPH B-NP O
7 437 444 2886572 induced VBN I-NP O
8 445 453 2886572 overflow NN I-NP O
9 454 456 2886572 in IN B-PP O
10 457 460 2886572 the DT B-NP O
11 461 468 2886572 vehicle NN I-NP O
12 468 469 2886572 - HYPH B-NP O
13 469 476 2886572 treated VBN I-NP O
14 477 482 2886572 group NN I-NP O
15 483 492 2886572 consisted VBD B-VP O
16 493 495 2886572 of IN B-PP O
17 496 510 2886572 norepinephrine NN B-NP D009638
18 511 515 2886572 only RB B-ADVP O
19 515 516 2886572 . . O O

1 517 524 2886572 However RB B-ADVP O
2 524 525 2886572 , , O O
3 526 537 2886572 epinephrine NN B-NP D004837
4 538 547 2886572 treatment NN I-NP O
5 548 556 2886572 resulted VBD B-VP O
6 557 559 2886572 in IN B-PP O
7 560 563 2886572 the DT B-NP O
8 564 577 2886572 incorporation NN I-NP O
9 578 580 2886572 of IN B-PP O
10 581 592 2886572 epinephrine NN B-NP D004837
11 593 597 2886572 into IN B-PP O
12 598 603 2886572 renal JJ B-NP O
13 604 617 2886572 catecholamine NN I-NP D002395
14 618 624 2886572 stores NNS I-NP O
15 625 629 2886572 such JJ B-ADJP O
16 630 634 2886572 that IN B-SBAR O
17 635 648 2886572 approximately RB B-NP O
18 649 652 2886572 40% CD I-NP O
19 653 655 2886572 of IN B-PP O
20 656 659 2886572 the DT B-NP O
21 660 673 2886572 catecholamine NN I-NP D002395
22 674 681 2886572 present NN I-NP O
23 682 685 2886572 was VBD B-VP O
24 686 697 2886572 epinephrine NN B-NP D004837
25 698 703 2886572 while IN B-SBAR O
26 704 707 2886572 the DT B-NP O
27 708 722 2886572 norepinephrine NN I-NP D009638
28 723 730 2886572 content NN I-NP O
29 731 734 2886572 was VBD B-VP O
30 735 742 2886572 reduced VBN I-VP O
31 743 745 2886572 by IN B-PP O
32 746 747 2886572 a DT B-NP O
33 748 755 2886572 similar JJ I-NP O
34 756 762 2886572 degree NN I-NP O
35 762 763 2886572 . . O O

1 764 769 2886572 Total JJ B-NP O
2 770 776 2886572 tissue NN I-NP O
3 777 790 2886572 catecholamine NN I-NP D002395
4 791 798 2886572 content NN I-NP O
5 799 801 2886572 of IN B-PP O
6 802 805 2886572 the DT B-NP O
7 806 812 2886572 kidney NN I-NP O
8 813 815 2886572 on IN B-PP O
9 816 817 2886572 a DT B-NP O
10 818 823 2886572 molar JJ I-NP O
11 824 829 2886572 basis NN I-NP O
12 830 833 2886572 was VBD B-VP O
13 834 843 2886572 unchanged JJ B-ADJP O
14 843 844 2886572 . . O O

1 845 853 2886572 Stimulus NN B-NP O
2 853 854 2886572 - HYPH O O
3 854 861 2886572 induced VBN B-NP O
4 862 872 2886572 fractional JJ I-NP O
5 873 881 2886572 overflow NN I-NP O
6 882 884 2886572 of IN B-PP O
7 885 901 2886572 neurotransmitter NN B-NP O
8 902 906 2886572 from IN B-PP O
9 907 910 2886572 the DT B-NP O
10 911 922 2886572 epinephrine NN I-NP D004837
11 922 923 2886572 - HYPH B-NP O
12 923 930 2886572 treated VBN I-NP O
13 931 938 2886572 kidneys NNS I-NP O
14 939 942 2886572 was VBD B-VP O
15 943 956 2886572 approximately RB B-ADVP O
16 957 962 2886572 twice RB B-ADJP O
17 963 969 2886572 normal JJ I-ADJP O
18 970 973 2886572 and CC O O
19 974 983 2886572 consisted VBD B-VP O
20 984 986 2886572 of IN B-PP O
21 987 991 2886572 both CC O O
22 992 1006 2886572 norepinephrine NN B-NP D009638
23 1007 1010 2886572 and CC I-NP O
24 1011 1022 2886572 epinephrine NN I-NP D004837
25 1023 1025 2886572 in IN B-PP O
26 1026 1037 2886572 proportions NNS B-NP O
27 1038 1045 2886572 similar JJ B-ADJP O
28 1046 1048 2886572 to TO B-PP O
29 1049 1054 2886572 those DT B-NP O
30 1055 1060 2886572 found VBN B-VP O
31 1061 1063 2886572 in IN B-PP O
32 1064 1067 2886572 the DT B-NP O
33 1068 1074 2886572 kidney NN I-NP O
34 1074 1075 2886572 . . O O

1 1076 1080 2886572 This DT B-NP O
2 1081 1091 2886572 difference NN I-NP O
3 1092 1094 2886572 in IN B-PP O
4 1095 1105 2886572 fractional JJ B-NP O
5 1106 1114 2886572 overflow NN I-NP O
6 1115 1122 2886572 between IN B-PP O
7 1123 1129 2886572 groups NNS B-NP O
8 1130 1133 2886572 was VBD B-VP O
9 1134 1137 2886572 not RB I-VP O
10 1138 1146 2886572 affected VBN I-VP O
11 1147 1149 2886572 by IN B-PP O
12 1150 1158 2886572 neuronal JJ B-NP O
13 1159 1162 2886572 and CC I-NP O
14 1163 1176 2886572 extraneuronal JJ I-NP O
15 1177 1183 2886572 uptake NN I-NP O
16 1184 1192 2886572 blockade NN I-NP O
17 1192 1193 2886572 . . O O

1 1194 1205 2886572 Propranolol NN B-NP D011433
2 1206 1209 2886572 had VBD B-VP O
3 1210 1212 2886572 no DT B-NP O
4 1213 1219 2886572 effect NN I-NP O
5 1220 1222 2886572 on IN B-PP O
6 1223 1231 2886572 stimulus NN B-NP O
7 1231 1232 2886572 - HYPH B-NP O
8 1232 1239 2886572 induced VBN I-NP O
9 1240 1248 2886572 overflow NN I-NP O
10 1249 1251 2886572 in IN B-PP O
11 1252 1258 2886572 either DT B-NP O
12 1259 1264 2886572 group NN I-NP O
13 1264 1265 2886572 . . O O

1 1266 1278 2886572 Phentolamine NN B-NP D010646
2 1279 1288 2886572 increased VBD B-VP O
3 1289 1297 2886572 stimulus NN B-NP O
4 1297 1298 2886572 - HYPH O O
5 1298 1305 2886572 induced VBN B-NP O
6 1306 1314 2886572 overflow NN I-NP O
7 1315 1317 2886572 in IN B-PP O
8 1318 1322 2886572 both DT B-NP O
9 1323 1329 2886572 groups NNS I-NP O
10 1330 1338 2886572 although IN B-SBAR O
11 1339 1342 2886572 the DT B-NP O
12 1343 1352 2886572 increment NN I-NP O
13 1353 1355 2886572 in IN B-PP O
14 1356 1364 2886572 overflow NN B-NP O
15 1365 1368 2886572 was VBD B-VP O
16 1369 1376 2886572 greater JJR B-ADJP O
17 1377 1379 2886572 in IN B-PP O
18 1380 1383 2886572 the DT B-NP O
19 1384 1395 2886572 epinephrine NN I-NP D004837
20 1395 1396 2886572 - HYPH B-NP O
21 1396 1403 2886572 treated VBN I-NP O
22 1404 1409 2886572 group NN I-NP O
23 1409 1410 2886572 . . O O

1 1411 1413 2886572 In IN B-PP O
2 1414 1424 2886572 conclusion NN B-NP O
3 1424 1425 2886572 , , O O
4 1426 1433 2886572 chronic JJ B-NP O
5 1434 1445 2886572 epinephrine NN I-NP D004837
6 1446 1455 2886572 treatment NN I-NP O
7 1456 1463 2886572 results VBZ B-VP O
8 1464 1466 2886572 in IN B-PP O
9 1467 1475 2886572 enhanced VBN B-NP O
10 1476 1486 2886572 fractional JJ I-NP O
11 1487 1503 2886572 neurotransmitter NN I-NP O
12 1504 1512 2886572 overflow NN I-NP O
13 1512 1513 2886572 . . O O

1 1514 1521 2886572 However RB B-ADVP O
2 1521 1522 2886572 , , O O
3 1523 1530 2886572 neither CC O O
4 1531 1542 2886572 alterations NNS B-NP O
5 1543 1545 2886572 in IN B-PP O
6 1546 1559 2886572 prejunctional JJ B-NP O
7 1560 1564 2886572 beta SYM I-NP O
8 1564 1565 2886572 - HYPH I-NP O
9 1565 1577 2886572 adrenoceptor NN I-NP O
10 1578 1588 2886572 influences NNS I-NP O
11 1589 1592 2886572 nor CC O O
12 1593 1604 2886572 alterations NNS B-NP O
13 1605 1607 2886572 in IN B-PP O
14 1608 1616 2886572 neuronal JJ B-NP O
15 1617 1620 2886572 and CC I-NP O
16 1621 1634 2886572 extraneuronal JJ I-NP O
17 1635 1641 2886572 uptake NN I-NP O
18 1642 1652 2886572 mechanisms NNS I-NP O
19 1653 1659 2886572 appear VBP B-VP O
20 1660 1662 2886572 to TO I-VP O
21 1663 1665 2886572 be VB I-VP O
22 1666 1677 2886572 responsible JJ B-ADJP O
23 1678 1681 2886572 for IN B-PP O
24 1682 1686 2886572 this DT B-NP O
25 1687 1697 2886572 alteration NN I-NP O
26 1697 1698 2886572 . . O O

1 1699 1710 2886572 Furthermore RB B-ADVP O
2 1710 1711 2886572 , , O O
3 1712 1716 2886572 data NNS B-NP O
4 1717 1725 2886572 obtained VBN B-VP O
5 1726 1730 2886572 with IN B-PP O
6 1731 1743 2886572 phentolamine NN B-NP D010646
7 1744 1749 2886572 alone RB B-ADVP O
8 1750 1752 2886572 do VBP B-VP O
9 1753 1756 2886572 not RB I-VP O
10 1757 1764 2886572 suggest VB I-VP O
11 1765 1770 2886572 alpha SYM B-NP O
12 1770 1771 2886572 - HYPH B-NP O
13 1771 1783 2886572 adrenoceptor NN I-NP O
14 1784 1799 2886572 desensitization NN I-NP O
15 1800 1802 2886572 as IN B-PP O
16 1803 1806 2886572 the DT B-NP O
17 1807 1812 2886572 cause NN I-NP O
18 1813 1815 2886572 of IN B-PP O
19 1816 1819 2886572 the DT B-NP O
20 1820 1828 2886572 enhanced VBN I-NP O
21 1829 1845 2886572 neurotransmitter NN I-NP O
22 1846 1854 2886572 overflow NN I-NP O
23 1855 1860 2886572 after IN B-PP O
24 1861 1872 2886572 epinephrine NN B-NP D004837
25 1873 1882 2886572 treatment NN I-NP O
26 1882 1883 2886572 . . O O

1 0 0 11573852 -DOCSTART- -X- -X- O

1 0 12 11573852 Amphotericin NN B-NP D000666
2 13 14 11573852 B NN I-NP D000666
3 14 15 11573852 - HYPH B-NP O
4 15 22 11573852 induced VBN I-NP O
5 23 31 11573852 seizures NNS I-NP D012640
6 32 34 11573852 in IN B-PP O
7 35 36 11573852 a DT B-NP O
8 37 44 11573852 patient NN I-NP O
9 45 49 11573852 with IN B-PP O
10 50 54 11573852 AIDS NN B-NP D000163
11 54 55 11573852 . . O O
12 56 65 11573852 OBJECTIVE NN B-NP O
13 65 66 11573852 : : O O
14 67 69 11573852 To TO B-VP O
15 70 76 11573852 report VB I-VP O
16 77 78 11573852 a DT B-NP O
17 79 83 11573852 case NN I-NP O
18 84 86 11573852 of IN B-PP O
19 87 95 11573852 multiple JJ B-NP O
20 96 104 11573852 episodes NNS I-NP O
21 105 107 11573852 of IN B-PP O
22 108 115 11573852 seizure NN B-NP D012640
23 116 124 11573852 activity NN I-NP O
24 125 127 11573852 in IN B-PP O
25 128 130 11573852 an DT B-NP O
26 131 135 11573852 AIDS NNP I-NP D000163
27 136 142 11573852 patent NN I-NP O
28 143 152 11573852 following VBG B-PP O
29 153 165 11573852 amphotericin NN B-NP D000666
30 166 167 11573852 B NN I-NP D000666
31 168 176 11573852 infusion NN I-NP O
32 176 177 11573852 . . O O

1 178 182 11573852 CASE NN B-NP O
2 183 190 11573852 SUMMARY NN I-NP O
3 190 191 11573852 : : O O
4 192 193 11573852 A DT B-NP O
5 194 196 11573852 46 CD I-NP O
6 196 197 11573852 - HYPH I-NP O
7 197 201 11573852 year NN I-NP O
8 201 202 11573852 - HYPH O O
9 202 205 11573852 old JJ B-NP O
10 206 213 11573852 African JJ I-NP O
11 213 214 11573852 - HYPH B-NP O
12 214 222 11573852 American JJ I-NP O
13 223 226 11573852 man NN I-NP O
14 227 238 11573852 experienced VBD B-VP O
15 239 248 11573852 recurrent JJ B-NP O
16 249 254 11573852 grand JJ I-NP D004830
17 255 258 11573852 mal JJ I-NP D004830
18 259 267 11573852 seizures NNS I-NP D004830
19 268 274 11573852 during IN B-PP O
20 275 286 11573852 intravenous JJ B-NP O
21 287 295 11573852 infusion NN I-NP O
22 296 298 11573852 of IN B-PP O
23 299 311 11573852 amphotericin NN B-NP D000666
24 312 313 11573852 B NN I-NP D000666
25 313 314 11573852 , , O O
26 315 319 11573852 then RB B-ADVP O
27 320 325 11573852 petit VBP B-VP O
28 326 329 11573852 mal JJ B-NP O
29 330 338 11573852 seizures NNS I-NP D012640
30 339 341 11573852 as IN B-PP O
31 342 345 11573852 the DT B-NP O
32 346 354 11573852 infusion NN I-NP O
33 355 358 11573852 was VBD B-VP O
34 359 366 11573852 stopped VBN I-VP O
35 367 370 11573852 and CC O O
36 371 374 11573852 the DT B-NP O
37 375 379 11573852 drug NN I-NP O
38 380 394 11573852 concentrations NNS I-NP O
39 395 404 11573852 decreased VBD B-VP O
40 405 409 11573852 with IN B-PP O
41 410 414 11573852 time NN B-NP O
42 414 415 11573852 . . O O

1 416 419 11573852 The DT B-NP O
2 420 428 11573852 patients NNS I-NP O
3 429 439 11573852 concurrent JJ B-NP O
4 440 451 11573852 medications NNS I-NP O
5 452 460 11573852 included VBD B-VP O
6 461 471 11573852 didanosine NN B-NP D016049
7 471 472 11573852 , , O O
8 473 484 11573852 hydroxyzine NN B-NP D006919
9 484 485 11573852 , , O O
10 486 498 11573852 promethazine NN B-NP D011398
11 498 499 11573852 , , O O
12 500 514 11573852 hydrocortisone NN B-NP D006854
13 514 515 11573852 , , O O
14 516 519 11573852 and CC O O
15 520 536 11573852 prochlorperazine NN B-NP D011346
16 536 537 11573852 . . O O

1 538 545 11573852 Despite IN B-PP O
2 546 560 11573852 administration NN B-NP O
3 561 563 11573852 of IN B-PP O
4 564 573 11573852 phenytoin NN B-NP D010672
5 574 577 11573852 and CC I-NP O
6 578 587 11573852 lorazepam NN I-NP D008140
7 587 588 11573852 , , O O
8 589 592 11573852 the DT B-NP O
9 593 601 11573852 seizures NNS I-NP D012640
10 602 611 11573852 persisted VBD B-VP O
11 612 615 11573852 and CC O O
12 616 624 11573852 occurred VBD B-VP O
13 625 629 11573852 only RB B-ADVP O
14 630 636 11573852 during IN B-PP O
15 637 648 11573852 amphotercin NN B-NP D000666
16 649 650 11573852 B NN I-NP D000666
17 651 665 11573852 administration NN I-NP O
18 665 666 11573852 . . O O

1 667 677 11573852 DISCUSSION NN B-NP O
2 677 678 11573852 : : O O
3 679 683 11573852 AIDS NN B-NP D000163
4 684 687 11573852 and CC O O
5 688 700 11573852 cryptococcal JJ B-NP D016919
6 701 711 11573852 meningitis NN I-NP D016919
7 711 712 11573852 , , O O
8 713 717 11573852 both DT B-NP O
9 718 720 11573852 of IN B-PP O
10 721 726 11573852 which WDT B-NP O
11 727 730 11573852 the DT B-NP O
12 731 738 11573852 patient NN I-NP O
13 739 742 11573852 had VBD B-VP O
14 742 743 11573852 , , O O
15 744 747 11573852 can MD B-VP O
16 748 759 11573852 potentially RB I-VP O
17 760 765 11573852 cause VB I-VP O
18 766 774 11573852 seizures NNS B-NP D012640
19 774 775 11573852 . . O O

1 776 779 11573852 The DT B-NP O
2 780 787 11573852 patient NN I-NP O
3 788 791 11573852 had VBD B-VP O
4 792 793 11573852 a DT B-NP O
5 794 801 11573852 history NN I-NP O
6 802 804 11573852 of IN B-PP O
7 805 812 11573852 alcohol NN B-NP D000437
8 813 818 11573852 abuse NN I-NP D000437
9 818 819 11573852 ; : O O
10 820 827 11573852 alcohol NN B-NP D000431
11 828 834 11573852 intake NN I-NP O
12 835 837 11573852 as RB B-CONJP O
13 838 842 11573852 well RB I-CONJP O
14 843 845 11573852 as IN I-CONJP O
15 846 856 11573852 withdrawal NN B-NP O
16 857 860 11573852 can MD B-VP O
17 861 865 11573852 also RB I-VP O
18 866 871 11573852 cause VB I-VP O
19 872 880 11573852 seizures NNS B-NP D012640
20 880 881 11573852 . . O O

1 882 892 11573852 Didanosine NN B-NP D016049
2 893 897 11573852 also RB B-ADVP O
3 898 901 11573852 has VBZ B-VP O
4 902 903 11573852 a DT B-NP O
5 904 913 11573852 potential NN I-NP O
6 914 917 11573852 for IN B-PP O
7 918 926 11573852 inducing VBG B-VP O
8 927 935 11573852 seizures NNS B-NP D012640
9 935 936 11573852 . . O O

1 937 944 11573852 However RB B-ADVP O
2 944 945 11573852 , , O O
3 946 951 11573852 these DT B-NP O
4 952 957 11573852 other JJ I-NP O
5 958 967 11573852 potential JJ I-NP O
6 968 974 11573852 causes NNS I-NP O
7 975 977 11573852 of IN B-PP O
8 978 985 11573852 seizure NN B-NP D012640
9 986 990 11573852 were VBD B-VP O
10 991 996 11573852 ruled VBN I-VP O
11 997 1000 11573852 out RP B-PRT O
12 1000 1001 11573852 . . O O

1 1002 1005 11573852 The DT B-NP O
2 1006 1010 11573852 time NN I-NP O
3 1011 1017 11573852 course NN I-NP O
4 1018 1020 11573852 of IN B-PP O
5 1021 1027 11573852 events NNS B-NP O
6 1028 1037 11573852 suggested VBD B-VP O
7 1038 1042 11573852 that IN B-SBAR O
8 1043 1055 11573852 amphotericin NN B-NP D000666
9 1056 1057 11573852 B NN I-NP D000666
10 1058 1061 11573852 was VBD B-VP O
11 1062 1065 11573852 the DT B-NP O
12 1066 1071 11573852 cause NN I-NP O
13 1072 1074 11573852 of IN B-PP O
14 1075 1078 11573852 the DT B-NP O
15 1079 1087 11573852 seizures NNS I-NP D012640
16 1088 1090 11573852 in IN B-PP O
17 1091 1095 11573852 this DT B-NP O
18 1096 1100 11573852 AIDS NNP I-NP D000163
19 1101 1108 11573852 patient NN I-NP O
20 1108 1109 11573852 . . O O

1 1110 1121 11573852 CONCLUSIONS NNS B-NP O
2 1121 1122 11573852 : : O O
3 1123 1135 11573852 Amphotericin NN B-NP D000666
4 1136 1137 11573852 B NN I-NP D000666
5 1138 1143 11573852 seems VBZ B-VP O
6 1144 1146 11573852 to TO I-VP O
7 1147 1149 11573852 be VB I-VP O
8 1150 1153 11573852 the DT B-NP O
9 1154 1162 11573852 probable JJ I-NP O
10 1163 1168 11573852 cause NN I-NP O
11 1169 1171 11573852 of IN B-PP O
12 1172 1175 11573852 the DT B-NP O
13 1176 1184 11573852 seizures NNS I-NP D012640
14 1184 1185 11573852 . . O O

1 1186 1188 11573852 To TO B-PP O
2 1189 1193 11573852 date NN B-NP O
3 1193 1194 11573852 , , O O
4 1195 1199 11573852 only RB B-NP O
5 1200 1205 11573852 three CD I-NP O
6 1206 1211 11573852 cases NNS I-NP O
7 1212 1214 11573852 of IN B-PP O
8 1215 1223 11573852 seizures NNS B-NP D012640
9 1224 1234 11573852 associated VBN B-VP O
10 1235 1239 11573852 with IN B-PP O
11 1240 1252 11573852 amphotericin NN B-NP D000666
12 1253 1254 11573852 B NN I-NP D000666
13 1255 1259 11573852 have VBP B-VP O
14 1260 1264 11573852 been VBN I-VP O
15 1265 1273 11573852 reported VBN I-VP O
16 1274 1276 11573852 in IN B-PP O
17 1277 1280 11573852 the DT B-NP O
18 1281 1291 11573852 literature NN I-NP O
19 1291 1292 11573852 , , O O
20 1293 1296 11573852 but CC O O
21 1297 1307 11573852 healthcare NN B-NP O
22 1308 1317 11573852 providers NNS I-NP O
23 1318 1324 11573852 should MD B-VP O
24 1325 1327 11573852 be VB I-VP O
25 1328 1333 11573852 aware JJ B-ADJP O
26 1334 1336 11573852 of IN B-PP O
27 1337 1340 11573852 the DT B-NP O
28 1341 1350 11573852 potential NN I-NP O
29 1351 1354 11573852 for IN B-PP O
30 1355 1359 11573852 this DT B-NP O
31 1360 1364 11573852 rare JJ I-NP O
32 1365 1372 11573852 adverse JJ I-NP O
33 1373 1379 11573852 effect NN I-NP O
34 1379 1380 11573852 . . O O

1 0 0 16960342 -DOCSTART- -X- -X- O

1 0 9 16960342 Sustained VBN B-NP O
2 10 18 16960342 clinical JJ I-NP O
3 19 30 16960342 improvement NN I-NP O
4 31 33 16960342 of IN B-PP O
5 34 35 16960342 a DT B-NP O
6 36 43 16960342 patient NN I-NP O
7 44 48 16960342 with IN B-PP O
8 49 62 16960342 decompensated VBN B-NP O
9 63 72 16960342 hepatitis NN I-NP D006509
10 73 74 16960342 B NN I-NP D006509
11 75 80 16960342 virus NN I-NP O
12 80 81 16960342 - HYPH B-NP O
13 81 88 16960342 related VBN I-NP O
14 89 98 16960342 cirrhosis NN I-NP D005355
15 99 104 16960342 after IN B-PP O
16 105 114 16960342 treatment NN B-NP O
17 115 119 16960342 with IN B-PP O
18 120 130 16960342 lamivudine NN B-NP D019259
19 131 142 16960342 monotherapy NN I-NP O
20 142 143 16960342 . . O O
21 144 153 16960342 Hepatitis NN B-NP D006509
22 154 155 16960342 B NN I-NP D006509
23 156 161 16960342 virus NN I-NP D006509
24 162 163 16960342 ( ( O D006509
25 163 166 16960342 HBV NN B-NP D006509
26 166 167 16960342 ) ) O D006509
27 168 177 16960342 infection NN B-NP D006509
28 177 178 16960342 , , O O
29 179 184 16960342 which WDT B-NP O
30 185 191 16960342 causes VBZ B-VP O
31 192 197 16960342 liver NN B-NP D008103
32 198 207 16960342 cirrhosis NN I-NP D008103
33 208 211 16960342 and CC O O
34 212 226 16960342 hepatocellular JJ B-NP D006528
35 227 236 16960342 carcinoma NN I-NP D006528
36 236 237 16960342 , , O O
37 238 245 16960342 remains VBZ B-VP O
38 246 247 16960342 a DT B-NP O
39 248 253 16960342 major JJ I-NP O
40 254 260 16960342 health NN I-NP O
41 261 268 16960342 problem NN I-NP O
42 269 271 16960342 in IN B-PP O
43 272 277 16960342 Asian JJ B-NP O
44 278 287 16960342 countries NNS I-NP O
45 287 288 16960342 . . O O

1 289 295 16960342 Recent JJ B-NP O
2 296 307 16960342 development NN I-NP O
3 308 310 16960342 of IN B-PP O
4 311 318 16960342 vaccine NN B-NP O
5 319 322 16960342 for IN B-PP O
6 323 333 16960342 prevention NN B-NP O
7 334 336 16960342 is VBZ B-VP O
8 337 345 16960342 reported VBN I-VP O
9 346 348 16960342 to TO I-VP O
10 349 351 16960342 be VB I-VP O
11 352 362 16960342 successful JJ B-ADJP O
12 363 365 16960342 in IN B-PP O
13 366 374 16960342 reducing VBG B-VP O
14 375 378 16960342 the DT B-NP O
15 379 383 16960342 size NN I-NP O
16 384 386 16960342 of IN B-PP O
17 387 398 16960342 chronically RB B-NP O
18 399 407 16960342 infected JJ I-NP O
19 408 416 16960342 carriers NNS I-NP O
20 416 417 16960342 , , O O
21 418 426 16960342 although IN B-SBAR O
22 427 430 16960342 the DT B-NP O
23 431 439 16960342 standard JJ I-NP O
24 440 447 16960342 medical JJ I-NP O
25 448 457 16960342 therapies NNS I-NP O
26 458 462 16960342 have VBP B-VP O
27 463 466 16960342 not RB I-VP O
28 467 471 16960342 been VBN I-VP O
29 472 483 16960342 established VBN I-VP O
30 484 486 16960342 up RP B-PRT O
31 487 489 16960342 to TO B-PP O
32 490 493 16960342 now RB B-NP O
33 493 494 16960342 . . O O

1 495 497 16960342 In IN B-PP O
2 498 502 16960342 this DT B-NP O
3 503 509 16960342 report NN I-NP O
4 509 510 16960342 , , O O
5 511 513 16960342 we PRP B-NP O
6 514 525 16960342 encountered VBD B-VP O
7 526 527 16960342 a DT B-NP O
8 528 535 16960342 patient NN I-NP O
9 536 540 16960342 with IN B-PP O
10 541 554 16960342 decompensated VBN B-NP O
11 555 558 16960342 HBV NN I-NP O
12 558 559 16960342 - HYPH O O
13 559 566 16960342 related VBN B-NP O
14 567 576 16960342 cirrhosis NN I-NP D005355
15 577 580 16960342 who WP B-NP O
16 581 590 16960342 exhibited VBD B-VP O
17 591 594 16960342 the DT B-NP O
18 595 603 16960342 dramatic JJ I-NP O
19 604 616 16960342 improvements NNS I-NP O
20 617 622 16960342 after IN B-PP O
21 623 632 16960342 antiviral JJ B-NP O
22 633 640 16960342 therapy NN I-NP O
23 640 641 16960342 . . O O

1 642 645 16960342 The DT B-NP O
2 646 653 16960342 patient NN I-NP O
3 654 657 16960342 was VBD B-VP O
4 658 659 16960342 a DT B-NP O
5 660 662 16960342 50 CD I-NP O
6 662 663 16960342 - HYPH I-NP O
7 663 667 16960342 year NN I-NP O
8 667 668 16960342 - HYPH O O
9 668 671 16960342 old JJ B-NP O
10 672 677 16960342 woman NN I-NP O
11 677 678 16960342 . . O O

1 679 687 16960342 Previous JJ B-NP O
2 688 700 16960342 conventional JJ I-NP O
3 701 708 16960342 medical JJ I-NP O
4 709 719 16960342 treatments NNS I-NP O
5 720 724 16960342 were VBD B-VP O
6 725 728 16960342 not RB O O
7 729 738 16960342 effective JJ B-ADJP O
8 739 742 16960342 for IN B-PP O
9 743 747 16960342 this DT B-NP O
10 748 755 16960342 patient NN I-NP O
11 755 756 16960342 , , O O
12 757 761 16960342 thus RB B-ADVP O
13 762 766 16960342 this DT B-NP O
14 767 774 16960342 patient NN I-NP O
15 775 778 16960342 had VBD B-VP O
16 779 783 16960342 been VBN I-VP O
17 784 792 16960342 referred VBN I-VP O
18 793 795 16960342 to TO B-PP O
19 796 799 16960342 our PRP$ B-NP O
20 800 808 16960342 hospital NN I-NP O
21 808 809 16960342 . . O O

1 810 817 16960342 However RB B-ADVP O
2 817 818 16960342 , , O O
3 819 822 16960342 the DT B-NP O
4 823 837 16960342 administration NN I-NP O
5 838 840 16960342 of IN B-PP O
6 841 851 16960342 lamivudine NN B-NP D019259
7 851 852 16960342 , , O O
8 853 854 16960342 a DT B-NP O
9 855 862 16960342 reverse JJ I-NP O
10 863 876 16960342 transcriptase NN I-NP O
11 877 886 16960342 inhibitor NN I-NP O
12 886 887 16960342 , , O O
13 888 891 16960342 for IN B-PP O
14 892 894 16960342 23 CD B-NP O
15 895 901 16960342 months NNS I-NP O
16 902 914 16960342 dramatically RB B-ADVP O
17 915 923 16960342 improved VBD B-VP O
18 924 927 16960342 her PRP$ B-NP O
19 928 933 16960342 liver NN I-NP O
20 934 942 16960342 severity NN I-NP O
21 942 943 16960342 . . O O

1 944 950 16960342 During IN B-PP O
2 951 955 16960342 this DT B-NP O
3 956 962 16960342 period NN I-NP O
4 962 963 16960342 , , O O
5 964 966 16960342 no DT B-NP O
6 967 971 16960342 drug NN I-NP O
7 972 981 16960342 resistant JJ I-NP O
8 982 988 16960342 mutant JJ I-NP O
9 989 992 16960342 HBV NN I-NP O
10 993 1000 16960342 emerged VBD B-VP O
11 1000 1001 16960342 , , O O
12 1002 1005 16960342 and CC O O
13 1006 1009 16960342 the DT B-NP O
14 1010 1015 16960342 serum NN I-NP O
15 1016 1019 16960342 HBV NN I-NP O
16 1019 1020 16960342 - HYPH I-NP O
17 1020 1023 16960342 DNA NN I-NP O
18 1024 1029 16960342 level NN I-NP O
19 1030 1033 16960342 was VBD B-VP O
20 1034 1046 16960342 continuously RB I-VP O
21 1047 1057 16960342 suppressed VBN I-VP O
22 1057 1058 16960342 . . O O

1 1059 1064 16960342 These DT B-NP O
2 1065 1076 16960342 virological JJ I-NP O
3 1077 1086 16960342 responses NNS I-NP O
4 1087 1091 16960342 were VBD B-VP O
5 1092 1096 16960342 also RB I-VP O
6 1097 1107 16960342 maintained VBN I-VP O
7 1108 1112 16960342 even RB B-ADVP O
8 1113 1118 16960342 after IN B-PP O
9 1119 1122 16960342 the DT B-NP O
10 1123 1132 16960342 antiviral JJ I-NP O
11 1133 1140 16960342 therapy NN I-NP O
12 1141 1144 16960342 was VBD B-VP O
13 1145 1157 16960342 discontinued VBN I-VP O
14 1157 1158 16960342 . . O O

1 1159 1167 16960342 Moreover RB B-ADVP O
2 1167 1168 16960342 , , O O
3 1169 1173 16960342 both CC O O
4 1174 1183 16960342 hepatitis NN B-NP D006514
5 1184 1185 16960342 B NN I-NP D006514
6 1186 1193 16960342 surface NN I-NP D006514
7 1194 1201 16960342 antigen NN I-NP D006514
8 1202 1205 16960342 and CC O D006514
9 1206 1207 16960342 e NN B-NP D006514
10 1208 1215 16960342 antigen NN I-NP D006514
11 1216 1220 16960342 were VBD B-VP O
12 1221 1229 16960342 observed VBN I-VP O
13 1230 1232 16960342 to TO I-VP O
14 1233 1237 16960342 have VB I-VP O
15 1238 1249 16960342 disappeared VBN I-VP O
16 1250 1252 16960342 in IN B-PP O
17 1253 1257 16960342 this DT B-NP O
18 1258 1265 16960342 patient NN I-NP O
19 1265 1266 16960342 . . O O

1 1267 1270 16960342 The DT B-NP O
2 1271 1285 16960342 administration NN I-NP O
3 1286 1288 16960342 of IN B-PP O
4 1289 1299 16960342 lamivudine NN B-NP D019259
5 1300 1302 16960342 to TO B-PP O
6 1303 1311 16960342 patients NNS B-NP O
7 1312 1316 16960342 with IN B-PP O
8 1317 1320 16960342 HBV NN B-NP O
9 1320 1321 16960342 - HYPH B-NP O
10 1321 1328 16960342 related VBN I-NP O
11 1329 1338 16960342 cirrhosis NN I-NP D005355
12 1338 1339 16960342 , , O O
13 1340 1344 16960342 like IN B-PP O
14 1345 1348 16960342 our PRP$ B-NP O
15 1349 1356 16960342 present JJ I-NP O
16 1357 1361 16960342 case NN I-NP O
17 1361 1362 16960342 , , O O
18 1363 1369 16960342 should MD B-VP O
19 1370 1372 16960342 be VB I-VP O
20 1373 1383 16960342 considered VBN I-VP O
21 1384 1386 16960342 as IN B-PP O
22 1387 1389 16960342 an DT B-NP O
23 1390 1397 16960342 initial JJ I-NP O
24 1398 1405 16960342 medical JJ I-NP O
25 1406 1417 16960342 therapeutic JJ I-NP O
26 1418 1424 16960342 option NN I-NP O
27 1424 1425 16960342 , , O O
28 1426 1436 16960342 especially RB B-ADVP O
29 1437 1439 16960342 in IN B-PP O
30 1440 1449 16960342 countries NNS B-NP O
31 1450 1455 16960342 where WRB B-ADVP O
32 1456 1461 16960342 liver NN B-NP O
33 1462 1477 16960342 transplantation NN I-NP O
34 1478 1480 16960342 is VBZ B-VP O
35 1481 1484 16960342 not RB O O
36 1485 1493 16960342 reliably RB B-ADJP O
37 1494 1503 16960342 available JJ I-ADJP O
38 1503 1504 16960342 . . O O

1 0 0 16364460 -DOCSTART- -X- -X- O

1 0 14 16364460 Microinjection NN B-NP O
2 15 17 16364460 of IN B-PP O
3 18 28 16364460 ritanserin NN B-NP D016713
4 29 33 16364460 into IN B-PP O
5 34 37 16364460 the DT B-NP O
6 38 41 16364460 CA1 NN I-NP O
7 42 48 16364460 region NN I-NP O
8 49 51 16364460 of IN B-PP O
9 52 63 16364460 hippocampus NN B-NP O
10 64 72 16364460 improves VBZ B-VP O
11 73 84 16364460 scopolamine NN B-NP D012601
12 84 85 16364460 - HYPH B-NP O
13 85 92 16364460 induced VBN I-NP O
14 93 100 16364460 amnesia NN I-NP D000647
15 101 103 16364460 in IN B-PP O
16 104 109 16364460 adult JJ B-NP O
17 110 114 16364460 male JJ I-NP O
18 115 119 16364460 rats NNS I-NP O
19 119 120 16364460 . . O O
20 121 124 16364460 The DT B-NP O
21 125 131 16364460 effect NN I-NP O
22 132 134 16364460 of IN B-PP O
23 135 145 16364460 ritanserin NN B-NP D016713
24 146 147 16364460 ( ( O O
25 147 148 16364460 5 CD B-NP O
26 148 149 16364460 - HYPH I-NP O
27 149 152 16364460 HT2 NN I-NP O
28 153 163 16364460 antagonist NN I-NP O
29 163 164 16364460 ) ) O O
30 165 167 16364460 on IN B-PP O
31 168 179 16364460 scopolamine NN B-NP D012601
32 180 181 16364460 ( ( O O
33 181 191 16364460 muscarinic JJ B-NP O
34 192 203 16364460 cholinergic JJ I-NP O
35 204 214 16364460 antagonist NN I-NP O
36 214 215 16364460 ) ) O O
37 215 216 16364460 - HYPH B-NP O
38 216 223 16364460 induced VBN I-NP O
39 224 231 16364460 amnesia NN I-NP D000647
40 232 234 16364460 in IN B-PP O
41 235 241 16364460 Morris NNP B-NP O
42 242 247 16364460 water NN I-NP O
43 248 252 16364460 maze NN I-NP O
44 253 254 16364460 ( ( O O
45 254 257 16364460 MWM NN B-NP O
46 257 258 16364460 ) ) O O
47 259 262 16364460 was VBD B-VP O
48 263 275 16364460 investigated VBN I-VP O
49 275 276 16364460 . . O O

1 277 281 16364460 Rats NNS B-NP O
2 282 286 16364460 were VBD B-VP O
3 287 294 16364460 divided VBN I-VP O
4 295 299 16364460 into IN B-PP O
5 300 305 16364460 eight CD B-NP O
6 306 312 16364460 groups NNS I-NP O
7 313 316 16364460 and CC O O
8 317 328 16364460 bilaterally RB B-VP O
9 329 339 16364460 cannulated VBN I-VP O
10 340 344 16364460 into IN B-PP O
11 345 348 16364460 CA1 NN B-NP O
12 349 355 16364460 region NN I-NP O
13 356 358 16364460 of IN B-PP O
14 359 362 16364460 the DT B-NP O
15 363 374 16364460 hippocampus NN I-NP O
16 374 375 16364460 . . O O

1 376 379 16364460 One CD B-NP O
2 380 384 16364460 week NN I-NP O
3 385 390 16364460 later RB B-ADVP O
4 390 391 16364460 , , O O
5 392 396 16364460 they PRP B-NP O
6 397 405 16364460 received VBD B-VP O
7 406 416 16364460 repeatedly RB B-ADVP O
8 417 425 16364460 vehicles NNS B-NP O
9 426 427 16364460 ( ( O O
10 427 433 16364460 saline NN B-NP O
11 433 434 16364460 , , O O
12 435 439 16364460 DMSO NN B-NP D004121
13 439 440 16364460 , , O O
14 441 447 16364460 saline NN B-NP O
15 447 448 16364460 + SYM B-NP O
16 448 452 16364460 DMSO NN I-NP D004121
17 452 453 16364460 ) ) O O
18 453 454 16364460 , , O O
19 455 466 16364460 scopolamine NN B-NP D012601
20 467 468 16364460 ( ( O O
21 468 469 16364460 2 CD B-NP O
22 470 476 16364460 microg NN I-NP O
23 476 477 16364460 / SYM B-NP O
24 477 480 16364460 0.5 CD B-NP O
25 481 487 16364460 microl NN I-NP O
26 488 494 16364460 saline NN I-NP O
27 494 495 16364460 / SYM B-NP O
28 495 499 16364460 side NN I-NP O
29 499 500 16364460 ; : O O
30 501 503 16364460 30 CD B-NP O
31 504 507 16364460 min NN I-NP O
32 508 514 16364460 before IN B-PP O
33 515 523 16364460 training NN B-NP O
34 523 524 16364460 ) ) O O
35 524 525 16364460 , , O O
36 526 536 16364460 ritanserin NN B-NP D016713
37 537 538 16364460 ( ( O O
38 538 539 16364460 2 CD B-NP O
39 539 540 16364460 , , I-NP O
40 541 542 16364460 4 CD I-NP O
41 543 546 16364460 and CC I-NP O
42 547 548 16364460 8 CD I-NP O
43 549 555 16364460 microg NN I-NP O
44 555 556 16364460 / SYM I-NP O
45 556 559 16364460 0.5 CD I-NP O
46 560 566 16364460 microl NN I-NP O
47 567 571 16364460 DMSO NN I-NP D004121
48 571 572 16364460 / SYM B-NP O
49 572 576 16364460 side NN I-NP O
50 576 577 16364460 ; : O O
51 578 580 16364460 20 CD B-NP O
52 581 584 16364460 min NN I-NP O
53 585 591 16364460 before IN B-PP O
54 592 600 16364460 training NN B-NP O
55 600 601 16364460 ) ) O O
56 602 605 16364460 and CC O O
57 606 617 16364460 scopolamine NN B-NP D012601
58 618 619 16364460 ( ( O O
59 619 620 16364460 2 CD B-NP O
60 621 627 16364460 microg NN I-NP O
61 627 628 16364460 / SYM B-NP O
62 628 631 16364460 0.5 CD B-NP O
63 632 638 16364460 microl NN I-NP O
64 638 639 16364460 ; : O O
65 640 642 16364460 30 CD B-NP O
66 643 646 16364460 min NN I-NP O
67 647 653 16364460 before IN B-PP O
68 654 664 16364460 ritanserin NN B-NP D016713
69 665 686 16364460 injection)+ritanserin NN I-NP D016713
70 687 688 16364460 ( ( O O
71 688 689 16364460 4 CD B-NP O
72 690 696 16364460 microg NN I-NP O
73 696 697 16364460 / SYM B-NP O
74 697 700 16364460 0.5 CD B-NP O
75 701 707 16364460 microl NN I-NP O
76 708 712 16364460 DMSO NN I-NP D004121
77 712 713 16364460 ) ) O O
78 714 721 16364460 through IN B-PP O
79 722 730 16364460 cannulae NNS B-NP O
80 731 735 16364460 each DT B-NP O
81 736 739 16364460 day NN I-NP O
82 739 740 16364460 . . O O

1 741 748 16364460 Animals NNS B-NP O
2 749 753 16364460 were VBD B-VP O
3 754 760 16364460 tested VBN I-VP O
4 761 764 16364460 for IN B-PP O
5 765 769 16364460 four CD B-NP O
6 770 781 16364460 consecutive JJ I-NP O
7 782 786 16364460 days NNS I-NP O
8 787 788 16364460 ( ( O O
9 788 789 16364460 4 CD B-NP O
10 790 795 16364460 trial NN I-NP O
11 795 796 16364460 / SYM B-NP O
12 796 799 16364460 day NN I-NP O
13 799 800 16364460 ) ) O O
14 801 803 16364460 in IN B-PP O
15 804 807 16364460 MWM NN B-NP O
16 808 814 16364460 during IN B-PP O
17 815 820 16364460 which WDT B-NP O
18 821 824 16364460 the DT B-NP O
19 825 833 16364460 position NN I-NP O
20 834 836 16364460 of IN B-PP O
21 837 843 16364460 hidden JJ B-NP O
22 844 852 16364460 platform NN I-NP O
23 853 856 16364460 was VBD B-VP O
24 857 866 16364460 unchanged JJ B-ADJP O
25 866 867 16364460 . . O O

1 868 870 16364460 In IN B-PP O
2 871 874 16364460 the DT B-NP O
3 875 880 16364460 fifth JJ I-NP O
4 881 884 16364460 day NN I-NP O
5 884 885 16364460 , , O O
6 886 889 16364460 the DT B-NP O
7 890 898 16364460 platform NN I-NP O
8 899 902 16364460 was VBD B-VP O
9 903 911 16364460 elevated VBN I-VP O
10 912 917 16364460 above IN B-PP O
11 918 921 16364460 the DT B-NP O
12 922 927 16364460 water NN I-NP O
13 928 935 16364460 surface NN I-NP O
14 936 938 16364460 in IN B-PP O
15 939 946 16364460 another DT B-NP O
16 947 955 16364460 position NN I-NP O
17 956 958 16364460 to TO B-VP O
18 959 967 16364460 evaluate VB I-VP O
19 968 971 16364460 the DT B-NP O
20 972 980 16364460 function NN I-NP O
21 981 983 16364460 of IN B-PP O
22 984 989 16364460 motor NN B-NP O
23 989 990 16364460 , , O O
24 991 1003 16364460 motivational JJ B-NP O
25 1004 1007 16364460 and CC I-NP O
26 1008 1014 16364460 visual JJ I-NP O
27 1015 1022 16364460 systems NNS I-NP O
28 1022 1023 16364460 . . O O

1 1024 1027 16364460 The DT B-NP O
2 1028 1035 16364460 results NNS I-NP O
3 1036 1042 16364460 showed VBD B-VP O
4 1043 1044 16364460 a DT B-NP O
5 1045 1056 16364460 significant JJ I-NP O
6 1057 1065 16364460 increase NN I-NP O
7 1066 1068 16364460 in IN B-PP O
8 1069 1075 16364460 escape NN B-NP O
9 1076 1085 16364460 latencies NNS I-NP O
10 1086 1089 16364460 and CC O O
11 1090 1098 16364460 traveled VBN B-NP O
12 1099 1108 16364460 distances NNS I-NP O
13 1109 1111 16364460 to TO B-VP O
14 1112 1116 16364460 find VB I-VP O
15 1117 1125 16364460 platform NN B-NP O
16 1126 1128 16364460 in IN B-PP O
17 1129 1140 16364460 scopolamine NN B-NP D012601
18 1140 1141 16364460 - HYPH B-NP O
19 1141 1148 16364460 treated VBN I-NP O
20 1149 1154 16364460 group NN I-NP O
21 1155 1157 16364460 as IN B-SBAR O
22 1158 1166 16364460 compared VBN B-PP O
23 1167 1169 16364460 to TO B-PP O
24 1170 1176 16364460 saline NN B-NP O
25 1177 1182 16364460 group NN I-NP O
26 1182 1183 16364460 . . O O

1 1184 1194 16364460 Ritanserin NN B-NP D016713
2 1194 1195 16364460 - HYPH B-NP O
3 1195 1202 16364460 treated VBN I-NP O
4 1203 1207 16364460 rats NNS I-NP O
5 1208 1209 16364460 ( ( O O
6 1209 1210 16364460 4 CD B-NP O
7 1211 1217 16364460 microg NN I-NP O
8 1217 1218 16364460 / SYM B-NP O
9 1218 1221 16364460 0.5 CD B-NP O
10 1222 1228 16364460 microl NN I-NP O
11 1228 1229 16364460 / SYM B-NP O
12 1229 1233 16364460 side NN I-NP O
13 1233 1234 16364460 ) ) O O
14 1235 1241 16364460 showed VBD B-VP O
15 1242 1243 16364460 a DT B-NP O
16 1244 1255 16364460 significant JJ I-NP O
17 1256 1264 16364460 decrease NN I-NP O
18 1265 1267 16364460 in IN B-PP O
19 1268 1271 16364460 the DT B-NP O
20 1272 1281 16364460 mentioned VBN I-NP O
21 1282 1292 16364460 parameters NNS I-NP O
22 1293 1295 16364460 as IN B-SBAR O
23 1296 1304 16364460 compared VBN B-VP O
24 1305 1307 16364460 to TO B-PP O
25 1308 1312 16364460 DMSO NN B-NP D004121
26 1312 1313 16364460 - HYPH B-NP O
27 1313 1320 16364460 treated VBN I-NP O
28 1321 1326 16364460 group NN I-NP O
29 1326 1327 16364460 . . O O

1 1328 1335 16364460 However RB B-ADVP O
2 1335 1336 16364460 , , O O
3 1337 1348 16364460 scopolamine NN B-NP D012601
4 1349 1352 16364460 and CC I-NP O
5 1353 1363 16364460 ritanserin NN I-NP D016713
6 1364 1366 16364460 co AFX O O
7 1366 1367 16364460 - HYPH B-NP O
8 1367 1381 16364460 administration NN I-NP O
9 1382 1390 16364460 resulted VBD B-VP O
10 1391 1393 16364460 in IN B-PP O
11 1394 1395 16364460 a DT B-NP O
12 1396 1407 16364460 significant JJ I-NP O
13 1408 1416 16364460 decrease NN I-NP O
14 1417 1419 16364460 in IN B-PP O
15 1420 1426 16364460 escape NN B-NP O
16 1427 1436 16364460 latencies NNS I-NP O
17 1437 1440 16364460 and CC O O
18 1441 1449 16364460 traveled VBN B-VP O
19 1450 1459 16364460 distances NNS B-NP O
20 1460 1462 16364460 as IN B-SBAR O
21 1463 1471 16364460 compared VBN B-VP O
22 1472 1474 16364460 to TO B-PP O
23 1475 1478 16364460 the DT B-NP O
24 1479 1490 16364460 scopolamine NN I-NP D012601
25 1490 1491 16364460 - HYPH B-NP O
26 1491 1498 16364460 treated VBN I-NP O
27 1499 1503 16364460 rats NNS I-NP O
28 1503 1504 16364460 . . O O

1 1505 1508 16364460 Our PRP$ B-NP O
2 1509 1517 16364460 findings NNS I-NP O
3 1518 1522 16364460 show VBP B-VP O
4 1523 1527 16364460 that IN B-SBAR O
5 1528 1542 16364460 microinjection NN B-NP O
6 1543 1545 16364460 of IN B-PP O
7 1546 1556 16364460 ritanserin NN B-NP D016713
8 1557 1561 16364460 into IN B-PP O
9 1562 1565 16364460 the DT B-NP O
10 1566 1569 16364460 CA1 NN I-NP O
11 1570 1576 16364460 region NN I-NP O
12 1577 1579 16364460 of IN B-PP O
13 1580 1583 16364460 the DT B-NP O
14 1584 1595 16364460 hippocampus NN I-NP O
15 1596 1604 16364460 improves VBZ B-VP O
16 1605 1608 16364460 the DT B-NP O
17 1609 1620 16364460 scopolamine NN I-NP D012601
18 1620 1621 16364460 - HYPH B-NP O
19 1621 1628 16364460 induced VBN I-NP O
20 1629 1636 16364460 amnesia NN I-NP D000647
21 1636 1637 16364460 . . O O

1 0 0 6728084 -DOCSTART- -X- -X- O

1 0 11 6728084 Nephrotoxic JJ B-NP D007674
2 12 19 6728084 effects NNS I-NP O
3 20 22 6728084 of IN B-PP O
4 23 37 6728084 aminoglycoside NN B-NP D000617
5 38 47 6728084 treatment NN I-NP O
6 48 50 6728084 on IN B-PP O
7 51 56 6728084 renal JJ B-NP O
8 57 64 6728084 protein NN I-NP O
9 65 77 6728084 reabsorption NN I-NP O
10 78 81 6728084 and CC I-NP O
11 82 94 6728084 accumulation NN I-NP O
12 94 95 6728084 . . O O
13 96 98 6728084 To TO B-VP O
14 99 107 6728084 quantify VB I-VP O
15 108 111 6728084 the DT B-NP O
16 112 119 6728084 effects NNS I-NP O
17 120 122 6728084 of IN B-PP O
18 123 133 6728084 gentamicin NN B-NP D005839
19 133 134 6728084 , , O O
20 135 144 6728084 kanamycin NN B-NP D007612
21 145 148 6728084 and CC I-NP O
22 149 159 6728084 netilmicin NN I-NP D009428
23 160 162 6728084 on IN B-PP O
24 163 168 6728084 renal JJ B-NP O
25 169 176 6728084 protein NN I-NP O
26 177 189 6728084 reabsorption NN I-NP O
27 190 193 6728084 and CC I-NP O
28 194 206 6728084 accumulation NN I-NP O
29 206 207 6728084 , , O O
30 208 213 6728084 these DT B-NP O
31 214 219 6728084 drugs NNS I-NP O
32 220 224 6728084 were VBD B-VP O
33 225 237 6728084 administered VBN I-VP O
34 238 240 6728084 to TO B-PP O
35 241 245 6728084 rats NNS B-NP O
36 246 263 6728084 intraperitoneally RB B-ADVP O
37 264 265 6728084 ( ( O O
38 265 267 6728084 30 CD B-NP O
39 268 270 6728084 mg NN I-NP O
40 270 271 6728084 / SYM B-NP O
41 271 273 6728084 kg NN I-NP O
42 273 274 6728084 / SYM B-NP O
43 274 277 6728084 day NN I-NP O
44 277 278 6728084 ) ) O O
45 279 282 6728084 for IN B-PP O
46 283 284 6728084 7 CD B-NP O
47 284 285 6728084 , , I-NP O
48 286 288 6728084 14 CD I-NP O
49 289 291 6728084 or CC I-NP O
50 292 294 6728084 21 CD I-NP O
51 295 299 6728084 days NNS I-NP O
52 299 300 6728084 . . O O

1 301 309 6728084 Scanning NN B-NP O
2 310 318 6728084 electron NN I-NP O
3 319 329 6728084 microscopy NN I-NP O
4 330 332 6728084 of IN B-PP O
5 333 336 6728084 the DT B-NP O
6 337 347 6728084 glomerular JJ I-NP O
7 348 358 6728084 endothelia NN I-NP O
8 358 359 6728084 , , O O
9 360 367 6728084 urinary JJ B-NP O
10 368 380 6728084 measurements NNS I-NP O
11 381 383 6728084 of IN B-PP O
12 384 390 6728084 sodium NN B-NP D012964
13 390 391 6728084 , , O O
14 392 401 6728084 potassium NN B-NP D011188
15 401 402 6728084 , , O O
16 403 413 6728084 endogenous JJ B-NP O
17 414 422 6728084 lysozyme NN I-NP O
18 422 423 6728084 , , O O
19 424 425 6728084 N NN B-NP O
20 425 426 6728084 - HYPH B-NP O
21 426 432 6728084 acetyl NN I-NP O
22 432 433 6728084 - HYPH O O
23 433 437 6728084 beta SYM B-NP O
24 437 438 6728084 - HYPH B-NP O
25 438 439 6728084 D NN I-NP O
26 439 440 6728084 - HYPH O O
27 440 455 6728084 glucosaminidase NN B-NP O
28 456 457 6728084 ( ( O O
29 457 460 6728084 NAG NN B-NP O
30 460 461 6728084 ) ) O O
31 462 464 6728084 as RB B-CONJP O
32 465 469 6728084 well RB I-CONJP O
33 470 472 6728084 as IN I-CONJP O
34 473 482 6728084 clearance NN B-NP O
35 483 486 6728084 and CC I-NP O
36 487 499 6728084 accumulation NN I-NP O
37 500 511 6728084 experiments NNS I-NP O
38 512 517 6728084 after IN B-PP O
39 518 521 6728084 i.v NN B-NP O
40 521 522 6728084 . . O O

1 523 537 6728084 administration NN B-NP O
2 538 540 6728084 of IN B-PP O
3 541 544 6728084 egg NN B-NP O
4 544 545 6728084 - HYPH B-NP O
5 545 550 6728084 white JJ I-NP O
6 551 559 6728084 lysozyme NN I-NP O
7 560 563 6728084 and CC I-NP O
8 564 576 6728084 measurements NNS I-NP O
9 577 579 6728084 of IN B-PP O
10 580 586 6728084 inulin NN B-NP O
11 587 596 6728084 clearance NN I-NP O
12 597 598 6728084 ( ( O O
13 598 601 6728084 GFR NN B-NP O
14 601 602 6728084 ) ) O O
15 603 607 6728084 were VBD B-VP O
16 608 612 6728084 done VBN I-VP O
17 613 615 6728084 in IN B-PP O
18 616 620 6728084 each DT B-NP O
19 621 630 6728084 treatment NN I-NP O
20 631 636 6728084 group NN I-NP O
21 636 637 6728084 . . O O

1 638 648 6728084 Gentamicin NN B-NP D005839
2 649 663 6728084 administration NN I-NP O
3 664 673 6728084 decreased VBD B-VP O
4 674 682 6728084 diameter NN B-NP O
5 682 683 6728084 , , I-NP O
6 684 691 6728084 density NN I-NP O
7 692 695 6728084 and CC I-NP O
8 696 701 6728084 shape NN I-NP O
9 702 704 6728084 of IN B-PP O
10 705 716 6728084 endothelial JJ B-NP O
11 717 726 6728084 fenestrae NNS I-NP O
12 726 727 6728084 . . O O

1 728 737 6728084 Kanamycin NN B-NP D007612
2 738 741 6728084 and CC I-NP O
3 742 752 6728084 netilmicin NN I-NP D009428
4 753 761 6728084 appeared VBD B-VP O
5 762 764 6728084 to TO I-VP O
6 765 769 6728084 have VB I-VP O
7 770 772 6728084 no DT B-NP O
8 773 779 6728084 effect NN I-NP O
9 780 782 6728084 at IN B-PP O
10 783 786 6728084 the DT B-NP O
11 787 791 6728084 dose NN I-NP O
12 792 796 6728084 used VBN B-VP O
13 796 797 6728084 . . O O

1 798 801 6728084 All DT B-NP O
2 802 807 6728084 three CD I-NP O
3 808 823 6728084 aminoglycosides NNS I-NP D000617
4 824 833 6728084 decreased VBD B-VP O
5 834 837 6728084 GFR NN B-NP O
6 838 841 6728084 and CC O O
7 842 851 6728084 increased VBD B-VP O
8 852 859 6728084 urinary JJ B-NP O
9 860 869 6728084 excretion NN I-NP O
10 870 872 6728084 of IN B-PP O
11 873 879 6728084 sodium NN B-NP D012964
12 880 883 6728084 and CC I-NP O
13 884 893 6728084 potassium NN I-NP D011188
14 893 894 6728084 . . O O

1 895 900 6728084 While IN B-SBAR O
2 901 911 6728084 gentamicin NN B-NP D005839
3 912 915 6728084 and CC I-NP O
4 916 925 6728084 kanamycin NN I-NP D007612
5 926 935 6728084 decreased VBD B-VP O
6 936 939 6728084 the DT B-NP O
7 940 950 6728084 percentage NN I-NP O
8 951 963 6728084 reabsorption NN I-NP O
9 964 967 6728084 and CC I-NP O
10 968 980 6728084 accumulation NN I-NP O
11 981 983 6728084 of IN B-PP O
12 984 992 6728084 lysozyme NN B-NP O
13 993 998 6728084 after IN B-PP O
14 999 1002 6728084 i.v NN B-NP O
15 1002 1003 6728084 . . O O

1 1004 1018 6728084 administration NN B-NP O
2 1019 1021 6728084 of IN B-PP O
3 1022 1025 6728084 egg NN B-NP O
4 1025 1026 6728084 - HYPH B-NP O
5 1026 1031 6728084 white JJ I-NP O
6 1032 1040 6728084 lysozyme NN I-NP O
7 1041 1051 6728084 netilmicin NN I-NP D009428
8 1052 1055 6728084 had VBD B-VP O
9 1056 1058 6728084 no DT B-NP O
10 1059 1065 6728084 effect NN I-NP O
11 1065 1066 6728084 . . O O

1 1067 1072 6728084 Daily JJ B-NP O
2 1073 1082 6728084 excretion NN I-NP O
3 1083 1085 6728084 of IN B-PP O
4 1086 1091 6728084 total JJ B-NP O
5 1092 1099 6728084 protein NN I-NP O
6 1099 1100 6728084 , , O O
7 1101 1111 6728084 endogenous JJ B-NP O
8 1112 1120 6728084 lysozyme NN I-NP O
9 1121 1124 6728084 and CC I-NP O
10 1125 1128 6728084 NAG NN I-NP O
11 1129 1138 6728084 increased VBD B-VP O
12 1139 1143 6728084 only RB B-ADVP O
13 1144 1149 6728084 after IN B-PP O
14 1150 1159 6728084 treatment NN B-NP O
15 1160 1164 6728084 with IN B-PP O
16 1165 1174 6728084 kanamycin NN B-NP D007612
17 1175 1178 6728084 and CC I-NP O
18 1179 1189 6728084 gentamicin NN I-NP D005839
19 1189 1190 6728084 . . O O

1 1191 1195 6728084 Thus RB B-ADVP O
2 1195 1196 6728084 , , O O
3 1197 1212 6728084 aminoglycosides NNS B-NP D000617
4 1213 1216 6728084 may MD B-VP O
5 1217 1220 6728084 act VB I-VP O
6 1221 1223 6728084 as IN B-PP O
7 1224 1239 6728084 nephrotoxicants NNS B-NP O
8 1240 1242 6728084 at IN B-PP O
9 1243 1253 6728084 glomerular JJ B-ADJP O
10 1254 1257 6728084 and CC O O
11 1257 1258 6728084 / SYM B-NP O
12 1258 1260 6728084 or CC O O
13 1261 1268 6728084 tubular JJ B-NP O
14 1269 1274 6728084 level NN I-NP O
15 1275 1283 6728084 inducing VBG B-VP O
16 1284 1294 6728084 impairment NN B-NP D007674
17 1295 1297 6728084 of IN B-PP D007674
18 1298 1303 6728084 renal JJ B-NP D007674
19 1304 1316 6728084 reabsorption NN I-NP D007674
20 1317 1320 6728084 and CC I-NP O
21 1321 1333 6728084 accumulation NN I-NP O
22 1334 1336 6728084 of IN B-PP O
23 1337 1345 6728084 proteins NNS B-NP O
24 1345 1346 6728084 . . O O

1 0 0 950631 -DOCSTART- -X- -X- O

1 0 15 950631 Immunopathology NN B-NP O
2 16 18 950631 of IN B-PP O
3 19 32 950631 penicillamine NN B-NP D010396
4 32 33 950631 - HYPH B-NP O
5 33 40 950631 induced VBN I-NP O
6 41 51 950631 glomerular JJ I-NP D007674
7 52 59 950631 disease NN I-NP D007674
8 59 60 950631 . . O O
9 61 65 950631 Four CD B-NP O
10 66 74 950631 patients NNS I-NP O
11 75 79 950631 with IN B-PP O
12 80 90 950631 rheumatoid JJ B-NP D001172
13 91 100 950631 arthritis NN I-NP D001172
14 101 110 950631 developed VBD B-VP O
15 111 116 950631 heavy JJ B-NP O
16 117 128 950631 proteinuria NN I-NP D011507
17 129 134 950631 after IN B-PP O
18 135 139 950631 five CD B-NP O
19 140 142 950631 to TO I-NP O
20 143 145 950631 12 CD I-NP O
21 146 152 950631 months NNS I-NP O
22 153 155 950631 of IN B-PP O
23 156 165 950631 treatment NN B-NP O
24 166 170 950631 with IN B-PP O
25 171 172 950631 D NN B-NP D010396
26 172 173 950631 - HYPH B-NP D010396
27 173 186 950631 penicillamine NN I-NP D010396
28 186 187 950631 . . O O

1 188 193 950631 Light NN B-NP O
2 194 204 950631 microscopy NN I-NP O
3 205 207 950631 of IN B-PP O
4 208 213 950631 renal JJ B-NP O
5 214 220 950631 biopsy NN I-NP O
6 221 228 950631 samples NNS I-NP O
7 229 235 950631 showed VBD B-VP O
8 236 243 950631 minimal JJ B-NP O
9 244 254 950631 glomerular JJ I-NP O
10 255 264 950631 capillary JJ I-NP O
11 265 269 950631 wall NN I-NP O
12 270 280 950631 thickening VBG B-VP O
13 281 284 950631 and CC O O
14 285 294 950631 mesangial JJ B-NP O
15 295 301 950631 matrix NN I-NP O
16 302 310 950631 increase NN I-NP O
17 310 311 950631 , , O O
18 312 314 950631 or CC O O
19 315 317 950631 no DT B-NP O
20 318 327 950631 departure NN I-NP O
21 328 332 950631 from IN B-PP O
22 333 339 950631 normal JJ B-ADJP O
23 339 340 950631 . . O O

1 341 349 950631 Electron NN B-NP O
2 350 360 950631 microscopy NN I-NP O
3 360 361 950631 , , O O
4 362 369 950631 however RB B-ADVP O
5 369 370 950631 , , O O
6 371 379 950631 revealed VBD B-VP O
7 380 393 950631 subepithelial JJ B-NP O
8 394 402 950631 electron NN I-NP O
9 402 403 950631 - HYPH B-NP O
10 403 408 950631 dense JJ I-NP O
11 409 417 950631 deposits NNS I-NP O
12 417 418 950631 , , O O
13 419 425 950631 fusion NN B-NP O
14 426 428 950631 of IN B-PP O
15 429 439 950631 epithelial JJ B-NP O
16 440 444 950631 cell NN I-NP O
17 445 449 950631 foot NN I-NP O
18 450 459 950631 processes NNS I-NP O
19 459 460 950631 , , O O
20 461 464 950631 and CC O O
21 465 473 950631 evidence NN B-NP O
22 474 476 950631 of IN B-PP O
23 477 486 950631 mesangial JJ B-NP O
24 487 491 950631 cell NN I-NP O
25 492 505 950631 hyperactivity NN I-NP O
26 505 506 950631 . . O O

1 507 525 950631 Immunofluorescence NN B-NP O
2 526 536 950631 microscopy NN I-NP O
3 537 549 950631 demonstrated VBD B-VP O
4 550 558 950631 granular JJ B-NP O
5 559 568 950631 capillary JJ I-NP O
6 569 573 950631 wall NN I-NP O
7 574 582 950631 deposits NNS I-NP O
8 583 585 950631 of IN B-PP O
9 586 589 950631 IgG NN B-NP O
10 590 593 950631 and CC I-NP O
11 594 596 950631 C3 NN I-NP O
12 596 597 950631 . . O O

1 598 601 950631 The DT B-NP O
2 602 610 950631 findings NNS I-NP O
3 611 615 950631 were VBD B-VP O
4 616 623 950631 similar JJ B-ADJP O
5 624 626 950631 to TO B-PP O
6 627 632 950631 those DT B-NP O
7 633 635 950631 in IN B-PP O
8 636 641 950631 early JJ B-NP O
9 642 652 950631 membranous JJ I-NP D015433
10 653 671 950631 glomerulonephritis NN I-NP D015433
11 671 672 950631 , , O O
12 673 684 950631 differences NNS B-NP O
13 685 690 950631 being VBG B-VP O
14 691 699 950631 observed VBN I-VP O
15 700 707 950631 however RB B-ADVP O
16 708 710 950631 in IN B-PP O
17 711 714 950631 the DT B-NP O
18 715 722 950631 results NNS I-NP O
19 723 725 950631 of IN B-PP O
20 726 734 950631 staining VBG B-VP O
21 735 738 950631 for IN B-PP O
22 739 742 950631 the DT B-NP O
23 743 748 950631 early JJ I-NP O
24 748 749 950631 - HYPH I-NP O
25 749 755 950631 acting VBG I-NP O
26 756 766 950631 complement NN I-NP O
27 767 777 950631 components NNS I-NP O
28 778 781 950631 C1q NN I-NP O
29 782 785 950631 and CC I-NP O
30 786 788 950631 C4 NN I-NP O
31 788 789 950631 . . O O

1 790 792 950631 It PRP B-NP O
2 793 795 950631 is VBZ B-VP O
3 796 807 950631 tentatively RB I-VP O
4 808 817 950631 concluded VBN I-VP O
5 818 822 950631 that IN B-SBAR O
6 823 833 950631 complement NN B-NP O
7 834 837 950631 was VBD B-VP O
8 838 847 950631 activated VBN I-VP O
9 848 850 950631 by IN B-PP O
10 851 854 950631 the DT B-NP O
11 855 864 950631 classical JJ I-NP O
12 865 872 950631 pathway NN I-NP O
13 872 873 950631 . . O O

1 0 0 9431903 -DOCSTART- -X- -X- O

1 0 6 9431903 Effect NN B-NP O
2 7 9 9431903 of IN B-PP O
3 10 18 9431903 glyceryl NN B-NP D005996
4 19 29 9431903 trinitrate NN I-NP D005996
5 30 32 9431903 on IN B-PP O
6 33 36 9431903 the DT B-NP O
7 37 46 9431903 sphincter NN I-NP D046628
8 47 49 9431903 of IN B-PP D046628
9 50 54 9431903 Oddi NNP B-NP D046628
10 55 60 9431903 spasm NN I-NP D046628
11 61 67 9431903 evoked VBN B-VP O
12 68 70 9431903 by IN B-PP O
13 71 82 9431903 prostigmine NN B-NP D009388
14 82 83 9431903 - HYPH B-NP O
15 83 91 9431903 morphine NN I-NP D009020
16 92 106 9431903 administration NN I-NP O
17 106 107 9431903 . . I-NP O
18 108 117 9431903 OBJECTIVE NN I-NP O
19 117 118 9431903 : : O O
20 119 121 9431903 In IN B-PP O
21 122 126 9431903 this DT B-NP O
22 127 132 9431903 study NN I-NP O
23 133 136 9431903 the DT B-NP O
24 137 143 9431903 effect NN I-NP O
25 144 146 9431903 of IN B-PP O
26 147 155 9431903 glyceryl NN B-NP D005996
27 156 166 9431903 trinitrate NN I-NP D005996
28 167 169 9431903 on IN B-PP O
29 170 173 9431903 the DT B-NP O
30 174 185 9431903 prostigmine NN I-NP D009388
31 185 186 9431903 - HYPH B-NP O
32 186 194 9431903 morphine NN I-NP D009020
33 194 195 9431903 - HYPH B-NP O
34 195 202 9431903 induced VBN I-NP O
35 203 212 9431903 sphincter NN I-NP D046628
36 213 215 9431903 of IN B-PP D046628
37 216 220 9431903 Oddi NNP B-NP D046628
38 221 226 9431903 spasm NN I-NP D046628
39 227 230 9431903 was VBD B-VP O
40 231 240 9431903 evaluated VBN I-VP O
41 241 243 9431903 in IN B-PP O
42 244 248 9431903 nine CD B-NP O
43 249 255 9431903 female JJ I-NP O
44 256 264 9431903 patients NNS I-NP O
45 265 269 9431903 with IN B-PP O
46 270 279 9431903 sphincter NN B-NP D046628
47 280 282 9431903 of IN B-PP D046628
48 283 287 9431903 Oddi NNP B-NP D046628
49 288 298 9431903 dyskinesia NN I-NP D046628
50 298 299 9431903 . . O O

1 300 306 9431903 METHOD NN B-NP O
2 306 307 9431903 : : O O
3 308 317 9431903 Sphincter NN B-NP D046628
4 318 320 9431903 of IN B-PP D046628
5 321 325 9431903 Oddi NNP B-NP D046628
6 326 331 9431903 spasm NN I-NP D046628
7 332 335 9431903 was VBD B-VP O
8 336 343 9431903 induced VBN I-VP O
9 344 346 9431903 by IN B-PP O
10 347 358 9431903 prostigmine NN B-NP D009388
11 358 359 9431903 - HYPH O O
12 359 367 9431903 morphine NN B-NP D009020
13 368 382 9431903 administration NN I-NP O
14 383 384 9431903 ( ( O O
15 384 387 9431903 0.5 CD B-NP O
16 388 390 9431903 mg NN I-NP O
17 391 402 9431903 prostigmine NN I-NP D009388
18 403 418 9431903 intramuscularly RB B-ADVP O
19 419 422 9431903 and CC O O
20 423 425 9431903 10 CD B-NP O
21 426 428 9431903 mg NN I-NP O
22 429 437 9431903 morphine NN I-NP D009020
23 438 452 9431903 subcutaneously RB B-ADVP O
24 452 453 9431903 ) ) O O
25 454 457 9431903 and CC O O
26 458 468 9431903 visualized VBN B-VP O
27 469 471 9431903 by IN B-PP O
28 472 484 9431903 quantitative JJ B-NP O
29 485 498 9431903 hepatobiliary JJ I-NP O
30 499 511 9431903 scintigraphy NN I-NP O
31 511 512 9431903 . . O O

1 513 516 9431903 The DT B-NP O
2 517 523 9431903 entire JJ I-NP O
3 524 533 9431903 procedure NN I-NP O
4 534 537 9431903 was VBD B-VP O
5 538 546 9431903 repeated VBN I-VP O
6 547 553 9431903 during IN B-PP O
7 554 562 9431903 glyceryl NN B-NP D005996
8 563 573 9431903 trinitrate NN I-NP D005996
9 574 582 9431903 infusion NN I-NP O
10 583 584 9431903 ( ( O O
11 584 596 9431903 Nitrolingual JJ B-NP D005996
12 597 598 9431903 1 CD I-NP O
13 599 605 9431903 microg NN I-NP O
14 605 606 9431903 / SYM B-NP O
15 606 608 9431903 kg NN I-NP O
16 608 609 9431903 / SYM B-NP O
17 609 612 9431903 min NN I-NP O
18 613 616 9431903 for IN B-PP O
19 617 620 9431903 120 CD B-NP O
20 621 624 9431903 min NN I-NP O
21 624 625 9431903 ) ) O O
22 625 626 9431903 . . O O

1 627 634 9431903 RESULTS NNS B-NP O
2 634 635 9431903 : : O O
3 636 647 9431903 Prostigmine NN B-NP D009388
4 647 648 9431903 - HYPH B-NP O
5 648 656 9431903 morphine NN I-NP D009020
6 657 668 9431903 provocation NN I-NP O
7 669 675 9431903 caused VBD B-VP O
8 676 687 9431903 significant JJ B-NP O
9 688 697 9431903 increases NNS I-NP O
10 698 700 9431903 in IN B-PP O
11 701 704 9431903 the DT B-NP O
12 705 709 9431903 time NN I-NP O
13 710 712 9431903 to TO B-PP O
14 713 717 9431903 peak JJ B-NP O
15 718 726 9431903 activity NN I-NP O
16 727 728 9431903 ( ( O O
17 728 732 9431903 Tmax NN B-NP O
18 732 733 9431903 ) ) O O
19 734 738 9431903 over IN B-PP O
20 739 742 9431903 the DT B-NP O
21 743 750 9431903 hepatic JJ I-NP O
22 751 756 9431903 hilum NN I-NP O
23 757 758 9431903 ( ( O O
24 758 760 9431903 HH NN B-NP O
25 760 761 9431903 : : O O
26 762 767 9431903 34.33 CD B-NP O
27 768 769 9431903 + SYM O O
28 769 770 9431903 / SYM O O
29 770 771 9431903 - SYM B-NP O
30 772 776 9431903 5.05 CD B-NP O
31 777 779 9431903 vs NNS I-NP O
32 779 780 9431903 . . O O
33 781 786 9431903 22.77 CD B-NP O
34 787 788 9431903 + SYM O O
35 788 789 9431903 / SYM O O
36 789 790 9431903 - SYM O O
37 791 795 9431903 3.26 CD B-NP O
38 795 796 9431903 ) ) O O
39 797 800 9431903 and CC O O
40 801 804 9431903 the DT B-NP O
41 805 811 9431903 common JJ I-NP O
42 812 816 9431903 bile NN I-NP O
43 817 821 9431903 duct NN I-NP O
44 822 823 9431903 ( ( O O
45 823 826 9431903 CBD NN B-NP O
46 826 827 9431903 : : O O
47 828 833 9431903 60.44 CD B-NP O
48 834 835 9431903 + SYM O O
49 835 836 9431903 / SYM O O
50 836 837 9431903 - SYM B-NP O
51 838 842 9431903 5.99 CD B-NP O
52 843 845 9431903 vs NNS I-NP O
53 845 846 9431903 . . O O
54 847 851 9431903 40.0 CD B-NP O
55 852 853 9431903 + SYM O O
56 853 854 9431903 / SYM O O
57 854 855 9431903 - SYM O O
58 856 860 9431903 2.88 CD B-NP O
59 860 861 9431903 ) ) O O
60 862 865 9431903 and CC O O
61 866 868 9431903 in IN B-PP O
62 869 872 9431903 the DT B-NP O
63 873 877 9431903 half JJ I-NP O
64 877 878 9431903 - HYPH I-NP O
65 878 882 9431903 time NN I-NP O
66 883 885 9431903 of IN B-PP O
67 886 895 9431903 excretion NN B-NP O
68 896 897 9431903 ( ( O O
69 897 899 9431903 T1 NN B-NP O
70 899 900 9431903 / SYM O O
71 900 901 9431903 2 CD B-NP O
72 901 902 9431903 ) ) O O
73 903 907 9431903 over IN B-PP O
74 908 911 9431903 the DT B-NP O
75 912 917 9431903 liver NN I-NP O
76 918 928 9431903 parenchyma NN I-NP O
77 929 930 9431903 ( ( O O
78 930 932 9431903 LP NN B-NP O
79 932 933 9431903 : : O O
80 934 940 9431903 120.04 CD B-NP O
81 941 942 9431903 + SYM O O
82 942 943 9431903 / SYM O O
83 943 944 9431903 - SYM B-NP O
84 945 950 9431903 16.01 CD B-NP O
85 951 953 9431903 vs NNS I-NP O
86 953 954 9431903 . . O O
87 955 960 9431903 27.37 CD B-NP O
88 961 962 9431903 + SYM O O
89 962 963 9431903 / SYM O O
90 963 964 9431903 - SYM O O
91 965 969 9431903 2.19 CD B-NP O
92 969 970 9431903 ) ) O O
93 970 971 9431903 , , O O
94 972 974 9431903 HH NN B-NP O
95 975 976 9431903 ( ( O O
96 976 982 9431903 117.61 CD B-NP O
97 983 984 9431903 + SYM O O
98 984 985 9431903 / SYM O O
99 985 986 9431903 - SYM O O
100 987 992 9431903 14.71 CD B-NP O
101 993 995 9431903 vs NNS I-NP O
102 995 996 9431903 . . O O
103 997 1002 9431903 31.85 CD B-NP O
104 1003 1004 9431903 + SYM O O
105 1004 1005 9431903 / SYM O O
106 1005 1006 9431903 - SYM O O
107 1007 1011 9431903 3.99 CD B-NP O
108 1011 1012 9431903 ) ) O O
109 1013 1016 9431903 and CC O O
110 1017 1020 9431903 CBD NN B-NP O
111 1021 1022 9431903 ( ( O O
112 1022 1028 9431903 158.11 CD B-NP O
113 1029 1030 9431903 + SYM O O
114 1030 1031 9431903 / SYM O O
115 1031 1032 9431903 - SYM O O
116 1033 1037 9431903 9.18 CD B-NP O
117 1038 1040 9431903 vs NNS I-NP O
118 1040 1041 9431903 . . O O
119 1042 1046 9431903 40.1 CD B-NP O
120 1047 1048 9431903 + SYM O O
121 1048 1049 9431903 / SYM O O
122 1049 1050 9431903 - SYM O O
123 1051 1055 9431903 6.24 CD B-NP O
124 1055 1056 9431903 ) ) O O
125 1056 1057 9431903 , , O O
126 1058 1068 9431903 indicating VBG B-VP O
127 1069 1070 9431903 a DT B-NP O
128 1071 1079 9431903 complete JJ I-NP O
129 1080 1085 9431903 spasm NN I-NP D013035
130 1086 1088 9431903 at IN B-PP O
131 1089 1092 9431903 the DT B-NP O
132 1093 1098 9431903 level NN I-NP O
133 1099 1101 9431903 of IN B-PP O
134 1102 1105 9431903 the DT B-NP O
135 1106 1115 9431903 sphincter NN I-NP O
136 1116 1118 9431903 of IN B-PP O
137 1119 1123 9431903 Oddi NNP B-NP O
138 1123 1124 9431903 . . O O

1 1125 1133 9431903 Glyceryl NN B-NP D005996
2 1134 1144 9431903 trinitrate NN I-NP D005996
3 1145 1153 9431903 infusion NN I-NP O
4 1154 1164 9431903 completely RB B-ADVP O
5 1165 1175 9431903 normalized VBD B-VP O
6 1176 1179 9431903 the DT B-NP O
7 1180 1191 9431903 prostigmine NN I-NP D009388
8 1191 1192 9431903 - HYPH B-NP O
9 1192 1200 9431903 morphine NN I-NP D009020
10 1200 1201 9431903 - HYPH B-NP O
11 1201 1208 9431903 induced VBN I-NP O
12 1209 1220 9431903 alterations NNS I-NP O
13 1221 1223 9431903 in IN B-PP O
14 1224 1229 9431903 these DT B-NP O
15 1230 1242 9431903 quantitative JJ I-NP O
16 1243 1253 9431903 parameters NNS I-NP O
17 1254 1255 9431903 ( ( O O
18 1255 1259 9431903 TmaX NN B-NP O
19 1260 1264 9431903 over IN B-PP O
20 1265 1268 9431903 the DT B-NP O
21 1269 1271 9431903 LP NN I-NP O
22 1271 1272 9431903 : : O O
23 1273 1278 9431903 11.33 CD B-NP O
24 1279 1280 9431903 + SYM O O
25 1280 1281 9431903 / SYM O O
26 1281 1282 9431903 - SYM O O
27 1283 1287 9431903 1.13 CD B-NP O
28 1287 1288 9431903 ; : O O
29 1289 1293 9431903 over IN B-PP O
30 1294 1297 9431903 the DT B-NP O
31 1298 1300 9431903 HH NN I-NP O
32 1300 1301 9431903 : : O O
33 1302 1307 9431903 18.88 CD B-NP O
34 1308 1309 9431903 + SYM O O
35 1309 1310 9431903 / SYM O O
36 1310 1311 9431903 - SYM O O
37 1312 1316 9431903 1.48 CD B-NP O
38 1316 1317 9431903 ; : O O
39 1318 1321 9431903 and CC O O
40 1322 1326 9431903 over IN B-PP O
41 1327 1330 9431903 the DT B-NP O
42 1331 1334 9431903 CBD NN I-NP O
43 1334 1335 9431903 : : O O
44 1336 1341 9431903 36.22 CD B-NP O
45 1342 1343 9431903 + SYM O O
46 1343 1344 9431903 / SYM O O
47 1344 1345 9431903 - SYM O O
48 1346 1350 9431903 1.92 CD B-NP O
49 1350 1351 9431903 ; : O O
50 1352 1355 9431903 and CC O O
51 1356 1358 9431903 T1 NN B-NP O
52 1358 1359 9431903 / SYM O O
53 1359 1360 9431903 2 CD B-NP O
54 1361 1365 9431903 over IN B-PP O
55 1366 1369 9431903 the DT B-NP O
56 1370 1372 9431903 LP NN I-NP O
57 1372 1373 9431903 : : O O
58 1374 1379 9431903 28.21 CD B-NP O
59 1380 1381 9431903 + SYM O O
60 1381 1382 9431903 / SYM O O
61 1382 1383 9431903 - SYM O O
62 1384 1388 9431903 1.83 CD B-NP O
63 1388 1389 9431903 ; : O O
64 1390 1394 9431903 over IN B-PP O
65 1395 1398 9431903 the DT B-NP O
66 1399 1401 9431903 HH NN I-NP O
67 1401 1402 9431903 : : O O
68 1403 1408 9431903 33.42 CD B-NP O
69 1409 1410 9431903 + SYM O O
70 1410 1411 9431903 / SYM O O
71 1411 1412 9431903 - SYM O O
72 1413 1417 9431903 3.10 CD B-NP O
73 1417 1418 9431903 ; : O O
74 1419 1422 9431903 and CC O O
75 1423 1427 9431903 over IN B-PP O
76 1428 1431 9431903 the DT B-NP O
77 1432 1435 9431903 CBD NN I-NP O
78 1435 1436 9431903 : : O O
79 1437 1442 9431903 41.66 CD B-NP O
80 1443 1444 9431903 + SYM O O
81 1444 1445 9431903 / SYM O O
82 1445 1446 9431903 - SYM O O
83 1447 1451 9431903 6.33 CD B-NP O
84 1451 1452 9431903 ) ) O O
85 1452 1453 9431903 , , O O
86 1454 1464 9431903 suggesting VBG B-VP O
87 1465 1467 9431903 an DT B-NP O
88 1468 1477 9431903 effective JJ I-NP O
89 1478 1487 9431903 sphincter NN I-NP O
90 1487 1488 9431903 - HYPH O O
91 1488 1496 9431903 relaxing VBG B-VP O
92 1497 1503 9431903 effect NN B-NP O
93 1504 1506 9431903 of IN B-PP O
94 1507 1515 9431903 glyceryl NN B-NP D005996
95 1516 1526 9431903 trinitrate NN I-NP D005996
96 1526 1527 9431903 . . O O

1 1528 1538 9431903 CONCLUSION NN B-NP O
2 1538 1539 9431903 : : O O
3 1540 1545 9431903 These DT B-NP O
4 1546 1553 9431903 results NNS I-NP O
5 1554 1561 9431903 provide VBP B-VP O
6 1562 1565 9431903 the DT B-NP O
7 1566 1571 9431903 first JJ I-NP O
8 1572 1580 9431903 evidence NN I-NP O
9 1581 1583 9431903 of IN B-PP O
10 1584 1587 9431903 the DT B-NP O
11 1588 1601 9431903 effectiveness NN I-NP O
12 1602 1604 9431903 of IN B-PP O
13 1605 1613 9431903 glyceryl NN B-NP D005996
14 1614 1624 9431903 trinitrate NN I-NP D005996
15 1625 1627 9431903 on IN B-PP O
16 1628 1631 9431903 the DT B-NP O
17 1632 1640 9431903 morphine NN I-NP D009020
18 1640 1641 9431903 - HYPH B-NP O
19 1641 1648 9431903 induced VBN I-NP O
20 1649 1658 9431903 sphincter NN I-NP D046628
21 1659 1661 9431903 of IN B-PP D046628
22 1662 1666 9431903 Oddi NNP B-NP D046628
23 1667 1672 9431903 spasm NN I-NP D046628
24 1673 1675 9431903 in IN B-PP O
25 1676 1682 9431903 humans NNS B-NP O
26 1682 1683 9431903 . . O O

1 1684 1689 9431903 Since IN B-SBAR O
2 1690 1698 9431903 glyceryl NN B-NP D005996
3 1699 1709 9431903 trinitrate NN I-NP D005996
4 1710 1712 9431903 is VBZ B-VP O
5 1713 1717 9431903 able JJ B-ADJP O
6 1718 1720 9431903 to TO B-VP O
7 1721 1729 9431903 overcome VB I-VP O
8 1730 1734 9431903 even RB B-NP O
9 1735 1738 9431903 the DT I-NP O
10 1739 1746 9431903 drastic JJ I-NP O
11 1747 1753 9431903 effect NN I-NP O
12 1754 1756 9431903 of IN B-PP O
13 1757 1765 9431903 morphine NN B-NP D009020
14 1765 1766 9431903 , , O O
15 1767 1769 9431903 it PRP B-NP O
16 1770 1775 9431903 might MD B-VP O
17 1776 1778 9431903 be VB I-VP O
18 1779 1781 9431903 of IN B-PP O
19 1782 1791 9431903 relevance NN B-NP O
20 1792 1794 9431903 in IN B-PP O
21 1795 1798 9431903 the DT B-NP O
22 1799 1808 9431903 treatment NN I-NP O
23 1809 1811 9431903 of IN B-PP O
24 1812 1821 9431903 sphincter NN B-NP D046628
25 1822 1824 9431903 of IN B-PP D046628
26 1825 1829 9431903 Oddi NNP B-NP D046628
27 1830 1840 9431903 dyskinesia NN I-NP D046628
28 1840 1841 9431903 . . O O

1 0 0 16710500 -DOCSTART- -X- -X- O

1 0 10 16710500 Ethambutol NN B-NP D004977
2 10 11 16710500 - HYPH B-VP O
3 11 21 16710500 associated VBN B-NP O
4 22 27 16710500 optic JJ I-NP D009901
5 28 38 16710500 neuropathy NN I-NP D009901
6 38 39 16710500 . . I-NP O
7 40 52 16710500 INTRODUCTION NN I-NP O
8 52 53 16710500 : : O O
9 54 64 16710500 Ethambutol NN B-NP D004977
10 65 67 16710500 is VBZ B-VP O
11 68 72 16710500 used VBN I-VP O
12 73 75 16710500 in IN B-PP O
13 76 79 16710500 the DT B-NP O
14 80 89 16710500 treatment NN I-NP O
15 90 92 16710500 of IN B-PP O
16 93 105 16710500 tuberculosis NN B-NP D014376
17 105 106 16710500 , , O O
18 107 112 16710500 which WDT B-NP O
19 113 115 16710500 is VBZ B-VP O
20 116 121 16710500 still RB B-ADVP O
21 122 131 16710500 prevalent JJ B-ADJP O
22 132 134 16710500 in IN B-PP O
23 135 144 16710500 Southeast NNP B-NP O
24 145 149 16710500 Asia NNP I-NP O
25 149 150 16710500 , , O O
26 151 154 16710500 and CC O O
27 155 158 16710500 can MD B-VP O
28 159 161 16710500 be VB I-VP O
29 162 172 16710500 associated VBN I-VP O
30 173 177 16710500 with IN B-PP O
31 178 187 16710500 permanent JJ B-NP O
32 188 194 16710500 visual JJ I-NP D014786
33 195 199 16710500 loss NN I-NP D014786
34 199 200 16710500 . . O O

1 201 203 16710500 We PRP B-NP O
2 204 210 16710500 report VBP B-VP O
3 211 212 16710500 3 CD B-NP O
4 213 218 16710500 cases NNS I-NP O
5 219 224 16710500 which WDT B-NP O
6 225 234 16710500 presented VBD B-VP O
7 235 239 16710500 with IN B-PP O
8 240 250 16710500 bitemporal JJ B-NP D006423
9 251 261 16710500 hemianopia NN I-NP D006423
10 261 262 16710500 . . O O

1 263 271 16710500 CLINICAL JJ B-NP O
2 272 279 16710500 PICTURE NN I-NP O
3 279 280 16710500 : : O O
4 281 286 16710500 Three CD B-NP O
5 287 295 16710500 patients NNS I-NP O
6 296 300 16710500 with IN B-PP O
7 301 311 16710500 ethambutol NN B-NP D004977
8 311 312 16710500 - HYPH O O
9 312 322 16710500 associated VBN B-VP O
10 323 328 16710500 toxic JJ B-NP O
11 329 334 16710500 optic JJ I-NP D009901
12 335 345 16710500 neuropathy NN I-NP D009901
13 346 349 16710500 are VBP B-VP O
14 350 359 16710500 described VBN I-VP O
15 359 360 16710500 . . O O

1 361 364 16710500 All DT B-NP O
2 365 366 16710500 3 CD I-NP O
3 367 375 16710500 patients NNS I-NP O
4 376 379 16710500 had VBD B-VP O
5 380 384 16710500 loss NN B-NP D014786
6 385 387 16710500 of IN B-PP D014786
7 388 395 16710500 central JJ B-NP D014786
8 396 402 16710500 visual JJ I-NP D014786
9 403 409 16710500 acuity NN I-NP D014786
10 409 410 16710500 , , O D014786
11 411 417 16710500 colour NN B-NP D014786
12 418 424 16710500 vision NN I-NP D014786
13 425 426 16710500 ( ( O D014786
14 426 434 16710500 Ishihara NN B-NP D014786
15 434 435 16710500 ) ) O D014786
16 436 439 16710500 and CC O D014786
17 440 446 16710500 visual JJ B-NP D014786
18 447 452 16710500 field NN I-NP D014786
19 452 453 16710500 . . O O

1 454 457 16710500 The DT B-NP O
2 458 464 16710500 visual JJ I-NP D014786
3 465 470 16710500 field NN I-NP D014786
4 471 475 16710500 loss NN I-NP D014786
5 476 479 16710500 had VBD B-VP O
6 480 481 16710500 a DT B-NP O
7 482 492 16710500 bitemporal JJ I-NP O
8 493 500 16710500 flavour NN I-NP O
9 500 501 16710500 , , O O
10 502 512 16710500 suggesting VBG B-VP O
11 513 524 16710500 involvement NN B-NP O
12 525 527 16710500 of IN B-PP O
13 528 531 16710500 the DT B-NP O
14 532 537 16710500 optic JJ I-NP O
15 538 544 16710500 chiasm NN I-NP O
16 544 545 16710500 . . O O

1 546 555 16710500 TREATMENT NN B-NP O
2 555 556 16710500 : : O O
3 557 564 16710500 Despite IN B-PP O
4 565 573 16710500 stopping VBG B-VP O
5 574 584 16710500 ethambutol NN B-NP D004977
6 585 587 16710500 on IN B-PP O
7 588 597 16710500 diagnosis NN B-NP O
8 597 598 16710500 , , O O
9 599 605 16710500 visual JJ B-NP O
10 606 614 16710500 function NN I-NP O
11 615 624 16710500 continued VBD B-VP O
12 625 627 16710500 to TO I-VP O
13 628 639 16710500 deteriorate VB I-VP O
14 640 643 16710500 for IN B-PP O
15 644 645 16710500 a DT B-NP O
16 646 649 16710500 few JJ I-NP O
17 650 656 16710500 months NNS I-NP O
18 656 657 16710500 . . O O

1 658 668 16710500 Subsequent JJ B-NP O
2 669 680 16710500 improvement NN I-NP O
3 681 684 16710500 was VBD B-VP O
4 685 689 16710500 mild JJ B-ADJP O
5 690 692 16710500 in IN B-PP O
6 693 694 16710500 2 CD B-NP O
7 695 700 16710500 cases NNS I-NP O
8 700 701 16710500 . . O O

1 702 704 16710500 In IN B-PP O
2 705 708 16710500 the DT B-NP O
3 709 714 16710500 third JJ I-NP O
4 715 719 16710500 case NN I-NP O
5 719 720 16710500 , , O O
6 721 727 16710500 visual JJ B-NP O
7 728 734 16710500 acuity NN I-NP O
8 735 738 16710500 and CC I-NP O
9 739 745 16710500 colour NN I-NP O
10 746 752 16710500 vision NN I-NP O
11 753 763 16710500 normalised VBD B-VP O
12 764 767 16710500 but CC O O
13 768 771 16710500 the DT B-NP O
14 772 777 16710500 optic JJ I-NP O
15 778 783 16710500 discs NNS I-NP O
16 784 788 16710500 were VBD B-VP O
17 789 793 16710500 pale JJ B-ADJP O
18 793 794 16710500 . . O O

1 795 802 16710500 OUTCOME NN B-NP O
2 802 803 16710500 : : O O
3 804 807 16710500 All DT B-NP O
4 808 809 16710500 3 CD I-NP O
5 810 818 16710500 patients NNS I-NP O
6 819 822 16710500 had VBD B-VP O
7 823 827 16710500 some DT B-NP O
8 828 837 16710500 permanent JJ I-NP O
9 838 842 16710500 loss NN I-NP D014786
10 843 845 16710500 of IN B-PP D014786
11 846 852 16710500 visual JJ B-NP D014786
12 853 861 16710500 function NN I-NP D014786
13 861 862 16710500 . . O O

1 863 874 16710500 CONCLUSIONS NNS B-NP O
2 874 875 16710500 : : O O
3 876 886 16710500 Ethambutol NN B-NP D004977
4 887 892 16710500 usage NN I-NP O
5 893 895 16710500 is VBZ B-VP O
6 896 906 16710500 associated VBN I-VP O
7 907 911 16710500 with IN B-PP O
8 912 921 16710500 permanent JJ B-NP O
9 922 928 16710500 visual JJ I-NP D014786
10 929 933 16710500 loss NN I-NP D014786
11 934 937 16710500 and CC O O
12 938 944 16710500 should MD B-VP O
13 945 947 16710500 be VB I-VP O
14 948 955 16710500 avoided VBN I-VP O
15 956 958 16710500 if IN B-SBAR O
16 959 967 16710500 possible JJ B-ADJP O
17 968 970 16710500 or CC O O
18 971 975 16710500 used VBN B-VP O
19 976 980 16710500 with IN B-PP O
20 981 988 16710500 caution NN B-NP O
21 989 992 16710500 and CC O O
22 993 999 16710500 proper JJ B-NP O
23 1000 1016 16710500 ophthalmological JJ I-NP O
24 1017 1023 16710500 follow VB B-VP O
25 1023 1024 16710500 - HYPH B-ADJP O
26 1024 1026 16710500 up RP B-PRT O
27 1026 1027 16710500 . . O O

1 1028 1031 16710500 The DT B-NP O
2 1032 1038 16710500 author NN I-NP O
3 1039 1049 16710500 postulates VBZ B-VP O
4 1050 1054 16710500 that IN B-SBAR O
5 1055 1057 16710500 in IN B-PP O
6 1058 1063 16710500 cases NNS B-NP O
7 1064 1066 16710500 of IN B-PP O
8 1067 1077 16710500 ethambutol NN B-NP D004977
9 1078 1088 16710500 associated JJ I-NP O
10 1089 1101 16710500 chiasmopathy NN I-NP O
11 1101 1102 16710500 , , O O
12 1103 1113 16710500 ethambutol NN B-NP D004977
13 1114 1117 16710500 may MD B-VP O
14 1118 1127 16710500 initially RB I-VP O
15 1128 1134 16710500 affect VB I-VP O
16 1135 1138 16710500 the DT B-NP O
17 1139 1144 16710500 optic JJ I-NP O
18 1145 1151 16710500 nerves NNS I-NP O
19 1152 1155 16710500 and CC O O
20 1156 1168 16710500 subsequently RB B-ADVP O
21 1169 1177 16710500 progress NN B-NP O
22 1178 1180 16710500 to TO B-VP O
23 1181 1188 16710500 involve VB I-VP O
24 1189 1192 16710500 the DT B-NP O
25 1193 1198 16710500 optic JJ I-NP O
26 1199 1205 16710500 chiasm NN I-NP O
27 1205 1206 16710500 . . O O

1 0 0 11078231 -DOCSTART- -X- -X- O

1 0 10 11078231 Myocardial JJ B-NP D017202
2 11 19 11078231 ischemia NN I-NP D017202
3 20 23 11078231 due JJ B-PP O
4 24 26 11078231 to TO B-PP O
5 27 35 11078231 coronary JJ B-NP D003329
6 36 42 11078231 artery NN I-NP D003329
7 43 48 11078231 spasm NN I-NP D003329
8 49 55 11078231 during IN B-PP O
9 56 66 11078231 dobutamine NN B-NP D004280
10 67 73 11078231 stress NN I-NP O
11 74 90 11078231 echocardiography NN I-NP O
12 90 91 11078231 . . O O
13 92 102 11078231 Dobutamine NN B-NP D004280
14 103 109 11078231 stress NN I-NP O
15 110 126 11078231 echocardiography NN I-NP O
16 127 128 11078231 ( ( O O
17 128 131 11078231 DSE NN B-NP O
18 131 132 11078231 ) ) O O
19 133 135 11078231 is VBZ B-VP O
20 136 137 11078231 a DT B-NP O
21 138 144 11078231 useful JJ I-NP O
22 145 148 11078231 and CC I-NP O
23 149 153 11078231 safe JJ I-NP O
24 154 165 11078231 provocation NN I-NP O
25 166 170 11078231 test NN I-NP O
26 171 174 11078231 for IN B-PP O
27 175 185 11078231 myocardial JJ B-NP D017202
28 186 194 11078231 ischemia NN I-NP D017202
29 194 195 11078231 . . O O

1 196 201 11078231 Until IN B-PP O
2 202 205 11078231 now RB B-NP O
3 205 206 11078231 , , O O
4 207 210 11078231 the DT B-NP O
5 211 215 11078231 test NN I-NP O
6 216 219 11078231 has VBZ B-VP O
7 220 224 11078231 been VBN I-VP O
8 225 232 11078231 focused VBN I-VP O
9 233 237 11078231 only RB B-ADVP O
10 238 240 11078231 on IN B-PP O
11 241 244 11078231 the DT B-NP O
12 245 252 11078231 organic JJ I-NP O
13 253 259 11078231 lesion NN I-NP O
14 260 262 11078231 in IN B-PP O
15 263 266 11078231 the DT B-NP O
16 267 275 11078231 coronary JJ I-NP O
17 276 282 11078231 artery NN I-NP O
18 282 283 11078231 , , O O
19 284 287 11078231 and CC O O
20 288 296 11078231 positive JJ B-NP O
21 297 300 11078231 DSE NN I-NP O
22 301 304 11078231 has VBZ B-VP O
23 305 314 11078231 indicated VBN I-VP O
24 315 318 11078231 the DT B-NP O
25 319 327 11078231 presence NN I-NP O
26 328 330 11078231 of IN B-PP O
27 331 342 11078231 significant JJ B-NP O
28 343 348 11078231 fixed VBN I-NP O
29 349 357 11078231 coronary JJ I-NP D023921
30 358 364 11078231 artery NN I-NP D023921
31 365 373 11078231 stenosis NN I-NP D023921
32 373 374 11078231 . . O O

1 375 378 11078231 The DT B-NP O
2 379 382 11078231 aim NN I-NP O
3 383 385 11078231 of IN B-PP O
4 386 389 11078231 the DT B-NP O
5 390 397 11078231 present JJ I-NP O
6 398 403 11078231 study NN I-NP O
7 404 406 11078231 is VBZ B-VP O
8 407 409 11078231 to TO B-VP O
9 410 417 11078231 examine VB I-VP O
10 418 425 11078231 whether IN B-SBAR O
11 426 436 11078231 myocardial JJ B-NP D017202
12 437 445 11078231 ischemia NN I-NP D017202
13 446 449 11078231 due JJ B-PP O
14 450 452 11078231 to TO B-PP O
15 453 461 11078231 coronary JJ B-NP D003329
16 462 467 11078231 spasm NN I-NP D003329
17 468 470 11078231 is VBZ B-VP O
18 471 478 11078231 induced VBN I-VP O
19 479 481 11078231 by IN B-PP O
20 482 492 11078231 dobutamine NN B-NP D004280
21 492 493 11078231 . . O O

1 494 496 11078231 We PRP B-NP O
2 497 506 11078231 performed VBD B-VP O
3 507 510 11078231 DSE NN B-NP O
4 511 513 11078231 on IN B-PP O
5 514 516 11078231 51 CD B-NP O
6 517 525 11078231 patients NNS I-NP O
7 526 530 11078231 with IN B-PP O
8 531 539 11078231 coronary JJ B-NP D000788
9 540 547 11078231 spastic JJ I-NP D000788
10 548 554 11078231 angina NN I-NP D000788
11 555 558 11078231 but CC B-PP O
12 559 566 11078231 without IN B-PP O
13 567 578 11078231 significant JJ B-NP O
14 579 584 11078231 fixed VBN I-NP O
15 585 593 11078231 coronary JJ I-NP D023921
16 594 600 11078231 artery NN I-NP D023921
17 601 609 11078231 stenosis NN I-NP D023921
18 609 610 11078231 . . O O

1 611 614 11078231 All DT B-NP O
2 615 623 11078231 patients NNS I-NP O
3 624 627 11078231 had VBD B-VP O
4 628 635 11078231 anginal JJ B-NP D000787
5 636 643 11078231 attacks NNS I-NP O
6 644 646 11078231 at IN B-PP O
7 647 651 11078231 rest NN B-NP O
8 652 656 11078231 with IN B-PP O
9 657 659 11078231 ST JJ B-NP O
10 660 669 11078231 elevation NN I-NP O
11 670 672 11078231 on IN B-PP O
12 673 676 11078231 the DT B-NP O
13 677 694 11078231 electrocardiogram NN I-NP O
14 695 696 11078231 ( ( O O
15 696 703 11078231 variant JJ B-NP D000788
16 704 710 11078231 angina NN I-NP D000788
17 710 711 11078231 ) ) O O
18 711 712 11078231 . . O O

1 713 721 11078231 Coronary JJ B-NP O
2 722 727 11078231 spasm NN I-NP O
3 728 731 11078231 was VBD B-VP O
4 732 739 11078231 induced VBN I-VP O
5 740 742 11078231 by IN B-PP O
6 743 756 11078231 intracoronary JJ B-NP O
7 757 766 11078231 injection NN I-NP O
8 767 769 11078231 of IN B-PP O
9 770 783 11078231 acetylcholine NN B-NP D000109
10 783 784 11078231 , , O O
11 785 788 11078231 and CC O O
12 789 791 11078231 no DT B-NP O
13 792 797 11078231 fixed VBN I-NP O
14 798 806 11078231 coronary JJ I-NP D023921
15 807 813 11078231 artery NN I-NP D023921
16 814 822 11078231 stenosis NN I-NP D023921
17 823 826 11078231 was VBD B-VP O
18 827 837 11078231 documented VBN I-VP O
19 838 840 11078231 on IN B-PP O
20 841 851 11078231 angiograms NNS B-NP O
21 852 854 11078231 in IN B-PP O
22 855 858 11078231 all DT B-NP O
23 859 867 11078231 patients NNS I-NP O
24 867 868 11078231 . . O O

1 869 872 11078231 DSE NN B-NP O
2 873 876 11078231 was VBD B-VP O
3 877 886 11078231 performed VBN I-VP O
4 887 891 11078231 with IN B-PP O
5 892 903 11078231 intravenous JJ B-NP O
6 904 914 11078231 dobutamine NN I-NP D004280
7 915 923 11078231 infusion NN I-NP O
8 924 928 11078231 with IN B-PP O
9 929 931 11078231 an DT B-NP O
10 932 943 11078231 incremental JJ I-NP O
11 944 949 11078231 doses NNS I-NP O
12 950 952 11078231 of IN B-PP O
13 953 954 11078231 5 CD B-NP O
14 954 955 11078231 , , I-NP O
15 956 958 11078231 10 CD I-NP O
16 958 959 11078231 , , I-NP O
17 960 962 11078231 20 CD I-NP O
18 962 963 11078231 , , I-NP O
19 964 966 11078231 30 CD I-NP O
20 966 967 11078231 , , O O
21 968 971 11078231 and CC O O
22 972 974 11078231 40 CD B-NP O
23 975 981 11078231 microg NN I-NP O
24 981 982 11078231 / SYM B-NP O
25 982 984 11078231 kg NN I-NP O
26 984 985 11078231 / SYM I-NP O
27 985 988 11078231 min NN I-NP O
28 989 994 11078231 every DT B-NP O
29 995 996 11078231 5 CD I-NP O
30 997 1004 11078231 minutes NNS I-NP O
31 1004 1005 11078231 . . O O

1 1006 1008 11078231 Of IN B-PP O
2 1009 1012 11078231 the DT B-NP O
3 1013 1015 11078231 51 CD I-NP O
4 1016 1024 11078231 patients NNS I-NP O
5 1024 1025 11078231 , , O O
6 1026 1027 11078231 7 CD B-NP O
7 1028 1036 11078231 patients NNS I-NP O
8 1037 1043 11078231 showed VBD B-VP O
9 1044 1052 11078231 asynergy NN B-NP O
10 1053 1057 11078231 with IN B-PP O
11 1058 1060 11078231 ST JJ B-NP O
12 1061 1070 11078231 elevation NN I-NP O
13 1070 1071 11078231 . . O O

1 1072 1075 11078231 All DT B-NP O
2 1076 1077 11078231 7 CD I-NP O
3 1078 1086 11078231 patients NNS I-NP O
4 1087 1088 11078231 ( ( O O
5 1088 1093 11078231 13.7% NN B-NP O
6 1093 1094 11078231 ) ) O O
7 1095 1098 11078231 had VBD B-VP O
8 1099 1104 11078231 chest NN B-NP D002637
9 1105 1109 11078231 pain NN I-NP D002637
10 1110 1116 11078231 during IN B-PP O
11 1117 1125 11078231 asynergy NN B-NP O
12 1125 1126 11078231 , , O O
13 1127 1130 11078231 and CC O O
14 1131 1135 11078231 both DT B-NP O
15 1136 1141 11078231 chest JJS I-NP D002637
16 1142 1146 11078231 pain NN I-NP D002637
17 1147 1150 11078231 and CC I-NP O
18 1151 1171 11078231 electrocardiographic JJ I-NP O
19 1172 1179 11078231 changes NNS I-NP O
20 1180 1184 11078231 were VBD B-VP O
21 1185 1193 11078231 preceded VBN I-VP O
22 1194 1196 11078231 by IN B-PP O
23 1197 1205 11078231 asynergy NN B-NP O
24 1205 1206 11078231 . . O O

1 1207 1212 11078231 These DT B-NP O
2 1213 1221 11078231 findings NNS I-NP O
3 1222 1230 11078231 indicate VBP B-VP O
4 1231 1235 11078231 that IN B-SBAR O
5 1236 1246 11078231 dobutamine NN B-NP D004280
6 1247 1250 11078231 can MD B-VP O
7 1251 1258 11078231 provoke VB I-VP O
8 1259 1267 11078231 coronary JJ B-NP D003329
9 1268 1273 11078231 spasm NN I-NP D003329
10 1274 1276 11078231 in IN B-PP O
11 1277 1281 11078231 some DT B-NP O
12 1282 1290 11078231 patients NNS I-NP O
13 1291 1295 11078231 with IN B-PP O
14 1296 1304 11078231 coronary JJ B-NP D000788
15 1305 1312 11078231 spastic JJ I-NP D000788
16 1313 1319 11078231 angina NN I-NP D000788
17 1319 1320 11078231 . . O O

1 1321 1325 11078231 When WRB B-ADVP O
2 1326 1329 11078231 DSE NN B-NP O
3 1330 1332 11078231 is VBZ B-VP O
4 1333 1342 11078231 performed VBN I-VP O
5 1343 1345 11078231 to TO I-VP O
6 1346 1354 11078231 evaluate VB I-VP O
7 1355 1363 11078231 coronary JJ B-NP D003324
8 1364 1370 11078231 artery NN I-NP D003324
9 1371 1378 11078231 disease NN I-NP D003324
10 1378 1379 11078231 , , O O
11 1380 1383 11078231 not RB B-CONJP O
12 1384 1388 11078231 only RB I-CONJP O
13 1389 1394 11078231 fixed VBN B-NP O
14 1395 1403 11078231 coronary JJ I-NP D023921
15 1404 1412 11078231 stenosis NN I-NP D023921
16 1412 1413 11078231 , , O O
17 1414 1417 11078231 but CC B-CONJP O
18 1418 1422 11078231 also RB I-CONJP O
19 1423 1431 11078231 coronary JJ B-NP D003329
20 1432 1437 11078231 spasm NN I-NP D003329
21 1438 1444 11078231 should MD B-VP O
22 1445 1447 11078231 be VB I-VP O
23 1448 1458 11078231 considered VBN I-VP O
24 1459 1461 11078231 as IN B-PP O
25 1462 1463 11078231 a DT B-NP O
26 1464 1471 11078231 genesis NN I-NP O
27 1472 1474 11078231 of IN B-PP O
28 1475 1483 11078231 asynergy NN B-NP O
29 1483 1484 11078231 . . O O

1 0 0 10728962 -DOCSTART- -X- -X- O

1 0 11 10728962 Vasopressin NN B-NP D014667
2 12 14 10728962 in IN B-PP O
3 15 18 10728962 the DT B-NP O
4 19 28 10728962 treatment NN I-NP O
5 29 31 10728962 of IN B-PP O
6 32 41 10728962 milrinone NN B-NP D020105
7 41 42 10728962 - HYPH B-NP O
8 42 49 10728962 induced VBN I-NP O
9 50 61 10728962 hypotension NN I-NP D007022
10 62 64 10728962 in IN B-PP O
11 65 71 10728962 severe JJ B-NP O
12 72 77 10728962 heart NN I-NP D006333
13 78 85 10728962 failure NN I-NP D006333
14 85 86 10728962 . . O O
15 87 90 10728962 The DT B-NP O
16 91 94 10728962 use NN I-NP O
17 95 97 10728962 of IN B-PP O
18 98 115 10728962 phosphodiesterase NN B-NP O
19 116 126 10728962 inhibitors NNS I-NP O
20 127 131 10728962 such JJ B-PP O
21 132 134 10728962 as IN I-PP O
22 135 144 10728962 milrinone NN B-NP D020105
23 145 147 10728962 in IN B-PP O
24 148 151 10728962 the DT B-NP O
25 152 161 10728962 treatment NN I-NP O
26 162 164 10728962 of IN B-PP O
27 165 171 10728962 severe JJ B-NP O
28 172 177 10728962 heart NN I-NP D006333
29 178 185 10728962 failure NN I-NP D006333
30 186 188 10728962 is VBZ B-VP O
31 189 199 10728962 frequently RB B-ADJP O
32 200 210 10728962 restricted JJ I-ADJP O
33 211 218 10728962 because IN B-SBAR O
34 219 223 10728962 they PRP B-NP O
35 224 229 10728962 cause VBP B-VP O
36 230 242 10728962 vasodilation NN B-NP O
37 243 246 10728962 and CC I-NP O
38 247 258 10728962 hypotension NN I-NP D007022
39 258 259 10728962 . . O O

1 260 262 10728962 In IN B-PP O
2 263 271 10728962 patients NNS B-NP O
3 272 276 10728962 with IN B-PP O
4 277 290 10728962 decompensated VBN B-NP O
5 291 296 10728962 heart NN I-NP D006333
6 297 304 10728962 failure NN I-NP D006333
7 305 309 10728962 with IN B-PP O
8 310 321 10728962 hypotension NN B-NP D007022
9 322 327 10728962 after IN B-PP O
10 328 337 10728962 treatment NN B-NP O
11 338 342 10728962 with IN B-PP O
12 343 352 10728962 milrinone NN B-NP D020105
13 352 353 10728962 , , O O
14 354 357 10728962 low JJ B-NP O
15 358 363 10728962 doses NNS I-NP O
16 364 366 10728962 of IN B-PP O
17 367 378 10728962 vasopressin NN B-NP D014667
18 379 387 10728962 restored VBD B-VP O
19 388 393 10728962 blood NN B-NP O
20 394 402 10728962 pressure NN I-NP O
21 403 410 10728962 without IN B-PP O
22 411 421 10728962 inhibiting VBG B-VP O
23 422 425 10728962 the DT B-NP O
24 426 435 10728962 inotropic JJ I-NP O
25 436 442 10728962 effect NN I-NP O
26 443 445 10728962 of IN B-PP O
27 446 455 10728962 milrinone NN B-NP D020105
28 455 456 10728962 . . O O

1 0 0 15930398 -DOCSTART- -X- -X- O

1 0 10 15930398 Assessment NN B-NP O
2 11 13 15930398 of IN B-PP O
3 14 17 15930398 the DT B-NP O
4 18 23 15930398 onset NN I-NP O
5 24 27 15930398 and CC I-NP O
6 28 39 15930398 persistence NN I-NP O
7 40 42 15930398 of IN B-PP O
8 43 50 15930398 amnesia NN B-NP D000647
9 51 57 15930398 during IN B-PP O
10 58 68 15930398 procedural JJ B-NP O
11 69 77 15930398 sedation NN I-NP O
12 78 82 15930398 with IN B-PP O
13 83 91 15930398 propofol NN B-NP D015742
14 91 92 15930398 . . O O
15 93 103 15930398 OBJECTIVES NNS B-NP O
16 103 104 15930398 : : O O
17 105 107 15930398 To TO B-VP O
18 108 114 15930398 assess VB I-VP O
19 115 123 15930398 patients NNS B-NP O
20 123 124 15930398 ' POS B-NP O
21 125 132 15930398 ability NN I-NP O
22 133 135 15930398 to TO B-VP O
23 136 142 15930398 repeat VB I-VP O
24 143 146 15930398 and CC I-VP O
25 147 153 15930398 recall VB I-VP O
26 154 159 15930398 words NNS B-NP O
27 160 169 15930398 presented VBN B-VP O
28 170 172 15930398 to TO B-PP O
29 173 177 15930398 them PRP B-NP O
30 178 183 15930398 while IN B-SBAR O
31 184 194 15930398 undergoing VBG B-VP O
32 195 205 15930398 procedural JJ B-NP O
33 206 214 15930398 sedation NN I-NP O
34 215 219 15930398 with IN B-PP O
35 220 228 15930398 propofol NN B-NP D015742
36 228 229 15930398 , , O O
37 230 233 15930398 and CC O O
38 234 243 15930398 correlate VBP B-VP O
39 244 249 15930398 their PRP$ B-NP O
40 250 256 15930398 recall NN I-NP O
41 257 261 15930398 with IN B-PP O
42 262 267 15930398 their PRP$ B-NP O
43 268 273 15930398 level NN I-NP O
44 274 276 15930398 of IN B-PP O
45 277 286 15930398 awareness NN B-NP O
46 287 289 15930398 as IN B-SBAR O
47 290 298 15930398 measured VBN B-VP O
48 299 301 15930398 by IN B-PP O
49 302 312 15930398 bispectral JJ B-NP O
50 313 318 15930398 index NN I-NP O
51 319 320 15930398 ( ( O O
52 320 323 15930398 BIS NN B-NP O
53 323 324 15930398 ) ) O O
54 325 335 15930398 monitoring NN B-NP O
55 335 336 15930398 . . O O

1 337 344 15930398 METHODS NNS B-NP O
2 344 345 15930398 : : O O
3 346 350 15930398 This DT B-NP O
4 351 354 15930398 was VBD B-VP O
5 355 356 15930398 a DT B-NP O
6 357 368 15930398 prospective JJ I-NP O
7 368 369 15930398 , , I-NP O
8 370 376 15930398 single JJ I-NP O
9 376 377 15930398 - HYPH I-NP O
10 377 389 15930398 intervention NN I-NP O
11 390 395 15930398 study NN I-NP O
12 396 398 15930398 of IN B-PP O
13 399 409 15930398 consenting VBG B-VP O
14 410 415 15930398 adult JJ B-NP O
15 416 424 15930398 patients NNS I-NP O
16 425 435 15930398 undergoing VBG B-VP O
17 436 446 15930398 procedural JJ B-NP O
18 447 455 15930398 sedation NN I-NP O
19 456 460 15930398 with IN B-PP O
20 461 469 15930398 propofol NN B-NP D015742
21 470 477 15930398 between IN B-PP O
22 478 486 15930398 December NNP B-NP O
23 487 489 15930398 28 CD I-NP O
24 489 490 15930398 , , I-NP O
25 491 495 15930398 2002 CD I-NP O
26 495 496 15930398 , , O O
27 497 500 15930398 and CC O O
28 501 508 15930398 October NNP B-NP O
29 509 511 15930398 31 CD I-NP O
30 511 512 15930398 , , I-NP O
31 513 517 15930398 2003 CD I-NP O
32 517 518 15930398 . . O O

1 519 522 15930398 BIS NN B-NP O
2 523 533 15930398 monitoring NN I-NP O
3 534 537 15930398 was VBD B-VP O
4 538 547 15930398 initiated VBN I-VP O
5 548 556 15930398 starting VBG B-PP O
6 557 558 15930398 3 CD B-NP O
7 559 566 15930398 minutes NNS I-NP O
8 567 573 15930398 before IN B-PP O
9 574 577 15930398 the DT B-NP O
10 578 587 15930398 procedure NN I-NP O
11 588 591 15930398 and CC O O
12 592 602 15930398 continuing VBG B-VP O
13 603 608 15930398 until IN B-SBAR O
14 609 612 15930398 the DT B-NP O
15 613 620 15930398 patient NN I-NP O
16 621 624 15930398 had VBD B-VP O
17 625 633 15930398 regained VBN I-VP O
18 634 642 15930398 baseline NN B-NP O
19 643 649 15930398 mental JJ I-NP O
20 650 656 15930398 status NN I-NP O
21 656 657 15930398 . . O O

1 658 660 15930398 At IN B-PP O
2 661 662 15930398 1 CD B-NP O
3 662 663 15930398 - HYPH I-NP O
4 663 669 15930398 minute JJ I-NP O
5 670 679 15930398 intervals NNS I-NP O
6 680 686 15930398 during IN B-PP O
7 687 690 15930398 the DT B-NP O
8 691 701 15930398 procedural JJ I-NP O
9 702 710 15930398 sedation NN I-NP O
10 710 711 15930398 , , O O
11 712 717 15930398 until IN B-SBAR O
12 718 721 15930398 the DT B-NP O
13 722 729 15930398 patient NN I-NP O
14 730 738 15930398 regained VBD B-VP O
15 739 747 15930398 baseline NN B-NP O
16 748 754 15930398 mental JJ I-NP O
17 755 761 15930398 status NN I-NP O
18 762 764 15930398 at IN B-PP O
19 765 768 15930398 the DT B-NP O
20 769 772 15930398 end NN I-NP O
21 773 775 15930398 of IN B-PP O
22 776 779 15930398 the DT B-NP O
23 780 789 15930398 procedure NN I-NP O
24 789 790 15930398 , , O O
25 791 792 15930398 a DT B-NP O
26 793 797 15930398 word NN I-NP O
27 798 802 15930398 from IN B-PP O
28 803 804 15930398 a DT B-NP O
29 805 817 15930398 standardized JJ I-NP O
30 818 822 15930398 list NN I-NP O
31 823 826 15930398 was VBD B-VP O
32 827 831 15930398 read VBN I-VP O
33 832 837 15930398 aloud RB B-ADVP O
34 837 838 15930398 , , O O
35 839 842 15930398 and CC O O
36 843 846 15930398 the DT B-NP O
37 847 854 15930398 patient NN I-NP O
38 855 858 15930398 was VBD B-VP O
39 859 864 15930398 asked VBN I-VP O
40 865 867 15930398 to TO B-VP O
41 868 879 15930398 immediately RB I-VP O
42 880 886 15930398 repeat VB I-VP O
43 887 890 15930398 the DT B-NP O
44 891 895 15930398 word NN I-NP O
45 896 898 15930398 to TO B-PP O
46 899 902 15930398 the DT B-NP O
47 903 915 15930398 investigator NN I-NP O
48 915 916 15930398 . . O O

1 917 920 15930398 The DT B-NP O
2 921 924 15930398 BIS NN I-NP O
3 925 930 15930398 score NN I-NP O
4 931 933 15930398 at IN B-PP O
5 934 937 15930398 the DT B-NP O
6 938 942 15930398 time NN I-NP O
7 943 946 15930398 the DT B-NP O
8 947 951 15930398 word NN I-NP O
9 952 955 15930398 was VBD B-VP O
10 956 960 15930398 read VBN I-VP O
11 961 964 15930398 and CC O O
12 965 968 15930398 the DT B-NP O
13 969 978 15930398 patient's NNS I-NP O
14 979 986 15930398 ability NN I-NP O
15 987 989 15930398 to TO B-VP O
16 990 996 15930398 repeat VB I-VP O
17 997 1000 15930398 the DT B-NP O
18 1001 1005 15930398 word NN I-NP O
19 1006 1010 15930398 were VBD B-VP O
20 1011 1019 15930398 recorded VBN I-VP O
21 1019 1020 15930398 . . O O

1 1021 1026 15930398 After IN B-PP O
2 1027 1030 15930398 the DT B-NP O
3 1031 1040 15930398 procedure NN I-NP O
4 1040 1041 15930398 , , O O
5 1042 1045 15930398 the DT B-NP O
6 1046 1053 15930398 patient NN I-NP O
7 1054 1057 15930398 was VBD B-VP O
8 1058 1063 15930398 asked VBN I-VP O
9 1064 1066 15930398 to TO I-VP O
10 1067 1072 15930398 state VB I-VP O
11 1073 1076 15930398 all DT B-NP O
12 1077 1079 15930398 of IN B-PP O
13 1080 1083 15930398 the DT B-NP O
14 1084 1089 15930398 words NNS I-NP O
15 1090 1094 15930398 from IN B-PP O
16 1095 1098 15930398 the DT B-NP O
17 1099 1103 15930398 list NN I-NP O
18 1104 1108 15930398 that IN B-SBAR O
19 1109 1111 15930398 he PRP B-NP O
20 1112 1114 15930398 or CC I-NP O
21 1115 1118 15930398 she PRP I-NP O
22 1119 1124 15930398 could MD B-VP O
23 1125 1131 15930398 recall VB I-VP O
24 1131 1132 15930398 , , O O
25 1133 1136 15930398 and CC O O
26 1137 1139 15930398 to TO B-VP O
27 1140 1148 15930398 identify VB I-VP O
28 1149 1152 15930398 the DT B-NP O
29 1153 1157 15930398 last JJ I-NP O
30 1158 1162 15930398 word NN I-NP O
31 1163 1171 15930398 recalled VBN B-VP O
32 1172 1176 15930398 from IN B-PP O
33 1177 1182 15930398 prior JJ B-ADJP O
34 1183 1185 15930398 to TO B-PP O
35 1186 1189 15930398 the DT B-NP O
36 1190 1195 15930398 start NN I-NP O
37 1196 1198 15930398 of IN B-PP O
38 1199 1202 15930398 the DT B-NP O
39 1203 1212 15930398 procedure NN I-NP O
40 1213 1216 15930398 and CC O O
41 1217 1220 15930398 the DT B-NP O
42 1221 1226 15930398 first JJ I-NP O
43 1227 1231 15930398 word NN I-NP O
44 1232 1240 15930398 recalled VBN B-VP O
45 1241 1245 15930398 from IN B-PP O
46 1246 1251 15930398 after IN B-PP O
47 1252 1255 15930398 the DT B-NP O
48 1256 1265 15930398 procedure NN I-NP O
49 1266 1269 15930398 was VBD B-VP O
50 1270 1279 15930398 completed VBN I-VP O
51 1279 1280 15930398 . . O O

1 1281 1288 15930398 RESULTS NNS B-NP O
2 1288 1289 15930398 : : O O
3 1290 1297 15930398 Seventy CD B-NP O
4 1297 1298 15930398 - HYPH I-NP O
5 1298 1302 15930398 five CD I-NP O
6 1303 1313 15930398 consenting NN I-NP O
7 1314 1322 15930398 patients NNS I-NP O
8 1323 1327 15930398 were VBD B-VP O
9 1328 1336 15930398 enrolled VBN I-VP O
10 1336 1337 15930398 ; : O O
11 1338 1341 15930398 one CD B-NP O
12 1342 1349 15930398 patient NN I-NP O
13 1350 1353 15930398 was VBD B-VP O
14 1354 1362 15930398 excluded VBN I-VP O
15 1363 1367 15930398 from IN B-PP O
16 1368 1372 15930398 data NNS B-NP O
17 1373 1381 15930398 analysis NN I-NP O
18 1382 1385 15930398 for IN B-PP O
19 1386 1387 15930398 a DT B-NP O
20 1388 1396 15930398 protocol NN I-NP O
21 1397 1406 15930398 violation NN I-NP O
22 1406 1407 15930398 . . O O

1 1408 1410 15930398 No DT B-NP O
2 1411 1418 15930398 serious JJ I-NP O
3 1419 1426 15930398 adverse JJ I-NP O
4 1427 1433 15930398 events NNS I-NP O
5 1434 1438 15930398 were VBD B-VP O
6 1439 1444 15930398 noted VBN I-VP O
7 1445 1451 15930398 during IN B-PP O
8 1452 1455 15930398 the DT B-NP O
9 1456 1466 15930398 procedural JJ I-NP O
10 1467 1476 15930398 sedations NNS I-NP O
11 1476 1477 15930398 . . O O

1 1478 1481 15930398 The DT B-NP O
2 1482 1486 15930398 mean JJ I-NP O
3 1487 1488 15930398 ( ( O O
4 1488 1489 15930398 + SYM O O
5 1489 1490 15930398 / SYM O O
6 1490 1491 15930398 - HYPH O O
7 1491 1499 15930398 standard JJ B-NP O
8 1500 1509 15930398 deviation NN I-NP O
9 1509 1510 15930398 ) ) O O
10 1511 1515 15930398 time NN B-NP O
11 1516 1518 15930398 of IN B-PP O
12 1519 1523 15930398 data NNS B-NP O
13 1524 1534 15930398 collection NN I-NP O
14 1535 1538 15930398 was VBD B-VP O
15 1539 1543 15930398 16.4 CD B-NP O
16 1544 1551 15930398 minutes NNS I-NP O
17 1552 1553 15930398 ( ( O O
18 1553 1554 15930398 + SYM B-NP O
19 1554 1555 15930398 / SYM O O
20 1555 1556 15930398 - SYM O O
21 1556 1559 15930398 7.1 CD B-NP O
22 1559 1560 15930398 ; : O O
23 1561 1566 15930398 range NN B-NP O
24 1567 1568 15930398 5 CD B-NP O
25 1569 1571 15930398 to TO I-NP O
26 1572 1574 15930398 34 CD I-NP O
27 1575 1582 15930398 minutes NNS I-NP O
28 1582 1583 15930398 ) ) O O
29 1583 1584 15930398 . . O O

1 1585 1588 15930398 The DT B-NP O
2 1589 1593 15930398 mean JJ I-NP O
3 1594 1601 15930398 initial JJ I-NP O
4 1602 1603 15930398 ( ( O O
5 1603 1615 15930398 preprocedure JJ B-ADJP O
6 1615 1616 15930398 ) ) O O
7 1617 1620 15930398 BIS NN B-NP O
8 1621 1626 15930398 score NN I-NP O
9 1627 1630 15930398 was VBD B-VP O
10 1631 1635 15930398 97.1 CD B-NP O
11 1636 1637 15930398 ( ( O O
12 1637 1638 15930398 + SYM B-NP O
13 1638 1639 15930398 / SYM O O
14 1639 1640 15930398 - SYM O O
15 1640 1643 15930398 2.3 CD B-NP O
16 1643 1644 15930398 ; : O O
17 1645 1650 15930398 range NN B-NP O
18 1651 1653 15930398 92 CD B-NP O
19 1654 1656 15930398 to TO I-NP O
20 1657 1659 15930398 99 CD I-NP O
21 1659 1660 15930398 ) ) O O
22 1660 1661 15930398 . . O O

1 1662 1665 15930398 The DT B-NP O
2 1666 1670 15930398 mean JJ I-NP O
3 1671 1677 15930398 lowest JJS I-NP O
4 1678 1681 15930398 BIS NN I-NP O
5 1682 1687 15930398 score NN I-NP O
6 1688 1697 15930398 occurring VBG B-VP O
7 1698 1704 15930398 during IN B-PP O
8 1705 1710 15930398 these DT B-NP O
9 1711 1721 15930398 procedural JJ I-NP O
10 1722 1731 15930398 sedations NNS I-NP O
11 1732 1735 15930398 was VBD B-VP O
12 1736 1740 15930398 66.9 CD B-NP O
13 1741 1742 15930398 ( ( O O
14 1742 1743 15930398 + SYM B-NP O
15 1743 1744 15930398 / SYM O O
16 1744 1745 15930398 - SYM O O
17 1745 1749 15930398 14.4 CD B-NP O
18 1749 1750 15930398 ; : O O
19 1751 1756 15930398 range NN B-NP O
20 1757 1759 15930398 33 CD B-NP O
21 1760 1762 15930398 to TO I-NP O
22 1763 1765 15930398 91 CD I-NP O
23 1765 1766 15930398 ) ) O O
24 1766 1767 15930398 . . O O

1 1768 1771 15930398 The DT B-NP O
2 1772 1776 15930398 mean JJ I-NP O
3 1777 1783 15930398 lowest JJS I-NP O
4 1784 1787 15930398 BIS NN I-NP O
5 1788 1793 15930398 score NN I-NP O
6 1794 1807 15930398 corresponding VBG B-VP O
7 1808 1810 15930398 to TO B-PP O
8 1811 1814 15930398 the DT B-NP O
9 1815 1822 15930398 ability NN I-NP O
10 1823 1825 15930398 of IN B-PP O
11 1826 1829 15930398 the DT B-NP O
12 1830 1837 15930398 patient NN I-NP O
13 1838 1840 15930398 to TO B-VP O
14 1841 1852 15930398 immediately RB I-VP O
15 1853 1859 15930398 repeat VB I-VP O
16 1860 1865 15930398 words NNS B-NP O
17 1866 1870 15930398 read VB B-VP O
18 1871 1875 15930398 from IN B-PP O
19 1876 1879 15930398 the DT B-NP O
20 1880 1884 15930398 list NN I-NP O
21 1885 1888 15930398 was VBD B-VP O
22 1889 1893 15930398 77.1 CD B-NP O
23 1894 1895 15930398 ( ( O O
24 1895 1898 15930398 95% CD B-NP O
25 1899 1901 15930398 CI NN I-NP O
26 1902 1903 15930398 = SYM B-VP O
27 1904 1908 15930398 74.3 CD B-NP O
28 1909 1911 15930398 to TO B-PP O
29 1912 1916 15930398 80.0 CD B-NP O
30 1916 1917 15930398 ) ) O O
31 1917 1918 15930398 . . O O

1 1919 1922 15930398 The DT B-NP O
2 1923 1927 15930398 mean JJ I-NP O
3 1928 1935 15930398 highest JJS I-NP O
4 1936 1939 15930398 BIS NN I-NP O
5 1940 1945 15930398 score NN I-NP O
6 1946 1959 15930398 corresponding VBG B-VP O
7 1960 1962 15930398 to TO B-PP O
8 1963 1966 15930398 the DT B-NP O
9 1967 1976 15930398 inability NN I-NP D000647
10 1977 1979 15930398 to TO B-VP D000647
11 1980 1986 15930398 repeat VB I-VP D000647
12 1987 1992 15930398 words NNS B-NP D000647
13 1993 1996 15930398 was VBD B-VP O
14 1997 2001 15930398 81.5 CD B-NP O
15 2002 2003 15930398 ( ( O O
16 2003 2006 15930398 95% CD B-NP O
17 2007 2009 15930398 CI NN I-NP O
18 2010 2011 15930398 = SYM B-VP O
19 2012 2016 15930398 78.1 CD B-NP O
20 2017 2019 15930398 to TO B-PP O
21 2020 2024 15930398 84.8 CD B-NP O
22 2024 2025 15930398 ) ) O O
23 2025 2026 15930398 . . O O

1 2027 2030 15930398 The DT B-NP O
2 2031 2035 15930398 mean JJ I-NP O
3 2036 2039 15930398 BIS NN I-NP O
4 2040 2045 15930398 score NN I-NP O
5 2046 2059 15930398 corresponding VBG B-VP O
6 2060 2062 15930398 to TO B-PP O
7 2063 2066 15930398 the DT B-NP O
8 2067 2071 15930398 last JJ I-NP O
9 2072 2076 15930398 word NN I-NP O
10 2077 2085 15930398 recalled VBN B-VP O
11 2086 2090 15930398 from IN B-PP O
12 2091 2096 15930398 prior JJ B-ADJP O
13 2097 2099 15930398 to TO B-PP O
14 2100 2103 15930398 the DT B-NP O
15 2104 2114 15930398 initiation NN I-NP O
16 2115 2117 15930398 of IN B-PP O
17 2118 2121 15930398 the DT B-NP O
18 2122 2130 15930398 sedation NN I-NP O
19 2131 2134 15930398 was VBD B-VP O
20 2135 2139 15930398 96.7 CD B-NP O
21 2140 2141 15930398 ( ( O O
22 2141 2142 15930398 + SYM B-NP O
23 2142 2143 15930398 / SYM O O
24 2143 2144 15930398 - SYM O O
25 2144 2147 15930398 2.4 CD B-NP O
26 2147 2148 15930398 ; : O O
27 2149 2154 15930398 range NN B-NP O
28 2155 2157 15930398 84 CD B-NP O
29 2158 2160 15930398 to TO I-NP O
30 2161 2163 15930398 98 CD I-NP O
31 2163 2164 15930398 ) ) O O
32 2164 2165 15930398 . . O O

1 2166 2169 15930398 The DT B-NP O
2 2170 2174 15930398 mean JJ I-NP O
3 2175 2178 15930398 BIS NN I-NP O
4 2179 2184 15930398 score NN I-NP O
5 2185 2198 15930398 corresponding VBG B-VP O
6 2199 2201 15930398 to TO B-PP O
7 2202 2205 15930398 the DT B-NP O
8 2206 2211 15930398 first JJ I-NP O
9 2212 2216 15930398 word NN I-NP O
10 2217 2225 15930398 recalled VBN B-VP O
11 2226 2231 15930398 after IN B-PP O
12 2232 2235 15930398 the DT B-NP O
13 2236 2245 15930398 procedure NN I-NP O
14 2246 2249 15930398 was VBD B-VP O
15 2250 2259 15930398 completed VBN I-VP O
16 2260 2263 15930398 was VBD B-VP O
17 2264 2268 15930398 91.2 CD B-NP O
18 2269 2270 15930398 ( ( O O
19 2270 2273 15930398 95% CD B-NP O
20 2274 2276 15930398 CI NN I-NP O
21 2277 2278 15930398 = SYM B-VP O
22 2279 2283 15930398 88.1 CD B-NP O
23 2284 2286 15930398 to TO B-PP O
24 2287 2291 15930398 94.3 CD B-NP O
25 2291 2292 15930398 ) ) O O
26 2292 2293 15930398 . . O O

1 2294 2297 15930398 All DT B-NP O
2 2298 2306 15930398 patients NNS I-NP O
3 2307 2315 15930398 recalled VBD B-VP O
4 2316 2318 15930398 at IN B-NP O
5 2319 2324 15930398 least JJS I-NP O
6 2325 2328 15930398 one CD I-NP O
7 2329 2333 15930398 word NN I-NP O
8 2334 2338 15930398 that WDT B-NP O
9 2339 2342 15930398 had VBD B-VP O
10 2343 2347 15930398 been VBN I-VP O
11 2348 2352 15930398 read VBN I-VP O
12 2353 2355 15930398 to TO B-PP O
13 2356 2360 15930398 them PRP B-NP O
14 2361 2367 15930398 during IN B-PP O
15 2368 2371 15930398 the DT B-NP O
16 2372 2380 15930398 protocol NN I-NP O
17 2380 2381 15930398 . . O O

1 2382 2385 15930398 The DT B-NP O
2 2386 2390 15930398 mean JJ I-NP O
3 2391 2397 15930398 lowest JJS I-NP O
4 2398 2401 15930398 BIS NN I-NP O
5 2402 2407 15930398 score NN I-NP O
6 2408 2411 15930398 for IN B-PP O
7 2412 2415 15930398 any DT B-NP O
8 2416 2424 15930398 recalled VBN I-NP O
9 2425 2429 15930398 word NN I-NP O
10 2430 2433 15930398 was VBD B-VP O
11 2434 2438 15930398 91.5 CD B-NP O
12 2439 2440 15930398 ( ( O O
13 2440 2441 15930398 + SYM B-NP O
14 2441 2442 15930398 / SYM O O
15 2442 2443 15930398 - SYM O O
16 2443 2447 15930398 11.1 CD B-NP O
17 2447 2448 15930398 ; : O O
18 2449 2454 15930398 range NN B-NP O
19 2455 2457 15930398 79 CD B-NP O
20 2458 2460 15930398 to TO I-NP O
21 2461 2463 15930398 98 CD I-NP O
22 2463 2464 15930398 ) ) O O
23 2464 2465 15930398 , , O O
24 2466 2469 15930398 and CC O O
25 2470 2472 15930398 no DT B-NP O
26 2473 2478 15930398 words NNS I-NP O
27 2479 2483 15930398 were VBD B-VP O
28 2484 2492 15930398 recalled VBN I-VP O
29 2493 2497 15930398 when WRB B-ADVP O
30 2498 2501 15930398 the DT B-NP O
31 2502 2515 15930398 corresponding VBG I-NP O
32 2516 2519 15930398 BIS NN I-NP O
33 2520 2525 15930398 score NN I-NP O
34 2526 2529 15930398 was VBD B-VP O
35 2530 2534 15930398 less JJR B-ADJP O
36 2535 2539 15930398 than IN B-PP O
37 2540 2542 15930398 90 CD B-NP O
38 2542 2543 15930398 . . O O

1 2544 2555 15930398 CONCLUSIONS NNS B-NP O
2 2555 2556 15930398 : : O O
3 2557 2562 15930398 There EX B-NP O
4 2563 2565 15930398 is VBZ B-VP O
5 2566 2567 15930398 a DT B-NP O
6 2568 2573 15930398 range NN I-NP O
7 2574 2576 15930398 of IN B-PP O
8 2577 2580 15930398 BIS NN B-NP O
9 2581 2587 15930398 scores NNS I-NP O
10 2588 2594 15930398 during IN B-PP O
11 2595 2600 15930398 which WDT B-NP O
12 2601 2608 15930398 sedated JJ B-NP O
13 2609 2617 15930398 patients NNS I-NP O
14 2618 2621 15930398 are VBP B-VP O
15 2622 2626 15930398 able JJ B-ADJP O
16 2627 2629 15930398 to TO B-VP O
17 2630 2636 15930398 repeat VB I-VP O
18 2637 2642 15930398 words NNS B-NP O
19 2643 2647 15930398 read VB B-VP O
20 2648 2650 15930398 to TO B-PP O
21 2651 2655 15930398 them PRP B-NP O
22 2656 2659 15930398 but CC O O
23 2660 2663 15930398 are VBP B-VP O
24 2664 2667 15930398 not RB O O
25 2668 2672 15930398 able JJ B-ADJP O
26 2673 2675 15930398 to TO B-VP O
27 2676 2688 15930398 subsequently RB I-VP O
28 2689 2695 15930398 recall VB I-VP O
29 2696 2701 15930398 these DT B-NP O
30 2702 2707 15930398 words NNS I-NP O
31 2707 2708 15930398 . . O O

1 2709 2720 15930398 Furthermore RB B-ADVP O
2 2720 2721 15930398 , , O O
3 2722 2730 15930398 patients NNS B-NP O
4 2731 2734 15930398 had VBD B-VP O
5 2735 2737 15930398 no DT B-NP O
6 2738 2744 15930398 recall NN I-NP O
7 2745 2747 15930398 of IN B-PP O
8 2748 2753 15930398 words NNS B-NP O
9 2754 2762 15930398 repeated VBN B-VP O
10 2763 2768 15930398 prior RB B-ADVP O
11 2769 2771 15930398 to TO B-PP O
12 2772 2782 15930398 procedural JJ B-NP O
13 2783 2791 15930398 sedation NN I-NP O
14 2792 2794 15930398 in IN B-PP O
15 2795 2798 15930398 BIS NN B-NP O
16 2799 2805 15930398 ranges NNS I-NP O
17 2806 2816 15930398 associated VBN B-VP O
18 2817 2821 15930398 with IN B-PP O
19 2822 2828 15930398 recall NN B-NP O
20 2829 2834 15930398 after IN B-PP O
21 2835 2845 15930398 procedural JJ B-NP O
22 2846 2854 15930398 sedation NN I-NP O
23 2854 2855 15930398 , , O O
24 2856 2866 15930398 suggestive JJ B-ADJP O
25 2867 2869 15930398 of IN B-PP O
26 2870 2880 15930398 retrograde JJ B-NP D000648
27 2881 2888 15930398 amnesia NN I-NP D000648
28 2888 2889 15930398 . . O O

1 0 0 3088349 -DOCSTART- -X- -X- O

1 0 9 3088349 Transient JJ B-NP O
2 10 23 3088349 contralateral JJ I-NP D009069
3 24 32 3088349 rotation NN I-NP D009069
4 33 42 3088349 following VBG B-PP O
5 43 53 3088349 unilateral JJ B-NP O
6 54 64 3088349 substantia NN I-NP -1
7 65 70 3088349 nigra NN I-NP -1
8 71 77 3088349 lesion NN I-NP -1
9 78 86 3088349 reflects VBZ B-VP O
10 87 101 3088349 susceptibility NN B-NP O
11 102 104 3088349 of IN B-PP O
12 105 108 3088349 the DT B-NP O
13 109 122 3088349 nigrostriatal JJ I-NP O
14 123 129 3088349 system NN I-NP O
15 130 132 3088349 to TO B-PP O
16 133 143 3088349 exhaustion NN B-NP O
17 144 146 3088349 by IN B-PP O
18 147 158 3088349 amphetamine NN B-NP D000661
19 158 159 3088349 . . O O
20 160 169 3088349 Following VBG B-VP O
21 170 180 3088349 unilateral JJ B-NP O
22 181 182 3088349 6 CD I-NP D016627
23 182 183 3088349 - HYPH I-NP D016627
24 183 187 3088349 OHDA NN I-NP D016627
25 188 195 3088349 induced VBN I-NP O
26 196 198 3088349 SN NN I-NP -1
27 199 205 3088349 lesion NN I-NP -1
28 205 206 3088349 , , O O
29 207 208 3088349 a DT B-NP O
30 209 218 3088349 transient JJ I-NP O
31 219 225 3088349 period NN I-NP O
32 226 228 3088349 of IN B-PP O
33 229 242 3088349 contralateral JJ B-NP D009069
34 243 251 3088349 rotation NN I-NP D009069
35 252 255 3088349 has VBZ B-VP O
36 256 260 3088349 been VBN I-VP O
37 261 269 3088349 reported VBN I-VP O
38 270 272 3088349 to TO I-VP O
39 273 280 3088349 precede VB I-VP O
40 281 284 3088349 the DT B-NP O
41 285 296 3088349 predominant JJ I-NP O
42 297 308 3088349 ipsilateral JJ I-NP D009069
43 309 317 3088349 circling NN I-NP D009069
44 317 318 3088349 . . O O

1 319 321 3088349 In IN B-SBAR O
2 322 327 3088349 order NN O O
3 328 330 3088349 to TO B-VP O
4 331 338 3088349 clarify VB I-VP O
5 339 342 3088349 the DT B-NP O
6 343 349 3088349 nature NN I-NP O
7 350 352 3088349 of IN B-PP O
8 353 357 3088349 this DT B-NP O
9 358 365 3088349 initial JJ I-NP O
10 366 379 3088349 contralateral JJ I-NP D009069
11 380 388 3088349 rotation NN I-NP D009069
12 389 391 3088349 we PRP B-NP O
13 392 400 3088349 examined VBD B-VP O
14 401 404 3088349 the DT B-NP O
15 405 411 3088349 effect NN I-NP O
16 412 414 3088349 of IN B-PP O
17 415 418 3088349 the DT B-NP O
18 419 427 3088349 duration NN I-NP O
19 428 430 3088349 of IN B-PP O
20 431 439 3088349 recovery NN B-NP O
21 440 446 3088349 period NN I-NP O
22 447 452 3088349 after IN B-PP O
23 453 456 3088349 the DT B-NP O
24 457 463 3088349 lesion NN I-NP O
25 463 464 3088349 , , O O
26 465 467 3088349 on IN B-PP O
27 468 479 3088349 amphetamine NN B-NP D000661
28 479 480 3088349 - HYPH B-NP O
29 480 487 3088349 induced VBN I-NP O
30 488 498 3088349 rotational JJ I-NP D009069
31 499 507 3088349 behavior NN I-NP D009069
32 507 508 3088349 . . O O

1 509 514 3088349 Three CD B-NP O
2 515 519 3088349 days NNS I-NP O
3 520 524 3088349 post IN B-PP O
4 525 531 3088349 lesion NN B-NP O
5 531 532 3088349 , , O O
6 533 537 3088349 most JJS B-NP O
7 538 542 3088349 rats NNS I-NP O
8 543 550 3088349 circled VBD B-VP O
9 551 564 3088349 predominantly RB B-ADJP O
10 565 580 3088349 contralaterally RB I-ADJP O
11 581 583 3088349 to TO B-PP O
12 584 587 3088349 the DT B-NP O
13 588 594 3088349 lesion NN I-NP O
14 594 595 3088349 . . O O

1 596 600 3088349 Such JJ B-NP O
2 601 614 3088349 contralateral JJ I-NP D009069
3 615 623 3088349 rotation NN I-NP D009069
4 624 627 3088349 may MD B-VP O
5 628 634 3088349 result VB I-VP O
6 635 639 3088349 from IN B-PP O
7 640 646 3088349 either CC O O
8 647 659 3088349 degeneration NN B-NP O
9 659 660 3088349 - HYPH O O
10 660 667 3088349 induced VBN B-NP O
11 668 677 3088349 breakdown NN I-NP O
12 678 680 3088349 of IN B-PP O
13 681 684 3088349 the DT B-NP O
14 685 687 3088349 DA NN I-NP O
15 688 692 3088349 pool NN I-NP O
16 692 693 3088349 , , O O
17 694 696 3088349 or CC O O
18 697 703 3088349 lesion NN B-NP O
19 703 704 3088349 - HYPH O O
20 704 711 3088349 induced VBN B-NP O
21 712 720 3088349 increase NN I-NP O
22 721 723 3088349 of IN B-PP O
23 724 726 3088349 DA NN B-NP O
24 727 735 3088349 turnover NN I-NP O
25 736 738 3088349 in IN B-PP O
26 739 742 3088349 the DT B-NP O
27 743 749 3088349 spared JJ I-NP O
28 750 757 3088349 neurons NNS I-NP O
29 757 758 3088349 . . O O

1 759 760 3088349 A DT B-NP O
2 761 772 3088349 substantial JJ I-NP O
3 773 779 3088349 degree NN I-NP O
4 780 782 3088349 of IN B-PP O
5 783 796 3088349 contralateral JJ B-NP O
6 797 807 3088349 preference NN I-NP O
7 808 811 3088349 was VBD B-VP O
8 812 817 3088349 still RB B-ADVP O
9 818 825 3088349 evident JJ B-ADJP O
10 826 830 3088349 when WRB B-ADVP O
11 831 842 3088349 amphetamine NN B-NP D000661
12 843 846 3088349 was VBD B-VP O
13 847 859 3088349 administered VBN I-VP O
14 860 863 3088349 for IN B-PP O
15 864 867 3088349 the DT B-NP O
16 868 873 3088349 first JJ I-NP O
17 874 878 3088349 time NN I-NP O
18 879 881 3088349 24 CD B-NP O
19 882 886 3088349 days NNS I-NP O
20 887 892 3088349 after IN B-PP O
21 893 902 3088349 lesioning VBG B-VP O
22 902 903 3088349 , , O O
23 904 914 3088349 indicating VBG B-VP O
24 915 926 3088349 involvement NN B-NP O
25 927 929 3088349 of IN B-PP O
26 930 936 3088349 spared VBN B-NP O
27 937 942 3088349 cells NNS I-NP O
28 943 945 3088349 in IN B-PP O
29 946 949 3088349 the DT B-NP O
30 950 963 3088349 contralateral JJ I-NP D009069
31 964 972 3088349 rotation NN I-NP D009069
32 972 973 3088349 . . O O

1 974 981 3088349 However RB B-ADVP O
2 981 982 3088349 , , O O
3 983 993 3088349 regardless RB B-ADVP O
4 994 996 3088349 of IN B-PP O
5 997 1000 3088349 the DT B-NP O
6 1001 1009 3088349 duration NN I-NP O
7 1010 1012 3088349 of IN B-PP O
8 1013 1021 3088349 recovery NN B-NP O
9 1022 1023 3088349 ( ( O O
10 1023 1026 3088349 and CC O O
11 1027 1039 3088349 irrespective JJ B-ADJP O
12 1040 1042 3088349 of IN B-PP O
13 1043 1049 3088349 either CC O O
14 1050 1056 3088349 lesion NN B-NP O
15 1057 1063 3088349 volume NN I-NP O
16 1063 1064 3088349 , , O O
17 1065 1076 3088349 amphetamine NN B-NP D000661
18 1077 1081 3088349 dose NN I-NP O
19 1081 1082 3088349 , , O O
20 1083 1085 3088349 or CC O O
21 1086 1090 3088349 post AFX B-NP O
22 1090 1091 3088349 - HYPH I-NP O
23 1091 1097 3088349 lesion NN I-NP O
24 1098 1103 3088349 motor NN I-NP O
25 1104 1112 3088349 exercise NN I-NP O
26 1112 1113 3088349 ) ) O O
27 1113 1114 3088349 , , O O
28 1115 1126 3088349 amphetamine NN B-NP D000661
29 1126 1127 3088349 - HYPH B-VP O
30 1127 1134 3088349 induced VBN B-NP O
31 1135 1143 3088349 rotation NN I-NP D009069
32 1144 1150 3088349 tended VBD B-VP O
33 1151 1153 3088349 to TO I-VP O
34 1154 1160 3088349 become VB I-VP O
35 1161 1170 3088349 gradually RB B-ADJP O
36 1171 1175 3088349 more RBR I-ADJP O
37 1176 1187 3088349 ipsilateral JJ I-ADJP O
38 1188 1190 3088349 as IN B-PP O
39 1191 1194 3088349 the DT B-NP O
40 1195 1206 3088349 observation NN I-NP O
41 1207 1214 3088349 session NN I-NP O
42 1215 1225 3088349 progressed VBD B-VP O
43 1225 1226 3088349 , , O O
44 1227 1230 3088349 and CC O O
45 1231 1234 3088349 all DT B-NP O
46 1235 1239 3088349 rats NNS I-NP O
47 1240 1247 3088349 circled VBD B-VP O
48 1248 1261 3088349 ipsilaterally RB B-ADVP O
49 1262 1264 3088349 to TO B-PP O
50 1265 1268 3088349 the DT B-NP O
51 1269 1275 3088349 lesion NN I-NP O
52 1276 1278 3088349 in IN B-PP O
53 1279 1287 3088349 response NN B-NP O
54 1288 1290 3088349 to TO B-PP O
55 1291 1298 3088349 further JJ B-NP O
56 1299 1310 3088349 amphetamine NN I-NP D000661
57 1311 1321 3088349 injections NNS I-NP O
58 1321 1322 3088349 . . O O

1 1323 1328 3088349 These DT B-NP O
2 1329 1337 3088349 findings NNS I-NP O
3 1338 1345 3088349 suggest VBP B-VP O
4 1346 1350 3088349 that IN B-SBAR O
5 1351 1362 3088349 amphetamine NN B-NP D000661
6 1363 1366 3088349 has VBZ B-VP O
7 1367 1369 3088349 an DT B-NP O
8 1370 1382 3088349 irreversible JJ I-NP O
9 1383 1389 3088349 effect NN I-NP O
10 1390 1392 3088349 on IN B-PP O
11 1393 1396 3088349 the DT B-NP O
12 1397 1401 3088349 post AFX I-NP O
13 1401 1402 3088349 - HYPH I-NP O
14 1402 1408 3088349 lesion NN I-NP O
15 1409 1411 3088349 DA NN I-NP O
16 1412 1416 3088349 pool NN I-NP O
17 1417 1429 3088349 contributing VBG B-VP O
18 1430 1432 3088349 to TO B-PP O
19 1433 1446 3088349 contralateral JJ B-NP D009069
20 1447 1455 3088349 rotation NN I-NP D009069
21 1455 1456 3088349 . . O O

1 0 0 9326871 -DOCSTART- -X- -X- O

1 0 14 9326871 Clarithromycin NN B-NP D017291
2 14 15 9326871 - HYPH O O
3 15 22 9326871 induced VBN B-NP O
4 23 34 9326871 ventricular JJ I-NP D017180
5 35 46 9326871 tachycardia NN I-NP D017180
6 46 47 9326871 . . I-NP O
7 48 62 9326871 Clarithromycin NN I-NP D017291
8 63 65 9326871 is VBZ B-VP O
9 66 67 9326871 a DT B-NP O
10 68 78 9326871 relatively RB I-NP O
11 79 82 9326871 new JJ I-NP O
12 83 92 9326871 macrolide NN I-NP D018942
13 93 103 9326871 antibiotic NN I-NP O
14 104 108 9326871 that WDT B-NP O
15 109 115 9326871 offers VBZ B-VP O
16 116 121 9326871 twice RB B-NP O
17 121 122 9326871 - HYPH I-NP O
18 122 127 9326871 daily JJ I-NP O
19 128 134 9326871 dosing NN I-NP O
20 134 135 9326871 . . O O

1 136 138 9326871 It PRP B-NP O
2 139 146 9326871 differs VBZ B-VP O
3 147 151 9326871 from IN B-PP O
4 152 164 9326871 erythromycin NN B-NP D004917
5 165 169 9326871 only RB B-ADVP O
6 170 172 9326871 in IN B-PP O
7 173 176 9326871 the DT B-NP O
8 177 188 9326871 methylation NN I-NP O
9 189 191 9326871 of IN B-PP O
10 192 195 9326871 the DT B-NP O
11 196 204 9326871 hydroxyl NN I-NP O
12 205 210 9326871 group NN I-NP O
13 211 213 9326871 at IN B-PP O
14 214 222 9326871 position NN B-NP O
15 223 224 9326871 6 CD I-NP O
16 224 225 9326871 . . O O

1 226 234 9326871 Although IN B-SBAR O
2 235 238 9326871 the DT B-NP O
3 239 243 9326871 side NN I-NP O
4 243 244 9326871 - HYPH B-NP O
5 244 250 9326871 effect NN I-NP O
6 251 258 9326871 profile NN I-NP O
7 259 261 9326871 of IN B-PP O
8 262 274 9326871 erythromycin NN B-NP D004917
9 275 277 9326871 is VBZ B-VP O
10 278 289 9326871 established VBN I-VP O
11 289 290 9326871 , , O O
12 291 300 9326871 including VBG B-PP O
13 301 316 9326871 gastroenteritis NN B-NP D005759
14 317 320 9326871 and CC I-NP O
15 321 333 9326871 interactions NNS I-NP O
16 334 338 9326871 with IN B-PP O
17 339 344 9326871 other JJ B-NP O
18 345 350 9326871 drugs NNS I-NP O
19 351 358 9326871 subject JJ B-ADJP O
20 359 361 9326871 to TO B-PP O
21 362 369 9326871 hepatic JJ B-NP O
22 370 375 9326871 mixed VBN I-NP O
23 375 376 9326871 - HYPH I-NP O
24 376 384 9326871 function NN I-NP O
25 385 392 9326871 oxidase NN I-NP O
26 393 403 9326871 metabolism NN I-NP O
27 403 404 9326871 , , O O
28 405 415 9326871 experience NN B-NP O
29 416 420 9326871 with IN B-PP O
30 421 424 9326871 the DT B-NP O
31 425 430 9326871 newer JJR I-NP O
32 431 441 9326871 macrolides NNS I-NP D018942
33 442 444 9326871 is VBZ B-VP O
34 445 450 9326871 still RB I-VP O
35 451 456 9326871 being VBG I-VP O
36 457 465 9326871 recorded VBN I-VP O
37 465 466 9326871 . . O O

1 467 481 9326871 Cardiotoxicity NN B-NP D066126
2 482 485 9326871 has VBZ B-VP O
3 486 490 9326871 been VBN I-VP O
4 491 503 9326871 demonstrated VBN I-VP O
5 504 509 9326871 after IN B-PP O
6 510 514 9326871 both CC B-NP O
7 515 526 9326871 intravenous JJ I-NP O
8 527 530 9326871 and CC I-NP O
9 531 535 9326871 oral JJ I-NP O
10 536 550 9326871 administration NN I-NP O
11 551 553 9326871 of IN B-PP O
12 554 566 9326871 erythromycin NN B-NP D004917
13 567 570 9326871 but CC O O
14 571 574 9326871 has VBZ B-VP O
15 575 580 9326871 never RB I-VP O
16 581 585 9326871 been VBN I-VP O
17 586 594 9326871 reported VBN I-VP O
18 595 599 9326871 with IN B-PP O
19 600 603 9326871 the DT B-NP O
20 604 609 9326871 newer JJR I-NP O
21 610 620 9326871 macrolides NNS I-NP D018942
22 620 621 9326871 . . O O

1 622 624 9326871 We PRP B-NP O
2 625 631 9326871 report VBP B-VP O
3 632 633 9326871 a DT B-NP O
4 634 638 9326871 case NN I-NP O
5 639 641 9326871 of IN B-PP O
6 642 653 9326871 ventricular JJ B-NP D001145
7 654 666 9326871 dysrhythmias NNS I-NP D001145
8 667 671 9326871 that WDT B-NP O
9 672 680 9326871 occurred VBD B-VP O
10 681 686 9326871 after IN B-SBAR O
11 687 690 9326871 six CD B-NP O
12 691 702 9326871 therapeutic JJ I-NP O
13 703 708 9326871 doses NNS I-NP O
14 709 711 9326871 of IN B-PP O
15 712 726 9326871 clarithromycin NN B-NP D017291
16 726 727 9326871 . . O O

1 728 731 9326871 The DT B-NP O
2 732 744 9326871 dysrhythmias NNS I-NP D001145
3 745 753 9326871 resolved VBN B-VP O
4 754 759 9326871 after IN B-PP O
5 760 775 9326871 discontinuation NN B-NP O
6 776 778 9326871 of IN B-PP O
7 779 782 9326871 the DT B-NP O
8 783 787 9326871 drug NN I-NP O
9 787 788 9326871 . . O O

1 0 0 7880714 -DOCSTART- -X- -X- O

1 0 8 7880714 Auditory JJ B-NP O
2 9 20 7880714 disturbance NN I-NP O
3 21 31 7880714 associated VBN B-VP O
4 32 36 7880714 with IN B-PP O
5 37 49 7880714 interscalene NN B-NP O
6 50 58 7880714 brachial JJ I-NP O
7 59 65 7880714 plexus NN I-NP O
8 66 71 7880714 block NN I-NP O
9 71 72 7880714 . . O O
10 73 75 7880714 We PRP B-NP O
11 76 85 7880714 performed VBD B-VP O
12 86 88 7880714 an DT B-NP O
13 89 100 7880714 audiometric JJ I-NP O
14 101 106 7880714 study NN I-NP O
15 107 109 7880714 in IN B-PP O
16 110 112 7880714 20 CD B-NP O
17 113 121 7880714 patients NNS I-NP O
18 122 125 7880714 who WP B-NP O
19 126 135 7880714 underwent VBD B-VP O
20 136 143 7880714 surgery NN B-NP O
21 144 146 7880714 of IN B-PP O
22 147 150 7880714 the DT B-NP O
23 151 159 7880714 shoulder NN I-NP O
24 160 166 7880714 region NN I-NP O
25 167 172 7880714 under IN B-PP O
26 173 175 7880714 an DT B-NP O
27 176 188 7880714 interscalene NN I-NP O
28 189 197 7880714 brachial JJ I-NP O
29 198 204 7880714 plexus NN I-NP O
30 205 210 7880714 block NN I-NP O
31 211 212 7880714 ( ( O O
32 212 216 7880714 IBPB NN B-NP O
33 216 217 7880714 ) ) O O
34 217 218 7880714 . . O O

1 219 230 7880714 Bupivacaine NN B-NP D002045
2 231 236 7880714 0.75% CD I-NP O
3 237 241 7880714 with IN B-PP O
4 242 252 7880714 adrenaline NN B-NP D004837
5 253 256 7880714 was VBD B-VP O
6 257 262 7880714 given VBN I-VP O
7 263 271 7880714 followed VBN I-VP O
8 272 274 7880714 by IN B-PP O
9 275 276 7880714 a DT B-NP O
10 277 279 7880714 24 CD I-NP O
11 279 280 7880714 - HYPH I-NP O
12 280 282 7880714 hr NN I-NP O
13 283 293 7880714 continuous JJ I-NP O
14 294 302 7880714 infusion NN I-NP O
15 303 305 7880714 of IN B-PP O
16 306 311 7880714 0.25% CD B-NP O
17 312 323 7880714 bupivacaine NN I-NP D002045
18 323 324 7880714 . . O O

1 325 330 7880714 Three CD B-NP O
2 331 342 7880714 audiometric JJ I-NP O
3 343 352 7880714 threshold NN I-NP O
4 353 365 7880714 measurements NNS I-NP O
5 366 367 7880714 ( ( O O
6 367 371 7880714 0.25 CD B-NP O
7 371 372 7880714 - HYPH I-NP O
8 372 374 7880714 18 CD I-NP O
9 375 378 7880714 kHz NN I-NP O
10 378 379 7880714 ) ) O O
11 380 384 7880714 were VBD B-VP O
12 385 389 7880714 made VBN I-VP O
13 389 390 7880714 : : O O
14 391 394 7880714 the DT B-NP O
15 395 400 7880714 first JJ I-NP O
16 401 407 7880714 before IN B-PP O
17 408 412 7880714 IBPB NN B-NP O
18 412 413 7880714 , , O O
19 414 417 7880714 the DT B-NP O
20 418 424 7880714 second JJ I-NP O
21 425 426 7880714 2 CD I-NP O
22 426 427 7880714 - HYPH I-NP O
23 427 428 7880714 6 CD I-NP O
24 429 430 7880714 h NN I-NP O
25 431 436 7880714 after IN B-PP O
26 437 444 7880714 surgery NN B-NP O
27 445 448 7880714 and CC O O
28 449 452 7880714 the DT B-NP O
29 453 458 7880714 third JJ I-NP O
30 459 461 7880714 on IN B-PP O
31 462 465 7880714 the DT B-NP O
32 466 471 7880714 first JJ I-NP O
33 472 475 7880714 day NN I-NP O
34 476 481 7880714 after IN B-PP O
35 482 491 7880714 operation NN B-NP O
36 491 492 7880714 . . O O

1 493 495 7880714 In IN B-PP O
2 496 500 7880714 four CD B-NP O
3 501 509 7880714 patients NNS I-NP O
4 510 517 7880714 hearing VBG B-VP D034381
5 518 528 7880714 impairment NN B-NP D034381
6 529 531 7880714 on IN B-PP O
7 532 535 7880714 the DT B-NP O
8 536 540 7880714 side NN I-NP O
9 541 543 7880714 of IN B-PP O
10 544 547 7880714 the DT B-NP O
11 548 553 7880714 block NN I-NP O
12 554 557 7880714 was VBD B-VP O
13 558 570 7880714 demonstrated VBN I-VP O
14 571 576 7880714 after IN B-PP O
15 577 586 7880714 operation NN B-NP O
16 586 587 7880714 , , O O
17 588 590 7880714 in IN B-PP O
18 591 596 7880714 three CD B-NP O
19 597 609 7880714 measurements NNS I-NP O
20 610 612 7880714 on IN B-PP O
21 613 616 7880714 the DT B-NP O
22 617 620 7880714 day NN I-NP O
23 621 623 7880714 of IN B-PP O
24 624 631 7880714 surgery NN B-NP O
25 632 635 7880714 and CC O O
26 636 638 7880714 in IN B-PP O
27 639 642 7880714 one CD B-NP O
28 643 645 7880714 on IN B-PP O
29 646 649 7880714 the DT B-NP O
30 650 659 7880714 following VBG I-NP O
31 660 663 7880714 day NN I-NP O
32 663 664 7880714 . . O O

1 665 668 7880714 The DT B-NP O
2 669 680 7880714 frequencies NNS I-NP O
3 681 683 7880714 at IN B-PP O
4 684 689 7880714 which WDT B-NP O
5 690 693 7880714 the DT B-NP O
6 694 704 7880714 impairment NN I-NP O
7 705 713 7880714 occurred VBD B-VP O
8 714 720 7880714 varied JJ B-ADJP O
9 721 728 7880714 between IN B-PP O
10 729 737 7880714 patients NNS B-NP O
11 737 738 7880714 ; : O O
12 739 741 7880714 in IN B-PP O
13 742 745 7880714 one CD B-NP O
14 746 750 7880714 only RB I-NP O
15 751 754 7880714 low JJ I-NP O
16 755 766 7880714 frequencies NNS I-NP O
17 767 768 7880714 ( ( O O
18 768 772 7880714 0.25 CD B-NP O
19 772 773 7880714 - HYPH I-NP O
20 773 776 7880714 0.5 CD I-NP O
21 777 780 7880714 kHz NN I-NP O
22 780 781 7880714 ) ) O O
23 782 786 7880714 were VBD B-VP O
24 787 795 7880714 involved VBN I-VP O
25 795 796 7880714 . . O O

1 797 800 7880714 The DT B-NP O
2 801 808 7880714 maximum JJ I-NP O
3 809 815 7880714 change NN I-NP O
4 816 818 7880714 in IN B-PP O
5 819 828 7880714 threshold NN B-NP O
6 829 832 7880714 was VBD B-VP O
7 833 835 7880714 35 CD B-NP O
8 836 838 7880714 dB NN I-NP O
9 839 841 7880714 at IN B-PP O
10 842 843 7880714 6 CD B-NP O
11 844 847 7880714 kHz NN I-NP O
12 848 856 7880714 measured VBN B-VP O
13 857 859 7880714 at IN B-PP O
14 860 863 7880714 the DT B-NP O
15 864 867 7880714 end NN I-NP O
16 868 870 7880714 of IN B-PP O
17 871 874 7880714 the DT B-NP O
18 875 885 7880714 continuous JJ I-NP O
19 886 894 7880714 infusion NN I-NP O
20 895 897 7880714 of IN B-PP O
21 898 909 7880714 bupivacaine NN B-NP D002045
22 909 910 7880714 . . O O

1 911 915 7880714 This DT B-NP O
2 916 923 7880714 patient NN I-NP O
3 924 927 7880714 had VBD B-VP O
4 928 935 7880714 hearing VBG I-VP O
5 936 945 7880714 threshold NN B-NP O
6 946 953 7880714 changes NNS I-NP O
7 954 955 7880714 ( ( O O
8 955 957 7880714 15 CD B-NP O
9 957 958 7880714 - HYPH I-NP O
10 958 960 7880714 20 CD I-NP O
11 961 963 7880714 dB NN I-NP O
12 963 964 7880714 ) ) O O
13 965 967 7880714 at IN B-PP O
14 968 969 7880714 6 CD B-NP O
15 969 970 7880714 - HYPH I-NP O
16 970 972 7880714 10 CD I-NP O
17 973 976 7880714 kHz NN I-NP O
18 977 979 7880714 on IN B-PP O
19 980 983 7880714 the DT B-NP O
20 984 992 7880714 opposite JJ I-NP O
21 993 997 7880714 side NN I-NP O
22 998 1002 7880714 also RB B-ADVP O
23 1002 1003 7880714 . . O O

1 1004 1008 7880714 IBPB NN B-NP O
2 1009 1012 7880714 may MD B-VP O
3 1013 1018 7880714 cause VB I-VP O
4 1019 1028 7880714 transient JJ B-NP O
5 1029 1037 7880714 auditory JJ I-NP D006311
6 1038 1049 7880714 dysfunction NN I-NP D006311
7 1050 1052 7880714 in IN B-PP O
8 1053 1056 7880714 the DT B-NP O
9 1057 1068 7880714 ipsilateral JJ I-NP O
10 1069 1072 7880714 ear NN I-NP O
11 1072 1073 7880714 , , O O
12 1074 1082 7880714 possibly RB B-ADVP O
13 1083 1086 7880714 via IN B-PP O
14 1087 1089 7880714 an DT B-NP O
15 1090 1096 7880714 effect NN I-NP O
16 1097 1099 7880714 on IN B-PP O
17 1100 1111 7880714 sympathetic JJ B-NP O
18 1112 1123 7880714 innervation NN I-NP O
19 1123 1124 7880714 . . O O

1 0 0 6504332 -DOCSTART- -X- -X- O

1 0 13 6504332 Phenobarbital NN B-NP D010634
2 13 14 6504332 - HYPH B-PP O
3 14 21 6504332 induced VBN B-NP O
4 22 32 6504332 dyskinesia NN I-NP D004409
5 33 35 6504332 in IN B-PP O
6 36 37 6504332 a DT B-NP O
7 38 52 6504332 neurologically RB I-NP D009422
8 52 53 6504332 - HYPH I-NP D009422
9 53 61 6504332 impaired JJ I-NP D009422
10 62 67 6504332 child NN I-NP O
11 67 68 6504332 . . O O
12 69 70 6504332 A NN B-NP O
13 71 72 6504332 2 CD I-NP O
14 72 73 6504332 - HYPH I-NP O
15 73 77 6504332 year NN I-NP O
16 77 78 6504332 - HYPH O O
17 78 81 6504332 old JJ B-NP O
18 82 87 6504332 child NN I-NP O
19 88 92 6504332 with IN B-PP O
20 93 98 6504332 known JJ B-NP O
21 99 109 6504332 neurologic JJ I-NP D009422
22 110 120 6504332 impairment NN I-NP D009422
23 121 130 6504332 developed VBD B-VP O
24 131 132 6504332 a DT B-NP O
25 133 143 6504332 dyskinesia NN I-NP D004409
26 144 148 6504332 soon RB B-ADVP O
27 149 154 6504332 after IN B-PP O
28 155 163 6504332 starting VBG B-VP O
29 164 177 6504332 phenobarbital NN B-NP D010634
30 178 185 6504332 therapy NN I-NP O
31 186 189 6504332 for IN B-PP O
32 190 198 6504332 seizures NNS B-NP D012640
33 198 199 6504332 . . O O

1 200 205 6504332 Known VBN B-NP O
2 206 212 6504332 causes NNS I-NP O
3 213 215 6504332 of IN B-PP O
4 216 224 6504332 movement NN B-NP D009069
5 225 234 6504332 disorders NNS I-NP D009069
6 235 239 6504332 were VBD B-VP O
7 240 250 6504332 eliminated VBN I-VP O
8 251 256 6504332 after IN B-PP O
9 257 267 6504332 evaluation NN B-NP O
10 267 268 6504332 . . O O

1 269 271 6504332 On IN B-PP O
2 272 278 6504332 repeat NN B-NP O
3 279 288 6504332 challenge NN I-NP O
4 289 293 6504332 with IN B-PP O
5 294 307 6504332 phenobarbital NN B-NP D010634
6 307 308 6504332 , , O O
7 309 312 6504332 the DT B-NP O
8 313 323 6504332 dyskinesia NN I-NP D004409
9 324 332 6504332 recurred VBD B-VP O
10 332 333 6504332 . . O O

1 334 347 6504332 Phenobarbital NN B-NP D010634
2 348 354 6504332 should MD B-VP O
3 355 357 6504332 be VB I-VP O
4 358 363 6504332 added VBN I-VP O
5 364 366 6504332 to TO B-PP O
6 367 370 6504332 the DT B-NP O
7 371 375 6504332 list NN I-NP O
8 376 378 6504332 of IN B-PP O
9 379 393 6504332 anticonvulsant JJ B-NP O
10 394 399 6504332 drugs NNS I-NP O
11 400 404 6504332 that WDT B-NP O
12 405 408 6504332 can MD B-VP O
13 409 414 6504332 cause VB I-VP O
14 415 423 6504332 movement NN B-NP D009069
15 424 433 6504332 disorders NNS I-NP D009069
16 433 434 6504332 . . O O

1 0 0 3431591 -DOCSTART- -X- -X- O

1 0 6 3431591 Recent JJ B-NP O
2 7 18 3431591 preclinical JJ I-NP O
3 19 22 3431591 and CC I-NP O
4 23 31 3431591 clinical JJ I-NP O
5 32 39 3431591 studies NNS I-NP O
6 40 44 3431591 with IN B-PP O
7 45 48 3431591 the DT B-NP O
8 49 60 3431591 thymidylate NN I-NP O
9 61 69 3431591 synthase NN I-NP O
10 70 79 3431591 inhibitor NN I-NP O
11 80 83 3431591 N10 NN I-NP C031662
12 83 84 3431591 - HYPH B-NP C031662
13 84 93 3431591 propargyl NN I-NP C031662
14 93 94 3431591 - HYPH B-NP C031662
15 94 97 3431591 5,8 CD I-NP C031662
16 97 98 3431591 - HYPH I-NP C031662
17 98 110 3431591 dideazafolic JJ I-NP C031662
18 111 115 3431591 acid NN I-NP C031662
19 116 117 3431591 ( ( O O
20 117 119 3431591 CB NN B-NP C031662
21 120 124 3431591 3717 CD I-NP C031662
22 124 125 3431591 ) ) O O
23 125 126 3431591 . . O O
24 127 129 3431591 CB NN B-NP C031662
25 130 134 3431591 3717 CD I-NP C031662
26 134 135 3431591 , , O O
27 136 139 3431591 N10 NN B-NP C031662
28 139 140 3431591 - HYPH B-NP C031662
29 140 149 3431591 propargyl NN I-NP C031662
30 149 150 3431591 - HYPH B-NP C031662
31 150 153 3431591 5,8 CD I-NP C031662
32 153 154 3431591 - HYPH I-NP C031662
33 154 166 3431591 dideazafolic JJ I-NP C031662
34 167 171 3431591 acid NN I-NP C031662
35 171 172 3431591 , , O O
36 173 175 3431591 is VBZ B-VP O
37 176 177 3431591 a DT B-NP O
38 178 183 3431591 tight JJ I-NP O
39 183 184 3431591 - HYPH I-NP O
40 184 191 3431591 binding VBG I-NP O
41 192 201 3431591 inhibitor NN I-NP O
42 202 204 3431591 of IN B-PP O
43 205 216 3431591 thymidylate NN B-NP O
44 217 225 3431591 synthase NN I-NP O
45 226 227 3431591 ( ( O O
46 227 229 3431591 TS NN B-NP O
47 229 230 3431591 ) ) O O
48 231 236 3431591 whose WP$ B-NP O
49 237 249 3431591 cytotoxicity NN I-NP D064420
50 250 252 3431591 is VBZ B-VP O
51 253 261 3431591 mediated VBN I-VP O
52 262 268 3431591 solely RB B-ADVP O
53 269 276 3431591 through IN B-PP O
54 277 280 3431591 the DT B-NP O
55 281 291 3431591 inhibition NN I-NP O
56 292 294 3431591 of IN B-PP O
57 295 299 3431591 this DT B-NP O
58 300 306 3431591 enzyme NN I-NP O
59 306 307 3431591 . . O O

1 308 314 3431591 Recent JJ B-NP O
2 315 326 3431591 preclinical JJ I-NP O
3 327 334 3431591 studies NNS I-NP O
4 335 339 3431591 have VBP B-VP O
5 340 347 3431591 focused VBN I-VP O
6 348 350 3431591 on IN B-PP O
7 351 354 3431591 the DT B-NP O
8 355 368 3431591 intracellular JJ I-NP O
9 369 378 3431591 formation NN I-NP O
10 379 381 3431591 of IN B-PP O
11 382 384 3431591 CB NN B-NP C031662
12 385 389 3431591 3717 CD B-NP C031662
13 390 404 3431591 polyglutamates NNS I-NP O
14 404 405 3431591 . . O O

1 406 415 3431591 Following VBG B-PP O
2 416 417 3431591 a DT B-NP O
3 418 420 3431591 12 CD I-NP O
4 420 421 3431591 - HYPH I-NP O
5 421 425 3431591 hour NN I-NP O
6 426 434 3431591 exposure NN I-NP O
7 435 437 3431591 of IN B-PP O
8 438 443 3431591 L1210 NN B-NP O
9 444 449 3431591 cells NNS I-NP O
10 450 452 3431591 to TO B-PP O
11 453 455 3431591 50 CD B-NP O
12 456 462 3431591 microM NN I-NP O
13 463 469 3431591 [3H]CB NN I-NP C031662
14 470 474 3431591 3717 CD I-NP C031662
15 474 475 3431591 , , I-NP O
16 476 479 3431591 30% CD I-NP O
17 480 482 3431591 of IN B-PP O
18 483 486 3431591 the DT B-NP O
19 487 498 3431591 extractable JJ I-NP O
20 499 512 3431591 radioactivity NN I-NP O
21 513 518 3431591 could MD B-VP O
22 519 521 3431591 be VB I-VP O
23 522 531 3431591 accounted VBN I-VP O
24 532 535 3431591 for IN B-PP O
25 536 538 3431591 as IN B-PP O
26 539 541 3431591 CB NN B-NP C031662
27 542 546 3431591 3717 CD I-NP C031662
28 547 552 3431591 tetra AFX O O
29 552 553 3431591 - HYPH O O
30 554 557 3431591 and CC O O
31 558 572 3431591 pentaglutamate NN B-NP O
32 572 573 3431591 , , O O
33 574 576 3431591 as IN B-SBAR O
34 577 587 3431591 determined VBN B-VP O
35 588 590 3431591 by IN B-PP O
36 591 595 3431591 high JJ B-NP O
37 595 596 3431591 - HYPH I-NP O
38 596 604 3431591 pressure NN I-NP O
39 605 611 3431591 liquid NN I-NP O
40 612 626 3431591 chromatography NN I-NP O
41 627 628 3431591 ( ( O O
42 628 632 3431591 HPLC NN B-NP O
43 632 633 3431591 ) ) O O
44 634 642 3431591 analyses NNS B-NP O
45 642 643 3431591 . . O O

1 644 646 3431591 As IN B-SBAR O
2 647 657 3431591 inhibitors NNS B-NP O
3 658 660 3431591 of IN B-PP O
4 661 669 3431591 isolated VBN B-NP O
5 670 675 3431591 L1210 NN I-NP O
6 676 678 3431591 TS NN I-NP O
7 678 679 3431591 , , O O
8 680 682 3431591 CB NN B-NP O
9 683 687 3431591 3717 CD I-NP O
10 688 690 3431591 di NN I-NP O
11 690 691 3431591 - HYPH B-ADJP O
12 691 692 3431591 , , O O
13 693 696 3431591 tri AFX O O
14 696 697 3431591 - HYPH O O
15 697 698 3431591 , , O O
16 699 704 3431591 tetra AFX O O
17 704 705 3431591 - HYPH O O
18 706 709 3431591 and CC O O
19 710 724 3431591 pentaglutamate NN B-NP O
20 725 728 3431591 are VBP B-VP O
21 729 731 3431591 26 CD B-NP O
22 731 732 3431591 - HYPH B-ADVP O
23 732 733 3431591 , , O O
24 734 736 3431591 87 CD B-NP O
25 736 737 3431591 - HYPH B-ADVP O
26 737 738 3431591 , , O O
27 739 742 3431591 119 CD B-NP O
28 742 743 3431591 - HYPH B-ADJP O
29 744 747 3431591 and CC O O
30 748 751 3431591 114 CD B-NP O
31 751 752 3431591 - HYPH O O
32 752 756 3431591 fold RB B-ADJP O
33 757 761 3431591 more RBR I-ADJP O
34 762 768 3431591 potent JJ I-ADJP O
35 769 773 3431591 than IN B-PP O
36 774 776 3431591 CB NN B-NP C031662
37 777 781 3431591 3717 CD I-NP C031662
38 781 782 3431591 , , O O
39 783 795 3431591 respectively RB B-ADVP O
40 795 796 3431591 , , O O
41 797 800 3431591 and CC O O
42 801 806 3431591 their PRP$ B-NP O
43 807 816 3431591 formation NN I-NP O
44 817 820 3431591 may MD B-VP O
45 820 821 3431591 , , O O
46 822 831 3431591 therefore RB B-ADVP O
47 831 832 3431591 , , O O
48 833 835 3431591 be VB B-VP O
49 836 838 3431591 an DT B-NP O
50 839 848 3431591 important JJ I-NP O
51 849 860 3431591 determinant NN I-NP O
52 861 863 3431591 of IN B-PP O
53 864 866 3431591 CB NN B-NP C031662
54 867 871 3431591 3717 CD I-NP C031662
55 872 884 3431591 cytotoxicity NN I-NP D064420
56 884 885 3431591 . . O O

1 886 888 3431591 In IN B-PP O
2 889 894 3431591 early JJ B-NP O
3 895 903 3431591 clinical JJ I-NP O
4 904 911 3431591 studies NNS I-NP O
5 912 916 3431591 with IN B-PP O
6 917 919 3431591 CB NN B-NP C031662
7 920 924 3431591 3717 CD I-NP C031662
8 924 925 3431591 , , O O
9 926 934 3431591 activity NN B-NP O
10 935 938 3431591 has VBZ B-VP O
11 939 943 3431591 been VBN I-VP O
12 944 948 3431591 seen VBN I-VP O
13 949 951 3431591 in IN B-PP O
14 952 958 3431591 breast NN B-NP D001943
15 959 965 3431591 cancer NN I-NP D001943
16 965 966 3431591 , , O O
17 967 974 3431591 ovarian JJ B-NP D010051
18 975 981 3431591 cancer NN I-NP D010051
19 981 982 3431591 , , O O
20 983 991 3431591 hepatoma NN B-NP D006528
21 991 992 3431591 , , O O
22 993 996 3431591 and CC O O
23 997 1009 3431591 mesothelioma NN B-NP D008654
24 1009 1010 3431591 . . O O

1 1011 1021 3431591 Toxicities NNS B-NP D064420
2 1022 1030 3431591 included VBD B-VP O
3 1031 1045 3431591 hepatotoxicity NN B-NP D056486
4 1045 1046 3431591 , , O O
5 1047 1054 3431591 malaise NN B-NP D005221
6 1054 1055 3431591 , , O O
7 1056 1059 3431591 and CC O O
8 1060 1064 3431591 dose NN B-NP O
9 1064 1065 3431591 - HYPH O O
10 1065 1073 3431591 limiting VBG B-VP O
11 1074 1088 3431591 nephrotoxicity NN B-NP D007674
12 1088 1089 3431591 . . O O

1 1090 1094 3431591 This DT B-NP O
2 1095 1101 3431591 latter JJ I-NP O
3 1102 1108 3431591 effect NN I-NP O
4 1109 1111 3431591 is VBZ B-VP O
5 1112 1119 3431591 thought VBN I-VP O
6 1120 1122 3431591 to TO I-VP O
7 1123 1125 3431591 be VB I-VP O
8 1126 1129 3431591 due IN B-PP O
9 1130 1132 3431591 to TO B-PP O
10 1133 1137 3431591 drug NN B-NP O
11 1138 1151 3431591 precipitation NN I-NP O
12 1152 1158 3431591 within IN B-PP O
13 1159 1162 3431591 the DT B-NP O
14 1163 1168 3431591 renal JJ I-NP O
15 1169 1175 3431591 tubule NN I-NP O
16 1176 1178 3431591 as IN B-PP O
17 1179 1180 3431591 a DT B-NP O
18 1181 1187 3431591 result NN I-NP O
19 1188 1190 3431591 of IN B-PP O
20 1191 1194 3431591 the DT B-NP O
21 1195 1199 3431591 poor JJ I-NP O
22 1200 1210 3431591 solubility NN I-NP O
23 1211 1213 3431591 of IN B-PP O
24 1214 1216 3431591 CB NN B-NP C031662
25 1217 1221 3431591 3717 CD I-NP C031662
26 1222 1227 3431591 under IN B-PP O
27 1228 1234 3431591 acidic JJ B-NP O
28 1235 1245 3431591 conditions NNS I-NP O
29 1245 1246 3431591 . . O O

1 1247 1249 3431591 In IN B-PP O
2 1250 1252 3431591 an DT B-NP O
3 1253 1260 3431591 attempt NN I-NP O
4 1261 1263 3431591 to TO B-VP O
5 1264 1272 3431591 overcome VB I-VP O
6 1273 1277 3431591 this DT B-NP O
7 1278 1285 3431591 problem NN I-NP O
8 1285 1286 3431591 , , O O
9 1287 1288 3431591 a DT B-NP O
10 1289 1297 3431591 clinical JJ I-NP O
11 1298 1303 3431591 trial NN I-NP O
12 1304 1306 3431591 of IN B-PP O
13 1307 1309 3431591 CB NN B-NP C031662
14 1310 1314 3431591 3717 CD I-NP C031662
15 1315 1327 3431591 administered VBN B-VP O
16 1328 1332 3431591 with IN B-PP O
17 1333 1341 3431591 alkaline NN B-NP O
18 1342 1350 3431591 diuresis NN I-NP O
19 1351 1353 3431591 is VBZ B-VP O
20 1354 1359 3431591 under IN B-PP O
21 1360 1363 3431591 way NN B-NP O
22 1363 1364 3431591 . . O O

1 1365 1376 3431591 Preliminary JJ B-NP O
2 1377 1384 3431591 results NNS I-NP O
3 1385 1387 3431591 at IN B-PP O
4 1388 1391 3431591 400 CD B-NP O
5 1392 1395 3431591 and CC I-NP O
6 1396 1399 3431591 500 CD I-NP O
7 1400 1402 3431591 mg NN I-NP O
8 1402 1403 3431591 / SYM B-NP O
9 1403 1405 3431591 m2 NN B-NP O
10 1406 1413 3431591 suggest VBP B-VP O
11 1414 1418 3431591 that IN B-SBAR O
12 1419 1420 3431591 a DT B-NP O
13 1421 1430 3431591 reduction NN I-NP O
14 1431 1433 3431591 in IN B-PP O
15 1434 1448 3431591 nephrotoxicity NN B-NP D007674
16 1449 1452 3431591 may MD B-VP O
17 1453 1457 3431591 have VB I-VP O
18 1458 1462 3431591 been VBN I-VP O
19 1463 1471 3431591 achieved VBN I-VP O
20 1472 1476 3431591 with IN B-PP O
21 1477 1481 3431591 only RB B-NP O
22 1482 1483 3431591 1 CD I-NP O
23 1484 1492 3431591 instance NN I-NP O
24 1493 1495 3431591 of IN B-PP O
25 1496 1501 3431591 renal JJ B-NP D007674
26 1502 1510 3431591 toxicity NN I-NP D007674
27 1511 1513 3431591 in IN B-PP O
28 1514 1516 3431591 10 CD B-NP O
29 1517 1525 3431591 patients NNS I-NP O
30 1525 1526 3431591 . . O O

1 1527 1541 3431591 Hepatotoxicity NN B-NP D056486
2 1542 1545 3431591 and CC I-NP O
3 1546 1553 3431591 malaise NN I-NP D005221
4 1554 1557 3431591 are VBP B-VP O
5 1558 1563 3431591 again RB B-ADVP O
6 1564 1567 3431591 the DT B-NP O
7 1568 1572 3431591 most RBS I-NP O
8 1573 1581 3431591 frequent JJ I-NP O
9 1582 1586 3431591 side NN I-NP O
10 1587 1594 3431591 effects NNS I-NP O
11 1594 1595 3431591 . . O O

1 1596 1604 3431591 Evidence NN B-NP O
2 1605 1607 3431591 of IN B-PP O
3 1608 1617 3431591 antitumor JJ B-NP O
4 1618 1626 3431591 activity NN I-NP O
5 1627 1630 3431591 has VBZ B-VP O
6 1631 1635 3431591 been VBN I-VP O
7 1636 1640 3431591 seen VBN I-VP O
8 1641 1643 3431591 in IN B-PP O
9 1644 1645 3431591 3 CD B-NP O
10 1646 1654 3431591 patients NNS I-NP O
11 1654 1655 3431591 . . O O

1 1656 1671 3431591 Pharmacokinetic JJ B-NP O
2 1672 1686 3431591 investigations NNS I-NP O
3 1687 1691 3431591 have VBP B-VP O
4 1692 1697 3431591 shown VBN I-VP O
5 1698 1702 3431591 that IN B-SBAR O
6 1703 1711 3431591 alkaline NN B-NP O
7 1712 1720 3431591 diuresis NN I-NP O
8 1721 1725 3431591 does VBZ B-VP O
9 1726 1729 3431591 not RB I-VP O
10 1730 1735 3431591 alter VB I-VP O
11 1736 1738 3431591 CB NN B-NP C031662
12 1739 1743 3431591 3717 CD I-NP C031662
13 1744 1750 3431591 plasma NN I-NP O
14 1751 1757 3431591 levels NNS I-NP O
15 1758 1760 3431591 or CC O O
16 1761 1768 3431591 urinary JJ B-NP O
17 1769 1778 3431591 excretion NN I-NP O
18 1779 1782 3431591 and CC O O
19 1783 1787 3431591 that IN B-SBAR O
20 1788 1800 3431591 satisfactory JJ B-NP O
21 1801 1808 3431591 urinary JJ I-NP O
22 1809 1823 3431591 alkalinization NN I-NP O
23 1824 1827 3431591 can MD B-VP O
24 1828 1830 3431591 be VB I-VP O
25 1831 1838 3431591 readily RB I-VP O
26 1839 1847 3431591 achieved VBN I-VP O
27 1847 1848 3431591 . . O O

1 0 0 12481039 -DOCSTART- -X- -X- O

1 0 7 12481039 Reduced VBN B-NP O
2 8 14 12481039 sodium NN I-NP D012964
3 15 22 12481039 channel NN I-NP O
4 23 30 12481039 density NN I-NP O
5 30 31 12481039 , , O O
6 32 39 12481039 altered VBD B-VP O
7 40 47 12481039 voltage NN B-NP O
8 48 58 12481039 dependence NN I-NP O
9 59 61 12481039 of IN B-PP O
10 62 74 12481039 inactivation NN B-NP O
11 74 75 12481039 , , O O
12 76 79 12481039 and CC O O
13 80 89 12481039 increased VBD B-VP O
14 90 104 12481039 susceptibility NN B-NP O
15 105 107 12481039 to TO B-PP O
16 108 116 12481039 seizures NNS B-NP D012640
17 117 119 12481039 in IN B-PP O
18 120 124 12481039 mice NNS B-NP O
19 125 132 12481039 lacking VBG B-VP O
20 133 139 12481039 sodium NN B-NP D012964
21 140 147 12481039 channel NN I-NP O
22 148 152 12481039 beta SYM B-NP O
23 153 154 12481039 2 CD I-NP O
24 154 155 12481039 - HYPH I-NP O
25 155 163 12481039 subunits NNS I-NP O
26 163 164 12481039 . . O O
27 165 171 12481039 Sodium NN B-NP D012964
28 172 179 12481039 channel NN I-NP O
29 180 184 12481039 beta SYM O O
30 184 185 12481039 - HYPH O O
31 185 193 12481039 subunits NNS B-NP O
32 194 202 12481039 modulate VBP B-VP O
33 203 210 12481039 channel NN B-NP O
34 211 217 12481039 gating NN I-NP O
35 217 218 12481039 , , O O
36 219 227 12481039 assembly NN B-NP O
37 227 228 12481039 , , O O
38 229 232 12481039 and CC O O
39 233 237 12481039 cell NN B-NP O
40 238 245 12481039 surface NN I-NP O
41 246 256 12481039 expression NN I-NP O
42 257 259 12481039 in IN B-PP O
43 260 272 12481039 heterologous JJ B-NP O
44 273 277 12481039 cell NN I-NP O
45 278 285 12481039 systems NNS I-NP O
46 285 286 12481039 . . O O

1 287 289 12481039 We PRP B-NP O
2 290 299 12481039 generated VBD B-VP O
3 300 306 12481039 beta2( SYM O O
4 306 307 12481039 - HYPH O O
5 307 308 12481039 / SYM O O
6 308 309 12481039 - SYM O O
7 309 310 12481039 ) ) O O
8 311 315 12481039 mice NNS B-NP O
9 316 318 12481039 to TO B-VP O
10 319 330 12481039 investigate VB I-VP O
11 331 334 12481039 the DT B-NP O
12 335 339 12481039 role NN I-NP O
13 340 342 12481039 of IN B-PP O
14 343 348 12481039 beta2 NN B-NP O
15 349 351 12481039 in IN B-PP O
16 352 359 12481039 control NN B-NP O
17 360 362 12481039 of IN B-PP O
18 363 369 12481039 sodium NN B-NP D012964
19 370 377 12481039 channel NN I-NP O
20 378 385 12481039 density NN I-NP O
21 385 386 12481039 , , O O
22 387 399 12481039 localization NN B-NP O
23 399 400 12481039 , , O O
24 401 404 12481039 and CC O O
25 405 413 12481039 function NN B-NP O
26 414 416 12481039 in IN B-PP O
27 417 424 12481039 neurons NNS B-NP O
28 425 427 12481039 in FW B-ADVP O
29 428 432 12481039 vivo FW I-ADVP O
30 432 433 12481039 . . O O

1 434 446 12481039 Measurements NNS B-NP O
2 447 449 12481039 of IN B-PP O
3 450 465 12481039 [(3)H]saxitoxin NN B-NP D012530
4 466 467 12481039 ( ( O O
5 467 470 12481039 STX NN B-NP D012530
6 470 471 12481039 ) ) O O
7 472 479 12481039 binding NN B-NP O
8 480 486 12481039 showed VBD B-VP O
9 487 488 12481039 a DT B-NP O
10 489 500 12481039 significant JJ I-NP O
11 501 510 12481039 reduction NN I-NP O
12 511 513 12481039 in IN B-PP O
13 514 517 12481039 the DT B-NP O
14 518 523 12481039 level NN I-NP O
15 524 526 12481039 of IN B-PP O
16 527 533 12481039 plasma NN B-NP O
17 534 542 12481039 membrane NN I-NP O
18 543 549 12481039 sodium NN I-NP D012964
19 550 558 12481039 channels NNS I-NP O
20 559 561 12481039 in IN B-PP O
21 562 568 12481039 beta2( NN B-NP O
22 568 569 12481039 - HYPH O O
23 569 570 12481039 / SYM O O
24 570 571 12481039 - SYM O O
25 571 572 12481039 ) ) O O
26 573 580 12481039 neurons NNS B-NP O
27 580 581 12481039 . . O O

1 582 585 12481039 The DT B-NP O
2 586 590 12481039 loss NN I-NP O
3 591 593 12481039 of IN B-PP O
4 594 599 12481039 beta2 NN B-NP O
5 600 608 12481039 resulted VBD B-VP O
6 609 611 12481039 in IN B-PP O
7 612 620 12481039 negative JJ B-NP O
8 621 627 12481039 shifts NNS I-NP O
9 628 630 12481039 in IN B-PP O
10 631 634 12481039 the DT B-NP O
11 635 642 12481039 voltage NN I-NP O
12 643 653 12481039 dependence NN I-NP O
13 654 656 12481039 of IN B-PP O
14 657 669 12481039 inactivation NN B-NP O
15 670 672 12481039 as RB B-CONJP O
16 673 677 12481039 well RB I-CONJP O
17 678 680 12481039 as IN I-CONJP O
18 681 692 12481039 significant JJ B-NP O
19 693 702 12481039 decreases NNS I-NP O
20 703 705 12481039 in IN B-PP O
21 706 712 12481039 sodium NN B-NP D012964
22 713 720 12481039 current NN I-NP O
23 721 728 12481039 density NN I-NP O
24 729 731 12481039 in IN B-PP O
25 732 739 12481039 acutely RB B-NP O
26 740 751 12481039 dissociated VBN I-NP O
27 752 763 12481039 hippocampal JJ I-NP O
28 764 771 12481039 neurons NNS I-NP O
29 771 772 12481039 . . O O

1 773 776 12481039 The DT B-NP O
2 777 785 12481039 integral NN I-NP O
3 786 788 12481039 of IN B-PP O
4 789 792 12481039 the DT B-NP O
5 793 801 12481039 compound NN I-NP O
6 802 808 12481039 action NN I-NP O
7 809 818 12481039 potential NN I-NP O
8 819 821 12481039 in IN B-PP O
9 822 827 12481039 optic JJ B-NP O
10 828 833 12481039 nerve NN I-NP O
11 834 837 12481039 was VBD B-VP O
12 838 851 12481039 significantly RB I-VP O
13 852 859 12481039 reduced VBN I-VP O
14 859 860 12481039 , , O O
15 861 864 12481039 and CC O O
16 865 868 12481039 the DT B-NP O
17 869 878 12481039 threshold NN I-NP O
18 879 882 12481039 for IN B-PP O
19 883 889 12481039 action NN B-NP O
20 890 899 12481039 potential NN I-NP O
21 900 910 12481039 generation NN I-NP O
22 911 914 12481039 was VBD B-VP O
23 915 924 12481039 increased VBN I-VP O
24 924 925 12481039 , , O O
25 926 936 12481039 indicating VBG B-VP O
26 937 938 12481039 a DT B-NP O
27 939 948 12481039 reduction NN I-NP O
28 949 951 12481039 in IN B-PP O
29 952 955 12481039 the DT B-NP O
30 956 961 12481039 level NN I-NP O
31 962 964 12481039 of IN B-PP O
32 965 975 12481039 functional JJ B-NP O
33 976 982 12481039 plasma NN I-NP O
34 983 991 12481039 membrane NN I-NP O
35 992 998 12481039 sodium NN I-NP D012964
36 999 1007 12481039 channels NNS I-NP O
37 1007 1008 12481039 . . O O

1 1009 1011 12481039 In IN B-PP O
2 1012 1020 12481039 contrast NN B-NP O
3 1020 1021 12481039 , , O O
4 1022 1025 12481039 the DT B-NP O
5 1026 1036 12481039 conduction NN I-NP O
6 1037 1045 12481039 velocity NN I-NP O
7 1045 1046 12481039 , , O O
8 1047 1050 12481039 the DT B-NP O
9 1051 1057 12481039 number NN I-NP O
10 1058 1061 12481039 and CC I-NP O
11 1062 1066 12481039 size NN I-NP O
12 1067 1069 12481039 of IN B-PP O
13 1070 1075 12481039 axons NNS B-NP O
14 1076 1078 12481039 in IN B-PP O
15 1079 1082 12481039 the DT B-NP O
16 1083 1088 12481039 optic JJ I-NP O
17 1089 1094 12481039 nerve NN I-NP O
18 1094 1095 12481039 , , O O
19 1096 1099 12481039 and CC O O
20 1100 1103 12481039 the DT B-NP O
21 1104 1112 12481039 specific JJ I-NP O
22 1113 1125 12481039 localization NN I-NP O
23 1126 1128 12481039 of IN B-PP O
24 1129 1137 12481039 Na(v)1.6 NN B-NP D012964
25 1138 1146 12481039 channels NNS I-NP O
26 1147 1149 12481039 in IN B-PP O
27 1150 1153 12481039 the DT B-NP O
28 1154 1159 12481039 nodes NNS I-NP O
29 1160 1162 12481039 of IN B-PP O
30 1163 1170 12481039 Ranvier NN B-NP O
31 1171 1175 12481039 were VBD B-VP O
32 1176 1185 12481039 unchanged JJ B-ADJP O
33 1185 1186 12481039 . . O O

1 1187 1193 12481039 beta2( SYM O O
2 1193 1194 12481039 - HYPH O O
3 1194 1195 12481039 / SYM O O
4 1195 1196 12481039 - SYM O O
5 1196 1197 12481039 ) ) O O
6 1198 1202 12481039 mice NNS B-NP O
7 1203 1212 12481039 displayed VBD B-VP O
8 1213 1222 12481039 increased VBN B-NP O
9 1223 1237 12481039 susceptibility NN I-NP O
10 1238 1240 12481039 to TO B-PP O
11 1241 1249 12481039 seizures NNS B-NP D012640
12 1249 1250 12481039 , , O O
13 1251 1253 12481039 as IN B-SBAR O
14 1254 1263 12481039 indicated VBN B-VP O
15 1264 1266 12481039 by IN B-PP O
16 1267 1274 12481039 reduced VBN B-NP O
17 1275 1282 12481039 latency NN I-NP O
18 1283 1286 12481039 and CC I-NP O
19 1287 1296 12481039 threshold NN I-NP O
20 1297 1300 12481039 for IN B-PP O
21 1301 1312 12481039 pilocarpine NN B-NP D010862
22 1312 1313 12481039 - HYPH B-NP O
23 1313 1320 12481039 induced VBN I-NP O
24 1321 1329 12481039 seizures NNS I-NP D012640
25 1329 1330 12481039 , , O O
26 1331 1334 12481039 but CC O O
27 1335 1341 12481039 seemed VBD B-VP O
28 1342 1348 12481039 normal JJ B-ADJP O
29 1349 1351 12481039 in IN B-PP O
30 1352 1357 12481039 other JJ B-NP O
31 1358 1370 12481039 neurological JJ I-NP O
32 1371 1376 12481039 tests NNS I-NP O
33 1376 1377 12481039 . . O O

1 1378 1381 12481039 Our PRP$ B-NP O
2 1382 1394 12481039 observations NNS I-NP O
3 1395 1399 12481039 show VBP B-VP O
4 1400 1404 12481039 that IN B-SBAR O
5 1405 1410 12481039 beta2 NN B-NP O
6 1410 1411 12481039 - HYPH B-NP O
7 1411 1419 12481039 subunits NNS I-NP O
8 1420 1424 12481039 play VBP B-VP O
9 1425 1427 12481039 an DT B-NP O
10 1428 1437 12481039 important JJ I-NP O
11 1438 1442 12481039 role NN I-NP O
12 1443 1445 12481039 in IN B-PP O
13 1446 1449 12481039 the DT B-NP O
14 1450 1460 12481039 regulation NN I-NP O
15 1461 1463 12481039 of IN B-PP O
16 1464 1470 12481039 sodium NN B-NP D012964
17 1471 1478 12481039 channel NN I-NP O
18 1479 1486 12481039 density NN I-NP O
19 1487 1490 12481039 and CC I-NP O
20 1491 1499 12481039 function NN I-NP O
21 1500 1502 12481039 in IN B-PP O
22 1503 1510 12481039 neurons NNS B-NP O
23 1511 1513 12481039 in FW B-ADVP O
24 1514 1518 12481039 vivo FW I-ADVP O
25 1519 1522 12481039 and CC O O
26 1523 1526 12481039 are VBP B-VP O
27 1527 1535 12481039 required VBN I-VP O
28 1536 1539 12481039 for IN B-PP O
29 1540 1546 12481039 normal JJ B-NP O
30 1547 1553 12481039 action NN I-NP O
31 1554 1563 12481039 potential NN I-NP O
32 1564 1574 12481039 generation NN I-NP O
33 1575 1578 12481039 and CC O O
34 1579 1586 12481039 control NN B-NP O
35 1587 1589 12481039 of IN B-PP O
36 1590 1602 12481039 excitability NN B-NP O
37 1602 1603 12481039 . . O O

1 0 0 8742498 -DOCSTART- -X- -X- O

1 0 9 8742498 Influence NN B-NP O
2 10 12 8742498 of IN B-PP O
3 13 17 8742498 diet NN B-NP O
4 18 22 8742498 free JJ B-ADJP O
5 23 25 8742498 of IN B-PP O
6 26 29 8742498 NAD NN B-NP D009243
7 29 30 8742498 - HYPH O O
8 30 40 8742498 precursors NNS B-NP O
9 41 43 8742498 on IN B-PP O
10 44 57 8742498 acetaminophen NN B-NP D000082
11 58 72 8742498 hepatotoxicity NN I-NP D056486
12 73 75 8742498 in IN B-PP O
13 76 80 8742498 mice NNS B-NP O
14 80 81 8742498 . . O O
15 82 90 8742498 Recently RB B-ADVP O
16 90 91 8742498 , , O O
17 92 94 8742498 we PRP B-NP O
18 95 107 8742498 demonstrated VBD B-VP O
19 108 111 8742498 the DT B-NP O
20 112 128 8742498 hepatoprotective JJ I-NP O
21 129 136 8742498 effects NNS I-NP O
22 137 139 8742498 of IN B-PP O
23 140 149 8742498 nicotinic JJ B-NP D009536
24 150 154 8742498 acid NN I-NP D009536
25 155 160 8742498 amide NN I-NP D009536
26 160 161 8742498 , , O O
27 162 163 8742498 a DT B-NP O
28 164 173 8742498 selective JJ I-NP O
29 174 183 8742498 inhibitor NN I-NP O
30 184 186 8742498 of IN B-PP O
31 187 195 8742498 poly(ADP NN B-NP D011064
32 195 196 8742498 - HYPH O D011064
33 196 203 8742498 ribose) NN B-NP D011064
34 204 214 8742498 polymerase NN I-NP O
35 215 216 8742498 ( ( O O
36 216 220 8742498 PARP NN B-NP O
37 220 221 8742498 ; : O O
38 222 224 8742498 EC NNP B-NP O
39 225 233 8742498 2.4.2.30 CD I-NP O
40 233 234 8742498 ) ) O O
41 235 237 8742498 on IN B-PP O
42 238 242 8742498 mice NNS B-NP O
43 243 252 8742498 suffering VBG B-VP O
44 253 257 8742498 from IN B-PP O
45 258 271 8742498 acetaminophen NN B-NP D000082
46 272 277 8742498 (AAP) NN I-NP D000082
47 277 278 8742498 - HYPH B-NP O
48 278 287 8742498 hepatitis NN I-NP D056486
49 287 288 8742498 , , O O
50 289 299 8742498 suggesting VBG B-VP O
51 300 304 8742498 that IN B-SBAR O
52 305 308 8742498 the DT B-NP O
53 309 312 8742498 AAP NN I-NP D000082
54 312 313 8742498 - HYPH B-VP O
55 313 320 8742498 induced VBN B-NP O
56 321 326 8742498 liver NN I-NP D056486
57 327 333 8742498 injury NN I-NP D056486
58 334 342 8742498 involves VBZ B-VP O
59 343 344 8742498 a DT B-NP O
60 345 349 8742498 step NN I-NP O
61 350 355 8742498 which WDT B-NP O
62 356 363 8742498 depends VBZ B-VP O
63 364 366 8742498 on IN B-PP O
64 367 384 8742498 adenoribosylation NN B-NP O
65 384 385 8742498 . . O O

1 386 389 8742498 The DT B-NP O
2 390 397 8742498 present JJ I-NP O
3 398 403 8742498 study NN I-NP O
4 404 416 8742498 investigates VBZ B-VP O
5 417 420 8742498 the DT B-NP O
6 421 428 8742498 effects NNS I-NP O
7 429 431 8742498 of IN B-PP O
8 432 433 8742498 a DT B-NP O
9 434 438 8742498 diet NN I-NP O
10 439 443 8742498 free JJ B-ADJP O
11 444 446 8742498 of IN B-PP O
12 447 457 8742498 precursors NNS B-NP O
13 458 460 8742498 of IN B-PP O
14 461 464 8742498 NAD NN B-NP D009243
15 464 465 8742498 , , O O
16 466 469 8742498 the DT B-NP O
17 470 479 8742498 substrate NN I-NP O
18 480 482 8742498 on IN B-PP O
19 483 488 8742498 which WDT B-NP O
20 489 493 8742498 PARP NN B-NP O
21 494 498 8742498 acts VBZ B-VP O
22 498 499 8742498 , , O O
23 500 502 8742498 in IN B-PP O
24 503 509 8742498 female JJ B-NP O
25 510 514 8742498 NMRI NN I-NP O
26 515 519 8742498 mice NNS I-NP O
27 520 524 8742498 with IN B-PP O
28 525 528 8742498 AAP NN B-NP D000082
29 529 538 8742498 hepatitis NN I-NP D056486
30 539 542 8742498 and CC O O
31 543 552 8742498 evaluates VBZ B-VP O
32 553 556 8742498 the DT B-NP O
33 557 566 8742498 influence NN I-NP O
34 567 569 8742498 of IN B-PP O
35 570 582 8742498 simultaneous JJ B-NP O
36 583 590 8742498 ethanol NN I-NP D000431
37 591 602 8742498 consumption NN I-NP O
38 603 605 8742498 in IN B-PP O
39 606 611 8742498 these DT B-NP O
40 612 619 8742498 animals NNS I-NP O
41 619 620 8742498 . . O O

1 621 626 8742498 Liver NN B-NP D056486
2 627 635 8742498 injuries NNS I-NP D056486
3 636 640 8742498 were VBD B-VP O
4 641 651 8742498 quantified VBN I-VP O
5 652 654 8742498 as IN B-PP O
6 655 660 8742498 serum NN B-NP O
7 661 671 8742498 activities NNS I-NP O
8 672 674 8742498 of IN B-PP O
9 675 684 8742498 glutamate NN B-NP D018698
10 684 685 8742498 - HYPH O O
11 685 697 8742498 oxaloacetate NN B-NP D062907
12 698 710 8742498 transaminase NN I-NP O
13 711 712 8742498 ( ( O O
14 712 715 8742498 GOT NN B-NP O
15 715 716 8742498 ) ) O O
16 717 720 8742498 and CC O O
17 721 730 8742498 glutamate NN B-NP D018698
18 730 731 8742498 - HYPH O O
19 731 739 8742498 pyruvate NN B-NP D019289
20 740 752 8742498 transaminase NN I-NP O
21 753 754 8742498 ( ( O O
22 754 757 8742498 GPT NN B-NP O
23 757 758 8742498 ) ) O O
24 758 759 8742498 . . O O

1 760 765 8742498 While IN B-SBAR O
2 766 769 8742498 AAP NN B-NP D000082
3 770 776 8742498 caused VBD B-VP O
4 777 778 8742498 a DT B-NP O
5 779 782 8742498 117 CD I-NP O
6 782 783 8742498 - HYPH I-NP O
7 783 787 8742498 fold JJ I-NP O
8 788 797 8742498 elevation NN I-NP O
9 798 800 8742498 of IN B-PP O
10 801 806 8742498 serum NN B-NP O
11 807 819 8742498 transaminase NN I-NP O
12 820 830 8742498 activities NNS I-NP O
13 831 833 8742498 in IN B-PP O
14 834 838 8742498 mice NNS B-NP O
15 839 843 8742498 kept VBN B-VP O
16 844 846 8742498 on IN B-PP O
17 847 848 8742498 a DT B-NP O
18 849 857 8742498 standard JJ I-NP O
19 858 868 8742498 laboratory NN I-NP O
20 869 873 8742498 diet NN I-NP O
21 873 874 8742498 , , O O
22 875 880 8742498 which WDT B-NP O
23 881 884 8742498 was VBD B-VP O
24 885 898 8742498 significantly RB I-VP O
25 899 910 8742498 exacerbated VBN I-VP O
26 911 913 8742498 by IN B-PP O
27 914 921 8742498 ethanol NN B-NP D000431
28 922 925 8742498 and CC O O
29 926 935 8742498 inhibited VBN B-VP O
30 936 938 8742498 by IN B-PP O
31 939 948 8742498 nicotinic JJ B-NP D009536
32 949 953 8742498 acid NN I-NP D009536
33 954 959 8742498 amide NN I-NP D009536
34 960 961 8742498 ( ( O O
35 961 964 8742498 NAA NN B-NP D009536
36 964 965 8742498 ) ) O O
37 965 966 8742498 , , O O
38 967 974 8742498 adverse JJ B-NP O
39 975 982 8742498 effects NNS I-NP O
40 983 987 8742498 were VBD B-VP O
41 988 993 8742498 noted VBN I-VP O
42 994 996 8742498 in IN B-PP O
43 997 1004 8742498 animals NNS B-NP O
44 1005 1008 8742498 fed VBN B-VP O
45 1009 1010 8742498 a DT B-NP O
46 1011 1015 8742498 diet NN I-NP O
47 1016 1020 8742498 free JJ B-ADJP O
48 1021 1023 8742498 of IN B-PP O
49 1024 1034 8742498 precursors NNS B-NP O
50 1035 1037 8742498 of IN B-PP O
51 1038 1041 8742498 NAD NN B-NP D009243
52 1041 1042 8742498 . . O O

1 1043 1045 8742498 In IN B-PP O
2 1046 1051 8742498 these DT B-NP O
3 1052 1059 8742498 animals NNS I-NP O
4 1059 1060 8742498 , , O O
5 1061 1065 8742498 only RB B-NP O
6 1066 1071 8742498 minor JJ I-NP O
7 1072 1081 8742498 increases NNS I-NP O
8 1082 1084 8742498 of IN B-PP O
9 1085 1090 8742498 serum NN B-NP O
10 1091 1103 8742498 transaminase NN I-NP O
11 1104 1114 8742498 activities NNS I-NP O
12 1115 1119 8742498 were VBD B-VP O
13 1120 1128 8742498 measured VBN I-VP O
14 1129 1131 8742498 in IN B-PP O
15 1132 1135 8742498 the DT B-NP O
16 1136 1144 8742498 presence NN I-NP O
17 1145 1147 8742498 of IN B-PP O
18 1148 1151 8742498 AAP NN B-NP D000082
19 1151 1152 8742498 , , O O
20 1153 1156 8742498 and CC O O
21 1157 1163 8742498 unlike IN B-PP O
22 1164 1167 8742498 the DT B-NP O
23 1168 1180 8742498 exacerbation NN I-NP O
24 1181 1187 8742498 caused VBN B-VP O
25 1188 1190 8742498 by IN B-PP O
26 1191 1198 8742498 ethanol NN B-NP D000431
27 1199 1201 8742498 in IN B-PP O
28 1202 1206 8742498 mice NNS B-NP O
29 1207 1209 8742498 on IN B-PP O
30 1210 1211 8742498 a DT B-NP O
31 1212 1220 8742498 standard JJ I-NP O
32 1221 1225 8742498 diet NN I-NP O
33 1225 1226 8742498 , , O O
34 1227 1230 8742498 the DT B-NP O
35 1231 1236 8742498 liver NN I-NP D056486
36 1237 1243 8742498 damage NN I-NP D056486
37 1244 1247 8742498 was VBD B-VP O
38 1248 1257 8742498 inhibited VBN I-VP O
39 1258 1260 8742498 by IN B-PP O
40 1261 1264 8742498 50% CD B-NP O
41 1265 1267 8742498 by IN B-PP O
42 1268 1275 8742498 ethanol NN B-NP D000431
43 1275 1276 8742498 . . O O

1 1277 1278 8742498 A DT B-NP O
2 1279 1286 8742498 further JJ I-NP O
3 1287 1290 8742498 64% CD I-NP O
4 1291 1300 8742498 reduction NN I-NP O
5 1301 1303 8742498 of IN B-PP O
6 1304 1313 8742498 hepatitis NN B-NP D056486
7 1314 1317 8742498 was VBD B-VP O
8 1318 1326 8742498 observed VBN I-VP O
9 1326 1327 8742498 , , O O
10 1328 1332 8742498 when WRB B-ADVP O
11 1333 1336 8742498 NAA NN B-NP D009536
12 1337 1340 8742498 was VBD B-VP O
13 1341 1346 8742498 given VBN I-VP O
14 1347 1349 8742498 to TO B-PP O
15 1350 1357 8742498 ethanol NN B-NP D000431
16 1357 1358 8742498 / SYM B-NP O
17 1358 1361 8742498 AAP NN I-NP D000082
18 1361 1362 8742498 - HYPH B-NP O
19 1362 1366 8742498 mice NNS I-NP O
20 1366 1367 8742498 . . O O

1 1368 1371 8742498 Our PRP$ B-NP O
2 1372 1379 8742498 results NNS I-NP O
3 1380 1387 8742498 provide VBP B-VP O
4 1388 1396 8742498 evidence NN B-NP O
5 1397 1401 8742498 that IN B-SBAR O
6 1402 1405 8742498 the DT B-NP O
7 1406 1409 8742498 AAP NN I-NP D000082
8 1409 1410 8742498 - HYPH B-VP O
9 1410 1417 8742498 induced VBN B-NP O
10 1418 1427 8742498 hepatitis NN I-NP D056486
11 1428 1431 8742498 and CC O O
12 1432 1435 8742498 its PRP$ B-NP O
13 1436 1448 8742498 exacerbation NN I-NP O
14 1449 1451 8742498 by IN B-PP O
15 1452 1459 8742498 ethanol NN B-NP D000431
16 1460 1463 8742498 can MD B-VP O
17 1464 1470 8742498 either CC O O
18 1471 1473 8742498 be VB B-VP O
19 1474 1481 8742498 reduced VBN I-VP O
20 1482 1484 8742498 by IN B-PP O
21 1485 1488 8742498 end NN B-NP O
22 1488 1489 8742498 - HYPH I-NP O
23 1489 1496 8742498 product NN I-NP O
24 1497 1507 8742498 inhibition NN I-NP O
25 1508 1510 8742498 of IN B-PP O
26 1511 1515 8742498 PARP NN B-NP O
27 1516 1518 8742498 by IN B-PP O
28 1519 1522 8742498 NAA NN B-NP D009536
29 1523 1525 8742498 or CC B-PP O
30 1526 1528 8742498 by IN B-PP O
31 1529 1536 8742498 dietary JJ B-NP O
32 1537 1546 8742498 depletion NN I-NP O
33 1547 1549 8742498 of IN B-PP O
34 1550 1553 8742498 the DT B-NP O
35 1554 1562 8742498 enzyme's NNS I-NP O
36 1563 1572 8742498 substrate NN I-NP O
37 1573 1576 8742498 NAD NN I-NP D009243
38 1576 1577 8742498 . . O O

1 1578 1580 8742498 We PRP B-NP O
2 1581 1584 8742498 see VBP B-VP O
3 1585 1588 8742498 the DT B-NP O
4 1589 1593 8742498 main JJ I-NP O
5 1594 1605 8742498 application NN I-NP O
6 1606 1608 8742498 of IN B-PP O
7 1609 1612 8742498 NAA NN B-NP D009536
8 1613 1615 8742498 as IN B-PP O
9 1616 1619 8742498 for IN B-PP O
10 1620 1623 8742498 the DT B-NP O
11 1624 1637 8742498 combinational JJ I-NP O
12 1638 1641 8742498 use NN I-NP O
13 1642 1644 8742498 in IN B-PP O
14 1645 1659 8742498 pharmaceutical JJ B-NP O
15 1660 1672 8742498 preparations NNS I-NP O
16 1673 1675 8742498 of IN B-PP O
17 1676 1689 8742498 acetaminophen NN B-NP D000082
18 1690 1692 8742498 in IN B-SBAR O
19 1693 1698 8742498 order NN O O
20 1699 1701 8742498 to TO B-VP O
21 1702 1707 8742498 avoid VB I-VP O
22 1708 1715 8742498 hepatic JJ B-NP D056486
23 1716 1722 8742498 damage NN I-NP D056486
24 1723 1725 8742498 in IN B-PP O
25 1726 1734 8742498 patients NNS B-NP O
26 1735 1742 8742498 treated VBN B-VP O
27 1743 1747 8742498 with IN B-PP O
28 1748 1752 8742498 this DT B-NP O
29 1753 1759 8742498 widely RB I-NP O
30 1760 1764 8742498 used VBN I-NP O
31 1765 1774 8742498 analgesic JJ B-ADJP O
32 1774 1775 8742498 . . O O

1 0 0 10840460 -DOCSTART- -X- -X- O

1 0 16 10840460 Cyclophosphamide NN B-NP D003520
2 16 17 10840460 - HYPH B-PP O
3 17 24 10840460 induced VBN B-NP O
4 25 33 10840460 cystitis NN I-NP D003556
5 34 36 10840460 in IN B-PP O
6 37 43 10840460 freely RB B-NP O
7 43 44 10840460 - HYPH I-NP O
8 44 50 10840460 moving VBG B-VP O
9 51 60 10840460 conscious JJ B-NP O
10 61 65 10840460 rats NNS I-NP O
11 65 66 10840460 : : O O
12 67 77 10840460 behavioral JJ B-NP O
13 78 86 10840460 approach NN I-NP O
14 87 89 10840460 to TO B-PP O
15 90 91 10840460 a DT B-NP O
16 92 95 10840460 new JJ I-NP O
17 96 101 10840460 model NN I-NP O
18 102 104 10840460 of IN B-PP O
19 105 113 10840460 visceral JJ B-NP D059265
20 114 118 10840460 pain NN I-NP D059265
21 118 119 10840460 . . I-NP O
22 120 127 10840460 PURPOSE NN I-NP O
23 127 128 10840460 : : O O
24 129 131 10840460 To TO B-VP O
25 132 139 10840460 develop VB I-VP O
26 140 141 10840460 a DT B-NP O
27 142 147 10840460 model NN I-NP O
28 148 150 10840460 of IN B-PP O
29 151 159 10840460 visceral JJ B-NP D059265
30 160 164 10840460 pain NN I-NP D059265
31 165 167 10840460 in IN B-PP O
32 168 172 10840460 rats NNS B-NP O
33 173 178 10840460 using VBG B-VP O
34 179 180 10840460 a DT B-NP O
35 181 191 10840460 behavioral JJ I-NP O
36 192 200 10840460 approach NN I-NP O
37 200 201 10840460 . . O O

1 202 218 10840460 Cyclophosphamide NN B-NP D003520
2 219 220 10840460 ( ( O O
3 220 222 10840460 CP NN B-NP D003520
4 222 223 10840460 ) ) O O
5 223 224 10840460 , , O O
6 225 227 10840460 an DT B-NP O
7 228 239 10840460 antitumoral JJ I-NP O
8 240 245 10840460 agent NN I-NP O
9 246 251 10840460 known VBN B-VP O
10 252 254 10840460 to TO B-VP O
11 255 262 10840460 produce VB I-VP O
12 263 268 10840460 toxic JJ B-NP O
13 269 276 10840460 effects NNS I-NP O
14 277 279 10840460 on IN B-PP O
15 280 283 10840460 the DT B-NP O
16 284 291 10840460 bladder NN I-NP O
17 292 296 10840460 wall NN I-NP O
18 297 304 10840460 through IN B-PP O
19 305 308 10840460 its PRP$ B-NP O
20 309 313 10840460 main JJ I-NP O
21 314 319 10840460 toxic JJ I-NP O
22 320 330 10840460 metabolite NN I-NP O
23 331 339 10840460 acrolein NN I-NP D000171
24 339 340 10840460 , , O O
25 341 344 10840460 was VBD B-VP O
26 345 349 10840460 used VBN I-VP O
27 350 352 10840460 to TO B-VP O
28 353 359 10840460 induce VB I-VP O
29 360 368 10840460 cystitis NN B-NP D003556
30 368 369 10840460 . . O O

1 370 379 10840460 MATERIALS NNS B-NP O
2 380 383 10840460 AND CC I-NP O
3 384 391 10840460 METHODS NNS I-NP O
4 391 392 10840460 : : O O
5 393 395 10840460 CP NN B-NP D003520
6 396 399 10840460 was VBD B-VP O
7 400 412 10840460 administered VBN I-VP O
8 413 415 10840460 at IN B-PP O
9 416 421 10840460 doses NNS B-NP O
10 422 424 10840460 of IN B-PP O
11 425 427 10840460 50 CD B-NP O
12 427 428 10840460 , , I-NP O
13 429 432 10840460 100 CD I-NP O
14 433 436 10840460 and CC I-NP O
15 437 440 10840460 200 CD I-NP O
16 441 443 10840460 mg NN I-NP O
17 443 444 10840460 . . O O
18 444 445 10840460 / SYM B-NP O
19 445 447 10840460 kg NN I-NP O
20 447 448 10840460 . . O O

1 449 452 10840460 i.p JJ B-ADJP O
2 452 453 10840460 . . O O

1 454 456 10840460 to TO B-PP O
2 457 461 10840460 male JJ B-NP O
3 462 466 10840460 rats NNS I-NP O
4 466 467 10840460 , , O O
5 468 471 10840460 and CC O O
6 472 477 10840460 their PRP$ B-NP O
7 478 486 10840460 behavior NN I-NP O
8 487 495 10840460 observed VBN B-VP O
9 496 499 10840460 and CC I-VP O
10 500 506 10840460 scored VBN I-VP O
11 506 507 10840460 . . O O

1 508 511 10840460 The DT B-NP O
2 512 519 10840460 effects NNS I-NP O
3 520 522 10840460 of IN B-PP O
4 523 531 10840460 morphine NN B-NP D009020
5 532 533 10840460 ( ( O O
6 533 536 10840460 0.5 CD B-NP O
7 537 539 10840460 to TO I-NP O
8 540 541 10840460 4 CD I-NP O
9 542 544 10840460 mg NN I-NP O
10 544 545 10840460 . . O O
11 545 546 10840460 / SYM B-NP O
12 546 548 10840460 kg NN I-NP O
13 548 549 10840460 . . O O

1 550 553 10840460 i.v JJ B-ADJP O
2 553 554 10840460 . . O O
3 554 555 10840460 ) ) O O
4 556 558 10840460 on IN B-PP O
5 559 561 10840460 CP NN B-NP D003520
6 561 562 10840460 - HYPH B-NP O
7 562 569 10840460 induced VBN I-NP O
8 570 580 10840460 behavioral NN I-NP O
9 581 594 10840460 modifications NNS I-NP O
10 595 599 10840460 were VBD B-VP O
11 600 606 10840460 tested VBN I-VP O
12 607 619 10840460 administered VBN I-VP O
13 620 625 10840460 alone RB B-ADVP O
14 626 629 10840460 and CC O O
15 630 635 10840460 after IN B-PP O
16 636 644 10840460 naloxone NN B-NP D009270
17 645 646 10840460 ( ( O O
18 646 647 10840460 1 CD B-NP O
19 648 650 10840460 mg NN I-NP O
20 650 651 10840460 . . O O
21 651 652 10840460 / SYM B-NP O
22 652 654 10840460 kg NN I-NP O
23 654 655 10840460 . . O O

1 656 659 10840460 s.c NN B-NP O
2 659 660 10840460 . . O O
3 660 661 10840460 ) ) O O
4 661 662 10840460 . . O O

1 663 665 10840460 In IN B-PP O
2 666 674 10840460 addition NN B-NP O
3 674 675 10840460 , , O O
4 676 678 10840460 90 CD B-NP O
5 679 686 10840460 minutes NNS I-NP O
6 687 692 10840460 after IN B-PP O
7 693 695 10840460 CP NN B-NP D003520
8 696 705 10840460 injection NN I-NP O
9 705 706 10840460 , , O O
10 707 711 10840460 that DT B-NP O
11 712 714 10840460 is VBZ B-VP O
12 714 715 10840460 , , O O
13 716 718 10840460 at IN B-PP O
14 719 722 10840460 the DT B-NP O
15 723 727 10840460 time NN I-NP O
16 728 730 10840460 of IN B-PP O
17 731 745 10840460 administration NN B-NP O
18 746 748 10840460 of IN B-PP O
19 749 757 10840460 morphine NN B-NP D009020
20 757 758 10840460 , , O O
21 759 762 10840460 the DT B-NP O
22 763 770 10840460 bladder NN I-NP O
23 771 774 10840460 was VBD B-VP O
24 775 782 10840460 removed VBN I-VP O
25 783 785 10840460 in IN B-PP O
26 786 790 10840460 some DT B-NP O
27 791 795 10840460 rats NNS I-NP O
28 796 799 10840460 for IN B-PP O
29 800 812 10840460 histological JJ B-NP O
30 813 824 10840460 examination NN I-NP O
31 824 825 10840460 . . O O

1 826 833 10840460 Finally RB B-ADVP O
2 833 834 10840460 , , O O
3 835 837 10840460 to TO B-VP O
4 838 842 10840460 show VB I-VP O
5 843 847 10840460 that IN B-SBAR O
6 848 851 10840460 the DT B-NP O
7 852 859 10840460 bladder NN I-NP O
8 860 862 10840460 is VBZ B-VP O
9 863 872 10840460 essential JJ B-ADJP O
10 873 876 10840460 for IN B-PP O
11 877 880 10840460 the DT B-NP O
12 881 883 10840460 CP NN I-NP D003520
13 883 884 10840460 - HYPH O O
14 884 891 10840460 induced VBN B-NP O
15 892 902 10840460 behavioral JJ I-NP O
16 903 916 10840460 modifications NNS I-NP O
17 916 917 10840460 , , O O
18 918 924 10840460 female JJ B-NP O
19 925 929 10840460 rats NNS I-NP O
20 930 934 10840460 also RB B-ADVP O
21 935 943 10840460 received VBD B-VP O
22 944 946 10840460 CP NN B-NP D003520
23 947 949 10840460 at IN B-PP O
24 950 955 10840460 doses NNS B-NP O
25 956 958 10840460 of IN B-PP O
26 959 962 10840460 200 CD B-NP O
27 963 965 10840460 mg NN I-NP O
28 965 966 10840460 . . O O
29 966 967 10840460 / SYM B-NP O
30 967 969 10840460 kg NN I-NP O
31 969 970 10840460 . . O O

1 971 974 10840460 i.p JJ B-ADJP O
2 974 975 10840460 . . O O

1 976 979 10840460 and CC O O
2 980 982 10840460 of IN B-PP O
3 983 985 10840460 20 CD B-NP O
4 986 988 10840460 mg NN I-NP O
5 988 989 10840460 . . O O

1 990 992 10840460 by IN B-PP O
2 993 996 10840460 the DT B-NP O
3 997 1009 10840460 intravesical JJ I-NP O
4 1010 1015 10840460 route NN I-NP O
5 1015 1016 10840460 , , O O
6 1017 1020 10840460 and CC O O
7 1021 1029 10840460 acrolein NN B-NP D000171
8 1030 1032 10840460 at IN B-PP O
9 1033 1038 10840460 doses NNS B-NP O
10 1039 1041 10840460 of IN B-PP O
11 1042 1045 10840460 0.5 CD B-NP O
12 1046 1048 10840460 mg NN I-NP O
13 1048 1049 10840460 . . O O

1 1050 1052 10840460 by IN B-PP O
2 1053 1056 10840460 the DT B-NP O
3 1057 1069 10840460 intravesical JJ I-NP O
4 1070 1075 10840460 route NN I-NP O
5 1076 1079 10840460 and CC B-PP O
6 1080 1082 10840460 of IN B-PP O
7 1083 1084 10840460 5 CD B-NP O
8 1085 1087 10840460 mg NN I-NP O
9 1087 1088 10840460 . . O O
10 1088 1089 10840460 / SYM B-NP O
11 1089 1091 10840460 kg NN I-NP O
12 1091 1092 10840460 . . O O

1 1093 1096 10840460 i.v JJ B-ADJP O
2 1096 1097 10840460 . . O O

1 1098 1105 10840460 RESULTS NNS B-NP O
2 1105 1106 10840460 : : O O
3 1107 1109 10840460 CP NN B-NP D003520
4 1110 1114 10840460 dose NN I-NP O
5 1114 1115 10840460 - HYPH B-VP O
6 1115 1124 10840460 relatedly RB I-VP O
7 1125 1132 10840460 induced VBN I-VP O
8 1133 1139 10840460 marked JJ B-NP O
9 1140 1150 10840460 behavioral JJ I-NP O
10 1151 1164 10840460 modifications NNS I-NP O
11 1165 1167 10840460 in IN B-PP O
12 1168 1172 10840460 male JJ B-NP O
13 1173 1177 10840460 rats NNS I-NP O
14 1177 1178 10840460 : : O O
15 1179 1188 10840460 breathing NN B-NP O
16 1189 1193 10840460 rate NN I-NP O
17 1194 1202 10840460 decrease NN I-NP O
18 1202 1203 10840460 , , O O
19 1204 1211 10840460 closing VBG B-VP O
20 1212 1214 10840460 of IN B-PP O
21 1215 1218 10840460 the DT B-NP O
22 1219 1223 10840460 eyes NNS I-NP O
23 1224 1227 10840460 and CC I-NP O
24 1228 1238 10840460 occurrence NN I-NP O
25 1239 1241 10840460 of IN B-PP O
26 1242 1250 10840460 specific JJ B-NP O
27 1251 1259 10840460 postures NNS I-NP O
28 1259 1260 10840460 . . O O

1 1261 1269 10840460 Morphine NN B-NP D009020
2 1270 1274 10840460 dose NN I-NP O
3 1274 1275 10840460 - HYPH B-NP O
4 1275 1286 10840460 dependently RB B-ADVP O
5 1287 1295 10840460 reversed VBD B-VP O
6 1296 1301 10840460 these DT B-NP O
7 1302 1312 10840460 behavioral JJ I-NP D001523
8 1313 1322 10840460 disorders NNS I-NP D001523
9 1322 1323 10840460 . . O O

1 1324 1325 10840460 A DT B-NP O
2 1326 1330 10840460 dose NN I-NP O
3 1331 1333 10840460 of IN B-PP O
4 1334 1337 10840460 0.5 CD B-NP O
5 1338 1340 10840460 mg NN I-NP O
6 1340 1341 10840460 . . O O
7 1341 1342 10840460 / SYM B-NP O
8 1342 1344 10840460 kg NN I-NP O
9 1344 1345 10840460 . . O O

1 1346 1354 10840460 produced VBN B-VP O
2 1355 1356 10840460 a DT B-NP O
3 1357 1366 10840460 reduction NN I-NP O
4 1367 1369 10840460 of IN B-PP O
5 1370 1376 10840460 almost RB B-NP O
6 1377 1380 10840460 50% CD I-NP O
7 1381 1383 10840460 of IN B-PP O
8 1384 1387 10840460 the DT B-NP O
9 1388 1398 10840460 behavioral JJ I-NP O
10 1399 1404 10840460 score NN I-NP O
11 1405 1412 10840460 induced VBN B-VP O
12 1413 1415 10840460 by IN B-PP O
13 1416 1418 10840460 CP NN B-NP D003520
14 1419 1422 10840460 200 CD I-NP O
15 1423 1425 10840460 mg NN I-NP O
16 1425 1426 10840460 . . O O
17 1426 1427 10840460 / SYM B-NP O
18 1427 1429 10840460 kg NN I-NP O
19 1429 1430 10840460 . . O O

1 1431 1435 10840460 This DT B-NP O
2 1436 1442 10840460 effect NN I-NP O
3 1443 1446 10840460 was VBD B-VP O
4 1447 1457 10840460 completely RB I-VP O
5 1458 1467 10840460 prevented VBN I-VP O
6 1468 1470 10840460 by IN B-PP O
7 1471 1483 10840460 pretreatment NN B-NP O
8 1484 1488 10840460 with IN B-PP O
9 1489 1497 10840460 naloxone NN B-NP D009270
10 1497 1498 10840460 . . O O

1 1499 1501 10840460 At IN B-PP O
2 1502 1505 10840460 the DT B-NP O
3 1506 1510 10840460 time NN I-NP O
4 1511 1513 10840460 of IN B-PP O
5 1514 1528 10840460 administration NN B-NP O
6 1529 1531 10840460 of IN B-PP O
7 1532 1540 10840460 morphine NN B-NP D009020
8 1540 1541 10840460 , , O O
9 1542 1554 10840460 histological JJ B-NP O
10 1555 1568 10840460 modifications NNS I-NP O
11 1569 1571 10840460 of IN B-PP O
12 1572 1575 10840460 the DT B-NP O
13 1576 1583 10840460 bladder NN I-NP O
14 1584 1588 10840460 wall NN I-NP O
15 1588 1589 10840460 , , O O
16 1590 1594 10840460 such JJ B-PP O
17 1595 1597 10840460 as IN I-PP O
18 1598 1607 10840460 chorionic JJ B-NP O
19 1608 1611 10840460 and CC I-NP O
20 1612 1618 10840460 muscle NN I-NP O
21 1619 1624 10840460 layer NN I-NP O
22 1625 1630 10840460 edema NN I-NP D004487
23 1630 1631 10840460 , , O O
24 1632 1636 10840460 were VBD B-VP O
25 1637 1645 10840460 observed VBN I-VP O
26 1645 1646 10840460 . . O O

1 1647 1649 10840460 In IN B-PP O
2 1650 1656 10840460 female JJ B-NP O
3 1657 1661 10840460 rats NNS I-NP O
4 1661 1662 10840460 , , O O
5 1663 1665 10840460 CP NN B-NP D003520
6 1666 1669 10840460 200 CD I-NP O
7 1670 1672 10840460 mg NN I-NP O
8 1672 1673 10840460 . . O O
9 1673 1674 10840460 / SYM B-NP O
10 1674 1676 10840460 kg NN I-NP O
11 1676 1677 10840460 . . O O

1 1678 1681 10840460 i.p JJ B-ADJP O
2 1681 1682 10840460 . . O O

1 1683 1691 10840460 produced VBD B-VP O
2 1692 1695 10840460 the DT B-NP O
3 1696 1700 10840460 same JJ I-NP O
4 1701 1707 10840460 marked JJ I-NP O
5 1708 1718 10840460 behavioral JJ I-NP O
6 1719 1732 10840460 modifications NNS I-NP O
7 1733 1735 10840460 as IN B-PP O
8 1736 1741 10840460 those DT B-NP O
9 1742 1750 10840460 observed VBN B-VP O
10 1751 1753 10840460 in IN B-PP O
11 1754 1758 10840460 male JJ B-NP O
12 1759 1763 10840460 rats NNS I-NP O
13 1763 1764 10840460 . . O O

1 1765 1777 10840460 Administered VBN B-VP O
2 1778 1780 10840460 at IN B-PP O
3 1781 1784 10840460 the DT B-NP O
4 1785 1789 10840460 dose NN I-NP O
5 1790 1792 10840460 of IN B-PP O
6 1793 1795 10840460 20 CD B-NP O
7 1796 1798 10840460 mg NN I-NP O
8 1798 1799 10840460 . . O O

1 1800 1814 10840460 intravesically RB B-ADVP O
2 1814 1815 10840460 , , O O
3 1816 1818 10840460 CP NN B-NP D003520
4 1819 1822 10840460 did VBD B-VP O
5 1823 1826 10840460 not RB I-VP O
6 1827 1834 10840460 produce VB I-VP O
7 1835 1838 10840460 any DT B-NP O
8 1839 1849 10840460 behavioral JJ I-NP O
9 1850 1857 10840460 effects NNS I-NP O
10 1857 1858 10840460 , , O O
11 1859 1866 10840460 whereas IN O O
12 1867 1875 10840460 acrolein NN B-NP D000171
13 1876 1878 10840460 at IN B-PP O
14 1879 1882 10840460 0.5 CD B-NP O
15 1883 1885 10840460 mg NN I-NP O
16 1885 1886 10840460 . . O O

1 1887 1901 10840460 intravesically RB B-NP O
2 1902 1909 10840460 induced VBN I-NP O
3 1910 1920 10840460 behavioral JJ I-NP O
4 1921 1934 10840460 modifications NNS I-NP O
5 1935 1944 10840460 identical JJ B-ADJP O
6 1945 1947 10840460 to TO B-PP O
7 1948 1953 10840460 those DT B-NP O
8 1954 1959 10840460 under IN B-PP O
9 1960 1962 10840460 CP NN B-NP D003520
10 1963 1966 10840460 200 CD I-NP O
11 1967 1969 10840460 mg NN I-NP O
12 1969 1970 10840460 . . O O
13 1970 1971 10840460 / SYM B-NP O
14 1971 1973 10840460 kg NN I-NP O
15 1973 1974 10840460 . . O O

1 1975 1978 10840460 i.p JJ B-NP O
2 1978 1979 10840460 . NN I-NP O
3 1979 1980 10840460 , , O O
4 1981 1985 10840460 with IN B-PP O
5 1986 1989 10840460 the DT B-NP O
6 1990 1994 10840460 same JJ I-NP O
7 1995 2002 10840460 maximal JJ I-NP O
8 2003 2009 10840460 levels NNS I-NP O
9 2009 2010 10840460 . . O O

1 2011 2021 10840460 Conversely RB B-ADVP O
2 2021 2022 10840460 , , O O
3 2023 2031 10840460 acrolein IN B-ADVP D000171
4 2032 2033 10840460 5 CD B-NP O
5 2034 2036 10840460 mg NN I-NP O
6 2036 2037 10840460 . . O O
7 2037 2038 10840460 / SYM B-NP O
8 2038 2040 10840460 kg NN I-NP O
9 2040 2041 10840460 . . O O

1 2042 2045 10840460 i.v JJ B-ADJP O
2 2045 2046 10840460 . . O O

1 2047 2050 10840460 did VBD B-VP O
2 2051 2054 10840460 not RB I-VP O
3 2055 2062 10840460 produce VB I-VP O
4 2063 2066 10840460 any DT B-NP O
5 2067 2077 10840460 behavioral JJ I-NP O
6 2078 2085 10840460 effects NNS I-NP O
7 2086 2088 10840460 at IN B-ADVP O
8 2089 2092 10840460 all DT I-ADVP O
9 2092 2093 10840460 . . O O

1 2094 2105 10840460 CONCLUSIONS NNS B-NP O
2 2105 2106 10840460 : : O O
3 2107 2114 10840460 Overall JJ B-ADJP O
4 2114 2115 10840460 , , O O
5 2116 2121 10840460 these DT B-NP O
6 2122 2129 10840460 results NNS I-NP O
7 2130 2138 10840460 indicate VBP B-VP O
8 2139 2143 10840460 that IN B-SBAR O
9 2144 2148 10840460 this DT B-NP O
10 2149 2161 10840460 experimental JJ I-NP O
11 2162 2167 10840460 model NN I-NP O
12 2168 2170 10840460 of IN B-PP O
13 2171 2173 10840460 CP NN B-NP D003520
14 2173 2174 10840460 - HYPH B-NP O
15 2174 2181 10840460 induced VBN I-NP O
16 2182 2190 10840460 cystitis NN I-NP D003556
17 2191 2194 10840460 may MD B-VP O
18 2195 2197 10840460 be VB I-VP O
19 2198 2200 10840460 an DT B-NP O
20 2201 2212 10840460 interesting JJ I-NP O
21 2213 2216 10840460 new JJ I-NP O
22 2217 2227 10840460 behavioral JJ I-NP O
23 2228 2233 10840460 model NN I-NP O
24 2234 2236 10840460 of IN B-PP O
25 2237 2249 10840460 inflammatory JJ B-NP O
26 2250 2258 10840460 visceral JJ I-NP D059265
27 2259 2263 10840460 pain NN I-NP D059265
28 2263 2264 10840460 , , O O
29 2265 2273 10840460 allowing VBG B-VP O
30 2274 2275 10840460 a DT B-NP O
31 2276 2282 10840460 better JJR I-NP O
32 2283 2296 10840460 understanding NN I-NP O
33 2297 2299 10840460 of IN B-PP O
34 2300 2305 10840460 these DT B-NP O
35 2306 2313 10840460 painful JJ I-NP D010146
36 2314 2323 10840460 syndromes NNS I-NP D010146
37 2324 2327 10840460 and CC O O
38 2328 2332 10840460 thus RB B-ADVP O
39 2333 2334 10840460 a DT B-NP O
40 2335 2341 10840460 better JJR I-NP O
41 2342 2353 10840460 therapeutic JJ I-NP O
42 2354 2362 10840460 approach NN I-NP O
43 2363 2365 10840460 to TO B-PP O
44 2366 2370 10840460 them PRP B-NP O
45 2370 2371 10840460 . . O O

1 0 0 2907585 -DOCSTART- -X- -X- O

1 0 8 2907585 Reversal NN B-NP O
2 9 11 2907585 of IN B-PP O
3 12 23 2907585 neuroleptic JJ B-NP O
4 23 24 2907585 - HYPH I-NP O
5 24 31 2907585 induced VBN I-NP O
6 32 41 2907585 catalepsy NN I-NP D002375
7 42 44 2907585 by IN B-PP O
8 45 50 2907585 novel JJ B-NP O
9 51 55 2907585 aryl NN I-NP -1
10 55 56 2907585 - HYPH B-NP -1
11 56 66 2907585 piperazine NN I-NP -1
12 67 77 2907585 anxiolytic JJ I-NP O
13 78 83 2907585 drugs NNS I-NP O
14 83 84 2907585 . . O O
15 85 88 2907585 The DT B-NP O
16 89 94 2907585 novel JJ I-NP O
17 95 105 2907585 anxiolytic JJ I-NP O
18 106 110 2907585 drug NN I-NP O
19 110 111 2907585 , , O O
20 112 121 2907585 buspirone NN B-NP D002065
21 121 122 2907585 , , O O
22 123 131 2907585 reverses VBZ B-VP O
23 132 141 2907585 catalepsy NN B-NP D002375
24 142 149 2907585 induced VBN B-VP O
25 150 152 2907585 by IN B-PP O
26 153 164 2907585 haloperidol NN B-NP D006220
27 164 165 2907585 . . O O

1 166 167 2907585 A DT B-NP O
2 168 174 2907585 series NN I-NP O
3 175 177 2907585 of IN B-PP O
4 178 182 2907585 aryl NN B-NP -1
5 182 183 2907585 - HYPH I-NP -1
6 183 193 2907585 piperazine NN I-NP -1
7 194 203 2907585 analogues NNS I-NP O
8 204 206 2907585 of IN B-PP O
9 207 216 2907585 buspirone NN B-NP D002065
10 217 220 2907585 and CC O O
11 221 226 2907585 other JJ B-NP O
12 227 228 2907585 5 CD I-NP D058825
13 228 229 2907585 - HYPH I-NP D058825
14 229 250 2907585 hydroxytryptaminergic JJ I-NP D058825
15 251 259 2907585 agonists NNS I-NP D058825
16 260 264 2907585 were VBD B-VP O
17 265 271 2907585 tested VBN I-VP O
18 272 275 2907585 for IN B-PP O
19 276 281 2907585 their PRP$ B-NP O
20 282 289 2907585 ability NN I-NP O
21 290 292 2907585 to TO B-VP O
22 293 300 2907585 reverse VB I-VP O
23 301 312 2907585 haloperidol NN B-NP D006220
24 313 320 2907585 induced JJ I-NP O
25 321 330 2907585 catalepsy NN I-NP D002375
26 330 331 2907585 . . O O

1 332 337 2907585 Those DT B-NP O
2 338 343 2907585 drugs NNS I-NP O
3 344 348 2907585 with IN B-PP O
4 349 355 2907585 strong JJ B-NP O
5 356 364 2907585 affinity NN I-NP O
6 365 368 2907585 for IN B-PP O
7 369 370 2907585 5 CD B-NP D012701
8 370 371 2907585 - HYPH I-NP D012701
9 371 390 2907585 hydroxytryptamine1a NN I-NP D012701
10 391 400 2907585 receptors NNS I-NP O
11 401 405 2907585 were VBD B-VP O
12 406 410 2907585 able JJ B-ADJP O
13 411 413 2907585 to TO B-VP O
14 414 421 2907585 reverse VB I-VP O
15 422 431 2907585 catalepsy NN B-NP D002375
16 431 432 2907585 . . O O

1 433 438 2907585 Drugs NNS B-NP O
2 439 443 2907585 with IN B-PP O
3 444 452 2907585 affinity NN B-NP O
4 453 456 2907585 for IN B-PP O
5 457 462 2907585 other JJ B-NP O
6 463 464 2907585 5 CD I-NP D012701
7 464 465 2907585 - HYPH I-NP D012701
8 465 467 2907585 HT NN I-NP D012701
9 468 477 2907585 receptors NNS I-NP O
10 478 480 2907585 or CC O O
11 481 485 2907585 weak JJ B-NP O
12 486 494 2907585 affinity NN I-NP O
13 495 499 2907585 were VBD B-VP O
14 500 511 2907585 ineffective JJ B-ADJP O
15 511 512 2907585 . . O O

1 513 520 2907585 However RB B-ADVP O
2 520 521 2907585 , , O O
3 522 532 2907585 inhibition NN B-NP O
4 533 535 2907585 of IN B-PP O
5 536 548 2907585 postsynaptic JJ B-NP O
6 549 550 2907585 5 CD I-NP D012701
7 550 551 2907585 - HYPH I-NP D012701
8 551 553 2907585 HT NN I-NP D012701
9 554 563 2907585 receptors NNS I-NP O
10 564 571 2907585 neither CC O O
11 572 581 2907585 inhibited VBD B-VP O
12 582 585 2907585 nor CC I-VP O
13 586 597 2907585 potentiated VBD I-VP O
14 598 606 2907585 reversal NN B-NP O
15 607 609 2907585 of IN B-PP O
16 610 619 2907585 catalepsy NN B-NP D002375
17 620 623 2907585 and CC O O
18 624 630 2907585 leaves VBZ B-VP O
19 631 635 2907585 open RP B-PRT O
20 636 639 2907585 the DT B-NP O
21 640 648 2907585 question NN I-NP O
22 649 651 2907585 as IN B-PP O
23 652 654 2907585 to TO B-PP O
24 655 658 2907585 the DT B-NP O
25 659 663 2907585 site NN I-NP O
26 664 666 2907585 or CC I-NP O
27 667 676 2907585 mechanism NN I-NP O
28 677 680 2907585 for IN B-PP O
29 681 685 2907585 this DT B-NP O
30 686 692 2907585 effect NN I-NP O
31 692 693 2907585 . . O O

1 0 0 1732442 -DOCSTART- -X- -X- O

1 0 9 1732442 Detection NN B-NP O
2 10 12 1732442 of IN B-PP O
3 13 21 1732442 abnormal JJ B-NP O
4 22 29 1732442 cardiac JJ I-NP O
5 30 40 1732442 adrenergic JJ I-NP O
6 41 47 1732442 neuron NN I-NP O
7 48 56 1732442 activity NN I-NP O
8 57 59 1732442 in IN B-PP O
9 60 70 1732442 adriamycin NN B-NP D004317
10 70 71 1732442 - HYPH B-NP O
11 71 78 1732442 induced VBN I-NP O
12 79 93 1732442 cardiomyopathy NN I-NP D009202
13 94 98 1732442 with IN B-PP O
14 99 105 1732442 iodine NN B-NP D019797
15 105 106 1732442 - HYPH B-NP D019797
16 106 109 1732442 125 CD I-NP D019797
17 109 110 1732442 - HYPH I-NP D019797
18 110 133 1732442 metaiodobenzylguanidine NN I-NP D019797
19 133 134 1732442 . . O O
20 135 147 1732442 Radiolabeled VBN B-NP D019797
21 148 171 1732442 metaiodobenzylguanidine NN I-NP D019797
22 172 173 1732442 ( ( O O
23 173 177 1732442 MIBG NN B-NP D019797
24 177 178 1732442 ) ) O O
25 178 179 1732442 , , O O
26 180 182 1732442 an DT B-NP O
27 183 189 1732442 analog NN I-NP O
28 190 192 1732442 of IN B-PP O
29 193 207 1732442 norepinephrine NN B-NP D009638
30 208 209 1732442 ( ( O O
31 209 211 1732442 NE NN B-NP D009638
32 211 212 1732442 ) ) O O
33 212 213 1732442 , , O O
34 214 220 1732442 serves VBZ B-VP O
35 221 223 1732442 as IN B-PP O
36 224 226 1732442 an DT B-NP O
37 227 232 1732442 index NN I-NP O
38 233 235 1732442 of IN B-PP O
39 236 246 1732442 adrenergic JJ B-NP O
40 247 253 1732442 neuron NN I-NP O
41 254 263 1732442 integrity NN I-NP O
42 264 267 1732442 and CC I-NP O
43 268 276 1732442 function NN I-NP O
44 276 277 1732442 . . O O

1 278 283 1732442 Using VBG B-VP O
2 284 285 1732442 a DT B-NP O
3 286 289 1732442 rat NN I-NP O
4 290 295 1732442 model NN I-NP O
5 296 298 1732442 of IN B-PP O
6 299 309 1732442 adriamycin NN B-NP D004317
7 309 310 1732442 - HYPH B-NP O
8 310 317 1732442 induced VBN I-NP O
9 318 332 1732442 cardiomyopathy NN I-NP D009202
10 332 333 1732442 , , O O
11 334 336 1732442 we PRP B-NP O
12 337 343 1732442 tested VBD B-VP O
13 344 347 1732442 the DT B-NP O
14 348 358 1732442 hypothesis NN I-NP O
15 359 363 1732442 that IN B-SBAR O
16 364 372 1732442 abnormal JJ B-NP O
17 373 380 1732442 cardiac JJ I-NP O
18 381 391 1732442 adrenergic JJ I-NP O
19 392 398 1732442 neuron NN I-NP O
20 399 407 1732442 activity NN I-NP O
21 408 411 1732442 may MD B-VP O
22 412 418 1732442 appear VB I-VP O
23 419 422 1732442 and CC O O
24 423 425 1732442 be VB B-VP O
25 426 437 1732442 exacerbated VBN I-VP O
26 438 442 1732442 dose NN B-NP O
27 442 443 1732442 - HYPH B-ADVP O
28 443 454 1732442 dependently RB B-ADVP O
29 455 457 1732442 in IN B-PP O
30 458 468 1732442 adriamycin NN B-NP D004317
31 469 483 1732442 cardiomyopathy NN I-NP D009202
32 483 484 1732442 . . O O

1 485 488 1732442 The DT B-NP O
2 489 495 1732442 degree NN I-NP O
3 496 498 1732442 of IN B-PP O
4 499 507 1732442 vacuolar JJ B-NP C536522
5 508 520 1732442 degeneration NN I-NP C536522
6 521 523 1732442 of IN B-PP C536522
7 524 534 1732442 myocardial JJ B-NP C536522
8 535 540 1732442 cells NNS I-NP C536522
9 541 544 1732442 was VBD B-VP O
10 545 553 1732442 analyzed VBN I-VP O
11 554 556 1732442 in IN B-PP O
12 557 565 1732442 relation NN B-NP O
13 566 568 1732442 to TO B-PP O
14 569 572 1732442 the DT B-NP O
15 573 581 1732442 duration NN I-NP O
16 582 584 1732442 of IN B-PP O
17 585 595 1732442 adriamycin NN B-NP D004317
18 596 605 1732442 treatment NN I-NP O
19 606 607 1732442 ( ( O O
20 607 608 1732442 2 CD B-NP O
21 609 611 1732442 mg NN I-NP O
22 611 612 1732442 / SYM B-NP O
23 612 614 1732442 kg NN I-NP O
24 614 615 1732442 , , O O
25 616 620 1732442 once RB B-ADVP O
26 621 622 1732442 a DT B-NP O
27 623 627 1732442 week NN I-NP O
28 627 628 1732442 ) ) O O
29 628 629 1732442 . . O O

1 630 635 1732442 There EX B-NP O
2 636 640 1732442 were VBD B-VP O
3 641 643 1732442 no DT B-NP O
4 644 657 1732442 abnormalities NNS I-NP O
5 658 660 1732442 or CC O O
6 661 665 1732442 only RB B-NP O
7 666 674 1732442 isolated VBN I-NP O
8 675 687 1732442 degeneration NN I-NP O
9 688 690 1732442 in IN B-PP O
10 691 694 1732442 the DT B-NP O
11 695 696 1732442 1 CD I-NP O
12 696 697 1732442 - HYPH I-NP O
13 698 700 1732442 or CC I-NP O
14 701 702 1732442 2 CD I-NP O
15 702 703 1732442 - HYPH I-NP O
16 703 705 1732442 wk NN I-NP O
17 706 715 1732442 treatment NN I-NP O
18 716 722 1732442 groups NNS I-NP O
19 722 723 1732442 , , O O
20 724 732 1732442 isolated VBN B-VP O
21 733 735 1732442 or CC O O
22 736 745 1732442 scattered VBN B-VP O
23 746 758 1732442 degeneration NN B-NP O
24 759 761 1732442 in IN B-PP O
25 762 766 1732442 half NN B-NP O
26 767 769 1732442 of IN B-PP O
27 770 773 1732442 the DT B-NP O
28 774 775 1732442 3 CD I-NP O
29 775 776 1732442 - HYPH I-NP O
30 776 778 1732442 wk NN I-NP O
31 779 784 1732442 group NN I-NP O
32 784 785 1732442 , , O O
33 786 794 1732442 frequent JJ B-NP O
34 795 804 1732442 scattered VBN I-NP O
35 805 817 1732442 degeneration NN I-NP O
36 818 820 1732442 in IN B-PP O
37 821 824 1732442 the DT B-NP O
38 825 826 1732442 4 CD I-NP O
39 826 827 1732442 - HYPH I-NP O
40 827 829 1732442 wk NN I-NP O
41 830 835 1732442 group NN I-NP O
42 835 836 1732442 , , O O
43 837 846 1732442 scattered JJ B-NP O
44 847 849 1732442 or CC I-NP O
45 850 855 1732442 focal JJ I-NP O
46 856 868 1732442 degeneration NN I-NP O
47 869 871 1732442 in IN B-PP O
48 872 875 1732442 the DT B-NP O
49 876 877 1732442 5 CD I-NP O
50 877 878 1732442 - HYPH I-NP O
51 878 880 1732442 wk NN I-NP O
52 881 886 1732442 group NN I-NP O
53 886 887 1732442 , , O O
54 888 891 1732442 and CC O O
55 892 901 1732442 extensive JJ B-NP O
56 902 914 1732442 degeneration NN I-NP O
57 915 917 1732442 in IN B-PP O
58 918 921 1732442 the DT B-NP O
59 922 923 1732442 8 CD I-NP O
60 923 924 1732442 - HYPH I-NP O
61 924 926 1732442 wk NN I-NP O
62 927 932 1732442 group NN I-NP O
63 932 933 1732442 . . O O

1 934 944 1732442 Myocardial JJ B-NP O
2 945 957 1732442 accumulation NN I-NP O
3 958 960 1732442 of IN B-PP O
4 961 971 1732442 [125I]MIBG NN B-NP D019797
5 972 973 1732442 4 CD I-NP O
6 974 976 1732442 hr NN I-NP O
7 977 982 1732442 after IN B-PP O
8 983 994 1732442 intravenous JJ B-NP O
9 995 1004 1732442 injection NN I-NP O
10 1005 1008 1732442 did VBD B-VP O
11 1009 1012 1732442 not RB I-VP O
12 1013 1019 1732442 differ VB I-VP O
13 1020 1027 1732442 between IN B-PP O
14 1028 1031 1732442 the DT B-NP O
15 1032 1040 1732442 controls NNS I-NP O
16 1041 1044 1732442 and CC O O
17 1045 1048 1732442 the DT B-NP O
18 1049 1055 1732442 groups NNS I-NP O
19 1056 1063 1732442 treated VBN B-VP O
20 1064 1065 1732442 3 CD B-NP O
21 1066 1068 1732442 wk NN I-NP O
22 1069 1071 1732442 or CC I-NP O
23 1072 1076 1732442 less JJR I-NP O
24 1076 1077 1732442 . . O O

1 1078 1085 1732442 However RB B-ADVP O
2 1085 1086 1732442 , , O O
3 1087 1090 1732442 the DT B-NP O
4 1091 1092 1732442 4 CD I-NP O
5 1092 1093 1732442 - HYPH I-NP O
6 1093 1095 1732442 wk NN I-NP O
7 1096 1101 1732442 group NN I-NP O
8 1102 1105 1732442 had VBD B-VP O
9 1106 1107 1732442 a DT B-NP O
10 1108 1116 1732442 slightly RB I-NP O
11 1117 1122 1732442 lower JJR I-NP O
12 1123 1135 1732442 accumulation NN I-NP O
13 1136 1138 1732442 in IN B-PP O
14 1139 1142 1732442 the DT B-NP O
15 1143 1148 1732442 right JJ I-NP O
16 1149 1160 1732442 ventricular JJ I-NP O
17 1161 1165 1732442 wall NN I-NP O
18 1166 1167 1732442 ( ( O O
19 1167 1170 1732442 82% CD B-NP O
20 1171 1173 1732442 of IN B-PP O
21 1174 1177 1732442 the DT B-NP O
22 1178 1185 1732442 control NN I-NP O
23 1185 1186 1732442 ) ) O O
24 1187 1190 1732442 and CC O O
25 1191 1204 1732442 significantly RB B-NP O
26 1205 1210 1732442 lower JJR I-NP O
27 1211 1223 1732442 accumulation NN I-NP O
28 1224 1226 1732442 in IN B-PP O
29 1227 1230 1732442 the DT B-NP O
30 1231 1235 1732442 left JJ I-NP O
31 1236 1247 1732442 ventricular JJ I-NP O
32 1248 1252 1732442 wall NN I-NP O
33 1253 1254 1732442 ( ( O O
34 1254 1259 1732442 about RB B-NP O
35 1260 1263 1732442 66% CD I-NP O
36 1264 1266 1732442 of IN B-PP O
37 1267 1270 1732442 the DT B-NP O
38 1271 1278 1732442 control NN I-NP O
39 1278 1279 1732442 : : O O
40 1280 1281 1732442 p NN B-NP O
41 1282 1286 1732442 less JJR B-ADJP O
42 1287 1291 1732442 than IN B-PP O
43 1292 1296 1732442 0.05 CD B-NP O
44 1296 1297 1732442 ) ) O O
45 1297 1298 1732442 . . O O

1 1299 1301 1732442 In IN B-PP O
2 1302 1305 1732442 the DT B-NP O
3 1306 1307 1732442 5 CD I-NP O
4 1307 1308 1732442 - HYPH I-NP O
5 1308 1310 1732442 wk NN I-NP O
6 1311 1316 1732442 group NN I-NP O
7 1316 1317 1732442 , , O O
8 1318 1322 1732442 MIBG NN B-NP D019797
9 1323 1335 1732442 accumulation NN I-NP O
10 1336 1338 1732442 in IN B-PP O
11 1339 1342 1732442 the DT B-NP O
12 1343 1348 1732442 right JJ I-NP O
13 1349 1352 1732442 and CC I-NP O
14 1353 1357 1732442 left JJ I-NP O
15 1358 1369 1732442 ventricular JJ I-NP O
16 1370 1374 1732442 wall NN I-NP O
17 1375 1378 1732442 was VBD B-VP O
18 1379 1382 1732442 35% CD B-NP O
19 1383 1386 1732442 and CC I-NP O
20 1387 1390 1732442 27% CD I-NP O
21 1391 1393 1732442 of IN B-PP O
22 1394 1398 1732442 that DT B-NP O
23 1399 1401 1732442 in IN B-PP O
24 1402 1410 1732442 controls NNS B-NP O
25 1410 1411 1732442 , , O O
26 1412 1424 1732442 respectively RB B-ADVP O
27 1425 1426 1732442 ( ( O O
28 1426 1427 1732442 p NN B-NP O
29 1428 1432 1732442 less JJR B-ADJP O
30 1433 1437 1732442 than IN B-PP O
31 1438 1443 1732442 0.001 CD B-NP O
32 1443 1444 1732442 ) ) O O
33 1444 1445 1732442 . . O O

1 1446 1448 1732442 In IN B-PP O
2 1449 1452 1732442 the DT B-NP O
3 1453 1454 1732442 8 CD I-NP O
4 1454 1455 1732442 - HYPH I-NP O
5 1455 1457 1732442 wk NN I-NP O
6 1458 1463 1732442 group NN I-NP O
7 1463 1464 1732442 , , O O
8 1465 1469 1732442 MIBG NN B-NP D019797
9 1470 1482 1732442 accumulation NN I-NP O
10 1483 1485 1732442 in IN B-PP O
11 1486 1489 1732442 the DT B-NP O
12 1490 1495 1732442 right JJ I-NP O
13 1496 1499 1732442 and CC I-NP O
14 1500 1504 1732442 left JJ I-NP O
15 1505 1516 1732442 ventricular JJ I-NP O
16 1517 1521 1732442 wall NN I-NP O
17 1522 1525 1732442 was VBD B-VP O
18 1526 1529 1732442 18% NN B-NP O
19 1530 1533 1732442 and CC I-NP O
20 1534 1537 1732442 14% NN I-NP O
21 1538 1540 1732442 of IN B-PP O
22 1541 1545 1732442 that DT B-NP O
23 1546 1548 1732442 in IN B-PP O
24 1549 1557 1732442 controls NNS B-NP O
25 1557 1558 1732442 , , O O
26 1559 1571 1732442 respectively RB B-ADVP O
27 1572 1573 1732442 ( ( O O
28 1573 1574 1732442 p NN B-NP O
29 1575 1579 1732442 less JJR B-ADJP O
30 1580 1584 1732442 than IN B-PP O
31 1585 1590 1732442 0.001 CD B-NP O
32 1590 1591 1732442 ) ) O O
33 1591 1592 1732442 . . O O

1 1593 1597 1732442 Thus RB B-ADVP O
2 1597 1598 1732442 , , O O
3 1599 1603 1732442 MIBG NN B-NP D019797
4 1604 1616 1732442 accumulation NN I-NP O
5 1617 1619 1732442 in IN B-PP O
6 1620 1623 1732442 the DT B-NP O
7 1624 1634 1732442 myocardium NN I-NP O
8 1635 1644 1732442 decreased VBD B-VP O
9 1645 1647 1732442 in IN B-PP O
10 1648 1650 1732442 an DT B-NP O
11 1651 1661 1732442 adriamycin NN I-NP D004317
12 1662 1666 1732442 dose NN I-NP O
13 1666 1667 1732442 - HYPH B-NP O
14 1667 1676 1732442 dependent JJ I-NP O
15 1677 1683 1732442 manner NN I-NP O
16 1683 1684 1732442 . . O O

1 1685 1688 1732442 The DT B-NP O
2 1689 1699 1732442 appearance NN I-NP O
3 1700 1702 1732442 of IN B-PP O
4 1703 1711 1732442 impaired JJ B-NP O
5 1712 1719 1732442 cardiac JJ I-NP O
6 1720 1730 1732442 adrenergic JJ I-NP O
7 1731 1737 1732442 neuron NN I-NP O
8 1738 1746 1732442 activity NN I-NP O
9 1747 1749 1732442 in IN B-PP O
10 1750 1753 1732442 the DT B-NP O
11 1754 1762 1732442 presence NN I-NP O
12 1763 1765 1732442 of IN B-PP O
13 1766 1772 1732442 slight JJ B-NP O
14 1773 1783 1732442 myocardial JJ I-NP D009202
15 1784 1794 1732442 impairment NN I-NP D009202
16 1795 1796 1732442 ( ( O O
17 1796 1805 1732442 scattered VBN B-VP O
18 1806 1808 1732442 or CC O O
19 1809 1814 1732442 focal JJ B-NP O
20 1815 1823 1732442 vacuolar JJ I-NP C536522
21 1824 1836 1732442 degeneration NN I-NP C536522
22 1836 1837 1732442 ) ) O O
23 1838 1847 1732442 indicates VBZ B-VP O
24 1848 1852 1732442 that IN B-SBAR O
25 1853 1857 1732442 MIBG NN B-NP D019797
26 1858 1870 1732442 scintigraphy NN I-NP O
27 1871 1874 1732442 may MD B-VP O
28 1875 1877 1732442 be VB I-VP O
29 1878 1879 1732442 a DT B-NP O
30 1880 1886 1732442 useful JJ I-NP O
31 1887 1893 1732442 method NN I-NP O
32 1894 1897 1732442 for IN B-PP O
33 1898 1907 1732442 detection NN B-NP O
34 1908 1910 1732442 of IN B-PP O
35 1911 1921 1732442 adriamycin NN B-NP D004317
36 1921 1922 1732442 - HYPH B-NP O
37 1922 1929 1732442 induced VBN I-NP O
38 1930 1944 1732442 cardiomyopathy NN I-NP D009202
39 1944 1945 1732442 . . O O

1 0 0 3300918 -DOCSTART- -X- -X- O

1 0 2 3300918 St NNP B-NP D004881
2 2 3 3300918 . . I-NP D004881
3 4 13 3300918 Anthony's NNP I-NP D004881
4 14 18 3300918 fire NN I-NP D004881
5 18 19 3300918 , , O O
6 20 24 3300918 then RB B-ADVP O
7 25 28 3300918 and CC O O
8 29 32 3300918 now RB B-ADVP O
9 32 33 3300918 : : O O
10 34 35 3300918 a DT B-NP O
11 36 40 3300918 case NN I-NP O
12 41 47 3300918 report NN I-NP O
13 48 51 3300918 and CC O O
14 52 62 3300918 historical JJ B-NP O
15 63 69 3300918 review NN I-NP O
16 69 70 3300918 . . O O
17 71 72 3300918 A DT B-NP O
18 73 77 3300918 rare JJ I-NP O
19 78 82 3300918 case NN I-NP O
20 83 85 3300918 of IN B-PP O
21 86 92 3300918 morbid NN B-NP O
22 93 102 3300918 vasospasm NN I-NP D014652
23 102 103 3300918 , , O O
24 104 112 3300918 together RB B-ADVP O
25 113 117 3300918 with IN B-PP O
26 118 126 3300918 striking JJ B-NP O
27 127 139 3300918 angiographic JJ I-NP O
28 140 148 3300918 findings NNS I-NP O
29 148 149 3300918 , , O O
30 150 152 3300918 is VBZ B-VP O
31 153 162 3300918 described VBN I-VP O
32 163 172 3300918 secondary JJ B-ADJP O
33 173 175 3300918 to TO B-PP O
34 176 179 3300918 the DT B-NP O
35 180 189 3300918 ingestion NN I-NP O
36 190 192 3300918 of IN B-PP O
37 193 205 3300918 methysergide NN B-NP D008784
38 206 208 3300918 by IN B-PP O
39 209 210 3300918 a DT B-NP O
40 211 213 3300918 48 CD I-NP O
41 213 214 3300918 - HYPH I-NP O
42 214 218 3300918 year NN I-NP O
43 218 219 3300918 - HYPH O O
44 219 222 3300918 old JJ B-NP O
45 223 228 3300918 woman NN I-NP O
46 228 229 3300918 . . O O

1 230 231 3300918 A DT B-NP O
2 232 237 3300918 brief JJ I-NP O
3 238 244 3300918 review NN I-NP O
4 245 247 3300918 of IN B-PP O
5 248 251 3300918 the DT B-NP O
6 252 262 3300918 literature NN I-NP O
7 263 265 3300918 on IN B-PP O
8 266 273 3300918 similar JJ B-NP O
9 274 279 3300918 cases NNS I-NP O
10 280 282 3300918 is VBZ B-VP O
11 283 292 3300918 presented VBN I-VP O
12 292 293 3300918 . . O O

1 294 295 3300918 A DT B-NP O
2 296 306 3300918 discussion NN I-NP O
3 307 309 3300918 of IN B-PP O
4 310 313 3300918 the DT B-NP O
5 314 321 3300918 history NN I-NP O
6 322 324 3300918 of IN B-PP O
7 325 330 3300918 ergot NN B-NP D004876
8 331 339 3300918 includes VBZ B-VP O
9 340 343 3300918 its PRP$ B-NP O
10 344 352 3300918 original JJ I-NP O
11 353 362 3300918 discovery NN I-NP O
12 362 363 3300918 , , O O
13 364 367 3300918 the DT B-NP O
14 368 377 3300918 epidemics NNS I-NP O
15 378 380 3300918 of IN B-PP O
16 381 389 3300918 gangrene NN B-NP D005734
17 390 394 3300918 that IN B-NP O
18 395 397 3300918 it PRP B-NP O
19 398 401 3300918 has VBZ B-VP O
20 402 408 3300918 caused VBN I-VP O
21 409 416 3300918 through IN B-PP O
22 417 420 3300918 the DT B-NP O
23 421 425 3300918 ages NNS I-NP O
24 426 429 3300918 and CC O O
25 430 433 3300918 its PRP$ B-NP O
26 434 438 3300918 past JJ I-NP O
27 439 442 3300918 and CC I-NP O
28 443 450 3300918 present JJ I-NP O
29 451 455 3300918 role NN I-NP O
30 456 458 3300918 in IN B-PP O
31 459 462 3300918 the DT B-NP O
32 463 473 3300918 management NN I-NP O
33 474 476 3300918 of IN B-PP O
34 477 485 3300918 migraine NN B-NP D008881
35 486 494 3300918 headache NN I-NP D008881
36 494 495 3300918 . . O O

1 496 503 3300918 Despite IN B-PP O
2 504 507 3300918 the DT B-NP O
3 508 514 3300918 advent NN I-NP O
4 515 517 3300918 of IN B-PP O
5 518 525 3300918 calcium NN B-NP D002118
6 526 533 3300918 channel NN I-NP O
7 534 542 3300918 blockers NNS I-NP O
8 543 546 3300918 and CC O O
9 547 551 3300918 beta SYM B-NP O
10 551 552 3300918 - HYPH O O
11 552 562 3300918 adrenergic JJ B-NP O
12 563 574 3300918 antagonists NNS I-NP O
13 574 575 3300918 , , O O
14 576 581 3300918 ergot NN B-NP D004876
15 582 594 3300918 preparations NNS I-NP O
16 595 603 3300918 continue VBP B-VP O
17 604 606 3300918 to TO I-VP O
18 607 611 3300918 play VB I-VP O
19 612 613 3300918 a DT B-NP O
20 614 619 3300918 major JJ I-NP O
21 620 624 3300918 role NN I-NP O
22 625 627 3300918 in IN B-PP O
23 628 636 3300918 migraine NN B-NP D008881
24 637 644 3300918 therapy NN I-NP O
25 644 645 3300918 , , O O
26 646 648 3300918 so IN B-SBAR O
27 649 653 3300918 that IN I-SBAR O
28 654 657 3300918 the DT B-NP O
29 658 664 3300918 danger NN I-NP O
30 665 667 3300918 of IN B-PP O
31 668 670 3300918 St NNP B-NP O
32 670 671 3300918 . . O O

1 672 681 3300918 Anthony's NNS B-NP O
2 682 686 3300918 fire NN I-NP O
3 687 695 3300918 persists VBZ B-VP O
4 695 696 3300918 . . O O

1 0 0 6415512 -DOCSTART- -X- -X- O

1 0 9 6415512 Myoclonic JJ B-NP D004831
2 9 10 6415512 , , I-NP D004831
3 11 17 6415512 atonic JJ I-NP D004831
4 17 18 6415512 , , O D004831
5 19 22 6415512 and CC O D004831
6 23 30 6415512 absence NN B-NP D004831
7 31 39 6415512 seizures NNS I-NP D004831
8 40 49 6415512 following VBG B-PP O
9 50 61 6415512 institution NN B-NP O
10 62 64 6415512 of IN B-PP O
11 65 78 6415512 carbamazepine NN B-NP D002220
12 79 86 6415512 therapy NN I-NP O
13 87 89 6415512 in IN B-PP O
14 90 98 6415512 children NNS B-NP O
15 98 99 6415512 . . O O
16 100 104 6415512 Five CD B-NP O
17 105 113 6415512 children NNS I-NP O
18 113 114 6415512 , , O O
19 115 119 6415512 aged VBN B-VP O
20 120 121 6415512 3 CD B-NP O
21 122 124 6415512 to TO I-NP O
22 125 127 6415512 11 CD I-NP O
23 128 133 6415512 years NNS I-NP O
24 133 134 6415512 , , O O
25 135 142 6415512 treated VBN B-VP O
26 143 147 6415512 with IN B-PP O
27 148 161 6415512 carbamazepine NN B-NP D002220
28 162 165 6415512 for IN B-PP O
29 166 174 6415512 epilepsy NN B-NP D004827
30 174 175 6415512 , , O O
31 176 179 6415512 had VBD B-VP O
32 180 182 6415512 an DT B-NP O
33 183 188 6415512 acute JJ I-NP O
34 189 197 6415512 aberrant JJ I-NP O
35 198 206 6415512 reaction NN I-NP O
36 207 220 6415512 characterized VBN B-VP O
37 221 223 6415512 by IN B-PP O
38 224 227 6415512 the DT B-NP O
39 228 233 6415512 onset NN I-NP O
40 234 236 6415512 of IN B-PP O
41 237 246 6415512 myoclonic JJ B-NP D004831
42 246 247 6415512 , , I-NP D004831
43 248 256 6415512 atypical JJ I-NP D004831
44 257 264 6415512 absence NN I-NP D004831
45 265 268 6415512 and CC O D004831
46 268 269 6415512 / SYM B-NP D004831
47 269 271 6415512 or CC O D004831
48 272 278 6415512 atonic JJ O D004831
49 279 280 6415512 ( ( O D004831
50 280 285 6415512 minor JJ B-NP D004831
51 286 291 6415512 motor NN I-NP D004831
52 291 292 6415512 ) ) O D004831
53 293 301 6415512 seizures NNS B-NP D004831
54 302 308 6415512 within IN B-PP O
55 309 310 6415512 a DT B-NP O
56 311 314 6415512 few JJ I-NP O
57 315 319 6415512 days NNS I-NP O
58 319 320 6415512 . . O O

1 321 325 6415512 When WRB B-ADVP O
2 326 329 6415512 the DT B-NP O
3 330 343 6415512 carbamazepine NN I-NP D002220
4 344 347 6415512 was VBD B-VP O
5 348 360 6415512 discontinued VBN I-VP O
6 360 361 6415512 , , O O
7 362 365 6415512 two CD B-NP O
8 366 368 6415512 of IN B-PP O
9 369 372 6415512 the DT B-NP O
10 373 381 6415512 children NNS I-NP O
11 382 390 6415512 returned VBD B-VP O
12 391 393 6415512 to TO B-PP O
13 394 399 6415512 their PRP$ B-NP O
14 400 406 6415512 former JJ I-NP O
15 407 412 6415512 state NN I-NP O
16 413 417 6415512 very RB B-ADVP O
17 418 425 6415512 quickly RB I-ADVP O
18 425 426 6415512 , , O O
19 427 430 6415512 two CD B-NP O
20 431 434 6415512 had VBD B-VP O
21 435 438 6415512 the DT B-NP O
22 439 444 6415512 minor JJ I-NP O
23 445 450 6415512 motor NN I-NP O
24 451 459 6415512 seizures NNS I-NP D012640
25 460 467 6415512 resolve VBP B-VP O
26 468 470 6415512 in IN B-PP O
27 471 472 6415512 3 CD B-NP O
28 473 476 6415512 and CC I-NP O
29 477 478 6415512 6 CD I-NP O
30 479 485 6415512 months NNS I-NP O
31 485 486 6415512 , , O O
32 487 490 6415512 and CC O O
33 491 494 6415512 one CD B-NP O
34 495 498 6415512 had VBD B-VP O
35 499 502 6415512 the DT B-NP O
36 503 511 6415512 seizures NNS I-NP D012640
37 512 519 6415512 persist VBP B-VP O
38 519 520 6415512 . . O O

1 521 524 6415512 The DT B-NP O
2 525 530 6415512 child NN I-NP O
3 531 533 6415512 in IN B-PP O
4 534 538 6415512 whom WP B-NP O
5 539 542 6415512 the DT B-NP O
6 543 551 6415512 seizures NNS I-NP D012640
7 552 561 6415512 persisted VBD B-VP O
8 562 565 6415512 was VBD B-VP O
9 566 571 6415512 later RB I-VP O
10 572 577 6415512 found VBN I-VP O
11 578 580 6415512 to TO I-VP O
12 581 585 6415512 have VB I-VP O
13 586 592 6415512 ceroid JJ B-NP D009472
14 593 607 6415512 lipofuscinosis NN I-NP D009472
15 607 608 6415512 . . O O

1 609 612 6415512 The DT B-NP O
2 613 618 6415512 other JJ I-NP O
3 619 627 6415512 children NNS I-NP O
4 628 631 6415512 are VBP B-VP O
5 632 637 6415512 doing VBG I-VP O
6 638 642 6415512 well RB B-ADVP O
7 643 645 6415512 on IN B-PP O
8 646 651 6415512 other JJ B-NP O
9 652 667 6415512 anticonvulsants NNS I-NP O
10 667 668 6415512 . . O O

1 0 0 6115999 -DOCSTART- -X- -X- O

1 0 7 6115999 Adverse JJ B-NP O
2 8 17 6115999 reactions NNS I-NP O
3 18 20 6115999 to TO B-PP O
4 21 35 6115999 bendrofluazide NN B-NP D001539
5 36 39 6115999 and CC I-NP O
6 40 51 6115999 propranolol NN I-NP D011433
7 52 55 6115999 for IN B-PP O
8 56 59 6115999 the DT B-NP O
9 60 69 6115999 treatment NN I-NP O
10 70 72 6115999 of IN B-PP O
11 73 77 6115999 mild JJ B-NP O
12 78 90 6115999 hypertension NN I-NP D006973
13 90 91 6115999 . . O O

1 92 98 6115999 Report NNP B-NP O
2 99 101 6115999 of IN B-PP O
3 102 109 6115999 Medical NNP B-NP O
4 110 118 6115999 Research NNP I-NP O
5 119 126 6115999 Council NNP I-NP O
6 127 134 6115999 Working NNP I-NP O
7 135 140 6115999 Party NNP I-NP O
8 141 143 6115999 on IN B-PP O
9 144 148 6115999 Mild NNP B-NP O
10 149 151 6115999 to TO B-PP O
11 152 160 6115999 Moderate NNP B-NP O
12 161 173 6115999 Hypertension NNP I-NP D006973
13 173 174 6115999 . . I-NP O
14 175 187 6115999 Participants NNPS I-NP O
15 188 190 6115999 in IN B-PP O
16 191 194 6115999 the DT B-NP O
17 195 202 6115999 Medical NNP I-NP O
18 203 211 6115999 Research NNP I-NP O
19 212 219 6115999 Council NNP I-NP O
20 220 229 6115999 treatment NN I-NP O
21 230 235 6115999 trial NN I-NP O
22 236 239 6115999 for IN B-PP O
23 240 244 6115999 mild JJ B-NP O
24 245 257 6115999 hypertension NN I-NP D006973
25 258 261 6115999 are VBP B-VP O
26 262 270 6115999 randomly RB I-VP O
27 271 280 6115999 allocated VBN I-VP O
28 281 283 6115999 to TO B-PP O
29 284 287 6115999 one CD B-NP O
30 288 290 6115999 of IN B-PP O
31 291 295 6115999 four CD B-NP O
32 296 305 6115999 treatment NN I-NP O
33 306 312 6115999 groups NNS I-NP O
34 312 313 6115999 : : O O
35 314 328 6115999 bendrofluazide NN B-NP D001539
36 328 329 6115999 , , O O
37 330 341 6115999 propranolol NN B-NP D011433
38 341 342 6115999 , , O O
39 343 345 6115999 or CC O O
40 346 347 6115999 a DT B-NP O
41 348 355 6115999 placebo NN I-NP O
42 356 359 6115999 for IN B-PP O
43 360 366 6115999 either DT B-NP O
44 367 369 6115999 of IN B-PP O
45 370 375 6115999 these DT B-NP O
46 376 381 6115999 drugs NNS I-NP O
47 381 382 6115999 . . O O

1 383 386 6115999 The DT B-NP O
2 387 392 6115999 trial NN I-NP O
3 393 395 6115999 is VBZ B-VP O
4 396 402 6115999 single JJ B-ADJP O
5 402 403 6115999 - HYPH O O
6 403 408 6115999 blind JJ B-ADJP O
7 408 409 6115999 . . O O

1 410 412 6115999 23 CD B-NP O
2 413 416 6115999 582 CD I-NP O
3 417 424 6115999 patient NN I-NP O
4 424 425 6115999 - HYPH B-NP O
5 425 430 6115999 years NNS I-NP O
6 431 433 6115999 of IN B-PP O
7 434 445 6115999 observation NN B-NP O
8 446 450 6115999 have VBP B-VP O
9 451 455 6115999 been VBN I-VP O
10 456 465 6115999 completed VBN I-VP O
11 466 468 6115999 so RB B-ADVP O
12 469 472 6115999 far RB I-ADVP O
13 472 473 6115999 , , O O
14 474 476 6115999 10 CD B-NP O
15 477 480 6115999 684 CD I-NP O
16 481 483 6115999 on IN B-PP O
17 484 490 6115999 active JJ B-NP O
18 491 496 6115999 drugs NNS I-NP O
19 497 500 6115999 and CC O O
20 501 503 6115999 12 CD B-NP O
21 504 507 6115999 898 CD I-NP O
22 508 510 6115999 on IN B-PP O
23 511 519 6115999 placebos NNS B-NP O
24 519 520 6115999 . . O O

1 521 524 6115999 The DT B-NP O
2 525 532 6115999 results NNS I-NP O
3 533 537 6115999 show VBP B-VP O
4 538 540 6115999 an DT B-NP O
5 541 552 6115999 association NN I-NP O
6 553 560 6115999 between IN B-PP O
7 561 575 6115999 bendrofluazide NN B-NP D001539
8 576 585 6115999 treatment NN I-NP O
9 586 589 6115999 and CC I-NP O
10 590 599 6115999 impotence NN I-NP D007172
11 599 600 6115999 , , O O
12 601 604 6115999 and CC O O
13 605 614 6115999 impotence NN B-NP D007172
14 615 619 6115999 also RB B-ADVP O
15 620 628 6115999 occurred VBD B-VP O
16 629 633 6115999 more RBR B-ADVP O
17 634 644 6115999 frequently RB I-ADVP O
18 645 647 6115999 in IN B-PP O
19 648 656 6115999 patients NNS B-NP O
20 657 663 6115999 taking VBG B-VP O
21 664 675 6115999 propranolol NN B-NP D011433
22 676 680 6115999 than IN B-PP O
23 681 683 6115999 in IN B-PP O
24 684 689 6115999 those DT B-NP O
25 690 696 6115999 taking VBG I-NP O
26 697 705 6115999 placebos NNS I-NP O
27 705 706 6115999 . . O O

1 707 712 6115999 Other JJ B-NP O
2 713 720 6115999 adverse JJ I-NP O
3 721 730 6115999 reactions NNS I-NP O
4 731 744 6115999 significantly RB B-VP O
5 745 751 6115999 linked VBN I-VP O
6 752 756 6115999 with IN B-PP O
7 757 763 6115999 active JJ B-NP O
8 764 769 6115999 drugs NNS I-NP O
9 770 777 6115999 include VBP B-VP O
10 778 786 6115999 impaired JJ B-NP D018149
11 787 794 6115999 glucose NN I-NP D018149
12 795 804 6115999 tolerance NN I-NP D018149
13 805 807 6115999 in IN B-PP O
14 808 811 6115999 men NNS B-NP O
15 812 815 6115999 and CC I-NP O
16 816 821 6115999 women NNS I-NP O
17 822 825 6115999 and CC O O
18 826 830 6115999 gout NN B-NP D006073
19 831 833 6115999 in IN B-PP O
20 834 837 6115999 men NNS B-NP O
21 837 838 6115999 , , O O
22 839 849 6115999 associated VBN B-VP O
23 850 854 6115999 with IN B-PP O
24 855 869 6115999 bendrofluazide NN B-NP D001539
25 870 879 6115999 treatment NN I-NP O
26 879 880 6115999 , , O O
27 881 884 6115999 and CC O O
28 885 894 6115999 Raynaud's NNS B-NP D011928
29 895 905 6115999 phenomenon NN I-NP D011928
30 906 909 6115999 and CC I-NP O
31 910 918 6115999 dyspnoea NN I-NP D004417
32 919 921 6115999 in IN B-PP O
33 922 925 6115999 men NNS B-NP O
34 926 929 6115999 and CC I-NP O
35 930 935 6115999 women NNS I-NP O
36 936 942 6115999 taking VBG B-VP O
37 943 954 6115999 propranolol NN B-NP D011433
38 954 955 6115999 . . O O

1 956 958 6115999 No DT B-NP O
2 959 966 6115999 corneal JJ I-NP D003316
3 967 974 6115999 disease NN I-NP D003316
4 975 977 6115999 is VBZ B-VP O
5 978 983 6115999 known VBN I-VP O
6 984 986 6115999 to TO I-VP O
7 987 991 6115999 have VB I-VP O
8 992 1000 6115999 occurred VBN I-VP O
9 1001 1003 6115999 in IN B-PP O
10 1004 1007 6115999 the DT B-NP O
11 1008 1019 6115999 propranolol NN I-NP D011433
12 1020 1025 6115999 group NN I-NP O
13 1025 1026 6115999 . . O O

1 1027 1031 6115999 Mean JJ B-NP O
2 1032 1037 6115999 serum NN I-NP O
3 1038 1047 6115999 potassium NN I-NP D011188
4 1048 1053 6115999 level NN I-NP O
5 1054 1058 6115999 fell VBD B-VP O
6 1058 1059 6115999 , , O O
7 1060 1063 6115999 and CC O O
8 1064 1068 6115999 urea NN B-NP D014508
9 1069 1072 6115999 and CC O O
10 1073 1077 6115999 uric JJ B-NP D014527
11 1078 1082 6115999 acid NN I-NP D014527
12 1083 1089 6115999 levels NNS I-NP O
13 1090 1094 6115999 rose VBD B-VP O
14 1094 1095 6115999 , , O O
15 1096 1098 6115999 in IN B-PP O
16 1099 1102 6115999 men NNS B-NP O
17 1103 1106 6115999 and CC I-NP O
18 1107 1112 6115999 women NNS I-NP O
19 1113 1119 6115999 taking VBG B-VP O
20 1120 1134 6115999 bendrofluazide NN B-NP D001539
21 1134 1135 6115999 . . O O

1 1136 1138 6115999 In IN B-PP O
2 1139 1142 6115999 the DT B-NP O
3 1143 1154 6115999 propranolol NN I-NP D011433
4 1155 1160 6115999 group NN I-NP O
5 1160 1161 6115999 , , O O
6 1162 1167 6115999 serum NN B-NP O
7 1168 1177 6115999 potassium NN I-NP D011188
8 1178 1181 6115999 and CC O O
9 1182 1186 6115999 uric JJ B-NP D014527
10 1187 1191 6115999 acid NN I-NP D014527
11 1192 1198 6115999 levels NNS I-NP O
12 1199 1203 6115999 rose VBD B-VP O
13 1204 1206 6115999 in IN B-PP O
14 1207 1211 6115999 both DT B-NP O
15 1212 1217 6115999 sexes NNS I-NP O
16 1217 1218 6115999 , , O O
17 1219 1222 6115999 but CC O O
18 1223 1226 6115999 the DT B-NP O
19 1227 1231 6115999 urea NN I-NP D014508
20 1232 1237 6115999 level NN I-NP O
21 1238 1242 6115999 rose VBD B-VP O
22 1243 1256 6115999 significantly RB B-ADVP O
23 1257 1259 6115999 in IN B-PP O
24 1260 1265 6115999 women NNS B-NP O
25 1266 1270 6115999 only RB B-ADVP O
26 1270 1271 6115999 . . O O

1 0 0 9105126 -DOCSTART- -X- -X- O

1 0 14 9105126 Postinfarction NN B-NP O
2 15 26 9105126 ventricular JJ I-NP D018658
3 27 33 9105126 septal JJ I-NP D018658
4 34 40 9105126 defect NN I-NP D018658
5 41 51 9105126 associated VBN B-VP O
6 52 56 9105126 with IN B-PP O
7 57 61 9105126 long JJ B-NP O
8 61 62 9105126 - HYPH I-NP O
9 62 66 9105126 term NN I-NP O
10 67 74 9105126 steroid NN I-NP D013256
11 75 82 9105126 therapy NN I-NP O
12 82 83 9105126 . . O O
13 84 87 9105126 Two CD B-NP O
14 88 93 9105126 cases NNS I-NP O
15 94 96 9105126 of IN B-PP O
16 97 111 9105126 postinfarction NN B-NP O
17 112 123 9105126 ventricular JJ I-NP D018658
18 124 130 9105126 septal JJ I-NP D018658
19 131 138 9105126 rupture NN I-NP D018658
20 139 141 9105126 in IN B-PP O
21 142 150 9105126 patients NNS B-NP O
22 151 153 9105126 on IN B-PP O
23 154 158 9105126 long JJ B-NP O
24 158 159 9105126 - HYPH I-NP O
25 159 163 9105126 term NN I-NP O
26 164 171 9105126 steroid NN I-NP D013256
27 172 179 9105126 therapy NN I-NP O
28 180 183 9105126 are VBP B-VP O
29 184 193 9105126 presented VBN I-VP O
30 194 197 9105126 and CC O O
31 198 201 9105126 the DT B-NP O
32 202 212 9105126 favourable JJ I-NP O
33 213 220 9105126 outcome NN I-NP O
34 221 223 9105126 in IN B-PP O
35 224 228 9105126 both DT B-NP O
36 229 234 9105126 cases NNS I-NP O
37 235 244 9105126 described VBN B-VP O
38 244 245 9105126 . . O O

1 246 247 9105126 A DT B-NP O
2 248 256 9105126 possible JJ I-NP O
3 257 268 9105126 association NN I-NP O
4 269 276 9105126 between IN B-PP O
5 277 284 9105126 steroid NN B-NP D013256
6 285 292 9105126 therapy NN I-NP O
7 293 296 9105126 and CC O O
8 297 307 9105126 subsequent JJ B-NP O
9 308 322 9105126 postinfarction NN I-NP O
10 323 329 9105126 septal JJ I-NP D018658
11 330 337 9105126 rupture NN I-NP D018658
12 338 340 9105126 is VBZ B-VP O
13 341 350 9105126 discussed VBN I-VP O
14 350 351 9105126 . . O O

1 0 0 18086064 -DOCSTART- -X- -X- O

1 0 15 18086064 Dexmedetomidine NN B-NP D020927
2 16 19 18086064 and CC I-NP O
3 20 27 18086064 cardiac JJ I-NP O
4 28 38 18086064 protection NN I-NP O
5 39 42 18086064 for IN B-PP O
6 43 46 18086064 non AFX B-NP O
7 46 47 18086064 - HYPH I-NP O
8 47 54 18086064 cardiac JJ I-NP O
9 55 62 18086064 surgery NN I-NP O
10 62 63 18086064 : : O O
11 64 65 18086064 a DT B-NP O
12 66 70 18086064 meta JJ I-NP O
13 70 71 18086064 - HYPH I-NP O
14 71 79 18086064 analysis NN I-NP O
15 80 82 18086064 of IN B-PP O
16 83 93 18086064 randomised VBN B-NP O
17 94 104 18086064 controlled VBN I-NP O
18 105 111 18086064 trials NNS I-NP O
19 111 112 18086064 . . O O
20 113 115 18086064 We PRP B-NP O
21 116 125 18086064 conducted VBD B-VP O
22 126 127 18086064 a DT B-NP O
23 128 138 18086064 systematic JJ I-NP O
24 139 145 18086064 review NN I-NP O
25 146 148 18086064 of IN B-PP O
26 149 152 18086064 the DT B-NP O
27 153 160 18086064 effects NNS I-NP O
28 161 163 18086064 of IN B-PP O
29 164 179 18086064 dexmedetomidine NN B-NP D020927
30 180 182 18086064 on IN B-PP O
31 183 190 18086064 cardiac JJ B-NP O
32 191 199 18086064 outcomes NNS I-NP O
33 200 209 18086064 following VBG B-PP O
34 210 213 18086064 non AFX B-NP O
35 213 214 18086064 - HYPH I-NP O
36 214 221 18086064 cardiac JJ I-NP O
37 222 229 18086064 surgery NN I-NP O
38 229 230 18086064 . . O O

1 231 233 18086064 We PRP B-NP O
2 234 242 18086064 included VBD B-VP O
3 243 254 18086064 prospective JJ B-ADJP O
4 254 255 18086064 , , O O
5 256 266 18086064 randomised VBD B-VP O
6 267 271 18086064 peri AFX B-NP O
7 271 272 18086064 - HYPH I-NP O
8 272 281 18086064 operative JJ B-NP O
9 282 289 18086064 studies NNS I-NP O
10 290 292 18086064 of IN B-PP O
11 293 308 18086064 dexmedetomidine NN B-NP D020927
12 309 313 18086064 that WDT B-NP O
13 314 322 18086064 reported VBD B-VP O
14 323 332 18086064 mortality NN B-NP O
15 332 333 18086064 , , O O
16 334 341 18086064 cardiac JJ B-NP O
17 342 351 18086064 morbidity NN I-NP O
18 352 354 18086064 or CC O O
19 355 362 18086064 adverse JJ B-NP O
20 363 367 18086064 drug NN I-NP O
21 368 374 18086064 events NNS I-NP O
22 374 375 18086064 . . O O

1 376 377 18086064 A DT B-NP O
2 378 384 18086064 PubMed NNP I-NP O
3 385 392 18086064 Central NNP I-NP O
4 393 396 18086064 and CC I-NP O
5 397 403 18086064 EMBASE NNP I-NP O
6 404 410 18086064 search NN I-NP O
7 411 414 18086064 was VBD B-VP O
8 415 424 18086064 conducted VBN I-VP O
9 425 427 18086064 up RP B-PRT O
10 428 430 18086064 to TO B-PP O
11 431 435 18086064 July NNP B-NP O
12 436 440 18086064 2007 CD I-NP O
13 440 441 18086064 . . O O

1 442 445 18086064 The DT B-NP O
2 446 455 18086064 reference NN I-NP O
3 456 461 18086064 lists NNS I-NP O
4 462 464 18086064 of IN B-PP O
5 465 475 18086064 identified VBN B-NP O
6 476 482 18086064 papers NNS I-NP O
7 483 487 18086064 were VBD B-VP O
8 488 496 18086064 examined VBN I-VP O
9 497 500 18086064 for IN B-PP O
10 501 508 18086064 further JJ B-NP O
11 509 515 18086064 trials NNS I-NP O
12 515 516 18086064 . . O O

1 517 519 18086064 Of IN B-PP O
2 520 523 18086064 425 CD B-NP O
3 524 531 18086064 studies NNS I-NP O
4 532 542 18086064 identified VBN B-VP O
5 542 543 18086064 , , O O
6 544 546 18086064 20 CD B-NP O
7 547 551 18086064 were VBD B-VP O
8 552 560 18086064 included VBN I-VP O
9 561 563 18086064 in IN B-PP O
10 564 567 18086064 the DT B-NP O
11 568 572 18086064 meta JJ I-NP O
12 572 573 18086064 - HYPH I-NP O
13 573 581 18086064 analysis NN I-NP O
14 582 583 18086064 ( ( O O
15 583 586 18086064 840 CD B-NP O
16 587 595 18086064 patients NNS I-NP O
17 595 596 18086064 ) ) O O
18 596 597 18086064 . . O O

1 598 613 18086064 Dexmedetomidine NN B-NP D020927
2 614 617 18086064 was VBD B-VP O
3 618 628 18086064 associated VBN I-VP O
4 629 633 18086064 with IN B-PP O
5 634 635 18086064 a DT B-NP O
6 636 641 18086064 trend NN I-NP O
7 642 649 18086064 towards IN B-PP O
8 650 658 18086064 improved VBN B-NP O
9 659 666 18086064 cardiac JJ I-NP O
10 667 675 18086064 outcomes NNS I-NP O
11 675 676 18086064 ; : O O
12 677 680 18086064 all RB B-NP O
13 680 681 18086064 - HYPH I-NP O
14 681 686 18086064 cause NN I-NP O
15 687 696 18086064 mortality NN I-NP O
16 697 698 18086064 ( ( O O
17 698 700 18086064 OR NN B-NP O
18 701 705 18086064 0.27 CD I-NP O
19 705 706 18086064 , , O O
20 707 710 18086064 95% CD B-NP O
21 711 713 18086064 CI NNP I-NP O
22 714 718 18086064 0.01 CD I-NP O
23 718 719 18086064 - HYPH I-NP O
24 719 723 18086064 7.13 CD I-NP O
25 723 724 18086064 , , O O
26 725 726 18086064 p NN B-NP O
27 727 728 18086064 = SYM B-VP O
28 729 733 18086064 0.44 CD B-NP O
29 733 734 18086064 ) ) O O
30 734 735 18086064 , , O O
31 736 739 18086064 non AFX O O
32 739 740 18086064 - HYPH B-NP O
33 740 745 18086064 fatal JJ I-NP O
34 746 756 18086064 myocardial JJ I-NP D009203
35 757 767 18086064 infarction NN I-NP D009203
36 768 769 18086064 ( ( O O
37 769 771 18086064 OR NN B-NP O
38 772 776 18086064 0.26 CD I-NP O
39 776 777 18086064 , , O O
40 778 781 18086064 95% CD B-NP O
41 782 784 18086064 CI NNP I-NP O
42 785 789 18086064 0.04 CD I-NP O
43 789 790 18086064 - HYPH I-NP O
44 790 794 18086064 1.60 CD I-NP O
45 794 795 18086064 , , O O
46 796 797 18086064 p NN B-NP O
47 798 799 18086064 = SYM B-VP O
48 800 804 18086064 0.14 CD B-NP O
49 804 805 18086064 ) ) O O
50 805 806 18086064 , , O O
51 807 810 18086064 and CC O O
52 811 821 18086064 myocardial JJ B-NP D017202
53 822 831 18086064 ischaemia NN I-NP D017202
54 832 833 18086064 ( ( O O
55 833 835 18086064 OR NN B-NP O
56 836 840 18086064 0.65 CD I-NP O
57 840 841 18086064 , , O O
58 842 845 18086064 95% CD B-NP O
59 846 848 18086064 CI NNP I-NP O
60 849 853 18086064 0.26 CD I-NP O
61 853 854 18086064 - HYPH I-NP O
62 854 858 18086064 1.63 CD I-NP O
63 858 859 18086064 , , O O
64 860 861 18086064 p NN B-NP O
65 862 863 18086064 = SYM B-VP O
66 864 868 18086064 0.36 CD B-NP O
67 868 869 18086064 ) ) O O
68 869 870 18086064 . . O O

1 871 875 18086064 Peri NNP B-NP O
2 875 876 18086064 - HYPH I-NP O
3 876 885 18086064 operative JJ I-NP O
4 886 897 18086064 hypotension NN I-NP D007022
5 898 899 18086064 ( ( O O
6 899 902 18086064 26% CD B-NP O
7 902 903 18086064 , , O O
8 904 906 18086064 OR NNP B-NP O
9 907 911 18086064 3.80 CD I-NP O
10 911 912 18086064 , , I-NP O
11 913 916 18086064 95% CD I-NP O
12 917 919 18086064 CI NNP I-NP O
13 920 924 18086064 1.91 CD I-NP O
14 924 925 18086064 - HYPH I-NP O
15 925 929 18086064 7.54 CD I-NP O
16 929 930 18086064 , , O O
17 931 932 18086064 p NN B-NP O
18 933 934 18086064 = SYM B-VP O
19 935 941 18086064 0.0001 CD B-NP O
20 941 942 18086064 ) ) O O
21 943 946 18086064 and CC O O
22 947 958 18086064 bradycardia NN B-NP D001919
23 959 960 18086064 ( ( O O
24 960 963 18086064 17% NN B-NP O
25 963 964 18086064 , , O O
26 965 967 18086064 OR NNP B-NP O
27 968 972 18086064 5.45 CD I-NP O
28 972 973 18086064 , , I-NP O
29 974 977 18086064 95% CD I-NP O
30 978 980 18086064 CI NNP I-NP O
31 981 985 18086064 2.98 CD I-NP O
32 985 986 18086064 - HYPH I-NP O
33 986 990 18086064 9.95 CD I-NP O
34 990 991 18086064 , , O O
35 992 993 18086064 p NN B-NP O
36 994 995 18086064 < SYM B-NP O
37 996 1003 18086064 0.00001 CD I-NP O
38 1003 1004 18086064 ) ) O O
39 1005 1009 18086064 were VBD B-VP O
40 1010 1023 18086064 significantly RB I-VP O
41 1024 1033 18086064 increased VBN I-VP O
42 1033 1034 18086064 . . O O

1 1035 1037 18086064 An DT B-NP O
2 1038 1053 18086064 anticholinergic JJ I-NP O
3 1054 1057 18086064 did VBD B-VP O
4 1058 1061 18086064 not RB I-VP O
5 1062 1068 18086064 reduce VB I-VP O
6 1069 1072 18086064 the DT B-NP O
7 1073 1082 18086064 incidence NN I-NP O
8 1083 1085 18086064 of IN B-PP O
9 1086 1097 18086064 bradycardia NN B-NP D001919
10 1098 1099 18086064 ( ( O O
11 1099 1100 18086064 p NN B-NP O
12 1101 1102 18086064 = SYM B-VP O
13 1103 1107 18086064 0.43 CD B-NP O
14 1107 1108 18086064 ) ) O O
15 1108 1109 18086064 . . O O

1 1110 1111 18086064 A DT B-NP O
2 1112 1122 18086064 randomised VBN I-NP O
3 1123 1130 18086064 placebo NN I-NP O
4 1130 1131 18086064 - HYPH O O
5 1131 1141 18086064 controlled VBN B-NP O
6 1142 1147 18086064 trial NN I-NP O
7 1148 1150 18086064 of IN B-PP O
8 1151 1166 18086064 dexmedetomidine NN B-NP D020927
9 1167 1169 18086064 is VBZ B-VP O
10 1170 1179 18086064 warranted VBN I-VP O
11 1179 1180 18086064 . . O O

1 0 0 8546130 -DOCSTART- -X- -X- O

1 0 14 8546130 Clarithromycin NN B-NP D017291
2 14 15 8546130 - HYPH O O
3 15 25 8546130 associated VBN B-VP O
4 26 32 8546130 visual JJ B-NP D006212
5 33 47 8546130 hallucinations NNS I-NP D006212
6 48 50 8546130 in IN B-PP O
7 51 52 8546130 a DT B-NP O
8 53 60 8546130 patient NN I-NP O
9 61 65 8546130 with IN B-PP O
10 66 73 8546130 chronic JJ B-NP D007676
11 74 79 8546130 renal JJ I-NP D007676
12 80 87 8546130 failure NN I-NP D007676
13 88 90 8546130 on IN B-PP O
14 91 101 8546130 continuous JJ B-NP O
15 102 112 8546130 ambulatory JJ I-NP O
16 113 123 8546130 peritoneal JJ I-NP O
17 124 132 8546130 dialysis NN I-NP O
18 132 133 8546130 . . O O
19 134 140 8546130 Visual JJ B-NP D006212
20 141 155 8546130 hallucinations NNS I-NP D006212
21 156 159 8546130 are VBP B-VP O
22 160 161 8546130 a DT B-NP O
23 162 166 8546130 rare JJ I-NP O
24 167 172 8546130 event NN I-NP O
25 173 175 8546130 in IN B-PP O
26 176 183 8546130 chronic JJ B-NP D007676
27 184 189 8546130 renal JJ I-NP D007676
28 190 197 8546130 failure NN I-NP D007676
29 198 201 8546130 and CC O O
30 202 205 8546130 not RB B-ADJP O
31 206 213 8546130 related JJ I-ADJP O
32 214 216 8546130 to TO B-PP O
33 217 223 8546130 uremia FW B-NP D014511
34 224 227 8546130 per FW I-NP O
35 228 230 8546130 se FW I-NP O
36 230 231 8546130 . . O O

1 232 242 8546130 Unreported VBN B-VP O
2 243 245 8546130 in IN B-PP O
3 246 249 8546130 the DT B-NP O
4 250 260 8546130 literature NN I-NP O
5 261 263 8546130 is VBZ B-VP O
6 264 270 8546130 visual JJ B-NP D006212
7 271 285 8546130 hallucinations NNS I-NP D006212
8 286 295 8546130 occurring VBG B-VP O
9 296 298 8546130 in IN B-PP O
10 299 310 8546130 association NN B-NP O
11 311 315 8546130 with IN B-PP O
12 316 319 8546130 the DT B-NP O
13 320 323 8546130 new JJ I-NP O
14 324 333 8546130 macrolide NN I-NP D018942
15 334 344 8546130 antibiotic NN I-NP O
16 344 345 8546130 , , O O
17 346 360 8546130 clarithromycin NN B-NP D017291
18 360 361 8546130 . . O O

1 362 364 8546130 We PRP B-NP O
2 365 373 8546130 describe VBP B-VP O
3 374 378 8546130 such PDT B-NP O
4 379 380 8546130 a DT I-NP O
5 381 385 8546130 case NN I-NP O
6 386 388 8546130 in IN B-PP O
7 389 390 8546130 a DT B-NP O
8 391 398 8546130 patient NN I-NP O
9 399 403 8546130 with IN B-PP O
10 404 407 8546130 end NN B-NP D007676
11 407 408 8546130 - HYPH I-NP D007676
12 408 413 8546130 stage NN I-NP D007676
13 414 419 8546130 renal JJ I-NP D007676
14 420 427 8546130 disease NN I-NP D007676
15 428 429 8546130 ( ( O O
16 429 433 8546130 ESRD NN B-NP D007676
17 433 434 8546130 ) ) O O
18 435 445 8546130 maintained VBN B-VP O
19 446 448 8546130 on IN B-PP O
20 449 459 8546130 continuous JJ B-NP O
21 460 470 8546130 ambulatory JJ I-NP O
22 471 481 8546130 peritoneal JJ I-NP O
23 482 490 8546130 dialysis NN I-NP O
24 491 492 8546130 ( ( O O
25 492 496 8546130 CAPD NN B-NP O
26 496 497 8546130 ) ) O O
27 497 498 8546130 . . O O

1 499 502 8546130 The DT B-NP O
2 503 514 8546130 combination NN I-NP O
3 515 517 8546130 of IN B-PP O
4 518 519 8546130 a DT B-NP O
5 520 530 8546130 relatively RB I-NP O
6 531 535 8546130 high JJ I-NP O
7 536 540 8546130 dose NN I-NP O
8 541 543 8546130 of IN B-PP O
9 544 558 8546130 clarithromycin NN B-NP D017291
10 559 561 8546130 in IN B-PP O
11 562 566 8546130 face NN B-NP O
12 567 569 8546130 of IN B-PP O
13 570 577 8546130 chronic JJ B-NP D007676
14 578 583 8546130 renal JJ I-NP D007676
15 584 591 8546130 failure NN I-NP D007676
16 592 594 8546130 in IN B-PP O
17 595 596 8546130 a DT B-NP O
18 597 609 8546130 functionally RB I-NP O
19 610 618 8546130 anephric JJ I-NP O
20 619 626 8546130 patient NN I-NP O
21 626 627 8546130 , , O O
22 628 632 8546130 with IN B-PP O
23 633 643 8546130 underlying VBG B-VP O
24 644 652 8546130 aluminum NN B-NP D000535
25 653 665 8546130 intoxication NN I-NP O
26 665 666 8546130 , , O O
27 667 670 8546130 may MD B-VP O
28 671 675 8546130 have VB I-VP O
29 676 687 8546130 facilitated VBN I-VP O
30 688 691 8546130 the DT B-NP O
31 692 702 8546130 appearance NN I-NP O
32 703 705 8546130 of IN B-PP O
33 706 710 8546130 this DT B-NP O
34 711 721 8546130 neurotoxic JJ I-NP D020258
35 722 726 8546130 side NN I-NP O
36 727 733 8546130 effect NN I-NP O
37 733 734 8546130 . . O O

1 735 737 8546130 It PRP B-NP O
2 738 740 8546130 is VBZ B-VP O
3 741 750 8546130 important JJ B-ADJP O
4 751 753 8546130 to TO B-VP O
5 754 764 8546130 understand VB I-VP O
6 765 768 8546130 the DT B-NP O
7 769 785 8546130 pharmacokinetics NNS I-NP O
8 786 788 8546130 of IN B-PP O
9 789 800 8546130 medications NNS B-NP O
10 801 803 8546130 in IN B-PP O
11 804 808 8546130 face NN B-NP O
12 809 811 8546130 of IN B-PP O
13 812 819 8546130 chronic JJ B-NP D007676
14 820 825 8546130 renal JJ I-NP D007676
15 826 833 8546130 failure NN I-NP D007676
16 833 834 8546130 , , O O
17 835 838 8546130 the DT B-NP O
18 839 850 8546130 possibility NN I-NP O
19 851 853 8546130 of IN B-PP O
20 854 858 8546130 drug NN B-NP O
21 859 871 8546130 interactions NNS I-NP O
22 871 872 8546130 , , O O
23 873 876 8546130 and CC O O
24 877 880 8546130 how WRB B-ADVP O
25 881 886 8546130 these DT B-NP O
26 887 894 8546130 factors NNS I-NP O
27 895 901 8546130 should MD B-VP O
28 902 906 8546130 help VB I-VP O
29 907 912 8546130 guide VB I-VP O
30 913 923 8546130 medication NN B-NP O
31 924 931 8546130 therapy NN I-NP O
32 932 934 8546130 in IN B-PP O
33 935 938 8546130 the DT B-NP O
34 939 943 8546130 ESRD NNP I-NP D007676
35 944 951 8546130 patient NN I-NP O
36 951 952 8546130 . . O O

1 0 0 16047871 -DOCSTART- -X- -X- O

1 0 8 16047871 Warfarin NN B-NP D014859
2 8 9 16047871 - HYPH O O
3 9 16 16047871 induced VBN B-NP O
4 17 33 16047871 leukocytoclastic JJ I-NP C535509
5 34 44 16047871 vasculitis NN I-NP C535509
6 44 45 16047871 . . O O
7 46 50 16047871 Skin NN B-NP O
8 51 60 16047871 reactions NNS I-NP O
9 61 71 16047871 associated VBN B-VP O
10 72 76 16047871 with IN B-PP O
11 77 81 16047871 oral JJ B-NP O
12 82 90 16047871 coumarin NN I-NP C030123
13 90 91 16047871 - HYPH B-NP O
14 91 98 16047871 derived VBN I-NP O
15 99 113 16047871 anticoagulants NNS I-NP O
16 114 117 16047871 are VBP B-VP O
17 118 120 16047871 an DT B-NP O
18 121 129 16047871 uncommon JJ I-NP O
19 130 140 16047871 occurrence NN I-NP O
20 140 141 16047871 . . O O

1 142 158 16047871 Leukocytoclastic JJ B-NP C535509
2 159 169 16047871 vasculitis NN I-NP C535509
3 170 171 16047871 ( ( O O
4 171 173 16047871 LV NN B-NP C535509
5 173 174 16047871 ) ) O O
6 175 177 16047871 is VBZ B-VP O
7 178 187 16047871 primarily RB B-ADVP O
8 188 189 16047871 a DT B-NP O
9 190 199 16047871 cutaneous JJ I-NP C565222
10 200 205 16047871 small JJ I-NP C565222
11 206 212 16047871 vessel NN I-NP C565222
12 213 223 16047871 vasculitis NN I-NP C565222
13 223 224 16047871 , , O O
14 225 231 16047871 though IN B-SBAR O
15 232 240 16047871 systemic JJ B-NP O
16 241 252 16047871 involvement NN I-NP O
17 253 256 16047871 may MD B-VP O
18 257 259 16047871 be VB I-VP O
19 260 271 16047871 encountered VBN I-VP O
20 271 272 16047871 . . O O

1 273 275 16047871 We PRP B-NP O
2 276 282 16047871 report VBP B-VP O
3 283 284 16047871 4 CD B-NP O
4 285 293 16047871 patients NNS I-NP O
5 294 298 16047871 with IN B-PP O
6 299 303 16047871 late JJ B-NP O
7 303 304 16047871 - HYPH I-NP O
8 304 309 16047871 onset NN I-NP O
9 310 312 16047871 LV NN I-NP C535509
10 313 321 16047871 probably RB B-ADVP O
11 322 325 16047871 due IN B-PP O
12 326 328 16047871 to TO B-PP O
13 329 337 16047871 warfarin NN B-NP D014859
14 337 338 16047871 . . O O

1 339 342 16047871 All DT B-NP O
2 343 344 16047871 4 CD I-NP O
3 345 353 16047871 patients NNS I-NP O
4 354 363 16047871 presented VBD B-VP O
5 364 368 16047871 with IN B-PP O
6 369 373 16047871 skin NN B-NP D012871
7 374 383 16047871 eruptions NNS I-NP D012871
8 384 388 16047871 that WDT B-NP O
9 389 398 16047871 developed VBD B-VP O
10 399 404 16047871 after IN B-PP O
11 405 414 16047871 receiving VBG B-VP O
12 415 423 16047871 warfarin NN B-NP D014859
13 424 427 16047871 for IN B-PP O
14 428 435 16047871 several JJ B-NP O
15 436 441 16047871 years NNS I-NP O
16 441 442 16047871 . . O O

1 443 446 16047871 The DT B-NP O
2 447 454 16047871 results NNS I-NP O
3 455 457 16047871 of IN B-PP O
4 458 462 16047871 skin NN B-NP D012871
5 463 469 16047871 lesion NN I-NP D012871
6 470 478 16047871 biopsies NNS I-NP O
7 479 483 16047871 were VBD B-VP O
8 484 493 16047871 available JJ B-ADJP O
9 494 496 16047871 in IN B-PP O
10 497 498 16047871 3 CD B-NP O
11 499 507 16047871 patients NNS I-NP O
12 507 508 16047871 , , O O
13 509 519 16047871 confirming VBG B-VP O
14 520 522 16047871 LV NN B-NP D018366
15 523 532 16047871 Cutaneous JJ I-NP D018366
16 533 540 16047871 lesions NNS I-NP D018366
17 541 549 16047871 resolved VBN B-VP O
18 550 552 16047871 in IN B-PP O
19 553 556 16047871 all DT B-NP O
20 557 565 16047871 patients NNS I-NP O
21 566 571 16047871 after IN B-SBAR O
22 572 580 16047871 warfarin NN B-NP D014859
23 581 584 16047871 was VBD B-VP O
24 585 597 16047871 discontinued VBN I-VP O
25 597 598 16047871 . . O O

1 599 601 16047871 In IN B-PP O
2 602 603 16047871 2 CD B-NP O
3 604 606 16047871 of IN B-PP O
4 607 610 16047871 the DT B-NP O
5 611 612 16047871 4 CD I-NP O
6 613 621 16047871 patients NNS I-NP O
7 621 622 16047871 , , O O
8 623 634 16047871 rechallenge VBP B-VP O
9 635 639 16047871 with IN B-PP O
10 640 648 16047871 warfarin NN B-NP D014859
11 649 652 16047871 led VBD B-VP O
12 653 655 16047871 to TO I-VP O
13 656 666 16047871 recurrence VB I-VP O
14 667 669 16047871 of IN B-PP O
15 670 673 16047871 the DT B-NP O
16 674 681 16047871 lesions NNS I-NP O
17 681 682 16047871 . . O O

1 683 685 16047871 LV NN B-NP C535509
2 686 689 16047871 may MD B-VP O
3 690 692 16047871 be VB I-VP O
4 693 694 16047871 a DT B-NP O
5 695 699 16047871 late JJ I-NP O
6 699 700 16047871 - HYPH I-NP O
7 700 705 16047871 onset NN I-NP O
8 706 713 16047871 adverse JJ I-NP O
9 714 722 16047871 reaction NN I-NP O
10 723 733 16047871 associated VBN B-VP O
11 734 738 16047871 with IN B-PP O
12 739 747 16047871 warfarin NN B-NP D014859
13 748 755 16047871 therapy NN I-NP O
14 755 756 16047871 . . O O

1 0 0 20735774 -DOCSTART- -X- -X- O

1 0 4 20735774 Long JJ B-NP O
2 4 5 20735774 - HYPH I-NP O
3 5 9 20735774 term NN I-NP O
4 10 19 20735774 prognosis NN I-NP O
5 20 23 20735774 for IN B-PP O
6 24 34 20735774 transplant NN B-NP O
7 34 35 20735774 - HYPH O O
8 35 39 20735774 free JJ B-NP O
9 40 49 20735774 survivors NNS I-NP O
10 50 52 20735774 of IN B-PP O
11 53 64 20735774 paracetamol NN B-NP D000082
12 64 65 20735774 - HYPH B-NP O
13 65 72 20735774 induced VBN I-NP O
14 73 78 20735774 acute JJ I-NP D017114
15 79 84 20735774 liver NN I-NP D017114
16 85 92 20735774 failure NN I-NP D017114
17 92 93 20735774 . . I-NP O
18 94 104 20735774 BACKGROUND NN I-NP O
19 104 105 20735774 : : O O
20 106 109 20735774 The DT B-NP O
21 110 119 20735774 prognosis NN I-NP O
22 120 123 20735774 for IN B-PP O
23 124 134 20735774 transplant NN B-NP O
24 134 135 20735774 - HYPH O O
25 135 139 20735774 free JJ B-NP O
26 140 149 20735774 survivors NNS I-NP O
27 150 152 20735774 of IN B-PP O
28 153 164 20735774 paracetamol NN B-NP D000082
29 164 165 20735774 - HYPH B-NP O
30 165 172 20735774 induced VBN I-NP O
31 173 178 20735774 acute JJ I-NP D017114
32 179 184 20735774 liver NN I-NP D017114
33 185 192 20735774 failure NN I-NP D017114
34 193 200 20735774 remains VBZ B-VP O
35 201 208 20735774 unknown JJ B-ADJP O
36 208 209 20735774 . . O O

1 210 213 20735774 AIM NN B-NP O
2 213 214 20735774 : : O O
3 215 217 20735774 To TO B-VP O
4 218 225 20735774 examine VB I-VP O
5 226 233 20735774 whether IN B-SBAR O
6 234 245 20735774 paracetamol NN B-NP D000082
7 245 246 20735774 - HYPH B-NP O
8 246 253 20735774 induced VBN I-NP O
9 254 259 20735774 acute JJ I-NP D017114
10 260 265 20735774 liver NN I-NP D017114
11 266 273 20735774 failure NN I-NP D017114
12 274 283 20735774 increases VBZ B-VP O
13 284 288 20735774 long JJ B-NP O
14 288 289 20735774 - HYPH I-NP O
15 289 293 20735774 term NN I-NP O
16 294 303 20735774 mortality NN I-NP O
17 303 304 20735774 . . O O

1 305 312 20735774 METHODS NNS B-NP O
2 312 313 20735774 : : O O
3 314 316 20735774 We PRP B-NP O
4 317 325 20735774 followed VBD B-VP O
5 326 328 20735774 up RP B-PRT O
6 329 332 20735774 all DT B-NP O
7 333 343 20735774 transplant NN I-NP O
8 343 344 20735774 - HYPH O O
9 344 348 20735774 free JJ B-NP O
10 349 358 20735774 survivors NNS I-NP O
11 359 361 20735774 of IN B-PP O
12 362 373 20735774 paracetamol NN B-NP D000082
13 373 374 20735774 - HYPH B-NP O
14 374 381 20735774 induced VBN I-NP O
15 382 387 20735774 acute JJ I-NP D056486
16 388 393 20735774 liver NN I-NP D056486
17 394 400 20735774 injury NN I-NP D056486
18 400 401 20735774 , , O O
19 402 414 20735774 hospitalized VBN B-VP O
20 415 417 20735774 in IN B-PP O
21 418 419 20735774 a DT B-NP O
22 420 426 20735774 Danish JJ I-NP O
23 427 435 20735774 national JJ I-NP O
24 436 444 20735774 referral JJ I-NP O
25 445 451 20735774 centre NN I-NP O
26 452 458 20735774 during IN B-PP O
27 459 463 20735774 1984 CD B-NP O
28 463 464 20735774 - : O O
29 464 468 20735774 2004 CD B-NP O
30 468 469 20735774 . . O O

1 470 472 20735774 We PRP B-NP O
2 473 481 20735774 compared VBD B-VP O
3 482 485 20735774 age NN B-NP O
4 485 486 20735774 - HYPH B-NP O
5 486 494 20735774 specific JJ I-NP O
6 495 504 20735774 mortality NN I-NP O
7 505 510 20735774 rates NNS I-NP O
8 511 515 20735774 from IN B-PP O
9 516 517 20735774 1 CD B-NP O
10 518 522 20735774 year NN I-NP O
11 523 527 20735774 post AFX O O
12 527 528 20735774 - HYPH O O
13 528 537 20735774 discharge NN B-NP O
14 538 545 20735774 through IN B-PP O
15 546 550 20735774 2008 CD B-NP O
16 551 558 20735774 between IN B-PP O
17 559 564 20735774 those DT B-NP O
18 565 567 20735774 in IN B-PP O
19 568 572 20735774 whom WP B-NP O
20 573 576 20735774 the DT B-NP O
21 577 582 20735774 liver NN I-NP D056486
22 583 589 20735774 injury NN I-NP D056486
23 590 593 20735774 led VBD B-VP O
24 594 596 20735774 to TO B-PP O
25 597 599 20735774 an DT B-NP O
26 600 605 20735774 acute JJ I-NP D017114
27 606 611 20735774 liver NN I-NP D017114
28 612 619 20735774 failure NN I-NP D017114
29 620 623 20735774 and CC O O
30 624 629 20735774 those DT B-NP O
31 630 632 20735774 in IN B-PP O
32 633 637 20735774 whom WP B-NP O
33 638 640 20735774 it PRP B-NP O
34 641 644 20735774 did VBD B-VP O
35 645 648 20735774 not RB O O
36 648 649 20735774 . . O O

1 650 657 20735774 RESULTS NNS B-NP O
2 657 658 20735774 : : O O
3 659 661 20735774 We PRP B-NP O
4 662 670 20735774 included VBD B-VP O
5 671 674 20735774 641 CD B-NP O
6 675 683 20735774 patients NNS I-NP O
7 683 684 20735774 . . O O

1 685 687 20735774 On IN B-PP O
2 688 695 20735774 average NN B-NP O
3 695 696 20735774 , , O O
4 697 700 20735774 age NN B-NP O
5 700 701 20735774 - HYPH B-NP O
6 701 709 20735774 specific JJ I-NP O
7 710 719 20735774 mortality NN I-NP O
8 720 725 20735774 rates NNS I-NP O
9 726 730 20735774 were VBD B-VP O
10 731 739 20735774 slightly RB B-ADJP O
11 740 746 20735774 higher JJR I-ADJP O
12 747 750 20735774 for IN B-PP O
13 751 754 20735774 the DT B-NP O
14 755 758 20735774 101 CD I-NP O
15 759 767 20735774 patients NNS I-NP O
16 768 773 20735774 whose WP$ B-NP O
17 774 785 20735774 paracetamol NN I-NP D000082
18 785 786 20735774 - HYPH B-NP O
19 786 793 20735774 induced VBN I-NP O
20 794 799 20735774 liver NN I-NP D056486
21 800 806 20735774 injury NN I-NP D056486
22 807 810 20735774 had VBD B-VP O
23 811 817 20735774 caused VBN I-VP O
24 818 820 20735774 an DT B-NP O
25 821 826 20735774 acute JJ I-NP D017114
26 827 832 20735774 liver NN I-NP D017114
27 833 840 20735774 failure NN I-NP D017114
28 841 842 20735774 ( ( O O
29 842 850 20735774 adjusted VBN B-NP O
30 851 860 20735774 mortality NN I-NP O
31 861 865 20735774 rate NN I-NP O
32 866 871 20735774 ratio NN I-NP O
33 872 873 20735774 = SYM B-VP O
34 874 878 20735774 1.70 CD B-NP O
35 878 879 20735774 , , O O
36 880 883 20735774 95% CD B-NP O
37 884 886 20735774 CI NNP I-NP O
38 887 891 20735774 1.02 CD I-NP O
39 891 892 20735774 - HYPH I-NP O
40 892 896 20735774 2.85 CD I-NP O
41 896 897 20735774 ) ) O O
42 897 898 20735774 , , O O
43 899 902 20735774 but CC O O
44 903 906 20735774 the DT B-NP O
45 907 918 20735774 association NN I-NP O
46 919 922 20735774 was VBD B-VP O
47 923 926 20735774 age NN B-NP O
48 926 927 20735774 - HYPH B-PP O
49 927 936 20735774 dependent JJ B-ADJP O
50 936 937 20735774 , , O O
51 938 941 20735774 and CC O O
52 942 944 20735774 no DT B-NP O
53 945 954 20735774 survivors NNS I-NP O
54 955 957 20735774 of IN B-PP O
55 958 963 20735774 acute JJ B-NP D017114
56 964 969 20735774 liver NN I-NP D017114
57 970 977 20735774 failure NN I-NP D017114
58 978 982 20735774 died VBD B-VP O
59 983 985 20735774 of IN B-PP O
60 986 991 20735774 liver NN B-NP D008107
61 992 999 20735774 disease NN I-NP D008107
62 999 1000 20735774 , , O O
63 1001 1008 20735774 whereas IN O O
64 1009 1017 20735774 suicides NNS B-NP O
65 1018 1022 20735774 were VBD B-VP O
66 1023 1031 20735774 frequent JJ B-ADJP O
67 1032 1034 20735774 in IN B-PP O
68 1035 1039 20735774 both DT B-NP O
69 1040 1046 20735774 groups NNS I-NP O
70 1046 1047 20735774 . . O O

1 1048 1053 20735774 These DT B-NP O
2 1054 1066 20735774 observations NNS I-NP O
3 1067 1072 20735774 speak VBP B-VP O
4 1073 1080 20735774 against IN B-PP O
5 1081 1085 20735774 long JJ B-NP O
6 1085 1086 20735774 - HYPH I-NP O
7 1086 1090 20735774 term NN I-NP O
8 1091 1098 20735774 effects NNS I-NP O
9 1099 1101 20735774 of IN B-PP O
10 1102 1107 20735774 acute JJ B-NP D017114
11 1108 1113 20735774 liver NN I-NP D017114
12 1114 1121 20735774 failure NN I-NP D017114
13 1121 1122 20735774 . . O O

1 1123 1127 20735774 More RBR B-ADVP O
2 1128 1134 20735774 likely JJ I-ADVP O
3 1134 1135 20735774 , , O O
4 1136 1139 20735774 the DT B-NP O
5 1140 1148 20735774 elevated JJ I-NP O
6 1149 1158 20735774 mortality NN I-NP O
7 1159 1163 20735774 rate NN I-NP O
8 1164 1169 20735774 ratio NN I-NP O
9 1170 1178 20735774 resulted VBD B-VP O
10 1179 1183 20735774 from IN B-PP O
11 1184 1194 20735774 incomplete JJ B-NP O
12 1195 1205 20735774 adjustment NN I-NP O
13 1206 1209 20735774 for IN B-PP O
14 1210 1213 20735774 the DT B-NP O
15 1214 1221 20735774 greater JJR I-NP O
16 1222 1232 20735774 prevalence NN I-NP O
17 1233 1235 20735774 of IN B-PP O
18 1236 1245 20735774 substance NN B-NP D019966
19 1246 1251 20735774 abuse NN I-NP D019966
20 1252 1257 20735774 among IN B-PP O
21 1258 1267 20735774 survivors NNS B-NP O
22 1268 1270 20735774 of IN B-PP O
23 1271 1276 20735774 acute JJ B-NP D017114
24 1277 1282 20735774 liver NN I-NP D017114
25 1283 1290 20735774 failure NN I-NP D017114
26 1290 1291 20735774 . . O O

1 1292 1303 20735774 CONCLUSIONS NNS B-NP O
2 1303 1304 20735774 : : O O
3 1305 1316 20735774 Paracetamol NN B-NP D000082
4 1316 1317 20735774 - HYPH O O
5 1317 1324 20735774 induced VBN B-NP O
6 1325 1330 20735774 acute JJ I-NP D017114
7 1331 1336 20735774 liver NN I-NP D017114
8 1337 1344 20735774 failure NN I-NP D017114
9 1345 1348 20735774 did VBD B-VP O
10 1349 1352 20735774 not RB I-VP O
11 1353 1359 20735774 affect VB I-VP O
12 1360 1364 20735774 long JJ B-NP O
13 1364 1365 20735774 - HYPH I-NP O
14 1365 1369 20735774 term NN I-NP O
15 1370 1379 20735774 mortality NN I-NP O
16 1379 1380 20735774 . . O O

1 1381 1389 20735774 Clinical JJ B-NP O
2 1390 1396 20735774 follow VB B-VP O
3 1396 1397 20735774 - HYPH O O
4 1397 1399 20735774 up RP B-PRT O
5 1400 1403 20735774 may MD B-VP O
6 1404 1406 20735774 be VB I-VP O
7 1407 1416 20735774 justified VBN I-VP O
8 1417 1419 20735774 by IN B-PP O
9 1420 1423 20735774 the DT B-NP O
10 1424 1429 20735774 cause NN I-NP O
11 1430 1432 20735774 of IN B-PP O
12 1433 1436 20735774 the DT B-NP O
13 1437 1442 20735774 liver NN I-NP D017093
14 1443 1450 20735774 failure NN I-NP D017093
15 1450 1451 20735774 , , O O
16 1452 1455 20735774 but CC B-PP O
17 1456 1459 20735774 not RB I-PP O
18 1460 1462 20735774 by IN B-PP O
19 1463 1466 20735774 the DT B-NP O
20 1467 1472 20735774 liver NN I-NP D017093
21 1473 1480 20735774 failure NN I-NP D017093
22 1481 1487 20735774 itself PRP B-NP O
23 1487 1488 20735774 . . O O

1 0 0 8012887 -DOCSTART- -X- -X- O

1 0 7 8012887 Failure NN B-NP O
2 8 10 8012887 of IN B-PP O
3 11 17 8012887 ancrod NN B-NP O
4 18 20 8012887 in IN B-PP O
5 21 24 8012887 the DT B-NP O
6 25 34 8012887 treatment NN I-NP O
7 35 37 8012887 of IN B-PP O
8 38 45 8012887 heparin NN B-NP D006493
9 45 46 8012887 - HYPH B-NP O
10 46 53 8012887 induced VBN I-NP O
11 54 62 8012887 arterial JJ I-NP O
12 63 73 8012887 thrombosis NN I-NP D013927
13 73 74 8012887 . . O O
14 75 78 8012887 The DT B-NP O
15 79 88 8012887 morbidity NN I-NP O
16 89 92 8012887 and CC I-NP O
17 93 102 8012887 mortality NN I-NP O
18 103 113 8012887 associated VBN B-VP O
19 114 118 8012887 with IN B-PP O
20 119 126 8012887 heparin NN B-NP D006493
21 126 127 8012887 - HYPH B-NP O
22 127 134 8012887 induced VBN I-NP O
23 135 145 8012887 thrombosis NN I-NP D013927
24 146 152 8012887 remain VBP B-VP O
25 153 157 8012887 high JJ B-ADJP O
26 158 165 8012887 despite IN B-PP O
27 166 174 8012887 numerous JJ B-NP O
28 175 184 8012887 empirical JJ I-NP O
29 185 194 8012887 therapies NNS I-NP O
30 194 195 8012887 . . O O

1 196 202 8012887 Ancrod NNP B-NP O
2 203 206 8012887 has VBZ B-VP O
3 207 211 8012887 been VBN I-VP O
4 212 216 8012887 used VBN I-VP O
5 217 229 8012887 successfully RB B-ADVP O
6 230 233 8012887 for IN B-PP O
7 234 245 8012887 prophylaxis NN B-NP O
8 246 253 8012887 against IN B-PP O
9 254 265 8012887 development NN B-NP O
10 266 268 8012887 of IN B-PP O
11 269 279 8012887 thrombosis NN B-NP D013927
12 280 282 8012887 in IN B-PP O
13 283 291 8012887 patients NNS B-NP O
14 292 296 8012887 with IN B-PP O
15 297 304 8012887 heparin NN B-NP D006493
16 305 312 8012887 induced VBD B-VP O
17 313 321 8012887 platelet NN B-NP D001791
18 322 333 8012887 aggregation NN I-NP D001791
19 334 337 8012887 who WP B-NP O
20 338 345 8012887 require VBP B-VP O
21 346 351 8012887 brief JJ B-NP O
22 352 362 8012887 reexposure NN I-NP O
23 363 365 8012887 to TO B-PP O
24 366 373 8012887 heparin NN B-NP D006493
25 373 374 8012887 , , O O
26 375 378 8012887 but CC O O
27 379 382 8012887 its PRP$ B-NP O
28 383 390 8012887 success NN I-NP O
29 391 393 8012887 in IN B-PP O
30 394 402 8012887 patients NNS B-NP O
31 403 406 8012887 who WP B-NP O
32 407 411 8012887 have VBP B-VP O
33 412 421 8012887 developed VBN I-VP O
34 422 425 8012887 the DT B-NP O
35 426 436 8012887 thrombosis NN I-NP D013927
36 437 445 8012887 syndrome NN I-NP O
37 446 448 8012887 is VBZ B-VP O
38 449 452 8012887 not RB I-VP O
39 453 457 8012887 well RB I-VP O
40 458 465 8012887 defined VBN I-VP O
41 465 466 8012887 . . O O

1 467 470 8012887 The DT B-NP O
2 471 478 8012887 authors NNS I-NP O
3 479 486 8012887 present VBP B-VP O
4 487 488 8012887 a DT B-NP O
5 489 493 8012887 case NN I-NP O
6 494 496 8012887 of IN B-PP O
7 497 504 8012887 failure NN B-NP O
8 505 507 8012887 of IN B-PP O
9 508 514 8012887 ancrod NN B-NP O
10 515 524 8012887 treatment NN I-NP O
11 525 527 8012887 in IN B-PP O
12 528 529 8012887 a DT B-NP O
13 530 537 8012887 patient NN I-NP O
14 538 542 8012887 with IN B-PP O
15 543 550 8012887 heparin NN B-NP D006493
16 550 551 8012887 - HYPH B-NP O
17 551 558 8012887 induced VBN I-NP O
18 559 569 8012887 thrombosis NN I-NP D013927
19 569 570 8012887 . . O O

1 0 0 12760988 -DOCSTART- -X- -X- O

1 0 13 12760988 Postoperative JJ B-NP D010149
2 14 21 12760988 myalgia NN I-NP D010149
3 22 27 12760988 after IN B-PP O
4 28 43 12760988 succinylcholine NN B-NP D013390
5 43 44 12760988 : : O O
6 45 47 12760988 no DT B-NP O
7 48 56 12760988 evidence NN I-NP O
8 57 60 12760988 for IN B-PP O
9 61 63 12760988 an DT B-NP O
10 64 76 12760988 inflammatory JJ I-NP O
11 77 83 12760988 origin NN I-NP O
12 83 84 12760988 . . O O
13 85 86 12760988 A DT B-NP O
14 87 93 12760988 common JJ I-NP O
15 94 98 12760988 side NN I-NP O
16 99 105 12760988 effect NN I-NP O
17 106 116 12760988 associated VBN B-VP O
18 117 121 12760988 with IN B-PP O
19 122 137 12760988 succinylcholine NN B-NP D013390
20 138 140 12760988 is VBZ B-VP O
21 141 154 12760988 postoperative JJ B-NP D010149
22 155 162 12760988 myalgia NN I-NP D010149
23 162 163 12760988 . . O O

1 164 167 12760988 The DT B-NP O
2 168 180 12760988 pathogenesis NN I-NP O
3 181 183 12760988 of IN B-PP O
4 184 188 12760988 this DT B-NP O
5 189 196 12760988 myalgia NN I-NP D063806
6 197 199 12760988 is VBZ B-VP O
7 200 205 12760988 still RB B-ADVP O
8 206 213 12760988 unclear JJ B-ADJP O
9 213 214 12760988 ; : O O
10 215 227 12760988 inflammation NN B-NP D007249
11 228 231 12760988 has VBZ B-VP O
12 232 236 12760988 been VBN I-VP O
13 237 246 12760988 suggested VBN I-VP O
14 247 250 12760988 but CC O O
15 251 258 12760988 without IN B-PP O
16 259 269 12760988 convincing VBG B-VP O
17 270 278 12760988 evidence NN B-NP O
18 278 279 12760988 . . O O

1 280 282 12760988 We PRP B-NP O
2 283 291 12760988 designed VBD B-VP O
3 292 295 12760988 the DT B-NP O
4 296 303 12760988 present JJ I-NP O
5 304 309 12760988 study NN I-NP O
6 310 312 12760988 to TO B-VP O
7 313 324 12760988 investigate VB I-VP O
8 325 332 12760988 whether IN B-SBAR O
9 333 335 12760988 an DT B-NP O
10 336 348 12760988 inflammatory JJ I-NP O
11 349 357 12760988 reaction NN I-NP O
12 358 369 12760988 contributes VBZ B-VP O
13 370 372 12760988 to TO B-PP O
14 373 377 12760988 this DT B-NP O
15 378 385 12760988 myalgia NN I-NP D063806
16 385 386 12760988 . . O O

1 387 390 12760988 The DT B-NP O
2 391 400 12760988 incidence NN I-NP O
3 401 404 12760988 and CC I-NP O
4 405 413 12760988 severity NN I-NP O
5 414 416 12760988 of IN B-PP O
6 417 432 12760988 succinylcholine NN B-NP D013390
7 432 433 12760988 - HYPH O O
8 433 443 12760988 associated VBN B-NP O
9 444 451 12760988 myalgia NN I-NP D063806
10 452 455 12760988 was VBD B-VP O
11 456 466 12760988 determined VBN I-VP O
12 467 469 12760988 in IN B-PP O
13 470 472 12760988 64 CD B-NP O
14 473 481 12760988 patients NNS I-NP O
15 482 492 12760988 pretreated VBN B-VP O
16 493 497 12760988 with IN B-PP O
17 498 504 12760988 saline NN B-NP O
18 505 507 12760988 or CC I-NP O
19 508 521 12760988 dexamethasone NN I-NP D003907
20 522 528 12760988 before IN B-PP O
21 529 544 12760988 succinylcholine NN B-NP D013390
22 545 546 12760988 ( ( O O
23 546 547 12760988 n NN B-NP O
24 548 549 12760988 = JJ B-VP O
25 550 552 12760988 32 CD B-NP O
26 553 556 12760988 for IN B-PP O
27 557 561 12760988 each DT B-NP O
28 561 562 12760988 ) ) O O
29 562 563 12760988 . . O O

1 564 573 12760988 Incidence NN B-NP O
2 574 577 12760988 and CC I-NP O
3 578 586 12760988 severity NN I-NP O
4 587 589 12760988 of IN B-PP O
5 590 597 12760988 myalgia NN B-NP D063806
6 598 601 12760988 did VBD B-VP O
7 602 605 12760988 not RB I-VP O
8 606 612 12760988 differ VB I-VP O
9 613 626 12760988 significantly RB B-ADVP O
10 627 634 12760988 between IN B-PP O
11 635 638 12760988 the DT B-NP O
12 639 642 12760988 two CD I-NP O
13 643 649 12760988 groups NNS I-NP O
14 649 650 12760988 : : O O
15 651 653 12760988 15 CD B-NP O
16 654 662 12760988 patients NNS I-NP O
17 663 665 12760988 in IN B-PP O
18 666 669 12760988 the DT B-NP O
19 670 683 12760988 dexamethasone NN I-NP D003907
20 684 689 12760988 group NN I-NP O
21 690 700 12760988 complained VBD B-VP O
22 701 703 12760988 of IN B-PP O
23 704 711 12760988 myalgia NN B-NP D063806
24 712 720 12760988 compared VBN B-PP O
25 721 725 12760988 with IN B-PP O
26 726 728 12760988 18 CD B-NP O
27 729 737 12760988 patients NNS I-NP O
28 738 740 12760988 in IN B-PP O
29 741 744 12760988 the DT B-NP O
30 745 751 12760988 saline NN I-NP O
31 752 757 12760988 group NN I-NP O
32 757 758 12760988 , , O O
33 759 762 12760988 and CC O O
34 763 769 12760988 severe JJ B-NP O
35 770 777 12760988 myalgia NN I-NP D063806
36 778 781 12760988 was VBD B-VP O
37 782 790 12760988 reported VBN I-VP O
38 791 793 12760988 by IN B-PP O
39 794 798 12760988 five CD B-NP O
40 799 807 12760988 patients NNS I-NP O
41 808 811 12760988 and CC O O
42 812 817 12760988 three CD B-NP O
43 818 826 12760988 patients NNS I-NP O
44 826 827 12760988 , , O O
45 828 840 12760988 respectively RB B-ADVP O
46 841 842 12760988 ( ( O O
47 842 845 12760988 not RB O O
48 846 857 12760988 significant JJ B-ADJP O
49 857 858 12760988 ) ) O O
50 858 859 12760988 . . O O

1 860 862 12760988 At IN B-PP O
2 863 865 12760988 48 CD B-NP O
3 866 867 12760988 h NN I-NP O
4 868 873 12760988 after IN B-PP O
5 874 881 12760988 surgery NN B-NP O
6 881 882 12760988 , , O O
7 883 885 12760988 12 CD B-NP O
8 886 894 12760988 patients NNS I-NP O
9 895 897 12760988 in IN B-PP O
10 898 902 12760988 both DT B-NP O
11 903 909 12760988 groups NNS I-NP O
12 910 915 12760988 still RB B-VP O
13 916 924 12760988 suffered VBN I-VP O
14 925 929 12760988 from IN B-PP O
15 930 937 12760988 myalgia NN B-NP D063806
16 938 939 12760988 ( ( O O
17 939 942 12760988 not RB O O
18 943 954 12760988 significant JJ B-ADJP O
19 954 955 12760988 ) ) O O
20 955 956 12760988 . . O O

1 957 959 12760988 In IN B-PP O
2 960 968 12760988 addition NN B-NP O
3 968 969 12760988 , , O O
4 970 981 12760988 interleukin NN B-NP O
5 981 982 12760988 - HYPH O O
6 982 983 12760988 6 CD B-NP O
7 984 985 12760988 ( ( O O
8 985 987 12760988 IL NN B-NP O
9 987 988 12760988 - HYPH O O
10 988 989 12760988 6 CD B-NP O
11 989 990 12760988 ) ) O O
12 991 993 12760988 as IN B-PP O
13 994 996 12760988 an DT B-NP O
14 997 1002 12760988 early JJ I-NP O
15 1003 1009 12760988 marker NN I-NP O
16 1010 1012 12760988 of IN B-PP O
17 1013 1025 12760988 inflammation NN B-NP D007249
18 1026 1029 12760988 was VBD B-VP O
19 1030 1038 12760988 assessed VBN I-VP O
20 1039 1041 12760988 in IN B-PP O
21 1042 1043 12760988 a DT B-NP O
22 1044 1052 12760988 subgroup NN I-NP O
23 1053 1055 12760988 of IN B-PP O
24 1056 1058 12760988 10 CD B-NP O
25 1059 1067 12760988 patients NNS I-NP O
26 1068 1078 12760988 pretreated VBN B-VP O
27 1079 1083 12760988 with IN B-PP O
28 1084 1090 12760988 saline NN B-NP O
29 1090 1091 12760988 . . O O

1 1092 1094 12760988 We PRP B-NP O
2 1095 1100 12760988 found VBD B-VP O
3 1101 1103 12760988 an DT B-NP O
4 1104 1112 12760988 increase NN I-NP O
5 1113 1115 12760988 of IN B-PP O
6 1116 1118 12760988 IL NN B-NP O
7 1118 1119 12760988 - HYPH B-NP O
8 1119 1120 12760988 6 CD I-NP O
9 1121 1124 12760988 for IN B-PP O
10 1125 1129 12760988 only RB B-NP O
11 1130 1135 12760988 three CD I-NP O
12 1136 1144 12760988 patients NNS I-NP O
13 1144 1145 12760988 , , O O
14 1146 1149 12760988 but CC O O
15 1150 1154 12760988 only RB B-NP O
16 1155 1158 12760988 one CD I-NP O
17 1159 1166 12760988 patient NN I-NP O
18 1167 1175 12760988 reported VBD B-VP O
19 1176 1183 12760988 myalgia NN B-NP D063806
20 1183 1184 12760988 ; : O O
21 1185 1187 12760988 no DT B-NP O
22 1188 1200 12760988 relationship NN I-NP O
23 1201 1208 12760988 between IN B-PP O
24 1209 1216 12760988 myalgia NN B-NP D063806
25 1217 1220 12760988 and CC O O
26 1221 1224 12760988 the DT B-NP O
27 1225 1233 12760988 increase NN I-NP O
28 1234 1236 12760988 of IN B-PP O
29 1237 1239 12760988 IL NN B-NP O
30 1239 1240 12760988 - HYPH B-NP O
31 1240 1241 12760988 6 CD I-NP O
32 1242 1245 12760988 was VBD B-VP O
33 1246 1251 12760988 found VBN I-VP O
34 1251 1252 12760988 . . O O

1 1253 1255 12760988 In IN B-PP O
2 1256 1266 12760988 conclusion NN B-NP O
3 1266 1267 12760988 , , O O
4 1268 1273 12760988 there EX B-NP O
5 1274 1276 12760988 is VBZ B-VP O
6 1277 1279 12760988 no DT B-NP O
7 1280 1288 12760988 evidence NN I-NP O
8 1289 1292 12760988 for IN B-PP O
9 1293 1295 12760988 an DT B-NP O
10 1296 1308 12760988 inflammatory JJ I-NP O
11 1309 1315 12760988 origin NN I-NP O
12 1316 1318 12760988 of IN B-PP O
13 1319 1334 12760988 succinylcholine NN B-NP D013390
14 1334 1335 12760988 - HYPH O O
15 1335 1345 12760988 associated VBN B-NP O
16 1346 1353 12760988 myalgia NN I-NP D063806
17 1353 1354 12760988 . . O O

1 1355 1367 12760988 IMPLICATIONS NNS B-NP O
2 1367 1368 12760988 : : O O
3 1369 1383 12760988 Administration NN B-NP O
4 1384 1386 12760988 of IN B-PP O
5 1387 1400 12760988 dexamethasone NN B-NP D003907
6 1401 1407 12760988 before IN B-PP O
7 1408 1423 12760988 succinylcholine NN B-NP D013390
8 1424 1427 12760988 was VBD B-VP O
9 1428 1431 12760988 not RB O O
10 1432 1441 12760988 effective JJ B-ADJP O
11 1442 1444 12760988 in IN B-PP O
12 1445 1455 12760988 decreasing VBG B-VP O
13 1456 1459 12760988 the DT B-NP O
14 1460 1469 12760988 incidence NN I-NP O
15 1470 1472 12760988 or CC O O
16 1473 1476 12760988 the DT B-NP O
17 1477 1485 12760988 severity NN I-NP O
18 1486 1488 12760988 of IN B-PP O
19 1489 1504 12760988 succinylcholine NN B-NP D013390
20 1504 1505 12760988 - HYPH B-NP O
21 1505 1512 12760988 induced VBN I-NP O
22 1513 1526 12760988 postoperative JJ I-NP D010149
23 1527 1534 12760988 myalgia NN I-NP D010149
24 1534 1535 12760988 . . O O

1 1536 1547 12760988 Furthermore RB B-ADVP O
2 1547 1548 12760988 , , O O
3 1549 1554 12760988 there EX B-NP O
4 1555 1558 12760988 was VBD B-VP O
5 1559 1561 12760988 no DT B-NP O
6 1562 1573 12760988 significant JJ I-NP O
7 1574 1586 12760988 relationship NN I-NP O
8 1587 1594 12760988 between IN B-PP O
9 1595 1608 12760988 postoperative JJ B-NP D010149
10 1609 1616 12760988 myalgia NN I-NP D010149
11 1617 1620 12760988 and CC I-NP O
12 1621 1625 12760988 time NN I-NP O
13 1626 1632 12760988 course NN I-NP O
14 1633 1635 12760988 of IN B-PP O
15 1636 1647 12760988 interleukin NN B-NP O
16 1647 1648 12760988 - HYPH B-NP O
17 1648 1649 12760988 6 CD I-NP O
18 1650 1664 12760988 concentrations NNS I-NP O
19 1664 1665 12760988 , , O O
20 1666 1667 12760988 a DT B-NP O
21 1668 1674 12760988 marker NN I-NP O
22 1675 1677 12760988 of IN B-PP O
23 1678 1690 12760988 inflammation NN B-NP D007249
24 1690 1691 12760988 . . O O

1 1692 1704 12760988 Pretreatment NN B-NP O
2 1705 1709 12760988 with IN B-PP O
3 1710 1723 12760988 dexamethasone NN B-NP D003907
4 1724 1726 12760988 is VBZ B-VP O
5 1727 1730 12760988 not RB O O
6 1731 1740 12760988 justified JJ B-ADJP O
7 1741 1743 12760988 to TO B-VP O
8 1744 1751 12760988 prevent VB I-VP O
9 1752 1765 12760988 postoperative JJ B-NP D010149
10 1766 1773 12760988 myalgia NN I-NP D010149
11 1774 1779 12760988 after IN B-PP O
12 1780 1795 12760988 succinylcholine NN B-NP D013390
13 1795 1796 12760988 . . O O

1 0 0 7059267 -DOCSTART- -X- -X- O

1 0 14 7059267 Chlorpropamide NN B-NP D002747
2 14 15 7059267 - HYPH O O
3 15 22 7059267 induced VBN B-NP O
4 23 28 7059267 optic JJ I-NP D009901
5 29 39 7059267 neuropathy NN I-NP D009901
6 39 40 7059267 . . O O
7 41 42 7059267 A NN B-NP O
8 43 45 7059267 65 CD I-NP O
9 45 46 7059267 - HYPH I-NP O
10 46 50 7059267 year NN I-NP O
11 50 51 7059267 - HYPH O O
12 51 54 7059267 old JJ B-NP O
13 55 60 7059267 woman NN I-NP O
14 61 65 7059267 with IN B-PP O
15 66 71 7059267 adult NN B-NP D003924
16 71 72 7059267 - HYPH B-NP D003924
17 72 77 7059267 onset NN I-NP D003924
18 78 86 7059267 diabetes NNS I-NP D003924
19 87 94 7059267 treated VBN B-VP O
20 95 99 7059267 with IN B-PP O
21 100 114 7059267 chlorpropamide NN B-NP D002747
22 115 116 7059267 ( ( O O
23 116 125 7059267 Diabenese NN B-NP D002747
24 125 126 7059267 ) ) O O
25 127 130 7059267 had VBD B-VP O
26 131 132 7059267 a DT B-NP O
27 133 138 7059267 toxic JJ I-NP D009901
28 139 144 7059267 optic JJ I-NP D009901
29 145 155 7059267 neuropathy NN I-NP D009901
30 156 160 7059267 that WDT B-NP O
31 161 169 7059267 resolved VBD B-VP O
32 170 174 7059267 with IN B-PP O
33 175 190 7059267 discontinuation NN B-NP O
34 191 193 7059267 of IN B-PP O
35 194 208 7059267 chlorpropamide NN B-NP D002747
36 209 216 7059267 therapy NN I-NP O
37 216 217 7059267 . . O O

1 218 224 7059267 Visual JJ B-NP D014786
2 225 229 7059267 loss NN I-NP D014786
3 230 236 7059267 occurs VBZ B-VP O
4 237 239 7059267 in IN B-PP O
5 240 249 7059267 diabetics NNS B-NP D003920
6 250 253 7059267 for IN B-PP O
7 254 255 7059267 a DT B-NP O
8 256 263 7059267 variety NN I-NP O
9 264 266 7059267 of IN B-PP O
10 267 274 7059267 reasons NNS B-NP O
11 274 275 7059267 , , O O
12 276 279 7059267 and CC O O
13 280 288 7059267 accurate JJ B-NP O
14 289 298 7059267 diagnosis NN I-NP O
15 299 301 7059267 is VBZ B-VP O
16 302 311 7059267 necessary JJ B-ADJP O
17 312 314 7059267 to TO B-VP O
18 315 324 7059267 institute VB I-VP O
19 325 336 7059267 appropriate JJ B-NP O
20 337 344 7059267 therapy NN I-NP O
21 344 345 7059267 . . O O

1 346 349 7059267 The DT B-NP O
2 350 361 7059267 possibility NN I-NP O
3 362 364 7059267 of IN B-PP O
4 365 366 7059267 a DT B-NP O
5 367 371 7059267 drug NN I-NP O
6 371 372 7059267 - HYPH O O
7 372 379 7059267 induced VBN B-NP O
8 380 385 7059267 optic JJ I-NP D009901
9 386 396 7059267 neuropathy NN I-NP D009901
10 397 403 7059267 should MD B-VP O
11 404 406 7059267 be VB I-VP O
12 407 417 7059267 considered VBN I-VP O
13 418 420 7059267 in IN B-PP O
14 421 424 7059267 the DT B-NP O
15 425 437 7059267 differential JJ I-NP O
16 438 447 7059267 diagnosis NN I-NP O
17 448 450 7059267 of IN B-PP O
18 451 457 7059267 visual JJ B-NP D014786
19 458 462 7059267 loss NN I-NP D014786
20 463 465 7059267 in IN B-PP O
21 466 475 7059267 diabetics NNS B-NP D003920
22 475 476 7059267 . . O O

1 0 0 3973521 -DOCSTART- -X- -X- O

1 0 4 3973521 Time NN B-NP O
2 5 11 3973521 course NN I-NP O
3 12 23 3973521 alterations NNS I-NP O
4 24 26 3973521 of IN B-PP O
5 27 30 3973521 QTC NN B-NP O
6 31 39 3973521 interval NN I-NP O
7 40 43 3973521 due JJ B-ADJP O
8 44 46 3973521 to TO B-VP O
9 47 54 3973521 hypaque VB I-VP C027278
10 55 57 3973521 76 CD B-NP C027278
11 57 58 3973521 . . O O
12 59 69 3973521 Sequential JJ B-NP O
13 70 81 3973521 measurement NN I-NP O
14 82 84 3973521 of IN B-PP O
15 85 87 3973521 QT NN B-NP O
16 88 96 3973521 interval NN I-NP O
17 97 103 3973521 during IN B-PP O
18 104 108 3973521 left JJ B-NP O
19 109 120 3973521 ventricular JJ I-NP O
20 121 132 3973521 angiography NN I-NP O
21 133 136 3973521 was VBD B-VP O
22 137 141 3973521 made VBN I-VP O
23 142 144 3973521 30 CD B-NP O
24 145 152 3973521 seconds NNS I-NP O
25 153 156 3973521 and CC O O
26 157 160 3973521 one CD B-NP O
27 160 161 3973521 , , I-NP O
28 162 167 3973521 three CD I-NP O
29 167 168 3973521 , , I-NP O
30 169 173 3973521 five CD I-NP O
31 174 177 3973521 and CC I-NP O
32 178 181 3973521 ten CD I-NP O
33 182 189 3973521 minutes NNS I-NP O
34 190 195 3973521 after IN B-PP O
35 196 205 3973521 injection NN B-NP O
36 206 208 3973521 of IN B-PP O
37 209 216 3973521 hypaque NN B-NP C027278
38 217 219 3973521 76 CD I-NP C027278
39 219 220 3973521 . . O O

1 221 224 3973521 The DT B-NP O
2 225 233 3973521 subjects NNS I-NP O
3 234 238 3973521 were VBD B-VP O
4 239 242 3973521 ten CD B-NP O
5 243 251 3973521 patients NNS I-NP O
6 252 257 3973521 found VBN B-VP O
7 258 260 3973521 to TO I-VP O
8 261 265 3973521 have VB I-VP O
9 266 272 3973521 normal JJ B-NP O
10 273 277 3973521 left JJ I-NP O
11 278 288 3973521 ventricles NNS I-NP O
12 289 292 3973521 and CC O O
13 293 301 3973521 coronary JJ B-NP O
14 302 310 3973521 arteries NNS I-NP O
15 310 311 3973521 . . O O

1 312 323 3973521 Significant JJ B-NP O
2 324 327 3973521 QTC NN I-NP D008133
3 328 340 3973521 prolongation NN I-NP D008133
4 341 349 3973521 occurred VBD B-VP O
5 350 352 3973521 in IN B-PP O
6 353 355 3973521 30 CD B-NP O
7 356 363 3973521 seconds NNS I-NP O
8 364 366 3973521 to TO B-PP O
9 367 370 3973521 one CD B-NP O
10 371 377 3973521 minute NN I-NP O
11 378 380 3973521 in IN B-PP O
12 381 392 3973521 association NN B-NP O
13 393 397 3973521 with IN B-PP O
14 398 404 3973521 marked JJ B-NP O
15 405 416 3973521 hypotension NN I-NP D007022
16 417 420 3973521 and CC I-NP O
17 421 430 3973521 elevation NN I-NP O
18 431 433 3973521 of IN B-PP O
19 434 441 3973521 cardiac JJ B-NP O
20 442 448 3973521 output NN I-NP O
21 448 449 3973521 . . O O

1 0 0 7421734 -DOCSTART- -X- -X- O

1 0 11 7421734 Endometrial JJ B-NP D016889
2 12 21 7421734 carcinoma NN I-NP D016889
3 22 27 7421734 after IN B-PP O
4 28 35 7421734 Hodgkin NN B-NP D006689
5 36 43 7421734 disease NN I-NP D006689
6 44 46 7421734 in IN B-PP O
7 47 56 7421734 childhood NN B-NP O
8 56 57 7421734 . . O O
9 58 59 7421734 A DT B-NP O
10 60 62 7421734 34 CD I-NP O
11 62 63 7421734 - HYPH I-NP O
12 63 67 7421734 year NN I-NP O
13 67 68 7421734 - HYPH O O
14 68 71 7421734 old JJ B-NP O
15 72 79 7421734 patient NN I-NP O
16 80 89 7421734 developed VBD B-VP O
17 90 98 7421734 metastic JJ B-NP O
18 99 110 7421734 endometrial JJ I-NP D016889
19 111 120 7421734 carcinoma NN I-NP D016889
20 121 126 7421734 after IN B-PP O
21 127 134 7421734 Hodgkin NN B-NP D006689
22 135 142 7421734 disease NN I-NP D006689
23 143 145 7421734 in IN B-PP O
24 146 155 7421734 childhood NN B-NP O
25 155 156 7421734 . . O O

1 157 160 7421734 She PRP B-NP O
2 161 164 7421734 had VBD B-VP O
3 165 172 7421734 ovarian JJ B-NP D010049
4 173 180 7421734 failure NN I-NP D010049
5 181 186 7421734 after IN B-PP O
6 187 196 7421734 abdominal JJ B-NP O
7 197 208 7421734 irradiation NN I-NP O
8 209 212 7421734 and CC I-NP O
9 213 225 7421734 chemotherapy NN I-NP O
10 226 229 7421734 for IN B-PP O
11 230 237 7421734 Hodgkin NN B-NP D006689
12 238 245 7421734 disease NN I-NP D006689
13 245 246 7421734 , , O O
14 247 250 7421734 and CC O O
15 251 259 7421734 received VBD B-VP O
16 260 269 7421734 exogenous JJ B-NP O
17 270 279 7421734 estrogens NNS I-NP D004967
18 279 280 7421734 , , O O
19 281 282 7421734 a DT B-NP O
20 283 292 7421734 treatment NN I-NP O
21 293 303 7421734 implicated VBN B-VP O
22 304 306 7421734 in IN B-PP O
23 307 310 7421734 the DT B-NP O
24 311 322 7421734 development NN I-NP O
25 323 325 7421734 of IN B-PP O
26 326 337 7421734 endometrial JJ B-NP D016889
27 338 344 7421734 cancer NN I-NP D016889
28 345 347 7421734 in IN B-PP O
29 348 358 7421734 menopausal JJ B-NP O
30 359 364 7421734 women NNS I-NP O
31 364 365 7421734 . . O O

1 366 371 7421734 Young JJ B-NP O
2 372 377 7421734 women NNS I-NP O
3 378 380 7421734 on IN B-PP O
4 381 392 7421734 replacement NN B-NP O
5 393 402 7421734 estrogens NNS I-NP D004967
6 403 406 7421734 for IN B-PP O
7 407 414 7421734 ovarian JJ B-NP D010049
8 415 422 7421734 failure NN I-NP D010049
9 423 428 7421734 after IN B-PP O
10 429 435 7421734 cancer NN B-NP D009369
11 436 443 7421734 therapy NN I-NP O
12 444 447 7421734 may MD B-VP O
13 448 452 7421734 also RB I-VP O
14 453 457 7421734 have VB I-VP O
15 458 467 7421734 increased VBN B-NP O
16 468 472 7421734 risk NN I-NP O
17 473 475 7421734 of IN B-PP O
18 476 487 7421734 endometrial JJ B-NP D016889
19 488 497 7421734 carcinoma NN I-NP D016889
20 498 501 7421734 and CC O O
21 502 508 7421734 should MD B-VP O
22 509 511 7421734 be VB I-VP O
23 512 520 7421734 examined VBN I-VP O
24 521 533 7421734 periodically RB B-ADVP O
25 533 534 7421734 . . O O

1 0 0 19996135 -DOCSTART- -X- -X- O

1 0 4 19996135 High JJ B-NP O
2 4 5 19996135 - HYPH I-NP O
3 5 9 19996135 dose NN I-NP O
4 10 20 19996135 tranexamic JJ I-NP D014148
5 21 25 19996135 Acid NN I-NP D014148
6 26 28 19996135 is VBZ B-VP O
7 29 39 19996135 associated VBN I-VP O
8 40 44 19996135 with IN B-PP O
9 45 56 19996135 nonischemic JJ B-NP O
10 57 65 19996135 clinical JJ I-NP O
11 66 74 19996135 seizures NNS I-NP D012640
12 75 77 19996135 in IN B-PP O
13 78 85 19996135 cardiac JJ B-NP O
14 86 94 19996135 surgical JJ I-NP O
15 95 103 19996135 patients NNS I-NP O
16 103 104 19996135 . . O O
17 105 115 19996135 BACKGROUND NN B-NP O
18 115 116 19996135 : : O O
19 117 119 19996135 In IN B-PP O
20 120 121 19996135 2 CD B-NP O
21 122 130 19996135 separate JJ I-NP O
22 131 138 19996135 centers NNS I-NP O
23 138 139 19996135 , , O O
24 140 142 19996135 we PRP B-NP O
25 143 151 19996135 observed VBD B-VP O
26 152 153 19996135 a DT B-NP O
27 154 161 19996135 notable JJ I-NP O
28 162 170 19996135 increase NN I-NP O
29 171 173 19996135 in IN B-PP O
30 174 177 19996135 the DT B-NP O
31 178 187 19996135 incidence NN I-NP O
32 188 190 19996135 of IN B-PP O
33 191 204 19996135 postoperative JJ B-NP O
34 205 215 19996135 convulsive JJ I-NP D012640
35 216 224 19996135 seizures NNS I-NP D012640
36 225 229 19996135 from IN B-PP O
37 230 234 19996135 1.3% CD B-NP O
38 235 237 19996135 to TO B-PP O
39 238 242 19996135 3.8% CD B-NP O
40 243 245 19996135 in IN B-PP O
41 246 254 19996135 patients NNS B-NP O
42 255 261 19996135 having VBG B-VP O
43 262 271 19996135 undergone VBN I-VP O
44 272 277 19996135 major JJ B-NP O
45 278 285 19996135 cardiac JJ I-NP O
46 286 294 19996135 surgical JJ I-NP O
47 295 305 19996135 procedures NNS I-NP O
48 305 306 19996135 . . O O

1 307 312 19996135 These DT B-NP O
2 313 319 19996135 events NNS I-NP O
3 320 324 19996135 were VBD B-VP O
4 325 335 19996135 temporally RB B-ADJP O
5 336 346 19996135 coincident JJ I-ADJP O
6 347 351 19996135 with IN B-PP O
7 352 355 19996135 the DT B-NP O
8 356 363 19996135 initial JJ I-NP O
9 364 367 19996135 use NN I-NP O
10 368 370 19996135 of IN B-PP O
11 371 375 19996135 high JJ B-NP O
12 375 376 19996135 - HYPH I-NP O
13 376 380 19996135 dose NN I-NP O
14 381 391 19996135 tranexamic JJ I-NP D014148
15 392 396 19996135 acid NN I-NP D014148
16 397 398 19996135 ( ( O O
17 398 401 19996135 TXA NN B-NP D014148
18 401 402 19996135 ) ) O O
19 403 410 19996135 therapy NN B-NP O
20 411 416 19996135 after IN B-PP O
21 417 427 19996135 withdrawal NN B-NP O
22 428 430 19996135 of IN B-PP O
23 431 440 19996135 aprotinin NN B-NP O
24 441 445 19996135 from IN B-PP O
25 446 453 19996135 general JJ B-NP O
26 454 462 19996135 clinical JJ I-NP O
27 463 468 19996135 usage NN I-NP O
28 468 469 19996135 . . O O

1 470 473 19996135 The DT B-NP O
2 474 481 19996135 purpose NN I-NP O
3 482 484 19996135 of IN B-PP O
4 485 489 19996135 this DT B-NP O
5 490 496 19996135 review NN I-NP O
6 497 500 19996135 was VBD B-VP O
7 501 503 19996135 to TO B-VP O
8 504 511 19996135 perform VB I-VP O
9 512 513 19996135 a DT B-NP O
10 514 527 19996135 retrospective JJ I-NP O
11 528 536 19996135 analysis NN I-NP O
12 537 539 19996135 to TO B-VP O
13 540 547 19996135 examine VB I-VP O
14 548 555 19996135 whether IN B-SBAR O
15 556 561 19996135 there EX B-NP O
16 562 565 19996135 was VBD B-VP O
17 566 567 19996135 a DT B-NP O
18 568 576 19996135 relation NN I-NP O
19 577 584 19996135 between IN B-PP O
20 585 588 19996135 TXA NN B-NP D014148
21 589 594 19996135 usage NN I-NP O
22 595 598 19996135 and CC O O
23 599 607 19996135 seizures NNS B-NP D012640
24 608 613 19996135 after IN B-PP O
25 614 621 19996135 cardiac JJ B-NP O
26 622 629 19996135 surgery NN I-NP O
27 629 630 19996135 . . O O

1 631 638 19996135 METHODS NNS B-NP O
2 638 639 19996135 : : O O
3 640 642 19996135 An DT B-NP O
4 643 645 19996135 in IN B-PP O
5 645 646 19996135 - HYPH B-NP O
6 646 651 19996135 depth NN I-NP O
7 652 657 19996135 chart NN I-NP O
8 658 664 19996135 review NN I-NP O
9 665 668 19996135 was VBD B-VP O
10 669 679 19996135 undertaken VBN I-VP O
11 680 682 19996135 in IN B-PP O
12 683 686 19996135 all DT B-NP O
13 687 689 19996135 24 CD I-NP O
14 690 698 19996135 patients NNS I-NP O
15 699 702 19996135 who WP B-NP O
16 703 712 19996135 developed VBD B-VP O
17 713 726 19996135 perioperative JJ B-NP O
18 727 735 19996135 seizures NNS I-NP D012640
19 735 736 19996135 . . O O

1 737 760 19996135 Electroencephalographic JJ B-NP O
2 761 769 19996135 activity NN I-NP O
3 770 773 19996135 was VBD B-VP O
4 774 782 19996135 recorded VBN I-VP O
5 783 785 19996135 in IN B-PP O
6 786 788 19996135 11 CD B-NP O
7 789 791 19996135 of IN B-PP O
8 792 797 19996135 these DT B-NP O
9 798 806 19996135 patients NNS I-NP O
10 806 807 19996135 , , O O
11 808 811 19996135 and CC O O
12 812 815 19996135 all DT B-NP O
13 816 824 19996135 patients NNS I-NP O
14 825 828 19996135 had VBD B-VP O
15 829 830 19996135 a DT B-NP O
16 831 837 19996135 formal JJ I-NP O
17 838 850 19996135 neurological JJ I-NP O
18 851 861 19996135 evaluation NN I-NP O
19 862 865 19996135 and CC I-NP O
20 866 871 19996135 brain NN I-NP O
21 872 879 19996135 imaging NN I-NP O
22 880 887 19996135 studies NNS I-NP O
23 887 888 19996135 . . O O

1 889 896 19996135 RESULTS NNS B-NP O
2 896 897 19996135 : : O O
3 898 904 19996135 Twenty CD B-NP O
4 904 905 19996135 - HYPH I-NP O
5 905 908 19996135 one CD I-NP O
6 909 911 19996135 of IN B-PP O
7 912 915 19996135 the DT B-NP O
8 916 918 19996135 24 CD I-NP O
9 919 927 19996135 patients NNS I-NP O
10 928 931 19996135 did VBD B-VP O
11 932 935 19996135 not RB I-VP O
12 936 940 19996135 have VB I-VP O
13 941 949 19996135 evidence NN B-NP O
14 950 952 19996135 of IN B-PP O
15 953 956 19996135 new JJ B-NP O
16 957 965 19996135 cerebral JJ I-NP D001930
17 966 974 19996135 ischemic JJ I-NP D001930
18 975 981 19996135 injury NN I-NP D001930
19 981 982 19996135 , , O O
20 983 986 19996135 but CC O O
21 987 995 19996135 seizures NNS B-NP D012640
22 996 1000 19996135 were VBD B-VP O
23 1001 1007 19996135 likely RB B-ADJP O
24 1008 1011 19996135 due JJ I-ADJP O
25 1012 1014 19996135 to TO B-PP O
26 1015 1023 19996135 ischemic JJ B-NP D001930
27 1024 1029 19996135 brain NN I-NP D001930
28 1030 1036 19996135 injury NN I-NP D001930
29 1037 1039 19996135 in IN B-PP O
30 1040 1041 19996135 3 CD B-NP O
31 1042 1050 19996135 patients NNS I-NP O
32 1050 1051 19996135 . . O O

1 1052 1055 19996135 All DT B-NP O
2 1056 1064 19996135 patients NNS I-NP O
3 1065 1069 19996135 with IN B-PP O
4 1070 1078 19996135 seizures NNS B-NP D012640
5 1079 1082 19996135 did VBD B-VP O
6 1083 1086 19996135 not RB I-VP O
7 1087 1091 19996135 have VB I-VP O
8 1092 1101 19996135 permanent JJ B-NP O
9 1102 1114 19996135 neurological JJ I-NP D009422
10 1115 1128 19996135 abnormalities NNS I-NP D009422
11 1128 1129 19996135 . . O O

1 1130 1133 19996135 All DT B-NP O
2 1134 1136 19996135 24 CD I-NP O
3 1137 1145 19996135 patients NNS I-NP O
4 1146 1150 19996135 with IN B-PP O
5 1151 1159 19996135 seizures NNS B-NP D012640
6 1160 1168 19996135 received VBD B-VP O
7 1169 1173 19996135 high JJ B-NP O
8 1174 1179 19996135 doses NNS I-NP O
9 1180 1182 19996135 of IN B-PP O
10 1183 1186 19996135 TXA NN B-NP D014148
11 1187 1203 19996135 intraoperatively RB B-VP O
12 1204 1211 19996135 ranging VBG I-VP O
13 1212 1216 19996135 from IN B-PP O
14 1217 1219 19996135 61 CD B-NP O
15 1220 1222 19996135 to TO I-NP O
16 1223 1226 19996135 259 CD I-NP O
17 1227 1229 19996135 mg NN I-NP O
18 1229 1230 19996135 / SYM B-NP O
19 1230 1232 19996135 kg NN I-NP O
20 1232 1233 19996135 , , O O
21 1234 1237 19996135 had VBD B-VP O
22 1238 1239 19996135 a DT B-NP O
23 1240 1244 19996135 mean JJ I-NP O
24 1245 1248 19996135 age NN I-NP O
25 1249 1251 19996135 of IN B-PP O
26 1252 1256 19996135 69.9 CD B-NP O
27 1257 1262 19996135 years NNS I-NP O
28 1262 1263 19996135 , , O O
29 1264 1267 19996135 and CC O O
30 1268 1270 19996135 21 CD B-NP O
31 1271 1273 19996135 of IN B-PP O
32 1274 1276 19996135 24 CD B-NP O
33 1277 1280 19996135 had VBD B-VP O
34 1281 1290 19996135 undergone VBN I-VP O
35 1291 1295 19996135 open JJ B-NP O
36 1296 1303 19996135 chamber NN I-NP O
37 1304 1310 19996135 rather RB B-PP O
38 1311 1315 19996135 than IN I-PP O
39 1316 1324 19996135 coronary JJ B-NP O
40 1325 1331 19996135 bypass NN I-NP O
41 1332 1342 19996135 procedures NNS I-NP O
42 1342 1343 19996135 . . O O

1 1344 1347 19996135 All DT B-NP O
2 1348 1351 19996135 but IN I-NP O
3 1352 1355 19996135 one CD I-NP O
4 1356 1363 19996135 patient NN I-NP O
5 1364 1368 19996135 were VBD B-VP O
6 1369 1376 19996135 managed VBN I-VP O
7 1377 1382 19996135 using VBG B-VP O
8 1383 1398 19996135 cardiopulmonary JJ B-NP O
9 1399 1405 19996135 bypass NN I-NP O
10 1405 1406 19996135 . . O O

1 1407 1409 19996135 No DT B-NP O
2 1410 1418 19996135 evidence NN I-NP O
3 1419 1421 19996135 of IN B-PP O
4 1422 1427 19996135 brain NN B-NP D002546
5 1428 1436 19996135 ischemic JJ I-NP D002546
6 1436 1437 19996135 , , I-NP O
7 1438 1447 19996135 metabolic JJ I-NP O
8 1447 1448 19996135 , , I-NP O
9 1449 1451 19996135 or CC I-NP O
10 1452 1464 19996135 hyperthermia NN I-NP D005334
11 1464 1465 19996135 - HYPH O O
12 1465 1472 19996135 induced VBN B-NP O
13 1473 1479 19996135 causes NNS I-NP O
14 1480 1483 19996135 for IN B-PP O
15 1484 1489 19996135 their PRP$ B-NP O
16 1490 1498 19996135 seizures NNS I-NP D012640
17 1499 1502 19996135 was VBD B-VP O
18 1503 1511 19996135 apparent JJ B-ADJP O
19 1511 1512 19996135 . . O O

1 1513 1523 19996135 CONCLUSION NN B-NP O
2 1523 1524 19996135 : : O O
3 1525 1528 19996135 Our PRP$ B-NP O
4 1529 1536 19996135 results NNS I-NP O
5 1537 1544 19996135 suggest VBP B-VP O
6 1545 1549 19996135 that IN B-SBAR O
7 1550 1553 19996135 use NN B-NP O
8 1554 1556 19996135 of IN B-PP O
9 1557 1561 19996135 high JJ B-NP O
10 1561 1562 19996135 - HYPH I-NP O
11 1562 1566 19996135 dose NN I-NP O
12 1567 1570 19996135 TXA NN I-NP D014148
13 1571 1573 19996135 in IN B-PP O
14 1574 1579 19996135 older JJR B-NP O
15 1580 1588 19996135 patients NNS I-NP O
16 1589 1591 19996135 in IN B-PP O
17 1592 1603 19996135 conjunction NN B-NP O
18 1604 1608 19996135 with IN B-PP O
19 1609 1624 19996135 cardiopulmonary JJ B-NP O
20 1625 1631 19996135 bypass NN I-NP O
21 1632 1635 19996135 and CC O O
22 1636 1640 19996135 open JJ B-NP O
23 1640 1641 19996135 - HYPH I-NP O
24 1641 1648 19996135 chamber NN I-NP O
25 1649 1656 19996135 cardiac JJ I-NP O
26 1657 1664 19996135 surgery NN I-NP O
27 1665 1667 19996135 is VBZ B-VP O
28 1668 1678 19996135 associated VBN I-VP O
29 1679 1683 19996135 with IN B-PP O
30 1684 1692 19996135 clinical JJ B-NP O
31 1693 1701 19996135 seizures NNS I-NP D012640
32 1702 1704 19996135 in IN B-PP O
33 1705 1716 19996135 susceptible JJ B-NP O
34 1717 1725 19996135 patients NNS I-NP O
35 1725 1726 19996135 . . O O

1 0 0 9305828 -DOCSTART- -X- -X- O

1 0 12 9305828 Neuropeptide NN B-NP O
2 12 13 9305828 - HYPH I-NP O
3 13 14 9305828 Y NN I-NP O
4 15 31 9305828 immunoreactivity NN I-NP O
5 32 34 9305828 in IN B-PP O
6 35 38 9305828 the DT B-NP O
7 39 50 9305828 pilocarpine NN I-NP D010862
8 51 56 9305828 model NN I-NP O
9 57 59 9305828 of IN B-PP O
10 60 68 9305828 temporal JJ B-NP D004833
11 69 73 9305828 lobe NN I-NP D004833
12 74 82 9305828 epilepsy NN I-NP D004833
13 82 83 9305828 . . B-NP O
14 84 96 9305828 Neuropeptide NN I-NP O
15 96 97 9305828 - HYPH O O
16 97 98 9305828 Y NN B-NP O
17 99 100 9305828 ( ( O O
18 100 103 9305828 NPY NN B-NP O
19 103 104 9305828 ) ) O O
20 105 107 9305828 is VBZ B-VP O
21 108 117 9305828 expressed VBN I-VP O
22 118 120 9305828 by IN B-PP O
23 121 128 9305828 granule NN B-NP O
24 129 134 9305828 cells NNS I-NP O
25 135 138 9305828 and CC O O
26 139 144 9305828 mossy JJ B-NP O
27 145 151 9305828 fibres NNS I-NP O
28 152 154 9305828 of IN B-PP O
29 155 158 9305828 the DT B-NP O
30 159 170 9305828 hippocampal JJ I-NP O
31 171 178 9305828 dentate NN I-NP O
32 179 184 9305828 gyrus NN I-NP O
33 185 191 9305828 during IN B-PP O
34 192 204 9305828 experimental JJ B-NP O
35 205 213 9305828 temporal JJ I-NP D004833
36 214 218 9305828 lobe NN I-NP D004833
37 219 227 9305828 epilepsy NN I-NP D004833
38 228 229 9305828 ( ( O O
39 229 232 9305828 TLE NN B-NP D004833
40 232 233 9305828 ) ) O O
41 233 234 9305828 . . O O

1 235 239 9305828 This DT B-NP O
2 240 250 9305828 expression NN I-NP O
3 251 254 9305828 may MD B-VP O
4 255 264 9305828 represent VB I-VP O
5 265 267 9305828 an DT B-NP O
6 268 278 9305828 endogenous JJ I-NP O
7 279 286 9305828 damping VBG I-NP O
8 287 296 9305828 mechanism NN I-NP O
9 297 302 9305828 since IN B-SBAR O
10 303 306 9305828 NPY NN B-NP O
11 307 310 9305828 has VBZ B-VP O
12 311 315 9305828 been VBN I-VP O
13 316 321 9305828 shown VBN I-VP O
14 322 324 9305828 to TO I-VP O
15 325 330 9305828 block VB I-VP O
16 331 338 9305828 seizure NN B-NP D012640
17 338 339 9305828 - HYPH O O
18 339 343 9305828 like JJ B-NP O
19 344 350 9305828 events NNS I-NP O
20 351 360 9305828 following VBG B-PP O
21 361 365 9305828 high JJ B-NP O
22 365 366 9305828 - HYPH I-NP O
23 366 375 9305828 frequency NN I-NP O
24 376 387 9305828 stimulation NN I-NP O
25 388 390 9305828 in IN B-PP O
26 391 402 9305828 hippocampal JJ B-NP O
27 403 409 9305828 slices NNS I-NP O
28 409 410 9305828 . . O O

1 411 414 9305828 The DT B-NP O
2 415 426 9305828 pilocarpine NN I-NP D010862
3 427 428 9305828 ( ( O O
4 428 432 9305828 PILO NN B-NP D010862
5 432 433 9305828 ) ) O O
6 434 439 9305828 model NN B-NP O
7 440 442 9305828 of IN B-PP O
8 443 451 9305828 epilepsy NN B-NP D004827
9 452 454 9305828 is VBZ B-VP O
10 455 468 9305828 characterized VBN I-VP O
11 469 471 9305828 by IN B-PP O
12 472 474 9305828 an DT B-NP O
13 475 480 9305828 acute JJ I-NP O
14 481 487 9305828 period NN I-NP O
15 488 490 9305828 of IN B-PP O
16 491 497 9305828 status NN B-NP D013226
17 498 509 9305828 epilepticus NN I-NP D013226
18 510 518 9305828 followed VBN B-VP O
19 519 521 9305828 by IN B-PP O
20 522 533 9305828 spontaneous JJ B-NP O
21 534 543 9305828 recurrent JJ I-NP O
22 544 552 9305828 seizures NNS I-NP D012640
23 553 556 9305828 and CC O O
24 557 564 9305828 related VBN B-NP O
25 565 570 9305828 brain NN I-NP D001930
26 571 577 9305828 damage NN I-NP D001930
27 577 578 9305828 . . O O

1 579 581 9305828 We PRP B-NP O
2 582 588 9305828 report VBP B-VP O
3 589 599 9305828 peroxidase NN B-NP O
4 599 600 9305828 - HYPH B-NP O
5 600 614 9305828 antiperoxidase NN I-NP O
6 615 629 9305828 immunostaining NN I-NP O
7 630 633 9305828 for IN B-PP O
8 634 637 9305828 NPY NN B-NP O
9 638 640 9305828 in IN B-PP O
10 641 648 9305828 several JJ B-NP O
11 649 654 9305828 brain NN I-NP O
12 655 662 9305828 regions NNS I-NP O
13 663 665 9305828 in IN B-PP O
14 666 670 9305828 this DT B-NP O
15 671 676 9305828 model NN I-NP O
16 676 677 9305828 . . O O

1 678 682 9305828 PILO NN B-NP D010862
2 682 683 9305828 - HYPH B-NP O
3 683 691 9305828 injected VBN I-NP O
4 692 699 9305828 animals NNS I-NP O
5 700 709 9305828 exhibited VBD B-VP O
6 710 713 9305828 NPY NN B-NP O
7 714 730 9305828 immunoreactivity NN I-NP O
8 731 733 9305828 in IN B-PP O
9 734 737 9305828 the DT B-NP O
10 738 744 9305828 region NN I-NP O
11 745 747 9305828 of IN B-PP O
12 748 751 9305828 the DT B-NP O
13 752 757 9305828 mossy NN I-NP O
14 758 763 9305828 fibre NN I-NP O
15 764 773 9305828 terminals NNS I-NP O
16 773 774 9305828 , , O O
17 775 777 9305828 in IN B-PP O
18 778 781 9305828 the DT B-NP O
19 782 789 9305828 dentate NN I-NP O
20 790 795 9305828 gyrus NN I-NP O
21 796 801 9305828 inner JJ I-NP O
22 802 811 9305828 molecular JJ I-NP O
23 812 817 9305828 layer NN I-NP O
24 818 821 9305828 and CC O O
25 821 822 9305828 , , O O
26 823 825 9305828 in IN B-PP O
27 826 827 9305828 a DT B-NP O
28 828 831 9305828 few JJ I-NP O
29 832 837 9305828 cases NNS I-NP O
30 837 838 9305828 , , O O
31 839 845 9305828 within IN B-PP O
32 846 854 9305828 presumed VBN B-NP O
33 855 862 9305828 granule NN I-NP O
34 863 868 9305828 cells NNS I-NP O
35 868 869 9305828 . . O O

1 870 873 9305828 NPY NN B-NP O
2 874 890 9305828 immunoreactivity NN I-NP O
3 891 894 9305828 was VBD B-VP O
4 895 899 9305828 also RB B-ADVP O
5 900 912 9305828 dramatically RB B-ADJP O
6 913 920 9305828 changed VBN I-ADJP O
7 921 923 9305828 in IN B-PP O
8 924 927 9305828 the DT B-NP O
9 928 938 9305828 entorhinal JJ I-NP O
10 939 945 9305828 cortex NN I-NP O
11 945 946 9305828 , , O O
12 947 955 9305828 amygdala NN B-NP O
13 956 959 9305828 and CC I-NP O
14 960 972 9305828 sensorimotor NN I-NP O
15 973 978 9305828 areas NNS I-NP O
16 978 979 9305828 . . O O

1 980 982 9305828 In IN B-PP O
2 983 991 9305828 addition NN B-NP O
3 991 992 9305828 , , O O
4 993 997 9305828 PILO NN B-NP D010862
5 998 1006 9305828 injected VBN I-NP O
6 1007 1014 9305828 animals NNS I-NP O
7 1015 1024 9305828 exhibited VBD B-VP O
8 1025 1026 9305828 a DT B-NP O
9 1027 1036 9305828 reduction NN I-NP O
10 1037 1039 9305828 in IN B-PP O
11 1040 1043 9305828 the DT B-NP O
12 1044 1050 9305828 number NN I-NP O
13 1051 1053 9305828 of IN B-PP O
14 1054 1057 9305828 NPY NN B-NP O
15 1057 1058 9305828 - HYPH B-NP O
16 1058 1072 9305828 immunoreactive JJ I-NP O
17 1073 1085 9305828 interneurons NNS I-NP O
18 1086 1094 9305828 compared VBN B-PP O
19 1095 1099 9305828 with IN B-PP O
20 1100 1108 9305828 controls NNS B-NP O
21 1108 1109 9305828 . . O O

1 1110 1113 9305828 The DT B-NP O
2 1114 1121 9305828 results NNS I-NP O
3 1122 1133 9305828 demonstrate VBP B-VP O
4 1134 1138 9305828 that IN B-SBAR O
5 1139 1146 9305828 changes NNS B-NP O
6 1147 1149 9305828 in IN B-PP O
7 1150 1153 9305828 NPY NN B-NP O
8 1154 1164 9305828 expression NN I-NP O
9 1164 1165 9305828 , , O O
10 1166 1175 9305828 including VBG B-PP O
11 1176 1186 9305828 expression NN B-NP O
12 1187 1189 9305828 in IN B-PP O
13 1190 1193 9305828 the DT B-NP O
14 1194 1201 9305828 granule NN I-NP O
15 1202 1207 9305828 cells NNS I-NP O
16 1208 1211 9305828 and CC O O
17 1212 1217 9305828 mossy NN B-NP O
18 1218 1224 9305828 fibres NNS I-NP O
19 1225 1228 9305828 and CC O O
20 1229 1232 9305828 the DT B-NP O
21 1233 1237 9305828 loss NN I-NP O
22 1238 1240 9305828 of IN B-PP O
23 1241 1251 9305828 vulnerable JJ B-NP O
24 1252 1255 9305828 NPY NN I-NP O
25 1256 1263 9305828 neurons NNS I-NP O
26 1263 1264 9305828 , , O O
27 1265 1268 9305828 are VBP B-VP O
28 1269 1276 9305828 present JJ B-ADJP O
29 1277 1279 9305828 in IN B-PP O
30 1280 1283 9305828 the DT B-NP O
31 1284 1288 9305828 PILO NN I-NP D010862
32 1289 1294 9305828 model NN I-NP O
33 1295 1297 9305828 of IN B-PP O
34 1298 1301 9305828 TLE NN B-NP D004833
35 1301 1302 9305828 . . O O

1 1303 1310 9305828 However RB B-ADVP O
2 1310 1311 9305828 , , O O
3 1312 1315 9305828 the DT B-NP O
4 1316 1328 9305828 significance NN I-NP O
5 1329 1331 9305828 of IN B-PP O
6 1332 1336 9305828 this DT B-NP O
7 1337 1344 9305828 changed VBN I-NP O
8 1345 1354 9305828 synthesis NN I-NP O
9 1355 1357 9305828 of IN B-PP O
10 1358 1361 9305828 NPY NN B-NP O
11 1362 1369 9305828 remains VBZ B-VP O
12 1370 1372 9305828 to TO I-VP O
13 1373 1375 9305828 be VB I-VP O
14 1376 1386 9305828 determined VBN I-VP O
15 1386 1387 9305828 . . O O

1 0 0 9061311 -DOCSTART- -X- -X- O

1 0 10 9061311 Neutrophil NN B-NP O
2 11 21 9061311 superoxide NN I-NP D013481
3 22 25 9061311 and CC O O
4 26 34 9061311 hydrogen NN B-NP D006861
5 35 43 9061311 peroxide NN I-NP D006861
6 44 54 9061311 production NN I-NP O
7 55 57 9061311 in IN B-PP O
8 58 66 9061311 patients NNS B-NP O
9 67 71 9061311 with IN B-PP O
10 72 77 9061311 acute JJ B-NP D017114
11 78 83 9061311 liver NN I-NP D017114
12 84 91 9061311 failure NN I-NP D017114
13 91 92 9061311 . . O O
14 93 100 9061311 Defects NNS B-NP O
15 101 103 9061311 in IN B-PP O
16 104 114 9061311 superoxide NN B-NP D013481
17 115 118 9061311 and CC I-NP O
18 119 127 9061311 hydrogen NN I-NP D006861
19 128 136 9061311 peroxide NN I-NP D006861
20 137 147 9061311 production NN I-NP O
21 148 151 9061311 may MD B-VP O
22 152 154 9061311 be VB I-VP O
23 155 165 9061311 implicated VBN I-VP O
24 166 168 9061311 in IN B-PP O
25 169 172 9061311 the DT B-NP O
26 173 177 9061311 high JJ I-NP O
27 178 187 9061311 incidence NN I-NP O
28 188 190 9061311 of IN B-PP O
29 191 200 9061311 bacterial JJ B-NP D001424
30 201 211 9061311 infections NNS I-NP D001424
31 212 214 9061311 in IN B-PP O
32 215 223 9061311 patients NNS B-NP O
33 224 228 9061311 with IN B-PP O
34 229 234 9061311 acute JJ B-NP D017114
35 235 240 9061311 liver NN I-NP D017114
36 241 248 9061311 failure NN I-NP D017114
37 249 250 9061311 ( ( O O
38 250 253 9061311 ALF NN B-NP D017114
39 253 254 9061311 ) ) O O
40 254 255 9061311 . . O O

1 256 258 9061311 In IN B-PP O
2 259 262 9061311 the DT B-NP O
3 263 270 9061311 present JJ I-NP O
4 271 276 9061311 study NN I-NP O
5 276 277 9061311 , , O O
6 278 284 9061311 oxygen NN B-NP D010100
7 285 292 9061311 radical NN I-NP O
8 293 303 9061311 production NN I-NP O
9 304 306 9061311 in IN B-PP O
10 307 315 9061311 patients NNS B-NP O
11 316 320 9061311 with IN B-PP O
12 321 324 9061311 ALF NN B-NP D017114
13 325 328 9061311 due JJ B-ADJP O
14 329 331 9061311 to TO B-PP O
15 332 343 9061311 paracetamol NN B-NP D000082
16 344 352 9061311 overdose NN I-NP D062787
17 353 356 9061311 was VBD B-VP O
18 357 365 9061311 compared VBN I-VP O
19 366 370 9061311 with IN B-PP O
20 371 375 9061311 that DT B-NP O
21 376 378 9061311 of IN B-PP O
22 379 386 9061311 healthy JJ B-NP O
23 387 397 9061311 volunteers NNS I-NP O
24 397 398 9061311 . . O O

1 399 410 9061311 Neutrophils NNS B-NP O
2 411 415 9061311 from IN B-PP O
3 416 418 9061311 14 CD B-NP O
4 419 422 9061311 ALF NN I-NP D017114
5 423 431 9061311 patients NNS I-NP O
6 432 436 9061311 were VBD B-VP O
7 437 447 9061311 stimulated VBN I-VP O
8 448 451 9061311 via IN B-PP O
9 452 455 9061311 the DT B-NP O
10 456 466 9061311 complement NN I-NP O
11 467 476 9061311 receptors NNS I-NP O
12 477 482 9061311 using VBG B-VP O
13 483 490 9061311 zymosan NN B-NP O
14 491 500 9061311 opsonized VBN B-VP O
15 501 505 9061311 with IN B-PP O
16 506 509 9061311 ALF NN B-NP D017114
17 510 512 9061311 or CC I-NP O
18 513 520 9061311 control NN I-NP O
19 521 526 9061311 serum NN I-NP O
20 526 527 9061311 . . O O

1 528 538 9061311 Superoxide NN B-NP D013481
2 539 542 9061311 and CC I-NP O
3 543 551 9061311 hydrogen NN I-NP D006861
4 552 560 9061311 peroxide NN I-NP D006861
5 561 571 9061311 production NN I-NP O
6 572 574 9061311 by IN B-PP O
7 575 578 9061311 ALF NN B-NP D017114
8 579 590 9061311 neutrophils NNS I-NP O
9 591 601 9061311 stimulated VBN B-VP O
10 602 606 9061311 with IN B-PP O
11 607 614 9061311 zymosan NN B-NP O
12 615 624 9061311 opsonized VBN B-VP O
13 625 629 9061311 with IN B-PP O
14 630 633 9061311 ALF NN B-NP D017114
15 634 639 9061311 serum NN I-NP O
16 640 643 9061311 was VBD B-VP O
17 644 657 9061311 significantly RB I-VP O
18 658 665 9061311 reduced VBN I-VP O
19 666 674 9061311 compared VBN B-PP O
20 675 679 9061311 with IN B-PP O
21 680 683 9061311 the DT B-NP O
22 684 691 9061311 control NN I-NP O
23 692 700 9061311 subjects NNS I-NP O
24 701 702 9061311 ( ( O O
25 702 703 9061311 P NN B-NP O
26 704 705 9061311 < SYM O O
27 706 710 9061311 0.01 CD B-NP O
28 710 711 9061311 ) ) O O
29 711 712 9061311 . . O O

1 713 717 9061311 This DT B-NP O
2 718 724 9061311 defect NN I-NP O
3 725 734 9061311 persisted VBD B-VP O
4 735 739 9061311 when WRB B-ADVP O
5 740 747 9061311 zymosan NN B-NP O
6 748 757 9061311 opsonized VBN B-VP O
7 758 760 9061311 by IN B-PP O
8 761 768 9061311 control NN B-NP O
9 769 774 9061311 serum NN I-NP O
10 775 778 9061311 was VBD B-VP O
11 779 783 9061311 used VBN I-VP O
12 784 785 9061311 ( ( O O
13 785 786 9061311 P NN B-NP O
14 787 788 9061311 < SYM O O
15 789 793 9061311 0.05 CD B-NP O
16 793 794 9061311 ) ) O O
17 794 795 9061311 . . O O

1 796 806 9061311 Superoxide NN B-NP D013481
2 807 810 9061311 and CC I-NP O
3 811 819 9061311 hydrogen NN I-NP D006861
4 820 828 9061311 peroxide NN I-NP D006861
5 829 839 9061311 production NN I-NP O
6 840 842 9061311 in IN B-PP O
7 843 854 9061311 neutrophils NNS B-NP O
8 855 865 9061311 stimulated VBN B-VP O
9 866 870 9061311 with IN B-PP O
10 871 877 9061311 formyl NN B-NP D009240
11 877 878 9061311 - HYPH B-NP D009240
12 878 887 9061311 methionyl NN I-NP D009240
13 887 888 9061311 - HYPH B-NP D009240
14 888 894 9061311 leucyl NN I-NP D009240
15 894 895 9061311 - HYPH O D009240
16 895 908 9061311 phenylalanine NN B-NP D009240
17 909 910 9061311 ( ( O O
18 910 914 9061311 fMLP NN B-NP D009240
19 914 915 9061311 ) ) O O
20 916 920 9061311 from IN B-PP O
21 921 922 9061311 a DT B-NP O
22 923 930 9061311 further JJ I-NP O
23 931 933 9061311 18 CD I-NP O
24 934 937 9061311 ALF NN I-NP D017114
25 938 946 9061311 patients NNS I-NP O
26 947 950 9061311 was VBD B-VP O
27 951 961 9061311 unaffected JJ B-ADJP O
28 962 970 9061311 compared VBN B-PP O
29 971 975 9061311 with IN B-PP O
30 976 983 9061311 control NN B-NP O
31 984 995 9061311 neutrophils NNS I-NP O
32 995 996 9061311 . . O O

1 997 1002 9061311 Serum NN B-NP O
2 1003 1005 9061311 C3 NN I-NP O
3 1006 1016 9061311 complement NN I-NP O
4 1017 1023 9061311 levels NNS I-NP O
5 1024 1028 9061311 were VBD B-VP O
6 1029 1042 9061311 significantly RB I-VP O
7 1043 1050 9061311 reduced VBN I-VP O
8 1051 1053 9061311 in IN B-PP O
9 1054 1057 9061311 ALF NN B-NP D017114
10 1058 1066 9061311 patients NNS I-NP O
11 1067 1075 9061311 compared VBN B-PP O
12 1076 1080 9061311 with IN B-PP O
13 1081 1088 9061311 control JJ B-NP O
14 1089 1097 9061311 subjects NNS I-NP O
15 1098 1099 9061311 ( ( O O
16 1099 1100 9061311 P NN B-NP O
17 1101 1102 9061311 < JJR B-NP O
18 1103 1109 9061311 0.0005 CD I-NP O
19 1109 1110 9061311 ) ) O O
20 1110 1111 9061311 . . O O

1 1112 1117 9061311 These DT B-NP O
2 1118 1125 9061311 results NNS I-NP O
3 1126 1137 9061311 demonstrate VBP B-VP O
4 1138 1139 9061311 a DT B-NP O
5 1140 1150 9061311 neutrophil NN I-NP O
6 1151 1157 9061311 defect NN I-NP O
7 1158 1160 9061311 in IN B-PP O
8 1161 1164 9061311 ALF NN B-NP D017114
9 1165 1168 9061311 due JJ B-ADJP O
10 1169 1171 9061311 to TO B-PP O
11 1172 1183 9061311 paracetamol NN B-NP D000082
12 1184 1192 9061311 overdose NN I-NP D062787
13 1192 1193 9061311 , , O O
14 1194 1198 9061311 that WDT B-NP O
15 1199 1201 9061311 is VBZ B-VP O
16 1202 1212 9061311 complement NN B-NP O
17 1213 1222 9061311 dependent JJ I-NP O
18 1223 1226 9061311 but CC I-NP O
19 1227 1238 9061311 independent JJ I-NP O
20 1239 1241 9061311 of IN B-PP O
21 1242 1247 9061311 serum NN B-NP O
22 1248 1258 9061311 complement NN I-NP O
23 1258 1259 9061311 , , O O
24 1260 1268 9061311 possibly RB B-VP O
25 1269 1278 9061311 connected VBN I-VP O
26 1279 1281 9061311 to TO B-PP O
27 1282 1285 9061311 the DT B-NP O
28 1286 1296 9061311 complement NN I-NP O
29 1297 1305 9061311 receptor NN I-NP O
30 1305 1306 9061311 . . O O

1 0 0 11838826 -DOCSTART- -X- -X- O

1 0 9 11838826 Treatment NN B-NP O
2 10 12 11838826 of IN B-PP O
3 13 24 11838826 risperidone NN B-NP D018967
4 24 25 11838826 - HYPH B-NP O
5 25 32 11838826 induced VBN I-NP O
6 33 51 11838826 hyperprolactinemia NN I-NP D006966
7 52 56 11838826 with IN B-PP O
8 57 58 11838826 a DT B-NP O
9 59 67 11838826 dopamine NN I-NP D004298
10 68 75 11838826 agonist NN I-NP O
11 76 78 11838826 in IN B-PP O
12 79 87 11838826 children NNS B-NP O
13 87 88 11838826 . . O O
14 89 99 11838826 BACKGROUND NN B-NP O
15 99 100 11838826 : : O O
16 101 112 11838826 Risperidone NN B-NP D018967
17 112 113 11838826 , , O O
18 114 115 11838826 a DT B-NP O
19 116 122 11838826 potent JJ I-NP O
20 123 133 11838826 antagonist NN I-NP O
21 134 136 11838826 of IN B-PP O
22 137 141 11838826 both CC O O
23 142 154 11838826 serotonergic JJ O O
24 155 156 11838826 ( ( O O
25 156 161 11838826 5HT2A NN B-NP O
26 161 162 11838826 ) ) O O
27 163 166 11838826 and CC O O
28 167 179 11838826 dopaminergic JJ B-NP O
29 180 182 11838826 D2 NN I-NP O
30 183 192 11838826 receptors NNS I-NP O
31 193 195 11838826 is VBZ B-VP O
32 196 206 11838826 associated VBN I-VP O
33 207 211 11838826 with IN B-PP O
34 212 230 11838826 hyperprolactinemia NN B-NP D006966
35 231 233 11838826 in IN B-PP O
36 234 240 11838826 adults NNS B-NP O
37 241 244 11838826 and CC I-NP O
38 245 253 11838826 children NNS I-NP O
39 253 254 11838826 . . O O

1 255 266 11838826 Chronically RB B-NP O
2 267 275 11838826 elevated JJ I-NP O
3 276 285 11838826 prolactin NN I-NP O
4 286 292 11838826 levels NNS I-NP O
5 293 295 11838826 in IN B-PP O
6 296 304 11838826 children NNS B-NP O
7 305 309 11838826 with IN B-PP O
8 310 323 11838826 prolactinomas NNS B-NP D015175
9 324 327 11838826 may MD B-VP O
10 328 330 11838826 be VB I-VP O
11 331 341 11838826 associated VBN I-VP O
12 342 346 11838826 with IN B-PP O
13 347 355 11838826 arrested VBN B-NP O
14 356 362 11838826 growth NN I-NP O
15 363 366 11838826 and CC I-NP O
16 367 378 11838826 development NN I-NP O
17 379 388 11838826 resulting VBG B-VP O
18 389 391 11838826 in IN B-PP O
19 392 398 11838826 either CC O O
20 399 406 11838826 delayed VBN B-VP D011628
21 407 414 11838826 puberty NN B-NP D011628
22 415 417 11838826 or CC O O
23 418 423 11838826 short JJ B-NP O
24 424 431 11838826 stature NN I-NP O
25 431 432 11838826 . . O O

1 433 438 11838826 These DT B-NP O
2 439 452 11838826 possibilities NNS I-NP O
3 453 459 11838826 stress VBP B-VP O
4 460 463 11838826 the DT B-NP O
5 464 474 11838826 importance NN I-NP O
6 475 477 11838826 of IN B-PP O
7 478 488 11838826 developing VBG B-VP O
8 489 490 11838826 a DT B-NP O
9 491 495 11838826 safe JJ I-NP O
10 496 499 11838826 and CC I-NP O
11 500 509 11838826 effective JJ I-NP O
12 510 518 11838826 approach NN I-NP O
13 519 521 11838826 to TO B-PP O
14 522 526 11838826 drug NN B-NP O
15 526 527 11838826 - HYPH B-NP O
16 527 534 11838826 induced VBN I-NP O
17 535 553 11838826 hyperprolactinemia NN I-NP D006966
18 554 556 11838826 in IN B-PP O
19 557 562 11838826 youth NN B-NP O
20 562 563 11838826 . . O O

1 564 566 11838826 We PRP B-NP O
2 567 573 11838826 report VBP B-VP O
3 574 577 11838826 the DT B-NP O
4 578 588 11838826 successful JJ I-NP O
5 589 598 11838826 treatment NN I-NP O
6 599 601 11838826 of IN B-PP O
7 602 613 11838826 risperidone NN B-NP D018967
8 613 614 11838826 - HYPH B-NP O
9 614 621 11838826 induced VBN I-NP O
10 622 640 11838826 hyperprolactinemia NN I-NP D006966
11 641 645 11838826 with IN B-PP O
12 646 657 11838826 cabergoline NN B-NP C047047
13 658 660 11838826 in IN B-PP O
14 661 666 11838826 youth NN B-NP O
15 666 667 11838826 . . O O

1 668 675 11838826 METHODS NNS B-NP O
2 675 676 11838826 : : O O
3 677 679 11838826 We PRP B-NP O
4 680 689 11838826 undertook VBD B-VP O
5 690 691 11838826 a DT B-NP O
6 692 705 11838826 retrospective JJ I-NP O
7 706 710 11838826 case NN I-NP O
8 711 717 11838826 review NN I-NP O
9 718 720 11838826 of IN B-PP O
10 721 725 11838826 four CD B-NP O
11 726 734 11838826 children NNS I-NP O
12 735 739 11838826 with IN B-PP O
13 740 751 11838826 risperidone NN B-NP D018967
14 751 752 11838826 - HYPH B-NP O
15 752 759 11838826 induced VBN I-NP O
16 760 778 11838826 hyperprolactinemia NN I-NP D006966
17 779 786 11838826 treated VBN B-VP O
18 787 791 11838826 with IN B-PP O
19 792 803 11838826 cabergoline NN B-NP C047047
20 803 804 11838826 . . O O

1 805 812 11838826 RESULTS NNS B-NP O
2 812 813 11838826 : : O O
3 814 818 11838826 Four CD B-NP O
4 819 824 11838826 males NNS I-NP O
5 825 826 11838826 ( ( O O
6 826 829 11838826 age NN B-NP O
7 830 831 11838826 6 CD I-NP O
8 831 832 11838826 - HYPH O O
9 832 834 11838826 11 CD B-NP O
10 835 840 11838826 years NNS I-NP O
11 840 841 11838826 ) ) O O
12 842 846 11838826 with IN B-PP O
13 847 857 11838826 Diagnostic NNP B-NP O
14 858 861 11838826 and CC I-NP O
15 862 873 11838826 Statistical NNP I-NP O
16 874 880 11838826 Manual NNP I-NP O
17 881 883 11838826 of IN B-PP O
18 884 890 11838826 Mental NNP B-NP D001523
19 891 900 11838826 Disorders NNP I-NP D001523
20 901 902 11838826 ( ( O O
21 902 908 11838826 fourth JJ B-NP O
22 909 916 11838826 edition NN I-NP O
23 916 917 11838826 ) ) I-NP O
24 918 925 11838826 bipolar JJ I-NP D001714
25 926 934 11838826 disorder NN I-NP D001714
26 935 937 11838826 or CC I-NP O
27 938 947 11838826 psychoses NNS I-NP D011605
28 947 948 11838826 , , O O
29 949 953 11838826 with IN B-PP O
30 954 965 11838826 risperidone NN B-NP D018967
31 965 966 11838826 - HYPH B-NP O
32 966 973 11838826 induced VBN I-NP O
33 974 984 11838826 elevations NNS I-NP O
34 985 987 11838826 in IN B-PP O
35 988 993 11838826 serum NN B-NP O
36 994 1003 11838826 prolactin NN I-NP O
37 1004 1010 11838826 levels NNS I-NP O
38 1011 1012 11838826 ( ( O O
39 1012 1016 11838826 57.5 CD B-NP O
40 1016 1017 11838826 - HYPH I-NP O
41 1017 1020 11838826 129 CD I-NP O
42 1021 1023 11838826 ng NN I-NP O
43 1023 1024 11838826 / SYM B-NP O
44 1024 1026 11838826 mL NN I-NP O
45 1026 1027 11838826 , , O O
46 1028 1034 11838826 normal JJ B-NP O
47 1035 1036 11838826 5 CD I-NP O
48 1036 1037 11838826 - HYPH I-NP O
49 1037 1039 11838826 15 CD I-NP O
50 1040 1042 11838826 ng NN I-NP O
51 1042 1043 11838826 / SYM I-NP O
52 1043 1045 11838826 mL NN I-NP O
53 1045 1046 11838826 ) ) O O
54 1046 1047 11838826 , , O O
55 1048 1052 11838826 were VBD B-VP O
56 1053 1060 11838826 treated VBN I-VP O
57 1061 1065 11838826 with IN B-PP O
58 1066 1077 11838826 cabergoline NN B-NP C047047
59 1078 1079 11838826 ( ( O O
60 1079 1083 11838826 mean JJ B-NP O
61 1084 1088 11838826 dose NN I-NP O
62 1089 1093 11838826 2.13 CD I-NP O
63 1094 1095 11838826 + SYM O O
64 1095 1096 11838826 / SYM O O
65 1096 1097 11838826 - SYM O O
66 1098 1102 11838826 0.09 CD B-NP O
67 1103 1105 11838826 mg NN I-NP O
68 1105 1106 11838826 / SYM B-NP O
69 1106 1110 11838826 week NN I-NP O
70 1110 1111 11838826 ) ) O O
71 1111 1112 11838826 . . O O

1 1113 1117 11838826 When WRB B-ADVP O
2 1118 1123 11838826 serum NN B-NP O
3 1124 1133 11838826 prolactin NN I-NP O
4 1134 1140 11838826 levels NNS I-NP O
5 1141 1151 11838826 normalized VBN B-VP O
6 1152 1154 11838826 in IN B-PP O
7 1155 1158 11838826 all DT B-NP O
8 1159 1163 11838826 four CD I-NP O
9 1164 1172 11838826 subjects NNS I-NP O
10 1173 1174 11838826 ( ( O O
11 1174 1178 11838826 mean NN B-NP O
12 1179 1183 11838826 11.2 CD I-NP O
13 1184 1185 11838826 + SYM O O
14 1185 1186 11838826 / SYM O O
15 1186 1187 11838826 - SYM O O
16 1188 1192 11838826 10.9 CD B-NP O
17 1193 1195 11838826 ng NN I-NP O
18 1195 1196 11838826 / SYM B-NP O
19 1196 1198 11838826 mL NN I-NP O
20 1198 1199 11838826 ) ) O O
21 1199 1200 11838826 , , O O
22 1201 1204 11838826 the DT B-NP O
23 1205 1216 11838826 cabergoline NN I-NP C047047
24 1217 1221 11838826 dose NN I-NP O
25 1222 1225 11838826 was VBD B-VP O
26 1226 1233 11838826 reduced VBN I-VP O
27 1234 1236 11838826 to TO B-PP O
28 1237 1238 11838826 1 CD B-NP O
29 1239 1241 11838826 mg NN I-NP O
30 1241 1242 11838826 / SYM B-NP O
31 1242 1246 11838826 week NN I-NP O
32 1247 1249 11838826 in IN B-PP O
33 1250 1255 11838826 three CD B-NP O
34 1256 1258 11838826 of IN I-NP O
35 1259 1263 11838826 four CD I-NP O
36 1264 1272 11838826 subjects NNS I-NP O
37 1272 1273 11838826 . . O O

1 1274 1277 11838826 The DT B-NP O
2 1278 1282 11838826 mean JJ I-NP O
3 1283 1291 11838826 duration NN I-NP O
4 1292 1294 11838826 of IN B-PP O
5 1295 1302 11838826 therapy NN B-NP O
6 1303 1307 11838826 with IN B-PP O
7 1308 1319 11838826 cabergoline NN B-NP C047047
8 1320 1323 11838826 was VBD B-VP O
9 1324 1329 11838826 523.5 CD B-NP O
10 1330 1331 11838826 + SYM O O
11 1331 1332 11838826 / SYM O O
12 1332 1333 11838826 - SYM B-NP O
13 1334 1339 11838826 129.7 CD B-NP O
14 1340 1344 11838826 days NNS I-NP O
15 1344 1345 11838826 , , O O
16 1346 1349 11838826 and CC O O
17 1350 1353 11838826 the DT B-NP O
18 1354 1358 11838826 mean JJ I-NP O
19 1359 1367 11838826 duration NN I-NP O
20 1368 1370 11838826 of IN B-PP O
21 1371 1378 11838826 therapy NN B-NP O
22 1379 1383 11838826 with IN B-PP O
23 1384 1395 11838826 risperidone NN B-NP D018967
24 1396 1399 11838826 was VBD B-VP O
25 1400 1405 11838826 788.5 CD B-NP O
26 1406 1407 11838826 + SYM O O
27 1407 1408 11838826 / SYM O O
28 1408 1409 11838826 - SYM B-NP O
29 1410 1415 11838826 162.5 CD B-NP O
30 1416 1420 11838826 days NNS I-NP O
31 1420 1421 11838826 . . O O

1 1422 1433 11838826 Cabergoline NN B-NP C047047
2 1434 1437 11838826 was VBD B-VP O
3 1438 1442 11838826 well RB I-VP O
4 1443 1452 11838826 tolerated VBN I-VP O
5 1453 1460 11838826 without IN B-PP O
6 1461 1468 11838826 adverse JJ B-NP O
7 1469 1476 11838826 effects NNS I-NP O
8 1476 1477 11838826 . . O O

1 1478 1489 11838826 CONCLUSIONS NNS B-NP O
2 1489 1490 11838826 : : O O
3 1491 1502 11838826 Cabergoline NN B-NP C047047
4 1503 1506 11838826 may MD B-VP O
5 1507 1509 11838826 be VB I-VP O
6 1510 1516 11838826 useful JJ B-ADJP O
7 1517 1520 11838826 for IN B-PP O
8 1521 1524 11838826 the DT B-NP O
9 1525 1534 11838826 treatment NN I-NP O
10 1535 1537 11838826 of IN B-PP O
11 1538 1549 11838826 risperidone NN B-NP D018967
12 1549 1550 11838826 - HYPH B-NP O
13 1550 1557 11838826 induced VBN I-NP O
14 1558 1576 11838826 hyperprolactinemia NN I-NP D006966
15 1577 1579 11838826 in IN B-PP O
16 1580 1585 11838826 youth NN B-NP O
17 1585 1586 11838826 ; : O O
18 1587 1594 11838826 however RB B-ADVP O
19 1594 1595 11838826 , , O O
20 1596 1603 11838826 further JJ B-NP O
21 1604 1612 11838826 research NN I-NP O
22 1613 1615 11838826 is VBZ B-VP O
23 1616 1622 11838826 needed VBN I-VP O
24 1622 1623 11838826 . . O O

1 0 0 19944736 -DOCSTART- -X- -X- O

1 0 1 19944736 A DT B-NP O
2 2 7 19944736 novel JJ I-NP O
3 8 14 19944736 animal NN I-NP O
4 15 20 19944736 model NN I-NP O
5 21 23 19944736 to TO B-VP O
6 24 32 19944736 evaluate VB I-VP O
7 33 36 19944736 the DT B-NP O
8 37 44 19944736 ability NN I-NP O
9 45 47 19944736 of IN B-PP O
10 48 49 19944736 a DT B-NP O
11 50 54 19944736 drug NN I-NP O
12 55 63 19944736 delivery NN I-NP O
13 64 70 19944736 system NN I-NP O
14 71 73 19944736 to TO B-VP O
15 74 81 19944736 promote VB I-VP O
16 82 85 19944736 the DT B-NP O
17 86 93 19944736 passage NN I-NP O
18 94 101 19944736 through IN B-PP O
19 102 105 19944736 the DT B-NP O
20 106 109 19944736 BBB NNP I-NP O
21 109 110 19944736 . . O O
22 111 114 19944736 The DT B-NP O
23 115 122 19944736 purpose NN I-NP O
24 123 125 19944736 of IN B-PP O
25 126 130 19944736 this DT B-NP O
26 131 144 19944736 investigation NN I-NP O
27 145 148 19944736 was VBD B-VP O
28 149 151 19944736 to TO B-VP O
29 152 159 19944736 explore VB I-VP O
30 160 163 19944736 the DT B-NP O
31 164 176 19944736 potentiality NN I-NP O
32 177 179 19944736 of IN B-PP O
33 180 181 19944736 a DT B-NP O
34 182 187 19944736 novel JJ I-NP O
35 188 194 19944736 animal NN I-NP O
36 195 200 19944736 model NN I-NP O
37 201 203 19944736 to TO B-VP O
38 204 206 19944736 be VB I-VP O
39 207 211 19944736 used VBN I-VP O
40 212 215 19944736 for IN B-PP O
41 216 219 19944736 the DT B-NP O
42 220 222 19944736 in FW I-NP O
43 223 227 19944736 vivo FW I-NP O
44 228 238 19944736 evaluation NN I-NP O
45 239 241 19944736 of IN B-PP O
46 242 245 19944736 the DT B-NP O
47 246 253 19944736 ability NN I-NP O
48 254 256 19944736 of IN B-PP O
49 257 258 19944736 a DT B-NP O
50 259 263 19944736 drug NN I-NP O
51 264 272 19944736 delivery NN I-NP O
52 273 279 19944736 system NN I-NP O
53 280 282 19944736 to TO B-VP O
54 283 290 19944736 promote VB I-VP O
55 291 294 19944736 the DT B-NP O
56 295 302 19944736 passage NN I-NP O
57 303 310 19944736 through IN B-PP O
58 311 314 19944736 the DT B-NP O
59 315 320 19944736 blood NN I-NP O
60 320 321 19944736 - HYPH I-NP O
61 321 326 19944736 brain NN I-NP O
62 327 334 19944736 barrier NN I-NP O
63 335 336 19944736 ( ( O O
64 336 339 19944736 BBB NN B-NP O
65 339 340 19944736 ) ) O O
66 341 344 19944736 and CC O O
67 344 345 19944736 / SYM B-NP O
68 345 347 19944736 or CC O O
69 348 350 19944736 to TO B-VP O
70 351 358 19944736 improve VB I-VP O
71 359 362 19944736 the DT B-NP O
72 363 368 19944736 brain NN I-NP O
73 369 381 19944736 localization NN I-NP O
74 382 384 19944736 of IN B-PP O
75 385 386 19944736 a DT B-NP O
76 387 396 19944736 bioactive JJ I-NP O
77 397 405 19944736 compound NN I-NP O
78 405 406 19944736 . . O O

1 407 408 19944736 A DT B-NP O
2 409 414 19944736 Tween CD I-NP O
3 415 417 19944736 80 CD I-NP O
4 417 418 19944736 - HYPH O O
5 418 424 19944736 coated VBN B-NP O
6 425 429 19944736 poly NN I-NP -1
7 429 430 19944736 - HYPH B-NP -1
8 430 431 19944736 L NN I-NP -1
9 431 432 19944736 - HYPH O -1
10 432 438 19944736 lactid JJ B-NP -1
11 439 443 19944736 acid NN I-NP -1
12 444 457 19944736 nanoparticles NNS I-NP O
13 458 461 19944736 was VBD B-VP O
14 462 466 19944736 used VBN I-VP O
15 467 469 19944736 as IN B-PP O
16 470 471 19944736 a DT B-NP O
17 472 477 19944736 model NN I-NP O
18 478 480 19944736 of IN B-PP O
19 481 490 19944736 colloidal JJ B-NP O
20 491 495 19944736 drug NN I-NP O
21 496 504 19944736 delivery NN I-NP O
22 505 511 19944736 system NN I-NP O
23 511 512 19944736 , , O O
24 513 517 19944736 able JJ B-ADJP O
25 518 520 19944736 to TO B-VP O
26 521 529 19944736 trespass VB I-VP O
27 530 533 19944736 the DT B-NP O
28 534 537 19944736 BBB NNP I-NP O
29 537 538 19944736 . . O O

1 539 546 19944736 Tacrine NN B-NP D013619
2 546 547 19944736 , , O O
3 548 560 19944736 administered VBN B-VP O
4 561 563 19944736 in IN B-PP O
5 564 568 19944736 LiCl NN B-NP D018021
6 569 572 19944736 pre AFX O O
7 572 573 19944736 - HYPH O O
8 573 580 19944736 treated VBN B-NP O
9 581 585 19944736 rats NNS I-NP O
10 585 586 19944736 , , O O
11 587 594 19944736 induces VBZ B-VP O
12 595 616 19944736 electrocorticographic JJ B-NP O
13 617 625 19944736 seizures NNS I-NP D012640
14 626 629 19944736 and CC O O
15 630 637 19944736 delayed VBN B-VP O
16 638 649 19944736 hippocampal JJ B-NP D001930
17 650 656 19944736 damage NN I-NP D001930
18 656 657 19944736 . . O O

1 658 661 19944736 The DT B-NP O
2 662 667 19944736 toxic JJ I-NP O
3 668 675 19944736 effects NNS I-NP O
4 676 678 19944736 of IN B-PP O
5 679 686 19944736 tacrine NN B-NP D013619
6 686 687 19944736 - HYPH O O
7 687 693 19944736 loaded VBN B-NP O
8 694 698 19944736 poly NN I-NP -1
9 698 699 19944736 - HYPH B-NP -1
10 699 700 19944736 L NN I-NP -1
11 700 701 19944736 - HYPH O -1
12 701 707 19944736 lactid JJ B-NP -1
13 708 712 19944736 acid NN I-NP -1
14 713 726 19944736 nanoparticles NNS I-NP O
15 727 728 19944736 ( ( O O
16 728 731 19944736 5mg NN B-NP O
17 731 732 19944736 / SYM O O
18 732 734 19944736 kg NN B-NP O
19 734 735 19944736 ) ) O O
20 735 736 19944736 , , O O
21 737 738 19944736 a DT B-NP O
22 739 745 19944736 saline NN I-NP O
23 746 754 19944736 solution NN I-NP O
24 755 757 19944736 of IN B-PP O
25 758 765 19944736 tacrine NN B-NP D013619
26 766 767 19944736 ( ( O O
27 767 770 19944736 5mg NN B-NP O
28 770 771 19944736 / SYM B-NP O
29 771 773 19944736 kg NN I-NP O
30 773 774 19944736 ) ) O O
31 775 778 19944736 and CC O O
32 779 781 19944736 an DT B-NP O
33 782 787 19944736 empty JJ I-NP O
34 788 797 19944736 colloidal JJ I-NP O
35 798 810 19944736 nanoparticle NN I-NP O
36 811 821 19944736 suspension NN I-NP O
37 822 826 19944736 were VBD B-VP O
38 827 835 19944736 compared VBN I-VP O
39 836 845 19944736 following VBG B-PP O
40 846 849 19944736 i.p NN B-NP O
41 849 850 19944736 . . O O

1 851 865 19944736 administration NN B-NP O
2 866 868 19944736 in IN B-PP O
3 869 873 19944736 LiCl NN B-NP D018021
4 873 874 19944736 - HYPH B-NP O
5 874 877 19944736 pre AFX I-NP O
6 877 878 19944736 - HYPH I-NP O
7 878 885 19944736 treated VBN I-NP O
8 886 892 19944736 Wistar NNP I-NP O
9 893 897 19944736 rats NNS I-NP O
10 897 898 19944736 . . O O

1 899 902 19944736 All PDT B-NP O
2 903 906 19944736 the DT I-NP O
3 907 914 19944736 animals NNS I-NP O
4 915 922 19944736 treated VBN B-VP O
5 923 927 19944736 with IN B-PP O
6 928 935 19944736 tacrine NN B-NP D013619
7 935 936 19944736 - HYPH B-NP O
8 936 942 19944736 loaded VBN I-NP O
9 943 956 19944736 nanoparticles NNS I-NP O
10 957 963 19944736 showed VBD B-VP O
11 964 966 19944736 an DT B-NP O
12 967 974 19944736 earlier JJR I-NP O
13 975 982 19944736 outcome NN I-NP O
14 983 985 19944736 of IN B-PP O
15 986 989 19944736 CNS NN B-NP O
16 990 997 19944736 adverse JJ I-NP O
17 998 1006 19944736 symptoms NNS I-NP O
18 1006 1007 19944736 , , O O
19 1008 1012 19944736 i.e. FW B-NP O
20 1013 1022 19944736 epileptic JJ I-NP D004827
21 1023 1028 19944736 onset NN I-NP O
22 1028 1029 19944736 , , O O
23 1030 1034 19944736 with IN B-PP O
24 1035 1042 19944736 respect NN B-NP O
25 1043 1045 19944736 to TO B-PP O
26 1046 1051 19944736 those DT B-NP O
27 1052 1059 19944736 animals NNS I-NP O
28 1060 1067 19944736 treated VBN B-VP O
29 1068 1072 19944736 with IN B-PP O
30 1073 1076 19944736 the DT B-NP O
31 1077 1081 19944736 free JJ I-NP O
32 1082 1090 19944736 compound NN I-NP O
33 1091 1092 19944736 ( ( O O
34 1092 1094 19944736 10 CD B-NP O
35 1095 1098 19944736 min NN I-NP O
36 1099 1101 19944736 vs NNS I-NP O
37 1101 1102 19944736 . . O O
38 1103 1105 19944736 22 CD B-NP O
39 1106 1109 19944736 min NN I-NP O
40 1110 1122 19944736 respectively RB B-ADVP O
41 1122 1123 19944736 ) ) O O
42 1123 1124 19944736 . . O O

1 1125 1127 19944736 In IN B-PP O
2 1128 1136 19944736 addition NN B-NP O
3 1136 1137 19944736 , , O O
4 1138 1145 19944736 tacrine NN B-NP D013619
5 1145 1146 19944736 - HYPH B-NP O
6 1146 1152 19944736 loaded VBN I-NP O
7 1153 1166 19944736 nanoparticles NNS I-NP O
8 1167 1181 19944736 administration NN I-NP O
9 1182 1189 19944736 induced VBD B-VP O
10 1190 1196 19944736 damage NN B-NP D001930
11 1197 1199 19944736 of IN B-PP D001930
12 1200 1208 19944736 neuronal JJ B-NP D001930
13 1209 1214 19944736 cells NNS I-NP D001930
14 1215 1217 19944736 in IN B-PP O
15 1218 1221 19944736 CA1 NN B-NP O
16 1222 1227 19944736 field NN I-NP O
17 1228 1230 19944736 of IN B-PP O
18 1231 1234 19944736 the DT B-NP O
19 1235 1246 19944736 hippocampus NN I-NP O
20 1247 1249 19944736 in IN B-PP O
21 1250 1253 19944736 all DT B-NP O
22 1254 1261 19944736 treated VBN I-NP O
23 1262 1269 19944736 animals NNS I-NP O
24 1269 1270 19944736 , , O O
25 1271 1276 19944736 while IN B-SBAR O
26 1277 1280 19944736 the DT B-NP O
27 1281 1287 19944736 saline NN I-NP O
28 1288 1296 19944736 solution NN I-NP O
29 1297 1299 19944736 of IN B-PP O
30 1300 1307 19944736 tacrine NN B-NP D013619
31 1308 1312 19944736 only RB B-ADVP O
32 1313 1315 19944736 in IN B-PP O
33 1316 1319 19944736 60% NN B-NP O
34 1320 1322 19944736 of IN B-PP O
35 1323 1330 19944736 animals NNS B-NP O
36 1330 1331 19944736 . . O O

1 1332 1337 19944736 Empty JJ B-NP O
2 1338 1351 19944736 nanoparticles NNS I-NP O
3 1352 1360 19944736 provided VBD B-VP O
4 1361 1368 19944736 similar JJ B-NP O
5 1369 1376 19944736 results NNS I-NP O
6 1377 1379 19944736 to TO B-PP O
7 1380 1387 19944736 control NN B-NP O
8 1388 1389 19944736 ( ( O O
9 1389 1395 19944736 saline NN B-NP O
10 1395 1396 19944736 - HYPH B-VP O
11 1396 1403 19944736 treated VBN I-VP O
12 1403 1404 19944736 ) ) O O
13 1405 1410 19944736 group NN B-NP O
14 1411 1413 19944736 of IN B-PP O
15 1414 1421 19944736 animals NNS B-NP O
16 1421 1422 19944736 . . O O

1 1423 1425 19944736 In IN B-PP O
2 1426 1436 19944736 conclusion NN B-NP O
3 1436 1437 19944736 , , O O
4 1438 1441 19944736 the DT B-NP O
5 1442 1452 19944736 evaluation NN I-NP O
6 1453 1455 19944736 of IN B-PP O
7 1456 1460 19944736 time NN B-NP O
8 1460 1461 19944736 - HYPH B-ADVP O
9 1461 1463 19944736 to TO B-PP O
10 1463 1464 19944736 - HYPH B-NP O
11 1464 1469 19944736 onset NN I-NP O
12 1470 1472 19944736 of IN B-PP O
13 1473 1481 19944736 symptoms NNS B-NP O
14 1482 1485 19944736 and CC O O
15 1486 1489 19944736 the DT B-NP O
16 1490 1498 19944736 severity NN I-NP O
17 1499 1501 19944736 of IN B-PP O
18 1502 1519 19944736 neurodegenerative JJ B-NP O
19 1520 1529 19944736 processes NNS I-NP O
20 1530 1537 19944736 induced VBN B-VP O
21 1538 1540 19944736 by IN B-PP O
22 1541 1544 19944736 the DT B-NP O
23 1545 1552 19944736 tacrine NN I-NP D013619
24 1552 1553 19944736 - HYPH B-NP O
25 1553 1560 19944736 lithium NN I-NP D008094
26 1561 1566 19944736 model NN I-NP O
27 1567 1569 19944736 of IN B-PP O
28 1570 1578 19944736 epilepsy NN B-NP D004827
29 1579 1581 19944736 in IN B-PP O
30 1582 1585 19944736 the DT B-NP O
31 1586 1589 19944736 rat NN I-NP O
32 1589 1590 19944736 , , O O
33 1591 1596 19944736 could MD B-VP O
34 1597 1599 19944736 be VB I-VP O
35 1600 1604 19944736 used VBN I-VP O
36 1605 1607 19944736 to TO B-VP O
37 1608 1616 19944736 evaluate VB I-VP O
38 1617 1630 19944736 preliminarily RB B-ADVP O
39 1631 1634 19944736 the DT B-NP O
40 1635 1645 19944736 capability NN I-NP O
41 1646 1648 19944736 of IN B-PP O
42 1649 1650 19944736 a DT B-NP O
43 1651 1655 19944736 drug NN I-NP O
44 1656 1664 19944736 delivery NN I-NP O
45 1665 1671 19944736 system NN I-NP O
46 1672 1674 19944736 to TO B-VP O
47 1675 1683 19944736 trespass VB I-VP O
48 1684 1685 19944736 ( ( O O
49 1685 1687 19944736 or CC O O
50 1688 1691 19944736 not RB O O
51 1691 1692 19944736 ) ) O O
52 1693 1696 19944736 the DT B-NP O
53 1697 1700 19944736 BBB NN I-NP O
54 1701 1703 19944736 in FW B-ADVP O
55 1704 1708 19944736 vivo FW I-ADVP O
56 1708 1709 19944736 . . O O

1 0 0 18657397 -DOCSTART- -X- -X- O

1 0 8 18657397 Detailed JJ B-NP O
2 9 17 18657397 spectral JJ I-NP O
3 18 25 18657397 profile NN I-NP O
4 26 34 18657397 analysis NN I-NP O
5 35 37 18657397 of IN B-PP O
6 38 48 18657397 penicillin NN B-NP D010406
7 48 49 18657397 - HYPH B-NP O
8 49 56 18657397 induced VBN I-NP O
9 57 69 18657397 epileptiform NN I-NP D004827
10 70 78 18657397 activity NN I-NP D004827
11 79 81 18657397 in IN B-PP O
12 82 94 18657397 anesthetized VBN B-NP O
13 95 99 18657397 rats NNS I-NP O
14 99 100 18657397 . . O O
15 101 111 18657397 Penicillin NNP B-NP D010406
16 112 117 18657397 model NN I-NP O
17 118 120 18657397 is VBZ B-VP O
18 121 122 18657397 a DT B-NP O
19 123 129 18657397 widely RB I-NP O
20 130 134 18657397 used VBN I-NP O
21 135 147 18657397 experimental JJ I-NP O
22 148 153 18657397 model NN I-NP O
23 154 157 18657397 for IN B-PP O
24 158 166 18657397 epilepsy NN B-NP D004827
25 167 175 18657397 research NN I-NP O
26 175 176 18657397 . . O O

1 177 179 18657397 In IN B-PP O
2 180 183 18657397 the DT B-NP O
3 184 191 18657397 present JJ I-NP O
4 192 197 18657397 study NN I-NP O
5 198 200 18657397 we PRP B-NP O
6 201 206 18657397 aimed VBD B-VP O
7 207 209 18657397 to TO I-VP O
8 210 217 18657397 portray VB I-VP O
9 218 219 18657397 a DT B-NP O
10 220 228 18657397 detailed JJ I-NP O
11 229 237 18657397 spectral JJ I-NP O
12 238 246 18657397 analysis NN I-NP O
13 247 249 18657397 of IN B-PP O
14 250 260 18657397 penicillin NN B-NP D010406
15 260 261 18657397 - HYPH B-NP O
16 261 268 18657397 induced VBN I-NP O
17 269 281 18657397 epileptiform NN I-NP D004827
18 282 290 18657397 activity NN I-NP D004827
19 291 293 18657397 in IN B-PP O
20 294 304 18657397 comparison NN B-NP O
21 305 309 18657397 with IN B-PP O
22 310 315 18657397 basal JJ B-NP O
23 316 321 18657397 brain NN I-NP O
24 322 330 18657397 activity NN I-NP O
25 331 333 18657397 in IN B-PP O
26 334 346 18657397 anesthetized VBN B-NP O
27 347 353 18657397 Wistar NNP I-NP O
28 354 358 18657397 rats NNS I-NP O
29 358 359 18657397 . . O O

1 360 364 18657397 Male JJ B-NP O
2 365 371 18657397 Wistar NNP I-NP O
3 372 376 18657397 rats NNS I-NP O
4 377 381 18657397 were VBD B-VP O
5 382 394 18657397 anesthetized VBN I-VP O
6 395 399 18657397 with IN B-PP O
7 400 403 18657397 i.p NN B-NP O
8 403 404 18657397 . . O O

1 405 413 18657397 urethane NN B-NP D014520
2 414 417 18657397 and CC O O
3 418 427 18657397 connected VBN B-VP O
4 428 430 18657397 to TO B-PP O
5 431 433 18657397 an DT B-NP O
6 434 452 18657397 electrocorticogram NN I-NP O
7 453 458 18657397 setup NN I-NP O
8 458 459 18657397 . . O O

1 460 465 18657397 After IN B-PP O
2 466 467 18657397 a DT B-NP O
3 468 473 18657397 short JJ I-NP O
4 474 480 18657397 period NN I-NP O
5 481 483 18657397 of IN B-PP O
6 484 489 18657397 basal JJ B-NP O
7 490 498 18657397 activity NN I-NP O
8 499 508 18657397 recording NN I-NP O
9 508 509 18657397 , , O O
10 510 519 18657397 epileptic JJ B-NP D004827
11 520 525 18657397 focus NN I-NP O
12 526 529 18657397 was VBD B-VP O
13 530 537 18657397 induced VBN I-VP O
14 538 540 18657397 by IN B-PP O
15 541 550 18657397 injecting VBG B-VP O
16 551 556 18657397 400IU NN B-NP O
17 556 557 18657397 / SYM B-NP O
18 557 558 18657397 2 CD I-NP O
19 559 565 18657397 microl NN I-NP O
20 566 576 18657397 penicillin NN I-NP D010400
21 576 577 18657397 - HYPH B-NP D010400
22 577 578 18657397 G NN I-NP D010400
23 579 588 18657397 potassium NN I-NP D010400
24 589 593 18657397 into IN B-PP O
25 594 597 18657397 the DT B-NP O
26 598 602 18657397 left JJ I-NP O
27 603 610 18657397 lateral JJ I-NP O
28 611 620 18657397 ventricle NN I-NP O
29 621 626 18657397 while IN B-SBAR O
30 627 630 18657397 the DT B-NP O
31 631 639 18657397 cortical JJ I-NP O
32 640 648 18657397 activity NN I-NP O
33 649 652 18657397 was VBD B-VP O
34 653 665 18657397 continuously RB I-VP O
35 666 674 18657397 recorded VBN I-VP O
36 674 675 18657397 . . O O

1 676 681 18657397 Basal JJ B-NP O
2 682 690 18657397 activity NN I-NP O
3 690 691 18657397 , , O O
4 692 698 18657397 latent JJ B-NP O
5 699 705 18657397 period NN I-NP O
6 706 709 18657397 and CC O O
7 710 713 18657397 the DT B-NP O
8 714 724 18657397 penicillin NN I-NP D010406
9 724 725 18657397 - HYPH B-NP O
10 725 732 18657397 induced VBN I-NP O
11 733 745 18657397 epileptiform NN I-NP D004827
12 746 754 18657397 activity NN I-NP D004827
13 755 762 18657397 periods NNS I-NP O
14 763 767 18657397 were VBD B-VP O
15 768 772 18657397 then RB I-VP O
16 773 781 18657397 analyzed VBN I-VP O
17 782 787 18657397 using VBG B-VP O
18 788 792 18657397 both CC O O
19 793 805 18657397 conventional JJ B-NP O
20 806 813 18657397 methods NNS I-NP O
21 814 817 18657397 and CC O O
22 818 826 18657397 spectral JJ B-NP O
23 827 835 18657397 analysis NN I-NP O
24 835 836 18657397 . . O O

1 837 845 18657397 Spectral JJ B-NP O
2 846 854 18657397 analyses NNS I-NP O
3 855 859 18657397 were VBD B-VP O
4 860 869 18657397 conducted VBN I-VP O
5 870 872 18657397 by IN B-PP O
6 873 881 18657397 dividing VBG B-VP O
7 882 885 18657397 the DT B-NP O
8 886 891 18657397 whole JJ I-NP O
9 892 900 18657397 spectrum NN I-NP O
10 901 905 18657397 into IN B-PP O
11 906 915 18657397 different JJ B-NP O
12 916 925 18657397 frequency NN I-NP O
13 926 931 18657397 bands NNS I-NP O
14 932 941 18657397 including VBG B-PP O
15 942 947 18657397 delta NN B-NP O
16 947 948 18657397 , , O O
17 949 954 18657397 theta NN B-NP O
18 955 956 18657397 ( ( O O
19 956 960 18657397 slow JJ B-ADJP O
20 961 964 18657397 and CC O O
21 965 969 18657397 fast JJ B-ADJP O
22 969 970 18657397 ) ) O O
23 970 971 18657397 , , O O
24 972 977 18657397 alpha SYM B-NP O
25 977 978 18657397 - HYPH B-VP O
26 978 983 18657397 sigma SYM B-NP O
27 983 984 18657397 , , O O
28 985 989 18657397 beta NN B-NP O
29 990 991 18657397 ( ( O O
30 991 992 18657397 1 CD B-NP O
31 993 996 18657397 and CC I-NP O
32 997 998 18657397 2 CD I-NP O
33 998 999 18657397 ) ) O O
34 1000 1003 18657397 and CC O O
35 1004 1009 18657397 gamma NN B-NP O
36 1010 1011 18657397 ( ( O O
37 1011 1012 18657397 1 CD B-NP O
38 1013 1016 18657397 and CC O O
39 1017 1018 18657397 2 CD O O
40 1018 1019 18657397 ) ) O O
41 1020 1025 18657397 bands NNS B-NP O
42 1025 1026 18657397 . . O O

1 1027 1030 18657397 Our PRP$ B-NP O
2 1031 1038 18657397 results NNS I-NP O
3 1039 1043 18657397 show VBP B-VP O
4 1044 1048 18657397 that IN B-SBAR O
5 1049 1052 18657397 the DT B-NP O
6 1053 1057 18657397 most RBS I-NP O
7 1058 1066 18657397 affected JJ I-NP O
8 1067 1076 18657397 frequency NN I-NP O
9 1077 1082 18657397 bands NNS I-NP O
10 1083 1087 18657397 were VBD B-VP O
11 1088 1093 18657397 delta SYM B-ADJP O
12 1093 1094 18657397 , , O O
13 1095 1100 18657397 theta SYM B-NP O
14 1100 1101 18657397 , , O O
15 1102 1106 18657397 beta SYM O O
16 1106 1107 18657397 - HYPH O O
17 1107 1108 18657397 2 CD B-NP O
18 1109 1112 18657397 and CC O O
19 1113 1118 18657397 gamma SYM B-NP O
20 1118 1119 18657397 - HYPH O O
21 1119 1120 18657397 2 CD B-NP O
22 1121 1126 18657397 bands NNS I-NP O
23 1127 1133 18657397 during IN B-PP O
24 1134 1137 18657397 the DT B-NP O
25 1138 1150 18657397 epileptiform NN I-NP D004827
26 1151 1159 18657397 activity NN I-NP D004827
27 1160 1163 18657397 and CC O O
28 1164 1169 18657397 there EX B-NP O
29 1170 1174 18657397 were VBD B-VP O
30 1175 1181 18657397 marked JJ B-NP O
31 1182 1193 18657397 differences NNS I-NP O
32 1194 1196 18657397 in IN B-PP O
33 1197 1202 18657397 terms NNS B-NP O
34 1203 1205 18657397 of IN B-PP O
35 1206 1214 18657397 spectral JJ B-NP O
36 1215 1224 18657397 densities NNS I-NP O
37 1225 1232 18657397 between IN B-PP O
38 1233 1238 18657397 three CD B-NP O
39 1239 1251 18657397 investigated VBN I-NP O
40 1252 1260 18657397 episodes NNS I-NP O
41 1261 1262 18657397 ( ( O O
42 1262 1267 18657397 basal JJ B-NP O
43 1268 1276 18657397 activity NN I-NP O
44 1276 1277 18657397 , , O O
45 1278 1284 18657397 latent JJ B-NP O
46 1285 1291 18657397 period NN I-NP O
47 1292 1295 18657397 and CC I-NP O
48 1296 1308 18657397 epileptiform NN I-NP D004827
49 1309 1317 18657397 activity NN I-NP D004827
50 1317 1318 18657397 ) ) O O
51 1318 1319 18657397 . . O O

1 1320 1323 18657397 Our PRP$ B-NP O
2 1324 1331 18657397 results NNS I-NP O
3 1332 1335 18657397 may MD B-VP O
4 1336 1340 18657397 help VB I-VP O
5 1341 1343 18657397 to TO I-VP O
6 1344 1351 18657397 analyze VB I-VP O
7 1352 1357 18657397 novel JJ B-NP O
8 1358 1362 18657397 data NNS I-NP O
9 1363 1371 18657397 obtained VBN B-VP O
10 1372 1377 18657397 using VBG B-VP O
11 1378 1385 18657397 similar JJ B-NP O
12 1386 1398 18657397 experimental JJ I-NP O
13 1399 1405 18657397 models NNS I-NP O
14 1406 1409 18657397 and CC O O
15 1410 1413 18657397 the DT B-NP O
16 1414 1420 18657397 simple JJ I-NP O
17 1421 1429 18657397 analysis NN I-NP O
18 1430 1436 18657397 method NN I-NP O
19 1437 1446 18657397 described VBN B-VP O
20 1447 1451 18657397 here RB B-ADVP O
21 1452 1455 18657397 can MD B-VP O
22 1456 1458 18657397 be VB I-VP O
23 1459 1463 18657397 used VBN I-VP O
24 1464 1466 18657397 in IN B-PP O
25 1467 1474 18657397 similar JJ B-NP O
26 1475 1482 18657397 studies NNS I-NP O
27 1483 1485 18657397 to TO B-VP O
28 1486 1497 18657397 investigate VB I-VP O
29 1498 1501 18657397 the DT B-NP O
30 1502 1507 18657397 basic JJ I-NP O
31 1508 1516 18657397 neuronal JJ I-NP O
32 1517 1526 18657397 mechanism NN I-NP O
33 1527 1529 18657397 of IN B-PP O
34 1530 1534 18657397 this DT B-NP O
35 1535 1537 18657397 or CC I-NP O
36 1538 1543 18657397 other JJ I-NP O
37 1544 1549 18657397 types NNS I-NP O
38 1550 1552 18657397 of IN B-PP O
39 1553 1565 18657397 experimental JJ B-NP O
40 1566 1576 18657397 epilepsies NNS I-NP D004827
41 1576 1577 18657397 . . O O

1 0 0 17965424 -DOCSTART- -X- -X- O

1 0 16 17965424 Gastrointestinal JJ B-NP O
2 17 29 17965424 tolerability NN I-NP O
3 30 32 17965424 of IN B-PP O
4 33 43 17965424 etoricoxib NN B-NP C422649
5 44 46 17965424 in IN B-PP O
6 47 57 17965424 rheumatoid JJ B-NP D001172
7 58 67 17965424 arthritis NN I-NP D001172
8 68 76 17965424 patients NNS I-NP O
9 76 77 17965424 : : O O
10 78 85 17965424 results NNS B-NP O
11 86 88 17965424 of IN B-PP O
12 89 92 17965424 the DT B-NP O
13 93 103 17965424 etoricoxib NN I-NP C422649
14 104 106 17965424 vs IN B-PP O
15 107 117 17965424 diclofenac NN B-NP D004008
16 118 124 17965424 sodium NN I-NP D004008
17 125 141 17965424 gastrointestinal JJ I-NP O
18 142 154 17965424 tolerability NN I-NP O
19 155 158 17965424 and CC I-NP O
20 159 172 17965424 effectiveness NN I-NP O
21 173 178 17965424 trial NN I-NP O
22 179 180 17965424 ( ( O O
23 180 184 17965424 EDGE NN B-NP O
24 184 185 17965424 - HYPH O O
25 185 187 17965424 II CD B-NP O
26 187 188 17965424 ) ) O O
27 188 189 17965424 . . O O
28 190 199 17965424 OBJECTIVE NN B-NP O
29 199 200 17965424 : : O O
30 201 202 17965424 A DT B-NP O
31 203 213 17965424 randomised VBN I-NP O
32 213 214 17965424 , , I-NP O
33 215 221 17965424 double JJ I-NP O
34 221 222 17965424 - HYPH I-NP O
35 222 227 17965424 blind JJ I-NP O
36 228 233 17965424 study NN I-NP O
37 234 236 17965424 to TO B-VP O
38 237 244 17965424 compare VB I-VP O
39 245 248 17965424 the DT B-NP O
40 249 265 17965424 gastrointestinal JJ I-NP O
41 266 267 17965424 ( ( O O
42 267 269 17965424 GI NN B-NP O
43 269 270 17965424 ) ) O O
44 271 283 17965424 tolerability NN B-NP O
45 283 284 17965424 , , O O
46 285 291 17965424 safety NN B-NP O
47 292 295 17965424 and CC I-NP O
48 296 304 17965424 efficacy NN I-NP O
49 305 307 17965424 of IN B-PP O
50 308 318 17965424 etoricoxib NN B-NP C422649
51 319 322 17965424 and CC I-NP O
52 323 333 17965424 diclofenac NN I-NP D004008
53 334 336 17965424 in IN B-PP O
54 337 345 17965424 patients NNS B-NP O
55 346 350 17965424 with IN B-PP O
56 351 361 17965424 rheumatoid JJ B-NP D001172
57 362 371 17965424 arthritis NN I-NP D001172
58 372 373 17965424 ( ( O O
59 373 375 17965424 RA NN B-NP D001172
60 375 376 17965424 ) ) O O
61 376 377 17965424 . . O O

1 378 386 17965424 PATIENTS NNS B-NP O
2 387 390 17965424 AND CC I-NP O
3 391 398 17965424 METHODS NNS I-NP O
4 398 399 17965424 : : O O
5 400 401 17965424 A DT B-NP O
6 402 407 17965424 total NN I-NP O
7 408 410 17965424 of IN B-PP O
8 411 415 17965424 4086 CD B-NP O
9 416 424 17965424 patients NNS I-NP O
10 425 426 17965424 ( ( O O
11 426 430 17965424 mean JJ B-NP O
12 431 434 17965424 age NN I-NP O
13 435 439 17965424 60.8 CD B-NP O
14 440 445 17965424 years NNS I-NP O
15 445 446 17965424 ) ) O O
16 447 456 17965424 diagnosed VBN B-VP O
17 457 461 17965424 with IN B-PP O
18 462 464 17965424 RA NN B-NP D001172
19 465 469 17965424 were VBD B-VP O
20 470 478 17965424 enrolled VBN I-VP O
21 479 482 17965424 and CC O O
22 483 491 17965424 received VBN B-VP O
23 492 502 17965424 etoricoxib NN B-NP C422649
24 503 505 17965424 90 CD I-NP O
25 506 508 17965424 mg NN I-NP O
26 509 514 17965424 daily JJ I-NP O
27 515 516 17965424 ( ( O O
28 516 517 17965424 n NN B-NP O
29 518 519 17965424 = SYM B-VP O
30 520 524 17965424 2032 CD B-NP O
31 524 525 17965424 ) ) O O
32 526 528 17965424 or CC O O
33 529 539 17965424 diclofenac NN B-NP D004008
34 540 542 17965424 75 CD B-NP O
35 543 545 17965424 mg NN I-NP O
36 546 551 17965424 twice RB B-ADVP O
37 552 557 17965424 daily RB O O
38 558 559 17965424 ( ( O O
39 559 560 17965424 n NN B-NP O
40 561 562 17965424 = SYM B-VP O
41 563 567 17965424 2054 CD B-NP O
42 567 568 17965424 ) ) O O
43 568 569 17965424 . . O O

1 570 573 17965424 Use NN B-NP O
2 574 576 17965424 of IN B-PP O
3 577 593 17965424 gastroprotective JJ B-NP O
4 594 600 17965424 agents NNS I-NP O
5 601 604 17965424 and CC O O
6 605 608 17965424 low JJ B-NP O
7 608 609 17965424 - HYPH I-NP O
8 609 613 17965424 dose NN I-NP O
9 614 621 17965424 aspirin NN I-NP D001241
10 622 625 17965424 was VBD B-VP O
11 626 633 17965424 allowed VBN I-VP O
12 633 634 17965424 . . O O

1 635 638 17965424 The DT B-NP O
2 639 651 17965424 prespecified VBN I-NP O
3 652 659 17965424 primary JJ I-NP O
4 660 663 17965424 end NN I-NP O
5 664 669 17965424 point NN I-NP O
6 670 679 17965424 consisted VBD B-VP O
7 680 682 17965424 of IN B-PP O
8 683 686 17965424 the DT B-NP O
9 687 697 17965424 cumulative JJ I-NP O
10 698 702 17965424 rate NN I-NP O
11 703 705 17965424 of IN B-PP O
12 706 713 17965424 patient NN B-NP O
13 714 730 17965424 discontinuations NNS I-NP O
14 731 734 17965424 due JJ B-ADJP O
15 735 737 17965424 to TO B-PP O
16 738 746 17965424 clinical JJ B-NP O
17 747 750 17965424 and CC I-NP O
18 751 761 17965424 laboratory JJ I-NP O
19 762 764 17965424 GI NN I-NP O
20 765 772 17965424 adverse JJ I-NP O
21 773 784 17965424 experiences NNS I-NP O
22 785 786 17965424 ( ( O O
23 786 789 17965424 AEs NNS B-NP O
24 789 790 17965424 ) ) O O
25 790 791 17965424 . . O O

1 792 799 17965424 General JJ B-NP O
2 800 806 17965424 safety NN I-NP O
3 807 810 17965424 was VBD B-VP O
4 811 815 17965424 also RB I-VP O
5 816 824 17965424 assessed VBN I-VP O
6 824 825 17965424 , , O O
7 826 835 17965424 including VBG B-PP O
8 836 847 17965424 adjudicated VBN B-NP O
9 848 858 17965424 thrombotic JJ I-NP D002318
10 859 873 17965424 cardiovascular JJ I-NP D002318
11 874 879 17965424 event NN I-NP O
12 880 884 17965424 data NNS I-NP O
13 884 885 17965424 . . O O

1 886 894 17965424 Efficacy NN B-NP O
2 895 898 17965424 was VBD B-VP O
3 899 908 17965424 evaluated VBN I-VP O
4 909 914 17965424 using VBG B-VP O
5 915 918 17965424 the DT B-NP O
6 919 926 17965424 Patient NN I-NP O
7 927 933 17965424 Global NNP I-NP O
8 934 944 17965424 Assessment NN I-NP O
9 945 947 17965424 of IN B-PP O
10 948 955 17965424 Disease NN B-NP O
11 956 962 17965424 Status NN I-NP O
12 963 964 17965424 ( ( O O
13 964 969 17965424 PGADS NN B-NP O
14 969 970 17965424 ; : O O
15 971 972 17965424 0 CD B-NP O
16 972 973 17965424 - HYPH I-NP O
17 973 974 17965424 4 CD I-NP O
18 975 980 17965424 point NN I-NP O
19 981 986 17965424 scale NN I-NP O
20 986 987 17965424 ) ) O O
21 987 988 17965424 . . O O

1 989 996 17965424 RESULTS NNS B-NP O
2 996 997 17965424 : : O O
3 998 1002 17965424 Mean NN B-NP O
4 1003 1004 17965424 ( ( O O
5 1004 1006 17965424 SD NN B-NP O
6 1006 1007 17965424 ; : O O
7 1008 1015 17965424 maximum NN B-NP O
8 1015 1016 17965424 ) ) O O
9 1017 1025 17965424 duration NN B-NP O
10 1026 1028 17965424 of IN B-PP O
11 1029 1038 17965424 treatment NN B-NP O
12 1039 1042 17965424 was VBD B-VP O
13 1043 1047 17965424 19.3 CD B-NP O
14 1048 1049 17965424 ( ( O O
15 1049 1053 17965424 10.3 CD B-NP O
16 1053 1054 17965424 ; : O O
17 1055 1059 17965424 32.9 CD B-NP O
18 1059 1060 17965424 ) ) O O
19 1061 1064 17965424 and CC O O
20 1065 1069 17965424 19.1 CD B-NP O
21 1070 1071 17965424 ( ( O O
22 1071 1075 17965424 10.4 CD B-NP O
23 1075 1076 17965424 ; : O O
24 1077 1081 17965424 33.1 CD B-NP O
25 1081 1082 17965424 ) ) O O
26 1083 1089 17965424 months NNS B-NP O
27 1090 1092 17965424 in IN B-PP O
28 1093 1096 17965424 the DT B-NP O
29 1097 1107 17965424 etoricoxib NN I-NP C422649
30 1108 1111 17965424 and CC I-NP O
31 1112 1122 17965424 diclofenac NN I-NP D004008
32 1123 1129 17965424 groups NNS I-NP O
33 1129 1130 17965424 , , O O
34 1131 1143 17965424 respectively RB B-ADVP O
35 1143 1144 17965424 . . O O

1 1145 1148 17965424 The DT B-NP O
2 1149 1159 17965424 cumulative JJ I-NP O
3 1160 1175 17965424 discontinuation NN I-NP O
4 1176 1180 17965424 rate NN I-NP O
5 1181 1184 17965424 due IN B-PP O
6 1185 1187 17965424 to TO I-PP O
7 1188 1190 17965424 GI NN B-NP D005767
8 1191 1194 17965424 AEs NNS I-NP D005767
9 1195 1198 17965424 was VBD B-VP O
10 1199 1212 17965424 significantly RB B-ADJP O
11 1213 1218 17965424 lower JJR I-ADJP O
12 1219 1223 17965424 with IN B-PP O
13 1224 1234 17965424 etoricoxib NN B-NP C422649
14 1235 1239 17965424 than IN B-PP O
15 1240 1250 17965424 diclofenac NN B-NP D004008
16 1251 1252 17965424 ( ( O O
17 1252 1255 17965424 5.2 CD B-NP O
18 1256 1258 17965424 vs IN I-NP O
19 1259 1262 17965424 8.5 CD I-NP O
20 1263 1269 17965424 events NNS I-NP O
21 1270 1273 17965424 per IN B-PP O
22 1274 1277 17965424 100 CD B-NP O
23 1278 1285 17965424 patient NN I-NP O
24 1285 1286 17965424 - HYPH B-NP O
25 1286 1291 17965424 years NNS I-NP O
26 1291 1292 17965424 , , O O
27 1293 1305 17965424 respectively RB B-ADVP O
28 1305 1306 17965424 ; : O O
29 1307 1313 17965424 hazard NN B-NP O
30 1314 1319 17965424 ratio NN I-NP O
31 1320 1324 17965424 0.62 CD I-NP O
32 1325 1326 17965424 ( ( O O
33 1326 1329 17965424 95% CD B-NP O
34 1330 1332 17965424 CI NNP I-NP O
35 1332 1333 17965424 : : O O
36 1334 1338 17965424 0.47 CD B-NP O
37 1338 1339 17965424 , , I-NP O
38 1340 1344 17965424 0.81 CD I-NP O
39 1344 1345 17965424 ; : O O
40 1346 1347 17965424 p NN B-NP O
41 1347 1348 17965424 < SYM B-NP O
42 1348 1350 17965424 or CC O O
43 1350 1351 17965424 = SYM B-VP O
44 1351 1356 17965424 0.001 CD B-NP O
45 1356 1357 17965424 ) ) O O
46 1357 1358 17965424 ) ) O O
47 1358 1359 17965424 . . O O

1 1360 1363 17965424 The DT B-NP O
2 1364 1373 17965424 incidence NN I-NP O
3 1374 1376 17965424 of IN B-PP O
4 1377 1393 17965424 discontinuations NNS B-NP O
5 1394 1397 17965424 for IN B-PP O
6 1398 1410 17965424 hypertension NN B-NP D006973
7 1410 1411 17965424 - HYPH B-NP O
8 1411 1418 17965424 related VBN I-NP O
9 1419 1422 17965424 and CC I-NP O
10 1423 1429 17965424 oedema NN I-NP D004487
11 1429 1430 17965424 - HYPH B-NP O
12 1430 1437 17965424 related VBN I-NP O
13 1438 1441 17965424 AEs NNS I-NP O
14 1442 1446 17965424 were VBD B-VP O
15 1447 1460 17965424 significantly RB B-ADJP O
16 1461 1467 17965424 higher JJR I-ADJP O
17 1468 1472 17965424 with IN B-PP O
18 1473 1483 17965424 etoricoxib NN B-NP C422649
19 1484 1485 17965424 ( ( O O
20 1485 1489 17965424 2.5% CD B-NP O
21 1490 1493 17965424 and CC I-NP O
22 1494 1498 17965424 1.1% CD I-NP O
23 1499 1511 17965424 respectively RB B-ADVP O
24 1511 1512 17965424 ) ) O O
25 1513 1521 17965424 compared VBN B-PP O
26 1522 1526 17965424 with IN B-PP O
27 1527 1537 17965424 diclofenac NN B-NP D004008
28 1538 1539 17965424 ( ( O O
29 1539 1543 17965424 1.5% CD B-NP O
30 1544 1547 17965424 and CC I-NP O
31 1548 1552 17965424 0.4% CD I-NP O
32 1553 1565 17965424 respectively RB B-ADVP O
33 1565 1566 17965424 ; : O O
34 1567 1568 17965424 p NN B-NP O
35 1568 1569 17965424 < SYM B-VP O
36 1569 1574 17965424 0.001 CD B-NP O
37 1575 1578 17965424 for IN B-PP O
38 1579 1591 17965424 hypertension NN B-NP D006973
39 1592 1595 17965424 and CC I-NP O
40 1596 1597 17965424 p NN I-NP O
41 1597 1598 17965424 < SYM B-NP O
42 1598 1602 17965424 0.01 CD B-NP O
43 1603 1606 17965424 for IN B-PP O
44 1607 1613 17965424 oedema NN B-NP D004487
45 1613 1614 17965424 ) ) O O
46 1614 1615 17965424 . . O O

1 1616 1626 17965424 Etoricoxib NN B-NP C422649
2 1627 1630 17965424 and CC I-NP O
3 1631 1641 17965424 diclofenac NN I-NP D004008
4 1642 1651 17965424 treatment NN I-NP O
5 1652 1660 17965424 resulted VBD B-VP O
6 1661 1663 17965424 in IN B-PP O
7 1664 1671 17965424 similar JJ B-NP O
8 1672 1680 17965424 efficacy NN I-NP O
9 1681 1682 17965424 ( ( O O
10 1682 1687 17965424 PGADS NN B-NP O
11 1688 1692 17965424 mean NN I-NP O
12 1693 1700 17965424 changes NNS I-NP O
13 1701 1705 17965424 from IN B-PP O
14 1706 1714 17965424 baseline NN B-NP O
15 1715 1716 17965424 - HYPH B-ADVP O
16 1716 1720 17965424 0.62 CD B-NP O
17 1721 1723 17965424 vs NNS I-NP O
18 1724 1725 17965424 - HYPH O O
19 1725 1729 17965424 0.58 CD B-NP O
20 1729 1730 17965424 , , O O
21 1731 1743 17965424 respectively RB B-ADVP O
22 1743 1744 17965424 ) ) O O
23 1744 1745 17965424 . . O O

1 1746 1757 17965424 CONCLUSIONS NNS B-NP O
2 1757 1758 17965424 : : O O
3 1759 1769 17965424 Etoricoxib NN B-NP C422649
4 1770 1772 17965424 90 CD B-NP O
5 1773 1775 17965424 mg NN I-NP O
6 1776 1788 17965424 demonstrated VBD B-VP O
7 1789 1790 17965424 a DT B-NP O
8 1791 1804 17965424 significantly RB I-NP O
9 1805 1810 17965424 lower JJR I-NP O
10 1811 1815 17965424 risk NN I-NP O
11 1816 1819 17965424 for IN B-PP O
12 1820 1833 17965424 discontinuing VBG B-VP O
13 1834 1843 17965424 treatment NN B-NP O
14 1844 1847 17965424 due IN B-PP O
15 1848 1850 17965424 to TO B-PP O
16 1851 1853 17965424 GI NN B-NP D005767
17 1854 1857 17965424 AEs NNS I-NP D005767
18 1858 1866 17965424 compared VBN B-PP O
19 1867 1871 17965424 with IN B-PP O
20 1872 1882 17965424 diclofenac NN B-NP D004008
21 1883 1886 17965424 150 CD I-NP O
22 1887 1889 17965424 mg NN I-NP O
23 1889 1890 17965424 . . O O

1 1891 1907 17965424 Discontinuations NNS B-NP O
2 1908 1912 17965424 from IN B-PP O
3 1913 1925 17965424 renovascular JJ B-NP O
4 1926 1929 17965424 AEs NNS I-NP O
5 1929 1930 17965424 , , O O
6 1931 1939 17965424 although IN B-SBAR O
7 1940 1944 17965424 less RBR B-ADJP O
8 1945 1951 17965424 common JJ I-ADJP O
9 1952 1956 17965424 than IN B-PP O
10 1957 1973 17965424 discontinuations NNS B-NP O
11 1974 1978 17965424 from IN B-PP O
12 1979 1981 17965424 GI NN B-NP D005767
13 1982 1985 17965424 AEs NNS I-NP D005767
14 1985 1986 17965424 , , O O
15 1987 1991 17965424 were VBD B-VP O
16 1992 2005 17965424 significantly RB B-ADJP O
17 2006 2012 17965424 higher JJR I-ADJP O
18 2013 2017 17965424 with IN B-PP O
19 2018 2028 17965424 etoricoxib NN B-NP C422649
20 2028 2029 17965424 . . O O

1 0 0 2533791 -DOCSTART- -X- -X- O

1 0 8 2533791 National JJ B-NP O
2 9 16 2533791 project NN I-NP O
3 17 19 2533791 on IN B-PP O
4 20 23 2533791 the DT B-NP O
5 24 34 2533791 prevention NN I-NP O
6 35 37 2533791 of IN B-PP O
7 38 44 2533791 mother NN B-NP O
8 44 45 2533791 - HYPH B-ADVP O
9 45 47 2533791 to TO B-PP O
10 47 48 2533791 - HYPH B-NP O
11 48 54 2533791 infant NN I-NP O
12 55 64 2533791 infection NN I-NP D006509
13 65 67 2533791 by IN B-PP D006509
14 68 77 2533791 hepatitis NN B-NP D006509
15 78 79 2533791 B NN I-NP D006509
16 80 85 2533791 virus NN I-NP D006509
17 86 88 2533791 in IN B-PP O
18 89 94 2533791 Japan NNP B-NP O
19 94 95 2533791 . . O O
20 96 98 2533791 In IN B-PP O
21 99 104 2533791 Japan NNP B-NP O
22 104 105 2533791 , , O O
23 106 107 2533791 a DT B-NP O
24 108 118 2533791 nationwide JJ I-NP O
25 119 129 2533791 prevention NN I-NP O
26 130 137 2533791 program NN I-NP O
27 138 145 2533791 against IN B-PP O
28 146 152 2533791 mother NN B-NP O
29 152 153 2533791 - HYPH B-ADJP O
30 153 155 2533791 to TO B-PP O
31 155 156 2533791 - HYPH B-NP O
32 156 162 2533791 infant NN I-NP O
33 163 172 2533791 infection NN I-NP D006509
34 173 175 2533791 by IN B-PP D006509
35 176 185 2533791 hepatitis NN B-NP D006509
36 186 187 2533791 B NN I-NP D006509
37 188 193 2533791 virus NN I-NP D006509
38 194 195 2533791 ( ( O O
39 195 198 2533791 HBV NN B-NP O
40 198 199 2533791 ) ) O O
41 200 207 2533791 started VBD B-VP O
42 208 210 2533791 in IN B-PP O
43 211 215 2533791 1985 CD B-NP O
44 215 216 2533791 . . O O

1 217 221 2533791 This DT B-NP O
2 222 229 2533791 program NN I-NP O
3 230 238 2533791 consists VBZ B-VP O
4 239 241 2533791 of IN B-PP O
5 242 248 2533791 double JJ B-NP O
6 249 259 2533791 screenings NNS I-NP O
7 260 262 2533791 of IN B-PP O
8 263 271 2533791 pregnant JJ B-NP O
9 272 277 2533791 women NNS I-NP O
10 278 281 2533791 and CC O O
11 282 294 2533791 prophylactic JJ B-NP O
12 295 304 2533791 treatment NN I-NP O
13 305 307 2533791 to TO B-PP O
14 308 311 2533791 the DT B-NP O
15 312 319 2533791 infants NNS I-NP O
16 320 324 2533791 born VBN B-VP O
17 325 327 2533791 to TO B-PP O
18 328 332 2533791 both CC O O
19 333 342 2533791 hepatitis NN B-NP D006514
20 343 344 2533791 B NN I-NP D006514
21 345 352 2533791 surface NN I-NP D006514
22 353 360 2533791 antigen NN I-NP D006514
23 361 362 2533791 ( ( O O
24 362 367 2533791 HBsAg NN B-NP D006514
25 367 368 2533791 ) ) O O
26 369 372 2533791 and CC O O
27 373 382 2533791 hepatitis NN B-NP D006513
28 383 384 2533791 B NN I-NP D006513
29 385 386 2533791 e NN I-NP D006513
30 387 394 2533791 antigen NN I-NP D006513
31 395 396 2533791 ( ( O O
32 396 401 2533791 HBeAg NN B-NP D006513
33 401 402 2533791 ) ) O O
34 403 411 2533791 positive JJ B-NP O
35 412 419 2533791 mothers NNS I-NP O
36 419 420 2533791 . . O O

1 421 426 2533791 These DT B-NP O
2 427 434 2533791 infants NNS I-NP O
3 435 438 2533791 are VBP B-VP O
4 439 446 2533791 treated VBN I-VP O
5 447 451 2533791 with IN B-PP O
6 452 455 2533791 two CD B-NP O
7 456 466 2533791 injections NNS I-NP O
8 467 469 2533791 of IN B-PP O
9 470 479 2533791 hepatitis NN B-NP D006509
10 480 481 2533791 B NN I-NP D006509
11 482 488 2533791 immune JJ I-NP O
12 489 497 2533791 globulin NN I-NP O
13 498 499 2533791 ( ( O O
14 499 503 2533791 HBIG NN B-NP O
15 503 504 2533791 ) ) O O
16 505 508 2533791 and CC O O
17 509 511 2533791 at IN B-NP O
18 512 517 2533791 least JJS I-NP O
19 518 523 2533791 three CD I-NP O
20 524 534 2533791 injections NNS I-NP O
21 535 537 2533791 of IN B-PP O
22 538 544 2533791 plasma NN B-NP O
23 545 552 2533791 derived VBN I-NP O
24 553 562 2533791 hepatitis NN I-NP D017325
25 563 564 2533791 B NN I-NP D017325
26 565 572 2533791 vaccine NN I-NP D017325
27 572 573 2533791 . . O O

1 574 576 2533791 We PRP B-NP O
2 577 581 2533791 sent VBD B-VP O
3 582 596 2533791 questionnaires NNS B-NP O
4 597 602 2533791 about IN B-PP O
5 603 606 2533791 the DT B-NP O
6 607 614 2533791 numbers NNS I-NP O
7 615 617 2533791 of IN B-PP O
8 618 622 2533791 each DT B-NP O
9 623 632 2533791 procedure NN I-NP O
10 633 635 2533791 or CC I-NP O
11 636 647 2533791 examination NN I-NP O
12 648 654 2533791 during IN B-PP O
13 655 659 2533791 nine CD B-NP O
14 660 666 2533791 months NNS I-NP O
15 667 669 2533791 of IN B-PP O
16 670 683 2533791 investigation NN B-NP O
17 684 690 2533791 period NN I-NP O
18 691 693 2533791 to TO B-PP O
19 694 698 2533791 each DT B-NP O
20 699 704 2533791 local JJ I-NP O
21 705 715 2533791 government NN I-NP O
22 716 718 2533791 in IN B-PP O
23 719 723 2533791 1986 CD B-NP O
24 724 727 2533791 and CC I-NP O
25 728 732 2533791 1987 CD I-NP O
26 732 733 2533791 . . O O

1 734 739 2533791 93.4% CD B-NP O
2 740 748 2533791 pregnant JJ I-NP O
3 749 754 2533791 women NNS I-NP O
4 755 758 2533791 had VBD B-VP O
5 759 762 2533791 the DT B-NP O
6 763 769 2533791 chance NN I-NP O
7 770 772 2533791 to TO B-VP O
8 773 775 2533791 be VB I-VP O
9 776 784 2533791 examined VBN I-VP O
10 785 788 2533791 for IN B-PP O
11 789 794 2533791 HBsAg NN B-NP D006514
12 794 795 2533791 , , O O
13 796 799 2533791 and CC O O
14 800 803 2533791 the DT B-NP O
15 804 812 2533791 positive JJ I-NP O
16 813 817 2533791 rate NN I-NP O
17 818 821 2533791 was VBD B-VP O
18 822 825 2533791 1.4 CD B-NP O
19 826 828 2533791 to TO B-PP O
20 829 833 2533791 1.5% CD B-NP O
21 833 834 2533791 . . O O

1 835 838 2533791 The DT B-NP O
2 839 844 2533791 HBeAg NN I-NP D006513
3 845 853 2533791 positive JJ I-NP O
4 854 858 2533791 rate NN I-NP O
5 859 861 2533791 in IN B-PP O
6 862 867 2533791 HBsAg NN B-NP D006514
7 868 876 2533791 positive JJ B-NP O
8 877 880 2533791 was VBD B-VP O
9 881 883 2533791 23 CD B-NP O
10 884 886 2533791 to TO B-PP O
11 887 890 2533791 26% CD B-NP O
12 890 891 2533791 . . O O

1 892 895 2533791 The DT B-NP O
2 896 901 2533791 HBsAg NN I-NP D006514
3 902 910 2533791 positive JJ I-NP O
4 911 915 2533791 rate NN I-NP O
5 916 918 2533791 in IN B-PP O
6 919 927 2533791 neonates NNS B-NP O
7 928 931 2533791 and CC B-PP O
8 932 934 2533791 in IN B-PP O
9 935 942 2533791 infants NNS B-NP O
10 943 949 2533791 before IN B-PP O
11 950 953 2533791 two CD B-NP O
12 954 960 2533791 months NNS I-NP O
13 961 965 2533791 were VBD B-VP O
14 966 968 2533791 3% NN B-NP O
15 969 972 2533791 and CC I-NP O
16 973 975 2533791 2% NN I-NP O
17 976 988 2533791 respectively RB B-ADVP O
18 988 989 2533791 . . O O

1 990 994 2533791 Some DT B-NP O
2 995 1003 2533791 problems NNS I-NP O
3 1004 1007 2533791 may MD B-VP O
4 1008 1013 2533791 arise VB I-VP O
5 1013 1014 2533791 , , O O
6 1015 1022 2533791 because IN B-SBAR O
7 1023 1025 2533791 27 CD B-NP O
8 1026 1028 2533791 to TO B-PP O
9 1029 1032 2533791 30% CD B-NP O
10 1033 1035 2533791 of IN B-PP O
11 1036 1043 2533791 infants NNS B-NP O
12 1044 1048 2533791 need VBP B-VP O
13 1049 1052 2533791 the DT B-NP O
14 1053 1059 2533791 fourth JJ I-NP O
15 1060 1071 2533791 vaccination NN I-NP O
16 1072 1074 2533791 in IN B-PP O
17 1075 1079 2533791 some DT B-NP O
18 1080 1090 2533791 restricted JJ I-NP O
19 1091 1096 2533791 areas NNS I-NP O
20 1096 1097 2533791 . . O O

1 0 0 11467664 -DOCSTART- -X- -X- O

1 0 11 11467664 Cholestatic JJ B-NP D041781
2 12 20 11467664 jaundice NN I-NP D041781
3 21 31 11467664 associated VBN B-VP O
4 32 36 11467664 with IN B-PP O
5 37 40 11467664 the DT B-NP O
6 41 44 11467664 use NN I-NP O
7 45 47 11467664 of IN B-PP O
8 48 57 11467664 metformin NN B-NP D008687
9 57 58 11467664 . . O O
10 59 61 11467664 We PRP B-NP O
11 62 68 11467664 report VBP B-VP O
12 69 70 11467664 a DT B-NP O
13 71 78 11467664 patient NN I-NP O
14 79 82 11467664 who WP B-NP O
15 83 92 11467664 developed VBD B-VP O
16 93 104 11467664 cholestatic JJ B-NP D041781
17 105 113 11467664 jaundice NN I-NP D041781
18 114 121 11467664 shortly RB B-ADVP O
19 122 127 11467664 after IN B-PP O
20 128 138 11467664 initiation NN B-NP O
21 139 141 11467664 of IN B-PP O
22 142 151 11467664 treatment NN B-NP O
23 152 156 11467664 with IN B-PP O
24 157 166 11467664 metformin NN B-NP D008687
25 167 180 11467664 hydrochloride NN I-NP D008687
26 180 181 11467664 . . O O

1 182 192 11467664 Ultrasound NN B-NP O
2 193 195 11467664 of IN B-PP O
3 196 199 11467664 the DT B-NP O
4 200 205 11467664 liver NN I-NP O
5 206 209 11467664 and CC O O
6 210 219 11467664 abdominal JJ B-NP O
7 220 222 11467664 CT NN I-NP O
8 223 227 11467664 were VBD B-VP O
9 228 234 11467664 normal JJ B-ADJP O
10 234 235 11467664 . . O O

1 236 238 11467664 An DT B-NP O
2 239 243 11467664 ERCP NN I-NP O
3 244 250 11467664 showed VBD B-VP O
4 251 257 11467664 normal JJ B-NP O
5 258 265 11467664 biliary JJ I-NP O
6 266 273 11467664 anatomy NN I-NP O
7 273 274 11467664 . . O O

1 275 276 11467664 A DT B-NP O
2 277 289 11467664 percutaneous JJ I-NP O
3 290 295 11467664 liver NN I-NP O
4 296 302 11467664 biopsy NN I-NP O
5 303 306 11467664 was VBD B-VP O
6 307 315 11467664 obtained VBN I-VP O
7 316 323 11467664 showing VBG B-VP O
8 324 330 11467664 marked JJ B-NP O
9 331 342 11467664 cholestasis NN I-NP D002779
10 342 343 11467664 , , O O
11 344 348 11467664 with IN B-PP O
12 349 355 11467664 portal JJ B-NP O
13 356 361 11467664 edema NN I-NP D004487
14 361 362 11467664 , , O O
15 363 371 11467664 ductular JJ B-NP O
16 372 385 11467664 proliferation NN I-NP O
17 385 386 11467664 , , O O
18 387 390 11467664 and CC O O
19 391 396 11467664 acute JJ B-NP O
20 397 409 11467664 inflammation NN I-NP D007249
21 409 410 11467664 . . O O

1 411 420 11467664 Metformin NN B-NP D008687
2 421 434 11467664 hydrochloride NN I-NP D008687
3 435 438 11467664 was VBD B-VP O
4 439 451 11467664 discontinued VBN I-VP O
5 451 452 11467664 , , O O
6 453 456 11467664 and CC O O
7 457 460 11467664 the DT B-NP O
8 461 470 11467664 patient's NNS I-NP O
9 471 479 11467664 jaundice VBP B-VP D007565
10 480 488 11467664 resolved VBN I-VP O
11 489 495 11467664 slowly RB B-ADVP O
12 496 500 11467664 over IN B-PP O
13 501 502 11467664 a DT B-NP O
14 503 509 11467664 period NN I-NP O
15 510 512 11467664 of IN B-PP O
16 513 520 11467664 several JJ B-NP O
17 521 527 11467664 months NNS I-NP O
18 527 528 11467664 . . O O

1 529 534 11467664 Given VBN B-PP O
2 535 538 11467664 the DT B-NP O
3 539 544 11467664 onset NN I-NP O
4 545 547 11467664 of IN B-PP O
5 548 551 11467664 his PRP$ B-NP O
6 552 560 11467664 jaundice NN I-NP D007565
7 561 562 11467664 2 CD I-NP O
8 563 565 11467664 wk NN I-NP O
9 566 571 11467664 after IN B-PP O
10 572 575 11467664 the DT B-NP O
11 576 586 11467664 initiation NN I-NP O
12 587 589 11467664 of IN B-PP O
13 590 599 11467664 metformin NN B-NP D008687
14 599 600 11467664 , , O O
15 601 603 11467664 we PRP B-NP O
16 604 611 11467664 believe VBP B-VP O
17 612 616 11467664 that IN B-SBAR O
18 617 621 11467664 this DT B-NP O
19 622 626 11467664 case NN I-NP O
20 627 637 11467664 represents VBZ B-VP O
21 638 640 11467664 an DT B-NP O
22 641 648 11467664 example NN I-NP O
23 649 651 11467664 of IN B-PP O
24 652 661 11467664 metformin NN B-NP D008687
25 661 662 11467664 - HYPH B-NP O
26 662 672 11467664 associated VBN I-NP O
27 673 687 11467664 hepatotoxicity NN I-NP D056486
28 687 688 11467664 , , O O
29 689 692 11467664 the DT B-NP O
30 693 698 11467664 first JJ I-NP O
31 699 703 11467664 such JJ I-NP O
32 704 708 11467664 case NN I-NP O
33 709 717 11467664 reported VBD B-VP O
34 717 718 11467664 . . O O

1 0 0 871943 -DOCSTART- -X- -X- O

1 0 3 871943 The DT B-NP O
2 4 7 871943 use NN I-NP O
3 8 10 871943 of IN B-PP O
4 11 16 871943 serum NN B-NP O
5 17 31 871943 cholinesterase NN I-NP O
6 32 34 871943 in IN B-PP O
7 35 50 871943 succinylcholine NN B-NP D013390
8 51 57 871943 apnoea NN I-NP D001049
9 57 58 871943 . . O O
10 59 66 871943 Fifteen CD B-NP O
11 67 75 871943 patients NNS I-NP O
12 76 89 871943 demonstrating VBG B-VP O
13 90 100 871943 unexpected JJ B-NP O
14 101 110 871943 prolonged VBN I-NP O
15 111 117 871943 apnoea NN I-NP D001049
16 118 125 871943 lasting VBG B-VP O
17 126 133 871943 several JJ B-NP O
18 134 139 871943 hours NNS I-NP O
19 140 145 871943 after IN B-PP O
20 146 161 871943 succinylcholine NN B-NP D013390
21 162 166 871943 have VBP B-VP O
22 167 171 871943 been VBN I-VP O
23 172 179 871943 treated VBN I-VP O
24 180 182 871943 by IN B-PP O
25 183 184 871943 a DT B-NP O
26 185 188 871943 new JJ I-NP O
27 189 200 871943 preparation NN I-NP O
28 201 203 871943 of IN B-PP O
29 204 209 871943 human JJ B-NP O
30 210 215 871943 serum NN I-NP O
31 216 230 871943 cholinesterase NN I-NP O
32 230 231 871943 . . O O

1 232 240 871943 Adequate JJ B-NP O
2 241 252 871943 spontaneous JJ I-NP O
3 253 264 871943 respiration NN I-NP O
4 265 268 871943 was VBD B-VP O
5 269 271 871943 re AFX B-ADJP O
6 271 272 871943 - HYPH B-NP O
7 272 283 871943 established VBN B-VP O
8 284 286 871943 in IN B-PP O
9 287 289 871943 an DT B-NP O
10 290 297 871943 average JJ I-NP O
11 298 304 871943 period NN I-NP O
12 305 307 871943 of IN B-PP O
13 308 311 871943 ten CD B-NP O
14 312 319 871943 minutes NNS I-NP O
15 320 325 871943 after IN B-PP O
16 326 329 871943 the DT B-NP O
17 330 339 871943 injection NN I-NP O
18 339 340 871943 . . O O

1 341 343 871943 In IN B-PP O
2 344 346 871943 12 CD B-NP O
3 347 355 871943 patients NNS I-NP O
4 356 367 871943 biochemical JJ B-NP O
5 368 375 871943 genetic JJ I-NP O
6 376 388 871943 examinations NNS I-NP O
7 389 398 871943 confirmed VBD B-VP O
8 399 402 871943 the DT B-NP O
9 403 411 871943 presence NN I-NP O
10 412 414 871943 of IN B-PP O
11 415 417 871943 an DT B-NP O
12 418 426 871943 atypical JJ I-NP O
13 427 432 871943 serum NN I-NP O
14 433 447 871943 cholinesterase NN I-NP O
15 447 448 871943 . . O O

1 449 451 871943 In IN B-PP O
2 452 457 871943 three CD B-NP O
3 458 466 871943 patients NNS I-NP O
4 467 471 871943 none NN I-NP O
5 472 474 871943 of IN B-PP O
6 475 478 871943 the DT B-NP O
7 479 484 871943 usual JJ I-NP O
8 485 493 871943 variants NNS I-NP O
9 494 498 871943 were VBD B-VP O
10 499 504 871943 found VBN I-VP O
11 504 505 871943 . . O O

1 506 508 871943 It PRP B-NP O
2 509 511 871943 is VBZ B-VP O
3 512 521 871943 therefore RB I-VP O
4 522 530 871943 supposed VBN I-VP O
5 531 535 871943 that IN B-SBAR O
6 536 541 871943 other JJ B-NP O
7 542 549 871943 unknown JJ I-NP O
8 550 558 871943 variants NNS I-NP O
9 559 561 871943 of IN B-PP O
10 562 567 871943 serum NN B-NP O
11 568 582 871943 cholinesterase NN I-NP O
12 583 588 871943 exist NN I-NP O
13 589 594 871943 which WDT B-NP O
14 595 601 871943 cannot MD B-VP O
15 602 611 871943 hydrolyze VB I-VP O
16 612 627 871943 succinylcholine NN B-NP D013390
17 627 628 871943 . . O O

1 629 632 871943 The DT B-NP O
2 633 636 871943 use NN I-NP O
3 637 639 871943 of IN B-PP O
4 640 645 871943 serum NN B-NP O
5 646 660 871943 cholinesterase NN I-NP O
6 661 663 871943 in IN B-PP O
7 664 679 871943 succinylcholine NN B-NP D013390
8 680 686 871943 apnoea NN I-NP D001049
9 687 695 871943 provided VBD B-VP O
10 696 708 871943 considerable JJ B-NP O
11 709 715 871943 relief NN I-NP O
12 716 718 871943 to TO B-PP O
13 719 723 871943 both CC O O
14 724 731 871943 patient NN B-NP O
15 732 735 871943 and CC I-NP O
16 736 748 871943 anaesthetist NN I-NP O
17 748 749 871943 . . O O

1 0 0 1595783 -DOCSTART- -X- -X- O

1 0 10 1595783 Amiodarone NN B-NP D000638
2 11 20 1595783 pulmonary JJ I-NP D008171
3 21 29 1595783 toxicity NN I-NP D008171
4 29 30 1595783 . . I-NP O
5 31 41 1595783 Amiodarone NN I-NP D000638
6 42 44 1595783 is VBZ B-VP O
7 45 47 1595783 an DT B-NP O
8 48 57 1595783 effective JJ I-NP O
9 58 72 1595783 antiarrhythmic JJ I-NP O
10 73 78 1595783 agent NN I-NP O
11 79 84 1595783 whose WP$ B-NP O
12 85 92 1595783 utility NN I-NP O
13 93 95 1595783 is VBZ B-VP O
14 96 103 1595783 limited VBN I-VP O
15 104 106 1595783 by IN B-PP O
16 107 111 1595783 many JJ B-NP O
17 112 116 1595783 side NN I-NP O
18 116 117 1595783 - HYPH I-NP O
19 117 124 1595783 effects NNS I-NP O
20 124 125 1595783 , , O O
21 126 129 1595783 the DT B-NP O
22 130 134 1595783 most RBS I-NP O
23 135 146 1595783 problematic JJ I-NP O
24 147 152 1595783 being VBG I-NP O
25 153 164 1595783 pneumonitis NN I-NP D011014
26 164 165 1595783 . . O O

1 166 169 1595783 The DT B-NP O
2 170 179 1595783 pulmonary JJ I-NP D008171
3 180 188 1595783 toxicity NN I-NP D008171
4 189 191 1595783 of IN B-PP O
5 192 202 1595783 amiodarone NN B-NP D000638
6 203 205 1595783 is VBZ B-VP O
7 206 213 1595783 thought VBN I-VP O
8 214 216 1595783 to TO I-VP O
9 217 223 1595783 result VB I-VP O
10 224 228 1595783 from IN B-PP O
11 229 235 1595783 direct JJ B-NP O
12 236 242 1595783 injury NN I-NP O
13 243 250 1595783 related VBN B-VP O
14 251 253 1595783 to TO B-PP O
15 254 257 1595783 the DT B-NP O
16 258 271 1595783 intracellular JJ I-NP O
17 272 284 1595783 accumulation NN I-NP O
18 285 287 1595783 of IN B-PP O
19 288 300 1595783 phospholipid NN B-NP O
20 301 304 1595783 and CC O O
21 305 306 1595783 T NN B-NP O
22 307 311 1595783 cell NN I-NP O
23 311 312 1595783 - HYPH B-NP O
24 312 320 1595783 mediated VBN I-NP O
25 321 337 1595783 hypersensitivity NN I-NP D004342
26 338 349 1595783 pneumonitis NN I-NP D004342
27 349 350 1595783 . . O O

1 351 354 1595783 The DT B-NP O
2 355 363 1595783 clinical JJ I-NP O
3 364 367 1595783 and CC I-NP O
4 368 380 1595783 radiographic JJ I-NP O
5 381 389 1595783 features NNS I-NP O
6 390 392 1595783 of IN B-PP O
7 393 403 1595783 amiodarone NN B-NP D000638
8 403 404 1595783 - HYPH B-NP O
9 404 411 1595783 induced VBN I-NP O
10 412 421 1595783 pulmonary JJ I-NP D008171
11 422 430 1595783 toxicity NN I-NP D008171
12 431 434 1595783 are VBP B-VP O
13 435 449 1595783 characteristic JJ B-ADJP O
14 450 453 1595783 but CC I-ADJP O
15 454 465 1595783 nonspecific JJ I-ADJP O
16 465 466 1595783 . . O O

1 467 470 1595783 The DT B-NP O
2 471 480 1595783 diagnosis NN I-NP O
3 481 488 1595783 depends VBZ B-VP O
4 489 491 1595783 on IN B-PP O
5 492 501 1595783 exclusion NN B-NP O
6 502 504 1595783 of IN B-PP O
7 505 510 1595783 other JJ B-NP O
8 511 519 1595783 entities NNS I-NP O
9 519 520 1595783 , , O O
10 521 525 1595783 such JJ B-PP O
11 526 528 1595783 as IN I-PP O
12 529 534 1595783 heart NN B-NP D006333
13 535 542 1595783 failure NN I-NP D006333
14 542 543 1595783 , , O O
15 544 553 1595783 infection NN B-NP D007239
16 553 554 1595783 , , O O
17 555 558 1595783 and CC O O
18 559 569 1595783 malignancy NN B-NP D009369
19 569 570 1595783 . . O O

1 571 576 1595783 While IN B-SBAR O
2 577 587 1595783 withdrawal NN B-NP O
3 588 590 1595783 of IN B-PP O
4 591 601 1595783 amiodarone NN B-NP D000638
5 602 607 1595783 leads VBZ B-VP O
6 608 610 1595783 to TO B-PP O
7 611 619 1595783 clinical JJ B-NP O
8 620 631 1595783 improvement NN I-NP O
9 632 634 1595783 in IN B-PP O
10 635 643 1595783 majority NN B-NP O
11 644 646 1595783 of IN B-PP O
12 647 652 1595783 cases NNS B-NP O
13 652 653 1595783 , , O O
14 654 658 1595783 this DT B-NP O
15 659 661 1595783 is VBZ B-VP O
16 662 665 1595783 not RB O O
17 666 672 1595783 always RB B-ADVP O
18 673 681 1595783 possible JJ B-ADJP O
19 682 684 1595783 or CC I-ADJP O
20 685 694 1595783 advisable JJ I-ADJP O
21 694 695 1595783 . . O O

1 696 700 1595783 Dose NN B-NP O
2 701 710 1595783 reduction NN I-NP O
3 711 713 1595783 or CC O O
4 714 725 1595783 concomitant JJ B-NP O
5 726 733 1595783 steroid NN I-NP D013256
6 734 741 1595783 therapy NN I-NP O
7 742 745 1595783 may MD B-VP O
8 746 750 1595783 have VB I-VP O
9 751 752 1595783 a DT B-NP O
10 753 757 1595783 role NN I-NP O
11 758 760 1595783 in IN B-PP O
12 761 769 1595783 selected VBN B-NP O
13 770 778 1595783 patients NNS I-NP O
14 778 779 1595783 . . O O

1 0 0 15897593 -DOCSTART- -X- -X- O

1 0 11 15897593 Dexrazoxane NN B-NP D064730
2 12 20 15897593 protects VBZ B-VP O
3 21 28 15897593 against IN B-PP O
4 29 45 15897593 myelosuppression NN B-NP D001855
5 46 50 15897593 from IN B-PP O
6 51 54 15897593 the DT B-NP O
7 55 58 15897593 DNA NN I-NP O
8 59 67 15897593 cleavage NN I-NP O
9 67 68 15897593 - HYPH O O
10 68 77 15897593 enhancing VBG B-VP O
11 78 83 15897593 drugs NNS B-NP O
12 84 93 15897593 etoposide NN I-NP D005047
13 94 97 15897593 and CC I-NP O
14 98 110 15897593 daunorubicin NN I-NP D003630
15 111 114 15897593 but CC B-NP O
16 115 118 15897593 not RB I-NP O
17 119 130 15897593 doxorubicin NN B-NP D004317
18 130 131 15897593 . . B-NP O
19 132 139 15897593 PURPOSE NN I-NP O
20 139 140 15897593 : : O O
21 141 144 15897593 The DT B-NP O
22 145 159 15897593 anthracyclines NNS I-NP D018943
23 160 172 15897593 daunorubicin NN I-NP D003630
24 173 176 15897593 and CC I-NP O
25 177 188 15897593 doxorubicin NN I-NP D004317
26 189 192 15897593 and CC O O
27 193 196 15897593 the DT B-NP O
28 197 215 15897593 epipodophyllotoxin NN I-NP D011034
29 216 225 15897593 etoposide NN I-NP D005047
30 226 229 15897593 are VBP B-VP O
31 230 236 15897593 potent JJ B-NP O
32 237 240 15897593 DNA NN I-NP O
33 241 249 15897593 cleavage NN I-NP O
34 249 250 15897593 - HYPH O O
35 250 259 15897593 enhancing VBG B-VP O
36 260 265 15897593 drugs NNS B-NP O
37 266 270 15897593 that WDT B-NP O
38 271 274 15897593 are VBP B-VP O
39 275 281 15897593 widely RB I-VP O
40 282 286 15897593 used VBN I-VP O
41 287 289 15897593 in IN B-PP O
42 290 298 15897593 clinical JJ B-NP O
43 299 307 15897593 oncology NN I-NP O
44 307 308 15897593 ; : O O
45 309 316 15897593 however RB B-ADVP O
46 316 317 15897593 , , O O
47 318 334 15897593 myelosuppression NN B-NP D001855
48 335 338 15897593 and CC O O
49 339 346 15897593 cardiac JJ B-NP D066126
50 347 355 15897593 toxicity NN I-NP D066126
51 356 361 15897593 limit VBP B-VP O
52 362 367 15897593 their PRP$ B-NP O
53 368 371 15897593 use NN I-NP O
54 371 372 15897593 . . O O

1 373 384 15897593 Dexrazoxane NN B-NP D064730
2 385 386 15897593 ( ( O O
3 386 390 15897593 ICRF NN B-NP D064730
4 390 391 15897593 - HYPH B-NP D064730
5 391 394 15897593 187 CD I-NP D064730
6 394 395 15897593 ) ) O O
7 396 398 15897593 is VBZ B-VP O
8 399 410 15897593 recommended VBN I-VP O
9 411 414 15897593 for IN B-PP O
10 415 425 15897593 protection NN B-NP O
11 426 433 15897593 against IN B-PP O
12 434 447 15897593 anthracycline NN B-NP D018943
13 447 448 15897593 - HYPH B-NP O
14 448 455 15897593 induced VBN I-NP O
15 456 470 15897593 cardiotoxicity NN I-NP D066126
16 470 471 15897593 . . O O

1 472 484 15897593 EXPERIMENTAL JJ B-NP O
2 485 491 15897593 DESIGN NN I-NP O
3 491 492 15897593 : : O O
4 493 500 15897593 Because IN B-PP O
5 501 503 15897593 of IN I-PP O
6 504 509 15897593 their PRP$ B-NP O
7 510 520 15897593 widespread JJ I-NP O
8 521 524 15897593 use NN I-NP O
9 524 525 15897593 , , O O
10 526 529 15897593 the DT B-NP O
11 530 541 15897593 hematologic JJ I-NP D006402
12 542 550 15897593 toxicity NN I-NP D006402
13 551 560 15897593 following VBG B-PP O
14 561 577 15897593 coadministration NN B-NP O
15 578 580 15897593 of IN B-PP O
16 581 592 15897593 dexrazoxane NN B-NP D064730
17 593 596 15897593 and CC O O
18 597 602 15897593 these DT B-NP O
19 603 608 15897593 three CD I-NP O
20 609 621 15897593 structurally RB I-NP O
21 622 631 15897593 different JJ I-NP O
22 632 635 15897593 DNA NN I-NP O
23 636 644 15897593 cleavage NN I-NP O
24 645 654 15897593 enhancers NNS I-NP O
25 655 658 15897593 was VBD B-VP O
26 659 671 15897593 investigated VBN I-VP O
27 671 672 15897593 : : O O
28 673 684 15897593 Sensitivity NN B-NP O
29 685 687 15897593 of IN B-PP O
30 688 693 15897593 human JJ B-NP O
31 694 697 15897593 and CC I-NP O
32 698 704 15897593 murine JJ I-NP O
33 705 710 15897593 blood NN I-NP O
34 711 721 15897593 progenitor NN I-NP O
35 722 727 15897593 cells NNS I-NP O
36 728 730 15897593 to TO B-PP O
37 731 740 15897593 etoposide NN B-NP D005047
38 740 741 15897593 , , O O
39 742 754 15897593 daunorubicin NN B-NP D003630
40 754 755 15897593 , , O O
41 756 759 15897593 and CC O O
42 760 771 15897593 doxorubicin NN B-NP D004317
43 772 773 15897593 + SYM B-NP O
44 773 774 15897593 / SYM O O
45 774 775 15897593 - HYPH O O
46 776 787 15897593 dexrazoxane NN B-NP D064730
47 788 791 15897593 was VBD B-VP O
48 792 802 15897593 determined VBN I-VP O
49 803 805 15897593 in IN B-PP O
50 806 817 15897593 granulocyte NN B-NP O
51 817 818 15897593 - HYPH I-NP O
52 818 828 15897593 macrophage NN I-NP O
53 829 835 15897593 colony NN I-NP O
54 836 843 15897593 forming VBG B-VP O
55 844 850 15897593 assays NNS B-NP O
56 850 851 15897593 . . O O

1 852 860 15897593 Likewise RB B-ADVP O
2 860 861 15897593 , , O O
3 862 864 15897593 in FW B-ADVP O
4 865 869 15897593 vivo FW I-ADVP O
5 869 870 15897593 , , O O
6 871 877 15897593 B6D2F1 NN B-NP O
7 878 882 15897593 mice NNS I-NP O
8 883 887 15897593 were VBD B-VP O
9 888 895 15897593 treated VBN I-VP O
10 896 900 15897593 with IN B-PP O
11 901 910 15897593 etoposide NN B-NP D005047
12 910 911 15897593 , , O O
13 912 924 15897593 daunorubicin NN B-NP D003630
14 924 925 15897593 , , O O
15 926 929 15897593 and CC O O
16 930 941 15897593 doxorubicin NN B-NP D004317
17 941 942 15897593 , , O O
18 943 947 15897593 with IN B-PP O
19 948 950 15897593 or CC B-PP O
20 951 958 15897593 without IN B-PP O
21 959 970 15897593 dexrazoxane NN B-NP D064730
22 971 975 15897593 over IN B-PP O
23 976 977 15897593 a DT B-NP O
24 978 982 15897593 wide JJ I-NP O
25 983 988 15897593 range NN I-NP O
26 989 991 15897593 of IN B-PP O
27 992 997 15897593 doses NNS B-NP O
28 997 998 15897593 : : O O
29 999 1012 15897593 posttreatment NN B-NP O
30 1012 1013 15897593 , , O O
31 1014 1015 15897593 a DT B-NP O
32 1016 1020 15897593 full JJ I-NP O
33 1021 1032 15897593 hematologic JJ I-NP O
34 1033 1043 15897593 evaluation NN I-NP O
35 1044 1047 15897593 was VBD B-VP O
36 1048 1052 15897593 done VBN I-VP O
37 1052 1053 15897593 . . O O

1 1054 1061 15897593 RESULTS NNS B-NP O
2 1061 1062 15897593 : : O O
3 1063 1071 15897593 Nontoxic JJ B-NP O
4 1072 1077 15897593 doses NNS I-NP O
5 1078 1080 15897593 of IN B-PP O
6 1081 1092 15897593 dexrazoxane NN B-NP D064730
7 1093 1100 15897593 reduced VBD B-VP O
8 1101 1117 15897593 myelosuppression NN B-NP D001855
9 1118 1121 15897593 and CC I-NP O
10 1122 1128 15897593 weight NN I-NP D015431
11 1129 1133 15897593 loss NN I-NP D015431
12 1134 1138 15897593 from IN B-PP O
13 1139 1151 15897593 daunorubicin NN B-NP D003630
14 1152 1155 15897593 and CC I-NP O
15 1156 1165 15897593 etoposide NN I-NP D005047
16 1166 1168 15897593 in IN B-PP O
17 1169 1173 15897593 mice NNS B-NP O
18 1174 1177 15897593 and CC O O
19 1178 1189 15897593 antagonized VBD B-VP O
20 1190 1195 15897593 their PRP$ B-NP O
21 1196 1213 15897593 antiproliferative JJ I-NP O
22 1214 1221 15897593 effects NNS I-NP O
23 1222 1224 15897593 in IN B-PP O
24 1225 1228 15897593 the DT B-NP O
25 1229 1235 15897593 colony NN I-NP O
26 1236 1241 15897593 assay NN I-NP O
27 1241 1242 15897593 ; : O O
28 1243 1250 15897593 however RB B-ADVP O
29 1250 1251 15897593 , , O O
30 1252 1263 15897593 dexrazoxane NN B-NP D064730
31 1264 1271 15897593 neither CC O O
32 1272 1279 15897593 reduced VBD B-VP O
33 1280 1296 15897593 myelosuppression NN B-NP D001855
34 1296 1297 15897593 , , O O
35 1298 1304 15897593 weight NN B-NP D015431
36 1305 1309 15897593 loss NN I-NP D015431
37 1309 1310 15897593 , , O O
38 1311 1314 15897593 nor CC O O
39 1315 1318 15897593 the DT B-NP O
40 1319 1321 15897593 in FW I-NP O
41 1322 1327 15897593 vitro FW I-NP O
42 1328 1340 15897593 cytotoxicity NN I-NP D064420
43 1341 1345 15897593 from IN B-PP O
44 1346 1357 15897593 doxorubicin NN B-NP D004317
45 1357 1358 15897593 . . O O

1 1359 1369 15897593 CONCLUSION NN B-NP O
2 1369 1370 15897593 : : O O
3 1371 1379 15897593 Although IN B-SBAR O
4 1380 1383 15897593 our PRP$ B-NP O
5 1384 1392 15897593 findings NNS I-NP O
6 1393 1400 15897593 support VBP B-VP O
7 1401 1404 15897593 the DT B-NP O
8 1405 1416 15897593 observation NN I-NP O
9 1417 1421 15897593 that IN B-SBAR O
10 1422 1433 15897593 dexrazoxane NN B-NP D064730
11 1434 1441 15897593 reduces VBZ B-VP O
12 1442 1449 15897593 neither CC O O
13 1450 1461 15897593 hematologic JJ B-NP O
14 1462 1470 15897593 activity NN I-NP O
15 1471 1474 15897593 nor CC O O
16 1475 1484 15897593 antitumor JJ B-NP O
17 1485 1493 15897593 activity NN I-NP O
18 1494 1498 15897593 from IN B-PP O
19 1499 1510 15897593 doxorubicin NN B-NP D004317
20 1511 1521 15897593 clinically RB B-ADVP O
21 1521 1522 15897593 , , O O
22 1523 1526 15897593 the DT B-NP O
23 1527 1533 15897593 potent JJ I-NP O
24 1534 1544 15897593 antagonism NN I-NP O
25 1545 1547 15897593 of IN B-PP O
26 1548 1560 15897593 daunorubicin NN B-NP D003630
27 1561 1569 15897593 activity NN I-NP O
28 1570 1576 15897593 raises VBZ B-VP O
29 1577 1584 15897593 concern NN B-NP O
30 1584 1585 15897593 ; : O O
31 1586 1587 15897593 a DT B-NP O
32 1588 1596 15897593 possible JJ I-NP O
33 1597 1609 15897593 interference NN I-NP O
34 1610 1614 15897593 with IN B-PP O
35 1615 1625 15897593 anticancer JJ B-NP O
36 1626 1634 15897593 efficacy NN I-NP O
37 1635 1644 15897593 certainly RB B-ADVP O
38 1645 1650 15897593 would MD B-VP O
39 1651 1655 15897593 call VB I-VP O
40 1656 1659 15897593 for IN B-PP O
41 1660 1667 15897593 renewed VBN B-NP O
42 1668 1677 15897593 attention NN I-NP O
43 1677 1678 15897593 . . O O

1 1679 1682 15897593 Our PRP$ B-NP O
2 1683 1687 15897593 data NNS I-NP O
3 1688 1692 15897593 also RB B-ADVP O
4 1693 1700 15897593 suggest VBP B-VP O
5 1701 1705 15897593 that IN B-SBAR O
6 1706 1717 15897593 significant JJ B-NP O
7 1718 1727 15897593 etoposide NN I-NP D005047
8 1728 1732 15897593 dose NN I-NP O
9 1733 1743 15897593 escalation NN I-NP O
10 1744 1746 15897593 is VBZ B-VP O
11 1747 1754 15897593 perhaps RB B-ADVP O
12 1755 1763 15897593 possible JJ B-ADJP O
13 1764 1766 15897593 by IN B-PP O
14 1767 1770 15897593 the DT B-NP O
15 1771 1774 15897593 use NN I-NP O
16 1775 1777 15897593 of IN B-PP O
17 1778 1789 15897593 dexrazoxane NN B-NP D064730
18 1789 1790 15897593 . . O O

1 1791 1799 15897593 Clinical JJ B-NP O
2 1800 1806 15897593 trials NNS I-NP O
3 1807 1809 15897593 in IN B-PP O
4 1810 1818 15897593 patients NNS B-NP O
5 1819 1823 15897593 with IN B-PP O
6 1824 1829 15897593 brain NN B-NP O
7 1830 1840 15897593 metastases NNS I-NP D009362
8 1841 1850 15897593 combining VBG B-VP O
9 1851 1862 15897593 dexrazoxane NN B-NP D064730
10 1863 1866 15897593 and CC O O
11 1867 1871 15897593 high JJ B-NP O
12 1872 1877 15897593 doses NNS I-NP O
13 1878 1880 15897593 of IN B-PP O
14 1881 1890 15897593 etoposide NN B-NP D005047
15 1891 1893 15897593 is VBZ B-VP O
16 1894 1901 15897593 ongoing VBG I-VP O
17 1902 1906 15897593 with IN B-PP O
18 1907 1910 15897593 the DT B-NP O
19 1911 1914 15897593 aim NN I-NP O
20 1915 1917 15897593 of IN B-PP O
21 1918 1927 15897593 improving VBG B-VP O
22 1928 1936 15897593 efficacy NN B-NP O
23 1937 1944 15897593 without IN B-PP O
24 1945 1956 15897593 aggravating VBG B-VP O
25 1957 1968 15897593 hematologic JJ B-NP D006402
26 1969 1977 15897593 toxicity NN I-NP D006402
27 1977 1978 15897593 . . O O

1 1979 1981 15897593 If IN B-SBAR O
2 1982 1992 15897593 successful JJ B-ADJP O
3 1992 1993 15897593 , , O O
4 1994 1998 15897593 this DT B-NP O
5 1999 2009 15897593 represents VBZ B-VP O
6 2010 2012 15897593 an DT B-NP O
7 2013 2021 15897593 exciting JJ I-NP O
8 2022 2031 15897593 mechanism NN I-NP O
9 2032 2035 15897593 for IN B-PP O
10 2036 2049 15897593 pharmacologic JJ B-NP O
11 2050 2060 15897593 regulation NN I-NP O
12 2061 2063 15897593 of IN B-PP O
13 2064 2068 15897593 side NN B-NP O
14 2069 2076 15897593 effects NNS I-NP O
15 2077 2081 15897593 from IN B-PP O
16 2082 2091 15897593 cytotoxic JJ B-NP O
17 2092 2104 15897593 chemotherapy NN I-NP O
18 2104 2105 15897593 . . O O

1 0 0 20635749 -DOCSTART- -X- -X- O

1 0 6 20635749 Severe JJ B-NP O
2 7 17 20635749 congestive JJ I-NP D006333
3 18 23 20635749 heart NN I-NP D006333
4 24 31 20635749 failure NN I-NP D006333
5 32 39 20635749 patient NN I-NP O
6 40 42 20635749 on IN B-PP O
7 43 53 20635749 amiodarone NN B-NP D000638
8 54 64 20635749 presenting VBG B-VP O
9 65 69 20635749 with IN B-PP O
10 70 79 20635749 myxedemic JJ B-NP D009230
11 80 84 20635749 coma NN I-NP D009230
12 84 85 20635749 : : O O
13 86 87 20635749 a DT B-NP O
14 88 92 20635749 case NN I-NP O
15 93 99 20635749 report NN I-NP O
16 99 100 20635749 . . O O
17 101 105 20635749 This DT B-NP O
18 106 108 20635749 is VBZ B-VP O
19 109 110 20635749 a DT B-NP O
20 111 115 20635749 case NN I-NP O
21 116 122 20635749 report NN I-NP O
22 123 125 20635749 of IN B-PP O
23 126 134 20635749 myxedema NN B-NP D009230
24 135 139 20635749 coma NN I-NP D009230
25 140 149 20635749 secondary JJ B-ADJP O
26 150 152 20635749 to TO B-PP O
27 153 163 20635749 amiodarone NN B-NP D000638
28 163 164 20635749 - HYPH B-NP O
29 164 171 20635749 induced VBN I-NP O
30 172 186 20635749 hypothyroidism NN I-NP D007037
31 187 189 20635749 in IN B-PP O
32 190 191 20635749 a DT B-NP O
33 192 199 20635749 patient NN I-NP O
34 200 204 20635749 with IN B-PP O
35 205 211 20635749 severe JJ B-NP O
36 212 222 20635749 congestive JJ I-NP D006333
37 223 228 20635749 heart NN I-NP D006333
38 229 236 20635749 failure NN I-NP D006333
39 237 238 20635749 ( ( O O
40 238 241 20635749 CHF NN B-NP D006333
41 241 242 20635749 ) ) O O
42 242 243 20635749 . . O O

1 244 246 20635749 To TO B-PP O
2 247 250 20635749 our PRP$ B-NP O
3 251 260 20635749 knowledge NN I-NP O
4 261 264 20635749 and CC B-PP O
5 265 270 20635749 after IN B-PP O
6 271 280 20635749 reviewing VBG B-VP O
7 281 284 20635749 the DT B-NP O
8 285 295 20635749 literature NN I-NP O
9 296 301 20635749 there EX B-NP O
10 302 304 20635749 is VBZ B-VP O
11 305 308 20635749 one CD B-NP O
12 309 313 20635749 case NN I-NP O
13 314 320 20635749 report NN I-NP O
14 321 323 20635749 of IN B-PP O
15 324 332 20635749 myxedema NN B-NP D009230
16 333 337 20635749 coma NN I-NP D009230
17 338 344 20635749 during IN B-PP O
18 345 349 20635749 long JJ B-NP O
19 350 354 20635749 term NN I-NP O
20 355 365 20635749 amiodarone NN I-NP D000638
21 366 373 20635749 therapy NN I-NP O
22 373 374 20635749 . . O O

1 375 383 20635749 Myxedema NN B-NP D009230
2 384 388 20635749 coma NN I-NP D009230
3 389 391 20635749 is VBZ B-VP O
4 392 393 20635749 a DT B-NP O
5 394 398 20635749 life NN I-NP O
6 399 410 20635749 threatening NN I-NP O
7 411 420 20635749 condition NN I-NP O
8 421 425 20635749 that WDT B-NP O
9 426 433 20635749 carries VBZ B-VP O
10 434 435 20635749 a DT B-NP O
11 436 445 20635749 mortality NN I-NP O
12 446 454 20635749 reaching VBG B-VP O
13 455 457 20635749 as RB B-ADJP O
14 458 462 20635749 high JJ I-ADJP O
15 463 465 20635749 as IN B-PP O
16 466 469 20635749 20% NN B-NP O
17 470 474 20635749 with IN B-PP O
18 475 484 20635749 treatment NN B-NP O
19 484 485 20635749 . . O O

1 486 489 20635749 The DT B-NP O
2 490 499 20635749 condition NN I-NP O
3 500 502 20635749 is VBZ B-VP O
4 503 510 20635749 treated VBN I-VP O
5 511 515 20635749 with IN B-PP O
6 516 527 20635749 intravenous JJ B-NP O
7 528 537 20635749 thyroxine NN I-NP D013974
8 538 539 20635749 ( ( O O
9 539 541 20635749 T4 NN B-NP D013974
10 541 542 20635749 ) ) O O
11 543 545 20635749 or CC O O
12 546 557 20635749 intravenous JJ B-ADJP O
13 558 561 20635749 tri AFX O D014284
14 561 562 20635749 - HYPH O D014284
15 562 566 20635749 iodo AFX O D014284
16 566 567 20635749 - HYPH O D014284
17 567 576 20635749 thyronine NN B-NP D014284
18 577 578 20635749 ( ( O O
19 578 580 20635749 T3 NN B-NP D014284
20 580 581 20635749 ) ) O O
21 581 582 20635749 . . O O

1 583 591 20635749 Patients NNS B-NP O
2 592 596 20635749 with IN B-PP O
3 597 600 20635749 CHF NN B-NP D006333
4 601 603 20635749 on IN B-PP O
5 604 614 20635749 amiodarone NN B-NP D000638
6 615 618 20635749 may MD B-VP O
7 619 625 20635749 suffer VB I-VP O
8 626 633 20635749 serious JJ B-NP O
9 634 643 20635749 morbidity NN I-NP O
10 644 647 20635749 and CC I-NP O
11 648 657 20635749 mortality NN I-NP O
12 658 662 20635749 from IN B-PP O
13 663 677 20635749 hypothyroidism NN B-NP D007037
14 677 678 20635749 , , O O
15 679 682 20635749 and CC O O
16 683 687 20635749 thus RB B-VP O
17 688 691 20635749 may MD I-VP O
18 692 699 20635749 deserve VB I-VP O
19 700 706 20635749 closer RBR B-VP O
20 707 713 20635749 follow VB I-VP O
21 714 716 20635749 up RP B-PRT O
22 717 720 20635749 for IN B-PP O
23 721 728 20635749 thyroid NN B-NP O
24 729 740 20635749 stimulating VBG B-VP O
25 741 748 20635749 hormone NN B-NP O
26 749 750 20635749 ( ( O O
27 750 753 20635749 TSH NN B-NP O
28 753 754 20635749 ) ) O O
29 755 761 20635749 levels NNS B-NP O
30 761 762 20635749 . . O O

1 763 767 20635749 This DT B-NP O
2 768 772 20635749 case NN I-NP O
3 773 779 20635749 report NN I-NP O
4 780 787 20635749 carries VBZ B-VP O
5 788 790 20635749 an DT B-NP O
6 791 800 20635749 important JJ I-NP O
7 801 809 20635749 clinical JJ I-NP O
8 810 821 20635749 application NN I-NP O
9 822 827 20635749 given VBN B-PP O
10 828 831 20635749 the DT B-NP O
11 832 840 20635749 frequent JJ I-NP O
12 841 846 20635749 usage NN I-NP O
13 847 849 20635749 of IN B-PP O
14 850 860 20635749 amiodarone NN B-NP D000638
15 861 866 20635749 among IN B-PP O
16 867 870 20635749 CHF NN B-NP D006333
17 871 879 20635749 patients NNS I-NP O
18 879 880 20635749 . . O O

1 881 884 20635749 The DT B-NP O
2 885 891 20635749 myriad JJ I-NP O
3 892 900 20635749 clinical JJ I-NP O
4 901 913 20635749 presentation NN I-NP O
5 914 916 20635749 of IN B-PP O
6 917 925 20635749 myxedema NN B-NP D009230
7 926 930 20635749 coma NN I-NP D009230
8 931 934 20635749 and CC O O
9 935 938 20635749 its PRP$ B-NP O
10 939 946 20635749 serious JJ I-NP O
11 947 956 20635749 morbidity NN I-NP O
12 957 960 20635749 and CC I-NP O
13 961 970 20635749 mortality NN I-NP O
14 971 979 20635749 stresses VBZ B-VP O
15 980 983 20635749 the DT B-NP O
16 984 988 20635749 need NN I-NP O
17 989 991 20635749 to TO B-VP O
18 992 999 20635749 suspect VB I-VP O
19 1000 1004 20635749 this DT B-NP O
20 1005 1013 20635749 clinical JJ I-NP O
21 1014 1022 20635749 syndrome NN I-NP O
22 1023 1028 20635749 among IN B-PP O
23 1029 1032 20635749 CHF NN B-NP D006333
24 1033 1041 20635749 patients NNS I-NP O
25 1042 1052 20635749 presenting VBG B-VP O
26 1053 1057 20635749 with IN B-PP O
27 1058 1069 20635749 hypotension NN B-NP D007022
28 1069 1070 20635749 , , O O
29 1071 1079 20635749 weakness NN B-NP D018908
30 1080 1082 20635749 or CC O O
31 1083 1088 20635749 other JJ B-NP O
32 1089 1100 20635749 unexplained JJ I-NP O
33 1101 1109 20635749 symptoms NNS I-NP O
34 1109 1110 20635749 . . O O

1 0 0 8492347 -DOCSTART- -X- -X- O

1 0 6 8492347 Tetany NN B-NP D013746
2 7 10 8492347 and CC I-NP O
3 11 25 8492347 rhabdomyolysis NN I-NP D012206
4 26 29 8492347 due JJ B-ADJP O
5 30 32 8492347 to TO B-PP O
6 33 46 8492347 surreptitious JJ B-NP O
7 47 57 8492347 furosemide NN I-NP D005665
8 57 58 8492347 - HYPH O O
9 58 59 8492347 - HYPH O O
10 59 69 8492347 importance NN B-NP O
11 70 72 8492347 of IN B-PP O
12 73 82 8492347 magnesium NN B-NP D008274
13 83 98 8492347 supplementation NN I-NP O
14 98 99 8492347 . . O O
15 100 109 8492347 Diuretics NNS B-NP O
16 110 113 8492347 may MD B-VP O
17 114 120 8492347 induce VB I-VP O
18 121 132 8492347 hypokalemia NN B-NP D007008
19 132 133 8492347 , , I-NP O
20 134 146 8492347 hypocalcemia NN I-NP D006996
21 147 150 8492347 and CC I-NP O
22 151 165 8492347 hypomagnesemia NN I-NP C537153
23 165 166 8492347 . . O O

1 167 172 8492347 While IN B-SBAR O
2 173 179 8492347 severe JJ B-NP O
3 180 191 8492347 hypokalemia NN I-NP D007008
4 192 195 8492347 may MD B-VP O
5 196 201 8492347 cause VB I-VP O
6 202 208 8492347 muscle NN B-NP D018908
7 209 217 8492347 weakness NN I-NP D018908
8 217 218 8492347 , , O O
9 219 225 8492347 severe JJ B-NP O
10 226 240 8492347 hypomagnesemia NN I-NP C537153
11 241 243 8492347 is VBZ B-VP O
12 244 254 8492347 associated VBN I-VP O
13 255 259 8492347 with IN B-PP O
14 260 266 8492347 muscle NN B-NP D013035
15 267 273 8492347 spasms NNS I-NP D013035
16 274 277 8492347 and CC O O
17 278 284 8492347 tetany NN B-NP D013746
18 285 290 8492347 which WDT B-NP O
19 291 297 8492347 cannot MD B-VP O
20 298 300 8492347 be VB I-VP O
21 301 310 8492347 corrected VBN I-VP O
22 311 313 8492347 by IN B-PP O
23 314 323 8492347 potassium NN B-NP D011188
24 324 327 8492347 and CC I-NP O
25 328 335 8492347 calcium NN I-NP D002118
26 336 351 8492347 supplementation NN I-NP O
27 352 357 8492347 alone RB B-ADVP O
28 358 359 8492347 ( ( O O
29 359 362 8492347 1,2 CD B-NP O
30 362 363 8492347 ) ) O O
31 363 364 8492347 . . O O

1 365 378 8492347 Surreptitious JJ B-NP O
2 379 387 8492347 diuretic JJ I-NP O
3 388 397 8492347 ingestion NN I-NP O
4 398 401 8492347 has VBZ B-VP O
5 402 406 8492347 been VBN I-VP O
6 407 416 8492347 described VBN I-VP O
7 416 417 8492347 , , O O
8 418 424 8492347 mainly RB B-ADVP O
9 425 427 8492347 in IN B-PP O
10 428 433 8492347 women NNS B-NP O
11 434 437 8492347 who WP B-NP O
12 438 441 8492347 are VBP B-VP O
13 442 451 8492347 concerned VBN I-VP O
14 452 456 8492347 that IN B-SBAR O
15 457 461 8492347 they PRP B-NP O
16 462 465 8492347 are VBP B-VP O
17 466 471 8492347 obese JJ B-ADJP D009765
18 472 474 8492347 or CC I-ADJP O
19 475 484 8492347 edematous JJ I-ADJP D004487
20 484 485 8492347 . . O O

1 486 497 8492347 Symptomatic JJ B-NP O
2 498 509 8492347 hypokalemia NN I-NP D007008
3 510 513 8492347 has VBZ B-VP O
4 514 518 8492347 been VBN I-VP O
5 519 527 8492347 reported VBN I-VP O
6 528 530 8492347 in IN B-PP O
7 531 535 8492347 such JJ B-NP O
8 536 544 8492347 patients NNS I-NP O
9 545 546 8492347 ( ( O O
10 546 547 8492347 3 CD B-NP O
11 547 548 8492347 - HYPH I-NP O
12 548 549 8492347 7 CD I-NP O
13 549 550 8492347 ) ) O O
14 551 554 8492347 and CC O O
15 555 557 8492347 in IN B-PP O
16 558 561 8492347 one CD B-NP O
17 562 566 8492347 case NN I-NP O
18 567 579 8492347 hypocalcemia NN I-NP D006996
19 580 583 8492347 was VBD B-VP O
20 584 592 8492347 observed VBN I-VP O
21 593 594 8492347 ( ( O O
22 594 595 8492347 8 CD B-NP O
23 595 596 8492347 ) ) O O
24 596 597 8492347 , , O O
25 598 601 8492347 but CC O O
26 602 605 8492347 the DT B-NP O
27 606 613 8492347 effects NNS I-NP O
28 614 616 8492347 of IN B-PP O
29 617 626 8492347 magnesium NN B-NP D008274
30 627 636 8492347 depletion NN I-NP O
31 637 641 8492347 were VBD B-VP O
32 642 645 8492347 not RB I-VP O
33 646 651 8492347 noted VBN I-VP O
34 652 654 8492347 in IN B-PP O
35 655 660 8492347 these DT B-NP O
36 661 669 8492347 patients NNS I-NP O
37 669 670 8492347 . . O O

1 0 0 11705128 -DOCSTART- -X- -X- O

1 0 10 11705128 Management NN B-NP O
2 11 21 11705128 strategies NNS I-NP O
3 22 25 11705128 for IN B-PP O
4 26 35 11705128 ribavirin NN B-NP D012254
5 35 36 11705128 - HYPH B-NP O
6 36 43 11705128 induced VBN I-NP O
7 44 53 11705128 hemolytic JJ I-NP D000743
8 54 60 11705128 anemia NN I-NP D000743
9 61 63 11705128 in IN B-PP O
10 64 67 11705128 the DT B-NP O
11 68 77 11705128 treatment NN I-NP O
12 78 80 11705128 of IN B-PP O
13 81 90 11705128 hepatitis NN B-NP D006526
14 91 92 11705128 C NN I-NP D006526
15 92 93 11705128 : : O O
16 94 102 11705128 clinical JJ B-NP O
17 103 106 11705128 and CC I-NP O
18 107 115 11705128 economic JJ I-NP O
19 116 128 11705128 implications NNS I-NP O
20 128 129 11705128 . . I-NP O
21 130 140 11705128 OBJECTIVES NNS I-NP O
22 140 141 11705128 : : O O
23 142 150 11705128 Recently RB B-NP O
24 151 160 11705128 published VBN I-NP O
25 161 168 11705128 studies NNS I-NP O
26 169 173 11705128 have VBP B-VP O
27 174 186 11705128 demonstrated VBN I-VP O
28 187 196 11705128 increased VBN B-NP O
29 197 205 11705128 efficacy NN I-NP O
30 206 209 11705128 and CC I-NP O
31 210 214 11705128 cost NN I-NP O
32 214 215 11705128 - HYPH O O
33 215 228 11705128 effectiveness NN B-NP O
34 229 231 11705128 of IN B-PP O
35 232 243 11705128 combination NN B-NP O
36 244 251 11705128 therapy NN I-NP O
37 252 256 11705128 with IN B-PP O
38 257 267 11705128 interferon NN B-NP O
39 268 271 11705128 and CC O O
40 272 277 11705128 alpha SYM B-NP O
41 277 278 11705128 - HYPH I-NP O
42 278 280 11705128 2b NN I-NP O
43 280 281 11705128 / SYM I-NP O
44 281 290 11705128 ribavirin NN I-NP D012254
45 291 299 11705128 compared VBN B-PP O
46 300 304 11705128 with IN B-PP O
47 305 315 11705128 interferon NN B-NP D016898
48 315 316 11705128 - HYPH O D016898
49 316 321 11705128 alpha SYM O D016898
50 322 333 11705128 monotherapy NN B-NP O
51 334 336 11705128 in IN B-PP O
52 337 340 11705128 the DT B-NP O
53 341 350 11705128 treatment NN I-NP O
54 351 353 11705128 of IN B-PP O
55 354 361 11705128 chronic JJ B-NP D019698
56 362 371 11705128 hepatitis NN I-NP D019698
57 372 373 11705128 C NN I-NP D019698
58 374 375 11705128 ( ( O O
59 375 378 11705128 CHC NN B-NP D019698
60 378 379 11705128 ) ) O O
61 379 380 11705128 . . O O

1 381 392 11705128 Combination NN B-NP O
2 393 400 11705128 therapy NN I-NP O
3 401 403 11705128 is VBZ B-VP O
4 404 414 11705128 associated VBN I-VP O
5 415 419 11705128 with IN B-PP O
6 420 421 11705128 a DT B-NP O
7 422 432 11705128 clinically RB I-NP O
8 433 442 11705128 important JJ I-NP O
9 443 450 11705128 adverse JJ I-NP O
10 451 457 11705128 effect NN I-NP O
11 457 458 11705128 : : O O
12 459 468 11705128 ribavirin NN B-NP D012254
13 468 469 11705128 - HYPH O O
14 469 476 11705128 induced VBN B-NP O
15 477 486 11705128 hemolytic JJ I-NP D000743
16 487 493 11705128 anemia NN I-NP D000743
17 494 495 11705128 ( ( O O
18 495 499 11705128 RIHA NN B-NP D000743
19 499 500 11705128 ) ) O O
20 500 501 11705128 . . O O

1 502 505 11705128 The DT B-NP O
2 506 515 11705128 objective NN I-NP O
3 516 518 11705128 of IN B-PP O
4 519 523 11705128 this DT B-NP O
5 524 529 11705128 study NN I-NP O
6 530 533 11705128 was VBD B-VP O
7 534 536 11705128 to TO B-VP O
8 537 545 11705128 evaluate VB I-VP O
9 546 549 11705128 the DT B-NP O
10 550 556 11705128 direct JJ I-NP O
11 557 563 11705128 health NN I-NP O
12 563 564 11705128 - HYPH I-NP O
13 564 568 11705128 care NN I-NP O
14 569 574 11705128 costs NNS I-NP O
15 575 578 11705128 and CC I-NP O
16 579 589 11705128 management NN I-NP O
17 590 592 11705128 of IN B-PP O
18 593 597 11705128 RIHA NN B-NP D000743
19 598 604 11705128 during IN B-PP O
20 605 614 11705128 treatment NN B-NP O
21 615 617 11705128 of IN B-PP O
22 618 621 11705128 CHC NN B-NP D019698
23 622 624 11705128 in IN B-PP O
24 625 626 11705128 a DT B-NP O
25 627 635 11705128 clinical JJ I-NP O
26 636 641 11705128 trial NN I-NP O
27 642 649 11705128 setting NN I-NP O
28 649 650 11705128 . . O O

1 651 658 11705128 METHODS NNS B-NP O
2 658 659 11705128 : : O O
3 660 661 11705128 A DT B-NP O
4 662 672 11705128 systematic JJ I-NP O
5 673 683 11705128 literature NN I-NP O
6 684 690 11705128 review NN I-NP O
7 691 694 11705128 was VBD B-VP O
8 695 704 11705128 conducted VBN I-VP O
9 705 707 11705128 to TO I-VP O
10 708 718 11705128 synthesize VB I-VP O
11 719 730 11705128 information NN B-NP O
12 731 733 11705128 on IN B-PP O
13 734 737 11705128 the DT B-NP O
14 738 747 11705128 incidence NN I-NP O
15 748 751 11705128 and CC I-NP O
16 752 762 11705128 management NN I-NP O
17 763 765 11705128 of IN B-PP O
18 766 770 11705128 RIHA NN B-NP D000743
19 770 771 11705128 . . O O

1 772 780 11705128 Decision NN B-NP O
2 780 781 11705128 - HYPH I-NP O
3 781 789 11705128 analytic JJ I-NP O
4 790 800 11705128 techniques NNS I-NP O
5 801 805 11705128 were VBD B-VP O
6 806 810 11705128 used VBN I-VP O
7 811 813 11705128 to TO B-VP O
8 814 822 11705128 estimate VB I-VP O
9 823 826 11705128 the DT B-NP O
10 827 831 11705128 cost NN I-NP O
11 832 834 11705128 of IN B-PP O
12 835 843 11705128 treating VBG B-VP O
13 844 848 11705128 RIHA NN B-NP D000743
14 848 849 11705128 . . O O

1 850 861 11705128 Uncertainty NN B-NP O
2 862 865 11705128 was VBD B-VP O
3 866 875 11705128 evaluated VBN I-VP O
4 876 881 11705128 using VBG B-VP O
5 882 893 11705128 sensitivity NN B-NP O
6 894 902 11705128 analyses NNS I-NP O
7 902 903 11705128 . . O O

1 904 911 11705128 RESULTS NNS B-NP O
2 911 912 11705128 : : O O
3 913 917 11705128 RIHA NN B-NP D000743
4 917 918 11705128 , , O O
5 919 926 11705128 defined VBN B-VP O
6 927 929 11705128 as IN B-PP O
7 930 931 11705128 a DT B-NP O
8 932 941 11705128 reduction NN I-NP O
9 942 944 11705128 in IN B-PP O
10 945 955 11705128 hemoglobin NN B-NP O
11 956 958 11705128 to TO B-PP O
12 959 963 11705128 less JJR B-NP O
13 964 968 11705128 than IN I-NP O
14 969 972 11705128 100 CD I-NP O
15 973 974 11705128 g NN I-NP O
16 974 975 11705128 / SYM I-NP O
17 975 976 11705128 L NN I-NP O
18 976 977 11705128 , , O O
19 978 984 11705128 occurs VBZ B-VP O
20 985 987 11705128 in IN B-PP O
21 988 1001 11705128 approximately RB B-NP O
22 1002 1004 11705128 7% CD I-NP O
23 1005 1007 11705128 to TO B-PP O
24 1008 1010 11705128 9% CD B-NP O
25 1011 1013 11705128 of IN B-PP O
26 1014 1022 11705128 patients NNS B-NP O
27 1023 1030 11705128 treated VBN B-VP O
28 1031 1035 11705128 with IN B-PP O
29 1036 1047 11705128 combination NN B-NP O
30 1048 1055 11705128 therapy NN I-NP O
31 1055 1056 11705128 . . O O

1 1057 1060 11705128 The DT B-NP O
2 1061 1069 11705128 standard NN I-NP O
3 1070 1072 11705128 of IN B-PP O
4 1073 1077 11705128 care NN B-NP O
5 1078 1081 11705128 for IN B-PP O
6 1082 1092 11705128 management NN B-NP O
7 1093 1095 11705128 of IN B-PP O
8 1096 1100 11705128 RIHA NN B-NP D000743
9 1101 1103 11705128 is VBZ B-VP O
10 1104 1113 11705128 reduction NN B-NP O
11 1114 1116 11705128 or CC I-NP O
12 1117 1132 11705128 discontinuation NN I-NP O
13 1133 1135 11705128 of IN B-PP O
14 1136 1139 11705128 the DT B-NP O
15 1140 1149 11705128 ribavirin NN I-NP D012254
16 1150 1156 11705128 dosage NN I-NP O
17 1156 1157 11705128 . . O O

1 1158 1160 11705128 We PRP B-NP O
2 1161 1170 11705128 estimated VBD B-VP O
3 1171 1174 11705128 the DT B-NP O
4 1175 1181 11705128 direct JJ I-NP O
5 1182 1186 11705128 cost NN I-NP O
6 1187 1189 11705128 of IN B-PP O
7 1190 1198 11705128 treating VBG B-VP O
8 1199 1209 11705128 clinically RB B-NP O
9 1210 1221 11705128 significant JJ I-NP O
10 1222 1226 11705128 RIHA NN I-NP D000743
11 1227 1229 11705128 to TO B-VP O
12 1230 1232 11705128 be VB I-VP O
13 1234 1237 11705128 170 CD B-NP O
14 1238 1241 11705128 per IN B-PP O
15 1242 1249 11705128 patient NN B-NP O
16 1250 1259 11705128 receiving VBG B-VP O
17 1260 1271 11705128 combination NN B-NP O
18 1272 1279 11705128 therapy NN I-NP O
19 1280 1283 11705128 per IN B-PP O
20 1284 1286 11705128 48 CD B-NP O
21 1286 1287 11705128 - HYPH B-NP O
22 1287 1291 11705128 week NN I-NP O
23 1292 1301 11705128 treatment NN I-NP O
24 1302 1308 11705128 course NN I-NP O
25 1309 1310 11705128 ( ( O O
26 1310 1315 11705128 range NN B-NP O
27 1317 1319 11705128 68 CD I-NP O
28 1319 1320 11705128 - HYPH B-NP O
29 1321 1324 11705128 692 CD I-NP O
30 1324 1325 11705128 ) ) O O
31 1325 1326 11705128 . . O O

1 1327 1330 11705128 The DT B-NP O
2 1331 1338 11705128 results NNS I-NP O
3 1339 1341 11705128 of IN B-PP O
4 1342 1345 11705128 the DT B-NP O
5 1346 1349 11705128 one CD I-NP O
6 1349 1350 11705128 - HYPH I-NP O
7 1350 1353 11705128 way NN I-NP O
8 1354 1365 11705128 sensitivity NN I-NP O
9 1366 1374 11705128 analyses NNS I-NP O
10 1375 1381 11705128 ranged VBD B-VP O
11 1382 1386 11705128 from IN B-PP O
12 1388 1390 11705128 57 CD B-NP O
13 1391 1393 11705128 to TO B-PP O
14 1395 1398 11705128 317 CD B-NP O
15 1398 1399 11705128 . . O O

1 1400 1402 11705128 In IN B-PP O
2 1403 1413 11705128 comparison NN B-NP O
3 1413 1414 11705128 , , O O
4 1415 1418 11705128 the DT B-NP O
5 1419 1423 11705128 cost NN I-NP O
6 1424 1426 11705128 of IN B-PP O
7 1427 1429 11705128 48 CD B-NP O
8 1430 1435 11705128 weeks NNS I-NP O
9 1436 1438 11705128 of IN B-PP O
10 1439 1450 11705128 combination NN B-NP O
11 1451 1458 11705128 therapy NN I-NP O
12 1459 1461 11705128 is VBZ B-VP O
13 1463 1469 11705128 16,459 CD B-NP O
14 1469 1470 11705128 . . O O

1 1471 1482 11705128 CONCLUSIONS NNS B-NP O
2 1482 1483 11705128 : : O O
3 1484 1487 11705128 The DT B-NP O
4 1488 1494 11705128 direct JJ I-NP O
5 1495 1499 11705128 cost NN I-NP O
6 1500 1502 11705128 of IN B-PP O
7 1503 1511 11705128 treating VBG B-VP O
8 1512 1522 11705128 clinically RB B-NP O
9 1523 1534 11705128 significant JJ I-NP O
10 1535 1539 11705128 RIHA NN I-NP D000743
11 1540 1542 11705128 is VBZ B-VP O
12 1543 1545 11705128 1% CD B-NP O
13 1546 1547 11705128 ( ( O O
14 1548 1551 11705128 170 CD B-NP O
15 1551 1552 11705128 / SYM O O
16 1553 1559 11705128 16,459 CD B-NP O
17 1559 1560 11705128 ) ) O O
18 1561 1563 11705128 of IN B-PP O
19 1564 1568 11705128 drug NN B-NP O
20 1569 1578 11705128 treatment NN I-NP O
21 1579 1584 11705128 costs NNS I-NP O
22 1584 1585 11705128 . . O O

1 1586 1595 11705128 Questions NNS B-NP O
2 1596 1602 11705128 remain VBP B-VP O
3 1603 1608 11705128 about IN B-PP O
4 1609 1612 11705128 the DT B-NP O
5 1613 1620 11705128 optimal JJ I-NP O
6 1621 1625 11705128 dose NN I-NP O
7 1626 1628 11705128 of IN B-PP O
8 1629 1638 11705128 ribavirin NN B-NP D012254
9 1639 1642 11705128 and CC O O
10 1643 1646 11705128 the DT B-NP O
11 1647 1656 11705128 incidence NN I-NP O
12 1657 1659 11705128 of IN B-PP O
13 1660 1664 11705128 RIHA NN B-NP D000743
14 1665 1667 11705128 in IN B-PP O
15 1668 1669 11705128 a DT B-NP O
16 1670 1674 11705128 real JJ I-NP O
17 1674 1675 11705128 - HYPH I-NP O
18 1675 1680 11705128 world NN I-NP O
19 1681 1691 11705128 population NN I-NP O
20 1691 1692 11705128 . . O O

1 1693 1700 11705128 Despite IN B-PP O
2 1701 1706 11705128 these DT B-NP O
3 1707 1720 11705128 uncertainties NNS I-NP O
4 1720 1721 11705128 , , O O
5 1722 1726 11705128 this DT B-NP O
6 1727 1734 11705128 initial JJ I-NP O
7 1735 1745 11705128 evaluation NN I-NP O
8 1746 1748 11705128 of IN B-PP O
9 1749 1752 11705128 the DT B-NP O
10 1753 1759 11705128 direct JJ I-NP O
11 1760 1764 11705128 cost NN I-NP O
12 1765 1767 11705128 of IN B-PP O
13 1768 1776 11705128 treating VBG B-VP O
14 1777 1781 11705128 RIHA NNP B-NP D000743
15 1782 1790 11705128 provides VBZ B-VP O
16 1791 1793 11705128 an DT B-NP O
17 1794 1802 11705128 estimate NN I-NP O
18 1803 1805 11705128 of IN B-PP O
19 1806 1809 11705128 the DT B-NP O
20 1810 1814 11705128 cost NN I-NP O
21 1815 1818 11705128 and CC I-NP O
22 1819 1829 11705128 management NN I-NP O
23 1830 1842 11705128 implications NNS I-NP O
24 1843 1845 11705128 of IN B-PP O
25 1846 1850 11705128 this DT B-NP O
26 1851 1861 11705128 clinically RB I-NP O
27 1862 1871 11705128 important JJ I-NP O
28 1872 1879 11705128 adverse JJ I-NP O
29 1880 1886 11705128 effect NN I-NP O
30 1886 1887 11705128 . . O O

1 0 0 3780814 -DOCSTART- -X- -X- O

1 0 4 3780814 Anti AFX B-NP O
2 4 5 3780814 - HYPH I-NP O
3 5 17 3780814 carcinogenic JJ B-NP D063646
4 18 24 3780814 action NN I-NP O
5 25 27 3780814 of IN B-PP O
6 28 41 3780814 phenobarbital NN B-NP D010634
7 42 47 3780814 given VBN B-VP O
8 48 62 3780814 simultaneously RB B-ADVP O
9 63 67 3780814 with IN B-PP O
10 68 86 3780814 diethylnitrosamine NN B-NP D004052
11 87 89 3780814 in IN B-PP O
12 90 93 3780814 the DT B-NP O
13 94 97 3780814 rat NN I-NP O
14 97 98 3780814 . . O O
15 99 102 3780814 The DT B-NP O
16 103 110 3780814 present JJ I-NP O
17 111 115 3780814 work NN I-NP O
18 116 119 3780814 has VBZ B-VP O
19 120 124 3780814 been VBN I-VP O
20 125 132 3780814 planned VBN I-VP O
21 133 135 3780814 in IN B-SBAR O
22 136 141 3780814 order NN O O
23 142 144 3780814 to TO B-VP O
24 145 154 3780814 elucidate VB I-VP O
25 155 158 3780814 the DT B-NP O
26 159 165 3780814 effect NN I-NP O
27 166 168 3780814 of IN B-PP O
28 169 182 3780814 phenobarbital NN B-NP D010634
29 183 184 3780814 ( ( O O
30 184 186 3780814 PB NN B-NP D010634
31 186 187 3780814 : : O O
32 188 190 3780814 15 CD B-NP O
33 191 193 3780814 mg NN I-NP O
34 194 197 3780814 per IN B-PP O
35 198 201 3780814 rat NN B-NP O
36 202 204 3780814 of IN B-PP O
37 205 213 3780814 ingested VBN B-NP O
38 214 218 3780814 dose NN I-NP O
39 218 219 3780814 ) ) O O
40 220 222 3780814 on IN B-PP O
41 223 237 3780814 carcinogenesis NN B-NP D063646
42 238 242 3780814 when WRB B-ADVP O
43 243 245 3780814 it PRP B-NP O
44 246 248 3780814 is VBZ B-VP O
45 249 261 3780814 administered VBN I-VP O
46 262 276 3780814 simultaneously RB B-ADVP O
47 277 281 3780814 with IN B-PP O
48 282 300 3780814 diethylnitrosamine NN B-NP D004052
49 301 302 3780814 ( ( O O
50 302 305 3780814 DEN NN B-NP D004052
51 305 306 3780814 : : O O
52 307 309 3780814 10 CD B-NP O
53 310 312 3780814 mg NN I-NP O
54 312 313 3780814 / SYM B-NP O
55 313 315 3780814 kg NN I-NP O
56 315 316 3780814 / SYM B-NP O
57 316 319 3780814 day NN I-NP O
58 319 320 3780814 ) ) O O
59 320 321 3780814 . . O O

1 322 328 3780814 Wistar NNP B-NP O
2 329 333 3780814 rats NNS I-NP O
3 334 335 3780814 ( ( O O
4 335 338 3780814 180 CD B-NP O
5 339 340 3780814 g NN I-NP O
6 340 341 3780814 ) ) O O
7 342 346 3780814 were VBD B-VP O
8 347 354 3780814 treated VBN I-VP O
9 355 357 3780814 by IN B-PP O
10 358 361 3780814 DEN NN B-NP D004052
11 362 367 3780814 alone RB B-ADVP O
12 368 370 3780814 or CC O O
13 371 373 3780814 by IN B-PP O
14 374 377 3780814 DEN NN B-NP D004052
15 378 379 3780814 + SYM B-NP O
16 380 382 3780814 PB NN I-NP D010634
17 383 389 3780814 during IN B-PP O
18 390 391 3780814 2 CD B-NP O
19 391 392 3780814 , , I-NP O
20 393 394 3780814 4 CD I-NP O
21 395 398 3780814 and CC I-NP O
22 399 400 3780814 6 CD I-NP O
23 401 406 3780814 weeks NNS I-NP O
24 407 416 3780814 according VBG B-PP O
25 417 419 3780814 to TO B-PP O
26 420 423 3780814 our PRP$ B-NP O
27 424 432 3780814 schedule NN I-NP O
28 433 436 3780814 for IN B-PP O
29 437 457 3780814 hepatocarcinogenesis NN B-NP D063646
30 457 458 3780814 . . O O

1 459 464 3780814 After IN B-PP O
2 465 468 3780814 the DT B-NP O
3 469 472 3780814 end NN I-NP O
4 473 475 3780814 of IN B-PP O
5 476 479 3780814 the DT B-NP O
6 480 489 3780814 treatment NN I-NP O
7 489 490 3780814 , , O O
8 491 494 3780814 the DT B-NP O
9 495 501 3780814 number NN I-NP O
10 502 505 3780814 and CC O O
11 506 509 3780814 the DT B-NP O
12 510 514 3780814 size NN I-NP O
13 515 517 3780814 of IN B-PP O
14 518 525 3780814 induced VBN B-NP O
15 526 529 3780814 PAS NN I-NP O
16 530 538 3780814 positive JJ I-NP O
17 539 552 3780814 preneoplastic JJ I-NP D011230
18 553 557 3780814 foci NNS I-NP D011230
19 558 561 3780814 was VBD B-VP O
20 562 575 3780814 significantly RB I-VP O
21 576 583 3780814 reduced VBN I-VP O
22 584 588 3780814 when WRB B-ADVP O
23 589 591 3780814 PB NN B-NP D010634
24 592 595 3780814 was VBD B-VP O
25 596 601 3780814 given VBN I-VP O
26 602 616 3780814 simultaneously RB B-ADVP O
27 617 621 3780814 with IN B-PP O
28 622 625 3780814 DEN NN B-NP D004052
29 626 629 3780814 for IN B-PP O
30 630 631 3780814 4 CD B-NP O
31 632 635 3780814 and CC I-NP O
32 636 637 3780814 6 CD I-NP O
33 638 643 3780814 weeks NNS I-NP O
34 643 644 3780814 . . O O

1 645 648 3780814 The DT B-NP O
2 649 656 3780814 mitotic JJ I-NP O
3 657 667 3780814 inhibition NN I-NP O
4 668 671 3780814 and CC O O
5 672 675 3780814 the DT B-NP O
6 676 686 3780814 production NN I-NP O
7 687 689 3780814 of IN B-PP O
8 690 701 3780814 micronuclei NNS B-NP O
9 702 710 3780814 normally RB B-VP O
10 711 719 3780814 observed VBN I-VP O
11 720 725 3780814 after IN B-PP O
12 726 733 3780814 partial JJ B-NP O
13 734 745 3780814 hepatectomy NN I-NP O
14 746 748 3780814 in IN B-PP O
15 749 752 3780814 DEN NN B-NP D004052
16 753 760 3780814 treated VBN I-NP O
17 761 765 3780814 rats NNS I-NP O
18 766 770 3780814 were VBD B-VP O
19 771 775 3780814 also RB B-ADVP O
20 776 789 3780814 significantly RB B-VP O
21 790 799 3780814 decreased VBN I-VP O
22 800 802 3780814 in IN B-PP O
23 803 806 3780814 DEN NN B-NP D004052
24 807 808 3780814 + SYM B-NP O
25 809 811 3780814 PB NN I-NP D010634
26 812 819 3780814 treated VBN B-NP O
27 820 824 3780814 rats NNS I-NP O
28 824 825 3780814 . . O O

1 826 830 3780814 When WRB B-ADVP O
2 831 834 3780814 the DT B-NP O
3 835 844 3780814 treatment NN I-NP O
4 845 849 3780814 last RB B-NP O
5 850 854 3780814 only RB I-NP O
6 855 856 3780814 2 CD I-NP O
7 857 862 3780814 weeks NNS I-NP O
8 862 863 3780814 , , O O
9 864 867 3780814 the DT B-NP O
10 868 876 3780814 presence NN I-NP O
11 877 879 3780814 of IN B-PP O
12 880 882 3780814 PB NN B-NP D010634
13 883 886 3780814 did VBD B-VP O
14 887 890 3780814 not RB I-VP O
15 891 897 3780814 change VB I-VP O
16 898 911 3780814 significantly RB B-ADVP O
17 912 915 3780814 the DT B-NP O
18 916 920 3780814 last JJ I-NP O
19 921 931 3780814 parameters NNS I-NP O
20 931 932 3780814 . . O O

1 933 935 3780814 In IN B-PP O
2 936 939 3780814 DEN NN B-NP D004052
3 940 941 3780814 + SYM B-NP O
4 942 944 3780814 PB NN I-NP D010634
5 945 952 3780814 treated VBN I-NP O
6 953 957 3780814 rats NNS I-NP O
7 957 958 3780814 , , O O
8 959 962 3780814 the DT B-NP O
9 963 971 3780814 survival NN I-NP O
10 972 975 3780814 was VBD B-VP O
11 976 985 3780814 prolonged JJ B-ADJP O
12 986 989 3780814 and CC O O
13 990 993 3780814 the DT B-NP O
14 994 999 3780814 tumor NN I-NP D009369
15 1000 1009 3780814 incidence NN I-NP O
16 1010 1019 3780814 decreased VBD B-VP O
17 1020 1022 3780814 as RB B-ADVP O
18 1023 1031 3780814 compared VBN B-PP O
19 1032 1036 3780814 with IN B-PP O
20 1037 1040 3780814 the DT B-NP O
21 1041 1048 3780814 results NNS I-NP O
22 1049 1057 3780814 obtained VBN B-VP O
23 1058 1060 3780814 by IN B-PP O
24 1061 1064 3780814 DEN NN B-NP D004052
25 1065 1070 3780814 alone RB B-ADVP O
26 1070 1071 3780814 . . O O

1 1072 1074 3780814 It PRP B-NP O
2 1075 1077 3780814 is VBZ B-VP O
3 1078 1087 3780814 concluded VBN I-VP O
4 1088 1092 3780814 that IN B-SBAR O
5 1093 1095 3780814 PB NN B-NP D010634
6 1095 1096 3780814 , , O O
7 1097 1102 3780814 which WDT B-NP O
8 1103 1111 3780814 promotes VBZ B-VP O
9 1112 1126 3780814 carcinogenesis NN B-NP D063646
10 1127 1131 3780814 when WRB B-ADVP O
11 1132 1144 3780814 administered VBN B-VP O
12 1145 1150 3780814 after IN B-PP O
13 1151 1154 3780814 the DT B-NP O
14 1155 1158 3780814 DEN NN I-NP D004052
15 1159 1168 3780814 treatment NN I-NP O
16 1168 1169 3780814 , , O O
17 1170 1177 3780814 reduces VBZ B-VP O
18 1178 1181 3780814 the DT B-NP O
19 1182 1192 3780814 carcinogen NN I-NP O
20 1193 1199 3780814 effect NN I-NP O
21 1200 1204 3780814 when WRB B-ADVP O
22 1205 1210 3780814 given VBN B-VP O
23 1211 1225 3780814 simultaneously RB B-ADVP O
24 1226 1230 3780814 with IN B-PP O
25 1231 1234 3780814 DEN NN B-NP D004052
26 1234 1235 3780814 . . O O

1 1236 1240 3780814 This DT B-NP O
2 1241 1242 3780814 ' `` I-NP O
3 1242 1246 3780814 anti AFX I-NP O
4 1246 1247 3780814 - HYPH I-NP O
5 1247 1257 3780814 carcinogen NN I-NP O
6 1257 1258 3780814 ' '' I-NP O
7 1259 1265 3780814 effect NN I-NP O
8 1266 1270 3780814 acts VBZ B-VP O
9 1271 1273 3780814 on IN B-PP O
10 1274 1277 3780814 the DT B-NP O
11 1278 1288 3780814 initiation NN I-NP O
12 1289 1291 3780814 as RB B-CONJP O
13 1292 1296 3780814 well RB I-CONJP O
14 1297 1299 3780814 as IN I-CONJP O
15 1300 1302 3780814 on IN B-PP O
16 1303 1306 3780814 the DT B-NP O
17 1307 1316 3780814 promotion NN I-NP O
18 1317 1319 3780814 of IN B-PP O
19 1320 1323 3780814 the DT B-NP O
20 1324 1336 3780814 precancerous JJ I-NP D011230
21 1337 1344 3780814 lesions NNS I-NP D011230
22 1344 1345 3780814 . . O O

1 1346 1357 3780814 Biochemical JJ B-NP O
2 1358 1372 3780814 investigations NNS I-NP O
3 1373 1376 3780814 are VBP B-VP O
4 1377 1379 3780814 in IN B-PP O
5 1380 1388 3780814 progress NN B-NP O
6 1389 1391 3780814 to TO B-VP O
7 1392 1398 3780814 obtain VB I-VP O
8 1399 1403 3780814 more JJR B-NP O
9 1404 1415 3780814 information NN I-NP O
10 1416 1421 3780814 about IN B-PP O
11 1422 1426 3780814 this DT B-NP O
12 1427 1428 3780814 ' `` I-NP O
13 1428 1439 3780814 paradoxical JJ I-NP O
14 1439 1440 3780814 ' '' I-NP O
15 1441 1443 3780814 PB NN I-NP D010634
16 1444 1450 3780814 effect NN I-NP O
17 1450 1451 3780814 . . O O

1 0 0 19105845 -DOCSTART- -X- -X- O

1 0 6 19105845 Effect NN B-NP O
2 7 9 19105845 of IN B-PP O
3 10 20 19105845 increasing VBG B-VP O
4 21 36 19105845 intraperitoneal JJ B-NP O
5 37 45 19105845 infusion NN I-NP O
6 46 51 19105845 rates NNS I-NP O
7 52 54 19105845 on IN B-PP O
8 55 64 19105845 bupropion NN B-NP D016642
9 65 78 19105845 hydrochloride NN I-NP D016642
10 78 79 19105845 - HYPH B-NP O
11 79 86 19105845 induced VBN I-NP O
12 87 95 19105845 seizures NNS I-NP D012640
13 96 98 19105845 in IN B-PP O
14 99 103 19105845 mice NNS B-NP O
15 103 104 19105845 . . O O
16 105 115 19105845 BACKGROUND NN B-NP O
17 115 116 19105845 : : O O
18 117 119 19105845 It PRP B-NP O
19 120 122 19105845 is VBZ B-VP O
20 123 126 19105845 not RB I-VP O
21 127 132 19105845 known VBN I-VP O
22 133 135 19105845 if IN B-SBAR O
23 136 141 19105845 there EX B-NP O
24 142 144 19105845 is VBZ B-VP O
25 145 146 19105845 a DT B-NP O
26 147 159 19105845 relationship NN I-NP O
27 160 167 19105845 between IN B-PP O
28 168 173 19105845 input NN B-NP O
29 174 178 19105845 rate NN I-NP O
30 179 182 19105845 and CC O O
31 183 192 19105845 incidence NN B-NP O
32 193 195 19105845 of IN B-PP O
33 196 205 19105845 bupropion NN B-NP D016642
34 205 206 19105845 - HYPH B-NP O
35 206 213 19105845 induced VBN I-NP O
36 214 222 19105845 seizures NNS I-NP D012640
37 222 223 19105845 . . O O

1 224 228 19105845 This DT B-NP O
2 229 231 19105845 is VBZ B-VP O
3 232 241 19105845 important JJ B-ADJP O
4 241 242 19105845 , , O O
5 243 248 19105845 since IN B-SBAR O
6 249 258 19105845 different JJ B-NP O
7 259 269 19105845 controlled VBN I-NP O
8 270 277 19105845 release NN I-NP O
9 278 290 19105845 formulations NNS I-NP O
10 291 293 19105845 of IN B-PP O
11 294 303 19105845 bupropion NN B-NP D016642
12 304 311 19105845 release NN I-NP O
13 312 315 19105845 the DT B-NP O
14 316 322 19105845 active JJ I-NP O
15 323 327 19105845 drug NN I-NP O
16 328 330 19105845 at IN B-PP O
17 331 340 19105845 different JJ B-NP O
18 341 346 19105845 rates NNS I-NP O
19 346 347 19105845 . . O O

1 348 355 19105845 METHODS NNS B-NP O
2 355 356 19105845 : : O O
3 357 359 19105845 We PRP B-NP O
4 360 372 19105845 investigated VBD B-VP O
5 373 376 19105845 the DT B-NP O
6 377 383 19105845 effect NN I-NP O
7 384 386 19105845 of IN B-PP O
8 387 394 19105845 varying VBG B-VP O
9 395 398 19105845 the DT B-NP O
10 399 414 19105845 intraperitoneal JJ I-NP O
11 415 423 19105845 infusion NN I-NP O
12 424 429 19105845 rates NNS I-NP O
13 430 432 19105845 of IN B-PP O
14 433 442 19105845 bupropion NN B-NP D016642
15 443 446 19105845 HCl NN I-NP D016642
16 447 450 19105845 120 CD I-NP O
17 451 453 19105845 mg NN I-NP O
18 453 454 19105845 / SYM B-NP O
19 454 456 19105845 kg NN I-NP O
20 456 457 19105845 , , O O
21 458 459 19105845 a DT B-NP O
22 460 465 19105845 known JJ I-NP O
23 466 476 19105845 convulsive JJ I-NP D012640
24 477 481 19105845 dose NN I-NP O
25 482 484 19105845 50 CD I-NP O
26 485 486 19105845 ( ( O O
27 486 490 19105845 CD50 NN B-NP O
28 490 491 19105845 ) ) O O
29 491 492 19105845 , , O O
30 493 495 19105845 on IN B-PP O
31 496 499 19105845 the DT B-NP O
32 500 509 19105845 incidence NN I-NP O
33 510 513 19105845 and CC I-NP O
34 514 522 19105845 severity NN I-NP O
35 523 525 19105845 of IN B-PP O
36 526 535 19105845 bupropion NN B-NP D016642
37 535 536 19105845 - HYPH B-NP O
38 536 543 19105845 induced VBN I-NP O
39 544 555 19105845 convulsions NNS I-NP D012640
40 556 558 19105845 in IN B-PP O
41 559 562 19105845 the DT B-NP O
42 563 568 19105845 Swiss JJ I-NP O
43 569 575 19105845 albino NN I-NP O
44 576 580 19105845 mice NNS I-NP O
45 580 581 19105845 . . O O

1 582 583 19105845 A DT B-NP O
2 584 589 19105845 total NN I-NP O
3 590 592 19105845 of IN B-PP O
4 593 595 19105845 69 CD B-NP O
5 596 600 19105845 mice NNS I-NP O
6 600 601 19105845 , , O O
7 602 615 19105845 approximately RB B-NP O
8 616 617 19105845 7 CD I-NP O
9 618 623 19105845 weeks NNS I-NP O
10 624 626 19105845 of IN B-PP O
11 627 630 19105845 age NN B-NP O
12 630 631 19105845 , , O O
13 632 635 19105845 and CC O O
14 636 644 19105845 weighing VBG B-VP O
15 645 649 19105845 21.0 CD B-NP O
16 650 652 19105845 to TO I-NP O
17 653 657 19105845 29.1 CD I-NP O
18 658 659 19105845 g NN I-NP O
19 660 664 19105845 were VBD B-VP O
20 665 673 19105845 randomly RB I-VP O
21 674 682 19105845 assigned VBN I-VP O
22 683 685 19105845 to TO B-PP O
23 686 695 19105845 bupropion NN B-NP D016642
24 696 699 19105845 HCl NN I-NP D016642
25 700 703 19105845 120 CD B-NP O
26 704 706 19105845 mg NN I-NP O
27 706 707 19105845 / SYM B-NP O
28 707 709 19105845 kg NN I-NP O
29 710 719 19105845 treatment NN I-NP O
30 720 722 19105845 by IN B-PP O
31 723 738 19105845 intraperitoneal JJ O O
32 739 740 19105845 ( ( O O
33 740 742 19105845 IP JJ B-ADJP O
34 742 743 19105845 ) ) O O
35 744 758 19105845 administration NN B-NP O
36 759 761 19105845 in IN B-PP O
37 762 763 19105845 7 CD B-NP O
38 764 770 19105845 groups NNS I-NP O
39 771 772 19105845 ( ( O O
40 772 773 19105845 9 CD B-NP O
41 774 776 19105845 to TO I-NP O
42 777 779 19105845 10 CD I-NP O
43 780 787 19105845 animals NNS I-NP O
44 788 791 19105845 per IN B-PP O
45 792 797 19105845 group NN B-NP O
46 797 798 19105845 ) ) O O
47 798 799 19105845 . . O O

1 800 809 19105845 Bupropion NN B-NP D016642
2 810 813 19105845 HCl NN I-NP D016642
3 814 817 19105845 was VBD B-VP O
4 818 825 19105845 infused VBN I-VP O
5 826 833 19105845 through IN B-PP O
6 834 835 19105845 a DT B-NP O
7 836 846 19105845 surgically RB I-NP O
8 847 856 19105845 implanted VBN I-NP O
9 857 859 19105845 IP NN I-NP O
10 860 866 19105845 dosing NN I-NP O
11 867 875 19105845 catheter NN I-NP O
12 876 880 19105845 with IN B-PP O
13 881 890 19105845 infusions NNS B-NP O
14 891 893 19105845 in IN B-PP O
15 894 898 19105845 each DT B-NP O
16 899 904 19105845 group NN I-NP O
17 905 907 19105845 of IN B-PP O
18 908 909 19105845 0 CD B-NP O
19 910 913 19105845 min NN I-NP O
20 913 914 19105845 , , O O
21 915 917 19105845 15 CD B-NP O
22 918 921 19105845 min NN I-NP O
23 921 922 19105845 , , O O
24 923 925 19105845 30 CD B-NP O
25 926 929 19105845 min NN I-NP O
26 929 930 19105845 , , O O
27 931 933 19105845 60 CD B-NP O
28 934 937 19105845 min NN I-NP O
29 937 938 19105845 , , O O
30 939 941 19105845 90 CD B-NP O
31 942 945 19105845 min NN I-NP O
32 945 946 19105845 , , O O
33 947 950 19105845 120 CD B-NP O
34 951 954 19105845 min NN I-NP O
35 954 955 19105845 , , O O
36 956 959 19105845 and CC O O
37 960 963 19105845 240 CD B-NP O
38 964 967 19105845 min NN I-NP O
39 967 968 19105845 . . O O

1 969 972 19105845 The DT B-NP O
2 973 979 19105845 number NN I-NP O
3 979 980 19105845 , , O O
4 981 985 19105845 time NN B-NP O
5 986 988 19105845 of IN B-PP O
6 989 994 19105845 onset NN B-NP O
7 994 995 19105845 , , O O
8 996 1004 19105845 duration NN B-NP O
9 1005 1008 19105845 and CC O O
10 1009 1012 19105845 the DT B-NP O
11 1013 1022 19105845 intensity NN I-NP O
12 1023 1025 19105845 of IN B-PP O
13 1026 1029 19105845 the DT B-NP O
14 1030 1041 19105845 convulsions NNS I-NP D012640
15 1042 1044 19105845 or CC I-NP O
16 1045 1052 19105845 absence NN I-NP O
17 1053 1055 19105845 of IN B-PP O
18 1056 1067 19105845 convulsions NNS B-NP D012640
19 1068 1072 19105845 were VBD B-VP O
20 1073 1081 19105845 recorded VBN I-VP O
21 1081 1082 19105845 . . O O

1 1083 1090 19105845 RESULTS NNS B-NP O
2 1090 1091 19105845 : : O O
3 1092 1095 19105845 The DT B-NP O
4 1096 1103 19105845 results NNS I-NP O
5 1104 1110 19105845 showed VBD B-VP O
6 1111 1115 19105845 that IN B-SBAR O
7 1116 1118 19105845 IP NN B-NP O
8 1119 1133 19105845 administration NN I-NP O
9 1134 1136 19105845 of IN B-PP O
10 1137 1146 19105845 bupropion NN B-NP D016642
11 1147 1150 19105845 HCl NN I-NP D016642
12 1151 1154 19105845 120 CD I-NP O
13 1155 1157 19105845 mg NN I-NP O
14 1157 1158 19105845 / SYM O O
15 1158 1160 19105845 kg NN B-NP O
16 1161 1163 19105845 by IN B-PP O
17 1164 1169 19105845 bolus NN B-NP O
18 1170 1179 19105845 injection NN I-NP O
19 1180 1187 19105845 induced VBD B-VP O
20 1188 1199 19105845 convulsions NNS B-NP D012640
21 1200 1202 19105845 in IN B-PP O
22 1203 1204 19105845 6 CD B-NP O
23 1205 1208 19105845 out IN I-NP O
24 1209 1211 19105845 of IN I-NP O
25 1212 1214 19105845 10 CD I-NP O
26 1215 1219 19105845 mice NNS I-NP O
27 1220 1221 19105845 ( ( O O
28 1221 1224 19105845 60% NN B-NP O
29 1225 1227 19105845 of IN B-PP O
30 1228 1238 19105845 convulsing VBG B-VP O
31 1239 1243 19105845 mice NNS B-NP O
32 1243 1244 19105845 ) ) O O
33 1245 1247 19105845 in IN B-PP O
34 1248 1253 19105845 group NN B-NP O
35 1254 1255 19105845 1 CD I-NP O
36 1255 1256 19105845 . . O O

1 1257 1265 19105845 Logistic JJ B-NP O
2 1266 1276 19105845 regression NN I-NP O
3 1277 1285 19105845 analysis NN I-NP O
4 1286 1294 19105845 revealed VBD B-VP O
5 1295 1299 19105845 that IN B-SBAR O
6 1300 1308 19105845 infusion NN B-NP O
7 1309 1313 19105845 time NN I-NP O
8 1314 1317 19105845 was VBD B-VP O
9 1318 1329 19105845 significant JJ B-ADJP O
10 1330 1331 19105845 ( ( O O
11 1331 1332 19105845 p NN B-NP O
12 1333 1334 19105845 = SYM B-VP O
13 1335 1341 19105845 0.0004 CD B-NP O
14 1341 1342 19105845 ; : O O
15 1343 1347 19105845 odds NNS B-NP O
16 1348 1353 19105845 ratio NN I-NP O
17 1354 1355 19105845 = SYM B-VP O
18 1356 1361 19105845 0.974 CD B-NP O
19 1361 1362 19105845 ) ) O O
20 1363 1366 19105845 and CC O O
21 1367 1377 19105845 increasing VBG B-VP O
22 1378 1381 19105845 the DT B-NP O
23 1382 1384 19105845 IP NN I-NP O
24 1385 1393 19105845 infusion NN I-NP O
25 1394 1398 19105845 time NN I-NP O
26 1399 1401 19105845 of IN B-PP O
27 1402 1411 19105845 bupropion NN B-NP D016642
28 1412 1415 19105845 HCl NN I-NP D016642
29 1416 1419 19105845 120 CD I-NP O
30 1420 1422 19105845 mg NN I-NP O
31 1422 1423 19105845 / SYM B-NP O
32 1423 1425 19105845 kg NN I-NP O
33 1426 1429 19105845 was VBD B-VP O
34 1430 1440 19105845 associated VBN I-VP O
35 1441 1445 19105845 with IN B-PP O
36 1446 1447 19105845 a DT B-NP O
37 1448 1451 19105845 91% CD I-NP O
38 1452 1459 19105845 reduced VBN I-NP O
39 1460 1464 19105845 odds NNS I-NP O
40 1465 1467 19105845 of IN B-PP O
41 1468 1479 19105845 convulsions NNS B-NP D012640
42 1480 1482 19105845 at IN B-PP O
43 1483 1491 19105845 infusion NN B-NP O
44 1492 1497 19105845 times NNS I-NP O
45 1498 1500 19105845 of IN B-PP O
46 1501 1503 19105845 15 CD B-NP O
47 1504 1506 19105845 to TO I-NP O
48 1507 1509 19105845 90 CD I-NP O
49 1510 1513 19105845 min NN I-NP O
50 1514 1522 19105845 compared VBN B-VP O
51 1523 1525 19105845 to TO B-PP O
52 1526 1531 19105845 bolus NN B-NP O
53 1532 1541 19105845 injection NN I-NP O
54 1541 1542 19105845 . . O O

1 1543 1550 19105845 Further JJ B-NP O
2 1551 1559 19105845 increase NN I-NP O
3 1560 1562 19105845 in IN B-PP O
4 1563 1571 19105845 infusion NN B-NP O
5 1572 1576 19105845 time NN I-NP O
6 1577 1585 19105845 resulted VBD B-VP O
7 1586 1588 19105845 in IN B-PP O
8 1589 1596 19105845 further JJ B-NP O
9 1597 1606 19105845 reduction NN I-NP O
10 1607 1609 19105845 in IN B-PP O
11 1610 1613 19105845 the DT B-NP O
12 1614 1618 19105845 odds NNS I-NP O
13 1619 1621 19105845 of IN B-PP O
14 1622 1633 19105845 convulsions NNS B-NP D012640
15 1634 1636 19105845 to TO B-PP O
16 1637 1642 19105845 99.8% CD B-NP O
17 1643 1652 19105845 reduction NN I-NP O
18 1653 1655 19105845 at IN B-PP O
19 1656 1659 19105845 240 CD B-NP O
20 1660 1663 19105845 min NN I-NP O
21 1663 1664 19105845 . . O O

1 1665 1675 19105845 CONCLUSION NN B-NP O
2 1675 1676 19105845 : : O O
3 1677 1679 19105845 In IN B-PP O
4 1680 1690 19105845 conclusion NN B-NP O
5 1690 1691 19105845 , , O O
6 1692 1695 19105845 the DT B-NP O
7 1696 1709 19105845 demonstration NN I-NP O
8 1710 1712 19105845 of IN B-PP O
9 1713 1715 19105845 an DT B-NP O
10 1716 1723 19105845 inverse JJ I-NP O
11 1724 1736 19105845 relationship NN I-NP O
12 1737 1744 19105845 between IN B-PP O
13 1745 1753 19105845 infusion NN B-NP O
14 1754 1758 19105845 time NN I-NP O
15 1759 1761 19105845 of IN B-PP O
16 1762 1763 19105845 a DT B-NP O
17 1764 1769 19105845 fixed VBN I-NP O
18 1770 1773 19105845 and CC I-NP O
19 1774 1784 19105845 convulsive JJ I-NP D012640
20 1785 1789 19105845 dose NN I-NP O
21 1790 1792 19105845 of IN B-PP O
22 1793 1802 19105845 bupropion NN B-NP D016642
23 1803 1806 19105845 and CC O O
24 1807 1810 19105845 the DT B-NP O
25 1811 1815 19105845 risk NN I-NP O
26 1816 1818 19105845 of IN B-PP O
27 1819 1830 19105845 convulsions NNS B-NP D012640
28 1831 1833 19105845 in IN B-PP O
29 1834 1835 19105845 a DT B-NP O
30 1836 1847 19105845 prospective JJ I-NP O
31 1848 1853 19105845 study NN I-NP O
32 1854 1856 19105845 is VBZ B-VP O
33 1857 1862 19105845 novel JJ B-ADJP O
34 1862 1863 19105845 . . O O

1 0 0 6732043 -DOCSTART- -X- -X- O

1 0 9 6732043 Induction NN B-NP O
2 10 12 6732043 of IN B-PP O
3 13 16 6732043 the DT B-NP O
4 17 28 6732043 obstructive JJ I-NP D020181
5 29 34 6732043 sleep NN I-NP D020181
6 35 40 6732043 apnea NN I-NP D020181
7 41 49 6732043 syndrome NN I-NP D020181
8 50 52 6732043 in IN B-PP O
9 53 54 6732043 a DT B-NP O
10 55 60 6732043 woman NN I-NP O
11 61 63 6732043 by IN B-PP O
12 64 73 6732043 exogenous JJ B-NP O
13 74 82 6732043 androgen NN I-NP D000728
14 83 97 6732043 administration NN I-NP O
15 97 98 6732043 . . O O
16 99 101 6732043 We PRP B-NP O
17 102 112 6732043 documented VBD B-VP O
18 113 119 6732043 airway NN B-NP O
19 120 129 6732043 occlusion NN I-NP O
20 130 136 6732043 during IN B-PP O
21 137 142 6732043 sleep NN B-NP O
22 143 146 6732043 and CC O O
23 147 149 6732043 an DT B-NP O
24 150 160 6732043 abnormally RB I-NP O
25 161 165 6732043 high JJ I-NP O
26 166 178 6732043 supraglottic JJ I-NP O
27 179 189 6732043 resistance NN I-NP O
28 190 195 6732043 while IN B-SBAR O
29 196 201 6732043 awake NN B-NP O
30 202 204 6732043 in IN B-PP O
31 205 206 6732043 a DT B-NP O
32 207 209 6732043 54 CD I-NP O
33 209 210 6732043 - HYPH I-NP O
34 210 212 6732043 yr NN I-NP O
35 212 213 6732043 - HYPH I-NP O
36 213 216 6732043 old JJ I-NP O
37 217 222 6732043 woman NN I-NP O
38 223 226 6732043 who WP B-NP O
39 227 230 6732043 had VBD B-VP O
40 231 240 6732043 developed VBN I-VP O
41 241 249 6732043 physical JJ B-NP O
42 250 257 6732043 changes NNS I-NP O
43 258 261 6732043 and CC O O
44 262 265 6732043 the DT B-NP O
45 266 274 6732043 syndrome NN I-NP D020181
46 275 277 6732043 of IN B-PP D020181
47 278 289 6732043 obstructive JJ B-NP D020181
48 290 295 6732043 sleep NN I-NP D020181
49 296 301 6732043 apnea NN I-NP D020181
50 302 307 6732043 while IN B-SBAR O
51 308 313 6732043 being VBG B-VP O
52 314 326 6732043 administered VBN I-VP O
53 327 336 6732043 exogenous JJ B-NP O
54 337 346 6732043 androgens NNS I-NP D000728
55 346 347 6732043 . . O O

1 348 352 6732043 When WRB B-ADVP O
2 353 356 6732043 the DT B-NP O
3 357 366 6732043 androgens NNS I-NP D000728
4 367 371 6732043 were VBD B-VP O
5 372 381 6732043 withdrawn VBN I-VP O
6 381 382 6732043 , , O O
7 383 386 6732043 the DT B-NP O
8 387 396 6732043 patient's NNS I-NP O
9 397 405 6732043 physical JJ B-NP O
10 406 413 6732043 changes NNS I-NP O
11 413 414 6732043 , , O O
12 415 423 6732043 symptoms NNS B-NP O
13 423 424 6732043 , , O O
14 425 430 6732043 sleep NN B-NP O
15 431 436 6732043 study NN I-NP O
16 436 437 6732043 , , O O
17 438 441 6732043 and CC O O
18 442 454 6732043 supraglottic JJ B-NP O
19 455 465 6732043 resistance NN I-NP O
20 466 469 6732043 all DT O O
21 470 478 6732043 returned VBD B-VP O
22 479 481 6732043 to TO B-PP O
23 482 488 6732043 normal JJ B-NP O
24 488 489 6732043 . . O O

1 490 491 6732043 A DT B-NP O
2 492 503 6732043 rechallenge NN I-NP O
3 504 508 6732043 with IN B-PP O
4 509 517 6732043 androgen NN B-NP D000728
5 518 526 6732043 produced VBD B-VP O
6 527 535 6732043 symptoms NNS B-NP O
7 536 538 6732043 of IN B-PP O
8 539 550 6732043 obstructive JJ B-NP D020181
9 551 556 6732043 sleep JJ I-NP D020181
10 557 562 6732043 apnea NN I-NP D020181
11 563 567 6732043 that WDT B-NP O
12 568 574 6732043 abated VBD B-VP O
13 575 579 6732043 upon IN B-PP O
14 580 590 6732043 withdrawal NN B-NP O
15 591 593 6732043 of IN B-PP O
16 594 597 6732043 the DT B-NP O
17 598 605 6732043 hormone NN I-NP O
18 605 606 6732043 . . O O

1 607 615 6732043 Previous JJ B-NP O
2 616 623 6732043 reports NNS I-NP O
3 624 628 6732043 have VBP B-VP O
4 629 636 6732043 favored VBN I-VP O
5 637 638 6732043 a DT B-NP O
6 639 643 6732043 role NN I-NP O
7 644 646 6732043 of IN B-PP O
8 647 656 6732043 androgens NNS B-NP D000728
9 657 659 6732043 in IN B-PP O
10 660 663 6732043 the DT B-NP O
11 664 676 6732043 pathogenesis NN I-NP O
12 677 679 6732043 of IN B-PP O
13 680 685 6732043 sleep NN B-NP D012891
14 686 691 6732043 apnea NN I-NP D012891
15 691 692 6732043 . . O O

1 693 696 6732043 Our PRP$ B-NP O
2 697 703 6732043 report NN I-NP O
3 704 712 6732043 provides VBZ B-VP O
4 713 719 6732043 direct JJ B-NP O
5 720 728 6732043 evidence NN I-NP O
6 729 732 6732043 for IN B-PP O
7 733 737 6732043 this DT B-NP O
8 738 742 6732043 role NN I-NP O
9 742 743 6732043 . . O O

1 744 754 6732043 Structural JJ B-NP O
2 755 758 6732043 and CC I-NP O
3 759 769 6732043 functional JJ I-NP O
4 770 782 6732043 measurements NNS I-NP O
5 783 791 6732043 indicate VBP B-VP O
6 792 796 6732043 that IN B-SBAR O
7 797 806 6732043 androgens NNS B-NP D000728
8 807 812 6732043 exert VBP B-VP O
9 813 814 6732043 a DT B-NP O
10 815 825 6732043 permissive JJ I-NP O
11 826 828 6732043 or CC I-NP O
12 829 838 6732043 necessary JJ I-NP O
13 839 845 6732043 action NN I-NP O
14 846 848 6732043 on IN B-PP O
15 849 852 6732043 the DT B-NP O
16 853 863 6732043 structural JJ I-NP O
17 864 877 6732043 configuration NN I-NP O
18 878 880 6732043 of IN B-PP O
19 881 884 6732043 the DT B-NP O
20 885 895 6732043 oropharynx NN I-NP O
21 896 900 6732043 that WDT B-NP O
22 901 912 6732043 predisposes VBZ B-VP O
23 913 915 6732043 to TO B-PP O
24 916 927 6732043 obstruction NN B-NP O
25 928 934 6732043 during IN B-PP O
26 935 940 6732043 sleep NN B-NP O
27 940 941 6732043 . . O O

1 942 953 6732043 Development NN B-NP O
2 954 956 6732043 of IN B-PP O
3 957 960 6732043 the DT B-NP O
4 961 972 6732043 obstructive JJ I-NP D020181
5 973 978 6732043 sleep NN I-NP D020181
6 979 984 6732043 apnea NN I-NP D020181
7 985 993 6732043 syndrome NN I-NP D020181
8 994 998 6732043 must MD B-VP O
9 999 1001 6732043 be VB I-VP O
10 1002 1012 6732043 considered VBN I-VP O
11 1013 1014 6732043 a DT B-NP O
12 1015 1023 6732043 possible JJ I-NP O
13 1024 1028 6732043 side NN I-NP O
14 1029 1035 6732043 effect NN I-NP O
15 1036 1038 6732043 of IN B-PP O
16 1039 1047 6732043 androgen NN B-NP D000728
17 1048 1055 6732043 therapy NN I-NP O
18 1055 1056 6732043 . . O O

1 0 0 12139551 -DOCSTART- -X- -X- O

1 0 7 12139551 Cardiac JJ B-NP D006323
2 8 14 12139551 arrest NN I-NP D006323
3 15 20 12139551 after IN B-PP O
4 21 32 12139551 intravenous JJ B-NP O
5 33 47 12139551 metoclopramide NN I-NP D008787
6 48 49 12139551 - HYPH O O
7 50 51 12139551 a DT B-NP O
8 52 56 12139551 case NN I-NP O
9 57 59 12139551 of IN B-PP O
10 60 64 12139551 five CD B-NP O
11 65 73 12139551 repeated VBN I-NP O
12 74 84 12139551 injections NNS I-NP O
13 85 87 12139551 of IN B-PP O
14 88 102 12139551 metoclopramide NN B-NP D008787
15 103 110 12139551 causing VBG B-VP O
16 111 115 12139551 five CD B-NP O
17 116 124 12139551 episodes NNS I-NP O
18 125 127 12139551 of IN B-PP O
19 128 135 12139551 cardiac JJ B-NP D006323
20 136 142 12139551 arrest NN I-NP D006323
21 142 143 12139551 . . O O
22 144 146 12139551 We PRP B-NP O
23 147 155 12139551 describe VBP B-VP O
24 156 157 12139551 a DT B-NP O
25 158 165 12139551 patient NN I-NP O
26 166 171 12139551 where WRB B-ADVP O
27 172 183 12139551 intravenous JJ B-NP O
28 184 193 12139551 injection NN I-NP O
29 194 196 12139551 of IN B-PP O
30 197 211 12139551 metoclopramide NN B-NP D008787
31 212 215 12139551 was VBD B-VP O
32 216 227 12139551 immediately RB I-VP O
33 228 236 12139551 followed VBN I-VP O
34 237 239 12139551 by IN B-PP O
35 240 248 12139551 asystole NN B-NP D006323
36 249 259 12139551 repeatedly RB B-ADVP O
37 259 260 12139551 . . O O

1 261 264 12139551 The DT B-NP O
2 265 272 12139551 patient NN I-NP O
3 273 281 12139551 received VBD B-VP O
4 282 296 12139551 metoclopramide NN B-NP D008787
5 297 299 12139551 10 CD I-NP O
6 300 302 12139551 mg NN I-NP O
7 303 306 12139551 i.v NN I-NP O
8 306 307 12139551 . . O O

1 308 312 12139551 five CD B-NP O
2 313 318 12139551 times NNS I-NP O
3 319 325 12139551 during IN B-PP O
4 326 328 12139551 48 CD B-NP O
5 329 330 12139551 h NN I-NP O
6 330 331 12139551 . . O O

1 332 337 12139551 After IN B-PP O
2 338 350 12139551 interviewing VBG B-VP O
3 351 354 12139551 the DT B-NP O
4 355 364 12139551 attending VBG I-NP O
5 365 371 12139551 nurses NNS I-NP O
6 372 375 12139551 and CC O O
7 376 385 12139551 reviewing VBG B-VP O
8 386 389 12139551 the DT B-NP O
9 390 397 12139551 written VBN I-NP O
10 398 411 12139551 documentation NN I-NP O
11 411 412 12139551 , , O O
12 413 415 12139551 it PRP B-NP O
13 416 418 12139551 is VBZ B-VP O
14 419 424 12139551 clear JJ B-ADJP O
15 425 429 12139551 that IN B-SBAR O
16 430 435 12139551 every DT B-NP O
17 436 450 12139551 administration NN I-NP O
18 451 453 12139551 of IN B-PP O
19 454 468 12139551 metoclopramide NN B-NP D008787
20 469 472 12139551 was VBD B-VP O
21 473 484 12139551 immediately RB B-ADVP O
22 485 486 12139551 ( ( O O
23 486 492 12139551 within IN B-PP O
24 493 494 12139551 s NNS B-NP O
25 494 495 12139551 ) ) O O
26 496 504 12139551 followed VBN B-VP O
27 505 507 12139551 by IN B-PP O
28 508 516 12139551 asystole NN B-NP D006323
29 516 517 12139551 . . O O

1 518 521 12139551 The DT B-NP O
2 522 530 12139551 asystole NN I-NP D006323
3 531 537 12139551 lasted VBD B-VP O
4 538 540 12139551 15 CD B-NP O
5 540 541 12139551 - HYPH I-NP O
6 541 543 12139551 30 CD I-NP O
7 544 545 12139551 s NN I-NP O
8 546 548 12139551 on IN B-PP O
9 549 553 12139551 four CD B-NP O
10 554 563 12139551 occasions NNS I-NP O
11 563 564 12139551 , , O O
12 565 567 12139551 on IN B-PP O
13 568 571 12139551 one CD B-NP O
14 572 580 12139551 occasion NN I-NP O
15 581 583 12139551 it PRP B-NP O
16 584 590 12139551 lasted VBD B-VP O
17 591 592 12139551 2 CD B-NP O
18 593 596 12139551 min NN I-NP O
19 596 597 12139551 . . O O

1 598 601 12139551 The DT B-NP O
2 602 609 12139551 patient NN I-NP O
3 610 618 12139551 received VBD B-VP O
4 619 627 12139551 atropine NN B-NP D001285
5 628 631 12139551 0.5 CD I-NP O
6 631 632 12139551 - HYPH I-NP O
7 632 633 12139551 1 CD I-NP O
8 634 636 12139551 mg NN I-NP O
9 637 640 12139551 and CC I-NP O
10 641 646 12139551 chest NN I-NP O
11 647 659 12139551 compressions NNS I-NP O
12 659 660 12139551 , , O O
13 661 667 12139551 before IN B-PP O
14 668 673 12139551 sinus NN B-NP O
15 674 680 12139551 rhythm NN I-NP O
16 681 686 12139551 again RB B-ADVP O
17 687 691 12139551 took VBD B-VP O
18 692 696 12139551 over RP B-PRT O
19 696 697 12139551 . . O O

1 698 700 12139551 We PRP B-NP O
2 701 710 12139551 interpret VBP B-VP O
3 711 715 12139551 this DT B-NP O
4 716 718 12139551 as IN B-PP O
5 719 727 12139551 episodes NNS B-NP O
6 728 730 12139551 of IN B-PP O
7 731 738 12139551 cardiac JJ B-NP D006323
8 739 745 12139551 arrest NN I-NP D006323
9 746 752 12139551 caused VBN B-VP O
10 753 755 12139551 by IN B-PP O
11 756 770 12139551 metoclopramide NN B-NP D008787
12 770 771 12139551 . . O O

1 772 775 12139551 The DT B-NP O
2 776 781 12139551 rapid JJ I-NP O
3 782 791 12139551 injection NN I-NP O
4 792 795 12139551 via IN B-PP O
5 796 799 12139551 the DT B-NP O
6 800 807 12139551 central JJ I-NP O
7 808 814 12139551 venous JJ I-NP O
8 815 820 12139551 route NN I-NP O
9 821 824 12139551 and CC O O
10 825 828 12139551 the DT B-NP O
11 829 840 12139551 concomitant JJ I-NP O
12 841 849 12139551 tapering NN I-NP O
13 850 852 12139551 of IN B-PP O
14 853 861 12139551 dopamine NN B-NP D004298
15 862 870 12139551 infusion NN I-NP O
16 871 876 12139551 might MD B-VP O
17 877 881 12139551 have VB I-VP O
18 882 893 12139551 contributed VBN I-VP O
19 894 896 12139551 in IN B-PP O
20 897 910 12139551 precipitating VBG B-VP O
21 911 914 12139551 the DT B-NP O
22 915 922 12139551 adverse JJ I-NP O
23 923 927 12139551 drug NN I-NP O
24 928 936 12139551 reaction NN I-NP O
25 936 937 12139551 . . O O

1 0 0 19234905 -DOCSTART- -X- -X- O

1 0 10 19234905 Comparison NN B-NP O
2 11 13 19234905 of IN B-PP O
3 14 24 19234905 unilateral JJ B-NP O
4 25 36 19234905 pallidotomy NN I-NP O
5 37 40 19234905 and CC I-NP O
6 41 55 19234905 subthalamotomy NN I-NP O
7 56 64 19234905 findings NNS I-NP O
8 65 67 19234905 in IN B-PP O
9 68 76 19234905 advanced VBN B-NP O
10 77 87 19234905 idiopathic JJ I-NP D010300
11 88 99 19234905 Parkinson's NNS I-NP D010300
12 100 107 19234905 disease NN I-NP D010300
13 107 108 19234905 . . O O
14 109 110 19234905 A DT B-NP O
15 111 122 19234905 prospective JJ I-NP O
16 122 123 19234905 , , I-NP O
17 124 134 19234905 randomized VBN I-NP O
18 134 135 19234905 , , I-NP O
19 136 142 19234905 double JJ I-NP O
20 142 143 19234905 - HYPH I-NP O
21 143 148 19234905 blind JJ I-NP O
22 149 154 19234905 pilot NN I-NP O
23 155 160 19234905 study NN I-NP O
24 161 163 19234905 to TO B-VP O
25 164 171 19234905 compare VB I-VP O
26 172 175 19234905 the DT B-NP O
27 176 183 19234905 results NNS I-NP O
28 184 186 19234905 of IN B-PP O
29 187 199 19234905 stereotactic JJ B-NP O
30 200 210 19234905 unilateral JJ I-NP O
31 211 222 19234905 pallidotomy NN I-NP O
32 223 226 19234905 and CC I-NP O
33 227 241 19234905 subthalamotomy NN I-NP O
34 242 244 19234905 in IN B-PP O
35 245 253 19234905 advanced VBN B-NP O
36 254 264 19234905 idiopathic JJ I-NP D010300
37 265 276 19234905 Parkinson's NNS I-NP D010300
38 277 284 19234905 disease NN I-NP D010300
39 285 286 19234905 ( ( O O
40 286 288 19234905 PD NN B-NP D010300
41 288 289 19234905 ) ) O O
42 290 300 19234905 refractory JJ B-ADJP O
43 301 303 19234905 to TO B-PP O
44 304 311 19234905 medical JJ B-NP O
45 312 321 19234905 treatment NN I-NP O
46 322 325 19234905 was VBD B-VP O
47 326 334 19234905 designed VBN I-VP O
48 334 335 19234905 . . O O

1 336 339 19234905 Ten CD B-NP O
2 340 351 19234905 consecutive JJ I-NP O
3 352 360 19234905 patients NNS I-NP O
4 361 362 19234905 ( ( O O
5 362 366 19234905 mean JJ B-NP O
6 367 370 19234905 age NN I-NP O
7 370 371 19234905 , , O O
8 372 376 19234905 58.4 CD B-NP O
9 377 378 19234905 + SYM O O
10 378 379 19234905 / SYM O O
11 379 380 19234905 - SYM O O
12 381 384 19234905 6.8 CD B-NP O
13 385 390 19234905 years NNS I-NP O
14 390 391 19234905 ; : O O
15 392 393 19234905 7 CD B-NP O
16 394 397 19234905 men NNS I-NP O
17 397 398 19234905 , , O O
18 399 400 19234905 3 CD B-NP O
19 401 406 19234905 women NNS I-NP O
20 406 407 19234905 ) ) O O
21 408 412 19234905 with IN B-PP O
22 413 420 19234905 similar JJ B-NP O
23 421 436 19234905 characteristics NNS I-NP O
24 437 439 19234905 at IN B-PP O
25 440 443 19234905 the DT B-NP O
26 444 452 19234905 duration NN I-NP O
27 453 455 19234905 of IN B-PP O
28 456 463 19234905 disease NN B-NP O
29 464 465 19234905 ( ( O O
30 465 469 19234905 mean JJ B-NP O
31 470 477 19234905 disease NN I-NP O
32 478 482 19234905 time NN I-NP O
33 482 483 19234905 , , O O
34 484 487 19234905 8.4 CD B-NP O
35 488 489 19234905 + SYM O O
36 489 490 19234905 / SYM O O
37 490 491 19234905 - SYM O O
38 492 495 19234905 3.5 CD B-NP O
39 496 501 19234905 years NNS I-NP O
40 501 502 19234905 ) ) O O
41 502 503 19234905 , , O O
42 504 513 19234905 disabling VBG B-VP O
43 514 519 19234905 motor NN B-NP O
44 520 532 19234905 fluctuations NNS I-NP O
45 533 534 19234905 ( ( O O
46 534 539 19234905 Hoehn NNP B-NP O
47 540 541 19234905 _ NNP I-NP O
48 542 546 19234905 Yahr NNP I-NP O
49 547 552 19234905 stage NN I-NP O
50 553 554 19234905 3 CD I-NP O
51 554 555 19234905 - HYPH B-NP O
52 555 556 19234905 5 CD I-NP O
53 557 559 19234905 in IN B-PP O
54 560 563 19234905 off JJ B-NP O
55 563 564 19234905 - HYPH I-NP O
56 564 568 19234905 drug NN I-NP O
57 569 575 19234905 phases NNS I-NP O
58 575 576 19234905 ) ) O O
59 577 580 19234905 and CC O O
60 581 589 19234905 levodopa NN B-NP D007980
61 589 590 19234905 - HYPH B-NP O
62 590 597 19234905 induced VBN I-NP O
63 598 609 19234905 dyskinesias NNS I-NP D004409
64 610 614 19234905 were VBD B-VP O
65 615 623 19234905 selected VBN I-VP O
66 623 624 19234905 . . O O

1 625 628 19234905 All DT B-NP O
2 629 637 19234905 patients NNS I-NP O
3 638 641 19234905 had VBD B-VP O
4 642 651 19234905 bilateral JJ B-NP O
5 652 660 19234905 symptoms NNS I-NP O
6 661 664 19234905 and CC O O
7 665 670 19234905 their PRP$ B-NP O
8 671 679 19234905 levodopa NN I-NP D007980
9 680 690 19234905 equivalent JJ I-NP O
10 691 697 19234905 dosing NN I-NP O
11 698 702 19234905 were VBD B-VP O
12 703 711 19234905 analysed VBN I-VP O
13 711 712 19234905 . . O O

1 713 716 19234905 Six CD B-NP O
2 717 725 19234905 patients NNS I-NP O
3 726 730 19234905 were VBD B-VP O
4 731 739 19234905 operated VBN I-VP O
5 740 742 19234905 on RP B-PRT O
6 743 745 19234905 in IN B-PP O
7 746 749 19234905 the DT B-NP O
8 750 756 19234905 globus NN I-NP O
9 757 765 19234905 pallidus NN I-NP O
10 766 773 19234905 interna NN I-NP O
11 774 775 19234905 ( ( O O
12 775 778 19234905 GPi NN B-NP O
13 778 779 19234905 ) ) O O
14 780 783 19234905 and CC O O
15 784 788 19234905 four CD B-NP O
16 789 791 19234905 in IN B-PP O
17 792 795 19234905 the DT B-NP O
18 796 807 19234905 subthalamic JJ I-NP O
19 808 815 19234905 nucleus NN I-NP O
20 816 817 19234905 ( ( O O
21 817 820 19234905 STN NN B-NP O
22 820 821 19234905 ) ) O O
23 821 822 19234905 . . O O

1 823 831 19234905 Clinical JJ B-NP O
2 832 842 19234905 evaluation NN I-NP O
3 843 851 19234905 included VBD B-VP O
4 852 855 19234905 the DT B-NP O
5 856 859 19234905 use NN I-NP O
6 860 862 19234905 of IN B-PP O
7 863 866 19234905 the DT B-NP O
8 867 874 19234905 Unified NNP I-NP O
9 875 886 19234905 Parkinson's NNP I-NP D010300
10 887 894 19234905 Disease NNP I-NP D010300
11 895 901 19234905 Rating NNP I-NP O
12 902 907 19234905 Scale NNP I-NP O
13 908 909 19234905 ( ( O O
14 909 914 19234905 UPDRS NNP B-NP O
15 914 915 19234905 ) ) O O
16 915 916 19234905 , , O O
17 917 927 19234905 Hoehn_Yahr NN B-NP O
18 928 933 19234905 score NN I-NP O
19 934 937 19234905 and CC O O
20 938 944 19234905 Schwab NNP B-NP O
21 945 952 19234905 England NNP I-NP O
22 953 963 19234905 activities NNS I-NP O
23 964 966 19234905 of IN B-PP O
24 967 972 19234905 daily JJ B-NP O
25 973 979 19234905 living NN I-NP O
26 980 981 19234905 ( ( O O
27 981 984 19234905 ADL NN B-NP O
28 984 985 19234905 ) ) O O
29 986 991 19234905 score NN B-NP O
30 992 994 19234905 in IN B-PP O
31 995 996 19234905 ' '' O O
32 996 998 19234905 on IN B-PP O
33 998 999 19234905 ' SYM B-NP O
34 999 1000 19234905 - HYPH I-NP O
35 1001 1004 19234905 and CC I-NP O
36 1005 1006 19234905 ' `` I-NP O
37 1006 1010 19234905 off' JJ I-NP O
38 1010 1011 19234905 - HYPH I-NP O
39 1011 1015 19234905 drug NN I-NP O
40 1016 1026 19234905 conditions NNS I-NP O
41 1027 1033 19234905 before IN B-PP O
42 1034 1041 19234905 surgery NN B-NP O
43 1042 1045 19234905 and CC O O
44 1046 1047 19234905 6 CD B-NP O
45 1048 1054 19234905 months NNS I-NP O
46 1055 1060 19234905 after IN B-PP O
47 1061 1068 19234905 surgery NN B-NP O
48 1068 1069 19234905 . . O O

1 1070 1075 19234905 There EX B-NP O
2 1076 1079 19234905 was VBD B-VP O
3 1080 1093 19234905 statistically RB B-NP O
4 1094 1105 19234905 significant JJ I-NP O
5 1106 1117 19234905 improvement NN I-NP O
6 1118 1120 19234905 in IN B-PP O
7 1121 1124 19234905 all DT B-NP O
8 1125 1138 19234905 contralateral JJ I-NP O
9 1139 1144 19234905 major JJ I-NP O
10 1145 1157 19234905 parkinsonian JJ I-NP D010300
11 1158 1163 19234905 motor NN I-NP O
12 1164 1169 19234905 signs NNS I-NP O
13 1170 1172 19234905 in IN B-PP O
14 1173 1176 19234905 all DT B-NP O
15 1177 1185 19234905 patients NNS I-NP O
16 1186 1194 19234905 followed VBN B-VP O
17 1195 1198 19234905 for IN B-PP O
18 1199 1200 19234905 6 CD B-NP O
19 1201 1207 19234905 months NNS I-NP O
20 1207 1208 19234905 . . O O

1 1209 1217 19234905 Levodopa NN B-NP D007980
2 1218 1228 19234905 equivalent JJ I-NP O
3 1229 1234 19234905 daily JJ I-NP O
4 1235 1241 19234905 intake NN I-NP O
5 1242 1245 19234905 was VBD B-VP O
6 1246 1259 19234905 significantly RB I-VP O
7 1260 1267 19234905 reduced VBN I-VP O
8 1268 1270 19234905 in IN B-PP O
9 1271 1274 19234905 the DT B-NP O
10 1275 1278 19234905 STN NN I-NP O
11 1279 1284 19234905 group NN I-NP O
12 1284 1285 19234905 . . O O

1 1286 1293 19234905 Changes NNS B-NP O
2 1294 1296 19234905 in IN B-PP O
3 1297 1302 19234905 UPDRS NNP B-NP O
4 1302 1303 19234905 , , O O
5 1304 1309 19234905 Hoehn NNP B-NP O
6 1310 1311 19234905 _ NNP I-NP O
7 1312 1316 19234905 Yahr NNP I-NP O
8 1317 1320 19234905 and CC O O
9 1321 1327 19234905 Schwab NNP B-NP O
10 1328 1335 19234905 England NNP I-NP O
11 1336 1339 19234905 ADL NNP I-NP O
12 1340 1346 19234905 scores NNS I-NP O
13 1347 1351 19234905 were VBD B-VP O
14 1352 1359 19234905 similar JJ B-ADJP O
15 1360 1362 19234905 in IN B-PP O
16 1363 1367 19234905 both DT B-NP O
17 1368 1374 19234905 groups NNS I-NP O
18 1374 1375 19234905 . . O O

1 1376 1385 19234905 Cognitive JJ B-NP O
2 1386 1395 19234905 functions NNS I-NP O
3 1396 1400 19234905 were VBD B-VP O
4 1401 1410 19234905 unchanged JJ B-ADJP O
5 1411 1413 19234905 in IN B-PP O
6 1414 1418 19234905 both DT B-NP O
7 1419 1425 19234905 groups NNS I-NP O
8 1425 1426 19234905 . . O O

1 1427 1440 19234905 Complications NNS B-NP O
2 1441 1445 19234905 were VBD B-VP O
3 1446 1454 19234905 observed VBN I-VP O
4 1455 1457 19234905 in IN B-PP O
5 1458 1461 19234905 two CD B-NP O
6 1462 1470 19234905 patients NNS I-NP O
7 1470 1471 19234905 : : O O
8 1472 1475 19234905 one CD B-NP O
9 1476 1479 19234905 had VBD B-VP O
10 1480 1481 19234905 a DT B-NP O
11 1482 1486 19234905 left JJ I-NP O
12 1487 1497 19234905 homonymous JJ I-NP D006423
13 1498 1509 19234905 hemianopsia NN I-NP D006423
14 1510 1515 19234905 after IN B-PP O
15 1516 1527 19234905 pallidotomy NN B-NP O
16 1528 1531 19234905 and CC O O
17 1532 1539 19234905 another DT B-NP O
18 1540 1543 19234905 one CD I-NP O
19 1544 1553 19234905 developed VBN B-VP O
20 1554 1558 19234905 left VBD B-VP O
21 1559 1572 19234905 hemiballistic JJ B-NP O
22 1573 1582 19234905 movements NNS I-NP O
23 1583 1584 19234905 3 CD B-NP O
24 1585 1589 19234905 days NNS I-NP O
25 1590 1595 19234905 after IN B-PP O
26 1596 1610 19234905 subthalamotomy NN B-NP O
27 1611 1616 19234905 which WDT B-NP O
28 1617 1623 19234905 partly RB B-ADVP O
29 1624 1632 19234905 improved VBD B-VP O
30 1633 1639 19234905 within IN B-PP O
31 1640 1641 19234905 1 CD B-NP O
32 1642 1647 19234905 month NN I-NP O
33 1648 1652 19234905 with IN B-PP O
34 1653 1662 19234905 Valproate NN B-NP D014635
35 1663 1667 19234905 1000 CD I-NP O
36 1668 1670 19234905 mg NN I-NP O
37 1670 1671 19234905 / SYM B-NP O
38 1671 1674 19234905 day NN I-NP O
39 1674 1675 19234905 . . O O

1 1676 1679 19234905 The DT B-NP O
2 1680 1688 19234905 findings NNS I-NP O
3 1689 1691 19234905 of IN B-PP O
4 1692 1696 19234905 this DT B-NP O
5 1697 1702 19234905 study NN I-NP O
6 1703 1710 19234905 suggest VBP B-VP O
7 1711 1715 19234905 that IN B-SBAR O
8 1716 1723 19234905 lesions NNS B-NP O
9 1724 1726 19234905 of IN B-PP O
10 1727 1730 19234905 the DT B-NP O
11 1731 1741 19234905 unilateral JJ I-NP O
12 1742 1745 19234905 STN NN I-NP O
13 1746 1749 19234905 and CC I-NP O
14 1750 1753 19234905 GPi NN I-NP O
15 1754 1757 19234905 are VBP B-VP O
16 1758 1765 19234905 equally RB B-NP O
17 1766 1775 19234905 effective JJ I-NP O
18 1776 1785 19234905 treatment NN I-NP O
19 1786 1789 19234905 for IN B-PP O
20 1790 1798 19234905 patients NNS B-NP O
21 1799 1803 19234905 with IN B-PP O
22 1804 1812 19234905 advanced JJ B-NP O
23 1813 1815 19234905 PD NN I-NP D010300
24 1816 1826 19234905 refractory JJ B-ADJP O
25 1827 1829 19234905 to TO B-PP O
26 1830 1837 19234905 medical JJ B-NP O
27 1838 1847 19234905 treatment NN I-NP O
28 1847 1848 19234905 . . O O

1 0 0 1535072 -DOCSTART- -X- -X- O

1 0 9 1535072 Yohimbine NN B-NP D015016
2 10 19 1535072 treatment NN I-NP O
3 20 22 1535072 of IN B-PP O
4 23 29 1535072 sexual JJ B-NP D020018
5 30 34 1535072 side NN I-NP D020018
6 35 42 1535072 effects NNS I-NP D020018
7 43 50 1535072 induced VBN B-VP O
8 51 53 1535072 by IN B-PP O
9 54 63 1535072 serotonin NN B-NP D012701
10 64 72 1535072 reuptake NN I-NP O
11 73 81 1535072 blockers NNS I-NP O
12 81 82 1535072 . . O O
13 83 93 1535072 BACKGROUND NN B-NP O
14 93 94 1535072 : : O O
15 95 106 1535072 Preclinical JJ B-NP O
16 107 110 1535072 and CC I-NP O
17 111 119 1535072 clinical JJ I-NP O
18 120 127 1535072 studies NNS I-NP O
19 128 135 1535072 suggest VBP B-VP O
20 136 140 1535072 that IN B-SBAR O
21 141 150 1535072 yohimbine PRP B-NP D015016
22 151 162 1535072 facilitates VBZ B-VP O
23 163 169 1535072 sexual JJ B-NP O
24 170 178 1535072 behavior NN I-NP O
25 179 182 1535072 and CC O O
26 183 186 1535072 may MD B-VP O
27 187 189 1535072 be VB I-VP O
28 190 197 1535072 helpful JJ B-ADJP O
29 198 200 1535072 in IN B-PP O
30 201 204 1535072 the DT B-NP O
31 205 214 1535072 treatment NN I-NP O
32 215 217 1535072 of IN B-PP O
33 218 222 1535072 male JJ B-NP D007172
34 223 232 1535072 impotence NN I-NP D007172
35 232 233 1535072 . . O O

1 234 235 1535072 A DT B-NP O
2 236 242 1535072 single JJ I-NP O
3 243 247 1535072 case NN I-NP O
4 248 254 1535072 report NN I-NP O
5 255 263 1535072 suggests VBZ B-VP O
6 264 268 1535072 that IN B-SBAR O
7 269 278 1535072 yohimbine PRP B-NP D015016
8 279 282 1535072 may MD B-VP O
9 283 285 1535072 be VB I-VP O
10 286 290 1535072 used VBN I-VP O
11 291 293 1535072 to TO B-VP O
12 294 299 1535072 treat VB I-VP O
13 300 303 1535072 the DT B-NP O
14 304 310 1535072 sexual JJ I-NP D020018
15 311 315 1535072 side NN I-NP D020018
16 316 323 1535072 effects NNS I-NP D020018
17 324 326 1535072 of IN B-PP O
18 327 339 1535072 clomipramine NN B-NP D002997
19 339 340 1535072 . . O O

1 341 345 1535072 This DT B-NP O
2 346 351 1535072 study NN I-NP O
3 352 361 1535072 evaluated VBD B-VP O
4 362 371 1535072 yohimbine PRP B-NP D015016
5 372 374 1535072 as IN B-PP O
6 375 376 1535072 a DT B-NP O
7 377 386 1535072 treatment NN I-NP O
8 387 390 1535072 for IN B-PP O
9 391 394 1535072 the DT B-NP O
10 395 401 1535072 sexual JJ I-NP D020018
11 402 406 1535072 side NN I-NP D020018
12 407 414 1535072 effects NNS I-NP D020018
13 415 421 1535072 caused VBN B-VP O
14 422 424 1535072 by IN B-PP O
15 425 434 1535072 serotonin NN B-NP D012701
16 435 443 1535072 reuptake NN I-NP O
17 444 452 1535072 blockers NNS I-NP O
18 452 453 1535072 . . O O

1 454 460 1535072 METHOD NN B-NP O
2 460 461 1535072 : : O O
3 462 465 1535072 Six CD B-NP O
4 466 474 1535072 patients NNS I-NP O
5 475 479 1535072 with IN B-PP O
6 480 486 1535072 either CC B-NP O
7 487 496 1535072 obsessive JJ I-NP D009771
8 497 507 1535072 compulsive JJ I-NP D009771
9 508 516 1535072 disorder NN I-NP D009771
10 516 517 1535072 , , O O
11 518 534 1535072 trichotillomania NN B-NP D014256
12 534 535 1535072 , , O O
13 536 543 1535072 anxiety NN B-NP D001008
14 543 544 1535072 , , O O
15 545 547 1535072 or CC O O
16 548 557 1535072 affective JJ B-NP D019964
17 558 567 1535072 disorders NNS I-NP D019964
18 568 571 1535072 who WP B-NP O
19 572 580 1535072 suffered VBD B-VP O
20 581 587 1535072 sexual JJ B-NP D020018
21 588 592 1535072 side NN I-NP D020018
22 593 600 1535072 effects NNS I-NP D020018
23 601 606 1535072 after IN B-PP O
24 607 616 1535072 treatment NN B-NP O
25 617 621 1535072 with IN B-PP O
26 622 631 1535072 serotonin NN B-NP D012701
27 632 640 1535072 reuptake NN I-NP O
28 641 649 1535072 blockers NNS I-NP O
29 650 654 1535072 were VBD B-VP O
30 655 660 1535072 given VBN I-VP O
31 661 670 1535072 yohimbine NN B-NP D015016
32 671 673 1535072 on IN B-PP O
33 674 675 1535072 a DT B-NP O
34 676 681 1535072 p.r.n NN I-NP O
35 681 682 1535072 . . O O

1 683 688 1535072 basis NN B-NP O
2 689 691 1535072 in IN B-PP O
3 692 694 1535072 an DT B-NP O
4 695 699 1535072 open JJ I-NP O
5 700 708 1535072 clinical JJ I-NP O
6 709 714 1535072 trial NN I-NP O
7 714 715 1535072 . . O O

1 716 723 1535072 Various JJ B-NP O
2 724 729 1535072 doses NNS I-NP O
3 730 732 1535072 of IN B-PP O
4 733 742 1535072 yohimbine NN B-NP D015016
5 743 747 1535072 were VBD B-VP O
6 748 752 1535072 used VBN I-VP O
7 753 755 1535072 to TO B-VP O
8 756 765 1535072 determine VB I-VP O
9 766 769 1535072 the DT B-NP O
10 770 775 1535072 ideal JJ I-NP O
11 776 780 1535072 dose NN I-NP O
12 781 784 1535072 for IN B-PP O
13 785 789 1535072 each DT B-NP O
14 790 797 1535072 patient NN I-NP O
15 797 798 1535072 . . O O

1 799 806 1535072 RESULTS NNS B-NP O
2 806 807 1535072 : : O O
3 808 812 1535072 Five CD B-NP O
4 813 815 1535072 of IN B-PP O
5 816 819 1535072 the DT B-NP O
6 820 823 1535072 six CD I-NP O
7 824 832 1535072 patients NNS I-NP O
8 833 844 1535072 experienced VBD B-VP O
9 845 853 1535072 improved VBN I-VP O
10 854 860 1535072 sexual JJ B-NP O
11 861 872 1535072 functioning VBG I-NP O
12 873 878 1535072 after IN B-PP O
13 879 885 1535072 taking VBG B-VP O
14 886 895 1535072 yohimbine NN B-NP D015016
15 895 896 1535072 . . O O

1 897 900 1535072 One CD B-NP O
2 901 908 1535072 patient NN I-NP O
3 909 912 1535072 who WP B-NP O
4 913 919 1535072 failed VBD B-VP O
5 920 922 1535072 to TO I-VP O
6 923 929 1535072 comply VB I-VP O
7 930 934 1535072 with IN B-PP O
8 935 944 1535072 yohimbine NN B-NP D015016
9 945 954 1535072 treatment NN I-NP O
10 955 958 1535072 had VBD B-VP O
11 959 961 1535072 no DT B-NP O
12 962 973 1535072 therapeutic JJ I-NP O
13 974 981 1535072 effects NNS I-NP O
14 981 982 1535072 . . O O

1 983 987 1535072 Side NN B-NP O
2 988 995 1535072 effects NNS I-NP O
3 996 998 1535072 of IN B-PP O
4 999 1008 1535072 yohimbine NN B-NP D015016
5 1009 1017 1535072 included VBD B-VP O
6 1018 1027 1535072 excessive JJ B-NP O
7 1028 1036 1535072 sweating NN I-NP O
8 1036 1037 1535072 , , O O
9 1038 1047 1535072 increased VBN B-NP O
10 1048 1055 1535072 anxiety NN I-NP D001008
11 1055 1056 1535072 , , O O
12 1057 1060 1535072 and CC O O
13 1061 1062 1535072 a DT B-NP O
14 1063 1068 1535072 wound VB I-NP O
15 1068 1069 1535072 - HYPH O O
16 1069 1071 1535072 up RP B-PRT O
17 1072 1079 1535072 feeling NN B-NP O
18 1080 1082 1535072 in IN B-PP O
19 1083 1087 1535072 some DT B-NP O
20 1088 1096 1535072 patients NNS I-NP O
21 1096 1097 1535072 . . O O

1 1098 1108 1535072 CONCLUSION NN B-NP O
2 1108 1109 1535072 : : O O
3 1110 1113 1535072 The DT B-NP O
4 1114 1121 1535072 results NNS I-NP O
5 1122 1124 1535072 of IN B-PP O
6 1125 1129 1535072 this DT B-NP O
7 1130 1135 1535072 study NN I-NP O
8 1136 1144 1535072 indicate VBP B-VP O
9 1145 1149 1535072 that IN B-SBAR O
10 1150 1159 1535072 yohimbine PRP B-NP D015016
11 1160 1163 1535072 may MD B-VP O
12 1164 1166 1535072 be VB I-VP O
13 1167 1169 1535072 an DT B-NP O
14 1170 1179 1535072 effective JJ I-NP O
15 1180 1189 1535072 treatment NN I-NP O
16 1190 1193 1535072 for IN B-PP O
17 1194 1197 1535072 the DT B-NP O
18 1198 1204 1535072 sexual JJ I-NP D020018
19 1205 1209 1535072 side NN I-NP D020018
20 1210 1217 1535072 effects NNS I-NP D020018
21 1218 1224 1535072 caused VBN B-VP O
22 1225 1227 1535072 by IN B-PP O
23 1228 1237 1535072 serotonin NN B-NP D012701
24 1238 1246 1535072 reuptake NN I-NP O
25 1247 1255 1535072 blockers NNS I-NP O
26 1255 1256 1535072 . . O O

1 1257 1263 1535072 Future JJ B-NP O
2 1264 1274 1535072 controlled JJ I-NP O
3 1275 1282 1535072 studies NNS I-NP O
4 1283 1286 1535072 are VBP B-VP O
5 1287 1293 1535072 needed VBN I-VP O
6 1294 1296 1535072 to TO B-VP O
7 1297 1304 1535072 further RB I-VP O
8 1305 1316 1535072 investigate VB I-VP O
9 1317 1320 1535072 the DT B-NP O
10 1321 1334 1535072 effectiveness NN I-NP O
11 1335 1338 1535072 and CC I-NP O
12 1339 1345 1535072 safety NN I-NP O
13 1346 1348 1535072 of IN B-PP O
14 1349 1358 1535072 yohimbine NN B-NP D015016
15 1359 1362 1535072 for IN B-PP O
16 1363 1367 1535072 this DT B-NP O
17 1368 1378 1535072 indication NN I-NP O
18 1378 1379 1535072 . . O O

1 0 0 9758264 -DOCSTART- -X- -X- O

1 0 13 9758264 Epileptogenic JJ B-NP O
2 14 22 9758264 activity NN I-NP O
3 23 25 9758264 of IN B-PP O
4 26 31 9758264 folic JJ B-NP D005492
5 32 36 9758264 acid NN I-NP D005492
6 37 42 9758264 after IN B-SBAR O
7 43 47 9758264 drug NN B-NP O
8 48 55 9758264 induces VBZ B-VP O
9 56 59 9758264 SLE NN B-NP D008180
10 60 61 9758264 ( ( O O
11 61 66 9758264 folic JJ B-NP D005492
12 67 71 9758264 acid NN I-NP D005492
13 72 75 9758264 and CC O O
14 76 84 9758264 epilepsy NN B-NP D004827
15 84 85 9758264 ) ) O O
16 86 95 9758264 OBJECTIVE NN B-NP O
17 95 96 9758264 : : O O
18 97 99 9758264 To TO B-VP O
19 100 105 9758264 study VB I-VP O
20 106 109 9758264 the DT B-NP O
21 110 116 9758264 effect NN I-NP O
22 117 119 9758264 of IN B-PP O
23 120 125 9758264 folic JJ B-NP D005492
24 126 130 9758264 acid NN I-NP D005492
25 130 131 9758264 - HYPH O O
26 131 141 9758264 containing VBG B-VP O
27 142 154 9758264 multivitamin NN B-NP O
28 155 170 9758264 supplementation NN I-NP O
29 171 173 9758264 in IN B-PP O
30 174 183 9758264 epileptic JJ B-NP D004827
31 184 189 9758264 women NNS I-NP O
32 190 196 9758264 before IN B-PP O
33 197 200 9758264 and CC I-PP O
34 201 207 9758264 during IN I-PP O
35 208 217 9758264 pregnancy NN B-NP O
36 218 220 9758264 in IN B-SBAR O
37 221 226 9758264 order NN O O
38 227 229 9758264 to TO B-VP O
39 230 239 9758264 determine VB I-VP O
40 240 243 9758264 the DT B-NP O
41 244 248 9758264 rate NN I-NP O
42 249 251 9758264 of IN B-PP O
43 252 262 9758264 structural JJ B-NP O
44 263 268 9758264 birth NN I-NP D000014
45 269 276 9758264 defects NNS I-NP D000014
46 277 280 9758264 and CC I-NP O
47 281 289 9758264 epilepsy NN I-NP D004827
48 289 290 9758264 - HYPH O O
49 290 297 9758264 related VBN B-NP O
50 298 302 9758264 side NN I-NP O
51 303 310 9758264 effects NNS I-NP O
52 310 311 9758264 . . O O

1 312 317 9758264 STUDY NN B-NP O
2 318 324 9758264 DESIGN NN I-NP O
3 324 325 9758264 : : O O
4 326 331 9758264 First RB B-NP O
5 332 333 9758264 a DT I-NP O
6 334 344 9758264 randomised VBN I-NP O
7 345 350 9758264 trial NN I-NP O
8 350 351 9758264 , , O O
9 352 357 9758264 later JJ B-NP O
10 358 372 9758264 periconception NN I-NP O
11 373 377 9758264 care NN I-NP O
12 378 387 9758264 including VBG B-PP O
13 388 390 9758264 in IN B-PP O
14 391 396 9758264 total JJ B-NP O
15 397 402 9758264 12225 CD I-NP O
16 403 410 9758264 females NNS I-NP O
17 410 411 9758264 . . O O

1 412 419 9758264 RESULTS NNS B-NP O
2 419 420 9758264 : : O O
3 421 423 9758264 Of IN B-PP O
4 424 426 9758264 60 CD B-NP O
5 427 436 9758264 epileptic JJ I-NP D004827
6 437 442 9758264 women NNS I-NP O
7 443 447 9758264 with IN B-PP O
8 448 464 9758264 periconceptional JJ B-NP O
9 465 470 9758264 folic JJ I-NP D005492
10 471 475 9758264 acid NN I-NP D005492
11 476 477 9758264 ( ( O O
12 477 480 9758264 0.8 CD B-NP O
13 481 483 9758264 mg NN I-NP O
14 483 484 9758264 ) ) O O
15 484 485 9758264 - HYPH O O
16 485 495 9758264 containing VBG B-VP O
17 496 508 9758264 multivitamin NN B-NP O
18 509 524 9758264 supplementation NN I-NP O
19 524 525 9758264 , , O O
20 526 528 9758264 no DT B-NP O
21 529 532 9758264 one NN I-NP O
22 533 542 9758264 developed VBD B-VP O
23 543 551 9758264 epilepsy NN B-NP D004827
24 551 552 9758264 - HYPH B-PP O
25 552 559 9758264 related VBN B-NP O
26 560 564 9758264 side NN I-NP O
27 565 572 9758264 effects NNS I-NP O
28 573 579 9758264 during IN B-PP O
29 580 583 9758264 the DT B-NP O
30 584 598 9758264 periconception NN I-NP O
31 599 605 9758264 period NN I-NP O
32 605 606 9758264 . . O O

1 607 610 9758264 One CD B-NP O
2 611 620 9758264 epileptic JJ I-NP D004827
3 621 626 9758264 woman NN I-NP O
4 627 636 9758264 delivered VBD B-VP O
5 637 638 9758264 a DT B-NP O
6 639 646 9758264 newborn NN I-NP O
7 647 651 9758264 with IN B-PP O
8 652 657 9758264 cleft NN B-NP D002971
9 658 661 9758264 lip NN I-NP D002971
10 662 665 9758264 and CC I-NP D002971
11 666 672 9758264 palate NN I-NP D002971
12 672 673 9758264 . . O O

1 674 681 9758264 Another DT B-NP O
2 682 689 9758264 patient NN I-NP O
3 690 699 9758264 exhibited VBD B-VP O
4 700 704 9758264 with IN B-PP O
5 705 706 9758264 a DT B-NP O
6 707 714 9758264 cluster NN I-NP O
7 715 717 9758264 of IN B-PP O
8 718 726 9758264 seizures NNS B-NP D012640
9 727 732 9758264 after IN B-PP O
10 733 736 9758264 the DT B-NP O
11 737 751 9758264 periconception NN I-NP O
12 752 758 9758264 period NN I-NP O
13 759 764 9758264 using VBG B-VP O
14 765 772 9758264 another DT B-NP O
15 773 785 9758264 multivitamin NN I-NP O
16 785 786 9758264 . . O O

1 787 791 9758264 This DT B-NP O
2 792 794 9758264 22 CD I-NP O
3 794 795 9758264 - HYPH I-NP O
4 795 799 9758264 year NN I-NP O
5 799 800 9758264 - HYPH O O
6 800 803 9758264 old JJ B-NP O
7 804 813 9758264 epileptic JJ I-NP D004827
8 814 819 9758264 woman NN I-NP O
9 820 823 9758264 was VBD B-VP O
10 824 831 9758264 treated VBN I-VP O
11 832 844 9758264 continuously RB B-ADVP O
12 845 847 9758264 by IN B-PP O
13 848 861 9758264 carbamazepine NN B-NP D002220
14 862 865 9758264 and CC O O
15 866 867 9758264 a DT B-NP O
16 868 873 9758264 folic JJ I-NP D005492
17 874 878 9758264 acid NN I-NP D005492
18 879 880 9758264 ( ( O O
19 880 881 9758264 1 CD B-NP O
20 882 884 9758264 mg NN I-NP O
21 884 885 9758264 ) ) O O
22 885 886 9758264 - HYPH O O
23 886 896 9758264 containing VBG B-VP O
24 897 909 9758264 multivitamin NN B-NP O
25 910 914 9758264 from IN B-PP O
26 915 918 9758264 the DT B-NP O
27 919 923 9758264 20th JJ I-NP O
28 924 928 9758264 week NN I-NP O
29 929 931 9758264 of IN B-PP O
30 932 941 9758264 gestation NN B-NP O
31 941 942 9758264 . . O O

1 943 946 9758264 She PRP B-NP O
2 947 956 9758264 developed VBD B-VP O
3 957 963 9758264 status NN B-NP D013226
4 964 975 9758264 epilepticus NN I-NP D013226
5 976 979 9758264 and CC O O
6 980 985 9758264 later JJ B-NP O
7 986 994 9758264 symptoms NNS I-NP O
8 995 997 9758264 of IN B-PP O
9 998 1006 9758264 systemic JJ B-NP D008180
10 1007 1012 9758264 lupus NN I-NP D008180
11 1013 1026 9758264 erythematodes NNS I-NP D008180
12 1026 1027 9758264 . . O O

1 1028 1031 9758264 Her PRP$ B-NP O
2 1032 1041 9758264 pregnancy NN I-NP O
3 1042 1047 9758264 ended VBD B-VP O
4 1048 1052 9758264 with IN B-PP O
5 1053 1063 9758264 stillbirth NN B-NP D050497
6 1063 1064 9758264 . . O O

1 1065 1076 9758264 CONCLUSIONS NNS B-NP O
2 1076 1077 9758264 : : O O
3 1078 1081 9758264 The DT B-NP O
4 1082 1091 9758264 epileptic JJ I-NP D004827
5 1092 1100 9758264 pregnant JJ I-NP O
6 1101 1110 9758264 patient's NNS I-NP O
7 1111 1121 9758264 autoimmune JJ B-NP D001327
8 1122 1129 9758264 disease NN I-NP D001327
9 1130 1131 9758264 ( ( O O
10 1131 1139 9758264 probably RB B-ADVP O
11 1140 1144 9758264 drug NN B-NP O
12 1144 1145 9758264 - HYPH B-NP O
13 1145 1152 9758264 induced VBN I-NP O
14 1153 1158 9758264 lupus NN I-NP D008180
15 1158 1159 9758264 ) ) O O
16 1160 1165 9758264 could MD B-VP O
17 1166 1172 9758264 damage VB I-VP O
18 1173 1176 9758264 the DT B-NP O
19 1177 1182 9758264 blood NN I-NP O
20 1182 1183 9758264 - HYPH I-NP O
21 1183 1188 9758264 brain NN I-NP O
22 1189 1196 9758264 barrier NN I-NP O
23 1196 1197 9758264 , , O O
24 1198 1207 9758264 therefore RB B-ADVP O
25 1208 1211 9758264 the DT B-NP O
26 1212 1223 9758264 therapeutic JJ I-NP O
27 1224 1228 9758264 dose NN I-NP O
28 1229 1230 9758264 ( ( O O
29 1230 1231 9758264 > SYM B-NP O
30 1232 1234 9758264 or CC O O
31 1235 1236 9758264 = SYM B-VP O
32 1236 1237 9758264 1 CD B-NP O
33 1238 1240 9758264 mg NN I-NP O
34 1240 1241 9758264 ) ) O O
35 1242 1244 9758264 of IN B-PP O
36 1245 1250 9758264 folic JJ B-NP D005492
37 1251 1255 9758264 acid NN I-NP D005492
38 1256 1265 9758264 triggered VBD B-VP O
39 1266 1267 9758264 a DT B-NP O
40 1268 1275 9758264 cluster NN I-NP O
41 1276 1278 9758264 of IN B-PP O
42 1279 1287 9758264 seizures NNS B-NP D012640
43 1287 1288 9758264 . . O O

1 1289 1302 9758264 Physiological JJ B-NP O
2 1303 1307 9758264 dose NN I-NP O
3 1308 1309 9758264 ( ( O O
4 1309 1310 9758264 < SYM B-NP O
5 1310 1311 9758264 1 CD I-NP O
6 1312 1314 9758264 mg NN I-NP O
7 1314 1315 9758264 ) ) O O
8 1316 1318 9758264 of IN B-PP O
9 1319 1324 9758264 folic JJ B-NP D005492
10 1325 1329 9758264 acid NN I-NP D005492
11 1330 1334 9758264 both CC B-PP O
12 1335 1337 9758264 in IN B-PP O
13 1338 1345 9758264 healthy JJ B-ADJP O
14 1346 1349 9758264 and CC O O
15 1350 1352 9758264 60 CD B-NP O
16 1353 1362 9758264 epileptic JJ I-NP D004827
17 1363 1368 9758264 women NNS I-NP O
18 1368 1369 9758264 , , O O
19 1370 1373 9758264 all DT B-NP O
20 1374 1381 9758264 without IN B-PP O
21 1382 1385 9758264 any DT B-NP O
22 1386 1396 9758264 autoimmune JJ I-NP D001327
23 1397 1404 9758264 disease NN I-NP D001327
24 1404 1405 9758264 , , O O
25 1406 1409 9758264 did VBD B-VP O
26 1410 1413 9758264 not RB I-VP O
27 1414 1422 9758264 increase VB I-VP O
28 1423 1426 9758264 the DT B-NP O
29 1427 1431 9758264 risk NN I-NP O
30 1432 1435 9758264 for IN B-PP O
31 1436 1445 9758264 epileptic JJ B-NP D004827
32 1446 1454 9758264 seizures NNS I-NP D004827
33 1454 1455 9758264 . . O O

1 0 0 11694026 -DOCSTART- -X- -X- O

1 0 12 11694026 Tolerability NN B-NP O
2 13 15 11694026 of IN B-PP O
3 16 26 11694026 nimesulide NN B-NP C012655
4 27 30 11694026 and CC I-NP O
5 31 42 11694026 paracetamol NN I-NP D000082
6 43 45 11694026 in IN B-PP O
7 46 54 11694026 patients NNS B-NP O
8 55 59 11694026 with IN B-PP O
9 60 65 11694026 NSAID NN B-NP D000894
10 65 66 11694026 - HYPH B-NP O
11 66 73 11694026 induced VBN I-NP O
12 74 83 11694026 urticaria NN I-NP D014581
13 83 84 11694026 / SYM B-NP O
14 84 94 11694026 angioedema NN I-NP D000799
15 94 95 11694026 . . O O
16 96 104 11694026 Previous JJ B-NP O
17 105 112 11694026 studies NNS I-NP O
18 113 122 11694026 evaluated VBD B-VP O
19 123 126 11694026 the DT B-NP O
20 127 136 11694026 tolerance NN I-NP O
21 137 139 11694026 of IN B-PP O
22 140 150 11694026 nimesulide NN B-NP C012655
23 151 154 11694026 and CC I-NP O
24 155 166 11694026 paracetamol NN I-NP D000082
25 167 169 11694026 in IN B-PP O
26 170 178 11694026 subjects NNS B-NP O
27 179 183 11694026 with IN B-PP O
28 184 193 11694026 cutaneous JJ B-NP O
29 193 194 11694026 , , I-NP O
30 195 206 11694026 respiratory JJ I-NP O
31 207 210 11694026 and CC I-NP O
32 211 224 11694026 anaphylactoid JJ I-NP O
33 225 234 11694026 reactions NNS I-NP O
34 235 242 11694026 induced VBN B-VP O
35 243 245 11694026 by IN B-PP O
36 246 258 11694026 nonsteroidal JJ B-NP D000894
37 259 263 11694026 anti AFX I-NP D000894
38 263 264 11694026 - HYPH I-NP D000894
39 264 276 11694026 inflammatory JJ I-NP D000894
40 277 282 11694026 drugs NNS I-NP D000894
41 283 284 11694026 ( ( O O
42 284 290 11694026 NSAIDs NNS B-NP D000894
43 290 291 11694026 ) ) O O
44 291 292 11694026 . . O O

1 293 295 11694026 In IN B-PP O
2 296 300 11694026 this DT B-NP O
3 301 306 11694026 study NN I-NP O
4 307 309 11694026 we PRP B-NP O
5 310 322 11694026 investigated VBD B-VP O
6 323 335 11694026 tolerability NN B-NP O
7 336 339 11694026 and CC I-NP O
8 340 351 11694026 reliability NN I-NP O
9 352 354 11694026 of IN B-PP O
10 355 365 11694026 nimesulide NN B-NP C012655
11 366 369 11694026 and CC I-NP O
12 370 381 11694026 paracetamol NN I-NP D000082
13 382 384 11694026 in IN B-PP O
14 385 386 11694026 a DT B-NP O
15 387 391 11694026 very RB I-NP O
16 392 397 11694026 large JJ I-NP O
17 398 404 11694026 number NN I-NP O
18 405 407 11694026 of IN B-PP O
19 408 416 11694026 patients NNS B-NP O
20 417 421 11694026 with IN B-PP O
21 422 424 11694026 an DT B-NP O
22 425 434 11694026 exclusive JJ I-NP O
23 435 439 11694026 well RB I-NP O
24 439 440 11694026 - HYPH I-NP O
25 440 450 11694026 documented VBN I-NP O
26 451 458 11694026 history NN I-NP O
27 459 461 11694026 of IN B-PP O
28 462 467 11694026 NSAID NN B-NP D000894
29 467 468 11694026 - HYPH B-NP O
30 468 475 11694026 induced VBN I-NP O
31 476 485 11694026 urticaria NN I-NP D014581
32 485 486 11694026 / SYM B-NP O
33 486 496 11694026 angioedema NN I-NP D000799
34 496 497 11694026 . . O O

1 498 509 11694026 Furthermore RB B-ADVP O
2 509 510 11694026 , , O O
3 511 513 11694026 we PRP B-NP O
4 514 523 11694026 evaluated VBD B-VP O
5 524 531 11694026 whether IN B-SBAR O
6 532 536 11694026 some DT B-NP O
7 537 544 11694026 factors NNS I-NP O
8 545 549 11694026 have VBP B-VP O
9 550 553 11694026 the DT B-NP O
10 554 563 11694026 potential NN I-NP O
11 564 566 11694026 to TO B-VP O
12 567 575 11694026 increase VB I-VP O
13 576 579 11694026 the DT B-NP O
14 580 584 11694026 risk NN I-NP O
15 585 587 11694026 of IN B-PP O
16 588 596 11694026 reaction NN B-NP O
17 597 599 11694026 to TO B-PP O
18 600 611 11694026 paracetamol NN B-NP D000082
19 612 615 11694026 and CC I-NP O
20 616 626 11694026 nimesulide NN I-NP C012655
21 626 627 11694026 . . O O

1 628 629 11694026 A DT B-NP O
2 630 636 11694026 single JJ I-NP O
3 636 637 11694026 - HYPH I-NP O
4 637 644 11694026 placebo NN I-NP O
5 644 645 11694026 - HYPH B-VP O
6 645 655 11694026 controlled VBN B-NP O
7 656 660 11694026 oral JJ I-NP O
8 661 670 11694026 challenge NN I-NP O
9 671 680 11694026 procedure NN I-NP O
10 681 685 11694026 with IN B-PP O
11 686 696 11694026 nimesulide NN B-NP C012655
12 697 699 11694026 or CC I-NP O
13 700 711 11694026 paracetamol NN I-NP D000082
14 712 715 11694026 was VBD B-VP O
15 716 723 11694026 applied VBN I-VP O
16 724 726 11694026 to TO B-PP O
17 727 730 11694026 829 CD B-NP O
18 731 739 11694026 patients NNS I-NP O
19 740 744 11694026 with IN B-PP O
20 745 746 11694026 a DT B-NP O
21 747 754 11694026 history NN I-NP O
22 755 757 11694026 of IN B-PP O
23 758 763 11694026 NSAID NN B-NP D000894
24 763 764 11694026 - HYPH B-NP O
25 764 771 11694026 induced VBN I-NP O
26 772 781 11694026 urticaria NN I-NP D014581
27 781 782 11694026 / SYM B-NP O
28 782 792 11694026 angioedema NN I-NP D000799
29 792 793 11694026 . . O O

1 794 795 11694026 A DT B-NP O
2 796 801 11694026 total NN I-NP O
3 802 804 11694026 of IN B-PP O
4 805 807 11694026 75 CD B-NP O
5 807 808 11694026 / SYM I-NP O
6 808 811 11694026 829 CD I-NP O
7 812 813 11694026 ( ( O O
8 813 817 11694026 9.4% CD B-NP O
9 817 818 11694026 ) ) O O
10 819 827 11694026 patients NNS B-NP O
11 828 839 11694026 experienced VBD B-VP O
12 840 849 11694026 reactions NNS B-NP O
13 850 852 11694026 to TO B-PP O
14 853 863 11694026 nimesulide NN B-NP C012655
15 864 866 11694026 or CC I-NP O
16 867 878 11694026 paracetamol NN I-NP D000082
17 878 879 11694026 . . O O

1 880 882 11694026 Of IN B-PP O
2 883 886 11694026 the DT B-NP O
3 887 890 11694026 715 CD I-NP O
4 891 899 11694026 patients NNS I-NP O
5 900 906 11694026 tested VBN B-VP O
6 907 911 11694026 with IN B-PP O
7 912 922 11694026 nimesulide NN B-NP C012655
8 923 925 11694026 62 CD I-NP O
9 926 927 11694026 ( ( O O
10 927 931 11694026 8.6% NN B-NP O
11 931 932 11694026 ) ) O O
12 933 939 11694026 showed VBD B-VP O
13 940 941 11694026 a DT B-NP O
14 942 950 11694026 positive JJ I-NP O
15 951 955 11694026 test NN I-NP O
16 955 956 11694026 , , O O
17 957 962 11694026 while IN B-SBAR O
18 963 965 11694026 of IN B-PP O
19 966 969 11694026 114 CD B-NP O
20 970 978 11694026 subjects NNS I-NP O
21 979 988 11694026 submitted VBN B-VP O
22 989 991 11694026 to TO B-PP O
23 992 995 11694026 the DT B-NP O
24 996 1005 11694026 challenge NN I-NP O
25 1006 1010 11694026 with IN B-PP O
26 1011 1022 11694026 paracetamol NN B-NP D000082
27 1022 1023 11694026 , , O O
28 1024 1026 11694026 13 CD B-NP O
29 1027 1028 11694026 ( ( O O
30 1028 1032 11694026 9.6% NN B-NP O
31 1032 1033 11694026 ) ) O O
32 1034 1037 11694026 did VBD B-VP O
33 1038 1041 11694026 not RB I-VP O
34 1042 1050 11694026 tolerate VB I-VP O
35 1051 1055 11694026 this DT B-NP O
36 1056 1060 11694026 drug NN I-NP O
37 1060 1061 11694026 . . O O

1 1062 1073 11694026 Furthermore RB B-ADVP O
2 1073 1074 11694026 , , O O
3 1075 1081 11694026 18.28% CD B-NP O
4 1082 1084 11694026 of IN B-PP O
5 1085 1093 11694026 patients NNS B-NP O
6 1094 1098 11694026 with IN B-PP O
7 1099 1100 11694026 a DT B-NP O
8 1101 1108 11694026 history NN I-NP O
9 1109 1111 11694026 of IN B-PP O
10 1112 1119 11694026 chronic JJ B-NP O
11 1120 1129 11694026 urticaria NN I-NP D014581
12 1130 1133 11694026 and CC I-NP O
13 1134 1139 11694026 11.8% NN I-NP O
14 1140 1142 11694026 of IN B-PP O
15 1143 1151 11694026 subjects NNS B-NP O
16 1152 1156 11694026 with IN B-PP O
17 1157 1159 11694026 an DT B-NP O
18 1160 1167 11694026 history NN I-NP O
19 1168 1170 11694026 of IN B-PP O
20 1171 1176 11694026 NSAID NN B-NP D000894
21 1176 1177 11694026 - HYPH B-NP O
22 1177 1184 11694026 induced VBN I-NP O
23 1185 1194 11694026 urticaria NN I-NP D014581
24 1194 1195 11694026 / SYM B-NP O
25 1195 1205 11694026 angioedema NN B-NP D000799
26 1206 1208 11694026 or CC I-NP O
27 1209 1219 11694026 angioedema NN I-NP D000799
28 1220 1225 11694026 alone RB B-ADVP O
29 1226 1227 11694026 ( ( O O
30 1227 1231 11694026 with IN B-PP O
31 1232 1234 11694026 or CC B-PP O
32 1235 1242 11694026 without IN B-PP O
33 1243 1250 11694026 chronic JJ B-NP O
34 1251 1260 11694026 urticaria NN I-NP D014581
35 1260 1261 11694026 ) ) O O
36 1262 1270 11694026 resulted VBD B-VP O
37 1271 1273 11694026 to TO I-VP O
38 1274 1276 11694026 be VB I-VP O
39 1277 1287 11694026 intolerant JJ B-ADJP O
40 1288 1290 11694026 to TO B-PP O
41 1291 1302 11694026 alternative JJ B-NP O
42 1303 1308 11694026 drugs NNS I-NP O
43 1308 1309 11694026 . . O O

1 1310 1315 11694026 Taken VBN B-VP O
2 1316 1324 11694026 together RB B-ADVP O
3 1324 1325 11694026 , , O O
4 1326 1329 11694026 our PRP$ B-NP O
5 1330 1337 11694026 results NNS I-NP O
6 1338 1345 11694026 confirm VBP B-VP O
7 1346 1349 11694026 the DT B-NP O
8 1350 1354 11694026 good JJ I-NP O
9 1355 1367 11694026 tolerability NN I-NP O
10 1368 1370 11694026 of IN B-PP O
11 1371 1381 11694026 nimesulide NN B-NP C012655
12 1382 1385 11694026 and CC I-NP O
13 1386 1397 11694026 paracetamol NN I-NP D000082
14 1398 1400 11694026 in IN B-PP O
15 1401 1409 11694026 patients NNS B-NP O
16 1410 1413 11694026 who WP B-NP O
17 1414 1425 11694026 experienced VBD B-VP O
18 1426 1435 11694026 urticaria NN B-NP D014581
19 1435 1436 11694026 / SYM B-NP O
20 1436 1446 11694026 angioedema NN I-NP D000799
21 1447 1453 11694026 caused VBN B-VP O
22 1454 1456 11694026 by IN B-PP O
23 1457 1463 11694026 NSAIDs NNS B-NP D000894
24 1463 1464 11694026 . . O O

1 1465 1472 11694026 However RB B-ADVP O
2 1472 1473 11694026 , , O O
3 1474 1477 11694026 the DT B-NP O
4 1478 1482 11694026 risk NN I-NP O
5 1483 1485 11694026 of IN B-PP O
6 1486 1494 11694026 reaction NN B-NP O
7 1495 1497 11694026 to TO B-PP O
8 1498 1503 11694026 these DT B-NP O
9 1504 1515 11694026 alternative JJ I-NP O
10 1516 1521 11694026 study NN I-NP O
11 1522 1527 11694026 drugs NNS I-NP O
12 1528 1530 11694026 is VBZ B-VP O
13 1531 1544 11694026 statistically RB I-VP O
14 1545 1554 11694026 increased VBN I-VP O
15 1555 1557 11694026 by IN B-PP O
16 1558 1559 11694026 a DT B-NP O
17 1560 1567 11694026 history NN I-NP O
18 1568 1570 11694026 of IN B-PP O
19 1571 1578 11694026 chronic JJ B-NP O
20 1579 1588 11694026 urticaria NN I-NP D014581
21 1589 1592 11694026 and CC O O
22 1592 1593 11694026 , , O O
23 1594 1599 11694026 above IN B-PP O
24 1600 1603 11694026 all DT B-NP O
25 1603 1604 11694026 , , O O
26 1605 1607 11694026 by IN B-PP O
27 1608 1609 11694026 a DT B-NP O
28 1610 1617 11694026 history NN I-NP O
29 1618 1620 11694026 of IN B-PP O
30 1621 1626 11694026 NSAID NN B-NP D000894
31 1626 1627 11694026 - HYPH B-NP O
32 1627 1634 11694026 induced VBN I-NP O
33 1635 1645 11694026 angioedema NN I-NP D000799
34 1645 1646 11694026 . . O O

1 0 0 17074608 -DOCSTART- -X- -X- O

1 0 9 17074608 Valproate NN B-NP D014635
2 9 10 17074608 - HYPH B-NP O
3 10 17 17074608 induced VBN I-NP O
4 18 24 17074608 chorea NN I-NP D002819
5 25 28 17074608 and CC I-NP O
6 29 43 17074608 encephalopathy NN I-NP D001927
7 44 46 17074608 in IN B-PP O
8 47 55 17074608 atypical JJ B-NP O
9 56 66 17074608 nonketotic JJ I-NP D020158
10 67 82 17074608 hyperglycinemia NN I-NP D020158
11 82 83 17074608 . . O O
12 84 94 17074608 Nonketotic JJ B-NP D020158
13 95 110 17074608 hyperglycinemia NN I-NP D020158
14 111 113 17074608 is VBZ B-VP O
15 114 115 17074608 a DT B-NP O
16 116 124 17074608 disorder NN I-NP D000592
17 125 127 17074608 of IN B-PP D000592
18 128 133 17074608 amino JJ B-NP D000592
19 134 138 17074608 acid NN I-NP D000592
20 139 149 17074608 metabolism NN I-NP D000592
21 150 152 17074608 in IN B-PP O
22 153 158 17074608 which WDT B-NP O
23 159 160 17074608 a DT B-NP O
24 161 167 17074608 defect NN I-NP O
25 168 170 17074608 in IN B-PP O
26 171 174 17074608 the DT B-NP O
27 175 182 17074608 glycine NN I-NP D005998
28 183 191 17074608 cleavage NN I-NP O
29 192 198 17074608 system NN I-NP O
30 199 204 17074608 leads VBZ B-VP O
31 205 207 17074608 to TO B-PP O
32 208 210 17074608 an DT B-NP O
33 211 223 17074608 accumulation NN I-NP O
34 224 226 17074608 of IN B-PP O
35 227 234 17074608 glycine NN B-NP D005998
36 235 237 17074608 in IN B-PP O
37 238 241 17074608 the DT B-NP O
38 242 247 17074608 brain NN I-NP O
39 248 251 17074608 and CC O O
40 252 257 17074608 other JJ B-NP O
41 258 262 17074608 body NN I-NP O
42 263 275 17074608 compartments NNS I-NP O
43 275 276 17074608 . . O O

1 277 279 17074608 In IN B-PP O
2 280 283 17074608 the DT B-NP O
3 284 293 17074608 classical JJ I-NP O
4 294 298 17074608 form NN I-NP O
5 299 301 17074608 it PRP B-NP O
6 302 310 17074608 presents VBZ B-VP O
7 311 313 17074608 as IN B-PP O
8 314 322 17074608 neonatal JJ B-NP O
9 323 328 17074608 apnea NN I-NP D001049
10 328 329 17074608 , , O O
11 330 341 17074608 intractable JJ B-NP O
12 342 350 17074608 seizures NNS I-NP D012640
13 350 351 17074608 , , O O
14 352 355 17074608 and CC O O
15 356 365 17074608 hypotonia NN B-NP D009123
16 365 366 17074608 , , O O
17 367 375 17074608 followed VBN B-VP O
18 376 378 17074608 by IN B-PP O
19 379 390 17074608 significant JJ B-NP O
20 391 402 17074608 psychomotor NN I-NP D011596
21 403 414 17074608 retardation NN I-NP D011596
22 414 415 17074608 . . O O

1 416 418 17074608 An DT B-NP O
2 419 428 17074608 important JJ I-NP O
3 429 435 17074608 subset NN I-NP O
4 436 438 17074608 of IN B-PP O
5 439 447 17074608 children NNS B-NP O
6 448 452 17074608 with IN B-PP O
7 453 463 17074608 nonketotic JJ B-NP D020158
8 464 479 17074608 hyperglycinemia NN I-NP D020158
9 480 483 17074608 are VBP B-VP O
10 484 492 17074608 atypical JJ B-NP O
11 493 501 17074608 variants NNS I-NP O
12 502 505 17074608 who WP B-NP O
13 506 513 17074608 present VBP B-VP O
14 514 516 17074608 in IN B-PP O
15 517 518 17074608 a DT B-NP O
16 519 532 17074608 heterogeneous JJ I-NP O
17 533 539 17074608 manner NN I-NP O
18 539 540 17074608 . . O O

1 541 545 17074608 This DT B-NP O
2 546 552 17074608 report NN I-NP O
3 553 562 17074608 describes VBZ B-VP O
4 563 564 17074608 a DT B-NP O
5 565 572 17074608 patient NN I-NP O
6 573 577 17074608 with IN B-PP O
7 578 582 17074608 mild JJ B-NP O
8 583 591 17074608 language NN I-NP D007805
9 592 597 17074608 delay NN I-NP D007805
10 598 601 17074608 and CC O O
11 602 608 17074608 mental JJ B-NP D008607
12 609 620 17074608 retardation NN I-NP D008607
13 620 621 17074608 , , O O
14 622 625 17074608 who WP B-NP O
15 626 629 17074608 was VBD B-VP O
16 630 635 17074608 found VBN I-VP O
17 636 638 17074608 to TO I-VP O
18 639 643 17074608 have VB I-VP O
19 644 654 17074608 nonketotic JJ B-NP D020158
20 655 670 17074608 hyperglycinemia NN I-NP D020158
21 671 680 17074608 following VBG B-PP O
22 681 684 17074608 her PRP$ B-NP O
23 685 697 17074608 presentation NN I-NP O
24 698 702 17074608 with IN B-PP O
25 703 708 17074608 acute JJ B-NP O
26 709 723 17074608 encephalopathy NN I-NP D001927
27 724 727 17074608 and CC I-NP O
28 728 734 17074608 chorea NN I-NP D002819
29 735 742 17074608 shortly RB B-ADVP O
30 743 748 17074608 after IN B-PP O
31 749 759 17074608 initiation NN B-NP O
32 760 762 17074608 of IN B-PP O
33 763 772 17074608 valproate NN B-NP D014635
34 773 780 17074608 therapy NN I-NP O
35 780 781 17074608 . . O O

1 0 0 7565311 -DOCSTART- -X- -X- O

1 0 5 7565311 Acute JJ B-NP D058186
2 6 11 7565311 renal JJ I-NP D058186
3 12 19 7565311 failure NN I-NP D058186
4 20 22 7565311 in IN B-PP O
5 23 27 7565311 high JJ B-NP O
6 28 32 7565311 dose NN I-NP O
7 33 44 7565311 carboplatin NN I-NP D016190
8 45 57 7565311 chemotherapy NN I-NP O
9 57 58 7565311 . . I-NP O
10 59 70 7565311 Carboplatin NN I-NP D016190
11 71 74 7565311 has VBZ B-VP O
12 75 79 7565311 been VBN I-VP O
13 80 88 7565311 reported VBN I-VP O
14 89 91 7565311 to TO I-VP O
15 92 97 7565311 cause VB I-VP O
16 98 103 7565311 acute JJ B-NP D058186
17 104 109 7565311 renal JJ I-NP D058186
18 110 117 7565311 failure NN I-NP D058186
19 118 122 7565311 when WRB B-ADVP O
20 123 135 7565311 administered VBN B-VP O
21 136 138 7565311 in IN B-PP O
22 139 143 7565311 high JJ B-NP O
23 144 149 7565311 doses NNS I-NP O
24 150 152 7565311 to TO B-PP O
25 153 158 7565311 adult JJ B-NP O
26 159 167 7565311 patients NNS I-NP O
27 167 168 7565311 . . O O

1 169 171 7565311 We PRP B-NP O
2 172 178 7565311 report VBP B-VP O
3 179 180 7565311 a DT B-NP O
4 181 182 7565311 4 CD I-NP O
5 183 184 7565311 1 CD I-NP O
6 184 185 7565311 / SYM B-NP O
7 185 186 7565311 2 CD I-NP O
8 186 187 7565311 - HYPH I-NP O
9 187 191 7565311 year NN I-NP O
10 191 192 7565311 - HYPH B-NP O
11 192 195 7565311 old JJ I-NP O
12 196 200 7565311 girl NN I-NP O
13 201 204 7565311 who WP B-NP O
14 205 208 7565311 was VBD B-VP O
15 209 216 7565311 treated VBN I-VP O
16 217 221 7565311 with IN B-PP O
17 222 226 7565311 high JJ B-NP O
18 226 227 7565311 - HYPH I-NP O
19 227 231 7565311 dose NN I-NP O
20 232 243 7565311 carboplatin NN I-NP D016190
21 244 247 7565311 for IN B-PP O
22 248 258 7565311 metastatic JJ B-NP O
23 259 272 7565311 parameningeal JJ I-NP O
24 273 282 7565311 embryonal JJ I-NP D018233
25 283 299 7565311 rhabdomyosarcoma NN I-NP D018233
26 299 300 7565311 . . O O

1 301 306 7565311 Acute JJ B-NP D058186
2 307 312 7565311 renal JJ I-NP D058186
3 313 320 7565311 failure NN I-NP D058186
4 321 330 7565311 developed VBD B-VP O
5 331 339 7565311 followed VBN I-VP O
6 340 342 7565311 by IN B-PP O
7 343 344 7565311 a DT B-NP O
8 345 349 7565311 slow JJ I-NP O
9 350 357 7565311 partial JJ I-NP O
10 358 366 7565311 recovery NN I-NP O
11 367 369 7565311 of IN B-PP O
12 370 375 7565311 renal JJ B-NP O
13 376 384 7565311 function NN I-NP O
14 384 385 7565311 . . O O

1 386 394 7565311 Possible JJ B-NP O
2 395 407 7565311 contributing VBG I-NP O
3 408 415 7565311 factors NNS I-NP O
4 416 419 7565311 are VBP B-VP O
5 420 429 7565311 discussed VBN I-VP O
6 429 430 7565311 . . O O

1 0 0 6674249 -DOCSTART- -X- -X- O

1 0 3 6674249 Why WRB B-ADVP O
2 4 7 6674249 may MD O O
3 8 15 6674249 epsilon NN B-NP D015119
4 15 16 6674249 - HYPH O D015119
5 16 28 6674249 aminocaproic JJ B-NP D015119
6 29 33 6674249 acid NN I-NP D015119
7 34 35 6674249 ( ( O O
8 35 39 6674249 EACA NN B-NP D015119
9 39 40 6674249 ) ) O O
10 41 47 6674249 induce VBP B-VP O
11 48 56 6674249 myopathy NN B-NP D009135
12 57 59 6674249 in IN B-PP O
13 60 63 6674249 man NN B-NP O
14 63 64 6674249 ? . O O
15 65 71 6674249 Report NNP B-NP O
16 72 74 6674249 of IN B-PP O
17 75 76 6674249 a DT B-NP O
18 77 81 6674249 case NN I-NP O
19 82 85 6674249 and CC I-NP O
20 86 96 6674249 literature NN I-NP O
21 97 103 6674249 review NN I-NP O
22 103 104 6674249 . . O O
23 105 106 6674249 A DT B-NP O
24 107 111 6674249 case NN I-NP O
25 112 114 6674249 of IN B-PP O
26 115 126 6674249 necrotizing VBG B-VP D009336
27 127 135 6674249 myopathy NN B-NP D009336
28 136 139 6674249 due JJ B-ADJP O
29 140 142 6674249 to TO B-PP O
30 143 144 6674249 a DT B-NP O
31 145 150 6674249 short JJ I-NP O
32 151 158 6674249 epsilon NN I-NP D015119
33 158 159 6674249 - HYPH B-NP D015119
34 159 171 6674249 aminocaproic JJ I-NP D015119
35 172 176 6674249 acid NN I-NP D015119
36 177 178 6674249 ( ( O O
37 178 182 6674249 EACA NN B-NP D015119
38 182 183 6674249 ) ) O O
39 184 193 6674249 treatment NN B-NP O
40 194 196 6674249 in IN B-PP O
41 197 198 6674249 a DT B-NP O
42 199 201 6674249 72 CD I-NP O
43 202 206 6674249 year NN I-NP O
44 206 207 6674249 - HYPH O O
45 207 210 6674249 old JJ B-NP O
46 211 218 6674249 patient NN I-NP O
47 219 223 6674249 with IN B-PP O
48 224 236 6674249 subarachnoid JJ B-NP D013345
49 237 248 6674249 haemorrhage NN I-NP D013345
50 249 250 6674249 ( ( O O
51 250 253 6674249 SAH NN B-NP D013345
52 253 254 6674249 ) ) O O
53 255 257 6674249 is VBZ B-VP O
54 258 267 6674249 described VBN I-VP O
55 267 268 6674249 . . O O

1 269 281 6674249 Pathogenetic JJ B-NP O
2 282 292 6674249 hypotheses NNS I-NP O
3 293 296 6674249 are VBP B-VP O
4 297 306 6674249 discussed VBN I-VP O
5 306 307 6674249 . . O O

1 0 0 11868798 -DOCSTART- -X- -X- O

1 0 14 11868798 Spironolactone NN B-NP D013148
2 14 15 11868798 : : O O
3 16 18 11868798 is VBZ B-VP O
4 19 21 11868798 it PRP B-NP O
5 22 23 11868798 a DT B-NP O
6 24 29 11868798 novel JJ I-NP O
7 30 34 11868798 drug NN I-NP O
8 35 38 11868798 for IN B-PP O
9 39 42 11868798 the DT B-NP O
10 43 53 11868798 prevention NN I-NP O
11 54 56 11868798 of IN B-PP O
12 57 69 11868798 amphotericin NN B-NP D000666
13 70 71 11868798 B NN I-NP D000666
14 71 72 11868798 - HYPH B-VP O
15 72 79 11868798 related VBN B-NP O
16 80 91 11868798 hypokalemia NN I-NP D007008
17 92 94 11868798 in IN B-PP O
18 95 101 11868798 cancer NN B-NP D009369
19 102 110 11868798 patients NNS I-NP O
20 110 111 11868798 ? . O O
21 112 121 11868798 OBJECTIVE NN B-NP O
22 121 122 11868798 : : O O
23 123 137 11868798 Nephrotoxicity NN B-NP D007674
24 138 140 11868798 is VBZ B-VP O
25 141 144 11868798 the DT B-NP O
26 145 150 11868798 major JJ I-NP O
27 151 158 11868798 adverse JJ I-NP O
28 159 165 11868798 effect NN I-NP O
29 166 168 11868798 of IN B-PP O
30 169 181 11868798 amphotericin NN B-NP D000666
31 182 183 11868798 B NN I-NP D000666
32 184 185 11868798 ( ( O O
33 185 188 11868798 AmB NN B-NP D000666
34 188 189 11868798 ) ) O O
35 189 190 11868798 , , O O
36 191 196 11868798 often RB B-ADVP O
37 197 205 11868798 limiting VBG B-VP O
38 206 220 11868798 administration NN B-NP O
39 221 223 11868798 of IN B-PP O
40 224 228 11868798 full JJ B-NP O
41 229 235 11868798 dosage NN I-NP O
42 235 236 11868798 . . O O

1 237 246 11868798 Selective JJ B-NP O
2 247 253 11868798 distal JJ I-NP O
3 254 261 11868798 tubular JJ I-NP O
4 262 272 11868798 epithelial JJ I-NP O
5 273 281 11868798 toxicity NN I-NP D064420
6 282 287 11868798 seems VBZ B-VP O
7 288 290 11868798 to TO I-VP O
8 291 293 11868798 be VB I-VP O
9 294 305 11868798 responsible JJ B-ADJP O
10 306 309 11868798 for IN B-PP O
11 310 313 11868798 the DT B-NP O
12 314 322 11868798 profound JJ I-NP O
13 323 332 11868798 potassium NN I-NP D011188
14 333 340 11868798 wasting NN I-NP O
15 341 345 11868798 that WDT B-NP O
16 346 348 11868798 is VBZ B-VP O
17 349 350 11868798 a DT B-NP O
18 351 356 11868798 major JJ I-NP O
19 357 365 11868798 clinical JJ I-NP O
20 366 370 11868798 side NN I-NP O
21 371 377 11868798 effect NN I-NP O
22 378 380 11868798 of IN B-PP O
23 381 390 11868798 treatment NN B-NP O
24 391 395 11868798 with IN B-PP O
25 396 399 11868798 AmB NN B-NP D000666
26 399 400 11868798 . . O O

1 401 410 11868798 Potassium NN B-NP D011188
2 411 420 11868798 depletion NN I-NP O
3 421 425 11868798 also RB B-ADVP O
4 426 437 11868798 potentiates VBZ B-VP O
5 438 441 11868798 the DT B-NP O
6 442 449 11868798 tubular JJ I-NP O
7 450 458 11868798 toxicity NN I-NP D064420
8 459 461 11868798 of IN B-PP O
9 462 465 11868798 AmB NN B-NP D000666
10 465 466 11868798 . . O O

1 467 471 11868798 This DT B-NP O
2 472 477 11868798 study NN I-NP O
3 478 481 11868798 was VBD B-VP O
4 482 490 11868798 designed VBN I-VP O
5 491 493 11868798 to TO B-VP O
6 494 500 11868798 assess VB I-VP O
7 501 504 11868798 the DT B-NP O
8 505 512 11868798 ability NN I-NP O
9 513 515 11868798 of IN B-PP O
10 516 530 11868798 spironolactone NN B-NP D013148
11 531 533 11868798 to TO B-VP O
12 534 540 11868798 reduce VB I-VP O
13 541 550 11868798 potassium NN B-NP D011188
14 551 563 11868798 requirements NNS I-NP O
15 564 567 11868798 and CC O O
16 568 570 11868798 to TO B-VP O
17 571 578 11868798 prevent VB I-VP O
18 579 590 11868798 hypokalemia NN B-NP D007008
19 591 593 11868798 in IN B-PP O
20 594 605 11868798 neutropenic JJ B-NP D009503
21 606 614 11868798 patients NNS I-NP O
22 615 617 11868798 on IN B-PP O
23 618 621 11868798 AmB NN B-NP D000666
24 622 631 11868798 treatment NN I-NP O
25 631 632 11868798 . . O O

1 633 640 11868798 METHODS NNS B-NP O
2 640 641 11868798 : : O O
3 642 644 11868798 In IN B-PP O
4 645 649 11868798 this DT B-NP O
5 650 655 11868798 study NN I-NP O
6 656 658 11868798 26 CD B-NP O
7 659 667 11868798 patients NNS I-NP O
8 668 672 11868798 with IN B-PP O
9 673 680 11868798 various JJ B-NP O
10 681 694 11868798 hematological JJ I-NP D006402
11 695 704 11868798 disorders NNS I-NP D006402
12 705 709 11868798 were VBD B-VP O
13 710 720 11868798 randomized VBN I-VP O
14 721 723 11868798 to TO B-VP O
15 724 731 11868798 receive VB I-VP O
16 732 738 11868798 either CC B-NP O
17 739 750 11868798 intravenous JJ I-NP O
18 751 754 11868798 AmB NN I-NP D000666
19 755 760 11868798 alone RB B-ADVP O
20 761 763 11868798 or CC O O
21 764 767 11868798 AmB NN B-NP D000666
22 768 771 11868798 and CC O O
23 772 776 11868798 oral JJ B-NP O
24 777 791 11868798 spironolactone NN I-NP D013148
25 792 795 11868798 100 CD B-NP O
26 796 798 11868798 mg NN I-NP O
27 799 804 11868798 twice RB B-ADVP O
28 805 810 11868798 daily RB I-ADVP O
29 811 815 11868798 when WRB B-ADVP O
30 816 826 11868798 developing VBG B-VP O
31 827 828 11868798 a DT B-NP O
32 829 835 11868798 proven VBN I-NP O
33 836 838 11868798 or CC I-NP O
34 839 848 11868798 suspected VBN I-NP O
35 849 855 11868798 fungal JJ I-NP D009181
36 856 865 11868798 infection NN I-NP D009181
37 865 866 11868798 . . O O

1 867 874 11868798 RESULTS NNS B-NP O
2 874 875 11868798 : : O O
3 876 884 11868798 Patients NNS B-NP O
4 885 894 11868798 receiving VBG B-VP O
5 895 906 11868798 concomitant JJ B-NP O
6 907 910 11868798 AmB NN I-NP D000666
7 911 914 11868798 and CC I-NP O
8 915 929 11868798 spironolactone NN I-NP D013148
9 930 933 11868798 had VBD B-VP O
10 934 947 11868798 significantly RB B-NP O
11 948 954 11868798 higher JJR I-NP O
12 955 961 11868798 plasma NN I-NP O
13 962 971 11868798 potassium NN I-NP D011188
14 972 978 11868798 levels NNS I-NP O
15 979 983 11868798 than IN B-PP O
16 984 989 11868798 those DT B-NP O
17 990 999 11868798 receiving VBG B-VP O
18 1000 1003 11868798 AmB NN B-NP D000666
19 1004 1009 11868798 alone RB B-ADVP O
20 1010 1011 11868798 ( ( O O
21 1011 1012 11868798 P NN B-NP O
22 1013 1014 11868798 = SYM B-VP O
23 1015 1021 11868798 0.0027 CD B-NP O
24 1021 1022 11868798 ) ) O O
25 1022 1023 11868798 . . O O

1 1024 1029 11868798 Those DT B-NP O
2 1030 1038 11868798 patients NNS I-NP O
3 1039 1048 11868798 receiving VBG B-VP O
4 1049 1052 11868798 AmB NN B-NP D000666
5 1053 1056 11868798 and CC I-NP O
6 1057 1071 11868798 spironolactone NN I-NP D013148
7 1072 1080 11868798 required VBD B-VP O
8 1081 1094 11868798 significantly RB B-NP O
9 1095 1099 11868798 less JJR I-NP O
10 1100 1109 11868798 potassium NN I-NP D011188
11 1110 1125 11868798 supplementation NN I-NP O
12 1126 1128 11868798 to TO B-VP O
13 1129 1137 11868798 maintain VB I-VP O
14 1138 1143 11868798 their PRP$ B-NP O
15 1144 1150 11868798 plasma NN I-NP O
16 1151 1160 11868798 potassium NN I-NP D011188
17 1161 1167 11868798 within IN B-PP O
18 1168 1171 11868798 the DT B-NP O
19 1172 1178 11868798 normal JJ I-NP O
20 1179 1184 11868798 range NN I-NP O
21 1185 1186 11868798 ( ( O O
22 1186 1187 11868798 P NN B-NP O
23 1188 1189 11868798 = SYM B-VP O
24 1190 1195 11868798 0.022 CD B-NP O
25 1195 1196 11868798 ) ) O O
26 1196 1197 11868798 . . O O

1 1198 1206 11868798 Moreover RB B-ADVP O
2 1206 1207 11868798 , , O O
3 1208 1215 11868798 urinary JJ B-NP O
4 1216 1225 11868798 potassium NN I-NP D011188
5 1226 1232 11868798 losses NNS I-NP O
6 1233 1237 11868798 were VBD B-VP O
7 1238 1251 11868798 significantly RB B-ADJP O
8 1252 1256 11868798 less JJR I-ADJP O
9 1257 1259 11868798 in IN B-PP O
10 1260 1268 11868798 patients NNS B-NP O
11 1269 1278 11868798 receiving VBG B-VP O
12 1279 1282 11868798 AmB NN B-NP D000666
13 1283 1286 11868798 and CC I-NP O
14 1287 1301 11868798 spironolactone NN I-NP D013148
15 1302 1306 11868798 than IN B-PP O
16 1307 1312 11868798 those DT B-NP O
17 1313 1322 11868798 receiving VBG I-NP O
18 1323 1326 11868798 AmB NN I-NP D000666
19 1327 1332 11868798 alone RB B-ADVP O
20 1333 1334 11868798 ( ( O O
21 1334 1335 11868798 P NN B-NP O
22 1336 1337 11868798 = SYM B-VP O
23 1338 1343 11868798 0.040 CD B-NP O
24 1343 1344 11868798 ) ) O O
25 1344 1345 11868798 . . O O

1 1346 1356 11868798 CONCLUSION NN B-NP O
2 1356 1357 11868798 : : O O
3 1358 1362 11868798 This DT B-NP O
4 1363 1368 11868798 study NN I-NP O
5 1369 1375 11868798 showed VBD B-VP O
6 1376 1380 11868798 that IN B-SBAR O
7 1381 1395 11868798 spironolactone NN B-NP D013148
8 1396 1399 11868798 can MD B-VP O
9 1400 1406 11868798 reduce VB I-VP O
10 1407 1416 11868798 potassium NN B-NP D011188
11 1417 1429 11868798 requirements NNS I-NP O
12 1430 1433 11868798 and CC O O
13 1434 1441 11868798 prevent VB B-VP O
14 1442 1453 11868798 hypokalemia NN B-NP D007008
15 1454 1456 11868798 by IN B-PP O
16 1457 1465 11868798 reducing VBG B-VP O
17 1466 1473 11868798 urinary JJ B-NP O
18 1474 1483 11868798 potassium NN I-NP D011188
19 1484 1488 11868798 loss NN I-NP O
20 1489 1491 11868798 in IN B-PP O
21 1492 1503 11868798 neutropenic JJ B-NP D009503
22 1504 1512 11868798 patients NNS I-NP O
23 1513 1515 11868798 on IN B-PP O
24 1516 1519 11868798 AmB NN B-NP D000666
25 1520 1529 11868798 treatment NN I-NP O
26 1529 1530 11868798 . . O O

1 0 0 6153967 -DOCSTART- -X- -X- O

1 0 13 6153967 Epileptogenic JJ B-NP O
2 14 24 6153967 properties NNS I-NP O
3 25 27 6153967 of IN B-PP O
4 28 37 6153967 enflurane NN B-NP D004737
5 38 41 6153967 and CC O O
6 42 47 6153967 their PRP$ B-NP O
7 48 56 6153967 clinical JJ I-NP O
8 57 71 6153967 interpretation NN I-NP O
9 71 72 6153967 . . O O
10 73 78 6153967 Three CD B-NP O
11 79 84 6153967 cases NNS I-NP O
12 85 87 6153967 of IN B-PP O
13 88 91 6153967 EEG NN B-NP O
14 92 99 6153967 changes NNS I-NP O
15 100 107 6153967 induced VBN B-VP O
16 108 110 6153967 by IN B-PP O
17 111 117 6153967 single JJ B-NP O
18 118 126 6153967 exposure NN I-NP O
19 127 129 6153967 to TO B-PP O
20 130 139 6153967 enflurane NN B-NP D004737
21 140 150 6153967 anesthesia NN I-NP O
22 151 154 6153967 are VBP B-VP O
23 155 163 6153967 reported VBN I-VP O
24 163 164 6153967 . . O O

1 165 167 6153967 In IN B-PP O
2 168 171 6153967 one CD B-NP O
3 172 179 6153967 patient NN I-NP O
4 179 180 6153967 , , O O
5 181 190 6153967 enflurane NN B-NP D004737
6 191 203 6153967 administered VBN B-VP O
7 204 210 6153967 during IN B-PP O
8 211 212 6153967 a DT B-NP O
9 213 218 6153967 donor NN I-NP O
10 219 230 6153967 nephrectomy NN I-NP O
11 231 239 6153967 resulted VBD B-VP O
12 240 242 6153967 in IN B-PP O
13 243 253 6153967 unexpected JJ B-NP O
14 254 261 6153967 partial JJ I-NP O
15 262 267 6153967 motor NN I-NP O
16 268 276 6153967 seizures NNS I-NP D012640
17 276 277 6153967 . . O O

1 278 283 6153967 Until IN B-PP O
2 284 287 6153967 the DT B-NP O
3 288 293 6153967 cause NN I-NP O
4 294 296 6153967 of IN B-PP O
5 297 300 6153967 the DT B-NP O
6 301 309 6153967 seizures NNS I-NP D012640
7 310 313 6153967 was VBD B-VP O
8 314 323 6153967 correctly RB I-VP O
9 324 334 6153967 identified VBN I-VP O
10 334 335 6153967 , , O O
11 336 339 6153967 the DT B-NP O
12 340 347 6153967 patient NN I-NP O
13 348 351 6153967 was VBD B-VP O
14 352 367 6153967 inappropriately RB I-VP O
15 368 375 6153967 treated VBN I-VP O
16 376 380 6153967 with IN B-PP O
17 381 396 6153967 anticonvulsants NNS B-NP O
18 396 397 6153967 . . O O

1 398 401 6153967 Two CD B-NP O
2 402 407 6153967 other JJ I-NP O
3 408 416 6153967 patients NNS I-NP O
4 417 425 6153967 suffered VBN B-VP O
5 426 430 6153967 from IN B-PP O
6 431 438 6153967 partial JJ B-NP O
7 438 439 6153967 , , I-NP O
8 440 447 6153967 complex JJ I-NP O
9 448 451 6153967 and CC I-NP O
10 452 463 6153967 generalized VBN I-NP O
11 464 472 6153967 seizures NNS I-NP D012640
12 473 485 6153967 uncontrolled JJ B-ADJP O
13 486 488 6153967 by IN B-PP O
14 489 499 6153967 medication NN B-NP O
15 499 500 6153967 . . O O

1 501 510 6153967 Epileptic JJ B-NP D004827
2 511 515 6153967 foci NNS I-NP O
3 516 526 6153967 delineated VBN B-VP O
4 527 530 6153967 and CC I-VP O
5 531 540 6153967 activated VBN I-VP O
6 541 543 6153967 by IN B-PP O
7 544 553 6153967 enflurane NN B-NP D004737
8 554 558 6153967 were VBD B-VP O
9 559 569 6153967 surgically RB I-VP O
10 570 577 6153967 ablated VBN I-VP O
11 578 581 6153967 and CC O O
12 582 585 6153967 the DT B-NP O
13 586 594 6153967 patients NNS I-NP O
14 595 598 6153967 are VBP B-VP O
15 599 602 6153967 now RB B-ADVP O
16 603 610 6153967 seizure NN B-NP D012640
17 610 611 6153967 - HYPH B-ADJP O
18 611 615 6153967 free JJ I-ADJP O
19 615 616 6153967 . . O O

1 617 625 6153967 Previous JJ B-NP O
2 626 635 6153967 exposures NNS I-NP O
3 636 638 6153967 to TO B-VP O
4 639 648 6153967 enflurane VB I-VP D004737
5 649 653 6153967 have VB I-VP O
6 654 656 6153967 to TO I-VP O
7 657 659 6153967 be VB I-VP O
8 660 669 6153967 disclosed VBN I-VP O
9 670 672 6153967 to TO I-VP O
10 673 678 6153967 avoid VB I-VP O
11 679 687 6153967 mistakes NNS B-NP O
12 688 690 6153967 in IN B-PP O
13 691 699 6153967 clinical JJ B-NP O
14 700 714 6153967 interpretation NN I-NP O
15 715 717 6153967 of IN B-PP O
16 718 721 6153967 the DT B-NP O
17 722 725 6153967 EEG NN I-NP O
18 725 726 6153967 . . O O

1 727 729 6153967 On IN B-PP O
2 730 733 6153967 the DT B-NP O
3 734 739 6153967 other JJ I-NP O
4 740 744 6153967 hand NN I-NP O
5 744 745 6153967 , , O O
6 746 755 6153967 enflurane NN B-NP D004737
7 756 759 6153967 may MD B-VP O
8 760 765 6153967 prove VB I-VP O
9 766 768 6153967 to TO I-VP O
10 769 771 6153967 be VB I-VP O
11 772 773 6153967 a DT B-NP O
12 774 778 6153967 safe JJ I-NP O
13 779 783 6153967 fast JJ I-NP O
14 784 790 6153967 acting VBG I-NP O
15 791 800 6153967 activator NN I-NP O
16 801 803 6153967 of IN B-PP O
17 804 813 6153967 epileptic JJ B-NP D004827
18 814 818 6153967 foci NNS I-NP O
19 819 825 6153967 during IN B-PP O
20 826 839 6153967 corticography NN B-NP O
21 840 842 6153967 or CC O O
22 843 848 6153967 depth JJ B-NP O
23 849 858 6153967 electrode NN I-NP O
24 859 873 6153967 intraoperative JJ I-NP O
25 874 884 6153967 recordings NNS I-NP O
26 884 885 6153967 . . O O

1 0 0 18405372 -DOCSTART- -X- -X- O

1 0 14 18405372 Hepatotoxicity NN B-NP D056486
2 15 25 18405372 associated VBN B-VP O
3 26 30 18405372 with IN B-PP O
4 31 44 18405372 sulfasalazine NN B-NP D012460
5 45 47 18405372 in IN B-PP O
6 48 60 18405372 inflammatory JJ B-NP O
7 61 70 18405372 arthritis NN I-NP D001168
8 70 71 18405372 : : O O
9 72 73 18405372 A DT B-NP O
10 74 78 18405372 case NN I-NP O
11 79 85 18405372 series NN I-NP O
12 86 90 18405372 from IN B-PP O
13 91 92 18405372 a DT B-NP O
14 93 98 18405372 local JJ I-NP O
15 99 111 18405372 surveillance NN I-NP O
16 112 114 18405372 of IN B-PP O
17 115 122 18405372 serious JJ B-NP O
18 123 130 18405372 adverse JJ I-NP O
19 131 137 18405372 events NNS I-NP O
20 137 138 18405372 . . I-NP O
21 139 149 18405372 BACKGROUND NN I-NP O
22 149 150 18405372 : : O O
23 151 162 18405372 Spontaneous JJ B-NP O
24 163 172 18405372 reporting NN I-NP O
25 173 180 18405372 systems NNS I-NP O
26 181 184 18405372 for IN B-PP O
27 185 192 18405372 adverse JJ B-NP O
28 193 197 18405372 drug NN I-NP O
29 198 207 18405372 reactions NNS I-NP O
30 208 209 18405372 ( ( O O
31 209 213 18405372 ADRs NNS B-NP O
32 213 214 18405372 ) ) O O
33 215 218 18405372 are VBP B-VP O
34 219 230 18405372 handicapped VBN I-VP O
35 231 233 18405372 by IN B-PP O
36 234 239 18405372 under IN B-PP O
37 239 240 18405372 - HYPH B-NP O
38 240 249 18405372 reporting VBG I-NP O
39 250 253 18405372 and CC I-NP O
40 254 261 18405372 limited JJ I-NP O
41 262 268 18405372 detail NN I-NP O
42 269 271 18405372 on IN B-PP O
43 272 282 18405372 individual JJ B-NP O
44 283 288 18405372 cases NNS I-NP O
45 288 289 18405372 . . O O

1 290 292 18405372 We PRP B-NP O
2 293 299 18405372 report VBP B-VP O
3 300 302 18405372 an DT B-NP O
4 303 316 18405372 investigation NN I-NP O
5 317 321 18405372 from IN B-PP O
6 322 323 18405372 a DT B-NP O
7 324 329 18405372 local JJ I-NP O
8 330 342 18405372 surveillance NN I-NP O
9 343 346 18405372 for IN B-PP O
10 347 354 18405372 serious JJ B-NP O
11 355 362 18405372 adverse JJ I-NP O
12 363 367 18405372 drug NN I-NP O
13 368 377 18405372 reactions NNS I-NP O
14 378 388 18405372 associated VBN B-VP O
15 389 393 18405372 with IN B-PP O
16 394 401 18405372 disease NN B-NP O
17 402 411 18405372 modifying VBG B-VP O
18 412 416 18405372 anti AFX B-NP O
19 416 417 18405372 - HYPH I-NP O
20 417 426 18405372 rheumatic JJ I-NP O
21 427 432 18405372 drugs NNS I-NP O
22 433 437 18405372 that WDT B-NP O
23 438 441 18405372 was VBD B-VP O
24 442 451 18405372 triggered VBN I-VP O
25 452 454 18405372 by IN B-PP O
26 455 458 18405372 the DT B-NP O
27 459 469 18405372 occurrence NN I-NP O
28 470 472 18405372 of IN B-PP O
29 473 478 18405372 liver NN B-NP D017093
30 479 486 18405372 failure NN I-NP D017093
31 487 489 18405372 in IN B-PP O
32 490 493 18405372 two CD B-NP O
33 494 496 18405372 of IN B-PP O
34 497 500 18405372 our PRP$ B-NP O
35 501 509 18405372 patients NNS I-NP O
36 509 510 18405372 . . O O

1 511 518 18405372 METHODS NNS B-NP O
2 518 519 18405372 : : O O
3 520 527 18405372 Serious JJ B-NP O
4 528 531 18405372 ADR NN I-NP O
5 532 539 18405372 reports NNS I-NP O
6 540 544 18405372 have VBP B-VP O
7 545 549 18405372 been VBN I-VP O
8 550 559 18405372 solicited VBN I-VP O
9 560 564 18405372 from IN B-PP O
10 565 570 18405372 local JJ B-NP O
11 571 581 18405372 clinicians NNS I-NP O
12 582 584 18405372 by IN B-PP O
13 585 592 18405372 regular JJ B-NP O
14 593 602 18405372 postcards NNS I-NP O
15 603 607 18405372 over IN B-PP O
16 608 611 18405372 the DT B-NP O
17 612 616 18405372 past JJ I-NP O
18 617 622 18405372 seven CD I-NP O
19 623 628 18405372 years NNS I-NP O
20 628 629 18405372 . . O O

1 630 639 18405372 Patients' RB B-ADVP O
2 639 640 18405372 , , O O
3 641 644 18405372 who WP B-NP O
4 645 648 18405372 had VBD B-VP O
5 649 663 18405372 hepatotoxicity NN B-NP D056486
6 664 666 18405372 on IN B-PP O
7 667 680 18405372 sulfasalazine NN B-NP D012460
8 681 684 18405372 and CC O O
9 685 688 18405372 met VBD B-VP O
10 689 690 18405372 a DT B-NP O
11 691 701 18405372 definition NN I-NP O
12 702 704 18405372 of IN B-PP O
13 705 706 18405372 a DT B-NP O
14 707 714 18405372 serious JJ I-NP O
15 715 718 18405372 ADR NN I-NP O
16 718 719 18405372 , , O O
17 720 724 18405372 were VBD B-VP O
18 725 735 18405372 identified VBN I-VP O
19 735 736 18405372 . . O O

1 737 740 18405372 Two CD B-NP O
2 741 751 18405372 clinicians NNS I-NP O
3 752 760 18405372 reviewed VBD B-VP O
4 761 771 18405372 structured VBN I-VP O
5 772 776 18405372 case NN B-NP O
6 777 784 18405372 reports NNS I-NP O
7 785 788 18405372 and CC O O
8 789 797 18405372 assessed VBN B-NP O
9 798 807 18405372 causality NN I-NP O
10 808 810 18405372 by IN B-PP O
11 811 820 18405372 consensus NN B-NP O
12 821 824 18405372 and CC B-PP O
13 825 827 18405372 by IN B-PP O
14 828 833 18405372 using VBG B-VP O
15 834 835 18405372 a DT B-NP O
16 836 845 18405372 causality NN I-NP O
17 846 856 18405372 assessment NN I-NP O
18 857 867 18405372 instrument NN I-NP O
19 867 868 18405372 . . O O

1 869 872 18405372 The DT B-NP O
2 873 879 18405372 likely JJ I-NP O
3 880 889 18405372 frequency NN I-NP O
4 890 892 18405372 of IN B-PP O
5 893 907 18405372 hepatotoxicity NN B-NP D056486
6 908 912 18405372 with IN B-PP O
7 913 926 18405372 sulfasalazine NN B-NP D012460
8 927 930 18405372 was VBD B-VP O
9 931 940 18405372 estimated VBN I-VP O
10 941 943 18405372 by IN B-PP O
11 944 950 18405372 making VBG B-VP O
12 951 952 18405372 a DT B-NP O
13 953 959 18405372 series NN I-NP O
14 960 962 18405372 of IN B-PP O
15 963 975 18405372 conservative JJ B-NP O
16 976 987 18405372 assumptions NNS I-NP O
17 987 988 18405372 . . O O

1 989 996 18405372 RESULTS NNS B-NP O
2 996 997 18405372 : : O O
3 998 1001 18405372 Ten CD B-NP O
4 1002 1007 18405372 cases NNS I-NP O
5 1008 1012 18405372 were VBD B-VP O
6 1013 1023 18405372 identified VBN I-VP O
7 1023 1024 18405372 : : O O
8 1025 1030 18405372 eight CD B-NP O
9 1031 1039 18405372 occurred VBD B-VP O
10 1040 1046 18405372 during IN B-PP O
11 1047 1059 18405372 surveillance NN B-NP O
12 1059 1060 18405372 . . O O

1 1061 1066 18405372 Eight CD B-NP O
2 1067 1075 18405372 patients NNS I-NP O
3 1076 1080 18405372 were VBD B-VP O
4 1081 1093 18405372 hospitalised VBN I-VP O
5 1093 1094 18405372 , , O O
6 1095 1098 18405372 two CD B-NP O
7 1099 1101 18405372 in IN B-PP O
8 1102 1109 18405372 hepatic JJ B-NP D017093
9 1110 1117 18405372 failure NN I-NP D017093
10 1118 1119 18405372 - HYPH B-NP O
11 1120 1123 18405372 one CD I-NP O
12 1124 1128 18405372 died VBD B-VP O
13 1129 1134 18405372 after IN B-PP O
14 1135 1136 18405372 a DT B-NP O
15 1137 1142 18405372 liver NN I-NP O
16 1143 1153 18405372 transplant NN I-NP O
17 1153 1154 18405372 . . O O

1 1155 1158 18405372 All DT B-NP O
2 1159 1162 18405372 but IN I-NP O
3 1163 1166 18405372 one CD I-NP O
4 1167 1172 18405372 event NN I-NP O
5 1173 1181 18405372 occurred VBD B-VP O
6 1182 1188 18405372 within IN B-PP O
7 1189 1190 18405372 6 CD B-NP O
8 1191 1196 18405372 weeks NNS I-NP O
9 1197 1199 18405372 of IN B-PP O
10 1200 1209 18405372 treatment NN B-NP O
11 1209 1210 18405372 . . O O

1 1211 1216 18405372 Seven CD B-NP O
2 1217 1225 18405372 patients NNS I-NP O
3 1226 1229 18405372 had VBD B-VP O
4 1230 1231 18405372 a DT B-NP O
5 1232 1236 18405372 skin NN I-NP D005076
6 1237 1241 18405372 rash NN I-NP D005076
7 1241 1242 18405372 , , O O
8 1243 1248 18405372 three CD B-NP O
9 1249 1261 18405372 eosinophilia NN I-NP D004802
10 1262 1265 18405372 and CC O O
11 1266 1269 18405372 one CD B-NP O
12 1270 1282 18405372 interstitial JJ I-NP D009395
13 1283 1292 18405372 nephritis NN I-NP D009395
14 1292 1293 18405372 . . O O

1 1294 1298 18405372 Five CD B-NP O
2 1299 1307 18405372 patients NNS I-NP O
3 1308 1312 18405372 were VBD B-VP O
4 1313 1315 18405372 of IN B-PP O
5 1316 1321 18405372 Black JJ B-NP O
6 1322 1329 18405372 British NNP I-NP O
7 1330 1332 18405372 of IN B-PP O
8 1333 1340 18405372 African JJ B-NP O
9 1341 1343 18405372 or CC I-NP O
10 1344 1353 18405372 Caribbean JJ I-NP O
11 1354 1361 18405372 descent NN I-NP O
12 1361 1362 18405372 . . O O

1 1363 1368 18405372 Liver NN B-NP O
2 1369 1376 18405372 enzymes NNS I-NP O
3 1377 1383 18405372 showed VBD B-VP O
4 1384 1385 18405372 a DT B-NP O
5 1386 1400 18405372 hepatocellular JJ I-NP O
6 1401 1408 18405372 pattern NN I-NP O
7 1409 1411 18405372 in IN B-PP O
8 1412 1416 18405372 four CD B-NP O
9 1417 1422 18405372 cases NNS I-NP O
10 1423 1426 18405372 and CC O O
11 1427 1428 18405372 a DT B-NP O
12 1429 1434 18405372 mixed VBN I-NP O
13 1435 1442 18405372 pattern NN I-NP O
14 1443 1445 18405372 in IN B-PP O
15 1446 1449 18405372 six CD B-NP O
16 1449 1450 18405372 . . O O

1 1451 1455 18405372 Drug NN B-NP O
2 1455 1456 18405372 - HYPH I-NP O
3 1456 1463 18405372 related VBN I-NP O
4 1464 1478 18405372 hepatotoxicity NN I-NP D056486
5 1479 1482 18405372 was VBD B-VP O
6 1483 1489 18405372 judged VBN I-VP O
7 1490 1498 18405372 probable JJ B-ADJP O
8 1499 1501 18405372 or CC O O
9 1502 1508 18405372 highly RB B-ADJP O
10 1509 1517 18405372 probable JJ I-ADJP O
11 1518 1520 18405372 in IN B-PP O
12 1521 1522 18405372 8 CD B-NP O
13 1523 1531 18405372 patients NNS I-NP O
14 1531 1532 18405372 . . O O

1 1533 1536 18405372 The DT B-NP O
2 1537 1543 18405372 likely JJ I-NP O
3 1544 1553 18405372 frequency NN I-NP O
4 1554 1556 18405372 of IN B-PP O
5 1557 1564 18405372 serious JJ B-NP O
6 1565 1579 18405372 hepatotoxicity NN I-NP D056486
7 1580 1584 18405372 with IN B-PP O
8 1585 1598 18405372 sulfasalazine NN B-NP D012460
9 1599 1602 18405372 was VBD B-VP O
10 1603 1612 18405372 estimated VBN I-VP O
11 1613 1615 18405372 at IN B-PP O
12 1616 1620 18405372 0.4% CD B-NP O
13 1621 1623 18405372 of IN B-PP O
14 1624 1631 18405372 treated VBN B-NP O
15 1632 1640 18405372 patients NNS I-NP O
16 1640 1641 18405372 . . O O

1 1642 1652 18405372 CONCLUSION NN B-NP O
2 1652 1653 18405372 : : O O
3 1654 1661 18405372 Serious JJ B-NP O
4 1662 1676 18405372 hepatotoxicity NN I-NP D056486
5 1677 1687 18405372 associated VBN B-VP O
6 1688 1692 18405372 with IN B-PP O
7 1693 1706 18405372 sulfasalazine NN B-NP D012460
8 1707 1714 18405372 appears VBZ B-VP O
9 1715 1717 18405372 to TO I-VP O
10 1718 1720 18405372 be VB I-VP O
11 1721 1726 18405372 under IN B-PP O
12 1726 1727 18405372 - HYPH B-NP O
13 1727 1738 18405372 appreciated VBN I-NP O
14 1739 1742 18405372 and CC I-NP O
15 1743 1752 18405372 intensive JJ I-NP O
16 1753 1763 18405372 monitoring NN I-NP O
17 1764 1767 18405372 and CC I-NP O
18 1768 1777 18405372 vigilance NN I-NP O
19 1778 1780 18405372 in IN B-PP O
20 1781 1784 18405372 the DT B-NP O
21 1785 1790 18405372 first JJ I-NP O
22 1791 1792 18405372 6 CD I-NP O
23 1793 1798 18405372 weeks NNS I-NP O
24 1799 1801 18405372 of IN B-PP O
25 1802 1811 18405372 treatment NN B-NP O
26 1812 1814 18405372 is VBZ B-VP O
27 1815 1825 18405372 especially RB B-ADJP O
28 1826 1835 18405372 important JJ I-ADJP O
29 1835 1836 18405372 . . O O

1 0 0 33969 -DOCSTART- -X- -X- O

1 0 13 33969 Ethopropazine NN B-NP C084820
2 14 17 33969 and CC I-NP O
3 18 29 33969 benztropine NN I-NP D001590
4 30 32 33969 in IN B-PP O
5 33 44 33969 neuroleptic JJ B-NP O
6 44 45 33969 - HYPH I-NP O
7 45 52 33969 induced VBN I-NP O
8 53 65 33969 parkinsonism NN I-NP D010302
9 65 66 33969 . . O O
10 67 69 33969 In IN B-PP O
11 70 71 33969 a DT B-NP O
12 72 74 33969 12 CD I-NP O
13 74 75 33969 - HYPH I-NP O
14 75 79 33969 week NN I-NP O
15 80 90 33969 controlled VBN I-NP O
16 91 96 33969 study NN I-NP O
17 97 110 33969 ethopropazine NN I-NP C084820
18 111 114 33969 was VBD B-VP O
19 115 123 33969 compared VBN I-VP O
20 124 126 33969 to TO B-PP O
21 127 138 33969 benztropine NN B-NP D001590
22 139 141 33969 in IN B-PP O
23 142 145 33969 the DT B-NP O
24 146 155 33969 treatment NN I-NP O
25 156 158 33969 of IN B-PP O
26 159 171 33969 parkinsonism NN B-NP D010302
27 172 179 33969 induced VBN B-VP O
28 180 182 33969 by IN B-PP O
29 183 195 33969 fluphenazine NN B-NP C017610
30 196 205 33969 enanthate NN I-NP C017610
31 206 208 33969 in IN B-PP O
32 209 211 33969 60 CD B-NP O
33 212 225 33969 schizophrenic JJ I-NP D012559
34 226 237 33969 outpatients NNS I-NP O
35 237 238 33969 . . O O

1 239 252 33969 Ethopropazine NN B-NP C084820
2 253 256 33969 and CC I-NP O
3 257 268 33969 benztropine NN I-NP D001590
4 269 273 33969 were VBD B-VP O
5 274 279 33969 found VBN I-VP O
6 280 282 33969 to TO I-VP O
7 283 285 33969 be VB I-VP O
8 286 293 33969 equally RB B-ADJP O
9 294 303 33969 effective JJ I-ADJP O
10 304 306 33969 in IN B-PP O
11 307 318 33969 controlling VBG B-VP O
12 319 331 33969 parkinsonian JJ B-NP D010302
13 332 340 33969 symptoms NNS I-NP D010302
14 341 344 33969 and CC O O
15 345 349 33969 were VBD B-VP O
16 350 352 33969 as RB B-ADJP O
17 353 364 33969 efficacious JJ I-ADJP O
18 365 367 33969 as IN B-PP O
19 368 380 33969 procyclidine NN B-NP D011352
20 380 381 33969 , , O O
21 382 387 33969 their PRP$ B-NP O
22 388 396 33969 previous JJ I-NP O
23 397 413 33969 antiparkinsonian JJ I-NP O
24 414 418 33969 drug NN I-NP O
25 418 419 33969 . . O O

1 420 427 33969 However RB B-ADVP O
2 427 428 33969 , , O O
3 429 440 33969 benztropine NN B-NP D001590
4 441 448 33969 treated VBN B-VP O
5 449 457 33969 patients NNS B-NP O
6 458 461 33969 had VBD B-VP O
7 462 463 33969 a DT B-NP O
8 464 475 33969 significant JJ I-NP O
9 476 484 33969 increase NN I-NP O
10 485 487 33969 in IN B-PP O
11 488 495 33969 tardive JJ B-NP D004409
12 496 506 33969 dyskinesia NN I-NP D004409
13 507 515 33969 compared VBN B-VP O
14 516 518 33969 to TO B-PP O
15 519 524 33969 their PRP$ B-NP O
16 525 534 33969 condition NN I-NP O
17 535 541 33969 during IN B-PP O
18 542 555 33969 procyclindine NN B-NP D011352
19 556 565 33969 treatment NN I-NP O
20 565 566 33969 , , O O
21 567 570 33969 and CC O O
22 571 584 33969 significantly RB B-NP O
23 585 589 33969 more JJR I-NP O
24 590 597 33969 anxiety NN I-NP D001008
25 598 601 33969 and CC I-NP O
26 602 612 33969 depression NN I-NP D003866
27 613 617 33969 than IN B-PP O
28 618 631 33969 ethopropazine NN B-NP C084820
29 632 639 33969 treated VBN B-VP O
30 640 648 33969 patients NNS B-NP O
31 648 649 33969 . . O O

1 650 654 33969 This DT B-NP O
2 655 663 33969 suggests VBZ B-VP O
3 664 668 33969 that IN B-SBAR O
4 669 680 33969 benztropine NN B-NP D001590
5 681 683 33969 is VBZ B-VP O
6 684 687 33969 not RB O O
7 688 691 33969 the DT B-NP O
8 692 707 33969 anticholinergic JJ I-NP O
9 708 712 33969 drug NN I-NP O
10 713 715 33969 of IN B-PP O
11 716 722 33969 choice NN B-NP O
12 723 725 33969 in IN B-PP O
13 726 729 33969 the DT B-NP O
14 730 739 33969 treatment NN I-NP O
15 740 742 33969 of IN B-PP O
16 743 754 33969 neuroleptic JJ B-NP O
17 754 755 33969 - HYPH I-NP O
18 755 762 33969 induced VBN I-NP O
19 763 775 33969 parkinsonian JJ I-NP D010302
20 776 784 33969 symptoms NNS I-NP D010302
21 784 785 33969 , , O O
22 786 793 33969 because IN B-PP O
23 794 796 33969 of IN I-PP O
24 797 800 33969 its PRP$ B-NP O
25 801 805 33969 more RBR I-NP O
26 806 811 33969 toxic JJ I-NP O
27 812 819 33969 central JJ I-NP O
28 820 823 33969 and CC I-NP O
29 824 834 33969 peripheral JJ I-NP O
30 835 844 33969 atropinic JJ I-NP O
31 845 851 33969 effect NN I-NP O
32 851 852 33969 . . O O

1 0 0 20394767 -DOCSTART- -X- -X- O

1 0 4 20394767 Fear NN B-NP O
2 4 5 20394767 - HYPH B-PP O
3 5 16 20394767 potentiated VBN B-NP O
4 17 24 20394767 startle NN I-NP D012021
5 24 25 20394767 , , B-PP O
6 26 29 20394767 but CC I-PP O
7 30 33 20394767 not RB O O
8 34 39 20394767 light NN B-NP O
9 39 40 20394767 - HYPH O O
10 40 48 20394767 enhanced VBN B-VP O
11 49 56 20394767 startle NN B-NP D012021
12 56 57 20394767 , , O O
13 58 60 20394767 is VBZ B-VP O
14 61 69 20394767 enhanced VBN I-VP O
15 70 72 20394767 by IN B-PP O
16 73 83 20394767 anxiogenic JJ B-NP O
17 84 89 20394767 drugs NNS I-NP O
18 89 90 20394767 . . O O
19 91 100 20394767 RATIONALE NN B-NP O
20 101 104 20394767 AND CC I-NP O
21 105 115 20394767 OBJECTIVES NNS I-NP O
22 115 116 20394767 : : O O
23 117 120 20394767 The DT B-NP O
24 121 126 20394767 light NN I-NP O
25 126 127 20394767 - HYPH B-VP O
26 127 135 20394767 enhanced VBN B-NP O
27 136 143 20394767 startle NN I-NP D012021
28 144 152 20394767 paradigm NN I-NP O
29 153 154 20394767 ( ( O O
30 154 157 20394767 LES NN B-NP O
31 157 158 20394767 ) ) O O
32 159 161 20394767 is VBZ B-VP O
33 162 171 20394767 suggested VBN I-VP O
34 172 174 20394767 to TO B-PP O
35 175 180 20394767 model NN B-NP O
36 181 188 20394767 anxiety NN I-NP D001008
37 188 189 20394767 , , O O
38 190 197 20394767 because IN B-PP O
39 198 200 20394767 of IN I-PP O
40 201 204 20394767 the DT B-NP O
41 205 208 20394767 non AFX I-NP O
42 208 209 20394767 - HYPH I-NP O
43 209 217 20394767 specific JJ I-NP O
44 218 221 20394767 cue NN I-NP O
45 222 225 20394767 and CC O O
46 226 229 20394767 the DT B-NP O
47 230 234 20394767 long JJ I-NP O
48 234 235 20394767 - HYPH I-NP O
49 235 239 20394767 term NN I-NP O
50 240 246 20394767 effect NN I-NP O
51 246 247 20394767 . . O O

1 248 250 20394767 In IN B-PP O
2 251 259 20394767 contrast NN B-NP O
3 259 260 20394767 , , O O
4 261 264 20394767 the DT B-NP O
5 265 269 20394767 fear NN I-NP O
6 269 270 20394767 - HYPH O O
7 270 281 20394767 potentiated VBN B-VP O
8 282 289 20394767 startle NN B-NP D012021
9 290 291 20394767 ( ( O O
10 291 294 20394767 FPS NN B-NP O
11 294 295 20394767 ) ) O O
12 296 298 20394767 is VBZ B-VP O
13 299 308 20394767 suggested VBN I-VP O
14 309 311 20394767 to TO I-VP O
15 312 317 20394767 model VB I-VP O
16 318 329 20394767 conditioned JJ B-NP O
17 330 334 20394767 fear NN I-NP O
18 334 335 20394767 . . O O

1 336 343 20394767 However RB B-ADVP O
2 343 344 20394767 , , O O
3 345 348 20394767 the DT B-NP O
4 349 364 20394767 pharmacological JJ I-NP O
5 365 373 20394767 profiles NNS I-NP O
6 374 376 20394767 of IN B-PP O
7 377 382 20394767 these DT B-NP O
8 383 386 20394767 two CD I-NP O
9 387 396 20394767 paradigms NNS I-NP O
10 397 400 20394767 are VBP B-VP O
11 401 405 20394767 very RB B-ADJP O
12 406 413 20394767 similar JJ I-ADJP O
13 413 414 20394767 . . O O

1 415 418 20394767 The DT B-NP O
2 419 426 20394767 present JJ I-NP O
3 427 432 20394767 study NN I-NP O
4 433 445 20394767 investigated VBD B-VP O
5 446 449 20394767 the DT B-NP O
6 450 457 20394767 effects NNS I-NP O
7 458 460 20394767 of IN B-PP O
8 461 469 20394767 putative JJ B-NP O
9 470 480 20394767 anxiogenic JJ I-NP O
10 481 486 20394767 drugs NNS I-NP O
11 487 489 20394767 on IN B-PP O
12 490 493 20394767 LES NN B-NP O
13 494 497 20394767 and CC I-NP O
14 498 501 20394767 FPS NN I-NP O
15 502 505 20394767 and CC O O
16 506 511 20394767 aimed VBN B-VP O
17 512 514 20394767 at IN B-PP O
18 515 526 20394767 determining VBG B-VP O
19 527 530 20394767 the DT B-NP O
20 531 542 20394767 sensitivity NN I-NP O
21 543 545 20394767 of IN B-PP O
22 546 549 20394767 LES NN B-NP O
23 550 553 20394767 for IN B-PP O
24 554 564 20394767 anxiogenic JJ B-NP O
25 565 570 20394767 drugs NNS I-NP O
26 571 574 20394767 and CC O O
27 575 577 20394767 to TO B-VP O
28 578 589 20394767 potentially RB I-VP O
29 590 597 20394767 showing VBG I-VP O
30 598 599 20394767 a DT B-NP O
31 600 615 20394767 pharmacological JJ I-NP O
32 616 631 20394767 differentiation NN I-NP O
33 632 639 20394767 between IN B-PP O
34 640 645 20394767 these DT B-NP O
35 646 649 20394767 two CD I-NP O
36 650 659 20394767 paradigms NNS I-NP O
37 659 660 20394767 . . O O

1 661 668 20394767 METHODS NNS B-NP O
2 668 669 20394767 : : O O
3 670 674 20394767 Male NNP B-NP O
4 675 681 20394767 Wistar NNP I-NP O
5 682 686 20394767 rats NNS I-NP O
6 687 695 20394767 received VBD B-VP O
7 696 700 20394767 each DT B-NP O
8 701 705 20394767 dose NN I-NP O
9 706 708 20394767 of IN B-PP O
10 709 712 20394767 the DT B-NP O
11 713 721 20394767 alpha(2) NN I-NP O
12 721 722 20394767 - HYPH B-NP O
13 722 734 20394767 adrenoceptor NN I-NP O
14 735 745 20394767 antagonist NN I-NP O
15 746 755 20394767 yohimbine NN I-NP D015016
16 756 757 20394767 ( ( O O
17 757 761 20394767 0.25 CD B-NP O
18 761 762 20394767 - HYPH I-NP O
19 762 767 20394767 1.0mg NN I-NP O
20 767 768 20394767 / SYM B-NP O
21 768 770 20394767 kg NN I-NP O
22 770 771 20394767 ) ) O O
23 771 772 20394767 , , O O
24 773 776 20394767 the DT B-NP O
25 777 778 20394767 5 CD I-NP D012701
26 778 779 20394767 - HYPH I-NP D012701
27 779 785 20394767 HT(2C) NN I-NP D012701
28 786 794 20394767 receptor NN I-NP O
29 795 802 20394767 agonist NN I-NP O
30 803 804 20394767 m NN I-NP C015068
31 804 805 20394767 - HYPH O C015068
32 805 827 20394767 chlorophenylpiperazine NN B-NP C015068
33 828 829 20394767 ( ( O O
34 829 833 20394767 mCPP NN B-NP C015068
35 833 834 20394767 , , O O
36 835 838 20394767 0.5 CD B-NP O
37 838 839 20394767 - HYPH I-NP O
38 839 844 20394767 2.0mg NN I-NP O
39 844 845 20394767 / SYM B-NP O
40 845 847 20394767 kg NN I-NP O
41 847 848 20394767 ) ) O O
42 849 851 20394767 or CC O O
43 852 855 20394767 the DT B-NP O
44 856 863 20394767 GABA(A) NN I-NP D005680
45 864 871 20394767 inverse NN I-NP O
46 872 880 20394767 receptor NN I-NP O
47 881 888 20394767 agonist NN I-NP O
48 889 907 20394767 pentylenetetrazole NN I-NP D010433
49 908 909 20394767 ( ( O O
50 909 912 20394767 PTZ NN B-NP D010433
51 912 913 20394767 , , O O
52 914 915 20394767 3 CD B-NP O
53 915 916 20394767 - HYPH I-NP O
54 916 920 20394767 30mg CD I-NP O
55 920 921 20394767 / SYM I-NP O
56 921 923 20394767 kg NN I-NP O
57 923 924 20394767 ) ) O O
58 925 928 20394767 and CC O O
59 929 933 20394767 were VBD B-VP O
60 934 946 20394767 subsequently RB I-VP O
61 947 953 20394767 tested VBN I-VP O
62 954 956 20394767 in IN B-PP O
63 957 963 20394767 either CC O O
64 964 967 20394767 LES NN B-NP O
65 968 970 20394767 or CC I-NP O
66 971 974 20394767 FPS NN I-NP O
67 974 975 20394767 . . O O

1 976 983 20394767 RESULTS NNS B-NP O
2 983 984 20394767 : : O O
3 985 989 20394767 None NN B-NP O
4 990 992 20394767 of IN B-PP O
5 993 996 20394767 the DT B-NP O
6 997 1002 20394767 drugs NNS I-NP O
7 1003 1011 20394767 enhanced VBD B-VP O
8 1012 1015 20394767 LES NNS B-NP O
9 1015 1016 20394767 , , O O
10 1017 1024 20394767 whereas IN O O
11 1025 1029 20394767 mCPP NN B-NP C015068
12 1030 1039 20394767 increased VBD B-VP O
13 1040 1050 20394767 percentage NN B-NP O
14 1051 1054 20394767 FPS NNS I-NP O
15 1055 1058 20394767 and CC O O
16 1059 1068 20394767 yohimbine NN B-NP D015016
17 1069 1078 20394767 increased VBD B-VP O
18 1079 1087 20394767 absolute JJ B-NP O
19 1088 1091 20394767 FPS NN I-NP O
20 1092 1098 20394767 values NNS I-NP O
21 1098 1099 20394767 . . O O

1 1100 1111 20394767 Furthermore RB B-ADVP O
2 1111 1112 20394767 , , O O
3 1113 1122 20394767 yohimbine NN B-NP D015016
4 1123 1132 20394767 increased VBD B-VP O
5 1133 1141 20394767 baseline NN B-NP O
6 1142 1149 20394767 startle NN I-NP D012021
7 1150 1159 20394767 amplitude NN I-NP O
8 1160 1162 20394767 in IN B-PP O
9 1163 1166 20394767 the DT B-NP O
10 1167 1170 20394767 LES NNP I-NP O
11 1170 1171 20394767 , , O O
12 1172 1177 20394767 while IN B-SBAR O
13 1178 1182 20394767 mCPP NN B-NP C015068
14 1183 1193 20394767 suppressed VBD B-VP O
15 1194 1202 20394767 baseline NN B-NP O
16 1203 1210 20394767 startle NN I-NP D012021
17 1211 1213 20394767 in IN B-PP O
18 1214 1218 20394767 both CC B-NP O
19 1219 1222 20394767 the DT I-NP O
20 1223 1226 20394767 LES NN I-NP O
21 1227 1230 20394767 and CC I-NP O
22 1231 1234 20394767 FPS NN I-NP O
23 1235 1238 20394767 and CC I-NP O
24 1239 1242 20394767 PTZ NN I-NP D010433
25 1243 1253 20394767 suppressed VBD B-VP O
26 1254 1262 20394767 baseline NN B-NP O
27 1263 1270 20394767 startle NN I-NP D012021
28 1271 1273 20394767 in IN B-PP O
29 1274 1277 20394767 the DT B-NP O
30 1278 1281 20394767 FPS NNP I-NP O
31 1281 1282 20394767 . . O O

1 1283 1294 20394767 CONCLUSIONS NNS B-NP O
2 1294 1295 20394767 : : O O
3 1296 1298 20394767 In IN B-PP O
4 1299 1307 20394767 contrast NN B-NP O
5 1308 1310 20394767 to TO B-PP O
6 1311 1319 20394767 findings NNS B-NP O
7 1320 1322 20394767 in IN B-PP O
8 1323 1326 20394767 the DT B-NP O
9 1327 1330 20394767 FPS NNP I-NP O
10 1331 1339 20394767 paradigm NN I-NP O
11 1339 1340 20394767 , , O O
12 1341 1345 20394767 none NN B-NP O
13 1346 1348 20394767 of IN B-PP O
14 1349 1352 20394767 the DT B-NP O
15 1353 1358 20394767 drugs NNS I-NP O
16 1359 1363 20394767 were VBD B-VP O
17 1364 1368 20394767 able JJ B-ADJP O
18 1369 1371 20394767 to TO B-VP O
19 1372 1382 20394767 exacerbate VB I-VP O
20 1383 1386 20394767 the DT B-NP O
21 1387 1390 20394767 LES NN I-NP O
22 1391 1399 20394767 response NN I-NP O
23 1399 1400 20394767 . . O O

1 1401 1405 20394767 Thus RB B-ADVP O
2 1405 1406 20394767 , , O O
3 1407 1408 20394767 a DT B-NP O
4 1409 1414 20394767 clear JJ I-NP O
5 1415 1430 20394767 pharmacological JJ I-NP O
6 1431 1446 20394767 differentiation NN I-NP O
7 1447 1450 20394767 was VBD B-VP O
8 1451 1456 20394767 found VBN I-VP O
9 1457 1464 20394767 between IN B-PP O
10 1465 1468 20394767 LES NNS B-NP O
11 1469 1472 20394767 and CC I-NP O
12 1473 1476 20394767 FPS NNS I-NP O
13 1476 1477 20394767 . . O O

1 0 0 14736955 -DOCSTART- -X- -X- O

1 0 13 14736955 Mitochondrial JJ B-NP O
2 14 17 14736955 DNA NN I-NP O
3 18 21 14736955 and CC O O
4 22 25 14736955 its PRP$ B-NP O
5 26 37 14736955 respiratory JJ I-NP O
6 38 43 14736955 chain NN I-NP O
7 44 52 14736955 products NNS I-NP O
8 53 56 14736955 are VBP B-VP O
9 57 66 14736955 defective JJ B-ADJP O
10 67 69 14736955 in IN B-PP O
11 70 81 14736955 doxorubicin NN B-NP D004317
12 82 91 14736955 nephrosis NN I-NP D009401
13 91 92 14736955 . . I-NP O
14 93 103 14736955 BACKGROUND NN I-NP O
15 103 104 14736955 : : O O
16 105 116 14736955 Doxorubicin NN B-NP D004317
17 117 124 14736955 induces VBZ B-VP O
18 125 126 14736955 a DT B-NP O
19 127 131 14736955 self NN I-NP O
20 131 132 14736955 - HYPH O O
21 132 144 14736955 perpetuating VBG B-VP O
22 145 156 14736955 nephropathy NN B-NP D007674
23 157 170 14736955 characterized VBN B-VP O
24 171 173 14736955 by IN B-PP O
25 174 179 14736955 early JJ B-NP O
26 180 190 14736955 glomerular JJ I-NP D007674
27 191 194 14736955 and CC I-NP D007674
28 195 199 14736955 late JJ I-NP D007674
29 199 200 14736955 - HYPH I-NP D007674
30 200 205 14736955 onset NN I-NP D007674
31 206 213 14736955 tubular JJ I-NP D007674
32 214 221 14736955 lesions NNS I-NP D007674
33 222 224 14736955 in IN B-PP O
34 225 229 14736955 rats NNS B-NP O
35 229 230 14736955 . . O O

1 231 233 14736955 We PRP B-NP O
2 234 246 14736955 investigated VBD B-VP O
3 247 250 14736955 the DT B-NP O
4 251 260 14736955 potential JJ I-NP O
5 261 265 14736955 role NN I-NP O
6 266 268 14736955 of IN B-PP O
7 269 282 14736955 mitochondrial JJ B-NP D028361
8 283 289 14736955 injury NN I-NP D028361
9 290 292 14736955 in IN B-PP O
10 293 296 14736955 the DT B-NP O
11 297 302 14736955 onset NN I-NP O
12 303 305 14736955 of IN B-PP O
13 306 311 14736955 these DT B-NP O
14 312 319 14736955 lesions NNS I-NP O
15 319 320 14736955 . . O O

1 321 328 14736955 METHODS NNS B-NP O
2 328 329 14736955 : : O O
3 330 334 14736955 Rats NNS B-NP O
4 335 339 14736955 were VBD B-VP O
5 340 347 14736955 treated VBN I-VP O
6 348 352 14736955 with IN B-PP O
7 353 364 14736955 intravenous JJ B-NP O
8 365 376 14736955 doxorubicin NN I-NP D004317
9 377 378 14736955 ( ( O O
10 378 379 14736955 1 CD B-NP O
11 380 382 14736955 mg NN I-NP O
12 383 386 14736955 kg( AFX O O
13 386 387 14736955 - HYPH O O
14 387 389 14736955 1) CD B-NP O
15 390 395 14736955 week( SYM I-NP O
16 395 396 14736955 - HYPH I-NP O
17 396 398 14736955 1) LS B-LST O
18 398 399 14736955 ) ) O O
19 400 403 14736955 for IN B-PP O
20 404 405 14736955 7 CD B-NP O
21 406 411 14736955 weeks NNS I-NP O
22 412 415 14736955 and CC O O
23 416 420 14736955 were VBD B-VP O
24 421 431 14736955 sacrificed VBN I-VP O
25 432 438 14736955 either CC O O
26 439 440 14736955 1 CD B-NP O
27 441 445 14736955 week NN I-NP O
28 446 447 14736955 ( ( O O
29 447 448 14736955 ' `` O O
30 448 453 14736955 short JJ B-NP O
31 453 454 14736955 - HYPH I-NP O
32 454 458 14736955 term NN I-NP O
33 458 459 14736955 ' '' O O
34 459 460 14736955 ) ) O O
35 461 463 14736955 or CC O O
36 464 466 14736955 30 CD B-NP O
37 467 472 14736955 weeks NNS I-NP O
38 473 474 14736955 ( ( O O
39 474 475 14736955 ' `` O O
40 475 479 14736955 long JJ B-NP O
41 479 480 14736955 - HYPH I-NP O
42 480 484 14736955 term NN I-NP O
43 484 485 14736955 ' '' O O
44 485 486 14736955 ) ) O O
45 487 496 14736955 following VBG B-PP O
46 497 500 14736955 the DT B-NP O
47 501 505 14736955 last JJ I-NP O
48 506 510 14736955 dose NN I-NP O
49 510 511 14736955 . . O O

1 512 522 14736955 Additional JJ B-NP O
2 523 527 14736955 rats NNS I-NP O
3 528 536 14736955 received VBD B-VP O
4 537 538 14736955 a DT B-NP O
5 539 545 14736955 single JJ I-NP O
6 546 550 14736955 dose NN I-NP O
7 551 557 14736955 either CC O O
8 558 559 14736955 6 CD B-NP O
9 560 564 14736955 days NNS I-NP O
10 565 567 14736955 or CC O O
11 568 569 14736955 2 CD B-NP O
12 570 571 14736955 h NN I-NP O
13 572 577 14736955 prior JJ B-ADJP O
14 578 580 14736955 to TO B-PP O
15 581 591 14736955 euthanasia NN B-NP O
16 591 592 14736955 . . O O

1 593 596 14736955 All DT B-NP O
2 597 601 14736955 rats NNS I-NP O
3 602 606 14736955 were VBD B-VP O
4 607 613 14736955 killed VBN I-VP O
5 614 616 14736955 at IN B-PP O
6 617 619 14736955 48 CD B-NP O
7 620 625 14736955 weeks NNS I-NP O
8 626 628 14736955 of IN B-PP O
9 629 632 14736955 age NN B-NP O
10 632 633 14736955 . . O O

1 634 644 14736955 Glomerular JJ B-NP D007674
2 645 648 14736955 and CC I-NP D007674
3 649 656 14736955 tubular JJ I-NP D007674
4 657 663 14736955 injury NN I-NP D007674
5 664 667 14736955 was VBD B-VP O
6 668 677 14736955 monitored VBN I-VP O
7 678 681 14736955 and CC O O
8 682 692 14736955 correlated VBN B-VP O
9 693 695 14736955 to TO B-PP O
10 696 699 14736955 the DT B-NP O
11 700 708 14736955 activity NN I-NP O
12 709 711 14736955 or CC I-NP O
13 712 722 14736955 expression NN I-NP O
14 723 725 14736955 of IN B-PP O
15 726 737 14736955 respiratory JJ B-NP O
16 738 743 14736955 chain NN I-NP O
17 744 754 14736955 components NNS I-NP O
18 754 755 14736955 . . O O

1 756 763 14736955 Finally RB B-ADVP O
2 763 764 14736955 , , O O
3 765 767 14736955 we PRP B-NP O
4 768 778 14736955 quantified VBD B-VP O
5 779 783 14736955 both CC O O
6 784 791 14736955 nuclear JJ B-NP O
7 792 795 14736955 and CC I-NP O
8 796 809 14736955 mitochondrial JJ I-NP O
9 810 813 14736955 DNA NN I-NP O
10 814 815 14736955 ( ( O O
11 815 820 14736955 mtDNA NN B-NP O
12 820 821 14736955 ) ) O O
13 822 824 14736955 as RB B-CONJP O
14 825 829 14736955 well RB I-CONJP O
15 830 832 14736955 as IN I-CONJP O
16 833 843 14736955 superoxide NN B-NP D013481
17 844 854 14736955 production NN I-NP O
18 855 858 14736955 and CC O O
19 859 862 14736955 the DT B-NP O
20 863 867 14736955 4834 CD I-NP O
21 868 872 14736955 base NN I-NP O
22 873 877 14736955 pair NN I-NP O
23 878 879 14736955 ' '' O O
24 879 885 14736955 common JJ B-NP O
25 885 886 14736955 ' `` I-NP O
26 887 892 14736955 mtDNA NN I-NP O
27 893 901 14736955 deletion NN I-NP O
28 901 902 14736955 . . O O

1 903 910 14736955 RESULTS NNS B-NP O
2 910 911 14736955 : : O O
3 912 915 14736955 The DT B-NP O
4 916 917 14736955 ' `` I-NP O
5 917 921 14736955 long JJ I-NP O
6 921 922 14736955 - HYPH I-NP O
7 922 926 14736955 term NN I-NP O
8 926 927 14736955 ' '' I-NP O
9 928 933 14736955 group NN I-NP O
10 934 937 14736955 had VBD B-VP O
11 938 949 14736955 significant JJ B-NP O
12 950 960 14736955 glomerular JJ I-NP D007674
13 961 964 14736955 and CC I-NP D007674
14 965 972 14736955 tubular JJ I-NP D007674
15 973 980 14736955 lesions NNS I-NP D007674
16 980 981 14736955 , , O O
17 982 991 14736955 depressed JJ B-NP O
18 992 1002 14736955 activities NNS I-NP O
19 1003 1005 14736955 of IN B-PP O
20 1006 1011 14736955 mtDNA NN B-NP O
21 1011 1012 14736955 - HYPH B-NP O
22 1012 1019 14736955 encoded VBN I-NP O
23 1020 1024 14736955 NADH NN I-NP O
24 1025 1038 14736955 dehydrogenase NN I-NP O
25 1039 1042 14736955 and CC I-NP O
26 1043 1053 14736955 cytochrome NN I-NP O
27 1053 1054 14736955 - HYPH O O
28 1054 1055 14736955 c NN B-NP O
29 1056 1063 14736955 oxidase NN I-NP O
30 1064 1065 14736955 ( ( O O
31 1065 1068 14736955 COX NN B-NP O
32 1068 1069 14736955 ) ) O O
33 1070 1073 14736955 and CC O O
34 1074 1083 14736955 increased VBN B-NP O
35 1084 1091 14736955 citrate NN I-NP C102006
36 1092 1100 14736955 synthase NN I-NP O
37 1101 1109 14736955 activity NN I-NP O
38 1109 1110 14736955 . . O O

1 1111 1113 14736955 In IN B-PP O
2 1114 1122 14736955 addition NN B-NP O
3 1122 1123 14736955 , , O O
4 1124 1134 14736955 expression NN B-NP O
5 1135 1137 14736955 of IN B-PP O
6 1138 1141 14736955 the DT B-NP O
7 1142 1147 14736955 mtDNA NN I-NP O
8 1147 1148 14736955 - HYPH B-VP O
9 1148 1155 14736955 encoded VBN B-NP O
10 1156 1159 14736955 COX NN I-NP O
11 1160 1167 14736955 subunit NN I-NP O
12 1168 1169 14736955 I PRP B-NP O
13 1170 1173 14736955 was VBD B-VP O
14 1174 1181 14736955 reduced VBN I-VP O
15 1182 1185 14736955 and CC O O
16 1186 1191 14736955 mtDNA NN B-NP O
17 1192 1198 14736955 levels NNS I-NP O
18 1199 1203 14736955 were VBD B-VP O
19 1204 1213 14736955 decreased VBN I-VP O
20 1213 1214 14736955 . . O O

1 1215 1217 14736955 In IN B-PP O
2 1218 1219 14736955 ' `` O O
3 1219 1224 14736955 short JJ B-NP O
4 1224 1225 14736955 - HYPH I-NP O
5 1225 1229 14736955 term NN I-NP O
6 1229 1230 14736955 ' '' I-NP O
7 1231 1235 14736955 rats NNS I-NP O
8 1235 1236 14736955 , , O O
9 1237 1242 14736955 there EX B-NP O
10 1243 1247 14736955 were VBD B-VP O
11 1248 1253 14736955 fewer JJR B-NP O
12 1254 1261 14736955 tubular JJ I-NP D007674
13 1262 1269 14736955 lesions NNS I-NP D007674
14 1269 1270 14736955 , , O O
15 1271 1274 14736955 but CC O O
16 1275 1282 14736955 similar JJ B-NP O
17 1283 1290 14736955 numbers NNS I-NP O
18 1291 1293 14736955 of IN B-PP O
19 1294 1304 14736955 glomerular JJ B-NP D007674
20 1305 1312 14736955 lesions NNS I-NP D007674
21 1313 1321 14736955 activity NN I-NP O
22 1321 1322 14736955 . . O O

1 1323 1328 14736955 Among IN B-PP O
2 1329 1332 14736955 all DT B-NP O
3 1333 1340 14736955 animals NNS I-NP O
4 1340 1341 14736955 , , O O
5 1342 1352 14736955 glomerular JJ B-NP D007674
6 1353 1356 14736955 and CC I-NP D007674
7 1357 1364 14736955 tubular JJ I-NP D007674
8 1365 1371 14736955 injury NN I-NP D007674
9 1372 1376 14736955 were VBD B-VP O
10 1377 1386 14736955 inversely RB I-VP O
11 1387 1397 14736955 correlated VBN I-VP O
12 1398 1402 14736955 with IN B-PP O
13 1403 1408 14736955 mtDNA NN B-NP O
14 1409 1415 14736955 levels NNS I-NP O
15 1415 1416 14736955 , , O O
16 1417 1422 14736955 mtDNA NN B-NP O
17 1422 1423 14736955 - HYPH B-VP O
18 1423 1430 14736955 encoded VBN B-NP O
19 1431 1442 14736955 respiratory JJ I-NP O
20 1443 1448 14736955 chain NN I-NP O
21 1449 1459 14736955 activities NNS I-NP O
22 1460 1463 14736955 and CC B-PP O
23 1464 1468 14736955 with IN B-PP O
24 1469 1472 14736955 the DT B-NP O
25 1473 1483 14736955 expression NN I-NP O
26 1484 1486 14736955 of IN B-PP O
27 1487 1490 14736955 the DT B-NP O
28 1491 1496 14736955 mtDNA NN I-NP O
29 1496 1497 14736955 - HYPH B-VP O
30 1497 1504 14736955 encoded VBN B-NP O
31 1505 1516 14736955 respiratory JJ I-NP O
32 1517 1522 14736955 chain NN I-NP O
33 1523 1530 14736955 subunit NN I-NP O
34 1531 1534 14736955 COX NN I-NP O
35 1534 1535 14736955 - HYPH B-NP O
36 1535 1536 14736955 I NN I-NP O
37 1536 1537 14736955 . . O O

1 1538 1544 14736955 Injury NN B-NP O
2 1545 1548 14736955 was VBD B-VP O
3 1549 1559 14736955 positively RB I-VP O
4 1560 1570 14736955 correlated VBN I-VP O
5 1571 1575 14736955 with IN B-PP O
6 1576 1586 14736955 superoxide NN B-NP D013481
7 1587 1597 14736955 production NN I-NP O
8 1598 1601 14736955 and CC O O
9 1602 1605 14736955 the DT B-NP O
10 1606 1616 14736955 activities NNS I-NP O
11 1617 1619 14736955 of IN B-PP O
12 1620 1627 14736955 nucleus NN B-NP O
13 1627 1628 14736955 - HYPH O O
14 1628 1635 14736955 encoded VBN B-VP O
15 1636 1649 14736955 mitochondrial JJ B-NP O
16 1650 1652 14736955 or CC I-NP O
17 1653 1664 14736955 cytoplasmic JJ I-NP O
18 1665 1672 14736955 enzymes NNS I-NP O
19 1672 1673 14736955 . . O O

1 1674 1681 14736955 Kidneys NNS B-NP O
2 1682 1686 14736955 from IN B-PP O
3 1687 1690 14736955 the DT B-NP O
4 1691 1692 14736955 ' `` I-NP O
5 1692 1696 14736955 long JJ I-NP O
6 1696 1697 14736955 - HYPH I-NP O
7 1697 1701 14736955 term NN I-NP O
8 1701 1702 14736955 ' '' I-NP O
9 1703 1708 14736955 group NN I-NP O
10 1709 1715 14736955 showed VBD B-VP O
11 1716 1720 14736955 more JJR B-NP O
12 1721 1726 14736955 mtDNA NN I-NP O
13 1727 1736 14736955 deletions NNS I-NP O
14 1737 1741 14736955 than IN B-PP O
15 1742 1744 14736955 in IN B-PP O
16 1745 1746 14736955 ' `` O O
17 1746 1751 14736955 short JJ B-NP O
18 1751 1752 14736955 - HYPH I-NP O
19 1752 1756 14736955 term NN I-NP O
20 1756 1757 14736955 ' '' I-NP O
21 1758 1765 14736955 animals NNS I-NP O
22 1766 1769 14736955 and CC O O
23 1770 1775 14736955 these DT B-NP O
24 1776 1780 14736955 were VBD B-VP O
25 1781 1784 14736955 not RB I-VP O
26 1785 1793 14736955 observed VBN I-VP O
27 1794 1796 14736955 in IN B-PP O
28 1797 1800 14736955 the DT B-NP O
29 1801 1806 14736955 other JJ I-NP O
30 1807 1813 14736955 groups NNS I-NP O
31 1813 1814 14736955 . . O O

1 1815 1826 14736955 CONCLUSIONS NNS B-NP O
2 1826 1827 14736955 : : O O
3 1828 1833 14736955 These DT B-NP O
4 1834 1841 14736955 results NNS I-NP O
5 1842 1849 14736955 suggest VBP B-VP O
6 1850 1852 14736955 an DT B-NP O
7 1853 1862 14736955 important JJ I-NP O
8 1863 1867 14736955 role NN I-NP O
9 1868 1871 14736955 for IN B-PP O
10 1872 1884 14736955 quantitative JJ B-NP O
11 1885 1888 14736955 and CC I-NP O
12 1889 1900 14736955 qualitative JJ I-NP O
13 1901 1906 14736955 mtDNA NN I-NP O
14 1907 1918 14736955 alterations NNS I-NP O
15 1919 1926 14736955 through IN B-PP O
16 1927 1930 14736955 the DT B-NP O
17 1931 1940 14736955 reduction NN I-NP O
18 1941 1943 14736955 of IN B-PP O
19 1944 1949 14736955 mtDNA NN B-NP O
20 1949 1950 14736955 - HYPH B-VP O
21 1950 1957 14736955 encoded VBN B-NP O
22 1958 1969 14736955 respiratory JJ I-NP O
23 1970 1975 14736955 chain NN I-NP O
24 1976 1984 14736955 function NN I-NP O
25 1985 1988 14736955 and CC O O
26 1989 1998 14736955 induction NN B-NP O
27 1999 2001 14736955 of IN B-PP O
28 2002 2012 14736955 superoxide NN B-NP D013481
29 2013 2015 14736955 in IN B-PP O
30 2016 2027 14736955 doxorubicin NN B-NP D004317
31 2027 2028 14736955 - HYPH B-NP O
32 2028 2035 14736955 induced VBN I-NP O
33 2036 2041 14736955 renal JJ I-NP D007674
34 2042 2049 14736955 lesions NNS I-NP D007674
35 2049 2050 14736955 . . O O

1 0 0 625456 -DOCSTART- -X- -X- O

1 0 8 625456 Obsolete JJ B-NP O
2 9 12 625456 but CC I-NP O
3 13 22 625456 dangerous JJ I-NP O
4 23 30 625456 antacid NN I-NP O
5 31 43 625456 preparations NNS I-NP O
6 43 44 625456 . . O O
7 45 48 625456 One CD B-NP O
8 49 53 625456 case NN I-NP O
9 54 56 625456 of IN B-PP O
10 57 62 625456 acute JJ B-NP O
11 63 77 625456 hypercalcaemia NN I-NP D006934
12 78 81 625456 and CC O O
13 82 85 625456 two CD B-NP O
14 86 88 625456 of IN B-PP O
15 89 98 625456 recurrent JJ B-NP O
16 99 114 625456 nephrolithiasis NN I-NP D053040
17 115 118 625456 are VBP B-VP O
18 119 127 625456 reported VBN I-VP O
19 128 130 625456 in IN B-PP O
20 131 139 625456 patients NNS B-NP O
21 140 143 625456 who WP B-NP O
22 144 147 625456 had VBD B-VP O
23 148 157 625456 regularly RB I-VP O
24 158 166 625456 consumed VBN I-VP O
25 167 172 625456 large JJ B-NP O
26 173 180 625456 amounts NNS I-NP O
27 181 183 625456 of IN B-PP O
28 184 191 625456 calcium NN B-NP D002119
29 192 198 625456 carbon NN I-NP D002119
30 198 199 625456 - HYPH B-NP D002119
31 199 202 625456 ate NN I-NP D002119
32 202 203 625456 - HYPH B-NP O
33 203 209 625456 sodium NN I-NP D017693
34 210 221 625456 bicarbonate NN I-NP D017693
35 222 229 625456 powders NNS I-NP O
36 230 233 625456 for IN B-PP O
37 234 238 625456 more JJR B-NP O
38 239 243 625456 than IN I-NP O
39 244 246 625456 20 CD I-NP O
40 247 252 625456 years NNS I-NP O
41 252 253 625456 . . O O

1 254 257 625456 The DT B-NP O
2 258 265 625456 powders NNS I-NP O
3 266 269 625456 had VBD B-VP O
4 270 274 625456 been VBN I-VP O
5 275 283 625456 obtained VBN I-VP O
6 284 288 625456 from IN B-PP O
7 289 300 625456 pharmacists NNS B-NP O
8 301 308 625456 unknown JJ B-ADJP O
9 309 311 625456 to TO B-PP O
10 312 315 625456 the DT B-NP O
11 316 324 625456 patients NNS I-NP O
12 324 325 625456 ' POS B-NP O
13 326 333 625456 medical JJ I-NP O
14 334 347 625456 practitioners NNS I-NP O
15 347 348 625456 . . O O

1 349 351 625456 It PRP B-NP O
2 352 354 625456 is VBZ B-VP O
3 355 364 625456 suggested VBN I-VP O
4 365 369 625456 that IN B-SBAR O
5 370 375 625456 these DT B-NP O
6 376 388 625456 preparations NNS I-NP O
7 389 393 625456 were VBD B-VP O
8 394 405 625456 responsible JJ B-ADJP O
9 406 409 625456 for IN B-PP O
10 410 413 625456 the DT B-NP O
11 414 423 625456 patient's NNS I-NP O
12 424 432 625456 problems NNS I-NP O
13 432 433 625456 , , O O
14 434 437 625456 and CC O O
15 438 442 625456 that IN B-SBAR O
16 443 447 625456 such JJ B-NP O
17 448 455 625456 powders NNS I-NP O
18 456 462 625456 should MD B-VP O
19 463 465 625456 no RB I-VP O
20 466 472 625456 longer RB I-VP O
21 473 475 625456 be VB I-VP O
22 476 482 625456 freely RB B-ADJP O
23 483 493 625456 obtainable JJ I-ADJP O
24 493 494 625456 . . O O

1 0 0 2826064 -DOCSTART- -X- -X- O

1 0 4 2826064 Beta SYM O O
2 4 5 2826064 - HYPH B-NP O
3 5 6 2826064 2 CD I-NP O
4 6 7 2826064 - HYPH I-NP O
5 7 19 2826064 adrenoceptor NN I-NP O
6 19 20 2826064 - HYPH O O
7 20 28 2826064 mediated VBN B-NP O
8 29 40 2826064 hypokalemia NN I-NP D007008
9 41 44 2826064 and CC O O
10 45 48 2826064 its PRP$ B-NP O
11 49 60 2826064 abolishment NN I-NP O
12 61 63 2826064 by IN B-PP O
13 64 74 2826064 oxprenolol NN B-NP D010096
14 74 75 2826064 . . O O
15 76 79 2826064 The DT B-NP O
16 80 84 2826064 time NN I-NP O
17 85 91 2826064 course NN I-NP O
18 92 95 2826064 and CC I-NP O
19 96 109 2826064 concentration NN I-NP O
20 109 110 2826064 - HYPH B-NP O
21 110 116 2826064 effect NN I-NP O
22 117 129 2826064 relationship NN I-NP O
23 130 132 2826064 of IN B-PP O
24 133 144 2826064 terbutaline NN B-NP D013726
25 144 145 2826064 - HYPH B-NP O
26 145 152 2826064 induced VBN I-NP O
27 153 164 2826064 hypokalemia NN I-NP D007008
28 165 168 2826064 was VBD B-VP O
29 169 176 2826064 studied VBN I-VP O
30 176 177 2826064 , , O O
31 178 183 2826064 using VBG B-VP O
32 184 192 2826064 computer NN B-NP O
33 192 193 2826064 - HYPH O O
34 193 198 2826064 aided VBN B-VP O
35 199 214 2826064 pharmacokinetic JJ B-NP O
36 214 215 2826064 - HYPH I-NP O
37 215 222 2826064 dynamic JJ I-NP O
38 223 231 2826064 modeling NN I-NP O
39 231 232 2826064 . . O O

1 233 245 2826064 Subsequently RB B-ADVP O
2 246 248 2826064 we PRP B-NP O
3 249 261 2826064 investigated VBD B-VP O
4 262 265 2826064 the DT B-NP O
5 266 274 2826064 efficacy NN I-NP O
6 275 277 2826064 of IN B-PP O
7 278 288 2826064 oxprenolol NN B-NP D010096
8 289 291 2826064 in IN B-PP O
9 292 304 2826064 antagonizing VBG B-VP O
10 305 309 2826064 such JJ B-NP O
11 310 321 2826064 hypokalemia NN I-NP D007008
12 321 322 2826064 , , O O
13 323 331 2826064 together RB B-ADVP O
14 332 336 2826064 with IN B-PP O
15 337 340 2826064 the DT B-NP O
16 341 356 2826064 pharmacokinetic JJ I-NP O
17 357 368 2826064 interaction NN I-NP O
18 369 376 2826064 between IN B-PP O
19 377 381 2826064 both DT B-NP O
20 382 387 2826064 drugs NNS I-NP O
21 387 388 2826064 . . O O

1 389 392 2826064 Six CD B-NP O
2 393 400 2826064 healthy JJ I-NP O
3 401 409 2826064 subjects NNS I-NP O
4 410 414 2826064 were VBD B-VP O
5 415 420 2826064 given VBN I-VP O
6 421 422 2826064 a DT B-NP O
7 423 426 2826064 0.5 CD I-NP O
8 427 429 2826064 mg NN I-NP O
9 430 442 2826064 subcutaneous JJ I-NP O
10 443 447 2826064 dose NN I-NP O
11 448 450 2826064 of IN B-PP O
12 451 462 2826064 terbutaline NN B-NP D013726
13 463 465 2826064 on IN B-PP O
14 466 469 2826064 two CD B-NP O
15 470 479 2826064 occasions NNS I-NP O
16 479 480 2826064 : : O O
17 481 482 2826064 1 CD B-NP O
18 483 487 2826064 hour NN I-NP O
19 488 493 2826064 after IN B-PP O
20 494 498 2826064 oral JJ B-NP O
21 499 513 2826064 administration NN I-NP O
22 514 516 2826064 of IN B-PP O
23 517 518 2826064 a DT B-NP O
24 519 526 2826064 placebo NN I-NP O
25 527 530 2826064 and CC I-NP O
26 531 532 2826064 1 CD I-NP O
27 533 537 2826064 hour NN I-NP O
28 538 543 2826064 after IN B-PP O
29 544 546 2826064 80 CD B-NP O
30 547 549 2826064 mg NN I-NP O
31 550 560 2826064 oxprenolol NN I-NP D010096
32 561 567 2826064 orally RB B-ADVP O
33 567 568 2826064 . . O O

1 569 571 2826064 In IN B-PP O
2 572 575 2826064 the DT B-NP O
3 576 577 2826064 7 CD I-NP O
4 577 578 2826064 - HYPH I-NP O
5 578 582 2826064 hour NN I-NP O
6 583 589 2826064 period NN I-NP O
7 590 595 2826064 after IN B-PP O
8 596 607 2826064 terbutaline NN B-NP D013726
9 608 622 2826064 administration NN I-NP O
10 622 623 2826064 , , O O
11 624 630 2826064 plasma NN B-NP O
12 631 638 2826064 samples NNS I-NP O
13 639 643 2826064 were VBD B-VP O
14 644 649 2826064 taken VBN I-VP O
15 650 653 2826064 for IN B-PP O
16 654 667 2826064 determination NN B-NP O
17 668 670 2826064 of IN B-PP O
18 671 677 2826064 plasma NN B-NP O
19 678 687 2826064 potassium NN I-NP D011188
20 688 694 2826064 levels NNS I-NP O
21 695 698 2826064 and CC O O
22 699 703 2826064 drug NN B-NP O
23 704 718 2826064 concentrations NNS I-NP O
24 718 719 2826064 . . O O

1 720 723 2826064 The DT B-NP O
2 724 731 2826064 sigmoid JJ I-NP O
3 732 736 2826064 Emax NN I-NP O
4 737 742 2826064 model NN I-NP O
5 743 750 2826064 offered VBD B-VP O
6 751 752 2826064 a DT B-NP O
7 753 757 2826064 good JJ I-NP O
8 758 769 2826064 description NN I-NP O
9 770 772 2826064 of IN B-PP O
10 773 776 2826064 the DT B-NP O
11 777 785 2826064 relation NN I-NP O
12 786 793 2826064 between IN B-PP O
13 794 805 2826064 terbutaline NN B-NP D013726
14 806 820 2826064 concentrations NNS I-NP O
15 821 824 2826064 and CC O O
16 825 834 2826064 potassium NN B-NP D011188
17 835 842 2826064 effects NNS I-NP O
18 842 843 2826064 . . O O

1 844 854 2826064 Oxprenolol NN B-NP D010096
2 855 861 2826064 caused VBD B-VP O
3 862 871 2826064 decreases NNS B-NP O
4 872 874 2826064 of IN B-PP O
5 875 878 2826064 65% NN B-NP O
6 879 882 2826064 and CC I-NP O
7 883 886 2826064 56% NN I-NP O
8 887 889 2826064 of IN B-PP O
9 890 901 2826064 terbutaline NN B-NP D013726
10 902 908 2826064 volume NN I-NP O
11 909 911 2826064 of IN B-PP O
12 912 924 2826064 distribution NN B-NP O
13 925 928 2826064 and CC I-NP O
14 929 938 2826064 clearance NN I-NP O
15 938 939 2826064 , , O O
16 940 952 2826064 respectively RB B-ADVP O
17 952 953 2826064 , , O O
18 954 957 2826064 and CC O O
19 958 960 2826064 an DT B-NP O
20 961 969 2826064 increase NN I-NP O
21 970 972 2826064 of IN B-PP O
22 973 977 2826064 130% CD B-NP O
23 978 980 2826064 of IN B-PP O
24 981 984 2826064 its PRP$ B-NP O
25 985 988 2826064 AUC NN I-NP O
26 988 989 2826064 . . O O

1 990 992 2826064 In IN B-PP O
2 993 998 2826064 spite NN B-NP O
3 999 1001 2826064 of IN B-PP O
4 1002 1008 2826064 higher JJR B-NP O
5 1009 1020 2826064 terbutaline NN I-NP D013726
6 1021 1035 2826064 concentrations NNS I-NP O
7 1036 1041 2826064 after IN B-PP O
8 1042 1052 2826064 oxprenolol NN B-NP D010096
9 1053 1065 2826064 pretreatment NN I-NP O
10 1065 1066 2826064 , , O O
11 1067 1070 2826064 the DT B-NP O
12 1071 1082 2826064 hypokalemia NN I-NP D007008
13 1083 1086 2826064 was VBD B-VP O
14 1087 1093 2826064 almost RB I-VP O
15 1094 1104 2826064 completely RB I-VP O
16 1105 1116 2826064 antagonized VBN I-VP O
17 1117 1119 2826064 by IN B-PP O
18 1120 1123 2826064 the DT B-NP O
19 1124 1128 2826064 beta SYM I-NP O
20 1129 1130 2826064 2 CD I-NP O
21 1130 1131 2826064 - HYPH I-NP O
22 1131 1139 2826064 blocking VBG B-VP O
23 1140 1146 2826064 action NN B-NP O
24 1146 1147 2826064 . . O O

1 0 0 12448656 -DOCSTART- -X- -X- O

1 0 1 12448656 A DT B-NP O
2 2 7 12448656 phase NN I-NP O
3 8 10 12448656 II CD I-NP O
4 11 16 12448656 study NN I-NP O
5 17 19 12448656 of IN B-PP O
6 20 31 12448656 thalidomide NN B-NP D013792
7 32 34 12448656 in IN B-PP O
8 35 43 12448656 advanced VBN B-NP O
9 44 54 12448656 metastatic JJ I-NP O
10 55 60 12448656 renal JJ I-NP D002292
11 61 65 12448656 cell NN I-NP D002292
12 66 75 12448656 carcinoma NN I-NP D002292
13 75 76 12448656 . . O O
14 77 87 12448656 OBJECTIVES NNS B-NP O
15 87 88 12448656 : : O O
16 89 91 12448656 To TO B-VP O
17 92 100 12448656 evaluate VB I-VP O
18 101 104 12448656 the DT B-NP O
19 105 113 12448656 toxicity NN I-NP D064420
20 114 117 12448656 and CC I-NP O
21 118 126 12448656 activity NN I-NP O
22 127 129 12448656 of IN B-PP O
23 130 141 12448656 thalidomide NN B-NP D013792
24 142 144 12448656 in IN B-PP O
25 145 153 12448656 patients NNS B-NP O
26 154 158 12448656 with IN B-PP O
27 159 167 12448656 advanced VBN B-NP O
28 168 178 12448656 metastatic JJ I-NP O
29 179 184 12448656 renal JJ I-NP D002292
30 185 189 12448656 cell NN I-NP D002292
31 190 196 12448656 cancer NN I-NP D002292
32 197 200 12448656 and CC O O
33 201 203 12448656 to TO B-VP O
34 204 211 12448656 measure VB I-VP O
35 212 219 12448656 changes NNS B-NP O
36 220 222 12448656 of IN B-PP O
37 223 226 12448656 one CD B-NP O
38 227 237 12448656 angiogenic JJ I-NP O
39 238 244 12448656 factor NN I-NP O
40 244 245 12448656 , , O O
41 246 254 12448656 vascular JJ B-NP O
42 255 266 12448656 endothelial JJ I-NP O
43 267 273 12448656 growth NN I-NP O
44 274 280 12448656 factor NN I-NP O
45 281 290 12448656 (VEGF)165 NN I-NP O
46 290 291 12448656 , , O O
47 292 296 12448656 with IN B-PP O
48 297 304 12448656 therapy NN B-NP O
49 304 305 12448656 . . O O

1 306 314 12448656 PATIENTS NNS B-NP O
2 315 318 12448656 AND CC I-NP O
3 319 326 12448656 METHODS NNS I-NP O
4 326 327 12448656 : : O O
5 328 330 12448656 29 CD B-NP O
6 331 339 12448656 patients NNS I-NP O
7 340 344 12448656 were VBD B-VP O
8 345 353 12448656 enrolled VBN I-VP O
9 354 356 12448656 on IN B-PP O
10 357 358 12448656 a DT B-NP O
11 359 364 12448656 study NN I-NP O
12 365 367 12448656 of IN B-PP O
13 368 379 12448656 thalidomide NN B-NP D013792
14 380 385 12448656 using VBG B-VP O
15 386 388 12448656 an DT B-NP O
16 389 394 12448656 intra AFX I-NP O
17 394 395 12448656 - HYPH I-NP O
18 395 402 12448656 patient NN I-NP O
19 403 407 12448656 dose NN I-NP O
20 408 418 12448656 escalation NN I-NP O
21 419 427 12448656 schedule NN I-NP O
22 427 428 12448656 . . O O

1 429 437 12448656 Patients NNS B-NP O
2 438 443 12448656 began VBD B-VP O
3 444 455 12448656 thalidomide NN B-NP D013792
4 456 458 12448656 at IN B-PP O
5 459 462 12448656 400 CD B-NP O
6 463 465 12448656 mg NN I-NP O
7 465 466 12448656 / SYM B-NP O
8 466 467 12448656 d NN B-NP O
9 468 471 12448656 and CC O O
10 472 481 12448656 escalated VBN B-VP O
11 482 484 12448656 as IN B-SBAR O
12 485 494 12448656 tolerated VBN B-VP O
13 495 497 12448656 to TO B-PP O
14 498 502 12448656 1200 CD B-NP O
15 503 505 12448656 mg NN I-NP O
16 505 506 12448656 / SYM O O
17 506 507 12448656 d NN B-NP O
18 508 510 12448656 by IN B-PP O
19 511 514 12448656 day NN B-NP O
20 515 517 12448656 54 CD I-NP O
21 517 518 12448656 . . O O

1 519 524 12448656 Fifty CD B-NP O
2 524 525 12448656 - HYPH I-NP O
3 525 529 12448656 nine CD I-NP O
4 530 533 12448656 per IN B-PP O
5 534 538 12448656 cent NN B-NP O
6 539 541 12448656 of IN B-PP O
7 542 550 12448656 patients NNS B-NP O
8 551 554 12448656 had VBD B-VP O
9 555 558 12448656 had VBN I-VP O
10 559 567 12448656 previous JJ B-NP O
11 568 575 12448656 therapy NN I-NP O
12 576 580 12448656 with IN B-PP O
13 581 583 12448656 IL NN B-NP O
14 583 584 12448656 - HYPH B-NP O
15 584 585 12448656 2 CD I-NP O
16 586 589 12448656 and CC I-NP O
17 590 593 12448656 52% CD I-NP O
18 594 598 12448656 were VBD B-VP O
19 599 610 12448656 performance NN B-NP O
20 611 617 12448656 status NN I-NP O
21 618 619 12448656 2 CD B-NP O
22 620 622 12448656 or CC I-NP O
23 623 624 12448656 3 CD I-NP O
24 624 625 12448656 . . O O

1 626 634 12448656 Systemic JJ B-NP O
2 635 641 12448656 plasma NN I-NP O
3 642 649 12448656 VEGF165 NN I-NP O
4 650 656 12448656 levels NNS I-NP O
5 657 661 12448656 were VBD B-VP O
6 662 670 12448656 measured VBN I-VP O
7 671 673 12448656 by IN B-PP O
8 674 678 12448656 dual JJ B-NP O
9 679 689 12448656 monoclonal JJ I-NP O
10 690 695 12448656 ELISA NN I-NP O
11 696 698 12448656 in IN B-PP O
12 699 700 12448656 8 CD B-NP O
13 701 709 12448656 patients NNS I-NP O
14 709 710 12448656 . . O O

1 711 718 12448656 RESULTS NNS B-NP O
2 718 719 12448656 : : O O
3 720 722 12448656 24 CD B-NP O
4 723 731 12448656 patients NNS I-NP O
5 732 736 12448656 were VBD B-VP O
6 737 746 12448656 evaluable JJ B-ADJP O
7 747 750 12448656 for IN B-PP O
8 751 759 12448656 response NN B-NP O
9 760 764 12448656 with IN B-PP O
10 765 768 12448656 one CD B-NP O
11 769 776 12448656 partial JJ I-NP O
12 777 785 12448656 response NN I-NP O
13 786 788 12448656 of IN B-PP O
14 789 791 12448656 11 CD B-NP O
15 792 798 12448656 months NNS I-NP O
16 799 807 12448656 duration NN I-NP O
17 808 810 12448656 of IN B-PP O
18 811 812 12448656 a DT B-NP O
19 813 820 12448656 patient NN I-NP O
20 821 825 12448656 with IN B-PP O
21 826 833 12448656 hepatic JJ B-NP O
22 834 837 12448656 and CC I-NP O
23 838 847 12448656 pulmonary JJ I-NP O
24 848 858 12448656 metastases NNS I-NP D009362
25 859 860 12448656 ( ( O O
26 860 862 12448656 4% NN B-NP O
27 862 863 12448656 ) ) O O
28 863 864 12448656 , , O O
29 865 868 12448656 one CD B-NP O
30 869 874 12448656 minor JJ I-NP O
31 875 883 12448656 response NN I-NP O
32 883 884 12448656 , , O O
33 885 888 12448656 and CC O O
34 889 890 12448656 2 CD B-NP O
35 891 899 12448656 patients NNS I-NP O
36 900 906 12448656 stable JJ B-ADJP O
37 907 910 12448656 for IN B-PP O
38 911 915 12448656 over IN B-NP O
39 916 917 12448656 6 CD I-NP O
40 918 924 12448656 months NNS I-NP O
41 924 925 12448656 . . O O

1 926 936 12448656 Somnolence NN B-NP D006970
2 937 940 12448656 and CC I-NP O
3 941 953 12448656 constipation NN I-NP D003248
4 954 958 12448656 were VBD B-VP O
5 959 968 12448656 prominent JJ B-NP O
6 969 979 12448656 toxicities NNS I-NP D064420
7 980 983 12448656 and CC O O
8 984 988 12448656 most JJS B-NP O
9 989 997 12448656 patients NNS I-NP O
10 998 1003 12448656 could MD B-VP O
11 1004 1007 12448656 not RB I-VP O
12 1008 1016 12448656 tolerate VB I-VP O
13 1017 1020 12448656 the DT B-NP O
14 1021 1025 12448656 1200 CD I-NP O
15 1026 1028 12448656 mg NN I-NP O
16 1028 1029 12448656 / SYM B-NP O
17 1029 1032 12448656 day NN I-NP O
18 1033 1037 12448656 dose NN I-NP O
19 1038 1043 12448656 level NN I-NP O
20 1043 1044 12448656 . . O O

1 1045 1053 12448656 Systemic JJ B-NP O
2 1054 1060 12448656 plasma NN I-NP O
3 1061 1068 12448656 VEGF165 NN I-NP O
4 1069 1075 12448656 levels NNS I-NP O
5 1076 1079 12448656 did VBD B-VP O
6 1080 1083 12448656 not RB I-VP O
7 1084 1090 12448656 change VB I-VP O
8 1091 1095 12448656 with IN B-PP O
9 1096 1103 12448656 therapy NN B-NP O
10 1103 1104 12448656 . . O O

1 1105 1115 12448656 CONCLUSION NN B-NP O
2 1115 1116 12448656 : : O O
3 1117 1122 12448656 These DT B-NP O
4 1123 1130 12448656 results NNS I-NP O
5 1131 1134 12448656 are VBP B-VP O
6 1135 1145 12448656 consistent JJ B-ADJP O
7 1146 1150 12448656 with IN B-PP O
8 1151 1152 12448656 a DT B-NP O
9 1153 1156 12448656 low JJ I-NP O
10 1157 1162 12448656 level NN I-NP O
11 1163 1165 12448656 of IN B-PP O
12 1166 1174 12448656 activity NN B-NP O
13 1175 1177 12448656 of IN B-PP O
14 1178 1189 12448656 thalidomide NN B-NP D013792
15 1190 1192 12448656 in IN B-PP O
16 1193 1198 12448656 renal JJ B-NP D002292
17 1199 1203 12448656 cell NN I-NP D002292
18 1204 1213 12448656 carcinoma NN I-NP D002292
19 1213 1214 12448656 . . O O

1 1215 1229 12448656 Administration NN B-NP O
2 1230 1232 12448656 of IN B-PP O
3 1233 1238 12448656 doses NNS B-NP O
4 1239 1243 12448656 over IN B-PP O
5 1244 1247 12448656 800 CD B-NP O
6 1248 1250 12448656 mg NN I-NP O
7 1250 1251 12448656 / SYM B-NP O
8 1251 1254 12448656 day NN I-NP O
9 1255 1258 12448656 was VBD B-VP O
10 1259 1268 12448656 difficult JJ B-ADJP O
11 1269 1271 12448656 to TO B-VP O
12 1272 1279 12448656 achieve VB I-VP O
13 1280 1282 12448656 in IN B-PP O
14 1283 1287 12448656 this DT B-NP O
15 1288 1295 12448656 patient NN I-NP O
16 1296 1306 12448656 population NN I-NP O
17 1306 1307 12448656 , , O O
18 1308 1315 12448656 however RB B-NP O
19 1316 1321 12448656 lower JJR I-NP O
20 1322 1327 12448656 doses NNS I-NP O
21 1328 1332 12448656 were VBD B-VP O
22 1333 1342 12448656 practical JJ B-ADJP O
23 1342 1343 12448656 . . O O

1 1344 1347 12448656 The DT B-NP O
2 1348 1352 12448656 dose NN I-NP O
3 1352 1353 12448656 - HYPH I-NP O
4 1353 1361 12448656 response NN I-NP O
5 1362 1374 12448656 relationship NN I-NP O
6 1374 1375 12448656 , , O O
7 1376 1378 12448656 if IN B-SBAR O
8 1379 1382 12448656 any DT B-NP O
9 1382 1383 12448656 , , O O
10 1384 1386 12448656 of IN B-PP O
11 1387 1398 12448656 thalidomide NN B-NP D013792
12 1399 1402 12448656 for IN B-PP O
13 1403 1408 12448656 renal JJ B-NP D002292
14 1409 1413 12448656 cell NN I-NP D002292
15 1414 1423 12448656 carcinoma NN I-NP D002292
16 1424 1426 12448656 is VBZ B-VP O
17 1427 1434 12448656 unclear JJ B-ADJP O
18 1434 1435 12448656 . . O O

1 0 0 18201582 -DOCSTART- -X- -X- O

1 0 7 18201582 Results NNS B-NP O
2 8 10 18201582 of IN B-PP O
3 11 12 18201582 a DT B-NP O
4 13 24 18201582 comparative JJ I-NP O
5 24 25 18201582 , , I-NP O
6 26 31 18201582 phase NN I-NP O
7 32 35 18201582 III CD I-NP O
8 35 36 18201582 , , I-NP O
9 37 39 18201582 12 CD I-NP O
10 39 40 18201582 - HYPH I-NP O
11 40 44 18201582 week NN I-NP O
12 44 45 18201582 , , O O
13 46 57 18201582 multicenter JJ B-NP O
14 57 58 18201582 , , I-NP O
15 59 70 18201582 prospective JJ I-NP O
16 70 71 18201582 , , I-NP O
17 72 82 18201582 randomized VBN I-NP O
18 82 83 18201582 , , I-NP O
19 84 90 18201582 double JJ I-NP O
20 90 91 18201582 - HYPH I-NP O
21 91 96 18201582 blind JJ I-NP O
22 97 107 18201582 assessment NN I-NP O
23 108 110 18201582 of IN B-PP O
24 111 114 18201582 the DT B-NP O
25 115 123 18201582 efficacy NN I-NP O
26 124 127 18201582 and CC I-NP O
27 128 140 18201582 tolerability NN I-NP O
28 141 143 18201582 of IN B-PP O
29 144 145 18201582 a DT B-NP O
30 146 151 18201582 fixed VBN I-NP O
31 151 152 18201582 - HYPH I-NP O
32 152 156 18201582 dose NN I-NP O
33 157 168 18201582 combination NN I-NP O
34 169 171 18201582 of IN B-PP O
35 172 183 18201582 telmisartan NN B-NP C084178
36 184 187 18201582 and CC I-NP O
37 188 198 18201582 amlodipine NN I-NP D017311
38 199 205 18201582 versus CC I-NP O
39 206 216 18201582 amlodipine NN I-NP D017311
40 217 228 18201582 monotherapy NN I-NP O
41 229 231 18201582 in IN B-PP O
42 232 238 18201582 Indian JJ B-NP O
43 239 245 18201582 adults NNS I-NP O
44 246 250 18201582 with IN B-PP O
45 251 256 18201582 stage NN B-NP O
46 257 259 18201582 II CD I-NP O
47 260 272 18201582 hypertension NN I-NP D006973
48 272 273 18201582 . . I-NP O
49 274 283 18201582 OBJECTIVE NN I-NP O
50 283 284 18201582 : : O O
51 285 288 18201582 The DT B-NP O
52 289 292 18201582 aim NN I-NP O
53 293 295 18201582 of IN B-PP O
54 296 300 18201582 this DT B-NP O
55 301 306 18201582 study NN I-NP O
56 307 310 18201582 was VBD B-VP O
57 311 313 18201582 to TO B-VP O
58 314 322 18201582 evaluate VB I-VP O
59 323 326 18201582 the DT B-NP O
60 327 335 18201582 efficacy NN I-NP O
61 336 339 18201582 and CC I-NP O
62 340 352 18201582 tolerability NN I-NP O
63 353 355 18201582 of IN B-PP O
64 356 357 18201582 a DT B-NP O
65 358 361 18201582 new JJ I-NP O
66 362 367 18201582 fixed VBN I-NP O
67 367 368 18201582 - HYPH I-NP O
68 368 372 18201582 dose NN I-NP O
69 373 384 18201582 combination NN I-NP O
70 385 386 18201582 ( ( O O
71 386 389 18201582 FDC NN B-NP O
72 389 390 18201582 ) ) O O
73 391 393 18201582 of IN B-PP O
74 394 405 18201582 telmisartan NN B-NP C084178
75 406 408 18201582 40 CD I-NP O
76 409 411 18201582 mg NN I-NP O
77 412 413 18201582 + SYM B-VP O
78 414 424 18201582 amlodipine NN B-NP D017311
79 425 426 18201582 5 CD I-NP O
80 427 429 18201582 mg NN I-NP O
81 430 431 18201582 ( ( O O
82 431 432 18201582 T NN B-NP O
83 432 433 18201582 + SYM B-NP O
84 433 434 18201582 A NN I-NP O
85 434 435 18201582 ) ) O O
86 436 444 18201582 compared VBN B-PP O
87 445 449 18201582 with IN B-PP O
88 450 460 18201582 amlodipine NN B-NP D017311
89 461 462 18201582 5 CD I-NP O
90 462 463 18201582 - HYPH I-NP O
91 463 465 18201582 mg NN I-NP O
92 466 477 18201582 monotherapy NN I-NP O
93 478 479 18201582 ( ( O O
94 479 480 18201582 A NN B-NP O
95 480 481 18201582 ) ) O O
96 482 484 18201582 in IN B-PP O
97 485 490 18201582 adult JJ B-NP O
98 491 497 18201582 Indian JJ I-NP O
99 498 506 18201582 patients NNS I-NP O
100 507 511 18201582 with IN B-PP O
101 512 517 18201582 stage NN B-NP O
102 518 520 18201582 II CD I-NP O
103 521 533 18201582 hypertension NN I-NP D006973
104 533 534 18201582 . . O O

1 535 542 18201582 METHODS NNS B-NP O
2 542 543 18201582 : : O O
3 544 548 18201582 This DT B-NP O
4 549 560 18201582 comparative JJ I-NP O
5 560 561 18201582 , , I-NP O
6 562 567 18201582 Phase NN I-NP O
7 568 571 18201582 III CD I-NP O
8 571 572 18201582 , , I-NP O
9 573 575 18201582 12 CD I-NP O
10 575 576 18201582 - HYPH I-NP O
11 576 580 18201582 week NN I-NP O
12 580 581 18201582 , , O O
13 582 593 18201582 multicenter JJ B-NP O
14 593 594 18201582 , , I-NP O
15 595 606 18201582 prospective JJ I-NP O
16 606 607 18201582 , , I-NP O
17 608 618 18201582 randomized VBN I-NP O
18 618 619 18201582 , , I-NP O
19 620 626 18201582 double JJ I-NP O
20 626 627 18201582 - HYPH I-NP O
21 627 632 18201582 blind JJ I-NP O
22 633 638 18201582 study NN I-NP O
23 639 642 18201582 was VBD B-VP O
24 643 652 18201582 conducted VBN I-VP O
25 653 655 18201582 in IN B-PP O
26 656 662 18201582 Indian JJ B-NP O
27 663 671 18201582 patients NNS I-NP O
28 672 676 18201582 aged VBN B-ADJP O
29 677 679 18201582 18 CD B-NP O
30 680 682 18201582 to TO I-NP O
31 683 685 18201582 65 CD I-NP O
32 686 691 18201582 years NNS I-NP O
33 692 696 18201582 with IN B-PP O
34 697 708 18201582 established VBN B-NP O
35 709 714 18201582 stage NN I-NP O
36 715 717 18201582 II CD I-NP O
37 718 730 18201582 hypertension NN I-NP D006973
38 730 731 18201582 . . O O

1 732 740 18201582 Patients NNS B-NP O
2 741 745 18201582 were VBD B-VP O
3 746 753 18201582 treated VBN I-VP O
4 754 758 18201582 with IN B-PP O
5 759 763 18201582 oral JJ B-NP O
6 764 767 18201582 FDC NN I-NP O
7 768 770 18201582 of IN B-PP O
8 771 772 18201582 T NN B-NP O
9 772 773 18201582 + CC I-NP O
10 773 774 18201582 A NN I-NP O
11 775 777 18201582 or CC I-NP O
12 778 779 18201582 A NN I-NP O
13 780 782 18201582 QD NN I-NP O
14 783 789 18201582 before IN B-PP O
15 790 799 18201582 breakfast NN B-NP O
16 800 803 18201582 for IN B-PP O
17 804 806 18201582 12 CD B-NP O
18 807 812 18201582 weeks NNS I-NP O
19 812 813 18201582 ; : O O
20 814 819 18201582 blood NN B-NP O
21 820 828 18201582 pressure NN I-NP O
22 829 830 18201582 ( ( O O
23 830 832 18201582 BP NN B-NP O
24 832 833 18201582 ) ) O O
25 834 837 18201582 and CC O O
26 838 843 18201582 heart NN B-NP O
27 844 848 18201582 rate NN I-NP O
28 849 853 18201582 were VBD B-VP O
29 854 862 18201582 measured VBN I-VP O
30 863 865 18201582 in IN B-PP O
31 866 869 18201582 the DT B-NP O
32 870 877 18201582 sitting VBG I-NP O
33 878 886 18201582 position NN I-NP O
34 886 887 18201582 . . O O

1 888 895 18201582 Primary JJ B-NP O
2 896 904 18201582 efficacy NN I-NP O
3 905 908 18201582 end NN I-NP O
4 909 915 18201582 points NNS I-NP O
5 916 920 18201582 were VBD B-VP O
6 921 930 18201582 reduction NN B-NP O
7 931 933 18201582 in IN B-PP O
8 934 942 18201582 clinical JJ B-NP O
9 943 951 18201582 systolic JJ I-NP O
10 952 954 18201582 BP NN I-NP O
11 955 956 18201582 ( ( O O
12 956 959 18201582 SBP NN B-NP O
13 959 960 18201582 ) ) O O
14 960 961 18201582 / SYM B-NP O
15 962 971 18201582 diastolic JJ I-NP O
16 972 974 18201582 BP NN I-NP O
17 975 976 18201582 ( ( O O
18 976 979 18201582 DBP NN B-NP O
19 979 980 18201582 ) ) O O
20 981 985 18201582 from IN B-PP O
21 986 994 18201582 baseline NN B-NP O
22 995 997 18201582 to TO B-VP O
23 998 1003 18201582 study VB I-VP O
24 1004 1007 18201582 end NN B-NP O
25 1008 1011 18201582 and CC I-NP O
26 1012 1018 18201582 number NN I-NP O
27 1019 1021 18201582 of IN B-PP O
28 1022 1032 18201582 responders NNS B-NP O
29 1033 1034 18201582 ( ( O O
30 1034 1036 18201582 ie FW B-NP O
31 1036 1037 18201582 , , O O
32 1038 1046 18201582 patients NNS B-NP O
33 1047 1050 18201582 who WP B-NP O
34 1051 1059 18201582 achieved VBD B-VP O
35 1060 1066 18201582 target NN B-NP O
36 1067 1070 18201582 SBP NN I-NP O
37 1070 1071 18201582 / SYM B-NP O
38 1072 1075 18201582 DBP NN I-NP O
39 1076 1077 18201582 < SYM B-NP O
40 1077 1080 18201582 130 CD I-NP O
41 1080 1081 18201582 / SYM B-NP O
42 1081 1082 18201582 < SYM I-NP O
43 1082 1084 18201582 80 CD I-NP O
44 1085 1087 18201582 mm NN I-NP O
45 1088 1090 18201582 Hg NN I-NP O
46 1090 1091 18201582 ) ) O O
47 1092 1094 18201582 at IN B-PP O
48 1095 1098 18201582 end NN B-NP O
49 1099 1101 18201582 of IN B-PP O
50 1102 1107 18201582 study NN B-NP O
51 1107 1108 18201582 . . O O

1 1109 1121 18201582 Tolerability NN B-NP O
2 1122 1125 18201582 was VBD B-VP O
3 1126 1134 18201582 assessed VBN I-VP O
4 1135 1137 18201582 by IN B-PP O
5 1138 1147 18201582 treatment NN B-NP O
6 1147 1148 18201582 - HYPH O O
7 1148 1156 18201582 emergent JJ B-NP O
8 1157 1164 18201582 adverse JJ I-NP O
9 1165 1171 18201582 events NNS I-NP O
10 1171 1172 18201582 , , O O
11 1173 1183 18201582 identified VBN B-VP O
12 1184 1189 18201582 using VBG B-VP O
13 1190 1198 18201582 physical JJ B-NP O
14 1199 1210 18201582 examination NN I-NP O
15 1210 1211 18201582 , , O O
16 1212 1222 18201582 laboratory NN B-NP O
17 1223 1231 18201582 analysis NN I-NP O
18 1231 1232 18201582 , , O O
19 1233 1236 18201582 and CC O O
20 1237 1256 18201582 electrocardiography NN B-NP O
21 1256 1257 18201582 . . O O

1 1258 1265 18201582 RESULTS NNS B-NP O
2 1265 1266 18201582 : : O O
3 1267 1268 18201582 A DT B-NP O
4 1269 1274 18201582 total NN I-NP O
5 1275 1277 18201582 of IN B-PP O
6 1278 1281 18201582 210 CD B-NP O
7 1282 1290 18201582 patients NNS I-NP O
8 1291 1295 18201582 were VBD B-VP O
9 1296 1304 18201582 enrolled VBN I-VP O
10 1305 1307 18201582 in IN B-PP O
11 1308 1311 18201582 the DT B-NP O
12 1312 1317 18201582 study NN I-NP O
13 1317 1318 18201582 ; : O O
14 1319 1322 18201582 203 CD B-NP O
15 1323 1331 18201582 patients NNS I-NP O
16 1332 1333 18201582 ( ( O O
17 1333 1336 18201582 143 CD B-NP O
18 1337 1340 18201582 men NNS I-NP O
19 1340 1341 18201582 , , O O
20 1342 1344 18201582 60 CD B-NP O
21 1345 1350 18201582 women NNS I-NP O
22 1350 1351 18201582 ) ) O O
23 1352 1361 18201582 completed VBD B-VP O
24 1362 1365 18201582 the DT B-NP O
25 1366 1371 18201582 study NN I-NP O
26 1372 1377 18201582 while IN B-SBAR O
27 1378 1379 18201582 7 CD B-NP O
28 1380 1384 18201582 were VBD B-VP O
29 1385 1389 18201582 lost VBN I-VP O
30 1390 1392 18201582 to TO I-VP O
31 1393 1399 18201582 follow VB I-VP O
32 1399 1400 18201582 - HYPH O O
33 1400 1402 18201582 up RP B-PRT O
34 1403 1404 18201582 ( ( O O
35 1404 1405 18201582 4 CD B-NP O
36 1406 1414 18201582 patients NNS I-NP O
37 1415 1417 18201582 in IN B-PP O
38 1418 1421 18201582 the DT B-NP O
39 1422 1423 18201582 T NN I-NP O
40 1423 1424 18201582 + SYM I-NP O
41 1424 1425 18201582 A NN I-NP O
42 1426 1431 18201582 group NN I-NP O
43 1432 1435 18201582 and CC O O
44 1436 1437 18201582 3 CD B-NP O
45 1438 1440 18201582 in IN B-PP O
46 1441 1444 18201582 the DT B-NP O
47 1445 1446 18201582 A NN I-NP O
48 1447 1452 18201582 group NN I-NP O
49 1452 1453 18201582 ) ) O O
50 1454 1457 18201582 and CC O O
51 1458 1468 18201582 considered VBN B-VP O
52 1469 1473 18201582 with IN B-PP O
53 1473 1474 18201582 - HYPH B-NP O
54 1474 1479 18201582 drawn VBN B-VP O
55 1479 1480 18201582 . . O O

1 1481 1483 18201582 At IN B-PP O
2 1484 1489 18201582 study NN B-NP O
3 1490 1493 18201582 end NN I-NP O
4 1493 1494 18201582 , , O O
5 1495 1508 18201582 statistically RB B-NP O
6 1509 1520 18201582 significant JJ I-NP O
7 1521 1531 18201582 percentage NN I-NP O
8 1532 1542 18201582 reductions NNS I-NP O
9 1543 1547 18201582 from IN B-PP O
10 1548 1556 18201582 baseline NN B-NP O
11 1557 1563 18201582 within IN B-PP O
12 1564 1570 18201582 groups NNS B-NP O
13 1571 1574 18201582 and CC B-PP O
14 1575 1582 18201582 between IN B-PP O
15 1583 1589 18201582 groups NNS B-NP O
16 1590 1594 18201582 were VBD B-VP O
17 1595 1603 18201582 observed VBN I-VP O
18 1604 1606 18201582 in IN B-PP O
19 1607 1610 18201582 SBP NN B-NP O
20 1611 1612 18201582 ( ( O O
21 1612 1613 18201582 T NN B-NP O
22 1613 1614 18201582 + CC O O
23 1614 1615 18201582 A NN B-NP O
24 1616 1617 18201582 [ ( O O
25 1617 1618 18201582 - HYPH B-NP O
26 1618 1623 18201582 27.4% NN I-NP O
27 1623 1624 18201582 ] ) O O
28 1624 1625 18201582 ; : O O
29 1626 1627 18201582 A DT B-NP O
30 1628 1629 18201582 [ ( I-NP O
31 1629 1630 18201582 - HYPH I-NP O
32 1630 1635 18201582 16.6% NN I-NP O
33 1635 1636 18201582 ] ) O O
34 1636 1637 18201582 ) ) O O
35 1638 1641 18201582 and CC O O
36 1642 1645 18201582 DBP NN B-NP O
37 1646 1647 18201582 ( ( O O
38 1647 1648 18201582 T NN B-NP O
39 1648 1649 18201582 + CC O O
40 1649 1650 18201582 A NN B-NP O
41 1651 1652 18201582 [ ( O O
42 1652 1653 18201582 - HYPH B-NP O
43 1653 1658 18201582 20.1% NN I-NP O
44 1658 1659 18201582 ] ) O O
45 1659 1660 18201582 ; : O O
46 1661 1662 18201582 A DT B-NP O
47 1663 1664 18201582 [ ( I-NP O
48 1664 1665 18201582 - HYPH I-NP O
49 1665 1670 18201582 13.3% NN I-NP O
50 1670 1671 18201582 ] ) O O
51 1671 1672 18201582 ) ) O O
52 1673 1674 18201582 ( ( O O
53 1674 1677 18201582 all DT B-NP O
54 1677 1678 18201582 , , O O
55 1679 1680 18201582 P NN B-NP O
56 1681 1682 18201582 < SYM B-NP O
57 1683 1687 18201582 0.05 CD I-NP O
58 1687 1688 18201582 ) ) O O
59 1688 1689 18201582 . . O O

1 1690 1698 18201582 Response NN B-NP O
2 1699 1704 18201582 rates NNS I-NP O
3 1705 1709 18201582 were VBD B-VP O
4 1710 1715 18201582 87.3% CD B-NP O
5 1716 1717 18201582 ( ( O O
6 1717 1719 18201582 89 CD B-NP O
7 1719 1720 18201582 / SYM O O
8 1720 1723 18201582 102 CD B-NP O
9 1723 1724 18201582 ) ) O O
10 1725 1727 18201582 in IN B-PP O
11 1728 1731 18201582 the DT B-NP O
12 1732 1733 18201582 T NN I-NP O
13 1733 1734 18201582 + SYM I-NP O
14 1734 1735 18201582 A NN I-NP O
15 1736 1741 18201582 group NN I-NP O
16 1742 1745 18201582 and CC O O
17 1746 1751 18201582 69.3% NN B-NP O
18 1752 1753 18201582 ( ( O O
19 1753 1755 18201582 70 CD B-NP O
20 1755 1756 18201582 / SYM I-NP O
21 1756 1759 18201582 101 CD I-NP O
22 1759 1760 18201582 ) ) O O
23 1761 1763 18201582 in IN B-PP O
24 1764 1767 18201582 the DT B-NP O
25 1768 1769 18201582 A NN I-NP O
26 1770 1775 18201582 group NN I-NP O
27 1776 1777 18201582 ( ( O O
28 1777 1778 18201582 P NN B-NP O
29 1779 1780 18201582 < SYM O O
30 1781 1785 18201582 0.05 CD B-NP O
31 1785 1786 18201582 ) ) O O
32 1786 1787 18201582 . . O O

1 1788 1791 18201582 The DT B-NP O
2 1792 1803 18201582 prevalences NNS I-NP O
3 1804 1806 18201582 of IN B-PP O
4 1807 1814 18201582 adverse JJ B-NP O
5 1815 1821 18201582 events NNS I-NP O
6 1822 1826 18201582 were VBD B-VP O
7 1827 1830 18201582 not RB B-ADJP O
8 1831 1844 18201582 significantly RB I-ADJP O
9 1845 1854 18201582 different JJ I-ADJP O
10 1855 1862 18201582 between IN B-PP O
11 1863 1866 18201582 the DT B-NP O
12 1867 1868 18201582 2 CD I-NP O
13 1869 1878 18201582 treatment NN I-NP O
14 1879 1885 18201582 groups NNS I-NP O
15 1886 1887 18201582 ( ( O O
16 1887 1888 18201582 T NN B-NP O
17 1888 1889 18201582 + SYM I-NP O
18 1889 1890 18201582 A NN I-NP O
19 1890 1891 18201582 , , O O
20 1892 1897 18201582 16.0% CD B-NP O
21 1898 1899 18201582 [ ( O O
22 1899 1901 18201582 17 CD B-NP O
23 1901 1902 18201582 / SYM I-NP O
24 1902 1905 18201582 106 CD I-NP O
25 1905 1906 18201582 ] ) O O
26 1906 1907 18201582 ; : O O
27 1908 1909 18201582 A DT B-NP O
28 1909 1910 18201582 , , O O
29 1911 1916 18201582 15.4% CD B-NP O
30 1917 1918 18201582 [ ( O O
31 1918 1920 18201582 16 CD B-NP O
32 1920 1921 18201582 / SYM I-NP O
33 1921 1924 18201582 104 CD I-NP O
34 1924 1925 18201582 ] ) O O
35 1925 1926 18201582 ) ) O O
36 1926 1927 18201582 . . O O

1 1928 1938 18201582 Peripheral JJ B-NP O
2 1939 1944 18201582 edema NN I-NP D004487
3 1945 1948 18201582 was VBD B-VP O
4 1949 1957 18201582 reported VBN I-VP O
5 1958 1960 18201582 in IN B-PP O
6 1961 1965 18201582 8.5% CD B-NP O
7 1966 1974 18201582 patients NNS I-NP O
8 1975 1976 18201582 ( ( O O
9 1976 1977 18201582 9 CD B-NP O
10 1977 1978 18201582 / SYM I-NP O
11 1978 1981 18201582 106 CD I-NP O
12 1981 1982 18201582 ) ) O O
13 1983 1985 18201582 in IN B-PP O
14 1986 1989 18201582 the DT B-NP O
15 1990 1991 18201582 T NN I-NP O
16 1991 1992 18201582 + SYM I-NP O
17 1992 1993 18201582 A NN I-NP O
18 1994 1999 18201582 group NN I-NP O
19 2000 2008 18201582 compared VBN B-PP O
20 2009 2013 18201582 with IN B-PP O
21 2014 2019 18201582 13.5% NN B-NP O
22 2020 2021 18201582 ( ( O O
23 2021 2023 18201582 14 CD B-NP O
24 2023 2024 18201582 / SYM I-NP O
25 2024 2027 18201582 104 CD I-NP O
26 2027 2028 18201582 ) ) O O
27 2029 2031 18201582 in IN B-PP O
28 2032 2035 18201582 the DT B-NP O
29 2036 2037 18201582 A NN I-NP O
30 2038 2043 18201582 group NN I-NP O
31 2043 2044 18201582 , , O O
32 2045 2048 18201582 and CC O O
33 2049 2054 18201582 cough NN B-NP D003371
34 2055 2058 18201582 was VBD B-VP O
35 2059 2067 18201582 reported VBN I-VP O
36 2068 2070 18201582 in IN B-PP O
37 2071 2075 18201582 3.8% CD B-NP O
38 2076 2084 18201582 patients NNS I-NP O
39 2085 2086 18201582 ( ( O O
40 2086 2087 18201582 4 CD B-NP O
41 2087 2088 18201582 / SYM I-NP O
42 2088 2091 18201582 106 CD I-NP O
43 2091 2092 18201582 ) ) O O
44 2093 2095 18201582 in IN B-PP O
45 2096 2099 18201582 the DT B-NP O
46 2100 2101 18201582 T NN I-NP O
47 2101 2102 18201582 + SYM I-NP O
48 2102 2103 18201582 A NN I-NP O
49 2104 2109 18201582 group NN I-NP O
50 2110 2113 18201582 and CC O O
51 2114 2118 18201582 1.0% CD B-NP O
52 2119 2120 18201582 ( ( O O
53 2120 2121 18201582 1 CD B-NP O
54 2121 2122 18201582 / SYM O O
55 2122 2125 18201582 104 CD O O
56 2125 2126 18201582 ) ) O O
57 2127 2135 18201582 patients NNS B-NP O
58 2136 2138 18201582 in IN B-PP O
59 2139 2142 18201582 the DT B-NP O
60 2143 2144 18201582 A NN I-NP O
61 2145 2150 18201582 group NN I-NP O
62 2150 2151 18201582 ; : O O
63 2152 2157 18201582 these DT B-NP O
64 2158 2169 18201582 differences NNS I-NP O
65 2170 2173 18201582 did VBD B-VP O
66 2174 2177 18201582 not RB I-VP O
67 2178 2183 18201582 reach VB I-VP O
68 2184 2195 18201582 statistical JJ B-NP O
69 2196 2208 18201582 significance NN I-NP O
70 2208 2209 18201582 . . O O

1 2210 2213 18201582 The DT B-NP O
2 2214 2224 18201582 incidences NNS I-NP O
3 2225 2227 18201582 of IN B-PP O
4 2228 2236 18201582 headache NN B-NP D006261
5 2236 2237 18201582 , , O O
6 2238 2247 18201582 dizziness NN B-NP D004244
7 2247 2248 18201582 , , O O
8 2249 2252 18201582 and CC O O
9 2253 2261 18201582 diarrhea NN B-NP D003967
10 2262 2266 18201582 were VBD B-VP O
11 2267 2274 18201582 similar JJ B-ADJP O
12 2275 2282 18201582 between IN B-PP O
13 2283 2286 18201582 the DT B-NP O
14 2287 2288 18201582 2 CD I-NP O
15 2289 2295 18201582 groups NNS I-NP O
16 2295 2296 18201582 . . O O

1 2297 2308 18201582 CONCLUSIONS NNS B-NP O
2 2308 2309 18201582 : : O O
3 2310 2315 18201582 Among IN B-PP O
4 2316 2321 18201582 these DT B-NP O
5 2322 2328 18201582 Indian JJ I-NP O
6 2329 2337 18201582 patients NNS I-NP O
7 2338 2342 18201582 with IN B-PP O
8 2343 2348 18201582 stage NN B-NP O
9 2349 2351 18201582 II CD I-NP O
10 2352 2364 18201582 hypertension NN I-NP D006973
11 2364 2365 18201582 , , O O
12 2366 2369 18201582 the DT B-NP O
13 2370 2373 18201582 FDC NN I-NP O
14 2374 2376 18201582 of IN B-PP O
15 2377 2378 18201582 T NN B-NP O
16 2378 2379 18201582 + SYM B-NP O
17 2379 2380 18201582 A NN I-NP O
18 2381 2384 18201582 was VBD B-VP O
19 2385 2390 18201582 found VBN I-VP O
20 2391 2393 18201582 to TO I-VP O
21 2394 2396 18201582 be VB I-VP O
22 2397 2410 18201582 significantly RB B-ADJP O
23 2411 2415 18201582 more RBR I-ADJP O
24 2416 2425 18201582 effective JJ I-ADJP O
25 2425 2426 18201582 , , O O
26 2427 2431 18201582 with IN B-PP O
27 2432 2438 18201582 regard NN B-NP O
28 2439 2441 18201582 to TO B-PP O
29 2442 2444 18201582 BP NN B-NP O
30 2445 2455 18201582 reductions NNS I-NP O
31 2455 2456 18201582 , , O O
32 2457 2461 18201582 than IN B-PP O
33 2462 2463 18201582 A NN B-NP O
34 2463 2464 18201582 , , O O
35 2465 2468 18201582 and CC O O
36 2469 2473 18201582 both DT B-NP O
37 2474 2484 18201582 treatments NNS I-NP O
38 2485 2489 18201582 were VBD B-VP O
39 2490 2494 18201582 well RB I-VP O
40 2495 2504 18201582 tolerated VBN I-VP O
41 2504 2505 18201582 . . O O

1 0 0 15579441 -DOCSTART- -X- -X- O

1 0 7 15579441 Hypoxia NN B-NP D000860
2 8 10 15579441 in IN B-PP O
3 11 16 15579441 renal JJ B-NP D007674
4 17 24 15579441 disease NN I-NP D007674
5 25 29 15579441 with IN B-PP O
6 30 41 15579441 proteinuria NN B-NP D011507
7 42 45 15579441 and CC O O
8 45 46 15579441 / SYM B-NP O
9 46 48 15579441 or CC O O
10 49 59 15579441 glomerular JJ B-NP O
11 60 72 15579441 hypertension NN I-NP D006973
12 72 73 15579441 . . O O
13 74 81 15579441 Despite IN B-PP O
14 82 85 15579441 the DT B-NP O
15 86 96 15579441 increasing VBG I-NP O
16 97 101 15579441 need NN I-NP O
17 102 104 15579441 to TO B-VP O
18 105 113 15579441 identify VB I-VP O
19 114 117 15579441 and CC I-VP O
20 118 126 15579441 quantify VB I-VP O
21 127 133 15579441 tissue NN B-NP O
22 134 145 15579441 oxygenation NN I-NP O
23 146 148 15579441 at IN B-PP O
24 149 152 15579441 the DT B-NP O
25 153 161 15579441 cellular JJ I-NP O
26 162 167 15579441 level NN I-NP O
27 167 168 15579441 , , O O
28 169 179 15579441 relatively RB B-NP O
29 180 183 15579441 few JJ I-NP O
30 184 191 15579441 methods NNS I-NP O
31 192 196 15579441 have VBP B-VP O
32 197 201 15579441 been VBN I-VP O
33 202 211 15579441 available JJ B-ADJP O
34 211 212 15579441 . . O O

1 213 215 15579441 In IN B-PP O
2 216 220 15579441 this DT B-NP O
3 221 226 15579441 study NN I-NP O
4 226 227 15579441 , , O O
5 228 230 15579441 we PRP B-NP O
6 231 240 15579441 developed VBD B-VP O
7 241 242 15579441 a DT B-NP O
8 243 246 15579441 new JJ I-NP O
9 247 254 15579441 hypoxia NN I-NP D000860
10 254 255 15579441 - HYPH B-NP O
11 255 265 15579441 responsive JJ I-NP O
12 266 274 15579441 reporter NN I-NP O
13 275 281 15579441 vector NN I-NP O
14 282 287 15579441 using VBG B-VP O
15 288 289 15579441 a DT B-NP O
16 290 297 15579441 hypoxia NN I-NP D000860
17 297 298 15579441 - HYPH B-NP O
18 298 308 15579441 responsive JJ I-NP O
19 309 316 15579441 element NN I-NP O
20 317 319 15579441 of IN B-PP O
21 320 323 15579441 the DT B-NP O
22 324 325 15579441 5 CD I-NP O
23 325 326 15579441 ' SYM I-NP O
24 327 335 15579441 vascular JJ I-NP O
25 336 347 15579441 endothelial JJ I-NP O
26 348 354 15579441 growth NN I-NP O
27 355 361 15579441 factor NN I-NP O
28 362 374 15579441 untranslated JJ I-NP O
29 375 381 15579441 region NN I-NP O
30 382 385 15579441 and CC O O
31 386 395 15579441 generated VBD B-VP O
32 396 397 15579441 a DT B-NP O
33 398 403 15579441 novel JJ I-NP O
34 404 411 15579441 hypoxia NN I-NP D000860
35 411 412 15579441 - HYPH O O
36 412 419 15579441 sensing VBG B-VP O
37 420 430 15579441 transgenic JJ B-NP O
38 431 434 15579441 rat NN I-NP O
39 434 435 15579441 . . O O

1 436 438 15579441 We PRP B-NP O
2 439 443 15579441 then RB B-ADVP O
3 444 451 15579441 applied VBD B-VP O
4 452 456 15579441 this DT B-NP O
5 457 463 15579441 animal NN I-NP O
6 464 469 15579441 model NN I-NP O
7 470 472 15579441 to TO B-PP O
8 473 476 15579441 the DT B-NP O
9 477 486 15579441 detection NN I-NP O
10 487 489 15579441 of IN B-PP O
11 490 508 15579441 tubulointerstitial JJ B-NP O
12 509 516 15579441 hypoxia NN I-NP D000860
13 517 519 15579441 in IN B-PP O
14 520 523 15579441 the DT B-NP O
15 524 532 15579441 diseased JJ I-NP D007674
16 533 539 15579441 kidney NN I-NP D007674
17 539 540 15579441 . . O O

1 541 545 15579441 With IN B-PP O
2 546 550 15579441 this DT B-NP O
3 551 556 15579441 model NN I-NP O
4 556 557 15579441 , , O O
5 558 560 15579441 we PRP B-NP O
6 561 565 15579441 were VBD B-VP O
7 566 570 15579441 able JJ B-ADJP O
8 571 573 15579441 to TO B-VP O
9 574 582 15579441 identify VB I-VP O
10 583 590 15579441 diffuse JJ B-NP O
11 591 599 15579441 cortical JJ I-NP O
12 600 607 15579441 hypoxia NN I-NP D000860
13 608 610 15579441 in IN B-PP O
14 611 614 15579441 the DT B-NP O
15 615 624 15579441 puromycin NN I-NP D011692
16 625 640 15579441 aminonucleoside NN I-NP D011692
17 640 641 15579441 - HYPH O O
18 641 648 15579441 induced VBN B-NP O
19 649 658 15579441 nephrotic JJ I-NP D009404
20 659 667 15579441 syndrome NN I-NP D009404
21 668 671 15579441 and CC O O
22 672 677 15579441 focal JJ B-NP O
23 678 681 15579441 and CC I-NP O
24 682 691 15579441 segmental JJ I-NP O
25 692 699 15579441 hypoxia NN I-NP D000860
26 700 702 15579441 in IN B-PP O
27 703 706 15579441 the DT B-NP O
28 707 714 15579441 remnant NN I-NP O
29 715 721 15579441 kidney NN I-NP O
30 722 727 15579441 model NN I-NP O
31 727 728 15579441 . . O O

1 729 739 15579441 Expression NN B-NP O
2 740 742 15579441 of IN B-PP O
3 743 746 15579441 the DT B-NP O
4 747 754 15579441 hypoxia NN I-NP D000860
5 754 755 15579441 - HYPH B-NP O
6 755 765 15579441 responsive JJ I-NP O
7 766 775 15579441 transgene NN I-NP O
8 776 785 15579441 increased VBD B-VP O
9 786 796 15579441 throughout IN B-PP O
10 797 800 15579441 the DT B-NP O
11 801 812 15579441 observation NN I-NP O
12 813 819 15579441 period NN I-NP O
13 819 820 15579441 , , O O
14 821 829 15579441 reaching VBG B-VP O
15 830 833 15579441 2.2 CD B-NP O
16 833 834 15579441 - HYPH B-ADJP O
17 834 838 15579441 fold RB B-ADVP O
18 839 841 15579441 at IN B-PP O
19 842 843 15579441 2 CD B-NP O
20 844 849 15579441 weeks NNS I-NP O
21 850 852 15579441 in IN B-PP O
22 853 856 15579441 the DT B-NP O
23 857 866 15579441 puromycin NN I-NP D011692
24 867 882 15579441 aminonucleoside NN I-NP D011692
25 883 888 15579441 model NN I-NP O
26 889 892 15579441 and CC O O
27 893 896 15579441 2.6 CD B-NP O
28 896 897 15579441 - HYPH O O
29 897 901 15579441 fold RB B-ADVP O
30 902 904 15579441 at IN B-PP O
31 905 906 15579441 4 CD B-NP O
32 907 912 15579441 weeks NNS I-NP O
33 913 915 15579441 in IN B-PP O
34 916 919 15579441 the DT B-NP O
35 920 927 15579441 remnant NN I-NP O
36 928 934 15579441 kidney NN I-NP O
37 935 940 15579441 model NN I-NP O
38 940 941 15579441 , , O O
39 942 949 15579441 whereas IN O O
40 950 954 15579441 that DT B-NP O
41 955 957 15579441 of IN B-PP O
42 958 966 15579441 vascular JJ B-NP O
43 967 978 15579441 endothelial JJ I-NP O
44 979 985 15579441 growth NN I-NP O
45 986 992 15579441 factor NN I-NP O
46 993 999 15579441 showed VBD B-VP O
47 1000 1001 15579441 a DT B-NP O
48 1002 1006 15579441 mild JJ I-NP O
49 1007 1015 15579441 decrease NN I-NP O
50 1015 1016 15579441 , , O O
51 1017 1027 15579441 reflecting VBG B-VP O
52 1028 1036 15579441 distinct JJ B-NP O
53 1037 1046 15579441 behaviors NNS I-NP O
54 1047 1049 15579441 of IN B-PP O
55 1050 1053 15579441 the DT B-NP O
56 1054 1057 15579441 two CD I-NP O
57 1058 1063 15579441 genes NNS I-NP O
58 1063 1064 15579441 . . O O

1 1065 1068 15579441 The DT B-NP O
2 1069 1075 15579441 degree NN I-NP O
3 1076 1078 15579441 of IN B-PP O
4 1079 1086 15579441 hypoxia NN B-NP D000860
5 1087 1093 15579441 showed VBD B-VP O
6 1094 1095 15579441 a DT B-NP O
7 1096 1104 15579441 positive JJ I-NP O
8 1105 1116 15579441 correlation NN I-NP O
9 1117 1121 15579441 with IN B-PP O
10 1122 1133 15579441 microscopic JJ B-NP O
11 1134 1152 15579441 tubulointerstitial JJ I-NP -1
12 1153 1159 15579441 injury NN I-NP -1
13 1160 1162 15579441 in IN B-PP O
14 1163 1167 15579441 both DT B-NP O
15 1168 1174 15579441 models NNS I-NP O
16 1174 1175 15579441 . . O O

1 1176 1183 15579441 Finally RB B-ADVP O
2 1183 1184 15579441 , , O O
3 1185 1187 15579441 we PRP B-NP O
4 1188 1198 15579441 identified VBD B-VP O
5 1199 1202 15579441 the DT B-NP O
6 1203 1215 15579441 localization NN I-NP O
7 1216 1218 15579441 of IN B-PP O
8 1219 1232 15579441 proliferating VBG B-VP O
9 1233 1237 15579441 cell NN B-NP O
10 1238 1245 15579441 nuclear JJ I-NP O
11 1246 1253 15579441 antigen NN I-NP O
12 1253 1254 15579441 - HYPH B-VP O
13 1254 1262 15579441 positive JJ B-ADJP O
14 1262 1263 15579441 , , O O
15 1264 1266 15579441 ED VBN B-VP O
16 1266 1267 15579441 - HYPH B-NP O
17 1267 1268 15579441 1 CD I-NP O
18 1268 1269 15579441 - HYPH I-NP O
19 1269 1277 15579441 positive JJ B-ADJP O
20 1277 1278 15579441 , , O O
21 1279 1282 15579441 and CC O O
22 1283 1291 15579441 terminal JJ B-NP O
23 1292 1296 15579441 dUTP NN I-NP O
24 1297 1301 15579441 nick NN I-NP O
25 1301 1302 15579441 - HYPH B-NP O
26 1302 1305 15579441 end NN I-NP O
27 1306 1313 15579441 labeled VBN B-VP O
28 1313 1314 15579441 - HYPH B-NP O
29 1314 1322 15579441 positive JJ I-NP O
30 1323 1328 15579441 cells NNS I-NP O
31 1329 1331 15579441 in IN B-PP O
32 1332 1335 15579441 the DT B-NP O
33 1336 1343 15579441 hypoxic JJ I-NP D000860
34 1344 1352 15579441 cortical JJ I-NP O
35 1353 1357 15579441 area NN I-NP O
36 1358 1360 15579441 in IN B-PP O
37 1361 1364 15579441 the DT B-NP O
38 1365 1372 15579441 remnant NN I-NP O
39 1373 1379 15579441 kidney NN I-NP O
40 1380 1385 15579441 model NN I-NP O
41 1385 1386 15579441 . . O O

1 1387 1389 15579441 We PRP B-NP O
2 1390 1397 15579441 propose VBP B-VP O
3 1398 1402 15579441 here RB B-ADVP O
4 1403 1404 15579441 a DT B-NP O
5 1405 1413 15579441 possible JJ I-NP O
6 1414 1426 15579441 pathological JJ I-NP O
7 1427 1430 15579441 tie NN I-NP O
8 1431 1438 15579441 between IN B-PP O
9 1439 1446 15579441 chronic JJ B-NP O
10 1447 1465 15579441 tubulointerstitial JJ I-NP O
11 1466 1473 15579441 hypoxia NN I-NP D000860
12 1474 1477 15579441 and CC O O
13 1478 1489 15579441 progressive JJ B-NP O
14 1490 1500 15579441 glomerular JJ I-NP D007674
15 1501 1509 15579441 diseases NNS I-NP D007674
16 1509 1510 15579441 . . O O

1 0 0 17975693 -DOCSTART- -X- -X- O

1 0 10 17975693 Anxiogenic JJ B-NP O
2 11 20 17975693 potential NN I-NP O
3 21 23 17975693 of IN B-PP O
4 24 37 17975693 ciprofloxacin NN B-NP D002939
5 38 41 17975693 and CC I-NP O
6 42 53 17975693 norfloxacin NN I-NP D009643
7 54 56 17975693 in IN B-PP O
8 57 61 17975693 rats NNS B-NP O
9 61 62 17975693 . . O O
10 63 75 17975693 INTRODUCTION NN B-NP O
11 75 76 17975693 : : O O
12 77 80 17975693 The DT B-NP O
13 81 89 17975693 possible JJ I-NP O
14 90 100 17975693 anxiogenic JJ I-NP O
15 101 108 17975693 effects NNS I-NP O
16 109 111 17975693 of IN B-PP O
17 112 128 17975693 fluoroquinolones NNS B-NP D024841
18 128 129 17975693 , , O O
19 130 136 17975693 namely RB B-NP O
20 137 150 17975693 ciprofloxacin NN I-NP D002939
21 151 154 17975693 and CC I-NP O
22 155 166 17975693 norfloxacin NN I-NP D009643
23 166 167 17975693 , , O O
24 168 172 17975693 were VBD B-VP O
25 173 185 17975693 investigated VBN I-VP O
26 186 188 17975693 in IN B-PP O
27 189 194 17975693 adult JJ B-NP O
28 195 202 17975693 Charles NNP I-NP O
29 203 209 17975693 Foster NNP I-NP O
30 210 216 17975693 albino NNP I-NP O
31 217 221 17975693 rats NNS I-NP O
32 222 224 17975693 of IN B-PP O
33 225 231 17975693 either DT B-NP O
34 232 235 17975693 sex NN I-NP O
35 235 236 17975693 , , O O
36 237 245 17975693 weighing VBG B-VP O
37 246 249 17975693 150 CD B-NP O
38 249 250 17975693 - HYPH I-NP O
39 250 253 17975693 200 CD I-NP O
40 254 255 17975693 g NN I-NP O
41 255 256 17975693 . . O O

1 257 264 17975693 METHODS NNS B-NP O
2 264 265 17975693 : : O O
3 266 269 17975693 The DT B-NP O
4 270 275 17975693 drugs NNS I-NP O
5 276 280 17975693 were VBD B-VP O
6 281 286 17975693 given VBN I-VP O
7 287 293 17975693 orally RB B-ADVP O
8 293 294 17975693 , , O O
9 295 297 17975693 in IN B-PP O
10 298 303 17975693 doses NNS B-NP O
11 304 306 17975693 of IN B-PP O
12 307 309 17975693 50 CD B-NP O
13 310 312 17975693 mg NN I-NP O
14 312 313 17975693 / SYM B-NP O
15 313 315 17975693 kg NN I-NP O
16 316 319 17975693 for IN B-PP O
17 320 324 17975693 five CD B-NP O
18 325 336 17975693 consecutive JJ I-NP O
19 337 341 17975693 days NNS I-NP O
20 342 345 17975693 and CC O O
21 346 349 17975693 the DT B-NP O
22 350 361 17975693 experiments NNS I-NP O
23 362 366 17975693 were VBD B-VP O
24 367 376 17975693 performed VBN I-VP O
25 377 379 17975693 on IN B-PP O
26 380 383 17975693 the DT B-NP O
27 384 389 17975693 fifth JJ I-NP O
28 390 393 17975693 day NN I-NP O
29 393 394 17975693 . . O O

1 395 398 17975693 The DT B-NP O
2 399 404 17975693 tests NNS I-NP O
3 405 413 17975693 included VBD B-VP O
4 414 418 17975693 open JJ B-NP O
5 418 419 17975693 - HYPH I-NP O
6 419 424 17975693 field NN I-NP O
7 425 436 17975693 exploratory NN I-NP O
8 437 446 17975693 behaviour NN I-NP O
9 446 447 17975693 , , O O
10 448 456 17975693 elevated VBD B-VP O
11 457 461 17975693 plus CC O O
12 462 466 17975693 maze NN B-NP O
13 467 470 17975693 and CC O O
14 471 479 17975693 elevated VBD B-VP O
15 480 484 17975693 zero CD B-NP O
16 485 489 17975693 maze NN I-NP O
17 489 490 17975693 , , O O
18 491 497 17975693 social JJ B-NP O
19 498 509 17975693 interaction NN I-NP O
20 510 513 17975693 and CC I-NP O
21 514 521 17975693 novelty NN I-NP O
22 521 522 17975693 - HYPH O O
23 522 532 17975693 suppressed VBN B-NP O
24 533 540 17975693 feeding NN I-NP O
25 541 548 17975693 latency NN I-NP O
26 549 558 17975693 behaviour NN I-NP O
27 558 559 17975693 . . O O

1 560 567 17975693 RESULTS NNS B-NP O
2 567 568 17975693 : : O O
3 569 572 17975693 The DT B-NP O
4 573 580 17975693 results NNS I-NP O
5 581 589 17975693 indicate VBP B-VP O
6 590 594 17975693 that IN B-SBAR O
7 595 608 17975693 ciprofloxacin NN B-NP D002939
8 608 609 17975693 - HYPH B-NP O
9 610 613 17975693 and CC I-NP O
10 614 625 17975693 norfloxacin NN I-NP D009643
11 625 626 17975693 - HYPH O O
12 626 633 17975693 treated VBN B-NP O
13 634 638 17975693 rats NNS I-NP O
14 639 645 17975693 showed VBD B-VP O
15 646 653 17975693 anxious JJ B-NP D001008
16 654 663 17975693 behaviour NN I-NP D001008
17 664 666 17975693 in IN B-PP O
18 667 677 17975693 comparison NN B-NP O
19 678 680 17975693 to TO B-PP O
20 681 688 17975693 control NN B-NP O
21 689 693 17975693 rats NNS I-NP O
22 694 696 17975693 in IN B-PP O
23 697 700 17975693 all PDT B-NP O
24 701 704 17975693 the DT I-NP O
25 705 715 17975693 parameters NNS I-NP O
26 716 723 17975693 studied VBN B-VP O
27 723 724 17975693 . . O O

1 725 732 17975693 However RB B-ADVP O
2 732 733 17975693 , , O O
3 734 747 17975693 ciprofloxacin NN B-NP D002939
4 747 748 17975693 - HYPH B-NP O
5 749 752 17975693 and CC I-NP O
6 753 764 17975693 norfloxacin NN I-NP D009643
7 764 765 17975693 - HYPH O O
8 765 772 17975693 treated VBN B-NP O
9 773 777 17975693 rats NNS I-NP O
10 778 781 17975693 did VBD B-VP O
11 782 785 17975693 not RB I-VP O
12 786 792 17975693 differ VB I-VP O
13 793 806 17975693 significantly RB B-ADVP O
14 807 811 17975693 from IN B-PP O
15 812 816 17975693 each DT B-NP O
16 817 822 17975693 other JJ I-NP O
17 823 825 17975693 in IN B-PP O
18 826 833 17975693 various JJ B-NP O
19 834 845 17975693 behavioural JJ I-NP O
20 846 856 17975693 parameters NNS I-NP O
21 856 857 17975693 . . O O

1 858 868 17975693 CONCLUSION NN B-NP O
2 868 869 17975693 : : O O
3 870 873 17975693 The DT B-NP O
4 874 881 17975693 present JJ I-NP O
5 882 894 17975693 experimental JJ I-NP O
6 895 903 17975693 findings NNS I-NP O
7 904 916 17975693 substantiate VBP B-VP O
8 917 920 17975693 the DT B-NP O
9 921 931 17975693 clinically RB I-NP O
10 932 940 17975693 observed VBN I-NP O
11 941 951 17975693 anxiogenic JJ I-NP O
12 952 961 17975693 potential NN I-NP O
13 962 964 17975693 of IN B-PP O
14 965 978 17975693 ciprofloxacin NN B-NP D002939
15 979 982 17975693 and CC I-NP O
16 983 994 17975693 norfloxacin NN I-NP D009643
17 994 995 17975693 . . O O

1 0 0 19058474 -DOCSTART- -X- -X- O

1 0 5 19058474 Fatal JJ B-NP O
2 6 22 19058474 haemopericardium NN I-NP D010490
3 23 26 19058474 and CC O O
4 27 43 19058474 gastrointestinal JJ B-NP D006471
5 44 55 19058474 haemorrhage NN I-NP D006471
6 56 59 19058474 due JJ B-PP O
7 60 62 19058474 to TO B-PP O
8 63 71 19058474 possible JJ B-NP O
9 72 83 19058474 interaction NN I-NP O
10 84 86 19058474 of IN B-PP O
11 87 96 19058474 cranberry NN B-NP O
12 97 102 19058474 juice NN I-NP O
13 103 107 19058474 with IN B-PP O
14 108 116 19058474 warfarin NN B-NP D014859
15 116 117 19058474 . . O O
16 118 120 19058474 We PRP B-NP O
17 121 127 19058474 report VBP B-VP O
18 128 129 19058474 a DT B-NP O
19 130 134 19058474 case NN I-NP O
20 135 137 19058474 of IN B-PP O
21 138 143 19058474 fatal JJ B-NP O
22 144 152 19058474 internal JJ I-NP O
23 153 164 19058474 haemorrhage NN I-NP D006470
24 165 167 19058474 in IN B-PP O
25 168 170 19058474 an DT B-NP O
26 171 178 19058474 elderly JJ I-NP O
27 179 182 19058474 man NN I-NP O
28 183 186 19058474 who WP B-NP O
29 187 195 19058474 consumed VBD B-VP O
30 196 200 19058474 only RB B-NP O
31 201 210 19058474 cranberry NN I-NP O
32 211 216 19058474 juice NN I-NP O
33 217 220 19058474 for IN B-PP O
34 221 224 19058474 two CD B-NP O
35 225 230 19058474 weeks NNS I-NP O
36 231 236 19058474 while IN B-SBAR O
37 237 248 19058474 maintaining VBG B-VP O
38 249 252 19058474 his PRP$ B-NP O
39 253 258 19058474 usual JJ I-NP O
40 259 265 19058474 dosage NN I-NP O
41 266 268 19058474 of IN B-PP O
42 269 277 19058474 warfarin NN B-NP D014859
43 277 278 19058474 . . O O

1 279 281 19058474 We PRP B-NP O
2 282 289 19058474 propose VBP B-VP O
3 290 294 19058474 that IN B-SBAR O
4 295 304 19058474 naturally RB B-ADVP O
5 305 314 19058474 occurring VBG B-VP O
6 315 324 19058474 compounds NNS B-NP O
7 325 329 19058474 such JJ B-PP O
8 330 332 19058474 as IN I-PP O
9 333 343 19058474 flavonoids NNS B-NP D005419
10 343 344 19058474 , , O O
11 345 350 19058474 which WDT B-NP O
12 351 354 19058474 are VBP B-VP O
13 355 362 19058474 present JJ B-ADJP O
14 363 365 19058474 in IN B-PP O
15 366 371 19058474 fruit NN B-NP O
16 372 378 19058474 juices NNS I-NP O
17 378 379 19058474 , , O O
18 380 383 19058474 may MD B-VP O
19 384 392 19058474 increase VB I-VP O
20 393 396 19058474 the DT B-NP O
21 397 404 19058474 potency NN I-NP O
22 405 407 19058474 of IN B-PP O
23 408 416 19058474 warfarin NN B-NP D014859
24 417 419 19058474 by IN B-PP O
25 420 429 19058474 competing VBG B-VP O
26 430 433 19058474 for IN B-PP O
27 434 437 19058474 the DT B-NP O
28 438 445 19058474 enzymes NNS I-NP O
29 446 450 19058474 that WDT B-NP O
30 451 459 19058474 normally RB B-ADVP O
31 460 470 19058474 inactivate VBP B-VP O
32 471 479 19058474 warfarin NN B-NP D014859
33 479 480 19058474 . . O O

1 481 486 19058474 While IN B-SBAR O
2 487 500 19058474 traditionally RB B-VP O
3 501 509 19058474 regarded VBN I-VP O
4 510 512 19058474 as IN B-PP O
5 513 523 19058474 foodstuffs NNS B-NP O
6 523 524 19058474 , , O O
7 525 536 19058474 consumption NN B-NP O
8 537 539 19058474 of IN B-PP O
9 540 545 19058474 fruit NN B-NP O
10 546 552 19058474 juices NNS I-NP O
11 553 559 19058474 should MD B-VP O
12 560 562 19058474 be VB I-VP O
13 563 573 19058474 considered VBN I-VP O
14 574 578 19058474 when WRB B-ADVP O
15 579 587 19058474 patients NNS B-NP O
16 588 595 19058474 develop VBP B-VP O
17 596 603 19058474 adverse JJ B-NP O
18 604 608 19058474 drug NN I-NP O
19 609 618 19058474 reactions NNS I-NP O
20 618 619 19058474 . . O O

1 0 0 2716967 -DOCSTART- -X- -X- O

1 0 9 2716967 Catalepsy NN B-NP D002375
2 10 17 2716967 induced VBN B-VP O
3 18 20 2716967 by IN B-PP O
4 21 33 2716967 combinations NNS B-NP O
5 34 36 2716967 of IN B-PP O
6 37 45 2716967 ketamine NN B-NP D007649
7 46 49 2716967 and CC I-NP O
8 50 58 2716967 morphine NN I-NP D009020
9 58 59 2716967 : : O O
10 60 72 2716967 potentiation NN B-NP O
11 72 73 2716967 , , O O
12 74 84 2716967 antagonism NN B-NP O
13 84 85 2716967 , , O O
14 86 95 2716967 tolerance NN B-NP O
15 96 99 2716967 and CC O O
16 100 105 2716967 cross AFX B-NP O
17 105 106 2716967 - HYPH I-NP O
18 106 115 2716967 tolerance NN B-NP O
19 116 118 2716967 in IN B-PP O
20 119 122 2716967 the DT B-NP O
21 123 126 2716967 rat NN I-NP O
22 126 127 2716967 . . O O
23 128 136 2716967 Previous JJ B-NP O
24 137 144 2716967 studies NNS I-NP O
25 145 157 2716967 demonstrated VBD B-VP O
26 158 162 2716967 that IN B-SBAR O
27 163 167 2716967 both CC O O
28 168 176 2716967 ketamine NN B-NP D007649
29 177 180 2716967 and CC I-NP O
30 181 189 2716967 morphine NN I-NP D009020
31 190 197 2716967 induced VBD B-VP O
32 198 207 2716967 analgesia NN B-NP D000699
33 208 211 2716967 and CC I-NP O
34 212 221 2716967 catalepsy NN I-NP D002375
35 222 224 2716967 in IN B-PP O
36 225 228 2716967 the DT B-NP O
37 229 232 2716967 rat NN I-NP O
38 232 233 2716967 . . O O

1 234 237 2716967 Pre AFX B-NP O
2 237 238 2716967 - HYPH I-NP O
3 238 247 2716967 treatment NN B-NP O
4 248 252 2716967 with IN B-PP O
5 253 261 2716967 ketamine NN B-NP D007649
6 262 270 2716967 produced VBD B-VP O
7 271 276 2716967 cross AFX B-NP O
8 276 277 2716967 - HYPH I-NP O
9 277 286 2716967 tolerance NN I-NP O
10 287 289 2716967 to TO B-PP O
11 290 298 2716967 morphine NN B-NP D009020
12 298 299 2716967 , , O O
13 300 307 2716967 whereas IN O O
14 308 320 2716967 pretreatment NN B-NP O
15 321 325 2716967 with IN B-PP O
16 326 334 2716967 morphine NN B-NP D009020
17 335 338 2716967 did VBD B-VP O
18 339 342 2716967 not RB I-VP O
19 343 349 2716967 induce VB I-VP O
20 350 355 2716967 cross AFX B-NP O
21 355 356 2716967 - HYPH I-NP O
22 356 365 2716967 tolerance NN B-NP O
23 366 368 2716967 to TO B-PP O
24 369 377 2716967 ketamine NN B-NP D007649
25 378 381 2716967 but CC O O
26 382 388 2716967 rather RB B-VP O
27 389 398 2716967 augmented VBD I-VP O
28 399 402 2716967 the DT B-NP O
29 403 413 2716967 cataleptic JJ I-NP D002375
30 414 422 2716967 response NN I-NP O
31 422 423 2716967 ; : O O
32 424 428 2716967 this DT B-NP O
33 429 441 2716967 augmentation NN I-NP O
34 442 445 2716967 was VBD B-VP O
35 446 456 2716967 attributed VBN I-VP O
36 457 459 2716967 to TO B-PP O
37 460 468 2716967 residual JJ B-NP O
38 469 477 2716967 morphine NN I-NP D009020
39 478 480 2716967 in IN B-PP O
40 481 484 2716967 the DT B-NP O
41 485 490 2716967 brain NN I-NP O
42 490 491 2716967 . . O O

1 492 495 2716967 The DT B-NP O
2 496 503 2716967 present JJ I-NP O
3 504 511 2716967 studies NNS I-NP O
4 512 520 2716967 explored VBD B-VP O
5 521 524 2716967 the DT B-NP O
6 525 533 2716967 duration NN I-NP O
7 534 536 2716967 of IN B-PP O
8 537 540 2716967 the DT B-NP O
9 541 545 2716967 loss NN I-NP O
10 546 548 2716967 of IN B-PP O
11 549 557 2716967 righting VBG B-VP O
12 558 564 2716967 reflex NN B-NP O
13 565 572 2716967 induced VBN B-VP O
14 573 575 2716967 by IN B-PP O
15 576 579 2716967 sub AFX B-NP O
16 579 580 2716967 - HYPH I-NP O
17 580 589 2716967 effective JJ I-NP O
18 590 595 2716967 doses NNS I-NP O
19 596 598 2716967 of IN B-PP O
20 599 607 2716967 ketamine NN B-NP D007649
21 608 611 2716967 and CC I-NP O
22 612 620 2716967 morphine NN I-NP D009020
23 620 621 2716967 , , O O
24 622 634 2716967 administered VBN B-VP O
25 635 649 2716967 simultaneously RB B-ADVP O
26 649 650 2716967 . . O O

1 651 656 2716967 There EX B-NP O
2 657 660 2716967 was VBD B-VP O
3 661 667 2716967 mutual JJ B-NP O
4 668 680 2716967 potentiation NN I-NP O
5 681 688 2716967 between IN B-PP O
6 689 692 2716967 sub AFX B-NP O
7 692 693 2716967 - HYPH I-NP O
8 693 702 2716967 effective JJ I-NP O
9 703 708 2716967 doses NNS I-NP O
10 709 711 2716967 of IN B-PP O
11 712 720 2716967 ketamine NN B-NP D007649
12 721 724 2716967 and CC I-NP O
13 725 733 2716967 morphine NN I-NP D009020
14 733 734 2716967 , , O O
15 735 738 2716967 but CC O O
16 739 742 2716967 sub AFX B-NP O
17 742 743 2716967 - HYPH I-NP O
18 743 752 2716967 effective JJ B-NP O
19 753 758 2716967 doses NNS I-NP O
20 759 761 2716967 of IN B-PP O
21 762 770 2716967 ketamine NN B-NP D007649
22 771 777 2716967 partly RB B-VP O
23 778 789 2716967 antagonized VBD I-VP O
24 790 795 2716967 fully RB B-ADJP O
25 795 796 2716967 - HYPH I-ADJP O
26 796 805 2716967 effective JJ B-NP O
27 806 811 2716967 doses NNS I-NP O
28 812 814 2716967 of IN B-PP O
29 815 823 2716967 morphine NN B-NP D009020
30 823 824 2716967 . . O O

1 825 832 2716967 Latency NN B-NP O
2 833 835 2716967 to TO B-PP O
3 836 839 2716967 the DT B-NP O
4 840 844 2716967 loss NN I-NP O
5 845 847 2716967 of IN B-PP O
6 848 856 2716967 righting VBG B-VP O
7 857 863 2716967 reflex NN B-NP O
8 863 864 2716967 , , I-NP O
9 865 873 2716967 rigidity NN I-NP D009127
10 874 877 2716967 and CC I-NP O
11 878 886 2716967 behavior NN I-NP O
12 887 889 2716967 on IN B-PP O
13 890 898 2716967 recovery NN B-NP O
14 898 899 2716967 , , O O
15 900 909 2716967 reflected VBD B-VP O
16 910 913 2716967 the DT B-NP O
17 914 922 2716967 relative JJ I-NP O
18 923 935 2716967 predominance NN I-NP O
19 936 938 2716967 of IN B-PP O
20 939 947 2716967 ketamine NN B-NP D007649
21 948 950 2716967 or CC I-NP O
22 951 959 2716967 morphine NN I-NP D009020
23 960 962 2716967 in IN B-PP O
24 963 967 2716967 each DT B-NP O
25 968 979 2716967 combination NN I-NP O
26 979 980 2716967 . . O O

1 981 989 2716967 Naloxone NN B-NP D009270
2 990 999 2716967 inhibited VBD B-VP O
3 1000 1003 2716967 the DT B-NP O
4 1004 1011 2716967 induced VBN I-NP O
5 1012 1022 2716967 cataleptic JJ I-NP D002375
6 1023 1030 2716967 effects NNS I-NP O
7 1030 1031 2716967 . . O O

1 1032 1035 2716967 The DT B-NP O
2 1036 1042 2716967 degree NN I-NP O
3 1043 1046 2716967 and CC I-NP O
4 1047 1051 2716967 time NN I-NP O
5 1052 1058 2716967 course NN I-NP O
6 1059 1061 2716967 of IN B-PP O
7 1062 1073 2716967 development NN B-NP O
8 1074 1076 2716967 of IN B-PP O
9 1077 1086 2716967 tolerance NN B-NP O
10 1087 1089 2716967 to TO B-PP O
11 1090 1095 2716967 daily JJ B-NP O
12 1096 1110 2716967 administration NN I-NP O
13 1111 1113 2716967 of IN B-PP O
14 1114 1117 2716967 sub AFX B-NP O
15 1117 1118 2716967 - HYPH I-NP O
16 1118 1127 2716967 effective JJ I-NP O
17 1128 1132 2716967 dose NN I-NP O
18 1133 1145 2716967 combinations NNS I-NP O
19 1146 1148 2716967 of IN B-PP O
20 1149 1157 2716967 ketamine NN B-NP D007649
21 1158 1161 2716967 and CC I-NP O
22 1162 1170 2716967 morphine NN I-NP D009020
23 1171 1175 2716967 were VBD B-VP O
24 1176 1183 2716967 similar JJ B-ADJP O
25 1183 1184 2716967 . . O O

1 1185 1189 2716967 Rats NNS B-NP O
2 1189 1190 2716967 , , O O
3 1191 1199 2716967 tolerant JJ B-ADJP O
4 1200 1202 2716967 to TO B-PP O
5 1203 1211 2716967 ketamine NN B-NP D007649
6 1211 1212 2716967 - HYPH B-NP O
7 1212 1220 2716967 dominant JJ I-NP O
8 1221 1233 2716967 combinations NNS I-NP O
9 1233 1234 2716967 , , O O
10 1235 1239 2716967 were VBD B-VP O
11 1240 1245 2716967 cross AFX B-ADJP O
12 1245 1246 2716967 - HYPH I-ADJP O
13 1246 1254 2716967 tolerant JJ B-ADJP O
14 1255 1257 2716967 to TO B-PP O
15 1258 1262 2716967 both DT B-NP O
16 1263 1268 2716967 drugs NNS I-NP O
17 1268 1269 2716967 , , O O
18 1270 1275 2716967 while IN B-SBAR O
19 1276 1281 2716967 those DT B-NP O
20 1282 1290 2716967 tolerant JJ B-ADJP O
21 1291 1293 2716967 to TO B-PP O
22 1294 1302 2716967 morphine NN B-NP D009020
23 1302 1303 2716967 - HYPH B-NP O
24 1303 1311 2716967 dominant JJ I-NP O
25 1312 1324 2716967 combinations NNS I-NP O
26 1325 1329 2716967 were VBD B-VP O
27 1330 1335 2716967 cross AFX B-ADJP O
28 1335 1336 2716967 - HYPH I-ADJP O
29 1336 1344 2716967 tolerant JJ B-ADJP O
30 1345 1347 2716967 to TO B-PP O
31 1348 1356 2716967 morphine NN B-NP D009020
32 1357 1360 2716967 but CC O O
33 1361 1367 2716967 showed VBD B-VP O
34 1368 1374 2716967 either CC O O
35 1375 1377 2716967 no DT B-NP O
36 1378 1383 2716967 cross AFX I-NP O
37 1383 1384 2716967 - HYPH I-NP O
38 1384 1393 2716967 tolerance NN I-NP O
39 1394 1396 2716967 or CC O O
40 1397 1399 2716967 an DT B-NP O
41 1400 1409 2716967 augmented JJ I-NP O
42 1410 1418 2716967 response NN I-NP O
43 1419 1421 2716967 to TO B-PP O
44 1422 1430 2716967 ketamine NN B-NP D007649
45 1430 1431 2716967 . . O O

1 1432 1437 2716967 While IN B-SBAR O
2 1438 1441 2716967 the DT B-NP O
3 1442 1448 2716967 mutual JJ I-NP O
4 1449 1461 2716967 potentiation NN I-NP O
5 1461 1462 2716967 , , O O
6 1463 1473 2716967 antagonism NN B-NP O
7 1474 1477 2716967 and CC O O
8 1478 1487 2716967 tolerance NN B-NP O
9 1488 1495 2716967 suggest VBP B-VP O
10 1496 1502 2716967 common JJ B-NP O
11 1503 1513 2716967 mechanisms NNS I-NP O
12 1514 1517 2716967 for IN B-PP O
13 1518 1521 2716967 the DT B-NP O
14 1522 1529 2716967 induced VBN I-NP O
15 1530 1539 2716967 catalepsy NN I-NP D002375
16 1539 1540 2716967 , , O O
17 1541 1552 2716967 differences NNS B-NP O
18 1553 1555 2716967 in IN B-PP O
19 1556 1563 2716967 latency NN B-NP O
20 1563 1564 2716967 , , I-NP O
21 1565 1573 2716967 rigidity NN I-NP D009127
22 1574 1577 2716967 and CC I-NP O
23 1578 1586 2716967 behavior NN I-NP O
24 1586 1587 2716967 , , O O
25 1588 1597 2716967 asymmetry NN B-NP O
26 1598 1600 2716967 of IN B-PP O
27 1601 1606 2716967 cross AFX B-NP O
28 1606 1607 2716967 - HYPH I-NP O
29 1607 1616 2716967 tolerance NN I-NP O
30 1617 1620 2716967 and CC O O
31 1621 1622 2716967 a DT B-NP O
32 1623 1629 2716967 widely RB I-NP O
33 1629 1630 2716967 - HYPH I-NP O
34 1630 1639 2716967 different JJ I-NP O
35 1640 1644 2716967 ID50 NN I-NP O
36 1645 1648 2716967 for IN B-PP O
37 1649 1657 2716967 naloxone NN B-NP D009270
38 1658 1663 2716967 would MD B-VP O
39 1664 1669 2716967 argue VB I-VP O
40 1670 1677 2716967 against IN B-PP O
41 1678 1680 2716967 an DT B-NP O
42 1681 1687 2716967 action NN I-NP O
43 1688 1690 2716967 at IN B-PP O
44 1691 1692 2716967 a DT B-NP O
45 1693 1699 2716967 single JJ I-NP O
46 1700 1706 2716967 opioid JJ I-NP O
47 1707 1711 2716967 site NN I-NP O
48 1711 1712 2716967 . . O O

1 0 0 8643973 -DOCSTART- -X- -X- O

1 0 10 8643973 Paclitaxel NN B-NP D017239
2 11 19 8643973 combined VBN B-VP O
3 20 24 8643973 with IN B-PP O
4 25 36 8643973 carboplatin NN B-NP D016190
5 37 39 8643973 in IN B-PP O
6 40 43 8643973 the DT B-NP O
7 44 49 8643973 first JJ I-NP O
8 49 50 8643973 - HYPH I-NP O
9 50 54 8643973 line NN I-NP O
10 55 64 8643973 treatment NN I-NP O
11 65 67 8643973 of IN B-PP O
12 68 76 8643973 advanced VBN B-NP O
13 77 84 8643973 ovarian JJ I-NP D010051
14 85 91 8643973 cancer NN I-NP D010051
15 91 92 8643973 . . O O
16 93 95 8643973 In IN B-PP O
17 96 97 8643973 a DT B-NP O
18 98 103 8643973 phase NN I-NP O
19 104 105 8643973 I CD I-NP O
20 106 111 8643973 study NN I-NP O
21 112 114 8643973 to TO B-VP O
22 115 124 8643973 determine VB I-VP O
23 125 128 8643973 the DT B-NP O
24 129 136 8643973 maximum NN I-NP O
25 137 146 8643973 tolerated VBN I-NP O
26 147 151 8643973 dose NN I-NP O
27 152 154 8643973 of IN B-PP O
28 155 165 8643973 paclitaxel NN B-NP D017239
29 166 167 8643973 ( ( O O
30 167 172 8643973 Taxol NN B-NP D017239
31 172 173 8643973 ; : O O
32 174 181 8643973 Bristol NNP B-NP O
33 181 182 8643973 - : O O
34 182 187 8643973 Myers NNP B-NP O
35 188 194 8643973 Squibb NNP I-NP O
36 195 202 8643973 Company NNP I-NP O
37 202 203 8643973 , , O O
38 204 213 8643973 Princeton NNP B-NP O
39 213 214 8643973 , , O O
40 215 217 8643973 NJ NNP B-NP O
41 217 218 8643973 ) ) O O
42 219 224 8643973 given VBN B-VP O
43 225 227 8643973 as IN B-PP O
44 228 229 8643973 a DT B-NP O
45 230 231 8643973 3 CD I-NP O
46 231 232 8643973 - HYPH I-NP O
47 232 236 8643973 hour NN I-NP O
48 237 245 8643973 infusion NN I-NP O
49 246 248 8643973 in IN B-PP O
50 249 260 8643973 combination NN B-NP O
51 261 265 8643973 with IN B-PP O
52 266 277 8643973 carboplatin NN B-NP D016190
53 278 290 8643973 administered VBN B-VP O
54 291 296 8643973 every DT B-NP O
55 297 299 8643973 21 CD I-NP O
56 300 304 8643973 days NNS I-NP O
57 305 307 8643973 to TO B-PP O
58 308 313 8643973 women NNS B-NP O
59 314 318 8643973 with IN B-PP O
60 319 327 8643973 advanced VBN B-NP O
61 328 335 8643973 ovarian JJ I-NP D010051
62 336 342 8643973 cancer NN I-NP D010051
63 342 343 8643973 , , O O
64 344 354 8643973 paclitaxel NN B-NP D017239
65 355 360 8643973 doses NNS I-NP O
66 361 365 8643973 were VBD B-VP O
67 366 375 8643973 escalated VBN I-VP O
68 376 378 8643973 as IN B-SBAR O
69 379 386 8643973 follows VBZ B-VP O
70 386 387 8643973 : : O O
71 388 393 8643973 level NN B-NP O
72 394 395 8643973 1 CD I-NP O
73 395 396 8643973 , , I-NP O
74 397 400 8643973 135 CD I-NP O
75 401 403 8643973 mg NN I-NP O
76 403 404 8643973 / SYM B-NP O
77 404 406 8643973 m2 NN I-NP O
78 406 407 8643973 ; : O O
79 408 413 8643973 level NN B-NP O
80 414 415 8643973 2 CD I-NP O
81 415 416 8643973 , , O O
82 417 420 8643973 160 CD B-NP O
83 421 423 8643973 mg NN I-NP O
84 423 424 8643973 / SYM B-NP O
85 424 426 8643973 m2 NN I-NP O
86 426 427 8643973 ; : O O
87 428 433 8643973 level NN B-NP O
88 434 435 8643973 3 CD I-NP O
89 435 436 8643973 , , I-NP O
90 437 440 8643973 185 CD I-NP O
91 441 443 8643973 mg NN I-NP O
92 443 444 8643973 / SYM B-NP O
93 444 446 8643973 m2 NN I-NP O
94 446 447 8643973 ; : O O
95 448 451 8643973 and CC O O
96 452 457 8643973 level NN B-NP O
97 458 463 8643973 4,210 CD I-NP O
98 464 466 8643973 mg NN I-NP O
99 466 467 8643973 / SYM B-NP O
100 467 469 8643973 m2 NN I-NP O
101 469 470 8643973 . . O O

1 471 474 8643973 The DT B-NP O
2 475 480 8643973 fixed VBN I-NP O
3 481 485 8643973 dose NN I-NP O
4 486 488 8643973 of IN B-PP O
5 489 500 8643973 carboplatin NN B-NP D016190
6 501 503 8643973 at IN B-PP O
7 504 510 8643973 levels NNS B-NP O
8 511 512 8643973 1 CD B-NP O
9 513 520 8643973 through IN B-PP O
10 521 522 8643973 4 CD B-NP O
11 523 526 8643973 was VBD B-VP O
12 527 532 8643973 given VBN I-VP O
13 533 535 8643973 to TO I-VP O
14 536 543 8643973 achieve VB I-VP O
15 544 546 8643973 an DT B-NP O
16 547 551 8643973 area NN I-NP O
17 552 557 8643973 under IN B-PP O
18 558 561 8643973 the DT B-NP O
19 562 575 8643973 concentration NN I-NP O
20 575 576 8643973 - HYPH O O
21 576 580 8643973 time NN B-NP O
22 581 586 8643973 curve NN I-NP O
23 587 588 8643973 ( ( O O
24 588 591 8643973 AUC NN B-NP O
25 591 592 8643973 ) ) O O
26 593 595 8643973 of IN B-PP O
27 596 597 8643973 5 CD B-NP O
28 598 603 8643973 using VBG B-VP O
29 604 607 8643973 the DT B-NP O
30 608 615 8643973 Calvert NNP I-NP O
31 616 623 8643973 formula NN I-NP O
32 623 624 8643973 . . O O

1 625 627 8643973 In IN B-PP O
2 628 634 8643973 levels NNS B-NP O
3 635 636 8643973 5 CD B-NP O
4 637 640 8643973 and CC I-NP O
5 641 642 8643973 6 CD I-NP O
6 643 646 8643973 the DT B-NP O
7 647 658 8643973 carboplatin NN I-NP D016190
8 659 663 8643973 dose NN I-NP O
9 664 667 8643973 was VBD B-VP O
10 668 676 8643973 targeted VBN I-VP O
11 677 679 8643973 at IN B-PP O
12 680 684 8643973 AUCs NNS B-NP O
13 685 687 8643973 of IN B-PP O
14 688 689 8643973 6 CD B-NP O
15 690 693 8643973 and CC I-NP O
16 694 697 8643973 7.5 CD I-NP O
17 697 698 8643973 , , O O
18 699 711 8643973 respectively RB B-ADVP O
19 711 712 8643973 , , O O
20 713 721 8643973 combined VBN B-VP O
21 722 726 8643973 with IN B-PP O
22 727 728 8643973 a DT B-NP O
23 729 734 8643973 fixed VBN I-NP O
24 735 745 8643973 paclitaxel NN I-NP D017239
25 746 750 8643973 dose NN I-NP O
26 751 753 8643973 of IN B-PP O
27 754 757 8643973 185 CD B-NP O
28 758 760 8643973 mg NN I-NP O
29 760 761 8643973 / SYM B-NP O
30 761 763 8643973 m2 NN I-NP O
31 763 764 8643973 . . O O

1 765 767 8643973 To TO B-PP O
2 768 772 8643973 date NN B-NP O
3 772 773 8643973 , , O O
4 774 776 8643973 30 CD B-NP O
5 777 787 8643973 previously RB I-NP O
6 788 797 8643973 untreated JJ I-NP O
7 798 806 8643973 patients NNS I-NP O
8 806 807 8643973 , , O O
9 808 811 8643973 all DT B-NP O
10 812 816 8643973 with IN B-PP O
11 817 818 8643973 a DT B-NP O
12 819 823 8643973 good JJ I-NP O
13 824 835 8643973 performance NN I-NP O
14 836 842 8643973 status NN I-NP O
15 843 844 8643973 ( ( O O
16 844 851 8643973 Eastern NNP B-NP O
17 852 863 8643973 Cooperative NNP I-NP O
18 864 872 8643973 Oncology NNP I-NP O
19 873 878 8643973 Group NNP I-NP O
20 879 880 8643973 0 CD I-NP O
21 881 883 8643973 to TO B-PP O
22 884 885 8643973 2 CD B-NP O
23 885 886 8643973 ) ) O O
24 887 891 8643973 have VBP B-VP O
25 892 896 8643973 been VBN I-VP O
26 897 904 8643973 entered VBN I-VP O
27 905 909 8643973 into IN B-PP O
28 910 914 8643973 this DT B-NP O
29 915 922 8643973 ongoing JJ I-NP O
30 923 928 8643973 study NN I-NP O
31 928 929 8643973 . . O O

1 930 933 8643973 The DT B-NP O
2 934 938 8643973 dose NN I-NP O
3 938 939 8643973 - HYPH O O
4 939 947 8643973 limiting VBG B-VP O
5 948 956 8643973 toxicity NN B-NP D064420
6 957 959 8643973 of IN B-PP O
7 960 963 8643973 the DT B-NP O
8 964 975 8643973 combination NN I-NP O
9 976 979 8643973 was VBD B-VP O
10 980 996 8643973 myelosuppression NN B-NP D001855
11 997 998 8643973 ( ( O O
12 998 1008 8643973 leukopenia NN B-NP D007970
13 1008 1009 8643973 , , O O
14 1010 1026 8643973 granulocytopenia NN B-NP D000380
15 1026 1027 8643973 , , O O
16 1028 1031 8643973 and CC O O
17 1032 1048 8643973 thrombocytopenia NN B-NP D013921
18 1048 1049 8643973 ) ) O O
19 1049 1050 8643973 . . O O

1 1051 1064 8643973 Neurotoxicity NN B-NP D020258
2 1065 1068 8643973 was VBD B-VP O
3 1069 1076 8643973 largely RB B-ADJP O
4 1077 1085 8643973 moderate JJ I-ADJP O
5 1085 1086 8643973 . . O O

1 1087 1089 8643973 So RB B-ADVP O
2 1090 1093 8643973 far RB I-ADVP O
3 1093 1094 8643973 , , O O
4 1095 1097 8643973 14 CD B-NP O
5 1098 1106 8643973 patients NNS I-NP O
6 1107 1110 8643973 are VBP B-VP O
7 1111 1120 8643973 evaluable JJ B-ADJP O
8 1121 1124 8643973 for IN B-PP O
9 1125 1133 8643973 response NN B-NP O
10 1133 1134 8643973 ; : O O
11 1135 1137 8643973 of IN B-PP O
12 1138 1143 8643973 these DT B-NP O
13 1143 1144 8643973 , , O O
14 1145 1150 8643973 eight CD B-NP O
15 1151 1152 8643973 ( ( O O
16 1152 1155 8643973 57% NN B-NP O
17 1155 1156 8643973 ) ) O O
18 1157 1163 8643973 showed VBD B-VP O
19 1164 1173 8643973 objective JJ B-ADJP O
20 1174 1175 8643973 ( ( O O
21 1175 1183 8643973 complete JJ B-ADJP O
22 1184 1186 8643973 or CC I-ADJP O
23 1187 1194 8643973 partial JJ I-ADJP O
24 1194 1195 8643973 ) ) O O
25 1196 1204 8643973 response NN B-NP O
26 1205 1208 8643973 and CC I-NP O
27 1209 1216 8643973 disease NN I-NP O
28 1217 1227 8643973 stabilized VBD B-VP O
29 1228 1230 8643973 in IN B-PP O
30 1231 1234 8643973 six CD B-NP O
31 1235 1243 8643973 patients NNS I-NP O
32 1243 1244 8643973 . . O O

1 1245 1247 8643973 No DT B-NP O
2 1248 1255 8643973 patient NN I-NP O
3 1256 1259 8643973 had VBD B-VP O
4 1260 1267 8643973 disease NN B-NP O
5 1268 1279 8643973 progression NN I-NP O
6 1279 1280 8643973 . . O O

1 1281 1283 8643973 We PRP B-NP O
2 1284 1292 8643973 conclude VBP B-VP O
3 1293 1297 8643973 that IN B-SBAR O
4 1298 1301 8643973 the DT B-NP O
5 1302 1313 8643973 combination NN I-NP O
6 1314 1316 8643973 of IN B-PP O
7 1317 1327 8643973 paclitaxel NN B-NP D017239
8 1328 1331 8643973 185 CD I-NP O
9 1332 1334 8643973 mg NN I-NP O
10 1334 1335 8643973 / SYM B-NP O
11 1335 1337 8643973 m2 NN I-NP O
12 1338 1350 8643973 administered VBN B-VP O
13 1351 1353 8643973 as IN B-PP O
14 1354 1355 8643973 a DT B-NP O
15 1356 1357 8643973 3 CD I-NP O
16 1357 1358 8643973 - HYPH I-NP O
17 1358 1362 8643973 hour NN I-NP O
18 1363 1371 8643973 infusion NN I-NP O
19 1372 1380 8643973 followed VBD B-VP O
20 1381 1392 8643973 immediately RB B-ADVP O
21 1393 1395 8643973 by IN B-PP O
22 1396 1397 8643973 a DT B-NP O
23 1398 1399 8643973 1 CD I-NP O
24 1399 1400 8643973 - HYPH I-NP O
25 1400 1404 8643973 hour NN I-NP O
26 1405 1413 8643973 infusion NN I-NP O
27 1414 1416 8643973 of IN B-PP O
28 1417 1428 8643973 carboplatin NN B-NP D016190
29 1429 1431 8643973 at IN B-PP O
30 1432 1434 8643973 an DT B-NP O
31 1435 1438 8643973 AUC NN I-NP O
32 1439 1441 8643973 of IN B-PP O
33 1442 1443 8643973 6 CD B-NP O
34 1444 1447 8643973 can MD B-VP O
35 1448 1450 8643973 be VB I-VP O
36 1451 1463 8643973 administered VBN I-VP O
37 1464 1470 8643973 safely RB B-ADVP O
38 1471 1473 8643973 in IN B-PP O
39 1474 1475 8643973 a DT B-NP O
40 1476 1478 8643973 21 CD I-NP O
41 1478 1479 8643973 - HYPH I-NP O
42 1479 1482 8643973 day NN I-NP O
43 1483 1491 8643973 schedule NN I-NP O
44 1492 1494 8643973 in IN B-PP O
45 1495 1498 8643973 the DT B-NP O
46 1499 1509 8643973 outpatient NN I-NP O
47 1510 1517 8643973 setting NN I-NP O
48 1517 1518 8643973 . . O O

1 1519 1522 8643973 The DT B-NP O
2 1523 1534 8643973 recommended VBN I-NP O
3 1535 1539 8643973 dose NN I-NP O
4 1540 1543 8643973 for IN B-PP O
5 1544 1549 8643973 phase NN B-NP O
6 1550 1553 8643973 III CD B-NP O
7 1554 1561 8643973 studies NNS I-NP O
8 1562 1564 8643973 is VBZ B-VP O
9 1565 1575 8643973 paclitaxel NN B-NP D017239
10 1576 1579 8643973 185 CD I-NP O
11 1580 1582 8643973 mg NN I-NP O
12 1582 1583 8643973 / SYM B-NP O
13 1583 1585 8643973 m2 NN I-NP O
14 1586 1589 8643973 and CC I-NP O
15 1590 1601 8643973 carboplatin NN I-NP D016190
16 1602 1605 8643973 AUC NN I-NP O
17 1606 1607 8643973 6 CD I-NP O
18 1607 1608 8643973 . . O O

1 0 0 16629641 -DOCSTART- -X- -X- O

1 0 10 16629641 Definition NN B-NP O
2 11 14 16629641 and CC I-NP O
3 15 25 16629641 management NN I-NP O
4 26 28 16629641 of IN B-PP O
5 29 35 16629641 anemia NN B-NP D000740
6 36 38 16629641 in IN B-PP O
7 39 47 16629641 patients NNS B-NP O
8 48 56 16629641 infected VBN B-VP D006526
9 57 61 16629641 with IN B-PP D006526
10 62 71 16629641 hepatitis NN B-NP D006526
11 72 73 16629641 C NN I-NP D006526
12 74 79 16629641 virus NN I-NP D006526
13 79 80 16629641 . . O O
14 81 88 16629641 Chronic JJ B-NP D019698
15 89 98 16629641 infection NN I-NP D019698
16 99 103 16629641 with IN B-PP D019698
17 104 113 16629641 hepatitis NN B-NP D019698
18 114 115 16629641 C NN I-NP D019698
19 116 121 16629641 virus NN I-NP D019698
20 122 123 16629641 ( ( O O
21 123 126 16629641 HCV NN B-NP O
22 126 127 16629641 ) ) O O
23 128 131 16629641 can MD B-VP O
24 132 140 16629641 progress VB I-VP O
25 141 143 16629641 to TO B-PP O
26 144 153 16629641 cirrhosis NN B-NP D005355
27 153 154 16629641 , , O O
28 155 169 16629641 hepatocellular JJ B-NP D006528
29 170 179 16629641 carcinoma NN I-NP D006528
30 179 180 16629641 , , O O
31 181 184 16629641 and CC O O
32 185 188 16629641 end NN B-NP D058625
33 188 189 16629641 - HYPH I-NP D058625
34 189 194 16629641 stage NN I-NP D058625
35 195 200 16629641 liver NN I-NP D058625
36 201 208 16629641 disease NN I-NP D058625
37 208 209 16629641 . . O O

1 210 213 16629641 The DT B-NP O
2 214 221 16629641 current JJ I-NP O
3 222 226 16629641 best JJS I-NP O
4 227 236 16629641 treatment NN I-NP O
5 237 240 16629641 for IN B-PP O
6 241 244 16629641 HCV NN B-NP D006526
7 245 254 16629641 infection NN I-NP D006526
8 255 257 16629641 is VBZ B-VP O
9 258 269 16629641 combination NN B-NP O
10 270 277 16629641 therapy NN I-NP O
11 278 282 16629641 with IN B-PP O
12 283 292 16629641 pegylated VBN B-NP O
13 293 303 16629641 interferon NN I-NP D007372
14 304 307 16629641 and CC I-NP O
15 308 317 16629641 ribavirin NN I-NP D012254
16 317 318 16629641 . . O O

1 319 327 16629641 Although IN B-SBAR O
2 328 332 16629641 this DT B-NP O
3 333 340 16629641 regimen NN I-NP O
4 341 349 16629641 produces VBZ B-VP O
5 350 359 16629641 sustained JJ B-NP O
6 360 369 16629641 virologic JJ I-NP O
7 370 379 16629641 responses NNS I-NP O
8 380 381 16629641 ( ( O O
9 381 385 16629641 SVRs NNS B-NP O
10 385 386 16629641 ) ) O O
11 387 389 16629641 in IN B-PP O
12 390 403 16629641 approximately RB B-NP O
13 404 407 16629641 50% CD I-NP O
14 408 410 16629641 of IN B-PP O
15 411 419 16629641 patients NNS B-NP O
16 419 420 16629641 , , O O
17 421 423 16629641 it PRP B-NP O
18 424 427 16629641 can MD B-VP O
19 428 430 16629641 be VB I-VP O
20 431 441 16629641 associated VBN I-VP O
21 442 446 16629641 with IN B-PP O
22 447 448 16629641 a DT B-NP O
23 449 460 16629641 potentially RB I-NP O
24 461 465 16629641 dose NN I-NP O
25 465 466 16629641 - HYPH O O
26 466 474 16629641 limiting VBG B-VP O
27 475 484 16629641 hemolytic JJ B-NP D000743
28 485 491 16629641 anemia NN I-NP D000743
29 491 492 16629641 . . O O

1 493 503 16629641 Hemoglobin NN B-NP O
2 504 518 16629641 concentrations NNS I-NP O
3 519 527 16629641 decrease VBP B-VP O
4 528 534 16629641 mainly RB B-ADVP O
5 535 537 16629641 as IN B-PP O
6 538 539 16629641 a DT B-NP O
7 540 546 16629641 result NN I-NP O
8 547 549 16629641 of IN B-PP O
9 550 559 16629641 ribavirin NN B-NP D012254
10 559 560 16629641 - HYPH B-NP O
11 560 567 16629641 induced VBN I-NP O
12 568 577 16629641 hemolysis NN I-NP D006461
13 577 578 16629641 , , O O
14 579 582 16629641 and CC O O
15 583 587 16629641 this DT B-NP O
16 588 594 16629641 anemia NN I-NP D000740
17 595 598 16629641 can MD B-VP O
18 599 601 16629641 be VB I-VP O
19 602 613 16629641 problematic JJ B-ADJP O
20 614 616 16629641 in IN B-PP O
21 617 625 16629641 patients NNS B-NP O
22 626 630 16629641 with IN B-PP O
23 631 634 16629641 HCV NN B-NP D006526
24 635 644 16629641 infection NN I-NP D006526
25 644 645 16629641 , , O O
26 646 656 16629641 especially RB B-ADVP O
27 657 662 16629641 those DT B-NP O
28 663 666 16629641 who WP B-NP O
29 667 671 16629641 have VBP B-VP O
30 672 680 16629641 comorbid VBN I-VP O
31 681 686 16629641 renal JJ B-NP D007674
32 687 689 16629641 or CC I-NP D007674
33 690 704 16629641 cardiovascular JJ I-NP D007674
34 705 714 16629641 disorders NNS I-NP D007674
35 714 715 16629641 . . O O

1 716 718 16629641 In IN B-PP O
2 719 726 16629641 general JJ B-ADJP O
3 726 727 16629641 , , O O
4 728 734 16629641 anemia NN B-NP D000740
5 735 738 16629641 can MD B-VP O
6 739 747 16629641 increase VB I-VP O
7 748 751 16629641 the DT B-NP O
8 752 756 16629641 risk NN I-NP O
9 757 759 16629641 of IN B-PP O
10 760 769 16629641 morbidity NN B-NP O
11 770 773 16629641 and CC I-NP O
12 774 783 16629641 mortality NN I-NP O
13 783 784 16629641 , , O O
14 785 788 16629641 and CC O O
15 789 792 16629641 may MD B-VP O
16 793 797 16629641 have VB I-VP O
17 798 806 16629641 negative JJ B-NP O
18 807 814 16629641 effects NNS I-NP O
19 815 817 16629641 on IN B-PP O
20 818 826 16629641 cerebral JJ B-NP O
21 827 835 16629641 function NN I-NP O
22 836 839 16629641 and CC I-NP O
23 840 847 16629641 quality NN I-NP O
24 848 850 16629641 of IN B-PP O
25 851 855 16629641 life NN B-NP O
26 855 856 16629641 . . O O

1 857 865 16629641 Although IN B-SBAR O
2 866 875 16629641 ribavirin NN B-NP D012254
3 875 876 16629641 - HYPH O O
4 876 886 16629641 associated VBN B-NP O
5 887 893 16629641 anemia NN I-NP D000740
6 894 897 16629641 can MD B-VP O
7 898 900 16629641 be VB I-VP O
8 901 909 16629641 reversed VBN I-VP O
9 910 912 16629641 by IN B-PP O
10 913 917 16629641 dose NN B-NP O
11 918 927 16629641 reduction NN I-NP O
12 928 930 16629641 or CC I-NP O
13 931 946 16629641 discontinuation NN I-NP O
14 946 947 16629641 , , O O
15 948 952 16629641 this DT B-NP O
16 953 961 16629641 approach NN I-NP O
17 962 973 16629641 compromises VBZ B-VP O
18 974 982 16629641 outcomes NNS B-NP O
19 983 985 16629641 by IN B-PP O
20 986 999 16629641 significantly RB B-VP O
21 1000 1010 16629641 decreasing VBG I-VP O
22 1011 1014 16629641 SVR NN B-NP O
23 1015 1020 16629641 rates NNS I-NP O
24 1020 1021 16629641 . . O O

1 1022 1033 16629641 Recombinant JJ B-NP O
2 1034 1039 16629641 human JJ I-NP O
3 1040 1054 16629641 erythropoietin NN I-NP O
4 1055 1058 16629641 has VBZ B-VP O
5 1059 1063 16629641 been VBN I-VP O
6 1064 1068 16629641 used VBN I-VP O
7 1069 1071 16629641 to TO I-VP O
8 1072 1078 16629641 manage VB I-VP O
9 1079 1088 16629641 ribavirin NN B-NP D012254
10 1088 1089 16629641 - HYPH O O
11 1089 1099 16629641 associated VBN B-NP O
12 1100 1106 16629641 anemia NN I-NP D000740
13 1107 1110 16629641 but CC O O
14 1111 1114 16629641 has VBZ B-VP O
15 1115 1120 16629641 other JJ B-NP O
16 1121 1130 16629641 potential JJ I-NP O
17 1131 1144 16629641 disadvantages NNS I-NP O
18 1144 1145 16629641 . . O O

1 1146 1156 16629641 Viramidine NN B-NP C026956
2 1156 1157 16629641 , , O O
3 1158 1159 16629641 a DT B-NP O
4 1160 1165 16629641 liver NN I-NP O
5 1165 1166 16629641 - HYPH O O
6 1166 1175 16629641 targeting VBG B-VP O
7 1176 1183 16629641 prodrug NN B-NP O
8 1184 1186 16629641 of IN B-PP O
9 1187 1196 16629641 ribavirin NN B-NP D012254
10 1196 1197 16629641 , , O O
11 1198 1201 16629641 has VBZ B-VP O
12 1202 1205 16629641 the DT B-NP O
13 1206 1215 16629641 potential NN I-NP O
14 1216 1218 16629641 to TO B-VP O
15 1219 1227 16629641 maintain VB I-VP O
16 1228 1231 16629641 the DT B-NP O
17 1232 1241 16629641 virologic JJ I-NP O
18 1242 1250 16629641 efficacy NN I-NP O
19 1251 1253 16629641 of IN B-PP O
20 1254 1263 16629641 ribavirin NN B-NP D012254
21 1264 1269 16629641 while IN B-SBAR O
22 1270 1280 16629641 decreasing VBG B-VP O
23 1281 1284 16629641 the DT B-NP O
24 1285 1289 16629641 risk NN I-NP O
25 1290 1292 16629641 of IN B-PP O
26 1293 1302 16629641 hemolytic JJ B-NP D000743
27 1303 1309 16629641 anemia NN I-NP D000743
28 1310 1312 16629641 in IN B-PP O
29 1313 1321 16629641 patients NNS B-NP O
30 1322 1326 16629641 with IN B-PP O
31 1327 1334 16629641 chronic JJ B-NP D019698
32 1335 1344 16629641 hepatitis NN I-NP D019698
33 1345 1346 16629641 C NN I-NP D019698
34 1346 1347 16629641 . . O O

1 0 0 18161408 -DOCSTART- -X- -X- O

1 0 10 18161408 Myocardial JJ B-NP D009203
2 11 21 18161408 infarction NN I-NP D009203
3 22 24 18161408 in IN B-PP O
4 25 34 18161408 pregnancy NN B-NP O
5 35 45 18161408 associated VBN B-VP O
6 46 50 18161408 with IN B-PP O
7 51 61 18161408 clomiphene NN B-NP D002996
8 62 69 18161408 citrate NN I-NP D002996
9 70 73 18161408 for IN B-PP O
10 74 83 18161408 ovulation NN B-NP O
11 84 93 18161408 induction NN I-NP O
12 93 94 18161408 : : O O
13 95 96 18161408 a DT B-NP O
14 97 101 18161408 case NN I-NP O
15 102 108 18161408 report NN I-NP O
16 108 109 18161408 . . I-NP O
17 110 120 18161408 BACKGROUND NN I-NP O
18 120 121 18161408 : : O O
19 122 132 18161408 Clomiphene NN B-NP D002996
20 133 140 18161408 citrate NN I-NP D002996
21 141 142 18161408 ( ( O O
22 142 144 18161408 CC NN B-NP D002996
23 144 145 18161408 ) ) O O
24 146 148 18161408 is VBZ B-VP O
25 149 157 18161408 commonly RB I-VP O
26 158 168 18161408 prescribed VBN I-VP O
27 169 172 18161408 for IN B-PP O
28 173 182 18161408 ovulation NN B-NP O
29 183 192 18161408 induction NN I-NP O
30 192 193 18161408 . . O O

1 194 196 18161408 It PRP B-NP O
2 197 199 18161408 is VBZ B-VP O
3 200 210 18161408 considered VBN I-VP O
4 211 215 18161408 safe JJ B-ADJP O
5 215 216 18161408 , , O O
6 217 221 18161408 with IN B-PP O
7 222 229 18161408 minimal JJ B-NP O
8 230 234 18161408 side NN I-NP O
9 235 242 18161408 effects NNS I-NP O
10 242 243 18161408 . . O O

1 244 259 18161408 Thromboembolism NN B-NP D013923
2 260 262 18161408 is VBZ B-VP O
3 263 264 18161408 a DT B-NP O
4 265 269 18161408 rare JJ I-NP O
5 270 273 18161408 but CC I-NP O
6 274 278 18161408 life NN I-NP O
7 278 279 18161408 - HYPH B-NP O
8 279 290 18161408 threatening VBG B-VP O
9 291 303 18161408 complication NN B-NP O
10 304 308 18161408 that WDT B-NP O
11 309 312 18161408 has VBZ B-VP O
12 313 317 18161408 been VBN I-VP O
13 318 326 18161408 reported VBN I-VP O
14 327 332 18161408 after IN B-PP O
15 333 342 18161408 ovulation NN B-NP O
16 343 352 18161408 induction NN I-NP O
17 353 357 18161408 with IN B-PP O
18 358 360 18161408 CC NN B-NP D002996
19 360 361 18161408 . . O O

1 362 373 18161408 Spontaneous JJ B-NP O
2 374 382 18161408 coronary JJ I-NP D003328
3 383 393 18161408 thrombosis NN I-NP D003328
4 394 396 18161408 or CC I-NP O
5 397 412 18161408 thromboembolism NN I-NP D013923
6 413 417 18161408 with IN B-PP O
7 418 428 18161408 subsequent JJ B-NP O
8 429 433 18161408 clot NN I-NP O
9 434 439 18161408 lysis NN I-NP O
10 440 443 18161408 has VBZ B-VP O
11 444 448 18161408 been VBN I-VP O
12 449 458 18161408 suggested VBN I-VP O
13 459 461 18161408 as IN B-PP O
14 462 465 18161408 one CD B-NP O
15 466 468 18161408 of IN B-PP O
16 469 472 18161408 the DT B-NP O
17 473 477 18161408 most RBS I-NP O
18 478 484 18161408 common JJ I-NP O
19 485 491 18161408 causes NNS I-NP O
20 492 494 18161408 of IN B-PP O
21 495 505 18161408 myocardial JJ B-NP D009203
22 506 516 18161408 infarction NN I-NP D009203
23 517 518 18161408 ( ( O O
24 518 520 18161408 MI NN B-NP D009203
25 520 521 18161408 ) ) O O
26 522 528 18161408 during IN B-PP O
27 529 538 18161408 pregnancy NN B-NP O
28 538 539 18161408 , , O O
29 540 544 18161408 with IN B-PP O
30 545 546 18161408 a DT B-NP O
31 547 559 18161408 subsequently RB I-NP O
32 560 566 18161408 normal JJ I-NP O
33 567 575 18161408 coronary JJ I-NP O
34 576 585 18161408 angiogram NN I-NP O
35 585 586 18161408 . . O O

1 587 591 18161408 CASE NN B-NP O
2 591 592 18161408 : : O O
3 593 594 18161408 A DT B-NP O
4 595 597 18161408 33 CD I-NP O
5 597 598 18161408 - HYPH I-NP O
6 598 602 18161408 year NN I-NP O
7 602 603 18161408 - HYPH O O
8 603 606 18161408 old JJ B-NP O
9 607 612 18161408 woman NN I-NP O
10 613 617 18161408 with IN B-PP O
11 618 619 18161408 a DT B-NP O
12 620 621 18161408 5 CD I-NP O
13 621 622 18161408 - HYPH I-NP O
14 622 626 18161408 week NN I-NP O
15 627 636 18161408 gestation NN I-NP O
16 637 640 18161408 had VBD B-VP O
17 641 649 18161408 recently RB I-VP O
18 650 658 18161408 received VBN I-VP O
19 659 661 18161408 CC NN B-NP D002996
20 662 665 18161408 for IN B-PP O
21 666 675 18161408 ovulation NN B-NP O
22 676 685 18161408 induction NN I-NP O
23 686 689 18161408 and CC O O
24 690 699 18161408 presented VBD B-VP O
25 700 704 18161408 with IN B-PP O
26 705 710 18161408 chest NN B-NP D002637
27 711 715 18161408 pain NN I-NP D002637
28 715 716 18161408 . . O O

1 717 719 18161408 An DT B-NP O
2 720 737 18161408 electrocardiogram NN I-NP O
3 738 744 18161408 showed VBD B-VP O
4 745 746 18161408 a DT B-NP O
5 747 754 18161408 lateral JJ I-NP O
6 755 758 18161408 and CC I-NP O
7 759 767 18161408 anterior JJ I-NP O
8 768 772 18161408 wall NN I-NP O
9 773 783 18161408 myocardial JJ I-NP D009203
10 784 794 18161408 infarction NN I-NP D009203
11 794 795 18161408 . . O O

1 796 803 18161408 Cardiac JJ B-NP O
2 804 811 18161408 enzymes NNS I-NP O
3 812 818 18161408 showed VBD B-VP O
4 819 820 18161408 a DT B-NP O
5 821 825 18161408 peak JJ I-NP O
6 826 830 18161408 rise NN I-NP O
7 831 833 18161408 in IN B-PP O
8 834 842 18161408 troponin NN B-NP O
9 843 844 18161408 I CD I-NP O
10 845 847 18161408 to TO I-NP O
11 848 852 18161408 9.10 CD I-NP O
12 853 855 18161408 ng NN I-NP O
13 855 856 18161408 / SYM B-NP O
14 856 858 18161408 mL NN I-NP O
15 858 859 18161408 . . O O

1 860 862 18161408 An DT B-NP O
2 863 870 18161408 initial JJ I-NP O
3 871 879 18161408 exercise NN I-NP O
4 880 886 18161408 stress NN I-NP O
5 887 891 18161408 test NN I-NP O
6 892 895 18161408 was VBD B-VP O
7 896 902 18161408 normal JJ B-ADJP O
8 902 903 18161408 . . O O

1 904 906 18161408 At IN B-PP O
2 907 910 18161408 the DT B-NP O
3 911 915 18161408 time NN I-NP O
4 916 918 18161408 of IN B-PP O
5 919 928 18161408 admission NN B-NP O
6 928 929 18161408 , , O O
7 930 933 18161408 the DT B-NP O
8 934 941 18161408 patient NN I-NP O
9 942 945 18161408 was VBD B-VP O
10 946 948 18161408 at IN B-PP O
11 949 953 18161408 high JJ B-NP O
12 954 958 18161408 risk NN I-NP O
13 959 961 18161408 of IN B-PP O
14 962 971 18161408 radiation NN B-NP D011832
15 972 978 18161408 injury NN I-NP D011832
16 979 981 18161408 to TO B-PP O
17 982 985 18161408 the DT B-NP O
18 986 991 18161408 fetus NN I-NP O
19 991 992 18161408 , , O O
20 993 995 18161408 so RB O O
21 996 997 18161408 a DT B-NP O
22 998 1006 18161408 coronary JJ I-NP O
23 1007 1016 18161408 angiogram NN I-NP O
24 1017 1020 18161408 was VBD B-VP O
25 1021 1030 18161408 postponed VBN I-VP O
26 1031 1036 18161408 until IN B-PP O
27 1037 1040 18161408 the DT B-NP O
28 1041 1047 18161408 second JJ I-NP O
29 1048 1057 18161408 trimester NN I-NP O
30 1057 1058 18161408 . . O O

1 1059 1061 18161408 It PRP B-NP O
2 1062 1068 18161408 showed VBD B-VP O
3 1069 1075 18161408 normal JJ B-NP O
4 1076 1084 18161408 coronary JJ I-NP O
5 1085 1092 18161408 vessels NNS I-NP O
6 1092 1093 18161408 . . O O

1 1094 1104 18161408 CONCLUSION NN B-NP O
2 1104 1105 18161408 : : O O
3 1106 1110 18161408 This DT B-NP O
4 1111 1118 18161408 appears VBZ B-VP O
5 1119 1121 18161408 to TO I-VP O
6 1122 1124 18161408 be VB I-VP O
7 1125 1128 18161408 the DT B-NP O
8 1129 1134 18161408 first JJ I-NP O
9 1135 1143 18161408 reported VBN I-NP O
10 1144 1148 18161408 case NN I-NP O
11 1149 1160 18161408 documenting VBG B-VP O
12 1161 1162 18161408 a DT B-NP O
13 1163 1171 18161408 possible JJ I-NP O
14 1172 1183 18161408 association NN I-NP O
15 1184 1191 18161408 between IN B-PP O
16 1192 1194 18161408 CC NN B-NP D002996
17 1195 1198 18161408 and CC O O
18 1199 1209 18161408 myocardial JJ B-NP D009203
19 1210 1220 18161408 infarction NN I-NP D009203
20 1220 1221 18161408 . . O O

1 1222 1232 18161408 Thrombosis NN B-NP D013927
2 1233 1238 18161408 might MD B-VP O
3 1239 1241 18161408 be VB I-VP O
4 1242 1243 18161408 a DT B-NP O
5 1244 1248 18161408 rare JJ I-NP O
6 1249 1252 18161408 but CC I-NP O
7 1253 1262 18161408 hazardous JJ I-NP O
8 1263 1275 18161408 complication NN I-NP O
9 1276 1278 18161408 of IN B-PP O
10 1279 1281 18161408 CC NN B-NP D002996
11 1281 1282 18161408 . . O O

1 1283 1288 18161408 Given VBN B-PP O
2 1289 1293 18161408 this DT B-NP O
3 1294 1298 18161408 life NN I-NP O
4 1298 1299 18161408 - HYPH B-VP O
5 1299 1310 18161408 threatening VBG I-VP O
6 1311 1323 18161408 complication NN B-NP O
7 1323 1324 18161408 , , O O
8 1325 1336 18161408 appropriate JJ B-NP O
9 1337 1349 18161408 prophylactic JJ I-NP O
10 1350 1358 18161408 measures NNS I-NP O
11 1359 1365 18161408 should MD B-VP O
12 1366 1368 18161408 be VB I-VP O
13 1369 1373 18161408 used VBN I-VP O
14 1374 1376 18161408 in IN B-PP O
15 1377 1381 18161408 high JJ B-NP O
16 1381 1382 18161408 - HYPH I-NP O
17 1382 1386 18161408 risk NN I-NP O
18 1387 1392 18161408 woman NN I-NP O
19 1393 1403 18161408 undergoing VBG B-VP O
20 1404 1411 18161408 ovarian JJ B-NP O
21 1412 1423 18161408 stimulation NN I-NP O
22 1423 1424 18161408 . . O O

1 0 0 19642243 -DOCSTART- -X- -X- O

1 0 5 19642243 Acute JJ B-NP D058186
2 6 11 19642243 renal JJ I-NP D058186
3 12 19 19642243 failure NN I-NP D058186
4 20 22 19642243 in IN B-PP O
5 23 31 19642243 patients NNS B-NP O
6 32 36 19642243 with IN B-PP O
7 37 41 19642243 AIDS NN B-NP D000163
8 42 44 19642243 on IN B-PP O
9 45 54 19642243 tenofovir NN B-NP C096918
10 55 60 19642243 while IN B-SBAR O
11 61 70 19642243 receiving VBG B-VP O
12 71 80 19642243 prolonged VBN B-NP O
13 81 91 19642243 vancomycin NN I-NP D014640
14 92 98 19642243 course NN I-NP O
15 99 102 19642243 for IN B-PP O
16 103 116 19642243 osteomyelitis NN B-NP D010019
17 116 117 19642243 . . O O
18 118 123 19642243 Renal JJ B-NP D051437
19 124 131 19642243 failure NN I-NP D051437
20 132 141 19642243 developed VBD B-VP O
21 142 147 19642243 after IN B-PP O
22 148 149 19642243 a DT B-NP O
23 150 159 19642243 prolonged JJ I-NP O
24 160 166 19642243 course NN I-NP O
25 167 169 19642243 of IN B-PP O
26 170 180 19642243 vancomycin NN B-NP D014640
27 181 188 19642243 therapy NN I-NP O
28 189 191 19642243 in IN B-PP O
29 192 193 19642243 2 CD B-NP O
30 194 202 19642243 patients NNS I-NP O
31 203 206 19642243 who WP B-NP O
32 207 211 19642243 were VBD B-VP O
33 212 221 19642243 receiving VBG I-VP O
34 222 231 19642243 tenofovir NN B-NP C418563
35 232 242 19642243 disoproxil NN I-NP C418563
36 243 251 19642243 fumarate NN I-NP C418563
37 252 254 19642243 as IN B-PP O
38 255 259 19642243 part NN B-NP O
39 260 262 19642243 of IN B-PP O
40 263 265 19642243 an DT B-NP O
41 266 280 19642243 antiretroviral JJ I-NP O
42 281 288 19642243 regimen NN I-NP O
43 288 289 19642243 . . O O

1 290 299 19642243 Tenofovir NN B-NP C096918
2 300 303 19642243 has VBZ B-VP O
3 304 308 19642243 been VBN I-VP O
4 309 319 19642243 implicated VBN I-VP O
5 320 322 19642243 in IN B-PP O
6 323 326 19642243 the DT B-NP O
7 327 338 19642243 development NN I-NP O
8 339 341 19642243 of IN B-PP O
9 342 349 19642243 Fanconi NNP B-NP D005198
10 350 358 19642243 syndrome NN I-NP D005198
11 359 362 19642243 and CC O O
12 363 368 19642243 renal JJ B-NP D051437
13 369 382 19642243 insufficiency NN I-NP D051437
14 383 390 19642243 because IN B-PP O
15 391 393 19642243 of IN I-PP O
16 394 397 19642243 its PRP$ B-NP O
17 398 405 19642243 effects NNS I-NP O
18 406 408 19642243 on IN B-PP O
19 409 412 19642243 the DT B-NP O
20 413 421 19642243 proximal JJ I-NP O
21 422 427 19642243 renal JJ I-NP O
22 428 434 19642243 tubule NN I-NP O
23 434 435 19642243 . . O O

1 436 446 19642243 Vancomycin NN B-NP D014640
2 447 461 19642243 nephrotoxicity NN I-NP D007674
3 462 464 19642243 is VBZ B-VP O
4 465 475 19642243 infrequent JJ B-ADJP O
5 476 479 19642243 but CC O O
6 480 483 19642243 may MD B-VP O
7 484 490 19642243 result VB I-VP O
8 491 495 19642243 from IN B-PP O
9 496 512 19642243 coadministration NN B-NP O
10 513 517 19642243 with IN B-PP O
11 518 519 19642243 a DT B-NP O
12 520 531 19642243 nephrotoxic JJ I-NP D007674
13 532 537 19642243 agent NN I-NP O
14 537 538 19642243 . . O O

1 539 549 19642243 Clinicians NNS B-NP O
2 550 556 19642243 should MD B-VP O
3 557 559 19642243 be VB I-VP O
4 560 565 19642243 aware JJ B-ADJP O
5 566 570 19642243 that DT B-NP O
6 571 580 19642243 tenofovir NN I-NP C096918
7 581 584 19642243 may MD B-VP O
8 585 590 19642243 raise VB I-VP O
9 591 594 19642243 the DT B-NP O
10 595 599 19642243 risk NN I-NP O
11 600 602 19642243 of IN B-PP O
12 603 608 19642243 renal JJ B-NP D051437
13 609 616 19642243 failure NN I-NP D051437
14 617 623 19642243 during IN B-PP O
15 624 633 19642243 prolonged JJ B-NP O
16 634 648 19642243 administration NN I-NP O
17 649 651 19642243 of IN B-PP O
18 652 662 19642243 vancomycin NN B-NP D014640
19 662 663 19642243 . . O O

1 0 0 2004 -DOCSTART- -X- -X- O

1 0 20 2004 Electrocardiographic JJ B-NP O
2 21 28 2004 changes NNS I-NP O
3 29 32 2004 and CC O O
4 33 40 2004 cardiac JJ B-NP D001145
5 41 52 2004 arrhythmias NNS I-NP D001145
6 53 55 2004 in IN B-PP O
7 56 64 2004 patients NNS B-NP O
8 65 74 2004 receiving VBG B-VP O
9 75 87 2004 psychotropic JJ B-NP O
10 88 93 2004 drugs NNS I-NP O
11 93 94 2004 . . O O
12 95 100 2004 Eight CD B-NP O
13 101 109 2004 patients NNS I-NP O
14 110 113 2004 had VBD B-VP O
15 114 121 2004 cardiac JJ B-NP O
16 122 136 2004 manifestations NNS I-NP O
17 137 141 2004 that WDT B-NP O
18 142 146 2004 were VBD B-VP O
19 147 151 2004 life NN B-NP O
20 151 152 2004 - HYPH O O
21 152 163 2004 threatening VBG B-VP O
22 164 166 2004 in IN B-PP O
23 167 171 2004 five CD B-NP O
24 172 177 2004 while IN B-SBAR O
25 178 184 2004 taking VBG B-VP O
26 185 197 2004 psychotropic JJ B-NP O
27 198 203 2004 drugs NNS I-NP O
28 203 204 2004 , , O O
29 205 211 2004 either CC O O
30 212 226 2004 phenothiazines NNS B-NP D010640
31 227 229 2004 or CC O O
32 230 239 2004 tricyclic JJ B-NP O
33 240 255 2004 antidepressants NNS I-NP O
34 255 256 2004 . . O O

1 257 265 2004 Although IN B-SBAR O
2 266 270 2004 most JJS B-NP O
3 271 279 2004 patients NNS I-NP O
4 280 284 2004 were VBD B-VP O
5 285 294 2004 receiving VBG I-VP O
6 295 302 2004 several JJ B-NP O
7 303 308 2004 drugs NNS I-NP O
8 308 309 2004 , , O O
9 310 318 2004 Mellaril NNP B-NP D013881
10 319 320 2004 ( ( O O
11 320 332 2004 thioridazine NN B-NP D013881
12 332 333 2004 ) ) O O
13 334 342 2004 appeared VBD B-VP O
14 343 345 2004 to TO I-VP O
15 346 348 2004 be VB I-VP O
16 349 360 2004 responsible JJ B-ADJP O
17 361 364 2004 for IN B-PP O
18 365 369 2004 five CD B-NP O
19 370 375 2004 cases NNS I-NP O
20 376 378 2004 of IN B-PP O
21 379 390 2004 ventricular JJ B-NP D017180
22 391 402 2004 tachycardia NN I-NP D017180
23 402 403 2004 , , O O
24 404 407 2004 one CD B-NP O
25 408 410 2004 of IN B-PP O
26 411 416 2004 which WDT B-NP O
27 417 420 2004 was VBD B-VP O
28 421 426 2004 fatal JJ B-ADJP O
29 427 429 2004 in IN B-PP O
30 430 431 2004 a DT B-NP O
31 432 434 2004 35 CD I-NP O
32 435 439 2004 year NN I-NP O
33 440 443 2004 old JJ I-NP O
34 444 449 2004 woman NN I-NP O
35 449 450 2004 . . O O

1 451 467 2004 Supraventricular JJ B-NP D013617
2 468 479 2004 tachycardia NN I-NP D013617
3 480 489 2004 developed VBN B-VP O
4 490 492 2004 in IN B-PP O
5 493 496 2004 one CD B-NP O
6 497 504 2004 patient NN I-NP O
7 505 514 2004 receiving VBG B-VP O
8 515 524 2004 Thorazine NN B-NP D002746
9 525 526 2004 ( ( O O
10 526 540 2004 chlorpromazine NN B-NP D002746
11 540 541 2004 ) ) O O
12 541 542 2004 . . O O

1 543 550 2004 Aventyl NN B-NP D009661
2 551 552 2004 ( ( O O
3 552 565 2004 nortriptyline NN B-NP D009661
4 565 566 2004 ) ) O O
5 567 570 2004 and CC O O
6 571 577 2004 Elavil NN B-NP D000639
7 578 579 2004 ( ( O O
8 579 592 2004 amitriptyline NN B-NP D000639
9 592 593 2004 ) ) O O
10 594 598 2004 each DT B-NP O
11 599 607 2004 produced VBD B-VP O
12 608 612 2004 left JJ B-NP D002037
13 613 619 2004 bundle NN I-NP D002037
14 620 626 2004 branch NN I-NP D002037
15 627 632 2004 block NN I-NP D002037
16 633 635 2004 in IN B-PP O
17 636 637 2004 a DT B-NP O
18 638 640 2004 73 CD I-NP O
19 641 645 2004 year NN I-NP O
20 646 649 2004 old JJ I-NP O
21 650 655 2004 woman NN I-NP O
22 655 656 2004 . . O O

1 657 677 2004 Electrocardiographic JJ B-NP O
2 678 679 2004 T NN I-NP O
3 680 683 2004 and CC I-NP O
4 684 685 2004 U NN I-NP O
5 686 690 2004 wave NN I-NP O
6 691 704 2004 abnormalities NNS I-NP O
7 705 709 2004 were VBD B-VP O
8 710 717 2004 present JJ B-ADJP O
9 718 720 2004 in IN B-PP O
10 721 725 2004 most JJS B-NP O
11 726 734 2004 patients NNS I-NP O
12 734 735 2004 . . O O

1 736 739 2004 The DT B-NP O
2 740 751 2004 ventricular JJ I-NP D001145
3 752 763 2004 arrhythmias NNS I-NP D001145
4 764 773 2004 responded VBD B-VP O
5 774 776 2004 to TO B-PP O
6 777 788 2004 intravenous JJ B-NP O
7 789 803 2004 administration NN I-NP O
8 804 806 2004 of IN B-PP O
9 807 816 2004 lidocaine NN B-NP D008012
10 817 820 2004 and CC O O
11 821 823 2004 to TO B-VP O
12 824 830 2004 direct VB I-VP O
13 831 838 2004 current JJ B-NP O
14 839 847 2004 electric JJ I-NP O
15 848 853 2004 shock NN I-NP O
16 853 854 2004 ; : O O
17 855 866 2004 ventricular JJ B-NP O
18 867 873 2004 pacing NN I-NP O
19 874 877 2004 was VBD B-VP O
20 878 886 2004 required VBN I-VP O
21 887 889 2004 in IN B-PP O
22 890 894 2004 some DT B-NP O
23 895 904 2004 instances NNS I-NP O
24 905 908 2004 and CC O O
25 909 920 2004 intravenous JJ B-NP O
26 921 935 2004 administration NN I-NP O
27 936 938 2004 of IN B-PP O
28 939 950 2004 propranolol NN B-NP D011433
29 951 959 2004 combined VBN B-VP O
30 960 964 2004 with IN B-PP O
31 965 976 2004 ventricular JJ B-NP O
32 977 983 2004 pacing NN I-NP O
33 984 986 2004 in IN B-PP O
34 987 990 2004 one CD B-NP O
35 990 991 2004 . . O O

1 992 995 2004 The DT B-NP O
2 996 1012 2004 tachyarrhythmias NNS I-NP D013610
3 1013 1022 2004 generally RB B-ADVP O
4 1023 1031 2004 subsided VBD B-VP O
5 1032 1038 2004 within IN B-PP O
6 1039 1041 2004 48 CD B-NP O
7 1042 1047 2004 hours NNS I-NP O
8 1048 1053 2004 after IN B-PP O
9 1054 1068 2004 administration NN B-NP O
10 1069 1071 2004 of IN B-PP O
11 1072 1075 2004 the DT B-NP O
12 1076 1081 2004 drugs NNS I-NP O
13 1082 1085 2004 was VBD B-VP O
14 1086 1093 2004 stopped VBN I-VP O
15 1093 1094 2004 . . O O

1 1095 1099 2004 Five CD B-NP O
2 1100 1102 2004 of IN B-PP O
3 1103 1106 2004 the DT B-NP O
4 1107 1112 2004 eight CD I-NP O
5 1113 1121 2004 patients NNS I-NP O
6 1122 1126 2004 were VBD B-VP O
7 1127 1129 2004 50 CD B-NP O
8 1130 1135 2004 years NNS I-NP O
9 1136 1138 2004 of IN B-PP O
10 1139 1142 2004 age NN B-NP O
11 1143 1145 2004 or CC O O
12 1146 1153 2004 younger JJR B-ADJP O
13 1153 1154 2004 ; : O O
14 1155 1159 2004 only RB B-NP O
15 1160 1163 2004 one CD I-NP O
16 1164 1171 2004 clearly RB B-ADVP O
17 1172 1175 2004 had VBD B-VP O
18 1176 1186 2004 antecedent JJ B-NP O
19 1187 1192 2004 heart NN I-NP D006331
20 1193 1200 2004 disease NN I-NP D006331
21 1200 1201 2004 . . O O

1 1202 1207 2004 Major JJ B-NP O
2 1208 1215 2004 cardiac JJ I-NP D001145
3 1216 1227 2004 arrhythmias NNS I-NP D001145
4 1228 1231 2004 are VBP B-VP O
5 1232 1233 2004 a DT B-NP O
6 1234 1243 2004 potential JJ I-NP O
7 1244 1250 2004 hazard NN I-NP O
8 1251 1253 2004 in IN B-PP O
9 1254 1262 2004 patients NNS B-NP O
10 1263 1270 2004 without IN B-PP O
11 1271 1276 2004 heart NN B-NP D006331
12 1277 1284 2004 disease NN I-NP D006331
13 1285 1288 2004 who WP B-NP O
14 1289 1292 2004 are VBP B-VP O
15 1293 1302 2004 receiving VBG I-VP O
16 1303 1312 2004 customary JJ B-NP O
17 1313 1324 2004 therapeutic JJ I-NP O
18 1325 1330 2004 doses NNS I-NP O
19 1331 1333 2004 of IN B-PP O
20 1334 1346 2004 psychotropic JJ B-NP O
21 1347 1352 2004 drugs NNS I-NP O
22 1352 1353 2004 . . O O

1 1354 1355 2004 A DT B-NP O
2 1356 1367 2004 prospective JJ I-NP O
3 1368 1376 2004 clinical JJ I-NP O
4 1377 1382 2004 trial NN I-NP O
5 1383 1385 2004 is VBZ B-VP O
6 1386 1395 2004 suggested VBN I-VP O
7 1396 1398 2004 to TO I-VP O
8 1399 1407 2004 quantify VB I-VP O
9 1408 1411 2004 the DT B-NP O
10 1412 1416 2004 risk NN I-NP O
11 1417 1419 2004 of IN B-PP O
12 1420 1427 2004 cardiac JJ B-NP D005117
13 1428 1441 2004 complications NNS I-NP D005117
14 1442 1444 2004 to TO B-PP O
15 1445 1453 2004 patients NNS B-NP O
16 1454 1463 2004 receiving VBG B-VP O
17 1464 1478 2004 phenothiazines NNS B-NP D010640
18 1479 1481 2004 or CC O O
19 1482 1491 2004 tricyclic JJ B-NP O
20 1492 1506 2004 antidepressant NN I-NP O
21 1507 1512 2004 drugs NNS I-NP O
22 1512 1513 2004 . . O O

1 0 0 8607407 -DOCSTART- -X- -X- O

1 0 5 8607407 Acute JJ B-NP O
2 6 11 8607407 blood NN I-NP O
3 12 20 8607407 pressure NN I-NP O
4 21 31 8607407 elevations NNS I-NP O
5 32 36 8607407 with IN B-PP O
6 37 45 8607407 caffeine NN B-NP D002110
7 46 48 8607407 in IN B-PP O
8 49 52 8607407 men NNS B-NP O
9 53 57 8607407 with IN B-PP O
10 58 68 8607407 borderline JJ B-NP O
11 69 77 8607407 systemic JJ I-NP O
12 78 90 8607407 hypertension NN I-NP D006973
13 90 91 8607407 . . O O
14 92 99 8607407 Whether IN B-PP O
15 100 103 8607407 the DT B-NP O
16 104 120 8607407 vasoconstrictive JJ I-NP O
17 121 128 8607407 actions NNS I-NP O
18 129 131 8607407 of IN B-PP O
19 132 140 8607407 caffeine NN B-NP D002110
20 141 144 8607407 are VBP B-VP O
21 145 153 8607407 enhanced VBN I-VP O
22 154 156 8607407 in IN B-PP O
23 157 169 8607407 hypertensive JJ B-NP D006973
24 170 177 8607407 persons NNS I-NP O
25 178 181 8607407 has VBZ B-VP O
26 182 185 8607407 not RB I-VP O
27 186 190 8607407 been VBN I-VP O
28 191 203 8607407 demonstrated VBN I-VP O
29 203 204 8607407 . . O O

1 205 209 8607407 Thus RB B-ADVP O
2 209 210 8607407 , , O O
3 211 219 8607407 caffeine NN B-NP D002110
4 220 221 8607407 ( ( O O
5 221 224 8607407 3.3 CD B-NP O
6 225 227 8607407 mg NN I-NP O
7 227 228 8607407 / SYM B-NP O
8 228 230 8607407 kg NN I-NP O
9 230 231 8607407 ) ) O O
10 232 238 8607407 versus IN B-PP O
11 239 246 8607407 placebo NN B-NP O
12 247 250 8607407 was VBD B-VP O
13 251 257 8607407 tested VBN I-VP O
14 258 260 8607407 in IN B-PP O
15 261 263 8607407 48 CD B-NP O
16 264 271 8607407 healthy JJ I-NP O
17 272 275 8607407 men NNS I-NP O
18 276 277 8607407 ( ( O O
19 277 281 8607407 aged VBN B-ADJP O
20 282 284 8607407 20 CD B-NP O
21 285 287 8607407 to TO I-NP O
22 288 290 8607407 35 CD I-NP O
23 291 296 8607407 years NNS I-NP O
24 296 297 8607407 ) ) O O
25 298 306 8607407 selected VBN B-VP O
26 307 312 8607407 after IN B-PP O
27 313 322 8607407 screening VBG B-VP O
28 323 325 8607407 on IN B-PP O
29 326 327 8607407 2 CD B-NP O
30 328 336 8607407 separate JJ I-NP O
31 337 346 8607407 occasions NNS I-NP O
32 346 347 8607407 . . O O

1 348 358 8607407 Borderline NN B-NP O
2 359 371 8607407 hypertensive JJ I-NP D006973
3 372 375 8607407 men NNS I-NP O
4 376 377 8607407 ( ( O O
5 377 378 8607407 n NN B-NP O
6 379 380 8607407 = SYM B-VP O
7 381 383 8607407 24 CD B-NP O
8 383 384 8607407 ) ) O O
9 385 389 8607407 were VBD B-VP O
10 390 398 8607407 selected VBN I-VP O
11 399 403 8607407 with IN B-PP O
12 404 413 8607407 screening VBG B-VP O
13 414 422 8607407 systolic JJ B-NP O
14 423 428 8607407 blood NN I-NP O
15 429 437 8607407 pressure NN I-NP O
16 438 439 8607407 ( ( O O
17 439 441 8607407 BP NN B-NP O
18 441 442 8607407 ) ) O O
19 443 445 8607407 of IN B-PP O
20 446 449 8607407 140 CD B-NP O
21 450 452 8607407 to TO I-NP O
22 453 456 8607407 160 CD I-NP O
23 457 459 8607407 mm NN I-NP O
24 460 462 8607407 Hg NN I-NP O
25 463 466 8607407 and CC O O
26 466 467 8607407 / SYM B-NP O
27 467 469 8607407 or CC O O
28 470 479 8607407 diastolic JJ B-NP O
29 480 482 8607407 BP NN I-NP O
30 483 485 8607407 90 CD B-NP O
31 486 488 8607407 to TO I-NP O
32 489 491 8607407 99 CD I-NP O
33 492 494 8607407 mm NN I-NP O
34 495 497 8607407 Hg NN I-NP O
35 497 498 8607407 . . O O

1 499 502 8607407 Low JJ B-NP O
2 502 503 8607407 - HYPH I-NP O
3 503 507 8607407 risk NN I-NP O
4 508 516 8607407 controls NNS I-NP O
5 517 518 8607407 ( ( O O
6 518 519 8607407 n NN B-NP O
7 520 521 8607407 = SYM B-VP O
8 522 524 8607407 24 CD B-NP O
9 524 525 8607407 ) ) O O
10 526 534 8607407 reported VBD B-VP O
11 535 537 8607407 no DT B-NP O
12 538 546 8607407 parental JJ I-NP O
13 547 554 8607407 history NN I-NP O
14 555 557 8607407 of IN B-PP O
15 558 570 8607407 hypertension NN B-NP D006973
16 571 574 8607407 and CC O O
17 575 578 8607407 had VBD B-VP O
18 579 588 8607407 screening NN B-NP O
19 589 591 8607407 BP NN I-NP O
20 592 593 8607407 < SYM B-NP O
21 594 597 8607407 130 CD B-NP O
22 597 598 8607407 / SYM I-NP O
23 598 600 8607407 85 CD I-NP O
24 601 603 8607407 mm NN I-NP O
25 604 606 8607407 Hg NN I-NP O
26 606 607 8607407 . . O O

1 608 620 8607407 Participants NNS B-NP O
2 621 625 8607407 were VBD B-VP O
3 626 630 8607407 then RB I-VP O
4 631 637 8607407 tested VBN I-VP O
5 638 640 8607407 on IN B-PP O
6 641 642 8607407 2 CD B-NP O
7 643 652 8607407 occasions NNS I-NP O
8 653 658 8607407 after IN B-PP O
9 659 661 8607407 12 CD B-NP O
10 661 662 8607407 - HYPH I-NP O
11 662 666 8607407 hour NN I-NP O
12 667 677 8607407 abstinence NN I-NP O
13 678 682 8607407 from IN B-PP O
14 683 691 8607407 caffeine NN B-NP D002110
15 692 694 8607407 in IN B-PP O
16 695 699 8607407 each DT B-NP O
17 700 702 8607407 of IN B-PP O
18 703 704 8607407 2 CD B-NP O
19 705 714 8607407 protocols NNS I-NP O
20 714 715 8607407 ; : O O
21 716 720 8607407 this DT B-NP O
22 721 729 8607407 required VBD B-VP O
23 730 731 8607407 a DT B-NP O
24 732 737 8607407 total NN I-NP O
25 738 740 8607407 of IN B-PP O
26 741 742 8607407 4 CD B-NP O
27 743 753 8607407 laboratory NN I-NP O
28 754 760 8607407 visits NNS I-NP O
29 760 761 8607407 . . O O

1 762 770 8607407 Caffeine NN B-NP D002110
2 770 771 8607407 - HYPH B-NP O
3 771 778 8607407 induced VBN I-NP O
4 779 786 8607407 changes NNS I-NP O
5 787 789 8607407 in IN B-PP O
6 790 799 8607407 diastolic JJ B-NP O
7 800 802 8607407 BP NN I-NP O
8 803 807 8607407 were VBD B-VP O
9 808 809 8607407 2 CD B-NP O
10 810 812 8607407 to TO B-PP O
11 813 814 8607407 3 CD B-ADJP O
12 815 820 8607407 times NNS I-ADJP O
13 821 827 8607407 larger JJR I-ADJP O
14 828 830 8607407 in IN B-PP O
15 831 841 8607407 borderline JJ B-NP O
16 842 850 8607407 subjects NNS I-NP O
17 851 855 8607407 than IN B-PP O
18 856 858 8607407 in IN B-PP O
19 859 867 8607407 controls NNS B-NP O
20 868 869 8607407 ( ( O O
21 869 870 8607407 + SYM B-NP O
22 870 873 8607407 8.4 CD I-NP O
23 874 876 8607407 vs CC I-NP O
24 877 878 8607407 + SYM I-NP O
25 878 881 8607407 3.8 CD I-NP O
26 882 884 8607407 mm NN I-NP O
27 885 887 8607407 Hg NN I-NP O
28 887 888 8607407 , , O O
29 889 890 8607407 p NN B-NP O
30 891 892 8607407 < SYM B-NP O
31 893 899 8607407 0.0001 CD I-NP O
32 899 900 8607407 ) ) O O
33 900 901 8607407 , , O O
34 902 905 8607407 and CC O O
35 906 910 8607407 were VBD B-VP O
36 911 923 8607407 attributable JJ B-ADJP O
37 924 926 8607407 to TO B-PP O
38 927 933 8607407 larger JJR B-NP O
39 934 941 8607407 changes NNS I-NP O
40 942 944 8607407 in IN B-PP O
41 945 954 8607407 impedance NN B-NP O
42 954 955 8607407 - HYPH B-NP O
43 955 962 8607407 derived VBN I-NP O
44 963 971 8607407 measures NNS I-NP O
45 972 974 8607407 of IN B-PP O
46 975 983 8607407 systemic JJ B-NP O
47 984 992 8607407 vascular JJ I-NP O
48 993 1003 8607407 resistance NN I-NP O
49 1004 1005 8607407 ( ( O O
50 1005 1006 8607407 + SYM B-NP O
51 1006 1009 8607407 135 CD B-NP O
52 1010 1012 8607407 vs NNS I-NP O
53 1013 1014 8607407 + SYM B-NP O
54 1014 1016 8607407 45 CD B-NP O
55 1017 1027 8607407 dynes.s.cm NN I-NP O
56 1027 1028 8607407 - HYPH B-NP O
57 1028 1029 8607407 5 CD I-NP O
58 1029 1030 8607407 , , O O
59 1031 1032 8607407 p NN B-NP O
60 1033 1034 8607407 < SYM B-NP O
61 1035 1040 8607407 0.004 CD I-NP O
62 1040 1041 8607407 ) ) O O
63 1041 1042 8607407 . . O O

1 1043 1048 8607407 These DT B-NP O
2 1049 1057 8607407 findings NNS I-NP O
3 1058 1062 8607407 were VBD B-VP O
4 1063 1073 8607407 consistent JJ B-ADJP O
5 1074 1077 8607407 and CC O O
6 1078 1085 8607407 reached VBN B-VP O
7 1086 1098 8607407 significance NN B-NP O
8 1099 1101 8607407 in IN B-PP O
9 1102 1106 8607407 both DT B-NP O
10 1107 1116 8607407 protocols NNS I-NP O
11 1116 1117 8607407 . . O O

1 1118 1121 8607407 The DT B-NP O
2 1122 1132 8607407 percentage NN I-NP O
3 1133 1135 8607407 of IN B-PP O
4 1136 1146 8607407 borderline JJ B-NP O
5 1147 1155 8607407 subjects NNS I-NP O
6 1156 1158 8607407 in IN B-PP O
7 1159 1163 8607407 whom WP B-NP O
8 1164 1173 8607407 diastolic JJ B-NP O
9 1174 1176 8607407 BP NN I-NP O
10 1177 1184 8607407 changes NNS I-NP O
11 1185 1193 8607407 exceeded VBD B-VP O
12 1194 1197 8607407 the DT B-NP O
13 1198 1204 8607407 median JJ I-NP O
14 1205 1212 8607407 control NN I-NP O
15 1213 1221 8607407 response NN I-NP O
16 1222 1225 8607407 was VBD B-VP O
17 1226 1229 8607407 96% CD B-NP O
18 1229 1230 8607407 . . O O

1 1231 1243 8607407 Consequently RB B-ADVP O
2 1243 1244 8607407 , , O O
3 1245 1252 8607407 whereas IN O O
4 1253 1256 8607407 all DT B-NP O
5 1257 1269 8607407 participants NNS I-NP O
6 1270 1279 8607407 exhibited VBD B-VP O
7 1280 1292 8607407 normotensive JJ B-NP O
8 1293 1299 8607407 levels NNS I-NP O
9 1300 1306 8607407 during IN B-PP O
10 1307 1310 8607407 the DT B-NP O
11 1311 1318 8607407 resting VBG I-NP O
12 1319 1326 8607407 predrug NN I-NP O
13 1327 1335 8607407 baseline NN I-NP O
14 1335 1336 8607407 , , O O
15 1337 1340 8607407 33% CD B-NP O
16 1341 1343 8607407 of IN B-PP O
17 1344 1354 8607407 borderline JJ B-NP O
18 1355 1363 8607407 subjects NNS I-NP O
19 1364 1372 8607407 achieved VBD B-VP O
20 1373 1385 8607407 hypertensive JJ B-NP D006973
21 1386 1388 8607407 BP NN I-NP O
22 1389 1395 8607407 levels NNS I-NP O
23 1396 1401 8607407 after IN B-PP O
24 1402 1410 8607407 caffeine NN B-NP D002110
25 1411 1420 8607407 ingestion NN I-NP O
26 1420 1421 8607407 . . O O

1 1422 1426 8607407 Thus RB B-ADVP O
2 1426 1427 8607407 , , O O
3 1428 1430 8607407 in IN B-PP O
4 1431 1441 8607407 borderline JJ B-NP O
5 1442 1454 8607407 hypertensive JJ I-NP D006973
6 1455 1458 8607407 men NNS I-NP O
7 1458 1459 8607407 , , O O
8 1460 1471 8607407 exaggerated VBD B-VP O
9 1472 1481 8607407 responses NNS B-NP O
10 1482 1484 8607407 to TO B-PP O
11 1485 1493 8607407 caffeine NN B-NP D002110
12 1494 1498 8607407 were VBD B-VP O
13 1498 1499 8607407 : : O O
14 1500 1509 8607407 selective JJ B-ADJP O
15 1510 1513 8607407 for IN B-PP O
16 1514 1523 8607407 diastolic JJ B-NP O
17 1524 1526 8607407 BP NN I-NP O
18 1526 1527 8607407 , , O O
19 1528 1538 8607407 consistent JJ B-ADJP O
20 1539 1543 8607407 with IN B-PP O
21 1544 1551 8607407 greater JJR B-NP O
22 1552 1568 8607407 vasoconstriction NN I-NP O
23 1568 1569 8607407 , , O O
24 1570 1580 8607407 replicated VBN B-VP O
25 1581 1583 8607407 in IN B-PP O
26 1584 1585 8607407 2 CD B-NP O
27 1586 1595 8607407 protocols NNS I-NP O
28 1595 1596 8607407 , , O O
29 1597 1600 8607407 and CC O O
30 1601 1615 8607407 representative NN B-NP O
31 1616 1618 8607407 of IN B-PP O
32 1619 1625 8607407 nearly RB B-NP O
33 1626 1629 8607407 all DT I-NP O
34 1630 1640 8607407 borderline JJ I-NP O
35 1641 1654 8607407 hypertensives NNS I-NP D006973
36 1654 1655 8607407 . . O O

1 1656 1658 8607407 We PRP B-NP O
2 1659 1666 8607407 suspect VBP B-VP O
3 1667 1671 8607407 that IN B-SBAR O
4 1672 1675 8607407 the DT B-NP O
5 1676 1685 8607407 potential NN I-NP O
6 1686 1689 8607407 for IN B-PP O
7 1690 1698 8607407 caffeine NN B-NP D002110
8 1699 1701 8607407 to TO B-VP O
9 1702 1711 8607407 stabilize VB I-VP O
10 1712 1716 8607407 high JJ B-NP O
11 1717 1727 8607407 resistance NN I-NP O
12 1728 1734 8607407 states NNS I-NP O
13 1735 1737 8607407 in IN B-PP O
14 1738 1749 8607407 susceptible JJ B-NP O
15 1750 1757 8607407 persons NNS I-NP O
16 1758 1766 8607407 suggests VBZ B-VP O
17 1767 1771 8607407 that IN B-SBAR O
18 1772 1775 8607407 its PRP$ B-NP O
19 1776 1779 8607407 use NN I-NP O
20 1780 1783 8607407 may MD B-VP O
21 1784 1794 8607407 facilitate VB I-VP O
22 1795 1800 8607407 their PRP$ B-NP O
23 1801 1808 8607407 disease NN I-NP O
24 1809 1820 8607407 progression NN I-NP O
25 1820 1821 8607407 , , O O
26 1822 1824 8607407 as RB B-CONJP O
27 1825 1829 8607407 well RB I-CONJP O
28 1830 1832 8607407 as IN I-CONJP O
29 1833 1839 8607407 hinder JJR B-NP O
30 1840 1848 8607407 accurate JJ I-NP O
31 1849 1858 8607407 diagnosis NN I-NP O
32 1859 1862 8607407 and CC I-NP O
33 1863 1872 8607407 treatment NN I-NP O
34 1872 1873 8607407 . . O O

1 0 0 8473723 -DOCSTART- -X- -X- O

1 0 8 8473723 Seizures NNS B-NP D012640
2 9 16 8473723 induced VBN B-VP O
3 17 19 8473723 by IN B-PP O
4 20 28 8473723 combined VBN B-NP O
5 29 44 8473723 levomepromazine NN I-NP D008728
6 44 45 8473723 - HYPH B-NP O
7 45 56 8473723 fluvoxamine NN I-NP D016666
8 57 66 8473723 treatment NN I-NP O
9 66 67 8473723 . . O O
10 68 70 8473723 We PRP B-NP O
11 71 77 8473723 report VBP B-VP O
12 78 79 8473723 a DT B-NP O
13 80 84 8473723 case NN I-NP O
14 85 87 8473723 of IN B-PP O
15 88 96 8473723 combined VBN B-NP O
16 97 112 8473723 levomepromazine NN I-NP D008728
17 112 113 8473723 - HYPH O O
18 113 124 8473723 fluvoxamine NN B-NP D016666
19 125 134 8473723 treatment NN I-NP O
20 134 135 8473723 - HYPH B-NP O
21 135 142 8473723 induced VBN I-NP O
22 143 151 8473723 seizures NNS I-NP D012640
23 151 152 8473723 . . O O

1 153 155 8473723 It PRP B-NP O
2 156 161 8473723 seems VBZ B-VP O
3 162 166 8473723 that IN B-SBAR O
4 167 175 8473723 combined VBN B-NP O
5 176 185 8473723 treatment NN I-NP O
6 186 188 8473723 of IN B-PP O
7 189 200 8473723 fluvoxamine NN B-NP D016666
8 201 205 8473723 with IN B-PP O
9 206 220 8473723 phenothiazines NNS B-NP D010640
10 221 224 8473723 may MD B-VP O
11 225 232 8473723 possess VB I-VP O
12 233 246 8473723 proconvulsive JJ B-NP O
13 247 255 8473723 activity NN I-NP O
14 255 256 8473723 . . O O

1 0 0 8766220 -DOCSTART- -X- -X- O

1 0 10 8766220 Nightmares NNS B-NP O
2 11 14 8766220 and CC I-NP O
3 15 29 8766220 hallucinations NNS I-NP D006212
4 30 35 8766220 after IN B-PP O
5 36 40 8766220 long JJ B-NP O
6 40 41 8766220 - HYPH I-NP O
7 41 45 8766220 term NN I-NP O
8 46 52 8766220 intake NN I-NP O
9 53 55 8766220 of IN B-PP O
10 56 64 8766220 tramadol NN B-NP D014147
11 65 73 8766220 combined VBN B-VP O
12 74 78 8766220 with IN B-PP O
13 79 94 8766220 antidepressants NNS B-NP O
14 94 95 8766220 . . O O
15 96 104 8766220 Tramadol NN B-NP D014147
16 105 107 8766220 is VBZ B-VP O
17 108 109 8766220 a DT B-NP O
18 110 114 8766220 weak JJ I-NP O
19 115 121 8766220 opioid NN I-NP O
20 122 126 8766220 with IN B-PP O
21 127 134 8766220 effects NNS B-NP O
22 135 137 8766220 on IN B-PP O
23 138 148 8766220 adrenergic JJ B-NP O
24 149 152 8766220 and CC I-NP O
25 153 165 8766220 serotonergic JJ I-NP O
26 166 183 8766220 neurotransmission NN I-NP O
27 184 188 8766220 that WDT B-NP O
28 189 191 8766220 is VBZ B-VP O
29 192 196 8766220 used VBN I-VP O
30 197 199 8766220 to TO B-VP O
31 200 205 8766220 treat VB I-VP O
32 206 212 8766220 cancer NN B-NP D009369
33 213 217 8766220 pain NN I-NP D010146
34 218 221 8766220 and CC O O
35 222 229 8766220 chronic JJ B-NP O
36 230 233 8766220 non JJ I-NP O
37 234 243 8766220 malignant JJ I-NP O
38 244 248 8766220 pain NN I-NP D010146
39 248 249 8766220 . . O O

1 250 254 8766220 This DT B-NP O
2 255 259 8766220 drug NN I-NP O
3 260 263 8766220 was VBD B-VP O
4 264 273 8766220 initiated VBN I-VP O
5 274 276 8766220 in IN B-PP O
6 277 288 8766220 association NN B-NP O
7 289 293 8766220 with IN B-PP O
8 294 304 8766220 paroxetine NN B-NP D017374
9 305 308 8766220 and CC I-NP O
10 309 319 8766220 dosulepine NN I-NP D004308
11 320 333 8766220 hydrochloride NN I-NP D004308
12 334 336 8766220 in IN B-PP O
13 337 338 8766220 a DT B-NP O
14 339 351 8766220 tetraparetic JJ I-NP -1
15 352 359 8766220 patient NN I-NP O
16 360 364 8766220 with IN B-PP O
17 365 372 8766220 chronic JJ B-NP D059350
18 373 377 8766220 pain NN I-NP D059350
19 377 378 8766220 . . O O

1 379 384 8766220 Fifty CD B-NP O
2 384 385 8766220 - HYPH I-NP O
3 385 388 8766220 six CD I-NP O
4 389 393 8766220 days NNS I-NP O
5 394 399 8766220 after IN B-PP O
6 400 410 8766220 initiation NN B-NP O
7 411 413 8766220 of IN B-PP O
8 414 417 8766220 the DT B-NP O
9 418 427 8766220 treatment NN I-NP O
10 428 431 8766220 the DT B-NP O
11 432 439 8766220 patient NN I-NP O
12 440 449 8766220 presented VBD B-VP O
13 450 464 8766220 hallucinations NNS B-NP D006212
14 465 469 8766220 that WDT B-NP O
15 470 474 8766220 only RB B-ADVP O
16 475 482 8766220 stopped VBD B-VP O
17 483 488 8766220 after IN B-PP O
18 489 492 8766220 the DT B-NP O
19 493 503 8766220 withdrawal NN I-NP O
20 504 506 8766220 of IN B-PP O
21 507 513 8766220 psycho AFX B-NP O
22 513 514 8766220 - HYPH B-NP O
23 514 520 8766220 active JJ I-NP O
24 521 526 8766220 drugs NNS I-NP O
25 527 530 8766220 and CC I-NP O
26 531 539 8766220 tramadol NN I-NP D014147
27 539 540 8766220 . . O O

1 541 544 8766220 The DT B-NP O
2 545 549 8766220 case NN I-NP O
3 550 556 8766220 report NN I-NP O
4 557 566 8766220 questions NNS I-NP O
5 567 570 8766220 the DT B-NP O
6 571 575 8766220 long JJ I-NP O
7 576 580 8766220 term NN I-NP O
8 581 584 8766220 use NN I-NP O
9 585 587 8766220 of IN B-PP O
10 588 592 8766220 pain NN B-NP D010146
11 593 600 8766220 killers NNS I-NP O
12 601 609 8766220 combined VBN B-VP O
13 610 614 8766220 with IN B-PP O
14 615 621 8766220 psycho AFX B-NP O
15 621 622 8766220 - HYPH I-NP O
16 622 628 8766220 active JJ I-NP O
17 629 634 8766220 drugs NNS I-NP O
18 635 637 8766220 in IN B-PP O
19 638 645 8766220 chronic JJ B-NP O
20 646 649 8766220 non JJ I-NP O
21 650 659 8766220 malignant JJ I-NP O
22 660 664 8766220 pain NN I-NP D010146
23 664 665 8766220 , , O O
24 666 676 8766220 especially RB B-ADVP O
25 677 679 8766220 if IN B-SBAR O
26 680 684 8766220 pain NN B-NP D010146
27 685 687 8766220 is VBZ B-VP O
28 688 693 8766220 under IN B-PP O
29 694 701 8766220 control NN B-NP O
30 701 702 8766220 . . O O

1 0 0 1848636 -DOCSTART- -X- -X- O

1 0 12 1848636 Debrisoquine NN B-NP D003647
2 13 22 1848636 phenotype NN I-NP O
3 23 26 1848636 and CC O O
4 27 30 1848636 the DT B-NP O
5 31 47 1848636 pharmacokinetics NNS I-NP O
6 48 51 1848636 and CC O O
7 52 56 1848636 beta SYM B-NP O
8 56 57 1848636 - HYPH B-NP O
9 57 58 1848636 2 CD I-NP O
10 59 67 1848636 receptor NN I-NP O
11 68 84 1848636 pharmacodynamics NNS I-NP O
12 85 87 1848636 of IN B-PP O
13 88 98 1848636 metoprolol NN B-NP D008790
14 99 102 1848636 and CC O O
15 103 106 1848636 its PRP$ B-NP O
16 107 118 1848636 enantiomers NNS I-NP O
17 118 119 1848636 . . O O
18 120 123 1848636 The DT B-NP O
19 124 134 1848636 metabolism NN I-NP O
20 135 137 1848636 of IN B-PP O
21 138 141 1848636 the DT B-NP O
22 142 157 1848636 cardioselective JJ I-NP O
23 158 162 1848636 beta SYM I-NP O
24 162 163 1848636 - HYPH I-NP O
25 163 170 1848636 blocker NN I-NP O
26 171 181 1848636 metoprolol NN I-NP D008790
27 182 184 1848636 is VBZ B-VP O
28 185 190 1848636 under IN B-PP O
29 191 198 1848636 genetic JJ B-NP O
30 199 206 1848636 control NN I-NP O
31 207 209 1848636 of IN B-PP O
32 210 213 1848636 the DT B-NP O
33 214 226 1848636 debrisoquine NN I-NP D003647
34 226 227 1848636 / SYM B-NP O
35 227 236 1848636 sparteine NN I-NP D013034
36 237 241 1848636 type NN I-NP O
37 241 242 1848636 . . O O

1 243 246 1848636 The DT B-NP O
2 247 250 1848636 two CD I-NP O
3 251 260 1848636 metabolic JJ I-NP O
4 261 271 1848636 phenotypes NNS I-NP O
5 271 272 1848636 , , O O
6 273 282 1848636 extensive JJ B-ADJP O
7 283 284 1848636 ( ( O O
8 284 286 1848636 EM NN B-NP O
9 286 287 1848636 ) ) O O
10 288 291 1848636 and CC O O
11 292 296 1848636 poor JJ B-NP O
12 297 309 1848636 metabolizers NNS I-NP O
13 310 311 1848636 ( ( O O
14 311 313 1848636 PM NN B-NP O
15 313 314 1848636 ) ) O O
16 314 315 1848636 , , O O
17 316 320 1848636 show VBP B-VP O
18 321 330 1848636 different JJ B-NP O
19 331 346 1848636 stereoselective JJ I-NP O
20 347 357 1848636 metabolism NN I-NP O
21 357 358 1848636 , , O O
22 359 368 1848636 resulting VBG B-VP O
23 369 371 1848636 in IN B-PP O
24 372 382 1848636 apparently RB B-ADVP O
25 383 389 1848636 higher JJR B-NP O
26 390 394 1848636 beta SYM I-NP O
27 394 395 1848636 - HYPH I-NP O
28 395 396 1848636 1 CD I-NP O
29 397 409 1848636 adrenoceptor NN I-NP O
30 410 422 1848636 antagonistic JJ I-NP O
31 423 430 1848636 potency NN I-NP O
32 431 433 1848636 of IN B-PP O
33 434 441 1848636 racemic JJ B-NP O
34 442 452 1848636 metoprolol NN I-NP D008790
35 453 455 1848636 in IN B-PP O
36 456 459 1848636 EMs NNS B-NP O
37 459 460 1848636 . . O O

1 461 463 1848636 We PRP B-NP O
2 464 476 1848636 investigated VBD B-VP O
3 477 479 1848636 if IN B-SBAR O
4 480 483 1848636 the DT B-NP O
5 484 490 1848636 latter JJ I-NP O
6 491 495 1848636 also RB B-ADVP O
7 496 503 1848636 applies VBZ B-VP O
8 504 506 1848636 to TO B-PP O
9 507 510 1848636 the DT B-NP O
10 511 515 1848636 beta SYM I-NP O
11 515 516 1848636 - HYPH I-NP O
12 516 517 1848636 2 CD I-NP O
13 518 530 1848636 adrenoceptor NN I-NP O
14 531 541 1848636 antagonism NN I-NP O
15 542 544 1848636 by IN B-PP O
16 545 555 1848636 metoprolol NN B-NP D008790
17 555 556 1848636 . . O O

1 557 560 1848636 The DT B-NP O
2 561 565 1848636 drug NN I-NP O
3 566 572 1848636 effect NN I-NP O
4 573 580 1848636 studied VBN B-VP O
5 581 584 1848636 was VBD B-VP O
6 585 588 1848636 the DT B-NP O
7 589 599 1848636 antagonism NN I-NP O
8 600 602 1848636 by IN B-PP O
9 603 613 1848636 metoprolol NN B-NP D008790
10 614 616 1848636 of IN B-PP O
11 617 628 1848636 terbutaline NN B-NP D013726
12 628 629 1848636 - HYPH B-NP O
13 629 636 1848636 induced VBN I-NP O
14 637 648 1848636 hypokalemia NN I-NP D007008
15 648 649 1848636 . . O O

1 650 652 1848636 By IN B-PP O
2 653 658 1848636 using VBG B-VP O
3 659 674 1848636 pharmacokinetic JJ B-NP O
4 675 690 1848636 pharmacodynamic JJ I-NP O
5 691 699 1848636 modeling NN I-NP O
6 700 703 1848636 the DT B-NP O
7 704 720 1848636 pharmacodynamics NNS I-NP O
8 721 723 1848636 of IN B-PP O
9 724 731 1848636 racemic JJ B-NP O
10 732 742 1848636 metoprolol NN I-NP D008790
11 743 746 1848636 and CC O O
12 747 750 1848636 the DT B-NP O
13 751 757 1848636 active JJ I-NP O
14 758 759 1848636 S NN I-NP O
15 759 760 1848636 - HYPH B-NP O
16 760 766 1848636 isomer NN I-NP O
17 766 767 1848636 , , O O
18 768 772 1848636 were VBD B-VP O
19 773 784 1848636 quantitated VBN I-VP O
20 785 787 1848636 in IN B-PP O
21 788 791 1848636 EMs NNS B-NP O
22 792 795 1848636 and CC I-NP O
23 796 799 1848636 PMs NNS I-NP O
24 800 802 1848636 in IN B-PP O
25 803 808 1848636 terms NNS B-NP O
26 809 811 1848636 of IN B-PP O
27 812 816 1848636 IC50 NN B-NP O
28 817 823 1848636 values NNS I-NP O
29 823 824 1848636 , , O O
30 825 837 1848636 representing VBG B-VP O
31 838 848 1848636 metoprolol NN B-NP D008790
32 849 855 1848636 plasma NN I-NP O
33 856 870 1848636 concentrations NNS I-NP O
34 871 880 1848636 resulting VBG B-VP O
35 881 883 1848636 in IN B-PP O
36 884 888 1848636 half JJ B-NP O
37 888 889 1848636 - HYPH I-NP O
38 889 896 1848636 maximum NN I-NP O
39 897 905 1848636 receptor NN I-NP O
40 906 915 1848636 occupancy NN I-NP O
41 915 916 1848636 . . O O

1 917 920 1848636 Six CD B-NP O
2 921 924 1848636 EMs NNS I-NP O
3 925 933 1848636 received VBD B-VP O
4 934 937 1848636 0.5 CD B-NP O
5 938 940 1848636 mg NN I-NP O
6 941 943 1848636 of IN B-PP O
7 944 955 1848636 terbutaline NN B-NP D013726
8 956 959 1848636 s.c NN I-NP O
9 959 960 1848636 . . O O

1 961 963 1848636 on IN B-PP O
2 964 967 1848636 two CD B-NP O
3 968 977 1848636 different JJ I-NP O
4 978 987 1848636 occasions NNS I-NP O
5 987 988 1848636 : : O O
6 989 990 1848636 1 CD B-NP O
7 990 991 1848636 ) ) O O
8 992 993 1848636 1 CD B-NP O
9 994 996 1848636 hr NN I-NP O
10 997 1002 1848636 after IN B-PP O
11 1003 1017 1848636 administration NN B-NP O
12 1018 1020 1848636 of IN B-PP O
13 1021 1022 1848636 a DT B-NP O
14 1023 1030 1848636 placebo NN I-NP O
15 1031 1034 1848636 and CC I-NP O
16 1035 1036 1848636 2 CD I-NP O
17 1036 1037 1848636 ) ) O O
18 1038 1039 1848636 1 CD B-NP O
19 1040 1042 1848636 hr NN I-NP O
20 1043 1048 1848636 after IN B-PP O
21 1049 1052 1848636 150 CD B-NP O
22 1053 1055 1848636 mg NN I-NP O
23 1056 1058 1848636 of IN B-PP O
24 1059 1069 1848636 metoprolol NN B-NP D008790
25 1070 1073 1848636 p.o NN I-NP O
26 1073 1074 1848636 . . O O

1 1075 1079 1848636 Five CD B-NP O
2 1080 1083 1848636 PMs NNS I-NP O
3 1084 1088 1848636 were VBD B-VP O
4 1089 1096 1848636 studied VBN I-VP O
5 1097 1106 1848636 according VBG B-PP O
6 1107 1109 1848636 to TO B-PP O
7 1110 1113 1848636 the DT B-NP O
8 1114 1118 1848636 same JJ I-NP O
9 1119 1127 1848636 protocol NN I-NP O
10 1127 1128 1848636 , , O O
11 1129 1135 1848636 except IN B-PP O
12 1136 1139 1848636 for IN B-PP O
13 1140 1141 1848636 a DT B-NP O
14 1142 1148 1848636 higher JJR I-NP O
15 1149 1160 1848636 terbutaline NN I-NP D013726
16 1161 1165 1848636 dose NN I-NP O
17 1166 1167 1848636 ( ( O O
18 1167 1171 1848636 0.75 CD B-NP O
19 1172 1174 1848636 mg NN I-NP O
20 1174 1175 1848636 ) ) O O
21 1176 1178 1848636 on IN B-PP O
22 1179 1182 1848636 day NN B-NP O
23 1183 1184 1848636 2 CD I-NP O
24 1184 1185 1848636 . . O O

1 1186 1191 1848636 Blood NN B-NP O
2 1192 1199 1848636 samples NNS I-NP O
3 1200 1203 1848636 for IN B-PP O
4 1204 1207 1848636 the DT B-NP O
5 1208 1216 1848636 analysis NN I-NP O
6 1217 1219 1848636 of IN B-PP O
7 1220 1226 1848636 plasma NN B-NP O
8 1227 1236 1848636 potassium NN I-NP D011188
9 1236 1237 1848636 , , O O
10 1238 1249 1848636 terbutaline NN B-NP D013726
11 1249 1250 1848636 , , O O
12 1251 1261 1848636 metoprolol NN B-NP D008790
13 1262 1263 1848636 ( ( O O
14 1263 1270 1848636 racemic JJ B-ADJP O
15 1270 1271 1848636 , , O O
16 1272 1273 1848636 R NN B-NP O
17 1273 1274 1848636 - HYPH B-NP O
18 1275 1278 1848636 and CC I-NP O
19 1279 1280 1848636 S NN I-NP O
20 1280 1281 1848636 - HYPH I-NP O
21 1281 1287 1848636 isomer NN I-NP O
22 1287 1288 1848636 ) ) O O
23 1288 1289 1848636 , , O O
24 1290 1293 1848636 and CC O O
25 1294 1299 1848636 alpha SYM O C029504
26 1299 1300 1848636 - HYPH O C029504
27 1300 1317 1848636 hydroxymetoprolol NN B-NP C029504
28 1318 1332 1848636 concentrations NNS I-NP O
29 1333 1337 1848636 were VBD B-VP O
30 1338 1343 1848636 taken VBN I-VP O
31 1344 1346 1848636 at IN B-PP O
32 1347 1354 1848636 regular JJ B-NP O
33 1355 1359 1848636 time NN I-NP O
34 1360 1369 1848636 intervals NNS I-NP O
35 1369 1370 1848636 , , O O
36 1371 1377 1848636 during IN B-PP O
37 1378 1379 1848636 8 CD B-NP O
38 1380 1382 1848636 hr NN I-NP O
39 1383 1388 1848636 after IN B-PP O
40 1389 1399 1848636 metoprolol NN B-NP D008790
41 1399 1400 1848636 . . O O

1 1401 1403 1848636 In IN B-PP O
2 1404 1407 1848636 PMs NNS B-NP O
3 1407 1408 1848636 , , O O
4 1409 1419 1848636 metoprolol NN B-NP D008790
5 1420 1429 1848636 increased VBD B-VP O
6 1430 1433 1848636 the DT B-NP O
7 1434 1445 1848636 terbutaline NN I-NP D013726
8 1446 1450 1848636 area NN I-NP O
9 1451 1456 1848636 under IN B-PP O
10 1457 1460 1848636 the DT B-NP O
11 1461 1467 1848636 plasma NN I-NP O
12 1468 1481 1848636 concentration NN I-NP O
13 1482 1484 1848636 vs NNS I-NP O
14 1484 1485 1848636 . . O O
15 1486 1490 1848636 time NN B-NP O
16 1491 1496 1848636 curve NN I-NP O
17 1497 1498 1848636 ( ( O O
18 1498 1499 1848636 + SYM B-NP O
19 1499 1502 1848636 67% CD I-NP O
20 1502 1503 1848636 ) ) O O
21 1503 1504 1848636 . . O O

1 1505 1511 1848636 Higher JJR B-NP O
2 1512 1522 1848636 metoprolol NN I-NP D008790
3 1522 1523 1848636 / SYM O O
4 1523 1528 1848636 alpha SYM O C029504
5 1528 1529 1848636 - HYPH O C029504
6 1529 1546 1848636 hydroxymetoprolol NN B-NP C029504
7 1547 1553 1848636 ratios NNS I-NP O
8 1554 1556 1848636 in IN B-PP O
9 1557 1560 1848636 PMs NNS B-NP O
10 1561 1565 1848636 were VBD B-VP O
11 1566 1576 1848636 predictive JJ B-ADJP O
12 1577 1580 1848636 for IN B-PP O
13 1581 1587 1848636 higher JJR B-NP O
14 1588 1589 1848636 R NN I-NP O
15 1589 1590 1848636 - HYPH O O
16 1590 1591 1848636 / SYM B-NP O
17 1591 1592 1848636 S NN I-NP O
18 1592 1593 1848636 - HYPH B-NP O
19 1593 1599 1848636 isomer NN I-NP O
20 1600 1606 1848636 ratios NNS I-NP O
21 1607 1609 1848636 of IN B-PP O
22 1610 1619 1848636 unchanged JJ B-NP O
23 1620 1624 1848636 drug NN I-NP O
24 1624 1625 1848636 . . O O

1 1626 1631 1848636 There EX B-NP O
2 1632 1635 1848636 was VBD B-VP O
3 1636 1637 1848636 a DT B-NP O
4 1638 1648 1848636 difference NN I-NP O
5 1649 1651 1848636 in IN B-PP O
6 1652 1662 1848636 metoprolol NN B-NP D008790
7 1663 1670 1848636 potency NN I-NP O
8 1671 1675 1848636 with IN B-PP O
9 1676 1682 1848636 higher JJR B-NP O
10 1683 1690 1848636 racemic JJ I-NP O
11 1691 1701 1848636 metoprolol NN I-NP D008790
12 1702 1706 1848636 IC50 NN I-NP O
13 1707 1713 1848636 values NNS I-NP O
14 1714 1716 1848636 in IN B-PP O
15 1717 1720 1848636 PMs NNS B-NP O
16 1721 1722 1848636 ( ( O O
17 1722 1724 1848636 72 CD B-NP O
18 1725 1726 1848636 + SYM O O
19 1726 1727 1848636 / SYM O O
20 1727 1728 1848636 - SYM O O
21 1729 1730 1848636 7 CD B-NP O
22 1731 1736 1848636 ng.ml NN I-NP O
23 1736 1737 1848636 - HYPH B-NP O
24 1737 1738 1848636 1 CD I-NP O
25 1738 1739 1848636 ) ) O O
26 1740 1744 1848636 than IN B-PP O
27 1745 1748 1848636 EMs NNS B-NP O
28 1749 1750 1848636 ( ( O O
29 1750 1752 1848636 42 CD B-NP O
30 1753 1754 1848636 + SYM O O
31 1754 1755 1848636 / SYM O O
32 1755 1756 1848636 - SYM O O
33 1757 1758 1848636 8 CD B-NP O
34 1759 1764 1848636 ng.ml NN I-NP O
35 1764 1765 1848636 - HYPH B-NP O
36 1765 1766 1848636 1 CD I-NP O
37 1766 1767 1848636 , , O O
38 1768 1769 1848636 P NN B-NP O
39 1770 1774 1848636 less JJR B-ADJP O
40 1775 1779 1848636 than IN B-PP O
41 1780 1795 1848636 .001).(ABSTRACT NN B-NP O
42 1796 1805 1848636 TRUNCATED VBN B-VP O
43 1806 1808 1848636 AT IN B-PP O
44 1809 1812 1848636 250 CD B-NP O
45 1813 1818 1848636 WORDS NNS I-NP O
46 1818 1819 1848636 ) ) O O

1 0 0 9848575 -DOCSTART- -X- -X- O

1 0 7 9848575 Chronic JJ B-NP O
2 8 15 9848575 effects NNS I-NP O
3 16 18 9848575 of IN B-PP O
4 19 20 9848575 a DT B-NP O
5 21 26 9848575 novel JJ I-NP O
6 27 36 9848575 synthetic JJ I-NP O
7 37 50 9848575 anthracycline NN I-NP D018943
8 51 61 9848575 derivative NN I-NP O
9 62 63 9848575 ( ( O O
10 63 65 9848575 SM NN B-NP C055866
11 65 66 9848575 - HYPH O C055866
12 66 70 9848575 5887 CD B-NP C055866
13 70 71 9848575 ) ) O O
14 72 74 9848575 on IN B-PP O
15 75 81 9848575 normal JJ B-NP O
16 82 87 9848575 heart NN I-NP O
17 88 91 9848575 and CC I-NP O
18 92 103 9848575 doxorubicin NN I-NP D004317
19 103 104 9848575 - HYPH B-NP O
20 104 111 9848575 induced VBN I-NP O
21 112 126 9848575 cardiomyopathy NN I-NP D009202
22 127 129 9848575 in IN B-PP O
23 130 136 9848575 beagle NN B-NP O
24 137 141 9848575 dogs NNS I-NP O
25 141 142 9848575 . . O O
26 143 147 9848575 This DT B-NP O
27 148 153 9848575 study NN I-NP O
28 154 157 9848575 was VBD B-VP O
29 158 166 9848575 designed VBN I-VP O
30 167 169 9848575 to TO B-VP O
31 170 181 9848575 investigate VB I-VP O
32 182 185 9848575 the DT B-NP O
33 186 193 9848575 chronic JJ I-NP O
34 194 205 9848575 cardiotoxic JJ I-NP D066126
35 206 215 9848575 potential NN I-NP O
36 216 218 9848575 of IN B-PP O
37 219 221 9848575 SM NN B-NP C055866
38 221 222 9848575 - HYPH B-NP C055866
39 222 226 9848575 5887 CD I-NP C055866
40 227 230 9848575 and CC O O
41 231 232 9848575 a DT B-NP O
42 233 241 9848575 possible JJ I-NP O
43 242 255 9848575 deteriorating VBG I-NP O
44 256 262 9848575 effect NN I-NP O
45 263 265 9848575 of IN B-PP O
46 266 268 9848575 SM NN B-NP C055866
47 268 269 9848575 - HYPH B-NP C055866
48 269 273 9848575 5887 CD I-NP C055866
49 274 276 9848575 on IN B-PP O
50 277 280 9848575 low JJ B-NP O
51 280 281 9848575 - HYPH I-NP O
52 281 286 9848575 grade NN I-NP O
53 287 301 9848575 cardiotoxicity NN I-NP D066126
54 302 305 9848575 pre AFX O O
55 305 306 9848575 - HYPH O O
56 306 313 9848575 induced VBN B-VP O
57 314 316 9848575 by IN B-PP O
58 317 328 9848575 doxorubicin NN B-NP D004317
59 329 331 9848575 in IN B-PP O
60 332 338 9848575 beagle NN B-NP O
61 339 343 9848575 dogs NNS I-NP O
62 343 344 9848575 . . O O

1 345 347 9848575 In IN B-PP O
2 348 351 9848575 the DT B-NP O
3 352 359 9848575 chronic JJ I-NP O
4 360 369 9848575 treatment NN I-NP O
5 369 370 9848575 , , O O
6 371 377 9848575 beagle NN B-NP O
7 378 382 9848575 dogs NNS I-NP O
8 383 385 9848575 of IN B-PP O
9 386 390 9848575 each DT B-NP O
10 391 394 9848575 sex NN I-NP O
11 395 399 9848575 were VBD B-VP O
12 400 405 9848575 given VBN I-VP O
13 406 419 9848575 intravenously RB B-ADVP O
14 420 424 9848575 once RB I-ADVP O
15 425 430 9848575 every DT B-NP O
16 431 432 9848575 3 CD I-NP O
17 433 438 9848575 weeks NNS I-NP O
18 438 439 9848575 , , O O
19 440 446 9848575 either CC O O
20 447 448 9848575 a DT B-NP O
21 449 458 9848575 sublethal JJ I-NP O
22 459 463 9848575 dose NN I-NP O
23 464 466 9848575 of IN B-PP O
24 467 478 9848575 doxorubicin NN B-NP D004317
25 479 480 9848575 ( ( O O
26 480 483 9848575 1.5 CD B-NP O
27 484 486 9848575 mg NN I-NP O
28 486 487 9848575 / SYM B-NP O
29 487 489 9848575 kg NN I-NP O
30 489 490 9848575 ) ) O O
31 491 493 9848575 or CC O O
32 494 496 9848575 SM NN B-NP C055866
33 496 497 9848575 - HYPH O C055866
34 497 501 9848575 5887 CD B-NP C055866
35 502 503 9848575 ( ( O O
36 503 506 9848575 2.5 CD B-NP O
37 507 509 9848575 mg NN I-NP O
38 509 510 9848575 / SYM B-NP O
39 510 512 9848575 kg NN I-NP O
40 512 513 9848575 ) ) O O
41 513 514 9848575 . . O O

1 515 518 9848575 The DT B-NP O
2 519 529 9848575 experiment NN I-NP O
3 530 533 9848575 was VBD B-VP O
4 534 544 9848575 terminated VBN I-VP O
5 545 546 9848575 3 CD B-NP O
6 547 552 9848575 weeks NNS I-NP O
7 553 558 9848575 after IN B-PP O
8 559 562 9848575 the DT B-NP O
9 563 568 9848575 ninth JJ I-NP O
10 569 575 9848575 dosing NN I-NP O
11 575 576 9848575 . . O O

1 577 584 9848575 Animals NNS B-NP O
2 585 590 9848575 which WDT B-NP O
3 591 599 9848575 received VBD B-VP O
4 600 604 9848575 over IN B-NP O
5 605 608 9848575 six CD I-NP O
6 609 616 9848575 courses NNS I-NP O
7 617 619 9848575 of IN B-PP O
8 620 631 9848575 doxorubicin NN B-NP D004317
9 632 644 9848575 demonstrated VBD B-VP O
10 645 648 9848575 the DT B-NP O
11 649 666 9848575 electrocardiogram NN I-NP O
12 667 668 9848575 ( ( O O
13 668 671 9848575 ECG NN B-NP O
14 671 672 9848575 ) ) O O
15 673 680 9848575 changes NNS B-NP O
16 680 681 9848575 , , O O
17 682 690 9848575 decrease NN B-NP O
18 691 693 9848575 of IN B-PP O
19 694 699 9848575 blood NN B-NP O
20 700 708 9848575 pressure NN I-NP O
21 709 712 9848575 and CC O O
22 713 717 9848575 high JJ B-NP O
23 717 718 9848575 - HYPH I-NP O
24 718 723 9848575 grade NN I-NP O
25 724 741 9848575 histopathological JJ I-NP O
26 742 756 9848575 cardiomyopathy NN I-NP D009202
27 756 757 9848575 , , O O
28 758 763 9848575 while IN B-SBAR O
29 764 771 9848575 animals NNS B-NP O
30 772 777 9848575 which WDT B-NP O
31 778 782 9848575 were VBD B-VP O
32 783 793 9848575 terminally RB I-VP O
33 794 804 9848575 sacrificed VBN I-VP O
34 805 810 9848575 after IN B-PP O
35 811 814 9848575 the DT B-NP O
36 815 817 9848575 SM NN I-NP C055866
37 817 818 9848575 - HYPH O C055866
38 818 822 9848575 5887 CD B-NP C055866
39 823 837 9848575 administration NN I-NP O
40 838 841 9848575 did VBD B-VP O
41 842 845 9848575 not RB I-VP O
42 846 850 9848575 show VB I-VP O
43 851 854 9848575 any DT B-NP O
44 855 862 9848575 changes NNS I-NP O
45 863 865 9848575 in IN B-PP O
46 866 869 9848575 ECG NN B-NP O
47 869 870 9848575 , , O O
48 871 876 9848575 blood NN B-NP O
49 877 885 9848575 pressure NN I-NP O
50 886 889 9848575 and CC O O
51 890 907 9848575 histopathological JJ B-NP O
52 908 920 9848575 examinations NNS I-NP O
53 920 921 9848575 . . O O

1 922 924 9848575 To TO B-VP O
2 925 932 9848575 examine VB I-VP O
3 933 934 9848575 a DT B-NP O
4 935 943 9848575 possibly RB I-NP O
5 944 957 9848575 deteriorating VBG I-NP O
6 958 969 9848575 cardiotoxic JJ I-NP D066126
7 970 976 9848575 effect NN I-NP O
8 977 979 9848575 of IN B-PP O
9 980 982 9848575 SM NN B-NP C055866
10 982 983 9848575 - HYPH B-NP C055866
11 983 987 9848575 5887 CD I-NP C055866
12 987 988 9848575 , , O O
13 989 992 9848575 low JJ B-NP O
14 992 993 9848575 - HYPH I-NP O
15 993 998 9848575 grade NN I-NP O
16 999 1013 9848575 cardiomyopathy NN I-NP D009202
17 1014 1017 9848575 was VBD B-VP O
18 1018 1025 9848575 induced VBN I-VP O
19 1026 1028 9848575 in IN B-PP O
20 1029 1033 9848575 dogs NNS B-NP O
21 1034 1036 9848575 by IN B-PP O
22 1037 1041 9848575 four CD B-NP O
23 1042 1049 9848575 courses NNS I-NP O
24 1050 1052 9848575 of IN B-PP O
25 1053 1064 9848575 doxorubicin NN B-NP D004317
26 1065 1066 9848575 ( ( O O
27 1066 1069 9848575 1.5 CD B-NP O
28 1070 1072 9848575 mg NN I-NP O
29 1072 1073 9848575 / SYM B-NP O
30 1073 1075 9848575 kg NN I-NP O
31 1075 1076 9848575 ) ) O O
32 1076 1077 9848575 . . O O

1 1078 1082 9848575 Nine CD B-NP O
2 1083 1088 9848575 weeks NNS I-NP O
3 1089 1094 9848575 after IN B-PP O
4 1095 1098 9848575 pre AFX B-NP O
5 1098 1099 9848575 - HYPH I-NP O
6 1099 1108 9848575 treatment NN I-NP O
7 1108 1109 9848575 , , O O
8 1110 1114 9848575 dogs NNS B-NP O
9 1115 1119 9848575 were VBD B-VP O
10 1120 1125 9848575 given VBN I-VP O
11 1126 1130 9848575 four CD B-NP O
12 1131 1138 9848575 courses NNS I-NP O
13 1139 1141 9848575 of IN B-PP O
14 1142 1148 9848575 either CC O O
15 1149 1160 9848575 doxorubicin NN B-NP D004317
16 1161 1162 9848575 ( ( O O
17 1162 1165 9848575 1.5 CD B-NP O
18 1166 1168 9848575 mg NN I-NP O
19 1168 1169 9848575 / SYM B-NP O
20 1169 1171 9848575 kg NN I-NP O
21 1171 1172 9848575 ) ) O O
22 1173 1175 9848575 or CC O O
23 1176 1178 9848575 SM NN B-NP C055866
24 1178 1179 9848575 - HYPH O C055866
25 1179 1183 9848575 5887 CD B-NP C055866
26 1184 1185 9848575 ( ( O O
27 1185 1188 9848575 2.5 CD B-NP O
28 1189 1191 9848575 mg NN I-NP O
29 1191 1192 9848575 / SYM B-NP O
30 1192 1194 9848575 kg NN I-NP O
31 1194 1195 9848575 ) ) O O
32 1196 1200 9848575 once RB B-ADVP O
33 1201 1206 9848575 every DT B-NP O
34 1207 1208 9848575 3 CD I-NP O
35 1209 1214 9848575 weeks NNS I-NP O
36 1214 1215 9848575 . . O O

1 1216 1219 9848575 The DT B-NP O
2 1220 1223 9848575 low JJ I-NP O
3 1223 1224 9848575 - HYPH I-NP O
4 1224 1229 9848575 grade NN I-NP O
5 1230 1241 9848575 cardiotoxic JJ I-NP D066126
6 1242 1249 9848575 changes NNS I-NP O
7 1250 1254 9848575 were VBD B-VP O
8 1255 1263 9848575 enhanced VBN I-VP O
9 1264 1266 9848575 by IN B-PP O
10 1267 1270 9848575 the DT B-NP O
11 1271 1281 9848575 additional JJ I-NP O
12 1282 1293 9848575 doxorubicin NN I-NP D004317
13 1294 1303 9848575 treatment NN I-NP O
14 1303 1304 9848575 . . O O

1 1305 1307 9848575 On IN B-PP O
2 1308 1311 9848575 the DT B-NP O
3 1312 1320 9848575 contrary NN I-NP O
4 1320 1321 9848575 , , O O
5 1322 1325 9848575 the DT B-NP O
6 1326 1328 9848575 SM NN I-NP C055866
7 1328 1329 9848575 - HYPH O C055866
8 1329 1333 9848575 5887 CD B-NP C055866
9 1334 1343 9848575 treatment NN I-NP O
10 1344 1347 9848575 did VBD B-VP O
11 1348 1351 9848575 not RB I-VP O
12 1352 1360 9848575 progress VB I-VP O
13 1361 1364 9848575 the DT B-NP O
14 1365 1370 9848575 grade NN I-NP O
15 1371 1373 9848575 of IN B-PP O
16 1374 1388 9848575 cardiomyopathy NN B-NP D009202
17 1388 1389 9848575 . . O O

1 1390 1392 9848575 In IN B-PP O
2 1393 1403 9848575 conclusion NN B-NP O
3 1403 1404 9848575 , , O O
4 1405 1407 9848575 SM NN B-NP C055866
5 1407 1408 9848575 - HYPH O C055866
6 1408 1412 9848575 5887 CD B-NP C055866
7 1413 1417 9848575 does VBZ B-VP O
8 1418 1421 9848575 not RB I-VP O
9 1422 1426 9848575 have VB I-VP O
10 1427 1430 9848575 any DT B-NP O
11 1431 1440 9848575 potential NN I-NP O
12 1441 1443 9848575 of IN B-PP O
13 1444 1451 9848575 chronic JJ B-NP O
14 1452 1466 9848575 cardiotoxicity NN I-NP D066126
15 1467 1470 9848575 and CC O O
16 1471 1484 9848575 deteriorating VBG B-NP O
17 1485 1491 9848575 effect NN I-NP O
18 1492 1494 9848575 on IN B-PP O
19 1495 1506 9848575 doxorubicin NN B-NP D004317
20 1506 1507 9848575 - HYPH B-NP O
21 1507 1514 9848575 induced VBN I-NP O
22 1515 1529 9848575 cardiotoxicity NN I-NP D066126
23 1530 1532 9848575 in IN B-PP O
24 1533 1537 9848575 dogs NNS B-NP O
25 1537 1538 9848575 . . O O

1 0 0 430165 -DOCSTART- -X- -X- O

1 0 9 430165 Transient JJ B-NP O
2 10 21 430165 hemiparesis NN I-NP D010291
3 21 22 430165 : : O O
4 23 24 430165 a DT B-NP O
5 25 29 430165 rare JJ I-NP O
6 30 43 430165 manifestation NN I-NP O
7 44 46 430165 of IN B-PP O
8 47 64 430165 diphenylhydantoin NN B-NP D010672
9 65 73 430165 toxicity NN I-NP D064420
10 73 74 430165 . . O O

1 75 81 430165 Report NN B-NP O
2 82 84 430165 of IN B-PP O
3 85 88 430165 two CD B-NP O
4 89 94 430165 cases NNS I-NP O
5 94 95 430165 . . O O
6 96 101 430165 Among IN B-PP O
7 102 105 430165 the DT B-NP O
8 106 112 430165 common JJ I-NP O
9 113 117 430165 side NN I-NP O
10 118 125 430165 effects NNS I-NP O
11 126 128 430165 of IN B-PP O
12 129 146 430165 diphenylhydantoin NN B-NP D010672
13 147 148 430165 ( ( O O
14 148 151 430165 DPH NN B-NP D010672
15 151 152 430165 ) ) O O
16 153 161 430165 overdose NN B-NP D062787
17 161 162 430165 , , O O
18 163 166 430165 the DT B-NP O
19 167 171 430165 most RBS I-NP O
20 172 182 430165 frequently RB I-NP O
21 183 194 430165 encountered VBN I-NP O
22 195 207 430165 neurological JJ I-NP O
23 208 213 430165 signs NNS I-NP O
24 214 217 430165 are VBP B-VP O
25 218 223 430165 those DT B-NP O
26 224 226 430165 of IN B-PP O
27 227 237 430165 cerebellar JJ B-NP D002526
28 238 249 430165 dysfunction NN I-NP D002526
29 249 250 430165 . . O O

1 251 255 430165 Very RB B-ADVP O
2 256 262 430165 rarely RB I-ADVP O
3 262 263 430165 , , O O
4 264 267 430165 the DT B-NP O
5 268 273 430165 toxic JJ I-NP O
6 274 286 430165 neurological JJ I-NP O
7 287 301 430165 manifestations NNS I-NP O
8 302 304 430165 of IN B-PP O
9 305 309 430165 this DT B-NP O
10 310 314 430165 drug NN I-NP O
11 315 318 430165 are VBP B-VP O
12 319 321 430165 of IN B-PP O
13 322 330 430165 cerebral JJ B-NP O
14 331 337 430165 origin NN I-NP O
15 337 338 430165 . . O O

1 339 342 430165 Two CD B-NP O
2 343 351 430165 patients NNS I-NP O
3 352 355 430165 are VBP B-VP O
4 356 365 430165 presented VBN I-VP O
5 366 369 430165 who WP B-NP O
6 370 378 430165 suffered VBD B-VP O
7 379 390 430165 progressive JJ B-NP O
8 391 402 430165 hemiparesis NN I-NP D010291
9 403 406 430165 due JJ B-ADJP O
10 407 409 430165 to TO B-PP O
11 410 413 430165 DPH NN B-NP D010672
12 414 422 430165 overdose NN I-NP D062787
13 422 423 430165 . . O O

1 424 428 430165 Both DT B-NP O
2 429 432 430165 had VBD B-VP O
3 433 438 430165 brain NN B-NP O
4 439 446 430165 surgery NN I-NP O
5 447 453 430165 before IN B-PP O
6 454 457 430165 DPH NN B-NP D010672
7 458 467 430165 treatment NN I-NP O
8 467 468 430165 . . O O

1 469 471 430165 It PRP B-NP O
2 472 474 430165 is VBZ B-VP O
3 475 482 430165 assumed VBN I-VP O
4 483 487 430165 that IN B-SBAR O
5 488 496 430165 patients NNS B-NP O
6 497 501 430165 with IN B-PP O
7 502 506 430165 some DT B-NP O
8 507 515 430165 cerebral JJ I-NP D001927
9 516 522 430165 damage NN I-NP D001927
10 523 526 430165 are VBP B-VP O
11 527 533 430165 liable JJ B-ADJP O
12 534 536 430165 to TO B-VP O
13 537 545 430165 manifest VB I-VP O
14 546 549 430165 DPH NN B-NP D010672
15 550 558 430165 toxicity NN I-NP D064420
16 559 561 430165 as IN B-PP O
17 562 567 430165 focal JJ B-NP O
18 568 580 430165 neurological JJ I-NP O
19 581 586 430165 signs NNS I-NP O
20 586 587 430165 . . O O

1 0 0 2980315 -DOCSTART- -X- -X- O

1 0 9 2980315 Selective JJ B-NP O
2 10 19 2980315 injection NN I-NP O
3 20 22 2980315 of IN B-PP O
4 23 31 2980315 iopentol NN B-NP C053571
5 31 32 2980315 , , I-NP O
6 33 40 2980315 iohexol NN I-NP D007472
7 41 44 2980315 and CC I-NP O
8 45 55 2980315 metrizoate NN I-NP D008794
9 56 60 2980315 into IN B-PP O
10 61 64 2980315 the DT B-NP O
11 65 69 2980315 left JJ I-NP O
12 70 78 2980315 coronary JJ I-NP O
13 79 85 2980315 artery NN I-NP O
14 86 88 2980315 of IN B-PP O
15 89 92 2980315 the DT B-NP O
16 93 96 2980315 dog NN I-NP O
17 96 97 2980315 . . O O

1 98 107 2980315 Induction NN B-NP O
2 108 110 2980315 of IN B-PP O
3 111 122 2980315 ventricular JJ B-NP D014693
4 123 135 2980315 fibrillation NN I-NP D014693
5 136 139 2980315 and CC I-NP O
6 140 148 2980315 decrease NN I-NP O
7 149 151 2980315 of IN B-PP O
8 152 158 2980315 aortic JJ B-NP O
9 159 167 2980315 pressure NN I-NP O
10 167 168 2980315 . . O O
11 169 171 2980315 In IN B-PP O
12 172 178 2980315 twenty JJ B-NP O
13 179 185 2980315 beagle NN I-NP O
14 186 190 2980315 dogs VBZ B-VP O
15 191 200 2980315 selective JJ B-NP O
16 201 211 2980315 injections NNS I-NP O
17 212 216 2980315 were VBD B-VP O
18 217 221 2980315 made VBN I-VP O
19 222 226 2980315 into IN B-PP O
20 227 230 2980315 the DT B-NP O
21 231 235 2980315 left JJ I-NP O
22 236 244 2980315 coronary JJ I-NP O
23 245 251 2980315 artery NN I-NP O
24 252 256 2980315 with IN B-PP O
25 257 265 2980315 iopentol NN B-NP C053571
26 265 266 2980315 , , I-NP O
27 267 274 2980315 iohexol NN I-NP D007472
28 275 278 2980315 and CC I-NP O
29 279 289 2980315 metrizoate NN I-NP D008794
30 290 292 2980315 in IN B-PP O
31 293 298 2980315 doses NNS B-NP O
32 299 301 2980315 of IN B-PP O
33 302 303 2980315 4 CD B-NP O
34 304 306 2980315 ml NN I-NP O
35 306 307 2980315 , , O O
36 308 309 2980315 8 CD B-NP O
37 310 312 2980315 ml NN I-NP O
38 313 316 2980315 and CC O O
39 317 319 2980315 16 CD B-NP O
40 320 322 2980315 ml NN I-NP O
41 322 323 2980315 . . O O

1 324 330 2980315 Thirty CD B-NP O
2 330 331 2980315 - HYPH I-NP O
3 331 334 2980315 six CD I-NP O
4 335 343 2980315 iopentol NN I-NP C053571
5 344 354 2980315 injections NNS I-NP O
6 354 355 2980315 , , O O
7 356 358 2980315 35 CD B-NP O
8 359 366 2980315 iohexol NN I-NP D007472
9 367 377 2980315 injections NNS I-NP O
10 378 381 2980315 and CC O O
11 382 384 2980315 37 CD B-NP O
12 385 395 2980315 metrizoate NN I-NP D008794
13 396 406 2980315 injections NNS I-NP O
14 407 411 2980315 were VBD B-VP O
15 412 416 2980315 made VBN I-VP O
16 416 417 2980315 . . O O

1 418 429 2980315 Frequencies NNS B-NP O
2 430 432 2980315 of IN B-PP O
3 433 444 2980315 ventricular JJ B-NP D014693
4 445 457 2980315 fibrillation NN I-NP D014693
5 458 462 2980315 were VBD B-VP O
6 463 476 2980315 significantly RB B-ADJP O
7 477 482 2980315 lower JJR I-ADJP O
8 483 484 2980315 ( ( O O
9 484 485 2980315 p NN B-NP O
10 486 490 2980315 less JJR B-ADJP O
11 491 495 2980315 than IN B-PP O
12 496 500 2980315 0.05 CD B-NP O
13 500 501 2980315 ) ) O O
14 502 507 2980315 after IN B-PP O
15 508 516 2980315 iopentol NN B-NP C053571
16 517 518 2980315 ( ( O O
17 518 520 2980315 0% NN B-NP O
18 520 521 2980315 ) ) O O
19 522 525 2980315 and CC O O
20 526 533 2980315 iohexol NN B-NP D007472
21 534 535 2980315 ( ( O O
22 535 537 2980315 3% NN B-NP O
23 537 538 2980315 ) ) O O
24 539 543 2980315 than IN B-PP O
25 544 549 2980315 after IN B-PP O
26 550 560 2980315 metrizoate NN B-NP D008794
27 561 562 2980315 ( ( O O
28 562 565 2980315 22% CD B-NP O
29 565 566 2980315 ) ) O O
30 566 567 2980315 . . O O

1 568 576 2980315 Iopentol NN B-NP C053571
2 577 580 2980315 and CC I-NP O
3 581 588 2980315 iohexol NN I-NP D007472
4 589 593 2980315 also RB B-ADVP O
5 594 602 2980315 produced VBD B-VP O
6 603 616 2980315 significantly RB B-NP O
7 617 621 2980315 less JJR I-NP O
8 622 630 2980315 decrease NN I-NP O
9 631 633 2980315 in IN B-PP O
10 634 640 2980315 aortic JJ B-NP O
11 641 646 2980315 blood NN I-NP O
12 647 655 2980315 pressure NN I-NP O
13 656 660 2980315 than IN B-PP O
14 661 671 2980315 metrizoate NN B-NP D008794
15 672 674 2980315 at IN B-PP O
16 675 678 2980315 the DT B-NP O
17 679 688 2980315 different JJ I-NP O
18 689 694 2980315 doses NNS I-NP O
19 694 695 2980315 . . O O

1 0 0 11524350 -DOCSTART- -X- -X- O

1 0 8 11524350 Systemic JJ B-NP O
2 9 17 11524350 toxicity NN I-NP D064420
3 18 21 11524350 and CC I-NP O
4 22 35 11524350 resuscitation NN I-NP O
5 36 38 11524350 in IN B-PP O
6 39 50 11524350 bupivacaine NN B-NP D002045
7 50 51 11524350 - HYPH B-NP O
8 51 52 11524350 , , O O
9 53 68 11524350 levobupivacaine NN B-NP C476513
10 68 69 11524350 - HYPH B-ADJP O
11 69 70 11524350 , , O O
12 71 73 11524350 or CC O O
13 74 85 11524350 ropivacaine NN B-NP C037663
14 85 86 11524350 - HYPH O O
15 86 93 11524350 infused VBN B-NP O
16 94 98 11524350 rats NNS I-NP O
17 98 99 11524350 . . O O
18 100 102 11524350 We PRP B-NP O
19 103 111 11524350 compared VBD B-VP O
20 112 115 11524350 the DT B-NP O
21 116 124 11524350 systemic JJ I-NP O
22 125 133 11524350 toxicity NN I-NP D064420
23 134 136 11524350 of IN B-PP O
24 137 148 11524350 bupivacaine NN B-NP D002045
25 148 149 11524350 , , O O
26 150 165 11524350 levobupivacaine NN B-NP C476513
27 165 166 11524350 , , O O
28 167 170 11524350 and CC O O
29 171 182 11524350 ropivacaine NN B-NP C037663
30 183 185 11524350 in IN B-PP O
31 186 198 11524350 anesthetized VBN B-NP O
32 199 203 11524350 rats NNS I-NP O
33 203 204 11524350 . . O O

1 205 207 11524350 We PRP B-NP O
2 208 212 11524350 also RB B-ADVP O
3 213 221 11524350 compared VBD B-VP O
4 222 225 11524350 the DT B-NP O
5 226 233 11524350 ability NN I-NP O
6 234 236 11524350 to TO B-VP O
7 237 248 11524350 resuscitate VB I-VP O
8 249 253 11524350 rats NNS B-NP O
9 254 259 11524350 after IN B-PP O
10 260 266 11524350 lethal JJ B-NP O
11 267 272 11524350 doses NNS I-NP O
12 273 275 11524350 of IN B-PP O
13 276 281 11524350 these DT B-NP O
14 282 287 11524350 local JJ I-NP O
15 288 299 11524350 anesthetics NNS I-NP O
16 299 300 11524350 . . O O

1 301 312 11524350 Bupivacaine NN B-NP D002045
2 312 313 11524350 , , O O
3 314 329 11524350 levobupivacaine NN B-NP C476513
4 329 330 11524350 , , O O
5 331 333 11524350 or CC O O
6 334 345 11524350 ropivacaine NN B-NP C037663
7 346 349 11524350 was VBD B-VP O
8 350 357 11524350 infused VBN I-VP O
9 358 360 11524350 at IN B-PP O
10 361 362 11524350 a DT B-NP O
11 363 367 11524350 rate NN I-NP O
12 368 370 11524350 of IN B-PP O
13 371 372 11524350 2 CD B-NP O
14 373 375 11524350 mg NN I-NP O
15 375 376 11524350 . . O O

1 377 380 11524350 kg( AFX B-NP O
2 380 381 11524350 - HYPH I-NP O
3 381 383 11524350 1) LS B-LST O
4 383 384 11524350 . . O O

1 385 389 11524350 min( AFX B-NP O
2 389 390 11524350 - HYPH I-NP O
3 390 392 11524350 1) LS B-LST O
4 393 398 11524350 while IN B-SBAR O
5 399 416 11524350 electrocardiogram NN B-NP O
6 416 417 11524350 , , O O
7 418 438 11524350 electroencephalogram NN B-NP O
8 438 439 11524350 , , O O
9 440 443 11524350 and CC O O
10 444 452 11524350 arterial JJ B-NP O
11 453 461 11524350 pressure NN I-NP O
12 462 466 11524350 were VBD B-VP O
13 467 479 11524350 continuously RB I-VP O
14 480 489 11524350 monitored VBN I-VP O
15 489 490 11524350 . . O O

1 491 495 11524350 When WRB B-ADVP O
2 496 504 11524350 asystole NN B-NP D006323
3 505 508 11524350 was VBD B-VP O
4 509 517 11524350 recorded VBN I-VP O
5 517 518 11524350 , , O O
6 519 523 11524350 drug NN B-NP O
7 524 532 11524350 infusion NN I-NP O
8 533 536 11524350 was VBD B-VP O
9 537 544 11524350 stopped VBN I-VP O
10 545 548 11524350 and CC O O
11 549 550 11524350 a DT B-NP O
12 551 564 11524350 resuscitation NN I-NP O
13 565 573 11524350 sequence NN I-NP O
14 574 577 11524350 was VBD B-VP O
15 578 583 11524350 begun VBN I-VP O
16 583 584 11524350 . . O O

1 585 596 11524350 Epinephrine NN B-NP D004837
2 597 601 11524350 0.01 CD I-NP O
3 602 604 11524350 mg NN I-NP O
4 604 605 11524350 / SYM B-NP O
5 605 607 11524350 kg NN I-NP O
6 608 611 11524350 was VBD B-VP O
7 612 624 11524350 administered VBN I-VP O
8 625 627 11524350 at IN B-PP O
9 628 629 11524350 1 CD B-NP O
10 629 630 11524350 - HYPH I-NP O
11 630 633 11524350 min NN I-NP O
12 634 643 11524350 intervals NNS I-NP O
13 644 649 11524350 while IN B-SBAR O
14 650 658 11524350 external JJ B-NP O
15 659 666 11524350 cardiac JJ I-NP O
16 667 679 11524350 compressions NNS I-NP O
17 680 684 11524350 were VBD B-VP O
18 685 692 11524350 applied VBN I-VP O
19 692 693 11524350 . . O O

1 694 707 11524350 Resuscitation NN B-NP O
2 708 711 11524350 was VBD B-VP O
3 712 722 11524350 considered VBN I-VP O
4 723 733 11524350 successful JJ B-ADJP O
5 734 738 11524350 when WRB B-ADVP O
6 739 740 11524350 a DT B-NP O
7 741 749 11524350 systolic JJ I-NP O
8 750 758 11524350 arterial JJ I-NP O
9 759 767 11524350 pressure NN I-NP O
10 768 769 11524350 > SYM B-VP O
11 770 772 11524350 or CC O O
12 773 774 11524350 = SYM B-VP O
13 774 777 11524350 100 CD B-NP O
14 778 780 11524350 mm NN I-NP O
15 781 783 11524350 Hg NN I-NP O
16 784 787 11524350 was VBD B-VP O
17 788 796 11524350 achieved VBN I-VP O
18 797 803 11524350 within IN B-PP O
19 804 805 11524350 5 CD B-NP O
20 806 809 11524350 min NN I-NP O
21 809 810 11524350 . . O O

1 811 814 11524350 The DT B-NP O
2 815 825 11524350 cumulative JJ I-NP O
3 826 831 11524350 doses NNS I-NP O
4 832 834 11524350 of IN B-PP O
5 835 850 11524350 levobupivacaine NN B-NP C476513
6 851 854 11524350 and CC I-NP O
7 855 866 11524350 ropivacaine NN I-NP C037663
8 867 871 11524350 that WDT B-NP O
9 872 880 11524350 produced VBD B-VP O
10 881 889 11524350 seizures NNS B-NP D012640
11 890 894 11524350 were VBD B-VP O
12 895 902 11524350 similar JJ B-ADJP O
13 903 906 11524350 and CC O O
14 907 911 11524350 were VBD B-VP O
15 912 918 11524350 larger JJR B-ADJP O
16 919 923 11524350 than IN B-PP O
17 924 929 11524350 those DT B-NP O
18 930 932 11524350 of IN B-PP O
19 933 944 11524350 bupivacaine NN B-NP D002045
20 944 945 11524350 . . O O

1 946 949 11524350 The DT B-NP O
2 950 960 11524350 cumulative JJ I-NP O
3 961 966 11524350 doses NNS I-NP O
4 967 969 11524350 of IN B-PP O
5 970 985 11524350 levobupivacaine NN B-NP C476513
6 986 990 11524350 that WDT B-NP O
7 991 999 11524350 produced VBD B-VP O
8 1000 1012 11524350 dysrhythmias NNS B-NP D001145
9 1013 1016 11524350 and CC I-NP O
10 1017 1025 11524350 asystole NN I-NP D006323
11 1026 1030 11524350 were VBD B-VP O
12 1031 1038 11524350 smaller JJR B-ADJP O
13 1039 1043 11524350 than IN B-PP O
14 1044 1047 11524350 the DT B-NP O
15 1048 1061 11524350 corresponding VBG I-NP O
16 1062 1067 11524350 doses NNS I-NP O
17 1068 1070 11524350 of IN B-PP O
18 1071 1082 11524350 ropivacaine NN B-NP C037663
19 1082 1083 11524350 , , O O
20 1084 1087 11524350 but CC O O
21 1088 1092 11524350 they PRP B-NP O
22 1093 1097 11524350 were VBD B-VP O
23 1098 1104 11524350 larger JJR B-ADJP O
24 1105 1109 11524350 than IN B-PP O
25 1110 1115 11524350 those DT B-NP O
26 1116 1118 11524350 of IN B-PP O
27 1119 1130 11524350 bupivacaine NN B-NP D002045
28 1130 1131 11524350 . . O O

1 1132 1135 11524350 The DT B-NP O
2 1136 1142 11524350 number NN I-NP O
3 1143 1145 11524350 of IN B-PP O
4 1146 1156 11524350 successful JJ B-NP O
5 1157 1171 11524350 resuscitations NNS I-NP O
6 1172 1175 11524350 did VBD B-VP O
7 1176 1179 11524350 not RB I-VP O
8 1180 1186 11524350 differ VB I-VP O
9 1187 1192 11524350 among IN B-PP O
10 1193 1199 11524350 groups NNS B-NP O
11 1199 1200 11524350 . . O O

1 1201 1208 11524350 However RB B-ADVP O
2 1208 1209 11524350 , , O O
3 1210 1211 11524350 a DT B-NP O
4 1212 1219 11524350 smaller JJR I-NP O
5 1220 1224 11524350 dose NN I-NP O
6 1225 1227 11524350 of IN B-PP O
7 1228 1239 11524350 epinephrine NN B-NP D004837
8 1240 1243 11524350 was VBD B-VP O
9 1244 1252 11524350 required VBN I-VP O
10 1253 1255 11524350 in IN B-PP O
11 1256 1259 11524350 the DT B-NP O
12 1260 1271 11524350 Ropivacaine NNP I-NP C037663
13 1272 1277 11524350 group NN I-NP O
14 1278 1282 11524350 than IN B-PP O
15 1283 1285 11524350 in IN B-PP O
16 1286 1289 11524350 the DT B-NP O
17 1290 1295 11524350 other JJ I-NP O
18 1296 1302 11524350 groups NNS I-NP O
19 1302 1303 11524350 . . O O

1 1304 1306 11524350 We PRP B-NP O
2 1307 1315 11524350 conclude VBP B-VP O
3 1316 1320 11524350 that IN B-SBAR O
4 1321 1324 11524350 the DT B-NP O
5 1325 1333 11524350 systemic JJ I-NP O
6 1334 1342 11524350 toxicity NN I-NP D064420
7 1343 1345 11524350 of IN B-PP O
8 1346 1361 11524350 levobupivacaine NN B-NP C476513
9 1362 1364 11524350 is VBZ B-VP O
10 1365 1377 11524350 intermediate JJ B-ADJP O
11 1378 1385 11524350 between IN B-PP O
12 1386 1390 11524350 that DT B-NP O
13 1391 1393 11524350 of IN B-PP O
14 1394 1405 11524350 ropivacaine NN B-NP C037663
15 1406 1409 11524350 and CC I-NP O
16 1410 1421 11524350 bupivacaine NN I-NP D002045
17 1422 1426 11524350 when WRB B-ADVP O
18 1427 1439 11524350 administered VBN B-VP O
19 1440 1442 11524350 at IN B-PP O
20 1443 1446 11524350 the DT B-NP O
21 1447 1451 11524350 same JJ I-NP O
22 1452 1456 11524350 rate NN I-NP O
23 1457 1460 11524350 and CC O O
24 1461 1465 11524350 that IN B-SBAR O
25 1466 1477 11524350 ropivacaine NN B-NP C037663
26 1477 1478 11524350 - HYPH B-NP O
27 1478 1485 11524350 induced VBN I-NP O
28 1486 1493 11524350 cardiac JJ I-NP D006323
29 1494 1500 11524350 arrest NN I-NP D006323
30 1501 1508 11524350 appears VBZ B-VP O
31 1509 1511 11524350 to TO I-VP O
32 1512 1514 11524350 be VB I-VP O
33 1515 1519 11524350 more RBR B-ADJP O
34 1520 1531 11524350 susceptible JJ I-ADJP O
35 1532 1534 11524350 to TO B-PP O
36 1535 1544 11524350 treatment NN B-NP O
37 1545 1549 11524350 than IN B-PP O
38 1550 1554 11524350 that DT B-NP O
39 1555 1562 11524350 induced VBN B-VP O
40 1563 1565 11524350 by IN B-PP O
41 1566 1577 11524350 bupivacaine NN B-NP D002045
42 1578 1580 11524350 or CC I-NP O
43 1581 1596 11524350 levobupivacaine NN I-NP C476513
44 1596 1597 11524350 . . O O

1 0 0 19893084 -DOCSTART- -X- -X- O

1 0 7 19893084 Dynamic JJ B-NP O
2 8 16 19893084 response NN I-NP O
3 17 19 19893084 of IN B-PP O
4 20 25 19893084 blood NN B-NP O
5 26 32 19893084 vessel NN I-NP O
6 33 35 19893084 in IN B-PP O
7 36 41 19893084 acute JJ B-NP D058186
8 42 47 19893084 renal JJ I-NP D058186
9 48 55 19893084 failure NN I-NP D058186
10 55 56 19893084 . . O O
11 57 59 19893084 In IN B-PP O
12 60 64 19893084 this DT B-NP O
13 65 70 19893084 study NN I-NP O
14 71 73 19893084 we PRP B-NP O
15 74 84 19893084 postulated VBD B-VP O
16 85 89 19893084 that IN B-SBAR O
17 90 96 19893084 during IN B-PP O
18 97 102 19893084 acute JJ B-NP D058186
19 103 108 19893084 renal JJ I-NP D058186
20 109 116 19893084 failure NN I-NP D058186
21 117 124 19893084 induced VBN B-VP O
22 125 127 19893084 by IN B-PP O
23 128 138 19893084 gentamicin NN B-NP D005839
24 139 142 19893084 the DT B-NP O
25 143 152 19893084 transient JJ I-NP O
26 153 155 19893084 or CC I-NP O
27 156 163 19893084 dynamic JJ I-NP O
28 164 172 19893084 response NN I-NP O
29 173 175 19893084 of IN B-PP O
30 176 181 19893084 blood NN B-NP O
31 182 189 19893084 vessels NNS I-NP O
32 190 195 19893084 could MD B-VP O
33 196 198 19893084 be VB I-VP O
34 199 207 19893084 affected VBN I-VP O
35 207 208 19893084 , , O O
36 209 212 19893084 and CC O O
37 213 217 19893084 that IN B-SBAR O
38 218 230 19893084 antioxidants NNS B-NP O
39 231 234 19893084 can MD B-VP O
40 235 242 19893084 prevent VB I-VP O
41 243 246 19893084 the DT B-NP O
42 247 254 19893084 changes NNS I-NP O
43 255 257 19893084 in IN B-PP O
44 258 265 19893084 dynamic JJ B-NP O
45 266 275 19893084 responses NNS I-NP O
46 276 278 19893084 of IN B-PP O
47 279 284 19893084 blood NN B-NP O
48 285 292 19893084 vessels NNS I-NP O
49 292 293 19893084 . . O O

1 294 297 19893084 The DT B-NP O
2 298 301 19893084 new JJ I-NP O
3 302 310 19893084 approach NN I-NP O
4 311 313 19893084 to TO B-PP O
5 314 316 19893084 ex FW B-NP O
6 317 321 19893084 vivo FW I-NP O
7 322 327 19893084 blood NN I-NP O
8 328 334 19893084 vessel NN I-NP O
9 335 346 19893084 experiments NNS I-NP O
10 347 349 19893084 in IN B-PP O
11 350 355 19893084 which WDT B-NP O
12 356 359 19893084 not RB B-CONJP O
13 360 364 19893084 only RB I-CONJP O
14 365 368 19893084 the DT B-NP O
15 369 372 19893084 end NN I-NP O
16 373 379 19893084 points NNS I-NP O
17 380 382 19893084 of IN B-PP O
18 383 390 19893084 vessels NNS B-NP O
19 391 399 19893084 response NN I-NP O
20 400 406 19893084 within IN B-PP O
21 407 410 19893084 the DT B-NP O
22 411 415 19893084 time NN I-NP O
23 416 424 19893084 interval NN I-NP O
24 425 427 19893084 is VBZ B-VP O
25 428 438 19893084 considered VBN I-VP O
26 438 439 19893084 , , O O
27 440 443 19893084 but CC B-CONJP O
28 444 448 19893084 also RB I-CONJP O
29 449 457 19893084 dynamics NNS B-NP O
30 458 460 19893084 of IN B-PP O
31 461 465 19893084 this DT B-NP O
32 466 474 19893084 response NN I-NP O
33 474 475 19893084 , , O O
34 476 479 19893084 was VBD B-VP O
35 480 484 19893084 used VBN I-VP O
36 485 487 19893084 in IN B-PP O
37 488 492 19893084 this DT B-NP O
38 493 498 19893084 paper NN I-NP O
39 498 499 19893084 . . O O

1 500 503 19893084 Our PRP$ B-NP O
2 504 511 19893084 results NNS I-NP O
3 512 519 19893084 confirm VBP B-VP O
4 520 523 19893084 the DT B-NP O
5 524 534 19893084 alteration NN I-NP O
6 535 537 19893084 in IN B-PP O
7 538 545 19893084 dynamic JJ B-NP O
8 546 554 19893084 response NN I-NP O
9 555 557 19893084 of IN B-PP O
10 558 563 19893084 blood NN B-NP O
11 564 571 19893084 vessels NNS I-NP O
12 572 578 19893084 during IN B-PP O
13 579 582 19893084 the DT B-NP O
14 583 589 19893084 change NN I-NP O
15 590 592 19893084 of IN B-PP O
16 593 601 19893084 pressure NN B-NP O
17 602 604 19893084 in IN B-PP O
18 605 615 19893084 gentamicin NN B-NP D005839
19 615 616 19893084 - HYPH B-NP O
20 616 623 19893084 treated VBN I-NP O
21 624 631 19893084 animals NNS I-NP O
22 631 632 19893084 . . O O

1 633 636 19893084 The DT B-NP O
2 637 647 19893084 beneficial JJ I-NP O
3 648 655 19893084 effects NNS I-NP O
4 656 658 19893084 of IN B-PP O
5 659 666 19893084 vitamin NN B-NP D001205
6 667 668 19893084 C NN I-NP D001205
7 669 683 19893084 administration NN I-NP O
8 684 686 19893084 to TO B-PP O
9 687 697 19893084 gentamicin NN B-NP D005839
10 697 698 19893084 - HYPH B-NP O
11 698 705 19893084 treated VBN I-NP O
12 706 713 19893084 animals NNS I-NP O
13 714 717 19893084 are VBP B-VP O
14 718 722 19893084 also RB I-VP O
15 723 732 19893084 confirmed VBN I-VP O
16 733 740 19893084 through IN B-PP O
17 740 741 19893084 : : O O
18 742 747 19893084 lower JJR B-NP O
19 748 753 19893084 level NN I-NP O
20 754 756 19893084 of IN B-PP O
21 757 762 19893084 blood NN B-NP O
22 763 767 19893084 urea NN I-NP D014508
23 768 771 19893084 and CC I-NP O
24 772 782 19893084 creatinine NN I-NP D003404
25 783 786 19893084 and CC O O
26 787 793 19893084 higher JJR B-NP O
27 794 799 19893084 level NN I-NP O
28 800 802 19893084 of IN B-PP O
29 803 812 19893084 potassium NN B-NP D011188
30 812 813 19893084 . . O O

1 814 817 19893084 The DT B-NP O
2 818 826 19893084 pressure NN I-NP O
3 827 834 19893084 dynamic JJ I-NP O
4 835 844 19893084 responses NNS I-NP O
5 845 847 19893084 of IN B-PP O
6 848 856 19893084 isolated VBN B-NP O
7 857 862 19893084 blood NN I-NP O
8 863 870 19893084 vessels NNS I-NP O
9 871 875 19893084 show VBP B-VP O
10 876 877 19893084 a DT B-NP O
11 878 884 19893084 faster JJR I-NP O
12 885 893 19893084 pressure NN I-NP O
13 894 900 19893084 change NN I-NP O
14 901 903 19893084 in IN B-PP O
15 904 914 19893084 gentamicin NN B-NP D005839
16 914 915 19893084 - HYPH B-NP O
17 915 922 19893084 treated VBN I-NP O
18 923 930 19893084 animals NNS I-NP O
19 931 932 19893084 ( ( O O
20 932 936 19893084 8.07 CD B-NP O
21 937 938 19893084 + SYM O O
22 938 939 19893084 / SYM B-NP O
23 939 940 19893084 - SYM I-NP O
24 941 944 19893084 1.7 CD I-NP O
25 945 946 19893084 s NN I-NP O
26 947 949 19893084 vs NNS I-NP O
27 949 950 19893084 . . O O
28 951 955 19893084 5.64 CD B-NP O
29 956 957 19893084 + SYM B-NP O
30 957 958 19893084 / SYM I-NP O
31 958 959 19893084 - SYM I-NP O
32 960 964 19893084 0.18 CD I-NP O
33 965 966 19893084 s NN I-NP O
34 966 967 19893084 ) ) O O
35 967 968 19893084 . . O O

1 969 976 19893084 Vitamin NN B-NP D001205
2 977 978 19893084 C NN I-NP D001205
3 979 993 19893084 administration NN I-NP O
4 994 1001 19893084 induced VBD B-VP O
5 1002 1010 19893084 slowdown NN B-NP O
6 1011 1013 19893084 of IN B-PP O
7 1014 1022 19893084 pressure NN B-NP O
8 1023 1029 19893084 change NN I-NP O
9 1030 1034 19893084 back RB B-ADVP O
10 1035 1037 19893084 to TO B-PP O
11 1038 1041 19893084 the DT B-NP O
12 1042 1049 19893084 control NN I-NP O
13 1050 1056 19893084 values NNS I-NP O
14 1056 1057 19893084 . . O O

1 1058 1061 19893084 The DT B-NP O
2 1062 1070 19893084 pressure NN I-NP O
3 1071 1078 19893084 dynamic JJ I-NP O
4 1079 1089 19893084 properties NNS I-NP O
5 1089 1090 19893084 , , O O
6 1091 1105 19893084 quantitatively RB B-VP O
7 1106 1113 19893084 defined VBN I-VP O
8 1114 1116 19893084 by IN B-PP O
9 1117 1128 19893084 comparative JJ B-NP O
10 1129 1137 19893084 pressure NN I-NP O
11 1138 1145 19893084 dynamic JJ I-NP O
12 1146 1149 19893084 and CC I-NP O
13 1150 1155 19893084 total JJ I-NP O
14 1156 1164 19893084 pressure NN I-NP O
15 1165 1172 19893084 dynamic JJ B-ADJP O
16 1172 1173 19893084 , , O O
17 1174 1181 19893084 confirm VBP B-VP O
18 1182 1185 19893084 the DT B-NP O
19 1186 1196 19893084 alteration NN I-NP O
20 1197 1199 19893084 in IN B-PP O
21 1200 1207 19893084 dynamic JJ B-NP O
22 1208 1216 19893084 response NN I-NP O
23 1217 1219 19893084 of IN B-PP O
24 1220 1225 19893084 blood NN B-NP O
25 1226 1233 19893084 vessels NNS I-NP O
26 1234 1240 19893084 during IN B-PP O
27 1241 1244 19893084 the DT B-NP O
28 1245 1251 19893084 change NN I-NP O
29 1252 1254 19893084 of IN B-PP O
30 1255 1263 19893084 pressure NN B-NP O
31 1264 1266 19893084 in IN B-PP O
32 1267 1277 19893084 gentamicin NN B-NP D005839
33 1277 1278 19893084 - HYPH B-NP O
34 1278 1285 19893084 treated VBN I-NP O
35 1286 1293 19893084 animals NNS I-NP O
36 1294 1297 19893084 and CC O O
37 1298 1308 19893084 beneficial JJ B-NP O
38 1309 1316 19893084 effects NNS I-NP O
39 1317 1319 19893084 of IN B-PP O
40 1320 1327 19893084 vitamin NN B-NP D001205
41 1328 1329 19893084 C NN I-NP D001205
42 1330 1344 19893084 administration NN I-NP O
43 1344 1345 19893084 . . O O

1 0 0 6615052 -DOCSTART- -X- -X- O

1 0 7 6615052 Heparin NN B-NP D006493
2 7 8 6615052 - HYPH B-NP O
3 8 15 6615052 induced VBN I-NP O
4 16 32 6615052 thrombocytopenia NN I-NP D013921
5 32 33 6615052 , , O O
6 34 44 6615052 thrombosis NN B-NP D013927
7 44 45 6615052 , , O O
8 46 49 6615052 and CC O O
9 50 60 6615052 hemorrhage NN B-NP D006470
10 60 61 6615052 . . O O
11 62 67 6615052 Sixty CD B-NP O
12 67 68 6615052 - HYPH O O
13 68 71 6615052 two CD B-NP O
14 72 80 6615052 patients NNS I-NP O
15 81 85 6615052 with IN B-PP O
16 86 87 6615052 a DT B-NP O
17 88 95 6615052 heparin NN I-NP D006493
18 95 96 6615052 - HYPH B-NP O
19 96 103 6615052 induced VBN I-NP O
20 104 120 6615052 thrombocytopenia NN I-NP D013921
21 121 124 6615052 are VBP B-VP O
22 125 133 6615052 reported VBN I-VP O
23 133 134 6615052 . . O O

1 135 143 6615052 Clinical JJ B-NP O
2 144 158 6615052 manifestations NNS I-NP O
3 159 161 6615052 of IN B-PP O
4 162 166 6615052 this DT B-NP O
5 167 175 6615052 disorder NN I-NP O
6 176 183 6615052 include VBP B-VP O
7 184 194 6615052 hemorrhage NN B-NP D006470
8 195 197 6615052 or CC O O
9 197 198 6615052 , , O O
10 199 203 6615052 more RBR B-ADVP O
11 204 214 6615052 frequently RB I-ADVP O
12 214 215 6615052 , , O O
13 216 230 6615052 thromboembolic JJ B-NP D013923
14 231 237 6615052 events NNS I-NP O
15 238 240 6615052 in IN B-PP O
16 241 249 6615052 patients NNS B-NP O
17 250 259 6615052 receiving VBG B-VP O
18 260 267 6615052 heparin NN B-NP D006493
19 267 268 6615052 . . O O

1 269 279 6615052 Laboratory NN B-NP O
2 280 287 6615052 testing NN I-NP O
3 288 291 6615052 has VBZ B-VP O
4 292 300 6615052 revealed VBN I-VP O
5 301 302 6615052 a DT B-NP D001791
6 303 310 6615052 falling VBG I-NP D001791
7 311 319 6615052 platelet NN I-NP D001791
8 320 325 6615052 count NN I-NP D001791
9 325 326 6615052 , , O O
10 327 336 6615052 increased VBD B-VP O
11 337 347 6615052 resistance NN B-NP O
12 348 350 6615052 to TO B-PP O
13 351 358 6615052 heparin NN B-NP D006493
14 358 359 6615052 , , O O
15 360 363 6615052 and CC O O
16 364 375 6615052 aggregation NN B-NP O
17 376 378 6615052 of IN B-PP O
18 379 388 6615052 platelets NNS B-NP O
19 389 391 6615052 by IN B-PP O
20 392 395 6615052 the DT B-NP O
21 396 405 6615052 patient's NNS I-NP O
22 406 412 6615052 plasma NN I-NP O
23 413 417 6615052 when WRB B-ADVP O
24 418 425 6615052 heparin NN B-NP D006493
25 426 428 6615052 is VBZ B-VP O
26 429 434 6615052 added VBN I-VP O
27 434 435 6615052 . . O O

1 436 447 6615052 Immunologic JJ B-NP O
2 448 455 6615052 testing NN I-NP O
3 456 459 6615052 has VBZ B-VP O
4 460 472 6615052 demonstrated VBN I-VP O
5 473 476 6615052 the DT B-NP O
6 477 485 6615052 presence NN I-NP O
7 486 488 6615052 of IN B-PP O
8 489 490 6615052 a DT B-NP O
9 491 498 6615052 heparin NN I-NP D006493
10 498 499 6615052 - HYPH B-NP O
11 499 508 6615052 dependent JJ I-NP O
12 509 517 6615052 platelet NN I-NP O
13 518 526 6615052 membrane NN I-NP O
14 527 535 6615052 antibody NN I-NP O
15 535 536 6615052 . . O O

1 537 540 6615052 The DT B-NP O
2 541 543 6615052 20 CD I-NP O
3 544 550 6615052 deaths NNS I-NP O
4 550 551 6615052 , , O O
5 552 554 6615052 52 CD B-NP O
6 555 566 6615052 hemorrhagic JJ I-NP D006470
7 567 570 6615052 and CC I-NP D006470
8 571 585 6615052 thromboembolic JJ I-NP D006470
9 586 599 6615052 complications NNS I-NP D006470
10 599 600 6615052 , , O O
11 601 604 6615052 and CC O O
12 605 607 6615052 21 CD B-NP O
13 608 616 6615052 surgical JJ I-NP O
14 617 627 6615052 procedures NNS I-NP O
15 628 630 6615052 to TO B-VP O
16 631 637 6615052 manage VB I-VP O
17 638 641 6615052 the DT B-NP O
18 642 655 6615052 complications NNS I-NP O
19 656 663 6615052 confirm VBP B-VP O
20 664 667 6615052 the DT B-NP O
21 668 679 6615052 seriousness NN I-NP O
22 680 682 6615052 of IN B-PP O
23 683 686 6615052 the DT B-NP O
24 687 695 6615052 disorder NN I-NP O
25 695 696 6615052 . . O O

1 697 705 6615052 Specific JJ B-NP O
2 706 710 6615052 risk NN I-NP O
3 711 718 6615052 factors NNS I-NP O
4 719 723 6615052 have VBP B-VP O
5 724 727 6615052 not RB I-VP O
6 728 732 6615052 been VBN I-VP O
7 733 743 6615052 identified VBN I-VP O
8 743 744 6615052 ; : O O
9 745 754 6615052 therefore RB B-ADVP O
10 754 755 6615052 , , O O
11 756 759 6615052 all DT B-NP O
12 760 768 6615052 patients NNS I-NP O
13 769 778 6615052 receiving VBG B-VP O
14 779 786 6615052 heparin NN B-NP D006493
15 787 793 6615052 should MD B-VP O
16 794 796 6615052 be VB I-VP O
17 797 806 6615052 monitored VBN I-VP O
18 806 807 6615052 . . O O

1 808 810 6615052 If IN B-SBAR O
2 811 814 6615052 the DT B-NP O
3 815 823 6615052 platelet NN I-NP O
4 824 829 6615052 count NN I-NP O
5 830 835 6615052 falls VBZ B-VP O
6 836 838 6615052 to TO B-PP O
7 839 843 6615052 less JJR B-NP O
8 844 848 6615052 than IN I-NP O
9 849 856 6615052 100,000 CD I-NP O
10 856 857 6615052 / SYM I-NP O
11 857 860 6615052 mm3 NN I-NP O
12 860 861 6615052 , , O O
13 862 867 6615052 while IN B-SBAR O
14 868 871 6615052 the DT B-NP O
15 872 879 6615052 patient NN I-NP O
16 880 882 6615052 is VBZ B-VP O
17 883 892 6615052 receiving VBG I-VP O
18 893 900 6615052 heparin NN B-NP D006493
19 900 901 6615052 , , O O
20 902 910 6615052 platelet NN B-NP D001791
21 911 922 6615052 aggregation NN I-NP D001791
22 923 930 6615052 testing NN I-NP O
23 930 931 6615052 , , O O
24 932 937 6615052 using VBG B-VP O
25 938 941 6615052 the DT B-NP O
26 942 951 6615052 patient's NNS I-NP O
27 952 958 6615052 plasma NN I-NP O
28 958 959 6615052 , , O O
29 960 962 6615052 is VBZ B-VP O
30 963 972 6615052 indicated VBN I-VP O
31 972 973 6615052 . . O O

1 974 984 6615052 Management NN B-NP O
2 985 993 6615052 consists VBZ B-VP O
3 994 996 6615052 of IN B-PP O
4 997 1006 6615052 cessation NN B-NP O
5 1007 1009 6615052 of IN B-PP O
6 1010 1017 6615052 heparin NN B-NP D006493
7 1017 1018 6615052 , , O O
8 1019 1027 6615052 platelet NN B-NP O
9 1028 1032 6615052 anti AFX O O
10 1032 1033 6615052 - HYPH O O
11 1033 1044 6615052 aggregating VBG B-NP O
12 1045 1051 6615052 agents NNS I-NP O
13 1051 1052 6615052 , , O O
14 1053 1056 6615052 and CC O O
15 1057 1066 6615052 alternate JJ B-NP O
16 1067 1072 6615052 forms NNS I-NP O
17 1073 1075 6615052 of IN B-PP O
18 1076 1091 6615052 anticoagulation NN B-NP O
19 1092 1096 6615052 when WRB B-ADVP O
20 1097 1106 6615052 indicated VBN B-VP O
21 1106 1107 6615052 . . O O

1 0 0 20466178 -DOCSTART- -X- -X- O

1 0 11 20466178 Rosaceiform NN B-NP O
2 12 22 20466178 dermatitis NN I-NP D003872
3 23 33 20466178 associated VBN B-VP O
4 34 38 20466178 with IN B-PP O
5 39 46 20466178 topical JJ B-NP O
6 47 57 20466178 tacrolimus NN I-NP D016559
7 58 67 20466178 treatment NN I-NP O
8 67 68 20466178 . . O O
9 69 71 20466178 We PRP B-NP O
10 72 80 20466178 describe VBP B-VP O
11 81 87 20466178 herein RB B-NP O
12 88 89 20466178 3 CD I-NP O
13 90 98 20466178 patients NNS I-NP O
14 99 102 20466178 who WP B-NP O
15 103 112 20466178 developed VBD B-VP O
16 113 120 20466178 rosacea NN B-NP D012393
17 120 121 20466178 - HYPH B-NP O
18 121 125 20466178 like JJ I-NP O
19 126 136 20466178 dermatitis NN I-NP D003872
20 137 146 20466178 eruptions NNS I-NP D003875
21 147 152 20466178 while IN B-SBAR O
22 153 158 20466178 using VBG B-VP O
23 159 164 20466178 0.03% CD B-NP O
24 165 167 20466178 or CC I-NP O
25 168 172 20466178 0.1% CD I-NP O
26 173 183 20466178 tacrolimus NN I-NP D016559
27 184 192 20466178 ointment NN I-NP O
28 193 196 20466178 for IN B-PP O
29 197 203 20466178 facial JJ B-NP D005148
30 204 214 20466178 dermatitis NN I-NP D005148
31 214 215 20466178 . . O O

1 216 220 20466178 Skin NN B-NP O
2 221 227 20466178 biopsy NN I-NP O
3 228 237 20466178 specimens NNS I-NP O
4 238 244 20466178 showed VBD B-VP O
5 245 259 20466178 telangiectasia NN B-NP D013684
6 260 263 20466178 and CC O O
7 264 276 20466178 noncaseating JJ B-NP O
8 277 288 20466178 epithelioid JJ I-NP O
9 289 302 20466178 granulomatous JJ I-NP O
10 303 309 20466178 tissue NN I-NP O
11 310 319 20466178 formation NN I-NP O
12 320 322 20466178 in IN B-PP O
13 323 326 20466178 the DT B-NP O
14 327 336 20466178 papillary JJ I-NP O
15 337 339 20466178 to TO B-PP O
16 340 343 20466178 mid JJ B-NP O
17 344 350 20466178 dermis NN I-NP O
18 350 351 20466178 . . O O

1 352 362 20466178 Continuous JJ B-NP O
2 363 370 20466178 topical JJ I-NP O
3 371 374 20466178 use NN I-NP O
4 375 377 20466178 of IN B-PP O
5 378 394 20466178 immunomodulators NNS B-NP O
6 395 399 20466178 such JJ B-PP O
7 400 402 20466178 as IN I-PP O
8 403 413 20466178 tacrolimus NN B-NP D016559
9 414 416 20466178 or CC I-NP O
10 417 429 20466178 pimecrolimus NN I-NP C117268
11 430 436 20466178 should MD B-VP O
12 437 439 20466178 be VB I-VP O
13 440 448 20466178 regarded VBN I-VP O
14 449 451 20466178 as IN B-PP O
15 452 453 20466178 a DT B-NP O
16 454 463 20466178 potential JJ I-NP O
17 464 469 20466178 cause NN I-NP O
18 470 472 20466178 of IN B-PP O
19 473 484 20466178 rosaceiform NN B-NP O
20 485 495 20466178 dermatitis NN I-NP D003872
21 495 496 20466178 , , O O
22 497 505 20466178 although IN B-SBAR O
23 506 510 20466178 many JJ B-NP O
24 511 516 20466178 cases NNS I-NP O
25 517 521 20466178 have VBP B-VP O
26 522 525 20466178 not RB I-VP O
27 526 530 20466178 been VBN I-VP O
28 531 539 20466178 reported VBN I-VP O
29 539 540 20466178 . . O O

1 0 0 19274460 -DOCSTART- -X- -X- O

1 0 4 19274460 DSMM NN B-NP O
2 5 7 19274460 XI NN I-NP O
3 8 13 19274460 study NN I-NP O
4 13 14 19274460 : : O O
5 15 19 19274460 dose NN B-NP O
6 20 30 19274460 definition NN I-NP O
7 31 34 19274460 for IN B-PP O
8 35 46 19274460 intravenous JJ B-NP O
9 47 63 19274460 cyclophosphamide NN I-NP D003520
10 64 66 19274460 in IN B-PP O
11 67 78 19274460 combination NN B-NP O
12 79 83 19274460 with IN B-PP O
13 84 94 19274460 bortezomib NN B-NP C400082
14 94 95 19274460 / SYM I-NP O
15 95 108 19274460 dexamethasone NN I-NP D003907
16 109 112 19274460 for IN B-PP O
17 113 122 19274460 remission NN B-NP O
18 123 132 19274460 induction NN I-NP O
19 133 135 19274460 in IN B-PP O
20 136 144 19274460 patients NNS B-NP O
21 145 149 19274460 with IN B-PP O
22 150 155 19274460 newly RB B-NP O
23 156 165 19274460 diagnosed VBN I-NP O
24 166 173 19274460 myeloma NN I-NP D009101
25 173 174 19274460 . . O O
26 175 176 19274460 A DT B-NP O
27 177 185 19274460 clinical JJ I-NP O
28 186 191 19274460 trial NN I-NP O
29 192 195 19274460 was VBD B-VP O
30 196 205 19274460 initiated VBN I-VP O
31 206 208 19274460 to TO I-VP O
32 209 217 19274460 evaluate VB I-VP O
33 218 221 19274460 the DT B-NP O
34 222 233 19274460 recommended VBN I-NP O
35 234 238 19274460 dose NN I-NP O
36 239 241 19274460 of IN B-PP O
37 242 258 19274460 cyclophosphamide NN B-NP D003520
38 259 261 19274460 in IN B-PP O
39 262 273 19274460 combination NN B-NP O
40 274 278 19274460 with IN B-PP O
41 279 289 19274460 bortezomib NN B-NP C400082
42 290 293 19274460 and CC I-NP O
43 294 307 19274460 dexamethasone NN I-NP D003907
44 308 310 19274460 as IN B-PP O
45 311 320 19274460 induction NN B-NP O
46 321 330 19274460 treatment NN I-NP O
47 331 337 19274460 before IN B-PP O
48 338 342 19274460 stem NN B-NP O
49 343 347 19274460 cell NN I-NP O
50 348 363 19274460 transplantation NN I-NP O
51 364 367 19274460 for IN B-PP O
52 368 375 19274460 younger JJR B-NP O
53 376 384 19274460 patients NNS I-NP O
54 385 389 19274460 with IN B-PP O
55 390 395 19274460 newly RB B-NP O
56 396 405 19274460 diagnosed VBN I-NP O
57 406 414 19274460 multiple JJ I-NP D009101
58 415 422 19274460 myeloma NN I-NP D009101
59 423 424 19274460 ( ( O O
60 424 426 19274460 MM NN B-NP D009101
61 426 427 19274460 ) ) O O
62 427 428 19274460 . . O O

1 429 435 19274460 Thirty CD B-NP O
2 436 444 19274460 patients NNS I-NP O
3 445 449 19274460 were VBD B-VP O
4 450 457 19274460 treated VBN I-VP O
5 458 462 19274460 with IN B-PP O
6 463 468 19274460 three CD B-NP O
7 469 471 19274460 21 CD I-NP O
8 471 472 19274460 - HYPH I-NP O
9 472 475 19274460 day NN I-NP O
10 476 482 19274460 cycles NNS I-NP O
11 483 485 19274460 of IN B-PP O
12 486 496 19274460 bortezomib NN B-NP C400082
13 497 500 19274460 1.3 CD I-NP O
14 501 503 19274460 mg NN I-NP O
15 503 504 19274460 / SYM B-NP O
16 504 508 19274460 m(2) NN I-NP O
17 509 511 19274460 on IN B-PP O
18 512 516 19274460 days NNS B-NP O
19 517 518 19274460 1 CD I-NP O
20 518 519 19274460 , , I-NP O
21 520 521 19274460 4 CD I-NP O
22 521 522 19274460 , , I-NP O
23 523 524 19274460 8 CD I-NP O
24 524 525 19274460 , , O O
25 526 529 19274460 and CC O O
26 530 532 19274460 11 CD B-NP O
27 533 537 19274460 plus CC O O
28 538 551 19274460 dexamethasone NN B-NP D003907
29 552 554 19274460 40 CD I-NP O
30 555 557 19274460 mg NN I-NP O
31 558 560 19274460 on IN B-PP O
32 561 564 19274460 the DT B-NP O
33 565 568 19274460 day NN I-NP O
34 569 571 19274460 of IN B-PP O
35 572 582 19274460 bortezomib NN B-NP C400082
36 583 592 19274460 injection NN I-NP O
37 593 596 19274460 and CC O O
38 597 600 19274460 the DT B-NP O
39 601 604 19274460 day NN I-NP O
40 605 610 19274460 after IN B-SBAR O
41 611 615 19274460 plus CC O O
42 616 632 19274460 cyclophosphamide NN B-NP D003520
43 633 635 19274460 at IN B-PP O
44 636 639 19274460 900 CD B-NP O
45 639 640 19274460 , , I-NP O
46 641 646 19274460 1,200 CD I-NP O
47 646 647 19274460 , , O O
48 648 650 19274460 or CC O O
49 651 656 19274460 1,500 CD B-NP O
50 657 659 19274460 mg NN I-NP O
51 659 660 19274460 / SYM B-NP O
52 660 664 19274460 m(2) NN I-NP O
53 665 667 19274460 on IN B-PP O
54 668 671 19274460 day NN B-NP O
55 672 673 19274460 1 CD I-NP O
56 673 674 19274460 . . O O

1 675 678 19274460 The DT B-NP O
2 679 686 19274460 maximum NN I-NP O
3 687 696 19274460 tolerated VBN I-NP O
4 697 701 19274460 dose NN I-NP O
5 702 704 19274460 of IN B-PP O
6 705 721 19274460 cyclophosphamide NN B-NP D003520
7 722 725 19274460 was VBD B-VP O
8 726 733 19274460 defined VBN I-VP O
9 734 736 19274460 as IN B-PP O
10 737 740 19274460 900 CD B-NP O
11 741 743 19274460 mg NN I-NP O
12 743 744 19274460 / SYM B-NP O
13 744 748 19274460 m(2) NN I-NP O
14 748 749 19274460 . . O O

1 750 752 19274460 At IN B-PP O
2 753 757 19274460 this DT B-NP O
3 758 762 19274460 dose NN I-NP O
4 763 768 19274460 level NN I-NP O
5 768 769 19274460 , , O O
6 770 773 19274460 92% CD B-NP O
7 774 776 19274460 of IN B-PP O
8 777 785 19274460 patients NNS B-NP O
9 786 794 19274460 achieved VBN B-VP O
10 795 797 19274460 at IN B-ADVP O
11 798 803 19274460 least JJS I-ADVP O
12 804 805 19274460 a DT B-NP O
13 806 813 19274460 partial JJ I-NP O
14 814 822 19274460 response NN I-NP O
15 822 823 19274460 . . O O

1 824 827 19274460 The DT B-NP O
2 828 835 19274460 overall JJ I-NP O
3 836 844 19274460 response NN I-NP O
4 845 849 19274460 rate NN I-NP O
5 850 851 19274460 [ ( O O
6 851 859 19274460 complete JJ B-NP O
7 860 868 19274460 response NN I-NP O
8 869 870 19274460 ( ( O O
9 870 872 19274460 CR NN B-NP O
10 872 873 19274460 ) ) O O
11 874 878 19274460 plus CC O O
12 879 886 19274460 partial JJ B-NP O
13 887 895 19274460 response NN I-NP O
14 896 897 19274460 ( ( O O
15 897 899 19274460 PR NN B-NP O
16 899 900 19274460 ) ) O O
17 900 901 19274460 ] ) O O
18 902 908 19274460 across IN B-PP O
19 909 912 19274460 all DT B-NP O
20 913 917 19274460 dose NN I-NP O
21 918 924 19274460 levels NNS I-NP O
22 925 928 19274460 was VBD B-VP O
23 929 932 19274460 77% CD B-NP O
24 932 933 19274460 , , O O
25 934 938 19274460 with IN B-PP O
26 939 940 19274460 a DT B-NP O
27 941 944 19274460 10% CD I-NP O
28 945 947 19274460 CR JJ I-NP O
29 948 952 19274460 rate NN I-NP O
30 952 953 19274460 . . O O

1 954 956 19274460 No DT B-NP O
2 957 964 19274460 patient NN I-NP O
3 965 976 19274460 experienced VBD B-VP O
4 977 988 19274460 progressive JJ B-NP O
5 989 996 19274460 disease NN I-NP O
6 996 997 19274460 . . O O

1 998 1001 19274460 The DT B-NP O
2 1002 1006 19274460 most RBS I-NP O
3 1007 1015 19274460 frequent JJ I-NP O
4 1016 1023 19274460 adverse JJ I-NP O
5 1024 1030 19274460 events NNS I-NP O
6 1031 1035 19274460 were VBD B-VP O
7 1036 1049 19274460 hematological JJ B-NP D006402
8 1050 1053 19274460 and CC I-NP D006402
9 1054 1070 19274460 gastrointestinal JJ I-NP D006402
10 1071 1081 19274460 toxicities NNS I-NP D006402
11 1082 1084 19274460 as RB B-CONJP O
12 1085 1089 19274460 well RB I-CONJP O
13 1090 1092 19274460 as IN I-CONJP O
14 1093 1103 19274460 neuropathy NN B-NP D009422
15 1103 1104 19274460 . . O O

1 1105 1108 19274460 The DT B-NP O
2 1109 1116 19274460 results NNS I-NP O
3 1117 1124 19274460 suggest VBP B-VP O
4 1125 1129 19274460 that IN B-SBAR O
5 1130 1140 19274460 bortezomib NN B-NP C400082
6 1141 1143 19274460 in IN B-PP O
7 1144 1155 19274460 combination NN B-NP O
8 1156 1160 19274460 with IN B-PP O
9 1161 1177 19274460 cyclophosphamide NN B-NP D003520
10 1178 1180 19274460 at IN B-PP O
11 1181 1184 19274460 900 CD B-NP O
12 1185 1187 19274460 mg NN I-NP O
13 1187 1188 19274460 / SYM B-NP O
14 1188 1192 19274460 m(2) NN I-NP O
15 1193 1196 19274460 and CC I-NP O
16 1197 1210 19274460 dexamethasone NN I-NP D003907
17 1211 1213 19274460 is VBZ B-VP O
18 1214 1216 19274460 an DT B-NP O
19 1217 1226 19274460 effective JJ I-NP O
20 1227 1236 19274460 induction NN I-NP O
21 1237 1246 19274460 treatment NN I-NP O
22 1247 1250 19274460 for IN B-PP O
23 1251 1259 19274460 patients NNS B-NP O
24 1260 1264 19274460 with IN B-PP O
25 1265 1270 19274460 newly RB B-NP O
26 1271 1280 19274460 diagnosed VBN I-NP O
27 1281 1283 19274460 MM NN I-NP D009101
28 1284 1288 19274460 that WDT B-NP O
29 1289 1297 19274460 warrants VBZ B-VP O
30 1298 1305 19274460 further JJ B-NP O
31 1306 1319 19274460 investigation NN I-NP O
32 1319 1320 19274460 . . O O

1 0 0 6892185 -DOCSTART- -X- -X- O

1 0 6 6892185 Effect NN B-NP O
2 7 9 6892185 of IN B-PP O
3 10 17 6892185 calcium NN B-NP D002122
4 18 26 6892185 chloride NN I-NP D002122
5 27 29 6892185 on IN B-PP O
6 30 35 6892185 gross JJ B-NP O
7 36 47 6892185 behavioural JJ I-NP O
8 48 55 6892185 changes NNS I-NP O
9 56 64 6892185 produced VBN B-VP O
10 65 67 6892185 by IN B-PP O
11 68 77 6892185 carbachol NN B-NP D002217
12 78 81 6892185 and CC I-NP O
13 82 89 6892185 eserine NN I-NP D010830
14 90 92 6892185 in IN B-PP O
15 93 97 6892185 cats NNS B-NP O
16 97 98 6892185 . . O O
17 99 102 6892185 The DT B-NP O
18 103 109 6892185 effect NN I-NP O
19 110 112 6892185 of IN B-PP O
20 113 120 6892185 calcium NN B-NP D002122
21 121 129 6892185 chloride NN I-NP D002122
22 130 138 6892185 injected VBN B-VP O
23 139 143 6892185 into IN B-PP O
24 144 147 6892185 the DT B-NP O
25 148 156 6892185 cerebral JJ I-NP O
26 157 167 6892185 ventricles NNS I-NP O
27 168 170 6892185 of IN B-PP O
28 171 176 6892185 group NN B-NP O
29 176 177 6892185 - HYPH O O
30 177 183 6892185 housed VBN B-NP O
31 184 199 6892185 unanaesthetized JJ I-NP O
32 200 204 6892185 cats NNS I-NP O
33 205 209 6892185 upon IN B-PP O
34 210 222 6892185 vocalization NN B-NP O
35 223 224 6892185 ( ( O O
36 224 228 6892185 rage NN B-NP O
37 228 229 6892185 , , O O
38 230 237 6892185 hissing NN B-NP O
39 238 241 6892185 and CC O O
40 242 250 6892185 snarling NN B-NP O
41 250 251 6892185 ) ) O O
42 251 252 6892185 , , O O
43 253 261 6892185 fighting NN B-NP O
44 262 263 6892185 ( ( O O
45 263 269 6892185 attack NN B-NP O
46 270 274 6892185 with IN B-PP O
47 275 279 6892185 paws NNS B-NP O
48 280 283 6892185 and CC I-NP O
49 284 289 6892185 claws NNS I-NP O
50 289 290 6892185 , , O O
51 291 298 6892185 defense NN B-NP O
52 299 303 6892185 with IN B-PP O
53 304 308 6892185 paws NNS B-NP O
54 309 312 6892185 and CC I-NP O
55 313 318 6892185 claws NNS I-NP O
56 319 322 6892185 and CC O O
57 323 329 6892185 biting VBG B-VP O
58 329 330 6892185 ) ) O O
59 330 331 6892185 , , O O
60 332 341 6892185 mydriasis NN B-NP D015878
61 341 342 6892185 , , O O
62 343 349 6892185 tremor NN B-NP D014202
63 350 353 6892185 and CC O O
64 354 360 6892185 clonic JJ B-NP D004830
65 360 361 6892185 - HYPH I-NP D004830
66 361 366 6892185 tonic JJ I-NP D004830
67 367 378 6892185 convulsions NNS I-NP D004830
68 379 387 6892185 produced VBN B-VP O
69 388 390 6892185 by IN B-PP O
70 391 400 6892185 carbachol NN B-NP D002217
71 401 404 6892185 and CC I-NP O
72 405 412 6892185 eserine NN I-NP D010830
73 413 421 6892185 injected VBN B-VP O
74 422 431 6892185 similarly RB B-ADVP O
75 432 435 6892185 was VBD B-VP O
76 436 448 6892185 investigated VBN I-VP O
77 448 449 6892185 . . O O

1 450 457 6892185 Calcium NN B-NP D002122
2 458 466 6892185 chloride NN I-NP D002122
3 467 476 6892185 depressed VBD B-VP O
4 477 479 6892185 or CC O O
5 480 486 6892185 almost RB B-ADVP O
6 487 497 6892185 completely RB I-ADVP O
7 498 507 6892185 abolished VBD B-VP O
8 508 511 6892185 the DT B-NP O
9 512 524 6892185 vocalization NN I-NP O
10 525 528 6892185 and CC I-NP O
11 529 537 6892185 fighting NN I-NP O
12 538 541 6892185 due JJ B-ADJP O
13 542 544 6892185 to TO B-PP O
14 545 554 6892185 carbachol NN B-NP D002217
15 555 558 6892185 and CC I-NP O
16 559 566 6892185 eserine NN I-NP D010830
17 566 567 6892185 . . O O

1 568 570 6892185 On IN B-PP O
2 571 574 6892185 the DT B-NP O
3 575 580 6892185 other JJ I-NP O
4 581 585 6892185 hand NN I-NP O
5 585 586 6892185 , , O O
6 587 596 6892185 mydriasis NN B-NP D015878
7 596 597 6892185 , , O O
8 598 604 6892185 tremor NN B-NP D014202
9 605 608 6892185 and CC O O
10 609 615 6892185 clonic JJ B-NP D004830
11 615 616 6892185 - HYPH I-NP D004830
12 616 621 6892185 tonic JJ I-NP D004830
13 622 633 6892185 convulsions NNS I-NP D004830
14 634 640 6892185 evoked VBN B-VP O
15 641 643 6892185 by IN B-PP O
16 644 653 6892185 carbachol NN B-NP D002217
17 654 657 6892185 and CC I-NP O
18 658 665 6892185 eserine NN I-NP D010830
19 666 670 6892185 were VBD B-VP O
20 671 674 6892185 not RB I-VP O
21 675 688 6892185 significantly RB I-VP O
22 689 696 6892185 changed VBN I-VP O
23 697 699 6892185 by IN B-PP O
24 700 707 6892185 calcium NN B-NP D002122
25 708 716 6892185 chloride NN I-NP D002122
26 716 717 6892185 . . O O

1 718 720 6892185 It PRP B-NP O
2 721 723 6892185 is VBZ B-VP O
3 724 732 6892185 apparent JJ B-ADJP O
4 733 737 6892185 that IN B-SBAR O
5 738 745 6892185 calcium NN B-NP D002122
6 746 754 6892185 chloride NN I-NP D002122
7 755 758 6892185 can MD B-VP O
8 759 760 6892185 " `` O O
9 760 770 6892185 dissociate VB B-VP O
10 770 771 6892185 " '' O O
11 772 784 6892185 vocalization NN B-NP O
12 785 788 6892185 and CC I-NP O
13 789 797 6892185 fighting NN I-NP O
14 798 802 6892185 from IN B-PP O
15 803 812 6892185 autonomic JJ B-NP O
16 813 816 6892185 and CC I-NP O
17 817 822 6892185 motor NN I-NP O
18 823 832 6892185 phenomena NNS I-NP O
19 833 837 6892185 such JJ B-PP O
20 838 840 6892185 as IN I-PP O
21 841 850 6892185 mydriasis NN B-NP D015878
22 850 851 6892185 , , O O
23 852 858 6892185 tremor NN B-NP D014202
24 859 862 6892185 and CC O O
25 863 869 6892185 clonic JJ B-NP D004830
26 869 870 6892185 - HYPH I-NP D004830
27 870 875 6892185 tonic JJ I-NP D004830
28 876 887 6892185 convulsions NNS I-NP D004830
29 888 894 6892185 caused VBN B-VP O
30 895 897 6892185 by IN B-PP O
31 898 907 6892185 carbachol NN B-NP D002217
32 908 911 6892185 and CC I-NP O
33 912 919 6892185 eserine NN I-NP D010830
34 919 920 6892185 . . O O

1 921 928 6892185 Calcium NN B-NP D002122
2 929 937 6892185 chloride NN I-NP D002122
3 938 947 6892185 inhibited VBD B-VP O
4 948 951 6892185 the DT B-NP O
5 952 964 6892185 vocalization NN I-NP O
6 965 968 6892185 and CC I-NP O
7 969 977 6892185 fighting NN I-NP O
8 978 986 6892185 produced VBN B-VP O
9 987 989 6892185 by IN B-PP O
10 990 999 6892185 carbachol NN B-NP D002217
11 1000 1003 6892185 and CC I-NP O
12 1004 1011 6892185 eserine NN I-NP D010830
13 1012 1016 6892185 most RBS B-ADVP O
14 1017 1025 6892185 probably RB I-ADVP O
15 1026 1028 6892185 by IN B-PP O
16 1029 1030 6892185 a DT B-NP O
17 1031 1042 6892185 nonspecific JJ I-NP O
18 1043 1054 6892185 stabilizing VBG I-NP O
19 1055 1061 6892185 action NN I-NP O
20 1062 1064 6892185 on IN B-PP O
21 1065 1072 6892185 central JJ B-NP O
22 1073 1083 6892185 muscarinic JJ I-NP O
23 1084 1098 6892185 cholinoceptive JJ I-NP O
24 1099 1104 6892185 sites NNS I-NP O
25 1104 1105 6892185 . . O O

1 1106 1111 6892185 These DT B-NP O
2 1112 1119 6892185 results NNS I-NP O
3 1120 1127 6892185 further RBR B-ADVP O
4 1128 1135 6892185 support VBP B-VP O
5 1136 1139 6892185 the DT B-NP O
6 1140 1144 6892185 view NN I-NP O
7 1145 1149 6892185 that IN B-SBAR O
8 1150 1157 6892185 calcium NN B-NP D002118
9 1158 1162 6892185 ions NNS I-NP O
10 1163 1165 6892185 in IN B-PP O
11 1166 1172 6892185 excess NN B-NP O
12 1173 1177 6892185 have VBP B-VP O
13 1178 1180 6892185 an DT B-NP O
14 1181 1189 6892185 atropine NN I-NP D001285
15 1189 1190 6892185 - HYPH B-NP O
16 1190 1194 6892185 like JJ I-NP O
17 1195 1201 6892185 action NN I-NP O
18 1202 1206 6892185 also RB B-ADVP O
19 1207 1209 6892185 in IN B-PP O
20 1210 1213 6892185 the DT B-NP O
21 1214 1221 6892185 central JJ I-NP O
22 1222 1229 6892185 nervous JJ I-NP O
23 1230 1236 6892185 system NN I-NP O
24 1236 1237 6892185 . . O O

1 0 0 7785794 -DOCSTART- -X- -X- O

1 0 10 7785794 Refractory JJ B-NP O
2 11 22 7785794 cardiogenic JJ I-NP D012770
3 23 28 7785794 shock NN I-NP D012770
4 29 32 7785794 and CC O O
5 33 41 7785794 complete JJ B-NP O
6 42 47 7785794 heart NN I-NP D006327
7 48 53 7785794 block NN I-NP D006327
8 54 59 7785794 after IN B-PP O
9 60 69 7785794 verapamil NN B-NP D014700
10 70 72 7785794 SR NN I-NP O
11 73 76 7785794 and CC O O
12 77 87 7785794 metoprolol NN B-NP D008790
13 88 97 7785794 treatment NN I-NP O
14 97 98 7785794 . . O O

1 99 100 7785794 A DT B-NP O
2 101 105 7785794 case NN I-NP O
3 106 112 7785794 report NN I-NP O
4 112 113 7785794 . . O O
5 114 115 7785794 A DT B-NP O
6 116 123 7785794 seventy JJ I-NP O
7 123 124 7785794 - HYPH I-NP O
8 124 129 7785794 eight CD I-NP O
9 129 130 7785794 - HYPH I-NP O
10 130 134 7785794 year NN I-NP O
11 134 135 7785794 - HYPH O O
12 135 138 7785794 old JJ B-NP O
13 139 144 7785794 woman NN I-NP O
14 145 154 7785794 presented VBD B-VP O
15 155 159 7785794 with IN B-PP O
16 160 168 7785794 complete JJ B-NP O
17 169 174 7785794 heart NN I-NP D006327
18 175 180 7785794 block NN I-NP D006327
19 181 184 7785794 and CC O O
20 185 195 7785794 refractory JJ B-NP O
21 196 207 7785794 hypotension NN I-NP D007022
22 208 211 7785794 two CD B-NP O
23 212 216 7785794 days NNS I-NP O
24 217 222 7785794 after IN B-PP O
25 223 224 7785794 a DT B-NP O
26 225 236 7785794 therapeutic JJ I-NP O
27 237 241 7785794 dose NN I-NP O
28 242 244 7785794 of IN B-PP O
29 245 254 7785794 sustained JJ B-NP O
30 254 255 7785794 - HYPH I-NP O
31 255 262 7785794 release NN I-NP O
32 263 272 7785794 verapamil NN I-NP D014700
33 273 277 7785794 with IN B-PP O
34 278 289 7785794 concomitant JJ B-NP O
35 290 293 7785794 use NN I-NP O
36 294 296 7785794 of IN B-PP O
37 297 307 7785794 metoprolol NN B-NP D008790
38 307 308 7785794 . . O O

1 309 312 7785794 The DT B-NP O
2 313 320 7785794 patient NN I-NP O
3 321 330 7785794 continued VBD B-VP O
4 331 333 7785794 to TO I-VP O
5 334 340 7785794 remain VB I-VP O
6 341 352 7785794 hypotensive JJ B-ADJP D007022
7 353 357 7785794 with IN B-PP O
8 358 366 7785794 complete JJ B-NP O
9 367 372 7785794 heart NN I-NP D006327
10 373 378 7785794 block NN I-NP D006327
11 378 379 7785794 , , O O
12 380 384 7785794 even RB B-ADVP O
13 385 389 7785794 with IN B-PP O
14 390 398 7785794 multiple JJ B-NP O
15 399 403 7785794 uses NNS I-NP O
16 404 406 7785794 of IN B-PP O
17 407 418 7785794 intravenous JJ B-NP O
18 419 427 7785794 atropine NN I-NP D001285
19 428 430 7785794 as RB B-CONJP O
20 431 435 7785794 well RB I-CONJP O
21 436 438 7785794 as IN I-CONJP O
22 439 443 7785794 high JJ B-NP O
23 444 449 7785794 doses NNS I-NP O
24 450 452 7785794 of IN B-PP O
25 453 460 7785794 pressor NN B-NP O
26 461 467 7785794 agents NNS I-NP O
27 468 472 7785794 such JJ B-PP O
28 473 475 7785794 as IN I-PP O
29 476 484 7785794 dopamine NN B-NP D004298
30 485 488 7785794 and CC I-NP O
31 489 499 7785794 dobutamine NN I-NP D004280
32 499 500 7785794 . . O O

1 501 508 7785794 However RB B-ADVP O
2 508 509 7785794 , , O O
3 510 517 7785794 shortly RB B-ADVP O
4 518 523 7785794 after IN B-PP O
5 524 527 7785794 the DT B-NP O
6 528 531 7785794 use NN I-NP O
7 532 534 7785794 of IN B-PP O
8 535 546 7785794 intravenous JJ B-NP O
9 547 554 7785794 calcium NN I-NP D002122
10 555 563 7785794 chloride NN I-NP D002122
11 563 564 7785794 , , O O
12 565 568 7785794 the DT B-NP O
13 569 579 7785794 refractory JJ I-NP O
14 580 591 7785794 hypotension NN I-NP D007022
15 592 595 7785794 and CC O O
16 596 604 7785794 complete JJ B-NP O
17 605 610 7785794 heart NN I-NP D006327
18 611 616 7785794 block NN I-NP D006327
19 617 625 7785794 resolved VBN B-VP O
20 625 626 7785794 . . O O

1 0 0 7803371 -DOCSTART- -X- -X- O

1 0 9 7803371 Cognitive JJ B-NP D003072
2 10 23 7803371 deterioration NN I-NP D003072
3 24 28 7803371 from IN B-PP O
4 29 33 7803371 long JJ B-NP O
5 33 34 7803371 - HYPH I-NP O
6 34 38 7803371 term NN I-NP O
7 39 44 7803371 abuse NN I-NP O
8 45 47 7803371 of IN B-PP O
9 48 64 7803371 dextromethorphan NN B-NP D003915
10 64 65 7803371 : : O O
11 66 67 7803371 a DT B-NP O
12 68 72 7803371 case NN I-NP O
13 73 79 7803371 report NN I-NP O
14 79 80 7803371 . . O O
15 81 97 7803371 Dextromethorphan NN B-NP D003915
16 98 99 7803371 ( ( O O
17 99 101 7803371 DM NN B-NP D003915
18 101 102 7803371 ) ) O O
19 102 103 7803371 , , O O
20 104 107 7803371 the DT B-NP O
21 108 122 7803371 dextrorotatory JJ I-NP O
22 123 129 7803371 isomer NN I-NP O
23 130 132 7803371 of IN B-PP O
24 133 134 7803371 3 CD B-NP D007981
25 134 135 7803371 - HYPH I-NP D007981
26 135 142 7803371 hydroxy NN I-NP D007981
27 142 143 7803371 - HYPH B-NP D007981
28 143 144 7803371 N NN I-NP D007981
29 144 145 7803371 - HYPH I-NP D007981
30 145 160 7803371 methylmorphinan NN I-NP D007981
31 160 161 7803371 , , O O
32 162 164 7803371 is VBZ B-VP O
33 165 168 7803371 the DT B-NP O
34 169 173 7803371 main JJ I-NP O
35 174 184 7803371 ingredient NN I-NP O
36 185 187 7803371 in IN B-PP O
37 188 189 7803371 a DT B-NP O
38 190 196 7803371 number NN I-NP O
39 197 199 7803371 of IN B-PP O
40 200 206 7803371 widely RB B-ADJP O
41 207 216 7803371 available JJ I-ADJP O
42 216 217 7803371 , , O O
43 218 222 7803371 over IN B-PP O
44 222 223 7803371 - HYPH B-NP O
45 223 226 7803371 the DT B-NP O
46 226 227 7803371 - HYPH I-NP O
47 227 234 7803371 counter NN I-NP O
48 235 247 7803371 antitussives NNS I-NP O
49 247 248 7803371 . . O O

1 249 256 7803371 Initial JJ B-NP O
2 257 264 7803371 studies NNS I-NP O
3 265 266 7803371 ( ( O O
4 266 275 7803371 Bornstein NN B-NP O
5 276 280 7803371 1968 CD I-NP O
6 280 281 7803371 ) ) O O
7 282 288 7803371 showed VBD B-VP O
8 289 293 7803371 that IN B-SBAR O
9 294 296 7803371 it PRP B-NP O
10 297 306 7803371 possessed VBD B-VP O
11 307 309 7803371 no DT B-NP O
12 310 321 7803371 respiratory JJ I-NP O
13 322 333 7803371 suppressant JJ I-NP O
14 334 341 7803371 effects NNS I-NP O
15 342 345 7803371 and CC O O
16 346 348 7803371 no DT B-NP O
17 349 358 7803371 addiction NN I-NP O
18 359 368 7803371 liability NN I-NP O
19 368 369 7803371 . . O O

1 370 382 7803371 Subsequently RB B-ADVP O
2 382 383 7803371 , , O O
3 384 391 7803371 however RB B-ADVP O
4 391 392 7803371 , , O O
5 393 400 7803371 several JJ B-NP O
6 401 409 7803371 articles NNS I-NP O
7 410 419 7803371 reporting VBG B-VP O
8 420 425 7803371 abuse NN B-NP O
9 426 428 7803371 of IN B-PP O
10 429 433 7803371 this DT B-NP O
11 434 438 7803371 drug NN I-NP O
12 439 443 7803371 have VBP B-VP O
13 444 452 7803371 appeared VBN I-VP O
14 453 455 7803371 in IN B-PP O
15 456 459 7803371 the DT B-NP O
16 460 470 7803371 literature NN I-NP O
17 470 471 7803371 . . O O

1 472 475 7803371 The DT B-NP O
2 476 480 7803371 drug NN I-NP O
3 481 483 7803371 is VBZ B-VP O
4 484 489 7803371 known VBN I-VP O
5 490 492 7803371 to TO I-VP O
6 493 498 7803371 cause VB I-VP O
7 499 500 7803371 a DT B-NP O
8 501 508 7803371 variety NN I-NP O
9 509 511 7803371 of IN B-PP O
10 512 517 7803371 acute JJ B-NP O
11 518 523 7803371 toxic JJ I-NP O
12 524 531 7803371 effects NNS I-NP O
13 531 532 7803371 , , O O
14 533 540 7803371 ranging VBG B-VP O
15 541 545 7803371 from IN B-PP O
16 546 552 7803371 nausea NN B-NP D009325
17 552 553 7803371 , , O O
18 554 566 7803371 restlessness NN B-NP D011595
19 566 567 7803371 , , O O
20 568 576 7803371 insomnia NN B-NP D007319
21 576 577 7803371 , , O O
22 578 584 7803371 ataxia NN B-NP D001259
23 584 585 7803371 , , O O
24 586 593 7803371 slurred VBD B-VP O
25 594 600 7803371 speech NN B-NP O
26 601 604 7803371 and CC I-NP O
27 605 614 7803371 nystagmus NN I-NP C564088
28 615 617 7803371 to TO B-PP O
29 618 622 7803371 mood NN B-NP O
30 623 630 7803371 changes NNS I-NP O
31 630 631 7803371 , , O O
32 632 642 7803371 perceptual JJ B-NP O
33 643 654 7803371 alterations NNS I-NP O
34 654 655 7803371 , , O O
35 656 667 7803371 inattention NN B-NP O
36 667 668 7803371 , , O O
37 669 683 7803371 disorientation NN B-NP O
38 684 687 7803371 and CC O O
39 688 698 7803371 aggressive JJ B-NP D001523
40 699 707 7803371 behavior NN I-NP D001523
41 708 709 7803371 ( ( O O
42 709 715 7803371 Rammer NNP B-NP O
43 716 718 7803371 et FW I-NP O
44 719 721 7803371 al JJ I-NP O
45 722 726 7803371 1988 CD I-NP O
46 726 727 7803371 ; : O O
47 728 734 7803371 Katona NNP B-NP O
48 735 738 7803371 and CC O O
49 739 745 7803371 Watson NNP B-NP O
50 746 750 7803371 1986 CD I-NP O
51 750 751 7803371 ; : O O
52 752 758 7803371 Isbell NNP B-NP O
53 759 762 7803371 and CC O O
54 763 769 7803371 Fraser NNP B-NP O
55 770 774 7803371 1953 CD I-NP O
56 774 775 7803371 ; : O O
57 776 782 7803371 Devlin NNP B-NP O
58 783 785 7803371 et FW I-NP O
59 786 788 7803371 al FW I-NP O
60 789 793 7803371 1985 CD I-NP O
61 793 794 7803371 ; : O O
62 795 803 7803371 McCarthy NNP B-NP O
63 804 808 7803371 1971 CD I-NP O
64 808 809 7803371 ; : O O
65 810 815 7803371 Dodds NNP B-NP O
66 816 819 7803371 and CC O O
67 820 825 7803371 Revai NNP B-NP O
68 826 830 7803371 1967 CD I-NP O
69 830 831 7803371 ; : O O
70 832 840 7803371 Degkwitz NNP B-NP O
71 841 845 7803371 1964 CD I-NP O
72 845 846 7803371 ; : O O
73 847 857 7803371 Hildebrand NNP B-NP O
74 858 860 7803371 et FW I-NP O
75 861 863 7803371 al FW I-NP O
76 864 868 7803371 1989 CD I-NP O
77 868 869 7803371 ) ) O O
78 869 870 7803371 . . O O

1 871 876 7803371 There EX B-NP O
2 877 881 7803371 have VBP B-VP O
3 882 886 7803371 also RB I-VP O
4 887 891 7803371 been VBN I-VP O
5 892 895 7803371 two CD B-NP O
6 896 904 7803371 reported VBN I-NP O
7 905 915 7803371 fatalities NNS I-NP O
8 916 920 7803371 from IN B-PP O
9 921 923 7803371 DM NN B-NP D003915
10 924 933 7803371 overdoses VBZ B-VP O
11 934 935 7803371 ( ( O O
12 935 942 7803371 Fleming VBG B-VP O
13 943 947 7803371 1986 CD B-NP O
14 947 948 7803371 ) ) O O
15 948 949 7803371 . . O O

1 950 957 7803371 However RB B-ADVP O
2 957 958 7803371 , , O O
3 959 964 7803371 there EX B-NP O
4 965 968 7803371 are VBP B-VP O
5 969 971 7803371 no DT B-NP O
6 972 979 7803371 reports NNS I-NP O
7 980 990 7803371 describing VBG B-VP O
8 991 994 7803371 the DT B-NP O
9 995 1002 7803371 effects NNS I-NP O
10 1003 1005 7803371 of IN B-PP O
11 1006 1013 7803371 chronic JJ B-NP O
12 1014 1019 7803371 abuse NN I-NP O
13 1019 1020 7803371 . . O O

1 1021 1025 7803371 This DT B-NP O
2 1026 1032 7803371 report NN I-NP O
3 1033 1042 7803371 describes VBZ B-VP O
4 1043 1044 7803371 a DT B-NP O
5 1045 1049 7803371 case NN I-NP O
6 1050 1052 7803371 of IN B-PP O
7 1053 1062 7803371 cognitive JJ B-NP D003072
8 1063 1076 7803371 deterioration NN I-NP D003072
9 1077 1086 7803371 resulting VBG B-VP O
10 1087 1091 7803371 from IN B-PP O
11 1092 1101 7803371 prolonged VBN B-NP O
12 1102 1105 7803371 use NN I-NP O
13 1106 1108 7803371 of IN B-PP O
14 1109 1111 7803371 DM NN B-NP D003915
15 1111 1112 7803371 . . O O

1 0 0 8643966 -DOCSTART- -X- -X- O

1 0 12 8643966 Chemotherapy NN B-NP O
2 13 15 8643966 of IN B-PP O
3 16 24 8643966 advanced VBN B-NP O
4 25 35 8643966 inoperable JJ I-NP O
5 36 39 8643966 non AFX I-NP D002289
6 39 40 8643966 - HYPH I-NP D002289
7 40 45 8643966 small JJ B-NP D002289
8 46 50 8643966 cell NN I-NP D002289
9 51 55 8643966 lung NN I-NP D002289
10 56 62 8643966 cancer NN I-NP D002289
11 63 67 8643966 with IN B-PP O
12 68 78 8643966 paclitaxel NN B-NP D017239
13 78 79 8643966 : : O O
14 80 81 8643966 a DT B-NP O
15 82 87 8643966 phase NN I-NP O
16 88 90 8643966 II CD I-NP O
17 91 96 8643966 trial NN I-NP O
18 96 97 8643966 . . O O
19 98 108 8643966 Paclitaxel NN B-NP D017239
20 109 110 8643966 ( ( O O
21 110 115 8643966 Taxol NN B-NP D017239
22 115 116 8643966 ; : O O
23 117 124 8643966 Bristol NNP B-NP O
24 124 125 8643966 - : O O
25 125 130 8643966 Myers NNP B-NP O
26 131 137 8643966 Squibb NNP I-NP O
27 138 145 8643966 Company NNP I-NP O
28 145 146 8643966 , , O O
29 147 156 8643966 Princeton NNP B-NP O
30 156 157 8643966 , , O O
31 158 160 8643966 NJ NNP B-NP O
32 160 161 8643966 ) ) O O
33 162 165 8643966 has VBZ B-VP O
34 166 178 8643966 demonstrated VBN I-VP O
35 179 190 8643966 significant JJ B-NP O
36 191 205 8643966 antineoplastic JJ I-NP O
37 206 214 8643966 activity NN I-NP O
38 215 222 8643966 against IN B-PP O
39 223 232 8643966 different JJ B-NP O
40 233 238 8643966 tumor NN I-NP D009369
41 239 244 8643966 types NNS I-NP O
42 244 245 8643966 , , O O
43 246 253 8643966 notably RB B-NP O
44 254 261 8643966 ovarian JJ I-NP D010051
45 262 265 8643966 and CC I-NP D010051
46 266 272 8643966 breast NN I-NP D010051
47 273 282 8643966 carcinoma NN I-NP D010051
48 282 283 8643966 . . O O

1 284 287 8643966 Two CD B-NP O
2 288 293 8643966 phase NN I-NP O
3 294 296 8643966 II CD B-NP O
4 297 303 8643966 trials NNS I-NP O
5 304 306 8643966 of IN B-PP O
6 307 309 8643966 24 CD B-NP O
7 309 310 8643966 - HYPH I-NP O
8 310 314 8643966 hour NN I-NP O
9 315 325 8643966 paclitaxel NN I-NP D017239
10 326 335 8643966 infusions NNS I-NP O
11 336 338 8643966 in IN B-PP O
12 339 351 8643966 chemotherapy NN B-NP O
13 351 352 8643966 - HYPH O O
14 352 357 8643966 naive JJ B-NP O
15 358 366 8643966 patients NNS I-NP O
16 367 371 8643966 with IN B-PP O
17 372 377 8643966 stage NN B-NP O
18 378 382 8643966 IIIB CD I-NP O
19 383 385 8643966 or CC I-NP O
20 386 388 8643966 IV CD I-NP O
21 389 392 8643966 non AFX O D002289
22 392 393 8643966 - HYPH O D002289
23 393 398 8643966 small JJ B-NP D002289
24 399 403 8643966 cell NN I-NP D002289
25 404 408 8643966 lung NN I-NP D002289
26 409 415 8643966 cancer NN I-NP D002289
27 416 417 8643966 ( ( O O
28 417 422 8643966 NSCLC NN B-NP D002289
29 422 423 8643966 ) ) O O
30 424 432 8643966 reported VBD B-VP O
31 433 441 8643966 response NN B-NP O
32 442 447 8643966 rates NNS I-NP O
33 448 450 8643966 of IN B-PP O
34 451 454 8643966 21% NN B-NP O
35 455 458 8643966 and CC I-NP O
36 459 462 8643966 24% NN I-NP O
37 462 463 8643966 . . O O

1 464 474 8643966 Leukopenia NNP B-NP D007970
2 475 478 8643966 was VBD B-VP O
3 479 483 8643966 dose NN B-NP O
4 484 492 8643966 limiting NN I-NP O
5 492 493 8643966 : : O O
6 494 496 8643966 as RB B-NP O
7 497 501 8643966 many JJ I-NP O
8 502 504 8643966 as IN I-NP O
9 505 510 8643966 62.5% CD I-NP O
10 511 513 8643966 of IN B-PP O
11 514 522 8643966 patients NNS B-NP O
12 523 534 8643966 experienced VBD B-VP O
13 535 540 8643966 grade NN B-NP O
14 541 542 8643966 4 CD I-NP O
15 543 553 8643966 leukopenia NN I-NP D007970
16 553 554 8643966 . . O O

1 555 557 8643966 We PRP B-NP O
2 558 570 8643966 investigated VBD B-VP O
3 571 574 8643966 the DT B-NP O
4 575 583 8643966 efficacy NN I-NP O
5 584 587 8643966 and CC I-NP O
6 588 596 8643966 toxicity NN I-NP D064420
7 597 599 8643966 of IN B-PP O
8 600 601 8643966 a DT B-NP O
9 602 603 8643966 3 CD I-NP O
10 603 604 8643966 - HYPH I-NP O
11 604 608 8643966 hour NN I-NP O
12 609 619 8643966 paclitaxel NN I-NP D017239
13 620 628 8643966 infusion NN I-NP O
14 629 631 8643966 in IN B-PP O
15 632 633 8643966 a DT B-NP O
16 634 639 8643966 phase NN I-NP O
17 640 642 8643966 II CD I-NP O
18 643 648 8643966 trial NN I-NP O
19 649 651 8643966 in IN B-PP O
20 652 660 8643966 patients NNS B-NP O
21 661 665 8643966 with IN B-PP O
22 666 676 8643966 inoperable JJ B-NP O
23 677 682 8643966 stage NN I-NP O
24 683 687 8643966 IIIB NN I-NP O
25 688 690 8643966 or CC O O
26 691 693 8643966 IV CD B-NP O
27 694 699 8643966 NSCLC NN I-NP D002289
28 699 700 8643966 . . O O

1 701 704 8643966 The DT B-NP O
2 705 707 8643966 58 CD I-NP O
3 708 716 8643966 patients NNS I-NP O
4 717 724 8643966 treated VBN B-VP O
5 725 726 8643966 ( ( O O
6 726 728 8643966 41 CD B-NP O
7 729 732 8643966 men NNS I-NP O
8 733 736 8643966 and CC O O
9 737 739 8643966 17 CD B-NP O
10 740 745 8643966 women NNS I-NP O
11 745 746 8643966 ) ) O O
12 747 750 8643966 had VBD B-VP O
13 751 752 8643966 a DT B-NP O
14 753 759 8643966 median JJ I-NP O
15 760 763 8643966 age NN I-NP O
16 764 766 8643966 of IN B-PP O
17 767 769 8643966 59 CD B-NP O
18 770 775 8643966 years NNS I-NP O
19 776 777 8643966 ( ( O O
20 777 780 8643966 age NN B-NP O
21 781 786 8643966 range NN I-NP O
22 786 787 8643966 , , O O
23 788 790 8643966 25 CD B-NP O
24 791 793 8643966 to TO B-PP O
25 794 796 8643966 75 CD B-NP O
26 796 797 8643966 ) ) O O
27 798 801 8643966 and CC O O
28 802 803 8643966 a DT B-NP O
29 804 815 8643966 performance NN I-NP O
30 816 822 8643966 status NN I-NP O
31 823 825 8643966 of IN B-PP O
32 826 827 8643966 0 CD B-NP O
33 828 835 8643966 through IN B-PP O
34 836 837 8643966 2 CD B-NP O
35 837 838 8643966 . . O O

1 839 843 8643966 Most JJS B-NP O
2 844 852 8643966 patients NNS I-NP O
3 853 854 8643966 ( ( O O
4 854 859 8643966 72.4% NN B-NP O
5 859 860 8643966 ) ) O O
6 861 864 8643966 had VBD B-VP O
7 865 870 8643966 stage NN B-NP O
8 871 873 8643966 IV CD I-NP O
9 874 879 8643966 NSCLC NN I-NP D002289
10 879 880 8643966 . . O O

1 881 891 8643966 Paclitaxel NN B-NP D017239
2 892 895 8643966 225 CD I-NP O
3 896 898 8643966 mg NN I-NP O
4 898 899 8643966 / SYM B-NP O
5 899 901 8643966 m2 NN I-NP O
6 902 905 8643966 was VBD B-VP O
7 906 913 8643966 infused VBN I-VP O
8 914 918 8643966 over IN B-PP O
9 919 920 8643966 3 CD B-NP O
10 921 926 8643966 hours NNS I-NP O
11 927 932 8643966 every DT B-NP O
12 933 934 8643966 3 CD I-NP O
13 935 940 8643966 weeks NNS I-NP O
14 941 945 8643966 with IN B-PP O
15 946 954 8643966 standard JJ B-NP O
16 955 967 8643966 prophylactic JJ I-NP O
17 968 981 8643966 premedication NN I-NP O
18 981 982 8643966 . . O O

1 983 985 8643966 Of IN B-PP O
2 986 988 8643966 50 CD B-NP O
3 989 997 8643966 patients NNS I-NP O
4 998 1007 8643966 evaluable JJ B-ADJP O
5 1008 1011 8643966 for IN B-PP O
6 1012 1020 8643966 response NN B-NP O
7 1020 1021 8643966 , , O O
8 1022 1024 8643966 12 CD B-NP O
9 1025 1026 8643966 ( ( O O
10 1026 1029 8643966 24% NN B-NP O
11 1029 1030 8643966 ) ) O O
12 1031 1034 8643966 had VBD B-VP O
13 1035 1042 8643966 partial JJ B-NP O
14 1043 1052 8643966 remission NN I-NP O
15 1052 1053 8643966 , , O O
16 1054 1056 8643966 26 CD B-NP O
17 1057 1058 8643966 ( ( O O
18 1058 1061 8643966 52% NN B-NP O
19 1061 1062 8643966 ) ) O O
20 1063 1066 8643966 had VBD B-VP O
21 1067 1069 8643966 no DT B-NP O
22 1070 1076 8643966 change NN I-NP O
23 1076 1077 8643966 , , O O
24 1078 1081 8643966 and CC O O
25 1082 1084 8643966 12 CD B-NP O
26 1085 1088 8643966 had VBD B-VP O
27 1089 1096 8643966 disease NN B-NP O
28 1097 1108 8643966 progression NN I-NP O
29 1109 1110 8643966 ( ( O O
30 1110 1113 8643966 24% NN B-NP O
31 1113 1114 8643966 ) ) O O
32 1114 1115 8643966 . . O O

1 1116 1127 8643966 Hematologic JJ B-NP O
2 1128 1138 8643966 toxicities NNS I-NP D064420
3 1139 1143 8643966 were VBD B-VP O
4 1144 1148 8643966 mild JJ B-ADJP O
5 1148 1149 8643966 : : O O
6 1150 1154 8643966 only RB B-NP O
7 1155 1158 8643966 one CD I-NP O
8 1159 1166 8643966 patient NN I-NP O
9 1167 1168 8643966 ( ( O O
10 1168 1170 8643966 2% NN B-NP O
11 1170 1171 8643966 ) ) O O
12 1172 1181 8643966 developed VBD B-VP O
13 1182 1187 8643966 grade NN B-NP O
14 1188 1189 8643966 3 CD I-NP O
15 1190 1192 8643966 or CC I-NP O
16 1193 1194 8643966 4 CD I-NP O
17 1195 1206 8643966 neutropenia NN I-NP D009503
18 1206 1207 8643966 , , O O
19 1208 1213 8643966 while IN B-SBAR O
20 1214 1217 8643966 29% CD B-NP O
21 1218 1221 8643966 had VBD B-VP O
22 1222 1227 8643966 grade NN B-NP O
23 1228 1229 8643966 1 CD I-NP O
24 1230 1232 8643966 or CC I-NP O
25 1233 1234 8643966 2 CD I-NP O
26 1234 1235 8643966 . . O O

1 1236 1241 8643966 Grade NN B-NP O
2 1242 1243 8643966 1 CD I-NP O
3 1244 1246 8643966 or CC I-NP O
4 1247 1248 8643966 2 CD I-NP O
5 1249 1263 8643966 polyneuropathy NN I-NP D011115
6 1264 1272 8643966 affected VBD B-VP O
7 1273 1276 8643966 56% CD B-NP O
8 1277 1279 8643966 of IN B-PP O
9 1280 1288 8643966 patients NNS B-NP O
10 1289 1294 8643966 while IN B-SBAR O
11 1295 1299 8643966 only RB B-NP O
12 1300 1303 8643966 one CD I-NP O
13 1304 1305 8643966 ( ( O O
14 1305 1307 8643966 2% NN B-NP O
15 1307 1308 8643966 ) ) O O
16 1309 1320 8643966 experienced VBD B-VP O
17 1321 1327 8643966 severe JJ B-NP O
18 1328 1342 8643966 polyneuropathy NN I-NP D011115
19 1342 1343 8643966 . . O O

1 1344 1353 8643966 Similarly RB B-ADVP O
2 1353 1354 8643966 , , O O
3 1355 1360 8643966 grade NN B-NP O
4 1361 1362 8643966 1 CD I-NP O
5 1363 1365 8643966 or CC I-NP O
6 1366 1367 8643966 2 CD I-NP O
7 1368 1375 8643966 myalgia NN I-NP D063806
8 1375 1376 8643966 / SYM B-NP O
9 1376 1386 8643966 arthralgia NN I-NP D018771
10 1387 1390 8643966 was VBD B-VP O
11 1391 1399 8643966 observed VBN I-VP O
12 1400 1402 8643966 in IN B-PP O
13 1403 1408 8643966 63.2% CD B-NP O
14 1409 1411 8643966 of IN B-PP O
15 1412 1420 8643966 patients NNS B-NP O
16 1420 1421 8643966 , , O O
17 1422 1425 8643966 but CC O O
18 1426 1430 8643966 only RB B-NP O
19 1431 1436 8643966 14.3% CD I-NP O
20 1437 1448 8643966 experienced JJ I-NP O
21 1449 1454 8643966 grade NN I-NP O
22 1455 1456 8643966 3 CD B-NP O
23 1457 1459 8643966 or CC I-NP O
24 1460 1461 8643966 4 CD I-NP O
25 1461 1462 8643966 . . O O

1 1463 1469 8643966 Nausea NN B-NP D009325
2 1470 1473 8643966 and CC I-NP O
3 1474 1482 8643966 vomiting NN I-NP D014839
4 1483 1487 8643966 were VBD B-VP O
5 1488 1498 8643966 infrequent JJ B-ADJP O
6 1498 1499 8643966 , , O O
7 1500 1504 8643966 with IN B-PP O
8 1505 1508 8643966 14% NN B-NP O
9 1509 1511 8643966 of IN B-PP O
10 1512 1520 8643966 patients NNS B-NP O
11 1521 1533 8643966 experiencing VBG B-VP O
12 1534 1539 8643966 grade NN B-NP O
13 1540 1541 8643966 1 CD I-NP O
14 1542 1544 8643966 or CC I-NP O
15 1545 1546 8643966 2 CD I-NP O
16 1547 1550 8643966 and CC O O
17 1551 1555 8643966 only RB B-NP O
18 1556 1558 8643966 2% JJ I-NP O
19 1559 1571 8643966 experiencing VBG I-NP O
20 1572 1577 8643966 grade NN I-NP O
21 1578 1579 8643966 3 CD I-NP O
22 1580 1582 8643966 or CC I-NP O
23 1583 1584 8643966 4 CD I-NP O
24 1584 1585 8643966 . . O O

1 1586 1596 8643966 Paclitaxel NN B-NP D017239
2 1597 1599 8643966 is VBZ B-VP O
3 1600 1604 8643966 thus RB B-ADVP O
4 1605 1607 8643966 an DT B-NP O
5 1608 1614 8643966 active JJ I-NP O
6 1615 1621 8643966 single JJ I-NP O
7 1622 1627 8643966 agent NN I-NP O
8 1628 1630 8643966 in IN B-PP O
9 1631 1635 8643966 this DT B-NP O
10 1636 1643 8643966 patient NN I-NP O
11 1644 1654 8643966 population NN I-NP O
12 1654 1655 8643966 , , O O
13 1656 1660 8643966 with IN B-PP O
14 1661 1662 8643966 a DT B-NP O
15 1663 1664 8643966 3 CD I-NP O
16 1664 1665 8643966 - HYPH I-NP O
17 1665 1669 8643966 hour NN I-NP O
18 1670 1678 8643966 infusion NN I-NP O
19 1679 1686 8643966 proving VBG B-VP O
20 1687 1697 8643966 comparably RB B-ADJP O
21 1698 1707 8643966 effective JJ I-ADJP O
22 1708 1710 8643966 to TO B-PP O
23 1711 1712 8643966 a DT B-NP O
24 1713 1715 8643966 24 CD I-NP O
25 1715 1716 8643966 - HYPH I-NP O
26 1716 1720 8643966 hour NN I-NP O
27 1721 1729 8643966 infusion NN I-NP O
28 1730 1733 8643966 and CC I-NP O
29 1734 1742 8643966 superior NN I-NP O
30 1743 1745 8643966 in IN B-PP O
31 1746 1751 8643966 terms NNS B-NP O
32 1752 1754 8643966 of IN B-PP O
33 1755 1758 8643966 the DT B-NP O
34 1759 1768 8643966 incidence NN I-NP O
35 1769 1771 8643966 of IN B-PP O
36 1772 1783 8643966 hematologic JJ B-NP O
37 1784 1787 8643966 and CC I-NP O
38 1788 1802 8643966 nonhematologic JJ I-NP O
39 1803 1811 8643966 toxicity NN I-NP D064420
40 1811 1812 8643966 . . O O

1 1813 1820 8643966 Further JJ B-NP O
2 1821 1826 8643966 phase NN I-NP O
3 1827 1829 8643966 II CD B-NP O
4 1830 1837 8643966 studies NNS I-NP O
5 1838 1842 8643966 with IN B-PP O
6 1843 1853 8643966 paclitaxel NN B-NP D017239
7 1854 1862 8643966 combined VBN B-VP O
8 1863 1867 8643966 with IN B-PP O
9 1868 1873 8643966 other JJ B-NP O
10 1874 1879 8643966 drugs NNS I-NP O
11 1880 1886 8643966 active JJ B-ADJP O
12 1887 1894 8643966 against IN B-PP O
13 1895 1900 8643966 NSCLC NN B-NP D002289
14 1901 1904 8643966 are VBP B-VP O
15 1905 1914 8643966 indicated VBN I-VP O
16 1914 1915 8643966 , , O O
17 1916 1919 8643966 and CC O O
18 1920 1925 8643966 phase NN B-NP O
19 1926 1929 8643966 III CD B-NP O
20 1930 1937 8643966 studies NNS I-NP O
21 1938 1947 8643966 comparing VBG B-VP O
22 1948 1958 8643966 paclitaxel NN B-NP D017239
23 1959 1963 8643966 with IN B-PP O
24 1964 1972 8643966 standard JJ B-NP O
25 1973 1985 8643966 chemotherapy NN I-NP O
26 1986 1992 8643966 remain VBP B-VP O
27 1993 1995 8643966 to TO I-VP O
28 1996 1998 8643966 be VB I-VP O
29 1999 2008 8643966 completed VBN I-VP O
30 2008 2009 8643966 . . O O

1 0 0 7542793 -DOCSTART- -X- -X- O

1 0 14 7542793 Nephrotoxicity NN B-NP D007674
2 15 17 7542793 of IN B-PP O
3 18 29 7542793 cyclosporin NN B-NP D016572
4 30 31 7542793 A NN I-NP D016572
5 32 35 7542793 and CC I-NP O
6 36 41 7542793 FK506 NN I-NP D016559
7 41 42 7542793 : : O O
8 43 53 7542793 inhibition NN B-NP O
9 54 56 7542793 of IN B-PP O
10 57 68 7542793 calcineurin NN B-NP O
11 69 80 7542793 phosphatase NN I-NP O
12 80 81 7542793 . . O O
13 82 93 7542793 Cyclosporin NN B-NP D016572
14 94 95 7542793 A NN I-NP D016572
15 96 97 7542793 ( ( O O
16 97 100 7542793 CsA NN B-NP D016572
17 100 101 7542793 ; : O O
18 102 104 7542793 50 CD B-NP O
19 105 107 7542793 mg NN I-NP O
20 107 108 7542793 / SYM B-NP O
21 108 110 7542793 kg NN I-NP O
22 110 111 7542793 ) ) O O
23 112 115 7542793 and CC O O
24 116 126 7542793 Fujimycine NN B-NP D016559
25 127 128 7542793 ( ( O O
26 128 133 7542793 FK506 NN B-NP D016559
27 133 134 7542793 ; : O O
28 135 136 7542793 5 CD B-NP O
29 137 139 7542793 mg NN I-NP O
30 139 140 7542793 / SYM B-NP O
31 140 142 7542793 kg NN I-NP O
32 142 143 7542793 ) ) O O
33 143 144 7542793 , , O O
34 145 148 7542793 but CC B-CONJP O
35 149 152 7542793 not RB I-CONJP O
36 153 156 7542793 the DT B-NP O
37 157 164 7542793 related VBN I-NP O
38 165 174 7542793 macrolide NN I-NP D018942
39 175 192 7542793 immunosuppressant NN I-NP O
40 193 202 7542793 rapamycin NN I-NP D020123
41 203 204 7542793 ( ( O O
42 204 205 7542793 5 CD B-NP O
43 206 208 7542793 mg NN I-NP O
44 208 209 7542793 / SYM B-NP O
45 209 211 7542793 kg NN I-NP O
46 211 212 7542793 ) ) O O
47 212 213 7542793 , , O O
48 214 220 7542793 caused VBD B-VP O
49 221 222 7542793 a DT B-NP O
50 223 232 7542793 reduction NN I-NP O
51 233 235 7542793 of IN B-PP O
52 236 246 7542793 glomerular JJ B-NP O
53 247 257 7542793 filtration NN I-NP O
54 258 262 7542793 rate NN I-NP O
55 262 263 7542793 , , O O
56 264 276 7542793 degenerative JJ B-NP O
57 277 284 7542793 changes NNS I-NP O
58 285 287 7542793 of IN B-PP O
59 288 296 7542793 proximal JJ B-NP O
60 297 304 7542793 tubular JJ I-NP O
61 305 315 7542793 epithelium NN I-NP O
62 315 316 7542793 , , O O
63 317 320 7542793 and CC O O
64 321 332 7542793 hypertrophy NN B-NP D006984
65 333 335 7542793 of IN B-PP O
66 336 339 7542793 the DT B-NP O
67 340 355 7542793 juxtaglomerular JJ I-NP O
68 356 365 7542793 apparatus NN I-NP O
69 366 368 7542793 in IN B-PP O
70 369 373 7542793 male JJ B-NP O
71 374 380 7542793 Wistar NNP I-NP O
72 381 385 7542793 rats NNS I-NP O
73 386 390 7542793 when WRB B-ADVP O
74 391 396 7542793 given VBN B-VP O
75 397 400 7542793 for IN B-PP O
76 401 403 7542793 10 CD B-NP O
77 404 408 7542793 days NNS I-NP O
78 408 409 7542793 . . O O

1 410 413 7542793 The DT B-NP O
2 414 423 7542793 molecular JJ I-NP O
3 424 434 7542793 mechanisms NNS I-NP O
4 435 437 7542793 of IN B-PP O
5 438 441 7542793 CsA NN B-NP D016572
6 442 445 7542793 and CC I-NP O
7 446 451 7542793 FK506 NN I-NP D016559
8 452 460 7542793 toxicity NN I-NP D064420
9 461 465 7542793 were VBD B-VP O
10 466 478 7542793 investigated VBN I-VP O
11 478 479 7542793 . . O O

1 480 491 7542793 Cyclophilin NN B-NP O
2 492 493 7542793 A NN I-NP O
3 494 497 7542793 and CC I-NP O
4 498 503 7542793 FK506 NN I-NP D016559
5 503 504 7542793 - HYPH O O
6 504 511 7542793 binding VBG B-NP O
7 512 519 7542793 protein NN I-NP O
8 519 520 7542793 , , O O
9 521 524 7542793 the DT B-NP O
10 525 529 7542793 main JJ I-NP O
11 530 546 7542793 intracytoplasmic JJ I-NP O
12 547 556 7542793 receptors NNS I-NP O
13 557 560 7542793 for IN B-PP O
14 561 564 7542793 CsA NN B-NP D016572
15 565 568 7542793 and CC I-NP O
16 569 574 7542793 FK506 NN I-NP D016559
17 574 575 7542793 , , O O
18 576 588 7542793 respectively RB B-ADVP O
19 588 589 7542793 , , O O
20 590 594 7542793 were VBD B-VP O
21 595 599 7542793 each DT B-NP O
22 600 608 7542793 detected VBN B-VP O
23 609 611 7542793 in IN B-PP O
24 612 617 7542793 renal JJ B-NP O
25 618 624 7542793 tissue NN I-NP O
26 625 632 7542793 extract NN I-NP O
27 632 633 7542793 . . O O

1 634 636 7542793 In IN B-PP O
2 637 640 7542793 the DT B-NP O
3 641 647 7542793 kidney NN I-NP O
4 647 648 7542793 , , O O
5 649 653 7542793 high JJ B-NP O
6 654 660 7542793 levels NNS I-NP O
7 661 663 7542793 of IN B-PP O
8 664 678 7542793 immunoreactive JJ B-NP O
9 679 682 7542793 and CC I-NP O
10 683 696 7542793 enzymatically RB I-NP O
11 697 703 7542793 active JJ I-NP O
12 704 715 7542793 calcineurin NN I-NP O
13 716 720 7542793 were VBD B-VP O
14 721 726 7542793 found VBN I-VP O
15 727 732 7542793 which WDT B-NP O
16 733 737 7542793 were VBD B-VP O
17 738 747 7542793 inhibited VBN I-VP O
18 748 750 7542793 by IN B-PP O
19 751 754 7542793 the DT B-NP O
20 755 773 7542793 immunosuppressants NNS I-NP O
21 774 777 7542793 CsA NN I-NP D016572
22 778 781 7542793 and CC I-NP O
23 782 787 7542793 FK506 NN I-NP D016559
24 787 788 7542793 , , B-PP O
25 789 792 7542793 but CC I-PP O
26 793 796 7542793 not RB B-PP O
27 797 799 7542793 by IN I-PP O
28 800 809 7542793 rapamycin NN B-NP D020123
29 809 810 7542793 . . O O

1 811 818 7542793 Finally RB B-ADVP O
2 818 819 7542793 , , O O
3 820 828 7542793 specific JJ B-NP O
4 829 841 7542793 immunophilin NN I-NP O
5 841 842 7542793 - HYPH B-NP O
6 842 846 7542793 drug NN I-NP O
7 846 847 7542793 - HYPH B-NP O
8 847 858 7542793 calcineurin NN I-NP O
9 859 868 7542793 complexes NNS I-NP O
10 869 875 7542793 formed VBD B-VP O
11 876 880 7542793 only RB B-ADVP O
12 881 883 7542793 in IN B-PP O
13 884 887 7542793 the DT I-PP O
14 888 896 7542793 presence NN I-PP O
15 897 899 7542793 of IN I-PP O
16 900 903 7542793 CsA NN B-NP D016572
17 904 907 7542793 and CC I-NP O
18 908 913 7542793 FK506 NN I-NP D016559
19 913 914 7542793 , , O O
20 915 918 7542793 but CC O O
21 919 922 7542793 not RB O O
22 923 932 7542793 rapamycin NN B-NP D020123
23 932 933 7542793 . . O O

1 934 939 7542793 These DT B-NP O
2 940 947 7542793 results NNS I-NP O
3 948 955 7542793 suggest VBP B-VP O
4 956 960 7542793 that IN B-SBAR O
5 961 964 7542793 the DT B-NP O
6 965 976 7542793 nephrotoxic JJ I-NP D007674
7 977 984 7542793 effects NNS I-NP O
8 985 987 7542793 of IN B-PP O
9 988 991 7542793 CsA NN B-NP D016572
10 992 995 7542793 and CC I-NP O
11 996 1001 7542793 FK506 NN I-NP D016559
12 1002 1004 7542793 is VBZ B-VP O
13 1005 1011 7542793 likely RB I-VP O
14 1012 1020 7542793 mediated VBN I-VP O
15 1021 1028 7542793 through IN B-PP O
16 1029 1036 7542793 binding NN B-NP O
17 1037 1039 7542793 to TO B-PP O
18 1040 1045 7542793 renal JJ B-NP O
19 1046 1058 7542793 immunophilin NN I-NP O
20 1059 1062 7542793 and CC O O
21 1063 1073 7542793 inhibiting VBG B-VP O
22 1074 1085 7542793 calcineurin NN B-NP O
23 1086 1097 7542793 phosphatase NN I-NP O
24 1097 1098 7542793 . . O O

1 0 0 11704023 -DOCSTART- -X- -X- O

1 0 10 11704023 Comparison NN B-NP O
2 11 13 11704023 of IN B-PP O
3 14 21 11704023 aqueous JJ B-NP O
4 22 25 11704023 and CC I-NP O
5 26 32 11704023 gellan JJ I-NP O
6 33 43 11704023 ophthalmic JJ I-NP O
7 44 51 11704023 timolol NN I-NP D013999
8 52 56 11704023 with IN B-PP O
9 57 64 11704023 placebo NN B-NP O
10 65 67 11704023 on IN B-PP O
11 68 71 11704023 the DT B-NP O
12 72 74 11704023 24 CD I-NP O
13 74 75 11704023 - HYPH I-NP O
14 75 79 11704023 hour NN I-NP O
15 80 85 11704023 heart NN I-NP O
16 86 90 11704023 rate NN I-NP O
17 91 99 11704023 response NN I-NP O
18 100 102 11704023 in IN B-PP O
19 103 111 11704023 patients NNS B-NP O
20 112 114 11704023 on IN B-PP O
21 115 124 11704023 treatment NN B-NP O
22 125 128 11704023 for IN B-PP O
23 129 137 11704023 glaucoma NN B-NP D005901
24 137 138 11704023 . . O O
25 139 146 11704023 PURPOSE NN B-NP O
26 146 147 11704023 : : O O
27 148 155 11704023 Topical JJ B-NP O
28 156 160 11704023 beta SYM I-NP O
29 160 161 11704023 - HYPH I-NP O
30 161 168 11704023 blocker NN I-NP O
31 169 178 11704023 treatment NN I-NP O
32 179 181 11704023 is VBZ B-VP O
33 182 189 11704023 routine JJ B-NP O
34 190 197 11704023 therapy NN I-NP O
35 198 200 11704023 in IN B-PP O
36 201 204 11704023 the DT B-NP O
37 205 215 11704023 management NN I-NP O
38 216 218 11704023 of IN B-PP O
39 219 227 11704023 patients NNS B-NP O
40 228 232 11704023 with IN B-PP O
41 233 241 11704023 glaucoma NN B-NP D005901
42 241 242 11704023 . . O O

1 243 250 11704023 Therapy NN B-NP O
2 251 258 11704023 results VBZ B-VP O
3 259 261 11704023 in IN B-PP O
4 262 270 11704023 systemic JJ B-NP O
5 271 281 11704023 absorption NN I-NP O
6 281 282 11704023 , , O O
7 283 290 11704023 however RB B-ADVP O
8 290 291 11704023 , , O O
9 292 295 11704023 the DT B-NP O
10 296 302 11704023 degree NN I-NP O
11 303 305 11704023 of IN B-PP O
12 306 315 11704023 reduction NN B-NP O
13 316 318 11704023 of IN B-PP O
14 319 326 11704023 resting VBG B-NP O
15 327 330 11704023 and CC I-NP O
16 331 335 11704023 peak JJ I-NP O
17 336 341 11704023 heart NN I-NP O
18 342 346 11704023 rate NN I-NP O
19 347 350 11704023 has VBZ B-VP O
20 351 354 11704023 not RB I-VP O
21 355 359 11704023 been VBN I-VP O
22 360 370 11704023 quantified VBN I-VP O
23 370 371 11704023 . . O O

1 372 378 11704023 DESIGN NN B-NP O
2 378 379 11704023 : : O O
3 380 384 11704023 This DT B-NP O
4 385 390 11704023 trial NN I-NP O
5 391 400 11704023 evaluated VBD B-VP O
6 401 404 11704023 the DT B-NP O
7 405 411 11704023 effect NN I-NP O
8 412 414 11704023 of IN B-PP O
9 415 422 11704023 placebo NN B-NP O
10 422 423 11704023 , , O O
11 424 428 11704023 0.5% CD B-NP O
12 429 436 11704023 aqueous JJ I-NP O
13 437 444 11704023 timolol NN I-NP D013999
14 445 446 11704023 ( ( O O
15 446 453 11704023 timolol NN B-NP D013999
16 454 462 11704023 solution NN I-NP O
17 462 463 11704023 ) ) O O
18 464 467 11704023 and CC O O
19 468 469 11704023 a DT B-NP O
20 470 474 11704023 0.5% CD I-NP O
21 475 482 11704023 timolol NN I-NP D013999
22 483 493 11704023 suspension NN I-NP O
23 494 498 11704023 that WDT B-NP O
24 499 504 11704023 forms VBZ B-VP O
25 505 506 11704023 a DT B-NP O
26 507 510 11704023 gel NN I-NP O
27 511 513 11704023 on IN B-PP O
28 514 525 11704023 application NN B-NP O
29 526 528 11704023 to TO B-PP O
30 529 532 11704023 the DT B-NP O
31 533 544 11704023 conjunctiva NN I-NP O
32 545 546 11704023 ( ( O O
33 546 553 11704023 timolol NN B-NP D013999
34 554 560 11704023 gellan NN I-NP O
35 560 561 11704023 ) ) O O
36 562 564 11704023 on IN B-PP O
37 565 568 11704023 the DT B-NP O
38 569 571 11704023 24 CD I-NP O
39 571 572 11704023 - HYPH I-NP O
40 572 576 11704023 hour NN I-NP O
41 577 582 11704023 heart NN I-NP O
42 583 587 11704023 rate NN I-NP O
43 588 590 11704023 in IN B-PP O
44 591 599 11704023 patients NNS B-NP O
45 600 609 11704023 currently RB B-VP O
46 610 615 11704023 being VBG I-VP O
47 616 623 11704023 treated VBN I-VP O
48 624 627 11704023 for IN B-PP O
49 628 636 11704023 glaucoma NN B-NP D005901
50 637 639 11704023 to TO B-VP O
51 640 648 11704023 quantify VB I-VP O
52 649 652 11704023 the DT B-NP O
53 653 662 11704023 reduction NN I-NP O
54 663 665 11704023 in IN B-PP O
55 666 670 11704023 mean JJ B-NP O
56 671 676 11704023 heart NN I-NP O
57 677 681 11704023 rate NN I-NP O
58 681 682 11704023 . . O O

1 683 690 11704023 METHODS NNS B-NP O
2 690 691 11704023 : : O O
3 692 697 11704023 Forty CD B-NP O
4 697 698 11704023 - HYPH I-NP O
5 698 703 11704023 three CD I-NP O
6 704 713 11704023 Caucasian JJ I-NP O
7 714 722 11704023 patients NNS I-NP O
8 723 727 11704023 with IN B-PP O
9 728 735 11704023 primary JJ B-NP O
10 736 740 11704023 open JJ I-NP D005902
11 740 741 11704023 - HYPH I-NP D005902
12 741 746 11704023 angle NN I-NP D005902
13 747 755 11704023 glaucoma NN I-NP D005902
14 756 758 11704023 or CC O O
15 759 765 11704023 ocular JJ B-NP D009798
16 766 778 11704023 hypertension NN I-NP D009798
17 779 783 11704023 with IN B-PP O
18 784 785 11704023 a DT B-NP O
19 786 790 11704023 mean JJ I-NP O
20 791 792 11704023 ( ( O O
21 792 793 11704023 + SYM O O
22 793 794 11704023 / SYM O O
23 794 795 11704023 - HYPH B-NP O
24 795 797 11704023 SD NN I-NP O
25 797 798 11704023 ) ) O O
26 799 802 11704023 age NN B-NP O
27 803 805 11704023 of IN B-PP O
28 806 808 11704023 63 CD B-NP O
29 809 810 11704023 ( ( O O
30 810 811 11704023 + SYM O O
31 811 812 11704023 / SYM O O
32 812 813 11704023 - SYM O O
33 813 814 11704023 8 CD O O
34 814 815 11704023 ) ) O O
35 816 821 11704023 years NNS B-NP O
36 822 826 11704023 were VBD B-VP O
37 827 837 11704023 randomized VBN I-VP O
38 838 841 11704023 and CC O O
39 842 849 11704023 crossed VBN B-VP O
40 850 854 11704023 over RP B-PRT O
41 855 857 11704023 in IN B-PP O
42 858 859 11704023 a DT B-NP O
43 860 866 11704023 double JJ I-NP O
44 866 867 11704023 - HYPH I-NP O
45 867 873 11704023 masked VBN I-NP O
46 874 880 11704023 manner NN I-NP O
47 881 883 11704023 to TO B-PP O
48 884 886 11704023 14 CD B-NP O
49 887 891 11704023 days NNS I-NP O
50 892 894 11704023 of IN B-PP O
51 895 904 11704023 treatment NN B-NP O
52 905 909 11704023 with IN B-PP O
53 910 917 11704023 placebo NN B-NP O
54 918 919 11704023 ( ( O O
55 919 926 11704023 morning NN B-NP O
56 927 930 11704023 and CC O O
57 931 938 11704023 evening NN B-NP O
58 939 941 11704023 in IN B-PP O
59 942 946 11704023 both DT B-NP O
60 947 951 11704023 eyes NNS I-NP O
61 951 952 11704023 ) ) O O
62 952 953 11704023 , , O O
63 954 961 11704023 timolol NN B-NP D013999
64 962 970 11704023 solution NN I-NP O
65 971 972 11704023 ( ( O O
66 972 979 11704023 morning NN B-NP O
67 980 983 11704023 and CC O O
68 984 991 11704023 evening NN B-NP O
69 992 994 11704023 in IN B-PP O
70 995 999 11704023 both DT B-NP O
71 1000 1004 11704023 eyes NNS I-NP O
72 1004 1005 11704023 ) ) O O
73 1005 1006 11704023 , , O O
74 1007 1009 11704023 or CC O O
75 1010 1017 11704023 timolol NN B-NP D013999
76 1018 1024 11704023 gellan NN I-NP O
77 1025 1026 11704023 ( ( O O
78 1026 1033 11704023 morning NN B-NP O
79 1034 1036 11704023 in IN B-PP O
80 1037 1041 11704023 both DT B-NP O
81 1042 1046 11704023 eyes NNS I-NP O
82 1047 1051 11704023 with IN B-PP O
83 1052 1059 11704023 placebo NN B-NP O
84 1060 1062 11704023 in IN B-PP O
85 1063 1066 11704023 the DT B-NP O
86 1067 1074 11704023 evening NN I-NP O
87 1074 1075 11704023 ) ) O O
88 1075 1076 11704023 . . O O

1 1077 1079 11704023 On IN B-PP O
2 1080 1083 11704023 the DT B-NP O
3 1084 1088 11704023 13th JJ I-NP O
4 1089 1092 11704023 day NN I-NP O
5 1093 1095 11704023 of IN B-PP O
6 1096 1100 11704023 each DT B-NP O
7 1101 1107 11704023 period NN I-NP O
8 1107 1108 11704023 , , O O
9 1109 1114 11704023 heart NN B-NP O
10 1115 1119 11704023 rate NN I-NP O
11 1120 1123 11704023 was VBD B-VP O
12 1124 1132 11704023 recorded VBN I-VP O
13 1133 1145 11704023 continuously RB B-ADVP O
14 1146 1152 11704023 during IN B-PP O
15 1153 1154 11704023 a DT B-NP O
16 1155 1162 11704023 typical JJ I-NP O
17 1162 1163 11704023 , , I-NP O
18 1164 1172 11704023 ambulant JJ I-NP O
19 1173 1175 11704023 24 CD I-NP O
20 1175 1176 11704023 - HYPH I-NP O
21 1176 1180 11704023 hour NN I-NP O
22 1181 1187 11704023 period NN I-NP O
23 1187 1188 11704023 . . O O

1 1189 1196 11704023 RESULTS NNS B-NP O
2 1196 1197 11704023 : : O O
3 1198 1202 11704023 Both CC O O
4 1203 1210 11704023 timolol NN B-NP D013999
5 1211 1219 11704023 solution NN I-NP O
6 1220 1223 11704023 and CC O O
7 1224 1231 11704023 timolol NN B-NP D013999
8 1232 1238 11704023 gellan NN I-NP O
9 1239 1246 11704023 reduced VBD B-VP O
10 1247 1250 11704023 the DT B-NP O
11 1251 1255 11704023 mean JJ I-NP O
12 1256 1258 11704023 24 CD I-NP O
13 1258 1259 11704023 - HYPH I-NP O
14 1259 1263 11704023 hour NN I-NP O
15 1264 1269 11704023 heart NN I-NP O
16 1270 1274 11704023 rate NN I-NP O
17 1275 1283 11704023 compared VBN B-PP O
18 1284 1288 11704023 with IN B-PP O
19 1289 1296 11704023 placebo NN B-NP O
20 1297 1298 11704023 ( ( O O
21 1298 1299 11704023 P NN B-NP O
22 1300 1301 11704023 < SYM B-VP O
23 1302 1304 11704023 or CC O O
24 1305 1306 11704023 = SYM B-VP O
25 1307 1311 11704023 .001 CD B-NP O
26 1311 1312 11704023 ) ) O O
27 1312 1313 11704023 , , O O
28 1314 1317 11704023 and CC O O
29 1318 1322 11704023 this DT B-NP O
30 1323 1332 11704023 reduction NN I-NP O
31 1333 1336 11704023 was VBD B-VP O
32 1337 1341 11704023 most RBS B-ADJP O
33 1342 1352 11704023 pronounced JJ I-ADJP O
34 1353 1359 11704023 during IN B-PP O
35 1360 1363 11704023 the DT B-NP O
36 1364 1371 11704023 daytime NN I-NP O
37 1372 1373 11704023 ( ( O O
38 1373 1374 11704023 - SYM B-NP O
39 1374 1378 11704023 7.5% CD B-NP O
40 1379 1385 11704023 change NN I-NP O
41 1386 1388 11704023 in IN B-PP O
42 1389 1393 11704023 mean JJ B-NP O
43 1394 1399 11704023 heart NN I-NP O
44 1400 1404 11704023 rate NN I-NP O
45 1404 1405 11704023 , , O O
46 1406 1407 11704023 - HYPH B-NP O
47 1407 1410 11704023 5.7 CD I-NP O
48 1411 1416 11704023 beats NNS I-NP O
49 1416 1417 11704023 / SYM B-NP O
50 1417 1420 11704023 min NN I-NP O
51 1420 1421 11704023 ) ) O O
52 1421 1422 11704023 . . O O

1 1423 1430 11704023 Timolol NN B-NP D013999
2 1431 1437 11704023 gellan NN I-NP O
3 1438 1444 11704023 showed VBD B-VP O
4 1445 1446 11704023 a DT B-NP O
5 1447 1458 11704023 numerically RB I-NP O
6 1459 1462 11704023 but CC B-PP O
7 1463 1466 11704023 not RB B-NP O
8 1467 1480 11704023 significantly RB I-NP O
9 1481 1488 11704023 smaller JJR I-NP O
10 1489 1498 11704023 reduction NN I-NP O
11 1499 1501 11704023 in IN B-PP O
12 1502 1504 11704023 24 CD B-NP O
13 1504 1505 11704023 - HYPH I-NP O
14 1505 1509 11704023 hour NN I-NP O
15 1510 1515 11704023 heart NN I-NP O
16 1516 1520 11704023 rate NN I-NP O
17 1520 1521 11704023 , , O O
18 1522 1530 11704023 compared VBN B-PP O
19 1531 1535 11704023 with IN B-PP O
20 1536 1543 11704023 timolol NN B-NP D013999
21 1544 1552 11704023 solution NN I-NP O
22 1552 1553 11704023 . . O O

1 1554 1560 11704023 During IN B-PP O
2 1561 1564 11704023 the DT B-NP O
3 1565 1570 11704023 night NN I-NP O
4 1570 1571 11704023 , , O O
5 1572 1575 11704023 the DT B-NP O
6 1576 1580 11704023 mean NN I-NP O
7 1581 1583 11704023 12 CD I-NP O
8 1583 1584 11704023 - HYPH I-NP O
9 1584 1588 11704023 hour NN I-NP O
10 1589 1594 11704023 heart NN I-NP O
11 1595 1599 11704023 rate NN I-NP O
12 1600 1602 11704023 on IN B-PP O
13 1603 1610 11704023 placebo NN B-NP O
14 1611 1614 11704023 and CC I-NP O
15 1615 1622 11704023 timolol NN I-NP D013999
16 1623 1629 11704023 gellan NN I-NP O
17 1630 1634 11704023 were VBD B-VP O
18 1635 1639 11704023 both DT O O
19 1640 1653 11704023 significantly RB B-ADJP O
20 1654 1658 11704023 less JJR I-ADJP O
21 1659 1663 11704023 than IN B-PP O
22 1664 1666 11704023 on IN B-PP O
23 1667 1674 11704023 timolol NN B-NP D013999
24 1675 1683 11704023 solution NN I-NP O
25 1683 1684 11704023 ; : O O
26 1685 1688 11704023 the DT B-NP O
27 1689 1699 11704023 difference NN I-NP O
28 1700 1707 11704023 between IN B-PP O
29 1708 1716 11704023 solution NN B-NP O
30 1717 1720 11704023 and CC I-NP O
31 1721 1727 11704023 gellan NN I-NP O
32 1728 1738 11704023 treatments NNS I-NP O
33 1739 1742 11704023 was VBD B-VP O
34 1743 1756 11704023 statistically RB B-ADJP O
35 1757 1768 11704023 significant JJ I-ADJP O
36 1769 1770 11704023 ( ( O O
37 1770 1771 11704023 P NN B-NP O
38 1772 1773 11704023 = SYM B-VP O
39 1774 1777 11704023 .01 CD B-NP O
40 1777 1778 11704023 ) ) O O
41 1778 1779 11704023 . . O O

1 1780 1791 11704023 CONCLUSIONS NNS B-NP O
2 1791 1792 11704023 : : O O
3 1793 1797 11704023 Both CC O O
4 1798 1805 11704023 timolol NN B-NP D013999
5 1806 1814 11704023 solution NN I-NP O
6 1815 1818 11704023 and CC O O
7 1819 1826 11704023 timolol NN B-NP D013999
8 1827 1833 11704023 gellan NN I-NP O
9 1834 1842 11704023 decrease VBP B-VP O
10 1843 1846 11704023 the DT B-NP O
11 1847 1851 11704023 mean JJ I-NP O
12 1852 1854 11704023 24 CD I-NP O
13 1854 1855 11704023 - HYPH I-NP O
14 1855 1859 11704023 hour NN I-NP O
15 1860 1865 11704023 heart NN I-NP O
16 1866 1870 11704023 rate NN I-NP O
17 1871 1879 11704023 compared VBN B-PP O
18 1880 1884 11704023 with IN B-PP O
19 1885 1892 11704023 placebo NN B-NP O
20 1892 1893 11704023 . . O O

1 1894 1898 11704023 This DT B-NP O
2 1899 1907 11704023 response NN I-NP O
3 1908 1911 11704023 was VBD B-VP O
4 1912 1916 11704023 most RBS B-ADJP O
5 1917 1927 11704023 pronounced JJ I-ADJP O
6 1928 1934 11704023 during IN B-PP O
7 1935 1938 11704023 the DT B-NP O
8 1939 1945 11704023 active JJ I-NP O
9 1946 1953 11704023 daytime NN I-NP O
10 1954 1960 11704023 period NN I-NP O
11 1960 1961 11704023 . . O O

1 1962 1967 11704023 These DT B-NP O
2 1968 1972 11704023 data NNS I-NP O
3 1973 1981 11704023 quantify VBP B-VP O
4 1982 1985 11704023 the DT B-NP O
5 1986 1992 11704023 modest JJ I-NP O
6 1993 2004 11704023 bradycardia NN I-NP D001919
7 2005 2015 11704023 associated VBN B-VP O
8 2016 2020 11704023 with IN B-PP O
9 2021 2031 11704023 ophthalmic JJ B-NP O
10 2032 2036 11704023 beta SYM I-NP O
11 2036 2037 11704023 - HYPH I-NP O
12 2037 2044 11704023 blocker NN I-NP O
13 2045 2052 11704023 therapy NN I-NP O
14 2053 2055 11704023 in IN B-PP O
15 2056 2057 11704023 a DT B-NP O
16 2058 2065 11704023 typical JJ I-NP O
17 2066 2073 11704023 patient NN I-NP O
18 2074 2084 11704023 population NN I-NP O
19 2085 2087 11704023 on IN B-PP O
20 2088 2095 11704023 therapy NN B-NP O
21 2096 2099 11704023 for IN B-PP O
22 2100 2108 11704023 glaucoma NN B-NP D005901
23 2108 2109 11704023 . . O O

1 2110 2118 11704023 Although IN B-SBAR O
2 2119 2127 11704023 exercise NN B-NP O
3 2128 2139 11704023 performance NN I-NP O
4 2140 2143 11704023 was VBD B-VP O
5 2144 2147 11704023 not RB I-VP O
6 2148 2156 11704023 assessed VBN I-VP O
7 2157 2159 11704023 in IN B-PP O
8 2160 2164 11704023 this DT B-NP O
9 2165 2170 11704023 trial NN I-NP O
10 2170 2171 11704023 , , O O
11 2172 2182 11704023 reductions NNS B-NP O
12 2183 2185 11704023 of IN B-PP O
13 2186 2190 11704023 this DT B-NP O
14 2191 2200 11704023 magnitude NN I-NP O
15 2201 2207 11704023 should MD B-VP O
16 2208 2211 11704023 not RB I-VP O
17 2212 2216 11704023 have VB I-VP O
18 2217 2228 11704023 substantial JJ B-NP O
19 2229 2237 11704023 clinical JJ I-NP O
20 2238 2250 11704023 consequences NNS I-NP O
21 2250 2251 11704023 . . O O

1 0 0 3653576 -DOCSTART- -X- -X- O

1 0 7 3653576 Urinary JJ B-NP O
2 8 15 3653576 enzymes NNS I-NP O
3 16 19 3653576 and CC O O
4 20 27 3653576 protein NN B-NP O
5 28 36 3653576 patterns NNS I-NP O
6 37 39 3653576 as IN B-PP O
7 40 50 3653576 indicators NNS B-NP O
8 51 53 3653576 of IN B-PP O
9 54 60 3653576 injury NN B-NP D007674
10 61 63 3653576 to TO B-PP D007674
11 64 73 3653576 different JJ B-NP D007674
12 74 81 3653576 regions NNS I-NP D007674
13 82 84 3653576 of IN B-PP D007674
14 85 88 3653576 the DT B-NP D007674
15 89 95 3653576 kidney NN I-NP D007674
16 95 96 3653576 . . O O
17 97 102 3653576 Acute JJ B-NP D058186
18 103 115 3653576 experimental JJ I-NP D058186
19 116 122 3653576 models NNS I-NP D058186
20 123 125 3653576 of IN B-PP D058186
21 126 131 3653576 renal JJ B-NP D058186
22 132 138 3653576 damage NN I-NP D058186
23 139 141 3653576 to TO B-PP O
24 142 145 3653576 the DT B-NP O
25 146 154 3653576 proximal JJ I-NP O
26 155 162 3653576 tubular JJ I-NP O
27 162 163 3653576 , , I-NP O
28 164 174 3653576 glomerular JJ I-NP O
29 174 175 3653576 , , O O
30 176 179 3653576 and CC O O
31 180 189 3653576 papillary JJ B-NP O
32 190 197 3653576 regions NNS I-NP O
33 198 200 3653576 of IN B-PP O
34 201 204 3653576 the DT B-NP O
35 205 208 3653576 rat NN I-NP O
36 209 213 3653576 were VBD B-VP O
37 214 222 3653576 produced VBN I-VP O
38 223 225 3653576 by IN B-PP O
39 226 240 3653576 administration NN B-NP O
40 241 243 3653576 of IN B-PP O
41 244 254 3653576 hexachloro AFX B-NP C001335
42 254 255 3653576 - HYPH I-NP C001335
43 255 256 3653576 1 CD I-NP C001335
44 256 257 3653576 : SYM I-NP C001335
45 257 258 3653576 3 CD I-NP C001335
46 258 259 3653576 - HYPH I-NP C001335
47 259 268 3653576 butadiene NN I-NP C001335
48 269 270 3653576 ( ( O O
49 270 274 3653576 HCBD NN B-NP C001335
50 274 275 3653576 ) ) O O
51 275 276 3653576 , , O O
52 277 286 3653576 puromycin NN B-NP D011692
53 287 302 3653576 aminonucleoside NN I-NP D011692
54 303 304 3653576 ( ( O O
55 304 307 3653576 PAN NN B-NP D011692
56 307 308 3653576 ) ) O O
57 308 309 3653576 , , O O
58 310 313 3653576 and CC O O
59 314 315 3653576 2 CD B-NP C004504
60 315 316 3653576 - HYPH I-NP C004504
61 316 331 3653576 bromoethylamine NN I-NP C004504
62 332 333 3653576 ( ( O O
63 333 336 3653576 BEA NN B-NP C004504
64 336 337 3653576 ) ) O O
65 337 338 3653576 , , O O
66 339 351 3653576 respectively RB B-ADVP O
67 351 352 3653576 . . O O

1 353 360 3653576 Several JJ B-NP O
2 361 368 3653576 routine JJ I-NP O
3 369 379 3653576 indicators NNS I-NP O
4 380 382 3653576 of IN B-PP O
5 383 397 3653576 nephrotoxicity NN B-NP D007674
6 397 398 3653576 , , O O
7 399 402 3653576 the DT B-NP O
8 403 410 3653576 enzymes NNS I-NP O
9 411 419 3653576 alkaline NN I-NP O
10 420 431 3653576 phosphatase NN I-NP O
11 432 435 3653576 and CC I-NP O
12 436 437 3653576 N NN I-NP O
13 437 438 3653576 - HYPH B-NP O
14 438 444 3653576 acetyl NN I-NP O
15 444 445 3653576 - HYPH O O
16 445 449 3653576 beta SYM O O
17 449 450 3653576 - HYPH O O
18 450 465 3653576 glucosaminidase NN B-NP O
19 465 466 3653576 , , O O
20 467 470 3653576 and CC O O
21 471 474 3653576 the DT B-NP O
22 475 484 3653576 molecular JJ I-NP O
23 485 491 3653576 weight NN I-NP O
24 492 494 3653576 of IN B-PP O
25 495 502 3653576 protein NN B-NP D011507
26 503 512 3653576 excretion NN I-NP D011507
27 513 517 3653576 were VBD B-VP O
28 518 528 3653576 determined VBN I-VP O
29 529 531 3653576 on IN B-PP O
30 532 537 3653576 urine NN B-NP O
31 538 545 3653576 samples NNS I-NP O
32 545 546 3653576 . . O O

1 547 554 3653576 Tubular JJ B-NP O
2 555 561 3653576 damage NN I-NP O
3 562 570 3653576 produced VBN B-VP O
4 571 573 3653576 by IN B-PP O
5 574 578 3653576 HCBD NN B-NP C001335
6 579 581 3653576 or CC I-NP O
7 582 585 3653576 BEA NN I-NP C004504
8 586 589 3653576 was VBD B-VP O
9 590 603 3653576 discriminated VBN I-VP O
10 604 608 3653576 both CC O O
11 609 623 3653576 quantitatively RB B-ADVP O
12 624 627 3653576 and CC I-ADVP O
13 628 641 3653576 qualitatively RB I-ADVP O
14 642 646 3653576 from IN B-PP O
15 647 657 3653576 glomerular JJ B-NP D007674
16 658 664 3653576 damage NN I-NP D007674
17 665 673 3653576 produced VBN B-VP O
18 674 676 3653576 by IN B-PP O
19 677 680 3653576 PAN NN B-NP D011692
20 680 681 3653576 . . O O

1 682 685 3653576 The DT B-NP O
2 686 692 3653576 latter JJ I-NP O
3 693 696 3653576 was VBD B-VP O
4 697 710 3653576 characterized VBN I-VP O
5 711 713 3653576 by IN B-PP O
6 714 715 3653576 a DT B-NP O
7 716 726 3653576 pronounced JJ I-NP O
8 727 735 3653576 increase NN I-NP O
9 736 738 3653576 in IN B-PP O
10 739 746 3653576 protein NN B-NP D011507
11 747 756 3653576 excretion NN I-NP D011507
12 756 757 3653576 , , O O
13 758 768 3653576 especially RB B-ADVP O
14 769 777 3653576 proteins NNS B-NP O
15 778 782 3653576 with IN B-PP O
16 783 792 3653576 molecular JJ B-NP O
17 793 799 3653576 weight NN I-NP O
18 800 807 3653576 greater JJR B-ADJP O
19 808 812 3653576 than IN B-PP O
20 813 819 3653576 40,000 CD B-NP O
21 820 822 3653576 Da NN I-NP O
22 822 823 3653576 . . O O

1 824 826 3653576 In IN B-PP O
2 827 835 3653576 contrast NN B-NP O
3 835 836 3653576 , , O O
4 837 844 3653576 protein NN B-NP D011507
5 845 854 3653576 excretion NN I-NP D011507
6 855 857 3653576 in IN B-PP O
7 858 865 3653576 tubular JJ B-NP O
8 866 872 3653576 damage NN I-NP O
9 873 876 3653576 was VBD B-VP O
10 877 883 3653576 raised VBN I-VP O
11 884 888 3653576 only RB B-ADVP O
12 889 897 3653576 slightly RB I-ADVP O
13 898 901 3653576 and CC O O
14 902 915 3653576 characterized VBN B-VP O
15 916 918 3653576 by IN B-PP O
16 919 928 3653576 excretion NN B-NP D011507
17 929 931 3653576 of IN B-PP D011507
18 932 940 3653576 proteins NNS B-NP D011507
19 941 943 3653576 of IN B-PP O
20 944 945 3653576 a DT B-NP O
21 946 950 3653576 wide JJ I-NP O
22 951 956 3653576 range NN I-NP O
23 957 959 3653576 of IN B-PP O
24 960 969 3653576 molecular JJ B-NP O
25 970 977 3653576 weights NNS I-NP O
26 977 978 3653576 . . O O

1 979 987 3653576 Proximal JJ B-NP O
2 988 995 3653576 tubular JJ I-NP O
3 996 1002 3653576 damage NN I-NP O
4 1003 1009 3653576 caused VBN B-VP O
5 1010 1012 3653576 by IN B-PP O
6 1013 1017 3653576 HCBD NN B-NP C001335
7 1018 1021 3653576 and CC O O
8 1022 1031 3653576 papillary JJ B-NP O
9 1032 1038 3653576 damage NN I-NP O
10 1039 1045 3653576 caused VBN B-VP O
11 1046 1048 3653576 by IN B-PP O
12 1049 1052 3653576 BEA NN B-NP C004504
13 1053 1057 3653576 were VBD B-VP O
14 1058 1071 3653576 distinguished VBN I-VP O
15 1072 1076 3653576 both CC O O
16 1077 1079 3653576 by IN B-PP O
17 1080 1092 3653576 conventional JJ B-NP O
18 1093 1103 3653576 urinalysis NN I-NP O
19 1104 1105 3653576 ( ( O O
20 1105 1111 3653576 volume NN B-NP O
21 1112 1115 3653576 and CC O O
22 1116 1124 3653576 specific JJ B-NP O
23 1125 1132 3653576 gravity NN I-NP O
24 1132 1133 3653576 ) ) O O
25 1134 1137 3653576 and CC O O
26 1138 1140 3653576 by IN B-PP O
27 1141 1152 3653576 measurement NN B-NP O
28 1153 1155 3653576 of IN B-PP O
29 1156 1159 3653576 the DT B-NP O
30 1160 1163 3653576 two CD I-NP O
31 1164 1171 3653576 urinary JJ I-NP O
32 1172 1179 3653576 enzymes NNS I-NP O
33 1179 1180 3653576 . . O O

1 1181 1189 3653576 Alkaline NN B-NP O
2 1190 1201 3653576 phosphatase NN I-NP O
3 1202 1205 3653576 and CC I-NP O
4 1206 1213 3653576 glucose NN I-NP D005947
5 1214 1218 3653576 were VBD B-VP O
6 1219 1227 3653576 markedly RB B-ADVP O
7 1228 1231 3653576 and CC O O
8 1232 1243 3653576 transiently RB B-ADJP O
9 1244 1252 3653576 elevated JJ I-ADJP O
10 1253 1255 3653576 in IN B-PP O
11 1256 1264 3653576 proximal JJ B-NP O
12 1265 1272 3653576 tubular JJ I-NP O
13 1273 1279 3653576 damage NN I-NP O
14 1280 1283 3653576 and CC I-NP O
15 1284 1285 3653576 N NN I-NP O
16 1285 1286 3653576 - HYPH B-NP O
17 1286 1292 3653576 acetyl NN I-NP O
18 1292 1293 3653576 - HYPH O O
19 1293 1297 3653576 beta SYM O O
20 1297 1298 3653576 - HYPH O O
21 1298 1313 3653576 glucosaminidase NN B-NP O
22 1314 1320 3653576 showed VBD B-VP O
23 1321 1322 3653576 a DT B-NP O
24 1323 1332 3653576 sustained JJ I-NP O
25 1333 1342 3653576 elevation NN I-NP O
26 1343 1345 3653576 in IN B-PP O
27 1346 1355 3653576 papillary JJ B-NP O
28 1356 1362 3653576 damage NN I-NP O
29 1362 1363 3653576 . . O O

1 1364 1366 3653576 It PRP B-NP O
2 1367 1369 3653576 is VBZ B-VP O
3 1370 1379 3653576 concluded VBN I-VP O
4 1380 1384 3653576 that IN B-SBAR O
5 1385 1389 3653576 both CC O O
6 1390 1399 3653576 selective JJ B-NP O
7 1400 1407 3653576 urinary JJ I-NP O
8 1408 1415 3653576 enzymes NNS I-NP O
9 1416 1419 3653576 and CC O O
10 1420 1423 3653576 the DT B-NP O
11 1424 1433 3653576 molecular JJ I-NP O
12 1434 1440 3653576 weight NN I-NP O
13 1441 1448 3653576 pattern NN I-NP O
14 1449 1451 3653576 of IN B-PP O
15 1452 1459 3653576 urinary JJ B-NP O
16 1460 1468 3653576 proteins NNS I-NP O
17 1469 1472 3653576 can MD B-VP O
18 1473 1475 3653576 be VB I-VP O
19 1476 1480 3653576 used VBN I-VP O
20 1481 1483 3653576 to TO B-VP O
21 1484 1491 3653576 provide VB I-VP O
22 1492 1502 3653576 diagnostic JJ B-NP O
23 1503 1514 3653576 information NN I-NP O
24 1515 1520 3653576 about IN B-PP O
25 1521 1524 3653576 the DT B-NP O
26 1525 1533 3653576 possible JJ I-NP O
27 1534 1538 3653576 site NN I-NP O
28 1539 1541 3653576 of IN B-PP O
29 1542 1547 3653576 renal JJ B-NP D007674
30 1548 1554 3653576 damage NN I-NP D007674
31 1554 1555 3653576 . . O O

1 0 0 8599504 -DOCSTART- -X- -X- O

1 0 10 8599504 Angioedema NN B-NP D000799
2 11 21 8599504 associated VBN B-VP O
3 22 26 8599504 with IN B-PP O
4 27 37 8599504 droperidol NN B-NP D004329
5 38 52 8599504 administration NN I-NP O
6 52 53 8599504 . . O O
7 54 64 8599504 Angioedema NNP B-NP D000799
8 64 65 8599504 , , O O
9 66 70 8599504 also RB B-VP O
10 71 76 8599504 known VBN I-VP O
11 77 79 8599504 as IN B-PP O
12 80 93 8599504 angioneurotic JJ B-NP D000799
13 94 99 8599504 edema NN I-NP D000799
14 100 102 8599504 or CC I-NP O
15 103 112 8599504 Quincke's NNS I-NP D000799
16 113 120 8599504 disease NN I-NP D000799
17 120 121 8599504 , , O O
18 122 124 8599504 is VBZ B-VP O
19 125 126 8599504 a DT B-NP O
20 127 131 8599504 well RB I-NP O
21 131 132 8599504 - HYPH I-NP O
22 132 142 8599504 demarcated VBN B-VP O
23 142 143 8599504 , , O O
24 144 153 8599504 localized VBN B-NP O
25 154 159 8599504 edema NN I-NP D004487
26 160 169 8599504 involving VBG B-VP O
27 170 173 8599504 the DT B-NP O
28 174 186 8599504 subcutaneous JJ I-NP O
29 187 194 8599504 tissues NNS I-NP O
30 195 199 8599504 that WDT B-NP O
31 200 203 8599504 may MD B-VP O
32 204 209 8599504 cause VB I-VP O
33 210 215 8599504 upper JJ B-NP D000402
34 215 216 8599504 - HYPH I-NP D000402
35 216 222 8599504 airway NN I-NP D000402
36 223 234 8599504 obstruction NN I-NP D000402
37 234 235 8599504 . . O O

1 236 238 8599504 We PRP B-NP O
2 239 245 8599504 report VBP B-VP O
3 246 249 8599504 the DT B-NP O
4 250 254 8599504 case NN I-NP O
5 255 257 8599504 of IN B-PP O
6 258 259 8599504 a DT B-NP O
7 260 270 8599504 previously RB I-NP O
8 271 278 8599504 healthy JJ I-NP O
9 279 281 8599504 19 CD I-NP O
10 281 282 8599504 - HYPH I-NP O
11 282 286 8599504 year NN I-NP O
12 286 287 8599504 - HYPH O O
13 287 290 8599504 old JJ B-NP O
14 291 294 8599504 man NN I-NP O
15 295 299 8599504 with IN B-PP O
16 300 302 8599504 no DT B-NP O
17 303 308 8599504 known VBN I-NP O
18 309 313 8599504 drug NN I-NP D004342
19 314 323 8599504 allergies NNS I-NP D004342
20 324 326 8599504 in IN B-PP O
21 327 331 8599504 whom WP B-NP O
22 332 342 8599504 angioedema NN B-NP D000799
23 343 347 8599504 with IN B-PP O
24 348 359 8599504 significant JJ B-NP O
25 360 366 8599504 tongue NN I-NP D014060
26 367 375 8599504 swelling NN I-NP D014060
27 376 379 8599504 and CC I-NP O
28 380 390 8599504 protrusion NN I-NP O
29 391 400 8599504 developed VBD B-VP O
30 401 407 8599504 within IN B-PP O
31 408 410 8599504 10 CD B-NP O
32 411 418 8599504 minutes NNS I-NP O
33 419 421 8599504 of IN B-PP O
34 422 425 8599504 the DT B-NP O
35 426 440 8599504 administration NN I-NP O
36 441 443 8599504 of IN B-PP O
37 444 445 8599504 a DT B-NP O
38 446 452 8599504 single JJ I-NP O
39 453 455 8599504 IV CD I-NP O
40 456 460 8599504 dose NN I-NP O
41 461 463 8599504 of IN B-PP O
42 464 474 8599504 droperidol NN B-NP D004329
43 474 475 8599504 . . O O

1 0 0 15565293 -DOCSTART- -X- -X- O

1 0 7 15565293 Optical JJ B-NP O
2 8 17 15565293 coherence NN I-NP O
3 18 28 15565293 tomography NN I-NP O
4 29 32 15565293 can MD B-VP O
5 33 40 15565293 measure VB I-VP O
6 41 47 15565293 axonal JJ B-NP O
7 48 52 15565293 loss NN I-NP O
8 53 55 15565293 in IN B-PP O
9 56 64 15565293 patients NNS B-NP O
10 65 69 15565293 with IN B-PP O
11 70 80 15565293 ethambutol NN B-NP D004977
12 80 81 15565293 - HYPH B-NP O
13 81 88 15565293 induced VBN I-NP O
14 89 94 15565293 optic JJ I-NP D009901
15 95 105 15565293 neuropathy NN I-NP D009901
16 105 106 15565293 . . I-NP O
17 107 114 15565293 PURPOSE NN I-NP O
18 114 115 15565293 : : O O
19 116 118 15565293 To TO B-VP O
20 119 122 15565293 map VB I-VP O
21 123 126 15565293 and CC I-VP O
22 127 135 15565293 identify VB I-VP O
23 136 139 15565293 the DT B-NP O
24 140 147 15565293 pattern NN I-NP O
25 147 148 15565293 , , O O
26 149 151 15565293 in FW B-ADVP O
27 152 156 15565293 vivo FW I-ADVP O
28 156 157 15565293 , , O O
29 158 160 15565293 of IN B-PP O
30 161 167 15565293 axonal JJ B-NP D009410
31 168 180 15565293 degeneration NN I-NP D009410
32 181 183 15565293 in IN B-PP O
33 184 194 15565293 ethambutol NN B-NP D004977
34 194 195 15565293 - HYPH B-NP O
35 195 202 15565293 induced VBN I-NP O
36 203 208 15565293 optic JJ I-NP D009901
37 209 219 15565293 neuropathy NN I-NP D009901
38 220 225 15565293 using VBG B-VP O
39 226 233 15565293 optical JJ B-NP O
40 234 243 15565293 coherence NN I-NP O
41 244 254 15565293 tomography NN I-NP O
42 255 256 15565293 ( ( O O
43 256 259 15565293 OCT NN B-NP O
44 259 260 15565293 ) ) O O
45 260 261 15565293 . . O O

1 262 272 15565293 Ethambutol NN B-NP D004977
2 273 275 15565293 is VBZ B-VP O
3 276 278 15565293 an DT B-NP O
4 279 296 15565293 antimycobacterial JJ I-NP O
5 297 302 15565293 agent NN I-NP O
6 303 308 15565293 often RB B-VP O
7 309 313 15565293 used VBN I-VP O
8 314 316 15565293 to TO B-VP O
9 317 322 15565293 treat VB I-VP O
10 323 335 15565293 tuberculosis NN B-NP D014376
11 335 336 15565293 . . O O

1 337 338 15565293 A DT B-NP O
2 339 346 15565293 serious JJ I-NP O
3 347 359 15565293 complication NN I-NP O
4 360 362 15565293 of IN B-PP O
5 363 373 15565293 ethambutol NN B-NP D004977
6 374 376 15565293 is VBZ B-VP O
7 377 379 15565293 an DT B-NP O
8 380 385 15565293 optic JJ I-NP D009901
9 386 396 15565293 neuropathy NN I-NP D009901
10 397 401 15565293 that WDT B-NP O
11 402 409 15565293 impairs VBZ B-VP O
12 410 416 15565293 visual JJ B-NP O
13 417 423 15565293 acuity NN I-NP O
14 423 424 15565293 , , O O
15 425 433 15565293 contrast NN B-NP O
16 434 445 15565293 sensitivity NN I-NP O
17 445 446 15565293 , , O O
18 447 450 15565293 and CC O O
19 451 456 15565293 color NN B-NP O
20 457 463 15565293 vision NN I-NP O
21 463 464 15565293 . . O O

1 465 472 15565293 However RB B-ADVP O
2 472 473 15565293 , , O O
3 474 479 15565293 early RB B-ADVP O
4 480 482 15565293 on IN B-PP O
5 482 483 15565293 , , O O
6 484 488 15565293 when WRB B-ADVP O
7 489 492 15565293 the DT B-NP O
8 493 498 15565293 toxic JJ I-NP O
9 499 504 15565293 optic JJ I-NP D009901
10 505 515 15565293 neuropathy NN I-NP D009901
11 516 518 15565293 is VBZ B-VP O
12 519 523 15565293 mild JJ B-ADJP O
13 524 527 15565293 and CC O O
14 528 534 15565293 partly RB B-ADJP O
15 535 545 15565293 reversible JJ I-ADJP O
16 545 546 15565293 , , O O
17 547 550 15565293 the DT B-NP O
18 551 562 15565293 funduscopic JJ I-NP O
19 563 571 15565293 findings NNS I-NP O
20 572 575 15565293 are VBP B-VP O
21 576 581 15565293 often RB B-ADVP O
22 582 588 15565293 subtle JJ B-ADJP O
23 589 592 15565293 and CC I-ADJP O
24 593 597 15565293 easy JJ I-ADJP O
25 598 600 15565293 to TO B-VP O
26 601 605 15565293 miss VB I-VP O
27 605 606 15565293 . . O O

1 607 614 15565293 METHODS NNS B-NP O
2 614 615 15565293 : : O O
3 616 621 15565293 Three CD B-NP O
4 622 630 15565293 subjects NNS I-NP O
5 631 635 15565293 with IN B-PP O
6 636 637 15565293 a DT B-NP O
7 638 645 15565293 history NN I-NP O
8 646 648 15565293 of IN B-PP O
9 649 659 15565293 ethambutol NN B-NP D004977
10 660 661 15565293 ( ( O O
11 661 664 15565293 EMB NN B-NP D004977
12 664 665 15565293 ) ) O O
13 665 666 15565293 - HYPH O O
14 666 673 15565293 induced VBN B-NP O
15 674 679 15565293 optic JJ I-NP D009901
16 680 690 15565293 neuropathy NN I-NP D009901
17 691 693 15565293 of IN B-PP O
18 694 699 15565293 short JJ B-NP O
19 699 700 15565293 - HYPH I-NP O
20 700 701 15565293 , , I-NP O
21 702 714 15565293 intermediate NN I-NP O
22 714 715 15565293 - HYPH I-NP O
23 715 716 15565293 , , O O
24 717 720 15565293 and CC O O
25 721 725 15565293 long JJ B-NP O
26 725 726 15565293 - HYPH I-NP O
27 726 730 15565293 term NN I-NP O
28 731 737 15565293 visual JJ I-NP D014786
29 738 746 15565293 deficits NNS I-NP D014786
30 747 751 15565293 were VBD B-VP O
31 752 764 15565293 administered VBN I-VP O
32 765 766 15565293 a DT B-NP O
33 767 771 15565293 full JJ I-NP O
34 772 777 15565293 neuro AFX I-NP O
35 777 778 15565293 - HYPH I-NP O
36 778 792 15565293 ophthalmologic JJ I-NP O
37 793 804 15565293 examination NN I-NP O
38 805 814 15565293 including VBG B-PP O
39 815 821 15565293 visual JJ B-NP O
40 822 828 15565293 acuity NN I-NP O
41 828 829 15565293 , , O O
42 830 835 15565293 color NN B-NP O
43 836 842 15565293 vision NN I-NP O
44 842 843 15565293 , , O O
45 844 852 15565293 contrast NN B-NP O
46 853 864 15565293 sensitivity NN I-NP O
47 864 865 15565293 , , O O
48 866 869 15565293 and CC O O
49 870 876 15565293 fundus NN B-NP O
50 877 888 15565293 examination NN I-NP O
51 888 889 15565293 . . O O

1 890 892 15565293 In IN B-PP O
2 893 901 15565293 addition NN B-NP O
3 901 902 15565293 , , O O
4 903 906 15565293 OCT NN B-NP O
5 907 908 15565293 ( ( O O
6 908 911 15565293 OCT NN B-NP O
7 912 916 15565293 3000 CD I-NP O
8 916 917 15565293 , , O O
9 918 926 15565293 Humphrey NNP B-NP O
10 926 927 15565293 - HYPH I-NP O
11 927 932 15565293 Zeiss NNP I-NP O
12 932 933 15565293 , , O O
13 934 940 15565293 Dublin NNP B-NP O
14 940 941 15565293 , , O O
15 942 944 15565293 CA NNP B-NP O
16 944 945 15565293 ) ) O O
17 946 949 15565293 was VBD B-VP O
18 950 959 15565293 performed VBN I-VP O
19 960 962 15565293 on IN B-PP O
20 963 967 15565293 both DT B-NP O
21 968 972 15565293 eyes NNS I-NP O
22 973 975 15565293 of IN B-PP O
23 976 980 15565293 each DT B-NP O
24 981 988 15565293 subject NN I-NP O
25 989 994 15565293 using VBG B-VP O
26 995 998 15565293 the DT B-NP O
27 999 1006 15565293 retinal JJ I-NP O
28 1007 1012 15565293 nerve NN I-NP O
29 1013 1018 15565293 fiber NN I-NP O
30 1019 1024 15565293 layer NN I-NP O
31 1025 1026 15565293 ( ( O O
32 1026 1030 15565293 RNFL NN B-NP O
33 1030 1031 15565293 ) ) O O
34 1032 1040 15565293 analysis NN B-NP O
35 1041 1049 15565293 protocol NN I-NP O
36 1049 1050 15565293 . . O O

1 1051 1054 15565293 OCT NN B-NP O
2 1055 1067 15565293 interpolates VBZ B-VP O
3 1068 1072 15565293 data NNS B-NP O
4 1073 1077 15565293 from IN B-PP O
5 1078 1081 15565293 100 CD B-NP O
6 1082 1088 15565293 points NNS I-NP O
7 1089 1095 15565293 around IN B-PP O
8 1096 1099 15565293 the DT B-NP O
9 1100 1105 15565293 optic JJ I-NP O
10 1106 1111 15565293 nerve NN I-NP O
11 1112 1114 15565293 to TO B-VP O
12 1115 1126 15565293 effectively RB I-VP O
13 1127 1130 15565293 map VB I-VP O
14 1131 1134 15565293 out RP B-PRT O
15 1135 1138 15565293 the DT B-NP O
16 1139 1143 15565293 RNFL NNP I-NP O
17 1143 1144 15565293 . . O O

1 1145 1152 15565293 RESULTS NNS B-NP O
2 1152 1153 15565293 : : O O
3 1154 1157 15565293 The DT B-NP O
4 1158 1165 15565293 results NNS I-NP O
5 1166 1170 15565293 were VBD B-VP O
6 1171 1179 15565293 compared VBN I-VP O
7 1180 1182 15565293 to TO B-PP O
8 1183 1186 15565293 the DT B-NP O
9 1187 1197 15565293 calculated VBN I-NP O
10 1198 1205 15565293 average JJ I-NP O
11 1206 1210 15565293 RNFL NNP I-NP O
12 1211 1213 15565293 of IN B-PP O
13 1214 1220 15565293 normal JJ B-NP O
14 1221 1225 15565293 eyes NNS I-NP O
15 1226 1237 15565293 accumulated VBN B-VP O
16 1238 1242 15565293 from IN B-PP O
17 1243 1247 15565293 four CD B-NP O
18 1248 1253 15565293 prior JJ I-NP O
19 1254 1261 15565293 studies NNS I-NP O
20 1262 1267 15565293 using VBG B-VP O
21 1268 1271 15565293 OCT NN B-NP O
22 1271 1272 15565293 , , O O
23 1273 1274 15565293 n NN B-NP O
24 1274 1275 15565293 = SYM B-VP O
25 1275 1278 15565293 661 CD B-NP O
26 1278 1279 15565293 . . O O

1 1280 1282 15565293 In IN B-PP O
2 1283 1286 15565293 all DT B-NP O
3 1287 1295 15565293 subjects NNS I-NP O
4 1296 1300 15565293 with IN B-PP O
5 1301 1308 15565293 history NN B-NP O
6 1309 1311 15565293 of IN B-PP O
7 1312 1315 15565293 EMB NN B-NP D004977
8 1315 1316 15565293 - HYPH B-NP O
9 1316 1323 15565293 induced VBN I-NP O
10 1324 1329 15565293 optic JJ I-NP D009901
11 1330 1340 15565293 neuropathy NN I-NP D009901
12 1340 1341 15565293 , , O O
13 1342 1347 15565293 there EX B-NP O
14 1348 1351 15565293 was VBD B-VP O
15 1352 1353 15565293 a DT B-NP O
16 1354 1358 15565293 mean JJ I-NP O
17 1359 1363 15565293 loss NN I-NP O
18 1364 1366 15565293 of IN B-PP O
19 1367 1370 15565293 72% CD B-NP O
20 1371 1376 15565293 nerve NN I-NP O
21 1377 1382 15565293 fiber NN I-NP O
22 1383 1388 15565293 layer NN I-NP O
23 1389 1398 15565293 thickness NN I-NP O
24 1399 1401 15565293 in IN B-PP O
25 1402 1405 15565293 the DT B-NP O
26 1406 1414 15565293 temporal JJ I-NP O
27 1415 1423 15565293 quadrant NN I-NP O
28 1424 1425 15565293 ( ( O O
29 1425 1432 15565293 patient NN B-NP O
30 1433 1434 15565293 A NN I-NP O
31 1434 1435 15565293 , , O O
32 1436 1440 15565293 with IN B-PP O
33 1441 1449 15565293 eventual JJ B-NP O
34 1450 1458 15565293 recovery NN I-NP O
35 1459 1461 15565293 of IN B-PP O
36 1462 1468 15565293 visual JJ B-NP O
37 1469 1475 15565293 acuity NN I-NP O
38 1476 1479 15565293 and CC I-NP O
39 1480 1486 15565293 fields NNS I-NP O
40 1486 1487 15565293 , , O O
41 1488 1491 15565293 58% JJ B-NP O
42 1492 1496 15565293 loss NN I-NP O
43 1496 1497 15565293 ; : O O
44 1498 1505 15565293 patient NN B-NP O
45 1506 1507 15565293 B NN I-NP O
46 1507 1508 15565293 , , O O
47 1509 1513 15565293 with IN B-PP O
48 1514 1526 15565293 intermediate JJ B-NP O
49 1527 1533 15565293 visual JJ I-NP D014786
50 1534 1542 15565293 deficits NNS I-NP D014786
51 1542 1543 15565293 , , O O
52 1544 1547 15565293 68% CD B-NP O
53 1548 1552 15565293 loss NN I-NP O
54 1552 1553 15565293 ; : O O
55 1554 1561 15565293 patient NN B-NP O
56 1562 1563 15565293 C NN I-NP O
57 1563 1564 15565293 , , O O
58 1565 1569 15565293 with IN B-PP O
59 1570 1577 15565293 chronic JJ B-NP O
60 1578 1584 15565293 visual JJ I-NP D014786
61 1585 1593 15565293 deficits NNS I-NP D014786
62 1593 1594 15565293 , , O O
63 1595 1598 15565293 90% CD B-NP O
64 1599 1603 15565293 loss NN I-NP O
65 1603 1604 15565293 ) ) O O
66 1604 1605 15565293 , , O O
67 1606 1610 15565293 with IN B-PP O
68 1611 1613 15565293 an DT B-NP O
69 1614 1621 15565293 average JJ I-NP O
70 1622 1626 15565293 mean JJ I-NP O
71 1627 1632 15565293 optic JJ I-NP O
72 1633 1638 15565293 nerve NN I-NP O
73 1639 1648 15565293 thickness NN I-NP O
74 1649 1651 15565293 of IN B-PP O
75 1652 1655 15565293 26+ JJ B-NP O
76 1655 1656 15565293 / SYM I-NP O
77 1656 1657 15565293 - SYM I-NP O
78 1657 1659 15565293 16 CD B-NP O
79 1660 1666 15565293 microm NN I-NP O
80 1666 1667 15565293 . . O O

1 1668 1673 15565293 There EX B-NP O
2 1674 1677 15565293 was VBD B-VP O
3 1678 1679 15565293 a DT B-NP O
4 1680 1688 15565293 combined JJ I-NP O
5 1689 1693 15565293 mean JJ I-NP O
6 1694 1698 15565293 loss NN I-NP O
7 1699 1701 15565293 of IN B-PP O
8 1702 1705 15565293 46% NN B-NP O
9 1706 1708 15565293 of IN B-PP O
10 1709 1715 15565293 fibers NNS B-NP O
11 1716 1720 15565293 from IN B-PP O
12 1721 1724 15565293 the DT B-NP O
13 1725 1733 15565293 superior JJ I-NP O
14 1733 1734 15565293 , , I-NP O
15 1735 1743 15565293 inferior JJ I-NP O
16 1743 1744 15565293 , , O O
17 1745 1748 15565293 and CC O O
18 1749 1754 15565293 nasal JJ B-NP O
19 1755 1764 15565293 quadrants NNS I-NP O
20 1765 1767 15565293 in IN B-PP O
21 1768 1771 15565293 the DT B-NP O
22 1772 1773 15565293 ( ( O O
23 1773 1776 15565293 six CD O O
24 1776 1777 15565293 ) ) O O
25 1778 1782 15565293 eyes NNS B-NP O
26 1783 1785 15565293 of IN B-PP O
27 1786 1789 15565293 all DT B-NP O
28 1790 1795 15565293 three CD I-NP O
29 1796 1804 15565293 subjects NNS I-NP O
30 1805 1806 15565293 ( ( O O
31 1806 1810 15565293 mean JJ B-NP O
32 1811 1818 15565293 average JJ I-NP O
33 1819 1828 15565293 thickness NN I-NP O
34 1829 1831 15565293 of IN B-PP O
35 1832 1835 15565293 55+ SYM B-NP O
36 1835 1836 15565293 / SYM B-NP O
37 1836 1837 15565293 - SYM B-VP O
38 1837 1839 15565293 29 CD B-NP O
39 1840 1846 15565293 microm NN I-NP O
40 1846 1847 15565293 ) ) O O
41 1847 1848 15565293 . . O O

1 1849 1851 15565293 In IN B-PP O
2 1852 1856 15565293 both DT B-NP O
3 1857 1861 15565293 sets NNS I-NP O
4 1862 1863 15565293 ( ( O O
5 1863 1867 15565293 four CD B-NP O
6 1867 1868 15565293 ) ) O O
7 1869 1871 15565293 of IN B-PP O
8 1872 1876 15565293 eyes NNS B-NP O
9 1877 1879 15565293 of IN B-PP O
10 1880 1883 15565293 the DT B-NP O
11 1884 1892 15565293 subjects NNS I-NP O
12 1893 1897 15565293 with IN B-PP O
13 1898 1908 15565293 persistent JJ B-NP O
14 1909 1915 15565293 visual JJ I-NP D014786
15 1916 1924 15565293 deficits NNS I-NP D014786
16 1925 1926 15565293 ( ( O O
17 1926 1934 15565293 patients NNS B-NP O
18 1935 1936 15565293 B NN B-NP O
19 1937 1940 15565293 and CC O O
20 1941 1942 15565293 C NN B-NP O
21 1942 1943 15565293 ) ) O O
22 1943 1944 15565293 , , O O
23 1945 1950 15565293 there EX B-NP O
24 1951 1954 15565293 was VBD B-VP O
25 1955 1957 15565293 an DT B-NP O
26 1958 1965 15565293 average JJ I-NP O
27 1966 1970 15565293 loss NN I-NP O
28 1971 1973 15565293 of IN B-PP O
29 1974 1977 15565293 79% NN B-NP O
30 1978 1980 15565293 of IN B-PP O
31 1981 1986 15565293 nerve NN B-NP O
32 1987 1992 15565293 fiber NN I-NP O
33 1993 2002 15565293 thickness NN I-NP O
34 2003 2005 15565293 in IN B-PP O
35 2006 2009 15565293 the DT B-NP O
36 2010 2018 15565293 temporal JJ I-NP O
37 2019 2027 15565293 quadrant NN I-NP O
38 2027 2028 15565293 . . O O

1 2029 2040 15565293 CONCLUSIONS NNS B-NP O
2 2040 2041 15565293 : : O O
3 2042 2045 15565293 The DT B-NP O
4 2046 2049 15565293 OCT NN I-NP O
5 2050 2057 15565293 results VBZ B-VP O
6 2058 2060 15565293 in IN B-PP O
7 2061 2066 15565293 these DT B-NP O
8 2067 2075 15565293 patients NNS I-NP O
9 2076 2080 15565293 with IN B-PP O
10 2081 2084 15565293 EMB NN B-NP D004977
11 2084 2085 15565293 - HYPH B-NP O
12 2085 2092 15565293 induced VBN I-NP O
13 2093 2098 15565293 optic JJ I-NP D009901
14 2099 2109 15565293 neuropathy NN I-NP D009901
15 2110 2114 15565293 show VBP B-VP O
16 2115 2127 15565293 considerable JJ B-NP O
17 2128 2132 15565293 loss NN I-NP O
18 2133 2143 15565293 especially RB B-ADVP O
19 2144 2146 15565293 of IN B-PP O
20 2147 2150 15565293 the DT B-NP O
21 2151 2159 15565293 temporal JJ I-NP O
22 2160 2166 15565293 fibers NNS I-NP O
23 2166 2167 15565293 . . O O

1 2168 2172 15565293 This DT B-NP O
2 2173 2175 15565293 is VBZ B-VP O
3 2176 2186 15565293 consistent JJ B-ADJP O
4 2187 2191 15565293 with IN B-PP O
5 2192 2197 15565293 prior JJ B-NP O
6 2198 2215 15565293 histopathological JJ I-NP O
7 2216 2223 15565293 studies NNS I-NP O
8 2224 2228 15565293 that WDT B-NP O
9 2229 2233 15565293 show VBP B-VP O
10 2234 2245 15565293 predominant JJ B-NP O
11 2246 2250 15565293 loss NN I-NP O
12 2251 2253 15565293 of IN B-PP O
13 2254 2259 15565293 parvo AFX B-NP O
14 2259 2260 15565293 - HYPH I-NP O
15 2260 2268 15565293 cellular JJ I-NP O
16 2269 2274 15565293 axons NNS I-NP O
17 2275 2276 15565293 ( ( O O
18 2276 2278 15565293 or CC O O
19 2279 2284 15565293 small JJ B-NP O
20 2284 2285 15565293 - HYPH I-NP O
21 2285 2292 15565293 caliber NN I-NP O
22 2293 2298 15565293 axons NNS I-NP O
23 2298 2299 15565293 ) ) O O
24 2300 2306 15565293 within IN B-PP O
25 2307 2310 15565293 the DT B-NP O
26 2311 2318 15565293 papillo AFX I-NP O
27 2318 2319 15565293 - HYPH I-NP O
28 2319 2326 15565293 macular JJ I-NP O
29 2327 2333 15565293 bundle NN I-NP O
30 2334 2336 15565293 in IN B-PP O
31 2337 2342 15565293 toxic JJ B-NP O
32 2343 2345 15565293 or CC I-NP O
33 2346 2356 15565293 hereditary JJ I-NP O
34 2357 2362 15565293 optic JJ I-NP D009901
35 2363 2375 15565293 neuropathies NNS I-NP D009901
36 2375 2376 15565293 . . O O

1 2377 2380 15565293 OCT NN B-NP O
2 2381 2384 15565293 can MD B-VP O
3 2385 2387 15565293 be VB I-VP O
4 2388 2389 15565293 a DT B-NP O
5 2390 2398 15565293 valuable JJ I-NP O
6 2399 2403 15565293 tool NN I-NP O
7 2404 2406 15565293 in IN B-PP O
8 2407 2410 15565293 the DT B-NP O
9 2411 2423 15565293 quantitative JJ I-NP O
10 2424 2432 15565293 analysis NN I-NP O
11 2433 2435 15565293 of IN B-PP O
12 2436 2441 15565293 optic JJ B-NP D009901
13 2442 2454 15565293 neuropathies NNS I-NP D009901
14 2454 2455 15565293 . . O O

1 2456 2468 15565293 Additionally RB B-ADVP O
2 2468 2469 15565293 , , O O
3 2470 2472 15565293 in IN B-PP O
4 2473 2478 15565293 terms NNS B-NP O
5 2479 2481 15565293 of IN B-PP O
6 2482 2492 15565293 management NN B-NP O
7 2493 2495 15565293 of IN B-PP O
8 2496 2499 15565293 EMB NN B-NP D004977
9 2499 2500 15565293 - HYPH B-NP O
10 2500 2507 15565293 induced VBN I-NP O
11 2508 2513 15565293 optic JJ I-NP D009901
12 2514 2524 15565293 neuropathy NN I-NP D009901
13 2524 2525 15565293 , , O O
14 2526 2528 15565293 it PRP B-NP O
15 2529 2531 15565293 is VBZ B-VP O
16 2532 2541 15565293 important JJ B-ADJP O
17 2542 2544 15565293 to TO B-VP O
18 2545 2553 15565293 properly RB I-VP O
19 2554 2560 15565293 manage VB I-VP O
20 2561 2571 15565293 ethambutol NN B-NP D004977
21 2572 2578 15565293 dosing NN I-NP O
22 2579 2581 15565293 in IN B-PP O
23 2582 2590 15565293 patients NNS B-NP O
24 2591 2595 15565293 with IN B-PP O
25 2596 2601 15565293 renal JJ B-NP D051437
26 2602 2612 15565293 impairment NN I-NP D051437
27 2613 2616 15565293 and CC O O
28 2617 2619 15565293 to TO B-VP O
29 2620 2627 15565293 achieve VB I-VP O
30 2628 2634 15565293 proper JJ B-NP O
31 2635 2645 15565293 transition NN I-NP O
32 2646 2648 15565293 to TO B-PP O
33 2649 2650 15565293 a DT B-NP O
34 2651 2662 15565293 maintenance NN I-NP O
35 2663 2667 15565293 dose NN I-NP O
36 2668 2672 15565293 once RB O O
37 2673 2675 15565293 an DT B-NP O
38 2676 2687 15565293 appropriate JJ I-NP O
39 2688 2695 15565293 loading NN I-NP O
40 2696 2700 15565293 dose NN I-NP O
41 2701 2704 15565293 has VBZ B-VP O
42 2705 2709 15565293 been VBN I-VP O
43 2710 2717 15565293 reached VBN I-VP O
44 2717 2718 15565293 . . O O

1 0 0 20164825 -DOCSTART- -X- -X- O

1 0 9 20164825 Metformin NN B-NP D008687
2 10 18 20164825 prevents VBZ B-VP O
3 19 31 20164825 experimental JJ B-NP O
4 32 42 20164825 gentamicin NN I-NP D005839
5 42 43 20164825 - HYPH B-NP O
6 43 50 20164825 induced VBN I-NP O
7 51 62 20164825 nephropathy NN I-NP D007674
8 63 65 20164825 by IN B-PP O
9 66 67 20164825 a DT B-NP O
10 68 80 20164825 mitochondria NNS I-NP O
11 80 81 20164825 - HYPH B-NP O
12 81 90 20164825 dependent JJ I-NP O
13 91 98 20164825 pathway NN I-NP O
14 98 99 20164825 . . O O
15 100 103 20164825 The DT B-NP O
16 104 116 20164825 antidiabetic JJ I-NP O
17 117 121 20164825 drug NN I-NP O
18 122 131 20164825 metformin NN I-NP D008687
19 132 135 20164825 can MD B-VP O
20 136 144 20164825 diminish VB I-VP O
21 145 154 20164825 apoptosis NN B-NP O
22 155 162 20164825 induced VBN B-VP O
23 163 165 20164825 by IN B-PP O
24 166 175 20164825 oxidative JJ B-NP O
25 176 182 20164825 stress NN I-NP O
26 183 185 20164825 in IN B-PP O
27 186 197 20164825 endothelial JJ B-NP O
28 198 203 20164825 cells NNS I-NP O
29 204 207 20164825 and CC O O
30 208 215 20164825 prevent VB B-VP O
31 216 224 20164825 vascular JJ B-NP D014652
32 225 236 20164825 dysfunction NN I-NP D014652
33 237 241 20164825 even RB B-ADVP O
34 242 244 20164825 in IN B-PP O
35 245 256 20164825 nondiabetic JJ B-NP O
36 257 265 20164825 patients NNS I-NP O
37 265 266 20164825 . . O O

1 267 271 20164825 Here RB B-ADVP O
2 272 274 20164825 we PRP B-NP O
3 275 281 20164825 tested VBD B-VP O
4 282 289 20164825 whether IN B-SBAR O
5 290 292 20164825 it PRP B-NP O
6 293 296 20164825 has VBZ B-VP O
7 297 298 20164825 a DT B-NP O
8 299 309 20164825 beneficial JJ I-NP O
9 310 316 20164825 effect NN I-NP O
10 317 319 20164825 in IN B-PP O
11 320 321 20164825 a DT B-NP O
12 322 325 20164825 rat NN I-NP O
13 326 331 20164825 model NN I-NP O
14 332 334 20164825 of IN B-PP O
15 335 345 20164825 gentamicin NN B-NP D005839
16 346 354 20164825 toxicity NN I-NP D064420
17 354 355 20164825 . . O O

1 356 369 20164825 Mitochondrial JJ B-NP O
2 370 378 20164825 analysis NN I-NP O
3 378 379 20164825 , , O O
4 380 391 20164825 respiration NN B-NP O
5 392 401 20164825 intensity NN I-NP O
6 401 402 20164825 , , O O
7 403 409 20164825 levels NNS B-NP O
8 410 412 20164825 of IN B-PP O
9 413 421 20164825 reactive JJ B-NP O
10 422 428 20164825 oxygen NN I-NP D010100
11 429 436 20164825 species NNS I-NP O
12 436 437 20164825 , , O O
13 438 450 20164825 permeability NN B-NP O
14 451 461 20164825 transition NN I-NP O
15 461 462 20164825 , , O O
16 463 466 20164825 and CC O O
17 467 477 20164825 cytochrome NN B-NP O
18 478 479 20164825 c NN I-NP O
19 480 487 20164825 release NN I-NP O
20 488 492 20164825 were VBD B-VP O
21 493 501 20164825 assessed VBN I-VP O
22 502 503 20164825 3 CD B-NP O
23 504 507 20164825 and CC I-NP O
24 508 509 20164825 6 CD I-NP O
25 510 514 20164825 days NNS I-NP O
26 515 520 20164825 after IN B-PP O
27 521 531 20164825 gentamicin NN B-NP D005839
28 532 546 20164825 administration NN I-NP O
29 546 547 20164825 . . O O

1 548 557 20164825 Metformin NN B-NP D008687
2 558 567 20164825 treatment NN I-NP O
3 568 573 20164825 fully RB B-VP O
4 574 581 20164825 blocked VBD I-VP O
5 582 592 20164825 gentamicin NN B-NP D005839
6 592 593 20164825 - HYPH O O
7 593 601 20164825 mediated VBN B-VP O
8 602 607 20164825 acute JJ B-NP D058186
9 608 613 20164825 renal JJ I-NP D058186
10 614 621 20164825 failure NN I-NP D058186
11 621 622 20164825 . . O O

1 623 627 20164825 This DT B-NP O
2 628 631 20164825 was VBD B-VP O
3 632 643 20164825 accompanied VBN I-VP O
4 644 646 20164825 by IN B-PP O
5 647 648 20164825 a DT B-NP O
6 649 654 20164825 lower JJR I-NP O
7 655 663 20164825 activity NN I-NP O
8 664 666 20164825 of IN B-PP O
9 667 668 20164825 N NN B-NP O
10 668 669 20164825 - HYPH B-NP O
11 669 675 20164825 acetyl NN I-NP O
12 675 676 20164825 - HYPH O O
13 676 680 20164825 beta SYM B-NP O
14 680 681 20164825 - HYPH B-NP O
15 681 682 20164825 D NN I-NP O
16 682 683 20164825 - HYPH O O
17 683 698 20164825 glucosaminidase NN B-NP O
18 698 699 20164825 , , O O
19 700 708 20164825 together RB B-ADVP O
20 709 713 20164825 with IN B-PP O
21 714 715 20164825 a DT B-NP O
22 716 724 20164825 decrease NN I-NP O
23 725 727 20164825 of IN B-PP O
24 728 733 20164825 lipid NN B-NP O
25 734 746 20164825 peroxidation NN I-NP O
26 747 750 20164825 and CC I-NP O
27 751 759 20164825 increase NN I-NP O
28 760 762 20164825 of IN B-PP O
29 763 774 20164825 antioxidant JJ B-NP O
30 775 782 20164825 systems NNS I-NP O
31 782 783 20164825 . . O O

1 784 793 20164825 Metformin NN B-NP D008687
2 794 798 20164825 also RB B-ADVP O
3 799 808 20164825 protected VBD B-VP O
4 809 812 20164825 the DT B-NP O
5 813 819 20164825 kidney NN I-NP O
6 820 824 20164825 from IN B-PP O
7 825 837 20164825 histological JJ B-NP O
8 838 844 20164825 damage NN I-NP O
9 845 846 20164825 6 CD B-NP O
10 847 851 20164825 days NNS I-NP O
11 852 857 20164825 after IN B-PP O
12 858 868 20164825 gentamicin NN B-NP D005839
13 869 883 20164825 administration NN I-NP O
14 883 884 20164825 . . O O

1 885 890 20164825 These DT B-NP O
2 891 893 20164825 in FW I-NP O
3 894 898 20164825 vivo FW I-NP O
4 899 906 20164825 markers NNS I-NP O
5 907 909 20164825 of IN B-PP O
6 910 916 20164825 kidney NN B-NP D007674
7 917 928 20164825 dysfunction NN I-NP D007674
8 929 932 20164825 and CC O O
9 933 938 20164825 their PRP$ B-NP O
10 939 949 20164825 correction NN I-NP O
11 950 952 20164825 by IN B-PP O
12 953 962 20164825 metformin NN B-NP D008687
13 963 967 20164825 were VBD B-VP O
14 968 980 20164825 complemented VBN I-VP O
15 981 983 20164825 by IN B-PP O
16 984 986 20164825 in FW B-NP O
17 987 992 20164825 vitro FW I-NP O
18 993 1000 20164825 studies NNS I-NP O
19 1001 1003 20164825 of IN B-PP O
20 1004 1017 20164825 mitochondrial JJ B-NP O
21 1018 1026 20164825 function NN I-NP O
22 1026 1027 20164825 . . O O

1 1028 1030 20164825 We PRP B-NP O
2 1031 1036 20164825 found VBD B-VP O
3 1037 1041 20164825 that IN B-SBAR O
4 1042 1052 20164825 gentamicin NN B-NP D005839
5 1053 1062 20164825 treatment NN I-NP O
6 1063 1071 20164825 depleted VBD B-VP O
7 1072 1083 20164825 respiratory JJ B-NP O
8 1084 1094 20164825 components NNS I-NP O
9 1095 1096 20164825 ( ( O O
10 1096 1106 20164825 cytochrome NN B-NP O
11 1107 1108 20164825 c NN I-NP O
12 1108 1109 20164825 , , O O
13 1110 1114 20164825 NADH NN B-NP O
14 1114 1115 20164825 ) ) O O
15 1115 1116 20164825 , , O O
16 1117 1125 20164825 probably RB B-ADVP O
17 1126 1129 20164825 due JJ B-ADJP O
18 1130 1132 20164825 to TO B-PP O
19 1133 1136 20164825 the DT B-NP O
20 1137 1144 20164825 opening NN I-NP O
21 1145 1147 20164825 of IN B-PP O
22 1148 1161 20164825 mitochondrial JJ B-NP O
23 1162 1172 20164825 transition NN I-NP O
24 1173 1178 20164825 pores NNS I-NP O
25 1178 1179 20164825 . . O O

1 1180 1185 20164825 These DT B-NP O
2 1186 1194 20164825 injuries NNS I-NP O
3 1194 1195 20164825 , , O O
4 1196 1202 20164825 partly RB B-VP O
5 1203 1211 20164825 mediated VBN I-VP O
6 1212 1214 20164825 by IN B-PP O
7 1215 1216 20164825 a DT B-NP O
8 1217 1221 20164825 rise NN I-NP O
9 1222 1224 20164825 in IN B-PP O
10 1225 1233 20164825 reactive JJ B-NP O
11 1234 1240 20164825 oxygen NN I-NP D010100
12 1241 1248 20164825 species NNS I-NP O
13 1249 1253 20164825 from IN B-PP O
14 1254 1257 20164825 the DT B-NP O
15 1258 1266 20164825 electron NN I-NP O
16 1267 1275 20164825 transfer NN I-NP O
17 1276 1281 20164825 chain NN I-NP O
18 1281 1282 20164825 , , O O
19 1283 1287 20164825 were VBD B-VP O
20 1288 1301 20164825 significantly RB I-VP O
21 1302 1311 20164825 decreased VBN I-VP O
22 1312 1314 20164825 by IN B-PP O
23 1315 1324 20164825 metformin NN B-NP D008687
24 1324 1325 20164825 . . O O

1 1326 1330 20164825 Thus RB B-ADVP O
2 1330 1331 20164825 , , O O
3 1332 1335 20164825 our PRP$ B-NP O
4 1336 1341 20164825 study NN I-NP O
5 1342 1350 20164825 suggests VBZ B-VP O
6 1351 1355 20164825 that IN B-SBAR O
7 1356 1367 20164825 pleiotropic JJ B-NP O
8 1368 1375 20164825 effects NNS I-NP O
9 1376 1378 20164825 of IN B-PP O
10 1379 1388 20164825 metformin NN B-NP D008687
11 1389 1392 20164825 can MD B-VP O
12 1393 1399 20164825 lessen VB I-VP O
13 1400 1410 20164825 gentamicin NN B-NP D005839
14 1411 1425 20164825 nephrotoxicity NN I-NP D007674
15 1426 1429 20164825 and CC O O
16 1430 1437 20164825 improve VB B-VP O
17 1438 1451 20164825 mitochondrial JJ B-NP O
18 1452 1463 20164825 homeostasis NN I-NP O
19 1463 1464 20164825 . . O O

1 0 0 6402369 -DOCSTART- -X- -X- O

1 0 9 6402369 Treatment NN B-NP O
2 10 12 6402369 of IN B-PP O
3 13 23 6402369 ifosfamide NN B-NP D007069
4 23 24 6402369 - HYPH B-NP O
5 24 31 6402369 induced VBN I-NP O
6 32 42 6402369 urothelial JJ I-NP D001745
7 43 51 6402369 toxicity NN I-NP D001745
8 52 54 6402369 by IN B-PP O
9 55 59 6402369 oral JJ B-NP O
10 60 74 6402369 administration NN I-NP O
11 75 77 6402369 of IN B-PP O
12 78 84 6402369 sodium NN B-NP D015080
13 85 86 6402369 2 CD I-NP D015080
14 86 87 6402369 - HYPH I-NP D015080
15 87 101 6402369 mercaptoethane NN I-NP D015080
16 102 112 6402369 sulphonate NN I-NP D015080
17 113 114 6402369 ( ( O O
18 114 119 6402369 MESNA NN B-NP D015080
19 119 120 6402369 ) ) O O
20 121 123 6402369 to TO B-PP O
21 124 132 6402369 patients NNS B-NP O
22 133 137 6402369 with IN B-PP O
23 138 148 6402369 inoperable JJ B-NP O
24 149 153 6402369 lung NN I-NP D008175
25 154 160 6402369 cancer NN I-NP D008175
26 160 161 6402369 . . O O
27 162 165 6402369 The DT B-NP O
28 166 176 6402369 protective JJ I-NP O
29 177 183 6402369 effect NN I-NP O
30 184 186 6402369 of IN B-PP O
31 187 191 6402369 oral JJ B-NP O
32 192 206 6402369 administration NN I-NP O
33 207 209 6402369 of IN B-PP O
34 210 213 6402369 the DT B-NP O
35 214 219 6402369 thiol NN I-NP D013438
36 220 228 6402369 compound NN I-NP O
37 229 235 6402369 sodium NN I-NP D015080
38 236 237 6402369 2 CD I-NP D015080
39 237 238 6402369 - HYPH I-NP D015080
40 238 252 6402369 mercaptoethane NN I-NP D015080
41 253 263 6402369 sulphonate NN I-NP D015080
42 264 265 6402369 ( ( O O
43 265 270 6402369 MESNA NN B-NP D015080
44 270 271 6402369 ) ) O O
45 272 279 6402369 against IN B-PP O
46 280 290 6402369 urothelial JJ B-NP D001745
47 291 299 6402369 toxicity NN I-NP D001745
48 300 307 6402369 induced VBN B-VP O
49 308 310 6402369 by IN B-PP O
50 311 321 6402369 ifosfamide NN B-NP D007069
51 322 323 6402369 ( ( O O
52 323 325 6402369 IF NN B-NP D007069
53 325 326 6402369 ) ) O O
54 327 330 6402369 was VBD B-VP O
55 331 337 6402369 tested VBN I-VP O
56 338 340 6402369 in IN B-PP O
57 341 342 6402369 a DT B-NP O
58 343 348 6402369 group NN I-NP O
59 349 351 6402369 of IN B-PP O
60 352 354 6402369 45 CD B-NP O
61 355 363 6402369 patients NNS I-NP O
62 364 368 6402369 with IN B-PP O
63 369 379 6402369 inoperable JJ B-NP O
64 380 384 6402369 lung NN I-NP D008175
65 385 391 6402369 cancer NN I-NP D008175
66 392 397 6402369 under IN B-PP O
67 398 407 6402369 treatment NN B-NP O
68 408 412 6402369 with IN B-PP O
69 413 415 6402369 IF NN B-NP D007069
70 416 417 6402369 ( ( O O
71 417 421 6402369 2250 CD B-NP O
72 422 424 6402369 mg NN I-NP O
73 424 425 6402369 / SYM B-NP O
74 425 427 6402369 m2 NN I-NP O
75 428 430 6402369 on IN B-PP O
76 431 435 6402369 days NNS B-NP O
77 436 437 6402369 2 CD B-NP O
78 437 438 6402369 - HYPH I-NP O
79 438 439 6402369 5 CD I-NP O
80 439 440 6402369 ) ) O O
81 441 443 6402369 as IN B-PP O
82 444 448 6402369 part NN B-NP O
83 449 451 6402369 of IN B-PP O
84 452 453 6402369 a DT B-NP O
85 454 470 6402369 polychemotherapy NN I-NP O
86 471 478 6402369 regimen NN I-NP O
87 479 487 6402369 repeated VBN B-VP O
88 488 490 6402369 in IN B-PP O
89 491 492 6402369 a DT B-NP O
90 493 494 6402369 4 CD I-NP O
91 494 495 6402369 - HYPH I-NP O
92 495 499 6402369 week NN I-NP O
93 500 505 6402369 cycle NN I-NP O
94 505 506 6402369 . . O O

1 507 512 6402369 MESNA NN B-NP D015080
2 513 516 6402369 was VBD B-VP O
3 517 522 6402369 given VBN I-VP O
4 523 529 6402369 orally RB B-ADVP O
5 530 532 6402369 on IN B-PP O
6 533 536 6402369 the DT B-NP O
7 537 541 6402369 days NNS I-NP O
8 542 544 6402369 of IN B-PP O
9 545 554 6402369 treatment NN B-NP O
10 555 559 6402369 with IN B-PP O
11 560 562 6402369 IF NN B-NP D007069
12 563 565 6402369 in IN B-PP O
13 566 567 6402369 3 CD B-NP O
14 568 573 6402369 doses NNS I-NP O
15 574 576 6402369 of IN B-PP O
16 577 580 6402369 840 CD B-NP O
17 581 583 6402369 mg NN I-NP O
18 583 584 6402369 / SYM B-NP O
19 584 586 6402369 m2 NN I-NP O
20 586 587 6402369 , , O O
21 588 592 6402369 each DT B-NP O
22 593 605 6402369 administered VBN B-VP O
23 606 608 6402369 at IN B-PP O
24 609 610 6402369 0 CD B-NP O
25 611 613 6402369 hr NN I-NP O
26 614 615 6402369 ( ( O O
27 615 616 6402369 = SYM B-VP O
28 617 626 6402369 injection NN B-NP O
29 627 629 6402369 of IN B-PP O
30 630 632 6402369 IF NN B-NP D007069
31 632 633 6402369 ) ) O O
32 633 634 6402369 , , O O
33 635 636 6402369 4 CD B-NP O
34 637 639 6402369 hr NN I-NP O
35 640 643 6402369 and CC O O
36 644 645 6402369 8 CD B-NP O
37 646 648 6402369 hr NN I-NP O
38 649 652 6402369 p.i NN I-NP O
39 652 653 6402369 . . O O

1 654 657 6402369 Out IN B-PP O
2 658 660 6402369 of IN B-PP O
3 661 662 6402369 a DT B-NP O
4 663 668 6402369 total NN I-NP O
5 669 671 6402369 of IN B-PP O
6 672 674 6402369 88 CD B-NP O
7 675 682 6402369 courses NNS I-NP O
8 683 685 6402369 of IN B-PP O
9 686 690 6402369 this DT B-NP O
10 691 700 6402369 treatment NN I-NP O
11 701 703 6402369 we PRP B-NP O
12 704 712 6402369 observed VBD B-VP O
13 713 715 6402369 10 CD B-NP O
14 716 724 6402369 episodes NNS I-NP O
15 725 727 6402369 of IN B-PP O
16 728 740 6402369 asymptomatic JJ B-NP O
17 741 752 6402369 microscopic JJ I-NP O
18 753 763 6402369 haematuria NN I-NP D006417
19 764 767 6402369 and CC O O
20 768 770 6402369 no DT B-NP O
21 771 779 6402369 episodes NNS I-NP O
22 780 782 6402369 of IN B-PP O
23 783 788 6402369 gross JJ B-NP O
24 789 799 6402369 haematuria NN I-NP D006417
25 799 800 6402369 . . O O

1 801 803 6402369 In IN B-PP O
2 804 808 6402369 this DT B-NP O
3 809 814 6402369 group NN I-NP O
4 815 817 6402369 of IN B-PP O
5 818 820 6402369 45 CD B-NP O
6 821 829 6402369 patients NNS I-NP O
7 830 835 6402369 under IN B-PP O
8 836 846 6402369 protection NN B-NP O
9 847 851 6402369 with IN B-PP O
10 852 857 6402369 MESNA NN B-NP D015080
11 858 863 6402369 there EX B-NP O
12 864 868 6402369 were VBD B-VP O
13 869 870 6402369 5 CD B-NP O
14 871 879 6402369 complete JJ I-NP O
15 880 890 6402369 remissions NNS I-NP O
16 891 894 6402369 and CC O O
17 895 896 6402369 9 CD B-NP O
18 897 904 6402369 partial JJ I-NP O
19 905 915 6402369 remissions NNS I-NP O
20 916 917 6402369 ( ( O O
21 917 922 6402369 total JJ B-NP O
22 923 926 6402369 31% NN I-NP O
23 926 927 6402369 ) ) O O
24 927 928 6402369 . . O O

1 929 930 6402369 A DT B-NP O
2 931 938 6402369 further JJ I-NP O
3 939 944 6402369 group NN I-NP O
4 945 947 6402369 of IN B-PP O
5 948 950 6402369 25 CD B-NP O
6 951 959 6402369 patients NNS I-NP O
7 960 965 6402369 under IN B-PP O
8 966 982 6402369 polychemotherapy NN B-NP O
9 983 987 6402369 with IN B-PP O
10 988 990 6402369 IF NN B-NP D007069
11 991 995 6402369 were VBD B-VP O
12 996 1003 6402369 treated VBN I-VP O
13 1004 1006 6402369 by IN B-PP O
14 1007 1019 6402369 conventional JJ B-NP O
15 1020 1032 6402369 prophylactic JJ I-NP O
16 1033 1041 6402369 measures NNS I-NP O
17 1042 1043 6402369 ( ( O O
18 1043 1049 6402369 raised VBN B-NP O
19 1050 1055 6402369 fluid NN I-NP O
20 1056 1062 6402369 intake NN I-NP O
21 1063 1066 6402369 and CC O O
22 1067 1073 6402369 forced VBN B-NP O
23 1074 1082 6402369 diuresis NN I-NP O
24 1082 1083 6402369 ) ) O O
25 1083 1084 6402369 . . O O

1 1085 1087 6402369 In IN B-PP O
2 1088 1092 6402369 this DT B-NP O
3 1093 1098 6402369 group NN I-NP O
4 1099 1104 6402369 there EX B-NP O
5 1105 1109 6402369 were VBD B-VP O
6 1110 1111 6402369 1 CD B-NP O
7 1112 1120 6402369 complete JJ I-NP O
8 1121 1124 6402369 and CC O O
9 1125 1126 6402369 5 CD B-NP O
10 1127 1134 6402369 partial JJ I-NP O
11 1135 1145 6402369 remissions NNS I-NP O
12 1146 1147 6402369 ( ( O O
13 1147 1152 6402369 total JJ B-NP O
14 1153 1156 6402369 24% NN I-NP O
15 1156 1157 6402369 ) ) O O
16 1157 1158 6402369 , , O O
17 1159 1162 6402369 but CC O O
18 1163 1169 6402369 nearly RB B-NP O
19 1170 1173 6402369 all DT I-NP O
20 1174 1182 6402369 patients NNS I-NP O
21 1183 1192 6402369 developed VBD B-VP O
22 1193 1199 6402369 either CC O O
23 1200 1205 6402369 gross JJ B-NP O
24 1206 1216 6402369 haematuria NN I-NP D006417
25 1217 1220 6402369 and CC O O
26 1220 1221 6402369 / SYM B-NP O
27 1221 1223 6402369 or CC O O
28 1224 1232 6402369 symptoms NNS B-NP O
29 1233 1235 6402369 of IN B-PP O
30 1236 1243 6402369 bladder NN B-NP D001745
31 1244 1254 6402369 irritation NN I-NP D001745
32 1255 1256 6402369 ( ( O O
33 1256 1264 6402369 cystitis NN B-NP D003556
34 1265 1268 6402369 and CC O O
35 1269 1281 6402369 pollakisuria NN B-NP D014555
36 1281 1282 6402369 ) ) O O
37 1282 1283 6402369 . . O O

1 1284 1289 6402369 There EX B-NP O
2 1290 1294 6402369 were VBD B-VP O
3 1295 1297 6402369 no DT B-NP O
4 1298 1309 6402369 appreciable JJ I-NP O
5 1310 1321 6402369 differences NNS I-NP O
6 1322 1329 6402369 between IN B-PP O
7 1330 1333 6402369 the DT B-NP O
8 1334 1339 6402369 MESNA NN I-NP D015080
9 1340 1346 6402369 series NN I-NP O
10 1347 1350 6402369 and CC O O
11 1351 1354 6402369 the DT B-NP O
12 1355 1367 6402369 conventional JJ I-NP O
13 1368 1379 6402369 prophylaxis NN I-NP O
14 1380 1386 6402369 series NN I-NP O
15 1387 1391 6402369 with IN B-PP O
16 1392 1399 6402369 respect NN B-NP O
17 1400 1402 6402369 to TO B-PP O
18 1403 1409 6402369 either CC O O
19 1410 1424 6402369 haematological JJ B-NP O
20 1425 1427 6402369 or CC I-NP O
21 1428 1436 6402369 systemic JJ I-NP O
22 1437 1445 6402369 toxicity NN I-NP D064420
23 1446 1448 6402369 of IN B-PP O
24 1449 1452 6402369 the DT B-NP O
25 1453 1463 6402369 cytostatic JJ I-NP O
26 1464 1473 6402369 treatment NN I-NP O
27 1473 1474 6402369 . . O O

1 1475 1478 6402369 Our PRP$ B-NP O
2 1479 1486 6402369 results NNS I-NP O
3 1487 1494 6402369 support VBP B-VP O
4 1495 1498 6402369 the DT B-NP O
5 1499 1503 6402369 view NN I-NP O
6 1504 1508 6402369 that IN B-SBAR O
7 1509 1514 6402369 MESNA NN B-NP D015080
8 1514 1515 6402369 , , O O
9 1516 1521 6402369 given VBN B-VP O
10 1522 1528 6402369 orally RB B-ADVP O
11 1529 1531 6402369 in IN B-PP O
12 1532 1543 6402369 conjunction NN B-NP O
13 1544 1548 6402369 with IN B-PP O
14 1549 1557 6402369 combined JJ B-NP O
15 1558 1568 6402369 cytostatic JJ I-NP O
16 1569 1577 6402369 regimens NNS I-NP O
17 1578 1583 6402369 which WDT B-NP O
18 1584 1591 6402369 include VBP B-VP O
19 1592 1594 6402369 IF NN B-NP D007069
20 1594 1595 6402369 , , O O
21 1596 1606 6402369 simplifies VBZ B-VP O
22 1607 1610 6402369 the DT B-NP O
23 1611 1620 6402369 treatment NN I-NP O
24 1621 1624 6402369 and CC O O
25 1625 1633 6402369 provides VBZ B-VP O
26 1634 1641 6402369 optimum JJ B-NP O
27 1642 1652 6402369 protection NN I-NP O
28 1653 1656 6402369 for IN B-PP O
29 1657 1660 6402369 the DT B-NP O
30 1661 1668 6402369 urinary JJ I-NP O
31 1669 1679 6402369 epithelium NN I-NP O
32 1679 1680 6402369 . . O O

1 1681 1691 6402369 Protection NN B-NP O
2 1692 1696 6402369 with IN B-PP O
3 1697 1701 6402369 oral JJ B-NP O
4 1702 1707 6402369 MESNA NN I-NP D015080
5 1708 1710 6402369 is VBZ B-VP O
6 1711 1723 6402369 particularly RB B-ADJP O
7 1724 1732 6402369 suitable JJ I-ADJP O
8 1733 1736 6402369 for IN B-PP O
9 1737 1748 6402369 outpatients NNS B-NP O
10 1748 1749 6402369 . . O O

1 0 0 11058428 -DOCSTART- -X- -X- O

1 0 4 11058428 High JJ B-NP O
2 4 5 11058428 - HYPH I-NP O
3 5 9 11058428 dose NN I-NP O
4 10 28 11058428 methylprednisolone NN I-NP D008775
5 29 32 11058428 may MD B-VP O
6 33 35 11058428 do VB I-VP O
7 36 40 11058428 more JJR B-NP O
8 41 45 11058428 harm NN I-NP O
9 46 49 11058428 for IN B-PP O
10 50 56 11058428 spinal JJ B-NP D013119
11 57 61 11058428 cord NN I-NP D013119
12 62 68 11058428 injury NN I-NP D013119
13 68 69 11058428 . . O O
14 70 77 11058428 Because IN B-PP O
15 78 80 11058428 of IN I-PP O
16 81 84 11058428 the DT B-NP O
17 85 93 11058428 National NNP I-NP O
18 94 99 11058428 Acute NNP I-NP O
19 100 106 11058428 Spinal NNP I-NP D013119
20 107 111 11058428 Cord NNP I-NP D013119
21 112 118 11058428 Injury NNP I-NP D013119
22 119 126 11058428 Studies NNP I-NP O
23 127 128 11058428 ( ( O O
24 128 134 11058428 NASCIS NNP B-NP O
25 134 135 11058428 ) ) O O
26 135 136 11058428 , , O O
27 137 141 11058428 high JJ B-NP O
28 141 142 11058428 - HYPH I-NP O
29 142 146 11058428 dose NN I-NP O
30 147 165 11058428 methylprednisolone NN I-NP D008775
31 166 172 11058428 became VBD B-VP O
32 173 176 11058428 the DT B-NP O
33 177 185 11058428 standard NN I-NP O
34 186 188 11058428 of IN B-PP O
35 189 193 11058428 care NN B-NP O
36 194 197 11058428 for IN B-PP O
37 198 201 11058428 the DT B-NP O
38 202 207 11058428 acute JJ I-NP O
39 208 214 11058428 spinal JJ I-NP D013119
40 215 219 11058428 cord NN I-NP D013119
41 220 226 11058428 injury NN I-NP D013119
42 226 227 11058428 . . O O

1 228 230 11058428 In IN B-PP O
2 231 234 11058428 the DT B-NP O
3 235 241 11058428 NASCIS NNP I-NP O
4 241 242 11058428 , , O O
5 243 248 11058428 there EX B-NP O
6 249 252 11058428 was VBD B-VP O
7 253 255 11058428 no DT B-NP O
8 256 263 11058428 mention NN I-NP O
9 264 273 11058428 regarding VBG B-VP O
10 274 277 11058428 the DT B-NP O
11 278 289 11058428 possibility NN I-NP O
12 290 292 11058428 of IN B-PP O
13 293 298 11058428 acute JJ B-NP O
14 299 313 11058428 corticosteroid NN I-NP D000305
15 314 322 11058428 myopathy NN I-NP D009135
16 323 327 11058428 that IN B-NP O
17 328 332 11058428 high JJ B-NP O
18 332 333 11058428 - HYPH I-NP O
19 333 337 11058428 dose NN I-NP O
20 338 356 11058428 methylprednisolone NN I-NP D008775
21 357 360 11058428 may MD B-VP O
22 361 366 11058428 cause VB I-VP O
23 366 367 11058428 . . O O

1 368 371 11058428 The DT B-NP O
2 372 378 11058428 dosage NN I-NP O
3 379 381 11058428 of IN B-PP O
4 382 400 11058428 methylprednisolone NN B-NP D008775
5 401 412 11058428 recommended VBN B-VP O
6 413 415 11058428 by IN B-PP O
7 416 419 11058428 the DT B-NP O
8 420 426 11058428 NASCIS NN I-NP O
9 427 428 11058428 3 CD I-NP O
10 429 431 11058428 is VBZ B-VP O
11 432 435 11058428 the DT B-NP O
12 436 443 11058428 highest JJS I-NP O
13 444 448 11058428 dose NN I-NP O
14 449 451 11058428 of IN B-PP O
15 452 460 11058428 steroids NNS B-NP D013256
16 461 465 11058428 ever RB B-VP O
17 466 471 11058428 being VBG I-VP O
18 472 476 11058428 used VBN I-VP O
19 477 483 11058428 during IN B-PP O
20 484 485 11058428 a DT B-NP O
21 486 487 11058428 2 CD I-NP O
22 487 488 11058428 - HYPH I-NP O
23 488 491 11058428 day NN I-NP O
24 492 498 11058428 period NN I-NP O
25 499 502 11058428 for IN B-PP O
26 503 506 11058428 any DT B-NP O
27 507 515 11058428 clinical JJ I-NP O
28 516 525 11058428 condition NN I-NP O
29 525 526 11058428 . . O O

1 527 529 11058428 We PRP B-NP O
2 530 541 11058428 hypothesize VBP B-VP O
3 542 546 11058428 that IN B-SBAR O
4 547 549 11058428 it PRP B-NP O
5 550 553 11058428 may MD B-VP O
6 554 559 11058428 cause VB I-VP O
7 560 564 11058428 some DT B-NP O
8 565 571 11058428 damage NN I-NP D009135
9 572 574 11058428 to TO B-PP D009135
10 575 578 11058428 the DT B-NP D009135
11 579 585 11058428 muscle NN I-NP D009135
12 586 588 11058428 of IN B-PP O
13 589 595 11058428 spinal JJ B-NP D013119
14 596 600 11058428 cord NN I-NP D013119
15 601 607 11058428 injury NN I-NP D013119
16 608 616 11058428 patients NNS I-NP O
17 616 617 11058428 . . O O

1 618 625 11058428 Further RB B-ADVP O
2 625 626 11058428 , , O O
3 627 634 11058428 steroid NN B-NP D013256
4 635 643 11058428 myopathy NN I-NP D009135
5 644 652 11058428 recovers VBZ B-VP O
6 653 662 11058428 naturally RB B-ADVP O
7 663 666 11058428 and CC O O
8 667 670 11058428 the DT B-NP O
9 671 683 11058428 neurological JJ I-NP O
10 684 695 11058428 improvement NN I-NP O
11 696 701 11058428 shown VBN B-VP O
12 702 704 11058428 in IN B-PP O
13 705 708 11058428 the DT B-NP O
14 709 715 11058428 NASCIS NNP I-NP O
15 716 719 11058428 may MD B-VP O
16 720 722 11058428 be VB I-VP O
17 723 727 11058428 just RB B-NP O
18 728 729 11058428 a DT I-NP O
19 730 739 11058428 recording NN I-NP O
20 740 742 11058428 of IN B-PP O
21 743 747 11058428 this DT B-NP O
22 748 755 11058428 natural JJ I-NP O
23 756 761 11058428 motor NN I-NP O
24 762 770 11058428 recovery NN I-NP O
25 771 775 11058428 from IN B-PP O
26 776 779 11058428 the DT B-NP O
27 780 787 11058428 steroid NN I-NP D013256
28 788 796 11058428 myopathy NN I-NP D009135
29 796 797 11058428 , , O O
30 798 805 11058428 instead RB B-PP O
31 806 808 11058428 of IN I-PP O
32 809 812 11058428 any DT B-NP O
33 813 823 11058428 protection NN I-NP O
34 824 828 11058428 that IN B-SBAR O
35 829 847 11058428 methylprednisolone NN B-NP D008775
36 848 854 11058428 offers VBZ B-VP O
37 855 857 11058428 to TO B-PP O
38 858 861 11058428 the DT B-NP O
39 862 868 11058428 spinal JJ I-NP D013119
40 869 873 11058428 cord NN I-NP D013119
41 874 880 11058428 injury NN I-NP D013119
42 880 881 11058428 . . O O

1 882 884 11058428 To TO B-PP O
2 885 888 11058428 our PRP$ B-NP O
3 889 898 11058428 knowledge NN I-NP O
4 898 899 11058428 , , O O
5 900 904 11058428 this DT B-NP O
6 905 907 11058428 is VBZ B-VP O
7 908 911 11058428 the DT B-NP O
8 912 917 11058428 first JJ I-NP O
9 918 928 11058428 discussion NN I-NP O
10 929 940 11058428 considering VBG B-VP O
11 941 944 11058428 the DT B-NP O
12 945 956 11058428 possibility NN I-NP O
13 957 961 11058428 that IN B-SBAR O
14 962 965 11058428 the DT B-NP O
15 966 984 11058428 methylprednisolone NN I-NP D008775
16 985 996 11058428 recommended VBN B-VP O
17 997 999 11058428 by IN B-PP O
18 1000 1006 11058428 NASCIS NNP B-NP O
19 1007 1010 11058428 may MD B-VP O
20 1011 1016 11058428 cause VB I-VP O
21 1017 1022 11058428 acute JJ B-NP O
22 1023 1037 11058428 corticosteroid NN I-NP D000305
23 1038 1046 11058428 myopathy NN I-NP D009135
24 1046 1047 11058428 . . O O

1 0 0 9205462 -DOCSTART- -X- -X- O

1 0 9 9205462 Granulosa NN B-NP C537296
2 10 14 9205462 cell NN I-NP C537296
3 15 20 9205462 tumor NN I-NP C537296
4 21 23 9205462 of IN B-PP C537296
5 24 27 9205462 the DT B-NP C537296
6 28 33 9205462 ovary NN I-NP C537296
7 34 44 9205462 associated VBN B-VP O
8 45 49 9205462 with IN B-PP O
9 50 60 9205462 antecedent JJ B-NP O
10 61 70 9205462 tamoxifen NN I-NP D013629
11 71 74 9205462 use NN I-NP O
12 74 75 9205462 . . I-NP O
13 76 86 9205462 BACKGROUND NN I-NP O
14 86 87 9205462 : : O O
15 88 97 9205462 Increased VBN B-NP O
16 98 107 9205462 attention NN I-NP O
17 108 111 9205462 has VBZ B-VP O
18 112 116 9205462 been VBN I-VP O
19 117 124 9205462 focused VBN I-VP O
20 125 133 9205462 recently RB B-ADVP O
21 134 136 9205462 on IN B-PP O
22 137 140 9205462 the DT B-NP O
23 141 151 9205462 estrogenic JJ I-NP O
24 152 159 9205462 effects NNS I-NP O
25 160 162 9205462 of IN B-PP O
26 163 172 9205462 tamoxifen NN B-NP D013629
27 172 173 9205462 . . O O

1 174 180 9205462 Review NN B-NP O
2 181 183 9205462 of IN B-PP O
3 184 187 9205462 the DT B-NP O
4 188 198 9205462 literature NN I-NP O
5 199 206 9205462 reveals VBZ B-VP O
6 207 209 9205462 an DT B-NP O
7 210 221 9205462 association NN I-NP O
8 222 229 9205462 between IN B-PP O
9 230 239 9205462 tamoxifen NN B-NP D013629
10 240 243 9205462 use NN I-NP O
11 244 247 9205462 and CC O O
12 248 259 9205462 gynecologic JJ B-NP O
13 260 266 9205462 tumors NNS I-NP D009369
14 266 267 9205462 . . O O

1 268 272 9205462 CASE NN B-NP O
2 272 273 9205462 : : O O
3 274 275 9205462 A DT B-NP O
4 276 278 9205462 52 CD I-NP O
5 278 279 9205462 - HYPH I-NP O
6 279 283 9205462 year NN I-NP O
7 283 284 9205462 - HYPH O O
8 284 287 9205462 old JJ B-NP O
9 288 302 9205462 postmenopausal JJ I-NP O
10 303 308 9205462 woman NN I-NP O
11 309 312 9205462 was VBD B-VP O
12 313 320 9205462 treated VBN I-VP O
13 321 325 9205462 with IN B-PP O
14 326 335 9205462 tamoxifen NN B-NP D013629
15 336 339 9205462 for IN B-PP O
16 340 345 9205462 stage NN B-NP O
17 346 348 9205462 II CD I-NP O
18 349 357 9205462 estrogen NN I-NP D004967
19 358 366 9205462 receptor NN I-NP O
20 366 367 9205462 - HYPH B-NP O
21 367 375 9205462 positive JJ I-NP O
22 376 382 9205462 breast NN I-NP D001943
23 383 392 9205462 carcinoma NN I-NP D001943
24 392 393 9205462 . . O O

1 394 397 9205462 Her PRP$ B-NP O
2 398 407 9205462 aspartate NN I-NP D001224
3 408 420 9205462 transaminase NN I-NP O
4 421 424 9205462 and CC I-NP O
5 425 432 9205462 alanine NN I-NP D000409
6 433 445 9205462 transaminase NN I-NP O
7 446 452 9205462 levels NNS I-NP O
8 453 461 9205462 increase VBP B-VP O
9 462 470 9205462 markedly RB B-ADVP O
10 471 476 9205462 after IN B-PP O
11 477 478 9205462 6 CD B-NP O
12 479 485 9205462 months NNS I-NP O
13 486 488 9205462 of IN B-PP O
14 489 498 9205462 tamoxifen NN B-NP D013629
15 499 502 9205462 use NN I-NP O
16 502 503 9205462 . . O O

1 504 509 9205462 After IN B-PP O
2 510 512 9205462 an DT B-NP O
3 513 523 9205462 additional JJ I-NP O
4 524 526 9205462 17 CD I-NP O
5 527 533 9205462 months NNS I-NP O
6 534 536 9205462 of IN B-PP O
7 537 545 9205462 elevated JJ B-NP O
8 546 551 9205462 serum NN I-NP O
9 552 565 9205462 transaminases NNS I-NP O
10 565 566 9205462 , , O O
11 567 570 9205462 the DT B-NP O
12 571 578 9205462 patient NN I-NP O
13 579 582 9205462 was VBD B-VP O
14 583 588 9205462 found VBN I-VP O
15 589 591 9205462 to TO I-VP O
16 592 596 9205462 have VB I-VP O
17 597 598 9205462 a DT B-NP O
18 599 604 9205462 stage NN I-NP O
19 605 607 9205462 Ic NN I-NP O
20 608 617 9205462 granulosa NN I-NP C537296
21 618 622 9205462 cell NN I-NP C537296
22 623 628 9205462 tumor NN I-NP C537296
23 629 631 9205462 of IN B-PP C537296
24 632 635 9205462 the DT B-NP C537296
25 636 641 9205462 ovary NN I-NP C537296
26 641 642 9205462 . . O O

1 643 653 9205462 CONCLUSION NN B-NP O
2 653 654 9205462 : : O O
3 655 663 9205462 Patients NNS B-NP O
4 664 668 9205462 with IN B-PP O
5 669 678 9205462 tamoxifen NN B-NP D013629
6 678 679 9205462 - HYPH O O
7 679 686 9205462 induced VBN B-NP O
8 687 692 9205462 liver NN I-NP D017093
9 693 704 9205462 dysfunction NN I-NP D017093
10 705 708 9205462 may MD B-VP O
11 709 711 9205462 be VB I-VP O
12 712 714 9205462 at IN B-PP O
13 715 724 9205462 increased VBN B-NP O
14 725 729 9205462 risk NN I-NP O
15 730 733 9205462 for IN B-PP O
16 734 743 9205462 granulosa NN B-NP D006106
17 744 748 9205462 cell NN I-NP D006106
18 749 755 9205462 tumors NNS I-NP D006106
19 756 763 9205462 because IN B-PP O
20 764 766 9205462 of IN I-PP O
21 767 778 9205462 alterations NNS B-NP O
22 779 781 9205462 in IN B-PP O
23 782 791 9205462 tamoxifen NN B-NP D013629
24 792 802 9205462 metabolism NN I-NP O
25 802 803 9205462 . . O O

1 0 0 17042884 -DOCSTART- -X- -X- O

1 0 7 17042884 Placebo AFX B-NP O
2 7 8 17042884 - HYPH I-NP O
3 8 13 17042884 level NN I-NP O
4 14 23 17042884 incidence NN I-NP O
5 24 26 17042884 of IN B-PP O
6 27 41 17042884 extrapyramidal JJ B-NP D001480
7 42 50 17042884 symptoms NNS I-NP D001480
8 51 52 17042884 ( ( O O
9 52 55 17042884 EPS NNS B-NP D001480
10 55 56 17042884 ) ) O O
11 57 61 17042884 with IN B-PP O
12 62 72 17042884 quetiapine NN B-NP C069541
13 73 75 17042884 in IN B-PP O
14 76 86 17042884 controlled JJ B-NP O
15 87 94 17042884 studies NNS I-NP O
16 95 97 17042884 of IN B-PP O
17 98 106 17042884 patients NNS B-NP O
18 107 111 17042884 with IN B-PP O
19 112 119 17042884 bipolar JJ B-NP D001714
20 120 125 17042884 mania NN I-NP D001714
21 125 126 17042884 . . I-NP O
22 127 137 17042884 OBJECTIVES NNS I-NP O
23 137 138 17042884 : : O O
24 139 141 17042884 To TO B-VP O
25 142 150 17042884 evaluate VB I-VP O
26 151 165 17042884 extrapyramidal JJ B-NP D001480
27 166 174 17042884 symptoms NNS I-NP D001480
28 175 176 17042884 ( ( O O
29 176 179 17042884 EPS NNS B-NP D001480
30 179 180 17042884 ) ) O O
31 180 181 17042884 , , O O
32 182 191 17042884 including VBG B-PP O
33 192 201 17042884 akathisia NN B-NP D017109
34 201 202 17042884 , , O O
35 203 207 17042884 with IN B-PP O
36 208 218 17042884 quetiapine NN B-NP C069541
37 219 221 17042884 in IN B-PP O
38 222 230 17042884 patients NNS B-NP O
39 231 235 17042884 with IN B-PP O
40 236 243 17042884 bipolar JJ B-NP D001714
41 244 249 17042884 mania NN I-NP D001714
42 249 250 17042884 . . O O

1 251 258 17042884 METHODS NNS B-NP O
2 258 259 17042884 : : O O
3 260 264 17042884 Data NNS B-NP O
4 265 269 17042884 were VBD B-VP O
5 270 278 17042884 analyzed VBN I-VP O
6 279 283 17042884 from IN B-PP O
7 284 288 17042884 four CD B-NP O
8 289 298 17042884 similarly RB I-NP O
9 299 307 17042884 designed VBN I-NP O
10 307 308 17042884 , , I-NP O
11 309 319 17042884 randomized VBN I-NP O
12 319 320 17042884 , , I-NP O
13 321 327 17042884 double JJ I-NP O
14 327 328 17042884 - HYPH I-NP O
15 328 333 17042884 blind JJ I-NP O
16 333 334 17042884 , , I-NP O
17 335 336 17042884 3 CD I-NP O
18 336 337 17042884 - HYPH I-NP O
19 338 340 17042884 to TO B-PP O
20 341 343 17042884 12 CD B-NP O
21 343 344 17042884 - HYPH I-NP O
22 344 348 17042884 week NN I-NP O
23 349 356 17042884 studies NNS I-NP O
24 356 357 17042884 . . O O

1 358 361 17042884 Two CD B-NP O
2 362 369 17042884 studies NNS I-NP O
3 370 379 17042884 evaluated VBD B-VP O
4 380 390 17042884 quetiapine NN B-NP C069541
5 391 402 17042884 monotherapy NN I-NP O
6 403 404 17042884 ( ( O O
7 404 406 17042884 up RB B-NP O
8 407 409 17042884 to TO I-NP O
9 410 413 17042884 800 CD I-NP O
10 414 416 17042884 mg NN I-NP O
11 416 417 17042884 / SYM B-NP O
12 417 420 17042884 day NN I-NP O
13 420 421 17042884 ) ) O O
14 422 423 17042884 ( ( O O
15 423 424 17042884 n NN B-NP O
16 425 426 17042884 = SYM B-VP O
17 427 430 17042884 209 CD B-NP O
18 430 431 17042884 ) ) O O
19 432 438 17042884 versus CC O O
20 439 446 17042884 placebo NN B-NP O
21 447 448 17042884 ( ( O O
22 448 449 17042884 n NN B-NP O
23 450 451 17042884 = SYM B-VP O
24 452 455 17042884 198 CD B-NP O
25 455 456 17042884 ) ) O O
26 456 457 17042884 , , O O
27 458 462 17042884 with IN B-PP O
28 463 470 17042884 lithium NN B-NP D008094
29 471 473 17042884 or CC I-NP O
30 474 485 17042884 haloperidol NN I-NP D006220
31 486 497 17042884 monotherapy NN I-NP O
32 498 500 17042884 as IN B-PP O
33 501 511 17042884 respective JJ B-NP O
34 512 518 17042884 active JJ I-NP O
35 519 527 17042884 controls NNS I-NP O
36 527 528 17042884 . . O O

1 529 532 17042884 Two CD B-NP O
2 533 540 17042884 studies NNS I-NP O
3 541 550 17042884 evaluated VBD B-VP O
4 551 561 17042884 quetiapine NN B-NP C069541
5 562 563 17042884 ( ( O O
6 563 565 17042884 up RB B-NP O
7 566 568 17042884 to TO I-NP O
8 569 572 17042884 800 CD I-NP O
9 573 575 17042884 mg NN I-NP O
10 575 576 17042884 / SYM B-NP O
11 576 579 17042884 day NN I-NP O
12 579 580 17042884 ) ) O O
13 581 583 17042884 in IN B-PP O
14 584 595 17042884 combination NN B-NP O
15 596 600 17042884 with IN B-PP O
16 601 602 17042884 a DT B-NP O
17 603 607 17042884 mood NN I-NP O
18 608 618 17042884 stabilizer NN I-NP O
19 619 620 17042884 ( ( O O
20 620 627 17042884 lithium NN B-NP D008094
21 628 630 17042884 or CC O O
22 631 641 17042884 divalproex NN B-NP D014635
23 641 642 17042884 , , O O
24 643 646 17042884 QTP NN B-NP C069541
25 647 648 17042884 + SYM B-NP O
26 649 651 17042884 Li NN I-NP D008094
27 651 652 17042884 / SYM I-NP O
28 652 655 17042884 DVP NN I-NP D014635
29 655 656 17042884 ) ) O O
30 657 658 17042884 ( ( O O
31 658 659 17042884 n NN B-NP O
32 660 661 17042884 = SYM B-VP O
33 662 665 17042884 196 CD B-NP O
34 665 666 17042884 ) ) O O
35 667 675 17042884 compared VBN B-VP O
36 676 678 17042884 to TO B-PP O
37 679 686 17042884 placebo NN B-NP O
38 687 690 17042884 and CC I-NP O
39 691 695 17042884 mood NN I-NP O
40 696 706 17042884 stabilizer NN I-NP O
41 707 708 17042884 ( ( O O
42 708 711 17042884 PBO NN B-NP O
43 712 713 17042884 + SYM B-NP O
44 714 716 17042884 Li NN I-NP D008094
45 716 717 17042884 / SYM I-NP O
46 717 720 17042884 DVP NN I-NP D014635
47 720 721 17042884 ) ) O O
48 722 723 17042884 ( ( O O
49 723 724 17042884 n NN B-NP O
50 725 726 17042884 = SYM B-VP O
51 727 730 17042884 203 CD B-NP O
52 730 731 17042884 ) ) O O
53 731 732 17042884 . . O O

1 733 747 17042884 Extrapyramidal JJ B-NP D001480
2 748 756 17042884 symptoms NNS I-NP D001480
3 757 761 17042884 were VBD B-VP O
4 762 771 17042884 evaluated VBN I-VP O
5 772 777 17042884 using VBG B-VP O
6 778 781 17042884 the DT B-NP O
7 782 789 17042884 Simpson NNP I-NP O
8 789 790 17042884 - HYPH I-NP O
9 790 795 17042884 Angus NNP I-NP O
10 796 801 17042884 Scale NNP I-NP O
11 802 803 17042884 ( ( O O
12 803 806 17042884 SAS NNP B-NP O
13 806 807 17042884 ) ) O O
14 807 808 17042884 , , O O
15 809 812 17042884 the DT B-NP O
16 813 819 17042884 Barnes NNP I-NP O
17 820 829 17042884 Akathisia NNP I-NP O
18 830 836 17042884 Rating NNP I-NP O
19 837 842 17042884 Scale NNP I-NP O
20 843 844 17042884 ( ( O O
21 844 848 17042884 BARS NNP B-NP O
22 848 849 17042884 ) ) O O
23 849 850 17042884 , , O O
24 851 858 17042884 adverse JJ B-NP O
25 859 864 17042884 event NN I-NP O
26 865 872 17042884 reports NNS I-NP O
27 873 876 17042884 and CC O O
28 877 892 17042884 anticholinergic JJ B-NP O
29 893 897 17042884 drug NN I-NP O
30 898 903 17042884 usage NN I-NP O
31 903 904 17042884 . . O O

1 905 912 17042884 RESULTS NNS B-NP O
2 912 913 17042884 : : O O
3 914 917 17042884 The DT B-NP O
4 918 927 17042884 incidence NN I-NP O
5 928 930 17042884 of IN B-PP O
6 931 934 17042884 EPS NN B-NP D001480
7 934 935 17042884 - HYPH O O
8 935 942 17042884 related VBN B-NP O
9 943 950 17042884 adverse JJ I-NP O
10 951 957 17042884 events NNS I-NP O
11 957 958 17042884 , , O O
12 959 968 17042884 including VBG B-PP O
13 969 978 17042884 akathisia NN B-NP D017109
14 978 979 17042884 , , O O
15 980 983 17042884 was VBD B-VP O
16 984 986 17042884 no DT B-NP O
17 987 996 17042884 different JJ I-NP O
18 997 1001 17042884 with IN B-PP O
19 1002 1012 17042884 quetiapine NN B-NP C069541
20 1013 1024 17042884 monotherapy NN I-NP O
21 1025 1026 17042884 ( ( O O
22 1026 1031 17042884 12.9% NN B-NP O
23 1031 1032 17042884 ) ) O O
24 1033 1037 17042884 than IN B-PP O
25 1038 1042 17042884 with IN B-PP O
26 1043 1050 17042884 placebo NN B-NP O
27 1051 1052 17042884 ( ( O O
28 1052 1057 17042884 13.1% NN B-NP O
29 1057 1058 17042884 ) ) O O
30 1058 1059 17042884 . . O O

1 1060 1069 17042884 Similarly RB B-ADVP O
2 1069 1070 17042884 , , O O
3 1071 1074 17042884 EPS NN B-NP D001480
4 1074 1075 17042884 - HYPH O O
5 1075 1082 17042884 related VBN B-NP O
6 1083 1090 17042884 adverse JJ I-NP O
7 1091 1097 17042884 events NNS I-NP O
8 1098 1102 17042884 with IN B-PP O
9 1103 1106 17042884 QTP NN B-NP C069541
10 1107 1108 17042884 + SYM I-NP O
11 1109 1111 17042884 Li NN I-NP D008094
12 1111 1112 17042884 / SYM O O
13 1112 1115 17042884 DVP NN B-NP D014635
14 1116 1117 17042884 ( ( O O
15 1117 1122 17042884 21.4% NN B-NP O
16 1122 1123 17042884 ) ) O O
17 1124 1128 17042884 were VBD B-VP O
18 1129 1131 17042884 no RB B-ADJP O
19 1132 1141 17042884 different JJ I-ADJP O
20 1142 1146 17042884 than IN B-PP O
21 1147 1151 17042884 with IN B-PP O
22 1152 1155 17042884 PBO NN B-NP O
23 1156 1157 17042884 + SYM B-NP O
24 1158 1160 17042884 Li NN I-NP D008094
25 1160 1161 17042884 / SYM B-NP O
26 1161 1164 17042884 DVP NN I-NP D014635
27 1165 1166 17042884 ( ( O O
28 1166 1171 17042884 19.2% CD B-NP O
29 1171 1172 17042884 ) ) O O
30 1172 1173 17042884 . . O O

1 1174 1181 17042884 Adverse JJ B-NP O
2 1182 1188 17042884 events NNS I-NP O
3 1189 1196 17042884 related VBN B-VP O
4 1197 1199 17042884 to TO B-PP O
5 1200 1203 17042884 EPS NNP B-NP D001480
6 1204 1212 17042884 occurred VBD B-VP O
7 1213 1215 17042884 in IN B-PP O
8 1216 1221 17042884 59.6% CD B-NP O
9 1222 1224 17042884 of IN B-PP O
10 1225 1233 17042884 patients NNS B-NP O
11 1234 1241 17042884 treated VBN B-VP O
12 1242 1246 17042884 with IN B-PP O
13 1247 1258 17042884 haloperidol NN B-NP D006220
14 1259 1260 17042884 ( ( O O
15 1260 1261 17042884 n NN B-NP O
16 1262 1263 17042884 = SYM B-VP O
17 1264 1266 17042884 99 CD B-NP O
18 1266 1267 17042884 ) ) O O
19 1268 1279 17042884 monotherapy NN B-NP O
20 1279 1280 17042884 , , O O
21 1281 1288 17042884 whereas IN O O
22 1289 1294 17042884 26.5% CD B-NP O
23 1295 1297 17042884 of IN B-PP O
24 1298 1306 17042884 patients NNS B-NP O
25 1307 1314 17042884 treated VBN B-VP O
26 1315 1319 17042884 with IN B-PP O
27 1320 1327 17042884 lithium NN B-NP D008094
28 1328 1329 17042884 ( ( O O
29 1329 1330 17042884 n NN B-NP O
30 1331 1332 17042884 = SYM B-VP O
31 1333 1335 17042884 98 CD B-NP O
32 1335 1336 17042884 ) ) O O
33 1337 1348 17042884 monotherapy NN B-NP O
34 1349 1360 17042884 experienced VBD B-VP O
35 1361 1368 17042884 adverse JJ B-NP O
36 1369 1375 17042884 events NNS I-NP O
37 1376 1383 17042884 related VBN B-VP O
38 1384 1386 17042884 to TO B-PP O
39 1387 1390 17042884 EPS NNP B-NP D001480
40 1390 1391 17042884 . . O O

1 1392 1395 17042884 The DT B-NP O
2 1396 1405 17042884 incidence NN I-NP O
3 1406 1408 17042884 of IN B-PP O
4 1409 1418 17042884 akathisia NN B-NP D017109
5 1419 1422 17042884 was VBD B-VP O
6 1423 1426 17042884 low JJ B-ADJP O
7 1427 1430 17042884 and CC I-ADJP O
8 1431 1438 17042884 similar JJ I-ADJP O
9 1439 1443 17042884 with IN B-PP O
10 1444 1454 17042884 quetiapine NN B-NP C069541
11 1455 1466 17042884 monotherapy NN I-NP O
12 1467 1468 17042884 ( ( O O
13 1468 1472 17042884 3.3% NN B-NP O
14 1472 1473 17042884 ) ) O O
15 1474 1477 17042884 and CC O O
16 1478 1485 17042884 placebo NN B-NP O
17 1486 1487 17042884 ( ( O O
18 1487 1491 17042884 6.1% CD B-NP O
19 1491 1492 17042884 ) ) O O
20 1492 1493 17042884 , , O O
21 1494 1497 17042884 and CC O O
22 1498 1502 17042884 with IN B-PP O
23 1503 1506 17042884 QTP NN B-NP C069541
24 1507 1508 17042884 + SYM B-NP O
25 1509 1511 17042884 Li NN I-NP D008094
26 1511 1512 17042884 / SYM O O
27 1512 1515 17042884 DVP NN B-NP D014635
28 1516 1517 17042884 ( ( O O
29 1517 1521 17042884 3.6% NN B-NP O
30 1521 1522 17042884 ) ) O O
31 1523 1526 17042884 and CC O O
32 1527 1530 17042884 PBO NN B-NP O
33 1531 1532 17042884 + SYM O O
34 1533 1535 17042884 Li NN O D008094
35 1535 1536 17042884 / SYM O O
36 1536 1539 17042884 DVP NN B-NP D014635
37 1540 1541 17042884 ( ( O O
38 1541 1545 17042884 4.9% CD B-NP O
39 1545 1546 17042884 ) ) O O
40 1546 1547 17042884 . . O O

1 1548 1555 17042884 Lithium NN B-NP D008094
2 1556 1559 17042884 was VBD B-VP O
3 1560 1570 17042884 associated VBN I-VP O
4 1571 1575 17042884 with IN B-PP O
5 1576 1577 17042884 a DT B-NP O
6 1578 1591 17042884 significantly RB I-NP O
7 1592 1598 17042884 higher JJR I-NP O
8 1599 1608 17042884 incidence NN I-NP O
9 1609 1610 17042884 ( ( O O
10 1610 1611 17042884 p NN B-NP O
11 1612 1613 17042884 < SYM O O
12 1614 1618 17042884 0.05 CD B-NP O
13 1618 1619 17042884 ) ) O O
14 1620 1622 17042884 of IN B-PP O
15 1623 1629 17042884 tremor NN B-NP D014202
16 1630 1631 17042884 ( ( O O
17 1631 1636 17042884 18.4% NN B-NP O
18 1636 1637 17042884 ) ) O O
19 1638 1642 17042884 than IN B-PP O
20 1643 1653 17042884 quetiapine NN B-NP C069541
21 1654 1655 17042884 ( ( O O
22 1655 1659 17042884 5.6% NN B-NP O
23 1659 1660 17042884 ) ) O O
24 1660 1661 17042884 ; : O O
25 1662 1672 17042884 cerebellar JJ B-NP O
26 1673 1679 17042884 tremor NN I-NP D014202
27 1679 1680 17042884 , , O O
28 1681 1686 17042884 which WDT B-NP O
29 1687 1689 17042884 is VBZ B-VP O
30 1690 1691 17042884 a DT B-NP O
31 1692 1697 17042884 known JJ I-NP O
32 1698 1705 17042884 adverse JJ I-NP O
33 1706 1712 17042884 effect NN I-NP O
34 1713 1715 17042884 of IN B-PP O
35 1716 1723 17042884 lithium NN B-NP D008094
36 1723 1724 17042884 , , O O
37 1725 1728 17042884 may MD B-VP O
38 1729 1733 17042884 have VB I-VP O
39 1734 1745 17042884 contributed VBN I-VP O
40 1746 1748 17042884 to TO B-PP O
41 1749 1752 17042884 the DT B-NP O
42 1753 1761 17042884 elevated VBN I-NP O
43 1762 1766 17042884 rate NN I-NP O
44 1767 1769 17042884 of IN B-PP O
45 1770 1776 17042884 tremor NN B-NP D014202
46 1777 1779 17042884 in IN B-PP O
47 1780 1788 17042884 patients NNS B-NP O
48 1789 1798 17042884 receiving VBG B-VP O
49 1799 1806 17042884 lithium NN B-NP D008094
50 1807 1814 17042884 therapy NN I-NP O
51 1814 1815 17042884 . . O O

1 1816 1827 17042884 Haloperidol NN B-NP D006220
2 1828 1835 17042884 induced VBD B-VP O
3 1836 1837 17042884 a DT B-NP O
4 1838 1851 17042884 significantly RB I-NP O
5 1852 1858 17042884 higher JJR I-NP O
6 1859 1868 17042884 incidence NN I-NP O
7 1869 1870 17042884 ( ( O O
8 1870 1871 17042884 p NN B-NP O
9 1872 1873 17042884 < SYM O O
10 1874 1879 17042884 0.001 CD B-NP O
11 1879 1880 17042884 ) ) O O
12 1881 1883 17042884 of IN B-PP O
13 1884 1893 17042884 akathisia NN B-NP D017109
14 1894 1895 17042884 ( ( O O
15 1895 1900 17042884 33.3% CD B-NP O
16 1901 1907 17042884 versus CC I-NP O
17 1908 1912 17042884 5.9% CD I-NP O
18 1912 1913 17042884 ) ) O O
19 1913 1914 17042884 , , O O
20 1915 1921 17042884 tremor NN B-NP D014202
21 1922 1923 17042884 ( ( O O
22 1923 1928 17042884 30.3% CD B-NP O
23 1929 1935 17042884 versus CC I-NP O
24 1936 1940 17042884 7.8% CD I-NP O
25 1940 1941 17042884 ) ) O O
26 1941 1942 17042884 , , O O
27 1943 1946 17042884 and CC O O
28 1947 1961 17042884 extrapyramidal JJ B-NP D001480
29 1962 1970 17042884 syndrome NN I-NP D001480
30 1971 1972 17042884 ( ( O O
31 1972 1977 17042884 35.4% CD B-NP O
32 1978 1984 17042884 versus CC I-NP O
33 1985 1989 17042884 5.9% CD I-NP O
34 1989 1990 17042884 ) ) O O
35 1991 1995 17042884 than IN B-PP O
36 1996 2006 17042884 quetiapine NN B-NP C069541
37 2006 2007 17042884 . . O O

1 2008 2010 17042884 No DT B-NP O
2 2011 2022 17042884 significant JJ I-NP O
3 2023 2034 17042884 differences NNS I-NP O
4 2035 2039 17042884 were VBD B-VP O
5 2040 2048 17042884 observed VBN I-VP O
6 2049 2056 17042884 between IN B-PP O
7 2057 2067 17042884 quetiapine NN B-NP C069541
8 2068 2071 17042884 and CC I-NP O
9 2072 2079 17042884 placebo NN I-NP O
10 2080 2082 17042884 on IN B-PP O
11 2083 2086 17042884 SAS NNP B-NP O
12 2087 2090 17042884 and CC I-NP O
13 2091 2095 17042884 BARS NNP I-NP O
14 2096 2102 17042884 scores NNS I-NP O
15 2102 2103 17042884 . . O O

1 2104 2119 17042884 Anticholinergic JJ B-NP O
2 2120 2123 17042884 use NN I-NP O
3 2124 2127 17042884 was VBD B-VP O
4 2128 2131 17042884 low JJ B-ADJP O
5 2132 2135 17042884 and CC I-ADJP O
6 2136 2143 17042884 similar JJ I-ADJP O
7 2144 2148 17042884 with IN B-PP O
8 2149 2159 17042884 quetiapine NN B-NP C069541
9 2160 2162 17042884 or CC I-NP O
10 2163 2170 17042884 placebo NN I-NP O
11 2170 2171 17042884 . . O O

1 2172 2183 17042884 CONCLUSIONS NNS B-NP O
2 2183 2184 17042884 : : O O
3 2185 2187 17042884 In IN B-PP O
4 2188 2195 17042884 bipolar JJ B-NP D001714
5 2196 2201 17042884 mania NN I-NP D001714
6 2201 2202 17042884 , , O O
7 2203 2206 17042884 the DT B-NP O
8 2207 2216 17042884 incidence NN I-NP O
9 2217 2219 17042884 of IN B-PP O
10 2220 2223 17042884 EPS NN B-NP D001480
11 2223 2224 17042884 , , O O
12 2225 2234 17042884 including VBG B-PP O
13 2235 2244 17042884 akathisia NN B-NP D017109
14 2244 2245 17042884 , , O O
15 2246 2250 17042884 with IN B-PP O
16 2251 2261 17042884 quetiapine NN B-NP C069541
17 2262 2269 17042884 therapy NN I-NP O
18 2270 2272 17042884 is VBZ B-VP O
19 2273 2280 17042884 similar JJ B-ADJP O
20 2281 2283 17042884 to TO B-PP O
21 2284 2288 17042884 that DT B-NP O
22 2289 2293 17042884 with IN B-PP O
23 2294 2301 17042884 placebo NN B-NP O
24 2301 2302 17042884 . . O O

1 0 0 7843916 -DOCSTART- -X- -X- O

1 0 13 7843916 Dexamethasone NN B-NP D003907
2 13 14 7843916 - HYPH O O
3 14 21 7843916 induced VBN B-NP O
4 22 28 7843916 ocular JJ I-NP D009798
5 29 41 7843916 hypertension NN I-NP D009798
6 42 44 7843916 in IN B-PP O
7 45 54 7843916 perfusion NN B-NP O
8 54 55 7843916 - HYPH O O
9 55 63 7843916 cultured VBN B-NP O
10 64 69 7843916 human JJ I-NP O
11 70 74 7843916 eyes NNS I-NP O
12 74 75 7843916 . . O O
13 76 83 7843916 PURPOSE NN B-NP O
14 83 84 7843916 : : O O
15 85 99 7843916 Glucocorticoid NN B-NP O
16 100 114 7843916 administration NN I-NP O
17 115 118 7843916 can MD B-VP O
18 119 123 7843916 lead VB I-VP O
19 124 126 7843916 to TO B-PP O
20 127 130 7843916 the DT B-NP O
21 131 142 7843916 development NN I-NP O
22 143 145 7843916 of IN B-PP O
23 146 152 7843916 ocular JJ B-NP D009798
24 153 165 7843916 hypertension NN I-NP D009798
25 166 169 7843916 and CC I-NP O
26 170 184 7843916 corticosteroid NN I-NP D005901
27 185 193 7843916 glaucoma NN I-NP D005901
28 194 196 7843916 in IN B-PP O
29 197 198 7843916 a DT B-NP O
30 199 205 7843916 subset NN I-NP O
31 206 208 7843916 of IN B-PP O
32 209 212 7843916 the DT B-NP O
33 213 223 7843916 population NN I-NP O
34 224 231 7843916 through IN B-PP O
35 232 233 7843916 a DT B-NP O
36 234 242 7843916 decrease NN I-NP O
37 243 245 7843916 in IN B-PP O
38 246 249 7843916 the DT B-NP O
39 250 257 7843916 aqueous JJ I-NP O
40 258 263 7843916 humor NN I-NP O
41 264 271 7843916 outflow NN I-NP O
42 272 280 7843916 facility NN I-NP O
43 280 281 7843916 . . O O

1 282 285 7843916 The DT B-NP O
2 286 293 7843916 purpose NN I-NP O
3 294 296 7843916 of IN B-PP O
4 297 301 7843916 this DT B-NP O
5 302 307 7843916 study NN I-NP O
6 308 311 7843916 was VBD B-VP O
7 312 314 7843916 to TO B-VP O
8 315 324 7843916 determine VB I-VP O
9 325 332 7843916 whether IN B-SBAR O
10 333 347 7843916 glucocorticoid NN B-NP O
11 348 357 7843916 treatment NN I-NP O
12 358 361 7843916 can MD B-VP O
13 362 370 7843916 directly RB I-VP O
14 371 377 7843916 affect VB I-VP O
15 378 381 7843916 the DT B-NP O
16 382 389 7843916 outflow NN I-NP O
17 390 398 7843916 facility NN I-NP O
18 399 401 7843916 of IN B-PP O
19 402 410 7843916 isolated VBN B-NP O
20 410 411 7843916 , , I-NP O
21 412 421 7843916 perfusion NN I-NP O
22 421 422 7843916 - HYPH I-NP O
23 422 430 7843916 cultured VBN B-NP O
24 431 436 7843916 human JJ I-NP O
25 437 441 7843916 eyes NNS I-NP O
26 441 442 7843916 . . O O

1 443 450 7843916 METHODS NNS B-NP O
2 450 451 7843916 : : O O
3 452 455 7843916 The DT B-NP O
4 456 464 7843916 anterior JJ I-NP O
5 465 473 7843916 segments NNS I-NP O
6 474 476 7843916 of IN B-PP O
7 477 482 7843916 human JJ B-NP O
8 483 488 7843916 donor NN I-NP O
9 489 493 7843916 eyes NNS I-NP O
10 494 498 7843916 from IN B-PP O
11 499 507 7843916 regional JJ B-NP O
12 508 511 7843916 eye NN I-NP O
13 512 517 7843916 banks NNS I-NP O
14 518 522 7843916 were VBD B-VP O
15 523 529 7843916 placed VBN I-VP O
16 530 532 7843916 in IN B-PP O
17 533 534 7843916 a DT B-NP O
18 535 543 7843916 constant JJ I-NP O
19 544 548 7843916 flow NN I-NP O
20 548 549 7843916 , , O O
21 550 558 7843916 variable JJ B-NP O
22 559 567 7843916 pressure NN I-NP O
23 568 577 7843916 perfusion NN I-NP O
24 578 585 7843916 culture NN I-NP O
25 586 592 7843916 system NN I-NP O
26 592 593 7843916 . . O O

1 594 600 7843916 Paired VBN B-NP O
2 601 605 7843916 eyes NNS I-NP O
3 606 610 7843916 were VBD B-VP O
4 611 619 7843916 perfused VBN I-VP O
5 620 622 7843916 in IN B-PP O
6 623 628 7843916 serum NN B-NP O
7 628 629 7843916 - HYPH O O
8 629 633 7843916 free JJ B-NP O
9 634 639 7843916 media NNS I-NP O
10 640 644 7843916 with IN B-PP O
11 645 647 7843916 or CC B-PP O
12 648 655 7843916 without IN B-PP O
13 656 659 7843916 10( CD B-NP O
14 659 660 7843916 - HYPH I-NP O
15 660 662 7843916 7) CD I-NP O
16 663 664 7843916 M NN I-NP O
17 665 678 7843916 dexamethasone NN I-NP D003907
18 679 682 7843916 for IN B-PP O
19 683 685 7843916 12 CD B-NP O
20 686 690 7843916 days NNS I-NP O
21 690 691 7843916 . . O O

1 692 703 7843916 Intraocular JJ B-NP O
2 704 712 7843916 pressure NN I-NP O
3 713 716 7843916 was VBD B-VP O
4 717 726 7843916 monitored VBN I-VP O
5 727 732 7843916 daily RB B-ADVP O
6 732 733 7843916 . . O O

1 734 739 7843916 After IN B-PP O
2 740 750 7843916 incubation NN B-NP O
3 750 751 7843916 , , O O
4 752 755 7843916 the DT B-NP O
5 756 760 7843916 eyes NNS I-NP O
6 761 765 7843916 were VBD B-VP O
7 766 781 7843916 morphologically RB I-VP O
8 782 795 7843916 characterized VBN I-VP O
9 796 798 7843916 by IN B-PP O
10 799 804 7843916 light NN B-NP O
11 805 815 7843916 microscopy NN I-NP O
12 815 816 7843916 , , O O
13 817 829 7843916 transmission NN B-NP O
14 830 833 7843916 and CC O O
15 834 842 7843916 scanning NN B-NP O
16 843 851 7843916 electron NN I-NP O
17 852 862 7843916 microscopy NN I-NP O
18 862 863 7843916 , , O O
19 864 867 7843916 and CC O O
20 868 876 7843916 scanning NN B-NP O
21 877 882 7843916 laser NN I-NP O
22 883 891 7843916 confocal JJ I-NP O
23 892 902 7843916 microscopy NN I-NP O
24 902 903 7843916 . . O O

1 904 911 7843916 RESULTS NNS B-NP O
2 911 912 7843916 : : O O
3 913 914 7843916 A DT B-NP O
4 915 926 7843916 significant JJ I-NP O
5 927 935 7843916 increase NN I-NP O
6 936 938 7843916 in IN B-PP O
7 939 950 7843916 intraocular JJ B-NP O
8 951 959 7843916 pressure NN I-NP O
9 960 969 7843916 developed VBN B-VP O
10 970 972 7843916 in IN B-PP O
11 973 975 7843916 13 CD B-NP O
12 976 978 7843916 of IN B-PP O
13 979 982 7843916 the DT B-NP O
14 983 985 7843916 44 CD I-NP O
15 986 991 7843916 pairs NNS I-NP O
16 992 994 7843916 of IN B-PP O
17 995 999 7843916 eyes NNS B-NP O
18 1000 1008 7843916 perfused VBN B-VP O
19 1009 1013 7843916 with IN B-PP O
20 1014 1027 7843916 dexamethasone NN B-NP D003907
21 1028 1032 7843916 with IN B-PP O
22 1033 1035 7843916 an DT B-NP O
23 1036 1043 7843916 average JJ I-NP O
24 1044 1052 7843916 pressure NN I-NP O
25 1053 1057 7843916 rise NN I-NP O
26 1058 1060 7843916 of IN B-PP O
27 1061 1065 7843916 17.5 CD B-NP O
28 1066 1067 7843916 + SYM O O
29 1067 1068 7843916 / SYM O O
30 1068 1069 7843916 - SYM O O
31 1070 1073 7843916 3.8 CD B-NP O
32 1074 1076 7843916 mm NN I-NP O
33 1077 1079 7843916 Hg NN I-NP O
34 1080 1085 7843916 after IN B-PP O
35 1086 1088 7843916 12 CD B-NP O
36 1089 1093 7843916 days NNS I-NP O
37 1094 1096 7843916 of IN B-PP O
38 1097 1110 7843916 dexamethasone NN B-NP D003907
39 1111 1119 7843916 exposure NN I-NP O
40 1119 1120 7843916 . . O O

1 1121 1124 7843916 The DT B-NP O
2 1125 1138 7843916 contralateral JJ I-NP O
3 1139 1146 7843916 control NN I-NP O
4 1147 1151 7843916 eyes NNS I-NP O
5 1151 1152 7843916 , , O O
6 1153 1158 7843916 which WDT B-NP O
7 1159 1162 7843916 did VBD B-VP O
8 1163 1166 7843916 not RB I-VP O
9 1167 1174 7843916 receive VB I-VP O
10 1175 1188 7843916 dexamethasone NN B-NP D003907
11 1188 1189 7843916 , , O O
12 1190 1200 7843916 maintained VBD B-VP O
13 1201 1202 7843916 a DT B-NP O
14 1203 1209 7843916 stable JJ I-NP O
15 1210 1221 7843916 intraocular JJ I-NP O
16 1222 1230 7843916 pressure NN I-NP O
17 1231 1237 7843916 during IN B-PP O
18 1238 1241 7843916 the DT B-NP O
19 1242 1246 7843916 same JJ I-NP O
20 1247 1253 7843916 period NN I-NP O
21 1253 1254 7843916 . . O O

1 1255 1258 7843916 The DT B-NP O
2 1259 1266 7843916 outflow NN I-NP O
3 1267 1274 7843916 pathway NN I-NP O
4 1275 1277 7843916 of IN B-PP O
5 1278 1281 7843916 the DT B-NP O
6 1282 1291 7843916 untreated JJ I-NP O
7 1292 1296 7843916 eyes NNS I-NP O
8 1297 1305 7843916 appeared VBD B-VP O
9 1306 1321 7843916 morphologically RB B-ADJP O
10 1322 1328 7843916 normal JJ I-ADJP O
11 1328 1329 7843916 . . O O

1 1330 1332 7843916 In IN B-PP O
2 1333 1341 7843916 contrast NN B-NP O
3 1341 1342 7843916 , , O O
4 1343 1346 7843916 the DT B-NP O
5 1347 1360 7843916 dexamethasone NN I-NP D003907
6 1360 1361 7843916 - HYPH O O
7 1361 1368 7843916 treated VBN B-VP O
8 1369 1381 7843916 hypertensive JJ B-NP D009798
9 1382 1386 7843916 eyes NNS I-NP D009798
10 1387 1390 7843916 had VBD B-VP O
11 1391 1400 7843916 thickened VBN I-VP O
12 1401 1411 7843916 trabecular JJ B-NP O
13 1412 1417 7843916 beams NNS I-NP O
14 1417 1418 7843916 , , O O
15 1419 1428 7843916 decreased VBD B-VP O
16 1429 1444 7843916 intertrabecular JJ B-NP O
17 1445 1451 7843916 spaces NNS I-NP O
18 1451 1452 7843916 , , O O
19 1453 1462 7843916 thickened VBD B-VP O
20 1463 1479 7843916 juxtacanalicular JJ B-NP O
21 1480 1486 7843916 tissue NN I-NP O
22 1486 1487 7843916 , , O O
23 1488 1497 7843916 activated VBN B-NP O
24 1498 1508 7843916 trabecular JJ I-NP O
25 1509 1517 7843916 meshwork NN I-NP O
26 1518 1523 7843916 cells NNS I-NP O
27 1523 1524 7843916 , , O O
28 1525 1528 7843916 and CC O O
29 1529 1538 7843916 increased VBN B-NP O
30 1539 1546 7843916 amounts NNS I-NP O
31 1547 1549 7843916 of IN B-PP O
32 1550 1565 7843916 amorphogranular JJ B-NP O
33 1566 1579 7843916 extracellular JJ I-NP O
34 1580 1588 7843916 material NN I-NP O
35 1588 1589 7843916 , , O O
36 1590 1600 7843916 especially RB B-ADVP O
37 1601 1603 7843916 in IN B-PP O
38 1604 1607 7843916 the DT B-NP O
39 1608 1624 7843916 juxtacanalicular JJ I-NP O
40 1625 1631 7843916 tissue NN I-NP O
41 1632 1635 7843916 and CC B-PP O
42 1636 1643 7843916 beneath IN B-PP O
43 1644 1647 7843916 the DT B-NP O
44 1648 1659 7843916 endothelial JJ I-NP O
45 1660 1666 7843916 lining NN I-NP O
46 1667 1669 7843916 of IN B-PP O
47 1670 1673 7843916 the DT B-NP O
48 1674 1679 7843916 canal NN I-NP O
49 1680 1682 7843916 of IN B-PP O
50 1683 1690 7843916 Schlemm NNP B-NP O
51 1690 1691 7843916 . . O O

1 1692 1695 7843916 The DT B-NP O
2 1696 1709 7843916 dexamethasone NN I-NP D003907
3 1709 1710 7843916 - HYPH B-VP O
4 1710 1717 7843916 treated VBN B-NP O
5 1718 1730 7843916 nonresponder JJ I-NP O
6 1731 1735 7843916 eyes NNS I-NP O
7 1736 1744 7843916 appeared VBD B-VP O
8 1745 1747 7843916 to TO I-VP O
9 1748 1750 7843916 be VB I-VP O
10 1751 1766 7843916 morphologically RB B-ADJP O
11 1767 1774 7843916 similar JJ I-ADJP O
12 1775 1777 7843916 to TO B-PP O
13 1778 1781 7843916 the DT B-NP O
14 1782 1791 7843916 untreated JJ I-NP O
15 1792 1796 7843916 eyes NNS I-NP O
16 1796 1797 7843916 , , O O
17 1798 1806 7843916 although IN B-SBAR O
18 1807 1814 7843916 several JJ B-NP O
19 1815 1821 7843916 subtle JJ I-NP O
20 1822 1835 7843916 dexamethasone NN I-NP D003907
21 1835 1836 7843916 - HYPH O O
22 1836 1843 7843916 induced VBN B-NP O
23 1844 1855 7843916 morphologic JJ I-NP O
24 1856 1863 7843916 changes NNS I-NP O
25 1864 1868 7843916 were VBD B-VP O
26 1869 1876 7843916 evident JJ B-ADJP O
27 1876 1877 7843916 . . O O

1 1878 1888 7843916 CONCLUSION NN B-NP O
2 1888 1889 7843916 : : O O
3 1890 1903 7843916 Dexamethasone NN B-NP D003907
4 1904 1913 7843916 treatment NN I-NP O
5 1914 1916 7843916 of IN B-PP O
6 1917 1925 7843916 isolated VBN B-NP O
7 1925 1926 7843916 , , I-NP O
8 1927 1936 7843916 perfusion NN I-NP O
9 1936 1937 7843916 - HYPH I-NP O
10 1937 1945 7843916 cultured VBN B-NP O
11 1946 1951 7843916 human JJ I-NP O
12 1952 1956 7843916 eyes NNS I-NP O
13 1957 1960 7843916 led VBD B-VP O
14 1961 1963 7843916 to TO B-PP O
15 1964 1967 7843916 the DT B-NP O
16 1968 1978 7843916 generation NN I-NP O
17 1979 1981 7843916 of IN B-PP O
18 1982 1988 7843916 ocular JJ B-NP D009798
19 1989 2001 7843916 hypertension NN I-NP D009798
20 2002 2004 7843916 in IN B-PP O
21 2005 2018 7843916 approximately RB B-NP O
22 2019 2022 7843916 30% CD I-NP O
23 2023 2025 7843916 of IN B-PP O
24 2026 2029 7843916 the DT B-NP O
25 2030 2043 7843916 dexamethasone NN I-NP D003907
26 2043 2044 7843916 - HYPH B-NP O
27 2044 2051 7843916 treated VBN I-NP O
28 2052 2056 7843916 eyes NNS I-NP O
29 2056 2057 7843916 . . O O

1 2058 2065 7843916 Steroid NN B-NP D013256
2 2066 2075 7843916 treatment NN I-NP O
3 2076 2084 7843916 resulted VBD B-VP O
4 2085 2087 7843916 in IN B-PP O
5 2088 2099 7843916 morphologic JJ B-NP O
6 2100 2107 7843916 changes NNS I-NP O
7 2108 2110 7843916 in IN B-PP O
8 2111 2114 7843916 the DT B-NP O
9 2115 2125 7843916 trabecular JJ I-NP O
10 2126 2134 7843916 meshwork NN I-NP O
11 2135 2142 7843916 similar JJ B-ADJP O
12 2143 2145 7843916 to TO B-PP O
13 2146 2151 7843916 those DT B-NP O
14 2152 2160 7843916 reported VBN B-VP O
15 2161 2164 7843916 for IN B-PP O
16 2165 2179 7843916 corticosteroid NN B-NP D005901
17 2180 2188 7843916 glaucoma NN I-NP D005901
18 2189 2192 7843916 and CC O O
19 2193 2197 7843916 open JJ B-NP D005902
20 2198 2203 7843916 angle NN I-NP D005902
21 2204 2212 7843916 glaucoma NN I-NP D005902
22 2212 2213 7843916 . . O O

1 2214 2218 7843916 This DT B-NP O
2 2219 2225 7843916 system NN I-NP O
3 2226 2229 7843916 may MD B-VP O
4 2230 2237 7843916 provide VB I-VP O
5 2238 2240 7843916 an DT B-NP O
6 2241 2246 7843916 acute JJ I-NP O
7 2247 2252 7843916 model NN I-NP O
8 2253 2255 7843916 in IN B-PP O
9 2256 2261 7843916 which WDT B-NP O
10 2262 2264 7843916 to TO B-VP O
11 2265 2270 7843916 study VB I-VP O
12 2271 2274 7843916 the DT B-NP O
13 2275 2285 7843916 pathogenic JJ I-NP O
14 2286 2296 7843916 mechanisms NNS I-NP O
15 2297 2305 7843916 involved VBN B-VP O
16 2306 2308 7843916 in IN B-PP O
17 2309 2316 7843916 steroid NN B-NP D005901
18 2317 2325 7843916 glaucoma NN I-NP D005901
19 2326 2329 7843916 and CC O O
20 2330 2337 7843916 primary JJ B-NP D005902
21 2338 2342 7843916 open JJ I-NP D005902
22 2343 2348 7843916 angle NN I-NP D005902
23 2349 2357 7843916 glaucoma NN I-NP D005902
24 2357 2358 7843916 . . O O

1 0 0 16563323 -DOCSTART- -X- -X- O

1 0 12 16563323 Remifentanil NN B-NP C071741
2 13 25 16563323 pretreatment NN I-NP O
3 26 33 16563323 reduces VBZ B-VP O
4 34 43 16563323 myoclonus NN B-NP D009207
5 44 49 16563323 after IN B-PP O
6 50 59 16563323 etomidate NN B-NP D005045
7 59 60 16563323 . . O O
8 61 66 16563323 STUDY NN B-NP O
9 67 76 16563323 OBJECTIVE NN I-NP O
10 76 77 16563323 : : O O
11 78 81 16563323 The DT B-NP O
12 82 85 16563323 aim NN I-NP O
13 86 88 16563323 of IN B-PP O
14 89 92 16563323 the DT B-NP O
15 93 98 16563323 study NN I-NP O
16 99 102 16563323 was VBD B-VP O
17 103 105 16563323 to TO B-VP O
18 106 113 16563323 compare VB I-VP O
19 114 117 16563323 the DT B-NP O
20 118 124 16563323 effect NN I-NP O
21 125 127 16563323 of IN B-PP O
22 128 140 16563323 pretreatment NN B-NP O
23 141 145 16563323 with IN B-PP O
24 146 158 16563323 remifentanil NN B-NP C071741
25 159 160 16563323 1 CD I-NP O
26 161 167 16563323 microg NN I-NP O
27 167 168 16563323 / SYM B-NP O
28 168 170 16563323 kg NN I-NP O
29 171 174 16563323 and CC O O
30 175 178 16563323 the DT B-NP O
31 179 185 16563323 effect NN I-NP O
32 186 188 16563323 of IN B-PP O
33 189 195 16563323 gender NN B-NP O
34 196 198 16563323 on IN B-PP O
35 199 202 16563323 the DT B-NP O
36 203 212 16563323 incidence NN I-NP O
37 213 215 16563323 of IN B-PP O
38 216 225 16563323 myoclonus NN B-NP D009207
39 226 231 16563323 after IN B-PP O
40 232 242 16563323 anesthesia NN B-NP O
41 243 252 16563323 induction NN I-NP O
42 253 257 16563323 with IN B-PP O
43 258 267 16563323 etomidate NN B-NP D005045
44 267 268 16563323 . . O O

1 269 275 16563323 DESIGN NN B-NP O
2 275 276 16563323 : : O O
3 277 281 16563323 This DT B-NP O
4 282 285 16563323 was VBD B-VP O
5 286 287 16563323 a DT B-NP O
6 288 298 16563323 randomized VBN I-NP O
7 298 299 16563323 , , I-NP O
8 300 306 16563323 double JJ I-NP O
9 306 307 16563323 - HYPH I-NP O
10 307 312 16563323 blind JJ I-NP O
11 313 318 16563323 study NN I-NP O
12 318 319 16563323 . . O O

1 320 327 16563323 SETTING NN B-NP O
2 327 328 16563323 : : O O
3 329 332 16563323 The DT B-NP O
4 333 338 16563323 study NN I-NP O
5 339 342 16563323 was VBD B-VP O
6 343 352 16563323 conducted VBN I-VP O
7 353 355 16563323 at IN B-PP O
8 356 357 16563323 a DT B-NP O
9 358 368 16563323 university NN I-NP O
10 369 377 16563323 hospital NN I-NP O
11 377 378 16563323 . . O O

1 379 387 16563323 PATIENTS NNS B-NP O
2 387 388 16563323 : : O O
3 389 394 16563323 Sixty CD B-NP O
4 395 403 16563323 patients NNS I-NP O
5 404 408 16563323 were VBD B-VP O
6 409 419 16563323 pretreated VBN I-VP O
7 420 422 16563323 in IN B-PP O
8 423 424 16563323 a DT B-NP O
9 425 435 16563323 randomized VBN I-NP O
10 436 442 16563323 double JJ I-NP O
11 442 443 16563323 - HYPH I-NP O
12 443 450 16563323 blinded JJ I-NP O
13 451 458 16563323 fashion NN I-NP O
14 459 463 16563323 with IN B-PP O
15 464 476 16563323 remifentanil NN B-NP C071741
16 477 478 16563323 1 CD I-NP O
17 479 485 16563323 microg NN I-NP O
18 485 486 16563323 / SYM B-VP O
19 486 488 16563323 kg NN B-NP O
20 489 491 16563323 or CC I-NP O
21 492 499 16563323 placebo NN I-NP O
22 499 500 16563323 . . O O

1 501 504 16563323 Two CD B-NP O
2 505 512 16563323 minutes NNS I-NP O
3 513 518 16563323 after IN B-PP O
4 519 531 16563323 remifentanil NN B-NP C071741
5 532 534 16563323 or CC I-NP O
6 535 542 16563323 placebo NN I-NP O
7 543 552 16563323 injection NN I-NP O
8 552 553 16563323 , , O O
9 554 563 16563323 etomidate NN B-NP D005045
10 564 567 16563323 0.3 CD I-NP O
11 568 570 16563323 mg NN I-NP O
12 570 571 16563323 / SYM B-NP O
13 571 573 16563323 kg NN I-NP O
14 574 577 16563323 was VBD B-VP O
15 578 583 16563323 given VBN I-VP O
16 583 584 16563323 . . O O

1 585 597 16563323 MEASUREMENTS NNS B-NP O
2 597 598 16563323 : : O O
3 599 608 16563323 Myoclonus NN B-NP D009207
4 609 612 16563323 was VBD B-VP O
5 613 621 16563323 recorded VBN I-VP O
6 622 626 16563323 with IN B-PP O
7 627 628 16563323 a DT B-NP O
8 629 634 16563323 scale NN I-NP O
9 635 637 16563323 of IN B-PP O
10 638 639 16563323 0 CD B-NP O
11 640 642 16563323 to TO B-PP O
12 643 644 16563323 3 CD B-NP O
13 644 645 16563323 . . O O

1 646 649 16563323 The DT B-NP O
2 650 655 16563323 grade NN I-NP O
3 656 658 16563323 of IN B-PP O
4 659 667 16563323 sedation NN B-NP O
5 668 669 16563323 ( ( O O
6 669 673 16563323 none NN B-NP O
7 673 674 16563323 , , O O
8 675 679 16563323 mild JJ B-NP O
9 679 680 16563323 , , I-NP O
10 681 689 16563323 moderate JJ I-NP O
11 689 690 16563323 , , I-NP O
12 691 697 16563323 severe JJ I-NP O
13 697 698 16563323 ) ) O O
14 698 699 16563323 , , O O
15 700 706 16563323 nausea NN B-NP D009325
16 706 707 16563323 , , O O
17 708 716 16563323 pruritus NN B-NP D011537
18 716 717 16563323 , , O O
19 718 721 16563323 and CC O O
20 722 727 16563323 apnea NN B-NP D001049
21 728 732 16563323 were VBD B-VP O
22 733 741 16563323 recorded VBN I-VP O
23 742 747 16563323 after IN B-PP O
24 748 757 16563323 injection NN B-NP O
25 758 760 16563323 of IN B-PP O
26 761 765 16563323 both DT B-NP O
27 766 771 16563323 drugs NNS I-NP O
28 771 772 16563323 . . O O

1 773 777 16563323 MAIN NN B-NP O
2 778 785 16563323 RESULTS NNS I-NP O
3 785 786 16563323 : : O O
4 787 790 16563323 The DT B-NP O
5 791 800 16563323 incidence NN I-NP O
6 801 803 16563323 of IN B-PP O
7 804 813 16563323 myoclonus NN B-NP D009207
8 814 817 16563323 was VBD B-VP O
9 818 831 16563323 significantly RB B-ADJP O
10 832 837 16563323 lower JJR I-ADJP O
11 838 840 16563323 in IN B-PP O
12 841 844 16563323 the DT B-NP O
13 845 857 16563323 remifentanil NN I-NP C071741
14 858 863 16563323 group NN I-NP O
15 864 865 16563323 ( ( O O
16 865 869 16563323 6.7% CD B-NP O
17 869 870 16563323 ) ) O O
18 871 875 16563323 than IN B-PP O
19 876 878 16563323 in IN B-PP O
20 879 882 16563323 the DT B-NP O
21 883 890 16563323 placebo NN I-NP O
22 891 896 16563323 group NN I-NP O
23 897 898 16563323 ( ( O O
24 898 901 16563323 70% CD B-NP O
25 901 902 16563323 ) ) O O
26 903 904 16563323 ( ( O O
27 904 905 16563323 P NN B-NP O
28 906 907 16563323 < SYM O O
29 908 913 16563323 0.001 CD B-NP O
30 913 914 16563323 ) ) O O
31 914 915 16563323 . . O O

1 916 920 16563323 None NN B-NP O
2 921 923 16563323 of IN B-PP O
3 924 927 16563323 the DT B-NP O
4 928 936 16563323 patients NNS I-NP O
5 937 948 16563323 experienced VBD B-VP O
6 949 957 16563323 sedation NN B-NP O
7 957 958 16563323 , , O O
8 959 964 16563323 apnea NN B-NP D001049
9 964 965 16563323 , , O O
10 966 972 16563323 nausea NN B-NP D009325
11 972 973 16563323 , , O O
12 974 976 16563323 or CC O O
13 977 985 16563323 pruritus NN B-NP D011537
14 986 991 16563323 after IN B-PP O
15 992 1001 16563323 injection NN B-NP O
16 1002 1004 16563323 of IN B-PP O
17 1005 1009 16563323 both DT B-NP O
18 1010 1015 16563323 drugs NNS I-NP O
19 1015 1016 16563323 . . O O

1 1017 1019 16563323 In IN B-PP O
2 1020 1023 16563323 the DT B-NP O
3 1024 1031 16563323 placebo NN I-NP O
4 1032 1037 16563323 group NN I-NP O
5 1037 1038 16563323 , , O O
6 1039 1043 16563323 male JJ B-NP O
7 1044 1052 16563323 patients NNS I-NP O
8 1053 1057 16563323 were VBD B-VP O
9 1058 1068 16563323 associated VBN I-VP O
10 1069 1073 16563323 with IN B-PP O
11 1074 1087 16563323 significantly RB B-NP O
12 1088 1097 16563323 increased VBN I-NP O
13 1098 1107 16563323 incidence NN I-NP O
14 1108 1110 16563323 of IN B-PP O
15 1111 1120 16563323 myoclonus NN B-NP D009207
16 1121 1126 16563323 after IN B-PP O
17 1127 1136 16563323 etomidate NN B-NP D005045
18 1137 1151 16563323 administration NN I-NP O
19 1151 1152 16563323 . . O O

1 1153 1163 16563323 CONCLUSION NN B-NP O
2 1163 1164 16563323 : : O O
3 1165 1177 16563323 Pretreatment NN B-NP O
4 1178 1182 16563323 with IN B-PP O
5 1183 1195 16563323 remifentanil NN B-NP C071741
6 1196 1197 16563323 1 CD I-NP O
7 1198 1204 16563323 microg NN I-NP O
8 1204 1205 16563323 / SYM B-NP O
9 1205 1207 16563323 kg NN I-NP O
10 1208 1215 16563323 reduced VBD B-VP O
11 1216 1225 16563323 myoclonus NN B-NP D009207
12 1226 1231 16563323 after IN B-PP O
13 1232 1241 16563323 etomidate NN B-NP D005045
14 1242 1251 16563323 induction NN I-NP O
15 1252 1259 16563323 without IN B-PP O
16 1260 1264 16563323 side JJ B-NP O
17 1265 1272 16563323 effects NNS I-NP O
18 1273 1277 16563323 such JJ B-PP O
19 1278 1280 16563323 as IN I-PP O
20 1281 1289 16563323 sedation NN B-NP O
21 1289 1290 16563323 , , O O
22 1291 1296 16563323 apnea NN B-NP D001049
23 1296 1297 16563323 , , O O
24 1298 1304 16563323 nausea NN B-NP D009325
25 1304 1305 16563323 , , O O
26 1306 1308 16563323 or CC O O
27 1309 1317 16563323 pruritus NN B-NP D011537
28 1317 1318 16563323 . . O O

1 1319 1322 16563323 Men NN B-NP O
2 1323 1333 16563323 experience NN I-NP O
3 1334 1343 16563323 increased VBD B-VP O
4 1344 1353 16563323 incidence NN B-NP O
5 1354 1356 16563323 of IN B-PP O
6 1357 1366 16563323 myoclonus NN B-NP D009207
7 1367 1371 16563323 than IN B-PP O
8 1372 1377 16563323 women NNS B-NP O
9 1378 1383 16563323 after IN B-PP O
10 1384 1393 16563323 etomidate NN B-NP D005045
11 1394 1408 16563323 administration NN I-NP O
12 1408 1409 16563323 . . O O

1 0 0 11208990 -DOCSTART- -X- -X- O

1 0 11 11208990 Association NN B-NP O
2 12 14 11208990 of IN B-PP O
3 15 21 11208990 nitric JJ B-NP D009569
4 22 27 11208990 oxide NN I-NP D009569
5 28 38 11208990 production NN I-NP O
6 39 42 11208990 and CC I-NP O
7 43 52 11208990 apoptosis NN I-NP O
8 53 55 11208990 in IN B-PP O
9 56 57 11208990 a DT B-NP O
10 58 63 11208990 model NN I-NP O
11 64 66 11208990 of IN B-PP O
12 67 79 11208990 experimental JJ B-NP O
13 80 91 11208990 nephropathy NN I-NP D007674
14 91 92 11208990 . . I-NP O
15 93 103 11208990 BACKGROUND NN I-NP O
16 103 104 11208990 : : O O
17 105 107 11208990 In IN B-PP O
18 108 114 11208990 recent JJ B-NP O
19 115 122 11208990 studies NNS I-NP O
20 123 132 11208990 increased VBD B-VP O
21 133 140 11208990 amounts NNS B-NP O
22 141 143 11208990 of IN B-PP O
23 144 150 11208990 nitric JJ B-NP D009569
24 151 156 11208990 oxide NN I-NP D009569
25 157 158 11208990 ( ( O O
26 158 160 11208990 NO NN B-NP D009569
27 160 161 11208990 ) ) O O
28 162 165 11208990 and CC O O
29 166 175 11208990 apoptosis NN B-NP O
30 176 180 11208990 have VBP B-VP O
31 181 185 11208990 been VBN I-VP O
32 186 196 11208990 implicated VBN I-VP O
33 197 199 11208990 in IN B-PP O
34 200 207 11208990 various JJ B-NP O
35 208 220 11208990 pathological JJ I-NP O
36 221 231 11208990 conditions NNS I-NP O
37 232 234 11208990 in IN B-PP O
38 235 238 11208990 the DT B-NP O
39 239 245 11208990 kidney NN I-NP O
40 245 246 11208990 . . O O

1 247 249 11208990 We PRP B-NP O
2 250 254 11208990 have VBP B-VP O
3 255 262 11208990 studied VBN I-VP O
4 263 266 11208990 the DT B-NP O
5 267 271 11208990 role NN I-NP O
6 272 274 11208990 of IN B-PP O
7 275 277 11208990 NO NN B-NP D009569
8 278 281 11208990 and CC O O
9 282 285 11208990 its PRP$ B-NP O
10 286 297 11208990 association NN I-NP O
11 298 302 11208990 with IN B-PP O
12 303 312 11208990 apoptosis NN B-NP O
13 313 315 11208990 in IN B-PP O
14 316 318 11208990 an DT B-NP O
15 319 331 11208990 experimental JJ I-NP O
16 332 337 11208990 model NN I-NP O
17 338 340 11208990 of IN B-PP O
18 341 350 11208990 nephrotic JJ B-NP D009404
19 351 359 11208990 syndrome NN I-NP D009404
20 360 367 11208990 induced VBN B-VP O
21 368 370 11208990 by IN B-PP O
22 371 372 11208990 a DT B-NP O
23 373 379 11208990 single JJ I-NP O
24 380 389 11208990 injection NN I-NP O
25 390 392 11208990 of IN B-PP O
26 393 403 11208990 adriamycin NN B-NP D004317
27 404 405 11208990 ( ( O O
28 405 408 11208990 ADR NN B-NP D004317
29 408 409 11208990 ) ) O O
30 409 410 11208990 . . O O

1 411 418 11208990 METHODS NNS B-NP O
2 418 419 11208990 : : O O
3 420 423 11208990 The DT B-NP O
4 424 434 11208990 alteration NN I-NP O
5 435 437 11208990 in IN B-PP O
6 438 441 11208990 the DT B-NP O
7 442 444 11208990 NO NN I-NP D009569
8 445 452 11208990 pathway NN I-NP O
9 453 456 11208990 was VBD B-VP O
10 457 465 11208990 assessed VBN I-VP O
11 466 468 11208990 by IN B-PP O
12 469 478 11208990 measuring VBG B-VP O
13 479 486 11208990 nitrite NN B-NP D009573
14 487 493 11208990 levels NNS I-NP O
15 494 496 11208990 in IN B-PP O
16 497 502 11208990 serum NN B-NP O
17 502 503 11208990 / SYM B-NP O
18 503 508 11208990 urine NN I-NP O
19 509 512 11208990 and CC B-PP O
20 513 515 11208990 by IN B-PP O
21 516 526 11208990 evaluating VBG B-VP O
22 527 530 11208990 the DT B-NP O
23 531 538 11208990 changes NNS I-NP O
24 539 541 11208990 in IN B-PP O
25 542 550 11208990 vascular JJ B-NP O
26 551 561 11208990 reactivity NN I-NP O
27 562 564 11208990 of IN B-PP O
28 565 568 11208990 the DT B-NP O
29 569 577 11208990 isolated VBN I-NP O
30 578 586 11208990 perfused VBN I-NP O
31 587 590 11208990 rat NN I-NP O
32 591 597 11208990 kidney NN I-NP O
33 598 599 11208990 ( ( O O
34 599 603 11208990 IPRK NN B-NP O
35 603 604 11208990 ) ) O O
36 605 611 11208990 system NN B-NP O
37 611 612 11208990 . . O O

1 613 617 11208990 Rats NNS B-NP O
2 618 622 11208990 were VBD B-VP O
3 623 633 11208990 stratified VBN I-VP O
4 634 638 11208990 into IN B-PP O
5 639 646 11208990 control NN B-NP O
6 647 653 11208990 groups NNS I-NP O
7 654 657 11208990 and CC I-NP O
8 658 661 11208990 ADR NN I-NP D004317
9 661 662 11208990 - HYPH B-NP O
10 662 669 11208990 induced VBN I-NP O
11 670 681 11208990 nephropathy NN I-NP D007674
12 682 688 11208990 groups NNS I-NP O
13 688 689 11208990 . . O O

1 690 695 11208990 These DT B-NP O
2 696 699 11208990 two CD I-NP O
3 700 706 11208990 groups NNS I-NP O
4 707 711 11208990 were VBD B-VP O
5 712 716 11208990 then RB I-VP O
6 717 724 11208990 divided VBN I-VP O
7 725 729 11208990 into IN B-PP O
8 729 730 11208990 : : O O
9 731 736 11208990 group NN B-NP O
10 737 738 11208990 1 CD I-NP O
11 738 739 11208990 , , O O
12 740 747 11208990 animals NNS B-NP O
13 748 757 11208990 receiving VBG B-VP O
14 758 764 11208990 saline NN B-NP O
15 764 765 11208990 ; : O O
16 766 769 11208990 and CC O O
17 770 775 11208990 group NN B-NP O
18 776 777 11208990 2 CD I-NP O
19 777 778 11208990 , , O O
20 779 786 11208990 animals NNS B-NP O
21 787 796 11208990 receiving VBG B-VP O
22 797 811 11208990 aminoguanidine NN B-NP C004479
23 812 813 11208990 ( ( O O
24 813 815 11208990 AG NN B-NP C004479
25 815 816 11208990 ) ) O O
26 817 822 11208990 which WDT B-NP O
27 823 825 11208990 is VBZ B-VP O
28 826 827 11208990 a DT B-NP O
29 828 836 11208990 specific JJ I-NP O
30 837 846 11208990 inhibitor NN I-NP O
31 847 849 11208990 of IN B-PP O
32 850 859 11208990 inducible JJ B-NP O
33 859 860 11208990 - HYPH I-NP O
34 860 862 11208990 NO NN I-NP D009569
35 863 871 11208990 synthase NN I-NP O
36 871 872 11208990 . . O O

1 873 875 11208990 On IN B-PP O
2 876 879 11208990 day NN B-NP O
3 880 882 11208990 21 CD I-NP O
4 882 883 11208990 , , O O
5 884 888 11208990 rats NNS B-NP O
6 889 893 11208990 were VBD B-VP O
7 894 904 11208990 sacrificed VBN I-VP O
8 905 910 11208990 after IN B-PP O
9 911 920 11208990 obtaining VBG B-VP O
10 921 929 11208990 material NN B-NP O
11 930 933 11208990 for IN B-PP O
12 934 945 11208990 biochemical JJ B-NP O
13 946 954 11208990 analysis NN I-NP O
14 954 955 11208990 . . O O

1 956 963 11208990 RESULTS NNS B-NP O
2 963 964 11208990 : : O O
3 965 982 11208990 Histopathological JJ B-NP O
4 983 994 11208990 examination NN I-NP O
5 995 997 11208990 of IN B-PP O
6 998 1001 11208990 the DT B-NP O
7 1002 1009 11208990 kidneys NNS I-NP O
8 1010 1012 11208990 of IN B-PP O
9 1013 1017 11208990 rats NNS B-NP O
10 1018 1025 11208990 treated VBN B-VP O
11 1026 1030 11208990 with IN B-PP O
12 1031 1034 11208990 ADR NN B-NP D004317
13 1035 1043 11208990 revealed VBD B-VP O
14 1044 1049 11208990 focal JJ B-NP O
15 1050 1055 11208990 areas NNS I-NP O
16 1056 1058 11208990 of IN B-PP O
17 1059 1068 11208990 mesangial JJ B-NP C537346
18 1069 1082 11208990 proliferation NN I-NP C537346
19 1083 1086 11208990 and CC O O
20 1087 1091 11208990 mild JJ B-NP O
21 1092 1110 11208990 tubulointerstitial JJ I-NP D009395
22 1111 1123 11208990 inflammation NN I-NP D009395
23 1123 1124 11208990 . . O O

1 1125 1129 11208990 They PRP B-NP O
2 1130 1134 11208990 also RB B-ADVP O
3 1135 1138 11208990 had VBD B-VP O
4 1139 1152 11208990 significantly RB B-NP O
5 1153 1159 11208990 higher JJR I-NP O
6 1160 1166 11208990 levels NNS I-NP O
7 1167 1169 11208990 of IN B-PP O
8 1170 1181 11208990 proteinuria NN B-NP D011507
9 1182 1190 11208990 compared VBN B-PP O
10 1191 1195 11208990 with IN B-PP O
11 1196 1203 11208990 control NN B-NP O
12 1204 1207 11208990 and CC I-NP O
13 1208 1217 11208990 treatment NN I-NP O
14 1218 1224 11208990 groups NNS I-NP O
15 1225 1226 11208990 ( ( O O
16 1226 1227 11208990 P NN B-NP O
17 1228 1229 11208990 < SYM O O
18 1230 1234 11208990 0.05 CD B-NP O
19 1234 1235 11208990 ) ) O O
20 1235 1236 11208990 . . O O

1 1237 1242 11208990 Urine NN B-NP O
2 1243 1250 11208990 nitrite NN I-NP D009573
3 1251 1257 11208990 levels NNS I-NP O
4 1258 1262 11208990 were VBD B-VP O
5 1263 1276 11208990 significantly RB I-VP O
6 1277 1286 11208990 increased VBN I-VP O
7 1287 1289 11208990 in IN B-PP O
8 1290 1293 11208990 the DT B-NP O
9 1294 1297 11208990 ADR NN I-NP D004317
10 1297 1298 11208990 - HYPH I-NP O
11 1298 1309 11208990 nephropathy NN I-NP D007674
12 1310 1315 11208990 group NN I-NP O
13 1316 1317 11208990 ( ( O O
14 1317 1318 11208990 P NN B-NP O
15 1319 1320 11208990 < SYM O O
16 1321 1325 11208990 0.05 CD B-NP O
17 1325 1326 11208990 ) ) O O
18 1326 1327 11208990 . . O O

1 1328 1330 11208990 In IN B-PP O
2 1331 1334 11208990 the DT B-NP O
3 1335 1339 11208990 IPRK NN I-NP O
4 1340 1353 11208990 phenylephrine NN I-NP D010656
5 1354 1357 11208990 and CC I-NP O
6 1358 1371 11208990 acetylcholine NN I-NP D000109
7 1372 1379 11208990 related VBN I-NP O
8 1380 1389 11208990 responses NNS I-NP O
9 1390 1394 11208990 were VBD B-VP O
10 1395 1408 11208990 significantly RB B-ADJP O
11 1409 1417 11208990 impaired JJ I-ADJP O
12 1418 1420 11208990 in IN B-PP O
13 1421 1424 11208990 the DT B-NP O
14 1425 1428 11208990 ADR NN I-NP D004317
15 1428 1429 11208990 - HYPH I-NP O
16 1429 1440 11208990 nephropathy NN I-NP D007674
17 1441 1446 11208990 group NN I-NP O
18 1446 1447 11208990 . . O O

1 1448 1457 11208990 Apoptosis NN B-NP O
2 1458 1461 11208990 was VBD B-VP O
3 1462 1465 11208990 not RB I-VP O
4 1466 1474 11208990 detected VBN I-VP O
5 1475 1477 11208990 in IN B-PP O
6 1478 1486 11208990 controls NNS B-NP O
7 1486 1487 11208990 . . O O

1 1488 1495 11208990 However RB B-ADVP O
2 1495 1496 11208990 , , O O
3 1497 1499 11208990 in IN B-PP O
4 1500 1503 11208990 the DT B-NP O
5 1504 1507 11208990 ADR NN I-NP D004317
6 1507 1508 11208990 - HYPH I-NP O
7 1508 1519 11208990 nephropathy NN I-NP D007674
8 1520 1525 11208990 group NN I-NP O
9 1525 1526 11208990 , , O O
10 1527 1535 11208990 numerous JJ B-NP O
11 1536 1545 11208990 apoptotic JJ I-NP O
12 1546 1551 11208990 cells NNS I-NP O
13 1552 1556 11208990 were VBD B-VP O
14 1557 1567 11208990 identified VBN I-VP O
15 1568 1570 11208990 in IN B-PP O
16 1571 1574 11208990 the DT B-NP O
17 1575 1593 11208990 tubulointerstitial JJ I-NP O
18 1594 1599 11208990 areas NNS I-NP O
19 1599 1600 11208990 . . O O

1 1601 1607 11208990 Double JJ B-NP O
2 1608 1616 11208990 staining NN I-NP O
3 1617 1625 11208990 revealed VBD B-VP O
4 1626 1634 11208990 numerous JJ B-NP O
5 1635 1647 11208990 interstitial JJ I-NP O
6 1648 1657 11208990 apoptotic JJ I-NP O
7 1658 1663 11208990 cells NNS I-NP O
8 1664 1666 11208990 to TO B-VP O
9 1667 1672 11208990 stain VB I-VP O
10 1673 1676 11208990 for IN B-PP O
11 1677 1680 11208990 ED1 NN B-NP O
12 1680 1681 11208990 , , O O
13 1682 1683 11208990 a DT B-NP O
14 1684 1690 11208990 marker NN I-NP O
15 1691 1694 11208990 for IN B-PP O
16 1695 1704 11208990 monocytes NNS B-NP O
17 1704 1705 11208990 / SYM B-VP O
18 1705 1716 11208990 macrophages NNS B-NP O
19 1716 1717 11208990 . . O O

1 1718 1727 11208990 Treatment NN B-NP O
2 1728 1732 11208990 with IN B-PP O
3 1733 1735 11208990 AG NN B-NP C004479
4 1736 1745 11208990 prevented VBD B-VP O
5 1746 1749 11208990 the DT B-NP O
6 1750 1760 11208990 impairment NN I-NP O
7 1761 1763 11208990 of IN B-PP O
8 1764 1769 11208990 renal JJ B-NP O
9 1770 1778 11208990 vascular JJ I-NP O
10 1779 1782 11208990 bed NN I-NP O
11 1783 1792 11208990 responses NNS I-NP O
12 1793 1796 11208990 and CC O O
13 1797 1804 11208990 reduced VBD B-VP O
14 1805 1809 11208990 both CC O O
15 1810 1815 11208990 urine NN B-NP O
16 1816 1823 11208990 nitrite NN I-NP D009573
17 1824 1830 11208990 levels NNS I-NP O
18 1831 1834 11208990 and CC O O
19 1835 1844 11208990 apoptosis NN B-NP O
20 1845 1847 11208990 to TO B-PP O
21 1848 1855 11208990 control NN B-NP O
22 1856 1862 11208990 levels NNS I-NP O
23 1862 1863 11208990 . . O O

1 1864 1874 11208990 CONCLUSION NN B-NP O
2 1874 1875 11208990 : : O O
3 1876 1878 11208990 We PRP B-NP O
4 1879 1886 11208990 suggest VBP B-VP O
5 1887 1891 11208990 that IN B-SBAR O
6 1892 1904 11208990 interactions NNS B-NP O
7 1905 1912 11208990 between IN B-PP O
8 1913 1915 11208990 NO NN B-NP D009569
9 1916 1919 11208990 and CC I-NP O
10 1920 1929 11208990 apoptosis NN I-NP O
11 1930 1933 11208990 are VBP B-VP O
12 1934 1943 11208990 important JJ B-ADJP O
13 1944 1946 11208990 in IN B-PP O
14 1947 1950 11208990 the DT B-NP O
15 1951 1963 11208990 pathogenesis NN I-NP O
16 1964 1966 11208990 of IN B-PP O
17 1967 1970 11208990 the DT B-NP O
18 1971 1974 11208990 ADR NN I-NP D004317
19 1974 1975 11208990 - HYPH B-NP O
20 1975 1982 11208990 induced VBN I-NP O
21 1983 1992 11208990 nephrosis NN I-NP D009401
22 1992 1993 11208990 . . O O

1 0 0 7007443 -DOCSTART- -X- -X- O

1 0 11 7007443 Circulating VBG B-VP O
2 12 21 7007443 lysosomal JJ B-NP O
3 22 29 7007443 enzymes NNS I-NP O
4 30 33 7007443 and CC O O
5 34 39 7007443 acute JJ B-NP D017114
6 40 47 7007443 hepatic JJ I-NP D017114
7 48 56 7007443 necrosis NN I-NP D017114
8 56 57 7007443 . . O O
9 58 61 7007443 The DT B-NP O
10 62 72 7007443 activities NNS I-NP O
11 73 75 7007443 of IN B-PP O
12 76 79 7007443 the DT B-NP O
13 80 89 7007443 lysosomal JJ I-NP O
14 90 97 7007443 enzymes NNS I-NP O
15 98 102 7007443 acid NN I-NP O
16 103 106 7007443 and CC O O
17 107 114 7007443 neutral JJ B-NP O
18 115 123 7007443 protease NN I-NP O
19 123 124 7007443 , , O O
20 125 126 7007443 N NN B-NP O
21 126 127 7007443 - HYPH B-NP O
22 127 148 7007443 acetylglucosaminidase NN I-NP O
23 148 149 7007443 , , O O
24 150 153 7007443 and CC O O
25 154 158 7007443 acid NN B-NP O
26 159 170 7007443 phosphatase NN I-NP O
27 171 175 7007443 were VBD B-VP O
28 176 184 7007443 measured VBN I-VP O
29 185 187 7007443 in IN B-PP O
30 188 191 7007443 the DT B-NP O
31 192 197 7007443 serum NN I-NP O
32 198 200 7007443 of IN B-PP O
33 201 209 7007443 patients NNS B-NP O
34 210 214 7007443 with IN B-PP O
35 215 224 7007443 fulminant JJ B-NP D017114
36 225 232 7007443 hepatic JJ I-NP D017114
37 233 240 7007443 failure NN I-NP D017114
38 240 241 7007443 . . O O

1 242 246 7007443 Acid NN B-NP O
2 247 255 7007443 protease NN I-NP O
3 256 257 7007443 ( ( O O
4 257 266 7007443 cathepsin NN B-NP O
5 267 268 7007443 D NN I-NP O
6 268 269 7007443 ) ) O O
7 270 278 7007443 activity NN B-NP O
8 279 282 7007443 was VBD B-VP O
9 283 292 7007443 increased VBN I-VP O
10 293 298 7007443 about RB B-ADJP O
11 299 306 7007443 tenfold RB I-ADJP O
12 307 309 7007443 in IN B-PP O
13 310 318 7007443 patients NNS B-NP O
14 319 322 7007443 who WP B-NP O
15 323 327 7007443 died VBD B-VP O
16 328 331 7007443 and CC O O
17 332 338 7007443 nearly RB B-ADVP O
18 339 347 7007443 fourfold RB I-ADVP O
19 348 350 7007443 in IN B-PP O
20 351 356 7007443 those DT B-NP O
21 357 360 7007443 who WP B-NP O
22 361 369 7007443 survived VBD B-VP O
23 370 379 7007443 fulminant JJ B-NP D017114
24 380 387 7007443 hepatic JJ I-NP D017114
25 388 395 7007443 failure NN I-NP D017114
26 396 401 7007443 after IN B-PP O
27 402 413 7007443 paracetamol NN B-NP D000082
28 414 422 7007443 overdose NN I-NP D062787
29 422 423 7007443 , , O O
30 424 431 7007443 whereas IN O O
31 432 442 7007443 activities NNS B-NP O
32 443 447 7007443 were VBD B-VP O
33 448 457 7007443 increased VBN I-VP O
34 458 465 7007443 equally RB B-ADVP O
35 466 468 7007443 in IN B-PP O
36 469 477 7007443 patients NNS B-NP O
37 478 482 7007443 with IN B-PP O
38 483 492 7007443 fulminant JJ B-NP D017114
39 493 500 7007443 hepatic JJ I-NP D017114
40 501 508 7007443 failure NN I-NP D017114
41 509 512 7007443 due JJ B-PP O
42 513 515 7007443 to TO B-PP O
43 516 521 7007443 viral JJ B-NP D006525
44 522 531 7007443 hepatitis NN I-NP D006525
45 532 539 7007443 whether IN B-SBAR O
46 540 542 7007443 or CC O O
47 543 546 7007443 not RB O O
48 547 551 7007443 they PRP B-NP O
49 552 560 7007443 survived VBD B-VP O
50 560 561 7007443 . . O O

1 562 563 7007443 A DT B-NP O
2 564 575 7007443 correlation NN I-NP O
3 576 579 7007443 was VBD B-VP O
4 580 585 7007443 found VBN I-VP O
5 586 593 7007443 between IN B-PP O
6 594 599 7007443 serum NN B-NP O
7 600 604 7007443 acid NN I-NP O
8 605 613 7007443 protease NN I-NP O
9 614 622 7007443 activity NN I-NP O
10 623 626 7007443 and CC O O
11 627 638 7007443 prothrombin NN B-NP O
12 639 643 7007443 time NN I-NP O
13 643 644 7007443 , , O O
14 645 648 7007443 and CC O O
15 649 652 7007443 the DT B-NP O
16 653 661 7007443 increase NN I-NP O
17 662 664 7007443 in IN B-PP O
18 665 674 7007443 cathepsin NN B-NP O
19 675 676 7007443 D NN I-NP O
20 677 685 7007443 activity NN I-NP O
21 686 689 7007443 was VBD B-VP O
22 690 699 7007443 sustained JJ B-ADJP O
23 700 704 7007443 over IN B-PP O
24 705 712 7007443 several JJ B-NP O
25 713 717 7007443 days NNS I-NP O
26 718 726 7007443 compared VBN B-PP O
27 727 731 7007443 with IN B-PP O
28 732 741 7007443 aspartate NN B-NP D001224
29 742 758 7007443 aminotransferase NN I-NP O
30 758 759 7007443 , , O O
31 760 765 7007443 which WDT B-NP O
32 766 772 7007443 showed VBD B-VP O
33 773 774 7007443 a DT B-NP O
34 775 780 7007443 sharp JJ I-NP O
35 781 786 7007443 early JJ I-NP O
36 787 791 7007443 peak NN I-NP O
37 792 795 7007443 and CC B-NP O
38 796 800 7007443 then RB I-NP O
39 801 802 7007443 a DT B-NP O
40 803 807 7007443 fall NN I-NP O
41 807 808 7007443 . . O O

1 809 820 7007443 Circulating VBG B-VP O
2 821 830 7007443 lysosomal JJ B-NP O
3 831 840 7007443 proteases NNS I-NP O
4 841 844 7007443 can MD B-VP O
5 845 851 7007443 damage VB I-VP O
6 852 857 7007443 other JJ B-NP O
7 858 864 7007443 organs NNS I-NP O
8 864 865 7007443 , , O O
9 866 869 7007443 and CC O O
10 870 881 7007443 measurement NN B-NP O
11 882 884 7007443 of IN B-PP O
12 885 890 7007443 their PRP$ B-NP O
13 891 899 7007443 activity NN I-NP O
14 900 903 7007443 may MD B-VP O
15 904 913 7007443 therefore RB I-VP O
16 914 916 7007443 be VB I-VP O
17 917 919 7007443 of IN B-PP O
18 920 925 7007443 added VBN B-NP O
19 926 931 7007443 value NN I-NP O
20 932 934 7007443 in IN B-PP O
21 935 944 7007443 assessing VBG B-VP O
22 945 954 7007443 prognosis NN B-NP O
23 955 957 7007443 in IN B-PP O
24 958 962 7007443 this DT B-NP O
25 963 972 7007443 condition NN I-NP O
26 972 973 7007443 . . O O

1 0 0 12734532 -DOCSTART- -X- -X- O

1 0 4 12734532 Case NN B-NP O
2 5 11 12734532 report NN I-NP O
3 11 12 12734532 : : O O
4 13 21 12734532 Dexatrim NN B-NP D010665
5 22 23 12734532 ( ( O O
6 23 42 12734532 Phenylpropanolamine NN B-NP D010665
7 42 43 12734532 ) ) O O
8 44 46 12734532 as IN B-PP O
9 47 48 12734532 a DT B-NP O
10 49 54 12734532 cause NN I-NP O
11 55 57 12734532 of IN B-PP O
12 58 68 12734532 myocardial JJ B-NP D009203
13 69 79 12734532 infarction NN I-NP D009203
14 79 80 12734532 . . O O
15 81 100 12734532 Phenylpropanolamine NN B-NP D010665
16 101 102 12734532 ( ( O O
17 102 105 12734532 PPA NN B-NP D010665
18 105 106 12734532 ) ) O O
19 107 109 12734532 is VBZ B-VP O
20 110 111 12734532 a DT B-NP O
21 112 123 12734532 sympathetic JJ I-NP O
22 124 129 12734532 amine NN I-NP D000588
23 130 134 12734532 used VBN B-VP O
24 135 137 12734532 in IN B-PP O
25 138 142 12734532 over IN B-PP O
26 142 143 12734532 - HYPH B-NP O
27 143 146 12734532 the DT B-NP O
28 146 147 12734532 - HYPH I-NP O
29 147 154 12734532 counter NN I-NP O
30 155 159 12734532 cold JJ I-NP O
31 160 168 12734532 remedies NNS I-NP O
32 169 172 12734532 and CC O O
33 173 179 12734532 weight NN B-NP O
34 179 180 12734532 - HYPH I-NP O
35 180 187 12734532 control NN I-NP O
36 188 200 12734532 preparations NNS I-NP O
37 201 210 12734532 worldwide RB B-ADVP O
38 210 211 12734532 . . O O

1 212 215 12734532 Its PRP$ B-NP O
2 216 219 12734532 use NN I-NP O
3 220 223 12734532 has VBZ B-VP O
4 224 228 12734532 been VBN I-VP O
5 229 239 12734532 associated VBN I-VP O
6 240 244 12734532 with IN B-PP O
7 245 257 12734532 hypertensive JJ B-NP D006973
8 258 266 12734532 episodes NNS I-NP O
9 267 270 12734532 and CC O O
10 271 282 12734532 hemorrhagic JJ B-NP D006470
11 283 290 12734532 strokes NNS I-NP D006470
12 291 293 12734532 in IN B-PP O
13 294 301 12734532 younger JJR B-NP O
14 302 307 12734532 women NNS I-NP O
15 307 308 12734532 . . O O

1 309 316 12734532 Several JJ B-NP O
2 317 324 12734532 reports NNS I-NP O
3 325 329 12734532 have VBP B-VP O
4 330 336 12734532 linked VBN I-VP O
5 337 340 12734532 the DT B-NP O
6 341 346 12734532 abuse NN I-NP O
7 347 349 12734532 of IN B-PP O
8 350 353 12734532 PPA NN B-NP D010665
9 354 358 12734532 with IN B-PP O
10 359 369 12734532 myocardial JJ B-NP D009202
11 370 376 12734532 injury NN I-NP D009202
12 376 377 12734532 , , O O
13 378 388 12734532 especially RB B-ADVP O
14 389 393 12734532 when WRB B-ADVP O
15 394 402 12734532 overdose NN B-NP D062787
16 403 405 12734532 is VBZ B-VP O
17 406 414 12734532 involved VBN I-VP O
18 414 415 12734532 . . O O

1 416 418 12734532 We PRP B-NP O
2 419 425 12734532 report VBP B-VP O
3 426 430 12734532 here RB B-ADVP O
4 431 434 12734532 the DT B-NP O
5 435 440 12734532 first JJ I-NP O
6 441 445 12734532 case NN I-NP O
7 446 448 12734532 of IN B-PP O
8 449 457 12734532 Dexatrim NN B-NP D010665
9 458 459 12734532 ( ( O O
10 459 462 12734532 PPA NN B-NP D010665
11 462 463 12734532 ) ) O O
12 463 464 12734532 - HYPH O O
13 464 471 12734532 induced VBN B-NP O
14 472 482 12734532 myocardial JJ I-NP D009202
15 483 489 12734532 injury NN I-NP D009202
16 490 492 12734532 in IN B-PP O
17 493 494 12734532 a DT B-NP O
18 495 500 12734532 young JJ I-NP O
19 501 506 12734532 woman NN I-NP O
20 507 510 12734532 who WP B-NP O
21 511 514 12734532 was VBD B-VP O
22 515 520 12734532 using VBG I-VP O
23 521 523 12734532 it PRP B-NP O
24 524 526 12734532 at IN B-PP O
25 527 538 12734532 recommended VBN B-NP O
26 539 544 12734532 doses NNS I-NP O
27 545 548 12734532 for IN B-PP O
28 549 555 12734532 weight NN B-NP O
29 556 563 12734532 control NN I-NP O
30 563 564 12734532 . . O O

1 565 567 12734532 In IN B-PP O
2 568 576 12734532 addition NN B-NP O
3 576 577 12734532 , , O O
4 578 580 12734532 we PRP B-NP O
5 581 587 12734532 review VBP B-VP O
6 588 591 12734532 the DT B-NP O
7 592 593 12734532 7 CD I-NP O
8 594 599 12734532 other JJ I-NP O
9 600 605 12734532 cases NNS I-NP O
10 606 608 12734532 of IN B-PP O
11 609 612 12734532 PPA NN B-NP D010665
12 613 620 12734532 related JJ I-NP O
13 621 631 12734532 myocardial JJ I-NP D009202
14 632 638 12734532 injury NN I-NP D009202
15 639 643 12734532 that WDT B-NP O
16 644 648 12734532 have VBP B-VP O
17 649 653 12734532 been VBN I-VP O
18 654 662 12734532 reported VBN I-VP O
19 663 665 12734532 so RB B-ADVP O
20 666 669 12734532 far RB I-ADVP O
21 669 670 12734532 . . O O

1 671 681 12734532 Physicians NNS B-NP O
2 682 685 12734532 and CC I-NP O
3 686 694 12734532 patients NNS I-NP O
4 695 701 12734532 should MD B-VP O
5 702 704 12734532 be VB I-VP O
6 705 710 12734532 alert JJ B-ADJP O
7 711 713 12734532 to TO B-PP O
8 714 717 12734532 the DT B-NP O
9 718 727 12734532 potential JJ I-NP O
10 728 735 12734532 cardiac JJ I-NP O
11 736 740 12734532 risk NN I-NP O
12 741 751 12734532 associated VBN B-VP O
13 752 756 12734532 with IN B-PP O
14 757 760 12734532 the DT B-NP O
15 761 764 12734532 use NN I-NP O
16 765 767 12734532 of IN B-PP O
17 768 771 12734532 PPA NN B-NP D010665
18 771 772 12734532 , , O O
19 773 777 12734532 even RB B-ADVP O
20 778 780 12734532 at IN B-PP O
21 781 786 12734532 doses NNS B-NP O
22 787 796 12734532 generally RB B-VP O
23 797 807 12734532 considered VBN I-VP O
24 808 810 12734532 to TO I-VP O
25 811 813 12734532 be VB I-VP O
26 814 818 12734532 safe JJ B-ADJP O
27 818 819 12734532 . . O O

1 0 0 11999899 -DOCSTART- -X- -X- O

1 0 10 11999899 Behavioral JJ B-NP O
2 11 18 11999899 effects NNS I-NP O
3 19 21 11999899 of IN B-PP O
4 22 24 11999899 MK NN B-NP D016291
5 24 25 11999899 - HYPH O D016291
6 25 28 11999899 801 CD B-NP D016291
7 29 31 11999899 on IN B-PP O
8 32 41 11999899 reserpine NN B-NP D012110
9 41 42 11999899 - HYPH B-NP O
10 42 49 11999899 treated VBN I-NP O
11 50 54 11999899 mice NNS I-NP O
12 54 55 11999899 . . O O
13 56 59 11999899 The DT B-NP O
14 60 67 11999899 effects NNS I-NP O
15 68 70 11999899 of IN B-PP O
16 71 82 11999899 dizocilpine NN B-NP D016291
17 83 84 11999899 ( ( O O
18 84 86 11999899 MK NN B-NP D016291
19 86 87 11999899 - HYPH O D016291
20 87 90 11999899 801 CD B-NP D016291
21 90 91 11999899 ) ) O O
22 91 92 11999899 , , O O
23 93 94 11999899 a DT B-NP O
24 95 109 11999899 noncompetitive JJ I-NP O
25 110 111 11999899 N NN I-NP D016202
26 111 112 11999899 - HYPH B-NP D016202
27 112 118 11999899 methyl NN I-NP D016202
28 118 119 11999899 - HYPH B-NP D016202
29 119 120 11999899 D NN I-NP D016202
30 120 121 11999899 - HYPH O D016202
31 121 130 11999899 aspartate NN B-NP D016202
32 131 132 11999899 ( ( O O
33 132 136 11999899 NMDA NN B-NP D016202
34 136 137 11999899 ) ) O O
35 138 146 11999899 receptor NN B-NP O
36 147 157 11999899 antagonist NN I-NP O
37 157 158 11999899 , , O O
38 159 163 11999899 were VBD B-VP O
39 164 171 11999899 studied VBN I-VP O
40 172 174 11999899 on IN B-PP O
41 175 183 11999899 dopamine NN B-NP D004298
42 183 184 11999899 - HYPH B-NP O
43 184 191 11999899 related VBN I-NP O
44 192 201 11999899 behaviors NNS I-NP O
45 202 209 11999899 induced VBN B-VP O
46 210 212 11999899 by IN B-PP O
47 213 222 11999899 reserpine NN B-NP D012110
48 223 233 11999899 treatments NNS I-NP O
49 233 234 11999899 . . O O

1 235 239 11999899 This DT B-NP O
2 240 245 11999899 study NN I-NP O
3 246 253 11999899 focuses VBZ B-VP O
4 254 256 11999899 on IN B-PP O
5 257 267 11999899 behavioral JJ B-NP O
6 268 277 11999899 syndromes NNS I-NP O
7 278 282 11999899 that WDT B-NP O
8 283 286 11999899 may MD B-VP O
9 287 291 11999899 used VBN I-VP O
10 292 294 11999899 as IN B-PP O
11 295 301 11999899 models NNS B-NP O
12 302 305 11999899 for IN B-PP O
13 306 317 11999899 Parkinson's NNS B-NP D010300
14 318 325 11999899 disease NN I-NP D010300
15 325 326 11999899 , , O O
16 327 329 11999899 or CC O O
17 330 337 11999899 tardive JJ B-NP D004409
18 338 348 11999899 dyskinesia NN I-NP D004409
19 348 349 11999899 , , O O
20 350 353 11999899 and CC O O
21 354 357 11999899 its PRP$ B-NP O
22 358 366 11999899 response NN I-NP O
23 367 372 11999899 after IN B-PP O
24 373 386 11999899 glutamatergic JJ B-NP O
25 387 395 11999899 blockage NN I-NP O
26 395 396 11999899 . . O O

1 397 406 11999899 Reserpine NN B-NP D012110
2 407 408 11999899 ( ( O O
3 408 409 11999899 1 CD B-NP O
4 410 412 11999899 mg NN I-NP O
5 412 413 11999899 / SYM B-NP O
6 413 415 11999899 kg NN I-NP O
7 415 416 11999899 ) ) O O
8 416 417 11999899 , , O O
9 418 430 11999899 administered VBN B-VP O
10 431 435 11999899 once RB B-ADVP O
11 436 441 11999899 every DT B-NP O
12 442 447 11999899 other JJ I-NP O
13 448 451 11999899 day NN I-NP O
14 452 455 11999899 for IN B-PP O
15 456 457 11999899 4 CD B-NP O
16 458 462 11999899 days NNS I-NP O
17 462 463 11999899 , , O O
18 464 472 11999899 produced VBD B-VP O
19 473 482 11999899 increases NNS B-NP O
20 483 485 11999899 in IN B-PP O
21 486 495 11999899 orofacial JJ B-NP D009069
22 496 506 11999899 dyskinesia NN I-NP D009069
23 506 507 11999899 , , O O
24 508 514 11999899 tongue NN B-NP O
25 515 525 11999899 protrusion NN I-NP O
26 526 529 11999899 and CC O O
27 530 537 11999899 vacuous JJ B-NP O
28 538 545 11999899 chewing NN I-NP O
29 546 548 11999899 in IN B-PP O
30 549 553 11999899 mice NNS B-NP O
31 553 554 11999899 , , O O
32 555 560 11999899 which WDT B-NP O
33 561 564 11999899 are VBP B-VP O
34 565 570 11999899 signs NNS B-NP O
35 571 581 11999899 indicative JJ B-ADJP O
36 582 584 11999899 of IN B-PP O
37 585 592 11999899 tardive JJ B-NP D004409
38 593 603 11999899 dyskinesia NN I-NP D004409
39 603 604 11999899 . . O O

1 605 614 11999899 Reserpine NN B-NP D012110
2 615 619 11999899 also RB B-ADVP O
3 620 628 11999899 produced VBD B-VP O
4 629 635 11999899 tremor NN B-NP D014202
5 636 639 11999899 and CC I-NP O
6 640 649 11999899 catalepsy NN I-NP D002375
7 649 650 11999899 , , O O
8 651 656 11999899 which WDT B-NP O
9 657 660 11999899 are VBP B-VP O
10 661 666 11999899 signs NNS B-NP O
11 667 677 11999899 suggestive JJ B-ADJP O
12 678 680 11999899 of IN B-PP O
13 681 692 11999899 Parkinson's NNS B-NP D010300
14 693 700 11999899 disease NN I-NP D010300
15 700 701 11999899 . . O O

1 702 704 11999899 MK NN B-NP D016291
2 704 705 11999899 - HYPH O D016291
3 705 708 11999899 801 CD B-NP D016291
4 709 710 11999899 ( ( O O
5 710 713 11999899 0.1 CD B-NP O
6 714 716 11999899 mg NN I-NP O
7 716 717 11999899 / SYM B-NP O
8 717 719 11999899 kg NN I-NP O
9 719 720 11999899 ) ) O O
10 720 721 11999899 , , O O
11 722 734 11999899 administered VBN B-VP O
12 735 737 11999899 30 CD B-NP O
13 738 741 11999899 min NN I-NP O
14 742 748 11999899 before IN B-PP O
15 749 752 11999899 the DT B-NP O
16 753 764 11999899 observation NN I-NP O
17 765 769 11999899 test NN I-NP O
18 769 770 11999899 , , O O
19 771 780 11999899 prevented VBD B-VP O
20 781 784 11999899 the DT B-NP O
21 785 792 11999899 vacuous JJ I-NP O
22 793 800 11999899 chewing NN I-NP O
23 801 810 11999899 movements NNS I-NP O
24 810 811 11999899 , , O O
25 812 818 11999899 tongue NN B-NP O
26 819 830 11999899 protrusions NNS I-NP O
27 831 834 11999899 and CC O O
28 835 844 11999899 catalepsy NN B-NP D002375
29 845 852 11999899 induced VBN B-VP O
30 853 855 11999899 by IN B-PP O
31 856 865 11999899 reserpine NN B-NP D012110
32 865 866 11999899 . . O O

1 867 874 11999899 However RB B-ADVP O
2 874 875 11999899 , , O O
3 876 878 11999899 MK NN B-NP D016291
4 878 879 11999899 - HYPH O D016291
5 879 882 11999899 801 CD B-NP D016291
6 883 892 11999899 injection NN I-NP O
7 893 901 11999899 produced VBD B-VP O
8 902 903 11999899 a DT B-NP O
9 904 915 11999899 significant JJ I-NP O
10 916 924 11999899 increase NN I-NP O
11 925 927 11999899 of IN B-PP O
12 928 934 11999899 tremor NN B-NP D014202
13 935 937 11999899 in IN B-PP O
14 938 947 11999899 reserpine NN B-NP D012110
15 947 948 11999899 - HYPH B-NP O
16 948 955 11999899 treated VBN I-NP O
17 956 960 11999899 mice NNS I-NP O
18 960 961 11999899 . . O O

1 962 971 11999899 Reserpine NN B-NP D012110
2 972 973 11999899 ( ( O O
3 973 974 11999899 1 CD B-NP O
4 975 977 11999899 mg NN I-NP O
5 977 978 11999899 / SYM B-NP O
6 978 980 11999899 kg NN I-NP O
7 980 981 11999899 ) ) O O
8 981 982 11999899 , , O O
9 983 995 11999899 administered VBN B-VP O
10 996 998 11999899 90 CD B-NP O
11 999 1002 11999899 min NN I-NP O
12 1003 1009 11999899 before IN B-PP O
13 1010 1013 11999899 the DT B-NP O
14 1014 1018 11999899 test NN I-NP O
15 1019 1022 11999899 and CC O O
16 1023 1031 11999899 followed VBN B-VP O
17 1032 1034 11999899 by IN B-PP O
18 1035 1045 11999899 apomophine NN B-NP D001058
19 1046 1055 11999899 injection NN I-NP O
20 1056 1057 11999899 ( ( O O
21 1057 1060 11999899 0.1 CD B-NP O
22 1061 1063 11999899 mg NN I-NP O
23 1063 1064 11999899 / SYM B-NP O
24 1064 1066 11999899 kg NN I-NP O
25 1066 1067 11999899 ) ) O O
26 1068 1069 11999899 5 CD B-NP O
27 1070 1073 11999899 min NN I-NP O
28 1074 1080 11999899 before IN B-PP O
29 1081 1084 11999899 the DT B-NP O
30 1085 1089 11999899 test NN I-NP O
31 1089 1090 11999899 , , O O
32 1091 1094 11999899 did VBD B-VP O
33 1095 1098 11999899 not RB I-VP O
34 1099 1106 11999899 produce VB I-VP O
35 1107 1111 11999899 oral JJ B-NP D009069
36 1112 1122 11999899 dyskinesia NN I-NP D009069
37 1123 1125 11999899 in IN B-PP O
38 1126 1130 11999899 mice NNS B-NP O
39 1130 1131 11999899 . . O O

1 1132 1134 11999899 On IN B-PP O
2 1135 1138 11999899 the DT B-NP O
3 1139 1144 11999899 other JJ I-NP O
4 1145 1149 11999899 hand NN I-NP O
5 1149 1150 11999899 , , O O
6 1151 1160 11999899 reserpine NN B-NP D012110
7 1161 1168 11999899 induced VBD B-VP O
8 1169 1178 11999899 increases NNS B-NP O
9 1179 1181 11999899 in IN B-PP O
10 1182 1188 11999899 tremor NN B-NP D014202
11 1189 1192 11999899 and CC I-NP O
12 1193 1202 11999899 catalepsy NN I-NP D002375
13 1203 1211 11999899 compared VBN B-VP O
14 1212 1214 11999899 to TO B-PP O
15 1215 1222 11999899 control NN B-NP O
16 1223 1227 11999899 mice NNS I-NP O
17 1227 1228 11999899 . . O O

1 1229 1231 11999899 MK NN B-NP D016291
2 1231 1232 11999899 - HYPH O D016291
3 1232 1235 11999899 801 CD B-NP D016291
4 1236 1237 11999899 ( ( O O
5 1237 1240 11999899 0.1 CD B-NP O
6 1241 1243 11999899 mg NN I-NP O
7 1243 1244 11999899 / SYM B-NP O
8 1244 1246 11999899 kg NN I-NP O
9 1246 1247 11999899 ) ) O O
10 1248 1262 11999899 administration NN B-NP O
11 1263 1273 11999899 attenuated VBD B-VP O
12 1274 1277 11999899 the DT B-NP O
13 1278 1287 11999899 catalepsy NN I-NP D002375
14 1288 1291 11999899 and CC I-NP O
15 1292 1298 11999899 tremor NN I-NP D014202
16 1299 1306 11999899 induced VBN B-VP O
17 1307 1309 11999899 by IN B-PP O
18 1310 1319 11999899 reserpine NN B-NP D012110
19 1319 1320 11999899 . . O O

1 1321 1333 11999899 Pretreatment NN B-NP O
2 1334 1338 11999899 with IN B-PP O
3 1339 1348 11999899 reserpine NN B-NP D012110
4 1349 1350 11999899 ( ( O O
5 1350 1351 11999899 1 CD B-NP O
6 1352 1354 11999899 mg NN I-NP O
7 1354 1355 11999899 / SYM B-NP O
8 1355 1357 11999899 kg NN I-NP O
9 1357 1358 11999899 ) ) O O
10 1359 1361 11999899 24 CD B-NP O
11 1362 1363 11999899 h NN I-NP O
12 1364 1370 11999899 before IN B-PP O
13 1371 1374 11999899 the DT B-NP O
14 1375 1386 11999899 observation NN I-NP O
15 1387 1391 11999899 test NN I-NP O
16 1392 1400 11999899 produced VBD B-VP O
17 1401 1410 11999899 increases NNS B-NP O
18 1411 1413 11999899 in IN B-PP O
19 1414 1421 11999899 vacuous JJ B-NP O
20 1422 1429 11999899 chewing NN I-NP O
21 1430 1439 11999899 movements NNS I-NP O
22 1440 1443 11999899 and CC O O
23 1444 1450 11999899 tongue NN B-NP O
24 1451 1461 11999899 protrusion NN I-NP O
25 1461 1462 11999899 , , O O
26 1463 1465 11999899 as RB B-CONJP O
27 1466 1470 11999899 well RB I-CONJP O
28 1471 1473 11999899 as IN I-CONJP O
29 1474 1483 11999899 increases NNS B-NP O
30 1484 1486 11999899 in IN B-PP O
31 1487 1493 11999899 tremor NN B-NP D014202
32 1494 1497 11999899 and CC I-NP O
33 1498 1507 11999899 catalepsy NN I-NP D002375
34 1507 1508 11999899 , , O O
35 1509 1516 11999899 whereas IN O O
36 1517 1519 11999899 MK NN O D016291
37 1519 1520 11999899 - HYPH O D016291
38 1520 1523 11999899 801 CD B-NP D016291
39 1524 1525 11999899 ( ( O O
40 1525 1528 11999899 0.1 CD B-NP O
41 1529 1531 11999899 mg NN I-NP O
42 1531 1532 11999899 / SYM B-NP O
43 1532 1534 11999899 kg NN I-NP O
44 1534 1535 11999899 ) ) O O
45 1536 1545 11999899 injection NN B-NP O
46 1546 1548 11999899 90 CD I-NP O
47 1549 1552 11999899 min NN I-NP O
48 1553 1559 11999899 before IN B-PP O
49 1560 1563 11999899 the DT B-NP O
50 1564 1568 11999899 test NN I-NP O
51 1569 1577 11999899 reversed VBD B-VP O
52 1578 1581 11999899 the DT B-NP O
53 1582 1589 11999899 effects NNS I-NP O
54 1590 1592 11999899 of IN B-PP O
55 1593 1602 11999899 reserpine NN B-NP D012110
56 1602 1603 11999899 . . O O

1 1604 1609 11999899 These DT B-NP O
2 1610 1617 11999899 results NNS I-NP O
3 1618 1622 11999899 show VBP B-VP O
4 1623 1627 11999899 that IN B-SBAR O
5 1628 1637 11999899 reserpine NN B-NP D012110
6 1638 1646 11999899 produces VBZ B-VP O
7 1647 1656 11999899 different JJ B-NP O
8 1657 1660 11999899 and CC I-NP O
9 1661 1669 11999899 abnormal JJ I-NP D004409
10 1670 1679 11999899 movements NNS I-NP D004409
11 1679 1680 11999899 , , O O
12 1681 1686 11999899 which WDT B-NP O
13 1687 1690 11999899 are VBP B-VP O
14 1691 1698 11999899 related VBN I-VP O
15 1699 1701 11999899 to TO B-PP O
16 1702 1706 11999899 dose NN B-NP O
17 1707 1710 11999899 and CC I-NP O
18 1711 1719 11999899 schedule NN I-NP O
19 1720 1728 11999899 employed VBN B-VP O
20 1729 1732 11999899 and CC O O
21 1733 1736 11999899 can MD B-VP O
22 1737 1739 11999899 be VB I-VP O
23 1740 1750 11999899 considered VBN I-VP O
24 1751 1753 11999899 as IN B-PP O
25 1754 1766 11999899 parkinsonian JJ B-NP D010300
26 1766 1767 11999899 - HYPH I-NP O
27 1767 1771 11999899 like JJ I-NP O
28 1772 1775 11999899 and CC I-NP O
29 1776 1783 11999899 tardive JJ I-NP D004409
30 1784 1794 11999899 dsykinesia NN I-NP D004409
31 1795 1800 11999899 signs NNS I-NP O
32 1800 1801 11999899 . . O O

1 1802 1805 11999899 The DT B-NP O
2 1806 1819 11999899 glutamatergic JJ I-NP O
3 1820 1828 11999899 blockage NN I-NP O
4 1829 1837 11999899 produced VBN B-VP O
5 1838 1840 11999899 by IN B-PP O
6 1841 1845 11999899 NMDA NN B-NP D016202
7 1846 1849 11999899 can MD B-VP O
8 1850 1857 11999899 restore VB I-VP O
9 1858 1863 11999899 these DT B-NP O
10 1864 1869 11999899 signs NNS I-NP O
11 1869 1870 11999899 , , O O
12 1871 1875 11999899 such JJ B-PP O
13 1876 1878 11999899 as IN I-PP O
14 1879 1886 11999899 vacuous JJ B-NP O
15 1887 1894 11999899 chewing NN I-NP O
16 1895 1904 11999899 movements NNS I-NP O
17 1904 1905 11999899 , , O O
18 1906 1912 11999899 tongue NN B-NP O
19 1913 1924 11999899 protrusions NNS I-NP O
20 1924 1925 11999899 , , O O
21 1926 1935 11999899 catalepsy NN B-NP D002375
22 1936 1939 11999899 and CC I-NP O
23 1940 1946 11999899 tremor NN I-NP D014202
24 1947 1956 11999899 according VBG B-PP O
25 1957 1959 11999899 to TO B-PP O
26 1960 1963 11999899 the DT B-NP O
27 1964 1972 11999899 employed VBN I-NP O
28 1973 1978 11999899 model NN I-NP O
29 1978 1979 11999899 . . O O

1 0 0 2750819 -DOCSTART- -X- -X- O

1 0 13 2750819 Neuromuscular JJ B-NP D020879
2 14 22 2750819 blockade NN I-NP D020879
3 23 27 2750819 with IN B-PP O
4 28 37 2750819 magnesium NN B-NP D008278
5 38 45 2750819 sulfate NN I-NP D008278
6 46 49 2750819 and CC I-NP O
7 50 60 2750819 nifedipine NN I-NP D009543
8 60 61 2750819 . . O O
9 62 63 2750819 A DT B-NP O
10 64 71 2750819 patient NN I-NP O
11 72 75 2750819 who WP B-NP O
12 76 84 2750819 received VBD B-VP O
13 85 94 2750819 tocolysis NN B-NP O
14 95 99 2750819 with IN B-PP O
15 100 110 2750819 nifedipine NN B-NP D009543
16 111 120 2750819 developed VBD B-VP O
17 121 134 2750819 neuromuscular JJ B-NP D020879
18 135 143 2750819 blockade NN I-NP D020879
19 144 149 2750819 after IN B-PP O
20 150 153 2750819 500 CD B-NP O
21 154 156 2750819 mg NN I-NP O
22 157 159 2750819 of IN B-PP O
23 160 169 2750819 magnesium NN B-NP D008278
24 170 177 2750819 sulfate NN I-NP D008278
25 178 181 2750819 was VBD B-VP O
26 182 194 2750819 administered VBN I-VP O
27 194 195 2750819 . . O O

1 196 200 2750819 This DT B-NP O
2 201 209 2750819 reaction NN I-NP O
3 210 222 2750819 demonstrates VBZ B-VP O
4 223 227 2750819 that IN B-SBAR O
5 228 238 2750819 nifedipine NN B-NP D009543
6 239 242 2750819 can MD B-VP O
7 243 252 2750819 seriously RB I-VP O
8 253 263 2750819 potentiate VB I-VP O
9 264 267 2750819 the DT B-NP O
10 268 276 2750819 toxicity NN I-NP D064420
11 277 279 2750819 of IN B-PP O
12 280 289 2750819 magnesium NN B-NP D008274
13 289 290 2750819 . . O O

1 291 298 2750819 Caution NN B-NP O
2 299 305 2750819 should MD B-VP O
3 306 308 2750819 be VB I-VP O
4 309 318 2750819 exercised VBN I-VP O
5 319 323 2750819 when WRB B-ADVP O
6 324 329 2750819 these DT B-NP O
7 330 333 2750819 two CD I-NP O
8 334 344 2750819 tocolytics NNS I-NP O
9 345 348 2750819 are VBP B-VP O
10 349 357 2750819 combined VBN I-VP O
11 357 358 2750819 . . O O

1 0 0 10091616 -DOCSTART- -X- -X- O

1 0 9 10091616 Worsening NN B-NP O
2 10 12 10091616 of IN B-PP O
3 13 21 10091616 levodopa NN B-NP D007980
4 21 22 10091616 - HYPH B-NP O
5 22 29 10091616 induced VBN I-NP O
6 30 41 10091616 dyskinesias NNS I-NP D004409
7 42 44 10091616 by IN B-PP O
8 45 50 10091616 motor NN B-NP O
9 51 54 10091616 and CC O O
10 55 61 10091616 mental JJ B-NP O
11 62 67 10091616 tasks NNS I-NP O
12 67 68 10091616 . . O O
13 69 72 10091616 Ten CD B-NP O
14 73 81 10091616 patients NNS I-NP O
15 82 85 10091616 who WP B-NP O
16 86 89 10091616 had VBD B-VP O
17 90 101 10091616 Parkinson's NNP B-NP D010300
18 102 109 10091616 disease NN I-NP D010300
19 110 114 10091616 with IN B-PP O
20 115 124 10091616 disabling VBG B-NP O
21 125 135 10091616 dyskinesia NN I-NP D004409
22 136 140 10091616 were VBD B-VP O
23 141 149 10091616 included VBN I-VP O
24 150 152 10091616 in IN B-PP O
25 153 157 10091616 this DT B-NP O
26 158 163 10091616 study NN I-NP O
27 164 166 10091616 to TO B-VP O
28 167 175 10091616 evaluate VB I-VP O
29 176 179 10091616 the DT B-NP O
30 180 184 10091616 role NN I-NP O
31 185 187 10091616 of IN B-PP O
32 188 194 10091616 mental JJ O O
33 195 196 10091616 ( ( O O
34 196 202 10091616 mental JJ B-NP O
35 203 214 10091616 calculation NN I-NP O
36 214 215 10091616 ) ) O O
37 216 219 10091616 and CC O O
38 220 225 10091616 motor NN B-NP O
39 226 227 10091616 ( ( O O
40 227 234 10091616 flexion NN B-NP O
41 234 235 10091616 / SYM B-NP O
42 235 244 10091616 extension NN I-NP O
43 245 247 10091616 of IN B-PP O
44 248 253 10091616 right JJ B-NP O
45 254 261 10091616 fingers NNS I-NP O
46 261 262 10091616 , , O O
47 263 270 10091616 flexion NN B-NP O
48 270 271 10091616 / SYM I-NP O
49 271 280 10091616 extension NN I-NP O
50 281 283 10091616 of IN B-PP O
51 284 288 10091616 left JJ B-NP O
52 289 296 10091616 fingers NNS I-NP O
53 296 297 10091616 , , O O
54 298 305 10091616 flexion NN B-NP O
55 305 306 10091616 / SYM I-NP O
56 306 315 10091616 extension NN I-NP O
57 316 318 10091616 of IN B-PP O
58 319 322 10091616 the DT B-NP O
59 323 327 10091616 neck NN I-NP O
60 327 328 10091616 , , O O
61 329 337 10091616 speaking VBG B-VP O
62 338 343 10091616 aloud RB B-ADVP O
63 343 344 10091616 ) ) O O
64 345 350 10091616 tasks NNS B-NP O
65 351 353 10091616 on IN B-PP O
66 354 357 10091616 the DT B-NP O
67 358 367 10091616 worsening NN I-NP O
68 368 370 10091616 of IN B-PP O
69 371 375 10091616 peak NN B-NP O
70 375 376 10091616 - HYPH B-NP O
71 376 380 10091616 dose NN I-NP O
72 381 391 10091616 dyskinesia NN I-NP D004409
73 392 401 10091616 following VBG B-PP O
74 402 416 10091616 administration NN B-NP O
75 417 419 10091616 of IN B-PP O
76 420 422 10091616 an DT B-NP O
77 423 432 10091616 effective JJ I-NP O
78 433 439 10091616 single JJ I-NP O
79 440 444 10091616 dose NN I-NP O
80 445 447 10091616 of IN B-PP O
81 448 459 10091616 apomorphine NN B-NP D001058
82 459 460 10091616 . . O O

1 461 469 10091616 Compared VBN B-PP O
2 470 474 10091616 with IN B-PP O
3 475 478 10091616 the DT B-NP O
4 479 484 10091616 score NN I-NP O
5 485 487 10091616 at IN B-PP O
6 488 492 10091616 rest NN B-NP O
7 493 494 10091616 ( ( O O
8 494 498 10091616 1.3+ SYM B-NP O
9 498 499 10091616 / SYM O O
10 499 500 10091616 - SYM O O
11 500 503 10091616 0.3 CD B-NP O
12 503 504 10091616 ) ) O O
13 504 505 10091616 , , O O
14 506 507 10091616 a DT B-NP O
15 508 519 10091616 significant JJ I-NP O
16 520 531 10091616 aggravation NN I-NP O
17 532 534 10091616 of IN B-PP O
18 535 538 10091616 the DT B-NP O
19 539 549 10091616 dyskinesia NN I-NP D004409
20 550 555 10091616 score NN I-NP O
21 556 559 10091616 was VBD B-VP O
22 560 568 10091616 observed VBN I-VP O
23 569 575 10091616 during IN B-PP O
24 576 584 10091616 speaking VBG B-VP O
25 585 590 10091616 aloud RB B-ADVP O
26 591 592 10091616 ( ( O O
27 592 596 10091616 5.2+ SYM B-NP O
28 596 597 10091616 / SYM O O
29 597 598 10091616 - SYM O O
30 598 601 10091616 1.1 CD B-NP O
31 601 602 10091616 , , O O
32 603 604 10091616 p NN B-NP O
33 604 605 10091616 < SYM B-NP O
34 605 609 10091616 0.05 CD I-NP O
35 609 610 10091616 ) ) O O
36 610 611 10091616 , , O O
37 612 621 10091616 movements NNS B-NP O
38 622 624 10091616 of IN B-PP O
39 625 630 10091616 right JJ O O
40 631 632 10091616 ( ( O O
41 632 636 10091616 4.5+ SYM B-NP O
42 636 637 10091616 / SYM O O
43 637 638 10091616 - SYM O O
44 638 641 10091616 1.0 CD B-NP O
45 641 642 10091616 , , O O
46 643 644 10091616 p NN B-NP O
47 644 645 10091616 < SYM B-NP O
48 645 649 10091616 0.05 CD I-NP O
49 649 650 10091616 ) ) O O
50 651 654 10091616 and CC O O
51 655 659 10091616 left VBN B-VP O
52 660 661 10091616 ( ( O O
53 661 665 10091616 3.7+ SYM B-NP O
54 665 666 10091616 / SYM O O
55 666 667 10091616 - SYM O O
56 667 670 10091616 0.8 CD B-NP O
57 670 671 10091616 , , O O
58 672 673 10091616 p NN B-NP O
59 673 674 10091616 < SYM O O
60 674 678 10091616 0.05 CD O O
61 678 679 10091616 ) ) O O
62 680 687 10091616 fingers NNS B-NP O
63 687 688 10091616 , , O O
64 689 698 10091616 movements NNS B-NP O
65 699 701 10091616 of IN B-PP O
66 702 705 10091616 the DT B-NP O
67 706 710 10091616 neck NN I-NP O
68 711 712 10091616 ( ( O O
69 712 716 10091616 5.1+ SYM B-NP O
70 716 717 10091616 / SYM O O
71 717 718 10091616 - SYM O O
72 718 721 10091616 1.0 CD B-NP O
73 721 722 10091616 , , O O
74 723 724 10091616 p NN B-NP O
75 724 725 10091616 < SYM B-NP O
76 725 729 10091616 0.05 CD I-NP O
77 729 730 10091616 ) ) O O
78 730 731 10091616 , , O O
79 732 735 10091616 and CC O O
80 736 742 10091616 mental JJ B-NP O
81 743 754 10091616 calculation NN I-NP O
82 755 756 10091616 ( ( O O
83 756 760 10091616 3.1+ SYM B-NP O
84 760 761 10091616 / SYM O O
85 761 762 10091616 - SYM O O
86 762 765 10091616 1.0 CD B-NP O
87 765 766 10091616 , , O O
88 767 768 10091616 p NN B-NP O
89 768 769 10091616 < SYM B-NP O
90 769 773 10091616 0.05 CD I-NP O
91 773 774 10091616 ) ) O O
92 774 775 10091616 . . O O

1 776 781 10091616 These DT B-NP O
2 782 789 10091616 results NNS I-NP O
3 790 797 10091616 suggest VBP B-VP O
4 798 802 10091616 that IN B-SBAR O
5 803 813 10091616 activation NN B-NP O
6 814 819 10091616 tasks NNS I-NP O
7 820 824 10091616 such JJ B-PP O
8 825 827 10091616 as IN I-PP O
9 828 829 10091616 " `` O O
10 829 837 10091616 speaking VBG B-VP O
11 838 843 10091616 aloud RB B-ADVP O
12 843 844 10091616 " '' O O
13 845 850 10091616 could MD B-VP O
14 851 853 10091616 be VB I-VP O
15 854 858 10091616 used VBN I-VP O
16 859 862 10091616 for IN B-PP O
17 863 872 10091616 objective JJ B-NP O
18 873 883 10091616 assessment NN I-NP O
19 884 886 10091616 of IN B-PP O
20 887 897 10091616 dyskinesia NN B-NP D004409
21 898 906 10091616 severity NN I-NP O
22 906 907 10091616 . . O O

1 0 0 11861791 -DOCSTART- -X- -X- O

1 0 10 11861791 Activation NN B-NP O
2 11 13 11861791 of IN B-PP O
3 14 22 11861791 poly(ADP NN B-NP D011064
4 22 23 11861791 - HYPH B-NP D011064
5 23 30 11861791 ribose) NN I-NP D011064
6 31 41 11861791 polymerase NN I-NP O
7 42 53 11861791 contributes VBZ B-VP O
8 54 56 11861791 to TO B-PP O
9 57 68 11861791 development NN B-NP O
10 69 71 11861791 of IN B-PP O
11 72 83 11861791 doxorubicin NN B-NP D004317
12 83 84 11861791 - HYPH B-NP O
13 84 91 11861791 induced VBN I-NP O
14 92 97 11861791 heart NN I-NP D006333
15 98 105 11861791 failure NN I-NP D006333
16 105 106 11861791 . . I-NP O
17 107 117 11861791 Activation NN I-NP O
18 118 120 11861791 of IN B-PP O
19 121 124 11861791 the DT B-NP O
20 125 132 11861791 nuclear JJ I-NP O
21 133 139 11861791 enzyme NN I-NP O
22 140 148 11861791 poly(ADP NN I-NP D011064
23 148 149 11861791 - HYPH B-NP D011064
24 149 156 11861791 ribose) NN I-NP D011064
25 157 167 11861791 polymerase NN I-NP O
26 168 169 11861791 ( ( O O
27 169 173 11861791 PARP NN B-NP O
28 173 174 11861791 ) ) O O
29 175 177 11861791 by IN B-PP O
30 178 185 11861791 oxidant NN B-NP O
31 185 186 11861791 - HYPH O O
32 186 194 11861791 mediated VBN B-NP O
33 195 198 11861791 DNA NN I-NP O
34 199 205 11861791 damage NN I-NP O
35 206 208 11861791 is VBZ B-VP O
36 209 211 11861791 an DT B-NP O
37 212 221 11861791 important JJ I-NP O
38 222 229 11861791 pathway NN I-NP O
39 230 232 11861791 of IN B-PP O
40 233 237 11861791 cell NN B-NP O
41 238 249 11861791 dysfunction NN I-NP O
42 250 253 11861791 and CC O O
43 254 260 11861791 tissue NN B-NP O
44 261 267 11861791 injury NN I-NP O
45 268 270 11861791 in IN B-PP O
46 271 281 11861791 conditions NNS B-NP O
47 282 292 11861791 associated VBN B-VP O
48 293 297 11861791 with IN B-PP O
49 298 307 11861791 oxidative JJ B-NP O
50 308 314 11861791 stress NN I-NP O
51 314 315 11861791 . . O O

1 316 325 11861791 Increased VBN B-NP O
2 326 335 11861791 oxidative JJ I-NP O
3 336 342 11861791 stress NN I-NP O
4 343 345 11861791 is VBZ B-VP O
5 346 347 11861791 a DT B-NP O
6 348 353 11861791 major JJ I-NP O
7 354 360 11861791 factor NN I-NP O
8 361 371 11861791 implicated VBN B-VP O
9 372 374 11861791 in IN B-PP O
10 375 378 11861791 the DT B-NP O
11 379 393 11861791 cardiotoxicity NN I-NP D066126
12 394 396 11861791 of IN B-PP O
13 397 408 11861791 doxorubicin NN B-NP D004317
14 409 410 11861791 ( ( O O
15 410 413 11861791 DOX NN B-NP D004317
16 413 414 11861791 ) ) O O
17 414 415 11861791 , , O O
18 416 417 11861791 a DT B-NP O
19 418 424 11861791 widely RB I-NP O
20 425 429 11861791 used VBN I-NP O
21 430 439 11861791 antitumor JJ I-NP O
22 440 453 11861791 anthracycline NN I-NP D018943
23 454 464 11861791 antibiotic NN I-NP O
24 464 465 11861791 . . O O

1 466 470 11861791 Thus RB B-ADVP O
2 470 471 11861791 , , O O
3 472 474 11861791 we PRP B-NP O
4 475 487 11861791 hypothesized VBD B-VP O
5 488 492 11861791 that IN B-SBAR O
6 493 496 11861791 the DT B-NP O
7 497 507 11861791 activation NN I-NP O
8 508 510 11861791 of IN B-PP O
9 511 515 11861791 PARP NN B-NP O
10 516 519 11861791 may MD B-VP O
11 520 530 11861791 contribute VB I-VP O
12 531 533 11861791 to TO B-PP O
13 534 537 11861791 the DT B-NP O
14 538 541 11861791 DOX NN I-NP D004317
15 541 542 11861791 - HYPH B-NP O
16 542 549 11861791 induced VBN I-NP O
17 550 564 11861791 cardiotoxicity NN I-NP D066126
18 564 565 11861791 . . O O

1 566 571 11861791 Using VBG B-VP O
2 572 573 11861791 a DT B-NP O
3 574 578 11861791 dual JJ I-NP O
4 579 587 11861791 approach NN I-NP O
5 588 590 11861791 of IN B-PP O
6 591 595 11861791 PARP NN B-NP O
7 595 596 11861791 - HYPH B-NP O
8 596 597 11861791 1 CD I-NP O
9 598 609 11861791 suppression NN I-NP O
10 609 610 11861791 , , O O
11 611 613 11861791 by IN B-PP O
12 614 621 11861791 genetic JJ B-NP O
13 622 630 11861791 deletion NN I-NP O
14 631 633 11861791 or CC O O
15 634 649 11861791 pharmacological JJ B-NP O
16 650 660 11861791 inhibition NN I-NP O
17 661 665 11861791 with IN B-PP O
18 666 669 11861791 the DT B-NP O
19 670 686 11861791 phenanthridinone NN I-NP O
20 687 691 11861791 PARP NN I-NP O
21 692 701 11861791 inhibitor NN I-NP O
22 702 706 11861791 PJ34 NN I-NP C434926
23 706 707 11861791 , , O O
24 708 710 11861791 we PRP B-NP O
25 711 714 11861791 now RB B-ADVP O
26 715 726 11861791 demonstrate VBP B-VP O
27 727 730 11861791 the DT B-NP O
28 731 735 11861791 role NN I-NP O
29 736 738 11861791 of IN B-PP O
30 739 743 11861791 PARP NN B-NP O
31 744 746 11861791 in IN B-PP O
32 747 750 11861791 the DT B-NP O
33 751 762 11861791 development NN I-NP O
34 763 765 11861791 of IN B-PP O
35 766 773 11861791 cardiac JJ B-NP D006331
36 774 785 11861791 dysfunction NN I-NP D006331
37 786 793 11861791 induced VBN B-VP O
38 794 796 11861791 by IN B-PP O
39 797 800 11861791 DOX NN B-NP D004317
40 800 801 11861791 . . O O

1 802 806 11861791 PARP NN B-NP O
2 806 807 11861791 - HYPH O O
3 807 809 11861791 1+ SYM B-NP O
4 809 810 11861791 / SYM B-NP O
5 810 811 11861791 + SYM B-NP O
6 812 815 11861791 and CC O O
7 816 820 11861791 PARP NN B-NP O
8 820 821 11861791 - HYPH B-NP O
9 821 822 11861791 1 CD I-NP O
10 822 823 11861791 - HYPH O O
11 823 824 11861791 / SYM O O
12 824 825 11861791 - HYPH O O
13 826 830 11861791 mice NNS B-NP O
14 831 839 11861791 received VBD B-VP O
15 840 841 11861791 a DT B-NP O
16 842 848 11861791 single JJ I-NP O
17 849 858 11861791 injection NN I-NP O
18 859 861 11861791 of IN B-PP O
19 862 865 11861791 DOX NN B-NP D004317
20 866 867 11861791 ( ( O O
21 867 869 11861791 25 CD B-NP O
22 870 872 11861791 mg NN I-NP O
23 872 873 11861791 / SYM B-NP O
24 873 875 11861791 kg NN I-NP O
25 876 879 11861791 i.p NN I-NP O
26 879 880 11861791 ) ) O O
27 880 881 11861791 . . O O

1 882 886 11861791 Five CD B-NP O
2 887 891 11861791 days NNS I-NP O
3 892 897 11861791 after IN B-PP O
4 898 901 11861791 DOX NN B-NP D004317
5 902 916 11861791 administration NN I-NP O
6 916 917 11861791 , , O O
7 918 922 11861791 left VBD B-VP O
8 923 934 11861791 ventricular JJ B-NP O
9 935 946 11861791 performance NN I-NP O
10 947 950 11861791 was VBD B-VP O
11 951 964 11861791 significantly RB I-VP O
12 965 974 11861791 depressed VBN I-VP O
13 975 977 11861791 in IN B-PP O
14 978 982 11861791 PARP NN B-NP O
15 982 983 11861791 - HYPH O O
16 983 985 11861791 1+ SYM B-NP O
17 985 986 11861791 / SYM B-VP O
18 986 987 11861791 + SYM B-NP O
19 988 992 11861791 mice NNS I-NP O
20 992 993 11861791 , , O O
21 994 997 11861791 but CC O O
22 998 1002 11861791 only RB B-ADVP O
23 1003 1005 11861791 to TO B-PP O
24 1006 1007 11861791 a DT B-NP O
25 1008 1015 11861791 smaller JJR I-NP O
26 1016 1022 11861791 extent NN I-NP O
27 1023 1025 11861791 in IN B-PP O
28 1026 1030 11861791 PARP NN B-NP O
29 1030 1031 11861791 - HYPH B-NP O
30 1031 1032 11861791 1 CD I-NP O
31 1032 1033 11861791 - HYPH B-NP O
32 1033 1034 11861791 / SYM I-NP O
33 1034 1035 11861791 - HYPH I-NP O
34 1036 1040 11861791 ones NNS B-NP O
35 1040 1041 11861791 . . O O

1 1042 1049 11861791 Similar JJ B-NP O
2 1050 1061 11861791 experiments NNS I-NP O
3 1062 1066 11861791 were VBD B-VP O
4 1067 1076 11861791 conducted VBN I-VP O
5 1077 1079 11861791 in IN B-PP O
6 1080 1084 11861791 BALB NN B-NP O
7 1084 1085 11861791 / SYM B-NP O
8 1085 1086 11861791 c NN I-NP O
9 1087 1091 11861791 mice NNS I-NP O
10 1092 1099 11861791 treated VBN B-VP O
11 1100 1104 11861791 with IN B-PP O
12 1105 1109 11861791 PJ34 NN B-NP C434926
13 1110 1112 11861791 or CC I-NP O
14 1113 1120 11861791 vehicle NN I-NP O
15 1120 1121 11861791 . . O O

1 1122 1131 11861791 Treatment NN B-NP O
2 1132 1136 11861791 with IN B-PP O
3 1137 1138 11861791 a DT B-NP O
4 1139 1143 11861791 PJ34 NN I-NP C434926
5 1144 1157 11861791 significantly RB B-ADVP O
6 1158 1166 11861791 improved VBD B-VP O
7 1167 1174 11861791 cardiac JJ B-NP D006331
8 1175 1186 11861791 dysfunction NN I-NP D006331
9 1187 1190 11861791 and CC O O
10 1191 1200 11861791 increased VBD B-VP O
11 1201 1204 11861791 the DT B-NP O
12 1205 1213 11861791 survival NN I-NP O
13 1214 1216 11861791 of IN B-PP O
14 1217 1220 11861791 the DT B-NP O
15 1221 1228 11861791 animals NNS I-NP O
16 1228 1229 11861791 . . O O

1 1230 1232 11861791 In IN B-PP O
2 1233 1241 11861791 addition NN B-NP O
3 1242 1246 11861791 PJ34 NN I-NP C434926
4 1247 1260 11861791 significantly RB B-ADVP O
5 1261 1268 11861791 reduced VBD B-VP O
6 1269 1272 11861791 the DT B-NP O
7 1273 1276 11861791 DOX NN I-NP D004317
8 1276 1277 11861791 - HYPH B-VP O
9 1277 1284 11861791 induced VBN B-NP O
10 1285 1293 11861791 increase NN I-NP O
11 1294 1296 11861791 in IN B-PP O
12 1297 1300 11861791 the DT B-NP O
13 1301 1306 11861791 serum NN I-NP O
14 1307 1314 11861791 lactate NN I-NP D019344
15 1315 1328 11861791 dehydrogenase NN I-NP O
16 1329 1332 11861791 and CC O O
17 1333 1341 11861791 creatine NN B-NP D003401
18 1342 1348 11861791 kinase NN I-NP O
19 1349 1359 11861791 activities NNS I-NP O
20 1360 1363 11861791 but CC B-NP O
21 1364 1367 11861791 not RB I-NP O
22 1368 1385 11861791 metalloproteinase NN B-NP O
23 1386 1396 11861791 activation NN I-NP O
24 1397 1399 11861791 in IN B-PP O
25 1400 1403 11861791 the DT B-NP O
26 1404 1409 11861791 heart NN I-NP O
27 1409 1410 11861791 . . O O

1 1411 1415 11861791 Thus RB B-ADVP O
2 1415 1416 11861791 , , O O
3 1417 1421 11861791 PARP NN B-NP O
4 1422 1432 11861791 activation NN I-NP O
5 1433 1444 11861791 contributes VBZ B-VP O
6 1445 1447 11861791 to TO B-PP O
7 1448 1451 11861791 the DT B-NP O
8 1452 1466 11861791 cardiotoxicity NN I-NP D066126
9 1467 1469 11861791 of IN B-PP O
10 1470 1473 11861791 DOX NN B-NP D004317
11 1473 1474 11861791 . . O O

1 1475 1479 11861791 PARP NN B-NP O
2 1480 1490 11861791 inhibitors NNS I-NP O
3 1491 1494 11861791 may MD B-VP O
4 1495 1500 11861791 exert VB I-VP O
5 1501 1511 11861791 protective JJ B-NP O
6 1512 1519 11861791 effects NNS I-NP O
7 1520 1527 11861791 against IN B-PP O
8 1528 1531 11861791 the DT B-NP O
9 1532 1543 11861791 development NN I-NP O
10 1544 1546 11861791 of IN B-PP O
11 1547 1553 11861791 severe JJ B-NP O
12 1554 1561 11861791 cardiac JJ I-NP D005117
13 1562 1575 11861791 complications NNS I-NP D005117
14 1576 1586 11861791 associated VBN B-VP O
15 1587 1591 11861791 with IN B-PP O
16 1592 1595 11861791 the DT B-NP O
17 1596 1599 11861791 DOX NN I-NP D004317
18 1600 1609 11861791 treatment NN I-NP O
19 1609 1610 11861791 . . O O

1 0 0 3780697 -DOCSTART- -X- -X- O

1 0 4 3780697 Post AFX B-NP O
2 4 5 3780697 - HYPH I-NP O
3 5 14 3780697 operative JJ I-NP O
4 15 23 3780697 rigidity NN I-NP D009127
5 24 29 3780697 after IN B-PP O
6 30 38 3780697 fentanyl NN B-NP D005283
7 39 53 3780697 administration NN I-NP O
8 53 54 3780697 . . O O
9 55 56 3780697 A DT B-NP O
10 57 61 3780697 case NN I-NP O
11 62 64 3780697 of IN B-PP O
12 65 72 3780697 thoraco AFX B-NP O
13 72 73 3780697 - HYPH I-NP O
14 73 82 3780697 abdominal JJ I-NP O
15 83 91 3780697 rigidity NN I-NP D009127
16 92 99 3780697 leading VBG B-VP O
17 100 102 3780697 to TO B-PP O
18 103 114 3780697 respiratory JJ B-NP D012131
19 115 122 3780697 failure NN I-NP D012131
20 123 125 3780697 is VBZ B-VP O
21 126 135 3780697 described VBN I-VP O
22 136 138 3780697 in IN B-PP O
23 139 142 3780697 the DT B-NP O
24 143 147 3780697 post AFX I-NP O
25 147 148 3780697 - HYPH I-NP O
26 148 157 3780697 operative JJ I-NP O
27 158 164 3780697 period NN I-NP O
28 165 167 3780697 in IN B-PP O
29 168 170 3780697 an DT B-NP O
30 171 178 3780697 elderly JJ I-NP O
31 179 186 3780697 patient NN I-NP O
32 187 190 3780697 who WP B-NP O
33 191 199 3780697 received VBD B-VP O
34 200 201 3780697 a DT B-NP O
35 202 210 3780697 moderate JJ I-NP O
36 211 215 3780697 dose NN I-NP O
37 216 218 3780697 of IN B-PP O
38 219 227 3780697 fentanyl NN B-NP D005283
39 227 228 3780697 . . O O

1 229 233 3780697 This DT B-NP O
2 234 237 3780697 was VBD B-VP O
3 238 250 3780697 successfully RB I-VP O
4 251 259 3780697 reversed VBN I-VP O
5 260 262 3780697 by IN B-PP O
6 263 271 3780697 naloxone NN B-NP D009270
7 271 272 3780697 . . O O

1 273 276 3780697 The DT B-NP O
2 277 287 3780697 mechanisms NNS I-NP O
3 288 296 3780697 possibly RB B-VP O
4 297 307 3780697 implicated VBN I-VP O
5 308 310 3780697 in IN B-PP O
6 311 315 3780697 this DT B-NP O
7 316 324 3780697 accident NN I-NP O
8 325 328 3780697 are VBP B-VP O
9 329 338 3780697 discussed VBN I-VP O
10 338 339 3780697 . . O O

1 0 0 803783 -DOCSTART- -X- -X- O

1 0 5 803783 Water JJ B-NP D014869
2 6 18 803783 intoxication NN I-NP D014869
3 19 29 803783 associated VBN B-VP O
4 30 34 803783 with IN B-PP O
5 35 43 803783 oxytocin NN B-NP D010121
6 44 58 803783 administration NN I-NP O
7 59 65 803783 during IN B-PP O
8 66 72 803783 saline NN B-NP O
9 72 73 803783 - HYPH B-NP O
10 73 80 803783 induced VBN I-NP O
11 81 89 803783 abortion NN I-NP D000031
12 89 90 803783 . . O O
13 91 95 803783 Four CD B-NP O
14 96 101 803783 cases NNS I-NP O
15 102 104 803783 of IN B-PP O
16 105 110 803783 water NN B-NP D014869
17 111 123 803783 intoxication NN I-NP D014869
18 124 126 803783 in IN B-PP O
19 127 137 803783 connection NN B-NP O
20 138 142 803783 with IN B-PP O
21 143 151 803783 oxytocin NN B-NP D010121
22 152 166 803783 administration NN I-NP O
23 167 173 803783 during IN B-PP O
24 174 180 803783 saline NN B-NP O
25 180 181 803783 - HYPH B-NP O
26 181 188 803783 induced VBN I-NP O
27 189 198 803783 abortions NNS I-NP D000031
28 199 202 803783 are VBP B-VP O
29 203 212 803783 described VBN I-VP O
30 212 213 803783 . . O O

1 214 217 803783 The DT B-NP O
2 218 227 803783 mechanism NN I-NP O
3 228 230 803783 of IN B-PP O
4 231 236 803783 water NN B-NP D014869
5 237 249 803783 intoxication NN I-NP D014869
6 250 252 803783 is VBZ B-VP O
7 253 262 803783 discussed VBN I-VP O
8 263 265 803783 in IN B-PP O
9 266 272 803783 regard NN B-NP O
10 273 275 803783 to TO B-PP O
11 276 281 803783 these DT B-NP O
12 282 287 803783 cases NNS I-NP O
13 287 288 803783 . . O O

1 289 297 803783 Oxytocin NN B-NP D010121
2 298 312 803783 administration NN I-NP O
3 313 319 803783 during IN B-PP O
4 320 332 803783 midtrimester NN B-NP O
5 332 333 803783 - HYPH B-NP O
6 333 340 803783 induced VBN I-NP O
7 341 350 803783 abortions NNS I-NP D000031
8 351 353 803783 is VBZ B-VP O
9 354 363 803783 advocated VBN I-VP O
10 364 368 803783 only RB B-SBAR O
11 369 371 803783 if IN I-SBAR O
12 372 374 803783 it PRP B-NP O
13 375 378 803783 can MD B-VP O
14 379 381 803783 be VB I-VP O
15 382 389 803783 carried VBN I-VP O
16 390 393 803783 out RP B-PRT O
17 394 399 803783 under IN B-PP O
18 400 407 803783 careful JJ B-NP O
19 408 420 803783 observations NNS I-NP O
20 421 423 803783 of IN B-PP O
21 424 426 803783 an DT B-NP O
22 427 432 803783 alert JJ I-NP O
23 433 440 803783 nursing NN I-NP O
24 441 446 803783 staff NN I-NP O
25 446 447 803783 , , O O
26 448 453 803783 aware JJ B-ADJP O
27 454 456 803783 of IN B-PP O
28 457 460 803783 the DT B-NP O
29 461 469 803783 symptoms NNS I-NP O
30 470 472 803783 of IN B-PP O
31 473 478 803783 water NN B-NP D014869
32 479 491 803783 intoxication NN I-NP D014869
33 492 495 803783 and CC O O
34 496 506 803783 instructed VBN B-VP O
35 507 509 803783 to TO B-VP O
36 510 515 803783 watch VB I-VP O
37 516 519 803783 the DT B-NP O
38 520 528 803783 diuresis NN I-NP O
39 529 532 803783 and CC I-NP O
40 533 539 803783 report NN I-NP O
41 540 544 803783 such JJ B-NP O
42 545 550 803783 early JJ I-NP O
43 551 556 803783 signs NNS I-NP O
44 557 559 803783 of IN B-PP O
45 560 563 803783 the DT B-NP O
46 564 572 803783 syndrome NN I-NP O
47 573 575 803783 as IN B-PP O
48 576 584 803783 asthenia NN B-NP D001247
49 584 585 803783 , , O O
50 586 594 803783 muscular JJ B-NP O
51 595 607 803783 irritability NN I-NP D001523
52 607 608 803783 , , O O
53 609 611 803783 or CC O O
54 612 621 803783 headaches NNS B-NP D006261
55 621 622 803783 . . O O

1 623 626 803783 The DT B-NP O
2 627 635 803783 oxytocin NN I-NP D010121
3 636 642 803783 should MD B-VP O
4 643 645 803783 be VB I-VP O
5 646 651 803783 given VBN I-VP O
6 652 656 803783 only RB B-ADVP O
7 657 659 803783 in IN B-PP O
8 660 667 803783 Ringers NNS B-NP O
9 668 675 803783 lactate NN I-NP D019344
10 676 678 803783 or CC O O
11 678 679 803783 , , O O
12 680 691 803783 alternately RB B-ADVP O
13 691 692 803783 , , O O
14 693 695 803783 in IN B-PP O
15 696 703 803783 Ringers NNS B-NP O
16 704 711 803783 lactate NN I-NP D019344
17 712 715 803783 and CC O O
18 716 717 803783 a DT B-NP O
19 718 719 803783 5 CD I-NP O
20 720 723 803783 per IN B-PP O
21 724 728 803783 cent NN B-NP O
22 729 737 803783 dextrose NN I-NP D005947
23 738 741 803783 and CC I-NP O
24 742 747 803783 water NN I-NP O
25 748 757 803783 solutions NNS I-NP O
26 757 758 803783 . . O O

1 759 762 803783 The DT B-NP O
2 763 770 803783 urinary JJ I-NP O
3 771 777 803783 output NN I-NP O
4 778 784 803783 should MD B-VP O
5 785 787 803783 be VB I-VP O
6 788 797 803783 monitored VBN I-VP O
7 798 801 803783 and CC O O
8 802 805 803783 the DT B-NP O
9 806 814 803783 oxytocin NN I-NP D010121
10 815 829 803783 administration NN I-NP O
11 830 842 803783 discontinued VBD B-VP O
12 843 846 803783 and CC O O
13 847 850 803783 the DT B-NP O
14 851 856 803783 serum NN I-NP O
15 857 869 803783 electrolytes NNS I-NP O
16 870 877 803783 checked VBD B-VP O
17 878 880 803783 if IN B-SBAR O
18 881 884 803783 the DT B-NP O
19 885 892 803783 urinary JJ I-NP O
20 893 899 803783 output NN I-NP O
21 900 909 803783 decreases NNS I-NP O
22 909 910 803783 . . O O

1 911 914 803783 The DT B-NP O
2 915 923 803783 oxytocin NN I-NP D010121
3 924 930 803783 should MD B-VP O
4 931 934 803783 not RB I-VP O
5 935 937 803783 be VB I-VP O
6 938 950 803783 administered VBN I-VP O
7 951 953 803783 in IN B-PP O
8 954 960 803783 excess NN B-NP O
9 961 963 803783 of IN B-PP O
10 964 966 803783 36 CD B-NP O
11 967 972 803783 hours NNS I-NP O
12 972 973 803783 . . O O

1 974 976 803783 If IN B-SBAR O
2 977 980 803783 the DT B-NP O
3 981 988 803783 patient NN I-NP O
4 989 992 803783 has VBZ B-VP O
5 993 996 803783 not RB I-VP O
6 997 1004 803783 aborted VBN I-VP O
7 1005 1007 803783 by IN B-PP O
8 1008 1012 803783 then RB B-ADVP O
9 1013 1016 803783 the DT B-NP O
10 1017 1025 803783 oxytocin NN I-NP D010121
11 1026 1032 803783 should MD B-VP O
12 1033 1035 803783 be VB I-VP O
13 1036 1048 803783 discontinued VBN I-VP O
14 1049 1052 803783 for IN B-PP O
15 1053 1055 803783 10 CD B-NP O
16 1056 1058 803783 to TO I-NP O
17 1059 1061 803783 12 CD I-NP O
18 1062 1067 803783 hours NNS I-NP O
19 1068 1070 803783 in IN B-SBAR O
20 1071 1076 803783 order NN O O
21 1077 1079 803783 to TO B-VP O
22 1080 1087 803783 perform VB I-VP O
23 1088 1099 803783 electrolyte NN B-NP O
24 1100 1114 803783 determinations NNS I-NP O
25 1115 1118 803783 and CC O O
26 1119 1126 803783 correct VB B-VP O
27 1127 1130 803783 any DT B-NP O
28 1131 1142 803783 electrolyte NN I-NP O
29 1143 1152 803783 imbalance NN I-NP O
30 1152 1153 803783 . . O O

1 0 0 3183120 -DOCSTART- -X- -X- O

1 0 10 3183120 Reversible JJ B-NP O
2 11 19 3183120 cerebral JJ I-NP D001927
3 20 27 3183120 lesions NNS I-NP D001927
4 28 38 3183120 associated VBN B-VP O
5 39 43 3183120 with IN B-PP O
6 44 54 3183120 tiazofurin NN B-NP C033706
7 55 60 3183120 usage NN I-NP O
8 60 61 3183120 : : O O
9 62 64 3183120 MR NN B-NP O
10 65 78 3183120 demonstration NN I-NP O
11 78 79 3183120 . . O O
12 80 90 3183120 Tiazofurin NN B-NP C033706
13 91 93 3183120 is VBZ B-VP O
14 94 96 3183120 an DT B-NP O
15 97 109 3183120 experimental JJ I-NP O
16 110 126 3183120 chemotherapeutic JJ I-NP O
17 127 132 3183120 agent NN I-NP O
18 133 142 3183120 currently RB B-VP O
19 143 153 3183120 undergoing VBG I-VP O
20 154 162 3183120 clinical JJ B-NP O
21 163 173 3183120 evaluation NN I-NP O
22 173 174 3183120 . . O O

1 175 177 3183120 We PRP B-NP O
2 178 184 3183120 report VBP B-VP O
3 185 188 3183120 our PRP$ B-NP O
4 189 196 3183120 results NNS I-NP O
5 197 201 3183120 with IN B-PP O
6 202 210 3183120 magnetic JJ B-NP O
7 211 220 3183120 resonance NN I-NP O
8 221 222 3183120 ( ( O O
9 222 224 3183120 MR NN B-NP O
10 224 225 3183120 ) ) O O
11 226 228 3183120 in IN B-PP O
12 229 242 3183120 demonstrating VBG B-VP O
13 243 253 3183120 reversible JJ B-NP O
14 254 262 3183120 cerebral JJ I-NP D001927
15 263 276 3183120 abnormalities NNS I-NP D001927
16 277 287 3183120 concurrent JJ B-ADJP O
17 288 292 3183120 with IN B-PP O
18 293 296 3183120 the DT B-NP O
19 297 300 3183120 use NN I-NP O
20 301 303 3183120 of IN B-PP O
21 304 308 3183120 this DT B-NP O
22 309 313 3183120 drug NN I-NP O
23 313 314 3183120 . . O O

1 315 318 3183120 The DT B-NP O
2 319 332 3183120 abnormalities NNS I-NP O
3 333 335 3183120 on IN B-PP O
4 336 338 3183120 MR NN B-NP O
5 339 343 3183120 were VBD B-VP O
6 344 354 3183120 correlated VBN I-VP O
7 355 359 3183120 with IN B-PP O
8 360 368 3183120 findings NNS B-NP O
9 369 371 3183120 on IN B-PP O
10 372 374 3183120 CT NN B-NP O
11 375 377 3183120 as RB B-CONJP O
12 378 382 3183120 well RB I-CONJP O
13 383 385 3183120 as IN I-CONJP O
14 386 390 3183120 with IN B-PP O
15 391 399 3183120 cerebral JJ B-NP O
16 400 411 3183120 angiography NN I-NP O
17 411 412 3183120 . . O O

1 413 416 3183120 The DT B-NP O
2 417 424 3183120 utility NN I-NP O
3 425 427 3183120 of IN B-PP O
4 428 430 3183120 MR NN B-NP O
5 431 433 3183120 in IN B-PP O
6 434 437 3183120 the DT B-NP O
7 438 448 3183120 evaluation NN I-NP O
8 449 451 3183120 of IN B-PP O
9 452 460 3183120 patients NNS B-NP O
10 461 470 3183120 receiving VBG B-VP O
11 471 475 3183120 this DT B-NP O
12 476 479 3183120 new JJ I-NP O
13 480 485 3183120 agent NN I-NP O
14 486 488 3183120 is VBZ B-VP O
15 489 500 3183120 illustrated VBN I-VP O
16 500 501 3183120 . . O O

1 0 0 20533999 -DOCSTART- -X- -X- O

1 0 8 20533999 Dopamine NN B-NP D004298
2 9 11 20533999 is VBZ B-VP O
3 12 15 20533999 not RB O O
4 16 25 20533999 essential JJ B-ADJP O
5 26 29 20533999 for IN B-PP O
6 30 33 20533999 the DT B-NP O
7 34 45 20533999 development NN I-NP O
8 46 48 20533999 of IN B-PP O
9 49 64 20533999 methamphetamine NN B-NP D008694
10 64 65 20533999 - HYPH B-NP O
11 65 72 20533999 induced VBN I-NP O
12 73 86 20533999 neurotoxicity NN I-NP D020258
13 86 87 20533999 . . O O
14 88 90 20533999 It PRP B-NP O
15 91 93 20533999 is VBZ B-VP O
16 94 100 20533999 widely RB I-VP O
17 101 109 20533999 believed VBN I-VP O
18 110 114 20533999 that IN B-SBAR O
19 115 123 20533999 dopamine NN B-NP D004298
20 124 125 20533999 ( ( O O
21 125 127 20533999 DA NN B-NP D004298
22 127 128 20533999 ) ) O O
23 129 137 20533999 mediates VBZ B-VP O
24 138 153 20533999 methamphetamine NN B-NP D008694
25 154 155 20533999 ( ( O O
26 155 159 20533999 METH NN B-NP D008694
27 159 160 20533999 ) ) O O
28 160 161 20533999 - HYPH B-NP O
29 161 168 20533999 induced VBN I-NP O
30 169 177 20533999 toxicity NN I-NP D064420
31 178 180 20533999 to TO B-VP O
32 181 186 20533999 brain VB I-VP O
33 187 199 20533999 dopaminergic JJ B-NP O
34 200 207 20533999 neurons NNS I-NP O
35 207 208 20533999 , , O O
36 209 216 20533999 because IN B-SBAR O
37 217 222 20533999 drugs NNS B-NP O
38 223 227 20533999 that WDT B-NP O
39 228 237 20533999 interfere VBP B-VP O
40 238 242 20533999 with IN B-PP O
41 243 245 20533999 DA NN B-NP D004298
42 246 263 20533999 neurotransmission NN I-NP O
43 264 272 20533999 decrease NN I-NP O
44 273 281 20533999 toxicity NN I-NP D064420
45 281 282 20533999 , , O O
46 283 290 20533999 whereas IN O O
47 291 296 20533999 drugs NNS B-NP O
48 297 301 20533999 that WDT B-NP O
49 302 310 20533999 increase VBP B-VP O
50 311 313 20533999 DA NN B-NP D004298
51 314 331 20533999 neurotransmission NN I-NP O
52 332 339 20533999 enhance VBP B-VP O
53 340 348 20533999 toxicity NN B-NP D064420
54 348 349 20533999 . . O O

1 350 357 20533999 However RB B-ADVP O
2 357 358 20533999 , , O O
3 359 370 20533999 temperature JJ B-NP O
4 371 378 20533999 effects NNS I-NP O
5 379 381 20533999 of IN B-PP O
6 382 387 20533999 drugs NNS B-NP O
7 388 392 20533999 that WDT B-NP O
8 393 397 20533999 have VBP B-VP O
9 398 402 20533999 been VBN I-VP O
10 403 407 20533999 used VBN I-VP O
11 408 410 20533999 to TO I-VP O
12 411 421 20533999 manipulate VB I-VP O
13 422 427 20533999 brain NN B-NP O
14 428 430 20533999 DA NN I-NP D004298
15 431 448 20533999 neurotransmission NN I-NP O
16 449 457 20533999 confound VBD B-VP O
17 458 472 20533999 interpretation NN B-NP O
18 473 475 20533999 of IN B-PP O
19 476 479 20533999 the DT B-NP O
20 480 484 20533999 data NNS I-NP O
21 484 485 20533999 . . O O

1 486 490 20533999 Here RB B-ADVP O
2 491 493 20533999 we PRP B-NP O
3 494 498 20533999 show VBP B-VP O
4 499 503 20533999 that IN B-SBAR O
5 504 507 20533999 the DT B-NP O
6 508 516 20533999 recently RB I-NP O
7 517 525 20533999 reported VBN I-NP O
8 526 533 20533999 ability NN I-NP O
9 534 536 20533999 of IN B-PP O
10 537 538 20533999 L NN B-NP D007980
11 538 539 20533999 - HYPH O D007980
12 539 561 20533999 dihydroxyphenylalanine NN B-NP D007980
13 562 564 20533999 to TO B-VP O
14 565 572 20533999 reverse VB I-VP O
15 573 576 20533999 the DT B-NP O
16 577 587 20533999 protective JJ I-NP O
17 588 594 20533999 effect NN I-NP O
18 595 597 20533999 of IN B-PP O
19 598 603 20533999 alpha SYM B-NP D019805
20 603 604 20533999 - HYPH I-NP D019805
21 604 610 20533999 methyl NN I-NP D019805
22 610 611 20533999 - HYPH O D019805
23 611 615 20533999 para AFX O D019805
24 615 616 20533999 - HYPH O D019805
25 616 624 20533999 tyrosine NN B-NP D019805
26 625 627 20533999 on IN B-PP O
27 628 632 20533999 METH NN B-NP D008694
28 632 633 20533999 - HYPH B-NP O
29 633 640 20533999 induced VBN I-NP O
30 641 643 20533999 DA NN I-NP D004298
31 644 657 20533999 neurotoxicity NN I-NP D020258
32 658 660 20533999 is VBZ B-VP O
33 661 665 20533999 also RB I-VP O
34 666 676 20533999 confounded VBN I-VP O
35 677 679 20533999 by IN B-PP O
36 680 684 20533999 drug NN B-NP O
37 685 692 20533999 effects NNS I-NP O
38 693 695 20533999 on IN B-PP O
39 696 700 20533999 body NN B-NP O
40 701 712 20533999 temperature NN I-NP O
41 712 713 20533999 . . O O

1 714 721 20533999 Further RB B-ADVP O
2 721 722 20533999 , , O O
3 723 725 20533999 we PRP B-NP O
4 726 730 20533999 show VBP B-VP O
5 731 735 20533999 that IN B-SBAR O
6 736 740 20533999 mice NNS B-NP O
7 741 752 20533999 genetically RB B-VP O
8 753 763 20533999 engineered VBN I-VP O
9 764 766 20533999 to TO I-VP O
10 767 769 20533999 be VB I-VP O
11 770 779 20533999 deficient JJ B-ADJP O
12 780 782 20533999 in IN B-PP O
13 783 788 20533999 brain NN B-NP O
14 789 791 20533999 DA NN I-NP D004298
15 792 799 20533999 develop VBP B-VP O
16 800 804 20533999 METH NN B-NP D008694
17 805 818 20533999 neurotoxicity NN I-NP D020258
18 818 819 20533999 , , O O
19 820 822 20533999 as RB B-ADVP O
20 823 827 20533999 long RB I-ADVP O
21 828 830 20533999 as IN B-SBAR O
22 831 834 20533999 the DT B-NP O
23 835 842 20533999 thermic JJ I-NP O
24 843 850 20533999 effects NNS I-NP O
25 851 853 20533999 of IN B-PP O
26 854 858 20533999 METH NN B-NP D008694
27 859 862 20533999 are VBP B-VP O
28 863 872 20533999 preserved VBN I-VP O
29 872 873 20533999 . . O O

1 874 876 20533999 In IN B-PP O
2 877 885 20533999 addition NN B-NP O
3 885 886 20533999 , , O O
4 887 889 20533999 we PRP B-NP O
5 890 901 20533999 demonstrate VBP B-VP O
6 902 906 20533999 that IN B-SBAR O
7 907 911 20533999 mice NNS B-NP O
8 912 923 20533999 genetically RB B-VP O
9 924 934 20533999 engineered VBN I-VP O
10 935 937 20533999 to TO I-VP O
11 938 942 20533999 have VB I-VP O
12 943 953 20533999 unilateral JJ B-NP O
13 954 959 20533999 brain NN I-NP O
14 960 962 20533999 DA NN I-NP D004298
15 963 971 20533999 deficits NNS I-NP O
16 972 979 20533999 develop VBP B-VP O
17 980 984 20533999 METH NN B-NP D008694
18 984 985 20533999 - HYPH O O
19 985 992 20533999 induced VBN B-NP O
20 993 1005 20533999 dopaminergic JJ I-NP D009461
21 1006 1014 20533999 deficits NNS I-NP D009461
22 1015 1019 20533999 that WDT B-NP O
23 1020 1023 20533999 are VBP B-VP O
24 1024 1026 20533999 of IN B-PP O
25 1027 1037 20533999 comparable JJ B-NP O
26 1038 1047 20533999 magnitude NN I-NP O
27 1048 1050 20533999 on IN B-PP O
28 1051 1055 20533999 both DT B-NP O
29 1056 1061 20533999 sides NNS I-NP O
30 1062 1064 20533999 of IN B-PP O
31 1065 1068 20533999 the DT B-NP O
32 1069 1074 20533999 brain NN I-NP O
33 1074 1075 20533999 . . O O

1 1076 1081 20533999 Taken VBN B-VP O
2 1082 1090 20533999 together RB B-ADVP O
3 1090 1091 20533999 , , O O
4 1092 1097 20533999 these DT B-NP O
5 1098 1106 20533999 findings NNS I-NP O
6 1107 1118 20533999 demonstrate VBP B-VP O
7 1119 1123 20533999 that IN B-SBAR O
8 1124 1126 20533999 DA NN B-NP D004298
9 1127 1129 20533999 is VBZ B-VP O
10 1130 1133 20533999 not RB O O
11 1134 1143 20533999 essential JJ B-ADJP O
12 1144 1147 20533999 for IN B-PP O
13 1148 1151 20533999 the DT B-NP O
14 1152 1163 20533999 development NN I-NP O
15 1164 1166 20533999 of IN B-PP O
16 1167 1171 20533999 METH NN B-NP D008694
17 1171 1172 20533999 - HYPH B-NP O
18 1172 1179 20533999 induced VBN I-NP O
19 1180 1192 20533999 dopaminergic JJ I-NP O
20 1193 1206 20533999 neurotoxicity NN I-NP D020258
21 1207 1210 20533999 and CC O O
22 1211 1218 20533999 suggest VBP B-VP O
23 1219 1223 20533999 that IN B-SBAR O
24 1224 1234 20533999 mechanisms NNS B-NP O
25 1235 1246 20533999 independent JJ B-ADJP O
26 1247 1249 20533999 of IN B-PP O
27 1250 1252 20533999 DA NN B-NP D004298
28 1253 1260 20533999 warrant NN I-NP O
29 1261 1265 20533999 more RBR B-NP O
30 1266 1273 20533999 intense JJ I-NP O
31 1274 1287 20533999 investigation NN I-NP O
32 1287 1288 20533999 . . O O

1 0 0 6323692 -DOCSTART- -X- -X- O

1 0 12 6323692 Modification NN B-NP O
2 13 15 6323692 of IN B-PP O
3 16 20 6323692 drug NN B-NP O
4 21 27 6323692 action NN I-NP O
5 28 30 6323692 by IN B-PP O
6 31 45 6323692 hyperammonemia NN B-NP D022124
7 45 46 6323692 . . O O
8 47 59 6323692 Pretreatment NN B-NP O
9 60 64 6323692 with IN B-PP O
10 65 73 6323692 ammonium NN B-NP C018824
11 74 81 6323692 acetate NN I-NP C018824
12 82 83 6323692 ( ( O O
13 83 88 6323692 NH4Ac NN B-NP C018824
14 88 89 6323692 ) ) O O
15 90 91 6323692 ( ( O O
16 91 92 6323692 6 CD B-NP O
17 93 97 6323692 mmol NN I-NP O
18 97 98 6323692 / SYM B-NP O
19 98 100 6323692 kg NN I-NP O
20 101 104 6323692 s.c NN I-NP O
21 104 105 6323692 . . O O
22 105 106 6323692 ) ) O O
23 107 120 6323692 approximately RB B-ADVP O
24 121 128 6323692 doubled VBD B-VP O
25 129 132 6323692 the DT B-NP O
26 133 137 6323692 time NN I-NP O
27 138 146 6323692 morphine NN I-NP D009020
28 146 147 6323692 - HYPH B-NP O
29 147 154 6323692 treated VBN I-NP O
30 155 159 6323692 mice NNS I-NP O
31 160 168 6323692 remained VBD B-VP O
32 169 171 6323692 on IN B-PP O
33 172 173 6323692 a DT B-NP O
34 174 177 6323692 hot JJ I-NP O
35 178 185 6323692 surface NN I-NP O
36 186 189 6323692 and CC O O
37 190 199 6323692 similarly RB B-NP O
38 200 209 6323692 increased VBN I-NP O
39 210 218 6323692 muscular JJ I-NP O
40 219 233 6323692 incoordination NN I-NP D001259
41 234 236 6323692 by IN B-PP O
42 237 245 6323692 diazepam NN B-NP D003975
43 245 246 6323692 , , O O
44 247 250 6323692 but CC O O
45 251 256 6323692 NH4Ac NN B-NP C018824
46 257 266 6323692 treatment NN I-NP O
47 267 272 6323692 alone RB B-ADVP O
48 273 276 6323692 had VBD B-VP O
49 277 279 6323692 no DT B-NP O
50 280 286 6323692 effect NN I-NP O
51 286 287 6323692 . . O O

1 288 292 6323692 Thus RB B-ADVP O
2 292 293 6323692 , , O O
3 294 308 6323692 hyperammonemia NN B-NP D022124
4 309 311 6323692 is VBZ B-VP O
5 312 319 6323692 capable JJ B-ADJP O
6 320 322 6323692 of IN B-PP O
7 323 331 6323692 altering VBG B-VP O
8 332 336 6323692 drug NN B-NP O
9 337 343 6323692 action NN I-NP O
10 344 347 6323692 and CC O O
11 348 352 6323692 must MD B-VP O
12 353 355 6323692 be VB I-VP O
13 356 366 6323692 considered VBN I-VP O
14 367 372 6323692 along IN B-ADVP O
15 373 377 6323692 with IN B-PP O
16 378 386 6323692 impaired VBN B-NP O
17 387 391 6323692 drug NN I-NP O
18 392 402 6323692 metabolism NN I-NP O
19 403 405 6323692 in IN B-PP O
20 406 414 6323692 enhanced VBN B-NP O
21 415 419 6323692 drug NN I-NP O
22 420 429 6323692 responses NNS I-NP O
23 430 440 6323692 associated VBN B-VP O
24 441 445 6323692 with IN B-PP O
25 446 451 6323692 liver NN B-NP D008107
26 452 459 6323692 disease NN I-NP D008107
27 459 460 6323692 . . O O

1 461 472 6323692 Experiments NNS B-NP O
2 473 475 6323692 in FW B-ADVP O
3 476 481 6323692 vitro FW I-ADVP O
4 482 488 6323692 showed VBD B-VP O
5 489 493 6323692 that IN B-SBAR O
6 494 507 6323692 acetylcholine NN B-NP D000109
7 507 508 6323692 - HYPH B-NP O
8 508 515 6323692 induced VBN I-NP O
9 516 529 6323692 catecholamine NN I-NP D002395
10 530 537 6323692 release NN I-NP O
11 538 542 6323692 from IN B-PP O
12 543 549 6323692 bovine JJ B-NP O
13 550 557 6323692 adrenal JJ I-NP O
14 558 565 6323692 medulla NN I-NP O
15 566 568 6323692 is VBZ B-VP O
16 569 578 6323692 depressed VBN I-VP O
17 579 581 6323692 as RB B-NP O
18 582 586 6323692 much JJ I-NP O
19 587 589 6323692 as IN I-NP O
20 590 593 6323692 50% CD I-NP O
21 594 596 6323692 by IN B-PP O
22 597 600 6323692 0.3 CD B-NP O
23 601 603 6323692 mM NN I-NP O
24 604 609 6323692 NH4Ac NN I-NP C018824
25 610 613 6323692 and CC I-NP O
26 614 617 6323692 KCl NN I-NP D011189
27 617 618 6323692 - HYPH B-NP O
28 618 625 6323692 induced VBN I-NP O
29 626 638 6323692 contractions NNS I-NP O
30 639 641 6323692 of IN B-PP O
31 642 648 6323692 guinea NN B-NP O
32 648 649 6323692 - HYPH B-NP O
33 649 652 6323692 pig NN I-NP O
34 653 658 6323692 ileum NN I-NP O
35 659 663 6323692 were VBD B-VP O
36 664 673 6323692 inhibited VBN I-VP O
37 674 677 6323692 20% CD B-NP O
38 678 680 6323692 by IN B-PP O
39 681 682 6323692 5 CD B-NP O
40 683 685 6323692 mM NN I-NP O
41 686 691 6323692 NH4Ac NN I-NP C018824
42 691 692 6323692 . . O O

1 693 701 6323692 Addition NN B-NP O
2 702 704 6323692 of IN B-PP O
3 705 711 6323692 excess JJ B-NP O
4 712 719 6323692 calcium NN I-NP D002118
5 720 728 6323692 reversed VBD B-VP O
6 729 732 6323692 the DT B-NP O
7 733 743 6323692 depression NN I-NP D003866
8 744 746 6323692 in IN B-PP O
9 747 751 6323692 both DT B-NP O
10 752 759 6323692 tissues NNS I-NP O
11 759 760 6323692 , , O O
12 761 764 6323692 but CC O O
13 765 772 6323692 calcium NN B-NP D002118
14 772 773 6323692 - HYPH B-NP O
15 773 784 6323692 independent JJ I-NP O
16 785 798 6323692 catecholamine NN I-NP D002395
17 799 806 6323692 release NN I-NP O
18 807 809 6323692 by IN B-PP O
19 810 822 6323692 acetaldehyde NN B-NP D000079
20 823 826 6323692 was VBD B-VP O
21 827 830 6323692 not RB I-VP O
22 831 838 6323692 blocked VBN I-VP O
23 839 841 6323692 by IN B-PP O
24 842 847 6323692 NH4Ac NN B-NP C018824
25 847 848 6323692 . . O O

1 849 854 6323692 These DT B-NP O
2 855 862 6323692 results NNS I-NP O
3 863 872 6323692 suggested VBD B-VP O
4 873 877 6323692 that IN B-SBAR O
5 878 885 6323692 ammonia NN B-NP D000641
6 886 892 6323692 blocks VBZ B-VP O
7 893 900 6323692 calcium NN B-NP D002118
8 901 909 6323692 channels NNS I-NP O
9 909 910 6323692 . . O O

1 911 920 6323692 Parallels NNS B-NP O
2 921 923 6323692 in IN B-PP O
3 924 927 6323692 the DT B-NP O
4 928 935 6323692 actions NNS I-NP O
5 936 938 6323692 of IN B-PP O
6 939 944 6323692 NH4Ac NN B-NP C018824
7 945 948 6323692 and CC O O
8 949 952 6323692 the DT B-NP O
9 953 960 6323692 calcium NN I-NP D002118
10 961 968 6323692 channel NN I-NP O
11 969 976 6323692 blocker NN I-NP O
12 977 986 6323692 verapamil NN I-NP D014700
13 987 994 6323692 support VBP B-VP O
14 995 999 6323692 this DT B-NP O
15 1000 1007 6323692 concept NN I-NP O
16 1007 1008 6323692 . . O O

1 1009 1013 6323692 Both CC O O
2 1014 1023 6323692 verapamil NN B-NP D014700
3 1024 1025 6323692 ( ( O O
4 1025 1027 6323692 10 CD B-NP O
5 1028 1030 6323692 mg NN I-NP O
6 1030 1031 6323692 / SYM B-NP O
7 1031 1033 6323692 kg NN I-NP O
8 1034 1037 6323692 i.p NN I-NP O
9 1037 1038 6323692 . . O O
10 1038 1039 6323692 ) ) O O
11 1040 1043 6323692 and CC O O
12 1044 1049 6323692 NH4Ac NN B-NP C018824
13 1050 1062 6323692 pretreatment NN I-NP O
14 1063 1071 6323692 enhanced VBD B-VP O
15 1072 1080 6323692 morphine NN B-NP D009020
16 1081 1090 6323692 analgesia NN I-NP D000699
17 1090 1091 6323692 - HYPH B-NP O
18 1092 1095 6323692 and CC I-NP O
19 1096 1104 6323692 diazepam NN I-NP D003975
20 1104 1105 6323692 - HYPH O O
21 1105 1112 6323692 induced VBN B-NP O
22 1113 1121 6323692 muscular JJ I-NP O
23 1122 1136 6323692 incoordination NN I-NP D001259
24 1137 1140 6323692 and CC O O
25 1141 1152 6323692 antagonized VBD B-VP O
26 1153 1164 6323692 amphetamine NN B-NP D000661
27 1164 1165 6323692 - HYPH B-NP O
28 1165 1172 6323692 induced VBN I-NP O
29 1173 1178 6323692 motor NN I-NP O
30 1179 1187 6323692 activity NN I-NP O
31 1187 1188 6323692 , , O O
32 1189 1192 6323692 and CC O O
33 1193 1200 6323692 neither CC O O
34 1201 1210 6323692 verapamil NN B-NP D014700
35 1211 1214 6323692 nor CC I-NP O
36 1215 1220 6323692 NH4Ac NN I-NP C018824
37 1221 1229 6323692 affected VBD B-VP O
38 1230 1233 6323692 the DT B-NP O
39 1234 1244 6323692 convulsant JJ I-NP O
40 1245 1251 6323692 action NN I-NP O
41 1252 1254 6323692 of IN B-PP O
42 1255 1263 6323692 metrazol NN B-NP D010433
43 1263 1264 6323692 . . O O

1 1265 1268 6323692 The DT B-NP O
2 1269 1273 6323692 data NNS I-NP O
3 1274 1281 6323692 suggest VBP B-VP O
4 1282 1286 6323692 that IN B-SBAR O
5 1287 1301 6323692 hyperammonemia NN B-NP D022124
6 1302 1308 6323692 exerts VBZ B-VP O
7 1309 1310 6323692 a DT B-NP O
8 1311 1318 6323692 calcium NN I-NP D002118
9 1319 1326 6323692 channel NN I-NP O
10 1327 1335 6323692 blocking VBG B-VP O
11 1336 1342 6323692 action NN B-NP O
12 1343 1348 6323692 which WDT B-NP O
13 1349 1357 6323692 enhances VBZ B-VP O
14 1358 1361 6323692 the DT B-NP O
15 1362 1369 6323692 effects NNS I-NP O
16 1370 1372 6323692 of IN B-PP O
17 1373 1380 6323692 central JJ B-NP O
18 1381 1388 6323692 nervous JJ I-NP O
19 1389 1395 6323692 system NN I-NP O
20 1396 1407 6323692 depressants NNS I-NP O
21 1408 1411 6323692 and CC O O
22 1412 1419 6323692 certain JJ B-NP O
23 1420 1426 6323692 opioid JJ I-NP O
24 1427 1437 6323692 analgesics NNS I-NP O
25 1437 1438 6323692 . . O O

1 0 0 14648024 -DOCSTART- -X- -X- O

1 0 3 14648024 All DT B-NP D014212
2 3 4 14648024 - HYPH I-NP D014212
3 5 10 14648024 trans AFX I-NP D014212
4 10 11 14648024 - HYPH I-NP D014212
5 11 19 14648024 retinoic JJ B-NP D014212
6 20 24 14648024 acid NN I-NP D014212
7 24 25 14648024 - HYPH B-NP O
8 25 32 14648024 induced VBN I-NP O
9 33 41 14648024 erythema NN I-NP D004893
10 42 49 14648024 nodosum NN I-NP D004893
11 50 52 14648024 in IN B-PP O
12 53 61 14648024 patients NNS B-NP O
13 62 66 14648024 with IN B-PP O
14 67 72 14648024 acute JJ B-NP D015473
15 73 86 14648024 promyelocytic JJ I-NP D015473
16 87 95 14648024 leukemia NN I-NP D015473
17 95 96 14648024 . . O O
18 97 105 14648024 Erythema NN B-NP D004893
19 106 113 14648024 nodosum NN I-NP D004893
20 114 124 14648024 associated VBN B-VP O
21 125 129 14648024 with IN B-PP O
22 130 133 14648024 all DT B-NP D014212
23 133 134 14648024 - HYPH I-NP D014212
24 135 140 14648024 trans AFX I-NP D014212
25 140 141 14648024 - HYPH I-NP D014212
26 141 149 14648024 retinoic JJ B-NP D014212
27 150 154 14648024 acid NN I-NP D014212
28 155 156 14648024 ( ( O O
29 156 160 14648024 ATRA NN B-NP D014212
30 160 161 14648024 ) ) O O
31 162 165 14648024 for IN B-PP O
32 166 171 14648024 acute JJ B-NP D015473
33 172 185 14648024 promyelocytic JJ I-NP D015473
34 186 194 14648024 leukemia NN I-NP D015473
35 195 196 14648024 ( ( O O
36 196 199 14648024 APL NN B-NP D015473
37 199 200 14648024 ) ) O O
38 201 203 14648024 is VBZ B-VP O
39 204 208 14648024 very RB B-ADJP O
40 209 213 14648024 rare JJ I-ADJP O
41 213 214 14648024 . . O O

1 215 217 14648024 We PRP B-NP O
2 218 226 14648024 describe VBP B-VP O
3 227 231 14648024 four CD B-NP O
4 232 240 14648024 patients NNS I-NP O
5 241 245 14648024 with IN B-PP O
6 246 253 14648024 classic JJ B-NP O
7 254 257 14648024 APL NN I-NP D015473
8 258 261 14648024 who WP B-NP O
9 262 271 14648024 developed VBD B-VP O
10 272 280 14648024 erythema NN B-NP D004893
11 281 288 14648024 nodosum NN I-NP D004893
12 289 295 14648024 during IN B-PP O
13 296 300 14648024 ATRA NN B-NP D014212
14 301 308 14648024 therapy NN I-NP O
15 308 309 14648024 . . O O

1 310 315 14648024 Fever RB B-ADVP D005334
2 316 319 14648024 and CC O O
3 320 330 14648024 subsequent JJ B-NP O
4 331 339 14648024 multiple JJ I-NP O
5 340 347 14648024 painful JJ I-NP D010146
6 348 360 14648024 erythematous JJ I-NP D004893
7 361 368 14648024 nodules NNS I-NP D004893
8 369 373 14648024 over IN B-PP O
9 374 385 14648024 extremities NNS B-NP O
10 386 395 14648024 developed VBN B-VP O
11 396 398 14648024 on IN B-PP O
12 399 402 14648024 D11 NN B-NP O
13 402 403 14648024 , , O O
14 404 407 14648024 D16 NN B-NP O
15 407 408 14648024 , , O O
16 409 412 14648024 D17 NN B-NP O
17 412 413 14648024 , , O O
18 414 417 14648024 and CC O O
19 418 421 14648024 D19 NN B-NP O
20 421 422 14648024 , , O O
21 423 435 14648024 respectively RB B-ADVP O
22 435 436 14648024 , , O O
23 437 442 14648024 after IN B-PP O
24 443 447 14648024 ATRA NN B-NP D014212
25 448 455 14648024 therapy NN I-NP O
26 455 456 14648024 . . O O

1 457 460 14648024 The DT B-NP O
2 461 465 14648024 skin NN I-NP O
3 466 472 14648024 biopsy NN I-NP O
4 473 478 14648024 taken VBN B-VP O
5 479 483 14648024 from IN B-PP O
6 484 488 14648024 each DT B-NP O
7 489 496 14648024 patient NN I-NP O
8 497 500 14648024 was VBD B-VP O
9 501 511 14648024 consistent JJ B-ADJP O
10 512 516 14648024 with IN B-PP O
11 517 525 14648024 erythema NN B-NP D004893
12 526 533 14648024 nodosum NN I-NP D004893
13 533 534 14648024 . . O O

1 535 538 14648024 All DT B-NP O
2 539 547 14648024 patients NNS I-NP O
3 548 556 14648024 received VBD B-VP O
4 557 562 14648024 short JJ B-NP O
5 563 569 14648024 course NN I-NP O
6 570 572 14648024 of IN B-PP O
7 573 581 14648024 steroids NNS B-NP D013256
8 581 582 14648024 . . O O

1 583 588 14648024 Fever NNP B-NP D005334
2 589 597 14648024 subsided VBD B-VP O
3 598 605 14648024 rapidly RB B-ADVP O
4 606 609 14648024 and CC O O
5 610 613 14648024 the DT B-NP O
6 614 618 14648024 skin NN I-NP O
7 619 626 14648024 lesions NNS I-NP O
8 627 636 14648024 regressed VBD B-VP O
9 637 647 14648024 completely RB B-ADVP O
10 647 648 14648024 . . O O

1 649 652 14648024 All DT B-NP O
2 653 661 14648024 patients NNS I-NP O
3 662 670 14648024 achieved VBD B-VP O
4 671 679 14648024 complete JJ B-NP O
5 680 689 14648024 remission NN I-NP O
6 690 697 14648024 without IN B-PP O
7 698 708 14648024 withdrawal NN B-NP O
8 709 711 14648024 of IN B-PP O
9 712 716 14648024 ATRA NN B-NP D014212
10 716 717 14648024 . . O O

1 718 722 14648024 ATRA NN B-NP D014212
2 723 729 14648024 seemed VBD B-VP O
3 730 732 14648024 to TO I-VP O
4 733 735 14648024 be VB I-VP O
5 736 739 14648024 the DT B-NP O
6 740 744 14648024 most RBS I-NP O
7 745 753 14648024 possible JJ I-NP O
8 754 762 14648024 etiology NN I-NP O
9 763 765 14648024 of IN B-PP O
10 766 774 14648024 erythema NN B-NP D004893
11 775 782 14648024 nodosum NN I-NP D004893
12 783 785 14648024 in IN B-PP O
13 786 789 14648024 our PRP$ B-NP O
14 790 798 14648024 patients NNS I-NP O
15 798 799 14648024 . . O O

1 800 805 14648024 Short JJ B-NP O
2 805 806 14648024 - HYPH I-NP O
3 806 810 14648024 term NN I-NP O
4 811 814 14648024 use NN I-NP O
5 815 817 14648024 of IN B-PP O
6 818 825 14648024 steroid NN B-NP D013256
7 826 828 14648024 is VBZ B-VP O
8 829 833 14648024 very RB B-ADJP O
9 834 843 14648024 effective JJ I-ADJP O
10 844 846 14648024 in IN B-PP O
11 847 851 14648024 ATRA NN B-NP D014212
12 851 852 14648024 - HYPH B-NP O
13 852 859 14648024 induced VBN I-NP O
14 860 868 14648024 erythema NN I-NP D004893
15 869 876 14648024 nodosum NN I-NP D004893
16 876 877 14648024 . . O O

1 0 0 6699841 -DOCSTART- -X- -X- O

1 0 5 6699841 Renal JJ B-NP D007681
2 6 15 6699841 papillary JJ I-NP D007681
3 16 24 6699841 necrosis NN I-NP D007681
4 25 28 6699841 due IN B-PP O
5 29 31 6699841 to TO B-PP O
6 32 40 6699841 naproxen NN B-NP D009288
7 40 41 6699841 . . O O
8 42 43 6699841 A NN B-NP O
9 44 46 6699841 31 CD I-NP O
10 46 47 6699841 - HYPH I-NP O
11 47 51 6699841 year NN I-NP O
12 51 52 6699841 - HYPH O O
13 52 55 6699841 old JJ B-NP O
14 56 59 6699841 man NN I-NP O
15 60 64 6699841 with IN B-PP O
16 65 75 6699841 rheumatoid JJ B-NP D001172
17 76 85 6699841 arthritis NN I-NP D001172
18 85 86 6699841 , , O O
19 87 90 6699841 who WP B-NP O
20 91 94 6699841 had VBD B-VP O
21 95 105 6699841 previously RB I-VP O
22 106 110 6699841 been VBN I-VP O
23 111 118 6699841 treated VBN I-VP O
24 119 123 6699841 with IN B-PP O
25 124 132 6699841 sulindac NN B-NP D013467
26 132 133 6699841 , , O O
27 134 144 6699841 fenoprofen NN B-NP D005279
28 145 152 6699841 calcium NN I-NP D005279
29 152 153 6699841 , , O O
30 154 158 6699841 high JJ B-NP O
31 159 163 6699841 dose NN I-NP O
32 164 175 6699841 salicylates NNS I-NP D012459
33 176 179 6699841 and CC O O
34 180 184 6699841 gold NN B-NP D006046
35 185 190 6699841 salts NNS I-NP O
36 190 191 6699841 , , O O
37 192 201 6699841 developed VBD B-VP O
38 202 207 6699841 renal JJ B-NP D007681
39 208 217 6699841 papillary JJ I-NP D007681
40 218 226 6699841 necrosis NN I-NP D007681
41 227 228 6699841 ( ( O O
42 228 231 6699841 RPN NN B-NP D007681
43 231 232 6699841 ) ) O O
44 233 234 6699841 4 CD B-NP O
45 235 241 6699841 months NNS I-NP O
46 242 247 6699841 after IN B-PP O
47 248 259 6699841 institution NN B-NP O
48 260 262 6699841 of IN B-PP O
49 263 271 6699841 naproxen NN B-NP D009288
50 272 279 6699841 therapy NN I-NP O
51 279 280 6699841 . . O O

1 281 283 6699841 No DT B-NP O
2 284 289 6699841 other JJ I-NP O
3 290 296 6699841 factor NN I-NP O
4 297 309 6699841 predisposing VBG B-VP O
5 310 312 6699841 to TO B-PP O
6 313 316 6699841 RPN NN B-NP D007681
7 317 322 6699841 could MD B-VP O
8 323 325 6699841 be VB I-VP O
9 326 336 6699841 discovered VBN I-VP O
10 336 337 6699841 . . O O

1 338 346 6699841 Sulindac NN B-NP D013467
2 347 350 6699841 was VBD B-VP O
3 351 362 6699841 substituted VBN I-VP O
4 363 366 6699841 for IN B-PP O
5 367 375 6699841 naproxen NN B-NP D009288
6 376 379 6699841 and CC O O
7 380 382 6699841 no DT B-NP O
8 383 390 6699841 further JJ I-NP O
9 391 398 6699841 adverse JJ I-NP O
10 399 404 6699841 renal JJ I-NP O
11 405 412 6699841 effects NNS I-NP O
12 413 421 6699841 occurred VBD B-VP O
13 422 426 6699841 over IN B-PP O
14 427 430 6699841 the DT B-NP O
15 431 435 6699841 next JJ I-NP O
16 436 438 6699841 12 CD I-NP O
17 439 445 6699841 months NNS I-NP O
18 445 446 6699841 . . O O

1 447 449 6699841 We PRP B-NP O
2 450 456 6699841 review VBP B-VP O
3 457 465 6699841 previous JJ B-NP O
4 466 473 6699841 reports NNS I-NP O
5 474 481 6699841 linking VBG B-VP O
6 482 485 6699841 RPN NN B-NP D007681
7 486 488 6699841 to TO B-PP O
8 489 505 6699841 antiinflammatory JJ B-NP O
9 506 510 6699841 drug NN I-NP O
10 511 514 6699841 use NN I-NP O
11 515 518 6699841 and CC O O
12 519 526 6699841 discuss VBP B-VP O
13 527 535 6699841 possible JJ B-NP O
14 536 546 6699841 advantages NNS I-NP O
15 547 549 6699841 of IN B-PP O
16 550 558 6699841 sulindac NN B-NP D013467
17 559 561 6699841 in IN B-PP O
18 562 570 6699841 patients NNS B-NP O
19 571 574 6699841 who WP B-NP O
20 575 579 6699841 have VBP B-VP O
21 580 591 6699841 experienced VBN I-VP O
22 592 597 6699841 renal JJ B-NP D007674
23 598 606 6699841 toxicity NN I-NP D007674
24 607 611 6699841 from IN B-PP O
25 612 617 6699841 other JJ B-NP O
26 618 634 6699841 antiinflammatory JJ I-NP O
27 635 641 6699841 agents NNS I-NP O
28 641 642 6699841 . . O O

1 0 0 17366349 -DOCSTART- -X- -X- O

1 0 11 17366349 Neuroleptic JJ B-NP D009459
2 12 21 17366349 malignant JJ I-NP D009459
3 22 30 17366349 syndrome NN I-NP D009459
4 31 38 17366349 induced VBN B-VP O
5 39 41 17366349 by IN B-PP O
6 42 53 17366349 ziprasidone NN B-NP C092292
7 54 56 17366349 on IN B-PP O
8 57 60 17366349 the DT B-NP O
9 61 67 17366349 second JJ I-NP O
10 68 71 17366349 day NN I-NP O
11 72 74 17366349 of IN B-PP O
12 75 84 17366349 treatment NN B-NP O
13 84 85 17366349 . . O O
14 86 97 17366349 Neuroleptic JJ B-NP D009459
15 98 107 17366349 malignant JJ I-NP D009459
16 108 116 17366349 syndrome NN I-NP D009459
17 117 118 17366349 ( ( O O
18 118 121 17366349 NMS NN B-NP D009459
19 121 122 17366349 ) ) O O
20 123 125 17366349 is VBZ B-VP O
21 126 129 17366349 the DT B-NP O
22 130 136 17366349 rarest NN I-NP O
23 137 140 17366349 and CC O O
24 141 145 17366349 most RBS B-ADJP O
25 146 153 17366349 serious JJ I-ADJP O
26 154 156 17366349 of IN B-PP O
27 157 160 17366349 the DT B-NP O
28 161 172 17366349 neuroleptic JJ I-NP O
29 172 173 17366349 - HYPH I-NP O
30 173 180 17366349 induced VBN I-NP O
31 181 189 17366349 movement NN I-NP D009069
32 190 199 17366349 disorders NNS I-NP D009069
33 199 200 17366349 . . O O

1 201 203 17366349 We PRP B-NP O
2 204 212 17366349 describe VBP B-VP O
3 213 214 17366349 a DT B-NP O
4 215 219 17366349 case NN I-NP O
5 220 222 17366349 of IN B-PP O
6 223 234 17366349 neuroleptic JJ B-NP D009459
7 235 244 17366349 malignant JJ I-NP D009459
8 245 253 17366349 syndrome NN I-NP D009459
9 254 255 17366349 ( ( O O
10 255 258 17366349 NMS NN B-NP D009459
11 258 259 17366349 ) ) O O
12 260 270 17366349 associated VBN B-VP O
13 271 275 17366349 with IN B-PP O
14 276 279 17366349 the DT B-NP O
15 280 283 17366349 use NN I-NP O
16 284 286 17366349 of IN B-PP O
17 287 298 17366349 ziprasidone NN B-NP C092292
18 298 299 17366349 . . O O

1 300 308 17366349 Although IN B-SBAR O
2 309 321 17366349 conventional JJ B-NP O
3 322 334 17366349 neuroleptics NNS I-NP O
4 335 338 17366349 are VBP B-VP O
5 339 343 17366349 more RBR I-VP O
6 344 354 17366349 frequently RB I-VP O
7 355 365 17366349 associated VBN I-VP O
8 366 370 17366349 with IN B-PP O
9 371 374 17366349 NMS NN B-NP D009459
10 374 375 17366349 , , O O
11 376 384 17366349 atypical JJ B-NP O
12 385 398 17366349 antipsychotic JJ I-NP O
13 399 404 17366349 drugs NNS I-NP O
14 405 409 17366349 like IN B-PP O
15 410 421 17366349 ziprasidone NN B-NP C092292
16 422 425 17366349 may MD B-VP O
17 426 430 17366349 also RB I-VP O
18 431 433 17366349 be VB I-VP O
19 434 435 17366349 a DT B-NP O
20 436 441 17366349 cause NN I-NP O
21 441 442 17366349 . . O O

1 443 446 17366349 The DT B-NP O
2 447 454 17366349 patient NN I-NP O
3 455 457 17366349 is VBZ B-VP O
4 458 459 17366349 a DT B-NP O
5 460 462 17366349 24 CD I-NP O
6 462 463 17366349 - HYPH I-NP O
7 463 467 17366349 year NN I-NP O
8 467 468 17366349 - HYPH O O
9 468 471 17366349 old JJ B-NP O
10 472 476 17366349 male NN I-NP O
11 477 481 17366349 with IN B-PP O
12 482 483 17366349 a DT B-NP O
13 484 491 17366349 history NN I-NP O
14 492 494 17366349 of IN B-PP O
15 495 508 17366349 schizophrenia NN B-NP D012559
16 509 512 17366349 who WP B-NP O
17 513 522 17366349 developed VBD B-VP O
18 523 528 17366349 signs NNS B-NP O
19 529 532 17366349 and CC I-NP O
20 533 541 17366349 symptoms NNS I-NP O
21 542 544 17366349 of IN B-PP O
22 545 548 17366349 NMS NN B-NP D009459
23 549 554 17366349 after IN B-PP O
24 555 556 17366349 2 CD B-NP O
25 557 561 17366349 days NNS I-NP O
26 562 564 17366349 of IN B-PP O
27 565 574 17366349 treatment NN B-NP O
28 575 579 17366349 with IN B-PP O
29 580 582 17366349 an DT B-NP O
30 583 585 17366349 80 CD I-NP O
31 585 586 17366349 - HYPH I-NP O
32 586 588 17366349 mg NN I-NP O
33 588 589 17366349 / SYM B-NP O
34 589 592 17366349 day NN I-NP O
35 593 597 17366349 dose NN I-NP O
36 598 600 17366349 of IN B-PP O
37 601 607 17366349 orally RB B-NP O
38 608 621 17366349 administrated VBN I-NP O
39 622 633 17366349 ziprasidone NN I-NP C092292
40 633 634 17366349 . . O O

1 635 639 17366349 This DT B-NP O
2 640 644 17366349 case NN I-NP O
3 645 647 17366349 is VBZ B-VP O
4 648 651 17366349 the DT B-NP O
5 652 660 17366349 earliest JJS I-NP O
6 661 662 17366349 ( ( O O
7 662 668 17366349 second JJ B-NP O
8 669 672 17366349 day NN I-NP O
9 673 675 17366349 of IN B-PP O
10 676 685 17366349 treatment NN B-NP O
11 685 686 17366349 ) ) O O
12 687 690 17366349 NMS NN B-NP D009459
13 691 694 17366349 due IN B-PP O
14 695 697 17366349 to TO B-PP O
15 698 709 17366349 ziprasidone NN B-NP C092292
16 710 718 17366349 reported VBN B-VP O
17 719 721 17366349 in IN B-PP O
18 722 725 17366349 the DT B-NP O
19 726 736 17366349 literature NN I-NP O
20 736 737 17366349 . . O O

1 0 0 2722224 -DOCSTART- -X- -X- O

1 0 14 2722224 Hydrocortisone NN B-NP D006854
2 14 15 2722224 - HYPH B-PP O
3 15 22 2722224 induced VBN B-NP O
4 23 35 2722224 hypertension NN I-NP D006973
5 36 38 2722224 in IN B-PP O
6 39 45 2722224 humans NNS B-NP O
7 45 46 2722224 : : O O
8 47 54 2722224 pressor NN B-NP O
9 55 69 2722224 responsiveness NN I-NP O
10 70 73 2722224 and CC O O
11 74 85 2722224 sympathetic JJ B-NP O
12 86 94 2722224 function NN I-NP O
13 94 95 2722224 . . O O
14 96 100 2722224 Oral JJ B-NP O
15 101 115 2722224 hydrocortisone NN I-NP D006854
16 116 125 2722224 increases VBZ B-VP O
17 126 131 2722224 blood NN B-NP O
18 132 140 2722224 pressure NN I-NP O
19 141 144 2722224 and CC O O
20 145 153 2722224 enhances VBZ B-VP O
21 154 161 2722224 pressor NN B-NP O
22 162 176 2722224 responsiveness NN I-NP O
23 177 179 2722224 in IN B-PP O
24 180 186 2722224 normal JJ B-NP O
25 187 192 2722224 human JJ I-NP O
26 193 201 2722224 subjects NNS I-NP O
27 201 202 2722224 . . O O

1 203 205 2722224 We PRP B-NP O
2 206 213 2722224 studied VBD B-VP O
3 214 217 2722224 the DT B-NP O
4 218 225 2722224 effects NNS I-NP O
5 226 228 2722224 of IN B-PP O
6 229 230 2722224 1 CD B-NP O
7 231 235 2722224 week NN I-NP O
8 236 238 2722224 of IN B-PP O
9 239 243 2722224 oral JJ B-NP O
10 244 258 2722224 hydrocortisone NN I-NP D006854
11 259 260 2722224 ( ( O O
12 260 263 2722224 200 CD B-NP O
13 264 266 2722224 mg NN I-NP O
14 266 267 2722224 / SYM B-NP O
15 267 270 2722224 day NN I-NP O
16 270 271 2722224 ) ) O O
17 272 274 2722224 on IN B-PP O
18 275 280 2722224 blood NN B-NP O
19 281 289 2722224 pressure NN I-NP O
20 289 290 2722224 , , O O
21 291 298 2722224 cardiac JJ B-NP O
22 299 305 2722224 output NN I-NP O
23 305 306 2722224 , , O O
24 307 312 2722224 total JJ B-NP O
25 313 323 2722224 peripheral JJ I-NP O
26 324 334 2722224 resistance NN I-NP O
27 334 335 2722224 , , O O
28 336 343 2722224 forearm NN B-NP O
29 344 352 2722224 vascular JJ I-NP O
30 353 363 2722224 resistance NN I-NP O
31 363 364 2722224 , , O O
32 365 368 2722224 and CC O O
33 369 383 2722224 norepinephrine NN B-NP D009638
34 384 393 2722224 spillover NN I-NP O
35 394 396 2722224 to TO B-PP O
36 397 403 2722224 plasma NN B-NP O
37 404 406 2722224 in IN B-PP O
38 407 412 2722224 eight CD B-NP O
39 413 420 2722224 healthy JJ I-NP O
40 421 425 2722224 male JJ I-NP O
41 426 436 2722224 volunteers NNS I-NP O
42 436 437 2722224 . . O O

1 438 446 2722224 Although IN B-SBAR O
2 447 456 2722224 diastolic JJ B-NP O
3 457 462 2722224 blood NN I-NP O
4 463 471 2722224 pressure NN I-NP O
5 472 480 2722224 remained VBD B-VP O
6 481 490 2722224 unchanged JJ B-NP O
7 490 491 2722224 , , I-NP O
8 492 500 2722224 systolic JJ I-NP O
9 501 506 2722224 blood NN I-NP O
10 507 515 2722224 pressure NN I-NP O
11 516 525 2722224 increased VBD B-VP O
12 526 530 2722224 from IN B-PP O
13 531 534 2722224 119 CD B-NP O
14 535 537 2722224 to TO I-NP O
15 538 541 2722224 135 CD I-NP O
16 542 544 2722224 mm NN I-NP O
17 545 547 2722224 Hg NN I-NP O
18 548 549 2722224 ( ( O O
19 549 552 2722224 SED VBN B-VP O
20 553 554 2722224 + SYM B-NP O
21 554 555 2722224 / SYM B-NP O
22 555 556 2722224 - SYM B-VP O
23 557 560 2722224 3.4 CD B-NP O
24 560 561 2722224 , , O O
25 562 563 2722224 p NN B-NP O
26 564 568 2722224 less JJR B-ADJP O
27 569 573 2722224 than IN B-PP O
28 574 578 2722224 0.01 CD B-NP O
29 578 579 2722224 ) ) O O
30 579 580 2722224 , , O O
31 581 591 2722224 associated VBN B-VP O
32 592 596 2722224 with IN B-PP O
33 597 599 2722224 an DT B-NP O
34 600 609 2722224 increased VBN I-NP D016534
35 610 617 2722224 cardiac JJ I-NP D016534
36 618 624 2722224 output NN I-NP D016534
37 625 626 2722224 ( ( O O
38 626 630 2722224 5.85 CD B-NP O
39 630 631 2722224 - HYPH I-NP O
40 631 635 2722224 7.73 CD I-NP O
41 636 637 2722224 l NN I-NP O
42 637 638 2722224 / SYM B-NP O
43 638 641 2722224 min NN I-NP O
44 641 642 2722224 , , O O
45 643 646 2722224 SED VBD B-VP O
46 647 648 2722224 + SYM B-NP O
47 648 649 2722224 / SYM B-NP O
48 649 650 2722224 - SYM B-VP O
49 651 655 2722224 0.46 CD B-NP O
50 655 656 2722224 , , O O
51 657 658 2722224 p NN B-NP O
52 659 663 2722224 less JJR B-ADJP O
53 664 668 2722224 than IN B-PP O
54 669 673 2722224 0.01 CD B-NP O
55 673 674 2722224 ) ) O O
56 674 675 2722224 . . O O

1 676 681 2722224 Total JJ B-NP O
2 682 692 2722224 peripheral JJ I-NP O
3 693 701 2722224 vascular JJ I-NP O
4 702 712 2722224 resistance NN I-NP O
5 713 717 2722224 fell VBD B-VP O
6 718 722 2722224 from IN B-PP O
7 723 727 2722224 15.1 CD B-NP O
8 728 730 2722224 to TO I-NP O
9 731 735 2722224 12.2 CD I-NP O
10 736 738 2722224 mm NN I-NP O
11 739 741 2722224 Hg NN I-NP O
12 741 742 2722224 / SYM B-NP O
13 742 743 2722224 l NN I-NP O
14 743 744 2722224 / SYM B-NP O
15 744 747 2722224 min NN I-NP O
16 748 749 2722224 ( ( O O
17 749 752 2722224 SED VBN B-VP O
18 753 754 2722224 + SYM B-NP O
19 754 755 2722224 / SYM B-NP O
20 755 756 2722224 - SYM B-VP O
21 757 761 2722224 1.03 CD B-NP O
22 761 762 2722224 , , O O
23 763 764 2722224 p NN B-NP O
24 765 769 2722224 less JJR B-ADJP O
25 770 774 2722224 than IN B-PP O
26 775 779 2722224 0.05 CD B-NP O
27 779 780 2722224 ) ) O O
28 780 781 2722224 . . O O

1 782 789 2722224 Resting VBG B-VP O
2 790 797 2722224 forearm NN B-NP O
3 798 806 2722224 vascular JJ I-NP O
4 807 817 2722224 resistance NN I-NP O
5 818 826 2722224 remained VBD B-VP O
6 827 836 2722224 unchanged JJ B-ADJP O
7 836 837 2722224 , , O O
8 838 841 2722224 but CC O O
9 842 845 2722224 the DT B-NP O
10 846 852 2722224 reflex NN I-NP O
11 853 861 2722224 response NN I-NP O
12 862 864 2722224 to TO B-PP O
13 865 868 2722224 the DT B-NP O
14 869 873 2722224 cold JJ I-NP O
15 874 881 2722224 pressor NN I-NP O
16 882 886 2722224 test NN I-NP O
17 887 890 2722224 was VBD B-VP O
18 891 902 2722224 accentuated VBN I-VP O
19 902 903 2722224 , , O O
20 904 907 2722224 the DT B-NP O
21 908 912 2722224 rise NN I-NP O
22 913 915 2722224 in IN B-PP O
23 916 926 2722224 resistance NN B-NP O
24 927 937 2722224 increasing VBG B-VP O
25 938 942 2722224 from IN B-PP O
26 943 947 2722224 10.5 CD B-NP O
27 948 950 2722224 mm NN I-NP O
28 951 953 2722224 Hg NN I-NP O
29 953 954 2722224 / SYM B-NP O
30 954 956 2722224 ml NN I-NP O
31 956 957 2722224 / SYM O O
32 957 960 2722224 100 CD B-NP O
33 961 963 2722224 ml NN I-NP O
34 963 964 2722224 / SYM B-NP O
35 964 967 2722224 min NN B-NP O
36 968 969 2722224 ( ( O O
37 969 970 2722224 R NN B-NP O
38 971 976 2722224 units NNS I-NP O
39 976 977 2722224 ) ) O O
40 978 984 2722224 before IN B-PP O
41 985 994 2722224 treatment NN B-NP O
42 995 997 2722224 to TO B-PP O
43 998 1002 2722224 32.6 CD B-NP O
44 1003 1004 2722224 R NN I-NP O
45 1005 1010 2722224 units NNS I-NP O
46 1011 1016 2722224 after IN B-PP O
47 1017 1026 2722224 treatment NN B-NP O
48 1027 1028 2722224 ( ( O O
49 1028 1031 2722224 SED VBN B-VP O
50 1032 1033 2722224 + SYM B-NP O
51 1033 1034 2722224 / SYM B-NP O
52 1034 1035 2722224 - SYM B-VP O
53 1036 1039 2722224 6.4 CD B-NP O
54 1039 1040 2722224 , , O O
55 1041 1042 2722224 p NN B-NP O
56 1043 1047 2722224 less JJR B-ADJP O
57 1048 1052 2722224 than IN B-PP O
58 1053 1058 2722224 0.025 CD B-NP O
59 1058 1059 2722224 ) ) O O
60 1059 1060 2722224 . . O O

1 1061 1064 2722224 The DT B-NP O
2 1065 1069 2722224 rise NN I-NP O
3 1070 1072 2722224 in IN B-PP O
4 1073 1080 2722224 forearm NN B-NP O
5 1081 1089 2722224 vascular JJ I-NP O
6 1090 1100 2722224 resistance NN I-NP O
7 1101 1113 2722224 accompanying VBG B-VP O
8 1114 1119 2722224 intra AFX B-NP O
9 1119 1120 2722224 - HYPH I-NP O
10 1120 1128 2722224 arterial JJ B-NP O
11 1129 1143 2722224 norepinephrine NN I-NP D009638
12 1144 1145 2722224 ( ( O O
13 1145 1147 2722224 25 CD B-NP O
14 1147 1148 2722224 , , I-NP O
15 1149 1151 2722224 50 CD I-NP O
16 1151 1152 2722224 , , O O
17 1153 1156 2722224 and CC O O
18 1157 1160 2722224 100 CD B-NP O
19 1161 1163 2722224 ng NN I-NP O
20 1163 1164 2722224 / SYM B-NP O
21 1164 1167 2722224 min NN I-NP O
22 1167 1168 2722224 ) ) O O
23 1169 1172 2722224 was VBD B-VP O
24 1173 1177 2722224 also RB B-ADVP O
25 1178 1191 2722224 significantly RB B-ADJP O
26 1192 1199 2722224 greater JJR I-ADJP O
27 1200 1205 2722224 after IN B-PP O
28 1206 1220 2722224 hydrocortisone NN B-NP D006854
29 1220 1221 2722224 , , O O
30 1222 1232 2722224 increasing VBG B-VP O
31 1233 1237 2722224 from IN B-PP O
32 1238 1240 2722224 an DT B-NP O
33 1241 1248 2722224 average NN I-NP O
34 1249 1251 2722224 of IN B-PP O
35 1252 1256 2722224 14.9 CD B-NP O
36 1257 1258 2722224 + SYM O O
37 1258 1259 2722224 / SYM B-NP O
38 1259 1260 2722224 - SYM B-NP O
39 1261 1264 2722224 2.4 CD I-NP O
40 1265 1266 2722224 R NN I-NP O
41 1267 1272 2722224 units NNS I-NP O
42 1273 1279 2722224 before IN B-PP O
43 1280 1289 2722224 treatment NN B-NP O
44 1290 1292 2722224 to TO B-PP O
45 1293 1297 2722224 35.1 CD B-NP O
46 1298 1299 2722224 + SYM O O
47 1299 1300 2722224 / SYM B-NP O
48 1300 1301 2722224 - SYM B-NP O
49 1302 1305 2722224 5.5 CD I-NP O
50 1306 1307 2722224 R NN I-NP O
51 1308 1313 2722224 units NNS I-NP O
52 1314 1319 2722224 after IN B-PP O
53 1320 1334 2722224 hydrocortisone NN B-NP D006854
54 1335 1336 2722224 ( ( O O
55 1336 1339 2722224 SED VBN B-VP O
56 1340 1341 2722224 + SYM B-NP O
57 1341 1342 2722224 / SYM B-NP O
58 1342 1343 2722224 - SYM B-VP O
59 1344 1347 2722224 6.0 CD B-NP O
60 1347 1348 2722224 , , O O
61 1349 1350 2722224 p NN B-NP O
62 1351 1355 2722224 less JJR B-ADJP O
63 1356 1360 2722224 than IN B-PP O
64 1361 1365 2722224 0.05 CD B-NP O
65 1365 1366 2722224 ) ) O O
66 1366 1367 2722224 . . O O

1 1368 1369 2722224 A DT B-NP O
2 1370 1375 2722224 shift NN I-NP O
3 1376 1378 2722224 to TO B-PP O
4 1379 1382 2722224 the DT B-NP O
5 1383 1387 2722224 left NN I-NP O
6 1388 1390 2722224 in IN B-PP O
7 1391 1394 2722224 the DT B-NP O
8 1395 1399 2722224 dose NN I-NP O
9 1399 1400 2722224 - HYPH B-NP O
10 1400 1408 2722224 response NN I-NP O
11 1409 1417 2722224 relation NN I-NP O
12 1418 1421 2722224 and CC I-NP O
13 1422 1426 2722224 fall NN I-NP O
14 1427 1429 2722224 in IN B-PP O
15 1430 1439 2722224 threshold NN B-NP O
16 1440 1449 2722224 suggested VBD B-VP O
17 1450 1459 2722224 increased VBN B-NP O
18 1460 1471 2722224 sensitivity NN I-NP O
19 1472 1474 2722224 to TO B-PP O
20 1475 1489 2722224 norepinephrine NN B-NP D009638
21 1490 1495 2722224 after IN B-PP O
22 1496 1505 2722224 treatment NN B-NP O
23 1505 1506 2722224 . . O O

1 1507 1518 2722224 Measurement NN B-NP O
2 1519 1521 2722224 of IN B-PP O
3 1522 1529 2722224 resting VBG B-NP O
4 1530 1544 2722224 norepinephrine NN I-NP D009638
5 1545 1554 2722224 spillover NN I-NP O
6 1555 1559 2722224 rate NN I-NP O
7 1560 1562 2722224 to TO B-PP O
8 1563 1569 2722224 plasma NN B-NP O
9 1570 1573 2722224 and CC I-NP O
10 1574 1588 2722224 norepinephrine NN I-NP D009638
11 1589 1595 2722224 uptake NN I-NP O
12 1596 1605 2722224 indicated VBD B-VP O
13 1606 1610 2722224 that IN B-SBAR O
14 1611 1618 2722224 overall RB B-ADVP O
15 1619 1626 2722224 resting VBG B-VP O
16 1627 1638 2722224 sympathetic JJ B-NP O
17 1639 1646 2722224 nervous JJ I-NP O
18 1647 1653 2722224 system NN I-NP O
19 1654 1662 2722224 activity NN I-NP O
20 1663 1666 2722224 was VBD B-VP O
21 1667 1670 2722224 not RB I-VP O
22 1671 1680 2722224 increased VBN I-VP O
23 1680 1681 2722224 . . O O

1 1682 1685 2722224 The DT B-NP O
2 1686 1690 2722224 rise NN I-NP D006973
3 1691 1693 2722224 in IN B-PP D006973
4 1694 1701 2722224 resting VBG B-NP D006973
5 1702 1707 2722224 blood NN I-NP D006973
6 1708 1716 2722224 pressure NN I-NP D006973
7 1717 1721 2722224 with IN B-PP O
8 1722 1736 2722224 hydrocortisone NN B-NP D006854
9 1737 1739 2722224 is VBZ B-VP O
10 1740 1750 2722224 associated VBN I-VP O
11 1751 1755 2722224 with IN B-PP O
12 1756 1758 2722224 an DT B-NP O
13 1759 1768 2722224 increased VBN I-NP D016534
14 1769 1776 2722224 cardiac JJ I-NP D016534
15 1777 1783 2722224 output NN I-NP D016534
16 1784 1785 2722224 ( ( O O
17 1785 1795 2722224 presumably RB B-ADVP O
18 1796 1799 2722224 due IN B-PP O
19 1800 1802 2722224 to TO B-PP O
20 1803 1812 2722224 increased VBN B-NP O
21 1813 1818 2722224 blood NN I-NP O
22 1819 1836 2722224 volume).(ABSTRACT NN I-NP O
23 1837 1846 2722224 TRUNCATED VBN B-VP O
24 1847 1849 2722224 AT IN B-PP O
25 1850 1853 2722224 250 CD B-NP O
26 1854 1859 2722224 WORDS NNS I-NP O
27 1859 1860 2722224 ) ) O O

1 0 0 8686832 -DOCSTART- -X- -X- O

1 0 3 8686832 Leg NNP B-NP D001416
2 4 7 8686832 and CC O D001416
3 8 12 8686832 back JJ B-NP D001416
4 13 17 8686832 pain NN I-NP D001416
5 18 23 8686832 after IN B-PP O
6 24 30 8686832 spinal JJ B-NP O
7 31 42 8686832 anaesthesia NN I-NP O
8 43 52 8686832 involving VBG B-VP O
9 53 63 8686832 hyperbaric JJ B-NP O
10 64 66 8686832 5% NN I-NP O
11 67 77 8686832 lignocaine NN I-NP D008012
12 77 78 8686832 . . O O
13 79 84 8686832 Fifty CD B-NP O
14 84 85 8686832 - HYPH O O
15 85 89 8686832 four CD B-NP O
16 90 98 8686832 patients NNS I-NP O
17 98 99 8686832 , , O O
18 100 104 8686832 aged VBN B-VP O
19 105 107 8686832 27 CD B-NP O
20 107 108 8686832 - HYPH I-NP O
21 108 110 8686832 90 CD I-NP O
22 111 116 8686832 years NNS I-NP O
23 116 117 8686832 , , O O
24 118 121 8686832 who WP B-NP O
25 122 126 8686832 were VBD B-VP O
26 127 132 8686832 given VBN I-VP O
27 133 143 8686832 lignocaine NN B-NP D008012
28 144 146 8686832 5% NN I-NP O
29 147 149 8686832 in IN B-PP O
30 150 154 8686832 6.8% CD B-NP O
31 155 162 8686832 glucose NN I-NP D005947
32 163 171 8686832 solution NN I-NP O
33 172 175 8686832 for IN B-PP O
34 176 182 8686832 spinal JJ B-NP O
35 183 194 8686832 anaesthesia NN I-NP O
36 195 199 8686832 were VBD B-VP O
37 200 207 8686832 studied VBN I-VP O
38 207 208 8686832 . . O O

1 209 217 8686832 Thirteen CD B-NP O
2 218 220 8686832 of IN B-PP O
3 221 226 8686832 these DT B-NP O
4 227 235 8686832 patients NNS I-NP O
5 236 247 8686832 experienced VBD B-VP O
6 248 252 8686832 pain NN B-NP D001416
7 253 255 8686832 in IN B-PP D001416
8 256 259 8686832 the DT B-NP D001416
9 260 264 8686832 legs NNS I-NP D001416
10 265 268 8686832 and CC O D001416
11 268 269 8686832 / SYM B-NP D001416
12 269 271 8686832 or CC O D001416
13 272 276 8686832 back RB B-ADVP D001416
14 277 282 8686832 after IN B-PP O
15 283 291 8686832 recovery NN B-NP O
16 292 296 8686832 from IN B-PP O
17 297 308 8686832 anaesthesia NN B-NP O
18 308 309 8686832 . . O O

1 310 313 8686832 The DT B-NP O
2 314 322 8686832 patients NNS I-NP O
3 323 331 8686832 affected VBN B-VP O
4 332 336 8686832 were VBD B-VP O
5 337 344 8686832 younger JJR B-ADJP O
6 345 346 8686832 ( ( O O
7 346 347 8686832 p NN B-NP O
8 348 349 8686832 < SYM O O
9 350 354 8686832 0.05 CD B-NP O
10 354 355 8686832 ) ) O O
11 356 359 8686832 and CC O O
12 360 363 8686832 the DT B-NP O
13 364 368 8686832 site NN I-NP O
14 369 371 8686832 of IN B-PP O
15 372 375 8686832 the DT B-NP O
16 376 381 8686832 dural JJ I-NP O
17 382 390 8686832 puncture NN I-NP O
18 391 394 8686832 was VBD B-VP O
19 395 401 8686832 higher JJR B-ADJP O
20 402 403 8686832 ( ( O O
21 403 404 8686832 p NN B-NP O
22 405 406 8686832 < SYM O O
23 407 411 8686832 0.01 CD B-NP O
24 411 412 8686832 ) ) O O
25 413 417 8686832 than IN B-PP O
26 418 423 8686832 those DT B-NP O
27 424 435 8686832 individuals NNS I-NP O
28 436 443 8686832 without IN B-PP O
29 444 448 8686832 pain NN B-NP D010146
30 448 449 8686832 . . O O

1 450 454 8686832 Five CD B-NP O
2 455 457 8686832 of IN B-PP O
3 458 461 8686832 the DT B-NP O
4 462 464 8686832 13 CD I-NP O
5 465 473 8686832 patients NNS I-NP O
6 474 475 8686832 ( ( B-LST O
7 475 478 8686832 38% LS I-LST O
8 478 479 8686832 ) ) O O
9 480 484 8686832 with IN B-PP O
10 485 489 8686832 pain NN B-NP D010146
11 490 493 8686832 and CC O O
12 494 499 8686832 seven CD B-NP O
13 500 502 8686832 of IN B-PP O
14 503 506 8686832 the DT B-NP O
15 507 509 8686832 41 CD I-NP O
16 510 518 8686832 patients NNS I-NP O
17 519 520 8686832 ( ( O O
18 520 523 8686832 17% NN B-NP O
19 523 524 8686832 ) ) O O
20 525 532 8686832 without IN B-PP O
21 533 537 8686832 pain NN B-NP D010146
22 538 546 8686832 admitted VBN B-VP O
23 547 549 8686832 to TO B-PP O
24 550 551 8686832 a DT B-NP O
25 552 556 8686832 high JJ I-NP O
26 557 564 8686832 alcohol NN I-NP D000431
27 565 571 8686832 intake NN I-NP O
28 571 572 8686832 , , O O
29 573 578 8686832 which WDT B-NP O
30 579 584 8686832 might MD B-VP O
31 585 587 8686832 be VB I-VP O
32 588 589 8686832 a DT B-NP O
33 590 602 8686832 contributing VBG I-NP O
34 603 609 8686832 factor NN I-NP O
35 609 610 8686832 . . O O

1 611 614 8686832 Leg NN B-NP D001416
2 615 618 8686832 and CC O D001416
3 618 619 8686832 / SYM B-NP D001416
4 619 621 8686832 or CC O D001416
5 622 626 8686832 back RB B-ADVP D001416
6 627 631 8686832 pain NN B-NP D001416
7 632 634 8686832 is VBZ B-VP O
8 635 645 8686832 associated VBN I-VP O
9 646 650 8686832 with IN B-PP O
10 651 654 8686832 the DT B-NP O
11 655 666 8686832 intrathecal JJ I-NP O
12 667 670 8686832 use NN I-NP O
13 671 673 8686832 of IN B-PP O
14 674 684 8686832 hyperbaric JJ B-NP O
15 685 687 8686832 5% NN I-NP O
16 688 698 8686832 lignocaine NN I-NP D008012
17 698 699 8686832 . . O O

1 0 0 9579567 -DOCSTART- -X- -X- O

1 0 10 9579567 Iatrogenic JJ B-NP O
2 11 16 9579567 risks NNS I-NP O
3 17 19 9579567 of IN B-PP O
4 20 31 9579567 endometrial JJ B-NP D016889
5 32 41 9579567 carcinoma NN I-NP D016889
6 42 47 9579567 after IN B-PP O
7 48 57 9579567 treatment NN B-NP O
8 58 61 9579567 for IN B-PP O
9 62 68 9579567 breast NN B-NP D001943
10 69 75 9579567 cancer NN I-NP D001943
11 76 78 9579567 in IN B-PP O
12 79 80 9579567 a DT B-NP O
13 81 86 9579567 large JJ I-NP O
14 87 93 9579567 French JJ I-NP O
15 94 98 9579567 case NN I-NP O
16 98 99 9579567 - HYPH B-NP O
17 99 106 9579567 control NN I-NP O
18 107 112 9579567 study NN I-NP O
19 112 113 9579567 . . O O

1 114 115 9579567 F NN B-NP O
2 117 118 9579567 d NN I-NP O
3 120 126 9579567 ration NN I-NP O
4 127 136 9579567 Nationale NNP I-NP O
5 137 140 9579567 des NNP I-NP O
6 141 148 9579567 Centres NNP I-NP O
7 149 151 9579567 de IN I-NP O
8 152 157 9579567 Lutte NNP I-NP O
9 158 164 9579567 Contre NNP I-NP O
10 165 167 9579567 le NNP I-NP O
11 168 174 9579567 Cancer NNP I-NP O
12 175 176 9579567 ( ( O O
13 176 182 9579567 FNCLCC NN B-NP O
14 182 183 9579567 ) ) O O
15 183 184 9579567 . . O O
16 185 190 9579567 Since IN B-SBAR O
17 191 200 9579567 tamoxifen NN B-NP D013629
18 201 203 9579567 is VBZ B-VP O
19 204 210 9579567 widely RB I-VP O
20 211 215 9579567 used VBN I-VP O
21 216 218 9579567 in IN B-PP O
22 219 225 9579567 breast NN B-NP D001943
23 226 232 9579567 cancer NN I-NP D001943
24 233 242 9579567 treatment NN I-NP O
25 243 246 9579567 and CC O O
26 247 250 9579567 has VBZ B-VP O
27 251 255 9579567 been VBN I-VP O
28 256 264 9579567 proposed VBN I-VP O
29 265 268 9579567 for IN B-PP O
30 269 272 9579567 the DT B-NP O
31 273 283 9579567 prevention NN I-NP O
32 284 286 9579567 of IN B-PP O
33 287 293 9579567 breast NN B-NP D001943
34 294 300 9579567 cancer NN I-NP D001943
35 300 301 9579567 , , O O
36 302 305 9579567 its PRP$ B-NP O
37 306 317 9579567 endometrial JJ I-NP O
38 318 328 9579567 iatrogenic JJ I-NP O
39 329 336 9579567 effects NNS I-NP O
40 337 341 9579567 must MD B-VP O
41 342 344 9579567 be VB I-VP O
42 345 354 9579567 carefully RB I-VP O
43 355 363 9579567 examined VBN I-VP O
44 363 364 9579567 . . O O

1 365 367 9579567 We PRP B-NP O
2 368 372 9579567 have VBP B-VP O
3 373 385 9579567 investigated VBN I-VP O
4 386 389 9579567 the DT B-NP O
5 390 401 9579567 association NN I-NP O
6 402 409 9579567 between IN B-PP O
7 410 421 9579567 endometrial JJ B-NP D016889
8 422 428 9579567 cancer NN I-NP D016889
9 429 432 9579567 and CC I-NP O
10 433 442 9579567 tamoxifen NN I-NP D013629
11 443 446 9579567 use NN I-NP O
12 447 449 9579567 or CC O O
13 450 455 9579567 other JJ B-NP O
14 456 466 9579567 treatments NNS I-NP O
15 467 469 9579567 in IN B-PP O
16 470 475 9579567 women NNS B-NP O
17 476 483 9579567 treated VBN B-VP O
18 484 487 9579567 for IN B-PP O
19 488 494 9579567 breast NN B-NP D001943
20 495 501 9579567 cancer NN I-NP D001943
21 502 504 9579567 in IN B-PP O
22 505 506 9579567 a DT B-NP O
23 507 511 9579567 case NN I-NP O
24 511 512 9579567 - HYPH B-NP O
25 512 519 9579567 control NN I-NP O
26 520 525 9579567 study NN I-NP O
27 525 526 9579567 . . O O

1 527 532 9579567 Cases NNS B-NP O
2 533 535 9579567 of IN B-PP O
3 536 547 9579567 endometrial JJ B-NP D016889
4 548 554 9579567 cancer NN I-NP D016889
5 555 564 9579567 diagnosed VBN B-VP O
6 565 570 9579567 after IN B-PP O
7 571 577 9579567 breast NN B-NP D001943
8 578 584 9579567 cancer NN I-NP D001943
9 585 586 9579567 ( ( O O
10 586 587 9579567 n NN B-NP O
11 588 589 9579567 = SYM B-VP O
12 590 593 9579567 135 CD B-NP O
13 593 594 9579567 ) ) O O
14 595 598 9579567 and CC O O
15 599 602 9579567 467 CD B-NP O
16 603 611 9579567 controls NNS I-NP O
17 612 619 9579567 matched VBN B-VP O
18 620 623 9579567 for IN B-PP O
19 624 627 9579567 age NN B-NP O
20 627 628 9579567 , , O O
21 629 633 9579567 year NN B-NP O
22 634 636 9579567 of IN B-PP O
23 637 646 9579567 diagnosis NN B-NP O
24 647 649 9579567 of IN B-PP O
25 650 656 9579567 breast NN B-NP D001943
26 657 663 9579567 cancer NN I-NP D001943
27 664 667 9579567 and CC O O
28 668 676 9579567 hospital NN B-NP O
29 677 680 9579567 and CC O O
30 681 689 9579567 survival NN B-NP O
31 690 694 9579567 time NN I-NP O
32 695 699 9579567 with IN B-PP O
33 700 702 9579567 an DT B-NP O
34 703 709 9579567 intact JJ I-NP O
35 710 716 9579567 uterus NN I-NP O
36 717 721 9579567 were VBD B-VP O
37 722 730 9579567 included VBN I-VP O
38 730 731 9579567 . . O O

1 732 737 9579567 Women NNS B-NP O
2 738 741 9579567 who WP B-NP O
3 742 745 9579567 had VBD B-VP O
4 746 754 9579567 received VBN I-VP O
5 755 764 9579567 tamoxifen NN B-NP D013629
6 765 769 9579567 were VBD B-VP O
7 770 783 9579567 significantly RB B-ADJP O
8 784 788 9579567 more RBR I-ADJP O
9 789 795 9579567 likely JJ I-ADJP O
10 796 798 9579567 to TO B-VP O
11 799 803 9579567 have VB I-VP O
12 804 815 9579567 endometrial JJ B-NP D016889
13 816 822 9579567 cancer NN I-NP D016889
14 823 832 9579567 diagnosed VBN B-VP O
15 833 837 9579567 than IN B-PP O
16 838 843 9579567 those DT B-NP O
17 844 847 9579567 who WP B-NP O
18 848 851 9579567 had VBD B-VP O
19 852 855 9579567 not RB O O
20 856 857 9579567 ( ( O O
21 857 862 9579567 crude JJ B-NP O
22 863 871 9579567 relative JJ I-NP O
23 872 876 9579567 risk NN I-NP O
24 877 878 9579567 = SYM B-VP O
25 879 882 9579567 4.9 CD B-NP O
26 882 883 9579567 , , O O
27 884 885 9579567 p NN B-NP O
28 886 887 9579567 = SYM B-VP O
29 888 894 9579567 0.0001 CD B-NP O
30 894 895 9579567 ) ) O O
31 895 896 9579567 . . O O

1 897 907 9579567 Univariate JJ B-NP O
2 908 911 9579567 and CC I-NP O
3 912 920 9579567 adjusted VBN I-NP O
4 921 929 9579567 analyses NNS I-NP O
5 930 936 9579567 showed VBD B-VP O
6 937 941 9579567 that IN B-SBAR O
7 942 945 9579567 the DT B-NP O
8 946 950 9579567 risk NN I-NP O
9 951 960 9579567 increased VBD B-VP O
10 961 965 9579567 with IN B-PP O
11 966 969 9579567 the DT B-NP O
12 970 976 9579567 length NN I-NP O
13 977 979 9579567 of IN B-PP O
14 980 989 9579567 treatment NN B-NP O
15 990 991 9579567 ( ( O O
16 991 992 9579567 p NN B-NP O
17 993 994 9579567 = SYM B-VP O
18 995 1001 9579567 0.0001 CD B-NP O
19 1001 1002 9579567 ) ) O O
20 1003 1005 9579567 or CC O O
21 1006 1009 9579567 the DT B-NP O
22 1010 1020 9579567 cumulative JJ I-NP O
23 1021 1025 9579567 dose NN I-NP O
24 1026 1028 9579567 of IN B-PP O
25 1029 1038 9579567 tamoxifen NN B-NP D013629
26 1039 1047 9579567 received VBD B-VP O
27 1048 1049 9579567 ( ( O O
28 1049 1050 9579567 p NN B-NP O
29 1051 1052 9579567 = SYM B-VP O
30 1053 1059 9579567 0.0001 CD B-NP O
31 1059 1060 9579567 ) ) O O
32 1060 1061 9579567 , , O O
33 1062 1074 9579567 irrespective JJ B-ADJP O
34 1075 1077 9579567 of IN B-PP O
35 1078 1081 9579567 the DT B-NP O
36 1082 1087 9579567 daily JJ I-NP O
37 1088 1092 9579567 dose NN I-NP O
38 1092 1093 9579567 . . O O

1 1094 1099 9579567 Women NNS B-NP O
2 1100 1103 9579567 who WP B-NP O
3 1104 1107 9579567 had VBD B-VP O
4 1108 1117 9579567 undergone VBN I-VP O
5 1118 1124 9579567 pelvic JJ B-NP O
6 1125 1137 9579567 radiotherapy NN I-NP O
7 1138 1142 9579567 also RB B-ADVP O
8 1143 1146 9579567 had VBD B-VP O
9 1147 1148 9579567 a DT B-NP O
10 1149 1155 9579567 higher JJR I-NP O
11 1156 1160 9579567 risk NN I-NP O
12 1161 1162 9579567 ( ( O O
13 1162 1167 9579567 crude JJ B-NP O
14 1168 1176 9579567 relative JJ I-NP O
15 1177 1181 9579567 risk NN I-NP O
16 1182 1183 9579567 = SYM B-VP O
17 1184 1187 9579567 7.8 CD B-NP O
18 1187 1188 9579567 , , O O
19 1189 1190 9579567 p NN B-NP O
20 1191 1192 9579567 = SYM B-VP O
21 1193 1199 9579567 0.0001 CD B-NP O
22 1199 1200 9579567 ) ) O O
23 1200 1201 9579567 . . O O

1 1202 1207 9579567 After IN B-PP O
2 1208 1217 9579567 adjusting VBG B-VP O
3 1218 1221 9579567 for IN B-PP O
4 1222 1233 9579567 confounding VBG B-VP O
5 1234 1241 9579567 factors NNS B-NP O
6 1241 1242 9579567 , , O O
7 1243 1246 9579567 the DT B-NP O
8 1247 1251 9579567 risk NN I-NP O
9 1252 1255 9579567 was VBD B-VP O
10 1256 1262 9579567 higher JJR B-ADJP O
11 1263 1266 9579567 for IN B-PP O
12 1267 1276 9579567 tamoxifen NN B-NP D013629
13 1277 1282 9579567 users NNS I-NP O
14 1283 1284 9579567 ( ( O O
15 1284 1285 9579567 p NN B-NP O
16 1286 1287 9579567 = SYM B-VP O
17 1288 1294 9579567 0.0012 CD B-NP O
18 1294 1295 9579567 ) ) O O
19 1295 1296 9579567 , , O O
20 1297 1306 9579567 treatment NN B-NP O
21 1307 1310 9579567 for IN B-PP O
22 1311 1315 9579567 more JJR B-NP O
23 1316 1320 9579567 than IN I-NP O
24 1321 1322 9579567 3 CD I-NP O
25 1323 1328 9579567 years NNS I-NP O
26 1329 1330 9579567 ( ( O O
27 1330 1333 9579567 all DT B-NP O
28 1334 1335 9579567 p NN I-NP O
29 1336 1337 9579567 < JJR B-NP O
30 1338 1342 9579567 0.03 CD I-NP O
31 1342 1343 9579567 ) ) O O
32 1344 1347 9579567 and CC O O
33 1348 1354 9579567 pelvic JJ B-NP O
34 1355 1367 9579567 radiotherapy NN I-NP O
35 1368 1369 9579567 ( ( O O
36 1369 1370 9579567 p NN B-NP O
37 1371 1372 9579567 = SYM B-VP O
38 1373 1378 9579567 0.012 CD B-NP O
39 1378 1379 9579567 ) ) O O
40 1379 1380 9579567 . . O O

1 1381 1386 9579567 Women NNS B-NP O
2 1387 1390 9579567 who WP B-NP O
3 1391 1394 9579567 had VBD B-VP O
4 1395 1406 9579567 endometrial JJ B-NP D016889
5 1407 1413 9579567 cancer NN I-NP D016889
6 1414 1417 9579567 and CC O O
7 1418 1421 9579567 had VBD B-VP O
8 1422 1430 9579567 received VBN I-VP O
9 1431 1440 9579567 tamoxifen NN B-NP D013629
10 1441 1444 9579567 had VBD B-VP O
11 1445 1449 9579567 more RBR B-NP O
12 1450 1458 9579567 advanced JJ I-NP D020178
13 1459 1466 9579567 disease NN I-NP D020178
14 1467 1470 9579567 and CC O O
15 1471 1477 9579567 poorer JJR B-NP O
16 1478 1487 9579567 prognosis NN I-NP O
17 1488 1492 9579567 than IN B-PP O
18 1493 1498 9579567 those DT B-NP O
19 1499 1503 9579567 with IN B-PP O
20 1504 1515 9579567 endometrial JJ B-NP D016889
21 1516 1522 9579567 cancer NN I-NP D016889
22 1523 1526 9579567 who WP B-NP O
23 1527 1530 9579567 had VBD B-VP O
24 1531 1534 9579567 not RB I-VP O
25 1535 1543 9579567 received VBN I-VP O
26 1544 1548 9579567 this DT B-NP O
27 1549 1558 9579567 treatment NN I-NP O
28 1558 1559 9579567 . . O O

1 1560 1563 9579567 Our PRP$ B-NP O
2 1564 1571 9579567 results NNS I-NP O
3 1572 1579 9579567 suggest VBP B-VP O
4 1580 1581 9579567 a DT B-NP O
5 1582 1588 9579567 causal JJ I-NP O
6 1589 1593 9579567 role NN I-NP O
7 1594 1596 9579567 of IN B-PP O
8 1597 1606 9579567 tamoxifen NN B-NP D013629
9 1607 1609 9579567 in IN B-PP O
10 1610 1621 9579567 endometrial JJ B-NP D016889
11 1622 1628 9579567 cancer NN I-NP D016889
12 1628 1629 9579567 , , O O
13 1630 1642 9579567 particularly RB B-ADVP O
14 1643 1647 9579567 when WRB B-ADVP O
15 1648 1652 9579567 used VBN B-VP O
16 1653 1655 9579567 as IN B-PP O
17 1656 1665 9579567 currently RB B-ADVP O
18 1666 1674 9579567 proposed VBN B-VP O
19 1675 1678 9579567 for IN B-PP O
20 1679 1685 9579567 breast NN B-NP D001943
21 1686 1692 9579567 cancer NN I-NP D001943
22 1693 1703 9579567 prevention NN I-NP O
23 1703 1704 9579567 . . O O

1 1705 1711 9579567 Pelvic JJ B-NP O
2 1712 1724 9579567 radiotherapy NN I-NP O
3 1725 1728 9579567 may MD B-VP O
4 1729 1731 9579567 be VB I-VP O
5 1732 1734 9579567 an DT B-NP O
6 1735 1745 9579567 additional JJ I-NP O
7 1746 1756 9579567 iatrogenic JJ I-NP O
8 1757 1763 9579567 factor NN I-NP O
9 1764 1767 9579567 for IN B-PP O
10 1768 1773 9579567 women NNS B-NP O
11 1774 1778 9579567 with IN B-PP O
12 1779 1785 9579567 breast NN B-NP D001943
13 1786 1792 9579567 cancer NN I-NP D001943
14 1792 1793 9579567 . . O O

1 1794 1805 9579567 Endometrial JJ B-NP D016889
2 1806 1813 9579567 cancers NNS I-NP D016889
3 1814 1823 9579567 diagnosed VBN B-VP O
4 1824 1826 9579567 in IN B-PP O
5 1827 1832 9579567 women NNS B-NP O
6 1833 1840 9579567 treated VBN B-VP O
7 1841 1845 9579567 with IN B-PP O
8 1846 1855 9579567 tamoxifen NN B-NP D013629
9 1856 1860 9579567 have VBP B-VP O
10 1861 1867 9579567 poorer JJR B-NP O
11 1868 1877 9579567 prognosis NN I-NP O
12 1877 1878 9579567 . . O O

1 1879 1884 9579567 Women NNS B-NP O
2 1885 1888 9579567 who WP B-NP O
3 1889 1896 9579567 receive VBP B-VP O
4 1897 1906 9579567 tamoxifen NN B-NP D013629
5 1907 1910 9579567 for IN B-PP O
6 1911 1917 9579567 breast NN B-NP D001943
7 1918 1924 9579567 cancer NN I-NP D001943
8 1925 1931 9579567 should MD B-VP O
9 1932 1934 9579567 be VB I-VP O
10 1935 1942 9579567 offered VBN I-VP O
11 1943 1957 9579567 gynaecological JJ B-NP O
12 1958 1970 9579567 surveillance NN I-NP O
13 1971 1977 9579567 during IN B-PP O
14 1978 1981 9579567 and CC I-PP O
15 1982 1987 9579567 after IN I-PP O
16 1988 1997 9579567 treatment NN B-NP O
17 1997 1998 9579567 . . O O

1 1999 2000 9579567 A DT B-NP O
2 2001 2005 9579567 long JJ I-NP O
3 2005 2006 9579567 - HYPH I-NP O
4 2006 2010 9579567 term NN I-NP O
5 2011 2021 9579567 evaluation NN I-NP O
6 2022 2024 9579567 of IN B-PP O
7 2025 2028 9579567 the DT B-NP O
8 2029 2033 9579567 risk NN I-NP O
9 2033 2034 9579567 - HYPH I-NP O
10 2034 2041 9579567 benefit NN I-NP O
11 2042 2047 9579567 ratio NN I-NP O
12 2048 2050 9579567 of IN B-PP O
13 2051 2060 9579567 tamoxifen NN B-NP D013629
14 2061 2063 9579567 as IN B-PP O
15 2064 2065 9579567 a DT B-NP O
16 2066 2076 9579567 preventive JJ I-NP O
17 2077 2086 9579567 treatment NN I-NP O
18 2087 2090 9579567 for IN B-PP O
19 2091 2097 9579567 breast NN B-NP D001943
20 2098 2104 9579567 cancer NN I-NP D001943
21 2105 2107 9579567 is VBZ B-VP O
22 2108 2115 9579567 clearly RB I-VP O
23 2116 2125 9579567 warranted VBN I-VP O
24 2125 2126 9579567 . . O O

1 0 0 18483878 -DOCSTART- -X- -X- O

1 0 11 18483878 Exaggerated VBN B-NP O
2 12 22 18483878 expression NN I-NP O
3 23 25 18483878 of IN B-PP O
4 26 38 18483878 inflammatory JJ B-NP O
5 39 48 18483878 mediators NNS I-NP O
6 49 51 18483878 in IN B-PP O
7 52 62 18483878 vasoactive JJ B-NP O
8 63 73 18483878 intestinal JJ I-NP O
9 74 85 18483878 polypeptide NN I-NP O
10 86 94 18483878 knockout NN I-NP O
11 95 96 18483878 ( ( O O
12 96 99 18483878 VIP NN B-NP O
13 99 100 18483878 - HYPH O O
14 100 101 18483878 / SYM O O
15 101 102 18483878 - SYM O O
16 102 103 18483878 ) ) O O
17 104 108 18483878 mice NNS B-NP O
18 109 113 18483878 with IN B-PP O
19 114 130 18483878 cyclophosphamide NN B-NP D003520
20 131 132 18483878 ( ( O O
21 132 135 18483878 CYP NN B-NP D003520
22 135 136 18483878 ) ) O O
23 136 137 18483878 - HYPH O O
24 137 144 18483878 induced VBN B-NP O
25 145 153 18483878 cystitis NN I-NP D003556
26 153 154 18483878 . . O O
27 155 165 18483878 Vasoactive JJ B-NP O
28 166 176 18483878 intestinal JJ I-NP O
29 177 188 18483878 polypeptide NN I-NP O
30 189 190 18483878 ( ( O O
31 190 193 18483878 VIP NN B-NP O
32 193 194 18483878 ) ) O O
33 195 197 18483878 is VBZ B-VP O
34 198 200 18483878 an DT B-NP O
35 201 217 18483878 immunomodulatory JJ I-NP O
36 218 230 18483878 neuropeptide NN I-NP O
37 231 242 18483878 distributed VBN B-VP O
38 243 245 18483878 in IN B-PP O
39 246 257 18483878 micturition NN B-NP O
40 258 266 18483878 pathways NNS I-NP O
41 266 267 18483878 . . O O

1 268 272 18483878 VIP( SYM O O
2 272 273 18483878 - HYPH O O
3 273 274 18483878 / SYM O O
4 274 275 18483878 - SYM O O
5 275 276 18483878 ) ) O O
6 277 281 18483878 mice NNS B-NP O
7 282 289 18483878 exhibit VBP B-VP O
8 290 297 18483878 altered VBN I-VP O
9 298 305 18483878 bladder NN B-NP O
10 306 314 18483878 function NN I-NP O
11 315 318 18483878 and CC O O
12 319 332 18483878 neurochemical JJ B-NP O
13 333 343 18483878 properties NNS I-NP O
14 344 346 18483878 in IN B-PP O
15 347 358 18483878 micturition NN B-NP O
16 359 367 18483878 pathways NNS I-NP O
17 368 373 18483878 after IN B-PP O
18 374 390 18483878 cyclophosphamide NN B-NP D003520
19 391 392 18483878 ( ( O O
20 392 395 18483878 CYP NN B-NP D003520
21 395 396 18483878 ) ) O O
22 396 397 18483878 - HYPH B-NP O
23 397 404 18483878 induced VBN I-NP O
24 405 413 18483878 cystitis NN I-NP D003556
25 413 414 18483878 . . O O

1 415 420 18483878 Given VBN B-NP O
2 421 426 18483878 VIP's NNS I-NP O
3 427 431 18483878 role NN I-NP O
4 432 434 18483878 as IN B-PP O
5 435 437 18483878 an DT B-NP O
6 438 442 18483878 anti AFX I-NP O
7 442 443 18483878 - HYPH I-NP O
8 443 455 18483878 inflammatory JJ I-NP O
9 456 464 18483878 mediator NN I-NP O
10 464 465 18483878 , , O O
11 466 468 18483878 we PRP B-NP O
12 469 481 18483878 hypothesized VBD B-VP O
13 482 486 18483878 that IN B-SBAR O
14 487 491 18483878 VIP( SYM O O
15 491 492 18483878 - HYPH O O
16 492 493 18483878 / SYM O O
17 493 494 18483878 - SYM O O
18 494 495 18483878 ) ) O O
19 496 500 18483878 mice NNS B-NP O
20 501 506 18483878 would MD B-VP O
21 507 514 18483878 exhibit VB I-VP O
22 515 523 18483878 enhanced VBN I-VP O
23 524 536 18483878 inflammatory JJ B-NP O
24 537 545 18483878 mediator NN I-NP O
25 546 556 18483878 expression NN I-NP O
26 557 562 18483878 after IN B-PP O
27 563 571 18483878 cystitis NN B-NP D003556
28 571 572 18483878 . . O O

1 573 574 18483878 A DT B-NP O
2 575 580 18483878 mouse NN I-NP O
3 581 593 18483878 inflammatory JJ I-NP O
4 594 602 18483878 cytokine NN I-NP O
5 603 606 18483878 and CC I-NP O
6 607 615 18483878 receptor NN I-NP O
7 616 619 18483878 RT2 NN I-NP O
8 620 628 18483878 profiler NN I-NP O
9 629 634 18483878 array NN I-NP O
10 635 638 18483878 was VBD B-VP O
11 639 643 18483878 used VBN I-VP O
12 644 646 18483878 to TO B-VP O
13 647 656 18483878 determine VB I-VP O
14 657 666 18483878 regulated JJ B-NP O
15 667 678 18483878 transcripts NNS I-NP O
16 679 681 18483878 in IN B-PP O
17 682 685 18483878 the DT B-NP O
18 686 693 18483878 urinary JJ I-NP O
19 694 701 18483878 bladder NN I-NP O
20 702 704 18483878 of IN B-PP O
21 705 709 18483878 wild JJ B-NP O
22 710 714 18483878 type NN I-NP O
23 715 716 18483878 ( ( O O
24 716 718 18483878 WT NN B-NP O
25 718 719 18483878 ) ) O O
26 720 723 18483878 and CC O O
27 724 728 18483878 VIP( SYM O O
28 728 729 18483878 - HYPH O O
29 729 730 18483878 / SYM O O
30 730 731 18483878 - SYM O O
31 731 732 18483878 ) ) O O
32 733 737 18483878 mice NNS B-NP O
33 738 742 18483878 with IN B-PP O
34 743 745 18483878 or CC B-PP O
35 746 753 18483878 without IN B-PP O
36 754 757 18483878 CYP NN B-NP D003520
37 757 758 18483878 - HYPH B-NP O
38 758 765 18483878 induced VBN I-NP O
39 766 774 18483878 cystitis NN I-NP D003556
40 775 776 18483878 ( ( O O
41 776 779 18483878 150 CD B-NP O
42 780 782 18483878 mg NN I-NP O
43 782 783 18483878 / SYM B-NP O
44 783 785 18483878 kg NN I-NP O
45 785 786 18483878 ; : O O
46 787 790 18483878 i.p NN B-NP O
47 790 791 18483878 . . O O
48 791 792 18483878 ; : O O
49 793 795 18483878 48 CD B-NP O
50 796 797 18483878 h NN I-NP O
51 797 798 18483878 ) ) O O
52 798 799 18483878 . . O O

1 800 804 18483878 Four CD B-NP O
2 805 811 18483878 binary JJ I-NP O
3 812 823 18483878 comparisons NNS I-NP O
4 824 828 18483878 were VBD B-VP O
5 829 833 18483878 made VBN I-VP O
6 833 834 18483878 : : O O
7 835 837 18483878 WT JJ B-NP O
8 838 845 18483878 control NN I-NP O
9 846 852 18483878 versus CC O O
10 853 856 18483878 CYP NN B-NP D003520
11 857 866 18483878 treatment NN I-NP O
12 867 868 18483878 ( ( O O
13 868 870 18483878 48 CD B-NP O
14 871 872 18483878 h NN I-NP O
15 872 873 18483878 ) ) O O
16 873 874 18483878 , , O O
17 875 879 18483878 VIP( ( O O
18 879 880 18483878 - HYPH O O
19 880 881 18483878 / SYM O O
20 881 882 18483878 - SYM O O
21 882 883 18483878 ) ) O O
22 884 891 18483878 control NN B-NP O
23 892 898 18483878 versus IN B-PP O
24 899 902 18483878 CYP NN B-NP D003520
25 903 912 18483878 treatment NN I-NP O
26 913 914 18483878 ( ( O O
27 914 916 18483878 48 CD B-NP O
28 917 918 18483878 h NN I-NP O
29 918 919 18483878 ) ) O O
30 919 920 18483878 , , O O
31 921 923 18483878 WT NN B-NP O
32 924 931 18483878 control NN I-NP O
33 932 938 18483878 versus IN B-PP O
34 939 943 18483878 VIP( SYM O O
35 943 944 18483878 - HYPH O O
36 944 945 18483878 / SYM O O
37 945 946 18483878 - SYM O O
38 946 947 18483878 ) ) O O
39 948 955 18483878 control NN B-NP O
40 955 956 18483878 , , O O
41 957 960 18483878 and CC O O
42 961 963 18483878 WT NN B-NP O
43 964 968 18483878 with IN B-PP O
44 969 972 18483878 CYP NN B-NP D003520
45 973 982 18483878 treatment NN I-NP O
46 983 984 18483878 ( ( O O
47 984 986 18483878 48 CD B-NP O
48 987 988 18483878 h NN I-NP O
49 988 989 18483878 ) ) O O
50 990 996 18483878 versus IN B-PP O
51 997 1001 18483878 VIP( SYM B-NP O
52 1001 1002 18483878 - HYPH O O
53 1002 1003 18483878 / SYM O O
54 1003 1004 18483878 - SYM O O
55 1004 1005 18483878 ) ) O O
56 1006 1010 18483878 with IN B-PP O
57 1011 1014 18483878 CYP NN B-NP D003520
58 1015 1024 18483878 treatment NN I-NP O
59 1025 1026 18483878 ( ( O O
60 1026 1028 18483878 48 CD B-NP O
61 1029 1030 18483878 h NN I-NP O
62 1030 1031 18483878 ) ) O O
63 1031 1032 18483878 . . O O

1 1033 1036 18483878 The DT B-NP O
2 1037 1042 18483878 genes NNS I-NP O
3 1043 1052 18483878 presented VBN B-VP O
4 1053 1062 18483878 represent VBP B-VP O
5 1063 1064 18483878 ( ( O O
6 1064 1065 18483878 1 CD B-NP O
7 1065 1066 18483878 ) ) O O
8 1067 1074 18483878 greater JJR B-NP O
9 1075 1079 18483878 than IN I-NP O
10 1080 1083 18483878 1.5 CD I-NP O
11 1083 1084 18483878 - HYPH I-NP O
12 1084 1088 18483878 fold JJ I-NP O
13 1089 1095 18483878 change NN I-NP O
14 1096 1098 18483878 in IN B-PP O
15 1099 1105 18483878 either CC O O
16 1106 1115 18483878 direction NN B-NP O
17 1116 1119 18483878 and CC O O
18 1120 1121 18483878 ( ( B-LST O
19 1121 1122 18483878 2 LS I-LST O
20 1122 1123 18483878 ) ) O O
21 1124 1127 18483878 the DT B-NP O
22 1128 1129 18483878 p NN I-NP O
23 1130 1135 18483878 value NN I-NP O
24 1136 1138 18483878 is VBZ B-VP O
25 1139 1143 18483878 less JJR B-NP O
26 1144 1148 18483878 than IN I-NP O
27 1149 1153 18483878 0.05 CD I-NP O
28 1154 1157 18483878 for IN B-PP O
29 1158 1161 18483878 the DT B-NP O
30 1162 1172 18483878 comparison NN I-NP O
31 1173 1178 18483878 being VBG B-VP O
32 1179 1183 18483878 made VBN I-VP O
33 1183 1184 18483878 . . O O

1 1185 1192 18483878 Several JJ B-NP O
2 1193 1202 18483878 regulated VBN I-NP O
3 1203 1208 18483878 genes NNS I-NP O
4 1209 1213 18483878 were VBD B-VP O
5 1214 1223 18483878 validated VBN I-VP O
6 1224 1229 18483878 using VBG B-VP O
7 1230 1236 18483878 enzyme NN B-NP O
8 1236 1237 18483878 - HYPH O O
9 1237 1243 18483878 linked VBN B-NP O
10 1244 1256 18483878 immunoassays NNS I-NP O
11 1257 1266 18483878 including VBG B-PP O
12 1267 1269 18483878 IL NN B-NP O
13 1269 1270 18483878 - HYPH B-NP O
14 1270 1275 18483878 1beta NN I-NP O
15 1276 1279 18483878 and CC I-NP O
16 1280 1285 18483878 CXCL1 NN I-NP O
17 1285 1286 18483878 . . O O

1 1287 1290 18483878 CYP NN B-NP D003520
2 1291 1300 18483878 treatment NN I-NP O
3 1301 1314 18483878 significantly RB B-ADVP O
4 1315 1316 18483878 ( ( O O
5 1316 1317 18483878 p NN B-NP O
6 1318 1319 18483878 < SYM B-VP O
7 1320 1322 18483878 or CC O O
8 1323 1324 18483878 = SYM B-VP O
9 1325 1330 18483878 0.001 CD B-NP O
10 1330 1331 18483878 ) ) O O
11 1332 1341 18483878 increased VBN B-NP O
12 1342 1352 18483878 expression NN I-NP O
13 1353 1355 18483878 of IN B-PP O
14 1356 1361 18483878 CXCL1 NN B-NP O
15 1362 1365 18483878 and CC I-NP O
16 1366 1368 18483878 IL NN I-NP O
17 1368 1369 18483878 - HYPH B-NP O
18 1369 1374 18483878 1beta NN I-NP O
19 1375 1377 18483878 in IN B-PP O
20 1378 1381 18483878 the DT B-NP O
21 1382 1389 18483878 urinary JJ I-NP O
22 1390 1397 18483878 bladder NN I-NP O
23 1398 1400 18483878 of IN B-PP O
24 1401 1403 18483878 WT NN B-NP O
25 1404 1407 18483878 and CC O O
26 1408 1412 18483878 VIP( ( O O
27 1412 1413 18483878 - HYPH O O
28 1413 1414 18483878 / SYM O O
29 1414 1415 18483878 - SYM O O
30 1415 1416 18483878 ) ) O O
31 1417 1421 18483878 mice NNS B-NP O
32 1421 1422 18483878 , , O O
33 1423 1426 18483878 but CC O O
34 1427 1437 18483878 expression NN B-NP O
35 1438 1440 18483878 in IN B-PP O
36 1441 1445 18483878 VIP( SYM B-NP O
37 1445 1446 18483878 - HYPH O O
38 1446 1447 18483878 / SYM O O
39 1447 1448 18483878 - SYM O O
40 1448 1449 18483878 ) ) O O
41 1450 1454 18483878 mice NNS B-NP O
42 1455 1459 18483878 with IN B-PP O
43 1460 1463 18483878 CYP NN B-NP D003520
44 1464 1473 18483878 treatment NN I-NP O
45 1474 1477 18483878 was VBD B-VP O
46 1478 1491 18483878 significantly RB B-ADVP O
47 1492 1493 18483878 ( ( O O
48 1493 1494 18483878 p NN B-NP O
49 1495 1496 18483878 < SYM B-VP O
50 1497 1499 18483878 or CC O O
51 1500 1501 18483878 = SYM B-VP O
52 1502 1507 18483878 0.001 CD B-NP O
53 1507 1508 18483878 ) ) O O
54 1509 1516 18483878 greater JJR B-ADJP O
55 1517 1518 18483878 ( ( O O
56 1518 1521 18483878 4.2 CD B-NP O
57 1521 1522 18483878 - HYPH O O
58 1523 1525 18483878 to TO B-PP O
59 1526 1528 18483878 13 CD B-NP O
60 1528 1529 18483878 - HYPH I-NP O
61 1529 1533 18483878 fold JJ I-NP O
62 1534 1542 18483878 increase NN I-NP O
63 1542 1543 18483878 ) ) O O
64 1544 1548 18483878 than IN B-PP O
65 1549 1553 18483878 that DT B-NP O
66 1554 1562 18483878 observed VBN B-VP O
67 1563 1565 18483878 in IN B-PP O
68 1566 1568 18483878 WT JJ B-NP O
69 1569 1576 18483878 urinary JJ I-NP O
70 1577 1584 18483878 bladder NN I-NP O
71 1585 1586 18483878 ( ( O O
72 1586 1589 18483878 3.6 CD B-NP O
73 1589 1590 18483878 - HYPH B-ADJP O
74 1591 1593 18483878 to TO B-PP O
75 1594 1595 18483878 5 CD B-NP O
76 1595 1596 18483878 - HYPH I-NP O
77 1596 1600 18483878 fold JJ I-NP O
78 1601 1609 18483878 increase NN I-NP O
79 1609 1610 18483878 ) ) O O
80 1610 1611 18483878 . . O O

1 1612 1615 18483878 The DT B-NP O
2 1616 1620 18483878 data NNS I-NP O
3 1621 1628 18483878 suggest VBP B-VP O
4 1629 1633 18483878 that IN B-SBAR O
5 1634 1636 18483878 in IN B-PP O
6 1637 1641 18483878 VIP( SYM B-NP O
7 1641 1642 18483878 - HYPH O O
8 1642 1643 18483878 / SYM O O
9 1643 1644 18483878 - SYM O O
10 1644 1645 18483878 ) ) O O
11 1646 1650 18483878 mice NNS B-NP O
12 1651 1655 18483878 with IN B-PP O
13 1656 1663 18483878 bladder NN B-NP D001745
14 1664 1676 18483878 inflammation NN I-NP D001745
15 1676 1677 18483878 , , O O
16 1678 1690 18483878 inflammatory JJ B-NP O
17 1691 1700 18483878 mediators NNS I-NP O
18 1701 1704 18483878 are VBP B-VP O
19 1705 1714 18483878 increased VBN I-VP O
20 1715 1720 18483878 above IN B-PP O
21 1721 1725 18483878 that DT B-NP O
22 1726 1734 18483878 observed VBN B-VP O
23 1735 1737 18483878 in IN B-PP O
24 1738 1740 18483878 WT NN B-NP O
25 1741 1745 18483878 with IN B-PP O
26 1746 1749 18483878 CYP NN B-NP D003520
27 1749 1750 18483878 . . O O

1 1751 1755 18483878 This DT B-NP O
2 1756 1761 18483878 shift NN I-NP O
3 1762 1764 18483878 in IN B-PP O
4 1765 1772 18483878 balance NN B-NP O
5 1773 1776 18483878 may MD B-VP O
6 1777 1787 18483878 contribute VB I-VP O
7 1788 1790 18483878 to TO B-PP O
8 1791 1800 18483878 increased VBN B-NP O
9 1801 1808 18483878 bladder NN I-NP D001745
10 1809 1820 18483878 dysfunction NN I-NP D001745
11 1821 1823 18483878 in IN B-PP O
12 1824 1828 18483878 VIP( SYM B-NP O
13 1828 1829 18483878 - HYPH O O
14 1829 1830 18483878 / SYM O O
15 1830 1831 18483878 - SYM O O
16 1831 1832 18483878 ) ) O O
17 1833 1837 18483878 mice NNS B-NP O
18 1838 1842 18483878 with IN B-PP O
19 1843 1850 18483878 bladder NN B-NP D001745
20 1851 1863 18483878 inflammation NN I-NP D001745
21 1864 1867 18483878 and CC O O
22 1868 1875 18483878 altered VBD B-VP O
23 1876 1889 18483878 neurochemical JJ B-NP O
24 1890 1900 18483878 expression NN I-NP O
25 1901 1903 18483878 in IN B-PP O
26 1904 1915 18483878 micturition NN B-NP O
27 1916 1924 18483878 pathways NNS I-NP O
28 1924 1925 18483878 . . O O

1 0 0 10523326 -DOCSTART- -X- -X- O

1 0 6 10523326 Nitric JJ B-NP D009569
2 7 12 10523326 oxide NN I-NP D009569
3 13 21 10523326 synthase NN I-NP O
4 22 32 10523326 expression NN I-NP O
5 33 35 10523326 in IN B-PP O
6 36 39 10523326 the DT B-NP O
7 40 46 10523326 course NN I-NP O
8 47 49 10523326 of IN B-PP O
9 50 54 10523326 lead NN B-NP D007854
10 54 55 10523326 - HYPH B-NP O
11 55 62 10523326 induced VBN I-NP O
12 63 75 10523326 hypertension NN I-NP D006973
13 75 76 10523326 . . O O
14 77 79 10523326 We PRP B-NP O
15 80 88 10523326 recently RB B-ADVP O
16 89 95 10523326 showed VBD B-VP O
17 96 104 10523326 elevated JJ B-NP O
18 105 113 10523326 reactive JJ I-NP O
19 114 120 10523326 oxygen NN I-NP D010100
20 121 128 10523326 species NNS I-NP O
21 129 130 10523326 ( ( O O
22 130 133 10523326 ROS NN B-NP O
23 133 134 10523326 ) ) O O
24 134 135 10523326 , , O O
25 136 143 10523326 reduced VBD B-VP O
26 144 151 10523326 urinary JJ B-NP O
27 152 161 10523326 excretion NN I-NP O
28 162 164 10523326 of IN B-PP O
29 165 167 10523326 NO NN B-NP D009569
30 168 179 10523326 metabolites NNS I-NP O
31 180 181 10523326 ( ( O O
32 181 184 10523326 NOx NN B-NP O
33 184 185 10523326 ) ) O O
34 185 186 10523326 , , O O
35 187 190 10523326 and CC O O
36 191 200 10523326 increased VBD B-VP O
37 201 203 10523326 NO NN B-NP D009569
38 204 217 10523326 sequestration NN I-NP O
39 218 220 10523326 as IN B-PP O
40 221 234 10523326 nitrotyrosine NN B-NP C002744
41 235 237 10523326 in IN B-PP O
42 238 245 10523326 various JJ B-NP O
43 246 253 10523326 tissues NNS I-NP O
44 254 256 10523326 in IN B-PP O
45 257 261 10523326 rats NNS B-NP O
46 262 266 10523326 with IN B-PP O
47 267 271 10523326 lead NN B-NP D007854
48 271 272 10523326 - HYPH B-NP O
49 272 279 10523326 induced VBN I-NP O
50 280 292 10523326 hypertension NN I-NP D006973
51 292 293 10523326 . . O O

1 294 298 10523326 This DT B-NP O
2 299 304 10523326 study NN I-NP O
3 305 308 10523326 was VBD B-VP O
4 309 317 10523326 designed VBN I-VP O
5 318 320 10523326 to TO B-VP O
6 321 328 10523326 discern VB I-VP O
7 329 336 10523326 whether IN B-SBAR O
8 337 340 10523326 the DT B-NP O
9 341 350 10523326 reduction NN I-NP O
10 351 353 10523326 in IN B-PP O
11 354 361 10523326 urinary JJ B-NP O
12 362 365 10523326 NOx NN I-NP O
13 366 368 10523326 in IN B-PP O
14 369 373 10523326 lead NN B-NP D007854
15 373 374 10523326 - HYPH B-NP O
16 374 381 10523326 induced VBN I-NP O
17 382 394 10523326 hypertension NN I-NP D006973
18 395 397 10523326 is VBZ B-VP O
19 397 398 10523326 , , O O
20 399 401 10523326 in IN B-PP O
21 402 406 10523326 part NN B-NP O
22 406 407 10523326 , , O O
23 408 411 10523326 due JJ B-PP O
24 412 414 10523326 to TO B-PP O
25 415 424 10523326 depressed JJ B-NP O
26 425 427 10523326 NO NN I-NP D009569
27 428 436 10523326 synthase NN I-NP O
28 437 438 10523326 ( ( O O
29 438 441 10523326 NOS NN B-NP O
30 441 442 10523326 ) ) O O
31 443 453 10523326 expression NN B-NP O
32 453 454 10523326 . . O O

1 455 459 10523326 Male JJ B-NP O
2 460 467 10523326 Sprague NNP I-NP O
3 467 468 10523326 - HYPH I-NP O
4 468 474 10523326 Dawley NNP I-NP O
5 475 479 10523326 rats NNS I-NP O
6 480 484 10523326 were VBD B-VP O
7 485 493 10523326 randomly RB I-VP O
8 494 502 10523326 assigned VBN I-VP O
9 503 505 10523326 to TO B-PP O
10 506 507 10523326 a DT B-NP O
11 508 512 10523326 lead NN I-NP D007854
12 512 513 10523326 - HYPH B-VP O
13 513 520 10523326 treated VBN B-NP O
14 521 526 10523326 group NN I-NP O
15 527 528 10523326 ( ( O O
16 528 533 10523326 given VBN B-NP O
17 534 538 10523326 lead NN I-NP C008261
18 539 546 10523326 acetate NN I-NP C008261
19 546 547 10523326 , , O O
20 548 551 10523326 100 CD B-NP O
21 552 555 10523326 ppm NN I-NP O
22 555 556 10523326 , , O O
23 557 559 10523326 in IN B-PP O
24 560 568 10523326 drinking NN B-NP O
25 569 574 10523326 water NN I-NP O
26 575 578 10523326 and CC O O
27 579 586 10523326 regular JJ B-NP O
28 587 590 10523326 rat NN I-NP O
29 591 595 10523326 chow NN I-NP O
30 595 596 10523326 ) ) O O
31 596 597 10523326 , , O O
32 598 599 10523326 a DT B-NP O
33 600 605 10523326 group NN I-NP O
34 606 611 10523326 given VBN B-PP O
35 612 616 10523326 lead NN B-NP D007854
36 617 620 10523326 and CC O O
37 621 628 10523326 vitamin NN B-NP D014810
38 629 630 10523326 E NN I-NP D014810
39 630 631 10523326 - HYPH B-VP O
40 631 640 10523326 fortified VBN B-NP O
41 641 645 10523326 chow NN I-NP O
42 645 646 10523326 , , O O
43 647 649 10523326 or CC O O
44 650 651 10523326 a DT B-NP O
45 652 658 10523326 normal JJ I-NP O
46 659 666 10523326 control NN I-NP O
47 667 672 10523326 group NN I-NP O
48 673 678 10523326 given VBN B-VP O
49 679 685 10523326 either CC B-NP O
50 686 693 10523326 regular JJ I-NP O
51 694 698 10523326 food NN I-NP O
52 699 702 10523326 and CC I-NP O
53 703 708 10523326 water NN I-NP O
54 709 711 10523326 or CC I-NP O
55 712 719 10523326 vitamin NN I-NP D014810
56 720 721 10523326 E NN I-NP D014810
57 721 722 10523326 - HYPH B-VP O
58 722 731 10523326 fortified VBN B-NP O
59 732 736 10523326 food NN I-NP O
60 737 740 10523326 for IN B-PP O
61 741 743 10523326 12 CD B-NP O
62 744 749 10523326 weeks NNS I-NP O
63 749 750 10523326 . . O O

1 751 755 10523326 Tail NN B-NP O
2 756 761 10523326 blood NN I-NP O
3 762 770 10523326 pressure NN I-NP O
4 770 771 10523326 , , O O
5 772 779 10523326 urinary JJ B-NP O
6 780 783 10523326 NOx NN I-NP O
7 784 793 10523326 excretion NN I-NP O
8 793 794 10523326 , , O O
9 795 801 10523326 plasma NN B-NP O
10 802 817 10523326 malondialdehyde NN I-NP D008315
11 818 819 10523326 ( ( O O
12 819 822 10523326 MDA NN B-NP D008315
13 822 823 10523326 ) ) O O
14 823 824 10523326 , , O O
15 825 828 10523326 and CC O O
16 829 840 10523326 endothelial JJ B-NP O
17 841 844 10523326 and CC I-NP O
18 845 854 10523326 inducible JJ I-NP O
19 855 858 10523326 NOS NN I-NP O
20 859 860 10523326 ( ( O O
21 860 864 10523326 eNOS NN B-NP O
22 865 868 10523326 and CC O O
23 869 873 10523326 iNOS NN B-NP O
24 873 874 10523326 ) ) O O
25 875 883 10523326 isotypes NNS B-NP O
26 884 886 10523326 in IN B-PP O
27 887 890 10523326 the DT B-NP O
28 891 896 10523326 aorta NN I-NP O
29 897 900 10523326 and CC I-NP O
30 901 907 10523326 kidney NN I-NP O
31 908 912 10523326 were VBD B-VP O
32 913 921 10523326 measured VBN I-VP O
33 921 922 10523326 . . O O

1 923 926 10523326 The DT B-NP O
2 927 931 10523326 lead NN I-NP D007854
3 931 932 10523326 - HYPH B-NP O
4 932 939 10523326 treated VBN I-NP O
5 940 945 10523326 group NN I-NP O
6 946 955 10523326 exhibited VBD B-VP O
7 956 957 10523326 a DT B-NP O
8 958 962 10523326 rise NN I-NP O
9 963 965 10523326 in IN B-PP O
10 966 971 10523326 blood NN B-NP O
11 972 980 10523326 pressure NN I-NP O
12 981 984 10523326 and CC O O
13 985 991 10523326 plasma NN B-NP O
14 992 995 10523326 MDA NN I-NP D008315
15 996 1009 10523326 concentration NN I-NP O
16 1009 1010 10523326 , , O O
17 1011 1012 10523326 a DT B-NP O
18 1013 1017 10523326 fall NN I-NP O
19 1018 1020 10523326 in IN B-PP O
20 1021 1028 10523326 urinary JJ B-NP O
21 1029 1032 10523326 NOx NN I-NP O
22 1033 1042 10523326 excretion NN I-NP O
23 1042 1043 10523326 , , O O
24 1044 1047 10523326 and CC O O
25 1048 1049 10523326 a DT B-NP O
26 1050 1061 10523326 paradoxical JJ I-NP O
27 1062 1066 10523326 rise NN I-NP O
28 1067 1069 10523326 in IN B-PP O
29 1070 1078 10523326 vascular JJ B-NP O
30 1079 1082 10523326 and CC I-NP O
31 1083 1088 10523326 renal JJ I-NP O
32 1089 1095 10523326 tissue NN I-NP O
33 1096 1100 10523326 eNOS NN I-NP O
34 1101 1104 10523326 and CC O O
35 1105 1109 10523326 iNOS NN B-NP O
36 1110 1120 10523326 expression NN I-NP O
37 1120 1121 10523326 . . O O

1 1122 1129 10523326 Vitamin NN B-NP D014810
2 1130 1131 10523326 E NN I-NP D014810
3 1132 1147 10523326 supplementation NN I-NP O
4 1148 1159 10523326 ameliorated VBD B-VP O
5 1160 1172 10523326 hypertension NN B-NP D006973
6 1172 1173 10523326 , , O O
7 1174 1181 10523326 lowered VBD B-VP O
8 1182 1188 10523326 plasma NN B-NP O
9 1189 1192 10523326 MDA NN I-NP D008315
10 1193 1206 10523326 concentration NN I-NP O
11 1206 1207 10523326 , , O O
12 1208 1211 10523326 and CC O O
13 1212 1218 10523326 raised VBD B-VP O
14 1219 1226 10523326 urinary JJ B-NP O
15 1227 1230 10523326 NOx NN I-NP O
16 1231 1240 10523326 excretion NN I-NP O
17 1241 1246 10523326 while IN B-SBAR O
18 1247 1260 10523326 significantly RB B-VP O
19 1261 1269 10523326 lowering VBG I-VP O
20 1270 1278 10523326 vascular JJ B-ADJP O
21 1278 1279 10523326 , , O O
22 1280 1283 10523326 but CC O O
23 1284 1287 10523326 not RB B-ADJP O
24 1288 1293 10523326 renal JJ I-ADJP O
25 1293 1294 10523326 , , O O
26 1295 1301 10523326 tissue NN B-NP O
27 1302 1306 10523326 eNOS NN I-NP O
28 1307 1310 10523326 and CC O O
29 1311 1315 10523326 iNOS NN B-NP O
30 1316 1326 10523326 expression NN I-NP O
31 1326 1327 10523326 . . O O

1 1328 1335 10523326 Vitamin NN B-NP D014810
2 1336 1337 10523326 E NN I-NP D014810
3 1338 1353 10523326 supplementation NN I-NP O
4 1354 1357 10523326 had VBD B-VP O
5 1358 1360 10523326 no DT B-NP O
6 1361 1367 10523326 effect NN I-NP O
7 1368 1370 10523326 on IN B-PP O
8 1371 1377 10523326 either CC O O
9 1378 1383 10523326 blood NN B-NP O
10 1384 1392 10523326 pressure NN I-NP O
11 1392 1393 10523326 , , O O
12 1394 1400 10523326 plasma NN B-NP O
13 1401 1404 10523326 MDA NN I-NP D008315
14 1404 1405 10523326 , , O O
15 1406 1408 10523326 or CC O O
16 1409 1412 10523326 NOS NN B-NP O
17 1413 1423 10523326 expression NN I-NP O
18 1424 1426 10523326 in IN B-PP O
19 1427 1430 10523326 the DT B-NP O
20 1431 1438 10523326 control NN I-NP O
21 1439 1444 10523326 group NN I-NP O
22 1444 1445 10523326 . . O O

1 1446 1449 10523326 The DT B-NP O
2 1450 1455 10523326 study NN I-NP O
3 1456 1460 10523326 also RB B-ADVP O
4 1461 1469 10523326 revealed VBD B-VP O
5 1470 1481 10523326 significant JJ B-NP O
6 1482 1492 10523326 inhibition NN I-NP O
7 1493 1495 10523326 of IN B-PP O
8 1496 1499 10523326 NOS NN B-NP O
9 1500 1509 10523326 enzymatic JJ I-NP O
10 1510 1518 10523326 activity NN I-NP O
11 1519 1521 10523326 by IN B-PP O
12 1522 1526 10523326 lead NN B-NP D007854
13 1527 1529 10523326 in IN B-PP O
14 1530 1534 10523326 cell NN B-NP O
15 1534 1535 10523326 - HYPH B-NP O
16 1535 1539 10523326 free JJ I-NP O
17 1540 1552 10523326 preparations NNS I-NP O
18 1552 1553 10523326 . . O O

1 1554 1556 10523326 In IN B-PP O
2 1557 1567 10523326 conclusion NN B-NP O
3 1567 1568 10523326 , , O O
4 1569 1573 10523326 lead NN B-NP D007854
5 1573 1574 10523326 - HYPH B-VP O
6 1574 1581 10523326 induced VBN B-NP O
7 1582 1594 10523326 hypertension NN I-NP D006973
8 1595 1597 10523326 in IN B-PP O
9 1598 1602 10523326 this DT B-NP O
10 1603 1608 10523326 model NN I-NP O
11 1609 1612 10523326 was VBD B-VP O
12 1613 1623 10523326 associated VBN I-VP O
13 1624 1628 10523326 with IN B-PP O
14 1629 1630 10523326 a DT B-NP O
15 1631 1643 10523326 compensatory JJ I-NP O
16 1644 1656 10523326 upregulation NN I-NP O
17 1657 1659 10523326 of IN B-PP O
18 1660 1665 10523326 renal JJ B-NP O
19 1666 1669 10523326 and CC I-NP O
20 1670 1678 10523326 vascular JJ I-NP O
21 1679 1683 10523326 eNOS NN I-NP O
22 1684 1687 10523326 and CC I-NP O
23 1688 1692 10523326 iNOS NN I-NP O
24 1693 1703 10523326 expression NN I-NP O
25 1703 1704 10523326 . . O O

1 1705 1709 10523326 This DT B-NP O
2 1710 1712 10523326 is VBZ B-VP O
3 1712 1713 10523326 , , O O
4 1714 1716 10523326 in IN B-PP O
5 1717 1721 10523326 part NN B-NP O
6 1721 1722 10523326 , , O O
7 1723 1726 10523326 due IN B-PP O
8 1727 1729 10523326 to TO I-PP O
9 1730 1733 10523326 ROS NN B-NP O
10 1733 1734 10523326 - HYPH B-NP O
11 1734 1742 10523326 mediated VBN I-NP O
12 1743 1745 10523326 NO NN I-NP D009569
13 1746 1758 10523326 inactivation NN I-NP O
14 1758 1759 10523326 , , O O
15 1760 1764 10523326 lead NN B-NP D007854
16 1764 1765 10523326 - HYPH B-VP O
17 1765 1775 10523326 associated VBN B-NP O
18 1776 1786 10523326 inhibition NN I-NP O
19 1787 1789 10523326 of IN B-PP O
20 1790 1793 10523326 NOS NN B-NP O
21 1794 1802 10523326 activity NN I-NP O
22 1802 1803 10523326 , , O O
23 1804 1807 10523326 and CC O O
24 1808 1815 10523326 perhaps RB B-NP O
25 1816 1827 10523326 stimulatory JJ I-NP O
26 1828 1835 10523326 actions NNS I-NP O
27 1836 1838 10523326 of IN B-PP O
28 1839 1848 10523326 increased VBN B-NP O
29 1849 1854 10523326 shear NN I-NP O
30 1855 1861 10523326 stress NN I-NP O
31 1862 1872 10523326 associated VBN B-VP O
32 1873 1877 10523326 with IN B-PP O
33 1878 1890 10523326 hypertension NN B-NP D006973
34 1890 1891 10523326 . . O O

1 0 0 11063349 -DOCSTART- -X- -X- O

1 0 10 11063349 Conversion NN B-NP O
2 11 13 11063349 to TO B-PP O
3 14 23 11063349 rapamycin NN B-NP D020123
4 24 41 11063349 immunosuppression NN I-NP O
5 42 44 11063349 in IN B-PP O
6 45 50 11063349 renal JJ B-NP O
7 51 61 11063349 transplant NN I-NP O
8 62 72 11063349 recipients NNS I-NP O
9 72 73 11063349 : : O O
10 74 80 11063349 report NN B-NP O
11 81 83 11063349 of IN B-PP O
12 84 86 11063349 an DT B-NP O
13 87 94 11063349 initial JJ I-NP O
14 95 105 11063349 experience NN I-NP O
15 105 106 11063349 . . I-NP O
16 107 117 11063349 BACKGROUND NN I-NP O
17 117 118 11063349 : : O O
18 119 122 11063349 The DT B-NP O
19 123 126 11063349 aim NN I-NP O
20 127 129 11063349 of IN B-PP O
21 130 134 11063349 this DT B-NP O
22 135 140 11063349 study NN I-NP O
23 141 143 11063349 is VBZ B-VP O
24 144 146 11063349 to TO B-VP O
25 147 155 11063349 evaluate VB I-VP O
26 156 159 11063349 the DT B-NP O
27 160 167 11063349 effects NNS I-NP O
28 168 170 11063349 of IN B-PP O
29 171 175 11063349 RAPA NN B-NP D020123
30 176 186 11063349 conversion NN I-NP O
31 187 189 11063349 in IN B-PP O
32 190 198 11063349 patients NNS B-NP O
33 199 209 11063349 undergoing VBG B-VP O
34 210 222 11063349 cyclosporine NN B-NP D016572
35 223 224 11063349 ( ( O O
36 224 227 11063349 CsA NN B-NP D016572
37 227 228 11063349 ) ) O O
38 229 231 11063349 or CC O O
39 232 242 11063349 tacrolimus NN B-NP D016559
40 243 244 11063349 ( ( O O
41 244 247 11063349 Tac NN B-NP D016559
42 247 248 11063349 ) ) O O
43 249 257 11063349 toxicity NN B-NP D064420
44 257 258 11063349 . . O O

1 259 266 11063349 METHODS NNS B-NP O
2 266 267 11063349 : : O O
3 268 274 11063349 Twenty CD B-NP O
4 275 280 11063349 renal JJ I-NP O
5 281 291 11063349 transplant NN I-NP O
6 292 302 11063349 recipients NNS I-NP O
7 303 307 11063349 were VBD B-VP O
8 308 316 11063349 switched VBN I-VP O
9 317 319 11063349 to TO B-PP O
10 320 325 11063349 fixed VBN B-NP O
11 326 330 11063349 dose NN I-NP O
12 331 340 11063349 rapamycin NN I-NP D020123
13 341 342 11063349 ( ( O O
14 342 346 11063349 RAPA NN B-NP D020123
15 346 347 11063349 ) ) O O
16 348 349 11063349 ( ( O O
17 349 350 11063349 5 CD B-NP O
18 351 353 11063349 mg NN I-NP O
19 353 354 11063349 / SYM B-NP O
20 354 357 11063349 day NN I-NP O
21 357 358 11063349 ) ) O O
22 359 360 11063349 0 CD B-NP O
23 361 363 11063349 to TO I-NP O
24 364 367 11063349 204 CD I-NP O
25 368 374 11063349 months NNS I-NP O
26 375 389 11063349 posttransplant NN I-NP O
27 389 390 11063349 . . O O

1 391 395 11063349 Drug NN B-NP O
2 396 406 11063349 monitoring NN I-NP O
3 407 410 11063349 was VBD B-VP O
4 411 414 11063349 not RB I-VP O
5 415 424 11063349 initially RB I-VP O
6 425 429 11063349 used VBN I-VP O
7 430 432 11063349 to TO B-VP O
8 433 439 11063349 adjust VB I-VP O
9 440 445 11063349 doses NNS B-NP O
10 445 446 11063349 . . O O

1 447 450 11063349 The DT B-NP O
2 451 462 11063349 indications NNS I-NP O
3 463 466 11063349 for IN B-PP O
4 467 473 11063349 switch NN B-NP O
5 474 478 11063349 were VBD B-VP O
6 479 486 11063349 chronic JJ B-NP O
7 487 490 11063349 CsA NN I-NP D016572
8 491 493 11063349 or CC O O
9 494 497 11063349 Tac NN B-NP D016559
10 498 512 11063349 nephrotoxicity NN I-NP D007674
11 513 514 11063349 ( ( O O
12 514 516 11063349 12 CD B-NP O
13 516 517 11063349 ) ) O O
14 517 518 11063349 , , O O
15 519 524 11063349 acute JJ B-NP O
16 525 528 11063349 CsA NN I-NP D016572
17 529 531 11063349 or CC O O
18 532 535 11063349 Tac NN B-NP D016559
19 536 544 11063349 toxicity NN I-NP D064420
20 545 546 11063349 ( ( O O
21 546 547 11063349 3 CD B-NP O
22 547 548 11063349 ) ) O O
23 548 549 11063349 , , O O
24 550 556 11063349 severe JJ B-NP O
25 557 563 11063349 facial JJ I-NP -1
26 564 575 11063349 dysmorphism NN I-NP -1
27 576 577 11063349 ( ( O O
28 577 578 11063349 2 CD B-NP O
29 578 579 11063349 ) ) O O
30 579 580 11063349 , , O O
31 581 595 11063349 posttransplant JJ B-NP D008232
32 596 615 11063349 lymphoproliferative JJ I-NP D008232
33 616 624 11063349 disorder NN I-NP D008232
34 625 626 11063349 ( ( O O
35 626 630 11063349 PTLD NN B-NP D008232
36 630 631 11063349 ) ) O O
37 632 634 11063349 in IN B-PP O
38 635 644 11063349 remission NN B-NP O
39 645 646 11063349 ( ( O O
40 646 647 11063349 2 CD B-NP O
41 647 648 11063349 ) ) O O
42 648 649 11063349 , , O O
43 650 653 11063349 and CC O O
44 654 668 11063349 hepatotoxicity NN B-NP D056486
45 669 671 11063349 in IN B-PP O
46 672 673 11063349 1 CD B-NP O
47 673 674 11063349 . . O O

1 675 681 11063349 Follow VB B-VP O
2 681 682 11063349 - HYPH O O
3 682 684 11063349 up RP B-PRT O
4 685 687 11063349 is VBZ B-VP O
5 688 689 11063349 7 CD B-NP O
6 690 692 11063349 to TO I-NP O
7 693 695 11063349 24 CD I-NP O
8 696 702 11063349 months NNS I-NP O
9 702 703 11063349 . . O O

1 704 711 11063349 RESULTS NNS B-NP O
2 711 712 11063349 : : O O
3 713 715 11063349 In IN B-PP O
4 716 719 11063349 the DT B-NP O
5 720 722 11063349 12 CD I-NP O
6 723 731 11063349 patients NNS I-NP O
7 732 740 11063349 switched VBD B-VP O
8 741 748 11063349 because IN B-PP O
9 749 751 11063349 of IN I-PP O
10 752 759 11063349 chronic JJ B-NP O
11 760 774 11063349 nephrotoxicity NN I-NP D007674
12 775 780 11063349 there EX B-NP O
13 781 784 11063349 was VBD B-VP O
14 785 786 11063349 a DT B-NP O
15 787 798 11063349 significant JJ I-NP O
16 799 807 11063349 decrease NN I-NP O
17 808 810 11063349 in IN B-PP O
18 811 816 11063349 serum NN B-NP O
19 817 827 11063349 creatinine NN I-NP D003404
20 828 829 11063349 [ ( O O
21 829 833 11063349 233+ SYM B-NP O
22 833 834 11063349 / SYM B-NP O
23 834 835 11063349 - SYM O O
24 835 837 11063349 34 CD B-NP O
25 838 840 11063349 to TO B-PP O
26 841 845 11063349 210+ CD B-NP O
27 845 846 11063349 / SYM O O
28 846 847 11063349 - SYM O O
29 847 849 11063349 56 CD B-NP O
30 850 858 11063349 micromol NN I-NP O
31 858 859 11063349 / SYM B-NP O
32 859 864 11063349 liter NN B-NP O
33 865 866 11063349 ( ( O O
34 866 867 11063349 P NN B-NP O
35 867 868 11063349 < SYM B-NP O
36 868 872 11063349 0.05 CD I-NP O
37 872 873 11063349 ) ) O O
38 874 876 11063349 at IN B-PP O
39 877 878 11063349 6 CD B-NP O
40 879 885 11063349 months NNS I-NP O
41 885 886 11063349 ] ) O O
42 886 887 11063349 . . O O

1 888 894 11063349 Facial JJ B-NP -1
2 895 906 11063349 dysmorphism NN I-NP -1
3 907 915 11063349 improved VBN B-VP O
4 916 918 11063349 in IN B-PP O
5 919 922 11063349 two CD B-NP O
6 923 931 11063349 patients NNS I-NP O
7 931 932 11063349 . . O O

1 933 935 11063349 No DT B-NP O
2 936 943 11063349 relapse NN I-NP O
3 944 946 11063349 of IN B-PP O
4 947 951 11063349 PTLD NN B-NP D008232
5 952 955 11063349 was VBD B-VP O
6 956 964 11063349 observed VBN I-VP O
7 964 965 11063349 . . O O

1 966 970 11063349 Five CD B-NP O
2 971 979 11063349 patients NNS I-NP O
3 980 989 11063349 developed VBD B-VP O
4 990 999 11063349 pneumonia NN B-NP D011014
5 1000 1001 11063349 ( ( O O
6 1001 1004 11063349 two CD B-NP O
7 1005 1017 11063349 Pneumocystis NN I-NP D011020
8 1018 1025 11063349 carinii NN I-NP D011020
9 1026 1035 11063349 pneumonia NN I-NP D011020
10 1035 1036 11063349 , , O O
11 1037 1040 11063349 one CD B-NP O
12 1041 1051 11063349 infectious JJ I-NP D007244
13 1052 1065 11063349 mononucleosis NN I-NP D007244
14 1066 1070 11063349 with IN B-PP O
15 1071 1081 11063349 polyclonal JJ B-NP O
16 1082 1086 11063349 PTLD NN I-NP D008232
17 1087 1091 11063349 lung NN I-NP O
18 1092 1102 11063349 infiltrate NN I-NP O
19 1102 1103 11063349 ) ) O O
20 1104 1107 11063349 and CC O O
21 1108 1111 11063349 two CD B-NP O
22 1112 1115 11063349 had VBD B-VP O
23 1116 1129 11063349 bronchiolitis NN B-NP D001989
24 1130 1140 11063349 obliterans NNS I-NP D001989
25 1140 1141 11063349 . . O O

1 1142 1147 11063349 There EX B-NP O
2 1148 1152 11063349 were VBD B-VP O
3 1153 1155 11063349 no DT B-NP O
4 1156 1162 11063349 deaths NNS I-NP O
5 1162 1163 11063349 . . O O

1 1164 1168 11063349 RAPA NN B-NP D020123
2 1169 1172 11063349 was VBD B-VP O
3 1173 1185 11063349 discontinued VBN I-VP O
4 1186 1188 11063349 in IN B-PP O
5 1189 1193 11063349 four CD B-NP O
6 1194 1202 11063349 patients NNS I-NP O
7 1202 1203 11063349 , , O O
8 1204 1211 11063349 because IN B-PP O
9 1212 1214 11063349 of IN I-PP O
10 1215 1224 11063349 pneumonia NN B-NP D011014
11 1225 1227 11063349 in IN B-PP O
12 1228 1231 11063349 two CD B-NP O
13 1231 1232 11063349 , , O O
14 1233 1237 11063349 PTLD NN B-NP D008232
15 1238 1240 11063349 in IN B-PP O
16 1241 1244 11063349 one CD B-NP O
17 1244 1245 11063349 , , O O
18 1246 1249 11063349 and CC O O
19 1250 1254 11063349 oral JJ B-NP O
20 1255 1262 11063349 aphtous JJ I-NP D013281
21 1263 1269 11063349 ulcers NNS I-NP D013281
22 1270 1272 11063349 in IN B-PP O
23 1273 1276 11063349 one CD B-NP O
24 1276 1277 11063349 . . O O

1 1278 1282 11063349 RAPA NN B-NP D020123
2 1283 1289 11063349 levels NNS I-NP O
3 1290 1294 11063349 were VBD B-VP O
4 1295 1299 11063349 high JJ B-ADJP O
5 1300 1301 11063349 ( ( O O
6 1301 1302 11063349 > JJR B-NP O
7 1302 1304 11063349 15 CD I-NP O
8 1305 1307 11063349 ng NN I-NP O
9 1307 1308 11063349 / SYM I-NP O
10 1308 1310 11063349 ml NN I-NP O
11 1310 1311 11063349 ) ) O O
12 1312 1314 11063349 in IN B-PP O
13 1315 1316 11063349 7 CD B-NP O
14 1317 1319 11063349 of IN B-PP O
15 1320 1322 11063349 13 CD B-NP O
16 1323 1324 11063349 ( ( O O
17 1324 1327 11063349 54% CD B-NP O
18 1327 1328 11063349 ) ) O O
19 1329 1337 11063349 patients NNS B-NP O
20 1337 1338 11063349 . . O O

1 1339 1350 11063349 CONCLUSIONS NNS B-NP O
2 1350 1351 11063349 : : O O
3 1352 1356 11063349 RAPA NN B-NP D020123
4 1357 1367 11063349 conversion NN I-NP O
5 1368 1376 11063349 provides VBZ B-VP O
6 1377 1385 11063349 adequate JJ B-NP O
7 1386 1403 11063349 immunosuppression NN I-NP O
8 1404 1406 11063349 to TO B-VP O
9 1407 1413 11063349 enable VB I-VP O
10 1414 1417 11063349 CsA NN B-NP D016572
11 1418 1428 11063349 withdrawal NN I-NP O
12 1428 1429 11063349 . . O O

1 1430 1437 11063349 However RB B-ADVP O
2 1437 1438 11063349 , , O O
3 1439 1443 11063349 when WRB B-ADVP O
4 1444 1454 11063349 converting VBG B-VP O
5 1455 1463 11063349 patients NNS B-NP O
6 1464 1466 11063349 to TO B-PP O
7 1467 1471 11063349 RAPA NN B-NP D020123
8 1472 1476 11063349 drug NN I-NP O
9 1477 1483 11063349 levels NNS I-NP O
10 1484 1490 11063349 should MD B-VP O
11 1491 1493 11063349 be VB I-VP O
12 1494 1503 11063349 monitored VBN I-VP O
13 1504 1506 11063349 to TO I-VP O
14 1507 1512 11063349 avoid VB I-VP O
15 1513 1517 11063349 over AFX B-NP O
16 1517 1518 11063349 - HYPH I-NP O
17 1518 1535 11063349 immunosuppression NN I-NP O
18 1536 1539 11063349 and CC I-NP O
19 1540 1548 11063349 adequate JJ I-NP O
20 1549 1558 11063349 antiviral JJ I-NP O
21 1559 1562 11063349 and CC I-NP O
22 1563 1575 11063349 Pneumocystis NN I-NP D011020
23 1576 1583 11063349 carinii NN I-NP D011020
24 1584 1593 11063349 pneumonia NN I-NP D011020
25 1594 1605 11063349 prophylaxis NN I-NP O
26 1606 1612 11063349 should MD B-VP O
27 1613 1615 11063349 be VB I-VP O
28 1616 1621 11063349 given VBN I-VP O
29 1621 1622 11063349 . . O O

1 0 0 10910842 -DOCSTART- -X- -X- O

1 0 12 10910842 Prednisolone NN B-NP D011239
2 12 13 10910842 - HYPH B-NP O
3 13 20 10910842 induced VBN I-NP O
4 21 27 10910842 muscle NN I-NP D018908
5 28 39 10910842 dysfunction NN I-NP D018908
6 40 42 10910842 is VBZ B-VP O
7 43 49 10910842 caused VBN I-VP O
8 50 54 10910842 more JJR B-NP O
9 55 57 10910842 by IN B-PP O
10 58 65 10910842 atrophy NN B-NP D001284
11 66 70 10910842 than IN B-PP O
12 71 73 10910842 by IN B-PP O
13 74 81 10910842 altered JJ B-NP O
14 82 95 10910842 acetylcholine NN I-NP D000109
15 96 104 10910842 receptor NN I-NP O
16 105 115 10910842 expression NN I-NP O
17 115 116 10910842 . . O O
18 117 122 10910842 Large JJ B-NP O
19 123 128 10910842 doses NNS I-NP O
20 129 131 10910842 of IN B-PP O
21 132 147 10910842 glucocorticoids NNS B-NP O
22 148 151 10910842 can MD B-VP O
23 152 157 10910842 alter VB I-VP O
24 158 164 10910842 muscle NN B-NP O
25 165 175 10910842 physiology NN I-NP O
26 176 179 10910842 and CC O O
27 180 194 10910842 susceptibility NN B-NP O
28 195 197 10910842 to TO B-PP O
29 198 211 10910842 neuromuscular JJ B-NP O
30 212 220 10910842 blocking VBG I-NP O
31 221 226 10910842 drugs NNS I-NP O
32 227 229 10910842 by IN B-PP O
33 230 240 10910842 mechanisms NNS B-NP O
34 241 244 10910842 not RB O O
35 245 252 10910842 clearly RB B-VP O
36 253 263 10910842 understood VBN I-VP O
37 263 264 10910842 . . O O

1 265 267 10910842 We PRP B-NP O
2 268 280 10910842 investigated VBD B-VP O
3 281 284 10910842 the DT B-NP O
4 285 292 10910842 effects NNS I-NP O
5 293 295 10910842 of IN B-PP O
6 296 304 10910842 moderate JJ B-NP O
7 305 308 10910842 and CC I-NP O
8 309 314 10910842 large JJ I-NP O
9 315 320 10910842 doses NNS I-NP O
10 321 323 10910842 of IN B-PP O
11 324 336 10910842 prednisolone NN B-NP D011239
12 337 339 10910842 on IN B-PP O
13 340 346 10910842 muscle NN B-NP O
14 347 355 10910842 function NN I-NP O
15 356 359 10910842 and CC I-NP O
16 360 372 10910842 pharmacology NN I-NP O
17 372 373 10910842 , , O O
18 374 377 10910842 and CC O O
19 378 383 10910842 their PRP$ B-NP O
20 384 396 10910842 relationship NN I-NP O
21 397 399 10910842 to TO B-PP O
22 400 407 10910842 changes NNS B-NP O
23 408 410 10910842 in IN B-PP O
24 411 417 10910842 muscle NN B-NP O
25 418 422 10910842 size NN I-NP O
26 423 426 10910842 and CC I-NP O
27 427 440 10910842 acetylcholine NN I-NP D000109
28 441 449 10910842 receptor NN I-NP O
29 450 451 10910842 ( ( O O
30 451 455 10910842 AChR NN B-NP O
31 455 456 10910842 ) ) O O
32 457 467 10910842 expression NN B-NP O
33 467 468 10910842 . . O O

1 469 473 10910842 With IN B-PP O
2 474 487 10910842 institutional JJ B-NP O
3 488 496 10910842 approval NN I-NP O
4 496 497 10910842 , , O O
5 498 500 10910842 35 CD B-NP O
6 501 508 10910842 Sprague NNP I-NP O
7 508 509 10910842 - HYPH I-NP O
8 509 515 10910842 Dawley NNP I-NP O
9 516 520 10910842 rats NNS I-NP O
10 521 525 10910842 were VBD B-VP O
11 526 534 10910842 randomly RB I-VP O
12 535 544 10910842 allocated VBN I-VP O
13 545 547 10910842 to TO I-VP O
14 548 555 10910842 receive VB I-VP O
15 556 561 10910842 daily JJ B-NP O
16 562 574 10910842 subcutaneous JJ I-NP O
17 575 580 10910842 doses NNS I-NP O
18 581 583 10910842 of IN B-PP O
19 584 586 10910842 10 CD B-NP O
20 587 589 10910842 mg NN I-NP O
21 589 590 10910842 / SYM O O
22 590 592 10910842 kg NN B-NP O
23 593 605 10910842 prednisolone NN I-NP D011239
24 606 607 10910842 ( ( O O
25 607 610 10910842 P10 NN B-NP O
26 611 616 10910842 group NN I-NP O
27 616 617 10910842 ) ) O O
28 617 618 10910842 , , O O
29 619 622 10910842 100 CD B-NP O
30 623 625 10910842 mg NN I-NP O
31 625 626 10910842 / SYM O O
32 626 628 10910842 kg NN B-NP O
33 629 641 10910842 prednisolone NN I-NP D011239
34 642 643 10910842 ( ( O O
35 643 647 10910842 P100 NN B-NP O
36 648 653 10910842 group NN I-NP O
37 653 654 10910842 ) ) O O
38 654 655 10910842 , , O O
39 656 658 10910842 or CC O O
40 659 661 10910842 an DT B-NP O
41 662 667 10910842 equal JJ I-NP O
42 668 674 10910842 volume NN I-NP O
43 675 677 10910842 of IN B-PP O
44 678 684 10910842 saline NN B-NP O
45 685 686 10910842 ( ( O O
46 686 687 10910842 S NN B-NP O
47 688 693 10910842 group NN I-NP O
48 693 694 10910842 ) ) O O
49 695 698 10910842 for IN B-PP O
50 699 700 10910842 7 CD B-NP O
51 701 705 10910842 days NNS I-NP O
52 705 706 10910842 . . O O

1 707 708 10910842 A DT B-NP O
2 709 715 10910842 fourth JJ I-NP O
3 716 721 10910842 group NN I-NP O
4 722 724 10910842 of IN B-PP O
5 725 729 10910842 rats NNS B-NP O
6 730 733 10910842 was VBD B-VP O
7 734 738 10910842 pair NN I-VP O
8 739 742 10910842 fed VBN I-VP O
9 743 744 10910842 ( ( O O
10 744 748 10910842 food NN B-NP O
11 749 759 10910842 restricted VBN B-VP O
12 759 760 10910842 ) ) O O
13 761 765 10910842 with IN B-PP O
14 766 769 10910842 the DT B-NP O
15 770 774 10910842 P100 NN I-NP O
16 775 779 10910842 rats NNS I-NP O
17 780 783 10910842 for IN B-PP O
18 784 785 10910842 7 CD B-NP O
19 786 790 10910842 days NNS I-NP O
20 791 792 10910842 ( ( O O
21 792 794 10910842 FR NN B-NP O
22 795 800 10910842 group NN I-NP O
23 800 801 10910842 ) ) O O
24 801 802 10910842 . . O O

1 803 805 10910842 On IN B-PP O
2 806 809 10910842 Day NN B-NP O
3 810 811 10910842 8 CD I-NP O
4 811 812 10910842 , , O O
5 813 816 10910842 the DT B-NP O
6 817 822 10910842 nerve NN I-NP O
7 822 823 10910842 - HYPH O O
8 823 829 10910842 evoked VBN B-VP O
9 830 834 10910842 peak JJ B-NP O
10 835 841 10910842 twitch NN I-NP O
11 842 850 10910842 tensions NNS I-NP O
12 850 851 10910842 , , O O
13 852 859 10910842 tetanic JJ B-NP D013746
14 860 868 10910842 tensions NNS I-NP O
15 868 869 10910842 , , O O
16 870 873 10910842 and CC O O
17 874 886 10910842 fatigability NN B-NP O
18 886 887 10910842 , , O O
19 888 891 10910842 and CC O O
20 892 895 10910842 the DT B-NP O
21 896 900 10910842 dose NN I-NP O
22 900 901 10910842 - HYPH B-NP O
23 901 909 10910842 response NN I-NP O
24 910 916 10910842 curves NNS I-NP O
25 917 919 10910842 of IN B-PP O
26 920 921 10910842 d NN B-NP D014403
27 921 922 10910842 - HYPH B-NP D014403
28 922 934 10910842 tubocurarine NN I-NP D014403
29 935 937 10910842 in IN B-PP O
30 938 941 10910842 the DT B-NP O
31 942 950 10910842 tibialis NN I-NP O
32 951 960 10910842 cranialis NN I-NP O
33 961 967 10910842 muscle NN I-NP O
34 968 972 10910842 were VBD B-VP O
35 973 981 10910842 measured VBN I-VP O
36 982 984 10910842 in FW B-ADVP O
37 985 989 10910842 vivo FW I-ADVP O
38 990 993 10910842 and CC O O
39 994 1001 10910842 related VBN B-VP O
40 1002 1004 10910842 to TO B-PP O
41 1005 1011 10910842 muscle NN B-NP O
42 1012 1016 10910842 mass NN I-NP O
43 1017 1019 10910842 or CC O O
44 1020 1030 10910842 expression NN B-NP O
45 1031 1033 10910842 of IN B-PP O
46 1034 1039 10910842 AChRs NNS B-NP O
47 1039 1040 10910842 . . O O

1 1041 1045 10910842 Rate NN B-NP O
2 1046 1048 10910842 of IN B-PP O
3 1049 1053 10910842 body NN B-NP O
4 1054 1060 10910842 weight NN I-NP O
5 1061 1065 10910842 gain NN I-NP O
6 1066 1069 10910842 was VBD B-VP O
7 1070 1079 10910842 depressed VBN I-VP O
8 1080 1082 10910842 in IN B-PP O
9 1083 1086 10910842 the DT B-NP O
10 1087 1091 10910842 P100 NN I-NP O
11 1091 1092 10910842 , , O O
12 1093 1095 10910842 FR NN B-NP O
13 1095 1096 10910842 , , O O
14 1097 1100 10910842 and CC O O
15 1101 1104 10910842 P10 NN B-NP O
16 1105 1111 10910842 groups NNS I-NP O
17 1112 1120 10910842 compared VBN B-PP O
18 1121 1125 10910842 with IN B-PP O
19 1126 1129 10910842 the DT B-NP O
20 1130 1131 10910842 S NN I-NP O
21 1132 1137 10910842 group NN I-NP O
22 1137 1138 10910842 . . O O

1 1139 1147 10910842 Tibialis NN B-NP O
2 1148 1154 10910842 muscle NN I-NP O
3 1155 1159 10910842 mass NN I-NP O
4 1160 1163 10910842 was VBD B-VP O
5 1164 1171 10910842 smaller JJR B-ADJP O
6 1172 1174 10910842 in IN B-PP O
7 1175 1178 10910842 the DT B-NP O
8 1179 1183 10910842 P100 NN I-NP O
9 1184 1189 10910842 group NN I-NP O
10 1190 1194 10910842 than IN B-PP O
11 1195 1197 10910842 in IN B-PP O
12 1198 1201 10910842 the DT B-NP O
13 1202 1205 10910842 P10 NN I-NP O
14 1206 1208 10910842 or CC I-NP O
15 1209 1210 10910842 S NN I-NP O
16 1211 1217 10910842 groups NNS I-NP O
17 1217 1218 10910842 . . O O

1 1219 1222 10910842 The DT B-NP O
2 1223 1229 10910842 evoked VBN I-NP O
3 1230 1234 10910842 peak JJ I-NP O
4 1235 1241 10910842 twitch NN I-NP O
5 1242 1245 10910842 and CC O O
6 1246 1253 10910842 tetanic JJ B-NP D013746
7 1254 1262 10910842 tensions NNS I-NP O
8 1263 1267 10910842 were VBD B-VP O
9 1268 1272 10910842 less JJR B-ADJP O
10 1273 1275 10910842 in IN B-PP O
11 1276 1279 10910842 the DT B-NP O
12 1280 1284 10910842 P100 NN I-NP O
13 1285 1290 10910842 group NN I-NP O
14 1291 1295 10910842 than IN B-PP O
15 1296 1298 10910842 in IN B-PP O
16 1299 1302 10910842 the DT B-NP O
17 1303 1306 10910842 P10 NN I-NP O
18 1307 1309 10910842 or CC I-NP O
19 1310 1311 10910842 S NN I-NP O
20 1312 1318 10910842 groups NNS I-NP O
21 1318 1319 10910842 , , O O
22 1320 1327 10910842 however RB B-ADVP O
23 1327 1328 10910842 , , O O
24 1329 1336 10910842 tension NN B-NP O
25 1337 1340 10910842 per IN B-PP O
26 1341 1350 10910842 milligram NN B-NP O
27 1351 1353 10910842 of IN B-PP O
28 1354 1360 10910842 muscle NN B-NP O
29 1361 1365 10910842 mass NN I-NP O
30 1366 1369 10910842 was VBD B-VP O
31 1370 1377 10910842 greater JJR B-ADJP O
32 1378 1380 10910842 in IN B-PP O
33 1381 1384 10910842 the DT B-NP O
34 1385 1389 10910842 P100 NN I-NP O
35 1390 1395 10910842 group NN I-NP O
36 1396 1400 10910842 than IN B-PP O
37 1401 1403 10910842 in IN B-PP O
38 1404 1407 10910842 the DT B-NP O
39 1408 1409 10910842 S NN I-NP O
40 1410 1415 10910842 group NN I-NP O
41 1415 1416 10910842 . . O O

1 1417 1420 10910842 The DT B-NP O
2 1421 1424 10910842 50% CD I-NP O
3 1425 1434 10910842 effective JJ I-NP O
4 1435 1439 10910842 dose NN I-NP O
5 1440 1442 10910842 of IN B-PP O
6 1443 1444 10910842 d NN B-NP D014403
7 1444 1445 10910842 - HYPH O D014403
8 1445 1457 10910842 tubocurarine NN B-NP D014403
9 1458 1459 10910842 ( ( O O
10 1459 1465 10910842 microg NN B-NP O
11 1465 1466 10910842 / SYM B-NP O
12 1466 1468 10910842 kg NN I-NP O
13 1468 1469 10910842 ) ) O O
14 1470 1472 10910842 in IN B-PP O
15 1473 1476 10910842 the DT B-NP O
16 1477 1485 10910842 tibialis NN I-NP O
17 1486 1492 10910842 muscle NN I-NP O
18 1493 1496 10910842 was VBD B-VP O
19 1497 1504 10910842 smaller JJR B-ADJP O
20 1505 1507 10910842 in IN B-PP O
21 1508 1511 10910842 the DT B-NP O
22 1512 1515 10910842 P10 NN I-NP O
23 1516 1517 10910842 ( ( O O
24 1517 1521 10910842 33.6 CD B-NP O
25 1522 1523 10910842 + SYM O O
26 1523 1524 10910842 / SYM O O
27 1524 1525 10910842 - SYM O O
28 1526 1529 10910842 5.4 CD B-NP O
29 1529 1530 10910842 ) ) O O
30 1531 1535 10910842 than IN B-PP O
31 1536 1538 10910842 in IN B-PP O
32 1539 1542 10910842 the DT B-NP O
33 1543 1544 10910842 S NN I-NP O
34 1545 1546 10910842 ( ( O O
35 1546 1550 10910842 61.9 CD B-NP O
36 1551 1552 10910842 + SYM O O
37 1552 1553 10910842 / SYM O O
38 1553 1554 10910842 - SYM O O
39 1555 1558 10910842 5.0 CD B-NP O
40 1558 1559 10910842 ) ) O O
41 1560 1562 10910842 or CC O O
42 1563 1566 10910842 the DT B-NP O
43 1567 1571 10910842 P100 NN I-NP O
44 1572 1573 10910842 ( ( O O
45 1573 1577 10910842 71.3 CD B-NP O
46 1578 1579 10910842 + SYM O O
47 1579 1580 10910842 / SYM O O
48 1580 1581 10910842 - SYM O O
49 1582 1585 10910842 9.6 CD O O
50 1585 1586 10910842 ) ) O O
51 1587 1593 10910842 groups NNS B-NP O
52 1593 1594 10910842 . . O O

1 1595 1599 10910842 AChR NN B-NP O
2 1600 1610 10910842 expression NN I-NP O
3 1611 1614 10910842 was VBD B-VP O
4 1615 1619 10910842 less JJR B-ADJP O
5 1620 1622 10910842 in IN B-PP O
6 1623 1626 10910842 the DT B-NP O
7 1627 1630 10910842 P10 NN I-NP O
8 1631 1636 10910842 group NN I-NP O
9 1637 1641 10910842 than IN B-PP O
10 1642 1644 10910842 in IN B-PP O
11 1645 1648 10910842 the DT B-NP O
12 1649 1650 10910842 S NN I-NP O
13 1651 1656 10910842 group NN I-NP O
14 1656 1657 10910842 . . O O

1 1658 1661 10910842 The DT B-NP O
2 1662 1668 10910842 evoked VBN I-NP O
3 1669 1677 10910842 tensions NNS I-NP O
4 1678 1688 10910842 correlated VBD B-VP O
5 1689 1693 10910842 with IN B-PP O
6 1694 1700 10910842 muscle NN B-NP O
7 1701 1705 10910842 mass NN I-NP O
8 1706 1707 10910842 ( ( O O
9 1707 1711 10910842 r(2) NN B-NP O
10 1712 1713 10910842 = SYM B-VP O
11 1714 1718 10910842 0.32 CD B-NP O
12 1718 1719 10910842 , , O O
13 1720 1721 10910842 P NN B-NP O
14 1722 1723 10910842 < SYM B-NP O
15 1724 1729 10910842 0.001 CD I-NP O
16 1729 1730 10910842 ) ) O O
17 1730 1731 10910842 , , O O
18 1732 1739 10910842 however RB B-ADVP O
19 1739 1740 10910842 , , B-PP O
20 1741 1744 10910842 not RB I-PP O
21 1745 1749 10910842 with IN B-PP O
22 1750 1760 10910842 expression NN B-NP O
23 1761 1763 10910842 of IN B-PP O
24 1764 1768 10910842 AChR NN B-NP O
25 1768 1769 10910842 . . O O

1 1770 1773 10910842 The DT B-NP O
2 1774 1777 10910842 50% CD I-NP O
3 1778 1787 10910842 effective JJ I-NP O
4 1788 1792 10910842 dose NN I-NP O
5 1793 1795 10910842 of IN B-PP O
6 1796 1797 10910842 d NN B-NP D014403
7 1797 1798 10910842 - HYPH O D014403
8 1798 1810 10910842 tubocurarine NN B-NP D014403
9 1811 1814 10910842 did VBD B-VP O
10 1815 1818 10910842 not RB I-VP O
11 1819 1828 10910842 correlate VB I-VP O
12 1829 1833 10910842 with IN B-PP O
13 1834 1840 10910842 muscle NN B-NP O
14 1841 1845 10910842 mass NN I-NP O
15 1846 1848 10910842 or CC O O
16 1849 1853 10910842 AChR NN B-NP O
17 1854 1864 10910842 expression NN I-NP O
18 1864 1865 10910842 . . O O

1 1866 1869 10910842 Our PRP$ B-NP O
2 1870 1877 10910842 results NNS I-NP O
3 1878 1885 10910842 suggest VBP B-VP O
4 1886 1890 10910842 that IN B-SBAR O
5 1891 1894 10910842 the DT B-NP O
6 1895 1908 10910842 neuromuscular JJ I-NP D009468
7 1909 1920 10910842 dysfunction NN I-NP D009468
8 1921 1926 10910842 after IN B-SBAR O
9 1927 1939 10910842 prednisolone NN B-NP D011239
10 1940 1942 10910842 is VBZ B-VP O
11 1943 1947 10910842 dose NN B-NP O
12 1947 1948 10910842 - HYPH O O
13 1948 1957 10910842 dependent JJ B-ADJP O
14 1957 1958 10910842 , , O O
15 1959 1962 10910842 and CC O O
16 1963 1970 10910842 derives VBZ B-VP O
17 1971 1980 10910842 primarily RB B-ADVP O
18 1981 1985 10910842 from IN B-PP O
19 1986 1992 10910842 muscle NN B-NP D009133
20 1993 2000 10910842 atrophy NN I-NP D009133
21 2001 2004 10910842 and CC O O
22 2005 2012 10910842 derives VBZ B-VP O
23 2013 2017 10910842 less RBR B-ADVP O
24 2018 2020 10910842 so RB I-ADVP O
25 2021 2025 10910842 from IN B-PP O
26 2026 2033 10910842 changes NNS B-NP O
27 2034 2036 10910842 in IN B-PP O
28 2037 2041 10910842 AChR NN B-NP O
29 2042 2052 10910842 expression NN I-NP O
30 2052 2053 10910842 . . O O

1 2054 2066 10910842 IMPLICATIONS NNS B-NP O
2 2066 2067 10910842 : : O O
3 2068 2071 10910842 The DT B-NP O
4 2072 2082 10910842 mechanisms NNS I-NP O
5 2083 2085 10910842 by IN B-PP O
6 2086 2091 10910842 which WDT B-NP O
7 2092 2099 10910842 chronic JJ B-NP O
8 2100 2114 10910842 glucocorticoid NN I-NP O
9 2115 2122 10910842 therapy NN I-NP O
10 2123 2129 10910842 alters VBZ B-VP O
11 2130 2143 10910842 neuromuscular JJ B-NP O
12 2144 2154 10910842 physiology NN I-NP O
13 2155 2158 10910842 and CC I-NP O
14 2159 2171 10910842 pharmacology NN I-NP O
15 2172 2175 10910842 are VBP B-VP O
16 2176 2183 10910842 unclear JJ B-ADJP O
17 2183 2184 10910842 . . O O

1 2185 2187 10910842 We PRP B-NP O
2 2188 2195 10910842 suggest VBP B-VP O
3 2196 2200 10910842 that IN B-SBAR O
4 2201 2204 10910842 the DT B-NP O
5 2205 2213 10910842 observed VBN I-NP O
6 2214 2221 10910842 effects NNS I-NP O
7 2222 2225 10910842 are VBP B-VP O
8 2226 2230 10910842 dose NN B-NP O
9 2230 2231 10910842 - HYPH B-ADJP O
10 2231 2240 10910842 dependent JJ I-ADJP O
11 2241 2244 10910842 and CC O O
12 2245 2251 10910842 derive VBP B-VP O
13 2252 2261 10910842 primarily RB B-ADVP O
14 2262 2266 10910842 from IN B-PP O
15 2267 2273 10910842 muscle NN B-NP D009133
16 2274 2281 10910842 atrophy NN I-NP D009133
17 2282 2285 10910842 and CC O O
18 2286 2292 10910842 derive VBP B-VP O
19 2293 2297 10910842 less JJR B-ADJP O
20 2298 2302 10910842 from IN B-PP O
21 2303 2310 10910842 changes NNS B-NP O
22 2311 2313 10910842 in IN B-PP O
23 2314 2327 10910842 acetylcholine NN B-NP D000109
24 2328 2336 10910842 receptor NN I-NP O
25 2337 2347 10910842 expression NN I-NP O
26 2347 2348 10910842 . . O O

1 0 0 17344330 -DOCSTART- -X- -X- O

1 0 7 17344330 Syncope NN B-NP D013575
2 8 11 17344330 and CC I-NP O
3 12 14 17344330 QT NN I-NP D008133
4 15 27 17344330 prolongation NN I-NP D008133
5 28 33 17344330 among IN B-PP O
6 34 42 17344330 patients NNS B-NP O
7 43 50 17344330 treated VBN B-VP O
8 51 55 17344330 with IN B-PP O
9 56 65 17344330 methadone NN B-NP D008691
10 66 69 17344330 for IN B-PP O
11 70 76 17344330 heroin NN B-NP D003932
12 77 87 17344330 dependence NN I-NP O
13 88 90 17344330 in IN B-PP O
14 91 94 17344330 the DT B-NP O
15 95 99 17344330 city NN I-NP O
16 100 102 17344330 of IN B-PP O
17 103 113 17344330 Copenhagen NN B-NP O
18 113 114 17344330 . . O O
19 115 125 17344330 BACKGROUND NN B-NP O
20 125 126 17344330 : : O O
21 127 136 17344330 Methadone NN B-NP D008691
22 137 139 17344330 is VBZ B-VP O
23 140 150 17344330 prescribed VBN I-VP O
24 151 153 17344330 to TO I-VP O
25 154 160 17344330 heroin VB I-VP D003932
26 161 168 17344330 addicts NNS B-NP O
27 169 171 17344330 to TO B-VP O
28 172 180 17344330 decrease VB I-VP O
29 181 188 17344330 illicit JJ B-NP O
30 189 195 17344330 opioid JJ I-NP O
31 196 199 17344330 use NN I-NP O
32 199 200 17344330 . . O O

1 201 213 17344330 Prolongation NN B-NP O
2 214 216 17344330 of IN B-PP O
3 217 220 17344330 the DT B-NP O
4 221 223 17344330 QT NN I-NP O
5 224 232 17344330 interval NN I-NP O
6 233 235 17344330 in IN B-PP O
7 236 239 17344330 the DT B-NP O
8 240 243 17344330 ECG NN I-NP O
9 244 246 17344330 of IN B-PP O
10 247 255 17344330 patients NNS B-NP O
11 256 260 17344330 with IN B-PP O
12 261 268 17344330 torsade FW B-NP D016171
13 269 271 17344330 de FW I-NP D016171
14 272 279 17344330 pointes FW I-NP D016171
15 280 281 17344330 ( ( O O
16 281 284 17344330 TdP NN B-NP D016171
17 284 285 17344330 ) ) O O
18 286 289 17344330 has VBZ B-VP O
19 290 294 17344330 been VBN I-VP O
20 295 303 17344330 reported VBN I-VP O
21 304 306 17344330 in IN B-PP O
22 307 316 17344330 methadone NN B-NP D008691
23 317 322 17344330 users NNS I-NP O
24 322 323 17344330 . . O O

1 324 326 17344330 As IN B-SBAR O
2 327 333 17344330 heroin NN B-NP D003932
3 334 341 17344330 addicts NNS I-NP O
4 342 351 17344330 sometimes RB B-ADVP O
5 352 357 17344330 faint VBP B-VP O
6 358 363 17344330 while IN B-SBAR O
7 364 369 17344330 using VBG B-VP O
8 370 377 17344330 illicit JJ B-NP O
9 378 383 17344330 drugs NNS I-NP O
10 383 384 17344330 , , O O
11 385 392 17344330 doctors NNS B-NP O
12 393 398 17344330 might MD B-VP O
13 399 408 17344330 attribute VB I-VP O
14 409 412 17344330 too RB B-NP O
15 413 417 17344330 many JJ I-NP O
16 418 426 17344330 episodes NNS I-NP O
17 427 429 17344330 of IN B-PP O
18 430 437 17344330 syncope NN B-NP D013575
19 438 440 17344330 to TO B-VP O
20 441 448 17344330 illicit VB I-VP O
21 449 453 17344330 drug NN B-NP O
22 454 457 17344330 use NN I-NP O
23 458 461 17344330 and CC O O
24 462 469 17344330 thereby RB B-VP O
25 470 483 17344330 underestimate VBP I-VP O
26 484 487 17344330 the DT B-NP O
27 488 497 17344330 incidence NN I-NP O
28 498 500 17344330 of IN B-PP O
29 501 504 17344330 TdP NN B-NP D016171
30 505 507 17344330 in IN B-PP O
31 508 512 17344330 this DT B-NP O
32 513 520 17344330 special JJ I-NP O
33 521 531 17344330 population NN I-NP O
34 531 532 17344330 , , O O
35 533 536 17344330 and CC O O
36 537 540 17344330 the DT B-NP O
37 541 545 17344330 high JJ I-NP O
38 546 555 17344330 mortality NN I-NP O
39 556 558 17344330 in IN B-PP O
40 559 563 17344330 this DT B-NP O
41 564 574 17344330 population NN I-NP O
42 575 578 17344330 may MD B-VP O
43 578 579 17344330 , , O O
44 580 582 17344330 in IN B-PP O
45 583 587 17344330 part NN B-NP O
46 587 588 17344330 , , O O
47 589 591 17344330 be VB B-VP O
48 592 598 17344330 caused VBN I-VP O
49 599 601 17344330 by IN B-PP O
50 602 605 17344330 the DT B-NP O
51 606 619 17344330 proarrhythmic JJ I-NP O
52 620 626 17344330 effect NN I-NP O
53 627 629 17344330 of IN B-PP O
54 630 639 17344330 methadone NN B-NP D008691
55 639 640 17344330 . . O O

1 641 648 17344330 METHODS NNS B-NP O
2 648 649 17344330 : : O O
3 650 652 17344330 In IN B-PP O
4 653 657 17344330 this DT B-NP O
5 658 663 17344330 cross AFX O O
6 663 664 17344330 - HYPH B-NP O
7 664 673 17344330 sectional JJ I-NP O
8 674 679 17344330 study NN I-NP O
9 680 689 17344330 interview NN I-NP O
10 689 690 17344330 , , O O
11 691 695 17344330 ECGs NNS B-NP O
12 696 699 17344330 and CC O O
13 700 705 17344330 blood NN B-NP O
14 706 713 17344330 samples NNS I-NP O
15 714 718 17344330 were VBD B-VP O
16 719 728 17344330 collected VBN I-VP O
17 729 731 17344330 in IN B-PP O
18 732 733 17344330 a DT B-NP O
19 734 744 17344330 population NN I-NP O
20 745 747 17344330 of IN B-PP O
21 748 753 17344330 adult JJ B-NP O
22 754 760 17344330 heroin NN I-NP D003932
23 761 768 17344330 addicts NNS I-NP O
24 769 776 17344330 treated VBN B-VP O
25 777 781 17344330 with IN B-PP O
26 782 791 17344330 methadone NN B-NP D008691
27 792 794 17344330 or CC I-NP O
28 795 808 17344330 buprenorphine NN I-NP D002047
29 809 811 17344330 on IN B-PP O
30 812 813 17344330 a DT B-NP O
31 814 819 17344330 daily JJ I-NP O
32 820 825 17344330 basis NN I-NP O
33 825 826 17344330 . . O O

1 827 829 17344330 Of IN B-PP O
2 830 833 17344330 the DT B-NP O
3 834 842 17344330 patients NNS I-NP O
4 843 845 17344330 at IN B-PP O
5 846 849 17344330 the DT B-NP O
6 850 854 17344330 Drug NNP I-NP O
7 855 864 17344330 Addiction NNP I-NP O
8 865 872 17344330 Service NNP I-NP O
9 873 875 17344330 in IN B-PP O
10 876 879 17344330 the DT B-NP O
11 880 889 17344330 municipal NN I-NP O
12 890 892 17344330 of IN B-PP O
13 893 903 17344330 Copenhagen NN B-NP O
14 903 904 17344330 , , O O
15 905 908 17344330 450 CD B-NP O
16 909 910 17344330 ( ( O O
17 910 923 17344330 approximately RB B-NP O
18 924 927 17344330 52% CD I-NP O
19 927 928 17344330 ) ) O O
20 929 933 17344330 were VBD B-VP O
21 934 942 17344330 included VBN I-VP O
22 942 943 17344330 . . O O

1 944 947 17344330 The DT B-NP O
2 948 950 17344330 QT NN I-NP O
3 951 959 17344330 interval NN I-NP O
4 960 963 17344330 was VBD B-VP O
5 964 973 17344330 estimated VBN I-VP O
6 974 978 17344330 from IN B-PP O
7 979 981 17344330 12 CD B-NP O
8 982 986 17344330 lead JJ I-NP O
9 987 991 17344330 ECGs NNS I-NP O
10 991 992 17344330 . . O O

1 993 996 17344330 All DT B-NP O
2 997 1009 17344330 participants NNS I-NP O
3 1010 1014 17344330 were VBD B-VP O
4 1015 1026 17344330 interviewed VBN I-VP O
5 1027 1032 17344330 about IN B-PP O
6 1033 1036 17344330 any DT B-NP O
7 1037 1047 17344330 experience NN I-NP O
8 1048 1050 17344330 of IN B-PP O
9 1051 1058 17344330 syncope NN B-NP D013575
10 1058 1059 17344330 . . O O

1 1060 1063 17344330 The DT B-NP O
2 1064 1075 17344330 association NN I-NP O
3 1076 1083 17344330 between IN B-PP O
4 1084 1090 17344330 opioid JJ B-NP O
5 1091 1095 17344330 dose NN I-NP O
6 1096 1099 17344330 and CC I-NP O
7 1100 1102 17344330 QT NN I-NP O
8 1102 1103 17344330 , , O O
9 1104 1107 17344330 and CC O O
10 1108 1117 17344330 methadone NN B-NP D008691
11 1118 1122 17344330 dose NN I-NP O
12 1123 1126 17344330 and CC O O
13 1127 1136 17344330 reporting NN B-NP O
14 1137 1139 17344330 of IN B-PP O
15 1140 1147 17344330 syncope NN B-NP D013575
16 1148 1151 17344330 was VBD B-VP O
17 1152 1160 17344330 assessed VBN I-VP O
18 1161 1166 17344330 using VBG B-VP O
19 1167 1179 17344330 multivariate JJ B-NP O
20 1180 1186 17344330 linear JJ I-NP O
21 1187 1197 17344330 regression NN I-NP O
22 1198 1201 17344330 and CC O O
23 1202 1210 17344330 logistic JJ B-NP O
24 1211 1221 17344330 regression NN I-NP O
25 1221 1222 17344330 , , O O
26 1223 1235 17344330 respectively RB B-ADVP O
27 1235 1236 17344330 . . O O

1 1237 1244 17344330 RESULTS NNS B-NP O
2 1244 1245 17344330 : : O O
3 1246 1255 17344330 Methadone NN B-NP D008691
4 1256 1260 17344330 dose NN I-NP O
5 1261 1264 17344330 was VBD B-VP O
6 1265 1275 17344330 associated VBN I-VP O
7 1276 1280 17344330 with IN B-PP O
8 1281 1287 17344330 longer JJR B-NP O
9 1288 1290 17344330 QT NN I-NP O
10 1291 1299 17344330 interval NN I-NP O
11 1300 1302 17344330 of IN B-PP O
12 1303 1308 17344330 0.140 CD B-NP O
13 1309 1311 17344330 ms NN I-NP O
14 1311 1312 17344330 / SYM B-NP O
15 1312 1314 17344330 mg NN B-NP O
16 1315 1316 17344330 ( ( O O
17 1316 1317 17344330 p NN B-NP O
18 1318 1319 17344330 = SYM B-VP O
19 1320 1325 17344330 0.002 CD B-NP O
20 1325 1326 17344330 ) ) O O
21 1326 1327 17344330 . . O O

1 1328 1330 17344330 No DT B-NP O
2 1331 1342 17344330 association NN I-NP O
3 1343 1350 17344330 between IN B-PP O
4 1351 1364 17344330 buprenorphine NN B-NP D002047
5 1365 1368 17344330 and CC I-NP O
6 1369 1372 17344330 QTc NN I-NP O
7 1373 1376 17344330 was VBD B-VP O
8 1377 1382 17344330 found VBN I-VP O
9 1382 1383 17344330 . . O O

1 1384 1389 17344330 Among IN B-PP O
2 1390 1393 17344330 the DT B-NP O
3 1394 1402 17344330 subjects NNS I-NP O
4 1403 1410 17344330 treated VBN B-VP O
5 1411 1415 17344330 with IN B-PP O
6 1416 1425 17344330 methadone NN B-NP D008691
7 1425 1426 17344330 , , O O
8 1427 1430 17344330 28% CD B-NP O
9 1431 1434 17344330 men NNS I-NP O
10 1435 1438 17344330 and CC O O
11 1439 1442 17344330 32% NN B-NP O
12 1443 1448 17344330 women NNS I-NP O
13 1449 1452 17344330 had VBD B-VP O
14 1453 1462 17344330 prolonged VBN I-VP D008133
15 1463 1466 17344330 QTc NN B-NP D008133
16 1467 1475 17344330 interval NN I-NP D008133
17 1475 1476 17344330 . . O O

1 1477 1481 17344330 None NN B-NP O
2 1482 1484 17344330 of IN B-PP O
3 1485 1488 17344330 the DT B-NP O
4 1489 1497 17344330 subjects NNS I-NP O
5 1498 1505 17344330 treated VBN B-VP O
6 1506 1510 17344330 with IN B-PP O
7 1511 1524 17344330 buprenorphine NN B-NP D002047
8 1525 1528 17344330 had VBD B-VP O
9 1529 1532 17344330 QTc NN B-NP O
10 1533 1541 17344330 interval NN I-NP O
11 1542 1543 17344330 > SYM O O
12 1543 1548 17344330 0.440 CD B-NP O
13 1549 1553 17344330 s((1 NN I-NP O
14 1553 1554 17344330 / SYM B-NP O
15 1554 1555 17344330 2 CD I-NP O
16 1555 1556 17344330 ) ) O O
17 1556 1557 17344330 ) ) O O
18 1557 1558 17344330 . . O O

1 1559 1560 17344330 A DT B-NP O
2 1561 1563 17344330 50 CD I-NP O
3 1564 1566 17344330 mg NN I-NP O
4 1567 1573 17344330 higher JJR B-NP O
5 1574 1583 17344330 methadone NN I-NP D008691
6 1584 1588 17344330 dose NN I-NP O
7 1589 1592 17344330 was VBD B-VP O
8 1593 1603 17344330 associated VBN I-VP O
9 1604 1608 17344330 with IN B-PP O
10 1609 1610 17344330 a DT B-NP O
11 1611 1614 17344330 1.2 CD I-NP O
12 1615 1616 17344330 ( ( O O
13 1616 1619 17344330 95% CD B-NP O
14 1620 1622 17344330 CI NN I-NP O
15 1623 1626 17344330 1.1 CD B-NP O
16 1627 1629 17344330 to TO I-NP O
17 1630 1633 17344330 1.4 CD I-NP O
18 1633 1634 17344330 ) ) O O
19 1635 1640 17344330 times NNS B-NP O
20 1641 1647 17344330 higher JJR B-NP O
21 1648 1652 17344330 odds NNS I-NP O
22 1653 1656 17344330 for IN B-PP O
23 1657 1664 17344330 syncope NN B-NP D013575
24 1664 1665 17344330 . . O O

1 1666 1677 17344330 CONCLUSIONS NNS B-NP O
2 1677 1678 17344330 : : O O
3 1679 1688 17344330 Methadone NN B-NP D008691
4 1689 1691 17344330 is VBZ B-VP O
5 1692 1702 17344330 associated VBN I-VP O
6 1703 1707 17344330 with IN B-PP O
7 1708 1710 17344330 QT NN B-NP D008133
8 1711 1723 17344330 prolongation NN I-NP D008133
9 1724 1727 17344330 and CC O O
10 1728 1734 17344330 higher JJR B-NP O
11 1735 1744 17344330 reporting NN I-NP O
12 1745 1747 17344330 of IN B-PP O
13 1748 1755 17344330 syncope NN B-NP D013575
14 1756 1758 17344330 in IN B-PP O
15 1759 1760 17344330 a DT B-NP O
16 1761 1771 17344330 population NN I-NP O
17 1772 1774 17344330 of IN B-PP O
18 1775 1781 17344330 heroin NN B-NP D003932
19 1782 1789 17344330 addicts NNS I-NP O
20 1789 1790 17344330 . . O O

1 0 0 1636026 -DOCSTART- -X- -X- O

1 0 7 1636026 Effects NNS B-NP O
2 8 10 1636026 of IN B-PP O
3 11 19 1636026 suprofen NN B-NP D013496
4 20 22 1636026 on IN B-PP O
5 23 26 1636026 the DT B-NP O
6 27 35 1636026 isolated VBN I-NP O
7 36 44 1636026 perfused VBN I-NP O
8 45 48 1636026 rat NN I-NP O
9 49 55 1636026 kidney NN I-NP O
10 55 56 1636026 . . O O
11 57 65 1636026 Although IN B-SBAR O
12 66 74 1636026 suprofen NN B-NP D013496
13 75 78 1636026 has VBZ B-VP O
14 79 83 1636026 been VBN I-VP O
15 84 94 1636026 associated VBN I-VP O
16 95 99 1636026 with IN B-PP O
17 100 103 1636026 the DT B-NP O
18 104 115 1636026 development NN I-NP O
19 116 118 1636026 of IN B-PP O
20 119 124 1636026 acute JJ B-NP D058186
21 125 130 1636026 renal JJ I-NP D058186
22 131 138 1636026 failure NN I-NP D058186
23 139 141 1636026 in IN B-PP O
24 142 149 1636026 greater JJR B-NP O
25 150 154 1636026 than IN I-NP O
26 155 158 1636026 100 CD I-NP O
27 159 167 1636026 subjects NNS I-NP O
28 167 168 1636026 , , O O
29 169 172 1636026 the DT B-NP O
30 173 182 1636026 mechanism NN I-NP O
31 183 185 1636026 of IN B-PP O
32 186 192 1636026 damage NN B-NP O
33 193 200 1636026 remains VBZ B-VP O
34 201 208 1636026 unclear JJ B-ADJP O
35 208 209 1636026 . . O O

1 210 213 1636026 The DT B-NP O
2 214 220 1636026 direct JJ I-NP O
3 221 232 1636026 nephrotoxic JJ I-NP D007674
4 233 240 1636026 effects NNS I-NP O
5 241 243 1636026 of IN B-PP O
6 244 245 1636026 a DT B-NP O
7 246 252 1636026 single JJ I-NP O
8 253 257 1636026 dose NN I-NP O
9 258 260 1636026 of IN B-PP O
10 261 263 1636026 15 CD B-NP O
11 264 266 1636026 mg NN I-NP O
12 267 269 1636026 of IN B-PP O
13 270 278 1636026 suprofen NN B-NP D013496
14 279 283 1636026 were VBD B-VP O
15 284 292 1636026 compared VBN I-VP O
16 293 295 1636026 in IN B-PP O
17 296 299 1636026 the DT B-NP O
18 300 313 1636026 recirculating VBG I-NP O
19 314 322 1636026 isolated VBN I-NP O
20 323 326 1636026 rat NN I-NP O
21 327 333 1636026 kidney NN I-NP O
22 334 342 1636026 perfused VBN B-VP O
23 343 347 1636026 with IN B-PP O
24 348 352 1636026 cell NN B-NP O
25 352 353 1636026 - HYPH B-NP O
26 353 357 1636026 free JJ I-NP O
27 358 364 1636026 buffer NN I-NP O
28 365 369 1636026 with IN B-PP O
29 370 372 1636026 or CC B-PP O
30 373 380 1636026 without IN B-PP O
31 381 384 1636026 the DT B-NP O
32 385 393 1636026 addition NN I-NP O
33 394 396 1636026 of IN B-PP O
34 397 398 1636026 5 CD B-NP O
35 399 401 1636026 mg NN I-NP O
36 401 402 1636026 / SYM B-NP O
37 402 404 1636026 dL NN I-NP O
38 405 407 1636026 of IN B-PP O
39 408 412 1636026 uric JJ B-NP D014527
40 413 417 1636026 acid NN I-NP D014527
41 417 418 1636026 . . O O

1 419 424 1636026 There EX B-NP O
2 425 429 1636026 were VBD B-VP O
3 430 432 1636026 no DT B-NP O
4 433 444 1636026 significant JJ I-NP O
5 445 456 1636026 differences NNS I-NP O
6 457 459 1636026 in IN B-PP O
7 460 465 1636026 renal JJ B-NP O
8 466 472 1636026 sodium NN I-NP D012964
9 473 482 1636026 excretion NN I-NP O
10 482 483 1636026 , , O O
11 484 490 1636026 oxygen NN B-NP D010100
12 491 502 1636026 consumption NN I-NP O
13 502 503 1636026 , , O O
14 504 506 1636026 or CC O O
15 507 514 1636026 urinary JJ B-NP O
16 515 519 1636026 flow NN I-NP O
17 520 525 1636026 rates NNS I-NP O
18 526 528 1636026 in IN B-PP O
19 529 536 1636026 kidneys NNS B-NP O
20 537 545 1636026 perfused VBN B-VP O
21 546 550 1636026 with IN B-PP O
22 551 559 1636026 suprofen NN B-NP D013496
23 560 568 1636026 compared VBN B-PP O
24 569 573 1636026 with IN B-PP O
25 574 577 1636026 the DT B-NP O
26 578 582 1636026 drug NN I-NP O
27 582 583 1636026 - HYPH O O
28 583 587 1636026 free JJ B-NP O
29 588 595 1636026 control NN I-NP O
30 596 602 1636026 groups NNS I-NP O
31 602 603 1636026 . . O O

1 604 606 1636026 In IN B-PP O
2 607 615 1636026 contrast NN B-NP O
3 615 616 1636026 , , O O
4 617 618 1636026 a DT B-NP O
5 619 630 1636026 significant JJ I-NP O
6 631 638 1636026 decline NN I-NP O
7 639 641 1636026 in IN B-PP O
8 642 652 1636026 glomerular JJ B-NP O
9 653 663 1636026 filtration NN I-NP O
10 664 668 1636026 rate NN I-NP O
11 669 672 1636026 was VBD B-VP O
12 673 678 1636026 found VBN I-VP O
13 679 684 1636026 after IN B-PP O
14 685 688 1636026 the DT B-NP O
15 689 701 1636026 introduction NN I-NP O
16 702 704 1636026 of IN B-PP O
17 705 713 1636026 suprofen NN B-NP D013496
18 714 716 1636026 to TO B-PP O
19 717 720 1636026 the DT B-NP O
20 721 727 1636026 kidney NN I-NP O
21 728 736 1636026 perfused VBN B-VP O
22 737 741 1636026 with IN B-PP O
23 742 746 1636026 uric JJ B-NP D014527
24 747 751 1636026 acid NN I-NP D014527
25 751 752 1636026 ; : O O
26 753 755 1636026 no DT B-NP O
27 756 763 1636026 changes NNS I-NP O
28 764 768 1636026 were VBD B-VP O
29 769 774 1636026 found VBN I-VP O
30 775 779 1636026 with IN B-PP O
31 780 788 1636026 suprofen NN B-NP D013496
32 789 791 1636026 in IN B-PP O
33 792 795 1636026 the DT B-NP O
34 796 803 1636026 absence NN I-NP O
35 804 806 1636026 of IN B-PP O
36 807 811 1636026 uric JJ B-NP D014527
37 812 816 1636026 acid NN I-NP D014527
38 816 817 1636026 . . O O

1 818 819 1636026 A DT B-NP O
2 820 831 1636026 significant JJ I-NP O
3 832 840 1636026 decrease NN I-NP O
4 841 843 1636026 in IN B-PP O
5 844 847 1636026 the DT B-NP O
6 848 856 1636026 baseline NN I-NP O
7 857 866 1636026 excretion NN I-NP O
8 867 871 1636026 rate NN I-NP O
9 872 874 1636026 of IN B-PP O
10 875 879 1636026 uric JJ B-NP D014527
11 880 884 1636026 acid NN I-NP D014527
12 885 888 1636026 was VBD B-VP O
13 889 894 1636026 found VBN I-VP O
14 895 897 1636026 in IN B-PP O
15 898 902 1636026 rats NNS B-NP O
16 903 908 1636026 given VBN B-PP O
17 909 917 1636026 suprofen NN B-NP D013496
18 917 918 1636026 , , O O
19 919 927 1636026 compared VBN B-PP O
20 928 932 1636026 with IN B-PP O
21 933 937 1636026 drug NN B-NP O
22 937 938 1636026 - HYPH B-NP O
23 938 942 1636026 free JJ I-NP O
24 943 951 1636026 controls NNS I-NP O
25 951 952 1636026 . . O O

1 953 960 1636026 However RB B-ADVP O
2 960 961 1636026 , , O O
3 962 965 1636026 the DT B-NP O
4 966 976 1636026 fractional JJ I-NP O
5 977 986 1636026 excretion NN I-NP O
6 987 989 1636026 of IN B-PP O
7 990 994 1636026 uric JJ B-NP D014527
8 995 999 1636026 acid NN I-NP D014527
9 1000 1003 1636026 was VBD B-VP O
10 1004 1013 1636026 unchanged JJ B-ADJP O
11 1014 1021 1636026 between IN B-PP O
12 1022 1025 1636026 the DT B-NP O
13 1026 1032 1636026 groups NNS I-NP O
14 1033 1037 1636026 over IN B-PP O
15 1038 1041 1636026 the DT B-NP O
16 1042 1054 1636026 experimental JJ I-NP O
17 1055 1061 1636026 period NN I-NP O
18 1061 1062 1636026 . . O O

1 1063 1065 1636026 In IN B-PP O
2 1066 1073 1636026 summary NN B-NP O
3 1073 1074 1636026 , , O O
4 1075 1083 1636026 suprofen NN B-NP D013496
5 1084 1090 1636026 causes VBZ B-VP O
6 1091 1096 1636026 acute JJ B-NP D058186
7 1097 1105 1636026 declines NNS I-NP D058186
8 1106 1108 1636026 in IN B-PP D058186
9 1109 1114 1636026 renal JJ B-NP D058186
10 1115 1123 1636026 function NN I-NP D058186
11 1123 1124 1636026 , , O O
12 1125 1129 1636026 most RBS B-ADVP O
13 1130 1136 1636026 likely RB I-ADVP O
14 1137 1139 1636026 by IN B-PP O
15 1140 1148 1636026 directly RB B-ADVP O
16 1149 1157 1636026 altering VBG B-VP O
17 1158 1161 1636026 the DT B-NP O
18 1162 1172 1636026 intrarenal JJ I-NP O
19 1173 1185 1636026 distribution NN I-NP O
20 1186 1188 1636026 of IN B-PP O
21 1189 1193 1636026 uric JJ B-NP D014527
22 1194 1198 1636026 acid NN I-NP D014527
23 1198 1199 1636026 . . O O

1 0 0 16820346 -DOCSTART- -X- -X- O

1 0 12 16820346 Atorvastatin NN B-NP C065179
2 13 22 16820346 prevented VBD B-VP O
3 23 26 16820346 and CC O O
4 27 35 16820346 reversed VBD B-VP O
5 36 49 16820346 dexamethasone NN B-NP D003907
6 49 50 16820346 - HYPH O O
7 50 57 16820346 induced VBN B-NP O
8 58 70 16820346 hypertension NN I-NP D006973
9 71 73 16820346 in IN B-PP O
10 74 77 16820346 the DT B-NP O
11 78 81 16820346 rat NN I-NP O
12 81 82 16820346 . . O O
13 83 85 16820346 To TO B-VP O
14 86 92 16820346 assess VB I-VP O
15 93 96 16820346 the DT B-NP O
16 97 108 16820346 antioxidant JJ I-NP O
17 109 116 16820346 effects NNS I-NP O
18 117 119 16820346 of IN B-PP O
19 120 132 16820346 atorvastatin NN B-NP C065179
20 133 134 16820346 ( ( O O
21 134 140 16820346 atorva NN B-NP C065179
22 140 141 16820346 ) ) O O
23 142 144 16820346 on IN B-PP O
24 145 158 16820346 dexamethasone NN B-NP D003907
25 159 160 16820346 ( ( O O
26 160 163 16820346 dex NN B-NP D003907
27 163 164 16820346 ) ) O O
28 164 165 16820346 - HYPH B-NP O
29 165 172 16820346 induced VBN I-NP O
30 173 185 16820346 hypertension NN I-NP D006973
31 185 186 16820346 , , O O
32 187 189 16820346 60 CD B-NP O
33 190 194 16820346 male JJ I-NP O
34 195 202 16820346 Sprague NNP I-NP O
35 202 203 16820346 - HYPH I-NP O
36 203 209 16820346 Dawley NNP I-NP O
37 210 214 16820346 rats NNS I-NP O
38 215 219 16820346 were VBD B-VP O
39 220 227 16820346 treated VBN I-VP O
40 228 232 16820346 with IN B-PP O
41 233 239 16820346 atorva NN B-NP C065179
42 240 242 16820346 30 CD I-NP O
43 243 245 16820346 mg NN I-NP O
44 245 246 16820346 / SYM B-NP O
45 246 248 16820346 kg NN I-NP O
46 248 249 16820346 / SYM B-NP O
47 249 252 16820346 day NN I-NP O
48 253 255 16820346 or CC O O
49 256 259 16820346 tap NN B-NP O
50 260 265 16820346 water NN I-NP O
51 266 269 16820346 for IN B-PP O
52 270 272 16820346 15 CD B-NP O
53 273 277 16820346 days NNS I-NP O
54 277 278 16820346 . . O O

1 279 282 16820346 Dex NN B-NP D003907
2 283 292 16820346 increased VBD B-VP O
3 293 301 16820346 systolic JJ B-NP O
4 302 307 16820346 blood NN I-NP O
5 308 316 16820346 pressure NN I-NP O
6 317 318 16820346 ( ( O O
7 318 321 16820346 SBP NN B-NP O
8 321 322 16820346 ) ) O O
9 323 327 16820346 from IN B-PP O
10 328 331 16820346 109 CD B-NP O
11 332 333 16820346 + SYM B-ADJP O
12 333 334 16820346 / SYM O O
13 334 335 16820346 - SYM O O
14 336 339 16820346 1.8 CD B-NP O
15 340 342 16820346 to TO B-PP O
16 343 346 16820346 135 CD B-NP O
17 347 348 16820346 + SYM O O
18 348 349 16820346 / SYM O O
19 349 350 16820346 - SYM O O
20 351 354 16820346 0.6 CD B-NP O
21 355 359 16820346 mmHg NN I-NP O
22 360 363 16820346 and CC O O
23 364 370 16820346 plasma NN B-NP O
24 371 381 16820346 superoxide NN I-NP D013481
25 382 383 16820346 ( ( O O
26 383 387 16820346 5711 CD B-NP O
27 388 389 16820346 + SYM O O
28 389 390 16820346 / SYM O O
29 390 391 16820346 - SYM O O
30 392 397 16820346 284.9 CD B-NP O
31 398 404 16820346 saline NN I-NP O
32 404 405 16820346 , , O O
33 406 410 16820346 7931 CD B-NP O
34 411 412 16820346 + SYM O O
35 412 413 16820346 / SYM O O
36 413 414 16820346 - SYM O O
37 415 420 16820346 392.8 CD B-NP O
38 421 422 16820346 U NN I-NP O
39 422 423 16820346 / SYM B-NP O
40 423 425 16820346 ml NN I-NP O
41 426 429 16820346 dex NN I-NP D003907
42 429 430 16820346 , , O O
43 431 432 16820346 P NN B-NP O
44 433 434 16820346 < SYM B-NP O
45 435 440 16820346 0.001 CD I-NP O
46 440 441 16820346 ) ) O O
47 441 442 16820346 . . O O

1 443 445 16820346 In IN B-PP O
2 446 450 16820346 this DT B-NP O
3 451 461 16820346 prevention NN I-NP O
4 462 467 16820346 study NN I-NP O
5 467 468 16820346 , , O O
6 469 472 16820346 SBP NN B-NP O
7 473 475 16820346 in IN B-PP O
8 476 479 16820346 the DT B-NP O
9 480 486 16820346 atorva NN I-NP C065179
10 487 488 16820346 + SYM B-NP O
11 489 492 16820346 dex NN I-NP D003907
12 493 498 16820346 group NN I-NP O
13 499 502 16820346 was VBD B-VP O
14 503 512 16820346 increased VBN I-VP O
15 513 517 16820346 from IN B-PP O
16 518 521 16820346 115 CD B-NP O
17 522 523 16820346 + SYM B-ADJP O
18 523 524 16820346 / SYM O O
19 524 525 16820346 - SYM O O
20 526 529 16820346 0.4 CD B-NP O
21 530 532 16820346 to TO B-PP O
22 533 536 16820346 124 CD B-NP O
23 537 538 16820346 + SYM O O
24 538 539 16820346 / SYM O O
25 539 540 16820346 - SYM O O
26 541 544 16820346 1.5 CD B-NP O
27 545 549 16820346 mmHg NN I-NP O
28 549 550 16820346 , , O O
29 551 554 16820346 but CC O O
30 555 559 16820346 this DT B-NP O
31 560 563 16820346 was VBD B-VP O
32 564 577 16820346 significantly RB B-ADJP O
33 578 583 16820346 lower JJR I-ADJP O
34 584 588 16820346 than IN B-PP O
35 589 591 16820346 in IN B-PP O
36 592 595 16820346 the DT B-NP O
37 596 599 16820346 dex NN I-NP D003907
38 599 600 16820346 - HYPH B-VP O
39 600 604 16820346 only RB B-NP O
40 605 610 16820346 group NN I-NP O
41 611 612 16820346 ( ( O O
42 612 613 16820346 P NN B-NP O
43 613 614 16820346 ' '' O O
44 615 616 16820346 < SYM B-NP O
45 617 621 16820346 0.05 CD I-NP O
46 621 622 16820346 ) ) O O
47 622 623 16820346 . . O O

1 624 630 16820346 Atorva NNP B-NP C065179
2 631 639 16820346 reversed VBD B-VP O
3 640 643 16820346 dex NN B-NP D003907
4 643 644 16820346 - HYPH O O
5 644 651 16820346 induced VBN B-NP O
6 652 664 16820346 hypertension NN I-NP D006973
7 665 666 16820346 ( ( O O
8 666 669 16820346 129 CD B-NP O
9 670 671 16820346 + SYM O O
10 671 672 16820346 / SYM O O
11 672 673 16820346 - SYM O O
12 674 677 16820346 0.6 CD B-NP O
13 678 682 16820346 mmHg NN I-NP O
14 682 683 16820346 , , O O
15 684 686 16820346 vs IN B-ADVP O
16 686 687 16820346 . . O O
17 688 691 16820346 135 CD B-NP O
18 692 693 16820346 + SYM O O
19 693 694 16820346 / SYM O O
20 694 695 16820346 - SYM O O
21 696 699 16820346 0.6 CD B-NP O
22 700 704 16820346 mmHg NN I-NP O
23 705 706 16820346 P NN I-NP O
24 706 707 16820346 ' '' O O
25 708 709 16820346 < SYM B-NP O
26 710 714 16820346 0.05 CD I-NP O
27 714 715 16820346 ) ) O O
28 716 719 16820346 and CC O O
29 720 729 16820346 decreased VBN B-NP O
30 730 736 16820346 plasma NN I-NP O
31 737 747 16820346 superoxide NN I-NP D013481
32 748 749 16820346 ( ( O O
33 749 753 16820346 7931 CD B-NP O
34 754 755 16820346 + SYM O O
35 755 756 16820346 / SYM O O
36 756 757 16820346 - SYM O O
37 758 763 16820346 392.8 CD B-NP O
38 764 767 16820346 dex NN I-NP D003907
39 767 768 16820346 , , O O
40 769 773 16820346 1187 CD B-NP O
41 774 775 16820346 + SYM O O
42 775 776 16820346 / SYM O O
43 776 777 16820346 - SYM O O
44 778 783 16820346 441.2 CD B-NP O
45 784 790 16820346 atorva NN I-NP C065179
46 791 792 16820346 + SYM O O
47 793 796 16820346 dex NN B-NP D003907
48 796 797 16820346 , , O O
49 798 799 16820346 P NN B-NP O
50 800 801 16820346 < SYM B-NP O
51 802 808 16820346 0.0001 CD I-NP O
52 808 809 16820346 ) ) O O
53 809 810 16820346 . . O O

1 811 817 16820346 Plasma NN B-NP O
2 818 825 16820346 nitrate NN I-NP D009566
3 825 826 16820346 / SYM O O
4 826 833 16820346 nitrite NN B-NP D009573
5 834 835 16820346 ( ( O O
6 835 838 16820346 NOx NN B-NP O
7 838 839 16820346 ) ) O O
8 840 843 16820346 was VBD B-VP O
9 844 853 16820346 decreased VBN I-VP O
10 854 856 16820346 in IN B-PP O
11 857 860 16820346 dex NN B-NP D003907
12 860 861 16820346 - HYPH B-NP O
13 861 868 16820346 treated VBN I-NP O
14 869 873 16820346 rats NNS I-NP O
15 874 882 16820346 compared VBN B-VP O
16 883 885 16820346 to TO B-PP O
17 886 892 16820346 saline NN B-NP O
18 892 893 16820346 - HYPH B-NP O
19 893 900 16820346 treated VBN I-NP O
20 901 905 16820346 rats NNS I-NP O
21 906 907 16820346 ( ( O O
22 907 911 16820346 11.2 CD B-NP O
23 912 913 16820346 + SYM O O
24 913 914 16820346 / SYM O O
25 914 915 16820346 - SYM O O
26 916 920 16820346 1.08 CD B-NP O
27 921 927 16820346 microm NN I-NP O
28 927 928 16820346 , , O O
29 929 933 16820346 15.3 CD B-NP O
30 934 935 16820346 + SYM O O
31 935 936 16820346 / SYM O O
32 936 937 16820346 - SYM O O
33 938 942 16820346 1.17 CD B-NP O
34 943 949 16820346 microm NN I-NP O
35 949 950 16820346 , , O O
36 951 963 16820346 respectively RB B-ADVP O
37 963 964 16820346 , , O O
38 965 966 16820346 P NN B-NP O
39 967 968 16820346 < SYM B-NP O
40 969 973 16820346 0.05 CD I-NP O
41 973 974 16820346 ) ) O O
42 974 975 16820346 . . O O

1 976 982 16820346 Atorva NNP B-NP C065179
2 983 991 16820346 affected VBD B-VP O
3 992 999 16820346 neither CC O O
4 1000 1006 16820346 plasma NN B-NP O
5 1007 1010 16820346 NOx NN I-NP O
6 1011 1014 16820346 nor CC O O
7 1015 1021 16820346 thymus NN B-NP O
8 1022 1028 16820346 weight NN I-NP O
9 1028 1029 16820346 . . O O

1 1030 1034 16820346 Thus RB B-ADVP O
2 1034 1035 16820346 , , O O
3 1036 1048 16820346 atorvastatin NN B-NP C065179
4 1049 1058 16820346 prevented VBD B-VP O
5 1059 1062 16820346 and CC O O
6 1063 1071 16820346 reversed VBD B-VP O
7 1072 1085 16820346 dexamethasone NN B-NP D003907
8 1085 1086 16820346 - HYPH O O
9 1086 1093 16820346 induced VBN B-NP O
10 1094 1106 16820346 hypertension NN I-NP D006973
11 1107 1109 16820346 in IN B-PP O
12 1110 1113 16820346 the DT B-NP O
13 1114 1117 16820346 rat NN I-NP O
14 1117 1118 16820346 . . O O

1 0 0 6454943 -DOCSTART- -X- -X- O

1 0 6 6454943 Effect NN B-NP O
2 7 9 6454943 of IN B-PP O
3 10 19 6454943 captopril NN B-NP D002216
4 20 22 6454943 on IN B-PP O
5 23 26 6454943 pre AFX B-NP O
6 26 27 6454943 - HYPH I-NP O
7 27 35 6454943 existing VBG I-NP O
8 36 39 6454943 and CC I-NP O
9 40 55 6454943 aminonucleoside NN I-NP D011692
10 55 56 6454943 - HYPH B-NP O
11 56 63 6454943 induced VBN I-NP O
12 64 75 6454943 proteinuria NN I-NP D011507
13 76 78 6454943 in IN B-PP O
14 79 92 6454943 spontaneously RB B-NP O
15 93 105 6454943 hypertensive JJ I-NP D006973
16 106 110 6454943 rats NNS I-NP O
17 110 111 6454943 . . O O
18 112 123 6454943 Proteinuria NNP B-NP D011507
19 124 126 6454943 is VBZ B-VP O
20 127 128 6454943 a DT B-NP O
21 129 133 6454943 side JJ I-NP O
22 134 140 6454943 effect NN I-NP O
23 141 143 6454943 of IN B-PP O
24 144 153 6454943 captopril NN B-NP D002216
25 154 163 6454943 treatment NN I-NP O
26 164 166 6454943 in IN B-PP O
27 167 179 6454943 hypertensive JJ B-NP D006973
28 180 188 6454943 patients NNS I-NP O
29 188 189 6454943 . . O O

1 190 193 6454943 The DT B-NP O
2 194 205 6454943 possibility NN I-NP O
3 206 208 6454943 of IN B-PP O
4 209 220 6454943 reproducing VBG B-VP O
5 221 224 6454943 the DT B-NP O
6 225 229 6454943 same JJ I-NP O
7 230 235 6454943 renal JJ I-NP D007674
8 236 247 6454943 abnormality NN I-NP D007674
9 248 252 6454943 with IN B-PP O
10 253 262 6454943 captopril NN B-NP D002216
11 263 266 6454943 was VBD B-VP O
12 267 275 6454943 examined VBN I-VP O
13 276 278 6454943 in IN B-PP O
14 279 282 6454943 SHR NN B-NP O
15 282 283 6454943 . . O O

1 284 288 6454943 Oral JJ B-NP O
2 289 303 6454943 administration NN I-NP O
3 304 306 6454943 of IN B-PP O
4 307 316 6454943 captopril NN B-NP D002216
5 317 319 6454943 at IN B-PP O
6 320 323 6454943 100 CD B-NP O
7 324 326 6454943 mg NN I-NP O
8 326 327 6454943 / SYM B-NP O
9 327 329 6454943 kg NN I-NP O
10 330 333 6454943 for IN B-PP O
11 334 336 6454943 14 CD B-NP O
12 337 341 6454943 days NNS I-NP O
13 342 348 6454943 failed VBD B-VP O
14 349 351 6454943 to TO I-VP O
15 352 361 6454943 aggravate VB I-VP O
16 362 373 6454943 proteinuria NN B-NP D011507
17 374 377 6454943 pre AFX O O
18 377 378 6454943 - HYPH O O
19 378 386 6454943 existing VBG B-VP O
20 387 389 6454943 in IN B-PP O
21 390 393 6454943 SHR NN B-NP O
22 393 394 6454943 . . O O

1 395 399 6454943 Also RB B-ADVP O
2 399 400 6454943 , , O O
3 401 410 6454943 captopril NN B-NP D002216
4 411 420 6454943 treatment NN I-NP O
5 421 427 6454943 failed VBD B-VP O
6 428 430 6454943 to TO I-VP O
7 431 441 6454943 potentiate VB I-VP O
8 442 444 6454943 or CC I-VP O
9 445 455 6454943 facilitate VB I-VP O
10 456 467 6454943 development NN B-NP O
11 468 470 6454943 of IN B-PP O
12 471 478 6454943 massive JJ B-NP O
13 479 490 6454943 proteinuria NN I-NP D011507
14 491 498 6454943 invoked VBN B-VP O
15 499 501 6454943 by IN B-PP O
16 502 511 6454943 puromycin NN B-NP D011692
17 512 527 6454943 aminonucleoside NN I-NP D011692
18 528 530 6454943 in IN B-PP O
19 531 534 6454943 SHR NN B-NP O
20 534 535 6454943 . . O O

1 536 545 6454943 Captopril NNP B-NP D002216
2 546 549 6454943 had VBD B-VP O
3 550 556 6454943 little JJ B-NP O
4 557 559 6454943 or CC I-NP O
5 560 562 6454943 no DT I-NP O
6 563 575 6454943 demonstrable JJ I-NP O
7 576 583 6454943 effects NNS I-NP O
8 584 586 6454943 on IN B-PP O
9 587 592 6454943 serum NN B-NP O
10 593 604 6454943 electrolyte NN I-NP O
11 605 619 6454943 concentrations NNS I-NP O
12 619 620 6454943 , , O O
13 621 630 6454943 excretion NN B-NP O
14 631 633 6454943 of IN B-PP O
15 634 639 6454943 urine NN B-NP O
16 639 640 6454943 , , I-NP O
17 641 647 6454943 sodium NN I-NP D012964
18 648 651 6454943 and CC I-NP O
19 652 661 6454943 potassium NN I-NP D011188
20 661 662 6454943 , , O O
21 663 673 6454943 endogenous JJ B-NP O
22 674 684 6454943 creatinine NN I-NP D003404
23 685 694 6454943 clearance NN I-NP O
24 694 695 6454943 , , O O
25 696 700 6454943 body NN B-NP O
26 701 707 6454943 weight NN I-NP O
27 707 708 6454943 , , O O
28 709 712 6454943 and CC O O
29 713 717 6454943 food NN B-NP O
30 718 721 6454943 and CC I-NP O
31 722 727 6454943 water NN I-NP O
32 728 739 6454943 consumption NN I-NP O
33 739 740 6454943 . . O O

1 741 748 6454943 However RB B-ADVP O
2 748 749 6454943 , , O O
3 750 756 6454943 ketone NN B-NP D007659
4 757 763 6454943 bodies NNS I-NP O
5 764 768 6454943 were VBD B-VP O
6 769 781 6454943 consistently RB B-ADJP O
7 782 789 6454943 present JJ I-ADJP O
8 790 792 6454943 in IN B-PP O
9 793 798 6454943 urine NN B-NP O
10 799 802 6454943 and CC O O
11 803 810 6454943 several JJ B-NP O
12 811 822 6454943 lethalities NNS I-NP O
13 823 831 6454943 occurred VBD B-VP O
14 832 838 6454943 during IN B-PP O
15 839 847 6454943 multiple JJ B-NP O
16 848 854 6454943 dosing NN I-NP O
17 855 857 6454943 of IN B-PP O
18 858 867 6454943 captopril NN B-NP D002216
19 868 870 6454943 in IN B-PP O
20 871 874 6454943 SHR NN B-NP O
21 874 875 6454943 . . O O

1 0 0 326460 -DOCSTART- -X- -X- O

1 0 12 326460 Amelioration NN B-NP O
2 13 15 326460 of IN B-PP O
3 16 30 326460 bendrofluazide NN B-NP D001539
4 30 31 326460 - HYPH B-NP O
5 31 38 326460 induced VBN I-NP O
6 39 50 326460 hypokalemia NN I-NP D007008
7 51 53 326460 by IN B-PP O
8 54 61 326460 timolol NN B-NP D013999
9 61 62 326460 . . O O
10 63 66 326460 The DT B-NP O
11 67 71 326460 beta NN I-NP O
12 72 82 326460 adrenergic JJ I-NP O
13 83 91 326460 blocking VBG I-NP O
14 92 96 326460 drug NN I-NP O
15 96 97 326460 , , O O
16 98 105 326460 timolol NN B-NP D013999
17 105 106 326460 , , O O
18 107 113 326460 tended VBD B-VP O
19 114 116 326460 to TO I-VP O
20 117 124 326460 correct VB I-VP O
21 125 128 326460 the DT B-NP O
22 129 140 326460 hypokalemia NN I-NP D007008
23 141 143 326460 of IN B-PP O
24 144 149 326460 short JJ B-NP O
25 149 150 326460 - HYPH I-NP O
26 150 154 326460 term NN I-NP O
27 155 169 326460 bendrofluazide NN I-NP D001539
28 170 179 326460 treatment NN I-NP O
29 180 182 326460 in IN B-PP O
30 183 184 326460 6 CD B-NP O
31 185 192 326460 healthy JJ I-NP O
32 193 197 326460 male JJ I-NP O
33 198 206 326460 subjects NNS I-NP O
34 207 210 326460 and CC O O
35 211 219 326460 although IN B-SBAR O
36 220 223 326460 the DT B-NP O
37 224 230 326460 effect NN I-NP O
38 231 234 326460 was VBD B-VP O
39 235 240 326460 small JJ B-ADJP O
40 241 243 326460 it PRP B-NP O
41 244 247 326460 was VBD B-VP O
42 248 259 326460 significant JJ B-ADJP O
43 259 260 326460 . . O O

1 261 268 326460 Timolol NN B-NP D013999
2 269 273 326460 also RB B-ADVP O
3 274 281 326460 reduced VBD B-VP O
4 282 285 326460 the DT B-NP O
5 286 290 326460 rise NN I-NP O
6 291 293 326460 in IN B-PP O
7 294 300 326460 plasma NN B-NP O
8 301 312 326460 aldosterone NN I-NP D000450
9 313 316 326460 and CC O O
10 317 322 326460 urine NN B-NP O
11 323 332 326460 potassium NN I-NP D011188
12 333 342 326460 excretion NN I-NP O
13 343 352 326460 following VBG B-PP O
14 353 367 326460 bendrofluazide NN B-NP D001539
15 368 371 326460 and CC O O
16 372 381 326460 increased VBD B-VP O
17 382 385 326460 the DT B-NP O
18 386 391 326460 urine NN I-NP O
19 392 398 326460 sodium NN I-NP D012964
20 398 399 326460 / SYM B-NP O
21 399 408 326460 potassium NN I-NP D011188
22 409 414 326460 ratio NN I-NP O
23 414 415 326460 . . O O

1 416 421 326460 There EX B-NP O
2 422 425 326460 was VBD B-VP O
3 426 428 326460 no DT B-NP O
4 429 437 326460 evidence NN I-NP O
5 438 440 326460 of IN B-PP O
6 441 442 326460 a DT B-NP O
7 443 448 326460 shift NN I-NP O
8 449 451 326460 of IN B-PP O
9 452 461 326460 potassium NN B-NP D011188
10 462 466 326460 from IN B-PP O
11 467 470 326460 the DT B-NP O
12 471 484 326460 intracellular JJ I-NP O
13 485 487 326460 to TO B-PP O
14 488 491 326460 the DT B-NP O
15 492 505 326460 extracellular JJ I-NP O
16 506 511 326460 space NN I-NP O
17 511 512 326460 . . O O

1 0 0 10524660 -DOCSTART- -X- -X- O

1 0 8 10524660 Glyceryl NN B-NP D005996
2 9 19 10524660 trinitrate NN I-NP D005996
3 20 27 10524660 induces VBZ B-VP O
4 28 35 10524660 attacks NNS B-NP O
5 36 38 10524660 of IN B-PP O
6 39 47 10524660 migraine NN B-NP D020326
7 48 55 10524660 without IN B-PP D020326
8 56 60 10524660 aura NN B-NP D020326
9 61 63 10524660 in IN B-PP O
10 64 73 10524660 sufferers NNS B-NP O
11 74 76 10524660 of IN B-PP O
12 77 85 10524660 migraine NN B-NP D020325
13 86 90 10524660 with IN B-PP D020325
14 91 95 10524660 aura NN B-NP D020325
15 95 96 10524660 . . O O
16 97 105 10524660 Migraine NN B-NP D020325
17 106 110 10524660 with IN B-PP D020325
18 111 115 10524660 aura NN B-NP D020325
19 116 119 10524660 and CC I-NP O
20 120 128 10524660 migraine NN I-NP D020326
21 129 136 10524660 without IN B-PP D020326
22 137 141 10524660 aura NN B-NP D020326
23 142 146 10524660 have VBP B-VP O
24 147 150 10524660 the DT B-NP O
25 151 155 10524660 same JJ I-NP O
26 156 160 10524660 pain NN I-NP D010146
27 161 166 10524660 phase NN I-NP O
28 166 167 10524660 , , O O
29 168 172 10524660 thus RB B-ADVP O
30 173 183 10524660 indicating VBG B-VP O
31 184 188 10524660 that IN B-SBAR O
32 189 197 10524660 migraine NN B-NP D020325
33 198 202 10524660 with IN B-PP D020325
34 203 207 10524660 aura NN B-NP D020325
35 208 211 10524660 and CC I-NP O
36 212 220 10524660 migraine NN I-NP D020326
37 221 228 10524660 without IN B-PP D020326
38 229 233 10524660 aura NN B-NP D020326
39 234 239 10524660 share VBP B-VP O
40 240 241 10524660 a DT B-NP O
41 242 248 10524660 common JJ I-NP O
42 249 256 10524660 pathway NN I-NP O
43 257 259 10524660 of IN B-PP O
44 260 271 10524660 nociception NN B-NP O
45 271 272 10524660 . . O O

1 273 275 10524660 In IN B-PP O
2 276 282 10524660 recent JJ B-NP O
3 283 288 10524660 years NNS I-NP O
4 288 289 10524660 , , O O
5 290 300 10524660 increasing VBG B-VP O
6 301 309 10524660 evidence NN B-NP O
7 310 313 10524660 has VBZ B-VP O
8 314 323 10524660 suggested VBN I-VP O
9 324 328 10524660 that IN B-SBAR O
10 329 332 10524660 the DT B-NP O
11 333 342 10524660 messenger NN I-NP O
12 343 351 10524660 molecule NN I-NP O
13 352 358 10524660 nitric JJ I-NP D009569
14 359 364 10524660 oxide NN I-NP D009569
15 365 366 10524660 ( ( O O
16 366 368 10524660 NO NN B-NP D009569
17 368 369 10524660 ) ) O O
18 370 372 10524660 is VBZ B-VP O
19 373 381 10524660 involved VBN I-VP O
20 382 384 10524660 in IN B-PP O
21 385 389 10524660 pain NN B-NP D010146
22 390 400 10524660 mechanisms NNS I-NP O
23 401 403 10524660 of IN B-PP O
24 404 412 10524660 migraine NN B-NP D020326
25 413 420 10524660 without IN B-PP D020326
26 421 425 10524660 aura NN B-NP D020326
27 425 426 10524660 . . O O

1 427 429 10524660 In IN B-SBAR O
2 430 435 10524660 order NN O O
3 436 438 10524660 to TO B-VP O
4 439 446 10524660 clarify VB I-VP O
5 447 454 10524660 whether IN B-SBAR O
6 455 458 10524660 the DT B-NP O
7 459 463 10524660 same JJ I-NP O
8 464 466 10524660 is VBZ B-VP O
9 467 471 10524660 true JJ B-ADJP O
10 472 475 10524660 for IN B-PP O
11 476 484 10524660 migraine NN B-NP D020325
12 485 489 10524660 with IN B-PP D020325
13 490 494 10524660 aura NN B-NP D020325
14 494 495 10524660 , , O O
15 496 498 10524660 in IN B-PP O
16 499 502 10524660 the DT B-NP O
17 503 510 10524660 present JJ I-NP O
18 511 516 10524660 study NN I-NP O
19 517 519 10524660 we PRP B-NP O
20 520 528 10524660 examined VBD B-VP O
21 529 532 10524660 the DT B-NP O
22 533 541 10524660 headache NN I-NP D006261
23 542 550 10524660 response NN I-NP O
24 551 553 10524660 to TO B-PP O
25 554 565 10524660 intravenous JJ B-NP O
26 566 574 10524660 infusion NN I-NP O
27 575 577 10524660 of IN B-PP O
28 578 586 10524660 glyceryl NN B-NP D005996
29 587 597 10524660 trinitrate NN I-NP D005996
30 598 599 10524660 ( ( O O
31 599 602 10524660 GTN NN B-NP D005996
32 602 603 10524660 ) ) O O
33 604 605 10524660 ( ( O O
34 605 608 10524660 0.5 CD B-NP O
35 609 615 10524660 microg NN I-NP O
36 615 616 10524660 / SYM B-NP O
37 616 618 10524660 kg NN I-NP O
38 618 619 10524660 / SYM B-NP O
39 619 622 10524660 min NN I-NP O
40 623 626 10524660 for IN B-PP O
41 627 629 10524660 20 CD B-NP O
42 630 633 10524660 min NN I-NP O
43 633 634 10524660 ) ) O O
44 635 637 10524660 in IN B-PP O
45 638 640 10524660 12 CD B-NP O
46 641 650 10524660 sufferers NNS I-NP O
47 651 653 10524660 of IN B-PP O
48 654 662 10524660 migraine NN B-NP D020325
49 663 667 10524660 with IN B-PP D020325
50 668 672 10524660 aura NN B-NP D020325
51 672 673 10524660 . . O O

1 674 677 10524660 The DT B-NP O
2 678 686 10524660 specific JJ I-NP O
3 687 690 10524660 aim NN I-NP O
4 691 694 10524660 was VBD B-VP O
5 695 697 10524660 to TO B-VP O
6 698 707 10524660 elucidate VB I-VP O
7 708 715 10524660 whether IN B-SBAR O
8 716 718 10524660 an DT B-NP O
9 719 723 10524660 aura NN I-NP O
10 724 727 10524660 and CC O O
11 727 728 10524660 / SYM B-NP O
12 728 730 10524660 or CC O O
13 731 733 10524660 an DT B-NP O
14 734 740 10524660 attack NN I-NP O
15 741 743 10524660 of IN B-PP O
16 744 752 10524660 migraine NN B-NP D020326
17 753 760 10524660 without IN B-PP D020326
18 761 765 10524660 aura NN B-NP D020326
19 766 771 10524660 could MD B-VP O
20 772 774 10524660 be VB I-VP O
21 775 782 10524660 induced VBN I-VP O
22 782 783 10524660 . . O O

1 784 792 10524660 Fourteen CD B-NP O
2 793 800 10524660 healthy JJ I-NP O
3 801 809 10524660 subjects NNS I-NP O
4 810 816 10524660 served VBD B-VP O
5 817 819 10524660 as IN B-PP O
6 820 828 10524660 controls NNS B-NP O
7 828 829 10524660 . . O O

1 830 834 10524660 Aura NNP B-NP O
2 835 843 10524660 symptoms NNS I-NP O
3 844 848 10524660 were VBD B-VP O
4 849 852 10524660 not RB I-VP O
5 853 861 10524660 elicited VBN I-VP O
6 862 864 10524660 in IN B-PP O
7 865 868 10524660 any DT B-NP O
8 869 876 10524660 subject NN I-NP O
9 876 877 10524660 . . O O

1 878 886 10524660 Headache PRP B-NP D006261
2 887 890 10524660 was VBD B-VP O
3 891 895 10524660 more RBR B-ADJP O
4 896 902 10524660 severe JJ I-ADJP O
5 903 905 10524660 in IN B-PP O
6 906 917 10524660 migraineurs NNS B-NP D008881
7 918 922 10524660 than IN B-PP O
8 923 925 10524660 in IN B-PP O
9 926 929 10524660 the DT B-NP O
10 930 938 10524660 controls NNS I-NP O
11 939 945 10524660 during IN B-PP O
12 946 949 10524660 and CC O O
13 950 961 10524660 immediately RB B-ADVP O
14 962 967 10524660 after IN B-PP O
15 968 971 10524660 GTN NN B-NP D005996
16 972 980 10524660 infusion NN I-NP O
17 981 982 10524660 ( ( O O
18 982 983 10524660 p NN B-NP O
19 983 984 10524660 = SYM B-VP O
20 984 989 10524660 0.037 CD B-NP O
21 989 990 10524660 ) ) O O
22 991 993 10524660 as RB B-CONJP O
23 994 998 10524660 well RB I-CONJP O
24 999 1001 10524660 as IN I-CONJP O
25 1002 1008 10524660 during IN B-PP O
26 1009 1012 10524660 the DT B-NP O
27 1013 1022 10524660 following VBG I-NP O
28 1023 1025 10524660 11 CD I-NP O
29 1026 1027 10524660 h NN I-NP O
30 1028 1029 10524660 ( ( O O
31 1029 1030 10524660 p NN B-NP O
32 1031 1032 10524660 = SYM B-VP O
33 1033 1038 10524660 0.008 CD B-NP O
34 1038 1039 10524660 ) ) O O
35 1039 1040 10524660 . . O O

1 1041 1043 10524660 In IN B-PP O
2 1044 1047 10524660 the DT B-NP O
3 1048 1056 10524660 controls NNS I-NP O
4 1056 1057 10524660 , , O O
5 1058 1061 10524660 the DT B-NP O
6 1062 1065 10524660 GTN NN I-NP D005996
7 1065 1066 10524660 - HYPH B-NP O
8 1066 1073 10524660 induced VBN I-NP O
9 1074 1082 10524660 headache NN I-NP D006261
10 1083 1092 10524660 gradually RB B-ADVP O
11 1093 1104 10524660 disappeared VBD B-VP O
12 1104 1105 10524660 , , O O
13 1106 1113 10524660 whereas IN O O
14 1114 1116 10524660 in IN B-PP O
15 1117 1128 10524660 migraineurs NNS B-NP D008881
16 1129 1133 10524660 peak VBP B-VP O
17 1134 1142 10524660 headache NN B-NP D006261
18 1143 1152 10524660 intensity NN I-NP O
19 1153 1161 10524660 occurred VBD B-VP O
20 1162 1164 10524660 at IN B-PP O
21 1165 1166 10524660 a DT B-NP O
22 1167 1171 10524660 mean JJ I-NP O
23 1172 1176 10524660 time NN I-NP O
24 1177 1179 10524660 of IN B-PP O
25 1180 1183 10524660 240 CD B-NP O
26 1184 1187 10524660 min NN I-NP O
27 1188 1192 10524660 post AFX B-NP O
28 1192 1193 10524660 - HYPH I-NP O
29 1193 1201 10524660 infusion NN B-NP O
30 1201 1202 10524660 . . O O

1 1203 1205 10524660 At IN B-PP O
2 1206 1210 10524660 this DT B-NP O
3 1211 1215 10524660 time NN I-NP O
4 1216 1219 10524660 the DT B-NP O
5 1220 1227 10524660 induced VBN I-NP O
6 1228 1236 10524660 headache NN I-NP D006261
7 1237 1239 10524660 in IN B-PP O
8 1240 1241 10524660 6 CD B-NP O
9 1242 1244 10524660 of IN B-PP O
10 1245 1247 10524660 12 CD B-NP O
11 1248 1259 10524660 migraineurs NNS I-NP D008881
12 1260 1269 10524660 fulfilled VBD B-VP O
13 1270 1273 10524660 the DT B-NP O
14 1274 1284 10524660 diagnostic JJ I-NP O
15 1285 1293 10524660 criteria NNS I-NP O
16 1294 1297 10524660 for IN B-PP O
17 1298 1306 10524660 migraine NN B-NP D020326
18 1307 1314 10524660 without IN B-PP D020326
19 1315 1319 10524660 aura NN B-NP D020326
20 1320 1322 10524660 of IN B-PP O
21 1323 1326 10524660 the DT B-NP O
22 1327 1340 10524660 International NNP I-NP O
23 1341 1349 10524660 Headache NNP I-NP D006261
24 1350 1357 10524660 Society NNP I-NP O
25 1357 1358 10524660 . . O O

1 1359 1362 10524660 The DT B-NP O
2 1363 1370 10524660 results NNS I-NP O
3 1371 1380 10524660 therefore RB B-ADVP O
4 1381 1388 10524660 suggest VBP B-VP O
5 1389 1393 10524660 that IN B-SBAR O
6 1394 1396 10524660 NO NN B-NP D009569
7 1397 1399 10524660 is VBZ B-VP O
8 1400 1408 10524660 involved VBN I-VP O
9 1409 1411 10524660 in IN B-PP O
10 1412 1415 10524660 the DT B-NP O
11 1416 1420 10524660 pain NN I-NP D010146
12 1421 1431 10524660 mechanisms NNS I-NP O
13 1432 1434 10524660 of IN B-PP O
14 1435 1443 10524660 migraine NN B-NP D020325
15 1444 1448 10524660 with IN B-PP D020325
16 1449 1453 10524660 aura NN B-NP D020325
17 1453 1454 10524660 . . O O

1 1455 1460 10524660 Since IN B-SBAR O
2 1461 1469 10524660 cortical JJ B-NP O
3 1470 1479 10524660 spreading VBG I-NP O
4 1480 1490 10524660 depression NN I-NP D003866
5 1491 1494 10524660 has VBZ B-VP O
6 1495 1499 10524660 been VBN I-VP O
7 1500 1505 10524660 shown VBN I-VP O
8 1506 1508 10524660 to TO I-VP O
9 1509 1517 10524660 liberate VB I-VP O
10 1518 1520 10524660 NO NN B-NP D009569
11 1521 1523 10524660 in IN B-PP O
12 1524 1531 10524660 animals NNS B-NP O
13 1531 1532 10524660 , , O O
14 1533 1537 10524660 this DT B-NP O
15 1538 1545 10524660 finding NN I-NP O
16 1546 1549 10524660 may MD B-VP O
17 1550 1554 10524660 help VB I-VP O
18 1555 1558 10524660 our PRP$ B-NP O
19 1559 1572 10524660 understanding NN I-NP O
20 1573 1575 10524660 of IN B-PP O
21 1576 1579 10524660 the DT B-NP O
22 1580 1588 10524660 coupling NN I-NP O
23 1589 1596 10524660 between IN B-PP O
24 1597 1605 10524660 cortical JJ B-NP O
25 1606 1615 10524660 spreading VBG I-NP O
26 1616 1626 10524660 depression NN I-NP D003866
27 1627 1630 10524660 and CC I-NP O
28 1631 1639 10524660 headache NN I-NP D006261
29 1640 1642 10524660 in IN B-PP O
30 1643 1651 10524660 migraine NN B-NP D020325
31 1652 1656 10524660 with IN B-PP D020325
32 1657 1661 10524660 aura NN B-NP D020325
33 1661 1662 10524660 . . O O

1 0 0 85485 -DOCSTART- -X- -X- O

1 0 7 85485 Changes NNS B-NP O
2 8 10 85485 in IN B-PP O
3 11 22 85485 peroxisomes NNS B-NP O
4 23 25 85485 in IN B-PP O
5 26 39 85485 preneoplastic JJ B-NP O
6 40 45 85485 liver NN I-NP O
7 46 49 85485 and CC I-NP O
8 50 58 85485 hepatoma NN I-NP D006528
9 59 61 85485 of IN B-PP O
10 62 66 85485 mice NNS B-NP O
11 67 74 85485 induced VBN B-VP O
12 75 77 85485 by IN B-PP O
13 78 83 85485 alpha SYM B-NP D001556
14 83 84 85485 - HYPH I-NP D001556
15 84 91 85485 benzene NN I-NP D001556
16 92 104 85485 hexachloride NN I-NP D001556
17 104 105 85485 . . O O
18 106 117 85485 Peroxisomes NNS B-NP O
19 118 120 85485 in IN B-PP O
20 121 130 85485 hepatomas NNS B-NP D006528
21 131 134 85485 and CC O O
22 135 147 85485 hyperplastic JJ B-NP O
23 148 161 85485 preneoplastic JJ I-NP O
24 162 167 85485 liver NN I-NP D017093
25 168 175 85485 lesions NNS I-NP D017093
26 176 183 85485 induced VBN B-VP O
27 184 186 85485 in IN B-PP O
28 187 191 85485 mice NNS B-NP O
29 192 194 85485 by IN B-PP O
30 195 198 85485 500 CD B-NP O
31 199 202 85485 ppm NN I-NP O
32 203 208 85485 alpha SYM B-NP D001556
33 208 209 85485 - HYPH B-NP D001556
34 209 216 85485 benzene NN I-NP D001556
35 217 229 85485 hexachloride NN I-NP D001556
36 230 234 85485 were VBD B-VP O
37 235 243 85485 examined VBN I-VP O
38 244 259 85485 histochemically RB B-ADVP O
39 260 263 85485 and CC O O
40 264 272 85485 electron NN B-NP O
41 273 288 85485 microscopically RB B-ADVP O
42 288 289 85485 . . O O

1 290 298 85485 Although IN B-SBAR O
2 299 303 85485 most JJS B-NP O
3 304 306 85485 of IN B-PP O
4 307 310 85485 the DT B-NP O
5 311 320 85485 hepatomas NNS I-NP D006528
6 321 325 85485 were VBD B-VP O
7 326 330 85485 well RB B-ADVP O
8 330 331 85485 - HYPH B-NP O
9 331 345 85485 differentiated VBN I-NP O
10 346 352 85485 tumors NNS I-NP D009369
11 353 356 85485 and CC O O
12 357 366 85485 contained VBD B-VP O
13 367 368 85485 a DT B-NP O
14 369 381 85485 considerable JJ I-NP O
15 382 388 85485 number NN I-NP O
16 389 391 85485 of IN B-PP O
17 392 403 85485 peroxisomes NNS B-NP O
18 403 404 85485 , , O O
19 405 408 85485 the DT B-NP O
20 409 414 85485 tumor NN I-NP D009369
21 415 420 85485 cells NNS I-NP O
22 421 424 85485 did VBD B-VP O
23 425 428 85485 not RB I-VP O
24 429 436 85485 respond VB I-VP O
25 437 439 85485 to TO B-PP O
26 440 445 85485 ethyl NN B-NP C012282
27 445 446 85485 - HYPH O C012282
28 446 451 85485 alpha SYM B-NP C012282
29 451 452 85485 - HYPH B-NP C012282
30 452 453 85485 p NN I-NP C012282
31 453 454 85485 - HYPH O C012282
32 454 478 85485 chlorophenoxyisobutyrate NN B-NP C012282
33 479 483 85485 with IN B-PP O
34 484 497 85485 proliferation NN B-NP O
35 498 500 85485 of IN B-PP O
36 501 512 85485 peroxisomes NNS B-NP O
37 512 513 85485 . . O O

1 514 516 85485 At IN B-PP O
2 517 520 85485 the DT B-NP O
3 521 525 85485 16th JJ I-NP O
4 526 530 85485 week NN I-NP O
5 531 533 85485 of IN B-PP O
6 534 544 85485 carcinogen NN B-NP O
7 545 552 85485 feeding NN I-NP O
8 552 553 85485 , , O O
9 554 566 85485 hyperplastic JJ B-NP O
10 567 574 85485 nodules NNS I-NP O
11 575 583 85485 appeared VBD B-VP O
12 584 587 85485 and CC O O
13 588 596 85485 advanced VBD B-VP O
14 597 599 85485 to TO B-PP O
15 600 607 85485 further JJ B-NP O
16 608 614 85485 stages NNS I-NP O
17 614 615 85485 . . O O

1 616 617 85485 A DT B-NP O
2 618 626 85485 majority NN I-NP O
3 627 629 85485 of IN B-PP O
4 630 633 85485 the DT B-NP O
5 634 641 85485 nodules NNS I-NP O
6 642 648 85485 showed VBD B-VP O
7 649 650 85485 a DT B-NP O
8 651 663 85485 considerable JJ I-NP O
9 664 670 85485 number NN I-NP O
10 671 673 85485 of IN B-PP O
11 674 685 85485 peroxisomes NNS B-NP O
12 686 689 85485 and CC O O
13 690 693 85485 the DT B-NP O
14 694 703 85485 inductive JJ I-NP O
15 704 717 85485 proliferation NN I-NP O
16 718 720 85485 of IN B-PP O
17 721 732 85485 peroxisomes NNS B-NP O
18 732 733 85485 . . O O

1 734 740 85485 Within IN B-PP O
2 741 744 85485 the DT B-NP O
3 745 752 85485 nodules NNS I-NP O
4 752 753 85485 , , O O
5 754 758 85485 foci NNS B-NP O
6 759 761 85485 of IN B-PP O
7 762 775 85485 proliferation NN B-NP O
8 776 778 85485 of IN B-PP O
9 779 782 85485 the DT B-NP O
10 783 788 85485 cells NNS I-NP O
11 789 793 85485 that WDT B-NP O
12 794 800 85485 showed VBD B-VP O
13 801 803 85485 no DT B-NP O
14 804 816 85485 inducibility NN I-NP O
15 817 819 85485 of IN B-PP O
16 820 833 85485 proliferation NN B-NP O
17 834 836 85485 of IN B-PP O
18 837 848 85485 peroxisomes NNS B-NP O
19 849 857 85485 appeared VBD B-VP O
20 857 858 85485 . . O O

1 859 864 85485 These DT B-NP O
2 865 870 85485 cells NNS I-NP O
3 871 883 85485 proliferated VBD B-VP O
4 884 891 85485 further RBR B-ADVP O
5 891 892 85485 , , O O
6 893 902 85485 replacing VBG B-VP O
7 903 906 85485 the DT B-NP O
8 907 911 85485 most JJS I-NP O
9 912 916 85485 part NN I-NP O
10 917 919 85485 of IN B-PP O
11 920 923 85485 the DT B-NP O
12 924 931 85485 nodules NNS I-NP O
13 931 932 85485 , , O O
14 933 936 85485 and CC O O
15 937 941 85485 with IN B-PP O
16 942 946 85485 this DT B-NP O
17 947 954 85485 process NN I-NP O
18 955 964 85485 hepatomas NNS I-NP D006528
19 965 973 85485 appeared VBD B-VP O
20 974 976 85485 to TO I-VP O
21 977 981 85485 have VB I-VP O
22 982 986 85485 been VBN I-VP O
23 987 993 85485 formed VBN I-VP O
24 993 994 85485 . . O O

1 995 997 85485 No DT B-NP O
2 998 1006 85485 abnormal JJ I-NP O
3 1007 1015 85485 matrical JJ I-NP O
4 1016 1026 85485 inclusions NNS I-NP O
5 1027 1029 85485 of IN B-PP O
6 1030 1041 85485 peroxisomes NNS B-NP O
7 1042 1046 85485 were VBD B-VP O
8 1047 1053 85485 formed VBN I-VP O
9 1054 1056 85485 in IN B-PP O
10 1057 1060 85485 the DT B-NP O
11 1061 1066 85485 cells NNS I-NP O
12 1067 1069 85485 of IN B-PP O
13 1070 1082 85485 hyperplastic JJ B-NP O
14 1083 1090 85485 nodules NNS I-NP O
15 1091 1093 85485 by IN B-PP O
16 1094 1099 85485 ethyl NN B-NP C012282
17 1099 1100 85485 - HYPH O C012282
18 1100 1105 85485 alpha SYM B-NP C012282
19 1105 1106 85485 - HYPH B-NP C012282
20 1106 1107 85485 p NN I-NP C012282
21 1107 1108 85485 - HYPH I-NP C012282
22 1108 1132 85485 chlorophenoxyisobutyrate NN I-NP C012282
23 1133 1139 85485 unlike IN B-PP O
24 1140 1142 85485 in IN B-PP O
25 1143 1146 85485 the DT B-NP O
26 1147 1151 85485 case NN I-NP O
27 1152 1154 85485 of IN B-PP O
28 1155 1159 85485 rats NNS B-NP O
29 1159 1160 85485 . . O O

1 0 0 8617710 -DOCSTART- -X- -X- O

1 0 7 8617710 Absence NN B-NP O
2 8 10 8617710 of IN B-PP O
3 11 17 8617710 effect NN B-NP O
4 18 20 8617710 of IN B-PP O
5 21 31 8617710 sertraline NN B-NP D020280
6 32 34 8617710 on IN B-PP O
7 35 39 8617710 time NN B-NP O
8 39 40 8617710 - HYPH O O
9 40 45 8617710 based VBN B-NP O
10 46 59 8617710 sensitization NN I-NP O
11 60 62 8617710 of IN B-PP O
12 63 72 8617710 cognitive JJ B-NP D003072
13 73 83 8617710 impairment NN I-NP D003072
14 84 88 8617710 with IN B-PP O
15 89 100 8617710 haloperidol NN B-NP D006220
16 100 101 8617710 . . O O
17 102 106 8617710 This DT B-NP O
18 107 113 8617710 double JJ I-NP O
19 113 114 8617710 - HYPH I-NP O
20 114 119 8617710 blind JJ I-NP O
21 119 120 8617710 , , I-NP O
22 121 131 8617710 randomized VBN I-NP O
23 131 132 8617710 , , I-NP O
24 133 140 8617710 placebo NN I-NP O
25 140 141 8617710 - HYPH I-NP O
26 141 151 8617710 controlled VBN B-NP O
27 152 157 8617710 study NN I-NP O
28 158 167 8617710 evaluated VBD B-VP O
29 168 171 8617710 the DT B-NP O
30 172 179 8617710 effects NNS I-NP O
31 180 182 8617710 of IN B-PP O
32 183 194 8617710 haloperidol NN B-NP D006220
33 195 200 8617710 alone RB B-ADVP O
34 201 204 8617710 and CC O O
35 205 216 8617710 haloperidol NN B-NP D006220
36 217 221 8617710 plus CC I-NP O
37 222 232 8617710 sertraline NN I-NP D020280
38 233 235 8617710 on IN B-PP O
39 236 245 8617710 cognitive JJ B-NP O
40 246 249 8617710 and CC I-NP O
41 250 261 8617710 psychomotor JJ I-NP O
42 262 270 8617710 function NN I-NP O
43 271 273 8617710 in IN B-PP O
44 274 276 8617710 24 CD B-NP O
45 277 284 8617710 healthy JJ I-NP O
46 285 289 8617710 male JJ I-NP O
47 290 298 8617710 subjects NNS I-NP O
48 298 299 8617710 . . O O

1 300 306 8617710 METHOD NN B-NP O
2 306 307 8617710 : : O O
3 308 311 8617710 All DT B-NP O
4 312 320 8617710 subjects NNS I-NP O
5 321 329 8617710 received VBD B-VP O
6 330 337 8617710 placebo NN B-NP O
7 338 340 8617710 on IN B-PP O
8 341 344 8617710 Day NN B-NP O
9 345 346 8617710 1 CD I-NP O
10 347 350 8617710 and CC O O
11 351 362 8617710 haloperidol NN B-NP D006220
12 363 364 8617710 2 CD I-NP O
13 365 367 8617710 mg NN I-NP O
14 368 370 8617710 on IN B-PP O
15 371 375 8617710 Days NNS B-NP O
16 376 377 8617710 2 CD B-NP O
17 378 381 8617710 and CC I-NP O
18 382 384 8617710 25 CD I-NP O
19 384 385 8617710 . . O O

1 386 390 8617710 From IN B-PP O
2 391 395 8617710 Days NNS B-NP O
3 396 397 8617710 9 CD B-NP O
4 398 400 8617710 to TO B-PP O
5 401 403 8617710 25 CD B-NP O
6 403 404 8617710 , , O O
7 405 413 8617710 subjects NNS B-NP O
8 414 418 8617710 were VBD B-VP O
9 419 427 8617710 randomly RB I-VP O
10 428 436 8617710 assigned VBN I-VP O
11 437 439 8617710 to TO B-PP O
12 440 446 8617710 either CC O O
13 447 457 8617710 sertraline NN B-NP D020280
14 458 459 8617710 ( ( O O
15 459 461 8617710 12 CD B-NP O
16 462 470 8617710 subjects NNS I-NP O
17 470 471 8617710 ) ) O O
18 472 474 8617710 or CC O O
19 475 482 8617710 placebo NN B-NP O
20 483 484 8617710 ( ( O O
21 484 486 8617710 12 CD B-NP O
22 487 495 8617710 subjects NNS I-NP O
23 495 496 8617710 ) ) O O
24 496 497 8617710 ; : O O
25 498 501 8617710 the DT B-NP O
26 502 512 8617710 sertraline NN I-NP D020280
27 513 517 8617710 dose NN I-NP O
28 518 521 8617710 was VBD B-VP O
29 522 530 8617710 titrated VBN I-VP O
30 531 535 8617710 from IN B-PP O
31 536 538 8617710 50 CD B-NP O
32 539 541 8617710 to TO I-NP O
33 542 545 8617710 200 CD I-NP O
34 546 548 8617710 mg NN I-NP O
35 548 549 8617710 / SYM B-NP O
36 549 552 8617710 day NN I-NP O
37 553 557 8617710 from IN B-PP O
38 558 562 8617710 Days NNS B-NP O
39 563 564 8617710 9 CD B-NP O
40 565 567 8617710 to TO B-PP O
41 568 570 8617710 16 CD B-NP O
42 570 571 8617710 , , O O
43 572 575 8617710 and CC O O
44 576 584 8617710 remained VBD B-VP O
45 585 587 8617710 at IN B-PP O
46 588 591 8617710 200 CD B-NP O
47 592 594 8617710 mg NN I-NP O
48 594 595 8617710 / SYM B-NP O
49 595 598 8617710 day NN I-NP O
50 599 602 8617710 for IN B-PP O
51 603 606 8617710 the DT B-NP O
52 607 612 8617710 final JJ I-NP O
53 613 615 8617710 10 CD I-NP O
54 616 620 8617710 days NNS I-NP O
55 621 623 8617710 of IN B-PP O
56 624 627 8617710 the DT B-NP O
57 628 632 8617710 drug NN I-NP O
58 633 647 8617710 administration NN I-NP O
59 648 654 8617710 period NN I-NP O
60 654 655 8617710 . . O O

1 656 665 8617710 Cognitive JJ B-NP O
2 666 674 8617710 function NN I-NP O
3 675 682 8617710 testing NN I-NP O
4 683 686 8617710 was VBD B-VP O
5 687 696 8617710 performed VBN I-VP O
6 697 703 8617710 before IN B-PP O
7 704 710 8617710 dosing NN B-NP O
8 711 714 8617710 and CC O O
9 715 719 8617710 over IN B-PP O
10 720 721 8617710 a DT B-NP O
11 722 724 8617710 24 CD I-NP O
12 724 725 8617710 - HYPH I-NP O
13 725 729 8617710 hour NN I-NP O
14 730 736 8617710 period NN I-NP O
15 737 742 8617710 after IN B-PP O
16 743 749 8617710 dosing NN B-NP O
17 750 752 8617710 on IN B-PP O
18 753 757 8617710 Days NNS B-NP O
19 758 759 8617710 1 CD I-NP O
20 759 760 8617710 , , I-NP O
21 761 762 8617710 2 CD I-NP O
22 762 763 8617710 , , O O
23 764 767 8617710 and CC O O
24 768 770 8617710 25 CD B-NP O
25 770 771 8617710 . . O O

1 772 779 8617710 RESULTS NNS B-NP O
2 779 780 8617710 : : O O
3 781 791 8617710 Impairment NN B-NP D003072
4 792 794 8617710 of IN B-PP D003072
5 795 804 8617710 cognitive JJ B-NP D003072
6 805 813 8617710 function NN I-NP D003072
7 814 817 8617710 was VBD B-VP O
8 818 826 8617710 observed VBN I-VP O
9 827 828 8617710 6 CD B-NP O
10 829 831 8617710 to TO I-NP O
11 832 833 8617710 8 CD I-NP O
12 834 839 8617710 hours NNS I-NP O
13 840 845 8617710 after IN B-PP O
14 846 860 8617710 administration NN B-NP O
15 861 863 8617710 of IN B-PP O
16 864 875 8617710 haloperidol NN B-NP D006220
17 876 878 8617710 on IN B-PP O
18 879 882 8617710 Day NN B-NP O
19 883 884 8617710 2 CD I-NP O
20 885 888 8617710 but CC O O
21 889 892 8617710 was VBD B-VP O
22 893 896 8617710 not RB O O
23 897 904 8617710 evident JJ B-ADJP O
24 905 907 8617710 23 CD B-NP O
25 908 913 8617710 hours NNS I-NP O
26 914 919 8617710 after IN B-PP O
27 920 926 8617710 dosing NN B-NP O
28 926 927 8617710 . . O O

1 928 932 8617710 When WRB B-ADVP O
2 933 939 8617710 single JJ B-NP O
3 939 940 8617710 - HYPH I-NP O
4 940 944 8617710 dose NN I-NP O
5 945 956 8617710 haloperidol NN I-NP D006220
6 957 960 8617710 was VBD B-VP O
7 961 966 8617710 given VBN I-VP O
8 967 972 8617710 again RB B-ADVP O
9 973 975 8617710 25 CD B-NP O
10 976 980 8617710 days NNS I-NP O
11 981 986 8617710 later RB B-ADVP O
12 986 987 8617710 , , O O
13 988 995 8617710 greater JJR B-NP O
14 996 1006 8617710 impairment NN I-NP O
15 1007 1011 8617710 with IN B-PP O
16 1012 1019 8617710 earlier JJR B-NP O
17 1020 1025 8617710 onset NN I-NP O
18 1026 1029 8617710 was VBD B-VP O
19 1030 1035 8617710 noted VBN I-VP O
20 1036 1038 8617710 in IN B-PP O
21 1039 1046 8617710 several JJ B-NP O
22 1047 1052 8617710 tests NNS I-NP O
23 1053 1055 8617710 in IN B-PP O
24 1056 1060 8617710 both DT B-NP O
25 1061 1070 8617710 treatment NN I-NP O
26 1071 1077 8617710 groups NNS I-NP O
27 1077 1078 8617710 , , O O
28 1079 1089 8617710 suggesting VBG B-VP O
29 1090 1101 8617710 enhancement NN B-NP O
30 1102 1104 8617710 of IN B-PP O
31 1105 1109 8617710 this DT B-NP O
32 1110 1116 8617710 effect NN I-NP O
33 1116 1117 8617710 . . O O

1 1118 1123 8617710 There EX B-NP O
2 1124 1127 8617710 was VBD B-VP O
3 1128 1130 8617710 no DT B-NP O
4 1131 1141 8617710 indication NN I-NP O
5 1142 1146 8617710 that IN B-SBAR O
6 1147 1157 8617710 sertraline NN B-NP D020280
7 1158 1169 8617710 exacerbated VBD B-VP O
8 1170 1173 8617710 the DT B-NP O
9 1174 1184 8617710 impairment NN I-NP O
10 1185 1193 8617710 produced VBN B-VP O
11 1194 1196 8617710 by IN B-PP O
12 1197 1208 8617710 haloperidol NN B-NP D006220
13 1209 1214 8617710 since IN B-PP O
14 1215 1217 8617710 an DT B-NP O
15 1218 1228 8617710 equivalent JJ I-NP O
16 1229 1235 8617710 effect NN I-NP O
17 1236 1240 8617710 also RB B-ADVP O
18 1241 1249 8617710 occurred VBD B-VP O
19 1250 1252 8617710 in IN B-PP O
20 1253 1256 8617710 the DT B-NP O
21 1257 1264 8617710 placebo NN I-NP O
22 1265 1270 8617710 group NN I-NP O
23 1270 1271 8617710 . . O O

1 1272 1277 8617710 Three CD B-NP O
2 1278 1286 8617710 subjects NNS I-NP O
3 1287 1288 8617710 ( ( O O
4 1288 1289 8617710 2 CD B-NP O
5 1290 1292 8617710 on IN B-PP O
6 1293 1303 8617710 sertraline NN B-NP D020280
7 1304 1307 8617710 and CC O O
8 1308 1309 8617710 1 CD B-NP O
9 1310 1312 8617710 on IN B-PP O
10 1313 1320 8617710 placebo NN B-NP O
11 1320 1321 8617710 ) ) O O
12 1322 1330 8617710 withdrew VBD B-VP O
13 1331 1335 8617710 from IN B-PP O
14 1336 1339 8617710 the DT B-NP O
15 1340 1345 8617710 study NN I-NP O
16 1346 1353 8617710 because IN B-PP O
17 1354 1356 8617710 of IN I-PP O
18 1357 1361 8617710 side NN B-NP O
19 1362 1369 8617710 effects NNS I-NP O
20 1369 1370 8617710 . . O O

1 1371 1374 8617710 Ten CD B-NP O
2 1375 1383 8617710 subjects NNS I-NP O
3 1384 1386 8617710 in IN B-PP O
4 1387 1391 8617710 each DT B-NP O
5 1392 1397 8617710 group NN I-NP O
6 1398 1406 8617710 reported VBD B-VP O
7 1407 1411 8617710 side JJ B-NP O
8 1412 1419 8617710 effects NNS I-NP O
9 1420 1427 8617710 related VBN B-VP O
10 1428 1430 8617710 to TO B-PP O
11 1431 1440 8617710 treatment NN B-NP O
12 1440 1441 8617710 . . O O

1 1442 1445 8617710 The DT B-NP O
2 1446 1450 8617710 side NN I-NP O
3 1451 1457 8617710 effect NN I-NP O
4 1458 1466 8617710 profiles NNS I-NP O
5 1467 1469 8617710 of IN B-PP O
6 1470 1480 8617710 sertraline NN B-NP D020280
7 1481 1484 8617710 and CC B-PP O
8 1485 1487 8617710 of IN B-PP O
9 1488 1495 8617710 placebo NN B-NP O
10 1496 1500 8617710 were VBD B-VP O
11 1501 1508 8617710 similar JJ B-ADJP O
12 1508 1509 8617710 . . O O

1 1510 1520 8617710 CONCLUSION NN B-NP O
2 1520 1521 8617710 : : O O
3 1522 1533 8617710 Haloperidol NN B-NP D006220
4 1534 1542 8617710 produced VBD B-VP O
5 1543 1544 8617710 a DT B-NP O
6 1545 1550 8617710 clear JJ I-NP O
7 1551 1558 8617710 profile NN I-NP O
8 1559 1561 8617710 of IN B-PP O
9 1562 1571 8617710 cognitive JJ B-NP D003072
10 1572 1582 8617710 impairment NN I-NP D003072
11 1583 1587 8617710 that WDT B-NP O
12 1588 1591 8617710 was VBD B-VP O
13 1592 1595 8617710 not RB I-VP O
14 1596 1604 8617710 worsened VBN I-VP O
15 1605 1607 8617710 by IN B-PP O
16 1608 1619 8617710 concomitant JJ B-NP O
17 1620 1630 8617710 sertraline NN I-NP D020280
18 1631 1645 8617710 administration NN I-NP O
19 1645 1646 8617710 . . O O

1 0 0 2557556 -DOCSTART- -X- -X- O

1 0 11 2557556 Involvement NN B-NP O
2 12 14 2557556 of IN B-PP O
3 15 18 2557556 the DT B-NP O
4 19 21 2557556 mu SYM I-NP O
5 21 22 2557556 - HYPH I-NP O
6 22 28 2557556 opiate NN I-NP O
7 29 37 2557556 receptor NN I-NP O
8 38 40 2557556 in IN B-PP O
9 41 51 2557556 peripheral JJ B-NP O
10 52 61 2557556 analgesia NN I-NP D000699
11 61 62 2557556 . . O O
12 63 66 2557556 The DT B-NP O
13 67 78 2557556 intradermal JJ I-NP O
14 79 88 2557556 injection NN I-NP O
15 89 91 2557556 of IN B-PP O
16 92 94 2557556 mu NN B-NP O
17 95 96 2557556 ( ( O O
18 96 104 2557556 morphine NN B-NP D009020
19 104 105 2557556 , , O O
20 106 109 2557556 Tyr NN B-NP D020875
21 109 110 2557556 - HYPH B-NP D020875
22 110 111 2557556 D NN I-NP D020875
23 111 112 2557556 - HYPH B-NP D020875
24 112 115 2557556 Ala NN I-NP D020875
25 115 116 2557556 - HYPH B-NP D020875
26 116 119 2557556 Gly NN I-NP D020875
27 119 120 2557556 - HYPH B-NP D020875
28 120 123 2557556 NMe NN I-NP D020875
29 123 124 2557556 - HYPH B-NP D020875
30 124 127 2557556 Phe NN I-NP D020875
31 127 128 2557556 - HYPH B-NP D020875
32 128 131 2557556 Gly NN I-NP D020875
33 131 132 2557556 - HYPH B-NP D020875
34 132 134 2557556 ol NN I-NP D020875
35 135 138 2557556 and CC O O
36 139 151 2557556 morphiceptin NN B-NP C028889
37 151 152 2557556 ) ) O O
38 152 153 2557556 , , O O
39 154 159 2557556 kappa NN B-NP O
40 160 161 2557556 ( ( O O
41 161 166 2557556 trans AFX B-NP D019900
42 166 167 2557556 - HYPH B-NP D019900
43 167 170 2557556 3,4 CD I-NP D019900
44 170 171 2557556 - HYPH O D019900
45 171 179 2557556 dichloro AFX O D019900
46 179 180 2557556 - HYPH B-NP D019900
47 180 181 2557556 N NN I-NP D019900
48 181 182 2557556 - HYPH B-NP D019900
49 182 188 2557556 methyl NN I-NP D019900
50 188 189 2557556 - HYPH B-NP D019900
51 189 192 2557556 N[2 NN I-NP D019900
52 192 193 2557556 - HYPH B-NP D019900
53 193 195 2557556 (1 NN I-NP D019900
54 195 196 2557556 - HYPH I-NP D019900
55 196 209 2557556 pyrrolidinyl) NN I-NP D019900
56 210 236 2557556 cyclohexyl]benzeneactemide NN I-NP D019900
57 236 237 2557556 ) ) O O
58 238 241 2557556 and CC O O
59 242 247 2557556 delta SYM B-NP O
60 248 249 2557556 ( ( O O
61 249 251 2557556 [D NN B-NP D020881
62 251 252 2557556 - HYPH B-NP D020881
63 252 259 2557556 Pen2.5] NN I-NP D020881
64 259 260 2557556 - HYPH B-NP D020881
65 260 270 2557556 enkephalin NN I-NP D020881
66 271 274 2557556 and CC I-NP O
67 275 277 2557556 [D NN I-NP C034318
68 277 278 2557556 - HYPH B-NP C034318
69 278 283 2557556 Ser2] NN I-NP C034318
70 283 284 2557556 - HYPH B-NP C034318
71 284 299 2557556 [Leu]enkephalin NN I-NP C034318
72 299 300 2557556 - HYPH I-NP C034318
73 300 303 2557556 Thr NN I-NP C034318
74 303 304 2557556 ) ) I-NP O
75 305 314 2557556 selective JJ I-NP O
76 315 321 2557556 opioid JJ I-NP O
77 321 322 2557556 - HYPH I-NP O
78 322 330 2557556 agonists NNS I-NP O
79 330 331 2557556 , , O O
80 332 334 2557556 by IN B-PP O
81 335 345 2557556 themselves PRP B-NP O
82 345 346 2557556 , , O O
83 347 350 2557556 did VBD B-VP O
84 351 354 2557556 not RB I-VP O
85 355 368 2557556 significantly RB I-VP O
86 369 375 2557556 affect VB I-VP O
87 376 379 2557556 the DT B-NP O
88 380 390 2557556 mechanical JJ I-NP O
89 391 402 2557556 nociceptive JJ I-NP O
90 403 412 2557556 threshold NN I-NP O
91 413 415 2557556 in IN B-PP O
92 416 419 2557556 the DT B-NP O
93 420 427 2557556 hindpaw NN I-NP O
94 428 430 2557556 of IN B-PP O
95 431 434 2557556 the DT B-NP O
96 435 438 2557556 rat NN I-NP O
97 438 439 2557556 . . O O

1 440 451 2557556 Intradermal JJ B-NP O
2 452 461 2557556 injection NN I-NP O
3 462 464 2557556 of IN B-PP O
4 465 467 2557556 mu NN B-NP O
5 467 468 2557556 , , O O
6 469 472 2557556 but CC O O
7 473 476 2557556 not RB O O
8 477 482 2557556 delta SYM B-NP O
9 483 485 2557556 or CC O O
10 486 491 2557556 kappa SYM B-NP O
11 492 498 2557556 opioid JJ I-NP O
12 498 499 2557556 - HYPH I-NP O
13 499 507 2557556 agonists NNS I-NP O
14 507 508 2557556 , , O O
15 509 516 2557556 however RB B-ADVP O
16 516 517 2557556 , , O O
17 518 526 2557556 produced VBD B-VP O
18 527 531 2557556 dose NN B-NP O
19 531 532 2557556 - HYPH B-NP O
20 532 541 2557556 dependent JJ I-NP O
21 542 552 2557556 inhibition NN I-NP O
22 553 555 2557556 of IN B-PP O
23 556 569 2557556 prostaglandin NN B-NP D015232
24 570 572 2557556 E2 NN I-NP D015232
25 572 573 2557556 - HYPH B-NP O
26 573 580 2557556 induced VBN I-NP O
27 581 593 2557556 hyperalgesia NN I-NP D006930
28 593 594 2557556 . . O O

1 595 598 2557556 The DT B-NP O
2 599 608 2557556 analgesic JJ I-NP O
3 609 615 2557556 effect NN I-NP O
4 616 618 2557556 of IN B-PP O
5 619 622 2557556 the DT B-NP O
6 623 625 2557556 mu SYM I-NP O
7 625 626 2557556 - HYPH I-NP O
8 626 633 2557556 agonist NN I-NP O
9 634 642 2557556 morphine NN I-NP D009020
10 643 646 2557556 was VBD B-VP O
11 647 651 2557556 dose NN B-NP O
12 651 652 2557556 - HYPH O O
13 652 663 2557556 dependently RB B-VP O
14 664 675 2557556 antagonized VBN I-VP O
15 676 678 2557556 by IN B-PP O
16 679 687 2557556 naloxone NN B-NP D009270
17 688 691 2557556 and CC O O
18 692 701 2557556 prevented VBN B-VP O
19 702 704 2557556 by IN B-PP O
20 705 707 2557556 co AFX B-NP O
21 707 708 2557556 - HYPH I-NP O
22 708 717 2557556 injection NN I-NP O
23 718 720 2557556 of IN B-PP O
24 721 730 2557556 pertussis NN B-NP O
25 731 736 2557556 toxin NN I-NP O
26 736 737 2557556 . . O O

1 738 746 2557556 Morphine NN B-NP D009020
2 747 750 2557556 did VBD B-VP O
3 751 754 2557556 not RB O O
4 754 755 2557556 , , O O
5 756 763 2557556 however RB B-ADVP O
6 763 764 2557556 , , O O
7 765 770 2557556 alter VB B-VP O
8 771 774 2557556 the DT B-NP O
9 775 787 2557556 hyperalgesia NN I-NP D006930
10 788 795 2557556 induced VBN B-VP O
11 796 798 2557556 by IN B-PP O
12 799 800 2557556 8 CD B-NP D015124
13 800 801 2557556 - HYPH I-NP D015124
14 801 806 2557556 bromo NN I-NP D015124
15 807 813 2557556 cyclic JJ I-NP D015124
16 814 823 2557556 adenosine NN I-NP D015124
17 824 837 2557556 monophosphate NN I-NP D015124
18 837 838 2557556 . . O O

1 839 841 2557556 We PRP B-NP O
2 842 850 2557556 conclude VBP B-VP O
3 851 855 2557556 that IN B-SBAR O
4 856 859 2557556 the DT B-NP O
5 860 869 2557556 analgesic JJ I-NP O
6 870 876 2557556 action NN I-NP O
7 877 879 2557556 of IN B-PP O
8 880 887 2557556 opioids NNS B-NP O
9 888 890 2557556 on IN B-PP O
10 891 894 2557556 the DT B-NP O
11 895 905 2557556 peripheral JJ I-NP O
12 906 915 2557556 terminals NNS I-NP O
13 916 918 2557556 of IN B-PP O
14 919 926 2557556 primary JJ B-NP O
15 927 936 2557556 afferents NNS I-NP O
16 937 939 2557556 is VBZ B-VP O
17 940 943 2557556 via IN B-PP O
18 944 945 2557556 a DT B-NP O
19 946 953 2557556 binding VBG I-NP O
20 954 958 2557556 site NN I-NP O
21 959 963 2557556 with IN B-PP O
22 964 979 2557556 characteristics NNS B-NP O
23 980 982 2557556 of IN B-PP O
24 983 986 2557556 the DT B-NP O
25 987 989 2557556 mu SYM I-NP O
26 989 990 2557556 - HYPH I-NP O
27 990 996 2557556 opioid JJ I-NP O
28 997 1005 2557556 receptor NN I-NP O
29 1006 1009 2557556 and CC O O
30 1010 1014 2557556 that IN B-SBAR O
31 1015 1019 2557556 this DT B-NP O
32 1020 1026 2557556 action NN I-NP O
33 1027 1029 2557556 is VBZ B-VP O
34 1030 1038 2557556 mediated VBN I-VP O
35 1039 1041 2557556 by IN B-PP O
36 1042 1052 2557556 inhibition NN B-NP O
37 1053 1055 2557556 of IN B-PP O
38 1056 1059 2557556 the DT B-NP O
39 1060 1066 2557556 cyclic JJ I-NP D000242
40 1067 1076 2557556 adenosine NN I-NP D000242
41 1077 1090 2557556 monophosphate NN I-NP D000242
42 1091 1097 2557556 second JJ I-NP O
43 1098 1107 2557556 messenger NN I-NP O
44 1108 1114 2557556 system NN I-NP O
45 1114 1115 2557556 . . O O

1 0 0 8638876 -DOCSTART- -X- -X- O

1 0 11 8638876 Coexistence NN B-NP O
2 12 14 8638876 of IN B-PP O
3 15 23 8638876 cerebral JJ B-NP D012851
4 24 30 8638876 venous JJ I-NP D012851
5 31 36 8638876 sinus NN I-NP D012851
6 37 40 8638876 and CC O D012851
7 41 49 8638876 internal JJ B-NP D012851
8 50 57 8638876 carotid JJ I-NP D012851
9 58 64 8638876 artery NN I-NP D012851
10 65 75 8638876 thrombosis NN I-NP D012851
11 76 86 8638876 associated VBN B-VP O
12 87 91 8638876 with IN B-PP O
13 92 101 8638876 exogenous JJ B-NP O
14 102 105 8638876 sex NN I-NP O
15 106 114 8638876 hormones NNS I-NP O
16 114 115 8638876 . . O O

1 116 117 8638876 A DT B-NP O
2 118 122 8638876 case NN I-NP O
3 123 129 8638876 report NN I-NP O
4 129 130 8638876 . . O O
5 131 132 8638876 A DT B-NP O
6 133 138 8638876 forty JJ I-NP O
7 138 139 8638876 - HYPH I-NP O
8 139 142 8638876 six CD I-NP O
9 143 147 8638876 year NN I-NP O
10 147 148 8638876 - HYPH O O
11 148 151 8638876 old JJ B-NP O
12 152 165 8638876 premenopausal JJ I-NP O
13 166 171 8638876 woman NN I-NP O
14 172 181 8638876 developed VBD B-VP O
15 182 190 8638876 headache NN B-NP D006261
16 190 191 8638876 , , I-NP O
17 192 198 8638876 nausea NN I-NP D009325
18 199 202 8638876 and CC I-NP O
19 203 211 8638876 vomiting NN I-NP D014839
20 211 212 8638876 , , O O
21 213 217 8638876 left VBD B-VP O
22 218 229 8638876 hemiparesis NN B-NP D010291
23 230 233 8638876 and CC I-NP O
24 234 241 8638876 seizure NN I-NP D012640
25 242 245 8638876 two CD B-NP O
26 246 250 8638876 days NNS I-NP O
27 251 256 8638876 after IN B-PP O
28 257 267 8638876 parenteral JJ B-NP O
29 268 271 8638876 use NN I-NP O
30 272 274 8638876 of IN B-PP O
31 275 287 8638876 progesterone NN B-NP D011374
32 288 291 8638876 and CC I-NP O
33 292 301 8638876 estradiol NN I-NP D004958
34 301 302 8638876 . . O O

1 303 311 8638876 Diabetes NN B-NP D003920
2 312 320 8638876 mellitus NN I-NP D003920
3 321 322 8638876 ( ( O O
4 322 324 8638876 DM NN B-NP D003920
5 324 325 8638876 ) ) O O
6 326 329 8638876 was VBD B-VP O
7 330 335 8638876 found VBN I-VP O
8 336 342 8638876 during IN B-PP O
9 343 352 8638876 admission NN B-NP O
10 352 353 8638876 . . O O

1 354 362 8638876 Computed VBN B-NP O
2 363 373 8638876 tomography NN I-NP O
3 374 380 8638876 showed VBD B-VP O
4 381 382 8638876 a DT B-NP O
5 383 394 8638876 hemorrhagic JJ I-NP D002543
6 395 402 8638876 infarct NN I-NP D002543
7 403 405 8638876 in IN B-PP O
8 406 409 8638876 the DT B-NP O
9 410 415 8638876 right JJ I-NP O
10 416 423 8638876 frontal JJ I-NP O
11 424 428 8638876 lobe NN I-NP O
12 429 432 8638876 and CC O O
13 433 442 8638876 increased VBN B-NP O
14 443 450 8638876 density NN I-NP O
15 451 453 8638876 in IN B-PP O
16 454 457 8638876 the DT B-NP O
17 458 466 8638876 superior JJ I-NP O
18 467 475 8638876 sagittal JJ I-NP O
19 476 481 8638876 sinus NN I-NP O
20 482 483 8638876 ( ( O O
21 483 486 8638876 SSS NN B-NP O
22 486 487 8638876 ) ) O O
23 487 488 8638876 . . O O

1 489 493 8638876 Left VBN B-NP O
2 494 501 8638876 carotid NN I-NP O
3 502 513 8638876 angiography NN I-NP O
4 514 519 8638876 found VBD B-VP O
5 520 529 8638876 occlusion NN B-NP D001157
6 530 532 8638876 of IN B-PP D001157
7 533 536 8638876 the DT B-NP D001157
8 537 541 8638876 left JJ I-NP D001157
9 542 550 8638876 internal JJ I-NP D001157
10 551 558 8638876 carotid NN I-NP D001157
11 559 565 8638876 artery NN I-NP D001157
12 566 567 8638876 ( ( O O
13 567 570 8638876 ICA NN B-NP O
14 570 571 8638876 ) ) O O
15 571 572 8638876 . . O O

1 573 578 8638876 Right RB B-ADVP O
2 579 586 8638876 carotid NN B-NP O
3 587 597 8638876 angiograms NNS I-NP O
4 598 604 8638876 failed VBD B-VP O
5 605 607 8638876 to TO I-VP O
6 608 612 8638876 show VB I-VP O
7 613 616 8638876 the DT B-NP O
8 617 620 8638876 SSS NN I-NP O
9 621 624 8638876 and CC O O
10 625 633 8638876 inferior JJ B-NP O
11 634 642 8638876 sagittal JJ I-NP O
12 643 648 8638876 sinus NN I-NP O
13 648 649 8638876 , , O O
14 650 660 8638876 suggestive JJ B-ADJP O
15 661 663 8638876 of IN B-PP O
16 664 670 8638876 venous JJ B-NP D012851
17 671 676 8638876 sinus NN I-NP D012851
18 677 687 8638876 thrombosis NN I-NP D012851
19 687 688 8638876 . . O O

1 689 700 8638876 Coexistence NN B-NP O
2 701 703 8638876 of IN B-PP O
3 704 707 8638876 the DT B-NP O
4 708 716 8638876 cerebral JJ I-NP D002544
5 717 723 8638876 artery NN I-NP D002544
6 724 727 8638876 and CC O D002544
7 728 731 8638876 the DT B-NP D002544
8 732 738 8638876 venous JJ I-NP D002544
9 739 744 8638876 sinus NN I-NP D002544
10 745 754 8638876 occlusion NN I-NP D002544
11 755 758 8638876 has VBZ B-VP O
12 759 763 8638876 been VBN I-VP O
13 764 773 8638876 described VBN I-VP O
14 774 786 8638876 infrequently RB B-ADVP O
15 786 787 8638876 . . O O

1 788 790 8638876 In IN B-PP O
2 791 795 8638876 this DT B-NP O
3 796 800 8638876 case NN I-NP O
4 800 801 8638876 , , O O
5 802 805 8638876 the DT B-NP O
6 806 813 8638876 authors NNS I-NP O
7 814 823 8638876 postulate VBP B-VP O
8 824 828 8638876 that IN B-SBAR O
9 829 832 8638876 the DT B-NP O
10 833 836 8638876 use NN I-NP O
11 837 839 8638876 of IN B-PP O
12 840 849 8638876 estradiol NN B-NP D004958
13 850 853 8638876 and CC I-NP O
14 854 866 8638876 progesterone NN I-NP D011374
15 867 870 8638876 and CC O O
16 871 874 8638876 the DT B-NP O
17 875 885 8638876 underlying VBG I-NP O
18 886 888 8638876 DM NN I-NP D003920
19 889 898 8638876 increased VBD B-VP O
20 899 907 8638876 vascular JJ B-NP O
21 908 923 8638876 thrombogenicity NN I-NP O
22 923 924 8638876 , , O O
23 925 930 8638876 which WDT B-NP O
24 931 939 8638876 provided VBD B-VP O
25 940 941 8638876 a DT B-NP O
26 942 948 8638876 common JJ I-NP O
27 949 960 8638876 denominator NN I-NP O
28 961 964 8638876 for IN B-PP O
29 965 975 8638876 thrombosis NN B-NP D002341
30 976 978 8638876 of IN B-PP D002341
31 979 983 8638876 both CC O D002341
32 984 987 8638876 the DT B-NP D002341
33 988 991 8638876 ICA NN I-NP D002341
34 992 995 8638876 and CC O D002341
35 996 999 8638876 the DT B-NP D002341
36 1000 1006 8638876 venous JJ I-NP D002341
37 1007 1012 8638876 sinus NN I-NP D002341
38 1012 1013 8638876 . . O O

1 0 0 9952311 -DOCSTART- -X- -X- O

1 0 10 9952311 Structural JJ B-NP D028361
2 11 14 9952311 and CC I-NP D028361
3 15 25 9952311 functional JJ I-NP D028361
4 26 36 9952311 impairment NN I-NP D028361
5 37 39 9952311 of IN B-PP D028361
6 40 52 9952311 mitochondria NNS B-NP D028361
7 53 55 9952311 in IN B-PP O
8 56 66 9952311 adriamycin NN B-NP D004317
9 66 67 9952311 - HYPH B-NP O
10 67 74 9952311 induced VBN I-NP O
11 75 89 9952311 cardiomyopathy NN I-NP D009202
12 90 92 9952311 in IN B-PP O
13 93 97 9952311 mice NNS B-NP O
14 97 98 9952311 : : O O
15 99 110 9952311 suppression NN B-NP O
16 111 113 9952311 of IN B-PP O
17 114 124 9952311 cytochrome NN B-NP O
18 125 126 9952311 c NN I-NP O
19 127 134 9952311 oxidase NN I-NP O
20 135 137 9952311 II CD I-NP O
21 138 142 9952311 gene NN I-NP O
22 143 153 9952311 expression NN I-NP O
23 153 154 9952311 . . O O
24 155 158 9952311 The DT B-NP O
25 159 162 9952311 use NN I-NP O
26 163 165 9952311 of IN B-PP O
27 166 176 9952311 adriamycin NN B-NP D004317
28 177 178 9952311 ( ( O O
29 178 181 9952311 ADR NN B-NP D004317
30 181 182 9952311 ) ) O O
31 183 185 9952311 in IN B-PP O
32 186 192 9952311 cancer NN B-NP D009369
33 193 205 9952311 chemotherapy NN I-NP O
34 206 209 9952311 has VBZ B-VP O
35 210 214 9952311 been VBN I-VP O
36 215 222 9952311 limited VBN I-VP O
37 223 226 9952311 due JJ B-ADJP O
38 227 229 9952311 to TO B-PP O
39 230 233 9952311 its PRP$ B-NP O
40 234 244 9952311 cumulative JJ I-NP O
41 245 259 9952311 cardiovascular JJ I-NP D002318
42 260 268 9952311 toxicity NN I-NP D002318
43 268 269 9952311 . . O O

1 270 277 9952311 Earlier JJR B-NP O
2 278 290 9952311 observations NNS I-NP O
3 291 295 9952311 that IN B-SBAR O
4 296 299 9952311 ADR NN B-NP D004317
5 300 309 9952311 interacts VBZ B-VP O
6 310 314 9952311 with IN B-PP O
7 315 328 9952311 mitochondrial JJ B-NP O
8 329 339 9952311 cytochrome NN I-NP O
9 340 341 9952311 c NN I-NP O
10 342 349 9952311 oxidase NN I-NP O
11 350 351 9952311 ( ( O O
12 351 354 9952311 COX NN B-NP O
13 354 355 9952311 ) ) O O
14 356 359 9952311 and CC O O
15 360 370 9952311 suppresses VBZ B-VP O
16 371 374 9952311 its PRP$ B-NP O
17 375 381 9952311 enzyme NN I-NP O
18 382 390 9952311 activity NN I-NP O
19 391 394 9952311 led VBD B-VP O
20 395 397 9952311 us PRP B-NP O
21 398 400 9952311 to TO B-VP O
22 401 412 9952311 investigate VB I-VP O
23 413 418 9952311 ADR's NNS B-NP D004317
24 419 425 9952311 action NN I-NP O
25 426 428 9952311 on IN B-PP O
26 429 432 9952311 the DT B-NP O
27 433 447 9952311 cardiovascular JJ I-NP O
28 448 457 9952311 functions NNS I-NP O
29 458 461 9952311 and CC O O
30 462 467 9952311 heart NN B-NP O
31 468 481 9952311 mitochondrial JJ I-NP O
32 482 492 9952311 morphology NN I-NP O
33 493 495 9952311 in IN B-PP O
34 496 500 9952311 Balb NN B-NP O
35 500 501 9952311 - HYPH B-NP O
36 501 502 9952311 c NN I-NP O
37 503 507 9952311 mice NNS I-NP O
38 508 511 9952311 i.p JJ B-ADJP O
39 511 512 9952311 . . O O

1 513 520 9952311 treated VBN B-VP O
2 521 525 9952311 with IN B-PP O
3 526 529 9952311 ADR NN B-NP D004317
4 530 533 9952311 for IN B-PP O
5 534 541 9952311 several JJ B-NP O
6 542 547 9952311 weeks NNS I-NP O
7 547 548 9952311 . . O O

1 549 551 9952311 At IN B-PP O
2 552 559 9952311 various JJ B-NP O
3 560 565 9952311 times NNS I-NP O
4 566 572 9952311 during IN B-PP O
5 573 582 9952311 treatment NN B-NP O
6 582 583 9952311 , , O O
7 584 587 9952311 the DT B-NP O
8 588 595 9952311 animals NNS I-NP O
9 596 600 9952311 were VBD B-VP O
10 601 609 9952311 assessed VBN I-VP O
11 610 613 9952311 for IN B-PP O
12 614 628 9952311 cardiovascular JJ B-NP O
13 629 638 9952311 functions NNS I-NP O
14 639 641 9952311 by IN B-PP O
15 642 661 9952311 electrocardiography NN B-NP O
16 662 665 9952311 and CC B-PP O
17 666 669 9952311 for IN B-PP O
18 670 675 9952311 heart NN B-NP O
19 676 682 9952311 tissue NN I-NP O
20 683 689 9952311 damage NN I-NP O
21 690 692 9952311 by IN B-PP O
22 693 701 9952311 electron NN B-NP O
23 702 712 9952311 microscopy NN I-NP O
24 712 713 9952311 . . O O

1 714 716 9952311 In IN B-PP O
2 717 725 9952311 parallel JJ B-NP O
3 725 726 9952311 , , I-NP O
4 727 732 9952311 total JJ I-NP O
5 733 736 9952311 RNA NN I-NP O
6 737 740 9952311 was VBD B-VP O
7 741 750 9952311 extracted VBN I-VP O
8 751 755 9952311 from IN B-PP O
9 756 763 9952311 samples NNS B-NP O
10 764 766 9952311 of IN B-PP O
11 767 776 9952311 dissected VBN B-NP O
12 777 782 9952311 heart NN I-NP O
13 783 786 9952311 and CC O O
14 787 795 9952311 analyzed VBN B-VP O
15 796 798 9952311 by IN B-PP O
16 799 807 9952311 Northern NN B-NP O
17 808 812 9952311 blot NN I-NP O
18 813 826 9952311 hybridization NN I-NP O
19 827 829 9952311 to TO B-VP O
20 830 839 9952311 determine VB I-VP O
21 840 843 9952311 the DT B-NP O
22 844 850 9952311 steady JJ I-NP O
23 850 851 9952311 - HYPH I-NP O
24 851 856 9952311 state NN I-NP O
25 857 862 9952311 level NN I-NP O
26 863 865 9952311 of IN B-PP O
27 866 871 9952311 three CD B-NP O
28 872 875 9952311 RNA NN I-NP O
29 876 887 9952311 transcripts NNS I-NP O
30 888 895 9952311 encoded VBN B-VP O
31 896 898 9952311 by IN B-PP O
32 899 902 9952311 the DT B-NP O
33 903 908 9952311 COXII NN I-NP O
34 908 909 9952311 , , O O
35 910 916 9952311 COXIII NN B-NP O
36 916 917 9952311 , , O O
37 918 921 9952311 and CC O O
38 922 927 9952311 COXIV NN B-NP O
39 928 933 9952311 genes NNS I-NP O
40 933 934 9952311 . . O O

1 935 944 9952311 Similarly RB B-ADVP O
2 944 945 9952311 , , O O
3 946 953 9952311 samples NNS B-NP O
4 954 962 9952311 obtained VBN B-VP O
5 963 967 9952311 from IN B-PP O
6 968 971 9952311 the DT B-NP O
7 972 977 9952311 liver NN I-NP O
8 978 980 9952311 of IN B-PP O
9 981 984 9952311 the DT B-NP O
10 985 989 9952311 same JJ I-NP O
11 990 997 9952311 animals NNS I-NP O
12 998 1002 9952311 were VBD B-VP O
13 1003 1011 9952311 analyzed VBN I-VP O
14 1012 1015 9952311 for IN B-PP O
15 1016 1027 9952311 comparative JJ B-NP O
16 1028 1035 9952311 studies NNS I-NP O
17 1035 1036 9952311 . . O O

1 1037 1040 9952311 Our PRP$ B-NP O
2 1041 1048 9952311 results NNS I-NP O
3 1049 1058 9952311 indicated VBD B-VP O
4 1059 1063 9952311 that IN B-SBAR O
5 1064 1065 9952311 1 LS B-LST O
6 1065 1066 9952311 ) ) O O
7 1067 1076 9952311 treatment NN B-NP O
8 1077 1079 9952311 of IN B-PP O
9 1080 1084 9952311 mice NNS B-NP O
10 1085 1089 9952311 with IN B-PP O
11 1090 1093 9952311 ADR NN B-NP D004317
12 1094 1100 9952311 caused VBD B-VP O
13 1101 1115 9952311 cardiovascular JJ B-NP D001145
14 1116 1127 9952311 arrhythmias NNS I-NP D001145
15 1128 1141 9952311 characterized VBN B-VP O
16 1142 1144 9952311 by IN B-PP O
17 1145 1156 9952311 bradycardia NN B-NP D001919
18 1156 1157 9952311 , , O O
19 1158 1167 9952311 extension NN B-NP O
20 1168 1170 9952311 of IN B-PP O
21 1171 1182 9952311 ventricular JJ B-NP O
22 1183 1197 9952311 depolarization NN I-NP O
23 1198 1202 9952311 time NN I-NP O
24 1203 1204 9952311 ( ( O O
25 1204 1208 9952311 tQRS NN B-NP O
26 1208 1209 9952311 ) ) O O
27 1209 1210 9952311 , , O O
28 1211 1214 9952311 and CC O O
29 1215 1222 9952311 failure NN B-NP O
30 1223 1225 9952311 of IN B-PP O
31 1226 1229 9952311 QRS NN B-NP O
32 1230 1232 9952311 at IN B-PP O
33 1233 1237 9952311 high JJ B-NP O
34 1238 1252 9952311 concentrations NNS I-NP O
35 1253 1254 9952311 ( ( O O
36 1254 1256 9952311 10 CD B-NP O
37 1256 1257 9952311 - HYPH I-NP O
38 1257 1259 9952311 14 CD I-NP O
39 1260 1262 9952311 mg NN I-NP O
40 1262 1263 9952311 / SYM I-NP O
41 1263 1265 9952311 kg NN I-NP O
42 1266 1270 9952311 body NN I-NP O
43 1271 1277 9952311 weight NN I-NP O
44 1278 1288 9952311 cumulative JJ I-NP O
45 1289 1293 9952311 dose NN I-NP O
46 1293 1294 9952311 ) ) O O
47 1294 1295 9952311 ; : O O
48 1296 1297 9952311 2 LS B-LST O
49 1297 1298 9952311 ) ) O O
50 1299 1302 9952311 the DT B-NP O
51 1303 1308 9952311 heart NN I-NP O
52 1309 1321 9952311 mitochondria NNS I-NP O
53 1322 1331 9952311 underwent VBD B-VP O
54 1332 1340 9952311 swelling NN B-NP D004487
55 1340 1341 9952311 , , O O
56 1342 1348 9952311 fusion NN B-NP O
57 1348 1349 9952311 , , O O
58 1350 1361 9952311 dissolution NN B-NP O
59 1361 1362 9952311 , , O O
60 1363 1366 9952311 and CC O O
61 1366 1367 9952311 / SYM B-NP O
62 1367 1369 9952311 or CC O O
63 1370 1380 9952311 disruption NN B-NP O
64 1381 1383 9952311 of IN B-PP O
65 1384 1397 9952311 mitochondrial JJ B-NP O
66 1398 1405 9952311 cristae NNS I-NP O
67 1406 1411 9952311 after IN B-PP O
68 1412 1419 9952311 several JJ B-NP O
69 1420 1425 9952311 weeks NNS I-NP O
70 1426 1428 9952311 of IN B-PP O
71 1429 1438 9952311 treatment NN B-NP O
72 1438 1439 9952311 . . O O

1 1440 1444 9952311 Such JJ B-NP O
2 1445 1458 9952311 abnormalities NNS I-NP O
3 1459 1463 9952311 were VBD B-VP O
4 1464 1467 9952311 not RB I-VP O
5 1468 1476 9952311 observed VBN I-VP O
6 1477 1479 9952311 in IN B-PP O
7 1480 1483 9952311 the DT B-NP O
8 1484 1496 9952311 mitochondria NNS I-NP O
9 1497 1499 9952311 of IN B-PP O
10 1500 1505 9952311 liver NN B-NP O
11 1506 1512 9952311 tissue NN I-NP O
12 1512 1513 9952311 ; : O O
13 1514 1517 9952311 and CC O O
14 1518 1519 9952311 3 LS B-LST O
15 1519 1520 9952311 ) ) O O
16 1521 1526 9952311 among IN B-PP O
17 1527 1530 9952311 the DT B-NP O
18 1531 1536 9952311 three CD I-NP O
19 1537 1542 9952311 genes NNS I-NP O
20 1543 1545 9952311 of IN B-PP O
21 1546 1549 9952311 COX NN B-NP O
22 1550 1556 9952311 enzyme NN I-NP O
23 1557 1565 9952311 examined VBN B-VP O
24 1565 1566 9952311 , , O O
25 1567 1571 9952311 only RB B-NP O
26 1572 1577 9952311 COXII NN I-NP O
27 1578 1582 9952311 gene NN I-NP O
28 1583 1593 9952311 expression NN I-NP O
29 1594 1597 9952311 was VBD B-VP O
30 1598 1608 9952311 suppressed VBN I-VP O
31 1609 1611 9952311 by IN B-PP O
32 1612 1615 9952311 ADR NN B-NP D004317
33 1616 1625 9952311 treatment NN I-NP O
34 1625 1626 9952311 , , O O
35 1627 1633 9952311 mainly RB B-ADVP O
36 1634 1639 9952311 after IN B-PP O
37 1640 1641 9952311 8 CD B-NP O
38 1642 1647 9952311 weeks NNS I-NP O
39 1648 1650 9952311 in IN B-PP O
40 1651 1655 9952311 both CC O O
41 1656 1661 9952311 heart NN B-NP O
42 1662 1665 9952311 and CC I-NP O
43 1666 1671 9952311 liver NN I-NP O
44 1671 1672 9952311 . . O O

1 1673 1680 9952311 Knowing VBG B-VP O
2 1681 1685 9952311 that IN B-SBAR O
3 1686 1691 9952311 heart NN B-NP O
4 1692 1704 9952311 mitochondria NNS I-NP O
5 1705 1714 9952311 represent VBP B-VP O
6 1715 1721 9952311 almost RB B-NP O
7 1722 1725 9952311 40% CD I-NP O
8 1726 1728 9952311 of IN B-PP O
9 1729 1734 9952311 heart NN B-NP O
10 1735 1741 9952311 muscle NN I-NP O
11 1742 1744 9952311 by IN B-PP O
12 1745 1751 9952311 weight NN B-NP O
13 1751 1752 9952311 , , O O
14 1753 1755 9952311 we PRP B-NP O
15 1756 1764 9952311 conclude VBP B-VP O
16 1765 1769 9952311 that IN B-SBAR O
17 1770 1773 9952311 the DT B-NP O
18 1774 1787 9952311 deteriorating VBG I-NP O
19 1788 1795 9952311 effects NNS I-NP O
20 1796 1798 9952311 of IN B-PP O
21 1799 1802 9952311 ADR NN B-NP D004317
22 1803 1805 9952311 on IN B-PP O
23 1806 1820 9952311 cardiovascular JJ B-NP O
24 1821 1829 9952311 function NN I-NP O
25 1830 1837 9952311 involve VBP B-VP O
26 1838 1851 9952311 mitochondrial JJ B-NP D028361
27 1852 1862 9952311 structural JJ I-NP D028361
28 1863 1866 9952311 and CC I-NP D028361
29 1867 1877 9952311 functional JJ I-NP D028361
30 1878 1888 9952311 impairment NN I-NP D028361
31 1888 1889 9952311 . . O O

1 0 0 11858397 -DOCSTART- -X- -X- O

1 0 7 11858397 Torsade FW B-NP D016171
2 8 10 11858397 de FW I-NP D016171
3 11 18 11858397 pointes FW I-NP D016171
4 19 26 11858397 induced VBN B-VP O
5 27 29 11858397 by IN B-PP O
6 30 44 11858397 metoclopramide NN B-NP D008787
7 45 47 11858397 in IN B-PP O
8 48 50 11858397 an DT B-NP O
9 51 58 11858397 elderly JJ I-NP O
10 59 64 11858397 woman NN I-NP O
11 65 69 11858397 with IN B-PP O
12 70 81 11858397 preexisting VBG B-VP O
13 82 90 11858397 complete JJ B-NP O
14 91 95 11858397 left JJ I-NP D002037
15 96 102 11858397 bundle NN I-NP D002037
16 103 109 11858397 branch NN I-NP D002037
17 110 115 11858397 block NN I-NP D002037
18 115 116 11858397 . . O O
19 117 122 11858397 There EX B-NP O
20 123 125 11858397 is VBZ B-VP O
21 126 127 11858397 a DT B-NP O
22 128 135 11858397 growing VBG I-NP O
23 136 140 11858397 list NN I-NP O
24 141 143 11858397 of IN B-PP O
25 144 149 11858397 drugs NNS B-NP O
26 150 160 11858397 implicated VBN B-VP O
27 161 163 11858397 in IN B-PP O
28 164 172 11858397 acquired VBN B-NP O
29 173 177 11858397 long JJ I-NP D008133
30 178 180 11858397 QT NN I-NP D008133
31 181 189 11858397 syndrome NN I-NP D008133
32 190 193 11858397 and CC O O
33 194 201 11858397 torsade FW B-NP D016171
34 202 204 11858397 de FW I-NP D016171
35 205 212 11858397 pointes FW I-NP D016171
36 212 213 11858397 . . O O

1 214 221 11858397 However RB B-ADVP O
2 221 222 11858397 , , O O
3 223 226 11858397 the DT B-NP O
4 227 239 11858397 torsadogenic JJ I-NP O
5 240 249 11858397 potential NN I-NP O
6 250 252 11858397 of IN B-PP O
7 253 267 11858397 metoclopramide NN B-NP D008787
8 267 268 11858397 , , O O
9 269 270 11858397 a DT B-NP O
10 271 279 11858397 commonly RB I-NP O
11 280 284 11858397 used VBN I-NP O
12 285 295 11858397 antiemetic JJ I-NP O
13 296 299 11858397 and CC I-NP O
14 300 310 11858397 prokinetic JJ I-NP O
15 311 315 11858397 drug NN I-NP O
16 315 316 11858397 , , O O
17 317 320 11858397 has VBZ B-VP O
18 321 324 11858397 not RB I-VP O
19 325 329 11858397 been VBN I-VP O
20 330 338 11858397 reported VBN I-VP O
21 339 341 11858397 in IN B-PP O
22 342 345 11858397 the DT B-NP O
23 346 356 11858397 literature NN I-NP O
24 356 357 11858397 , , O O
25 358 365 11858397 despite IN B-PP O
26 366 369 11858397 its PRP$ B-NP O
27 370 378 11858397 chemical JJ I-NP O
28 379 389 11858397 similarity NN I-NP O
29 390 392 11858397 to TO B-PP O
30 393 405 11858397 procainamide NN B-NP D011342
31 405 406 11858397 . . O O

1 407 409 11858397 We PRP B-NP O
2 410 416 11858397 report VBP B-VP O
3 417 419 11858397 on IN B-PP O
4 420 421 11858397 a DT B-NP O
5 422 424 11858397 92 CD I-NP O
6 424 425 11858397 - HYPH I-NP O
7 425 429 11858397 year NN I-NP O
8 429 430 11858397 - HYPH O O
9 430 433 11858397 old JJ B-NP O
10 434 439 11858397 woman NN I-NP O
11 440 444 11858397 with IN B-PP O
12 445 456 11858397 preexisting VBG B-VP O
13 457 465 11858397 complete JJ B-NP O
14 466 470 11858397 left JJ I-NP D002037
15 471 477 11858397 bundle NN I-NP D002037
16 478 484 11858397 branch NN I-NP D002037
17 485 490 11858397 block NN I-NP D002037
18 491 494 11858397 who WP B-NP O
19 495 504 11858397 developed VBD B-VP O
20 505 512 11858397 torsade FW B-NP D016171
21 513 515 11858397 de FW I-NP D016171
22 516 523 11858397 pointes FW I-NP D016171
23 524 529 11858397 after IN B-PP O
24 530 541 11858397 intravenous JJ B-NP O
25 542 545 11858397 and CC I-NP O
26 546 550 11858397 oral JJ I-NP O
27 551 565 11858397 administration NN I-NP O
28 566 568 11858397 of IN B-PP O
29 569 583 11858397 metoclopramide NN B-NP D008787
30 583 584 11858397 . . O O

1 585 589 11858397 This DT B-NP O
2 590 597 11858397 patient NN I-NP O
3 598 602 11858397 also RB B-ADVP O
4 603 612 11858397 developed VBD B-VP O
5 613 620 11858397 torsade FW B-NP D016171
6 621 623 11858397 de FW I-NP D016171
7 624 631 11858397 pointes FW I-NP D016171
8 632 636 11858397 when WRB B-ADVP O
9 637 646 11858397 cisapride NN B-NP D020117
10 647 650 11858397 and CC I-NP O
11 651 663 11858397 erythromycin NN I-NP D004917
12 664 668 11858397 were VBD B-VP O
13 669 674 11858397 given VBN I-VP O
14 675 689 11858397 simultaneously RB B-ADVP O
15 689 690 11858397 . . O O

1 691 696 11858397 These DT B-NP O
2 697 700 11858397 two CD I-NP O
3 701 709 11858397 episodes NNS I-NP O
4 710 714 11858397 were VBD B-VP O
5 715 725 11858397 suppressed VBN I-VP O
6 726 738 11858397 successfully RB B-ADVP O
7 739 744 11858397 after IN B-PP O
8 745 758 11858397 discontinuing VBG B-VP O
9 759 762 11858397 the DT B-NP O
10 763 772 11858397 offending VBG I-NP O
11 773 778 11858397 drugs NNS I-NP O
12 779 782 11858397 and CC O O
13 783 796 11858397 administering VBG B-VP O
14 797 802 11858397 class NN B-NP O
15 803 805 11858397 IB NN I-NP O
16 806 811 11858397 drugs NNS I-NP O
17 811 812 11858397 . . O O

1 813 817 11858397 This DT B-NP O
2 818 820 11858397 is VBZ B-VP O
3 821 824 11858397 the DT B-NP O
4 825 830 11858397 first JJ I-NP O
5 831 844 11858397 documentation NN I-NP O
6 845 849 11858397 that IN B-NP O
7 850 864 11858397 metoclopramide NN B-NP D008787
8 865 873 11858397 provokes NNS I-NP O
9 874 881 11858397 torsade FW B-NP D016171
10 882 884 11858397 de FW I-NP D016171
11 885 892 11858397 pointes FW I-NP D016171
12 893 903 11858397 clinically RB B-ADVP O
13 903 904 11858397 . . O O

1 905 919 11858397 Metoclopramide NN B-NP D008787
2 920 926 11858397 should MD B-VP O
3 927 929 11858397 be VB I-VP O
4 930 934 11858397 used VBN I-VP O
5 935 945 11858397 cautiously RB B-ADVP O
6 946 948 11858397 in IN B-PP O
7 949 957 11858397 patients NNS B-NP O
8 958 962 11858397 with IN B-PP O
9 963 964 11858397 a DT B-NP O
10 965 969 11858397 risk NN I-NP O
11 970 972 11858397 of IN B-PP O
12 973 980 11858397 torsade FW B-NP D016171
13 981 983 11858397 de FW I-NP D016171
14 984 991 11858397 pointes FW I-NP D016171
15 991 992 11858397 . . O O

1 0 0 14745746 -DOCSTART- -X- -X- O

1 0 4 14745746 Does VBZ O O
2 5 12 14745746 hormone NN B-NP O
3 13 20 14745746 therapy NN I-NP O
4 21 24 14745746 for IN B-PP O
5 25 28 14745746 the DT B-NP O
6 29 38 14745746 treatment NN I-NP O
7 39 41 14745746 of IN B-PP O
8 42 48 14745746 breast NN B-NP D001943
9 49 55 14745746 cancer NN I-NP D001943
10 56 60 14745746 have VBP B-VP O
11 61 62 14745746 a DT B-NP O
12 63 74 14745746 detrimental JJ I-NP D008569
13 75 81 14745746 effect NN I-NP D008569
14 82 84 14745746 on IN B-PP D008569
15 85 91 14745746 memory NN B-NP D008569
16 92 95 14745746 and CC I-NP D008569
17 96 105 14745746 cognition NN I-NP D008569
18 105 106 14745746 ? . O O
19 107 108 14745746 A DT B-NP O
20 109 114 14745746 pilot JJ I-NP O
21 115 120 14745746 study NN I-NP O
22 120 121 14745746 . . O O
23 122 126 14745746 This DT B-NP O
24 127 132 14745746 pilot JJ I-NP O
25 133 138 14745746 study NN I-NP O
26 139 147 14745746 examines VBZ B-VP O
27 148 155 14745746 whether IN B-SBAR O
28 156 163 14745746 hormone NN B-NP O
29 164 171 14745746 therapy NN I-NP O
30 172 175 14745746 for IN B-PP O
31 176 182 14745746 breast NN B-NP D001943
32 183 189 14745746 cancer NN I-NP D001943
33 190 197 14745746 affects VBZ B-VP O
34 198 207 14745746 cognition NN B-NP O
35 207 208 14745746 . . O O

1 209 217 14745746 Patients NNS B-NP O
2 218 231 14745746 participating VBG B-VP O
3 232 234 14745746 in IN B-PP O
4 235 236 14745746 a DT B-NP O
5 237 247 14745746 randomised VBN I-NP O
6 248 253 14745746 trial NN I-NP O
7 254 256 14745746 of IN B-PP O
8 257 268 14745746 anastrozole NN B-NP C090450
9 268 269 14745746 , , O O
10 270 279 14745746 tamoxifen NN B-NP D013629
11 280 285 14745746 alone RB B-ADVP O
12 286 288 14745746 or CC O O
13 289 297 14745746 combined VBN B-VP O
14 298 299 14745746 ( ( O O
15 299 303 14745746 ATAC NN B-NP O
16 303 304 14745746 ) ) O O
17 305 306 14745746 ( ( O O
18 306 307 14745746 n NN B-NP O
19 307 308 14745746 = SYM B-VP O
20 308 310 14745746 94 CD B-NP O
21 310 311 14745746 ) ) O O
22 312 315 14745746 and CC O O
23 316 317 14745746 a DT B-NP O
24 318 323 14745746 group NN I-NP O
25 324 326 14745746 of IN B-PP O
26 327 332 14745746 women NNS B-NP O
27 333 340 14745746 without IN B-PP O
28 341 347 14745746 breast NN B-NP D001943
29 348 354 14745746 cancer NN I-NP D001943
30 355 356 14745746 ( ( O O
31 356 357 14745746 n NN B-NP O
32 357 358 14745746 = SYM B-VP O
33 358 360 14745746 35 CD B-NP O
34 360 361 14745746 ) ) O O
35 362 371 14745746 completed VBD B-VP O
36 372 373 14745746 a DT B-NP O
37 374 381 14745746 battery NN I-NP O
38 382 384 14745746 of IN B-PP O
39 385 403 14745746 neuropsychological JJ B-NP O
40 404 412 14745746 measures NNS I-NP O
41 412 413 14745746 . . O O

1 414 422 14745746 Compared VBN B-PP O
2 423 427 14745746 with IN B-PP O
3 428 431 14745746 the DT B-NP O
4 432 439 14745746 control NN I-NP O
5 440 445 14745746 group NN I-NP O
6 445 446 14745746 , , O O
7 447 450 14745746 the DT B-NP O
8 451 459 14745746 patients NNS I-NP O
9 460 464 14745746 were VBD B-VP O
10 465 473 14745746 impaired VBN I-VP O
11 474 476 14745746 on IN B-PP O
12 477 478 14745746 a DT B-NP O
13 479 489 14745746 processing NN I-NP O
14 490 495 14745746 speed NN I-NP O
15 496 500 14745746 task NN I-NP O
16 501 502 14745746 ( ( O O
17 502 503 14745746 p NN B-NP O
18 503 504 14745746 = SYM B-VP O
19 504 509 14745746 0.032 CD B-NP O
20 509 510 14745746 ) ) O O
21 511 514 14745746 and CC O O
22 515 517 14745746 on IN B-PP O
23 518 519 14745746 a DT B-NP O
24 520 527 14745746 measure NN I-NP O
25 528 530 14745746 of IN B-PP O
26 531 540 14745746 immediate JJ B-NP O
27 541 547 14745746 verbal JJ I-NP O
28 548 554 14745746 memory NN I-NP O
29 555 556 14745746 ( ( O O
30 556 557 14745746 p NN B-NP O
31 557 558 14745746 = SYM B-VP O
32 558 563 14745746 0.026 CD B-NP O
33 563 564 14745746 ) ) O O
34 565 570 14745746 after IN B-PP O
35 571 582 14745746 controlling VBG B-VP O
36 583 586 14745746 for IN B-PP O
37 587 590 14745746 the DT B-NP O
38 591 594 14745746 use NN I-NP O
39 595 597 14745746 of IN B-PP O
40 598 605 14745746 hormone NN B-NP O
41 606 617 14745746 replacement NN I-NP O
42 618 625 14745746 therapy NN I-NP O
43 626 628 14745746 in IN B-PP O
44 629 633 14745746 both DT B-NP O
45 634 640 14745746 groups NNS I-NP O
46 640 641 14745746 . . O O

1 642 649 14745746 Patient NN B-NP O
2 650 655 14745746 group NN I-NP O
3 656 667 14745746 performance NN I-NP O
4 668 671 14745746 was VBD B-VP O
5 672 675 14745746 not RB O O
6 676 689 14745746 significantly RB B-ADJP O
7 690 697 14745746 related VBN I-ADJP O
8 698 700 14745746 to TO B-PP O
9 701 707 14745746 length NN B-NP O
10 708 710 14745746 of IN B-PP O
11 711 720 14745746 treatment NN B-NP O
12 721 723 14745746 or CC I-NP O
13 724 732 14745746 measures NNS I-NP O
14 733 735 14745746 of IN B-PP O
15 736 749 14745746 psychological JJ B-NP O
16 750 759 14745746 morbidity NN I-NP O
17 759 760 14745746 . . O O

1 761 764 14745746 The DT B-NP O
2 765 772 14745746 results NNS I-NP O
3 773 779 14745746 showed VBD B-VP O
4 780 788 14745746 specific JJ B-NP O
5 789 800 14745746 impairments NNS I-NP O
6 801 803 14745746 in IN B-PP O
7 804 814 14745746 processing VBG B-VP O
8 815 820 14745746 speed NN B-NP O
9 821 824 14745746 and CC O O
10 825 831 14745746 verbal JJ B-NP O
11 832 838 14745746 memory NN I-NP O
12 839 841 14745746 in IN B-PP O
13 842 847 14745746 women NNS B-NP O
14 848 857 14745746 receiving VBG B-VP O
15 858 866 14745746 hormonal JJ B-NP O
16 867 874 14745746 therapy NN I-NP O
17 875 878 14745746 for IN B-PP O
18 879 882 14745746 the DT B-NP O
19 883 892 14745746 treatment NN I-NP O
20 893 895 14745746 of IN B-PP O
21 896 902 14745746 breast NN B-NP D001943
22 903 909 14745746 cancer NN I-NP D001943
23 909 910 14745746 . . O O

1 911 917 14745746 Verbal JJ B-NP O
2 918 924 14745746 memory NN I-NP O
3 925 928 14745746 may MD B-VP O
4 929 931 14745746 be VB I-VP O
5 932 942 14745746 especially RB B-ADJP O
6 943 952 14745746 sensitive JJ I-ADJP O
7 953 955 14745746 to TO B-PP O
8 956 963 14745746 changes NNS B-NP O
9 964 966 14745746 in IN B-PP O
10 967 976 14745746 oestrogen NN B-NP D004967
11 977 983 14745746 levels NNS I-NP O
12 983 984 14745746 , , O O
13 985 986 14745746 a DT B-NP O
14 987 994 14745746 finding NN I-NP O
15 995 1003 14745746 commonly RB B-VP O
16 1004 1012 14745746 reported VBN I-VP O
17 1013 1015 14745746 in IN B-PP O
18 1016 1023 14745746 studies NNS B-NP O
19 1024 1026 14745746 of IN B-PP O
20 1027 1034 14745746 hormone NN B-NP O
21 1035 1046 14745746 replacement NN I-NP O
22 1047 1054 14745746 therapy NN I-NP O
23 1055 1057 14745746 in IN B-PP O
24 1058 1065 14745746 healthy JJ B-NP O
25 1066 1071 14745746 women NNS I-NP O
26 1071 1072 14745746 . . O O

1 1073 1075 14745746 In IN B-PP O
2 1076 1080 14745746 view NN B-NP O
3 1081 1083 14745746 of IN B-PP O
4 1084 1087 14745746 the DT B-NP O
5 1088 1097 14745746 increased VBN I-NP O
6 1098 1101 14745746 use NN I-NP O
7 1102 1104 14745746 of IN B-PP O
8 1105 1112 14745746 hormone NN B-NP O
9 1113 1122 14745746 therapies NNS I-NP O
10 1123 1125 14745746 in IN B-PP O
11 1126 1128 14745746 an DT B-NP O
12 1129 1137 14745746 adjuvant JJ I-NP O
13 1138 1141 14745746 and CC I-NP O
14 1142 1154 14745746 preventative JJ I-NP O
15 1155 1162 14745746 setting VBG I-NP O
16 1163 1168 14745746 their PRP$ B-NP O
17 1169 1175 14745746 impact NN I-NP O
18 1176 1178 14745746 on IN B-PP O
19 1179 1188 14745746 cognitive JJ B-NP O
20 1189 1200 14745746 functioning NN I-NP O
21 1201 1207 14745746 should MD B-VP O
22 1208 1210 14745746 be VB I-VP O
23 1211 1223 14745746 investigated VBN I-VP O
24 1224 1228 14745746 more RBR B-ADVP O
25 1229 1239 14745746 thoroughly RB I-ADVP O
26 1239 1240 14745746 . . O O

1 0 0 2320800 -DOCSTART- -X- -X- O

1 0 6 2320800 Lethal JJ B-NP O
2 7 13 2320800 anuria NN I-NP D001002
3 14 26 2320800 complicating VBG B-VP O
4 27 31 2320800 high JJ B-NP O
5 32 36 2320800 dose NN I-NP O
6 37 47 2320800 ifosfamide NN I-NP D007069
7 48 60 2320800 chemotherapy NN I-NP O
8 61 63 2320800 in IN B-PP O
9 64 65 2320800 a DT B-NP O
10 66 72 2320800 breast NN I-NP D001943
11 73 79 2320800 cancer NN I-NP D001943
12 80 87 2320800 patient NN I-NP O
13 88 92 2320800 with IN B-PP O
14 93 95 2320800 an DT B-NP O
15 96 104 2320800 impaired JJ I-NP D007674
16 105 110 2320800 renal JJ I-NP D007674
17 111 119 2320800 function NN I-NP D007674
18 119 120 2320800 . . O O
19 121 122 2320800 A DT B-NP O
20 123 128 2320800 sixty JJ I-NP O
21 128 129 2320800 - HYPH I-NP O
22 129 133 2320800 year NN I-NP O
23 133 134 2320800 - HYPH O O
24 134 137 2320800 old JJ B-NP O
25 138 143 2320800 woman NN I-NP O
26 144 148 2320800 with IN B-PP O
27 149 157 2320800 advanced VBN B-NP O
28 158 164 2320800 breast NN I-NP D001943
29 165 171 2320800 cancer NN I-NP D001943
30 171 172 2320800 , , O O
31 173 183 2320800 previously RB B-VP O
32 184 191 2320800 treated VBN I-VP O
33 192 196 2320800 with IN B-PP O
34 197 206 2320800 cisplatin NN B-NP D002945
35 206 207 2320800 , , O O
36 208 217 2320800 developed VBD B-VP O
37 218 220 2320800 an DT B-NP O
38 221 233 2320800 irreversible JJ I-NP O
39 234 240 2320800 lethal JJ I-NP O
40 241 246 2320800 renal JJ I-NP D051437
41 247 254 2320800 failure NN I-NP D051437
42 255 259 2320800 with IN B-PP O
43 260 266 2320800 anuria NN B-NP D001002
44 266 267 2320800 , , O O
45 268 271 2320800 the DT B-NP O
46 272 275 2320800 day NN I-NP O
47 276 281 2320800 after IN B-PP O
48 282 283 2320800 5 CD B-NP O
49 284 285 2320800 g NN I-NP O
50 285 286 2320800 / SYM B-NP O
51 286 288 2320800 m2 NN I-NP O
52 289 294 2320800 bolus NN I-NP O
53 295 305 2320800 ifosfamide NN I-NP D007069
54 305 306 2320800 . . O O

1 307 316 2320800 Postrenal JJ B-NP D007674
2 317 324 2320800 failure NN I-NP D007674
3 325 328 2320800 was VBD B-VP O
4 329 337 2320800 excluded VBN I-VP O
5 338 340 2320800 by IN B-PP O
6 341 351 2320800 echography NN B-NP O
7 351 352 2320800 . . O O

1 353 354 2320800 A DT B-NP O
2 355 363 2320800 prerenal JJ I-NP O
3 364 373 2320800 component NN I-NP O
4 374 379 2320800 could MD B-VP O
5 380 384 2320800 have VB I-VP O
6 385 396 2320800 contributed VBN I-VP O
7 397 399 2320800 to TO B-PP O
8 400 405 2320800 renal JJ B-NP D051437
9 406 413 2320800 failure NN I-NP D051437
10 414 421 2320800 because IN B-PP O
11 422 424 2320800 of IN I-PP O
12 425 426 2320800 a DT B-NP O
13 427 436 2320800 transient JJ I-NP O
14 437 448 2320800 hypotension NN I-NP D007022
15 448 449 2320800 , , O O
16 450 453 2320800 due IN B-PP O
17 454 456 2320800 to TO B-PP O
18 457 459 2320800 an DT B-NP O
19 460 470 2320800 increasing VBG I-NP O
20 471 478 2320800 ascitis NN I-NP O
21 478 479 2320800 , , O O
22 480 489 2320800 occurring VBG B-VP O
23 490 494 2320800 just RB B-ADVP O
24 495 501 2320800 before IN B-PP O
25 502 508 2320800 anuria NN B-NP D001002
26 508 509 2320800 . . O O

1 510 517 2320800 However RB B-ADVP O
2 517 518 2320800 , , O O
3 519 529 2320800 correction NN B-NP O
4 530 532 2320800 of IN B-PP O
5 533 536 2320800 the DT B-NP O
6 537 548 2320800 hemodynamic JJ I-NP O
7 549 559 2320800 parameters NNS I-NP O
8 560 563 2320800 did VBD B-VP O
9 564 567 2320800 not RB I-VP O
10 568 575 2320800 improve VB I-VP O
11 576 581 2320800 renal JJ B-NP O
12 582 590 2320800 function NN I-NP O
13 590 591 2320800 . . O O

1 592 602 2320800 Ifosfamide NN B-NP D007069
2 603 605 2320800 is VBZ B-VP O
3 606 607 2320800 a DT B-NP O
4 608 613 2320800 known JJ I-NP O
5 614 625 2320800 nephrotoxic JJ I-NP D007674
6 626 630 2320800 drug NN I-NP O
7 631 635 2320800 with IN B-PP O
8 636 648 2320800 demonstrated VBN B-NP O
9 649 662 2320800 tubulopathies NNS I-NP D007674
10 662 663 2320800 . . O O

1 664 666 2320800 We PRP B-NP O
2 667 675 2320800 strongly RB B-ADVP O
3 676 683 2320800 suspect VBP B-VP O
4 684 688 2320800 that IN B-SBAR O
5 689 693 2320800 this DT B-NP O
6 694 700 2320800 lethal JJ I-NP O
7 701 707 2320800 anuria NN I-NP D001002
8 708 711 2320800 was VBD B-VP O
9 712 718 2320800 mainly RB B-ADJP O
10 719 722 2320800 due JJ I-ADJP O
11 723 725 2320800 to TO B-PP O
12 726 736 2320800 ifosfamide NN B-NP D007069
13 736 737 2320800 , , O O
14 738 747 2320800 occurring VBG B-VP O
15 748 750 2320800 in IN B-PP O
16 751 752 2320800 a DT B-NP O
17 753 760 2320800 patient NN I-NP O
18 761 767 2320800 having VBG B-VP O
19 768 776 2320800 received VBN I-VP O
20 777 785 2320800 previous JJ B-NP O
21 786 795 2320800 cisplatin NN I-NP D002945
22 796 808 2320800 chemotherapy NN I-NP O
23 809 812 2320800 and CC B-PP O
24 813 817 2320800 with IN B-PP O
25 818 822 2320800 poor JJ B-NP O
26 823 829 2320800 kidney NN I-NP O
27 830 839 2320800 perfusion NN I-NP O
28 840 843 2320800 due JJ B-ADJP O
29 844 846 2320800 to TO B-PP O
30 847 856 2320800 transient JJ B-NP O
31 857 868 2320800 hypotension NN I-NP D007022
32 868 869 2320800 . . O O

1 870 872 2320800 We PRP B-NP O
2 873 882 2320800 recommend VBP B-VP O
3 883 890 2320800 careful JJ B-NP O
4 891 894 2320800 use NN I-NP O
5 895 897 2320800 of IN B-PP O
6 898 908 2320800 ifosfamide NN B-NP D007069
7 909 911 2320800 in IN B-PP O
8 912 920 2320800 patients NNS B-NP O
9 921 931 2320800 pretreated VBN B-VP O
10 932 936 2320800 with IN B-PP O
11 937 948 2320800 nephrotoxic JJ B-NP D007674
12 949 961 2320800 chemotherapy NN I-NP O
13 962 965 2320800 and CC O O
14 966 976 2320800 inadequate JJ B-NP O
15 977 982 2320800 renal JJ I-NP O
16 983 992 2320800 perfusion NN I-NP O
17 992 993 2320800 . . O O

1 0 0 2917114 -DOCSTART- -X- -X- O

1 0 14 2917114 Glycopyrronium NN B-NP D006024
2 15 27 2917114 requirements NNS I-NP O
3 28 31 2917114 for IN B-PP O
4 32 42 2917114 antagonism NN B-NP O
5 43 45 2917114 of IN B-PP O
6 46 49 2917114 the DT B-NP O
7 50 60 2917114 muscarinic JJ I-NP O
8 61 65 2917114 side NN I-NP O
9 66 73 2917114 effects NNS I-NP O
10 74 76 2917114 of IN B-PP O
11 77 88 2917114 edrophonium NN B-NP D004491
12 88 89 2917114 . . O O
13 90 92 2917114 We PRP B-NP O
14 93 97 2917114 have VBP B-VP O
15 98 106 2917114 compared VBN I-VP O
16 106 107 2917114 , , O O
17 108 110 2917114 in IN B-PP O
18 111 113 2917114 60 CD B-NP O
19 114 119 2917114 adult JJ I-NP O
20 120 128 2917114 patients NNS I-NP O
21 128 129 2917114 , , O O
22 130 133 2917114 the DT B-NP O
23 134 148 2917114 cardiovascular JJ I-NP O
24 149 156 2917114 effects NNS I-NP O
25 157 159 2917114 of IN B-PP O
26 160 174 2917114 glycopyrronium NN B-NP D006024
27 175 176 2917114 5 CD I-NP O
28 177 187 2917114 micrograms NNS I-NP O
29 188 190 2917114 kg NN I-NP O
30 190 191 2917114 - HYPH B-NP O
31 191 192 2917114 1 CD I-NP O
32 193 196 2917114 and CC I-NP O
33 197 199 2917114 10 CD I-NP O
34 200 210 2917114 micrograms NNS I-NP O
35 211 213 2917114 kg NN I-NP O
36 213 214 2917114 - HYPH B-NP O
37 214 215 2917114 1 CD I-NP O
38 216 221 2917114 given VBN B-VP O
39 222 228 2917114 either CC O O
40 229 243 2917114 simultaneously RB B-ADVP O
41 244 246 2917114 or CC O O
42 247 248 2917114 1 CD B-NP O
43 249 252 2917114 min NN I-NP O
44 253 259 2917114 before IN B-PP O
45 260 271 2917114 edrophonium NN B-NP D004491
46 272 273 2917114 1 CD I-NP O
47 274 276 2917114 mg NN I-NP O
48 277 279 2917114 kg NN I-NP O
49 279 280 2917114 - HYPH B-NP O
50 280 281 2917114 1 CD I-NP O
51 281 282 2917114 . . O O

1 283 294 2917114 Significant JJ B-NP O
2 295 306 2917114 differences NNS I-NP O
3 307 314 2917114 between IN B-PP O
4 315 318 2917114 the DT B-NP O
5 319 323 2917114 four CD I-NP O
6 324 330 2917114 groups NNS I-NP O
7 331 335 2917114 were VBD B-VP O
8 336 344 2917114 detected VBN I-VP O
9 345 346 2917114 ( ( O O
10 346 347 2917114 P NN B-NP O
11 348 352 2917114 less JJR B-ADJP O
12 353 357 2917114 than IN B-PP O
13 358 363 2917114 0.001 CD B-NP O
14 363 364 2917114 ) ) O O
15 364 365 2917114 . . O O

1 366 370 2917114 Both DT B-NP O
2 371 377 2917114 groups NNS I-NP O
3 378 387 2917114 receiving VBG B-VP O
4 388 390 2917114 10 CD B-NP O
5 391 401 2917114 micrograms NNS I-NP O
6 402 404 2917114 kg NN I-NP O
7 404 405 2917114 - HYPH B-NP O
8 405 406 2917114 1 CD I-NP O
9 407 413 2917114 showed VBD B-VP O
10 414 423 2917114 increases NNS B-NP O
11 424 426 2917114 in IN B-PP O
12 427 432 2917114 heart NN B-NP O
13 433 437 2917114 rate NN I-NP O
14 438 440 2917114 of IN B-PP O
15 441 443 2917114 up IN B-NP O
16 444 446 2917114 to TO I-NP O
17 447 449 2917114 30 CD I-NP O
18 450 454 2917114 beat NN I-NP O
19 455 458 2917114 min NN I-NP O
20 458 459 2917114 - HYPH B-NP O
21 459 460 2917114 1 CD I-NP O
22 461 462 2917114 ( ( O O
23 462 465 2917114 95% CD B-NP O
24 466 476 2917114 confidence NN I-NP O
25 477 483 2917114 limits VBZ B-VP O
26 484 486 2917114 28 CD B-NP O
27 486 487 2917114 - HYPH I-NP O
28 487 489 2917114 32 CD I-NP O
29 490 494 2917114 beat JJ I-NP O
30 495 498 2917114 min NN I-NP O
31 498 499 2917114 - HYPH B-NP O
32 499 500 2917114 1 CD I-NP O
33 500 501 2917114 ) ) O O
34 501 502 2917114 . . O O

1 503 506 2917114 Use NN B-NP O
2 507 509 2917114 of IN B-PP O
3 510 524 2917114 glycopyrronium NN B-NP D006024
4 525 526 2917114 5 CD I-NP O
5 527 537 2917114 micrograms NNS I-NP O
6 538 540 2917114 kg NN I-NP O
7 540 541 2917114 - HYPH B-NP O
8 541 542 2917114 1 CD I-NP O
9 543 551 2917114 provided VBD B-VP O
10 552 559 2917114 greater JJR B-NP O
11 560 574 2917114 cardiovascular JJ I-NP O
12 575 584 2917114 stability NN I-NP O
13 585 588 2917114 and CC O O
14 588 589 2917114 , , O O
15 590 595 2917114 given VBN B-PP O
16 596 597 2917114 1 CD B-NP O
17 598 601 2917114 min NN I-NP O
18 602 608 2917114 before IN B-PP O
19 609 612 2917114 the DT B-NP O
20 613 624 2917114 edrophonium NN I-NP D004491
21 624 625 2917114 , , O O
22 626 629 2917114 was VBD B-VP O
23 630 640 2917114 sufficient JJ B-ADJP O
24 641 643 2917114 to TO B-VP O
25 644 652 2917114 minimize VB I-VP O
26 653 658 2917114 early RB B-ADVP O
27 658 659 2917114 , , O O
28 660 671 2917114 edrophonium NN B-NP D004491
29 671 672 2917114 - HYPH B-NP O
30 672 679 2917114 induced VBN I-NP O
31 680 692 2917114 bradycardias NNS I-NP D001919
32 692 693 2917114 . . O O

1 694 698 2917114 This DT B-NP O
2 699 702 2917114 low JJ I-NP O
3 703 707 2917114 dose NN I-NP O
4 708 710 2917114 of IN B-PP O
5 711 725 2917114 glycopyrronium NN B-NP D006024
6 726 734 2917114 provided VBD B-VP O
7 735 739 2917114 good JJ B-NP O
8 740 747 2917114 control NN I-NP O
9 748 750 2917114 of IN B-PP O
10 751 764 2917114 oropharyngeal JJ B-NP O
11 765 775 2917114 secretions NNS I-NP O
12 775 776 2917114 . . O O

1 0 0 1445986 -DOCSTART- -X- -X- O

1 0 9 1445986 Cefotetan NN B-NP D015313
2 9 10 1445986 - HYPH O O
3 10 17 1445986 induced VBN B-NP O
4 18 24 1445986 immune JJ I-NP O
5 25 34 1445986 hemolytic JJ I-NP D000743
6 35 41 1445986 anemia NN I-NP D000743
7 41 42 1445986 . . O O
8 43 49 1445986 Immune JJ B-NP O
9 50 59 1445986 hemolytic JJ I-NP D000743
10 60 66 1445986 anemia NN I-NP D000743
11 67 70 1445986 due JJ B-PP O
12 71 73 1445986 to TO B-PP O
13 74 75 1445986 a DT B-NP O
14 76 80 1445986 drug NN I-NP O
15 80 81 1445986 - HYPH B-NP O
16 81 91 1445986 adsorption NN I-NP O
17 92 101 1445986 mechanism NN I-NP O
18 102 105 1445986 has VBZ B-VP O
19 106 110 1445986 been VBN I-VP O
20 111 120 1445986 described VBN I-VP O
21 121 130 1445986 primarily RB B-ADVP O
22 131 133 1445986 in IN B-PP O
23 134 142 1445986 patients NNS B-NP O
24 143 152 1445986 receiving VBG B-VP O
25 153 164 1445986 penicillins NNS B-NP D010406
26 165 168 1445986 and CC O O
27 169 174 1445986 first JJ B-NP O
28 174 175 1445986 - HYPH I-NP O
29 175 185 1445986 generation NN I-NP O
30 186 200 1445986 cephalosporins NNS I-NP D002511
31 200 201 1445986 . . O O

1 202 204 1445986 We PRP B-NP O
2 205 213 1445986 describe VBP B-VP O
3 214 215 1445986 a DT B-NP O
4 216 223 1445986 patient NN I-NP O
5 224 227 1445986 who WP B-NP O
6 228 237 1445986 developed VBD B-VP O
7 238 244 1445986 anemia NN B-NP D000740
8 245 250 1445986 while IN B-SBAR O
9 251 260 1445986 receiving VBG B-VP O
10 261 272 1445986 intravenous JJ B-NP O
11 273 282 1445986 cefotetan NN I-NP D015313
12 282 283 1445986 . . O O

1 284 293 1445986 Cefotetan NN B-NP D015313
2 293 294 1445986 - HYPH I-NP O
3 294 303 1445986 dependent JJ I-NP O
4 304 314 1445986 antibodies NNS I-NP O
5 315 319 1445986 were VBD B-VP O
6 320 328 1445986 detected VBN I-VP O
7 329 331 1445986 in IN B-PP O
8 332 335 1445986 the DT B-NP O
9 336 345 1445986 patient's NNS I-NP O
10 346 351 1445986 serum NN I-NP O
11 352 355 1445986 and CC B-PP O
12 356 358 1445986 in IN B-PP O
13 359 361 1445986 an DT B-NP O
14 362 368 1445986 eluate NN I-NP O
15 369 377 1445986 prepared VBN B-VP O
16 378 382 1445986 from IN B-PP O
17 383 386 1445986 his PRP$ B-NP O
18 387 390 1445986 red JJ I-NP O
19 391 396 1445986 blood NN I-NP O
20 397 402 1445986 cells NNS I-NP O
21 402 403 1445986 . . O O

1 404 407 1445986 The DT B-NP O
2 408 414 1445986 eluate NN I-NP O
3 415 419 1445986 also RB B-ADVP O
4 420 427 1445986 reacted VBD B-VP O
5 428 434 1445986 weakly RB B-ADVP O
6 435 439 1445986 with IN B-PP O
7 440 443 1445986 red JJ B-NP O
8 444 449 1445986 blood NN I-NP O
9 450 455 1445986 cells NNS I-NP O
10 456 458 1445986 in IN B-PP O
11 459 462 1445986 the DT B-NP O
12 463 470 1445986 absence NN I-NP O
13 471 473 1445986 of IN B-PP O
14 474 483 1445986 cefotetan NN B-NP D015313
15 483 484 1445986 , , O O
16 485 495 1445986 suggesting VBG B-VP O
17 496 499 1445986 the DT B-NP O
18 500 511 1445986 concomitant JJ I-NP O
19 512 521 1445986 formation NN I-NP O
20 522 524 1445986 of IN B-PP O
21 525 529 1445986 warm NN B-NP O
22 529 530 1445986 - HYPH B-NP O
23 530 538 1445986 reactive JJ I-NP O
24 539 553 1445986 autoantibodies NNS I-NP O
25 553 554 1445986 . . O O

1 555 560 1445986 These DT B-NP O
2 561 573 1445986 observations NNS I-NP O
3 573 574 1445986 , , O O
4 575 577 1445986 in IN B-PP O
5 578 589 1445986 conjunction NN B-NP O
6 590 594 1445986 with IN B-PP O
7 595 603 1445986 clinical JJ B-NP O
8 604 607 1445986 and CC I-NP O
9 608 618 1445986 laboratory JJ I-NP O
10 619 627 1445986 evidence NN I-NP O
11 628 630 1445986 of IN B-PP O
12 631 644 1445986 extravascular JJ B-NP O
13 645 654 1445986 hemolysis NN I-NP D006461
14 654 655 1445986 , , O O
15 656 659 1445986 are VBP B-VP O
16 660 670 1445986 consistent JJ B-ADJP O
17 671 675 1445986 with IN B-PP O
18 676 680 1445986 drug NN B-NP O
19 680 681 1445986 - HYPH B-NP O
20 681 688 1445986 induced VBN I-NP O
21 689 698 1445986 hemolytic JJ I-NP D000743
22 699 705 1445986 anemia NN I-NP D000743
23 705 706 1445986 , , O O
24 707 715 1445986 possibly RB B-VP O
25 716 725 1445986 involving VBG I-VP O
26 726 730 1445986 both CC O O
27 731 735 1445986 drug NN B-NP O
28 735 736 1445986 - HYPH B-NP O
29 736 746 1445986 adsorption NN I-NP O
30 747 750 1445986 and CC I-NP O
31 751 763 1445986 autoantibody NN I-NP O
32 764 773 1445986 formation NN I-NP O
33 774 784 1445986 mechanisms NNS I-NP O
34 784 785 1445986 . . O O

1 786 790 1445986 This DT B-NP O
2 791 795 1445986 case NN I-NP O
3 796 806 1445986 emphasizes VBZ B-VP O
4 807 810 1445986 the DT B-NP O
5 811 815 1445986 need NN I-NP O
6 816 819 1445986 for IN B-PP O
7 820 829 1445986 increased VBN B-NP O
8 830 839 1445986 awareness NN I-NP O
9 840 842 1445986 of IN B-PP O
10 843 852 1445986 hemolytic JJ B-NP O
11 853 862 1445986 reactions NNS I-NP O
12 863 865 1445986 to TO B-PP O
13 866 869 1445986 all DT B-NP O
14 870 884 1445986 cephalosporins NNS I-NP D002511
15 884 885 1445986 . . O O

1 0 0 8800187 -DOCSTART- -X- -X- O

1 0 6 8800187 Effect NN B-NP O
2 7 9 8800187 of IN B-PP O
3 10 17 8800187 calcium NN B-NP D002122
4 18 26 8800187 chloride NN I-NP D002122
5 27 30 8800187 and CC O O
6 31 32 8800187 4 CD B-NP D015761
7 32 33 8800187 - HYPH I-NP D015761
8 33 46 8800187 aminopyridine NN I-NP D015761
9 47 54 8800187 therapy NN I-NP O
10 55 57 8800187 on IN B-PP O
11 58 69 8800187 desipramine NN B-NP D003891
12 70 78 8800187 toxicity NN I-NP D064420
13 79 81 8800187 in IN B-PP O
14 82 86 8800187 rats NNS B-NP O
15 86 87 8800187 . . O O
16 88 98 8800187 BACKGROUND NN B-NP O
17 98 99 8800187 : : O O
18 100 111 8800187 Hypotension NN B-NP D007022
19 112 114 8800187 is VBZ B-VP O
20 115 116 8800187 a DT B-NP O
21 117 122 8800187 major JJ I-NP O
22 123 134 8800187 contributor NN I-NP O
23 135 137 8800187 to TO B-PP O
24 138 147 8800187 mortality NN B-NP O
25 148 150 8800187 in IN B-PP O
26 151 160 8800187 tricyclic JJ B-NP O
27 161 175 8800187 antidepressant NN I-NP O
28 176 184 8800187 overdose NN I-NP D062787
29 184 185 8800187 . . O O

1 186 192 8800187 Recent JJ B-NP O
2 193 197 8800187 data NNS I-NP O
3 198 205 8800187 suggest VBP B-VP O
4 206 210 8800187 that IN B-SBAR O
5 211 220 8800187 tricyclic JJ B-NP O
6 221 236 8800187 antidepressants NNS I-NP O
7 237 244 8800187 inhibit VBP B-VP O
8 245 252 8800187 calcium NN B-NP D002118
9 253 259 8800187 influx NN I-NP O
10 260 262 8800187 in IN B-PP O
11 263 267 8800187 some DT B-NP O
12 268 275 8800187 tissues NNS I-NP O
13 275 276 8800187 . . O O

1 277 281 8800187 This DT B-NP O
2 282 287 8800187 study NN I-NP O
3 288 297 8800187 addressed VBD B-VP O
4 298 301 8800187 the DT B-NP O
5 302 311 8800187 potential JJ I-NP O
6 312 316 8800187 role NN I-NP O
7 317 319 8800187 of IN B-PP O
8 320 327 8800187 calcium NN B-NP D002118
9 328 335 8800187 channel NN I-NP O
10 336 344 8800187 blockade NN I-NP O
11 345 347 8800187 in IN B-PP O
12 348 357 8800187 tricyclic JJ B-NP O
13 358 372 8800187 antidepressant NN I-NP O
14 372 373 8800187 - HYPH B-NP O
15 373 380 8800187 induced VBN I-NP O
16 381 392 8800187 hypotension NN I-NP D007022
17 392 393 8800187 . . O O

1 394 401 8800187 METHODS NNS B-NP O
2 401 402 8800187 : : O O
3 403 406 8800187 Two CD B-NP O
4 407 420 8800187 interventions NNS I-NP O
5 421 425 8800187 were VBD B-VP O
6 426 433 8800187 studied VBN I-VP O
7 434 438 8800187 that WDT B-NP O
8 439 443 8800187 have VBP B-VP O
9 444 448 8800187 been VBN I-VP O
10 449 454 8800187 shown VBN I-VP O
11 455 465 8800187 previously RB B-ADVP O
12 466 468 8800187 to TO B-VP O
13 469 476 8800187 improve VB I-VP O
14 477 482 8800187 blood NN B-NP O
15 483 491 8800187 pressure NN I-NP O
16 492 496 8800187 with IN B-PP O
17 497 504 8800187 calcium NN B-NP D002118
18 505 512 8800187 channel NN I-NP O
19 513 520 8800187 blocker NN I-NP O
20 521 529 8800187 overdose NN I-NP D062787
21 529 530 8800187 . . O O

1 531 536 8800187 CaCl2 NN B-NP D002122
2 537 540 8800187 and CC O O
3 541 542 8800187 4 CD B-NP D015761
4 542 543 8800187 - HYPH I-NP D015761
5 543 556 8800187 aminopyridine NN I-NP D015761
6 556 557 8800187 . . O O

1 558 570 8800187 Anesthetized VBN B-NP O
2 571 575 8800187 rats NNS I-NP O
3 576 584 8800187 received VBD B-VP O
4 585 588 8800187 the DT B-NP O
5 589 598 8800187 tricyclic JJ I-NP O
6 599 613 8800187 antidepressant NN I-NP O
7 614 625 8800187 desipramine NN I-NP D003891
8 626 628 8800187 IP NN I-NP O
9 629 631 8800187 to TO B-VP O
10 632 639 8800187 produce VB I-VP O
11 640 651 8800187 hypotension NN B-NP D007022
12 651 652 8800187 , , O O
13 653 656 8800187 QRS NN B-NP O
14 657 669 8800187 prolongation NN I-NP O
15 669 670 8800187 , , O O
16 671 674 8800187 and CC O O
17 675 686 8800187 bradycardia NN B-NP D001919
18 686 687 8800187 . . O O

1 688 695 8800187 Fifteen CD B-NP O
2 696 699 8800187 min NN I-NP O
3 700 705 8800187 later RB B-ADVP O
4 705 706 8800187 , , O O
5 707 714 8800187 animals NNS B-NP O
6 715 723 8800187 received VBD B-VP O
7 724 729 8800187 CaCl2 NN B-NP D002122
8 729 730 8800187 , , O O
9 731 737 8800187 NaHCO3 NN B-NP D017693
10 737 738 8800187 , , O O
11 739 741 8800187 or CC O O
12 742 748 8800187 saline NN B-NP O
13 748 749 8800187 . . O O

1 750 752 8800187 In IN B-PP O
2 753 754 8800187 a DT B-NP O
3 755 761 8800187 second JJ I-NP O
4 762 772 8800187 experiment NN I-NP O
5 772 773 8800187 , , O O
6 774 778 8800187 rats NNS B-NP O
7 779 787 8800187 received VBD B-VP O
8 788 797 8800187 tricyclic JJ B-NP O
9 798 812 8800187 antidepressant NN I-NP O
10 813 824 8800187 desipramine NN I-NP D003891
11 825 827 8800187 IP NN I-NP O
12 828 836 8800187 followed VBN B-VP O
13 837 839 8800187 in IN B-PP O
14 840 842 8800187 15 CD B-NP O
15 843 846 8800187 min NN I-NP O
16 847 849 8800187 by IN B-PP O
17 850 851 8800187 4 CD B-NP D015761
18 851 852 8800187 - HYPH I-NP D015761
19 852 865 8800187 aminopyridine NN I-NP D015761
20 866 868 8800187 or CC I-NP O
21 869 875 8800187 saline NN I-NP O
22 875 876 8800187 . . O O

1 877 884 8800187 RESULTS NNS B-NP O
2 884 885 8800187 : : O O
3 886 892 8800187 NaHCO3 NN B-NP D017693
4 893 900 8800187 briefly NN I-NP O
5 901 902 8800187 ( ( O O
6 902 903 8800187 5 CD B-NP O
7 904 907 8800187 min NN I-NP O
8 907 908 8800187 ) ) O O
9 909 917 8800187 reversed VBD B-VP O
10 918 929 8800187 hypotension NN B-NP D007022
11 930 933 8800187 and CC I-NP O
12 934 937 8800187 QRS NN I-NP O
13 938 950 8800187 prolongation NN I-NP O
14 950 951 8800187 . . O O

1 952 957 8800187 CaCl2 NN B-NP D002122
2 958 961 8800187 and CC O O
3 962 963 8800187 4 CD B-NP D015761
4 963 964 8800187 - HYPH I-NP D015761
5 964 977 8800187 aminopyridine NN I-NP D015761
6 978 984 8800187 failed VBD B-VP O
7 985 987 8800187 to TO I-VP O
8 988 995 8800187 improve VB I-VP O
9 996 1001 8800187 blood NN B-NP O
10 1002 1010 8800187 pressure NN I-NP O
11 1010 1011 8800187 . . O O

1 1012 1015 8800187 The DT B-NP O
2 1016 1025 8800187 incidence NN I-NP O
3 1026 1028 8800187 of IN B-PP O
4 1029 1040 8800187 ventricular JJ B-NP D001145
5 1041 1052 8800187 arrhythmias NNS I-NP D001145
6 1053 1054 8800187 ( ( O O
7 1054 1055 8800187 p NN B-NP O
8 1056 1057 8800187 = SYM B-VP O
9 1058 1063 8800187 0.004 CD B-NP O
10 1063 1064 8800187 ) ) O O
11 1065 1068 8800187 and CC O O
12 1069 1077 8800187 seizures NNS B-NP D012640
13 1078 1079 8800187 ( ( O O
14 1079 1080 8800187 p NN B-NP O
15 1081 1082 8800187 = SYM B-VP O
16 1083 1087 8800187 0.03 CD B-NP O
17 1087 1088 8800187 ) ) O O
18 1089 1091 8800187 in IN B-PP O
19 1092 1095 8800187 the DT B-NP O
20 1096 1101 8800187 CaCl2 NN I-NP D002122
21 1102 1107 8800187 group NN I-NP O
22 1108 1111 8800187 was VBD B-VP O
23 1112 1118 8800187 higher JJR B-ADJP O
24 1119 1123 8800187 than IN B-PP O
25 1124 1127 8800187 the DT B-NP O
26 1128 1133 8800187 other JJ I-NP O
27 1134 1140 8800187 groups NNS I-NP O
28 1140 1141 8800187 . . O O

1 1142 1152 8800187 CONCLUSION NN B-NP O
2 1152 1153 8800187 : : O O
3 1154 1157 8800187 The DT B-NP O
4 1158 1172 8800187 administration NN I-NP O
5 1173 1175 8800187 of IN B-PP O
6 1176 1181 8800187 CaCl2 NN B-NP D002122
7 1182 1184 8800187 or CC O O
8 1185 1186 8800187 4 CD B-NP D015761
9 1186 1187 8800187 - HYPH I-NP D015761
10 1187 1200 8800187 aminopyridine NN I-NP D015761
11 1201 1204 8800187 did VBD B-VP O
12 1205 1208 8800187 not RB I-VP O
13 1209 1216 8800187 reverse VB I-VP O
14 1217 1226 8800187 tricyclic JJ B-NP O
15 1227 1241 8800187 antidepressant NN I-NP O
16 1241 1242 8800187 - HYPH B-NP O
17 1242 1249 8800187 induced VBN I-NP O
18 1250 1261 8800187 hypotension NN I-NP D007022
19 1262 1264 8800187 in IN B-PP O
20 1265 1269 8800187 rats NNS B-NP O
21 1269 1270 8800187 . . O O

1 1271 1276 8800187 CaCl2 NN B-NP D002122
2 1277 1284 8800187 therapy NN I-NP O
3 1285 1288 8800187 may MD B-VP O
4 1289 1297 8800187 possibly RB I-VP O
5 1298 1304 8800187 worsen VB I-VP O
6 1305 1309 8800187 both CC O O
7 1310 1324 8800187 cardiovascular JJ B-NP D002318
8 1325 1328 8800187 and CC I-NP D002318
9 1329 1336 8800187 central JJ I-NP D002318
10 1337 1344 8800187 nervous JJ I-NP D002318
11 1345 1351 8800187 system NN I-NP D002318
12 1352 1360 8800187 toxicity NN I-NP D002318
13 1360 1361 8800187 . . O O

1 1362 1367 8800187 These DT B-NP O
2 1368 1376 8800187 findings NNS I-NP O
3 1377 1379 8800187 do VBP B-VP O
4 1380 1383 8800187 not RB I-VP O
5 1384 1391 8800187 support VB I-VP O
6 1392 1393 8800187 a DT B-NP O
7 1394 1398 8800187 role NN I-NP O
8 1399 1402 8800187 for IN B-PP O
9 1403 1410 8800187 calcium NN B-NP D002118
10 1411 1418 8800187 channel NN I-NP O
11 1419 1429 8800187 inhibition NN I-NP O
12 1430 1432 8800187 in IN B-PP O
13 1433 1436 8800187 the DT B-NP O
14 1437 1449 8800187 pathogenesis NN I-NP O
15 1450 1452 8800187 of IN B-PP O
16 1453 1462 8800187 tricyclic JJ B-NP O
17 1463 1477 8800187 antidepressant NN I-NP O
18 1477 1478 8800187 - HYPH B-NP O
19 1478 1485 8800187 induced VBN I-NP O
20 1486 1497 8800187 hypotension NN I-NP D007022
21 1497 1498 8800187 . . O O

1 0 0 1141447 -DOCSTART- -X- -X- O

1 0 3 1141447 The DT B-NP O
2 4 9 1141447 renal JJ I-NP O
3 10 19 1141447 pathology NN I-NP O
4 20 22 1141447 in IN B-PP O
5 23 24 1141447 a DT B-NP O
6 25 29 1141447 case NN I-NP O
7 30 32 1141447 of IN B-PP O
8 33 40 1141447 lithium NN B-NP D008094
9 40 41 1141447 - HYPH B-NP O
10 41 48 1141447 induced VBN I-NP O
11 49 57 1141447 diabetes NN I-NP D003919
12 58 67 1141447 insipidus NN I-NP D003919
13 67 68 1141447 . . O O
14 69 70 1141447 A DT B-NP O
15 71 75 1141447 case NN I-NP O
16 76 78 1141447 of IN B-PP O
17 79 86 1141447 lithium NN B-NP D008094
18 86 87 1141447 - HYPH B-NP O
19 87 94 1141447 induced VBN I-NP O
20 95 103 1141447 diabetes NN I-NP D003919
21 104 113 1141447 insipidus NN I-NP D003919
22 114 116 1141447 is VBZ B-VP O
23 117 125 1141447 reported VBN I-VP O
24 125 126 1141447 . . O O

1 127 129 1141447 At IN B-PP O
2 130 138 1141447 necropsy NN B-NP O
3 139 149 1141447 microscopy NN I-NP O
4 150 155 1141447 shoed VBD B-VP O
5 156 162 1141447 unique JJ B-NP O
6 163 166 1141447 and CC I-NP O
7 167 176 1141447 extensive JJ I-NP O
8 177 183 1141447 damage NN I-NP O
9 184 186 1141447 to TO B-PP O
10 187 192 1141447 cells NNS B-NP O
11 193 199 1141447 lining VBG B-VP O
12 200 203 1141447 the DT B-NP O
13 204 210 1141447 distal JJ I-NP O
14 211 218 1141447 nephron NN I-NP O
15 218 219 1141447 . . O O

1 220 222 1141447 It PRP B-NP O
2 223 225 1141447 is VBZ B-VP O
3 226 235 1141447 suggested VBN I-VP O
4 236 240 1141447 that IN B-SBAR O
5 241 246 1141447 these DT B-NP O
6 247 254 1141447 changes NNS I-NP O
7 255 264 1141447 represent VBP B-VP O
8 265 266 1141447 a DT B-NP O
9 267 275 1141447 specific JJ I-NP O
10 276 281 1141447 toxic JJ I-NP O
11 282 288 1141447 effect NN I-NP O
12 289 291 1141447 of IN B-PP O
13 292 299 1141447 lithium NN B-NP D008094
14 299 300 1141447 , , O O
15 301 309 1141447 reported VBN B-VP O
16 310 314 1141447 here RB B-ADVP O
17 315 318 1141447 for IN B-PP O
18 319 322 1141447 the DT B-NP O
19 323 328 1141447 first JJ I-NP O
20 329 333 1141447 time NN I-NP O
21 334 336 1141447 in IN B-PP O
22 337 340 1141447 man NN B-NP O
23 340 341 1141447 . . O O

1 0 0 783197 -DOCSTART- -X- -X- O

1 0 7 783197 Effects NNS B-NP O
2 8 10 783197 of IN B-PP O
3 11 18 783197 ouabain NN B-NP D010042
4 19 21 783197 on IN B-PP O
5 22 32 783197 myocardial JJ B-NP O
6 33 39 783197 oxygen NN I-NP D010100
7 40 46 783197 supply NN I-NP O
8 47 50 783197 and CC O O
9 51 57 783197 demand NN B-NP O
10 58 60 783197 in IN B-PP O
11 61 69 783197 patients NNS B-NP O
12 70 74 783197 with IN B-PP O
13 75 82 783197 chronic JJ B-NP O
14 83 91 783197 coronary JJ I-NP D003324
15 92 98 783197 artery NN I-NP D003324
16 99 106 783197 disease NN I-NP D003324
17 106 107 783197 . . O O

1 108 109 783197 A DT B-NP O
2 110 121 783197 hemodynamic JJ I-NP O
3 121 122 783197 , , I-NP O
4 123 133 783197 volumetric JJ I-NP O
5 133 134 783197 , , O O
6 135 138 783197 and CC O O
7 139 148 783197 metabolic JJ B-NP O
8 149 154 783197 study NN I-NP O
9 155 157 783197 in IN B-PP O
10 158 166 783197 patients NNS B-NP O
11 167 174 783197 without IN B-PP O
12 175 180 783197 heart NN B-NP D006333
13 181 188 783197 failure NN I-NP D006333
14 188 189 783197 . . O O
15 190 193 783197 The DT B-NP O
16 194 201 783197 effects NNS I-NP O
17 202 204 783197 of IN B-PP O
18 205 214 783197 digitalis NN B-NP D004071
19 215 225 783197 glycosides NNS I-NP D004071
20 226 228 783197 on IN B-PP O
21 229 239 783197 myocardial JJ B-NP O
22 240 246 783197 oxygen NN I-NP D010100
23 247 253 783197 supply NN I-NP O
24 254 257 783197 and CC O O
25 258 264 783197 demand NN B-NP O
26 265 268 783197 are VBP B-VP O
27 269 271 783197 of IN B-PP O
28 272 282 783197 particular JJ B-NP O
29 283 291 783197 interest NN I-NP O
30 292 294 783197 in IN B-PP O
31 295 298 783197 the DT B-NP O
32 299 307 783197 presence NN I-NP O
33 308 310 783197 of IN B-PP O
34 311 322 783197 obstructive JJ B-NP O
35 323 331 783197 coronary JJ I-NP D003324
36 332 338 783197 artery NN I-NP D003324
37 339 346 783197 disease NN I-NP D003324
38 346 347 783197 , , O O
39 348 351 783197 but CC O O
40 352 356 783197 have VBP B-VP O
41 357 360 783197 not RB I-VP O
42 361 365 783197 been VBN I-VP O
43 366 374 783197 measured VBN I-VP O
44 375 385 783197 previously RB B-ADVP O
45 386 388 783197 in IN B-PP O
46 389 392 783197 man NN B-NP O
47 392 393 783197 . . O O

1 394 396 783197 We PRP B-NP O
2 397 405 783197 assessed VBD B-VP O
3 406 409 783197 the DT B-NP O
4 410 417 783197 effects NNS I-NP O
5 418 420 783197 of IN B-PP O
6 421 428 783197 ouabain NN B-NP D010042
7 429 430 783197 ( ( O O
8 430 435 783197 0.015 CD B-NP O
9 436 438 783197 mg NN I-NP O
10 438 439 783197 / SYM B-NP O
11 439 441 783197 kg NN I-NP O
12 442 446 783197 body NN I-NP O
13 447 453 783197 weight NN I-NP O
14 453 454 783197 ) ) O O
15 455 457 783197 on IN B-PP O
16 458 469 783197 hemodynamic JJ B-NP O
17 469 470 783197 , , I-NP O
18 471 481 783197 volumetric JJ I-NP O
19 481 482 783197 , , O O
20 483 486 783197 and CC O O
21 487 496 783197 metabolic JJ B-NP O
22 497 507 783197 parameters NNS I-NP O
23 508 510 783197 in IN B-PP O
24 511 513 783197 11 CD B-NP O
25 514 522 783197 patients NNS I-NP O
26 523 527 783197 with IN B-PP O
27 528 534 783197 severe JJ B-NP O
28 535 542 783197 chronic JJ I-NP O
29 543 551 783197 coronary JJ I-NP D003324
30 552 558 783197 artery NN I-NP D003324
31 559 566 783197 disease NN I-NP D003324
32 567 574 783197 without IN B-PP O
33 575 583 783197 clinical JJ B-NP O
34 584 594 783197 congestive JJ I-NP D006333
35 595 600 783197 heart NN I-NP D006333
36 601 608 783197 failure NN I-NP D006333
37 608 609 783197 . . O O

1 610 617 783197 Because IN B-SBAR O
2 618 621 783197 the DT B-NP O
3 622 630 783197 protocol NN I-NP O
4 631 634 783197 was VBD B-VP O
5 635 639 783197 long JJ B-NP O
6 640 643 783197 and CC I-NP O
7 644 652 783197 involved VBN I-NP O
8 653 666 783197 interventions NNS I-NP O
9 667 672 783197 which WDT B-NP O
10 673 678 783197 might MD B-VP O
11 679 685 783197 affect VB I-VP O
12 686 689 783197 the DT B-NP O
13 690 704 783197 determinations NNS I-NP O
14 704 705 783197 , , O O
15 706 708 783197 we PRP B-NP O
16 709 713 783197 also RB B-ADVP O
17 714 721 783197 studied VBD B-VP O
18 722 724 783197 in IN B-PP O
19 725 729 783197 nine CD B-NP O
20 730 738 783197 patients NNS I-NP O
21 739 744 783197 using VBG B-VP O
22 745 747 783197 an DT B-NP O
23 748 757 783197 identical JJ I-NP O
24 758 766 783197 protocol NN I-NP O
25 767 773 783197 except IN B-PP O
26 774 778 783197 that IN B-SBAR O
27 779 786 783197 ouabain NN B-NP D010042
28 787 801 783197 administration NN I-NP O
29 802 805 783197 was VBD B-VP O
30 806 813 783197 omitted VBN I-VP O
31 813 814 783197 . . O O

1 815 819 783197 Left VBN B-NP O
2 820 831 783197 ventricular JJ I-NP O
3 832 835 783197 end NN I-NP O
4 835 836 783197 - HYPH B-NP O
5 836 845 783197 diastolic JJ I-NP O
6 846 854 783197 pressure NN I-NP O
7 855 858 783197 and CC O O
8 859 863 783197 left VBD B-VP O
9 864 875 783197 ventricular JJ B-NP O
10 876 879 783197 end NN I-NP O
11 879 880 783197 - HYPH B-NP O
12 880 889 783197 diastolic JJ I-NP O
13 890 896 783197 volume NN I-NP O
14 897 901 783197 fell VBD B-VP O
15 902 904 783197 in IN B-PP O
16 905 909 783197 each DT B-NP O
17 910 917 783197 patient NN I-NP O
18 918 923 783197 given VBN B-PP O
19 924 931 783197 ouabain NN B-NP D010042
20 931 932 783197 , , O O
21 933 937 783197 even RB B-SBAR O
22 938 944 783197 though IN I-SBAR O
23 945 949 783197 they PRP B-NP O
24 950 954 783197 were VBD B-VP O
25 955 964 783197 initially RB I-VP O
26 965 973 783197 elevated VBN I-VP O
27 974 976 783197 in IN B-PP O
28 977 981 783197 only RB B-NP O
29 982 985 783197 two CD I-NP O
30 986 994 783197 patients NNS I-NP O
31 994 995 783197 . . O O

1 996 1000 783197 Left VBN B-NP O
2 1001 1012 783197 ventricular JJ I-NP O
3 1013 1016 783197 end NN I-NP O
4 1016 1017 783197 - HYPH B-NP O
5 1017 1026 783197 diastolic JJ I-NP O
6 1027 1035 783197 pressure NN I-NP O
7 1036 1040 783197 fell VBD B-VP O
8 1041 1045 783197 from IN B-PP O
9 1046 1051 783197 11.5+ SYM B-NP O
10 1051 1052 783197 / SYM B-ADVP O
11 1052 1053 783197 - SYM O O
12 1053 1056 783197 1.4 CD B-NP O
13 1057 1058 783197 ( ( O O
14 1058 1063 783197 mean+ NN B-NP O
15 1063 1064 783197 / SYM O O
16 1064 1065 783197 - HYPH O O
17 1065 1067 783197 SE NN B-NP O
18 1067 1068 783197 ) ) O O
19 1069 1071 783197 to TO B-PP O
20 1072 1076 783197 5.6+ SYM B-NP O
21 1076 1077 783197 / SYM B-NP O
22 1077 1078 783197 - SYM B-VP O
23 1078 1081 783197 0.9 CD B-NP O
24 1082 1084 783197 mm NN I-NP O
25 1085 1087 783197 Hg NN I-NP O
26 1088 1089 783197 ( ( O O
27 1089 1090 783197 P NN B-NP O
28 1091 1095 783197 less JJR B-ADJP O
29 1096 1100 783197 than IN B-PP O
30 1101 1106 783197 0.001 CD B-NP O
31 1106 1107 783197 ) ) O O
32 1108 1111 783197 and CC O O
33 1112 1116 783197 left VBD B-VP O
34 1117 1128 783197 ventricular JJ B-NP O
35 1129 1132 783197 end NN I-NP O
36 1132 1133 783197 - HYPH B-NP O
37 1133 1142 783197 diastolic JJ I-NP O
38 1143 1149 783197 volume NN I-NP O
39 1150 1154 783197 fell VBD B-VP O
40 1155 1159 783197 from IN B-PP O
41 1160 1164 783197 100+ JJ B-NP O
42 1164 1165 783197 / SYM I-NP O
43 1165 1166 783197 - SYM I-NP O
44 1166 1168 783197 17 CD B-NP O
45 1169 1171 783197 to TO B-PP O
46 1172 1175 783197 82+ CD B-NP O
47 1175 1176 783197 / SYM B-NP O
48 1176 1177 783197 - SYM I-NP O
49 1177 1179 783197 12 CD I-NP O
50 1180 1182 783197 ml NN I-NP O
51 1182 1183 783197 / SYM B-NP O
52 1183 1185 783197 m2 NN B-NP O
53 1186 1187 783197 ( ( O O
54 1187 1188 783197 P NN B-NP O
55 1189 1193 783197 less JJR B-ADJP O
56 1194 1198 783197 than IN B-PP O
57 1199 1203 783197 0.01 CD B-NP O
58 1203 1204 783197 ) ) O O
59 1205 1206 783197 1 CD B-NP O
60 1207 1208 783197 h NN I-NP O
61 1209 1214 783197 after IN B-PP O
62 1215 1222 783197 ouabain NN B-NP D010042
63 1223 1231 783197 infusion NN I-NP O
64 1232 1235 783197 was VBD B-VP O
65 1236 1245 783197 completed VBN I-VP O
66 1245 1246 783197 . . O O

1 1247 1250 783197 The DT B-NP O
2 1251 1258 783197 maximum JJ I-NP O
3 1259 1267 783197 velocity NN I-NP O
4 1268 1270 783197 of IN B-PP O
5 1271 1282 783197 contractile JJ B-NP O
6 1283 1290 783197 element NN I-NP O
7 1291 1301 783197 shortening NN I-NP O
8 1302 1311 783197 increased VBD B-VP O
9 1312 1316 783197 from IN B-PP O
10 1317 1322 783197 1.68+ CD B-NP O
11 1322 1323 783197 / SYM B-NP O
12 1323 1324 783197 - SYM I-NP O
13 1324 1328 783197 0.11 CD I-NP O
14 1329 1331 783197 ml NN I-NP O
15 1331 1332 783197 / SYM I-NP O
16 1332 1333 783197 s NN I-NP O
17 1334 1336 783197 to TO B-PP O
18 1337 1342 783197 2.18+ JJ B-NP O
19 1342 1343 783197 / SYM I-NP O
20 1343 1344 783197 - SYM I-NP O
21 1344 1348 783197 0.21 CD B-NP O
22 1349 1355 783197 muscle NN I-NP O
23 1355 1356 783197 - HYPH B-NP O
24 1356 1363 783197 lengths NN I-NP O
25 1363 1364 783197 / SYM I-NP O
26 1364 1365 783197 s NN I-NP O
27 1366 1367 783197 ( ( O O
28 1367 1368 783197 P NN B-NP O
29 1369 1373 783197 less JJR B-ADJP O
30 1374 1378 783197 than IN B-PP O
31 1379 1383 783197 0.05 CD B-NP O
32 1383 1384 783197 ) ) O O
33 1385 1388 783197 and CC O O
34 1389 1391 783197 is VBZ B-VP O
35 1392 1402 783197 consistent JJ B-ADJP O
36 1403 1407 783197 with IN B-PP O
37 1408 1410 783197 an DT B-NP O
38 1411 1419 783197 increase NN I-NP O
39 1420 1422 783197 in IN B-PP O
40 1423 1436 783197 contractility NN B-NP O
41 1436 1437 783197 . . O O

1 1438 1440 783197 No DT B-NP O
2 1441 1452 783197 significant JJ I-NP O
3 1453 1459 783197 change NN I-NP O
4 1460 1462 783197 in IN B-PP O
5 1463 1468 783197 these DT B-NP O
6 1469 1479 783197 parameters NNS I-NP O
7 1480 1488 783197 occurred VBD B-VP O
8 1489 1491 783197 in IN B-PP O
9 1492 1495 783197 the DT B-NP O
10 1496 1503 783197 control NN I-NP O
11 1504 1512 783197 patients NNS I-NP O
12 1512 1513 783197 . . O O

1 1514 1516 783197 No DT B-NP O
2 1517 1528 783197 significant JJ I-NP O
3 1529 1535 783197 change NN I-NP O
4 1536 1538 783197 in IN B-PP O
5 1539 1549 783197 myocardial JJ B-NP O
6 1550 1556 783197 oxygen NN I-NP D010100
7 1557 1568 783197 consumption NN I-NP O
8 1569 1577 783197 occurred VBD B-VP O
9 1578 1583 783197 after IN B-SBAR O
10 1584 1591 783197 ouabain NN B-NP D010042
11 1592 1606 783197 administration NN I-NP O
12 1607 1610 783197 but CC O O
13 1611 1615 783197 this DT B-NP O
14 1616 1619 783197 may MD B-VP O
15 1620 1622 783197 be VB I-VP O
16 1623 1630 783197 related JJ B-ADJP O
17 1631 1633 783197 to TO B-PP O
18 1634 1635 783197 a DT B-NP O
19 1636 1643 783197 greater JJR I-NP O
20 1644 1652 783197 decrease NN I-NP O
21 1653 1655 783197 in IN B-PP O
22 1656 1660 783197 mean JJ B-NP O
23 1661 1669 783197 arterial JJ I-NP O
24 1670 1678 783197 pressure NN I-NP O
25 1679 1681 783197 in IN B-PP O
26 1682 1685 783197 the DT B-NP O
27 1686 1693 783197 ouabain NN I-NP D010042
28 1694 1702 783197 patients NNS I-NP O
29 1703 1707 783197 than IN B-PP O
30 1708 1710 783197 in IN B-PP O
31 1711 1714 783197 the DT B-NP O
32 1715 1722 783197 control NN I-NP O
33 1723 1731 783197 patients NNS I-NP O
34 1731 1732 783197 . . O O

1 1733 1735 783197 We PRP B-NP O
2 1736 1744 783197 conclude VBP B-VP O
3 1745 1749 783197 that IN B-SBAR O
4 1750 1752 783197 in IN B-PP O
5 1753 1761 783197 patients NNS B-NP O
6 1762 1766 783197 with IN B-PP O
7 1767 1774 783197 chronic JJ B-NP O
8 1775 1783 783197 coronary JJ I-NP D003324
9 1784 1790 783197 artery NN I-NP D003324
10 1791 1798 783197 disease NN I-NP D003324
11 1799 1802 783197 who WP B-NP O
12 1803 1806 783197 are VBP B-VP O
13 1807 1810 783197 not RB O O
14 1811 1813 783197 in IN B-PP O
15 1814 1822 783197 clinical JJ B-NP O
16 1823 1833 783197 congestive JJ I-NP D006333
17 1834 1839 783197 heart NN I-NP D006333
18 1840 1847 783197 failure NN I-NP D006333
19 1848 1852 783197 left VBD B-VP D002303
20 1853 1864 783197 ventricular JJ B-NP D002303
21 1865 1868 783197 end NN I-NP D002303
22 1868 1869 783197 - HYPH B-NP D002303
23 1869 1878 783197 diastolic JJ I-NP D002303
24 1879 1885 783197 volume NN I-NP D002303
25 1886 1891 783197 falls VBZ B-VP D002303
26 1892 1897 783197 after IN B-PP O
27 1898 1905 783197 ouabain NN B-NP D010042
28 1906 1920 783197 administration NN I-NP O
29 1921 1925 783197 even RB B-ADVP O
30 1926 1930 783197 when WRB B-ADVP O
31 1931 1933 783197 it PRP B-NP O
32 1934 1936 783197 is VBZ B-VP O
33 1937 1946 783197 initially RB B-ADJP O
34 1947 1953 783197 normal JJ I-ADJP O
35 1953 1954 783197 . . O O

1 1955 1961 783197 Though IN B-SBAR O
2 1962 1966 783197 this DT B-NP O
3 1967 1971 783197 fall NN I-NP O
4 1972 1977 783197 would MD B-VP O
5 1978 1980 783197 be VB I-VP O
6 1981 1991 783197 associated VBN I-VP O
7 1992 1996 783197 with IN B-PP O
8 1997 1998 783197 a DT B-NP O
9 1999 2007 783197 decrease NN I-NP O
10 2008 2010 783197 in IN B-PP O
11 2011 2015 783197 wall NN B-NP O
12 2016 2023 783197 tension NN I-NP O
13 2023 2024 783197 , , O O
14 2025 2028 783197 and CC O O
15 2028 2029 783197 , , O O
16 2030 2039 783197 therefore RB B-ADVP O
17 2039 2040 783197 , , O O
18 2041 2043 783197 of IN B-PP O
19 2044 2054 783197 myocardial JJ B-NP O
20 2055 2061 783197 oxygen NN I-NP D010100
21 2062 2073 783197 consumption NN I-NP O
22 2073 2074 783197 , , O O
23 2075 2077 783197 it PRP B-NP O
24 2078 2081 783197 may MD B-VP O
25 2082 2085 783197 not RB I-VP O
26 2086 2088 783197 be VB I-VP O
27 2089 2091 783197 of IN B-PP O
28 2092 2102 783197 sufficient JJ B-NP O
29 2103 2112 783197 magnitude NN I-NP O
30 2113 2115 783197 to TO B-VP O
31 2116 2123 783197 prevent VB I-VP O
32 2124 2125 783197 a DT B-NP O
33 2126 2129 783197 net JJ I-NP O
34 2130 2138 783197 increase NN I-NP O
35 2139 2141 783197 in IN B-PP O
36 2142 2152 783197 myocardial JJ B-NP O
37 2153 2159 783197 oxygen NN I-NP D010100
38 2160 2171 783197 consumption NN I-NP O
39 2171 2172 783197 . . O O

1 2173 2185 783197 Nevertheless RB B-ADVP O
2 2185 2186 783197 , , O O
3 2187 2199 783197 compensatory JJ B-NP O
4 2200 2210 783197 mechanisms NNS I-NP O
5 2211 2218 783197 prevent VBP B-VP O
6 2219 2220 783197 a DT B-NP O
7 2221 2234 783197 deterioration NN I-NP O
8 2235 2237 783197 of IN B-PP O
9 2238 2245 783197 resting VBG B-NP O
10 2246 2256 783197 myocardial JJ I-NP O
11 2257 2267 783197 metabolism NN I-NP O
12 2267 2268 783197 . . O O

1 0 0 18513945 -DOCSTART- -X- -X- O

1 0 3 18513945 The DT B-NP O
2 4 16 18513945 hemodynamics NNS I-NP O
3 17 19 18513945 of IN B-PP O
4 20 28 18513945 oxytocin NN B-NP D010121
5 29 32 18513945 and CC O O
6 33 38 18513945 other JJ B-NP O
7 39 49 18513945 vasoactive JJ I-NP O
8 50 56 18513945 agents NNS I-NP O
9 57 63 18513945 during IN B-PP O
10 64 73 18513945 neuraxial JJ B-NP O
11 74 84 18513945 anesthesia NN I-NP O
12 85 88 18513945 for IN B-PP O
13 89 97 18513945 cesarean JJ B-NP O
14 98 106 18513945 delivery NN I-NP O
15 106 107 18513945 : : O O
16 108 116 18513945 findings NNS B-NP O
17 117 119 18513945 in IN B-PP O
18 120 123 18513945 six CD B-NP O
19 124 129 18513945 cases NNS I-NP O
20 129 130 18513945 . . O O
21 131 139 18513945 Oxytocin NN B-NP D010121
22 140 142 18513945 is VBZ B-VP O
23 143 144 18513945 a DT B-NP O
24 145 153 18513945 commonly RB I-NP O
25 154 158 18513945 used VBN I-NP O
26 159 169 18513945 uterotonic JJ I-NP O
27 170 174 18513945 that WDT B-NP O
28 175 178 18513945 can MD B-VP O
29 179 184 18513945 cause VB I-VP O
30 185 196 18513945 significant JJ B-NP O
31 197 200 18513945 and CC I-NP O
32 201 205 18513945 even RB I-NP O
33 206 211 18513945 fatal JJ I-NP O
34 212 223 18513945 hypotension NN I-NP D007022
35 223 224 18513945 , , O O
36 225 237 18513945 particularly RB B-ADVP O
37 238 242 18513945 when WRB B-ADVP O
38 243 248 18513945 given VBN B-VP O
39 249 251 18513945 as IN B-PP O
40 252 253 18513945 a DT B-NP O
41 254 259 18513945 bolus NN I-NP O
42 259 260 18513945 . . O O

1 261 264 18513945 The DT B-NP O
2 265 274 18513945 resulting VBG I-NP O
3 275 286 18513945 hypotension NN I-NP D007022
4 287 290 18513945 can MD B-VP O
5 291 293 18513945 be VB I-VP O
6 294 302 18513945 produced VBN I-VP O
7 303 305 18513945 by IN B-PP O
8 306 307 18513945 a DT B-NP O
9 308 316 18513945 decrease NN I-NP O
10 317 319 18513945 in IN B-PP O
11 320 328 18513945 systemic JJ B-NP O
12 329 337 18513945 vascular JJ I-NP O
13 338 348 18513945 resistance NN I-NP O
14 349 351 18513945 or CC O O
15 352 359 18513945 cardiac JJ B-NP O
16 360 366 18513945 output NN I-NP O
17 367 374 18513945 through IN B-PP O
18 375 376 18513945 a DT B-NP O
19 377 385 18513945 decrease NN I-NP O
20 386 388 18513945 in IN B-PP O
21 389 395 18513945 venous JJ B-NP O
22 396 402 18513945 return NN I-NP O
23 402 403 18513945 . . O O

1 404 415 18513945 Parturients NNS B-NP O
2 416 420 18513945 with IN B-PP O
3 421 427 18513945 normal JJ B-NP O
4 428 434 18513945 volume NN I-NP O
5 435 441 18513945 status NN I-NP O
6 441 442 18513945 , , O O
7 443 448 18513945 heart NN B-NP O
8 449 455 18513945 valves NNS I-NP O
9 456 459 18513945 and CC O O
10 460 469 18513945 pulmonary JJ B-NP O
11 470 481 18513945 vasculature NN I-NP O
12 482 486 18513945 most RBS B-ADVP O
13 487 492 18513945 often RB I-ADVP O
14 493 500 18513945 respond VBP B-VP O
15 501 503 18513945 to TO B-PP O
16 504 508 18513945 this DT B-NP O
17 509 520 18513945 hypotension NN I-NP D007022
18 521 525 18513945 with IN B-PP O
19 526 527 18513945 a DT B-NP O
20 528 540 18513945 compensatory JJ I-NP O
21 541 549 18513945 increase NN I-NP O
22 550 552 18513945 in IN B-PP O
23 553 558 18513945 heart NN B-NP O
24 559 563 18513945 rate NN I-NP O
25 564 567 18513945 and CC O O
26 568 574 18513945 stroke NN B-NP D020521
27 575 581 18513945 volume NN I-NP O
28 581 582 18513945 . . O O

1 583 591 18513945 Oxytocin NN B-NP D010121
2 591 592 18513945 - HYPH B-NP O
3 592 599 18513945 induced VBN I-NP O
4 600 611 18513945 hypotension NN I-NP D007022
5 612 614 18513945 at IN B-PP O
6 615 623 18513945 cesarean JJ B-NP O
7 624 632 18513945 delivery NN I-NP O
8 633 636 18513945 may MD B-VP O
9 637 639 18513945 be VB I-VP O
10 640 651 18513945 incorrectly RB I-VP O
11 652 662 18513945 attributed VBN I-VP O
12 663 665 18513945 to TO B-PP O
13 666 671 18513945 blood NN B-NP D006473
14 672 676 18513945 loss NN I-NP D006473
15 676 677 18513945 . . O O

1 678 683 18513945 Pulse NN B-NP O
2 684 689 18513945 power NN I-NP O
3 690 698 18513945 analysis NN I-NP O
4 699 700 18513945 ( ( O O
5 700 704 18513945 also RB B-VP O
6 705 711 18513945 called VBN I-VP O
7 712 713 18513945 " `` O O
8 713 718 18513945 pulse NN B-NP O
9 719 726 18513945 contour NN I-NP O
10 727 735 18513945 analysis NN I-NP O
11 735 736 18513945 " '' O O
12 736 737 18513945 ) ) O O
13 738 740 18513945 of IN B-PP O
14 741 743 18513945 an DT B-NP O
15 744 752 18513945 arterial JJ I-NP O
16 753 761 18513945 pressure NN I-NP O
17 762 766 18513945 wave NN I-NP O
18 767 771 18513945 form NN I-NP O
19 772 778 18513945 allows VBZ B-VP O
20 779 789 18513945 continuous JJ B-NP O
21 790 800 18513945 evaluation NN I-NP O
22 801 803 18513945 of IN B-PP O
23 804 812 18513945 systemic JJ B-NP O
24 813 821 18513945 vascular JJ I-NP O
25 822 832 18513945 resistance NN I-NP O
26 833 836 18513945 and CC O O
27 837 844 18513945 cardiac JJ B-NP O
28 845 851 18513945 output NN I-NP O
29 852 854 18513945 in IN B-PP O
30 855 859 18513945 real JJ B-NP O
31 860 864 18513945 time NN I-NP O
32 864 865 18513945 , , O O
33 866 873 18513945 thereby RB B-VP O
34 874 885 18513945 elucidating VBG I-VP O
35 886 889 18513945 the DT B-NP O
36 890 899 18513945 causative JJ I-NP O
37 900 907 18513945 factors NNS I-NP O
38 908 914 18513945 behind IN B-PP O
39 915 922 18513945 changes NNS B-NP O
40 923 925 18513945 in IN B-PP O
41 926 931 18513945 blood NN B-NP O
42 932 940 18513945 pressure NN I-NP O
43 940 941 18513945 . . O O

1 942 947 18513945 Pulse NN B-NP O
2 948 953 18513945 power NN I-NP O
3 954 962 18513945 analysis NN I-NP O
4 963 966 18513945 was VBD B-VP O
5 967 976 18513945 conducted VBN I-VP O
6 977 979 18513945 in IN B-PP O
7 980 983 18513945 six CD B-NP O
8 984 989 18513945 cases NNS I-NP O
9 990 992 18513945 of IN B-PP O
10 993 1001 18513945 cesarean JJ B-NP O
11 1002 1010 18513945 delivery NN I-NP O
12 1011 1020 18513945 performed VBN B-VP O
13 1021 1026 18513945 under IN B-PP O
14 1027 1036 18513945 neuraxial JJ B-NP O
15 1037 1047 18513945 anesthesia NN I-NP O
16 1047 1048 18513945 . . O O

1 1049 1060 18513945 Hypotension NN B-NP D007022
2 1061 1063 18513945 in IN B-PP O
3 1064 1072 18513945 response NN B-NP O
4 1073 1075 18513945 to TO B-PP O
5 1076 1084 18513945 oxytocin NN B-NP D010121
6 1085 1088 18513945 was VBD B-VP O
7 1089 1099 18513945 associated VBN I-VP O
8 1100 1104 18513945 with IN B-PP O
9 1105 1106 18513945 a DT B-NP O
10 1107 1115 18513945 decrease NN I-NP O
11 1116 1118 18513945 in IN B-PP O
12 1119 1127 18513945 systemic JJ B-NP O
13 1128 1136 18513945 vascular JJ I-NP O
14 1137 1147 18513945 resistance NN I-NP O
15 1148 1151 18513945 and CC O O
16 1152 1153 18513945 a DT B-NP O
17 1154 1166 18513945 compensatory JJ I-NP O
18 1167 1175 18513945 increase NN I-NP O
19 1176 1178 18513945 in IN B-PP O
20 1179 1185 18513945 stroke NN B-NP D020521
21 1186 1192 18513945 volume NN I-NP O
22 1192 1193 18513945 , , O O
23 1194 1199 18513945 heart NN B-NP O
24 1200 1204 18513945 rate NN I-NP O
25 1205 1208 18513945 and CC O O
26 1209 1216 18513945 cardiac JJ B-NP O
27 1217 1223 18513945 output NN I-NP O
28 1223 1224 18513945 . . O O

1 1225 1230 18513945 Pulse NN B-NP O
2 1231 1236 18513945 power NN I-NP O
3 1237 1245 18513945 analysis NN I-NP O
4 1246 1249 18513945 may MD B-VP O
5 1250 1252 18513945 be VB I-VP O
6 1253 1260 18513945 helpful JJ B-ADJP O
7 1261 1263 18513945 in IN B-PP O
8 1264 1275 18513945 determining VBG B-VP O
9 1276 1279 18513945 the DT B-NP O
10 1280 1288 18513945 etiology NN I-NP O
11 1289 1291 18513945 of IN B-PP O
12 1292 1295 18513945 and CC O O
13 1296 1304 18513945 treating VBG B-VP O
14 1305 1316 18513945 hypotension NN B-NP D007022
15 1317 1323 18513945 during IN B-PP O
16 1324 1332 18513945 cesarean JJ B-NP O
17 1333 1341 18513945 delivery NN I-NP O
18 1342 1347 18513945 under IN B-PP O
19 1348 1357 18513945 neuraxial JJ B-NP O
20 1358 1368 18513945 anesthesia NN I-NP O
21 1368 1369 18513945 . . O O

1 0 0 8475949 -DOCSTART- -X- -X- O

1 0 4 8475949 Case NN B-NP O
2 5 11 8475949 report NN I-NP O
3 11 12 8475949 : : O O
4 13 24 8475949 pentamidine NN B-NP D010419
5 25 28 8475949 and CC O O
6 29 40 8475949 polymorphic JJ B-NP O
7 41 52 8475949 ventricular JJ I-NP D017180
8 53 64 8475949 tachycardia NN I-NP D017180
9 65 74 8475949 revisited VBN B-VP O
10 74 75 8475949 . . O O
11 76 87 8475949 Pentamidine NNP B-NP D010419
12 88 99 8475949 isethionate NN I-NP D010419
13 100 103 8475949 has VBZ B-VP O
14 104 108 8475949 been VBN I-VP O
15 109 119 8475949 associated VBN I-VP O
16 120 124 8475949 with IN B-PP O
17 125 136 8475949 ventricular JJ B-NP D017180
18 137 153 8475949 tachyarrhythmias NNS I-NP D017180
19 153 154 8475949 , , O O
20 155 164 8475949 including VBG B-PP O
21 165 172 8475949 torsade FW B-NP D016171
22 173 175 8475949 de FW I-NP D016171
23 176 183 8475949 pointes FW I-NP D016171
24 183 184 8475949 . . O O

1 185 189 8475949 This DT B-NP O
2 190 197 8475949 article NN I-NP O
3 198 205 8475949 reports VBZ B-VP O
4 206 209 8475949 two CD B-NP O
5 210 215 8475949 cases NNS I-NP O
6 216 218 8475949 of IN B-PP O
7 219 223 8475949 this DT B-NP O
8 224 236 8475949 complication NN I-NP O
9 237 240 8475949 and CC O O
10 241 248 8475949 reviews VBZ B-VP O
11 249 252 8475949 all DT B-NP O
12 253 261 8475949 reported VBN I-NP O
13 262 267 8475949 cases NNS I-NP O
14 268 270 8475949 to TO B-PP O
15 271 275 8475949 date NN B-NP O
16 275 276 8475949 . . O O

1 277 288 8475949 Pentamidine NN B-NP D010419
2 288 289 8475949 - HYPH O O
3 289 296 8475949 induced VBN B-VP O
4 297 304 8475949 torsade FW B-NP D016171
5 305 307 8475949 de FW I-NP D016171
6 308 315 8475949 pointes NNS I-NP D016171
7 316 319 8475949 may MD B-VP O
8 320 322 8475949 be VB I-VP O
9 323 330 8475949 related VBN I-VP O
10 331 333 8475949 to TO B-PP O
11 334 339 8475949 serum NN B-NP O
12 340 349 8475949 magnesium NN I-NP D008274
13 350 356 8475949 levels NNS I-NP O
14 357 360 8475949 and CC O O
15 361 375 8475949 hypomagnesemia NN B-NP C537153
16 376 379 8475949 may MD B-VP O
17 380 395 8475949 synergistically RB I-VP O
18 396 402 8475949 induce VB I-VP O
19 403 410 8475949 torsade NN B-NP O
20 410 411 8475949 . . O O

1 412 419 8475949 Torsade FW B-NP D016171
2 420 422 8475949 de FW I-NP D016171
3 423 430 8475949 pointes FW I-NP D016171
4 431 439 8475949 occurred VBD B-VP O
5 440 445 8475949 after IN B-PP O
6 446 448 8475949 an DT B-NP O
7 449 456 8475949 average NN I-NP O
8 457 459 8475949 of IN B-PP O
9 460 462 8475949 10 CD B-NP O
10 463 467 8475949 days NNS I-NP O
11 468 470 8475949 of IN B-PP O
12 471 480 8475949 treatment NN B-NP O
13 481 485 8475949 with IN B-PP O
14 486 497 8475949 pentamidine NN B-NP D010419
15 497 498 8475949 . . O O

1 499 501 8475949 In IN B-PP O
2 502 507 8475949 these DT B-NP O
3 508 516 8475949 patients NNS I-NP O
4 516 517 8475949 , , O O
5 518 520 8475949 no DT B-NP O
6 521 526 8475949 other JJ I-NP O
7 527 532 8475949 acute JJ I-NP O
8 533 537 8475949 side NN I-NP O
9 538 545 8475949 effects NNS I-NP O
10 546 548 8475949 of IN B-PP O
11 549 560 8475949 pentamidine NN B-NP D010419
12 561 565 8475949 were VBD B-VP O
13 566 574 8475949 observed VBN I-VP O
14 574 575 8475949 . . O O

1 576 583 8475949 Torsade NNP B-NP D016171
2 584 586 8475949 de FW I-NP D016171
3 587 594 8475949 pointes FW I-NP D016171
4 595 598 8475949 can MD B-VP O
5 599 601 8475949 be VB I-VP O
6 602 609 8475949 treated VBN I-VP O
7 610 614 8475949 when WRB B-ADVP O
8 615 625 8475949 recognized VBN B-VP O
9 626 631 8475949 early RB B-ADVP O
10 631 632 8475949 , , O O
11 633 641 8475949 possibly RB B-ADVP O
12 642 649 8475949 without IN B-PP O
13 650 665 8475949 discontinuation NN B-NP O
14 666 668 8475949 of IN B-PP O
15 669 680 8475949 pentamidine NN B-NP D010419
16 680 681 8475949 . . O O

1 682 686 8475949 When WRB B-ADVP O
2 687 690 8475949 QTc NN B-NP D008133
3 691 699 8475949 interval NN I-NP D008133
4 700 712 8475949 prolongation NN I-NP D008133
5 713 715 8475949 is VBZ B-VP O
6 716 724 8475949 observed VBN I-VP O
7 724 725 8475949 , , O O
8 726 731 8475949 early JJ B-NP O
9 732 741 8475949 magnesium NN I-NP D008274
10 742 757 8475949 supplementation NN I-NP O
11 758 760 8475949 is VBZ B-VP O
12 761 770 8475949 advocated VBN I-VP O
13 770 771 8475949 . . O O

1 0 0 10533019 -DOCSTART- -X- -X- O

1 0 5 10533019 Rapid JJ B-NP O
2 6 14 10533019 reversal NN I-NP O
3 15 17 10533019 of IN B-PP O
4 18 22 10533019 life NN B-NP O
5 22 23 10533019 - HYPH O O
6 23 34 10533019 threatening VBG B-VP O
7 35 44 10533019 diltiazem NN B-NP D004110
8 44 45 10533019 - HYPH O O
9 45 52 10533019 induced VBN B-NP O
10 53 59 10533019 tetany NN I-NP D013746
11 60 64 10533019 with IN B-PP O
12 65 72 10533019 calcium NN B-NP D002122
13 73 81 10533019 chloride NN I-NP D002122
14 81 82 10533019 . . O O
15 83 85 10533019 We PRP B-NP O
16 86 94 10533019 describe VBP B-VP O
17 95 96 10533019 a DT B-NP O
18 97 104 10533019 patient NN I-NP O
19 105 108 10533019 who WP B-NP O
20 109 118 10533019 developed VBD B-VP O
21 119 125 10533019 tetany NN B-NP D013746
22 126 130 10533019 with IN B-PP O
23 131 137 10533019 sudden JJ B-NP O
24 138 149 10533019 respiratory JJ I-NP D012131
25 150 156 10533019 arrest NN I-NP D012131
26 157 162 10533019 after IN B-PP O
27 163 166 10533019 the DT B-NP O
28 167 175 10533019 infusion NN I-NP O
29 176 178 10533019 of IN B-PP O
30 179 190 10533019 intravenous JJ B-NP O
31 191 200 10533019 diltiazem NN I-NP D004110
32 200 201 10533019 . . O O

1 202 205 10533019 The DT B-NP O
2 206 220 10533019 administration NN I-NP O
3 221 223 10533019 of IN B-PP O
4 224 231 10533019 calcium NN B-NP D002122
5 232 240 10533019 chloride NN I-NP D002122
6 241 248 10533019 rapidly RB B-ADVP O
7 249 257 10533019 resolved VBD B-VP O
8 258 261 10533019 the DT B-NP O
9 262 271 10533019 patient's NNS I-NP O
10 272 278 10533019 tetany VBP B-VP D013746
11 279 283 10533019 with IN B-PP O
12 284 290 10533019 prompt JJ B-NP O
13 291 299 10533019 recovery NN I-NP O
14 300 302 10533019 of IN B-PP O
15 303 314 10533019 respiratory JJ B-NP O
16 315 323 10533019 function NN I-NP O
17 323 324 10533019 , , O O
18 325 333 10533019 averting VBG B-VP O
19 334 337 10533019 the DT B-NP O
20 338 342 10533019 need NN I-NP O
21 343 346 10533019 for IN B-PP O
22 347 351 10533019 more RBR B-NP O
23 352 362 10533019 aggressive JJ I-NP O
24 363 369 10533019 airway NN I-NP O
25 370 380 10533019 management NN I-NP O
26 381 384 10533019 and CC O O
27 385 396 10533019 ventilatory JJ B-NP O
28 397 404 10533019 support NN I-NP O
29 404 405 10533019 . . O O

1 406 409 10533019 The DT B-NP O
2 410 419 10533019 emergency NN I-NP O
3 420 429 10533019 physician NN I-NP O
4 430 436 10533019 should MD B-VP O
5 437 439 10533019 be VB I-VP O
6 440 445 10533019 aware JJ B-ADJP O
7 446 450 10533019 that IN B-SBAR O
8 451 455 10533019 life NN B-NP O
9 455 456 10533019 - HYPH O O
10 456 467 10533019 threatening VBG B-VP O
11 468 474 10533019 tetany NN B-NP D013746
12 475 478 10533019 may MD B-VP O
13 479 488 10533019 accompany VB I-VP O
14 489 492 10533019 the DT B-NP O
15 493 507 10533019 administration NN I-NP O
16 508 510 10533019 of IN B-PP O
17 511 522 10533019 intravenous JJ B-NP O
18 523 532 10533019 diltiazem NN I-NP D004110
19 533 536 10533019 and CC O O
20 537 541 10533019 that IN B-SBAR O
21 542 549 10533019 calcium NN B-NP D002122
22 550 558 10533019 chloride NN I-NP D002122
23 559 562 10533019 may MD B-VP O
24 563 565 10533019 be VB I-VP O
25 566 567 10533019 a DT B-NP O
26 568 573 10533019 rapid JJ I-NP O
27 574 577 10533019 and CC I-NP O
28 578 587 10533019 effective JJ I-NP O
29 588 594 10533019 remedy NN I-NP O
30 594 595 10533019 . . O O

1 0 0 18006530 -DOCSTART- -X- -X- O

1 0 9 18006530 Reduction NN B-NP O
2 10 12 18006530 of IN B-PP O
3 13 17 18006530 pain NN B-NP D010146
4 18 24 18006530 during IN B-PP O
5 25 34 18006530 induction NN B-NP O
6 35 39 18006530 with IN B-PP O
7 40 46 18006530 target NN B-NP O
8 46 47 18006530 - HYPH B-NP O
9 47 57 18006530 controlled VBN I-NP O
10 58 66 18006530 propofol NN I-NP D015742
11 67 70 18006530 and CC I-NP O
12 71 83 18006530 remifentanil NN I-NP C071741
13 83 84 18006530 . . I-NP O
14 85 95 18006530 BACKGROUND NN I-NP O
15 95 96 18006530 : : O O
16 97 101 18006530 Pain NN B-NP D010146
17 102 104 18006530 on IN B-PP O
18 105 114 18006530 injection NN B-NP O
19 115 117 18006530 of IN B-PP O
20 118 126 18006530 propofol NN B-NP D015742
21 127 129 18006530 is VBZ B-VP O
22 130 140 18006530 unpleasant JJ B-ADJP O
23 140 141 18006530 . . O O

1 142 144 18006530 We PRP B-NP O
2 145 157 18006530 hypothesized VBD B-VP O
3 158 162 18006530 that IN B-SBAR O
4 163 171 18006530 propofol NN B-NP D015742
5 172 180 18006530 infusion NN I-NP O
6 181 185 18006530 pain NN I-NP D010146
7 186 191 18006530 might MD B-VP O
8 192 194 18006530 be VB I-VP O
9 195 204 18006530 prevented VBN I-VP O
10 205 207 18006530 by IN B-PP O
11 208 216 18006530 infusing VBG B-VP O
12 217 229 18006530 remifentanil NN B-NP C071741
13 230 236 18006530 before IN B-PP O
14 237 245 18006530 starting VBG B-VP O
15 246 249 18006530 the DT B-NP O
16 250 258 18006530 propofol NN I-NP D015742
17 259 267 18006530 infusion NN I-NP O
18 268 270 18006530 in IN B-PP O
19 271 272 18006530 a DT B-NP O
20 273 281 18006530 clinical JJ I-NP O
21 282 289 18006530 setting NN I-NP O
22 290 295 18006530 where WRB B-ADVP O
23 296 302 18006530 target NN B-NP O
24 302 303 18006530 - HYPH B-NP O
25 303 313 18006530 controlled VBN I-NP O
26 314 323 18006530 infusions NNS I-NP O
27 324 325 18006530 ( ( O O
28 325 328 18006530 TCI NN B-NP O
29 328 329 18006530 ) ) O O
30 330 332 18006530 of IN B-PP O
31 333 337 18006530 both DT B-NP O
32 338 343 18006530 drugs NNS I-NP O
33 344 348 18006530 were VBD B-VP O
34 349 353 18006530 used VBN I-VP O
35 353 354 18006530 . . O O

1 355 356 18006530 A DT B-NP O
2 357 368 18006530 prospective JJ I-NP O
3 368 369 18006530 , , I-NP O
4 370 380 18006530 randomized VBN I-NP O
5 380 381 18006530 , , I-NP O
6 382 388 18006530 double JJ I-NP O
7 388 389 18006530 - HYPH I-NP O
8 389 394 18006530 blind JJ I-NP O
9 394 395 18006530 , , I-NP O
10 396 403 18006530 placebo NN I-NP O
11 403 404 18006530 - HYPH I-NP O
12 404 414 18006530 controlled VBN B-NP O
13 415 420 18006530 trial NN I-NP O
14 421 424 18006530 was VBD B-VP O
15 425 434 18006530 performed VBN I-VP O
16 435 437 18006530 to TO B-VP O
17 438 447 18006530 determine VB I-VP O
18 448 451 18006530 the DT B-NP O
19 452 458 18006530 effect NN I-NP O
20 458 459 18006530 - HYPH O O
21 459 463 18006530 site NN B-NP O
22 464 477 18006530 concentration NN I-NP O
23 478 479 18006530 ( ( O O
24 479 481 18006530 Ce NN B-NP O
25 481 482 18006530 ) ) O O
26 483 485 18006530 of IN B-PP O
27 486 498 18006530 remifentanil NN B-NP C071741
28 499 501 18006530 to TO B-VP O
29 502 509 18006530 prevent VB I-VP O
30 510 513 18006530 the DT B-NP O
31 514 518 18006530 pain NN I-NP D010146
32 519 526 18006530 without IN B-PP O
33 527 536 18006530 producing VBG B-VP O
34 537 550 18006530 complications NNS B-NP O
35 550 551 18006530 . . O O

1 552 559 18006530 METHODS NNS B-NP O
2 559 560 18006530 : : O O
3 561 562 18006530 A DT B-NP O
4 563 568 18006530 total NN I-NP O
5 569 571 18006530 of IN B-PP O
6 572 575 18006530 128 CD B-NP O
7 576 584 18006530 patients NNS I-NP O
8 585 595 18006530 undergoing VBG B-VP O
9 596 603 18006530 general JJ B-NP O
10 604 611 18006530 surgery NN I-NP O
11 612 616 18006530 were VBD B-VP O
12 617 625 18006530 randomly RB I-VP O
13 626 635 18006530 allocated VBN I-VP O
14 636 638 18006530 to TO I-VP O
15 639 646 18006530 receive VB I-VP O
16 647 653 18006530 normal JJ B-NP O
17 654 660 18006530 saline NN I-NP O
18 661 662 18006530 ( ( O O
19 662 669 18006530 control NN B-NP O
20 669 670 18006530 ) ) O O
21 671 673 18006530 or CC O O
22 674 686 18006530 remifentanil NN B-NP C071741
23 687 689 18006530 to TO B-PP O
24 690 691 18006530 a DT B-NP O
25 692 698 18006530 target NN I-NP O
26 699 701 18006530 Ce NN I-NP O
27 702 704 18006530 of IN B-PP O
28 705 706 18006530 2 CD B-NP O
29 707 709 18006530 ng NN I-NP O
30 710 713 18006530 ml( AFX B-VP O
31 713 714 18006530 - HYPH B-ADJP O
32 714 716 18006530 1) LS B-LST O
33 717 718 18006530 ( ( O O
34 718 720 18006530 R2 NN B-NP O
35 720 721 18006530 ) ) O O
36 721 722 18006530 , , O O
37 723 724 18006530 4 CD B-NP O
38 725 727 18006530 ng NN I-NP O
39 728 731 18006530 ml( AFX B-VP O
40 731 732 18006530 - HYPH B-ADJP O
41 732 734 18006530 1) LS B-LST O
42 735 736 18006530 ( ( O O
43 736 738 18006530 R4 NN B-NP O
44 738 739 18006530 ) ) O O
45 739 740 18006530 , , O O
46 741 743 18006530 or CC O O
47 744 745 18006530 6 CD B-NP O
48 746 748 18006530 ng NN I-NP O
49 749 752 18006530 ml( AFX B-VP O
50 752 753 18006530 - HYPH B-ADJP O
51 753 755 18006530 1) LS B-LST O
52 756 757 18006530 ( ( O O
53 757 759 18006530 R6 NN B-NP O
54 759 760 18006530 ) ) O O
55 761 773 18006530 administered VBN B-VP O
56 774 777 18006530 via IN B-PP O
57 778 781 18006530 TCI NN B-NP O
58 781 782 18006530 . . O O

1 783 788 18006530 After IN B-PP O
2 789 792 18006530 the DT B-NP O
3 793 799 18006530 target NN I-NP O
4 800 802 18006530 Ce NN I-NP O
5 803 806 18006530 was VBD B-VP O
6 807 815 18006530 achieved VBN I-VP O
7 815 816 18006530 , , O O
8 817 820 18006530 the DT B-NP O
9 821 829 18006530 infusion NN I-NP O
10 830 832 18006530 of IN B-PP O
11 833 841 18006530 propofol NN B-NP D015742
12 842 845 18006530 was VBD B-VP O
13 846 853 18006530 started VBN I-VP O
14 853 854 18006530 . . O O

1 855 867 18006530 Remifentanil NN B-NP C071741
2 867 868 18006530 - HYPH B-NP O
3 868 875 18006530 related VBN I-NP O
4 876 889 18006530 complications NNS I-NP O
5 890 894 18006530 were VBD B-VP O
6 895 903 18006530 assessed VBN I-VP O
7 904 910 18006530 during IN B-PP O
8 911 914 18006530 the DT B-NP O
9 915 927 18006530 remifentanil NN I-NP C071741
10 928 936 18006530 infusion NN I-NP O
11 936 937 18006530 , , O O
12 938 941 18006530 and CC O O
13 942 946 18006530 pain NN B-NP D010146
14 947 953 18006530 caused VBN B-VP O
15 954 956 18006530 by IN B-PP O
16 957 965 18006530 propofol NN B-NP D015742
17 966 969 18006530 was VBD B-VP O
18 970 979 18006530 evaluated VBN I-VP O
19 980 985 18006530 using VBG I-VP O
20 986 987 18006530 a DT B-NP O
21 988 992 18006530 four CD I-NP O
22 992 993 18006530 - HYPH I-NP O
23 993 998 18006530 point NN I-NP O
24 999 1004 18006530 scale NN I-NP O
25 1005 1011 18006530 during IN B-PP O
26 1012 1015 18006530 the DT B-NP O
27 1016 1024 18006530 propofol NN I-NP D015742
28 1025 1033 18006530 infusion NN I-NP O
29 1033 1034 18006530 . . O O

1 1035 1042 18006530 RESULTS NNS B-NP O
2 1042 1043 18006530 : : O O
3 1044 1047 18006530 The DT B-NP O
4 1048 1057 18006530 incidence NN I-NP O
5 1058 1060 18006530 of IN B-PP O
6 1061 1065 18006530 pain NN B-NP D010146
7 1066 1069 18006530 was VBD B-VP O
8 1070 1083 18006530 significantly RB B-ADJP O
9 1084 1089 18006530 lower JJR I-ADJP O
10 1090 1092 18006530 in IN B-PP O
11 1093 1099 18006530 Groups NNS B-NP O
12 1100 1102 18006530 R4 NN I-NP O
13 1103 1106 18006530 and CC I-NP O
14 1107 1109 18006530 R6 NN I-NP O
15 1110 1114 18006530 than IN B-PP O
16 1115 1117 18006530 in IN B-PP O
17 1118 1121 18006530 the DT B-NP O
18 1122 1129 18006530 control NN I-NP O
19 1130 1133 18006530 and CC I-NP O
20 1134 1136 18006530 R2 NN I-NP O
21 1137 1143 18006530 groups NNS I-NP O
22 1144 1145 18006530 ( ( O O
23 1145 1147 18006530 12 CD B-NP O
24 1147 1148 18006530 / SYM I-NP O
25 1148 1150 18006530 32 CD I-NP O
26 1151 1154 18006530 and CC I-NP O
27 1155 1156 18006530 6 CD I-NP O
28 1156 1157 18006530 / SYM I-NP O
29 1157 1159 18006530 31 CD I-NP O
30 1160 1162 18006530 vs IN I-NP O
31 1163 1165 18006530 26 CD I-NP O
32 1165 1166 18006530 / SYM I-NP O
33 1166 1168 18006530 31 CD I-NP O
34 1169 1172 18006530 and CC I-NP O
35 1173 1175 18006530 25 CD I-NP O
36 1175 1176 18006530 / SYM I-NP O
37 1176 1178 18006530 32 CD I-NP O
38 1178 1179 18006530 , , O O
39 1180 1192 18006530 respectively RB B-ADVP O
40 1192 1193 18006530 , , O O
41 1194 1195 18006530 P NN B-NP O
42 1195 1196 18006530 < SYM B-NP O
43 1196 1201 18006530 0.001 CD I-NP O
44 1201 1202 18006530 ) ) O O
45 1202 1203 18006530 . . O O

1 1204 1208 18006530 Pain NN B-NP D010146
2 1209 1212 18006530 was VBD B-VP O
3 1213 1217 18006530 less RBR B-ADJP O
4 1218 1224 18006530 severe JJ I-ADJP O
5 1225 1227 18006530 in IN B-PP O
6 1228 1234 18006530 Groups NNS B-NP O
7 1235 1237 18006530 R4 NN I-NP O
8 1238 1241 18006530 and CC I-NP O
9 1242 1244 18006530 R6 NN I-NP O
10 1245 1249 18006530 than IN B-PP O
11 1250 1252 18006530 in IN B-PP O
12 1253 1256 18006530 the DT B-NP O
13 1257 1264 18006530 control NN I-NP O
14 1265 1268 18006530 and CC I-NP O
15 1269 1271 18006530 R2 NN I-NP O
16 1272 1278 18006530 groups NNS I-NP O
17 1279 1280 18006530 ( ( O O
18 1280 1281 18006530 P NN B-NP O
19 1281 1282 18006530 < SYM O O
20 1282 1287 18006530 0.001 CD B-NP O
21 1287 1288 18006530 ) ) O O
22 1288 1289 18006530 . . O O

1 1290 1297 18006530 However RB B-ADVP O
2 1297 1298 18006530 , , O O
3 1299 1303 18006530 both CC O O
4 1304 1313 18006530 incidence NN B-NP O
5 1314 1317 18006530 and CC I-NP O
6 1318 1326 18006530 severity NN I-NP O
7 1327 1329 18006530 of IN B-PP O
8 1330 1334 18006530 pain NN B-NP D010146
9 1335 1339 18006530 were VBD B-VP O
10 1340 1343 18006530 not RB B-ADJP O
11 1344 1353 18006530 different JJ I-ADJP O
12 1354 1361 18006530 between IN B-PP O
13 1362 1368 18006530 Groups NNS B-NP O
14 1369 1371 18006530 R4 NN I-NP O
15 1372 1375 18006530 and CC I-NP O
16 1376 1378 18006530 R6 NN I-NP O
17 1378 1379 18006530 . . O O

1 1380 1382 18006530 No DT B-NP O
2 1383 1394 18006530 significant JJ I-NP O
3 1395 1408 18006530 complications NNS I-NP O
4 1409 1413 18006530 were VBD B-VP O
5 1414 1422 18006530 observed VBN I-VP O
6 1423 1429 18006530 during IN B-PP O
7 1430 1433 18006530 the DT B-NP O
8 1434 1439 18006530 study NN I-NP O
9 1439 1440 18006530 . . O O

1 1441 1452 18006530 CONCLUSIONS NNS B-NP O
2 1452 1453 18006530 : : O O
3 1454 1460 18006530 During IN B-PP O
4 1461 1470 18006530 induction NN B-NP O
5 1471 1473 18006530 of IN B-PP O
6 1474 1485 18006530 anaesthesia NN B-NP O
7 1486 1490 18006530 with IN B-PP O
8 1491 1494 18006530 TCI NN B-NP O
9 1495 1497 18006530 of IN B-PP O
10 1498 1506 18006530 propofol NN B-NP D015742
11 1507 1510 18006530 and CC I-NP O
12 1511 1523 18006530 remifentanil NN I-NP C071741
13 1523 1524 18006530 , , O O
14 1525 1526 18006530 a DT B-NP O
15 1527 1538 18006530 significant JJ I-NP O
16 1539 1548 18006530 reduction NN I-NP O
17 1549 1551 18006530 in IN B-PP O
18 1552 1560 18006530 propofol NN B-NP D015742
19 1561 1569 18006530 infusion NN I-NP O
20 1570 1574 18006530 pain NN I-NP D010146
21 1575 1578 18006530 was VBD B-VP O
22 1579 1587 18006530 achieved VBN I-VP O
23 1588 1595 18006530 without IN B-PP O
24 1596 1607 18006530 significant JJ B-NP O
25 1608 1621 18006530 complications NNS I-NP O
26 1622 1624 18006530 by IN B-PP O
27 1625 1630 18006530 prior JJ B-NP O
28 1631 1645 18006530 administration NN I-NP O
29 1646 1648 18006530 of IN B-PP O
30 1649 1661 18006530 remifentanil NN B-NP C071741
31 1662 1664 18006530 at IN B-PP O
32 1665 1666 18006530 a DT B-NP O
33 1667 1673 18006530 target NN I-NP O
34 1674 1676 18006530 Ce NN I-NP O
35 1677 1679 18006530 of IN B-PP O
36 1680 1681 18006530 4 CD B-NP O
37 1682 1684 18006530 ng NN I-NP O
38 1685 1688 18006530 ml( AFX B-VP O
39 1688 1689 18006530 - HYPH B-ADJP O
40 1689 1691 18006530 1) LS B-LST O
41 1691 1692 18006530 . . O O

1 0 0 15517007 -DOCSTART- -X- -X- O

1 0 9 15517007 Consensus NNP B-NP O
2 10 19 15517007 statement NN I-NP O
3 20 30 15517007 concerning VBG B-VP O
4 31 45 15517007 cardiotoxicity NN B-NP D066126
5 46 55 15517007 occurring VBG B-VP O
6 56 62 15517007 during IN B-PP O
7 63 77 15517007 haematopoietic JJ B-NP O
8 78 82 15517007 stem NN I-NP O
9 83 87 15517007 cell NN I-NP O
10 88 103 15517007 transplantation NN I-NP O
11 104 106 15517007 in IN B-PP O
12 107 110 15517007 the DT B-NP O
13 111 120 15517007 treatment NN I-NP O
14 121 123 15517007 of IN B-PP O
15 124 134 15517007 autoimmune JJ B-NP D001327
16 135 143 15517007 diseases NNS I-NP D001327
17 143 144 15517007 , , O O
18 145 149 15517007 with IN B-PP O
19 150 157 15517007 special JJ B-NP O
20 158 167 15517007 reference NN I-NP O
21 168 170 15517007 to TO B-PP O
22 171 179 15517007 systemic JJ B-NP D012595
23 180 189 15517007 sclerosis NN I-NP D012595
24 190 193 15517007 and CC O O
25 194 202 15517007 multiple JJ B-NP D009103
26 203 212 15517007 sclerosis NN I-NP D009103
27 212 213 15517007 . . O O
28 214 224 15517007 Autologous JJ B-NP O
29 225 239 15517007 haematopoietic JJ I-NP O
30 240 244 15517007 stem NN I-NP O
31 245 249 15517007 cell NN I-NP O
32 250 265 15517007 transplantation NN I-NP O
33 266 268 15517007 is VBZ B-VP O
34 269 272 15517007 now RB B-ADVP O
35 273 274 15517007 a DT B-NP O
36 275 283 15517007 feasible JJ I-NP O
37 284 287 15517007 and CC I-NP O
38 288 297 15517007 effective JJ I-NP O
39 298 307 15517007 treatment NN I-NP O
40 308 311 15517007 for IN B-PP O
41 312 320 15517007 selected VBN B-NP O
42 321 329 15517007 patients NNS I-NP O
43 330 334 15517007 with IN B-PP O
44 335 341 15517007 severe JJ B-NP O
45 342 352 15517007 autoimmune JJ I-NP D001327
46 353 361 15517007 diseases NNS I-NP D001327
47 361 362 15517007 . . O O

1 363 372 15517007 Worldwide RB B-ADVP O
2 372 373 15517007 , , O O
3 374 378 15517007 over IN B-PP O
4 379 382 15517007 650 CD B-NP O
5 383 391 15517007 patients NNS I-NP O
6 392 396 15517007 have VBP B-VP O
7 397 401 15517007 been VBN I-VP O
8 402 414 15517007 transplanted VBN I-VP O
9 415 417 15517007 in IN B-PP O
10 418 421 15517007 the DT B-NP O
11 422 429 15517007 context NN I-NP O
12 430 432 15517007 of IN B-PP O
13 433 438 15517007 phase NN B-NP O
14 439 440 15517007 I CD I-NP O
15 441 444 15517007 and CC I-NP O
16 445 447 15517007 II CD I-NP O
17 448 456 15517007 clinical JJ I-NP O
18 457 463 15517007 trials NNS I-NP O
19 463 464 15517007 . . O O

1 465 468 15517007 The DT B-NP O
2 469 476 15517007 results NNS I-NP O
3 477 480 15517007 are VBP B-VP O
4 481 492 15517007 encouraging VBG I-VP O
5 493 499 15517007 enough RB B-ADVP O
6 500 502 15517007 to TO B-VP O
7 503 508 15517007 begin VB I-VP O
8 509 519 15517007 randomised VBN I-VP O
9 520 525 15517007 phase NN B-NP O
10 526 529 15517007 III CD B-NP O
11 530 536 15517007 trials NNS I-NP O
12 536 537 15517007 . . O O

1 538 545 15517007 However RB B-ADVP O
2 545 546 15517007 , , O O
3 547 549 15517007 as IN B-SBAR O
4 550 559 15517007 predicted VBN B-VP O
5 559 560 15517007 , , O O
6 561 572 15517007 significant JJ B-NP O
7 573 583 15517007 transplant NN I-NP O
8 583 584 15517007 - HYPH B-NP O
9 584 591 15517007 related VBN I-NP O
10 592 601 15517007 morbidity NN I-NP O
11 602 605 15517007 and CC I-NP O
12 606 615 15517007 mortality NN I-NP O
13 616 620 15517007 have VBP B-VP O
14 621 625 15517007 been VBN I-VP O
15 626 634 15517007 observed VBN I-VP O
16 634 635 15517007 . . O O

1 636 640 15517007 This DT B-NP O
2 641 643 15517007 is VBZ B-VP O
3 644 653 15517007 primarily RB B-ADJP O
4 654 657 15517007 due JJ I-ADJP O
5 658 660 15517007 to TO B-PP O
6 661 674 15517007 complications NNS B-NP O
7 675 682 15517007 related VBN B-VP O
8 683 685 15517007 to TO B-PP O
9 686 692 15517007 either CC O O
10 693 696 15517007 the DT B-NP O
11 697 702 15517007 stage NN I-NP O
12 703 705 15517007 of IN B-PP O
13 706 709 15517007 the DT B-NP O
14 710 717 15517007 disease NN I-NP O
15 718 720 15517007 at IN B-PP O
16 721 731 15517007 transplant NN B-NP O
17 732 734 15517007 or CC O O
18 735 738 15517007 due JJ B-ADJP O
19 739 741 15517007 to TO B-PP O
20 742 752 15517007 infections NNS B-NP D007239
21 752 753 15517007 . . O O

1 754 757 15517007 The DT B-NP O
2 758 764 15517007 number NN I-NP O
3 765 767 15517007 of IN B-PP O
4 768 774 15517007 deaths NNS B-NP O
5 775 782 15517007 related VBN B-VP O
6 783 785 15517007 to TO B-PP O
7 786 793 15517007 cardiac JJ B-NP D066126
8 794 802 15517007 toxicity NN I-NP D066126
9 803 805 15517007 is VBZ B-VP O
10 806 809 15517007 low JJ B-ADJP O
11 809 810 15517007 . . O O

1 811 818 15517007 However RB B-ADVP O
2 818 819 15517007 , , O O
3 820 827 15517007 caution NN B-NP O
4 828 830 15517007 is VBZ B-VP O
5 831 839 15517007 required VBN I-VP O
6 840 844 15517007 when WRB B-ADVP O
7 845 861 15517007 cyclophosphamide NN B-NP D003520
8 862 864 15517007 or CC O O
9 865 879 15517007 anthracyclines NNS B-NP D018943
10 880 884 15517007 such JJ B-PP O
11 885 887 15517007 as IN I-PP O
12 888 900 15517007 mitoxantrone NN B-NP D008942
13 901 904 15517007 are VBP B-VP O
14 905 909 15517007 used VBN I-VP O
15 910 912 15517007 in IN B-PP O
16 913 921 15517007 patients NNS B-NP O
17 922 926 15517007 with IN B-PP O
18 927 928 15517007 a DT B-NP O
19 929 937 15517007 possible JJ I-NP O
20 938 948 15517007 underlying VBG I-NP O
21 949 954 15517007 heart NN I-NP D006331
22 955 961 15517007 damage NN I-NP D006331
23 961 962 15517007 , , O O
24 963 966 15517007 for IN B-PP O
25 967 974 15517007 example NN B-NP O
26 974 975 15517007 , , O O
27 976 984 15517007 systemic JJ B-NP D012595
28 985 994 15517007 sclerosis NN I-NP D012595
29 995 1003 15517007 patients NNS I-NP O
30 1003 1004 15517007 . . O O

1 1005 1007 15517007 In IN B-PP O
2 1008 1016 15517007 November NNP B-NP O
3 1017 1021 15517007 2002 CD I-NP O
4 1021 1022 15517007 , , O O
5 1023 1024 15517007 a DT B-NP O
6 1025 1032 15517007 meeting NN I-NP O
7 1033 1036 15517007 was VBD B-VP O
8 1037 1041 15517007 held VBN I-VP O
9 1042 1044 15517007 in IN B-PP O
10 1045 1053 15517007 Florence NN B-NP O
11 1053 1054 15517007 , , O O
12 1055 1063 15517007 bringing VBG B-VP O
13 1064 1072 15517007 together RB B-ADVP O
14 1073 1074 15517007 a DT B-NP O
15 1075 1081 15517007 number NN I-NP O
16 1082 1084 15517007 of IN B-PP O
17 1085 1092 15517007 experts NNS B-NP O
18 1093 1095 15517007 in IN B-PP O
19 1096 1103 15517007 various JJ B-NP O
20 1104 1110 15517007 fields NNS I-NP O
21 1110 1111 15517007 , , O O
22 1112 1121 15517007 including VBG B-PP O
23 1122 1134 15517007 rheumatology NN B-NP O
24 1134 1135 15517007 , , O O
25 1136 1146 15517007 cardiology NN B-NP O
26 1146 1147 15517007 , , O O
27 1148 1157 15517007 neurology NN B-NP O
28 1157 1158 15517007 , , O O
29 1159 1171 15517007 pharmacology NN B-NP O
30 1172 1175 15517007 and CC O O
31 1176 1191 15517007 transplantation NN B-NP O
32 1192 1200 15517007 medicine NN I-NP O
33 1200 1201 15517007 . . O O

1 1202 1205 15517007 The DT B-NP O
2 1206 1212 15517007 object NN I-NP O
3 1213 1215 15517007 of IN B-PP O
4 1216 1219 15517007 the DT B-NP O
5 1220 1227 15517007 meeting NN I-NP O
6 1228 1231 15517007 was VBD B-VP O
7 1232 1234 15517007 to TO B-VP O
8 1235 1242 15517007 analyse VB I-VP O
9 1243 1251 15517007 existing VBG B-NP O
10 1252 1256 15517007 data NNS I-NP O
11 1256 1257 15517007 , , O O
12 1258 1262 15517007 both CC O O
13 1263 1272 15517007 published VBN B-VP O
14 1273 1275 15517007 or CC O O
15 1276 1285 15517007 available JJ B-ADJP O
16 1285 1286 15517007 , , O O
17 1287 1289 15517007 in IN B-PP O
18 1290 1293 15517007 the DT B-NP O
19 1294 1302 15517007 European NNP I-NP O
20 1303 1308 15517007 Group NNP I-NP O
21 1309 1312 15517007 for IN B-PP O
22 1313 1318 15517007 Blood NNP B-NP O
23 1319 1322 15517007 and CC I-NP O
24 1323 1329 15517007 Marrow NNP I-NP O
25 1330 1345 15517007 Transplantation NNP I-NP O
26 1346 1356 15517007 autoimmune JJ I-NP D001327
27 1357 1364 15517007 disease NN I-NP D001327
28 1365 1373 15517007 database NN I-NP O
29 1373 1374 15517007 , , O O
30 1375 1378 15517007 and CC O O
31 1379 1381 15517007 to TO B-VP O
32 1382 1389 15517007 propose VB I-VP O
33 1390 1391 15517007 a DT B-NP O
34 1392 1396 15517007 safe JJ I-NP O
35 1397 1405 15517007 approach NN I-NP O
36 1406 1408 15517007 to TO B-PP O
37 1409 1413 15517007 such JJ B-NP O
38 1414 1422 15517007 patients NNS I-NP O
39 1422 1423 15517007 . . O O

1 1424 1425 15517007 A DT B-NP O
2 1426 1430 15517007 full JJ I-NP O
3 1431 1444 15517007 cardiological JJ I-NP O
4 1445 1455 15517007 assessment NN I-NP O
5 1456 1462 15517007 before IN B-PP O
6 1463 1466 15517007 and CC I-PP O
7 1467 1473 15517007 during IN I-PP O
8 1474 1477 15517007 the DT B-NP O
9 1478 1488 15517007 transplant NN I-NP O
10 1489 1496 15517007 emerged VBD B-VP O
11 1497 1499 15517007 as IN B-PP O
12 1500 1503 15517007 the DT B-NP O
13 1504 1509 15517007 major JJ I-NP O
14 1510 1524 15517007 recommendation NN I-NP O
15 1524 1525 15517007 . . O O

1 0 0 12745515 -DOCSTART- -X- -X- O

1 0 7 12745515 Seizure NN B-NP D012640
2 8 18 12745515 associated VBN B-VP O
3 19 23 12745515 with IN B-PP O
4 24 29 12745515 sleep NN B-NP D012892
5 30 41 12745515 deprivation NN I-NP D012892
6 42 45 12745515 and CC O O
7 46 55 12745515 sustained VBN B-VP O
8 55 56 12745515 - HYPH B-NP O
9 56 63 12745515 release NN I-NP O
10 64 73 12745515 bupropion NN I-NP D016642
11 73 74 12745515 . . O O
12 75 79 12745515 This DT B-NP O
13 80 84 12745515 case NN I-NP O
14 85 91 12745515 report NN I-NP O
15 92 101 12745515 describes VBZ B-VP O
16 102 103 12745515 a DT B-NP O
17 104 115 12745515 generalized VBN I-NP O
18 116 123 12745515 seizure NN I-NP D012640
19 124 134 12745515 associated VBN B-VP O
20 135 139 12745515 with IN B-PP O
21 140 149 12745515 sustained JJ B-NP O
22 149 150 12745515 - HYPH I-NP O
23 150 157 12745515 release NN I-NP O
24 158 167 12745515 bupropion NN I-NP D016642
25 168 171 12745515 use NN I-NP O
26 172 175 12745515 and CC O O
27 176 181 12745515 sleep NN B-NP D012892
28 182 193 12745515 deprivation NN I-NP D012892
29 193 194 12745515 . . O O

1 195 198 12745515 The DT B-NP O
2 199 206 12745515 subject NN I-NP O
3 206 207 12745515 , , O O
4 208 209 12745515 a DT B-NP O
5 210 212 12745515 31 CD I-NP O
6 212 213 12745515 - HYPH I-NP O
7 213 217 12745515 year NN I-NP O
8 217 218 12745515 - HYPH O O
9 218 221 12745515 old JJ B-NP O
10 222 228 12745515 female JJ I-NP O
11 229 235 12745515 smoker NN I-NP O
12 235 236 12745515 , , O O
13 237 240 12745515 was VBD B-VP O
14 241 254 12745515 participating VBG I-VP O
15 255 257 12745515 in IN B-PP O
16 258 259 12745515 a DT B-NP O
17 260 268 12745515 clinical JJ I-NP O
18 269 274 12745515 trial NN I-NP O
19 275 285 12745515 evaluating VBG B-VP O
20 286 288 12745515 an DT B-NP O
21 289 304 12745515 investigational JJ I-NP O
22 305 315 12745515 medication NN I-NP O
23 316 319 12745515 for IN B-PP O
24 320 327 12745515 smoking NN B-NP O
25 328 337 12745515 cessation NN I-NP O
26 338 342 12745515 that WDT B-NP O
27 343 347 12745515 used VBD B-VP O
28 348 357 12745515 sustained JJ B-NP O
29 357 358 12745515 - HYPH I-NP O
30 358 365 12745515 release NN I-NP O
31 366 375 12745515 bupropion NN I-NP D016642
32 376 378 12745515 as IN B-PP O
33 379 381 12745515 an DT B-NP O
34 382 388 12745515 active JJ I-NP O
35 389 396 12745515 control NN I-NP O
36 396 397 12745515 . . O O

1 398 403 12745515 After IN B-PP O
2 404 405 12745515 5 CD B-NP O
3 406 411 12745515 weeks NNS I-NP O
4 412 414 12745515 of IN B-PP O
5 415 424 12745515 bupropion NN B-NP D016642
6 425 428 12745515 use NN I-NP O
7 428 429 12745515 , , O O
8 430 433 12745515 the DT B-NP O
9 434 441 12745515 subject NN I-NP O
10 442 453 12745515 experienced VBD B-VP O
11 454 455 12745515 a DT B-NP O
12 456 467 12745515 generalized VBN I-NP O
13 468 473 12745515 tonic JJ I-NP O
14 474 480 12745515 clonic JJ I-NP O
15 481 488 12745515 seizure NN I-NP D012640
16 489 494 12745515 after IN B-PP O
17 495 502 12745515 staying VBG B-VP O
18 503 505 12745515 up RP B-PRT O
19 506 512 12745515 nearly RB B-NP O
20 513 516 12745515 all DT I-NP O
21 517 522 12745515 night NN I-NP O
22 523 530 12745515 packing NN I-NP O
23 531 534 12745515 and CC O O
24 535 541 12745515 moving VBG B-VP O
25 542 544 12745515 to TO B-PP O
26 545 546 12745515 a DT B-NP O
27 547 550 12745515 new JJ I-NP O
28 551 560 12745515 residence NN I-NP O
29 560 561 12745515 . . O O

1 562 565 12745515 The DT B-NP O
2 566 573 12745515 patient NN I-NP O
3 574 577 12745515 had VBD B-VP O
4 578 580 12745515 no DT B-NP O
5 581 586 12745515 other JJ I-NP O
6 587 591 12745515 risk NN I-NP O
7 592 599 12745515 factors NNS I-NP O
8 600 603 12745515 for IN B-PP O
9 604 612 12745515 seizures NNS B-NP D012640
10 612 613 12745515 . . O O

1 614 616 12745515 We PRP B-NP O
2 617 624 12745515 suggest VBP B-VP O
3 625 629 12745515 that IN B-SBAR O
4 630 635 12745515 sleep NN B-NP D012892
5 636 647 12745515 deprivation NN I-NP D012892
6 648 651 12745515 may MD B-VP O
7 652 655 12745515 add VB I-VP O
8 656 658 12745515 to TO B-PP O
9 659 662 12745515 the DT B-NP O
10 663 667 12745515 risk NN I-NP O
11 668 670 12745515 of IN B-PP O
12 671 680 12745515 bupropion NN B-NP D016642
13 680 681 12745515 - HYPH B-NP O
14 681 691 12745515 associated VBN I-NP O
15 692 700 12745515 seizures NNS I-NP D012640
16 700 701 12745515 . . O O

1 0 0 11027904 -DOCSTART- -X- -X- O

1 0 4 11027904 Pain NN B-NP D010146
2 5 14 11027904 responses NNS I-NP O
3 15 17 11027904 in IN B-PP O
4 18 27 11027904 methadone NN B-NP D008691
5 27 28 11027904 - HYPH O O
6 28 38 11027904 maintained VBN B-NP O
7 39 45 11027904 opioid JJ I-NP O
8 46 53 11027904 abusers NNS I-NP O
9 53 54 11027904 . . O O
10 55 64 11027904 Providing VBG B-VP O
11 65 69 11027904 pain JJ B-NP D010146
12 70 80 11027904 management NN I-NP O
13 81 84 11027904 for IN B-PP O
14 85 90 11027904 known JJ B-NP O
15 91 97 11027904 opioid JJ I-NP O
16 98 105 11027904 abusers NNS I-NP O
17 106 108 11027904 is VBZ B-VP O
18 109 110 11027904 a DT B-NP O
19 111 122 11027904 challenging JJ I-NP O
20 123 131 11027904 clinical JJ I-NP O
21 132 136 11027904 task NN I-NP O
22 136 137 11027904 , , O O
23 138 140 11027904 in IN B-PP O
24 141 145 11027904 part NN B-NP O
25 146 153 11027904 because IN B-SBAR O
26 154 160 11027904 little JJ B-NP O
27 161 163 11027904 is VBZ B-VP O
28 164 169 11027904 known VBN I-VP O
29 170 175 11027904 about IN B-PP O
30 176 181 11027904 their PRP$ B-NP O
31 182 186 11027904 pain NN I-NP D010146
32 187 197 11027904 experience NN I-NP O
33 198 201 11027904 and CC O O
34 202 211 11027904 analgesic JJ B-NP O
35 212 224 11027904 requirements NNS I-NP O
36 224 225 11027904 . . O O

1 226 230 11027904 This DT B-NP O
2 231 236 11027904 study NN I-NP O
3 237 240 11027904 was VBD B-VP O
4 241 249 11027904 designed VBN I-VP O
5 250 252 11027904 to TO B-VP O
6 253 261 11027904 describe VB I-VP O
7 262 266 11027904 pain NN B-NP D010146
8 267 276 11027904 tolerance NN I-NP O
9 277 280 11027904 and CC O O
10 281 290 11027904 analgesic JJ B-NP O
11 291 299 11027904 response NN I-NP O
12 300 302 11027904 in IN B-PP O
13 303 304 11027904 a DT B-NP O
14 305 311 11027904 sample NN I-NP O
15 312 314 11027904 of IN B-PP O
16 315 321 11027904 opioid JJ B-NP D009293
17 322 329 11027904 addicts NNS I-NP D009293
18 330 340 11027904 stabilized VBN B-VP O
19 341 343 11027904 in IN B-PP O
20 344 353 11027904 methadone NN B-NP D008691
21 353 354 11027904 - HYPH O O
22 354 365 11027904 maintenance NN B-NP O
23 366 367 11027904 ( ( O O
24 367 369 11027904 MM NN B-NP O
25 369 370 11027904 ) ) O O
26 371 380 11027904 treatment NN B-NP O
27 381 382 11027904 ( ( O O
28 382 383 11027904 n NN B-NP O
29 384 385 11027904 = SYM B-VP O
30 386 388 11027904 60 CD B-NP O
31 388 389 11027904 ) ) O O
32 390 392 11027904 in IN B-PP O
33 393 403 11027904 comparison NN B-NP O
34 404 406 11027904 to TO B-PP O
35 407 414 11027904 matched VBN B-NP O
36 415 427 11027904 nondependent JJ I-NP O
37 428 435 11027904 control JJ I-NP O
38 436 444 11027904 subjects NNS I-NP O
39 445 446 11027904 ( ( O O
40 446 447 11027904 n NN B-NP O
41 448 449 11027904 = SYM B-VP O
42 450 452 11027904 60 CD B-NP O
43 452 453 11027904 ) ) O O
44 453 454 11027904 . . O O

1 455 457 11027904 By IN B-PP O
2 458 463 11027904 using VBG B-VP O
3 464 465 11027904 a DT B-NP O
4 466 473 11027904 placebo NN I-NP O
5 473 474 11027904 - HYPH O O
6 474 484 11027904 controlled VBN B-VP O
7 484 485 11027904 , , O O
8 486 489 11027904 two CD B-NP O
9 489 490 11027904 - HYPH I-NP O
10 490 493 11027904 way NN I-NP O
11 494 503 11027904 factorial JJ I-NP O
12 504 510 11027904 design NN I-NP O
13 510 511 11027904 , , O O
14 512 521 11027904 tolerance NN B-NP O
15 522 524 11027904 to TO B-PP O
16 525 529 11027904 cold JJ B-NP O
17 529 530 11027904 - HYPH I-NP O
18 530 537 11027904 pressor NN I-NP O
19 538 539 11027904 ( ( O O
20 539 541 11027904 CP NN B-NP O
21 541 542 11027904 ) ) O O
22 543 547 11027904 pain NN B-NP D010146
23 548 551 11027904 was VBD B-VP O
24 552 560 11027904 examined VBN I-VP O
25 560 561 11027904 , , O O
26 562 566 11027904 both CC O O
27 567 573 11027904 before IN B-PP O
28 574 577 11027904 and CC I-PP O
29 578 583 11027904 after IN I-PP O
30 584 588 11027904 oral JJ B-NP O
31 589 603 11027904 administration NN I-NP O
32 604 606 11027904 of IN B-PP O
33 607 618 11027904 therapeutic JJ B-NP O
34 619 624 11027904 doses NNS I-NP O
35 625 627 11027904 of IN B-PP O
36 628 634 11027904 common JJ B-NP O
37 635 641 11027904 opioid NN I-NP O
38 642 643 11027904 ( ( O O
39 643 656 11027904 hydromorphone NN B-NP D004091
40 657 658 11027904 2 CD I-NP O
41 659 661 11027904 mg NN I-NP O
42 661 662 11027904 ) ) O O
43 663 666 11027904 and CC O O
44 667 679 11027904 nonsteroidal JJ B-NP O
45 680 684 11027904 anti AFX I-NP O
46 684 685 11027904 - HYPH I-NP O
47 685 697 11027904 inflammatory JJ I-NP O
48 698 699 11027904 ( ( O O
49 699 708 11027904 ketorolac NN B-NP D020910
50 709 711 11027904 10 CD I-NP O
51 712 714 11027904 mg NN I-NP O
52 714 715 11027904 ) ) I-NP O
53 716 725 11027904 analgesic JJ I-NP O
54 726 732 11027904 agents NNS I-NP O
55 732 733 11027904 . . O O

1 734 741 11027904 Results NNS B-NP O
2 742 748 11027904 showed VBD B-VP O
3 749 753 11027904 that IN B-SBAR O
4 754 756 11027904 MM NN B-NP O
5 757 768 11027904 individuals NNS I-NP O
6 769 773 11027904 were VBD B-VP O
7 774 787 11027904 significantly RB B-ADJP O
8 788 792 11027904 less RBR I-ADJP O
9 793 801 11027904 tolerant JJ I-ADJP O
10 802 804 11027904 of IN B-PP O
11 805 807 11027904 CP NN B-NP O
12 808 812 11027904 pain NN I-NP D010146
13 813 817 11027904 than IN B-PP O
14 818 825 11027904 control JJ B-NP O
15 826 834 11027904 subjects NNS I-NP O
16 834 835 11027904 , , O O
17 836 847 11027904 replicating VBG B-VP O
18 848 856 11027904 previous JJ B-NP O
19 857 861 11027904 work NN I-NP O
20 861 862 11027904 . . O O

1 863 872 11027904 Analgesic JJ B-NP O
2 873 880 11027904 effects NNS I-NP O
3 881 885 11027904 were VBD B-VP O
4 886 897 11027904 significant JJ B-ADJP O
5 898 905 11027904 neither CC B-PP O
6 906 909 11027904 for IN B-PP O
7 910 920 11027904 medication NN B-NP O
8 921 924 11027904 nor CC I-NP O
9 925 930 11027904 group NN I-NP O
10 930 931 11027904 . . O O

1 932 937 11027904 These DT B-NP O
2 938 942 11027904 data NNS I-NP O
3 943 951 11027904 indicate VBP B-VP O
4 952 956 11027904 that IN B-SBAR O
5 957 959 11027904 MM NN B-NP O
6 960 966 11027904 opioid JJ I-NP O
7 967 974 11027904 abusers NNS I-NP O
8 975 984 11027904 represent VBP B-VP O
9 985 986 11027904 a DT B-NP O
10 987 991 11027904 pain NN I-NP D006930
11 991 992 11027904 - HYPH B-NP D006930
12 992 1002 11027904 intolerant JJ I-NP D006930
13 1003 1009 11027904 subset NN I-NP O
14 1010 1012 11027904 of IN B-PP O
15 1013 1021 11027904 clinical JJ B-NP O
16 1022 1030 11027904 patients NNS I-NP O
17 1030 1031 11027904 . . O O

1 1032 1037 11027904 Their PRP$ B-NP O
2 1038 1048 11027904 complaints NNS I-NP O
3 1049 1051 11027904 of IN B-PP O
4 1052 1056 11027904 pain NN B-NP D010146
5 1057 1063 11027904 should MD B-VP O
6 1064 1066 11027904 be VB I-VP O
7 1067 1076 11027904 evaluated VBN I-VP O
8 1077 1086 11027904 seriously RB B-ADVP O
9 1087 1090 11027904 and CC O O
10 1091 1098 11027904 managed VBD B-VP O
11 1099 1111 11027904 aggressively RB B-ADVP O
12 1111 1112 11027904 . . O O

1 0 0 16428827 -DOCSTART- -X- -X- O

1 0 8 16428827 Daidzein NN B-NP C004742
2 9 18 16428827 activates VBZ B-VP O
3 19 26 16428827 choline NN B-NP D002794
4 27 44 16428827 acetyltransferase NN I-NP O
5 45 49 16428827 from IN B-PP O
6 50 52 16428827 MC NN B-NP O
7 52 53 16428827 - HYPH I-NP O
8 53 56 16428827 IXC NN I-NP O
9 57 62 16428827 cells NNS I-NP O
10 63 66 16428827 and CC O O
11 67 75 16428827 improves VBZ B-VP O
12 76 80 16428827 drug NN B-NP O
13 80 81 16428827 - HYPH B-NP O
14 81 88 16428827 induced VBN I-NP O
15 89 96 16428827 amnesia NN I-NP D000647
16 96 97 16428827 . . O O
17 98 101 16428827 The DT B-NP O
18 102 109 16428827 choline NN I-NP D002794
19 110 127 16428827 acetyltransferase NN I-NP O
20 128 129 16428827 ( ( O O
21 129 133 16428827 ChAT NN B-NP O
22 133 134 16428827 ) ) O O
23 135 144 16428827 activator NN B-NP O
24 144 145 16428827 , , O O
25 146 151 16428827 which WDT B-NP O
26 152 160 16428827 enhances VBZ B-VP O
27 161 172 16428827 cholinergic JJ B-NP O
28 173 185 16428827 transmission NN I-NP O
29 186 189 16428827 via IN B-PP O
30 190 192 16428827 an DT B-NP O
31 193 205 16428827 augmentation NN I-NP O
32 206 208 16428827 of IN B-PP O
33 209 212 16428827 the DT B-NP O
34 213 222 16428827 enzymatic JJ I-NP O
35 223 233 16428827 production NN I-NP O
36 234 236 16428827 of IN B-PP O
37 237 250 16428827 acetylcholine NN B-NP D000109
38 251 252 16428827 ( ( O O
39 252 255 16428827 ACh NN B-NP D000109
40 255 256 16428827 ) ) O O
41 256 257 16428827 , , O O
42 258 260 16428827 is VBZ B-VP O
43 261 263 16428827 an DT B-NP O
44 264 273 16428827 important JJ I-NP O
45 274 280 16428827 factor NN I-NP O
46 281 283 16428827 in IN B-PP O
47 284 287 16428827 the DT B-NP O
48 288 297 16428827 treatment NN I-NP O
49 298 300 16428827 of IN B-PP O
50 301 312 16428827 Alzheimer's NNS B-NP D000544
51 313 320 16428827 disease NN B-NP D000544
52 321 322 16428827 ( ( O O
53 322 324 16428827 AD NN B-NP D000544
54 324 325 16428827 ) ) O O
55 325 326 16428827 . . O O

1 327 337 16428827 Methanolic JJ B-NP O
2 338 346 16428827 extracts NNS I-NP O
3 347 351 16428827 from IN B-PP O
4 352 360 16428827 Pueraria NNP B-NP O
5 361 373 16428827 thunbergiana NNP I-NP O
6 374 383 16428827 exhibited VBD B-VP O
7 384 386 16428827 an DT B-NP O
8 387 397 16428827 activation NN I-NP O
9 398 404 16428827 effect NN I-NP O
10 405 406 16428827 ( ( O O
11 406 409 16428827 46% CD B-NP O
12 409 410 16428827 ) ) O O
13 411 413 16428827 on IN B-PP O
14 414 418 16428827 ChAT NN B-NP O
15 419 421 16428827 in FW B-ADVP O
16 422 427 16428827 vitro FW I-ADVP O
17 427 428 16428827 . . O O

1 429 432 16428827 Via IN B-PP O
2 433 436 16428827 the DT B-NP O
3 437 447 16428827 sequential JJ I-NP O
4 448 457 16428827 isolation NN I-NP O
5 458 460 16428827 of IN B-PP O
6 461 469 16428827 Pueraria NNP B-NP O
7 470 482 16428827 thunbergiana NNP I-NP O
8 482 483 16428827 , , O O
9 484 487 16428827 the DT B-NP O
10 488 494 16428827 active JJ I-NP O
11 495 504 16428827 component NN I-NP O
12 505 508 16428827 was VBD B-VP O
13 509 519 16428827 ultimately RB I-VP O
14 520 530 16428827 identified VBN I-VP O
15 531 533 16428827 as IN B-PP O
16 534 542 16428827 daidzein NN B-NP C004742
17 543 544 16428827 ( ( O O
18 544 548 16428827 4',7 CD B-NP C004742
19 548 549 16428827 - HYPH I-NP C004742
20 549 558 16428827 dihydroxy NN I-NP C004742
21 558 559 16428827 - HYPH I-NP C004742
22 559 569 16428827 isoflavone NN I-NP C004742
23 569 570 16428827 ) ) O O
24 570 571 16428827 . . O O

1 572 574 16428827 In IN B-SBAR O
2 575 580 16428827 order NN O O
3 581 583 16428827 to TO B-VP O
4 584 595 16428827 investigate VB I-VP O
5 596 599 16428827 the DT B-NP O
6 600 607 16428827 effects NNS I-NP O
7 608 610 16428827 of IN B-PP O
8 611 619 16428827 daidzein NN B-NP C004742
9 620 624 16428827 from IN B-PP O
10 625 633 16428827 Pueraria NNP B-NP O
11 634 646 16428827 thunbergiana NN I-NP O
12 647 649 16428827 on IN B-PP O
13 650 661 16428827 scopolamine NN B-NP D012601
14 661 662 16428827 - HYPH B-NP O
15 662 669 16428827 induced VBN I-NP O
16 670 681 16428827 impairments NNS I-NP D007859
17 682 684 16428827 of IN B-PP D007859
18 685 693 16428827 learning NN B-NP D007859
19 694 697 16428827 and CC I-NP D007859
20 698 704 16428827 memory NN I-NP D007859
21 704 705 16428827 , , O O
22 706 708 16428827 we PRP B-NP O
23 709 718 16428827 conducted VBD B-VP O
24 719 720 16428827 a DT B-NP O
25 721 727 16428827 series NN I-NP O
26 728 730 16428827 of IN B-PP O
27 731 733 16428827 in FW B-NP O
28 734 738 16428827 vivo FW I-NP O
29 739 744 16428827 tests NNS I-NP O
30 744 745 16428827 . . O O

1 746 760 16428827 Administration NN B-NP O
2 761 763 16428827 of IN B-PP O
3 764 772 16428827 daidzein NN B-NP C004742
4 773 774 16428827 ( ( O O
5 774 777 16428827 4.5 CD B-NP O
6 778 780 16428827 mg NN I-NP O
7 780 781 16428827 / SYM B-NP O
8 781 783 16428827 kg NN I-NP O
9 784 788 16428827 body NN I-NP O
10 789 795 16428827 weight NN I-NP O
11 795 796 16428827 ) ) O O
12 797 799 16428827 to TO B-PP O
13 800 804 16428827 mice NNS B-NP O
14 805 808 16428827 was VBD B-VP O
15 809 814 16428827 shown VBN I-VP O
16 815 828 16428827 significantly RB B-ADVP O
17 829 831 16428827 to TO B-VP O
18 832 839 16428827 reverse VB I-VP O
19 840 851 16428827 scopolamine NN B-NP D012601
20 851 852 16428827 - HYPH B-NP O
21 852 859 16428827 induced VBN I-NP O
22 860 867 16428827 amnesia NN I-NP D000647
23 867 868 16428827 , , O O
24 869 878 16428827 according VBG B-PP O
25 879 881 16428827 to TO B-PP O
26 882 885 16428827 the DT B-NP O
27 886 893 16428827 results NNS I-NP O
28 894 896 16428827 of IN B-PP O
29 897 898 16428827 a DT B-NP O
30 899 900 16428827 Y NN I-NP O
31 900 901 16428827 - HYPH B-NP O
32 901 905 16428827 maze NN I-NP O
33 906 910 16428827 test NN I-NP O
34 910 911 16428827 . . O O

1 912 922 16428827 Injections NNS B-NP O
2 923 925 16428827 of IN B-PP O
3 926 937 16428827 scopolamine NN B-NP D012601
4 938 942 16428827 into IN B-PP O
5 943 947 16428827 mice NNS B-NP O
6 948 956 16428827 resulted VBD B-VP O
7 957 959 16428827 in IN B-PP O
8 960 968 16428827 impaired JJ B-NP O
9 969 980 16428827 performance NN I-NP O
10 981 983 16428827 on IN B-PP O
11 984 985 16428827 Y NN B-NP O
12 985 986 16428827 - HYPH B-NP O
13 986 990 16428827 maze NN I-NP O
14 991 996 16428827 tests NNS I-NP O
15 997 998 16428827 ( ( O O
16 998 999 16428827 a DT B-NP O
17 1000 1003 16428827 37% NN I-NP O
18 1004 1013 16428827 decreases VBZ B-VP O
19 1014 1016 16428827 in IN B-PP O
20 1017 1028 16428827 alternation NN B-NP O
21 1029 1037 16428827 behavior NN I-NP O
22 1037 1038 16428827 ) ) O O
23 1038 1039 16428827 . . O O

1 1040 1042 16428827 By IN B-PP O
2 1043 1046 16428827 way NN B-NP O
3 1047 1049 16428827 of IN B-PP O
4 1050 1058 16428827 contrast NN B-NP O
5 1058 1059 16428827 , , O O
6 1060 1064 16428827 mice NNS B-NP O
7 1065 1072 16428827 treated VBN B-VP O
8 1073 1077 16428827 with IN B-PP O
9 1078 1086 16428827 daidzein NN B-NP C004742
10 1087 1092 16428827 prior JJ B-ADJP O
11 1093 1095 16428827 to TO B-PP O
12 1096 1099 16428827 the DT B-NP O
13 1100 1111 16428827 scopolamine NN I-NP D012601
14 1112 1122 16428827 injections NNS I-NP O
15 1123 1127 16428827 were VBD B-VP O
16 1128 1138 16428827 noticeably RB I-VP O
17 1139 1148 16428827 protected VBN I-VP O
18 1149 1153 16428827 from IN B-PP O
19 1154 1158 16428827 this DT B-NP O
20 1159 1170 16428827 performance NN I-NP O
21 1171 1181 16428827 impairment NN I-NP O
22 1182 1183 16428827 ( ( O O
23 1183 1185 16428827 an DT B-NP O
24 1186 1199 16428827 approximately RB I-NP O
25 1200 1203 16428827 12% NN I-NP O
26 1203 1204 16428827 - HYPH O O
27 1204 1207 16428827 21% CD B-NP O
28 1208 1216 16428827 decrease NN I-NP O
29 1217 1219 16428827 in IN B-PP O
30 1220 1231 16428827 alternation NN B-NP O
31 1232 1240 16428827 behavior NN I-NP O
32 1240 1241 16428827 ) ) O O
33 1241 1242 16428827 . . O O

1 1243 1248 16428827 These DT B-NP O
2 1249 1256 16428827 results NNS I-NP O
3 1257 1265 16428827 indicate VBP B-VP O
4 1266 1270 16428827 that IN B-SBAR O
5 1271 1279 16428827 daidzein NN B-NP C004742
6 1280 1285 16428827 might MD B-VP O
7 1286 1290 16428827 play VB I-VP O
8 1291 1292 16428827 a DT B-NP O
9 1293 1297 16428827 role NN I-NP O
10 1298 1300 16428827 in IN B-PP O
11 1301 1314 16428827 acetylcholine NN B-NP D000109
12 1315 1327 16428827 biosynthesis NN I-NP O
13 1328 1330 16428827 as IN B-PP O
14 1331 1332 16428827 a DT B-NP O
15 1333 1337 16428827 ChAT NN I-NP O
16 1338 1347 16428827 activator NN I-NP O
17 1347 1348 16428827 , , O O
18 1349 1352 16428827 and CC O O
19 1353 1357 16428827 that IN B-SBAR O
20 1358 1360 16428827 it PRP B-NP O
21 1361 1365 16428827 also RB B-ADVP O
22 1366 1377 16428827 ameliorates VBZ B-VP O
23 1378 1389 16428827 scopolamine NN B-NP D012601
24 1389 1390 16428827 - HYPH B-NP O
25 1390 1397 16428827 induced VBN I-NP O
26 1398 1405 16428827 amnesia NN I-NP D000647
27 1405 1406 16428827 . . O O

1 0 0 17574447 -DOCSTART- -X- -X- O

1 0 14 17574447 Hepatonecrosis NN B-NP -1
2 15 18 17574447 and CC I-NP O
3 19 30 17574447 cholangitis NN I-NP D002761
4 31 38 17574447 related VBN B-VP O
5 39 41 17574447 to TO B-PP O
6 42 46 17574447 long JJ B-NP O
7 46 47 17574447 - HYPH I-NP O
8 47 51 17574447 term NN I-NP O
9 52 65 17574447 phenobarbital NN I-NP D010634
10 66 73 17574447 therapy NN I-NP O
11 73 74 17574447 : : O O
12 75 77 17574447 an DT B-NP O
13 78 85 17574447 autopsy NN I-NP O
14 86 92 17574447 report NN I-NP O
15 93 95 17574447 of IN B-PP O
16 96 99 17574447 two CD B-NP O
17 100 108 17574447 patients NNS I-NP O
18 108 109 17574447 . . O O
19 110 123 17574447 Phenobarbital NN B-NP D010634
20 124 125 17574447 ( ( O O
21 125 127 17574447 PB NN B-NP D010634
22 127 128 17574447 ) ) O O
23 129 132 17574447 has VBZ B-VP O
24 133 134 17574447 a DT B-NP O
25 135 145 17574447 reputation NN I-NP O
26 146 149 17574447 for IN B-PP O
27 150 156 17574447 safety NN B-NP O
28 156 157 17574447 , , O O
29 158 161 17574447 and CC O O
30 162 164 17574447 it PRP B-NP O
31 165 167 17574447 is VBZ B-VP O
32 168 176 17574447 commonly RB I-VP O
33 177 185 17574447 believed VBN I-VP O
34 186 190 17574447 that IN B-SBAR O
35 191 193 17574447 PB NN B-NP D010634
36 193 194 17574447 - HYPH B-NP O
37 194 201 17574447 related VBN I-NP O
38 202 211 17574447 increases NNS I-NP O
39 212 214 17574447 in IN B-PP O
40 215 220 17574447 serum NN B-NP O
41 221 237 17574447 aminotransferase NN I-NP O
42 238 244 17574447 levels NNS I-NP O
43 245 247 17574447 do VBP B-VP O
44 248 251 17574447 not RB I-VP O
45 252 260 17574447 indicate VB I-VP O
46 261 263 17574447 or CC I-VP O
47 264 271 17574447 predict VB I-VP O
48 272 275 17574447 the DT B-NP O
49 276 287 17574447 development NN I-NP O
50 288 290 17574447 of IN B-PP O
51 291 302 17574447 significant JJ B-NP O
52 303 310 17574447 chronic JJ I-NP O
53 311 316 17574447 liver NN I-NP D008107
54 317 324 17574447 disease NN I-NP D008107
55 324 325 17574447 . . O O

1 326 330 17574447 Here RB B-ADVP O
2 331 333 17574447 we PRP B-NP O
3 334 340 17574447 report VBP B-VP O
4 341 343 17574447 of IN B-PP O
5 344 347 17574447 two CD B-NP O
6 348 353 17574447 adult JJ I-NP O
7 354 362 17574447 patients NNS I-NP O
8 363 367 17574447 with IN B-PP O
9 368 369 17574447 a DT B-NP O
10 370 374 17574447 long JJ I-NP O
11 375 382 17574447 history NN I-NP O
12 383 385 17574447 of IN B-PP O
13 386 394 17574447 epilepsy NN B-NP D004827
14 395 402 17574447 treated VBN B-VP O
15 403 407 17574447 with IN B-PP O
16 408 410 17574447 PB NN B-NP D010634
17 411 414 17574447 who WP B-NP O
18 415 419 17574447 died VBD B-VP O
19 420 428 17574447 suddenly RB B-ADVP O
20 428 429 17574447 : : O O
21 430 433 17574447 one CD B-NP O
22 434 436 17574447 as IN B-PP O
23 437 448 17574447 consequence NN B-NP O
24 449 451 17574447 of IN B-PP O
25 452 459 17574447 cardiac JJ B-NP D006323
26 460 466 17574447 arrest NN I-NP D006323
27 466 467 17574447 , , O O
28 468 471 17574447 the DT B-NP O
29 472 477 17574447 other NN I-NP O
30 478 480 17574447 of IN B-PP O
31 481 486 17574447 acute JJ B-NP O
32 487 503 17574447 bronchopneumonia NN I-NP D001996
33 503 504 17574447 . . O O

1 505 507 17574447 At IN B-PP O
2 508 515 17574447 autopsy NN B-NP O
3 515 516 17574447 , , O O
4 517 525 17574447 analysis NN B-NP O
5 526 528 17574447 of IN B-PP O
6 529 534 17574447 liver NN B-NP O
7 535 545 17574447 parenchyma NN I-NP O
8 546 554 17574447 revealed VBD B-VP O
9 555 559 17574447 rich JJ B-NP O
10 560 566 17574447 portal JJ I-NP O
11 567 579 17574447 inflammatory JJ I-NP O
12 580 590 17574447 infiltrate NN I-NP O
13 590 591 17574447 , , O O
14 592 597 17574447 which WDT B-NP O
15 598 607 17574447 consisted VBD B-VP O
16 608 610 17574447 of IN B-PP O
17 611 616 17574447 mixed VBN B-NP O
18 617 627 17574447 eosinophil NN I-NP O
19 628 631 17574447 and CC I-NP O
20 632 640 17574447 monocyte NN I-NP O
21 641 646 17574447 cells NNS I-NP O
22 646 647 17574447 , , O O
23 648 658 17574447 associated VBN B-VP O
24 659 663 17574447 with IN B-PP O
25 664 671 17574447 several JJ B-NP O
26 672 676 17574447 foci NNS I-NP O
27 677 679 17574447 of IN B-PP O
28 680 688 17574447 necrosis NN B-NP D009336
29 689 699 17574447 surrounded VBN B-VP O
30 700 702 17574447 by IN B-PP O
31 703 704 17574447 a DT B-NP O
32 705 709 17574447 hard JJ I-NP O
33 710 714 17574447 ring NN I-NP O
34 715 717 17574447 of IN B-PP O
35 718 721 17574447 non AFX B-NP O
36 721 722 17574447 - HYPH I-NP O
37 722 730 17574447 specific JJ I-NP O
38 731 744 17574447 granulomatous JJ I-NP O
39 745 751 17574447 tissue NN I-NP O
40 751 752 17574447 . . O O

1 753 765 17574447 Inflammatory JJ B-NP O
2 766 775 17574447 reactions NNS I-NP O
3 776 778 17574447 of IN B-PP O
4 779 787 17574447 internal JJ B-NP O
5 788 791 17574447 and CC I-NP O
6 792 800 17574447 external JJ I-NP O
7 801 808 17574447 hepatic JJ I-NP O
8 809 816 17574447 biliary JJ I-NP O
9 817 822 17574447 ducts NNS I-NP O
10 823 827 17574447 were VBD B-VP O
11 828 832 17574447 also RB I-VP O
12 833 837 17574447 seen VBN I-VP O
13 837 838 17574447 . . O O

1 839 842 17574447 Our PRP$ B-NP O
2 843 851 17574447 findings NNS I-NP O
3 852 862 17574447 illustrate VBP B-VP O
4 863 867 17574447 that IN B-SBAR O
5 868 870 17574447 PB NN B-NP D010634
6 871 874 17574447 may MD B-VP O
7 875 877 17574447 be VB I-VP O
8 878 888 17574447 associated VBN I-VP O
9 889 893 17574447 with IN B-PP O
10 894 901 17574447 chronic JJ B-NP O
11 902 907 17574447 liver NN I-NP D008107
12 908 914 17574447 damage NN I-NP D008107
13 914 915 17574447 , , O O
14 916 921 17574447 which WDT B-NP O
15 922 925 17574447 may MD B-VP O
16 926 930 17574447 lead VB I-VP O
17 931 933 17574447 to TO B-PP O
18 934 938 17574447 more RBR B-NP O
19 939 946 17574447 serious JJ I-NP O
20 947 950 17574447 and CC I-NP O
21 951 962 17574447 deleterious JJ I-NP O
22 963 975 17574447 consequences NNS I-NP O
23 975 976 17574447 . . O O

1 977 980 17574447 For IN B-PP O
2 981 985 17574447 this DT B-NP O
3 986 992 17574447 reason NN I-NP O
4 992 993 17574447 , , O O
5 994 998 17574447 each DT B-NP O
6 999 1008 17574447 clinician NN I-NP O
7 1009 1015 17574447 should MD B-VP O
8 1016 1025 17574447 recognize VB I-VP O
9 1026 1030 17574447 this DT B-NP O
10 1031 1037 17574447 entity NN I-NP O
11 1038 1040 17574447 in IN B-PP O
12 1041 1044 17574447 the DT B-NP O
13 1045 1057 17574447 differential JJ I-NP O
14 1058 1067 17574447 diagnosis NN I-NP O
15 1068 1070 17574447 of IN B-PP O
16 1071 1073 17574447 PB NN B-NP D010634
17 1073 1074 17574447 - HYPH O O
18 1074 1081 17574447 related VBN B-VP O
19 1082 1094 17574447 asymptomatic JJ B-NP O
20 1095 1102 17574447 chronic JJ I-NP D056487
21 1103 1110 17574447 hepatic JJ I-NP D056487
22 1111 1117 17574447 enzyme NN I-NP D056487
23 1118 1129 17574447 dysfunction NN I-NP D056487
24 1129 1130 17574447 . . O O

1 0 0 11583940 -DOCSTART- -X- -X- O

1 0 9 11583940 Sirolimus NN B-NP D020123
2 10 13 11583940 and CC I-NP O
3 14 27 11583940 mycophenolate NN I-NP C063008
4 28 35 11583940 mofetil NN I-NP C063008
5 36 39 11583940 for IN B-PP O
6 40 51 11583940 calcineurin NN B-NP O
7 51 52 11583940 - HYPH B-NP O
8 52 56 11583940 free JJ I-NP O
9 57 74 11583940 immunosuppression NN I-NP O
10 75 77 11583940 in IN B-PP O
11 78 83 11583940 renal JJ B-NP O
12 84 94 11583940 transplant NN I-NP O
13 95 105 11583940 recipients NNS I-NP O
14 105 106 11583940 . . O O
15 107 118 11583940 Calcineurin NN B-NP O
16 119 129 11583940 inhibitors NNS I-NP O
17 129 130 11583940 , , O O
18 131 135 11583940 such JJ B-PP O
19 136 138 11583940 as IN I-PP O
20 139 151 11583940 cyclosporine NN B-NP D016572
21 152 155 11583940 and CC I-NP O
22 156 166 11583940 tacrolimus NN I-NP D016559
23 166 167 11583940 , , O O
24 168 172 11583940 have VBP B-VP O
25 173 177 11583940 been VBN I-VP O
26 178 187 11583940 available JJ B-ADJP O
27 188 191 11583940 for IN B-PP O
28 192 198 11583940 almost RB B-NP O
29 199 201 11583940 20 CD I-NP O
30 202 207 11583940 years NNS I-NP O
31 207 208 11583940 . . O O

1 209 217 11583940 Although IN B-SBAR O
2 218 223 11583940 these DT B-NP O
3 224 229 11583940 drugs NNS I-NP O
4 230 233 11583940 are VBP B-VP O
5 234 240 11583940 highly RB B-ADJP O
6 241 250 11583940 effective JJ I-ADJP O
7 251 254 11583940 and CC O O
8 255 264 11583940 represent VBP B-VP O
9 265 268 11583940 the DT B-NP O
10 269 277 11583940 mainstay NN I-NP O
11 278 280 11583940 of IN B-PP O
12 281 291 11583940 transplant NN B-NP O
13 292 309 11583940 immunosuppression NN I-NP O
14 309 310 11583940 , , O O
15 311 315 11583940 they PRP B-NP O
16 316 319 11583940 are VBP B-VP O
17 320 330 11583940 associated VBN I-VP O
18 331 335 11583940 with IN B-PP O
19 336 341 11583940 acute JJ B-NP O
20 342 345 11583940 and CC I-NP O
21 346 353 11583940 chronic JJ I-NP O
22 354 368 11583940 nephrotoxicity NN I-NP D007674
23 368 369 11583940 . . O O

1 370 375 11583940 Acute JJ B-NP O
2 376 390 11583940 nephrotoxicity NN I-NP D007674
3 390 391 11583940 , , O O
4 392 397 11583940 which WDT B-NP O
5 398 404 11583940 occurs VBZ B-VP O
6 405 407 11583940 in IN B-PP O
7 408 411 11583940 the DT B-NP O
8 412 417 11583940 early JJ I-NP O
9 418 424 11583940 period NN I-NP O
10 425 430 11583940 after IN B-PP O
11 431 446 11583940 transplantation NN B-NP O
12 446 447 11583940 , , O O
13 448 453 11583940 leads VBZ B-VP O
14 454 456 11583940 to TO B-PP O
15 457 458 11583940 a DT B-NP O
16 459 465 11583940 higher JJR I-NP O
17 466 470 11583940 rate NN I-NP O
18 471 473 11583940 of IN B-PP O
19 474 482 11583940 dialysis NN B-NP O
20 482 483 11583940 , , O O
21 484 487 11583940 and CC O O
22 488 495 11583940 chronic JJ B-NP O
23 496 510 11583940 nephrotoxicity NN I-NP D007674
24 511 514 11583940 may MD B-VP O
25 515 525 11583940 eventually RB I-VP O
26 526 532 11583940 result VB I-VP O
27 533 535 11583940 in IN B-PP O
28 536 541 11583940 graft NN B-NP O
29 542 546 11583940 loss NN I-NP O
30 546 547 11583940 . . O O

1 548 553 11583940 Acute JJ B-NP O
2 554 557 11583940 and CC I-NP O
3 558 565 11583940 chronic JJ I-NP O
4 566 580 11583940 nephrotoxicity NN I-NP D007674
5 581 583 11583940 is VBZ B-VP O
6 584 592 11583940 becoming VBG I-VP O
7 593 597 11583940 more RBR B-ADJP O
8 598 604 11583940 common JJ I-ADJP O
9 605 607 11583940 as IN B-PP O
10 608 611 11583940 the DT B-NP O
11 612 615 11583940 use NN I-NP O
12 616 618 11583940 of IN B-PP O
13 619 627 11583940 marginal JJ B-NP O
14 628 635 11583940 kidneys NNS I-NP O
15 636 639 11583940 for IN B-PP O
16 640 655 11583940 transplantation NN B-NP O
17 656 665 11583940 increases NNS I-NP O
18 665 666 11583940 . . O O

1 667 670 11583940 Two CD B-NP O
2 671 679 11583940 recently RB I-NP O
3 680 689 11583940 available JJ I-NP O
4 690 707 11583940 immunosuppressive JJ I-NP O
5 708 714 11583940 agents NNS I-NP O
6 714 715 11583940 , , O O
7 716 729 11583940 mycophenolate NN B-NP C063008
8 730 737 11583940 mofetil NN I-NP C063008
9 738 741 11583940 and CC O O
10 742 751 11583940 sirolimus NN B-NP D020123
11 752 753 11583940 ( ( O O
12 753 762 11583940 rapamycin NN B-NP D020123
13 762 763 11583940 ) ) O O
14 763 764 11583940 , , O O
15 765 769 11583940 have VBP B-VP O
16 770 772 11583940 no DT B-NP O
17 773 787 11583940 nephrotoxicity NN I-NP D007674
18 787 788 11583940 . . O O

1 789 792 11583940 The DT B-NP O
2 793 796 11583940 use NN I-NP O
3 797 799 11583940 of IN B-PP O
4 800 805 11583940 these DT B-NP O
5 806 811 11583940 drugs NNS I-NP O
6 812 814 11583940 in IN B-PP O
7 815 826 11583940 combination NN B-NP O
8 827 831 11583940 with IN B-PP O
9 832 837 11583940 other JJ B-NP O
10 838 844 11583940 agents NNS I-NP O
11 845 848 11583940 has VBZ B-VP O
12 849 852 11583940 led VBN I-VP O
13 853 855 11583940 to TO B-PP O
14 856 859 11583940 the DT B-NP O
15 860 871 11583940 development NN I-NP O
16 872 874 11583940 of IN B-PP O
17 875 878 11583940 new JJ B-NP O
18 879 888 11583940 paradigms NNS I-NP O
19 889 891 11583940 of IN B-PP O
20 892 909 11583940 immunosuppressive JJ B-NP O
21 910 917 11583940 therapy NN I-NP O
22 917 918 11583940 . . O O

1 919 923 11583940 This DT B-NP O
2 924 929 11583940 paper NN I-NP O
3 930 937 11583940 reviews VBZ B-VP O
4 938 941 11583940 the DT B-NP O
5 942 949 11583940 results NNS I-NP O
6 950 952 11583940 of IN B-PP O
7 953 961 11583940 clinical JJ B-NP O
8 962 968 11583940 trials NNS I-NP O
9 969 973 11583940 that WDT B-NP O
10 974 978 11583940 have VBP B-VP O
11 979 991 11583940 investigated VBN I-VP O
12 992 997 11583940 these DT B-NP O
13 998 1001 11583940 new JJ I-NP O
14 1002 1012 11583940 approaches NNS I-NP O
15 1013 1015 11583940 to TO B-PP O
16 1016 1033 11583940 immunosuppression NN B-NP O
17 1034 1036 11583940 in IN B-PP O
18 1037 1042 11583940 renal JJ B-NP O
19 1043 1053 11583940 transplant NN I-NP O
20 1054 1064 11583940 recipients NNS I-NP O
21 1064 1065 11583940 . . O O

1 0 0 4069770 -DOCSTART- -X- -X- O

1 0 10 4069770 Gentamicin NN B-NP D005839
2 11 22 4069770 nephropathy NN I-NP D007674
3 23 25 4069770 in IN B-PP O
4 26 27 4069770 a DT B-NP O
5 28 35 4069770 neonate NN I-NP O
6 35 36 4069770 . . O O
7 37 40 4069770 The DT B-NP O
8 41 49 4069770 clinical JJ I-NP O
9 50 53 4069770 and CC I-NP O
10 54 61 4069770 autopsy NN I-NP O
11 62 70 4069770 findings NNS I-NP O
12 71 73 4069770 in IN B-PP O
13 74 75 4069770 a DT B-NP O
14 76 85 4069770 premature JJ I-NP O
15 86 90 4069770 baby NN I-NP O
16 91 94 4069770 who WP B-NP O
17 95 99 4069770 died VBD B-VP O
18 100 102 4069770 of IN B-PP O
19 103 108 4069770 acute JJ B-NP D058186
20 109 114 4069770 renal JJ I-NP D058186
21 115 122 4069770 failure NN I-NP D058186
22 123 128 4069770 after IN B-PP O
23 129 136 4069770 therapy NN B-NP O
24 137 141 4069770 with IN B-PP O
25 142 152 4069770 gentamicin NN B-NP D005839
26 153 154 4069770 ( ( O O
27 154 155 4069770 5 CD B-NP O
28 156 158 4069770 mg NN I-NP O
29 158 159 4069770 / SYM B-NP O
30 159 161 4069770 kg NN I-NP O
31 161 162 4069770 / SYM B-NP O
32 162 165 4069770 day NN I-NP O
33 165 166 4069770 ) ) O O
34 167 170 4069770 and CC O O
35 171 181 4069770 penicillin NN B-NP D010406
36 182 185 4069770 are VBP B-VP O
37 186 195 4069770 presented VBN I-VP O
38 195 196 4069770 . . O O

1 197 200 4069770 The DT B-NP O
2 201 206 4069770 serum NN I-NP O
3 207 217 4069770 gentamicin NN I-NP D005839
4 218 231 4069770 concentration NN I-NP O
5 232 235 4069770 had VBD B-VP O
6 236 243 4069770 reached VBN I-VP O
7 244 249 4069770 toxic JJ B-NP O
8 250 256 4069770 levels NNS I-NP O
9 257 261 4069770 when WRB B-ADVP O
10 262 268 4069770 anuria NN B-NP D001002
11 269 278 4069770 developed VBD B-VP O
12 278 279 4069770 . . O O

1 280 288 4069770 Numerous JJ B-NP O
2 289 297 4069770 periodic JJ I-NP D010504
3 298 302 4069770 acid NN I-NP D010504
4 303 309 4069770 Schiff NNP I-NP O
5 310 311 4069770 ( ( O O
6 311 314 4069770 PAS NNP B-NP O
7 314 315 4069770 ) ) O O
8 316 324 4069770 positive JJ B-NP O
9 324 325 4069770 , , I-NP O
10 326 334 4069770 diastase NN I-NP O
11 335 344 4069770 resistant JJ I-NP O
12 345 356 4069770 cytoplasmic JJ I-NP O
13 357 366 4069770 inclusion NN I-NP O
14 367 373 4069770 bodies NNS I-NP O
15 374 379 4069770 which WDT B-NP O
16 380 388 4069770 appeared VBD B-VP O
17 389 391 4069770 as IN B-SBAR O
18 392 398 4069770 myelin JJ B-NP O
19 399 406 4069770 figures NNS I-NP O
20 407 409 4069770 in IN B-PP O
21 410 424 4069770 cytosegresomes NNS B-NP O
22 425 430 4069770 under IN B-PP O
23 431 434 4069770 the DT B-NP O
24 435 443 4069770 electron NN I-NP O
25 444 454 4069770 microscope NN I-NP O
26 455 459 4069770 were VBD B-VP O
27 460 470 4069770 identified VBN I-VP O
28 471 473 4069770 in IN B-PP O
29 474 477 4069770 the DT B-NP O
30 478 486 4069770 proximal JJ I-NP O
31 487 497 4069770 convoluted JJ I-NP O
32 498 505 4069770 tubules NNS I-NP O
33 505 506 4069770 . . O O

1 507 510 4069770 The DT B-NP O
2 511 523 4069770 pathological JJ I-NP O
3 524 531 4069770 changes NNS I-NP O
4 532 539 4069770 induced VBN B-VP O
5 540 542 4069770 by IN B-PP O
6 543 553 4069770 gentamicin NN B-NP D005839
7 554 556 4069770 in IN B-PP O
8 557 560 4069770 the DT B-NP O
9 561 566 4069770 human JJ I-NP O
10 567 575 4069770 neonatal JJ I-NP O
11 576 583 4069770 kidneys NNS I-NP O
12 584 588 4069770 have VBP B-VP O
13 589 592 4069770 not RB I-VP O
14 593 597 4069770 been VBN I-VP O
15 598 608 4069770 previously RB I-VP O
16 609 617 4069770 reported VBN I-VP O
17 617 618 4069770 . . O O

1 0 0 20973483 -DOCSTART- -X- -X- O

1 0 2 20973483 In FW B-NP O
2 3 7 20973483 vivo FW I-NP O
3 8 24 20973483 characterization NN I-NP O
4 25 27 20973483 of IN B-PP O
5 28 29 20973483 a DT B-NP O
6 30 34 20973483 dual JJ I-NP O
7 35 44 20973483 adenosine NN I-NP D058915
8 45 48 20973483 A2A NN I-NP D058915
9 48 49 20973483 / SYM B-NP D058915
10 49 51 20973483 A1 NN I-NP D058915
11 52 60 20973483 receptor NN I-NP D058915
12 61 71 20973483 antagonist NN I-NP D058915
13 72 74 20973483 in IN B-PP O
14 75 81 20973483 animal NN B-NP O
15 82 88 20973483 models NNS I-NP O
16 89 91 20973483 of IN B-PP O
17 92 103 20973483 Parkinson's NNS B-NP D010300
18 104 111 20973483 disease NN I-NP D010300
19 111 112 20973483 . . O O
20 113 116 20973483 The DT B-NP O
21 117 119 20973483 in FW I-NP O
22 120 124 20973483 vivo FW I-NP O
23 125 141 20973483 characterization NN I-NP O
24 142 144 20973483 of IN B-PP O
25 145 146 20973483 a DT B-NP O
26 147 151 20973483 dual JJ I-NP O
27 152 161 20973483 adenosine NN I-NP D058915
28 162 167 20973483 A(2A) NN I-NP D058915
29 167 168 20973483 / SYM B-NP D058915
30 168 172 20973483 A(1) NN I-NP D058915
31 173 181 20973483 receptor NN I-NP D058915
32 182 192 20973483 antagonist NN I-NP D058915
33 193 195 20973483 in IN B-PP O
34 196 203 20973483 several JJ B-NP O
35 204 210 20973483 animal NN I-NP O
36 211 217 20973483 models NNS I-NP O
37 218 220 20973483 of IN B-PP O
38 221 232 20973483 Parkinson's NNP B-NP D010300
39 233 240 20973483 disease NN I-NP D010300
40 241 243 20973483 is VBZ B-VP O
41 244 253 20973483 described VBN I-VP O
42 253 254 20973483 . . O O

1 255 264 20973483 Discovery NNP B-NP O
2 265 268 20973483 and CC O O
3 269 274 20973483 scale VB B-VP O
4 274 275 20973483 - HYPH O O
5 275 277 20973483 up RP B-PRT O
6 278 287 20973483 syntheses NNS B-NP O
7 288 290 20973483 of IN B-PP O
8 291 299 20973483 compound NN B-NP O
9 300 301 20973483 1 CD I-NP O
10 302 305 20973483 are VBP B-VP O
11 306 315 20973483 described VBN I-VP O
12 316 318 20973483 in IN B-PP O
13 319 325 20973483 detail NN B-NP O
14 325 326 20973483 , , O O
15 327 339 20973483 highlighting VBG B-VP O
16 340 352 20973483 optimization NN B-NP O
17 353 358 20973483 steps NNS I-NP O
18 359 363 20973483 that WDT B-NP O
19 364 373 20973483 increased VBD B-VP O
20 374 377 20973483 the DT B-NP O
21 378 385 20973483 overall JJ I-NP O
22 386 391 20973483 yield NN I-NP O
23 392 394 20973483 of IN B-PP O
24 395 396 20973483 1 CD B-NP O
25 397 401 20973483 from IN B-PP O
26 402 407 20973483 10.0% CD B-NP O
27 408 410 20973483 to TO B-PP O
28 411 416 20973483 30.5% CD B-NP O
29 416 417 20973483 . . O O

1 418 426 20973483 Compound NN B-NP O
2 427 428 20973483 1 CD I-NP O
3 429 431 20973483 is VBZ B-VP O
4 432 433 20973483 a DT B-NP O
5 434 440 20973483 potent JJ I-NP O
6 441 446 20973483 A(2A) NN I-NP O
7 446 447 20973483 / SYM B-NP O
8 447 451 20973483 A(1) NN I-NP O
9 452 460 20973483 receptor NN I-NP O
10 461 471 20973483 antagonist NN I-NP O
11 472 474 20973483 in FW B-ADVP O
12 475 480 20973483 vitro FW I-ADVP O
13 481 482 20973483 ( ( O O
14 482 487 20973483 A(2A) NN B-NP O
15 488 492 20973483 K(i) NN I-NP O
16 493 494 20973483 = SYM B-VP O
17 495 498 20973483 4.1 CD B-NP O
18 499 501 20973483 nM NN I-NP O
19 501 502 20973483 ; : O O
20 503 507 20973483 A(1) NN B-NP O
21 508 512 20973483 K(i) NN I-NP O
22 513 514 20973483 = SYM B-VP O
23 515 519 20973483 17.0 CD B-NP O
24 520 522 20973483 nM NN I-NP O
25 522 523 20973483 ) ) O O
26 524 528 20973483 that WDT B-NP O
27 529 532 20973483 has VBZ B-VP O
28 533 542 20973483 excellent JJ B-NP O
29 543 551 20973483 activity NN I-NP O
30 551 552 20973483 , , O O
31 553 558 20973483 after IN B-SBAR O
32 559 563 20973483 oral JJ B-NP O
33 564 578 20973483 administration NN I-NP O
34 578 579 20973483 , , O O
35 580 586 20973483 across IN B-PP O
36 587 588 20973483 a DT B-NP O
37 589 595 20973483 number NN I-NP O
38 596 598 20973483 of IN B-PP O
39 599 605 20973483 animal NN B-NP O
40 606 612 20973483 models NNS I-NP O
41 613 615 20973483 of IN B-PP O
42 616 627 20973483 Parkinson's NNS B-NP D010300
43 628 635 20973483 disease NN I-NP D010300
44 636 645 20973483 including VBG B-PP O
45 646 651 20973483 mouse NN B-NP O
46 652 655 20973483 and CC I-NP O
47 656 659 20973483 rat NN I-NP O
48 660 666 20973483 models NNS I-NP O
49 667 669 20973483 of IN B-PP O
50 670 681 20973483 haloperidol NN B-NP D006220
51 681 682 20973483 - HYPH B-NP O
52 682 689 20973483 induced VBN I-NP O
53 690 699 20973483 catalepsy NN I-NP D002375
54 699 700 20973483 , , O O
55 701 706 20973483 mouse NN B-NP O
56 707 712 20973483 model NN I-NP O
57 713 715 20973483 of IN B-PP O
58 716 725 20973483 reserpine NN B-NP D012110
59 725 726 20973483 - HYPH B-NP O
60 726 733 20973483 induced VBN I-NP O
61 734 742 20973483 akinesia NN I-NP D004409
62 742 743 20973483 , , O O
63 744 747 20973483 rat NN B-NP O
64 748 749 20973483 6 CD I-NP D016627
65 749 750 20973483 - HYPH I-NP D016627
66 750 765 20973483 hydroxydopamine NN I-NP D016627
67 766 767 20973483 ( ( O O
68 767 768 20973483 6 CD B-NP D016627
69 768 769 20973483 - HYPH I-NP D016627
70 769 773 20973483 OHDA NN I-NP D016627
71 773 774 20973483 ) ) I-NP O
72 775 781 20973483 lesion NN I-NP O
73 782 787 20973483 model NN I-NP O
74 788 790 20973483 of IN B-PP O
75 791 795 20973483 drug NN B-NP O
76 795 796 20973483 - HYPH B-NP O
77 796 803 20973483 induced VBN I-NP O
78 804 812 20973483 rotation NN I-NP O
79 812 813 20973483 , , O O
80 814 817 20973483 and CC O O
81 818 822 20973483 MPTP NN B-NP D015632
82 822 823 20973483 - HYPH O O
83 823 830 20973483 treated VBN B-VP O
84 831 834 20973483 non AFX B-ADJP O
85 834 835 20973483 - HYPH B-NP O
86 835 840 20973483 human JJ I-NP O
87 841 848 20973483 primate JJ I-NP O
88 849 854 20973483 model NN I-NP O
89 854 855 20973483 . . O O

1 0 0 18997632 -DOCSTART- -X- -X- O

1 0 1 18997632 A DT B-NP O
2 2 6 18997632 case NN I-NP O
3 7 9 18997632 of IN B-PP O
4 10 21 18997632 ventricular JJ B-NP D017180
5 22 33 18997632 tachycardia NN I-NP D017180
6 34 41 18997632 related VBN B-VP O
7 42 44 18997632 to TO B-PP O
8 45 53 18997632 caffeine NN B-NP D002110
9 54 66 18997632 pretreatment NN I-NP O
10 66 67 18997632 . . O O
11 68 78 18997632 Suboptimal JJ B-NP O
12 79 86 18997632 seizure NN I-NP D012640
13 87 95 18997632 duration NN I-NP O
14 96 98 18997632 is VBZ B-VP O
15 99 107 18997632 commonly RB I-VP O
16 108 119 18997632 encountered VBN I-VP O
17 120 122 18997632 in IN B-PP O
18 123 140 18997632 electroconvulsive JJ B-NP O
19 141 148 18997632 therapy NN I-NP O
20 149 157 18997632 practice NN I-NP O
21 157 158 18997632 , , O O
22 159 169 18997632 especially RB B-ADVP O
23 170 172 18997632 in IN B-PP O
24 173 178 18997632 older JJR B-NP O
25 179 187 18997632 patients NNS I-NP O
26 188 192 18997632 with IN B-PP O
27 193 199 18997632 higher JJR B-NP O
28 200 207 18997632 seizure NN I-NP D012640
29 208 218 18997632 thresholds NNS I-NP O
30 218 219 18997632 . . O O

1 220 231 18997632 Intravenous JJ B-NP O
2 232 240 18997632 caffeine NN I-NP D002110
3 241 243 18997632 is VBZ B-VP O
4 244 252 18997632 commonly RB I-VP O
5 253 257 18997632 used VBN I-VP O
6 258 260 18997632 to TO B-VP O
7 261 268 18997632 improve VB I-VP O
8 269 276 18997632 seizure NN B-NP D012640
9 277 285 18997632 duration NN I-NP O
10 286 289 18997632 and CC I-NP O
11 290 297 18997632 quality NN I-NP O
12 298 300 18997632 in IN B-PP O
13 301 305 18997632 such JJ B-NP O
14 306 314 18997632 patients NNS I-NP O
15 315 318 18997632 and CC O O
16 319 321 18997632 is VBZ B-VP O
17 322 331 18997632 generally RB I-VP O
18 332 336 18997632 well RB I-VP O
19 337 346 18997632 tolerated VBN I-VP O
20 347 352 18997632 aside RB B-ADVP O
21 353 357 18997632 from IN B-PP O
22 358 368 18997632 occasional JJ B-NP O
23 369 376 18997632 reports NNS I-NP O
24 377 379 18997632 of IN B-PP O
25 380 390 18997632 relatively RB B-NP O
26 391 397 18997632 benign JJ I-NP O
27 398 409 18997632 ventricular JJ I-NP D018879
28 410 416 18997632 ectopy NN I-NP D018879
29 416 417 18997632 . . O O

1 418 420 18997632 We PRP B-NP O
2 421 429 18997632 describe VBP B-VP O
3 430 431 18997632 a DT B-NP O
4 432 439 18997632 patient NN I-NP O
5 440 444 18997632 with IN B-PP O
6 445 447 18997632 no DT B-NP O
7 448 456 18997632 previous JJ I-NP O
8 457 464 18997632 history NN I-NP O
9 465 467 18997632 of IN B-PP O
10 468 475 18997632 cardiac JJ B-NP D006331
11 476 483 18997632 disease NN I-NP D006331
12 484 486 18997632 or CC O O
13 487 497 18997632 arrhythmia NN B-NP D001145
14 498 501 18997632 who WP B-NP O
15 502 511 18997632 developed VBD B-VP O
16 512 521 18997632 sustained JJ B-NP O
17 522 530 18997632 bigeminy JJ I-NP O
18 531 534 18997632 and CC I-NP O
19 535 536 18997632 2 CD I-NP O
20 537 542 18997632 brief JJ I-NP O
21 543 547 18997632 runs NNS I-NP O
22 548 550 18997632 of IN B-PP O
23 551 562 18997632 ventricular JJ B-NP D017180
24 563 574 18997632 tachycardia NN I-NP D017180
25 575 580 18997632 after IN B-PP O
26 581 589 18997632 caffeine NN B-NP D002110
27 590 604 18997632 administration NN I-NP O
28 604 605 18997632 . . O O

1 606 614 18997632 Although IN B-SBAR O
2 615 626 18997632 intravenous JJ B-NP O
3 627 635 18997632 caffeine NN I-NP D002110
4 636 638 18997632 is VBZ B-VP O
5 639 648 18997632 generally RB I-VP O
6 649 653 18997632 well RB I-VP O
7 654 663 18997632 tolerated VBN I-VP O
8 663 664 18997632 , , O O
9 665 668 18997632 the DT B-NP O
10 669 678 18997632 clinician NN I-NP O
11 679 685 18997632 should MD B-VP O
12 686 688 18997632 be VB I-VP O
13 689 694 18997632 aware JJ B-ADJP O
14 695 697 18997632 of IN B-PP O
15 698 701 18997632 the DT B-NP O
16 702 711 18997632 potential NN I-NP O
17 712 715 18997632 for IN B-PP O
18 716 729 18997632 unpredictable JJ B-NP O
19 730 733 18997632 and CC I-NP O
20 734 741 18997632 serious JJ I-NP O
21 742 753 18997632 ventricular JJ I-NP D001145
22 754 765 18997632 arrhythmias NNS I-NP D001145
23 765 766 18997632 . . O O

1 0 0 1728915 -DOCSTART- -X- -X- O

1 0 13 1728915 Carbamazepine NN B-NP D002220
2 13 14 1728915 - HYPH O O
3 14 21 1728915 induced VBN B-NP O
4 22 29 1728915 cardiac JJ I-NP D006331
5 30 41 1728915 dysfunction NN I-NP D006331
6 41 42 1728915 . . O O

1 43 59 1728915 Characterization NN B-NP O
2 60 62 1728915 of IN B-PP O
3 63 66 1728915 two CD B-NP O
4 67 75 1728915 distinct JJ I-NP O
5 76 84 1728915 clinical JJ I-NP O
6 85 94 1728915 syndromes NNS I-NP O
7 94 95 1728915 . . O O
8 96 97 1728915 A DT B-NP O
9 98 105 1728915 patient NN I-NP O
10 106 110 1728915 with IN B-PP O
11 111 116 1728915 sinus NN B-NP O
12 117 128 1728915 bradycardia NN I-NP D001919
13 129 132 1728915 and CC O O
14 133 149 1728915 atrioventricular JJ B-NP D054537
15 150 155 1728915 block NN I-NP D054537
16 155 156 1728915 , , O O
17 157 164 1728915 induced VBN B-VP O
18 165 167 1728915 by IN B-PP O
19 168 181 1728915 carbamazepine NN B-NP D002220
20 181 182 1728915 , , O O
21 183 191 1728915 prompted VBD B-VP O
22 192 194 1728915 an DT B-NP O
23 195 204 1728915 extensive JJ I-NP O
24 205 215 1728915 literature NN I-NP O
25 216 222 1728915 review NN I-NP O
26 223 225 1728915 of IN B-PP O
27 226 229 1728915 all DT B-NP O
28 230 240 1728915 previously RB I-NP O
29 241 249 1728915 reported VBN I-NP O
30 250 255 1728915 cases NNS I-NP O
31 255 256 1728915 . . O O

1 257 261 1728915 From IN B-PP O
2 262 265 1728915 the DT B-NP O
3 266 274 1728915 analysis NN I-NP O
4 275 277 1728915 of IN B-PP O
5 278 283 1728915 these DT B-NP O
6 284 289 1728915 cases NNS I-NP O
7 289 290 1728915 , , O O
8 291 294 1728915 two CD B-NP O
9 295 303 1728915 distinct JJ I-NP O
10 304 309 1728915 forms NNS I-NP O
11 310 312 1728915 of IN B-PP O
12 313 326 1728915 carbamazepine NN B-NP D002220
13 326 327 1728915 - HYPH O O
14 327 337 1728915 associated VBN B-VP O
15 338 345 1728915 cardiac JJ B-NP D006331
16 346 357 1728915 dysfunction NN I-NP D006331
17 358 365 1728915 emerged VBD B-VP O
18 365 366 1728915 . . O O

1 367 370 1728915 One CD B-NP O
2 371 378 1728915 patient NN I-NP O
3 379 384 1728915 group NN I-NP O
4 385 394 1728915 developed VBD B-VP O
5 395 400 1728915 sinus NN B-NP D013616
6 401 413 1728915 tachycardias NNS I-NP D013616
7 414 416 1728915 in IN B-PP O
8 417 420 1728915 the DT B-NP O
9 421 428 1728915 setting NN I-NP O
10 429 431 1728915 of IN B-PP O
11 432 433 1728915 a DT B-NP O
12 434 441 1728915 massive JJ I-NP O
13 442 455 1728915 carbamazepine NN I-NP D002220
14 456 464 1728915 overdose NN I-NP D062787
15 464 465 1728915 . . O O

1 466 469 1728915 The DT B-NP O
2 470 476 1728915 second JJ I-NP O
3 477 482 1728915 group NN I-NP O
4 483 492 1728915 consisted VBD B-VP O
5 493 499 1728915 almost RB B-ADVP O
6 500 511 1728915 exclusively RB I-ADVP O
7 512 514 1728915 of IN B-PP O
8 515 522 1728915 elderly JJ B-NP O
9 523 528 1728915 women NNS I-NP O
10 529 532 1728915 who WP B-NP O
11 533 542 1728915 developed VBD B-VP O
12 543 554 1728915 potentially RB B-NP O
13 555 559 1728915 life NN I-NP O
14 559 560 1728915 - HYPH O O
15 560 571 1728915 threatening VBG B-VP O
16 572 588 1728915 bradyarrhythmias NNS B-NP D001919
17 589 591 1728915 or CC O O
18 592 608 1728915 atrioventricular JJ B-NP D054537
19 609 619 1728915 conduction NN I-NP D054537
20 620 625 1728915 delay NN I-NP D054537
21 625 626 1728915 , , O O
22 627 637 1728915 associated VBN B-VP O
23 638 642 1728915 with IN B-PP O
24 643 649 1728915 either CC O O
25 650 661 1728915 therapeutic JJ B-ADJP O
26 662 664 1728915 or CC O O
27 665 673 1728915 modestly RB B-NP O
28 674 682 1728915 elevated JJ I-NP O
29 683 696 1728915 carbamazepine NN I-NP D002220
30 697 702 1728915 serum NN I-NP O
31 703 709 1728915 levels NNS I-NP O
32 709 710 1728915 . . O O

1 711 718 1728915 Because IN B-SBAR O
2 719 732 1728915 carbamazepine NN B-NP D002220
3 733 735 1728915 is VBZ B-VP O
4 736 742 1728915 widely RB I-VP O
5 743 747 1728915 used VBN I-VP O
6 748 750 1728915 in IN B-PP O
7 751 754 1728915 the DT B-NP O
8 755 764 1728915 treatment NN I-NP O
9 765 767 1728915 of IN B-PP O
10 768 772 1728915 many JJ B-NP O
11 773 783 1728915 neurologic JJ I-NP O
12 784 787 1728915 and CC I-NP O
13 788 799 1728915 psychiatric JJ I-NP D001523
14 800 810 1728915 conditions NNS I-NP O
15 810 811 1728915 , , O O
16 812 815 1728915 the DT B-NP O
17 816 827 1728915 recognition NN I-NP O
18 828 830 1728915 of IN B-PP O
19 831 834 1728915 the DT B-NP O
20 835 841 1728915 latter JJ I-NP O
21 842 850 1728915 syndrome NN I-NP O
22 851 854 1728915 has VBZ B-VP O
23 855 864 1728915 important JJ B-NP O
24 865 877 1728915 implications NNS I-NP O
25 878 881 1728915 for IN B-PP O
26 882 885 1728915 the DT B-NP O
27 886 889 1728915 use NN I-NP O
28 890 892 1728915 of IN B-PP O
29 893 897 1728915 this DT B-NP O
30 898 902 1728915 drug NN I-NP O
31 903 905 1728915 in IN B-PP O
32 906 913 1728915 elderly JJ B-NP O
33 914 922 1728915 patients NNS I-NP O
34 922 923 1728915 . . O O

1 0 0 1545575 -DOCSTART- -X- -X- O

1 0 11 1545575 Hemorrhagic JJ B-NP D006470
2 12 20 1545575 cystitis NN I-NP D006470
3 21 33 1545575 complicating VBG B-VP O
4 34 38 1545575 bone NN B-NP O
5 39 45 1545575 marrow NN I-NP O
6 46 61 1545575 transplantation NN I-NP O
7 61 62 1545575 . . O O
8 63 74 1545575 Hemorrhagic JJ B-NP D006470
9 75 83 1545575 cystitis NN I-NP D006470
10 84 86 1545575 is VBZ B-VP O
11 87 88 1545575 a DT B-NP O
12 89 100 1545575 potentially RB I-NP O
13 101 108 1545575 serious JJ I-NP O
14 109 121 1545575 complication NN I-NP O
15 122 124 1545575 of IN B-PP O
16 125 129 1545575 high JJ B-NP O
17 129 130 1545575 - HYPH I-NP O
18 130 134 1545575 dose NN I-NP O
19 135 151 1545575 cyclophosphamide NN I-NP D003520
20 152 159 1545575 therapy NN I-NP O
21 160 172 1545575 administered VBN B-VP O
22 173 179 1545575 before IN B-PP O
23 180 184 1545575 bone NN B-NP O
24 185 191 1545575 marrow NN I-NP O
25 192 207 1545575 transplantation NN I-NP O
26 207 208 1545575 . . O O

1 209 211 1545575 As IN B-SBAR O
2 212 220 1545575 standard JJ B-NP O
3 221 229 1545575 practice NN I-NP O
4 230 232 1545575 at IN B-PP O
5 233 236 1545575 our PRP$ B-NP O
6 237 248 1545575 institution NN I-NP O
7 248 249 1545575 , , O O
8 250 258 1545575 patients NNS B-NP O
9 259 262 1545575 who WP B-NP O
10 263 266 1545575 are VBP B-VP O
11 267 276 1545575 scheduled VBN I-VP O
12 277 279 1545575 to TO I-VP O
13 280 287 1545575 receive VB I-VP O
14 288 289 1545575 a DT B-NP O
15 290 294 1545575 bone NN I-NP O
16 295 301 1545575 marrow NN I-NP O
17 302 312 1545575 transplant NN I-NP O
18 313 316 1545575 are VBP B-VP O
19 317 324 1545575 treated VBN I-VP O
20 325 341 1545575 prophylactically RB B-ADVP O
21 342 346 1545575 with IN B-PP O
22 347 353 1545575 forced VBN B-NP O
23 354 363 1545575 hydration NN I-NP O
24 364 367 1545575 and CC I-NP O
25 368 375 1545575 bladder NN I-NP O
26 376 386 1545575 irrigation NN I-NP O
27 386 387 1545575 . . O O

1 388 390 1545575 In IN B-PP O
2 391 393 1545575 an DT B-NP O
3 394 401 1545575 attempt NN I-NP O
4 402 404 1545575 to TO B-VP O
5 405 412 1545575 obviate VB I-VP O
6 413 416 1545575 the DT B-NP O
7 417 430 1545575 inconvenience NN I-NP O
8 431 433 1545575 of IN B-PP O
9 434 441 1545575 bladder NN B-NP O
10 442 452 1545575 irrigation NN I-NP O
11 452 453 1545575 , , O O
12 454 456 1545575 we PRP B-NP O
13 457 466 1545575 conducted VBD B-VP O
14 467 468 1545575 a DT B-NP O
15 469 480 1545575 feasibility NN I-NP O
16 481 486 1545575 trial NN I-NP O
17 487 489 1545575 of IN B-PP O
18 490 504 1545575 uroprophylaxis NN B-NP O
19 505 509 1545575 with IN B-PP O
20 510 515 1545575 mesna NN B-NP D015080
21 515 516 1545575 , , O O
22 517 522 1545575 which WDT B-NP O
23 523 534 1545575 neutralizes VBZ B-VP O
24 535 538 1545575 the DT B-NP O
25 539 546 1545575 hepatic JJ I-NP O
26 547 557 1545575 metabolite NN I-NP O
27 558 560 1545575 of IN B-PP O
28 561 577 1545575 cyclophosphamide NN B-NP D003520
29 578 582 1545575 that WDT B-NP O
30 583 589 1545575 causes VBZ B-VP O
31 590 601 1545575 hemorrhagic JJ B-NP D006470
32 602 610 1545575 cystitis NN I-NP D006470
33 610 611 1545575 . . O O

1 612 614 1545575 Of IN B-PP O
2 615 617 1545575 97 CD B-NP O
3 618 626 1545575 patients NNS I-NP O
4 627 630 1545575 who WP B-NP O
5 631 639 1545575 received VBD B-VP O
6 640 648 1545575 standard JJ B-NP O
7 649 660 1545575 prophylaxis NN I-NP O
8 660 661 1545575 , , O O
9 662 663 1545575 4 CD B-NP O
10 664 667 1545575 had VBD B-VP O
11 668 679 1545575 symptomatic JJ B-NP O
12 680 691 1545575 hemorrhagic JJ I-NP D006470
13 692 700 1545575 cystitis NN I-NP D006470
14 700 701 1545575 . . O O

1 702 704 1545575 In IN B-PP O
2 705 713 1545575 contrast NN B-NP O
3 713 714 1545575 , , O O
4 715 718 1545575 two CD B-NP O
5 719 721 1545575 of IN I-NP O
6 722 726 1545575 four CD I-NP O
7 727 738 1545575 consecutive JJ I-NP O
8 739 747 1545575 patients NNS I-NP O
9 748 751 1545575 who WP B-NP O
10 752 760 1545575 received VBD B-VP O
11 761 766 1545575 mesna NN B-NP D015080
12 767 781 1545575 uroprophylaxis NN I-NP O
13 782 788 1545575 before IN B-PP O
14 789 799 1545575 allogeneic JJ B-NP O
15 800 804 1545575 bone NN I-NP O
16 805 811 1545575 marrow NN I-NP O
17 812 827 1545575 transplantation NN I-NP O
18 828 831 1545575 had VBD B-VP O
19 832 838 1545575 severe JJ B-NP O
20 839 850 1545575 hemorrhagic JJ I-NP D006470
21 851 859 1545575 cystitis NN I-NP D006470
22 860 863 1545575 for IN B-PP O
23 864 866 1545575 at IN B-NP O
24 867 872 1545575 least JJS I-NP O
25 873 874 1545575 2 CD I-NP O
26 875 880 1545575 weeks NNS I-NP O
27 880 881 1545575 . . O O

1 882 889 1545575 Because IN B-PP O
2 890 892 1545575 of IN I-PP O
3 893 897 1545575 this DT B-NP O
4 898 908 1545575 suboptimal JJ I-NP O
5 909 915 1545575 result NN I-NP O
6 915 916 1545575 , , O O
7 917 919 1545575 we PRP B-NP O
8 920 927 1545575 resumed VBD B-VP O
9 928 931 1545575 the DT B-NP O
10 932 935 1545575 use NN I-NP O
11 936 938 1545575 of IN B-PP O
12 939 946 1545575 bladder NN B-NP O
13 947 957 1545575 irrigation NN I-NP O
14 958 961 1545575 and CC O O
15 962 968 1545575 forced VBN B-NP O
16 969 978 1545575 hydration NN I-NP O
17 979 981 1545575 to TO B-VP O
18 982 990 1545575 minimize VB I-VP O
19 991 994 1545575 the DT B-NP O
20 995 999 1545575 risk NN I-NP O
21 1000 1002 1545575 of IN B-PP O
22 1003 1014 1545575 hemorrhagic JJ B-NP D006470
23 1015 1023 1545575 cystitis NN I-NP D006470
24 1023 1024 1545575 . . O O

1 0 0 15531665 -DOCSTART- -X- -X- O

1 0 4 15531665 Does VBZ O O
2 5 17 15531665 supplemental JJ B-NP O
3 18 25 15531665 vitamin NN I-NP D001205
4 26 27 15531665 C NN I-NP D001205
5 28 36 15531665 increase VBP B-VP O
6 37 51 15531665 cardiovascular JJ B-NP D002318
7 52 59 15531665 disease NN I-NP D002318
8 60 64 15531665 risk NN I-NP O
9 65 67 15531665 in IN B-PP O
10 68 73 15531665 women NNS B-NP O
11 74 78 15531665 with IN B-PP O
12 79 87 15531665 diabetes NN B-NP D003920
13 87 88 15531665 ? . O O
14 89 99 15531665 BACKGROUND NN B-NP O
15 99 100 15531665 : : O O
16 101 108 15531665 Vitamin NN B-NP D001205
17 109 110 15531665 C NN I-NP D001205
18 111 115 15531665 acts VBZ B-VP O
19 116 118 15531665 as IN B-PP O
20 119 120 15531665 a DT B-NP O
21 121 127 15531665 potent JJ I-NP O
22 128 139 15531665 antioxidant NN I-NP O
23 139 140 15531665 ; : O O
24 141 148 15531665 however RB B-ADVP O
25 148 149 15531665 , , O O
26 150 152 15531665 it PRP B-NP O
27 153 156 15531665 can MD B-VP O
28 157 161 15531665 also RB I-VP O
29 162 164 15531665 be VB I-VP O
30 165 166 15531665 a DT B-NP O
31 167 177 15531665 prooxidant NN I-NP O
32 178 181 15531665 and CC I-NP O
33 182 189 15531665 glycate NN I-NP O
34 190 197 15531665 protein NN I-NP O
35 198 203 15531665 under IN B-PP O
36 204 211 15531665 certain JJ B-NP O
37 212 225 15531665 circumstances NNS I-NP O
38 226 228 15531665 in FW B-ADVP O
39 229 234 15531665 vitro FW I-ADVP O
40 234 235 15531665 . . O O

1 236 241 15531665 These DT B-NP O
2 242 254 15531665 observations NNS I-NP O
3 255 258 15531665 led VBD B-VP O
4 259 261 15531665 us PRP B-NP O
5 262 264 15531665 to TO B-VP O
6 265 276 15531665 hypothesize VB I-VP O
7 277 281 15531665 that IN B-SBAR O
8 282 283 15531665 a DT B-NP O
9 284 288 15531665 high JJ I-NP O
10 289 295 15531665 intake NN I-NP O
11 296 298 15531665 of IN B-PP O
12 299 306 15531665 vitamin NN B-NP D001205
13 307 308 15531665 C NN I-NP D001205
14 309 311 15531665 in IN B-PP O
15 312 320 15531665 diabetic JJ B-NP D003920
16 321 328 15531665 persons NNS I-NP O
17 329 334 15531665 might MD B-VP O
18 335 342 15531665 promote VB I-VP O
19 343 358 15531665 atherosclerosis NN B-NP D050197
20 358 359 15531665 . . O O

1 360 369 15531665 OBJECTIVE NN B-NP O
2 369 370 15531665 : : O O
3 371 374 15531665 The DT B-NP O
4 375 384 15531665 objective NN I-NP O
5 385 388 15531665 was VBD B-VP O
6 389 391 15531665 to TO B-VP O
7 392 399 15531665 examine VB I-VP O
8 400 403 15531665 the DT B-NP O
9 404 412 15531665 relation NN I-NP O
10 413 420 15531665 between IN B-PP O
11 421 428 15531665 vitamin NN B-NP D001205
12 429 430 15531665 C NN I-NP D001205
13 431 437 15531665 intake NN I-NP O
14 438 441 15531665 and CC I-NP O
15 442 451 15531665 mortality NN I-NP O
16 452 456 15531665 from IN B-PP O
17 457 471 15531665 cardiovascular JJ B-NP D002318
18 472 479 15531665 disease NN I-NP D002318
19 479 480 15531665 . . O O

1 481 487 15531665 DESIGN NN B-NP O
2 487 488 15531665 : : O O
3 489 491 15531665 We PRP B-NP O
4 492 499 15531665 studied VBD B-VP O
5 500 503 15531665 the DT B-NP O
6 504 512 15531665 relation NN I-NP O
7 513 520 15531665 between IN B-PP O
8 521 528 15531665 vitamin NN B-NP D001205
9 529 530 15531665 C NN I-NP D001205
10 531 537 15531665 intake NN I-NP O
11 538 541 15531665 and CC I-NP O
12 542 551 15531665 mortality NN I-NP O
13 552 556 15531665 from IN B-PP O
14 557 562 15531665 total JJ B-NP O
15 563 577 15531665 cardiovascular JJ I-NP D002318
16 578 585 15531665 disease NN I-NP D002318
17 586 587 15531665 ( ( O O
18 587 588 15531665 n NN B-NP O
19 589 590 15531665 = SYM B-VP O
20 591 594 15531665 281 CD B-NP O
21 594 595 15531665 ) ) O O
22 595 596 15531665 , , O O
23 597 605 15531665 coronary JJ B-NP D003324
24 606 612 15531665 artery NN I-NP D003324
25 613 620 15531665 disease NN I-NP D003324
26 621 622 15531665 ( ( O O
27 622 623 15531665 n NN B-NP O
28 624 625 15531665 = SYM B-VP O
29 626 629 15531665 175 CD B-NP O
30 629 630 15531665 ) ) O O
31 630 631 15531665 , , O O
32 632 635 15531665 and CC O O
33 636 642 15531665 stroke NN B-NP D020521
34 643 644 15531665 ( ( O O
35 644 645 15531665 n NN B-NP O
36 646 647 15531665 = SYM B-VP O
37 648 650 15531665 57 CD B-NP O
38 650 651 15531665 ) ) O O
39 652 654 15531665 in IN B-PP O
40 655 659 15531665 1923 CD B-NP O
41 660 674 15531665 postmenopausal JJ I-NP O
42 675 680 15531665 women NNS I-NP O
43 681 684 15531665 who WP B-NP O
44 685 693 15531665 reported VBD B-VP O
45 694 699 15531665 being VBG I-VP O
46 700 708 15531665 diabetic JJ B-ADJP D003920
47 709 711 15531665 at IN B-PP O
48 712 720 15531665 baseline NN B-NP O
49 720 721 15531665 . . O O

1 722 726 15531665 Diet NN B-NP O
2 727 730 15531665 was VBD B-VP O
3 731 739 15531665 assessed VBN I-VP O
4 740 744 15531665 with IN B-PP O
5 745 746 15531665 a DT B-NP O
6 747 751 15531665 food NN I-NP O
7 751 752 15531665 - HYPH I-NP O
8 752 761 15531665 frequency NN I-NP O
9 762 775 15531665 questionnaire NN I-NP O
10 776 778 15531665 at IN B-PP O
11 779 787 15531665 baseline NN B-NP O
12 787 788 15531665 , , O O
13 789 792 15531665 and CC O O
14 793 801 15531665 subjects NNS B-NP O
15 802 811 15531665 initially RB B-ADJP O
16 812 816 15531665 free JJ I-ADJP O
17 817 819 15531665 of IN B-PP O
18 820 828 15531665 coronary JJ B-NP D003324
19 829 835 15531665 artery NN I-NP D003324
20 836 843 15531665 disease NN I-NP D003324
21 844 848 15531665 were VBD B-VP O
22 849 862 15531665 prospectively RB I-VP O
23 863 871 15531665 followed VBN I-VP O
24 872 875 15531665 for IN B-PP O
25 876 878 15531665 15 CD B-NP O
26 879 880 15531665 y NN I-NP O
27 880 881 15531665 . . O O

1 882 889 15531665 RESULTS NNS B-NP O
2 889 890 15531665 : : O O
3 891 896 15531665 After IN B-PP O
4 897 907 15531665 adjustment NN B-NP O
5 908 911 15531665 for IN B-PP O
6 912 926 15531665 cardiovascular JJ B-NP D002318
7 927 934 15531665 disease NN I-NP D002318
8 935 939 15531665 risk NN I-NP O
9 940 947 15531665 factors NNS I-NP O
10 947 948 15531665 , , O O
11 949 953 15531665 type NN B-NP O
12 954 956 15531665 of IN B-PP O
13 957 965 15531665 diabetes NN B-NP D003920
14 966 976 15531665 medication NN I-NP O
15 977 981 15531665 used VBN B-VP O
16 981 982 15531665 , , O O
17 983 991 15531665 duration NN B-NP O
18 992 994 15531665 of IN B-PP O
19 995 1003 15531665 diabetes NN B-NP D003920
20 1003 1004 15531665 , , O O
21 1005 1008 15531665 and CC O O
22 1009 1016 15531665 intakes NNS B-NP O
23 1017 1019 15531665 of IN B-PP O
24 1020 1026 15531665 folate NN B-NP D005492
25 1026 1027 15531665 , , O O
26 1028 1035 15531665 vitamin NN B-NP D014810
27 1036 1037 15531665 E NN I-NP D014810
28 1037 1038 15531665 , , O O
29 1039 1042 15531665 and CC O O
30 1043 1047 15531665 beta SYM O D019207
31 1047 1048 15531665 - HYPH O D019207
32 1048 1056 15531665 carotene NN B-NP D019207
33 1056 1057 15531665 , , O O
34 1058 1061 15531665 the DT B-NP O
35 1062 1070 15531665 adjusted VBN I-NP O
36 1071 1079 15531665 relative JJ I-NP O
37 1080 1085 15531665 risks NNS I-NP O
38 1086 1088 15531665 of IN B-PP O
39 1089 1094 15531665 total JJ B-NP O
40 1095 1109 15531665 cardiovascular JJ I-NP D002318
41 1110 1117 15531665 disease NN I-NP D002318
42 1118 1127 15531665 mortality NN I-NP O
43 1128 1132 15531665 were VBD B-VP O
44 1133 1136 15531665 1.0 CD B-NP O
45 1136 1137 15531665 , , I-NP O
46 1138 1142 15531665 0.97 CD I-NP O
47 1142 1143 15531665 , , I-NP O
48 1144 1148 15531665 1.11 CD I-NP O
49 1148 1149 15531665 , , I-NP O
50 1150 1154 15531665 1.47 CD I-NP O
51 1154 1155 15531665 , , O O
52 1156 1159 15531665 and CC O O
53 1160 1164 15531665 1.84 CD B-NP O
54 1165 1166 15531665 ( ( O O
55 1166 1167 15531665 P NN B-NP O
56 1168 1171 15531665 for IN B-PP O
57 1172 1177 15531665 trend NN B-NP O
58 1178 1179 15531665 < SYM B-NP O
59 1180 1184 15531665 0.01 CD I-NP O
60 1184 1185 15531665 ) ) O O
61 1186 1192 15531665 across IN B-PP O
62 1193 1202 15531665 quintiles NNS B-NP O
63 1203 1205 15531665 of IN B-PP O
64 1206 1211 15531665 total JJ B-NP O
65 1212 1219 15531665 vitamin NN I-NP D001205
66 1220 1221 15531665 C NN I-NP D001205
67 1222 1228 15531665 intake NN I-NP O
68 1229 1233 15531665 from IN B-PP O
69 1234 1238 15531665 food NN B-NP O
70 1239 1242 15531665 and CC I-NP O
71 1243 1254 15531665 supplements NNS I-NP O
72 1254 1255 15531665 . . O O

1 1256 1264 15531665 Adjusted VBN B-NP O
2 1265 1273 15531665 relative JJ I-NP O
3 1274 1279 15531665 risks NNS I-NP O
4 1280 1282 15531665 of IN B-PP O
5 1283 1291 15531665 coronary JJ B-NP D003324
6 1292 1298 15531665 artery NN I-NP D003324
7 1299 1306 15531665 disease NN I-NP D003324
8 1307 1311 15531665 were VBD B-VP O
9 1312 1315 15531665 1.0 CD B-NP O
10 1315 1316 15531665 , , I-NP O
11 1317 1321 15531665 0.81 CD I-NP O
12 1321 1322 15531665 , , I-NP O
13 1323 1327 15531665 0.99 CD I-NP O
14 1327 1328 15531665 , , I-NP O
15 1329 1333 15531665 1.26 CD I-NP O
16 1333 1334 15531665 , , O O
17 1335 1338 15531665 and CC O O
18 1339 1343 15531665 1.91 CD B-NP O
19 1344 1345 15531665 ( ( O O
20 1345 1346 15531665 P NN B-NP O
21 1347 1350 15531665 for IN B-PP O
22 1351 1356 15531665 trend NN B-NP O
23 1357 1358 15531665 = SYM B-VP O
24 1359 1363 15531665 0.01 CD B-NP O
25 1363 1364 15531665 ) ) O O
26 1365 1368 15531665 and CC O O
27 1369 1371 15531665 of IN B-PP O
28 1372 1378 15531665 stroke NN B-NP D020521
29 1379 1383 15531665 were VBD B-VP O
30 1384 1387 15531665 1.0 CD B-NP O
31 1387 1388 15531665 , , I-NP O
32 1389 1393 15531665 0.52 CD I-NP O
33 1393 1394 15531665 , , I-NP O
34 1395 1399 15531665 1.23 CD I-NP O
35 1399 1400 15531665 , , I-NP O
36 1401 1405 15531665 2.22 CD I-NP O
37 1405 1406 15531665 , , O O
38 1407 1410 15531665 and CC O O
39 1411 1415 15531665 2.57 CD B-NP O
40 1416 1417 15531665 ( ( O O
41 1417 1418 15531665 P NN B-NP O
42 1419 1422 15531665 for IN B-PP O
43 1423 1428 15531665 trend NN B-NP O
44 1429 1430 15531665 < SYM B-NP O
45 1431 1435 15531665 0.01 CD I-NP O
46 1435 1436 15531665 ) ) O O
47 1436 1437 15531665 . . O O

1 1438 1442 15531665 When WRB B-ADVP O
2 1443 1450 15531665 dietary JJ B-NP O
3 1451 1454 15531665 and CC I-NP O
4 1455 1467 15531665 supplemental JJ I-NP O
5 1468 1475 15531665 vitamin NN I-NP D001205
6 1476 1477 15531665 C NN I-NP D001205
7 1478 1482 15531665 were VBD B-VP O
8 1483 1491 15531665 analyzed VBN I-VP O
9 1492 1502 15531665 separately RB B-ADVP O
10 1502 1503 15531665 , , O O
11 1504 1508 15531665 only RB B-NP O
12 1509 1521 15531665 supplemental JJ I-NP O
13 1522 1529 15531665 vitamin NN I-NP D001205
14 1530 1531 15531665 C NN I-NP D001205
15 1532 1538 15531665 showed VBD B-VP O
16 1539 1540 15531665 a DT B-NP O
17 1541 1549 15531665 positive JJ I-NP O
18 1550 1561 15531665 association NN I-NP O
19 1562 1566 15531665 with IN B-PP O
20 1567 1576 15531665 mortality NN B-NP O
21 1577 1586 15531665 endpoints NNS I-NP O
22 1586 1587 15531665 . . O O

1 1588 1595 15531665 Vitamin NN B-NP D001205
2 1596 1597 15531665 C NN I-NP D001205
3 1598 1604 15531665 intake NN I-NP O
4 1605 1608 15531665 was VBD B-VP O
5 1609 1618 15531665 unrelated JJ B-ADJP O
6 1619 1621 15531665 to TO B-PP O
7 1622 1631 15531665 mortality NN B-NP O
8 1632 1636 15531665 from IN B-PP O
9 1637 1651 15531665 cardiovascular JJ B-NP D002318
10 1652 1659 15531665 disease NN I-NP D002318
11 1660 1662 15531665 in IN B-PP O
12 1663 1666 15531665 the DT B-NP O
13 1667 1678 15531665 nondiabetic JJ I-NP O
14 1679 1687 15531665 subjects NNS I-NP O
15 1688 1690 15531665 at IN B-PP O
16 1691 1699 15531665 baseline NN B-NP O
17 1699 1700 15531665 . . O O

1 1701 1711 15531665 CONCLUSION NN B-NP O
2 1711 1712 15531665 : : O O
3 1713 1714 15531665 A DT B-NP O
4 1715 1719 15531665 high JJ I-NP O
5 1720 1727 15531665 vitamin NN I-NP D001205
6 1728 1729 15531665 C NN I-NP D001205
7 1730 1736 15531665 intake NN I-NP O
8 1737 1741 15531665 from IN B-PP O
9 1742 1753 15531665 supplements NNS B-NP O
10 1754 1756 15531665 is VBZ B-VP O
11 1757 1767 15531665 associated VBN I-VP O
12 1768 1772 15531665 with IN B-PP O
13 1773 1775 15531665 an DT B-NP O
14 1776 1785 15531665 increased VBN I-NP O
15 1786 1790 15531665 risk NN I-NP O
16 1791 1793 15531665 of IN B-PP O
17 1794 1808 15531665 cardiovascular JJ B-NP D002318
18 1809 1816 15531665 disease NN I-NP D002318
19 1817 1826 15531665 mortality NN I-NP O
20 1827 1829 15531665 in IN B-PP O
21 1830 1844 15531665 postmenopausal JJ B-NP O
22 1845 1850 15531665 women NNS I-NP O
23 1851 1855 15531665 with IN B-PP O
24 1856 1864 15531665 diabetes NN B-NP D003920
25 1864 1865 15531665 . . O O

1 0 0 3769769 -DOCSTART- -X- -X- O

1 0 11 3769769 Bradycardia NNP B-NP D001919
2 12 15 3769769 due IN B-PP O
3 16 18 3769769 to TO B-PP O
4 19 34 3769769 trihexyphenidyl NN B-NP D014282
5 35 48 3769769 hydrochloride NN I-NP D014282
6 48 49 3769769 . . O O
7 50 51 3769769 A DT B-NP O
8 52 59 3769769 chronic JJ I-NP O
9 60 73 3769769 schizophrenic JJ I-NP D012559
10 74 81 3769769 patient NN I-NP O
11 82 85 3769769 was VBD B-VP O
12 86 93 3769769 treated VBN I-VP O
13 94 98 3769769 with IN B-PP O
14 99 101 3769769 an DT B-NP O
15 102 117 3769769 anticholinergic JJ I-NP O
16 118 122 3769769 drug NN I-NP O
17 122 123 3769769 , , O O
18 124 139 3769769 trihexyphenidyl NN B-NP D014282
19 140 153 3769769 hydrochloride NN I-NP D014282
20 153 154 3769769 . . O O

1 155 158 3769769 The DT B-NP O
2 159 166 3769769 patient NN I-NP O
3 167 176 3769769 developed VBD B-VP O
4 176 177 3769769 , , O O
5 178 191 3769769 paradoxically RB B-ADVP O
6 191 192 3769769 , , O O
7 193 198 3769769 sinus NN B-NP O
8 199 210 3769769 bradycardia NN I-NP D001919
9 210 211 3769769 . . O O

1 212 215 3769769 The DT B-NP O
2 216 224 3769769 reaction NN I-NP O
3 225 228 3769769 was VBD B-VP O
4 229 237 3769769 specific JJ B-ADJP O
5 238 240 3769769 to TO B-PP O
6 241 256 3769769 trihexyphenidyl NN B-NP D014282
7 257 260 3769769 and CC O O
8 261 264 3769769 not RB O O
9 265 267 3769769 to TO B-PP O
10 268 273 3769769 other JJ B-NP O
11 274 289 3769769 anticholinergic JJ I-NP O
12 290 295 3769769 drugs NNS I-NP O
13 295 296 3769769 . . O O

1 297 301 3769769 This DT B-NP O
2 302 316 3769769 antidyskinetic JJ I-NP O
3 317 321 3769769 drug NN I-NP O
4 322 324 3769769 is VBZ B-VP O
5 325 331 3769769 widely RB I-VP O
6 332 336 3769769 used VBN I-VP O
7 337 339 3769769 in IN B-PP O
8 340 348 3769769 clinical JJ B-NP O
9 349 360 3769769 psychiatric JJ I-NP D001523
10 361 369 3769769 practice NN I-NP O
11 370 373 3769769 and CC I-NP O
12 374 384 3769769 physicians NNS I-NP O
13 385 391 3769769 should MD B-VP O
14 392 394 3769769 be VB I-VP O
15 395 400 3769769 aware JJ B-ADJP O
16 401 403 3769769 of IN B-PP O
17 404 408 3769769 this DT B-NP O
18 409 413 3769769 side NN I-NP O
19 414 420 3769769 effect NN I-NP O
20 420 421 3769769 . . O O

1 0 0 591536 -DOCSTART- -X- -X- O

1 0 8 591536 Arterial JJ B-NP O
2 9 24 591536 thromboembolism NN I-NP D013923
3 25 27 591536 in IN B-PP O
4 28 36 591536 patients NNS B-NP O
5 37 46 591536 receiving VBG B-VP O
6 47 55 591536 systemic JJ B-NP O
7 56 63 591536 heparin NN I-NP D006493
8 64 71 591536 therapy NN I-NP O
9 71 72 591536 : : O O
10 73 74 591536 a DT B-NP O
11 75 87 591536 complication NN I-NP O
12 88 98 591536 associated VBN B-VP O
13 99 103 591536 with IN B-PP O
14 104 111 591536 heparin NN B-NP D006493
15 111 112 591536 - HYPH B-NP O
16 112 119 591536 induced VBN I-NP O
17 120 136 591536 thrombocytopenia NN I-NP D013921
18 136 137 591536 . . I-NP O
19 138 146 591536 Arterial JJ I-NP O
20 147 162 591536 thromboembolism NN I-NP D013923
21 163 165 591536 is VBZ B-VP O
22 166 167 591536 a DT B-NP O
23 168 178 591536 recognized VBN I-NP O
24 179 191 591536 complication NN I-NP O
25 192 194 591536 of IN B-PP O
26 195 203 591536 systemic JJ B-NP O
27 204 211 591536 heparin NN I-NP D006493
28 212 219 591536 therapy NN I-NP O
29 219 220 591536 . . O O

1 221 235 591536 Characteristic JJ B-NP O
2 236 238 591536 of IN B-PP O
3 239 242 591536 the DT B-NP O
4 243 249 591536 entity NN I-NP O
5 250 252 591536 is VBZ B-VP O
6 253 261 591536 arterial JJ B-NP D001157
7 262 271 591536 occlusion NN I-NP D001157
8 272 274 591536 by IN B-PP O
9 275 283 591536 platelet NN B-NP O
10 283 284 591536 - HYPH I-NP O
11 284 290 591536 fibrin NN I-NP O
12 291 298 591536 thrombi NN I-NP D013927
13 299 303 591536 with IN B-PP O
14 304 310 591536 distal JJ B-NP O
15 311 319 591536 ischemia NN I-NP D007511
16 320 329 591536 occurring VBG B-VP O
17 330 334 591536 four CD B-NP O
18 335 337 591536 to TO I-NP O
19 338 344 591536 twenty CD I-NP O
20 345 349 591536 days NNS I-NP O
21 350 355 591536 after IN B-PP O
22 356 359 591536 the DT B-NP O
23 360 370 591536 initiation NN I-NP O
24 371 373 591536 of IN B-PP O
25 374 381 591536 heparin NN B-NP D006493
26 382 389 591536 therapy NN I-NP O
27 389 390 591536 , , O O
28 391 399 591536 preceded VBN B-VP O
29 400 402 591536 by IN B-PP O
30 403 411 591536 profound JJ B-NP O
31 412 428 591536 thrombocytopenia NN I-NP D013921
32 429 433 591536 with IN B-PP O
33 434 442 591536 platelet NN B-NP O
34 443 449 591536 counts NNS I-NP O
35 450 452 591536 in IN B-PP O
36 453 456 591536 the DT B-NP O
37 457 462 591536 range NN I-NP O
38 463 465 591536 of IN B-PP O
39 466 472 591536 30,000 CD B-NP O
40 473 475 591536 to TO B-PP O
41 476 482 591536 40,000 CD B-NP O
42 483 486 591536 per IN B-PP O
43 487 492 591536 cubic JJ B-NP O
44 493 503 591536 millimeter NN I-NP O
45 503 504 591536 . . O O

1 505 508 591536 The DT B-NP O
2 509 519 591536 clinically RB I-NP O
3 520 528 591536 apparent JJ I-NP O
4 529 538 591536 occlusion NN I-NP O
5 539 542 591536 may MD B-VP O
6 543 545 591536 be VB I-VP O
7 546 554 591536 preceded VBN I-VP O
8 555 557 591536 by IN B-PP O
9 558 574 591536 gastrointestinal JJ B-NP D005767
10 575 578 591536 and CC I-NP D005767
11 579 594 591536 musculoskeletal JJ I-NP D005767
12 595 603 591536 symptoms NNS I-NP D005767
13 604 608 591536 that WDT B-NP O
14 609 615 591536 appear VBP B-VP O
15 616 618 591536 to TO I-VP O
16 619 621 591536 be VB I-VP O
17 622 630 591536 ischemic JJ B-ADJP D007511
18 631 633 591536 in IN B-PP O
19 634 640 591536 origin NN B-NP O
20 640 641 591536 , , O O
21 642 645 591536 and CC O O
22 646 651 591536 might MD B-VP O
23 652 657 591536 serve VB I-VP O
24 658 660 591536 to TO I-VP O
25 661 665 591536 warn VB I-VP O
26 666 669 591536 the DT B-NP O
27 670 679 591536 clinician NN I-NP O
28 680 682 591536 of IN B-PP O
29 683 688 591536 these DT B-NP O
30 689 702 591536 complications NNS I-NP O
31 702 703 591536 . . O O

1 704 712 591536 Previous JJ B-NP O
2 713 720 591536 reports NNS I-NP O
3 721 723 591536 of IN B-PP O
4 724 729 591536 these DT B-NP O
5 730 739 591536 phenomena NNS I-NP O
6 740 742 591536 as RB B-CONJP O
7 743 747 591536 well RB I-CONJP O
8 748 750 591536 as IN I-CONJP O
9 751 757 591536 recent JJ B-NP O
10 758 765 591536 studies NNS I-NP O
11 766 768 591536 of IN B-PP O
12 769 772 591536 the DT B-NP O
13 773 779 591536 effect NN I-NP O
14 780 782 591536 of IN B-PP O
15 783 790 591536 heparin NN B-NP D006493
16 791 794 591536 are VBP B-VP O
17 795 803 591536 reviewed VBN I-VP O
18 803 804 591536 . . O O

1 805 808 591536 The DT B-NP O
2 809 815 591536 common JJ I-NP O
3 816 822 591536 factor NN I-NP O
4 823 831 591536 relating VBG B-VP O
5 832 847 591536 thromboembolism NN B-NP D013923
6 848 851 591536 and CC I-NP O
7 852 868 591536 thrombocytopenia NN I-NP D013921
8 869 871 591536 is VBZ B-VP O
9 872 879 591536 heparin NN B-NP D006493
10 879 880 591536 - HYPH B-NP O
11 880 887 591536 induced VBN I-NP O
12 888 896 591536 platelet NN I-NP D001791
13 897 908 591536 aggregation NN I-NP D001791
14 908 909 591536 . . O O

1 910 921 591536 Appropriate JJ B-NP O
2 922 931 591536 treatment NN I-NP O
3 932 940 591536 consists VBZ B-VP O
4 941 943 591536 of IN B-PP O
5 944 959 591536 discontinuation NN B-NP O
6 960 962 591536 of IN B-PP O
7 963 970 591536 heparin NN B-NP D006493
8 970 971 591536 , , O O
9 972 975 591536 and CC O O
10 976 991 591536 anticoagulation NN B-NP O
11 992 996 591536 with IN B-PP O
12 997 1003 591536 sodium NN B-NP D014859
13 1004 1012 591536 warfarin NN I-NP D014859
14 1013 1015 591536 if IN B-SBAR O
15 1016 1025 591536 necessary JJ B-ADJP O
16 1025 1026 591536 . . O O

1 1027 1035 591536 Vascular JJ B-NP O
2 1036 1046 591536 procedures NNS I-NP O
3 1047 1050 591536 are VBP B-VP O
4 1051 1060 591536 performed VBN I-VP O
5 1061 1063 591536 as IN B-SBAR O
6 1064 1073 591536 indicated VBN B-VP O
7 1073 1074 591536 . . O O

1 0 0 7752389 -DOCSTART- -X- -X- O

1 0 13 7752389 Prostaglandin NN B-NP D015232
2 14 16 7752389 E2 NN I-NP D015232
3 16 17 7752389 - HYPH B-NP O
4 17 24 7752389 induced VBN I-NP O
5 25 32 7752389 bladder NN I-NP D053201
6 33 46 7752389 hyperactivity NN I-NP D053201
7 47 49 7752389 in IN B-PP O
8 50 56 7752389 normal JJ B-NP O
9 56 57 7752389 , , I-NP O
10 58 67 7752389 conscious JJ I-NP O
11 68 72 7752389 rats NNS I-NP O
12 72 73 7752389 : : O O
13 74 85 7752389 involvement NN B-NP O
14 86 88 7752389 of IN B-PP O
15 89 100 7752389 tachykinins NNS B-NP D015320
16 100 101 7752389 ? . O O
17 102 104 7752389 In IN B-PP O
18 105 111 7752389 normal JJ B-NP O
19 112 121 7752389 conscious JJ I-NP O
20 122 126 7752389 rats NNS I-NP O
21 127 139 7752389 investigated VBN B-VP O
22 140 142 7752389 by IN B-PP O
23 143 153 7752389 continuous JJ B-NP O
24 154 164 7752389 cystometry NN I-NP O
25 164 165 7752389 , , O O
26 166 180 7752389 intravesically RB B-VP O
27 181 190 7752389 instilled VBN I-VP O
28 191 204 7752389 prostaglandin NN B-NP D015232
29 205 206 7752389 ( ( O D015232
30 206 208 7752389 PG NN B-NP D015232
31 208 209 7752389 ) ) O D015232
32 210 212 7752389 E2 NN B-NP D015232
33 213 224 7752389 facilitated VBD B-VP O
34 225 236 7752389 micturition NN B-NP O
35 237 240 7752389 and CC O O
36 241 250 7752389 increased VBD B-VP O
37 251 256 7752389 basal JJ B-NP O
38 257 269 7752389 intravesical JJ I-NP O
39 270 278 7752389 pressure NN I-NP O
40 278 279 7752389 . . O O

1 280 283 7752389 The DT B-NP O
2 284 290 7752389 effect NN I-NP O
3 291 294 7752389 was VBD B-VP O
4 295 305 7752389 attenuated VBN I-VP O
5 306 308 7752389 by IN B-PP O
6 309 313 7752389 both CC O O
7 314 317 7752389 the DT B-NP O
8 318 321 7752389 NK1 NN I-NP O
9 322 330 7752389 receptor NN I-NP O
10 331 340 7752389 selective JJ I-NP O
11 341 351 7752389 antagonist NN I-NP O
12 352 354 7752389 RP NN I-NP C071693
13 355 361 7752389 67,580 CD I-NP C071693
14 362 365 7752389 and CC O O
15 366 369 7752389 the DT B-NP O
16 370 373 7752389 NK2 NN I-NP O
17 374 382 7752389 receptor NN I-NP O
18 383 392 7752389 selective JJ I-NP O
19 393 403 7752389 antagonist NN I-NP O
20 404 406 7752389 SR NN I-NP C073839
21 407 413 7752389 48,968 CD I-NP C073839
22 413 414 7752389 , , O O
23 415 420 7752389 given VBN B-PP O
24 421 426 7752389 intra AFX B-NP O
25 426 427 7752389 - HYPH I-NP O
26 427 437 7752389 arterially RB B-ADVP O
27 437 438 7752389 , , O O
28 439 449 7752389 suggesting VBG B-VP O
29 450 454 7752389 that IN B-SBAR O
30 455 457 7752389 it PRP B-NP O
31 458 461 7752389 was VBD B-VP O
32 462 470 7752389 mediated VBN I-VP O
33 471 473 7752389 by IN B-PP O
34 474 485 7752389 stimulation NN B-NP O
35 486 488 7752389 of IN B-PP O
36 489 493 7752389 both CC O O
37 494 497 7752389 NK1 NN B-NP O
38 498 501 7752389 and CC I-NP O
39 502 505 7752389 NK2 NN I-NP O
40 506 515 7752389 receptors NNS I-NP O
41 515 516 7752389 . . O O

1 517 522 7752389 Intra AFX B-NP O
2 522 523 7752389 - HYPH B-VP O
3 523 533 7752389 arterially RB B-NP O
4 534 539 7752389 given VBN I-NP O
5 540 544 7752389 PGE2 NN I-NP D015232
6 545 553 7752389 produced VBD B-VP O
7 554 555 7752389 a DT B-NP O
8 556 564 7752389 distinct JJ I-NP O
9 565 573 7752389 increase NN I-NP O
10 574 576 7752389 in IN B-PP O
11 577 584 7752389 bladder NN B-NP O
12 585 593 7752389 pressure NN I-NP O
13 594 600 7752389 before IN B-PP O
14 601 611 7752389 initiating VBG B-VP O
15 612 613 7752389 a DT B-NP O
16 614 625 7752389 micturition NN I-NP O
17 626 632 7752389 reflex NN I-NP O
18 632 633 7752389 , , O O
19 634 644 7752389 indicating VBG B-VP O
20 645 649 7752389 that IN B-SBAR O
21 650 653 7752389 the DT B-NP O
22 654 656 7752389 PG NN I-NP D011453
23 657 660 7752389 had VBD B-VP O
24 661 662 7752389 a DT B-NP O
25 663 669 7752389 direct JJ I-NP O
26 670 681 7752389 contractant NN I-NP O
27 682 688 7752389 effect NN I-NP O
28 689 691 7752389 on IN B-PP O
29 692 695 7752389 the DT B-NP O
30 696 704 7752389 detrusor NN I-NP O
31 705 711 7752389 smooth JJ I-NP O
32 712 718 7752389 muscle NN I-NP O
33 718 719 7752389 . . O O

1 720 723 7752389 The DT B-NP O
2 724 730 7752389 effect NN I-NP O
3 731 733 7752389 of IN B-PP O
4 734 739 7752389 intra AFX B-NP O
5 739 740 7752389 - HYPH I-NP O
6 740 748 7752389 arterial JJ I-NP O
7 749 753 7752389 PGE2 NN I-NP D015232
8 754 759 7752389 could MD B-VP O
9 760 763 7752389 not RB I-VP O
10 764 766 7752389 be VB I-VP O
11 767 774 7752389 blocked VBN I-VP O
12 775 777 7752389 by IN B-PP O
13 778 783 7752389 intra AFX B-NP O
14 783 784 7752389 - HYPH I-NP O
15 784 792 7752389 arterial JJ B-NP O
16 793 795 7752389 RP NN I-NP C071693
17 796 802 7752389 67,580 CD B-NP C071693
18 803 805 7752389 or CC O O
19 806 808 7752389 SR NN B-NP C073839
20 809 815 7752389 48,968 CD I-NP C073839
21 815 816 7752389 , , O O
22 817 822 7752389 which WDT B-NP O
23 823 828 7752389 opens VBZ B-VP O
24 829 832 7752389 the DT B-NP O
25 833 844 7752389 possibility NN I-NP O
26 845 849 7752389 that IN B-SBAR O
27 850 853 7752389 the DT B-NP O
28 854 865 7752389 micturition NN I-NP O
29 866 872 7752389 reflex NN I-NP O
30 873 881 7752389 elicited VBN B-VP O
31 882 884 7752389 by IN B-PP O
32 885 890 7752389 intra AFX B-NP O
33 890 891 7752389 - HYPH I-NP O
34 891 899 7752389 arterial JJ I-NP O
35 900 904 7752389 PGE2 NN I-NP D015232
36 905 908 7752389 was VBD B-VP O
37 909 917 7752389 mediated VBN I-VP O
38 918 920 7752389 by IN B-PP O
39 921 929 7752389 pathways NNS B-NP O
40 930 935 7752389 other JJ B-ADJP O
41 936 940 7752389 than IN B-PP O
42 941 944 7752389 the DT B-NP O
43 945 951 7752389 reflex NN I-NP O
44 952 961 7752389 initiated VBN B-VP O
45 962 966 7752389 when WRB B-ADVP O
46 967 970 7752389 the DT B-NP O
47 971 973 7752389 PG NN I-NP D011453
48 974 977 7752389 was VBD B-VP O
49 978 983 7752389 given VBN I-VP O
50 984 998 7752389 intravesically RB B-ADVP O
51 998 999 7752389 . . O O

1 1000 1003 7752389 The DT B-NP O
2 1004 1011 7752389 present JJ I-NP O
3 1012 1019 7752389 results NNS I-NP O
4 1020 1024 7752389 thus RB B-ADVP O
5 1025 1032 7752389 suggest VBP B-VP O
6 1033 1037 7752389 that IN B-SBAR O
7 1038 1043 7752389 intra AFX B-NP O
8 1043 1044 7752389 - HYPH I-NP O
9 1044 1052 7752389 arterial JJ I-NP O
10 1053 1057 7752389 PGE2 NN I-NP D015232
11 1057 1058 7752389 , , O O
12 1059 1064 7752389 given VBN B-PP O
13 1065 1069 7752389 near IN B-PP O
14 1070 1073 7752389 the DT B-NP O
15 1074 1081 7752389 bladder NN I-NP O
16 1081 1082 7752389 , , O O
17 1083 1086 7752389 may MD B-VP O
18 1087 1095 7752389 initiate VB I-VP O
19 1096 1107 7752389 micturition NN B-NP O
20 1108 1110 7752389 in IN B-PP O
21 1111 1114 7752389 the DT B-NP O
22 1115 1121 7752389 normal JJ I-NP O
23 1122 1125 7752389 rat NN I-NP O
24 1126 1133 7752389 chiefly RB B-ADVP O
25 1134 1136 7752389 by IN B-PP O
26 1137 1145 7752389 directly RB B-VP O
27 1146 1157 7752389 contracting VBG I-VP O
28 1158 1161 7752389 the DT B-NP O
29 1162 1168 7752389 smooth JJ I-NP O
30 1169 1175 7752389 muscle NN I-NP O
31 1176 1178 7752389 of IN B-PP O
32 1179 1182 7752389 the DT B-NP O
33 1183 1191 7752389 detrusor NN I-NP O
34 1191 1192 7752389 . . O O

1 1193 1200 7752389 However RB B-ADVP O
2 1200 1201 7752389 , , O O
3 1202 1206 7752389 when WRB B-ADVP O
4 1207 1212 7752389 given VBN B-VP O
5 1213 1227 7752389 intravesically RB B-ADVP O
6 1227 1228 7752389 , , O O
7 1229 1233 7752389 PGE2 NN B-NP D015232
8 1234 1237 7752389 may MD B-VP O
9 1238 1247 7752389 stimulate VB I-VP O
10 1248 1259 7752389 micturition NN B-NP O
11 1260 1262 7752389 by IN B-PP O
12 1263 1272 7752389 releasing VBG B-VP O
13 1273 1284 7752389 tachykinins NNS B-NP D015320
14 1285 1289 7752389 from IN B-PP O
15 1290 1296 7752389 nerves NNS B-NP O
16 1297 1299 7752389 in IN B-PP O
17 1300 1303 7752389 and CC O O
18 1303 1304 7752389 / SYM B-NP O
19 1304 1306 7752389 or CC O O
20 1307 1318 7752389 immediately RB B-ADVP O
21 1319 1324 7752389 below IN B-PP O
22 1325 1328 7752389 the DT B-NP O
23 1329 1339 7752389 urothelium NN I-NP O
24 1339 1340 7752389 . . O O

1 1341 1346 7752389 These DT B-NP O
2 1347 1358 7752389 tachykinins NNS I-NP D015320
3 1358 1359 7752389 , , O O
4 1360 1362 7752389 in IN B-PP O
5 1363 1367 7752389 turn NN B-NP O
6 1367 1368 7752389 , , O O
7 1369 1377 7752389 initiate VB B-VP O
8 1378 1379 7752389 a DT B-NP O
9 1380 1391 7752389 micturition NN I-NP O
10 1392 1398 7752389 reflex NN I-NP O
11 1399 1401 7752389 by IN B-PP O
12 1402 1413 7752389 stimulating VBG B-VP O
13 1414 1417 7752389 NK1 NN B-NP O
14 1418 1421 7752389 and CC I-NP O
15 1422 1425 7752389 NK2 NN I-NP O
16 1426 1435 7752389 receptors NNS I-NP O
17 1435 1436 7752389 . . O O

1 1437 1448 7752389 Prostanoids NNS B-NP D011453
2 1449 1452 7752389 may MD B-VP O
3 1452 1453 7752389 , , O O
4 1454 1457 7752389 via IN B-PP O
5 1458 1465 7752389 release NN B-NP O
6 1466 1468 7752389 of IN B-PP O
7 1469 1480 7752389 tachykinins NNS B-NP D015320
8 1480 1481 7752389 , , O O
9 1482 1492 7752389 contribute VBP B-VP O
10 1493 1495 7752389 to TO B-PP O
11 1496 1500 7752389 both CC O O
12 1501 1505 7752389 urge NN B-NP O
13 1506 1509 7752389 and CC I-NP O
14 1510 1517 7752389 bladder NN I-NP D053201
15 1518 1531 7752389 hyperactivity NN I-NP D053201
16 1532 1536 7752389 seen VBN B-VP O
17 1537 1539 7752389 in IN B-PP O
18 1540 1552 7752389 inflammatory JJ B-NP O
19 1553 1563 7752389 conditions NNS I-NP O
20 1564 1566 7752389 of IN B-PP O
21 1567 1570 7752389 the DT B-NP O
22 1571 1576 7752389 lower JJR I-NP O
23 1577 1584 7752389 urinary JJ I-NP O
24 1585 1590 7752389 tract NN I-NP O
25 1590 1591 7752389 . . O O

1 0 0 1286498 -DOCSTART- -X- -X- O

1 0 8 1286498 Reversal NN B-NP O
2 9 11 1286498 of IN B-PP O
3 12 19 1286498 central JJ B-NP O
4 20 34 1286498 benzodiazepine NN I-NP D001569
5 35 42 1286498 effects NNS I-NP O
6 43 45 1286498 by IN B-PP O
7 46 56 1286498 flumazenil NN B-NP D005442
8 57 62 1286498 after IN B-PP O
9 63 74 1286498 intravenous JJ B-NP O
10 75 84 1286498 conscious JJ I-NP O
11 85 93 1286498 sedation NN I-NP O
12 94 98 1286498 with IN B-PP O
13 99 107 1286498 diazepam NN B-NP D003975
14 108 111 1286498 and CC I-NP O
15 112 119 1286498 opioids NNS I-NP O
16 119 120 1286498 : : O O
17 121 127 1286498 report NN B-NP O
18 128 130 1286498 of IN B-PP O
19 131 132 1286498 a DT B-NP O
20 133 139 1286498 double JJ I-NP O
21 139 140 1286498 - HYPH I-NP O
22 140 145 1286498 blind JJ I-NP O
23 146 157 1286498 multicenter JJ I-NP O
24 158 163 1286498 study NN I-NP O
25 163 164 1286498 . . O O

1 165 168 1286498 The DT B-NP O
2 169 179 1286498 Flumazenil NNP I-NP D005442
3 180 182 1286498 in IN B-PP O
4 183 194 1286498 Intravenous JJ B-NP O
5 195 204 1286498 Conscious JJ I-NP O
6 205 213 1286498 Sedation NN I-NP O
7 214 218 1286498 with IN B-PP O
8 219 227 1286498 Diazepam NNP B-NP D003975
9 228 239 1286498 Multicenter NNP I-NP O
10 240 245 1286498 Study NNP I-NP O
11 246 251 1286498 Group NNP I-NP O
12 252 254 1286498 II NNP I-NP O
13 254 255 1286498 . . O O
14 256 259 1286498 The DT B-NP O
15 260 268 1286498 efficacy NN I-NP O
16 269 272 1286498 and CC I-NP O
17 273 279 1286498 safety NN I-NP O
18 280 282 1286498 of IN B-PP O
19 283 284 1286498 a DT B-NP O
20 285 288 1286498 new JJ I-NP O
21 289 303 1286498 benzodiazepine NN I-NP D001569
22 304 314 1286498 antagonist NN I-NP O
23 314 315 1286498 , , O O
24 316 326 1286498 flumazenil NN B-NP D005442
25 326 327 1286498 , , O O
26 328 332 1286498 were VBD B-VP O
27 333 341 1286498 assessed VBN I-VP O
28 342 344 1286498 in IN B-PP O
29 345 346 1286498 a DT B-NP O
30 347 353 1286498 double JJ I-NP O
31 353 354 1286498 - HYPH I-NP O
32 354 359 1286498 blind JJ I-NP O
33 360 371 1286498 multicenter JJ I-NP O
34 372 377 1286498 study NN I-NP O
35 377 378 1286498 . . O O

1 379 389 1286498 Flumazenil NN B-NP D005442
2 390 391 1286498 ( ( O O
3 391 395 1286498 mean JJ B-NP O
4 396 400 1286498 dose NN I-NP O
5 400 401 1286498 , , O O
6 402 406 1286498 0.76 CD B-NP O
7 407 409 1286498 mg NN I-NP O
8 409 410 1286498 ) ) O O
9 411 413 1286498 or CC O O
10 414 421 1286498 placebo NN B-NP O
11 422 423 1286498 ( ( O O
12 423 427 1286498 mean JJ B-NP O
13 428 432 1286498 dose NN I-NP O
14 432 433 1286498 , , O O
15 434 437 1286498 8.9 CD B-NP O
16 438 440 1286498 ml NN I-NP O
17 440 441 1286498 ) ) O O
18 442 445 1286498 was VBD B-VP O
19 446 458 1286498 administered VBN I-VP O
20 459 472 1286498 intravenously RB B-ADVP O
21 473 475 1286498 to TO B-PP O
22 476 479 1286498 130 CD B-NP O
23 480 483 1286498 and CC I-NP O
24 484 486 1286498 67 CD I-NP O
25 487 495 1286498 patients NNS I-NP O
26 495 496 1286498 , , O O
27 497 509 1286498 respectively RB B-ADVP O
28 509 510 1286498 , , O O
29 511 514 1286498 who WP B-NP O
30 515 518 1286498 had VBD B-VP O
31 519 523 1286498 been VBN I-VP O
32 524 529 1286498 given VBN I-VP O
33 530 538 1286498 diazepam NN B-NP D003975
34 539 541 1286498 in IN B-PP O
35 542 553 1286498 conjunction NN B-NP O
36 554 558 1286498 with IN B-PP O
37 559 561 1286498 an DT B-NP O
38 562 568 1286498 opioid JJ I-NP O
39 569 570 1286498 ( ( O O
40 570 578 1286498 fentanyl NN B-NP D005283
41 578 579 1286498 , , O O
42 580 590 1286498 meperidine NN B-NP D008614
43 590 591 1286498 , , O O
44 592 594 1286498 or CC O O
45 595 603 1286498 morphine NN B-NP D009020
46 603 604 1286498 ) ) O O
47 605 608 1286498 for IN B-PP O
48 609 612 1286498 the DT B-NP O
49 613 622 1286498 induction NN I-NP O
50 623 626 1286498 and CC I-NP O
51 627 638 1286498 maintenance NN I-NP O
52 639 641 1286498 of IN B-PP O
53 642 653 1286498 intravenous JJ B-NP O
54 654 663 1286498 conscious JJ I-NP O
55 664 672 1286498 sedation NN I-NP O
56 673 676 1286498 for IN B-PP O
57 677 687 1286498 diagnostic JJ B-NP O
58 688 690 1286498 or CC I-NP O
59 691 702 1286498 therapeutic JJ I-NP O
60 703 711 1286498 surgical JJ I-NP O
61 712 722 1286498 procedures NNS I-NP O
62 722 723 1286498 . . O O

1 724 727 1286498 The DT B-NP O
2 728 733 1286498 group NN I-NP O
3 734 744 1286498 assessable JJ B-ADJP O
4 745 748 1286498 for IN B-PP O
5 749 757 1286498 efficacy NN B-NP O
6 758 767 1286498 comprised VBD B-VP O
7 768 771 1286498 122 CD B-NP O
8 772 780 1286498 patients NNS I-NP O
9 781 788 1286498 treated VBN B-VP O
10 789 793 1286498 with IN B-PP O
11 794 804 1286498 flumazenil NN B-NP D005442
12 805 808 1286498 and CC O O
13 809 811 1286498 64 CD B-NP O
14 812 820 1286498 patients NNS I-NP O
15 821 826 1286498 given VBN B-PP O
16 827 834 1286498 placebo NN B-NP O
17 834 835 1286498 . . O O

1 836 841 1286498 After IN B-PP O
2 842 843 1286498 5 CD B-NP O
3 844 851 1286498 minutes NNS I-NP O
4 851 852 1286498 , , O O
5 853 855 1286498 80 CD B-NP O
6 855 856 1286498 / SYM O O
7 856 859 1286498 115 CD B-NP O
8 860 861 1286498 ( ( O O
9 861 864 1286498 70% CD B-NP O
10 864 865 1286498 ) ) O O
11 866 876 1286498 flumazenil NN B-NP D005442
12 876 877 1286498 - HYPH B-NP O
13 877 884 1286498 treated VBN I-NP O
14 885 893 1286498 patients NNS I-NP O
15 893 894 1286498 , , O O
16 895 903 1286498 compared VBN B-PP O
17 904 908 1286498 with IN B-PP O
18 909 911 1286498 21 CD B-NP O
19 911 912 1286498 / SYM I-NP O
20 912 914 1286498 63 CD I-NP O
21 915 916 1286498 ( ( O O
22 916 919 1286498 33% NN B-NP O
23 919 920 1286498 ) ) O O
24 921 928 1286498 placebo NN B-NP O
25 928 929 1286498 - HYPH B-NP O
26 929 936 1286498 treated VBN I-NP O
27 937 945 1286498 patients NNS I-NP O
28 945 946 1286498 , , O O
29 947 951 1286498 were VBD B-VP O
30 952 962 1286498 completely RB B-ADVP O
31 963 968 1286498 awake NN B-NP O
32 969 972 1286498 and CC I-NP O
33 973 978 1286498 alert NN I-NP O
34 978 979 1286498 , , O O
35 980 982 1286498 as IN B-SBAR O
36 983 992 1286498 indicated VBN B-VP O
37 993 995 1286498 by IN B-PP O
38 996 997 1286498 a DT B-NP O
39 998 1003 1286498 score NN I-NP O
40 1004 1006 1286498 of IN B-PP O
41 1007 1008 1286498 5 CD B-NP O
42 1009 1011 1286498 on IN B-PP O
43 1012 1015 1286498 the DT B-NP O
44 1016 1026 1286498 Observer's NNP I-NP O
45 1027 1037 1286498 Assessment NN I-NP O
46 1038 1040 1286498 of IN B-PP O
47 1041 1050 1286498 Alertness NN B-NP O
48 1050 1051 1286498 / SYM B-NP O
49 1051 1059 1286498 Sedation NN I-NP O
50 1060 1065 1286498 Scale NN I-NP O
51 1065 1066 1286498 . . O O

1 1067 1073 1286498 Ninety CD B-NP O
2 1073 1074 1286498 - HYPH I-NP O
3 1074 1078 1286498 five CD I-NP O
4 1079 1086 1286498 percent NN I-NP O
5 1087 1089 1286498 of IN B-PP O
6 1090 1098 1286498 patients NNS B-NP O
7 1099 1101 1286498 in IN B-PP O
8 1102 1106 1286498 each DT B-NP O
9 1107 1112 1286498 group NN I-NP O
10 1113 1116 1286498 who WP B-NP O
11 1117 1125 1286498 attained VBD B-VP O
12 1126 1127 1286498 a DT B-NP O
13 1128 1133 1286498 score NN I-NP O
14 1134 1136 1286498 of IN B-PP O
15 1137 1138 1286498 5 CD B-NP O
16 1139 1141 1286498 at IN B-PP O
17 1142 1145 1286498 the DT B-NP O
18 1146 1147 1286498 5 CD I-NP O
19 1147 1148 1286498 - HYPH I-NP O
20 1148 1154 1286498 minute NN I-NP O
21 1155 1165 1286498 assessment NN I-NP O
22 1166 1172 1286498 showed VBD B-VP O
23 1173 1175 1286498 no DT B-NP O
24 1176 1180 1286498 loss NN I-NP O
25 1181 1183 1286498 of IN B-PP O
26 1184 1193 1286498 alertness NN B-NP O
27 1194 1204 1286498 throughout IN B-PP O
28 1205 1208 1286498 the DT B-NP O
29 1209 1212 1286498 180 CD I-NP O
30 1212 1213 1286498 - HYPH I-NP O
31 1213 1219 1286498 minute NN I-NP O
32 1220 1230 1286498 assessment NN I-NP O
33 1231 1237 1286498 period NN I-NP O
34 1237 1238 1286498 . . O O

1 1239 1249 1286498 Flumazenil NN B-NP D005442
2 1249 1250 1286498 - HYPH B-NP O
3 1250 1257 1286498 treated VBN I-NP O
4 1258 1266 1286498 patients NNS I-NP O
5 1267 1271 1286498 also RB B-ADVP O
6 1272 1281 1286498 performed VBD B-VP O
7 1282 1295 1286498 significantly RB B-ADJP O
8 1296 1302 1286498 better JJR I-ADJP O
9 1303 1305 1286498 on IN B-PP O
10 1306 1309 1286498 the DT B-NP O
11 1310 1316 1286498 Finger NN I-NP O
12 1316 1317 1286498 - HYPH B-ADJP O
13 1317 1319 1286498 to TO B-PP O
14 1319 1320 1286498 - HYPH B-NP O
15 1320 1324 1286498 Nose NN I-NP O
16 1325 1329 1286498 Test NN I-NP O
17 1330 1333 1286498 and CC O O
18 1334 1337 1286498 the DT B-NP O
19 1338 1344 1286498 recall NN I-NP O
20 1345 1347 1286498 of IN B-PP O
21 1348 1356 1286498 pictures NNS B-NP O
22 1357 1362 1286498 shown VBN B-VP O
23 1363 1365 1286498 at IN B-PP O
24 1366 1369 1286498 the DT B-NP O
25 1370 1371 1286498 5 CD I-NP O
26 1371 1372 1286498 - HYPH I-NP O
27 1372 1378 1286498 minute NN I-NP O
28 1379 1389 1286498 assessment NN I-NP O
29 1389 1390 1286498 . . O O

1 1391 1401 1286498 Flumazenil NN B-NP D005442
2 1402 1405 1286498 was VBD B-VP O
3 1406 1410 1286498 well RB I-VP O
4 1411 1420 1286498 tolerated VBN I-VP O
5 1420 1421 1286498 , , O O
6 1422 1426 1286498 with IN B-PP O
7 1427 1429 1286498 no DT B-NP O
8 1430 1437 1286498 serious JJ I-NP O
9 1438 1445 1286498 adverse JJ I-NP O
10 1446 1453 1286498 effects NNS I-NP O
11 1454 1462 1286498 reported VBN B-VP O
12 1462 1463 1286498 . . O O

1 1464 1470 1286498 Thirty CD B-NP O
2 1470 1471 1286498 - HYPH I-NP O
3 1471 1475 1286498 nine CD I-NP O
4 1476 1477 1286498 ( ( O O
5 1477 1480 1286498 30% CD B-NP O
6 1480 1481 1286498 ) ) O O
7 1482 1484 1286498 of IN B-PP O
8 1485 1495 1286498 flumazenil NN B-NP D005442
9 1495 1496 1286498 - HYPH B-NP O
10 1496 1503 1286498 treated VBN I-NP O
11 1504 1512 1286498 patients NNS I-NP O
12 1512 1513 1286498 , , O O
13 1514 1522 1286498 compared VBN B-PP O
14 1523 1527 1286498 with IN B-PP O
15 1528 1530 1286498 17 CD B-NP O
16 1531 1532 1286498 ( ( O O
17 1532 1535 1286498 25% NN B-NP O
18 1535 1536 1286498 ) ) O O
19 1537 1539 1286498 of IN B-PP O
20 1540 1547 1286498 placebo NN B-NP O
21 1547 1548 1286498 - HYPH B-NP O
22 1548 1555 1286498 treated VBN I-NP O
23 1556 1564 1286498 patients NNS I-NP O
24 1565 1568 1286498 had VBD B-VP O
25 1569 1572 1286498 one CD B-NP O
26 1573 1575 1286498 or CC I-NP O
27 1576 1580 1286498 more JJR I-NP O
28 1581 1585 1286498 drug NN I-NP O
29 1585 1586 1286498 - HYPH O O
30 1586 1593 1286498 related VBN B-NP O
31 1594 1601 1286498 adverse JJ I-NP O
32 1602 1613 1286498 experiences NNS I-NP O
33 1613 1614 1286498 . . O O

1 1615 1618 1286498 The DT B-NP O
2 1619 1623 1286498 most RBS I-NP O
3 1624 1630 1286498 common JJ I-NP O
4 1631 1638 1286498 adverse JJ I-NP O
5 1639 1646 1286498 effects NNS I-NP O
6 1647 1651 1286498 were VBD B-VP O
7 1652 1658 1286498 nausea NN B-NP D009325
8 1659 1662 1286498 and CC I-NP O
9 1663 1671 1286498 vomiting NN I-NP D014839
10 1672 1674 1286498 in IN B-PP O
11 1675 1678 1286498 the DT B-NP O
12 1679 1689 1286498 flumazenil NN I-NP D005442
13 1690 1695 1286498 group NN I-NP O
14 1696 1699 1286498 and CC O O
15 1700 1706 1286498 nausea NN B-NP D009325
16 1707 1710 1286498 and CC I-NP O
17 1711 1720 1286498 injection NN I-NP O
18 1720 1721 1286498 - HYPH B-NP O
19 1721 1725 1286498 site NN I-NP O
20 1726 1730 1286498 pain NN I-NP D010146
21 1731 1733 1286498 in IN B-PP O
22 1734 1737 1286498 the DT B-NP O
23 1738 1745 1286498 placebo NN I-NP O
24 1746 1751 1286498 group NN I-NP O
25 1751 1752 1286498 . . O O

1 1753 1763 1286498 Flumazenil NN B-NP D005442
2 1764 1767 1286498 was VBD B-VP O
3 1768 1773 1286498 found VBN I-VP O
4 1774 1776 1286498 to TO I-VP O
5 1777 1785 1286498 promptly RB I-VP O
6 1786 1793 1286498 reverse VB I-VP O
7 1794 1802 1286498 sedation NN B-NP O
8 1803 1810 1286498 induced VBN B-VP O
9 1811 1813 1286498 by IN B-PP O
10 1814 1822 1286498 diazepam NN B-NP D003975
11 1823 1825 1286498 in IN B-PP O
12 1826 1829 1286498 the DT B-NP O
13 1830 1838 1286498 presence NN I-NP O
14 1839 1841 1286498 of IN B-PP O
15 1842 1849 1286498 opioids NNS B-NP O
16 1849 1850 1286498 . . O O

1 0 0 2051906 -DOCSTART- -X- -X- O

1 0 10 2051906 Reversible JJ B-NP O
2 11 22 2051906 cholestasis NN I-NP D002779
3 23 27 2051906 with IN B-PP O
4 28 32 2051906 bile NN B-NP D002779
5 33 37 2051906 duct NN I-NP D002779
6 38 44 2051906 injury NN I-NP D002779
7 45 54 2051906 following VBG B-PP O
8 55 67 2051906 azathioprine NN B-NP D001379
9 68 75 2051906 therapy NN I-NP O
10 75 76 2051906 . . O O

1 77 78 2051906 A DT B-NP O
2 79 83 2051906 case NN I-NP O
3 84 90 2051906 report NN I-NP O
4 90 91 2051906 . . O O
5 92 93 2051906 A DT B-NP O
6 94 96 2051906 67 CD I-NP O
7 96 97 2051906 - HYPH I-NP O
8 97 101 2051906 year NN I-NP O
9 101 102 2051906 - HYPH O O
10 102 105 2051906 old JJ B-NP O
11 106 113 2051906 patient NN I-NP O
12 113 114 2051906 , , O O
13 115 119 2051906 with IN B-PP O
14 120 127 2051906 primary JJ B-NP O
15 128 140 2051906 polymyositis NN I-NP D017285
16 141 144 2051906 and CC O O
17 145 152 2051906 without IN B-PP O
18 153 161 2051906 previous JJ B-NP O
19 162 170 2051906 evidence NN I-NP O
20 171 173 2051906 of IN B-PP O
21 174 179 2051906 liver NN B-NP D008107
22 180 187 2051906 disease NN I-NP D008107
23 187 188 2051906 , , O O
24 189 198 2051906 developed VBD B-VP O
25 199 207 2051906 clinical JJ B-NP O
26 208 211 2051906 and CC I-NP O
27 212 223 2051906 biochemical JJ I-NP O
28 224 232 2051906 features NNS I-NP O
29 233 235 2051906 of IN B-PP O
30 236 242 2051906 severe JJ B-NP O
31 243 254 2051906 cholestasis NN I-NP D002779
32 255 256 2051906 3 CD B-NP O
33 257 263 2051906 months NNS I-NP O
34 264 269 2051906 after IN B-PP O
35 270 280 2051906 initiation NN B-NP O
36 281 283 2051906 of IN B-PP O
37 284 296 2051906 azathioprine NN B-NP D001379
38 297 304 2051906 therapy NN I-NP O
39 304 305 2051906 . . O O

1 306 311 2051906 Liver NN B-NP O
2 312 318 2051906 biopsy NN I-NP O
3 319 325 2051906 showed VBD B-VP O
4 326 337 2051906 cholestasis NN B-NP D002779
5 338 342 2051906 with IN B-PP O
6 343 347 2051906 both CC B-NP O
7 348 359 2051906 cytological JJ I-NP O
8 360 363 2051906 and CC I-NP O
9 364 377 2051906 architectural JJ I-NP O
10 378 389 2051906 alterations NNS I-NP O
11 390 392 2051906 of IN B-PP O
12 393 405 2051906 interlobular JJ B-NP O
13 406 410 2051906 bile NN I-NP O
14 411 416 2051906 ducts NNS I-NP O
15 416 417 2051906 . . O O

1 418 430 2051906 Azathioprine NN B-NP D001379
2 431 441 2051906 withdrawal NN I-NP O
3 442 450 2051906 resulted VBD B-VP O
4 451 456 2051906 after IN B-PP O
5 457 458 2051906 7 CD B-NP O
6 459 464 2051906 weeks NNS I-NP O
7 465 467 2051906 in IN B-PP O
8 468 471 2051906 the DT B-NP O
9 472 482 2051906 resolution NN I-NP O
10 483 485 2051906 of IN B-PP O
11 486 494 2051906 clinical JJ B-NP O
12 495 498 2051906 and CC I-NP O
13 499 510 2051906 biochemical JJ I-NP O
14 511 524 2051906 abnormalities NNS I-NP O
15 524 525 2051906 . . O O

1 526 528 2051906 It PRP B-NP O
2 529 531 2051906 is VBZ B-VP O
3 532 540 2051906 believed VBN I-VP O
4 541 545 2051906 that IN B-SBAR O
5 546 550 2051906 this DT B-NP O
6 551 553 2051906 is VBZ B-VP O
7 554 557 2051906 the DT B-NP O
8 558 563 2051906 first JJ I-NP O
9 564 572 2051906 reported VBN I-NP O
10 573 577 2051906 case NN I-NP O
11 578 580 2051906 of IN B-PP O
12 581 591 2051906 reversible JJ B-NP O
13 592 604 2051906 azathioprine NN I-NP D001379
14 604 605 2051906 - HYPH B-NP O
15 605 612 2051906 induced VBN I-NP O
16 613 624 2051906 cholestasis NN I-NP D002779
17 625 635 2051906 associated VBN B-VP O
18 636 640 2051906 with IN B-PP O
19 641 653 2051906 histological JJ B-NP O
20 654 662 2051906 evidence NN I-NP O
21 663 665 2051906 of IN B-PP O
22 666 670 2051906 bile NN B-NP D002779
23 671 675 2051906 duct NN I-NP D002779
24 676 682 2051906 injury NN I-NP D002779
25 682 683 2051906 . . O O

1 0 0 10411803 -DOCSTART- -X- -X- O

1 0 6 10411803 Severe JJ B-NP O
2 7 13 10411803 immune JJ I-NP O
3 14 23 10411803 hemolytic JJ I-NP D000743
4 24 30 10411803 anemia NN I-NP D000743
5 31 41 10411803 associated VBN B-VP O
6 42 46 10411803 with IN B-PP O
7 47 59 10411803 prophylactic JJ B-NP O
8 60 63 10411803 use NN I-NP O
9 64 66 10411803 of IN B-PP O
10 67 76 10411803 cefotetan NN B-NP D015313
11 77 79 10411803 in IN B-PP O
12 80 89 10411803 obstetric JJ B-NP O
13 90 93 10411803 and CC I-NP O
14 94 105 10411803 gynecologic JJ I-NP O
15 106 116 10411803 procedures NNS I-NP O
16 116 117 10411803 . . O O
17 118 124 10411803 Second JJ B-NP O
18 124 125 10411803 - : I-NP O
19 126 129 10411803 and CC I-NP O
20 130 135 10411803 third JJ I-NP O
21 135 136 10411803 - HYPH I-NP O
22 136 146 10411803 generation NN I-NP O
23 147 161 10411803 cephalosporins NNS I-NP D002511
24 161 162 10411803 , , O O
25 163 173 10411803 especially RB B-NP O
26 174 183 10411803 cefotetan NN I-NP D015313
27 183 184 10411803 , , O O
28 185 188 10411803 are VBP B-VP O
29 189 201 10411803 increasingly RB I-VP O
30 202 212 10411803 associated VBN I-VP O
31 213 217 10411803 with IN B-PP O
32 218 224 10411803 severe JJ B-NP O
33 224 225 10411803 , , I-NP O
34 226 235 10411803 sometimes RB I-NP O
35 236 241 10411803 fatal JJ I-NP O
36 242 248 10411803 immune JJ I-NP O
37 249 258 10411803 hemolytic JJ I-NP D000743
38 259 265 10411803 anemia NN I-NP D000743
39 265 266 10411803 . . O O

1 267 269 10411803 We PRP B-NP O
2 270 277 10411803 noticed VBD B-VP O
3 278 282 10411803 that IN B-SBAR O
4 283 285 10411803 10 CD B-NP O
5 286 288 10411803 of IN B-PP O
6 289 292 10411803 our PRP$ B-NP O
7 293 295 10411803 35 CD I-NP O
8 296 301 10411803 cases NNS I-NP O
9 302 304 10411803 of IN B-PP O
10 305 314 10411803 cefotetan NN B-NP D015313
11 314 315 10411803 - HYPH O O
12 315 322 10411803 induced VBN B-NP O
13 323 332 10411803 hemolytic JJ I-NP D000743
14 333 340 10411803 anemias NNS I-NP D000743
15 341 345 10411803 were VBD B-VP O
16 346 348 10411803 in IN B-PP O
17 349 357 10411803 patients NNS B-NP O
18 358 361 10411803 who WP B-NP O
19 362 365 10411803 had VBD B-VP O
20 366 374 10411803 received VBN I-VP O
21 375 384 10411803 cefotetan NN B-NP D015313
22 385 401 10411803 prophylactically RB B-ADVP O
23 402 405 10411803 for IN B-PP O
24 406 415 10411803 obstetric JJ B-NP O
25 416 419 10411803 and CC I-NP O
26 420 431 10411803 gynecologic JJ I-NP O
27 432 442 10411803 procedures NNS I-NP O
28 442 443 10411803 . . O O

1 444 449 10411803 Eight CD B-NP O
2 450 452 10411803 of IN B-PP O
3 453 458 10411803 these DT B-NP O
4 459 464 10411803 cases NNS I-NP O
5 465 467 10411803 of IN B-PP O
6 468 474 10411803 severe JJ B-NP O
7 475 481 10411803 immune JJ I-NP O
8 482 491 10411803 hemolytic JJ I-NP D000743
9 492 498 10411803 anemia NN I-NP D000743
10 499 502 10411803 are VBP B-VP O
11 503 512 10411803 described VBN I-VP O
12 512 513 10411803 . . O O

1 0 0 16844102 -DOCSTART- -X- -X- O

1 0 6 16844102 Effect NN B-NP O
2 7 9 16844102 of IN B-PP O
3 10 15 16844102 alpha SYM B-NP D024502
4 15 16 16844102 - HYPH I-NP D024502
5 16 26 16844102 tocopherol NN I-NP D024502
6 27 30 16844102 and CC I-NP O
7 31 43 16844102 deferoxamine NN I-NP D003676
8 44 46 16844102 on IN B-PP O
9 47 62 16844102 methamphetamine NN B-NP D008694
10 62 63 16844102 - HYPH B-NP O
11 63 70 16844102 induced VBN I-NP O
12 71 84 16844102 neurotoxicity NN I-NP D020258
13 84 85 16844102 . . O O
14 86 101 16844102 Methamphetamine NN B-NP D008694
15 102 103 16844102 ( ( O O
16 103 105 16844102 MA NN B-NP D008694
17 105 106 16844102 ) ) O O
18 106 107 16844102 - HYPH O O
19 107 114 16844102 induced VBN B-NP O
20 115 127 16844102 dopaminergic JJ I-NP O
21 128 141 16844102 neurotoxicity NN I-NP D020258
22 142 144 16844102 is VBZ B-VP O
23 145 153 16844102 believed VBN I-VP O
24 154 156 16844102 to TO I-VP O
25 157 159 16844102 be VB I-VP O
26 160 170 16844102 associated VBN I-VP O
27 171 175 16844102 with IN B-PP O
28 176 179 16844102 the DT B-NP O
29 180 189 16844102 increased VBN I-NP O
30 190 199 16844102 formation NN I-NP O
31 200 202 16844102 of IN B-PP O
32 203 207 16844102 free JJ B-NP O
33 208 216 16844102 radicals NNS I-NP O
34 216 217 16844102 . . O O

1 218 222 16844102 This DT B-NP O
2 223 228 16844102 study NN I-NP O
3 229 237 16844102 examined VBD B-VP O
4 238 241 16844102 the DT B-NP O
5 242 248 16844102 effect NN I-NP O
6 249 251 16844102 of IN B-PP O
7 252 257 16844102 alpha SYM O D024502
8 257 258 16844102 - HYPH O D024502
9 258 268 16844102 tocopherol NN B-NP D024502
10 269 270 16844102 ( ( O O
11 270 275 16844102 alpha SYM O D024502
12 275 276 16844102 - HYPH O D024502
13 276 278 16844102 TC NN B-NP D024502
14 278 279 16844102 ) ) O O
15 279 280 16844102 , , O O
16 281 282 16844102 a DT B-NP O
17 283 292 16844102 scavenger NN I-NP O
18 293 295 16844102 of IN B-PP O
19 296 304 16844102 reactive JJ B-NP O
20 305 311 16844102 oxygen NN I-NP D010100
21 312 319 16844102 species NNS I-NP O
22 319 320 16844102 , , O O
23 321 324 16844102 and CC O O
24 325 337 16844102 deferoxamine NN B-NP D003676
25 338 339 16844102 ( ( O O
26 339 342 16844102 DFO NN B-NP D003676
27 342 343 16844102 ) ) O O
28 343 344 16844102 , , O O
29 345 347 16844102 an DT B-NP O
30 348 352 16844102 iron NN I-NP D007501
31 353 361 16844102 chelator NN I-NP O
32 361 362 16844102 , , O O
33 363 365 16844102 on IN B-PP O
34 366 369 16844102 the DT B-NP O
35 370 372 16844102 MA NN I-NP D008694
36 372 373 16844102 - HYPH B-NP O
37 373 380 16844102 induced VBN I-NP O
38 381 394 16844102 neurotoxicity NN I-NP D020258
39 394 395 16844102 . . O O

1 396 400 16844102 Male JJ B-NP O
2 401 405 16844102 rats NNS I-NP O
3 406 410 16844102 were VBD B-VP O
4 411 418 16844102 treated VBN I-VP O
5 419 423 16844102 with IN B-PP O
6 424 426 16844102 MA NN B-NP D008694
7 427 428 16844102 ( ( O O
8 428 430 16844102 10 CD B-NP O
9 431 433 16844102 mg NN I-NP O
10 433 434 16844102 / SYM B-NP O
11 434 436 16844102 kg NN I-NP O
12 436 437 16844102 , , O O
13 438 443 16844102 every DT B-NP O
14 444 445 16844102 2 CD I-NP O
15 446 447 16844102 h NN I-NP O
16 448 451 16844102 for IN B-PP O
17 452 456 16844102 four CD B-NP O
18 457 467 16844102 injections NNS I-NP O
19 467 468 16844102 ) ) O O
20 468 469 16844102 . . O O

1 470 473 16844102 The DT B-NP O
2 474 477 16844102 rat NN I-NP O
3 478 486 16844102 received VBD B-VP O
4 487 493 16844102 either CC O O
5 494 499 16844102 alpha SYM O D024502
6 499 500 16844102 - HYPH O D024502
7 500 502 16844102 TC NN B-NP D024502
8 503 504 16844102 ( ( O O
9 504 506 16844102 20 CD B-NP O
10 507 509 16844102 mg NN I-NP O
11 509 510 16844102 / SYM B-NP O
12 510 512 16844102 kg NN I-NP O
13 512 513 16844102 ) ) O O
14 514 531 16844102 intraperitoneally RB B-ADVP O
15 532 535 16844102 for IN B-PP O
16 536 537 16844102 3 CD B-NP O
17 538 542 16844102 days NNS I-NP O
18 543 546 16844102 and CC O O
19 547 549 16844102 30 CD B-NP O
20 550 553 16844102 min NN I-NP O
21 554 559 16844102 prior JJ B-ADJP O
22 560 562 16844102 to TO B-PP O
23 563 565 16844102 MA JJ B-NP D008694
24 566 580 16844102 administration NN I-NP O
25 581 583 16844102 or CC I-NP O
26 584 587 16844102 DFO NN I-NP D003676
27 588 589 16844102 ( ( O O
28 589 591 16844102 50 CD B-NP O
29 592 594 16844102 mg NN I-NP O
30 594 595 16844102 / SYM B-NP O
31 595 597 16844102 kg NN I-NP O
32 597 598 16844102 ) ) O O
33 599 613 16844102 subcutaneously RB B-NP O
34 614 616 16844102 30 CD I-NP O
35 617 620 16844102 min NN I-NP O
36 621 627 16844102 before IN B-PP O
37 628 630 16844102 MA JJ B-NP D008694
38 631 645 16844102 administration NN I-NP O
39 645 646 16844102 . . O O

1 647 650 16844102 The DT B-NP O
2 651 665 16844102 concentrations NNS I-NP O
3 666 668 16844102 of IN B-PP O
4 669 677 16844102 dopamine NN B-NP D004298
5 678 679 16844102 ( ( O O
6 679 681 16844102 DA NN B-NP D004298
7 681 682 16844102 ) ) O O
8 682 683 16844102 , , O O
9 684 693 16844102 serotonin NN B-NP D012701
10 694 697 16844102 and CC O O
11 698 703 16844102 their PRP$ B-NP O
12 704 715 16844102 metabolites NNS I-NP O
13 716 725 16844102 decreased VBD B-VP O
14 726 739 16844102 significantly RB B-ADVP O
15 740 745 16844102 after IN B-SBAR O
16 746 748 16844102 MA JJ B-NP D008694
17 749 763 16844102 administration NN I-NP O
18 763 764 16844102 , , O O
19 765 770 16844102 which WDT B-NP O
20 771 774 16844102 was VBD B-VP O
21 775 784 16844102 inhibited VBN I-VP O
22 785 787 16844102 by IN B-PP O
23 788 791 16844102 the DT B-NP O
24 792 797 16844102 alpha SYM I-NP D024502
25 797 798 16844102 - HYPH I-NP D024502
26 798 800 16844102 TC NN I-NP D024502
27 801 804 16844102 and CC I-NP O
28 805 808 16844102 DFO NN I-NP D003676
29 809 821 16844102 pretreatment NN I-NP O
30 821 822 16844102 . . O O

1 823 828 16844102 alpha SYM O D024502
2 828 829 16844102 - HYPH B-NP D024502
3 829 831 16844102 TC NN I-NP D024502
4 832 835 16844102 and CC I-NP O
5 836 839 16844102 DFO NN I-NP D003676
6 840 850 16844102 attenuated VBD B-VP O
7 851 854 16844102 the DT B-NP O
8 855 857 16844102 MA NN I-NP D008694
9 857 858 16844102 - HYPH B-NP O
10 858 865 16844102 induced VBN I-NP O
11 866 878 16844102 hyperthermia NN I-NP D005334
12 879 881 16844102 as RB B-CONJP O
13 882 886 16844102 well RB I-CONJP O
14 887 889 16844102 as IN I-CONJP O
15 890 893 16844102 the DT B-NP O
16 894 905 16844102 alterations NNS I-NP O
17 906 908 16844102 in IN B-PP O
18 909 912 16844102 the DT B-NP O
19 913 922 16844102 locomotor NN I-NP O
20 923 931 16844102 activity NN I-NP O
21 931 932 16844102 . . O O

1 933 936 16844102 The DT B-NP O
2 937 942 16844102 level NN I-NP O
3 943 945 16844102 of IN B-PP O
4 946 951 16844102 lipid NN B-NP O
5 952 964 16844102 peroxidation NN I-NP O
6 965 968 16844102 was VBD B-VP O
7 969 975 16844102 higher JJR B-ADJP O
8 976 979 16844102 and CC O O
9 980 983 16844102 the DT B-NP O
10 984 991 16844102 reduced VBN I-NP O
11 992 1003 16844102 glutathione NN I-NP D005978
12 1004 1017 16844102 concentration NN I-NP O
13 1018 1021 16844102 was VBD B-VP O
14 1022 1027 16844102 lower JJR B-ADJP O
15 1028 1030 16844102 in IN B-PP O
16 1031 1034 16844102 the DT B-NP O
17 1035 1037 16844102 MA NN I-NP D008694
18 1037 1038 16844102 - HYPH B-NP O
19 1038 1045 16844102 treated VBN I-NP O
20 1046 1050 16844102 rats NNS I-NP O
21 1050 1051 16844102 . . O O

1 1052 1057 16844102 These DT B-NP O
2 1058 1065 16844102 changes NNS I-NP O
3 1066 1070 16844102 were VBD B-VP O
4 1071 1084 16844102 significantly RB I-VP O
5 1085 1095 16844102 attenuated VBN I-VP O
6 1096 1098 16844102 by IN B-PP O
7 1099 1104 16844102 alpha SYM B-NP D024502
8 1104 1105 16844102 - HYPH I-NP D024502
9 1105 1107 16844102 TC NN I-NP D024502
10 1108 1111 16844102 and CC I-NP O
11 1112 1115 16844102 DFO NN I-NP D003676
12 1115 1116 16844102 . . O O

1 1117 1121 16844102 This DT B-NP O
2 1122 1130 16844102 suggests VBZ B-VP O
3 1131 1135 16844102 that IN B-SBAR O
4 1136 1141 16844102 alpha SYM B-NP D024502
5 1141 1142 16844102 - HYPH I-NP D024502
6 1142 1144 16844102 TC NN I-NP D024502
7 1145 1148 16844102 and CC I-NP O
8 1149 1152 16844102 DFO NN I-NP D003676
9 1153 1163 16844102 ameliorate VBP B-VP O
10 1164 1167 16844102 the DT B-NP O
11 1168 1170 16844102 MA NN I-NP D008694
12 1170 1171 16844102 - HYPH O O
13 1171 1178 16844102 induced VBN B-NP O
14 1179 1187 16844102 neuronal JJ I-NP D009422
15 1188 1194 16844102 damage NN I-NP D009422
16 1195 1197 16844102 by IN B-PP O
17 1198 1208 16844102 decreasing VBG B-VP O
18 1209 1212 16844102 the DT B-NP O
19 1213 1218 16844102 level NN I-NP O
20 1219 1221 16844102 of IN B-PP O
21 1222 1231 16844102 oxidative JJ B-NP O
22 1232 1238 16844102 stress NN I-NP O
23 1238 1239 16844102 . . O O

1 0 0 1628552 -DOCSTART- -X- -X- O

1 0 11 1628552 Chloroquine NN B-NP D002738
2 12 19 1628552 related JJ I-NP O
3 20 28 1628552 complete JJ I-NP O
4 29 34 1628552 heart NN I-NP D006327
5 35 40 1628552 block NN I-NP D006327
6 41 45 1628552 with IN B-PP O
7 46 55 1628552 blindness NN B-NP D001766
8 55 56 1628552 : : O O
9 57 61 1628552 case NN B-NP O
10 62 68 1628552 report NN I-NP O
11 68 69 1628552 . . O O
12 70 71 1628552 A DT B-NP O
13 72 74 1628552 27 CD I-NP O
14 74 75 1628552 - HYPH I-NP O
15 75 79 1628552 year NN I-NP O
16 80 83 1628552 old JJ I-NP O
17 84 91 1628552 African JJ I-NP O
18 92 97 1628552 woman NN I-NP O
19 98 102 1628552 with IN B-PP O
20 103 110 1628552 history NN B-NP O
21 111 113 1628552 of IN B-PP O
22 114 121 1628552 regular JJ B-NP O
23 122 133 1628552 chloroquine NN I-NP D002738
24 134 143 1628552 ingestion NN I-NP O
25 144 153 1628552 presented VBD B-VP O
26 154 158 1628552 with IN B-PP O
27 159 170 1628552 progressive JJ B-NP O
28 171 184 1628552 deterioration NN I-NP D015354
29 185 187 1628552 of IN B-PP D015354
30 188 194 1628552 vision NN B-NP D015354
31 194 195 1628552 , , O O
32 196 200 1628552 easy JJ B-NP O
33 201 214 1628552 fatiguability NN I-NP D005221
34 214 215 1628552 , , O O
35 216 224 1628552 dyspnoea NN B-NP D004417
36 224 225 1628552 , , O O
37 226 235 1628552 dizziness NN B-NP D004244
38 236 247 1628552 progressing VBG B-VP O
39 248 250 1628552 to TO B-PP O
40 251 259 1628552 syncopal JJ B-NP D013575
41 260 267 1628552 attacks NNS I-NP D013575
42 267 268 1628552 . . O O

1 269 285 1628552 Ophthalmological JJ B-NP O
2 286 296 1628552 assessment NN I-NP O
3 297 305 1628552 revealed VBD B-VP O
4 306 314 1628552 features NNS B-NP O
5 315 317 1628552 of IN B-PP O
6 318 329 1628552 chloroquine NN B-NP D002738
7 330 341 1628552 retinopathy NN I-NP D012164
8 341 342 1628552 , , O O
9 343 350 1628552 cardiac JJ B-NP O
10 351 361 1628552 assessment NN I-NP O
11 362 370 1628552 revealed VBD B-VP O
12 371 379 1628552 features NNS B-NP O
13 380 382 1628552 of IN B-PP O
14 383 388 1628552 heart NN B-NP D006333
15 389 396 1628552 failure NN I-NP D006333
16 397 400 1628552 and CC O O
17 401 402 1628552 a DT B-NP O
18 403 411 1628552 complete JJ I-NP O
19 412 417 1628552 heart NN I-NP D006327
20 418 423 1628552 block NN I-NP D006327
21 424 428 1628552 with IN B-PP O
22 429 434 1628552 right JJ B-NP D002037
23 435 441 1628552 bundle NN I-NP D002037
24 442 448 1628552 branch NN I-NP D002037
25 449 454 1628552 block NN I-NP D002037
26 455 462 1628552 pattern NN I-NP O
27 462 463 1628552 . . O O

1 464 467 1628552 The DT B-NP O
2 468 473 1628552 heart NN I-NP D006327
3 474 479 1628552 block NN I-NP D006327
4 480 483 1628552 was VBD B-VP O
5 484 491 1628552 treated VBN I-VP O
6 492 494 1628552 by IN B-PP O
7 495 504 1628552 pacemaker NN B-NP O
8 505 514 1628552 insertion NN I-NP O
9 515 518 1628552 and CC O O
10 519 522 1628552 the DT B-NP O
11 523 528 1628552 heart NN I-NP D006333
12 529 536 1628552 failure NN I-NP D006333
13 537 545 1628552 resolved VBD B-VP O
14 546 559 1628552 spontaneously RB I-VP O
15 560 569 1628552 following VBG I-VP O
16 570 581 1628552 chloroquine NN B-NP D002738
17 582 597 1628552 discontinuation NN I-NP O
18 597 598 1628552 . . O O

1 599 602 1628552 She PRP B-NP O
2 603 610 1628552 however RB B-ADVP O
3 611 618 1628552 remains VBZ B-VP O
4 619 624 1628552 blind JJ B-ADJP D001766
5 624 625 1628552 . . O O

1 0 0 16192988 -DOCSTART- -X- -X- O

1 0 15 16192988 Methamphetamine NN B-NP D008694
2 16 22 16192988 causes VBZ B-VP O
3 23 34 16192988 alterations NNS B-NP O
4 35 37 16192988 in IN B-PP O
5 38 41 16192988 the DT B-NP O
6 42 45 16192988 MAP NN I-NP O
7 46 52 16192988 kinase NN I-NP O
8 52 53 16192988 - HYPH B-NP O
9 53 60 16192988 related VBN I-NP O
10 61 69 16192988 pathways NNS I-NP O
11 70 72 16192988 in IN B-PP O
12 73 76 16192988 the DT B-NP O
13 77 83 16192988 brains NNS I-NP O
14 84 86 16192988 of IN B-PP O
15 87 91 16192988 mice NNS B-NP O
16 92 96 16192988 that WDT B-NP O
17 97 104 16192988 display VBP B-VP O
18 105 114 16192988 increased VBN B-NP O
19 115 129 16192988 aggressiveness NN I-NP D001523
20 129 130 16192988 . . O O
21 131 141 16192988 Aggressive JJ B-NP D001523
22 142 151 16192988 behaviors NNS I-NP D001523
23 152 156 16192988 have VBP B-VP O
24 157 161 16192988 been VBN I-VP O
25 162 170 16192988 reported VBN I-VP O
26 171 173 16192988 in IN B-PP O
27 174 182 16192988 patients NNS B-NP O
28 183 186 16192988 who WP B-NP O
29 187 193 16192988 suffer VBP B-VP O
30 194 198 16192988 from IN B-PP O
31 199 203 16192988 some DT B-NP O
32 204 215 16192988 psychiatric JJ I-NP D001523
33 216 225 16192988 disorders NNS I-NP D001523
34 225 226 16192988 , , O O
35 227 230 16192988 and CC O O
36 231 234 16192988 are VBP B-VP O
37 235 241 16192988 common JJ B-ADJP O
38 242 244 16192988 in IN B-PP O
39 245 260 16192988 methamphetamine NN B-NP D008694
40 261 262 16192988 ( ( O O
41 262 266 16192988 METH NN B-NP D008694
42 266 267 16192988 ) ) O O
43 268 275 16192988 abusers NNS B-NP O
44 275 276 16192988 . . O O

1 277 283 16192988 Herein RB B-ADVP O
2 283 284 16192988 , , O O
3 285 287 16192988 we PRP B-NP O
4 288 294 16192988 report VBP B-VP O
5 295 299 16192988 that IN B-SBAR O
6 300 308 16192988 multiple JJ B-NP O
7 309 310 16192988 ( ( O O
8 310 313 16192988 but CC O O
9 314 317 16192988 not RB O O
10 318 324 16192988 single JJ B-ADJP O
11 324 325 16192988 ) ) O O
12 326 336 16192988 injections NNS B-NP O
13 337 339 16192988 of IN B-PP O
14 340 344 16192988 METH NN B-NP D008694
15 345 358 16192988 significantly RB B-ADVP O
16 359 368 16192988 increased VBD B-VP O
17 369 383 16192988 aggressiveness NN B-NP D001523
18 384 386 16192988 in IN B-PP O
19 387 391 16192988 male JJ B-NP O
20 392 394 16192988 CD NN I-NP O
21 394 395 16192988 - HYPH B-NP O
22 395 396 16192988 1 CD I-NP O
23 397 401 16192988 mice NNS I-NP O
24 401 402 16192988 . . O O

1 403 407 16192988 This DT B-NP O
2 408 416 16192988 increase NN I-NP O
3 417 419 16192988 in IN B-PP O
4 420 434 16192988 aggressiveness NN B-NP D001523
5 435 438 16192988 was VBD B-VP O
6 439 442 16192988 not RB O O
7 443 452 16192988 secondary JJ B-ADJP O
8 453 455 16192988 to TO B-PP O
9 456 460 16192988 METH NN B-NP D008694
10 460 461 16192988 - HYPH B-NP O
11 461 468 16192988 induced VBN I-NP O
12 469 482 16192988 hyperactivity NN I-NP D006948
13 482 483 16192988 . . O O

1 484 492 16192988 Analysis NN B-NP O
2 493 495 16192988 of IN B-PP O
3 496 503 16192988 protein NN B-NP O
4 504 514 16192988 expression NN I-NP O
5 515 520 16192988 using VBG B-VP O
6 521 529 16192988 antibody NN B-NP O
7 530 541 16192988 microarrays NNS I-NP O
8 542 545 16192988 and CC O O
9 546 553 16192988 Western JJ B-NP O
10 554 562 16192988 blotting NN I-NP O
11 563 571 16192988 revealed VBD B-VP O
12 572 584 16192988 differential JJ B-NP O
13 585 592 16192988 changes NNS I-NP O
14 593 595 16192988 in IN B-PP O
15 596 599 16192988 MAP NN B-NP O
16 600 606 16192988 kinase NN I-NP O
17 606 607 16192988 - HYPH B-NP O
18 607 614 16192988 related VBN I-NP O
19 615 623 16192988 pathways NNS I-NP O
20 624 629 16192988 after IN B-PP O
21 630 638 16192988 multiple JJ B-NP O
22 639 642 16192988 and CC I-NP O
23 643 649 16192988 single JJ I-NP O
24 650 654 16192988 METH NN I-NP D008694
25 655 665 16192988 injections NNS I-NP O
26 665 666 16192988 . . O O

1 667 672 16192988 There EX B-NP O
2 673 677 16192988 were VBD B-VP O
3 678 691 16192988 statistically RB B-ADJP O
4 692 703 16192988 significant JJ I-ADJP O
5 704 705 16192988 ( ( O O
6 705 706 16192988 p NN B-NP O
7 706 707 16192988 < SYM B-NP O
8 707 711 16192988 0.05 CD I-NP O
9 711 712 16192988 ) ) O O
10 713 722 16192988 decreases VBZ B-VP O
11 723 725 16192988 in IN B-PP O
12 726 730 16192988 MEK1 NN B-NP O
13 730 731 16192988 , , O O
14 732 737 16192988 Erk2p NN B-NP O
15 737 738 16192988 , , O O
16 739 748 16192988 GSK3alpha NN B-NP O
17 748 749 16192988 , , O O
18 750 752 16192988 14 CD B-NP O
19 752 753 16192988 - HYPH I-NP O
20 753 754 16192988 3 CD I-NP O
21 754 755 16192988 - HYPH I-NP O
22 755 757 16192988 3e CD I-NP O
23 757 758 16192988 , , O O
24 759 762 16192988 and CC O O
25 763 767 16192988 MEK7 NN B-NP O
26 768 770 16192988 in IN B-PP O
27 771 774 16192988 the DT B-NP O
28 775 782 16192988 striata NNS I-NP O
29 783 785 16192988 of IN B-PP O
30 786 790 16192988 mice NNS B-NP O
31 791 796 16192988 after IN B-PP O
32 797 805 16192988 multiple JJ B-NP O
33 806 816 16192988 injections NNS I-NP O
34 817 819 16192988 of IN B-PP O
35 820 824 16192988 METH NN B-NP D008694
36 824 825 16192988 . . O O

1 826 830 16192988 MEK1 NN B-NP O
2 831 834 16192988 was VBD B-VP O
3 835 848 16192988 significantly RB I-VP O
4 849 858 16192988 decreased VBN I-VP O
5 859 863 16192988 also RB B-ADVP O
6 864 869 16192988 after IN B-PP O
7 870 871 16192988 a DT B-NP O
8 872 878 16192988 single JJ I-NP O
9 879 888 16192988 injection NN I-NP O
10 889 891 16192988 of IN B-PP O
11 892 896 16192988 METH NN B-NP D008694
12 896 897 16192988 , , O O
13 898 901 16192988 but CC O O
14 902 904 16192988 to TO B-PP O
15 905 906 16192988 a DT B-NP O
16 907 911 16192988 much RB I-NP O
17 912 918 16192988 lesser JJR I-NP O
18 919 925 16192988 degree NN I-NP O
19 926 930 16192988 than IN B-PP O
20 931 936 16192988 after IN B-PP O
21 937 945 16192988 multiple JJ B-NP O
22 946 956 16192988 injections NNS I-NP O
23 957 959 16192988 of IN B-PP O
24 960 964 16192988 METH NN B-NP D008694
25 964 965 16192988 . . O O

1 966 968 16192988 In IN B-PP O
2 969 972 16192988 the DT B-NP O
3 973 980 16192988 frontal JJ I-NP O
4 981 987 16192988 cortex NN I-NP O
5 987 988 16192988 , , O O
6 989 994 16192988 there EX B-NP O
7 995 998 16192988 was VBD B-VP O
8 999 1000 16192988 a DT B-NP O
9 1001 1014 16192988 statistically RB I-NP O
10 1015 1026 16192988 significant JJ I-NP O
11 1027 1035 16192988 decrease NN I-NP O
12 1036 1038 16192988 in IN B-PP O
13 1039 1048 16192988 GSK3alpha NN B-NP O
14 1049 1054 16192988 after IN B-PP O
15 1055 1063 16192988 multiple JJ B-NP O
16 1064 1065 16192988 ( ( O O
17 1065 1068 16192988 but CC O O
18 1069 1072 16192988 not RB O O
19 1073 1079 16192988 single JJ B-ADJP O
20 1079 1080 16192988 ) ) O O
21 1081 1091 16192988 injections NNS B-NP O
22 1092 1094 16192988 of IN B-PP O
23 1095 1099 16192988 METH NN B-NP D008694
24 1099 1100 16192988 . . O O

1 1101 1106 16192988 These DT B-NP O
2 1107 1115 16192988 findings NNS I-NP O
3 1116 1123 16192988 suggest VBP B-VP O
4 1124 1128 16192988 that IN B-SBAR O
5 1129 1140 16192988 alterations NNS B-NP O
6 1141 1143 16192988 in IN B-PP O
7 1144 1147 16192988 MAP NN B-NP O
8 1148 1154 16192988 kinase NN I-NP O
9 1154 1155 16192988 - HYPH B-NP O
10 1155 1162 16192988 related VBN I-NP O
11 1163 1171 16192988 pathways NNS I-NP O
12 1172 1174 16192988 in IN B-PP O
13 1175 1178 16192988 the DT B-NP O
14 1179 1188 16192988 prefronto AFX I-NP O
15 1188 1189 16192988 - HYPH I-NP O
16 1189 1197 16192988 striatal JJ I-NP O
17 1198 1209 16192988 circuitries NNS I-NP O
18 1210 1215 16192988 might MD B-VP O
19 1216 1218 16192988 be VB I-VP O
20 1219 1227 16192988 involved VBN I-VP O
21 1228 1230 16192988 in IN B-PP O
22 1231 1234 16192988 the DT B-NP O
23 1235 1248 16192988 manifestation NN I-NP O
24 1249 1251 16192988 of IN B-PP O
25 1252 1262 16192988 aggressive JJ B-NP D001523
26 1263 1272 16192988 behaviors NNS I-NP D001523
27 1273 1275 16192988 in IN B-PP O
28 1276 1280 16192988 mice NNS B-NP O
29 1280 1281 16192988 . . O O

1 0 0 20195852 -DOCSTART- -X- -X- O

1 0 4 20195852 Risk NN B-NP O
2 5 7 20195852 of IN B-PP O
3 8 19 20195852 nephropathy NN B-NP D007674
4 20 25 20195852 after IN B-PP O
5 26 37 20195852 consumption NN B-NP O
6 38 40 20195852 of IN B-PP O
7 41 49 20195852 nonionic JJ B-NP O
8 50 58 20195852 contrast NN I-NP D003287
9 59 64 20195852 media NNS I-NP D003287
10 65 67 20195852 by IN B-PP O
11 68 76 20195852 children NNS B-NP O
12 77 87 20195852 undergoing VBG B-VP O
13 88 95 20195852 cardiac JJ B-NP O
14 96 107 20195852 angiography NN I-NP O
15 107 108 20195852 : : O O
16 109 110 20195852 a DT B-NP O
17 111 122 20195852 prospective JJ I-NP O
18 123 128 20195852 study NN I-NP O
19 128 129 20195852 . . O O
20 130 137 20195852 Despite IN B-PP O
21 138 148 20195852 increasing VBG B-VP O
22 149 156 20195852 reports NNS B-NP O
23 157 159 20195852 on IN B-PP O
24 160 168 20195852 nonionic JJ B-NP O
25 169 177 20195852 contrast NN I-NP D003287
26 178 183 20195852 media NN I-NP D003287
27 183 184 20195852 - HYPH B-NP O
28 184 191 20195852 induced VBN I-NP O
29 192 203 20195852 nephropathy NN I-NP D007674
30 204 205 20195852 ( ( O O
31 205 208 20195852 CIN NN B-NP D007674
32 208 209 20195852 ) ) O O
33 210 212 20195852 in IN B-PP O
34 213 225 20195852 hospitalized VBN B-NP O
35 226 231 20195852 adult JJ I-NP O
36 232 240 20195852 patients NNS I-NP O
37 241 247 20195852 during IN B-PP O
38 248 255 20195852 cardiac JJ B-NP O
39 256 266 20195852 procedures NNS I-NP O
40 266 267 20195852 , , O O
41 268 271 20195852 the DT B-NP O
42 272 279 20195852 studies NNS I-NP O
43 280 282 20195852 in IN B-PP O
44 283 293 20195852 pediatrics NNS B-NP O
45 294 297 20195852 are VBP B-VP O
46 298 305 20195852 limited VBN I-VP O
47 305 306 20195852 , , O O
48 307 311 20195852 with IN B-PP O
49 312 316 20195852 even RB B-NP O
50 317 321 20195852 less JJR I-NP O
51 322 327 20195852 focus NN I-NP O
52 328 330 20195852 on IN B-PP O
53 331 339 20195852 possible JJ B-NP O
54 340 352 20195852 predisposing VBG I-NP O
55 353 360 20195852 factors NNS I-NP O
56 361 364 20195852 and CC O O
57 365 375 20195852 preventive JJ B-NP O
58 376 384 20195852 measures NNS I-NP O
59 385 388 20195852 for IN B-PP O
60 389 397 20195852 patients NNS B-NP O
61 398 408 20195852 undergoing VBG B-VP O
62 409 416 20195852 cardiac JJ B-NP O
63 417 428 20195852 angiography NN I-NP O
64 428 429 20195852 . . O O

1 430 434 20195852 This DT B-NP O
2 435 446 20195852 prospective JJ I-NP O
3 447 452 20195852 study NN I-NP O
4 453 463 20195852 determined VBD B-VP O
5 464 467 20195852 the DT B-NP O
6 468 477 20195852 incidence NN I-NP O
7 478 480 20195852 of IN B-PP O
8 481 484 20195852 CIN NN B-NP D007674
9 485 488 20195852 for IN B-PP O
10 489 492 20195852 two CD B-NP O
11 493 501 20195852 nonionic JJ I-NP O
12 502 510 20195852 contrast NN I-NP D003287
13 511 516 20195852 media NNS I-NP D003287
14 517 518 20195852 ( ( O O
15 518 520 20195852 CM NN B-NP D003287
16 520 521 20195852 ) ) O O
17 521 522 20195852 , , O O
18 523 532 20195852 iopromide NN B-NP C038192
19 533 536 20195852 and CC I-NP O
20 537 544 20195852 iohexol NN I-NP D007472
21 544 545 20195852 , , O O
22 546 551 20195852 among IN B-PP O
23 552 554 20195852 80 CD B-NP O
24 555 563 20195852 patients NNS I-NP O
25 564 571 20195852 younger JJR B-ADJP O
26 572 576 20195852 than IN B-PP O
27 577 579 20195852 18 CD B-NP O
28 580 585 20195852 years NNS I-NP O
29 586 589 20195852 and CC O O
30 590 598 20195852 compared VBD B-VP O
31 599 602 20195852 the DT B-NP O
32 603 608 20195852 rates NNS I-NP O
33 609 612 20195852 for IN B-PP O
34 613 617 20195852 this DT B-NP O
35 618 630 20195852 complication NN I-NP O
36 631 633 20195852 in IN B-PP O
37 634 642 20195852 relation NN B-NP O
38 643 645 20195852 to TO B-PP O
39 646 649 20195852 the DT B-NP O
40 650 654 20195852 type NN I-NP O
41 655 658 20195852 and CC I-NP O
42 659 665 20195852 dosage NN I-NP O
43 666 668 20195852 of IN B-PP O
44 669 671 20195852 CM NN B-NP D003287
45 672 675 20195852 and CC O O
46 676 679 20195852 the DT B-NP O
47 680 688 20195852 presence NN I-NP O
48 689 691 20195852 of IN B-PP O
49 692 700 20195852 cyanosis NN B-NP D003490
50 700 701 20195852 . . O O

1 702 705 20195852 The DT B-NP O
2 706 708 20195852 80 CD I-NP O
3 709 717 20195852 patients NNS I-NP O
4 718 720 20195852 in IN B-PP O
5 721 724 20195852 the DT B-NP O
6 725 730 20195852 study NN I-NP O
7 731 744 20195852 consecutively RB B-ADVP O
8 745 753 20195852 received VBD B-VP O
9 754 760 20195852 either CC O O
10 761 770 20195852 iopromide NN B-NP C038192
11 771 772 20195852 ( ( O O
12 772 777 20195852 group NN B-NP O
13 778 779 20195852 A NN I-NP O
14 779 780 20195852 , , O O
15 781 782 20195852 n NN B-NP O
16 783 784 20195852 = SYM B-VP O
17 785 787 20195852 40 CD B-NP O
18 787 788 20195852 ) ) O O
19 789 791 20195852 or CC O O
20 792 799 20195852 iohexol NN B-NP D007472
21 800 801 20195852 ( ( O O
22 801 806 20195852 group NN B-NP O
23 807 808 20195852 B NN I-NP O
24 808 809 20195852 , , O O
25 810 811 20195852 n NN B-NP O
26 812 813 20195852 = SYM B-VP O
27 814 816 20195852 40 CD B-NP O
28 816 817 20195852 ) ) O O
29 817 818 20195852 . . O O

1 819 824 20195852 Serum NN B-NP O
2 825 831 20195852 sodium NN I-NP D012964
3 832 833 20195852 ( ( O O
4 833 835 20195852 Na NN B-NP D012964
5 835 836 20195852 ) ) O O
6 836 837 20195852 , , O O
7 838 847 20195852 potassium NN B-NP D011188
8 848 849 20195852 ( ( O O
9 849 850 20195852 K NN B-NP D011188
10 850 851 20195852 ) ) O O
11 851 852 20195852 , , O O
12 853 856 20195852 and CC O O
13 857 867 20195852 creatinine NN B-NP D003404
14 868 869 20195852 ( ( O O
15 869 871 20195852 Cr NN B-NP D003404
16 871 872 20195852 ) ) O O
17 873 877 20195852 were VBD B-VP O
18 878 886 20195852 measured VBN I-VP O
19 887 889 20195852 24 CD B-NP O
20 890 891 20195852 h NN I-NP O
21 892 898 20195852 before IN B-PP O
22 899 910 20195852 angiography NN B-NP O
23 911 913 20195852 as IN B-PP O
24 914 922 20195852 baseline NN B-NP O
25 923 929 20195852 values NNS I-NP O
26 929 930 20195852 , , O O
27 931 935 20195852 then RB B-VP O
28 936 944 20195852 measured VBN I-VP O
29 945 950 20195852 again RB B-ADVP O
30 951 953 20195852 at IN B-PP O
31 954 956 20195852 12 CD B-NP O
32 956 957 20195852 - HYPH B-ADJP O
33 957 958 20195852 , , O O
34 959 961 20195852 24 CD B-NP O
35 961 962 20195852 - HYPH B-ADJP O
36 962 963 20195852 , , O O
37 964 967 20195852 and CC O O
38 968 970 20195852 48 CD B-NP O
39 970 971 20195852 - HYPH I-NP O
40 971 972 20195852 h NN I-NP O
41 973 982 20195852 intervals NNS I-NP O
42 983 988 20195852 after IN B-PP O
43 989 991 20195852 CM NN B-NP D003287
44 992 995 20195852 use NN I-NP O
45 995 996 20195852 . . O O

1 997 1002 20195852 Urine NN B-NP O
2 1003 1010 20195852 samples NNS I-NP O
3 1011 1014 20195852 for IN B-PP O
4 1015 1017 20195852 Na NN B-NP D012964
5 1018 1021 20195852 and CC I-NP O
6 1022 1024 20195852 Cr NN I-NP D003404
7 1025 1029 20195852 also RB B-ADVP O
8 1030 1034 20195852 were VBD B-VP O
9 1035 1042 20195852 checked VBN I-VP O
10 1043 1045 20195852 at IN B-PP O
11 1046 1049 20195852 the DT B-NP O
12 1050 1054 20195852 same JJ I-NP O
13 1055 1064 20195852 intervals NNS I-NP O
14 1064 1065 20195852 . . O O

1 1066 1070 20195852 Risk NN B-NP O
2 1071 1073 20195852 of IN B-PP O
3 1074 1079 20195852 renal JJ B-NP D051437
4 1080 1087 20195852 failure NN I-NP D051437
5 1087 1088 20195852 , , O O
6 1089 1095 20195852 Injury NNP B-NP D058186
7 1096 1098 20195852 to TO B-PP D058186
8 1099 1102 20195852 the DT B-NP D058186
9 1103 1109 20195852 kidney NN I-NP D058186
10 1109 1110 20195852 , , O O
11 1111 1118 20195852 Failure NN B-NP D051437
12 1119 1121 20195852 of IN B-PP D051437
13 1122 1128 20195852 kidney NN B-NP D051437
14 1129 1137 20195852 function NN I-NP D051437
15 1137 1138 20195852 , , O O
16 1139 1143 20195852 Loss NN B-NP D051437
17 1144 1146 20195852 of IN B-PP D051437
18 1147 1153 20195852 kidney NN B-NP D051437
19 1154 1162 20195852 function NN I-NP D051437
20 1162 1163 20195852 , , O O
21 1164 1167 20195852 and CC O O
22 1168 1171 20195852 End NN B-NP O
23 1171 1172 20195852 - HYPH O O
24 1172 1177 20195852 stage NN B-NP O
25 1178 1183 20195852 renal JJ I-NP D007674
26 1184 1190 20195852 damage NN I-NP D007674
27 1191 1192 20195852 ( ( O O
28 1192 1197 20195852 RIFLE NN B-NP O
29 1198 1206 20195852 criteria NNS I-NP O
30 1206 1207 20195852 ) ) O O
31 1208 1212 20195852 were VBD B-VP O
32 1213 1217 20195852 used VBN I-VP O
33 1218 1220 20195852 to TO B-VP O
34 1221 1227 20195852 define VB I-VP O
35 1228 1231 20195852 CIN NN B-NP D007674
36 1232 1235 20195852 and CC O O
37 1236 1239 20195852 its PRP$ B-NP O
38 1240 1249 20195852 incidence NN I-NP O
39 1250 1252 20195852 in IN B-PP O
40 1253 1256 20195852 the DT B-NP O
41 1257 1262 20195852 study NN I-NP O
42 1263 1273 20195852 population NN I-NP O
43 1273 1274 20195852 . . O O

1 1275 1286 20195852 Accordingly RB B-ADVP O
2 1286 1287 20195852 , , O O
3 1288 1293 20195852 among IN B-PP O
4 1294 1297 20195852 the DT B-NP O
5 1298 1300 20195852 15 CD I-NP O
6 1301 1304 20195852 CIN NN I-NP D007674
7 1305 1313 20195852 patients NNS I-NP O
8 1314 1315 20195852 ( ( O O
9 1315 1321 20195852 18.75% NN B-NP O
10 1321 1322 20195852 ) ) O O
11 1322 1323 20195852 , , O O
12 1324 1328 20195852 7.5% CD B-NP O
13 1329 1331 20195852 of IN B-PP O
14 1332 1335 20195852 the DT B-NP O
15 1336 1344 20195852 patients NNS I-NP O
16 1345 1347 20195852 in IN B-PP O
17 1348 1353 20195852 group NN B-NP O
18 1354 1355 20195852 A NN I-NP O
19 1356 1359 20195852 had VBD B-VP O
20 1360 1369 20195852 increased VBN I-VP O
21 1370 1374 20195852 risk NN B-NP O
22 1375 1378 20195852 and CC I-NP O
23 1379 1384 20195852 3.75% NN I-NP O
24 1385 1388 20195852 had VBD B-VP O
25 1389 1394 20195852 renal JJ B-NP D058186
26 1395 1401 20195852 injury NN I-NP D058186
27 1401 1402 20195852 , , O O
28 1403 1410 20195852 whereas IN O O
29 1411 1413 20195852 5% NN B-NP O
30 1414 1416 20195852 of IN B-PP O
31 1417 1422 20195852 group NN B-NP O
32 1423 1424 20195852 B NN I-NP O
33 1425 1428 20195852 had VBD B-VP O
34 1429 1438 20195852 increased VBN I-VP O
35 1439 1443 20195852 risk NN B-NP O
36 1444 1447 20195852 and CC I-NP O
37 1448 1452 20195852 2.5% NN I-NP O
38 1453 1456 20195852 had VBD B-VP O
39 1457 1462 20195852 renal JJ B-NP D058186
40 1463 1469 20195852 injury NN I-NP D058186
41 1469 1470 20195852 . . O O

1 1471 1478 20195852 Whereas IN B-PP O
2 1479 1484 20195852 33.3% NN B-NP O
3 1485 1487 20195852 of IN B-PP O
4 1488 1491 20195852 the DT B-NP O
5 1492 1500 20195852 patients NNS I-NP O
6 1501 1505 20195852 with IN B-PP O
7 1506 1509 20195852 CIN NN B-NP D007674
8 1510 1514 20195852 were VBD B-VP O
9 1515 1520 20195852 among IN B-PP O
10 1521 1526 20195852 those DT B-NP O
11 1527 1530 20195852 who WP B-NP O
12 1531 1539 20195852 received VBD B-VP O
13 1540 1543 20195852 the DT B-NP O
14 1544 1550 20195852 proper JJ I-NP O
15 1551 1557 20195852 dosage NN I-NP O
16 1558 1560 20195852 of IN B-PP O
17 1561 1563 20195852 CM NN B-NP D003287
18 1563 1564 20195852 , , O O
19 1565 1568 20195852 the DT B-NP O
20 1569 1579 20195852 percentage NN I-NP O
21 1580 1589 20195852 increased VBD B-VP O
22 1590 1592 20195852 to TO I-VP O
23 1593 1598 20195852 66.6% VB I-VP O
24 1599 1604 20195852 among IN B-PP O
25 1605 1610 20195852 those DT B-NP O
26 1611 1614 20195852 who WP B-NP O
27 1615 1623 20195852 received VBD B-VP O
28 1624 1630 20195852 larger JJR B-NP O
29 1631 1636 20195852 doses NNS I-NP O
30 1636 1637 20195852 , , O O
31 1638 1642 20195852 with IN B-PP O
32 1643 1644 20195852 a DT B-NP O
33 1645 1656 20195852 significant JJ I-NP O
34 1657 1667 20195852 difference NN I-NP O
35 1668 1670 20195852 in IN B-PP O
36 1671 1674 20195852 the DT B-NP O
37 1675 1684 20195852 incidence NN I-NP O
38 1685 1687 20195852 of IN B-PP O
39 1688 1691 20195852 CIN NN B-NP D007674
40 1692 1699 20195852 related VBN B-VP O
41 1700 1702 20195852 to TO B-PP O
42 1703 1706 20195852 the DT B-NP O
43 1707 1716 20195852 different JJ I-NP O
44 1717 1724 20195852 dosages NNS I-NP O
45 1725 1727 20195852 of IN B-PP O
46 1728 1730 20195852 CM NN B-NP D003287
47 1731 1732 20195852 ( ( O O
48 1732 1733 20195852 p NN B-NP O
49 1734 1735 20195852 = SYM B-VP O
50 1736 1741 20195852 0.014 CD B-NP O
51 1741 1742 20195852 ) ) O O
52 1742 1743 20195852 . . O O

1 1744 1749 20195852 Among IN B-PP O
2 1750 1753 20195852 the DT B-NP O
3 1754 1756 20195852 15 CD I-NP O
4 1757 1765 20195852 patients NNS I-NP O
5 1766 1770 20195852 with IN B-PP O
6 1771 1774 20195852 CIN NN B-NP D007674
7 1774 1775 20195852 , , O O
8 1776 1777 20195852 6 CD B-NP O
9 1778 1781 20195852 had VBD B-VP O
10 1782 1790 20195852 cyanotic JJ B-NP O
11 1791 1801 20195852 congenital JJ I-NP D006331
12 1802 1807 20195852 heart NN I-NP D006331
13 1808 1816 20195852 diseases NNS I-NP D006331
14 1816 1817 20195852 , , O O
15 1818 1821 20195852 but CC O O
16 1822 1825 20195852 the DT B-NP O
17 1826 1835 20195852 incidence NN I-NP O
18 1836 1839 20195852 did VBD B-VP O
19 1840 1843 20195852 not RB I-VP O
20 1844 1850 20195852 differ VB I-VP O
21 1851 1864 20195852 significantly RB B-ADVP O
22 1865 1869 20195852 from IN B-PP O
23 1870 1874 20195852 that DT B-NP O
24 1875 1878 20195852 for IN B-PP O
25 1879 1882 20195852 the DT B-NP O
26 1883 1894 20195852 noncyanotic JJ I-NP O
27 1895 1903 20195852 patients NNS I-NP O
28 1904 1905 20195852 ( ( O O
29 1905 1906 20195852 p NN B-NP O
30 1907 1908 20195852 = SYM B-VP O
31 1909 1914 20195852 0.243 CD B-NP O
32 1914 1915 20195852 ) ) O O
33 1915 1916 20195852 . . O O

1 1917 1925 20195852 Although IN B-SBAR O
2 1926 1936 20195852 clinically RB B-ADJP O
3 1937 1943 20195852 silent JJ I-ADJP O
4 1943 1944 20195852 , , O O
5 1945 1948 20195852 CIN NN B-NP D007674
6 1949 1951 20195852 is VBZ B-VP O
7 1952 1955 20195852 not RB O O
8 1956 1960 20195852 rare JJ B-ADJP O
9 1961 1963 20195852 in IN B-PP O
10 1964 1974 20195852 pediatrics NNS B-NP O
11 1974 1975 20195852 . . O O

1 1976 1979 20195852 The DT B-NP O
2 1980 1989 20195852 incidence NN I-NP O
3 1990 1997 20195852 depends VBZ B-VP O
4 1998 2000 20195852 on IN B-PP O
5 2001 2007 20195852 dosage NN B-NP O
6 2008 2011 20195852 but CC B-PP O
7 2012 2015 20195852 not RB B-PP O
8 2016 2018 20195852 on IN I-PP O
9 2019 2022 20195852 the DT B-NP O
10 2023 2027 20195852 type NN I-NP O
11 2028 2030 20195852 of IN B-PP O
12 2031 2039 20195852 consumed JJ B-NP O
13 2040 2048 20195852 nonionic JJ I-NP O
14 2049 2051 20195852 CM NN I-NP D003287
15 2051 2052 20195852 , , B-PP O
16 2053 2056 20195852 nor CC I-PP O
17 2057 2059 20195852 on IN B-PP O
18 2060 2063 20195852 the DT B-NP O
19 2064 2072 20195852 presence NN I-NP O
20 2073 2075 20195852 of IN B-PP O
21 2076 2084 20195852 cyanosis NN B-NP D003490
22 2084 2085 20195852 , , O O
23 2086 2089 20195852 and CC O O
24 2090 2098 20195852 although IN B-SBAR O
25 2099 2102 20195852 CIN NN B-NP D007674
26 2103 2110 20195852 usually RB B-ADVP O
27 2111 2113 20195852 is VBZ B-VP O
28 2114 2124 20195852 reversible JJ B-NP O
29 2124 2125 20195852 , , I-NP O
30 2126 2130 20195852 more JJR I-NP O
31 2131 2138 20195852 concern NN I-NP O
32 2139 2141 20195852 is VBZ B-VP O
33 2142 2148 20195852 needed VBN I-VP O
34 2149 2152 20195852 for IN B-PP O
35 2153 2156 20195852 the DT B-NP O
36 2157 2167 20195852 prevention NN I-NP O
37 2168 2170 20195852 of IN B-PP O
38 2171 2175 20195852 such JJ B-NP O
39 2176 2177 20195852 a DT I-NP O
40 2178 2190 20195852 complication NN I-NP O
41 2191 2193 20195852 in IN B-PP O
42 2194 2202 20195852 children NNS B-NP O
43 2202 2203 20195852 . . O O

1 0 0 15867025 -DOCSTART- -X- -X- O

1 0 10 15867025 Assessment NN B-NP O
2 11 13 15867025 of IN B-PP O
3 14 23 15867025 perinatal JJ B-NP O
4 24 33 15867025 hepatitis NN I-NP D006509
5 34 35 15867025 B NN I-NP D006509
6 36 39 15867025 and CC O O
7 40 47 15867025 rubella NN B-NP D012409
8 48 58 15867025 prevention NN I-NP O
9 59 61 15867025 in IN B-PP O
10 62 65 15867025 New NNP B-NP O
11 66 75 15867025 Hampshire NNP I-NP O
12 76 84 15867025 delivery NN I-NP O
13 85 94 15867025 hospitals NNS I-NP O
14 94 95 15867025 . . O O
15 96 105 15867025 OBJECTIVE NN B-NP O
16 105 106 15867025 : : O O
17 107 109 15867025 To TO B-VP O
18 110 118 15867025 evaluate VB I-VP O
19 119 126 15867025 current JJ B-NP O
20 127 138 15867025 performance NN I-NP O
21 139 141 15867025 on IN B-PP O
22 142 153 15867025 recommended VBN B-NP O
23 154 163 15867025 perinatal JJ I-NP O
24 164 173 15867025 hepatitis NN I-NP D006509
25 174 175 15867025 B NN I-NP D006509
26 176 179 15867025 and CC O O
27 180 187 15867025 rubella NN B-NP D012409
28 188 198 15867025 prevention NN I-NP O
29 199 208 15867025 practices NNS I-NP O
30 209 211 15867025 in IN B-PP O
31 212 215 15867025 New NNP B-NP O
32 216 225 15867025 Hampshire NNP I-NP O
33 225 226 15867025 . . O O

1 227 234 15867025 METHODS NNS B-NP O
2 234 235 15867025 : : O O
3 236 240 15867025 Data NNS B-NP O
4 241 245 15867025 were VBD B-VP O
5 246 255 15867025 extracted VBN I-VP O
6 256 260 15867025 from IN B-PP O
7 261 265 15867025 2021 CD B-NP O
8 266 272 15867025 paired JJ I-NP O
9 273 279 15867025 mother NN I-NP O
10 279 280 15867025 - HYPH O O
11 280 286 15867025 infant NN B-NP O
12 287 294 15867025 records NNS I-NP O
13 295 298 15867025 for IN B-PP O
14 299 302 15867025 the DT B-NP O
15 303 307 15867025 year NN I-NP O
16 308 312 15867025 2000 CD I-NP O
17 313 318 15867025 birth NN I-NP O
18 319 325 15867025 cohort NN I-NP O
19 326 328 15867025 in IN B-PP O
20 329 332 15867025 New NNP B-NP O
21 333 344 15867025 Hampshire's NNP I-NP O
22 345 347 15867025 25 CD I-NP O
23 348 356 15867025 delivery NN I-NP O
24 357 366 15867025 hospitals NNS I-NP O
25 366 367 15867025 . . O O

1 368 378 15867025 Assessment NN B-NP O
2 379 382 15867025 was VBD B-VP O
3 383 387 15867025 done VBN I-VP O
4 388 390 15867025 on IN B-PP O
5 391 394 15867025 the DT B-NP O
6 395 404 15867025 following NN I-NP O
7 404 405 15867025 : : O O
8 406 414 15867025 prenatal JJ B-NP O
9 415 424 15867025 screening NN I-NP O
10 425 428 15867025 for IN B-PP O
11 429 438 15867025 hepatitis NN B-NP D006509
12 439 440 15867025 B NN I-NP D006509
13 441 444 15867025 and CC O O
14 445 452 15867025 rubella NN B-NP D012409
15 452 453 15867025 , , O O
16 454 468 15867025 administration NN B-NP O
17 469 471 15867025 of IN B-PP O
18 472 475 15867025 the DT B-NP O
19 476 485 15867025 hepatitis NN I-NP D006509
20 486 487 15867025 B NN I-NP D006509
21 488 495 15867025 vaccine NN I-NP O
22 496 501 15867025 birth NN I-NP O
23 502 506 15867025 dose NN I-NP O
24 507 509 15867025 to TO B-PP O
25 510 513 15867025 all DT B-NP O
26 514 521 15867025 infants NNS I-NP O
27 521 522 15867025 , , O O
28 523 537 15867025 administration NN B-NP O
29 538 540 15867025 of IN B-PP O
30 541 550 15867025 hepatitis NN B-NP D006509
31 551 552 15867025 B NN I-NP D006509
32 553 559 15867025 immune JJ I-NP O
33 560 568 15867025 globulin NN I-NP O
34 569 571 15867025 to TO B-PP O
35 572 579 15867025 infants NNS B-NP O
36 580 583 15867025 who WP B-NP O
37 584 588 15867025 were VBD B-VP O
38 589 593 15867025 born VBN I-VP O
39 594 596 15867025 to TO B-PP O
40 597 606 15867025 hepatitis NN B-NP D006514
41 607 608 15867025 B NN I-NP D006514
42 609 616 15867025 surface NN I-NP D006514
43 617 624 15867025 antigen NN I-NP D006514
44 624 625 15867025 - HYPH B-NP O
45 625 633 15867025 positive JJ I-NP O
46 634 641 15867025 mothers NNS I-NP O
47 641 642 15867025 , , O O
48 643 650 15867025 rubella NN B-NP D012409
49 651 659 15867025 immunity NN I-NP O
50 659 660 15867025 , , O O
51 661 664 15867025 and CC O O
52 665 679 15867025 administration NN B-NP O
53 680 682 15867025 of IN B-PP O
54 683 685 15867025 in IN B-PP O
55 685 686 15867025 - HYPH B-NP O
56 686 694 15867025 hospital NN I-NP O
57 695 705 15867025 postpartum NN I-NP O
58 706 713 15867025 rubella NN I-NP D012409
59 714 721 15867025 vaccine NN I-NP O
60 722 724 15867025 to TO B-VP O
61 725 732 15867025 rubella VB I-VP D012409
62 733 742 15867025 nonimmune JJ B-NP O
63 743 748 15867025 women NNS I-NP O
64 748 749 15867025 . . O O

1 750 757 15867025 RESULTS NNS B-NP O
2 757 758 15867025 : : O O
3 759 767 15867025 Prenatal JJ B-NP O
4 768 777 15867025 screening NN I-NP O
5 778 783 15867025 rates NNS I-NP O
6 784 787 15867025 for IN B-PP O
7 788 797 15867025 hepatitis NN B-NP D006509
8 798 799 15867025 B NN I-NP D006509
9 800 801 15867025 ( ( O O
10 801 806 15867025 98.8% CD B-NP O
11 806 807 15867025 ) ) O O
12 808 811 15867025 and CC O O
13 812 819 15867025 rubella NN B-NP D012409
14 820 821 15867025 ( ( O O
15 821 826 15867025 99.4% CD B-NP O
16 826 827 15867025 ) ) O O
17 828 832 15867025 were VBD B-VP O
18 833 837 15867025 high JJ B-ADJP O
19 837 838 15867025 . . O O

1 839 848 15867025 Hepatitis NN B-NP D006509
2 849 850 15867025 B NN I-NP D006509
3 851 858 15867025 vaccine NN I-NP O
4 859 864 15867025 birth NN I-NP O
5 865 869 15867025 dose NN I-NP O
6 870 873 15867025 was VBD B-VP O
7 874 886 15867025 administered VBN I-VP O
8 887 889 15867025 to TO B-PP O
9 890 895 15867025 76.2% CD B-NP O
10 896 898 15867025 of IN B-PP O
11 899 902 15867025 all DT B-NP O
12 903 910 15867025 infants NNS I-NP O
13 910 911 15867025 . . O O

1 912 915 15867025 All DT B-NP O
2 916 923 15867025 infants NNS I-NP O
3 924 927 15867025 who WP B-NP O
4 928 932 15867025 were VBD B-VP O
5 933 937 15867025 born VBN I-VP O
6 938 940 15867025 to TO B-PP O
7 941 950 15867025 hepatitis NN B-NP D006514
8 951 952 15867025 B NN I-NP D006514
9 953 960 15867025 surface NN I-NP D006514
10 961 968 15867025 antigen NN I-NP D006514
11 968 969 15867025 - HYPH B-NP O
12 969 977 15867025 positive JJ I-NP O
13 978 985 15867025 mothers NNS I-NP O
14 986 990 15867025 also RB B-ADVP O
15 991 999 15867025 received VBD B-VP O
16 1000 1009 15867025 hepatitis NN B-NP D006509
17 1010 1011 15867025 B NN I-NP D006509
18 1012 1018 15867025 immune JJ I-NP O
19 1019 1027 15867025 globulin NN I-NP O
20 1027 1028 15867025 . . O O

1 1029 1041 15867025 Multivariate JJ B-NP O
2 1042 1050 15867025 logistic JJ I-NP O
3 1051 1061 15867025 regression NN I-NP O
4 1062 1068 15867025 showed VBD B-VP O
5 1069 1073 15867025 that IN B-SBAR O
6 1074 1077 15867025 the DT B-NP O
7 1078 1083 15867025 month NN I-NP O
8 1084 1086 15867025 of IN B-PP O
9 1087 1095 15867025 delivery NN B-NP O
10 1096 1099 15867025 and CC I-NP O
11 1100 1106 15867025 infant NN I-NP O
12 1107 1112 15867025 birth NN I-NP O
13 1113 1119 15867025 weight NN I-NP O
14 1120 1124 15867025 were VBD B-VP O
15 1125 1136 15867025 independent JJ B-NP O
16 1137 1147 15867025 predictors NNS I-NP O
17 1148 1150 15867025 of IN B-PP O
18 1151 1160 15867025 hepatitis NN B-NP D006509
19 1161 1162 15867025 B NN I-NP D006509
20 1163 1174 15867025 vaccination NN I-NP O
21 1174 1175 15867025 . . O O

1 1176 1179 15867025 The DT B-NP O
2 1180 1190 15867025 proportion NN I-NP O
3 1191 1193 15867025 of IN B-PP O
4 1194 1201 15867025 infants NNS B-NP O
5 1202 1205 15867025 who WP B-NP O
6 1206 1210 15867025 were VBD B-VP O
7 1211 1221 15867025 vaccinated VBN I-VP O
8 1222 1224 15867025 in IN B-PP O
9 1225 1232 15867025 January NNP B-NP O
10 1233 1236 15867025 and CC O O
11 1237 1245 15867025 February NNP B-NP O
12 1246 1250 15867025 2000 CD I-NP O
13 1251 1252 15867025 ( ( O O
14 1252 1257 15867025 48.5% CD B-NP O
15 1258 1261 15867025 and CC I-NP O
16 1262 1267 15867025 67.5% CD I-NP O
17 1267 1268 15867025 , , O O
18 1269 1281 15867025 respectively RB B-ADVP O
19 1281 1282 15867025 ) ) O O
20 1283 1286 15867025 was VBD B-VP O
21 1287 1291 15867025 less JJR B-ADJP O
22 1292 1296 15867025 than IN B-PP O
23 1297 1300 15867025 any DT B-NP O
24 1301 1306 15867025 other JJ I-NP O
25 1307 1313 15867025 months NNS I-NP O
26 1313 1314 15867025 , , O O
27 1315 1322 15867025 whereas IN O O
28 1323 1326 15867025 the DT B-NP O
29 1327 1337 15867025 proportion NN I-NP O
30 1338 1341 15867025 who WP B-NP O
31 1342 1346 15867025 were VBD B-VP O
32 1347 1357 15867025 vaccinated VBN I-VP O
33 1358 1360 15867025 in IN B-PP O
34 1361 1369 15867025 December NNP B-NP O
35 1370 1374 15867025 2000 CD I-NP O
36 1375 1376 15867025 ( ( O O
37 1376 1381 15867025 88.2% NN B-NP O
38 1381 1382 15867025 ) ) O O
39 1383 1386 15867025 was VBD B-VP O
40 1387 1390 15867025 the DT B-NP O
41 1391 1398 15867025 highest JJS I-NP O
42 1398 1399 15867025 . . O O

1 1400 1405 15867025 Women NNS B-NP O
2 1406 1409 15867025 who WP B-NP O
3 1410 1414 15867025 were VBD B-VP O
4 1415 1419 15867025 born VBN I-VP O
5 1420 1427 15867025 between IN B-PP O
6 1428 1432 15867025 1971 CD B-NP O
7 1433 1436 15867025 and CC I-NP O
8 1437 1441 15867025 1975 CD I-NP O
9 1442 1445 15867025 had VBD B-VP O
10 1446 1449 15867025 the DT B-NP O
11 1450 1457 15867025 highest JJS I-NP O
12 1458 1462 15867025 rate NN I-NP O
13 1463 1465 15867025 of IN B-PP O
14 1466 1473 15867025 rubella NN B-NP D012409
15 1474 1485 15867025 nonimmunity NN I-NP O
16 1486 1487 15867025 ( ( O O
17 1487 1491 15867025 9.5% CD B-NP O
18 1491 1492 15867025 ) ) O O
19 1492 1493 15867025 . . O O

1 1494 1496 15867025 In IN B-PP O
2 1496 1497 15867025 - HYPH B-NP O
3 1497 1505 15867025 hospital NN I-NP O
4 1506 1516 15867025 postpartum NN I-NP O
5 1517 1524 15867025 rubella NN I-NP D012409
6 1525 1532 15867025 vaccine NN I-NP O
7 1533 1547 15867025 administration NN I-NP O
8 1548 1551 15867025 was VBD B-VP O
9 1552 1562 15867025 documented VBN I-VP O
10 1563 1566 15867025 for IN B-PP O
11 1567 1572 15867025 75.6% NN B-NP O
12 1573 1575 15867025 of IN B-PP O
13 1576 1585 15867025 nonimmune JJ B-NP O
14 1586 1591 15867025 women NNS I-NP O
15 1591 1592 15867025 . . O O

1 1593 1603 15867025 CONCLUSION NN B-NP O
2 1603 1604 15867025 : : O O
3 1605 1609 15867025 This DT B-NP O
4 1610 1615 15867025 study NN I-NP O
5 1616 1625 15867025 documents VBZ B-VP O
6 1626 1630 15867025 good JJ B-NP O
7 1631 1641 15867025 compliance NN I-NP O
8 1642 1644 15867025 in IN B-PP O
9 1645 1648 15867025 New NNP B-NP O
10 1649 1660 15867025 Hampshire's NNP I-NP O
11 1661 1669 15867025 birthing NN I-NP O
12 1670 1679 15867025 hospitals NNS I-NP O
13 1680 1684 15867025 with IN B-PP O
14 1685 1693 15867025 national JJ B-NP O
15 1694 1704 15867025 guidelines NNS I-NP O
16 1705 1708 15867025 for IN B-PP O
17 1709 1718 15867025 perinatal JJ B-NP O
18 1719 1728 15867025 hepatitis NN I-NP D006509
19 1729 1730 15867025 B NN I-NP D006509
20 1731 1734 15867025 and CC O O
21 1735 1742 15867025 rubella NN B-NP D012409
22 1743 1753 15867025 prevention NN I-NP O
23 1754 1757 15867025 and CC O O
24 1758 1768 15867025 highlights VBZ B-VP O
25 1769 1778 15867025 potential JJ B-NP O
26 1779 1784 15867025 areas NNS I-NP O
27 1785 1788 15867025 for IN B-PP O
28 1789 1800 15867025 improvement NN B-NP O
29 1800 1801 15867025 . . O O

1 0 0 11230490 -DOCSTART- -X- -X- O

1 0 7 11230490 Reduced VBN B-NP O
2 8 22 11230490 cardiotoxicity NN I-NP D066126
3 23 26 11230490 and CC O O
4 27 36 11230490 preserved VBN B-VP O
5 37 46 11230490 antitumor JJ B-NP O
6 47 55 11230490 efficacy NN I-NP O
7 56 58 11230490 of IN B-PP O
8 59 67 11230490 liposome NN B-NP O
9 67 68 11230490 - HYPH B-NP O
10 68 80 11230490 encapsulated VBN I-NP O
11 81 92 11230490 doxorubicin NN I-NP D004317
12 93 96 11230490 and CC I-NP O
13 97 113 11230490 cyclophosphamide NN I-NP D003520
14 114 122 11230490 compared VBN B-PP O
15 123 127 11230490 with IN B-PP O
16 128 140 11230490 conventional JJ B-NP O
17 141 152 11230490 doxorubicin NN I-NP D004317
18 153 156 11230490 and CC I-NP O
19 157 173 11230490 cyclophosphamide NN I-NP D003520
20 174 176 11230490 in IN B-PP O
21 177 178 11230490 a DT B-NP O
22 179 189 11230490 randomized VBN I-NP O
23 189 190 11230490 , , I-NP O
24 191 202 11230490 multicenter JJ I-NP O
25 203 208 11230490 trial NN I-NP O
26 209 211 11230490 of IN B-PP O
27 212 222 11230490 metastatic JJ B-NP O
28 223 229 11230490 breast NN I-NP D001943
29 230 236 11230490 cancer NN I-NP D001943
30 236 237 11230490 . . I-NP O
31 238 245 11230490 PURPOSE NN I-NP O
32 245 246 11230490 : : O O
33 247 249 11230490 To TO B-VP O
34 250 259 11230490 determine VB I-VP O
35 260 267 11230490 whether IN B-SBAR O
36 268 274 11230490 Myocet NN B-NP D004317
37 275 276 11230490 ( ( O O
38 276 284 11230490 liposome NN B-NP O
39 284 285 11230490 - HYPH O O
40 285 297 11230490 encapsulated VBN B-NP O
41 298 309 11230490 doxorubicin NN I-NP D004317
42 309 310 11230490 ; : O O
43 311 314 11230490 The DT B-NP O
44 315 323 11230490 Liposome NNP I-NP O
45 324 331 11230490 Company NNP I-NP O
46 331 332 11230490 , , O O
47 333 337 11230490 Elan NNP B-NP O
48 338 349 11230490 Corporation NNP I-NP O
49 349 350 11230490 , , O O
50 351 360 11230490 Princeton NNP B-NP O
51 360 361 11230490 , , O O
52 362 364 11230490 NJ NNP B-NP O
53 364 365 11230490 ) ) O O
54 366 368 11230490 in IN B-PP O
55 369 380 11230490 combination NN B-NP O
56 381 385 11230490 with IN B-PP O
57 386 402 11230490 cyclophosphamide NN B-NP D003520
58 403 416 11230490 significantly RB B-ADVP O
59 417 424 11230490 reduces VBZ B-VP O
60 425 436 11230490 doxorubicin NN B-NP D004317
61 437 451 11230490 cardiotoxicity NN I-NP D066126
62 452 457 11230490 while IN B-SBAR O
63 458 467 11230490 providing VBG B-VP O
64 468 478 11230490 comparable JJ B-NP O
65 479 488 11230490 antitumor JJ I-NP O
66 489 497 11230490 efficacy NN I-NP O
67 498 500 11230490 in IN B-PP O
68 501 506 11230490 first JJ B-NP O
69 506 507 11230490 - HYPH I-NP O
70 507 511 11230490 line NN I-NP O
71 512 521 11230490 treatment NN I-NP O
72 522 524 11230490 of IN B-PP O
73 525 535 11230490 metastatic JJ B-NP O
74 536 542 11230490 breast NN I-NP D001943
75 543 549 11230490 cancer NN I-NP D001943
76 550 551 11230490 ( ( O O
77 551 554 11230490 MBC NN B-NP D001943
78 554 555 11230490 ) ) O O
79 555 556 11230490 . . O O

1 557 565 11230490 PATIENTS NNS B-NP O
2 566 569 11230490 AND CC I-NP O
3 570 577 11230490 METHODS NNS I-NP O
4 577 578 11230490 : : O O
5 579 582 11230490 Two CD B-NP O
6 583 590 11230490 hundred CD I-NP O
7 591 597 11230490 ninety CD I-NP O
8 597 598 11230490 - HYPH O O
9 598 603 11230490 seven CD B-NP O
10 604 612 11230490 patients NNS I-NP O
11 613 617 11230490 with IN B-PP O
12 618 621 11230490 MBC NN B-NP D001943
13 622 625 11230490 and CC O O
14 626 628 11230490 no DT B-NP O
15 629 634 11230490 prior JJ I-NP O
16 635 647 11230490 chemotherapy NN I-NP O
17 648 651 11230490 for IN B-PP O
18 652 662 11230490 metastatic JJ B-NP O
19 663 670 11230490 disease NN I-NP O
20 671 675 11230490 were VBD B-VP O
21 676 686 11230490 randomized VBN I-VP O
22 687 689 11230490 to TO B-VP O
23 690 697 11230490 receive VB I-VP O
24 698 704 11230490 either CC O O
25 705 707 11230490 60 CD B-NP O
26 708 710 11230490 mg NN I-NP O
27 710 711 11230490 / SYM B-NP O
28 711 715 11230490 m(2) NN I-NP O
29 716 718 11230490 of IN B-PP O
30 719 725 11230490 Myocet NN B-NP D004317
31 726 727 11230490 ( ( O O
32 727 728 11230490 M NN B-NP O
33 728 729 11230490 ) ) O O
34 730 732 11230490 or CC O O
35 733 745 11230490 conventional JJ B-NP O
36 746 757 11230490 doxorubicin NN I-NP D004317
37 758 759 11230490 ( ( O O
38 759 760 11230490 A NN B-NP O
39 760 761 11230490 ) ) O O
40 761 762 11230490 , , O O
41 763 765 11230490 in IN B-PP O
42 766 777 11230490 combination NN B-NP O
43 778 782 11230490 with IN B-PP O
44 783 786 11230490 600 CD B-NP O
45 787 789 11230490 mg NN I-NP O
46 789 790 11230490 / SYM B-NP O
47 790 794 11230490 m(2) NN I-NP O
48 795 797 11230490 of IN B-PP O
49 798 814 11230490 cyclophosphamide NN B-NP D003520
50 815 816 11230490 ( ( O O
51 816 817 11230490 C NN B-NP O
52 817 818 11230490 ) ) O O
53 818 819 11230490 , , O O
54 820 825 11230490 every DT B-NP O
55 826 827 11230490 3 CD I-NP O
56 828 833 11230490 weeks NNS I-NP O
57 834 839 11230490 until IN B-PP O
58 840 847 11230490 disease NN B-NP O
59 848 859 11230490 progression NN I-NP O
60 860 862 11230490 or CC O O
61 863 875 11230490 unacceptable JJ B-NP O
62 876 884 11230490 toxicity NN I-NP D064420
63 884 885 11230490 . . O O

1 886 900 11230490 Cardiotoxicity NN B-NP D066126
2 901 904 11230490 was VBD B-VP O
3 905 912 11230490 defined VBN I-VP O
4 913 915 11230490 by IN B-PP O
5 916 926 11230490 reductions NNS B-NP O
6 927 929 11230490 in IN B-PP O
7 930 934 11230490 left JJ B-NP O
8 934 935 11230490 - HYPH I-NP O
9 935 946 11230490 ventricular JJ I-NP O
10 947 955 11230490 ejection NN I-NP O
11 956 964 11230490 fraction NN I-NP O
12 964 965 11230490 , , O O
13 966 974 11230490 assessed VBN B-VP O
14 975 977 11230490 by IN B-PP O
15 978 984 11230490 serial JJ B-NP O
16 985 995 11230490 multigated JJ I-NP O
17 996 1008 11230490 radionuclide NN I-NP O
18 1009 1020 11230490 angiography NN I-NP O
19 1021 1026 11230490 scans NNS I-NP O
20 1026 1027 11230490 , , O O
21 1028 1030 11230490 or CC O O
22 1031 1041 11230490 congestive JJ B-NP D006333
23 1042 1047 11230490 heart NN I-NP D006333
24 1048 1055 11230490 failure NN I-NP D006333
25 1056 1057 11230490 ( ( O O
26 1057 1060 11230490 CHF NN B-NP D006333
27 1060 1061 11230490 ) ) O O
28 1061 1062 11230490 . . O O

1 1063 1072 11230490 Antitumor JJ B-NP O
2 1073 1081 11230490 efficacy NN I-NP O
3 1082 1085 11230490 was VBD B-VP O
4 1086 1094 11230490 assessed VBN I-VP O
5 1095 1097 11230490 by IN B-PP O
6 1098 1107 11230490 objective JJ B-NP O
7 1108 1113 11230490 tumor NN I-NP D009369
8 1114 1122 11230490 response NN I-NP O
9 1123 1128 11230490 rates NNS I-NP O
10 1129 1130 11230490 ( ( O O
11 1130 1135 11230490 World NNP B-NP O
12 1136 1142 11230490 Health NNP I-NP O
13 1143 1155 11230490 Organization NNP I-NP O
14 1156 1164 11230490 criteria NNS I-NP O
15 1164 1165 11230490 ) ) O O
16 1165 1166 11230490 , , O O
17 1167 1171 11230490 time NN B-NP O
18 1172 1174 11230490 to TO B-PP O
19 1175 1186 11230490 progression NN B-NP O
20 1186 1187 11230490 , , O O
21 1188 1191 11230490 and CC O O
22 1192 1200 11230490 survival NN B-NP O
23 1200 1201 11230490 . . O O

1 1202 1209 11230490 RESULTS NNS B-NP O
2 1209 1210 11230490 : : O O
3 1211 1214 11230490 Six CD B-NP O
4 1215 1222 11230490 percent NN I-NP O
5 1223 1225 11230490 of IN B-PP O
6 1226 1228 11230490 MC NN B-NP O
7 1229 1237 11230490 patients NNS I-NP O
8 1238 1244 11230490 versus IN B-PP O
9 1245 1248 11230490 21% CD B-NP O
10 1249 1250 11230490 ( ( O O
11 1250 1259 11230490 including VBG B-PP O
12 1260 1264 11230490 five CD B-NP O
13 1265 1270 11230490 cases NNS I-NP O
14 1271 1273 11230490 of IN B-PP O
15 1274 1277 11230490 CHF NN B-NP D006333
16 1277 1278 11230490 ) ) O O
17 1279 1281 11230490 of IN B-PP O
18 1282 1284 11230490 AC NN B-NP O
19 1285 1293 11230490 patients NNS I-NP O
20 1294 1303 11230490 developed VBD B-VP O
21 1304 1318 11230490 cardiotoxicity NN B-NP D066126
22 1319 1320 11230490 ( ( O O
23 1320 1321 11230490 P NN B-NP O
24 1322 1323 11230490 = SYM B-VP O
25 1323 1328 11230490 .0002 CD B-NP O
26 1328 1329 11230490 ) ) O O
27 1329 1330 11230490 . . O O

1 1331 1337 11230490 Median JJ B-NP O
2 1338 1348 11230490 cumulative JJ I-NP O
3 1349 1360 11230490 doxorubicin NN I-NP D004317
4 1361 1365 11230490 dose NN I-NP O
5 1366 1368 11230490 at IN B-PP O
6 1369 1374 11230490 onset NN B-NP O
7 1375 1378 11230490 was VBD B-VP O
8 1379 1383 11230490 more JJR B-NP O
9 1384 1388 11230490 than IN I-NP O
10 1389 1394 11230490 2,220 CD I-NP O
11 1395 1397 11230490 mg NN I-NP O
12 1397 1398 11230490 / SYM B-NP O
13 1398 1402 11230490 m(2) NN I-NP O
14 1403 1406 11230490 for IN B-PP O
15 1407 1409 11230490 MC NN B-NP O
16 1410 1416 11230490 versus IN B-PP O
17 1417 1420 11230490 480 CD B-NP O
18 1421 1423 11230490 mg NN I-NP O
19 1423 1424 11230490 / SYM B-NP O
20 1424 1428 11230490 m(2) NN I-NP O
21 1429 1432 11230490 for IN B-PP O
22 1433 1435 11230490 AC NN B-NP O
23 1436 1437 11230490 ( ( O O
24 1437 1438 11230490 P NN B-NP O
25 1439 1440 11230490 = SYM B-VP O
26 1440 1445 11230490 .0001 CD B-NP O
27 1445 1446 11230490 , , O O
28 1447 1453 11230490 hazard NN B-NP O
29 1454 1459 11230490 ratio NN I-NP O
30 1459 1460 11230490 , , O O
31 1461 1465 11230490 5.04 CD B-NP O
32 1465 1466 11230490 ) ) O O
33 1466 1467 11230490 . . O O

1 1468 1470 11230490 MC NN B-NP O
2 1471 1479 11230490 patients NNS I-NP O
3 1480 1484 11230490 also RB B-ADVP O
4 1485 1496 11230490 experienced VBD B-VP O
5 1497 1501 11230490 less JJR B-NP O
6 1502 1507 11230490 grade NN I-NP O
7 1508 1509 11230490 4 CD I-NP O
8 1510 1521 11230490 neutropenia NN I-NP D009503
9 1521 1522 11230490 . . O O

1 1523 1532 11230490 Antitumor JJ B-NP O
2 1533 1541 11230490 efficacy NN I-NP O
3 1542 1544 11230490 of IN B-PP O
4 1545 1547 11230490 MC NN B-NP O
5 1548 1554 11230490 versus IN B-PP O
6 1555 1557 11230490 AC NN B-NP O
7 1558 1561 11230490 was VBD B-VP O
8 1562 1572 11230490 comparable JJ B-ADJP O
9 1572 1573 11230490 : : O O
10 1574 1583 11230490 objective JJ B-NP O
11 1584 1592 11230490 response NN I-NP O
12 1593 1598 11230490 rates NNS I-NP O
13 1598 1599 11230490 , , O O
14 1600 1603 11230490 43% CD B-NP O
15 1604 1610 11230490 versus CC I-NP O
16 1611 1614 11230490 43% CD I-NP O
17 1614 1615 11230490 ; : O O
18 1616 1622 11230490 median JJ B-NP O
19 1623 1627 11230490 time NN I-NP O
20 1628 1630 11230490 to TO B-PP O
21 1631 1642 11230490 progression NN B-NP O
22 1642 1643 11230490 , , O O
23 1644 1648 11230490 5.1% CD B-NP O
24 1649 1655 11230490 versus IN I-NP O
25 1656 1659 11230490 5.5 CD I-NP O
26 1660 1666 11230490 months NNS I-NP O
27 1666 1667 11230490 ; : O O
28 1668 1674 11230490 median JJ B-NP O
29 1675 1679 11230490 time NN I-NP O
30 1680 1682 11230490 to TO B-PP O
31 1683 1692 11230490 treatment NN B-NP O
32 1693 1700 11230490 failure NN I-NP O
33 1700 1701 11230490 , , O O
34 1702 1705 11230490 4.6 CD B-NP O
35 1706 1712 11230490 versus IN B-PP O
36 1713 1716 11230490 4.4 CD B-NP O
37 1717 1723 11230490 months NNS I-NP O
38 1723 1724 11230490 ; : O O
39 1725 1728 11230490 and CC O O
40 1729 1735 11230490 median JJ B-NP O
41 1736 1744 11230490 survival NN I-NP O
42 1744 1745 11230490 , , O O
43 1746 1748 11230490 19 CD B-NP O
44 1749 1755 11230490 versus IN I-NP O
45 1756 1758 11230490 16 CD I-NP O
46 1759 1765 11230490 months NNS I-NP O
47 1765 1766 11230490 . . O O

1 1767 1777 11230490 CONCLUSION NN B-NP O
2 1777 1778 11230490 : : O O
3 1779 1785 11230490 Myocet NN B-NP D004317
4 1786 1794 11230490 improves VBZ B-VP O
5 1795 1798 11230490 the DT B-NP O
6 1799 1810 11230490 therapeutic JJ I-NP O
7 1811 1816 11230490 index NN I-NP O
8 1817 1819 11230490 of IN B-PP O
9 1820 1831 11230490 doxorubicin NN B-NP D004317
10 1832 1834 11230490 by IN B-PP O
11 1835 1848 11230490 significantly RB B-VP O
12 1849 1857 11230490 reducing VBG I-VP O
13 1858 1872 11230490 cardiotoxicity NN B-NP D066126
14 1873 1876 11230490 and CC O O
15 1877 1882 11230490 grade NN B-NP O
16 1883 1884 11230490 4 CD I-NP O
17 1885 1896 11230490 neutropenia NN I-NP D009503
18 1897 1900 11230490 and CC O O
19 1901 1909 11230490 provides VBZ B-VP O
20 1910 1920 11230490 comparable JJ B-NP O
21 1921 1930 11230490 antitumor JJ I-NP O
22 1931 1939 11230490 efficacy NN I-NP O
23 1939 1940 11230490 , , O O
24 1941 1945 11230490 when WRB B-ADVP O
25 1946 1950 11230490 used VBN B-VP O
26 1951 1953 11230490 in IN B-PP O
27 1954 1965 11230490 combination NN B-NP O
28 1966 1970 11230490 with IN B-PP O
29 1971 1987 11230490 cyclophosphamide NN B-NP D003520
30 1988 1990 11230490 as IN B-PP O
31 1991 1996 11230490 first JJ B-NP O
32 1996 1997 11230490 - HYPH I-NP O
33 1997 2001 11230490 line NN I-NP O
34 2002 2009 11230490 therapy NN I-NP O
35 2010 2013 11230490 for IN B-PP O
36 2014 2017 11230490 MBC NN B-NP D001943
37 2017 2018 11230490 . . O O

1 0 0 17786501 -DOCSTART- -X- -X- O

1 0 10 17786501 Disulfiram NN B-NP D004221
2 10 11 17786501 - HYPH O O
3 11 18 17786501 induced VBN B-NP O
4 19 28 17786501 transient JJ I-NP O
5 29 34 17786501 optic JJ I-NP D009901
6 35 38 17786501 and CC I-NP D009901
7 39 49 17786501 peripheral JJ I-NP D009901
8 50 60 17786501 neuropathy NN I-NP D009901
9 60 61 17786501 : : O O
10 62 63 17786501 a DT B-NP O
11 64 68 17786501 case NN I-NP O
12 69 75 17786501 report NN I-NP O
13 75 76 17786501 . . I-NP O
14 77 80 17786501 AIM NN I-NP O
15 80 81 17786501 : : O O
16 82 84 17786501 To TO B-VP O
17 85 91 17786501 report VB I-VP O
18 92 93 17786501 a DT B-NP O
19 94 98 17786501 case NN I-NP O
20 99 101 17786501 of IN B-PP O
21 102 107 17786501 optic JJ B-NP D009901
22 108 111 17786501 and CC I-NP D009901
23 112 122 17786501 peripheral JJ I-NP D009901
24 123 133 17786501 neuropathy NN I-NP D009901
25 134 139 17786501 after IN B-PP O
26 140 147 17786501 chronic JJ B-NP O
27 148 151 17786501 use NN I-NP O
28 152 154 17786501 of IN B-PP O
29 155 165 17786501 disulfiram NN B-NP D004221
30 166 169 17786501 for IN B-PP O
31 170 177 17786501 alcohol NN B-NP D000437
32 178 188 17786501 dependence NN I-NP D000437
33 189 199 17786501 management NN I-NP O
34 199 200 17786501 . . O O

1 201 210 17786501 MATERIALS NNS B-NP O
2 211 214 17786501 AND CC I-NP O
3 215 222 17786501 METHODS NNS I-NP O
4 222 223 17786501 : : O O
5 224 225 17786501 A DT B-NP O
6 226 230 17786501 case NN I-NP O
7 231 237 17786501 report NN I-NP O
8 237 238 17786501 . . O O

1 239 246 17786501 RESULTS NNS B-NP O
2 246 247 17786501 : : O O
3 248 249 17786501 A DT B-NP O
4 250 252 17786501 57 CD I-NP O
5 252 253 17786501 - HYPH I-NP O
6 253 257 17786501 year NN I-NP O
7 257 258 17786501 - HYPH O O
8 258 261 17786501 old JJ B-NP O
9 262 266 17786501 male JJ I-NP O
10 267 276 17786501 presented VBN B-VP O
11 277 281 17786501 with IN B-PP O
12 282 289 17786501 gradual JJ B-NP O
13 290 294 17786501 loss NN I-NP D014786
14 295 297 17786501 of IN B-PP D014786
15 298 304 17786501 vision NN B-NP D014786
16 305 307 17786501 in IN B-PP O
17 308 312 17786501 both DT B-NP O
18 313 317 17786501 eyes NNS I-NP O
19 318 322 17786501 with IN B-PP O
20 323 335 17786501 intermittent JJ B-NP O
21 336 345 17786501 headaches NNS I-NP D006261
22 346 349 17786501 for IN B-PP O
23 350 351 17786501 2 CD B-NP O
24 352 358 17786501 months NNS I-NP O
25 358 359 17786501 . . O O

1 360 362 17786501 He PRP B-NP O
2 363 367 17786501 also RB B-ADVP O
3 368 378 17786501 complained VBD B-VP O
4 379 381 17786501 of IN B-PP O
5 382 394 17786501 paraesthesia NN B-NP D010292
6 395 399 17786501 with IN B-PP O
7 400 408 17786501 numbness NN B-NP D006987
8 409 411 17786501 in IN B-PP O
9 412 416 17786501 both DT B-NP O
10 417 421 17786501 feet NNS I-NP O
11 421 422 17786501 . . O O

1 423 426 17786501 His PRP$ B-NP O
2 427 433 17786501 vision NN I-NP O
3 434 437 17786501 was VBD B-VP O
4 438 439 17786501 6 CD B-NP O
5 439 440 17786501 / SYM B-NP O
6 440 442 17786501 15 CD I-NP O
7 443 446 17786501 and CC I-NP O
8 447 448 17786501 2 CD I-NP O
9 448 449 17786501 / SYM I-NP O
10 449 451 17786501 60 CD I-NP O
11 452 454 17786501 in IN B-PP O
12 455 458 17786501 the DT B-NP O
13 459 464 17786501 right JJ I-NP O
14 465 468 17786501 and CC I-NP O
15 469 473 17786501 left JJ I-NP O
16 474 478 17786501 eyes NNS I-NP O
17 478 479 17786501 , , O O
18 480 492 17786501 respectively RB B-ADVP O
19 492 493 17786501 . . O O

1 494 504 17786501 Fundoscopy NNP B-NP O
2 505 513 17786501 revealed VBD B-VP O
3 514 525 17786501 bilaterally RB I-VP O
4 526 533 17786501 swollen VBN I-VP O
5 534 539 17786501 optic JJ B-NP O
6 540 545 17786501 nerve NN I-NP O
7 546 551 17786501 heads NNS I-NP O
8 551 552 17786501 . . O O

1 553 559 17786501 Visual JJ B-NP O
2 560 565 17786501 field NN I-NP O
3 566 573 17786501 testing NN I-NP O
4 574 583 17786501 confirmed VBD B-VP O
5 584 593 17786501 bilateral JJ B-NP O
6 594 601 17786501 central JJ I-NP O
7 601 602 17786501 - HYPH I-NP O
8 602 608 17786501 caecal JJ I-NP O
9 609 618 17786501 scotomata NNS I-NP D012607
10 618 619 17786501 . . O O

1 620 622 17786501 He PRP B-NP O
2 623 626 17786501 had VBD B-VP O
3 627 631 17786501 been VBN I-VP O
4 632 638 17786501 taking VBG I-VP O
5 639 649 17786501 disulfiram NN B-NP D004221
6 650 653 17786501 for IN B-PP O
7 654 661 17786501 alcohol NN B-NP D000437
8 662 672 17786501 dependence NN I-NP D000437
9 673 676 17786501 for IN B-PP O
10 677 680 17786501 the DT B-NP O
11 681 690 17786501 preceding VBG I-NP O
12 691 692 17786501 3 CD I-NP O
13 693 698 17786501 years NNS I-NP O
14 698 699 17786501 . . O O

1 700 710 17786501 Disulfiram NN B-NP D004221
2 711 726 17786501 discontinuation NN I-NP O
3 727 731 17786501 lead VBP B-VP O
4 732 734 17786501 to TO B-PP O
5 735 737 17786501 an DT B-NP O
6 738 747 17786501 immediate JJ I-NP O
7 748 759 17786501 symptomatic JJ I-NP O
8 760 771 17786501 improvement NN I-NP O
9 771 772 17786501 . . O O

1 773 783 17786501 CONCLUSION NN B-NP O
2 783 784 17786501 : : O O
3 785 795 17786501 Physicians NNS B-NP O
4 796 806 17786501 initiating VBG B-VP O
5 807 811 17786501 long JJ B-NP O
6 811 812 17786501 - HYPH I-NP O
7 812 816 17786501 term NN I-NP O
8 817 827 17786501 disulfiram NN I-NP D004221
9 828 835 17786501 therapy NN I-NP O
10 836 842 17786501 should MD B-VP O
11 843 845 17786501 be VB I-VP O
12 846 851 17786501 aware JJ B-ADJP O
13 852 854 17786501 of IN B-PP O
14 855 860 17786501 these DT B-NP O
15 861 868 17786501 adverse JJ I-NP O
16 869 876 17786501 effects NNS I-NP O
17 876 877 17786501 . . O O

1 878 882 17786501 They PRP B-NP O
2 883 889 17786501 should MD B-VP O
3 890 899 17786501 recommend VB I-VP O
4 900 906 17786501 annual JJ B-NP O
5 907 917 17786501 ophthalmic JJ I-NP O
6 918 925 17786501 reviews NNS I-NP O
7 926 930 17786501 with IN B-PP O
8 931 937 17786501 visual JJ B-NP O
9 938 943 17786501 field NN I-NP O
10 944 951 17786501 testing NN I-NP O
11 951 952 17786501 . . O O

1 953 961 17786501 Patients NNS B-NP O
2 962 968 17786501 should MD B-VP O
3 969 971 17786501 be VB I-VP O
4 972 981 17786501 reassured VBN I-VP O
5 982 986 17786501 with IN B-PP O
6 987 994 17786501 respect NN B-NP O
7 995 997 17786501 to TO B-PP O
8 998 1001 17786501 the DT B-NP O
9 1002 1015 17786501 reversibility NN I-NP O
10 1016 1018 17786501 of IN B-PP O
11 1019 1024 17786501 these DT B-NP O
12 1025 1032 17786501 adverse JJ I-NP O
13 1033 1040 17786501 effects NNS I-NP O
14 1040 1041 17786501 . . O O

1 0 0 7647582 -DOCSTART- -X- -X- O

1 0 11 7647582 Halogenated VBN B-NP O
2 12 23 7647582 anesthetics NNS I-NP O
3 24 28 7647582 form VBP B-VP O
4 29 34 7647582 liver NN B-NP O
5 35 42 7647582 adducts NNS I-NP O
6 43 46 7647582 and CC I-NP O
7 47 55 7647582 antigens NNS I-NP O
8 56 60 7647582 that IN B-NP O
9 61 66 7647582 cross AFX B-NP O
10 66 67 7647582 - HYPH I-NP O
11 67 72 7647582 react NN I-NP O
12 73 77 7647582 with IN B-PP O
13 78 87 7647582 halothane NN B-NP D006221
14 87 88 7647582 - HYPH B-NP O
15 88 95 7647582 induced VBN I-NP O
16 96 106 7647582 antibodies NNS I-NP O
17 106 107 7647582 . . O O
18 108 111 7647582 Two CD B-NP O
19 112 123 7647582 halogenated VBD B-VP O
20 124 135 7647582 anesthetics NNS B-NP O
21 135 136 7647582 , , O O
22 137 146 7647582 enflurane NN B-NP D004737
23 147 150 7647582 and CC I-NP O
24 151 161 7647582 isoflurane NN I-NP D007530
25 161 162 7647582 , , O O
26 163 167 7647582 have VBP B-VP O
27 168 172 7647582 been VBN I-VP O
28 173 183 7647582 associated VBN I-VP O
29 184 188 7647582 with IN B-PP O
30 189 191 7647582 an DT B-NP O
31 192 200 7647582 allergic JJ I-NP O
32 200 201 7647582 - HYPH I-NP O
33 201 205 7647582 type NN I-NP O
34 206 213 7647582 hepatic JJ I-NP D056486
35 214 220 7647582 injury NN I-NP D056486
36 221 225 7647582 both CC O O
37 226 231 7647582 alone RB B-ADVP O
38 232 235 7647582 and CC O O
39 236 245 7647582 following VBG B-PP O
40 246 254 7647582 previous JJ B-NP O
41 255 263 7647582 exposure NN I-NP O
42 264 266 7647582 to TO B-PP O
43 267 276 7647582 halothane NN B-NP D006221
44 276 277 7647582 . . O O

1 278 287 7647582 Halothane NN B-NP D006221
2 288 297 7647582 hepatitis NN I-NP D056486
3 298 305 7647582 appears VBZ B-VP O
4 306 308 7647582 to TO I-VP O
5 309 316 7647582 involve VB I-VP O
6 317 319 7647582 an DT B-NP O
7 320 328 7647582 aberrant JJ I-NP O
8 329 335 7647582 immune JJ I-NP O
9 336 344 7647582 response NN I-NP O
10 344 345 7647582 . . O O

1 346 348 7647582 An DT B-NP O
2 349 357 7647582 antibody NN I-NP O
3 358 366 7647582 response NN I-NP O
4 367 369 7647582 to TO B-PP O
5 370 371 7647582 a DT B-NP O
6 372 379 7647582 protein NN I-NP O
7 379 380 7647582 - HYPH O O
8 380 385 7647582 bound VBN B-NP O
9 386 403 7647582 biotransformation NN I-NP O
10 404 411 7647582 product NN I-NP O
11 412 413 7647582 ( ( O O
12 413 428 7647582 trifluoroacetyl NN B-NP D014269
13 429 435 7647582 adduct NN I-NP O
14 435 436 7647582 ) ) O O
15 437 440 7647582 has VBZ B-VP O
16 441 445 7647582 been VBN I-VP O
17 446 454 7647582 detected VBN I-VP O
18 455 457 7647582 on IN B-PP O
19 458 467 7647582 halothane NN B-NP D006221
20 468 477 7647582 hepatitis NN I-NP D056486
21 478 486 7647582 patients NNS I-NP O
22 486 487 7647582 . . O O

1 488 492 7647582 This DT B-NP O
2 493 498 7647582 study NN I-NP O
3 499 502 7647582 was VBD B-VP O
4 503 512 7647582 performed VBN I-VP O
5 513 515 7647582 to TO B-VP O
6 516 525 7647582 determine VB I-VP O
7 526 531 7647582 cross AFX B-NP O
8 531 532 7647582 - HYPH I-NP O
9 532 542 7647582 reactivity NN I-NP O
10 543 550 7647582 between IN B-PP O
11 551 560 7647582 enflurane NN B-NP D004737
12 561 564 7647582 and CC I-NP O
13 565 575 7647582 isoflurane NN I-NP D007530
14 576 580 7647582 with IN B-PP O
15 581 584 7647582 the DT B-NP O
16 585 601 7647582 hypersensitivity NN I-NP D004342
17 602 609 7647582 induced VBN B-VP O
18 610 612 7647582 by IN B-PP O
19 613 622 7647582 halothane NN B-NP D006221
20 622 623 7647582 . . O O

1 624 627 7647582 The DT B-NP O
2 628 639 7647582 subcellular JJ I-NP O
3 640 643 7647582 and CC I-NP O
4 644 651 7647582 lobular JJ I-NP O
5 652 662 7647582 production NN I-NP O
6 663 665 7647582 of IN B-PP O
7 666 673 7647582 hepatic JJ B-NP O
8 674 685 7647582 neoantigens NNS I-NP O
9 686 696 7647582 recognized VBN B-VP O
10 697 699 7647582 by IN B-PP O
11 700 709 7647582 halothane NN B-NP D006221
12 709 710 7647582 - HYPH B-NP O
13 710 717 7647582 induced VBN I-NP O
14 718 728 7647582 antibodies NNS I-NP O
15 729 738 7647582 following VBG B-PP O
16 739 748 7647582 enflurane NN B-NP D004737
17 749 752 7647582 and CC I-NP O
18 753 763 7647582 isoflurane NN I-NP D007530
19 763 764 7647582 , , O O
20 765 768 7647582 and CC O O
21 769 772 7647582 the DT B-NP O
22 773 784 7647582 biochemical JJ I-NP O
23 785 791 7647582 nature NN I-NP O
24 792 794 7647582 of IN B-PP O
25 795 800 7647582 these DT B-NP O
26 801 812 7647582 neoantigens NNS I-NP O
27 813 816 7647582 was VBD B-VP O
28 817 829 7647582 investigated VBN I-VP O
29 830 832 7647582 in IN B-PP O
30 833 836 7647582 two CD B-NP O
31 837 843 7647582 animal NN I-NP O
32 844 850 7647582 models NNS I-NP O
33 850 851 7647582 . . O O

1 852 861 7647582 Enflurane NN B-NP D004737
2 862 876 7647582 administration NN I-NP O
3 877 885 7647582 resulted VBD B-VP O
4 886 888 7647582 in IN B-PP O
5 889 900 7647582 neoantigens NNS B-NP O
6 901 909 7647582 detected VBN B-VP O
7 910 912 7647582 in IN B-PP O
8 913 917 7647582 both CC B-NP O
9 918 921 7647582 the DT I-NP O
10 922 932 7647582 microsomal JJ I-NP O
11 933 936 7647582 and CC I-NP O
12 937 946 7647582 cytosolic JJ I-NP O
13 947 955 7647582 fraction NN I-NP O
14 956 958 7647582 of IN B-PP O
15 959 964 7647582 liver NN B-NP O
16 965 976 7647582 homogenates NNS I-NP O
17 977 980 7647582 and CC B-PP O
18 981 983 7647582 in IN B-PP O
19 984 987 7647582 the DT B-NP O
20 988 1001 7647582 centrilobular JJ I-NP O
21 1002 1008 7647582 region NN I-NP O
22 1009 1011 7647582 of IN B-PP O
23 1012 1015 7647582 the DT B-NP O
24 1016 1021 7647582 liver NN I-NP O
25 1021 1022 7647582 . . O O

1 1023 1025 7647582 In IN B-PP O
2 1026 1029 7647582 the DT B-NP O
3 1030 1034 7647582 same JJ I-NP O
4 1035 1040 7647582 liver NN I-NP O
5 1040 1041 7647582 , , O O
6 1042 1053 7647582 biochemical JJ B-NP O
7 1054 1062 7647582 analysis NN I-NP O
8 1063 1071 7647582 detected VBD B-VP O
9 1072 1083 7647582 fluorinated VBN I-VP O
10 1084 1089 7647582 liver NN B-NP O
11 1090 1097 7647582 adducts NNS I-NP O
12 1098 1102 7647582 that WDT B-NP O
13 1103 1107 7647582 were VBD B-VP O
14 1108 1110 7647582 up RB B-NP O
15 1111 1113 7647582 to TO I-NP O
16 1114 1116 7647582 20 CD I-NP O
17 1116 1117 7647582 - HYPH O O
18 1117 1121 7647582 fold RB B-ADJP O
19 1122 1129 7647582 greater JJR I-ADJP O
20 1130 1132 7647582 in IN B-PP O
21 1133 1139 7647582 guinea NN B-NP O
22 1140 1144 7647582 pigs NNS I-NP O
23 1145 1149 7647582 than IN B-PP O
24 1150 1152 7647582 in IN B-PP O
25 1153 1157 7647582 rats NNS B-NP O
26 1157 1158 7647582 . . O O

1 1159 1163 7647582 This DT B-NP O
2 1164 1172 7647582 supports VBZ B-VP O
3 1173 1176 7647582 and CC I-VP O
4 1177 1184 7647582 extends VBZ I-VP O
5 1185 1193 7647582 previous JJ B-NP O
6 1194 1202 7647582 evidence NN I-NP O
7 1203 1206 7647582 for IN B-PP O
8 1207 1208 7647582 a DT B-NP O
9 1209 1218 7647582 mechanism NN I-NP O
10 1219 1221 7647582 by IN B-PP O
11 1222 1227 7647582 which WDT B-NP O
12 1228 1237 7647582 enflurane NN B-NP D004737
13 1238 1241 7647582 and CC O O
14 1241 1242 7647582 / SYM B-NP O
15 1242 1244 7647582 or CC O O
16 1245 1255 7647582 isoflurane NN B-NP D007530
17 1256 1261 7647582 could MD B-VP O
18 1262 1269 7647582 produce VB I-VP O
19 1270 1271 7647582 a DT B-NP O
20 1272 1288 7647582 hypersensitivity NN I-NP D004342
21 1289 1298 7647582 condition NN I-NP O
22 1299 1306 7647582 similar JJ B-ADJP O
23 1307 1309 7647582 to TO B-PP O
24 1310 1314 7647582 that DT B-NP O
25 1315 1317 7647582 of IN B-PP O
26 1318 1327 7647582 halothane NN B-NP D006221
27 1328 1337 7647582 hepatitis NN I-NP D056486
28 1338 1344 7647582 either CC O O
29 1345 1350 7647582 alone RB B-ADVP O
30 1351 1353 7647582 or CC O O
31 1354 1364 7647582 subsequent JJ B-ADJP O
32 1365 1367 7647582 to TO B-PP O
33 1368 1377 7647582 halothane NN B-NP D006221
34 1378 1392 7647582 administration NN I-NP O
35 1392 1393 7647582 . . O O

1 1394 1397 7647582 The DT B-NP O
2 1398 1404 7647582 guinea NN I-NP O
3 1405 1408 7647582 pig NN I-NP O
4 1409 1414 7647582 would MD B-VP O
5 1415 1421 7647582 appear VB I-VP O
6 1422 1424 7647582 to TO I-VP O
7 1425 1427 7647582 be VB I-VP O
8 1428 1429 7647582 a DT B-NP O
9 1430 1436 7647582 useful JJ I-NP O
10 1437 1442 7647582 model NN I-NP O
11 1443 1446 7647582 for IN B-PP O
12 1447 1454 7647582 further JJ B-NP O
13 1455 1469 7647582 investigations NNS I-NP O
14 1470 1472 7647582 of IN B-PP O
15 1473 1476 7647582 the DT B-NP O
16 1477 1490 7647582 immunological JJ I-NP O
17 1491 1499 7647582 response NN I-NP O
18 1500 1502 7647582 to TO B-PP O
19 1503 1508 7647582 these DT B-NP O
20 1509 1517 7647582 antigens NNS I-NP O
21 1517 1518 7647582 . . O O

1 0 0 14975762 -DOCSTART- -X- -X- O

1 0 10 14975762 Expression NN B-NP O
2 11 13 14975762 of IN B-PP O
3 14 18 14975762 p300 NN B-NP O
4 19 27 14975762 protects VBZ B-VP O
5 28 35 14975762 cardiac JJ B-NP O
6 36 44 14975762 myocytes NNS I-NP O
7 45 49 14975762 from IN B-PP O
8 50 59 14975762 apoptosis NN B-NP O
9 60 62 14975762 in FW B-ADVP O
10 63 67 14975762 vivo FW I-ADVP O
11 67 68 14975762 . . B-NP O
12 69 80 14975762 Doxorubicin NN I-NP D004317
13 81 83 14975762 is VBZ B-VP O
14 84 86 14975762 an DT B-NP O
15 87 91 14975762 anti AFX I-NP O
16 91 92 14975762 - HYPH I-NP O
17 92 97 14975762 tumor NN I-NP D009369
18 98 103 14975762 agent NN I-NP O
19 104 108 14975762 that WDT B-NP O
20 109 118 14975762 represses VBZ B-VP O
21 119 126 14975762 cardiac JJ B-NP O
22 126 127 14975762 - HYPH I-NP O
23 127 135 14975762 specific JJ I-NP O
24 136 140 14975762 gene NN I-NP O
25 141 151 14975762 expression NN I-NP O
26 152 155 14975762 and CC O O
27 156 163 14975762 induces VBZ B-VP O
28 164 174 14975762 myocardial JJ B-NP O
29 175 179 14975762 cell NN I-NP O
30 180 189 14975762 apoptosis NN I-NP O
31 189 190 14975762 . . O O

1 191 202 14975762 Doxorubicin NN B-NP D004317
2 203 211 14975762 depletes VBZ B-VP O
3 212 219 14975762 cardiac JJ B-NP O
4 220 224 14975762 p300 NN I-NP O
5 224 225 14975762 , , O O
6 226 227 14975762 a DT B-NP O
7 228 243 14975762 transcriptional JJ I-NP O
8 244 255 14975762 coactivator NN I-NP O
9 256 260 14975762 that WDT B-NP O
10 261 263 14975762 is VBZ B-VP O
11 264 272 14975762 required VBN I-VP O
12 273 276 14975762 for IN B-PP O
13 277 280 14975762 the DT B-NP O
14 281 292 14975762 maintenance NN I-NP O
15 293 295 14975762 of IN B-PP O
16 296 299 14975762 the DT B-NP O
17 300 314 14975762 differentiated VBN I-NP O
18 315 324 14975762 phenotype NN I-NP O
19 325 327 14975762 of IN B-PP O
20 328 335 14975762 cardiac JJ B-NP O
21 336 344 14975762 myocytes NNS I-NP O
22 344 345 14975762 . . O O

1 346 353 14975762 However RB B-ADVP O
2 353 354 14975762 , , O O
3 355 358 14975762 the DT B-NP O
4 359 363 14975762 role NN I-NP O
5 364 366 14975762 of IN B-PP O
6 367 371 14975762 p300 NN B-NP O
7 372 374 14975762 in IN B-PP O
8 375 385 14975762 protection NN B-NP O
9 386 393 14975762 against IN B-PP O
10 394 405 14975762 doxorubicin NN B-NP D004317
11 405 406 14975762 - HYPH B-NP O
12 406 413 14975762 induced VBN I-NP O
13 414 423 14975762 apoptosis NN I-NP O
14 424 426 14975762 is VBZ B-VP O
15 427 434 14975762 unknown JJ B-ADJP O
16 434 435 14975762 . . O O

1 436 446 14975762 Transgenic JJ B-NP O
2 447 451 14975762 mice NNS I-NP O
3 452 466 14975762 overexpressing VBG B-VP O
4 467 471 14975762 p300 NN B-NP O
5 472 474 14975762 in IN B-PP O
6 475 478 14975762 the DT B-NP O
7 479 484 14975762 heart NN I-NP O
8 485 488 14975762 and CC I-NP O
9 489 493 14975762 wild JJ I-NP O
10 493 494 14975762 - HYPH I-NP O
11 494 498 14975762 type NN I-NP O
12 499 503 14975762 mice NNS I-NP O
13 504 508 14975762 were VBD B-VP O
14 509 518 14975762 subjected VBN I-VP O
15 519 521 14975762 to TO B-PP O
16 522 533 14975762 doxorubicin NN B-NP D004317
17 534 543 14975762 treatment NN I-NP O
18 543 544 14975762 . . O O

1 545 553 14975762 Compared VBN B-PP O
2 554 558 14975762 with IN B-PP O
3 559 563 14975762 wild JJ B-NP O
4 563 564 14975762 - HYPH I-NP O
5 564 568 14975762 type NN I-NP O
6 569 573 14975762 mice NNS I-NP O
7 573 574 14975762 , , O O
8 575 585 14975762 transgenic JJ B-NP O
9 586 590 14975762 mice NNS I-NP O
10 591 600 14975762 exhibited VBD B-VP O
11 601 607 14975762 higher JJR B-NP O
12 608 616 14975762 survival NN I-NP O
13 617 621 14975762 rate NN I-NP O
14 622 624 14975762 as RB B-CONJP O
15 625 629 14975762 well RB I-CONJP O
16 630 632 14975762 as IN I-CONJP O
17 633 637 14975762 more JJR B-NP O
18 638 647 14975762 preserved VBN I-NP O
19 648 652 14975762 left JJ I-NP O
20 653 664 14975762 ventricular JJ I-NP O
21 665 673 14975762 function NN I-NP O
22 674 677 14975762 and CC O O
23 678 685 14975762 cardiac JJ B-NP O
24 686 696 14975762 expression NN I-NP O
25 697 699 14975762 of IN B-PP O
26 700 705 14975762 alpha SYM B-NP O
27 705 706 14975762 - HYPH B-NP O
28 706 716 14975762 sarcomeric JJ I-NP O
29 717 722 14975762 actin NN I-NP O
30 722 723 14975762 . . O O

1 724 735 14975762 Doxorubicin NN B-NP D004317
2 736 743 14975762 induced VBD B-VP O
3 744 754 14975762 myocardial JJ B-NP O
4 755 759 14975762 cell NN I-NP O
5 760 769 14975762 apoptosis NN I-NP O
6 770 772 14975762 in IN B-PP O
7 773 777 14975762 wild JJ B-NP O
8 777 778 14975762 - HYPH I-NP O
9 778 782 14975762 type NN I-NP O
10 783 787 14975762 mice NNS I-NP O
11 788 791 14975762 but CC B-PP O
12 792 795 14975762 not RB B-PP O
13 796 798 14975762 in IN I-PP O
14 799 809 14975762 transgenic JJ B-NP O
15 810 814 14975762 mice NNS I-NP O
16 814 815 14975762 . . O O

1 816 826 14975762 Expression NN B-NP O
2 827 829 14975762 of IN B-PP O
3 830 834 14975762 p300 NN B-NP O
4 835 844 14975762 increased VBD B-VP O
5 845 848 14975762 the DT B-NP O
6 849 856 14975762 cardiac JJ I-NP O
7 857 862 14975762 level NN I-NP O
8 863 865 14975762 of IN B-PP O
9 866 869 14975762 bcl NN B-NP O
10 869 870 14975762 - HYPH B-NP O
11 870 871 14975762 2 CD I-NP O
12 872 875 14975762 and CC I-NP O
13 876 879 14975762 mdm NN I-NP O
14 879 880 14975762 - HYPH O O
15 880 881 14975762 2 CD B-NP O
16 881 882 14975762 , , O O
17 883 886 14975762 but CC B-CONJP O
18 887 890 14975762 not RB I-CONJP O
19 891 895 14975762 that DT B-NP O
20 896 898 14975762 of IN B-PP O
21 899 902 14975762 p53 NN B-NP O
22 903 905 14975762 or CC O O
23 906 911 14975762 other JJ B-NP O
24 912 919 14975762 members NNS I-NP O
25 920 922 14975762 of IN B-PP O
26 923 926 14975762 the DT B-NP O
27 927 930 14975762 bcl NN I-NP O
28 930 931 14975762 - HYPH B-NP O
29 931 932 14975762 2 CD I-NP O
30 933 939 14975762 family NN I-NP O
31 939 940 14975762 . . O O

1 941 946 14975762 These DT B-NP O
2 947 955 14975762 findings NNS I-NP O
3 956 967 14975762 demonstrate VBP B-VP O
4 968 972 14975762 that IN B-SBAR O
5 973 987 14975762 overexpression NN B-NP O
6 988 990 14975762 of IN B-PP O
7 991 995 14975762 p300 NN B-NP O
8 996 1004 14975762 protects VBZ B-VP O
9 1005 1012 14975762 cardiac JJ B-NP O
10 1013 1021 14975762 myocytes NNS I-NP O
11 1022 1026 14975762 from IN B-PP O
12 1027 1038 14975762 doxorubicin NN B-NP D004317
13 1038 1039 14975762 - HYPH B-NP O
14 1039 1046 14975762 induced VBN I-NP O
15 1047 1056 14975762 apoptosis NN I-NP O
16 1057 1060 14975762 and CC O O
17 1061 1068 14975762 reduces VBZ B-VP O
18 1069 1072 14975762 the DT B-NP O
19 1073 1079 14975762 extent NN I-NP O
20 1080 1082 14975762 of IN B-PP O
21 1083 1088 14975762 acute JJ B-NP O
22 1089 1094 14975762 heart NN I-NP D006333
23 1095 1102 14975762 failure NN I-NP D006333
24 1103 1105 14975762 in IN B-PP O
25 1106 1111 14975762 adult JJ B-NP O
26 1112 1116 14975762 mice NNS I-NP O
27 1117 1119 14975762 in FW B-ADVP O
28 1120 1124 14975762 vivo FW I-ADVP O
29 1124 1125 14975762 . . O O

1 0 0 18541230 -DOCSTART- -X- -X- O

1 0 10 18541230 Protective JJ B-NP O
2 11 18 18541230 effects NNS I-NP O
3 19 21 18541230 of IN B-PP O
4 22 34 18541230 antithrombin NN B-NP O
5 35 37 18541230 on IN B-PP O
6 38 47 18541230 puromycin NN B-NP D011692
7 48 63 18541230 aminonucleoside NN I-NP D011692
8 64 73 18541230 nephrosis NN I-NP D009401
9 74 76 18541230 in IN B-PP O
10 77 81 18541230 rats NNS B-NP O
11 81 82 18541230 . . O O
12 83 85 18541230 We PRP B-NP O
13 86 98 18541230 investigated VBD B-VP O
14 99 102 18541230 the DT B-NP O
15 103 110 18541230 effects NNS I-NP O
16 111 113 18541230 of IN B-PP O
17 114 126 18541230 antithrombin NN B-NP O
18 126 127 18541230 , , O O
19 128 129 18541230 a DT B-NP O
20 130 136 18541230 plasma NN I-NP O
21 137 146 18541230 inhibitor NN I-NP O
22 147 149 18541230 of IN B-PP O
23 150 161 18541230 coagulation NN B-NP O
24 162 169 18541230 factors NNS I-NP O
25 169 170 18541230 , , O O
26 171 173 18541230 in IN B-PP O
27 174 178 18541230 rats NNS B-NP O
28 179 183 18541230 with IN B-PP O
29 184 193 18541230 puromycin NN B-NP D011692
30 194 209 18541230 aminonucleoside NN I-NP D011692
31 209 210 18541230 - HYPH B-NP O
32 210 217 18541230 induced VBN I-NP O
33 218 227 18541230 nephrosis NN I-NP D009401
34 227 228 18541230 , , O O
35 229 234 18541230 which WDT B-NP O
36 235 237 18541230 is VBZ B-VP O
37 238 240 18541230 an DT B-NP O
38 241 253 18541230 experimental JJ I-NP O
39 254 259 18541230 model NN I-NP O
40 260 262 18541230 of IN B-PP O
41 263 268 18541230 human JJ B-NP O
42 269 278 18541230 nephrotic JJ I-NP D009404
43 279 287 18541230 syndrome NN I-NP D009404
44 287 288 18541230 . . O O

1 289 301 18541230 Antithrombin NN B-NP O
2 302 303 18541230 ( ( O O
3 303 305 18541230 50 CD B-NP O
4 306 308 18541230 or CC I-NP O
5 309 312 18541230 500 CD I-NP O
6 313 315 18541230 IU NN I-NP O
7 315 316 18541230 / SYM B-NP O
8 316 318 18541230 kg NN I-NP O
9 318 319 18541230 / SYM I-NP O
10 319 322 18541230 i.v NN I-NP O
11 322 323 18541230 . . O O
12 323 324 18541230 ) ) O O
13 325 328 18541230 was VBD B-VP O
14 329 341 18541230 administered VBN I-VP O
15 342 344 18541230 to TO B-PP O
16 345 349 18541230 rats NNS B-NP O
17 350 354 18541230 once IN B-SBAR O
18 355 356 18541230 a DT B-NP O
19 357 360 18541230 day NN I-NP O
20 361 364 18541230 for IN B-PP O
21 365 367 18541230 10 CD B-NP O
22 368 372 18541230 days NNS I-NP O
23 373 384 18541230 immediately RB B-ADVP O
24 385 390 18541230 after IN B-PP O
25 391 394 18541230 the DT B-NP O
26 395 404 18541230 injection NN I-NP O
27 405 407 18541230 of IN B-PP O
28 408 417 18541230 puromycin NN B-NP D011692
29 418 433 18541230 aminonucleoside NN I-NP D011692
30 434 435 18541230 ( ( O O
31 435 437 18541230 50 CD B-NP O
32 438 440 18541230 mg NN I-NP O
33 440 441 18541230 / SYM B-NP O
34 441 443 18541230 kg NN I-NP O
35 443 444 18541230 / SYM B-NP O
36 444 447 18541230 i.v NN I-NP O
37 447 448 18541230 . . O O
38 448 449 18541230 ) ) O O
39 449 450 18541230 . . O O

1 451 460 18541230 Treatment NN B-NP O
2 461 465 18541230 with IN B-PP O
3 466 478 18541230 antithrombin NN B-NP O
4 479 489 18541230 attenuated VBD B-VP O
5 490 493 18541230 the DT B-NP O
6 494 503 18541230 puromycin NN I-NP D011692
7 504 519 18541230 aminonucleoside NN I-NP D011692
8 519 520 18541230 - HYPH O O
9 520 527 18541230 induced VBN B-NP O
10 528 541 18541230 hematological JJ I-NP D006402
11 542 555 18541230 abnormalities NNS I-NP D006402
12 555 556 18541230 . . O O

1 557 566 18541230 Puromycin NN B-NP D011692
2 567 582 18541230 aminonucleoside NN I-NP D011692
3 582 583 18541230 - HYPH O O
4 583 590 18541230 induced VBN B-NP O
5 591 596 18541230 renal JJ I-NP D007674
6 597 608 18541230 dysfunction NN I-NP D007674
7 609 612 18541230 and CC I-NP O
8 613 627 18541230 hyperlipidemia NN I-NP D006949
9 628 632 18541230 were VBD B-VP O
10 633 637 18541230 also RB I-VP O
11 638 648 18541230 suppressed VBN I-VP O
12 648 649 18541230 . . O O

1 650 667 18541230 Histopathological JJ B-NP O
2 668 679 18541230 examination NN I-NP O
3 680 688 18541230 revealed VBD B-VP O
4 689 695 18541230 severe JJ B-NP O
5 696 701 18541230 renal JJ I-NP D007674
6 702 708 18541230 damage NN I-NP D007674
7 709 713 18541230 such JJ B-PP O
8 714 716 18541230 as IN I-PP O
9 717 730 18541230 proteinaceous JJ B-NP O
10 731 736 18541230 casts NNS I-NP O
11 737 739 18541230 in IN B-PP O
12 740 746 18541230 tubuli NNS B-NP O
13 747 750 18541230 and CC O O
14 751 758 18541230 tubular JJ B-NP O
15 759 768 18541230 expansion NN I-NP O
16 769 771 18541230 in IN B-PP O
17 772 775 18541230 the DT B-NP O
18 776 782 18541230 kidney NN I-NP O
19 783 785 18541230 of IN B-PP O
20 786 793 18541230 control NN B-NP O
21 794 798 18541230 rats NNS I-NP O
22 798 799 18541230 , , O O
23 800 805 18541230 while IN B-SBAR O
24 806 808 18541230 an DT B-NP O
25 809 820 18541230 improvement NN I-NP O
26 821 823 18541230 of IN B-PP O
27 824 827 18541230 the DT B-NP O
28 828 834 18541230 damage NN I-NP O
29 835 838 18541230 was VBD B-VP O
30 839 843 18541230 seen VBN I-VP O
31 844 846 18541230 in IN B-PP O
32 847 859 18541230 antithrombin NN B-NP O
33 859 860 18541230 - HYPH B-NP O
34 860 867 18541230 treated VBN I-NP O
35 868 872 18541230 rats NNS I-NP O
36 872 873 18541230 . . O O

1 874 876 18541230 In IN B-PP O
2 877 885 18541230 addition NN B-NP O
3 885 886 18541230 , , O O
4 887 899 18541230 antithrombin NN B-NP O
5 900 909 18541230 treatment NN I-NP O
6 910 918 18541230 markedly RB B-ADVP O
7 919 929 18541230 suppressed VBD B-VP O
8 930 939 18541230 puromycin NN B-NP D011692
9 940 955 18541230 aminonucleoside NN I-NP D011692
10 955 956 18541230 - HYPH B-NP O
11 956 963 18541230 induced VBN I-NP O
12 964 973 18541230 apoptosis NN I-NP O
13 974 976 18541230 of IN B-PP O
14 977 982 18541230 renal JJ B-NP O
15 983 990 18541230 tubular JJ I-NP O
16 991 1001 18541230 epithelial JJ I-NP O
17 1002 1007 18541230 cells NNS I-NP O
18 1007 1008 18541230 . . O O

1 1009 1020 18541230 Furthermore RB B-ADVP O
2 1020 1021 18541230 , , O O
3 1022 1031 18541230 puromycin NN B-NP D011692
4 1032 1047 18541230 aminonucleoside NN I-NP D011692
5 1047 1048 18541230 - HYPH B-NP O
6 1048 1055 18541230 induced VBN I-NP O
7 1056 1065 18541230 increases NNS I-NP O
8 1066 1068 18541230 in IN B-PP O
9 1069 1074 18541230 renal JJ B-NP O
10 1075 1083 18541230 cytokine NN I-NP O
11 1084 1091 18541230 content NN I-NP O
12 1092 1096 18541230 were VBD B-VP O
13 1097 1101 18541230 also RB I-VP O
14 1102 1111 18541230 decreased VBN I-VP O
15 1111 1112 18541230 . . O O

1 1113 1118 18541230 These DT B-NP O
2 1119 1127 18541230 findings NNS I-NP O
3 1128 1135 18541230 suggest VBP B-VP O
4 1136 1140 18541230 that IN B-SBAR O
5 1141 1149 18541230 thrombin NN B-NP O
6 1150 1155 18541230 plays VBZ B-VP O
7 1156 1158 18541230 an DT B-NP O
8 1159 1168 18541230 important JJ I-NP O
9 1169 1173 18541230 role NN I-NP O
10 1174 1176 18541230 in IN B-PP O
11 1177 1180 18541230 the DT B-NP O
12 1181 1193 18541230 pathogenesis NN I-NP O
13 1194 1196 18541230 of IN B-PP O
14 1197 1206 18541230 puromycin NN B-NP D011692
15 1207 1222 18541230 aminonucleoside NN I-NP D011692
16 1222 1223 18541230 - HYPH O O
17 1223 1230 18541230 induced VBN B-NP O
18 1231 1240 18541230 nephrotic JJ I-NP D009404
19 1241 1249 18541230 syndrome NN I-NP D009404
20 1249 1250 18541230 . . O O

1 1251 1260 18541230 Treatment NN B-NP O
2 1261 1265 18541230 with IN B-PP O
3 1266 1278 18541230 antithrombin NN B-NP O
4 1279 1282 18541230 may MD B-VP O
5 1283 1285 18541230 be VB I-VP O
6 1286 1296 18541230 clinically RB B-ADJP O
7 1297 1306 18541230 effective JJ I-ADJP O
8 1307 1309 18541230 in IN B-PP O
9 1310 1318 18541230 patients NNS B-NP O
10 1319 1323 18541230 with IN B-PP O
11 1324 1333 18541230 nephrotic JJ B-NP D009404
12 1334 1342 18541230 syndrome NN I-NP D009404
13 1342 1343 18541230 . . O O

1 0 0 12013711 -DOCSTART- -X- -X- O

1 0 11 12013711 Risperidone NN B-NP D018967
2 11 12 12013711 - HYPH O O
3 12 22 12013711 associated VBN B-VP O
4 22 23 12013711 , , O O
5 24 30 12013711 benign JJ B-NP O
6 31 40 12013711 transient JJ I-NP O
7 41 47 12013711 visual JJ I-NP D010468
8 48 60 12013711 disturbances NNS I-NP D010468
9 61 63 12013711 in IN B-PP O
10 64 77 12013711 schizophrenic JJ B-NP D012559
11 78 86 12013711 patients NNS I-NP O
12 87 91 12013711 with IN B-PP O
13 92 93 12013711 a DT B-NP O
14 94 98 12013711 past JJ I-NP O
15 99 106 12013711 history NN I-NP O
16 107 109 12013711 of IN B-PP O
17 110 113 12013711 LSD NN B-NP D008238
18 114 119 12013711 abuse NN I-NP O
19 119 120 12013711 . . O O
20 121 124 12013711 Two CD B-NP O
21 125 138 12013711 schizophrenic JJ I-NP D012559
22 139 147 12013711 patients NNS I-NP O
23 147 148 12013711 , , O O
24 149 152 12013711 who WP B-NP O
25 153 156 12013711 had VBD B-VP O
26 157 158 12013711 a DT B-NP O
27 159 164 12013711 prior JJ I-NP O
28 165 172 12013711 history NN I-NP O
29 173 175 12013711 of IN B-PP O
30 176 179 12013711 LSD NN B-NP D008238
31 180 185 12013711 abuse NN I-NP O
32 186 189 12013711 and CC O O
33 190 193 12013711 who WP B-NP O
34 194 197 12013711 had VBD B-VP O
35 198 208 12013711 previously RB I-VP O
36 209 218 12013711 developed VBN I-VP O
37 219 222 12013711 EPS NN B-NP D001480
38 223 227 12013711 with IN B-PP O
39 228 235 12013711 classic JJ B-NP O
40 236 250 12013711 antipsychotics NNS I-NP O
41 250 251 12013711 , , O O
42 252 256 12013711 were VBD B-VP O
43 257 269 12013711 successfully RB I-VP O
44 270 277 12013711 treated VBN I-VP O
45 278 282 12013711 with IN B-PP O
46 283 294 12013711 risperidone NN B-NP D018967
47 294 295 12013711 . . O O

1 296 300 12013711 They PRP B-NP O
2 301 305 12013711 both DT O O
3 306 314 12013711 reported VBD B-VP O
4 315 320 12013711 short JJ B-NP O
5 321 329 12013711 episodes NNS I-NP O
6 330 332 12013711 of IN B-PP O
7 333 342 12013711 transient JJ B-NP O
8 343 349 12013711 visual JJ I-NP D010468
9 350 362 12013711 disturbances NNS I-NP D010468
10 362 363 12013711 , , O O
11 364 369 12013711 which WDT B-NP O
12 370 378 12013711 appeared VBD B-VP O
13 379 390 12013711 immediately RB B-ADVP O
14 391 396 12013711 after IN B-PP O
15 397 405 12013711 starting VBG B-VP O
16 406 415 12013711 treatment NN B-NP O
17 416 420 12013711 with IN B-PP O
18 421 432 12013711 risperidone NN B-NP D018967
19 432 433 12013711 . . O O

1 434 438 12013711 This DT B-NP O
2 439 446 12013711 imagery NN I-NP O
3 447 456 12013711 resembled VBD B-VP O
4 457 463 12013711 visual JJ B-NP D010468
5 464 476 12013711 disturbances NNS I-NP D010468
6 477 487 12013711 previously RB B-ADVP O
7 488 499 12013711 experienced VBD B-VP O
8 500 502 12013711 as IN B-PP O
9 503 504 12013711 " `` O O
10 504 514 12013711 flashbacks NNS B-NP O
11 514 515 12013711 " '' O O
12 516 523 12013711 related JJ B-ADJP O
13 524 526 12013711 to TO B-PP O
14 527 532 12013711 prior JJ B-NP O
15 533 536 12013711 LSD NN I-NP D008238
16 537 548 12013711 consumption NN I-NP O
17 548 549 12013711 . . O O

1 550 561 12013711 Risperidone NN B-NP D018967
2 562 576 12013711 administration NN I-NP O
3 577 580 12013711 was VBD B-VP O
4 581 590 12013711 continued VBN I-VP O
5 591 594 12013711 and CC O O
6 595 598 12013711 the DT B-NP O
7 599 605 12013711 visual JJ I-NP D010468
8 606 618 12013711 disturbances NNS I-NP D010468
9 619 628 12013711 gradually RB B-ADVP O
10 629 633 12013711 wore VBD B-VP O
11 634 637 12013711 off RP B-PRT O
12 637 638 12013711 . . O O

1 639 645 12013711 During IN B-PP O
2 646 647 12013711 a DT B-NP O
3 648 651 12013711 six CD I-NP O
4 651 652 12013711 - HYPH I-NP O
5 652 657 12013711 month NN I-NP O
6 658 664 12013711 follow VB B-VP O
7 664 665 12013711 - HYPH O O
8 665 667 12013711 up RP B-PRT O
9 668 674 12013711 period NN B-NP O
10 674 675 12013711 , , O O
11 676 681 12013711 there EX B-NP O
12 682 685 12013711 was VBD B-VP O
13 686 688 12013711 no DT B-NP O
14 689 699 12013711 recurrence NN I-NP O
15 700 702 12013711 of IN B-PP O
16 703 709 12013711 visual JJ B-NP D010468
17 710 722 12013711 disturbances NNS I-NP D010468
18 722 723 12013711 . . O O

1 724 728 12013711 This DT B-NP O
2 729 739 12013711 phenomenon NN I-NP O
3 740 743 12013711 may MD B-VP O
4 744 746 12013711 be VB I-VP O
5 747 758 12013711 interpreted VBN I-VP O
6 759 761 12013711 as IN B-PP O
7 762 763 12013711 a DT B-NP O
8 764 770 12013711 benign JJ I-NP O
9 770 771 12013711 , , I-NP O
10 772 777 12013711 short JJ I-NP O
11 777 778 12013711 - HYPH I-NP O
12 778 782 12013711 term NN I-NP O
13 783 786 12013711 and CC I-NP O
14 787 791 12013711 self NN I-NP O
15 791 792 12013711 - HYPH O O
16 792 800 12013711 limiting VBG B-VP O
17 801 805 12013711 side NN B-NP O
18 806 812 12013711 effect NN I-NP O
19 813 818 12013711 which WDT B-NP O
20 819 823 12013711 does VBZ B-VP O
21 824 827 12013711 not RB I-VP O
22 828 842 12013711 contraindicate VB I-VP O
23 843 846 12013711 the DT B-NP O
24 847 850 12013711 use NN I-NP O
25 851 853 12013711 of IN B-PP O
26 854 865 12013711 risperidone NN B-NP D018967
27 866 868 12013711 or CC O O
28 869 878 12013711 interfere VB B-VP O
29 879 883 12013711 with IN B-PP O
30 884 893 12013711 treatment NN B-NP O
31 893 894 12013711 . . O O

1 895 906 12013711 Conclusions NNS B-NP O
2 907 912 12013711 based VBN B-PP O
3 913 915 12013711 on IN B-PP O
4 916 919 12013711 two CD B-NP O
5 920 924 12013711 case NN I-NP O
6 925 932 12013711 reports NNS I-NP O
7 933 939 12013711 should MD B-VP O
8 940 942 12013711 be VB I-VP O
9 943 948 12013711 taken VBN I-VP O
10 949 953 12013711 with IN B-PP O
11 954 965 12013711 appropriate JJ B-NP O
12 966 973 12013711 caution NN I-NP O
13 973 974 12013711 . . O O

1 0 0 8958188 -DOCSTART- -X- -X- O

1 0 1 8958188 A DT B-NP O
2 2 7 8958188 phase NN I-NP O
3 8 9 8958188 I CD I-NP O
4 10 18 8958188 clinical JJ I-NP O
5 19 24 8958188 study NN I-NP O
6 25 27 8958188 of IN B-PP O
7 28 31 8958188 the DT B-NP O
8 32 42 8958188 antipurine JJ I-NP D000983
9 43 53 8958188 antifolate JJ I-NP O
10 54 64 8958188 lometrexol NN I-NP C045894
11 65 66 8958188 ( ( O O
12 66 72 8958188 DDATHF NN B-NP C045894
13 72 73 8958188 ) ) O O
14 74 79 8958188 given VBN B-PP O
15 80 84 8958188 with IN B-PP O
16 85 89 8958188 oral JJ B-NP O
17 90 95 8958188 folic JJ I-NP D005492
18 96 100 8958188 acid NN I-NP D005492
19 100 101 8958188 . . O O
20 102 112 8958188 Lometrexol NN B-NP C045894
21 113 115 8958188 is VBZ B-VP O
22 116 118 8958188 an DT B-NP O
23 119 129 8958188 antifolate NN I-NP O
24 130 135 8958188 which WDT B-NP O
25 136 144 8958188 inhibits VBZ B-VP O
26 145 156 8958188 glycinamide NN B-NP C402896
27 157 171 8958188 ribonucleotide NN I-NP C402896
28 172 189 8958188 formyltransferase NN I-NP O
29 190 191 8958188 ( ( O O
30 191 196 8958188 GARFT NN B-NP O
31 196 197 8958188 ) ) O O
32 197 198 8958188 , , O O
33 199 201 8958188 an DT B-NP O
34 202 208 8958188 enzyme NN I-NP O
35 209 218 8958188 essential JJ B-ADJP O
36 219 222 8958188 for IN B-PP O
37 223 225 8958188 de FW B-NP O
38 226 230 8958188 novo FW I-NP O
39 231 237 8958188 purine NN I-NP D011687
40 238 247 8958188 synthesis NN I-NP O
41 247 248 8958188 . . O O

1 249 258 8958188 Extensive JJ B-NP O
2 259 271 8958188 experimental JJ I-NP O
3 272 275 8958188 and CC I-NP O
4 276 283 8958188 limited JJ I-NP O
5 284 292 8958188 clinical JJ I-NP O
6 293 297 8958188 data NNS I-NP O
7 298 302 8958188 have VBP B-VP O
8 303 308 8958188 shown VBN I-VP O
9 309 313 8958188 that IN B-SBAR O
10 314 324 8958188 lometrexol NN B-NP C045894
11 325 328 8958188 has VBZ B-VP O
12 329 337 8958188 activity NN B-NP O
13 338 345 8958188 against IN B-PP O
14 346 353 8958188 tumours NNS B-NP D009369
15 354 359 8958188 which WDT B-NP O
16 360 363 8958188 are VBP B-VP O
17 364 374 8958188 refractory JJ B-ADJP O
18 375 377 8958188 to TO B-PP O
19 378 383 8958188 other JJ B-NP O
20 384 389 8958188 drugs NNS I-NP O
21 389 390 8958188 , , O O
22 391 398 8958188 notably RB B-NP O
23 399 411 8958188 methotrexate NN I-NP D008727
24 411 412 8958188 . . O O

1 413 420 8958188 However RB B-ADVP O
2 420 421 8958188 , , O O
3 422 425 8958188 the DT B-NP O
4 426 433 8958188 initial JJ I-NP O
5 434 442 8958188 clinical JJ I-NP O
6 443 454 8958188 development NN I-NP O
7 455 457 8958188 of IN B-PP O
8 458 468 8958188 lometrexol NN B-NP C045894
9 469 472 8958188 was VBD B-VP O
10 473 482 8958188 curtailed VBN I-VP O
11 483 490 8958188 because IN B-PP O
12 491 493 8958188 of IN I-PP O
13 494 500 8958188 severe JJ B-NP O
14 501 504 8958188 and CC I-NP O
15 505 515 8958188 cumulative JJ I-NP O
16 516 533 8958188 antiproliferative JJ I-NP O
17 534 544 8958188 toxicities NNS I-NP D064420
18 544 545 8958188 . . O O

1 546 557 8958188 Preclinical JJ B-NP O
2 558 564 8958188 murine JJ I-NP O
3 565 572 8958188 studies NNS I-NP O
4 573 585 8958188 demonstrated VBD B-VP O
5 586 590 8958188 that IN B-SBAR O
6 591 594 8958188 the DT B-NP O
7 595 603 8958188 toxicity NN I-NP D064420
8 604 606 8958188 of IN B-PP O
9 607 617 8958188 lometrexol NN B-NP C045894
10 618 621 8958188 can MD B-VP O
11 622 624 8958188 be VB I-VP O
12 625 634 8958188 prevented VBN I-VP O
13 635 637 8958188 by IN B-PP O
14 638 641 8958188 low JJ B-NP O
15 642 646 8958188 dose NN I-NP O
16 647 652 8958188 folic JJ I-NP D005492
17 653 657 8958188 acid NN I-NP D005492
18 658 672 8958188 administration NN I-NP O
19 672 673 8958188 , , O O
20 674 678 8958188 i.e. FW B-PP O
21 679 682 8958188 for IN B-PP O
22 683 684 8958188 7 CD B-NP O
23 685 689 8958188 days NNS I-NP O
24 690 695 8958188 prior JJ B-ADJP O
25 696 698 8958188 to TO B-PP O
26 699 702 8958188 and CC O O
27 703 704 8958188 7 CD B-NP O
28 705 709 8958188 days NNS I-NP O
29 710 719 8958188 following VBG B-PP O
30 720 721 8958188 a DT B-NP O
31 722 728 8958188 single JJ I-NP O
32 729 734 8958188 bolus NN I-NP O
33 735 739 8958188 dose NN I-NP O
34 739 740 8958188 . . O O

1 741 745 8958188 This DT B-NP O
2 746 757 8958188 observation NN I-NP O
3 758 766 8958188 prompted VBD B-VP O
4 767 768 8958188 a DT B-NP O
5 769 774 8958188 Phase NN I-NP O
6 775 776 8958188 I CD I-NP O
7 777 785 8958188 clinical JJ I-NP O
8 786 791 8958188 study NN I-NP O
9 792 794 8958188 of IN B-PP O
10 795 805 8958188 lometrexol NN B-NP C045894
11 806 811 8958188 given VBN B-VP O
12 812 816 8958188 with IN B-PP O
13 817 822 8958188 folic JJ B-NP D005492
14 823 827 8958188 acid NN I-NP D005492
15 828 843 8958188 supplementation NN I-NP O
16 844 849 8958188 which WDT B-NP O
17 850 853 8958188 has VBZ B-VP O
18 854 863 8958188 confirmed VBN I-VP O
19 864 868 8958188 that IN B-SBAR O
20 869 872 8958188 the DT B-NP O
21 873 881 8958188 toxicity NN I-NP D064420
22 882 884 8958188 of IN B-PP O
23 885 895 8958188 lometrexol NN B-NP C045894
24 896 899 8958188 can MD B-VP O
25 900 902 8958188 be VB I-VP O
26 903 911 8958188 markedly RB I-VP O
27 912 919 8958188 reduced VBN I-VP O
28 920 922 8958188 by IN B-PP O
29 923 928 8958188 folic JJ B-NP D005492
30 929 933 8958188 acid NN I-NP D005492
31 934 949 8958188 supplementation NN I-NP O
32 949 950 8958188 . . O O

1 951 967 8958188 Thrombocytopenia NN B-NP D013921
2 968 971 8958188 and CC I-NP O
3 972 981 8958188 mucositis NN I-NP D052016
4 982 986 8958188 were VBD B-VP O
5 987 990 8958188 the DT B-NP O
6 991 996 8958188 major JJ I-NP O
7 997 1007 8958188 toxicities NNS I-NP D064420
8 1007 1008 8958188 . . O O

1 1009 1014 8958188 There EX B-NP O
2 1015 1018 8958188 was VBD B-VP O
3 1019 1021 8958188 no DT B-NP O
4 1022 1027 8958188 clear JJ I-NP O
5 1028 1040 8958188 relationship NN I-NP O
6 1041 1048 8958188 between IN B-PP O
7 1049 1057 8958188 clinical JJ B-NP O
8 1058 1066 8958188 toxicity NN I-NP D064420
9 1067 1070 8958188 and CC O O
10 1071 1074 8958188 the DT B-NP O
11 1075 1081 8958188 extent NN I-NP O
12 1082 1084 8958188 of IN B-PP O
13 1085 1091 8958188 plasma NN B-NP O
14 1092 1098 8958188 folate NN I-NP D005492
15 1099 1108 8958188 elevation NN I-NP O
16 1108 1109 8958188 . . O O

1 1110 1120 8958188 Associated VBN B-NP O
2 1121 1128 8958188 studies NNS I-NP O
3 1129 1141 8958188 demonstrated VBD B-VP O
4 1142 1146 8958188 that IN B-SBAR O
5 1147 1157 8958188 lometrexol NN B-NP C045894
6 1158 1164 8958188 plasma NN I-NP O
7 1165 1181 8958188 pharmacokinetics NNS I-NP O
8 1182 1186 8958188 were VBD B-VP O
9 1187 1190 8958188 not RB I-VP O
10 1191 1198 8958188 altered VBN I-VP O
11 1199 1201 8958188 by IN B-PP O
12 1202 1207 8958188 folic JJ B-NP D005492
13 1208 1212 8958188 acid NN I-NP D005492
14 1213 1227 8958188 administration NN I-NP O
15 1228 1238 8958188 indicating VBG B-VP O
16 1239 1243 8958188 that IN B-SBAR O
17 1244 1259 8958188 supplementation NN B-NP O
18 1260 1262 8958188 is VBZ B-VP O
19 1263 1271 8958188 unlikely JJ B-ADJP O
20 1272 1274 8958188 to TO B-VP O
21 1275 1281 8958188 reduce VB I-VP O
22 1282 1290 8958188 toxicity NN B-NP D064420
23 1291 1293 8958188 by IN B-PP O
24 1294 1303 8958188 enhancing VBG B-VP O
25 1304 1314 8958188 lometrexol NN B-NP C045894
26 1315 1321 8958188 plasma NN I-NP O
27 1322 1331 8958188 clearance NN I-NP O
28 1331 1332 8958188 . . O O

1 1333 1336 8958188 The DT B-NP O
2 1337 1341 8958188 work NN I-NP O
3 1342 1351 8958188 described VBN B-VP O
4 1352 1354 8958188 in IN B-PP O
5 1355 1359 8958188 this DT B-NP O
6 1360 1366 8958188 report NN I-NP O
7 1367 1370 8958188 has VBZ B-VP O
8 1371 1381 8958188 identified VBN I-VP O
9 1382 1385 8958188 for IN B-PP O
10 1386 1389 8958188 the DT B-NP O
11 1390 1395 8958188 first JJ I-NP O
12 1396 1400 8958188 time NN I-NP O
13 1401 1402 8958188 a DT B-NP O
14 1403 1413 8958188 clinically RB I-NP O
15 1414 1424 8958188 acceptable JJ I-NP O
16 1425 1433 8958188 schedule NN I-NP O
17 1434 1437 8958188 for IN B-PP O
18 1438 1441 8958188 the DT B-NP O
19 1442 1456 8958188 administration NN I-NP O
20 1457 1459 8958188 of IN B-PP O
21 1460 1461 8958188 a DT B-NP O
22 1462 1467 8958188 GARFT NN I-NP O
23 1468 1477 8958188 inhibitor NN I-NP O
24 1477 1478 8958188 . . O O

1 1479 1483 8958188 This DT B-NP O
2 1484 1495 8958188 information NN I-NP O
3 1496 1500 8958188 will MD B-VP O
4 1501 1511 8958188 facilitate VB I-VP O
5 1512 1515 8958188 the DT B-NP O
6 1516 1522 8958188 future JJ I-NP O
7 1523 1533 8958188 evaluation NN I-NP O
8 1534 1536 8958188 of IN B-PP O
9 1537 1541 8958188 this DT B-NP O
10 1542 1547 8958188 class NN I-NP O
11 1548 1550 8958188 of IN B-PP O
12 1551 1560 8958188 compounds NNS B-NP O
13 1561 1563 8958188 in IN B-PP O
14 1564 1570 8958188 cancer NN B-NP D009369
15 1571 1578 8958188 therapy NN I-NP O
16 1578 1579 8958188 . . O O

1 0 0 12101159 -DOCSTART- -X- -X- O

1 0 7 12101159 Delayed VBN B-NP O
2 8 17 12101159 asystolic JJ I-NP D006323
3 18 25 12101159 cardiac JJ I-NP D006323
4 26 32 12101159 arrest NN I-NP D006323
5 33 38 12101159 after IN B-PP O
6 39 48 12101159 diltiazem NN B-NP D004110
7 49 57 12101159 overdose NN I-NP D062787
8 57 58 12101159 ; : O O
9 59 72 12101159 resuscitation NN B-NP O
10 73 77 12101159 with IN B-PP O
11 78 82 12101159 high JJ B-NP O
12 83 87 12101159 dose NN I-NP O
13 88 99 12101159 intravenous JJ I-NP O
14 100 107 12101159 calcium NN I-NP D002118
15 107 108 12101159 . . O O
16 109 110 12101159 A DT B-NP O
17 111 113 12101159 51 CD I-NP O
18 114 118 12101159 year NN I-NP O
19 119 122 12101159 old JJ I-NP O
20 123 126 12101159 man NN I-NP O
21 127 131 12101159 took VBD B-VP O
22 132 133 12101159 a DT B-NP O
23 134 139 12101159 mixed VBN I-NP O
24 140 148 12101159 overdose NN I-NP D062787
25 149 158 12101159 including VBG B-PP O
26 159 162 12101159 1.8 CD B-NP O
27 162 163 12101159 - HYPH I-NP O
28 163 166 12101159 3.6 CD I-NP O
29 167 168 12101159 g NN I-NP O
30 169 171 12101159 of IN B-PP O
31 172 181 12101159 diltiazem NN B-NP D004110
32 181 182 12101159 , , O O
33 183 194 12101159 paracetamol NN B-NP D000082
34 194 195 12101159 , , O O
35 196 203 12101159 aspirin NN B-NP D001241
36 203 204 12101159 , , O O
37 205 215 12101159 isosorbide NN B-NP D007547
38 216 223 12101159 nitrate NN I-NP D009566
39 223 224 12101159 , , O O
40 225 228 12101159 and CC O O
41 229 236 12101159 alcohol NN B-NP D000431
42 236 237 12101159 . . O O

1 238 240 12101159 He PRP B-NP O
2 241 250 12101159 initially RB B-ADVP O
3 251 260 12101159 presented VBD B-VP O
4 261 263 12101159 to TO B-PP O
5 264 272 12101159 hospital NN B-NP O
6 273 278 12101159 after IN B-PP O
7 279 282 12101159 six CD B-NP O
8 283 288 12101159 hours NNS I-NP O
9 289 293 12101159 with IN B-PP O
10 294 298 12101159 mild JJ B-NP O
11 299 310 12101159 hypotension NN I-NP D007022
12 311 314 12101159 and CC O O
13 315 318 12101159 was VBD B-VP O
14 319 326 12101159 treated VBN I-VP O
15 327 331 12101159 with IN B-PP O
16 332 341 12101159 activated VBN B-NP O
17 342 350 12101159 charcoal NN I-NP O
18 351 354 12101159 and CC O O
19 355 366 12101159 intravenous JJ B-NP O
20 367 373 12101159 fluids NNS I-NP O
21 373 374 12101159 . . O O

1 375 383 12101159 Eighteen CD B-NP O
2 384 389 12101159 hours NNS I-NP O
3 390 395 12101159 after IN B-PP O
4 396 399 12101159 the DT B-NP O
5 400 408 12101159 overdose NN I-NP D062787
6 409 411 12101159 he PRP B-NP O
7 412 415 12101159 had VBD B-VP O
8 416 419 12101159 two CD B-NP O
9 420 431 12101159 generalised VBN I-NP O
10 432 437 12101159 tonic JJ I-NP D004830
11 437 438 12101159 - HYPH I-NP D004830
12 438 444 12101159 clonic JJ I-NP D004830
13 445 453 12101159 seizures NNS I-NP D004830
14 453 454 12101159 . . O O

1 455 458 12101159 The DT B-NP O
2 459 466 12101159 patient NN I-NP O
3 467 475 12101159 remained VBD B-VP O
4 476 488 12101159 unresponsive JJ B-ADJP O
5 489 493 12101159 with IN B-PP O
6 494 504 12101159 junctional JJ B-NP O
7 505 516 12101159 bradycardia NN I-NP D001919
8 516 517 12101159 , , O O
9 518 530 12101159 unrecordable JJ B-NP O
10 531 536 12101159 blood NN I-NP O
11 537 545 12101159 pressure NN I-NP O
12 545 546 12101159 , , O O
13 547 550 12101159 and CC O O
14 551 555 12101159 then RB O O
15 556 562 12101159 became VBD B-VP O
16 563 572 12101159 asystolic JJ B-ADJP D006323
17 572 573 12101159 . . O O

1 574 576 12101159 He PRP B-NP O
2 577 580 12101159 was VBD B-VP O
3 581 593 12101159 resuscitated VBN I-VP O
4 594 598 12101159 with IN B-PP O
5 599 603 12101159 high JJ B-NP O
6 604 608 12101159 dose NN I-NP O
7 609 610 12101159 ( ( O O
8 610 614 12101159 13.5 CD B-NP O
9 615 616 12101159 g NN I-NP O
10 616 617 12101159 ) ) O O
11 618 629 12101159 intravenous JJ B-NP O
12 630 637 12101159 calcium NN I-NP D002118
13 638 641 12101159 and CC O O
14 642 652 12101159 adrenaline NN B-NP D004837
15 653 654 12101159 ( ( O O
16 654 665 12101159 epinephrine NN B-NP D004837
17 665 666 12101159 ) ) O O
18 666 667 12101159 . . O O

1 668 670 12101159 He PRP B-NP O
2 671 679 12101159 required VBD B-VP O
3 680 689 12101159 inotropic JJ B-NP O
4 690 697 12101159 support NN I-NP O
5 698 701 12101159 and CC O O
6 702 711 12101159 temporary JJ B-NP O
7 712 718 12101159 pacing NN I-NP O
8 719 723 12101159 over IN B-PP O
9 724 727 12101159 the DT B-NP O
10 728 732 12101159 next JJ I-NP O
11 733 735 12101159 48 CD I-NP O
12 736 741 12101159 hours NNS I-NP O
13 741 742 12101159 . . O O

1 743 747 12101159 This DT B-NP O
2 748 752 12101159 case NN I-NP O
3 753 761 12101159 suggests VBZ B-VP O
4 762 767 12101159 there EX B-NP O
5 768 770 12101159 is VBZ B-VP O
6 771 772 12101159 a DT B-NP O
7 773 777 12101159 role NN I-NP O
8 778 781 12101159 for IN B-PP O
9 782 792 12101159 aggressive JJ B-NP O
10 793 797 12101159 high JJ I-NP O
11 798 802 12101159 dose NN I-NP O
12 803 814 12101159 intravenous JJ I-NP O
13 815 822 12101159 calcium NN I-NP D002118
14 823 830 12101159 therapy NN I-NP O
15 831 833 12101159 in IN B-PP O
16 834 840 12101159 severe JJ B-NP O
17 841 850 12101159 diltiazem NN I-NP D004110
18 851 859 12101159 overdose NN I-NP D062787
19 859 860 12101159 , , O O
20 861 873 12101159 particularly RB B-ADVP O
21 874 878 12101159 with IN B-PP O
22 879 882 12101159 the DT B-NP O
23 883 888 12101159 onset NN I-NP O
24 889 891 12101159 of IN B-PP O
25 892 900 12101159 asystole NN B-NP D006323
26 900 901 12101159 . . O O

1 902 904 12101159 It PRP B-NP O
2 905 911 12101159 should MD B-VP O
3 912 914 12101159 be VB I-VP O
4 915 925 12101159 considered VBN I-VP O
5 926 931 12101159 early RB B-ADVP O
6 932 934 12101159 in IN B-PP O
7 935 940 12101159 cases NNS B-NP O
8 941 943 12101159 of IN B-PP O
9 944 951 12101159 cardiac JJ B-NP D006323
10 952 958 12101159 arrest NN I-NP D006323
11 959 964 12101159 after IN B-PP O
12 965 974 12101159 diltiazem NN B-NP D004110
13 975 983 12101159 overdose NN I-NP D062787
14 983 984 12101159 . . O O

1 985 988 12101159 The DT B-NP O
2 989 993 12101159 case NN I-NP O
3 994 998 12101159 also RB B-ADVP O
4 999 1009 12101159 highlights VBZ B-VP O
5 1010 1013 12101159 the DT B-NP O
6 1014 1022 12101159 problems NNS I-NP O
7 1023 1027 12101159 with IN B-PP O
8 1028 1035 12101159 delayed VBN B-NP O
9 1036 1044 12101159 toxicity NN I-NP D064420
10 1045 1049 12101159 when WRB B-ADVP O
11 1050 1055 12101159 whole JJ B-NP O
12 1056 1061 12101159 bowel NN I-NP O
13 1062 1072 12101159 irrigation NN I-NP O
14 1073 1075 12101159 is VBZ B-VP O
15 1076 1079 12101159 not RB I-VP O
16 1080 1092 12101159 administered VBN I-VP O
17 1092 1093 12101159 . . O O

1 0 0 11282081 -DOCSTART- -X- -X- O

1 0 7 11282081 Effects NNS B-NP O
2 8 10 11282081 of IN B-PP O
3 11 20 11282081 verapamil NN B-NP D014700
4 21 23 11282081 on IN B-PP O
5 24 30 11282081 atrial JJ B-NP D001281
6 31 43 11282081 fibrillation NN I-NP D001281
7 44 47 11282081 and CC O O
8 48 51 11282081 its PRP$ B-NP O
9 52 72 11282081 electrophysiological JJ I-NP O
10 73 85 11282081 determinants NNS I-NP O
11 86 88 11282081 in IN B-PP O
12 89 93 11282081 dogs NNS B-NP O
13 93 94 11282081 . . O O
14 95 105 11282081 BACKGROUND NN B-NP O
15 105 106 11282081 : : O O
16 107 113 11282081 Atrial JJ B-NP D013617
17 114 125 11282081 tachycardia NN I-NP D013617
18 125 126 11282081 - HYPH B-NP O
19 126 133 11282081 induced VBN I-NP O
20 134 144 11282081 remodeling NN I-NP O
21 145 153 11282081 promotes VBZ B-VP O
22 154 157 11282081 the DT B-NP O
23 158 168 11282081 occurrence NN I-NP O
24 169 172 11282081 and CC I-NP O
25 173 184 11282081 maintenance NN I-NP O
26 185 187 11282081 of IN B-PP O
27 188 194 11282081 atrial JJ B-NP D001281
28 195 207 11282081 fibrillation NN I-NP D001281
29 208 209 11282081 ( ( O O
30 209 211 11282081 AF NN B-NP D001281
31 211 212 11282081 ) ) O O
32 213 216 11282081 and CC O O
33 217 226 11282081 decreases VBZ B-VP O
34 227 228 11282081 L NN B-NP O
35 228 229 11282081 - HYPH I-NP O
36 229 233 11282081 type NN I-NP O
37 234 240 11282081 Ca(2+) NN I-NP D002118
38 241 248 11282081 current NN I-NP O
39 248 249 11282081 . . O O

1 250 255 11282081 There EX B-NP O
2 256 258 11282081 is VBZ B-VP O
3 259 263 11282081 also RB B-ADVP O
4 264 265 11282081 a DT B-NP O
5 266 274 11282081 clinical JJ I-NP O
6 275 285 11282081 suggestion NN I-NP O
7 286 290 11282081 that IN B-NP O
8 291 296 11282081 acute JJ B-NP O
9 297 298 11282081 L NN I-NP O
10 298 299 11282081 - HYPH I-NP O
11 299 303 11282081 type NN I-NP O
12 304 309 11282081 Ca(2) NN I-NP D002118
13 310 317 11282081 channel NN I-NP O
14 318 326 11282081 blockade NN I-NP O
15 327 330 11282081 can MD B-VP O
16 331 338 11282081 promote VB I-VP O
17 339 341 11282081 AF NN B-NP D001281
18 341 342 11282081 , , O O
19 343 353 11282081 consistent JJ B-ADJP O
20 354 358 11282081 with IN B-PP O
21 359 361 11282081 an DT B-NP O
22 362 364 11282081 AF NN I-NP D001281
23 365 374 11282081 promoting VBG B-VP O
24 375 381 11282081 effect NN B-NP O
25 382 384 11282081 of IN B-PP O
26 385 391 11282081 Ca(2+) NN B-NP D002118
27 392 399 11282081 channel NN I-NP O
28 400 410 11282081 inhibition NN I-NP O
29 410 411 11282081 . . O O

1 412 419 11282081 METHODS NNS B-NP O
2 419 420 11282081 : : O O
3 421 423 11282081 To TO B-VP O
4 424 432 11282081 evaluate VB I-VP O
5 433 436 11282081 the DT B-NP O
6 437 446 11282081 potential JJ I-NP O
7 447 457 11282081 mechanisms NNS I-NP O
8 458 460 11282081 of IN B-PP O
9 461 463 11282081 AF NN B-NP D001281
10 464 473 11282081 promotion NN I-NP O
11 474 476 11282081 by IN B-PP O
12 477 483 11282081 Ca(2+) NN B-NP D002118
13 484 491 11282081 channel NN I-NP O
14 492 500 11282081 blockers NNS I-NP O
15 500 501 11282081 , , O O
16 502 504 11282081 we PRP B-NP O
17 505 517 11282081 administered VBD B-VP O
18 518 527 11282081 verapamil NN B-NP D014700
19 528 530 11282081 to TO B-PP O
20 531 539 11282081 morphine NN B-NP D009020
21 539 540 11282081 - HYPH B-NP O
22 540 550 11282081 chloralose NN I-NP D002698
23 551 563 11282081 anesthetized VBN B-NP O
24 564 568 11282081 dogs NNS I-NP O
25 568 569 11282081 . . O O

1 570 579 11282081 Diltiazem NN B-NP D004110
2 580 583 11282081 was VBD B-VP O
3 584 588 11282081 used VBN I-VP O
4 589 591 11282081 as IN B-PP O
5 592 593 11282081 a DT B-NP O
6 594 604 11282081 comparison NN I-NP O
7 605 609 11282081 drug NN I-NP O
8 610 613 11282081 and CC O O
9 614 623 11282081 autonomic JJ B-NP O
10 624 632 11282081 blockade NN I-NP O
11 633 637 11282081 with IN B-PP O
12 638 646 11282081 atropine NN B-NP D001285
13 647 650 11282081 and CC I-NP O
14 651 658 11282081 nadolol NN I-NP D009248
15 659 662 11282081 was VBD B-VP O
16 663 670 11282081 applied VBN I-VP O
17 671 673 11282081 in IN B-PP O
18 674 678 11282081 some DT B-NP O
19 679 690 11282081 experiments NNS I-NP O
20 690 691 11282081 . . O O

1 692 702 11282081 Epicardial NNP B-NP O
2 703 710 11282081 mapping VBG B-VP O
3 711 715 11282081 with IN B-PP O
4 716 719 11282081 240 CD B-NP O
5 720 730 11282081 epicardial JJ I-NP O
6 731 741 11282081 electrodes NNS I-NP O
7 742 745 11282081 was VBD B-VP O
8 746 750 11282081 used VBN I-VP O
9 751 753 11282081 to TO B-VP O
10 754 762 11282081 evaluate VB I-VP O
11 763 773 11282081 activation NN B-NP O
12 774 780 11282081 during IN B-PP O
13 781 783 11282081 AF NN B-NP D001281
14 783 784 11282081 . . O O

1 785 792 11282081 RESULTS NNS B-NP O
2 792 793 11282081 : : O O
3 794 803 11282081 Verapamil NN B-NP D014700
4 804 810 11282081 caused VBD B-VP O
5 811 813 11282081 AF NN B-NP D001281
6 814 823 11282081 promotion NN I-NP O
7 824 826 11282081 in IN B-PP O
8 827 830 11282081 six CD B-NP O
9 831 835 11282081 dogs NNS I-NP O
10 835 836 11282081 , , O O
11 837 847 11282081 increasing VBG B-VP O
12 848 852 11282081 mean JJ B-NP O
13 853 861 11282081 duration NN I-NP O
14 862 864 11282081 of IN B-PP O
15 865 867 11282081 AF NN B-NP D001281
16 868 875 11282081 induced VBN B-VP O
17 876 878 11282081 by IN B-PP O
18 879 884 11282081 burst NN B-NP O
19 885 891 11282081 pacing NN I-NP O
20 891 892 11282081 , , O O
21 893 897 11282081 from IN B-PP O
22 898 900 11282081 8+ JJ B-NP O
23 900 901 11282081 / SYM I-NP O
24 901 902 11282081 - SYM I-NP O
25 902 903 11282081 4 CD I-NP O
26 904 905 11282081 s NN I-NP O
27 906 907 11282081 ( ( O O
28 907 912 11282081 mean+ SYM B-NP O
29 912 913 11282081 / SYM O O
30 913 914 11282081 - HYPH B-NP O
31 914 917 11282081 S.E NN I-NP O
32 917 918 11282081 . . O O
33 918 919 11282081 ) ) O O
34 920 922 11282081 to TO B-PP O
35 923 926 11282081 95+ SYM B-NP O
36 926 927 11282081 / SYM B-NP O
37 927 928 11282081 - SYM I-NP O
38 928 930 11282081 39 CD I-NP O
39 931 932 11282081 s NN I-NP O
40 933 934 11282081 ( ( O O
41 934 935 11282081 P NN B-NP O
42 935 936 11282081 < SYM O O
43 936 940 11282081 0.01 CD B-NP O
44 941 943 11282081 vs NNS I-NP O
45 943 944 11282081 . . O O
46 945 952 11282081 control NN B-NP O
47 952 953 11282081 ) ) O O
48 954 956 11282081 at IN B-PP O
49 957 958 11282081 a DT B-NP O
50 959 966 11282081 loading NN I-NP O
51 967 971 11282081 dose NN I-NP O
52 972 974 11282081 of IN B-PP O
53 975 978 11282081 0.1 CD B-NP O
54 979 981 11282081 mg NN I-NP O
55 981 982 11282081 / SYM B-NP O
56 982 984 11282081 kg NN I-NP O
57 985 988 11282081 and CC O O
58 989 993 11282081 228+ JJ B-NP O
59 993 994 11282081 / SYM I-NP O
60 994 995 11282081 - HYPH I-NP O
61 995 998 11282081 101 CD I-NP O
62 999 1000 11282081 s NN I-NP O
63 1001 1002 11282081 ( ( O O
64 1002 1003 11282081 P NN B-NP O
65 1003 1004 11282081 < SYM O O
66 1004 1010 11282081 0.0005 CD B-NP O
67 1011 1013 11282081 vs NNS I-NP O
68 1013 1014 11282081 . . O O
69 1015 1022 11282081 control NN B-NP O
70 1022 1023 11282081 ) ) O O
71 1024 1026 11282081 at IN B-PP O
72 1027 1028 11282081 a DT B-NP O
73 1029 1033 11282081 dose NN I-NP O
74 1034 1036 11282081 of IN B-PP O
75 1037 1040 11282081 0.2 CD B-NP O
76 1041 1043 11282081 mg NN I-NP O
77 1043 1044 11282081 / SYM B-NP O
78 1044 1046 11282081 kg NN I-NP O
79 1046 1047 11282081 . . O O

1 1048 1058 11282081 Underlying VBG B-VP O
2 1059 1079 11282081 electrophysiological JJ B-NP O
3 1080 1090 11282081 mechanisms NNS I-NP O
4 1091 1095 11282081 were VBD B-VP O
5 1096 1103 11282081 studied VBN I-VP O
6 1104 1106 11282081 in IN B-PP O
7 1107 1113 11282081 detail NN B-NP O
8 1114 1116 11282081 in IN B-PP O
9 1117 1121 11282081 five CD B-NP O
10 1122 1132 11282081 additional JJ I-NP O
11 1133 1137 11282081 dogs NNS I-NP O
12 1138 1143 11282081 under IN B-PP O
13 1144 1151 11282081 control NN B-NP O
14 1152 1162 11282081 conditions NNS I-NP O
15 1163 1166 11282081 and CC B-PP O
16 1167 1169 11282081 in IN B-PP O
17 1170 1173 11282081 the DT B-NP O
18 1174 1182 11282081 presence NN I-NP O
19 1183 1185 11282081 of IN B-PP O
20 1186 1189 11282081 the DT B-NP O
21 1190 1196 11282081 higher JJR I-NP O
22 1197 1201 11282081 dose NN I-NP O
23 1202 1204 11282081 of IN B-PP O
24 1205 1214 11282081 verapamil NN B-NP D014700
25 1214 1215 11282081 . . O O

1 1216 1218 11282081 In IN B-PP O
2 1219 1224 11282081 these DT B-NP O
3 1225 1236 11282081 experiments NNS I-NP O
4 1236 1237 11282081 , , O O
5 1238 1247 11282081 verapamil NN B-NP D014700
6 1248 1257 11282081 shortened VBD B-VP O
7 1258 1262 11282081 mean JJ B-NP O
8 1263 1272 11282081 effective JJ I-NP O
9 1273 1283 11282081 refractory JJ I-NP O
10 1284 1290 11282081 period NN I-NP O
11 1291 1292 11282081 ( ( O O
12 1292 1295 11282081 ERP NN B-NP O
13 1295 1296 11282081 ) ) O O
14 1297 1301 11282081 from IN B-PP O
15 1302 1306 11282081 122+ SYM B-NP O
16 1306 1307 11282081 / SYM B-NP O
17 1307 1308 11282081 - SYM B-NP O
18 1308 1309 11282081 5 CD B-NP O
19 1310 1312 11282081 to TO I-NP O
20 1313 1317 11282081 114+ CD I-NP O
21 1317 1318 11282081 / SYM I-NP O
22 1318 1319 11282081 - SYM I-NP O
23 1319 1320 11282081 4 CD B-NP O
24 1321 1323 11282081 ms NN I-NP O
25 1324 1325 11282081 ( ( O O
26 1325 1326 11282081 P NN B-NP O
27 1326 1327 11282081 < JJR B-NP O
28 1327 1331 11282081 0.02 CD I-NP O
29 1331 1332 11282081 ) ) O O
30 1333 1335 11282081 at IN B-PP O
31 1336 1337 11282081 a DT B-NP O
32 1338 1343 11282081 cycle NN I-NP O
33 1344 1350 11282081 length NN I-NP O
34 1351 1353 11282081 of IN B-PP O
35 1354 1357 11282081 300 CD B-NP O
36 1358 1360 11282081 ms NN I-NP O
37 1360 1361 11282081 , , O O
38 1362 1371 11282081 decreased VBD B-VP O
39 1372 1375 11282081 ERP NN B-NP O
40 1376 1389 11282081 heterogeneity NN I-NP O
41 1390 1391 11282081 ( ( O O
42 1391 1395 11282081 from IN B-PP O
43 1396 1399 11282081 15+ SYM B-NP O
44 1399 1400 11282081 / SYM B-NP O
45 1400 1401 11282081 - SYM O O
46 1401 1402 11282081 1 CD B-NP O
47 1403 1405 11282081 to TO B-PP O
48 1406 1409 11282081 10+ CD B-NP O
49 1409 1410 11282081 / SYM I-NP O
50 1410 1411 11282081 - HYPH I-NP O
51 1411 1413 11282081 1% NN B-NP O
52 1413 1414 11282081 , , O O
53 1415 1416 11282081 P NN B-NP O
54 1416 1417 11282081 < SYM B-NP O
55 1417 1421 11282081 0.05 CD I-NP O
56 1421 1422 11282081 ) ) O O
57 1422 1423 11282081 , , O O
58 1424 1439 11282081 heterogeneously RB B-ADVP O
59 1440 1451 11282081 accelerated VBD B-VP O
60 1452 1458 11282081 atrial JJ B-NP O
61 1459 1469 11282081 conduction NN I-NP O
62 1470 1473 11282081 and CC O O
63 1474 1483 11282081 decreased VBD B-VP O
64 1484 1487 11282081 the DT B-NP O
65 1488 1493 11282081 cycle NN I-NP O
66 1494 1500 11282081 length NN I-NP O
67 1501 1503 11282081 of IN B-PP O
68 1504 1506 11282081 AF NN B-NP D001281
69 1507 1508 11282081 ( ( O O
70 1508 1511 11282081 94+ SYM B-NP O
71 1511 1512 11282081 / SYM O O
72 1512 1513 11282081 - SYM O O
73 1513 1514 11282081 4 CD B-NP O
74 1515 1517 11282081 to TO B-PP O
75 1518 1521 11282081 84+ SYM B-NP O
76 1521 1522 11282081 / SYM O O
77 1522 1523 11282081 - SYM O O
78 1523 1524 11282081 3 CD B-NP O
79 1525 1527 11282081 ms NN I-NP O
80 1527 1528 11282081 , , O O
81 1529 1530 11282081 P NN B-NP O
82 1530 1531 11282081 < SYM B-NP O
83 1531 1536 11282081 0.005 CD I-NP O
84 1536 1537 11282081 ) ) O O
85 1537 1538 11282081 . . O O

1 1539 1548 11282081 Diltiazem NNP B-NP D004110
2 1549 1552 11282081 did VBD B-VP O
3 1553 1556 11282081 not RB I-VP O
4 1557 1563 11282081 affect VB I-VP O
5 1564 1567 11282081 ERP NN B-NP O
6 1567 1568 11282081 , , O O
7 1569 1571 11282081 AF NN B-NP D001281
8 1572 1577 11282081 cycle NN I-NP O
9 1578 1584 11282081 length NN I-NP O
10 1585 1587 11282081 or CC O O
11 1588 1590 11282081 AF NN B-NP D001281
12 1591 1599 11282081 duration NN I-NP O
13 1599 1600 11282081 , , O O
14 1601 1604 11282081 but CC O O
15 1605 1613 11282081 produced VBD B-VP O
16 1614 1624 11282081 conduction NN B-NP O
17 1625 1637 11282081 acceleration NN I-NP O
18 1638 1645 11282081 similar JJ B-ADJP O
19 1646 1648 11282081 to TO B-PP O
20 1649 1653 11282081 that DT B-NP O
21 1654 1660 11282081 caused VBN B-VP O
22 1661 1663 11282081 by IN B-PP O
23 1664 1673 11282081 verapamil NN B-NP D014700
24 1674 1675 11282081 ( ( O O
25 1675 1676 11282081 n NN B-NP O
26 1676 1677 11282081 = SYM B-VP O
27 1677 1678 11282081 5 CD B-NP O
28 1678 1679 11282081 ) ) O O
29 1679 1680 11282081 . . O O

1 1681 1683 11282081 In IN B-PP O
2 1684 1687 11282081 the DT B-NP O
3 1688 1696 11282081 presence NN I-NP O
4 1697 1699 11282081 of IN B-PP O
5 1700 1709 11282081 autonomic JJ B-NP O
6 1710 1718 11282081 blockade NN I-NP O
7 1718 1719 11282081 , , O O
8 1720 1729 11282081 verapamil NN B-NP D014700
9 1730 1736 11282081 failed VBD B-VP O
10 1737 1739 11282081 to TO I-VP O
11 1740 1747 11282081 promote VB I-VP O
12 1748 1750 11282081 AF NN B-NP D001281
13 1751 1754 11282081 and CC O O
14 1755 1764 11282081 increased VBD B-VP O
15 1764 1765 11282081 , , O O
16 1766 1772 11282081 rather RB B-PP O
17 1773 1777 11282081 than IN I-PP O
18 1778 1788 11282081 decreasing VBG B-VP O
19 1788 1789 11282081 , , O O
20 1790 1804 11282081 refractoriness NN B-NP O
21 1804 1805 11282081 . . O O

1 1806 1813 11282081 Neither CC O O
2 1814 1823 11282081 verapamil NN B-NP D014700
3 1824 1827 11282081 nor CC I-NP O
4 1828 1837 11282081 diltiazem NN I-NP D004110
5 1838 1846 11282081 affected VBD B-VP O
6 1847 1853 11282081 atrial JJ B-NP O
7 1854 1864 11282081 conduction NN I-NP O
8 1865 1867 11282081 in IN B-PP O
9 1868 1871 11282081 the DT B-NP O
10 1872 1880 11282081 presence NN I-NP O
11 1881 1883 11282081 of IN B-PP O
12 1884 1893 11282081 autonomic JJ B-NP O
13 1894 1902 11282081 blockade NN I-NP O
14 1902 1903 11282081 . . O O

1 1904 1914 11282081 Epicardial JJ B-NP O
2 1915 1922 11282081 mapping NN I-NP O
3 1923 1932 11282081 suggested VBD B-VP O
4 1933 1937 11282081 that IN B-SBAR O
5 1938 1947 11282081 verapamil NN B-NP D014700
6 1948 1956 11282081 promoted VBD B-VP O
7 1957 1959 11282081 AF NN B-NP D001281
8 1960 1962 11282081 by IN B-PP O
9 1963 1973 11282081 increasing VBG B-VP O
10 1974 1977 11282081 the DT B-NP O
11 1978 1984 11282081 number NN I-NP O
12 1985 1987 11282081 of IN B-PP O
13 1988 2000 11282081 simultaneous JJ B-NP O
14 2001 2011 11282081 wavefronts NNS I-NP O
15 2012 2021 11282081 reflected VBN B-VP O
16 2022 2024 11282081 by IN B-PP O
17 2025 2033 11282081 separate JJ B-NP O
18 2034 2039 11282081 zones NNS I-NP O
19 2040 2042 11282081 of IN B-PP O
20 2043 2055 11282081 reactivation NN B-NP O
21 2056 2058 11282081 in IN B-PP O
22 2059 2063 11282081 each DT B-NP O
23 2064 2069 11282081 cycle NN I-NP O
24 2069 2070 11282081 . . O O

1 2071 2082 11282081 CONCLUSIONS NNS B-NP O
2 2082 2083 11282081 : : O O
3 2084 2093 11282081 Verapamil NN B-NP D014700
4 2094 2102 11282081 promotes VBZ B-VP O
5 2103 2105 11282081 AF NN B-NP D001281
6 2106 2108 11282081 in IN B-PP O
7 2109 2115 11282081 normal JJ B-NP O
8 2116 2120 11282081 dogs NNS I-NP O
9 2121 2123 11282081 by IN B-PP O
10 2124 2133 11282081 promoting VBG B-VP O
11 2134 2142 11282081 multiple JJ B-NP O
12 2143 2150 11282081 circuit NN I-NP O
13 2151 2158 11282081 reentry NN I-NP O
14 2158 2159 11282081 , , O O
15 2160 2162 11282081 an DT B-NP O
16 2163 2169 11282081 effect NN I-NP O
17 2170 2179 11282081 dependent JJ B-ADJP O
18 2180 2182 11282081 on IN B-PP O
19 2183 2189 11282081 intact JJ B-NP O
20 2190 2199 11282081 autonomic JJ I-NP O
21 2200 2204 11282081 tone NN I-NP O
22 2205 2208 11282081 and CC O O
23 2209 2212 11282081 not RB B-VP O
24 2213 2219 11282081 shared VBN I-VP O
25 2220 2222 11282081 by IN B-PP O
26 2223 2232 11282081 diltiazem NN B-NP D004110
27 2232 2233 11282081 . . O O

1 0 0 17241657 -DOCSTART- -X- -X- O

1 0 7 17241657 Effects NNS B-NP O
2 8 10 17241657 of IN B-PP O
3 11 16 17241657 UMB24 NN B-NP C519696
4 17 20 17241657 and CC O O
5 21 22 17241657 ( ( O O
6 22 23 17241657 + SYM B-NP O
7 23 24 17241657 / SYM O O
8 24 25 17241657 - SYM O O
9 25 26 17241657 ) ) O O
10 26 27 17241657 - HYPH O O
11 27 29 17241657 SM NN B-NP C107044
12 30 32 17241657 21 CD I-NP C107044
13 32 33 17241657 , , O O
14 34 42 17241657 putative JJ B-NP O
15 43 49 17241657 sigma2 NN I-NP O
16 49 50 17241657 - HYPH O O
17 50 60 17241657 preferring VBG B-VP O
18 61 72 17241657 antagonists NNS B-NP O
19 72 73 17241657 , , O O
20 74 76 17241657 on IN B-PP O
21 77 87 17241657 behavioral JJ B-NP O
22 88 93 17241657 toxic JJ I-NP O
23 94 97 17241657 and CC I-NP O
24 98 107 17241657 stimulant JJ I-NP O
25 108 115 17241657 effects NNS I-NP O
26 116 118 17241657 of IN B-PP O
27 119 126 17241657 cocaine NN B-NP D003042
28 127 129 17241657 in IN B-PP O
29 130 134 17241657 mice NNS B-NP O
30 134 135 17241657 . . O O
31 136 143 17241657 Earlier JJR B-NP O
32 144 151 17241657 studies NNS I-NP O
33 152 156 17241657 have VBP B-VP O
34 157 169 17241657 demonstrated VBN I-VP O
35 170 174 17241657 that IN B-SBAR O
36 175 185 17241657 antagonism NN B-NP O
37 186 188 17241657 of IN B-PP O
38 189 195 17241657 sigma1 NN B-NP O
39 196 205 17241657 receptors NNS I-NP O
40 206 216 17241657 attenuates VBZ B-VP O
41 217 220 17241657 the DT B-NP O
42 221 231 17241657 convulsive JJ I-NP D012640
43 231 232 17241657 , , I-NP O
44 233 239 17241657 lethal JJ I-NP O
45 239 240 17241657 , , I-NP O
46 241 250 17241657 locomotor JJ I-NP O
47 251 262 17241657 stimulatory JJ I-NP O
48 263 266 17241657 and CC I-NP O
49 267 276 17241657 rewarding JJ I-NP O
50 277 284 17241657 actions NNS I-NP O
51 285 287 17241657 of IN B-PP O
52 288 295 17241657 cocaine NN B-NP D003042
53 296 298 17241657 in IN B-PP O
54 299 303 17241657 mice NNS B-NP O
55 303 304 17241657 . . O O

1 305 307 17241657 In IN B-PP O
2 308 316 17241657 contrast NN B-NP O
3 316 317 17241657 , , O O
4 318 321 17241657 the DT B-NP O
5 322 334 17241657 contribution NN I-NP O
6 335 337 17241657 of IN B-PP O
7 338 344 17241657 sigma2 NN B-NP O
8 345 354 17241657 receptors NNS I-NP O
9 355 357 17241657 is VBZ B-VP O
10 358 365 17241657 unclear JJ B-ADJP O
11 366 373 17241657 because IN B-SBAR O
12 374 386 17241657 experimental JJ B-NP O
13 387 392 17241657 tools NNS I-NP O
14 393 395 17241657 to TO B-VP O
15 396 407 17241657 selectively RB I-VP O
16 408 414 17241657 target VB I-VP O
17 415 419 17241657 this DT B-NP O
18 420 427 17241657 subtype NN I-NP O
19 428 431 17241657 are VBP B-VP O
20 432 443 17241657 unavailable JJ B-ADJP O
21 443 444 17241657 . . O O

1 445 447 17241657 To TO B-VP O
2 448 453 17241657 begin VB I-VP O
3 454 464 17241657 addressing VBG I-VP O
4 465 469 17241657 this DT B-NP O
5 470 474 17241657 need NN I-NP O
6 474 475 17241657 , , O O
7 476 478 17241657 we PRP B-NP O
8 479 492 17241657 characterized VBD B-VP O
9 493 498 17241657 UMB24 NN B-NP C519696
10 499 500 17241657 ( ( O O
11 500 501 17241657 1 CD B-NP C519696
12 501 502 17241657 - HYPH O C519696
13 502 504 17241657 (2 CD B-NP C519696
14 504 505 17241657 - HYPH I-NP C519696
15 505 515 17241657 phenethyl) NN I-NP C519696
16 515 516 17241657 - HYPH B-NP C519696
17 516 517 17241657 4 CD I-NP C519696
18 517 518 17241657 - HYPH I-NP C519696
19 518 520 17241657 (2 CD I-NP C519696
20 520 521 17241657 - HYPH I-NP C519696
21 521 529 17241657 pyridyl) NN I-NP C519696
22 529 530 17241657 - HYPH I-NP C519696
23 530 540 17241657 piperazine NN I-NP C519696
24 540 541 17241657 ) ) O O
25 542 545 17241657 and CC O O
26 546 547 17241657 ( ( O O
27 547 548 17241657 + SYM B-NP O
28 548 549 17241657 / SYM O O
29 549 550 17241657 - SYM O O
30 550 551 17241657 ) ) O O
31 551 552 17241657 - HYPH O O
32 552 554 17241657 SM NN B-NP C107044
33 555 557 17241657 21 CD I-NP C107044
34 558 559 17241657 ( ( O O
35 559 565 17241657 3alpha NN B-NP C107044
36 565 566 17241657 - HYPH B-NP C107044
37 566 574 17241657 tropanyl NN I-NP C107044
38 574 575 17241657 - HYPH B-NP C107044
39 575 576 17241657 2 CD I-NP C107044
40 576 577 17241657 - HYPH I-NP C107044
41 577 579 17241657 (4 CD I-NP C107044
42 579 580 17241657 - HYPH I-NP C107044
43 580 601 17241657 chorophenoxy)butyrate NN I-NP C107044
44 601 602 17241657 ) ) O O
45 603 605 17241657 in IN B-PP O
46 606 614 17241657 receptor NN B-NP O
47 615 622 17241657 binding NN I-NP O
48 623 626 17241657 and CC O O
49 627 637 17241657 behavioral JJ B-NP O
50 638 645 17241657 studies NNS I-NP O
51 645 646 17241657 . . O O

1 647 655 17241657 Receptor NN B-NP O
2 656 663 17241657 binding NN I-NP O
3 664 671 17241657 studies NNS I-NP O
4 672 681 17241657 confirmed VBD B-VP O
5 682 686 17241657 that IN B-SBAR O
6 687 692 17241657 UMB24 NN B-NP C519696
7 693 696 17241657 and CC O O
8 697 698 17241657 ( ( O O
9 698 699 17241657 + SYM B-NP O
10 699 700 17241657 / SYM O O
11 700 701 17241657 - SYM O O
12 701 702 17241657 ) ) O O
13 702 703 17241657 - HYPH O O
14 703 705 17241657 SM NN B-NP C107044
15 706 708 17241657 21 CD I-NP C107044
16 709 716 17241657 display NN I-NP O
17 717 729 17241657 preferential JJ I-NP O
18 730 738 17241657 affinity NN I-NP O
19 739 742 17241657 for IN B-PP O
20 743 749 17241657 sigma2 NN B-NP O
21 750 754 17241657 over IN B-PP O
22 755 761 17241657 sigma1 NN B-NP O
23 762 771 17241657 receptors NNS I-NP O
24 771 772 17241657 . . O O

1 773 775 17241657 In IN B-PP O
2 776 786 17241657 behavioral JJ B-NP O
3 787 794 17241657 studies NNS I-NP O
4 794 795 17241657 , , O O
5 796 808 17241657 pretreatment NN B-NP O
6 809 811 17241657 of IN B-PP O
7 812 817 17241657 Swiss JJ B-NP O
8 818 825 17241657 Webster NNP I-NP O
9 826 830 17241657 mice NNS I-NP O
10 831 835 17241657 with IN B-PP O
11 836 841 17241657 UMB24 NN B-NP C519696
12 842 844 17241657 or CC O O
13 845 846 17241657 ( ( O O
14 846 847 17241657 + SYM O O
15 847 848 17241657 / SYM O O
16 848 849 17241657 - SYM O O
17 849 850 17241657 ) ) O O
18 850 851 17241657 - HYPH O O
19 851 853 17241657 SM NN B-NP C107044
20 854 856 17241657 21 CD I-NP C107044
21 857 870 17241657 significantly RB B-ADVP O
22 871 881 17241657 attenuated VBD B-VP O
23 882 889 17241657 cocaine NN B-NP D003042
24 889 890 17241657 - HYPH B-NP O
25 890 897 17241657 induced VBN I-NP O
26 898 909 17241657 convulsions NNS I-NP D012640
27 910 913 17241657 and CC O O
28 914 923 17241657 locomotor NN B-NP O
29 924 932 17241657 activity NN I-NP O
30 932 933 17241657 , , O O
31 934 937 17241657 but CC O O
32 938 941 17241657 not RB O O
33 942 951 17241657 lethality NN B-NP O
34 951 952 17241657 . . O O

1 953 957 17241657 When WRB B-ADVP O
2 958 970 17241657 administered VBN B-VP O
3 971 976 17241657 alone RB B-ADVP O
4 976 977 17241657 , , O O
5 978 979 17241657 ( ( O O
6 979 980 17241657 + SYM B-NP O
7 980 981 17241657 / SYM O O
8 981 982 17241657 - SYM O O
9 982 983 17241657 ) ) O O
10 983 984 17241657 - HYPH O O
11 984 986 17241657 SM NN B-NP C107044
12 987 989 17241657 21 CD I-NP C107044
13 990 998 17241657 produced VBD B-VP O
14 999 1001 17241657 no DT B-NP O
15 1002 1013 17241657 significant JJ I-NP O
16 1014 1021 17241657 effects NNS I-NP O
17 1022 1030 17241657 compared VBN B-VP O
18 1031 1033 17241657 to TO B-VP O
19 1034 1041 17241657 control VB I-VP O
20 1042 1052 17241657 injections NNS B-NP O
21 1053 1055 17241657 of IN B-PP O
22 1056 1062 17241657 saline NN B-NP O
23 1062 1063 17241657 , , O O
24 1064 1067 17241657 but CC O O
25 1068 1073 17241657 UMB24 NN B-NP C519696
26 1074 1077 17241657 had VBD B-VP O
27 1078 1087 17241657 locomotor JJ B-NP O
28 1088 1098 17241657 depressant JJ I-NP O
29 1099 1106 17241657 actions NNS I-NP O
30 1106 1107 17241657 . . O O

1 1108 1116 17241657 Together RB B-ADVP O
2 1116 1117 17241657 , , O O
3 1118 1121 17241657 the DT B-NP O
4 1122 1126 17241657 data NNS I-NP O
5 1127 1134 17241657 suggest VBP B-VP O
6 1135 1139 17241657 that IN B-SBAR O
7 1140 1146 17241657 sigma2 NN B-NP O
8 1147 1155 17241657 receptor NN I-NP O
9 1156 1167 17241657 antagonists NNS I-NP O
10 1168 1172 17241657 have VBP B-VP O
11 1173 1176 17241657 the DT B-NP O
12 1177 1186 17241657 potential NN I-NP O
13 1187 1189 17241657 to TO B-VP O
14 1190 1199 17241657 attenuate VB I-VP O
15 1200 1204 17241657 some DT B-NP O
16 1205 1207 17241657 of IN B-PP O
17 1208 1211 17241657 the DT B-NP O
18 1212 1222 17241657 behavioral JJ I-NP O
19 1223 1230 17241657 effects NNS I-NP O
20 1231 1233 17241657 of IN B-PP O
21 1234 1241 17241657 cocaine NN B-NP D003042
22 1241 1242 17241657 , , O O
23 1243 1246 17241657 and CC O O
24 1247 1254 17241657 further JJ B-NP O
25 1255 1266 17241657 development NN I-NP O
26 1267 1269 17241657 of IN B-PP O
27 1270 1274 17241657 more RBR B-NP O
28 1275 1284 17241657 selective JJ I-NP O
29 1284 1285 17241657 , , I-NP O
30 1286 1290 17241657 high JJ I-NP O
31 1291 1299 17241657 affinity NN I-NP O
32 1300 1307 17241657 ligands NNS I-NP O
33 1308 1311 17241657 are VBP B-VP O
34 1312 1321 17241657 warranted VBN I-VP O
35 1321 1322 17241657 . . O O

1 0 0 7707116 -DOCSTART- -X- -X- O

1 0 5 7707116 Phase NN B-NP O
2 6 7 7707116 I CD I-NP O
3 8 13 7707116 trial NN I-NP O
4 14 16 7707116 of IN B-PP O
5 17 19 7707116 13 CD B-NP D015474
6 19 20 7707116 - HYPH I-NP D015474
7 20 23 7707116 cis NN I-NP D015474
8 23 24 7707116 - HYPH B-NP D015474
9 24 32 7707116 retinoic JJ I-NP D015474
10 33 37 7707116 acid NN I-NP D015474
11 38 40 7707116 in IN B-PP O
12 41 49 7707116 children NNS B-NP O
13 50 54 7707116 with IN B-PP O
14 55 68 7707116 neuroblastoma NN B-NP D009447
15 69 78 7707116 following VBG B-PP O
16 79 83 7707116 bone NN B-NP O
17 84 90 7707116 marrow NN I-NP O
18 91 106 7707116 transplantation NN I-NP O
19 106 107 7707116 . . I-NP O
20 108 115 7707116 PURPOSE NN I-NP O
21 115 116 7707116 : : O O
22 117 126 7707116 Treatment NN B-NP O
23 127 129 7707116 of IN B-PP O
24 130 143 7707116 neuroblastoma NN B-NP D009447
25 144 148 7707116 cell NN I-NP O
26 149 154 7707116 lines NNS I-NP O
27 155 159 7707116 with IN B-PP O
28 160 162 7707116 13 CD B-NP D015474
29 162 163 7707116 - HYPH I-NP D015474
30 163 166 7707116 cis NN I-NP D015474
31 166 167 7707116 - HYPH O D015474
32 167 175 7707116 retinoic JJ B-NP D015474
33 176 180 7707116 acid NN I-NP D015474
34 181 182 7707116 ( ( O O
35 182 185 7707116 cis NN B-NP D015474
36 185 186 7707116 - HYPH O D015474
37 186 188 7707116 RA NN B-NP D015474
38 188 189 7707116 ) ) O O
39 190 193 7707116 can MD B-VP O
40 194 199 7707116 cause VB I-VP O
41 200 209 7707116 sustained JJ B-NP O
42 210 220 7707116 inhibition NN I-NP O
43 221 223 7707116 of IN B-PP O
44 224 237 7707116 proliferation NN B-NP O
45 237 238 7707116 . . O O

1 239 244 7707116 Since IN B-SBAR O
2 245 248 7707116 cis NN B-NP D015474
3 248 249 7707116 - HYPH B-NP D015474
4 249 251 7707116 RA NN I-NP D015474
5 252 255 7707116 has VBZ B-VP O
6 256 268 7707116 demonstrated VBN I-VP O
7 269 277 7707116 clinical JJ B-NP O
8 278 287 7707116 responses NNS I-NP O
9 288 290 7707116 in IN B-PP O
10 291 304 7707116 neuroblastoma NN B-NP D009447
11 305 313 7707116 patients NNS I-NP O
12 313 314 7707116 , , O O
13 315 317 7707116 it PRP B-NP O
14 318 321 7707116 may MD B-VP O
15 322 324 7707116 be VB I-VP O
16 325 334 7707116 effective JJ B-ADJP O
17 335 337 7707116 in IN B-PP O
18 338 348 7707116 preventing VBG B-VP O
19 349 356 7707116 relapse NN B-NP O
20 357 362 7707116 after IN B-PP O
21 363 372 7707116 cytotoxic JJ B-NP O
22 373 380 7707116 therapy NN I-NP O
23 380 381 7707116 . . O O

1 382 386 7707116 This DT B-NP O
2 387 392 7707116 phase NN I-NP O
3 393 394 7707116 I CD I-NP O
4 395 400 7707116 trial NN I-NP O
5 401 404 7707116 was VBD B-VP O
6 405 413 7707116 designed VBN I-VP O
7 414 416 7707116 to TO B-VP O
8 417 426 7707116 determine VB I-VP O
9 427 430 7707116 the DT B-NP O
10 431 438 7707116 maximal JJ I-NP O
11 438 439 7707116 - HYPH I-NP O
12 439 448 7707116 tolerated VBN I-NP O
13 449 455 7707116 dosage NN I-NP O
14 456 457 7707116 ( ( O O
15 457 460 7707116 MTD NN B-NP O
16 460 461 7707116 ) ) O O
17 461 462 7707116 , , O O
18 463 473 7707116 toxicities NNS B-NP D064420
19 473 474 7707116 , , O O
20 475 478 7707116 and CC O O
21 479 495 7707116 pharmacokinetics NNS B-NP O
22 496 498 7707116 of IN B-PP O
23 499 502 7707116 cis NN B-NP D015474
24 502 503 7707116 - HYPH B-NP D015474
25 503 505 7707116 RA NN I-NP D015474
26 506 518 7707116 administered VBN B-VP O
27 519 521 7707116 on IN B-PP O
28 522 524 7707116 an DT B-NP O
29 525 537 7707116 intermittent JJ I-NP O
30 538 546 7707116 schedule NN I-NP O
31 547 549 7707116 in IN B-PP O
32 550 558 7707116 children NNS B-NP O
33 559 563 7707116 with IN B-PP O
34 564 577 7707116 neuroblastoma NN B-NP D009447
35 578 587 7707116 following VBG B-PP O
36 588 592 7707116 bone NN B-NP O
37 593 599 7707116 marrow NN I-NP O
38 600 615 7707116 transplantation NN I-NP O
39 616 617 7707116 ( ( O O
40 617 620 7707116 BMT NN B-NP O
41 620 621 7707116 ) ) O O
42 621 622 7707116 . . O O

1 623 631 7707116 PATIENTS NNS B-NP O
2 632 635 7707116 AND CC I-NP O
3 636 643 7707116 METHODS NNS I-NP O
4 643 644 7707116 : : O O
5 645 650 7707116 Fifty CD B-NP O
6 650 651 7707116 - HYPH I-NP O
7 651 654 7707116 one CD I-NP O
8 655 665 7707116 assessable JJ I-NP O
9 666 674 7707116 patients NNS I-NP O
10 674 675 7707116 , , O O
11 676 677 7707116 2 CD B-NP O
12 678 680 7707116 to TO I-NP O
13 681 683 7707116 12 CD I-NP O
14 684 689 7707116 years NNS I-NP O
15 690 692 7707116 of IN B-PP O
16 693 696 7707116 age NN B-NP O
17 696 697 7707116 , , O O
18 698 702 7707116 were VBD B-VP O
19 703 710 7707116 treated VBN I-VP O
20 711 715 7707116 with IN B-PP O
21 716 720 7707116 oral JJ B-NP O
22 721 724 7707116 cis NN I-NP D015474
23 724 725 7707116 - HYPH B-NP D015474
24 725 727 7707116 RA NN I-NP D015474
25 728 740 7707116 administered VBN B-VP O
26 741 743 7707116 in IN B-PP O
27 744 747 7707116 two CD B-NP O
28 748 755 7707116 equally RB I-NP O
29 756 763 7707116 divided VBN I-NP O
30 764 769 7707116 doses NNS I-NP O
31 770 775 7707116 daily RB B-ADVP O
32 776 779 7707116 for IN B-PP O
33 780 781 7707116 2 CD B-NP O
34 782 787 7707116 weeks NNS I-NP O
35 787 788 7707116 , , O O
36 789 797 7707116 followed VBN B-VP O
37 798 800 7707116 by IN B-PP O
38 801 802 7707116 a DT B-NP O
39 803 804 7707116 2 CD I-NP O
40 804 805 7707116 - HYPH I-NP O
41 805 809 7707116 week NN I-NP O
42 810 814 7707116 rest NN I-NP O
43 815 821 7707116 period NN I-NP O
44 821 822 7707116 , , O O
45 823 826 7707116 for IN B-PP O
46 827 829 7707116 up IN B-NP O
47 830 832 7707116 to TO I-NP O
48 833 835 7707116 12 CD I-NP O
49 836 843 7707116 courses NNS I-NP O
50 843 844 7707116 . . O O

1 845 848 7707116 The DT B-NP O
2 849 853 7707116 dose NN I-NP O
3 854 857 7707116 was VBD B-VP O
4 858 867 7707116 escalated VBN I-VP O
5 868 872 7707116 from IN B-PP O
6 873 876 7707116 100 CD B-NP O
7 877 879 7707116 to TO I-NP O
8 880 883 7707116 200 CD I-NP O
9 884 886 7707116 mg NN I-NP O
10 886 887 7707116 / SYM B-NP O
11 887 889 7707116 m2 NN I-NP O
12 889 890 7707116 / SYM B-NP O
13 890 891 7707116 d NN I-NP O
14 892 897 7707116 until IN B-PP O
15 898 902 7707116 dose NN B-NP O
16 902 903 7707116 - HYPH O O
17 903 911 7707116 limiting VBG B-VP O
18 912 920 7707116 toxicity NN B-NP D064420
19 921 922 7707116 ( ( O O
20 922 925 7707116 DLT NN B-NP O
21 925 926 7707116 ) ) O O
22 927 930 7707116 was VBD B-VP O
23 931 939 7707116 observed VBN I-VP O
24 939 940 7707116 . . O O

1 941 942 7707116 A DT B-NP O
2 943 949 7707116 single JJ I-NP O
3 950 962 7707116 intrapatient JJ I-NP O
4 963 967 7707116 dose NN I-NP O
5 968 978 7707116 escalation NN I-NP O
6 979 982 7707116 was VBD B-VP O
7 983 992 7707116 permitted VBN I-VP O
8 992 993 7707116 . . O O

1 994 1001 7707116 RESULTS NNS B-NP O
2 1001 1002 7707116 : : O O
3 1003 1006 7707116 The DT B-NP O
4 1007 1010 7707116 MTD NN I-NP O
5 1011 1013 7707116 of IN B-PP O
6 1014 1017 7707116 cis NN B-NP D015474
7 1017 1018 7707116 - HYPH B-NP D015474
8 1018 1020 7707116 RA NN I-NP D015474
9 1021 1024 7707116 was VBD B-VP O
10 1025 1028 7707116 160 CD B-NP O
11 1029 1031 7707116 mg NN I-NP O
12 1031 1032 7707116 / SYM B-NP O
13 1032 1034 7707116 m2 NN I-NP O
14 1034 1035 7707116 / SYM I-NP O
15 1035 1036 7707116 d NN I-NP O
16 1036 1037 7707116 . . O O

1 1038 1042 7707116 Dose NN B-NP O
2 1042 1043 7707116 - HYPH O O
3 1043 1051 7707116 limiting VBG B-VP O
4 1052 1062 7707116 toxicities NNS B-NP D064420
5 1063 1065 7707116 in IN B-PP O
6 1066 1069 7707116 six CD B-NP O
7 1070 1072 7707116 of IN B-PP O
8 1073 1077 7707116 nine CD B-NP O
9 1078 1086 7707116 patients NNS I-NP O
10 1087 1089 7707116 at IN B-PP O
11 1090 1093 7707116 200 CD B-NP O
12 1094 1096 7707116 mg NN I-NP O
13 1096 1097 7707116 / SYM B-NP O
14 1097 1099 7707116 m2 NN I-NP O
15 1099 1100 7707116 / SYM B-NP O
16 1100 1101 7707116 d NN I-NP O
17 1102 1110 7707116 included VBD B-VP O
18 1111 1124 7707116 hypercalcemia NN B-NP D006934
19 1125 1126 7707116 ( ( O O
20 1126 1127 7707116 n NN B-NP O
21 1128 1129 7707116 = SYM B-VP O
22 1130 1131 7707116 3 CD B-NP O
23 1131 1132 7707116 ) ) O O
24 1132 1133 7707116 , , O O
25 1134 1138 7707116 rash NN B-NP D005076
26 1139 1140 7707116 ( ( O O
27 1140 1141 7707116 n NN B-NP O
28 1142 1143 7707116 = SYM B-VP O
29 1144 1145 7707116 2 CD B-NP O
30 1145 1146 7707116 ) ) O O
31 1146 1147 7707116 , , O O
32 1148 1151 7707116 and CC O O
33 1152 1158 7707116 anemia NN B-NP D000740
34 1158 1159 7707116 / SYM I-NP O
35 1159 1175 7707116 thrombocytopenia NN I-NP D013921
36 1175 1176 7707116 / SYM B-NP O
37 1176 1182 7707116 emesis NN I-NP D014839
38 1182 1183 7707116 / SYM O O
39 1183 1187 7707116 rash NN B-NP D005076
40 1188 1189 7707116 ( ( O O
41 1189 1190 7707116 n NN B-NP O
42 1191 1192 7707116 = SYM B-VP O
43 1193 1194 7707116 1 CD B-NP O
44 1194 1195 7707116 ) ) O O
45 1195 1196 7707116 . . O O

1 1197 1200 7707116 All DT B-NP O
2 1201 1211 7707116 toxicities NNS I-NP D064420
3 1212 1220 7707116 resolved VBN B-VP O
4 1221 1226 7707116 after IN B-PP O
5 1227 1230 7707116 cis NN B-NP D015474
6 1230 1231 7707116 - HYPH B-NP D015474
7 1231 1233 7707116 RA NN I-NP D015474
8 1234 1237 7707116 was VBD B-VP O
9 1238 1250 7707116 discontinued VBN I-VP O
10 1250 1251 7707116 . . O O

1 1252 1257 7707116 Three CD B-NP O
2 1258 1266 7707116 complete JJ I-NP O
3 1267 1276 7707116 responses NNS I-NP O
4 1277 1281 7707116 were VBD B-VP O
5 1282 1290 7707116 observed VBN I-VP O
6 1291 1293 7707116 in IN B-PP O
7 1294 1300 7707116 marrow NN B-NP O
8 1301 1311 7707116 metastases NNS I-NP D009362
9 1311 1312 7707116 . . O O

1 1313 1318 7707116 Serum NN B-NP O
2 1319 1325 7707116 levels NNS I-NP O
3 1326 1328 7707116 of IN B-PP O
4 1329 1332 7707116 7.4 CD B-NP O
5 1333 1334 7707116 + SYM O O
6 1334 1335 7707116 / SYM O O
7 1335 1336 7707116 - SYM O O
8 1337 1340 7707116 3.0 CD B-NP O
9 1341 1346 7707116 mumol NN I-NP O
10 1346 1347 7707116 / SYM B-NP O
11 1347 1348 7707116 L NN B-NP O
12 1349 1350 7707116 ( ( O O
13 1350 1354 7707116 peak NN B-NP O
14 1354 1355 7707116 ) ) O O
15 1356 1359 7707116 and CC O O
16 1360 1363 7707116 4.0 CD B-NP O
17 1364 1365 7707116 + SYM O O
18 1365 1366 7707116 / SYM O O
19 1366 1367 7707116 - SYM O O
20 1368 1371 7707116 2.8 CD B-NP O
21 1372 1377 7707116 mumol NN I-NP O
22 1377 1378 7707116 / SYM B-NP O
23 1378 1379 7707116 L NN B-NP O
24 1380 1381 7707116 ( ( O O
25 1381 1387 7707116 trough NN B-NP O
26 1387 1388 7707116 ) ) O O
27 1389 1391 7707116 at IN B-PP O
28 1392 1395 7707116 the DT B-NP O
29 1396 1399 7707116 MTD NN I-NP O
30 1400 1404 7707116 were VBD B-VP O
31 1405 1415 7707116 maintained VBN I-VP O
32 1416 1422 7707116 during IN B-PP O
33 1423 1425 7707116 14 CD B-NP O
34 1426 1430 7707116 days NNS I-NP O
35 1431 1433 7707116 of IN B-PP O
36 1434 1441 7707116 therapy NN B-NP O
37 1441 1442 7707116 . . O O

1 1443 1446 7707116 The DT B-NP O
2 1447 1450 7707116 DLT NN I-NP O
3 1451 1461 7707116 correlated VBD B-VP O
4 1462 1466 7707116 with IN B-PP O
5 1467 1472 7707116 serum NN B-NP O
6 1473 1479 7707116 levels NNS I-NP O
7 1480 1481 7707116 > SYM B-VP O
8 1482 1484 7707116 or CC O O
9 1485 1486 7707116 = SYM B-NP O
10 1487 1489 7707116 10 CD B-NP O
11 1490 1495 7707116 mumol NN I-NP O
12 1495 1496 7707116 / SYM B-NP O
13 1496 1497 7707116 L NN I-NP O
14 1497 1498 7707116 . . O O

1 1499 1509 7707116 CONCLUSION NN B-NP O
2 1509 1510 7707116 : : O O
3 1511 1514 7707116 The DT B-NP O
4 1515 1518 7707116 MTD NN I-NP O
5 1519 1521 7707116 of IN B-PP O
6 1522 1525 7707116 cis NN B-NP D015474
7 1525 1526 7707116 - HYPH B-NP D015474
8 1526 1528 7707116 RA NN I-NP D015474
9 1529 1534 7707116 given VBN B-PP O
10 1535 1537 7707116 on IN B-PP O
11 1538 1542 7707116 this DT B-NP O
12 1543 1555 7707116 intermittent JJ I-NP O
13 1556 1564 7707116 schedule NN I-NP O
14 1565 1568 7707116 was VBD B-VP O
15 1569 1572 7707116 160 CD B-NP O
16 1573 1575 7707116 mg NN I-NP O
17 1575 1576 7707116 / SYM B-NP O
18 1576 1578 7707116 m2 NN I-NP O
19 1578 1579 7707116 / SYM I-NP O
20 1579 1580 7707116 d NN I-NP O
21 1580 1581 7707116 . . O O

1 1582 1587 7707116 Serum NN B-NP O
2 1588 1594 7707116 levels NNS I-NP O
3 1595 1600 7707116 known VBN B-VP O
4 1601 1603 7707116 to TO I-VP O
5 1604 1606 7707116 be VB I-VP O
6 1607 1616 7707116 effective JJ B-ADJP O
7 1617 1624 7707116 against IN B-PP O
8 1625 1638 7707116 neuroblastoma NN B-NP D009447
9 1639 1641 7707116 in FW B-ADVP O
10 1642 1647 7707116 vitro FW I-ADVP O
11 1648 1652 7707116 were VBD B-VP O
12 1653 1661 7707116 achieved VBN I-VP O
13 1662 1664 7707116 at IN B-PP O
14 1665 1669 7707116 this DT B-NP O
15 1670 1674 7707116 dose NN I-NP O
16 1674 1675 7707116 . . O O

1 1676 1679 7707116 The DT B-NP O
2 1680 1683 7707116 DLT NN I-NP O
3 1684 1692 7707116 included VBD B-VP O
4 1693 1706 7707116 hypercalcemia NN B-NP D006934
5 1706 1707 7707116 , , O O
6 1708 1711 7707116 and CC O O
7 1712 1715 7707116 may MD B-VP O
8 1716 1718 7707116 be VB I-VP O
9 1719 1728 7707116 predicted VBN I-VP O
10 1729 1731 7707116 by IN B-PP O
11 1732 1737 7707116 serum NN B-NP O
12 1738 1741 7707116 cis NN I-NP D015474
13 1741 1742 7707116 - HYPH B-NP D015474
14 1742 1744 7707116 RA NN I-NP D015474
15 1745 1751 7707116 levels NNS I-NP O
16 1751 1752 7707116 . . O O

1 1753 1763 7707116 Monitoring NN B-NP O
2 1764 1766 7707116 of IN B-PP O
3 1767 1772 7707116 serum NN B-NP O
4 1773 1780 7707116 calcium NN I-NP D002118
5 1781 1784 7707116 and CC I-NP O
6 1785 1788 7707116 cis NN I-NP D015474
7 1788 1789 7707116 - HYPH B-NP D015474
8 1789 1791 7707116 RA NN I-NP D015474
9 1792 1798 7707116 levels NNS I-NP O
10 1799 1801 7707116 is VBZ B-VP O
11 1802 1811 7707116 indicated VBN I-VP O
12 1812 1814 7707116 in IN B-PP O
13 1815 1821 7707116 future JJ B-NP O
14 1822 1828 7707116 trials NNS I-NP O
15 1828 1829 7707116 . . O O

1 0 0 3108839 -DOCSTART- -X- -X- O

1 0 9 3108839 Mitomycin NN B-NP D016685
2 10 11 3108839 C NN I-NP D016685
3 12 22 3108839 associated VBN B-VP O
4 23 32 3108839 hemolytic JJ B-NP D006463
5 33 39 3108839 uremic JJ I-NP D006463
6 40 48 3108839 syndrome NN I-NP D006463
7 48 49 3108839 . . O O
8 50 59 3108839 Mitomycin NN B-NP D016685
9 60 61 3108839 C NN I-NP D016685
10 62 72 3108839 associated VBN B-VP O
11 73 82 3108839 Hemolytic JJ B-NP D006463
12 83 89 3108839 Uremic JJ I-NP D006463
13 90 98 3108839 Syndrome NN I-NP D006463
14 99 100 3108839 ( ( O O
15 100 103 3108839 HUS NN B-NP D006463
16 103 104 3108839 ) ) O O
17 105 107 3108839 is VBZ B-VP O
18 108 109 3108839 a DT B-NP O
19 110 121 3108839 potentially RB I-NP O
20 122 127 3108839 fatal JJ I-NP O
21 128 131 3108839 but CC I-NP O
22 132 140 3108839 uncommon JJ I-NP O
23 141 150 3108839 condition NN I-NP O
24 151 155 3108839 that WDT B-NP O
25 156 158 3108839 is VBZ B-VP O
26 159 162 3108839 not RB I-VP O
27 163 166 3108839 yet RB I-VP O
28 167 173 3108839 widely RB I-VP O
29 174 184 3108839 recognised VBN I-VP O
30 184 185 3108839 . . O O

1 186 188 3108839 It PRP B-NP O
2 189 197 3108839 consists VBZ B-VP O
3 198 200 3108839 of IN B-PP O
4 201 217 3108839 microangiopathic JJ B-NP O
5 218 227 3108839 hemolytic JJ I-NP D000743
6 228 234 3108839 anemia NN I-NP D000743
7 234 235 3108839 , , O O
8 236 252 3108839 thrombocytopenia NN B-NP D013921
9 253 256 3108839 and CC O O
10 257 268 3108839 progressive JJ B-NP O
11 269 274 3108839 renal JJ I-NP D051437
12 275 282 3108839 failure NN I-NP D051437
13 283 293 3108839 associated VBN B-VP O
14 294 298 3108839 with IN B-PP O
15 299 308 3108839 mitomycin NN B-NP D016685
16 309 310 3108839 C NN I-NP D016685
17 311 320 3108839 treatment NN I-NP O
18 321 324 3108839 and CC O O
19 325 332 3108839 affects VBZ B-VP O
20 333 338 3108839 about RB B-NP O
21 339 342 3108839 10% CD I-NP O
22 343 345 3108839 of IN B-PP O
23 346 354 3108839 patients NNS B-NP O
24 355 362 3108839 treated VBN B-VP O
25 363 367 3108839 with IN B-PP O
26 368 372 3108839 this DT B-NP O
27 373 378 3108839 agent NN I-NP O
28 378 379 3108839 . . O O

1 380 383 3108839 The DT B-NP O
2 384 389 3108839 renal JJ I-NP D051437
3 390 397 3108839 failure NN I-NP D051437
4 398 405 3108839 usually RB B-ADVP O
5 406 414 3108839 develops VBZ B-VP O
6 415 420 3108839 about RB B-NP O
7 421 422 3108839 8 CD I-NP O
8 422 423 3108839 - HYPH I-NP O
9 423 425 3108839 10 CD I-NP O
10 426 429 3108839 mth NN I-NP O
11 430 435 3108839 after IN B-PP O
12 436 441 3108839 start NN B-NP O
13 442 444 3108839 of IN B-PP O
14 445 454 3108839 mitomycin NN B-NP D016685
15 455 456 3108839 C NN I-NP D016685
16 457 466 3108839 treatment NN I-NP O
17 467 470 3108839 and CC O O
18 471 474 3108839 the DT B-NP O
19 475 484 3108839 mortality NN I-NP O
20 485 487 3108839 is VBZ B-VP O
21 488 501 3108839 approximately RB B-ADJP O
22 502 505 3108839 60% JJ I-ADJP O
23 506 510 3108839 from IN B-PP O
24 511 516 3108839 renal JJ B-NP D051437
25 517 524 3108839 failure NN I-NP D051437
26 525 527 3108839 or CC O O
27 528 537 3108839 pulmonary JJ B-NP D011654
28 538 543 3108839 edema NN I-NP D011654
29 543 544 3108839 . . O O

1 545 550 3108839 Renal JJ B-NP D051437
2 551 558 3108839 lesions NNS I-NP D051437
3 559 562 3108839 are VBP B-VP O
4 563 570 3108839 similar JJ B-ADJP O
5 571 573 3108839 to TO B-PP O
6 574 579 3108839 those DT B-NP O
7 580 584 3108839 seen VBN B-VP O
8 585 587 3108839 in IN B-PP O
9 588 598 3108839 idiopathic JJ B-NP O
10 599 602 3108839 HUS NNS I-NP D006463
11 603 606 3108839 and CC O O
12 607 614 3108839 include VBP B-VP O
13 615 625 3108839 arteriolar JJ B-NP O
14 626 632 3108839 fibrin NN I-NP O
15 633 640 3108839 thrombi NN I-NP D013927
16 640 641 3108839 , , O O
17 642 650 3108839 expanded VBD B-VP O
18 651 665 3108839 subendothelial JJ B-NP O
19 666 671 3108839 zones NNS I-NP O
20 672 674 3108839 in IN B-PP O
21 675 685 3108839 glomerular JJ B-NP O
22 686 695 3108839 capillary JJ I-NP O
23 696 701 3108839 walls NNS I-NP O
24 701 702 3108839 , , O O
25 703 711 3108839 ischemic JJ B-NP D007511
26 712 721 3108839 wrinkling NN I-NP O
27 722 724 3108839 of IN B-PP O
28 725 735 3108839 glomerular JJ B-NP O
29 736 744 3108839 basement NN I-NP O
30 745 754 3108839 membranes NNS I-NP O
31 755 758 3108839 and CC I-NP O
32 759 772 3108839 mesangiolysis NN I-NP O
33 772 773 3108839 . . O O

1 774 777 3108839 The DT B-NP O
2 778 787 3108839 mechanism NN I-NP O
3 788 790 3108839 of IN B-PP O
4 791 797 3108839 action NN B-NP O
5 798 800 3108839 is VBZ B-VP O
6 801 811 3108839 postulated VBN I-VP O
7 812 814 3108839 as IN B-PP O
8 815 824 3108839 mitomycin NN B-NP D016685
9 825 826 3108839 C NN I-NP D016685
10 826 827 3108839 - HYPH O O
11 827 834 3108839 induced VBN B-NP O
12 835 846 3108839 endothelial JJ I-NP O
13 847 851 3108839 cell NN I-NP O
14 852 858 3108839 damage NN I-NP O
15 858 859 3108839 . . O O

1 860 862 3108839 We PRP B-NP O
2 863 871 3108839 describe VBP B-VP O
3 872 875 3108839 the DT B-NP O
4 876 884 3108839 clinical JJ I-NP O
5 885 891 3108839 course NN I-NP O
6 892 895 3108839 and CC O O
7 896 908 3108839 pathological JJ B-NP O
8 909 917 3108839 findings NNS I-NP O
9 918 920 3108839 in IN B-PP O
10 921 922 3108839 a DT B-NP O
11 923 925 3108839 65 CD I-NP O
12 926 928 3108839 yr NN I-NP O
13 928 929 3108839 - HYPH B-NP O
14 929 932 3108839 old JJ I-NP O
15 933 936 3108839 man NN I-NP O
16 937 941 3108839 with IN B-PP O
17 942 949 3108839 gastric JJ B-NP D013274
18 950 964 3108839 adenocarcinoma NN I-NP D013274
19 965 968 3108839 who WP B-NP O
20 969 978 3108839 developed VBD B-VP O
21 979 984 3108839 renal JJ B-NP D051437
22 985 992 3108839 failure NN I-NP D051437
23 993 996 3108839 and CC I-NP O
24 997 1013 3108839 thrombocytopenia NN I-NP D013921
25 1014 1019 3108839 while IN B-SBAR O
26 1020 1022 3108839 on IN B-PP O
27 1023 1032 3108839 treatment NN B-NP O
28 1033 1037 3108839 with IN B-PP O
29 1038 1047 3108839 mitomycin NN B-NP D016685
30 1048 1049 3108839 C NN I-NP D016685
31 1050 1053 3108839 and CC O O
32 1054 1058 3108839 died VBD B-VP O
33 1059 1061 3108839 in IN B-PP O
34 1062 1071 3108839 pulmonary JJ B-NP D011654
35 1072 1077 3108839 edema NN I-NP D011654
36 1077 1078 3108839 . . O O

1 0 0 7650771 -DOCSTART- -X- -X- O

1 0 11 7650771 Cholinergic JJ B-NP O
2 12 20 7650771 toxicity NN I-NP D064420
3 21 30 7650771 resulting VBG B-VP O
4 31 35 7650771 from IN B-PP O
5 36 42 7650771 ocular JJ B-NP O
6 43 55 7650771 instillation NN I-NP O
7 56 58 7650771 of IN B-PP O
8 59 72 7650771 echothiophate NN B-NP D004456
9 73 79 7650771 iodide NN I-NP D004456
10 80 83 7650771 eye NN I-NP O
11 84 89 7650771 drops VBZ B-VP O
12 89 90 7650771 . . O O
13 91 92 7650771 A DT B-NP O
14 93 100 7650771 patient NN I-NP O
15 101 110 7650771 developed VBD B-VP O
16 111 112 7650771 a DT B-NP O
17 113 119 7650771 severe JJ I-NP O
18 120 131 7650771 cholinergic JJ I-NP O
19 132 140 7650771 syndrome NN I-NP O
20 141 145 7650771 from IN B-PP O
21 146 149 7650771 the DT B-NP O
22 150 153 7650771 use NN I-NP O
23 154 156 7650771 of IN B-PP O
24 157 170 7650771 echothiophate NN B-NP D004456
25 171 177 7650771 iodide NN I-NP D004456
26 178 188 7650771 ophthalmic JJ I-NP O
27 189 194 7650771 drops NNS I-NP O
28 194 195 7650771 , , O O
29 196 205 7650771 presented VBD B-VP O
30 206 210 7650771 with IN B-PP O
31 211 219 7650771 profound JJ B-NP O
32 220 226 7650771 muscle NN I-NP D018908
33 227 235 7650771 weakness NN I-NP D018908
34 236 239 7650771 and CC O O
35 240 243 7650771 was VBD B-VP O
36 244 253 7650771 initially RB I-VP O
37 254 259 7650771 given VBN I-VP O
38 260 263 7650771 the DT B-NP O
39 264 273 7650771 diagnosis NN I-NP O
40 274 276 7650771 of IN B-PP O
41 277 287 7650771 myasthenia NN B-NP D009157
42 288 294 7650771 gravis NN I-NP D009157
43 294 295 7650771 . . O O

1 296 299 7650771 Red JJ B-NP O
2 300 305 7650771 blood NN I-NP O
3 306 310 7650771 cell NN I-NP O
4 311 314 7650771 and CC I-NP O
5 315 320 7650771 serum NN I-NP O
6 321 335 7650771 cholinesterase NN I-NP O
7 336 342 7650771 levels NNS I-NP O
8 343 347 7650771 were VBD B-VP O
9 348 356 7650771 severely RB I-VP O
10 357 366 7650771 depressed VBN I-VP O
11 367 370 7650771 and CC O O
12 371 379 7650771 symptoms NNS B-NP O
13 380 388 7650771 resolved VBN B-VP O
14 389 402 7650771 spontaneously RB I-VP O
15 403 412 7650771 following VBG I-VP O
16 413 428 7650771 discontinuation NN B-NP O
17 429 431 7650771 of IN B-PP O
18 432 435 7650771 the DT B-NP O
19 436 439 7650771 eye NN I-NP O
20 440 445 7650771 drops VBZ B-VP O
21 445 446 7650771 . . O O

1 0 0 8494478 -DOCSTART- -X- -X- O

1 0 13 8494478 Ciprofloxacin NN B-NP D002939
2 13 14 8494478 - HYPH B-NP O
3 14 21 8494478 induced VBN I-NP O
4 22 36 8494478 nephrotoxicity NN I-NP D007674
5 37 39 8494478 in IN B-PP O
6 40 48 8494478 patients NNS B-NP O
7 49 53 8494478 with IN B-PP O
8 54 60 8494478 cancer NN B-NP D009369
9 60 61 8494478 . . B-NP O
10 62 76 8494478 Nephrotoxicity NN I-NP D007674
11 77 87 8494478 associated VBD B-VP O
12 88 92 8494478 with IN B-PP O
13 93 106 8494478 ciprofloxacin NN B-NP D002939
14 107 109 8494478 is VBZ B-VP O
15 110 118 8494478 uncommon JJ B-ADJP O
16 118 119 8494478 . . O O

1 120 124 8494478 Five CD B-NP O
2 125 133 8494478 patients NNS I-NP O
3 134 138 8494478 with IN B-PP O
4 139 145 8494478 cancer NN B-NP D009369
5 146 149 8494478 who WP B-NP O
6 150 159 8494478 developed VBD B-VP O
7 160 165 8494478 acute JJ B-NP D058186
8 166 171 8494478 renal JJ I-NP D058186
9 172 179 8494478 failure NN I-NP D058186
10 180 184 8494478 that WDT B-NP O
11 185 193 8494478 followed VBD B-VP O
12 194 203 8494478 treatment NN B-NP O
13 204 208 8494478 with IN B-PP O
14 209 222 8494478 ciprofloxacin NN B-NP D002939
15 223 226 8494478 are VBP B-VP O
16 227 236 8494478 described VBN I-VP O
17 237 240 8494478 and CC O O
18 241 243 8494478 an DT B-NP O
19 244 254 8494478 additional JJ I-NP O
20 255 257 8494478 15 CD I-NP O
21 258 263 8494478 cases NNS I-NP O
22 264 272 8494478 reported VBN B-VP O
23 273 275 8494478 in IN B-PP O
24 276 279 8494478 the DT B-NP O
25 280 290 8494478 literature NN I-NP O
26 291 294 8494478 are VBP B-VP O
27 295 303 8494478 reviewed VBN I-VP O
28 303 304 8494478 . . O O

1 305 310 8494478 Other JJ B-ADJP O
2 311 315 8494478 than IN B-PP O
3 316 325 8494478 elevation NN B-NP O
4 326 328 8494478 of IN B-PP O
5 329 334 8494478 serum NN B-NP O
6 335 345 8494478 creatinine NN I-NP D003404
7 346 352 8494478 levels NNS I-NP O
8 352 353 8494478 , , O O
9 354 368 8494478 characteristic JJ B-NP O
10 369 377 8494478 clinical JJ I-NP O
11 378 392 8494478 manifestations NNS I-NP O
12 393 396 8494478 and CC O O
13 397 405 8494478 abnormal JJ B-NP O
14 406 416 8494478 laboratory NN I-NP O
15 417 425 8494478 findings NNS I-NP O
16 426 429 8494478 are VBP B-VP O
17 430 433 8494478 not RB O O
18 434 444 8494478 frequently RB B-ADJP O
19 445 452 8494478 present JJ I-ADJP O
20 452 453 8494478 . . O O

1 454 462 8494478 Allergic JJ B-NP O
2 463 475 8494478 interstitial JJ I-NP D009395
3 476 485 8494478 nephritis NN I-NP D009395
4 486 488 8494478 is VBZ B-VP O
5 489 497 8494478 believed VBN I-VP O
6 498 500 8494478 to TO I-VP O
7 501 503 8494478 be VB I-VP O
8 504 507 8494478 the DT B-NP O
9 508 518 8494478 underlying VBG I-NP O
10 519 531 8494478 pathological JJ I-NP O
11 531 532 8494478 - HYPH I-NP O
12 532 539 8494478 process NN I-NP O
13 539 540 8494478 . . O O

1 541 551 8494478 Definitive JJ B-NP O
2 552 561 8494478 diagnosis NN I-NP O
3 562 570 8494478 requires VBZ B-VP O
4 571 582 8494478 performance NN B-NP O
5 583 585 8494478 of IN B-PP O
6 586 591 8494478 renal JJ B-NP O
7 592 598 8494478 biopsy NN I-NP O
8 598 599 8494478 , , O O
9 600 608 8494478 although IN B-SBAR O
10 609 613 8494478 this DT B-NP O
11 614 616 8494478 is VBZ B-VP O
12 617 620 8494478 not RB O O
13 621 627 8494478 always RB B-ADVP O
14 628 636 8494478 feasible JJ B-ADJP O
15 636 637 8494478 . . O O

1 638 640 8494478 An DT B-NP O
2 641 652 8494478 improvement NN I-NP O
3 653 655 8494478 in IN B-PP O
4 656 661 8494478 renal JJ B-NP O
5 662 670 8494478 function NN I-NP O
6 671 675 8494478 that WDT B-NP O
7 676 684 8494478 followed VBD B-VP O
8 685 688 8494478 the DT B-NP O
9 689 704 8494478 discontinuation NN I-NP O
10 705 707 8494478 of IN B-PP O
11 708 711 8494478 the DT B-NP O
12 712 721 8494478 offending VBG I-NP O
13 722 732 8494478 antibiotic NN I-NP O
14 733 741 8494478 supports VBZ B-VP O
15 742 745 8494478 the DT B-NP O
16 746 757 8494478 presumptive JJ I-NP O
17 758 767 8494478 diagnosis NN I-NP O
18 768 770 8494478 of IN B-PP O
19 771 784 8494478 ciprofloxacin NN B-NP D002939
20 784 785 8494478 - HYPH B-NP O
21 785 792 8494478 induced VBN I-NP O
22 793 798 8494478 acute JJ I-NP D058186
23 799 804 8494478 renal JJ I-NP D058186
24 805 812 8494478 failure NN I-NP D058186
25 812 813 8494478 . . O O

1 0 0 11099450 -DOCSTART- -X- -X- O

1 0 8 11099450 Evidence NN B-NP O
2 9 11 11099450 of IN B-PP O
3 12 22 11099450 functional JJ B-NP O
4 23 33 11099450 somatotopy NN I-NP O
5 34 36 11099450 in IN B-PP O
6 37 40 11099450 GPi NNP B-NP O
7 41 45 11099450 from IN B-PP O
8 46 53 11099450 results NNS B-NP O
9 54 56 11099450 of IN B-PP O
10 57 68 11099450 pallidotomy NN B-NP O
11 68 69 11099450 . . O O
12 70 73 11099450 The DT B-NP O
13 74 83 11099450 objective NN I-NP O
14 84 86 11099450 of IN B-PP O
15 87 91 11099450 this DT B-NP O
16 92 97 11099450 study NN I-NP O
17 98 101 11099450 was VBD B-VP O
18 102 104 11099450 to TO B-VP O
19 105 112 11099450 explore VB I-VP O
20 113 116 11099450 the DT B-NP O
21 117 127 11099450 functional JJ I-NP O
22 128 135 11099450 anatomy NN I-NP O
23 136 138 11099450 of IN B-PP O
24 139 142 11099450 the DT B-NP O
25 143 149 11099450 globus NN I-NP O
26 150 158 11099450 pallidus NN I-NP O
27 159 167 11099450 internus NN I-NP O
28 168 169 11099450 ( ( O O
29 169 172 11099450 GPi NN B-NP O
30 172 173 11099450 ) ) O O
31 174 176 11099450 by IN B-PP O
32 177 185 11099450 studying VBG B-VP O
33 186 189 11099450 the DT B-NP O
34 190 197 11099450 effects NNS I-NP O
35 198 200 11099450 of IN B-PP O
36 201 211 11099450 unilateral JJ B-NP O
37 212 223 11099450 pallidotomy NN I-NP O
38 224 226 11099450 on IN B-PP O
39 227 239 11099450 parkinsonian NN B-NP D010300
40 240 241 11099450 ' POS B-NP O
41 241 244 11099450 off RP B-PRT O
42 244 245 11099450 ' POS B-NP O
43 246 251 11099450 signs NNS I-NP O
44 252 255 11099450 and CC I-NP O
45 256 264 11099450 levodopa NN I-NP D007980
46 264 265 11099450 - HYPH B-NP O
47 265 272 11099450 induced VBN I-NP O
48 273 284 11099450 dyskinesias NNS I-NP D004409
49 285 286 11099450 ( ( O O
50 286 289 11099450 LID NN B-NP D004409
51 289 290 11099450 ) ) O O
52 290 291 11099450 . . O O

1 292 294 11099450 We PRP B-NP O
2 295 300 11099450 found VBD B-VP O
3 301 312 11099450 significant JJ B-NP O
4 313 321 11099450 positive JJ I-NP O
5 322 334 11099450 correlations NNS I-NP O
6 335 342 11099450 between IN B-PP O
7 343 346 11099450 the DT B-NP O
8 347 359 11099450 preoperative JJ I-NP O
9 360 368 11099450 levodopa NN I-NP D007980
10 369 383 11099450 responsiveness NN I-NP O
11 384 386 11099450 of IN B-PP O
12 387 392 11099450 motor NN B-NP O
13 393 398 11099450 signs NNS I-NP O
14 399 402 11099450 and CC O O
15 403 406 11099450 the DT B-NP O
16 407 415 11099450 levodopa NN I-NP D007980
17 416 430 11099450 responsiveness NN I-NP O
18 431 433 11099450 of IN B-PP O
19 434 440 11099450 scores NNS B-NP O
20 441 443 11099450 in IN B-PP O
21 444 449 11099450 timed VBN B-NP O
22 450 455 11099450 tests NNS I-NP O
23 456 457 11099450 ( ( O O
24 457 461 11099450 Core NNP B-NP O
25 462 472 11099450 Assessment NNP I-NP O
26 473 480 11099450 Program NNP I-NP O
27 481 484 11099450 for IN B-PP O
28 485 498 11099450 Intracerebral NNP B-NP O
29 499 515 11099450 Transplantations NNP I-NP O
30 515 516 11099450 ) ) O O
31 517 519 11099450 in IN B-PP O
32 520 523 11099450 the DT B-NP O
33 524 537 11099450 contralateral JJ I-NP O
34 538 543 11099450 limbs NNS I-NP O
35 544 547 11099450 and CC O O
36 548 551 11099450 the DT B-NP O
37 552 563 11099450 improvement NN I-NP O
38 564 566 11099450 in IN B-PP O
39 567 572 11099450 these DT B-NP O
40 573 579 11099450 scores NNS I-NP O
41 580 585 11099450 after IN B-PP O
42 586 593 11099450 surgery NN B-NP O
43 593 594 11099450 , , O O
44 595 602 11099450 whereas IN O O
45 603 608 11099450 there EX B-NP O
46 609 612 11099450 was VBD B-VP O
47 613 615 11099450 no DT B-NP O
48 616 627 11099450 correlation NN I-NP O
49 628 632 11099450 with IN B-PP O
50 633 636 11099450 the DT B-NP O
51 637 648 11099450 improvement NN I-NP O
52 649 651 11099450 in IN B-PP O
53 652 655 11099450 LID NN B-NP D004409
54 655 656 11099450 . . O O

1 657 659 11099450 We PRP B-NP O
2 660 664 11099450 also RB B-ADVP O
3 665 670 11099450 found VBD B-VP O
4 671 672 11099450 a DT B-NP O
5 673 679 11099450 highly RB I-NP O
6 680 691 11099450 significant JJ I-NP O
7 692 703 11099450 correlation NN I-NP O
8 704 705 11099450 ( ( O O
9 705 706 11099450 P NN B-NP O
10 706 707 11099450 : : O O
11 708 709 11099450 < SYM B-NP O
12 710 716 11099450 0.0001 CD I-NP O
13 716 717 11099450 , , O O
14 718 719 11099450 r NN B-NP O
15 720 721 11099450 = SYM B-VP O
16 722 725 11099450 0.8 CD B-NP O
17 725 726 11099450 ) ) O O
18 727 734 11099450 between IN B-PP O
19 735 738 11099450 the DT B-NP O
20 739 745 11099450 volume NN I-NP O
21 746 748 11099450 of IN B-PP O
22 749 752 11099450 the DT B-NP O
23 753 760 11099450 ventral JJ I-NP O
24 761 767 11099450 lesion NN I-NP O
25 768 770 11099450 in IN B-PP O
26 771 774 11099450 the DT B-NP O
27 775 778 11099450 GPi NNP I-NP O
28 779 782 11099450 and CC O O
29 783 786 11099450 the DT B-NP O
30 787 798 11099450 improvement NN I-NP O
31 799 801 11099450 in IN B-PP O
32 802 805 11099450 LID NN B-NP D004409
33 806 808 11099450 in IN B-PP O
34 809 812 11099450 the DT B-NP O
35 813 826 11099450 contralateral JJ I-NP O
36 827 832 11099450 limbs NNS I-NP O
37 832 833 11099450 , , O O
38 834 841 11099450 whereas IN O O
39 842 847 11099450 there EX B-NP O
40 848 851 11099450 was VBD B-VP O
41 852 854 11099450 no DT B-NP O
42 855 866 11099450 correlation NN I-NP O
43 867 874 11099450 between IN B-PP O
44 875 878 11099450 the DT B-NP O
45 879 886 11099450 ventral JJ I-NP O
46 887 893 11099450 volume NN I-NP O
47 894 897 11099450 and CC O O
48 898 901 11099450 the DT B-NP O
49 902 913 11099450 improvement NN I-NP O
50 914 916 11099450 in IN B-PP O
51 917 929 11099450 parkinsonian NN B-NP D010300
52 930 931 11099450 ' POS B-NP O
53 931 934 11099450 off RP B-PRT O
54 934 935 11099450 ' POS B-NP O
55 936 941 11099450 signs NNS I-NP O
56 941 942 11099450 . . O O

1 943 946 11099450 The DT B-NP O
2 947 954 11099450 volumes NNS I-NP O
3 955 957 11099450 of IN B-PP O
4 958 961 11099450 the DT B-NP O
5 962 967 11099450 total JJ I-NP O
6 968 974 11099450 lesion NN I-NP O
7 975 983 11099450 cylinder NN I-NP O
8 984 987 11099450 and CC O O
9 988 991 11099450 the DT B-NP O
10 992 998 11099450 dorsal JJ I-NP O
11 999 1005 11099450 lesion NN I-NP O
12 1006 1009 11099450 did VBD B-VP O
13 1010 1013 11099450 not RB I-VP O
14 1014 1023 11099450 correlate VB I-VP O
15 1024 1028 11099450 with IN B-PP O
16 1029 1032 11099450 the DT B-NP O
17 1033 1040 11099450 outcome NN I-NP O
18 1041 1043 11099450 of IN B-PP O
19 1044 1050 11099450 either CC B-NP O
20 1051 1062 11099450 dyskinesias NNS I-NP D004409
21 1063 1065 11099450 or CC I-NP O
22 1066 1078 11099450 parkinsonian NN I-NP D010300
23 1079 1080 11099450 ' '' O O
24 1080 1083 11099450 off RP B-PRT O
25 1083 1084 11099450 ' POS B-NP O
26 1085 1090 11099450 signs NNS I-NP O
27 1090 1091 11099450 . . O O

1 1092 1095 11099450 The DT B-NP O
2 1096 1108 11099450 differential JJ I-NP O
3 1109 1119 11099450 predictive JJ I-NP O
4 1120 1125 11099450 value NN I-NP O
5 1126 1128 11099450 of IN B-PP O
6 1129 1137 11099450 levodopa NN B-NP D007980
7 1138 1152 11099450 responsiveness NN I-NP O
8 1153 1156 11099450 for IN B-PP O
9 1157 1160 11099450 the DT B-NP O
10 1161 1168 11099450 outcome NN I-NP O
11 1169 1171 11099450 of IN B-PP O
12 1172 1184 11099450 parkinsonian NN B-NP D010300
13 1185 1186 11099450 ' POS B-NP O
14 1186 1189 11099450 off RP B-PRT O
15 1189 1190 11099450 ' POS B-NP O
16 1191 1196 11099450 signs NNS I-NP O
17 1197 1200 11099450 and CC I-NP O
18 1201 1204 11099450 LID NN I-NP D004409
19 1205 1208 11099450 and CC O O
20 1209 1212 11099450 the DT B-NP O
21 1213 1222 11099450 different JJ I-NP O
22 1223 1235 11099450 correlations NNS I-NP O
23 1236 1238 11099450 of IN B-PP O
24 1239 1246 11099450 ventral JJ B-NP O
25 1247 1253 11099450 lesion NN I-NP O
26 1254 1260 11099450 volume NN I-NP O
27 1261 1265 11099450 with IN B-PP O
28 1266 1277 11099450 dyskinesias NNS B-NP D004409
29 1278 1281 11099450 and CC I-NP O
30 1282 1294 11099450 parkinsonian NN I-NP D010300
31 1295 1296 11099450 ' '' O O
32 1296 1299 11099450 off RP B-PRT O
33 1299 1300 11099450 ' POS B-NP O
34 1301 1306 11099450 signs NNS I-NP O
35 1307 1315 11099450 indicate VBP B-VP O
36 1316 1320 11099450 that IN B-SBAR O
37 1321 1330 11099450 different JJ B-NP O
38 1331 1341 11099450 anatomical JJ I-NP O
39 1342 1344 11099450 or CC I-NP O
40 1345 1363 11099450 pathophysiological JJ I-NP O
41 1364 1374 11099450 substrates NNS I-NP O
42 1375 1378 11099450 may MD B-VP O
43 1379 1381 11099450 be VB I-VP O
44 1382 1393 11099450 responsible JJ B-ADJP O
45 1394 1397 11099450 for IN B-PP O
46 1398 1401 11099450 the DT B-NP O
47 1402 1412 11099450 generation NN I-NP O
48 1413 1415 11099450 of IN B-PP O
49 1416 1428 11099450 parkinsonian NN B-NP D010300
50 1429 1430 11099450 ' POS B-NP O
51 1430 1433 11099450 off RP B-PRT O
52 1433 1434 11099450 ' POS B-NP O
53 1435 1440 11099450 signs NNS I-NP O
54 1441 1444 11099450 and CC I-NP O
55 1445 1456 11099450 dyskinesias NNS I-NP D004409
56 1456 1457 11099450 . . O O

1 1458 1465 11099450 Whereas IN B-PP O
2 1466 1471 11099450 cells NNS B-NP O
3 1472 1474 11099450 in IN B-PP O
4 1475 1476 11099450 a DT B-NP O
5 1477 1482 11099450 wider JJR I-NP O
6 1483 1487 11099450 area NN I-NP O
7 1488 1490 11099450 of IN B-PP O
8 1491 1494 11099450 the DT B-NP O
9 1495 1498 11099450 GPi NNP I-NP O
10 1499 1502 11099450 may MD B-VP O
11 1503 1505 11099450 be VB I-VP O
12 1506 1516 11099450 implicated VBN I-VP O
13 1517 1519 11099450 in IN B-PP O
14 1520 1532 11099450 parkinsonism NN B-NP D010300
15 1532 1533 11099450 , , O O
16 1534 1537 11099450 the DT B-NP O
17 1538 1545 11099450 ventral JJ I-NP O
18 1546 1549 11099450 GPi NNP I-NP O
19 1550 1555 11099450 seems VBZ B-VP O
20 1556 1558 11099450 to TO I-VP O
21 1559 1561 11099450 be VB I-VP O
22 1562 1569 11099450 crucial JJ B-ADJP O
23 1570 1573 11099450 for IN B-PP O
24 1574 1577 11099450 the DT B-NP O
25 1578 1591 11099450 manifestation NN I-NP O
26 1592 1594 11099450 of IN B-PP O
27 1595 1598 11099450 LID NN B-NP D004409
28 1598 1599 11099450 . . O O

1 1600 1602 11099450 We PRP B-NP O
2 1603 1610 11099450 suggest VBP B-VP O
3 1611 1615 11099450 that IN B-SBAR O
4 1616 1619 11099450 our PRP$ B-NP O
5 1620 1632 11099450 observations NNS I-NP O
6 1633 1636 11099450 are VBP B-VP O
7 1637 1647 11099450 additional JJ B-NP O
8 1648 1653 11099450 proof NN I-NP O
9 1654 1656 11099450 of IN B-PP O
10 1657 1660 11099450 the DT B-NP O
11 1661 1671 11099450 functional JJ I-NP O
12 1672 1682 11099450 somatotopy NN I-NP O
13 1683 1685 11099450 of IN B-PP O
14 1686 1689 11099450 the DT B-NP O
15 1690 1697 11099450 systems NNS I-NP O
16 1698 1704 11099450 within IN B-PP O
17 1705 1708 11099450 the DT B-NP O
18 1709 1712 11099450 GPi NNP I-NP O
19 1713 1717 11099450 that WDT B-NP O
20 1718 1725 11099450 mediate VBP B-VP O
21 1726 1738 11099450 parkinsonism NN B-NP D010300
22 1739 1742 11099450 and CC I-NP O
23 1743 1754 11099450 dyskinesias NNS I-NP D004409
24 1754 1755 11099450 , , O O
25 1756 1766 11099450 especially RB B-ADVP O
26 1767 1772 11099450 along IN B-PP O
27 1773 1776 11099450 the DT B-NP O
28 1777 1789 11099450 dorsoventral JJ I-NP O
29 1790 1800 11099450 trajectory NN I-NP O
30 1801 1805 11099450 used VBN B-VP O
31 1806 1808 11099450 in IN B-PP O
32 1809 1820 11099450 pallidotomy NN B-NP O
33 1820 1821 11099450 . . O O

1 1822 1825 11099450 The DT B-NP O
2 1826 1833 11099450 outcome NN I-NP O
3 1834 1836 11099450 of IN B-PP O
4 1837 1848 11099450 pallidotomy NN B-NP O
5 1849 1851 11099450 in IN B-PP O
6 1852 1857 11099450 which WDT B-NP O
7 1858 1861 11099450 the DT B-NP O
8 1862 1868 11099450 lesion NN I-NP O
9 1869 1877 11099450 involves VBZ B-VP O
10 1878 1881 11099450 the DT B-NP O
11 1882 1889 11099450 ventral JJ I-NP O
12 1890 1893 11099450 and CC I-NP O
13 1894 1900 11099450 dorsal JJ I-NP O
14 1901 1904 11099450 GPi NNP I-NP O
15 1905 1910 11099450 could MD B-VP O
16 1911 1913 11099450 be VB I-VP O
17 1914 1917 11099450 the DT B-NP O
18 1918 1921 11099450 net JJ I-NP O
19 1922 1928 11099450 effect NN I-NP O
20 1929 1931 11099450 of IN B-PP O
21 1932 1942 11099450 alteration NN B-NP O
22 1943 1945 11099450 in IN B-PP O
23 1946 1949 11099450 the DT B-NP O
24 1950 1958 11099450 activity NN I-NP O
25 1959 1961 11099450 of IN B-PP O
26 1962 1970 11099450 pathways NNS B-NP O
27 1971 1976 11099450 which WDT B-NP O
28 1977 1984 11099450 mediate VBP B-VP O
29 1985 1994 11099450 different JJ B-NP O
30 1995 2003 11099450 symptoms NNS I-NP O
31 2003 2004 11099450 , , O O
32 2005 2008 11099450 and CC O O
33 2009 2014 11099450 hence RB B-VP O
34 2015 2020 11099450 could MD I-VP O
35 2021 2023 11099450 be VB I-VP O
36 2024 2032 11099450 variable JJ B-ADJP O
37 2032 2033 11099450 . . O O

1 0 0 11077455 -DOCSTART- -X- -X- O

1 0 7 11077455 Electro AFX B-NP O
2 7 8 11077455 - HYPH I-NP O
3 8 19 11077455 oculography NN B-NP O
4 19 20 11077455 , , O O
5 21 40 11077455 electroretinography NN B-NP O
6 40 41 11077455 , , O O
7 42 48 11077455 visual JJ B-NP O
8 49 55 11077455 evoked JJ I-NP O
9 56 66 11077455 potentials NNS I-NP O
10 66 67 11077455 , , O O
11 68 71 11077455 and CC O O
12 72 82 11077455 multifocal JJ B-NP O
13 83 102 11077455 electroretinography NN I-NP O
14 103 105 11077455 in IN B-PP O
15 106 114 11077455 patients NNS B-NP O
16 115 119 11077455 with IN B-PP O
17 120 130 11077455 vigabatrin NN B-NP D020888
18 130 131 11077455 - HYPH O O
19 131 141 11077455 attributed VBN B-NP O
20 142 148 11077455 visual JJ I-NP D014786
21 149 154 11077455 field NN I-NP D014786
22 155 167 11077455 constriction NN I-NP D014786
23 167 168 11077455 . . I-NP O
24 169 176 11077455 PURPOSE NN I-NP O
25 176 177 11077455 : : O O
26 178 189 11077455 Symptomatic JJ B-NP O
27 190 196 11077455 visual JJ I-NP D014786
28 197 202 11077455 field NN I-NP D014786
29 203 215 11077455 constriction NN I-NP D014786
30 216 223 11077455 thought VBN B-VP O
31 224 226 11077455 to TO I-VP O
32 227 229 11077455 be VB I-VP O
33 230 240 11077455 associated VBN I-VP O
34 241 245 11077455 with IN B-PP O
35 246 256 11077455 vigabatrin NN B-NP D020888
36 257 260 11077455 has VBZ B-VP O
37 261 265 11077455 been VBN I-VP O
38 266 274 11077455 reported VBN I-VP O
39 274 275 11077455 . . O O

1 276 279 11077455 The DT B-NP O
2 280 287 11077455 current JJ I-NP O
3 288 293 11077455 study NN I-NP O
4 294 306 11077455 investigated VBD B-VP O
5 307 310 11077455 the DT B-NP O
6 311 317 11077455 visual JJ I-NP O
7 318 324 11077455 fields NNS I-NP O
8 325 328 11077455 and CC O O
9 329 335 11077455 visual JJ B-NP O
10 336 353 11077455 electrophysiology NN I-NP O
11 354 356 11077455 of IN B-PP O
12 357 362 11077455 eight CD B-NP O
13 363 371 11077455 patients NNS I-NP O
14 372 376 11077455 with IN B-PP O
15 377 382 11077455 known VBN B-NP O
16 383 393 11077455 vigabatrin NN I-NP D020888
17 393 394 11077455 - HYPH B-VP O
18 394 404 11077455 attributed VBN B-NP O
19 405 411 11077455 visual JJ I-NP D014786
20 412 417 11077455 field NN I-NP D014786
21 418 422 11077455 loss NN I-NP D014786
22 422 423 11077455 , , O O
23 424 429 11077455 three CD B-NP O
24 430 432 11077455 of IN B-PP O
25 433 437 11077455 whom WP B-NP O
26 438 442 11077455 were VBD B-VP O
27 443 451 11077455 reported VBN I-VP O
28 452 462 11077455 previously RB B-ADVP O
29 462 463 11077455 . . O O

1 464 467 11077455 Six CD B-NP O
2 468 470 11077455 of IN B-PP O
3 471 474 11077455 the DT B-NP O
4 475 483 11077455 patients NNS I-NP O
5 484 488 11077455 were VBD B-VP O
6 489 491 11077455 no RB B-ADVP O
7 492 498 11077455 longer RBR I-ADVP O
8 499 508 11077455 receiving VBG B-VP O
9 509 519 11077455 vigabatrin NN B-NP D020888
10 519 520 11077455 . . O O

1 521 528 11077455 METHODS NNS B-NP O
2 528 529 11077455 : : O O
3 530 533 11077455 The DT B-NP O
4 534 541 11077455 central JJ I-NP O
5 542 545 11077455 and CC I-NP O
6 546 556 11077455 peripheral JJ I-NP O
7 557 563 11077455 fields NNS I-NP O
8 564 568 11077455 were VBD B-VP O
9 569 577 11077455 examined VBN I-VP O
10 578 582 11077455 with IN B-PP O
11 583 586 11077455 the DT B-NP O
12 587 595 11077455 Humphrey NNP I-NP O
13 596 602 11077455 Visual NNP I-NP O
14 603 608 11077455 Field NNP I-NP O
15 609 617 11077455 Analyzer NNP I-NP O
16 617 618 11077455 . . O O

1 619 623 11077455 Full JJ B-NP O
2 624 630 11077455 visual JJ I-NP O
3 631 648 11077455 electrophysiology NN I-NP O
4 648 649 11077455 , , O O
5 650 659 11077455 including VBG B-PP O
6 660 665 11077455 flash NN B-NP O
7 666 685 11077455 electroretinography NN I-NP O
8 686 687 11077455 ( ( O O
9 687 690 11077455 ERG NN B-NP O
10 690 691 11077455 ) ) O O
11 691 692 11077455 , , O O
12 693 700 11077455 pattern NN B-NP O
13 701 720 11077455 electroretinography NN I-NP O
14 720 721 11077455 , , O O
15 722 732 11077455 multifocal JJ B-NP O
16 733 736 11077455 ERG NN I-NP O
17 737 742 11077455 using VBG B-VP O
18 743 746 11077455 the DT B-NP O
19 747 752 11077455 VERIS NN I-NP O
20 753 759 11077455 system NN I-NP O
21 759 760 11077455 , , O O
22 761 768 11077455 electro AFX O O
23 768 769 11077455 - HYPH O O
24 769 780 11077455 oculography NN B-NP O
25 780 781 11077455 , , O O
26 782 785 11077455 and CC O O
27 786 791 11077455 flash NN B-NP O
28 792 795 11077455 and CC I-NP O
29 796 803 11077455 pattern NN I-NP O
30 804 810 11077455 visual JJ I-NP O
31 811 817 11077455 evoked JJ I-NP O
32 818 828 11077455 potentials NNS I-NP O
33 828 829 11077455 , , O O
34 830 833 11077455 was VBD B-VP O
35 834 844 11077455 undertaken VBN I-VP O
36 844 845 11077455 . . O O

1 846 853 11077455 RESULTS NNS B-NP O
2 853 854 11077455 : : O O
3 855 860 11077455 Seven CD B-NP O
4 861 869 11077455 patients NNS I-NP O
5 870 876 11077455 showed VBD B-VP O
6 877 883 11077455 marked JJ B-NP O
7 884 890 11077455 visual JJ I-NP D014786
8 891 896 11077455 field NN I-NP D014786
9 897 909 11077455 constriction NN I-NP D014786
10 910 914 11077455 with IN B-PP O
11 915 919 11077455 some DT B-NP O
12 920 927 11077455 sparing NN I-NP O
13 928 930 11077455 of IN B-PP O
14 931 934 11077455 the DT B-NP O
15 935 943 11077455 temporal JJ I-NP O
16 944 950 11077455 visual JJ I-NP O
17 951 956 11077455 field NN I-NP O
18 956 957 11077455 . . O O

1 958 961 11077455 The DT B-NP O
2 962 968 11077455 eighth NN I-NP O
3 969 978 11077455 exhibited VBD B-VP O
4 979 989 11077455 concentric JJ B-NP O
5 990 1002 11077455 constriction NN I-NP O
6 1002 1003 11077455 . . O O

1 1004 1008 11077455 Most JJS B-NP O
2 1009 1029 11077455 electrophysiological JJ I-NP O
3 1030 1039 11077455 responses NNS I-NP O
4 1040 1044 11077455 were VBD B-VP O
5 1045 1052 11077455 usually RB B-ADVP O
6 1053 1057 11077455 just RB B-ADVP O
7 1058 1064 11077455 within IN B-PP O
8 1065 1071 11077455 normal JJ B-NP O
9 1072 1078 11077455 limits NNS I-NP O
10 1078 1079 11077455 ; : O O
11 1080 1083 11077455 two CD B-NP O
12 1084 1092 11077455 patients NNS I-NP O
13 1093 1096 11077455 had VBD B-VP O
14 1097 1106 11077455 subnormal JJ B-NP O
15 1107 1112 11077455 Arden NNP I-NP O
16 1113 1120 11077455 electro AFX O O
17 1120 1121 11077455 - HYPH O O
18 1121 1132 11077455 oculography NN B-NP O
19 1133 1140 11077455 indices NNS I-NP O
20 1140 1141 11077455 ; : O O
21 1142 1145 11077455 and CC O O
22 1146 1149 11077455 one CD B-NP O
23 1150 1157 11077455 patient NN I-NP O
24 1158 1164 11077455 showed VBD B-VP O
25 1165 1167 11077455 an DT B-NP O
26 1168 1178 11077455 abnormally RB I-NP O
27 1179 1186 11077455 delayed VBN I-NP O
28 1187 1195 11077455 photopic JJ I-NP O
29 1196 1197 11077455 b NN I-NP O
30 1198 1202 11077455 wave NN I-NP O
31 1202 1203 11077455 . . O O

1 1204 1211 11077455 However RB B-ADVP O
2 1211 1212 11077455 , , O O
3 1213 1217 11077455 five CD B-NP O
4 1218 1226 11077455 patients NNS I-NP O
5 1227 1233 11077455 showed VBD B-VP O
6 1234 1241 11077455 delayed VBN I-VP O
7 1242 1244 11077455 30 CD B-NP O
8 1244 1245 11077455 - HYPH I-NP O
9 1245 1247 11077455 Hz NN I-NP O
10 1248 1255 11077455 flicker NN I-NP O
11 1256 1257 11077455 b NN I-NP O
12 1258 1263 11077455 waves NNS I-NP O
13 1263 1264 11077455 , , O O
14 1265 1268 11077455 and CC O O
15 1269 1274 11077455 seven CD B-NP O
16 1275 1283 11077455 patients NNS I-NP O
17 1284 1290 11077455 showed VBD B-VP O
18 1291 1298 11077455 delayed VBN I-VP O
19 1299 1310 11077455 oscillatory JJ B-NP O
20 1311 1321 11077455 potentials NNS I-NP O
21 1321 1322 11077455 . . O O

1 1323 1333 11077455 Multifocal JJ B-NP O
2 1334 1337 11077455 ERG NN I-NP O
3 1338 1344 11077455 showed VBD B-VP O
4 1345 1358 11077455 abnormalities NNS B-NP O
5 1359 1363 11077455 that WDT B-NP O
6 1364 1373 11077455 sometimes RB B-ADVP O
7 1374 1384 11077455 correlated VBD B-VP O
8 1385 1389 11077455 with IN B-PP O
9 1390 1393 11077455 the DT B-NP O
10 1394 1400 11077455 visual JJ I-NP O
11 1401 1406 11077455 field NN I-NP O
12 1407 1417 11077455 appearance NN I-NP O
13 1418 1421 11077455 and CC O O
14 1422 1431 11077455 confirmed VBD B-VP O
15 1432 1436 11077455 that IN B-SBAR O
16 1437 1440 11077455 the DT B-NP O
17 1441 1448 11077455 deficit NN I-NP O
18 1449 1455 11077455 occurs VBZ B-VP O
19 1456 1458 11077455 at IN B-PP O
20 1459 1462 11077455 the DT B-NP O
21 1463 1470 11077455 retinal JJ I-NP O
22 1471 1476 11077455 level NN I-NP O
23 1476 1477 11077455 . . O O

1 1478 1488 11077455 CONCLUSION NN B-NP O
2 1488 1489 11077455 : : O O
3 1490 1496 11077455 Marked VBN B-NP O
4 1497 1503 11077455 visual JJ I-NP D014786
5 1504 1509 11077455 field NN I-NP D014786
6 1510 1522 11077455 constriction NN I-NP D014786
7 1523 1530 11077455 appears VBZ B-VP O
8 1531 1533 11077455 to TO I-VP O
9 1534 1536 11077455 be VB I-VP O
10 1537 1547 11077455 associated VBN I-VP O
11 1548 1552 11077455 with IN B-PP O
12 1553 1563 11077455 vigabatrin NN B-NP D020888
13 1564 1571 11077455 therapy NN I-NP O
14 1571 1572 11077455 . . O O

1 1573 1576 11077455 The DT B-NP O
2 1577 1582 11077455 field NN I-NP O
3 1583 1590 11077455 defects NNS I-NP O
4 1591 1594 11077455 and CC O O
5 1595 1599 11077455 some DT B-NP O
6 1600 1620 11077455 electrophysiological JJ I-NP O
7 1621 1634 11077455 abnormalities NNS I-NP O
8 1635 1642 11077455 persist VBP B-VP O
9 1643 1647 11077455 when WRB B-ADVP O
10 1648 1658 11077455 vigabatrin NN B-NP D020888
11 1659 1666 11077455 therapy NN I-NP O
12 1667 1669 11077455 is VBZ B-VP O
13 1670 1679 11077455 withdrawn VBN I-VP O
14 1679 1680 11077455 . . O O

1 0 0 14633084 -DOCSTART- -X- -X- O

1 0 3 14633084 Use NN B-NP O
2 4 6 14633084 of IN B-PP O
3 7 20 14633084 dexamethasone NN B-NP D003907
4 21 25 14633084 with IN B-PP O
5 26 31 14633084 mesna NN B-NP D015080
6 32 35 14633084 for IN B-PP O
7 36 39 14633084 the DT B-NP O
8 40 50 14633084 prevention NN I-NP O
9 51 53 14633084 of IN B-PP O
10 54 64 14633084 ifosfamide NN B-NP D007069
11 64 65 14633084 - HYPH B-NP O
12 65 72 14633084 induced VBN I-NP O
13 73 84 14633084 hemorrhagic JJ I-NP D006470
14 85 93 14633084 cystitis NN I-NP D006470
15 93 94 14633084 . . I-NP O
16 95 98 14633084 AIM NN I-NP O
17 98 99 14633084 : : O O
18 100 111 14633084 Hemorrhagic JJ B-NP D006470
19 112 120 14633084 cystitis NN I-NP D006470
20 121 122 14633084 ( ( O O
21 122 124 14633084 HC NN B-NP D006470
22 124 125 14633084 ) ) O O
23 126 128 14633084 is VBZ B-VP O
24 129 130 14633084 a DT B-NP O
25 131 139 14633084 limiting VBG I-NP O
26 140 144 14633084 side NN I-NP O
27 144 145 14633084 - HYPH B-NP O
28 145 151 14633084 effect NN I-NP O
29 152 154 14633084 of IN B-PP O
30 155 167 14633084 chemotherapy NN B-NP O
31 168 172 14633084 with IN B-PP O
32 173 183 14633084 ifosfamide NN B-NP D007069
33 184 185 14633084 ( ( O O
34 185 188 14633084 IFS NN B-NP D007069
35 188 189 14633084 ) ) O O
36 189 190 14633084 . . O O

1 191 193 14633084 In IN B-PP O
2 194 197 14633084 the DT B-NP O
3 198 203 14633084 study NN I-NP O
4 204 213 14633084 presented VBN B-VP O
5 214 218 14633084 here RB B-ADVP O
6 218 219 14633084 , , O O
7 220 222 14633084 we PRP B-NP O
8 223 235 14633084 investigated VBD B-VP O
9 236 239 14633084 the DT B-NP O
10 240 243 14633084 use NN I-NP O
11 244 246 14633084 of IN B-PP O
12 247 260 14633084 dexamethasone NN B-NP D003907
13 261 263 14633084 in IN B-PP O
14 264 275 14633084 combination NN B-NP O
15 276 280 14633084 with IN B-PP O
16 281 286 14633084 mesna NN B-NP D015080
17 287 290 14633084 for IN B-PP O
18 291 294 14633084 the DT B-NP O
19 295 305 14633084 prevention NN I-NP O
20 306 308 14633084 of IN B-PP O
21 309 312 14633084 IFS NN B-NP D007069
22 312 313 14633084 - HYPH B-NP O
23 313 320 14633084 induced VBN I-NP O
24 321 323 14633084 HC NN I-NP D006470
25 323 324 14633084 . . O O

1 325 332 14633084 METHODS NNS B-NP O
2 332 333 14633084 : : O O
3 334 338 14633084 Male NNP B-NP O
4 339 345 14633084 Wistar NNP I-NP O
5 346 350 14633084 rats NNS I-NP O
6 351 352 14633084 ( ( O O
7 352 355 14633084 150 CD B-NP O
8 355 356 14633084 - HYPH I-NP O
9 356 359 14633084 200 CD I-NP O
10 360 361 14633084 g NN I-NP O
11 361 362 14633084 ; : O O
12 363 364 14633084 6 CD B-NP O
13 365 369 14633084 rats NNS I-NP O
14 370 373 14633084 per IN B-PP O
15 374 379 14633084 group NN B-NP O
16 379 380 14633084 ) ) O O
17 381 385 14633084 were VBD B-VP O
18 386 393 14633084 treated VBN I-VP O
19 394 398 14633084 with IN B-PP O
20 399 405 14633084 saline NN B-NP O
21 406 408 14633084 or CC I-NP O
22 409 414 14633084 mesna NN I-NP D015080
23 415 416 14633084 5 CD I-NP O
24 417 420 14633084 min NN I-NP O
25 421 422 14633084 ( ( O O
26 422 425 14633084 i.p JJ O O
27 425 426 14633084 . . O O
28 426 427 14633084 ) ) O O
29 428 434 14633084 before IN B-PP O
30 435 438 14633084 and CC B-NP O
31 439 440 14633084 2 CD I-NP O
32 441 444 14633084 and CC I-NP O
33 445 446 14633084 6 CD I-NP O
34 447 448 14633084 h NN I-NP O
35 449 454 14633084 after IN B-PP O
36 455 456 14633084 ( ( O O
37 456 459 14633084 v.o JJ O O
38 459 460 14633084 . . O O
39 460 461 14633084 ) ) O O
40 462 476 14633084 administration NN B-NP O
41 477 479 14633084 of IN B-PP O
42 480 483 14633084 IFS NN B-NP D007069
43 483 484 14633084 . . O O

1 485 488 14633084 One CD B-NP O
2 488 489 14633084 , , I-NP O
3 490 493 14633084 two CD I-NP O
4 494 496 14633084 or CC I-NP O
5 497 502 14633084 three CD I-NP O
6 503 508 14633084 doses NNS I-NP O
7 509 511 14633084 of IN B-PP O
8 512 517 14633084 mesna NNS B-NP D015080
9 518 522 14633084 were VBD B-VP O
10 523 531 14633084 replaced VBN I-VP O
11 532 536 14633084 with IN B-PP O
12 537 550 14633084 dexamethasone NN B-NP D003907
13 551 556 14633084 alone RB B-ADVP O
14 557 559 14633084 or CC O O
15 560 564 14633084 with IN B-PP O
16 565 578 14633084 dexamethasone NN B-NP D003907
17 579 583 14633084 plus CC I-NP O
18 584 589 14633084 mesna NN I-NP D015080
19 589 590 14633084 . . O O

1 591 599 14633084 Cystitis NN B-NP D003556
2 600 603 14633084 was VBD B-VP O
3 604 613 14633084 evaluated VBN I-VP O
4 614 616 14633084 24 CD B-NP O
5 617 618 14633084 h NN I-NP O
6 619 624 14633084 after IN B-PP O
7 625 628 14633084 its PRP$ B-NP O
8 629 638 14633084 induction NN I-NP O
9 639 641 14633084 by IN B-PP O
10 642 645 14633084 the DT B-NP O
11 646 653 14633084 changes NNS I-NP O
12 654 656 14633084 in IN B-PP O
13 657 664 14633084 bladder NN B-NP O
14 665 668 14633084 wet JJ I-NP O
15 669 675 14633084 weight NN I-NP O
16 676 679 14633084 and CC B-PP O
17 680 682 14633084 by IN B-PP O
18 683 694 14633084 macroscopic JJ B-NP O
19 695 698 14633084 and CC I-NP O
20 699 710 14633084 microscopic JJ I-NP O
21 711 719 14633084 analysis NN I-NP O
22 719 720 14633084 . . O O

1 721 728 14633084 RESULTS NNS B-NP O
2 728 729 14633084 : : O O
3 730 733 14633084 The DT B-NP O
4 734 745 14633084 replacement NN I-NP O
5 746 748 14633084 of IN B-PP O
6 749 752 14633084 the DT B-NP O
7 753 757 14633084 last JJ I-NP O
8 758 762 14633084 dose NN I-NP O
9 763 765 14633084 or CC O O
10 766 769 14633084 the DT B-NP O
11 770 774 14633084 last JJ I-NP O
12 775 778 14633084 two CD I-NP O
13 779 784 14633084 doses NNS I-NP O
14 785 787 14633084 of IN B-PP O
15 788 793 14633084 mesna NN B-NP D015080
16 794 798 14633084 with IN B-PP O
17 799 812 14633084 dexamethasone NN B-NP D003907
18 813 820 14633084 reduced VBD B-VP O
19 821 824 14633084 the DT B-NP O
20 825 833 14633084 increase NN I-NP O
21 834 836 14633084 in IN B-PP O
22 837 844 14633084 bladder NN B-NP O
23 845 848 14633084 wet JJ I-NP O
24 849 855 14633084 weight NN I-NP O
25 856 863 14633084 induced VBN B-VP O
26 864 866 14633084 by IN B-PP O
27 867 870 14633084 IFS NN B-NP D007069
28 871 873 14633084 by IN B-PP O
29 874 880 14633084 84.79% NN B-NP O
30 881 884 14633084 and CC I-NP O
31 885 891 14633084 89.13% NN I-NP O
32 891 892 14633084 , , O O
33 893 905 14633084 respectively RB B-ADVP O
34 905 906 14633084 . . O O

1 907 909 14633084 In IN B-PP O
2 910 918 14633084 addition NN B-NP O
3 918 919 14633084 , , O O
4 920 922 14633084 it PRP B-NP O
5 923 929 14633084 almost RB B-ADVP O
6 930 939 14633084 abolished VBD B-VP O
7 940 943 14633084 the DT B-NP O
8 944 955 14633084 macroscopic JJ I-NP O
9 956 959 14633084 and CC I-NP O
10 960 971 14633084 microscopic JJ I-NP O
11 972 983 14633084 alterations NNS I-NP O
12 984 991 14633084 induced VBN B-VP O
13 992 994 14633084 by IN B-PP O
14 995 998 14633084 IFS NN B-NP D007069
15 998 999 14633084 . . O O

1 1000 1008 14633084 Moreover RB B-ADVP O
2 1008 1009 14633084 , , O O
3 1010 1013 14633084 the DT B-NP O
4 1014 1022 14633084 addition NN I-NP O
5 1023 1025 14633084 of IN B-PP O
6 1026 1039 14633084 dexamethasone NN B-NP D003907
7 1040 1042 14633084 to TO B-PP O
8 1043 1046 14633084 the DT B-NP O
9 1047 1051 14633084 last JJ I-NP O
10 1052 1055 14633084 two CD I-NP O
11 1056 1061 14633084 doses NNS I-NP O
12 1062 1064 14633084 of IN B-PP O
13 1065 1070 14633084 mesna NN B-NP D015080
14 1071 1074 14633084 was VBD B-VP O
15 1075 1079 14633084 more RBR B-ADJP O
16 1080 1089 14633084 efficient JJ I-ADJP O
17 1090 1094 14633084 than IN B-PP O
18 1095 1100 14633084 three CD B-NP O
19 1101 1106 14633084 doses NNS I-NP O
20 1107 1109 14633084 of IN B-PP O
21 1110 1115 14633084 mesna NN B-NP D015080
22 1116 1121 14633084 alone RB B-ADVP O
23 1122 1126 14633084 when WRB B-ADVP O
24 1127 1136 14633084 evaluated VBN B-VP O
25 1137 1152 14633084 microscopically RB B-ADVP O
26 1152 1153 14633084 . . O O

1 1154 1164 14633084 CONCLUSION NN B-NP O
2 1164 1165 14633084 : : O O
3 1166 1179 14633084 Dexamethasone NN B-NP D003907
4 1180 1182 14633084 in IN B-PP O
5 1183 1194 14633084 combination NN B-NP O
6 1195 1199 14633084 with IN B-PP O
7 1200 1205 14633084 mesna NN B-NP D015080
8 1206 1209 14633084 was VBD B-VP O
9 1210 1219 14633084 efficient JJ B-ADJP O
10 1220 1222 14633084 in IN B-PP O
11 1223 1231 14633084 blocking VBG B-VP O
12 1232 1235 14633084 IFS NN B-NP D007069
13 1235 1236 14633084 - HYPH B-NP O
14 1236 1243 14633084 induced VBN I-NP O
15 1244 1246 14633084 HC NN I-NP D006470
16 1246 1247 14633084 . . O O

1 1248 1255 14633084 However RB B-ADVP O
2 1255 1256 14633084 , , O O
3 1257 1260 14633084 the DT B-NP O
4 1261 1272 14633084 replacement NN I-NP O
5 1273 1275 14633084 of IN B-PP O
6 1276 1280 14633084 last JJ B-NP O
7 1281 1284 14633084 two CD I-NP O
8 1285 1290 14633084 doses NNS I-NP O
9 1291 1293 14633084 of IN B-PP O
10 1294 1299 14633084 mesna NN B-NP D015080
11 1300 1304 14633084 with IN B-PP O
12 1305 1311 14633084 saline NN B-NP O
13 1312 1314 14633084 or CC O O
14 1315 1318 14633084 all DT B-NP O
15 1319 1321 14633084 of IN B-PP O
16 1322 1325 14633084 the DT B-NP O
17 1326 1331 14633084 mesna NN I-NP D015080
18 1332 1337 14633084 doses VBZ B-VP O
19 1338 1342 14633084 with IN B-PP O
20 1343 1356 14633084 dexamethasone NN B-NP D003907
21 1357 1360 14633084 did VBD B-VP O
22 1361 1364 14633084 not RB I-VP O
23 1365 1372 14633084 prevent VB I-VP O
24 1373 1375 14633084 HC NN B-NP D006470
25 1375 1376 14633084 . . O O

1 0 0 2894433 -DOCSTART- -X- -X- O

1 0 8 2894433 Diazepam NN B-NP D003975
2 9 20 2894433 facilitates VBZ B-VP O
3 21 27 2894433 reflex NN B-NP O
4 28 39 2894433 bradycardia NN I-NP D001919
5 40 42 2894433 in IN B-PP O
6 43 52 2894433 conscious JJ B-NP O
7 53 57 2894433 rats NNS I-NP O
8 57 58 2894433 . . O O
9 59 62 2894433 The DT B-NP O
10 63 70 2894433 effects NNS I-NP O
11 71 73 2894433 of IN B-PP O
12 74 82 2894433 diazepam NN B-NP D003975
13 83 85 2894433 on IN B-PP O
14 86 100 2894433 cardiovascular JJ B-NP O
15 101 109 2894433 function NN I-NP O
16 110 114 2894433 were VBD B-VP O
17 115 123 2894433 assessed VBN I-VP O
18 124 126 2894433 in IN B-PP O
19 127 136 2894433 conscious JJ B-NP O
20 137 141 2894433 rats NNS I-NP O
21 141 142 2894433 . . O O

1 143 154 2894433 Intravenous JJ B-NP O
2 155 169 2894433 administration NN I-NP O
3 170 172 2894433 of IN B-PP O
4 173 181 2894433 diazepam NN B-NP D003975
5 182 183 2894433 ( ( O O
6 183 184 2894433 1 CD B-NP O
7 184 185 2894433 - HYPH I-NP O
8 185 187 2894433 30 CD I-NP O
9 188 190 2894433 mg NN I-NP O
10 191 193 2894433 kg NN I-NP O
11 193 194 2894433 - HYPH B-NP O
12 194 195 2894433 1 CD I-NP O
13 195 196 2894433 ) ) O O
14 197 205 2894433 produced VBD B-VP O
15 206 207 2894433 a DT B-NP O
16 208 212 2894433 dose NN I-NP O
17 212 213 2894433 - HYPH B-NP O
18 213 222 2894433 dependent JJ I-NP O
19 223 231 2894433 decrease NN I-NP O
20 232 234 2894433 in IN B-PP O
21 235 239 2894433 both CC B-NP O
22 240 243 2894433 the DT I-NP O
23 244 248 2894433 mean JJ I-NP O
24 249 257 2894433 arterial JJ I-NP O
25 258 266 2894433 pressure NN I-NP O
26 267 270 2894433 and CC O O
27 271 274 2894433 the DT B-NP O
28 275 280 2894433 heart NN I-NP O
29 281 285 2894433 rate NN I-NP O
30 285 286 2894433 . . O O

1 287 291 2894433 Also RB B-ADVP O
2 291 292 2894433 , , O O
3 293 299 2894433 reflex NN B-NP O
4 300 311 2894433 bradycardia NN I-NP D001919
5 312 315 2894433 was VBD B-VP O
6 316 324 2894433 produced VBN I-VP O
7 325 327 2894433 in IN B-PP O
8 328 332 2894433 rats NNS B-NP O
9 333 335 2894433 by IN B-PP O
10 336 347 2894433 intravenous JJ B-NP O
11 348 356 2894433 infusion NN I-NP O
12 357 359 2894433 of IN B-PP O
13 360 370 2894433 adrenaline NN B-NP D004837
14 371 372 2894433 ( ( O O
15 372 376 2894433 1.25 CD B-NP O
16 376 377 2894433 - HYPH I-NP O
17 377 380 2894433 2.5 CD I-NP O
18 381 391 2894433 micrograms NNS I-NP O
19 392 394 2894433 kg NN I-NP O
20 394 395 2894433 - HYPH B-NP O
21 395 396 2894433 1 CD I-NP O
22 396 397 2894433 ) ) O O
23 397 398 2894433 . . O O

1 399 410 2894433 Intravenous JJ B-NP O
2 411 423 2894433 pretreatment NN I-NP O
3 424 426 2894433 of IN B-PP O
4 427 430 2894433 the DT B-NP O
5 431 435 2894433 rats NNS I-NP O
6 436 440 2894433 with IN B-PP O
7 441 449 2894433 diazepam NN B-NP D003975
8 449 450 2894433 , , O O
9 451 459 2894433 although IN B-SBAR O
10 460 467 2894433 causing VBG B-VP O
11 468 470 2894433 no DT B-NP O
12 471 477 2894433 change NN I-NP O
13 478 480 2894433 in IN B-PP O
14 481 484 2894433 the DT B-NP O
15 485 495 2894433 adrenaline NN I-NP D004837
16 495 496 2894433 - HYPH B-NP O
17 496 503 2894433 induced VBN I-NP O
18 504 511 2894433 pressor NN I-NP O
19 512 518 2894433 effect NN I-NP O
20 518 519 2894433 , , O O
21 520 523 2894433 did VBD B-VP O
22 524 531 2894433 enhance VB I-VP O
23 532 535 2894433 the DT B-NP O
24 536 546 2894433 adrenaline NN I-NP D004837
25 546 547 2894433 - HYPH B-NP O
26 547 554 2894433 induced VBN I-NP O
27 555 561 2894433 reflex NN I-NP O
28 562 573 2894433 bradycardia NN I-NP D001919
29 573 574 2894433 . . O O

1 575 582 2894433 However RB B-ADVP O
2 582 583 2894433 , , O O
3 584 587 2894433 the DT B-NP O
4 588 596 2894433 diazepam NN I-NP D003975
5 597 608 2894433 enhancement NN I-NP O
6 609 611 2894433 of IN B-PP O
7 612 622 2894433 adrenaline NN B-NP D004837
8 622 623 2894433 - HYPH B-NP O
9 623 630 2894433 induced VBN I-NP O
10 631 637 2894433 reflex NN I-NP O
11 638 649 2894433 bradycardia NN I-NP D001919
12 650 653 2894433 was VBD B-VP O
13 654 665 2894433 antagonized VBN I-VP O
14 666 668 2894433 by IN B-PP O
15 669 681 2894433 pretreatment NN B-NP O
16 682 684 2894433 of IN B-PP O
17 685 689 2894433 rats NNS B-NP O
18 690 694 2894433 with IN B-PP O
19 695 697 2894433 an DT B-NP O
20 698 709 2894433 intravenous JJ I-NP O
21 710 714 2894433 dose NN I-NP O
22 715 717 2894433 of IN B-PP O
23 718 728 2894433 picrotoxin NN B-NP D010852
24 729 730 2894433 ( ( O O
25 730 732 2894433 an DT B-NP O
26 733 738 2894433 agent NN I-NP O
27 739 745 2894433 blocks VBZ B-VP O
28 746 754 2894433 chloride NN B-NP D002712
29 755 763 2894433 channels NNS I-NP O
30 764 766 2894433 by IN B-PP O
31 767 774 2894433 binding VBG B-VP O
32 775 777 2894433 to TO B-PP O
33 778 783 2894433 sites NNS B-NP O
34 784 794 2894433 associated VBN B-VP O
35 795 799 2894433 with IN B-PP O
36 800 803 2894433 the DT B-NP O
37 804 818 2894433 benzodiazepine NN I-NP D001569
38 818 819 2894433 - HYPH B-NP O
39 819 823 2894433 GABA NN I-NP D005680
40 823 824 2894433 - HYPH I-NP O
41 824 832 2894433 chloride NN I-NP D002712
42 833 840 2894433 channel NN I-NP O
43 841 855 2894433 macromolecular JJ I-NP O
44 856 863 2894433 complex NN I-NP O
45 863 864 2894433 ) ) O O
46 864 865 2894433 . . O O

1 866 869 2894433 The DT B-NP O
2 870 874 2894433 data NNS I-NP O
3 875 883 2894433 indicate VBP B-VP O
4 884 888 2894433 that IN B-SBAR O
5 889 897 2894433 diazepam NN B-NP D003975
6 898 902 2894433 acts VBZ B-VP O
7 903 910 2894433 through IN B-PP O
8 911 914 2894433 the DT B-NP O
9 915 929 2894433 benzodiazepine NN I-NP D001569
10 929 930 2894433 - HYPH B-NP O
11 930 934 2894433 GABA NN I-NP D005680
12 934 935 2894433 - HYPH I-NP O
13 935 943 2894433 chloride NN I-NP D002712
14 944 951 2894433 channel NN I-NP O
15 952 966 2894433 macromolecular JJ I-NP O
16 967 974 2894433 complex NN I-NP O
17 975 981 2894433 within IN B-PP O
18 982 985 2894433 the DT B-NP O
19 986 993 2894433 central JJ I-NP O
20 994 1001 2894433 nervous JJ I-NP O
21 1002 1008 2894433 system NN I-NP O
22 1009 1011 2894433 to TO B-VP O
23 1012 1022 2894433 facilitate VB I-VP O
24 1023 1029 2894433 reflex NN B-NP O
25 1030 1041 2894433 bradycardia NN I-NP D001919
26 1042 1050 2894433 mediated VBN B-VP O
27 1051 1058 2894433 through IN B-PP O
28 1059 1071 2894433 baroreceptor NN B-NP O
29 1072 1080 2894433 reflexes NNS I-NP O
30 1081 1083 2894433 in IN B-PP O
31 1084 1092 2894433 response NN B-NP O
32 1093 1095 2894433 to TO B-PP O
33 1096 1098 2894433 an DT B-NP O
34 1099 1104 2894433 acute JJ I-NP O
35 1105 1113 2894433 increase NN I-NP O
36 1114 1116 2894433 in IN B-PP O
37 1117 1125 2894433 arterial JJ B-NP O
38 1126 1134 2894433 pressure NN I-NP O
39 1134 1135 2894433 . . O O

1 0 0 6496797 -DOCSTART- -X- -X- O

1 0 8 6496797 Complete JJ B-NP O
2 9 14 6496797 heart NN I-NP D006327
3 15 20 6496797 block NN I-NP D006327
4 21 30 6496797 following VBG B-PP O
5 31 32 6496797 a DT B-NP O
6 33 39 6496797 single JJ I-NP O
7 40 44 6496797 dose NN I-NP O
8 45 47 6496797 of IN B-PP O
9 48 57 6496797 trazodone NN B-NP D014196
10 57 58 6496797 . . O O
11 59 64 6496797 Forty CD B-NP O
12 65 72 6496797 minutes NNS I-NP O
13 73 78 6496797 after IN B-PP O
14 79 88 6496797 receiving VBG B-VP O
15 89 90 6496797 a DT B-NP O
16 91 97 6496797 single JJ I-NP O
17 98 106 6496797 starting VBG I-NP O
18 107 111 6496797 dose NN I-NP O
19 112 114 6496797 of IN B-PP O
20 115 124 6496797 trazodone NN B-NP D014196
21 124 125 6496797 , , O O
22 126 127 6496797 a DT B-NP O
23 128 135 6496797 patient NN I-NP O
24 136 145 6496797 developed VBD B-VP O
25 146 154 6496797 complete JJ B-NP O
26 155 160 6496797 heart NN I-NP D006327
27 161 166 6496797 block NN I-NP D006327
28 166 167 6496797 . . O O

1 168 171 6496797 The DT B-NP O
2 172 176 6496797 case NN I-NP O
3 177 188 6496797 illustrates VBZ B-VP O
4 189 193 6496797 that IN B-SBAR O
5 193 194 6496797 , , O O
6 195 202 6496797 despite IN B-PP O
7 203 206 6496797 the DT B-NP O
8 207 214 6496797 results NNS I-NP O
9 215 217 6496797 of IN B-PP O
10 218 225 6496797 earlier JJR B-NP O
11 226 233 6496797 studies NNS I-NP O
12 233 234 6496797 , , O O
13 235 246 6496797 trazodone's NNS B-NP D014196
14 247 253 6496797 effect NN I-NP O
15 254 256 6496797 on IN B-PP O
16 257 264 6496797 cardiac JJ B-NP O
17 265 275 6496797 conduction NN I-NP O
18 276 279 6496797 may MD B-VP O
19 280 282 6496797 be VB I-VP O
20 283 289 6496797 severe JJ B-ADJP O
21 290 292 6496797 in IN B-PP O
22 293 304 6496797 individuals NNS B-NP O
23 305 307 6496797 at IN B-PP O
24 308 312 6496797 risk NN B-NP O
25 313 316 6496797 for IN B-PP O
26 317 327 6496797 conduction NN B-NP O
27 328 333 6496797 delay NN I-NP O
28 333 334 6496797 . . O O

1 0 0 2334179 -DOCSTART- -X- -X- O

1 0 1 2334179 D NN B-NP D010396
2 1 2 2334179 - HYPH I-NP D010396
3 2 15 2334179 penicillamine NN I-NP D010396
4 16 18 2334179 in IN B-PP O
5 19 22 2334179 the DT B-NP O
6 23 32 2334179 treatment NN I-NP O
7 33 35 2334179 of IN B-PP O
8 36 45 2334179 localized VBN B-NP D012594
9 46 57 2334179 scleroderma NN I-NP D012594
10 57 58 2334179 . . I-NP O
11 59 68 2334179 Localized JJ I-NP D012594
12 69 80 2334179 scleroderma NN I-NP D012594
13 81 84 2334179 has VBZ B-VP O
14 85 87 2334179 no DT B-NP O
15 88 98 2334179 recognized VBN I-NP O
16 99 107 2334179 internal JJ I-NP O
17 108 113 2334179 organ NN I-NP O
18 114 125 2334179 involvement NN I-NP O
19 126 129 2334179 but CC O O
20 130 133 2334179 may MD B-VP O
21 134 136 2334179 be VB I-VP O
22 137 148 2334179 disfiguring VBG I-VP O
23 149 152 2334179 and CC I-VP O
24 153 162 2334179 disabling VBG I-VP O
25 163 167 2334179 when WRB B-ADVP O
26 168 171 2334179 the DT B-NP O
27 172 181 2334179 cutaneous JJ I-NP O
28 182 189 2334179 lesions NNS I-NP O
29 190 193 2334179 are VBP B-VP O
30 194 203 2334179 extensive JJ B-NP O
31 204 206 2334179 or CC I-NP O
32 207 213 2334179 affect NN I-NP O
33 214 222 2334179 children NNS I-NP O
34 222 223 2334179 . . O O

1 224 229 2334179 There EX B-NP O
2 230 232 2334179 is VBZ B-VP O
3 233 235 2334179 no DT B-NP O
4 236 244 2334179 accepted VBN I-NP O
5 245 247 2334179 or CC I-NP O
6 248 254 2334179 proven VBN I-NP O
7 255 264 2334179 treatment NN I-NP O
8 265 268 2334179 for IN B-PP O
9 269 278 2334179 localized VBN B-NP D012594
10 279 290 2334179 scleroderma NN I-NP D012594
11 290 291 2334179 . . O O

1 292 296 2334179 Case NN B-NP O
2 297 304 2334179 reports NNS I-NP O
3 305 307 2334179 of IN B-PP O
4 308 310 2334179 11 CD B-NP O
5 311 319 2334179 patients NNS I-NP O
6 320 324 2334179 with IN B-PP O
7 325 331 2334179 severe JJ B-NP O
8 331 332 2334179 , , I-NP O
9 333 342 2334179 extensive JJ I-NP O
10 343 352 2334179 localized JJ I-NP D012594
11 353 364 2334179 scleroderma NN I-NP D012594
12 365 368 2334179 who WP B-NP O
13 369 373 2334179 were VBD B-VP O
14 374 381 2334179 treated VBN I-VP O
15 382 386 2334179 with IN B-PP O
16 387 388 2334179 D NN B-NP D010396
17 388 389 2334179 - HYPH I-NP D010396
18 389 402 2334179 penicillamine NN I-NP D010396
19 403 406 2334179 are VBP B-VP O
20 407 417 2334179 summarized VBN I-VP O
21 418 420 2334179 in IN B-PP O
22 421 425 2334179 this DT B-NP O
23 426 433 2334179 article NN I-NP O
24 433 434 2334179 . . O O

1 435 439 2334179 This DT B-NP O
2 440 444 2334179 drug NN I-NP O
3 445 448 2334179 was VBD B-VP O
4 449 455 2334179 judged VBN I-VP O
5 456 458 2334179 to TO I-VP O
6 459 463 2334179 have VB I-VP O
7 464 465 2334179 a DT B-NP O
8 466 475 2334179 favorable JJ I-NP O
9 476 482 2334179 effect NN I-NP O
10 483 485 2334179 on IN B-PP O
11 486 489 2334179 the DT B-NP O
12 490 497 2334179 disease NN I-NP O
13 498 504 2334179 course NN I-NP O
14 505 507 2334179 in IN B-PP O
15 508 509 2334179 7 CD B-NP O
16 510 511 2334179 ( ( O O
17 511 514 2334179 64% CD B-NP O
18 514 515 2334179 ) ) O O
19 516 518 2334179 of IN B-PP O
20 519 521 2334179 11 CD B-NP O
21 522 530 2334179 patients NNS I-NP O
22 530 531 2334179 . . O O

1 532 543 2334179 Improvement NN B-NP O
2 544 549 2334179 began VBD B-VP O
3 550 556 2334179 within IN B-PP O
4 557 558 2334179 3 CD B-NP O
5 559 561 2334179 to TO I-NP O
6 562 563 2334179 6 CD I-NP O
7 564 570 2334179 months NNS I-NP O
8 571 574 2334179 and CC O O
9 575 584 2334179 consisted VBD B-VP O
10 585 587 2334179 of IN B-PP O
11 588 597 2334179 cessation NN B-NP O
12 598 600 2334179 of IN B-PP O
13 601 607 2334179 active JJ B-NP O
14 608 617 2334179 cutaneous JJ I-NP O
15 618 625 2334179 lesions NNS I-NP O
16 626 628 2334179 in IN B-PP O
17 629 632 2334179 all DT B-NP O
18 633 634 2334179 7 CD I-NP O
19 635 643 2334179 patients NNS I-NP O
20 643 644 2334179 , , O O
21 645 649 2334179 skin NN B-NP O
22 650 659 2334179 softening NN I-NP O
23 660 662 2334179 in IN B-PP O
24 663 664 2334179 5 CD B-NP O
25 664 665 2334179 , , O O
26 666 669 2334179 and CC O O
27 670 674 2334179 more RBR B-NP O
28 675 681 2334179 normal JJ I-NP O
29 682 688 2334179 growth NN I-NP O
30 689 691 2334179 of IN B-PP O
31 692 695 2334179 the DT B-NP O
32 696 704 2334179 affected VBN I-NP O
33 705 709 2334179 limb NN I-NP O
34 710 712 2334179 in IN B-PP O
35 713 714 2334179 2 CD B-NP O
36 715 717 2334179 of IN B-PP O
37 718 719 2334179 3 CD B-NP O
38 720 728 2334179 children NNS I-NP O
39 728 729 2334179 . . O O

1 730 735 2334179 Joint NN B-NP O
2 736 745 2334179 stiffness NN I-NP O
3 746 749 2334179 and CC I-NP O
4 750 762 2334179 contractures NNS I-NP D003286
5 763 767 2334179 also RB B-ADVP O
6 768 776 2334179 improved VBD B-VP O
7 776 777 2334179 . . O O

1 778 781 2334179 The DT B-NP O
2 782 786 2334179 dose NN I-NP O
3 787 789 2334179 of IN B-PP O
4 790 791 2334179 D NN B-NP D010396
5 791 792 2334179 - HYPH B-NP D010396
6 792 805 2334179 penicillamine NN I-NP D010396
7 806 816 2334179 associated VBN B-VP O
8 817 821 2334179 with IN B-PP O
9 822 823 2334179 a DT B-NP O
10 824 833 2334179 favorable JJ I-NP O
11 834 842 2334179 response NN I-NP O
12 843 846 2334179 was VBD B-VP O
13 847 849 2334179 as RB B-ADJP O
14 850 853 2334179 low JJ I-ADJP O
15 854 856 2334179 as IN B-PP O
16 857 858 2334179 2 CD B-NP O
17 859 861 2334179 to TO I-NP O
18 862 863 2334179 5 CD I-NP O
19 864 866 2334179 mg NN I-NP O
20 866 867 2334179 / SYM B-NP O
21 867 869 2334179 kg NN I-NP O
22 870 873 2334179 per IN B-PP O
23 874 877 2334179 day NN B-NP O
24 878 883 2334179 given VBN B-VP O
25 884 888 2334179 over IN B-PP O
26 889 890 2334179 a DT B-NP O
27 891 897 2334179 period NN I-NP O
28 898 905 2334179 ranging VBG B-VP O
29 906 910 2334179 from IN B-PP O
30 911 913 2334179 15 CD B-NP O
31 914 916 2334179 to TO I-NP O
32 917 919 2334179 53 CD I-NP O
33 920 926 2334179 months NNS I-NP O
34 926 927 2334179 . . O O

1 928 929 2334179 D NN B-NP D010396
2 929 930 2334179 - HYPH I-NP D010396
3 930 943 2334179 Penicillamine NN I-NP D010396
4 944 950 2334179 caused VBD B-VP O
5 951 960 2334179 nephrotic JJ B-NP D009404
6 961 969 2334179 syndrome NN I-NP D009404
7 970 972 2334179 in IN B-PP O
8 973 974 2334179 1 CD B-NP O
9 975 982 2334179 patient NN I-NP O
10 983 986 2334179 and CC O O
11 987 993 2334179 milder JJR B-NP O
12 994 1004 2334179 reversible JJ I-NP O
13 1005 1016 2334179 proteinuria NN I-NP D011507
14 1017 1019 2334179 in IN B-PP O
15 1020 1021 2334179 3 CD B-NP O
16 1022 1027 2334179 other JJ I-NP O
17 1028 1036 2334179 patients NNS I-NP O
18 1036 1037 2334179 ; : O O
19 1038 1042 2334179 none NN B-NP O
20 1043 1052 2334179 developed VBD B-VP O
21 1053 1058 2334179 renal JJ B-NP D051437
22 1059 1072 2334179 insufficiency NN I-NP D051437
23 1072 1073 2334179 . . O O

1 1074 1079 2334179 These DT B-NP O
2 1080 1084 2334179 data NNS I-NP O
3 1085 1092 2334179 suggest VBP B-VP O
4 1093 1097 2334179 that IN B-SBAR O
5 1098 1099 2334179 D NN B-NP D010396
6 1099 1100 2334179 - HYPH B-NP D010396
7 1100 1113 2334179 penicillamine NN I-NP D010396
8 1114 1117 2334179 may MD B-VP O
9 1118 1120 2334179 be VB I-VP O
10 1121 1130 2334179 effective JJ B-ADJP O
11 1131 1133 2334179 in IN B-PP O
12 1134 1140 2334179 severe JJ B-NP O
13 1141 1146 2334179 cases NNS I-NP O
14 1147 1149 2334179 of IN B-PP O
15 1150 1159 2334179 localized VBN B-NP D012594
16 1160 1171 2334179 scleroderma NN I-NP D012594
17 1171 1172 2334179 . . O O

1 0 0 9098464 -DOCSTART- -X- -X- O

1 0 1 9098464 A DT B-NP O
2 2 8 9098464 murine JJ I-NP O
3 9 14 9098464 model NN I-NP O
4 15 17 9098464 of IN B-PP O
5 18 29 9098464 adenomyosis NN B-NP D062788
6 29 30 9098464 : : O O
7 31 34 9098464 the DT B-NP O
8 35 42 9098464 effects NNS I-NP O
9 43 45 9098464 of IN B-PP O
10 46 64 9098464 hyperprolactinemia NN B-NP D006966
11 65 72 9098464 induced VBN B-VP O
12 73 75 9098464 by IN B-PP O
13 76 86 9098464 fluoxetine NN B-NP D005473
14 87 100 9098464 hydrochloride NN I-NP D005473
15 100 101 9098464 , , O O
16 102 103 9098464 a DT B-NP O
17 104 113 9098464 selective JJ I-NP O
18 114 123 9098464 serotonin NN I-NP D012701
19 124 132 9098464 reuptake NN I-NP O
20 133 142 9098464 inhibitor NN I-NP O
21 142 143 9098464 , , O O
22 144 146 9098464 on IN B-PP O
23 147 158 9098464 adenomyosis NN B-NP D062788
24 159 168 9098464 induction NN I-NP O
25 169 171 9098464 in IN B-PP O
26 172 178 9098464 Wistar NNP B-NP O
27 179 185 9098464 albino NNP I-NP O
28 186 190 9098464 rats NNS I-NP O
29 190 191 9098464 . . I-NP O
30 192 201 9098464 OBJECTIVE NN I-NP O
31 201 202 9098464 : : O O
32 203 206 9098464 The DT B-NP O
33 207 210 9098464 aim NN I-NP O
34 211 213 9098464 of IN B-PP O
35 214 218 9098464 this DT B-NP O
36 219 224 9098464 study NN I-NP O
37 225 228 9098464 was VBD B-VP O
38 229 231 9098464 to TO B-VP O
39 232 243 9098464 investigate VB I-VP O
40 244 251 9098464 whether IN B-SBAR O
41 252 262 9098464 fluoxetine NN B-NP D005473
42 263 268 9098464 given VBN B-VP O
43 269 271 9098464 to TO B-PP O
44 272 281 9098464 castrated VBN B-NP O
45 282 285 9098464 and CC I-NP O
46 286 298 9098464 noncastrated JJ I-NP O
47 299 303 9098464 rats NNS I-NP O
48 304 310 9098464 caused VBD B-VP O
49 311 329 9098464 hyperprolactinemia NN B-NP D006966
50 330 333 9098464 and CC O O
51 334 337 9098464 its PRP$ B-NP O
52 338 345 9098464 effects NNS I-NP O
53 346 350 9098464 with IN B-PP O
54 351 358 9098464 respect NN B-NP O
55 359 361 9098464 to TO B-PP O
56 362 373 9098464 adenomyosis NN B-NP D062788
57 373 374 9098464 . . O O

1 375 381 9098464 DESIGN NN B-NP O
2 381 382 9098464 : : O O
3 383 393 9098464 Fluoxetine NN B-NP D005473
4 393 394 9098464 , , O O
5 395 396 9098464 a DT B-NP O
6 397 406 9098464 serotonin NN I-NP D012701
7 407 415 9098464 reuptake NN I-NP O
8 416 425 9098464 inhibitor NN I-NP O
9 425 426 9098464 , , O O
10 427 430 9098464 was VBD B-VP O
11 431 436 9098464 given VBN I-VP O
12 437 439 9098464 to TO B-PP O
13 440 446 9098464 Wistar NNP B-NP O
14 447 453 9098464 Albino NNP I-NP O
15 454 458 9098464 rats NNS I-NP O
16 459 462 9098464 for IN B-PP O
17 463 465 9098464 98 CD B-NP O
18 466 470 9098464 days NNS I-NP O
19 471 473 9098464 to TO B-VP O
20 474 481 9098464 produce VB I-VP O
21 482 500 9098464 hyperprolactinemia NN B-NP D006966
22 500 501 9098464 . . O O

1 502 505 9098464 The DT B-NP O
2 506 510 9098464 drug NN I-NP O
3 511 514 9098464 was VBD B-VP O
4 515 520 9098464 given VBN I-VP O
5 521 523 9098464 to TO B-PP O
6 524 527 9098464 two CD B-NP O
7 528 534 9098464 groups NNS I-NP O
8 535 545 9098464 consisting VBG B-VP O
9 546 548 9098464 of IN B-PP O
10 549 558 9098464 castrated VBN B-NP O
11 559 562 9098464 and CC I-NP O
12 563 575 9098464 noncastrated JJ I-NP O
13 576 580 9098464 rats NNS I-NP O
14 581 584 9098464 and CC O O
15 585 593 9098464 compared VBN B-VP O
16 594 596 9098464 to TO B-PP O
17 597 600 9098464 two CD B-NP O
18 601 607 9098464 groups NNS I-NP O
19 608 610 9098464 of IN B-PP O
20 611 620 9098464 castrated VBN B-NP O
21 621 624 9098464 and CC I-NP O
22 625 637 9098464 noncastrated JJ I-NP O
23 638 646 9098464 controls NNS I-NP O
24 646 647 9098464 . . O O

1 648 657 9098464 Prolactin NN B-NP O
2 658 664 9098464 levels NNS I-NP O
3 665 669 9098464 were VBD B-VP O
4 670 678 9098464 measured VBN I-VP O
5 679 682 9098464 and CC O O
6 683 686 9098464 the DT B-NP O
7 687 692 9098464 uteri NN I-NP O
8 693 695 9098464 of IN B-PP O
9 696 699 9098464 the DT B-NP O
10 700 704 9098464 rats NNS I-NP O
11 705 709 9098464 were VBD B-VP O
12 710 717 9098464 removed VBN I-VP O
13 718 721 9098464 for IN B-PP O
14 722 739 9098464 histopathological JJ B-NP O
15 740 748 9098464 analysis NN I-NP O
16 749 751 9098464 at IN B-PP O
17 752 755 9098464 the DT B-NP O
18 756 759 9098464 end NN I-NP O
19 760 762 9098464 of IN B-PP O
20 763 765 9098464 98 CD B-NP O
21 766 770 9098464 days NNS I-NP O
22 770 771 9098464 . . O O

1 772 779 9098464 SETTING NN B-NP O
2 779 780 9098464 : : O O
3 781 788 9098464 Marmara NNP B-NP O
4 789 799 9098464 University NNP I-NP O
5 800 806 9098464 School NNP I-NP O
6 807 809 9098464 of IN B-PP O
7 810 818 9098464 Medicine NNP B-NP O
8 818 819 9098464 , , O O
9 820 830 9098464 Department NNP B-NP O
10 831 833 9098464 of IN B-PP O
11 834 843 9098464 Histology NNP B-NP O
12 844 847 9098464 and CC I-NP O
13 848 858 9098464 Embryology NNP I-NP O
14 858 859 9098464 , , O O
15 860 866 9098464 Zeynep NNP B-NP O
16 867 872 9098464 Kamil NNP I-NP O
17 873 878 9098464 Women NNP I-NP O
18 879 882 9098464 and CC O O
19 883 893 9098464 Children's NNP B-NP O
20 894 902 9098464 Hospital NNP I-NP O
21 902 903 9098464 . . O O

1 904 908 9098464 MAIN NNP B-NP O
2 909 916 9098464 OUTCOME NNP I-NP O
3 917 925 9098464 MEASURES NNP I-NP O
4 925 926 9098464 : : O O
5 927 932 9098464 Serum NN B-NP O
6 933 942 9098464 prolactin NN I-NP O
7 943 949 9098464 levels NNS I-NP O
8 949 950 9098464 , , O O
9 951 958 9098464 uterine JJ B-NP O
10 959 973 9098464 histopathology NN I-NP O
11 973 974 9098464 . . O O

1 975 982 9098464 RESULTS NNS B-NP O
2 982 983 9098464 : : O O
3 984 987 9098464 The DT B-NP O
4 988 997 9098464 prolactin NN I-NP O
5 998 1004 9098464 levels NNS I-NP O
6 1005 1007 9098464 of IN B-PP O
7 1008 1017 9098464 castrated VBN B-NP O
8 1018 1021 9098464 and CC I-NP O
9 1022 1034 9098464 noncastrated JJ I-NP O
10 1035 1041 9098464 groups NNS I-NP O
11 1042 1049 9098464 treated VBN B-VP O
12 1050 1054 9098464 with IN B-PP O
13 1055 1065 9098464 fluoxetine NN B-NP D005473
14 1066 1070 9098464 were VBD B-VP O
15 1071 1084 9098464 statistically RB B-ADVP O
16 1085 1098 9098464 significantly RB B-ADJP O
17 1099 1105 9098464 higher JJR I-ADJP O
18 1106 1110 9098464 when WRB B-ADVP O
19 1111 1119 9098464 compared VBN B-VP O
20 1120 1122 9098464 to TO B-PP O
21 1123 1128 9098464 their PRP$ B-NP O
22 1129 1139 9098464 respective JJ I-NP O
23 1140 1147 9098464 control NN I-NP O
24 1148 1154 9098464 groups NNS I-NP O
25 1154 1155 9098464 . . O O

1 1156 1168 9098464 Histological JJ B-NP O
2 1169 1176 9098464 studies NNS I-NP O
3 1177 1185 9098464 revealed VBD B-VP O
4 1186 1188 9098464 11 CD B-NP O
5 1189 1194 9098464 cases NNS I-NP O
6 1195 1197 9098464 of IN B-PP O
7 1198 1209 9098464 adenomyosis NN B-NP D062788
8 1209 1210 9098464 , , O O
9 1211 1214 9098464 all DT B-NP O
10 1215 1221 9098464 within IN B-PP O
11 1222 1225 9098464 the DT B-NP O
12 1226 1238 9098464 noncastrated JJ I-NP O
13 1239 1244 9098464 group NN I-NP O
14 1245 1254 9098464 receiving VBG B-VP O
15 1255 1265 9098464 fluoxetine NN B-NP D005473
16 1265 1266 9098464 . . O O

1 1267 1277 9098464 CONCLUSION NN B-NP O
2 1277 1278 9098464 : : O O
3 1279 1281 9098464 It PRP B-NP O
4 1282 1285 9098464 was VBD B-VP O
5 1286 1295 9098464 suggested VBN I-VP O
6 1296 1300 9098464 that IN B-SBAR O
7 1301 1305 9098464 high JJ B-NP O
8 1306 1311 9098464 serum NN I-NP O
9 1312 1321 9098464 prolactin NN I-NP O
10 1322 1328 9098464 levels NNS I-NP O
11 1329 1334 9098464 cause VBP B-VP O
12 1335 1347 9098464 degeneration NN B-NP O
13 1348 1350 9098464 of IN B-PP O
14 1351 1361 9098464 myometrial JJ B-NP O
15 1362 1367 9098464 cells NNS I-NP O
16 1368 1370 9098464 in IN B-PP O
17 1371 1374 9098464 the DT I-PP O
18 1375 1383 9098464 presence NN I-PP O
19 1384 1386 9098464 of IN I-PP O
20 1387 1394 9098464 ovarian JJ B-NP O
21 1395 1403 9098464 steroids NNS I-NP D013256
22 1404 1408 9098464 that WDT B-NP O
23 1409 1416 9098464 results VBZ B-VP O
24 1417 1419 9098464 in IN B-PP O
25 1420 1421 9098464 a DT B-NP O
26 1422 1432 9098464 myometrial JJ I-NP O
27 1433 1441 9098464 invasion NN I-NP O
28 1442 1444 9098464 by IN B-PP O
29 1445 1456 9098464 endometrial JJ B-NP O
30 1457 1463 9098464 stroma NN I-NP O
31 1463 1464 9098464 . . O O

1 1465 1469 9098464 This DT B-NP O
2 1470 1478 9098464 invasion NN I-NP O
3 1479 1489 9098464 eventually RB B-ADVP O
4 1490 1500 9098464 progresses VBZ B-VP O
5 1501 1503 9098464 to TO B-PP O
6 1504 1515 9098464 adenomyosis NN B-NP D062788
7 1515 1516 9098464 . . O O

1 0 0 14982270 -DOCSTART- -X- -X- O

1 0 11 14982270 Methimazole NN B-NP D008713
2 11 12 14982270 - HYPH O O
3 12 19 14982270 induced VBN B-NP O
4 20 31 14982270 cholestatic JJ I-NP D041781
5 32 40 14982270 jaundice NN I-NP D041781
6 40 41 14982270 . . I-NP O
7 42 53 14982270 Methimazole NN I-NP D008713
8 54 56 14982270 is VBZ B-VP O
9 57 58 14982270 a DT B-NP O
10 59 65 14982270 widely RB I-NP O
11 66 70 14982270 used VBN I-NP O
12 71 74 14982270 and CC O O
13 75 84 14982270 generally RB B-ADVP O
14 85 89 14982270 well RB I-ADVP O
15 89 90 14982270 - HYPH B-NP O
16 90 99 14982270 tolerated VBN I-NP O
17 100 111 14982270 antithyroid JJ I-NP O
18 112 117 14982270 agent NN I-NP O
19 117 118 14982270 . . O O

1 119 120 14982270 A DT B-NP O
2 121 123 14982270 43 CD I-NP O
3 123 124 14982270 - HYPH I-NP O
4 124 128 14982270 year NN I-NP O
5 128 129 14982270 - HYPH O O
6 129 132 14982270 old JJ B-NP O
7 133 138 14982270 woman NN I-NP O
8 139 142 14982270 had VBD B-VP O
9 143 149 14982270 severe JJ B-NP O
10 150 158 14982270 jaundice NN I-NP D007565
11 159 162 14982270 and CC O O
12 163 170 14982270 itching VBG B-VP D011537
13 171 172 14982270 1 CD B-NP O
14 173 178 14982270 month NN I-NP O
15 179 184 14982270 after IN B-PP O
16 185 194 14982270 receiving VBG B-VP O
17 195 206 14982270 methimazole NN B-NP D008713
18 207 208 14982270 ( ( O O
19 208 210 14982270 10 CD B-NP O
20 211 213 14982270 mg NN I-NP O
21 214 217 14982270 tid NN I-NP O
22 217 218 14982270 ) ) O O
23 219 222 14982270 and CC O O
24 223 234 14982270 propranolol NN B-NP D011433
25 235 236 14982270 ( ( O O
26 236 238 14982270 20 CD B-NP O
27 239 241 14982270 mg NN I-NP O
28 242 245 14982270 tid NN I-NP O
29 245 246 14982270 ) ) O O
30 247 250 14982270 for IN B-PP O
31 251 260 14982270 treatment NN B-NP O
32 261 263 14982270 of IN B-PP O
33 264 279 14982270 hyperthyroidism NN B-NP D006980
34 279 280 14982270 . . O O

1 281 284 14982270 The DT B-NP O
2 285 292 14982270 patient NN I-NP O
3 293 302 14982270 continued VBD B-VP O
4 303 312 14982270 treatment NN B-NP O
5 313 316 14982270 for IN B-PP O
6 317 324 14982270 another DT B-NP O
7 325 326 14982270 4 CD I-NP O
8 327 331 14982270 days NNS I-NP O
9 332 337 14982270 after IN B-PP O
10 338 341 14982270 the DT B-NP O
11 342 352 14982270 appearance NN I-NP O
12 353 355 14982270 of IN B-PP O
13 356 364 14982270 jaundice NN B-NP D007565
14 365 370 14982270 until IN B-SBAR O
15 371 374 14982270 she PRP B-NP O
16 375 383 14982270 finished VBD B-VP O
17 384 388 14982270 both DT B-NP O
18 389 400 14982270 medications NNS I-NP O
19 400 401 14982270 . . O O

1 402 406 14982270 When WRB B-ADVP O
2 407 411 14982270 seen VBN B-VP O
3 412 414 14982270 at IN B-PP O
4 415 418 14982270 the DT B-NP O
5 419 428 14982270 emergency NN I-NP O
6 429 439 14982270 department NN I-NP O
7 440 441 14982270 2 CD B-NP O
8 442 447 14982270 weeks NNS I-NP O
9 448 453 14982270 later RB B-ADVP O
10 453 454 14982270 , , O O
11 455 458 14982270 she PRP B-NP O
12 459 464 14982270 still RB B-ADVP O
13 465 468 14982270 had VBD B-VP O
14 469 475 14982270 severe JJ B-NP O
15 476 483 14982270 icterus NN I-NP D007565
16 483 484 14982270 , , O O
17 485 493 14982270 pruritus NN B-NP D011537
18 493 494 14982270 , , O O
19 495 498 14982270 and CC O O
20 499 517 14982270 hyperbilirubinemia NN B-NP D006932
21 517 518 14982270 , , O O
22 519 525 14982270 formed VBN B-VP O
23 526 532 14982270 mainly RB B-ADVP O
24 533 535 14982270 of IN B-PP O
25 536 539 14982270 the DT B-NP O
26 540 550 14982270 conjugated VBN I-NP O
27 551 559 14982270 fraction NN I-NP O
28 559 560 14982270 . . O O

1 561 572 14982270 Methimazole NN B-NP D008713
2 572 573 14982270 - HYPH B-NP O
3 573 580 14982270 induced VBN I-NP O
4 581 592 14982270 cholestasis NN I-NP D002779
5 593 596 14982270 was VBD B-VP O
6 597 606 14982270 diagnosed VBN I-VP O
7 606 607 14982270 , , O O
8 608 611 14982270 and CC O O
9 612 623 14982270 propranolol NN B-NP D011433
10 624 631 14982270 therapy NN I-NP O
11 632 635 14982270 was VBD B-VP O
12 636 643 14982270 resumed VBN I-VP O
13 643 644 14982270 . . O O

1 645 649 14982270 Over IN B-PP O
2 650 653 14982270 the DT B-NP O
3 654 663 14982270 following VBG I-NP O
4 664 665 14982270 9 CD I-NP O
5 666 670 14982270 days NNS I-NP O
6 670 671 14982270 , , O O
7 672 675 14982270 the DT B-NP O
8 676 684 14982270 symptoms NNS I-NP O
9 685 693 14982270 improved VBD B-VP O
10 694 697 14982270 and CC O O
11 698 704 14982270 plasma NN B-NP O
12 705 714 14982270 bilirubin NN I-NP D001663
13 715 721 14982270 levels NNS I-NP O
14 722 726 14982270 were VBD B-VP O
15 727 733 14982270 normal JJ B-ADJP O
16 734 739 14982270 after IN B-PP O
17 740 742 14982270 12 CD B-NP O
18 743 748 14982270 weeks NNS I-NP O
19 749 756 14982270 without IN B-PP O
20 757 768 14982270 methimazole NN B-NP D008713
21 768 769 14982270 . . O O

1 770 772 14982270 In IN B-PP O
2 773 777 14982270 rare JJ B-NP O
3 778 783 14982270 cases NNS I-NP O
4 784 790 14982270 within IN B-PP O
5 791 794 14982270 the DT B-NP O
6 795 800 14982270 first JJ I-NP O
7 801 804 14982270 few JJ I-NP O
8 805 810 14982270 weeks NNS I-NP O
9 811 813 14982270 of IN B-PP O
10 814 821 14982270 therapy NN B-NP O
11 821 822 14982270 , , O O
12 823 827 14982270 this DT B-NP O
13 828 832 14982270 drug NN I-NP O
14 833 836 14982270 can MD B-VP O
15 837 842 14982270 cause VB I-VP O
16 843 849 14982270 severe JJ B-NP O
17 850 853 14982270 and CC I-NP O
18 854 864 14982270 reversible JJ I-NP O
19 865 876 14982270 cholestatic JJ I-NP D041781
20 877 885 14982270 jaundice NN I-NP D041781
21 885 886 14982270 . . O O

1 887 897 14982270 Physicians NNS B-NP O
2 898 901 14982270 and CC I-NP O
3 902 910 14982270 patients NNS I-NP O
4 911 917 14982270 should MD B-VP O
5 918 920 14982270 be VB I-VP O
6 921 926 14982270 aware JJ B-ADJP O
7 927 929 14982270 of IN B-PP O
8 930 934 14982270 this DT B-NP O
9 935 942 14982270 adverse JJ I-NP O
10 943 949 14982270 effect NN I-NP O
11 950 952 14982270 so RB B-SBAR O
12 953 957 14982270 that IN I-SBAR O
13 957 958 14982270 , , O O
14 959 963 14982270 upon IN B-PP O
15 964 974 14982270 occurrence NN B-NP O
16 974 975 14982270 , , O O
17 976 980 14982270 they PRP B-NP O
18 981 984 14982270 can MD B-VP O
19 985 996 14982270 discontinue VB I-VP O
20 997 1008 14982270 methimazole NN B-NP D008713
21 1009 1016 14982270 therapy NN I-NP O
22 1017 1020 14982270 and CC O O
23 1021 1026 14982270 avoid VB B-VP O
24 1027 1038 14982270 unnecessary JJ B-NP O
25 1039 1047 14982270 invasive JJ I-NP O
26 1048 1058 14982270 procedures NNS I-NP O
27 1058 1059 14982270 . . O O

1 0 0 2220369 -DOCSTART- -X- -X- O

1 0 7 2220369 Central JJ B-NP O
2 8 12 2220369 vein NN I-NP D020246
3 13 23 2220369 thrombosis NN I-NP D020246
4 24 27 2220369 and CC O O
5 28 35 2220369 topical JJ B-NP O
6 36 45 2220369 dipivalyl NN I-NP C015173
7 46 57 2220369 epinephrine NN I-NP C015173
8 57 58 2220369 . . I-NP O
9 59 60 2220369 A NN I-NP O
10 61 67 2220369 report NN I-NP O
11 68 70 2220369 is VBZ B-VP O
12 71 76 2220369 given VBN I-VP O
13 77 79 2220369 on IN B-PP O
14 80 82 2220369 an DT B-NP O
15 83 85 2220369 83 CD I-NP O
16 85 86 2220369 - HYPH I-NP O
17 86 90 2220369 year NN I-NP O
18 90 91 2220369 - HYPH B-NP O
19 91 94 2220369 old JJ I-NP O
20 95 101 2220369 female NN I-NP O
21 102 105 2220369 who WP B-NP O
22 106 114 2220369 acquired VBD B-VP O
23 115 122 2220369 central JJ B-NP O
24 123 127 2220369 vein NN I-NP D020246
25 128 138 2220369 thrombosis NN I-NP D020246
26 139 141 2220369 in IN B-PP O
27 142 145 2220369 her PRP$ B-NP O
28 146 152 2220369 seeing VBG I-NP O
29 153 156 2220369 eye NN I-NP O
30 157 160 2220369 one CD I-NP O
31 161 164 2220369 day NN I-NP O
32 165 170 2220369 after IN B-PP O
33 171 177 2220369 having VBG B-VP O
34 178 185 2220369 started VBN I-VP O
35 186 193 2220369 topical JJ B-NP O
36 194 204 2220369 medication NN I-NP O
37 205 209 2220369 with IN B-PP O
38 210 219 2220369 dipivalyl NN B-NP C015173
39 220 231 2220369 epinephrine NN I-NP C015173
40 232 235 2220369 for IN B-PP O
41 236 244 2220369 advanced VBN B-NP O
42 245 253 2220369 glaucoma NN I-NP D005901
43 254 264 2220369 discovered VBN B-VP O
44 265 267 2220369 in IN B-PP O
45 268 271 2220369 the DT B-NP O
46 272 277 2220369 other JJ I-NP O
47 278 281 2220369 eye NN I-NP O
48 281 282 2220369 . . O O

1 283 287 2220369 From IN B-PP O
2 288 295 2220369 present JJ B-NP O
3 296 305 2220369 knowledge NN I-NP O
4 306 311 2220369 about IN B-PP O
5 312 315 2220369 the DT B-NP O
6 316 323 2220369 effects NNS I-NP O
7 324 326 2220369 of IN B-PP O
8 327 337 2220369 adrenergic JJ B-NP O
9 338 341 2220369 eye NN I-NP O
10 342 347 2220369 drops VBZ B-VP O
11 348 350 2220369 on IN B-PP O
12 351 357 2220369 ocular JJ B-NP O
13 358 363 2220369 blood NN I-NP O
14 364 375 2220369 circulation NN I-NP O
15 375 376 2220369 , , O O
16 377 379 2220369 it PRP B-NP O
17 380 382 2220369 is VBZ B-VP O
18 383 392 2220369 difficult JJ B-ADJP O
19 393 395 2220369 to TO B-VP O
20 396 403 2220369 suggest VB I-VP O
21 404 406 2220369 an DT B-NP O
22 407 418 2220369 association NN I-NP O
23 419 426 2220369 between IN B-PP O
24 427 430 2220369 the DT B-NP O
25 431 434 2220369 two CD I-NP O
26 435 441 2220369 events NNS I-NP O
27 441 442 2220369 , , O O
28 443 448 2220369 which WDT B-NP O
29 449 452 2220369 may MD B-VP O
30 453 455 2220369 be VB I-VP O
31 456 468 2220369 coincidental JJ B-ADJP O
32 469 473 2220369 only RB B-ADVP O
33 473 474 2220369 . . O O

1 0 0 1355091 -DOCSTART- -X- -X- O

1 0 11 1355091 Orthostatic JJ B-NP D007024
2 12 23 1355091 hypotension NN I-NP D007024
3 24 30 1355091 occurs VBZ B-VP O
4 31 40 1355091 following VBG I-VP O
5 41 46 1355091 alpha SYM B-NP O
6 47 48 1355091 2 CD I-NP O
7 48 49 1355091 - HYPH I-NP O
8 49 61 1355091 adrenoceptor NN I-NP O
9 62 70 1355091 blockade NN I-NP O
10 71 73 1355091 in IN B-PP O
11 74 81 1355091 chronic JJ B-NP O
12 82 90 1355091 prazosin NN I-NP D011224
13 90 91 1355091 - HYPH O O
14 91 101 1355091 pretreated VBN B-VP O
15 102 111 1355091 conscious JJ B-NP O
16 112 125 1355091 spontaneously RB I-NP O
17 126 138 1355091 hypertensive JJ I-NP D006973
18 139 143 1355091 rats NNS I-NP O
19 143 144 1355091 . . O O
20 145 146 1355091 1 CD B-NP O
21 146 147 1355091 . . O O

1 148 155 1355091 Studies NNS B-NP O
2 156 160 1355091 were VBD B-VP O
3 161 170 1355091 performed VBN I-VP O
4 171 173 1355091 to TO I-VP O
5 174 182 1355091 evaluate VB I-VP O
6 183 190 1355091 whether IN B-SBAR O
7 191 198 1355091 chronic JJ B-NP O
8 199 207 1355091 prazosin NN I-NP D011224
9 208 217 1355091 treatment NN I-NP O
10 218 224 1355091 alters VBZ B-VP O
11 225 228 1355091 the DT B-NP O
12 229 234 1355091 alpha SYM I-NP O
13 235 236 1355091 2 CD I-NP O
14 236 237 1355091 - HYPH I-NP O
15 237 249 1355091 adrenoceptor NN I-NP O
16 250 258 1355091 function NN I-NP O
17 259 262 1355091 for IN B-PP O
18 263 274 1355091 orthostatic JJ B-NP O
19 275 282 1355091 control NN I-NP O
20 283 285 1355091 of IN B-PP O
21 286 294 1355091 arterial JJ B-NP O
22 295 300 1355091 blood NN I-NP O
23 301 309 1355091 pressure NN I-NP O
24 310 312 1355091 in IN B-PP O
25 313 322 1355091 conscious JJ B-NP O
26 323 336 1355091 spontaneously RB I-NP O
27 337 349 1355091 hypertensive JJ I-NP D006973
28 350 354 1355091 rats NNS I-NP O
29 355 356 1355091 ( ( O O
30 356 359 1355091 SHR NN B-NP O
31 359 360 1355091 ) ) O O
32 360 361 1355091 . . O O
33 362 363 1355091 2 CD B-NP O
34 363 364 1355091 . . O O

1 365 374 1355091 Conscious JJ B-NP O
2 375 378 1355091 SHR NN I-NP O
3 379 380 1355091 ( ( O O
4 380 384 1355091 male JJ B-NP O
5 385 388 1355091 300 CD I-NP O
6 388 389 1355091 - HYPH I-NP O
7 389 392 1355091 350 CD I-NP O
8 393 394 1355091 g NN I-NP O
9 394 395 1355091 ) ) O O
10 396 400 1355091 were VBD B-VP O
11 401 410 1355091 subjected VBN I-VP O
12 411 413 1355091 to TO B-PP O
13 414 416 1355091 90 CD B-NP O
14 417 424 1355091 degrees NNS I-NP O
15 425 429 1355091 head VB B-VP O
16 429 430 1355091 - HYPH O O
17 430 432 1355091 up RP B-PRT O
18 433 438 1355091 tilts NNS B-NP O
19 439 442 1355091 for IN B-PP O
20 443 445 1355091 60 CD B-NP O
21 446 447 1355091 s NN I-NP O
22 448 457 1355091 following VBG B-PP O
23 458 463 1355091 acute JJ B-NP O
24 464 478 1355091 administration NN I-NP O
25 479 481 1355091 of IN B-PP O
26 482 490 1355091 prazosin NN B-NP D011224
27 491 492 1355091 ( ( O O
28 492 495 1355091 0.1 CD B-NP O
29 496 498 1355091 mg NN I-NP O
30 499 501 1355091 kg NN I-NP O
31 501 502 1355091 - HYPH B-NP O
32 502 503 1355091 1 CD I-NP O
33 504 507 1355091 i.p NN I-NP O
34 507 508 1355091 . . O O
35 508 509 1355091 ) ) O O
36 510 512 1355091 or CC O O
37 513 524 1355091 rauwolscine NN B-NP D015016
38 525 526 1355091 ( ( O O
39 526 527 1355091 3 CD B-NP O
40 528 530 1355091 mg NN I-NP O
41 531 533 1355091 kg NN I-NP O
42 533 534 1355091 - HYPH B-NP O
43 534 535 1355091 1 CD I-NP O
44 536 539 1355091 i.v NN I-NP O
45 539 540 1355091 . . O O
46 540 541 1355091 ) ) O O
47 541 542 1355091 . . O O

1 543 554 1355091 Orthostatic JJ B-NP D007024
2 555 566 1355091 hypotension NN I-NP D007024
3 567 570 1355091 was VBD B-VP O
4 571 581 1355091 determined VBN I-VP O
5 582 584 1355091 by IN B-PP O
6 585 588 1355091 the DT B-NP O
7 589 596 1355091 average JJ I-NP O
8 597 605 1355091 decrease NN I-NP O
9 606 607 1355091 ( ( O O
10 607 608 1355091 % NN B-NP O
11 608 609 1355091 ) ) O O
12 610 612 1355091 in IN B-PP O
13 613 617 1355091 mean JJ B-NP O
14 618 626 1355091 arterial JJ I-NP O
15 627 635 1355091 pressure NN I-NP O
16 636 637 1355091 ( ( O O
17 637 640 1355091 MAP NN B-NP O
18 641 648 1355091 femoral JJ B-ADJP O
19 648 649 1355091 ) ) O O
20 650 654 1355091 over IN B-PP O
21 655 658 1355091 the DT B-NP O
22 659 661 1355091 60 CD I-NP O
23 661 662 1355091 - HYPH I-NP O
24 662 663 1355091 s NN I-NP O
25 664 668 1355091 tilt NN I-NP O
26 669 675 1355091 period NN I-NP O
27 675 676 1355091 . . O O

1 677 680 1355091 The DT B-NP O
2 681 686 1355091 basal JJ I-NP O
3 687 690 1355091 MAP NN I-NP O
4 691 693 1355091 of IN B-PP O
5 694 703 1355091 conscious JJ B-NP O
6 704 707 1355091 SHR NN I-NP O
7 708 711 1355091 was VBD B-VP O
8 712 719 1355091 reduced VBN I-VP O
9 720 722 1355091 to TO B-PP O
10 723 724 1355091 a DT B-NP O
11 725 732 1355091 similar JJ I-NP O
12 733 739 1355091 extent NN I-NP O
13 740 742 1355091 by IN B-PP O
14 743 751 1355091 prazosin NN B-NP D011224
15 752 753 1355091 ( ( O O
16 753 754 1355091 - SYM B-NP O
17 754 758 1355091 23%( CD I-NP O
18 758 759 1355091 - HYPH O O
19 759 760 1355091 ) ) O O
20 760 761 1355091 - HYPH B-NP O
21 761 764 1355091 26% NN I-NP O
22 765 768 1355091 MAP NN I-NP O
23 768 769 1355091 ) ) O O
24 770 773 1355091 and CC O O
25 774 785 1355091 rauwolscine NN B-NP D015016
26 786 787 1355091 ( ( O O
27 787 788 1355091 - SYM B-NP O
28 788 792 1355091 16%( CD I-NP O
29 792 793 1355091 - HYPH O O
30 793 794 1355091 ) ) O O
31 794 795 1355091 - HYPH B-NP O
32 795 798 1355091 33% NN I-NP O
33 799 802 1355091 MAP NN I-NP O
34 802 803 1355091 ) ) O O
35 803 804 1355091 . . O O

1 805 812 1355091 However RB B-ADVP O
2 812 813 1355091 , , O O
3 814 817 1355091 the DT B-NP O
4 818 822 1355091 head VB I-NP O
5 822 823 1355091 - HYPH B-VP O
6 823 825 1355091 up RP B-PRT O
7 826 830 1355091 tilt NN B-NP O
8 831 838 1355091 induced VBD B-VP O
9 839 850 1355091 orthostatic JJ B-NP D007024
10 851 862 1355091 hypotension NN I-NP D007024
11 863 865 1355091 in IN B-PP O
12 866 869 1355091 the DT B-NP O
13 870 873 1355091 SHR NN I-NP O
14 874 881 1355091 treated VBN B-VP O
15 882 886 1355091 with IN B-PP O
16 887 895 1355091 prazosin NN B-NP D011224
17 896 897 1355091 ( ( O O
18 897 898 1355091 - SYM B-NP O
19 898 901 1355091 16% NN I-NP O
20 902 905 1355091 MAP NN I-NP O
21 905 906 1355091 , , O O
22 907 908 1355091 n NN B-NP O
23 909 910 1355091 = JJ B-VP O
24 911 912 1355091 6 CD B-NP O
25 912 913 1355091 ) ) O O
26 913 914 1355091 , , O O
27 915 918 1355091 but CC B-PP O
28 919 922 1355091 not RB B-PP O
29 923 925 1355091 in IN I-PP O
30 926 929 1355091 the DT B-NP O
31 930 933 1355091 SHR NN I-NP O
32 934 941 1355091 treated VBN B-VP O
33 942 946 1355091 with IN B-PP O
34 947 958 1355091 rauwolscine NN B-NP D015016
35 959 960 1355091 ( ( O O
36 960 964 1355091 less JJR B-ADJP O
37 965 969 1355091 than IN B-PP O
38 970 971 1355091 + SYM B-NP O
39 971 973 1355091 2% NN I-NP O
40 974 977 1355091 MAP NN I-NP O
41 977 978 1355091 , , O O
42 979 980 1355091 n NN B-NP O
43 981 982 1355091 = JJ B-VP O
44 983 984 1355091 6 CD B-NP O
45 984 985 1355091 ) ) O O
46 985 986 1355091 . . O O

1 987 988 1355091 3 LS B-LST O
2 988 989 1355091 . . O O

1 990 999 1355091 Conscious JJ B-NP O
2 1000 1003 1355091 SHR NN I-NP O
3 1004 1008 1355091 were VBD B-VP O
4 1009 1016 1355091 treated VBN I-VP O
5 1017 1020 1355091 for IN B-PP O
6 1021 1022 1355091 4 CD B-NP O
7 1023 1027 1355091 days NNS I-NP O
8 1028 1032 1355091 with IN B-PP O
9 1033 1041 1355091 prazosin NN B-NP D011224
10 1042 1044 1355091 at IN B-PP O
11 1045 1046 1355091 2 CD B-NP O
12 1047 1049 1355091 mg NN I-NP O
13 1050 1052 1355091 kg NN I-NP O
14 1052 1053 1355091 - HYPH B-NP O
15 1053 1054 1355091 1 CD I-NP O
16 1055 1058 1355091 day NN I-NP O
17 1058 1059 1355091 - HYPH B-NP O
18 1059 1060 1355091 1 CD I-NP O
19 1061 1064 1355091 i.p NN I-NP O
20 1064 1065 1355091 . . O O

1 1066 1069 1355091 for IN B-PP O
2 1070 1077 1355091 chronic JJ B-NP O
3 1078 1083 1355091 alpha SYM I-NP O
4 1084 1085 1355091 1 CD I-NP O
5 1085 1086 1355091 - HYPH I-NP O
6 1086 1098 1355091 adrenoceptor NN I-NP O
7 1099 1107 1355091 blockade NN I-NP O
8 1107 1108 1355091 . . O O

1 1109 1112 1355091 MAP NN B-NP O
2 1113 1115 1355091 in IN B-PP O
3 1116 1125 1355091 conscious JJ B-NP O
4 1126 1129 1355091 SHR NN I-NP O
5 1130 1135 1355091 after IN B-PP O
6 1136 1143 1355091 chronic JJ B-NP O
7 1144 1152 1355091 prazosin NN I-NP D011224
8 1153 1162 1355091 treatment NN I-NP O
9 1163 1166 1355091 was VBD B-VP O
10 1167 1170 1355091 14% CD B-NP O
11 1171 1176 1355091 lower JJR B-ADJP O
12 1177 1181 1355091 than IN B-PP O
13 1182 1184 1355091 in IN B-PP O
14 1185 1188 1355091 the DT B-NP O
15 1189 1198 1355091 untreated JJ I-NP O
16 1199 1202 1355091 SHR NN I-NP O
17 1203 1204 1355091 ( ( O O
18 1204 1205 1355091 n NN B-NP O
19 1206 1207 1355091 = SYM B-VP O
20 1208 1209 1355091 8 CD B-NP O
21 1209 1210 1355091 ) ) O O
22 1210 1211 1355091 . . O O

1 1212 1216 1355091 Head VB B-VP O
2 1216 1217 1355091 - HYPH O O
3 1217 1219 1355091 up RP B-PRT O
4 1220 1225 1355091 tilts NNS B-NP O
5 1226 1228 1355091 in IN B-PP O
6 1229 1234 1355091 these DT B-NP O
7 1235 1239 1355091 rats NNS I-NP O
8 1240 1243 1355091 did VBD B-VP O
9 1244 1247 1355091 not RB I-VP O
10 1248 1255 1355091 produce VB I-VP O
11 1256 1267 1355091 orthostatic JJ B-NP D007024
12 1268 1279 1355091 hypotension NN I-NP D007024
13 1280 1284 1355091 when WRB B-ADVP O
14 1285 1294 1355091 performed VBN B-VP O
15 1295 1301 1355091 either CC O O
16 1302 1307 1355091 prior JJ B-ADJP O
17 1308 1310 1355091 to TO B-PP O
18 1311 1313 1355091 or CC B-PP O
19 1314 1319 1355091 after IN I-PP O
20 1320 1325 1355091 acute JJ B-NP O
21 1326 1332 1355091 dosing NN I-NP O
22 1333 1335 1355091 of IN B-PP O
23 1336 1344 1355091 prazosin NN B-NP D011224
24 1345 1346 1355091 ( ( O O
25 1346 1349 1355091 0.1 CD B-NP O
26 1350 1352 1355091 mg NN I-NP O
27 1353 1355 1355091 kg NN I-NP O
28 1355 1356 1355091 - HYPH B-NP O
29 1356 1357 1355091 1 CD I-NP O
30 1358 1361 1355091 i.p NN I-NP O
31 1361 1362 1355091 . . O O
32 1362 1363 1355091 ) ) O O
33 1363 1364 1355091 . . O O

1 1365 1375 1355091 Conversely RB B-ADVP O
2 1375 1376 1355091 , , O O
3 1377 1391 1355091 administration NN B-NP O
4 1392 1394 1355091 of IN B-PP O
5 1395 1406 1355091 rauwolscine NN B-NP D015016
6 1407 1408 1355091 ( ( O O
7 1408 1409 1355091 3 CD B-NP O
8 1410 1412 1355091 mg NN I-NP O
9 1413 1415 1355091 kg NN I-NP O
10 1415 1416 1355091 - HYPH B-NP O
11 1416 1417 1355091 1 CD I-NP O
12 1418 1421 1355091 i.v NN I-NP O
13 1421 1422 1355091 . . O O
14 1422 1423 1355091 ) ) O O
15 1424 1426 1355091 in IN B-PP O
16 1427 1434 1355091 chronic JJ B-NP O
17 1435 1443 1355091 prazosin NN I-NP D011224
18 1444 1451 1355091 treated VBN B-NP O
19 1452 1455 1355091 SHR NN I-NP O
20 1456 1465 1355091 decreased VBD B-VP O
21 1466 1469 1355091 the DT B-NP O
22 1470 1475 1355091 basal JJ I-NP O
23 1476 1479 1355091 MAP NN I-NP O
24 1480 1482 1355091 by IN B-PP O
25 1483 1485 1355091 12 CD B-NP O
26 1485 1486 1355091 - HYPH I-NP O
27 1486 1489 1355091 31% CD I-NP O
28 1490 1491 1355091 ( ( O O
29 1491 1492 1355091 n NN B-NP O
30 1493 1494 1355091 = SYM B-VP O
31 1495 1496 1355091 4 CD B-NP O
32 1496 1497 1355091 ) ) O O
33 1497 1498 1355091 , , O O
34 1499 1502 1355091 and CC O O
35 1503 1513 1355091 subsequent JJ B-NP O
36 1514 1519 1355091 tilts NNS I-NP O
37 1520 1527 1355091 induced VBD B-VP O
38 1528 1535 1355091 further JJ B-NP O
39 1536 1541 1355091 drops NNS I-NP O
40 1542 1544 1355091 of IN B-PP O
41 1545 1548 1355091 MAP NN B-NP O
42 1549 1551 1355091 by IN B-PP O
43 1552 1554 1355091 19 CD B-NP O
44 1554 1555 1355091 - HYPH I-NP O
45 1555 1558 1355091 23% CD I-NP O
46 1559 1561 1355091 in IN B-PP O
47 1562 1567 1355091 these DT B-NP O
48 1568 1572 1355091 rats NNS I-NP O
49 1572 1573 1355091 . . O O

1 1574 1575 1355091 4 LS B-LST O
2 1575 1576 1355091 . . O O

1 1577 1580 1355091 The DT B-NP O
2 1581 1588 1355091 pressor NN I-NP O
3 1589 1598 1355091 responses NNS I-NP O
4 1599 1602 1355091 and CC O O
5 1603 1614 1355091 bradycardia NN B-NP D001919
6 1615 1617 1355091 to TO B-PP O
7 1618 1621 1355091 the DT B-NP O
8 1622 1627 1355091 alpha SYM I-NP O
9 1628 1629 1355091 1 CD I-NP O
10 1629 1630 1355091 - HYPH I-NP O
11 1630 1637 1355091 agonist NN I-NP O
12 1638 1648 1355091 cirazoline NN I-NP C014282
13 1649 1650 1355091 ( ( O O
14 1650 1653 1355091 0.6 CD B-NP O
15 1654 1657 1355091 and CC I-NP O
16 1658 1659 1355091 2 CD I-NP O
17 1660 1670 1355091 micrograms NNS I-NP O
18 1671 1673 1355091 kg NN I-NP O
19 1673 1674 1355091 - HYPH B-NP O
20 1674 1675 1355091 1 CD I-NP O
21 1676 1679 1355091 i.v NN I-NP O
22 1679 1680 1355091 . . O O
23 1680 1681 1355091 ) ) O O
24 1681 1682 1355091 , , O O
25 1683 1686 1355091 the DT B-NP O
26 1687 1692 1355091 alpha SYM I-NP O
27 1693 1694 1355091 2 CD I-NP O
28 1694 1695 1355091 - HYPH I-NP O
29 1695 1702 1355091 agonist NN I-NP O
30 1703 1709 1355091 Abbott NN I-NP C056299
31 1709 1710 1355091 - HYPH O C056299
32 1710 1715 1355091 53693 CD B-NP C056299
33 1716 1717 1355091 ( ( O O
34 1717 1718 1355091 1 CD B-NP O
35 1719 1722 1355091 and CC I-NP O
36 1723 1724 1355091 3 CD I-NP O
37 1725 1735 1355091 micrograms NNS I-NP O
38 1736 1738 1355091 kg NN I-NP O
39 1738 1739 1355091 - HYPH B-NP O
40 1739 1740 1355091 1 CD I-NP O
41 1741 1744 1355091 i.v NN I-NP O
42 1744 1745 1355091 . . O O
43 1745 1746 1355091 ) ) O O
44 1746 1747 1355091 , , O O
45 1748 1751 1355091 and CC O O
46 1752 1765 1355091 noradrenaline NN B-NP D009638
47 1766 1767 1355091 ( ( O O
48 1767 1770 1355091 0.1 CD B-NP O
49 1771 1774 1355091 and CC I-NP O
50 1775 1778 1355091 1.0 CD I-NP O
51 1779 1789 1355091 micrograms NNS I-NP O
52 1790 1792 1355091 kg NN I-NP O
53 1792 1793 1355091 - HYPH B-NP O
54 1793 1794 1355091 1 CD I-NP O
55 1795 1798 1355091 i.v NN I-NP O
56 1798 1799 1355091 . . O O
57 1799 1800 1355091 ) ) O O
58 1801 1805 1355091 were VBD B-VP O
59 1806 1816 1355091 determined VBN I-VP O
60 1817 1819 1355091 in IN B-PP O
61 1820 1829 1355091 conscious JJ B-NP O
62 1830 1833 1355091 SHR NN I-NP O
63 1834 1838 1355091 with IN B-PP O
64 1839 1842 1355091 and CC O O
65 1843 1850 1355091 without IN B-PP O
66 1851 1858 1355091 chronic JJ B-NP O
67 1859 1867 1355091 prazosin NN I-NP D011224
68 1868 1880 1355091 pretreatment NN I-NP O
69 1880 1881 1355091 . . O O

1 1882 1886 1355091 Both CC O O
2 1887 1890 1355091 the DT B-NP O
3 1891 1898 1355091 pressor NN I-NP O
4 1899 1902 1355091 and CC I-NP O
5 1903 1914 1355091 bradycardia NN I-NP D001919
6 1915 1922 1355091 effects NNS I-NP O
7 1923 1925 1355091 of IN B-PP O
8 1926 1936 1355091 cirazoline NN B-NP C014282
9 1937 1941 1355091 were VBD B-VP O
10 1942 1951 1355091 abolished VBN I-VP O
11 1952 1954 1355091 in IN B-PP O
12 1955 1962 1355091 chronic JJ B-NP O
13 1963 1971 1355091 prazosin NN I-NP D011224
14 1972 1979 1355091 treated VBN B-VP O
15 1980 1983 1355091 SHR NN B-NP O
16 1984 1985 1355091 ( ( O O
17 1985 1986 1355091 n NN B-NP O
18 1987 1988 1355091 = SYM B-VP O
19 1989 1990 1355091 4 CD B-NP O
20 1990 1991 1355091 ) ) O O
21 1992 1994 1355091 as IN B-SBAR O
22 1995 2003 1355091 compared VBN B-VP O
23 2004 2006 1355091 to TO B-PP O
24 2007 2010 1355091 the DT B-NP O
25 2011 2020 1355091 untreated JJ I-NP O
26 2021 2024 1355091 SHR NN I-NP O
27 2025 2026 1355091 ( ( O O
28 2026 2027 1355091 n NN B-NP O
29 2028 2029 1355091 = SYM B-VP O
30 2030 2031 1355091 4 CD B-NP O
31 2031 2032 1355091 ) ) O O
32 2032 2033 1355091 . . O O

1 2034 2036 1355091 On IN B-PP O
2 2037 2040 1355091 the DT B-NP O
3 2041 2046 1355091 other JJ I-NP O
4 2047 2051 1355091 hand NN I-NP O
5 2051 2052 1355091 , , O O
6 2053 2056 1355091 the DT B-NP O
7 2057 2064 1355091 pressor NN I-NP O
8 2065 2072 1355091 effects NNS I-NP O
9 2073 2075 1355091 of IN B-PP O
10 2076 2082 1355091 Abbott NN B-NP C056299
11 2082 2083 1355091 - HYPH B-NP C056299
12 2083 2088 1355091 53693 CD I-NP C056299
13 2089 2093 1355091 were VBD B-VP O
14 2094 2101 1355091 similar JJ B-ADJP O
15 2102 2104 1355091 in IN B-PP O
16 2105 2109 1355091 both DT B-NP O
17 2110 2116 1355091 groups NNS I-NP O
18 2117 2119 1355091 of IN B-PP O
19 2120 2123 1355091 SHR NN B-NP O
20 2123 2124 1355091 , , O O
21 2125 2128 1355091 but CC O O
22 2129 2132 1355091 the DT B-NP O
23 2133 2145 1355091 accompanying VBG I-NP O
24 2146 2157 1355091 bradycardia NN I-NP D001919
25 2158 2161 1355091 was VBD B-VP O
26 2162 2169 1355091 greater JJR B-ADJP O
27 2170 2172 1355091 in IN B-PP O
28 2173 2176 1355091 SHR NN B-NP O
29 2177 2181 1355091 with IN B-PP O
30 2182 2189 1355091 chronic JJ B-NP O
31 2190 2198 1355091 prazosin NN I-NP D011224
32 2199 2208 1355091 treatment NN I-NP O
33 2209 2213 1355091 than IN B-PP O
34 2214 2221 1355091 without IN B-PP O
35 2222 2226 1355091 such JJ B-NP O
36 2227 2236 1355091 treatment NN I-NP O
37 2236 2237 1355091 . . O O

1 2238 2249 1355091 Furthermore RB B-ADVP O
2 2249 2250 1355091 , , O O
3 2251 2254 1355091 the DT B-NP O
4 2255 2266 1355091 bradycardia NN I-NP D001919
5 2267 2271 1355091 that WDT B-NP O
6 2272 2283 1355091 accompanied VBD B-VP O
7 2284 2287 1355091 the DT B-NP O
8 2288 2301 1355091 noradrenaline NN I-NP D009638
9 2301 2302 1355091 - HYPH B-NP O
10 2302 2309 1355091 induced VBN I-NP O
11 2310 2317 1355091 pressor NN I-NP O
12 2318 2324 1355091 effect NN I-NP O
13 2325 2327 1355091 in IN B-PP O
14 2328 2331 1355091 SHR NN B-NP O
15 2332 2335 1355091 was VBD B-VP O
16 2336 2343 1355091 similar JJ B-ADJP O
17 2344 2348 1355091 with IN B-PP O
18 2349 2352 1355091 and CC O O
19 2353 2360 1355091 without IN B-PP O
20 2361 2368 1355091 chronic JJ B-NP O
21 2369 2377 1355091 prazosin NN I-NP D011224
22 2378 2387 1355091 treatment NN I-NP O
23 2388 2395 1355091 despite IN B-PP O
24 2396 2397 1355091 a DT B-NP O
25 2398 2400 1355091 47 CD I-NP O
26 2400 2401 1355091 - HYPH I-NP O
27 2401 2404 1355091 71% CD I-NP O
28 2405 2414 1355091 reduction NN I-NP O
29 2415 2417 1355091 of IN B-PP O
30 2418 2421 1355091 the DT B-NP O
31 2422 2429 1355091 pressor NN I-NP O
32 2430 2436 1355091 effect NN I-NP O
33 2437 2439 1355091 in IN B-PP O
34 2440 2447 1355091 chronic JJ B-NP O
35 2448 2453 1355091 alpha SYM I-NP O
36 2454 2455 1355091 1 CD I-NP O
37 2455 2456 1355091 - HYPH I-NP O
38 2456 2464 1355091 receptor NN I-NP O
39 2465 2472 1355091 blocked VBD B-VP O
40 2473 2486 1355091 SHR.(ABSTRACT NN B-NP O
41 2487 2496 1355091 TRUNCATED VBN B-VP O
42 2497 2499 1355091 AT IN B-PP O
43 2500 2503 1355091 400 CD B-NP O
44 2504 2509 1355091 WORDS NNS I-NP O
45 2509 2510 1355091 ) ) O O

1 0 0 9523850 -DOCSTART- -X- -X- O

1 0 5 9523850 Value NN B-NP O
2 6 8 9523850 of IN B-PP O
3 9 27 9523850 methylprednisolone NN B-NP D008775
4 28 30 9523850 in IN B-PP O
5 31 41 9523850 prevention NN B-NP O
6 42 44 9523850 of IN B-PP O
7 45 48 9523850 the DT B-NP O
8 49 59 9523850 arthralgia NN I-NP D018771
9 59 60 9523850 - HYPH B-NP O
10 60 67 9523850 myalgia NN I-NP D063806
11 68 76 9523850 syndrome NN I-NP O
12 77 87 9523850 associated VBN B-VP O
13 88 92 9523850 with IN B-PP O
14 93 96 9523850 the DT B-NP O
15 97 102 9523850 total JJ I-NP O
16 103 107 9523850 dose NN I-NP O
17 108 116 9523850 infusion NN I-NP O
18 117 119 9523850 of IN B-PP O
19 120 124 9523850 iron NN B-NP D007505
20 125 132 9523850 dextran NN I-NP D007505
21 132 133 9523850 : : O O
22 134 135 9523850 a DT B-NP O
23 136 142 9523850 double JJ I-NP O
24 143 148 9523850 blind JJ I-NP O
25 149 159 9523850 randomized VBN I-NP O
26 160 165 9523850 trial NN I-NP O
27 165 166 9523850 . . O O
28 167 170 9523850 The DT B-NP O
29 171 177 9523850 safety NN I-NP O
30 178 181 9523850 and CC I-NP O
31 182 190 9523850 efficacy NN I-NP O
32 191 193 9523850 of IN B-PP O
33 194 199 9523850 total JJ B-NP O
34 200 204 9523850 dose NN I-NP O
35 205 213 9523850 infusion NN I-NP O
36 214 215 9523850 ( ( O O
37 215 218 9523850 TDI NN B-NP O
38 218 219 9523850 ) ) O O
39 220 222 9523850 of IN B-PP O
40 223 227 9523850 iron NN B-NP D007505
41 228 235 9523850 dextran NN I-NP D007505
42 236 239 9523850 has VBZ B-VP O
43 240 244 9523850 been VBN I-VP O
44 245 249 9523850 well RB I-VP O
45 250 260 9523850 documented VBN I-VP O
46 260 261 9523850 . . O O

1 262 264 9523850 In IN B-PP O
2 265 268 9523850 40% CD B-NP O
3 269 271 9523850 of IN B-PP O
4 272 279 9523850 treated JJ B-NP O
5 280 288 9523850 patients NNS I-NP O
6 288 289 9523850 , , O O
7 290 292 9523850 an DT B-NP O
8 293 303 9523850 arthralgia NN I-NP D018771
9 303 304 9523850 - HYPH I-NP O
10 304 311 9523850 myalgia NN I-NP D063806
11 312 320 9523850 syndrome NN I-NP O
12 321 329 9523850 develops VBZ B-VP O
13 329 330 9523850 . . O O

1 331 334 9523850 The DT B-NP O
2 335 342 9523850 purpose NN I-NP O
3 343 345 9523850 of IN B-PP O
4 346 350 9523850 this DT B-NP O
5 351 361 9523850 randomized VBN I-NP O
6 361 362 9523850 , , I-NP O
7 363 369 9523850 double JJ I-NP O
8 369 370 9523850 - HYPH I-NP O
9 370 375 9523850 blind JJ I-NP O
10 375 376 9523850 , , I-NP O
11 377 388 9523850 prospective JJ I-NP O
12 389 394 9523850 study NN I-NP O
13 395 398 9523850 was VBD B-VP O
14 399 401 9523850 to TO B-VP O
15 402 413 9523850 investigate VB I-VP O
16 414 421 9523850 whether IN B-SBAR O
17 422 433 9523850 intravenous JJ O O
18 434 435 9523850 ( ( O O
19 435 438 9523850 i.v JJ O O
20 438 439 9523850 . . O O
21 439 440 9523850 ) ) O O
22 441 455 9523850 administration NN B-NP O
23 456 458 9523850 of IN B-PP O
24 459 477 9523850 methylprednisolone NN B-NP D008775
25 478 479 9523850 ( ( O O
26 479 481 9523850 MP NN B-NP D008775
27 481 482 9523850 ) ) O O
28 483 491 9523850 prevents VBZ B-VP O
29 492 496 9523850 this DT B-NP O
30 497 509 9523850 complication NN I-NP O
31 509 510 9523850 . . O O

1 511 516 9523850 Sixty CD B-NP O
2 516 517 9523850 - HYPH I-NP O
3 517 521 9523850 five CD I-NP O
4 522 530 9523850 patients NNS I-NP O
5 530 531 9523850 , , O O
6 532 534 9523850 34 CD B-NP O
7 535 540 9523850 women NNS I-NP O
8 541 544 9523850 and CC O O
9 545 547 9523850 31 CD B-NP O
10 548 551 9523850 men NNS I-NP O
11 551 552 9523850 , , O O
12 553 557 9523850 ages NNS B-NP O
13 558 560 9523850 36 CD B-NP O
14 561 563 9523850 to TO I-NP O
15 564 566 9523850 80 CD I-NP O
16 567 572 9523850 years NNS I-NP O
17 572 573 9523850 , , O O
18 574 582 9523850 received JJ B-NP O
19 583 589 9523850 either CC I-NP O
20 590 596 9523850 normal JJ I-NP O
21 597 603 9523850 saline NN I-NP O
22 604 610 9523850 before IN B-PP O
23 611 614 9523850 and CC I-PP O
24 615 620 9523850 after IN I-PP O
25 621 624 9523850 TDI NN B-NP O
26 625 626 9523850 ( ( O O
27 626 631 9523850 group NN B-NP O
28 632 633 9523850 1 CD I-NP O
29 633 634 9523850 ) ) O O
30 634 635 9523850 , , O O
31 636 639 9523850 125 CD B-NP O
32 640 642 9523850 mg NN I-NP O
33 643 646 9523850 i.v NN I-NP O
34 646 647 9523850 . . O O

1 648 650 9523850 MP NN B-NP D008775
2 651 657 9523850 before IN B-PP O
3 658 661 9523850 and CC O O
4 662 668 9523850 saline NN B-NP O
5 669 674 9523850 after IN B-PP O
6 675 678 9523850 TDI NN B-NP O
7 679 680 9523850 ( ( O O
8 680 685 9523850 group NN B-NP O
9 686 687 9523850 2 CD I-NP O
10 687 688 9523850 ) ) O O
11 688 689 9523850 , , O O
12 690 692 9523850 or CC O O
13 693 696 9523850 125 CD B-NP O
14 697 699 9523850 mg NN I-NP O
15 700 703 9523850 i.v NN I-NP O
16 703 704 9523850 . . O O

1 705 707 9523850 MP NN B-NP D008775
2 708 714 9523850 before IN B-PP O
3 715 718 9523850 and CC I-PP O
4 719 724 9523850 after IN I-PP O
5 725 728 9523850 TDI NN B-NP O
6 729 730 9523850 ( ( O O
7 730 735 9523850 group NN B-NP O
8 736 737 9523850 3 CD I-NP O
9 737 738 9523850 ) ) O O
10 738 739 9523850 . . O O

1 740 748 9523850 Patients NNS B-NP O
2 749 753 9523850 were VBD B-VP O
3 754 762 9523850 observed VBN I-VP O
4 763 766 9523850 for IN B-PP O
5 767 769 9523850 72 CD B-NP O
6 770 775 9523850 hours NNS I-NP O
7 776 779 9523850 and CC I-NP O
8 780 789 9523850 reactions NNS I-NP O
9 790 794 9523850 were VBD B-VP O
10 795 803 9523850 recorded VBN I-VP O
11 804 807 9523850 and CC I-VP O
12 808 814 9523850 graded VBN I-VP O
13 815 824 9523850 according VBG B-PP O
14 825 827 9523850 to TO B-PP O
15 828 836 9523850 severity NN B-NP O
16 836 837 9523850 . . O O

1 838 843 9523850 Fifty CD B-NP O
2 843 844 9523850 - HYPH I-NP O
3 844 849 9523850 eight CD I-NP O
4 850 857 9523850 percent NN I-NP O
5 858 860 9523850 of IN B-PP O
6 861 866 9523850 group NN B-NP O
7 867 868 9523850 1 CD I-NP O
8 869 877 9523850 patients NNS I-NP O
9 877 878 9523850 , , O O
10 879 882 9523850 33% NN B-NP O
11 883 885 9523850 of IN B-PP O
12 886 891 9523850 group NN B-NP O
13 892 893 9523850 2 CD I-NP O
14 893 894 9523850 , , O O
15 895 898 9523850 and CC O O
16 899 902 9523850 26% CD B-NP O
17 903 905 9523850 of IN B-PP O
18 906 911 9523850 group NN B-NP O
19 912 913 9523850 3 CD I-NP O
20 914 917 9523850 had VBD B-VP O
21 918 927 9523850 reactions NNS B-NP O
22 928 930 9523850 to TO B-PP O
23 931 934 9523850 TDI NNP B-NP O
24 934 935 9523850 . . O O

1 936 939 9523850 The DT B-NP O
2 940 948 9523850 severity NN I-NP O
3 949 951 9523850 of IN B-PP O
4 952 961 9523850 reactions NNS B-NP O
5 962 963 9523850 ( ( O O
6 963 970 9523850 minimal JJ B-NP O
7 970 971 9523850 , , I-NP O
8 972 976 9523850 mild JJ I-NP O
9 976 977 9523850 , , I-NP O
10 978 981 9523850 and CC I-NP O
11 982 990 9523850 moderate JJ I-NP O
12 990 991 9523850 , , O O
13 992 1004 9523850 respectively RB B-ADVP O
14 1004 1005 9523850 ) ) O O
15 1006 1009 9523850 was VBD B-VP O
16 1010 1012 9523850 as IN B-SBAR O
17 1013 1020 9523850 follows VBZ B-VP O
18 1020 1021 9523850 : : O O
19 1022 1027 9523850 group NN B-NP O
20 1028 1029 9523850 1 CD I-NP O
21 1029 1030 9523850 - HYPH I-NP O
22 1030 1031 9523850 - SYM I-NP O
23 1031 1032 9523850 6 CD I-NP O
24 1032 1033 9523850 , , I-NP O
25 1034 1035 9523850 6 CD I-NP O
26 1035 1036 9523850 , , O O
27 1037 1040 9523850 and CC O O
28 1041 1042 9523850 2 CD B-NP O
29 1042 1043 9523850 ; : O O
30 1044 1049 9523850 group NN B-NP O
31 1050 1051 9523850 2 CD I-NP O
32 1051 1052 9523850 - HYPH B-NP O
33 1052 1053 9523850 - SYM I-NP O
34 1053 1054 9523850 1 CD I-NP O
35 1054 1055 9523850 , , I-NP O
36 1056 1057 9523850 5 CD I-NP O
37 1057 1058 9523850 , , O O
38 1059 1062 9523850 and CC O O
39 1063 1064 9523850 0 CD B-NP O
40 1064 1065 9523850 ; : O O
41 1066 1071 9523850 group NN B-NP O
42 1072 1073 9523850 3 CD I-NP O
43 1073 1074 9523850 - HYPH I-NP O
44 1074 1075 9523850 - SYM I-NP O
45 1075 1076 9523850 5 CD I-NP O
46 1076 1077 9523850 , , I-NP O
47 1078 1079 9523850 1 CD I-NP O
48 1079 1080 9523850 , , O O
49 1081 1084 9523850 and CC O O
50 1085 1086 9523850 0 CD B-NP O
51 1086 1087 9523850 . . O O

1 1088 1092 9523850 Data NNS B-NP O
2 1093 1097 9523850 were VBD B-VP O
3 1098 1106 9523850 analyzed VBN I-VP O
4 1107 1109 9523850 by IN B-PP O
5 1110 1113 9523850 the DT B-NP O
6 1114 1117 9523850 two CD I-NP O
7 1117 1118 9523850 - HYPH I-NP O
8 1118 1123 9523850 sided JJ I-NP O
9 1124 1132 9523850 Fisher's NNS I-NP O
10 1133 1138 9523850 exact JJ I-NP O
11 1139 1143 9523850 test NN I-NP O
12 1144 1149 9523850 using VBG B-VP O
13 1150 1153 9523850 95% CD B-NP O
14 1154 1164 9523850 confidence NN I-NP O
15 1165 1174 9523850 intervals NNS I-NP O
16 1175 1179 9523850 with IN B-PP O
17 1180 1183 9523850 the DT B-NP O
18 1184 1197 9523850 approximation NN I-NP O
19 1198 1200 9523850 of IN B-PP O
20 1201 1206 9523850 Woolf NNP B-NP O
21 1206 1207 9523850 . . O O

1 1208 1213 9523850 These DT B-NP O
2 1214 1218 9523850 data NNS I-NP O
3 1219 1230 9523850 demonstrate VBP B-VP O
4 1231 1235 9523850 that IN B-SBAR O
5 1236 1250 9523850 administration NN B-NP O
6 1251 1253 9523850 of IN B-PP O
7 1254 1256 9523850 MP NN B-NP D008775
8 1257 1263 9523850 before IN B-PP O
9 1264 1267 9523850 and CC I-PP O
10 1268 1273 9523850 after IN I-PP O
11 1274 1277 9523850 TDI NN B-NP O
12 1278 1285 9523850 reduces VBZ B-VP O
13 1286 1289 9523850 the DT B-NP O
14 1290 1299 9523850 frequency NN I-NP O
15 1300 1303 9523850 and CC I-NP O
16 1304 1312 9523850 severity NN I-NP O
17 1313 1315 9523850 of IN B-PP O
18 1316 1319 9523850 the DT B-NP O
19 1320 1330 9523850 arthralgia NN I-NP D018771
20 1330 1331 9523850 - HYPH B-NP O
21 1331 1338 9523850 myalgia NN I-NP D063806
22 1339 1347 9523850 syndrome NN I-NP O
23 1347 1348 9523850 . . O O

1 1349 1351 9523850 We PRP B-NP O
2 1352 1360 9523850 conclude VBP B-VP O
3 1361 1365 9523850 that IN B-SBAR O
4 1366 1369 9523850 125 CD B-NP O
5 1370 1372 9523850 mg NN I-NP O
6 1373 1376 9523850 i.v NN I-NP O
7 1376 1377 9523850 . . O O

1 1378 1380 9523850 MP NN B-NP D008775
2 1381 1387 9523850 should MD B-VP O
3 1388 1390 9523850 be VB I-VP O
4 1391 1396 9523850 given VBN I-VP O
5 1397 1406 9523850 routinely RB B-ADVP O
6 1407 1413 9523850 before IN B-PP O
7 1414 1417 9523850 and CC I-PP O
8 1418 1423 9523850 after IN I-PP O
9 1424 1427 9523850 TDI NN B-NP O
10 1428 1430 9523850 of IN B-PP O
11 1431 1435 9523850 iron NN B-NP D007505
12 1436 1443 9523850 dextran NN I-NP D007505
13 1443 1444 9523850 . . O O

1 0 0 6942642 -DOCSTART- -X- -X- O

1 0 8 6942642 Thiazide NN B-NP D049971
2 9 18 6942642 diuretics NNS I-NP O
3 18 19 6942642 , , O O
4 20 31 6942642 hypokalemia NN B-NP D007008
5 32 35 6942642 and CC O O
6 36 43 6942642 cardiac JJ B-NP D001145
7 44 55 6942642 arrhythmias NNS I-NP D001145
8 55 56 6942642 . . O O
9 57 65 6942642 Thiazide NN B-NP D049971
10 66 75 6942642 diuretics NNS I-NP O
11 76 79 6942642 are VBP B-VP O
12 80 86 6942642 widely RB I-VP O
13 87 95 6942642 accepted VBN I-VP O
14 96 98 6942642 as IN B-PP O
15 99 102 6942642 the DT B-NP O
16 103 114 6942642 cornerstone NN I-NP O
17 115 117 6942642 of IN B-PP O
18 118 134 6942642 antihypertensive JJ B-NP O
19 135 144 6942642 treatment NN I-NP O
20 145 153 6942642 programs NNS I-NP O
21 153 154 6942642 . . O O

1 155 166 6942642 Hypokalemia NN B-NP D007008
2 167 169 6942642 is VBZ B-VP O
3 170 171 6942642 a DT B-NP O
4 172 180 6942642 commonly RB I-NP O
5 181 192 6942642 encountered VBN I-NP O
6 193 202 6942642 metabolic JJ I-NP O
7 203 214 6942642 consequence NN I-NP O
8 215 217 6942642 of IN B-PP O
9 218 225 6942642 chronic JJ B-NP O
10 226 234 6942642 thiazide NN I-NP D049971
11 235 242 6942642 therapy NN I-NP O
12 242 243 6942642 . . O O

1 244 246 6942642 We PRP B-NP O
2 247 254 6942642 treated VBD B-VP O
3 255 257 6942642 38 CD B-NP O
4 258 266 6942642 patients NNS I-NP O
5 267 268 6942642 ( ( O O
6 268 270 6942642 22 CD B-NP O
7 271 274 6942642 low JJ I-NP O
8 275 280 6942642 renin NN I-NP O
9 280 281 6942642 , , O O
10 282 284 6942642 16 CD B-NP O
11 285 291 6942642 normal JJ I-NP O
12 292 297 6942642 renin NN I-NP O
13 297 298 6942642 ) ) O O
14 299 303 6942642 with IN B-PP O
15 304 312 6942642 moderate JJ B-NP O
16 313 322 6942642 diastolic JJ I-NP C563897
17 323 335 6942642 hypertension NN I-NP C563897
18 336 340 6942642 with IN B-PP O
19 341 360 6942642 hydrochlorothiazide NN B-NP D006852
20 361 362 6942642 ( ( O O
21 362 366 6942642 HCTC NN B-NP D006852
22 366 367 6942642 ) ) O O
23 368 380 6942642 administered VBN B-VP O
24 381 383 6942642 on IN B-PP O
25 384 385 6942642 a DT B-NP O
26 386 391 6942642 twice RB I-NP O
27 392 397 6942642 daily JJ I-NP O
28 398 406 6942642 schedule NN I-NP O
29 406 407 6942642 . . O O

1 408 415 6942642 Initial JJ B-NP O
2 416 420 6942642 dose NN I-NP O
3 421 424 6942642 was VBD B-VP O
4 425 427 6942642 50 CD B-NP O
5 428 430 6942642 mg NN I-NP O
6 431 434 6942642 and CC O O
7 435 438 6942642 the DT B-NP O
8 439 443 6942642 dose NN I-NP O
9 444 447 6942642 was VBD B-VP O
10 448 457 6942642 increased VBN I-VP O
11 458 460 6942642 at IN B-PP O
12 461 468 6942642 monthly JJ B-NP O
13 469 478 6942642 intervals NNS I-NP O
14 479 481 6942642 to TO B-PP O
15 482 485 6942642 100 CD B-NP O
16 486 488 6942642 mg NN I-NP O
17 488 489 6942642 , , O O
18 490 493 6942642 150 CD B-NP O
19 494 496 6942642 mg NN I-NP O
20 497 500 6942642 and CC O O
21 501 504 6942642 200 CD B-NP O
22 505 507 6942642 mg NN I-NP O
23 508 513 6942642 daily RB B-ADVP O
24 514 519 6942642 until IN B-PP O
25 520 525 6942642 blood NN B-NP O
26 526 534 6942642 pressure NN I-NP O
27 535 545 6942642 normalized VBD B-VP O
28 545 546 6942642 . . O O

1 547 550 6942642 The DT B-NP O
2 551 556 6942642 serum NN I-NP O
3 557 558 6942642 K NN I-NP D011188
4 559 565 6942642 during IN B-PP O
5 566 569 6942642 the DT B-NP O
6 570 577 6942642 control NN I-NP O
7 578 584 6942642 period NN I-NP O
8 585 588 6942642 was VBD B-VP O
9 589 592 6942642 4.5 CD B-NP O
10 593 594 6942642 + SYM O O
11 594 595 6942642 / SYM O O
12 595 596 6942642 - SYM O O
13 597 600 6942642 0.2 CD B-NP O
14 601 604 6942642 mEq NN I-NP O
15 604 605 6942642 / SYM B-NP O
16 605 606 6942642 l NN I-NP O
17 607 609 6942642 an DT O O
18 610 612 6942642 on IN B-PP O
19 613 615 6942642 50 CD B-NP O
20 615 616 6942642 , , I-NP O
21 617 620 6942642 100 CD I-NP O
22 620 621 6942642 , , I-NP O
23 622 625 6942642 150 CD I-NP O
24 626 629 6942642 and CC I-NP O
25 630 633 6942642 200 CD I-NP O
26 634 636 6942642 mg NN I-NP O
27 637 641 6942642 HCTZ NN I-NP D006852
28 642 647 6942642 daily RB B-ADVP O
29 648 651 6942642 3.9 CD B-NP O
30 652 653 6942642 + SYM B-NP O
31 653 654 6942642 / SYM I-NP O
32 654 655 6942642 - SYM I-NP O
33 656 659 6942642 0.3 CD I-NP O
34 659 660 6942642 , , I-NP O
35 661 664 6942642 3.4 CD I-NP O
36 665 666 6942642 + SYM B-NP O
37 666 667 6942642 / SYM I-NP O
38 667 668 6942642 - SYM I-NP O
39 669 672 6942642 0.2 CD I-NP O
40 672 673 6942642 , , I-NP O
41 674 677 6942642 2.9 CD I-NP O
42 678 679 6942642 + SYM O O
43 679 680 6942642 / SYM O O
44 680 681 6942642 - SYM O O
45 682 685 6942642 0.2 CD B-NP O
46 685 686 6942642 , , O O
47 687 690 6942642 and CC O O
48 691 694 6942642 2.4 CD B-NP O
49 695 696 6942642 + SYM O O
50 696 697 6942642 / SYM O O
51 697 698 6942642 - SYM O O
52 699 702 6942642 0.3 CD B-NP O
53 703 706 6942642 mEq NN I-NP O
54 706 707 6942642 / SYM O O
55 707 708 6942642 l NN B-NP O
56 708 709 6942642 , , O O
57 710 722 6942642 respectively RB B-ADVP O
58 722 723 6942642 . . O O

1 724 737 6942642 Corresponding VBG B-VP O
2 738 745 6942642 figures NNS B-NP O
3 746 749 6942642 for IN B-PP O
4 750 755 6942642 whole JJ B-NP O
5 756 760 6942642 body NN I-NP O
6 761 762 6942642 K NN I-NP D011188
7 763 767 6942642 were VBD B-VP O
8 768 772 6942642 4107 CD B-NP O
9 773 774 6942642 + SYM B-NP O
10 774 775 6942642 / SYM I-NP O
11 775 776 6942642 - SYM I-NP O
12 777 780 6942642 208 CD I-NP O
13 780 781 6942642 , , I-NP O
14 782 786 6942642 3722 CD I-NP O
15 787 788 6942642 + SYM B-NP O
16 788 789 6942642 / SYM I-NP O
17 789 790 6942642 - SYM I-NP O
18 791 794 6942642 319 CD I-NP O
19 794 795 6942642 , , I-NP O
20 796 800 6942642 3628 CD I-NP O
21 801 802 6942642 + SYM B-NP O
22 802 803 6942642 / SYM I-NP O
23 803 804 6942642 - SYM I-NP O
24 805 808 6942642 257 CD I-NP O
25 808 809 6942642 , , I-NP O
26 810 814 6942642 3551 CD I-NP O
27 815 816 6942642 + SYM O O
28 816 817 6942642 / SYM O O
29 817 818 6942642 - SYM O O
30 819 822 6942642 336 CD B-NP O
31 822 823 6942642 , , O O
32 824 827 6942642 and CC O O
33 828 832 6942642 3269 CD B-NP O
34 833 834 6942642 + SYM O O
35 834 835 6942642 / SYM O O
36 835 836 6942642 - SYM O O
37 837 840 6942642 380 CD B-NP O
38 841 844 6942642 mEq NN I-NP O
39 844 845 6942642 , , O O
40 846 858 6942642 respectively RB B-ADVP O
41 858 859 6942642 . . O O

1 860 862 6942642 In IN B-PP O
2 863 865 6942642 13 CD B-NP O
3 866 874 6942642 patients NNS I-NP O
4 875 877 6942642 we PRP B-NP O
5 878 886 6942642 observed VBD B-VP O
6 887 890 6942642 the DT B-NP O
7 891 898 6942642 effects NNS I-NP O
8 899 901 6942642 of IN B-PP O
9 902 906 6942642 HCTZ NN B-NP D006852
10 907 914 6942642 therapy NN I-NP O
11 915 916 6942642 ( ( O O
12 916 919 6942642 100 CD B-NP O
13 920 922 6942642 mg NN I-NP O
14 923 928 6942642 daily RB B-ADVP O
15 928 929 6942642 ) ) O O
16 930 932 6942642 on IN B-PP O
17 933 936 6942642 the DT B-NP O
18 937 947 6942642 occurrence NN I-NP O
19 948 950 6942642 of IN B-PP O
20 951 956 6942642 PVC's NNS B-NP O
21 957 963 6942642 during IN B-PP O
22 964 968 6942642 rest NN B-NP O
23 969 971 6942642 as RB B-CONJP O
24 972 976 6942642 well RB I-CONJP O
25 977 979 6942642 as IN I-CONJP O
26 980 986 6942642 during IN B-PP O
27 987 993 6942642 static JJ B-NP O
28 994 997 6942642 and CC I-NP O
29 998 1005 6942642 dynamic JJ I-NP O
30 1006 1014 6942642 exercise NN I-NP O
31 1014 1015 6942642 . . O O

1 1016 1022 6942642 During IN B-PP O
2 1023 1027 6942642 rest NN B-NP O
3 1028 1030 6942642 we PRP B-NP O
4 1031 1039 6942642 observed VBD B-VP O
5 1040 1043 6942642 0.6 CD B-NP O
6 1044 1045 6942642 + SYM O O
7 1045 1046 6942642 / SYM O O
8 1046 1047 6942642 - SYM O O
9 1048 1052 6942642 0.08 CD B-NP O
10 1053 1056 6942642 PVC NN I-NP O
11 1057 1062 6942642 beats NNS I-NP O
12 1062 1063 6942642 / SYM B-NP O
13 1063 1066 6942642 min NN I-NP O
14 1067 1068 6942642 + SYM O O
15 1068 1069 6942642 / SYM O O
16 1069 1070 6942642 - HYPH O O
17 1071 1074 6942642 SEM NN B-NP O
18 1075 1078 6942642 and CC B-PP O
19 1079 1085 6942642 during IN B-PP O
20 1086 1092 6942642 static JJ B-NP O
21 1093 1096 6942642 and CC I-NP O
22 1097 1104 6942642 dynamic JJ I-NP O
23 1105 1113 6942642 exercise NN I-NP O
24 1114 1117 6942642 0.6 CD I-NP O
25 1118 1119 6942642 + SYM O O
26 1119 1120 6942642 / SYM O O
27 1120 1121 6942642 - SYM B-NP O
28 1122 1126 6942642 0.06 CD B-NP O
29 1127 1130 6942642 and CC I-NP O
30 1131 1134 6942642 0.8 CD I-NP O
31 1135 1136 6942642 + SYM B-NP O
32 1136 1137 6942642 / SYM B-NP O
33 1137 1138 6942642 - SYM B-VP O
34 1139 1143 6942642 0.15 CD B-NP O
35 1143 1144 6942642 , , O O
36 1145 1157 6942642 respectively RB B-ADVP O
37 1157 1158 6942642 . . O O

1 1159 1172 6942642 Corresponding VBG B-VP O
2 1173 1180 6942642 figures NNS B-NP O
3 1181 1187 6942642 during IN B-PP O
4 1188 1192 6942642 HCTZ NN B-NP D006852
5 1193 1200 6942642 therapy NN I-NP O
6 1201 1204 6942642 100 CD I-NP O
7 1205 1207 6942642 mg NN I-NP O
8 1208 1213 6942642 daily RB B-ADVP O
9 1214 1218 6942642 were VBD B-VP O
10 1219 1222 6942642 1.4 CD B-NP O
11 1223 1224 6942642 + SYM B-NP O
12 1224 1225 6942642 / SYM I-NP O
13 1225 1226 6942642 - SYM I-NP O
14 1227 1230 6942642 0.1 CD I-NP O
15 1230 1231 6942642 , , I-NP O
16 1232 1235 6942642 3.6 CD I-NP O
17 1236 1237 6942642 + SYM O O
18 1237 1238 6942642 / SYM O O
19 1238 1239 6942642 - SYM B-NP O
20 1240 1243 6942642 0.7 CD B-NP O
21 1244 1247 6942642 and CC I-NP O
22 1248 1251 6942642 5.7 CD I-NP O
23 1252 1253 6942642 4 CD I-NP O
24 1253 1254 6942642 / SYM B-NP O
25 1254 1255 6942642 - SYM B-VP O
26 1256 1259 6942642 0.8 CD B-NP O
27 1259 1260 6942642 , , O O
28 1261 1273 6942642 respectively RB B-ADVP O
29 1273 1274 6942642 . . O O

1 1275 1278 6942642 The DT B-NP O
2 1279 1289 6942642 occurrence NN I-NP O
3 1290 1292 6942642 of IN B-PP O
4 1293 1298 6942642 PVC's NNS B-NP O
5 1299 1309 6942642 correlated VBD B-VP O
6 1310 1323 6942642 significantly RB B-ADVP O
7 1324 1328 6942642 with IN B-PP O
8 1329 1332 6942642 the DT B-NP O
9 1333 1337 6942642 fall NN I-NP O
10 1338 1340 6942642 in IN B-PP O
11 1341 1346 6942642 serum NN B-NP O
12 1347 1349 6942642 K+ NN I-NP D011188
13 1350 1358 6942642 observed VBN B-VP O
14 1359 1360 6942642 r NN B-NP O
15 1361 1362 6942642 = SYM B-VP O
16 1363 1367 6942642 0.72 CD B-NP O
17 1367 1368 6942642 , , O O
18 1369 1370 6942642 p NN B-NP O
19 1371 1375 6942642 less JJR B-ADJP O
20 1376 1380 6942642 than IN B-PP O
21 1381 1386 6942642 0.001 CD B-NP O
22 1386 1387 6942642 . . O O

1 1388 1390 6942642 In IN B-PP O
2 1391 1401 6942642 conclusion NN B-NP O
3 1402 1404 6942642 we PRP B-NP O
4 1405 1410 6942642 found VBD B-VP O
5 1411 1415 6942642 that IN B-SBAR O
6 1416 1424 6942642 thiazide NN B-NP D049971
7 1425 1434 6942642 diuretics NNS I-NP O
8 1435 1440 6942642 cause VBP B-VP O
9 1441 1452 6942642 hypokalemia NN B-NP D007008
10 1453 1456 6942642 and CC I-NP O
11 1457 1466 6942642 depletion NN I-NP O
12 1467 1469 6942642 of IN B-PP O
13 1470 1474 6942642 body NN B-NP O
14 1475 1484 6942642 potassium NN I-NP D011188
15 1484 1485 6942642 . . O O

1 1486 1489 6942642 The DT B-NP O
2 1490 1494 6942642 more RBR I-NP O
3 1495 1503 6942642 profound JJ I-NP O
4 1504 1515 6942642 hypokalemia NN I-NP D007008
5 1515 1516 6942642 , , O O
6 1517 1520 6942642 the DT O O
7 1521 1528 6942642 greater JJR O O
8 1529 1532 6942642 the DT B-NP O
9 1533 1543 6942642 propensity NN I-NP O
10 1544 1547 6942642 for IN B-PP O
11 1548 1551 6942642 the DT B-NP O
12 1552 1562 6942642 occurrence NN I-NP O
13 1563 1565 6942642 of IN B-PP O
14 1566 1571 6942642 PVC's NNS B-NP O
15 1571 1572 6942642 . . O O

1 0 0 11185967 -DOCSTART- -X- -X- O

1 0 9 11185967 Screening NN B-NP O
2 10 13 11185967 for IN B-PP O
3 14 23 11185967 stimulant JJ B-NP O
4 24 27 11185967 use NN I-NP O
5 28 30 11185967 in IN B-PP O
6 31 36 11185967 adult JJ B-NP O
7 37 46 11185967 emergency NN I-NP O
8 47 57 11185967 department NN I-NP O
9 58 65 11185967 seizure NN I-NP D012640
10 66 74 11185967 patients NNS I-NP O
11 74 75 11185967 . . I-NP O
12 76 85 11185967 OBJECTIVE NN I-NP O
13 85 86 11185967 : : O O
14 87 90 11185967 The DT B-NP O
15 91 100 11185967 objective NN I-NP O
16 101 103 11185967 of IN B-PP O
17 104 108 11185967 this DT B-NP O
18 109 114 11185967 study NN I-NP O
19 115 118 11185967 was VBD B-VP O
20 119 121 11185967 to TO B-VP O
21 122 131 11185967 determine VB I-VP O
22 132 135 11185967 the DT B-NP O
23 136 146 11185967 prevalence NN I-NP O
24 147 149 11185967 of IN B-PP O
25 150 158 11185967 positive JJ B-NP O
26 159 165 11185967 plasma NN I-NP O
27 166 170 11185967 drug NN I-NP O
28 171 180 11185967 screening NN I-NP O
29 181 184 11185967 for IN B-PP O
30 185 192 11185967 cocaine NN B-NP D003042
31 193 195 11185967 or CC I-NP O
32 196 207 11185967 amphetamine NN I-NP D000661
33 208 210 11185967 in IN B-PP O
34 211 216 11185967 adult JJ B-NP O
35 217 226 11185967 emergency NN I-NP O
36 227 237 11185967 department NN I-NP O
37 238 245 11185967 seizure NN I-NP D012640
38 246 254 11185967 patients NNS I-NP O
39 254 255 11185967 . . O O

1 256 263 11185967 METHODS NNS B-NP O
2 263 264 11185967 : : O O
3 265 269 11185967 This DT B-NP O
4 270 281 11185967 prospective JJ I-NP O
5 282 287 11185967 study NN I-NP O
6 288 297 11185967 evaluated VBD B-VP O
7 298 309 11185967 consecutive JJ B-NP O
8 310 318 11185967 eligible JJ I-NP O
9 319 326 11185967 seizure NN I-NP D012640
10 327 335 11185967 patients NNS I-NP O
11 336 339 11185967 who WP B-NP O
12 340 343 11185967 had VBD B-VP O
13 344 345 11185967 a DT B-NP O
14 346 352 11185967 plasma NN I-NP O
15 353 359 11185967 sample NN I-NP O
16 360 369 11185967 collected VBN B-VP O
17 370 372 11185967 as IN B-PP O
18 373 377 11185967 part NN B-NP O
19 378 380 11185967 of IN B-PP O
20 381 386 11185967 their PRP$ B-NP O
21 387 395 11185967 clinical JJ I-NP O
22 396 406 11185967 evaluation NN I-NP O
23 406 407 11185967 . . O O

1 408 414 11185967 Plasma NN B-NP O
2 415 418 11185967 was VBD B-VP O
3 419 425 11185967 tested VBN I-VP O
4 426 429 11185967 for IN B-PP O
5 430 441 11185967 amphetamine NN B-NP D000661
6 442 445 11185967 and CC O O
7 446 449 11185967 the DT B-NP O
8 450 457 11185967 cocaine NN I-NP D003042
9 458 468 11185967 metabolite NN I-NP O
10 469 484 11185967 benzoylecgonine NN I-NP C005618
11 485 490 11185967 using VBG B-VP O
12 491 497 11185967 enzyme NN B-NP O
13 497 498 11185967 - HYPH O O
14 498 506 11185967 mediated VBN B-NP O
15 507 518 11185967 immunoassay NN I-NP O
16 519 530 11185967 methodology NN I-NP O
17 530 531 11185967 . . O O

1 532 538 11185967 Plasma NN B-NP O
2 539 546 11185967 samples NNS I-NP O
3 547 551 11185967 with IN B-PP O
4 552 567 11185967 benzoylecgonine NN B-NP C005618
5 568 575 11185967 greater JJR B-ADJP O
6 576 580 11185967 than IN B-PP O
7 581 584 11185967 150 CD B-NP O
8 585 587 11185967 ng NN I-NP O
9 587 588 11185967 / SYM B-NP O
10 588 590 11185967 mL NN B-NP O
11 591 593 11185967 or CC O O
12 594 596 11185967 an DT B-NP O
13 597 608 11185967 amphetamine NN I-NP D000661
14 609 616 11185967 greater JJR B-ADJP O
15 617 621 11185967 than IN B-PP O
16 622 625 11185967 500 CD B-NP O
17 626 628 11185967 ng NN I-NP O
18 628 629 11185967 / SYM B-NP O
19 629 631 11185967 mL NN I-NP O
20 632 636 11185967 were VBD B-VP O
21 637 644 11185967 defined VBN I-VP O
22 645 647 11185967 as IN B-PP O
23 648 656 11185967 positive JJ B-ADJP O
24 656 657 11185967 . . O O

1 658 665 11185967 Patient NN B-NP O
2 666 678 11185967 demographics NNS I-NP O
3 678 679 11185967 , , O O
4 680 687 11185967 history NN B-NP O
5 688 690 11185967 of IN B-PP O
6 691 701 11185967 underlying VBG B-VP O
7 702 706 11185967 drug NN B-NP O
8 707 709 11185967 or CC I-NP O
9 710 717 11185967 alcohol NN I-NP D000431
10 717 718 11185967 - HYPH O O
11 718 725 11185967 related VBN B-NP O
12 726 733 11185967 seizure NN I-NP D012640
13 734 742 11185967 disorder NN I-NP O
14 742 743 11185967 , , O O
15 744 753 11185967 estimated VBN B-VP O
16 754 758 11185967 time NN B-NP O
17 759 763 11185967 from IN B-PP O
18 764 771 11185967 seizure NN B-NP D012640
19 772 774 11185967 to TO B-PP O
20 775 781 11185967 sample NN B-NP O
21 782 792 11185967 collection NN I-NP O
22 792 793 11185967 , , O O
23 794 801 11185967 history NN B-NP O
24 802 804 11185967 or CC I-NP O
25 805 814 11185967 suspicion NN I-NP O
26 815 817 11185967 of IN B-PP O
27 818 825 11185967 cocaine NN B-NP D019970
28 826 828 11185967 or CC I-NP D019970
29 829 840 11185967 amphetamine NN I-NP D019970
30 841 846 11185967 abuse NN I-NP D019970
31 846 847 11185967 , , O O
32 848 855 11185967 results NNS B-NP O
33 856 858 11185967 of IN B-PP O
34 859 867 11185967 clinical JJ B-NP O
35 868 873 11185967 urine NN I-NP O
36 874 881 11185967 testing NN I-NP O
37 882 885 11185967 for IN B-PP O
38 886 891 11185967 drugs NNS B-NP O
39 892 894 11185967 of IN B-PP O
40 895 900 11185967 abuse NN B-NP O
41 900 901 11185967 , , O O
42 902 905 11185967 and CC O O
43 906 911 11185967 assay NN B-NP O
44 912 919 11185967 results NNS I-NP O
45 920 924 11185967 were VBD B-VP O
46 925 933 11185967 recorded VBN I-VP O
47 934 941 11185967 without IN B-PP O
48 942 949 11185967 patient NN B-NP O
49 950 961 11185967 identifiers NNS I-NP O
50 961 962 11185967 . . O O

1 963 970 11185967 RESULTS NNS B-NP O
2 970 971 11185967 : : O O
3 972 980 11185967 Fourteen CD B-NP O
4 981 983 11185967 of IN B-PP O
5 984 987 11185967 248 CD B-NP O
6 988 989 11185967 ( ( O O
7 989 993 11185967 5.6% CD B-NP O
8 993 994 11185967 , , O O
9 995 998 11185967 95% CD B-NP O
10 999 1001 11185967 CI NNP I-NP O
11 1002 1006 11185967 2.7% CD I-NP O
12 1006 1007 11185967 - HYPH I-NP O
13 1007 1011 11185967 8.5% NN I-NP O
14 1011 1012 11185967 ) ) O O
15 1013 1019 11185967 plasma NN B-NP O
16 1020 1027 11185967 samples NNS I-NP O
17 1028 1032 11185967 were VBD B-VP O
18 1033 1041 11185967 positive JJ B-ADJP O
19 1042 1044 11185967 by IN B-PP O
20 1045 1056 11185967 immunoassay NN B-NP O
21 1057 1064 11185967 testing NN I-NP O
22 1065 1068 11185967 for IN B-PP O
23 1069 1084 11185967 benzoylecgonine NN B-NP C005618
24 1085 1088 11185967 and CC O O
25 1089 1091 11185967 no DT B-NP O
26 1092 1099 11185967 samples NNS I-NP O
27 1100 1101 11185967 ( ( O O
28 1101 1103 11185967 0% CD B-NP O
29 1103 1104 11185967 , , O O
30 1105 1108 11185967 95% CD B-NP O
31 1109 1111 11185967 CI NNP I-NP O
32 1112 1113 11185967 0 CD I-NP O
33 1113 1114 11185967 - HYPH I-NP O
34 1114 1118 11185967 1.2% CD I-NP O
35 1118 1119 11185967 ) ) O O
36 1120 1124 11185967 were VBD B-VP O
37 1125 1133 11185967 positive JJ B-ADJP O
38 1134 1137 11185967 for IN B-PP O
39 1138 1149 11185967 amphetamine NN B-NP D000661
40 1149 1150 11185967 . . O O

1 1151 1159 11185967 Positive JJ B-NP O
2 1160 1164 11185967 test NN I-NP O
3 1165 1172 11185967 results NNS I-NP O
4 1173 1177 11185967 were VBD B-VP O
5 1178 1182 11185967 more RBR B-ADJP O
6 1183 1189 11185967 common JJ I-ADJP O
7 1190 1192 11185967 in IN B-PP O
8 1193 1200 11185967 patient NN B-NP O
9 1201 1207 11185967 visits NNS I-NP O
10 1208 1213 11185967 where WRB B-ADVP O
11 1214 1219 11185967 there EX B-NP O
12 1220 1223 11185967 was VBD B-VP O
13 1224 1225 11185967 a DT B-NP O
14 1226 1233 11185967 history NN I-NP O
15 1234 1236 11185967 or CC I-NP O
16 1237 1246 11185967 suspicion NN I-NP O
17 1247 1249 11185967 of IN B-PP O
18 1250 1257 11185967 cocaine NN B-NP D019970
19 1258 1260 11185967 or CC O D019970
20 1261 1272 11185967 amphetamine NN B-NP D019970
21 1273 1278 11185967 abuse NN I-NP D019970
22 1279 1280 11185967 ( ( O O
23 1280 1281 11185967 p NN B-NP O
24 1282 1283 11185967 < JJR B-NP O
25 1284 1290 11185967 0.0005 CD I-NP O
26 1290 1291 11185967 ) ) O O
27 1291 1292 11185967 . . O O

1 1293 1304 11185967 CONCLUSIONS NNS B-NP O
2 1304 1305 11185967 : : O O
3 1306 1312 11185967 During IN B-PP O
4 1313 1317 11185967 this DT B-NP O
5 1318 1323 11185967 study NN I-NP O
6 1324 1330 11185967 period NN I-NP O
7 1330 1331 11185967 , , O O
8 1332 1339 11185967 routine JJ B-NP O
9 1340 1346 11185967 plasma NN I-NP O
10 1347 1356 11185967 screening NN I-NP O
11 1357 1360 11185967 for IN B-PP O
12 1361 1368 11185967 cocaine NN B-NP D003042
13 1369 1372 11185967 and CC I-NP O
14 1373 1385 11185967 amphetamines NNS I-NP D000662
15 1386 1388 11185967 in IN B-PP O
16 1389 1394 11185967 adult JJ B-NP O
17 1395 1402 11185967 seizure NN I-NP D012640
18 1403 1411 11185967 patients NNS I-NP O
19 1412 1415 11185967 had VBD B-VP O
20 1416 1417 11185967 a DT B-NP O
21 1418 1421 11185967 low JJ I-NP O
22 1422 1427 11185967 yield NN I-NP O
23 1427 1428 11185967 . . O O

1 1429 1431 11185967 As IN B-PP O
2 1432 1433 11185967 a DT B-NP O
3 1434 1440 11185967 result NN I-NP O
4 1440 1441 11185967 , , O O
5 1442 1449 11185967 routine JJ B-NP O
6 1450 1456 11185967 plasma NN I-NP O
7 1457 1466 11185967 screening NN I-NP O
8 1467 1472 11185967 would MD B-VP O
9 1473 1478 11185967 yield VB I-VP O
10 1479 1482 11185967 few JJ B-NP O
11 1483 1488 11185967 cases NNS I-NP O
12 1489 1491 11185967 of IN B-PP O
13 1492 1501 11185967 stimulant JJ B-NP O
14 1502 1506 11185967 drug NN I-NP O
15 1507 1509 11185967 in IN B-PP O
16 1510 1515 11185967 which WDT B-NP O
17 1516 1521 11185967 there EX B-NP O
18 1522 1525 11185967 was VBD B-VP O
19 1526 1533 11185967 neither CC O O
20 1534 1535 11185967 a DT B-NP O
21 1536 1543 11185967 history NN I-NP O
22 1544 1547 11185967 nor CC I-NP O
23 1548 1557 11185967 suspicion NN I-NP O
24 1558 1560 11185967 of IN B-PP O
25 1561 1565 11185967 drug NN B-NP D019966
26 1566 1571 11185967 abuse NN I-NP D019966
27 1572 1574 11185967 in IN B-PP O
28 1575 1579 11185967 this DT B-NP O
29 1580 1590 11185967 population NN I-NP O
30 1590 1591 11185967 . . O O

1 0 0 6127992 -DOCSTART- -X- -X- O

1 0 7 6127992 Adverse JJ B-NP O
2 8 19 6127992 interaction NN I-NP O
3 20 27 6127992 between IN B-PP O
4 28 32 6127992 beta SYM B-NP D000319
5 32 33 6127992 - HYPH B-PP D000319
6 33 43 6127992 adrenergic JJ B-NP D000319
7 44 52 6127992 blocking VBG I-NP D000319
8 53 58 6127992 drugs NNS I-NP D000319
9 59 62 6127992 and CC I-NP O
10 63 72 6127992 verapamil NN I-NP D014700
11 72 73 6127992 - HYPH O O
12 73 74 6127992 - HYPH O O
13 74 80 6127992 report NN B-NP O
14 81 83 6127992 of IN B-PP O
15 84 89 6127992 three CD B-NP O
16 90 95 6127992 cases NNS I-NP O
17 95 96 6127992 . . O O
18 97 102 6127992 Three CD B-NP O
19 103 111 6127992 patients NNS I-NP O
20 112 116 6127992 with IN B-PP O
21 117 126 6127992 ischaemic JJ B-NP D017202
22 127 132 6127992 heart NN I-NP D017202
23 133 140 6127992 disease NN I-NP D017202
24 141 150 6127992 developed VBD B-VP O
25 151 159 6127992 profound JJ B-NP O
26 160 167 6127992 cardiac JJ I-NP D006333
27 168 175 6127992 failure NN I-NP D006333
28 175 176 6127992 , , O O
29 177 188 6127992 hypotension NN B-NP D007022
30 189 192 6127992 and CC I-NP O
31 193 204 6127992 bradycardia NN I-NP D001919
32 205 211 6127992 during IN B-PP O
33 212 220 6127992 combined VBN B-NP O
34 221 228 6127992 therapy NN I-NP O
35 229 233 6127992 with IN B-PP O
36 234 243 6127992 verapamil NN B-NP D014700
37 244 247 6127992 and CC O O
38 248 252 6127992 beta SYM B-NP D000319
39 252 253 6127992 - HYPH O D000319
40 253 263 6127992 adrenergic JJ B-NP D000319
41 264 272 6127992 blocking VBG I-NP D000319
42 273 278 6127992 drugs NNS I-NP D000319
43 278 279 6127992 . . O O

1 280 284 6127992 This DT B-NP O
2 285 293 6127992 clinical JJ I-NP O
3 294 301 6127992 picture NN I-NP O
4 302 310 6127992 resolved VBN B-VP O
5 311 321 6127992 completely RB B-ADVP O
6 322 326 6127992 with IN B-PP O
7 327 336 6127992 cessation NN B-NP O
8 337 339 6127992 of IN B-PP O
9 340 343 6127992 the DT B-NP O
10 344 352 6127992 combined JJ I-NP O
11 353 360 6127992 therapy NN I-NP O
12 360 361 6127992 . . O O

1 362 370 6127992 Baseline NNP B-NP O
2 371 375 6127992 left VBD B-VP O
3 376 387 6127992 ventricular JJ B-NP O
4 388 396 6127992 function NN I-NP O
5 396 397 6127992 , , O O
6 398 406 6127992 assessed VBN B-VP O
7 407 409 6127992 by IN B-PP O
8 410 417 6127992 cardiac JJ B-NP O
9 418 433 6127992 catheterisation NN I-NP O
10 434 436 6127992 or CC O O
11 437 444 6127992 nuclear JJ B-NP O
12 445 456 6127992 angiography NN I-NP O
13 456 457 6127992 , , O O
14 458 461 6127992 was VBD B-VP O
15 462 468 6127992 normal JJ B-ADJP O
16 469 471 6127992 in IN B-PP O
17 472 475 6127992 two CD B-NP O
18 476 484 6127992 patients NNS I-NP O
19 485 488 6127992 and CC O O
20 489 493 6127992 only RB B-VP O
21 494 500 6127992 mildly RB I-VP O
22 501 508 6127992 reduced VBN I-VP O
23 509 511 6127992 in IN B-PP O
24 512 515 6127992 the DT B-NP O
25 516 521 6127992 other JJ I-NP O
26 521 522 6127992 . . O O

1 523 537 6127992 Simultaneously RB B-NP O
2 538 552 6127992 administration NN I-NP O
3 553 555 6127992 of IN B-PP O
4 556 560 6127992 beta SYM B-NP D000319
5 560 561 6127992 - HYPH O D000319
6 561 571 6127992 adrenergic JJ B-NP D000319
7 572 580 6127992 blocking VBG I-NP D000319
8 581 586 6127992 drugs NNS I-NP D000319
9 587 590 6127992 and CC I-NP O
10 591 600 6127992 verapamil NN I-NP D014700
11 601 604 6127992 may MD B-VP O
12 605 611 6127992 result VB I-VP O
13 612 614 6127992 in IN B-PP O
14 615 623 6127992 profound JJ B-NP O
15 624 631 6127992 adverse JJ I-NP O
16 632 644 6127992 interactions NNS I-NP O
17 645 648 6127992 and CC O O
18 649 655 6127992 should MD B-VP O
19 656 660 6127992 only RB I-VP O
20 661 663 6127992 be VB I-VP O
21 664 676 6127992 administered VBN I-VP O
22 677 681 6127992 with IN B-PP O
23 682 687 6127992 great JJ B-NP O
24 688 695 6127992 caution NN I-NP O
25 695 696 6127992 . . O O

1 0 0 18177388 -DOCSTART- -X- -X- O

1 0 7 18177388 Reverse JJ B-ADJP O
2 8 10 18177388 or CC O O
3 11 19 18177388 inverted VBN B-VP O
4 20 24 18177388 left VBD B-VP D054549
5 25 36 18177388 ventricular JJ B-NP D054549
6 37 43 18177388 apical JJ I-NP D054549
7 44 54 18177388 ballooning NN I-NP D054549
8 55 63 18177388 syndrome NN I-NP D054549
9 64 65 18177388 ( ( O O
10 65 72 18177388 reverse JJ B-NP O
11 73 82 18177388 Takotsubo NNP I-NP D054549
12 83 97 18177388 cardiomyopathy NN I-NP D054549
13 97 98 18177388 ) ) O O
14 99 101 18177388 in IN B-PP O
15 102 103 18177388 a DT B-NP O
16 104 109 18177388 young JJ I-NP O
17 110 115 18177388 woman NN I-NP O
18 116 118 18177388 in IN B-PP O
19 119 122 18177388 the DT B-NP O
20 123 130 18177388 setting NN I-NP O
21 131 133 18177388 of IN B-PP O
22 134 145 18177388 amphetamine NN B-NP D000661
23 146 149 18177388 use NN I-NP O
24 149 150 18177388 . . O O
25 151 160 18177388 Transient JJ O O
26 161 165 18177388 left VBD B-VP D054549
27 166 177 18177388 ventricular JJ B-NP D054549
28 178 184 18177388 apical JJ I-NP D054549
29 185 195 18177388 ballooning NN I-NP D054549
30 196 204 18177388 syndrome NN I-NP D054549
31 205 208 18177388 was VBD B-VP O
32 209 214 18177388 first RB I-VP O
33 215 224 18177388 described VBN I-VP O
34 225 227 18177388 in IN B-PP O
35 228 233 18177388 Japan NNP B-NP O
36 234 236 18177388 as IN B-SBAR O
37 237 238 18177388 " `` O O
38 238 247 18177388 Takotsubo NN B-NP D054549
39 248 262 18177388 cardiomyopathy NN I-NP D054549
40 262 263 18177388 . . O O
41 263 264 18177388 " '' O O
42 265 269 18177388 This DT B-NP O
43 270 278 18177388 syndrome NN I-NP O
44 279 282 18177388 has VBZ B-VP O
45 283 287 18177388 been VBN I-VP O
46 288 298 18177388 identified VBN I-VP O
47 299 301 18177388 in IN B-PP O
48 302 306 18177388 many JJ B-NP O
49 307 312 18177388 other JJ I-NP O
50 313 322 18177388 countries NNS I-NP O
51 322 323 18177388 . . O O

1 324 328 18177388 Many JJ B-NP O
2 329 339 18177388 variations NNS I-NP O
3 340 342 18177388 of IN B-PP O
4 343 347 18177388 this DT B-NP O
5 348 356 18177388 syndrome NN I-NP O
6 357 361 18177388 have VBP B-VP O
7 362 366 18177388 been VBN I-VP O
8 367 375 18177388 recently RB I-VP O
9 376 385 18177388 described VBN I-VP O
10 386 388 18177388 in IN B-PP O
11 389 392 18177388 the DT B-NP O
12 393 403 18177388 literature NN I-NP O
13 403 404 18177388 . . O O

1 405 408 18177388 One CD B-NP O
2 409 411 18177388 of IN B-PP O
3 412 415 18177388 the DT B-NP O
4 416 422 18177388 rarest NN I-NP O
5 423 425 18177388 is VBZ B-VP O
6 426 429 18177388 the DT B-NP O
7 430 437 18177388 reverse JJ I-NP O
8 438 442 18177388 type NN I-NP O
9 443 445 18177388 of IN B-PP O
10 446 450 18177388 this DT B-NP O
11 451 459 18177388 syndrome NN I-NP O
12 459 460 18177388 , , O O
13 461 465 18177388 with IN B-PP O
14 466 478 18177388 hyperdynamic JJ B-NP O
15 479 483 18177388 apex NN I-NP O
16 484 487 18177388 and CC O O
17 488 496 18177388 complete JJ B-NP O
18 497 505 18177388 akinesia NN I-NP D004409
19 506 508 18177388 of IN B-PP O
20 509 512 18177388 the DT B-NP O
21 513 517 18177388 base NN I-NP O
22 518 519 18177388 ( ( O O
23 519 521 18177388 as IN B-SBAR O
24 522 529 18177388 opposed VBN B-VP O
25 530 532 18177388 to TO B-PP O
26 533 536 18177388 the DT B-NP O
27 537 544 18177388 classic JJ I-NP O
28 545 551 18177388 apical JJ I-NP D054549
29 552 562 18177388 ballooning NN I-NP D054549
30 562 563 18177388 ) ) O O
31 563 564 18177388 . . O O

1 565 567 18177388 In IN B-PP O
2 568 572 18177388 this DT B-NP O
3 573 580 18177388 article NN I-NP O
4 580 581 18177388 , , O O
5 582 584 18177388 we PRP B-NP O
6 585 591 18177388 report VBP B-VP O
7 592 594 18177388 an DT B-NP O
8 595 606 18177388 interesting JJ I-NP O
9 607 611 18177388 case NN I-NP O
10 612 614 18177388 of IN B-PP O
11 615 616 18177388 a DT B-NP O
12 617 622 18177388 young JJ I-NP O
13 623 628 18177388 woman NN I-NP O
14 629 632 18177388 who WP B-NP O
15 633 642 18177388 presented VBD B-VP O
16 643 647 18177388 with IN B-PP O
17 648 652 18177388 this DT B-NP O
18 653 657 18177388 rare JJ I-NP O
19 658 662 18177388 type NN I-NP O
20 663 665 18177388 of IN B-PP O
21 666 673 18177388 reverse JJ B-NP O
22 674 680 18177388 apical JJ I-NP D054549
23 681 691 18177388 ballooning NN I-NP D054549
24 692 700 18177388 syndrome NN I-NP D054549
25 701 710 18177388 occurring VBG B-VP O
26 711 716 18177388 after IN B-PP O
27 717 728 18177388 amphetamine NN B-NP D000661
28 729 732 18177388 use NN I-NP O
29 732 733 18177388 . . O O

1 734 738 18177388 This DT B-NP O
2 739 745 18177388 report NN I-NP O
3 746 748 18177388 is VBZ B-VP O
4 749 757 18177388 followed VBN I-VP O
5 758 760 18177388 by IN B-PP O
6 761 767 18177388 review NN B-NP O
7 768 770 18177388 of IN B-PP O
8 771 774 18177388 the DT B-NP O
9 775 785 18177388 literature NN I-NP O
10 785 786 18177388 . . O O

1 0 0 6381653 -DOCSTART- -X- -X- O

1 0 8 6381653 Levodopa NN B-NP D007980
2 8 9 6381653 - HYPH B-NP O
3 9 16 6381653 induced VBN I-NP O
4 17 27 6381653 dyskinesia NN I-NP D004409
5 28 31 6381653 and CC I-NP O
6 32 43 6381653 thalamotomy NN I-NP O
7 43 44 6381653 . . I-NP O
8 45 53 6381653 Levodopa NN I-NP D007980
9 53 54 6381653 - HYPH B-NP O
10 54 61 6381653 induced VBN I-NP O
11 62 72 6381653 dyskinesia NN I-NP D004409
12 73 75 6381653 of IN B-PP O
13 76 79 6381653 the DT B-NP O
14 80 85 6381653 limbs NNS I-NP O
15 86 88 6381653 in IN B-PP O
16 89 97 6381653 thirteen CD B-NP O
17 98 103 6381653 cases NNS I-NP O
18 104 106 6381653 of IN B-PP O
19 107 119 6381653 Parkinsonism NNP B-NP D010302
20 119 120 6381653 , , O O
21 121 126 6381653 which WDT B-NP O
22 127 130 6381653 was VBD B-VP O
23 131 138 6381653 choreic JJ B-ADJP O
24 138 139 6381653 , , O O
25 140 149 6381653 ballistic JJ B-ADJP O
26 150 152 6381653 or CC I-ADJP O
27 153 161 6381653 dystonic JJ I-ADJP D020821
28 162 164 6381653 in IN B-PP O
29 165 169 6381653 type NN B-NP O
30 169 170 6381653 , , O O
31 171 174 6381653 was VBD B-VP O
32 175 185 6381653 alleviated VBN I-VP O
33 186 192 6381653 almost RB B-ADVP O
34 193 203 6381653 completely RB I-ADVP O
35 204 206 6381653 by IN B-PP O
36 207 218 6381653 stereotaxic JJ B-NP O
37 219 226 6381653 surgery NN I-NP O
38 227 232 6381653 using VBG B-VP O
39 233 234 6381653 a DT B-NP O
40 235 249 6381653 microelectrode NN I-NP O
41 250 259 6381653 technique NN I-NP O
42 260 263 6381653 for IN B-PP O
43 264 267 6381653 the DT B-NP O
44 268 277 6381653 ventralis NN I-NP O
45 278 284 6381653 oralis VBZ B-VP O
46 285 293 6381653 anterior JJ B-NP O
47 294 297 6381653 and CC I-NP O
48 298 307 6381653 posterior JJ I-NP O
49 308 314 6381653 nuclei NNS I-NP O
50 315 317 6381653 of IN B-PP O
51 318 321 6381653 the DT B-NP O
52 322 330 6381653 thalamus NN I-NP O
53 330 331 6381653 , , O O
54 332 335 6381653 but CC O O
55 336 340 6381653 much RB B-ADJP O
56 341 345 6381653 less JJR I-ADJP O
57 346 348 6381653 by IN B-PP O
58 349 352 6381653 the DT B-NP O
59 353 362 6381653 ventralis NN I-NP O
60 363 374 6381653 intermedius NN I-NP O
61 375 382 6381653 nucleus NN I-NP O
62 382 383 6381653 . . O O

1 384 391 6381653 Control NN B-NP O
2 392 394 6381653 of IN B-PP O
3 395 403 6381653 levodopa NN B-NP D007980
4 403 404 6381653 - HYPH B-NP O
5 404 411 6381653 induced VBN I-NP O
6 412 423 6381653 dyskinesias NNS I-NP D004409
7 424 426 6381653 by IN B-PP O
8 427 435 6381653 thalamic JJ B-NP D013786
9 436 443 6381653 lesions NNS I-NP D013786
10 444 446 6381653 in IN B-PP O
11 447 450 6381653 the DT B-NP O
12 451 457 6381653 course NN I-NP O
13 458 460 6381653 of IN B-PP O
14 461 468 6381653 routine JJ B-NP O
15 469 478 6381653 treatment NN I-NP O
16 479 481 6381653 of IN B-PP O
17 482 494 6381653 Parkinsonism NN B-NP D010302
18 495 497 6381653 is VBZ B-VP O
19 498 507 6381653 discussed VBN I-VP O
20 507 508 6381653 . . O O

1 0 0 2594614 -DOCSTART- -X- -X- O

1 0 10 2594614 Protective JJ B-NP O
2 11 17 2594614 effect NN I-NP O
3 18 20 2594614 of IN B-PP O
4 21 22 2594614 a DT B-NP O
5 23 31 2594614 specific JJ I-NP O
6 32 40 2594614 platelet NN I-NP O
7 40 41 2594614 - HYPH O O
8 41 51 2594614 activating VBG B-VP O
9 52 58 2594614 factor NN B-NP O
10 59 69 2594614 antagonist NN I-NP O
11 69 70 2594614 , , O O
12 71 73 2594614 BN NN B-NP C045856
13 74 79 2594614 52021 CD I-NP C045856
14 79 80 2594614 , , O O
15 81 83 2594614 on IN B-PP O
16 84 95 2594614 bupivacaine NN B-NP D002045
17 95 96 2594614 - HYPH O O
18 96 103 2594614 induced VBN B-NP O
19 104 118 2594614 cardiovascular JJ I-NP D002318
20 119 130 2594614 impairments NNS I-NP D002318
21 131 133 2594614 in IN B-PP O
22 134 138 2594614 rats NNS B-NP O
23 138 139 2594614 . . O O
24 140 154 2594614 Administration NN B-NP O
25 155 157 2594614 of IN B-PP O
26 158 161 2594614 the DT B-NP O
27 162 167 2594614 local JJ I-NP O
28 168 179 2594614 anaesthetic JJ I-NP O
29 180 191 2594614 bupivacaine NN I-NP D002045
30 192 193 2594614 ( ( O O
31 193 196 2594614 1.5 CD B-NP O
32 197 199 2594614 or CC I-NP O
33 200 201 2594614 2 CD I-NP O
34 202 204 2594614 mg NN I-NP O
35 204 205 2594614 / SYM B-NP O
36 205 207 2594614 kg NN I-NP O
37 207 208 2594614 , , O O
38 209 212 2594614 i.v JJ B-ADJP O
39 212 213 2594614 . . O O
40 213 214 2594614 ) ) O O
41 215 217 2594614 to TO B-PP O
42 218 222 2594614 rats NNS B-NP O
43 223 231 2594614 elicited VBD B-VP O
44 232 233 2594614 a DT B-NP O
45 234 240 2594614 marked JJ I-NP O
46 241 249 2594614 decrease NN I-NP D007022
47 250 252 2594614 of IN B-PP D007022
48 253 257 2594614 mean JJ B-NP D007022
49 258 266 2594614 arterial JJ I-NP D007022
50 267 272 2594614 blood NN I-NP D007022
51 273 281 2594614 pressure NN I-NP D007022
52 282 283 2594614 ( ( O D007022
53 283 286 2594614 MBP NN B-NP D007022
54 286 287 2594614 ) ) O D007022
55 288 291 2594614 and CC O D007022
56 292 297 2594614 heart NN B-NP D007022
57 298 302 2594614 rate NN I-NP D007022
58 303 304 2594614 ( ( O D007022
59 304 306 2594614 HR NN B-NP D007022
60 306 307 2594614 ) ) O D007022
61 308 315 2594614 leading VBG B-VP O
62 316 318 2594614 to TO B-PP O
63 319 324 2594614 death NN B-NP O
64 325 326 2594614 ( ( O O
65 326 328 2594614 in IN B-PP O
66 329 332 2594614 67% CD B-NP O
67 333 335 2594614 or CC I-NP O
68 336 339 2594614 90% CD I-NP O
69 340 342 2594614 of IN B-PP O
70 343 350 2594614 animals NNS B-NP O
71 351 363 2594614 respectively RB B-ADVP O
72 363 364 2594614 ) ) O O
73 364 365 2594614 . . O O

1 366 377 2594614 Intravenous JJ B-NP O
2 378 387 2594614 injection NN I-NP O
3 388 390 2594614 of IN B-PP O
4 391 394 2594614 the DT B-NP O
5 395 403 2594614 specific JJ I-NP O
6 404 412 2594614 platelet NN I-NP O
7 412 413 2594614 - HYPH O O
8 413 423 2594614 activating VBG B-VP O
9 424 430 2594614 factor NN B-NP O
10 431 432 2594614 ( ( O O
11 432 435 2594614 PAF NN B-NP O
12 435 436 2594614 ) ) O O
13 437 447 2594614 antagonist NN B-NP O
14 448 450 2594614 BN NN I-NP C045856
15 451 456 2594614 52021 CD I-NP C045856
16 457 458 2594614 ( ( O O
17 458 460 2594614 10 CD B-NP O
18 461 463 2594614 mg NN I-NP O
19 463 464 2594614 / SYM B-NP O
20 464 466 2594614 kg NN I-NP O
21 466 467 2594614 ) ) O O
22 467 468 2594614 , , O O
23 469 471 2594614 30 CD B-NP O
24 472 475 2594614 min NN I-NP O
25 476 482 2594614 before IN B-PP O
26 483 494 2594614 bupivacaine NN B-NP D002045
27 495 509 2594614 administration NN I-NP O
28 510 511 2594614 ( ( O O
29 511 512 2594614 2 CD B-NP O
30 513 515 2594614 mg NN I-NP O
31 515 516 2594614 / SYM B-NP O
32 516 518 2594614 kg NN I-NP O
33 519 522 2594614 i.v JJ B-ADJP O
34 522 523 2594614 . . O O
35 523 524 2594614 ) ) O O
36 525 535 2594614 suppressed VBD B-VP O
37 536 540 2594614 both CC O O
38 541 544 2594614 the DT B-NP O
39 545 553 2594614 decrease NN I-NP D007022
40 554 556 2594614 of IN B-PP D007022
41 557 560 2594614 MBP NN B-NP D007022
42 561 564 2594614 and CC I-NP D007022
43 565 567 2594614 HR NN I-NP D007022
44 567 568 2594614 . . O O

1 569 571 2594614 In IN B-PP O
2 572 580 2594614 contrast NN B-NP O
3 580 581 2594614 , , O O
4 582 587 2594614 doses NNS B-NP O
5 588 590 2594614 of IN B-PP O
6 591 592 2594614 1 CD B-NP O
7 593 595 2594614 mg NN I-NP O
8 595 596 2594614 / SYM O O
9 596 598 2594614 kg NN B-NP O
10 599 601 2594614 BN NN I-NP C045856
11 602 607 2594614 52021 CD I-NP C045856
12 608 613 2594614 given VBN B-VP O
13 614 616 2594614 30 CD B-NP O
14 617 620 2594614 min NN I-NP O
15 621 627 2594614 before IN B-PP O
16 628 630 2594614 or CC O O
17 631 633 2594614 10 CD B-NP O
18 634 636 2594614 mg NN I-NP O
19 636 637 2594614 / SYM B-NP O
20 637 639 2594614 kg NN I-NP O
21 640 652 2594614 administered VBN B-VP O
22 653 654 2594614 5 CD B-NP O
23 655 658 2594614 min NN I-NP O
24 659 665 2594614 before IN B-PP O
25 666 669 2594614 i.v NN B-NP O
26 669 670 2594614 . . O O

1 671 680 2594614 injection NN B-NP O
2 681 683 2594614 of IN B-PP O
3 684 695 2594614 bupivacaine NN B-NP D002045
4 696 700 2594614 were VBD B-VP O
5 701 712 2594614 ineffective JJ B-ADJP O
6 712 713 2594614 . . O O

1 714 718 2594614 When WRB B-ADVP O
2 719 721 2594614 BN NN B-NP C045856
3 722 727 2594614 52021 CD I-NP C045856
4 728 729 2594614 ( ( O O
5 729 731 2594614 20 CD B-NP O
6 732 734 2594614 mg NN I-NP O
7 734 735 2594614 / SYM B-NP O
8 735 737 2594614 kg NN I-NP O
9 738 741 2594614 i.v JJ B-ADJP O
10 741 742 2594614 . . O O
11 742 743 2594614 ) ) O O
12 744 747 2594614 was VBD B-VP O
13 748 756 2594614 injected VBN I-VP O
14 757 768 2594614 immediately RB B-ADVP O
15 769 774 2594614 after IN B-PP O
16 775 786 2594614 bupivacaine NN B-NP D002045
17 787 788 2594614 ( ( O O
18 788 789 2594614 2 CD B-NP O
19 790 792 2594614 mg NN I-NP O
20 792 793 2594614 / SYM B-NP O
21 793 795 2594614 kg NN I-NP O
22 795 796 2594614 ) ) O O
23 796 797 2594614 , , O O
24 798 799 2594614 a DT B-NP O
25 800 807 2594614 partial JJ I-NP O
26 808 817 2594614 reversion NN I-NP O
27 818 820 2594614 of IN B-PP O
28 821 824 2594614 the DT B-NP O
29 825 833 2594614 decrease NN I-NP D007022
30 834 836 2594614 of IN B-PP D007022
31 837 840 2594614 MBP NN B-NP D007022
32 841 844 2594614 and CC I-NP D007022
33 845 847 2594614 HR NN I-NP D007022
34 848 851 2594614 was VBD B-VP O
35 852 860 2594614 observed VBN I-VP O
36 860 861 2594614 , , O O
37 862 869 2594614 whereas IN O O
38 870 873 2594614 the DT B-NP O
39 874 878 2594614 dose NN I-NP O
40 879 881 2594614 of IN B-PP O
41 882 884 2594614 10 CD B-NP O
42 885 887 2594614 mg NN I-NP O
43 887 888 2594614 / SYM B-NP O
44 888 890 2594614 kg NN I-NP O
45 891 894 2594614 was VBD B-VP O
46 895 906 2594614 ineffective JJ B-ADJP O
47 906 907 2594614 . . O O

1 908 909 2594614 A DT B-NP O
2 910 917 2594614 partial JJ I-NP O
3 918 926 2594614 recovery NN I-NP O
4 927 929 2594614 of IN B-PP O
5 930 941 2594614 bupivacaine NN B-NP D002045
6 941 942 2594614 - HYPH B-NP O
7 942 949 2594614 induced VBN I-NP O
8 950 953 2594614 ECG NN I-NP O
9 954 965 2594614 alterations NNS I-NP O
10 966 969 2594614 was VBD B-VP O
11 970 978 2594614 observed VBN I-VP O
12 979 984 2594614 after IN B-PP O
13 985 997 2594614 pretreatment NN B-NP O
14 998 1000 2594614 of IN B-PP O
15 1001 1004 2594614 the DT B-NP O
16 1005 1009 2594614 rats NNS I-NP O
17 1010 1014 2594614 with IN B-PP O
18 1015 1017 2594614 BN NN B-NP C045856
19 1018 1023 2594614 52021 CD I-NP C045856
20 1023 1024 2594614 . . O O

1 1025 1030 2594614 Since IN B-SBAR O
2 1031 1034 2594614 the DT B-NP O
3 1035 1049 2594614 administration NN I-NP O
4 1050 1052 2594614 of IN B-PP O
5 1053 1055 2594614 BN NN B-NP C045856
6 1056 1061 2594614 52021 CD I-NP C045856
7 1061 1062 2594614 , , O O
8 1063 1065 2594614 at IN B-PP O
9 1066 1069 2594614 all DT B-NP O
10 1070 1075 2594614 doses NNS I-NP O
11 1076 1083 2594614 studied VBN B-VP O
12 1083 1084 2594614 , , O O
13 1085 1088 2594614 did VBD B-VP O
14 1089 1092 2594614 not RB I-VP O
15 1093 1098 2594614 alter VB I-VP O
16 1099 1102 2594614 MBP NN B-NP O
17 1103 1106 2594614 and CC I-NP O
18 1107 1109 2594614 HR NN I-NP O
19 1110 1112 2594614 at IN B-PP O
20 1113 1116 2594614 the DT B-NP O
21 1117 1122 2594614 doses NNS I-NP O
22 1123 1127 2594614 used VBN B-VP O
23 1127 1128 2594614 , , O O
24 1129 1132 2594614 the DT B-NP O
25 1133 1137 2594614 bulk NN I-NP O
26 1138 1140 2594614 of IN B-PP O
27 1141 1146 2594614 these DT B-NP O
28 1147 1154 2594614 results NNS I-NP O
29 1155 1162 2594614 clearly RB B-ADVP O
30 1163 1174 2594614 demonstrate VBP B-VP O
31 1175 1176 2594614 a DT B-NP O
32 1177 1187 2594614 protective JJ I-NP O
33 1188 1194 2594614 action NN I-NP O
34 1195 1197 2594614 of IN B-PP O
35 1198 1200 2594614 BN NN B-NP C045856
36 1201 1206 2594614 52021 CD I-NP C045856
37 1206 1207 2594614 , , O O
38 1208 1209 2594614 a DT B-NP O
39 1210 1218 2594614 specific JJ I-NP O
40 1219 1229 2594614 antagonist NN I-NP O
41 1230 1232 2594614 of IN B-PP O
42 1233 1236 2594614 PAF NN B-NP O
43 1236 1237 2594614 , , O O
44 1238 1245 2594614 against IN B-PP O
45 1246 1257 2594614 bupivacaine NN B-NP D002045
46 1257 1258 2594614 - HYPH B-NP O
47 1258 1265 2594614 induced VBN I-NP O
48 1266 1280 2594614 cardiovascular JJ I-NP D002318
49 1281 1289 2594614 toxicity NN I-NP D002318
50 1289 1290 2594614 . . O O

1 1291 1295 2594614 Thus RB B-ADVP O
2 1295 1296 2594614 , , O O
3 1297 1307 2594614 consistent JJ B-ADJP O
4 1308 1312 2594614 with IN B-PP O
5 1313 1316 2594614 its PRP$ B-NP O
6 1317 1323 2594614 direct JJ I-NP O
7 1324 1330 2594614 effect NN I-NP O
8 1331 1333 2594614 on IN B-PP O
9 1334 1339 2594614 heart NN B-NP O
10 1339 1340 2594614 , , O O
11 1341 1344 2594614 PAF NN B-NP O
12 1345 1352 2594614 appears VBZ B-VP O
13 1353 1355 2594614 to TO I-VP O
14 1356 1358 2594614 be VB I-VP O
15 1359 1369 2594614 implicated VBN I-VP O
16 1370 1372 2594614 in IN B-PP O
17 1373 1384 2594614 bupivacaine NN B-NP D002045
18 1384 1385 2594614 - HYPH B-NP O
19 1385 1392 2594614 induced VBN I-NP O
20 1393 1407 2594614 cardiovascular JJ I-NP D018376
21 1408 1419 2594614 alterations NNS I-NP D018376
22 1419 1420 2594614 . . O O

1 0 0 7651879 -DOCSTART- -X- -X- O

1 0 7 7651879 Seizure NN B-NP D012640
2 8 13 7651879 after IN B-PP O
3 14 24 7651879 flumazenil NN B-NP D005442
4 25 39 7651879 administration NN I-NP O
5 40 42 7651879 in IN B-PP O
6 43 44 7651879 a DT B-NP O
7 45 54 7651879 pediatric JJ I-NP O
8 55 62 7651879 patient NN I-NP O
9 62 63 7651879 . . O O
10 64 74 7651879 Flumazenil NNP B-NP D005442
11 75 77 7651879 is VBZ B-VP O
12 78 79 7651879 a DT B-NP O
13 80 94 7651879 benzodiazepine NN I-NP D001569
14 95 103 7651879 receptor NN I-NP O
15 104 114 7651879 antagonist NN I-NP O
16 115 119 7651879 used VBN B-VP O
17 120 122 7651879 to TO B-VP O
18 123 130 7651879 reverse VB I-VP O
19 131 139 7651879 sedation NN B-NP O
20 140 143 7651879 and CC O O
21 144 155 7651879 respiratory JJ B-NP D012131
22 156 166 7651879 depression NN I-NP D012131
23 167 174 7651879 induced VBN B-VP O
24 175 177 7651879 by IN B-PP O
25 178 193 7651879 benzodiazepines NNS B-NP D001569
26 193 194 7651879 . . O O

1 195 203 7651879 Seizures NNS B-NP D012640
2 204 207 7651879 and CC O O
3 208 215 7651879 cardiac JJ B-NP D001145
4 216 227 7651879 arrhythmias NNS I-NP D001145
5 228 232 7651879 have VBP B-VP O
6 233 244 7651879 complicated VBN I-VP O
7 245 248 7651879 its PRP$ B-NP O
8 249 252 7651879 use NN I-NP O
9 253 255 7651879 in IN B-PP O
10 256 261 7651879 adult JJ B-NP O
11 262 270 7651879 patients NNS I-NP O
12 270 271 7651879 . . O O

1 272 280 7651879 Overdose NN B-NP D062787
2 281 289 7651879 patients NNS I-NP O
3 290 293 7651879 who WP B-NP O
4 294 298 7651879 have VBP B-VP O
5 299 309 7651879 coingested VBN I-VP O
6 310 319 7651879 tricyclic JJ B-NP O
7 320 335 7651879 antidepressants NNS I-NP O
8 336 340 7651879 have VBP B-VP O
9 341 342 7651879 a DT B-NP O
10 343 349 7651879 higher JJR I-NP O
11 350 354 7651879 risk NN I-NP O
12 355 357 7651879 of IN B-PP O
13 358 363 7651879 these DT B-NP O
14 364 377 7651879 complications NNS I-NP O
15 377 378 7651879 . . O O

1 379 385 7651879 Little JJ B-NP O
2 386 397 7651879 information NN I-NP O
3 398 404 7651879 exists VBZ B-VP O
4 405 415 7651879 concerning VBG I-VP O
5 416 423 7651879 adverse JJ B-NP O
6 424 431 7651879 effects NNS I-NP O
7 432 434 7651879 of IN B-PP O
8 435 445 7651879 flumazenil NN B-NP D005442
9 446 448 7651879 in IN B-PP O
10 449 457 7651879 children NNS B-NP O
11 457 458 7651879 . . O O

1 459 461 7651879 We PRP B-NP O
2 462 468 7651879 report VBP B-VP O
3 469 472 7651879 the DT B-NP O
4 473 483 7651879 occurrence NN I-NP O
5 484 486 7651879 of IN B-PP O
6 487 488 7651879 a DT B-NP O
7 489 500 7651879 generalized VBN I-NP O
8 501 506 7651879 tonic JJ I-NP D012640
9 506 507 7651879 - HYPH I-NP D012640
10 507 513 7651879 clonic JJ I-NP D012640
11 514 521 7651879 seizure NN I-NP D012640
12 522 524 7651879 in IN B-PP O
13 525 526 7651879 a DT B-NP O
14 527 536 7651879 pediatric JJ I-NP O
15 537 544 7651879 patient NN I-NP O
16 545 554 7651879 following VBG B-PP O
17 555 558 7651879 the DT B-NP O
18 559 573 7651879 administration NN I-NP O
19 574 576 7651879 of IN B-PP O
20 577 587 7651879 flumazenil NN B-NP D005442
21 587 588 7651879 . . O O

1 0 0 15096016 -DOCSTART- -X- -X- O

1 0 8 15096016 Pallidal JJ B-NP O
2 9 20 15096016 stimulation NN I-NP O
3 20 21 15096016 : : O O
4 22 24 15096016 an DT B-NP O
5 25 36 15096016 alternative NN I-NP O
6 37 39 15096016 to TO B-VP O
7 40 51 15096016 pallidotomy VB I-VP O
8 51 52 15096016 ? . O O
9 53 54 15096016 A DT B-NP O
10 55 65 15096016 resurgence NN I-NP O
11 66 68 15096016 of IN B-PP O
12 69 77 15096016 interest NN B-NP O
13 78 80 15096016 in IN B-PP O
14 81 84 15096016 the DT B-NP O
15 85 93 15096016 surgical JJ I-NP O
16 94 103 15096016 treatment NN I-NP O
17 104 106 15096016 of IN B-PP O
18 107 118 15096016 Parkinson's NNS B-NP D010300
19 119 126 15096016 disease NN B-NP D010300
20 127 128 15096016 ( ( O O
21 128 130 15096016 PD NN B-NP D010300
22 130 131 15096016 ) ) O O
23 132 136 15096016 came VBD B-VP O
24 137 141 15096016 with IN B-PP O
25 142 145 15096016 the DT B-NP O
26 146 157 15096016 rediscovery NN I-NP O
27 158 160 15096016 of IN B-PP O
28 161 175 15096016 posteroventral JJ B-NP O
29 176 187 15096016 pallidotomy NN I-NP O
30 188 190 15096016 by IN B-PP O
31 191 199 15096016 Laitinen NNP B-NP O
32 200 202 15096016 in IN B-PP O
33 203 207 15096016 1985 CD B-NP O
34 207 208 15096016 . . O O

1 209 219 15096016 Laitinen's NNS B-NP O
2 220 229 15096016 procedure NN I-NP O
3 230 238 15096016 improved VBD B-VP O
4 239 243 15096016 most JJS B-NP O
5 244 252 15096016 symptoms NNS I-NP O
6 253 255 15096016 in IN B-PP O
7 256 260 15096016 drug NN B-NP O
8 260 261 15096016 - HYPH B-NP O
9 261 270 15096016 resistant JJ I-NP O
10 271 273 15096016 PD NN I-NP D010300
11 273 274 15096016 , , O O
12 275 280 15096016 which WDT B-NP O
13 281 291 15096016 engendered VBD B-VP O
14 292 296 15096016 wide JJ B-NP O
15 297 305 15096016 interest NN I-NP O
16 306 308 15096016 in IN B-PP O
17 309 312 15096016 the DT B-NP O
18 313 326 15096016 neurosurgical JJ I-NP O
19 327 336 15096016 community NN I-NP O
20 336 337 15096016 . . O O

1 338 345 15096016 Another DT B-NP O
2 346 355 15096016 lesioning VBG I-NP O
3 356 365 15096016 procedure NN I-NP O
4 365 366 15096016 , , O O
5 367 380 15096016 ventrolateral JJ B-NP O
6 381 392 15096016 thalamotomy NN I-NP O
7 392 393 15096016 , , O O
8 394 397 15096016 has VBZ B-VP O
9 398 404 15096016 become VBN I-VP O
10 405 406 15096016 a DT B-NP O
11 407 415 15096016 powerful JJ I-NP O
12 416 427 15096016 alternative NN I-NP O
13 428 430 15096016 to TO B-VP O
14 431 440 15096016 stimulate VB I-VP O
15 441 444 15096016 the DT B-NP O
16 445 452 15096016 nucleus NN I-NP O
17 453 462 15096016 ventralis NN I-NP O
18 463 474 15096016 intermedius NN I-NP O
19 474 475 15096016 , , O O
20 476 485 15096016 producing VBG B-VP O
21 486 490 15096016 high JJ B-NP O
22 491 495 15096016 long JJ I-NP O
23 495 496 15096016 - HYPH I-NP O
24 496 500 15096016 term NN I-NP O
25 501 508 15096016 success NN I-NP O
26 509 514 15096016 rates NNS I-NP O
27 515 518 15096016 and CC O O
28 519 522 15096016 low JJ B-NP O
29 523 532 15096016 morbidity NN I-NP O
30 533 538 15096016 rates NNS I-NP O
31 538 539 15096016 . . O O

1 540 548 15096016 Pallidal JJ B-NP O
2 549 560 15096016 stimulation NN I-NP O
3 561 564 15096016 has VBZ B-VP O
4 565 568 15096016 not RB I-VP O
5 569 572 15096016 met VBN I-VP O
6 573 577 15096016 with IN B-PP O
7 578 581 15096016 the DT B-NP O
8 582 586 15096016 same JJ I-NP O
9 587 594 15096016 success NN I-NP O
10 594 595 15096016 . . O O

1 596 605 15096016 According VBG B-PP O
2 606 608 15096016 to TO B-PP O
3 609 612 15096016 the DT B-NP O
4 613 623 15096016 literature NN I-NP O
5 624 635 15096016 pallidotomy NN I-NP O
6 636 644 15096016 improves VBZ B-VP O
7 645 648 15096016 the DT B-NP O
8 649 650 15096016 " `` I-NP O
9 650 652 15096016 on IN B-PP O
10 652 653 15096016 " '' O O
11 654 662 15096016 symptoms NNS B-NP O
12 663 665 15096016 of IN B-PP O
13 666 668 15096016 PD NN B-NP D010300
14 668 669 15096016 , , O O
15 670 674 15096016 such JJ B-PP O
16 675 677 15096016 as IN I-PP O
17 678 689 15096016 dyskinesias NNS B-NP D004409
18 689 690 15096016 , , O O
19 691 693 15096016 as RB B-CONJP O
20 694 698 15096016 well RB I-CONJP O
21 699 701 15096016 as IN I-CONJP O
22 702 705 15096016 the DT B-NP O
23 706 707 15096016 " `` I-NP O
24 707 710 15096016 off RP B-PRT O
25 710 711 15096016 " '' B-NP O
26 712 720 15096016 symptoms NNS I-NP O
27 720 721 15096016 , , O O
28 722 726 15096016 such JJ B-PP O
29 727 729 15096016 as IN I-PP O
30 730 738 15096016 rigidity NN B-NP D009127
31 738 739 15096016 , , O O
32 740 752 15096016 bradykinesia NN B-NP D018476
33 752 753 15096016 , , O O
34 754 757 15096016 and CC O O
35 758 760 15096016 on VB B-VP O
36 760 761 15096016 - HYPH B-NP O
37 761 764 15096016 off RP I-NP O
38 765 777 15096016 fluctuations NNS B-NP O
39 777 778 15096016 . . O O

1 779 787 15096016 Pallidal JJ B-NP O
2 788 799 15096016 stimulation NN I-NP O
3 800 808 15096016 improves VBZ B-VP O
4 809 821 15096016 bradykinesia NN B-NP D018476
5 822 825 15096016 and CC I-NP O
6 826 834 15096016 rigidity NN I-NP D009127
7 835 837 15096016 to TO B-PP O
8 838 839 15096016 a DT B-NP O
9 840 845 15096016 minor JJ I-NP O
10 846 852 15096016 extent NN I-NP O
11 852 853 15096016 ; : O O
12 854 861 15096016 however RB B-ADVP O
13 861 862 15096016 , , O O
14 863 866 15096016 its PRP$ B-NP O
15 867 875 15096016 strength NN I-NP O
16 876 881 15096016 seems VBZ B-VP O
17 882 884 15096016 to TO I-VP O
18 885 887 15096016 be VB I-VP O
19 888 890 15096016 in IN B-PP O
20 891 900 15096016 improving VBG B-VP O
21 901 909 15096016 levodopa NN B-NP D007980
22 909 910 15096016 - HYPH B-NP O
23 910 917 15096016 induced VBN I-NP O
24 918 929 15096016 dyskinesias NNS I-NP D004409
25 929 930 15096016 . . O O

1 931 942 15096016 Stimulation NN B-NP O
2 943 948 15096016 often RB B-ADVP O
3 949 957 15096016 produces VBZ B-VP O
4 958 960 15096016 an DT B-NP O
5 961 972 15096016 improvement NN I-NP O
6 973 975 15096016 in IN B-PP O
7 976 979 15096016 the DT B-NP O
8 980 985 15096016 hyper NN I-NP D006948
9 985 986 15096016 - HYPH B-VP D006948
10 987 989 15096016 or CC O D006948
11 990 1000 15096016 dyskinetic JJ B-NP D006948
12 1001 1006 15096016 upper JJ I-NP O
13 1007 1012 15096016 limbs NNS I-NP O
14 1012 1013 15096016 , , O O
15 1014 1017 15096016 but CC O O
16 1018 1027 15096016 increases VBZ B-VP O
17 1028 1031 15096016 the DT B-NP O
18 1032 1033 15096016 " `` I-NP O
19 1033 1041 15096016 freezing JJ I-NP O
20 1041 1042 15096016 " '' I-NP O
21 1043 1053 15096016 phenomenon NN I-NP O
22 1054 1056 15096016 in IN B-PP O
23 1057 1060 15096016 the DT B-NP O
24 1061 1066 15096016 lower JJR I-NP O
25 1067 1072 15096016 limbs NNS I-NP O
26 1073 1075 15096016 at IN B-PP O
27 1076 1079 15096016 the DT B-NP O
28 1080 1084 15096016 same JJ I-NP O
29 1085 1089 15096016 time NN I-NP O
30 1089 1090 15096016 . . O O

1 1091 1102 15096016 Considering VBG B-VP O
2 1103 1106 15096016 the DT B-NP O
3 1107 1112 15096016 small JJ I-NP O
4 1113 1121 15096016 increase NN I-NP O
5 1122 1124 15096016 in IN B-PP O
6 1125 1128 15096016 the DT B-NP O
7 1129 1138 15096016 patient's NNS I-NP O
8 1139 1151 15096016 independence NN I-NP O
9 1151 1152 15096016 , , O O
10 1153 1156 15096016 the DT B-NP O
11 1157 1161 15096016 high JJ I-NP O
12 1162 1167 15096016 costs NNS I-NP O
13 1168 1170 15096016 of IN B-PP O
14 1171 1180 15096016 bilateral JJ B-NP O
15 1181 1189 15096016 implants NNS I-NP O
16 1189 1190 15096016 , , O O
17 1191 1194 15096016 and CC O O
18 1195 1198 15096016 the DT B-NP O
19 1199 1209 15096016 difficulty NN I-NP O
20 1210 1214 15096016 most JJS B-NP O
21 1215 1223 15096016 patients NNS I-NP O
22 1224 1234 15096016 experience VBP B-VP O
23 1235 1237 15096016 in IN B-PP O
24 1238 1246 15096016 handling VBG B-VP O
25 1247 1250 15096016 the DT B-NP O
26 1251 1258 15096016 devices NNS I-NP O
27 1258 1259 15096016 , , O O
28 1260 1263 15096016 the DT B-NP O
29 1264 1272 15096016 question NN I-NP O
30 1273 1279 15096016 arises VBZ B-VP O
31 1280 1282 15096016 as IN B-PP O
32 1283 1285 15096016 to TO B-PP O
33 1286 1293 15096016 whether IN B-SBAR O
34 1294 1303 15096016 bilateral JJ B-NP O
35 1304 1312 15096016 pallidal JJ I-NP O
36 1313 1324 15096016 stimulation NN I-NP O
37 1325 1327 15096016 is VBZ B-VP O
38 1328 1329 15096016 a DT B-NP O
39 1330 1334 15096016 real JJ I-NP O
40 1335 1346 15096016 alternative NN I-NP O
41 1347 1349 15096016 to TO B-PP O
42 1350 1361 15096016 pallidotomy NN B-NP O
43 1361 1362 15096016 . . O O

1 0 0 20042557 -DOCSTART- -X- -X- O

1 0 8 20042557 Sedation NN B-NP O
2 9 14 20042557 depth NN I-NP O
3 15 21 20042557 during IN B-PP O
4 22 28 20042557 spinal JJ B-NP O
5 29 39 20042557 anesthesia NN I-NP O
6 40 43 20042557 and CC O O
7 44 47 20042557 the DT B-NP O
8 48 59 20042557 development NN I-NP O
9 60 62 20042557 of IN B-PP O
10 63 76 20042557 postoperative JJ B-NP D011183
11 77 85 20042557 delirium NN I-NP D011183
12 86 88 20042557 in IN B-PP O
13 89 96 20042557 elderly JJ B-NP O
14 97 105 20042557 patients NNS I-NP O
15 106 116 20042557 undergoing VBG B-VP O
16 117 120 20042557 hip NN B-NP D006620
17 121 129 20042557 fracture NN I-NP D006620
18 130 136 20042557 repair NN I-NP O
19 136 137 20042557 . . I-NP O
20 138 147 20042557 OBJECTIVE NN I-NP O
21 147 148 20042557 : : O O
22 149 151 20042557 To TO B-VP O
23 152 161 20042557 determine VB I-VP O
24 162 169 20042557 whether IN B-SBAR O
25 170 178 20042557 limiting VBG B-VP O
26 179 193 20042557 intraoperative JJ B-NP O
27 194 202 20042557 sedation NN I-NP O
28 203 208 20042557 depth NN I-NP O
29 209 215 20042557 during IN B-PP O
30 216 222 20042557 spinal JJ B-NP O
31 223 233 20042557 anesthesia NN I-NP O
32 234 237 20042557 for IN B-PP O
33 238 241 20042557 hip NN B-NP D006620
34 242 250 20042557 fracture NN I-NP D006620
35 251 257 20042557 repair NN I-NP O
36 258 260 20042557 in IN B-PP O
37 261 268 20042557 elderly JJ B-NP O
38 269 277 20042557 patients NNS I-NP O
39 278 281 20042557 can MD B-VP O
40 282 290 20042557 decrease VB I-VP O
41 291 294 20042557 the DT B-NP O
42 295 305 20042557 prevalence NN I-NP O
43 306 308 20042557 of IN B-PP O
44 309 322 20042557 postoperative JJ B-NP D011183
45 323 331 20042557 delirium NN I-NP D011183
46 331 332 20042557 . . O O

1 333 341 20042557 PATIENTS NNS B-NP O
2 342 345 20042557 AND CC I-NP O
3 346 353 20042557 METHODS NNS I-NP O
4 353 354 20042557 : : O O
5 355 357 20042557 We PRP B-NP O
6 358 367 20042557 performed VBD B-VP O
7 368 369 20042557 a DT B-NP O
8 370 376 20042557 double JJ I-NP O
9 376 377 20042557 - HYPH I-NP O
10 377 382 20042557 blind JJ I-NP O
11 382 383 20042557 , , O O
12 384 394 20042557 randomized VBN B-VP O
13 395 405 20042557 controlled VBN B-NP O
14 406 411 20042557 trial NN I-NP O
15 412 414 20042557 at IN B-PP O
16 415 417 20042557 an DT B-NP O
17 418 426 20042557 academic JJ I-NP O
18 427 434 20042557 medical JJ I-NP O
19 435 441 20042557 center NN I-NP O
20 442 444 20042557 of IN B-PP O
21 445 452 20042557 elderly JJ B-NP O
22 453 461 20042557 patients NNS I-NP O
23 462 463 20042557 ( ( O O
24 463 464 20042557 > SYM B-NP O
25 464 466 20042557 or CC O O
26 466 467 20042557 = SYM B-VP O
27 467 469 20042557 65 CD B-NP O
28 470 475 20042557 years NNS I-NP O
29 475 476 20042557 ) ) O O
30 477 484 20042557 without IN B-PP O
31 485 497 20042557 preoperative JJ B-NP O
32 498 506 20042557 delirium NN I-NP D003693
33 507 509 20042557 or CC O O
34 510 516 20042557 severe JJ B-NP O
35 517 525 20042557 dementia NN I-NP D003704
36 526 529 20042557 who WP B-NP O
37 530 539 20042557 underwent VBD B-VP O
38 540 543 20042557 hip NN B-NP D006620
39 544 552 20042557 fracture NN I-NP D006620
40 553 559 20042557 repair NN I-NP O
41 560 565 20042557 under IN B-PP O
42 566 572 20042557 spinal JJ B-NP O
43 573 583 20042557 anesthesia NN I-NP O
44 584 588 20042557 with IN B-PP O
45 589 597 20042557 propofol NN B-NP D015742
46 598 606 20042557 sedation NN I-NP O
47 606 607 20042557 . . O O

1 608 616 20042557 Sedation NN B-NP O
2 617 622 20042557 depth NN I-NP O
3 623 626 20042557 was VBD B-VP O
4 627 635 20042557 titrated VBN I-VP O
5 636 641 20042557 using VBG B-VP O
6 642 651 20042557 processed VBN B-NP O
7 652 674 20042557 electroencephalography NN I-NP O
8 675 679 20042557 with IN B-PP O
9 680 683 20042557 the DT B-NP O
10 684 694 20042557 bispectral JJ I-NP O
11 695 700 20042557 index NN I-NP O
12 701 702 20042557 ( ( O O
13 702 705 20042557 BIS NN B-NP O
14 705 706 20042557 ) ) O O
15 706 707 20042557 , , O O
16 708 711 20042557 and CC O O
17 712 720 20042557 patients NNS B-NP O
18 721 725 20042557 were VBD B-VP O
19 726 736 20042557 randomized VBN I-VP O
20 737 739 20042557 to TO B-VP O
21 740 747 20042557 receive VB I-VP O
22 748 754 20042557 either CC I-VP O
23 755 759 20042557 deep VB I-VP O
24 760 761 20042557 ( ( O O
25 761 764 20042557 BIS NN B-NP O
26 764 765 20042557 , , O O
27 766 779 20042557 approximately RB B-NP O
28 780 782 20042557 50 CD I-NP O
29 782 783 20042557 ) ) O O
30 784 786 20042557 or CC O O
31 787 792 20042557 light NN B-NP O
32 793 794 20042557 ( ( O O
33 794 797 20042557 BIS NN B-NP O
34 797 798 20042557 , , O O
35 799 800 20042557 > SYM B-NP O
36 800 802 20042557 or CC O O
37 802 803 20042557 = SYM B-VP O
38 803 805 20042557 80 CD B-NP O
39 805 806 20042557 ) ) O O
40 807 815 20042557 sedation NN B-NP O
41 815 816 20042557 . . O O

1 817 830 20042557 Postoperative JJ B-NP D011183
2 831 839 20042557 delirium NN I-NP D011183
3 840 843 20042557 was VBD B-VP O
4 844 852 20042557 assessed VBN I-VP O
5 853 855 20042557 as IN B-SBAR O
6 856 863 20042557 defined VBN B-VP O
7 864 866 20042557 by IN B-PP O
8 867 877 20042557 Diagnostic NNP B-NP O
9 878 881 20042557 and CC I-NP O
10 882 893 20042557 Statistical NNP I-NP O
11 894 900 20042557 Manual NNP I-NP O
12 901 903 20042557 of IN B-PP O
13 904 910 20042557 Mental NNP B-NP D001523
14 911 920 20042557 Disorders NNP I-NP D001523
15 921 922 20042557 ( ( O O
16 922 927 20042557 Third NNP B-NP O
17 928 935 20042557 Edition NNP I-NP O
18 936 943 20042557 Revised NNP I-NP O
19 943 944 20042557 ) ) O O
20 945 953 20042557 criteria NNS B-NP O
21 954 959 20042557 using VBG B-VP O
22 960 963 20042557 the DT B-NP O
23 964 973 20042557 Confusion NNP I-NP O
24 974 984 20042557 Assessment NNP I-NP O
25 985 991 20042557 Method NNP I-NP O
26 992 1001 20042557 beginning VBG B-VP O
27 1002 1004 20042557 at IN B-PP O
28 1005 1008 20042557 any DT B-NP O
29 1009 1013 20042557 time NN I-NP O
30 1014 1018 20042557 from IN B-PP O
31 1019 1022 20042557 the DT B-NP O
32 1023 1029 20042557 second JJ I-NP O
33 1030 1033 20042557 day NN I-NP O
34 1034 1039 20042557 after IN B-PP O
35 1040 1047 20042557 surgery NN B-NP O
36 1047 1048 20042557 . . O O

1 1049 1056 20042557 RESULTS NNS B-NP O
2 1056 1057 20042557 : : O O
3 1058 1062 20042557 From IN B-PP O
4 1063 1068 20042557 April NNP B-NP O
5 1069 1070 20042557 2 CD I-NP O
6 1070 1071 20042557 , , I-NP O
7 1072 1076 20042557 2005 CD I-NP O
8 1076 1077 20042557 , , O O
9 1078 1085 20042557 through IN B-PP O
10 1086 1093 20042557 October NNP B-NP O
11 1094 1096 20042557 30 CD I-NP O
12 1096 1097 20042557 , , I-NP O
13 1098 1102 20042557 2008 CD I-NP O
14 1102 1103 20042557 , , O O
15 1104 1105 20042557 a DT B-NP O
16 1106 1111 20042557 total NN I-NP O
17 1112 1114 20042557 of IN B-PP O
18 1115 1118 20042557 114 CD B-NP O
19 1119 1127 20042557 patients NNS I-NP O
20 1128 1132 20042557 were VBD B-VP O
21 1133 1143 20042557 randomized VBN I-VP O
22 1143 1144 20042557 . . O O

1 1145 1148 20042557 The DT B-NP O
2 1149 1159 20042557 prevalence NN I-NP O
3 1160 1162 20042557 of IN B-PP O
4 1163 1176 20042557 postoperative JJ B-NP D011183
5 1177 1185 20042557 delirium NN I-NP D011183
6 1186 1189 20042557 was VBD B-VP O
7 1190 1203 20042557 significantly RB B-ADJP O
8 1204 1209 20042557 lower JJR I-ADJP O
9 1210 1212 20042557 in IN B-PP O
10 1213 1216 20042557 the DT B-NP O
11 1217 1222 20042557 light JJ I-NP O
12 1223 1231 20042557 sedation NN I-NP O
13 1232 1237 20042557 group NN I-NP O
14 1238 1239 20042557 ( ( O O
15 1239 1241 20042557 11 CD B-NP O
16 1241 1242 20042557 / SYM B-NP O
17 1242 1244 20042557 57 CD I-NP O
18 1245 1246 20042557 [ ( I-NP O
19 1246 1249 20042557 19% CD I-NP O
20 1249 1250 20042557 ] ) O O
21 1251 1253 20042557 vs IN B-PP O
22 1254 1256 20042557 23 CD B-NP O
23 1256 1257 20042557 / SYM I-NP O
24 1257 1259 20042557 57 CD I-NP O
25 1260 1261 20042557 [ ( I-NP O
26 1261 1264 20042557 40% NN I-NP O
27 1264 1265 20042557 ] ) O O
28 1266 1268 20042557 in IN B-PP O
29 1269 1272 20042557 the DT B-NP O
30 1273 1277 20042557 deep JJ I-NP O
31 1278 1286 20042557 sedation NN I-NP O
32 1287 1292 20042557 group NN I-NP O
33 1292 1293 20042557 ; : O O
34 1294 1295 20042557 P NN B-NP O
35 1295 1296 20042557 = SYM B-VP O
36 1296 1299 20042557 .02 CD B-NP O
37 1299 1300 20042557 ) ) O O
38 1300 1301 20042557 , , O O
39 1302 1312 20042557 indicating VBG B-VP O
40 1313 1317 20042557 that IN B-SBAR O
41 1318 1319 20042557 1 CD B-NP O
42 1320 1328 20042557 incident NN I-NP O
43 1329 1331 20042557 of IN B-PP O
44 1332 1340 20042557 delirium NN B-NP D003693
45 1341 1345 20042557 will MD B-VP O
46 1346 1348 20042557 be VB I-VP O
47 1349 1358 20042557 prevented VBN I-VP O
48 1359 1362 20042557 for IN B-PP O
49 1363 1368 20042557 every DT B-NP O
50 1369 1372 20042557 4.7 CD I-NP O
51 1373 1381 20042557 patients NNS I-NP O
52 1382 1389 20042557 treated VBN B-VP O
53 1390 1394 20042557 with IN B-PP O
54 1395 1400 20042557 light JJ B-NP O
55 1401 1409 20042557 sedation NN I-NP O
56 1409 1410 20042557 . . O O

1 1411 1414 20042557 The DT B-NP O
2 1415 1419 20042557 mean NN I-NP O
3 1420 1421 20042557 + SYM B-VP O
4 1421 1422 20042557 / SYM B-NP O
5 1422 1423 20042557 - HYPH I-NP O
6 1424 1426 20042557 SD NN I-NP O
7 1427 1433 20042557 number NN I-NP O
8 1434 1436 20042557 of IN B-PP O
9 1437 1441 20042557 days NNS B-NP O
10 1442 1444 20042557 of IN B-PP O
11 1445 1453 20042557 delirium NN B-NP D003693
12 1454 1460 20042557 during IN B-PP O
13 1461 1476 20042557 hospitalization NN B-NP O
14 1477 1480 20042557 was VBD B-VP O
15 1481 1486 20042557 lower JJR B-ADJP O
16 1487 1489 20042557 in IN B-PP O
17 1490 1493 20042557 the DT B-NP O
18 1494 1499 20042557 light JJ I-NP O
19 1500 1508 20042557 sedation NN I-NP O
20 1509 1514 20042557 group NN I-NP O
21 1515 1519 20042557 than IN B-PP O
22 1520 1522 20042557 in IN B-PP O
23 1523 1526 20042557 the DT B-NP O
24 1527 1531 20042557 deep JJ I-NP O
25 1532 1540 20042557 sedation NN I-NP O
26 1541 1546 20042557 group NN I-NP O
27 1547 1548 20042557 ( ( O O
28 1548 1552 20042557 0.5+ SYM B-NP O
29 1552 1553 20042557 / SYM O O
30 1553 1554 20042557 - SYM O O
31 1554 1557 20042557 1.5 CD B-NP O
32 1558 1562 20042557 days NNS I-NP O
33 1563 1565 20042557 vs IN B-PP O
34 1566 1570 20042557 1.4+ CD B-NP O
35 1570 1571 20042557 / SYM I-NP O
36 1571 1572 20042557 - SYM I-NP O
37 1572 1575 20042557 4.0 CD I-NP O
38 1576 1580 20042557 days NNS I-NP O
39 1580 1581 20042557 ; : O O
40 1582 1583 20042557 P NN B-NP O
41 1583 1584 20042557 = SYM B-VP O
42 1584 1587 20042557 .01 CD B-NP O
43 1587 1588 20042557 ) ) O O
44 1588 1589 20042557 . . O O

1 1590 1600 20042557 CONCLUSION NN B-NP O
2 1600 1601 20042557 : : O O
3 1602 1605 20042557 The DT B-NP O
4 1606 1609 20042557 use NN I-NP O
5 1610 1612 20042557 of IN B-PP O
6 1613 1618 20042557 light JJ B-NP O
7 1619 1627 20042557 propofol NN I-NP D015742
8 1628 1636 20042557 sedation NN I-NP O
9 1637 1646 20042557 decreased VBD B-VP O
10 1647 1650 20042557 the DT B-NP O
11 1651 1661 20042557 prevalence NN I-NP O
12 1662 1664 20042557 of IN B-PP O
13 1665 1678 20042557 postoperative JJ B-NP D011183
14 1679 1687 20042557 delirium NN I-NP D011183
15 1688 1690 20042557 by IN B-PP O
16 1691 1694 20042557 50% CD B-NP O
17 1695 1703 20042557 compared VBN B-PP O
18 1704 1708 20042557 with IN B-PP O
19 1709 1713 20042557 deep JJ B-NP O
20 1714 1722 20042557 sedation NN I-NP O
21 1722 1723 20042557 . . O O

1 1724 1732 20042557 Limiting VBG B-VP O
2 1733 1738 20042557 depth NN B-NP O
3 1739 1741 20042557 of IN B-PP O
4 1742 1750 20042557 sedation NN B-NP O
5 1751 1757 20042557 during IN B-PP O
6 1758 1764 20042557 spinal JJ B-NP O
7 1765 1775 20042557 anesthesia NN I-NP O
8 1776 1778 20042557 is VBZ B-VP O
9 1779 1780 20042557 a DT B-NP O
10 1781 1787 20042557 simple JJ I-NP O
11 1787 1788 20042557 , , I-NP O
12 1789 1793 20042557 safe JJ I-NP O
13 1793 1794 20042557 , , I-NP O
14 1795 1798 20042557 and CC I-NP O
15 1799 1803 20042557 cost NN I-NP O
16 1803 1804 20042557 - HYPH I-NP O
17 1804 1813 20042557 effective JJ I-NP O
18 1814 1826 20042557 intervention NN I-NP O
19 1827 1830 20042557 for IN B-PP O
20 1831 1841 20042557 preventing VBG B-VP O
21 1842 1855 20042557 postoperative JJ B-NP D011183
22 1856 1864 20042557 delirium NN I-NP D011183
23 1865 1867 20042557 in IN B-PP O
24 1868 1875 20042557 elderly JJ B-NP O
25 1876 1884 20042557 patients NNS I-NP O
26 1885 1889 20042557 that WDT B-NP O
27 1890 1895 20042557 could MD B-VP O
28 1896 1898 20042557 be VB I-VP O
29 1899 1905 20042557 widely RB B-ADVP O
30 1906 1909 20042557 and CC I-ADVP O
31 1910 1917 20042557 readily RB I-ADVP O
32 1918 1925 20042557 adopted VBN B-VP O
33 1925 1926 20042557 . . O O

1 0 0 18356633 -DOCSTART- -X- -X- O

1 0 2 18356633 An DT B-NP O
2 3 13 18356633 evaluation NN I-NP O
3 14 16 18356633 of IN B-PP O
4 17 25 18356633 amikacin NN B-NP D000583
5 26 40 18356633 nephrotoxicity NN I-NP D007674
6 41 43 18356633 in IN B-PP O
7 44 47 18356633 the DT B-NP O
8 48 58 18356633 hematology NN I-NP O
9 58 59 18356633 / SYM B-NP O
10 59 67 18356633 oncology NN I-NP O
11 68 78 18356633 population NN I-NP O
12 78 79 18356633 . . I-NP O
13 80 88 18356633 Amikacin NN I-NP D000583
14 89 91 18356633 is VBZ B-VP O
15 92 94 18356633 an DT B-NP O
16 95 109 18356633 aminoglycoside NN I-NP D000617
17 110 118 18356633 commonly RB B-VP O
18 119 123 18356633 used VBN I-VP O
19 124 126 18356633 to TO B-VP O
20 127 134 18356633 provide VB I-VP O
21 135 144 18356633 empirical JJ B-NP O
22 145 151 18356633 double JJ I-NP O
23 152 156 18356633 gram NN I-NP O
24 156 157 18356633 - HYPH B-NP O
25 157 165 18356633 negative JJ I-NP O
26 166 175 18356633 treatment NN I-NP O
27 176 179 18356633 for IN B-PP O
28 180 187 18356633 febrile JJ B-NP D009503
29 188 199 18356633 neutropenia NN I-NP D009503
30 200 203 18356633 and CC O O
31 204 209 18356633 other JJ B-NP O
32 210 219 18356633 suspected VBN I-NP O
33 220 230 18356633 infections NNS I-NP D007239
34 230 231 18356633 . . O O

1 232 242 18356633 Strategies NNS B-NP O
2 243 245 18356633 of IN B-PP O
3 246 254 18356633 extended VBN B-NP O
4 254 255 18356633 - HYPH I-NP O
5 255 263 18356633 interval JJ I-NP O
6 264 267 18356633 and CC I-NP O
7 268 280 18356633 conventional JJ I-NP O
8 281 287 18356633 dosing NN I-NP O
9 288 292 18356633 have VBP B-VP O
10 293 297 18356633 been VBN I-VP O
11 298 306 18356633 utilized VBN I-VP O
12 307 318 18356633 extensively RB B-ADVP O
13 319 321 18356633 in IN B-PP O
14 322 325 18356633 the DT B-NP O
15 326 333 18356633 general JJ I-NP O
16 334 341 18356633 medical JJ I-NP O
17 342 352 18356633 population NN I-NP O
18 352 353 18356633 ; : O O
19 354 361 18356633 however RB B-ADVP O
20 361 362 18356633 , , O O
21 363 367 18356633 data NNS B-NP O
22 368 371 18356633 are VBP B-VP O
23 372 379 18356633 lacking VBG I-VP O
24 380 382 18356633 to TO I-VP O
25 383 390 18356633 support VB I-VP O
26 391 392 18356633 a DT B-NP O
27 393 399 18356633 dosing NN I-NP O
28 400 408 18356633 strategy NN I-NP O
29 409 411 18356633 in IN B-PP O
30 412 415 18356633 the DT B-NP O
31 416 426 18356633 hematology NN I-NP O
32 426 427 18356633 / SYM B-NP O
33 427 435 18356633 oncology NN I-NP O
34 436 446 18356633 population NN I-NP O
35 446 447 18356633 . . O O

1 448 450 18356633 To TO B-VP O
2 451 459 18356633 evaluate VB I-VP O
3 460 468 18356633 amikacin NN B-NP D000583
4 468 469 18356633 - HYPH O O
5 469 479 18356633 associated VBN B-NP O
6 480 494 18356633 nephrotoxicity NN I-NP D007674
7 495 497 18356633 in IN B-PP O
8 498 500 18356633 an DT B-NP O
9 501 506 18356633 adult JJ I-NP O
10 507 517 18356633 hematology NN I-NP O
11 517 518 18356633 / SYM B-NP O
12 518 526 18356633 oncology NN I-NP O
13 527 537 18356633 population NN I-NP O
14 537 538 18356633 , , O O
15 539 540 18356633 a DT B-NP O
16 541 552 18356633 prospective JJ I-NP O
17 552 553 18356633 , , I-NP O
18 554 564 18356633 randomized VBN I-NP O
19 564 565 18356633 , , I-NP O
20 566 570 18356633 open JJ I-NP O
21 570 571 18356633 - HYPH I-NP O
22 571 576 18356633 label NN I-NP O
23 577 582 18356633 trial NN I-NP O
24 583 586 18356633 was VBD B-VP O
25 587 596 18356633 conducted VBN I-VP O
26 597 599 18356633 at IN B-PP O
27 600 601 18356633 a DT B-NP O
28 602 612 18356633 university NN I-NP O
29 612 613 18356633 - HYPH O O
30 613 623 18356633 affiliated VBN B-VP O
31 624 631 18356633 medical JJ B-NP O
32 632 638 18356633 center NN I-NP O
33 638 639 18356633 . . O O

1 640 645 18356633 Forty CD B-NP O
2 646 654 18356633 patients NNS I-NP O
3 655 659 18356633 with IN B-PP O
4 660 661 18356633 a DT B-NP O
5 662 671 18356633 diagnosis NN I-NP O
6 672 682 18356633 consistent JJ B-ADJP O
7 683 687 18356633 with IN B-PP O
8 688 689 18356633 a DT B-NP O
9 690 701 18356633 hematologic JJ I-NP D006402
10 701 702 18356633 / SYM I-NP D006402
11 702 711 18356633 oncologic JJ I-NP D006402
12 712 720 18356633 disorder NN I-NP D006402
13 721 725 18356633 that WDT B-NP O
14 726 734 18356633 required VBD B-VP O
15 735 744 18356633 treatment NN B-NP O
16 745 749 18356633 with IN B-PP O
17 750 752 18356633 an DT B-NP O
18 753 767 18356633 aminoglycoside NN I-NP D000617
19 768 772 18356633 were VBD B-VP O
20 773 783 18356633 randomized VBN I-VP O
21 784 786 18356633 to TO B-PP O
22 787 793 18356633 either CC O O
23 794 806 18356633 conventional JJ B-NP O
24 807 809 18356633 or CC I-NP O
25 810 818 18356633 extended JJ I-NP O
26 818 819 18356633 - HYPH I-NP O
27 819 827 18356633 interval NN I-NP O
28 828 836 18356633 amikacin NN I-NP D000583
29 836 837 18356633 . . O O

1 838 841 18356633 The DT B-NP O
2 842 852 18356633 occurrence NN I-NP O
3 853 855 18356633 of IN B-PP O
4 856 870 18356633 nephrotoxicity NN B-NP D007674
5 871 873 18356633 by IN B-PP O
6 874 879 18356633 means NNS B-NP O
7 880 882 18356633 of IN B-PP O
8 883 885 18356633 an DT B-NP O
9 886 894 18356633 increase NN I-NP O
10 895 897 18356633 in IN B-PP O
11 898 903 18356633 serum NN B-NP O
12 904 914 18356633 creatinine NN I-NP D003404
13 915 918 18356633 and CC I-NP O
14 919 929 18356633 evaluation NN I-NP O
15 930 932 18356633 of IN B-PP O
16 933 941 18356633 efficacy NN B-NP O
17 942 945 18356633 via IN B-PP O
18 946 954 18356633 amikacin NN B-NP D000583
19 955 960 18356633 serum NN I-NP O
20 961 975 18356633 concentrations NNS I-NP O
21 976 980 18356633 with IN B-PP O
22 981 991 18356633 respective JJ B-NP O
23 992 1001 18356633 pathogens NNS I-NP O
24 1002 1006 18356633 were VBD B-VP O
25 1007 1015 18356633 assessed VBN I-VP O
26 1015 1016 18356633 . . O O

1 1017 1020 18356633 The DT B-NP O
2 1021 1031 18356633 occurrence NN I-NP O
3 1032 1034 18356633 of IN B-PP O
4 1035 1049 18356633 nephrotoxicity NN B-NP D007674
5 1050 1053 18356633 was VBD B-VP O
6 1054 1061 18356633 similar JJ B-ADJP O
7 1062 1069 18356633 between IN B-PP O
8 1070 1073 18356633 the DT B-NP O
9 1074 1086 18356633 conventional JJ I-NP O
10 1087 1090 18356633 and CC I-NP O
11 1091 1099 18356633 extended JJ I-NP O
12 1099 1100 18356633 - HYPH I-NP O
13 1100 1108 18356633 interval NN I-NP O
14 1109 1115 18356633 groups NNS I-NP O
15 1115 1116 18356633 , , O O
16 1117 1119 18356633 at IN B-PP O
17 1120 1123 18356633 10% CD B-NP O
18 1124 1127 18356633 and CC I-NP O
19 1128 1130 18356633 5% CD I-NP O
20 1130 1131 18356633 , , O O
21 1132 1144 18356633 respectively RB B-ADVP O
22 1145 1146 18356633 ( ( O O
23 1146 1147 18356633 P NN B-NP O
24 1148 1149 18356633 = SYM B-VP O
25 1150 1154 18356633 1.00 CD B-NP O
26 1154 1155 18356633 ) ) O O
27 1155 1156 18356633 . . O O

1 1157 1160 18356633 Six CD B-NP O
2 1161 1169 18356633 patients NNS I-NP O
3 1170 1172 18356633 in IN B-PP O
4 1173 1176 18356633 the DT B-NP O
5 1177 1189 18356633 conventional JJ I-NP O
6 1190 1195 18356633 group NN I-NP O
7 1196 1199 18356633 had VBD B-VP O
8 1200 1201 18356633 a DT B-NP O
9 1202 1210 18356633 positive JJ I-NP O
10 1211 1218 18356633 culture NN I-NP O
11 1218 1219 18356633 , , O O
12 1220 1228 18356633 compared VBN B-PP O
13 1229 1233 18356633 with IN B-PP O
14 1234 1238 18356633 none NN B-NP O
15 1239 1241 18356633 in IN B-PP O
16 1242 1245 18356633 the DT B-NP O
17 1246 1254 18356633 extended VBN I-NP O
18 1254 1255 18356633 - HYPH I-NP O
19 1255 1263 18356633 interval NN I-NP O
20 1264 1269 18356633 group NN I-NP O
21 1270 1271 18356633 ( ( O O
22 1271 1272 18356633 P NN B-NP O
23 1273 1274 18356633 = SYM B-VP O
24 1275 1280 18356633 0.002 CD B-NP O
25 1280 1281 18356633 ) ) O O
26 1281 1282 18356633 . . O O

1 1283 1286 18356633 The DT B-NP O
2 1287 1297 18356633 occurrence NN I-NP O
3 1298 1300 18356633 of IN B-PP O
4 1301 1315 18356633 nephrotoxicity NN B-NP D007674
5 1316 1319 18356633 was VBD B-VP O
6 1320 1327 18356633 similar JJ B-ADJP O
7 1328 1335 18356633 between IN B-PP O
8 1336 1339 18356633 the DT B-NP O
9 1340 1343 18356633 two CD I-NP O
10 1344 1350 18356633 dosing NN I-NP O
11 1351 1359 18356633 regimens NNS I-NP O
12 1359 1360 18356633 , , O O
13 1361 1364 18356633 but CC O O
14 1365 1368 18356633 the DT B-NP O
15 1369 1381 18356633 distribution NN I-NP O
16 1382 1384 18356633 of IN B-PP O
17 1385 1389 18356633 risk NN B-NP O
18 1390 1397 18356633 factors NNS I-NP O
19 1398 1401 18356633 was VBD B-VP O
20 1402 1410 18356633 variable JJ B-ADJP O
21 1411 1418 18356633 between IN B-PP O
22 1419 1422 18356633 the DT B-NP O
23 1423 1426 18356633 two CD I-NP O
24 1427 1433 18356633 groups NNS I-NP O
25 1433 1434 18356633 . . O O

1 1435 1443 18356633 Efficacy NN B-NP O
2 1444 1449 18356633 could MD B-VP O
3 1450 1453 18356633 not RB I-VP O
4 1454 1456 18356633 be VB I-VP O
5 1457 1465 18356633 assessed VBN I-VP O
6 1465 1466 18356633 . . O O

1 0 0 15764424 -DOCSTART- -X- -X- O

1 0 12 15764424 Quantitative JJ B-NP O
2 13 17 15764424 drug NN I-NP O
3 18 24 15764424 levels NNS I-NP O
4 25 27 15764424 in IN B-PP O
5 28 37 15764424 stimulant JJ B-NP O
6 38 47 15764424 psychosis NN I-NP D011605
7 47 48 15764424 : : O O
8 49 61 15764424 relationship NN B-NP O
9 62 64 15764424 to TO B-PP O
10 65 72 15764424 symptom NN B-NP O
11 73 81 15764424 severity NN I-NP O
12 81 82 15764424 , , O O
13 83 97 15764424 catecholamines NNS B-NP D002395
14 98 101 15764424 and CC O O
15 102 114 15764424 hyperkinesia NN B-NP D006948
16 114 115 15764424 . . O O
17 116 118 15764424 To TO B-VP O
18 119 126 15764424 examine VB I-VP O
19 127 130 15764424 the DT B-NP O
20 131 143 15764424 relationship NN I-NP O
21 144 151 15764424 between IN B-PP O
22 152 164 15764424 quantitative JJ B-NP O
23 165 174 15764424 stimulant JJ I-NP O
24 175 179 15764424 drug NN I-NP O
25 180 186 15764424 levels NNS I-NP O
26 186 187 15764424 , , O O
27 188 202 15764424 catecholamines NNS B-NP D002395
28 202 203 15764424 , , O O
29 204 207 15764424 and CC O O
30 208 217 15764424 psychotic JJ B-NP D011605
31 218 226 15764424 symptoms NNS I-NP D011605
32 226 227 15764424 , , O O
33 228 236 15764424 nineteen CD B-NP O
34 237 245 15764424 patients NNS I-NP O
35 246 248 15764424 in IN B-PP O
36 249 250 15764424 a DT B-NP O
37 251 262 15764424 psychiatric JJ I-NP D001523
38 263 272 15764424 emergency NN I-NP O
39 273 280 15764424 service NN I-NP O
40 281 285 15764424 with IN B-PP O
41 286 287 15764424 a DT B-NP O
42 288 297 15764424 diagnosis NN I-NP O
43 298 300 15764424 of IN B-PP O
44 301 312 15764424 amphetamine NN B-NP D000661
45 312 313 15764424 - HYPH B-NP O
46 314 316 15764424 or CC I-NP O
47 317 324 15764424 cocaine NN I-NP D003042
48 324 325 15764424 - HYPH O O
49 325 332 15764424 induced VBN B-NP O
50 333 342 15764424 psychosis NN I-NP D011605
51 343 347 15764424 were VBD B-VP O
52 348 359 15764424 interviewed VBN I-VP O
53 359 360 15764424 , , O O
54 361 364 15764424 and CC O O
55 365 371 15764424 plasma NN B-NP O
56 372 375 15764424 and CC I-NP O
57 376 381 15764424 urine NN I-NP O
58 382 386 15764424 were VBD B-VP O
59 387 396 15764424 collected VBN I-VP O
60 397 400 15764424 for IN B-PP O
61 401 413 15764424 quantitative JJ B-NP O
62 414 420 15764424 assays NNS I-NP O
63 421 423 15764424 of IN B-PP O
64 424 433 15764424 stimulant NN B-NP O
65 434 438 15764424 drug NN I-NP O
66 439 442 15764424 and CC O O
67 443 456 15764424 catecholamine NN B-NP D002395
68 457 467 15764424 metabolite NN I-NP O
69 468 474 15764424 levels NNS I-NP O
70 474 475 15764424 . . O O

1 476 491 15764424 Methamphetamine NN B-NP D008694
2 492 494 15764424 or CC I-NP O
3 495 506 15764424 amphetamine NN I-NP D000661
4 507 513 15764424 levels NNS I-NP O
5 514 518 15764424 were VBD B-VP O
6 519 526 15764424 related VBN I-VP O
7 527 529 15764424 to TO B-PP O
8 530 537 15764424 several JJ B-NP O
9 538 553 15764424 psychopathology NN I-NP O
10 554 560 15764424 scores NNS I-NP O
11 561 564 15764424 and CC O O
12 565 568 15764424 the DT B-NP O
13 569 575 15764424 global JJ I-NP O
14 576 588 15764424 hyperkinesia NN I-NP D006948
15 589 595 15764424 rating NN I-NP O
16 595 596 15764424 . . O O

1 597 600 15764424 HVA NN B-NP O
2 601 607 15764424 levels NNS I-NP O
3 608 612 15764424 were VBD B-VP O
4 613 620 15764424 related VBN I-VP O
5 621 623 15764424 to TO B-PP O
6 624 630 15764424 global JJ B-NP O
7 631 643 15764424 hyperkinesia NN I-NP D006948
8 644 647 15764424 but CC B-PP O
9 648 651 15764424 not RB B-PP O
10 652 654 15764424 to TO I-PP O
11 655 670 15764424 psychopathology NN B-NP O
12 671 678 15764424 ratings NNS I-NP O
13 678 679 15764424 . . O O

1 680 688 15764424 Although IN B-SBAR O
2 689 693 15764424 many JJ B-NP O
3 694 699 15764424 other JJ I-NP O
4 700 707 15764424 factors NNS I-NP O
5 708 712 15764424 such JJ B-PP O
6 713 715 15764424 as IN I-PP O
7 716 729 15764424 sensitization NN B-NP O
8 730 733 15764424 may MD B-VP O
9 734 738 15764424 play VB I-VP O
10 739 740 15764424 a DT B-NP O
11 741 745 15764424 role NN I-NP O
12 745 746 15764424 , , O O
13 747 756 15764424 intensity NN B-NP O
14 757 759 15764424 of IN B-PP O
15 760 769 15764424 stimulant NN B-NP O
16 769 770 15764424 - HYPH O O
17 770 777 15764424 induced VBN B-NP O
18 778 787 15764424 psychotic JJ I-NP D011605
19 788 796 15764424 symptoms NNS I-NP D011605
20 797 800 15764424 and CC I-NP O
21 801 813 15764424 stereotypies NNS I-NP D019956
22 814 821 15764424 appears VBZ B-VP O
23 822 824 15764424 to TO I-VP O
24 825 827 15764424 be VB I-VP O
25 828 830 15764424 at IN B-ADVP O
26 831 836 15764424 least JJS I-ADVP O
27 837 839 15764424 in IN B-PP O
28 840 844 15764424 part NN B-NP O
29 845 849 15764424 dose NN I-NP O
30 849 850 15764424 - HYPH B-ADJP O
31 850 857 15764424 related VBN I-ADJP O
32 857 858 15764424 . . O O

1 0 0 3950060 -DOCSTART- -X- -X- O

1 0 7 3950060 Factors NNS B-NP O
2 8 18 3950060 associated VBN B-VP O
3 19 23 3950060 with IN B-PP O
4 24 38 3950060 nephrotoxicity NN B-NP D007674
5 39 42 3950060 and CC O O
6 43 51 3950060 clinical JJ B-NP O
7 52 59 3950060 outcome NN I-NP O
8 60 62 3950060 in IN B-PP O
9 63 71 3950060 patients NNS B-NP O
10 72 81 3950060 receiving VBG B-VP O
11 82 90 3950060 amikacin NN B-NP D000583
12 90 91 3950060 . . O O
13 92 96 3950060 Data NN B-NP O
14 97 101 3950060 from IN B-PP O
15 102 104 3950060 60 CD B-NP O
16 105 113 3950060 patients NNS I-NP O
17 114 121 3950060 treated VBN B-VP O
18 122 126 3950060 with IN B-PP O
19 127 135 3950060 amikacin NN B-NP D000583
20 136 140 3950060 were VBD B-VP O
21 141 149 3950060 analyzed VBN I-VP O
22 150 153 3950060 for IN B-PP O
23 154 161 3950060 factors NNS B-NP O
24 162 172 3950060 associated VBN B-VP O
25 173 177 3950060 with IN B-PP O
26 178 192 3950060 nephrotoxicity NN B-NP D007674
27 192 193 3950060 . . O O

1 194 196 3950060 In IN B-PP O
2 197 199 3950060 42 CD B-NP O
3 200 202 3950060 of IN B-PP O
4 203 208 3950060 these DT B-NP O
5 209 217 3950060 patients NNS I-NP O
6 217 218 3950060 , , O O
7 219 223 3950060 data NNS B-NP O
8 224 228 3950060 were VBD B-VP O
9 229 237 3950060 examined VBN I-VP O
10 238 241 3950060 for IN B-PP O
11 242 249 3950060 factors NNS B-NP O
12 250 260 3950060 associated VBN B-VP O
13 261 265 3950060 with IN B-PP O
14 266 274 3950060 clinical JJ B-NP O
15 275 282 3950060 outcome NN I-NP O
16 282 283 3950060 . . O O

1 284 293 3950060 Variables NNS B-NP O
2 294 303 3950060 evaluated VBN B-VP O
3 304 312 3950060 included VBD B-VP O
4 313 320 3950060 patient NN B-NP O
5 321 327 3950060 weight NN I-NP O
6 327 328 3950060 , , O O
7 329 332 3950060 age NN B-NP O
8 332 333 3950060 , , O O
9 334 337 3950060 sex NN B-NP O
10 337 338 3950060 , , O O
11 339 344 3950060 serum NN B-NP O
12 345 355 3950060 creatinine NN I-NP D003404
13 356 361 3950060 level NN I-NP O
14 361 362 3950060 , , O O
15 363 373 3950060 creatinine NN B-NP D003404
16 374 383 3950060 clearance NN I-NP O
17 383 384 3950060 , , O O
18 385 393 3950060 duration NN B-NP O
19 394 396 3950060 of IN B-PP O
20 397 404 3950060 therapy NN B-NP O
21 404 405 3950060 , , O O
22 406 411 3950060 total JJ B-NP O
23 412 416 3950060 dose NN I-NP O
24 416 417 3950060 , , O O
25 418 422 3950060 mean JJ B-NP O
26 423 428 3950060 daily JJ I-NP O
27 429 433 3950060 dose NN I-NP O
28 433 434 3950060 , , O O
29 435 443 3950060 organism NN B-NP O
30 444 451 3950060 minimum JJ I-NP O
31 452 462 3950060 inhibitory JJ I-NP O
32 463 476 3950060 concentration NN I-NP O
33 477 478 3950060 ( ( O O
34 478 481 3950060 MIC NN B-NP O
35 481 482 3950060 ) ) O O
36 482 483 3950060 , , O O
37 484 488 3950060 mean JJ B-NP O
38 489 493 3950060 peak JJ I-NP O
39 494 500 3950060 levels NNS I-NP O
40 500 501 3950060 , , O O
41 502 506 3950060 mean JJ B-NP O
42 507 513 3950060 trough NN I-NP O
43 514 520 3950060 levels NNS I-NP O
44 520 521 3950060 , , O O
45 522 526 3950060 mean JJ B-NP O
46 527 531 3950060 area NN I-NP O
47 532 537 3950060 under IN B-PP O
48 538 541 3950060 the DT B-NP O
49 542 547 3950060 serum NN I-NP O
50 548 561 3950060 concentration NN I-NP O
51 561 562 3950060 - HYPH O O
52 562 566 3950060 time NN B-NP O
53 567 572 3950060 curve NN I-NP O
54 573 574 3950060 ( ( O O
55 574 577 3950060 AUC NN B-NP O
56 577 578 3950060 ) ) O O
57 578 579 3950060 , , O O
58 580 585 3950060 total JJ B-NP O
59 586 589 3950060 AUC NN I-NP O
60 589 590 3950060 , , O O
61 591 595 3950060 mean JJ B-NP O
62 596 599 3950060 AUC NN I-NP O
63 600 607 3950060 greater JJR B-ADJP O
64 608 612 3950060 than IN B-PP O
65 613 616 3950060 MIC NN B-NP O
66 616 617 3950060 , , O O
67 618 623 3950060 total JJ B-NP O
68 624 627 3950060 AUC NN I-NP O
69 628 635 3950060 greater JJR B-ADJP O
70 636 640 3950060 than IN B-PP O
71 641 644 3950060 MIC NN B-NP O
72 644 645 3950060 , , O O
73 646 650 3950060 mean JJ B-NP O
74 651 663 3950060 Schumacher's NNP I-NP O
75 664 673 3950060 intensity NN I-NP O
76 674 680 3950060 factor NN I-NP O
77 681 682 3950060 ( ( O O
78 682 684 3950060 IF NN B-NP O
79 684 685 3950060 ) ) O O
80 685 686 3950060 , , O O
81 687 692 3950060 total JJ B-NP O
82 693 695 3950060 IF NN I-NP O
83 695 696 3950060 , , O O
84 697 699 3950060 In IN B-PP O
85 700 701 3950060 ( ( O O
86 701 705 3950060 mean JJ B-NP O
87 706 713 3950060 maximum JJ I-NP O
88 714 727 3950060 concentration NN I-NP O
89 728 729 3950060 [ ( O O
90 729 733 3950060 Cmax NN B-NP O
91 733 734 3950060 ] ) O O
92 734 735 3950060 / SYM B-NP O
93 735 738 3950060 MIC NN I-NP O
94 738 739 3950060 ) ) O O
95 739 740 3950060 . . O O

1 741 746 3950060 Model NN B-NP O
2 746 747 3950060 - HYPH I-NP O
3 747 756 3950060 dependent JJ I-NP O
4 757 772 3950060 pharmacokinetic JJ I-NP O
5 773 783 3950060 parameters NNS I-NP O
6 784 788 3950060 were VBD B-VP O
7 789 799 3950060 calculated VBN I-VP O
8 800 802 3950060 by IN B-PP O
9 803 811 3950060 computer NN B-NP O
10 812 817 3950060 based VBN B-VP O
11 818 820 3950060 on IN B-PP O
12 821 822 3950060 a DT B-NP O
13 823 826 3950060 one CD I-NP O
14 826 827 3950060 - HYPH I-NP O
15 827 838 3950060 compartment NN I-NP O
16 839 844 3950060 model NN I-NP O
17 844 845 3950060 . . O O

1 846 850 3950060 When WRB B-ADVP O
2 851 854 3950060 the DT B-NP O
3 855 865 3950060 parameters NNS I-NP O
4 866 870 3950060 were VBD B-VP O
5 871 879 3950060 examined VBN I-VP O
6 880 892 3950060 individually RB B-ADVP O
7 892 893 3950060 , , O O
8 894 902 3950060 duration NN B-NP O
9 903 905 3950060 of IN B-PP O
10 906 913 3950060 therapy NN B-NP O
11 914 917 3950060 and CC O O
12 918 923 3950060 total JJ B-NP O
13 924 927 3950060 AUC NN I-NP O
14 928 938 3950060 correlated VBD B-VP O
15 939 952 3950060 significantly RB B-ADVP O
16 953 954 3950060 ( ( O O
17 954 955 3950060 P NN B-NP O
18 956 960 3950060 less JJR B-ADJP O
19 961 965 3950060 than IN B-PP O
20 966 969 3950060 .05 CD B-NP O
21 969 970 3950060 ) ) O O
22 971 975 3950060 with IN B-PP O
23 976 990 3950060 nephrotoxicity NN B-NP D007674
24 990 991 3950060 . . O O

1 992 994 3950060 In IN B-PP O
2 995 1003 3950060 contrast NN B-NP O
3 1003 1004 3950060 , , O O
4 1005 1006 3950060 a DT B-NP O
5 1007 1015 3950060 stepwise JJ I-NP O
6 1016 1028 3950060 discriminant JJ I-NP O
7 1029 1037 3950060 function NN I-NP O
8 1038 1046 3950060 analysis NN I-NP O
9 1047 1057 3950060 identified VBD B-VP O
10 1058 1062 3950060 only RB B-NP O
11 1063 1071 3950060 duration NN I-NP O
12 1072 1074 3950060 of IN B-PP O
13 1075 1082 3950060 therapy NN B-NP O
14 1083 1084 3950060 ( ( O O
15 1084 1085 3950060 P NN B-NP O
16 1086 1090 3950060 less JJR B-ADJP O
17 1091 1095 3950060 than IN B-PP O
18 1096 1100 3950060 .001 CD B-NP O
19 1100 1101 3950060 ) ) O O
20 1102 1104 3950060 as IN B-PP O
21 1105 1107 3950060 an DT B-NP O
22 1108 1117 3950060 important JJ I-NP O
23 1118 1124 3950060 factor NN I-NP O
24 1124 1125 3950060 . . O O

1 1126 1131 3950060 Based VBN B-PP O
2 1132 1134 3950060 on IN B-PP O
3 1135 1139 3950060 this DT B-NP O
4 1140 1145 3950060 model NN I-NP O
5 1146 1149 3950060 and CC B-PP O
6 1150 1152 3950060 on IN B-PP O
7 1153 1159 3950060 Bayes' NN B-NP O
8 1160 1167 3950060 theorem NN I-NP O
9 1167 1168 3950060 , , O O
10 1169 1172 3950060 the DT B-NP O
11 1173 1183 3950060 predictive JJ I-NP O
12 1184 1192 3950060 accuracy NN I-NP O
13 1193 1195 3950060 of IN B-PP O
14 1196 1207 3950060 identifying VBG B-VP O
15 1208 1209 3950060 " `` B-NP O
16 1209 1220 3950060 nephrotoxic JJ I-NP D007674
17 1220 1221 3950060 " '' I-NP O
18 1222 1230 3950060 patients NNS I-NP O
19 1231 1240 3950060 increased VBD B-VP O
20 1241 1245 3950060 from IN B-PP O
21 1246 1250 3950060 0.17 CD B-NP O
22 1251 1253 3950060 to TO B-PP O
23 1254 1258 3950060 0.39 CD B-NP O
24 1258 1259 3950060 . . O O

1 1260 1264 3950060 When WRB B-ADVP O
2 1265 1273 3950060 examined VBN B-VP O
3 1274 1286 3950060 individually RB B-ADVP O
4 1286 1287 3950060 , , O O
5 1288 1292 3950060 mean JJ B-NP O
6 1293 1295 3950060 IF NNP I-NP O
7 1295 1296 3950060 , , O O
8 1297 1300 3950060 MIC NNP B-NP O
9 1300 1301 3950060 , , O O
10 1302 1307 3950060 total JJ B-NP O
11 1308 1312 3950060 dose NN I-NP O
12 1312 1313 3950060 , , O O
13 1314 1318 3950060 mean JJ B-NP O
14 1319 1324 3950060 daily JJ I-NP O
15 1325 1329 3950060 dose NN I-NP O
16 1329 1330 3950060 , , O O
17 1331 1334 3950060 and CC O O
18 1335 1337 3950060 ln NN B-NP O
19 1338 1339 3950060 ( ( O O
20 1339 1343 3950060 mean JJ B-NP O
21 1344 1348 3950060 Cmax NN I-NP O
22 1348 1349 3950060 / SYM B-NP O
23 1349 1352 3950060 MIC NN I-NP O
24 1352 1353 3950060 ) ) O O
25 1354 1364 3950060 correlated VBD B-VP O
26 1365 1378 3950060 significantly RB B-ADVP O
27 1379 1380 3950060 ( ( O O
28 1380 1381 3950060 P NN B-NP O
29 1382 1386 3950060 less JJR B-ADJP O
30 1387 1391 3950060 than IN B-PP O
31 1392 1395 3950060 .05 CD B-NP O
32 1395 1396 3950060 ) ) O O
33 1397 1401 3950060 with IN B-PP O
34 1402 1406 3950060 cure NN B-NP O
35 1406 1407 3950060 . . O O

1 1408 1410 3950060 In IN B-PP O
2 1411 1419 3950060 contrast NN B-NP O
3 1419 1420 3950060 , , O O
4 1421 1422 3950060 a DT B-NP O
5 1423 1435 3950060 simultaneous JJ I-NP O
6 1436 1449 3950060 multivariable JJ I-NP O
7 1450 1458 3950060 analysis NN I-NP O
8 1459 1469 3950060 identified VBD B-VP O
9 1470 1472 3950060 IF NN B-NP O
10 1472 1473 3950060 , , O O
11 1474 1477 3950060 MIC NN B-NP O
12 1477 1478 3950060 , , O O
13 1479 1482 3950060 and CC O O
14 1483 1488 3950060 total JJ B-NP O
15 1489 1493 3950060 dose NN I-NP O
16 1494 1503 3950060 according VBG B-PP O
17 1504 1506 3950060 to TO B-PP O
18 1507 1510 3950060 one CD B-NP O
19 1511 1516 3950060 model NN I-NP O
20 1517 1520 3950060 and CC O O
21 1521 1523 3950060 ln NN B-NP O
22 1524 1525 3950060 ( ( O O
23 1525 1529 3950060 mean JJ B-NP O
24 1530 1534 3950060 Cmax NN I-NP O
25 1534 1535 3950060 / SYM B-NP O
26 1535 1538 3950060 MIC NN I-NP O
27 1538 1539 3950060 ) ) O O
28 1540 1549 3950060 according VBG B-PP O
29 1550 1552 3950060 to TO B-PP O
30 1553 1554 3950060 a DT B-NP O
31 1555 1561 3950060 second JJ I-NP O
32 1562 1573 3950060 statistical JJ I-NP O
33 1574 1579 3950060 model NN I-NP O
34 1580 1582 3950060 of IN B-PP O
35 1583 1593 3950060 parameters NNS B-NP O
36 1594 1602 3950060 selected VBN B-VP O
37 1603 1605 3950060 to TO I-VP O
38 1606 1610 3950060 have VB I-VP O
39 1611 1614 3950060 the DT B-NP O
40 1615 1623 3950060 greatest JJS I-NP O
41 1624 1635 3950060 prospective JJ I-NP O
42 1636 1641 3950060 value NN I-NP O
43 1641 1642 3950060 . . O O

1 1643 1648 3950060 Based VBN B-PP O
2 1649 1651 3950060 on IN B-PP O
3 1652 1658 3950060 Bayes' NN B-NP O
4 1659 1666 3950060 theorem NN I-NP O
5 1667 1670 3950060 and CC O O
6 1671 1674 3950060 the DT B-NP O
7 1675 1680 3950060 first JJ I-NP O
8 1681 1686 3950060 model NN I-NP O
9 1686 1687 3950060 , , O O
10 1688 1691 3950060 the DT B-NP O
11 1692 1702 3950060 predictive JJ I-NP O
12 1703 1711 3950060 accuracy NN I-NP O
13 1712 1714 3950060 of IN B-PP O
14 1715 1726 3950060 identifying VBG B-VP O
15 1727 1735 3950060 patients NNS B-NP O
16 1736 1739 3950060 not RB B-VP O
17 1740 1745 3950060 cured VBN I-VP O
18 1746 1755 3950060 increased VBD B-VP O
19 1756 1760 3950060 from IN B-PP O
20 1761 1765 3950060 0.19 CD B-NP O
21 1766 1768 3950060 to TO B-PP O
22 1769 1773 3950060 0.83 CD B-NP O
23 1773 1774 3950060 . . O O

1 1775 1778 3950060 For IN B-PP O
2 1779 1782 3950060 the DT B-NP O
3 1783 1789 3950060 second JJ I-NP O
4 1790 1795 3950060 model NN I-NP O
5 1795 1796 3950060 , , O O
6 1797 1800 3950060 the DT B-NP O
7 1801 1811 3950060 predictive JJ I-NP O
8 1812 1820 3950060 accuracy NN I-NP O
9 1821 1830 3950060 increased VBD B-VP O
10 1831 1835 3950060 from IN B-PP O
11 1836 1840 3950060 0.19 CD B-NP O
12 1841 1843 3950060 to TO B-PP O
13 1844 1858 3950060 0.50.(ABSTRACT NN B-NP O
14 1859 1868 3950060 TRUNCATED VBN B-VP O
15 1869 1871 3950060 AT IN B-PP O
16 1872 1875 3950060 250 CD B-NP O
17 1876 1881 3950060 WORDS NNS I-NP O
18 1881 1882 3950060 ) ) O O

1 0 0 7102237 -DOCSTART- -X- -X- O

1 0 9 7102237 Midazolam NN B-NP D008874
2 10 18 7102237 compared VBN B-PP O
3 19 23 7102237 with IN B-PP O
4 24 35 7102237 thiopentone NN B-NP D013874
5 36 38 7102237 as IN B-PP O
6 39 41 7102237 an DT B-NP O
7 42 51 7102237 induction NN I-NP O
8 52 57 7102237 agent NN I-NP O
9 57 58 7102237 . . O O
10 59 61 7102237 In IN B-PP O
11 62 70 7102237 patients NNS B-NP O
12 71 83 7102237 premedicated VBN B-VP O
13 84 88 7102237 with IN B-PP O
14 89 100 7102237 scopolamine NN B-NP D012601
15 101 102 7102237 + SYM B-NP O
16 103 111 7102237 morphine NN I-NP D009020
17 112 113 7102237 ( ( O O
18 113 114 7102237 + SYM B-NP O
19 114 115 7102237 5 CD I-NP O
20 116 118 7102237 mg NN I-NP O
21 119 129 7102237 nitrazepam NN I-NP D009567
22 130 133 7102237 the DT B-NP O
23 134 141 7102237 evening NN I-NP O
24 142 148 7102237 before IN B-PP O
25 149 156 7102237 surgery NN B-NP O
26 156 157 7102237 ) ) O O
27 157 158 7102237 , , O O
28 159 162 7102237 the DT B-NP O
29 163 168 7102237 sleep NN I-NP O
30 168 169 7102237 - HYPH O O
31 169 177 7102237 inducing VBG B-VP O
32 178 184 7102237 effect NN B-NP O
33 185 187 7102237 of IN B-PP O
34 188 197 7102237 midazolam NN B-NP D008874
35 198 202 7102237 0.15 CD I-NP O
36 203 205 7102237 mg NN I-NP O
37 205 206 7102237 / SYM B-NP O
38 206 208 7102237 kg NN I-NP O
39 209 212 7102237 i.v NN I-NP O
40 212 213 7102237 . . O O

1 214 217 7102237 was VBD B-VP O
2 218 225 7102237 clearly RB B-ADJP O
3 226 232 7102237 slower JJR I-ADJP O
4 233 235 7102237 in IN B-PP O
5 236 241 7102237 onset NN B-NP O
6 242 246 7102237 than IN B-PP O
7 247 251 7102237 that DT B-NP O
8 252 254 7102237 of IN B-PP O
9 255 266 7102237 thiopentone NN B-NP D013874
10 267 271 7102237 4.67 CD I-NP O
11 272 274 7102237 mg NN I-NP O
12 274 275 7102237 / SYM B-NP O
13 275 277 7102237 kg NN I-NP O
14 278 281 7102237 i.v NN I-NP O
15 281 282 7102237 . . O O

1 283 291 7102237 Somewhat RB B-NP O
2 292 297 7102237 fewer JJR I-NP O
3 298 312 7102237 cardiovascular JJ I-NP O
4 313 316 7102237 and CC I-NP O
5 317 322 7102237 local JJ I-NP O
6 323 331 7102237 sequelae NNS I-NP O
7 332 336 7102237 were VBD B-VP O
8 337 342 7102237 found VBN I-VP O
9 343 345 7102237 in IN B-PP O
10 346 349 7102237 the DT B-NP O
11 350 359 7102237 midazolam NN I-NP D008874
12 360 365 7102237 group NN I-NP O
13 365 366 7102237 , , O O
14 367 370 7102237 but CC O O
15 370 371 7102237 , , O O
16 372 380 7102237 although IN B-SBAR O
17 381 387 7102237 apnoea NN B-NP D001049
18 388 396 7102237 occurred VBD B-VP O
19 397 401 7102237 less RBR B-ADVP O
20 402 407 7102237 often RB I-ADVP O
21 408 410 7102237 in IN B-PP O
22 411 414 7102237 the DT B-NP O
23 415 424 7102237 midazolam NN I-NP D008874
24 425 430 7102237 group NN I-NP O
25 431 433 7102237 it PRP B-NP O
26 434 440 7102237 lasted VBD B-VP O
27 441 447 7102237 longer RBR B-ADVP O
28 447 448 7102237 . . O O

1 449 451 7102237 On IN B-PP O
2 452 455 7102237 the DT B-NP O
3 456 461 7102237 whole NN I-NP O
4 461 462 7102237 , , O O
5 463 466 7102237 the DT B-NP O
6 467 478 7102237 differences NNS I-NP O
7 479 486 7102237 between IN B-PP O
8 487 496 7102237 midazolam NN B-NP D008874
9 497 500 7102237 and CC I-NP O
10 501 512 7102237 thiopentone NN I-NP D013874
11 513 516 7102237 had VBD B-VP O
12 517 519 7102237 no DT B-NP O
13 520 528 7102237 apparent JJ I-NP O
14 529 537 7102237 clinical JJ I-NP O
15 538 550 7102237 consequences NNS I-NP O
16 550 551 7102237 . . O O

1 552 561 7102237 Midazolam NN B-NP D008874
2 562 564 7102237 is VBZ B-VP O
3 565 566 7102237 a DT B-NP O
4 567 570 7102237 new JJ I-NP O
5 571 582 7102237 alternative JJ I-NP O
6 583 588 7102237 agent NN I-NP O
7 589 592 7102237 for IN B-PP O
8 593 602 7102237 induction NN B-NP O
9 603 605 7102237 in IN B-PP O
10 606 617 7102237 combination NN B-NP O
11 618 629 7102237 anaesthesia NN I-NP O
12 629 630 7102237 . . O O

1 0 0 7710775 -DOCSTART- -X- -X- O

1 0 4 7710775 Time NN B-NP O
2 5 15 7710775 dependence NN I-NP O
3 16 18 7710775 of IN B-PP O
4 19 25 7710775 plasma NN B-NP O
5 26 41 7710775 malondialdehyde NN I-NP D008315
6 41 42 7710775 , , O O
7 43 53 7710775 oxypurines NNS B-NP -1
8 53 54 7710775 , , O O
9 55 58 7710775 and CC O O
10 59 70 7710775 nucleosides NNS B-NP D009705
11 71 77 7710775 during IN B-PP O
12 78 88 7710775 incomplete JJ B-NP O
13 89 97 7710775 cerebral JJ I-NP D002545
14 98 106 7710775 ischemia NN I-NP D002545
15 107 109 7710775 in IN B-PP O
16 110 113 7710775 the DT B-NP O
17 114 117 7710775 rat NN I-NP O
18 117 118 7710775 . . O O
19 119 129 7710775 Incomplete JJ B-NP O
20 130 138 7710775 cerebral JJ I-NP D002545
21 139 147 7710775 ischemia NN I-NP D002545
22 148 149 7710775 ( ( O O
23 149 151 7710775 30 CD B-NP O
24 152 155 7710775 min NN I-NP O
25 155 156 7710775 ) ) O O
26 157 160 7710775 was VBD B-VP O
27 161 168 7710775 induced VBN I-VP O
28 169 171 7710775 in IN B-PP O
29 172 175 7710775 the DT B-NP O
30 176 179 7710775 rat NN I-NP O
31 180 182 7710775 by IN B-PP O
32 183 194 7710775 bilaterally RB B-VP O
33 195 203 7710775 clamping VBG I-VP O
34 204 207 7710775 the DT B-NP O
35 208 214 7710775 common JJ I-NP O
36 215 222 7710775 carotid NN I-NP O
37 223 231 7710775 arteries NNS I-NP O
38 231 232 7710775 . . O O

1 233 243 7710775 Peripheral JJ B-NP O
2 244 250 7710775 venous JJ I-NP O
3 251 256 7710775 blood NN I-NP O
4 257 264 7710775 samples NNS I-NP O
5 265 269 7710775 were VBD B-VP O
6 270 279 7710775 withdrawn VBN I-VP O
7 280 284 7710775 from IN B-PP O
8 285 288 7710775 the DT B-NP O
9 289 296 7710775 femoral JJ I-NP O
10 297 301 7710775 vein NN I-NP O
11 302 306 7710775 four CD B-NP O
12 307 312 7710775 times NNS I-NP O
13 313 314 7710775 ( ( O O
14 314 318 7710775 once RB B-ADVP O
15 319 324 7710775 every DT B-NP O
16 325 326 7710775 5 CD I-NP O
17 327 330 7710775 min NN I-NP O
18 330 331 7710775 ) ) O O
19 332 338 7710775 before IN B-PP O
20 339 347 7710775 ischemia NN B-NP D007511
21 348 349 7710775 ( ( O O
22 349 350 7710775 0 CD B-NP O
23 351 355 7710775 time NN I-NP O
24 355 356 7710775 ) ) O O
25 357 360 7710775 and CC O O
26 361 362 7710775 5 CD B-NP O
27 362 363 7710775 , , I-NP O
28 364 366 7710775 15 CD I-NP O
29 366 367 7710775 , , O O
30 368 371 7710775 and CC O O
31 372 374 7710775 30 CD B-NP O
32 375 378 7710775 min NN I-NP O
33 379 384 7710775 after IN B-PP O
34 385 393 7710775 ischemia NN B-NP D007511
35 393 394 7710775 . . O O

1 395 401 7710775 Plasma NN B-NP O
2 402 410 7710775 extracts NNS I-NP O
3 411 415 7710775 were VBD B-VP O
4 416 424 7710775 analyzed VBN I-VP O
5 425 427 7710775 by IN B-PP O
6 428 429 7710775 a DT B-NP O
7 430 436 7710775 highly RB I-NP O
8 437 446 7710775 sensitive JJ I-NP O
9 447 451 7710775 high JJ I-NP O
10 451 452 7710775 - HYPH I-NP O
11 452 463 7710775 performance NN I-NP O
12 464 470 7710775 liquid JJ I-NP O
13 471 486 7710775 chromatographic JJ I-NP O
14 487 493 7710775 method NN I-NP O
15 494 497 7710775 for IN B-PP O
16 498 501 7710775 the DT B-NP O
17 502 508 7710775 direct JJ I-NP O
18 509 522 7710775 determination NN I-NP O
19 523 525 7710775 of IN B-PP O
20 526 541 7710775 malondialdehyde NN B-NP D008315
21 541 542 7710775 , , O O
22 543 553 7710775 oxypurines NNS B-NP -1
23 553 554 7710775 , , O O
24 555 558 7710775 and CC O O
25 559 570 7710775 nucleosides NNS B-NP D009705
26 570 571 7710775 . . O O

1 572 578 7710775 During IN B-PP O
2 579 587 7710775 ischemia NN B-NP D007511
3 587 588 7710775 , , O O
4 589 590 7710775 a DT B-NP O
5 591 595 7710775 time NN I-NP O
6 595 596 7710775 - HYPH B-NP O
7 596 605 7710775 dependent JJ I-NP O
8 606 614 7710775 increase NN I-NP O
9 615 617 7710775 of IN B-PP O
10 618 624 7710775 plasma NN B-NP O
11 625 635 7710775 oxypurines NNS I-NP -1
12 636 639 7710775 and CC I-NP O
13 640 651 7710775 nucleosides NNS I-NP D009705
14 652 655 7710775 was VBD B-VP O
15 656 664 7710775 observed VBN I-VP O
16 664 665 7710775 . . O O

1 666 672 7710775 Plasma NN B-NP O
2 673 688 7710775 malondialdehyde NN I-NP D008315
3 688 689 7710775 , , O O
4 690 695 7710775 which WDT B-NP O
5 696 699 7710775 was VBD B-VP O
6 700 707 7710775 present JJ B-ADJP O
7 708 710 7710775 in IN B-PP O
8 711 718 7710775 minimal JJ B-NP O
9 719 725 7710775 amount NN I-NP O
10 726 728 7710775 at IN B-PP O
11 729 733 7710775 zero CD B-NP O
12 734 738 7710775 time NN I-NP O
13 739 740 7710775 ( ( O O
14 740 745 7710775 0.058 CD B-NP O
15 746 751 7710775 mumol NN I-NP O
16 751 752 7710775 / SYM B-NP O
17 752 757 7710775 liter NN I-NP O
18 758 764 7710775 plasma NN I-NP O
19 764 765 7710775 ; : O O
20 766 768 7710775 SD NN B-NP O
21 769 774 7710775 0.015 CD I-NP O
22 774 775 7710775 ) ) O O
23 775 776 7710775 , , O O
24 777 786 7710775 increased VBD B-VP O
25 787 792 7710775 after IN B-PP O
26 793 794 7710775 5 CD B-NP O
27 795 798 7710775 min NN I-NP O
28 799 801 7710775 of IN B-PP O
29 802 810 7710775 ischemia NN B-NP D007511
30 810 811 7710775 , , O O
31 812 821 7710775 resulting VBG B-VP O
32 822 824 7710775 in IN B-PP O
33 825 826 7710775 a DT B-NP O
34 827 835 7710775 fivefold JJ I-NP O
35 836 844 7710775 increase NN I-NP O
36 845 850 7710775 after IN B-PP O
37 851 853 7710775 30 CD B-NP O
38 854 857 7710775 min NN I-NP O
39 858 860 7710775 of IN B-PP O
40 861 868 7710775 carotid NN B-NP O
41 869 878 7710775 occlusion NN I-NP O
42 879 880 7710775 ( ( O O
43 880 885 7710775 0.298 CD B-NP O
44 886 891 7710775 mumol NN I-NP O
45 891 892 7710775 / SYM B-NP O
46 892 897 7710775 liter NN I-NP O
47 898 904 7710775 plasma NN I-NP O
48 904 905 7710775 ; : O O
49 906 908 7710775 SD NN B-NP O
50 909 914 7710775 0.078 CD I-NP O
51 914 915 7710775 ) ) O O
52 915 916 7710775 . . O O

1 917 926 7710775 Increased VBN B-NP O
2 927 933 7710775 plasma NN I-NP O
3 934 949 7710775 malondialdehyde NN I-NP D008315
4 950 953 7710775 was VBD B-VP O
5 954 958 7710775 also RB I-VP O
6 959 967 7710775 recorded VBN I-VP O
7 968 970 7710775 in IN B-PP O
8 971 974 7710775 two CD B-NP O
9 975 980 7710775 other JJ I-NP O
10 981 987 7710775 groups NNS I-NP O
11 988 990 7710775 of IN B-PP O
12 991 998 7710775 animals NNS B-NP O
13 999 1008 7710775 subjected VBN B-VP O
14 1009 1011 7710775 to TO B-PP O
15 1012 1015 7710775 the DT B-NP O
16 1016 1020 7710775 same JJ I-NP O
17 1021 1033 7710775 experimental JJ I-NP O
18 1034 1039 7710775 model NN I-NP O
19 1039 1040 7710775 , , O O
20 1041 1044 7710775 one CD B-NP O
21 1045 1054 7710775 receiving VBG B-VP O
22 1055 1057 7710775 20 CD B-NP O
23 1058 1060 7710775 mg NN I-NP O
24 1060 1061 7710775 / SYM O O
25 1061 1063 7710775 kg NN B-NP O
26 1064 1067 7710775 b.w NN I-NP O
27 1067 1068 7710775 . . O O

1 1069 1071 7710775 of IN B-PP O
2 1072 1075 7710775 the DT B-NP O
3 1076 1090 7710775 cyclooxygenase NN I-NP O
4 1091 1100 7710775 inhibitor NN I-NP O
5 1101 1117 7710775 acetylsalicylate NN I-NP D001241
6 1118 1131 7710775 intravenously RB B-ADVP O
7 1132 1143 7710775 immediately RB I-ADVP O
8 1144 1150 7710775 before IN B-PP O
9 1151 1159 7710775 ischemia NN B-NP D007511
10 1159 1160 7710775 , , O O
11 1161 1164 7710775 the DT B-NP O
12 1165 1170 7710775 other JJ I-NP O
13 1171 1180 7710775 receiving VBG B-VP O
14 1181 1184 7710775 650 CD B-NP O
15 1185 1195 7710775 micrograms NNS I-NP O
16 1195 1196 7710775 / SYM B-NP O
17 1196 1198 7710775 kg NN I-NP O
18 1199 1202 7710775 b.w NN I-NP O
19 1202 1203 7710775 . . O O

1 1204 1206 7710775 of IN B-PP O
2 1207 1210 7710775 the DT B-NP O
3 1211 1222 7710775 hypotensive JJ I-NP D007022
4 1223 1227 7710775 drug NN I-NP O
5 1228 1241 7710775 nitroprusside NN I-NP D009599
6 1242 1244 7710775 at IN B-PP O
7 1245 1246 7710775 a DT B-NP O
8 1247 1251 7710775 flow NN I-NP O
9 1252 1256 7710775 rate NN I-NP O
10 1257 1259 7710775 of IN B-PP O
11 1260 1263 7710775 103 CD B-NP O
12 1264 1275 7710775 microliters NNS I-NP O
13 1275 1276 7710775 / SYM B-NP O
14 1276 1279 7710775 min NN I-NP O
15 1280 1293 7710775 intravenously RB B-ADVP O
16 1294 1300 7710775 during IN B-PP O
17 1301 1309 7710775 ischemia NN B-NP D007511
18 1309 1310 7710775 , , O O
19 1311 1319 7710775 although IN B-SBAR O
20 1320 1322 7710775 in IN B-PP O
21 1323 1327 7710775 this DT B-NP O
22 1328 1334 7710775 latter JJ I-NP O
23 1335 1340 7710775 group NN I-NP O
24 1341 1356 7710775 malondialdehyde NN I-NP D008315
25 1357 1360 7710775 was VBD B-VP O
26 1361 1374 7710775 significantly RB B-ADJP O
27 1375 1381 7710775 higher JJR I-ADJP O
28 1381 1382 7710775 . . O O

1 1383 1386 7710775 The DT B-NP O
2 1387 1394 7710775 present JJ I-NP O
3 1395 1399 7710775 data NNS I-NP O
4 1400 1408 7710775 indicate VBP B-VP O
5 1409 1413 7710775 that IN B-SBAR O
6 1414 1417 7710775 the DT B-NP O
7 1418 1431 7710775 determination NN I-NP O
8 1432 1434 7710775 of IN B-PP O
9 1435 1450 7710775 malondialdehyde NN B-NP D008315
10 1450 1451 7710775 , , O O
11 1452 1462 7710775 oxypurines NNS B-NP -1
12 1462 1463 7710775 , , O O
13 1464 1467 7710775 and CC O O
14 1468 1479 7710775 nucleosides NNS B-NP D009705
15 1480 1482 7710775 in IN B-PP O
16 1483 1493 7710775 peripheral JJ B-NP O
17 1494 1499 7710775 blood NN I-NP O
18 1499 1500 7710775 , , O O
19 1501 1504 7710775 may MD B-VP O
20 1505 1507 7710775 be VB I-VP O
21 1508 1512 7710775 used VBN I-VP O
22 1513 1515 7710775 to TO B-VP O
23 1516 1523 7710775 monitor VB I-VP O
24 1524 1527 7710775 the DT B-NP O
25 1528 1537 7710775 metabolic JJ I-NP O
26 1538 1549 7710775 alterations NNS I-NP O
27 1550 1552 7710775 of IN B-PP O
28 1553 1560 7710775 tissues NNS B-NP O
29 1561 1570 7710775 occurring VBG B-VP O
30 1571 1577 7710775 during IN B-PP O
31 1578 1586 7710775 ischemic JJ B-NP D007511
32 1587 1606 7710775 phenomena.(ABSTRACT NN I-NP O
33 1607 1616 7710775 TRUNCATED VBN B-VP O
34 1617 1619 7710775 AT IN B-PP O
35 1620 1623 7710775 250 CD B-NP O
36 1624 1629 7710775 WORDS NNS I-NP O
37 1629 1630 7710775 ) ) O O

1 0 0 8251368 -DOCSTART- -X- -X- O

1 0 16 8251368 Photodistributed VBN B-NP O
2 17 27 8251368 nifedipine NN I-NP D009543
3 27 28 8251368 - HYPH B-VP O
4 28 35 8251368 induced VBN B-NP O
5 36 42 8251368 facial JJ I-NP O
6 43 57 8251368 telangiectasia NN I-NP D013684
7 57 58 8251368 . . O O
8 59 63 8251368 Five CD B-NP O
9 64 70 8251368 months NNS I-NP O
10 71 76 8251368 after IN B-PP O
11 77 85 8251368 starting VBG B-VP O
12 86 96 8251368 nifedipine NN B-NP D009543
13 97 98 8251368 ( ( O O
14 98 104 8251368 Adalat NN B-NP D009543
15 104 105 8251368 ) ) O O
16 105 106 8251368 , , O O
17 107 110 8251368 two CD B-NP O
18 111 119 8251368 patients NNS I-NP O
19 120 129 8251368 developed VBD B-VP O
20 130 146 8251368 photodistributed VBN I-VP O
21 147 153 8251368 facial JJ B-NP O
22 154 168 8251368 telangiectasia NN I-NP D013684
23 168 169 8251368 , , O O
24 170 175 8251368 which WDT B-NP O
25 176 182 8251368 became VBD B-VP O
26 183 187 8251368 more RBR B-ADJP O
27 188 198 8251368 noticeable JJ I-ADJP O
28 199 203 8251368 with IN B-PP O
29 204 208 8251368 time NN B-NP O
30 208 209 8251368 . . O O

1 210 217 8251368 Neither DT B-NP O
2 218 225 8251368 patient NN I-NP O
3 226 236 8251368 complained VBD B-VP O
4 237 239 8251368 of IN B-PP O
5 240 256 8251368 photosensitivity NN B-NP O
6 257 259 8251368 or CC I-NP O
7 260 268 8251368 flushing NN I-NP D005483
8 268 269 8251368 . . O O

1 270 274 8251368 Both DT B-NP O
2 275 283 8251368 patients NNS I-NP O
3 284 292 8251368 reported VBD B-VP O
4 293 294 8251368 a DT B-NP O
5 295 306 8251368 significant JJ I-NP O
6 307 315 8251368 cosmetic JJ I-NP O
7 316 327 8251368 improvement NN I-NP O
8 328 333 8251368 after IN B-PP O
9 334 347 8251368 discontinuing VBG B-VP O
10 348 351 8251368 the DT B-NP O
11 352 356 8251368 drug NN I-NP O
12 356 357 8251368 . . O O

1 358 361 8251368 One CD B-NP O
2 362 371 8251368 commenced VBD B-VP O
3 372 375 8251368 the DT B-NP O
4 376 383 8251368 closely RB I-NP O
5 384 391 8251368 related JJ I-NP O
6 392 396 8251368 drug NN I-NP O
7 397 407 8251368 amlodipine NN I-NP D017311
8 408 409 8251368 3 CD B-NP O
9 410 415 8251368 years NNS I-NP O
10 416 421 8251368 later RB B-ADVP O
11 421 422 8251368 , , O O
12 423 427 8251368 with IN B-PP O
13 428 438 8251368 recurrence NN B-NP O
14 439 441 8251368 of IN B-PP O
15 442 456 8251368 telangiectasia NN B-NP D013684
16 456 457 8251368 . . O O

1 458 461 8251368 The DT B-NP O
2 462 479 8251368 photodistribution NN I-NP O
3 480 482 8251368 of IN B-PP O
4 483 486 8251368 the DT B-NP O
5 487 501 8251368 telangiectasia NN I-NP D013684
6 502 510 8251368 suggests VBZ B-VP O
7 511 512 8251368 a DT B-NP O
8 513 524 8251368 significant JJ I-NP O
9 525 529 8251368 drug NN I-NP O
10 529 530 8251368 / SYM B-NP O
11 530 535 8251368 light NN I-NP O
12 536 547 8251368 interaction NN I-NP O
13 547 548 8251368 . . O O

1 0 0 10743694 -DOCSTART- -X- -X- O

1 0 9 10743694 Treatment NN B-NP O
2 10 12 10743694 of IN B-PP O
3 13 23 10743694 tacrolimus NN B-NP D016559
4 23 24 10743694 - HYPH O O
5 24 31 10743694 related VBN B-NP O
6 32 39 10743694 adverse JJ I-NP O
7 40 47 10743694 effects NNS I-NP O
8 48 50 10743694 by IN B-PP O
9 51 61 10743694 conversion NN B-NP O
10 62 64 10743694 to TO B-PP O
11 65 77 10743694 cyclosporine NN B-NP D016572
12 78 80 10743694 in IN B-PP O
13 81 86 10743694 liver NN B-NP O
14 87 97 10743694 transplant NN I-NP O
15 98 108 10743694 recipients NNS I-NP O
16 108 109 10743694 . . O O
17 110 114 10743694 When WRB B-ADVP O
18 115 125 10743694 tacrolimus NN B-NP D016559
19 126 130 10743694 side NN I-NP O
20 131 138 10743694 effects NNS I-NP O
21 139 146 10743694 persist VBP B-VP O
22 147 154 10743694 despite IN B-PP O
23 155 159 10743694 dose NN B-NP O
24 160 169 10743694 reduction NN I-NP O
25 169 170 10743694 , , O O
26 171 181 10743694 conversion NN B-NP O
27 182 184 10743694 to TO B-PP O
28 185 197 10743694 cyclosporine NN B-NP D016572
29 197 198 10743694 - HYPH O O
30 198 203 10743694 based VBN B-VP O
31 204 221 10743694 immunosuppression NN B-NP O
32 222 223 10743694 ( ( O O
33 223 226 10743694 CyA NN B-NP O
34 226 227 10743694 ) ) O O
35 228 230 10743694 is VBZ B-VP O
36 231 240 10743694 necessary JJ B-ADJP O
37 240 241 10743694 . . O O

1 242 244 10743694 We PRP B-NP O
2 245 258 10743694 characterized VBD B-VP O
3 259 269 10743694 tacrolimus NN B-NP D016559
4 270 274 10743694 side NN I-NP O
5 275 282 10743694 effects NNS I-NP O
6 283 287 10743694 that WDT B-NP O
7 288 297 10743694 warranted VBD B-VP O
8 298 313 10743694 discontinuation NN B-NP O
9 314 316 10743694 of IN B-PP O
10 317 320 10743694 the DT B-NP O
11 321 325 10743694 drug NN I-NP O
12 325 326 10743694 , , O O
13 327 330 10743694 and CC O O
14 331 339 10743694 outcomes VBZ B-VP O
15 340 345 10743694 after IN B-PP O
16 346 356 10743694 conversion NN B-NP O
17 356 357 10743694 . . O O

1 358 360 10743694 Of IN B-PP O
2 361 364 10743694 388 CD B-NP O
3 365 370 10743694 liver NN I-NP O
4 371 381 10743694 recipients NNS I-NP O
5 382 385 10743694 who WP B-NP O
6 386 394 10743694 received VBD B-VP O
7 395 405 10743694 tacrolimus NN B-NP D016559
8 406 408 10743694 as IN B-PP O
9 409 416 10743694 primary JJ B-NP O
10 417 434 10743694 immunosuppression NN I-NP O
11 434 435 10743694 , , O O
12 436 438 10743694 70 CD B-NP O
13 439 447 10743694 required VBD B-VP O
14 448 458 10743694 conversion NN B-NP O
15 459 461 10743694 to TO B-PP O
16 462 465 10743694 CyA NN B-NP O
17 465 466 10743694 . . O O

1 467 469 10743694 We PRP B-NP O
2 470 478 10743694 recorded VBD B-VP O
3 479 489 10743694 indication NN B-NP O
4 490 493 10743694 for IN B-PP O
5 494 504 10743694 conversion NN B-NP O
6 504 505 10743694 , , O O
7 506 513 10743694 whether IN B-SBAR O
8 514 524 10743694 conversion NN B-NP O
9 525 528 10743694 was VBD B-VP O
10 529 534 10743694 early JJ B-ADJP O
11 535 537 10743694 or CC I-ADJP O
12 538 542 10743694 late JJ I-ADJP O
13 543 548 10743694 after IN B-PP O
14 549 564 10743694 transplantation NN B-NP O
15 564 565 10743694 , , O O
16 566 576 10743694 tacrolimus NN B-NP D016559
17 577 581 10743694 dose NN I-NP O
18 582 585 10743694 and CC I-NP O
19 586 592 10743694 trough NN I-NP O
20 593 598 10743694 blood NN I-NP O
21 599 604 10743694 level NN I-NP O
22 605 607 10743694 at IN B-PP O
23 608 618 10743694 conversion NN B-NP O
24 618 619 10743694 , , O O
25 620 623 10743694 and CC O O
26 624 633 10743694 incidence NN B-NP O
27 634 636 10743694 of IN B-PP O
28 637 646 10743694 rejection NN B-NP O
29 647 652 10743694 after IN B-PP O
30 653 663 10743694 conversion NN B-NP O
31 663 664 10743694 . . O O

1 665 675 10743694 Conversion NN B-NP O
2 676 679 10743694 was VBD B-VP O
3 680 685 10743694 early JJ B-ADVP O
4 686 688 10743694 in IN B-PP O
5 689 691 10743694 29 CD B-NP O
6 692 700 10743694 patients NNS I-NP O
7 701 702 10743694 ( ( O O
8 702 707 10743694 41.4% NN B-NP O
9 707 708 10743694 ) ) O O
10 709 712 10743694 and CC O O
11 713 717 10743694 late RB B-ADVP O
12 718 720 10743694 in IN B-PP O
13 721 723 10743694 41 CD B-NP O
14 724 725 10743694 ( ( O O
15 725 730 10743694 58.6% CD B-NP O
16 730 731 10743694 ) ) O O
17 731 732 10743694 . . O O

1 733 744 10743694 Indications NNS B-NP O
2 745 748 10743694 for IN B-PP O
3 749 754 10743694 early JJ B-NP O
4 755 765 10743694 conversion NN I-NP O
5 766 770 10743694 were VBD B-VP O
6 771 784 10743694 neurotoxicity NN B-NP D020258
7 785 786 10743694 ( ( O O
8 786 788 10743694 20 CD B-NP O
9 788 789 10743694 ) ) O O
10 789 790 10743694 , , O O
11 791 792 10743694 ( ( O D003922
12 792 799 10743694 insulin NN B-NP D003922
13 799 800 10743694 - HYPH O D003922
14 800 809 10743694 dependent JJ O D003922
15 809 810 10743694 ) ) O D003922
16 811 819 10743694 diabetes NN B-NP D003922
17 820 828 10743694 mellitus NN I-NP D003922
18 829 830 10743694 ( ( O O
19 830 834 10743694 IDDM NN B-NP D003922
20 834 835 10743694 ) ) O O
21 836 837 10743694 ( ( O O
22 837 838 10743694 5 CD B-NP O
23 838 839 10743694 ) ) O O
24 839 840 10743694 , , O O
25 841 855 10743694 nephrotoxicity NN B-NP D007674
26 856 857 10743694 ( ( O O
27 857 858 10743694 3 CD B-NP O
28 858 859 10743694 ) ) O O
29 859 860 10743694 , , O O
30 861 877 10743694 gastrointestinal JJ B-ADJP D005767
31 878 879 10743694 ( ( O D005767
32 879 881 10743694 GI NN B-NP D005767
33 881 882 10743694 ) ) O D005767
34 883 891 10743694 toxicity NN B-NP D005767
35 892 893 10743694 ( ( O O
36 893 894 10743694 6 CD B-NP O
37 894 895 10743694 ) ) O O
38 895 896 10743694 , , O O
39 897 900 10743694 and CC O O
40 901 915 10743694 cardiomyopathy NN B-NP D009202
41 916 917 10743694 ( ( O O
42 917 918 10743694 1 CD B-NP O
43 918 919 10743694 ) ) O O
44 919 920 10743694 , , O O
45 921 924 10743694 and CC O O
46 925 928 10743694 for IN B-PP O
47 929 933 10743694 late JJ B-NP O
48 934 944 10743694 conversion NN I-NP O
49 945 949 10743694 were VBD B-VP O
50 950 963 10743694 neurotoxicity NN B-NP D020258
51 964 965 10743694 ( ( O O
52 965 967 10743694 15 CD B-NP O
53 967 968 10743694 ) ) O O
54 968 969 10743694 , , O O
55 970 974 10743694 IDDM NN B-NP D003922
56 975 976 10743694 ( ( O O
57 976 978 10743694 12 CD B-NP O
58 978 979 10743694 ) ) O O
59 979 980 10743694 , , O O
60 981 995 10743694 nephrotoxicity NN B-NP D007674
61 996 997 10743694 ( ( O O
62 997 998 10743694 3 CD B-NP O
63 998 999 10743694 ) ) O O
64 999 1000 10743694 , , O O
65 1001 1003 10743694 GI NN B-NP D005767
66 1004 1012 10743694 toxicity NN I-NP D005767
67 1013 1014 10743694 ( ( O O
68 1014 1015 10743694 5 CD B-NP O
69 1015 1016 10743694 ) ) O O
70 1016 1017 10743694 , , O O
71 1018 1032 10743694 hepatotoxicity NN B-NP D056486
72 1033 1034 10743694 ( ( O O
73 1034 1035 10743694 6 CD B-NP O
74 1035 1036 10743694 ) ) O O
75 1036 1037 10743694 , , O O
76 1038 1042 10743694 post AFX B-NP D008232
77 1042 1043 10743694 - HYPH I-NP D008232
78 1043 1053 10743694 transplant NN I-NP D008232
79 1054 1070 10743694 lmphoproliferate NN I-NP D008232
80 1071 1078 10743694 disease NN I-NP D008232
81 1079 1080 10743694 ( ( O O
82 1080 1084 10743694 PTLD NN B-NP D008232
83 1084 1085 10743694 ) ) O O
84 1086 1087 10743694 ( ( O O
85 1087 1088 10743694 2 CD B-NP O
86 1088 1089 10743694 ) ) O O
87 1089 1090 10743694 , , O O
88 1091 1105 10743694 cardiomyopathy NN B-NP D009202
89 1106 1107 10743694 ( ( O O
90 1107 1108 10743694 1 CD B-NP O
91 1108 1109 10743694 ) ) O O
92 1109 1110 10743694 , , O O
93 1111 1120 10743694 hemolytic JJ B-NP D000743
94 1121 1127 10743694 anemia NN I-NP D000743
95 1128 1129 10743694 ( ( O O
96 1129 1130 10743694 1 CD B-NP O
97 1130 1131 10743694 ) ) O O
98 1131 1132 10743694 , , O O
99 1133 1136 10743694 and CC O O
100 1137 1145 10743694 pruritus NN B-NP D011537
101 1146 1147 10743694 ( ( O O
102 1147 1148 10743694 1 CD B-NP O
103 1148 1149 10743694 ) ) O O
104 1149 1150 10743694 . . O O

1 1151 1154 10743694 All DT B-NP O
2 1155 1160 10743694 early JJ I-NP O
3 1160 1161 10743694 - HYPH I-NP O
4 1161 1171 10743694 conversion NN B-NP O
5 1172 1180 10743694 patients NNS I-NP O
6 1181 1187 10743694 showed VBD B-VP O
7 1188 1199 10743694 improvement NN B-NP O
8 1199 1200 10743694 / SYM I-NP O
9 1200 1210 10743694 resolution NN I-NP O
10 1211 1213 10743694 of IN B-PP O
11 1214 1222 10743694 symptoms NNS B-NP O
12 1222 1223 10743694 . . O O

1 1224 1229 10743694 Among IN B-PP O
2 1230 1234 10743694 late JJ B-NP O
3 1234 1235 10743694 - HYPH I-NP O
4 1235 1245 10743694 conversion NN I-NP O
5 1246 1254 10743694 patients NNS I-NP O
6 1254 1255 10743694 , , O O
7 1256 1258 10743694 37 CD B-NP O
8 1259 1260 10743694 ( ( O O
9 1260 1265 10743694 90.2% NN B-NP O
10 1265 1266 10743694 ) ) O O
11 1267 1270 10743694 had VBD B-VP O
12 1271 1282 10743694 improvement NN B-NP O
13 1282 1283 10743694 / SYM I-NP O
14 1283 1293 10743694 resolution NN I-NP O
15 1293 1294 10743694 ; : O O
16 1295 1297 10743694 in IN B-PP O
17 1298 1299 10743694 4 CD B-NP O
18 1300 1301 10743694 ( ( O O
19 1301 1305 10743694 9.8% NN B-NP O
20 1305 1306 10743694 ) ) O O
21 1306 1307 10743694 , , O O
22 1308 1315 10743694 adverse JJ B-NP O
23 1316 1323 10743694 effects NNS I-NP O
24 1324 1333 10743694 persisted VBD B-VP O
25 1333 1334 10743694 . . O O

1 1335 1338 10743694 The DT B-NP O
2 1339 1346 10743694 overall JJ I-NP O
3 1347 1356 10743694 rejection NN I-NP O
4 1357 1361 10743694 rate NN I-NP O
5 1362 1365 10743694 was VBD B-VP O
6 1366 1369 10743694 30% CD B-NP O
7 1369 1370 10743694 . . O O

1 1371 1376 10743694 Sixty CD B-NP O
2 1376 1377 10743694 - HYPH I-NP O
3 1377 1380 10743694 two CD B-NP O
4 1381 1389 10743694 patients NNS I-NP O
5 1390 1391 10743694 ( ( O O
6 1391 1396 10743694 88.6% NN B-NP O
7 1396 1397 10743694 ) ) O O
8 1398 1401 10743694 are VBP B-VP O
9 1402 1407 10743694 alive JJ B-ADJP O
10 1408 1412 10743694 with IN B-PP O
11 1413 1424 10743694 functioning VBG B-VP O
12 1425 1431 10743694 grafts NNS B-NP O
13 1432 1435 10743694 686 CD B-NP O
14 1436 1437 10743694 + SYM O O
15 1437 1438 10743694 / SYM O O
16 1438 1439 10743694 - SYM B-NP O
17 1440 1443 10743694 362 CD B-NP O
18 1444 1448 10743694 days NNS I-NP O
19 1449 1450 10743694 ( ( O O
20 1450 1455 10743694 range NN B-NP O
21 1455 1456 10743694 , , O O
22 1457 1460 10743694 154 CD B-NP O
23 1460 1461 10743694 - HYPH I-NP O
24 1461 1465 10743694 1433 CD I-NP O
25 1466 1470 10743694 days NNS I-NP O
26 1470 1471 10743694 ) ) O O
27 1472 1477 10743694 after IN B-PP O
28 1478 1488 10743694 conversion NN B-NP O
29 1488 1489 10743694 . . O O

1 1490 1494 10743694 When WRB B-ADVP O
2 1495 1505 10743694 tacrolimus NN B-NP D016559
3 1506 1510 10743694 side NN I-NP O
4 1511 1518 10743694 effects NNS I-NP O
5 1519 1522 10743694 are VBP B-VP O
6 1523 1535 10743694 unresponsive JJ B-ADJP O
7 1536 1538 10743694 to TO B-PP O
8 1539 1543 10743694 dose NN B-NP O
9 1544 1553 10743694 reduction NN I-NP O
10 1553 1554 10743694 , , O O
11 1555 1565 10743694 conversion NN B-NP O
12 1566 1568 10743694 to TO B-PP O
13 1569 1572 10743694 CyA NN B-NP O
14 1573 1576 10743694 can MD B-VP O
15 1577 1579 10743694 be VB I-VP O
16 1580 1592 10743694 accomplished VBN I-VP O
17 1593 1599 10743694 safely RB B-ADVP O
18 1599 1600 10743694 , , O O
19 1601 1605 10743694 with IN B-PP O
20 1606 1608 10743694 no DT B-NP O
21 1609 1618 10743694 increased VBN I-NP O
22 1619 1623 10743694 risk NN I-NP O
23 1624 1626 10743694 of IN B-PP O
24 1627 1636 10743694 rejection NN B-NP O
25 1637 1640 10743694 and CC O O
26 1641 1650 10743694 excellent JJ B-NP O
27 1651 1655 10743694 long JJ I-NP O
28 1655 1656 10743694 - HYPH I-NP O
29 1656 1660 10743694 term NN I-NP O
30 1661 1668 10743694 outcome NN I-NP O
31 1668 1669 10743694 . . O O

1 0 0 15042318 -DOCSTART- -X- -X- O

1 0 6 15042318 Atrial JJ B-NP D001281
2 7 19 15042318 fibrillation NN I-NP D001281
3 20 29 15042318 following VBG B-PP O
4 30 42 15042318 chemotherapy NN B-NP O
5 43 46 15042318 for IN B-PP O
6 47 52 15042318 stage NN B-NP O
7 53 57 15042318 IIIE CD I-NP O
8 58 65 15042318 diffuse JJ I-NP O
9 66 71 15042318 large JJ I-NP O
10 72 73 15042318 B NN I-NP O
11 73 74 15042318 - HYPH B-NP O
12 74 78 15042318 cell NN I-NP O
13 79 86 15042318 gastric JJ I-NP C535648
14 87 95 15042318 lymphoma NN I-NP C535648
15 96 98 15042318 in IN B-PP O
16 99 100 15042318 a DT B-NP O
17 101 108 15042318 patient NN I-NP O
18 109 113 15042318 with IN B-PP O
19 114 122 15042318 myotonic JJ B-NP D009223
20 123 132 15042318 dystrophy NN I-NP D009223
21 133 134 15042318 ( ( O O
22 134 144 15042318 Steinert's NNS B-NP D009223
23 145 152 15042318 disease NN I-NP D009223
24 152 153 15042318 ) ) O O
25 153 154 15042318 . . O O
26 155 158 15042318 The DT B-NP O
27 159 166 15042318 authors NNS I-NP O
28 167 175 15042318 describe VBP B-VP O
29 176 179 15042318 the DT B-NP O
30 180 187 15042318 unusual JJ I-NP O
31 188 199 15042318 association NN I-NP O
32 200 207 15042318 between IN B-PP O
33 208 215 15042318 diffuse JJ B-NP O
34 216 217 15042318 B NN I-NP O
35 217 218 15042318 - HYPH B-NP O
36 218 222 15042318 cell NN I-NP O
37 223 230 15042318 gastric JJ I-NP C535648
38 231 239 15042318 lymphoma NN I-NP C535648
39 240 243 15042318 and CC O O
40 244 252 15042318 myotonic JJ B-NP D009223
41 253 262 15042318 dystrophy NN I-NP D009223
42 262 263 15042318 , , O O
43 264 267 15042318 the DT B-NP O
44 268 272 15042318 most RBS I-NP O
45 273 279 15042318 common JJ I-NP O
46 280 284 15042318 form NN I-NP O
47 285 287 15042318 of IN B-PP O
48 288 293 15042318 adult JJ B-NP O
49 294 302 15042318 muscular JJ I-NP D009136
50 303 312 15042318 dystrophy NN I-NP D009136
51 312 313 15042318 , , O O
52 314 317 15042318 and CC O O
53 318 324 15042318 sudden JJ B-NP O
54 325 331 15042318 atrial JJ I-NP D001281
55 332 344 15042318 fibrillation NN I-NP D001281
56 345 354 15042318 following VBG B-PP O
57 355 358 15042318 one CD B-NP O
58 359 364 15042318 cycle NN I-NP O
59 365 367 15042318 of IN B-PP O
60 368 379 15042318 doxorubicin NN B-NP D004317
61 379 380 15042318 - HYPH O O
62 380 385 15042318 based VBN B-NP O
63 386 398 15042318 chemotherapy NN I-NP O
64 399 401 15042318 in IN B-PP O
65 402 405 15042318 the DT B-NP O
66 406 410 15042318 same JJ I-NP O
67 411 418 15042318 patient NN I-NP O
68 418 419 15042318 . . O O

1 420 426 15042318 Atrial JJ B-NP D001281
2 427 439 15042318 fibrillation NN I-NP D001281
3 440 442 15042318 or CC O O
4 443 448 15042318 other JJ B-NP O
5 449 456 15042318 cardiac JJ I-NP D001145
6 457 468 15042318 arrhythmias NNS I-NP D001145
7 469 472 15042318 are VBP B-VP O
8 473 480 15042318 unusual JJ B-NP O
9 481 494 15042318 complications NNS I-NP O
10 495 497 15042318 in IN B-PP O
11 498 506 15042318 patients NNS B-NP O
12 507 514 15042318 treated VBN B-VP O
13 515 519 15042318 with IN B-PP O
14 520 532 15042318 chemotherapy NN B-NP O
15 532 533 15042318 . . O O

1 534 537 15042318 The DT B-NP O
2 538 545 15042318 cardiac JJ I-NP D066126
3 546 554 15042318 toxicity NN I-NP D066126
4 555 568 15042318 intrinsically RB B-VP O
5 569 579 15042318 associated VBN I-VP O
6 580 584 15042318 with IN B-PP O
7 585 588 15042318 the DT B-NP O
8 589 599 15042318 aggressive JJ I-NP O
9 600 612 15042318 chemotherapy NN I-NP O
10 613 621 15042318 employed VBN B-VP O
11 622 627 15042318 could MD B-VP O
12 628 636 15042318 function VB I-VP O
13 637 639 15042318 as IN B-PP O
14 640 641 15042318 a DT B-NP O
15 642 652 15042318 triggering NN I-NP O
16 653 659 15042318 factor NN I-NP O
17 660 663 15042318 for IN B-PP O
18 664 667 15042318 the DT B-NP O
19 668 678 15042318 arrhythmia NN I-NP D001145
20 679 681 15042318 in IN B-PP O
21 682 685 15042318 the DT B-NP O
22 686 697 15042318 predisposed VBN I-NP O
23 698 708 15042318 myocardium NN I-NP O
24 709 711 15042318 of IN B-PP O
25 712 716 15042318 this DT B-NP O
26 717 724 15042318 patient NN I-NP O
27 724 725 15042318 . . O O

1 0 0 7910951 -DOCSTART- -X- -X- O

1 0 9 7910951 Prolonged JJ B-NP O
2 10 19 7910951 paralysis NN I-NP D010243
3 20 23 7910951 due JJ B-ADJP O
4 24 26 7910951 to TO B-PP O
5 27 42 7910951 nondepolarizing VBG B-VP D003473
6 43 56 7910951 neuromuscular JJ B-NP D003473
7 57 65 7910951 blocking VBG I-NP D003473
8 66 72 7910951 agents NNS I-NP D003473
9 73 76 7910951 and CC I-NP O
10 77 92 7910951 corticosteroids NNS I-NP D000305
11 92 93 7910951 . . O O
12 94 97 7910951 The DT B-NP O
13 98 102 7910951 long JJ I-NP O
14 102 103 7910951 - HYPH I-NP O
15 103 107 7910951 term NN I-NP O
16 108 111 7910951 use NN I-NP O
17 112 114 7910951 of IN B-PP O
18 115 130 7910951 nondepolarizing VBG B-VP D003473
19 131 144 7910951 neuromuscular JJ B-NP D003473
20 145 153 7910951 blocking VBG I-NP D003473
21 154 160 7910951 agents NNS I-NP D003473
22 161 162 7910951 ( ( O O
23 162 164 7910951 ND NN B-NP D003473
24 164 165 7910951 - HYPH B-NP D003473
25 165 169 7910951 NMBA NN I-NP D003473
26 169 170 7910951 ) ) O O
27 171 174 7910951 has VBZ B-VP O
28 175 183 7910951 recently RB I-VP O
29 184 188 7910951 been VBN I-VP O
30 189 199 7910951 implicated VBN I-VP O
31 200 202 7910951 as IN B-PP O
32 203 204 7910951 a DT B-NP O
33 205 210 7910951 cause NN I-NP O
34 211 213 7910951 of IN B-PP O
35 214 223 7910951 prolonged VBN B-NP O
36 224 230 7910951 muscle NN I-NP D018908
37 231 239 7910951 weakness NN I-NP D018908
38 239 240 7910951 , , O O
39 241 249 7910951 although IN B-SBAR O
40 250 253 7910951 the DT B-NP O
41 254 258 7910951 site NN I-NP O
42 259 261 7910951 of IN B-PP O
43 262 265 7910951 the DT B-NP O
44 266 272 7910951 lesion NN I-NP O
45 273 276 7910951 and CC O O
46 277 280 7910951 the DT B-NP O
47 281 293 7910951 predisposing VBG I-NP O
48 294 301 7910951 factors NNS I-NP O
49 302 306 7910951 have VBP B-VP O
50 307 311 7910951 been VBN I-VP O
51 312 319 7910951 unclear JJ B-ADJP O
52 319 320 7910951 . . O O

1 321 323 7910951 We PRP B-NP O
2 324 330 7910951 report VBP B-VP O
3 331 332 7910951 3 CD B-NP O
4 333 341 7910951 patients NNS I-NP O
5 342 343 7910951 ( ( O O
6 343 346 7910951 age NN B-NP O
7 347 349 7910951 37 CD I-NP O
8 349 350 7910951 - HYPH O O
9 350 352 7910951 52 CD B-NP O
10 353 358 7910951 years NNS I-NP O
11 358 359 7910951 ) ) O O
12 360 364 7910951 with IN B-PP O
13 365 370 7910951 acute JJ B-NP O
14 371 382 7910951 respiratory JJ I-NP D012131
15 383 396 7910951 insufficiency NN I-NP D012131
16 397 400 7910951 who WP B-NP O
17 401 410 7910951 developed VBD B-VP O
18 411 420 7910951 prolonged VBN I-VP O
19 421 429 7910951 weakness NN B-NP D018908
20 430 439 7910951 following VBG B-PP O
21 440 443 7910951 the DT B-NP O
22 444 459 7910951 discontinuation NN I-NP O
23 460 462 7910951 of IN B-PP O
24 463 465 7910951 ND NN B-NP D003473
25 465 466 7910951 - HYPH B-NP D003473
26 466 471 7910951 NMBAs NNS I-NP D003473
27 471 472 7910951 . . O O

1 473 476 7910951 Two CD B-NP O
2 477 485 7910951 patients NNS I-NP O
3 486 490 7910951 also RB B-ADVP O
4 491 499 7910951 received VBD B-VP O
5 500 511 7910951 intravenous JJ B-NP O
6 512 527 7910951 corticosteroids NNS I-NP D000305
7 527 528 7910951 . . O O

1 529 534 7910951 Renal JJ B-NP O
2 535 543 7910951 function NN I-NP O
3 544 547 7910951 was VBD B-VP O
4 548 554 7910951 normal JJ B-NP O
5 555 558 7910951 but CC I-NP O
6 559 566 7910951 hepatic JJ I-NP O
7 567 575 7910951 function NN I-NP O
8 576 579 7910951 was VBD B-VP O
9 580 588 7910951 impaired VBN I-VP O
10 589 591 7910951 in IN B-PP O
11 592 595 7910951 all DT B-NP O
12 596 604 7910951 patients NNS I-NP O
13 604 605 7910951 , , O O
14 606 609 7910951 and CC O O
15 610 613 7910951 all DT B-NP O
16 614 617 7910951 had VBD B-VP O
17 618 626 7910951 acidosis NN B-NP D000138
18 626 627 7910951 . . O O

1 628 646 7910951 Electrophysiologic JJ B-NP O
2 647 654 7910951 studies NNS I-NP O
3 655 663 7910951 revealed VBD B-VP O
4 664 667 7910951 low JJ B-NP O
5 668 677 7910951 amplitude NN I-NP O
6 678 686 7910951 compound NN I-NP O
7 687 692 7910951 motor NN I-NP O
8 693 699 7910951 action NN I-NP O
9 700 710 7910951 potentials NNS I-NP O
10 710 711 7910951 , , O O
11 712 718 7910951 normal JJ B-NP O
12 719 726 7910951 sensory JJ I-NP O
13 727 734 7910951 studies NNS I-NP O
14 734 735 7910951 , , O O
15 736 739 7910951 and CC O O
16 740 753 7910951 fibrillations NNS B-NP O
17 753 754 7910951 . . O O

1 755 765 7910951 Repetitive JJ B-NP O
2 766 777 7910951 stimulation NN I-NP O
3 778 780 7910951 at IN B-PP O
4 781 782 7910951 2 CD B-NP O
5 783 785 7910951 Hz NN I-NP O
6 786 792 7910951 showed VBD B-VP O
7 793 794 7910951 a DT B-NP O
8 795 806 7910951 decremental JJ I-NP O
9 807 815 7910951 response NN I-NP O
10 816 818 7910951 in IN B-PP O
11 819 820 7910951 2 CD B-NP O
12 821 829 7910951 patients NNS I-NP O
13 829 830 7910951 . . O O

1 831 834 7910951 The DT B-NP O
2 835 840 7910951 serum NN I-NP O
3 841 851 7910951 vecuronium NN I-NP D014673
4 852 857 7910951 level NN I-NP O
5 858 866 7910951 measured VBN B-VP O
6 867 869 7910951 in IN B-PP O
7 870 871 7910951 1 CD B-NP O
8 872 879 7910951 patient NN I-NP O
9 880 882 7910951 14 CD B-NP O
10 883 887 7910951 days NNS I-NP O
11 888 893 7910951 after IN B-PP O
12 894 897 7910951 the DT B-NP O
13 898 902 7910951 drug NN I-NP O
14 903 906 7910951 had VBD B-VP O
15 907 911 7910951 been VBN I-VP O
16 912 924 7910951 discontinued VBN I-VP O
17 925 928 7910951 was VBD B-VP O
18 929 932 7910951 172 CD B-NP O
19 933 935 7910951 ng NN I-NP O
20 935 936 7910951 / SYM B-NP O
21 936 938 7910951 mL NN I-NP O
22 938 939 7910951 . . O O

1 940 941 7910951 A DT B-NP O
2 942 948 7910951 muscle NN I-NP O
3 949 955 7910951 biopsy NN I-NP O
4 956 958 7910951 in IN B-PP O
5 959 963 7910951 this DT B-NP O
6 964 971 7910951 patient NN I-NP O
7 972 978 7910951 showed VBD B-VP O
8 979 983 7910951 loss NN B-NP D009135
9 984 986 7910951 of IN B-PP D009135
10 987 992 7910951 thick JJ B-NP D009135
11 992 993 7910951 , , I-NP D009135
12 994 1000 7910951 myosin NN I-NP D009135
13 1001 1010 7910951 filaments NNS I-NP D009135
14 1010 1011 7910951 . . O O

1 1012 1015 7910951 The DT B-NP O
2 1016 1024 7910951 weakness NN I-NP D018908
3 1025 1027 7910951 in IN B-PP O
4 1028 1033 7910951 these DT B-NP O
5 1034 1042 7910951 patients NNS I-NP O
6 1043 1045 7910951 is VBZ B-VP O
7 1046 1049 7910951 due IN B-PP O
8 1050 1052 7910951 to TO B-PP O
9 1053 1062 7910951 pathology NN B-NP D009468
10 1063 1065 7910951 at IN B-PP D009468
11 1066 1070 7910951 both CC O D009468
12 1071 1074 7910951 the DT B-NP D009468
13 1075 1088 7910951 neuromuscular JJ I-NP D009468
14 1089 1097 7910951 junction NN I-NP D009468
15 1098 1099 7910951 ( ( O O
16 1099 1103 7910951 most RBS B-ADVP O
17 1104 1110 7910951 likely RB I-ADVP O
18 1111 1114 7910951 due IN B-PP O
19 1115 1117 7910951 to TO B-PP O
20 1118 1120 7910951 ND NN B-NP D003473
21 1120 1121 7910951 - HYPH I-NP D003473
22 1121 1125 7910951 NMBA NN I-NP D003473
23 1125 1126 7910951 ) ) O O
24 1127 1130 7910951 and CC O O
25 1131 1137 7910951 muscle NN B-NP O
26 1138 1139 7910951 ( ( O O
27 1139 1143 7910951 most RBS B-ADVP O
28 1144 1150 7910951 likely RB I-ADVP O
29 1151 1154 7910951 due IN B-PP O
30 1155 1157 7910951 to TO B-PP O
31 1158 1173 7910951 corticosteroids NNS B-NP D000305
32 1173 1174 7910951 ) ) O O
33 1174 1175 7910951 . . O O

1 1176 1183 7910951 Hepatic JJ B-NP D008107
2 1184 1195 7910951 dysfunction NN I-NP D008107
3 1196 1199 7910951 and CC I-NP O
4 1200 1208 7910951 acidosis NN I-NP D000138
5 1209 1212 7910951 are VBP B-VP O
6 1213 1225 7910951 contributing VBG I-VP O
7 1226 1230 7910951 risk NN B-NP O
8 1231 1238 7910951 factors NNS I-NP O
9 1238 1239 7910951 . . O O

1 0 0 6150641 -DOCSTART- -X- -X- O

1 0 10 6150641 Comparison NN B-NP O
2 11 13 6150641 of IN B-PP O
3 14 17 6150641 the DT B-NP O
4 18 31 6150641 effectiveness NN I-NP O
5 32 34 6150641 of IN B-PP O
6 35 45 6150641 ranitidine NN B-NP D011899
7 46 49 6150641 and CC I-NP O
8 50 60 6150641 cimetidine NN I-NP D002927
9 61 63 6150641 in IN B-PP O
10 64 74 6150641 inhibiting VBG B-VP O
11 75 79 6150641 acid NN B-NP O
12 80 89 6150641 secretion NN I-NP O
13 90 92 6150641 in IN B-PP O
14 93 101 6150641 patients NNS B-NP O
15 102 106 6150641 with IN B-PP O
16 107 114 6150641 gastric JJ B-NP O
17 115 129 6150641 hypersecretory NN I-NP O
18 130 136 6150641 states NNS I-NP O
19 136 137 6150641 . . O O
20 138 141 6150641 The DT B-NP O
21 142 144 6150641 H2 NN I-NP O
22 144 145 6150641 - HYPH B-NP O
23 145 154 6150641 histamine NN I-NP D006632
24 155 163 6150641 receptor NN I-NP O
25 164 175 6150641 antagonists NNS I-NP O
26 176 186 6150641 ranitidine NN I-NP D011899
27 187 190 6150641 and CC I-NP O
28 191 201 6150641 cimetidine NN I-NP D002927
29 202 206 6150641 were VBD B-VP O
30 207 215 6150641 compared VBN I-VP O
31 216 219 6150641 for IN B-PP O
32 220 225 6150641 their PRP$ B-NP O
33 226 235 6150641 abilities NNS I-NP O
34 236 238 6150641 to TO B-VP O
35 239 246 6150641 control VB I-VP O
36 247 254 6150641 gastric JJ B-NP O
37 255 259 6150641 acid NN I-NP O
38 260 274 6150641 hypersecretion NN I-NP O
39 275 277 6150641 on IN B-PP O
40 278 279 6150641 a DT B-NP O
41 280 285 6150641 short JJ I-NP O
42 285 286 6150641 - HYPH I-NP O
43 287 290 6150641 and CC I-NP O
44 291 295 6150641 long JJ I-NP O
45 295 296 6150641 - HYPH I-NP O
46 296 300 6150641 term NN I-NP O
47 301 306 6150641 basis NN I-NP O
48 307 309 6150641 in IN B-PP O
49 310 312 6150641 22 CD B-NP O
50 313 321 6150641 patients NNS I-NP O
51 322 326 6150641 with IN B-PP O
52 327 334 6150641 gastric JJ B-NP O
53 335 339 6150641 acid NN I-NP O
54 340 354 6150641 hypersecretory JJ I-NP O
55 355 361 6150641 states NNS I-NP O
56 361 362 6150641 . . O O

1 363 371 6150641 Nineteen CD B-NP O
2 372 380 6150641 patients NNS I-NP O
3 381 384 6150641 had VBD B-VP O
4 385 394 6150641 Zollinger NN B-NP D015043
5 394 395 6150641 - HYPH I-NP D015043
6 395 402 6150641 Ellison NN I-NP D015043
7 403 411 6150641 syndrome NN I-NP D015043
8 411 412 6150641 , , O O
9 413 416 6150641 one CD B-NP O
10 417 424 6150641 patient NN I-NP O
11 425 428 6150641 had VBD B-VP O
12 429 437 6150641 systemic JJ B-NP D034721
13 438 450 6150641 mastocytosis NN I-NP D034721
14 450 451 6150641 , , O O
15 452 455 6150641 and CC O O
16 456 459 6150641 two CD B-NP O
17 460 468 6150641 patients NNS I-NP O
18 469 472 6150641 had VBD B-VP O
19 473 483 6150641 idiopathic JJ B-NP O
20 484 498 6150641 hypersecretion NN I-NP O
21 498 499 6150641 . . O O

1 500 503 6150641 The DT B-NP O
2 504 509 6150641 rates NNS I-NP O
3 510 512 6150641 of IN B-PP O
4 513 518 6150641 onset NN B-NP O
5 519 521 6150641 of IN B-PP O
6 522 525 6150641 the DT B-NP O
7 526 532 6150641 action NN I-NP O
8 533 535 6150641 of IN B-PP O
9 536 546 6150641 cimetidine NN B-NP D002927
10 547 550 6150641 and CC I-NP O
11 551 561 6150641 ranitidine NN I-NP D011899
12 562 566 6150641 were VBD B-VP O
13 567 570 6150641 the DT B-NP O
14 571 575 6150641 same JJ I-NP O
15 575 576 6150641 . . O O

1 577 580 6150641 The DT B-NP O
2 581 588 6150641 actions NNS I-NP O
3 589 591 6150641 of IN B-PP O
4 592 596 6150641 both DT B-NP O
5 597 602 6150641 drugs NNS I-NP O
6 603 607 6150641 were VBD B-VP O
7 608 617 6150641 increased VBN I-VP O
8 618 620 6150641 by IN B-PP O
9 621 636 6150641 anticholinergic JJ B-NP O
10 637 643 6150641 agents NNS I-NP O
11 643 644 6150641 , , O O
12 645 648 6150641 and CC O O
13 649 654 6150641 there EX B-NP O
14 655 658 6150641 was VBD B-VP O
15 659 660 6150641 a DT B-NP O
16 661 666 6150641 close JJ I-NP O
17 667 678 6150641 correlation NN I-NP O
18 679 686 6150641 between IN B-PP O
19 687 690 6150641 the DT B-NP O
20 691 696 6150641 daily JJ I-NP O
21 697 708 6150641 maintenance NN I-NP O
22 709 713 6150641 dose NN I-NP O
23 714 716 6150641 of IN B-PP O
24 717 721 6150641 each DT B-NP O
25 722 726 6150641 drug NN I-NP O
26 727 733 6150641 needed VBN B-VP O
27 734 736 6150641 to TO B-VP O
28 737 744 6150641 control VB I-VP O
29 745 749 6150641 acid NN B-NP O
30 750 759 6150641 secretion NN I-NP O
31 759 760 6150641 . . O O

1 761 768 6150641 However RB B-ADVP O
2 768 769 6150641 , , O O
3 770 780 6150641 ranitidine NN B-NP D011899
4 781 784 6150641 was VBD B-VP O
5 785 794 6150641 threefold RB B-ADJP O
6 795 799 6150641 more RBR I-ADJP O
7 800 806 6150641 potent JJ I-ADJP O
8 807 811 6150641 than IN B-PP O
9 812 822 6150641 cimetidine NN B-NP D002927
10 823 827 6150641 both CC B-PP O
11 828 830 6150641 in IN B-PP O
12 831 836 6150641 acute JJ B-NP O
13 837 847 6150641 inhibition NN I-NP O
14 848 855 6150641 studies NNS I-NP O
15 856 859 6150641 and CC B-PP O
16 860 862 6150641 in IN B-PP O
17 863 866 6150641 the DT B-NP O
18 867 873 6150641 median JJ I-NP O
19 874 885 6150641 maintenance NN I-NP O
20 886 890 6150641 dose NN I-NP O
21 891 897 6150641 needed VBN B-VP O
22 898 899 6150641 ( ( O O
23 899 902 6150641 1.2 CD B-NP O
24 903 904 6150641 g NN I-NP O
25 905 908 6150641 per IN B-PP O
26 909 912 6150641 day NN B-NP O
27 913 916 6150641 for IN B-PP O
28 917 927 6150641 ranitidine NN B-NP D011899
29 928 931 6150641 and CC O O
30 932 935 6150641 3.6 CD B-NP O
31 936 937 6150641 g NN I-NP O
32 938 941 6150641 per IN B-PP O
33 942 945 6150641 day NN B-NP O
34 946 949 6150641 for IN B-PP O
35 950 960 6150641 cimetidine NN B-NP D002927
36 960 961 6150641 ) ) O O
37 961 962 6150641 . . O O

1 963 968 6150641 Sixty CD B-NP O
2 969 976 6150641 percent NN I-NP O
3 977 979 6150641 of IN B-PP O
4 980 983 6150641 the DT B-NP O
5 984 989 6150641 males NNS I-NP O
6 990 999 6150641 developed VBD B-VP O
7 1000 1006 6150641 breast NN B-NP O
8 1007 1014 6150641 changes NNS I-NP O
9 1015 1017 6150641 or CC O O
10 1018 1027 6150641 impotence NN B-NP D007172
11 1028 1033 6150641 while IN B-SBAR O
12 1034 1040 6150641 taking VBG B-VP O
13 1041 1051 6150641 cimetidine NN B-NP D002927
14 1052 1055 6150641 and CC B-PP O
15 1056 1058 6150641 in IN B-PP O
16 1059 1062 6150641 all DT B-NP O
17 1063 1068 6150641 cases NNS I-NP O
18 1069 1074 6150641 these DT B-NP O
19 1075 1082 6150641 changes NNS I-NP O
20 1083 1094 6150641 disappeared VBD B-VP O
21 1095 1099 6150641 when WRB B-ADVP O
22 1100 1110 6150641 cimetidine NN B-NP D002927
23 1111 1114 6150641 was VBD B-VP O
24 1115 1123 6150641 replaced VBN I-VP O
25 1124 1126 6150641 by IN B-PP O
26 1127 1137 6150641 ranitidine NN B-NP D011899
27 1137 1138 6150641 . . O O

1 1139 1148 6150641 Treatment NN B-NP O
2 1149 1153 6150641 with IN B-PP O
3 1154 1158 6150641 high JJ B-NP O
4 1159 1164 6150641 doses NNS I-NP O
5 1165 1167 6150641 of IN B-PP O
6 1168 1178 6150641 cimetidine NN B-NP D002927
7 1179 1180 6150641 ( ( O O
8 1180 1183 6150641 one CD B-NP O
9 1184 1186 6150641 to TO I-NP O
10 1187 1189 6150641 60 CD I-NP O
11 1190 1196 6150641 months NNS I-NP O
12 1196 1197 6150641 ; : O O
13 1198 1204 6150641 median NN B-NP O
14 1204 1205 6150641 , , O O
15 1206 1208 6150641 11 CD B-NP O
16 1209 1215 6150641 months NNS I-NP O
17 1215 1216 6150641 ) ) O O
18 1217 1219 6150641 or CC O O
19 1220 1230 6150641 ranitidine NN B-NP D011899
20 1231 1232 6150641 ( ( O O
21 1232 1235 6150641 two CD B-NP O
22 1236 1238 6150641 to TO I-NP O
23 1239 1241 6150641 31 CD I-NP O
24 1242 1248 6150641 months NNS I-NP O
25 1248 1249 6150641 ; : O O
26 1250 1256 6150641 median NN B-NP O
27 1256 1257 6150641 , , O O
28 1258 1260 6150641 14 CD B-NP O
29 1261 1267 6150641 months NNS I-NP O
30 1267 1268 6150641 ) ) O O
31 1269 1272 6150641 was VBD B-VP O
32 1273 1276 6150641 not RB I-VP O
33 1277 1287 6150641 associated VBN I-VP O
34 1288 1292 6150641 with IN B-PP O
35 1293 1300 6150641 hepatic JJ B-NP D056486
36 1301 1303 6150641 or CC I-NP D056486
37 1304 1315 6150641 hematologic JJ I-NP D056486
38 1316 1324 6150641 toxicity NN I-NP D056486
39 1325 1327 6150641 or CC I-NP O
40 1328 1339 6150641 alterations NNS I-NP O
41 1340 1342 6150641 of IN B-PP O
42 1343 1348 6150641 serum NN B-NP O
43 1349 1356 6150641 gastrin NN I-NP O
44 1357 1371 6150641 concentrations NNS I-NP O
45 1371 1372 6150641 , , O O
46 1373 1376 6150641 but CC O O
47 1377 1387 6150641 ranitidine NN B-NP D011899
48 1388 1395 6150641 therapy NN I-NP O
49 1396 1399 6150641 was VBD B-VP O
50 1400 1410 6150641 associated VBN I-VP O
51 1411 1415 6150641 with IN B-PP O
52 1416 1417 6150641 a DT B-NP O
53 1418 1431 6150641 significantly RB I-NP O
54 1432 1437 6150641 lower JJR I-NP O
55 1438 1443 6150641 serum NN I-NP O
56 1444 1454 6150641 creatinine NN I-NP D003404
57 1455 1460 6150641 level NN I-NP O
58 1461 1465 6150641 than IN B-SBAR O
59 1466 1470 6150641 seen VBN B-VP O
60 1471 1475 6150641 with IN B-PP O
61 1476 1486 6150641 cimetidine NN B-NP D002927
62 1487 1494 6150641 therapy NN I-NP O
63 1494 1495 6150641 . . O O

1 1496 1499 6150641 The DT B-NP O
2 1500 1507 6150641 results NNS I-NP O
3 1508 1512 6150641 show VBP B-VP O
4 1513 1517 6150641 that IN B-SBAR O
5 1518 1522 6150641 both DT B-NP O
6 1523 1528 6150641 drugs NNS I-NP O
7 1529 1532 6150641 can MD B-VP O
8 1533 1543 6150641 adequately RB I-VP O
9 1544 1551 6150641 inhibit VB I-VP O
10 1552 1556 6150641 acid NN B-NP O
11 1557 1566 6150641 secretion NN I-NP O
12 1567 1569 6150641 in IN B-PP O
13 1570 1578 6150641 patients NNS B-NP O
14 1579 1583 6150641 with IN B-PP O
15 1584 1591 6150641 gastric JJ B-NP O
16 1592 1606 6150641 hypersecretory NN I-NP O
17 1607 1613 6150641 states NNS I-NP O
18 1613 1614 6150641 . . O O

1 1615 1619 6150641 Both DT B-NP O
2 1620 1623 6150641 are VBP B-VP O
3 1624 1628 6150641 safe JJ B-ADJP O
4 1629 1631 6150641 at IN B-PP O
5 1632 1636 6150641 high JJ B-NP O
6 1637 1642 6150641 doses NNS I-NP O
7 1642 1643 6150641 , , O O
8 1644 1647 6150641 but CC O O
9 1648 1658 6150641 ranitidine NN B-NP D011899
10 1659 1661 6150641 is VBZ B-VP O
11 1662 1671 6150641 threefold RB B-ADJP O
12 1672 1676 6150641 more RBR I-ADJP O
13 1677 1683 6150641 potent JJ I-ADJP O
14 1684 1687 6150641 and CC O O
15 1688 1692 6150641 does VBZ B-VP O
16 1693 1696 6150641 not RB I-VP O
17 1697 1702 6150641 cause VB I-VP O
18 1703 1706 6150641 the DT B-NP O
19 1707 1719 6150641 antiandrogen NN I-NP O
20 1720 1724 6150641 side NN I-NP O
21 1725 1732 6150641 effects NNS I-NP O
22 1733 1743 6150641 frequently RB B-VP O
23 1744 1748 6150641 seen VBN I-VP O
24 1749 1753 6150641 with IN B-PP O
25 1754 1758 6150641 high JJ B-NP O
26 1759 1764 6150641 doses NNS I-NP O
27 1765 1767 6150641 of IN B-PP O
28 1768 1778 6150641 cimetidine NN B-NP D002927
29 1778 1779 6150641 . . O O

1 0 0 1079693 -DOCSTART- -X- -X- O

1 0 6 1079693 Ocular JJ B-NP O
2 7 21 1079693 manifestations NNS I-NP O
3 22 24 1079693 of IN B-PP O
4 25 33 1079693 juvenile JJ B-NP D001171
5 34 44 1079693 rheumatoid JJ I-NP D001171
6 45 54 1079693 arthritis NN I-NP D001171
7 54 55 1079693 . . O O
8 56 58 1079693 We PRP B-NP O
9 59 67 1079693 followed VBD B-VP O
10 68 71 1079693 210 CD B-NP O
11 72 77 1079693 cases NNS I-NP O
12 78 80 1079693 of IN B-PP O
13 81 89 1079693 juvenile JJ B-NP D001171
14 90 100 1079693 rheumatoid JJ I-NP D001171
15 101 110 1079693 arthritis NN I-NP D001171
16 111 118 1079693 closely RB B-ADVP O
17 119 122 1079693 for IN B-PP O
18 123 129 1079693 eleven CD B-NP O
19 130 135 1079693 years NNS I-NP O
20 135 136 1079693 . . O O

1 137 143 1079693 Thirty CD B-NP O
2 143 144 1079693 - HYPH I-NP O
3 144 147 1079693 six CD I-NP O
4 148 150 1079693 of IN B-PP O
5 151 154 1079693 the DT B-NP O
6 155 158 1079693 210 CD I-NP O
7 159 167 1079693 patients NNS I-NP O
8 168 169 1079693 ( ( O O
9 169 174 1079693 17.2% NN B-NP O
10 174 175 1079693 ) ) O O
11 176 185 1079693 developed VBD B-VP O
12 186 199 1079693 iridocyclitis NN B-NP D015863
13 199 200 1079693 . . O O

1 201 214 1079693 Iridocyclitis NN B-NP D015863
2 215 218 1079693 was VBD B-VP O
3 219 223 1079693 seen VBN I-VP O
4 224 228 1079693 most RBS B-ADVP O
5 229 239 1079693 frequently RB I-ADVP O
6 240 242 1079693 in IN B-PP O
7 243 248 1079693 young JJ B-NP O
8 249 255 1079693 female JJ I-NP O
9 256 264 1079693 patients NNS I-NP O
10 265 266 1079693 ( ( O O
11 266 267 1079693 0 CD B-NP O
12 268 270 1079693 to TO I-NP O
13 271 272 1079693 4 CD I-NP O
14 273 278 1079693 years NNS I-NP O
15 278 279 1079693 ) ) O O
16 280 284 1079693 with IN B-PP O
17 285 288 1079693 the DT B-NP O
18 289 302 1079693 monoarticular JJ I-NP O
19 303 305 1079693 or CC I-NP O
20 306 320 1079693 pauciatricular JJ I-NP O
21 321 325 1079693 form NN I-NP O
22 326 328 1079693 of IN B-PP O
23 329 332 1079693 the DT B-NP O
24 333 342 1079693 arthritis NN I-NP D001168
25 342 343 1079693 . . O O

1 344 351 1079693 However RB B-ADVP O
2 351 352 1079693 , , O O
3 353 356 1079693 30% CD B-NP O
4 357 359 1079693 of IN B-PP O
5 360 363 1079693 the DT B-NP O
6 364 372 1079693 patients NNS I-NP O
7 373 382 1079693 developed VBD B-VP O
8 383 390 1079693 uveitis NN B-NP D014605
9 391 396 1079693 after IN B-PP O
10 397 399 1079693 16 CD B-NP O
11 400 405 1079693 years NNS I-NP O
12 406 408 1079693 of IN B-PP O
13 409 412 1079693 age NN B-NP O
14 412 413 1079693 . . O O

1 414 422 1079693 Although IN B-SBAR O
2 423 426 1079693 61% CD B-NP O
3 427 429 1079693 of IN B-PP O
4 430 438 1079693 patients NNS B-NP O
5 439 442 1079693 had VBD B-VP O
6 443 444 1079693 a DT B-NP O
7 445 460 1079693 noncontributory JJ I-NP O
8 461 467 1079693 ocular JJ I-NP O
9 468 475 1079693 history NN I-NP O
10 476 478 1079693 on IN B-PP O
11 479 484 1079693 entry NN B-NP O
12 484 485 1079693 , , O O
13 486 489 1079693 42% NN B-NP O
14 490 493 1079693 had VBD B-VP O
15 494 500 1079693 active JJ B-NP O
16 501 508 1079693 uveitis NN I-NP D014605
17 509 511 1079693 on IN B-PP O
18 512 517 1079693 entry NN B-NP O
19 517 518 1079693 . . O O

1 519 522 1079693 Our PRP$ B-NP O
2 523 531 1079693 approach NN I-NP O
3 532 535 1079693 was VBD B-VP O
4 536 545 1079693 effective JJ B-ADJP O
5 546 548 1079693 in IN B-PP O
6 549 558 1079693 detecting VBG B-VP O
7 559 566 1079693 uveitis NN B-NP D014605
8 567 569 1079693 in IN B-PP O
9 570 573 1079693 new JJ B-NP O
10 574 579 1079693 cases NNS I-NP O
11 580 583 1079693 and CC I-NP O
12 584 597 1079693 exacerbations NNS I-NP O
13 598 600 1079693 of IN B-PP O
14 601 608 1079693 uveitis NN B-NP D014605
15 609 611 1079693 in IN B-PP O
16 612 623 1079693 established VBN B-NP O
17 624 629 1079693 cases NNS I-NP O
18 629 630 1079693 . . O O

1 631 636 1079693 Forty CD B-NP O
2 636 637 1079693 - HYPH I-NP O
3 637 641 1079693 four CD I-NP O
4 642 649 1079693 percent NN I-NP O
5 650 652 1079693 of IN B-PP O
6 653 661 1079693 patients NNS B-NP O
7 662 666 1079693 with IN B-PP O
8 667 674 1079693 uveitis NN B-NP D014605
9 675 678 1079693 had VBD B-VP O
10 679 682 1079693 one CD B-NP O
11 683 685 1079693 or CC I-NP O
12 686 690 1079693 more JJR I-NP O
13 691 703 1079693 identifiable JJ I-NP O
14 704 709 1079693 signs NNS I-NP O
15 710 712 1079693 or CC I-NP O
16 713 721 1079693 symptoms NNS I-NP O
17 721 722 1079693 , , O O
18 723 727 1079693 such JJ B-PP O
19 728 730 1079693 as IN I-PP O
20 731 734 1079693 red JJ B-NP O
21 735 738 1079693 eye NN I-NP O
22 738 739 1079693 , , O O
23 740 746 1079693 ocular JJ B-NP D058447
24 747 751 1079693 pain NN I-NP D058447
25 751 752 1079693 , , O O
26 753 762 1079693 decreased VBD B-VP D014786
27 763 769 1079693 visual JJ B-NP D014786
28 770 776 1079693 acuity NN I-NP D014786
29 776 777 1079693 , , O O
30 778 780 1079693 or CC O O
31 781 792 1079693 photophobia NN B-NP D020795
32 792 793 1079693 , , O O
33 794 796 1079693 in IN B-PP O
34 797 802 1079693 order NN B-NP O
35 803 805 1079693 of IN B-PP O
36 806 816 1079693 decreasing VBG B-VP O
37 817 826 1079693 frequency NN B-NP O
38 826 827 1079693 . . O O

1 828 832 1079693 Even RB B-ADVP O
2 833 838 1079693 after IN B-PP O
3 839 844 1079693 early JJ B-NP O
4 845 854 1079693 detection NN I-NP O
5 855 858 1079693 and CC O O
6 859 865 1079693 prompt JJ B-NP O
7 866 875 1079693 treatment NN I-NP O
8 875 876 1079693 , , O O
9 877 880 1079693 41% CD B-NP O
10 881 883 1079693 of IN B-PP O
11 884 889 1079693 cases NNS B-NP O
12 890 892 1079693 of IN B-PP O
13 893 900 1079693 uveitis NN B-NP D014605
14 901 904 1079693 did VBD B-VP O
15 905 908 1079693 not RB I-VP O
16 909 916 1079693 respond VB I-VP O
17 917 919 1079693 to TO B-PP O
18 920 924 1079693 more JJR B-NP O
19 925 929 1079693 than IN I-NP O
20 930 933 1079693 six CD I-NP O
21 934 940 1079693 months NNS I-NP O
22 941 943 1079693 of IN B-PP O
23 944 953 1079693 intensive JJ B-NP O
24 954 961 1079693 topical JJ I-NP O
25 962 971 1079693 treatment NN I-NP O
26 972 976 1079693 with IN B-PP O
27 977 992 1079693 corticosteroids NNS B-NP D000305
28 993 996 1079693 and CC I-NP O
29 997 1007 1079693 mydriatics NNS I-NP O
30 1007 1008 1079693 . . O O

1 1009 1016 1079693 Despite IN B-PP O
2 1017 1021 1079693 this DT B-NP O
3 1021 1022 1079693 , , O O
4 1023 1028 1079693 there EX B-NP O
5 1029 1032 1079693 was VBD B-VP O
6 1033 1034 1079693 a DT B-NP O
7 1035 1043 1079693 dramatic JJ I-NP O
8 1044 1052 1079693 decrease NN I-NP O
9 1053 1055 1079693 in IN B-PP O
10 1056 1059 1079693 the DT B-NP O
11 1060 1063 1079693 50% CD I-NP O
12 1064 1073 1079693 incidence NN I-NP O
13 1074 1076 1079693 of IN B-PP O
14 1077 1085 1079693 blinding VBG B-VP O
15 1086 1099 1079693 complications NNS B-NP O
16 1100 1102 1079693 of IN B-PP O
17 1103 1110 1079693 uveitis NN B-NP D014605
18 1111 1116 1079693 cited VBN B-VP O
19 1117 1119 1079693 in IN B-PP O
20 1120 1127 1079693 earlier JJR B-NP O
21 1128 1135 1079693 studies NNS I-NP O
22 1135 1136 1079693 . . O O

1 1137 1145 1079693 Cataract NN B-NP D002386
2 1146 1149 1079693 and CC I-NP O
3 1150 1154 1079693 band NN I-NP C562399
4 1155 1166 1079693 keratopathy NN I-NP C562399
5 1167 1175 1079693 occurred VBD B-VP O
6 1176 1178 1079693 in IN B-PP O
7 1179 1183 1079693 only RB B-NP O
8 1184 1186 1079693 22 CD I-NP O
9 1187 1190 1079693 and CC I-NP O
10 1191 1194 1079693 13% CD I-NP O
11 1195 1197 1079693 of IN B-PP O
12 1198 1201 1079693 our PRP$ B-NP O
13 1202 1207 1079693 group NN I-NP O
14 1207 1208 1079693 , , O O
15 1209 1221 1079693 respectively RB B-ADVP O
16 1221 1222 1079693 . . O O

1 1223 1225 1079693 We PRP B-NP O
2 1226 1230 1079693 used VBD B-VP O
3 1231 1242 1079693 chloroquine NN B-NP D002738
4 1243 1245 1079693 or CC I-NP O
5 1246 1264 1079693 hydroxychloroquine NN I-NP D006886
6 1265 1267 1079693 in IN B-PP O
7 1268 1271 1079693 173 CD B-NP O
8 1272 1274 1079693 of IN B-PP O
9 1275 1278 1079693 210 CD B-NP O
10 1279 1284 1079693 cases NNS I-NP O
11 1285 1288 1079693 and CC O O
12 1289 1294 1079693 found VBN B-VP O
13 1295 1299 1079693 only RB B-NP O
14 1300 1303 1079693 one CD I-NP O
15 1304 1308 1079693 case NN I-NP O
16 1309 1311 1079693 of IN B-PP O
17 1312 1329 1079693 chorioretinopathy NN B-NP D012164
18 1330 1342 1079693 attributable JJ B-ADJP O
19 1343 1345 1079693 to TO B-PP O
20 1346 1351 1079693 these DT B-NP O
21 1352 1357 1079693 drugs NNS I-NP O
22 1357 1358 1079693 . . O O

1 1359 1371 1079693 Systemically RB B-NP O
2 1372 1384 1079693 administered VBN I-NP O
3 1385 1400 1079693 corticosteroids NNS I-NP D000305
4 1401 1405 1079693 were VBD B-VP O
5 1406 1410 1079693 used VBN I-VP O
6 1411 1413 1079693 in IN B-PP O
7 1414 1416 1079693 75 CD B-NP O
8 1417 1419 1079693 of IN B-PP O
9 1420 1423 1079693 210 CD B-NP O
10 1424 1429 1079693 cases NNS I-NP O
11 1429 1430 1079693 ; : O O
12 1431 1432 1079693 a DT B-NP O
13 1433 1444 1079693 significant JJ I-NP O
14 1445 1451 1079693 number NN I-NP O
15 1452 1454 1079693 of IN B-PP O
16 1455 1464 1079693 posterior JJ B-NP O
17 1465 1476 1079693 subcapsular JJ I-NP O
18 1477 1486 1079693 cataracts NNS I-NP D002386
19 1487 1490 1079693 was VBD B-VP O
20 1491 1496 1079693 found VBN I-VP O
21 1496 1497 1079693 . . O O

1 1498 1505 1079693 Typical JJ B-NP O
2 1506 1526 1079693 keratoconjunctivitis NN I-NP D007637
3 1527 1532 1079693 sicca NN I-NP O
4 1533 1542 1079693 developed VBN B-VP O
5 1543 1545 1079693 in IN B-PP O
6 1546 1551 1079693 three CD B-NP O
7 1552 1554 1079693 of IN B-PP O
8 1555 1558 1079693 the DT B-NP O
9 1559 1566 1079693 uveitis NN I-NP D014605
10 1567 1572 1079693 cases NNS I-NP O
11 1572 1573 1079693 . . O O

1 1574 1578 1079693 This DT B-NP O
2 1579 1590 1079693 association NN I-NP O
3 1591 1595 1079693 with IN B-PP O
4 1596 1603 1079693 uveitis NN B-NP D014605
5 1604 1607 1079693 and CC I-NP O
6 1608 1611 1079693 JRA NN I-NP O
7 1612 1615 1079693 was VBD B-VP O
8 1616 1619 1079693 not RB I-VP O
9 1620 1625 1079693 noted VBN I-VP O
10 1626 1636 1079693 previously RB B-ADVP O
11 1636 1637 1079693 . . O O

1 1638 1646 1079693 Surgical JJ B-NP O
2 1647 1656 1079693 treatment NN I-NP O
3 1657 1659 1079693 of IN B-PP O
4 1660 1669 1079693 cataracts NNS B-NP D002386
5 1669 1670 1079693 , , O O
6 1671 1675 1079693 band NN B-NP C562399
7 1676 1687 1079693 keratopathy NN I-NP C562399
8 1687 1688 1079693 , , O O
9 1689 1692 1079693 and CC O O
10 1693 1701 1079693 glaucoma NN B-NP D005901
11 1702 1710 1079693 achieved VBD B-VP O
12 1711 1720 1079693 uniformly RB I-VP O
13 1721 1733 1079693 discouraging VBG I-VP O
14 1734 1741 1079693 results NNS B-NP O
15 1741 1742 1079693 . . O O

1 0 0 1700207 -DOCSTART- -X- -X- O

1 0 14 1700207 Antiarrhythmic JJ B-NP O
2 15 22 1700207 effects NNS I-NP O
3 23 25 1700207 of IN B-PP O
4 26 33 1700207 optical JJ B-NP O
5 34 41 1700207 isomers NNS I-NP O
6 42 44 1700207 of IN B-PP O
7 45 56 1700207 cibenzoline NN B-NP C032151
8 57 59 1700207 on IN B-PP O
9 60 66 1700207 canine JJ B-NP O
10 67 78 1700207 ventricular JJ I-NP D001145
11 79 90 1700207 arrhythmias NNS I-NP D001145
12 90 91 1700207 . . O O
13 92 106 1700207 Antiarrhythmic JJ B-NP O
14 107 114 1700207 effects NNS I-NP O
15 115 117 1700207 of IN B-PP O
16 118 121 1700207 (+) SYM B-NP O
17 121 122 1700207 - HYPH B-NP O
18 122 133 1700207 cibenzoline NN I-NP C032151
19 134 137 1700207 and CC O O
20 138 139 1700207 ( ( O O
21 139 140 1700207 - SYM O O
22 140 141 1700207 ) ) O O
23 141 142 1700207 - HYPH B-NP O
24 142 153 1700207 cibenzoline NN I-NP C032151
25 154 158 1700207 were VBD B-VP O
26 159 167 1700207 examined VBN I-VP O
27 168 173 1700207 using VBG B-VP O
28 174 177 1700207 two CD B-NP O
29 178 184 1700207 canine JJ I-NP O
30 185 196 1700207 ventricular JJ I-NP D001145
31 197 207 1700207 arrhythmia NN I-NP D001145
32 208 214 1700207 models NNS I-NP O
33 214 215 1700207 . . O O

1 216 225 1700207 Digitalis NNP B-NP D004070
2 226 236 1700207 arrhythmia NN I-NP D001145
3 236 237 1700207 , , O O
4 238 243 1700207 which WDT B-NP O
5 244 246 1700207 is VBZ B-VP O
6 247 257 1700207 suppressed VBN I-VP O
7 258 260 1700207 by IN B-PP O
8 261 263 1700207 Na NN B-NP D012964
9 264 271 1700207 channel NN I-NP O
10 272 280 1700207 blockers NNS I-NP O
11 280 281 1700207 , , O O
12 282 285 1700207 was VBD B-VP O
13 286 293 1700207 induced VBN I-VP O
14 294 296 1700207 by IN B-PP O
15 297 309 1700207 intermittent JJ B-NP O
16 310 321 1700207 intravenous JJ I-NP O
17 322 323 1700207 ( ( O O
18 323 326 1700207 i.v JJ O O
19 326 327 1700207 . . O O
20 327 328 1700207 ) ) O O
21 329 338 1700207 injection NN B-NP O
22 339 341 1700207 of IN B-PP O
23 342 349 1700207 ouabain NN B-NP D010042
24 350 352 1700207 in IN B-PP O
25 353 366 1700207 pentobarbital NN B-NP D010424
26 366 367 1700207 - HYPH B-NP O
27 367 379 1700207 anesthetized VBN I-NP O
28 380 384 1700207 dogs NNS I-NP O
29 384 385 1700207 . . O O

1 386 396 1700207 Adrenaline NN B-NP D001145
2 397 407 1700207 arrhythmia NN I-NP D001145
3 407 408 1700207 , , O O
4 409 414 1700207 which WDT B-NP O
5 415 417 1700207 is VBZ B-VP O
6 418 428 1700207 suppressed VBN I-VP O
7 429 431 1700207 by IN B-PP O
8 432 434 1700207 Ca NN B-NP D002118
9 435 442 1700207 channel NN I-NP O
10 443 451 1700207 blockers NNS I-NP O
11 451 452 1700207 , , O O
12 453 456 1700207 was VBD B-VP O
13 457 464 1700207 induced VBN I-VP O
14 465 467 1700207 by IN B-PP O
15 468 478 1700207 adrenaline NN B-NP D004837
16 479 487 1700207 infusion NN I-NP O
17 488 490 1700207 in IN B-PP O
18 491 500 1700207 halothane NN B-NP D006221
19 500 501 1700207 - HYPH B-NP O
20 501 513 1700207 anesthetized VBN I-NP O
21 514 518 1700207 dogs NNS I-NP O
22 518 519 1700207 . . O O

1 520 523 1700207 Ten CD B-NP O
2 524 527 1700207 and CC I-NP O
3 528 529 1700207 5 CD I-NP O
4 530 532 1700207 mg NN I-NP O
5 532 533 1700207 / SYM B-NP O
6 533 535 1700207 kg NN I-NP O
7 536 539 1700207 i.v NN I-NP O
8 539 540 1700207 . . O O

1 541 544 1700207 (+) LS B-LST O
2 544 545 1700207 - : O O
3 545 556 1700207 cibenzoline NN B-NP C032151
4 557 567 1700207 suppressed VBD B-VP O
5 568 577 1700207 digitalis NN B-NP D004070
6 577 578 1700207 - HYPH B-NP O
7 579 582 1700207 and CC I-NP O
8 583 593 1700207 adrenaline NN I-NP D004837
9 593 594 1700207 - HYPH O O
10 594 601 1700207 induced VBN B-NP O
11 602 613 1700207 arrhythmias NNS I-NP D001145
12 613 614 1700207 , , O O
13 615 627 1700207 respectively RB B-ADVP O
14 627 628 1700207 . . O O

1 629 632 1700207 The DT B-NP O
2 633 640 1700207 minimum JJ I-NP O
3 641 650 1700207 effective JJ I-NP O
4 651 657 1700207 plasma NN I-NP O
5 658 672 1700207 concentrations NNS I-NP O
6 673 675 1700207 of IN B-PP O
7 676 679 1700207 (+) SYM B-NP O
8 679 680 1700207 - HYPH B-NP O
9 680 691 1700207 cibenzoline NN I-NP C032151
10 692 695 1700207 for IN B-PP O
11 696 705 1700207 digitalis NN B-NP D004070
12 705 706 1700207 - HYPH B-NP O
13 707 710 1700207 and CC O O
14 711 721 1700207 adrenaline NN B-NP D004837
15 721 722 1700207 - HYPH B-NP O
16 722 729 1700207 induced VBN I-NP O
17 730 741 1700207 arrhythmias NNS I-NP D001145
18 742 746 1700207 were VBD B-VP O
19 747 750 1700207 1.4 CD B-NP O
20 751 752 1700207 + SYM O O
21 752 753 1700207 / SYM O O
22 753 754 1700207 - SYM B-NP O
23 755 758 1700207 0.4 CD B-NP O
24 759 762 1700207 and CC I-NP O
25 763 766 1700207 2.0 CD I-NP O
26 767 768 1700207 + SYM B-NP O
27 768 769 1700207 / SYM B-NP O
28 769 770 1700207 - SYM B-VP O
29 771 774 1700207 0.6 CD B-NP O
30 775 785 1700207 micrograms NNS I-NP O
31 785 786 1700207 / SYM B-NP O
32 786 788 1700207 ml NN I-NP O
33 788 789 1700207 , , O O
34 790 802 1700207 respectively RB B-ADVP O
35 803 804 1700207 ( ( O O
36 804 808 1700207 mean NN B-NP O
37 809 810 1700207 + SYM O O
38 810 811 1700207 / SYM O O
39 811 812 1700207 - HYPH O O
40 813 815 1700207 SD NN B-NP O
41 815 816 1700207 , , O O
42 817 818 1700207 n NN B-NP O
43 819 820 1700207 = JJ B-VP O
44 821 822 1700207 6 CD B-NP O
45 822 823 1700207 ) ) O O
46 823 824 1700207 . . O O

1 825 826 1700207 A DT B-NP O
2 827 832 1700207 lower JJR I-NP O
3 833 837 1700207 dose NN I-NP O
4 838 840 1700207 of IN B-PP O
5 841 842 1700207 1 CD B-NP O
6 843 845 1700207 mg NN I-NP O
7 845 846 1700207 / SYM B-NP O
8 846 848 1700207 kg NN I-NP O
9 849 852 1700207 i.v NN I-NP O
10 852 853 1700207 . . O O

1 854 856 1700207 of IN B-PP O
2 857 858 1700207 ( ( O O
3 858 859 1700207 - SYM O O
4 859 860 1700207 ) ) O O
5 860 861 1700207 - HYPH B-NP O
6 861 872 1700207 cibenzoline NN I-NP C032151
7 873 883 1700207 suppressed VBD B-VP O
8 884 887 1700207 the DT B-NP O
9 888 897 1700207 digitalis NN I-NP D004070
10 897 898 1700207 - HYPH B-NP O
11 898 905 1700207 induced VBN I-NP O
12 906 916 1700207 arrhythmia NN I-NP D001145
13 916 917 1700207 , , O O
14 918 925 1700207 whereas IN O O
15 926 927 1700207 5 CD B-NP O
16 928 930 1700207 mg NN I-NP O
17 930 931 1700207 / SYM B-NP O
18 931 933 1700207 kg NN I-NP O
19 934 937 1700207 i.v NN I-NP O
20 937 938 1700207 . . O O

1 939 942 1700207 was VBD B-VP O
2 943 949 1700207 needed VBN I-VP O
3 950 952 1700207 to TO B-VP O
4 953 961 1700207 suppress VB I-VP O
5 962 972 1700207 adrenaline NN B-NP D004837
6 972 973 1700207 - HYPH B-NP O
7 973 980 1700207 induced VBN I-NP O
8 981 992 1700207 arrhythmias NNS I-NP D001145
9 992 993 1700207 . . O O

1 994 997 1700207 The DT B-NP O
2 998 1005 1700207 minimum JJ I-NP O
3 1006 1015 1700207 effective JJ I-NP O
4 1016 1022 1700207 plasma NN I-NP O
5 1023 1037 1700207 concentrations NNS I-NP O
6 1038 1040 1700207 of IN B-PP O
7 1041 1042 1700207 ( ( O O
8 1042 1043 1700207 - SYM O O
9 1043 1044 1700207 ) ) O O
10 1044 1045 1700207 - HYPH B-NP O
11 1045 1056 1700207 cibenzoline NN I-NP C032151
12 1057 1060 1700207 for IN B-PP O
13 1061 1070 1700207 digitalis NN B-NP D004070
14 1070 1071 1700207 - HYPH B-NP O
15 1072 1075 1700207 and CC I-NP O
16 1076 1086 1700207 adrenaline NN I-NP D004837
17 1086 1087 1700207 - HYPH O O
18 1087 1094 1700207 induced VBN B-NP O
19 1095 1105 1700207 arrhythmia NN I-NP D001145
20 1106 1110 1700207 were VBD B-VP O
21 1111 1115 1700207 0.06 CD B-NP O
22 1116 1117 1700207 + SYM O O
23 1117 1118 1700207 / SYM O O
24 1118 1119 1700207 - SYM B-NP O
25 1120 1124 1700207 0.04 CD B-NP O
26 1125 1128 1700207 and CC I-NP O
27 1129 1132 1700207 0.7 CD I-NP O
28 1133 1134 1700207 + SYM B-NP O
29 1134 1135 1700207 / SYM B-NP O
30 1135 1136 1700207 - SYM B-VP O
31 1137 1140 1700207 0.1 CD B-NP O
32 1141 1151 1700207 micrograms NNS I-NP O
33 1151 1152 1700207 / SYM B-NP O
34 1152 1154 1700207 ml NN I-NP O
35 1154 1155 1700207 , , O O
36 1156 1168 1700207 respectively RB B-ADVP O
37 1169 1170 1700207 ( ( O O
38 1170 1174 1700207 mean NN B-NP O
39 1175 1176 1700207 + SYM O O
40 1176 1177 1700207 / SYM O O
41 1177 1178 1700207 - HYPH O O
42 1179 1181 1700207 SD NN B-NP O
43 1181 1182 1700207 , , O O
44 1183 1184 1700207 n NN B-NP O
45 1185 1186 1700207 = JJ B-VP O
46 1187 1188 1700207 6 CD B-NP O
47 1188 1189 1700207 ) ) O O
48 1189 1190 1700207 . . O O

1 1191 1194 1700207 The DT B-NP O
2 1195 1203 1700207 stronger JJR I-NP O
3 1204 1218 1700207 antiarrhythmic JJ I-NP O
4 1219 1225 1700207 effect NN I-NP O
5 1226 1228 1700207 of IN B-PP O
6 1229 1230 1700207 ( ( O O
7 1230 1231 1700207 - SYM O O
8 1231 1232 1700207 ) ) O O
9 1232 1233 1700207 - HYPH B-NP O
10 1233 1244 1700207 cibenzoline NN I-NP C032151
11 1245 1254 1700207 indicates VBZ B-VP O
12 1255 1259 1700207 that IN B-SBAR O
13 1260 1261 1700207 ( ( O O
14 1261 1262 1700207 - SYM O O
15 1262 1263 1700207 ) ) O O
16 1263 1264 1700207 - HYPH B-NP O
17 1264 1270 1700207 isomer NN I-NP O
18 1271 1274 1700207 may MD B-VP O
19 1275 1279 1700207 have VB I-VP O
20 1280 1282 1700207 an DT B-NP O
21 1283 1289 1700207 effect NN I-NP O
22 1290 1296 1700207 nearly RB B-NP O
23 1297 1298 1700207 5 CD I-NP O
24 1298 1299 1700207 - HYPH I-NP O
25 1299 1301 1700207 20 CD I-NP O
26 1302 1307 1700207 times NNS I-NP O
27 1308 1316 1700207 stronger JJR I-NP O
28 1317 1319 1700207 in IN B-PP O
29 1320 1331 1700207 suppressing VBG B-VP O
30 1332 1334 1700207 Na NN B-NP D012964
31 1335 1343 1700207 channels NNS I-NP O
32 1343 1344 1700207 , , O O
33 1345 1348 1700207 but CC O O
34 1349 1356 1700207 effects NNS B-NP O
35 1357 1359 1700207 of IN B-PP O
36 1360 1364 1700207 both DT B-NP O
37 1365 1370 1700207 drugs NNS I-NP O
38 1371 1373 1700207 on IN B-PP O
39 1374 1376 1700207 Ca NN B-NP D002118
40 1377 1385 1700207 channels NNS I-NP O
41 1386 1389 1700207 may MD B-VP O
42 1390 1392 1700207 be VB I-VP O
43 1393 1399 1700207 almost RB B-ADJP O
44 1400 1410 1700207 equipotent JJ I-ADJP O
45 1410 1411 1700207 . . O O

1 0 0 2893236 -DOCSTART- -X- -X- O

1 0 4 2893236 GABA NN B-NP D005680
2 5 16 2893236 involvement NN I-NP O
3 17 19 2893236 in IN B-PP O
4 20 28 2893236 naloxone NN B-NP D009270
5 29 36 2893236 induced VBD B-VP O
6 37 45 2893236 reversal NN B-NP O
7 46 48 2893236 of IN B-PP O
8 49 60 2893236 respiratory JJ B-NP D012133
9 61 70 2893236 paralysis NN I-NP D012133
10 71 79 2893236 produced VBN B-VP O
11 80 82 2893236 by IN B-PP O
12 83 93 2893236 thiopental NN B-NP D013874
13 93 94 2893236 . . O O
14 95 97 2893236 No DT B-NP O
15 98 103 2893236 agent NN I-NP O
16 104 106 2893236 is VBZ B-VP O
17 107 110 2893236 yet RB B-ADJP O
18 111 120 2893236 available JJ I-ADJP O
19 121 123 2893236 to TO B-VP O
20 124 131 2893236 reverse VB I-VP O
21 132 143 2893236 respiratory JJ B-NP D012133
22 144 153 2893236 paralysis NN I-NP D012133
23 154 162 2893236 produced VBN B-VP O
24 163 165 2893236 by IN B-PP O
25 166 169 2893236 CNS NN B-NP O
26 170 181 2893236 depressants NNS I-NP O
27 181 182 2893236 , , O O
28 183 187 2893236 such JJ B-PP O
29 188 190 2893236 as IN I-PP O
30 191 198 2893236 general JJ B-NP O
31 199 210 2893236 anesthetics NNS I-NP O
32 210 211 2893236 . . O O

1 212 214 2893236 In IN B-PP O
2 215 219 2893236 this DT B-NP O
3 220 225 2893236 study NN I-NP O
4 226 234 2893236 naloxone NN I-NP D009270
5 235 243 2893236 reversed VBD B-VP O
6 244 255 2893236 respiratory JJ B-NP D012133
7 256 265 2893236 paralysis NN I-NP D012133
8 266 273 2893236 induced VBN B-VP O
9 274 276 2893236 by IN B-PP O
10 277 287 2893236 thiopental NN B-NP D013874
11 288 290 2893236 in IN B-PP O
12 291 295 2893236 rats NNS B-NP O
13 295 296 2893236 . . O O

1 297 299 2893236 25 CD B-NP O
2 300 302 2893236 mg NN I-NP O
3 302 303 2893236 / SYM O O
4 303 305 2893236 kg NN B-NP O
5 305 306 2893236 , , O O
6 307 310 2893236 i.v NN B-NP O
7 310 311 2893236 . . O O

1 312 322 2893236 thiopental NN B-NP D013874
2 323 331 2893236 produced VBD B-VP O
3 332 342 2893236 anesthesia NN B-NP O
4 343 350 2893236 without IN B-PP O
5 351 359 2893236 altering VBG B-VP O
6 360 371 2893236 respiratory JJ B-NP O
7 372 376 2893236 rate NN I-NP O
8 376 377 2893236 , , O O
9 378 387 2893236 increased VBN B-NP O
10 388 392 2893236 GABA NN I-NP D005680
11 392 393 2893236 , , O O
12 394 403 2893236 decreased VBN B-NP O
13 404 413 2893236 glutamate NN I-NP D018698
14 413 414 2893236 , , O O
15 415 418 2893236 and CC O O
16 419 422 2893236 had VBD B-VP O
17 423 425 2893236 no DT B-NP O
18 426 432 2893236 effect NN I-NP O
19 433 435 2893236 on IN B-PP O
20 436 445 2893236 aspartate NN B-NP D001224
21 446 448 2893236 or CC I-NP O
22 449 456 2893236 glycine NN I-NP D005998
23 457 463 2893236 levels NNS I-NP O
24 464 472 2893236 compared VBN B-VP O
25 473 475 2893236 to TO B-PP O
26 476 484 2893236 controls NNS B-NP O
27 485 487 2893236 in IN B-PP O
28 488 491 2893236 rat NN B-NP O
29 492 498 2893236 cortex NN I-NP O
30 499 502 2893236 and CC I-NP O
31 503 508 2893236 brain NN I-NP O
32 509 513 2893236 stem NN I-NP O
33 513 514 2893236 . . O O

1 515 527 2893236 Pretreatment NN B-NP O
2 528 530 2893236 of IN B-PP O
3 531 535 2893236 rats NNS B-NP O
4 536 540 2893236 with IN B-PP O
5 541 558 2893236 thiosemicarbazide NN B-NP C005151
6 559 562 2893236 for IN B-PP O
7 563 565 2893236 30 CD B-NP O
8 566 573 2893236 minutes NNS I-NP O
9 574 583 2893236 abolished VBD B-VP O
10 584 587 2893236 the DT B-NP O
11 588 598 2893236 anesthetic JJ I-NP O
12 599 605 2893236 action NN I-NP O
13 606 608 2893236 as RB B-CONJP O
14 609 613 2893236 well RB I-CONJP O
15 614 616 2893236 as IN I-CONJP O
16 617 620 2893236 the DT B-NP O
17 621 632 2893236 respiratory JJ I-NP O
18 633 643 2893236 depressant NN I-NP O
19 644 650 2893236 action NN I-NP O
20 651 653 2893236 of IN B-PP O
21 654 664 2893236 thiopental NN B-NP D013874
22 664 665 2893236 . . O O

1 666 668 2893236 50 CD B-NP O
2 669 671 2893236 mg NN I-NP O
3 671 672 2893236 / SYM B-NP O
4 672 674 2893236 kg NN B-NP O
5 674 675 2893236 , , O O
6 676 679 2893236 i.v NN B-NP O
7 679 680 2893236 . . O O

1 681 691 2893236 thiopental NN B-NP D013874
2 692 700 2893236 produced VBD B-VP O
3 701 712 2893236 respiratory JJ B-NP D012131
4 713 719 2893236 arrest NN I-NP D012131
5 720 724 2893236 with IN B-PP O
6 725 732 2893236 further JJ B-NP O
7 733 741 2893236 increase NN I-NP O
8 742 744 2893236 in IN B-PP O
9 745 749 2893236 GABA NN B-NP D005680
10 750 753 2893236 and CC I-NP O
11 754 762 2893236 decrease NN I-NP O
12 763 765 2893236 in IN B-PP O
13 766 775 2893236 glutamate NN B-NP D018698
14 776 781 2893236 again RB B-ADVP O
15 782 784 2893236 in IN B-PP O
16 785 791 2893236 cortex NN B-NP O
17 792 795 2893236 and CC I-NP O
18 796 801 2893236 brain NN I-NP O
19 802 806 2893236 stem NN I-NP O
20 807 814 2893236 without IN B-PP O
21 815 824 2893236 affecting VBG B-VP O
22 825 828 2893236 any DT B-NP O
23 829 831 2893236 of IN B-PP O
24 832 835 2893236 the DT B-NP O
25 836 841 2893236 amino JJ I-NP D000596
26 842 847 2893236 acids NNS I-NP D000596
27 848 855 2893236 studied VBN B-VP O
28 856 858 2893236 in IN B-PP O
29 859 863 2893236 four CD B-NP O
30 864 871 2893236 regions NNS I-NP O
31 872 874 2893236 of IN B-PP O
32 875 878 2893236 rat NN B-NP O
33 879 884 2893236 brain NN I-NP O
34 884 885 2893236 . . O O

1 886 894 2893236 Naloxone NN B-NP D009270
2 895 896 2893236 ( ( O O
3 896 899 2893236 2.5 CD B-NP O
4 900 902 2893236 mg NN I-NP O
5 902 903 2893236 / SYM B-NP O
6 903 905 2893236 kg NN I-NP O
7 905 906 2893236 , , O O
8 907 910 2893236 i.v JJ B-ADJP O
9 910 911 2893236 . . O O
10 911 912 2893236 ) ) O O
11 913 921 2893236 reversed VBD B-VP O
12 922 933 2893236 respiratory JJ B-NP D012133
13 934 943 2893236 paralysis NN I-NP D012133
14 943 944 2893236 , , O O
15 945 954 2893236 glutamate NN B-NP D018698
16 955 958 2893236 and CC I-NP O
17 959 963 2893236 GABA NN I-NP D005680
18 964 970 2893236 levels NNS I-NP O
19 971 973 2893236 to TO B-VP O
20 974 981 2893236 control VB I-VP O
21 982 988 2893236 values NNS B-NP O
22 989 991 2893236 in IN B-PP O
23 992 997 2893236 brain NN B-NP O
24 998 1002 2893236 stem NN I-NP O
25 1003 1006 2893236 and CC O O
26 1007 1013 2893236 cortex NN B-NP O
27 1014 1018 2893236 with IN B-PP O
28 1019 1021 2893236 no DT B-NP O
29 1022 1029 2893236 changes NNS I-NP O
30 1030 1032 2893236 in IN B-PP O
31 1033 1040 2893236 caudate NN B-NP O
32 1041 1043 2893236 or CC I-NP O
33 1044 1054 2893236 cerebellum NN I-NP O
34 1054 1055 2893236 . . O O

1 1056 1061 2893236 These DT B-NP O
2 1062 1066 2893236 data NNS I-NP O
3 1067 1074 2893236 suggest VBP B-VP O
4 1075 1083 2893236 naloxone NN B-NP D009270
5 1084 1092 2893236 reverses VBZ B-VP O
6 1093 1104 2893236 respiratory JJ B-NP D012133
7 1105 1114 2893236 paralysis NN I-NP D012133
8 1115 1123 2893236 produced VBN B-VP O
9 1124 1126 2893236 by IN B-PP O
10 1127 1137 2893236 thiopental NN B-NP D013874
11 1138 1141 2893236 and CC O O
12 1142 1150 2893236 involves VBZ B-VP O
13 1151 1155 2893236 GABA NN B-NP D005680
14 1156 1158 2893236 in IN B-PP O
15 1159 1162 2893236 its PRP$ B-NP O
16 1163 1169 2893236 action NN I-NP O
17 1169 1170 2893236 . . O O

1 0 0 3220106 -DOCSTART- -X- -X- O

1 0 8 3220106 Receptor NN B-NP O
2 9 19 3220106 mechanisms NNS I-NP O
3 20 22 3220106 of IN B-PP O
4 23 31 3220106 nicotine NN B-NP D009538
5 31 32 3220106 - HYPH B-NP O
6 32 39 3220106 induced VBN I-NP O
7 40 49 3220106 locomotor NN I-NP D006948
8 50 63 3220106 hyperactivity NN I-NP D006948
9 64 66 3220106 in IN B-PP O
10 67 74 3220106 chronic JJ B-NP O
11 75 83 3220106 nicotine NN I-NP D009538
12 83 84 3220106 - HYPH B-NP O
13 84 91 3220106 treated VBN I-NP O
14 92 96 3220106 rats NNS I-NP O
15 96 97 3220106 . . O O
16 98 102 3220106 Rats NNS B-NP O
17 103 107 3220106 were VBD B-VP O
18 108 118 3220106 pretreated VBN I-VP O
19 119 123 3220106 with IN B-PP O
20 124 130 3220106 saline NN B-NP O
21 131 133 3220106 or CC I-NP O
22 134 142 3220106 nicotine NN I-NP D009538
23 143 144 3220106 ( ( O O
24 144 147 3220106 1.5 CD B-NP O
25 148 150 3220106 mg NN I-NP O
26 150 151 3220106 / SYM B-NP O
27 151 153 3220106 kg NN I-NP O
28 154 157 3220106 per IN B-PP O
29 158 161 3220106 day NN B-NP O
30 161 162 3220106 ) ) O O
31 163 165 3220106 by IN B-PP O
32 166 180 3220106 subcutaneously RB B-VP O
33 181 191 3220106 implanting VBG I-VP O
34 192 196 3220106 each DT B-NP O
35 197 203 3220106 animal NN I-NP O
36 204 208 3220106 with IN B-PP O
37 209 211 3220106 an DT B-NP O
38 212 217 3220106 Alzet NNP I-NP O
39 218 225 3220106 osmotic JJ I-NP O
40 226 230 3220106 mini AFX I-NP O
41 230 231 3220106 - HYPH I-NP O
42 231 235 3220106 pump NN I-NP O
43 236 241 3220106 which WDT B-NP O
44 242 254 3220106 continuously RB B-ADVP O
45 255 263 3220106 released VBD B-VP O
46 264 270 3220106 saline NN B-NP O
47 271 273 3220106 or CC I-NP O
48 274 282 3220106 nicotine NN I-NP D009538
49 283 286 3220106 for IN B-PP O
50 287 288 3220106 1 CD B-NP O
51 288 289 3220106 , , I-NP O
52 290 291 3220106 5 CD I-NP O
53 292 295 3220106 and CC I-NP O
54 296 298 3220106 14 CD I-NP O
55 299 303 3220106 days NNS I-NP O
56 303 304 3220106 . . O O

1 305 307 3220106 At IN B-PP O
2 308 311 3220106 the DT B-NP O
3 312 315 3220106 end NN I-NP O
4 316 318 3220106 of IN B-PP O
5 319 323 3220106 each DT B-NP O
6 324 336 3220106 pretreatment NN I-NP O
7 337 343 3220106 period NN I-NP O
8 343 344 3220106 , , O O
9 345 352 3220106 animals NNS B-NP O
10 353 357 3220106 were VBD B-VP O
11 358 362 3220106 used VBN I-VP O
12 363 366 3220106 for IN B-PP O
13 367 370 3220106 (i) LS O O
14 371 382 3220106 determining VBG B-VP O
15 383 388 3220106 their PRP$ B-NP O
16 389 398 3220106 locomotor NN I-NP O
17 399 407 3220106 response NN I-NP O
18 408 410 3220106 to TO B-PP O
19 411 418 3220106 acutely RB B-NP O
20 419 427 3220106 injected VBN I-NP O
21 428 436 3220106 nicotine NN I-NP D009538
22 437 438 3220106 ( ( O O
23 438 441 3220106 0.2 CD B-NP O
24 442 444 3220106 mg NN I-NP O
25 444 445 3220106 / SYM B-NP O
26 445 447 3220106 kg NN I-NP O
27 447 448 3220106 , , O O
28 449 452 3220106 s.c NN B-NP O
29 452 453 3220106 . . O O
30 453 454 3220106 ) ) O O
31 455 458 3220106 and CC O O
32 459 463 3220106 (ii) LS B-NP O
33 464 473 3220106 measuring VBG B-VP O
34 474 477 3220106 the DT B-NP O
35 478 485 3220106 density NN I-NP O
36 486 488 3220106 of IN B-PP O
37 489 490 3220106 L NN B-NP O
38 490 491 3220106 - HYPH B-NP O
39 491 503 3220106 [3H]nicotine NN I-NP D009538
40 504 507 3220106 and CC I-NP O
41 508 521 3220106 [3H]spiperone NN I-NP D013134
42 522 529 3220106 binding NN I-NP O
43 530 535 3220106 sites NNS I-NP O
44 536 538 3220106 in IN B-PP O
45 539 542 3220106 the DT B-NP O
46 543 551 3220106 striatum NN I-NP O
47 551 552 3220106 . . O O

1 553 555 3220106 We PRP B-NP O
2 556 564 3220106 observed VBD B-VP O
3 565 567 3220106 no DT B-NP O
4 568 575 3220106 changes NNS I-NP O
5 576 578 3220106 in IN B-PP O
6 579 587 3220106 nicotine NN B-NP D009538
7 587 588 3220106 - HYPH B-NP O
8 588 595 3220106 induced VBN I-NP O
9 596 605 3220106 locomotor NN I-NP O
10 606 614 3220106 response NN I-NP O
11 614 615 3220106 , , O O
12 616 624 3220106 striatal JJ B-NP O
13 625 626 3220106 L NN I-NP O
14 626 627 3220106 - HYPH B-NP O
15 627 639 3220106 [3H]nicotine NN I-NP D009538
16 640 643 3220106 and CC I-NP O
17 644 657 3220106 [3H]spiperone NN I-NP D013134
18 658 665 3220106 binding NN I-NP O
19 666 668 3220106 in IN B-PP O
20 669 672 3220106 the DT B-NP O
21 673 680 3220106 animals NNS I-NP O
22 681 691 3220106 pretreated VBN B-VP O
23 692 696 3220106 with IN B-PP O
24 697 705 3220106 nicotine NN B-NP D009538
25 706 709 3220106 for IN B-PP O
26 710 711 3220106 1 CD B-NP O
27 712 715 3220106 day NN I-NP O
28 715 716 3220106 . . O O

1 717 719 3220106 In IN B-PP O
2 720 724 3220106 rats NNS B-NP O
3 725 730 3220106 which WDT B-NP O
4 731 735 3220106 were VBD B-VP O
5 736 746 3220106 pretreated VBN I-VP O
6 747 751 3220106 with IN B-PP O
7 752 760 3220106 nicotine NN B-NP D009538
8 761 764 3220106 for IN B-PP O
9 765 766 3220106 5 CD B-NP O
10 767 771 3220106 days NNS I-NP O
11 771 772 3220106 , , O O
12 773 778 3220106 there EX B-NP O
13 779 782 3220106 was VBD B-VP O
14 783 784 3220106 a DT B-NP O
15 785 796 3220106 significant JJ I-NP O
16 797 805 3220106 increase NN I-NP O
17 806 808 3220106 in IN B-PP O
18 809 812 3220106 the DT B-NP O
19 813 821 3220106 nicotine NN I-NP D009538
20 821 822 3220106 - HYPH B-VP O
21 822 832 3220106 stimulated VBN B-NP O
22 833 842 3220106 locomotor NN I-NP O
23 843 851 3220106 response NN I-NP O
24 852 857 3220106 which WDT B-NP O
25 858 861 3220106 was VBD B-VP O
26 862 872 3220106 associated VBN I-VP O
27 873 877 3220106 with IN B-PP O
28 878 880 3220106 an DT B-NP O
29 881 889 3220106 increase NN I-NP O
30 890 892 3220106 in IN B-PP O
31 893 896 3220106 the DT B-NP O
32 897 903 3220106 number NN I-NP O
33 904 906 3220106 of IN B-PP O
34 907 908 3220106 L NN B-NP O
35 908 909 3220106 - HYPH B-NP O
36 909 921 3220106 [3H]nicotine NN I-NP D009538
37 922 929 3220106 binding NN I-NP O
38 930 935 3220106 sites NNS I-NP O
39 936 939 3220106 and CC O O
40 940 944 3220106 also RB B-ADVP O
41 945 949 3220106 with IN B-PP O
42 950 952 3220106 an DT B-NP O
43 953 961 3220106 elevated VBN I-NP O
44 962 970 3220106 dopamine NN I-NP D004298
45 971 972 3220106 ( ( O O
46 972 974 3220106 DA NN B-NP D004298
47 974 975 3220106 ) ) O O
48 976 981 3220106 level NN B-NP O
49 982 984 3220106 in IN B-PP O
50 985 988 3220106 the DT B-NP O
51 989 997 3220106 striatum NN I-NP O
52 997 998 3220106 . . O O

1 999 1002 3220106 The DT B-NP O
2 1003 1009 3220106 number NN I-NP O
3 1010 1012 3220106 of IN B-PP O
4 1013 1021 3220106 striatal JJ B-NP O
5 1022 1035 3220106 [3H]spiperone NN I-NP D013134
6 1036 1043 3220106 binding NN I-NP O
7 1044 1049 3220106 sites NNS I-NP O
8 1050 1053 3220106 was VBD B-VP O
9 1054 1057 3220106 not RB I-VP O
10 1058 1066 3220106 affected VBN I-VP O
11 1066 1067 3220106 . . O O

1 1068 1070 3220106 In IN B-PP O
2 1071 1078 3220106 animals NNS B-NP O
3 1079 1089 3220106 pretreated VBN B-VP O
4 1090 1094 3220106 with IN B-PP O
5 1095 1103 3220106 nicotine NN B-NP D009538
6 1104 1107 3220106 for IN B-PP O
7 1108 1110 3220106 14 CD B-NP O
8 1111 1115 3220106 days NNS I-NP O
9 1115 1116 3220106 , , O O
10 1117 1120 3220106 the DT B-NP O
11 1121 1129 3220106 nicotine NN I-NP D009538
12 1129 1130 3220106 - HYPH B-NP O
13 1130 1137 3220106 induced VBN I-NP O
14 1138 1147 3220106 locomotor NN I-NP O
15 1148 1156 3220106 response NN I-NP O
16 1157 1165 3220106 remained VBD B-VP O
17 1166 1168 3220106 to TO I-VP O
18 1169 1171 3220106 be VB I-VP O
19 1172 1183 3220106 potentiated VBN I-VP O
20 1183 1184 3220106 . . O O

1 1185 1192 3220106 However RB B-ADVP O
2 1192 1193 3220106 , , O O
3 1194 1198 3220106 this DT B-NP O
4 1199 1207 3220106 response NN I-NP O
5 1208 1211 3220106 was VBD B-VP O
6 1212 1222 3220106 correlated VBN I-VP O
7 1223 1227 3220106 with IN B-PP O
8 1228 1230 3220106 an DT B-NP O
9 1231 1239 3220106 elevated JJ I-NP O
10 1240 1246 3220106 number NN I-NP O
11 1247 1249 3220106 of IN B-PP O
12 1250 1258 3220106 striatal JJ B-NP O
13 1259 1272 3220106 [3H]spiperone NN I-NP D013134
14 1273 1280 3220106 binding NN I-NP O
15 1281 1286 3220106 sites NNS I-NP O
16 1286 1287 3220106 , , O O
17 1288 1295 3220106 whereas IN O O
18 1296 1299 3220106 the DT B-NP O
19 1300 1306 3220106 number NN I-NP O
20 1307 1309 3220106 of IN B-PP O
21 1310 1318 3220106 striatal JJ B-NP O
22 1319 1320 3220106 L NN I-NP O
23 1320 1321 3220106 - HYPH B-NP O
24 1321 1333 3220106 [3H]nicotine NN I-NP D009538
25 1334 1341 3220106 binding NN I-NP O
26 1342 1347 3220106 sites NNS I-NP O
27 1348 1351 3220106 and CC O O
28 1352 1355 3220106 the DT B-NP O
29 1356 1364 3220106 striatal JJ I-NP O
30 1365 1367 3220106 DA NN I-NP D004298
31 1368 1373 3220106 level NN I-NP O
32 1374 1378 3220106 were VBD B-VP O
33 1379 1385 3220106 normal JJ B-ADJP O
34 1385 1386 3220106 . . O O

1 1387 1392 3220106 These DT B-NP O
2 1393 1400 3220106 results NNS I-NP O
3 1401 1408 3220106 suggest VBP B-VP O
4 1409 1413 3220106 that IN B-SBAR O
5 1414 1421 3220106 chronic JJ B-NP O
6 1422 1430 3220106 nicotine NN I-NP D009538
7 1430 1431 3220106 - HYPH B-NP O
8 1431 1438 3220106 treated VBN I-NP O
9 1439 1443 3220106 rats NNS I-NP O
10 1444 1451 3220106 develop VBP B-VP O
11 1452 1461 3220106 locomotor NN B-NP D006948
12 1462 1475 3220106 hyperactivity NN I-NP D006948
13 1476 1478 3220106 in IN B-PP O
14 1479 1487 3220106 response NN I-PP O
15 1488 1490 3220106 to TO I-PP O
16 1491 1499 3220106 nicotine NN B-NP D009538
17 1500 1509 3220106 initially RB B-ADJP O
18 1510 1513 3220106 due JJ I-ADJP O
19 1514 1516 3220106 to TO B-PP O
20 1517 1526 3220106 increases NNS B-NP O
21 1527 1529 3220106 of IN B-PP O
22 1530 1534 3220106 both CC O O
23 1535 1538 3220106 the DT B-NP O
24 1539 1546 3220106 density NN I-NP O
25 1547 1549 3220106 of IN B-PP O
26 1550 1559 3220106 nicotinic JJ B-NP O
27 1560 1569 3220106 receptors NNS I-NP O
28 1570 1573 3220106 and CC O O
29 1574 1576 3220106 DA NN B-NP D004298
30 1577 1590 3220106 concentration NN I-NP O
31 1590 1591 3220106 , , O O
32 1592 1600 3220106 followed VBN B-VP O
33 1601 1603 3220106 by IN B-PP O
34 1604 1612 3220106 inducing VBG B-VP O
35 1613 1615 3220106 DA NN B-NP D004298
36 1616 1624 3220106 receptor NN I-NP O
37 1625 1641 3220106 supersensitivity NN I-NP O
38 1642 1644 3220106 in IN B-PP O
39 1645 1648 3220106 the DT B-NP O
40 1649 1657 3220106 striatum NN I-NP O
41 1657 1658 3220106 . . O O

1 0 0 2322844 -DOCSTART- -X- -X- O

1 0 11 2322844 Nociceptive JJ B-NP O
2 12 19 2322844 effects NNS I-NP O
3 20 27 2322844 induced VBN B-VP O
4 28 30 2322844 by IN B-PP O
5 31 42 2322844 intrathecal JJ B-NP O
6 43 57 2322844 administration NN I-NP O
7 58 60 2322844 of IN B-PP O
8 61 74 2322844 prostaglandin NN B-NP D015230
9 75 77 2322844 D2 NN I-NP D015230
10 77 78 2322844 , , O D015230
11 79 81 2322844 E2 NN B-NP D015230
12 81 82 2322844 , , O D015230
13 83 85 2322844 or CC O D015230
14 86 88 2322844 F2 NN B-NP D015230
15 89 94 2322844 alpha NN I-NP D015230
16 95 97 2322844 to TO B-PP O
17 98 107 2322844 conscious JJ B-NP O
18 108 112 2322844 mice NNS I-NP O
19 112 113 2322844 . . O O
20 114 117 2322844 The DT B-NP O
21 118 125 2322844 effects NNS I-NP O
22 126 128 2322844 of IN B-PP O
23 129 140 2322844 intrathecal JJ B-NP O
24 141 155 2322844 administration NN I-NP O
25 156 158 2322844 of IN B-PP O
26 159 173 2322844 prostaglandins NNS B-NP D011453
27 174 176 2322844 on IN B-PP O
28 177 181 2322844 pain NN B-NP D010146
29 182 191 2322844 responses NNS I-NP O
30 192 194 2322844 in IN B-PP O
31 195 204 2322844 conscious JJ B-NP O
32 205 209 2322844 mice NNS I-NP O
33 210 214 2322844 were VBD B-VP O
34 215 224 2322844 evaluated VBN I-VP O
35 225 227 2322844 by IN B-PP O
36 228 233 2322844 using VBG B-VP O
37 234 237 2322844 hot JJ B-NP O
38 238 243 2322844 plate NN I-NP O
39 244 247 2322844 and CC O O
40 248 254 2322844 acetic JJ B-NP D019342
41 255 259 2322844 acid NN I-NP D019342
42 260 268 2322844 writhing NN I-NP O
43 269 274 2322844 tests NNS I-NP O
44 274 275 2322844 . . O O

1 276 289 2322844 Prostaglandin NN B-NP D015230
2 290 292 2322844 D2 NN I-NP D015230
3 293 294 2322844 ( ( O O
4 294 297 2322844 0.5 CD B-NP O
5 297 298 2322844 - HYPH I-NP O
6 298 299 2322844 3 CD I-NP O
7 300 302 2322844 ng NN I-NP O
8 302 303 2322844 / SYM B-NP O
9 303 308 2322844 mouse NN I-NP O
10 308 309 2322844 ) ) O O
11 310 313 2322844 had VBD B-VP O
12 314 315 2322844 a DT B-NP O
13 316 328 2322844 hyperalgesic JJ I-NP D006930
14 329 335 2322844 action NN I-NP O
15 336 338 2322844 on IN B-PP O
16 339 342 2322844 the DT B-NP O
17 343 351 2322844 response NN I-NP O
18 352 354 2322844 to TO B-PP O
19 355 356 2322844 a DT B-NP O
20 357 360 2322844 hot JJ I-NP O
21 361 366 2322844 plate NN I-NP O
22 367 373 2322844 during IN B-PP O
23 374 375 2322844 a DT B-NP O
24 376 377 2322844 3 CD I-NP O
25 377 378 2322844 - HYPH I-NP O
26 378 380 2322844 60 CD I-NP O
27 381 384 2322844 min NN I-NP O
28 385 391 2322844 period NN I-NP O
29 392 397 2322844 after IN B-PP O
30 398 407 2322844 injection NN B-NP O
31 407 408 2322844 . . O O

1 409 422 2322844 Prostaglandin NN B-NP D015232
2 423 425 2322844 E2 NN I-NP D015232
3 426 432 2322844 showed VBD B-VP O
4 433 434 2322844 a DT B-NP O
5 435 447 2322844 hyperalgesic JJ I-NP D006930
6 448 454 2322844 effect NN I-NP O
7 455 457 2322844 at IN B-PP O
8 458 463 2322844 doses NNS B-NP O
9 464 466 2322844 of IN B-PP O
10 467 468 2322844 1 CD B-NP O
11 469 471 2322844 pg NN I-NP D011453
12 472 474 2322844 to TO B-PP O
13 475 477 2322844 10 CD B-NP O
14 478 480 2322844 ng NN I-NP O
15 480 481 2322844 / SYM B-NP O
16 481 486 2322844 mouse NN I-NP O
17 486 487 2322844 , , O O
18 488 491 2322844 but CC O O
19 492 495 2322844 the DT B-NP O
20 496 502 2322844 effect NN I-NP O
21 503 509 2322844 lasted VBD B-VP O
22 510 517 2322844 shorter JJR B-ADJP O
23 518 519 2322844 ( ( O O
24 519 520 2322844 3 CD B-NP O
25 520 521 2322844 - HYPH I-NP O
26 521 523 2322844 30 CD I-NP O
27 524 527 2322844 min NN I-NP O
28 527 528 2322844 ) ) O O
29 529 533 2322844 than IN B-PP O
30 534 538 2322844 that DT B-NP O
31 539 541 2322844 of IN B-PP O
32 542 555 2322844 prostaglandin NN B-NP D015230
33 556 558 2322844 D2 NN I-NP D015230
34 558 559 2322844 . . O O

1 560 567 2322844 Similar JJ B-NP O
2 568 575 2322844 results NNS I-NP O
3 576 580 2322844 were VBD B-VP O
4 581 589 2322844 obtained VBN I-VP O
5 590 592 2322844 by IN B-PP O
6 593 599 2322844 acetic JJ B-NP D019342
7 600 604 2322844 acid NN I-NP D019342
8 605 613 2322844 writhing NN I-NP O
9 614 619 2322844 tests NNS I-NP O
10 619 620 2322844 . . O O

1 621 624 2322844 The DT B-NP O
2 625 637 2322844 hyperalgesic JJ I-NP D006930
3 638 644 2322844 effect NN I-NP O
4 645 647 2322844 of IN B-PP O
5 648 661 2322844 prostaglandin NN B-NP D015230
6 662 664 2322844 D2 NN I-NP D015230
7 665 668 2322844 was VBD B-VP O
8 669 676 2322844 blocked VBN I-VP O
9 677 679 2322844 by IN B-PP O
10 680 692 2322844 simultaneous JJ B-NP O
11 693 702 2322844 injection NN I-NP O
12 703 705 2322844 of IN B-PP O
13 706 707 2322844 a DT B-NP O
14 708 717 2322844 substance NN I-NP O
15 718 719 2322844 P NN I-NP O
16 720 730 2322844 antagonist NN I-NP O
17 731 732 2322844 ( ( O O
18 732 739 2322844 greater JJR B-ADJP O
19 740 744 2322844 than IN B-PP O
20 745 747 2322844 or CC O O
21 748 753 2322844 equal JJ B-ADJP O
22 754 756 2322844 to TO B-PP O
23 757 760 2322844 100 CD B-NP O
24 761 763 2322844 ng NN I-NP O
25 763 764 2322844 ) ) O O
26 765 768 2322844 but CC B-PP O
27 769 772 2322844 not RB B-NP O
28 773 775 2322844 by IN B-PP O
29 776 782 2322844 AH6809 NN B-NP C053876
30 782 783 2322844 , , O O
31 784 785 2322844 a DT B-NP O
32 786 796 2322844 prostanoid NN I-NP O
33 797 800 2322844 EP1 NN I-NP O
34 800 801 2322844 - HYPH B-NP O
35 801 809 2322844 receptor NN I-NP O
36 810 820 2322844 antagonist NN I-NP O
37 820 821 2322844 . . O O

1 822 832 2322844 Conversely RB B-ADVP O
2 832 833 2322844 , , O O
3 834 847 2322844 prostaglandin NN B-NP D015232
4 848 850 2322844 E2 NN I-NP D015232
5 850 851 2322844 - HYPH B-NP O
6 851 858 2322844 induced VBN I-NP O
7 859 871 2322844 hyperalgesia NN I-NP D006930
8 872 875 2322844 was VBD B-VP O
9 876 883 2322844 blocked VBN I-VP O
10 884 886 2322844 by IN B-PP O
11 887 893 2322844 AH6809 NN B-NP C053876
12 894 895 2322844 ( ( O O
13 895 902 2322844 greater JJR B-ADJP O
14 903 907 2322844 than IN B-PP O
15 908 910 2322844 or CC O O
16 911 916 2322844 equal JJ B-ADJP O
17 917 919 2322844 to TO B-PP O
18 920 923 2322844 500 CD B-NP O
19 924 926 2322844 ng NN I-NP O
20 926 927 2322844 ) ) O O
21 928 931 2322844 but CC B-PP O
22 932 935 2322844 not RB B-PP O
23 936 938 2322844 by IN I-PP O
24 939 942 2322844 the DT B-NP O
25 943 952 2322844 substance NN I-NP O
26 953 954 2322844 P NN I-NP O
27 955 965 2322844 antagonist NN I-NP O
28 965 966 2322844 . . O O

1 967 980 2322844 Prostaglandin NN B-NP D015237
2 981 983 2322844 F2 NN I-NP D015237
3 984 989 2322844 alpha NN I-NP D015237
4 990 993 2322844 had VBD B-VP O
5 994 1000 2322844 little JJ B-NP O
6 1001 1007 2322844 effect NN I-NP O
7 1008 1010 2322844 on IN B-PP O
8 1011 1015 2322844 pain NN B-NP D010146
9 1016 1025 2322844 responses NNS I-NP O
10 1025 1026 2322844 . . O O

1 1027 1032 2322844 These DT B-NP O
2 1033 1040 2322844 results NNS I-NP O
3 1041 1052 2322844 demonstrate VBP B-VP O
4 1053 1057 2322844 that IN B-SBAR O
5 1058 1062 2322844 both CC O O
6 1063 1076 2322844 prostaglandin NN B-NP D015230
7 1077 1079 2322844 D2 NN I-NP D015230
8 1080 1083 2322844 and CC O O
9 1084 1097 2322844 prostaglandin NN B-NP D015232
10 1098 1100 2322844 E2 NN I-NP D015232
11 1101 1106 2322844 exert VBP B-VP O
12 1107 1119 2322844 hyperalgesia NN B-NP D006930
13 1120 1122 2322844 in IN B-PP O
14 1123 1126 2322844 the DT B-NP O
15 1127 1133 2322844 spinal JJ I-NP O
16 1134 1138 2322844 cord NN I-NP O
17 1138 1139 2322844 , , O O
18 1140 1143 2322844 but CC O O
19 1144 1146 2322844 in IN B-PP O
20 1147 1156 2322844 different JJ B-NP O
21 1157 1161 2322844 ways NNS I-NP O
22 1161 1162 2322844 . . O O

1 0 0 19289093 -DOCSTART- -X- -X- O

1 0 14 19289093 Identification NN B-NP O
2 15 17 19289093 of IN B-PP O
3 18 19 19289093 a DT B-NP O
4 20 26 19289093 simple JJ I-NP O
5 27 30 19289093 and CC I-NP O
6 31 40 19289093 sensitive JJ I-NP O
7 41 51 19289093 microplate NN I-NP O
8 52 58 19289093 method NN I-NP O
9 59 62 19289093 for IN B-PP O
10 63 66 19289093 the DT B-NP O
11 67 76 19289093 detection NN I-NP O
12 77 79 19289093 of IN B-PP O
13 80 92 19289093 oversulfated JJ B-NP O
14 93 104 19289093 chondroitin NN I-NP D002809
15 105 112 19289093 sulfate NN I-NP D002809
16 113 115 19289093 in IN B-PP O
17 116 123 19289093 heparin NN B-NP D006493
18 124 132 19289093 products NNS I-NP O
19 132 133 19289093 . . O O
20 134 141 19289093 Heparin NN B-NP D006493
21 142 144 19289093 is VBZ B-VP O
22 145 146 19289093 a DT B-NP O
23 147 155 19289093 commonly RB I-NP O
24 156 167 19289093 implemented VBN I-NP O
25 168 181 19289093 anticoagulant NN I-NP O
26 182 186 19289093 used VBN B-VP O
27 187 189 19289093 to TO B-VP O
28 190 195 19289093 treat VB I-VP O
29 196 206 19289093 critically RB B-NP O
30 207 210 19289093 ill JJ I-NP O
31 211 219 19289093 patients NNS I-NP O
32 219 220 19289093 . . O O

1 221 229 19289093 Recently RB B-ADVP O
2 229 230 19289093 , , O O
3 231 232 19289093 a DT B-NP O
4 233 239 19289093 number NN I-NP O
5 240 242 19289093 of IN B-PP O
6 243 253 19289093 commercial JJ B-NP O
7 254 258 19289093 lots NNS I-NP O
8 259 261 19289093 of IN B-PP O
9 262 269 19289093 heparin NN B-NP D006493
10 270 278 19289093 products NNS I-NP O
11 279 283 19289093 were VBD B-VP O
12 284 289 19289093 found VBN I-VP O
13 290 292 19289093 to TO I-VP O
14 293 295 19289093 be VB I-VP O
15 296 308 19289093 contaminated VBN I-VP O
16 309 313 19289093 with IN B-PP O
17 314 316 19289093 an DT B-NP O
18 317 329 19289093 oversulfated JJ I-NP O
19 330 341 19289093 chondroitin NN I-NP D002809
20 342 349 19289093 sulfate NN I-NP D002809
21 350 351 19289093 ( ( O O
22 351 355 19289093 OSCS NN B-NP O
23 355 356 19289093 ) ) O O
24 357 367 19289093 derivative NN B-NP O
25 368 372 19289093 that WDT B-NP O
26 373 378 19289093 could MD B-VP O
27 379 385 19289093 elicit VB I-VP O
28 386 387 19289093 a DT B-NP O
29 388 399 19289093 hypotensive JJ I-NP D007022
30 400 408 19289093 response NN I-NP O
31 409 411 19289093 in IN B-PP O
32 412 416 19289093 pigs NNS B-NP O
33 417 426 19289093 following VBG B-PP O
34 427 428 19289093 a DT B-NP O
35 429 435 19289093 single JJ I-NP O
36 436 440 19289093 high JJ I-NP O
37 440 441 19289093 - HYPH I-NP O
38 441 445 19289093 dose NN I-NP O
39 446 454 19289093 infusion NN I-NP O
40 454 455 19289093 . . O O

1 456 461 19289093 Using VBG B-VP O
2 462 466 19289093 both CC O O
3 467 479 19289093 contaminated VBN B-NP O
4 480 487 19289093 heparin NN I-NP D006493
5 488 496 19289093 products NNS I-NP O
6 497 500 19289093 and CC O O
7 501 504 19289093 the DT B-NP O
8 505 518 19289093 synthetically RB I-NP O
9 519 527 19289093 produced VBN I-NP O
10 528 538 19289093 derivative NN I-NP O
11 538 539 19289093 , , O O
12 540 542 19289093 we PRP B-NP O
13 543 549 19289093 showed VBD B-VP O
14 550 554 19289093 that IN B-SBAR O
15 555 558 19289093 the DT B-NP O
16 559 563 19289093 OSCS NN I-NP O
17 564 572 19289093 produces VBZ B-VP O
18 573 577 19289093 dose NN B-NP O
19 577 578 19289093 - HYPH I-NP O
20 578 587 19289093 dependent JJ I-NP O
21 588 599 19289093 hypotension NN I-NP D007022
22 600 602 19289093 in IN B-PP O
23 603 607 19289093 pigs NNS B-NP O
24 607 608 19289093 . . O O

1 609 612 19289093 The DT B-NP O
2 613 615 19289093 no DT I-NP O
3 616 624 19289093 observed VBN I-NP O
4 625 631 19289093 effect NN I-NP O
5 632 637 19289093 level NN I-NP O
6 638 639 19289093 ( ( O O
7 639 643 19289093 NOEL NN B-NP O
8 643 644 19289093 ) ) O O
9 645 648 19289093 for IN B-PP O
10 649 653 19289093 this DT B-NP O
11 654 665 19289093 contaminant NN I-NP O
12 666 673 19289093 appears VBZ B-VP O
13 674 676 19289093 to TO I-VP O
14 677 679 19289093 be VB I-VP O
15 680 693 19289093 approximately RB B-NP O
16 694 697 19289093 1mg NN I-NP O
17 697 698 19289093 / SYM I-NP O
18 698 700 19289093 kg NN I-NP O
19 700 701 19289093 , , O O
20 702 715 19289093 corresponding VBG B-VP O
21 716 718 19289093 to TO B-PP O
22 719 720 19289093 a DT B-NP O
23 721 734 19289093 contamination NN I-NP O
24 735 740 19289093 level NN I-NP O
25 741 743 19289093 of IN B-PP O
26 744 757 19289093 approximately RB B-NP O
27 758 760 19289093 3% CD I-NP O
28 760 761 19289093 . . O O

1 762 764 19289093 We PRP B-NP O
2 765 769 19289093 also RB B-ADVP O
3 770 782 19289093 demonstrated VBD B-VP O
4 783 787 19289093 that IN B-SBAR O
5 788 792 19289093 OSCS NN B-NP O
6 793 796 19289093 can MD B-VP O
7 797 799 19289093 be VB I-VP O
8 800 810 19289093 identified VBN I-VP O
9 811 813 19289093 in IN B-PP O
10 814 821 19289093 heparin NN B-NP D006493
11 822 830 19289093 products NNS I-NP O
12 831 836 19289093 using VBG B-VP O
13 837 838 19289093 a DT B-NP O
14 839 845 19289093 simple JJ I-NP O
15 845 846 19289093 , , I-NP O
16 847 858 19289093 inexpensive JJ I-NP O
17 858 859 19289093 , , I-NP O
18 860 872 19289093 commercially RB I-NP O
19 873 882 19289093 available JJ I-NP O
20 883 890 19289093 heparin NN I-NP D006493
21 891 897 19289093 enzyme NN I-NP O
22 898 909 19289093 immunoassay NN I-NP O
23 910 911 19289093 ( ( O O
24 911 914 19289093 EIA NN B-NP O
25 914 915 19289093 ) ) O O
26 916 919 19289093 kit NN B-NP O
27 920 924 19289093 that WDT B-NP O
28 925 928 19289093 has VBZ B-VP O
29 929 930 19289093 a DT B-NP O
30 931 936 19289093 limit NN I-NP O
31 937 939 19289093 of IN B-PP O
32 940 949 19289093 detection NN B-NP O
33 950 952 19289093 of IN B-PP O
34 953 966 19289093 approximately RB B-NP O
35 967 971 19289093 0.1% CD I-NP O
36 971 972 19289093 , , O O
37 973 977 19289093 well RB B-ADVP O
38 978 983 19289093 below IN B-PP O
39 984 987 19289093 the DT B-NP O
40 988 992 19289093 NOEL NN I-NP O
41 992 993 19289093 . . O O

1 994 998 19289093 This DT B-NP O
2 999 1002 19289093 kit NN I-NP O
3 1003 1006 19289093 may MD B-VP O
4 1007 1014 19289093 provide VB I-VP O
5 1015 1016 19289093 a DT B-NP O
6 1017 1023 19289093 useful JJ I-NP O
7 1024 1030 19289093 method NN I-NP O
8 1031 1033 19289093 to TO B-VP O
9 1034 1038 19289093 test VB I-VP O
10 1039 1046 19289093 heparin NN B-NP D006493
11 1047 1055 19289093 products NNS I-NP O
12 1056 1059 19289093 for IN B-PP O
13 1060 1073 19289093 contamination NN B-NP O
14 1074 1078 19289093 with IN B-PP O
15 1079 1091 19289093 oversulfated JJ B-NP O
16 1092 1095 19289093 GAG NN I-NP O
17 1096 1107 19289093 derivatives NNS I-NP O
18 1107 1108 19289093 . . O O

1 0 0 15858223 -DOCSTART- -X- -X- O

1 0 8 15858223 Valproic JJ B-NP D014635
2 9 13 15858223 acid NN I-NP D014635
3 14 15 15858223 I CD I-NP O
4 15 16 15858223 : : O O
5 17 21 15858223 time NN B-NP O
6 22 28 15858223 course NN I-NP O
7 29 31 15858223 of IN B-PP O
8 32 37 15858223 lipid NN B-NP O
9 38 50 15858223 peroxidation NN I-NP O
10 51 61 15858223 biomarkers NNS I-NP O
11 61 62 15858223 , , O O
12 63 68 15858223 liver NN B-NP D056486
13 69 77 15858223 toxicity NN I-NP D056486
14 77 78 15858223 , , O O
15 79 82 15858223 and CC O O
16 83 91 15858223 valproic JJ B-NP D014635
17 92 96 15858223 acid NN I-NP D014635
18 97 107 15858223 metabolite NN I-NP O
19 108 114 15858223 levels NNS I-NP O
20 115 117 15858223 in IN B-PP O
21 118 122 15858223 rats NNS B-NP O
22 122 123 15858223 . . O O
23 124 125 15858223 A DT B-NP O
24 126 132 15858223 single JJ I-NP O
25 133 137 15858223 dose NN I-NP O
26 138 140 15858223 of IN B-PP O
27 141 149 15858223 valproic JJ B-NP D014635
28 150 154 15858223 acid NN I-NP D014635
29 155 156 15858223 ( ( O O
30 156 159 15858223 VPA NN B-NP D014635
31 159 160 15858223 ) ) O O
32 160 161 15858223 , , O O
33 162 167 15858223 which WDT B-NP O
34 168 170 15858223 is VBZ B-VP O
35 171 172 15858223 a DT B-NP O
36 173 179 15858223 widely RB I-NP O
37 180 184 15858223 used VBN I-NP O
38 185 198 15858223 antiepileptic JJ I-NP O
39 199 203 15858223 drug NN I-NP O
40 203 204 15858223 , , O O
41 205 207 15858223 is VBZ B-VP O
42 208 218 15858223 associated VBN I-VP O
43 219 223 15858223 with IN B-PP O
44 224 233 15858223 oxidative JJ B-NP O
45 234 240 15858223 stress NN I-NP O
46 241 243 15858223 in IN B-PP O
47 244 248 15858223 rats NNS B-NP O
48 248 249 15858223 , , O O
49 250 252 15858223 as IN B-SBAR O
50 253 261 15858223 recently RB B-ADVP O
51 262 274 15858223 demonstrated VBN B-VP O
52 275 277 15858223 by IN B-PP O
53 278 286 15858223 elevated VBN B-NP O
54 287 293 15858223 levels NNS I-NP O
55 294 296 15858223 of IN B-PP O
56 297 299 15858223 15 CD B-NP C075750
57 299 300 15858223 - HYPH I-NP C075750
58 300 305 15858223 F(2t) NN I-NP C075750
59 305 306 15858223 - HYPH O C075750
60 306 317 15858223 isoprostane NN B-NP C075750
61 318 319 15858223 ( ( O O
62 319 321 15858223 15 CD B-NP C075750
63 321 322 15858223 - HYPH I-NP C075750
64 322 327 15858223 F(2t) NN I-NP C075750
65 327 328 15858223 - HYPH I-NP C075750
66 328 332 15858223 IsoP NN I-NP C075750
67 332 333 15858223 ) ) O O
68 333 334 15858223 . . O O

1 335 337 15858223 To TO B-VP O
2 338 347 15858223 determine VB I-VP O
3 348 355 15858223 whether IN B-SBAR O
4 356 361 15858223 there EX B-NP O
5 362 365 15858223 was VBD B-VP O
6 366 367 15858223 a DT B-NP O
7 368 376 15858223 temporal JJ I-NP O
8 377 389 15858223 relationship NN I-NP O
9 390 397 15858223 between IN B-PP O
10 398 401 15858223 VPA NN B-NP D014635
11 401 402 15858223 - HYPH O O
12 402 412 15858223 associated VBN B-NP O
13 413 422 15858223 oxidative JJ I-NP O
14 423 429 15858223 stress NN I-NP O
15 430 433 15858223 and CC I-NP O
16 434 448 15858223 hepatotoxicity NN I-NP D056486
17 448 449 15858223 , , O O
18 450 455 15858223 adult JJ B-NP O
19 456 460 15858223 male JJ I-NP O
20 461 468 15858223 Sprague NNP I-NP O
21 468 469 15858223 - HYPH I-NP O
22 469 475 15858223 Dawley NNP I-NP O
23 476 480 15858223 rats NNS I-NP O
24 481 485 15858223 were VBD B-VP O
25 486 493 15858223 treated VBN I-VP O
26 494 496 15858223 ip RB B-ADVP O
27 497 501 15858223 with IN B-PP O
28 502 505 15858223 VPA NN B-NP D014635
29 506 507 15858223 ( ( O O
30 507 510 15858223 500 CD B-NP O
31 511 513 15858223 mg NN I-NP O
32 513 514 15858223 / SYM B-NP O
33 514 516 15858223 kg NN I-NP O
34 516 517 15858223 ) ) O O
35 518 520 15858223 or CC O O
36 521 525 15858223 0.9% CD B-NP O
37 526 532 15858223 saline NN I-NP O
38 533 534 15858223 ( ( O O
39 534 541 15858223 vehicle NN B-NP O
40 541 542 15858223 ) ) O O
41 543 547 15858223 once RB B-ADVP O
42 548 553 15858223 daily RB I-ADVP O
43 554 557 15858223 for IN B-PP O
44 558 559 15858223 2 CD B-NP O
45 559 560 15858223 , , I-NP O
46 561 562 15858223 4 CD I-NP O
47 562 563 15858223 , , I-NP O
48 564 565 15858223 7 CD I-NP O
49 565 566 15858223 , , I-NP O
50 567 569 15858223 10 CD I-NP O
51 569 570 15858223 , , O O
52 571 573 15858223 or CC O O
53 574 576 15858223 14 CD B-NP O
54 577 581 15858223 days NNS I-NP O
55 581 582 15858223 . . O O

1 583 592 15858223 Oxidative JJ B-NP O
2 593 599 15858223 stress NN I-NP O
3 600 603 15858223 was VBD B-VP O
4 604 612 15858223 assessed VBN I-VP O
5 613 615 15858223 by IN B-PP O
6 616 627 15858223 determining VBG B-VP O
7 628 634 15858223 plasma NN B-NP O
8 635 638 15858223 and CC I-NP O
9 639 644 15858223 liver NN I-NP O
10 645 651 15858223 levels NNS I-NP O
11 652 654 15858223 of IN B-PP O
12 655 657 15858223 15 CD B-NP C075750
13 657 658 15858223 - HYPH I-NP C075750
14 658 663 15858223 F(2t) NN I-NP C075750
15 663 664 15858223 - HYPH O C075750
16 664 668 15858223 IsoP NN B-NP C075750
17 668 669 15858223 , , O O
18 670 675 15858223 lipid NN B-NP D008054
19 676 690 15858223 hydroperoxides NNS I-NP D008054
20 691 692 15858223 ( ( O O
21 692 695 15858223 LPO NN B-NP D008054
22 695 696 15858223 ) ) O O
23 696 697 15858223 , , O O
24 698 701 15858223 and CC O O
25 702 716 15858223 thiobarbituric JJ B-NP D017392
26 717 721 15858223 acid NN I-NP D017392
27 722 730 15858223 reactive JJ I-NP D017392
28 731 741 15858223 substances NNS I-NP D017392
29 742 743 15858223 ( ( O O
30 743 748 15858223 TBARs NNS B-NP D017392
31 748 749 15858223 ) ) O O
32 749 750 15858223 . . O O

1 751 757 15858223 Plasma NN B-NP O
2 758 761 15858223 and CC O O
3 762 767 15858223 liver NN B-NP O
4 768 770 15858223 15 CD I-NP C075750
5 770 771 15858223 - HYPH I-NP C075750
6 771 776 15858223 F(2t) NN I-NP C075750
7 776 777 15858223 - HYPH I-NP C075750
8 777 781 15858223 IsoP NN I-NP C075750
9 782 786 15858223 were VBD B-VP O
10 787 795 15858223 elevated VBN I-VP O
11 796 799 15858223 and CC O O
12 800 807 15858223 reached VBD B-VP O
13 808 809 15858223 a DT B-NP O
14 810 817 15858223 plateau NN I-NP O
15 818 823 15858223 after IN B-PP O
16 824 827 15858223 day NN B-NP O
17 828 829 15858223 2 CD I-NP O
18 830 832 15858223 of IN B-PP O
19 833 836 15858223 VPA NN B-NP D014635
20 837 846 15858223 treatment NN I-NP O
21 847 855 15858223 compared VBN B-VP O
22 856 858 15858223 to TO B-PP O
23 859 866 15858223 control NN B-NP O
24 866 867 15858223 . . O O

1 868 873 15858223 Liver NN B-NP O
2 874 877 15858223 LPO NN I-NP D008054
3 878 884 15858223 levels NNS I-NP O
4 885 889 15858223 were VBD B-VP O
5 890 893 15858223 not RB I-VP O
6 894 902 15858223 elevated VBN I-VP O
7 903 908 15858223 until IN B-PP O
8 909 912 15858223 day NN B-NP O
9 913 914 15858223 7 CD I-NP O
10 915 917 15858223 of IN B-PP O
11 918 927 15858223 treatment NN B-NP O
12 928 929 15858223 ( ( O O
13 929 932 15858223 1.8 CD B-NP O
14 932 933 15858223 - HYPH O O
15 933 937 15858223 fold RB O O
16 938 944 15858223 versus CC O O
17 945 952 15858223 control NN B-NP O
18 952 953 15858223 , , O O
19 954 955 15858223 p NN B-NP O
20 956 957 15858223 < SYM B-NP O
21 958 962 15858223 0.05 CD I-NP O
22 962 963 15858223 ) ) O O
23 963 964 15858223 . . O O

1 965 970 15858223 Liver NN B-NP O
2 971 974 15858223 and CC I-NP O
3 975 981 15858223 plasma NN I-NP O
4 982 987 15858223 TBARs NNS I-NP D017392
5 988 992 15858223 were VBD B-VP O
6 993 996 15858223 not RB I-VP O
7 997 1006 15858223 increased VBN I-VP O
8 1007 1012 15858223 until IN B-PP O
9 1013 1015 15858223 14 CD B-NP O
10 1016 1020 15858223 days NNS I-NP O
11 1021 1022 15858223 ( ( O O
12 1022 1023 15858223 2 CD B-NP O
13 1023 1024 15858223 - HYPH I-NP O
14 1024 1028 15858223 fold JJ I-NP O
15 1029 1031 15858223 vs NNS I-NP O
16 1031 1032 15858223 . . O O
17 1033 1040 15858223 control NN B-NP O
18 1040 1041 15858223 , , O O
19 1042 1043 15858223 p NN B-NP O
20 1044 1045 15858223 < SYM B-NP O
21 1046 1050 15858223 0.05 CD I-NP O
22 1050 1051 15858223 ) ) O O
23 1051 1052 15858223 . . O O

1 1053 1058 15858223 Liver NN B-NP D056486
2 1059 1067 15858223 toxicity NN I-NP D056486
3 1068 1071 15858223 was VBD B-VP O
4 1072 1081 15858223 evaluated VBN I-VP O
5 1082 1087 15858223 based VBN B-PP O
6 1088 1090 15858223 on IN B-PP O
7 1091 1096 15858223 serum NN B-NP O
8 1097 1103 15858223 levels NNS I-NP O
9 1104 1106 15858223 of IN B-PP O
10 1107 1112 15858223 alpha SYM B-NP O
11 1112 1113 15858223 - HYPH O O
12 1113 1124 15858223 glutathione NN B-NP D005978
13 1125 1126 15858223 S NN I-NP O
14 1126 1127 15858223 - HYPH B-NP O
15 1127 1138 15858223 transferase NN I-NP O
16 1139 1140 15858223 ( ( O O
17 1140 1145 15858223 alpha SYM O O
18 1145 1146 15858223 - HYPH O O
19 1146 1149 15858223 GST NN B-NP O
20 1149 1150 15858223 ) ) O O
21 1151 1154 15858223 and CC O O
22 1155 1157 15858223 by IN B-PP O
23 1158 1167 15858223 histology NN B-NP O
24 1167 1168 15858223 . . O O

1 1169 1174 15858223 Serum NN B-NP O
2 1175 1180 15858223 alpha SYM O O
3 1180 1181 15858223 - HYPH O O
4 1181 1184 15858223 GST NN B-NP O
5 1185 1191 15858223 levels NNS I-NP O
6 1192 1196 15858223 were VBD B-VP O
7 1197 1210 15858223 significantly RB I-VP O
8 1211 1219 15858223 elevated VBN I-VP O
9 1220 1222 15858223 by IN B-PP O
10 1223 1226 15858223 day NN B-NP O
11 1227 1228 15858223 4 CD I-NP O
12 1228 1229 15858223 , , O O
13 1230 1235 15858223 which WDT B-NP O
14 1236 1248 15858223 corresponded VBD B-VP O
15 1249 1251 15858223 to TO B-PP O
16 1252 1266 15858223 hepatotoxicity NN B-NP D056486
17 1267 1269 15858223 as IN B-SBAR O
18 1270 1275 15858223 shown VBN B-VP O
19 1276 1278 15858223 by IN B-PP O
20 1279 1282 15858223 the DT B-NP O
21 1283 1293 15858223 increasing VBG I-NP O
22 1294 1303 15858223 incidence NN I-NP O
23 1304 1306 15858223 of IN B-PP O
24 1307 1319 15858223 inflammation NN B-NP D007249
25 1320 1322 15858223 of IN B-PP O
26 1323 1326 15858223 the DT B-NP O
27 1327 1332 15858223 liver NN I-NP O
28 1333 1340 15858223 capsule NN I-NP O
29 1340 1341 15858223 , , O O
30 1342 1350 15858223 necrosis NN B-NP D009336
31 1350 1351 15858223 , , O O
32 1352 1355 15858223 and CC O O
33 1356 1365 15858223 steatosis NN B-NP D005234
34 1366 1376 15858223 throughout IN B-PP O
35 1377 1380 15858223 the DT B-NP O
36 1381 1386 15858223 study NN I-NP O
37 1386 1387 15858223 . . O O

1 1388 1391 15858223 The DT B-NP O
2 1392 1397 15858223 liver NN I-NP O
3 1398 1404 15858223 levels NNS I-NP O
4 1405 1407 15858223 of IN B-PP O
5 1408 1412 15858223 beta SYM B-NP O
6 1412 1413 15858223 - HYPH B-NP O
7 1413 1422 15858223 oxidation NN I-NP O
8 1423 1434 15858223 metabolites NNS I-NP O
9 1435 1437 15858223 of IN B-PP O
10 1438 1441 15858223 VPA NN B-NP D014635
11 1442 1446 15858223 were VBD B-VP O
12 1447 1456 15858223 decreased VBN I-VP O
13 1457 1459 15858223 by IN B-PP O
14 1460 1463 15858223 day NN B-NP O
15 1464 1466 15858223 14 CD I-NP O
16 1466 1467 15858223 , , O O
17 1468 1473 15858223 while IN B-SBAR O
18 1474 1477 15858223 the DT B-NP O
19 1478 1484 15858223 levels NNS I-NP O
20 1485 1487 15858223 of IN B-PP O
21 1488 1489 15858223 4 CD B-NP C045022
22 1489 1490 15858223 - HYPH I-NP C045022
23 1490 1493 15858223 ene NN I-NP C045022
24 1493 1494 15858223 - HYPH I-NP C045022
25 1494 1497 15858223 VPA NN I-NP C045022
26 1498 1501 15858223 and CC I-NP O
27 1502 1505 15858223 (E) NN I-NP O
28 1505 1506 15858223 - HYPH B-NP O
29 1506 1509 15858223 2,4 CD I-NP C556631
30 1509 1510 15858223 - HYPH I-NP C556631
31 1510 1515 15858223 diene NN I-NP C556631
32 1515 1516 15858223 - HYPH I-NP C556631
33 1516 1519 15858223 VPA NN I-NP C556631
34 1520 1524 15858223 were VBD B-VP O
35 1525 1528 15858223 not RB O O
36 1529 1537 15858223 elevated JJ B-ADJP O
37 1538 1548 15858223 throughout IN B-PP O
38 1549 1552 15858223 the DT B-NP O
39 1553 1558 15858223 study NN I-NP O
40 1558 1559 15858223 . . O O

1 1560 1567 15858223 Overall RB B-ADVP O
2 1567 1568 15858223 , , O O
3 1569 1574 15858223 these DT B-NP O
4 1575 1583 15858223 findings NNS I-NP O
5 1584 1592 15858223 indicate VBP B-VP O
6 1593 1597 15858223 that IN B-SBAR O
7 1598 1601 15858223 VPA NN B-NP D014635
8 1602 1611 15858223 treatment NN I-NP O
9 1612 1619 15858223 results VBZ B-VP O
10 1620 1622 15858223 in IN B-PP O
11 1623 1632 15858223 oxidative JJ B-NP O
12 1633 1639 15858223 stress NN I-NP O
13 1639 1640 15858223 , , O O
14 1641 1643 15858223 as IN B-SBAR O
15 1644 1652 15858223 measured VBN B-VP O
16 1653 1655 15858223 by IN B-PP O
17 1656 1662 15858223 levels NNS B-NP O
18 1663 1665 15858223 of IN B-PP O
19 1666 1668 15858223 15 CD B-NP C075750
20 1668 1669 15858223 - HYPH I-NP C075750
21 1669 1674 15858223 F(2t) NN I-NP C075750
22 1674 1675 15858223 - HYPH O C075750
23 1675 1679 15858223 IsoP NN B-NP C075750
24 1679 1680 15858223 , , O O
25 1681 1686 15858223 which WDT B-NP O
26 1687 1695 15858223 precedes VBZ B-VP O
27 1696 1699 15858223 the DT B-NP O
28 1700 1705 15858223 onset NN I-NP O
29 1706 1708 15858223 of IN B-PP O
30 1709 1717 15858223 necrosis NN B-NP D009336
31 1717 1718 15858223 , , O O
32 1719 1728 15858223 steatosis NN B-NP D005234
33 1728 1729 15858223 , , O O
34 1730 1733 15858223 and CC O O
35 1734 1742 15858223 elevated VBN B-NP O
36 1743 1749 15858223 levels NNS I-NP O
37 1750 1752 15858223 of IN B-PP O
38 1753 1758 15858223 serum NN B-NP O
39 1759 1764 15858223 alpha SYM B-NP O
40 1764 1765 15858223 - HYPH B-VP O
41 1765 1768 15858223 GST NN B-NP O
42 1768 1769 15858223 . . O O

1 0 0 12042105 -DOCSTART- -X- -X- O

1 0 10 12042105 Topiramate NN B-NP C052342
2 10 11 12042105 - HYPH B-NP O
3 11 18 12042105 induced VBN I-NP O
4 19 34 12042105 nephrolithiasis NN I-NP D053040
5 34 35 12042105 . . I-NP O
6 36 46 12042105 Topiramate NN I-NP C052342
7 47 49 12042105 is VBZ B-VP O
8 50 51 12042105 a DT B-NP O
9 52 60 12042105 recently RB I-NP O
10 61 70 12042105 developed VBN I-NP O
11 71 84 12042105 antiepileptic JJ I-NP O
12 85 95 12042105 medication NN I-NP O
13 96 100 12042105 that WDT B-NP O
14 101 103 12042105 is VBZ B-VP O
15 104 112 12042105 becoming VBG I-VP O
16 113 117 12042105 more RBR B-VP O
17 118 124 12042105 widely RB I-VP O
18 125 135 12042105 prescribed VBN I-VP O
19 136 143 12042105 because IN B-PP O
20 144 146 12042105 of IN I-PP O
21 147 150 12042105 its PRP$ B-NP O
22 151 159 12042105 efficacy NN I-NP O
23 160 162 12042105 in IN B-PP O
24 163 171 12042105 treating VBG B-VP O
25 172 182 12042105 refractory JJ B-NP D004827
26 183 191 12042105 seizures NNS I-NP D004827
27 191 192 12042105 . . O O

1 193 203 12042105 Urologists NNS B-NP O
2 204 210 12042105 should MD B-VP O
3 211 213 12042105 be VB I-VP O
4 214 219 12042105 aware JJ B-ADJP O
5 220 224 12042105 that IN B-SBAR O
6 225 229 12042105 this DT B-NP O
7 230 240 12042105 medication NN I-NP O
8 241 244 12042105 can MD B-VP O
9 245 250 12042105 cause VB I-VP O
10 251 260 12042105 metabolic JJ B-NP D000138
11 261 269 12042105 acidosis NN I-NP D000138
12 270 272 12042105 in IN B-PP O
13 273 281 12042105 patients NNS B-NP O
14 282 291 12042105 secondary JJ B-ADJP O
15 292 294 12042105 to TO B-PP O
16 295 305 12042105 inhibition NN B-NP O
17 306 308 12042105 of IN B-PP O
18 309 317 12042105 carbonic JJ B-NP O
19 318 327 12042105 anhydrase NN I-NP O
20 327 328 12042105 . . O O

1 329 331 12042105 In IN B-PP O
2 332 340 12042105 addition NN B-NP O
3 340 341 12042105 , , O O
4 342 343 12042105 a DT B-NP O
5 344 350 12042105 distal JJ I-NP O
6 351 358 12042105 tubular JJ I-NP O
7 359 372 12042105 acidification NN I-NP O
8 373 379 12042105 defect NN I-NP O
9 380 383 12042105 may MD B-VP O
10 384 390 12042105 result VB I-VP O
11 390 391 12042105 , , O O
12 392 396 12042105 thus RB B-ADVP O
13 397 406 12042105 impairing VBG B-VP O
14 407 410 12042105 the DT B-NP O
15 411 417 12042105 normal JJ I-NP O
16 418 430 12042105 compensatory JJ I-NP O
17 431 435 12042105 drop NN I-NP O
18 436 438 12042105 in IN B-PP O
19 439 444 12042105 urine NN B-NP O
20 445 447 12042105 pH NN I-NP O
21 447 448 12042105 . . O O

1 449 454 12042105 These DT B-NP O
2 455 462 12042105 factors NNS I-NP O
3 463 466 12042105 can MD B-VP O
4 467 471 12042105 lead VB I-VP O
5 472 474 12042105 to TO B-PP O
6 475 478 12042105 the DT B-NP O
7 479 490 12042105 development NN I-NP O
8 491 493 12042105 of IN B-PP O
9 494 501 12042105 calcium NN B-NP C020243
10 502 511 12042105 phosphate NN I-NP C020243
11 512 527 12042105 nephrolithiasis NN I-NP D053040
12 527 528 12042105 . . O O

1 529 531 12042105 We PRP B-NP O
2 532 538 12042105 report VBP B-VP O
3 539 542 12042105 the DT B-NP O
4 543 548 12042105 first JJ I-NP O
5 549 552 12042105 two CD I-NP O
6 553 558 12042105 cases NNS I-NP O
7 559 561 12042105 of IN B-PP O
8 562 572 12042105 topiramate NN B-NP C052342
9 572 573 12042105 - HYPH B-NP O
10 573 580 12042105 induced VBN I-NP O
11 581 596 12042105 nephrolithiasis NN I-NP D053040
12 597 599 12042105 in IN B-PP O
13 600 603 12042105 the DT B-NP O
14 604 612 12042105 urologic JJ I-NP O
15 613 623 12042105 literature NN I-NP O
16 623 624 12042105 . . O O

1 0 0 7263204 -DOCSTART- -X- -X- O

1 0 5 7263204 Fatal JJ B-NP O
2 6 14 7263204 aplastic JJ I-NP D000741
3 15 21 7263204 anemia NN I-NP D000741
4 22 25 7263204 due JJ B-ADJP O
5 26 28 7263204 to TO B-PP O
6 29 41 7263204 indomethacin NN B-NP D007213
7 41 42 7263204 - HYPH I-NP O
8 42 43 7263204 - HYPH I-NP O
9 43 53 7263204 lymphocyte NN I-NP O
10 54 68 7263204 transformation NN I-NP O
11 69 74 7263204 tests NNS I-NP O
12 75 77 7263204 in FW B-ADVP O
13 78 83 7263204 vitro FW I-ADVP O
14 83 84 7263204 . . O O
15 85 93 7263204 Although IN B-SBAR O
16 94 106 7263204 indomethacin NN B-NP D007213
17 107 110 7263204 has VBZ B-VP O
18 111 115 7263204 been VBN I-VP O
19 116 126 7263204 implicated VBN I-VP O
20 127 129 7263204 as IN B-PP O
21 130 131 7263204 a DT B-NP O
22 132 140 7263204 possible JJ I-NP O
23 141 146 7263204 cause NN I-NP O
24 147 149 7263204 of IN B-PP O
25 150 158 7263204 aplastic JJ B-NP D000741
26 159 165 7263204 anemia NN I-NP D000741
27 166 168 7263204 on IN B-PP O
28 169 172 7263204 the DT B-NP O
29 173 178 7263204 basis NN I-NP O
30 179 181 7263204 of IN B-PP O
31 182 183 7263204 a DT B-NP O
32 184 187 7263204 few JJ I-NP O
33 188 196 7263204 clinical JJ I-NP O
34 197 209 7263204 observations NNS I-NP O
35 209 210 7263204 , , O O
36 211 214 7263204 its PRP$ B-NP O
37 215 219 7263204 role NN I-NP O
38 220 223 7263204 has VBZ B-VP O
39 224 227 7263204 not RB I-VP O
40 228 232 7263204 been VBN I-VP O
41 233 243 7263204 definitely RB I-VP O
42 244 255 7263204 established VBN I-VP O
43 255 256 7263204 . . O O

1 257 258 7263204 A DT B-NP O
2 259 263 7263204 case NN I-NP O
3 264 266 7263204 of IN B-PP O
4 267 272 7263204 fatal JJ B-NP O
5 273 281 7263204 aplastic JJ I-NP D000741
6 282 288 7263204 anemia NN I-NP D000741
7 289 291 7263204 is VBZ B-VP O
8 292 301 7263204 described VBN I-VP O
9 302 304 7263204 in IN B-PP O
10 305 310 7263204 which WDT B-NP O
11 311 313 7263204 no DT B-NP O
12 314 319 7263204 drugs NNS I-NP O
13 320 325 7263204 other JJ B-ADJP O
14 326 330 7263204 than IN B-PP O
15 331 342 7263204 allopurinol NN B-NP D000493
16 343 346 7263204 and CC I-NP O
17 347 359 7263204 indomethacin NN I-NP D007213
18 360 364 7263204 were VBD B-VP O
19 365 370 7263204 given VBN I-VP O
20 370 371 7263204 . . O O

1 372 384 7263204 Indomethacin NN B-NP D007213
2 385 388 7263204 was VBD B-VP O
3 389 394 7263204 first RB I-VP O
4 395 400 7263204 given VBN I-VP O
5 401 405 7263204 four CD B-NP O
6 406 411 7263204 weeks NNS I-NP O
7 412 417 7263204 prior RB B-ADVP O
8 418 420 7263204 to TO B-PP O
9 421 424 7263204 the DT B-NP O
10 425 430 7263204 onset NN I-NP O
11 431 433 7263204 of IN B-PP O
12 434 442 7263204 symptoms NNS B-NP O
13 442 443 7263204 . . O O

1 444 445 7263204 A DT B-NP O
2 446 454 7263204 positive JJ I-NP O
3 455 465 7263204 lymphocyte NN I-NP O
4 466 480 7263204 transformation NN I-NP O
5 481 485 7263204 test NN I-NP O
6 486 490 7263204 with IN B-PP O
7 491 503 7263204 indomethacin NN B-NP D007213
8 504 506 7263204 in FW B-ADVP O
9 507 512 7263204 vitro FW I-ADVP O
10 513 520 7263204 further RBR B-ADVP O
11 521 534 7263204 substantiates VBZ B-VP O
12 535 538 7263204 the DT B-NP O
13 539 548 7263204 potential JJ I-NP O
14 549 553 7263204 role NN I-NP O
15 554 556 7263204 of IN B-PP O
16 557 561 7263204 this DT B-NP O
17 562 566 7263204 drug NN I-NP O
18 567 569 7263204 in IN B-PP O
19 570 577 7263204 causing VBG B-VP O
20 578 586 7263204 aplastic JJ B-NP D000741
21 587 593 7263204 anemia NN I-NP D000741
22 594 596 7263204 in IN B-PP O
23 597 598 7263204 a DT B-NP O
24 599 610 7263204 susceptible JJ I-NP O
25 611 618 7263204 patient NN I-NP O
26 618 619 7263204 . . O O

1 620 631 7263204 Fortunately RB B-ADVP O
2 631 632 7263204 , , O O
3 633 637 7263204 this DT B-NP O
4 638 643 7263204 seems VBZ B-VP O
5 644 646 7263204 to TO I-VP O
6 647 649 7263204 be VB I-VP O
7 650 651 7263204 a DT B-NP O
8 652 656 7263204 very RB I-NP O
9 657 661 7263204 rare JJ I-NP O
10 662 674 7263204 complication NN I-NP O
11 674 675 7263204 . . O O

1 0 0 14704468 -DOCSTART- -X- -X- O

1 0 6 14704468 Effect NN B-NP O
2 7 9 14704468 of IN B-PP O
3 10 14 14704468 some DT B-NP O
4 15 26 14704468 convulsants NNS I-NP O
5 27 29 14704468 on IN B-PP O
6 30 33 14704468 the DT B-NP O
7 34 44 14704468 protective JJ I-NP O
8 45 53 14704468 activity NN I-NP O
9 54 56 14704468 of IN B-PP O
10 57 68 14704468 loreclezole NN B-NP C066440
11 69 72 14704468 and CC O O
12 73 76 14704468 its PRP$ B-NP O
13 77 89 14704468 combinations NNS I-NP O
14 90 94 14704468 with IN B-PP O
15 95 104 14704468 valproate NN B-NP D014635
16 105 107 14704468 or CC I-NP O
17 108 118 14704468 clonazepam NN I-NP D002998
18 119 121 14704468 in IN B-PP O
19 122 130 14704468 amygdala NN B-NP O
20 130 131 14704468 - HYPH B-NP O
21 131 138 14704468 kindled VBN I-NP O
22 139 143 14704468 rats NNS I-NP O
23 143 144 14704468 . . O O
24 145 156 14704468 Loreclezole NN B-NP C066440
25 157 158 14704468 ( ( O O
26 158 159 14704468 5 CD B-NP O
27 160 162 14704468 mg NN I-NP O
28 162 163 14704468 / SYM B-NP O
29 163 165 14704468 kg NN I-NP O
30 165 166 14704468 ) ) O O
31 167 174 14704468 exerted VBD B-VP O
32 175 176 14704468 a DT B-NP O
33 177 188 14704468 significant JJ I-NP O
34 189 199 14704468 protective JJ I-NP O
35 200 206 14704468 action NN I-NP O
36 207 209 14704468 in IN B-PP O
37 210 218 14704468 amygdala NN B-NP O
38 218 219 14704468 - HYPH B-NP O
39 219 226 14704468 kindled VBN I-NP O
40 227 231 14704468 rats NNS I-NP O
41 231 232 14704468 , , O O
42 233 241 14704468 reducing VBG B-VP O
43 242 246 14704468 both CC O O
44 247 254 14704468 seizure NN B-NP D012640
45 255 258 14704468 and CC O O
46 259 273 14704468 afterdischarge JJ B-NP O
47 274 283 14704468 durations NNS I-NP O
48 283 284 14704468 . . O O

1 285 288 14704468 The DT B-NP O
2 289 301 14704468 combinations NNS I-NP O
3 302 304 14704468 of IN B-PP O
4 305 316 14704468 loreclezole NN B-NP C066440
5 317 318 14704468 ( ( O O
6 318 321 14704468 2.5 CD B-NP O
7 322 324 14704468 mg NN I-NP O
8 324 325 14704468 / SYM B-NP O
9 325 327 14704468 kg NN I-NP O
10 327 328 14704468 ) ) O O
11 329 333 14704468 with IN B-PP O
12 334 343 14704468 valproate NN B-NP D014635
13 343 344 14704468 , , O O
14 345 355 14704468 clonazepam NN B-NP D002998
15 355 356 14704468 , , O O
16 357 359 14704468 or CC O O
17 360 373 14704468 carbamazepine NN B-NP D002220
18 374 375 14704468 ( ( O O
19 375 382 14704468 applied VBN B-VP O
20 383 385 14704468 at IN B-PP O
21 386 391 14704468 their PRP$ B-NP O
22 392 405 14704468 subprotective JJ I-NP O
23 406 411 14704468 doses NNS I-NP O
24 411 412 14704468 ) ) O O
25 413 417 14704468 also RB B-ADVP O
26 418 427 14704468 exhibited VBD B-VP O
27 428 439 14704468 antiseizure JJ B-NP O
28 440 446 14704468 effect NN I-NP O
29 447 449 14704468 in IN B-PP O
30 450 454 14704468 this DT B-NP O
31 455 459 14704468 test NN I-NP O
32 459 460 14704468 . . O O

1 461 468 14704468 However RB B-ADVP O
2 468 469 14704468 , , O O
3 470 474 14704468 only RB B-NP O
4 475 478 14704468 two CD I-NP O
5 479 484 14704468 first JJ I-NP O
6 485 497 14704468 combinations NNS I-NP O
7 498 506 14704468 occurred VBD B-VP O
8 507 509 14704468 to TO I-VP O
9 510 512 14704468 be VB I-VP O
10 513 515 14704468 of IN B-PP O
11 516 531 14704468 pharmacodynamic JJ B-NP O
12 532 538 14704468 nature NN I-NP O
13 538 539 14704468 . . O O

1 540 545 14704468 Among IN B-PP O
2 546 553 14704468 several JJ B-NP O
3 554 570 14704468 chemoconvulsants NNS I-NP O
4 570 571 14704468 , , O O
5 572 583 14704468 bicuculline NN B-NP D001640
6 583 584 14704468 , , O O
7 585 586 14704468 N NN B-NP D016202
8 586 587 14704468 - HYPH B-NP D016202
9 587 593 14704468 methyl NN I-NP D016202
10 593 594 14704468 - HYPH B-NP D016202
11 594 595 14704468 D NN I-NP D016202
12 595 596 14704468 - HYPH B-NP D016202
13 596 604 14704468 aspartic JJ I-NP D016202
14 605 609 14704468 acid NN I-NP D016202
15 610 613 14704468 and CC I-NP O
16 614 617 14704468 BAY NN I-NP D001498
17 618 619 14704468 k NN I-NP D001498
18 619 620 14704468 - HYPH B-NP D001498
19 620 624 14704468 8644 CD I-NP D001498
20 625 626 14704468 ( ( O O
21 626 629 14704468 the DT B-NP O
22 630 636 14704468 opener NN I-NP O
23 637 639 14704468 of IN B-PP O
24 640 641 14704468 L NN B-NP O
25 641 642 14704468 - HYPH B-NP O
26 642 646 14704468 type NN I-NP O
27 647 654 14704468 calcium NN I-NP D002118
28 655 663 14704468 channels NNS I-NP O
29 663 664 14704468 ) ) O O
30 665 673 14704468 reversed VBD B-VP O
31 674 677 14704468 the DT B-NP O
32 678 688 14704468 protective JJ I-NP O
33 689 697 14704468 activity NN I-NP O
34 698 700 14704468 of IN B-PP O
35 701 712 14704468 loreclezole NN B-NP C066440
36 713 718 14704468 alone RB B-ADVP O
37 719 722 14704468 and CC O O
38 723 726 14704468 its PRP$ B-NP O
39 727 738 14704468 combination NN I-NP O
40 739 743 14704468 with IN B-PP O
41 744 753 14704468 valproate NN B-NP D014635
42 753 754 14704468 . . O O

1 755 757 14704468 On IN B-PP O
2 758 761 14704468 the DT B-NP O
3 762 767 14704468 other JJ I-NP O
4 768 772 14704468 hand NN I-NP O
5 772 773 14704468 , , O O
6 774 785 14704468 bicuculline NN B-NP D001640
7 785 786 14704468 , , O O
8 787 800 14704468 aminophylline NN B-NP D000628
9 801 804 14704468 and CC O O
10 805 808 14704468 BAY NN B-NP D001498
11 809 810 14704468 k NN I-NP D001498
12 810 811 14704468 - HYPH B-NP D001498
13 811 815 14704468 8644 CD I-NP D001498
14 816 825 14704468 inhibited VBD B-VP O
15 826 829 14704468 the DT B-NP O
16 830 844 14704468 anticonvulsive JJ I-NP O
17 845 851 14704468 action NN I-NP O
18 852 854 14704468 of IN B-PP O
19 855 866 14704468 loreclezole NN B-NP C066440
20 867 875 14704468 combined VBN B-VP O
21 876 880 14704468 with IN B-PP O
22 881 891 14704468 clonazepam NN B-NP D002998
23 891 892 14704468 . . O O

1 893 896 14704468 The DT B-NP O
2 897 904 14704468 results NNS I-NP O
3 905 912 14704468 support VBP B-VP O
4 913 916 14704468 the DT B-NP O
5 917 927 14704468 hypothesis NN I-NP O
6 928 932 14704468 that IN B-SBAR O
7 933 936 14704468 the DT B-NP O
8 937 947 14704468 protective JJ I-NP O
9 948 956 14704468 activity NN I-NP O
10 957 959 14704468 of IN B-PP O
11 960 971 14704468 loreclezole NN B-NP C066440
12 972 975 14704468 and CC O O
13 976 979 14704468 its PRP$ B-NP O
14 980 992 14704468 combinations NNS I-NP O
15 993 997 14704468 with IN B-PP O
16 998 1003 14704468 other JJ B-NP O
17 1004 1018 14704468 antiepileptics NNS I-NP O
18 1019 1022 14704468 may MD B-VP O
19 1023 1030 14704468 involve VB I-VP O
20 1031 1043 14704468 potentiation NN B-NP O
21 1044 1046 14704468 of IN B-PP O
22 1047 1056 14704468 GABAergic JJ B-NP O
23 1057 1074 14704468 neurotransmission NN I-NP O
24 1075 1078 14704468 and CC I-NP O
25 1079 1087 14704468 blockade NN I-NP O
26 1088 1090 14704468 of IN B-PP O
27 1091 1092 14704468 L NN B-NP O
28 1092 1093 14704468 - HYPH O O
29 1093 1097 14704468 type NN B-NP O
30 1098 1100 14704468 of IN B-PP O
31 1101 1108 14704468 calcium NN B-NP D002118
32 1109 1117 14704468 channels NNS I-NP O
33 1117 1118 14704468 . . O O

1 0 0 19761039 -DOCSTART- -X- -X- O

1 0 6 19761039 Effect NN B-NP O
2 7 9 19761039 of IN B-PP O
3 10 18 19761039 Hibiscus NNP B-NP D010936
4 19 23 19761039 rosa NNP I-NP D010936
5 24 32 19761039 sinensis NN I-NP D010936
6 33 35 19761039 on IN B-PP O
7 36 45 19761039 reserpine NN B-NP D012110
8 45 46 19761039 - HYPH B-NP O
9 46 53 19761039 induced VBN I-NP O
10 54 69 19761039 neurobehavioral JJ I-NP O
11 70 73 19761039 and CC I-NP O
12 74 85 19761039 biochemical JJ I-NP O
13 86 97 19761039 alterations NNS I-NP O
14 98 100 19761039 in IN B-PP O
15 101 105 19761039 rats NNS B-NP O
16 105 106 19761039 . . O O
17 107 113 19761039 Effect NN B-NP O
18 114 116 19761039 of IN B-PP O
19 117 127 19761039 methanolic JJ B-NP O
20 128 135 19761039 extract NN I-NP O
21 136 138 19761039 of IN B-PP O
22 139 147 19761039 Hibiscus NNP B-NP D010936
23 148 152 19761039 rosa NN I-NP D010936
24 153 161 19761039 sinensis NN I-NP D010936
25 162 163 19761039 ( ( O O
26 163 166 19761039 100 CD B-NP O
27 166 167 19761039 - HYPH I-NP O
28 167 170 19761039 300 CD I-NP O
29 171 173 19761039 mg NN I-NP O
30 173 174 19761039 / SYM B-NP O
31 174 176 19761039 kg NN I-NP O
32 176 177 19761039 ) ) O O
33 178 181 19761039 was VBD B-VP O
34 182 189 19761039 studied VBN I-VP O
35 190 192 19761039 on IN B-PP O
36 193 202 19761039 reserpine NN B-NP D012110
37 202 203 19761039 - HYPH B-NP O
38 203 210 19761039 induced VBN I-NP O
39 211 220 19761039 orofacial JJ I-NP O
40 221 231 19761039 dyskinesia NN I-NP D004409
41 232 235 19761039 and CC O O
42 236 249 19761039 neurochemical JJ B-NP O
43 250 261 19761039 alterations NNS I-NP O
44 261 262 19761039 . . O O

1 263 266 19761039 The DT B-NP O
2 267 271 19761039 rats NNS I-NP O
3 272 276 19761039 were VBD B-VP O
4 277 284 19761039 treated VBN I-VP O
5 285 289 19761039 with IN B-PP O
6 290 305 19761039 intraperitoneal JJ B-NP O
7 306 315 19761039 reserpine NN I-NP D012110
8 316 317 19761039 ( ( O O
9 317 318 19761039 1 CD B-NP O
10 319 321 19761039 mg NN I-NP O
11 321 322 19761039 / SYM B-NP O
12 322 324 19761039 kg NN I-NP O
13 324 325 19761039 , , O O
14 326 328 19761039 ip RB B-ADVP O
15 328 329 19761039 ) ) O O
16 330 333 19761039 for IN B-PP O
17 334 335 19761039 3 CD B-NP O
18 336 340 19761039 days NNS I-NP O
19 341 346 19761039 every DT B-NP O
20 347 352 19761039 other JJ I-NP O
21 353 356 19761039 day NN I-NP O
22 356 357 19761039 . . O O

1 358 360 19761039 On IN B-PP O
2 361 364 19761039 day NN B-NP O
3 365 366 19761039 5 CD I-NP O
4 366 367 19761039 , , O O
5 368 375 19761039 vacuous JJ B-NP O
6 376 383 19761039 chewing NN I-NP O
7 384 393 19761039 movements NNS I-NP O
8 394 397 19761039 and CC O O
9 398 404 19761039 tongue NN B-NP O
10 405 416 19761039 protrusions NNS I-NP O
11 417 421 19761039 were VBD B-VP O
12 422 429 19761039 counted VBN I-VP O
13 430 433 19761039 for IN B-PP O
14 434 435 19761039 5 CD B-NP O
15 436 439 19761039 min NN I-NP O
16 439 440 19761039 . . O O

1 441 450 19761039 Reserpine NN B-NP D012110
2 451 458 19761039 treated VBN I-NP O
3 459 463 19761039 rats NNS I-NP O
4 464 477 19761039 significantly RB B-ADVP O
5 478 487 19761039 developed VBD B-VP O
6 488 495 19761039 vacuous JJ B-NP O
7 496 503 19761039 chewing NN I-NP O
8 504 513 19761039 movements NNS I-NP O
9 514 517 19761039 and CC O O
10 518 524 19761039 tongue NN B-NP O
11 525 536 19761039 protrusions NNS I-NP O
12 537 544 19761039 however RB B-ADVP O
13 544 545 19761039 , , O O
14 546 562 19761039 coadministration NN B-NP O
15 563 565 19761039 of IN B-PP O
16 566 574 19761039 Hibiscus NNP B-NP D010936
17 575 579 19761039 rosa NNP I-NP D010936
18 580 588 19761039 sinensis NN I-NP D010936
19 589 594 19761039 roots NNS I-NP O
20 595 602 19761039 extract NN I-NP O
21 603 604 19761039 ( ( O O
22 604 607 19761039 100 CD B-NP O
23 607 608 19761039 , , I-NP O
24 609 612 19761039 200 CD I-NP O
25 613 616 19761039 and CC I-NP O
26 617 620 19761039 300 CD I-NP O
27 621 623 19761039 mg NN I-NP O
28 623 624 19761039 / SYM B-NP O
29 624 626 19761039 kg NN I-NP O
30 626 627 19761039 , , O O
31 628 631 19761039 per IN B-PP O
32 632 638 19761039 orally RB B-ADVP O
33 638 639 19761039 ) ) O O
34 640 650 19761039 attenuated VBD B-VP O
35 651 654 19761039 the DT B-NP O
36 655 662 19761039 effects NNS I-NP O
37 662 663 19761039 . . O O

1 664 675 19761039 Biochemical JJ B-NP O
2 676 684 19761039 analysis NN I-NP O
3 685 687 19761039 of IN B-PP O
4 688 693 19761039 brain NN B-NP O
5 694 702 19761039 revealed VBD B-VP O
6 703 707 19761039 that IN B-SBAR O
7 708 711 19761039 the DT B-NP O
8 712 721 19761039 reserpine NN I-NP D012110
9 722 731 19761039 treatment NN I-NP O
10 732 745 19761039 significantly RB B-ADVP O
11 746 755 19761039 increased VBD B-VP O
12 756 761 19761039 lipid NN B-NP O
13 762 774 19761039 peroxidation NN I-NP O
14 775 778 19761039 and CC O O
15 779 788 19761039 decreased VBD B-VP O
16 789 795 19761039 levels NNS B-NP O
17 796 798 19761039 of IN B-PP O
18 799 809 19761039 superoxide NN B-NP D013481
19 810 819 19761039 dismutase NN I-NP O
20 820 821 19761039 ( ( O O
21 821 824 19761039 SOD NN B-NP O
22 824 825 19761039 ) ) O O
23 825 826 19761039 , , O O
24 827 835 19761039 catalase NN B-NP O
25 836 837 19761039 ( ( O O
26 837 840 19761039 CAT NN B-NP O
27 840 841 19761039 ) ) O O
28 842 845 19761039 and CC O O
29 846 857 19761039 glutathione NN B-NP D005978
30 858 867 19761039 reductase NN I-NP O
31 868 869 19761039 ( ( O O
32 869 872 19761039 GSH NN B-NP O
33 872 873 19761039 ) ) O O
34 873 874 19761039 , , O O
35 875 877 19761039 an DT B-NP O
36 878 883 19761039 index NN I-NP O
37 884 886 19761039 of IN B-PP O
38 887 896 19761039 oxidative JJ B-NP O
39 897 903 19761039 stress NN I-NP O
40 904 911 19761039 process NN I-NP O
41 911 912 19761039 . . O O

1 913 929 19761039 Coadministration NN B-NP O
2 930 932 19761039 of IN B-PP O
3 933 940 19761039 extract NN B-NP O
4 941 954 19761039 significantly RB B-ADVP O
5 955 962 19761039 reduced VBD B-VP O
6 963 966 19761039 the DT B-NP O
7 967 972 19761039 lipid NN I-NP O
8 973 985 19761039 peroxidation NN I-NP O
9 986 989 19761039 and CC O O
10 990 998 19761039 reversed VBD B-VP O
11 999 1002 19761039 the DT B-NP O
12 1003 1011 19761039 decrease NN I-NP O
13 1012 1014 19761039 in IN B-PP O
14 1015 1020 19761039 brain NN B-NP O
15 1021 1024 19761039 SOD NN I-NP O
16 1024 1025 19761039 , , O O
17 1026 1029 19761039 CAT NN B-NP O
18 1030 1033 19761039 and CC I-NP O
19 1034 1037 19761039 GSH NN I-NP O
20 1038 1044 19761039 levels NNS I-NP O
21 1044 1045 19761039 . . O O

1 1046 1049 19761039 The DT B-NP O
2 1050 1057 19761039 results NNS I-NP O
3 1058 1060 19761039 of IN B-PP O
4 1061 1064 19761039 the DT B-NP O
5 1065 1072 19761039 present JJ I-NP O
6 1073 1078 19761039 study NN I-NP O
7 1079 1088 19761039 suggested VBD B-VP O
8 1089 1093 19761039 that IN B-SBAR O
9 1094 1102 19761039 Hibiscus NNP B-NP D010936
10 1103 1107 19761039 rosa NNP I-NP D010936
11 1108 1116 19761039 sinensis NN I-NP D010936
12 1117 1120 19761039 had VBD B-VP O
13 1121 1122 19761039 a DT B-NP O
14 1123 1133 19761039 protective JJ I-NP O
15 1134 1138 19761039 role NN I-NP O
16 1139 1146 19761039 against IN B-PP O
17 1147 1156 19761039 reserpine NN B-NP D012110
18 1156 1157 19761039 - HYPH B-NP O
19 1157 1164 19761039 induced VBN I-NP O
20 1165 1174 19761039 orofacial JJ I-NP O
21 1175 1185 19761039 dyskinesia NN I-NP D004409
22 1186 1189 19761039 and CC O O
23 1190 1199 19761039 oxidative JJ B-NP O
24 1200 1206 19761039 stress NN I-NP O
25 1206 1207 19761039 . . O O

1 0 0 3115150 -DOCSTART- -X- -X- O

1 0 10 3115150 Ketanserin NN B-NP D007650
2 11 23 3115150 pretreatment NN I-NP O
3 24 32 3115150 reverses VBZ B-VP O
4 33 43 3115150 alfentanil NN B-NP D015760
5 43 44 3115150 - HYPH B-NP O
6 44 51 3115150 induced VBN I-NP O
7 52 58 3115150 muscle NN I-NP D009127
8 59 67 3115150 rigidity NN I-NP D009127
9 67 68 3115150 . . O O
10 69 77 3115150 Systemic JJ B-NP O
11 78 90 3115150 pretreatment NN I-NP O
12 91 95 3115150 with IN B-PP O
13 96 106 3115150 ketanserin NN B-NP D007650
14 106 107 3115150 , , O O
15 108 109 3115150 a DT B-NP O
16 110 120 3115150 relatively RB I-NP O
17 121 129 3115150 specific JJ I-NP O
18 130 134 3115150 type NN I-NP O
19 134 135 3115150 - HYPH I-NP O
20 135 136 3115150 2 CD I-NP O
21 137 146 3115150 serotonin NN I-NP D012701
22 147 155 3115150 receptor NN I-NP O
23 156 166 3115150 antagonist NN I-NP O
24 166 167 3115150 , , O O
25 168 181 3115150 significantly RB B-VP O
26 182 192 3115150 attenuated VBD I-VP O
27 193 196 3115150 the DT B-NP O
28 197 203 3115150 muscle NN I-NP D009127
29 204 212 3115150 rigidity NN I-NP D009127
30 213 221 3115150 produced VBN B-VP O
31 222 224 3115150 in IN B-PP O
32 225 229 3115150 rats NNS B-NP O
33 230 232 3115150 by IN B-PP O
34 233 236 3115150 the DT B-NP O
35 237 243 3115150 potent JJ I-NP O
36 244 249 3115150 short JJ I-NP O
37 249 250 3115150 - HYPH I-NP O
38 250 256 3115150 acting VBG I-NP O
39 257 263 3115150 opiate NN I-NP O
40 264 271 3115150 agonist NN I-NP O
41 272 282 3115150 alfentanil NN I-NP D015760
42 282 283 3115150 . . O O

1 284 293 3115150 Following VBG B-PP O
2 294 303 3115150 placement NN B-NP O
3 304 306 3115150 of IN B-PP O
4 307 319 3115150 subcutaneous JJ B-NP O
5 320 330 3115150 electrodes NNS I-NP O
6 331 333 3115150 in IN B-PP O
7 334 338 3115150 each DT B-NP O
8 339 347 3115150 animal's NNS I-NP O
9 348 352 3115150 left VBD B-VP O
10 353 366 3115150 gastrocnemius NN B-NP O
11 367 373 3115150 muscle NN I-NP O
12 373 374 3115150 , , O O
13 375 383 3115150 rigidity NN B-NP D009127
14 384 387 3115150 was VBD B-VP O
15 388 396 3115150 assessed VBN I-VP O
16 397 399 3115150 by IN B-PP O
17 400 409 3115150 analyzing VBG B-VP O
18 410 414 3115150 root NN B-NP O
19 414 415 3115150 - HYPH B-NP O
20 415 419 3115150 mean JJ I-NP O
21 419 420 3115150 - HYPH I-NP O
22 420 426 3115150 square NN I-NP O
23 427 444 3115150 electromyographic JJ I-NP O
24 445 453 3115150 activity NN I-NP O
25 453 454 3115150 . . O O

1 455 470 3115150 Intraperitoneal JJ B-NP O
2 471 481 3115150 ketanserin NN I-NP D007650
3 482 496 3115150 administration NN I-NP O
4 497 499 3115150 at IN B-PP O
5 500 505 3115150 doses NNS B-NP O
6 506 508 3115150 of IN B-PP O
7 509 513 3115150 0.63 CD B-NP O
8 514 517 3115150 and CC I-NP O
9 518 521 3115150 2.5 CD I-NP O
10 522 524 3115150 mg NN I-NP O
11 524 525 3115150 / SYM B-NP O
12 525 527 3115150 kg NN I-NP O
13 528 537 3115150 prevented VBD B-VP O
14 538 541 3115150 the DT B-NP O
15 542 552 3115150 alfentanil NN I-NP D015760
16 552 553 3115150 - HYPH B-VP O
17 553 560 3115150 induced VBN B-NP O
18 561 569 3115150 increase NN I-NP O
19 570 572 3115150 in IN B-PP O
20 573 590 3115150 electromyographic JJ B-NP O
21 591 599 3115150 activity NN I-NP O
22 600 608 3115150 compared VBN B-PP O
23 609 613 3115150 with IN B-PP O
24 614 621 3115150 animals NNS B-NP O
25 622 632 3115150 pretreated VBN B-VP O
26 633 637 3115150 with IN B-PP O
27 638 644 3115150 saline NN B-NP O
28 644 645 3115150 . . O O

1 646 662 3115150 Chlordiazepoxide NN B-NP D002707
2 663 665 3115150 at IN B-PP O
3 666 671 3115150 doses NNS B-NP O
4 672 674 3115150 up RB B-NP O
5 675 677 3115150 to TO I-NP O
6 678 680 3115150 10 CD I-NP O
7 681 683 3115150 mg NN I-NP O
8 683 684 3115150 / SYM I-NP O
9 684 686 3115150 kg NN I-NP O
10 687 693 3115150 failed VBD B-VP O
11 694 696 3115150 to TO I-VP O
12 697 710 3115150 significantly RB I-VP O
13 711 720 3115150 influence VB I-VP O
14 721 724 3115150 the DT B-NP O
15 725 733 3115150 rigidity NN I-NP D009127
16 734 742 3115150 produced VBN B-VP O
17 743 745 3115150 by IN B-PP O
18 746 756 3115150 alfentanil NN B-NP D015760
19 756 757 3115150 . . O O

1 758 765 3115150 Despite IN B-PP O
2 766 769 3115150 the DT B-NP O
3 770 777 3115150 absence NN I-NP O
4 778 780 3115150 of IN B-PP O
5 781 789 3115150 rigidity NN B-NP D009127
6 789 790 3115150 , , O O
7 791 798 3115150 animals NNS B-NP O
8 799 803 3115150 that WDT B-NP O
9 804 812 3115150 received VBD B-VP O
10 813 823 3115150 ketanserin NN B-NP D007650
11 824 825 3115150 ( ( O O
12 825 832 3115150 greater JJR B-NP O
13 833 837 3115150 than IN I-NP O
14 838 842 3115150 0.31 CD I-NP O
15 843 845 3115150 mg NN I-NP O
16 845 846 3115150 / SYM B-NP O
17 846 848 3115150 kg NN I-NP O
18 849 852 3115150 i.p NN I-NP O
19 852 853 3115150 . . O O
20 853 854 3115150 ) ) O O
21 855 863 3115150 followed VBN B-VP O
22 864 866 3115150 by IN B-PP O
23 867 877 3115150 alfentanil NN B-NP D015760
24 878 882 3115150 were VBD B-VP O
25 883 893 3115150 motionless JJ B-ADJP O
26 893 894 3115150 , , O O
27 895 902 3115150 flaccid NN B-NP O
28 902 903 3115150 , , O O
29 904 907 3115150 and CC O O
30 908 912 3115150 less RBR B-ADJP O
31 913 923 3115150 responsive JJ I-ADJP O
32 924 926 3115150 to TO B-PP O
33 927 935 3115150 external JJ B-NP O
34 936 943 3115150 stimuli NNS I-NP O
35 944 948 3115150 than IN B-SBAR O
36 949 953 3115150 were VBD B-VP O
37 954 961 3115150 animals NNS B-NP O
38 962 971 3115150 receiving VBG B-VP O
39 972 982 3115150 alfentanil NN B-NP D015760
40 983 988 3115150 alone RB B-ADVP O
41 988 989 3115150 . . O O

1 990 994 3115150 Rats NNS B-NP O
2 995 999 3115150 that WDT B-NP O
3 1000 1008 3115150 received VBD B-VP O
4 1009 1019 3115150 ketanserin NN B-NP D007650
5 1020 1023 3115150 and CC I-NP O
6 1024 1034 3115150 alfentanil NN I-NP D015760
7 1035 1044 3115150 exhibited VBD B-VP O
8 1045 1049 3115150 less RBR B-NP O
9 1050 1057 3115150 rearing JJ I-NP O
10 1058 1061 3115150 and CC I-NP O
11 1062 1073 3115150 exploratory JJ I-NP O
12 1074 1082 3115150 behavior NN I-NP O
13 1083 1085 3115150 at IN B-PP O
14 1086 1089 3115150 the DT B-NP O
15 1090 1093 3115150 end NN I-NP O
16 1094 1096 3115150 of IN B-PP O
17 1097 1100 3115150 the DT B-NP O
18 1101 1103 3115150 60 CD I-NP O
19 1103 1104 3115150 - HYPH I-NP O
20 1104 1107 3115150 min NN I-NP O
21 1108 1117 3115150 recording NN I-NP O
22 1118 1124 3115150 period NN I-NP O
23 1125 1129 3115150 than IN B-SBAR O
24 1130 1133 3115150 did VBD O O
25 1134 1141 3115150 animals NNS B-NP O
26 1142 1146 3115150 that WDT B-NP O
27 1147 1155 3115150 received VBD B-VP O
28 1156 1166 3115150 ketanserin NN B-NP D007650
29 1167 1172 3115150 alone RB B-ADVP O
30 1172 1173 3115150 . . O O

1 1174 1179 3115150 These DT B-NP O
2 1180 1187 3115150 results NNS I-NP O
3 1187 1188 3115150 , , O O
4 1189 1191 3115150 in IN B-PP O
5 1192 1203 3115150 combination NN B-NP O
6 1204 1208 3115150 with IN B-PP O
7 1209 1217 3115150 previous JJ B-NP O
8 1218 1222 3115150 work NN I-NP O
9 1222 1223 3115150 , , O O
10 1224 1231 3115150 suggest VBP B-VP O
11 1232 1236 3115150 that IN B-SBAR O
12 1237 1243 3115150 muscle NN B-NP D009127
13 1244 1252 3115150 rigidity NN I-NP D009127
14 1252 1253 3115150 , , O O
15 1254 1255 3115150 a DT B-NP O
16 1256 1266 3115150 clinically RB I-NP O
17 1267 1275 3115150 relevant JJ I-NP O
18 1276 1280 3115150 side NN I-NP O
19 1280 1281 3115150 - HYPH B-NP O
20 1281 1287 3115150 effect NN I-NP O
21 1288 1290 3115150 of IN B-PP O
22 1291 1301 3115150 parenteral JJ B-NP O
23 1302 1310 3115150 narcotic JJ I-NP O
24 1311 1325 3115150 administration NN I-NP O
25 1325 1326 3115150 , , O O
26 1327 1330 3115150 may MD B-VP O
27 1331 1333 3115150 be VB I-VP O
28 1334 1340 3115150 partly RB I-VP O
29 1341 1349 3115150 mediated VBN I-VP O
30 1350 1353 3115150 via IN B-PP O
31 1354 1366 3115150 serotonergic JJ B-NP O
32 1367 1375 3115150 pathways NNS I-NP O
33 1375 1376 3115150 . . O O

1 1377 1389 3115150 Pretreatment NN B-NP O
2 1390 1394 3115150 with IN B-PP O
3 1395 1399 3115150 type NN B-NP O
4 1399 1400 3115150 - HYPH I-NP O
5 1400 1401 3115150 2 CD I-NP O
6 1402 1411 3115150 serotonin NN I-NP D012701
7 1412 1423 3115150 antagonists NNS I-NP O
8 1424 1427 3115150 may MD B-VP O
9 1428 1430 3115150 be VB I-VP O
10 1431 1441 3115150 clinically RB B-ADJP O
11 1442 1448 3115150 useful JJ I-ADJP O
12 1449 1451 3115150 in IN B-PP O
13 1452 1463 3115150 attenuating VBG B-VP O
14 1464 1470 3115150 opiate NN B-NP O
15 1470 1471 3115150 - HYPH B-NP O
16 1471 1478 3115150 induced VBN I-NP O
17 1479 1487 3115150 rigidity NN I-NP D009127
18 1487 1488 3115150 , , O O
19 1489 1497 3115150 although IN B-SBAR O
20 1498 1505 3115150 further JJ B-NP O
21 1506 1513 3115150 studies NNS I-NP O
22 1514 1518 3115150 will MD B-VP O
23 1519 1521 3115150 be VB I-VP O
24 1522 1531 3115150 necessary JJ B-ADJP O
25 1532 1534 3115150 to TO B-VP O
26 1535 1541 3115150 assess VB I-VP O
27 1542 1545 3115150 the DT B-NP O
28 1546 1557 3115150 interaction NN I-NP O
29 1558 1560 3115150 of IN B-PP O
30 1561 1569 3115150 possibly RB B-NP O
31 1570 1578 3115150 enhanced VBN I-NP O
32 1579 1582 3115150 CNS NN I-NP O
33 1582 1583 3115150 , , O O
34 1584 1598 3115150 cardiovascular JJ B-ADJP D002318
35 1598 1599 3115150 , , O D002318
36 1600 1603 3115150 and CC O D002318
37 1604 1615 3115150 respiratory JJ B-NP D002318
38 1616 1626 3115150 depression NN I-NP D002318
39 1626 1627 3115150 . . O O

1 0 0 3413271 -DOCSTART- -X- -X- O

1 0 10 3413271 Mechanisms NNS B-NP O
2 11 13 3413271 of IN B-PP O
3 14 24 3413271 myocardial JJ B-NP D017202
4 25 33 3413271 ischemia NN I-NP D017202
5 34 41 3413271 induced VBN B-VP O
6 42 44 3413271 by IN B-PP O
7 45 56 3413271 epinephrine NN B-NP D004837
8 56 57 3413271 : : O O
9 58 68 3413271 comparison NN B-NP O
10 69 73 3413271 with IN B-PP O
11 74 82 3413271 exercise NN B-NP O
12 82 83 3413271 - HYPH B-NP O
13 83 90 3413271 induced VBN I-NP O
14 91 99 3413271 ischemia NN I-NP D007511
15 99 100 3413271 . . O O
16 101 104 3413271 The DT B-NP O
17 105 109 3413271 role NN I-NP O
18 110 112 3413271 of IN B-PP O
19 113 124 3413271 epinephrine NN B-NP D004837
20 125 127 3413271 in IN B-PP O
21 128 137 3413271 eliciting VBG B-VP O
22 138 148 3413271 myocardial JJ B-NP D017202
23 149 157 3413271 ischemia NN I-NP D017202
24 158 161 3413271 was VBD B-VP O
25 162 170 3413271 examined VBN I-VP O
26 171 173 3413271 in IN B-PP O
27 174 182 3413271 patients NNS B-NP O
28 183 187 3413271 with IN B-PP O
29 188 196 3413271 coronary JJ B-NP D003324
30 197 203 3413271 artery NN I-NP D003324
31 204 211 3413271 disease NN I-NP D003324
32 211 212 3413271 . . O O

1 213 222 3413271 Objective JJ B-NP O
2 223 228 3413271 signs NNS I-NP O
3 229 231 3413271 of IN B-PP O
4 232 240 3413271 ischemia NN B-NP D007511
5 241 244 3413271 and CC I-NP O
6 245 252 3413271 factors NNS I-NP O
7 253 263 3413271 increasing VBG B-VP O
8 264 274 3413271 myocardial JJ B-NP O
9 275 281 3413271 oxygen NN I-NP D010100
10 282 293 3413271 consumption NN I-NP O
11 294 298 3413271 were VBD B-VP O
12 299 307 3413271 compared VBN I-VP O
13 308 314 3413271 during IN B-PP O
14 315 326 3413271 epinephrine NN B-NP D004837
15 327 335 3413271 infusion NN I-NP O
16 336 339 3413271 and CC O O
17 340 346 3413271 supine NN B-NP O
18 347 354 3413271 bicycle NN I-NP O
19 355 363 3413271 exercise NN I-NP O
20 363 364 3413271 . . O O

1 365 369 3413271 Both CC O O
2 370 381 3413271 epinephrine NN B-NP D004837
3 382 385 3413271 and CC I-NP O
4 386 394 3413271 exercise NN I-NP O
5 395 403 3413271 produced VBD B-VP O
6 404 414 3413271 myocardial JJ B-NP D017202
7 415 423 3413271 ischemia NN I-NP D017202
8 424 426 3413271 as IN B-SBAR O
9 427 436 3413271 evidenced VBN B-VP O
10 437 439 3413271 by IN B-PP O
11 440 442 3413271 ST JJ B-NP O
12 443 450 3413271 segment NN I-NP O
13 451 461 3413271 depression NN I-NP D003866
14 462 465 3413271 and CC I-NP O
15 466 472 3413271 angina NN I-NP D000787
16 472 473 3413271 . . O O

1 474 481 3413271 However RB B-ADVP O
2 481 482 3413271 , , O O
3 483 486 3413271 the DT B-NP O
4 487 497 3413271 mechanisms NNS I-NP O
5 498 500 3413271 of IN B-PP O
6 501 511 3413271 myocardial JJ B-NP D017202
7 512 520 3413271 ischemia NN I-NP D017202
8 521 528 3413271 induced VBN B-VP O
9 529 531 3413271 by IN B-PP O
10 532 543 3413271 epinephrine NN B-NP D004837
11 544 548 3413271 were VBD B-VP O
12 549 562 3413271 significantly RB B-ADJP O
13 563 572 3413271 different JJ I-ADJP O
14 573 577 3413271 from IN B-PP O
15 578 583 3413271 those DT B-NP O
16 584 586 3413271 of IN B-PP O
17 587 595 3413271 exercise NN B-NP O
18 595 596 3413271 . . O O

1 597 605 3413271 Exercise NN B-NP O
2 605 606 3413271 - HYPH O O
3 606 613 3413271 induced VBN B-NP O
4 614 624 3413271 myocardial JJ I-NP D017202
5 625 633 3413271 ischemia NN I-NP D017202
6 634 637 3413271 was VBD B-VP O
7 638 644 3413271 marked VBN I-VP O
8 645 658 3413271 predominantly RB B-ADVP O
9 659 661 3413271 by IN B-PP O
10 662 671 3413271 increased VBN B-NP O
11 672 677 3413271 heart NN I-NP O
12 678 682 3413271 rate NN I-NP O
13 683 686 3413271 and CC I-NP O
14 687 691 3413271 rate NN I-NP O
15 691 692 3413271 - HYPH B-NP O
16 692 700 3413271 pressure NN I-NP O
17 701 708 3413271 product NN I-NP O
18 709 713 3413271 with IN B-PP O
19 714 715 3413271 a DT B-NP O
20 716 721 3413271 minor JJ I-NP O
21 722 734 3413271 contribution NN I-NP O
22 735 737 3413271 of IN B-PP O
23 738 741 3413271 end NN B-NP O
24 741 742 3413271 - HYPH I-NP O
25 742 751 3413271 diastolic JJ I-NP O
26 752 758 3413271 volume NN I-NP O
27 758 759 3413271 , , O O
28 760 765 3413271 while IN B-SBAR O
29 766 777 3413271 epinephrine NN B-NP D004837
30 777 778 3413271 - HYPH B-NP O
31 778 785 3413271 induced VBN I-NP O
32 786 794 3413271 ischemia NN I-NP D007511
33 795 798 3413271 was VBD B-VP O
34 799 812 3413271 characterized VBN I-VP O
35 813 815 3413271 by IN B-PP O
36 816 817 3413271 a DT B-NP O
37 818 824 3413271 marked JJ I-NP O
38 825 833 3413271 increase NN I-NP O
39 834 836 3413271 in IN B-PP O
40 837 850 3413271 contractility NN B-NP O
41 851 854 3413271 and CC O O
42 855 856 3413271 a DT B-NP O
43 857 861 3413271 less RBR I-NP O
44 862 872 3413271 pronounced JJ I-NP O
45 873 881 3413271 increase NN I-NP O
46 882 884 3413271 in IN B-PP O
47 885 890 3413271 heart NN B-NP O
48 891 895 3413271 rate NN I-NP O
49 896 899 3413271 and CC I-NP O
50 900 904 3413271 rate NN I-NP O
51 904 905 3413271 - HYPH B-NP O
52 905 913 3413271 pressure NN I-NP O
53 914 921 3413271 product NN I-NP O
54 921 922 3413271 . . O O

1 923 928 3413271 These DT B-NP O
2 929 937 3413271 findings NNS I-NP O
3 938 946 3413271 indicate VBP B-VP O
4 947 951 3413271 that IN B-SBAR O
5 952 960 3413271 ischemia NN B-NP D007511
6 961 969 3413271 produced VBN B-VP O
7 970 972 3413271 by IN B-PP O
8 973 984 3413271 epinephrine NN B-NP D004837
9 984 985 3413271 , , O O
10 986 988 3413271 as IN B-SBAR O
11 989 992 3413271 may MD B-VP O
12 993 998 3413271 occur VB I-VP O
13 999 1005 3413271 during IN B-PP O
14 1006 1012 3413271 states NNS B-NP O
15 1013 1015 3413271 of IN B-PP O
16 1016 1025 3413271 emotional JJ B-NP O
17 1026 1034 3413271 distress NN I-NP O
18 1034 1035 3413271 , , O O
19 1036 1039 3413271 has VBZ B-VP O
20 1040 1041 3413271 a DT B-NP O
21 1042 1051 3413271 mechanism NN I-NP O
22 1052 1060 3413271 distinct JJ B-ADJP O
23 1061 1065 3413271 from IN B-PP O
24 1066 1070 3413271 that DT B-NP O
25 1071 1074 3413271 due JJ B-PP O
26 1075 1077 3413271 to TO B-PP O
27 1078 1086 3413271 physical JJ B-NP O
28 1087 1095 3413271 exertion NN I-NP O
29 1095 1096 3413271 . . O O

1 0 0 6695415 -DOCSTART- -X- -X- O

1 0 8 6695415 Cerebral JJ B-NP D002543
2 9 19 6695415 hemorrhage NN I-NP D002543
3 20 30 6695415 associated VBN B-VP O
4 31 35 6695415 with IN B-PP O
5 36 55 6695415 phenylpropanolamine NN B-NP D010665
6 56 58 6695415 in IN B-PP O
7 59 70 6695415 combination NN B-NP O
8 71 75 6695415 with IN B-PP O
9 76 84 6695415 caffeine NN B-NP D002110
10 84 85 6695415 . . O O
11 86 105 6695415 Phenylpropanolamine NN B-NP D010665
12 106 107 6695415 ( ( O O
13 107 110 6695415 PPA NN B-NP D010665
14 110 111 6695415 ) ) O O
15 112 114 6695415 is VBZ B-VP O
16 115 116 6695415 a DT B-NP O
17 117 121 6695415 drug NN I-NP O
18 122 126 6695415 that WDT B-NP O
19 127 130 6695415 has VBZ B-VP O
20 131 135 6695415 been VBN I-VP O
21 136 146 6695415 associated VBN I-VP O
22 147 151 6695415 with IN B-PP O
23 152 159 6695415 serious JJ B-NP O
24 160 164 6695415 side NN I-NP O
25 165 172 6695415 effects NNS I-NP O
26 173 182 6695415 including VBG B-PP O
27 183 189 6695415 stroke NN B-NP D020521
28 189 190 6695415 . . O O

1 191 193 6695415 It PRP B-NP O
2 194 196 6695415 is VBZ B-VP O
3 197 202 6695415 often RB I-VP O
4 203 211 6695415 combined VBN I-VP O
5 212 216 6695415 with IN B-PP O
6 217 225 6695415 caffeine NN B-NP D002110
7 226 228 6695415 in IN B-PP O
8 229 233 6695415 diet NN B-NP O
9 234 246 6695415 preparations NNS I-NP O
10 247 250 6695415 and CC O O
11 251 252 6695415 " `` O O
12 252 256 6695415 look NN B-NP O
13 256 257 6695415 - HYPH I-NP O
14 257 262 6695415 alike JJ I-NP O
15 262 263 6695415 " '' I-NP O
16 264 269 6695415 pills NNS I-NP O
17 269 270 6695415 . . O O

1 271 273 6695415 In IN B-SBAR O
2 274 279 6695415 order NN O O
3 280 282 6695415 to TO B-VP O
4 283 292 6695415 determine VB I-VP O
5 293 295 6695415 if IN B-SBAR O
6 296 299 6695415 PPA NN B-NP D010665
7 299 300 6695415 / SYM B-NP O
8 300 308 6695415 caffeine NN I-NP D002110
9 309 312 6695415 can MD B-VP O
10 313 317 6695415 lead VB I-VP O
11 318 320 6695415 to TO I-VP O
12 321 327 6695415 stroke VB I-VP D020521
13 328 330 6695415 in IN B-PP O
14 331 343 6695415 normotensive JJ B-ADJP O
15 344 347 6695415 and CC O O
16 347 348 6695415 / SYM B-NP O
17 348 350 6695415 or CC O O
18 351 363 6695415 hypertensive JJ B-NP D006973
19 364 368 6695415 rats NNS I-NP O
20 368 369 6695415 , , O O
21 370 372 6695415 we PRP B-NP O
22 373 385 6695415 administered VBD B-VP O
23 386 389 6695415 the DT B-NP O
24 390 401 6695415 combination NN I-NP O
25 402 404 6695415 in IN B-PP O
26 405 408 6695415 six CD B-NP O
27 409 414 6695415 times NNS I-NP O
28 415 418 6695415 the DT I-NP O
29 419 426 6695415 allowed VBN I-NP O
30 427 432 6695415 human JJ I-NP O
31 433 437 6695415 dose NN I-NP O
32 438 448 6695415 calculated VBN B-VP O
33 449 451 6695415 on IN B-PP O
34 452 453 6695415 a DT B-NP O
35 454 457 6695415 per IN B-PP O
36 458 464 6695415 weight NN B-NP O
37 465 470 6695415 basis NN I-NP O
38 471 474 6695415 for IN B-PP O
39 475 478 6695415 the DT B-NP O
40 479 483 6695415 rats NNS I-NP O
41 484 487 6695415 two CD B-NP O
42 488 493 6695415 times NNS I-NP O
43 494 497 6695415 per IN B-PP O
44 498 501 6695415 day NN B-NP O
45 502 505 6695415 for IN B-PP O
46 506 510 6695415 five CD B-NP O
47 511 515 6695415 days NNS I-NP O
48 515 516 6695415 . . O O

1 517 529 6695415 Subarachnoid JJ B-NP D013345
2 530 533 6695415 and CC I-NP D013345
3 534 542 6695415 cerebral JJ I-NP D013345
4 543 553 6695415 hemorrhage NN I-NP D013345
5 554 557 6695415 was VBD B-VP O
6 558 563 6695415 noted VBN I-VP O
7 564 566 6695415 in IN B-PP O
8 567 570 6695415 18% NN B-NP O
9 571 573 6695415 of IN B-PP O
10 574 577 6695415 the DT B-NP O
11 578 590 6695415 hypertensive JJ I-NP D006973
12 591 595 6695415 rats NNS I-NP O
13 595 596 6695415 . . O O

1 597 598 6695415 A DT B-NP O
2 599 605 6695415 single JJ I-NP O
3 606 609 6695415 PPA NN I-NP D010665
4 609 610 6695415 / SYM B-VP O
5 610 618 6695415 caffeine NN B-NP D002110
6 619 633 6695415 administration NN I-NP O
7 634 635 6695415 ( ( O O
8 635 639 6695415 same JJ B-NP O
9 640 644 6695415 dose NN I-NP O
10 644 645 6695415 ) ) O O
11 646 650 6695415 lead VBP B-VP O
12 651 653 6695415 to TO B-PP O
13 654 659 6695415 acute JJ B-NP O
14 660 672 6695415 hypertension NN I-NP D006973
15 673 675 6695415 in IN B-PP O
16 676 680 6695415 both CC B-NP O
17 681 684 6695415 the DT I-NP O
18 685 697 6695415 normotensive JJ I-NP O
19 698 701 6695415 and CC I-NP O
20 702 714 6695415 hypertensive JJ I-NP D006973
21 715 722 6695415 animals NNS I-NP O
22 722 723 6695415 . . O O

1 724 729 6695415 These DT B-NP O
2 730 737 6695415 results NNS I-NP O
3 738 745 6695415 suggest VBP B-VP O
4 746 750 6695415 that IN B-SBAR O
5 751 754 6695415 PPA NN B-NP D010665
6 754 755 6695415 / SYM B-NP O
7 755 763 6695415 caffeine NN I-NP D002110
8 764 767 6695415 can MD B-VP O
9 768 772 6695415 lead VB I-VP O
10 773 775 6695415 to TO B-PP O
11 776 784 6695415 cerebral JJ B-NP D002543
12 785 795 6695415 hemorrhage NN I-NP D002543
13 796 798 6695415 in IN B-PP O
14 799 809 6695415 previously RB B-NP O
15 810 822 6695415 hypertensive JJ I-NP D006973
16 823 830 6695415 animals NNS I-NP O
17 831 835 6695415 when WRB B-ADVP O
18 836 848 6695415 administered VBN B-VP O
19 849 851 6695415 in IN B-PP O
20 852 859 6695415 greater JJR B-ADJP O
21 860 864 6695415 than IN B-PP O
22 865 868 6695415 the DT B-NP O
23 869 876 6695415 allowed VBN I-NP O
24 877 883 6695415 dosage NN I-NP O
25 883 884 6695415 . . O O

1 885 887 6695415 An DT B-NP O
2 888 893 6695415 acute JJ I-NP O
3 894 903 6695415 elevation NN I-NP O
4 904 906 6695415 in IN B-PP O
5 907 912 6695415 blood NN B-NP O
6 913 921 6695415 pressure NN I-NP O
7 922 925 6695415 may MD B-VP O
8 926 928 6695415 be VB I-VP O
9 929 930 6695415 a DT B-NP O
10 931 943 6695415 contributing VBG I-NP O
11 944 950 6695415 factor NN I-NP O
12 950 951 6695415 . . O O

1 0 0 6111982 -DOCSTART- -X- -X- O

1 0 12 6111982 Pharmacology NN B-NP O
2 13 15 6111982 of IN B-PP O
3 16 20 6111982 GYKI NN B-NP C025725
4 20 21 6111982 - HYPH O C025725
5 21 23 6111982 41 CD B-NP C025725
6 24 27 6111982 099 CD I-NP C025725
7 28 29 6111982 ( ( O O
8 29 42 6111982 chlorpropanol NN B-NP C025725
9 42 43 6111982 , , O O
10 44 51 6111982 Tobanum NNP B-NP C025725
11 51 52 6111982 ) ) O O
12 53 54 6111982 a DT B-NP O
13 55 58 6111982 new JJ I-NP O
14 59 65 6111982 potent JJ I-NP O
15 66 70 6111982 beta SYM I-NP O
16 70 71 6111982 - HYPH I-NP O
17 71 81 6111982 adrenergic JJ I-NP O
18 82 92 6111982 antagonist NN I-NP O
19 92 93 6111982 . . O O
20 94 97 6111982 The DT B-NP O
21 98 106 6111982 compound NN I-NP O
22 107 111 6111982 GYKI NN I-NP C025725
23 111 112 6111982 - HYPH O C025725
24 112 114 6111982 41 CD B-NP C025725
25 115 118 6111982 099 CD I-NP C025725
26 118 119 6111982 , , O O
27 120 122 6111982 as IN B-PP O
28 123 124 6111982 a DT B-NP O
29 125 129 6111982 beta SYM I-NP O
30 129 130 6111982 - HYPH I-NP O
31 130 140 6111982 adrenergic JJ I-NP O
32 141 151 6111982 antagonist NN I-NP O
33 151 152 6111982 , , O O
34 153 155 6111982 is VBZ B-VP O
35 156 157 6111982 3 CD B-NP O
36 157 158 6111982 - HYPH I-NP O
37 158 159 6111982 8 CD I-NP O
38 160 165 6111982 times NNS I-NP O
39 166 170 6111982 more RBR B-ADJP O
40 171 177 6111982 potent JJ I-ADJP O
41 178 182 6111982 than IN B-PP O
42 183 194 6111982 propranolol NN B-NP D011433
43 195 197 6111982 in FW B-ADVP O
44 198 203 6111982 vitro FW I-ADVP O
45 204 207 6111982 and CC O O
46 208 210 6111982 in FW B-ADVP O
47 211 215 6111982 vivo FW I-ADVP O
48 215 216 6111982 . . O O

1 217 220 6111982 Its PRP$ B-NP O
2 221 235 6111982 antiarrhythmic JJ I-NP O
3 236 249 6111982 effectiveness NN I-NP O
4 250 259 6111982 surpasses VBZ B-VP O
5 260 264 6111982 that DT B-NP O
6 265 267 6111982 of IN B-PP O
7 268 279 6111982 propranolol NN B-NP D011433
8 280 283 6111982 and CC I-NP O
9 284 292 6111982 pindolol NN I-NP D010869
10 293 303 6111982 inhibiting VBG B-VP O
11 304 307 6111982 the DT B-NP O
12 308 315 6111982 ouabain NN I-NP D010042
13 316 326 6111982 arrhythmia NN I-NP D001145
14 327 329 6111982 in IN B-PP O
15 330 334 6111982 dogs NNS B-NP O
16 335 338 6111982 and CC I-NP O
17 339 343 6111982 cats NNS I-NP O
18 343 344 6111982 . . O O

1 345 349 6111982 GYKI NN B-NP -1
2 349 350 6111982 - HYPH O -1
3 350 352 6111982 41 CD B-NP -1
4 353 356 6111982 900 CD I-NP -1
5 357 360 6111982 has VBZ B-VP O
6 361 362 6111982 a DT B-NP O
7 363 373 6111982 negligible JJ I-NP O
8 374 390 6111982 cardiodepressant NN I-NP O
9 391 399 6111982 activity NN I-NP O
10 399 400 6111982 ; : O O
11 401 403 6111982 it PRP B-NP O
12 404 406 6111982 is VBZ B-VP O
13 407 410 6111982 not RB O O
14 411 426 6111982 cardioselective JJ B-ADJP O
15 426 427 6111982 . . O O

1 428 431 6111982 The DT B-NP O
2 432 440 6111982 compound NN I-NP O
3 441 446 6111982 shows VBZ B-VP O
4 447 448 6111982 a DT B-NP O
5 449 454 6111982 rapid JJ I-NP O
6 455 458 6111982 and CC I-NP O
7 459 463 6111982 long JJ I-NP O
8 464 471 6111982 lasting JJ I-NP O
9 472 478 6111982 effect NN I-NP O
10 478 479 6111982 . . O O

1 480 485 6111982 There EX B-NP O
2 486 489 6111982 was VBD B-VP O
3 490 491 6111982 a DT B-NP O
4 492 501 6111982 prolonged VBN I-NP O
5 502 513 6111982 elimination NN I-NP O
6 514 516 6111982 of IN B-PP O
7 517 520 6111982 the DT B-NP O
8 521 534 6111982 radioactivity NN I-NP O
9 535 540 6111982 after IN B-PP O
10 541 544 6111982 the DT B-NP O
11 545 554 6111982 injection NN I-NP O
12 555 557 6111982 of IN B-PP O
13 558 561 6111982 14C NN B-NP -1
14 561 562 6111982 - HYPH O -1
15 562 564 6111982 41 CD B-NP -1
16 565 568 6111982 099 CD I-NP -1
17 569 571 6111982 to TO B-PP O
18 572 576 6111982 rats NNS B-NP O
19 577 580 6111982 and CC I-NP O
20 581 585 6111982 dogs NNS I-NP O
21 585 586 6111982 . . O O

1 587 590 6111982 The DT B-NP O
2 591 595 6111982 half JJ I-NP O
3 596 600 6111982 life NN I-NP O
4 601 603 6111982 of IN B-PP O
5 604 607 6111982 the DT B-NP O
6 608 617 6111982 unlabeled JJ I-NP O
7 618 627 6111982 substance NN I-NP O
8 628 630 6111982 in IN B-PP O
9 631 637 6111982 humans NNS B-NP O
10 638 641 6111982 was VBD B-VP O
11 642 646 6111982 more JJR B-NP O
12 647 651 6111982 than IN I-NP O
13 652 654 6111982 10 CD I-NP O
14 655 660 6111982 hours NNS I-NP O
15 660 661 6111982 . . O O

1 0 0 19707748 -DOCSTART- -X- -X- O

1 0 8 19707748 Seizures NNS B-NP D012640
2 9 19 19707748 associated VBN B-VP O
3 20 24 19707748 with IN B-PP O
4 25 37 19707748 levofloxacin NN B-NP D064704
5 37 38 19707748 : : O O
6 39 43 19707748 case NN B-NP O
7 44 56 19707748 presentation NN I-NP O
8 57 60 19707748 and CC I-NP O
9 61 71 19707748 literature NN I-NP O
10 72 78 19707748 review NN I-NP O
11 78 79 19707748 . . I-NP O
12 80 87 19707748 PURPOSE NN I-NP O
13 87 88 19707748 : : O O
14 89 91 19707748 We PRP B-NP O
15 92 99 19707748 present VBP B-VP O
16 100 101 19707748 a DT B-NP O
17 102 106 19707748 case NN I-NP O
18 107 109 19707748 of IN B-PP O
19 110 111 19707748 a DT B-NP O
20 112 119 19707748 patient NN I-NP O
21 120 123 19707748 who WP B-NP O
22 124 133 19707748 developed VBD B-VP O
23 134 142 19707748 seizures NNS B-NP D012640
24 143 150 19707748 shortly RB B-ADVP O
25 151 156 19707748 after IN B-PP O
26 157 167 19707748 initiating VBG B-VP O
27 168 177 19707748 treatment NN B-NP O
28 178 182 19707748 with IN B-PP O
29 183 195 19707748 levofloxacin NN B-NP D064704
30 196 199 19707748 and CC O O
31 200 202 19707748 to TO B-VP O
32 203 210 19707748 discuss VB I-VP O
33 211 214 19707748 the DT B-NP O
34 215 224 19707748 potential JJ I-NP O
35 225 229 19707748 drug NN I-NP O
36 229 230 19707748 - HYPH B-NP O
37 230 234 19707748 drug NN I-NP O
38 235 247 19707748 interactions NNS I-NP O
39 248 255 19707748 related VBN B-VP O
40 256 258 19707748 to TO B-PP O
41 259 262 19707748 the DT B-NP O
42 263 273 19707748 inhibition NN I-NP O
43 274 276 19707748 of IN B-PP O
44 277 287 19707748 cytochrome NN B-NP O
45 288 292 19707748 P450 NN I-NP O
46 293 294 19707748 ( ( O O
47 294 297 19707748 CYP NN B-NP O
48 297 298 19707748 ) ) O O
49 299 302 19707748 1A2 NN B-NP O
50 303 305 19707748 in IN B-PP O
51 306 310 19707748 this DT B-NP O
52 311 315 19707748 case NN I-NP O
53 315 316 19707748 , , O O
54 317 319 19707748 as RB B-CONJP O
55 320 324 19707748 well RB I-CONJP O
56 325 327 19707748 as IN I-CONJP O
57 328 330 19707748 in IN B-PP O
58 331 336 19707748 other JJ B-NP O
59 337 342 19707748 cases NNS I-NP O
60 342 343 19707748 , , O O
61 344 346 19707748 of IN B-PP O
62 347 359 19707748 levofloxacin NN B-NP D064704
63 359 360 19707748 - HYPH B-NP O
64 360 367 19707748 induced VBN I-NP O
65 368 376 19707748 seizures NNS I-NP D012640
66 376 377 19707748 . . O O

1 378 385 19707748 METHODS NNS B-NP O
2 385 386 19707748 : : O O
3 387 394 19707748 Several JJ B-NP O
4 395 405 19707748 biomedical JJ I-NP O
5 406 415 19707748 databases NNS I-NP O
6 416 420 19707748 were VBD B-VP O
7 421 429 19707748 searched VBN I-VP O
8 430 439 19707748 including VBG B-PP O
9 440 447 19707748 MEDLINE NNP B-NP O
10 447 448 19707748 , , I-NP O
11 449 457 19707748 Cochrane NNP I-NP O
12 458 461 19707748 and CC I-NP O
13 462 466 19707748 Ovid NNP I-NP O
14 466 467 19707748 . . O O

1 468 471 19707748 The DT B-NP O
2 472 476 19707748 main JJ I-NP O
3 477 483 19707748 search NN I-NP O
4 484 489 19707748 terms NNS I-NP O
5 490 498 19707748 utilized VBN B-VP O
6 499 503 19707748 were VBD B-VP O
7 504 508 19707748 case NN B-NP O
8 509 515 19707748 report NN I-NP O
9 516 519 19707748 and CC I-NP O
10 520 532 19707748 levofloxacin NN I-NP D064704
11 532 533 19707748 . . O O

1 534 537 19707748 The DT B-NP O
2 538 544 19707748 search NN I-NP O
3 545 548 19707748 was VBD B-VP O
4 549 556 19707748 limited VBN I-VP O
5 557 559 19707748 to TO B-PP O
6 560 567 19707748 studies NNS B-NP O
7 568 577 19707748 published VBN B-VP O
8 578 580 19707748 in IN B-PP O
9 581 588 19707748 English NNP B-NP O
10 588 589 19707748 . . O O

1 590 597 19707748 RESULTS NNS B-NP O
2 597 598 19707748 : : O O
3 599 602 19707748 Six CD B-NP O
4 603 608 19707748 cases NNS I-NP O
5 609 611 19707748 of IN B-PP O
6 612 624 19707748 levofloxacin NN B-NP D064704
7 624 625 19707748 - HYPH B-NP O
8 625 632 19707748 induced VBN I-NP O
9 633 641 19707748 seizures NNS I-NP D012640
10 642 646 19707748 have VBP B-VP O
11 647 651 19707748 been VBN I-VP O
12 652 660 19707748 reported VBN I-VP O
13 661 663 19707748 in IN B-PP O
14 664 667 19707748 the DT B-NP O
15 668 678 19707748 literature NN I-NP O
16 678 679 19707748 . . O O

1 680 684 19707748 Drug NN B-NP O
2 684 685 19707748 - HYPH I-NP O
3 685 689 19707748 drug NN I-NP O
4 690 702 19707748 interactions NNS I-NP O
5 703 710 19707748 related VBN B-VP O
6 711 713 19707748 to TO B-PP O
7 714 717 19707748 the DT B-NP O
8 718 728 19707748 inhibition NN I-NP O
9 729 731 19707748 of IN B-PP O
10 732 738 19707748 CYP1A2 NN B-NP O
11 739 741 19707748 by IN B-PP O
12 742 754 19707748 levofloxacin NN B-NP D064704
13 755 758 19707748 are VBP B-VP O
14 759 765 19707748 likely RB I-VP O
15 766 774 19707748 involved VBN I-VP O
16 775 777 19707748 in IN B-PP O
17 778 781 19707748 the DT B-NP O
18 782 790 19707748 clinical JJ I-NP O
19 791 798 19707748 outcome NN I-NP O
20 799 801 19707748 of IN B-PP O
21 802 807 19707748 these DT B-NP O
22 808 813 19707748 cases NNS I-NP O
23 813 814 19707748 . . O O

1 815 826 19707748 CONCLUSIONS NNS B-NP O
2 826 827 19707748 : : O O
3 828 838 19707748 Clinicians NNS B-NP O
4 839 842 19707748 are VBP B-VP O
5 843 851 19707748 exhorted VBN I-VP O
6 852 854 19707748 to TO I-VP O
7 855 858 19707748 pay VB I-VP O
8 859 864 19707748 close JJ B-NP O
9 865 874 19707748 attention NN I-NP O
10 875 879 19707748 when WRB B-ADVP O
11 880 890 19707748 initiating VBG B-VP O
12 891 903 19707748 levofloxacin NN B-NP D064704
13 904 911 19707748 therapy NN I-NP O
14 912 914 19707748 in IN B-PP O
15 915 923 19707748 patients NNS B-NP O
16 924 930 19707748 taking VBG B-VP O
17 931 942 19707748 medications NNS B-NP O
18 943 947 19707748 with IN B-PP O
19 948 961 19707748 epileptogenic JJ B-NP O
20 962 972 19707748 properties NNS I-NP O
21 973 977 19707748 that WDT B-NP O
22 978 981 19707748 are VBP B-VP O
23 982 988 19707748 CYP1A2 NN B-NP O
24 989 999 19707748 substrates NNS I-NP O
25 999 1000 19707748 . . O O

1 0 0 2528969 -DOCSTART- -X- -X- O

1 0 6 2528969 Nature NN B-NP O
2 6 7 2528969 , , O O
3 8 12 2528969 time NN B-NP O
4 13 19 2528969 course NN I-NP O
5 20 23 2528969 and CC O O
6 24 28 2528969 dose NN B-NP O
7 29 39 2528969 dependence NN I-NP O
8 40 42 2528969 of IN B-PP O
9 43 53 2528969 zidovudine NN B-NP D015215
10 53 54 2528969 - HYPH B-NP O
11 54 61 2528969 related VBN I-NP O
12 62 66 2528969 side NN I-NP O
13 67 74 2528969 effects NNS I-NP O
14 74 75 2528969 : : O O
15 76 83 2528969 results NNS B-NP O
16 84 88 2528969 from IN B-PP O
17 89 92 2528969 the DT B-NP O
18 93 104 2528969 Multicenter NNP I-NP O
19 105 113 2528969 Canadian NNP I-NP O
20 114 128 2528969 Azidothymidine NNP I-NP D015215
21 129 134 2528969 Trial NNP I-NP O
22 134 135 2528969 . . O O
23 136 138 2528969 To TO B-VP O
24 139 151 2528969 characterize VB I-VP O
25 152 155 2528969 the DT B-NP O
26 156 162 2528969 nature NN I-NP O
27 162 163 2528969 , , O O
28 164 168 2528969 time NN B-NP O
29 169 175 2528969 course NN I-NP O
30 176 179 2528969 and CC O O
31 180 184 2528969 dose NN B-NP O
32 185 195 2528969 dependency NN I-NP O
33 196 198 2528969 of IN B-PP O
34 199 209 2528969 zidovudine NN B-NP D015215
35 209 210 2528969 - HYPH B-NP O
36 210 217 2528969 related VBN I-NP O
37 218 222 2528969 side NN I-NP O
38 223 230 2528969 effects NNS I-NP O
39 230 231 2528969 , , O O
40 232 234 2528969 we PRP B-NP O
41 235 244 2528969 undertook VBD B-VP O
42 245 246 2528969 a DT B-NP O
43 247 258 2528969 multicenter JJ I-NP O
44 258 259 2528969 , , I-NP O
45 260 271 2528969 prospective JJ I-NP O
46 271 272 2528969 , , I-NP O
47 273 277 2528969 dose NN I-NP O
48 277 278 2528969 - HYPH I-NP O
49 278 283 2528969 range NN I-NP O
50 284 291 2528969 finding NN I-NP O
51 292 297 2528969 study NN I-NP O
52 297 298 2528969 . . O O

1 299 302 2528969 Our PRP$ B-NP O
2 303 308 2528969 study NN I-NP O
3 309 314 2528969 group NN I-NP O
4 315 324 2528969 consisted VBD B-VP O
5 325 327 2528969 of IN B-PP O
6 328 330 2528969 74 CD B-NP O
7 331 334 2528969 HIV NN I-NP O
8 334 335 2528969 - HYPH B-NP O
9 335 343 2528969 positive JJ I-NP O
10 344 354 2528969 homosexual JJ I-NP O
11 355 358 2528969 men NNS I-NP O
12 359 368 2528969 belonging VBG B-VP O
13 369 371 2528969 to TO B-PP O
14 372 378 2528969 groups NNS B-NP O
15 379 381 2528969 II CD B-NP O
16 382 383 2528969 B NN I-NP O
17 383 384 2528969 , , O O
18 385 388 2528969 III CD B-NP O
19 389 392 2528969 and CC I-NP O
20 393 395 2528969 IV CD I-NP O
21 396 398 2528969 C2 NN I-NP O
22 399 403 2528969 from IN B-PP O
23 404 407 2528969 the DT B-NP O
24 408 415 2528969 Centers NNPS I-NP O
25 416 419 2528969 for IN B-PP O
26 420 427 2528969 Disease NN B-NP O
27 428 435 2528969 Control NN I-NP O
28 436 437 2528969 ( ( O O
29 437 440 2528969 CDC NN B-NP O
30 440 441 2528969 ) ) O O
31 442 456 2528969 classification NN B-NP O
32 457 459 2528969 of IN B-PP O
33 460 463 2528969 HIV NN B-NP D015658
34 464 471 2528969 disease NN I-NP D015658
35 471 472 2528969 . . O O

1 473 482 2528969 Following VBG B-PP O
2 483 484 2528969 a DT B-NP O
3 485 486 2528969 3 CD I-NP O
4 486 487 2528969 - HYPH I-NP O
5 487 491 2528969 week NN I-NP O
6 492 503 2528969 observation NN I-NP O
7 504 510 2528969 period NN I-NP O
8 510 511 2528969 , , O O
9 512 522 2528969 volunteers NNS B-NP O
10 523 527 2528969 were VBD B-VP O
11 528 535 2528969 treated VBN I-VP O
12 536 540 2528969 with IN B-PP O
13 541 551 2528969 zidovudine NN B-NP D015215
14 552 555 2528969 600 CD I-NP O
15 556 558 2528969 mg NN I-NP O
16 558 559 2528969 / SYM B-NP O
17 559 562 2528969 day NN I-NP O
18 563 566 2528969 for IN B-PP O
19 567 569 2528969 18 CD B-NP O
20 570 575 2528969 weeks NNS I-NP O
21 575 576 2528969 , , O O
22 577 580 2528969 900 CD B-NP O
23 581 583 2528969 mg NN I-NP O
24 583 584 2528969 / SYM B-NP O
25 584 587 2528969 day NN I-NP O
26 588 591 2528969 for IN B-PP O
27 592 593 2528969 9 CD B-NP O
28 594 599 2528969 weeks NNS I-NP O
29 600 603 2528969 and CC O O
30 604 608 2528969 1200 CD B-NP O
31 609 611 2528969 mg NN I-NP O
32 611 612 2528969 / SYM B-NP O
33 612 615 2528969 day NN I-NP O
34 616 619 2528969 for IN B-PP O
35 620 621 2528969 9 CD B-NP O
36 622 627 2528969 weeks NNS I-NP O
37 627 628 2528969 , , O O
38 629 637 2528969 followed VBN B-VP O
39 638 640 2528969 by IN B-PP O
40 641 642 2528969 a DT B-NP O
41 643 650 2528969 washout NN I-NP O
42 651 657 2528969 period NN I-NP O
43 658 660 2528969 of IN B-PP O
44 661 662 2528969 6 CD B-NP O
45 663 668 2528969 weeks NNS I-NP O
46 669 674 2528969 after IN B-PP O
47 675 680 2528969 which WDT B-NP O
48 681 685 2528969 they PRP B-NP O
49 686 690 2528969 were VBD B-VP O
50 691 693 2528969 re AFX B-ADJP O
51 693 694 2528969 - HYPH I-ADJP O
52 694 701 2528969 started VBN B-VP O
53 702 704 2528969 on IN B-PP O
54 705 709 2528969 1200 CD B-NP O
55 710 712 2528969 mg NN I-NP O
56 712 713 2528969 / SYM B-NP O
57 713 716 2528969 day NN I-NP O
58 717 719 2528969 or CC O O
59 720 723 2528969 the DT B-NP O
60 724 731 2528969 highest JJS I-NP O
61 732 741 2528969 tolerated VBN I-NP O
62 742 746 2528969 dose NN I-NP O
63 747 749 2528969 at IN B-PP O
64 750 751 2528969 8 CD B-NP O
65 751 752 2528969 - HYPH I-NP O
66 752 758 2528969 hourly JJ I-NP O
67 759 768 2528969 intervals NNS I-NP O
68 768 769 2528969 . . O O

1 770 778 2528969 Subjects NNS B-NP O
2 779 783 2528969 were VBD B-VP O
3 784 792 2528969 randomly RB I-VP O
4 793 801 2528969 assigned VBN I-VP O
5 802 804 2528969 to TO B-PP O
6 805 806 2528969 4 CD B-NP O
7 806 807 2528969 - HYPH O O
8 807 813 2528969 hourly RB B-ADVP O
9 814 816 2528969 or CC O O
10 817 818 2528969 8 CD B-NP O
11 818 819 2528969 - HYPH I-NP O
12 819 825 2528969 hourly JJ I-NP O
13 826 834 2528969 regimens NNS I-NP O
14 835 841 2528969 within IN B-PP O
15 842 845 2528969 CDC NN B-NP O
16 846 852 2528969 groups NNS I-NP O
17 853 858 2528969 while IN B-SBAR O
18 859 865 2528969 taking VBG B-VP O
19 866 869 2528969 600 CD B-NP O
20 870 873 2528969 and CC I-NP O
21 874 878 2528969 1200 CD I-NP O
22 879 881 2528969 mg NN I-NP O
23 881 882 2528969 / SYM B-NP O
24 882 885 2528969 day NN I-NP O
25 885 886 2528969 . . O O

1 887 895 2528969 Clinical JJ B-NP O
2 896 899 2528969 and CC I-NP O
3 900 910 2528969 laboratory NN I-NP O
4 911 922 2528969 evaluations NNS I-NP O
5 923 927 2528969 were VBD B-VP O
6 928 937 2528969 performed VBN I-VP O
7 938 940 2528969 at IN B-PP O
8 941 942 2528969 3 CD B-NP O
9 942 943 2528969 - HYPH I-NP O
10 943 947 2528969 week NN I-NP O
11 948 957 2528969 intervals NNS I-NP O
12 957 958 2528969 . . O O

1 959 970 2528969 Symptomatic JJ B-NP O
2 971 978 2528969 adverse JJ I-NP O
3 979 986 2528969 effects NNS I-NP O
4 987 991 2528969 were VBD B-VP O
5 992 999 2528969 present JJ B-ADJP O
6 1000 1002 2528969 in IN B-PP O
7 1003 1006 2528969 96% CD B-NP O
8 1007 1009 2528969 of IN B-PP O
9 1010 1018 2528969 subjects NNS B-NP O
10 1018 1019 2528969 , , O O
11 1020 1024 2528969 most JJS B-NP O
12 1025 1033 2528969 commonly RB I-NP O
13 1034 1040 2528969 nausea NN I-NP D009325
14 1041 1042 2528969 ( ( O O
15 1042 1045 2528969 64% CD B-NP O
16 1045 1046 2528969 ) ) O O
17 1046 1047 2528969 , , O O
18 1048 1055 2528969 fatigue NN B-NP D005221
19 1056 1057 2528969 ( ( O O
20 1057 1060 2528969 55% NN B-NP O
21 1060 1061 2528969 ) ) O O
22 1062 1065 2528969 and CC O O
23 1066 1074 2528969 headache NN B-NP D006261
24 1075 1076 2528969 ( ( O O
25 1076 1079 2528969 49% CD B-NP O
26 1079 1080 2528969 ) ) O O
27 1080 1081 2528969 . . O O

1 1082 1087 2528969 These DT B-NP O
2 1088 1092 2528969 were VBD B-VP O
3 1093 1102 2528969 generally RB B-ADVP O
4 1103 1107 2528969 self AFX O O
5 1107 1108 2528969 - HYPH O O
6 1108 1115 2528969 limited VBN B-VP O
7 1115 1116 2528969 , , O O
8 1117 1128 2528969 reappearing VBG B-VP O
9 1129 1136 2528969 briefly RB B-ADVP O
10 1137 1139 2528969 at IN B-PP O
11 1140 1144 2528969 each DT B-NP O
12 1145 1149 2528969 dose NN I-NP O
13 1150 1159 2528969 increment NN I-NP O
14 1159 1160 2528969 . . O O

1 1161 1162 2528969 A DT B-NP O
2 1163 1171 2528969 decrease NN I-NP O
3 1172 1174 2528969 in IN B-PP O
4 1175 1185 2528969 hemoglobin NN B-NP O
5 1186 1194 2528969 occurred VBD B-VP O
6 1195 1202 2528969 shortly RB B-ADVP O
7 1203 1208 2528969 after IN B-PP O
8 1209 1219 2528969 initiation NN B-NP O
9 1220 1222 2528969 of IN B-PP O
10 1223 1230 2528969 therapy NN B-NP O
11 1230 1231 2528969 . . O O

1 1232 1236 2528969 This DT B-NP O
2 1237 1240 2528969 was VBD B-VP O
3 1241 1244 2528969 not RB O O
4 1245 1249 2528969 dose NN B-ADJP O
5 1250 1259 2528969 dependent JJ I-ADJP O
6 1260 1263 2528969 and CC O O
7 1264 1272 2528969 reversed VBN B-VP O
8 1273 1280 2528969 rapidly RB B-ADVP O
9 1281 1285 2528969 upon IN B-PP O
10 1286 1301 2528969 discontinuation NN B-NP O
11 1302 1304 2528969 of IN B-PP O
12 1305 1314 2528969 treatment NN B-NP O
13 1314 1315 2528969 . . O O

1 1316 1317 2528969 A DT B-NP O
2 1318 1321 2528969 red JJ I-NP O
3 1322 1327 2528969 blood NN I-NP O
4 1328 1332 2528969 cell NN I-NP O
5 1333 1338 2528969 count NN I-NP O
6 1339 1347 2528969 decrease NN I-NP O
7 1347 1348 2528969 , , O O
8 1349 1350 2528969 a DT B-NP O
9 1351 1355 2528969 mean JJ I-NP O
10 1356 1360 2528969 cell NN I-NP O
11 1361 1367 2528969 volume NN I-NP O
12 1368 1376 2528969 increase NN I-NP O
13 1377 1380 2528969 and CC O O
14 1381 1382 2528969 a DT B-NP O
15 1383 1394 2528969 granulocyte NN I-NP O
16 1395 1400 2528969 count NN I-NP O
17 1401 1409 2528969 decrease NN I-NP O
18 1410 1419 2528969 developed VBD B-VP O
19 1420 1425 2528969 early RB B-ADVP O
20 1426 1428 2528969 in IN B-PP O
21 1429 1430 2528969 a DT B-NP O
22 1431 1435 2528969 dose NN I-NP O
23 1435 1436 2528969 - HYPH B-NP O
24 1436 1447 2528969 independent JJ I-NP O
25 1448 1455 2528969 fashion NN I-NP O
26 1455 1456 2528969 , , O O
27 1457 1466 2528969 reverting VBG B-VP O
28 1467 1469 2528969 at IN B-ADVP O
29 1470 1475 2528969 least JJS I-ADVP O
30 1476 1485 2528969 partially RB B-ADVP O
31 1486 1492 2528969 during IN B-PP O
32 1493 1496 2528969 the DT B-NP O
33 1497 1504 2528969 washout NN I-NP O
34 1505 1510 2528969 phase NN I-NP O
35 1510 1511 2528969 . . O O

1 1512 1515 2528969 The DT B-NP O
2 1516 1524 2528969 decrease NN I-NP O
3 1525 1527 2528969 in IN B-PP O
4 1528 1540 2528969 reticulocyte NN B-NP O
5 1541 1546 2528969 count NN I-NP O
6 1547 1550 2528969 was VBD B-VP O
7 1551 1555 2528969 dose NN B-ADJP O
8 1556 1563 2528969 related JJ I-ADJP O
9 1564 1571 2528969 between IN B-PP O
10 1572 1575 2528969 600 CD B-NP O
11 1576 1579 2528969 and CC I-NP O
12 1580 1583 2528969 900 CD I-NP O
13 1584 1586 2528969 mg NN I-NP O
14 1586 1587 2528969 / SYM B-NP O
15 1587 1590 2528969 day NN I-NP O
16 1591 1595 2528969 with IN B-PP O
17 1596 1598 2528969 no DT B-NP O
18 1599 1606 2528969 further JJ I-NP O
19 1607 1613 2528969 change NN I-NP O
20 1614 1618 2528969 when WRB B-ADVP O
21 1619 1622 2528969 the DT B-NP O
22 1623 1627 2528969 dose NN I-NP O
23 1628 1631 2528969 was VBD B-VP O
24 1632 1641 2528969 escalated VBN I-VP O
25 1642 1644 2528969 to TO B-PP O
26 1645 1649 2528969 1200 CD B-NP O
27 1650 1652 2528969 mg NN I-NP O
28 1652 1653 2528969 / SYM B-NP O
29 1653 1656 2528969 day NN I-NP O
30 1656 1657 2528969 . . O O

1 1658 1662 2528969 Bone NN B-NP O
2 1663 1669 2528969 marrow NN I-NP O
3 1670 1677 2528969 changes NNS I-NP O
4 1678 1686 2528969 occurred VBD B-VP O
5 1687 1694 2528969 rapidly RB B-VP O
6 1695 1697 2528969 as RB I-VP O
7 1698 1710 2528969 demonstrated VBN I-VP O
8 1711 1713 2528969 by IN B-PP O
9 1714 1729 2528969 megaloblastosis NN B-NP -1
10 1730 1732 2528969 in IN B-PP O
11 1733 1736 2528969 95% CD B-NP O
12 1737 1739 2528969 of IN B-PP O
13 1740 1742 2528969 65 CD B-NP O
14 1743 1752 2528969 specimens NNS I-NP O
15 1753 1755 2528969 at IN B-PP O
16 1756 1760 2528969 week NN B-NP O
17 1761 1773 2528969 18.(ABSTRACT NN I-NP O
18 1774 1783 2528969 TRUNCATED VBN B-VP O
19 1784 1786 2528969 AT IN B-PP O
20 1787 1790 2528969 250 CD B-NP O
21 1791 1796 2528969 WORDS NNS I-NP O
22 1796 1797 2528969 ) ) O O

1 0 0 873132 -DOCSTART- -X- -X- O

1 0 9 873132 Increased VBN B-NP O
2 10 19 873132 sulfation NN I-NP O
3 20 23 873132 and CC O O
4 24 33 873132 decreased VBD B-VP O
5 34 40 873132 7alpha NN B-NP O
6 40 41 873132 - HYPH B-NP O
7 41 54 873132 hydroxylation NN I-NP O
8 55 57 873132 of IN B-PP O
9 58 69 873132 deoxycholic JJ B-NP D003840
10 70 74 873132 acid NN I-NP D003840
11 75 77 873132 in IN B-PP O
12 78 85 873132 ethinyl NN B-NP D004997
13 86 95 873132 estradiol NN I-NP D004997
14 95 96 873132 - HYPH B-NP O
15 96 103 873132 induced VBN I-NP O
16 104 115 873132 cholestasis NN I-NP D002779
17 116 118 873132 in IN B-PP O
18 119 123 873132 rats NNS B-NP O
19 123 124 873132 . . O O
20 125 136 873132 Deoxycholic JJ B-NP D003840
21 137 141 873132 acid NN I-NP D003840
22 142 153 873132 conjugation NN I-NP O
23 153 154 873132 , , O O
24 155 164 873132 transport NN B-NP O
25 165 173 873132 capacity NN I-NP O
26 173 174 873132 , , O O
27 175 178 873132 and CC O O
28 179 189 873132 metabolism NN B-NP O
29 190 194 873132 were VBD B-VP O
30 195 203 873132 compared VBN I-VP O
31 204 206 873132 in IN B-PP O
32 207 214 873132 control NN B-NP O
33 215 218 873132 and CC O O
34 219 226 873132 ethinyl NN B-NP D004997
35 227 236 873132 estradiol NN I-NP D004997
36 236 237 873132 - HYPH B-NP O
37 237 244 873132 treated VBN I-NP O
38 245 249 873132 rats NNS I-NP O
39 249 250 873132 . . O O

1 251 258 873132 Control NN B-NP O
2 259 263 873132 rats NNS I-NP O
3 264 268 873132 were VBD B-VP O
4 269 274 873132 found VBN I-VP O
5 275 277 873132 to TO I-VP O
6 278 282 873132 have VB I-VP O
7 283 284 873132 a DT B-NP O
8 285 290 873132 lower JJR I-NP O
9 291 299 873132 capacity NN I-NP O
10 300 302 873132 to TO B-VP O
11 303 312 873132 transport VB I-VP O
12 313 324 873132 deoxycholic JJ B-NP D003840
13 325 329 873132 acid NN I-NP D003840
14 330 334 873132 than IN B-PP O
15 335 351 873132 taurodeoxycholic JJ B-NP D013657
16 352 356 873132 acid NN I-NP D013657
17 356 357 873132 , , O O
18 358 361 873132 and CC O O
19 362 366 873132 both DT B-NP O
20 367 371 873132 were VBD B-VP O
21 372 381 873132 decreased VBN I-VP O
22 382 384 873132 by IN B-PP O
23 385 392 873132 ethinyl NN B-NP D004997
24 393 402 873132 estradiol NN I-NP D004997
25 403 412 873132 treatment NN I-NP O
26 412 413 873132 . . O O

1 414 420 873132 During IN B-PP O
2 421 424 873132 [24 CD B-NP O
3 424 425 873132 - HYPH I-NP O
4 425 435 873132 14C]sodium NN I-NP D003840
5 436 448 873132 deoxycholate NN I-NP D003840
6 449 457 873132 infusion NN I-NP O
7 457 458 873132 , , O O
8 459 471 873132 [14C]biliary JJ B-NP O
9 472 476 873132 bile NN I-NP D001647
10 477 481 873132 acid NN I-NP D001647
11 482 491 873132 secretion NN I-NP O
12 492 501 873132 increased VBD B-VP O
13 501 502 873132 , , O O
14 503 506 873132 but CC O O
15 507 511 873132 bile NN B-NP O
16 512 516 873132 flow NN I-NP O
17 517 520 873132 did VBD B-VP O
18 521 524 873132 not RB I-VP O
19 525 531 873132 change VB I-VP O
20 532 545 873132 significantly RB B-ADVP O
21 546 548 873132 in IN B-PP O
22 549 555 873132 either CC O O
23 556 563 873132 control NN B-NP O
24 564 566 873132 or CC O O
25 567 574 873132 ethinyl NN B-NP D004997
26 575 584 873132 estradiol NN I-NP D004997
27 584 585 873132 - HYPH B-NP O
28 585 592 873132 treated VBN I-NP O
29 593 597 873132 rats NNS I-NP O
30 597 598 873132 . . O O

1 599 606 873132 Ethinyl NN B-NP D004997
2 607 616 873132 estradiol NN I-NP D004997
3 616 617 873132 - HYPH B-NP O
4 617 624 873132 treated VBN I-NP O
5 625 632 873132 animals NNS I-NP O
6 633 641 873132 excreted VBD B-VP O
7 642 655 873132 significantly RB B-NP O
8 656 660 873132 less JJR I-NP O
9 661 664 873132 14C NN I-NP O
10 665 667 873132 as IN B-PP O
11 668 679 873132 taurocholic JJ B-NP D013656
12 680 684 873132 acid NN I-NP D013656
13 685 689 873132 than IN B-SBAR O
14 690 693 873132 did VBD O O
15 694 701 873132 control NN B-NP O
16 702 709 873132 animals NNS I-NP O
17 709 710 873132 , , O O
18 711 721 873132 consistent JJ B-ADJP O
19 722 726 873132 with IN B-PP O
20 727 729 873132 an DT B-NP O
21 730 740 873132 impairment NN I-NP O
22 741 743 873132 of IN B-PP O
23 744 750 873132 7alpha NN B-NP O
24 750 751 873132 - HYPH B-NP O
25 751 764 873132 hydroxylation NN I-NP O
26 765 767 873132 of IN B-PP O
27 768 784 873132 taurodeoxycholic JJ B-NP D013657
28 785 789 873132 acid NN I-NP D013657
29 789 790 873132 . . O O

1 791 798 873132 Ethinyl NN B-NP D004997
2 799 808 873132 estradiol NN I-NP D004997
3 809 818 873132 treatment NN I-NP O
4 819 822 873132 did VBD B-VP O
5 823 826 873132 not RB I-VP O
6 827 833 873132 impair VB I-VP O
7 834 845 873132 conjugation NN B-NP O
8 846 848 873132 of IN B-PP O
9 849 860 873132 deoxycholic JJ B-NP D003840
10 861 865 873132 acid NN I-NP D003840
11 865 866 873132 , , O O
12 867 870 873132 but CC O O
13 871 874 873132 did VBD B-VP O
14 875 881 873132 result VB I-VP O
15 882 884 873132 in IN B-PP O
16 885 887 873132 an DT B-NP O
17 888 896 873132 increase NN I-NP O
18 897 899 873132 in IN B-PP O
19 900 909 873132 sulfation NN B-NP O
20 910 912 873132 of IN B-PP O
21 913 929 873132 taurodeoxycholic JJ B-NP D013657
22 930 934 873132 acid NN I-NP D013657
23 935 939 873132 from IN B-PP O
24 940 944 873132 1.5% CD B-NP O
25 945 947 873132 in IN B-PP O
26 948 956 873132 controls NNS B-NP O
27 957 959 873132 to TO B-PP O
28 960 966 873132 nearly RB B-NP O
29 967 971 873132 4.0% CD I-NP O
30 972 973 873132 ( ( O O
31 973 974 873132 P NN B-NP O
32 975 979 873132 less JJR B-ADJP O
33 980 984 873132 than IN B-PP O
34 985 989 873132 0.01 CD B-NP O
35 989 990 873132 ) ) O O
36 990 991 873132 . . O O

1 992 997 873132 These DT B-NP O
2 998 1005 873132 results NNS I-NP O
3 1006 1009 873132 are VBP B-VP O
4 1010 1020 873132 consistent JJ B-ADJP O
5 1021 1025 873132 with IN B-PP O
6 1026 1029 873132 the DT B-NP O
7 1030 1040 873132 hypothesis NN I-NP O
8 1041 1045 873132 that IN B-SBAR O
9 1046 1049 873132 the DT B-NP O
10 1050 1053 873132 rat NN I-NP O
11 1054 1057 873132 has VBZ B-VP O
12 1058 1059 873132 a DT B-NP O
13 1060 1066 873132 poorer JJR I-NP O
14 1067 1076 873132 tolerance NN I-NP O
15 1077 1080 873132 for IN B-PP O
16 1081 1092 873132 deoxycholic JJ B-NP D003840
17 1093 1097 873132 acid NN I-NP D003840
18 1098 1102 873132 than IN B-SBAR O
19 1103 1105 873132 do VBP B-VP O
20 1106 1113 873132 certain JJ B-NP O
21 1114 1119 873132 other JJ I-NP O
22 1120 1127 873132 species NNS I-NP O
23 1127 1128 873132 . . O O

1 1129 1140 873132 Furthermore RB B-ADVP O
2 1140 1141 873132 , , O O
3 1142 1145 873132 the DT B-NP O
4 1146 1149 873132 rat NN I-NP O
5 1150 1158 873132 converts VBZ B-VP O
6 1159 1170 873132 deoxycholic JJ B-NP D003840
7 1171 1175 873132 acid NN I-NP D003840
8 1175 1176 873132 , , O O
9 1177 1178 873132 a DT B-NP O
10 1179 1183 873132 poor JJ I-NP O
11 1184 1194 873132 choleretic JJ I-NP O
12 1194 1195 873132 , , O O
13 1196 1198 873132 to TO B-PP O
14 1199 1210 873132 taurocholic JJ B-NP D013656
15 1211 1215 873132 acid NN I-NP D013656
16 1215 1216 873132 , , O O
17 1217 1218 873132 a DT B-NP O
18 1219 1223 873132 good JJ I-NP O
19 1224 1234 873132 choleretic NN I-NP O
20 1234 1235 873132 . . O O

1 1236 1240 873132 When WRB B-ADVP O
2 1241 1245 873132 this DT B-NP O
3 1246 1256 873132 conversion NN I-NP O
4 1257 1259 873132 is VBZ B-VP O
5 1260 1268 873132 impaired VBN I-VP O
6 1269 1273 873132 with IN B-PP O
7 1274 1281 873132 ethinyl NN B-NP D004997
8 1282 1291 873132 estradiol NN I-NP D004997
9 1292 1301 873132 treatment NN I-NP O
10 1301 1302 873132 , , O O
11 1303 1312 873132 sulfation NN B-NP O
12 1313 1316 873132 may MD B-VP O
13 1317 1319 873132 be VB I-VP O
14 1320 1322 873132 an DT B-NP O
15 1323 1332 873132 important JJ I-NP O
16 1333 1342 873132 alternate JJ I-NP O
17 1343 1350 873132 pathway NN I-NP O
18 1351 1354 873132 for IN B-PP O
19 1355 1364 873132 excretion NN B-NP O
20 1365 1367 873132 of IN B-PP O
21 1368 1372 873132 this DT B-NP O
22 1373 1384 873132 potentially RB I-NP O
23 1385 1392 873132 harmful JJ I-NP O
24 1393 1397 873132 bile NN I-NP D001647
25 1398 1402 873132 acid NN I-NP D001647
26 1402 1403 873132 . . O O

1 0 0 3732088 -DOCSTART- -X- -X- O

1 0 9 3732088 Diuretics NNS B-NP O
2 9 10 3732088 , , O O
3 11 20 3732088 potassium NN B-NP D011188
4 21 24 3732088 and CC I-NP O
5 25 36 3732088 arrhythmias NNS I-NP D001145
6 37 39 3732088 in IN B-PP O
7 40 52 3732088 hypertensive JJ B-NP D006973
8 53 61 3732088 coronary JJ I-NP D003327
9 62 69 3732088 disease NN I-NP D003327
10 69 70 3732088 . . O O
11 71 73 3732088 It PRP B-NP O
12 74 77 3732088 has VBZ B-VP O
13 78 82 3732088 been VBN I-VP O
14 83 91 3732088 proposed VBN I-VP O
15 92 96 3732088 that IN B-SBAR O
16 97 103 3732088 modest JJ B-NP O
17 104 111 3732088 changes NNS I-NP O
18 112 114 3732088 in IN B-PP O
19 115 121 3732088 plasma NN B-NP O
20 122 131 3732088 potassium NN I-NP D011188
21 132 135 3732088 can MD B-VP O
22 136 141 3732088 alter VB I-VP O
23 142 145 3732088 the DT B-NP O
24 146 154 3732088 tendency NN I-NP O
25 155 162 3732088 towards IN B-PP O
26 163 170 3732088 cardiac JJ B-NP D001145
27 171 182 3732088 arrhythmias NNS I-NP D001145
28 182 183 3732088 . . O O

1 184 186 3732088 If IN B-SBAR O
2 187 191 3732088 this DT B-NP O
3 192 196 3732088 were VBD B-VP O
4 197 199 3732088 so RB B-ADVP O
5 199 200 3732088 , , O O
6 201 209 3732088 patients NNS B-NP O
7 210 214 3732088 with IN B-PP O
8 215 223 3732088 coronary JJ B-NP D003324
9 224 230 3732088 artery NN I-NP D003324
10 231 238 3732088 disease NN I-NP D003324
11 239 244 3732088 might MD B-VP O
12 245 247 3732088 be VB I-VP O
13 248 258 3732088 especially RB B-ADJP O
14 259 270 3732088 susceptible JJ I-ADJP O
15 270 271 3732088 . . O O

1 272 276 3732088 Thus RB B-ADVP O
2 276 277 3732088 , , O O
3 278 288 3732088 myocardial JJ B-NP O
4 289 299 3732088 electrical JJ I-NP O
5 300 312 3732088 excitability NN I-NP O
6 313 316 3732088 was VBD B-VP O
7 317 325 3732088 measured VBN I-VP O
8 326 328 3732088 in IN B-PP O
9 329 337 3732088 patients NNS B-NP O
10 338 342 3732088 with IN B-PP O
11 343 347 3732088 mild JJ B-NP O
12 348 357 3732088 essential JJ I-NP O
13 358 370 3732088 hypertension NN I-NP D006973
14 371 374 3732088 and CC O O
15 375 380 3732088 known VBN B-NP O
16 381 389 3732088 coronary JJ I-NP D003324
17 390 396 3732088 artery NN I-NP D003324
18 397 404 3732088 disease NN I-NP D003324
19 405 410 3732088 after IN B-PP O
20 411 412 3732088 8 CD B-NP O
21 413 418 3732088 weeks NNS I-NP O
22 419 421 3732088 of IN B-PP O
23 422 431 3732088 treatment NN B-NP O
24 432 436 3732088 with IN B-PP O
25 437 438 3732088 a DT B-NP O
26 439 448 3732088 potassium NN I-NP D011188
27 448 449 3732088 - HYPH O O
28 449 459 3732088 conserving VBG B-VP O
29 460 468 3732088 diuretic JJ B-ADJP O
30 469 470 3732088 ( ( O O
31 470 479 3732088 amiloride NN B-NP D000584
32 479 480 3732088 ) ) O O
33 481 484 3732088 and CC O O
34 485 486 3732088 a DT B-NP O
35 487 494 3732088 similar JJ I-NP O
36 495 501 3732088 period NN I-NP O
37 502 504 3732088 on IN B-PP O
38 505 506 3732088 a DT B-NP O
39 507 516 3732088 potassium NN I-NP D011188
40 516 517 3732088 - HYPH B-VP O
41 517 523 3732088 losing VBG I-VP O
42 524 532 3732088 diuretic JJ B-NP O
43 533 534 3732088 ( ( O O
44 534 548 3732088 chlorthalidone NN B-NP D002752
45 548 549 3732088 ) ) O O
46 550 552 3732088 in IN B-PP O
47 553 554 3732088 a DT B-NP O
48 555 565 3732088 randomised VBN I-NP O
49 566 571 3732088 study NN I-NP O
50 571 572 3732088 . . O O

1 573 579 3732088 Plasma NN B-NP O
2 580 589 3732088 potassium NN I-NP D011188
3 590 604 3732088 concentrations NNS I-NP O
4 605 609 3732088 were VBD B-VP O
5 610 612 3732088 on IN B-PP O
6 613 620 3732088 average NN B-NP O
7 621 622 3732088 1 CD I-NP O
8 623 627 3732088 mmol NN I-NP O
9 627 628 3732088 / SYM B-PP O
10 628 629 3732088 L NN B-NP O
11 630 635 3732088 lower JJR B-ADJP O
12 636 642 3732088 during IN B-PP O
13 643 646 3732088 the DT B-NP O
14 647 661 3732088 chlorthalidone NN I-NP D002752
15 662 667 3732088 phase NN I-NP O
16 668 676 3732088 compared VBN B-VP O
17 677 679 3732088 to TO B-PP O
18 680 689 3732088 amiloride NN B-NP D000584
19 690 697 3732088 therapy NN I-NP O
20 697 698 3732088 . . O O

1 699 704 3732088 Blood NN B-NP O
2 705 713 3732088 pressure NN I-NP O
3 714 717 3732088 and CC I-NP O
4 718 724 3732088 volume NN I-NP O
5 725 731 3732088 states NNS I-NP O
6 732 734 3732088 as IN B-SBAR O
7 735 743 3732088 assessed VBN B-VP O
8 744 746 3732088 by IN B-PP O
9 747 757 3732088 bodyweight NN B-NP O
10 757 758 3732088 , , O O
11 759 765 3732088 plasma NN B-NP O
12 766 771 3732088 renin NN I-NP O
13 772 775 3732088 and CC O O
14 776 789 3732088 noradrenaline NN B-NP D009638
15 790 791 3732088 ( ( O O
16 791 805 3732088 norepinephrine NN B-NP D009638
17 805 806 3732088 ) ) O O
18 807 821 3732088 concentrations NNS B-NP O
19 822 826 3732088 were VBD B-VP O
20 827 834 3732088 similar JJ B-ADJP O
21 835 837 3732088 on IN B-PP O
22 838 841 3732088 the DT B-NP O
23 842 843 3732088 2 CD I-NP O
24 844 852 3732088 regimens NNS I-NP O
25 852 853 3732088 . . O O

1 854 862 3732088 Compared VBN B-PP O
2 863 865 3732088 to TO B-PP O
3 866 875 3732088 amiloride NN B-NP D000584
4 876 885 3732088 treatment NN I-NP O
5 885 886 3732088 , , O O
6 887 890 3732088 the DT B-NP O
7 891 905 3732088 chlorthalidone NN I-NP D002752
8 906 911 3732088 phase NN I-NP O
9 912 915 3732088 was VBD B-VP O
10 916 926 3732088 associated VBN I-VP O
11 927 931 3732088 with IN B-PP O
12 932 934 3732088 an DT B-NP O
13 935 944 3732088 increased VBN I-NP O
14 945 954 3732088 frequency NN I-NP O
15 955 957 3732088 of IN B-PP O
16 958 969 3732088 ventricular JJ B-NP D018879
17 970 977 3732088 ectopic JJ I-NP D018879
18 978 983 3732088 beats NNS I-NP D018879
19 984 985 3732088 ( ( O O
20 985 987 3732088 24 CD B-NP O
21 987 988 3732088 - HYPH I-NP O
22 988 992 3732088 hour NN I-NP O
23 993 999 3732088 Holter NN I-NP O
24 1000 1010 3732088 monitoring NN I-NP O
25 1010 1011 3732088 ) ) O O
26 1012 1015 3732088 and CC O O
27 1016 1017 3732088 a DT B-NP O
28 1018 1024 3732088 higher JJR I-NP O
29 1025 1029 3732088 Lown JJ I-NP O
30 1030 1037 3732088 grading NN I-NP O
31 1037 1038 3732088 , , O O
32 1039 1048 3732088 increased VBN B-NP O
33 1049 1056 3732088 upslope NN I-NP O
34 1057 1060 3732088 and CC I-NP O
35 1061 1069 3732088 duration NN I-NP O
36 1070 1072 3732088 of IN B-PP O
37 1073 1076 3732088 the DT B-NP O
38 1077 1087 3732088 monophasic JJ I-NP O
39 1088 1094 3732088 action NN I-NP O
40 1095 1104 3732088 potential NN I-NP O
41 1104 1105 3732088 , , O O
42 1106 1115 3732088 prolonged VBD B-VP O
43 1116 1127 3732088 ventricular JJ B-NP O
44 1128 1137 3732088 effective JJ I-NP O
45 1138 1148 3732088 refractory JJ I-NP O
46 1149 1155 3732088 period NN I-NP O
47 1155 1156 3732088 , , O O
48 1157 1160 3732088 and CC O O
49 1161 1170 3732088 increased VBN B-NP O
50 1171 1181 3732088 electrical JJ I-NP O
51 1182 1193 3732088 instability NN I-NP O
52 1194 1200 3732088 during IN B-PP O
53 1201 1211 3732088 programmed VBN B-NP O
54 1212 1223 3732088 ventricular JJ I-NP O
55 1224 1235 3732088 stimulation NN I-NP O
56 1235 1236 3732088 . . O O

1 1237 1240 3732088 The DT B-NP O
2 1241 1246 3732088 above JJ I-NP O
3 1247 1254 3732088 results NNS I-NP O
4 1255 1263 3732088 indicate VBP B-VP O
5 1264 1268 3732088 that IN B-SBAR O
6 1269 1276 3732088 because IN B-SBAR O
7 1277 1286 3732088 potassium NN B-NP D011188
8 1286 1287 3732088 - HYPH B-VP O
9 1287 1293 3732088 losing VBG I-VP O
10 1294 1302 3732088 diuretic JJ B-NP O
11 1303 1310 3732088 therapy NN I-NP O
12 1311 1314 3732088 can MD B-VP O
13 1315 1323 3732088 increase VB I-VP O
14 1324 1334 3732088 myocardial JJ B-NP O
15 1335 1345 3732088 electrical JJ I-NP O
16 1346 1358 3732088 excitability NN I-NP O
17 1359 1361 3732088 in IN B-PP O
18 1362 1370 3732088 patients NNS B-NP O
19 1371 1375 3732088 with IN B-PP O
20 1376 1385 3732088 ischaemic JJ B-NP D017202
21 1386 1391 3732088 heart NN I-NP D017202
22 1392 1399 3732088 disease NN I-NP D017202
23 1399 1400 3732088 , , O O
24 1401 1405 3732088 even RB B-NP O
25 1406 1411 3732088 minor JJ I-NP O
26 1412 1417 3732088 falls NNS I-NP O
27 1418 1420 3732088 in IN B-PP O
28 1421 1427 3732088 plasma NN B-NP O
29 1428 1437 3732088 potassium NN I-NP D011188
30 1438 1452 3732088 concentrations NNS I-NP O
31 1453 1456 3732088 are VBP B-VP O
32 1457 1465 3732088 probably RB B-ADVP O
33 1466 1470 3732088 best RBS B-VP O
34 1471 1478 3732088 avoided VBN I-VP O
35 1479 1481 3732088 in IN B-PP O
36 1482 1486 3732088 such JJ B-NP O
37 1487 1495 3732088 patients NNS I-NP O
38 1495 1496 3732088 . . O O

1 0 0 7905523 -DOCSTART- -X- -X- O

1 0 3 7905523 The DT B-NP O
2 4 10 7905523 safety NN I-NP O
3 11 14 7905523 and CC I-NP O
4 15 23 7905523 efficacy NN I-NP O
5 24 26 7905523 of IN B-PP O
6 27 38 7905523 combination NN B-NP O
7 39 40 7905523 N NN I-NP C059896
8 40 41 7905523 - HYPH B-NP C059896
9 41 46 7905523 butyl NN I-NP C059896
10 46 47 7905523 - HYPH B-NP C059896
11 47 63 7905523 deoxynojirimycin NN I-NP C059896
12 64 65 7905523 ( ( O O
13 65 67 7905523 SC NN B-NP C059896
14 67 68 7905523 - HYPH B-NP C059896
15 68 73 7905523 48334 CD I-NP C059896
16 73 74 7905523 ) ) O O
17 75 78 7905523 and CC O O
18 79 89 7905523 zidovudine NN B-NP D015215
19 90 92 7905523 in IN B-PP O
20 93 101 7905523 patients NNS B-NP O
21 102 106 7905523 with IN B-PP O
22 107 110 7905523 HIV NN B-NP D015658
23 110 111 7905523 - HYPH B-NP D015658
24 111 112 7905523 1 CD I-NP D015658
25 113 122 7905523 infection NN I-NP D015658
26 123 126 7905523 and CC O O
27 127 130 7905523 200 CD B-NP O
28 130 131 7905523 - HYPH I-NP O
29 131 134 7905523 500 CD I-NP O
30 135 138 7905523 CD4 NN I-NP O
31 139 144 7905523 cells NNS I-NP O
32 144 145 7905523 / SYM B-VP O
33 145 148 7905523 mm3 NN B-NP O
34 148 149 7905523 . . O O
35 150 152 7905523 We PRP B-NP O
36 153 162 7905523 conducted VBD B-VP O
37 163 164 7905523 a DT B-NP O
38 165 171 7905523 double JJ I-NP O
39 171 172 7905523 - HYPH I-NP O
40 172 177 7905523 blind JJ I-NP O
41 177 178 7905523 , , O O
42 179 189 7905523 randomized VBD B-VP O
43 190 195 7905523 phase NN B-NP O
44 196 198 7905523 II CD I-NP O
45 199 204 7905523 study NN I-NP O
46 205 207 7905523 to TO B-VP O
47 208 216 7905523 evaluate VB I-VP O
48 217 220 7905523 the DT B-NP O
49 221 227 7905523 safety NN I-NP O
50 228 231 7905523 and CC I-NP O
51 232 240 7905523 activity NN I-NP O
52 241 243 7905523 of IN B-PP O
53 244 255 7905523 combination NN B-NP O
54 256 263 7905523 therapy NN I-NP O
55 264 268 7905523 with IN B-PP O
56 269 270 7905523 N NN B-NP C059896
57 270 271 7905523 - HYPH B-NP C059896
58 271 276 7905523 butyl NN I-NP C059896
59 276 277 7905523 - HYPH B-NP C059896
60 277 293 7905523 deoxynojirimycin NN I-NP C059896
61 294 295 7905523 ( ( O O
62 295 297 7905523 SC NN B-NP C059896
63 297 298 7905523 - HYPH B-NP C059896
64 298 303 7905523 48334 CD I-NP C059896
65 303 304 7905523 ) ) O O
66 305 306 7905523 ( ( O O
67 306 308 7905523 an DT B-NP O
68 309 314 7905523 alpha SYM I-NP O
69 314 315 7905523 - HYPH I-NP O
70 315 326 7905523 glucosidase NN I-NP O
71 327 328 7905523 I CD I-NP O
72 329 338 7905523 inhibitor NN I-NP O
73 338 339 7905523 ) ) O O
74 340 343 7905523 and CC O O
75 344 354 7905523 zidovudine NN B-NP D015215
76 355 361 7905523 versus IN B-PP O
77 362 372 7905523 zidovudine NN B-NP D015215
78 373 378 7905523 alone RB B-ADVP O
79 378 379 7905523 . . O O

1 380 388 7905523 Patients NNS B-NP O
2 389 393 7905523 with IN B-PP O
3 394 397 7905523 200 CD B-NP O
4 398 400 7905523 to TO I-NP O
5 401 404 7905523 500 CD I-NP O
6 405 408 7905523 CD4 NN I-NP O
7 409 414 7905523 cells NNS I-NP O
8 414 415 7905523 / SYM O O
9 415 418 7905523 mm3 NN B-NP O
10 419 422 7905523 who WP B-NP O
11 423 432 7905523 tolerated VBD B-VP O
12 433 434 7905523 < SYM B-NP O
13 435 437 7905523 or CC O O
14 438 439 7905523 = SYM B-VP O
15 440 442 7905523 12 CD B-NP O
16 443 448 7905523 weeks NNS I-NP O
17 449 451 7905523 of IN B-PP O
18 452 457 7905523 prior JJ B-NP O
19 458 468 7905523 zidovudine NN I-NP D015215
20 469 476 7905523 therapy NN I-NP O
21 477 485 7905523 received VBD B-VP O
22 486 488 7905523 SC NN B-NP C059896
23 488 489 7905523 - HYPH O C059896
24 489 494 7905523 48334 CD B-NP C059896
25 495 496 7905523 ( ( O O
26 496 500 7905523 1000 CD B-NP O
27 501 503 7905523 mg NN I-NP O
28 504 509 7905523 every DT B-NP O
29 510 511 7905523 8 CD I-NP O
30 512 513 7905523 h NN I-NP O
31 513 514 7905523 ) ) O O
32 515 518 7905523 and CC O O
33 519 529 7905523 zidovudine NN B-NP D015215
34 530 531 7905523 ( ( O O
35 531 534 7905523 100 CD B-NP O
36 535 537 7905523 mg NN I-NP O
37 538 543 7905523 every DT B-NP O
38 544 545 7905523 8 CD I-NP O
39 546 547 7905523 h NN I-NP O
40 547 548 7905523 ) ) O O
41 549 551 7905523 or CC O O
42 552 562 7905523 zidovudine NN B-NP D015215
43 563 566 7905523 and CC I-NP O
44 567 574 7905523 placebo NN I-NP O
45 574 575 7905523 . . O O

1 576 581 7905523 Sixty CD B-NP O
2 582 590 7905523 patients NNS I-NP O
3 591 599 7905523 received VBD B-VP O
4 600 611 7905523 combination NN B-NP O
5 612 619 7905523 therapy NN I-NP O
6 620 623 7905523 and CC O O
7 624 626 7905523 58 CD B-NP O
8 626 627 7905523 , , O O
9 628 638 7905523 zidovudine NN B-NP D015215
10 639 642 7905523 and CC I-NP O
11 643 650 7905523 placebo NN I-NP O
12 650 651 7905523 . . O O

1 652 658 7905523 Twenty CD B-NP O
2 658 659 7905523 - HYPH I-NP O
3 659 664 7905523 three CD B-NP O
4 665 673 7905523 patients NNS I-NP O
5 674 675 7905523 ( ( B-LST O
6 675 678 7905523 38% LS I-LST O
7 678 679 7905523 ) ) O O
8 680 683 7905523 and CC O O
9 684 686 7905523 15 CD B-NP O
10 687 688 7905523 ( ( O O
11 688 691 7905523 26% NN B-NP O
12 691 692 7905523 ) ) O O
13 692 693 7905523 , , O O
14 694 696 7905523 in IN B-PP O
15 697 700 7905523 the DT B-NP O
16 701 712 7905523 combination NN I-NP O
17 713 716 7905523 and CC I-NP O
18 717 727 7905523 zidovudine NN I-NP D015215
19 728 734 7905523 groups NNS I-NP O
20 734 735 7905523 , , O O
21 736 748 7905523 respectively RB B-ADVP O
22 748 749 7905523 , , O O
23 750 762 7905523 discontinued VBN B-NP O
24 763 770 7905523 therapy NN I-NP O
25 771 772 7905523 ( ( O O
26 772 773 7905523 p NN B-NP O
27 774 775 7905523 = SYM B-VP O
28 776 780 7905523 0.15 CD B-NP O
29 780 781 7905523 ) ) O O
30 781 782 7905523 . . O O

1 783 786 7905523 The DT B-NP O
2 787 791 7905523 mean JJ I-NP O
3 792 794 7905523 SC NN I-NP C059896
4 794 795 7905523 - HYPH O C059896
5 795 800 7905523 48334 CD B-NP C059896
6 801 807 7905523 steady JJ I-NP O
7 807 808 7905523 - HYPH I-NP O
8 808 813 7905523 state NN I-NP O
9 814 820 7905523 trough NN I-NP O
10 821 826 7905523 level NN I-NP O
11 827 828 7905523 ( ( O O
12 828 832 7905523 4.04 CD B-NP O
13 833 834 7905523 + SYM O O
14 834 835 7905523 / SYM O O
15 835 836 7905523 - SYM O O
16 837 841 7905523 0.99 CD B-NP O
17 842 852 7905523 micrograms NNS I-NP O
18 852 853 7905523 / SYM B-NP O
19 853 855 7905523 ml NN I-NP O
20 855 856 7905523 ) ) O O
21 857 860 7905523 was VBD B-VP O
22 861 866 7905523 below IN B-PP O
23 867 870 7905523 the DT B-NP O
24 871 873 7905523 in FW I-NP O
25 874 879 7905523 vitro FW I-NP O
26 880 890 7905523 inhibitory JJ I-NP O
27 891 904 7905523 concentration NN I-NP O
28 905 908 7905523 for IN B-PP O
29 909 914 7905523 human JJ B-NP O
30 915 931 7905523 immunodeficiency NN I-NP D007153
31 932 937 7905523 virus NN I-NP O
32 938 939 7905523 ( ( O O
33 939 942 7905523 HIV NN B-NP O
34 942 943 7905523 ) ) O O
35 943 944 7905523 . . O O

1 945 948 7905523 The DT B-NP O
2 949 953 7905523 mean JJ I-NP O
3 954 962 7905523 increase NN I-NP O
4 963 965 7905523 in IN B-PP O
5 966 969 7905523 CD4 NN B-NP O
6 970 975 7905523 cells NNS I-NP O
7 976 978 7905523 at IN B-PP O
8 979 983 7905523 week NN B-NP O
9 984 985 7905523 4 CD I-NP O
10 986 989 7905523 was VBD B-VP O
11 990 994 7905523 73.8 CD B-NP O
12 995 1000 7905523 cells NNS I-NP O
13 1000 1001 7905523 / SYM B-NP O
14 1001 1004 7905523 mm3 NN B-NP O
15 1005 1008 7905523 and CC O O
16 1009 1013 7905523 52.4 CD B-NP O
17 1014 1019 7905523 cells NNS I-NP O
18 1019 1020 7905523 / SYM O O
19 1020 1023 7905523 mm3 NN B-NP O
20 1024 1027 7905523 for IN B-PP O
21 1028 1031 7905523 the DT B-NP O
22 1032 1043 7905523 combination NN I-NP O
23 1044 1047 7905523 and CC I-NP O
24 1048 1058 7905523 zidovudine NN I-NP D015215
25 1059 1065 7905523 groups NNS I-NP O
26 1065 1066 7905523 , , O O
27 1067 1079 7905523 respectively RB B-ADVP O
28 1080 1081 7905523 ( ( O O
29 1081 1082 7905523 p NN B-NP O
30 1083 1084 7905523 > JJR B-NP O
31 1085 1089 7905523 0.36 CD I-NP O
32 1089 1090 7905523 ) ) O O
33 1090 1091 7905523 . . O O

1 1092 1095 7905523 For IN B-PP O
2 1096 1104 7905523 patients NNS B-NP O
3 1105 1109 7905523 with IN B-PP O
4 1110 1115 7905523 prior JJ B-NP O
5 1116 1126 7905523 zidovudine NN I-NP D015215
6 1127 1134 7905523 therapy NN I-NP O
7 1134 1135 7905523 , , O O
8 1136 1139 7905523 the DT B-NP O
9 1140 1144 7905523 mean JJ I-NP O
10 1145 1151 7905523 change NN I-NP O
11 1152 1154 7905523 in IN B-PP O
12 1155 1158 7905523 CD4 NN B-NP O
13 1159 1164 7905523 cells NNS I-NP O
14 1165 1167 7905523 in IN B-PP O
15 1168 1171 7905523 the DT B-NP O
16 1172 1183 7905523 combination NN I-NP O
17 1184 1187 7905523 and CC I-NP O
18 1188 1198 7905523 zidovudine NN I-NP D015215
19 1199 1205 7905523 groups NNS I-NP O
20 1206 1209 7905523 was VBD B-VP O
21 1210 1214 7905523 63.7 CD B-NP O
22 1215 1220 7905523 cells NNS I-NP O
23 1220 1221 7905523 / SYM B-NP O
24 1221 1224 7905523 mm3 NN B-NP O
25 1225 1228 7905523 and CC O O
26 1229 1232 7905523 4.9 CD B-NP O
27 1233 1238 7905523 cells NNS I-NP O
28 1238 1239 7905523 / SYM O O
29 1239 1242 7905523 mm3 NN B-NP O
30 1243 1245 7905523 at IN B-PP O
31 1246 1250 7905523 week NN B-NP O
32 1251 1252 7905523 8 CD I-NP O
33 1253 1256 7905523 and CC I-NP O
34 1257 1260 7905523 6.8 CD I-NP O
35 1261 1266 7905523 cells NNS I-NP O
36 1266 1267 7905523 / SYM B-NP O
37 1267 1270 7905523 mm3 NN B-NP O
38 1271 1274 7905523 and CC O O
39 1275 1276 7905523 - SYM B-NP O
40 1276 1280 7905523 45.1 CD B-NP O
41 1281 1286 7905523 cells NNS I-NP O
42 1286 1287 7905523 / SYM O O
43 1287 1290 7905523 mm3 NN B-NP O
44 1291 1293 7905523 at IN B-PP O
45 1294 1298 7905523 week NN B-NP O
46 1299 1301 7905523 16 CD I-NP O
47 1301 1302 7905523 , , O O
48 1303 1315 7905523 respectively RB B-ADVP O
49 1315 1316 7905523 . . O O

1 1317 1320 7905523 The DT B-NP O
2 1321 1327 7905523 number NN I-NP O
3 1328 1330 7905523 of IN B-PP O
4 1331 1339 7905523 patients NNS B-NP O
5 1340 1344 7905523 with IN B-PP O
6 1345 1356 7905523 suppression NN B-NP O
7 1357 1359 7905523 of IN B-PP O
8 1360 1363 7905523 HIV NN B-NP O
9 1364 1367 7905523 p24 NN I-NP O
10 1368 1379 7905523 antigenemia NN I-NP O
11 1380 1382 7905523 in IN B-PP O
12 1383 1386 7905523 the DT B-NP O
13 1387 1398 7905523 combination NN I-NP O
14 1399 1402 7905523 and CC I-NP O
15 1403 1413 7905523 zidovudine NN I-NP D015215
16 1414 1420 7905523 groups NNS I-NP O
17 1421 1424 7905523 was VBD B-VP O
18 1425 1428 7905523 six CD B-NP O
19 1429 1430 7905523 ( ( O O
20 1430 1433 7905523 40% CD B-NP O
21 1433 1434 7905523 ) ) O O
22 1435 1438 7905523 and CC O O
23 1439 1442 7905523 two CD B-NP O
24 1443 1444 7905523 ( ( O O
25 1444 1447 7905523 11% NN B-NP O
26 1447 1448 7905523 ) ) O O
27 1449 1451 7905523 at IN B-PP O
28 1452 1456 7905523 week NN B-NP O
29 1457 1458 7905523 4 CD I-NP O
30 1459 1460 7905523 ( ( O O
31 1460 1461 7905523 p NN B-NP O
32 1462 1463 7905523 = SYM B-VP O
33 1464 1468 7905523 0.10 CD B-NP O
34 1468 1469 7905523 ) ) O O
35 1470 1473 7905523 and CC O O
36 1474 1478 7905523 five CD B-NP O
37 1479 1480 7905523 ( ( O O
38 1480 1483 7905523 45% NN B-NP O
39 1483 1484 7905523 ) ) O O
40 1485 1488 7905523 and CC O O
41 1489 1492 7905523 two CD B-NP O
42 1493 1494 7905523 ( ( O O
43 1494 1497 7905523 14% NN B-NP O
44 1497 1498 7905523 ) ) O O
45 1499 1501 7905523 at IN B-PP O
46 1502 1506 7905523 week NN B-NP O
47 1507 1509 7905523 24 CD I-NP O
48 1510 1511 7905523 ( ( O O
49 1511 1512 7905523 p NN B-NP O
50 1513 1514 7905523 = SYM B-VP O
51 1515 1519 7905523 0.08 CD B-NP O
52 1519 1520 7905523 ) ) O O
53 1520 1521 7905523 , , O O
54 1522 1534 7905523 respectively RB B-ADVP O
55 1534 1535 7905523 . . O O

1 1536 1544 7905523 Diarrhea NN B-NP D003967
2 1544 1545 7905523 , , O O
3 1546 1556 7905523 flatulence NN B-NP D005414
4 1556 1557 7905523 , , O O
5 1558 1567 7905523 abdominal JJ B-NP D015746
6 1568 1572 7905523 pain NN I-NP D015746
7 1572 1573 7905523 , , O O
8 1574 1577 7905523 and CC O O
9 1578 1584 7905523 weight NN B-NP D015431
10 1585 1589 7905523 loss NN I-NP D015431
11 1590 1594 7905523 were VBD B-VP O
12 1595 1601 7905523 common JJ B-ADJP O
13 1602 1605 7905523 for IN B-PP O
14 1606 1617 7905523 combination NN B-NP O
15 1618 1638 7905523 recipients.(ABSTRACT NN I-NP O
16 1639 1648 7905523 TRUNCATED VBN B-VP O
17 1649 1651 7905523 AT IN B-PP O
18 1652 1655 7905523 250 CD B-NP O
19 1656 1661 7905523 WORDS NNS I-NP O
20 1661 1662 7905523 ) ) O O

1 0 0 1415380 -DOCSTART- -X- -X- O

1 0 9 1415380 Hemolytic JJ B-NP D006463
2 9 10 1415380 - HYPH I-NP D006463
3 10 16 1415380 uremic JJ I-NP D006463
4 17 25 1415380 syndrome NN I-NP D006463
5 26 36 1415380 associated VBN B-VP O
6 37 41 1415380 with IN B-PP O
7 42 51 1415380 ingestion NN B-NP O
8 52 54 1415380 of IN B-PP O
9 55 62 1415380 quinine NN B-NP D011803
10 62 63 1415380 . . O O
11 64 73 1415380 Hemolytic JJ B-NP D006463
12 73 74 1415380 - HYPH I-NP D006463
13 74 80 1415380 uremic JJ I-NP D006463
14 81 89 1415380 syndrome NN I-NP D006463
15 90 99 1415380 following VBG B-PP O
16 100 107 1415380 quinine NN B-NP D011803
17 108 117 1415380 ingestion NN I-NP O
18 118 120 1415380 is VBZ B-VP O
19 121 122 1415380 a DT B-NP O
20 123 128 1415380 newly RB I-NP O
21 129 138 1415380 described VBN I-NP O
22 139 149 1415380 phenomenon NN I-NP O
23 149 150 1415380 , , O O
24 151 155 1415380 with IN B-PP O
25 156 160 1415380 just RB B-NP O
26 161 164 1415380 two CD I-NP O
27 165 173 1415380 previous JJ I-NP O
28 174 186 1415380 descriptions NNS I-NP O
29 187 189 1415380 of IN B-PP O
30 190 191 1415380 4 CD B-NP O
31 192 197 1415380 cases NNS I-NP O
32 198 200 1415380 in IN B-PP O
33 201 204 1415380 the DT B-NP O
34 205 215 1415380 literature NN I-NP O
35 215 216 1415380 . . O O

1 217 219 1415380 We PRP B-NP O
2 220 228 1415380 describe VBP B-VP O
3 229 230 1415380 a DT B-NP O
4 231 234 1415380 5th JJ I-NP O
5 235 239 1415380 case NN I-NP O
6 239 240 1415380 . . O O

1 241 244 1415380 The DT B-NP O
2 245 253 1415380 reaction NN I-NP O
3 254 257 1415380 may MD B-VP O
4 258 260 1415380 be VB I-VP O
5 261 269 1415380 mediated VBN I-VP O
6 270 272 1415380 by IN B-PP O
7 273 276 1415380 the DT B-NP O
8 277 285 1415380 presence NN I-NP O
9 286 288 1415380 of IN B-PP O
10 289 299 1415380 antibodies NNS B-NP O
11 300 308 1415380 reactive JJ B-ADJP O
12 309 316 1415380 against IN B-PP O
13 317 326 1415380 platelets NNS B-NP O
14 327 329 1415380 in IN B-PP O
15 330 333 1415380 the DT I-PP O
16 334 342 1415380 presence NN I-PP O
17 343 345 1415380 of IN I-PP O
18 346 353 1415380 quinine NN B-NP D011803
19 353 354 1415380 . . O O

1 355 364 1415380 Treatment NN B-NP O
2 365 368 1415380 has VBZ B-VP O
3 369 377 1415380 included VBN I-VP O
4 378 381 1415380 use NN B-NP O
5 382 384 1415380 of IN B-PP O
6 385 391 1415380 plasma NN B-NP O
7 392 400 1415380 exchange NN I-NP O
8 400 401 1415380 , , O O
9 402 412 1415380 prednisone NN B-NP D011241
10 412 413 1415380 , , O O
11 414 421 1415380 aspirin NN B-NP D001241
12 421 422 1415380 , , O O
13 423 426 1415380 and CC O O
14 427 439 1415380 dipyridamole NN B-NP D004176
15 439 440 1415380 . . O O

1 441 444 1415380 The DT B-NP O
2 445 453 1415380 patients NNS I-NP O
3 454 458 1415380 have VBP B-VP O
4 459 462 1415380 all DT O O
5 463 471 1415380 regained VBD B-VP O
6 472 476 1415380 some DT B-NP O
7 477 483 1415380 degree NN I-NP O
8 484 486 1415380 of IN B-PP O
9 487 492 1415380 renal JJ B-NP O
10 493 501 1415380 function NN I-NP O
11 501 502 1415380 . . O O

1 503 510 1415380 However RB B-ADVP O
2 510 511 1415380 , , O O
3 512 514 1415380 it PRP B-NP O
4 515 517 1415380 is VBZ B-VP O
5 518 525 1415380 unclear JJ B-ADJP O
6 526 533 1415380 whether IN B-SBAR O
7 534 549 1415380 pharmacological JJ B-NP O
8 550 559 1415380 treatment NN I-NP O
9 560 562 1415380 or CC O O
10 563 574 1415380 spontaneous JJ B-NP O
11 575 585 1415380 resolution NN I-NP O
12 586 588 1415380 is VBZ B-VP O
13 589 600 1415380 responsible JJ B-ADJP O
14 601 604 1415380 for IN B-PP O
15 605 608 1415380 the DT B-NP O
16 609 620 1415380 improvement NN I-NP O
17 620 621 1415380 . . O O

1 622 629 1415380 Quinine NN B-NP D011803
2 629 630 1415380 - HYPH O O
3 630 640 1415380 associated VBN B-NP O
4 641 650 1415380 hemolytic JJ I-NP D006463
5 650 651 1415380 - HYPH I-NP D006463
6 651 657 1415380 uremic JJ I-NP D006463
7 658 666 1415380 syndrome NN I-NP D006463
8 667 675 1415380 probably RB B-ADVP O
9 676 682 1415380 occurs VBZ B-VP O
10 683 687 1415380 more RBR B-ADVP O
11 688 693 1415380 often RB I-ADVP O
12 694 698 1415380 than IN B-SBAR O
13 699 701 1415380 is VBZ B-VP O
14 702 712 1415380 recognized VBN I-VP O
15 712 713 1415380 . . O O

1 714 716 1415380 It PRP B-NP O
2 717 719 1415380 is VBZ B-VP O
3 720 729 1415380 important JJ B-ADJP O
4 730 732 1415380 to TO B-VP O
5 733 742 1415380 recognize VB I-VP O
6 743 747 1415380 this DT B-NP O
7 748 756 1415380 reaction NN I-NP O
8 757 761 1415380 when WRB B-ADVP O
9 762 764 1415380 it PRP B-NP O
10 765 771 1415380 occurs VBZ B-VP O
11 772 775 1415380 and CC O O
12 776 778 1415380 to TO B-VP O
13 779 784 1415380 avoid VB I-VP O
14 785 792 1415380 further JJ B-NP O
15 793 800 1415380 quinine NN I-NP D011803
16 801 809 1415380 exposure NN I-NP O
17 809 810 1415380 , , O O
18 811 816 1415380 since IN B-SBAR O
19 817 820 1415380 the DT B-NP O
20 821 829 1415380 reaction NN I-NP O
21 830 835 1415380 seems VBZ B-VP O
22 836 838 1415380 to TO I-VP O
23 839 841 1415380 be VB I-VP O
24 842 851 1415380 recurrent JJ B-ADJP O
25 851 852 1415380 . . O O

1 0 0 2021202 -DOCSTART- -X- -X- O

1 0 5 2021202 Renal JJ B-NP O
2 6 14 2021202 function NN I-NP O
3 15 18 2021202 and CC I-NP O
4 19 31 2021202 hemodynamics NNS I-NP O
5 32 38 2021202 during IN B-PP O
6 39 48 2021202 prolonged VBN B-NP O
7 49 59 2021202 isoflurane NN I-NP D007530
8 59 60 2021202 - HYPH O O
9 60 67 2021202 induced VBN B-NP O
10 68 79 2021202 hypotension NN I-NP D007022
11 80 82 2021202 in IN B-PP O
12 83 89 2021202 humans NNS B-NP O
13 89 90 2021202 . . O O
14 91 94 2021202 The DT B-NP O
15 95 101 2021202 effect NN I-NP O
16 102 104 2021202 of IN B-PP O
17 105 115 2021202 isoflurane NN B-NP D007530
18 115 116 2021202 - HYPH B-NP O
19 116 123 2021202 induced VBN I-NP O
20 124 135 2021202 hypotension NN I-NP D007022
21 136 138 2021202 on IN B-PP O
22 139 149 2021202 glomerular JJ B-NP O
23 150 158 2021202 function NN I-NP O
24 159 162 2021202 and CC O O
25 163 168 2021202 renal JJ B-NP O
26 169 174 2021202 blood NN I-NP O
27 175 179 2021202 flow NN I-NP O
28 180 183 2021202 was VBD B-VP O
29 184 196 2021202 investigated VBN I-VP O
30 197 199 2021202 in IN B-PP O
31 200 202 2021202 20 CD B-NP O
32 203 208 2021202 human JJ I-NP O
33 209 217 2021202 subjects NNS I-NP O
34 217 218 2021202 . . O O

1 219 229 2021202 Glomerular JJ B-NP O
2 230 240 2021202 filtration NN I-NP O
3 241 245 2021202 rate NN I-NP O
4 246 247 2021202 ( ( O O
5 247 250 2021202 GFR NN B-NP O
6 250 251 2021202 ) ) O O
7 252 255 2021202 and CC O O
8 256 265 2021202 effective JJ B-NP O
9 266 271 2021202 renal JJ I-NP O
10 272 278 2021202 plasma NN I-NP O
11 279 283 2021202 flow NN I-NP O
12 284 285 2021202 ( ( O O
13 285 289 2021202 ERPF NN B-NP O
14 289 290 2021202 ) ) O O
15 291 295 2021202 were VBD B-VP O
16 296 304 2021202 measured VBN I-VP O
17 305 307 2021202 by IN B-PP O
18 308 314 2021202 inulin NN B-NP O
19 315 318 2021202 and CC O O
20 319 323 2021202 para AFX O D010130
21 323 324 2021202 - HYPH O D010130
22 324 338 2021202 aminohippurate NN B-NP D010130
23 339 340 2021202 ( ( O O
24 340 343 2021202 PAH NN B-NP D010130
25 343 344 2021202 ) ) O O
26 345 354 2021202 clearance NN B-NP O
27 354 355 2021202 , , O O
28 356 368 2021202 respectively RB B-ADVP O
29 368 369 2021202 . . O O

1 370 380 2021202 Anesthesia NNP B-NP O
2 381 384 2021202 was VBD B-VP O
3 385 395 2021202 maintained VBN I-VP O
4 396 400 2021202 with IN B-PP O
5 401 409 2021202 fentanyl NN B-NP D005283
6 409 410 2021202 , , O O
7 411 418 2021202 nitrous JJ B-NP D009609
8 419 424 2021202 oxide NN I-NP D009609
9 424 425 2021202 , , O O
10 426 432 2021202 oxygen NN B-NP D010100
11 432 433 2021202 , , O O
12 434 437 2021202 and CC O O
13 438 448 2021202 isoflurane NN B-NP D007530
14 448 449 2021202 . . O O

1 450 461 2021202 Hypotension NN B-NP D007022
2 462 465 2021202 was VBD B-VP O
3 466 473 2021202 induced VBN I-VP O
4 474 477 2021202 for IN B-PP O
5 478 483 2021202 236.9 CD B-NP O
6 484 485 2021202 + SYM O O
7 485 486 2021202 / SYM O O
8 486 487 2021202 - SYM O O
9 488 492 2021202 15.1 CD B-NP O
10 493 496 2021202 min NN I-NP O
11 497 499 2021202 by IN B-PP O
12 500 510 2021202 increasing VBG B-VP O
13 511 514 2021202 the DT B-NP O
14 515 525 2021202 isoflurane NN I-NP D007530
15 526 534 2021202 inspired VBD B-VP O
16 535 548 2021202 concentration NN B-NP O
17 549 551 2021202 to TO B-VP O
18 552 560 2021202 maintain VB I-VP O
19 561 562 2021202 a DT B-NP O
20 563 567 2021202 mean JJ I-NP O
21 568 576 2021202 arterial JJ I-NP O
22 577 585 2021202 pressure NN I-NP O
23 586 588 2021202 of IN B-PP O
24 589 593 2021202 59.8 CD B-NP O
25 594 595 2021202 + SYM O O
26 595 596 2021202 / SYM O O
27 596 597 2021202 - SYM O O
28 598 601 2021202 0.4 CD B-NP O
29 602 606 2021202 mmHg NN I-NP O
30 606 607 2021202 . . O O

1 608 611 2021202 GFR NN B-NP O
2 612 615 2021202 and CC I-NP O
3 616 620 2021202 ERPF NN I-NP O
4 621 630 2021202 decreased VBD B-VP O
5 631 635 2021202 with IN B-PP O
6 636 639 2021202 the DT B-NP O
7 640 649 2021202 induction NN I-NP O
8 650 652 2021202 of IN B-PP O
9 653 663 2021202 anesthesia NN B-NP O
10 664 667 2021202 but CC O O
11 668 671 2021202 not RB O O
12 672 685 2021202 significantly RB B-ADJP O
13 686 690 2021202 more JJR I-ADJP O
14 691 697 2021202 during IN B-PP O
15 698 709 2021202 hypotension NN B-NP D007022
16 709 710 2021202 . . O O

1 711 726 2021202 Postoperatively RB B-ADVP O
2 726 727 2021202 , , O O
3 728 732 2021202 ERPF NN B-NP O
4 733 741 2021202 returned VBD B-VP O
5 742 744 2021202 to TO B-PP O
6 745 757 2021202 preoperative JJ B-NP O
7 758 764 2021202 values NNS I-NP O
8 764 765 2021202 , , O O
9 766 773 2021202 whereas IN O O
10 774 777 2021202 GFR NN B-NP O
11 778 781 2021202 was VBD B-VP O
12 782 788 2021202 higher JJR B-ADJP O
13 789 793 2021202 than IN B-PP O
14 794 806 2021202 preoperative JJ B-NP O
15 807 813 2021202 values NNS I-NP O
16 813 814 2021202 . . O O

1 815 820 2021202 Renal JJ B-NP O
2 821 829 2021202 vascular JJ I-NP O
3 830 840 2021202 resistance NN I-NP O
4 841 850 2021202 increased VBD B-VP O
5 851 857 2021202 during IN B-PP O
6 858 868 2021202 anesthesia NN B-NP O
7 869 872 2021202 but CC O O
8 873 882 2021202 decreased VBD B-VP O
9 883 887 2021202 when WRB B-ADVP O
10 888 899 2021202 hypotension NN B-NP D007022
11 900 903 2021202 was VBD B-VP O
12 904 911 2021202 induced VBN I-VP O
13 911 912 2021202 , , O O
14 913 921 2021202 allowing VBG B-VP O
15 922 925 2021202 the DT B-NP O
16 926 937 2021202 maintenance NN I-NP O
17 938 940 2021202 of IN B-PP O
18 941 946 2021202 renal JJ B-NP O
19 947 952 2021202 blood NN I-NP O
20 953 957 2021202 flow NN I-NP O
21 957 958 2021202 . . O O

1 959 961 2021202 We PRP B-NP O
2 962 970 2021202 conclude VBP B-VP O
3 971 975 2021202 that IN B-SBAR O
4 976 981 2021202 renal JJ B-NP O
5 982 994 2021202 compensatory JJ I-NP O
6 995 1005 2021202 mechanisms NNS I-NP O
7 1006 1009 2021202 are VBP B-VP O
8 1010 1019 2021202 preserved VBN I-VP O
9 1020 1026 2021202 during IN B-PP O
10 1027 1037 2021202 isoflurane NN B-NP D007530
11 1037 1038 2021202 - HYPH O O
12 1038 1045 2021202 induced VBN B-NP O
13 1046 1057 2021202 hypotension NN I-NP D007022
14 1058 1061 2021202 and CC O O
15 1062 1066 2021202 that IN B-SBAR O
16 1067 1072 2021202 renal JJ B-NP O
17 1073 1081 2021202 function NN I-NP O
18 1082 1085 2021202 and CC I-NP O
19 1086 1098 2021202 hemodynamics NNS I-NP O
20 1099 1106 2021202 quickly RB B-ADVP O
21 1107 1113 2021202 return VB B-VP O
22 1114 1116 2021202 to TO B-PP O
23 1117 1123 2021202 normal JJ B-NP O
24 1124 1128 2021202 when WRB B-ADVP O
25 1129 1141 2021202 normotension NN B-NP O
26 1142 1144 2021202 is VBZ B-VP O
27 1145 1152 2021202 resumed VBN I-VP O
28 1152 1153 2021202 . . O O

1 0 0 12739036 -DOCSTART- -X- -X- O

1 0 12 12739036 Differential JJ B-NP O
2 13 22 12739036 diagnosis NN I-NP O
3 23 25 12739036 of IN B-PP O
4 26 30 12739036 high JJ B-NP O
5 31 36 12739036 serum NN I-NP O
6 37 45 12739036 creatine NN I-NP D003401
7 46 52 12739036 kinase NN I-NP O
8 53 59 12739036 levels NNS I-NP O
9 60 62 12739036 in IN B-PP O
10 63 71 12739036 systemic JJ B-NP D008180
11 72 77 12739036 lupus NN I-NP D008180
12 78 91 12739036 erythematosus NN I-NP D008180
13 91 92 12739036 . . O O
14 93 95 12739036 We PRP B-NP O
15 96 102 12739036 report VBP B-VP O
16 103 106 12739036 the DT B-NP O
17 107 115 12739036 clinical JJ I-NP O
18 116 119 12739036 and CC I-NP O
19 120 127 12739036 bioptic JJ I-NP O
20 128 136 12739036 findings NNS I-NP O
21 137 140 12739036 for IN B-PP O
22 141 142 12739036 a DT B-NP O
23 143 145 12739036 57 CD I-NP O
24 145 146 12739036 - HYPH I-NP O
25 146 150 12739036 year NN I-NP O
26 150 151 12739036 - HYPH O O
27 151 154 12739036 old JJ B-NP O
28 155 160 12739036 woman NN I-NP O
29 161 165 12739036 with IN B-PP O
30 166 172 12739036 severe JJ B-NP O
31 173 184 12739036 chloroquine NN I-NP D002738
32 184 185 12739036 - HYPH B-NP O
33 185 192 12739036 induced VBN I-NP O
34 193 201 12739036 myopathy NN I-NP D009135
35 201 202 12739036 . . O O

1 203 208 12739036 Since IN B-PP O
2 209 213 12739036 1989 CD B-NP O
3 213 214 12739036 , , O O
4 215 218 12739036 she PRP B-NP O
5 219 222 12739036 had VBD B-VP O
6 223 227 12739036 been VBN I-VP O
7 228 237 12739036 suffering VBG I-VP O
8 238 242 12739036 from IN B-PP O
9 243 251 12739036 systemic JJ B-NP D008180
10 252 257 12739036 lupus NN I-NP D008180
11 258 271 12739036 erythematosus NN I-NP D008180
12 272 273 12739036 ( ( O O
13 273 276 12739036 SLE NN B-NP D008180
14 276 277 12739036 ) ) O O
15 278 282 12739036 with IN B-PP O
16 283 288 12739036 renal JJ B-NP D007674
17 289 300 12739036 involvement NN I-NP D007674
18 301 304 12739036 and CC I-NP O
19 305 314 12739036 undergone NN I-NP O
20 315 322 12739036 periods NNS I-NP O
21 323 325 12739036 of IN B-PP O
22 326 335 12739036 treatment NN B-NP O
23 336 340 12739036 with IN B-PP O
24 341 353 12739036 azathioprine NN B-NP D001379
25 354 357 12739036 and CC I-NP O
26 358 374 12739036 cyclophosphamide NN I-NP D003520
27 374 375 12739036 . . O O

1 376 386 12739036 Additional JJ B-NP O
2 387 394 12739036 therapy NN I-NP O
3 395 399 12739036 with IN B-PP O
4 400 411 12739036 chloroquine NN B-NP D002738
5 412 413 12739036 ( ( O O
6 413 415 12739036 CQ NN B-NP D002738
7 415 416 12739036 ) ) O O
8 417 420 12739036 was VBD B-VP O
9 421 428 12739036 started VBN I-VP O
10 429 436 12739036 because IN B-PP O
11 437 439 12739036 of IN I-PP O
12 440 450 12739036 arthralgia NN B-NP D018771
13 450 451 12739036 . . O O

1 452 454 12739036 At IN B-PP O
2 455 458 12739036 the DT B-NP O
3 459 463 12739036 same JJ I-NP O
4 464 468 12739036 time NN I-NP O
5 468 469 12739036 , , O O
6 470 478 12739036 slightly RB B-VP O
7 479 488 12739036 increased VBD I-VP O
8 489 497 12739036 creatine NN B-NP D003401
9 498 504 12739036 kinase NN I-NP O
10 505 506 12739036 ( ( O O
11 506 508 12739036 CK NN B-NP O
12 508 509 12739036 ) ) O O
13 510 516 12739036 levels NNS B-NP O
14 517 521 12739036 were VBD B-VP O
15 522 527 12739036 noted VBN I-VP O
16 527 528 12739036 . . O O

1 529 537 12739036 Myositis NN B-NP D009220
2 538 541 12739036 was VBD B-VP O
3 542 551 12739036 suspected VBN I-VP O
4 551 552 12739036 , , O O
5 553 556 12739036 and CC O O
6 557 560 12739036 the DT B-NP O
7 561 568 12739036 patient NN I-NP O
8 569 572 12739036 was VBD B-VP O
9 573 580 12739036 treated VBN I-VP O
10 581 585 12739036 with IN B-PP O
11 586 594 12739036 steroids NNS B-NP D013256
12 594 595 12739036 . . O O

1 596 599 12739036 The DT B-NP O
2 600 602 12739036 CK NN I-NP O
3 603 611 12739036 increase NN I-NP O
4 612 621 12739036 persisted VBD B-VP O
5 621 622 12739036 , , O O
6 623 630 12739036 however RB B-ADVP O
7 630 631 12739036 , , O O
8 632 635 12739036 and CC O O
9 636 639 12739036 she PRP B-NP O
10 640 649 12739036 developed VBD B-VP O
11 650 661 12739036 progressive JJ B-NP O
12 662 670 12739036 muscular JJ I-NP D018908
13 671 679 12739036 weakness NN I-NP D018908
14 680 683 12739036 and CC O O
15 684 692 12739036 muscular JJ B-NP D009133
16 693 700 12739036 atrophy NN I-NP D009133
17 700 701 12739036 . . O O

1 702 709 12739036 Routine NN B-NP O
2 710 718 12739036 controls NNS I-NP O
3 719 727 12739036 revealed VBD B-VP O
4 728 736 12739036 markedly RB B-NP O
5 737 745 12739036 elevated JJ I-NP O
6 746 748 12739036 CK NN I-NP O
7 749 755 12739036 levels NNS I-NP O
8 756 758 12739036 of IN B-PP O
9 759 764 12739036 1,700 CD B-NP O
10 765 766 12739036 U NN I-NP O
11 766 767 12739036 / SYM B-NP O
12 767 768 12739036 l NN I-NP O
13 768 769 12739036 . . O O

1 770 773 12739036 The DT B-NP O
2 774 786 12739036 neurological JJ I-NP O
3 787 790 12739036 and CC I-NP O
4 791 811 12739036 electrophysiological JJ I-NP O
5 812 820 12739036 findings NNS I-NP O
6 821 825 12739036 were VBD B-VP O
7 826 829 12739036 not RB O O
8 830 837 12739036 typical JJ B-ADJP O
9 838 840 12739036 of IN B-PP O
10 841 849 12739036 myositis NN B-NP D009220
11 849 850 12739036 . . O O

1 851 855 12739036 Thus RB B-ADVP O
2 855 856 12739036 , , O O
3 857 863 12739036 muscle NN B-NP O
4 864 870 12739036 biopsy NN I-NP O
5 871 873 12739036 of IN B-PP O
6 874 877 12739036 the DT B-NP O
7 878 885 12739036 deltoid JJ I-NP O
8 886 892 12739036 muscle NN I-NP O
9 893 896 12739036 was VBD B-VP O
10 897 906 12739036 performed VBN I-VP O
11 907 909 12739036 in IN B-SBAR O
12 910 915 12739036 order NN O O
13 916 918 12739036 to TO B-VP O
14 919 926 12739036 exclude VB I-VP O
15 927 939 12739036 polymyositis NN B-NP D017285
16 940 942 12739036 or CC O O
17 943 948 12739036 toxic JJ B-NP O
18 949 957 12739036 myopathy NN I-NP D009135
19 957 958 12739036 . . O O

1 959 961 12739036 As IN B-SBAR O
2 962 964 12739036 it PRP B-NP O
3 965 973 12739036 revealed VBD B-VP O
4 974 985 12739036 chloroquine NN B-NP D002738
5 985 986 12739036 - HYPH B-NP O
6 986 993 12739036 induced VBN I-NP O
7 994 1002 12739036 myopathy NN I-NP D009135
8 1002 1003 12739036 , , O O
9 1004 1014 12739036 medication NN B-NP O
10 1015 1018 12739036 was VBD B-VP O
11 1019 1026 12739036 stopped VBN I-VP O
12 1026 1027 12739036 . . O O

1 1028 1042 12739036 Discriminating VBG B-VP O
2 1043 1050 12739036 between IN B-PP O
3 1051 1058 12739036 primary JJ B-NP O
4 1059 1062 12739036 SLE NN I-NP D008180
5 1062 1063 12739036 - HYPH B-NP O
6 1063 1070 12739036 induced VBN I-NP O
7 1071 1080 12739036 affection NN I-NP D009140
8 1081 1083 12739036 of IN B-PP D009140
9 1084 1087 12739036 the DT B-NP D009140
10 1088 1103 12739036 musculoskeletal JJ I-NP D009140
11 1104 1110 12739036 system NN I-NP D009140
12 1111 1114 12739036 and CC I-NP O
13 1115 1119 12739036 drug NN I-NP O
14 1119 1120 12739036 - HYPH B-NP O
15 1120 1127 12739036 induced VBN I-NP O
16 1128 1132 12739036 side NN I-NP O
17 1133 1140 12739036 effects NNS I-NP O
18 1141 1143 12739036 is VBZ B-VP O
19 1144 1153 12739036 important JJ B-ADJP O
20 1154 1157 12739036 for IN B-PP O
21 1158 1169 12739036 appropriate JJ B-NP O
22 1170 1179 12739036 treatment NN I-NP O
23 1180 1182 12739036 of IN B-PP O
24 1183 1186 12739036 SLE NN B-NP D008180
25 1187 1195 12739036 patients NNS I-NP O
26 1195 1196 12739036 . . O O

1 0 0 8424298 -DOCSTART- -X- -X- O

1 0 7 8424298 Effects NNS B-NP O
2 8 10 8424298 of IN B-PP O
3 11 21 8424298 deliberate JJ B-NP O
4 22 33 8424298 hypotension NN I-NP D007022
5 34 41 8424298 induced VBN B-VP O
6 42 44 8424298 by IN B-PP O
7 45 54 8424298 labetalol NN B-NP D007741
8 55 59 8424298 with IN B-PP O
9 60 70 8424298 isoflurane NN B-NP D007530
10 71 73 8424298 on IN B-PP O
11 74 92 8424298 neuropsychological JJ B-NP O
12 93 101 8424298 function NN I-NP O
13 101 102 8424298 . . O O
14 103 106 8424298 The DT B-NP O
15 107 113 8424298 effect NN I-NP O
16 114 116 8424298 of IN B-PP O
17 117 127 8424298 deliberate JJ B-NP O
18 128 139 8424298 hypotension NN I-NP D007022
19 140 142 8424298 on IN B-PP O
20 143 148 8424298 brain NN B-NP O
21 149 157 8424298 function NN I-NP O
22 158 166 8424298 measured VBN B-VP O
23 167 169 8424298 by IN B-PP O
24 170 188 8424298 neuropsychological JJ B-NP O
25 189 194 8424298 tests NNS I-NP O
26 195 198 8424298 was VBD B-VP O
27 199 206 8424298 studied VBN I-VP O
28 207 209 8424298 in IN B-PP O
29 210 212 8424298 41 CD B-NP O
30 213 218 8424298 adult JJ I-NP O
31 219 227 8424298 patients NNS I-NP O
32 227 228 8424298 . . O O

1 229 235 8424298 Twenty CD B-NP O
2 235 236 8424298 - HYPH I-NP O
3 236 240 8424298 four CD I-NP O
4 241 249 8424298 patients NNS I-NP O
5 250 254 8424298 were VBD B-VP O
6 255 268 8424298 anaesthetized VBN I-VP O
7 269 272 8424298 for IN B-PP O
8 273 279 8424298 middle JJ B-NP O
9 279 280 8424298 - HYPH I-NP O
10 280 283 8424298 ear NN I-NP O
11 284 291 8424298 surgery NN I-NP O
12 292 296 8424298 with IN B-PP O
13 297 307 8424298 deliberate JJ B-NP O
14 308 319 8424298 hypotension NN I-NP D007022
15 320 327 8424298 induced VBN B-VP O
16 328 330 8424298 by IN B-PP O
17 331 340 8424298 labetalol NN B-NP D007741
18 341 345 8424298 with IN B-PP O
19 346 356 8424298 isoflurane NN B-NP D007530
20 357 358 8424298 ( ( O O
21 358 369 8424298 hypotensive JJ B-NP D007022
22 370 375 8424298 group NN I-NP O
23 375 376 8424298 ) ) O O
24 376 377 8424298 . . O O

1 378 387 8424298 Seventeen CD B-NP O
2 388 396 8424298 patients NNS I-NP O
3 397 404 8424298 without IN B-PP O
4 405 416 8424298 hypotension NN B-NP D007022
5 417 423 8424298 served VBD B-VP O
6 424 426 8424298 as IN B-PP O
7 427 428 8424298 a DT B-NP O
8 429 436 8424298 control NN I-NP O
9 437 442 8424298 group NN I-NP O
10 442 443 8424298 . . O O

1 444 447 8424298 The DT B-NP O
2 448 452 8424298 mean JJ I-NP O
3 453 461 8424298 arterial JJ I-NP O
4 462 470 8424298 pressure NN I-NP O
5 471 474 8424298 was VBD B-VP O
6 475 477 8424298 77 CD B-NP O
7 478 479 8424298 + SYM O O
8 479 480 8424298 / SYM O O
9 480 481 8424298 - SYM O O
10 482 483 8424298 2 CD B-NP O
11 484 488 8424298 mmHg NN I-NP O
12 489 490 8424298 ( ( O O
13 490 494 8424298 10.3 CD B-NP O
14 495 496 8424298 + SYM O O
15 496 497 8424298 / SYM O O
16 497 498 8424298 - SYM O O
17 499 502 8424298 0.3 CD B-NP O
18 503 506 8424298 kPa NN I-NP O
19 506 507 8424298 ) ) O O
20 508 514 8424298 before IN B-PP O
21 515 526 8424298 hypotension NN B-NP D007022
22 527 530 8424298 and CC O O
23 531 533 8424298 50 CD B-NP O
24 534 535 8424298 + SYM O O
25 535 536 8424298 / SYM O O
26 536 537 8424298 - SYM O O
27 538 539 8424298 0 CD B-NP O
28 540 544 8424298 mmHg NN I-NP O
29 545 546 8424298 ( ( O O
30 546 549 8424298 6.7 CD B-NP O
31 550 551 8424298 + SYM O O
32 551 552 8424298 / SYM O O
33 552 553 8424298 - SYM O O
34 554 557 8424298 0.0 CD B-NP O
35 558 561 8424298 kPa NN I-NP O
36 561 562 8424298 ) ) O O
37 563 569 8424298 during IN B-PP O
38 570 581 8424298 hypotension NN B-NP D007022
39 582 584 8424298 in IN B-PP O
40 585 588 8424298 the DT B-NP O
41 589 600 8424298 hypotensive JJ I-NP D007022
42 601 606 8424298 group NN I-NP O
43 606 607 8424298 , , O O
44 608 611 8424298 and CC O O
45 612 614 8424298 86 CD B-NP O
46 615 616 8424298 + SYM O O
47 616 617 8424298 / SYM O O
48 617 618 8424298 - SYM O O
49 619 620 8424298 2 CD B-NP O
50 621 625 8424298 mmHg NN I-NP O
51 626 627 8424298 ( ( O O
52 627 631 8424298 11.5 CD B-NP O
53 632 633 8424298 + SYM O O
54 633 634 8424298 / SYM O O
55 634 635 8424298 - SYM O O
56 636 639 8424298 0.3 CD B-NP O
57 640 643 8424298 kPa NN I-NP O
58 643 644 8424298 ) ) O O
59 645 651 8424298 during IN B-PP O
60 652 663 8424298 anaesthesia NN B-NP O
61 664 666 8424298 in IN B-PP O
62 667 670 8424298 the DT B-NP O
63 671 678 8424298 control NN I-NP O
64 679 684 8424298 group NN I-NP O
65 684 685 8424298 . . O O

1 686 689 8424298 The DT B-NP O
2 690 699 8424298 following VBG I-NP O
3 700 713 8424298 psychological JJ I-NP O
4 714 719 8424298 tests NNS I-NP O
5 720 724 8424298 were VBD B-VP O
6 725 734 8424298 performed VBN I-VP O
7 734 735 8424298 : : O O
8 736 740 8424298 four CD B-NP O
9 741 749 8424298 subtests NNS I-NP O
10 750 752 8424298 of IN B-PP O
11 753 756 8424298 the DT B-NP O
12 757 765 8424298 Wechsler NNP I-NP O
13 766 771 8424298 Adult NNP I-NP O
14 772 784 8424298 Intelligence NNP I-NP O
15 785 790 8424298 Scale NNP I-NP O
16 791 792 8424298 ( ( O O
17 792 804 8424298 similarities NNS B-NP O
18 804 805 8424298 , , O O
19 806 811 8424298 digit NN B-NP O
20 812 816 8424298 span NN I-NP O
21 816 817 8424298 , , O O
22 818 828 8424298 vocabulary NN B-NP O
23 829 832 8424298 and CC I-NP O
24 833 838 8424298 digit NN I-NP O
25 839 845 8424298 symbol NN I-NP O
26 845 846 8424298 ) ) O O
27 846 847 8424298 , , O O
28 848 853 8424298 Trail NN B-NP O
29 853 854 8424298 - HYPH O O
30 854 860 8424298 Making VBG B-VP O
31 861 866 8424298 tests NNS B-NP O
32 867 868 8424298 A NN I-NP O
33 869 872 8424298 and CC I-NP O
34 873 874 8424298 B NN I-NP O
35 874 875 8424298 , , O O
36 876 880 8424298 Zung NN B-NP O
37 881 886 8424298 tests NNS I-NP O
38 887 888 8424298 ( ( O O
39 888 892 8424298 self NN B-NP O
40 892 893 8424298 - HYPH O O
41 893 899 8424298 rating VBG B-VP O
42 900 907 8424298 anxiety NN B-NP D001008
43 908 913 8424298 scale NN I-NP O
44 914 917 8424298 and CC I-NP O
45 918 922 8424298 self NN I-NP O
46 922 923 8424298 - HYPH O O
47 923 929 8424298 rating VBG B-VP O
48 930 940 8424298 depression NN B-NP D003866
49 941 946 8424298 scale NN I-NP O
50 946 947 8424298 ) ) O O
51 948 951 8424298 and CC O O
52 952 955 8424298 two CD B-NP O
53 955 956 8424298 - HYPH I-NP O
54 956 960 8424298 part NN I-NP O
55 961 967 8424298 memory NN I-NP O
56 968 972 8424298 test NN I-NP O
57 973 980 8424298 battery NN I-NP O
58 981 985 8424298 with IN B-PP O
59 986 995 8424298 immediate JJ B-NP O
60 996 999 8424298 and CC I-NP O
61 1000 1007 8424298 delayed VBN I-NP O
62 1008 1014 8424298 recall NN I-NP O
63 1014 1015 8424298 . . O O

1 1016 1019 8424298 The DT B-NP O
2 1020 1025 8424298 tests NNS I-NP O
3 1026 1030 8424298 were VBD B-VP O
4 1031 1040 8424298 performed VBN I-VP O
5 1041 1055 8424298 preoperatively RB B-ADVP O
6 1056 1059 8424298 and CC O O
7 1060 1061 8424298 2 CD B-NP O
8 1062 1066 8424298 days NNS I-NP O
9 1067 1082 8424298 postoperatively RB B-ADVP O
10 1082 1083 8424298 . . O O

1 1084 1089 8424298 There EX B-NP O
2 1090 1094 8424298 were VBD B-VP O
3 1095 1097 8424298 no DT B-NP O
4 1098 1111 8424298 statistically RB I-NP O
5 1112 1123 8424298 significant JJ I-NP O
6 1124 1135 8424298 differences NNS I-NP O
7 1136 1143 8424298 between IN B-PP O
8 1144 1147 8424298 the DT B-NP O
9 1148 1154 8424298 groups NNS I-NP O
10 1155 1157 8424298 in IN B-PP O
11 1158 1161 8424298 any DT B-NP O
12 1162 1164 8424298 of IN B-PP O
13 1165 1168 8424298 the DT B-NP O
14 1169 1174 8424298 tests NNS I-NP O
15 1175 1177 8424298 in IN B-PP O
16 1178 1181 8424298 the DT B-NP O
17 1182 1189 8424298 changes NNS I-NP O
18 1190 1194 8424298 from IN B-PP O
19 1195 1207 8424298 preoperative JJ B-NP O
20 1208 1213 8424298 value NN I-NP O
21 1214 1216 8424298 to TO B-PP O
22 1217 1230 8424298 postoperative JJ B-NP O
23 1231 1236 8424298 value NN I-NP O
24 1236 1237 8424298 . . O O

1 1238 1241 8424298 The DT B-NP O
2 1242 1249 8424298 results NNS I-NP O
3 1250 1258 8424298 indicate VBP B-VP O
4 1259 1263 8424298 that IN B-SBAR O
5 1264 1275 8424298 hypotension NN B-NP D007022
6 1276 1283 8424298 induced VBN B-VP O
7 1284 1286 8424298 by IN B-PP O
8 1287 1296 8424298 labetalol NN B-NP D007741
9 1297 1301 8424298 with IN B-PP O
10 1302 1312 8424298 isoflurane NN B-NP D007530
11 1313 1316 8424298 has VBZ B-VP O
12 1317 1319 8424298 no DT B-NP O
13 1320 1331 8424298 significant JJ I-NP O
14 1332 1339 8424298 harmful JJ I-NP O
15 1340 1347 8424298 effects NNS I-NP O
16 1348 1350 8424298 on IN B-PP O
17 1351 1357 8424298 mental JJ B-NP O
18 1358 1367 8424298 functions NNS I-NP O
19 1368 1376 8424298 compared VBN B-VP O
20 1377 1379 8424298 to TO B-PP O
21 1380 1392 8424298 normotensive JJ B-NP O
22 1393 1404 8424298 anaesthesia NN I-NP O
23 1404 1405 8424298 . . O O

1 0 0 6817363 -DOCSTART- -X- -X- O

1 0 7 6817363 Effects NNS B-NP O
2 8 10 6817363 of IN B-PP O
3 11 14 6817363 the DT B-NP O
4 15 20 6817363 novel JJ I-NP O
5 21 29 6817363 compound NN I-NP O
6 30 40 6817363 aniracetam NN I-NP C036466
7 41 42 6817363 ( ( O O
8 42 44 6817363 Ro NN B-NP C036466
9 45 47 6817363 13 CD I-NP C036466
10 47 48 6817363 - HYPH B-NP C036466
11 48 52 6817363 5057 CD I-NP C036466
12 52 53 6817363 ) ) O O
13 54 58 6817363 upon IN B-PP O
14 59 67 6817363 impaired JJ B-NP D007859
15 68 76 6817363 learning NN I-NP D007859
16 77 80 6817363 and CC I-NP D007859
17 81 87 6817363 memory NN I-NP D007859
18 88 90 6817363 in IN B-PP O
19 91 98 6817363 rodents NNS B-NP O
20 98 99 6817363 . . O O
21 100 103 6817363 The DT B-NP O
22 104 110 6817363 effect NN I-NP O
23 111 113 6817363 of IN B-PP O
24 114 124 6817363 aniracetam NN B-NP C036466
25 125 126 6817363 ( ( O O
26 126 128 6817363 Ro NN B-NP C036466
27 129 131 6817363 13 CD I-NP C036466
28 131 132 6817363 - HYPH B-NP C036466
29 132 136 6817363 5057 CD I-NP C036466
30 136 137 6817363 , , I-NP O
31 138 139 6817363 1 CD I-NP C036466
32 139 140 6817363 - HYPH I-NP C036466
33 140 147 6817363 anisoyl NN I-NP C036466
34 147 148 6817363 - HYPH B-NP C036466
35 148 149 6817363 2 CD I-NP C036466
36 149 150 6817363 - HYPH I-NP C036466
37 150 163 6817363 pyrrolidinone NN I-NP C036466
38 163 164 6817363 ) ) O O
39 165 168 6817363 was VBD B-VP O
40 169 176 6817363 studied VBN I-VP O
41 177 179 6817363 on IN B-PP O
42 180 187 6817363 various JJ B-NP O
43 188 193 6817363 forms NNS I-NP O
44 194 196 6817363 of IN B-PP O
45 197 211 6817363 experimentally RB B-NP O
46 212 220 6817363 impaired JJ I-NP D003072
47 221 230 6817363 cognitive JJ I-NP D003072
48 231 240 6817363 functions NNS I-NP D003072
49 241 242 6817363 ( ( O O
50 242 250 6817363 learning NN B-NP O
51 251 254 6817363 and CC O O
52 255 261 6817363 memory NN B-NP O
53 261 262 6817363 ) ) O O
54 263 265 6817363 in IN B-PP O
55 266 273 6817363 rodents NNS B-NP O
56 274 277 6817363 and CC O O
57 278 286 6817363 produced VBD B-VP O
58 287 290 6817363 the DT B-NP O
59 291 300 6817363 following JJ I-NP O
60 301 308 6817363 effects NNS I-NP O
61 308 309 6817363 : : O O
62 310 311 6817363 ( ( B-LST O
63 311 312 6817363 1 LS I-LST O
64 312 313 6817363 ) ) O O
65 314 320 6817363 almost RB B-NP O
66 321 329 6817363 complete JJ I-NP O
67 330 340 6817363 prevention NN I-NP O
68 341 343 6817363 of IN B-PP O
69 344 347 6817363 the DT B-NP O
70 348 358 6817363 incapacity NN I-NP O
71 359 361 6817363 to TO B-VP O
72 362 367 6817363 learn VB I-VP O
73 368 369 6817363 a DT B-NP O
74 370 378 6817363 discrete JJ I-NP O
75 379 385 6817363 escape NN I-NP O
76 386 394 6817363 response NN I-NP O
77 395 397 6817363 in IN B-PP O
78 398 402 6817363 rats NNS B-NP O
79 403 410 6817363 exposed VBN B-VP O
80 411 413 6817363 to TO B-PP O
81 414 423 6817363 sublethal JJ B-NP O
82 424 435 6817363 hypercapnia NN I-NP D006935
83 436 447 6817363 immediately RB B-ADVP O
84 448 454 6817363 before IN B-PP O
85 455 458 6817363 the DT B-NP O
86 459 470 6817363 acquisition NN I-NP O
87 471 478 6817363 session NN I-NP O
88 478 479 6817363 ; : O O
89 480 481 6817363 ( ( B-LST O
90 481 482 6817363 2 LS I-LST O
91 482 483 6817363 ) ) O O
92 484 491 6817363 partial JJ O O
93 492 493 6817363 ( ( O O
94 493 497 6817363 rats NNS B-NP O
95 497 498 6817363 ) ) O O
96 499 501 6817363 or CC O O
97 502 510 6817363 complete JJ B-ADJP O
98 511 512 6817363 ( ( O O
99 512 516 6817363 mice NNS B-NP O
100 516 517 6817363 ) ) O O
101 518 528 6817363 prevention NN B-NP O
102 529 531 6817363 of IN B-PP O
103 532 535 6817363 the DT B-NP O
104 536 547 6817363 scopolamine NN I-NP D012601
105 547 548 6817363 - HYPH O O
106 548 555 6817363 induced VBN B-NP O
107 556 561 6817363 short JJ I-NP O
108 561 562 6817363 - HYPH I-NP O
109 562 566 6817363 term NN I-NP O
110 567 574 6817363 amnesia NN I-NP D000647
111 575 578 6817363 for IN B-PP O
112 579 580 6817363 a DT B-NP O
113 581 588 6817363 passive JJ I-NP O
114 589 598 6817363 avoidance NN I-NP O
115 599 603 6817363 task NN I-NP O
116 603 604 6817363 ; : O O
117 605 606 6817363 ( ( B-LST O
118 606 607 6817363 3 LS I-LST O
119 607 608 6817363 ) ) O O
120 609 617 6817363 complete JJ B-NP O
121 618 628 6817363 protection NN I-NP O
122 629 636 6817363 against IN B-PP O
123 637 644 6817363 amnesia NN B-NP D000647
124 645 648 6817363 for IN B-PP O
125 649 650 6817363 a DT B-NP O
126 651 658 6817363 passive JJ I-NP O
127 659 668 6817363 avoidance NN I-NP O
128 669 673 6817363 task NN I-NP O
129 674 676 6817363 in IN B-PP O
130 677 681 6817363 rats NNS B-NP O
131 682 691 6817363 submitted VBN B-VP O
132 692 694 6817363 to TO B-PP O
133 695 712 6817363 electroconvulsive JJ B-NP O
134 713 718 6817363 shock NN I-NP O
135 719 730 6817363 immediately RB B-ADVP O
136 731 736 6817363 after IN B-PP O
137 737 746 6817363 avoidance NN B-NP O
138 747 758 6817363 acquisition NN I-NP O
139 758 759 6817363 ; : O O
140 760 761 6817363 ( ( B-LST O
141 761 762 6817363 4 LS I-LST O
142 762 763 6817363 ) ) O O
143 764 774 6817363 prevention NN B-NP O
144 775 777 6817363 of IN B-PP O
145 778 781 6817363 the DT B-NP O
146 782 786 6817363 long JJ I-NP O
147 786 787 6817363 - HYPH I-NP O
148 787 791 6817363 term NN I-NP O
149 792 801 6817363 retention NN I-NP O
150 801 802 6817363 - HYPH B-VP O
151 803 805 6817363 or CC O O
152 806 815 6817363 retrieval NN O O
153 815 816 6817363 - HYPH O O
154 816 823 6817363 deficit NN B-NP O
155 824 827 6817363 for IN B-PP O
156 828 829 6817363 a DT B-NP O
157 830 837 6817363 passive JJ I-NP O
158 838 847 6817363 avoidance NN I-NP O
159 848 852 6817363 task NN I-NP O
160 853 860 6817363 induced VBN B-VP O
161 861 863 6817363 in IN B-PP O
162 864 868 6817363 rats NNS B-NP O
163 869 872 6817363 and CC I-NP O
164 873 877 6817363 mice NNS I-NP O
165 878 880 6817363 by IN B-PP O
166 881 896 6817363 chloramphenicol NN B-NP D002701
167 897 899 6817363 or CC I-NP O
168 900 913 6817363 cycloheximide NN I-NP D003513
169 914 926 6817363 administered VBN B-VP O
170 927 938 6817363 immediately RB B-ADVP O
171 939 944 6817363 after IN B-PP O
172 945 956 6817363 acquisition NN B-NP O
173 956 957 6817363 ; : O O
174 958 959 6817363 ( ( B-LST O
175 959 960 6817363 5 LS I-LST O
176 960 961 6817363 ) ) O O
177 962 970 6817363 reversal NN B-NP O
178 970 971 6817363 , , O O
179 972 976 6817363 when WRB B-ADVP O
180 977 989 6817363 administered VBN B-VP O
181 990 992 6817363 as IN B-PP O
182 993 997 6817363 late RB B-NP O
183 998 1000 6817363 as IN I-NP O
184 1001 1002 6817363 1 CD I-NP O
185 1003 1004 6817363 h NN I-NP O
186 1005 1011 6817363 before IN B-PP O
187 1012 1015 6817363 the DT B-NP O
188 1016 1025 6817363 retention NN I-NP O
189 1026 1030 6817363 test NN I-NP O
190 1030 1031 6817363 , , O O
191 1032 1034 6817363 of IN B-PP O
192 1035 1038 6817363 the DT B-NP O
193 1039 1046 6817363 deficit NN I-NP O
194 1047 1049 6817363 in IN B-PP O
195 1050 1059 6817363 retention NN B-NP O
196 1060 1062 6817363 or CC I-NP O
197 1063 1072 6817363 retrieval NN I-NP O
198 1073 1075 6817363 of IN B-PP O
199 1076 1077 6817363 a DT B-NP O
200 1078 1085 6817363 passive JJ I-NP O
201 1086 1095 6817363 avoidance NN I-NP O
202 1096 1100 6817363 task NN I-NP O
203 1101 1108 6817363 induced VBN B-VP O
204 1109 1111 6817363 by IN B-PP O
205 1112 1125 6817363 cycloheximide NN B-NP D003513
206 1126 1134 6817363 injected VBN B-VP O
207 1135 1136 6817363 2 CD B-NP O
208 1137 1141 6817363 days NNS I-NP O
209 1142 1152 6817363 previously RB B-ADVP O
210 1152 1153 6817363 ; : O O
211 1154 1155 6817363 ( ( O O
212 1155 1156 6817363 6 CD B-NP O
213 1156 1157 6817363 ) ) O O
214 1158 1168 6817363 prevention NN B-NP O
215 1169 1171 6817363 of IN B-PP O
216 1172 1175 6817363 the DT B-NP O
217 1176 1183 6817363 deficit NN I-NP O
218 1184 1186 6817363 in IN B-PP O
219 1187 1190 6817363 the DT B-NP O
220 1191 1200 6817363 retrieval NN I-NP O
221 1201 1203 6817363 of IN B-PP O
222 1204 1206 6817363 an DT B-NP O
223 1207 1213 6817363 active JJ I-NP O
224 1214 1223 6817363 avoidance NN I-NP O
225 1224 1228 6817363 task NN I-NP O
226 1229 1236 6817363 induced VBN B-VP O
227 1237 1239 6817363 in IN B-PP O
228 1240 1244 6817363 mice NNS B-NP O
229 1245 1247 6817363 by IN B-PP O
230 1248 1261 6817363 subconvulsant NN B-NP O
231 1262 1274 6817363 electroshock NN I-NP O
232 1275 1277 6817363 or CC I-NP O
233 1278 1289 6817363 hypercapnia NN I-NP D006935
234 1290 1297 6817363 applied VBN B-VP O
235 1298 1309 6817363 immediately RB B-ADVP O
236 1310 1316 6817363 before IN B-PP O
237 1317 1326 6817363 retrieval NN B-NP O
238 1327 1334 6817363 testing NN I-NP O
239 1335 1336 6817363 ( ( O O
240 1336 1338 6817363 24 CD B-NP O
241 1339 1340 6817363 h NN I-NP O
242 1341 1346 6817363 after IN B-PP O
243 1347 1358 6817363 acquisition NN B-NP O
244 1358 1359 6817363 ) ) O O
245 1359 1360 6817363 . . O O

1 1361 1366 6817363 These DT B-NP O
2 1367 1379 6817363 improvements NNS I-NP O
3 1380 1382 6817363 or CC I-NP O
4 1383 1397 6817363 normalizations NNS I-NP O
5 1398 1400 6817363 of IN B-PP O
6 1401 1409 6817363 impaired JJ B-NP D003072
7 1410 1419 6817363 cognitive JJ I-NP D003072
8 1420 1429 6817363 functions NNS I-NP D003072
9 1430 1434 6817363 were VBD B-VP O
10 1435 1439 6817363 seen VBN I-VP O
11 1440 1442 6817363 at IN B-PP O
12 1443 1447 6817363 oral JJ B-NP O
13 1448 1458 6817363 aniracetam NN I-NP C036466
14 1459 1464 6817363 doses NNS I-NP O
15 1465 1467 6817363 of IN B-PP O
16 1468 1470 6817363 10 CD B-NP O
17 1470 1471 6817363 - HYPH I-NP O
18 1471 1474 6817363 100 CD I-NP O
19 1475 1477 6817363 mg NN I-NP O
20 1477 1478 6817363 / SYM I-NP O
21 1478 1480 6817363 kg NN I-NP O
22 1480 1481 6817363 . . O O

1 1482 1491 6817363 Generally RB B-ADVP O
2 1491 1492 6817363 , , O O
3 1493 1496 6817363 the DT B-NP O
4 1497 1501 6817363 dose NN I-NP O
5 1501 1502 6817363 - HYPH B-NP O
6 1502 1510 6817363 response NN I-NP O
7 1511 1517 6817363 curves NNS I-NP O
8 1518 1522 6817363 were VBD B-VP O
9 1523 1527 6817363 bell NN B-NP O
10 1527 1528 6817363 - HYPH O O
11 1528 1534 6817363 shaped VBN B-VP O
12 1534 1535 6817363 . . O O

1 1536 1539 6817363 The DT B-NP O
2 1540 1550 6817363 mechanisms NNS I-NP O
3 1551 1561 6817363 underlying VBG B-VP O
4 1562 1565 6817363 the DT B-NP O
5 1566 1574 6817363 activity NN I-NP O
6 1575 1577 6817363 of IN B-PP O
7 1578 1588 6817363 aniracetam NN B-NP C036466
8 1589 1592 6817363 and CC O O
9 1593 1596 6817363 its PRP$ B-NP O
10 1597 1598 6817363 ' `` I-NP O
11 1598 1609 6817363 therapeutic JJ I-NP O
12 1610 1616 6817363 window NN I-NP O
13 1616 1617 6817363 ' '' O O
14 1618 1621 6817363 are VBP B-VP O
15 1622 1629 6817363 unknown JJ B-ADJP O
16 1629 1630 6817363 . . O O

1 1631 1640 6817363 Piracetam NNP B-NP D010889
2 1640 1641 6817363 , , O O
3 1642 1649 6817363 another DT B-NP O
4 1650 1663 6817363 pyrrolidinone NN I-NP D011760
5 1664 1674 6817363 derivative NN I-NP O
6 1675 1678 6817363 was VBD B-VP O
7 1679 1683 6817363 used VBN I-VP O
8 1684 1687 6817363 for IN B-PP O
9 1688 1698 6817363 comparison NN B-NP O
10 1698 1699 6817363 . . O O

1 1700 1702 6817363 It PRP B-NP O
2 1703 1706 6817363 was VBD B-VP O
3 1707 1713 6817363 active JJ B-ADJP O
4 1714 1718 6817363 only RB B-PP O
5 1719 1721 6817363 in IN I-PP O
6 1722 1725 6817363 six CD B-NP O
7 1726 1728 6817363 of IN B-PP O
8 1729 1733 6817363 nine CD B-NP O
9 1734 1739 6817363 tests NNS I-NP O
10 1740 1743 6817363 and CC O O
11 1744 1747 6817363 had VBD B-VP O
12 1748 1753 6817363 about RB B-NP O
13 1754 1757 6817363 one CD I-NP O
14 1757 1758 6817363 - HYPH I-NP O
15 1758 1763 6817363 tenth NN I-NP O
16 1764 1767 6817363 the DT B-NP O
17 1768 1775 6817363 potency NN I-NP O
18 1776 1778 6817363 of IN B-PP O
19 1779 1789 6817363 aniracetam NN B-NP C036466
20 1789 1790 6817363 . . O O

1 1791 1794 6817363 The DT B-NP O
2 1795 1802 6817363 results NNS I-NP O
3 1803 1811 6817363 indicate VBP B-VP O
4 1812 1816 6817363 that IN B-SBAR O
5 1817 1827 6817363 aniracetam NN B-NP C036466
6 1828 1836 6817363 improves VBZ B-VP O
7 1837 1846 6817363 cognitive JJ B-NP O
8 1847 1856 6817363 functions NNS I-NP O
9 1857 1862 6817363 which WDT B-NP O
10 1863 1866 6817363 are VBP B-VP O
11 1867 1875 6817363 impaired VBN I-VP O
12 1876 1878 6817363 by IN B-PP O
13 1879 1888 6817363 different JJ B-NP O
14 1889 1898 6817363 procedure NN I-NP O
15 1899 1902 6817363 and CC B-PP O
16 1903 1905 6817363 in IN B-PP O
17 1906 1915 6817363 different JJ B-NP O
18 1916 1922 6817363 phases NNS I-NP O
19 1923 1925 6817363 of IN B-PP O
20 1926 1929 6817363 the DT B-NP O
21 1930 1938 6817363 learning NN I-NP O
22 1939 1942 6817363 and CC I-NP O
23 1943 1949 6817363 memory NN I-NP O
24 1950 1957 6817363 process NN I-NP O
25 1957 1958 6817363 . . O O

1 0 0 11302406 -DOCSTART- -X- -X- O

1 0 11 11302406 Fluconazole NN B-NP D015725
2 11 12 11302406 - HYPH O O
3 12 19 11302406 induced VBN B-VP O
4 20 27 11302406 torsade FW B-NP D016171
5 28 30 11302406 de FW I-NP D016171
6 31 38 11302406 pointes FW I-NP D016171
7 38 39 11302406 . . I-NP O
8 40 49 11302406 OBJECTIVE NN I-NP O
9 49 50 11302406 : : O O
10 51 53 11302406 To TO B-VP O
11 54 61 11302406 present VB I-VP O
12 62 63 11302406 a DT B-NP O
13 64 68 11302406 case NN I-NP O
14 69 71 11302406 of IN B-PP O
15 72 83 11302406 fluconazole NN B-NP D015725
16 83 84 11302406 - HYPH O O
17 84 94 11302406 associated VBN B-VP O
18 95 102 11302406 torsade FW B-NP D016171
19 103 105 11302406 de FW I-NP D016171
20 106 113 11302406 pointes FW I-NP D016171
21 114 115 11302406 ( ( O O
22 115 118 11302406 TDP NN B-NP D016171
23 118 119 11302406 ) ) O O
24 120 123 11302406 and CC O O
25 124 131 11302406 discuss NN B-NP O
26 132 145 11302406 fluconazole's NNS I-NP D015725
27 146 150 11302406 role NN I-NP O
28 151 153 11302406 in IN B-PP O
29 154 161 11302406 causing VBG B-VP O
30 162 165 11302406 TDP NN B-NP D016171
31 165 166 11302406 . . O O

1 167 171 11302406 CASE NN B-NP O
2 172 179 11302406 SUMMARY NN I-NP O
3 179 180 11302406 : : O O
4 181 182 11302406 A DT B-NP O
5 183 185 11302406 68 CD I-NP O
6 185 186 11302406 - HYPH I-NP O
7 186 190 11302406 year NN I-NP O
8 190 191 11302406 - HYPH B-NP O
9 191 194 11302406 old JJ I-NP O
10 195 200 11302406 white JJ I-NP O
11 201 206 11302406 woman NN I-NP O
12 207 211 11302406 with IN B-PP O
13 212 219 11302406 Candida NNP B-NP O
14 220 228 11302406 glabrata NNS I-NP O
15 229 237 11302406 isolated VBN B-VP O
16 238 242 11302406 from IN B-PP O
17 243 244 11302406 a DT B-NP O
18 245 254 11302406 presacral JJ I-NP O
19 255 262 11302406 abscess NN I-NP O
20 263 272 11302406 developed VBD B-VP O
21 273 276 11302406 TDP NN B-NP D016171
22 277 282 11302406 eight CD B-NP O
23 283 287 11302406 days NNS I-NP O
24 288 293 11302406 after IN B-PP O
25 294 304 11302406 commencing VBG B-VP O
26 305 309 11302406 oral JJ B-NP O
27 310 321 11302406 fluconazole NN I-NP D015725
28 322 325 11302406 The DT B-NP O
29 326 333 11302406 patient NN I-NP O
30 334 337 11302406 had VBD B-VP O
31 338 340 11302406 no DT B-NP O
32 341 346 11302406 other JJ I-NP O
33 347 351 11302406 risk NN I-NP O
34 352 359 11302406 factors NNS I-NP O
35 360 363 11302406 for IN B-PP O
36 364 367 11302406 TDP NN B-NP D016171
37 367 368 11302406 , , O O
38 369 378 11302406 including VBG B-PP O
39 379 387 11302406 coronary JJ B-NP D003324
40 388 394 11302406 artery NN I-NP D003324
41 395 402 11302406 disease NN I-NP D003324
42 402 403 11302406 , , O O
43 404 418 11302406 cardiomyopathy NN B-NP D009202
44 418 419 11302406 , , O O
45 420 430 11302406 congestive JJ B-NP D006333
46 431 436 11302406 heart NN I-NP D006333
47 437 444 11302406 failure NN I-NP D006333
48 444 445 11302406 , , O O
49 446 449 11302406 and CC O O
50 450 461 11302406 electrolyte NN B-NP O
51 462 475 11302406 abnormalities NNS I-NP O
52 476 481 11302406 There EX B-NP O
53 482 485 11302406 was VBD B-VP O
54 486 487 11302406 a DT B-NP O
55 488 496 11302406 temporal JJ I-NP O
56 497 508 11302406 association NN I-NP O
57 509 516 11302406 between IN B-PP O
58 517 520 11302406 the DT B-NP O
59 521 531 11302406 initiation NN I-NP O
60 532 534 11302406 of IN B-PP O
61 535 546 11302406 fluconazole NN B-NP D015725
62 547 550 11302406 and CC I-NP O
63 551 554 11302406 TDP NN I-NP D016171
64 554 555 11302406 . . O O

1 556 559 11302406 The DT B-NP O
2 560 563 11302406 TDP NN I-NP D016171
3 564 572 11302406 resolved VBN B-VP O
4 573 577 11302406 when WRB B-ADVP O
5 578 589 11302406 fluconazole NN B-NP D015725
6 590 593 11302406 was VBD B-VP O
7 594 606 11302406 discontinued VBN I-VP O
8 606 607 11302406 ; : O O
9 608 615 11302406 however RB B-ADVP O
10 615 616 11302406 , , O O
11 617 620 11302406 the DT B-NP O
12 621 628 11302406 patient NN I-NP O
13 629 638 11302406 continued VBD B-VP O
14 639 641 11302406 to TO I-VP O
15 642 646 11302406 have VB I-VP O
16 647 656 11302406 premature JJ B-NP D018879
17 657 668 11302406 ventricular JJ I-NP D018879
18 669 681 11302406 contractions NNS I-NP D018879
19 682 685 11302406 and CC O O
20 686 698 11302406 nonsustained JJ B-NP O
21 699 710 11302406 ventricular JJ I-NP D017180
22 711 722 11302406 tachycardia NN I-NP D017180
23 723 724 11302406 ( ( O O
24 724 728 11302406 NSVT NN B-NP D017180
25 728 729 11302406 ) ) O O
26 730 735 11302406 until IN B-PP O
27 736 739 11302406 six CD B-NP O
28 740 744 11302406 days NNS I-NP O
29 745 750 11302406 after IN B-PP O
30 751 755 11302406 drug NN B-NP O
31 756 765 11302406 cessation NN I-NP O
32 766 776 11302406 DISCUSSION NN I-NP O
33 776 777 11302406 : : O O
34 778 781 11302406 Use NN B-NP O
35 782 784 11302406 of IN B-PP O
36 785 788 11302406 the DT B-NP O
37 789 796 11302406 Naranjo NNP I-NP O
38 797 808 11302406 probability NN I-NP O
39 809 814 11302406 scale NN I-NP O
40 815 824 11302406 indicates VBZ B-VP O
41 825 826 11302406 a DT B-NP O
42 827 835 11302406 probable JJ I-NP O
43 836 848 11302406 relationship NN I-NP O
44 849 856 11302406 between IN B-PP O
45 857 860 11302406 the DT B-NP O
46 861 864 11302406 use NN I-NP O
47 865 867 11302406 of IN B-PP O
48 868 879 11302406 fluconazole NN B-NP D015725
49 880 883 11302406 and CC O O
50 884 887 11302406 the DT B-NP O
51 888 899 11302406 development NN I-NP O
52 900 902 11302406 of IN B-PP O
53 903 906 11302406 TDP NN B-NP D016171
54 906 907 11302406 . . O O

1 908 911 11302406 The DT B-NP O
2 912 920 11302406 possible JJ I-NP O
3 921 930 11302406 mechanism NN I-NP O
4 931 933 11302406 is VBZ B-VP O
5 934 944 11302406 depression NN B-NP D003866
6 945 947 11302406 of IN B-PP O
7 948 955 11302406 rapidly RB B-VP O
8 956 966 11302406 activating VBG I-VP O
9 967 974 11302406 delayed VBN I-VP O
10 975 984 11302406 rectifier JJR B-NP O
11 985 994 11302406 potassium NN I-NP D011188
12 995 1003 11302406 currents NNS I-NP O
13 1003 1004 11302406 . . O O

1 1005 1007 11302406 In IN B-PP O
2 1008 1011 11302406 our PRP$ B-NP O
3 1012 1019 11302406 patient NN I-NP O
4 1019 1020 11302406 , , O O
5 1021 1026 11302406 there EX B-NP O
6 1027 1030 11302406 was VBD B-VP O
7 1031 1033 11302406 no DT B-NP O
8 1034 1039 11302406 other JJ I-NP O
9 1040 1048 11302406 etiology NN I-NP O
10 1049 1059 11302406 identified VBD B-VP O
11 1060 1064 11302406 that WDT B-NP O
12 1065 1070 11302406 could MD B-VP O
13 1071 1078 11302406 explain VB I-VP O
14 1079 1081 11302406 QT NN B-NP D008133
15 1082 1094 11302406 prolongation NN I-NP D008133
16 1095 1097 11302406 or CC O O
17 1098 1101 11302406 TDP NN B-NP D016171
18 1102 1105 11302406 The DT B-NP O
19 1106 1114 11302406 complete JJ I-NP O
20 1115 1128 11302406 disappearance NN I-NP O
21 1129 1131 11302406 of IN B-PP O
22 1132 1136 11302406 NSVT NN B-NP D017180
23 1137 1140 11302406 and CC O O
24 1141 1150 11302406 premature JJ B-NP D018879
25 1151 1162 11302406 ventricular JJ I-NP D018879
26 1163 1175 11302406 contractions NNS I-NP D018879
27 1176 1184 11302406 followed VBN B-VP O
28 1185 1187 11302406 by IN B-PP O
29 1188 1201 11302406 normalization NN B-NP O
30 1202 1204 11302406 of IN B-PP O
31 1205 1207 11302406 QT NN B-NP O
32 1208 1216 11302406 interval NN I-NP O
33 1217 1222 11302406 after IN B-PP O
34 1223 1226 11302406 the DT B-NP O
35 1227 1231 11302406 drug NN I-NP O
36 1232 1235 11302406 was VBD B-VP O
37 1236 1243 11302406 stopped VBN I-VP O
38 1244 1252 11302406 strongly RB B-ADVP O
39 1253 1261 11302406 suggests VBZ B-VP O
40 1262 1273 11302406 fluconazole NN B-NP D015725
41 1274 1276 11302406 as IN B-SBAR O
42 1277 1280 11302406 the DT B-NP O
43 1281 1289 11302406 etiology NN I-NP O
44 1289 1290 11302406 . . O O

1 1291 1302 11302406 CONCLUSIONS NNS B-NP O
2 1302 1303 11302406 : : O O
3 1304 1314 11302406 Clinicians NNS B-NP O
4 1315 1321 11302406 should MD B-VP O
5 1322 1324 11302406 be VB I-VP O
6 1325 1330 11302406 aware JJ B-ADJP O
7 1331 1335 11302406 that IN B-SBAR O
8 1336 1347 11302406 fluconazole NN B-NP D015725
9 1347 1348 11302406 , , O O
10 1349 1353 11302406 even RB B-ADVP O
11 1354 1356 11302406 at IN B-PP O
12 1357 1360 11302406 low JJ B-NP O
13 1361 1366 11302406 doses NNS I-NP O
14 1366 1367 11302406 , , O O
15 1368 1371 11302406 may MD B-VP O
16 1372 1377 11302406 cause VB I-VP O
17 1378 1390 11302406 prolongation NN B-NP D008133
18 1391 1393 11302406 of IN B-PP D008133
19 1394 1397 11302406 the DT B-NP D008133
20 1398 1400 11302406 QT NN I-NP D008133
21 1401 1409 11302406 interval NN I-NP D008133
22 1409 1410 11302406 , , O O
23 1411 1418 11302406 leading VBG B-VP O
24 1419 1421 11302406 to TO B-PP O
25 1422 1425 11302406 TDP NN B-NP D016171
26 1425 1426 11302406 . . O O

1 1427 1433 11302406 Serial JJ B-NP O
2 1434 1454 11302406 electrocardiographic JJ I-NP O
3 1455 1465 11302406 monitoring NN I-NP O
4 1466 1469 11302406 may MD B-VP O
5 1470 1472 11302406 be VB I-VP O
6 1473 1483 11302406 considered VBN I-VP O
7 1484 1488 11302406 when WRB B-ADVP O
8 1489 1500 11302406 fluconazole NN B-NP D015725
9 1501 1503 11302406 is VBZ B-VP O
10 1504 1516 11302406 administered VBN I-VP O
11 1517 1519 11302406 in IN B-PP O
12 1520 1528 11302406 patients NNS B-NP O
13 1529 1532 11302406 who WP B-NP O
14 1533 1536 11302406 are VBP B-VP O
15 1537 1539 11302406 at IN B-PP O
16 1540 1544 11302406 risk NN B-NP O
17 1545 1548 11302406 for IN B-PP O
18 1549 1560 11302406 ventricular JJ B-NP D001145
19 1561 1572 11302406 arrhythmias NNS I-NP D001145
20 1572 1573 11302406 . . O O

1 0 0 10565806 -DOCSTART- -X- -X- O

1 0 9 10565806 Hypomania NN B-NP D001714
2 9 10 10565806 - HYPH I-NP O
3 10 14 10565806 like JJ I-NP O
4 15 23 10565806 syndrome NN I-NP O
5 24 31 10565806 induced VBN B-VP O
6 32 34 10565806 by IN B-PP O
7 35 45 10565806 olanzapine NN B-NP C076029
8 45 46 10565806 . . O O
9 47 49 10565806 We PRP B-NP O
10 50 56 10565806 report VBP B-VP O
11 57 58 10565806 a DT B-NP O
12 59 65 10565806 female JJ I-NP O
13 66 73 10565806 patient NN I-NP O
14 74 78 10565806 with IN B-PP O
15 79 80 10565806 a DT B-NP O
16 81 90 10565806 diagnosis NN I-NP O
17 91 93 10565806 of IN B-PP O
18 94 95 10565806 a DT O O
19 96 99 10565806 not RB O O
20 100 109 10565806 otherwise RB B-ADVP O
21 110 119 10565806 specified VBD B-VP O
22 120 129 10565806 psychotic JJ B-NP D011618
23 130 138 10565806 disorder NN I-NP D011618
24 139 140 10565806 ( ( O O
25 140 143 10565806 DSM NN B-NP O
26 143 144 10565806 - HYPH B-NP O
27 144 146 10565806 IV CD I-NP O
28 146 147 10565806 ) ) O O
29 148 151 10565806 who WP B-NP O
30 152 161 10565806 developed VBD B-VP O
31 162 171 10565806 hypomania NN B-NP D001714
32 172 179 10565806 shortly RB B-ADVP O
33 180 185 10565806 after IN B-PP O
34 186 189 10565806 the DT B-NP O
35 190 202 10565806 introduction NN I-NP O
36 203 205 10565806 of IN B-PP O
37 206 216 10565806 olanzapine NN B-NP C076029
38 217 226 10565806 treatment NN I-NP O
39 226 227 10565806 . . O O

1 0 0 12842176 -DOCSTART- -X- -X- O

1 0 6 12842176 Effect NN B-NP O
2 7 9 12842176 of IN B-PP O
3 10 17 12842176 lindane NN B-NP D001556
4 18 20 12842176 on IN B-PP O
5 21 28 12842176 hepatic JJ B-NP O
6 29 32 12842176 and CC I-NP O
7 33 38 12842176 brain NN I-NP O
8 39 49 12842176 cytochrome NN I-NP O
9 50 55 12842176 P450s NNS I-NP O
10 56 59 12842176 and CC I-NP O
11 60 69 12842176 influence NN I-NP O
12 70 72 12842176 of IN B-PP O
13 73 77 12842176 P450 NN B-NP O
14 78 88 12842176 modulation NN I-NP O
15 89 91 12842176 in IN B-PP O
16 92 99 12842176 lindane NN B-NP D001556
17 100 107 12842176 induced JJ I-NP O
18 108 121 12842176 neurotoxicity NN I-NP D020258
19 121 122 12842176 . . O O
20 123 127 12842176 Oral JJ B-NP O
21 128 142 12842176 administration NN I-NP O
22 143 145 12842176 of IN B-PP O
23 146 153 12842176 lindane NN B-NP D001556
24 154 155 12842176 ( ( O O
25 155 158 12842176 2.5 CD B-NP O
26 158 159 12842176 , , I-NP O
27 160 161 12842176 5 CD I-NP O
28 161 162 12842176 , , I-NP O
29 163 165 12842176 10 CD I-NP O
30 166 169 12842176 and CC I-NP O
31 170 172 12842176 15 CD I-NP O
32 173 175 12842176 mg NN I-NP O
33 175 176 12842176 / SYM I-NP O
34 176 178 12842176 kg NN I-NP O
35 178 179 12842176 , , O O
36 180 184 12842176 body NN B-NP O
37 185 191 12842176 weight NN I-NP O
38 191 192 12842176 ) ) O O
39 193 196 12842176 for IN B-PP O
40 197 198 12842176 5 CD B-NP O
41 199 203 12842176 days NNS I-NP O
42 204 207 12842176 was VBD B-VP O
43 208 213 12842176 found VBN I-VP O
44 214 216 12842176 to TO I-VP O
45 217 224 12842176 produce VB I-VP O
46 225 226 12842176 a DT B-NP O
47 227 231 12842176 dose NN I-NP O
48 231 232 12842176 - HYPH B-NP O
49 232 241 12842176 dependent JJ I-NP O
50 242 250 12842176 increase NN I-NP O
51 251 253 12842176 in IN B-PP O
52 254 257 12842176 the DT B-NP O
53 258 266 12842176 activity NN I-NP O
54 267 269 12842176 of IN B-PP O
55 270 274 12842176 P450 NN B-NP O
56 275 284 12842176 dependent JJ B-NP O
57 285 286 12842176 7 CD I-NP O
58 286 287 12842176 - HYPH I-NP O
59 287 302 12842176 ethoxyresorufin NN I-NP O
60 302 303 12842176 - HYPH B-NP O
61 303 304 12842176 O NN I-NP O
62 304 305 12842176 - HYPH O O
63 305 315 12842176 deethylase NN B-NP O
64 316 317 12842176 ( ( O O
65 317 321 12842176 EROD NN B-NP O
66 321 322 12842176 ) ) O O
67 322 323 12842176 , , O O
68 324 325 12842176 7 CD B-NP O
69 325 326 12842176 - HYPH I-NP O
70 326 342 12842176 pentoxyresorufin NN I-NP O
71 342 343 12842176 - HYPH B-NP O
72 343 344 12842176 O NN I-NP O
73 344 345 12842176 - HYPH O O
74 345 355 12842176 dealkylase NN B-NP O
75 356 357 12842176 ( ( O O
76 357 361 12842176 PROD NN B-NP O
77 361 362 12842176 ) ) O O
78 363 366 12842176 and CC O O
79 367 368 12842176 N NN B-NP D004128
80 368 369 12842176 - HYPH O D004128
81 369 389 12842176 nitrosodimethylamine NN B-NP D004128
82 390 401 12842176 demethylase NN I-NP O
83 402 403 12842176 ( ( O O
84 403 407 12842176 NDMA NN B-NP D004128
85 407 408 12842176 - HYPH B-NP O
86 408 409 12842176 d NN I-NP O
87 409 410 12842176 ) ) O O
88 411 413 12842176 in IN B-PP O
89 414 417 12842176 rat NN B-NP O
90 418 423 12842176 brain NN I-NP O
91 424 427 12842176 and CC I-NP O
92 428 433 12842176 liver NN I-NP O
93 433 434 12842176 . . O O

1 435 436 12842176 A DT B-NP O
2 437 448 12842176 significant JJ I-NP O
3 449 457 12842176 increase NN I-NP O
4 458 460 12842176 in IN B-PP O
5 461 464 12842176 the DT B-NP O
6 465 472 12842176 hepatic JJ I-NP O
7 473 476 12842176 and CC I-NP O
8 477 482 12842176 brain NN I-NP O
9 483 487 12842176 P450 NN I-NP O
10 488 502 12842176 monooxygenases NNS I-NP O
11 503 506 12842176 was VBD B-VP O
12 507 511 12842176 also RB I-VP O
13 512 520 12842176 observed VBN I-VP O
14 521 525 12842176 when WRB B-ADVP O
15 526 529 12842176 the DT B-NP O
16 530 538 12842176 duration NN I-NP O
17 539 541 12842176 of IN B-PP O
18 542 550 12842176 exposure NN B-NP O
19 551 553 12842176 of IN B-PP O
20 554 557 12842176 low JJ B-NP O
21 558 562 12842176 dose NN I-NP O
22 563 564 12842176 ( ( O O
23 564 567 12842176 2.5 CD B-NP O
24 568 570 12842176 mg NN I-NP O
25 570 571 12842176 / SYM B-NP O
26 571 573 12842176 kg NN I-NP O
27 573 574 12842176 ) ) O O
28 575 577 12842176 of IN B-PP O
29 578 585 12842176 lindane NN B-NP D001556
30 586 589 12842176 was VBD B-VP O
31 590 599 12842176 increased VBN I-VP O
32 600 604 12842176 from IN B-PP O
33 605 606 12842176 5 CD B-NP O
34 607 611 12842176 days NNS I-NP O
35 612 614 12842176 to TO B-PP O
36 615 617 12842176 15 CD B-NP O
37 618 620 12842176 or CC I-NP O
38 621 623 12842176 21 CD I-NP O
39 624 628 12842176 days NNS I-NP O
40 628 629 12842176 . . O O

1 630 632 12842176 As IN B-SBAR O
2 633 641 12842176 observed VBN B-VP O
3 642 646 12842176 with IN B-PP O
4 647 656 12842176 different JJ B-NP O
5 657 662 12842176 doses NNS I-NP O
6 662 663 12842176 , , O O
7 664 667 12842176 the DT B-NP O
8 668 677 12842176 magnitude NN I-NP O
9 678 680 12842176 of IN B-PP O
10 681 690 12842176 induction NN B-NP O
11 691 693 12842176 in IN B-PP O
12 694 697 12842176 the DT B-NP O
13 698 706 12842176 activity NN I-NP O
14 707 709 12842176 of IN B-PP O
15 710 714 12842176 P450 NN B-NP O
16 715 729 12842176 monooxygenases NNS I-NP O
17 730 733 12842176 was VBD B-VP O
18 734 741 12842176 several JJ B-ADJP O
19 742 746 12842176 fold RB B-ADJP O
20 747 753 12842176 higher JJR I-ADJP O
21 754 756 12842176 in IN B-PP O
22 757 762 12842176 liver NN B-NP O
23 763 773 12842176 microsomes NNS I-NP O
24 774 778 12842176 when WRB B-ADVP O
25 779 787 12842176 compared VBN B-PP O
26 788 792 12842176 with IN B-PP O
27 793 796 12842176 the DT B-NP O
28 797 802 12842176 brain NN I-NP O
29 802 803 12842176 . . O O

1 804 811 12842176 Western NN B-NP O
2 812 820 12842176 blotting NN I-NP O
3 821 828 12842176 studies NNS I-NP O
4 829 833 12842176 have VBP B-VP O
5 834 843 12842176 indicated VBN I-VP O
6 844 848 12842176 that IN B-SBAR O
7 849 852 12842176 the DT B-NP O
8 853 861 12842176 increase NN I-NP O
9 862 864 12842176 in IN B-PP O
10 865 868 12842176 the DT B-NP O
11 869 873 12842176 P450 NN I-NP O
12 874 881 12842176 enzymes NNS I-NP O
13 882 887 12842176 could MD B-VP O
14 888 890 12842176 be VB I-VP O
15 891 894 12842176 due JJ B-ADJP O
16 895 897 12842176 to TO B-PP O
17 898 901 12842176 the DT B-NP O
18 902 910 12842176 increase NN I-NP O
19 911 913 12842176 in IN B-PP O
20 914 917 12842176 the DT B-NP O
21 918 928 12842176 expression NN I-NP O
22 929 931 12842176 of IN B-PP O
23 932 936 12842176 P450 NN B-NP O
24 937 940 12842176 1A1 NN I-NP O
25 940 941 12842176 / SYM B-NP O
26 941 944 12842176 1A2 NN I-NP O
27 944 945 12842176 , , O O
28 946 949 12842176 2B1 NN B-NP O
29 949 950 12842176 / SYM B-NP O
30 950 953 12842176 2B2 NN I-NP O
31 954 957 12842176 and CC I-NP O
32 958 961 12842176 2E1 NN I-NP O
33 962 972 12842176 isoenzymes NNS I-NP O
34 972 973 12842176 . . O O

1 974 976 12842176 In FW B-NP O
2 977 982 12842176 vitro FW I-NP O
3 983 990 12842176 studies NNS I-NP O
4 991 996 12842176 using VBG B-VP O
5 997 1004 12842176 organic JJ B-NP O
6 1005 1015 12842176 inhibitors NNS I-NP O
7 1016 1024 12842176 specific JJ B-ADJP O
8 1025 1028 12842176 for IN B-PP O
9 1029 1039 12842176 individual JJ B-NP O
10 1040 1044 12842176 P450 NN I-NP O
11 1045 1055 12842176 isoenzymes NNS I-NP O
12 1056 1059 12842176 and CC O O
13 1060 1068 12842176 antibody NN B-NP O
14 1069 1079 12842176 inhibition NN I-NP O
15 1080 1091 12842176 experiments NNS I-NP O
16 1092 1096 12842176 have VBP B-VP O
17 1097 1104 12842176 further RBR I-VP O
18 1105 1117 12842176 demonstrated VBN I-VP O
19 1118 1122 12842176 that IN B-SBAR O
20 1123 1126 12842176 the DT B-NP O
21 1127 1135 12842176 increase NN I-NP O
22 1136 1138 12842176 in IN B-PP O
23 1139 1142 12842176 the DT B-NP O
24 1143 1151 12842176 activity NN I-NP O
25 1152 1154 12842176 of IN B-PP O
26 1155 1159 12842176 PROD NN B-NP O
27 1159 1160 12842176 , , I-NP O
28 1161 1165 12842176 EROD NN I-NP O
29 1166 1169 12842176 and CC I-NP O
30 1170 1174 12842176 NDMA NN I-NP D004128
31 1174 1175 12842176 - HYPH B-NP O
32 1175 1176 12842176 d NN I-NP O
33 1177 1180 12842176 are VBP B-VP O
34 1181 1184 12842176 due JJ B-ADJP O
35 1185 1187 12842176 to TO B-PP O
36 1188 1191 12842176 the DT B-NP O
37 1192 1200 12842176 increase NN I-NP O
38 1201 1203 12842176 in IN B-PP O
39 1204 1207 12842176 the DT B-NP O
40 1208 1214 12842176 levels NNS I-NP O
41 1215 1217 12842176 of IN B-PP O
42 1218 1222 12842176 P450 NN B-NP O
43 1223 1226 12842176 2B1 NN I-NP O
44 1226 1227 12842176 / SYM B-NP O
45 1227 1230 12842176 2B2 NN I-NP O
46 1230 1231 12842176 , , O O
47 1232 1235 12842176 1A1 NN B-NP O
48 1235 1236 12842176 / SYM B-NP O
49 1236 1239 12842176 1A2 NN I-NP O
50 1240 1243 12842176 and CC I-NP O
51 1244 1247 12842176 2E1 NN I-NP O
52 1248 1258 12842176 isoenzymes NNS I-NP O
53 1258 1259 12842176 , , O O
54 1260 1272 12842176 respectively RB B-ADVP O
55 1272 1273 12842176 . . O O

1 1274 1283 12842176 Induction NN B-NP O
2 1284 1291 12842176 studies NNS I-NP O
3 1292 1296 12842176 have VBP B-VP O
4 1297 1304 12842176 further RBR I-VP O
5 1305 1310 12842176 shown VBN I-VP O
6 1311 1315 12842176 that IN B-SBAR O
7 1316 1321 12842176 while IN B-SBAR O
8 1322 1334 12842176 pretreatment NN B-NP O
9 1335 1337 12842176 of IN B-PP O
10 1338 1339 12842176 3 CD B-NP D008748
11 1339 1340 12842176 - HYPH I-NP D008748
12 1340 1358 12842176 methylcholanthrene NN I-NP D008748
13 1359 1360 12842176 ( ( O O
14 1360 1362 12842176 MC NN B-NP D008748
15 1362 1363 12842176 ) ) O O
16 1363 1364 12842176 , , O O
17 1365 1367 12842176 an DT B-NP O
18 1368 1375 12842176 inducer NN I-NP O
19 1376 1378 12842176 of IN B-PP O
20 1379 1386 12842176 P4501A1 NN B-NP O
21 1386 1387 12842176 / SYM O O
22 1387 1390 12842176 1A2 NN B-NP O
23 1390 1391 12842176 , , O O
24 1392 1395 12842176 did VBD B-VP O
25 1396 1399 12842176 not RB I-VP O
26 1400 1407 12842176 produce VB I-VP O
27 1408 1411 12842176 any DT B-NP O
28 1412 1423 12842176 significant JJ I-NP O
29 1424 1430 12842176 effect NN I-NP O
30 1431 1433 12842176 in IN B-PP O
31 1434 1437 12842176 the DT B-NP O
32 1438 1447 12842176 incidence NN I-NP O
33 1448 1450 12842176 of IN B-PP O
34 1451 1458 12842176 lindane NN B-NP D001556
35 1459 1466 12842176 induced VBN I-NP O
36 1467 1478 12842176 convulsions NNS I-NP D012640
37 1478 1479 12842176 , , O O
38 1480 1492 12842176 pretreatment NN B-NP O
39 1493 1497 12842176 with IN B-PP O
40 1498 1511 12842176 phenobarbital NN B-NP D010634
41 1512 1513 12842176 ( ( O O
42 1513 1515 12842176 PB NN B-NP O
43 1515 1516 12842176 ) ) O O
44 1516 1517 12842176 , , O O
45 1518 1520 12842176 an DT B-NP O
46 1521 1528 12842176 inducer NN I-NP O
47 1529 1531 12842176 of IN B-PP O
48 1532 1536 12842176 P450 NN B-NP O
49 1537 1540 12842176 2B1 NN I-NP O
50 1540 1541 12842176 / SYM B-VP O
51 1541 1544 12842176 2B2 NN B-NP O
52 1545 1547 12842176 or CC I-NP O
53 1548 1555 12842176 ethanol NN I-NP D000431
54 1555 1556 12842176 , , O O
55 1557 1559 12842176 an DT B-NP O
56 1560 1567 12842176 inducer NN I-NP O
57 1568 1570 12842176 of IN B-PP O
58 1571 1575 12842176 P450 NN B-NP O
59 1576 1579 12842176 2E1 NN I-NP O
60 1580 1589 12842176 catalysed VBD B-VP O
61 1590 1599 12842176 reactions NNS B-NP O
62 1599 1600 12842176 , , O O
63 1601 1614 12842176 significantly RB B-VP O
64 1615 1624 12842176 increased VBD I-VP O
65 1625 1628 12842176 the DT B-NP O
66 1629 1638 12842176 incidence NN I-NP O
67 1639 1641 12842176 of IN B-PP O
68 1642 1649 12842176 lindane NN B-NP D001556
69 1650 1657 12842176 induced VBN I-NP O
70 1658 1669 12842176 convulsions NNS I-NP D012640
71 1669 1670 12842176 . . O O

1 1671 1680 12842176 Similarly RB B-ADVP O
2 1680 1681 12842176 , , O O
3 1682 1686 12842176 when WRB B-ADVP O
4 1687 1690 12842176 the DT B-NP O
5 1691 1695 12842176 P450 NN I-NP O
6 1695 1696 12842176 - HYPH B-VP O
7 1696 1704 12842176 mediated VBN B-NP O
8 1705 1715 12842176 metabolism NN I-NP O
9 1716 1718 12842176 of IN B-PP O
10 1719 1726 12842176 lindane NN B-NP D001556
11 1727 1730 12842176 was VBD B-VP O
12 1731 1738 12842176 blocked VBN I-VP O
13 1739 1741 12842176 by IN B-PP O
14 1742 1748 12842176 cobalt NN B-NP C018021
15 1749 1757 12842176 chloride NN I-NP C018021
16 1758 1767 12842176 incidence NN I-NP O
17 1768 1770 12842176 of IN B-PP O
18 1771 1782 12842176 convulsions NNS B-NP D012640
19 1783 1786 12842176 was VBD B-VP O
20 1787 1796 12842176 increased VBN I-VP O
21 1797 1799 12842176 in IN B-PP O
22 1800 1807 12842176 animals NNS B-NP O
23 1808 1815 12842176 treated VBN B-VP O
24 1816 1820 12842176 with IN B-PP O
25 1821 1828 12842176 lindane NN B-NP D001556
26 1829 1839 12842176 indicating VBG B-VP O
27 1840 1844 12842176 that IN B-SBAR O
28 1845 1852 12842176 lindane NN B-NP D001556
29 1853 1856 12842176 per FW B-ADVP O
30 1857 1859 12842176 se FW I-ADVP O
31 1860 1862 12842176 or CC O O
32 1863 1866 12842176 its PRP$ B-NP O
33 1867 1878 12842176 metabolites NNS I-NP O
34 1879 1885 12842176 formed VBN B-VP O
35 1886 1888 12842176 by IN B-PP O
36 1889 1891 12842176 PB NN B-NP O
37 1892 1894 12842176 or CC I-NP O
38 1895 1902 12842176 ethanol NN I-NP D000431
39 1903 1912 12842176 inducible JJ I-NP O
40 1913 1917 12842176 P450 NN I-NP O
41 1918 1928 12842176 isoenzymes NNS I-NP O
42 1929 1932 12842176 are VBP B-VP O
43 1933 1941 12842176 involved VBN I-VP O
44 1942 1944 12842176 in IN B-PP O
45 1945 1948 12842176 its PRP$ B-NP O
46 1949 1964 12842176 neurobehavioral JJ I-NP O
47 1965 1973 12842176 toxicity NN I-NP D064420
48 1973 1974 12842176 . . O O

1 0 0 2790457 -DOCSTART- -X- -X- O

1 0 7 2790457 Chronic JJ B-NP O
2 8 21 2790457 carbamazepine NN I-NP D002220
3 22 30 2790457 inhibits VBZ B-VP O
4 31 34 2790457 the DT B-NP O
5 35 46 2790457 development NN I-NP O
6 47 49 2790457 of IN B-PP O
7 50 55 2790457 local JJ B-NP O
8 56 66 2790457 anesthetic JJ I-NP O
9 67 75 2790457 seizures NNS I-NP D012640
10 76 83 2790457 kindled VBN B-VP O
11 84 86 2790457 by IN B-PP O
12 87 94 2790457 cocaine NN B-NP D003042
13 95 98 2790457 and CC I-NP O
14 99 108 2790457 lidocaine NN I-NP D008012
15 108 109 2790457 . . O O
16 110 113 2790457 The DT B-NP O
17 114 121 2790457 effects NNS I-NP O
18 122 124 2790457 of IN B-PP O
19 125 138 2790457 carbamazepine NN B-NP D002220
20 139 140 2790457 ( ( O O
21 140 143 2790457 CBZ NN B-NP D002220
22 143 144 2790457 ) ) O O
23 145 154 2790457 treatment NN B-NP O
24 155 157 2790457 on IN B-PP O
25 158 163 2790457 local JJ B-NP O
26 164 174 2790457 anesthetic JJ I-NP O
27 174 175 2790457 - HYPH I-NP O
28 175 182 2790457 kindled VBN I-NP O
29 183 191 2790457 seizures NNS I-NP D012640
30 192 195 2790457 and CC I-NP O
31 196 205 2790457 lethality NN I-NP O
32 206 210 2790457 were VBD B-VP O
33 211 220 2790457 evaluated VBN I-VP O
34 221 223 2790457 in IN B-PP O
35 224 233 2790457 different JJ B-NP O
36 234 240 2790457 stages NNS I-NP O
37 241 243 2790457 of IN B-PP O
38 244 247 2790457 the DT B-NP O
39 248 256 2790457 kindling NN I-NP O
40 257 264 2790457 process NN I-NP O
41 265 268 2790457 and CC B-PP O
42 269 274 2790457 under IN B-PP O
43 275 284 2790457 different JJ B-NP O
44 285 292 2790457 methods NNS I-NP O
45 293 295 2790457 of IN B-PP O
46 296 299 2790457 CBZ NN B-NP D002220
47 300 314 2790457 administration NN I-NP O
48 314 315 2790457 . . O O

1 316 323 2790457 Chronic JJ B-NP O
2 324 328 2790457 oral JJ I-NP O
3 329 332 2790457 CBZ NN I-NP D002220
4 333 342 2790457 inhibited VBD B-VP O
5 343 346 2790457 the DT B-NP O
6 347 358 2790457 development NN I-NP O
7 359 361 2790457 of IN B-PP O
8 362 366 2790457 both CC O O
9 367 376 2790457 lidocaine NN B-NP D008012
10 376 377 2790457 - HYPH B-NP O
11 378 381 2790457 and CC I-NP O
12 382 389 2790457 cocaine NN I-NP D003042
13 389 390 2790457 - HYPH O O
14 390 397 2790457 induced VBN B-NP O
15 398 406 2790457 seizures NNS I-NP D012640
16 406 407 2790457 , , O O
17 408 411 2790457 but CC O O
18 412 415 2790457 had VBD B-VP O
19 416 422 2790457 little JJ B-NP O
20 423 429 2790457 effect NN I-NP O
21 430 432 2790457 on IN B-PP O
22 433 436 2790457 the DT B-NP O
23 437 442 2790457 fully RB I-NP O
24 443 452 2790457 developed VBN I-NP O
25 453 458 2790457 local JJ I-NP O
26 459 469 2790457 anesthetic JJ I-NP O
27 470 478 2790457 seizures NNS I-NP D012640
28 478 479 2790457 . . O O

1 480 487 2790457 Chronic JJ B-NP O
2 488 491 2790457 CBZ NN I-NP D002220
3 492 496 2790457 also RB B-ADVP O
4 497 506 2790457 decreased VBD B-VP O
5 507 510 2790457 the DT B-NP O
6 511 520 2790457 incidence NN I-NP O
7 521 523 2790457 of IN B-PP O
8 524 531 2790457 seizure NN B-NP D012640
9 531 532 2790457 - HYPH O O
10 532 539 2790457 related VBN B-NP O
11 540 549 2790457 mortality NN I-NP O
12 550 552 2790457 in IN B-PP O
13 553 556 2790457 the DT B-NP O
14 557 564 2790457 cocaine NN I-NP D003042
15 564 565 2790457 - HYPH B-NP O
16 565 573 2790457 injected VBN I-NP O
17 574 578 2790457 rats NNS I-NP O
18 578 579 2790457 . . O O

1 580 585 2790457 Acute JJ B-NP O
2 586 589 2790457 CBZ NN I-NP D002220
3 590 594 2790457 over IN B-PP O
4 595 596 2790457 a DT B-NP O
5 597 602 2790457 range NN I-NP O
6 603 605 2790457 of IN B-PP O
7 606 611 2790457 doses NNS B-NP O
8 612 613 2790457 ( ( O O
9 613 615 2790457 15 CD B-NP O
10 615 616 2790457 - HYPH I-NP O
11 616 618 2790457 50 CD I-NP O
12 619 621 2790457 mg NN I-NP O
13 621 622 2790457 / SYM B-NP O
14 622 624 2790457 kg NN I-NP O
15 624 625 2790457 ) ) O O
16 626 629 2790457 had VBD B-VP O
17 630 632 2790457 no DT B-NP O
18 633 639 2790457 effect NN I-NP O
19 640 642 2790457 on IN B-PP O
20 643 652 2790457 completed VBN B-NP O
21 653 662 2790457 lidocaine NN I-NP D008012
22 662 663 2790457 - HYPH B-VP O
23 663 670 2790457 kindled VBN I-VP O
24 671 673 2790457 or CC O O
25 674 679 2790457 acute JJ B-NP O
26 680 687 2790457 cocaine NN I-NP D003042
27 687 688 2790457 - HYPH B-NP O
28 688 695 2790457 induced VBN I-NP O
29 696 704 2790457 seizures NNS I-NP D012640
30 704 705 2790457 . . O O

1 706 714 2790457 Repeated VBN B-NP O
2 715 718 2790457 i.p NN I-NP O
3 718 719 2790457 . . O O

1 720 729 2790457 injection NN B-NP O
2 730 732 2790457 of IN B-PP O
3 733 736 2790457 CBZ NN B-NP D002220
4 737 738 2790457 ( ( O O
5 738 740 2790457 15 CD B-NP O
6 741 743 2790457 mg NN I-NP O
7 743 744 2790457 / SYM B-NP O
8 744 746 2790457 kg NN I-NP O
9 746 747 2790457 ) ) O O
10 748 752 2790457 also RB B-ADVP O
11 753 756 2790457 was VBD B-VP O
12 757 764 2790457 without IN B-PP O
13 765 771 2790457 effect NN B-NP O
14 772 774 2790457 on IN B-PP O
15 775 778 2790457 the DT B-NP O
16 779 790 2790457 development NN I-NP O
17 791 793 2790457 of IN B-PP O
18 794 803 2790457 lidocaine NN B-NP D008012
19 803 804 2790457 - HYPH B-NP O
20 805 807 2790457 or CC I-NP O
21 808 815 2790457 cocaine NN I-NP D003042
22 815 816 2790457 - HYPH O O
23 816 823 2790457 kindled VBN B-NP O
24 824 832 2790457 seizures NNS I-NP D012640
25 832 833 2790457 . . O O

1 834 837 2790457 The DT B-NP O
2 838 850 2790457 differential JJ I-NP O
3 851 858 2790457 effects NNS I-NP O
4 859 861 2790457 of IN B-PP O
5 862 865 2790457 CBZ NN B-NP D002220
6 866 875 2790457 depending VBG B-VP O
7 876 880 2790457 upon IN B-PP O
8 881 886 2790457 stage NN B-NP O
9 887 889 2790457 of IN B-PP O
10 890 897 2790457 seizure NN B-NP D012640
11 898 909 2790457 development NN I-NP O
12 910 917 2790457 suggest VBP B-VP O
13 918 922 2790457 that IN B-SBAR O
14 923 931 2790457 distinct JJ B-NP O
15 932 942 2790457 mechanisms NNS I-NP O
16 943 951 2790457 underlie VBP B-VP O
17 952 955 2790457 the DT B-NP O
18 956 967 2790457 development NN I-NP O
19 968 974 2790457 versus IN B-PP O
20 975 986 2790457 maintenance NN B-NP O
21 987 989 2790457 of IN B-PP O
22 990 995 2790457 local JJ B-NP O
23 996 1006 2790457 anesthetic NN I-NP O
24 1006 1007 2790457 - HYPH B-NP O
25 1007 1014 2790457 kindled VBN I-NP O
26 1015 1023 2790457 seizures NNS I-NP D012640
27 1023 1024 2790457 . . O O

1 1025 1028 2790457 The DT B-NP O
2 1029 1042 2790457 effectiveness NN I-NP O
3 1043 1045 2790457 of IN B-PP O
4 1046 1053 2790457 chronic JJ B-NP O
5 1054 1057 2790457 but CC I-NP O
6 1058 1061 2790457 not RB I-NP O
7 1062 1070 2790457 repeated VBN I-NP O
8 1070 1071 2790457 , , O O
9 1072 1084 2790457 intermittent JJ B-NP O
10 1085 1095 2790457 injections NNS I-NP O
11 1096 1098 2790457 of IN B-PP O
12 1099 1102 2790457 CBZ NN B-NP D002220
13 1103 1111 2790457 suggests VBZ B-VP O
14 1112 1116 2790457 that IN B-SBAR O
15 1117 1126 2790457 different JJ B-NP O
16 1127 1138 2790457 biochemical JJ I-NP O
17 1139 1151 2790457 consequences NNS I-NP O
18 1152 1158 2790457 result VBP B-VP O
19 1159 1163 2790457 from IN B-PP O
20 1164 1167 2790457 the DT B-NP O
21 1168 1177 2790457 different JJ I-NP O
22 1178 1187 2790457 treatment NN I-NP O
23 1188 1196 2790457 regimens NNS I-NP O
24 1196 1197 2790457 . . O O

1 1198 1201 2790457 The DT B-NP O
2 1202 1210 2790457 possible JJ I-NP O
3 1211 1218 2790457 utility NN I-NP O
4 1219 1221 2790457 of IN B-PP O
5 1222 1229 2790457 chronic JJ B-NP O
6 1230 1233 2790457 CBZ NN I-NP D002220
7 1234 1236 2790457 in IN B-PP O
8 1237 1247 2790457 preventing VBG B-VP O
9 1248 1251 2790457 the DT B-NP O
10 1252 1263 2790457 development NN I-NP O
11 1264 1266 2790457 of IN B-PP O
12 1267 1272 2790457 toxic JJ B-NP O
13 1273 1277 2790457 side NN I-NP O
14 1278 1285 2790457 effects NNS I-NP O
15 1286 1288 2790457 in IN B-PP O
16 1289 1294 2790457 human JJ B-NP O
17 1295 1302 2790457 cocaine NN I-NP D003042
18 1303 1308 2790457 users NNS I-NP O
19 1309 1311 2790457 is VBZ B-VP O
20 1312 1321 2790457 suggested VBN I-VP O
21 1322 1324 2790457 by IN B-PP O
22 1325 1330 2790457 these DT B-NP O
23 1331 1335 2790457 data NNS I-NP O
24 1335 1336 2790457 , , O O
25 1337 1340 2790457 but CC O O
26 1341 1348 2790457 remains VBZ B-VP O
27 1349 1351 2790457 to TO I-VP O
28 1352 1354 2790457 be VB I-VP O
29 1355 1363 2790457 directly RB I-VP O
30 1364 1373 2790457 evaluated VBN I-VP O
31 1373 1374 2790457 . . O O

1 0 0 16418614 -DOCSTART- -X- -X- O

1 0 3 16418614 PTU NN B-NP D011441
2 3 4 16418614 - HYPH B-PP O
3 4 14 16418614 associated VBN B-NP O
4 15 25 16418614 vasculitis NN I-NP D014657
5 26 28 16418614 in IN B-PP O
6 29 30 16418614 a DT B-NP O
7 31 35 16418614 girl NN I-NP O
8 36 40 16418614 with IN B-PP O
9 41 47 16418614 Turner NN B-NP D014424
10 48 56 16418614 Syndrome NN I-NP D014424
11 57 60 16418614 and CC O O
12 61 68 16418614 Graves' NN B-NP D006111
13 69 76 16418614 disease NN I-NP D006111
14 76 77 16418614 . . O O
15 78 86 16418614 Palpable JJ B-NP O
16 87 94 16418614 purpura NN I-NP D011693
17 95 97 16418614 is VBZ B-VP O
18 98 99 16418614 a DT B-NP O
19 100 110 16418614 concerning VBG I-NP O
20 111 119 16418614 clinical JJ I-NP O
21 120 127 16418614 finding NN I-NP O
22 128 130 16418614 in IN B-PP O
23 131 140 16418614 pediatric JJ B-NP O
24 141 149 16418614 patients NNS I-NP O
25 150 153 16418614 and CC O O
26 154 157 16418614 can MD B-VP O
27 158 162 16418614 have VB I-VP O
28 163 167 16418614 many JJ B-NP O
29 168 174 16418614 causes NNS I-NP O
30 174 175 16418614 , , O O
31 176 185 16418614 including VBG B-PP O
32 186 196 16418614 infectious JJ B-NP O
33 197 200 16418614 and CC I-NP O
34 201 211 16418614 autoimmune JJ I-NP O
35 212 221 16418614 processes NNS I-NP O
36 221 222 16418614 . . O O

1 223 224 16418614 A DT B-NP O
2 225 229 16418614 rare JJ I-NP O
3 230 235 16418614 cause NN I-NP O
4 235 236 16418614 , , O O
5 237 241 16418614 drug NN B-NP O
6 241 242 16418614 - HYPH B-NP O
7 242 249 16418614 induced VBN I-NP O
8 250 260 16418614 vasculitis NN I-NP D014657
9 260 261 16418614 , , O O
10 262 265 16418614 may MD B-VP O
11 266 272 16418614 result VB I-VP O
12 273 277 16418614 from IN B-PP O
13 278 281 16418614 the DT B-NP O
14 282 292 16418614 production NN I-NP O
15 293 295 16418614 of IN B-PP O
16 296 310 16418614 antineutrophil NN B-NP O
17 311 322 16418614 cytoplasmic JJ I-NP O
18 323 333 16418614 antibodies NNS I-NP O
19 334 335 16418614 ( ( O O
20 335 340 16418614 ANCAs NNS B-NP O
21 340 341 16418614 ) ) O O
22 342 344 16418614 in IN B-PP O
23 345 353 16418614 response NN B-NP O
24 354 356 16418614 to TO B-PP O
25 357 358 16418614 a DT B-NP O
26 359 369 16418614 medication NN I-NP O
27 369 370 16418614 . . O O

1 371 373 16418614 We PRP B-NP O
2 374 380 16418614 report VBP B-VP O
3 381 382 16418614 a DT B-NP O
4 383 387 16418614 girl NN I-NP O
5 388 392 16418614 with IN B-PP O
6 393 399 16418614 Turner NN B-NP D014424
7 400 408 16418614 syndrome NN I-NP D014424
8 409 412 16418614 and CC I-NP O
9 413 420 16418614 Graves' NN I-NP D006111
10 421 428 16418614 disease NN I-NP D006111
11 429 432 16418614 who WP B-NP O
12 433 442 16418614 presented VBD B-VP O
13 443 447 16418614 with IN B-PP O
14 448 456 16418614 palpable JJ B-NP O
15 457 465 16418614 purpuric JJ I-NP D011693
16 466 473 16418614 lesions NNS I-NP D011693
17 473 474 16418614 . . O O

1 475 478 16418614 The DT B-NP O
2 479 488 16418614 diagnosis NN I-NP O
3 489 491 16418614 of IN B-PP O
4 492 508 16418614 propylthiouracil NN B-NP D011441
5 509 510 16418614 ( ( O O
6 510 513 16418614 PTU NN B-NP D011441
7 513 514 16418614 ) ) O O
8 514 515 16418614 - HYPH O O
9 515 525 16418614 associated VBN B-NP O
10 526 536 16418614 vasculitis NN I-NP D014657
11 537 540 16418614 was VBD B-VP O
12 541 545 16418614 made VBN I-VP O
13 546 548 16418614 by IN B-PP O
14 549 560 16418614 observation NN B-NP O
15 561 563 16418614 of IN B-PP O
16 564 574 16418614 consistent JJ B-NP O
17 575 583 16418614 clinical JJ I-NP O
18 584 592 16418614 features NNS I-NP O
19 592 593 16418614 , , O O
20 594 597 16418614 the DT B-NP O
21 598 607 16418614 detection NN I-NP O
22 608 610 16418614 of IN B-PP O
23 611 619 16418614 elevated JJ B-NP O
24 620 623 16418614 ANA NN I-NP O
25 624 627 16418614 and CC I-NP O
26 628 632 16418614 ANCA NN I-NP O
27 633 635 16418614 in IN B-PP O
28 636 639 16418614 the DT B-NP O
29 640 645 16418614 blood NN I-NP O
30 645 646 16418614 , , O O
31 647 650 16418614 and CC O O
32 651 654 16418614 the DT B-NP O
33 655 663 16418614 observed VBN I-NP O
34 664 672 16418614 clinical JJ I-NP O
35 673 683 16418614 resolution NN I-NP O
36 684 686 16418614 of IN B-PP O
37 687 695 16418614 symptoms NNS B-NP O
38 696 705 16418614 following VBG B-PP O
39 706 716 16418614 withdrawal NN B-NP O
40 717 719 16418614 of IN B-PP O
41 720 723 16418614 PTU NN B-NP D011441
42 723 724 16418614 . . O O

1 725 735 16418614 Subsequent JJ B-NP O
2 736 745 16418614 treatment NN I-NP O
3 746 748 16418614 of IN B-PP O
4 749 759 16418614 persistent JJ B-NP O
5 760 775 16418614 hyperthyroidism NN I-NP D006980
6 776 780 16418614 with IN B-PP O
7 781 794 16418614 radioablation NN B-NP O
8 795 798 16418614 did VBD B-VP O
9 799 802 16418614 not RB I-VP O
10 803 809 16418614 result VB I-VP O
11 810 812 16418614 in IN B-PP O
12 813 815 16418614 an DT B-NP O
13 816 828 16418614 exacerbation NN I-NP O
14 829 831 16418614 of IN B-PP O
15 832 835 16418614 the DT B-NP O
16 836 846 16418614 vasculitis NN I-NP D014657
17 846 847 16418614 , , O O
18 848 849 16418614 a DT B-NP O
19 850 862 16418614 complication NN I-NP O
20 863 872 16418614 described VBN B-VP O
21 873 875 16418614 in IN B-PP O
22 876 881 16418614 prior JJ B-NP O
23 882 886 16418614 case NN I-NP O
24 887 894 16418614 reports NNS I-NP O
25 894 895 16418614 . . O O

1 0 0 2576810 -DOCSTART- -X- -X- O

1 0 4 2576810 Some DT B-NP O
2 5 12 2576810 central JJ I-NP O
3 13 20 2576810 effects NNS I-NP O
4 21 23 2576810 of IN B-PP O
5 24 32 2576810 repeated VBN B-NP O
6 33 42 2576810 treatment NN I-NP O
7 43 47 2576810 with IN B-PP O
8 48 59 2576810 fluvoxamine NN B-NP D016666
9 59 60 2576810 . . O O
10 61 63 2576810 We PRP B-NP O
11 64 76 2576810 investigated VBD B-VP O
12 77 80 2576810 the DT B-NP O
13 81 87 2576810 effect NN I-NP O
14 88 90 2576810 of IN B-PP O
15 91 99 2576810 repeated VBN B-NP O
16 100 109 2576810 treatment NN I-NP O
17 110 114 2576810 with IN B-PP O
18 115 126 2576810 fluvoxamine NN B-NP D016666
19 126 127 2576810 , , O O
20 128 129 2576810 a DT B-NP O
21 130 139 2576810 selective JJ I-NP O
22 140 149 2576810 serotonin NN I-NP D012701
23 150 156 2576810 uptake NN I-NP O
24 157 166 2576810 inhibitor NN I-NP O
25 166 167 2576810 , , O O
26 168 170 2576810 on IN B-PP O
27 171 181 2576810 behavioral JJ B-NP O
28 182 189 2576810 effects NNS I-NP O
29 190 192 2576810 of IN B-PP O
30 193 209 2576810 dopaminomimetics NNS B-NP O
31 210 213 2576810 and CC O O
32 214 225 2576810 methoxamine NN B-NP D008729
33 226 229 2576810 and CC B-PP O
34 230 232 2576810 on IN B-PP O
35 233 236 2576810 the DT B-NP O
36 237 243 2576810 animal NN I-NP O
37 244 252 2576810 behavior NN I-NP O
38 253 255 2576810 in IN B-PP O
39 256 259 2576810 the DT B-NP O
40 260 261 2576810 " `` I-NP O
41 261 271 2576810 behavioral JJ I-NP O
42 272 279 2576810 despair NN I-NP O
43 279 280 2576810 " '' I-NP O
44 281 285 2576810 test NN I-NP O
45 285 286 2576810 . . O O

1 287 288 2576810 A DT B-NP O
2 289 297 2576810 repeated VBN I-NP O
3 298 307 2576810 treatment NN I-NP O
4 308 312 2576810 with IN B-PP O
5 313 324 2576810 fluvoxamine NN B-NP D016666
6 325 326 2576810 ( ( O O
7 326 331 2576810 twice RB B-ADVP O
8 332 337 2576810 daily RB I-ADVP O
9 338 341 2576810 for IN B-PP O
10 342 344 2576810 14 CD B-NP O
11 345 349 2576810 days NNS I-NP O
12 349 350 2576810 ) ) O O
13 351 362 2576810 potentiated VBD B-VP O
14 363 365 2576810 in IN B-PP O
15 366 370 2576810 mice NNS B-NP O
16 371 374 2576810 and CC B-PP O
17 375 377 2576810 in IN B-PP O
18 378 382 2576810 rats NNS B-NP O
19 383 384 2576810 ( ( O O
20 384 390 2576810 weaker JJR B-ADJP O
21 390 391 2576810 ) ) O O
22 392 395 2576810 the DT B-NP O
23 396 407 2576810 amphetamine NN I-NP D000661
24 407 408 2576810 - HYPH B-NP O
25 408 415 2576810 induced VBN I-NP O
26 416 429 2576810 hyperactivity NN I-NP D006948
27 429 430 2576810 . . O O

1 431 434 2576810 The DT B-NP O
2 435 448 2576810 hyperactivity NN I-NP D006948
3 449 456 2576810 induced VBN B-VP O
4 457 459 2576810 by IN B-PP O
5 460 471 2576810 nomifensine NN B-NP D009627
6 472 474 2576810 in IN B-PP O
7 475 479 2576810 mice NNS B-NP O
8 480 488 2576810 remained VBD B-VP O
9 489 499 2576810 unaffected JJ B-ADJP O
10 500 502 2576810 by IN B-PP O
11 503 514 2576810 fluvoxamine NN B-NP D016666
12 514 515 2576810 . . O O

1 516 519 2576810 The DT B-NP O
2 520 531 2576810 stimulation NN I-NP O
3 532 534 2576810 of IN B-PP O
4 535 544 2576810 locomotor NN B-NP O
5 545 553 2576810 activity NN I-NP O
6 554 556 2576810 by IN B-PP O
7 557 582 2576810 intracerebroventricularly RB B-NP O
8 583 595 2576810 administered VBN I-NP O
9 596 607 2576810 methoxamine NN I-NP D008729
10 608 611 2576810 was VBD B-VP O
11 612 615 2576810 not RB I-VP O
12 616 624 2576810 affected VBN I-VP O
13 625 627 2576810 by IN B-PP O
14 628 636 2576810 repeated VBN B-NP O
15 637 646 2576810 treatment NN I-NP O
16 647 651 2576810 with IN B-PP O
17 652 663 2576810 fluvoxamine NN B-NP D016666
18 663 664 2576810 . . O O

1 665 670 2576810 Given VBN B-VP O
2 671 676 2576810 three CD B-NP O
3 677 682 2576810 times NNS I-NP O
4 683 694 2576810 fluvoxamine NN I-NP D016666
5 695 698 2576810 had VBD B-VP O
6 699 701 2576810 no DT B-NP O
7 702 708 2576810 effect NN I-NP O
8 709 711 2576810 on IN B-PP O
9 712 715 2576810 the DT B-NP O
10 716 730 2576810 immobilization NN I-NP O
11 731 735 2576810 time NN I-NP O
12 736 738 2576810 in IN B-PP O
13 739 742 2576810 the DT B-NP O
14 743 744 2576810 " `` I-NP O
15 744 754 2576810 behavioral JJ I-NP O
16 755 762 2576810 despair NN I-NP O
17 762 763 2576810 " '' I-NP O
18 764 768 2576810 test NN I-NP O
19 769 771 2576810 in IN B-PP O
20 772 776 2576810 rats NNS B-NP O
21 776 777 2576810 . . O O

1 778 781 2576810 The DT B-NP O
2 782 789 2576810 results NNS I-NP O
3 790 798 2576810 indicate VBP B-VP O
4 799 803 2576810 that IN B-SBAR O
5 804 815 2576810 fluvoxamine NN B-NP D016666
6 816 821 2576810 given VBN B-VP O
7 822 832 2576810 repeatedly RB B-ADVP O
8 833 837 2576810 acts VBZ B-VP O
9 838 849 2576810 differently RB B-ADVP O
10 850 854 2576810 than IN B-PP O
11 855 865 2576810 citalopram NN B-NP D015283
12 865 866 2576810 , , O O
13 867 874 2576810 another DT B-NP O
14 875 884 2576810 selective JJ I-NP O
15 885 894 2576810 serotonin NN I-NP D012701
16 895 901 2576810 uptake NN I-NP O
17 902 911 2576810 inhibitor NN I-NP O
18 911 912 2576810 , , O O
19 913 916 2576810 and CC O O
20 917 924 2576810 differs VBZ B-VP O
21 925 929 2576810 also RB B-ADVP O
22 930 934 2576810 from IN B-PP O
23 935 940 2576810 other JJ B-NP O
24 941 955 2576810 antidepressant JJ I-NP O
25 956 961 2576810 drugs NNS I-NP O
26 961 962 2576810 . . O O

1 0 0 17263743 -DOCSTART- -X- -X- O

1 0 7 17263743 Cardiac JJ B-NP D006323
2 8 14 17263743 arrest NN I-NP D006323
3 15 17 17263743 in IN B-PP O
4 18 19 17263743 a DT B-NP O
5 20 25 17263743 child NN I-NP O
6 26 30 17263743 with IN B-PP O
7 31 39 17263743 cerebral JJ B-NP D002547
8 40 45 17263743 palsy JJ I-NP D002547
9 46 56 17263743 undergoing VBG I-NP O
10 57 68 17263743 sevoflurane NN I-NP C009250
11 69 78 17263743 induction NN I-NP O
12 79 81 17263743 of IN B-PP O
13 82 92 17263743 anesthesia NN B-NP O
14 93 98 17263743 after IN B-PP O
15 99 111 17263743 preoperative JJ B-NP O
16 112 121 17263743 clonidine NN I-NP D003000
17 121 122 17263743 . . I-NP O
18 123 132 17263743 Clonidine NN I-NP D003000
19 133 135 17263743 is VBZ B-VP O
20 136 137 17263743 a DT B-NP O
21 138 148 17263743 frequently RB I-NP O
22 149 161 17263743 administered VBN I-NP O
23 162 168 17263743 alpha2 NN I-NP O
24 168 169 17263743 - HYPH I-NP O
25 169 179 17263743 adrenergic JJ I-NP O
26 180 187 17263743 agonist NN I-NP O
27 188 193 17263743 which WDT B-NP O
28 194 197 17263743 can MD B-VP O
29 198 206 17263743 decrease VB I-VP O
30 207 212 17263743 heart NN B-NP O
31 213 217 17263743 rate NN I-NP O
32 218 221 17263743 and CC O O
33 222 227 17263743 blood NN B-NP O
34 228 236 17263743 pressure NN I-NP O
35 236 237 17263743 . . O O

1 238 240 17263743 We PRP B-NP O
2 241 248 17263743 present VBP B-VP O
3 249 250 17263743 a DT B-NP O
4 251 255 17263743 case NN I-NP O
5 256 258 17263743 of IN B-PP O
6 259 260 17263743 a DT B-NP O
7 261 262 17263743 5 CD I-NP O
8 262 263 17263743 - HYPH I-NP O
9 263 267 17263743 year NN I-NP O
10 267 268 17263743 - HYPH O O
11 268 271 17263743 old JJ B-NP O
12 272 277 17263743 child NN I-NP O
13 278 282 17263743 with IN B-PP O
14 283 291 17263743 cerebral JJ B-NP D002547
15 292 297 17263743 palsy NN I-NP D002547
16 298 301 17263743 and CC I-NP O
17 302 309 17263743 seizure NN I-NP D004827
18 310 318 17263743 disorder NN I-NP D004827
19 318 319 17263743 , , O O
20 320 329 17263743 receiving VBG B-VP O
21 330 339 17263743 clonidine NN B-NP D003000
22 340 343 17263743 for IN B-PP O
23 344 356 17263743 restlessness NN B-NP D011595
24 356 357 17263743 , , O O
25 358 361 17263743 who WP B-NP O
26 362 371 17263743 presented VBD B-VP O
27 372 375 17263743 for IN B-PP O
28 376 385 17263743 placement NN B-NP O
29 386 388 17263743 of IN B-PP O
30 389 390 17263743 a DT B-NP O
31 391 399 17263743 baclofen NN I-NP D001418
32 400 404 17263743 pump NN I-NP O
33 404 405 17263743 . . O O

1 406 413 17263743 Without IN B-PP O
2 414 417 17263743 the DT B-NP O
3 418 427 17263743 knowledge NN I-NP O
4 428 430 17263743 of IN B-PP O
5 431 434 17263743 the DT B-NP O
6 435 442 17263743 medical JJ I-NP O
7 443 452 17263743 personnel NNS I-NP O
8 452 453 17263743 , , O O
9 454 457 17263743 the DT B-NP O
10 458 467 17263743 patient's NNS I-NP O
11 468 474 17263743 mother NN I-NP O
12 475 487 17263743 administered VBN B-VP O
13 488 493 17263743 three CD B-NP O
14 494 499 17263743 doses NNS I-NP O
15 500 502 17263743 of IN B-PP O
16 503 512 17263743 clonidine NN B-NP D003000
17 513 519 17263743 during IN B-PP O
18 520 523 17263743 the DT B-NP O
19 524 531 17263743 evening NN I-NP O
20 532 538 17263743 before IN B-PP O
21 539 542 17263743 and CC O O
22 543 550 17263743 morning NN B-NP O
23 551 553 17263743 of IN B-PP O
24 554 561 17263743 surgery NN B-NP O
25 562 564 17263743 to TO B-VP O
26 565 571 17263743 reduce VB I-VP O
27 572 579 17263743 anxiety NN B-NP D001008
28 579 580 17263743 . . O O

1 581 587 17263743 During IN B-PP O
2 588 597 17263743 induction NN B-NP O
3 598 600 17263743 of IN B-PP O
4 601 611 17263743 anesthesia NN B-NP O
5 611 612 17263743 , , O O
6 613 616 17263743 the DT B-NP O
7 617 624 17263743 patient NN I-NP O
8 625 634 17263743 developed VBD B-VP O
9 635 646 17263743 bradycardia NN B-NP D001919
10 647 650 17263743 and CC I-NP O
11 651 662 17263743 hypotension NN I-NP D007022
12 663 672 17263743 requiring VBG B-VP O
13 673 680 17263743 cardiac JJ B-NP O
14 681 694 17263743 resuscitation NN I-NP O
15 694 695 17263743 . . O O

1 696 701 17263743 There EX B-NP O
2 702 705 17263743 are VBP B-VP O
3 706 708 17263743 no DT B-NP O
4 709 717 17263743 previous JJ I-NP O
5 718 725 17263743 reports NNS I-NP O
6 726 728 17263743 of IN B-PP O
7 729 738 17263743 clonidine NN B-NP D003000
8 738 739 17263743 - HYPH O O
9 739 749 17263743 associated VBN B-VP O
10 750 757 17263743 cardiac JJ B-NP D006323
11 758 764 17263743 arrest NN I-NP D006323
12 765 767 17263743 in IN B-PP O
13 768 769 17263743 a DT B-NP O
14 770 775 17263743 child NN I-NP O
15 776 786 17263743 undergoing VBG B-VP O
16 787 796 17263743 induction NN B-NP O
17 797 799 17263743 of IN B-PP O
18 800 810 17263743 anesthesia NN B-NP O
19 810 811 17263743 . . O O

1 0 0 11827497 -DOCSTART- -X- -X- O

1 0 7 11827497 Delayed VBN B-VP O
2 7 8 11827497 - HYPH B-NP O
3 8 13 11827497 onset NN I-NP O
4 14 21 11827497 heparin NN I-NP D006493
5 21 22 11827497 - HYPH B-NP O
6 22 29 11827497 induced VBN I-NP O
7 30 46 11827497 thrombocytopenia NN I-NP D013921
8 46 47 11827497 . . I-NP O
9 48 58 11827497 BACKGROUND NN I-NP O
10 58 59 11827497 : : O O
11 60 67 11827497 Heparin NN B-NP D006493
12 67 68 11827497 - HYPH B-NP O
13 68 75 11827497 induced VBN I-NP O
14 76 92 11827497 thrombocytopenia NN I-NP D013921
15 93 101 11827497 presents NNS I-NP O
16 102 103 11827497 5 CD B-NP O
17 104 106 11827497 to TO I-NP O
18 107 109 11827497 12 CD I-NP O
19 110 114 11827497 days NNS I-NP O
20 115 120 11827497 after IN B-PP O
21 121 128 11827497 heparin NN B-NP D006493
22 129 137 11827497 exposure NN I-NP O
23 137 138 11827497 , , O O
24 139 143 11827497 with IN B-PP O
25 144 146 11827497 or CC B-PP O
26 147 154 11827497 without IN B-PP O
27 155 163 11827497 arterial JJ B-NP D001157
28 164 166 11827497 or CC I-NP D001157
29 167 173 11827497 venous JJ I-NP D001157
30 174 187 11827497 thromboemboli NNS I-NP D001157
31 187 188 11827497 . . O O

1 189 196 11827497 Delayed VBN B-NP O
2 197 208 11827497 recognition NN I-NP O
3 209 212 11827497 and CC I-NP O
4 213 222 11827497 treatment NN I-NP O
5 223 225 11827497 of IN B-PP O
6 226 233 11827497 heparin NN B-NP D006493
7 233 234 11827497 - HYPH B-NP O
8 234 241 11827497 induced VBN I-NP O
9 242 258 11827497 thrombocytopenia NN I-NP D013921
10 259 269 11827497 contribute VBP B-VP O
11 270 272 11827497 to TO B-PP O
12 273 277 11827497 poor JJ B-NP O
13 278 285 11827497 patient NN I-NP O
14 286 294 11827497 outcomes NNS I-NP O
15 294 295 11827497 . . O O

1 296 305 11827497 OBJECTIVE NN B-NP O
2 305 306 11827497 : : O O
3 307 309 11827497 To TO B-VP O
4 310 318 11827497 describe VB I-VP O
5 319 322 11827497 and CC I-VP O
6 323 331 11827497 increase VB I-VP O
7 332 341 11827497 awareness NN B-NP O
8 342 344 11827497 of IN B-PP O
9 345 346 11827497 a DT B-NP O
10 347 355 11827497 clinical JJ I-NP O
11 356 364 11827497 scenario NN I-NP O
12 365 367 11827497 in IN B-PP O
13 368 373 11827497 which WDT B-NP O
14 374 377 11827497 the DT B-NP O
15 378 383 11827497 onset NN I-NP O
16 384 386 11827497 or CC I-NP O
17 387 401 11827497 manifestations NNS I-NP O
18 402 404 11827497 of IN B-PP O
19 405 412 11827497 heparin NN B-NP D006493
20 412 413 11827497 - HYPH B-NP O
21 413 420 11827497 induced VBN I-NP O
22 421 437 11827497 thrombocytopenia NN I-NP D013921
23 438 441 11827497 are VBP B-VP O
24 442 449 11827497 delayed VBN I-VP O
25 449 450 11827497 . . O O

1 451 457 11827497 DESIGN NN B-NP O
2 457 458 11827497 : : O O
3 459 472 11827497 Retrospective JJ B-NP O
4 473 477 11827497 case NN I-NP O
5 478 484 11827497 series NN I-NP O
6 484 485 11827497 . . O O

1 486 493 11827497 SETTING NN B-NP O
2 493 494 11827497 : : O O
3 495 500 11827497 Three CD B-NP O
4 501 506 11827497 large JJ I-NP O
5 507 512 11827497 urban JJ I-NP O
6 513 522 11827497 hospitals NNS I-NP O
7 523 524 11827497 ( ( O O
8 524 528 11827497 with IN B-PP O
9 529 535 11827497 active JJ B-NP O
10 536 550 11827497 cardiovascular JJ I-NP O
11 551 558 11827497 surgery NN I-NP O
12 559 567 11827497 programs NNS I-NP O
13 567 568 11827497 ) ) O O
14 568 569 11827497 . . O O

1 570 578 11827497 PATIENTS NNS B-NP O
2 578 579 11827497 : : O O
3 580 582 11827497 14 CD B-NP O
4 583 591 11827497 patients NNS I-NP O
5 592 596 11827497 seen VBN B-VP O
6 597 601 11827497 over IN B-PP O
7 602 603 11827497 a DT B-NP O
8 604 605 11827497 3 CD I-NP O
9 605 606 11827497 - HYPH I-NP O
10 606 610 11827497 year NN I-NP O
11 611 617 11827497 period NN I-NP O
12 618 620 11827497 in IN B-PP O
13 621 625 11827497 whom WP B-NP O
14 626 633 11827497 heparin NN I-NP D006493
15 633 634 11827497 - HYPH B-NP O
16 634 641 11827497 induced VBN I-NP O
17 642 658 11827497 thrombocytopenia NN I-NP D013921
18 659 665 11827497 became VBD B-VP O
19 666 674 11827497 apparent JJ B-ADJP O
20 675 677 11827497 on IN B-PP O
21 678 685 11827497 delayed VBN B-NP O
22 686 698 11827497 presentation NN I-NP O
23 699 703 11827497 with IN B-PP O
24 704 718 11827497 thromboembolic JJ B-NP D013923
25 719 732 11827497 complications NNS I-NP O
26 732 733 11827497 . . O O

1 734 746 11827497 MEASUREMENTS NNS B-NP O
2 746 747 11827497 : : O O
3 748 756 11827497 Platelet NN B-NP O
4 757 763 11827497 counts NNS I-NP O
5 763 764 11827497 , , O O
6 765 770 11827497 onset NN B-NP O
7 771 773 11827497 of IN B-PP O
8 774 785 11827497 objectively RB B-NP O
9 786 796 11827497 determined VBN I-NP O
10 797 812 11827497 thromboembolism NN I-NP D013923
11 812 813 11827497 , , O O
12 814 821 11827497 results NNS B-NP O
13 822 824 11827497 of IN B-PP O
14 825 832 11827497 heparin NN B-NP D006493
15 832 833 11827497 - HYPH B-NP O
16 833 840 11827497 induced VBN I-NP O
17 841 849 11827497 platelet NN I-NP O
18 850 856 11827497 factor NN I-NP O
19 857 858 11827497 4 CD I-NP O
20 859 867 11827497 antibody NN I-NP O
21 868 873 11827497 tests NNS I-NP O
22 873 874 11827497 , , O O
23 875 878 11827497 and CC O O
24 879 887 11827497 outcomes NNS B-NP O
25 887 888 11827497 . . O O

1 889 896 11827497 RESULTS NNS B-NP O
2 896 897 11827497 : : O O
3 898 906 11827497 Patients NNS B-NP O
4 907 911 11827497 went VBD B-VP O
5 912 916 11827497 home RB B-ADVP O
6 917 922 11827497 after IN B-PP O
7 923 939 11827497 hospitalizations NNS B-NP O
8 940 944 11827497 that WDT B-NP O
9 945 948 11827497 had VBD B-VP O
10 949 957 11827497 included VBN I-VP O
11 958 965 11827497 heparin NN B-NP D006493
12 966 974 11827497 exposure NN I-NP O
13 974 975 11827497 - HYPH B-VP O
14 975 976 11827497 - SYM B-NP O
15 976 978 11827497 in IN B-PP O
16 979 983 11827497 most JJS B-NP O
17 984 989 11827497 cases NNS I-NP O
18 989 990 11827497 , , O O
19 991 995 11827497 with IN B-PP O
20 996 998 11827497 no DT B-NP O
21 999 1015 11827497 thrombocytopenia NN I-NP D013921
22 1016 1026 11827497 recognized VBN B-VP O
23 1026 1027 11827497 - HYPH B-ADJP O
24 1027 1028 11827497 - HYPH B-CONJP O
25 1028 1032 11827497 only RB B-ADVP O
26 1033 1035 11827497 to TO B-VP O
27 1036 1042 11827497 return VB I-VP O
28 1043 1045 11827497 to TO B-PP O
29 1046 1049 11827497 the DT B-NP O
30 1050 1058 11827497 hospital NN I-NP O
31 1059 1060 11827497 ( ( O O
32 1060 1066 11827497 median NN B-NP O
33 1066 1067 11827497 , , O O
34 1068 1071 11827497 day NN B-NP O
35 1072 1074 11827497 14 CD I-NP O
36 1074 1075 11827497 ) ) O O
37 1076 1080 11827497 with IN B-PP O
38 1081 1095 11827497 thromboembolic JJ B-NP D013923
39 1096 1109 11827497 complications NNS I-NP O
40 1109 1110 11827497 . . O O

1 1111 1124 11827497 Thromboemboli NNP B-NP D013923
2 1125 1129 11827497 were VBD B-VP O
3 1130 1136 11827497 venous JJ B-ADJP O
4 1137 1138 11827497 ( ( O O
5 1138 1140 11827497 12 CD B-NP O
6 1141 1149 11827497 patients NNS I-NP O
7 1149 1150 11827497 , , O O
8 1151 1152 11827497 7 CD B-NP O
9 1153 1157 11827497 with IN B-PP O
10 1158 1167 11827497 pulmonary JJ B-NP D011655
11 1168 1174 11827497 emboli NNS I-NP D011655
12 1174 1175 11827497 ) ) O O
13 1176 1178 11827497 or CC O O
14 1179 1187 11827497 arterial JJ B-ADJP O
15 1188 1189 11827497 ( ( O O
16 1189 1190 11827497 4 CD B-NP O
17 1191 1199 11827497 patients NNS I-NP O
18 1199 1200 11827497 ) ) O O
19 1201 1203 11827497 or CC O O
20 1204 1208 11827497 both DT B-NP O
21 1208 1209 11827497 . . O O

1 1210 1218 11827497 Platelet NN B-NP O
2 1219 1225 11827497 counts NNS I-NP O
3 1226 1230 11827497 were VBD B-VP O
4 1231 1237 11827497 mildly RB I-VP O
5 1238 1247 11827497 decreased VBN I-VP O
6 1248 1250 11827497 in IN B-PP O
7 1251 1254 11827497 all DT B-NP O
8 1255 1258 11827497 but CC I-NP O
9 1259 1260 11827497 2 CD I-NP O
10 1261 1269 11827497 patients NNS I-NP O
11 1270 1272 11827497 on IN B-PP O
12 1273 1279 11827497 second JJ B-NP O
13 1280 1292 11827497 presentation NN I-NP O
14 1292 1293 11827497 . . O O

1 1294 1296 11827497 On IN B-PP O
2 1297 1308 11827497 readmission NN B-NP O
3 1308 1309 11827497 , , O O
4 1310 1312 11827497 11 CD B-NP O
5 1313 1321 11827497 patients NNS I-NP O
6 1322 1330 11827497 received VBD B-VP O
7 1331 1342 11827497 therapeutic JJ B-NP O
8 1343 1350 11827497 heparin NN I-NP D006493
9 1350 1351 11827497 , , O O
10 1352 1357 11827497 which WDT B-NP O
11 1358 1366 11827497 worsened VBD B-VP O
12 1367 1370 11827497 the DT B-NP O
13 1371 1379 11827497 patients NNS I-NP O
14 1379 1380 11827497 ' POS B-NP O
15 1381 1389 11827497 clinical JJ I-NP O
16 1390 1399 11827497 condition NN I-NP O
17 1400 1403 11827497 and CC O O
18 1403 1404 11827497 , , O O
19 1405 1407 11827497 in IN B-PP O
20 1408 1411 11827497 all DT B-NP O
21 1412 1414 11827497 11 CD I-NP O
22 1415 1420 11827497 cases NNS I-NP O
23 1420 1421 11827497 , , O O
24 1422 1431 11827497 decreased VBD B-VP O
25 1432 1435 11827497 the DT B-NP O
26 1436 1444 11827497 platelet NN I-NP O
27 1445 1450 11827497 count NN I-NP O
28 1451 1452 11827497 ( ( O O
29 1452 1456 11827497 mean NN B-NP O
30 1457 1459 11827497 at IN B-PP O
31 1460 1471 11827497 readmission NN B-NP O
32 1471 1472 11827497 , , O O
33 1473 1476 11827497 143 CD B-NP O
34 1477 1478 11827497 x CC I-NP O
35 1479 1484 11827497 10(9) CD I-NP O
36 1485 1490 11827497 cells NNS I-NP O
37 1490 1491 11827497 / SYM O O
38 1491 1492 11827497 L NN B-NP O
39 1492 1493 11827497 ; : O O
40 1494 1498 11827497 mean JJ B-NP O
41 1499 1504 11827497 nadir NN I-NP O
42 1505 1510 11827497 after IN B-PP O
43 1511 1518 11827497 heparin NN B-NP D006493
44 1519 1521 11827497 re AFX O O
45 1521 1522 11827497 - HYPH O O
46 1522 1530 11827497 exposure NN B-NP O
47 1530 1531 11827497 , , O O
48 1532 1534 11827497 39 CD B-NP O
49 1535 1536 11827497 x CC I-NP O
50 1537 1542 11827497 10(9) CD I-NP O
51 1543 1548 11827497 cells NNS I-NP O
52 1548 1549 11827497 / SYM O O
53 1549 1550 11827497 L NN B-NP O
54 1550 1551 11827497 ) ) O O
55 1551 1552 11827497 . . O O

1 1553 1560 11827497 Results NNS B-NP O
2 1561 1563 11827497 of IN B-PP O
3 1564 1573 11827497 serologic JJ B-NP O
4 1574 1579 11827497 tests NNS I-NP O
5 1580 1583 11827497 for IN B-PP O
6 1584 1591 11827497 heparin NN B-NP D006493
7 1591 1592 11827497 - HYPH B-NP O
8 1592 1599 11827497 induced VBN I-NP O
9 1600 1610 11827497 antibodies NNS I-NP O
10 1611 1615 11827497 were VBD B-VP O
11 1616 1624 11827497 positive JJ B-ADJP O
12 1625 1627 11827497 in IN B-PP O
13 1628 1631 11827497 all DT B-NP O
14 1632 1640 11827497 patients NNS I-NP O
15 1640 1641 11827497 . . O O

1 1642 1652 11827497 Subsequent JJ B-NP O
2 1653 1663 11827497 treatments NNS I-NP O
3 1664 1672 11827497 included VBD B-VP O
4 1673 1684 11827497 alternative JJ B-NP O
5 1685 1699 11827497 anticoagulants NNS I-NP O
6 1700 1701 11827497 ( ( O O
7 1701 1703 11827497 11 CD B-NP O
8 1704 1712 11827497 patients NNS I-NP O
9 1712 1713 11827497 ) ) O O
10 1713 1714 11827497 , , O O
11 1715 1727 11827497 thrombolytic JJ B-NP O
12 1728 1733 11827497 drugs NNS I-NP O
13 1734 1735 11827497 ( ( O O
14 1735 1736 11827497 3 CD B-NP O
15 1737 1745 11827497 patients NNS I-NP O
16 1745 1746 11827497 ) ) O O
17 1746 1747 11827497 , , O O
18 1748 1756 11827497 inferior JJ B-NP O
19 1757 1761 11827497 vena NN I-NP O
20 1762 1766 11827497 cava NN I-NP O
21 1767 1774 11827497 filters NNS I-NP O
22 1775 1776 11827497 ( ( O O
23 1776 1777 11827497 3 CD B-NP O
24 1778 1786 11827497 patients NNS I-NP O
25 1786 1787 11827497 ) ) O O
26 1788 1791 11827497 and CC O O
27 1791 1792 11827497 , , O O
28 1793 1803 11827497 eventually RB B-ADVP O
29 1803 1804 11827497 , , O O
30 1805 1813 11827497 warfarin NN B-NP D014859
31 1814 1815 11827497 ( ( O O
32 1815 1817 11827497 11 CD B-NP O
33 1818 1826 11827497 patients NNS I-NP O
34 1826 1827 11827497 ) ) O O
35 1827 1828 11827497 . . O O

1 1829 1834 11827497 Three CD B-NP O
2 1835 1843 11827497 patients NNS I-NP O
3 1844 1848 11827497 died VBD B-VP O
4 1848 1849 11827497 . . O O

1 1850 1861 11827497 CONCLUSIONS NNS B-NP O
2 1861 1862 11827497 : : O O
3 1863 1870 11827497 Delayed VBN B-VP O
4 1870 1871 11827497 - HYPH B-NP O
5 1871 1876 11827497 onset NN I-NP O
6 1877 1884 11827497 heparin NN I-NP D006493
7 1884 1885 11827497 - HYPH B-NP O
8 1885 1892 11827497 induced VBN I-NP O
9 1893 1909 11827497 thrombocytopenia NN I-NP D013921
10 1910 1912 11827497 is VBZ B-VP O
11 1913 1925 11827497 increasingly RB I-VP O
12 1926 1931 11827497 being VBG I-VP O
13 1932 1942 11827497 recognized VBN I-VP O
14 1942 1943 11827497 . . O O

1 1944 1946 11827497 To TO B-VP O
2 1947 1952 11827497 avoid VB I-VP O
3 1953 1963 11827497 disastrous JJ B-NP O
4 1964 1972 11827497 outcomes NNS I-NP O
5 1972 1973 11827497 , , O O
6 1974 1984 11827497 physicians NNS B-NP O
7 1985 1989 11827497 must MD B-VP O
8 1990 1998 11827497 consider VB I-VP O
9 1999 2006 11827497 heparin NN B-NP D006493
10 2006 2007 11827497 - HYPH B-NP O
11 2007 2014 11827497 induced VBN I-NP O
12 2015 2031 11827497 thrombocytopenia NN I-NP D013921
13 2032 2040 11827497 whenever WRB B-ADVP O
14 2041 2042 11827497 a DT B-NP O
15 2043 2051 11827497 recently RB I-NP O
16 2052 2064 11827497 hospitalized VBN I-NP O
17 2065 2072 11827497 patient NN I-NP O
18 2073 2080 11827497 returns NNS I-NP O
19 2081 2085 11827497 with IN B-PP O
20 2086 2101 11827497 thromboembolism NN B-NP D013923
21 2101 2102 11827497 ; : O O
22 2103 2110 11827497 therapy NN B-NP O
23 2111 2115 11827497 with IN B-PP O
24 2116 2127 11827497 alternative JJ B-NP O
25 2128 2142 11827497 anticoagulants NNS I-NP O
26 2142 2143 11827497 , , B-NP O
27 2144 2147 11827497 not RB I-NP O
28 2148 2155 11827497 heparin NN I-NP D006493
29 2155 2156 11827497 , , O O
30 2157 2163 11827497 should MD B-VP O
31 2164 2166 11827497 be VB I-VP O
32 2167 2176 11827497 initiated VBN I-VP O
33 2176 2177 11827497 . . O O

1 0 0 17285209 -DOCSTART- -X- -X- O

1 0 11 17285209 Angiotensin NN B-NP O
2 11 12 17285209 - HYPH O O
3 12 22 17285209 converting VBG B-VP O
4 23 29 17285209 enzyme NN B-NP O
5 30 31 17285209 ( ( O O
6 31 34 17285209 ACE NN B-NP O
7 34 35 17285209 ) ) O O
8 36 45 17285209 inhibitor NN B-NP O
9 45 46 17285209 - HYPH O O
10 46 56 17285209 associated VBN B-NP O
11 57 67 17285209 angioedema NN I-NP D000799
12 68 70 17285209 of IN B-PP O
13 71 74 17285209 the DT B-NP O
14 75 82 17285209 stomach NN I-NP O
15 83 86 17285209 and CC O O
16 87 92 17285209 small JJ B-NP O
17 93 102 17285209 intestine NN I-NP O
18 102 103 17285209 : : O O
19 104 105 17285209 a DT B-NP O
20 106 110 17285209 case NN I-NP O
21 111 117 17285209 report NN I-NP O
22 117 118 17285209 . . O O
23 119 123 17285209 This DT B-NP O
24 124 126 17285209 is VBZ B-VP O
25 127 128 17285209 a DT B-NP O
26 129 133 17285209 case NN I-NP O
27 134 140 17285209 report NN I-NP O
28 141 143 17285209 on IN B-PP O
29 144 145 17285209 a DT B-NP O
30 146 148 17285209 45 CD I-NP O
31 148 149 17285209 - HYPH I-NP O
32 149 153 17285209 year NN I-NP O
33 154 157 17285209 old JJ I-NP O
34 158 165 17285209 African JJ I-NP O
35 165 166 17285209 - HYPH I-NP O
36 166 174 17285209 American JJ I-NP O
37 175 181 17285209 female NN I-NP O
38 182 186 17285209 with IN B-PP O
39 187 192 17285209 newly RB B-NP O
40 193 202 17285209 diagnosed VBN I-NP O
41 203 215 17285209 hypertension NN I-NP D006973
42 215 216 17285209 , , O O
43 217 220 17285209 who WP B-NP O
44 221 224 17285209 was VBD B-VP O
45 225 232 17285209 started VBN I-VP O
46 233 235 17285209 on IN B-PP O
47 236 237 17285209 a DT B-NP O
48 238 249 17285209 combination NN I-NP O
49 250 254 17285209 pill NN I-NP O
50 255 257 17285209 of IN B-PP O
51 258 268 17285209 amlodipine NN B-NP D017311
52 268 269 17285209 / SYM O O
53 269 279 17285209 benazapril NN B-NP C044946
54 280 282 17285209 10 CD I-NP O
55 282 283 17285209 / SYM I-NP O
56 283 284 17285209 5 CD I-NP O
57 285 287 17285209 mg NN I-NP O
58 287 288 17285209 . . O O

1 289 292 17285209 The DT B-NP O
2 293 297 17285209 very RB I-NP O
3 298 302 17285209 next JJ I-NP O
4 303 306 17285209 day NN I-NP O
5 306 307 17285209 , , O O
6 308 311 17285209 she PRP B-NP O
7 312 321 17285209 presented VBD B-VP O
8 322 324 17285209 at IN B-PP O
9 325 328 17285209 the DT B-NP O
10 329 338 17285209 emergency NN I-NP O
11 339 343 17285209 room NN I-NP O
12 344 345 17285209 ( ( O O
13 345 347 17285209 ER NN B-NP O
14 347 348 17285209 ) ) O O
15 349 353 17285209 with IN B-PP O
16 354 363 17285209 abdominal JJ B-NP D015746
17 364 368 17285209 pain NN I-NP D015746
18 368 369 17285209 , , I-NP O
19 370 376 17285209 nausea NN I-NP D009325
20 377 380 17285209 and CC I-NP O
21 381 389 17285209 vomiting NN I-NP D014839
22 389 390 17285209 . . O O

1 391 399 17285209 Physical JJ B-NP O
2 400 404 17285209 exam NN I-NP O
3 404 405 17285209 , , O O
4 406 414 17285209 complete JJ B-NP O
5 415 424 17285209 metabolic JJ I-NP O
6 425 430 17285209 panel NN I-NP O
7 430 431 17285209 , , O O
8 432 435 17285209 and CC O O
9 436 444 17285209 hemogram NN B-NP O
10 445 449 17285209 were VBD B-VP O
11 450 452 17285209 in IN B-PP O
12 453 456 17285209 the DT B-NP O
13 457 463 17285209 normal JJ I-NP O
14 464 469 17285209 range NN I-NP O
15 469 470 17285209 . . O O

1 471 474 17285209 She PRP B-NP O
2 475 478 17285209 was VBD B-VP O
3 479 489 17285209 discharged VBN I-VP O
4 490 494 17285209 from IN B-PP O
5 495 498 17285209 the DT B-NP O
6 499 501 17285209 ER NN I-NP O
7 502 507 17285209 after IN B-PP O
8 508 509 17285209 a DT B-NP O
9 510 513 17285209 few JJ I-NP O
10 514 519 17285209 hours NNS I-NP O
11 520 522 17285209 of IN B-PP O
12 523 532 17285209 treatment NN B-NP O
13 533 537 17285209 with IN B-PP O
14 538 543 17285209 fluid NN B-NP O
15 544 547 17285209 and CC I-NP O
16 548 558 17285209 analgesics NNS I-NP O
17 558 559 17285209 . . O O

1 560 567 17285209 However RB B-ADVP O
2 567 568 17285209 , , O O
3 569 572 17285209 she PRP B-NP O
4 573 581 17285209 returned VBD B-VP O
5 582 584 17285209 to TO B-PP O
6 585 588 17285209 the DT B-NP O
7 589 591 17285209 ER NN I-NP O
8 592 595 17285209 the DT B-NP O
9 596 600 17285209 next JJ I-NP O
10 601 604 17285209 day NN I-NP O
11 605 609 17285209 with IN B-PP O
12 610 613 17285209 the DT B-NP O
13 614 618 17285209 same JJ I-NP O
14 619 629 17285209 complaints NNS I-NP O
15 629 630 17285209 . . O O

1 631 635 17285209 This DT B-NP O
2 636 640 17285209 time NN I-NP O
3 641 644 17285209 the DT B-NP O
4 645 653 17285209 physical JJ I-NP O
5 654 658 17285209 exam NN I-NP O
6 659 662 17285209 was VBD B-VP O
7 663 674 17285209 significant JJ B-ADJP O
8 675 678 17285209 for IN B-PP O
9 679 680 17285209 a DT B-NP O
10 681 690 17285209 distended JJ I-NP O
11 691 698 17285209 abdomen NN I-NP O
12 699 703 17285209 with IN B-PP O
13 704 712 17285209 dullness NN B-NP O
14 713 715 17285209 to TO B-PP O
15 716 726 17285209 percussion NN B-NP O
16 726 727 17285209 . . O O

1 728 730 17285209 CT NN B-NP O
2 731 735 17285209 scan NN I-NP O
3 736 738 17285209 of IN B-PP O
4 739 742 17285209 the DT B-NP O
5 743 750 17285209 abdomen NN I-NP O
6 751 759 17285209 revealed VBD B-VP O
7 760 768 17285209 markedly RB B-NP O
8 769 778 17285209 thickened VBN I-NP O
9 779 785 17285209 antrum NN I-NP O
10 786 788 17285209 of IN B-PP O
11 789 792 17285209 the DT B-NP O
12 793 800 17285209 stomach NN I-NP O
13 800 801 17285209 , , I-NP O
14 802 810 17285209 duodenum NN I-NP O
15 811 814 17285209 and CC I-NP O
16 815 822 17285209 jejunum NN I-NP O
17 822 823 17285209 , , O O
18 824 829 17285209 along IN B-PP O
19 830 834 17285209 with IN B-PP O
20 835 840 17285209 fluid NN B-NP O
21 841 843 17285209 in IN B-PP O
22 844 847 17285209 the DT B-NP O
23 848 857 17285209 abdominal JJ I-NP O
24 858 861 17285209 and CC I-NP O
25 862 868 17285209 pelvic JJ I-NP O
26 869 875 17285209 cavity NN I-NP O
27 875 876 17285209 . . O O

1 877 888 17285209 Angiotensin NN B-NP O
2 888 889 17285209 - HYPH O O
3 889 899 17285209 converting VBG B-VP O
4 900 906 17285209 enzyme NN B-NP O
5 907 916 17285209 inhibitor NN I-NP O
6 917 918 17285209 ( ( O O
7 918 922 17285209 ACEI NN B-NP O
8 922 923 17285209 ) ) O O
9 923 924 17285209 - HYPH B-NP O
10 924 931 17285209 induced VBN I-NP O
11 932 942 17285209 angioedema NN I-NP D000799
12 943 946 17285209 was VBD B-VP O
13 947 956 17285209 suspected VBN I-VP O
14 956 957 17285209 , , O O
15 958 961 17285209 and CC O O
16 962 966 17285209 anti AFX B-NP O
17 966 967 17285209 - HYPH I-NP O
18 967 979 17285209 hypertensive JJ I-NP D006973
19 980 991 17285209 medications NNS I-NP O
20 992 996 17285209 were VBD B-VP O
21 997 1009 17285209 discontinued VBN I-VP O
22 1009 1010 17285209 . . O O

1 1011 1014 17285209 Her PRP$ B-NP O
2 1015 1023 17285209 symptoms NNS I-NP O
3 1024 1032 17285209 improved VBN B-VP O
4 1033 1039 17285209 within IN B-PP O
5 1040 1043 17285209 the DT B-NP O
6 1044 1048 17285209 next JJ I-NP O
7 1049 1051 17285209 24 CD I-NP O
8 1052 1057 17285209 hours NNS I-NP O
9 1057 1058 17285209 , , O O
10 1059 1062 17285209 and CC O O
11 1063 1069 17285209 repeat NN B-NP O
12 1070 1072 17285209 CT NN I-NP O
13 1073 1078 17285209 after IN B-PP O
14 1079 1081 17285209 72 CD B-NP O
15 1082 1087 17285209 hours NNS I-NP O
16 1088 1096 17285209 revealed VBD B-VP O
17 1097 1103 17285209 marked JJ B-NP O
18 1104 1115 17285209 improvement NN I-NP O
19 1116 1118 17285209 in IN B-PP O
20 1119 1126 17285209 stomach NN B-NP O
21 1127 1130 17285209 and CC O O
22 1131 1136 17285209 small JJ B-NP O
23 1137 1142 17285209 bowel NN I-NP O
24 1143 1153 17285209 thickening NN I-NP O
25 1154 1157 17285209 and CC I-NP O
26 1158 1168 17285209 resolution NN I-NP O
27 1169 1171 17285209 of IN B-PP O
28 1172 1179 17285209 ascites NNS B-NP D001201
29 1179 1180 17285209 . . O O

1 1181 1184 17285209 The DT B-NP O
2 1185 1196 17285209 recognition NN I-NP O
3 1197 1199 17285209 of IN B-PP O
4 1200 1211 17285209 angiotensin NN B-NP D000809
5 1211 1212 17285209 - HYPH O O
6 1212 1222 17285209 converting VBG B-VP O
7 1223 1229 17285209 enzyme NN B-NP O
8 1230 1231 17285209 ( ( O O
9 1231 1234 17285209 ACE NN B-NP O
10 1234 1235 17285209 ) ) O O
11 1236 1239 17285209 and CC O O
12 1240 1251 17285209 angiotensin NN B-NP D000809
13 1252 1260 17285209 receptor NN I-NP O
14 1261 1268 17285209 blocker NN I-NP O
15 1269 1270 17285209 ( ( O O
16 1270 1273 17285209 ARB NN B-NP O
17 1273 1274 17285209 ) ) O O
18 1275 1285 17285209 intestinal JJ B-NP D007410
19 1286 1296 17285209 angioedema NN I-NP D007410
20 1297 1308 17285209 constitutes VBZ B-VP O
21 1309 1310 17285209 a DT B-NP O
22 1311 1320 17285209 challenge NN I-NP O
23 1321 1323 17285209 to TO B-PP O
24 1324 1331 17285209 primary JJ B-NP O
25 1332 1336 17285209 care NN I-NP O
26 1337 1347 17285209 physicians NNS I-NP O
27 1347 1348 17285209 , , O O
28 1349 1359 17285209 internists NNS B-NP O
29 1359 1360 17285209 , , O O
30 1361 1370 17285209 emergency NN B-NP O
31 1371 1375 17285209 room NN I-NP O
32 1376 1384 17285209 personal JJ B-ADJP O
33 1385 1388 17285209 and CC O O
34 1389 1397 17285209 surgeons NNS B-NP O
35 1397 1398 17285209 . . O O

1 0 0 3703509 -DOCSTART- -X- -X- O

1 0 13 3703509 Hyperglycemic JJ B-NP D006943
2 14 22 3703509 acidotic JJ I-NP D006943
3 23 27 3703509 coma NN I-NP D006943
4 28 31 3703509 and CC I-NP O
5 32 37 3703509 death NN I-NP O
6 38 40 3703509 in IN B-PP O
7 41 47 3703509 Kearns NNP B-NP D007625
8 47 48 3703509 - HYPH B-NP D007625
9 48 53 3703509 Sayre NNP I-NP D007625
10 54 62 3703509 syndrome NN I-NP D007625
11 62 63 3703509 . . O O
12 64 68 3703509 This DT B-NP O
13 69 74 3703509 paper NN I-NP O
14 75 83 3703509 presents VBZ B-VP O
15 84 87 3703509 the DT B-NP O
16 88 96 3703509 clinical JJ I-NP O
17 97 100 3703509 and CC I-NP O
18 101 110 3703509 metabolic JJ I-NP O
19 111 119 3703509 findings NNS I-NP O
20 120 122 3703509 in IN B-PP O
21 123 126 3703509 two CD B-NP O
22 127 132 3703509 young JJ I-NP O
23 133 137 3703509 boys NNS I-NP O
24 138 142 3703509 with IN B-PP O
25 143 147 3703509 long RB B-NP O
26 147 148 3703509 - HYPH I-NP O
27 148 156 3703509 standing VBG B-VP O
28 157 163 3703509 Kearns NNP B-NP D007625
29 163 164 3703509 - HYPH I-NP D007625
30 164 169 3703509 Sayre NNP I-NP D007625
31 170 178 3703509 syndrome NN I-NP D007625
32 178 179 3703509 . . O O

1 180 189 3703509 Following VBG B-PP O
2 190 195 3703509 short JJ B-NP O
3 196 204 3703509 exposure NN I-NP O
4 205 207 3703509 to TO B-PP O
5 208 212 3703509 oral JJ B-NP O
6 213 223 3703509 prednisone NN I-NP D011241
7 223 224 3703509 , , O O
8 225 229 3703509 both DT B-NP O
9 230 234 3703509 boys NNS I-NP O
10 235 244 3703509 developed VBD B-VP O
11 245 253 3703509 lethargy NN B-NP D053609
12 253 254 3703509 , , O O
13 255 265 3703509 increasing VBG B-VP O
14 266 276 3703509 somnolence NN B-NP D006970
15 276 277 3703509 , , O O
16 278 288 3703509 polydipsia NN B-NP D059606
17 288 289 3703509 , , O O
18 290 300 3703509 polyphagia NN B-NP D006963
19 300 301 3703509 , , O O
20 302 305 3703509 and CC O O
21 306 314 3703509 polyuria NN B-NP D011141
22 314 315 3703509 . . O O

1 316 320 3703509 Both DT B-NP O
2 321 330 3703509 presented VBD B-VP O
3 331 333 3703509 in IN B-PP O
4 334 337 3703509 the DT B-NP O
5 338 347 3703509 emergency NN I-NP O
6 348 352 3703509 room NN I-NP O
7 353 357 3703509 with IN B-PP O
8 358 366 3703509 profound JJ B-NP O
9 367 371 3703509 coma NN I-NP D003128
10 371 372 3703509 , , O O
11 373 384 3703509 hypotension NN B-NP D007022
12 384 385 3703509 , , O O
13 386 392 3703509 severe JJ B-NP O
14 393 406 3703509 hyperglycemia NN I-NP D006943
15 406 407 3703509 , , O O
16 408 411 3703509 and CC O O
17 412 420 3703509 acidosis NN B-NP D000138
18 420 421 3703509 . . O O

1 422 432 3703509 Nonketotic JJ B-NP O
2 433 439 3703509 lactic JJ I-NP D000140
3 440 448 3703509 acidosis NN I-NP D000140
4 449 452 3703509 was VBD B-VP O
5 453 460 3703509 present JJ B-ADJP O
6 461 463 3703509 in IN B-PP O
7 464 467 3703509 one CD B-NP O
8 468 471 3703509 and CC O O
9 472 479 3703509 ketosis NN B-NP D007662
10 480 487 3703509 without IN B-PP O
11 488 489 3703509 a DT B-NP O
12 490 495 3703509 known VBN I-NP O
13 496 501 3703509 serum NN I-NP O
14 502 509 3703509 lactate NN I-NP D019344
15 510 515 3703509 level NN I-NP O
16 516 519 3703509 was VBD B-VP O
17 520 527 3703509 present JJ B-ADJP O
18 528 530 3703509 in IN B-PP O
19 531 534 3703509 the DT B-NP O
20 535 540 3703509 other JJ I-NP O
21 540 541 3703509 . . O O

1 542 553 3703509 Respiratory JJ B-NP D012131
2 554 561 3703509 failure NN I-NP D012131
3 562 569 3703509 rapidly RB B-ADVP O
4 570 576 3703509 ensued VBD B-VP O
5 577 580 3703509 and CC O O
6 581 585 3703509 both DT B-NP O
7 586 594 3703509 patients NNS I-NP O
8 595 602 3703509 expired VBD B-VP O
9 603 605 3703509 in IN B-PP O
10 606 611 3703509 spite NN B-NP O
11 612 614 3703509 of IN B-PP O
12 615 622 3703509 efforts NNS B-NP O
13 623 625 3703509 at IN B-PP O
14 626 639 3703509 resuscitation NN B-NP O
15 639 640 3703509 . . O O

1 641 643 3703509 We PRP B-NP O
2 644 651 3703509 believe VBP B-VP O
3 652 657 3703509 these DT B-NP O
4 658 661 3703509 two CD I-NP O
5 662 667 3703509 cases NNS I-NP O
6 668 677 3703509 represent VBP B-VP O
7 678 679 3703509 a DT B-NP O
8 680 685 3703509 newly RB I-NP O
9 686 695 3703509 described VBN I-NP O
10 696 699 3703509 and CC I-NP O
11 700 712 3703509 catastrophic JJ I-NP O
12 713 722 3703509 metabolic JJ I-NP -1
13 722 723 3703509 - HYPH I-NP -1
14 723 732 3703509 endocrine JJ I-NP -1
15 733 740 3703509 failure NN I-NP -1
16 741 743 3703509 in IN B-PP O
17 744 747 3703509 the DT B-NP O
18 748 754 3703509 Kearns NNP I-NP D007625
19 754 755 3703509 - HYPH I-NP D007625
20 755 760 3703509 Sayre NNP I-NP D007625
21 761 769 3703509 syndrome NN I-NP D007625
22 769 770 3703509 . . O O

1 0 0 12549952 -DOCSTART- -X- -X- O

1 0 5 12549952 Acute JJ B-NP D017114
2 6 11 12549952 liver NN I-NP D017114
3 12 19 12549952 failure NN I-NP D017114
4 20 24 12549952 with IN B-PP O
5 25 35 12549952 concurrent JJ B-NP O
6 36 45 12549952 bupropion NN I-NP D016642
7 46 49 12549952 and CC I-NP O
8 50 61 12549952 carbimazole NN I-NP D002231
9 62 69 12549952 therapy NN I-NP O
10 69 70 12549952 . . I-NP O
11 71 80 12549952 OBJECTIVE NN I-NP O
12 80 81 12549952 : : O O
13 82 84 12549952 To TO B-VP O
14 85 91 12549952 report VB I-VP O
15 92 93 12549952 a DT B-NP O
16 94 98 12549952 case NN I-NP O
17 99 101 12549952 of IN B-PP O
18 102 107 12549952 fatal JJ B-NP O
19 108 113 12549952 liver NN I-NP D017093
20 114 121 12549952 failure NN I-NP D017093
21 122 130 12549952 possibly RB B-VP O
22 131 141 12549952 associated VBN I-VP O
23 142 146 12549952 with IN B-PP O
24 147 157 12549952 concurrent JJ B-NP O
25 158 161 12549952 use NN I-NP O
26 162 164 12549952 of IN B-PP O
27 165 174 12549952 bupropion NN B-NP D016642
28 175 178 12549952 and CC I-NP O
29 179 190 12549952 carbimazole NN I-NP D002231
30 190 191 12549952 . . O O

1 192 196 12549952 CASE NN B-NP O
2 197 204 12549952 SUMMARY NN I-NP O
3 204 205 12549952 : : O O
4 206 207 12549952 A DT B-NP O
5 208 210 12549952 41 CD I-NP O
6 210 211 12549952 - HYPH I-NP O
7 211 215 12549952 year NN I-NP O
8 215 216 12549952 - HYPH O O
9 216 219 12549952 old JJ B-NP O
10 220 227 12549952 Chinese JJ I-NP O
11 228 231 12549952 man NN I-NP O
12 232 236 12549952 with IN B-PP O
13 237 238 12549952 a DT B-NP O
14 239 246 12549952 history NN I-NP O
15 247 249 12549952 of IN B-PP O
16 250 265 12549952 hyperthyroidism NN B-NP D006980
17 266 269 12549952 had VBD B-VP O
18 270 274 12549952 been VBN I-VP O
19 275 282 12549952 treated VBN I-VP O
20 283 287 12549952 with IN B-PP O
21 288 299 12549952 carbimazole NN B-NP D002231
22 300 303 12549952 and CC I-NP O
23 304 315 12549952 propranolol NN I-NP D011433
24 316 319 12549952 for IN B-PP O
25 320 323 12549952 the DT B-NP O
26 324 328 12549952 past JJ I-NP O
27 329 330 12549952 5 CD I-NP O
28 331 336 12549952 years NNS I-NP O
29 336 337 12549952 . . O O

1 338 340 12549952 He PRP B-NP O
2 341 349 12549952 received VBD B-VP O
3 350 351 12549952 a DT B-NP O
4 352 354 12549952 10 CD I-NP O
5 354 355 12549952 - HYPH I-NP O
6 355 358 12549952 day NN I-NP O
7 359 365 12549952 course NN I-NP O
8 366 368 12549952 of IN B-PP O
9 369 378 12549952 bupropion NN B-NP D016642
10 379 381 12549952 as IN B-PP O
11 382 384 12549952 an DT B-NP O
12 385 388 12549952 aid NN I-NP O
13 389 392 12549952 for IN B-PP O
14 393 400 12549952 smoking VBG B-VP O
15 401 410 12549952 cessation NN B-NP O
16 411 413 12549952 10 CD B-NP O
17 414 419 12549952 weeks NNS I-NP O
18 420 425 12549952 prior RB B-ADVP O
19 426 428 12549952 to TO B-PP O
20 429 441 12549952 presentation NN B-NP O
21 441 442 12549952 . . O O

1 443 445 12549952 He PRP B-NP O
2 446 455 12549952 developed VBD B-VP O
3 456 461 12549952 acute JJ B-NP D017114
4 462 467 12549952 liver NN I-NP D017114
5 468 475 12549952 failure NN I-NP D017114
6 476 480 12549952 with IN B-PP O
7 481 486 12549952 rapid JJ B-NP O
8 487 500 12549952 deterioration NN I-NP O
9 501 503 12549952 of IN B-PP O
10 504 509 12549952 renal JJ B-NP O
11 510 518 12549952 function NN I-NP O
12 518 519 12549952 . . O O

1 520 525 12549952 Liver NN B-NP O
2 526 532 12549952 biopsy NN I-NP O
3 533 539 12549952 showed VBD B-VP O
4 540 548 12549952 evidence NN B-NP O
5 549 551 12549952 of IN B-PP O
6 552 563 12549952 nonspecific JJ B-NP O
7 564 568 12549952 drug NN I-NP D056486
8 568 569 12549952 - HYPH O D056486
9 569 576 12549952 induced VBN B-NP D056486
10 577 582 12549952 acute JJ I-NP D056486
11 583 588 12549952 liver NN I-NP D056486
12 589 595 12549952 injury NN I-NP D056486
13 595 596 12549952 . . O O

1 597 600 12549952 His PRP$ B-NP O
2 601 610 12549952 condition NN I-NP O
3 611 614 12549952 was VBD B-VP O
4 615 622 12549952 further RBR I-VP O
5 623 634 12549952 complicated VBN I-VP O
6 635 637 12549952 by IN B-PP O
7 638 644 12549952 sepsis NN B-NP D018805
8 645 648 12549952 and CC I-NP O
9 649 661 12549952 coagulopathy NN I-NP D001778
10 661 662 12549952 . . O O

1 663 668 12549952 Death NN B-NP O
2 669 677 12549952 resulted VBD B-VP O
3 678 680 12549952 19 CD B-NP O
4 681 685 12549952 days NNS I-NP O
5 686 691 12549952 after IN B-PP O
6 692 695 12549952 the DT B-NP O
7 696 701 12549952 onset NN I-NP O
8 702 704 12549952 of IN B-PP O
9 705 713 12549952 symptoms NNS B-NP O
10 713 714 12549952 . . O O

1 715 718 12549952 The DT B-NP O
2 719 729 12549952 likelihood NN I-NP O
3 730 734 12549952 that IN B-SBAR O
4 735 744 12549952 bupropion NN B-NP D016642
5 745 752 12549952 induced VBD B-VP O
6 753 767 12549952 hepatotoxicity NN B-NP D056486
7 768 770 12549952 in IN B-PP O
8 771 774 12549952 our PRP$ B-NP O
9 775 782 12549952 patient NN I-NP O
10 783 786 12549952 was VBD B-VP O
11 787 795 12549952 possible JJ B-ADJP O
12 795 796 12549952 , , O O
13 797 802 12549952 based VBN B-PP O
14 803 805 12549952 on IN B-PP O
15 806 809 12549952 the DT B-NP O
16 810 817 12549952 Naranjo NNP I-NP O
17 818 829 12549952 probability NN I-NP O
18 830 835 12549952 scale NN I-NP O
19 835 836 12549952 . . O O

1 837 847 12549952 DISCUSSION NN B-NP O
2 847 848 12549952 : : O O
3 849 857 12549952 Although IN B-SBAR O
4 858 863 12549952 there EX B-NP O
5 864 866 12549952 is VBZ B-VP O
6 867 877 12549952 increasing VBG I-VP O
7 878 886 12549952 evidence NN B-NP O
8 887 889 12549952 of IN B-PP O
9 890 904 12549952 hepatotoxicity NN B-NP D056486
10 905 912 12549952 induced VBN B-VP O
11 913 915 12549952 by IN B-PP O
12 916 925 12549952 bupropion NN B-NP D016642
13 925 926 12549952 , , O O
14 927 931 12549952 this DT B-NP O
15 932 934 12549952 is VBZ B-VP O
16 935 938 12549952 the DT B-NP O
17 939 944 12549952 first JJ I-NP O
18 945 949 12549952 case NN I-NP O
19 950 952 12549952 of IN B-PP O
20 953 961 12549952 fatality NN B-NP O
21 962 966 12549952 that WDT B-NP O
22 967 972 12549952 could MD B-VP O
23 973 977 12549952 have VB I-VP O
24 978 986 12549952 resulted VBN I-VP O
25 987 991 12549952 from IN B-PP O
26 992 997 12549952 acute JJ B-NP D017114
27 998 1003 12549952 liver NN I-NP D017114
28 1004 1011 12549952 failure NN I-NP D017114
29 1012 1014 12549952 in IN B-PP O
30 1015 1016 12549952 a DT B-NP O
31 1017 1024 12549952 patient NN I-NP O
32 1025 1034 12549952 receiving VBG B-VP O
33 1035 1044 12549952 bupropion NN B-NP D016642
34 1045 1050 12549952 while IN B-SBAR O
35 1051 1053 12549952 on IN B-PP O
36 1054 1065 12549952 concomitant JJ B-NP O
37 1066 1075 12549952 treatment NN I-NP O
38 1076 1080 12549952 with IN B-PP O
39 1081 1092 12549952 carbimazole NN B-NP D002231
40 1092 1093 12549952 . . O O

1 1094 1105 12549952 CONCLUSIONS NNS B-NP O
2 1105 1106 12549952 : : O O
3 1107 1117 12549952 Clinicians NNS B-NP O
4 1118 1124 12549952 should MD B-VP O
5 1125 1127 12549952 be VB I-VP O
6 1128 1133 12549952 aware JJ B-ADJP O
7 1134 1136 12549952 of IN B-PP O
8 1137 1140 12549952 the DT B-NP O
9 1141 1152 12549952 possibility NN I-NP O
10 1153 1155 12549952 of IN B-PP O
11 1156 1161 12549952 acute JJ B-NP D017114
12 1162 1167 12549952 liver NN I-NP D017114
13 1168 1174 12549952 insult NN I-NP D017114
14 1175 1182 12549952 induced VBN B-VP O
15 1183 1185 12549952 by IN B-PP O
16 1186 1195 12549952 bupropion NN B-NP D016642
17 1196 1201 12549952 given VBN B-VP O
18 1202 1214 12549952 concurrently RB B-ADVP O
19 1215 1219 12549952 with IN B-PP O
20 1220 1225 12549952 other JJ B-NP O
21 1226 1237 12549952 hepatotoxic JJ I-NP D056486
22 1238 1243 12549952 drugs NNS I-NP O
23 1243 1244 12549952 . . O O

1 0 0 3057041 -DOCSTART- -X- -X- O

1 0 11 3057041 Multicenter JJ B-NP O
2 11 12 3057041 , , I-NP O
3 13 19 3057041 double JJ I-NP O
4 19 20 3057041 - HYPH I-NP O
5 20 25 3057041 blind JJ I-NP O
6 25 26 3057041 , , I-NP O
7 27 35 3057041 multiple JJ I-NP O
8 35 36 3057041 - HYPH I-NP O
9 36 40 3057041 dose NN I-NP O
10 40 41 3057041 , , O O
11 42 50 3057041 parallel JJ B-NP O
12 50 51 3057041 - HYPH I-NP O
13 51 57 3057041 groups NNS I-NP O
14 58 66 3057041 efficacy NN I-NP O
15 67 70 3057041 and CC I-NP O
16 71 77 3057041 safety NN I-NP O
17 78 83 3057041 trial NN I-NP O
18 84 86 3057041 of IN B-PP O
19 87 97 3057041 azelastine NN B-NP C020976
20 97 98 3057041 , , O O
21 99 115 3057041 chlorpheniramine NN B-NP D002744
22 115 116 3057041 , , O O
23 117 120 3057041 and CC O O
24 121 128 3057041 placebo NN B-NP O
25 129 131 3057041 in IN B-PP O
26 132 135 3057041 the DT B-NP O
27 136 145 3057041 treatment NN I-NP O
28 146 148 3057041 of IN B-PP O
29 149 155 3057041 spring NN B-NP D006255
30 156 164 3057041 allergic JJ I-NP D006255
31 165 173 3057041 rhinitis NN I-NP D006255
32 173 174 3057041 . . I-NP O
33 175 185 3057041 Azelastine NN I-NP C020976
34 185 186 3057041 , , O O
35 187 188 3057041 a DT B-NP O
36 189 194 3057041 novel JJ I-NP O
37 195 207 3057041 antiallergic JJ I-NP O
38 208 218 3057041 medication NN I-NP O
39 218 219 3057041 , , O O
40 220 223 3057041 was VBD B-VP O
41 224 232 3057041 compared VBN I-VP O
42 233 237 3057041 with IN B-PP O
43 238 254 3057041 chlorpheniramine NN B-NP D002744
44 255 262 3057041 maleate NN I-NP D002744
45 263 266 3057041 and CC I-NP O
46 267 274 3057041 placebo NN I-NP O
47 275 278 3057041 for IN B-PP O
48 279 287 3057041 efficacy NN B-NP O
49 288 291 3057041 and CC I-NP O
50 292 298 3057041 safety NN I-NP O
51 299 301 3057041 in IN B-PP O
52 302 305 3057041 the DT B-NP O
53 306 315 3057041 treatment NN I-NP O
54 316 318 3057041 of IN B-PP O
55 319 325 3057041 spring NN B-NP D006255
56 326 334 3057041 allergic JJ I-NP D006255
57 335 343 3057041 rhinitis NN I-NP D006255
58 344 346 3057041 in IN B-PP O
59 347 348 3057041 a DT B-NP O
60 349 360 3057041 multicenter JJ I-NP O
61 360 361 3057041 , , I-NP O
62 362 368 3057041 double JJ I-NP O
63 368 369 3057041 - HYPH I-NP O
64 369 374 3057041 blind JJ I-NP O
65 374 375 3057041 , , I-NP O
66 376 384 3057041 multiple JJ I-NP O
67 384 385 3057041 - HYPH I-NP O
68 385 389 3057041 dose NN I-NP O
69 389 390 3057041 , , O O
70 391 399 3057041 parallel JJ B-NP O
71 399 400 3057041 - HYPH I-NP O
72 400 406 3057041 groups NNS I-NP O
73 407 412 3057041 study NN I-NP O
74 412 413 3057041 . . O O

1 414 417 3057041 One CD B-NP O
2 418 425 3057041 hundred CD I-NP O
3 426 431 3057041 fifty CD I-NP O
4 431 432 3057041 - HYPH I-NP O
5 432 436 3057041 five CD I-NP O
6 437 445 3057041 subjects NNS I-NP O
7 446 458 3057041 participated VBD B-VP O
8 458 459 3057041 . . O O

1 460 468 3057041 Subjects NNS B-NP O
2 469 475 3057041 ranged VBD B-VP O
3 476 478 3057041 in IN B-PP O
4 479 482 3057041 age NN B-NP O
5 483 487 3057041 from IN B-PP O
6 488 490 3057041 18 CD B-NP O
7 491 493 3057041 to TO I-NP O
8 494 496 3057041 60 CD I-NP O
9 497 502 3057041 years NNS I-NP O
10 503 505 3057041 of IN B-PP O
11 506 509 3057041 age NN B-NP O
12 510 513 3057041 and CC O O
13 514 517 3057041 had VBD B-VP O
14 518 520 3057041 at IN B-ADVP O
15 521 526 3057041 least JJS I-ADVP O
16 527 528 3057041 a DT B-NP O
17 529 530 3057041 2 CD I-NP O
18 530 531 3057041 - HYPH I-NP O
19 531 535 3057041 year NN I-NP O
20 536 543 3057041 history NN I-NP O
21 544 546 3057041 of IN B-PP O
22 547 553 3057041 spring NN B-NP D006255
23 554 562 3057041 allergic JJ I-NP D006255
24 563 571 3057041 rhinitis NN I-NP D006255
25 571 572 3057041 , , O O
26 573 582 3057041 confirmed VBN B-VP O
27 583 585 3057041 by IN B-PP O
28 586 594 3057041 positive JJ B-NP O
29 595 599 3057041 skin NN I-NP O
30 600 604 3057041 test NN I-NP O
31 605 607 3057041 to TO B-PP O
32 608 614 3057041 spring NN B-NP O
33 615 628 3057041 aeroallergens NNS I-NP O
34 628 629 3057041 . . O O

1 630 641 3057041 Medications NNS B-NP O
2 642 646 3057041 were VBD B-VP O
3 647 652 3057041 given VBN I-VP O
4 653 657 3057041 four CD B-NP O
5 658 663 3057041 times NNS I-NP O
6 664 669 3057041 daily RB I-NP O
7 669 670 3057041 ; : O O
8 671 674 3057041 the DT B-NP O
9 675 685 3057041 azelastine NN I-NP C020976
10 686 692 3057041 groups NNS I-NP O
11 693 701 3057041 received VBD B-VP O
12 702 705 3057041 0.5 CD B-NP O
13 705 706 3057041 , , I-NP O
14 707 710 3057041 1.0 CD I-NP O
15 710 711 3057041 , , O O
16 712 714 3057041 or CC O O
17 715 718 3057041 2.0 CD B-NP O
18 719 721 3057041 mg NN I-NP O
19 722 724 3057041 in IN B-PP O
20 725 728 3057041 the DT B-NP O
21 729 736 3057041 morning NN I-NP O
22 737 740 3057041 and CC I-NP O
23 741 748 3057041 evening NN I-NP O
24 749 753 3057041 with IN B-PP O
25 754 761 3057041 placebo NN B-NP O
26 762 764 3057041 in IN B-PP O
27 765 768 3057041 the DT B-NP O
28 769 774 3057041 early JJ I-NP O
29 775 778 3057041 and CC I-NP O
30 779 783 3057041 late JJ I-NP O
31 784 793 3057041 afternoon NN I-NP O
32 793 794 3057041 ; : O O
33 795 798 3057041 the DT B-NP O
34 799 815 3057041 chlorpheniramine NN I-NP D002744
35 816 821 3057041 group NN I-NP O
36 822 830 3057041 received VBD B-VP O
37 831 834 3057041 4.0 CD B-NP O
38 835 837 3057041 mg NN I-NP O
39 838 842 3057041 four CD B-NP O
40 843 848 3057041 times NNS I-NP O
41 849 854 3057041 daily RB I-NP O
42 854 855 3057041 . . O O

1 856 861 3057041 Daily JJ B-NP O
2 862 869 3057041 subject NN I-NP O
3 870 877 3057041 symptom NN I-NP O
4 878 883 3057041 cards NNS I-NP O
5 884 888 3057041 were VBD B-VP O
6 889 898 3057041 completed VBN I-VP O
7 899 905 3057041 during IN B-PP O
8 906 907 3057041 a DT B-NP O
9 908 917 3057041 screening NN I-NP O
10 918 924 3057041 period NN I-NP O
11 925 927 3057041 to TO B-VP O
12 928 934 3057041 assess VB I-VP O
13 935 947 3057041 pretreatment NN B-NP O
14 948 956 3057041 symptoms NNS I-NP O
15 957 960 3057041 and CC B-PP O
16 961 967 3057041 during IN B-PP O
17 968 969 3057041 a DT B-NP O
18 970 971 3057041 4 CD I-NP O
19 971 972 3057041 - HYPH I-NP O
20 972 976 3057041 week NN I-NP O
21 977 986 3057041 treatment NN I-NP O
22 987 993 3057041 period NN I-NP O
23 994 999 3057041 while IN B-SBAR O
24 1000 1008 3057041 subjects NNS B-NP O
25 1009 1017 3057041 received VBD B-VP O
26 1018 1023 3057041 study NN B-NP O
27 1024 1035 3057041 medications NNS I-NP O
28 1035 1036 3057041 . . O O

1 1037 1047 3057041 Individual JJ B-NP O
2 1048 1056 3057041 symptoms NNS I-NP O
3 1056 1057 3057041 , , O O
4 1058 1063 3057041 total JJ B-NP O
5 1064 1072 3057041 symptoms NNS I-NP O
6 1072 1073 3057041 , , O O
7 1074 1077 3057041 and CC O O
8 1078 1083 3057041 major JJ B-NP O
9 1084 1092 3057041 symptoms NNS I-NP O
10 1093 1097 3057041 were VBD B-VP O
11 1098 1106 3057041 compared VBN I-VP O
12 1107 1109 3057041 to TO B-VP O
13 1110 1119 3057041 determine VB I-VP O
14 1120 1128 3057041 efficacy NN B-NP O
15 1129 1131 3057041 of IN B-PP O
16 1132 1142 3057041 medication NN B-NP O
17 1142 1143 3057041 . . O O

1 1144 1152 3057041 Elicited VBN B-VP O
2 1152 1153 3057041 , , O O
3 1154 1165 3057041 volunteered VBN B-VP O
4 1165 1166 3057041 , , O O
5 1167 1170 3057041 and CC O O
6 1171 1179 3057041 observed VBD B-VP O
7 1180 1187 3057041 adverse JJ B-NP O
8 1188 1199 3057041 experiences NNS I-NP O
9 1200 1204 3057041 were VBD B-VP O
10 1205 1213 3057041 recorded VBN I-VP O
11 1214 1217 3057041 for IN B-PP O
12 1218 1222 3057041 each DT B-NP O
13 1223 1230 3057041 subject NN I-NP O
14 1231 1234 3057041 and CC O O
15 1235 1243 3057041 compared VBN B-VP O
16 1244 1249 3057041 among IN B-PP O
17 1250 1256 3057041 groups NNS B-NP O
18 1256 1257 3057041 . . O O

1 1258 1263 3057041 Vital JJ B-NP O
2 1264 1269 3057041 signs NNS I-NP O
3 1269 1270 3057041 , , O O
4 1271 1275 3057041 body NN B-NP O
5 1276 1283 3057041 weights NNS I-NP O
6 1283 1284 3057041 , , O O
7 1285 1290 3057041 serum NN B-NP O
8 1291 1300 3057041 chemistry NN I-NP O
9 1301 1307 3057041 values NNS I-NP O
10 1307 1308 3057041 , , O O
11 1309 1317 3057041 complete JJ B-NP O
12 1318 1323 3057041 blood NN I-NP O
13 1324 1328 3057041 cell NN I-NP O
14 1329 1335 3057041 counts NNS I-NP O
15 1335 1336 3057041 , , O O
16 1337 1342 3057041 urine NN B-NP O
17 1343 1350 3057041 studies NNS I-NP O
18 1350 1351 3057041 , , O O
19 1352 1355 3057041 and CC O O
20 1356 1374 3057041 electrocardiograms NNS B-NP O
21 1375 1379 3057041 were VBD B-VP O
22 1380 1388 3057041 obtained VBN I-VP O
23 1389 1392 3057041 for IN B-PP O
24 1393 1397 3057041 each DT B-NP O
25 1398 1405 3057041 subject NN I-NP O
26 1406 1409 3057041 and CC O O
27 1410 1418 3057041 compared VBN B-VP O
28 1419 1424 3057041 among IN B-PP O
29 1425 1431 3057041 groups NNS B-NP O
30 1431 1432 3057041 . . O O

1 1433 1441 3057041 Symptoms NNS B-NP O
2 1442 1448 3057041 relief NN I-NP O
3 1449 1451 3057041 in IN B-PP O
4 1452 1455 3057041 the DT B-NP O
5 1456 1461 3057041 group NN I-NP O
6 1462 1471 3057041 receiving VBG B-VP O
7 1472 1475 3057041 the DT B-NP O
8 1476 1483 3057041 highest JJS I-NP O
9 1484 1497 3057041 concentration NN I-NP O
10 1498 1500 3057041 of IN B-PP O
11 1501 1511 3057041 azelastine NN B-NP C020976
12 1512 1513 3057041 ( ( O O
13 1513 1516 3057041 2.0 CD B-NP O
14 1517 1519 3057041 mg NN I-NP O
15 1520 1525 3057041 twice RB B-ADVP O
16 1526 1531 3057041 daily RB I-ADVP O
17 1531 1532 3057041 ) ) O O
18 1533 1536 3057041 was VBD B-VP O
19 1537 1550 3057041 statistically RB B-ADJP O
20 1551 1558 3057041 greater JJR I-ADJP O
21 1559 1563 3057041 than IN B-PP O
22 1564 1566 3057041 in IN B-PP O
23 1567 1570 3057041 the DT B-NP O
24 1571 1578 3057041 placebo NN I-NP O
25 1579 1584 3057041 group NN I-NP O
26 1585 1591 3057041 during IN B-PP O
27 1592 1595 3057041 all DT B-NP O
28 1596 1601 3057041 weeks NNS I-NP O
29 1602 1604 3057041 of IN B-PP O
30 1605 1608 3057041 the DT B-NP O
31 1609 1614 3057041 study NN I-NP O
32 1614 1615 3057041 . . O O

1 1616 1621 3057041 Lower JJR B-NP O
2 1622 1627 3057041 doses NNS I-NP O
3 1628 1630 3057041 of IN B-PP O
4 1631 1641 3057041 azelastine NN B-NP C020976
5 1642 1646 3057041 were VBD B-VP O
6 1647 1660 3057041 statistically RB B-ADJP O
7 1661 1665 3057041 more RBR I-ADJP O
8 1666 1675 3057041 effective JJ I-ADJP O
9 1676 1680 3057041 than IN B-PP O
10 1681 1688 3057041 placebo NN B-NP O
11 1689 1693 3057041 only RB B-ADVP O
12 1694 1700 3057041 during IN B-PP O
13 1701 1709 3057041 portions NNS B-NP O
14 1710 1712 3057041 of IN B-PP O
15 1713 1716 3057041 the DT B-NP O
16 1717 1722 3057041 first JJ I-NP O
17 1723 1724 3057041 3 CD I-NP O
18 1725 1730 3057041 weeks NNS I-NP O
19 1731 1733 3057041 of IN B-PP O
20 1734 1737 3057041 the DT B-NP O
21 1738 1743 3057041 study NN I-NP O
22 1743 1744 3057041 . . O O

1 1745 1747 3057041 In IN B-PP O
2 1748 1756 3057041 contrast NN B-NP O
3 1756 1757 3057041 , , O O
4 1758 1766 3057041 although IN B-SBAR O
5 1767 1770 3057041 the DT B-NP O
6 1771 1787 3057041 chlorpheniramine NN I-NP D002744
7 1788 1793 3057041 group NN I-NP O
8 1794 1797 3057041 did VBD B-VP O
9 1798 1802 3057041 have VB I-VP O
10 1803 1808 3057041 fewer JJR B-NP O
11 1809 1817 3057041 symptoms NNS I-NP O
12 1818 1822 3057041 than IN B-PP O
13 1823 1826 3057041 the DT B-NP O
14 1827 1834 3057041 placebo NN I-NP O
15 1835 1840 3057041 group NN I-NP O
16 1841 1847 3057041 during IN B-PP O
17 1848 1851 3057041 the DT B-NP O
18 1852 1857 3057041 study NN I-NP O
19 1857 1858 3057041 , , O O
20 1859 1862 3057041 the DT B-NP O
21 1863 1873 3057041 difference NN I-NP O
22 1874 1879 3057041 never RB B-ADVP O
23 1880 1887 3057041 reached VBD B-VP O
24 1888 1899 3057041 statistical JJ B-NP O
25 1900 1912 3057041 significance NN I-NP O
26 1913 1919 3057041 during IN B-PP O
27 1920 1923 3057041 any DT B-NP O
28 1924 1928 3057041 week NN I-NP O
29 1929 1931 3057041 of IN B-PP O
30 1932 1935 3057041 the DT B-NP O
31 1936 1941 3057041 study NN I-NP O
32 1941 1942 3057041 . . O O

1 1943 1948 3057041 There EX B-NP O
2 1949 1953 3057041 were VBD B-VP O
3 1954 1956 3057041 no DT B-NP O
4 1957 1964 3057041 serious JJ I-NP O
5 1965 1969 3057041 side NN I-NP O
6 1970 1977 3057041 effects NNS I-NP O
7 1978 1980 3057041 in IN B-PP O
8 1981 1984 3057041 any DT B-NP O
9 1985 1987 3057041 of IN B-PP O
10 1988 1991 3057041 the DT B-NP O
11 1992 2001 3057041 treatment NN I-NP O
12 2002 2008 3057041 groups NNS I-NP O
13 2008 2009 3057041 . . O O

1 2010 2020 3057041 Drowsiness NN B-NP D006970
2 2021 2024 3057041 and CC I-NP O
3 2025 2032 3057041 altered JJ I-NP D013651
4 2033 2038 3057041 taste NN I-NP D013651
5 2039 2049 3057041 perception NN I-NP D013651
6 2050 2054 3057041 were VBD B-VP O
7 2055 2064 3057041 increased VBN I-VP O
8 2065 2078 3057041 significantly RB B-ADVP O
9 2079 2083 3057041 over IN B-PP O
10 2084 2091 3057041 placebo NN B-NP O
11 2092 2096 3057041 only RB B-ADVP O
12 2097 2099 3057041 in IN B-PP O
13 2100 2103 3057041 the DT B-NP O
14 2104 2108 3057041 high JJ I-NP O
15 2108 2109 3057041 - HYPH I-NP O
16 2109 2113 3057041 dose NN I-NP O
17 2114 2124 3057041 azelastine NN I-NP C020976
18 2125 2130 3057041 group NN I-NP O
19 2130 2131 3057041 . . O O

1 2132 2142 3057041 Azelastine NN B-NP C020976
2 2143 2150 3057041 appears VBZ B-VP O
3 2151 2153 3057041 to TO I-VP O
4 2154 2156 3057041 be VB I-VP O
5 2157 2158 3057041 a DT B-NP O
6 2159 2163 3057041 safe JJ I-NP O
7 2163 2164 3057041 , , I-NP O
8 2165 2176 3057041 efficacious JJ I-NP O
9 2177 2187 3057041 medication NN I-NP O
10 2188 2191 3057041 for IN B-PP O
11 2192 2200 3057041 seasonal JJ B-NP D006255
12 2201 2209 3057041 allergic JJ I-NP D006255
13 2210 2218 3057041 rhinitis NN I-NP D006255
14 2218 2219 3057041 . . O O

1 0 0 3015327 -DOCSTART- -X- -X- O

1 0 11 3015327 Remodelling NN B-NP O
2 12 14 3015327 of IN B-PP O
3 15 20 3015327 nerve NN B-NP O
4 21 30 3015327 structure NN I-NP O
5 31 33 3015327 in IN B-PP O
6 34 46 3015327 experimental JJ B-NP O
7 47 56 3015327 isoniazid NN I-NP D007538
8 57 67 3015327 neuropathy NN I-NP D009422
9 68 70 3015327 in IN B-PP O
10 71 74 3015327 the DT B-NP O
11 75 78 3015327 rat NN I-NP O
12 78 79 3015327 . . O O
13 80 83 3015327 The DT B-NP O
14 84 94 3015327 neuropathy NN I-NP D009422
15 95 101 3015327 caused VBN B-VP O
16 102 104 3015327 by IN B-PP O
17 105 106 3015327 a DT B-NP O
18 107 113 3015327 single JJ I-NP O
19 114 118 3015327 dose NN I-NP O
20 119 121 3015327 of IN B-PP O
21 122 131 3015327 isoniazid NN B-NP D007538
22 132 134 3015327 in IN B-PP O
23 135 139 3015327 rats NNS B-NP O
24 140 143 3015327 was VBD B-VP O
25 144 151 3015327 studied VBN I-VP O
26 152 156 3015327 with IN B-PP O
27 157 158 3015327 a DT B-NP O
28 159 167 3015327 computer NN I-NP O
29 167 168 3015327 - HYPH O O
30 168 176 3015327 assisted VBN B-VP O
31 177 189 3015327 morphometric JJ B-NP O
32 190 196 3015327 method NN I-NP O
33 196 197 3015327 . . O O

1 198 205 3015327 Scatter NN B-NP O
2 206 214 3015327 diagrams NNS I-NP O
3 215 217 3015327 of IN B-PP O
4 218 221 3015327 the DT B-NP O
5 222 223 3015327 g NN I-NP O
6 224 229 3015327 ratio NN I-NP O
7 230 231 3015327 ( ( O O
8 231 239 3015327 quotient NN B-NP O
9 240 245 3015327 fibre NN I-NP O
10 246 254 3015327 diameter NN I-NP O
11 254 255 3015327 / SYM B-NP O
12 255 259 3015327 axon NN I-NP O
13 260 268 3015327 diameter NN I-NP O
14 268 269 3015327 ) ) O O
15 270 276 3015327 define NN B-NP O
16 277 289 3015327 regenerating VBG B-VP O
17 290 296 3015327 fibres NNS B-NP O
18 297 299 3015327 as IN B-PP O
19 300 301 3015327 a DT B-NP O
20 302 310 3015327 distinct JJ I-NP O
21 311 321 3015327 population NN I-NP O
22 321 322 3015327 , , O O
23 323 338 3015327 distinguishable JJ B-ADJP O
24 339 343 3015327 from IN B-PP O
25 344 347 3015327 the DT B-NP O
26 348 357 3015327 surviving VBG I-NP O
27 358 364 3015327 fibres NNS I-NP O
28 365 367 3015327 by IN B-PP O
29 368 375 3015327 reduced VBN B-NP O
30 376 382 3015327 sheath NN I-NP O
31 383 392 3015327 thickness NN I-NP O
32 393 396 3015327 and CC O O
33 397 404 3015327 reduced VBD B-VP O
34 405 409 3015327 axon NN B-NP O
35 410 417 3015327 calibre NN I-NP O
36 417 418 3015327 . . O O

1 419 424 3015327 There EX B-NP O
2 425 428 3015327 was VBD B-VP O
3 429 433 3015327 also RB B-ADVP O
4 434 442 3015327 evidence NN B-NP O
5 443 445 3015327 of IN B-PP O
6 446 447 3015327 a DT B-NP O
7 448 454 3015327 subtle JJ I-NP O
8 455 461 3015327 direct JJ I-NP O
9 462 467 3015327 toxic JJ I-NP O
10 468 474 3015327 effect NN I-NP O
11 475 477 3015327 on IN B-PP O
12 478 481 3015327 the DT B-NP O
13 482 488 3015327 entire JJ I-NP O
14 489 494 3015327 fibre JJ I-NP O
15 495 505 3015327 population NN I-NP O
16 505 506 3015327 , , O O
17 507 514 3015327 causing VBG B-VP O
18 515 519 3015327 axon NN B-NP O
19 520 529 3015327 shrinkage NN I-NP O
20 530 536 3015327 masked VBN B-VP O
21 537 539 3015327 by IN B-PP O
22 540 552 3015327 readjustment NN B-NP O
23 553 555 3015327 of IN B-PP O
24 556 559 3015327 the DT B-NP O
25 560 566 3015327 myelin NN I-NP O
26 567 573 3015327 sheath NN I-NP O
27 573 574 3015327 . . O O

1 0 0 11860278 -DOCSTART- -X- -X- O

1 0 8 11860278 Dopamine NN B-NP D004298
2 9 11 11860278 D2 NN I-NP O
3 12 20 11860278 receptor NN I-NP O
4 21 30 11860278 signaling NN I-NP O
5 31 39 11860278 controls VBZ B-VP O
6 40 48 11860278 neuronal JJ B-NP O
7 49 53 11860278 cell NN I-NP O
8 54 59 11860278 death NN I-NP O
9 60 67 11860278 induced VBN B-VP O
10 68 70 11860278 by IN B-PP O
11 71 81 11860278 muscarinic JJ B-NP O
12 82 85 11860278 and CC I-NP O
13 86 99 11860278 glutamatergic JJ I-NP O
14 100 105 11860278 drugs NNS I-NP O
15 105 106 11860278 . . O O
16 107 115 11860278 Dopamine NN B-NP D004298
17 116 117 11860278 ( ( O O
18 117 119 11860278 DA NN B-NP D004298
19 119 120 11860278 ) ) O O
20 120 121 11860278 , , O O
21 122 129 11860278 through IN B-PP O
22 130 132 11860278 D1 NN B-NP O
23 132 133 11860278 / SYM O O
24 133 135 11860278 D2 NN B-NP O
25 136 144 11860278 receptor NN I-NP O
26 144 145 11860278 - HYPH B-VP O
27 145 153 11860278 mediated VBN B-NP O
28 154 163 11860278 signaling NN I-NP O
29 163 164 11860278 , , O O
30 165 170 11860278 plays VBZ B-VP O
31 171 172 11860278 a DT B-NP O
32 173 178 11860278 major JJ I-NP O
33 179 183 11860278 role NN I-NP O
34 184 186 11860278 in IN B-PP O
35 187 190 11860278 the DT B-NP O
36 191 198 11860278 control NN I-NP O
37 199 201 11860278 of IN B-PP O
38 202 211 11860278 epileptic JJ B-NP D004827
39 212 220 11860278 seizures NNS I-NP D004827
40 221 228 11860278 arising VBG B-VP O
41 229 231 11860278 in IN B-PP O
42 232 235 11860278 the DT B-NP O
43 236 242 11860278 limbic JJ I-NP O
44 243 249 11860278 system NN I-NP O
45 249 250 11860278 . . O O

1 251 265 11860278 Excitotoxicity NN B-NP -1
2 266 273 11860278 leading VBG B-VP O
3 274 276 11860278 to TO B-PP O
4 277 285 11860278 neuronal JJ B-NP O
5 286 290 11860278 cell NN I-NP O
6 291 296 11860278 death NN I-NP O
7 297 299 11860278 in IN B-PP O
8 300 303 11860278 the DT B-NP O
9 304 312 11860278 affected VBN I-NP O
10 313 318 11860278 areas NNS I-NP O
11 319 321 11860278 is VBZ B-VP O
12 322 323 11860278 a DT B-NP O
13 324 329 11860278 major JJ I-NP O
14 330 341 11860278 consequence NN I-NP O
15 342 344 11860278 of IN B-PP O
16 345 353 11860278 seizures NNS B-NP D012640
17 354 356 11860278 at IN B-PP O
18 357 360 11860278 the DT B-NP O
19 361 369 11860278 cellular JJ I-NP O
20 370 375 11860278 level NN I-NP O
21 375 376 11860278 . . O O

1 377 379 11860278 In IN B-PP O
2 380 384 11860278 this DT B-NP O
3 385 392 11860278 respect NN I-NP O
4 392 393 11860278 , , O O
5 394 400 11860278 little JJ B-NP O
6 401 403 11860278 is VBZ B-VP O
7 404 409 11860278 known VBN I-VP O
8 410 415 11860278 about IN B-PP O
9 416 419 11860278 the DT B-NP O
10 420 424 11860278 role NN I-NP O
11 425 427 11860278 of IN B-PP O
12 428 430 11860278 DA NN B-NP D004298
13 431 440 11860278 receptors NNS I-NP O
14 441 443 11860278 in IN B-PP O
15 444 447 11860278 the DT B-NP O
16 448 458 11860278 occurrence NN I-NP O
17 459 461 11860278 of IN B-PP O
18 462 470 11860278 epilepsy NN B-NP D004827
19 470 471 11860278 - HYPH B-NP O
20 471 478 11860278 induced VBN I-NP O
21 479 487 11860278 neuronal JJ I-NP O
22 488 492 11860278 cell NN I-NP O
23 493 498 11860278 death NN I-NP O
24 498 499 11860278 . . O O

1 500 504 11860278 Here RB B-ADVP O
2 505 507 11860278 we PRP B-NP O
3 508 515 11860278 analyze VBP B-VP O
4 516 519 11860278 the DT B-NP O
5 520 530 11860278 occurrence NN I-NP O
6 531 533 11860278 of IN B-PP O
7 534 542 11860278 seizures NNS B-NP D012640
8 543 546 11860278 and CC O O
9 547 560 11860278 neurotoxicity NN B-NP D020258
10 561 563 11860278 in IN B-PP O
11 564 567 11860278 D2R NN B-NP O
12 568 569 11860278 - HYPH O O
13 569 570 11860278 / SYM O O
14 570 571 11860278 - HYPH O O
15 572 576 11860278 mice NNS B-NP O
16 577 584 11860278 treated VBN B-VP O
17 585 589 11860278 with IN B-PP O
18 590 593 11860278 the DT B-NP O
19 594 605 11860278 cholinergic JJ I-NP O
20 606 613 11860278 agonist NN I-NP O
21 614 625 11860278 pilocarpine NN I-NP D010862
22 625 626 11860278 . . O O

1 627 629 11860278 We PRP B-NP O
2 630 638 11860278 compared VBD B-VP O
3 639 644 11860278 these DT B-NP O
4 645 652 11860278 results NNS I-NP O
5 653 657 11860278 with IN B-PP O
6 658 663 11860278 those DT B-NP O
7 664 674 11860278 previously RB B-VP O
8 675 683 11860278 obtained VBN I-VP O
9 684 688 11860278 with IN B-PP O
10 689 695 11860278 kainic JJ B-NP D007608
11 696 700 11860278 acid NN I-NP D007608
12 701 702 11860278 ( ( O O
13 702 704 11860278 KA NN B-NP D007608
14 704 705 11860278 ) ) O O
15 705 706 11860278 , , O O
16 707 708 11860278 a DT B-NP O
17 709 715 11860278 potent JJ I-NP O
18 716 725 11860278 glutamate NN I-NP D018698
19 726 733 11860278 agonist NN I-NP O
20 733 734 11860278 . . O O

1 735 746 11860278 Importantly RB B-ADVP O
2 746 747 11860278 , , O O
3 748 751 11860278 D2R NN B-NP O
4 752 753 11860278 - HYPH O O
5 753 754 11860278 / SYM O O
6 754 755 11860278 - HYPH O O
7 756 760 11860278 mice NNS B-NP O
8 761 768 11860278 develop VBP B-VP O
9 769 777 11860278 seizures NNS B-NP D012640
10 778 780 11860278 at IN B-PP O
11 781 786 11860278 doses NNS B-NP O
12 787 789 11860278 of IN B-PP O
13 790 794 11860278 both DT B-NP O
14 795 800 11860278 drugs NNS I-NP O
15 801 805 11860278 that WDT B-NP O
16 806 809 11860278 are VBP B-VP O
17 810 813 11860278 not RB O O
18 814 827 11860278 epileptogenic JJ B-ADJP O
19 828 831 11860278 for IN B-PP O
20 832 834 11860278 WT JJ B-NP O
21 835 846 11860278 littermates NNS I-NP O
22 847 850 11860278 and CC O O
23 851 855 11860278 show VB B-VP O
24 856 863 11860278 greater JJR B-NP O
25 864 877 11860278 neurotoxicity NN I-NP D020258
26 877 878 11860278 . . O O

1 879 886 11860278 However RB B-ADVP O
2 886 887 11860278 , , O O
3 888 899 11860278 pilocarpine NN B-NP D010862
4 899 900 11860278 - HYPH B-NP O
5 900 907 11860278 induced VBN I-NP O
6 908 916 11860278 seizures NNS I-NP D012640
7 917 923 11860278 result VBP B-VP O
8 924 926 11860278 in IN B-PP O
9 927 928 11860278 a DT B-NP O
10 929 933 11860278 more RBR I-NP O
11 934 944 11860278 widespread JJ I-NP O
12 945 953 11860278 neuronal JJ I-NP O
13 954 959 11860278 death NN I-NP O
14 960 962 11860278 in IN B-PP O
15 963 967 11860278 both CC O O
16 968 970 11860278 WT NN B-NP O
17 971 974 11860278 and CC I-NP O
18 975 978 11860278 D2R NN I-NP O
19 979 980 11860278 - HYPH O O
20 980 981 11860278 / SYM O O
21 981 982 11860278 - HYPH O O
22 983 989 11860278 brains NNS B-NP O
23 990 992 11860278 in IN B-PP O
24 993 1003 11860278 comparison NN B-NP O
25 1004 1006 11860278 to TO B-PP O
26 1007 1009 11860278 KA NN B-NP D007608
27 1009 1010 11860278 . . O O

1 1011 1015 11860278 Thus RB B-ADVP O
2 1015 1016 11860278 , , O O
3 1017 1020 11860278 the DT B-NP O
4 1021 1028 11860278 absence NN I-NP O
5 1029 1031 11860278 of IN B-PP O
6 1032 1035 11860278 D2R NN B-NP O
7 1036 1042 11860278 lowers VBZ B-VP O
8 1043 1046 11860278 the DT B-NP O
9 1047 1056 11860278 threshold NN I-NP O
10 1057 1060 11860278 for IN B-PP O
11 1061 1069 11860278 seizures NNS B-NP D012640
12 1070 1077 11860278 induced VBN B-VP O
13 1078 1080 11860278 by IN B-PP O
14 1081 1085 11860278 both CC O O
15 1086 1095 11860278 glutamate NN B-NP D018698
16 1096 1099 11860278 and CC I-NP O
17 1100 1113 11860278 acetylcholine NN I-NP D000109
18 1113 1114 11860278 . . O O

1 1115 1123 11860278 Moreover RB B-ADVP O
2 1123 1124 11860278 , , O O
3 1125 1128 11860278 the DT B-NP O
4 1129 1141 11860278 dopaminergic JJ I-NP O
5 1142 1149 11860278 control NN I-NP O
6 1150 1152 11860278 of IN B-PP O
7 1153 1161 11860278 epilepsy NN B-NP D004827
8 1161 1162 11860278 - HYPH B-NP O
9 1162 1169 11860278 induced VBN I-NP O
10 1170 1187 11860278 neurodegeneration NN I-NP D019636
11 1188 1193 11860278 seems VBZ B-VP O
12 1194 1196 11860278 to TO I-VP O
13 1197 1199 11860278 be VB I-VP O
14 1200 1208 11860278 mediated VBN I-VP O
15 1209 1211 11860278 by IN B-PP O
16 1212 1220 11860278 distinct JJ B-NP O
17 1221 1233 11860278 interactions NNS I-NP O
18 1234 1236 11860278 of IN B-PP O
19 1237 1240 11860278 D2R NN B-NP O
20 1241 1250 11860278 signaling NN I-NP O
21 1251 1255 11860278 with IN B-PP O
22 1256 1261 11860278 these DT B-NP O
23 1262 1265 11860278 two CD I-NP O
24 1266 1283 11860278 neurotransmitters NNS I-NP O
25 1283 1284 11860278 . . O O

1 0 0 8278214 -DOCSTART- -X- -X- O

1 0 12 8278214 Hyperalgesia NN B-NP D006930
2 13 16 8278214 and CC I-NP O
3 17 26 8278214 myoclonus NN I-NP D009207
4 27 29 8278214 in IN B-PP O
5 30 38 8278214 terminal JJ B-NP O
6 39 45 8278214 cancer NN I-NP D009369
7 46 54 8278214 patients NNS I-NP O
8 55 62 8278214 treated VBN B-VP O
9 63 67 8278214 with IN B-PP O
10 68 78 8278214 continuous JJ B-NP O
11 79 90 8278214 intravenous JJ I-NP O
12 91 99 8278214 morphine NN I-NP D009020
13 99 100 8278214 . . O O
14 101 106 8278214 Eight CD B-NP O
15 107 113 8278214 cancer NN I-NP D009369
16 114 122 8278214 patients NNS I-NP O
17 123 125 8278214 in IN B-PP O
18 126 129 8278214 the DT B-NP O
19 130 138 8278214 terminal JJ I-NP O
20 139 145 8278214 stages NNS I-NP O
21 146 148 8278214 of IN B-PP O
22 149 152 8278214 the DT B-NP O
23 153 160 8278214 disease NN I-NP O
24 161 168 8278214 treated VBN B-VP O
25 169 173 8278214 with IN B-PP O
26 174 178 8278214 high JJ B-NP O
27 179 184 8278214 doses NNS I-NP O
28 185 187 8278214 of IN B-PP O
29 188 199 8278214 intravenous JJ B-NP O
30 200 208 8278214 morphine NN I-NP D009020
31 209 218 8278214 developed VBD B-VP O
32 219 231 8278214 hyperalgesia NN B-NP D006930
33 231 232 8278214 . . O O

1 233 236 8278214 All DT B-NP O
2 237 242 8278214 cases NNS I-NP O
3 243 247 8278214 were VBD B-VP O
4 248 263 8278214 retrospectively RB I-VP O
5 264 271 8278214 sampled VBN I-VP O
6 272 276 8278214 from IN B-PP O
7 277 282 8278214 three CD B-NP O
8 283 292 8278214 different JJ I-NP O
9 293 302 8278214 hospitals NNS I-NP O
10 303 305 8278214 in IN B-PP O
11 306 316 8278214 Copenhagen NN B-NP O
12 316 317 8278214 . . O O

1 318 322 8278214 Five CD B-NP O
2 323 331 8278214 patients NNS I-NP O
3 332 341 8278214 developed VBD B-VP O
4 342 351 8278214 universal JJ B-NP O
5 352 364 8278214 hyperalgesia NN I-NP D006930
6 365 368 8278214 and CC I-NP O
7 369 382 8278214 hyperesthesia NN I-NP D006941
8 383 388 8278214 which WDT B-NP O
9 389 391 8278214 in IN B-PP O
10 392 393 8278214 2 CD B-NP O
11 394 399 8278214 cases NNS I-NP O
12 400 404 8278214 were VBD B-VP O
13 405 416 8278214 accompanied VBN I-VP O
14 417 419 8278214 by IN B-PP O
15 420 429 8278214 myoclonus NN B-NP D009207
16 429 430 8278214 . . O O

1 431 433 8278214 In IN B-PP O
2 434 435 8278214 3 CD B-NP O
3 436 444 8278214 patients NNS I-NP O
4 445 446 8278214 a DT B-NP O
5 447 450 8278214 pre AFX I-NP O
6 450 451 8278214 - HYPH I-NP O
7 451 459 8278214 existing VBG I-NP O
8 460 469 8278214 neuralgia NN I-NP D009437
9 470 479 8278214 increased VBD B-VP O
10 480 482 8278214 to TO B-PP O
11 483 495 8278214 excruciating VBG B-NP O
12 496 505 8278214 intensity NN I-NP O
13 506 509 8278214 and CC O O
14 510 512 8278214 in IN B-PP O
15 513 514 8278214 2 CD B-NP O
16 515 517 8278214 of IN B-PP O
17 518 523 8278214 these DT B-NP O
18 524 529 8278214 cases NNS I-NP O
19 530 539 8278214 myoclonus NN I-NP D009207
20 540 548 8278214 occurred VBD B-VP O
21 549 563 8278214 simultaneously RB B-ADVP O
22 563 564 8278214 . . O O

1 565 573 8278214 Although IN B-SBAR O
2 574 578 8278214 only JJ B-NP O
3 579 582 8278214 few JJ I-NP O
4 583 591 8278214 clinical JJ I-NP O
5 592 604 8278214 descriptions NNS I-NP O
6 605 607 8278214 of IN B-PP O
7 608 611 8278214 the DT B-NP O
8 612 624 8278214 relationship NN I-NP O
9 625 632 8278214 between IN B-PP O
10 633 645 8278214 hyperalgesia NN B-NP D006930
11 645 646 8278214 / SYM B-NP O
12 646 655 8278214 myoclonus NN I-NP D009207
13 656 659 8278214 and CC O O
14 660 664 8278214 high JJ B-NP O
15 665 670 8278214 doses NNS I-NP O
16 671 673 8278214 of IN B-PP O
17 674 682 8278214 morphine NN B-NP D009020
18 683 686 8278214 are VBP B-VP O
19 687 696 8278214 available JJ B-ADJP O
20 696 697 8278214 , , O O
21 698 710 8278214 experimental JJ B-NP O
22 711 718 8278214 support NN I-NP O
23 719 723 8278214 from IN B-PP O
24 724 730 8278214 animal NN B-NP O
25 731 738 8278214 studies NNS I-NP O
26 739 748 8278214 indicates VBZ B-VP O
27 749 753 8278214 that IN B-SBAR O
28 754 762 8278214 morphine NN B-NP D009020
29 762 763 8278214 , , O O
30 764 766 8278214 or CC O O
31 767 770 8278214 its PRP$ B-NP O
32 771 782 8278214 metabolites NNS I-NP O
33 782 783 8278214 , , O O
34 784 789 8278214 plays VBZ B-VP O
35 790 791 8278214 a DT B-NP O
36 792 801 8278214 causative JJ I-NP O
37 802 806 8278214 role NN I-NP O
38 807 810 8278214 for IN B-PP O
39 811 814 8278214 the DT B-NP O
40 815 823 8278214 observed VBN I-NP O
41 824 835 8278214 behavioural JJ I-NP O
42 836 844 8278214 syndrome NN I-NP O
43 844 845 8278214 . . O O

1 846 849 8278214 The DT B-NP O
2 850 858 8278214 possible JJ I-NP O
3 859 869 8278214 mechanisms NNS I-NP O
4 870 873 8278214 are VBP B-VP O
5 874 883 8278214 discussed VBN I-VP O
6 884 887 8278214 and CC O O
7 888 897 8278214 treatment NN B-NP O
8 898 907 8278214 proposals NNS I-NP O
9 908 913 8278214 given VBN B-PP O
10 914 924 8278214 suggesting VBG B-VP O
11 925 928 8278214 the DT B-NP O
12 929 932 8278214 use NN I-NP O
13 933 935 8278214 of IN B-PP O
14 936 940 8278214 more JJR B-NP O
15 941 952 8278214 efficacious JJ I-NP O
16 953 960 8278214 opioids NNS I-NP O
17 961 965 8278214 with IN B-PP O
18 966 970 8278214 less RBR B-NP O
19 971 981 8278214 excitatory JJ I-NP O
20 982 989 8278214 potency NN I-NP O
21 990 992 8278214 in IN B-PP O
22 993 998 8278214 these DT B-NP O
23 999 1009 8278214 situations NNS I-NP O
24 1009 1010 8278214 . . O O

1 0 0 28952 -DOCSTART- -X- -X- O

1 0 7 28952 Initial JJ B-NP O
2 8 17 28952 potassium NN I-NP D011188
3 18 22 28952 loss NN I-NP O
4 23 26 28952 and CC I-NP O
5 27 39 28952 hypokalaemia NN I-NP D007008
6 40 46 28952 during IN B-PP O
7 47 61 28952 chlorthalidone NN B-NP D002752
8 62 76 28952 administration NN I-NP O
9 77 79 28952 in IN B-PP O
10 80 88 28952 patients NNS B-NP O
11 89 93 28952 with IN B-PP O
12 94 103 28952 essential JJ B-NP O
13 104 116 28952 hypertension NN I-NP D006973
14 116 117 28952 : : O O
15 118 121 28952 the DT B-NP O
16 122 131 28952 influence NN I-NP O
17 132 134 28952 of IN B-PP O
18 135 142 28952 dietary JJ B-NP O
19 143 149 28952 sodium NN I-NP D012964
20 150 161 28952 restriction NN I-NP O
21 161 162 28952 . . O O
22 163 165 28952 To TO B-VP O
23 166 177 28952 investigate VB I-VP O
24 178 181 28952 the DT B-NP O
25 182 189 28952 initial JJ I-NP O
26 190 199 28952 potassium NN I-NP D011188
27 200 204 28952 loss NN I-NP O
28 205 208 28952 and CC I-NP O
29 209 220 28952 development NN I-NP O
30 221 223 28952 of IN B-PP O
31 224 236 28952 hypokalaemia NN B-NP D007008
32 237 243 28952 during IN B-PP O
33 244 247 28952 the DT B-NP O
34 248 262 28952 administration NN I-NP O
35 263 265 28952 of IN B-PP O
36 266 268 28952 an DT B-NP O
37 269 273 28952 oral JJ I-NP O
38 274 282 28952 diuretic JJ I-NP O
39 282 283 28952 , , I-NP O
40 284 293 28952 metabolic JJ I-NP O
41 294 301 28952 balance NN I-NP O
42 302 309 28952 studies NNS I-NP O
43 310 314 28952 were VBD B-VP O
44 315 324 28952 performed VBN I-VP O
45 325 327 28952 in IN B-PP O
46 328 331 28952 ten CD B-NP O
47 332 340 28952 patients NNS I-NP O
48 341 345 28952 with IN B-PP O
49 346 355 28952 essential JJ B-NP O
50 356 368 28952 hypertension NN I-NP D006973
51 369 372 28952 who WP B-NP O
52 373 376 28952 had VBD B-VP O
53 377 382 28952 shown VBN I-VP O
54 383 395 28952 hypokalaemia NN B-NP D007008
55 396 401 28952 under IN B-PP O
56 402 407 28952 prior JJ B-NP O
57 408 412 28952 oral JJ I-NP O
58 413 421 28952 diuretic JJ I-NP O
59 422 431 28952 treatment NN I-NP O
60 431 432 28952 . . O O

1 433 447 28952 Chlorthalidone NN B-NP D002752
2 448 449 28952 ( ( O O
3 449 451 28952 50 CD B-NP O
4 452 454 28952 mg NN I-NP O
5 455 460 28952 daily JJ I-NP O
6 460 461 28952 ) ) O O
7 462 465 28952 was VBD B-VP O
8 466 471 28952 given VBN I-VP O
9 472 475 28952 for IN B-PP O
10 476 478 28952 14 CD B-NP O
11 479 483 28952 days NNS I-NP O
12 483 484 28952 . . O O

1 485 488 28952 Six CD B-NP O
2 489 497 28952 patients NNS I-NP O
3 498 506 28952 received VBD B-VP O
4 507 508 28952 a DT B-NP O
5 509 515 28952 normal JJ I-NP O
6 515 516 28952 - HYPH I-NP O
7 516 522 28952 sodium NN I-NP D012964
8 523 527 28952 diet NN I-NP O
9 528 531 28952 and CC O O
10 532 536 28952 four CD B-NP O
11 537 538 28952 a DT B-NP O
12 539 542 28952 low JJ I-NP O
13 542 543 28952 - HYPH I-NP O
14 543 549 28952 sodium NN I-NP D012964
15 550 551 28952 ( ( O O
16 551 553 28952 17 CD B-NP O
17 554 558 28952 mmol NN I-NP O
18 558 559 28952 / SYM B-NP O
19 559 562 28952 day NN I-NP O
20 562 563 28952 ) ) O O
21 564 568 28952 diet NN B-NP O
22 568 569 28952 . . O O

1 570 573 28952 All DT B-NP O
2 574 582 28952 patients NNS I-NP O
3 583 586 28952 had VBD B-VP O
4 587 588 28952 a DT B-NP O
5 589 595 28952 normal JJ I-NP O
6 596 603 28952 initial JJ I-NP O
7 604 609 28952 total JJ I-NP O
8 610 614 28952 body NN I-NP O
9 615 624 28952 potassium NN I-NP D011188
10 625 626 28952 ( ( O O
11 626 629 28952 40K NN B-NP O
12 629 630 28952 ) ) O O
13 630 631 28952 . . O O

1 632 635 28952 The DT B-NP O
2 636 647 28952 electrolyte NN I-NP O
3 648 656 28952 balances NNS I-NP O
4 656 657 28952 , , O O
5 658 664 28952 weight NN B-NP O
6 664 665 28952 , , O O
7 666 673 28952 bromide NN B-NP O
8 674 679 28952 space NN I-NP O
9 679 680 28952 , , O O
10 681 687 28952 plasma NN B-NP O
11 688 693 28952 renin NN I-NP O
12 694 702 28952 activity NN I-NP O
13 702 703 28952 , , O O
14 704 707 28952 and CC O O
15 708 719 28952 aldosterone NN B-NP D000450
16 720 729 28952 secretion NN I-NP O
17 730 734 28952 rate NN I-NP O
18 735 739 28952 were VBD B-VP O
19 740 748 28952 measured VBN I-VP O
20 748 749 28952 . . O O

1 750 752 28952 In IN B-PP O
2 753 757 28952 both DT B-NP O
3 758 764 28952 groups NNS I-NP O
4 765 766 28952 a DT B-NP O
5 767 776 28952 potassium NN I-NP D011188
6 777 784 28952 deficit NN I-NP O
7 785 794 28952 developed VBD B-VP O
8 794 795 28952 , , O O
9 796 800 28952 with IN B-PP O
10 801 815 28952 proportionally RB B-NP O
11 816 822 28952 larger JJR I-NP O
12 823 829 28952 losses NNS I-NP O
13 830 834 28952 from IN B-PP O
14 835 838 28952 the DT B-NP O
15 839 852 28952 extracellular JJ I-NP O
16 853 857 28952 than IN B-PP O
17 858 862 28952 from IN B-PP O
18 863 866 28952 the DT B-NP O
19 867 880 28952 intracellular JJ I-NP O
20 881 892 28952 compartment NN I-NP O
21 892 893 28952 . . O O

1 894 896 28952 In IN B-PP O
2 897 900 28952 the DT B-NP O
3 901 907 28952 normal JJ I-NP O
4 907 908 28952 - HYPH I-NP O
5 908 914 28952 sodium NN I-NP D012964
6 915 920 28952 group NN I-NP O
7 921 924 28952 the DT B-NP O
8 925 932 28952 highest JJS I-NP O
9 933 937 28952 mean JJ I-NP O
10 938 947 28952 potassium NN I-NP D011188
11 948 955 28952 deficit NN I-NP O
12 956 959 28952 was VBD B-VP O
13 960 963 28952 176 CD B-NP O
14 964 968 28952 mmol NN I-NP O
15 969 971 28952 on IN B-PP O
16 972 975 28952 day NN B-NP O
17 976 977 28952 9 CD I-NP O
18 977 978 28952 , , O O
19 979 984 28952 after IN B-PP O
20 985 990 28952 which WDT B-NP O
21 991 995 28952 some DT B-NP O
22 996 1005 28952 potassium NN I-NP D011188
23 1006 1009 28952 was VBD B-VP O
24 1010 1018 28952 regained VBN I-VP O
25 1018 1019 28952 ; : O O
26 1020 1022 28952 in IN B-PP O
27 1023 1026 28952 the DT B-NP O
28 1027 1030 28952 low JJ I-NP O
29 1030 1031 28952 - HYPH I-NP O
30 1031 1037 28952 sodium NN I-NP D012964
31 1038 1043 28952 group NN I-NP O
32 1044 1047 28952 the DT B-NP O
33 1048 1055 28952 highest JJS I-NP O
34 1056 1063 28952 deficit NN I-NP O
35 1064 1067 28952 was VBD B-VP O
36 1068 1071 28952 276 CD B-NP O
37 1072 1076 28952 mmol NN I-NP O
38 1077 1079 28952 on IN B-PP O
39 1080 1083 28952 day NN B-NP O
40 1084 1086 28952 13 CD I-NP O
41 1086 1087 28952 . . O O

1 1088 1091 28952 The DT B-NP O
2 1092 1098 28952 normal JJ I-NP O
3 1098 1099 28952 - HYPH I-NP O
4 1099 1105 28952 sodium NN I-NP D012964
5 1106 1111 28952 group NN I-NP O
6 1112 1118 28952 showed VBD B-VP O
7 1119 1121 28952 an DT B-NP O
8 1122 1131 28952 immediate JJ I-NP O
9 1132 1135 28952 but CC I-NP O
10 1136 1145 28952 temporary JJ I-NP O
11 1146 1150 28952 rise NN I-NP O
12 1151 1153 28952 of IN B-PP O
13 1154 1157 28952 the DT B-NP O
14 1158 1163 28952 renin NN I-NP O
15 1164 1167 28952 and CC I-NP O
16 1168 1179 28952 aldosterone NN I-NP D000450
17 1180 1186 28952 levels NNS I-NP O
18 1186 1187 28952 ; : O O
19 1188 1190 28952 in IN B-PP O
20 1191 1194 28952 the DT B-NP O
21 1195 1198 28952 low JJ I-NP O
22 1198 1199 28952 - HYPH I-NP O
23 1199 1205 28952 sodium NN I-NP D012964
24 1206 1211 28952 group NN I-NP O
25 1212 1217 28952 renin NN I-NP O
26 1218 1221 28952 and CC I-NP O
27 1222 1233 28952 aldosterone NN I-NP D000450
28 1234 1243 28952 increased VBD B-VP O
29 1244 1248 28952 more RBR B-ADVP O
30 1249 1255 28952 slowly RB I-ADVP O
31 1256 1259 28952 but CC O O
32 1260 1268 28952 remained VBD B-VP O
33 1269 1277 28952 elevated VBN I-VP O
34 1277 1278 28952 . . O O

1 1279 1281 28952 It PRP B-NP O
2 1282 1284 28952 is VBZ B-VP O
3 1285 1294 28952 concluded VBN I-VP O
4 1295 1299 28952 that IN B-SBAR O
5 1300 1307 28952 dietary JJ B-NP O
6 1308 1314 28952 sodium NN I-NP D012964
7 1315 1326 28952 restriction NN I-NP O
8 1327 1336 28952 increases VBZ B-VP O
9 1337 1345 28952 diuretic JJ B-ADJP O
10 1345 1346 28952 - HYPH B-NP O
11 1346 1353 28952 induced VBN I-NP O
12 1354 1363 28952 potassium NN I-NP D011188
13 1364 1368 28952 loss NN I-NP O
14 1368 1369 28952 , , O O
15 1370 1380 28952 presumably RB B-ADVP O
16 1381 1383 28952 by IN B-PP O
17 1384 1386 28952 an DT B-NP O
18 1387 1396 28952 increased VBN I-NP O
19 1397 1405 28952 activity NN I-NP O
20 1406 1408 28952 of IN B-PP O
21 1409 1412 28952 the DT B-NP O
22 1413 1418 28952 renin NN I-NP O
23 1418 1419 28952 - HYPH B-NP O
24 1419 1430 28952 angiotensin NN I-NP D000809
25 1430 1431 28952 - HYPH I-NP O
26 1431 1442 28952 aldosterone NN I-NP D000450
27 1443 1449 28952 system NN I-NP O
28 1449 1450 28952 , , O O
29 1451 1456 28952 while IN B-SBAR O
30 1457 1463 28952 sodium NN B-NP D012964
31 1464 1472 28952 delivery NN I-NP O
32 1473 1475 28952 to TO B-PP O
33 1476 1479 28952 the DT B-NP O
34 1480 1486 28952 distal JJ I-NP O
35 1487 1492 28952 renal JJ I-NP O
36 1493 1500 28952 tubules NNS I-NP O
37 1501 1508 28952 remains VBZ B-VP O
38 1509 1521 28952 sufficiently RB B-ADJP O
39 1522 1526 28952 high JJ I-ADJP O
40 1527 1529 28952 to TO B-VP O
41 1530 1535 28952 allow VB I-VP O
42 1536 1545 28952 increased VBN B-NP O
43 1546 1555 28952 potassium NN I-NP D011188
44 1556 1565 28952 secretion NN I-NP O
45 1565 1566 28952 . . O O

1 0 0 3084782 -DOCSTART- -X- -X- O

1 0 8 3084782 Toxicity NN B-NP D064420
2 9 12 3084782 due IN B-PP O
3 13 15 3084782 to TO B-PP O
4 16 25 3084782 remission NN B-NP O
5 26 34 3084782 inducing VBG I-NP O
6 35 40 3084782 drugs NNS I-NP O
7 41 43 3084782 in IN B-PP O
8 44 54 3084782 rheumatoid JJ B-NP D001172
9 55 64 3084782 arthritis NN I-NP D001172
10 64 65 3084782 . . O O

1 66 77 3084782 Association NN B-NP O
2 78 82 3084782 with IN B-PP O
3 83 86 3084782 HLA NN B-NP O
4 86 87 3084782 - HYPH B-NP O
5 87 90 3084782 B35 NN I-NP O
6 91 94 3084782 and CC I-NP O
7 95 98 3084782 Cw4 NN I-NP O
8 99 107 3084782 antigens NNS I-NP O
9 107 108 3084782 . . O O
10 109 115 3084782 Twenty CD B-NP O
11 115 116 3084782 - HYPH O O
12 116 120 3084782 five CD B-NP O
13 121 129 3084782 patients NNS I-NP O
14 130 134 3084782 with IN B-PP O
15 135 145 3084782 rheumatoid JJ B-NP D001172
16 146 155 3084782 arthritis NN I-NP D001172
17 156 157 3084782 ( ( O O
18 157 159 3084782 RA NN B-NP D001172
19 159 160 3084782 ) ) O O
20 161 164 3084782 who WP B-NP O
21 165 174 3084782 developed VBD B-VP O
22 175 183 3084782 toxicity NN B-NP D064420
23 184 189 3084782 while IN B-SBAR O
24 190 196 3084782 taking VBG B-VP O
25 197 206 3084782 remission NN B-NP O
26 207 215 3084782 inducing VBG I-NP O
27 216 221 3084782 drugs NNS I-NP O
28 222 225 3084782 and CC O O
29 226 228 3084782 30 CD B-NP O
30 229 236 3084782 without IN B-PP O
31 237 245 3084782 toxicity NN B-NP D064420
32 246 250 3084782 were VBD B-VP O
33 251 258 3084782 studied VBN I-VP O
34 259 262 3084782 for IN B-PP O
35 263 271 3084782 possible JJ B-NP O
36 272 284 3084782 associations NNS I-NP O
37 285 289 3084782 with IN B-PP O
38 290 295 3084782 class NN B-NP O
39 296 297 3084782 I CD I-NP O
40 298 301 3084782 and CC I-NP O
41 302 304 3084782 II CD I-NP O
42 305 308 3084782 HLA NN I-NP O
43 309 317 3084782 antigens NNS I-NP O
44 317 318 3084782 . . O O

1 319 320 3084782 A DT B-NP O
2 321 327 3084782 strong JJ I-NP O
3 328 339 3084782 association NN I-NP O
4 340 343 3084782 has VBZ B-VP O
5 344 348 3084782 been VBN I-VP O
6 349 354 3084782 found VBN I-VP O
7 355 362 3084782 between IN B-PP O
8 363 372 3084782 nephritis NN B-NP D009393
9 373 376 3084782 and CC I-NP O
10 377 387 3084782 dermatitis NN I-NP D003872
11 388 391 3084782 due JJ B-ADJP O
12 392 394 3084782 to TO B-PP O
13 395 404 3084782 Tiopronin NN B-NP D008625
14 405 406 3084782 ( ( O O
15 406 407 3084782 a DT B-NP O
16 408 409 3084782 D NN I-NP D010396
17 409 410 3084782 - HYPH B-NP D010396
18 410 423 3084782 Penicillamine NN I-NP D010396
19 424 428 3084782 like JJ I-NP O
20 429 437 3084782 compound NN I-NP O
21 437 438 3084782 ) ) O O
22 439 442 3084782 and CC O O
23 443 448 3084782 class NN B-NP O
24 449 450 3084782 I CD I-NP O
25 451 459 3084782 antigens NNS I-NP O
26 460 463 3084782 B35 NN I-NP O
27 463 464 3084782 - HYPH B-NP O
28 464 467 3084782 Cw4 NN I-NP O
29 467 468 3084782 , , O O
30 469 472 3084782 and CC O O
31 473 480 3084782 between IN B-PP O
32 481 491 3084782 dermatitis NN B-NP D003872
33 492 495 3084782 due JJ B-ADJP O
34 496 498 3084782 to TO B-PP O
35 499 503 3084782 gold NN B-NP D006046
36 504 516 3084782 thiosulphate NN I-NP -1
37 517 520 3084782 and CC I-NP O
38 521 524 3084782 B35 NN I-NP O
39 524 525 3084782 . . O O

1 526 534 3084782 Compared VBN B-PP O
2 535 537 3084782 to TO B-PP O
3 538 545 3084782 healthy JJ B-NP O
4 546 554 3084782 controls NNS I-NP O
5 555 556 3084782 a DT B-NP O
6 557 562 3084782 lower JJR I-NP O
7 563 566 3084782 DR5 NN I-NP O
8 567 576 3084782 frequency NN I-NP O
9 577 580 3084782 was VBD B-VP O
10 581 589 3084782 observed VBN I-VP O
11 590 592 3084782 in IN B-PP O
12 593 601 3084782 patients NNS B-NP O
13 602 606 3084782 with IN B-PP O
14 607 609 3084782 RA NN B-NP D001172
15 610 616 3084782 except IN B-PP O
16 617 620 3084782 for IN B-PP O
17 621 624 3084782 the DT B-NP O
18 625 634 3084782 Tiopronin NN I-NP D008625
19 635 642 3084782 related JJ I-NP O
20 643 652 3084782 nephritis NN I-NP D009393
21 653 658 3084782 group NN I-NP O
22 658 659 3084782 . . O O

1 0 0 11243580 -DOCSTART- -X- -X- O

1 0 3 11243580 The DT B-NP O
2 4 8 11243580 role NN I-NP O
3 9 11 11243580 of IN B-PP O
4 12 21 11243580 nitrergic JJ B-NP O
5 22 28 11243580 system NN I-NP O
6 29 31 11243580 in IN B-PP O
7 32 41 11243580 lidocaine NN B-NP D008012
8 41 42 11243580 - HYPH B-NP O
9 42 49 11243580 induced VBN I-NP O
10 50 60 11243580 convulsion NN I-NP D012640
11 61 63 11243580 in IN B-PP O
12 64 67 11243580 the DT B-NP O
13 68 73 11243580 mouse NN I-NP O
14 73 74 11243580 . . O O
15 75 78 11243580 The DT B-NP O
16 79 86 11243580 effects NNS I-NP O
17 87 89 11243580 of IN B-PP O
18 90 91 11243580 N NN B-NP D019331
19 91 92 11243580 - HYPH B-NP D019331
20 92 97 11243580 nitro NN I-NP D019331
21 97 98 11243580 - HYPH B-NP D019331
22 98 99 11243580 L NN I-NP D019331
23 99 100 11243580 - HYPH B-NP D019331
24 100 108 11243580 arginine NN I-NP D019331
25 108 109 11243580 - HYPH B-NP D019331
26 109 115 11243580 methyl NN I-NP D019331
27 116 121 11243580 ester NN I-NP D019331
28 122 123 11243580 ( ( O O
29 123 124 11243580 L NN B-NP D019331
30 124 125 11243580 - HYPH B-NP D019331
31 125 129 11243580 NAME NN I-NP D019331
32 129 130 11243580 ) ) O O
33 131 132 11243580 a DT B-NP O
34 133 139 11243580 nitric JJ I-NP D009569
35 140 145 11243580 oxide NN I-NP D009569
36 146 147 11243580 ( ( O O
37 147 149 11243580 NO NN B-NP D009569
38 149 150 11243580 ) ) O O
39 151 159 11243580 synthase NN B-NP O
40 160 169 11243580 inhibitor NN I-NP O
41 170 173 11243580 and CC I-NP O
42 174 175 11243580 L NN I-NP D001120
43 175 176 11243580 - HYPH B-NP D001120
44 176 184 11243580 arginine NN I-NP D001120
45 184 185 11243580 , , O O
46 186 187 11243580 a DT B-NP O
47 188 190 11243580 NO NN I-NP D009569
48 191 200 11243580 precursor NN I-NP O
49 200 201 11243580 , , O O
50 202 206 11243580 were VBD B-VP O
51 207 219 11243580 investigated VBN I-VP O
52 220 222 11243580 on IN B-PP O
53 223 232 11243580 lidocaine NN B-NP D008012
54 232 233 11243580 - HYPH B-NP O
55 233 240 11243580 induced VBN I-NP O
56 241 252 11243580 convulsions NNS I-NP D012640
57 252 253 11243580 . . O O

1 254 256 11243580 In IN B-PP O
2 257 260 11243580 the DT B-NP O
3 261 266 11243580 first JJ I-NP O
4 267 277 11243580 experiment NN I-NP O
5 277 278 11243580 , , O O
6 279 283 11243580 four CD B-NP O
7 284 290 11243580 groups NNS I-NP O
8 291 293 11243580 of IN B-PP O
9 294 298 11243580 mice NNS B-NP O
10 299 307 11243580 received VBD B-VP O
11 308 321 11243580 physiological JJ B-NP O
12 322 328 11243580 saline NN I-NP O
13 329 330 11243580 ( ( O O
14 330 334 11243580 0.9% CD B-NP O
15 334 335 11243580 ) ) O O
16 335 336 11243580 , , O O
17 337 338 11243580 L NN B-NP D001120
18 338 339 11243580 - HYPH O D001120
19 339 347 11243580 arginine NN B-NP D001120
20 348 349 11243580 ( ( O O
21 349 352 11243580 300 CD B-NP O
22 353 355 11243580 mg NN I-NP O
23 355 356 11243580 / SYM B-NP O
24 356 358 11243580 kg NN I-NP O
25 358 359 11243580 , , O O
26 360 363 11243580 i.p NN B-NP O
27 363 364 11243580 . . O O
28 364 365 11243580 ) ) O O
29 365 366 11243580 , , O O
30 367 368 11243580 L NN B-NP D019331
31 368 369 11243580 - HYPH O D019331
32 369 373 11243580 NAME NN B-NP D019331
33 374 375 11243580 ( ( O O
34 375 378 11243580 100 CD B-NP O
35 379 381 11243580 mg NN I-NP O
36 381 382 11243580 / SYM B-NP O
37 382 384 11243580 kg NN I-NP O
38 384 385 11243580 , , O O
39 386 389 11243580 i.p NN B-NP O
40 389 390 11243580 . . O O
41 390 391 11243580 ) ) O O
42 392 395 11243580 and CC O O
43 396 404 11243580 diazepam NN B-NP D003975
44 405 406 11243580 ( ( O O
45 406 407 11243580 2 CD B-NP O
46 408 410 11243580 mg NN I-NP O
47 410 411 11243580 / SYM B-NP O
48 411 413 11243580 kg NN I-NP O
49 413 414 11243580 ) ) O O
50 414 415 11243580 , , O O
51 416 428 11243580 respectively RB B-ADVP O
52 428 429 11243580 . . O O

1 430 436 11243580 Thirty CD B-NP O
2 437 444 11243580 minutes NNS I-NP O
3 445 450 11243580 after IN B-PP O
4 451 456 11243580 these DT B-NP O
5 457 467 11243580 injections NNS I-NP O
6 467 468 11243580 , , O O
7 469 472 11243580 all DT B-NP O
8 473 477 11243580 mice NNS I-NP O
9 478 486 11243580 received VBD B-VP O
10 487 496 11243580 lidocaine NN B-NP D008012
11 497 498 11243580 ( ( O O
12 498 500 11243580 50 CD B-NP O
13 501 503 11243580 mg NN I-NP O
14 503 504 11243580 / SYM B-NP O
15 504 506 11243580 kg NN I-NP O
16 506 507 11243580 , , O O
17 508 511 11243580 i.p NN B-NP O
18 511 512 11243580 . . O O
19 512 513 11243580 ) ) O O
20 513 514 11243580 . . O O

1 515 517 11243580 In IN B-PP O
2 518 521 11243580 the DT B-NP O
3 522 528 11243580 second JJ I-NP O
4 529 539 11243580 experiment NN I-NP O
5 539 540 11243580 , , O O
6 541 545 11243580 four CD B-NP O
7 546 552 11243580 groups NNS I-NP O
8 553 555 11243580 of IN B-PP O
9 556 560 11243580 mice NNS B-NP O
10 561 569 11243580 received VBD B-VP O
11 570 577 11243580 similar JJ B-NP O
12 578 587 11243580 treatment NN I-NP O
13 588 590 11243580 in IN B-PP O
14 591 594 11243580 the DT B-NP O
15 595 600 11243580 first JJ I-NP O
16 601 611 11243580 experiment NN I-NP O
17 611 612 11243580 , , O O
18 613 616 11243580 and CC O O
19 617 619 11243580 30 CD B-NP O
20 620 623 11243580 min NN I-NP O
21 624 629 11243580 after IN B-PP O
22 630 635 11243580 these DT B-NP O
23 636 646 11243580 injections NNS I-NP O
24 646 647 11243580 , , O O
25 648 651 11243580 all DT B-NP O
26 652 656 11243580 mice NNS I-NP O
27 657 665 11243580 received VBD B-VP O
28 666 667 11243580 a DT B-NP O
29 668 674 11243580 higher JJR I-NP O
30 675 679 11243580 dose NN I-NP O
31 680 682 11243580 of IN B-PP O
32 683 692 11243580 lidocaine NN B-NP D008012
33 693 694 11243580 ( ( O O
34 694 696 11243580 80 CD B-NP O
35 697 699 11243580 mg NN I-NP O
36 699 700 11243580 / SYM B-NP O
37 700 702 11243580 kg NN I-NP O
38 702 703 11243580 ) ) O O
39 703 704 11243580 . . O O

1 705 706 11243580 L NN B-NP D019331
2 706 707 11243580 - HYPH O D019331
3 707 711 11243580 NAME NN B-NP D019331
4 712 713 11243580 ( ( O O
5 713 716 11243580 100 CD B-NP O
6 717 719 11243580 mg NN I-NP O
7 719 720 11243580 / SYM B-NP O
8 720 722 11243580 kg NN I-NP O
9 722 723 11243580 , , O O
10 724 727 11243580 i.p NN B-NP O
11 727 728 11243580 . . O O
12 728 729 11243580 ) ) O O
13 730 733 11243580 and CC O O
14 734 742 11243580 diazepam NN B-NP D003975
15 743 744 11243580 ( ( O O
16 744 745 11243580 2 CD B-NP O
17 746 748 11243580 mg NN I-NP O
18 748 749 11243580 / SYM B-NP O
19 749 751 11243580 kg NN I-NP O
20 751 752 11243580 ) ) O O
21 753 766 11243580 significantly RB B-ADVP O
22 767 776 11243580 decreased VBD B-VP O
23 777 780 11243580 the DT B-NP O
24 781 790 11243580 incidence NN I-NP O
25 791 793 11243580 of IN B-PP O
26 794 803 11243580 lidocaine NN B-NP D008012
27 804 805 11243580 ( ( O O
28 805 807 11243580 50 CD B-NP O
29 808 810 11243580 mg NN I-NP O
30 810 811 11243580 / SYM B-NP O
31 811 813 11243580 kg NN I-NP O
32 813 814 11243580 ) ) O O
33 814 815 11243580 - HYPH B-NP O
34 815 822 11243580 induced VBN I-NP O
35 823 834 11243580 convulsions NNS I-NP D012640
36 834 835 11243580 . . O O

1 836 838 11243580 In IN B-PP O
2 839 847 11243580 contrast NN B-NP O
3 847 848 11243580 , , O O
4 849 852 11243580 the DT B-NP O
5 853 854 11243580 L NN I-NP D001120
6 854 855 11243580 - HYPH B-NP D001120
7 855 863 11243580 arginine NN I-NP D001120
8 864 873 11243580 treatment NN I-NP O
9 874 883 11243580 increased VBD B-VP O
10 884 887 11243580 the DT B-NP O
11 888 897 11243580 incidence NN I-NP O
12 898 900 11243580 of IN B-PP O
13 901 910 11243580 lidocaine NN B-NP D008012
14 911 912 11243580 ( ( O O
15 912 914 11243580 80 CD B-NP O
16 915 917 11243580 mg NN I-NP O
17 917 918 11243580 / SYM B-NP O
18 918 920 11243580 kg NN I-NP O
19 920 921 11243580 , , O O
20 922 925 11243580 i.p NN B-NP O
21 925 926 11243580 . . O O
22 926 927 11243580 ) ) O O
23 927 928 11243580 - HYPH B-NP O
24 928 935 11243580 induced VBN I-NP O
25 936 947 11243580 convulsions NNS I-NP D012640
26 948 961 11243580 significantly RB B-ADVP O
27 961 962 11243580 . . O O

1 963 968 11243580 These DT B-NP O
2 969 976 11243580 results NNS I-NP O
3 977 980 11243580 may MD B-VP O
4 981 988 11243580 suggest VB I-VP O
5 989 993 11243580 that IN B-SBAR O
6 994 996 11243580 NO NN B-NP D009569
7 997 999 11243580 is VBZ B-VP O
8 1000 1001 11243580 a DT B-NP O
9 1002 1015 11243580 proconvulsant JJ I-NP O
10 1016 1024 11243580 mediator NN I-NP O
11 1025 1027 11243580 in IN B-PP O
12 1028 1037 11243580 lidocaine NN B-NP D008012
13 1037 1038 11243580 - HYPH B-NP O
14 1038 1045 11243580 induced VBN I-NP O
15 1046 1057 11243580 convulsions NNS I-NP D012640
16 1057 1058 11243580 . . O O

1 0 0 9549528 -DOCSTART- -X- -X- O

1 0 8 9549528 Cortical JJ B-NP O
2 9 14 9549528 motor NN I-NP O
3 15 29 9549528 overactivation NN I-NP O
4 30 32 9549528 in IN B-PP O
5 33 45 9549528 parkinsonian JJ B-NP D020734
6 46 54 9549528 patients NNS I-NP O
7 55 59 9549528 with IN B-PP O
8 60 61 9549528 L NN B-NP D007980
9 61 62 9549528 - HYPH B-NP D007980
10 62 66 9549528 dopa NN I-NP D007980
11 66 67 9549528 - HYPH O O
12 67 74 9549528 induced VBN B-NP O
13 75 79 9549528 peak NN I-NP O
14 79 80 9549528 - HYPH B-NP O
15 80 84 9549528 dose NN I-NP O
16 85 95 9549528 dyskinesia NN I-NP D004409
17 95 96 9549528 . . O O
18 97 99 9549528 We PRP B-NP O
19 100 104 9549528 have VBP B-VP O
20 105 112 9549528 studied VBN I-VP O
21 113 116 9549528 the DT B-NP O
22 117 125 9549528 regional JJ I-NP O
23 126 134 9549528 cerebral JJ I-NP O
24 135 140 9549528 blood NN I-NP O
25 141 145 9549528 flow NN I-NP O
26 146 147 9549528 ( ( O O
27 147 151 9549528 rCBF NN B-NP O
28 151 152 9549528 ) ) O O
29 153 160 9549528 changes NNS B-NP O
30 161 168 9549528 induced VBN B-VP O
31 169 171 9549528 by IN B-PP O
32 172 175 9549528 the DT B-NP O
33 176 185 9549528 execution NN I-NP O
34 186 188 9549528 of IN B-PP O
35 189 190 9549528 a DT B-NP O
36 191 197 9549528 finger NN I-NP O
37 197 198 9549528 - HYPH B-ADJP O
38 198 200 9549528 to TO B-PP O
39 200 201 9549528 - HYPH B-NP O
40 201 206 9549528 thumb NN I-NP O
41 207 217 9549528 opposition NN I-NP O
42 218 223 9549528 motor NN I-NP O
43 224 228 9549528 task NN I-NP O
44 229 231 9549528 in IN B-PP O
45 232 235 9549528 the DT B-NP O
46 236 249 9549528 supplementary JJ I-NP O
47 250 253 9549528 and CC I-NP O
48 254 261 9549528 primary JJ I-NP O
49 262 267 9549528 motor NN I-NP O
50 268 274 9549528 cortex NN I-NP O
51 275 277 9549528 of IN B-PP O
52 278 281 9549528 two CD B-NP O
53 282 288 9549528 groups NNS I-NP O
54 289 291 9549528 of IN B-PP O
55 292 304 9549528 parkinsonian JJ B-NP D020734
56 305 313 9549528 patients NNS I-NP O
57 314 316 9549528 on IN B-PP O
58 317 318 9549528 L NN B-NP D007980
59 318 319 9549528 - HYPH B-NP D007980
60 319 323 9549528 dopa NN I-NP D007980
61 324 334 9549528 medication NN I-NP O
62 334 335 9549528 , , O O
63 336 339 9549528 the DT B-NP O
64 340 345 9549528 first JJ I-NP O
65 346 349 9549528 one NN I-NP O
66 350 357 9549528 without IN B-PP O
67 358 359 9549528 L NN B-NP D007980
68 359 360 9549528 - HYPH I-NP D007980
69 360 364 9549528 dopa NN I-NP D007980
70 365 372 9549528 induced VBN I-NP O
71 373 383 9549528 dyskinesia NN I-NP D004409
72 384 385 9549528 ( ( O O
73 385 386 9549528 n NN B-NP O
74 387 388 9549528 = SYM B-VP O
75 389 391 9549528 23 CD B-NP O
76 391 392 9549528 ) ) O O
77 393 396 9549528 and CC O O
78 397 400 9549528 the DT B-NP O
79 401 406 9549528 other JJ I-NP O
80 407 411 9549528 with IN B-PP O
81 412 420 9549528 moderate JJ B-NP O
82 421 425 9549528 peak NN I-NP O
83 425 426 9549528 - HYPH O O
84 426 430 9549528 dose NN B-NP O
85 431 441 9549528 dyskinesia NN I-NP D004409
86 442 443 9549528 ( ( O O
87 443 444 9549528 n NN B-NP O
88 445 446 9549528 = SYM B-VP O
89 447 449 9549528 15 CD B-NP O
90 449 450 9549528 ) ) O O
91 450 451 9549528 , , O O
92 452 455 9549528 and CC O O
93 456 458 9549528 of IN B-PP O
94 459 460 9549528 a DT B-NP O
95 461 466 9549528 group NN I-NP O
96 467 469 9549528 of IN B-PP O
97 470 472 9549528 14 CD B-NP O
98 473 479 9549528 normal JJ I-NP O
99 480 488 9549528 subjects NNS I-NP O
100 488 489 9549528 . . O O

1 490 496 9549528 Single JJ B-NP O
2 497 503 9549528 photon NN I-NP O
3 504 512 9549528 emission NN I-NP O
4 513 523 9549528 tomography NN I-NP O
5 524 528 9549528 with IN B-PP O
6 529 532 9549528 i.v NN B-NP O
7 532 533 9549528 . . O O

1 534 539 9549528 133Xe NN B-NP O
2 540 543 9549528 was VBD B-VP O
3 544 548 9549528 used VBN I-VP O
4 549 551 9549528 to TO B-VP O
5 552 559 9549528 measure VB I-VP O
6 560 563 9549528 the DT B-NP O
7 564 568 9549528 rCBF NN I-NP O
8 569 576 9549528 changes NNS I-NP O
9 576 577 9549528 . . O O

1 578 581 9549528 The DT B-NP O
2 582 592 9549528 dyskinetic JJ I-NP D004409
3 593 605 9549528 parkinsonian JJ I-NP D020734
4 606 614 9549528 patients NNS I-NP O
5 615 624 9549528 exhibited VBD B-VP O
6 625 626 9549528 a DT B-NP O
7 627 634 9549528 pattern NN I-NP O
8 635 637 9549528 of IN B-PP O
9 638 646 9549528 response NN B-NP O
10 647 652 9549528 which WDT B-NP O
11 653 656 9549528 was VBD B-VP O
12 657 665 9549528 markedly RB B-ADJP O
13 666 675 9549528 different JJ I-ADJP O
14 676 680 9549528 from IN B-PP O
15 681 686 9549528 those DT B-NP O
16 687 689 9549528 of IN B-PP O
17 690 693 9549528 the DT B-NP O
18 694 700 9549528 normal JJ I-NP O
19 701 709 9549528 subjects NNS I-NP O
20 710 713 9549528 and CC O O
21 714 717 9549528 non AFX B-NP O
22 717 718 9549528 - HYPH I-NP O
23 718 728 9549528 dyskinetic JJ I-NP D004409
24 729 741 9549528 parkinsonian JJ I-NP D020734
25 742 750 9549528 patients NNS I-NP O
26 750 751 9549528 , , O O
27 752 756 9549528 with IN B-PP O
28 757 758 9549528 a DT B-NP O
29 759 770 9549528 significant JJ I-NP O
30 771 785 9549528 overactivation NN I-NP O
31 786 788 9549528 in IN B-PP O
32 789 792 9549528 the DT B-NP O
33 793 806 9549528 supplementary JJ I-NP O
34 807 812 9549528 motor NN I-NP O
35 813 817 9549528 area NN I-NP O
36 818 821 9549528 and CC O O
37 822 825 9549528 the DT B-NP O
38 826 830 9549528 ipsi AFX I-NP O
39 830 831 9549528 - HYPH I-NP O
40 832 835 9549528 and CC I-NP O
41 836 849 9549528 contralateral JJ I-NP O
42 850 857 9549528 primary JJ I-NP O
43 858 863 9549528 motor NN I-NP O
44 864 869 9549528 areas NNS I-NP O
45 869 870 9549528 . . O O

1 871 876 9549528 These DT B-NP O
2 877 884 9549528 results NNS I-NP O
3 885 888 9549528 are VBP B-VP O
4 889 899 9549528 compatible JJ B-ADJP O
5 900 904 9549528 with IN B-PP O
6 905 908 9549528 the DT B-NP O
7 909 919 9549528 hypothesis NN I-NP O
8 920 924 9549528 that IN B-SBAR O
9 925 927 9549528 an DT B-NP O
10 928 940 9549528 hyperkinetic JJ I-NP D006948
11 941 949 9549528 abnormal JJ I-NP D004409
12 950 961 9549528 involuntary JJ I-NP D004409
13 962 970 9549528 movement NN I-NP D004409
14 970 971 9549528 , , O O
15 972 976 9549528 like IN B-PP O
16 977 978 9549528 L NN B-NP D007980
17 978 979 9549528 - HYPH B-NP D007980
18 979 983 9549528 dopa NN I-NP D007980
19 983 984 9549528 - HYPH B-NP O
20 984 991 9549528 induced VBN I-NP O
21 992 996 9549528 peak NN I-NP O
22 997 1001 9549528 dose NN I-NP O
23 1002 1012 9549528 dyskinesia NN I-NP D004409
24 1012 1013 9549528 , , O O
25 1014 1016 9549528 is VBZ B-VP O
26 1017 1020 9549528 due JJ B-ADJP O
27 1021 1023 9549528 to TO B-PP O
28 1024 1025 9549528 a DT B-NP O
29 1026 1039 9549528 disinhibition NN I-NP O
30 1040 1042 9549528 of IN B-PP O
31 1043 1046 9549528 the DT B-NP O
32 1047 1054 9549528 primary JJ I-NP O
33 1055 1058 9549528 and CC I-NP O
34 1059 1069 9549528 associated VBN I-NP O
35 1070 1075 9549528 motor NN I-NP O
36 1076 1082 9549528 cortex NN I-NP O
37 1083 1092 9549528 secondary JJ B-ADJP O
38 1093 1095 9549528 to TO B-PP O
39 1096 1098 9549528 an DT B-NP O
40 1099 1108 9549528 excessive JJ I-NP O
41 1109 1116 9549528 outflow NN I-NP O
42 1117 1119 9549528 of IN B-PP O
43 1120 1123 9549528 the DT B-NP O
44 1124 1146 9549528 pallidothalamocortical JJ I-NP O
45 1147 1152 9549528 motor NN I-NP O
46 1153 1157 9549528 loop NN I-NP O
47 1157 1158 9549528 . . O O

1 0 0 9672273 -DOCSTART- -X- -X- O

1 0 10 9672273 Prevention NN B-NP O
2 11 13 9672273 of IN B-PP O
3 14 20 9672273 breast NN B-NP D001943
4 21 27 9672273 cancer NN I-NP D001943
5 28 32 9672273 with IN B-PP O
6 33 42 9672273 tamoxifen NN B-NP D013629
7 42 43 9672273 : : O O
8 44 55 9672273 preliminary JJ B-NP O
9 56 64 9672273 findings NNS I-NP O
10 65 69 9672273 from IN B-PP O
11 70 73 9672273 the DT B-NP O
12 74 81 9672273 Italian JJ I-NP O
13 82 92 9672273 randomised VBN I-NP O
14 93 98 9672273 trial NN I-NP O
15 99 104 9672273 among IN B-PP O
16 105 120 9672273 hysterectomised JJ B-NP O
17 121 126 9672273 women NNS I-NP O
18 126 127 9672273 . . O O

1 128 135 9672273 Italian JJ B-NP O
2 136 145 9672273 Tamoxifen NNP I-NP D013629
3 146 156 9672273 Prevention NNP I-NP O
4 157 162 9672273 Study NNP I-NP O
5 162 163 9672273 . . I-NP O
6 164 174 9672273 BACKGROUND NN I-NP O
7 174 175 9672273 : : O O
8 176 185 9672273 Tamoxifen NN B-NP D013629
9 186 188 9672273 is VBZ B-VP O
10 189 190 9672273 a DT B-NP O
11 191 200 9672273 candidate NN I-NP O
12 201 216 9672273 chemopreventive JJ I-NP O
13 217 222 9672273 agent NN I-NP O
14 223 225 9672273 in IN B-PP O
15 226 232 9672273 breast NN B-NP D001943
16 233 239 9672273 cancer NN I-NP D001943
17 239 240 9672273 , , O O
18 241 249 9672273 although IN B-SBAR O
19 250 253 9672273 the DT B-NP O
20 254 258 9672273 drug NN I-NP O
21 259 262 9672273 may MD B-VP O
22 263 265 9672273 be VB I-VP O
23 266 276 9672273 associated VBN I-VP O
24 277 281 9672273 with IN B-PP O
25 282 285 9672273 the DT B-NP O
26 286 297 9672273 development NN I-NP O
27 298 300 9672273 of IN B-PP O
28 301 312 9672273 endometrial JJ B-NP D016889
29 313 319 9672273 cancer NN I-NP D016889
30 319 320 9672273 . . O O

1 321 330 9672273 Therefore RB B-ADVP O
2 331 333 9672273 we PRP B-NP O
3 334 337 9672273 did VBD B-VP O
4 338 339 9672273 a DT B-NP O
5 340 345 9672273 trial NN I-NP O
6 346 348 9672273 in IN B-PP O
7 349 364 9672273 hysterectomised VBN B-NP O
8 365 370 9672273 women NNS I-NP O
9 371 373 9672273 of IN B-PP O
10 374 383 9672273 tamoxifen NN B-NP D013629
11 384 386 9672273 as IN B-PP O
12 387 388 9672273 a DT B-NP O
13 389 404 9672273 chemopreventive NN I-NP O
14 404 405 9672273 . . O O

1 406 413 9672273 METHODS NNS B-NP O
2 413 414 9672273 : : O O
3 415 417 9672273 In IN B-PP O
4 418 425 9672273 October NNP B-NP O
5 425 426 9672273 , , O O
6 427 431 9672273 1992 CD B-NP O
7 431 432 9672273 , , O O
8 433 435 9672273 we PRP B-NP O
9 436 443 9672273 started VBD B-VP O
10 444 445 9672273 a DT B-NP O
11 446 452 9672273 double JJ I-NP O
12 452 453 9672273 - HYPH I-NP O
13 453 458 9672273 blind JJ I-NP O
14 459 466 9672273 placebo NN I-NP O
15 466 467 9672273 - HYPH O O
16 467 477 9672273 controlled VBN B-VP O
17 477 478 9672273 , , O O
18 479 489 9672273 randomised VBN B-NP O
19 490 495 9672273 trial NN I-NP O
20 496 498 9672273 of IN B-PP O
21 499 508 9672273 tamoxifen NN B-NP D013629
22 509 511 9672273 in IN B-PP O
23 512 517 9672273 women NNS B-NP O
24 518 519 9672273 ( ( O O
25 519 525 9672273 mainly RB B-ADVP O
26 526 528 9672273 in IN B-PP O
27 529 534 9672273 Italy NNP B-NP O
28 534 535 9672273 ) ) O O
29 536 539 9672273 who WP B-NP O
30 540 543 9672273 did VBD B-VP O
31 544 547 9672273 not RB I-VP O
32 548 552 9672273 have VB I-VP O
33 553 559 9672273 breast NN B-NP D001943
34 560 566 9672273 cancer NN I-NP D001943
35 567 570 9672273 and CC O O
36 571 574 9672273 who WP B-NP O
37 575 578 9672273 had VBD B-VP O
38 579 582 9672273 had VBN I-VP O
39 583 584 9672273 a DT B-NP O
40 585 597 9672273 hysterectomy NN I-NP O
41 597 598 9672273 . . O O

1 599 604 9672273 Women NNS B-NP O
2 605 609 9672273 were VBD B-VP O
3 610 620 9672273 randomised VBN I-VP O
4 621 623 9672273 to TO I-VP O
5 624 631 9672273 receive VB I-VP O
6 632 641 9672273 tamoxifen NN B-NP D013629
7 642 644 9672273 20 CD I-NP O
8 645 647 9672273 mg NN I-NP O
9 648 651 9672273 per IN B-PP O
10 652 655 9672273 day NN B-NP O
11 656 658 9672273 or CC O O
12 659 666 9672273 placebo NN B-NP O
13 666 667 9672273 , , O O
14 668 672 9672273 both CC B-PP O
15 673 679 9672273 orally RB I-PP O
16 680 683 9672273 for IN B-PP O
17 684 685 9672273 5 CD B-NP O
18 686 691 9672273 years NNS I-NP O
19 691 692 9672273 . . O O

1 693 696 9672273 The DT B-NP O
2 697 705 9672273 original JJ I-NP O
3 706 710 9672273 plan NN I-NP O
4 711 714 9672273 was VBD B-VP O
5 715 717 9672273 to TO B-VP O
6 718 724 9672273 follow VB I-VP O
7 725 728 9672273 the DT B-NP O
8 729 741 9672273 intervention NN I-NP O
9 742 747 9672273 phase NN I-NP O
10 748 750 9672273 by IN B-PP O
11 751 752 9672273 5 CD B-NP O
12 753 758 9672273 years NNS I-NP O
13 758 759 9672273 ' POS B-NP O
14 760 766 9672273 follow VB B-VP O
15 766 767 9672273 - HYPH B-ADJP O
16 767 769 9672273 up RP B-PRT O
17 769 770 9672273 . . O O

1 771 773 9672273 In IN B-PP O
2 774 778 9672273 June NNP B-NP O
3 778 779 9672273 , , O O
4 780 784 9672273 1997 CD B-NP O
5 784 785 9672273 , , O O
6 786 789 9672273 the DT B-NP O
7 790 799 9672273 trialists NNS I-NP O
8 800 803 9672273 and CC O O
9 804 807 9672273 the DT B-NP O
10 808 812 9672273 data NNS I-NP O
11 812 813 9672273 - HYPH O O
12 813 823 9672273 monitoring VBG B-VP O
13 824 833 9672273 committee NN B-NP O
14 834 841 9672273 decided VBD B-VP O
15 842 844 9672273 to TO I-VP O
16 845 848 9672273 end VB I-VP O
17 849 860 9672273 recruitment NN B-NP O
18 861 870 9672273 primarily RB B-ADVP O
19 871 878 9672273 because IN B-PP O
20 879 881 9672273 of IN I-PP O
21 882 885 9672273 the DT B-NP O
22 886 892 9672273 number NN I-NP O
23 893 895 9672273 of IN B-PP O
24 896 901 9672273 women NNS B-NP O
25 902 910 9672273 dropping VBG B-VP O
26 911 914 9672273 out IN B-PP O
27 915 917 9672273 of IN B-PP O
28 918 921 9672273 the DT B-NP O
29 922 927 9672273 study NN I-NP O
30 927 928 9672273 . . O O

1 929 940 9672273 Recruitment NN B-NP O
2 941 946 9672273 ended VBD B-VP O
3 947 949 9672273 on IN B-PP O
4 950 954 9672273 July NNP B-NP O
5 955 957 9672273 11 CD I-NP O
6 957 958 9672273 , , I-NP O
7 959 963 9672273 1997 CD I-NP O
8 963 964 9672273 , , O O
9 965 968 9672273 and CC O O
10 969 972 9672273 the DT B-NP O
11 973 978 9672273 study NN I-NP O
12 979 983 9672273 will MD B-VP O
13 984 992 9672273 continue VB I-VP O
14 993 995 9672273 as IN B-SBAR O
15 996 1003 9672273 planned VBN B-VP O
16 1003 1004 9672273 . . O O

1 1005 1008 9672273 The DT B-NP O
2 1009 1016 9672273 primary JJ I-NP O
3 1017 1026 9672273 endpoints NNS I-NP O
4 1027 1030 9672273 are VBP B-VP O
5 1031 1034 9672273 the DT B-NP O
6 1035 1045 9672273 occurrence NN I-NP O
7 1046 1048 9672273 of IN B-PP O
8 1049 1052 9672273 and CC O O
9 1053 1059 9672273 deaths NNS B-NP O
10 1060 1064 9672273 from IN B-PP O
11 1065 1071 9672273 breast NN B-NP D001943
12 1072 1078 9672273 cancer NN I-NP D001943
13 1078 1079 9672273 . . O O

1 1080 1084 9672273 This DT B-NP O
2 1085 1096 9672273 preliminary JJ I-NP O
3 1097 1104 9672273 interim JJ I-NP O
4 1105 1113 9672273 analysis NN I-NP O
5 1114 1116 9672273 is VBZ B-VP O
6 1117 1122 9672273 based VBN I-VP O
7 1123 1125 9672273 on IN B-PP O
8 1126 1135 9672273 intention NN B-NP O
9 1135 1136 9672273 - HYPH B-ADVP O
10 1136 1138 9672273 to TO B-PP O
11 1138 1139 9672273 - HYPH B-NP O
12 1139 1144 9672273 treat NN I-NP O
13 1144 1145 9672273 . . O O

1 1146 1154 9672273 FINDINGS NNS B-NP O
2 1154 1155 9672273 : : O O
3 1156 1160 9672273 5408 CD B-NP O
4 1161 1166 9672273 women NNS I-NP O
5 1167 1171 9672273 were VBD B-VP O
6 1172 1182 9672273 randomised VBN I-VP O
7 1182 1183 9672273 ; : O O
8 1184 1197 9672273 participating VBG B-NP O
9 1198 1203 9672273 women NNS I-NP O
10 1204 1208 9672273 have VBP B-VP O
11 1209 1210 9672273 a DT B-NP O
12 1211 1217 9672273 median JJ I-NP O
13 1218 1224 9672273 follow VB I-NP O
14 1224 1225 9672273 - HYPH B-VP O
15 1225 1227 9672273 up RP B-PRT O
16 1228 1230 9672273 of IN B-PP O
17 1231 1233 9672273 46 CD B-NP O
18 1234 1240 9672273 months NNS I-NP O
19 1241 1244 9672273 for IN B-PP O
20 1245 1250 9672273 major JJ B-NP O
21 1251 1260 9672273 endpoints NNS I-NP O
22 1260 1261 9672273 . . O O

1 1262 1264 9672273 41 CD B-NP O
2 1265 1270 9672273 cases NNS I-NP O
3 1271 1273 9672273 of IN B-PP O
4 1274 1280 9672273 breast NN B-NP D001943
5 1281 1287 9672273 cancer NN I-NP D001943
6 1288 1296 9672273 occurred VBD B-VP O
7 1297 1299 9672273 so RB B-ADVP O
8 1300 1303 9672273 far RB I-ADVP O
9 1303 1304 9672273 ; : O O
10 1305 1310 9672273 there EX B-NP O
11 1311 1315 9672273 have VBP B-VP O
12 1316 1320 9672273 been VBN I-VP O
13 1321 1323 9672273 no DT B-NP O
14 1324 1330 9672273 deaths NNS I-NP O
15 1331 1335 9672273 from IN B-PP O
16 1336 1342 9672273 breast NN B-NP D001943
17 1343 1349 9672273 cancer NN I-NP D001943
18 1349 1350 9672273 . . O O

1 1351 1356 9672273 There EX B-NP O
2 1357 1359 9672273 is VBZ B-VP O
3 1360 1362 9672273 no DT B-NP O
4 1363 1373 9672273 difference NN I-NP O
5 1374 1376 9672273 in IN B-PP O
6 1377 1383 9672273 breast NN B-NP D001943
7 1383 1384 9672273 - HYPH B-NP D001943
8 1384 1390 9672273 cancer NN I-NP D001943
9 1391 1400 9672273 frequency NN I-NP O
10 1401 1408 9672273 between IN B-PP O
11 1409 1412 9672273 the DT B-NP O
12 1413 1420 9672273 placebo NN I-NP O
13 1421 1422 9672273 ( ( O O
14 1422 1424 9672273 22 CD B-NP O
15 1425 1430 9672273 cases NNS I-NP O
16 1430 1431 9672273 ) ) O O
17 1432 1435 9672273 and CC O O
18 1436 1445 9672273 tamoxifen NN B-NP D013629
19 1446 1447 9672273 ( ( O O
20 1447 1449 9672273 19 CD B-NP O
21 1449 1450 9672273 ) ) O O
22 1451 1455 9672273 arms NNS B-NP O
23 1455 1456 9672273 . . O O

1 1457 1462 9672273 There EX B-NP O
2 1463 1465 9672273 is VBZ B-VP O
3 1466 1467 9672273 a DT B-NP O
4 1468 1481 9672273 statistically RB I-NP O
5 1482 1493 9672273 significant JJ I-NP O
6 1494 1503 9672273 reduction NN I-NP O
7 1504 1506 9672273 of IN B-PP O
8 1507 1513 9672273 breast NN B-NP D001943
9 1514 1520 9672273 cancer NN I-NP D001943
10 1521 1526 9672273 among IN B-PP O
11 1527 1532 9672273 women NNS B-NP O
12 1533 1542 9672273 receiving VBG B-VP O
13 1543 1552 9672273 tamoxifen NN B-NP D013629
14 1553 1556 9672273 who WP B-NP O
15 1557 1561 9672273 also RB B-ADVP O
16 1562 1566 9672273 used VBD B-VP O
17 1567 1574 9672273 hormone NN B-NP O
18 1574 1575 9672273 - HYPH B-NP O
19 1575 1586 9672273 replacement NN I-NP O
20 1587 1594 9672273 therapy NN I-NP O
21 1595 1601 9672273 during IN B-PP O
22 1602 1605 9672273 the DT B-NP O
23 1606 1611 9672273 trial NN I-NP O
24 1611 1612 9672273 : : O O
25 1613 1618 9672273 among IN B-PP O
26 1619 1622 9672273 390 CD B-NP O
27 1623 1628 9672273 women NNS I-NP O
28 1629 1631 9672273 on IN B-PP O
29 1632 1636 9672273 such JJ B-NP O
30 1637 1644 9672273 therapy NN I-NP O
31 1645 1648 9672273 and CC O O
32 1649 1658 9672273 allocated VBN B-VP O
33 1659 1661 9672273 to TO B-PP O
34 1662 1669 9672273 placebo NN B-NP O
35 1669 1670 9672273 , , O O
36 1671 1673 9672273 we PRP B-NP O
37 1674 1679 9672273 found VBD B-VP O
38 1680 1685 9672273 eight CD B-NP O
39 1686 1691 9672273 cases NNS I-NP O
40 1692 1694 9672273 of IN B-PP O
41 1695 1701 9672273 breast NN B-NP D001943
42 1702 1708 9672273 cancer NN I-NP D001943
43 1709 1717 9672273 compared VBN B-VP O
44 1718 1722 9672273 with IN B-PP O
45 1723 1726 9672273 one CD B-NP O
46 1727 1731 9672273 case NN I-NP O
47 1732 1737 9672273 among IN B-PP O
48 1738 1741 9672273 362 CD B-NP O
49 1742 1747 9672273 women NNS I-NP O
50 1748 1757 9672273 allocated VBN B-VP O
51 1758 1760 9672273 to TO B-PP O
52 1761 1770 9672273 tamoxifen NN B-NP D013629
53 1770 1771 9672273 . . O O

1 1772 1780 9672273 Compared VBN B-PP O
2 1781 1785 9672273 with IN B-PP O
3 1786 1789 9672273 the DT B-NP O
4 1790 1797 9672273 placebo NN I-NP O
5 1798 1803 9672273 group NN I-NP O
6 1803 1804 9672273 , , O O
7 1805 1810 9672273 there EX B-NP O
8 1811 1814 9672273 was VBD B-VP O
9 1815 1816 9672273 a DT B-NP O
10 1817 1830 9672273 significantly RB I-NP O
11 1831 1840 9672273 increased VBN I-NP O
12 1841 1845 9672273 risk NN I-NP O
13 1846 1848 9672273 of IN B-PP O
14 1849 1857 9672273 vascular JJ B-NP D014652
15 1858 1864 9672273 events NNS I-NP D014652
16 1865 1868 9672273 and CC O O
17 1869 1890 9672273 hypertriglyceridaemia NN B-NP D015228
18 1891 1896 9672273 among IN B-PP O
19 1897 1902 9672273 women NNS B-NP O
20 1903 1905 9672273 on IN B-PP O
21 1906 1915 9672273 tamoxifen NN B-NP D013629
22 1915 1916 9672273 . . O O

1 1917 1931 9672273 INTERPRETATION NN B-NP O
2 1931 1932 9672273 : : O O
3 1933 1941 9672273 Although IN B-SBAR O
4 1942 1946 9672273 this DT B-NP O
5 1947 1958 9672273 preliminary JJ I-NP O
6 1959 1967 9672273 analysis NN I-NP O
7 1968 1971 9672273 has VBZ B-VP O
8 1972 1975 9672273 low JJ B-NP O
9 1976 1981 9672273 power NN I-NP O
10 1981 1982 9672273 , , O O
11 1983 1985 9672273 in IN B-PP O
12 1986 1990 9672273 this DT B-NP O
13 1991 1997 9672273 cohort NN I-NP O
14 1998 2000 9672273 of IN B-PP O
15 2001 2006 9672273 women NNS B-NP O
16 2007 2009 9672273 at IN B-PP O
17 2010 2013 9672273 low JJ B-NP O
18 2013 2014 9672273 - HYPH I-NP O
19 2014 2016 9672273 to TO B-PP O
20 2016 2017 9672273 - HYPH B-NP O
21 2017 2023 9672273 normal JJ I-NP O
22 2024 2028 9672273 risk NN I-NP O
23 2029 2031 9672273 of IN B-PP O
24 2032 2038 9672273 breast NN B-NP D001943
25 2039 2045 9672273 cancer NN I-NP D001943
26 2045 2046 9672273 , , O O
27 2047 2050 9672273 the DT B-NP O
28 2051 2061 9672273 postulated VBN I-NP O
29 2062 2072 9672273 protective JJ I-NP O
30 2073 2080 9672273 effects NNS I-NP O
31 2081 2083 9672273 of IN B-PP O
32 2084 2093 9672273 tamoxifen NN B-NP D013629
33 2094 2097 9672273 are VBP B-VP O
34 2098 2101 9672273 not RB O O
35 2102 2105 9672273 yet RB B-ADJP O
36 2106 2114 9672273 apparent JJ I-ADJP O
37 2114 2115 9672273 . . O O

1 2116 2121 9672273 Women NNS B-NP O
2 2122 2127 9672273 using VBG B-VP O
3 2128 2135 9672273 hormone NN B-NP O
4 2135 2136 9672273 - HYPH I-NP O
5 2136 2147 9672273 replacement NN I-NP O
6 2148 2155 9672273 therapy NN I-NP O
7 2156 2162 9672273 appear VBP B-VP O
8 2163 2165 9672273 to TO I-VP O
9 2166 2170 9672273 have VB I-VP O
10 2171 2180 9672273 benefited VBN I-VP O
11 2181 2185 9672273 from IN B-PP O
12 2186 2189 9672273 use NN B-NP O
13 2190 2192 9672273 of IN B-PP O
14 2193 2202 9672273 tamoxifen NN B-NP D013629
15 2202 2203 9672273 . . O O

1 2204 2209 9672273 There EX B-NP O
2 2210 2214 9672273 were VBD B-VP O
3 2215 2217 9672273 no DT B-NP O
4 2218 2224 9672273 deaths NNS I-NP O
5 2225 2229 9672273 from IN B-PP O
6 2230 2236 9672273 breast NN B-NP D001943
7 2237 2243 9672273 cancer NN I-NP D001943
8 2244 2252 9672273 recorded VBN B-VP O
9 2253 2255 9672273 in IN B-PP O
10 2256 2261 9672273 women NNS B-NP O
11 2262 2264 9672273 in IN B-PP O
12 2265 2268 9672273 the DT B-NP O
13 2269 2274 9672273 study NN I-NP O
14 2274 2275 9672273 . . O O

1 2276 2278 9672273 It PRP B-NP O
2 2279 2281 9672273 is VBZ B-VP O
3 2282 2291 9672273 essential JJ B-ADJP O
4 2292 2294 9672273 to TO B-VP O
5 2295 2303 9672273 continue VB I-VP O
6 2304 2310 9672273 follow VB I-VP O
7 2310 2311 9672273 - HYPH O O
8 2311 2313 9672273 up RP B-PRT O
9 2314 2316 9672273 to TO B-VP O
10 2317 2325 9672273 quantify VB I-VP O
11 2326 2329 9672273 the DT B-NP O
12 2330 2334 9672273 long JJ I-NP O
13 2334 2335 9672273 - HYPH I-NP O
14 2335 2339 9672273 term NN I-NP O
15 2340 2345 9672273 risks NNS I-NP O
16 2346 2349 9672273 and CC I-NP O
17 2350 2358 9672273 benefits NNS I-NP O
18 2359 2361 9672273 of IN B-PP O
19 2362 2371 9672273 tamoxifen NN B-NP D013629
20 2372 2379 9672273 therapy NN I-NP O
21 2379 2380 9672273 . . O O

1 0 0 3762968 -DOCSTART- -X- -X- O

1 0 13 3762968 Transketolase NN B-NP O
2 14 25 3762968 abnormality NN I-NP O
3 26 28 3762968 in IN B-PP O
4 29 39 3762968 tolazamide NN B-NP D014042
5 39 40 3762968 - HYPH B-NP O
6 40 47 3762968 induced VBN I-NP O
7 48 58 3762968 Wernicke's NNS I-NP D014899
8 59 73 3762968 encephalopathy NN I-NP D014899
9 73 74 3762968 . . O O
10 75 77 3762968 We PRP B-NP O
11 78 85 3762968 studied VBD B-VP O
12 86 87 3762968 a DT B-NP O
13 88 96 3762968 thiamine NN I-NP D013831
14 96 97 3762968 - HYPH B-NP O
15 97 106 3762968 dependent JJ I-NP O
16 107 113 3762968 enzyme NN I-NP O
17 113 114 3762968 , , O O
18 115 128 3762968 transketolase NN B-NP O
19 128 129 3762968 , , O O
20 130 134 3762968 from IN B-PP O
21 135 146 3762968 fibroblasts NNS B-NP O
22 147 149 3762968 of IN B-PP O
23 150 151 3762968 a DT B-NP O
24 152 160 3762968 diabetic JJ I-NP D003920
25 161 168 3762968 patient NN I-NP O
26 169 172 3762968 who WP B-NP O
27 173 182 3762968 developed VBD B-VP O
28 183 193 3762968 Wernicke's NNP B-NP D014899
29 194 208 3762968 encephalopathy NN I-NP D014899
30 209 213 3762968 when WRB B-ADVP O
31 214 221 3762968 treated VBN B-VP O
32 222 226 3762968 with IN B-PP O
33 227 237 3762968 tolazamide NN B-NP D014042
34 237 238 3762968 , , O O
35 239 241 3762968 in IN B-SBAR O
36 242 247 3762968 order NN O O
37 248 250 3762968 to TO B-VP O
38 251 260 3762968 delineate VB I-VP O
39 261 263 3762968 if IN B-SBAR O
40 264 268 3762968 this DT B-NP O
41 269 276 3762968 patient NN I-NP O
42 277 281 3762968 also RB B-ADVP O
43 282 285 3762968 had VBD B-VP O
44 286 299 3762968 transketolase NN B-NP O
45 300 311 3762968 abnormality NN I-NP O
46 312 313 3762968 [ ( O O
47 313 317 3762968 high JJ B-NP O
48 318 320 3762968 Km NN I-NP O
49 321 324 3762968 for IN B-PP O
50 325 333 3762968 thiamine NN B-NP D013835
51 334 347 3762968 pyrophosphate NN I-NP D013835
52 348 349 3762968 ( ( O O
53 349 352 3762968 TPP NN B-NP D013835
54 352 353 3762968 ) ) O O
55 353 354 3762968 ] ) O O
56 354 355 3762968 , , O O
57 356 358 3762968 as RB O O
58 359 369 3762968 previously RB B-ADVP O
59 370 378 3762968 reported VBN B-VP O
60 379 381 3762968 in IN B-PP O
61 382 395 3762968 postalcoholic JJ B-NP O
62 396 404 3762968 Wernicke NNP I-NP D020915
63 404 405 3762968 - HYPH I-NP D020915
64 405 414 3762968 Korsakoff NNP I-NP D020915
65 415 423 3762968 syndrome NN I-NP D020915
66 423 424 3762968 . . O O

1 425 427 3762968 In IN B-PP O
2 428 436 3762968 addition NN B-NP O
3 437 439 3762968 to TO B-PP O
4 440 444 3762968 this DT B-NP O
5 445 452 3762968 patient NN I-NP O
6 452 453 3762968 , , O O
7 454 456 3762968 we PRP B-NP O
8 457 461 3762968 also RB B-ADVP O
9 462 469 3762968 studied VBD B-VP O
10 470 474 3762968 this DT B-NP O
11 475 481 3762968 enzyme NN I-NP O
12 482 486 3762968 from IN B-PP O
13 487 492 3762968 three CD B-NP O
14 493 501 3762968 diabetic JJ I-NP D003920
15 502 510 3762968 kindreds NNS I-NP O
16 511 518 3762968 without IN B-PP O
17 519 522 3762968 any DT B-NP O
18 523 530 3762968 history NN I-NP O
19 531 533 3762968 of IN B-PP O
20 534 544 3762968 Wernicke's NNS B-NP D014899
21 545 559 3762968 encephalopathy NN I-NP D014899
22 560 563 3762968 and CC B-PP O
23 564 568 3762968 from IN B-PP O
24 569 573 3762968 four CD B-NP O
25 574 580 3762968 normal JJ I-NP O
26 581 589 3762968 controls NNS I-NP O
27 589 590 3762968 . . O O

1 591 593 3762968 We PRP B-NP O
2 594 599 3762968 found VBD B-VP O
3 600 604 3762968 that IN B-SBAR O
4 605 608 3762968 the DT B-NP O
5 609 614 3762968 above RB I-NP O
6 614 615 3762968 - HYPH I-NP O
7 615 624 3762968 mentioned VBN I-NP O
8 625 632 3762968 patient NN I-NP O
9 633 636 3762968 and CC O O
10 637 640 3762968 one CD B-NP O
11 641 643 3762968 of IN B-PP O
12 644 647 3762968 the DT B-NP O
13 648 656 3762968 diabetic JJ I-NP D003920
14 657 665 3762968 kindreds NNS I-NP O
15 666 670 3762968 with IN B-PP O
16 671 673 3762968 no DT B-NP O
17 674 681 3762968 history NN I-NP O
18 682 684 3762968 of IN B-PP O
19 685 695 3762968 Wernicke's NNS B-NP D014899
20 696 710 3762968 encephalopathy NN I-NP D014899
21 711 714 3762968 had VBD B-VP O
22 715 723 3762968 abnormal JJ B-NP O
23 724 737 3762968 transketolase NN I-NP O
24 738 740 3762968 as IN B-SBAR O
25 741 751 3762968 determined VBN B-VP O
26 752 754 3762968 by IN B-PP O
27 755 758 3762968 its PRP$ B-NP O
28 759 761 3762968 Km NN I-NP O
29 762 765 3762968 for IN B-PP O
30 766 769 3762968 TPP NN B-NP D013835
31 769 770 3762968 . . O O

1 771 776 3762968 These DT B-NP O
2 777 781 3762968 data NNS I-NP O
3 782 789 3762968 suggest VBP B-VP O
4 790 791 3762968 a DT B-NP O
5 792 802 3762968 similarity NN I-NP O
6 803 810 3762968 between IN B-PP O
7 811 824 3762968 postalcoholic JJ B-NP O
8 825 833 3762968 Wernicke NNP I-NP D020915
9 833 834 3762968 - HYPH I-NP D020915
10 834 843 3762968 Korsakoff NNP I-NP D020915
11 844 852 3762968 syndrome NN I-NP D020915
12 853 856 3762968 and CC O O
13 857 860 3762968 the DT B-NP O
14 861 868 3762968 patient NN I-NP O
15 869 873 3762968 with IN B-PP O
16 874 884 3762968 tolazamide NN B-NP D014042
17 884 885 3762968 - HYPH B-NP O
18 885 892 3762968 induced VBN I-NP O
19 893 903 3762968 Wernicke's NNS I-NP D014899
20 904 918 3762968 encephalopathy NN I-NP D014899
21 919 923 3762968 from IN B-PP O
22 924 927 3762968 the DT B-NP O
23 928 938 3762968 standpoint NN I-NP O
24 939 941 3762968 of IN B-PP O
25 942 955 3762968 transketolase NN B-NP O
26 956 967 3762968 abnormality NN I-NP O
27 967 968 3762968 . . O O

1 0 0 20304337 -DOCSTART- -X- -X- O

1 0 9 20304337 Brainstem NN B-NP -1
2 10 20 20304337 dysgenesis NN I-NP -1
3 21 23 20304337 in IN B-PP O
4 24 26 20304337 an DT B-NP O
5 27 33 20304337 infant NN I-NP O
6 34 44 20304337 prenatally RB B-VP O
7 45 52 20304337 exposed VBN I-VP O
8 53 55 20304337 to TO B-PP O
9 56 63 20304337 cocaine NN B-NP D003042
10 63 64 20304337 . . O O
11 65 69 20304337 Many JJ B-NP O
12 70 77 20304337 authors NNS I-NP O
13 78 87 20304337 described VBD B-VP O
14 88 91 20304337 the DT B-NP O
15 92 99 20304337 effects NNS I-NP O
16 100 102 20304337 on IN B-PP O
17 103 106 20304337 the DT B-NP O
18 107 112 20304337 fetus NN I-NP O
19 113 115 20304337 of IN B-PP O
20 116 124 20304337 maternal JJ B-NP O
21 125 132 20304337 cocaine NN I-NP D019970
22 133 138 20304337 abuse NN I-NP D019970
23 139 145 20304337 during IN B-PP O
24 146 155 20304337 pregnancy NN B-NP O
25 155 156 20304337 . . O O

1 157 173 20304337 Vasoconstriction NN B-NP O
2 174 181 20304337 appears VBZ B-VP O
3 182 184 20304337 to TO I-VP O
4 185 187 20304337 be VB I-VP O
5 188 191 20304337 the DT B-NP O
6 192 198 20304337 common JJ I-NP O
7 199 208 20304337 mechanism NN I-NP O
8 209 211 20304337 of IN B-PP O
9 212 218 20304337 action NN B-NP O
10 219 226 20304337 leading VBG B-VP O
11 227 229 20304337 to TO B-PP O
12 230 231 20304337 a DT B-NP O
13 232 236 20304337 wide JJ I-NP O
14 237 242 20304337 range NN I-NP O
15 243 245 20304337 of IN B-PP O
16 246 251 20304337 fetal JJ B-NP D005315
17 252 261 20304337 anomalies NNS I-NP D005315
18 261 262 20304337 . . O O

1 263 265 20304337 We PRP B-NP O
2 266 272 20304337 report VBP B-VP O
3 273 275 20304337 on IN B-PP O
4 276 278 20304337 an DT B-NP O
5 279 285 20304337 infant NN I-NP O
6 286 290 20304337 with IN B-PP O
7 291 299 20304337 multiple JJ B-NP D003389
8 300 307 20304337 cranial JJ I-NP D003389
9 307 308 20304337 - HYPH I-NP D003389
10 308 313 20304337 nerve NN I-NP D003389
11 314 325 20304337 involvement NN I-NP D003389
12 326 338 20304337 attributable JJ B-ADJP O
13 339 341 20304337 to TO B-PP O
14 342 351 20304337 brainstem NN B-NP -1
15 352 362 20304337 dysgenesis NN I-NP -1
16 362 363 20304337 , , O O
17 364 368 20304337 born VBN B-VP O
18 369 371 20304337 to TO B-PP O
19 372 373 20304337 a DT B-NP O
20 374 381 20304337 cocaine NN I-NP D019970
21 381 382 20304337 - HYPH O D019970
22 382 390 20304337 addicted VBN B-NP D019970
23 391 397 20304337 mother NN I-NP O
24 397 398 20304337 . . O O

1 0 0 2422478 -DOCSTART- -X- -X- O

1 0 7 2422478 Midline NN B-NP O
2 8 10 2422478 B3 NN I-NP O
3 11 20 2422478 serotonin NN I-NP D012701
4 21 27 2422478 nerves VBZ B-VP O
5 28 30 2422478 in IN B-PP O
6 31 34 2422478 rat NN B-NP O
7 35 42 2422478 medulla NN I-NP O
8 43 46 2422478 are VBP B-VP O
9 47 55 2422478 involved VBN I-VP O
10 56 58 2422478 in IN B-PP O
11 59 70 2422478 hypotensive JJ B-NP D007022
12 71 77 2422478 effect NN I-NP O
13 78 80 2422478 of IN B-PP O
14 81 91 2422478 methyldopa NN B-NP D008750
15 91 92 2422478 . . O O
16 93 101 2422478 Previous JJ B-NP O
17 102 113 2422478 experiments NNS I-NP O
18 114 116 2422478 in IN B-PP O
19 117 121 2422478 this DT B-NP O
20 122 132 2422478 laboratory NN I-NP O
21 133 137 2422478 have VBP B-VP O
22 138 143 2422478 shown VBN I-VP O
23 144 148 2422478 that IN B-SBAR O
24 149 163 2422478 microinjection NN B-NP O
25 164 166 2422478 of IN B-PP O
26 167 177 2422478 methyldopa NN B-NP D008750
27 178 182 2422478 onto IN B-PP O
28 183 186 2422478 the DT B-NP O
29 187 200 2422478 ventrolateral JJ I-NP O
30 201 206 2422478 cells NNS I-NP O
31 207 209 2422478 of IN B-PP O
32 210 213 2422478 the DT B-NP O
33 214 216 2422478 B3 NN I-NP O
34 217 226 2422478 serotonin NN I-NP D012701
35 227 234 2422478 neurons NNS I-NP O
36 235 237 2422478 in IN B-PP O
37 238 241 2422478 the DT B-NP O
38 242 249 2422478 medulla NN I-NP O
39 250 257 2422478 elicits VBZ B-VP O
40 258 259 2422478 a DT B-NP O
41 260 271 2422478 hypotensive JJ I-NP D007022
42 272 280 2422478 response NN I-NP O
43 281 289 2422478 mediated VBN B-VP O
44 290 292 2422478 by IN B-PP O
45 293 294 2422478 a DT B-NP O
46 295 305 2422478 projection NN I-NP O
47 306 316 2422478 descending VBG B-VP O
48 317 321 2422478 into IN B-PP O
49 322 325 2422478 the DT B-NP O
50 326 332 2422478 spinal JJ I-NP O
51 333 337 2422478 cord NN I-NP O
52 337 338 2422478 . . O O

1 339 342 2422478 The DT B-NP O
2 343 350 2422478 present JJ I-NP O
3 351 362 2422478 experiments NNS I-NP O
4 363 367 2422478 were VBD B-VP O
5 368 376 2422478 designed VBN I-VP O
6 377 379 2422478 to TO B-VP O
7 380 391 2422478 investigate VB I-VP O
8 392 395 2422478 the DT B-NP O
9 396 400 2422478 role NN I-NP O
10 401 403 2422478 of IN B-PP O
11 404 407 2422478 the DT B-NP O
12 408 415 2422478 midline NN I-NP O
13 416 421 2422478 cells NNS I-NP O
14 422 424 2422478 of IN B-PP O
15 425 428 2422478 the DT B-NP O
16 429 431 2422478 B3 NN I-NP O
17 432 441 2422478 serotonin NN I-NP D012701
18 442 449 2422478 neurons NNS I-NP O
19 450 452 2422478 in IN B-PP O
20 453 456 2422478 the DT B-NP O
21 457 464 2422478 medulla NN I-NP O
22 464 465 2422478 , , O O
23 466 476 2422478 coinciding VBG B-VP O
24 477 481 2422478 with IN B-PP O
25 482 485 2422478 the DT B-NP O
26 486 491 2422478 raphe NN I-NP O
27 492 498 2422478 magnus NN I-NP O
28 498 499 2422478 . . O O

1 500 502 2422478 In IN B-PP O
2 503 516 2422478 spontaneously RB B-NP O
3 517 529 2422478 hypertensive JJ I-NP D006973
4 529 530 2422478 , , I-NP O
5 531 537 2422478 stroke NN I-NP D020521
6 537 538 2422478 - HYPH I-NP O
7 538 543 2422478 prone JJ I-NP O
8 544 548 2422478 rats NNS I-NP O
9 548 549 2422478 , , O O
10 550 564 2422478 microinjection NN B-NP O
11 565 567 2422478 of IN B-PP O
12 568 578 2422478 methyldopa NN B-NP D008750
13 579 583 2422478 into IN B-PP O
14 584 587 2422478 the DT B-NP O
15 588 592 2422478 area NN I-NP O
16 593 595 2422478 of IN B-PP O
17 596 599 2422478 the DT B-NP O
18 600 607 2422478 midline NN I-NP O
19 608 610 2422478 B3 NN I-NP O
20 611 620 2422478 serotonin NN I-NP D012701
21 621 625 2422478 cell NN I-NP O
22 626 631 2422478 group NN I-NP O
23 632 634 2422478 in IN B-PP O
24 635 638 2422478 the DT B-NP O
25 639 646 2422478 ventral JJ I-NP O
26 647 654 2422478 medulla NN I-NP O
27 655 661 2422478 caused VBD B-VP O
28 662 663 2422478 a DT B-NP O
29 664 670 2422478 potent JJ I-NP O
30 671 682 2422478 hypotension NN I-NP D007022
31 683 685 2422478 of IN B-PP O
32 686 688 2422478 30 CD B-NP O
33 688 689 2422478 - HYPH I-NP O
34 689 691 2422478 40 CD I-NP O
35 692 694 2422478 mm NN I-NP O
36 695 697 2422478 Hg NN I-NP O
37 697 698 2422478 , , O O
38 699 704 2422478 which WDT B-NP O
39 705 708 2422478 was VBD B-VP O
40 709 716 2422478 maximal JJ B-NP O
41 717 718 2422478 2 CD I-NP O
42 718 719 2422478 - HYPH I-NP O
43 719 720 2422478 3 CD I-NP O
44 721 722 2422478 h NN I-NP O
45 723 728 2422478 after IN B-PP O
46 729 743 2422478 administration NN B-NP O
47 744 747 2422478 and CC O O
48 748 751 2422478 was VBD B-VP O
49 752 761 2422478 abolished VBN I-VP O
50 762 764 2422478 by IN B-PP O
51 765 768 2422478 the DT B-NP O
52 769 778 2422478 serotonin NN I-NP D012701
53 779 789 2422478 neurotoxin NN I-NP O
54 790 793 2422478 5,7 CD I-NP D015116
55 793 794 2422478 - HYPH I-NP D015116
56 794 813 2422478 dihydroxytryptamine NN I-NP D015116
57 814 815 2422478 ( ( O O
58 815 818 2422478 5,7 CD B-NP D015116
59 818 819 2422478 - HYPH I-NP D015116
60 819 822 2422478 DHT NN I-NP D015116
61 822 823 2422478 ) ) O O
62 824 832 2422478 injected VBN B-VP O
63 833 858 2422478 intracerebroventricularly RB B-ADVP O
64 858 859 2422478 . . O O

1 860 867 2422478 However RB B-ADVP O
2 867 868 2422478 , , O O
3 869 880 2422478 intraspinal JJ B-NP O
4 881 890 2422478 injection NN I-NP O
5 891 893 2422478 of IN B-PP O
6 894 897 2422478 5,7 CD B-NP D015116
7 897 898 2422478 - HYPH I-NP D015116
8 898 901 2422478 DHT NN I-NP D015116
9 902 904 2422478 to TO B-VP O
10 905 912 2422478 produce VB I-VP O
11 913 914 2422478 a DT B-NP O
12 915 919 2422478 more RBR I-NP O
13 920 929 2422478 selective JJ I-NP O
14 930 936 2422478 lesion NN I-NP O
15 937 939 2422478 of IN B-PP O
16 940 944 2422478 only RB B-VP O
17 945 955 2422478 descending VBG I-VP O
18 956 965 2422478 serotonin NN B-NP D012701
19 966 977 2422478 projections NNS I-NP O
20 978 980 2422478 in IN B-PP O
21 981 984 2422478 the DT B-NP O
22 985 991 2422478 spinal JJ I-NP O
23 992 996 2422478 cord NN I-NP O
24 997 1000 2422478 did VBD B-VP O
25 1001 1004 2422478 not RB I-VP O
26 1005 1011 2422478 affect VB I-VP O
27 1012 1016 2422478 this DT B-NP O
28 1017 1028 2422478 hypotension NN I-NP D007022
29 1028 1029 2422478 . . O O

1 1030 1037 2422478 Further RB B-ADVP O
2 1037 1038 2422478 , , O O
3 1039 1042 2422478 5,7 CD B-NP D015116
4 1042 1043 2422478 - HYPH I-NP D015116
5 1043 1046 2422478 DHT NN I-NP D015116
6 1047 1053 2422478 lesion NN I-NP O
7 1054 1056 2422478 of IN B-PP O
8 1057 1066 2422478 serotonin NN B-NP D012701
9 1067 1073 2422478 nerves VBZ B-VP O
10 1074 1084 2422478 travelling NN B-NP O
11 1085 1087 2422478 in IN B-PP O
12 1088 1091 2422478 the DT B-NP O
13 1092 1098 2422478 median JJ I-NP O
14 1099 1108 2422478 forebrain NN I-NP O
15 1109 1115 2422478 bundle NN I-NP O
16 1115 1116 2422478 , , O O
17 1117 1120 2422478 one CD B-NP O
18 1121 1123 2422478 of IN B-PP O
19 1124 1127 2422478 the DT B-NP O
20 1128 1132 2422478 main JJ I-NP O
21 1133 1142 2422478 ascending JJ I-NP O
22 1143 1151 2422478 pathways NNS I-NP O
23 1152 1156 2422478 from IN B-PP O
24 1157 1160 2422478 the DT B-NP O
25 1161 1163 2422478 B3 NN I-NP O
26 1164 1173 2422478 serotonin NN I-NP D012701
27 1174 1179 2422478 cells NNS I-NP O
28 1179 1180 2422478 , , O O
29 1181 1184 2422478 did VBD B-VP O
30 1185 1188 2422478 not RB I-VP O
31 1189 1195 2422478 affect VB I-VP O
32 1196 1199 2422478 the DT B-NP O
33 1200 1204 2422478 fall NN I-NP O
34 1205 1207 2422478 in IN B-PP O
35 1208 1213 2422478 blood NN B-NP O
36 1214 1222 2422478 pressure NN I-NP O
37 1223 1233 2422478 associated VBN B-VP O
38 1234 1238 2422478 with IN B-PP O
39 1239 1240 2422478 a DT B-NP O
40 1241 1248 2422478 midline NN I-NP O
41 1249 1251 2422478 B3 NN I-NP O
42 1252 1261 2422478 serotonin NN I-NP D012701
43 1262 1272 2422478 methyldopa NN I-NP D008750
44 1273 1282 2422478 injection NN I-NP O
45 1282 1283 2422478 . . O O

1 1284 1286 2422478 It PRP B-NP O
2 1287 1289 2422478 is VBZ B-VP O
3 1290 1299 2422478 concluded VBN I-VP O
4 1300 1309 2422478 therefore RB B-ADVP O
5 1310 1314 2422478 that IN B-SBAR O
6 1314 1315 2422478 , , O O
7 1316 1322 2422478 unlike IN B-PP O
8 1323 1326 2422478 the DT B-NP O
9 1327 1340 2422478 ventrolateral JJ I-NP O
10 1341 1343 2422478 B3 NN I-NP O
11 1344 1349 2422478 cells NNS I-NP O
12 1350 1355 2422478 which WDT B-NP O
13 1356 1363 2422478 mediate VBP B-VP O
14 1364 1365 2422478 a DT B-NP O
15 1366 1376 2422478 methyldopa NN I-NP D008750
16 1376 1377 2422478 - HYPH O O
17 1377 1384 2422478 induced VBN B-NP O
18 1385 1396 2422478 hypotension NN I-NP D007022
19 1397 1400 2422478 via IN B-PP O
20 1401 1411 2422478 descending VBG B-VP O
21 1412 1423 2422478 projections NNS B-NP O
22 1423 1424 2422478 , , O O
23 1425 1428 2422478 the DT B-NP O
24 1429 1436 2422478 midline NN I-NP O
25 1437 1446 2422478 serotonin NN I-NP D012701
26 1447 1449 2422478 B3 NN I-NP O
27 1450 1455 2422478 cells NNS I-NP O
28 1456 1458 2422478 in IN B-PP O
29 1459 1462 2422478 the DT B-NP O
30 1463 1470 2422478 medulla NN I-NP O
31 1471 1481 2422478 contribute VBP B-VP O
32 1482 1484 2422478 to TO B-PP O
33 1485 1488 2422478 the DT B-NP O
34 1489 1500 2422478 hypotensive JJ I-NP D007022
35 1501 1507 2422478 action NN I-NP O
36 1508 1510 2422478 of IN B-PP O
37 1511 1521 2422478 methyldopa NN B-NP D008750
38 1521 1522 2422478 , , O O
39 1523 1529 2422478 either CC O O
40 1530 1532 2422478 by IN B-PP O
41 1533 1536 2422478 way NN B-NP O
42 1537 1539 2422478 of IN B-PP O
43 1540 1542 2422478 an DT B-NP O
44 1543 1552 2422478 ascending VBG I-NP O
45 1553 1563 2422478 projection NN I-NP O
46 1564 1569 2422478 which WDT B-NP O
47 1570 1574 2422478 does VBZ B-VP O
48 1575 1578 2422478 not RB I-VP O
49 1579 1583 2422478 pass VB I-VP O
50 1584 1591 2422478 through IN B-PP O
51 1592 1595 2422478 the DT B-NP O
52 1596 1602 2422478 median JJ I-NP O
53 1603 1612 2422478 forebrain NN I-NP O
54 1613 1619 2422478 bundle NN I-NP O
55 1619 1620 2422478 , , O O
56 1621 1623 2422478 or CC O O
57 1624 1631 2422478 through IN B-PP O
58 1632 1633 2422478 a DT B-NP O
59 1634 1644 2422478 projection NN I-NP O
60 1645 1655 2422478 restricted VBN B-VP O
61 1656 1658 2422478 to TO B-PP O
62 1659 1662 2422478 the DT B-NP O
63 1663 1669 2422478 caudal JJ I-NP O
64 1670 1679 2422478 brainstem NN I-NP O
65 1679 1680 2422478 . . O O

1 0 0 16157917 -DOCSTART- -X- -X- O

1 0 11 16157917 Lamotrigine NN B-NP C047781
2 12 22 16157917 associated VBN B-VP O
3 23 27 16157917 with IN B-PP O
4 28 40 16157917 exacerbation NN B-NP O
5 41 43 16157917 or CC B-NP O
6 44 46 16157917 de FW I-NP O
7 47 51 16157917 novo FW I-NP O
8 52 61 16157917 myoclonus NN I-NP D009207
9 62 64 16157917 in IN B-PP O
10 65 75 16157917 idiopathic JJ B-NP C562694
11 76 87 16157917 generalized VBN I-NP C562694
12 88 98 16157917 epilepsies NNS I-NP C562694
13 98 99 16157917 . . O O
14 100 104 16157917 Five CD B-NP O
15 105 113 16157917 patients NNS I-NP O
16 114 118 16157917 with IN B-PP O
17 119 129 16157917 idiopathic JJ B-NP C562694
18 130 141 16157917 generalized VBN I-NP C562694
19 142 152 16157917 epilepsies NNS I-NP C562694
20 153 154 16157917 ( ( O O
21 154 157 16157917 IGE NN B-NP C562694
22 157 158 16157917 ) ) O O
23 159 166 16157917 treated VBN B-VP O
24 167 171 16157917 with IN B-PP O
25 172 183 16157917 lamotrigine NN B-NP C047781
26 184 185 16157917 ( ( I-NP O
27 185 188 16157917 LTG NN I-NP C047781
28 188 189 16157917 ) ) I-NP O
29 190 201 16157917 experienced JJ I-NP O
30 202 214 16157917 exacerbation NN I-NP O
31 215 217 16157917 or CC I-NP O
32 218 220 16157917 de FW I-NP O
33 221 225 16157917 novo FW I-NP O
34 226 236 16157917 appearance NN I-NP O
35 237 239 16157917 of IN B-PP O
36 240 249 16157917 myoclonic JJ B-NP D009207
37 250 255 16157917 jerks NNS I-NP D009207
38 256 257 16157917 ( ( O O
39 257 259 16157917 MJ NN B-NP D009207
40 259 260 16157917 ) ) O O
41 260 261 16157917 . . O O

1 262 264 16157917 In IN B-PP O
2 265 270 16157917 three CD B-NP O
3 271 279 16157917 patients NNS I-NP O
4 279 280 16157917 , , O O
5 281 284 16157917 LTG NN B-NP C047781
6 285 296 16157917 exacerbated VBD B-VP O
7 297 299 16157917 MJ NN B-NP D009207
8 300 302 16157917 in IN B-PP O
9 303 304 16157917 a DT B-NP O
10 305 309 16157917 dose NN I-NP O
11 309 310 16157917 - HYPH B-NP O
12 310 319 16157917 dependent JJ I-NP O
13 320 326 16157917 manner NN I-NP O
14 327 331 16157917 with IN B-PP O
15 332 337 16157917 early JJ B-NP O
16 338 349 16157917 aggravation NN I-NP O
17 350 356 16157917 during IN B-PP O
18 357 366 16157917 titration NN B-NP O
19 366 367 16157917 . . O O

1 368 370 16157917 MJ NN B-NP D009207
2 371 382 16157917 disappeared VBD B-VP O
3 383 387 16157917 when WRB B-ADVP O
4 388 391 16157917 LTG NN B-NP C047781
5 392 396 16157917 dose NN I-NP O
6 397 400 16157917 was VBD B-VP O
7 401 410 16157917 decreased VBN I-VP O
8 411 413 16157917 by IN B-PP O
9 414 416 16157917 25 CD B-NP O
10 417 419 16157917 to TO B-PP O
11 420 423 16157917 50% CD B-NP O
12 423 424 16157917 . . O O

1 425 427 16157917 In IN B-PP O
2 428 431 16157917 two CD B-NP O
3 432 440 16157917 patients NNS I-NP O
4 440 441 16157917 , , O O
5 442 445 16157917 LTG NN B-NP C047781
6 446 457 16157917 exacerbated VBD B-VP O
7 458 460 16157917 MJ NN B-NP D009207
8 461 463 16157917 in IN B-PP O
9 464 465 16157917 a DT B-NP O
10 466 473 16157917 delayed VBN I-NP O
11 474 477 16157917 but CC I-NP O
12 478 482 16157917 more RBR I-NP O
13 483 489 16157917 severe JJ I-NP O
14 490 496 16157917 manner NN I-NP O
15 496 497 16157917 , , O O
16 498 502 16157917 with IN B-PP O
17 503 512 16157917 myoclonic JJ B-NP D009207
18 513 519 16157917 status NN I-NP D009207
19 520 524 16157917 that WDT B-NP O
20 525 529 16157917 only RB B-ADVP O
21 530 536 16157917 ceased VBD B-VP O
22 537 542 16157917 after IN B-PP O
23 543 546 16157917 LTG NN B-NP C047781
24 547 557 16157917 withdrawal NN I-NP O
25 557 558 16157917 . . O O

1 0 0 20510337 -DOCSTART- -X- -X- O

1 0 8 20510337 Coenzyme NN B-NP C024989
2 9 12 20510337 Q10 NN I-NP C024989
3 13 22 20510337 treatment NN I-NP O
4 23 34 20510337 ameliorates VBZ B-VP O
5 35 40 20510337 acute JJ B-NP O
6 41 50 20510337 cisplatin NN I-NP D002945
7 51 65 20510337 nephrotoxicity NN I-NP D007674
8 66 68 20510337 in IN B-PP O
9 69 73 20510337 mice NNS B-NP O
10 73 74 20510337 . . O O
11 75 78 20510337 The DT B-NP O
12 79 95 20510337 nephroprotective JJ I-NP O
13 96 102 20510337 effect NN I-NP O
14 103 105 20510337 of IN B-PP O
15 106 114 20510337 coenzyme NN B-NP C024989
16 115 118 20510337 Q10 NN I-NP C024989
17 119 122 20510337 was VBD B-VP O
18 123 135 20510337 investigated VBN I-VP O
19 136 138 20510337 in IN B-PP O
20 139 143 20510337 mice NNS B-NP O
21 144 148 20510337 with IN B-PP O
22 149 154 20510337 acute JJ B-NP D058186
23 155 160 20510337 renal JJ I-NP D058186
24 161 167 20510337 injury NN I-NP D058186
25 168 175 20510337 induced VBN B-VP O
26 176 178 20510337 by IN B-PP O
27 179 180 20510337 a DT B-NP O
28 181 187 20510337 single JJ I-NP O
29 188 191 20510337 i.p NN I-NP O
30 191 192 20510337 . . O O

1 193 202 20510337 injection NN B-NP O
2 203 205 20510337 of IN B-PP O
3 206 215 20510337 cisplatin NN B-NP D002945
4 216 217 20510337 ( ( O O
5 217 218 20510337 5 CD B-NP O
6 219 221 20510337 mg NN I-NP O
7 221 222 20510337 / SYM B-NP O
8 222 224 20510337 kg NN I-NP O
9 224 225 20510337 ) ) O O
10 225 226 20510337 . . O O

1 227 235 20510337 Coenzyme NN B-NP C024989
2 236 239 20510337 Q10 NN I-NP C024989
3 240 249 20510337 treatment NN I-NP O
4 250 251 20510337 ( ( O O
5 251 253 20510337 10 CD B-NP O
6 254 256 20510337 mg NN I-NP O
7 256 257 20510337 / SYM B-NP O
8 257 259 20510337 kg NN I-NP O
9 259 260 20510337 / SYM B-NP O
10 260 263 20510337 day NN I-NP O
11 263 264 20510337 , , O O
12 265 268 20510337 i.p NN B-NP O
13 268 269 20510337 . . O O
14 269 270 20510337 ) ) O O
15 271 274 20510337 was VBD B-VP O
16 275 282 20510337 applied VBN I-VP O
17 283 286 20510337 for IN B-PP O
18 287 288 20510337 6 CD B-NP O
19 289 300 20510337 consecutive JJ I-NP O
20 301 305 20510337 days NNS I-NP O
21 305 306 20510337 , , O O
22 307 315 20510337 starting VBG B-VP O
23 316 317 20510337 1 CD B-NP O
24 318 321 20510337 day NN I-NP O
25 322 328 20510337 before IN B-PP O
26 329 338 20510337 cisplatin NN B-NP D002945
27 339 353 20510337 administration NN I-NP O
28 353 354 20510337 . . O O

1 355 363 20510337 Coenzyme NN B-NP C024989
2 364 367 20510337 Q10 NN I-NP C024989
3 368 381 20510337 significantly RB B-ADVP O
4 382 389 20510337 reduced VBD B-VP O
5 390 395 20510337 blood NN B-NP D001806
6 396 400 20510337 urea NN I-NP D001806
7 401 409 20510337 nitrogen NN I-NP D001806
8 410 413 20510337 and CC I-NP O
9 414 419 20510337 serum NN I-NP O
10 420 430 20510337 creatinine NN I-NP D003404
11 431 437 20510337 levels NNS I-NP O
12 438 443 20510337 which WDT B-NP O
13 444 448 20510337 were VBD B-VP O
14 449 458 20510337 increased VBN I-VP O
15 459 461 20510337 by IN B-PP O
16 462 471 20510337 cisplatin NN B-NP D002945
17 471 472 20510337 . . O O

1 473 481 20510337 Coenzyme NN B-NP C024989
2 482 485 20510337 Q10 NN I-NP C024989
3 486 499 20510337 significantly RB B-ADVP O
4 500 511 20510337 compensated VBD B-VP O
5 512 520 20510337 deficits NNS B-NP O
6 521 523 20510337 in IN B-PP O
7 524 527 20510337 the DT B-NP O
8 528 539 20510337 antioxidant JJ I-NP O
9 540 547 20510337 defense NN I-NP O
10 548 558 20510337 mechanisms NNS I-NP O
11 559 560 20510337 ( ( O O
12 560 567 20510337 reduced VBN B-NP D005978
13 568 579 20510337 glutathione NN I-NP D005978
14 580 585 20510337 level NN I-NP O
15 586 589 20510337 and CC I-NP O
16 590 600 20510337 superoxide NN I-NP D013481
17 601 610 20510337 dismutase NN I-NP O
18 611 619 20510337 activity NN I-NP O
19 619 620 20510337 ) ) O O
20 620 621 20510337 , , O O
21 622 632 20510337 suppressed VBD B-VP O
22 633 638 20510337 lipid NN B-NP O
23 639 651 20510337 peroxidation NN I-NP O
24 651 652 20510337 , , O O
25 653 662 20510337 decreased VBD B-VP O
26 663 666 20510337 the DT B-NP O
27 667 677 20510337 elevations NNS I-NP O
28 678 680 20510337 of IN B-PP O
29 681 686 20510337 tumor NN B-NP D009369
30 687 695 20510337 necrosis NN I-NP D009336
31 696 702 20510337 factor NN I-NP O
32 702 703 20510337 - HYPH O O
33 703 708 20510337 alpha SYM B-NP O
34 708 709 20510337 , , O O
35 710 716 20510337 nitric JJ B-NP D009569
36 717 722 20510337 oxide NN I-NP D009569
37 723 726 20510337 and CC I-NP O
38 727 735 20510337 platinum NN I-NP D010984
39 736 739 20510337 ion NN I-NP O
40 740 753 20510337 concentration NN I-NP O
41 753 754 20510337 , , O O
42 755 758 20510337 and CC O O
43 759 769 20510337 attenuated VBD B-VP O
44 770 773 20510337 the DT B-NP O
45 774 784 20510337 reductions NNS I-NP O
46 785 787 20510337 of IN B-PP O
47 788 796 20510337 selenium NN B-NP D012643
48 797 800 20510337 and CC I-NP O
49 801 805 20510337 zinc NN I-NP D015032
50 806 810 20510337 ions NNS I-NP O
51 811 813 20510337 in IN B-PP O
52 814 819 20510337 renal JJ B-NP O
53 820 826 20510337 tissue NN I-NP O
54 827 835 20510337 resulted VBD B-VP O
55 836 840 20510337 from IN B-PP O
56 841 850 20510337 cisplatin NN B-NP D002945
57 851 865 20510337 administration NN I-NP O
58 865 866 20510337 . . O O

1 867 871 20510337 Also RB B-ADVP O
2 871 872 20510337 , , O O
3 873 890 20510337 histopathological JJ B-NP O
4 891 896 20510337 renal JJ I-NP D007674
5 897 903 20510337 tissue NN I-NP D007674
6 904 910 20510337 damage NN I-NP D007674
7 911 919 20510337 mediated VBN B-VP O
8 920 922 20510337 by IN B-PP O
9 923 932 20510337 cisplatin NN B-NP D002945
10 933 936 20510337 was VBD B-VP O
11 937 948 20510337 ameliorated VBN I-VP O
12 949 951 20510337 by IN B-PP O
13 952 960 20510337 coenzyme NN B-NP C024989
14 961 964 20510337 Q10 NN I-NP C024989
15 965 974 20510337 treatment NN I-NP O
16 974 975 20510337 . . O O

1 976 995 20510337 Immunohistochemical JJ B-NP O
2 996 1004 20510337 analysis NN I-NP O
3 1005 1013 20510337 revealed VBD B-VP O
4 1014 1018 20510337 that IN B-SBAR O
5 1019 1027 20510337 coenzyme NN B-NP C024989
6 1028 1031 20510337 Q10 NN I-NP C024989
7 1032 1045 20510337 significantly RB B-ADVP O
8 1046 1055 20510337 decreased VBD B-VP O
9 1056 1059 20510337 the DT B-NP O
10 1060 1069 20510337 cisplatin NN I-NP D002945
11 1069 1070 20510337 - HYPH B-NP O
12 1070 1077 20510337 induced VBN I-NP O
13 1078 1092 20510337 overexpression NN I-NP O
14 1093 1095 20510337 of IN B-PP O
15 1096 1105 20510337 inducible JJ B-NP O
16 1106 1112 20510337 nitric JJ I-NP D009569
17 1113 1118 20510337 oxide NN I-NP D009569
18 1119 1127 20510337 synthase NN I-NP O
19 1127 1128 20510337 , , O O
20 1129 1136 20510337 nuclear JJ B-NP O
21 1137 1143 20510337 factor NN I-NP O
22 1143 1144 20510337 - HYPH B-NP O
23 1144 1150 20510337 kappaB NN I-NP O
24 1150 1151 20510337 , , O O
25 1152 1159 20510337 caspase NN B-NP O
26 1159 1160 20510337 - HYPH B-NP O
27 1160 1161 20510337 3 CD I-NP O
28 1162 1165 20510337 and CC O O
29 1166 1169 20510337 p53 NN B-NP O
30 1170 1172 20510337 in IN B-PP O
31 1173 1178 20510337 renal JJ B-NP O
32 1179 1185 20510337 tissue NN I-NP O
33 1185 1186 20510337 . . O O

1 1187 1189 20510337 It PRP B-NP O
2 1190 1193 20510337 was VBD B-VP O
3 1194 1203 20510337 concluded VBN I-VP O
4 1204 1208 20510337 that IN B-SBAR O
5 1209 1217 20510337 coenzyme NN B-NP C024989
6 1218 1221 20510337 Q10 NN I-NP C024989
7 1222 1232 20510337 represents VBZ B-VP O
8 1233 1234 20510337 a DT B-NP O
9 1235 1244 20510337 potential JJ I-NP O
10 1245 1256 20510337 therapeutic JJ I-NP O
11 1257 1263 20510337 option NN I-NP O
12 1264 1266 20510337 to TO B-VP O
13 1267 1274 20510337 protect VB I-VP O
14 1275 1282 20510337 against IN B-PP O
15 1283 1288 20510337 acute JJ B-NP O
16 1289 1298 20510337 cisplatin NN I-NP D002945
17 1299 1313 20510337 nephrotoxicity NN I-NP D007674
18 1314 1322 20510337 commonly RB B-VP O
19 1323 1334 20510337 encountered VBN I-VP O
20 1335 1337 20510337 in IN B-PP O
21 1338 1346 20510337 clinical JJ B-NP O
22 1347 1355 20510337 practice NN I-NP O
23 1355 1356 20510337 . . O O

1 0 0 4090988 -DOCSTART- -X- -X- O

1 0 9 4090988 Induction NN B-NP O
2 10 12 4090988 by IN B-PP O
3 13 24 4090988 paracetamol NN B-NP D000082
4 25 27 4090988 of IN B-PP O
5 28 35 4090988 bladder NN B-NP D001749
6 36 39 4090988 and CC I-NP D001749
7 40 45 4090988 liver NN I-NP D001749
8 46 53 4090988 tumours NNS I-NP D001749
9 54 56 4090988 in IN B-PP O
10 57 60 4090988 the DT B-NP O
11 61 64 4090988 rat NN I-NP O
12 64 65 4090988 . . O O

1 66 73 4090988 Effects NNS B-NP O
2 74 76 4090988 on IN B-PP O
3 77 87 4090988 hepatocyte NN B-NP O
4 88 92 4090988 fine NN I-NP O
5 93 102 4090988 structure NN I-NP O
6 102 103 4090988 . . O O
7 104 110 4090988 Groups NNS B-NP O
8 111 113 4090988 of IN B-PP O
9 114 118 4090988 male JJ B-NP O
10 119 122 4090988 and CC I-NP O
11 123 129 4090988 female JJ I-NP O
12 130 136 4090988 inbred JJ I-NP O
13 137 142 4090988 Leeds NNS I-NP O
14 143 149 4090988 strain NN I-NP O
15 150 154 4090988 rats NNS I-NP O
16 155 159 4090988 were VBD B-VP O
17 160 163 4090988 fed VBN I-VP O
18 164 169 4090988 diets NNS B-NP O
19 170 180 4090988 containing VBG B-VP O
20 181 187 4090988 either CC O O
21 188 192 4090988 0.5% CD B-NP O
22 193 195 4090988 or CC I-NP O
23 196 200 4090988 1.0% CD I-NP O
24 201 212 4090988 paracetamol NN I-NP D000082
25 213 215 4090988 by IN B-PP O
26 216 222 4090988 weight NN B-NP O
27 223 226 4090988 for IN B-PP O
28 227 229 4090988 up RB B-NP O
29 230 232 4090988 to TO I-NP O
30 233 235 4090988 18 CD I-NP O
31 236 242 4090988 months NNS I-NP O
32 242 243 4090988 . . O O

1 244 246 4090988 At IN B-PP O
2 247 250 4090988 the DT B-NP O
3 251 255 4090988 1.0% CD I-NP O
4 256 262 4090988 dosage NN I-NP O
5 263 268 4090988 level NN I-NP O
6 268 269 4090988 , , O O
7 270 273 4090988 20% CD B-NP O
8 274 276 4090988 of IN B-PP O
9 277 281 4090988 rats NNS B-NP O
10 282 284 4090988 of IN B-PP O
11 285 289 4090988 both DT B-NP O
12 290 295 4090988 sexes NNS I-NP O
13 296 305 4090988 developed VBD B-VP O
14 306 316 4090988 neoplastic JJ B-NP O
15 317 324 4090988 nodules NNS I-NP O
16 325 327 4090988 of IN B-PP O
17 328 331 4090988 the DT B-NP O
18 332 337 4090988 liver NN I-NP O
19 337 338 4090988 , , O O
20 339 340 4090988 a DT B-NP O
21 341 354 4090988 statistically RB I-NP O
22 355 366 4090988 significant JJ I-NP O
23 367 376 4090988 incidence NN I-NP O
24 376 377 4090988 . . O O

1 378 383 4090988 These DT B-NP O
2 384 388 4090988 rats NNS I-NP O
3 389 393 4090988 also RB B-ADVP O
4 394 400 4090988 showed VBD B-VP O
5 401 406 4090988 gross JJ B-NP O
6 407 418 4090988 enlargement NN I-NP O
7 419 421 4090988 of IN B-PP O
8 422 427 4090988 their PRP$ B-NP O
9 428 434 4090988 livers NNS I-NP O
10 435 438 4090988 and CC O O
11 439 441 4090988 an DT B-NP O
12 442 450 4090988 increase NN I-NP O
13 451 453 4090988 in IN B-PP O
14 454 458 4090988 foci NNS B-NP O
15 459 461 4090988 of IN B-PP O
16 462 470 4090988 cellular JJ B-NP O
17 471 481 4090988 alteration NN I-NP O
18 481 482 4090988 , , O O
19 483 486 4090988 the DT B-NP O
20 487 493 4090988 latter JJ I-NP O
21 494 498 4090988 also RB B-VP O
22 499 504 4090988 being VBG I-VP O
23 505 513 4090988 observed VBN I-VP O
24 514 516 4090988 in IN B-PP O
25 517 520 4090988 the DT B-NP O
26 521 524 4090988 low JJ I-NP O
27 525 531 4090988 dosage NN I-NP O
28 532 536 4090988 male JJ I-NP O
29 537 541 4090988 rats NNS I-NP O
30 541 542 4090988 . . O O

1 543 553 4090988 Papillomas NNS B-NP D010212
2 554 556 4090988 of IN B-PP O
3 557 560 4090988 the DT B-NP O
4 561 573 4090988 transitional JJ I-NP O
5 574 584 4090988 epithelium NN I-NP O
6 585 587 4090988 of IN B-PP O
7 588 591 4090988 the DT B-NP O
8 592 599 4090988 bladder NN I-NP O
9 600 609 4090988 developed VBN B-VP O
10 610 612 4090988 in IN B-PP O
11 613 616 4090988 all DT B-NP O
12 617 628 4090988 paracetamol NN I-NP D000082
13 628 629 4090988 - HYPH B-NP O
14 629 636 4090988 treated VBN I-NP O
15 637 643 4090988 groups NNS I-NP O
16 643 644 4090988 , , O O
17 645 648 4090988 and CC O O
18 649 654 4090988 three CD B-NP O
19 655 659 4090988 rats NNS I-NP O
20 660 664 4090988 bore VBD B-VP O
21 665 672 4090988 bladder NN B-NP D001749
22 673 683 4090988 carcinomas NNS I-NP D001749
23 683 684 4090988 . . O O

1 685 692 4090988 However RB B-ADVP O
2 692 693 4090988 , , O O
3 694 705 4090988 significant JJ B-NP O
4 706 712 4090988 yields NNS I-NP O
5 713 715 4090988 of IN B-PP O
6 716 723 4090988 bladder NN B-NP D001749
7 724 731 4090988 tumours NNS I-NP D001749
8 732 736 4090988 were VBD B-VP O
9 737 741 4090988 only RB I-VP O
10 742 750 4090988 obtained VBN I-VP O
11 751 755 4090988 from IN B-PP O
12 756 759 4090988 low JJ B-NP O
13 760 766 4090988 dosage NN I-NP O
14 767 774 4090988 females NNS I-NP O
15 775 778 4090988 and CC O O
16 779 783 4090988 high JJ B-NP O
17 784 790 4090988 dosage NN I-NP O
18 791 796 4090988 males NNS I-NP O
19 796 797 4090988 . . O O

1 798 810 4090988 Additionally RB B-ADVP O
2 810 811 4090988 , , O O
3 812 814 4090988 20 CD B-NP O
4 815 817 4090988 to TO B-PP O
5 818 821 4090988 25% CD B-NP O
6 822 824 4090988 of IN B-PP O
7 825 836 4090988 paracetamol NN B-NP D000082
8 836 837 4090988 - HYPH B-NP O
9 837 844 4090988 treated VBN I-NP O
10 845 849 4090988 rats NNS I-NP O
11 850 859 4090988 developed VBD B-VP O
12 860 871 4090988 hyperplasia NN B-NP D006965
13 872 874 4090988 of IN B-PP O
14 875 878 4090988 the DT B-NP O
15 879 886 4090988 bladder NN I-NP O
16 887 897 4090988 epithelium NN I-NP O
17 897 898 4090988 , , O O
18 899 904 4090988 which WDT B-NP O
19 905 908 4090988 was VBD B-VP O
20 909 912 4090988 not RB O O
21 913 923 4090988 coincident JJ B-ADJP O
22 924 928 4090988 with IN B-PP O
23 929 932 4090988 the DT B-NP O
24 933 941 4090988 presence NN I-NP O
25 942 944 4090988 of IN B-PP O
26 945 952 4090988 bladder NN B-NP D001744
27 953 960 4090988 calculi NNS I-NP D001744
28 960 961 4090988 . . O O

1 962 963 4090988 A DT B-NP O
2 964 967 4090988 low JJ I-NP O
3 968 973 4090988 yield NN I-NP O
4 974 976 4090988 of IN B-PP O
5 977 984 4090988 tumours NNS B-NP D009369
6 985 987 4090988 at IN B-PP O
7 988 995 4090988 various JJ B-NP O
8 996 1001 4090988 other JJ I-NP O
9 1002 1007 4090988 sites NNS I-NP O
10 1008 1012 4090988 also RB B-ADVP O
11 1013 1018 4090988 arose VBP B-VP O
12 1019 1028 4090988 following VBG B-PP O
13 1029 1040 4090988 paracetamol NN B-NP D000082
14 1041 1048 4090988 feeding NN I-NP O
15 1048 1049 4090988 . . O O

1 1050 1052 4090988 An DT B-NP O
2 1053 1061 4090988 electron NN I-NP O
3 1062 1072 4090988 microscope NN I-NP O
4 1073 1078 4090988 study NN I-NP O
5 1079 1081 4090988 of IN B-PP O
6 1082 1085 4090988 the DT B-NP O
7 1086 1092 4090988 livers NNS I-NP O
8 1093 1095 4090988 of IN B-PP O
9 1096 1107 4090988 paracetamol NN B-NP D000082
10 1107 1108 4090988 - HYPH B-NP O
11 1108 1115 4090988 treated VBN I-NP O
12 1116 1120 4090988 rats NNS I-NP O
13 1121 1129 4090988 revealed VBD B-VP O
14 1130 1145 4090988 ultrastructural JJ B-NP O
15 1146 1153 4090988 changes NNS I-NP O
16 1154 1156 4090988 in IN B-PP O
17 1157 1160 4090988 the DT B-NP O
18 1161 1172 4090988 hepatocytes NNS I-NP O
19 1173 1177 4090988 that WDT B-NP O
20 1178 1186 4090988 resemble VBP B-VP O
21 1187 1192 4090988 those DT B-NP O
22 1193 1197 4090988 that WDT B-NP O
23 1198 1204 4090988 result VBP B-VP O
24 1205 1209 4090988 from IN B-PP O
25 1210 1218 4090988 exposure NN B-NP O
26 1219 1221 4090988 to TO B-PP O
27 1222 1223 4090988 a DT B-NP O
28 1224 1231 4090988 variety NN I-NP O
29 1232 1234 4090988 of IN B-PP O
30 1235 1240 4090988 known JJ B-NP O
31 1241 1258 4090988 hepatocarcinogens NNS I-NP D008113
32 1258 1259 4090988 . . O O

1 0 0 16132524 -DOCSTART- -X- -X- O

1 0 13 16132524 Intracavitary JJ B-NP O
2 14 26 16132524 chemotherapy NN I-NP O
3 27 28 16132524 ( ( O O
4 28 38 16132524 paclitaxel NN B-NP D017239
5 38 39 16132524 / SYM O O
6 39 50 16132524 carboplatin NN B-NP D016190
7 51 57 16132524 liquid JJ I-NP O
8 58 69 16132524 crystalline NN I-NP O
9 70 75 16132524 cubic JJ I-NP O
10 76 82 16132524 phases NNS I-NP O
11 82 83 16132524 ) ) O O
12 84 87 16132524 for IN B-PP O
13 88 97 16132524 recurrent JJ B-NP O
14 98 110 16132524 glioblastoma NN I-NP D005909
15 111 112 16132524 - HYPH O O
16 112 113 16132524 - HYPH O O
17 114 122 16132524 clinical JJ B-NP O
18 123 135 16132524 observations NNS I-NP O
19 135 136 16132524 . . O O
20 137 142 16132524 Human JJ B-NP O
21 143 152 16132524 malignant JJ I-NP O
22 153 158 16132524 brain NN I-NP D001932
23 159 165 16132524 tumors NNS I-NP D001932
24 166 170 16132524 have VBP B-VP O
25 171 172 16132524 a DT B-NP O
26 173 177 16132524 poor JJ I-NP O
27 178 187 16132524 prognosis NN I-NP O
28 188 190 16132524 in IN B-PP O
29 191 196 16132524 spite NN B-NP O
30 197 199 16132524 of IN B-PP O
31 200 207 16132524 surgery NN B-NP O
32 208 211 16132524 and CC I-NP O
33 212 221 16132524 radiation NN I-NP O
34 222 229 16132524 therapy NN I-NP O
35 229 230 16132524 . . O O

1 231 236 16132524 Cubic JJ B-NP O
2 237 243 16132524 phases NNS I-NP O
3 244 251 16132524 consist VBP B-VP O
4 252 254 16132524 of IN B-PP O
5 255 261 16132524 curved VBN B-NP O
6 262 275 16132524 biocontinuous JJ I-NP O
7 276 281 16132524 lipid NN I-NP O
8 282 290 16132524 bilayers NNS I-NP O
9 290 291 16132524 , , O O
10 292 302 16132524 separating VBG B-VP O
11 303 306 16132524 two CD B-NP O
12 307 316 16132524 congruent JJ I-NP O
13 317 325 16132524 networks NNS I-NP O
14 326 328 16132524 of IN B-PP O
15 329 334 16132524 water NN B-NP O
16 335 343 16132524 channels NNS I-NP O
17 343 344 16132524 . . O O

1 345 349 16132524 Used VBN B-VP O
2 350 352 16132524 as IN B-PP O
3 353 354 16132524 a DT B-NP O
4 355 359 16132524 host NN I-NP O
5 360 363 16132524 for IN B-PP O
6 364 373 16132524 cytotoxic JJ B-NP O
7 374 379 16132524 drugs NNS I-NP O
8 379 380 16132524 , , O O
9 381 384 16132524 the DT B-NP O
10 385 388 16132524 gel NN I-NP O
11 388 389 16132524 - HYPH B-NP O
12 389 393 16132524 like JJ I-NP O
13 394 400 16132524 matrix NN I-NP O
14 401 404 16132524 can MD B-VP O
15 405 411 16132524 easily RB I-VP O
16 412 414 16132524 be VB I-VP O
17 415 422 16132524 applied VBN I-VP O
18 423 425 16132524 to TO B-PP O
19 426 429 16132524 the DT B-NP O
20 430 435 16132524 walls NNS I-NP O
21 436 438 16132524 of IN B-PP O
22 439 440 16132524 a DT B-NP O
23 441 449 16132524 surgical JJ I-NP O
24 450 459 16132524 resection NN I-NP O
25 460 466 16132524 cavity NN I-NP O
26 466 467 16132524 . . O O

1 468 471 16132524 For IN B-PP O
2 472 477 16132524 human JJ B-NP O
3 478 490 16132524 glioblastoma NN I-NP D005909
4 491 502 16132524 recurrences NNS I-NP O
5 502 503 16132524 , , O O
6 504 507 16132524 the DT B-NP O
7 508 519 16132524 feasibility NN I-NP O
8 519 520 16132524 , , O O
9 521 527 16132524 safety NN B-NP O
10 527 528 16132524 , , O O
11 529 532 16132524 and CC O O
12 533 538 16132524 short JJ B-NP O
13 538 539 16132524 - HYPH I-NP O
14 539 543 16132524 term NN I-NP O
15 544 551 16132524 effects NNS I-NP O
16 552 554 16132524 of IN B-PP O
17 555 556 16132524 a DT B-NP O
18 557 565 16132524 surgical JJ I-NP O
19 566 579 16132524 intracavitary JJ I-NP O
20 580 591 16132524 application NN I-NP O
21 592 594 16132524 of IN B-PP O
22 595 605 16132524 paclitaxel NN B-NP D017239
23 606 609 16132524 and CC I-NP O
24 610 621 16132524 carboplatin NN I-NP D016190
25 622 634 16132524 encapsulated VBN B-VP O
26 635 637 16132524 by IN B-PP O
27 638 644 16132524 liquid JJ B-NP O
28 645 656 16132524 crystalline NN I-NP O
29 657 662 16132524 cubic JJ I-NP O
30 663 669 16132524 phases NNS I-NP O
31 670 673 16132524 are VBP B-VP O
32 674 682 16132524 examined VBN I-VP O
33 683 685 16132524 in IN B-PP O
34 686 687 16132524 a DT B-NP O
35 688 693 16132524 pilot NN I-NP O
36 694 699 16132524 study NN I-NP O
37 699 700 16132524 . . O O

1 701 702 16132524 A DT B-NP O
2 703 708 16132524 total NN I-NP O
3 709 711 16132524 of IN B-PP O
4 712 714 16132524 12 CD B-NP O
5 715 723 16132524 patients NNS I-NP O
6 724 728 16132524 with IN B-PP O
7 729 730 16132524 a DT B-NP O
8 731 741 16132524 recurrence NN I-NP O
9 742 744 16132524 of IN B-PP O
10 745 746 16132524 a DT B-NP O
11 747 759 16132524 glioblastoma NN I-NP D005909
12 760 770 16132524 multiforme NN I-NP O
13 771 780 16132524 underwent VBD B-VP O
14 781 783 16132524 re AFX B-NP O
15 783 784 16132524 - HYPH I-NP O
16 784 793 16132524 resection NN I-NP O
17 794 797 16132524 and CC O O
18 798 806 16132524 received VBD B-VP O
19 807 809 16132524 an DT B-NP O
20 810 823 16132524 intracavitary JJ I-NP O
21 824 835 16132524 application NN I-NP O
22 836 838 16132524 of IN B-PP O
23 839 849 16132524 paclitaxel NN B-NP D017239
24 850 853 16132524 and CC O O
25 854 865 16132524 carboplatin NN B-NP D016190
26 866 871 16132524 cubic JJ I-NP O
27 872 878 16132524 phases NNS I-NP O
28 879 881 16132524 in IN B-PP O
29 882 891 16132524 different JJ B-NP O
30 892 899 16132524 dosages NNS I-NP O
31 899 900 16132524 . . O O

1 901 904 16132524 Six CD B-NP O
2 905 907 16132524 of IN B-PP O
3 908 911 16132524 the DT B-NP O
4 912 920 16132524 patients NNS I-NP O
5 921 929 16132524 received VBD B-VP O
6 930 934 16132524 more JJR B-NP O
7 935 939 16132524 than IN I-NP O
8 940 942 16132524 15 CD I-NP O
9 943 945 16132524 mg NN I-NP O
10 946 956 16132524 paclitaxel NN I-NP D017239
11 957 960 16132524 and CC O O
12 961 969 16132524 suffered VBD B-VP O
13 970 974 16132524 from IN B-PP O
14 975 983 16132524 moderate JJ B-ADJP O
15 984 986 16132524 to TO B-PP O
16 987 993 16132524 severe JJ B-NP O
17 994 999 16132524 brain NN I-NP D001929
18 1000 1005 16132524 edema NN I-NP D001929
19 1005 1006 16132524 , , O O
20 1007 1012 16132524 while IN B-SBAR O
21 1013 1016 16132524 the DT B-NP O
22 1017 1026 16132524 remaining VBG I-NP O
23 1027 1035 16132524 patients NNS I-NP O
24 1036 1044 16132524 received VBD B-VP O
25 1045 1049 16132524 only RB B-NP O
26 1050 1051 16132524 a DT I-NP O
27 1052 1057 16132524 total NN I-NP O
28 1058 1060 16132524 of IN B-PP O
29 1061 1063 16132524 15 CD B-NP O
30 1064 1066 16132524 mg NN I-NP O
31 1067 1077 16132524 paclitaxel NN I-NP D017239
32 1077 1078 16132524 . . O O

1 1079 1081 16132524 In IN B-PP O
2 1082 1085 16132524 the DT B-NP O
3 1086 1092 16132524 latter JJ I-NP O
4 1093 1098 16132524 group NN I-NP O
5 1098 1099 16132524 , , O O
6 1100 1105 16132524 brain NN B-NP D001929
7 1106 1111 16132524 edema NN I-NP D001929
8 1112 1115 16132524 was VBD B-VP O
9 1116 1124 16132524 markedly RB I-VP O
10 1125 1132 16132524 reduced VBN I-VP O
11 1133 1136 16132524 and CC O O
12 1137 1142 16132524 dealt VBN B-VP O
13 1143 1152 16132524 medically RB B-ADVP O
14 1152 1153 16132524 . . O O

1 1154 1167 16132524 Intracavitary JJ B-NP O
2 1168 1180 16132524 chemotherapy NN I-NP O
3 1181 1183 16132524 in IN B-PP O
4 1184 1193 16132524 recurrent JJ B-NP O
5 1194 1206 16132524 glioblastoma NN I-NP D005909
6 1207 1212 16132524 using VBG B-VP O
7 1213 1218 16132524 cubic JJ B-NP O
8 1219 1225 16132524 phases NNS I-NP O
9 1226 1228 16132524 is VBZ B-VP O
10 1229 1237 16132524 feasible JJ B-ADJP O
11 1238 1241 16132524 and CC I-ADJP O
12 1242 1246 16132524 safe JJ I-ADJP O
13 1246 1247 16132524 , , O O
14 1248 1251 16132524 yet RB B-ADVP O
15 1252 1255 16132524 the DT B-NP O
16 1256 1264 16132524 clinical JJ I-NP O
17 1265 1272 16132524 benefit NN I-NP O
18 1273 1280 16132524 remains VBZ B-VP O
19 1281 1283 16132524 to TO I-VP O
20 1284 1286 16132524 be VB I-VP O
21 1287 1295 16132524 examined VBN I-VP O
22 1296 1298 16132524 in IN B-PP O
23 1299 1300 16132524 a DT B-NP O
24 1301 1309 16132524 clinical JJ I-NP O
25 1310 1315 16132524 phase NN I-NP O
26 1316 1318 16132524 II CD I-NP O
27 1319 1324 16132524 study NN I-NP O
28 1324 1325 16132524 . . O O

1 0 0 15974569 -DOCSTART- -X- -X- O

1 0 3 15974569 Two CD B-NP O
2 4 12 15974569 prodrugs NNS I-NP O
3 13 15 15974569 of IN B-PP O
4 16 22 15974569 potent JJ B-NP O
5 23 26 15974569 and CC I-NP O
6 27 36 15974569 selective JJ I-NP O
7 37 42 15974569 GluR5 NN I-NP O
8 43 50 15974569 kainate NN I-NP D007608
9 51 59 15974569 receptor NN I-NP O
10 60 71 15974569 antagonists NNS I-NP O
11 72 79 15974569 actives NNS I-NP O
12 80 82 15974569 in IN B-PP O
13 83 88 15974569 three CD B-NP O
14 89 95 15974569 animal NN I-NP O
15 96 102 15974569 models NNS I-NP O
16 103 105 15974569 of IN B-PP O
17 106 110 15974569 pain NN B-NP D010146
18 110 111 15974569 . . O O
19 112 117 15974569 Amino NN B-NP O
20 118 123 15974569 acids NNS I-NP O
21 124 125 15974569 5 CD B-NP O
22 126 129 15974569 and CC I-NP O
23 130 131 15974569 7 CD I-NP O
24 131 132 15974569 , , O O
25 133 136 15974569 two CD B-NP O
26 137 143 15974569 potent JJ I-NP O
27 144 147 15974569 and CC I-NP O
28 148 157 15974569 selective JJ I-NP O
29 158 169 15974569 competitive JJ I-NP O
30 170 175 15974569 GluR5 NN I-NP O
31 176 178 15974569 KA NN I-NP D007608
32 179 187 15974569 receptor NN I-NP O
33 188 199 15974569 antagonists NNS I-NP O
34 199 200 15974569 , , O O
35 201 210 15974569 exhibited VBD B-VP O
36 211 215 15974569 high JJ B-NP O
37 216 221 15974569 GluR5 NN I-NP O
38 222 230 15974569 receptor NN I-NP O
39 231 239 15974569 affinity NN I-NP O
40 240 244 15974569 over IN B-PP O
41 245 250 15974569 other JJ B-NP O
42 251 260 15974569 glutamate NN I-NP D018698
43 261 270 15974569 receptors NNS I-NP O
44 270 271 15974569 . . O O

1 272 277 15974569 Their PRP$ B-NP O
2 278 283 15974569 ester NN I-NP O
3 284 292 15974569 prodrugs NNS I-NP O
4 293 294 15974569 6 CD B-NP O
5 295 298 15974569 and CC I-NP O
6 299 300 15974569 8 CD I-NP O
7 301 305 15974569 were VBD B-VP O
8 306 312 15974569 orally RB B-ADJP O
9 313 319 15974569 active JJ I-ADJP O
10 320 322 15974569 in IN B-PP O
11 323 328 15974569 three CD B-NP O
12 329 335 15974569 models NNS I-NP O
13 336 338 15974569 of IN B-PP O
14 339 343 15974569 pain NN B-NP D010146
15 343 344 15974569 : : O O
16 345 353 15974569 reversal NN B-NP O
17 354 356 15974569 of IN B-PP O
18 357 365 15974569 formalin NN B-NP D005557
19 365 366 15974569 - HYPH B-NP O
20 366 373 15974569 induced VBN I-NP O
21 374 377 15974569 paw NN I-NP O
22 378 385 15974569 licking NN I-NP O
23 385 386 15974569 , , O O
24 387 398 15974569 carrageenan NN B-NP D002351
25 398 399 15974569 - HYPH O O
26 399 406 15974569 induced VBN B-NP O
27 407 414 15974569 thermal JJ I-NP D006930
28 415 427 15974569 hyperalgesia NN I-NP D006930
29 427 428 15974569 , , O O
30 429 432 15974569 and CC O O
31 433 442 15974569 capsaicin NN B-NP D002211
32 442 443 15974569 - HYPH O O
33 443 450 15974569 induced VBN B-NP O
34 451 461 15974569 mechanical JJ I-NP D006930
35 462 474 15974569 hyperalgesia NN I-NP D006930
36 474 475 15974569 . . O O

1 0 0 16471092 -DOCSTART- -X- -X- O

1 0 7 16471092 Urinary JJ B-NP O
2 8 16 16471092 symptoms NNS I-NP O
3 17 20 16471092 and CC O O
4 21 28 16471092 quality NN B-NP O
5 29 31 16471092 of IN B-PP O
6 32 36 16471092 life NN B-NP O
7 37 44 16471092 changes NNS I-NP O
8 45 47 16471092 in IN B-PP O
9 48 52 16471092 Thai JJ B-NP O
10 53 58 16471092 women NNS I-NP O
11 59 63 16471092 with IN B-PP O
12 64 74 16471092 overactive JJ B-NP D053201
13 75 82 16471092 bladder NN I-NP D053201
14 83 88 16471092 after IN B-PP O
15 89 100 16471092 tolterodine NN B-NP C099041
16 101 110 16471092 treatment NN I-NP O
17 110 111 16471092 . . O O
18 112 122 16471092 OBJECTIVES NNS B-NP O
19 122 123 16471092 : : O O
20 124 126 16471092 To TO B-VP O
21 127 132 16471092 study VB I-VP O
22 133 136 16471092 the DT B-NP O
23 137 144 16471092 urinary JJ I-NP O
24 145 153 16471092 symptoms NNS I-NP O
25 154 157 16471092 and CC O O
26 158 165 16471092 quality NN B-NP O
27 166 168 16471092 of IN B-PP O
28 169 173 16471092 life NN B-NP O
29 174 181 16471092 changes NNS I-NP O
30 182 184 16471092 in IN B-PP O
31 185 189 16471092 Thai JJ B-NP O
32 190 195 16471092 women NNS I-NP O
33 196 200 16471092 with IN B-PP O
34 201 211 16471092 overactive JJ B-NP D053201
35 212 219 16471092 bladder NN I-NP D053201
36 220 221 16471092 ( ( O O
37 221 224 16471092 OAB NN B-NP D053201
38 224 225 16471092 ) ) O O
39 226 231 16471092 after IN B-PP O
40 232 243 16471092 tolterodine NN B-NP C099041
41 244 253 16471092 treatment NN I-NP O
42 253 254 16471092 . . O O

1 255 263 16471092 MATERIAL NN B-NP O
2 264 267 16471092 AND CC I-NP O
3 268 274 16471092 METHOD NN I-NP O
4 274 275 16471092 : : O O
5 276 282 16471092 Thirty CD B-NP O
6 283 288 16471092 women NNS I-NP O
7 289 290 16471092 ( ( O O
8 290 294 16471092 aged VBN B-VP O
9 295 297 16471092 30 CD B-NP O
10 297 298 16471092 - HYPH I-NP O
11 298 300 16471092 77 CD I-NP O
12 301 306 16471092 years NNS I-NP O
13 306 307 16471092 ) ) O O
14 308 317 16471092 diagnosed VBN B-VP O
15 318 320 16471092 as IN B-PP O
16 321 327 16471092 having VBG B-VP O
17 328 331 16471092 OAB NN B-NP D053201
18 332 334 16471092 at IN B-PP O
19 335 338 16471092 the DT B-NP O
20 339 349 16471092 Gynecology NNP I-NP O
21 350 356 16471092 Clinic NNP I-NP O
22 356 357 16471092 , , O O
23 358 362 16471092 King NNP B-NP O
24 363 376 16471092 Chulalongkorn NNP I-NP O
25 377 385 16471092 Memorial NNP I-NP O
26 386 394 16471092 Hospital NNP I-NP O
27 395 399 16471092 from IN B-PP O
28 400 407 16471092 January NNP B-NP O
29 408 410 16471092 to TO B-PP O
30 411 416 16471092 April NNP B-NP O
31 417 421 16471092 2004 CD I-NP O
32 422 426 16471092 were VBD B-VP O
33 427 435 16471092 included VBN I-VP O
34 436 438 16471092 in IN B-PP O
35 439 442 16471092 the DT B-NP O
36 443 450 16471092 present JJ I-NP O
37 451 456 16471092 study NN I-NP O
38 456 457 16471092 . . O O

1 458 469 16471092 Tolterodine NN B-NP C099041
2 470 471 16471092 2 CD I-NP O
3 472 474 16471092 mg NN I-NP O
4 474 475 16471092 , , O O
5 476 481 16471092 twice RB B-ADVP O
6 482 487 16471092 daily RB I-ADVP O
7 488 491 16471092 was VBD B-VP O
8 492 497 16471092 given VBN I-VP O
9 497 498 16471092 . . O O

1 499 504 16471092 After IN B-PP O
2 505 506 16471092 8 CD B-NP O
3 507 512 16471092 weeks NNS I-NP O
4 513 522 16471092 treatment NN I-NP O
5 522 523 16471092 , , O O
6 524 531 16471092 changes NNS B-NP O
7 532 534 16471092 in IN B-PP O
8 535 546 16471092 micturition NN B-NP O
9 547 552 16471092 diary JJ I-NP O
10 553 562 16471092 variables NNS I-NP O
11 563 566 16471092 and CC I-NP O
12 567 579 16471092 tolerability NN I-NP O
13 580 584 16471092 were VBD B-VP O
14 585 595 16471092 determined VBN I-VP O
15 595 596 16471092 . . O O

1 597 602 16471092 Short JJ B-NP O
2 603 607 16471092 form NN I-NP O
3 608 610 16471092 36 CD I-NP O
4 611 612 16471092 ( ( O O
5 612 616 16471092 SF36 NN B-NP O
6 616 617 16471092 ) ) O O
7 618 631 16471092 questionaires VBZ B-VP O
8 632 633 16471092 ( ( O O
9 633 637 16471092 Thai JJ B-NP O
10 638 645 16471092 version NN I-NP O
11 645 646 16471092 ) ) O O
12 647 651 16471092 were VBD B-VP O
13 652 657 16471092 given VBN I-VP O
14 658 664 16471092 before IN B-PP O
15 665 668 16471092 and CC I-PP O
16 669 674 16471092 after IN I-PP O
17 675 676 16471092 8 CD B-NP O
18 677 682 16471092 weeks NNS I-NP O
19 683 685 16471092 of IN B-PP O
20 686 695 16471092 treatment NN B-NP O
21 695 696 16471092 . . O O

1 697 704 16471092 RESULTS NNS B-NP O
2 704 705 16471092 : : O O
3 706 708 16471092 At IN B-NP O
4 709 710 16471092 8 CD I-NP O
5 711 716 16471092 weeks NNS I-NP O
6 716 717 16471092 , , O O
7 718 721 16471092 all DT B-NP O
8 722 733 16471092 micturition NN I-NP O
9 734 737 16471092 per IN B-PP O
10 738 741 16471092 day NN B-NP O
11 742 751 16471092 decreased VBD B-VP O
12 752 756 16471092 from IN B-PP O
13 757 759 16471092 16 CD B-NP O
14 759 760 16471092 . . O O

1 761 762 16471092 7 CD B-NP O
2 763 764 16471092 + SYM B-NP O
3 764 765 16471092 / SYM I-NP O
4 765 766 16471092 - SYM I-NP O
5 767 768 16471092 5 CD I-NP O
6 768 769 16471092 . SYM I-NP O
7 770 771 16471092 3 CD I-NP O
8 772 774 16471092 to TO B-PP O
9 775 776 16471092 6 CD B-NP O
10 776 777 16471092 . . O O

1 778 779 16471092 7 CD B-NP O
2 780 781 16471092 + SYM O O
3 781 782 16471092 / SYM B-NP O
4 782 783 16471092 - SYM B-NP O
5 784 787 16471092 2.4 CD B-NP O
6 788 793 16471092 times NNS I-NP O
7 794 797 16471092 per IN B-PP O
8 798 801 16471092 day NN B-NP O
9 801 802 16471092 . . O O

1 803 806 16471092 The DT B-NP O
2 807 813 16471092 number NN I-NP O
3 814 816 16471092 of IN B-PP O
4 817 825 16471092 nocturia NN B-NP D053158
5 826 834 16471092 episodes NNS I-NP O
6 835 844 16471092 decreased VBD B-VP O
7 845 849 16471092 from IN B-PP O
8 850 853 16471092 5.4 CD B-NP O
9 854 855 16471092 + SYM B-ADJP O
10 855 856 16471092 / SYM O O
11 856 857 16471092 - SYM O O
12 858 861 16471092 4.2 CD B-NP O
13 862 864 16471092 to TO B-PP O
14 865 868 16471092 1.1 CD B-NP O
15 869 870 16471092 + SYM O O
16 870 871 16471092 / SYM O O
17 871 872 16471092 - SYM O O
18 873 876 16471092 1.0 CD B-NP O
19 877 882 16471092 times NNS I-NP O
20 883 886 16471092 per IN B-PP O
21 887 892 16471092 night NN B-NP O
22 892 893 16471092 . . O O

1 894 897 16471092 The DT B-NP O
2 898 902 16471092 most RBS I-NP O
3 903 909 16471092 common JJ I-NP O
4 910 914 16471092 side NN I-NP O
5 915 921 16471092 effect NN I-NP O
6 922 925 16471092 was VBD B-VP O
7 926 929 16471092 dry JJ B-NP D014987
8 930 935 16471092 month NN I-NP D014987
9 936 938 16471092 in IN B-PP O
10 939 940 16471092 5 CD B-NP O
11 941 946 16471092 cases NNS I-NP O
12 947 948 16471092 ( ( O O
13 948 953 16471092 16.7% NN B-NP O
14 953 954 16471092 ) ) O O
15 955 959 16471092 with IN B-PP O
16 960 961 16471092 2 CD B-NP O
17 962 967 16471092 cases NNS I-NP O
18 968 977 16471092 reporting VBG B-VP O
19 978 979 16471092 a DT B-NP O
20 980 988 16471092 moderate JJ I-NP O
21 989 995 16471092 degree NN I-NP O
22 996 999 16471092 and CC O O
23 1000 1001 16471092 1 CD B-NP O
24 1002 1006 16471092 case NN I-NP O
25 1007 1011 16471092 with IN B-PP O
26 1012 1018 16471092 severe JJ B-NP O
27 1019 1025 16471092 degree NN I-NP O
28 1025 1026 16471092 . . O O

1 1027 1031 16471092 Only RB B-NP O
2 1032 1035 16471092 one CD I-NP O
3 1036 1040 16471092 case NN I-NP O
4 1041 1042 16471092 ( ( O O
5 1042 1046 16471092 3.3% NN B-NP O
6 1046 1047 16471092 ) ) O O
7 1048 1056 16471092 withdrew VBD B-VP O
8 1057 1061 16471092 from IN B-PP O
9 1062 1065 16471092 the DT B-NP O
10 1066 1073 16471092 present JJ I-NP O
11 1074 1079 16471092 study NN I-NP O
12 1080 1083 16471092 due JJ B-PP O
13 1084 1086 16471092 to TO B-PP O
14 1087 1088 16471092 a DT B-NP O
15 1089 1095 16471092 severe JJ I-NP O
16 1096 1099 16471092 dry JJ I-NP D014987
17 1100 1105 16471092 mouth NN I-NP D014987
18 1105 1106 16471092 . . O O

1 1107 1110 16471092 The DT B-NP O
2 1111 1113 16471092 SF NN I-NP O
3 1113 1114 16471092 - HYPH O O
4 1114 1116 16471092 36 CD B-NP O
5 1117 1123 16471092 scores NNS I-NP O
6 1124 1131 16471092 changed VBD B-VP O
7 1132 1145 16471092 significantly RB B-ADVP O
8 1146 1148 16471092 in IN B-PP O
9 1149 1152 16471092 the DT B-NP O
10 1153 1160 16471092 domains NNS I-NP O
11 1161 1163 16471092 of IN B-PP O
12 1164 1172 16471092 physical JJ B-NP O
13 1173 1184 16471092 functioning NN I-NP O
14 1184 1185 16471092 , , O O
15 1186 1190 16471092 role NN B-NP O
16 1191 1199 16471092 function NN I-NP O
17 1200 1209 16471092 emotional JJ B-NP O
18 1209 1210 16471092 , , I-NP O
19 1211 1217 16471092 social JJ I-NP O
20 1218 1226 16471092 function NN I-NP O
21 1227 1230 16471092 and CC O O
22 1231 1237 16471092 mental JJ B-NP O
23 1238 1243 16471092 heath NN I-NP O
24 1243 1244 16471092 . . O O

1 1245 1255 16471092 CONCLUSION NN B-NP O
2 1255 1256 16471092 : : O O
3 1257 1268 16471092 Tolterodine NN B-NP C099041
4 1269 1272 16471092 was VBD B-VP O
5 1273 1277 16471092 well RB I-VP O
6 1278 1287 16471092 tolerated VBN I-VP O
7 1288 1291 16471092 and CC O O
8 1292 1295 16471092 its PRP$ B-NP O
9 1296 1303 16471092 effects NNS I-NP O
10 1304 1312 16471092 improved VBD B-VP O
11 1313 1316 16471092 the DT B-NP O
12 1317 1324 16471092 quality NN I-NP O
13 1325 1327 16471092 of IN B-PP O
14 1328 1332 16471092 life NN B-NP O
15 1333 1335 16471092 in IN B-PP O
16 1336 1340 16471092 Thai JJ B-NP O
17 1341 1346 16471092 women NNS I-NP O
18 1347 1351 16471092 with IN B-PP O
19 1352 1355 16471092 OAB NN B-NP D053201
20 1355 1356 16471092 . . O O

1 0 0 15638391 -DOCSTART- -X- -X- O

1 0 5 15638391 Aging VBG B-VP O
2 6 13 15638391 process NN B-NP O
3 14 16 15638391 of IN B-PP O
4 17 27 15638391 epithelial JJ B-NP O
5 28 33 15638391 cells NNS I-NP O
6 34 36 15638391 of IN B-PP O
7 37 40 15638391 the DT B-NP O
8 41 44 15638391 rat NN I-NP O
9 45 53 15638391 prostate NN I-NP O
10 54 61 15638391 lateral JJ I-NP O
11 62 66 15638391 lobe NN I-NP O
12 67 69 15638391 in IN B-PP O
13 70 82 15638391 experimental JJ B-NP O
14 83 101 15638391 hyperprolactinemia NN I-NP D006966
15 102 109 15638391 induced VBN B-VP O
16 110 112 15638391 by IN B-PP O
17 113 124 15638391 haloperidol NN B-NP D006220
18 124 125 15638391 . . O O
19 126 129 15638391 The DT B-NP O
20 130 133 15638391 aim NN I-NP O
21 134 136 15638391 of IN B-PP O
22 137 140 15638391 the DT B-NP O
23 141 146 15638391 study NN I-NP O
24 147 150 15638391 was VBD B-VP O
25 151 153 15638391 to TO B-VP O
26 154 161 15638391 examine VB I-VP O
27 162 165 15638391 the DT B-NP O
28 166 175 15638391 influence NN I-NP O
29 176 178 15638391 of IN B-PP O
30 179 197 15638391 hyperprolactinemia NN B-NP D006966
31 197 198 15638391 , , O O
32 199 206 15638391 induced VBN B-VP O
33 207 209 15638391 by IN B-PP O
34 210 221 15638391 haloperidol NN B-NP D006220
35 222 223 15638391 ( ( O O
36 223 226 15638391 HAL NN B-NP D006220
37 226 227 15638391 ) ) O O
38 228 230 15638391 on IN B-PP O
39 231 234 15638391 age NN B-NP O
40 235 242 15638391 related VBN I-NP O
41 243 253 15638391 morphology NN I-NP O
42 254 257 15638391 and CC I-NP O
43 258 266 15638391 function NN I-NP O
44 267 274 15638391 changes NNS I-NP O
45 275 277 15638391 of IN B-PP O
46 278 288 15638391 epithelial JJ B-NP O
47 289 294 15638391 cells NNS I-NP O
48 295 297 15638391 in IN B-PP O
49 298 301 15638391 rat NN B-NP O
50 302 310 15638391 prostate NN I-NP O
51 311 318 15638391 lateral JJ I-NP O
52 319 323 15638391 lobe NN I-NP O
53 323 324 15638391 . . O O

1 325 328 15638391 The DT B-NP O
2 329 334 15638391 study NN I-NP O
3 335 338 15638391 was VBD B-VP O
4 339 348 15638391 performed VBN I-VP O
5 349 351 15638391 on IN B-PP O
6 352 360 15638391 sexually RB B-NP O
7 361 367 15638391 mature JJ I-NP O
8 368 372 15638391 male JJ I-NP O
9 373 377 15638391 rats NNS I-NP O
10 377 378 15638391 . . O O

1 379 384 15638391 Serum NN B-NP O
2 385 399 15638391 concentrations NNS I-NP O
3 400 402 15638391 of IN B-PP O
4 403 412 15638391 prolactin NN B-NP O
5 413 414 15638391 ( ( O O
6 414 417 15638391 PRL NN B-NP D011388
7 417 418 15638391 ) ) O O
8 419 422 15638391 and CC O O
9 423 435 15638391 testosterone NN B-NP D013739
10 436 437 15638391 ( ( O O
11 437 438 15638391 T NN B-NP D013739
12 438 439 15638391 ) ) O O
13 440 444 15638391 were VBD B-VP O
14 445 453 15638391 measured VBN I-VP O
15 453 454 15638391 . . O O

1 455 461 15638391 Tissue NN B-NP O
2 462 470 15638391 sections NNS I-NP O
3 471 475 15638391 were VBD B-VP O
4 476 485 15638391 evaluated VBN I-VP O
5 486 490 15638391 with IN B-PP O
6 491 496 15638391 light NN B-NP O
7 497 500 15638391 and CC I-NP O
8 501 509 15638391 electron NN I-NP O
9 510 520 15638391 microscopy NN I-NP O
10 520 521 15638391 . . O O

1 522 541 15638391 Immunohistochemical JJ B-NP O
2 542 551 15638391 reactions NNS I-NP O
3 552 555 15638391 for IN B-PP O
4 556 560 15638391 Anti AFX B-NP O
5 560 561 15638391 - HYPH I-NP O
6 561 574 15638391 Proliferating VBG B-VP O
7 575 579 15638391 Cell NN B-NP O
8 580 587 15638391 Nuclear JJ I-NP O
9 588 595 15638391 Antigen NN I-NP O
10 596 597 15638391 ( ( O O
11 597 601 15638391 PCNA NN B-NP O
12 601 602 15638391 ) ) O O
13 603 607 15638391 were VBD B-VP O
14 608 617 15638391 performed VBN I-VP O
15 617 618 15638391 . . O O

1 619 621 15638391 In IN B-PP O
2 622 626 15638391 rats NNS B-NP O
3 627 629 15638391 of IN B-PP O
4 630 633 15638391 the DT B-NP O
5 634 646 15638391 experimental JJ I-NP O
6 647 652 15638391 group NN I-NP O
7 652 653 15638391 , , O O
8 654 657 15638391 the DT B-NP O
9 658 662 15638391 mean JJ I-NP O
10 663 676 15638391 concentration NN I-NP O
11 677 679 15638391 of IN B-PP O
12 679 680 15638391 : : O O
13 681 684 15638391 PRL NN B-NP D011388
14 685 688 15638391 was VBD B-VP O
15 689 693 15638391 more JJR B-NP O
16 694 698 15638391 than IN I-NP O
17 699 704 15638391 twice RB I-NP O
18 705 711 15638391 higher JJR I-NP O
19 711 712 15638391 , , O O
20 713 720 15638391 whereas IN O O
21 721 722 15638391 T NN B-NP D013739
22 723 736 15638391 concentration NN I-NP O
23 737 740 15638391 was VBD B-VP O
24 741 747 15638391 almost RB B-ADJP O
25 748 753 15638391 twice RB I-ADJP O
26 754 759 15638391 lower JJR I-ADJP O
27 760 764 15638391 than IN B-PP O
28 765 769 15638391 that DT B-NP O
29 770 772 15638391 in IN B-PP O
30 773 776 15638391 the DT B-NP O
31 777 784 15638391 control NN I-NP O
32 785 790 15638391 group NN I-NP O
33 790 791 15638391 . . O O

1 792 797 15638391 Light NN B-NP O
2 798 808 15638391 microscopy NN I-NP O
3 809 819 15638391 visualized VBD B-VP O
4 820 823 15638391 the DT B-NP O
5 824 833 15638391 following NN I-NP O
6 833 834 15638391 : : O O
7 835 846 15638391 hypertrophy NN B-NP D006984
8 847 850 15638391 and CC I-NP O
9 851 861 15638391 epithelium NN I-NP O
10 862 873 15638391 hyperplasia NN I-NP D006965
11 874 876 15638391 of IN B-PP O
12 877 880 15638391 the DT B-NP O
13 881 890 15638391 glandular JJ I-NP O
14 891 896 15638391 ducts NNS I-NP O
15 896 897 15638391 , , O O
16 898 908 15638391 associated VBN B-VP O
17 909 913 15638391 with IN B-PP O
18 914 923 15638391 increased VBN B-NP O
19 924 928 15638391 PCNA NN I-NP O
20 929 939 15638391 expression NN I-NP O
21 939 940 15638391 . . O O

1 941 949 15638391 Electron NN B-NP O
2 950 960 15638391 microscopy NN I-NP O
3 961 969 15638391 revealed VBD B-VP O
4 970 977 15638391 changes NNS B-NP O
5 978 980 15638391 in IN B-PP O
6 981 989 15638391 columnar JJ B-NP O
7 990 1000 15638391 epithelial JJ I-NP O
8 1001 1006 15638391 cells NNS I-NP O
9 1006 1007 15638391 , , O O
10 1008 1018 15638391 concerning VBG B-VP O
11 1019 1029 15638391 organelles NNS B-NP O
12 1029 1030 15638391 , , O O
13 1031 1038 15638391 engaged VBN B-VP O
14 1039 1041 15638391 in IN B-PP O
15 1042 1049 15638391 protein NN B-NP O
16 1050 1059 15638391 synthesis NN I-NP O
17 1060 1063 15638391 and CC I-NP O
18 1064 1073 15638391 secretion NN I-NP O
19 1073 1074 15638391 . . O O

1 0 0 7437994 -DOCSTART- -X- -X- O

1 0 4 7437994 Long JJ B-NP O
2 4 5 7437994 - HYPH I-NP O
3 5 9 7437994 term NN I-NP O
4 10 17 7437994 lithium NN I-NP D008094
5 18 27 7437994 treatment NN I-NP O
6 28 31 7437994 and CC O O
7 32 35 7437994 the DT B-NP O
8 36 42 7437994 kidney NN I-NP O
9 42 43 7437994 . . O O

1 44 51 7437994 Interim JJ B-NP O
2 52 58 7437994 report NN I-NP O
3 59 61 7437994 on IN B-PP O
4 62 67 7437994 fifty CD B-NP O
5 68 76 7437994 patients NNS I-NP O
6 76 77 7437994 . . O O
7 78 82 7437994 This DT B-NP O
8 83 85 7437994 is VBZ B-VP O
9 86 87 7437994 a DT B-NP O
10 88 94 7437994 report NN I-NP O
11 95 97 7437994 on IN B-PP O
12 98 101 7437994 the DT B-NP O
13 102 107 7437994 first JJ I-NP O
14 108 112 7437994 part NN I-NP O
15 113 115 7437994 of IN B-PP O
16 116 119 7437994 our PRP$ B-NP O
17 120 125 7437994 study NN I-NP O
18 126 128 7437994 of IN B-PP O
19 129 132 7437994 the DT B-NP O
20 133 140 7437994 effects NNS I-NP O
21 141 143 7437994 of IN B-PP O
22 144 148 7437994 long JJ B-NP O
23 148 149 7437994 - HYPH I-NP O
24 149 153 7437994 term NN I-NP O
25 154 161 7437994 lithium NN I-NP D008094
26 162 171 7437994 treatment NN I-NP O
27 172 174 7437994 on IN B-PP O
28 175 178 7437994 the DT B-NP O
29 179 185 7437994 kidney NN I-NP O
30 185 186 7437994 . . O O

1 187 197 7437994 Creatinine NN B-NP D003404
2 198 207 7437994 clearance NN I-NP O
3 207 208 7437994 , , O O
4 209 216 7437994 maximum JJ B-NP O
5 217 224 7437994 urinary JJ I-NP O
6 225 235 7437994 osmolality NN I-NP O
7 236 239 7437994 and CC O O
8 240 242 7437994 24 CD B-NP O
9 243 247 7437994 hour NN I-NP O
10 248 253 7437994 urine NN I-NP O
11 254 260 7437994 volume NN I-NP O
12 261 265 7437994 have VBP B-VP O
13 266 270 7437994 been VBN I-VP O
14 271 277 7437994 tested VBN I-VP O
15 278 280 7437994 in IN B-PP O
16 281 283 7437994 50 CD B-NP O
17 284 295 7437994 affectively RB I-NP O
18 296 299 7437994 ill JJ I-NP O
19 300 308 7437994 patients NNS I-NP O
20 309 312 7437994 who WP B-NP O
21 313 317 7437994 have VBP B-VP O
22 318 322 7437994 been VBN I-VP O
23 323 325 7437994 on IN B-PP O
24 326 330 7437994 long JJ B-NP O
25 330 331 7437994 - HYPH I-NP O
26 331 335 7437994 term NN I-NP O
27 336 343 7437994 lithium NN I-NP D008094
28 344 347 7437994 for IN B-PP O
29 348 352 7437994 more JJR B-NP O
30 353 357 7437994 than IN I-NP O
31 358 361 7437994 one CD I-NP O
32 362 366 7437994 year NN I-NP O
33 366 367 7437994 . . O O

1 368 373 7437994 These DT B-NP O
2 374 382 7437994 findings NNS I-NP O
3 383 387 7437994 have VBP B-VP O
4 388 392 7437994 been VBN I-VP O
5 393 401 7437994 compared VBN I-VP O
6 402 406 7437994 with IN B-PP O
7 407 412 7437994 norms NNS B-NP O
8 413 416 7437994 and CC B-PP O
9 417 421 7437994 with IN B-PP O
10 422 428 7437994 values NNS B-NP O
11 429 431 7437994 of IN B-PP O
12 432 435 7437994 the DT B-NP O
13 436 440 7437994 same JJ I-NP O
14 441 446 7437994 tests NNS I-NP O
15 447 451 7437994 from IN B-PP O
16 452 461 7437994 screening VBG B-VP O
17 462 467 7437994 prior JJ B-ADVP O
18 468 470 7437994 to TO B-PP O
19 471 478 7437994 lithium NN B-NP D008094
20 478 479 7437994 , , O O
21 480 489 7437994 available JJ B-ADJP O
22 490 493 7437994 for IN B-PP O
23 494 498 7437994 most JJS B-NP O
24 499 501 7437994 of IN B-PP O
25 502 505 7437994 our PRP$ B-NP O
26 506 514 7437994 patients NNS I-NP O
27 514 515 7437994 . . O O

1 516 518 7437994 No DT B-NP O
2 519 527 7437994 evidence NN I-NP O
3 528 531 7437994 was VBD B-VP O
4 532 537 7437994 found VBN I-VP O
5 538 541 7437994 for IN B-PP O
6 542 545 7437994 any DT B-NP O
7 546 555 7437994 reduction NN I-NP O
8 556 558 7437994 of IN B-PP O
9 559 569 7437994 glomerular JJ B-NP O
10 570 580 7437994 filtration NN I-NP O
11 581 587 7437994 during IN B-PP O
12 588 595 7437994 lithium NN B-NP D008094
13 596 605 7437994 treatment NN I-NP O
14 605 606 7437994 . . O O

1 607 610 7437994 Low JJ B-NP O
2 611 620 7437994 clearance NN I-NP O
3 621 627 7437994 values NNS I-NP O
4 628 633 7437994 found VBN B-VP O
5 634 636 7437994 in IN B-PP O
6 637 644 7437994 several JJ B-NP O
7 645 653 7437994 patients NNS I-NP O
8 654 659 7437994 could MD B-VP O
9 660 662 7437994 be VB I-VP O
10 663 672 7437994 accounted VBN I-VP O
11 673 676 7437994 for IN B-PP O
12 677 679 7437994 by IN B-PP O
13 680 685 7437994 their PRP$ B-NP O
14 686 689 7437994 age NN I-NP O
15 690 693 7437994 and CC O O
16 694 699 7437994 their PRP$ B-NP O
17 700 703 7437994 pre AFX I-NP O
18 703 704 7437994 - HYPH I-NP O
19 704 711 7437994 lithium NN I-NP D008094
20 712 718 7437994 values NNS I-NP O
21 718 719 7437994 . . O O

1 720 727 7437994 Urinary JJ B-NP O
2 728 741 7437994 concentration NN I-NP O
3 742 748 7437994 defect NN I-NP O
4 749 757 7437994 appeared VBD B-VP O
5 758 766 7437994 frequent JJ B-ADJP O
6 767 770 7437994 but CC O O
7 771 774 7437994 the DT B-NP O
8 775 781 7437994 extent NN I-NP O
9 782 784 7437994 of IN B-PP O
10 785 788 7437994 the DT B-NP O
11 789 799 7437994 impairment NN I-NP O
12 800 802 7437994 is VBZ B-VP O
13 803 812 7437994 difficult JJ B-ADJP O
14 813 815 7437994 to TO B-VP O
15 816 822 7437994 assess VB I-VP O
16 823 830 7437994 because IN B-PP O
17 831 833 7437994 of IN I-PP O
18 834 837 7437994 the DT B-NP O
19 838 849 7437994 uncertainty NN I-NP O
20 850 855 7437994 about IN B-PP O
21 856 859 7437994 the DT B-NP O
22 860 865 7437994 norms NNS I-NP O
23 866 876 7437994 applicable JJ B-ADJP O
24 877 879 7437994 to TO B-PP O
25 880 884 7437994 this DT B-NP O
26 885 890 7437994 group NN I-NP O
27 891 893 7437994 of IN B-PP O
28 894 902 7437994 patients NNS B-NP O
29 902 903 7437994 . . O O

1 904 907 7437994 The DT B-NP O
2 908 921 7437994 concentration NN I-NP O
3 922 928 7437994 defect NN I-NP O
4 929 937 7437994 appeared VBD B-VP O
5 938 948 7437994 reversible JJ B-ADJP O
6 948 949 7437994 , , O O
7 950 952 7437994 at IN B-ADVP O
8 953 958 7437994 least JJS I-ADVP O
9 959 961 7437994 in IN B-PP O
10 962 966 7437994 part NN B-NP O
11 966 967 7437994 . . O O

1 968 976 7437994 Polyuria NN B-NP D011141
2 977 982 7437994 above IN B-PP O
3 983 984 7437994 3 CD B-NP O
4 985 991 7437994 litres NNS I-NP O
5 991 992 7437994 / SYM B-NP O
6 992 994 7437994 24 CD B-NP O
7 995 1000 7437994 hours NNS I-NP O
8 1001 1004 7437994 was VBD B-VP O
9 1005 1010 7437994 found VBN I-VP O
10 1011 1013 7437994 in IN B-PP O
11 1014 1017 7437994 10% CD B-NP O
12 1018 1020 7437994 of IN B-PP O
13 1021 1029 7437994 patients NNS B-NP O
14 1029 1030 7437994 . . O O

1 1031 1033 7437994 An DT B-NP O
2 1034 1041 7437994 attempt NN I-NP O
3 1042 1044 7437994 is VBZ B-VP O
4 1045 1049 7437994 made VBN I-VP O
5 1050 1052 7437994 to TO I-VP O
6 1053 1057 7437994 draw VB I-VP O
7 1058 1067 7437994 practical JJ B-NP O
8 1068 1079 7437994 conclusions NNS I-NP O
9 1080 1084 7437994 from IN B-PP O
10 1085 1088 7437994 the DT B-NP O
11 1089 1100 7437994 preliminary JJ I-NP O
12 1101 1109 7437994 findings NNS I-NP O
13 1109 1110 7437994 . . O O

1 0 0 6203632 -DOCSTART- -X- -X- O

1 0 11 6203632 Development NN B-NP O
2 12 14 6203632 of IN B-PP O
3 15 28 6203632 isoproterenol NN B-NP D007545
4 28 29 6203632 - HYPH B-NP O
5 29 36 6203632 induced VBN I-NP O
6 37 44 6203632 cardiac JJ I-NP D006332
7 45 56 6203632 hypertrophy NN I-NP D006332
8 56 57 6203632 . . O O
9 58 61 6203632 The DT B-NP O
10 62 73 6203632 development NN I-NP O
11 74 76 6203632 of IN B-PP O
12 77 84 6203632 cardiac JJ B-NP D006332
13 85 96 6203632 hypertrophy NN I-NP D006332
14 97 100 6203632 was VBD B-VP O
15 101 108 6203632 studied VBN I-VP O
16 109 111 6203632 in IN B-PP O
17 112 117 6203632 adult JJ B-NP O
18 118 124 6203632 female JJ I-NP O
19 125 131 6203632 Wistar NNP I-NP O
20 132 136 6203632 rats NNS I-NP O
21 137 146 6203632 following VBG B-PP O
22 147 152 6203632 daily JJ B-NP O
23 153 165 6203632 subcutaneous JJ I-NP O
24 166 176 6203632 injections NNS I-NP O
25 177 179 6203632 of IN B-PP O
26 180 193 6203632 isoproterenol NN B-NP D007545
27 194 195 6203632 ( ( O O
28 195 198 6203632 ISO NN B-NP D007545
29 198 199 6203632 ) ) O O
30 200 201 6203632 ( ( O O
31 201 204 6203632 0.3 CD B-NP O
32 205 207 6203632 mg NN I-NP O
33 207 208 6203632 / SYM B-NP O
34 208 210 6203632 kg NN I-NP O
35 211 215 6203632 body NN I-NP O
36 216 222 6203632 weight NN I-NP O
37 222 223 6203632 ) ) O O
38 223 224 6203632 . . O O

1 225 226 6203632 A DT B-NP O
2 227 231 6203632 time NN I-NP O
3 232 238 6203632 course NN I-NP O
4 239 242 6203632 was VBD B-VP O
5 243 254 6203632 established VBN I-VP O
6 255 258 6203632 for IN B-PP O
7 259 262 6203632 the DT B-NP O
8 263 269 6203632 change NN I-NP O
9 270 272 6203632 in IN B-PP O
10 273 279 6203632 tissue NN B-NP O
11 280 284 6203632 mass NN I-NP O
12 284 285 6203632 , , O O
13 286 289 6203632 RNA NN B-NP O
14 290 293 6203632 and CC I-NP O
15 294 297 6203632 DNA NN I-NP O
16 298 305 6203632 content NN I-NP O
17 305 306 6203632 , , O O
18 307 309 6203632 as RB B-CONJP O
19 310 314 6203632 well RB I-CONJP O
20 315 317 6203632 as IN I-CONJP O
21 318 332 6203632 hydroxyproline NN B-NP D006909
22 333 340 6203632 content NN I-NP O
23 340 341 6203632 . . O O

1 342 347 6203632 Heart NN B-NP O
2 348 354 6203632 weight NN I-NP O
3 355 364 6203632 increased VBD B-VP O
4 365 368 6203632 44% CD B-NP O
5 369 374 6203632 after IN B-PP O
6 375 376 6203632 8 CD B-NP O
7 377 381 6203632 days NNS I-NP O
8 382 384 6203632 of IN B-PP O
9 385 394 6203632 treatment NN B-NP O
10 395 399 6203632 with IN B-PP O
11 400 401 6203632 a DT B-NP O
12 402 406 6203632 half JJ I-NP O
13 407 411 6203632 time NN I-NP O
14 412 414 6203632 of IN B-PP O
15 415 418 6203632 3.4 CD B-NP O
16 419 423 6203632 days NNS I-NP O
17 423 424 6203632 . . O O

1 425 436 6203632 Ventricular JJ B-NP O
2 437 440 6203632 RNA NN I-NP O
3 441 448 6203632 content NN I-NP O
4 449 452 6203632 was VBD B-VP O
5 453 461 6203632 elevated VBN I-VP O
6 462 465 6203632 26% CD B-NP O
7 466 471 6203632 after IN B-SBAR O
8 472 474 6203632 24 CD B-NP O
9 475 476 6203632 h NN I-NP O
10 477 479 6203632 of IN B-PP O
11 480 481 6203632 a DT B-NP O
12 482 488 6203632 single JJ I-NP O
13 489 498 6203632 injection NN I-NP O
14 499 502 6203632 and CC O O
15 503 510 6203632 reached VBD B-VP O
16 511 512 6203632 a DT B-NP O
17 513 520 6203632 maximal JJ I-NP O
18 521 526 6203632 level NN I-NP O
19 527 536 6203632 following VBG B-PP O
20 537 538 6203632 8 CD B-NP O
21 539 543 6203632 days NNS I-NP O
22 544 546 6203632 of IN B-PP O
23 547 554 6203632 therapy NN B-NP O
24 554 555 6203632 . . O O

1 556 559 6203632 The DT B-NP O
2 560 564 6203632 half JJ I-NP O
3 565 569 6203632 time NN I-NP O
4 570 573 6203632 for IN B-PP O
5 574 577 6203632 RNA NN B-NP O
6 578 590 6203632 accumulation NN I-NP O
7 591 594 6203632 was VBD B-VP O
8 595 598 6203632 2.0 CD B-NP O
9 599 603 6203632 days NNS I-NP O
10 603 604 6203632 . . O O

1 605 608 6203632 The DT B-NP O
2 609 614 6203632 total JJ I-NP O
3 615 622 6203632 content NN I-NP O
4 623 625 6203632 of IN B-PP O
5 626 640 6203632 hydroxyproline NN B-NP D006909
6 641 649 6203632 remained VBD B-VP O
7 650 656 6203632 stable JJ B-ADJP O
8 657 663 6203632 during IN B-PP O
9 664 667 6203632 the DT B-NP O
10 668 673 6203632 first JJ I-NP O
11 674 675 6203632 2 CD I-NP O
12 676 680 6203632 days NNS I-NP O
13 681 683 6203632 of IN B-PP O
14 684 693 6203632 treatment NN B-NP O
15 694 697 6203632 but CC O O
16 698 707 6203632 increased VBD B-VP O
17 708 711 6203632 46% CD B-NP O
18 712 717 6203632 after IN B-PP O
19 718 719 6203632 4 CD B-NP O
20 720 724 6203632 days NNS I-NP O
21 725 727 6203632 of IN B-PP O
22 728 735 6203632 therapy NN B-NP O
23 735 736 6203632 . . O O

1 737 748 6203632 Ventricular JJ B-NP O
2 749 752 6203632 DNA NN I-NP O
3 753 760 6203632 content NN I-NP O
4 761 764 6203632 was VBD B-VP O
5 765 774 6203632 unchanged JJ B-ADJP O
6 775 781 6203632 during IN B-PP O
7 782 785 6203632 the DT B-NP O
8 786 791 6203632 early JJ I-NP O
9 792 797 6203632 stage NN I-NP O
10 798 799 6203632 ( ( O O
11 799 800 6203632 1 CD B-NP O
12 800 801 6203632 - HYPH I-NP O
13 801 802 6203632 4 CD I-NP O
14 803 807 6203632 days NNS I-NP O
15 807 808 6203632 ) ) O O
16 809 811 6203632 of IN B-PP O
17 812 824 6203632 hypertrophic JJ B-NP D006984
18 825 831 6203632 growth NN I-NP O
19 832 835 6203632 but CC O O
20 836 845 6203632 increased VBD B-VP O
21 846 848 6203632 to TO B-PP O
22 849 850 6203632 a DT B-NP O
23 851 854 6203632 new JJ I-NP O
24 855 861 6203632 steady JJ I-NP O
25 861 862 6203632 - HYPH I-NP O
26 862 867 6203632 state NN I-NP O
27 868 873 6203632 level NN I-NP O
28 874 877 6203632 19% CD I-NP O
29 878 883 6203632 above IN B-PP O
30 884 887 6203632 the DT B-NP O
31 888 896 6203632 controls NNS I-NP O
32 897 902 6203632 after IN B-PP O
33 903 904 6203632 8 CD B-NP O
34 905 909 6203632 days NNS I-NP O
35 910 912 6203632 of IN B-PP O
36 913 922 6203632 treatment NN B-NP O
37 922 923 6203632 . . O O

1 924 940 6203632 Intraventricular JJ B-NP O
2 941 950 6203632 pressures NNS I-NP O
3 951 954 6203632 and CC O O
4 955 963 6203632 coronary JJ B-NP O
5 964 968 6203632 flow NN I-NP O
6 969 977 6203632 measures NNS I-NP O
7 978 982 6203632 were VBD B-VP O
8 983 990 6203632 similar JJ B-ADJP O
9 991 994 6203632 for IN B-PP O
10 995 1002 6203632 control NN B-NP O
11 1003 1006 6203632 and CC O O
12 1007 1019 6203632 experimental JJ B-NP O
13 1020 1027 6203632 animals NNS I-NP O
14 1028 1037 6203632 following VBG B-PP O
15 1038 1039 6203632 4 CD B-NP O
16 1040 1044 6203632 days NNS I-NP O
17 1045 1047 6203632 of IN B-PP O
18 1048 1057 6203632 developed VBN B-NP O
19 1058 1069 6203632 hypertrophy NN I-NP D006984
20 1069 1070 6203632 . . O O

1 1071 1078 6203632 However RB B-ADVP O
2 1078 1079 6203632 , , O O
3 1080 1082 6203632 dP NN B-NP O
4 1082 1083 6203632 / SYM I-NP O
5 1083 1085 6203632 dt NN I-NP O
6 1086 1088 6203632 in IN B-PP O
7 1089 1092 6203632 the DT B-NP O
8 1093 1096 6203632 ISO NN I-NP D007545
9 1096 1097 6203632 - HYPH B-NP O
10 1097 1104 6203632 treated VBN I-NP O
11 1105 1111 6203632 hearts NNS I-NP O
12 1112 1115 6203632 was VBD B-VP O
13 1116 1124 6203632 slightly RB B-ADVP O
14 1125 1128 6203632 but CC O O
15 1129 1142 6203632 significantly RB B-ADVP O
16 1143 1144 6203632 ( ( O O
17 1144 1145 6203632 P NN B-NP O
18 1146 1150 6203632 less JJR B-ADJP O
19 1151 1155 6203632 than IN B-PP O
20 1156 1160 6203632 0.05 CD B-NP O
21 1160 1161 6203632 ) ) O O
22 1162 1170 6203632 elevated VBN B-VP O
23 1170 1171 6203632 . . O O

1 1172 1177 6203632 These DT B-NP O
2 1178 1182 6203632 data NNS I-NP O
3 1183 1191 6203632 indicate VBP B-VP O
4 1192 1196 6203632 that IN B-SBAR O
5 1197 1200 6203632 the DT B-NP O
6 1201 1209 6203632 adaptive JJ I-NP O
7 1210 1218 6203632 response NN I-NP O
8 1219 1221 6203632 to TO B-PP O
9 1222 1225 6203632 ISO NN B-NP D007545
10 1226 1231 6203632 shows VBZ B-VP O
11 1232 1234 6203632 an DT B-NP O
12 1235 1240 6203632 early JJ I-NP O
13 1241 1253 6203632 hypertrophic JJ I-NP D006984
14 1254 1259 6203632 phase NN I-NP O
15 1260 1261 6203632 ( ( O O
16 1261 1262 6203632 1 CD B-NP O
17 1262 1263 6203632 - HYPH I-NP O
18 1263 1264 6203632 4 CD I-NP O
19 1265 1269 6203632 days NNS I-NP O
20 1269 1270 6203632 ) ) O O
21 1271 1284 6203632 characterized VBN B-VP O
22 1285 1287 6203632 by IN B-PP O
23 1288 1289 6203632 a DT B-NP O
24 1290 1301 6203632 substantial JJ I-NP O
25 1302 1310 6203632 increase NN I-NP O
26 1311 1313 6203632 in IN B-PP O
27 1314 1317 6203632 RNA NN B-NP O
28 1318 1325 6203632 content NN I-NP O
29 1326 1329 6203632 and CC O O
30 1330 1337 6203632 cardiac JJ B-NP O
31 1338 1342 6203632 mass NN I-NP O
32 1343 1345 6203632 in IN B-PP O
33 1346 1349 6203632 the DT B-NP O
34 1350 1357 6203632 absence NN I-NP O
35 1358 1360 6203632 of IN B-PP O
36 1361 1368 6203632 changes NNS B-NP O
37 1369 1371 6203632 in IN B-PP O
38 1372 1375 6203632 DNA NN B-NP O
39 1375 1376 6203632 . . O O

1 1377 1384 6203632 However RB B-ADVP O
2 1384 1385 6203632 , , O O
3 1386 1395 6203632 prolonged VBN B-NP O
4 1396 1407 6203632 stimulation NN I-NP O
5 1408 1409 6203632 ( ( O O
6 1409 1410 6203632 8 CD B-NP O
7 1410 1411 6203632 - HYPH I-NP O
8 1411 1413 6203632 12 CD I-NP O
9 1414 1418 6203632 days NNS I-NP O
10 1418 1419 6203632 ) ) O O
11 1420 1427 6203632 appears VBZ B-VP O
12 1428 1430 6203632 to TO I-VP O
13 1431 1440 6203632 represent VB I-VP O
14 1441 1442 6203632 a DT B-NP O
15 1443 1450 6203632 complex JJ I-NP O
16 1451 1462 6203632 integration NN I-NP O
17 1463 1465 6203632 of IN B-PP O
18 1466 1470 6203632 both CC B-NP O
19 1471 1479 6203632 cellular JJ I-NP O
20 1480 1491 6203632 hypertrophy NN I-NP D006984
21 1492 1495 6203632 and CC I-NP O
22 1496 1507 6203632 hyperplasia NN I-NP D006965
23 1508 1514 6203632 within IN B-PP O
24 1515 1518 6203632 the DT B-NP O
25 1519 1524 6203632 heart NN I-NP O
26 1524 1525 6203632 . . O O

1 0 0 8888541 -DOCSTART- -X- -X- O

1 0 9 8888541 Serotonin NN B-NP D020230
2 10 18 8888541 syndrome NN I-NP D020230
3 19 23 8888541 from IN B-PP O
4 24 35 8888541 venlafaxine NN B-NP C047426
5 35 36 8888541 - HYPH B-NP O
6 36 51 8888541 tranylcypromine NN I-NP D014191
7 52 63 8888541 interaction NN I-NP O
8 63 64 8888541 . . O O
9 65 74 8888541 Excessive JJ B-NP O
10 75 86 8888541 stimulation NN I-NP O
11 87 89 8888541 of IN B-PP O
12 90 99 8888541 serotonin NN B-NP D012701
13 100 105 8888541 5HT1A NN I-NP O
14 106 115 8888541 receptors NNS I-NP O
15 116 122 8888541 causes VBZ B-VP O
16 123 124 8888541 a DT B-NP O
17 125 133 8888541 syndrome NN I-NP O
18 134 136 8888541 of IN B-PP O
19 137 146 8888541 serotonin NN B-NP D012701
20 147 153 8888541 excess NN I-NP O
21 154 158 8888541 that WDT B-NP O
22 159 167 8888541 consists VBZ B-VP O
23 168 170 8888541 of IN B-PP O
24 171 180 8888541 shivering NN B-NP O
25 180 181 8888541 , , O O
26 182 188 8888541 muscle NN B-NP D009127
27 189 197 8888541 rigidity NN I-NP D009127
28 197 198 8888541 , , O O
29 199 209 8888541 salivation NN B-NP D012798
30 209 210 8888541 , , O O
31 211 220 8888541 confusion NN B-NP D003221
32 220 221 8888541 , , O O
33 222 231 8888541 agitation NN B-NP D011595
34 232 235 8888541 and CC I-NP O
35 236 248 8888541 hyperthermia NN I-NP D005334
36 248 249 8888541 . . O O

1 250 253 8888541 The DT B-NP O
2 254 258 8888541 most RBS I-NP O
3 259 265 8888541 common JJ I-NP O
4 266 271 8888541 cause NN I-NP O
5 272 274 8888541 of IN B-PP O
6 275 279 8888541 this DT B-NP O
7 280 288 8888541 syndrome NN I-NP O
8 289 291 8888541 is VBZ B-VP O
9 292 294 8888541 an DT B-NP O
10 295 306 8888541 interaction NN I-NP O
11 307 314 8888541 between IN B-PP O
12 315 316 8888541 a DT B-NP O
13 317 326 8888541 monoamine NN I-NP O
14 327 334 8888541 oxidase NN I-NP O
15 335 344 8888541 inhibitor NN I-NP O
16 345 346 8888541 ( ( O O
17 346 350 8888541 MAOI NN B-NP O
18 350 351 8888541 ) ) O O
19 352 355 8888541 and CC O O
20 356 357 8888541 a DT B-NP O
21 358 366 8888541 specific JJ I-NP O
22 367 376 8888541 serotonin NN I-NP D012701
23 377 385 8888541 reuptake NN I-NP O
24 386 395 8888541 inhibitor NN I-NP O
25 395 396 8888541 . . O O

1 397 408 8888541 Venlafaxine NN B-NP C047426
2 409 411 8888541 is VBZ B-VP O
3 412 413 8888541 a DT B-NP O
4 414 417 8888541 new JJ I-NP O
5 418 432 8888541 antidepressant NN I-NP O
6 433 438 8888541 agent NN I-NP O
7 439 443 8888541 that WDT B-NP O
8 444 452 8888541 inhibits VBZ B-VP O
9 453 456 8888541 the DT B-NP O
10 457 465 8888541 reuptake NN I-NP O
11 466 468 8888541 of IN B-PP O
12 469 478 8888541 serotonin NN B-NP D012701
13 479 482 8888541 and CC I-NP O
14 483 497 8888541 norepinephrine NN I-NP D009638
15 497 498 8888541 . . O O

1 499 501 8888541 We PRP B-NP O
2 502 508 8888541 report VBP B-VP O
3 509 510 8888541 a DT B-NP O
4 511 522 8888541 venlafaxine NN I-NP C047426
5 522 523 8888541 - HYPH I-NP O
6 523 527 8888541 MAOI NN I-NP O
7 528 539 8888541 interaction NN I-NP O
8 540 544 8888541 that WDT B-NP O
9 545 553 8888541 resulted VBD B-VP O
10 554 556 8888541 in IN B-PP O
11 557 560 8888541 the DT B-NP O
12 561 570 8888541 serotonin NN I-NP D020230
13 571 579 8888541 syndrome NN I-NP D020230
14 580 582 8888541 in IN B-PP O
15 583 584 8888541 a DT B-NP O
16 585 587 8888541 23 CD I-NP O
17 587 588 8888541 - HYPH I-NP O
18 588 589 8888541 y NN I-NP O
19 589 590 8888541 - HYPH I-NP O
20 590 593 8888541 old JJ I-NP O
21 594 598 8888541 male NN I-NP O
22 599 602 8888541 who WP B-NP O
23 603 606 8888541 was VBD B-VP O
24 607 613 8888541 taking VBG I-VP O
25 614 629 8888541 tranylcypromine NN B-NP D014191
26 630 633 8888541 for IN B-PP O
27 634 644 8888541 depression NN B-NP D003866
28 644 645 8888541 . . O O

1 646 648 8888541 He PRP B-NP O
2 649 652 8888541 had VBD B-VP O
3 653 657 8888541 been VBN I-VP O
4 658 662 8888541 well RB B-ADVP O
5 663 668 8888541 until IN B-SBAR O
6 669 672 8888541 the DT B-NP O
7 673 680 8888541 morning NN I-NP O
8 681 683 8888541 of IN B-PP O
9 684 696 8888541 presentation NN B-NP O
10 697 701 8888541 when WRB B-ADVP O
11 702 704 8888541 he PRP B-NP O
12 705 709 8888541 took VBD B-VP O
13 710 711 8888541 1 CD B-NP O
14 711 712 8888541 / SYM B-NP O
15 712 713 8888541 2 CD I-NP O
16 714 717 8888541 tab NN I-NP O
17 718 720 8888541 of IN B-PP O
18 721 732 8888541 venlafaxine NN B-NP C047426
19 732 733 8888541 . . O O

1 734 740 8888541 Within IN B-PP O
2 741 742 8888541 2 CD B-NP O
3 743 744 8888541 h NN I-NP O
4 745 747 8888541 he PRP B-NP O
5 748 754 8888541 became VBD B-VP O
6 755 763 8888541 confused VBN B-ADJP O
7 764 768 8888541 with IN B-PP O
8 769 776 8888541 jerking VBG B-VP O
9 777 786 8888541 movements NNS B-NP O
10 787 789 8888541 of IN B-PP O
11 790 793 8888541 his PRP$ B-NP O
12 794 805 8888541 extremities NNS I-NP O
13 805 806 8888541 , , I-NP O
14 807 814 8888541 tremors NNS I-NP D014202
15 815 818 8888541 and CC I-NP O
16 819 827 8888541 rigidity NN I-NP D009127
17 827 828 8888541 . . O O

1 829 831 8888541 He PRP B-NP O
2 832 835 8888541 was VBD B-VP O
3 836 843 8888541 brought VBN I-VP O
4 844 852 8888541 directly RB B-ADVP O
5 853 855 8888541 to TO B-PP O
6 856 857 8888541 a DT B-NP O
7 858 866 8888541 hospital NN I-NP O
8 867 872 8888541 where WRB B-ADVP O
9 873 875 8888541 he PRP B-NP O
10 876 879 8888541 was VBD B-VP O
11 880 885 8888541 found VBN I-VP O
12 886 888 8888541 to TO I-VP O
13 889 891 8888541 be VB I-VP O
14 892 900 8888541 agitated VBN I-VP O
15 901 904 8888541 and CC I-VP O
16 905 913 8888541 confused VBN I-VP O
17 914 918 8888541 with IN B-PP O
18 919 928 8888541 shivering VBG B-VP O
19 928 929 8888541 , , O O
20 930 939 8888541 myoclonic JJ B-NP D009207
21 940 945 8888541 jerks NNS I-NP D009207
22 945 946 8888541 , , O O
23 947 955 8888541 rigidity NN B-NP D009127
24 955 956 8888541 , , O O
25 957 967 8888541 salivation NN B-NP D012798
26 968 971 8888541 and CC I-NP O
27 972 983 8888541 diaphoresis NN I-NP O
28 983 984 8888541 . . O O

1 985 988 8888541 His PRP$ B-NP O
2 989 995 8888541 pupils NNS I-NP O
3 996 1000 8888541 were VBD B-VP O
4 1001 1002 8888541 7 CD B-NP O
5 1003 1005 8888541 mm NN I-NP O
6 1006 1009 8888541 and CC O O
7 1010 1020 8888541 sluggishly RB B-ADJP O
8 1021 1029 8888541 reactive JJ I-ADJP O
9 1030 1032 8888541 to TO B-PP O
10 1033 1038 8888541 light NN B-NP O
11 1038 1039 8888541 . . O O

1 1040 1045 8888541 Vital JJ B-NP O
2 1046 1051 8888541 signs NNS I-NP O
3 1052 1056 8888541 were VBD B-VP O
4 1056 1057 8888541 : : O O
5 1058 1063 8888541 blood NN B-NP O
6 1064 1072 8888541 pressure NN I-NP O
7 1073 1076 8888541 120 CD B-NP O
8 1076 1077 8888541 / SYM I-NP O
9 1077 1079 8888541 67 CD I-NP O
10 1080 1082 8888541 mm NN I-NP O
11 1083 1085 8888541 Hg NN I-NP O
12 1085 1086 8888541 , , O O
13 1087 1092 8888541 heart NN B-NP O
14 1093 1097 8888541 rate NN I-NP O
15 1098 1101 8888541 127 CD I-NP O
16 1101 1102 8888541 / SYM I-NP O
17 1102 1105 8888541 min NN I-NP O
18 1105 1106 8888541 , , O O
19 1107 1118 8888541 respiratory JJ B-NP O
20 1119 1123 8888541 rate NN I-NP O
21 1124 1126 8888541 28 CD I-NP O
22 1126 1127 8888541 / SYM I-NP O
23 1127 1130 8888541 min NN I-NP O
24 1130 1131 8888541 , , O O
25 1132 1135 8888541 and CC O O
26 1136 1147 8888541 temperature NN B-NP O
27 1148 1150 8888541 97 CD I-NP O
28 1151 1152 8888541 F NN I-NP O
29 1152 1153 8888541 . . O O

1 1154 1159 8888541 After IN B-PP O
2 1160 1163 8888541 180 CD B-NP O
3 1164 1166 8888541 mg NN I-NP O
4 1167 1169 8888541 of IN B-PP O
5 1170 1178 8888541 diazepam NN B-NP D003975
6 1179 1182 8888541 i.v NN I-NP O
7 1182 1183 8888541 . . O O

1 1184 1186 8888541 he PRP B-NP O
2 1187 1195 8888541 remained VBD B-VP O
3 1196 1205 8888541 tremulous JJ B-ADJP O
4 1206 1210 8888541 with IN B-PP O
5 1211 1217 8888541 muscle NN B-NP D009127
6 1218 1226 8888541 rigidity NN I-NP D009127
7 1227 1230 8888541 and CC O O
8 1231 1239 8888541 clenched JJ B-NP O
9 1240 1244 8888541 jaws NNS I-NP O
10 1244 1245 8888541 . . O O

1 1246 1248 8888541 He PRP B-NP O
2 1249 1252 8888541 was VBD B-VP O
3 1253 1262 8888541 intubated VBN I-VP O
4 1263 1266 8888541 for IN B-PP O
5 1267 1273 8888541 airway NN B-NP O
6 1274 1284 8888541 protection NN I-NP O
7 1285 1288 8888541 and CC O O
8 1289 1296 8888541 because RB B-PP O
9 1297 1299 8888541 of IN I-PP O
10 1300 1315 8888541 hypoventilation NN B-NP D007040
11 1315 1316 8888541 , , O O
12 1317 1320 8888541 and CC O O
13 1321 1324 8888541 was VBD B-VP O
14 1325 1334 8888541 paralyzed VBN I-VP D010243
15 1335 1337 8888541 to TO I-VP O
16 1338 1345 8888541 control VB I-VP O
17 1346 1352 8888541 muscle NN B-NP D009127
18 1353 1361 8888541 rigidity NN I-NP D009127
19 1361 1362 8888541 . . O O

1 1363 1366 8888541 His PRP$ B-NP O
2 1367 1377 8888541 subsequent JJ I-NP O
3 1378 1384 8888541 course NN I-NP O
4 1385 1388 8888541 was VBD B-VP O
5 1389 1399 8888541 remarkable JJ B-ADJP O
6 1400 1403 8888541 for IN B-PP O
7 1404 1407 8888541 non AFX B-NP O
8 1407 1408 8888541 - HYPH I-NP O
9 1408 1414 8888541 immune JJ I-NP O
10 1415 1431 8888541 thrombocytopenia NN I-NP D013921
11 1432 1437 8888541 which WDT B-NP O
12 1438 1446 8888541 resolved VBD B-VP O
13 1446 1447 8888541 . . O O

1 1448 1451 8888541 The DT B-NP O
2 1452 1461 8888541 patient's NNS I-NP O
3 1462 1469 8888541 maximal JJ I-NP O
4 1470 1481 8888541 temperature NN I-NP O
5 1482 1485 8888541 was VBD B-VP O
6 1486 1491 8888541 101.2 CD B-NP O
7 1492 1493 8888541 F NN I-NP O
8 1494 1497 8888541 and CC O O
9 1498 1501 8888541 his PRP$ B-NP O
10 1502 1505 8888541 CPK NN I-NP O
11 1506 1514 8888541 remained VBD B-VP O
12 1515 1516 8888541 < SYM B-ADJP O
13 1517 1520 8888541 500 CD B-NP O
14 1521 1526 8888541 units NNS I-NP O
15 1526 1527 8888541 / SYM B-NP O
16 1527 1528 8888541 L NN I-NP O
17 1529 1533 8888541 with IN B-PP O
18 1534 1536 8888541 no DT B-NP O
19 1537 1542 8888541 other JJ I-NP O
20 1543 1551 8888541 evidence NN I-NP O
21 1552 1554 8888541 of IN B-PP O
22 1555 1569 8888541 rhabdomyolysis NN B-NP D012206
23 1569 1570 8888541 . . O O

1 1571 1574 8888541 His PRP$ B-NP O
2 1575 1581 8888541 mental JJ I-NP O
3 1582 1588 8888541 status NN I-NP O
4 1589 1599 8888541 normalized VBN B-VP O
5 1600 1603 8888541 and CC O O
6 1604 1606 8888541 he PRP B-NP O
7 1607 1610 8888541 was VBD B-VP O
8 1611 1622 8888541 transferred VBN I-VP O
9 1623 1625 8888541 to TO B-PP O
10 1626 1627 8888541 a DT B-NP O
11 1628 1638 8888541 psychiatry NN I-NP O
12 1639 1643 8888541 ward NN I-NP O
13 1643 1644 8888541 . . O O

1 1645 1649 8888541 This DT B-NP O
2 1650 1657 8888541 patient NN I-NP O
3 1658 1666 8888541 survived VBD B-VP O
4 1667 1674 8888541 without IN B-PP O
5 1675 1683 8888541 sequelae NNS B-NP O
6 1684 1687 8888541 due JJ B-ADJP O
7 1688 1690 8888541 to TO B-PP O
8 1691 1694 8888541 the DT B-NP O
9 1695 1705 8888541 aggressive JJ I-NP O
10 1706 1714 8888541 sedation NN I-NP O
11 1715 1718 8888541 and CC O O
12 1719 1732 8888541 neuromuscular JJ B-NP O
13 1733 1742 8888541 paralysis NN I-NP D010243
14 1742 1743 8888541 . . O O

1 0 0 12911170 -DOCSTART- -X- -X- O

1 0 13 12911170 Ciprofloxacin NN B-NP D002939
2 13 14 12911170 - HYPH O O
3 14 21 12911170 induced VBN B-NP O
4 22 27 12911170 acute JJ I-NP O
5 28 40 12911170 interstitial JJ I-NP D009395
6 41 50 12911170 nephritis NN I-NP D009395
7 51 54 12911170 and CC O O
8 55 65 12911170 autoimmune JJ B-NP D000744
9 66 75 12911170 hemolytic JJ I-NP D000744
10 76 82 12911170 anemia NN I-NP D000744
11 82 83 12911170 . . I-NP O
12 84 97 12911170 Ciprofloxacin NN I-NP D002939
13 98 101 12911170 has VBZ B-VP O
14 102 106 12911170 been VBN I-VP O
15 107 117 12911170 associated VBN I-VP O
16 118 122 12911170 with IN B-PP O
17 123 130 12911170 several JJ B-NP O
18 131 135 12911170 side NN I-NP O
19 136 143 12911170 effects NNS I-NP O
20 144 153 12911170 including VBG B-PP O
21 154 166 12911170 interstitial JJ B-NP D009395
22 167 176 12911170 nephritis NN I-NP D009395
23 177 180 12911170 and CC O O
24 181 190 12911170 hemolytic JJ B-NP D000743
25 191 197 12911170 anemia NN I-NP D000743
26 197 198 12911170 . . O O

1 199 202 12911170 The DT B-NP O
2 203 214 12911170 combination NN I-NP O
3 215 217 12911170 of IN B-PP O
4 218 222 12911170 both DT B-NP O
5 223 227 12911170 side JJ I-NP O
6 228 235 12911170 effects NNS I-NP O
7 236 238 12911170 is VBZ B-VP O
8 239 248 12911170 extremely RB B-ADJP O
9 249 253 12911170 rare JJ I-ADJP O
10 253 254 12911170 . . O O

1 255 257 12911170 In IN B-PP O
2 258 262 12911170 this DT B-NP O
3 263 269 12911170 report NN I-NP O
4 269 270 12911170 , , O O
5 271 273 12911170 we PRP B-NP O
6 274 282 12911170 describe VBP B-VP O
7 283 284 12911170 a DT B-NP O
8 285 289 12911170 case NN I-NP O
9 290 292 12911170 of IN B-PP O
10 293 306 12911170 ciprofloxacin NN B-NP D002939
11 306 307 12911170 - HYPH B-NP O
12 307 314 12911170 induced VBN I-NP O
13 315 327 12911170 interstitial JJ I-NP D009395
14 328 337 12911170 nephritis NN I-NP D009395
15 338 341 12911170 and CC O O
16 342 352 12911170 autoimmune JJ B-NP D000744
17 353 362 12911170 hemolytic JJ I-NP D000744
18 363 369 12911170 anemia NN I-NP D000744
19 369 370 12911170 . . O O

1 371 380 12911170 Hemolytic JJ B-NP D000743
2 381 387 12911170 anemia NN I-NP D000743
3 388 396 12911170 improved VBD B-VP O
4 397 402 12911170 after IN B-PP O
5 403 411 12911170 stopping VBG B-VP O
6 412 415 12911170 the DT B-NP O
7 416 420 12911170 drug NN I-NP O
8 421 424 12911170 and CC I-NP O
9 425 435 12911170 initiation NN I-NP O
10 436 438 12911170 of IN B-PP O
11 439 446 12911170 steroid NN B-NP D013256
12 447 454 12911170 therapy NN I-NP O
13 454 455 12911170 . . O O

1 456 469 12911170 Unfortunately RB B-ADVP O
2 469 470 12911170 , , O O
3 471 476 12911170 acute JJ B-NP O
4 477 489 12911170 interstitial JJ I-NP D009395
5 490 499 12911170 nephritis NN I-NP D009395
6 500 503 12911170 was VBD B-VP O
7 504 516 12911170 irreversible JJ B-ADJP O
8 517 520 12911170 and CC O O
9 521 524 12911170 the DT B-NP O
10 525 532 12911170 patient NN I-NP O
11 533 542 12911170 developed VBD B-VP O
12 543 546 12911170 end NN B-NP D007676
13 546 547 12911170 - HYPH I-NP D007676
14 547 552 12911170 stage NN I-NP D007676
15 553 558 12911170 renal JJ I-NP D007676
16 559 566 12911170 disease NN I-NP D007676
17 566 567 12911170 . . O O

1 0 0 18239197 -DOCSTART- -X- -X- O

1 0 9 18239197 Increased VBN B-NP O
2 10 16 18239197 mental JJ I-NP D003072
3 17 24 18239197 slowing NN I-NP D003072
4 25 35 18239197 associated VBN B-VP O
5 36 40 18239197 with IN B-PP O
6 41 44 18239197 the DT B-NP O
7 45 49 18239197 APOE NN I-NP O
8 50 58 18239197 epsilon4 NN I-NP O
9 59 65 18239197 allele NN I-NP O
10 66 71 18239197 after IN B-PP O
11 72 87 18239197 trihexyphenidyl NN B-NP D014282
12 88 92 18239197 oral JJ I-NP O
13 93 108 18239197 anticholinergic JJ I-NP O
14 109 118 18239197 challenge NN I-NP O
15 119 121 18239197 in IN B-PP O
16 122 129 18239197 healthy JJ B-NP O
17 130 137 18239197 elderly JJ I-NP O
18 137 138 18239197 . . I-NP O
19 139 149 18239197 OBJECTIVES NNS I-NP O
20 149 150 18239197 : : O O
21 151 154 18239197 The DT B-NP O
22 155 165 18239197 objectives NNS I-NP O
23 166 168 18239197 of IN B-PP O
24 169 173 18239197 this DT B-NP O
25 174 179 18239197 study NN I-NP O
26 180 184 18239197 were VBD B-VP O
27 185 187 18239197 to TO I-VP O
28 188 195 18239197 examine VB I-VP O
29 196 199 18239197 the DT B-NP O
30 200 212 18239197 relationship NN I-NP O
31 213 220 18239197 between IN B-PP O
32 221 225 18239197 APOE NN B-NP O
33 226 234 18239197 epsilon4 NN I-NP O
34 235 238 18239197 and CC O O
35 239 249 18239197 subjective JJ B-NP O
36 250 257 18239197 effects NNS I-NP O
37 258 260 18239197 of IN B-PP O
38 261 276 18239197 trihexyphenidyl NN B-NP D014282
39 277 279 18239197 on IN B-PP O
40 280 288 18239197 measures NNS B-NP O
41 289 299 18239197 reflecting VBG B-VP O
42 300 308 18239197 sedation NN B-NP O
43 309 312 18239197 and CC I-NP O
44 313 322 18239197 confusion NN I-NP D003221
45 323 326 18239197 and CC O O
46 327 329 18239197 to TO B-VP O
47 330 341 18239197 investigate VB I-VP O
48 342 345 18239197 the DT B-NP O
49 346 358 18239197 relationship NN I-NP O
50 359 366 18239197 between IN B-PP O
51 367 382 18239197 trihexyphenidyl NN B-NP D014282
52 382 383 18239197 - HYPH O O
53 383 390 18239197 induced VBN B-NP O
54 391 401 18239197 subjective JJ I-NP O
55 402 409 18239197 effects NNS I-NP O
56 410 413 18239197 and CC O O
57 414 423 18239197 objective JJ B-NP O
58 424 430 18239197 memory NN I-NP O
59 431 442 18239197 performance NN I-NP O
60 442 443 18239197 . . O O

1 444 451 18239197 METHODS NNS B-NP O
2 451 452 18239197 : : O O
3 453 457 18239197 This DT B-NP O
4 458 463 18239197 study NN I-NP O
5 464 473 18239197 comprised VBD B-VP O
6 474 476 18239197 24 CD B-NP O
7 477 488 18239197 cognitively RB I-NP O
8 489 495 18239197 intact JJ I-NP O
9 495 496 18239197 , , I-NP O
10 497 503 18239197 health NN I-NP O
11 504 511 18239197 elderly JJ I-NP O
12 512 518 18239197 adults NNS I-NP O
13 519 520 18239197 ( ( O O
14 520 522 18239197 12 CD B-NP O
15 523 527 18239197 APOE NN I-NP O
16 528 536 18239197 epsilon4 NN I-NP O
17 537 545 18239197 carriers NNS I-NP O
18 545 546 18239197 ) ) O O
19 547 549 18239197 at IN B-PP O
20 550 552 18239197 an DT B-NP O
21 553 563 18239197 outpatient NN I-NP O
22 564 573 18239197 geriatric JJ I-NP O
23 574 584 18239197 psychiatry NN I-NP O
24 585 593 18239197 research NN I-NP O
25 594 600 18239197 clinic NN I-NP O
26 600 601 18239197 . . O O

1 602 606 18239197 This DT B-NP O
2 607 610 18239197 was VBD B-VP O
3 611 612 18239197 a DT B-NP O
4 613 623 18239197 randomized VBN I-NP O
5 623 624 18239197 , , I-NP O
6 625 631 18239197 double JJ I-NP O
7 632 637 18239197 blind JJ I-NP O
8 637 638 18239197 , , I-NP O
9 639 646 18239197 placebo NN I-NP O
10 646 647 18239197 - HYPH I-NP O
11 647 657 18239197 controlled VBN B-VP O
12 657 658 18239197 , , O O
13 659 664 18239197 three CD B-NP O
14 664 665 18239197 - HYPH I-NP O
15 665 668 18239197 way NN I-NP O
16 668 669 18239197 , , O O
17 670 679 18239197 crossover VB B-VP O
18 680 692 18239197 experimental JJ B-NP O
19 693 699 18239197 design NN I-NP O
20 699 700 18239197 . . O O

1 701 704 18239197 All DT B-NP O
2 705 717 18239197 participants NNS I-NP O
3 718 726 18239197 received VBD B-VP O
4 727 730 18239197 1.0 CD B-NP O
5 731 733 18239197 mg NN I-NP O
6 734 736 18239197 or CC O O
7 737 740 18239197 2.0 CD B-NP O
8 741 743 18239197 mg NN I-NP O
9 744 759 18239197 trihexyphenidyl NN I-NP D014282
10 760 762 18239197 or CC I-NP O
11 763 770 18239197 placebo NN I-NP O
12 771 783 18239197 administered VBN B-VP O
13 784 786 18239197 in IN B-PP O
14 787 802 18239197 counterbalanced JJ B-NP O
15 803 812 18239197 sequences NNS I-NP O
16 813 817 18239197 over IN B-PP O
17 818 819 18239197 a DT B-NP O
18 820 826 18239197 period NN I-NP O
19 827 829 18239197 of IN B-PP O
20 830 835 18239197 three CD B-NP O
21 836 847 18239197 consecutive JJ I-NP O
22 848 853 18239197 weeks NNS I-NP O
23 853 854 18239197 . . O O

1 855 859 18239197 Bond NNP B-NP O
2 860 863 18239197 and CC I-NP O
3 864 871 18239197 Lader's NNP I-NP O
4 872 878 18239197 visual JJ I-NP O
5 879 885 18239197 analog NN I-NP O
6 886 892 18239197 scales NNS I-NP O
7 893 896 18239197 and CC O O
8 897 906 18239197 alternate JJ B-NP O
9 907 915 18239197 versions NNS I-NP O
10 916 918 18239197 of IN B-PP O
11 919 922 18239197 the DT B-NP O
12 923 930 18239197 Buschke NNP I-NP O
13 931 940 18239197 Selective NNP I-NP O
14 941 950 18239197 Reminding NNP I-NP O
15 951 955 18239197 Test NNP I-NP O
16 956 960 18239197 were VBD B-VP O
17 961 973 18239197 administered VBN I-VP O
18 974 976 18239197 in IN B-PP O
19 977 978 18239197 a DT B-NP O
20 979 987 18239197 repeated VBN I-NP O
21 988 996 18239197 measures VBZ B-VP O
22 997 1003 18239197 design NN B-NP O
23 1004 1006 18239197 at IN B-PP O
24 1007 1015 18239197 baseline NN B-NP O
25 1015 1016 18239197 , , O O
26 1017 1018 18239197 1 CD B-NP O
27 1018 1019 18239197 , , I-NP O
28 1020 1023 18239197 2.5 CD I-NP O
29 1023 1024 18239197 , , O O
30 1025 1028 18239197 and CC O O
31 1029 1030 18239197 5 CD B-NP O
32 1031 1036 18239197 hours NNS I-NP O
33 1037 1045 18239197 postdrug JJ B-NP O
34 1046 1060 18239197 administration NN I-NP O
35 1060 1061 18239197 . . O O

1 1062 1069 18239197 RESULTS NNS B-NP O
2 1069 1070 18239197 : : O O
3 1071 1072 18239197 A DT B-NP O
4 1073 1076 18239197 2.0 CD I-NP O
5 1076 1077 18239197 - HYPH I-NP O
6 1077 1079 18239197 mg NN I-NP O
7 1080 1084 18239197 oral JJ I-NP O
8 1085 1089 18239197 dose NN I-NP O
9 1090 1092 18239197 of IN B-PP O
10 1093 1108 18239197 trihexyphenidyl NN B-NP D014282
11 1109 1117 18239197 resulted VBD B-VP O
12 1118 1120 18239197 in IN B-PP O
13 1121 1130 18239197 increased VBN B-NP O
14 1131 1141 18239197 subjective JJ I-NP O
15 1142 1149 18239197 ratings NNS I-NP O
16 1150 1152 18239197 of IN B-PP O
17 1153 1159 18239197 mental JJ B-NP D003072
18 1160 1168 18239197 slowness NN I-NP D003072
19 1169 1171 18239197 in IN B-PP O
20 1172 1180 18239197 carriers NNS B-NP O
21 1181 1183 18239197 of IN B-PP O
22 1184 1187 18239197 the DT B-NP O
23 1188 1192 18239197 APOE NN I-NP O
24 1193 1201 18239197 epsilon4 NN I-NP O
25 1202 1208 18239197 allele NN I-NP O
26 1209 1213 18239197 only RB B-ADVP O
27 1213 1214 18239197 . . O O

1 1215 1219 18239197 Drug NN B-NP O
2 1220 1227 18239197 effects NNS I-NP O
3 1228 1230 18239197 as IN B-SBAR O
4 1231 1241 18239197 determined VBN B-VP O
5 1242 1244 18239197 by IN B-PP O
6 1245 1255 18239197 difference NN B-NP O
7 1256 1262 18239197 scores NNS I-NP O
8 1263 1270 18239197 between IN B-PP O
9 1271 1274 18239197 2.0 CD B-NP O
10 1275 1277 18239197 mg NN I-NP O
11 1278 1293 18239197 trihexyphenidyl NN I-NP D014282
12 1294 1297 18239197 and CC I-NP O
13 1298 1305 18239197 placebo NN I-NP O
14 1306 1308 18239197 on IN B-PP O
15 1309 1316 18239197 ratings NNS B-NP O
16 1317 1319 18239197 of IN B-PP O
17 1320 1326 18239197 mental JJ B-NP D003072
18 1327 1335 18239197 slowness NN I-NP D003072
19 1336 1349 18239197 significantly RB B-VP O
20 1350 1360 18239197 correlated VBD I-VP O
21 1361 1365 18239197 with IN B-PP O
22 1366 1371 18239197 total JJ B-NP O
23 1372 1375 18239197 and CC I-NP O
24 1376 1383 18239197 delayed VBN I-NP O
25 1384 1390 18239197 recall NN I-NP O
26 1391 1393 18239197 on IN B-PP O
27 1394 1397 18239197 the DT B-NP O
28 1398 1405 18239197 Buschke NNP I-NP O
29 1406 1415 18239197 Selective NNP I-NP O
30 1416 1425 18239197 Reminding NNP I-NP O
31 1426 1430 18239197 Test NNP I-NP O
32 1431 1433 18239197 in IN B-PP O
33 1434 1442 18239197 carriers NNS B-NP O
34 1443 1445 18239197 of IN B-PP O
35 1446 1449 18239197 the DT B-NP O
36 1450 1454 18239197 APOE NN I-NP O
37 1455 1463 18239197 epsilon4 NN I-NP O
38 1464 1470 18239197 allele NN I-NP O
39 1471 1475 18239197 only RB B-ADVP O
40 1475 1476 18239197 . . O O

1 1477 1484 18239197 However RB B-ADVP O
2 1484 1485 18239197 , , O O
3 1486 1488 18239197 no DT B-NP O
4 1489 1500 18239197 significant JJ I-NP O
5 1501 1508 18239197 effects NNS I-NP O
6 1509 1513 18239197 were VBD B-VP O
7 1514 1519 18239197 found VBN I-VP O
8 1520 1524 18239197 with IN B-PP O
9 1525 1530 18239197 other JJ B-NP O
10 1531 1537 18239197 visual JJ I-NP O
11 1538 1544 18239197 analog NN I-NP O
12 1545 1551 18239197 scales NNS I-NP O
13 1552 1562 18239197 reflecting VBG B-VP O
14 1563 1573 18239197 subjective JJ B-NP O
15 1574 1582 18239197 sedation NN I-NP O
16 1583 1586 18239197 and CC O O
17 1587 1592 18239197 clear JJ B-NP O
18 1592 1593 18239197 - HYPH I-NP O
19 1593 1603 18239197 headedness NN I-NP O
20 1603 1604 18239197 . . O O

1 1605 1615 18239197 CONCLUSION NN B-NP O
2 1615 1616 18239197 : : O O
3 1617 1620 18239197 The DT B-NP O
4 1621 1629 18239197 epsilon4 NN I-NP O
5 1630 1636 18239197 allele NN I-NP O
6 1637 1639 18239197 in IN B-PP O
7 1640 1647 18239197 healthy JJ B-NP O
8 1648 1655 18239197 elderly JJ I-NP O
9 1656 1659 18239197 was VBD B-VP O
10 1660 1670 18239197 associated VBN I-VP O
11 1671 1675 18239197 with IN B-PP O
12 1676 1685 18239197 increased VBN B-NP O
13 1686 1696 18239197 subjective JJ I-NP O
14 1697 1703 18239197 mental JJ I-NP D003072
15 1704 1711 18239197 slowing NN I-NP D003072
16 1712 1717 18239197 after IN B-PP O
17 1718 1733 18239197 trihexyphenidyl NN B-NP D014282
18 1734 1749 18239197 anticholinergic JJ I-NP O
19 1750 1759 18239197 challenge NN I-NP O
20 1759 1760 18239197 . . O O

1 0 0 10027919 -DOCSTART- -X- -X- O

1 0 2 10027919 22 CD B-NP C051883
2 2 3 10027919 - HYPH I-NP C051883
3 3 16 10027919 oxacalcitriol NN I-NP C051883
4 17 27 10027919 suppresses VBZ B-VP O
5 28 37 10027919 secondary JJ B-NP D006962
6 38 57 10027919 hyperparathyroidism NN I-NP D006962
7 58 65 10027919 without IN B-PP O
8 66 74 10027919 inducing VBG B-VP O
9 75 78 10027919 low JJ B-NP D001851
10 79 83 10027919 bone NN I-NP D001851
11 84 92 10027919 turnover NN I-NP D001851
12 93 95 10027919 in IN B-PP O
13 96 100 10027919 dogs NNS B-NP O
14 101 105 10027919 with IN B-PP O
15 106 111 10027919 renal JJ B-NP D051437
16 112 119 10027919 failure NN I-NP D051437
17 119 120 10027919 . . I-NP O
18 121 131 10027919 BACKGROUND NN I-NP O
19 131 132 10027919 : : O O
20 133 143 10027919 Calcitriol NN B-NP D002117
21 144 151 10027919 therapy NN I-NP O
22 152 162 10027919 suppresses VBZ B-VP O
23 163 168 10027919 serum NN B-NP O
24 169 175 10027919 levels NNS I-NP O
25 176 178 10027919 of IN B-PP O
26 179 190 10027919 parathyroid NN B-NP O
27 191 198 10027919 hormone NN I-NP O
28 199 200 10027919 ( ( O O
29 200 203 10027919 PTH NN B-NP O
30 203 204 10027919 ) ) O O
31 205 207 10027919 in IN B-PP O
32 208 216 10027919 patients NNS B-NP O
33 217 221 10027919 with IN B-PP O
34 222 227 10027919 renal JJ B-NP D051437
35 228 235 10027919 failure NN I-NP D051437
36 236 239 10027919 but CC O O
37 240 243 10027919 has VBZ B-VP O
38 244 251 10027919 several JJ B-NP O
39 252 261 10027919 drawbacks NNS I-NP O
40 261 262 10027919 , , O O
41 263 272 10027919 including VBG B-PP O
42 273 286 10027919 hypercalcemia NN B-NP D006934
43 287 290 10027919 and CC O O
44 290 291 10027919 / SYM B-NP O
45 291 293 10027919 or CC O O
46 294 300 10027919 marked JJ B-NP O
47 301 312 10027919 suppression NN I-NP D001851
48 313 315 10027919 of IN B-PP D001851
49 316 320 10027919 bone NN B-NP D001851
50 321 329 10027919 turnover NN I-NP D001851
51 329 330 10027919 , , O O
52 331 336 10027919 which WDT B-NP O
53 337 340 10027919 may MD B-VP O
54 341 345 10027919 lead VB I-VP O
55 346 348 10027919 to TO B-PP O
56 349 357 10027919 adynamic JJ B-NP D001851
57 358 362 10027919 bone NN I-NP D001851
58 363 370 10027919 disease NN I-NP D001851
59 370 371 10027919 . . O O

1 372 373 10027919 A DT B-NP O
2 374 377 10027919 new JJ I-NP O
3 378 385 10027919 vitamin NN I-NP D014807
4 386 387 10027919 D NN I-NP D014807
5 388 396 10027919 analogue NN I-NP O
6 396 397 10027919 , , O O
7 398 400 10027919 22 CD B-NP C051883
8 400 401 10027919 - HYPH I-NP C051883
9 401 414 10027919 oxacalcitriol NN I-NP C051883
10 415 416 10027919 ( ( O O
11 416 419 10027919 OCT NN B-NP C051883
12 419 420 10027919 ) ) O O
13 420 421 10027919 , , O O
14 422 425 10027919 has VBZ B-VP O
15 426 430 10027919 been VBN I-VP O
16 431 436 10027919 shown VBN I-VP O
17 437 439 10027919 to TO I-VP O
18 440 444 10027919 have VB I-VP O
19 445 454 10027919 promising JJ B-NP O
20 455 470 10027919 characteristics NNS I-NP O
21 470 471 10027919 . . O O

1 472 476 10027919 This DT B-NP O
2 477 482 10027919 study NN I-NP O
3 483 486 10027919 was VBD B-VP O
4 487 497 10027919 undertaken VBN I-VP O
5 498 500 10027919 to TO B-VP O
6 501 510 10027919 determine VB I-VP O
7 511 514 10027919 the DT B-NP O
8 515 522 10027919 effects NNS I-NP O
9 523 525 10027919 of IN B-PP O
10 526 529 10027919 OCT NN B-NP C051883
11 530 532 10027919 on IN B-PP O
12 533 538 10027919 serum NN B-NP O
13 539 542 10027919 PTH NN I-NP O
14 543 549 10027919 levels NNS I-NP O
15 550 553 10027919 and CC O O
16 554 558 10027919 bone NN B-NP O
17 559 567 10027919 turnover NN I-NP O
18 568 570 10027919 in IN B-PP O
19 571 577 10027919 states NNS B-NP O
20 578 580 10027919 of IN B-PP O
21 581 587 10027919 normal JJ B-NP O
22 588 590 10027919 or CC I-NP O
23 591 599 10027919 impaired JJ I-NP D007674
24 600 605 10027919 renal JJ I-NP D007674
25 606 614 10027919 function NN I-NP D007674
26 614 615 10027919 . . O O

1 616 623 10027919 METHODS NNS B-NP O
2 623 624 10027919 : : O O
3 625 630 10027919 Sixty CD B-NP O
4 631 635 10027919 dogs NNS I-NP O
5 636 640 10027919 were VBD B-VP O
6 641 647 10027919 either CC O O
7 648 662 10027919 nephrectomized VBN B-VP O
8 663 664 10027919 ( ( O O
9 664 666 10027919 Nx NN B-NP O
10 666 667 10027919 , , O O
11 668 669 10027919 N NN B-NP O
12 670 671 10027919 = SYM B-VP O
13 672 674 10027919 38 CD B-NP O
14 674 675 10027919 ) ) O O
15 676 678 10027919 or CC O O
16 679 683 10027919 sham NN B-NP O
17 683 684 10027919 - HYPH B-VP O
18 684 692 10027919 operated VBN I-VP O
19 693 694 10027919 ( ( O O
20 694 698 10027919 Sham NN B-NP O
21 698 699 10027919 , , O O
22 700 701 10027919 N NN B-NP O
23 702 703 10027919 = SYM B-VP O
24 704 706 10027919 22 CD B-NP O
25 706 707 10027919 ) ) O O
26 707 708 10027919 . . O O

1 709 712 10027919 The DT B-NP O
2 713 720 10027919 animals NNS I-NP O
3 721 729 10027919 received VBD B-VP O
4 730 742 10027919 supplemental JJ B-NP O
5 743 752 10027919 phosphate NN I-NP D010710
6 753 755 10027919 to TO B-VP O
7 756 763 10027919 enhance VB I-VP O
8 764 767 10027919 PTH NN B-NP O
9 768 777 10027919 secretion NN I-NP O
10 777 778 10027919 . . O O

1 779 787 10027919 Fourteen CD B-NP O
2 788 793 10027919 weeks NNS I-NP O
3 794 799 10027919 after IN B-PP O
4 800 803 10027919 the DT B-NP O
5 804 809 10027919 start NN I-NP O
6 810 812 10027919 of IN B-PP O
7 813 822 10027919 phosphate NN B-NP D010710
8 823 838 10027919 supplementation NN I-NP O
9 838 839 10027919 , , O O
10 840 844 10027919 half NN B-NP O
11 845 847 10027919 of IN B-PP O
12 848 851 10027919 the DT B-NP O
13 852 854 10027919 Nx NNP I-NP O
14 855 858 10027919 and CC I-NP O
15 859 863 10027919 Sham NNP I-NP O
16 864 868 10027919 dogs NNS I-NP O
17 869 877 10027919 received VBD B-VP O
18 878 883 10027919 doses NNS B-NP O
19 884 886 10027919 of IN B-PP O
20 887 890 10027919 OCT NN B-NP C051883
21 891 892 10027919 ( ( O O
22 892 897 10027919 three CD B-NP O
23 898 903 10027919 times NNS I-NP O
24 904 907 10027919 per IN B-PP O
25 908 912 10027919 week NN B-NP O
26 912 913 10027919 ) ) O O
27 913 914 10027919 ; : O O
28 915 918 10027919 the DT B-NP O
29 919 924 10027919 other JJ I-NP O
30 925 929 10027919 half NN I-NP O
31 930 934 10027919 were VBD B-VP O
32 935 940 10027919 given VBN I-VP O
33 941 948 10027919 vehicle NN B-NP O
34 949 952 10027919 for IN B-PP O
35 953 955 10027919 60 CD B-NP O
36 956 961 10027919 weeks NNS I-NP O
37 961 962 10027919 . . O O

1 963 973 10027919 Thereafter RB B-ADVP O
2 973 974 10027919 , , O O
3 975 978 10027919 the DT B-NP O
4 979 988 10027919 treatment NN I-NP O
5 989 999 10027919 modalities NNS I-NP O
6 1000 1003 10027919 for IN B-PP O
7 1004 1005 10027919 a DT B-NP O
8 1006 1012 10027919 subset NN I-NP O
9 1013 1015 10027919 of IN B-PP O
10 1016 1023 10027919 animals NNS B-NP O
11 1024 1028 10027919 were VBD B-VP O
12 1029 1036 10027919 crossed VBN I-VP O
13 1037 1041 10027919 over RP B-PRT O
14 1042 1045 10027919 for IN B-PP O
15 1046 1048 10027919 an DT B-NP O
16 1049 1059 10027919 additional JJ I-NP O
17 1060 1065 10027919 eight CD I-NP O
18 1066 1072 10027919 months NNS I-NP O
19 1072 1073 10027919 . . O O

1 1074 1085 10027919 Biochemical JJ B-NP O
2 1086 1089 10027919 and CC I-NP O
3 1090 1098 10027919 hormonal JJ I-NP O
4 1099 1106 10027919 indices NNS I-NP O
5 1107 1109 10027919 of IN B-PP O
6 1110 1117 10027919 calcium NN B-NP D002118
7 1118 1121 10027919 and CC I-NP O
8 1122 1126 10027919 bone NN I-NP O
9 1127 1137 10027919 metabolism NN I-NP O
10 1138 1142 10027919 were VBD B-VP O
11 1143 1151 10027919 measured VBN I-VP O
12 1152 1162 10027919 throughout IN B-PP O
13 1163 1166 10027919 the DT B-NP O
14 1167 1172 10027919 study NN I-NP O
15 1172 1173 10027919 , , O O
16 1174 1177 10027919 and CC O O
17 1178 1182 10027919 bone NN B-NP O
18 1183 1191 10027919 biopsies NNS I-NP O
19 1192 1196 10027919 were VBD B-VP O
20 1197 1201 10027919 done VBN I-VP O
21 1202 1204 10027919 at IN B-PP O
22 1205 1213 10027919 baseline NN B-NP O
23 1213 1214 10027919 , , O O
24 1215 1217 10027919 60 CD B-NP O
25 1218 1223 10027919 weeks NNS I-NP O
26 1224 1229 10027919 after IN B-PP O
27 1230 1233 10027919 OCT NN B-NP C051883
28 1234 1236 10027919 or CC O O
29 1237 1244 10027919 vehicle NN B-NP O
30 1245 1254 10027919 treatment NN I-NP O
31 1254 1255 10027919 , , O O
32 1256 1259 10027919 and CC O O
33 1260 1262 10027919 at IN B-PP O
34 1263 1266 10027919 the DT B-NP O
35 1267 1270 10027919 end NN I-NP O
36 1271 1273 10027919 of IN B-PP O
37 1274 1277 10027919 the DT B-NP O
38 1278 1287 10027919 crossover NN I-NP O
39 1288 1294 10027919 period NN I-NP O
40 1294 1295 10027919 . . O O

1 1296 1303 10027919 RESULTS NNS B-NP O
2 1303 1304 10027919 : : O O
3 1305 1307 10027919 In IN B-PP O
4 1308 1310 10027919 Nx NN B-NP O
5 1311 1315 10027919 dogs NNS I-NP O
6 1315 1316 10027919 , , O O
7 1317 1320 10027919 OCT NN B-NP C051883
8 1321 1334 10027919 significantly RB B-ADVP O
9 1335 1344 10027919 decreased VBD B-VP O
10 1345 1350 10027919 serum NN B-NP O
11 1351 1354 10027919 PTH NN I-NP O
12 1355 1361 10027919 levels NNS I-NP O
13 1362 1366 10027919 soon RB B-ADVP O
14 1367 1372 10027919 after IN B-PP O
15 1373 1376 10027919 the DT B-NP O
16 1377 1386 10027919 induction NN I-NP O
17 1387 1389 10027919 of IN B-PP O
18 1390 1395 10027919 renal JJ B-NP D051437
19 1396 1409 10027919 insufficiency NN I-NP D051437
20 1409 1410 10027919 . . O O

1 1411 1413 10027919 In IN B-PP O
2 1414 1418 10027919 long RB B-ADVP O
3 1418 1419 10027919 - HYPH O O
4 1419 1427 10027919 standing VBG B-VP O
5 1428 1437 10027919 secondary JJ B-NP D006962
6 1438 1457 10027919 hyperparathyroidism NN I-NP D006962
7 1457 1458 10027919 , , O O
8 1459 1462 10027919 OCT NN B-NP C051883
9 1463 1464 10027919 ( ( O O
10 1464 1468 10027919 0.03 CD B-NP O
11 1469 1475 10027919 microg NN I-NP O
12 1475 1476 10027919 / SYM B-NP O
13 1476 1478 10027919 kg NN I-NP O
14 1478 1479 10027919 ) ) O O
15 1480 1490 10027919 stabilized VBD B-VP O
16 1491 1496 10027919 serum NN B-NP O
17 1497 1500 10027919 PTH NN I-NP O
18 1501 1507 10027919 levels NNS I-NP O
19 1508 1514 10027919 during IN B-PP O
20 1515 1518 10027919 the DT B-NP O
21 1519 1524 10027919 first JJ I-NP O
22 1525 1531 10027919 months NNS I-NP O
23 1531 1532 10027919 . . O O

1 1533 1538 10027919 Serum NN B-NP O
2 1539 1542 10027919 PTH NN I-NP O
3 1543 1549 10027919 levels NNS I-NP O
4 1550 1554 10027919 rose VBD B-VP O
5 1555 1565 10027919 thereafter RB B-ADVP O
6 1565 1566 10027919 , , O O
7 1567 1570 10027919 but CC O O
8 1571 1574 10027919 the DT B-NP O
9 1575 1579 10027919 rise NN I-NP O
10 1580 1583 10027919 was VBD B-VP O
11 1584 1588 10027919 less RBR B-ADJP O
12 1589 1599 10027919 pronounced JJ I-ADJP O
13 1600 1608 10027919 compared VBN B-PP O
14 1609 1613 10027919 with IN B-PP O
15 1614 1622 10027919 baseline NN B-NP O
16 1623 1627 10027919 than IN B-PP O
17 1628 1631 10027919 the DT B-NP O
18 1632 1636 10027919 rise NN I-NP O
19 1637 1641 10027919 seen VBN B-VP O
20 1642 1644 10027919 in IN B-PP O
21 1645 1647 10027919 Nx NN B-NP O
22 1648 1655 10027919 control NN I-NP O
23 1655 1656 10027919 . . O O

1 1657 1662 10027919 These DT B-NP O
2 1663 1670 10027919 effects NNS I-NP O
3 1671 1675 10027919 were VBD B-VP O
4 1676 1687 10027919 accompanied VBN I-VP O
5 1688 1690 10027919 by IN B-PP O
6 1691 1699 10027919 episodes NNS B-NP O
7 1700 1702 10027919 of IN B-PP O
8 1703 1716 10027919 hypercalcemia NN B-NP D006934
9 1717 1720 10027919 and CC I-NP O
10 1721 1738 10027919 hyperphosphatemia NN I-NP D054559
11 1738 1739 10027919 . . O O

1 1740 1742 10027919 In IN B-PP O
2 1743 1750 10027919 animals NNS B-NP O
3 1751 1755 10027919 with IN B-PP O
4 1756 1762 10027919 normal JJ B-NP O
5 1763 1768 10027919 renal JJ I-NP O
6 1769 1777 10027919 function NN I-NP O
7 1777 1778 10027919 , , O O
8 1779 1782 10027919 OCT NN B-NP C051883
9 1783 1790 10027919 induced VBD B-VP O
10 1791 1792 10027919 a DT B-NP O
11 1793 1802 10027919 transient JJ I-NP O
12 1803 1811 10027919 decrease NN I-NP O
13 1812 1814 10027919 in IN B-PP O
14 1815 1820 10027919 serum NN B-NP O
15 1821 1824 10027919 PTH NN I-NP O
16 1825 1831 10027919 levels NNS I-NP O
17 1832 1834 10027919 at IN B-PP O
18 1835 1836 10027919 a DT B-NP O
19 1837 1841 10027919 dose NN I-NP O
20 1842 1844 10027919 of IN B-PP O
21 1845 1848 10027919 0.1 CD B-NP O
22 1849 1855 10027919 microg NN I-NP O
23 1855 1856 10027919 / SYM B-NP O
24 1856 1858 10027919 kg NN I-NP O
25 1858 1859 10027919 , , O O
26 1860 1865 10027919 which WDT B-NP O
27 1866 1869 10027919 was VBD B-VP O
28 1870 1873 10027919 not RB I-VP O
29 1874 1883 10027919 sustained VBN I-VP O
30 1884 1888 10027919 with IN B-PP O
31 1889 1897 10027919 lowering VBG B-NP O
32 1898 1900 10027919 of IN B-PP O
33 1901 1904 10027919 the DT B-NP O
34 1905 1910 10027919 doses NNS I-NP O
35 1910 1911 10027919 . . O O

1 1912 1914 10027919 In IN B-PP O
2 1915 1917 10027919 Nx NN B-NP O
3 1918 1922 10027919 dogs NNS I-NP O
4 1922 1923 10027919 , , O O
5 1924 1927 10027919 OCT NN B-NP C051883
6 1928 1936 10027919 reversed VBD B-VP O
7 1937 1945 10027919 abnormal JJ B-NP O
8 1946 1950 10027919 bone NN I-NP O
9 1951 1960 10027919 formation NN I-NP O
10 1960 1961 10027919 , , O O
11 1962 1966 10027919 such JJ B-PP O
12 1967 1969 10027919 as IN I-PP O
13 1970 1975 10027919 woven JJ B-NP -1
14 1976 1983 10027919 osteoid JJ I-NP -1
15 1984 1987 10027919 and CC I-NP O
16 1988 1996 10027919 fibrosis NN I-NP D005355
17 1996 1997 10027919 , , O O
18 1998 2001 10027919 but CC O O
19 2002 2005 10027919 did VBD B-VP O
20 2006 2009 10027919 not RB I-VP O
21 2010 2023 10027919 significantly RB I-VP O
22 2024 2029 10027919 alter VB I-VP O
23 2030 2033 10027919 the DT B-NP O
24 2034 2039 10027919 level NN I-NP O
25 2040 2042 10027919 of IN B-PP O
26 2043 2047 10027919 bone NN B-NP O
27 2048 2056 10027919 turnover NN I-NP O
28 2056 2057 10027919 . . O O

1 2058 2060 10027919 In IN B-PP O
2 2061 2069 10027919 addition NN B-NP O
3 2069 2070 10027919 , , O O
4 2071 2074 10027919 OCT NN B-NP C051883
5 2075 2083 10027919 improved VBD B-VP O
6 2084 2098 10027919 mineralization NN B-NP O
7 2099 2102 10027919 lag NN I-NP O
8 2103 2107 10027919 time NN I-NP O
9 2107 2108 10027919 , , O O
10 2109 2110 10027919 ( ( O O
11 2110 2114 10027919 that DT B-NP O
12 2115 2117 10027919 is VBZ B-VP O
13 2117 2118 10027919 , , O O
14 2119 2122 10027919 the DT B-NP O
15 2123 2127 10027919 rate NN I-NP O
16 2128 2130 10027919 at IN B-PP O
17 2131 2136 10027919 which WDT B-NP O
18 2137 2144 10027919 osteoid JJ B-NP O
19 2145 2156 10027919 mineralizes NNS I-NP O
20 2156 2157 10027919 ) ) O O
21 2158 2160 10027919 in IN B-PP O
22 2161 2165 10027919 both CC O O
23 2166 2168 10027919 Nx NN B-NP O
24 2169 2172 10027919 and CC I-NP O
25 2173 2177 10027919 Sham NN I-NP O
26 2178 2182 10027919 dogs NNS I-NP O
27 2182 2183 10027919 . . O O

1 2184 2195 10027919 CONCLUSIONS NNS B-NP O
2 2195 2196 10027919 : : O O
3 2197 2202 10027919 These DT B-NP O
4 2203 2210 10027919 results NNS I-NP O
5 2211 2219 10027919 indicate VBP B-VP O
6 2220 2224 10027919 that IN B-SBAR O
7 2225 2229 10027919 even RB B-SBAR O
8 2230 2236 10027919 though IN I-SBAR O
9 2237 2240 10027919 OCT NN B-NP C051883
10 2241 2245 10027919 does VBZ B-VP O
11 2246 2249 10027919 not RB I-VP O
12 2250 2260 10027919 completely RB I-VP O
13 2261 2268 10027919 prevent VB I-VP O
14 2269 2272 10027919 the DT B-NP O
15 2273 2283 10027919 occurrence NN I-NP O
16 2284 2286 10027919 of IN B-PP O
17 2287 2300 10027919 hypercalcemia NN B-NP D006934
18 2301 2303 10027919 in IN B-PP O
19 2304 2316 10027919 experimental JJ B-NP O
20 2317 2321 10027919 dogs NNS I-NP O
21 2322 2326 10027919 with IN B-PP O
22 2327 2332 10027919 renal JJ B-NP D051437
23 2333 2346 10027919 insufficiency NN I-NP D051437
24 2346 2347 10027919 , , O O
25 2348 2350 10027919 it PRP B-NP O
26 2351 2354 10027919 may MD B-VP O
27 2355 2357 10027919 be VB I-VP O
28 2358 2360 10027919 of IN B-PP O
29 2361 2364 10027919 use NN B-NP O
30 2365 2367 10027919 in IN B-PP O
31 2368 2371 10027919 the DT B-NP O
32 2372 2382 10027919 management NN I-NP O
33 2383 2385 10027919 of IN B-PP O
34 2386 2395 10027919 secondary JJ B-NP D006962
35 2396 2415 10027919 hyperparathyroidism NN I-NP D006962
36 2416 2423 10027919 because IN B-SBAR O
37 2424 2426 10027919 it PRP B-NP O
38 2427 2431 10027919 does VBZ B-VP O
39 2432 2435 10027919 not RB I-VP O
40 2436 2442 10027919 induce VB I-VP O
41 2443 2446 10027919 low JJ B-NP D001851
42 2447 2451 10027919 bone NN I-NP D001851
43 2452 2460 10027919 turnover NN I-NP D001851
44 2461 2464 10027919 and CC O O
45 2464 2465 10027919 , , O O
46 2466 2475 10027919 therefore RB B-ADVP O
47 2475 2476 10027919 , , O O
48 2477 2481 10027919 does VBZ B-VP O
49 2482 2485 10027919 not RB I-VP O
50 2486 2494 10027919 increase VB I-VP O
51 2495 2498 10027919 the DT B-NP O
52 2499 2503 10027919 risk NN I-NP O
53 2504 2506 10027919 of IN B-PP O
54 2507 2515 10027919 adynamic JJ B-NP D001851
55 2516 2520 10027919 bone NN I-NP D001851
56 2521 2528 10027919 disease NN I-NP D001851
57 2528 2529 10027919 . . O O

1 0 0 7066357 -DOCSTART- -X- -X- O

1 0 6 7066357 Plasma NN B-NP O
2 7 10 7066357 and CC I-NP O
3 11 18 7066357 urinary JJ I-NP O
4 19 25 7066357 lipids NNS I-NP O
5 26 29 7066357 and CC I-NP O
6 30 42 7066357 lipoproteins NNS I-NP O
7 43 49 7066357 during IN B-PP O
8 50 53 7066357 the DT B-NP O
9 54 65 7066357 development NN I-NP O
10 66 68 7066357 of IN B-PP O
11 69 78 7066357 nephrotic JJ B-NP D009404
12 79 87 7066357 syndrome NN I-NP D009404
13 88 95 7066357 induced VBN B-VP O
14 96 98 7066357 in IN B-PP O
15 99 102 7066357 the DT B-NP O
16 103 106 7066357 rat NN I-NP O
17 107 109 7066357 by IN B-PP O
18 110 119 7066357 puromycin NN B-NP D011692
19 120 135 7066357 aminonucleoside NN I-NP D011692
20 135 136 7066357 . . O O
21 137 141 7066357 This DT B-NP O
22 142 147 7066357 study NN I-NP O
23 148 151 7066357 was VBD B-VP O
24 152 162 7066357 undertaken VBN I-VP O
25 163 165 7066357 to TO I-VP O
26 166 175 7066357 ascertain VB I-VP O
27 176 183 7066357 whether IN B-SBAR O
28 184 187 7066357 the DT B-NP O
29 188 199 7066357 alterations NNS I-NP O
30 200 202 7066357 of IN B-PP O
31 203 209 7066357 plasma NN B-NP O
32 210 222 7066357 lipoproteins NNS I-NP O
33 223 228 7066357 found VBN B-VP O
34 229 231 7066357 in IN B-PP O
35 232 241 7066357 nephrotic JJ B-NP D009404
36 242 250 7066357 syndrome NN I-NP D009404
37 251 258 7066357 induced VBN B-VP O
38 259 261 7066357 by IN B-PP O
39 262 271 7066357 puromycin NN B-NP D011692
40 272 287 7066357 aminonucleoside NN I-NP D011692
41 288 292 7066357 were VBD B-VP O
42 293 296 7066357 due JJ B-ADJP O
43 297 299 7066357 to TO B-PP O
44 300 309 7066357 nephrotic JJ B-NP D009404
45 310 318 7066357 syndrome NN I-NP D009404
46 319 322 7066357 per FW B-ADVP O
47 323 325 7066357 se FW I-ADVP O
48 325 326 7066357 , , O O
49 327 329 7066357 or CC O O
50 329 330 7066357 , , O O
51 331 333 7066357 at IN B-ADVP O
52 334 339 7066357 least JJS I-ADVP O
53 340 342 7066357 in IN B-PP O
54 343 347 7066357 part NN B-NP O
55 347 348 7066357 , , O O
56 349 351 7066357 to TO B-PP O
57 352 355 7066357 the DT B-NP O
58 356 371 7066357 aminonucleoside NN I-NP D011692
59 371 372 7066357 . . O O

1 373 376 7066357 The DT B-NP O
2 377 384 7066357 purpose NN I-NP O
3 385 387 7066357 of IN B-PP O
4 388 391 7066357 the DT B-NP O
5 392 399 7066357 present JJ I-NP O
6 400 405 7066357 study NN I-NP O
7 406 409 7066357 was VBD B-VP O
8 410 412 7066357 to TO B-VP O
9 413 424 7066357 investigate VB I-VP O
10 425 428 7066357 the DT B-NP O
11 429 436 7066357 changes NNS I-NP O
12 437 439 7066357 in IN B-PP O
13 440 446 7066357 plasma NN B-NP O
14 447 450 7066357 and CC O O
15 451 458 7066357 urinary JJ B-NP O
16 459 471 7066357 lipoproteins NNS I-NP O
17 472 478 7066357 during IN B-PP O
18 479 482 7066357 the DT B-NP O
19 483 497 7066357 administration NN I-NP O
20 498 500 7066357 of IN B-PP O
21 501 510 7066357 puromycin NN B-NP D011692
22 511 526 7066357 aminonucleoside NN I-NP D011692
23 527 528 7066357 ( ( O O
24 528 530 7066357 20 CD B-NP O
25 531 533 7066357 mg NN I-NP O
26 533 534 7066357 / SYM B-NP O
27 534 536 7066357 kg NN I-NP O
28 537 540 7066357 for IN B-PP O
29 541 542 7066357 7 CD B-NP O
30 543 547 7066357 days NNS I-NP O
31 547 548 7066357 ) ) O O
32 549 552 7066357 and CC O O
33 553 556 7066357 the DT B-NP O
34 557 567 7066357 subsequent JJ I-NP O
35 568 579 7066357 development NN I-NP O
36 580 582 7066357 of IN B-PP O
37 583 592 7066357 nephrotic JJ B-NP D009404
38 593 601 7066357 syndrome NN I-NP D009404
39 601 602 7066357 . . O O

1 603 608 7066357 Since IN B-SBAR O
2 609 616 7066357 massive JJ B-NP O
3 617 628 7066357 albuminuria NN I-NP D000419
4 629 637 7066357 occurred VBD B-VP O
5 638 643 7066357 after IN B-PP O
6 644 645 7066357 6 CD B-NP O
7 646 650 7066357 days NNS I-NP O
8 651 653 7066357 of IN B-PP O
9 654 663 7066357 treatment NN B-NP O
10 663 664 7066357 , , O O
11 665 668 7066357 the DT B-NP O
12 669 673 7066357 time NN I-NP O
13 673 674 7066357 - HYPH B-NP O
14 674 680 7066357 course NN I-NP O
15 681 686 7066357 study NN I-NP O
16 687 690 7066357 was VBD B-VP O
17 691 698 7066357 divided VBN I-VP O
18 699 703 7066357 into IN B-PP O
19 704 707 7066357 two CD B-NP O
20 708 714 7066357 stages NNS I-NP O
21 714 715 7066357 : : O O
22 716 719 7066357 pre AFX O O
23 719 720 7066357 - HYPH O O
24 720 729 7066357 nephrotic JJ B-NP D009404
25 730 735 7066357 stage NN I-NP O
26 736 737 7066357 ( ( O O
27 737 740 7066357 day NN B-NP O
28 741 742 7066357 1 CD I-NP O
29 742 743 7066357 - HYPH B-NP O
30 743 744 7066357 5 CD I-NP O
31 744 745 7066357 ) ) O O
32 746 749 7066357 and CC O O
33 750 759 7066357 nephrotic JJ B-NP D009404
34 760 765 7066357 stage NN I-NP O
35 766 767 7066357 ( ( O O
36 767 770 7066357 day NN B-NP O
37 771 772 7066357 6 CD I-NP O
38 772 773 7066357 - HYPH B-NP O
39 773 775 7066357 11 CD I-NP O
40 775 776 7066357 ) ) O O
41 776 777 7066357 . . O O

1 778 780 7066357 In IN B-PP O
2 781 784 7066357 pre AFX B-NP O
3 784 785 7066357 - HYPH B-NP O
4 785 794 7066357 nephrotic JJ I-NP D009404
5 795 800 7066357 stage NN I-NP O
6 801 804 7066357 the DT B-NP O
7 805 811 7066357 plasma NN I-NP O
8 812 817 7066357 level NN I-NP O
9 818 820 7066357 of IN B-PP O
10 821 826 7066357 fatty JJ B-NP D005227
11 827 832 7066357 acids NNS I-NP D005227
12 832 833 7066357 , , O O
13 834 849 7066357 triacylglycerol NN B-NP D014280
14 850 853 7066357 and CC I-NP O
15 854 858 7066357 VLDL NN I-NP O
16 859 868 7066357 decreased VBD B-VP O
17 869 874 7066357 while IN B-SBAR O
18 875 879 7066357 that DT B-NP O
19 880 882 7066357 of IN B-PP O
20 883 895 7066357 phospholipid NN B-NP O
21 895 896 7066357 , , O O
22 897 908 7066357 cholesteryl NN B-NP D002788
23 909 915 7066357 esters NNS I-NP D002788
24 916 919 7066357 and CC O O
25 920 923 7066357 HDL NN B-NP O
26 924 932 7066357 remained VBD B-VP O
27 933 941 7066357 constant JJ B-ADJP O
28 941 942 7066357 . . O O

1 943 949 7066357 Plasma NN B-NP O
2 950 964 7066357 apolipoprotein NN I-NP O
3 965 966 7066357 A NN I-NP O
4 966 967 7066357 - HYPH O O
5 967 968 7066357 I PRP B-NP O
6 969 975 7066357 tended VBD B-VP O
7 976 978 7066357 to TO I-VP O
8 979 987 7066357 increase VB I-VP O
9 988 989 7066357 ( ( O O
10 989 992 7066357 40% JJ B-NP O
11 993 1001 7066357 increase NN I-NP O
12 1002 1004 7066357 at IN B-PP O
13 1005 1008 7066357 day NN B-NP O
14 1009 1010 7066357 5 CD I-NP O
15 1010 1011 7066357 ) ) O O
16 1011 1012 7066357 . . O O

1 1013 1015 7066357 At IN B-PP O
2 1016 1019 7066357 the DT B-NP O
3 1020 1029 7066357 beginning NN I-NP O
4 1030 1032 7066357 of IN B-PP O
5 1033 1042 7066357 nephrotic JJ B-NP D009404
6 1043 1048 7066357 stage NN I-NP O
7 1049 1050 7066357 ( ( O O
8 1050 1053 7066357 day NN B-NP O
9 1054 1055 7066357 6 CD I-NP O
10 1055 1056 7066357 ) ) O O
11 1057 1060 7066357 the DT B-NP O
12 1061 1074 7066357 concentration NN I-NP O
13 1075 1077 7066357 of IN B-PP O
14 1078 1084 7066357 plasma NN B-NP O
15 1085 1092 7066357 albumin NN I-NP O
16 1093 1100 7066357 dropped VBD B-VP O
17 1101 1103 7066357 to TO B-PP O
18 1104 1105 7066357 a DT B-NP O
19 1106 1110 7066357 very RB I-NP O
20 1111 1114 7066357 low JJ I-NP O
21 1115 1120 7066357 level NN I-NP O
22 1120 1121 7066357 , , O O
23 1122 1127 7066357 while IN B-SBAR O
24 1128 1132 7066357 that DT B-NP O
25 1133 1135 7066357 of IN B-PP O
26 1136 1150 7066357 apolipoprotein NN B-NP O
27 1151 1152 7066357 A NN I-NP O
28 1152 1153 7066357 - HYPH O O
29 1153 1154 7066357 I PRP B-NP O
30 1155 1164 7066357 increased VBD B-VP O
31 1165 1173 7066357 abruptly RB B-ADVP O
32 1174 1175 7066357 ( ( O O
33 1175 1176 7066357 4 CD B-NP O
34 1176 1177 7066357 - HYPH I-NP O
35 1177 1181 7066357 fold JJ I-NP O
36 1182 1190 7066357 increase NN I-NP O
37 1190 1191 7066357 ) ) O O
38 1192 1195 7066357 and CC O O
39 1196 1205 7066357 continued VBD B-VP O
40 1206 1208 7066357 to TO I-VP O
41 1209 1213 7066357 rise VB I-VP O
42 1213 1214 7066357 , , O O
43 1215 1223 7066357 although IN B-SBAR O
44 1224 1228 7066357 less RBR B-ADVP O
45 1229 1236 7066357 steeply RB I-ADVP O
46 1236 1237 7066357 , , O O
47 1238 1240 7066357 in IN B-PP O
48 1241 1244 7066357 the DT B-NP O
49 1245 1254 7066357 following VBG I-NP O
50 1255 1259 7066357 days NNS I-NP O
51 1259 1260 7066357 . . O O

1 1261 1264 7066357 The DT B-NP O
2 1265 1271 7066357 plasma NN I-NP O
3 1272 1285 7066357 concentration NN I-NP O
4 1286 1288 7066357 of IN B-PP O
5 1289 1292 7066357 HDL NN B-NP O
6 1293 1301 7066357 followed VBD B-VP O
7 1302 1305 7066357 the DT B-NP O
8 1306 1310 7066357 same JJ I-NP O
9 1311 1318 7066357 pattern NN I-NP O
10 1318 1319 7066357 . . O O

1 1320 1326 7066357 Plasma NN B-NP O
2 1327 1331 7066357 VLDL NN I-NP O
3 1332 1335 7066357 and CC I-NP O
4 1336 1339 7066357 LDL NN I-NP O
5 1340 1349 7066357 increased VBD B-VP O
6 1350 1352 7066357 at IN B-PP O
7 1353 1354 7066357 a DT B-NP O
8 1355 1360 7066357 later JJ I-NP O
9 1361 1366 7066357 stage NN I-NP O
10 1367 1368 7066357 ( ( O O
11 1368 1371 7066357 day NN B-NP O
12 1372 1373 7066357 9 CD I-NP O
13 1373 1374 7066357 ) ) O O
14 1374 1375 7066357 . . O O

1 1376 1382 7066357 Plasma NN B-NP O
2 1383 1397 7066357 apolipoprotein NN I-NP O
3 1398 1399 7066357 A NN I-NP O
4 1399 1400 7066357 - HYPH O O
5 1400 1401 7066357 I PRP B-NP O
6 1402 1405 7066357 was VBD B-VP O
7 1406 1411 7066357 found VBN I-VP O
8 1412 1415 7066357 not RB B-CONJP O
9 1416 1420 7066357 only RB I-CONJP O
10 1421 1423 7066357 in IN B-PP O
11 1424 1427 7066357 HDL NN B-NP O
12 1428 1429 7066357 ( ( O O
13 1429 1434 7066357 1.063 CD B-NP O
14 1434 1435 7066357 - HYPH I-NP O
15 1435 1440 7066357 1.210 CD I-NP O
16 1441 1442 7066357 g NN I-NP O
17 1442 1443 7066357 / SYM B-NP O
18 1443 1445 7066357 ml NN I-NP O
19 1445 1446 7066357 ) ) O O
20 1447 1450 7066357 but CC B-CONJP O
21 1451 1455 7066357 also RB I-CONJP O
22 1456 1458 7066357 in IN B-PP O
23 1459 1462 7066357 the DT B-NP O
24 1463 1466 7066357 LDL NN I-NP O
25 1467 1474 7066357 density NN I-NP O
26 1475 1480 7066357 class NN I-NP O
27 1481 1482 7066357 ( ( O O
28 1482 1487 7066357 1.025 CD B-NP O
29 1487 1488 7066357 - HYPH I-NP O
30 1488 1493 7066357 1.050 CD I-NP O
31 1494 1495 7066357 g NN I-NP O
32 1495 1496 7066357 / SYM B-NP O
33 1496 1498 7066357 ml NN I-NP O
34 1498 1499 7066357 ) ) O O
35 1499 1500 7066357 . . O O

1 1501 1503 7066357 In IN B-PP O
2 1504 1507 7066357 the DT B-NP O
3 1508 1511 7066357 pre AFX I-NP O
4 1511 1512 7066357 - HYPH I-NP O
5 1512 1521 7066357 nephrotic JJ I-NP D009404
6 1522 1527 7066357 stage NN I-NP O
7 1528 1543 7066357 lipoproteinuria NN I-NP O
8 1544 1547 7066357 was VBD B-VP O
9 1548 1558 7066357 negligible JJ B-ADJP O
10 1558 1559 7066357 , , O O
11 1560 1565 7066357 while IN B-SBAR O
12 1566 1568 7066357 in IN B-PP O
13 1569 1572 7066357 the DT B-NP O
14 1573 1578 7066357 early JJ I-NP O
15 1579 1588 7066357 nephrotic JJ I-NP D009404
16 1589 1594 7066357 stage NN I-NP O
17 1595 1598 7066357 the DT B-NP O
18 1599 1606 7066357 urinary JJ I-NP O
19 1607 1611 7066357 loss NN I-NP O
20 1612 1614 7066357 of IN B-PP O
21 1615 1621 7066357 plasma NN B-NP O
22 1622 1634 7066357 lipoproteins NNS I-NP O
23 1635 1644 7066357 consisted VBD B-VP O
24 1645 1651 7066357 mainly RB B-ADVP O
25 1652 1654 7066357 of IN B-PP O
26 1655 1658 7066357 HDL NN B-NP O
27 1658 1659 7066357 . . O O

1 1660 1665 7066357 These DT B-NP O
2 1666 1678 7066357 observations NNS I-NP O
3 1679 1687 7066357 indicate VBP B-VP O
4 1688 1692 7066357 that IN B-SBAR O
5 1693 1702 7066357 puromycin NN B-NP D011692
6 1703 1718 7066357 aminonucleoside NN I-NP D011692
7 1719 1725 7066357 alters VBZ B-VP O
8 1726 1732 7066357 plasma NN B-NP O
9 1733 1745 7066357 lipoproteins NNS I-NP O
10 1746 1748 7066357 by IN B-PP O
11 1749 1757 7066357 lowering VBG B-VP O
12 1758 1762 7066357 VLDL NN B-NP O
13 1763 1766 7066357 and CC O O
14 1767 1777 7066357 increasing VBG B-NP O
15 1778 1781 7066357 HDL NN I-NP O
16 1781 1782 7066357 . . O O

1 1783 1785 7066357 It PRP B-NP O
2 1786 1788 7066357 is VBZ B-VP O
3 1789 1795 7066357 likely JJ B-ADJP O
4 1796 1800 7066357 that IN B-SBAR O
5 1801 1804 7066357 the DT B-NP O
6 1805 1810 7066357 early JJ I-NP O
7 1811 1814 7066357 and CC I-NP O
8 1815 1823 7066357 striking JJ I-NP O
9 1824 1832 7066357 increase NN I-NP O
10 1833 1835 7066357 of IN B-PP O
11 1836 1842 7066357 plasma NN B-NP O
12 1843 1846 7066357 HDL NN I-NP O
13 1847 1852 7066357 found VBN B-VP O
14 1853 1855 7066357 in IN B-PP O
15 1856 1865 7066357 nephrotic JJ B-NP D009404
16 1866 1870 7066357 rats NNS I-NP O
17 1871 1873 7066357 is VBZ B-VP O
18 1874 1881 7066357 related JJ B-ADJP O
19 1882 1884 7066357 to TO B-PP O
20 1885 1886 7066357 a DT B-NP O
21 1887 1893 7066357 direct JJ I-NP O
22 1894 1900 7066357 effect NN I-NP O
23 1901 1903 7066357 of IN B-PP O
24 1904 1907 7066357 the DT B-NP O
25 1908 1912 7066357 drug NN I-NP O
26 1913 1915 7066357 on IN B-PP O
27 1916 1919 7066357 HDL NN B-NP O
28 1920 1930 7066357 metabolism NN I-NP O
29 1930 1931 7066357 . . O O

1 0 0 133615 -DOCSTART- -X- -X- O

1 0 14 133615 Progestational JJ B-NP O
2 15 21 133615 agents NNS I-NP O
3 22 25 133615 and CC O O
4 26 31 133615 blood NN B-NP D001778
5 32 43 133615 coagulation NN I-NP D001778
6 43 44 133615 . . O O

1 45 48 133615 VII CD B-NP O
2 48 49 133615 . . O O

1 50 64 133615 Thromboembolic JJ B-NP D013923
2 65 68 133615 and CC I-NP O
3 69 74 133615 other JJ I-NP O
4 75 88 133615 complications NNS I-NP O
5 89 91 133615 of IN B-PP O
6 92 96 133615 oral JJ B-NP D003276
7 97 110 133615 contraceptive JJ I-NP D003276
8 111 118 133615 therapy NN I-NP O
9 119 121 133615 in IN B-PP O
10 122 134 133615 relationship NN B-NP O
11 135 137 133615 to TO B-PP O
12 138 150 133615 pretreatment NN B-NP O
13 151 157 133615 levels NNS I-NP O
14 158 160 133615 of IN B-PP O
15 161 166 133615 blood NN B-NP D001778
16 167 178 133615 coagulation NN I-NP D001778
17 179 186 133615 factors NNS I-NP O
18 186 187 133615 : : O O
19 188 195 133615 summary JJ B-NP O
20 196 202 133615 report NN I-NP O
21 203 205 133615 of IN B-PP O
22 206 207 133615 a DT B-NP O
23 208 211 133615 ten CD I-NP O
24 211 212 133615 - HYPH I-NP O
25 212 216 133615 year NN I-NP O
26 217 222 133615 study NN I-NP O
27 222 223 133615 . . O O
28 224 230 133615 During IN B-PP O
29 231 232 133615 a DT B-NP O
30 233 236 133615 ten CD I-NP O
31 236 237 133615 - HYPH I-NP O
32 237 241 133615 year NN I-NP O
33 242 248 133615 period NN I-NP O
34 248 249 133615 , , O O
35 250 253 133615 348 CD B-NP O
36 254 259 133615 women NNS I-NP O
37 260 264 133615 were VBD B-VP O
38 265 272 133615 studied VBN I-VP O
39 273 276 133615 for IN B-PP O
40 277 278 133615 a DT B-NP O
41 279 284 133615 total NN I-NP O
42 285 287 133615 of IN B-PP O
43 288 293 133615 5,877 CD B-NP O
44 294 301 133615 patient NN I-NP O
45 302 308 133615 months NNS I-NP O
46 309 311 133615 in IN B-PP O
47 312 316 133615 four CD B-NP O
48 317 325 133615 separate JJ I-NP O
49 326 333 133615 studies NNS I-NP O
50 334 342 133615 relating VBG B-VP O
51 343 347 133615 oral JJ B-NP D003276
52 348 362 133615 contraceptives NNS I-NP D003276
53 363 365 133615 to TO B-PP O
54 366 373 133615 changes NNS B-NP O
55 374 376 133615 in IN B-PP O
56 377 388 133615 hematologic JJ B-NP O
57 389 399 133615 parameters NNS I-NP O
58 399 400 133615 . . O O

1 401 412 133615 Significant JJ B-NP O
2 413 422 133615 increases NNS I-NP O
3 423 425 133615 in IN B-PP O
4 426 433 133615 certain JJ B-NP O
5 434 441 133615 factors NNS I-NP O
6 442 444 133615 of IN B-PP O
7 445 448 133615 the DT B-NP O
8 449 454 133615 blood NN I-NP D001778
9 455 466 133615 coagulation NN I-NP D001778
10 467 470 133615 and CC I-NP O
11 471 483 133615 fibrinolysin NN I-NP O
12 484 491 133615 systems NNS I-NP O
13 492 493 133615 ( ( O O
14 493 500 133615 factors NNS B-NP O
15 501 517 133615 I,II,VII,VIII,IX NN I-NP O
16 517 518 133615 , , O O
17 519 522 133615 and CC O O
18 523 524 133615 X NN B-NP O
19 525 528 133615 and CC I-NP O
20 529 540 133615 plasminogen NN I-NP O
21 540 541 133615 ) ) O O
22 542 546 133615 were VBD B-VP O
23 547 555 133615 observed VBN I-VP O
24 556 558 133615 in IN B-PP O
25 559 562 133615 the DT B-NP O
26 563 570 133615 treated VBN I-NP O
27 571 577 133615 groups NNS I-NP O
28 577 578 133615 . . O O

1 579 585 133615 Severe JJ B-NP O
2 586 599 133615 complications NNS I-NP O
3 600 609 133615 developed VBD B-VP O
4 610 612 133615 in IN B-PP O
5 613 617 133615 four CD B-NP O
6 618 626 133615 patients NNS I-NP O
7 626 627 133615 . . O O

1 628 631 133615 All DT B-NP O
2 632 636 133615 four CD I-NP O
3 637 640 133615 had VBD B-VP O
4 641 643 133615 an DT B-NP O
5 644 652 133615 abnormal JJ I-NP O
6 653 658 133615 blood NN I-NP D001778
7 659 670 133615 coagulation NN I-NP D001778
8 671 678 133615 profile NN I-NP O
9 678 679 133615 , , O O
10 680 690 133615 suggesting VBG B-VP O
11 691 692 133615 " `` O O
12 692 710 133615 hypercoagulability NN B-NP D019851
13 710 711 133615 " '' O O
14 712 718 133615 before IN B-PP O
15 719 729 133615 initiation NN B-NP O
16 730 732 133615 of IN B-PP O
17 733 740 133615 therapy NN B-NP O
18 740 741 133615 . . O O

1 742 746 133615 Some DT B-NP O
2 747 749 133615 of IN B-PP O
3 750 755 133615 these DT B-NP O
4 756 764 133615 findings NNS I-NP O
5 765 776 133615 represented VBD B-VP O
6 777 780 133615 the DT B-NP O
7 781 785 133615 most RBS I-NP O
8 786 793 133615 extreme JJ I-NP O
9 794 807 133615 abnormalities NNS I-NP O
10 808 812 133615 seen VBN B-VP O
11 813 815 133615 in IN B-PP O
12 816 819 133615 the DT B-NP O
13 820 826 133615 entire JJ I-NP O
14 827 832 133615 group NN I-NP O
15 833 835 133615 of IN B-PP O
16 836 844 133615 patients NNS B-NP O
17 844 845 133615 ; : O O
18 846 850 133615 some DT B-NP O
19 851 860 133615 increased VBN B-VP O
20 861 868 133615 further RBR B-ADVP O
21 869 875 133615 during IN B-PP O
22 876 883 133615 therapy NN B-NP O
23 883 884 133615 . . O O

1 885 888 133615 One CD B-NP O
2 889 891 133615 of IN B-PP O
3 892 897 133615 these DT B-NP O
4 898 906 133615 patients NNS I-NP O
5 907 916 133615 developed VBD B-VP O
6 917 918 133615 a DT B-NP O
7 919 929 133615 myocardial JJ I-NP D009203
8 930 940 133615 infarction NN I-NP D009203
9 941 947 133615 before IN B-PP O
10 948 957 133615 receiving VBG B-VP O
11 958 961 133615 any DT B-NP O
12 962 972 133615 medication NN I-NP O
13 972 973 133615 , , O O
14 974 981 133615 shortly RB B-ADVP O
15 982 987 133615 after IN B-PP O
16 988 991 133615 the DT B-NP O
17 992 996 133615 base NN I-NP O
18 996 997 133615 - HYPH I-NP O
19 997 1001 133615 line NN I-NP O
20 1002 1008 133615 values NNS I-NP O
21 1009 1013 133615 were VBD B-VP O
22 1014 1022 133615 obtained VBN I-VP O
23 1022 1023 133615 . . O O

1 1024 1027 133615 One CD B-NP O
2 1028 1035 133615 patient NN I-NP O
3 1036 1045 133615 developed VBD B-VP O
4 1046 1057 133615 retinopathy NN B-NP D012164
5 1058 1060 133615 19 CD B-NP O
6 1061 1067 133615 months NNS I-NP O
7 1068 1073 133615 after IN B-SBAR O
8 1074 1077 133615 she PRP B-NP O
9 1078 1083 133615 began VBD B-VP O
10 1084 1091 133615 therapy NN B-NP O
11 1091 1092 133615 , , O O
12 1093 1096 133615 and CC O O
13 1097 1104 133615 another DT B-NP O
14 1105 1114 133615 developed VBN I-NP O
15 1115 1131 133615 thrombophlebitis NN I-NP D013924
16 1132 1137 133615 after IN B-PP O
17 1138 1140 133615 27 CD B-NP O
18 1141 1147 133615 months NNS I-NP O
19 1148 1150 133615 of IN B-PP O
20 1151 1158 133615 therapy NN B-NP O
21 1158 1159 133615 . . O O

1 1160 1163 133615 The DT B-NP O
2 1164 1170 133615 fourth JJ I-NP O
3 1171 1178 133615 patient NN I-NP O
4 1179 1188 133615 developed VBD B-VP O
5 1189 1205 133615 thrombophlebitis NN B-NP D013924
6 1206 1208 133615 14 CD B-NP O
7 1209 1213 133615 days NNS I-NP O
8 1214 1219 133615 after IN B-PP O
9 1220 1230 133615 initiation NN B-NP O
10 1231 1233 133615 of IN B-PP O
11 1234 1247 133615 contraceptive JJ B-NP O
12 1248 1255 133615 therapy NN I-NP O
13 1255 1256 133615 . . O O

1 1257 1260 133615 All DT B-NP O
2 1261 1265 133615 four CD I-NP O
3 1266 1274 133615 patients NNS I-NP O
4 1275 1279 133615 were VBD B-VP O
5 1280 1282 133615 of IN B-PP O
6 1283 1286 133615 the DT B-NP O
7 1287 1288 133615 A NN I-NP O
8 1289 1291 133615 or CC I-NP O
9 1292 1294 133615 AB NN I-NP O
10 1295 1300 133615 blood NN I-NP O
11 1301 1306 133615 group NN I-NP O
12 1306 1307 133615 . . O O

1 1308 1316 133615 Previous JJ B-NP O
2 1317 1324 133615 studies NNS I-NP O
3 1325 1334 133615 suggested VBD B-VP O
4 1335 1338 133615 the DT B-NP O
5 1339 1351 133615 possiblility NN I-NP O
6 1352 1354 133615 of IN B-PP O
7 1355 1364 133615 increased VBN B-NP O
8 1365 1375 133615 propensity NN I-NP O
9 1376 1379 133615 for IN B-PP O
10 1380 1394 133615 thromboembolic JJ B-NP D013923
11 1395 1403 133615 episodes NNS I-NP D013923
12 1404 1406 133615 in IN B-PP O
13 1407 1415 133615 patients NNS B-NP O
14 1416 1426 133615 possessing VBG B-VP O
15 1427 1430 133615 the DT B-NP O
16 1431 1432 133615 A NN I-NP O
17 1433 1440 133615 antigen NN I-NP O
18 1440 1441 133615 . . O O

1 1442 1444 133615 It PRP B-NP O
2 1445 1452 133615 appears VBZ B-VP O
3 1453 1457 133615 from IN B-PP O
4 1458 1463 133615 these DT B-NP O
5 1464 1468 133615 data NNS I-NP O
6 1469 1473 133615 that IN B-NP O
7 1474 1485 133615 hematologic JJ B-NP O
8 1486 1490 133615 work NN I-NP O
9 1490 1491 133615 - HYPH O O
10 1491 1494 133615 ups NNS B-NP O
11 1495 1498 133615 may MD B-VP O
12 1499 1501 133615 be VB I-VP O
13 1502 1508 133615 useful JJ B-ADJP O
14 1509 1511 133615 in IN B-PP O
15 1512 1517 133615 women NNS B-NP O
16 1518 1521 133615 who WP B-NP O
17 1522 1525 133615 are VBP B-VP O
18 1526 1531 133615 about IN O O
19 1532 1534 133615 to TO B-VP O
20 1535 1540 133615 start VB I-VP O
21 1541 1545 133615 long JJ B-NP O
22 1545 1546 133615 - HYPH I-NP O
23 1546 1550 133615 term NN I-NP O
24 1551 1555 133615 oral JJ I-NP D003276
25 1556 1569 133615 contraceptive JJ I-NP D003276
26 1570 1577 133615 therapy NN I-NP O
27 1577 1578 133615 . . O O

1 0 0 9545159 -DOCSTART- -X- -X- O

1 0 12 9545159 Prolongation NN B-NP D008133
2 13 15 9545159 of IN B-PP D008133
3 16 19 9545159 the DT B-NP D008133
4 20 22 9545159 QT NN I-NP D008133
5 23 31 9545159 interval NN I-NP D008133
6 32 39 9545159 related VBN B-VP O
7 40 42 9545159 to TO B-PP O
8 43 52 9545159 cisapride NN B-NP D020117
9 52 53 9545159 - HYPH I-NP O
10 53 62 9545159 diltiazem NN I-NP D004110
11 63 74 9545159 interaction NN I-NP O
12 74 75 9545159 . . I-NP O
13 76 85 9545159 Cisapride NN I-NP D020117
14 85 86 9545159 , , O O
15 87 88 9545159 a DT B-NP O
16 89 99 9545159 cytochrome NN I-NP O
17 100 104 9545159 P450 NN I-NP O
18 105 108 9545159 3A4 NN I-NP O
19 109 110 9545159 ( ( O O
20 110 116 9545159 CYP3A4 NN B-NP O
21 116 117 9545159 ) ) O O
22 118 127 9545159 substrate NN B-NP O
23 127 128 9545159 , , O O
24 129 131 9545159 is VBZ B-VP O
25 132 138 9545159 widely RB I-VP O
26 139 149 9545159 prescribed VBN I-VP O
27 150 153 9545159 for IN B-PP O
28 154 157 9545159 the DT B-NP O
29 158 167 9545159 treatment NN I-NP O
30 168 170 9545159 of IN B-PP O
31 171 187 9545159 gastrointestinal JJ B-NP D015835
32 188 196 9545159 motility NN I-NP D015835
33 197 206 9545159 disorders NNS I-NP D015835
34 206 207 9545159 . . O O

1 208 220 9545159 Prolongation NN B-NP D008133
2 221 223 9545159 of IN B-PP D008133
3 224 226 9545159 QT NN B-NP D008133
4 227 235 9545159 interval NN I-NP D008133
5 235 236 9545159 , , O O
6 237 245 9545159 torsades FW B-NP D016171
7 246 248 9545159 de FW I-NP D016171
8 249 256 9545159 pointes FW I-NP D016171
9 256 257 9545159 , , O O
10 258 261 9545159 and CC O O
11 262 268 9545159 sudden JJ B-NP D016757
12 269 276 9545159 cardiac JJ I-NP D016757
13 277 282 9545159 death NN I-NP D016757
14 283 287 9545159 have VBP B-VP O
15 288 292 9545159 been VBN I-VP O
16 293 301 9545159 reported VBN I-VP O
17 302 307 9545159 after IN B-PP O
18 308 319 9545159 concomitant JJ B-NP O
19 320 334 9545159 administration NN I-NP O
20 335 339 9545159 with IN B-PP O
21 340 352 9545159 erythromycin NN B-NP D004917
22 353 355 9545159 or CC I-NP O
23 356 361 9545159 azole NN I-NP D001393
24 362 372 9545159 antifungal JJ I-NP O
25 373 379 9545159 agents NNS I-NP O
26 379 380 9545159 , , B-PP O
27 381 384 9545159 but CC I-PP O
28 385 388 9545159 not RB B-PP O
29 389 393 9545159 with IN I-PP O
30 394 399 9545159 other JJ B-NP O
31 400 406 9545159 CYP3A4 NN I-NP O
32 407 417 9545159 inhibitors NNS I-NP O
33 417 418 9545159 . . O O

1 419 420 9545159 A DT B-NP O
2 421 429 9545159 possible JJ I-NP O
3 430 434 9545159 drug NN I-NP O
4 435 446 9545159 interaction NN I-NP O
5 447 455 9545159 occurred VBD B-VP O
6 456 458 9545159 in IN B-PP O
7 459 460 9545159 a DT B-NP O
8 461 463 9545159 45 CD I-NP O
9 463 464 9545159 - HYPH I-NP O
10 464 468 9545159 year NN I-NP O
11 468 469 9545159 - HYPH B-NP O
12 469 472 9545159 old JJ I-NP O
13 473 478 9545159 woman NN I-NP O
14 479 482 9545159 who WP B-NP O
15 483 486 9545159 was VBD B-VP O
16 487 493 9545159 taking VBG I-VP O
17 494 503 9545159 cisapride NN B-NP D020117
18 504 507 9545159 for IN B-PP O
19 508 524 9545159 gastroesophageal JJ B-NP D005764
20 525 531 9545159 reflux NN I-NP D005764
21 532 540 9545159 disorder NN I-NP D005764
22 541 544 9545159 and CC I-NP O
23 545 554 9545159 diltiazem NN I-NP D004110
24 554 555 9545159 , , O O
25 556 558 9545159 an DT B-NP O
26 559 564 9545159 agent NN I-NP O
27 565 569 9545159 that WDT B-NP O
28 570 573 9545159 has VBZ B-VP O
29 574 584 9545159 inhibitory JJ B-NP O
30 585 591 9545159 effect NN I-NP O
31 592 594 9545159 on IN B-PP O
32 595 601 9545159 CYP3A4 NN B-NP O
33 601 602 9545159 , , O O
34 603 606 9545159 for IN B-PP O
35 607 619 9545159 hypertension NN B-NP D006973
36 619 620 9545159 . . O O

1 621 624 9545159 The DT B-NP O
2 625 632 9545159 patient NN I-NP O
3 633 636 9545159 was VBD B-VP O
4 637 639 9545159 in IN B-PP O
5 640 644 9545159 near JJ B-NP O
6 645 652 9545159 syncope NN I-NP D013575
7 653 656 9545159 and CC O O
8 657 660 9545159 had VBD B-VP O
9 661 663 9545159 QT NN B-NP D008133
10 663 664 9545159 - HYPH B-NP D008133
11 664 672 9545159 interval NN I-NP D008133
12 673 685 9545159 prolongation NN I-NP D008133
13 685 686 9545159 . . O O

1 687 692 9545159 After IN B-PP O
2 693 706 9545159 discontinuing VBG B-VP O
3 707 716 9545159 cisapride NN B-NP D020117
4 716 717 9545159 , , O O
5 718 721 9545159 the DT B-NP O
6 722 724 9545159 QT NN I-NP O
7 725 733 9545159 interval NN I-NP O
8 734 742 9545159 returned VBD B-VP O
9 743 745 9545159 to TO B-PP O
10 746 752 9545159 normal JJ B-NP O
11 753 756 9545159 and CC O O
12 757 765 9545159 symptoms NNS B-NP O
13 766 769 9545159 did VBD B-VP O
14 770 773 9545159 not RB I-VP O
15 774 779 9545159 recur VB I-VP O
16 779 780 9545159 . . O O

1 781 783 9545159 We PRP B-NP O
2 784 791 9545159 suggest VBP B-VP O
3 792 796 9545159 that IN B-SBAR O
4 797 804 9545159 caution NN B-NP O
5 805 807 9545159 be VB B-VP O
6 808 813 9545159 taken VBN I-VP O
7 814 818 9545159 when WRB B-ADVP O
8 819 828 9545159 cisapride NN B-NP D020117
9 829 831 9545159 is VBZ B-VP O
10 832 842 9545159 prescribed VBN I-VP O
11 843 847 9545159 with IN B-PP O
12 848 851 9545159 any DT B-NP O
13 852 858 9545159 potent JJ I-NP O
14 859 868 9545159 inhibitor NN I-NP O
15 869 871 9545159 of IN B-PP O
16 872 878 9545159 CYP3A4 NN B-NP O
17 878 879 9545159 , , O O
18 880 889 9545159 including VBG B-PP O
19 890 899 9545159 diltiazem NN B-NP D004110
20 899 900 9545159 . . O O

1 0 0 3137399 -DOCSTART- -X- -X- O

1 0 1 3137399 A DT B-NP O
2 2 13 3137399 prospective JJ I-NP O
3 14 19 3137399 study NN I-NP O
4 20 22 3137399 on IN B-PP O
5 23 26 3137399 the DT B-NP O
6 27 31 3137399 dose NN I-NP O
7 32 42 3137399 dependency NN I-NP O
8 43 45 3137399 of IN B-PP O
9 46 60 3137399 cardiotoxicity NN B-NP D066126
10 61 68 3137399 induced VBN B-VP O
11 69 71 3137399 by IN B-PP O
12 72 81 3137399 mitomycin NN B-NP D016685
13 82 83 3137399 C NN I-NP D016685
14 83 84 3137399 . . O O
15 85 90 3137399 Since IN B-NP O
16 91 95 3137399 1975 CD I-NP O
17 96 105 3137399 mitomycin NN I-NP D016685
18 106 107 3137399 C NN I-NP D016685
19 108 109 3137399 ( ( O O
20 109 112 3137399 MMC NN B-NP D016685
21 112 113 3137399 ) ) O O
22 114 117 3137399 has VBZ B-VP O
23 118 122 3137399 been VBN I-VP O
24 123 132 3137399 suggested VBN I-VP O
25 133 135 3137399 to TO I-VP O
26 136 138 3137399 be VB I-VP O
27 139 150 3137399 cardiotoxic JJ B-ADJP D066126
28 150 151 3137399 , , O O
29 152 162 3137399 especially RB B-ADVP O
30 163 167 3137399 when WRB B-ADVP O
31 168 176 3137399 combined VBN B-VP O
32 177 181 3137399 with IN B-PP O
33 182 184 3137399 or CC O O
34 185 190 3137399 given VBN B-PP O
35 191 200 3137399 following VBG B-PP O
36 201 212 3137399 doxorubicin NN B-NP D004317
37 212 213 3137399 . . O O

1 214 218 3137399 Data NNS B-NP O
2 219 221 3137399 on IN B-PP O
3 222 226 3137399 dose NN B-NP O
4 227 237 3137399 dependency NN I-NP O
5 238 240 3137399 or CC I-NP O
6 241 250 3137399 incidence NN I-NP O
7 251 261 3137399 concerning VBG B-VP O
8 262 266 3137399 this DT B-NP O
9 267 271 3137399 side NN I-NP O
10 272 278 3137399 effect NN I-NP O
11 279 283 3137399 were VBD B-VP O
12 284 287 3137399 not RB I-VP O
13 288 293 3137399 known VBN I-VP O
14 293 294 3137399 . . O O

1 295 297 3137399 We PRP B-NP O
2 298 302 3137399 have VBP B-VP O
3 303 312 3137399 initiated VBN I-VP O
4 313 314 3137399 a DT B-NP O
5 315 326 3137399 prospective JJ I-NP O
6 327 332 3137399 study NN I-NP O
7 333 335 3137399 to TO B-VP O
8 336 342 3137399 obtain VB I-VP O
9 343 347 3137399 some DT B-NP O
10 348 352 3137399 more JJR I-NP O
11 353 357 3137399 data NNS I-NP O
12 358 360 3137399 on IN B-PP O
13 361 366 3137399 these DT B-NP O
14 367 375 3137399 subjects NNS I-NP O
15 375 376 3137399 . . O O

1 377 382 3137399 Forty CD B-NP O
2 382 383 3137399 - HYPH I-NP O
3 383 387 3137399 four CD I-NP O
4 388 391 3137399 MMC NN I-NP D016685
5 391 392 3137399 - HYPH O O
6 392 399 3137399 treated VBN B-NP O
7 400 408 3137399 patients NNS I-NP O
8 409 413 3137399 were VBD B-VP O
9 414 421 3137399 studied VBN I-VP O
10 421 422 3137399 , , O O
11 423 425 3137399 37 CD B-NP O
12 426 428 3137399 of IN B-PP O
13 429 433 3137399 them PRP B-NP O
14 434 439 3137399 could MD B-VP O
15 440 442 3137399 be VB I-VP O
16 443 452 3137399 evaluated VBN I-VP O
17 452 453 3137399 . . O O

1 454 457 3137399 All DT B-NP O
2 458 466 3137399 patients NNS I-NP O
3 467 471 3137399 were VBD B-VP O
4 472 479 3137399 studied VBN I-VP O
5 480 482 3137399 by IN B-PP O
6 483 491 3137399 repeated VBN B-NP O
7 492 500 3137399 physical JJ I-NP O
8 501 513 3137399 examinations NNS I-NP O
9 513 514 3137399 , , O O
10 515 520 3137399 chest NN B-NP O
11 521 522 3137399 X SYM B-NP O
12 522 523 3137399 - HYPH B-NP O
13 523 527 3137399 rays NNS I-NP O
14 527 528 3137399 , , O O
15 529 536 3137399 electro AFX B-NP O
16 536 537 3137399 - HYPH I-NP O
17 538 541 3137399 and CC I-NP O
18 542 558 3137399 echocardiography NN I-NP O
19 559 562 3137399 and CC I-NP O
20 563 575 3137399 radionuclide NN I-NP O
21 576 580 3137399 left VBD B-VP O
22 581 592 3137399 ventricular JJ B-NP O
23 593 601 3137399 ejection NN I-NP O
24 602 610 3137399 fraction NN I-NP O
25 611 612 3137399 ( ( O O
26 612 614 3137399 EF NN B-NP O
27 614 615 3137399 ) ) O O
28 616 630 3137399 determinations NNS B-NP O
29 630 631 3137399 . . O O

1 632 635 3137399 The DT B-NP O
2 636 643 3137399 results NNS I-NP O
3 644 648 3137399 were VBD B-VP O
4 649 658 3137399 evaluated VBN I-VP O
5 659 662 3137399 per IN B-PP O
6 663 673 3137399 cumulative JJ B-NP O
7 674 678 3137399 dose NN I-NP O
8 679 684 3137399 level NN I-NP O
9 684 685 3137399 . . O O

1 686 689 3137399 One CD B-NP O
2 690 692 3137399 of IN B-PP O
3 693 696 3137399 the DT B-NP O
4 697 705 3137399 patients NNS I-NP O
5 706 715 3137399 developed VBD B-VP O
6 716 723 3137399 cardiac JJ B-NP D006333
7 724 731 3137399 failure NN I-NP D006333
8 732 737 3137399 after IN B-PP O
9 738 740 3137399 30 CD B-NP O
10 741 743 3137399 mg NN I-NP O
11 744 745 3137399 m NN I-NP O
12 745 746 3137399 - HYPH O O
13 746 747 3137399 2 CD B-NP O
14 748 751 3137399 MMC NN I-NP D016685
15 752 755 3137399 and CC O O
16 756 760 3137399 only RB B-NP O
17 761 764 3137399 150 CD I-NP O
18 765 767 3137399 mg NN I-NP O
19 768 769 3137399 m NN I-NP O
20 769 770 3137399 - HYPH B-NP O
21 770 771 3137399 2 CD I-NP O
22 772 783 3137399 doxorubicin NN I-NP D004317
23 783 784 3137399 . . O O

1 785 788 3137399 The DT B-NP O
2 789 796 3137399 cardiac JJ I-NP D006333
3 797 804 3137399 failure NN I-NP D006333
4 805 808 3137399 was VBD B-VP O
5 809 818 3137399 predicted VBN I-VP O
6 819 821 3137399 by IN B-PP O
7 822 823 3137399 a DT B-NP O
8 824 828 3137399 drop NN I-NP O
9 829 831 3137399 in IN B-PP O
10 832 834 3137399 EF NN B-NP O
11 835 845 3137399 determined VBN B-VP O
12 846 852 3137399 during IN B-PP O
13 853 854 3137399 a DT B-NP O
14 855 859 3137399 cold JJ I-NP O
15 860 867 3137399 pressor NN I-NP O
16 868 872 3137399 test NN I-NP O
17 872 873 3137399 . . O O

1 874 878 3137399 None NN B-NP O
2 879 881 3137399 of IN B-PP O
3 882 885 3137399 the DT B-NP O
4 886 891 3137399 other JJ I-NP O
5 892 900 3137399 patients NNS I-NP O
6 901 910 3137399 developed VBD B-VP O
7 911 919 3137399 clinical JJ B-NP O
8 920 934 3137399 cardiotoxicity NN I-NP D066126
9 934 935 3137399 , , O O
10 936 939 3137399 nor CC O O
11 940 943 3137399 did VBD O O
12 944 947 3137399 the DT B-NP O
13 948 955 3137399 studied VBN I-NP O
14 956 966 3137399 parameters NNS I-NP O
15 967 973 3137399 change VBP B-VP O
16 973 974 3137399 . . O O

1 975 978 3137399 The DT B-NP O
2 979 989 3137399 literature NN I-NP O
3 990 992 3137399 on IN B-PP O
4 993 997 3137399 this DT B-NP O
5 998 1005 3137399 subject NN I-NP O
6 1006 1009 3137399 was VBD B-VP O
7 1010 1014 3137399 also RB I-VP O
8 1015 1023 3137399 reviewed VBN I-VP O
9 1023 1024 3137399 . . O O

1 1025 1030 3137399 Based VBN B-PP O
2 1031 1033 3137399 on IN B-PP O
3 1034 1037 3137399 the DT B-NP O
4 1038 1046 3137399 combined VBN I-NP O
5 1047 1051 3137399 data NNS I-NP O
6 1052 1056 3137399 from IN B-PP O
7 1057 1060 3137399 the DT B-NP O
8 1061 1068 3137399 present JJ I-NP O
9 1069 1074 3137399 study NN I-NP O
10 1075 1078 3137399 and CC O O
11 1079 1082 3137399 the DT B-NP O
12 1083 1093 3137399 literature NN I-NP O
13 1093 1094 3137399 , , O O
14 1095 1097 3137399 we PRP B-NP O
15 1098 1105 3137399 suggest VBP B-VP O
16 1106 1110 3137399 that IN B-SBAR O
17 1111 1114 3137399 MMC NN B-NP D016685
18 1114 1115 3137399 - HYPH B-NP O
19 1115 1122 3137399 related VBN I-NP O
20 1123 1137 3137399 cardiotoxicity NN I-NP D066126
21 1138 1140 3137399 is VBZ B-VP O
22 1141 1145 3137399 dose NN B-NP O
23 1146 1155 3137399 dependent JJ I-NP O
24 1155 1156 3137399 , , O O
25 1157 1166 3137399 occurring VBG B-VP O
26 1167 1169 3137399 at IN B-PP O
27 1170 1180 3137399 cumulative JJ B-NP O
28 1181 1185 3137399 dose NN I-NP O
29 1186 1192 3137399 levels NNS I-NP O
30 1193 1195 3137399 of IN B-PP O
31 1196 1198 3137399 30 CD B-NP O
32 1199 1201 3137399 mg NN I-NP O
33 1202 1203 3137399 m NN I-NP O
34 1203 1204 3137399 - HYPH B-NP O
35 1204 1205 3137399 2 CD I-NP O
36 1206 1208 3137399 or CC I-NP O
37 1209 1213 3137399 more JJR I-NP O
38 1213 1214 3137399 , , O O
39 1215 1221 3137399 mainly RB B-ADVP O
40 1222 1224 3137399 in IN B-PP O
41 1225 1233 3137399 patients NNS B-NP O
42 1234 1238 3137399 also RB B-ADVP O
43 1239 1240 3137399 ( ( O O
44 1240 1250 3137399 previously RB B-ADVP O
45 1251 1253 3137399 or CC I-ADVP O
46 1254 1268 3137399 simultaneously RB I-ADVP O
47 1268 1269 3137399 ) ) O O
48 1270 1277 3137399 treated VBN B-VP O
49 1278 1282 3137399 with IN B-PP O
50 1283 1294 3137399 doxorubicin NN B-NP D004317
51 1294 1295 3137399 . . O O

1 1296 1299 3137399 The DT B-NP O
2 1300 1309 3137399 incidence NN I-NP O
3 1310 1312 3137399 is VBZ B-VP O
4 1313 1319 3137399 likely JJ B-ADJP O
5 1320 1322 3137399 to TO B-VP O
6 1323 1325 3137399 be VB I-VP O
7 1326 1330 3137399 less JJR B-NP O
8 1331 1335 3137399 than IN I-NP O
9 1336 1339 3137399 10% CD I-NP O
10 1340 1344 3137399 even RB I-NP O
11 1345 1348 3137399 for IN B-PP O
12 1349 1353 3137399 this DT B-NP O
13 1354 1358 3137399 risk NN I-NP O
14 1359 1364 3137399 group NN I-NP O
15 1364 1365 3137399 . . O O

1 0 0 3001299 -DOCSTART- -X- -X- O

1 0 7 3001299 Thyroid JJ B-NP O
2 8 16 3001299 function NN I-NP O
3 17 20 3001299 and CC I-NP O
4 21 26 3001299 urine NN I-NP O
5 26 27 3001299 - HYPH O O
6 27 40 3001299 concentrating VBG B-VP O
7 41 48 3001299 ability NN B-NP O
8 49 55 3001299 during IN B-PP O
9 56 63 3001299 lithium NN B-NP D008094
10 64 73 3001299 treatment NN I-NP O
11 73 74 3001299 . . O O
12 75 77 3001299 It PRP B-NP O
13 78 81 3001299 has VBZ B-VP O
14 82 86 3001299 been VBN I-VP O
15 87 96 3001299 suggested VBN I-VP O
16 97 101 3001299 that IN B-SBAR O
17 102 111 3001299 adenylate NN B-NP O
18 112 119 3001299 cyclase NN I-NP O
19 120 130 3001299 inhibition NN I-NP O
20 131 134 3001299 may MD B-VP O
21 135 137 3001299 be VB I-VP O
22 138 147 3001299 important JJ B-ADJP O
23 148 150 3001299 in IN B-PP O
24 151 154 3001299 the DT B-NP O
25 155 166 3001299 development NN I-NP O
26 167 169 3001299 of IN B-PP O
27 170 174 3001299 both CC B-NP O
28 175 186 3001299 nephrogenic JJ I-NP D018500
29 187 195 3001299 diabetes NNS I-NP D018500
30 196 205 3001299 insipidus NN I-NP D018500
31 206 209 3001299 and CC I-NP O
32 210 224 3001299 hypothyroidism NN I-NP D007037
33 225 231 3001299 during IN B-PP O
34 232 239 3001299 lithium NN B-NP D008094
35 240 249 3001299 treatment NN I-NP O
36 249 250 3001299 . . O O

1 251 253 3001299 We PRP B-NP O
2 254 262 3001299 measured VBD B-VP O
3 263 268 3001299 serum NN B-NP O
4 269 278 3001299 thyroxine NN I-NP D013974
5 279 282 3001299 and CC I-NP O
6 283 288 3001299 urine NN I-NP O
7 288 289 3001299 - HYPH O O
8 289 302 3001299 concentrating VBG B-VP O
9 303 310 3001299 ability NN B-NP O
10 311 312 3001299 ( ( O O
11 312 316 3001299 Umax NN B-NP O
12 316 317 3001299 ) ) O O
13 318 320 3001299 in IN B-PP O
14 321 329 3001299 response NN I-PP O
15 330 332 3001299 to TO I-PP O
16 333 345 3001299 desmopressin NN B-NP O
17 346 347 3001299 ( ( O O
18 347 352 3001299 DDAVP NN B-NP O
19 352 353 3001299 ) ) O O
20 354 356 3001299 in IN B-PP O
21 357 359 3001299 85 CD B-NP O
22 360 368 3001299 patients NNS I-NP O
23 369 378 3001299 receiving VBG B-VP O
24 379 386 3001299 lithium NN B-NP D008094
25 386 387 3001299 . . O O

1 388 402 3001299 Hypothyroidism NN B-NP D007037
2 403 412 3001299 developed VBD B-VP O
3 413 415 3001299 in IN B-PP O
4 416 421 3001299 eight CD B-NP O
5 422 430 3001299 patients NNS I-NP O
6 431 436 3001299 while IN B-SBAR O
7 437 441 3001299 they PRP B-NP O
8 442 446 3001299 were VBD B-VP O
9 447 453 3001299 taking VBG I-VP O
10 454 461 3001299 lithium NN B-NP D008094
11 461 462 3001299 . . O O

1 463 471 3001299 Impaired JJ B-NP O
2 472 476 3001299 Umax NN I-NP O
3 477 480 3001299 was VBD B-VP O
4 481 486 3001299 found VBN I-VP O
5 487 489 3001299 in IN B-PP O
6 490 494 3001299 both CC B-NP O
7 495 504 3001299 euthyroid JJ I-NP O
8 505 508 3001299 and CC I-NP O
9 509 520 3001299 hypothyroid JJ I-NP D007037
10 521 529 3001299 patients NNS I-NP O
11 530 535 3001299 while IN B-SBAR O
12 536 540 3001299 some DT B-NP O
13 541 552 3001299 hypothyroid JJ I-NP D007037
14 553 561 3001299 patients NNS I-NP O
15 562 574 3001299 concentrated VBD B-VP O
16 575 580 3001299 their PRP$ B-NP O
17 581 586 3001299 urine NN I-NP O
18 587 591 3001299 well RB B-ADVP O
19 591 592 3001299 . . O O

1 593 595 3001299 It PRP B-NP O
2 596 598 3001299 is VBZ B-VP O
3 599 608 3001299 concluded VBN I-VP O
4 609 613 3001299 that IN B-SBAR O
5 614 617 3001299 the DT B-NP O
6 618 626 3001299 dominant JJ I-NP O
7 627 637 3001299 mechanisms NNS I-NP O
8 638 640 3001299 by IN B-PP O
9 641 646 3001299 which WDT B-NP O
10 647 654 3001299 lithium NN B-NP D008094
11 655 661 3001299 exerts VBZ B-VP O
12 662 667 3001299 these DT B-NP O
13 668 671 3001299 two CD I-NP O
14 672 679 3001299 effects NNS I-NP O
15 680 683 3001299 are VBP B-VP O
16 684 693 3001299 different JJ B-ADJP O
17 693 694 3001299 . . O O

1 0 0 2709684 -DOCSTART- -X- -X- O

1 0 9 2709684 Phlorizin NN B-NP D010695
2 9 10 2709684 - HYPH B-PP O
3 10 17 2709684 induced VBN B-NP O
4 18 28 2709684 glycosuria NN I-NP D006029
5 29 33 2709684 does VBZ B-VP O
6 34 37 2709684 not RB I-VP O
7 38 45 2709684 prevent VB I-VP O
8 46 56 2709684 gentamicin NN B-NP D005839
9 57 71 2709684 nephrotoxicity NN I-NP D007674
10 72 74 2709684 in IN B-PP O
11 75 79 2709684 rats NNS B-NP O
12 79 80 2709684 . . O O
13 81 88 2709684 Because IN B-SBAR O
14 89 93 2709684 rats NNS B-NP O
15 94 98 2709684 with IN B-PP O
16 99 113 2709684 streptozotocin NN B-NP D013311
17 113 114 2709684 - HYPH B-NP O
18 114 121 2709684 induced VBN I-NP O
19 122 130 2709684 diabetes NN I-NP D003920
20 131 139 2709684 mellitus NN I-NP D003920
21 140 141 2709684 ( ( O O
22 141 143 2709684 DM NN B-NP D003920
23 143 144 2709684 ) ) O O
24 145 149 2709684 have VBP B-VP O
25 150 151 2709684 a DT B-NP O
26 152 156 2709684 high JJ I-NP O
27 157 163 2709684 solute JJ I-NP O
28 164 172 2709684 diuresis NN I-NP O
29 173 174 2709684 ( ( O O
30 174 184 2709684 glycosuria NN B-NP D006029
31 185 187 2709684 of IN B-PP O
32 188 190 2709684 10 CD B-NP O
33 191 193 2709684 to TO I-NP O
34 194 196 2709684 12 CD I-NP O
35 197 198 2709684 g NN I-NP O
36 198 199 2709684 / SYM B-NP O
37 199 202 2709684 day NN I-NP O
38 202 203 2709684 ) ) O O
39 203 204 2709684 , , O O
40 205 207 2709684 we PRP B-NP O
41 208 212 2709684 have VBP B-VP O
42 213 222 2709684 suggested VBN I-VP O
43 223 227 2709684 that IN B-SBAR O
44 228 232 2709684 this DT B-NP O
45 233 236 2709684 may NN I-NP O
46 237 239 2709684 in IN B-PP O
47 240 244 2709684 part NN B-NP O
48 245 247 2709684 be VB B-VP O
49 248 259 2709684 responsible JJ B-ADJP O
50 260 263 2709684 for IN B-PP O
51 264 269 2709684 their PRP$ B-NP O
52 270 280 2709684 resistance NN I-NP O
53 281 283 2709684 to TO B-PP O
54 284 294 2709684 gentamicin NN B-NP D005839
55 294 295 2709684 - HYPH B-NP O
56 295 302 2709684 induced VBN I-NP O
57 303 308 2709684 acute JJ I-NP D058186
58 309 314 2709684 renal JJ I-NP D058186
59 315 322 2709684 failure NN I-NP D058186
60 323 324 2709684 ( ( O O
61 324 327 2709684 ARF NN B-NP D058186
62 327 328 2709684 ) ) O O
63 328 329 2709684 . . O O

1 330 333 2709684 The DT B-NP O
2 334 344 2709684 protection NN I-NP O
3 345 349 2709684 from IN B-PP O
4 350 360 2709684 gentamicin NN B-NP D005839
5 361 375 2709684 nephrotoxicity NN I-NP D007674
6 376 379 2709684 was VBD B-VP O
7 380 387 2709684 studied VBN I-VP O
8 388 390 2709684 in IN B-PP O
9 391 394 2709684 non AFX B-NP O
10 394 395 2709684 - HYPH I-NP O
11 395 403 2709684 diabetic JJ B-NP D003920
12 404 408 2709684 rats NNS I-NP O
13 409 413 2709684 with IN B-PP O
14 414 421 2709684 chronic JJ B-NP O
15 422 428 2709684 solute JJ I-NP O
16 429 437 2709684 diuresis NN I-NP O
17 438 445 2709684 induced VBN B-VP O
18 446 448 2709684 by IN B-PP O
19 449 457 2709684 blockage NN B-NP O
20 458 460 2709684 of IN B-PP O
21 461 468 2709684 tubular JJ B-NP O
22 469 476 2709684 glucose NN I-NP D005947
23 477 489 2709684 reabsorption NN I-NP O
24 490 494 2709684 with IN B-PP O
25 495 504 2709684 phlorizin NN B-NP D010695
26 505 506 2709684 ( ( O O
27 506 507 2709684 P NN B-NP D010695
28 507 508 2709684 ) ) O O
29 508 509 2709684 . . O O

1 510 512 2709684 DM NN B-NP D003920
2 513 517 2709684 rats NNS I-NP O
3 518 522 2709684 with IN B-PP O
4 523 527 2709684 mild JJ B-NP O
5 528 538 2709684 glycosuria NN I-NP D006029
6 539 540 2709684 ( ( O O
7 540 547 2709684 similar JJ B-ADJP O
8 548 550 2709684 in IN B-PP O
9 551 557 2709684 degree NN B-NP O
10 558 560 2709684 to TO B-PP O
11 561 565 2709684 that DT B-NP O
12 566 568 2709684 of IN B-PP O
13 569 572 2709684 the DT B-NP O
14 573 574 2709684 P NN I-NP D010695
15 575 582 2709684 treated VBN I-NP O
16 583 590 2709684 animals NNS I-NP O
17 590 591 2709684 ) ) O O
18 592 596 2709684 were VBD B-VP O
19 597 601 2709684 also RB I-VP O
20 602 609 2709684 studied VBN I-VP O
21 609 610 2709684 . . O O

1 611 625 2709684 Unanesthetized JJ B-NP O
2 626 631 2709684 adult JJ I-NP O
3 632 638 2709684 female NN I-NP O
4 638 639 2709684 , , O O
5 640 647 2709684 Sprague NNP B-NP O
6 647 648 2709684 - HYPH I-NP O
7 648 654 2709684 Dawley NNP I-NP O
8 655 659 2709684 rats NNS I-NP O
9 660 664 2709684 were VBD B-VP O
10 665 672 2709684 divided VBN I-VP O
11 673 675 2709684 in IN B-PP O
12 676 680 2709684 four CD B-NP O
13 681 687 2709684 groups NNS I-NP O
14 688 691 2709684 and CC O O
15 692 699 2709684 studied VBN B-VP O
16 700 703 2709684 for IN B-PP O
17 704 706 2709684 15 CD B-NP O
18 707 711 2709684 days NNS I-NP O
19 711 712 2709684 . . O O

1 713 718 2709684 Group NN B-NP O
2 719 720 2709684 1 CD I-NP O
3 721 722 2709684 ( ( O O
4 722 723 2709684 P NN B-NP D010695
5 724 729 2709684 alone RB B-ADVP O
6 729 730 2709684 ) ) O O
7 731 739 2709684 received VBD B-VP O
8 740 741 2709684 P NN B-NP D010695
9 741 742 2709684 , , O O
10 743 746 2709684 360 CD B-NP O
11 747 749 2709684 mg NN I-NP O
12 749 750 2709684 / SYM B-NP O
13 750 753 2709684 day NN I-NP O
14 753 754 2709684 , , O O
15 755 758 2709684 for IN B-PP O
16 759 761 2709684 15 CD B-NP O
17 762 766 2709684 days NNS I-NP O
18 766 767 2709684 ; : O O
19 768 773 2709684 Group NN B-NP O
20 774 776 2709684 II CD I-NP O
21 777 778 2709684 ( ( O O
22 778 779 2709684 P NN B-NP D010695
23 780 781 2709684 + SYM O O
24 782 792 2709684 gentamicin NN B-NP D005839
25 792 793 2709684 ) ) O O
26 793 794 2709684 ; : O O
27 795 800 2709684 Group NN B-NP O
28 801 804 2709684 III CD I-NP O
29 805 806 2709684 ( ( O O
30 806 816 2709684 gentamicin NN B-NP D005839
31 817 822 2709684 alone RB B-ADVP O
32 822 823 2709684 ) ) O O
33 824 827 2709684 and CC O O
34 828 833 2709684 Group NN B-NP O
35 834 836 2709684 IV CD I-NP O
36 837 838 2709684 ( ( O O
37 838 842 2709684 mild JJ B-NP O
38 843 845 2709684 DM NN I-NP D003920
39 846 847 2709684 + SYM B-NP O
40 848 858 2709684 gentamicin NN I-NP D005839
41 858 859 2709684 ) ) O O
42 859 860 2709684 . . O O

1 861 872 2709684 Nephrotoxic JJ B-NP D007674
2 873 878 2709684 doses NNS I-NP O
3 879 880 2709684 ( ( O O
4 880 882 2709684 40 CD B-NP O
5 883 885 2709684 mg NN I-NP O
6 885 886 2709684 / SYM B-NP O
7 886 888 2709684 kg NN I-NP O
8 889 893 2709684 body NN I-NP O
9 894 896 2709684 wt NN I-NP O
10 896 897 2709684 / SYM B-NP O
11 897 900 2709684 day NN I-NP O
12 900 901 2709684 ) ) O O
13 902 904 2709684 of IN B-PP O
14 905 915 2709684 gentamicin NN B-NP D005839
15 916 920 2709684 were VBD B-VP O
16 921 929 2709684 injected VBN I-VP O
17 930 936 2709684 during IN B-PP O
18 937 940 2709684 the DT B-NP O
19 941 945 2709684 last JJ I-NP O
20 946 950 2709684 nine CD I-NP O
21 951 955 2709684 days NNS I-NP O
22 956 958 2709684 of IN B-PP O
23 959 964 2709684 study NN B-NP O
24 965 967 2709684 to TO B-PP O
25 968 971 2709684 the DT B-NP O
26 972 979 2709684 animals NNS I-NP O
27 980 982 2709684 of IN B-PP O
28 983 989 2709684 groups NNS B-NP O
29 990 992 2709684 II CD B-NP O
30 993 995 2709684 to TO B-PP O
31 996 998 2709684 IV CD B-NP O
32 998 999 2709684 . . O O

1 1000 1002 2709684 In IN B-PP O
2 1003 1008 2709684 Group NN B-NP O
3 1009 1010 2709684 I NN I-NP O
4 1010 1011 2709684 , , O O
5 1012 1013 2709684 P NN B-NP D010695
6 1014 1021 2709684 induced VBD B-VP O
7 1022 1023 2709684 a DT B-NP O
8 1024 1032 2709684 moderate JJ I-NP O
9 1033 1036 2709684 and CC I-NP O
10 1037 1043 2709684 stable JJ I-NP O
11 1044 1054 2709684 glycosuria NN I-NP D006029
12 1055 1056 2709684 ( ( O O
13 1056 1059 2709684 3.9 CD B-NP O
14 1060 1061 2709684 + SYM O O
15 1061 1062 2709684 / SYM O O
16 1062 1063 2709684 - SYM O O
17 1064 1067 2709684 0.1 CD B-NP O
18 1068 1069 2709684 g NN I-NP O
19 1069 1070 2709684 / SYM B-NP O
20 1070 1073 2709684 day NN I-NP O
21 1073 1074 2709684 , , O O
22 1075 1077 2709684 SE NN B-NP O
23 1077 1078 2709684 ) ) O O
24 1078 1079 2709684 , , O O
25 1080 1083 2709684 and CC O O
26 1084 1086 2709684 no DT B-NP O
27 1087 1097 2709684 functional JJ I-NP O
28 1098 1100 2709684 or CC I-NP O
29 1101 1112 2709684 morphologic JJ I-NP O
30 1113 1121 2709684 evidence NN I-NP O
31 1122 1124 2709684 of IN B-PP O
32 1125 1130 2709684 renal JJ B-NP D007674
33 1131 1142 2709684 dysfunction NN I-NP D007674
34 1143 1144 2709684 ( ( O O
35 1144 1152 2709684 baseline NN B-NP O
36 1153 1156 2709684 CCr NN I-NP O
37 1157 1160 2709684 2.1 CD I-NP O
38 1161 1162 2709684 + SYM O O
39 1162 1163 2709684 / SYM O O
40 1163 1164 2709684 - SYM O O
41 1165 1168 2709684 0.1 CD B-NP O
42 1169 1171 2709684 ml NN I-NP O
43 1171 1172 2709684 / SYM B-NP O
44 1172 1175 2709684 min NN I-NP O
45 1175 1176 2709684 , , O O
46 1177 1189 2709684 undetectable JJ B-NP O
47 1190 1201 2709684 lysozymuria NN I-NP O
48 1201 1202 2709684 ) ) O O
49 1203 1205 2709684 or CC O O
50 1206 1212 2709684 damage NN B-NP O
51 1213 1214 2709684 ( ( O O
52 1214 1221 2709684 tubular JJ B-NP D009956
53 1222 1230 2709684 necrosis NN I-NP D009956
54 1231 1236 2709684 score NN I-NP O
55 1237 1238 2709684 [ ( O O
56 1238 1245 2709684 maximum NN B-NP O
57 1246 1247 2709684 4 CD I-NP O
58 1247 1248 2709684 ] ) O O
59 1248 1249 2709684 , , O O
60 1250 1254 2709684 zero CD B-NP O
61 1254 1255 2709684 ) ) O O
62 1255 1256 2709684 . . O O

1 1257 1259 2709684 In IN B-PP O
2 1260 1265 2709684 Group NN B-NP O
3 1266 1268 2709684 II CD I-NP O
4 1268 1269 2709684 , , O O
5 1270 1271 2709684 P NN B-NP D010695
6 1272 1275 2709684 did VBD B-VP O
7 1276 1279 2709684 not RB I-VP O
8 1280 1287 2709684 prevent VB I-VP O
9 1288 1298 2709684 gentamicin NN B-NP D005839
10 1298 1299 2709684 - HYPH B-NP O
11 1299 1302 2709684 ARF NN I-NP D058186
12 1303 1304 2709684 ( ( O O
13 1304 1311 2709684 maximal JJ B-NP O
14 1312 1320 2709684 decrease NN I-NP O
15 1321 1323 2709684 in IN B-PP O
16 1324 1327 2709684 CCr NN B-NP O
17 1328 1330 2709684 at IN B-PP O
18 1331 1334 2709684 day NN B-NP O
19 1335 1340 2709684 9.89% NN I-NP O
20 1340 1341 2709684 , , O O
21 1342 1343 2709684 P NN B-NP D010695
22 1344 1348 2709684 less JJR B-ADJP O
23 1349 1353 2709684 than IN B-PP O
24 1354 1359 2709684 0.001 CD B-NP O
25 1359 1360 2709684 ; : O O
26 1361 1365 2709684 peak JJ B-NP O
27 1366 1377 2709684 lysozymuria NN I-NP O
28 1377 1378 2709684 , , O O
29 1379 1383 2709684 1863 CD B-NP O
30 1384 1385 2709684 + SYM O O
31 1385 1386 2709684 / SYM O O
32 1386 1387 2709684 - SYM B-NP O
33 1388 1391 2709684 321 CD B-NP O
34 1392 1402 2709684 micrograms NNS I-NP O
35 1402 1403 2709684 / SYM B-NP O
36 1403 1406 2709684 day NN I-NP O
37 1406 1407 2709684 ; : O O
38 1408 1411 2709684 and CC O O
39 1412 1419 2709684 tubular JJ B-NP D009956
40 1420 1428 2709684 necrosis NN I-NP D009956
41 1429 1434 2709684 score NN I-NP O
42 1434 1435 2709684 , , O O
43 1436 1439 2709684 3.9 CD B-NP O
44 1440 1441 2709684 + SYM O O
45 1441 1442 2709684 / SYM O O
46 1442 1443 2709684 - SYM O O
47 1444 1447 2709684 0.1 CD B-NP O
48 1447 1448 2709684 ) ) O O
49 1448 1449 2709684 . . O O

1 1450 1455 2709684 These DT B-NP O
2 1456 1462 2709684 values NNS I-NP O
3 1463 1467 2709684 were VBD B-VP O
4 1468 1471 2709684 not RB B-ADJP O
5 1472 1481 2709684 different JJ I-ADJP O
6 1482 1486 2709684 from IN B-PP O
7 1487 1492 2709684 those DT B-NP O
8 1493 1495 2709684 of IN B-PP O
9 1496 1501 2709684 Group NN B-NP O
10 1502 1505 2709684 III CD I-NP O
11 1505 1506 2709684 : : O O
12 1507 1514 2709684 maximal JJ B-NP O
13 1515 1523 2709684 decrease NN I-NP O
14 1524 1526 2709684 in IN B-PP O
15 1527 1530 2709684 CCr NN B-NP O
16 1531 1534 2709684 73% NN I-NP O
17 1535 1536 2709684 ( ( O O
18 1536 1537 2709684 P NN B-NP D010695
19 1538 1542 2709684 less JJR B-ADJP O
20 1543 1547 2709684 than IN B-PP O
21 1548 1553 2709684 0.001 CD B-NP O
22 1553 1554 2709684 ) ) O O
23 1554 1555 2709684 ; : O O
24 1556 1567 2709684 lysozymuria NN B-NP O
25 1567 1568 2709684 , , O O
26 1569 1573 2709684 2147 CD B-NP O
27 1574 1575 2709684 + SYM O O
28 1575 1576 2709684 / SYM O O
29 1576 1577 2709684 - SYM B-NP O
30 1578 1581 2709684 701 CD B-NP O
31 1582 1592 2709684 micrograms NNS I-NP O
32 1592 1593 2709684 / SYM B-NP O
33 1593 1596 2709684 day NN I-NP O
34 1596 1597 2709684 ; : O O
35 1598 1605 2709684 tubular JJ B-NP D009956
36 1606 1614 2709684 necrosis NN I-NP D009956
37 1615 1620 2709684 score NN I-NP O
38 1620 1621 2709684 , , O O
39 1622 1625 2709684 3.8 CD B-NP O
40 1626 1627 2709684 + SYM O O
41 1627 1628 2709684 / SYM O O
42 1628 1629 2709684 - HYPH O O
43 1630 1643 2709684 0.1.(ABSTRACT NN B-NP O
44 1644 1653 2709684 TRUNCATED VBN B-VP O
45 1654 1656 2709684 AT IN B-PP O
46 1657 1660 2709684 250 CD B-NP O
47 1661 1666 2709684 WORDS NNS I-NP O
48 1666 1667 2709684 ) ) O O

1 0 0 384871 -DOCSTART- -X- -X- O

1 0 9 384871 Bilateral JJ B-NP D009901
2 10 15 384871 optic JJ I-NP D009901
3 16 26 384871 neuropathy NN I-NP D009901
4 27 30 384871 due JJ B-PP O
5 31 33 384871 to TO B-PP O
6 34 42 384871 combined VBN B-NP O
7 43 53 384871 ethambutol NN I-NP D004977
8 54 57 384871 and CC I-NP O
9 58 67 384871 isoniazid NN I-NP D007538
10 68 77 384871 treatment NN I-NP O
11 77 78 384871 . . O O
12 79 82 384871 The DT B-NP O
13 83 87 384871 case NN I-NP O
14 88 90 384871 of IN B-PP O
15 91 92 384871 a DT B-NP O
16 93 95 384871 40 CD I-NP O
17 95 96 384871 - HYPH I-NP O
18 96 100 384871 year NN I-NP O
19 100 101 384871 - HYPH B-NP O
20 101 104 384871 old JJ I-NP O
21 105 112 384871 patient NN I-NP O
22 113 116 384871 who WP B-NP O
23 117 126 384871 underwent VBD B-VP O
24 127 129 384871 an DT B-NP O
25 130 142 384871 unsuccessful JJ I-NP O
26 143 150 384871 cadaver NN I-NP O
27 151 157 384871 kidney NN I-NP O
28 158 173 384871 transplantation NN I-NP O
29 174 177 384871 and CC O O
30 178 181 384871 was VBD B-VP O
31 182 189 384871 treated VBN I-VP O
32 190 194 384871 with IN B-PP O
33 195 205 384871 ethambutol NN B-NP D004977
34 206 209 384871 and CC I-NP O
35 210 219 384871 isoniazid NN I-NP D007538
36 220 222 384871 is VBZ B-VP O
37 223 231 384871 reported VBN I-VP O
38 231 232 384871 . . O O

1 233 234 384871 A DT B-NP O
2 235 244 384871 bilateral JJ I-NP D009901
3 245 256 384871 retrobulbar NN I-NP D009901
4 257 267 384871 neuropathy NN I-NP D009901
5 268 272 384871 with IN B-PP O
6 273 275 384871 an DT B-NP O
7 276 283 384871 unusual JJ I-NP O
8 284 291 384871 central JJ I-NP O
9 292 302 384871 bitemporal JJ I-NP O
10 303 313 384871 hemianopic JJ I-NP O
11 314 321 384871 scotoma NN I-NP D012607
12 322 325 384871 was VBD B-VP O
13 326 331 384871 found VBN I-VP O
14 331 332 384871 . . O O

1 333 343 384871 Ethambutol NN B-NP D004977
2 344 347 384871 was VBD B-VP O
3 348 355 384871 stopped VBN I-VP O
4 356 359 384871 and CC O O
5 360 364 384871 only RB B-NP O
6 365 370 384871 small JJ I-NP O
7 371 382 384871 improvement NN I-NP O
8 383 385 384871 of IN B-PP O
9 386 389 384871 the DT B-NP O
10 390 396 384871 visual JJ I-NP O
11 397 403 384871 acuity NN I-NP O
12 404 412 384871 followed VBD B-VP O
13 412 413 384871 . . O O

1 414 423 384871 Isoniazid NN B-NP D007538
2 424 427 384871 was VBD B-VP O
3 428 440 384871 discontinued VBN I-VP O
4 441 446 384871 later RB B-ADVP O
5 446 447 384871 , , O O
6 448 456 384871 followed VBN B-VP O
7 457 459 384871 by IN B-PP O
8 460 461 384871 a DT B-NP O
9 462 470 384871 dramatic JJ I-NP O
10 471 482 384871 improvement NN I-NP O
11 483 485 384871 in IN B-PP O
12 486 489 384871 the DT B-NP O
13 490 496 384871 visual JJ I-NP O
14 497 503 384871 acuity NN I-NP O
15 503 504 384871 . . O O

1 505 508 384871 The DT B-NP O
2 509 516 384871 hazards NNS I-NP O
3 517 519 384871 of IN B-PP O
4 520 525 384871 optic JJ B-NP O
5 526 531 384871 nerve NN I-NP O
6 532 540 384871 toxicity NN I-NP D064420
7 541 544 384871 due IN B-PP O
8 545 547 384871 to TO I-PP O
9 548 558 384871 ethambutol NN B-NP D004977
10 559 562 384871 are VBP B-VP O
11 563 568 384871 known VBN I-VP O
12 568 569 384871 . . O O

1 570 572 384871 We PRP B-NP O
2 573 582 384871 emphasize VBP B-VP O
3 583 586 384871 the DT B-NP O
4 587 596 384871 potential JJ I-NP O
5 597 603 384871 danger NN I-NP O
6 604 606 384871 in IN B-PP O
7 607 610 384871 the DT B-NP O
8 611 614 384871 use NN I-NP O
9 615 617 384871 of IN B-PP O
10 618 628 384871 ethambutol NN B-NP D004977
11 629 632 384871 and CC I-NP O
12 633 642 384871 isoniazid NN I-NP D007538
13 642 643 384871 . . O O

1 0 0 9022662 -DOCSTART- -X- -X- O

1 0 8 9022662 Pemoline NN B-NP D010389
2 9 16 9022662 induced VBD B-VP O
3 17 22 9022662 acute JJ B-NP O
4 23 38 9022662 choreoathetosis NN I-NP D002819
5 38 39 9022662 : : O O
6 40 44 9022662 case NN B-NP O
7 45 51 9022662 report NN I-NP O
8 52 55 9022662 and CC O O
9 56 62 9022662 review NN B-NP O
10 63 65 9022662 of IN B-PP O
11 66 69 9022662 the DT B-NP O
12 70 80 9022662 literature NN I-NP O
13 80 81 9022662 . . I-NP O
14 82 92 9022662 BACKGROUND NN I-NP O
15 92 93 9022662 : : O O
16 94 102 9022662 Pemoline NN B-NP D010389
17 103 105 9022662 is VBZ B-VP O
18 106 108 9022662 an DT B-NP O
19 109 120 9022662 oxazolidine NN I-NP C064210
20 121 131 9022662 derivative NN I-NP O
21 132 136 9022662 that WDT B-NP O
22 137 139 9022662 is VBZ B-VP O
23 140 152 9022662 structurally RB B-ADJP O
24 153 162 9022662 different JJ I-ADJP O
25 163 167 9022662 from IN B-PP O
26 168 180 9022662 amphetamines NNS B-NP D000662
27 181 184 9022662 and CC O O
28 185 189 9022662 used VBN B-VP O
29 190 192 9022662 in IN B-PP O
30 193 196 9022662 the DT B-NP O
31 197 206 9022662 treatment NN I-NP O
32 207 209 9022662 of IN B-PP O
33 210 219 9022662 attention NN B-NP D001289
34 220 227 9022662 deficit NN I-NP D001289
35 228 236 9022662 disorder NN I-NP D001289
36 236 237 9022662 . . O O

1 238 246 9022662 Pemoline NN B-NP D010389
2 247 250 9022662 has VBZ B-VP O
3 251 254 9022662 not RB I-VP O
4 255 259 9022662 been VBN I-VP O
5 260 268 9022662 commonly RB I-VP O
6 269 279 9022662 associated VBN I-VP O
7 280 282 9022662 in IN B-PP O
8 283 286 9022662 the DT B-NP O
9 287 297 9022662 literature NN I-NP O
10 298 300 9022662 as IN B-PP O
11 301 302 9022662 a DT B-NP O
12 303 308 9022662 cause NN I-NP O
13 309 311 9022662 of IN B-PP O
14 312 317 9022662 acute JJ B-NP O
15 318 326 9022662 movement NN I-NP D009069
16 327 336 9022662 disorders NNS I-NP D009069
17 336 337 9022662 . . O O

1 338 341 9022662 The DT B-NP O
2 342 351 9022662 following VBG I-NP O
3 352 356 9022662 case NN I-NP O
4 357 366 9022662 describes VBZ B-VP O
5 367 370 9022662 two CD B-NP O
6 371 379 9022662 children NNS I-NP O
7 380 387 9022662 acutely RB B-VP O
8 388 396 9022662 poisoned VBN I-VP O
9 397 401 9022662 with IN B-PP O
10 402 410 9022662 pemoline NN B-NP D010389
11 411 414 9022662 who WP B-NP O
12 415 426 9022662 experienced VBD B-VP O
13 427 435 9022662 profound JJ B-NP O
14 436 451 9022662 choreoathetosis NN I-NP D002819
15 451 452 9022662 . . O O

1 453 457 9022662 CASE NN B-NP O
2 458 464 9022662 REPORT NN I-NP O
3 464 465 9022662 : : O O
4 466 469 9022662 Two CD B-NP O
5 469 470 9022662 , , I-NP O
6 471 472 9022662 3 CD I-NP O
7 472 473 9022662 - HYPH I-NP O
8 473 477 9022662 year NN I-NP O
9 477 478 9022662 - HYPH O O
10 478 481 9022662 old JJ B-NP O
11 482 486 9022662 male JJ I-NP O
12 486 487 9022662 , , I-NP O
13 488 497 9022662 identical JJ I-NP O
14 498 502 9022662 twin NN I-NP O
15 503 511 9022662 siblings NNS I-NP O
16 512 521 9022662 presented VBN B-VP O
17 522 524 9022662 to TO B-PP O
18 525 528 9022662 the DT B-NP O
19 529 538 9022662 emergency NN I-NP O
20 539 549 9022662 department NN I-NP O
21 550 555 9022662 after IN B-PP O
22 556 561 9022662 found VBN B-NP O
23 562 569 9022662 playing NN I-NP O
24 570 574 9022662 with IN B-PP O
25 575 576 9022662 a DT B-NP O
26 577 579 9022662 an DT I-NP O
27 580 585 9022662 empty JJ I-NP O
28 586 592 9022662 bottle NN I-NP O
29 593 595 9022662 of IN B-PP O
30 596 604 9022662 pemoline NN B-NP D010389
31 605 615 9022662 originally RB B-VP O
32 616 626 9022662 containing VBG I-VP O
33 627 629 9022662 59 CD B-NP O
34 630 637 9022662 tablets NNS I-NP O
35 637 638 9022662 . . O O

1 639 642 9022662 The DT B-NP O
2 643 651 9022662 children NNS I-NP O
3 652 655 9022662 had VBD B-VP O
4 656 657 9022662 a DT B-NP O
5 658 665 9022662 medical JJ I-NP O
6 666 673 9022662 history NN I-NP O
7 674 685 9022662 significant JJ B-ADJP O
8 686 689 9022662 for IN B-PP O
9 690 699 9022662 attention NN B-NP D001289
10 700 707 9022662 deficit NN I-NP D001289
11 708 716 9022662 disorder NN I-NP D001289
12 717 727 9022662 previously RB B-VP O
13 728 735 9022662 treated VBN I-VP O
14 736 740 9022662 with IN B-PP O
15 741 756 9022662 methylphenidate NN B-NP D008774
16 757 764 9022662 without IN B-PP O
17 765 772 9022662 success NN B-NP O
18 772 773 9022662 . . O O

1 774 778 9022662 This DT B-NP O
2 779 782 9022662 was VBD B-VP O
3 783 788 9022662 their PRP$ B-NP O
4 789 794 9022662 first JJ I-NP O
5 795 798 9022662 day NN I-NP O
6 799 801 9022662 of IN B-PP O
7 802 810 9022662 pemoline NN B-NP D010389
8 811 818 9022662 therapy NN I-NP O
9 818 819 9022662 . . O O

1 820 823 9022662 The DT B-NP O
2 824 838 9022662 choreoathetoid JJ I-NP D002819
3 839 848 9022662 movements NNS I-NP O
4 849 854 9022662 began VBD B-VP O
5 855 857 9022662 45 CD B-NP O
6 858 861 9022662 min NN I-NP O
7 862 864 9022662 to TO B-PP O
8 865 866 9022662 1 CD B-NP O
9 867 868 9022662 h NN I-NP O
10 869 874 9022662 after IN B-PP O
11 875 884 9022662 ingestion NN B-NP O
12 884 885 9022662 . . O O

1 886 889 9022662 The DT B-NP O
2 890 898 9022662 children NNS I-NP O
3 899 903 9022662 gave VBD B-VP O
4 904 906 9022662 no DT B-NP O
5 907 914 9022662 history NN I-NP O
6 915 917 9022662 of IN B-PP O
7 918 923 9022662 prior JJ B-NP O
8 924 932 9022662 movement NN I-NP D009069
9 933 942 9022662 disorders NNS I-NP D009069
10 943 946 9022662 and CC O O
11 947 952 9022662 there EX B-NP O
12 953 956 9022662 was VBD B-VP O
13 957 959 9022662 no DT B-NP O
14 960 966 9022662 family NN I-NP O
15 967 974 9022662 history NN I-NP O
16 975 977 9022662 of IN B-PP O
17 978 986 9022662 movement NN B-NP D009069
18 987 996 9022662 disorders NNS I-NP D009069
19 996 997 9022662 . . O O

1 998 1001 9022662 The DT B-NP O
2 1002 1010 9022662 children NNS I-NP O
3 1011 1019 9022662 received VBD B-VP O
4 1020 1036 9022662 gastrointestinal JJ B-NP O
5 1037 1052 9022662 decontamination NN I-NP O
6 1053 1056 9022662 and CC O O
7 1057 1061 9022662 high JJ B-NP O
8 1062 1067 9022662 doses NNS I-NP O
9 1068 1070 9022662 of IN B-PP O
10 1071 1082 9022662 intravenous JJ B-NP O
11 1083 1098 9022662 benzodiazepines NNS I-NP D001569
12 1099 1101 9022662 in IN B-PP O
13 1102 1104 9022662 an DT B-NP O
14 1105 1112 9022662 attempt NN I-NP O
15 1113 1115 9022662 to TO B-VP O
16 1116 1123 9022662 control VB I-VP O
17 1124 1127 9022662 the DT B-NP O
18 1128 1142 9022662 choreoathetoid JJ I-NP D002819
19 1143 1152 9022662 movements NNS I-NP O
20 1152 1153 9022662 . . O O

1 1154 1161 9022662 Despite IN B-PP O
2 1162 1171 9022662 treatment NN B-NP O
3 1171 1172 9022662 , , O O
4 1173 1176 9022662 the DT B-NP O
5 1177 1185 9022662 children NNS I-NP O
6 1186 1195 9022662 continued VBD B-VP O
7 1196 1198 9022662 to TO I-VP O
8 1199 1203 9022662 have VB I-VP O
9 1204 1219 9022662 choreoathetosis NN B-NP D002819
10 1220 1223 9022662 for IN B-PP O
11 1224 1237 9022662 approximately RB B-NP O
12 1238 1240 9022662 24 CD I-NP O
13 1241 1246 9022662 hours NNS I-NP O
14 1246 1247 9022662 . . O O

1 1248 1253 9022662 Forty CD B-NP O
2 1253 1254 9022662 - HYPH I-NP O
3 1254 1259 9022662 eight CD I-NP O
4 1260 1265 9022662 hours NNS I-NP O
5 1266 1271 9022662 after IN B-PP O
6 1272 1281 9022662 admission NN B-NP O
7 1281 1282 9022662 , , O O
8 1283 1286 9022662 the DT B-NP O
9 1287 1295 9022662 children NNS I-NP O
10 1296 1304 9022662 appeared VBD B-VP O
11 1305 1307 9022662 to TO I-VP O
12 1308 1310 9022662 be VB I-VP O
13 1311 1313 9022662 at IN B-PP O
14 1314 1319 9022662 their PRP$ B-NP O
15 1320 1328 9022662 baseline NN I-NP O
16 1329 1332 9022662 and CC O O
17 1333 1337 9022662 were VBD B-VP O
18 1338 1348 9022662 discharged VBN I-VP O
19 1349 1353 9022662 home NN B-NP O
20 1353 1354 9022662 . . O O

1 1355 1365 9022662 CONCLUSION NN B-NP O
2 1365 1366 9022662 : : O O
3 1367 1375 9022662 Pemoline NN B-NP D010389
4 1376 1386 9022662 associated VBN I-NP O
5 1387 1395 9022662 movement NN I-NP D009069
6 1396 1404 9022662 disorder NN I-NP D009069
7 1405 1408 9022662 has VBZ B-VP O
8 1409 1413 9022662 been VBN I-VP O
9 1414 1420 9022662 rarely RB I-VP O
10 1421 1429 9022662 reported VBN I-VP O
11 1430 1432 9022662 in IN B-PP O
12 1433 1436 9022662 the DT B-NP O
13 1437 1442 9022662 acute JJ I-NP O
14 1443 1453 9022662 toxicology NN I-NP O
15 1454 1464 9022662 literature NN I-NP O
16 1464 1465 9022662 . . O O

1 1466 1469 9022662 The DT B-NP O
2 1470 1481 9022662 possibility NN I-NP O
3 1482 1484 9022662 of IN B-PP O
4 1485 1499 9022662 choreoathetoid JJ B-NP D002819
5 1500 1509 9022662 movements NNS I-NP O
6 1510 1516 9022662 should MD B-VP O
7 1517 1519 9022662 be VB I-VP O
8 1520 1530 9022662 considered VBN I-VP O
9 1531 1533 9022662 in IN B-PP O
10 1534 1542 9022662 patients NNS B-NP O
11 1543 1553 9022662 presenting VBG B-VP O
12 1554 1559 9022662 after IN B-PP O
13 1560 1568 9022662 pemoline NN B-NP D010389
14 1569 1577 9022662 overdose NN I-NP D062787
15 1577 1578 9022662 . . O O

1 0 0 9226773 -DOCSTART- -X- -X- O

1 0 10 9226773 Persistent JJ B-NP O
2 11 22 9226773 nephrogenic JJ I-NP D018500
3 23 31 9226773 diabetes NN I-NP D018500
4 32 41 9226773 insipidus NN I-NP D018500
5 42 51 9226773 following VBG B-PP O
6 52 59 9226773 lithium NN B-NP D008094
7 60 67 9226773 therapy NN I-NP O
8 67 68 9226773 . . O O
9 69 71 9226773 We PRP B-NP O
10 72 78 9226773 report VBP B-VP O
11 79 82 9226773 the DT B-NP O
12 83 87 9226773 case NN I-NP O
13 88 90 9226773 of IN B-PP O
14 91 92 9226773 a DT B-NP O
15 93 100 9226773 patient NN I-NP O
16 101 104 9226773 who WP B-NP O
17 105 114 9226773 developed VBD B-VP O
18 115 121 9226773 severe JJ B-NP O
19 122 136 9226773 hypernatraemic JJ I-NP O
20 137 148 9226773 dehydration NN I-NP D003681
21 149 158 9226773 following VBG B-PP O
22 159 160 9226773 a DT B-NP O
23 161 165 9226773 head NN I-NP D006259
24 166 172 9226773 injury NN I-NP D006259
25 172 173 9226773 . . O O

1 174 177 9226773 Ten CD B-NP O
2 178 183 9226773 years NNS I-NP O
3 184 194 9226773 previously RB B-ADVP O
4 195 197 9226773 he PRP B-NP O
5 198 201 9226773 had VBD B-VP O
6 202 206 9226773 been VBN I-VP O
7 207 216 9226773 diagnosed VBN I-VP O
8 217 219 9226773 to TO I-VP O
9 220 224 9226773 have VB I-VP O
10 225 232 9226773 lithium NN B-NP D008094
11 232 233 9226773 - HYPH O O
12 233 240 9226773 induced VBN B-NP O
13 241 252 9226773 nephrogenic JJ I-NP D018500
14 253 261 9226773 diabetes NN I-NP D018500
15 262 271 9226773 insipidus NN I-NP D018500
16 271 272 9226773 , , O O
17 273 276 9226773 and CC O O
18 277 284 9226773 lithium NN B-NP D008094
19 285 292 9226773 therapy NN I-NP O
20 293 296 9226773 had VBD B-VP O
21 297 301 9226773 been VBN I-VP O
22 302 314 9226773 discontinued VBN I-VP O
23 314 315 9226773 . . O O

1 316 318 9226773 He PRP B-NP O
2 319 327 9226773 remained VBD B-VP O
3 328 335 9226773 thirsty JJ B-ADJP O
4 336 339 9226773 and CC I-ADJP O
5 340 348 9226773 polyuric JJ I-ADJP D011141
6 349 356 9226773 despite IN B-PP O
7 357 366 9226773 cessation NN B-NP O
8 367 369 9226773 of IN B-PP O
9 370 377 9226773 lithium NN B-NP D008094
10 378 381 9226773 and CC I-NP O
11 382 396 9226773 investigations NNS I-NP O
12 397 399 9226773 on IN B-PP O
13 400 409 9226773 admission NN B-NP O
14 410 416 9226773 showed VBD B-VP O
15 417 420 9226773 him PRP B-NP O
16 421 423 9226773 to TO B-VP O
17 424 428 9226773 have VB I-VP O
18 429 435 9226773 normal JJ B-NP O
19 436 449 9226773 osmoregulated JJ I-NP O
20 450 456 9226773 thirst NN I-NP O
21 457 460 9226773 and CC I-NP O
22 461 472 9226773 vasopressin NN I-NP D014667
23 473 482 9226773 secretion NN I-NP O
24 482 483 9226773 , , O O
25 484 488 9226773 with IN B-PP O
26 489 494 9226773 clear JJ B-NP O
27 495 503 9226773 evidence NN I-NP O
28 504 506 9226773 of IN B-PP O
29 507 518 9226773 nephrogenic JJ B-NP D018500
30 519 527 9226773 diabetes NN I-NP D018500
31 528 537 9226773 insipidus NN I-NP D018500
32 537 538 9226773 . . O O

1 539 546 9226773 Lithium NN B-NP D008094
2 547 554 9226773 induced VBD B-VP O
3 555 566 9226773 nephrogenic JJ B-NP D018500
4 567 575 9226773 diabetes NN I-NP D018500
5 576 585 9226773 insipidus NN I-NP D018500
6 586 588 9226773 is VBZ B-VP O
7 589 599 9226773 considered VBN I-VP O
8 600 602 9226773 to TO I-VP O
9 603 605 9226773 be VB I-VP O
10 606 616 9226773 reversible JJ B-ADJP O
11 617 619 9226773 on IN B-PP O
12 620 629 9226773 cessation NN B-NP O
13 630 632 9226773 of IN B-PP O
14 633 640 9226773 therapy NN B-NP O
15 641 644 9226773 but CC O O
16 645 653 9226773 polyuria NN B-NP D011141
17 654 663 9226773 persisted VBD B-VP O
18 664 666 9226773 in IN B-PP O
19 667 671 9226773 this DT B-NP O
20 672 679 9226773 patient NN I-NP O
21 680 683 9226773 for IN B-PP O
22 684 687 9226773 ten CD B-NP O
23 688 693 9226773 years NNS I-NP O
24 694 699 9226773 after IN B-SBAR O
25 700 707 9226773 lithium NN B-NP D008094
26 708 711 9226773 was VBD B-VP O
27 712 719 9226773 stopped VBN I-VP O
28 719 720 9226773 . . O O

1 721 723 9226773 We PRP B-NP O
2 724 731 9226773 discuss VBP B-VP O
3 732 735 9226773 the DT B-NP O
4 736 744 9226773 possible JJ I-NP O
5 745 750 9226773 renal JJ I-NP O
6 751 761 9226773 mechanisms NNS I-NP O
7 762 765 9226773 and CC O O
8 766 769 9226773 the DT B-NP O
9 770 782 9226773 implications NNS I-NP O
10 783 786 9226773 for IN B-PP O
11 787 797 9226773 management NN B-NP O
12 798 800 9226773 of IN B-PP O
13 801 809 9226773 patients NNS B-NP O
14 810 814 9226773 with IN B-PP O
15 815 822 9226773 lithium NN B-NP D008094
16 822 823 9226773 - HYPH B-NP O
17 823 830 9226773 induced VBN I-NP O
18 831 842 9226773 nephrogenic JJ I-NP D018500
19 843 851 9226773 diabetes NN I-NP D018500
20 852 861 9226773 insipidus NN I-NP D018500
21 861 862 9226773 . . O O

1 0 0 804391 -DOCSTART- -X- -X- O

1 0 5 804391 Light NN B-NP O
2 6 11 804391 chain NN I-NP O
3 12 23 804391 proteinuria NN I-NP D011507
4 24 27 804391 and CC O O
5 28 36 804391 cellular JJ B-NP O
6 37 45 804391 mediated VBN I-NP O
7 46 54 804391 immunity NN I-NP O
8 55 57 804391 in IN B-PP O
9 58 66 804391 rifampin NN B-NP D012293
10 67 74 804391 treated VBN B-VP O
11 75 83 804391 patients NNS B-NP O
12 84 88 804391 with IN B-PP O
13 89 101 804391 tuberculosis NN B-NP D014376
14 101 102 804391 . . O O
15 103 108 804391 Light NN B-NP O
16 109 114 804391 chain NN I-NP O
17 115 126 804391 proteinuria NN I-NP D011507
18 127 130 804391 was VBD B-VP O
19 131 136 804391 found VBN I-VP O
20 137 139 804391 in IN B-PP O
21 140 141 804391 9 CD B-NP O
22 142 144 804391 of IN B-PP O
23 145 147 804391 17 CD B-NP O
24 148 160 804391 tuberculosis NN I-NP D014376
25 161 169 804391 patients NNS I-NP O
26 170 177 804391 treated VBN B-VP O
27 178 182 804391 with IN B-PP O
28 183 191 804391 rifampin NN B-NP D012293
29 191 192 804391 . . O O

1 193 204 804391 Concomitant JJ B-NP O
2 205 210 804391 assay NN I-NP O
3 211 213 804391 of IN B-PP O
4 214 222 804391 cellular JJ B-NP O
5 223 231 804391 mediated VBN I-NP O
6 232 240 804391 immunity NN I-NP O
7 241 243 804391 in IN B-PP O
8 244 249 804391 these DT B-NP O
9 250 258 804391 patients NNS I-NP O
10 259 264 804391 using VBG B-VP O
11 265 269 804391 skin NN B-NP O
12 270 274 804391 test NN I-NP O
13 275 282 804391 antigen NN I-NP O
14 283 286 804391 and CC O O
15 287 288 804391 a DT B-NP O
16 289 299 804391 lymphokine NN I-NP O
17 300 302 804391 in FW B-NP O
18 303 308 804391 vitro FW I-NP O
19 309 313 804391 test NN I-NP O
20 314 322 804391 provided VBD B-VP O
21 323 330 804391 results NNS B-NP O
22 331 335 804391 that WDT B-NP O
23 336 340 804391 were VBD B-VP O
24 341 350 804391 different JJ B-ADJP O
25 350 351 804391 . . O O

1 352 360 804391 Response NN B-NP O
2 361 363 804391 to TO B-PP O
3 364 372 804391 Varidase NN B-NP O
4 373 377 804391 skin NN I-NP O
5 378 382 804391 test NN I-NP O
6 383 390 804391 antigen NN I-NP O
7 391 394 804391 was VBD B-VP O
8 395 403 804391 negative JJ B-ADJP O
9 404 407 804391 for IN B-PP O
10 408 411 804391 all DT B-NP O
11 412 417 804391 eight CD I-NP O
12 418 430 804391 tuberculosis NN I-NP D014376
13 431 439 804391 patients NNS I-NP O
14 440 446 804391 tested VBN B-VP O
15 446 447 804391 , , O O
16 448 451 804391 but CC O O
17 452 457 804391 there EX B-NP O
18 458 466 804391 occurred VBD B-VP O
19 467 468 804391 a DT B-NP O
20 469 474 804391 hyper NN I-NP O
21 474 475 804391 - HYPH B-NP O
22 475 489 804391 responsiveness NN I-NP O
23 490 492 804391 of IN B-PP O
24 493 496 804391 the DT B-NP O
25 497 508 804391 lymphocytes NNS I-NP O
26 509 511 804391 of IN B-PP O
27 512 517 804391 these DT B-NP O
28 518 523 804391 eight CD I-NP O
29 524 532 804391 patients NNS I-NP O
30 533 535 804391 to TO B-PP O
31 536 548 804391 phytomitogen NN B-NP O
32 549 550 804391 ( ( O O
33 550 553 804391 PHA NN B-NP O
34 553 554 804391 - HYPH O O
35 554 555 804391 P NN B-NP O
36 555 556 804391 ) ) O O
37 556 557 804391 . . O O
38 558 560 804391 as RB B-CONJP O
39 561 565 804391 well RB I-CONJP O
40 566 568 804391 as IN I-CONJP O
41 569 571 804391 of IN B-PP O
42 572 577 804391 those DT B-NP O
43 578 580 804391 of IN B-PP O
44 581 586 804391 seven CD B-NP O
45 587 592 804391 other JJ I-NP O
46 593 604 804391 tuberculous JJ I-NP D014376
47 605 613 804391 patients NNS I-NP O
48 613 614 804391 . . O O

1 615 619 804391 This DT B-NP O
2 620 624 804391 last JJ I-NP O
3 625 632 804391 finding NN I-NP O
4 633 636 804391 may MD B-VP O
5 637 639 804391 be VB I-VP O
6 640 647 804391 related VBN I-VP O
7 648 650 804391 to TO B-PP O
8 651 655 804391 time NN B-NP O
9 656 658 804391 of IN B-PP O
10 659 666 804391 testing NN B-NP O
11 667 670 804391 and CC O O
12 670 671 804391 / SYM B-NP O
13 671 673 804391 or CC O O
14 674 684 804391 endogenous JJ B-NP O
15 685 690 804391 serum NN I-NP O
16 691 698 804391 binding NN I-NP O
17 699 701 804391 of IN B-PP O
18 702 710 804391 rifampin NN B-NP D012293
19 711 716 804391 which WDT B-NP O
20 717 722 804391 could MD B-VP O
21 723 727 804391 have VB I-VP O
22 728 737 804391 inhibited VBN I-VP O
23 738 745 804391 mitogen NN B-NP O
24 746 754 804391 activity NN I-NP O
25 755 758 804391 for IN B-PP O
26 759 762 804391 the DT B-NP O
27 763 773 804391 lymphocyte NN I-NP O
28 773 774 804391 . . O O

1 0 0 15075188 -DOCSTART- -X- -X- O

1 0 9 15075188 Increased VBN B-NP O
2 10 20 15075188 expression NN I-NP O
3 21 24 15075188 and CC O O
4 25 31 15075188 apical JJ B-NP O
5 32 41 15075188 targeting NN I-NP O
6 42 44 15075188 of IN B-PP O
7 45 50 15075188 renal JJ B-NP O
8 51 55 15075188 ENaC NN I-NP O
9 56 64 15075188 subunits NNS I-NP O
10 65 67 15075188 in IN B-PP O
11 68 77 15075188 puromycin NN B-NP D011692
12 78 93 15075188 aminonucleoside NN I-NP D011692
13 93 94 15075188 - HYPH O O
14 94 101 15075188 induced VBN B-NP O
15 102 111 15075188 nephrotic JJ I-NP D009404
16 112 120 15075188 syndrome NN I-NP D009404
17 121 123 15075188 in IN B-PP O
18 124 128 15075188 rats NNS B-NP O
19 128 129 15075188 . . O O
20 130 139 15075188 Nephrotic JJ B-NP D009404
21 140 148 15075188 syndrome NN I-NP D009404
22 149 151 15075188 is VBZ B-VP O
23 152 157 15075188 often RB I-VP O
24 158 169 15075188 accompanied VBN I-VP O
25 170 172 15075188 by IN B-PP O
26 173 179 15075188 sodium NN B-NP D012964
27 180 189 15075188 retention NN I-NP O
28 190 193 15075188 and CC O O
29 194 205 15075188 generalized VBN B-NP O
30 206 211 15075188 edema NN I-NP D004487
31 211 212 15075188 . . O O

1 213 220 15075188 However RB B-ADVP O
2 220 221 15075188 , , O O
3 222 225 15075188 the DT B-NP O
4 226 235 15075188 molecular JJ I-NP O
5 236 241 15075188 basis NN I-NP O
6 242 245 15075188 for IN B-PP O
7 246 249 15075188 the DT B-NP O
8 250 259 15075188 decreased VBN I-NP O
9 260 265 15075188 renal JJ I-NP O
10 266 272 15075188 sodium NN I-NP D012964
11 273 282 15075188 excretion NN I-NP O
12 283 290 15075188 remains VBZ B-VP O
13 291 300 15075188 undefined JJ B-ADJP O
14 300 301 15075188 . . O O

1 302 304 15075188 We PRP B-NP O
2 305 317 15075188 hypothesized VBD B-VP O
3 318 322 15075188 that IN B-SBAR O
4 323 333 15075188 epithelial JJ B-NP O
5 334 336 15075188 Na NN I-NP D012964
6 337 344 15075188 channel NN I-NP O
7 345 346 15075188 ( ( O O
8 346 350 15075188 ENaC NN B-NP O
9 350 351 15075188 ) ) O O
10 352 359 15075188 subunit NN B-NP O
11 360 373 15075188 dysregulation NN I-NP O
12 374 377 15075188 may MD B-VP O
13 378 380 15075188 be VB I-VP O
14 381 392 15075188 responsible JJ B-ADJP O
15 393 396 15075188 for IN B-PP O
16 397 400 15075188 the DT B-NP O
17 401 410 15075188 increased VBN I-NP O
18 411 417 15075188 sodium NN I-NP D012964
19 418 427 15075188 retention NN I-NP O
20 427 428 15075188 . . O O

1 429 431 15075188 An DT B-NP O
2 432 444 15075188 experimental JJ I-NP O
3 445 450 15075188 group NN I-NP O
4 451 453 15075188 of IN B-PP O
5 454 458 15075188 rats NNS B-NP O
6 459 462 15075188 was VBD B-VP O
7 463 470 15075188 treated VBN I-VP O
8 471 475 15075188 with IN B-PP O
9 476 485 15075188 puromycin NN B-NP D011692
10 486 501 15075188 aminonucleoside NN I-NP D011692
11 502 503 15075188 ( ( O O
12 503 506 15075188 PAN NN B-NP D011692
13 506 507 15075188 ; : O O
14 508 511 15075188 180 CD B-NP O
15 512 514 15075188 mg NN I-NP O
16 514 515 15075188 / SYM B-NP O
17 515 517 15075188 kg NN I-NP O
18 518 520 15075188 iv NN I-NP O
19 520 521 15075188 ) ) O O
20 521 522 15075188 , , O O
21 523 530 15075188 whereas IN O O
22 531 534 15075188 the DT B-NP O
23 535 542 15075188 control NN I-NP O
24 543 548 15075188 group NN I-NP O
25 549 557 15075188 received VBD B-VP O
26 558 562 15075188 only RB B-NP O
27 563 570 15075188 vehicle NN I-NP O
28 570 571 15075188 . . O O

1 572 577 15075188 After IN B-PP O
2 578 579 15075188 7 CD B-NP O
3 580 584 15075188 days NNS I-NP O
4 584 585 15075188 , , O O
5 586 589 15075188 PAN NN B-NP D011692
6 590 599 15075188 treatment NN I-NP O
7 600 607 15075188 induced VBD B-VP O
8 608 619 15075188 significant JJ B-NP O
9 620 631 15075188 proteinuria NN I-NP D011507
10 631 632 15075188 , , O O
11 633 648 15075188 hypoalbuminemia NN B-NP D034141
12 648 649 15075188 , , O O
13 650 659 15075188 decreased VBD B-VP O
14 660 667 15075188 urinary JJ B-NP O
15 668 674 15075188 sodium NN I-NP D012964
16 675 684 15075188 excretion NN I-NP O
17 684 685 15075188 , , O O
18 686 689 15075188 and CC O O
19 690 699 15075188 extensive JJ B-NP O
20 700 707 15075188 ascites NNS I-NP D001201
21 707 708 15075188 . . O O

1 709 712 15075188 The DT B-NP O
2 713 720 15075188 protein NN I-NP O
3 721 730 15075188 abundance NN I-NP O
4 731 733 15075188 of IN B-PP O
5 734 739 15075188 alpha SYM O O
6 739 740 15075188 - HYPH O O
7 740 744 15075188 ENaC NN B-NP O
8 745 748 15075188 and CC O O
9 749 753 15075188 beta SYM O O
10 753 754 15075188 - HYPH O O
11 754 758 15075188 ENaC NN B-NP O
12 759 762 15075188 was VBD B-VP O
13 763 772 15075188 increased VBN I-VP O
14 773 775 15075188 in IN B-PP O
15 776 779 15075188 the DT B-NP O
16 780 785 15075188 inner JJ I-NP O
17 786 792 15075188 stripe NN I-NP O
18 793 795 15075188 of IN B-PP O
19 796 799 15075188 the DT B-NP O
20 800 805 15075188 outer JJ I-NP O
21 806 813 15075188 medulla NN I-NP O
22 814 815 15075188 ( ( O O
23 815 819 15075188 ISOM NN B-NP O
24 819 820 15075188 ) ) O O
25 821 824 15075188 and CC O O
26 825 827 15075188 in IN B-PP O
27 828 831 15075188 the DT B-NP O
28 832 837 15075188 inner JJ I-NP O
29 838 845 15075188 medulla NN I-NP O
30 846 847 15075188 ( ( O O
31 847 849 15075188 IM NN B-NP O
32 849 850 15075188 ) ) O O
33 851 854 15075188 but CC O O
34 855 858 15075188 was VBD B-VP O
35 859 862 15075188 not RB I-VP O
36 863 870 15075188 altered VBN I-VP O
37 871 873 15075188 in IN B-PP O
38 874 877 15075188 the DT B-NP O
39 878 884 15075188 cortex NN I-NP O
40 884 885 15075188 . . O O

1 886 891 15075188 gamma SYM O O
2 891 892 15075188 - HYPH B-NP O
3 892 896 15075188 ENaC NN I-NP O
4 897 906 15075188 abundance NN I-NP O
5 907 910 15075188 was VBD B-VP O
6 911 920 15075188 increased VBN I-VP O
7 921 923 15075188 in IN B-PP O
8 924 927 15075188 the DT B-NP O
9 928 934 15075188 cortex NN I-NP O
10 934 935 15075188 , , O O
11 936 940 15075188 ISOM NN B-NP O
12 940 941 15075188 , , O O
13 942 945 15075188 and CC O O
14 946 948 15075188 IM NN B-NP O
15 948 949 15075188 . . O O

1 950 966 15075188 Immunoperoxidase NN B-NP O
2 967 978 15075188 brightfield NN I-NP O
3 978 979 15075188 - HYPH B-NP O
4 980 983 15075188 and CC I-NP O
5 984 989 15075188 laser NN I-NP O
6 989 990 15075188 - HYPH O O
7 990 998 15075188 scanning VBG B-VP O
8 999 1007 15075188 confocal JJ B-NP O
9 1008 1020 15075188 fluorescence NN I-NP O
10 1021 1031 15075188 microscopy NN I-NP O
11 1032 1044 15075188 demonstrated VBD B-VP O
12 1045 1054 15075188 increased VBN I-VP O
13 1055 1064 15075188 targeting VBG B-NP O
14 1065 1067 15075188 of IN B-PP O
15 1068 1073 15075188 alpha SYM O O
16 1073 1074 15075188 - HYPH O O
17 1074 1078 15075188 ENaC NN B-NP O
18 1078 1079 15075188 , , O O
19 1080 1084 15075188 beta SYM O O
20 1084 1085 15075188 - HYPH O O
21 1085 1089 15075188 ENaC NN B-NP O
22 1089 1090 15075188 , , O O
23 1091 1094 15075188 and CC O O
24 1095 1100 15075188 gamma SYM O O
25 1100 1101 15075188 - HYPH O O
26 1101 1105 15075188 ENaC NN B-NP O
27 1106 1114 15075188 subunits NNS I-NP O
28 1115 1117 15075188 to TO B-PP O
29 1118 1121 15075188 the DT B-NP O
30 1122 1128 15075188 apical JJ I-NP O
31 1129 1135 15075188 plasma NN I-NP O
32 1136 1144 15075188 membrane NN I-NP O
33 1145 1147 15075188 in IN B-PP O
34 1148 1151 15075188 the DT B-NP O
35 1152 1158 15075188 distal JJ I-NP O
36 1159 1169 15075188 convoluted JJ I-NP O
37 1170 1176 15075188 tubule NN I-NP O
38 1177 1178 15075188 ( ( O O
39 1178 1182 15075188 DCT2 NN B-NP O
40 1182 1183 15075188 ) ) O O
41 1183 1184 15075188 , , O O
42 1185 1195 15075188 connecting VBG B-VP O
43 1196 1202 15075188 tubule NN B-NP O
44 1202 1203 15075188 , , O O
45 1204 1207 15075188 and CC O O
46 1208 1216 15075188 cortical JJ B-NP O
47 1217 1220 15075188 and CC I-NP O
48 1221 1230 15075188 medullary JJ I-NP O
49 1231 1241 15075188 collecting VBG I-NP O
50 1242 1246 15075188 duct NN I-NP O
51 1247 1255 15075188 segments NNS I-NP O
52 1255 1256 15075188 . . O O

1 1257 1271 15075188 Immunoelectron NN B-NP O
2 1272 1282 15075188 microscopy NN I-NP O
3 1283 1290 15075188 further RBR B-ADVP O
4 1291 1299 15075188 revealed VBD B-VP O
5 1300 1302 15075188 an DT B-NP O
6 1303 1312 15075188 increased VBN I-NP O
7 1313 1321 15075188 labeling NN I-NP O
8 1322 1324 15075188 of IN B-PP O
9 1325 1330 15075188 alpha SYM B-NP O
10 1330 1331 15075188 - HYPH B-VP O
11 1331 1335 15075188 ENaC NN B-NP O
12 1336 1338 15075188 in IN B-PP O
13 1339 1342 15075188 the DT B-NP O
14 1343 1349 15075188 apical JJ I-NP O
15 1350 1356 15075188 plasma NN I-NP O
16 1357 1365 15075188 membrane NN I-NP O
17 1366 1368 15075188 of IN B-PP O
18 1369 1377 15075188 cortical JJ B-NP O
19 1378 1388 15075188 collecting VBG I-NP O
20 1389 1393 15075188 duct NN I-NP O
21 1394 1403 15075188 principal JJ I-NP O
22 1404 1409 15075188 cells NNS I-NP O
23 1410 1412 15075188 of IN B-PP O
24 1413 1416 15075188 PAN NN B-NP D011692
25 1416 1417 15075188 - HYPH B-NP O
26 1417 1424 15075188 treated VBN I-NP O
27 1425 1429 15075188 rats NNS I-NP O
28 1429 1430 15075188 , , O O
29 1431 1441 15075188 indicating VBG B-VP O
30 1442 1450 15075188 enhanced VBN B-NP O
31 1451 1457 15075188 apical JJ I-NP O
32 1458 1467 15075188 targeting NN I-NP O
33 1468 1470 15075188 of IN B-PP O
34 1471 1476 15075188 alpha SYM B-NP O
35 1476 1477 15075188 - HYPH B-NP O
36 1477 1481 15075188 ENaC NN I-NP O
37 1482 1490 15075188 subunits NNS I-NP O
38 1490 1491 15075188 . . O O

1 1492 1494 15075188 In IN B-PP O
2 1495 1503 15075188 contrast NN B-NP O
3 1503 1504 15075188 , , O O
4 1505 1508 15075188 the DT B-NP O
5 1509 1516 15075188 protein NN I-NP O
6 1517 1527 15075188 abundances NNS I-NP O
7 1528 1530 15075188 of IN B-PP O
8 1531 1536 15075188 Na(+) NN B-NP D012964
9 1536 1537 15075188 / SYM B-NP O
10 1537 1541 15075188 H(+) NN I-NP D006859
11 1542 1551 15075188 exchanger NN I-NP O
12 1552 1556 15075188 type NN I-NP O
13 1557 1558 15075188 3 CD I-NP O
14 1559 1560 15075188 ( ( O O
15 1560 1564 15075188 NHE3 NN B-NP O
16 1564 1565 15075188 ) ) O O
17 1565 1566 15075188 , , O O
18 1567 1572 15075188 Na(+) NN B-NP D012964
19 1572 1573 15075188 - HYPH B-NP O
20 1573 1577 15075188 K(+) NN I-NP D011188
21 1577 1578 15075188 - HYPH B-NP O
22 1578 1582 15075188 2Cl( NN I-NP D002713
23 1582 1583 15075188 - HYPH O O
24 1583 1584 15075188 ) ) O O
25 1585 1598 15075188 cotransporter NN B-NP O
26 1599 1600 15075188 ( ( O O
27 1600 1603 15075188 BSC NN B-NP O
28 1603 1604 15075188 - HYPH B-NP O
29 1604 1605 15075188 1 CD I-NP O
30 1605 1606 15075188 ) ) O O
31 1606 1607 15075188 , , O O
32 1608 1611 15075188 and CC O O
33 1612 1620 15075188 thiazide NN B-NP D049971
34 1620 1621 15075188 - HYPH O O
35 1621 1630 15075188 sensitive JJ B-NP O
36 1631 1636 15075188 Na(+) NN I-NP D012964
37 1636 1637 15075188 - HYPH O O
38 1637 1640 15075188 Cl( SYM O D002713
39 1640 1641 15075188 - HYPH O O
40 1641 1642 15075188 ) ) O O
41 1643 1656 15075188 cotransporter NN B-NP O
42 1657 1658 15075188 ( ( O O
43 1658 1661 15075188 TSC NN B-NP O
44 1661 1662 15075188 ) ) O O
45 1663 1667 15075188 were VBD B-VP O
46 1668 1677 15075188 decreased VBN I-VP O
47 1677 1678 15075188 . . O O

1 1679 1687 15075188 Moreover RB B-ADVP O
2 1687 1688 15075188 , , O O
3 1689 1692 15075188 the DT B-NP O
4 1693 1702 15075188 abundance NN I-NP O
5 1703 1705 15075188 of IN B-PP O
6 1706 1709 15075188 the DT B-NP O
7 1710 1718 15075188 alpha(1) NN I-NP O
8 1718 1719 15075188 - HYPH B-NP O
9 1719 1726 15075188 subunit NN I-NP O
10 1727 1729 15075188 of IN B-PP O
11 1730 1733 15075188 the DT B-NP O
12 1734 1736 15075188 Na NN I-NP D012964
13 1736 1737 15075188 - HYPH B-NP O
14 1737 1738 15075188 K NN I-NP D011188
15 1738 1739 15075188 - HYPH O O
16 1739 1745 15075188 ATPase NN B-NP O
17 1746 1749 15075188 was VBD B-VP O
18 1750 1759 15075188 decreased VBN I-VP O
19 1760 1762 15075188 in IN B-PP O
20 1763 1766 15075188 the DT B-NP O
21 1767 1773 15075188 cortex NN I-NP O
22 1774 1777 15075188 and CC I-NP O
23 1778 1782 15075188 ISOM NN I-NP O
24 1782 1783 15075188 , , O O
25 1784 1787 15075188 but CC O O
26 1788 1790 15075188 it PRP B-NP O
27 1791 1799 15075188 remained VBD B-VP O
28 1800 1809 15075188 unchanged JJ B-ADJP O
29 1810 1812 15075188 in IN B-PP O
30 1813 1816 15075188 the DT B-NP O
31 1817 1819 15075188 IM NN I-NP O
32 1819 1820 15075188 . . O O

1 1821 1823 15075188 In IN B-PP O
2 1824 1834 15075188 conclusion NN B-NP O
3 1834 1835 15075188 , , O O
4 1836 1839 15075188 the DT B-NP O
5 1840 1849 15075188 increased VBN I-NP O
6 1850 1852 15075188 or CC I-NP O
7 1853 1862 15075188 sustained VBN I-NP O
8 1863 1873 15075188 expression NN I-NP O
9 1874 1876 15075188 of IN B-PP O
10 1877 1881 15075188 ENaC NN B-NP O
11 1882 1890 15075188 subunits NNS I-NP O
12 1891 1899 15075188 combined VBN B-VP O
13 1900 1904 15075188 with IN B-PP O
14 1905 1914 15075188 increased VBN B-NP O
15 1915 1921 15075188 apical JJ I-NP O
16 1922 1931 15075188 targeting NN I-NP O
17 1932 1934 15075188 in IN B-PP O
18 1935 1938 15075188 the DT B-NP O
19 1939 1943 15075188 DCT2 NN I-NP O
20 1943 1944 15075188 , , O O
21 1945 1955 15075188 connecting VBG B-VP O
22 1956 1962 15075188 tubule NN B-NP O
23 1962 1963 15075188 , , O O
24 1964 1967 15075188 and CC O O
25 1968 1978 15075188 collecting VBG B-VP O
26 1979 1983 15075188 duct NN B-NP O
27 1984 1987 15075188 are VBP B-VP O
28 1988 1994 15075188 likely JJ B-ADJP O
29 1995 1997 15075188 to TO B-VP O
30 1998 2002 15075188 play VB I-VP O
31 2003 2004 15075188 a DT B-NP O
32 2005 2009 15075188 role NN I-NP O
33 2010 2012 15075188 in IN B-PP O
34 2013 2016 15075188 the DT B-NP O
35 2017 2023 15075188 sodium NN I-NP D012964
36 2024 2033 15075188 retention NN I-NP O
37 2034 2044 15075188 associated VBN B-VP O
38 2045 2049 15075188 with IN B-PP O
39 2050 2053 15075188 PAN NN B-NP D011692
40 2053 2054 15075188 - HYPH B-NP O
41 2054 2061 15075188 induced VBN I-NP O
42 2062 2071 15075188 nephrotic JJ I-NP D009404
43 2072 2080 15075188 syndrome NN I-NP D009404
44 2080 2081 15075188 . . O O

1 2082 2085 15075188 The DT B-NP O
2 2086 2095 15075188 decreased VBN I-NP O
3 2096 2105 15075188 abundance NN I-NP O
4 2106 2108 15075188 of IN B-PP O
5 2109 2113 15075188 NHE3 NN B-NP O
6 2113 2114 15075188 , , O O
7 2115 2118 15075188 BSC NN B-NP O
8 2118 2119 15075188 - HYPH B-NP O
9 2119 2120 15075188 1 CD I-NP O
10 2120 2121 15075188 , , O O
11 2122 2125 15075188 TSC NN B-NP O
12 2125 2126 15075188 , , O O
13 2127 2130 15075188 and CC O O
14 2131 2133 15075188 Na NN B-NP D012964
15 2133 2134 15075188 - HYPH B-NP O
16 2134 2135 15075188 K NN I-NP D011188
17 2135 2136 15075188 - HYPH I-NP O
18 2136 2142 15075188 ATPase NN I-NP O
19 2143 2146 15075188 may MD B-VP O
20 2147 2151 15075188 play VB I-VP O
21 2152 2153 15075188 a DT B-NP O
22 2154 2166 15075188 compensatory JJ I-NP O
23 2167 2171 15075188 role NN I-NP O
24 2172 2174 15075188 to TO B-VP O
25 2175 2182 15075188 promote VB I-VP O
26 2183 2189 15075188 sodium NN B-NP D012964
27 2190 2199 15075188 excretion NN I-NP O
28 2199 2200 15075188 . . O O

1 0 0 19203554 -DOCSTART- -X- -X- O

1 0 10 19203554 Proteinase NN B-NP O
2 11 12 19203554 3 CD I-NP O
3 12 13 19203554 - HYPH I-NP O
4 13 27 19203554 antineutrophil NN I-NP O
5 28 39 19203554 cytoplasmic JJ I-NP O
6 40 48 19203554 antibody NN I-NP O
7 48 49 19203554 - HYPH B-NP O
8 49 53 19203554 (PR3 NN I-NP O
9 53 54 19203554 - HYPH I-NP O
10 54 59 19203554 ANCA) NN I-NP O
11 60 68 19203554 positive JJ I-NP O
12 69 80 19203554 necrotizing VBG I-NP O
13 81 99 19203554 glomerulonephritis NN I-NP D005921
14 100 105 19203554 after IN B-PP O
15 106 116 19203554 restarting VBG B-VP O
16 117 131 19203554 sulphasalazine NN B-NP D012460
17 132 141 19203554 treatment NN I-NP O
18 141 142 19203554 . . O O
19 143 144 19203554 A DT B-NP O
20 145 147 19203554 59 CD I-NP O
21 147 148 19203554 - HYPH I-NP O
22 148 152 19203554 year NN I-NP O
23 152 153 19203554 - HYPH O O
24 153 156 19203554 old JJ B-NP O
25 157 162 19203554 woman NN I-NP O
26 163 167 19203554 with IN B-PP O
27 168 178 19203554 ulcerative JJ B-NP D003093
28 179 186 19203554 colitis NN I-NP D003093
29 187 196 19203554 developed VBD B-VP O
30 197 200 19203554 red JJ B-NP D005128
31 201 205 19203554 eyes NNS I-NP D005128
32 205 206 19203554 , , O O
33 207 214 19203554 pleural JJ B-NP D010996
34 215 223 19203554 effusion NN I-NP D010996
35 223 224 19203554 , , O O
36 225 237 19203554 eosinophilia NN B-NP D004802
37 238 241 19203554 and CC O O
38 242 249 19203554 urinary JJ B-NP D001745
39 250 263 19203554 abnormalities NNS I-NP D001745
40 264 269 19203554 after IN B-PP O
41 270 280 19203554 restarting VBG B-VP O
42 281 283 19203554 of IN B-PP O
43 284 298 19203554 sulphasalazine NN B-NP D012460
44 299 308 19203554 treatment NN I-NP O
45 308 309 19203554 . . O O

1 310 315 19203554 Light NN B-NP O
2 316 326 19203554 microscopy NN I-NP O
3 327 329 19203554 of IN B-PP O
4 330 331 19203554 a DT B-NP O
5 332 338 19203554 kidney NN I-NP O
6 339 345 19203554 biopsy NN I-NP O
7 346 354 19203554 revealed VBD B-VP O
8 355 364 19203554 segmental JJ B-NP D005923
9 365 376 19203554 necrotizing VBG I-NP D005923
10 377 395 19203554 glomerulonephritis NN I-NP D005923
11 396 403 19203554 without IN B-PP O
12 404 414 19203554 deposition NN B-NP O
13 415 417 19203554 of IN B-PP O
14 418 432 19203554 immunoglobulin NN B-NP O
15 433 435 19203554 or CC I-NP O
16 436 446 19203554 complement NN I-NP O
17 446 447 19203554 . . O O

1 448 458 19203554 Proteinase NN B-NP O
2 459 460 19203554 3 CD I-NP O
3 460 461 19203554 - HYPH I-NP O
4 461 475 19203554 antineutrophil NN I-NP O
5 476 487 19203554 cytoplasmic JJ I-NP O
6 488 496 19203554 antibody NN I-NP O
7 497 498 19203554 ( ( O O
8 498 501 19203554 PR3 NN B-NP O
9 501 502 19203554 - HYPH B-NP O
10 502 506 19203554 ANCA NN I-NP O
11 506 507 19203554 ) ) O O
12 508 513 19203554 titer NN B-NP O
13 514 517 19203554 was VBD B-VP O
14 518 526 19203554 elevated VBN I-VP O
15 527 529 19203554 at IN B-PP O
16 530 533 19203554 183 CD B-NP O
17 534 539 19203554 ELISA NN I-NP O
18 540 545 19203554 units NNS I-NP O
19 546 547 19203554 ( ( O O
20 547 549 19203554 EU NN B-NP O
21 549 550 19203554 ) ) O O
22 551 553 19203554 in IN B-PP O
23 554 558 19203554 sera NNS B-NP O
24 559 560 19203554 ( ( O O
25 560 566 19203554 normal JJ B-NP O
26 567 572 19203554 range NN I-NP O
27 573 577 19203554 less JJR B-NP O
28 578 582 19203554 than IN I-NP O
29 583 585 19203554 10 CD I-NP O
30 586 588 19203554 EU NN I-NP O
31 588 589 19203554 ) ) O O
32 589 590 19203554 , , O O
33 591 606 19203554 myeloperoxidase NN B-NP O
34 606 607 19203554 - HYPH B-NP O
35 607 611 19203554 ANCA NN I-NP O
36 612 615 19203554 was VBD B-VP O
37 616 624 19203554 negative JJ B-ADJP O
38 624 625 19203554 . . O O

1 626 629 19203554 PR3 NN B-NP O
2 629 630 19203554 - HYPH I-NP O
3 630 634 19203554 ANCA NN I-NP O
4 635 640 19203554 titer NN I-NP O
5 641 644 19203554 was VBD B-VP O
6 645 648 19203554 250 CD B-NP O
7 649 652 19203554 and CC I-NP O
8 653 658 19203554 1,070 CD I-NP O
9 659 661 19203554 EU NN I-NP O
10 662 664 19203554 in IN B-PP O
11 665 672 19203554 pleural JJ B-NP D010996
12 673 682 19203554 effusions NNS I-NP D010996
13 683 685 19203554 on IN B-PP O
14 686 691 19203554 right JJ B-NP O
15 692 695 19203554 and CC I-NP O
16 696 700 19203554 left JJ I-NP O
17 701 705 19203554 side NN I-NP O
18 705 706 19203554 , , O O
19 707 719 19203554 respectively RB B-ADVP O
20 719 720 19203554 . . O O

1 721 729 19203554 Although IN B-SBAR O
2 730 739 19203554 cessation NN B-NP O
3 740 742 19203554 of IN B-PP O
4 743 757 19203554 sulphasalazine NN B-NP D012460
5 758 767 19203554 treatment NN I-NP O
6 768 776 19203554 resulted VBD B-VP O
7 777 779 19203554 in IN B-PP O
8 780 792 19203554 improvements NNS B-NP O
9 793 795 19203554 in IN B-PP O
10 796 801 19203554 fever NN B-NP D005334
11 801 802 19203554 , , O O
12 803 806 19203554 red JJ B-NP D005128
13 807 811 19203554 eyes NNS I-NP D005128
14 811 812 19203554 , , O O
15 813 818 19203554 chest NN B-NP D002637
16 819 823 19203554 pain NN I-NP D002637
17 823 824 19203554 , , O O
18 825 830 19203554 titer NN B-NP O
19 831 833 19203554 of IN B-PP O
20 834 835 19203554 C NN B-NP O
21 835 836 19203554 - HYPH B-NP O
22 836 844 19203554 reactive JJ I-NP O
23 845 852 19203554 protein NN I-NP O
24 853 856 19203554 and CC I-NP O
25 857 863 19203554 volume NN I-NP O
26 864 866 19203554 of IN B-PP O
27 867 870 19203554 the DT B-NP O
28 871 878 19203554 pleural JJ I-NP D010996
29 879 888 19203554 effusions NNS I-NP D010996
30 888 889 19203554 , , O O
31 890 892 19203554 we PRP B-NP O
32 893 902 19203554 initiated VBD B-VP O
33 903 910 19203554 steroid NN B-NP D013256
34 911 918 19203554 therapy NN I-NP O
35 918 919 19203554 , , O O
36 920 927 19203554 because IN B-SBAR O
37 928 931 19203554 PR3 NN B-NP O
38 931 932 19203554 - HYPH B-NP O
39 932 936 19203554 ANCA NN I-NP O
40 937 942 19203554 titer NN I-NP O
41 943 947 19203554 rose VBD B-VP O
42 948 950 19203554 to TO B-PP O
43 951 954 19203554 320 CD B-NP O
44 955 957 19203554 EU NN I-NP O
45 957 958 19203554 , , O O
46 959 969 19203554 eosinophil NN B-NP O
47 970 975 19203554 count NN I-NP O
48 976 985 19203554 increased VBD B-VP O
49 986 988 19203554 to TO B-PP O
50 989 994 19203554 1,100 CD B-NP O
51 995 1000 19203554 cells NNS I-NP O
52 1000 1001 19203554 / SYM O O
53 1001 1007 19203554 microl NN B-NP O
54 1007 1008 19203554 , , O O
55 1009 1012 19203554 and CC O O
56 1013 1016 19203554 the DT B-NP O
57 1017 1024 19203554 pleural JJ I-NP D010996
58 1025 1033 19203554 effusion NN I-NP D010996
59 1034 1042 19203554 remained VBD B-VP O
60 1042 1043 19203554 . . O O

1 1044 1047 19203554 One CD B-NP O
2 1048 1053 19203554 month NN I-NP O
3 1054 1059 19203554 after IN B-PP O
4 1060 1067 19203554 steroid NN B-NP D013256
5 1068 1075 19203554 therapy NN I-NP O
6 1075 1076 19203554 , , O O
7 1077 1080 19203554 the DT B-NP O
8 1081 1088 19203554 pleural JJ I-NP D010996
9 1089 1097 19203554 effusion NN I-NP D010996
10 1098 1109 19203554 disappeared VBD B-VP O
11 1109 1110 19203554 , , O O
12 1111 1114 19203554 and CC O O
13 1115 1118 19203554 PR3 NN B-NP O
14 1118 1119 19203554 - HYPH I-NP O
15 1119 1123 19203554 ANCA NN I-NP O
16 1124 1129 19203554 titer NN I-NP O
17 1130 1140 19203554 normalized VBD B-VP O
18 1141 1142 19203554 3 CD B-NP O
19 1143 1149 19203554 months NNS I-NP O
20 1150 1155 19203554 later RB B-ADVP O
21 1155 1156 19203554 . . O O

1 1157 1161 19203554 This DT B-NP O
2 1162 1166 19203554 case NN I-NP O
3 1167 1175 19203554 suggests VBZ B-VP O
4 1176 1180 19203554 that IN B-SBAR O
5 1181 1195 19203554 sulphasalazine NN B-NP D012460
6 1196 1199 19203554 can MD B-VP O
7 1200 1206 19203554 induce VB I-VP O
8 1207 1210 19203554 PR3 NN B-NP O
9 1210 1211 19203554 - HYPH B-NP O
10 1211 1215 19203554 ANCA NN I-NP O
11 1215 1216 19203554 - HYPH B-NP O
12 1216 1224 19203554 positive JJ I-NP O
13 1225 1236 19203554 necrotizing VBG I-NP O
14 1237 1255 19203554 glomerulonephritis NN I-NP D005921
15 1255 1256 19203554 . . O O

1 0 0 16600756 -DOCSTART- -X- -X- O

1 0 5 16600756 Nerve NN B-NP O
2 6 12 16600756 growth NN I-NP O
3 13 19 16600756 factor NN I-NP O
4 20 23 16600756 and CC O O
5 24 38 16600756 prostaglandins NNS B-NP D011453
6 39 41 16600756 in IN B-PP O
7 42 45 16600756 the DT B-NP O
8 46 51 16600756 urine NN I-NP O
9 52 54 16600756 of IN B-PP O
10 55 61 16600756 female JJ B-NP O
11 62 70 16600756 patients NNS I-NP O
12 71 75 16600756 with IN B-PP O
13 76 86 16600756 overactive JJ B-NP D053201
14 87 94 16600756 bladder NN I-NP D053201
15 94 95 16600756 . . I-NP O
16 96 103 16600756 PURPOSE NN I-NP O
17 103 104 16600756 : : O O
18 105 108 16600756 NGF NN B-NP O
19 109 112 16600756 and CC I-NP O
20 113 116 16600756 PGs NNS I-NP D011453
21 117 119 16600756 in IN B-PP O
22 120 123 16600756 the DT B-NP O
23 124 131 16600756 bladder NN I-NP O
24 132 135 16600756 can MD B-VP O
25 136 138 16600756 be VB I-VP O
26 139 147 16600756 affected VBN I-VP O
27 148 150 16600756 by IN B-PP O
28 151 163 16600756 pathological JJ B-NP O
29 164 171 16600756 changes NNS I-NP O
30 172 174 16600756 in IN B-PP O
31 175 178 16600756 the DT B-NP O
32 179 186 16600756 bladder NN I-NP O
33 187 190 16600756 and CC O O
34 191 196 16600756 these DT B-NP O
35 197 204 16600756 changes NNS I-NP O
36 205 208 16600756 can MD B-VP O
37 209 211 16600756 be VB I-VP O
38 212 220 16600756 detected VBN I-VP O
39 221 223 16600756 in IN B-PP O
40 224 229 16600756 urine NN B-NP O
41 229 230 16600756 . . O O

1 231 233 16600756 We PRP B-NP O
2 234 246 16600756 investigated VBD B-VP O
3 247 254 16600756 changes NNS B-NP O
4 255 257 16600756 in IN B-PP O
5 258 265 16600756 urinary JJ B-NP O
6 266 269 16600756 NGF NN I-NP O
7 270 273 16600756 and CC I-NP O
8 274 277 16600756 PGs NNS I-NP D011453
9 278 280 16600756 in IN B-PP O
10 281 286 16600756 women NNS B-NP O
11 287 291 16600756 with IN B-PP O
12 292 295 16600756 OAB NN B-NP D053201
13 295 296 16600756 . . O O

1 297 306 16600756 MATERIALS NNS B-NP O
2 307 310 16600756 AND CC I-NP O
3 311 318 16600756 METHODS NNS I-NP O
4 318 319 16600756 : : O O
5 320 323 16600756 The DT B-NP O
6 324 329 16600756 study NN I-NP O
7 330 336 16600756 groups NNS I-NP O
8 337 345 16600756 included VBD B-VP O
9 346 348 16600756 65 CD B-NP O
10 349 354 16600756 women NNS I-NP O
11 355 359 16600756 with IN B-PP O
12 360 363 16600756 OAB NN B-NP D053201
13 364 367 16600756 and CC O O
14 368 370 16600756 20 CD B-NP O
15 371 378 16600756 without IN B-PP O
16 379 386 16600756 bladder NN B-NP O
17 387 395 16600756 symptoms NNS I-NP O
18 396 399 16600756 who WP B-NP O
19 400 406 16600756 served VBD B-VP O
20 407 409 16600756 as IN B-PP O
21 410 418 16600756 controls NNS B-NP O
22 418 419 16600756 . . O O

1 420 430 16600756 Evaluation NN B-NP O
2 431 439 16600756 included VBD B-VP O
3 440 447 16600756 patient NN B-NP O
4 448 455 16600756 history NN I-NP O
5 455 456 16600756 , , O O
6 457 467 16600756 urinalysis NN B-NP O
7 467 468 16600756 , , O O
8 469 470 16600756 a DT B-NP O
9 471 478 16600756 voiding NN I-NP O
10 479 484 16600756 diary NN I-NP O
11 485 488 16600756 and CC O O
12 489 499 16600756 urodynamic JJ B-NP O
13 500 507 16600756 studies NNS I-NP O
14 507 508 16600756 . . O O

1 509 514 16600756 Urine NN B-NP O
2 515 522 16600756 samples NNS I-NP O
3 523 527 16600756 were VBD B-VP O
4 528 537 16600756 collected VBN I-VP O
5 537 538 16600756 . . O O

1 539 542 16600756 NGF NN B-NP O
2 542 543 16600756 , , I-NP O
3 544 548 16600756 PGE2 NN I-NP D015232
4 548 549 16600756 , , I-NP O
5 550 559 16600756 PGF2alpha NN I-NP D015237
6 560 563 16600756 and CC I-NP O
7 564 568 16600756 PGI2 NN I-NP D011464
8 569 573 16600756 were VBD B-VP O
9 574 582 16600756 measured VBN I-VP O
10 583 588 16600756 using VBG B-VP O
11 589 595 16600756 enzyme NN B-NP O
12 595 596 16600756 - HYPH O O
13 596 602 16600756 linked VBN B-VP O
14 603 616 16600756 immunosorbent JJ B-NP O
15 617 622 16600756 assay NN I-NP O
16 623 626 16600756 and CC O O
17 627 635 16600756 compared VBN B-VP O
18 636 643 16600756 between IN B-PP O
19 644 647 16600756 the DT B-NP O
20 648 654 16600756 groups NNS I-NP O
21 654 655 16600756 . . O O

1 656 658 16600756 In IN B-PP O
2 659 667 16600756 addition NN B-NP O
3 667 668 16600756 , , O O
4 669 681 16600756 correlations NNS B-NP O
5 682 689 16600756 between IN B-PP O
6 690 697 16600756 urinary JJ B-NP O
7 698 701 16600756 NGF NN I-NP O
8 702 705 16600756 and CC I-NP O
9 706 708 16600756 PG NN I-NP D011453
10 708 709 16600756 , , O O
11 710 713 16600756 and CC O O
12 714 724 16600756 urodynamic JJ B-NP O
13 725 735 16600756 parameters NNS I-NP O
14 736 738 16600756 in IN B-PP O
15 739 747 16600756 patients NNS B-NP O
16 748 752 16600756 with IN B-PP O
17 753 756 16600756 OAB NN B-NP D053201
18 757 761 16600756 were VBD B-VP O
19 762 770 16600756 examined VBN I-VP O
20 770 771 16600756 . . O O

1 772 779 16600756 RESULTS NNS B-NP O
2 779 780 16600756 : : O O
3 781 788 16600756 Urinary JJ B-NP O
4 789 792 16600756 NGF NN I-NP O
5 792 793 16600756 , , O O
6 794 798 16600756 PGE2 NN B-NP D015232
7 799 802 16600756 and CC I-NP O
8 803 812 16600756 PGF2alpha NN I-NP D015237
9 813 817 16600756 were VBD B-VP O
10 818 831 16600756 significantly RB I-VP O
11 832 841 16600756 increased VBN I-VP O
12 842 844 16600756 in IN B-PP O
13 845 853 16600756 patients NNS B-NP O
14 854 858 16600756 with IN B-PP O
15 859 862 16600756 OAB NN B-NP D053201
16 863 871 16600756 compared VBN B-PP O
17 872 876 16600756 with IN B-PP O
18 877 885 16600756 controls NNS B-NP O
19 886 887 16600756 ( ( O O
20 887 888 16600756 p NN B-NP O
21 889 890 16600756 < SYM O O
22 890 894 16600756 0.05 CD B-NP O
23 894 895 16600756 ) ) O O
24 895 896 16600756 . . O O

1 897 904 16600756 However RB B-ADVP O
2 904 905 16600756 , , O O
3 906 913 16600756 urinary JJ B-NP O
4 914 918 16600756 PGI2 NN I-NP D011464
5 919 922 16600756 was VBD B-VP O
6 923 926 16600756 not RB O O
7 927 936 16600756 different JJ B-ADJP O
8 937 944 16600756 between IN B-PP O
9 945 953 16600756 controls NNS B-NP O
10 954 957 16600756 and CC O O
11 958 966 16600756 patients NNS B-NP O
12 967 971 16600756 with IN B-PP O
13 972 975 16600756 OAB NN B-NP D053201
14 975 976 16600756 . . O O

1 977 979 16600756 In IN B-PP O
2 980 988 16600756 patients NNS B-NP O
3 989 993 16600756 with IN B-PP O
4 994 997 16600756 OAB NN B-NP D053201
5 998 1005 16600756 urinary JJ I-NP O
6 1006 1010 16600756 PGE2 NN I-NP D015232
7 1011 1021 16600756 positively RB B-ADVP O
8 1022 1032 16600756 correlated VBD B-VP O
9 1033 1037 16600756 with IN B-PP O
10 1038 1044 16600756 volume NN B-NP O
11 1045 1047 16600756 at IN B-PP O
12 1048 1053 16600756 first JJ B-NP O
13 1054 1060 16600756 desire NN I-NP O
14 1061 1063 16600756 to TO B-PP O
15 1064 1068 16600756 void NN B-NP O
16 1069 1072 16600756 and CC O O
17 1073 1080 16600756 maximum JJ B-NP O
18 1081 1092 16600756 cystometric JJ I-NP O
19 1093 1101 16600756 capacity NN I-NP O
20 1102 1103 16600756 ( ( O O
21 1103 1104 16600756 p NN B-NP O
22 1105 1106 16600756 < SYM O O
23 1106 1110 16600756 0.05 CD B-NP O
24 1110 1111 16600756 ) ) O O
25 1111 1112 16600756 . . O O

1 1113 1120 16600756 Urinary JJ B-NP O
2 1121 1124 16600756 NGF NN I-NP O
3 1124 1125 16600756 , , I-NP O
4 1126 1135 16600756 PGF2alpha NN I-NP D015237
5 1136 1139 16600756 and CC I-NP O
6 1140 1144 16600756 PGI2 NN I-NP D011464
7 1145 1148 16600756 did VBD B-VP O
8 1149 1152 16600756 not RB I-VP O
9 1153 1162 16600756 correlate VB I-VP O
10 1163 1167 16600756 with IN B-PP O
11 1168 1178 16600756 urodynamic JJ B-NP O
12 1179 1189 16600756 parameters NNS I-NP O
13 1190 1192 16600756 in IN B-PP O
14 1193 1201 16600756 patients NNS B-NP O
15 1202 1206 16600756 with IN B-PP O
16 1207 1210 16600756 OAB NN B-NP D053201
17 1210 1211 16600756 . . O O

1 1212 1223 16600756 CONCLUSIONS NNS B-NP O
2 1223 1224 16600756 : : O O
3 1225 1228 16600756 NGF NN B-NP O
4 1229 1232 16600756 and CC I-NP O
5 1233 1236 16600756 PGs NNS I-NP D011453
6 1237 1241 16600756 have VBP B-VP O
7 1242 1251 16600756 important JJ B-NP O
8 1252 1257 16600756 roles NNS I-NP O
9 1258 1260 16600756 in IN B-PP O
10 1261 1264 16600756 the DT B-NP O
11 1265 1276 16600756 development NN I-NP O
12 1277 1279 16600756 of IN B-PP O
13 1280 1283 16600756 OAB NN B-NP D053201
14 1284 1292 16600756 symptoms NNS I-NP O
15 1293 1295 16600756 in IN B-PP O
16 1296 1302 16600756 female JJ B-NP O
17 1303 1311 16600756 patients NNS I-NP O
18 1311 1312 16600756 . . O O

1 1313 1320 16600756 Urinary JJ B-NP O
2 1321 1327 16600756 levels NNS I-NP O
3 1328 1330 16600756 of IN B-PP O
4 1331 1336 16600756 these DT B-NP O
5 1337 1344 16600756 factors NNS I-NP O
6 1345 1348 16600756 may MD B-VP O
7 1349 1351 16600756 be VB I-VP O
8 1352 1356 16600756 used VBN I-VP O
9 1357 1359 16600756 as IN B-SBAR O
10 1360 1367 16600756 markers NNS B-NP O
11 1368 1370 16600756 to TO B-VP O
12 1371 1379 16600756 evaluate VB I-VP O
13 1380 1383 16600756 OAB NN B-NP D053201
14 1384 1392 16600756 symptoms NNS I-NP O
15 1392 1393 16600756 . . O O

1 0 0 11271907 -DOCSTART- -X- -X- O

1 0 5 11271907 Fatal JJ B-NP O
2 6 18 11271907 haemorrhagic JJ I-NP D006470
3 19 30 11271907 myocarditis NN I-NP D006470
4 31 40 11271907 secondary JJ B-ADJP O
5 41 43 11271907 to TO B-PP O
6 44 60 11271907 cyclophosphamide NN B-NP D003520
7 61 68 11271907 therapy NN I-NP O
8 68 69 11271907 . . O O
9 70 82 11271907 Haemorrhagic JJ B-NP D006470
10 83 94 11271907 myocarditis NN I-NP D006470
11 95 97 11271907 is VBZ B-VP O
12 98 99 11271907 a DT B-NP O
13 100 104 11271907 rare JJ I-NP O
14 105 108 11271907 but CC I-NP O
15 109 118 11271907 important JJ I-NP O
16 119 131 11271907 complication NN I-NP O
17 132 134 11271907 of IN B-PP O
18 135 151 11271907 cyclophosphamide NN B-NP D003520
19 152 159 11271907 therapy NN I-NP O
20 159 160 11271907 . . O O

1 161 178 11271907 Echocardiographic JJ B-NP O
2 179 193 11271907 identification NN I-NP O
3 194 196 11271907 of IN B-PP O
4 197 200 11271907 the DT B-NP O
5 201 209 11271907 disorder NN I-NP O
6 210 213 11271907 can MD B-VP O
7 214 216 11271907 be VB I-VP O
8 217 221 11271907 made VBN I-VP O
9 221 222 11271907 . . O O

1 223 225 11271907 We PRP B-NP O
2 226 233 11271907 believe VBP B-VP O
3 234 238 11271907 that IN B-SBAR O
4 239 242 11271907 the DT B-NP O
5 243 253 11271907 ultrasound JJ I-NP O
6 254 262 11271907 features NNS I-NP O
7 263 265 11271907 of IN B-PP O
8 266 270 11271907 this DT B-NP O
9 271 279 11271907 disorder NN I-NP O
10 280 284 11271907 have VBP B-VP O
11 285 288 11271907 not RB I-VP O
12 289 293 11271907 been VBN I-VP O
13 294 304 11271907 previously RB I-VP O
14 305 313 11271907 reported VBN I-VP O
15 313 314 11271907 . . O O

1 0 0 12907924 -DOCSTART- -X- -X- O

1 0 15 12907924 Methylphenidate NN B-NP D008774
2 15 16 12907924 - HYPH O O
3 16 23 12907924 induced VBN B-NP O
4 24 33 12907924 obsessive JJ I-NP D009771
5 33 34 12907924 - HYPH I-NP D009771
6 34 44 12907924 compulsive JJ I-NP D009771
7 45 53 12907924 symptoms NNS I-NP D009771
8 54 56 12907924 in IN B-PP O
9 57 59 12907924 an DT B-NP O
10 60 67 12907924 elderly JJ I-NP O
11 68 71 12907924 man NN I-NP O
12 71 72 12907924 . . O O
13 73 75 12907924 An DT B-NP O
14 76 78 12907924 82 CD I-NP O
15 78 79 12907924 - HYPH I-NP O
16 79 83 12907924 year NN I-NP O
17 83 84 12907924 - HYPH O O
18 84 87 12907924 old JJ B-NP O
19 88 91 12907924 man NN I-NP O
20 92 96 12907924 with IN B-PP O
21 97 106 12907924 treatment NN B-NP D061218
22 106 107 12907924 - HYPH O D061218
23 107 116 12907924 resistant JJ B-NP D061218
24 117 127 12907924 depression NN I-NP D061218
25 128 131 12907924 and CC O O
26 132 137 12907924 early JJ B-NP O
27 138 149 12907924 Alzheimer's NNS I-NP D000544
28 150 157 12907924 disease NN I-NP D000544
29 158 161 12907924 was VBD B-VP O
30 162 169 12907924 started VBN I-VP O
31 170 172 12907924 on IN B-PP O
32 173 188 12907924 methylphenidate NN B-NP D008774
33 188 189 12907924 . . O O

1 190 201 12907924 Significant JJ B-NP O
2 202 211 12907924 obsessive JJ I-NP D009771
3 211 212 12907924 - HYPH I-NP D009771
4 212 222 12907924 compulsive JJ I-NP D009771
5 223 231 12907924 behavior NN I-NP D009771
6 232 238 12907924 ensued VBD B-VP O
7 239 242 12907924 but CC I-VP O
8 243 253 12907924 diminished VBD I-VP O
9 254 258 12907924 over IN B-PP O
10 259 266 12907924 several JJ B-NP O
11 267 272 12907924 weeks NNS I-NP O
12 273 277 12907924 when WRB B-ADVP O
13 278 293 12907924 methylphenidate NN B-NP D008774
14 294 297 12907924 was VBD B-VP O
15 298 306 12907924 replaced VBN I-VP O
16 307 309 12907924 by IN B-PP O
17 310 321 12907924 fluvoxamine NN B-NP D016666
18 321 322 12907924 . . O O

1 323 326 12907924 The DT B-NP O
2 327 334 12907924 patient NN I-NP O
3 335 338 12907924 had VBD B-VP O
4 339 341 12907924 no DT B-NP O
5 342 347 12907924 prior JJ I-NP O
6 348 359 12907924 psychiatric JJ I-NP D001523
7 360 367 12907924 history NN I-NP O
8 367 368 12907924 , , O O
9 369 372 12907924 but CC O O
10 373 375 12907924 he PRP B-NP O
11 376 379 12907924 had VBD B-VP O
12 380 381 12907924 a DT B-NP O
13 382 388 12907924 sister NN I-NP O
14 389 393 12907924 with IN B-PP O
15 394 403 12907924 obsessive JJ B-NP D009771
16 403 404 12907924 - HYPH I-NP D009771
17 404 414 12907924 compulsive JJ I-NP D009771
18 415 423 12907924 disorder NN I-NP D009771
19 423 424 12907924 . . O O

1 425 427 12907924 It PRP B-NP O
2 428 435 12907924 appears VBZ B-VP O
3 436 440 12907924 that IN B-SBAR O
4 441 456 12907924 methylphenidate NN B-NP D008774
5 457 469 12907924 precipitated VBD B-VP O
6 470 473 12907924 the DT B-NP O
7 474 483 12907924 patient's NNS I-NP O
8 484 496 12907924 pathological JJ B-NP O
9 497 505 12907924 behavior NN I-NP O
10 505 506 12907924 . . O O

1 0 0 17490790 -DOCSTART- -X- -X- O

1 0 10 17490790 Peripheral JJ B-NP O
2 11 15 17490790 iron NN I-NP D007505
3 16 23 17490790 dextran NN I-NP D007505
4 24 31 17490790 induced VBD B-VP O
5 32 44 17490790 degeneration NN B-NP D009410
6 45 47 17490790 of IN B-PP D009410
7 48 60 17490790 dopaminergic JJ B-NP D009410
8 61 68 17490790 neurons NNS I-NP D009410
9 69 71 17490790 in IN B-PP O
10 72 75 17490790 rat NN B-NP O
11 76 86 17490790 substantia NN I-NP O
12 87 92 17490790 nigra NN I-NP O
13 92 93 17490790 . . O O
14 94 98 17490790 Iron NNP B-NP D007501
15 99 111 17490790 accumulation NN I-NP O
16 112 114 17490790 is VBZ B-VP O
17 115 125 17490790 considered VBN I-VP O
18 126 128 17490790 to TO I-VP O
19 129 131 17490790 be VB I-VP O
20 132 140 17490790 involved VBN I-VP O
21 141 143 17490790 in IN B-PP O
22 144 147 17490790 the DT B-NP O
23 148 160 17490790 pathogenesis NN I-NP O
24 161 163 17490790 of IN B-PP O
25 164 175 17490790 Parkinson's NNP B-NP D010300
26 176 183 17490790 disease NN I-NP D010300
27 183 184 17490790 . . O O

1 185 187 17490790 To TO B-VP O
2 188 199 17490790 demonstrate VB I-VP O
3 200 203 17490790 the DT B-NP O
4 204 216 17490790 relationship NN I-NP O
5 217 224 17490790 between IN B-PP O
6 225 235 17490790 peripheral JJ B-NP O
7 236 240 17490790 iron NN I-NP D007501
8 241 249 17490790 overload NN I-NP O
9 250 253 17490790 and CC O O
10 254 266 17490790 dopaminergic JJ B-NP O
11 267 273 17490790 neuron NN I-NP O
12 274 278 17490790 loss NN I-NP O
13 279 281 17490790 in IN B-PP O
14 282 285 17490790 rat NN B-NP O
15 286 296 17490790 substantia NN I-NP O
16 297 302 17490790 nigra NN I-NP O
17 303 304 17490790 ( ( O O
18 304 306 17490790 SN NN B-NP O
19 306 307 17490790 ) ) O O
20 307 308 17490790 , , O O
21 309 311 17490790 in IN B-PP O
22 312 315 17490790 the DT B-NP O
23 316 323 17490790 present JJ I-NP O
24 324 329 17490790 study NN I-NP O
25 330 332 17490790 we PRP B-NP O
26 333 337 17490790 used VBD B-VP O
27 338 342 17490790 fast JJ B-NP O
28 343 349 17490790 cyclic JJ I-NP O
29 350 361 17490790 voltammetry NN I-NP O
30 361 362 17490790 , , O O
31 363 371 17490790 tyrosine NN B-NP D014443
32 372 383 17490790 hydroxylase NN I-NP O
33 384 385 17490790 ( ( O O
34 385 387 17490790 TH NN B-NP O
35 387 388 17490790 ) ) O O
36 389 409 17490790 immunohistochemistry NN B-NP O
37 409 410 17490790 , , O O
38 411 417 17490790 Perls' NN B-NP O
39 418 422 17490790 iron NN I-NP D007501
40 423 431 17490790 staining NN I-NP O
41 431 432 17490790 , , O O
42 433 436 17490790 and CC O O
43 437 441 17490790 high JJ B-NP O
44 442 453 17490790 performance NN I-NP O
45 454 460 17490790 liquid NN I-NP O
46 461 475 17490790 chromatography NN I-NP O
47 475 476 17490790 - HYPH B-NP O
48 476 491 17490790 electrochemical JJ I-NP O
49 492 501 17490790 detection NN I-NP O
50 502 504 17490790 to TO B-VP O
51 505 510 17490790 study VB I-VP O
52 511 514 17490790 the DT B-NP O
53 515 527 17490790 degeneration NN I-NP D009410
54 528 530 17490790 of IN B-PP D009410
55 531 543 17490790 dopaminergic JJ B-NP D009410
56 544 551 17490790 neurons NNS I-NP D009410
57 552 555 17490790 and CC O O
58 556 565 17490790 increased VBN B-NP O
59 566 570 17490790 iron NN I-NP D007501
60 571 578 17490790 content NN I-NP O
61 579 581 17490790 in IN B-PP O
62 582 585 17490790 the DT B-NP O
63 586 588 17490790 SN NN I-NP O
64 589 591 17490790 of IN B-PP O
65 592 596 17490790 iron NN B-NP D007505
66 597 604 17490790 dextran NN I-NP D007505
67 605 615 17490790 overloaded VBD B-VP O
68 616 623 17490790 animals NNS B-NP O
69 623 624 17490790 . . O O

1 625 628 17490790 The DT B-NP O
2 629 637 17490790 findings NNS I-NP O
3 638 644 17490790 showed VBD B-VP O
4 645 649 17490790 that IN B-SBAR O
5 650 660 17490790 peripheral JJ B-NP O
6 661 665 17490790 iron NN I-NP D007505
7 666 673 17490790 dextran NN I-NP D007505
8 674 682 17490790 overload NN I-NP O
9 683 692 17490790 increased VBD B-VP O
10 693 696 17490790 the DT B-NP O
11 697 701 17490790 iron NN I-NP D007501
12 702 710 17490790 staining VBG B-VP O
13 711 719 17490790 positive JJ B-NP O
14 720 725 17490790 cells NNS I-NP O
15 726 729 17490790 and CC O O
16 730 737 17490790 reduced VBD B-VP O
17 738 741 17490790 the DT B-NP O
18 742 748 17490790 number NN I-NP O
19 749 751 17490790 of IN B-PP O
20 752 754 17490790 TH NN B-NP O
21 754 755 17490790 - HYPH B-NP O
22 755 769 17490790 immunoreactive JJ I-NP O
23 770 777 17490790 neurons NNS I-NP O
24 778 780 17490790 in IN B-PP O
25 781 784 17490790 the DT B-NP O
26 785 787 17490790 SN NN I-NP O
27 787 788 17490790 . . O O

1 789 791 17490790 As IN B-PP O
2 792 793 17490790 a DT B-NP O
3 794 800 17490790 result NN I-NP O
4 800 801 17490790 , , O O
5 802 810 17490790 dopamine NN B-NP D004298
6 811 818 17490790 release NN I-NP O
7 819 822 17490790 and CC I-NP O
8 823 830 17490790 content NN I-NP O
9 830 831 17490790 , , O O
10 832 834 17490790 as RB B-CONJP O
11 835 839 17490790 well RB I-CONJP O
12 840 842 17490790 as IN I-CONJP O
13 843 846 17490790 its PRP$ B-NP O
14 847 858 17490790 metabolites NNS I-NP O
15 859 867 17490790 contents NNS I-NP O
16 868 872 17490790 were VBD B-VP O
17 873 882 17490790 decreased VBN I-VP O
18 883 885 17490790 in IN B-PP O
19 886 893 17490790 caudate JJ B-NP O
20 894 901 17490790 putamen NNS I-NP O
21 901 902 17490790 . . O O

1 903 907 17490790 Even RB B-NP O
2 908 912 17490790 more RBR I-NP O
3 913 921 17490790 dramatic JJ I-NP O
4 922 929 17490790 changes NNS I-NP O
5 930 934 17490790 were VBD B-VP O
6 935 940 17490790 found VBN I-VP O
7 941 943 17490790 in IN B-PP O
8 944 951 17490790 chronic JJ B-NP O
9 952 960 17490790 overload JJ I-NP O
10 961 966 17490790 group NN I-NP O
11 966 967 17490790 . . O O

1 968 973 17490790 These DT B-NP O
2 974 981 17490790 results NNS I-NP O
3 982 989 17490790 suggest VBP B-VP O
4 990 994 17490790 that IN B-SBAR O
5 995 1005 17490790 peripheral JJ B-NP O
6 1006 1010 17490790 iron NN I-NP D007505
7 1011 1018 17490790 dextran NN I-NP D007505
8 1019 1022 17490790 can MD B-VP O
9 1023 1031 17490790 increase VB I-VP O
10 1032 1035 17490790 the DT B-NP O
11 1036 1040 17490790 iron NN I-NP D007501
12 1041 1046 17490790 level NN I-NP O
13 1047 1049 17490790 in IN B-PP O
14 1050 1053 17490790 the DT B-NP O
15 1054 1056 17490790 SN NN I-NP O
16 1056 1057 17490790 , , O O
17 1058 1063 17490790 where WRB B-ADVP O
18 1064 1073 17490790 excessive JJ B-NP O
19 1074 1078 17490790 iron NN I-NP D007501
20 1079 1085 17490790 causes VBZ B-VP O
21 1086 1089 17490790 the DT B-NP O
22 1090 1102 17490790 degeneration NN I-NP D009410
23 1103 1105 17490790 of IN B-PP D009410
24 1106 1118 17490790 dopaminergic JJ B-NP D009410
25 1119 1126 17490790 neurons NNS I-NP D009410
26 1126 1127 17490790 . . O O

1 1128 1131 17490790 The DT B-NP O
2 1132 1139 17490790 chronic JJ I-NP O
3 1140 1144 17490790 iron NN I-NP D007501
4 1145 1153 17490790 overload NN I-NP O
5 1154 1157 17490790 may MD B-VP O
6 1158 1160 17490790 be VB I-VP O
7 1161 1165 17490790 more RBR B-ADJP O
8 1166 1177 17490790 destructive JJ I-ADJP O
9 1178 1180 17490790 to TO B-PP O
10 1181 1193 17490790 dopaminergic JJ B-NP O
11 1194 1201 17490790 neurons NNS I-NP O
12 1202 1206 17490790 than IN B-PP O
13 1207 1210 17490790 the DT B-NP O
14 1211 1216 17490790 acute JJ I-NP O
15 1217 1221 17490790 iron NN I-NP D007501
16 1222 1230 17490790 overload NN I-NP O
17 1230 1231 17490790 . . O O

1 0 0 19692487 -DOCSTART- -X- -X- O

1 0 4 19692487 Mice NNS B-NP O
2 5 12 19692487 lacking VBG B-VP O
3 13 18 19692487 mPGES NN B-NP O
4 18 19 19692487 - HYPH B-NP O
5 19 20 19692487 1 CD I-NP O
6 21 24 19692487 are VBP B-VP O
7 25 34 19692487 resistant JJ B-ADJP O
8 35 37 19692487 to TO B-PP O
9 38 45 19692487 lithium NN B-NP D008094
10 45 46 19692487 - HYPH B-NP O
11 46 53 19692487 induced VBN I-NP O
12 54 62 19692487 polyuria NN I-NP D011141
13 62 63 19692487 . . I-NP O
14 64 78 19692487 Cyclooxygenase NN I-NP O
15 78 79 19692487 - HYPH B-NP O
16 79 80 19692487 2 CD I-NP O
17 81 89 19692487 activity NN I-NP O
18 90 92 19692487 is VBZ B-VP O
19 93 101 19692487 required VBN I-VP O
20 102 105 19692487 for IN B-PP O
21 106 109 19692487 the DT B-NP O
22 110 121 19692487 development NN I-NP O
23 122 124 19692487 of IN B-PP O
24 125 132 19692487 lithium NN B-NP D008094
25 132 133 19692487 - HYPH B-NP O
26 133 140 19692487 induced VBN I-NP O
27 141 149 19692487 polyuria NN I-NP D011141
28 149 150 19692487 . . O O

1 151 158 19692487 However RB B-ADVP O
2 158 159 19692487 , , O O
3 160 163 19692487 the DT B-NP O
4 164 175 19692487 involvement NN I-NP O
5 176 178 19692487 of IN B-PP O
6 179 180 19692487 a DT B-NP O
7 181 189 19692487 specific JJ I-NP O
8 189 190 19692487 , , I-NP O
9 191 199 19692487 terminal JJ I-NP O
10 200 213 19692487 prostaglandin NN I-NP D011453
11 214 215 19692487 ( ( O O
12 215 217 19692487 PG NN B-NP D011453
13 217 218 19692487 ) ) O O
14 219 228 19692487 isomerase NN B-NP O
15 229 232 19692487 has VBZ B-VP O
16 233 236 19692487 not RB I-VP O
17 237 241 19692487 been VBN I-VP O
18 242 251 19692487 evaluated VBN I-VP O
19 251 252 19692487 . . O O

1 253 256 19692487 The DT B-NP O
2 257 264 19692487 present JJ I-NP O
3 265 270 19692487 study NN I-NP O
4 271 274 19692487 was VBD B-VP O
5 275 285 19692487 undertaken VBN I-VP O
6 286 288 19692487 to TO I-VP O
7 289 295 19692487 assess VB I-VP O
8 296 303 19692487 lithium NN B-NP D008094
9 303 304 19692487 - HYPH B-NP O
10 304 311 19692487 induced VBN I-NP O
11 312 320 19692487 polyuria NN I-NP D011141
12 321 323 19692487 in IN B-PP O
13 324 328 19692487 mice NNS B-NP O
14 329 338 19692487 deficient JJ B-ADJP O
15 339 341 19692487 in IN B-PP O
16 342 352 19692487 microsomal JJ B-NP O
17 353 366 19692487 prostaglandin NN I-NP D011458
18 367 368 19692487 E NN I-NP D011458
19 369 377 19692487 synthase NN I-NP O
20 377 378 19692487 - HYPH B-NP O
21 378 379 19692487 1 CD I-NP O
22 380 381 19692487 ( ( O O
23 381 386 19692487 mPGES NN B-NP O
24 386 387 19692487 - HYPH B-NP O
25 387 388 19692487 1 CD I-NP O
26 388 389 19692487 ) ) O O
27 389 390 19692487 . . O O

1 391 392 19692487 A DT B-NP O
2 393 394 19692487 2 CD I-NP O
3 394 395 19692487 - HYPH I-NP O
4 395 397 19692487 wk NN I-NP O
5 398 412 19692487 administration NN I-NP O
6 413 415 19692487 of IN B-PP O
7 416 420 19692487 LiCl NN B-NP D018021
8 421 422 19692487 ( ( O O
9 422 423 19692487 4 CD B-NP O
10 424 432 19692487 mmol.kg( NN I-NP O
11 432 433 19692487 - HYPH B-NP O
12 433 440 19692487 1).day( CD I-NP O
13 440 441 19692487 - HYPH I-NP O
14 441 443 19692487 1) CD I-NP O
15 444 446 19692487 ip NN I-NP O
16 446 447 19692487 ) ) O O
17 448 450 19692487 in IN B-PP O
18 451 456 19692487 mPGES NN B-NP O
19 456 457 19692487 - HYPH B-NP O
20 457 458 19692487 1 CD I-NP O
21 459 460 19692487 + SYM O O
22 460 461 19692487 / SYM O O
23 461 462 19692487 + SYM O O
24 463 467 19692487 mice NNS B-NP O
25 468 471 19692487 led VBD B-VP O
26 472 474 19692487 to TO B-PP O
27 475 476 19692487 a DT B-NP O
28 477 483 19692487 marked JJ I-NP O
29 484 492 19692487 polyuria NN I-NP D011141
30 493 497 19692487 with IN B-PP O
31 498 508 19692487 hyposmotic JJ B-NP O
32 509 514 19692487 urine NN I-NP O
33 514 515 19692487 . . O O

1 516 520 19692487 This DT B-NP O
2 521 524 19692487 was VBD B-VP O
3 525 535 19692487 associated VBN I-VP O
4 536 540 19692487 with IN B-PP O
5 541 549 19692487 elevated JJ B-NP O
6 550 555 19692487 renal JJ I-NP O
7 556 561 19692487 mPGES NN I-NP O
8 561 562 19692487 - HYPH B-NP O
9 562 563 19692487 1 CD I-NP O
10 564 571 19692487 protein NN I-NP O
11 572 582 19692487 expression NN I-NP O
12 583 586 19692487 and CC O O
13 587 596 19692487 increased VBD B-VP O
14 597 602 19692487 urine NN B-NP O
15 603 609 19692487 PGE(2) NN I-NP D015232
16 610 619 19692487 excretion NN I-NP O
17 619 620 19692487 . . O O

1 621 623 19692487 In IN B-PP O
2 624 632 19692487 contrast NN B-NP O
3 632 633 19692487 , , O O
4 634 639 19692487 mPGES NN B-NP O
5 639 640 19692487 - HYPH B-NP O
6 640 641 19692487 1 CD I-NP O
7 642 643 19692487 - HYPH B-NP O
8 643 644 19692487 / SYM I-NP O
9 644 645 19692487 - HYPH I-NP O
10 646 650 19692487 mice NNS B-NP O
11 651 655 19692487 were VBD B-VP O
12 656 663 19692487 largely RB B-ADJP O
13 664 673 19692487 resistant JJ I-ADJP O
14 674 676 19692487 to TO B-PP O
15 677 684 19692487 lithium NN B-NP D008094
16 684 685 19692487 - HYPH O O
17 685 692 19692487 induced VBN B-NP O
18 693 701 19692487 polyuria NN I-NP D011141
19 702 705 19692487 and CC O O
20 706 707 19692487 a DT B-NP O
21 708 713 19692487 urine NN I-NP O
22 714 727 19692487 concentrating VBG I-NP O
23 728 734 19692487 defect NN I-NP O
24 734 735 19692487 , , O O
25 736 747 19692487 accompanied VBN B-VP O
26 748 750 19692487 by IN B-PP O
27 751 757 19692487 nearly RB B-NP O
28 758 766 19692487 complete JJ I-NP O
29 767 775 19692487 blockade NN I-NP O
30 776 778 19692487 of IN B-PP O
31 779 783 19692487 high JJ B-NP O
32 784 789 19692487 urine NN I-NP O
33 790 796 19692487 PGE(2) NN I-NP D015232
34 797 800 19692487 and CC O O
35 801 805 19692487 cAMP NN B-NP O
36 806 812 19692487 output NN I-NP O
37 812 813 19692487 . . O O

1 814 828 19692487 Immunoblotting NN B-NP O
2 828 829 19692487 , , O O
3 830 850 19692487 immunohistochemistry NN B-NP O
4 850 851 19692487 , , O O
5 852 855 19692487 and CC O O
6 856 868 19692487 quantitative JJ B-ADJP O
7 869 870 19692487 ( ( O O
8 870 871 19692487 q NN B-NP O
9 871 872 19692487 ) ) O O
10 873 875 19692487 RT NN B-NP O
11 875 876 19692487 - HYPH O O
12 876 879 19692487 PCR NN B-NP O
13 880 892 19692487 consistently RB B-ADVP O
14 893 901 19692487 detected VBD B-VP O
15 902 903 19692487 a DT B-NP O
16 904 915 19692487 significant JJ I-NP O
17 916 924 19692487 decrease NN I-NP O
18 925 927 19692487 in IN B-PP O
19 928 937 19692487 aquaporin NN B-NP O
20 937 938 19692487 - HYPH B-NP O
21 938 939 19692487 2 CD I-NP O
22 940 941 19692487 ( ( O O
23 941 945 19692487 AQP2 NN B-NP O
24 945 946 19692487 ) ) O O
25 947 954 19692487 protein NN B-NP O
26 955 965 19692487 expression NN I-NP O
27 966 968 19692487 in IN B-PP O
28 969 973 19692487 both CC O O
29 974 977 19692487 the DT B-NP O
30 978 983 19692487 renal JJ I-NP O
31 984 990 19692487 cortex NN I-NP O
32 991 994 19692487 and CC I-NP O
33 995 1002 19692487 medulla NN I-NP O
34 1003 1005 19692487 of IN B-PP O
35 1006 1013 19692487 lithium NN B-NP D008094
36 1013 1014 19692487 - HYPH O O
37 1014 1021 19692487 treated VBN B-VP O
38 1022 1023 19692487 + SYM B-NP O
39 1023 1024 19692487 / SYM B-NP O
40 1024 1025 19692487 + SYM B-VP O
41 1026 1030 19692487 mice NNS B-NP O
42 1030 1031 19692487 . . O O

1 1032 1036 19692487 This DT B-NP O
2 1037 1045 19692487 decrease NN I-NP O
3 1046 1049 19692487 was VBD B-VP O
4 1050 1063 19692487 significantly RB I-VP O
5 1064 1074 19692487 attenuated VBN I-VP O
6 1075 1077 19692487 in IN B-PP O
7 1078 1081 19692487 the DT B-NP O
8 1082 1083 19692487 - HYPH I-NP O
9 1083 1084 19692487 / SYM I-NP O
10 1084 1085 19692487 - HYPH I-NP O
11 1086 1090 19692487 mice NNS B-NP O
12 1090 1091 19692487 . . O O

1 1092 1095 19692487 qRT NN B-NP O
2 1095 1096 19692487 - HYPH I-NP O
3 1096 1099 19692487 PCR NN I-NP O
4 1100 1108 19692487 detected VBD B-VP O
5 1109 1116 19692487 similar JJ B-NP O
6 1117 1125 19692487 patterns NNS I-NP O
7 1126 1128 19692487 of IN B-PP O
8 1129 1136 19692487 changes NNS B-NP O
9 1137 1139 19692487 in IN B-PP O
10 1140 1144 19692487 AQP2 NN B-NP O
11 1145 1149 19692487 mRNA NN I-NP O
12 1150 1152 19692487 in IN B-PP O
13 1153 1156 19692487 the DT B-NP O
14 1157 1164 19692487 medulla NN I-NP O
15 1165 1168 19692487 but CC B-PP O
16 1169 1172 19692487 not RB B-PP O
17 1173 1175 19692487 in IN I-PP O
18 1176 1179 19692487 the DT B-NP O
19 1180 1186 19692487 cortex NN I-NP O
20 1186 1187 19692487 . . O O

1 1188 1197 19692487 Similarly RB B-ADVP O
2 1197 1198 19692487 , , O O
3 1199 1202 19692487 the DT B-NP O
4 1203 1208 19692487 total JJ I-NP O
5 1209 1216 19692487 protein NN I-NP O
6 1217 1226 19692487 abundance NN I-NP O
7 1227 1229 19692487 of IN B-PP O
8 1230 1233 19692487 the DT B-NP O
9 1234 1236 19692487 Na NN I-NP D012964
10 1236 1237 19692487 - HYPH B-NP O
11 1237 1238 19692487 K NN I-NP D011188
12 1238 1239 19692487 - HYPH O O
13 1239 1242 19692487 2Cl NN B-NP D002713
14 1243 1256 19692487 cotransporter NN I-NP O
15 1257 1258 19692487 ( ( O O
16 1258 1263 19692487 NKCC2 NN B-NP O
17 1263 1264 19692487 ) ) O O
18 1265 1267 19692487 in IN B-PP O
19 1268 1271 19692487 the DT B-NP O
20 1272 1279 19692487 medulla NN I-NP O
21 1280 1283 19692487 but CC B-PP O
22 1284 1287 19692487 not RB B-PP O
23 1288 1290 19692487 in IN I-PP O
24 1291 1294 19692487 the DT B-NP O
25 1295 1301 19692487 cortex NN I-NP O
26 1302 1304 19692487 of IN B-PP O
27 1305 1308 19692487 the DT B-NP O
28 1309 1310 19692487 + SYM I-NP O
29 1310 1311 19692487 / SYM I-NP O
30 1311 1312 19692487 + SYM I-NP O
31 1313 1317 19692487 mice NNS I-NP O
32 1318 1321 19692487 was VBD B-VP O
33 1322 1335 19692487 significantly RB I-VP O
34 1336 1343 19692487 reduced VBN I-VP O
35 1344 1346 19692487 by IN B-PP O
36 1347 1354 19692487 lithium NN B-NP D008094
37 1355 1364 19692487 treatment NN I-NP O
38 1364 1365 19692487 . . O O

1 1366 1368 19692487 In IN B-PP O
2 1369 1377 19692487 contrast NN B-NP O
3 1377 1378 19692487 , , O O
4 1379 1382 19692487 the DT B-NP O
5 1383 1396 19692487 dowregulation NN I-NP O
6 1397 1399 19692487 of IN B-PP O
7 1400 1405 19692487 renal JJ B-NP O
8 1406 1415 19692487 medullary JJ I-NP O
9 1416 1421 19692487 NKCC2 NN I-NP O
10 1422 1432 19692487 expression NN I-NP O
11 1433 1436 19692487 was VBD B-VP O
12 1437 1450 19692487 significantly RB I-VP O
13 1451 1461 19692487 attenuated VBN I-VP O
14 1462 1464 19692487 in IN B-PP O
15 1465 1468 19692487 the DT B-NP O
16 1469 1470 19692487 - HYPH I-NP O
17 1470 1471 19692487 / SYM I-NP O
18 1471 1472 19692487 - HYPH I-NP O
19 1473 1477 19692487 mice NNS B-NP O
20 1477 1478 19692487 . . O O

1 1479 1481 19692487 We PRP B-NP O
2 1482 1490 19692487 conclude VBP B-VP O
3 1491 1495 19692487 that IN B-SBAR O
4 1496 1501 19692487 mPGES NN B-NP O
5 1501 1502 19692487 - HYPH B-NP O
6 1502 1503 19692487 1 CD I-NP O
7 1503 1504 19692487 - HYPH I-NP O
8 1504 1511 19692487 derived VBN I-NP O
9 1512 1518 19692487 PGE(2) NN I-NP D015232
10 1519 1527 19692487 mediates VBZ B-VP O
11 1528 1535 19692487 lithium NN B-NP D008094
12 1535 1536 19692487 - HYPH B-NP O
13 1536 1543 19692487 induced VBN I-NP O
14 1544 1552 19692487 polyuria NN I-NP D011141
15 1553 1559 19692487 likely RB B-ADJP O
16 1560 1563 19692487 via IN B-PP O
17 1564 1574 19692487 inhibition NN B-NP O
18 1575 1577 19692487 of IN B-PP O
19 1578 1582 19692487 AQP2 NN B-NP O
20 1583 1586 19692487 and CC I-NP O
21 1587 1592 19692487 NKCC2 NN I-NP O
22 1593 1603 19692487 expression NN I-NP O
23 1603 1604 19692487 . . O O

1 0 0 19135948 -DOCSTART- -X- -X- O

1 0 5 19135948 Graft NN B-NP D006086
2 5 6 19135948 - HYPH B-ADJP D006086
3 6 12 19135948 versus IN B-PP D006086
4 12 13 19135948 - HYPH B-NP D006086
5 13 17 19135948 host NN I-NP D006086
6 18 25 19135948 disease NN I-NP D006086
7 26 37 19135948 prophylaxis NN I-NP O
8 38 42 19135948 with IN B-PP O
9 43 53 19135948 everolimus NN B-NP C107135
10 54 57 19135948 and CC I-NP O
11 58 68 19135948 tacrolimus NN I-NP D016559
12 69 71 19135948 is VBZ B-VP O
13 72 82 19135948 associated VBN I-VP O
14 83 87 19135948 with IN B-PP O
15 88 89 19135948 a DT B-NP O
16 90 94 19135948 high JJ I-NP O
17 95 104 19135948 incidence NN I-NP O
18 105 107 19135948 of IN B-PP O
19 108 118 19135948 sinusoidal JJ B-NP D006504
20 119 130 19135948 obstruction NN I-NP D006504
21 131 139 19135948 syndrome NN I-NP D006504
22 140 143 19135948 and CC I-NP O
23 144 159 19135948 microangiopathy NN I-NP D014652
24 159 160 19135948 : : O O
25 161 168 19135948 results NNS B-NP O
26 169 171 19135948 of IN B-PP O
27 172 175 19135948 the DT B-NP O
28 176 181 19135948 EVTAC NN I-NP O
29 182 187 19135948 trial NN I-NP O
30 187 188 19135948 . . I-NP O
31 189 190 19135948 A NN I-NP O
32 191 202 19135948 calcineurin NN I-NP O
33 203 212 19135948 inhibitor NN I-NP O
34 213 221 19135948 combined VBN B-VP O
35 222 226 19135948 with IN B-PP O
36 227 239 19135948 methotrexate NN B-NP D008727
37 240 242 19135948 is VBZ B-VP O
38 243 246 19135948 the DT B-NP O
39 247 255 19135948 standard JJ I-NP O
40 256 267 19135948 prophylaxis NN I-NP O
41 268 271 19135948 for IN B-PP O
42 272 277 19135948 graft NN B-NP D006086
43 277 278 19135948 - HYPH B-ADVP D006086
44 278 284 19135948 versus IN B-PP D006086
45 284 285 19135948 - HYPH B-NP D006086
46 285 289 19135948 host NN I-NP D006086
47 290 297 19135948 disease NN I-NP D006086
48 298 299 19135948 ( ( O O
49 299 303 19135948 GVHD NN B-NP D006086
50 303 304 19135948 ) ) O O
51 305 310 19135948 after IN B-PP O
52 311 321 19135948 allogeneic JJ B-NP O
53 322 335 19135948 hematopoietic JJ I-NP O
54 336 340 19135948 stem NN I-NP O
55 341 345 19135948 cell NN I-NP O
56 346 361 19135948 transplantation NN I-NP O
57 362 363 19135948 ( ( O O
58 363 367 19135948 HSCT NN B-NP O
59 367 368 19135948 ) ) O O
60 368 369 19135948 . . O O

1 370 380 19135948 Everolimus RB B-ADVP C107135
2 380 381 19135948 , , O O
3 382 383 19135948 a DT B-NP O
4 384 394 19135948 derivative NN I-NP O
5 395 397 19135948 of IN B-PP O
6 398 407 19135948 sirolimus NN B-NP D020123
7 407 408 19135948 , , O O
8 409 414 19135948 seems VBZ B-VP O
9 415 417 19135948 to TO I-VP O
10 418 425 19135948 mediate VB I-VP O
11 426 438 19135948 antileukemia JJ B-NP O
12 439 446 19135948 effects NNS I-NP O
13 446 447 19135948 . . O O

1 448 450 19135948 We PRP B-NP O
2 451 457 19135948 report VBP B-VP O
3 458 460 19135948 on IN B-PP O
4 461 462 19135948 a DT B-NP O
5 463 474 19135948 combination NN I-NP O
6 475 477 19135948 of IN B-PP O
7 478 488 19135948 everolimus NN B-NP C107135
8 489 492 19135948 and CC I-NP O
9 493 503 19135948 tacrolimus NN I-NP D016559
10 504 506 19135948 in IN B-PP O
11 507 509 19135948 24 CD B-NP O
12 510 518 19135948 patients NNS I-NP O
13 519 520 19135948 ( ( O O
14 520 526 19135948 median JJ B-NP O
15 527 530 19135948 age NN I-NP O
16 530 531 19135948 , , O O
17 532 534 19135948 62 CD B-NP O
18 535 540 19135948 years NNS I-NP O
19 540 541 19135948 ) ) O O
20 542 546 19135948 with IN B-PP O
21 547 553 19135948 either CC B-NP O
22 554 569 19135948 myelodysplastic JJ I-NP D009190
23 570 578 19135948 syndrome NN I-NP D009190
24 579 580 19135948 ( ( O O
25 580 583 19135948 MDS NN B-NP D009190
26 583 584 19135948 ; : O O
27 585 586 19135948 n NN B-NP O
28 587 588 19135948 = SYM B-VP O
29 589 591 19135948 17 CD B-NP O
30 591 592 19135948 ) ) O O
31 593 595 19135948 or CC O O
32 596 601 19135948 acute JJ B-NP D015470
33 602 609 19135948 myeloid JJ I-NP D015470
34 610 618 19135948 leukemia NN I-NP D015470
35 619 620 19135948 ( ( O O
36 620 623 19135948 AML NN B-NP D015470
37 623 624 19135948 ; : O O
38 625 626 19135948 n NN B-NP O
39 627 628 19135948 = SYM B-VP O
40 629 630 19135948 7 CD B-NP O
41 630 631 19135948 ) ) O O
42 632 642 19135948 undergoing VBG B-VP O
43 643 652 19135948 intensive JJ B-NP O
44 653 665 19135948 conditioning NN I-NP O
45 666 674 19135948 followed VBN B-VP O
46 675 677 19135948 by IN B-PP O
47 678 682 19135948 HSCT NN B-NP O
48 683 687 19135948 from IN B-PP O
49 688 695 19135948 related JJ B-NP O
50 696 697 19135948 ( ( O O
51 697 698 19135948 n NN B-NP O
52 699 700 19135948 = SYM B-VP O
53 701 702 19135948 4 CD B-NP O
54 702 703 19135948 ) ) O O
55 704 706 19135948 or CC O O
56 707 716 19135948 unrelated JJ B-NP O
57 717 718 19135948 ( ( O O
58 718 719 19135948 n NN B-NP O
59 720 721 19135948 = SYM B-VP O
60 722 724 19135948 20 CD B-NP O
61 724 725 19135948 ) ) O O
62 726 732 19135948 donors NNS B-NP O
63 732 733 19135948 . . O O

1 734 737 19135948 All DT B-NP O
2 738 746 19135948 patients NNS I-NP O
3 747 756 19135948 engrafted VBN B-VP O
4 756 757 19135948 , , O O
5 758 761 19135948 and CC O O
6 762 766 19135948 only RB B-NP O
7 767 768 19135948 1 CD I-NP O
8 769 776 19135948 patient NN I-NP O
9 777 788 19135948 experienced VBD B-VP O
10 789 794 19135948 grade NN B-NP O
11 795 797 19135948 IV CD I-NP O
12 798 807 19135948 mucositis NN I-NP D052016
13 807 808 19135948 . . O O

1 809 813 19135948 Nine CD B-NP O
2 814 822 19135948 patients NNS I-NP O
3 823 824 19135948 ( ( O O
4 824 827 19135948 37% NN B-NP O
5 827 828 19135948 ) ) O O
6 829 838 19135948 developed VBD B-VP O
7 839 844 19135948 acute JJ B-NP O
8 845 850 19135948 grade NN I-NP O
9 851 853 19135948 II CD I-NP O
10 853 854 19135948 - HYPH I-NP O
11 854 856 19135948 IV CD I-NP O
12 857 861 19135948 GVHD NN I-NP D006086
13 861 862 19135948 , , O O
14 863 866 19135948 and CC O O
15 867 869 19135948 11 CD B-NP O
16 870 872 19135948 of IN B-PP O
17 873 875 19135948 17 CD B-NP O
18 876 885 19135948 evaluable JJ I-NP O
19 886 894 19135948 patients NNS I-NP O
20 895 896 19135948 ( ( O O
21 896 899 19135948 64% NN B-NP O
22 899 900 19135948 ) ) O O
23 901 910 19135948 developed VBD B-VP O
24 911 918 19135948 chronic JJ B-NP O
25 919 928 19135948 extensive JJ I-NP O
26 929 933 19135948 GVHD NN I-NP D006086
27 933 934 19135948 . . O O

1 935 950 19135948 Transplantation NN B-NP D014652
2 950 951 19135948 - HYPH O D014652
3 951 961 19135948 associated VBN B-VP D014652
4 962 977 19135948 microangiopathy NN B-NP D014652
5 978 979 19135948 ( ( O O
6 979 982 19135948 TMA NN B-NP D014652
7 982 983 19135948 ) ) O O
8 984 992 19135948 occurred VBD B-VP O
9 993 995 19135948 in IN B-PP O
10 996 997 19135948 7 CD B-NP O
11 998 1006 19135948 patients NNS I-NP O
12 1007 1008 19135948 ( ( O O
13 1008 1011 19135948 29% CD B-NP O
14 1011 1012 19135948 ) ) O O
15 1012 1013 19135948 , , O O
16 1014 1018 19135948 with IN B-PP O
17 1019 1020 19135948 2 CD B-NP O
18 1021 1026 19135948 cases NNS I-NP O
19 1027 1029 19135948 of IN B-PP O
20 1030 1035 19135948 acute JJ B-NP D058186
21 1036 1041 19135948 renal JJ I-NP D058186
22 1042 1049 19135948 failure NN I-NP D058186
23 1049 1050 19135948 . . O O

1 1051 1054 19135948 The DT B-NP O
2 1055 1060 19135948 study NN I-NP O
3 1061 1064 19135948 was VBD B-VP O
4 1065 1075 19135948 terminated VBN I-VP O
5 1076 1087 19135948 prematurely RB B-ADVP O
6 1088 1095 19135948 because IN B-SBAR O
7 1096 1098 19135948 an DT B-NP O
8 1099 1109 19135948 additional JJ I-NP O
9 1110 1111 19135948 6 CD I-NP O
10 1112 1120 19135948 patients NNS I-NP O
11 1121 1122 19135948 ( ( O O
12 1122 1125 19135948 25% NN B-NP O
13 1125 1126 19135948 ) ) O O
14 1127 1136 19135948 developed VBD B-VP O
15 1137 1147 19135948 sinusoidal JJ B-NP D006504
16 1148 1159 19135948 obstruction NN I-NP D006504
17 1160 1168 19135948 syndrome NN I-NP D006504
18 1169 1170 19135948 ( ( O O
19 1170 1173 19135948 SOS NN B-NP D006504
20 1173 1174 19135948 ) ) O O
21 1174 1175 19135948 , , O O
22 1176 1181 19135948 which WDT B-NP O
23 1182 1185 19135948 was VBD B-VP O
24 1186 1191 19135948 fatal JJ B-ADJP O
25 1192 1194 19135948 in IN B-PP O
26 1195 1196 19135948 2 CD B-NP O
27 1197 1202 19135948 cases NNS I-NP O
28 1202 1203 19135948 . . O O

1 1204 1208 19135948 With IN B-PP O
2 1209 1210 19135948 a DT B-NP O
3 1211 1217 19135948 median JJ I-NP O
4 1218 1224 19135948 follow VB B-VP O
5 1224 1225 19135948 - HYPH O O
6 1225 1227 19135948 up RP B-PRT O
7 1228 1230 19135948 of IN B-PP O
8 1231 1233 19135948 26 CD B-NP O
9 1234 1240 19135948 months NNS I-NP O
10 1240 1241 19135948 , , O O
11 1242 1245 19135948 the DT B-NP O
12 1246 1247 19135948 2 CD I-NP O
13 1247 1248 19135948 - HYPH I-NP O
14 1248 1252 19135948 year NN I-NP O
15 1253 1260 19135948 overall JJ I-NP O
16 1261 1269 19135948 survival NN I-NP O
17 1270 1274 19135948 rate NN I-NP O
18 1275 1278 19135948 was VBD B-VP O
19 1279 1282 19135948 47% CD B-NP O
20 1282 1283 19135948 . . O O

1 1284 1292 19135948 Although IN B-SBAR O
2 1293 1297 19135948 this DT B-NP O
3 1298 1301 19135948 new JJ I-NP O
4 1302 1313 19135948 combination NN I-NP O
5 1314 1321 19135948 appears VBZ B-VP O
6 1322 1324 19135948 to TO I-VP O
7 1325 1327 19135948 be VB I-VP O
8 1328 1337 19135948 effective JJ B-ADJP O
9 1338 1340 19135948 as IN B-PP O
10 1341 1342 19135948 a DT B-NP O
11 1343 1355 19135948 prophylactic JJ I-NP O
12 1356 1363 19135948 regimen NN I-NP O
13 1364 1367 19135948 for IN B-PP O
14 1368 1373 19135948 acute JJ B-NP O
15 1374 1378 19135948 GVHD NN I-NP D006086
16 1378 1379 19135948 , , O O
17 1380 1383 19135948 the DT B-NP O
18 1384 1393 19135948 incidence NN I-NP O
19 1394 1396 19135948 of IN B-PP O
20 1397 1400 19135948 TMA NN B-NP D014652
21 1401 1404 19135948 and CC I-NP O
22 1405 1408 19135948 SOS NN I-NP D006504
23 1409 1411 19135948 is VBZ B-VP O
24 1412 1424 19135948 considerably RB B-ADJP O
25 1425 1431 19135948 higher JJR I-ADJP O
26 1432 1436 19135948 than IN B-SBAR O
27 1437 1441 19135948 seen VBN B-VP O
28 1442 1446 19135948 with IN B-PP O
29 1447 1452 19135948 other JJ B-NP O
30 1453 1461 19135948 regimens NNS I-NP O
31 1461 1462 19135948 . . O O

1 0 0 7604176 -DOCSTART- -X- -X- O

1 0 11 7604176 Pravastatin NN B-NP D017035
2 11 12 7604176 - HYPH B-PP O
3 12 22 7604176 associated VBN B-NP O
4 23 31 7604176 myopathy NN I-NP D009135
5 31 32 7604176 . . O O

1 33 39 7604176 Report NN B-NP O
2 40 42 7604176 of IN B-PP O
3 43 44 7604176 a DT B-NP O
4 45 49 7604176 case NN I-NP O
5 49 50 7604176 . . O O
6 51 52 7604176 A DT B-NP O
7 53 57 7604176 case NN I-NP O
8 58 60 7604176 of IN B-PP O
9 61 66 7604176 acute JJ B-NP O
10 67 79 7604176 inflammatory JJ I-NP D009220
11 80 88 7604176 myopathy NN I-NP D009220
12 89 99 7604176 associated VBN B-VP O
13 100 104 7604176 with IN B-PP O
14 105 108 7604176 the DT B-NP O
15 109 112 7604176 use NN I-NP O
16 113 115 7604176 of IN B-PP O
17 116 127 7604176 pravastatin NN B-NP D017035
18 127 128 7604176 , , O O
19 129 130 7604176 a DT B-NP O
20 131 134 7604176 new JJ I-NP O
21 135 146 7604176 hydrophilic JJ I-NP O
22 147 148 7604176 3 CD I-NP O
23 148 149 7604176 - HYPH I-NP O
24 149 156 7604176 hydroxy NN I-NP O
25 156 157 7604176 - HYPH B-NP O
26 157 158 7604176 3 CD I-NP O
27 159 173 7604176 methylglutaril NN I-NP O
28 174 182 7604176 coenzyme NN I-NP O
29 183 184 7604176 A NN I-NP O
30 185 194 7604176 reductase NN I-NP O
31 195 204 7604176 inhibitor NN I-NP O
32 204 205 7604176 , , O O
33 206 208 7604176 is VBZ B-VP O
34 209 217 7604176 reported VBN I-VP O
35 217 218 7604176 . . O O

1 219 222 7604176 The DT B-NP O
2 223 230 7604176 patient NN I-NP O
3 230 231 7604176 , , O O
4 232 233 7604176 a DT B-NP O
5 234 236 7604176 69 CD I-NP O
6 236 237 7604176 - HYPH I-NP O
7 237 241 7604176 year NN I-NP O
8 241 242 7604176 - HYPH O O
9 242 245 7604176 old JJ B-NP O
10 246 249 7604176 man NN I-NP O
11 250 253 7604176 was VBD B-VP O
12 254 262 7604176 affected VBN I-VP O
13 263 265 7604176 by IN B-PP O
14 266 269 7604176 non AFX B-NP D003924
15 269 270 7604176 - HYPH I-NP D003924
16 270 277 7604176 insulin NN I-NP D003924
17 277 278 7604176 - HYPH I-NP D003924
18 278 287 7604176 dependent JJ I-NP D003924
19 288 296 7604176 diabetes NNS I-NP D003924
20 297 305 7604176 mellitus NN I-NP D003924
21 306 309 7604176 and CC I-NP O
22 310 322 7604176 hypertension NN I-NP D006973
23 322 323 7604176 . . O O

1 324 326 7604176 He PRP B-NP O
2 327 334 7604176 assumed VBD B-VP O
3 335 346 7604176 pravastatin NN B-NP D017035
4 347 348 7604176 ( ( O O
5 348 350 7604176 20 CD B-NP O
6 351 353 7604176 mg NN I-NP O
7 353 354 7604176 / SYM B-NP O
8 354 357 7604176 day NN I-NP O
9 357 358 7604176 ) ) O O
10 359 366 7604176 because IN B-PP O
11 367 369 7604176 of IN I-PP O
12 370 390 7604176 hypercholesterolemia NN B-NP D006937
13 390 391 7604176 . . O O

1 392 394 7604176 He PRP B-NP O
2 395 398 7604176 was VBD B-VP O
3 399 407 7604176 admitted VBN I-VP O
4 408 412 7604176 with IN B-PP O
5 413 418 7604176 acute JJ B-NP O
6 419 427 7604176 myopathy NN I-NP D009135
7 428 430 7604176 of IN B-PP O
8 431 434 7604176 the DT B-NP O
9 435 440 7604176 lower JJR I-NP O
10 441 446 7604176 limbs NNS I-NP O
11 447 452 7604176 which WDT B-NP O
12 453 461 7604176 resolved VBD B-VP O
13 462 464 7604176 in IN B-PP O
14 465 466 7604176 a DT B-NP O
15 467 470 7604176 few JJ I-NP O
16 471 475 7604176 days NNS I-NP O
17 476 481 7604176 after IN B-PP O
18 482 493 7604176 pravastatin NN B-NP D017035
19 494 509 7604176 discontinuation NN I-NP O
20 509 510 7604176 . . O O

1 511 512 7604176 A DT B-NP O
2 513 523 7604176 previously RB I-NP O
3 524 531 7604176 unknown JJ I-NP O
4 532 546 7604176 hypothyroidism NN I-NP D007037
5 546 547 7604176 , , O O
6 548 556 7604176 probably RB B-ADVP O
7 557 560 7604176 due JJ B-ADJP O
8 561 563 7604176 to TO B-PP O
9 564 571 7604176 chronic JJ B-NP O
10 572 582 7604176 autoimmune JJ I-NP D013967
11 583 594 7604176 thyroiditis NN I-NP D013967
12 594 595 7604176 , , O O
13 596 599 7604176 was VBD B-VP O
14 600 609 7604176 evidenced VBN I-VP O
15 609 610 7604176 . . O O

1 611 617 7604176 Muscle NN B-NP O
2 618 624 7604176 biopsy NN I-NP O
3 625 626 7604176 ( ( O O
4 626 630 7604176 left JJ B-NP O
5 631 644 7604176 gastrocnemius NN I-NP O
6 644 645 7604176 ) ) O O
7 646 654 7604176 revealed VBD B-VP O
8 655 656 7604176 a DT B-NP O
9 657 667 7604176 perimysial JJ I-NP O
10 668 671 7604176 and CC I-NP O
11 672 682 7604176 endomysial JJ I-NP O
12 683 695 7604176 inflammatory JJ I-NP O
13 696 706 7604176 infiltrate NN I-NP O
14 707 711 7604176 with IN B-PP O
15 712 713 7604176 a DT B-NP O
16 714 724 7604176 prevalence NN I-NP O
17 725 727 7604176 of IN B-PP O
18 728 732 7604176 CD4+ JJ B-NP O
19 733 744 7604176 lymphocytes NNS I-NP O
20 744 745 7604176 . . O O

1 746 751 7604176 While IN B-SBAR O
2 752 762 7604176 lovastatin NN B-NP D008148
3 763 766 7604176 and CC I-NP O
4 767 778 7604176 simvastatin NN I-NP D019821
5 779 783 7604176 have VBP B-VP O
6 784 788 7604176 been VBN I-VP O
7 789 799 7604176 associated VBN I-VP O
8 800 804 7604176 with IN B-PP O
9 805 810 7604176 toxic JJ B-NP O
10 811 819 7604176 myopathy NN I-NP D009135
11 819 820 7604176 , , O O
12 821 832 7604176 pravastatin NN B-NP D017035
13 832 833 7604176 - HYPH B-VP O
14 833 843 7604176 associated VBN B-NP O
15 844 852 7604176 myopathy NN I-NP D009135
16 853 858 7604176 could MD B-VP O
17 859 868 7604176 represent VB I-VP O
18 869 870 7604176 a DT B-NP O
19 871 879 7604176 distinct JJ I-NP O
20 879 880 7604176 , , I-NP O
21 881 893 7604176 inflammatory JJ I-NP O
22 894 900 7604176 entity NN I-NP O
23 900 901 7604176 . . O O

1 0 0 17194457 -DOCSTART- -X- -X- O

1 0 10 17194457 Behavioral JJ B-NP O
2 11 18 17194457 effects NNS I-NP O
3 19 21 17194457 of IN B-PP O
4 22 30 17194457 pubertal JJ B-NP O
5 31 39 17194457 anabolic JJ I-NP O
6 40 50 17194457 androgenic JJ I-NP O
7 51 58 17194457 steroid NN I-NP D013256
8 59 67 17194457 exposure NN I-NP O
9 68 70 17194457 in IN B-PP O
10 71 75 17194457 male JJ B-NP O
11 76 80 17194457 rats NNS I-NP O
12 81 85 17194457 with IN B-PP O
13 86 89 17194457 low JJ B-NP O
14 90 99 17194457 serotonin NN I-NP D012701
15 99 100 17194457 . . O O
16 101 104 17194457 The DT B-NP O
17 105 109 17194457 goal NN I-NP O
18 110 112 17194457 of IN B-PP O
19 113 117 17194457 this DT B-NP O
20 118 123 17194457 study NN I-NP O
21 124 127 17194457 was VBD B-VP O
22 128 130 17194457 to TO B-VP O
23 131 137 17194457 assess VB I-VP O
24 138 141 17194457 the DT B-NP O
25 142 153 17194457 interactive JJ I-NP O
26 154 161 17194457 effects NNS I-NP O
27 162 164 17194457 of IN B-PP O
28 165 172 17194457 chronic JJ B-NP O
29 173 181 17194457 anabolic JJ I-NP O
30 182 192 17194457 androgenic JJ I-NP O
31 193 200 17194457 steroid NN I-NP D013256
32 201 202 17194457 ( ( O O
33 202 205 17194457 AAS NN B-NP O
34 205 206 17194457 ) ) O O
35 207 215 17194457 exposure NN B-NP O
36 216 219 17194457 and CC O O
37 220 225 17194457 brain NN B-NP O
38 226 235 17194457 serotonin NN I-NP D012701
39 236 237 17194457 ( ( O O
40 237 238 17194457 5 CD B-NP D012701
41 238 239 17194457 - HYPH I-NP D012701
42 239 256 17194457 hydroxytryptamine NN I-NP D012701
43 256 257 17194457 , , O O
44 258 259 17194457 5 CD B-NP D012701
45 259 260 17194457 - HYPH I-NP D012701
46 260 262 17194457 HT NN I-NP D012701
47 262 263 17194457 ) ) O O
48 264 273 17194457 depletion NN B-NP O
49 274 276 17194457 on IN B-PP O
50 277 285 17194457 behavior NN B-NP O
51 286 288 17194457 of IN B-PP O
52 289 297 17194457 pubertal JJ B-NP O
53 298 302 17194457 male JJ I-NP O
54 303 307 17194457 rats NNS I-NP O
55 307 308 17194457 . . O O

1 309 318 17194457 Serotonin NN B-NP D012701
2 319 322 17194457 was VBD B-VP O
3 323 331 17194457 depleted VBN I-VP O
4 332 341 17194457 beginning VBG B-PP O
5 342 344 17194457 on IN B-PP O
6 345 354 17194457 postnatal JJ B-NP O
7 355 358 17194457 day NN I-NP O
8 359 361 17194457 26 CD I-NP O
9 362 366 17194457 with IN B-PP O
10 367 390 17194457 parachlorophenylalanine NN B-NP -1
11 391 392 17194457 ( ( O O
12 392 396 17194457 PCPA NN B-NP -1
13 397 400 17194457 100 CD I-NP O
14 401 403 17194457 mg NN I-NP O
15 403 404 17194457 / SYM B-NP O
16 404 406 17194457 kg NN I-NP O
17 406 407 17194457 , , O O
18 408 413 17194457 every DT B-NP O
19 414 419 17194457 other JJ I-NP O
20 420 423 17194457 day NN I-NP O
21 423 424 17194457 ) ) O O
22 424 425 17194457 ; : O O
23 426 434 17194457 controls NNS B-NP O
24 435 443 17194457 received VBD B-VP O
25 444 450 17194457 saline NN B-NP O
26 450 451 17194457 . . O O

1 452 454 17194457 At IN B-PP O
2 455 462 17194457 puberty NN B-NP O
3 463 464 17194457 ( ( O O
4 464 467 17194457 P40 NN B-NP O
5 467 468 17194457 ) ) O O
6 468 469 17194457 , , O O
7 470 474 17194457 half PDT B-NP O
8 475 478 17194457 the DT I-NP O
9 479 483 17194457 PCPA NN I-NP -1
10 483 484 17194457 - HYPH B-NP O
11 484 491 17194457 treated VBN I-NP O
12 492 496 17194457 rats NNS I-NP O
13 497 500 17194457 and CC O O
14 501 505 17194457 half PDT B-NP O
15 506 509 17194457 the DT I-NP O
16 510 516 17194457 saline NN I-NP O
17 516 517 17194457 - HYPH B-NP O
18 517 524 17194457 treated VBN I-NP O
19 525 529 17194457 rats NNS I-NP O
20 530 535 17194457 began VBD B-VP O
21 536 545 17194457 treatment NN B-NP O
22 546 550 17194457 with IN B-PP O
23 551 563 17194457 testosterone NN B-NP D013739
24 564 565 17194457 ( ( O O
25 565 566 17194457 T NN B-NP D013739
26 566 567 17194457 , , O O
27 568 569 17194457 5 CD B-NP O
28 570 572 17194457 mg NN I-NP O
29 572 573 17194457 / SYM B-NP O
30 573 575 17194457 kg NN I-NP O
31 575 576 17194457 , , O O
32 577 578 17194457 5 CD B-NP O
33 579 583 17194457 days NNS I-NP O
34 583 584 17194457 / SYM B-NP O
35 584 588 17194457 week NN I-NP O
36 588 589 17194457 ) ) O O
37 589 590 17194457 . . O O

1 591 601 17194457 Behavioral JJ B-NP O
2 602 610 17194457 measures NNS I-NP O
3 611 619 17194457 included VBD B-VP O
4 620 630 17194457 locomotion NN B-NP O
5 630 631 17194457 , , O O
6 632 644 17194457 irritability NN B-NP D001523
7 644 645 17194457 , , O O
8 646 656 17194457 copulation NN B-NP O
9 656 657 17194457 , , O O
10 658 665 17194457 partner NN B-NP O
11 666 676 17194457 preference NN I-NP O
12 676 677 17194457 , , O O
13 678 681 17194457 and CC O O
14 682 692 17194457 aggression NN B-NP D001523
15 692 693 17194457 . . O O

1 694 701 17194457 Animals NNS B-NP O
2 702 706 17194457 were VBD B-VP O
3 707 713 17194457 tested VBN I-VP O
4 714 717 17194457 for IN B-PP O
5 718 728 17194457 aggression NN B-NP D001523
6 729 731 17194457 in IN B-PP O
7 732 737 17194457 their PRP$ B-NP O
8 738 742 17194457 home NN I-NP O
9 743 747 17194457 cage NN I-NP O
10 747 748 17194457 , , O O
11 749 753 17194457 both CC B-PP O
12 754 758 17194457 with IN I-PP O
13 759 762 17194457 and CC O O
14 763 770 17194457 without IN B-PP O
15 771 779 17194457 physical JJ B-NP O
16 780 791 17194457 provocation NN I-NP O
17 792 793 17194457 ( ( O O
18 793 797 17194457 mild JJ B-NP O
19 798 802 17194457 tail NN I-NP O
20 803 808 17194457 pinch NN I-NP O
21 808 809 17194457 ) ) O O
22 809 810 17194457 . . O O

1 811 816 17194457 Brain NN B-NP O
2 817 823 17194457 levels NNS I-NP O
3 824 826 17194457 of IN B-PP O
4 827 828 17194457 5 CD B-NP D012701
5 828 829 17194457 - HYPH I-NP D012701
6 829 831 17194457 HT NN I-NP D012701
7 832 835 17194457 and CC O O
8 836 839 17194457 its PRP$ B-NP O
9 840 850 17194457 metabolite NN I-NP O
10 850 851 17194457 , , O O
11 852 853 17194457 5 CD B-NP D006897
12 853 854 17194457 - HYPH I-NP D006897
13 854 873 17194457 hydroxyindoleacetic JJ I-NP D006897
14 874 878 17194457 acid NN I-NP D006897
15 879 880 17194457 ( ( O O
16 880 881 17194457 5 CD B-NP D006897
17 881 882 17194457 - HYPH I-NP D006897
18 882 886 17194457 HIAA NN I-NP D006897
19 886 887 17194457 ) ) O O
20 887 888 17194457 , , O O
21 889 893 17194457 were VBD B-VP O
22 894 904 17194457 determined VBN I-VP O
23 905 910 17194457 using VBG B-VP O
24 911 915 17194457 HPLC NN B-NP O
25 915 916 17194457 . . O O

1 917 921 17194457 PCPA NN B-NP -1
2 922 935 17194457 significantly RB B-VP O
3 936 939 17194457 and CC I-VP O
4 940 953 17194457 substantially RB I-VP O
5 954 962 17194457 depleted VBD I-VP O
6 963 964 17194457 5 CD B-NP D012701
7 964 965 17194457 - HYPH I-NP D012701
8 965 967 17194457 HT NN I-NP D012701
9 968 971 17194457 and CC I-NP O
10 972 973 17194457 5 CD I-NP D006897
11 973 974 17194457 - HYPH I-NP D006897
12 974 978 17194457 HIAA NN I-NP D006897
13 979 981 17194457 in IN B-PP O
14 982 985 17194457 all DT B-NP O
15 986 991 17194457 brain NN I-NP O
16 992 999 17194457 regions NNS I-NP O
17 1000 1008 17194457 examined VBN B-VP O
18 1008 1009 17194457 . . O O

1 1010 1017 17194457 Chronic JJ B-NP O
2 1018 1019 17194457 T NN I-NP D013739
3 1020 1029 17194457 treatment NN I-NP O
4 1030 1043 17194457 significantly RB B-ADVP O
5 1044 1053 17194457 decreased VBD B-VP O
6 1054 1055 17194457 5 CD B-NP D012701
7 1055 1056 17194457 - HYPH I-NP D012701
8 1056 1058 17194457 HT NN I-NP D012701
9 1059 1062 17194457 and CC I-NP O
10 1063 1064 17194457 5 CD I-NP D006897
11 1064 1065 17194457 - HYPH I-NP D006897
12 1065 1069 17194457 HIAA NN I-NP D006897
13 1070 1072 17194457 in IN B-PP O
14 1073 1080 17194457 certain JJ B-NP O
15 1081 1086 17194457 brain NN I-NP O
16 1087 1092 17194457 areas NNS I-NP O
17 1092 1093 17194457 , , O O
18 1094 1097 17194457 but CC O O
19 1098 1100 17194457 to TO B-PP O
20 1101 1102 17194457 a DT B-NP O
21 1103 1107 17194457 much RB I-NP O
22 1108 1114 17194457 lesser JJR I-NP O
23 1115 1121 17194457 extent NN I-NP O
24 1122 1126 17194457 than IN B-PP O
25 1127 1131 17194457 PCPA NN B-NP -1
26 1131 1132 17194457 . . O O

1 1133 1140 17194457 Chronic JJ B-NP O
2 1141 1149 17194457 exposure NN I-NP O
3 1150 1152 17194457 to TO B-PP O
4 1153 1157 17194457 PCPA NN B-NP -1
5 1158 1163 17194457 alone RB B-ADVP O
6 1164 1177 17194457 significantly RB B-VP O
7 1178 1187 17194457 decreased VBD I-VP O
8 1188 1197 17194457 locomotor NN B-NP O
9 1198 1206 17194457 activity NN I-NP O
10 1207 1210 17194457 and CC O O
11 1211 1220 17194457 increased VBD B-VP O
12 1221 1233 17194457 irritability NN B-NP D001523
13 1234 1237 17194457 but CC O O
14 1238 1241 17194457 had VBD B-VP O
15 1242 1244 17194457 no DT B-NP O
16 1245 1251 17194457 effect NN I-NP O
17 1252 1254 17194457 on IN B-PP O
18 1255 1261 17194457 sexual JJ B-NP O
19 1262 1270 17194457 behavior NN I-NP O
20 1270 1271 17194457 , , O O
21 1272 1279 17194457 partner NN B-NP O
22 1280 1290 17194457 preference NN I-NP O
23 1290 1291 17194457 , , O O
24 1292 1294 17194457 or CC O O
25 1295 1305 17194457 aggression NN B-NP D001523
26 1305 1306 17194457 . . O O

1 1307 1308 17194457 T NN B-NP D013739
2 1309 1314 17194457 alone RB B-ADVP O
3 1315 1318 17194457 had VBD B-VP O
4 1319 1321 17194457 no DT B-NP O
5 1322 1328 17194457 effect NN I-NP O
6 1329 1331 17194457 on IN B-PP O
7 1332 1342 17194457 locomotion NN B-NP O
8 1342 1343 17194457 , , O O
9 1344 1356 17194457 irritability NN B-NP D001523
10 1356 1357 17194457 , , O O
11 1358 1360 17194457 or CC O O
12 1361 1367 17194457 sexual JJ B-NP O
13 1368 1376 17194457 behavior NN I-NP O
14 1377 1380 17194457 but CC O O
15 1381 1390 17194457 increased VBD B-VP O
16 1391 1398 17194457 partner NN B-NP O
17 1399 1409 17194457 preference NN I-NP O
18 1410 1413 17194457 and CC I-NP O
19 1414 1424 17194457 aggression NN I-NP D001523
20 1424 1425 17194457 . . O O

1 1426 1429 17194457 The DT B-NP O
2 1430 1434 17194457 most RBS I-NP O
3 1435 1443 17194457 striking JJ I-NP O
4 1444 1450 17194457 effect NN I-NP O
5 1451 1453 17194457 of IN B-PP O
6 1454 1463 17194457 combining VBG B-NP O
7 1464 1465 17194457 T NN I-NP D013739
8 1465 1466 17194457 + SYM I-NP O
9 1466 1470 17194457 PCPA NN I-NP -1
10 1471 1474 17194457 was VBD B-VP O
11 1475 1476 17194457 a DT B-NP O
12 1477 1488 17194457 significant JJ I-NP O
13 1489 1497 17194457 increase NN I-NP O
14 1498 1500 17194457 in IN B-PP O
15 1501 1507 17194457 attack NN B-NP O
16 1508 1517 17194457 frequency NN I-NP O
17 1518 1520 17194457 as RB B-CONJP O
18 1521 1525 17194457 well RB I-CONJP O
19 1526 1528 17194457 as IN I-CONJP O
20 1529 1530 17194457 a DT B-NP O
21 1531 1542 17194457 significant JJ I-NP O
22 1543 1551 17194457 decrease NN I-NP O
23 1552 1554 17194457 in IN B-PP O
24 1555 1558 17194457 the DT B-NP O
25 1559 1566 17194457 latency NN I-NP O
26 1567 1569 17194457 to TO B-VP O
27 1570 1576 17194457 attack VB I-VP O
28 1576 1577 17194457 , , O O
29 1578 1590 17194457 particularly RB B-ADVP O
30 1591 1600 17194457 following VBG B-PP O
31 1601 1609 17194457 physical JJ B-NP O
32 1610 1621 17194457 provocation NN I-NP O
33 1621 1622 17194457 . . O O

1 1623 1628 17194457 Based VBN B-PP O
2 1629 1631 17194457 on IN B-PP O
3 1632 1637 17194457 these DT B-NP O
4 1638 1642 17194457 data NNS I-NP O
5 1642 1643 17194457 , , O O
6 1644 1646 17194457 it PRP B-NP O
7 1647 1650 17194457 can MD B-VP O
8 1651 1653 17194457 be VB I-VP O
9 1654 1664 17194457 speculated VBN I-VP O
10 1665 1669 17194457 that IN B-SBAR O
11 1670 1678 17194457 pubertal JJ B-NP O
12 1679 1682 17194457 AAS NN I-NP O
13 1683 1688 17194457 users NNS I-NP O
14 1689 1693 17194457 with IN B-PP O
15 1694 1697 17194457 low JJ B-NP O
16 1698 1705 17194457 central JJ I-NP O
17 1706 1707 17194457 5 CD I-NP D012701
18 1707 1708 17194457 - HYPH I-NP D012701
19 1708 1710 17194457 HT NN I-NP D012701
20 1711 1714 17194457 may MD B-VP O
21 1715 1717 17194457 be VB I-VP O
22 1718 1728 17194457 especially RB B-ADJP O
23 1729 1734 17194457 prone JJ I-ADJP O
24 1735 1737 17194457 to TO B-VP O
25 1738 1745 17194457 exhibit VB I-VP O
26 1746 1756 17194457 aggressive JJ B-NP D001523
27 1757 1765 17194457 behavior NN I-NP D001523
28 1765 1766 17194457 . . O O

1 0 0 10539815 -DOCSTART- -X- -X- O

1 0 10 10539815 Predictors NNS B-NP O
2 11 13 10539815 of IN B-PP O
3 14 23 10539815 decreased VBN B-NP D051437
4 24 29 10539815 renal JJ I-NP D051437
5 30 38 10539815 function NN I-NP D051437
6 39 41 10539815 in IN B-PP O
7 42 50 10539815 patients NNS B-NP O
8 51 55 10539815 with IN B-PP O
9 56 61 10539815 heart NN B-NP D006333
10 62 69 10539815 failure NN I-NP D006333
11 70 76 10539815 during IN B-PP O
12 77 88 10539815 angiotensin NN B-NP D000809
13 88 89 10539815 - HYPH O O
14 89 99 10539815 converting VBG B-VP O
15 100 106 10539815 enzyme NN B-NP O
16 107 116 10539815 inhibitor NN I-NP O
17 117 124 10539815 therapy NN I-NP O
18 124 125 10539815 : : O O
19 126 133 10539815 results NNS B-NP O
20 134 138 10539815 from IN B-PP O
21 139 142 10539815 the DT B-NP O
22 143 150 10539815 studies NNS I-NP O
23 151 153 10539815 of IN B-PP O
24 154 158 10539815 left JJ B-NP D018487
25 159 170 10539815 ventricular JJ I-NP D018487
26 171 182 10539815 dysfunction NN I-NP D018487
27 183 184 10539815 ( ( O O
28 184 189 10539815 SOLVD NN B-NP O
29 189 190 10539815 ) ) O O
30 191 201 10539815 BACKGROUND NN B-NP O
31 201 202 10539815 : : O O
32 203 211 10539815 Although IN B-SBAR O
33 212 223 10539815 angiotensin NN B-NP D000809
34 223 224 10539815 - HYPH O O
35 224 234 10539815 converting VBG B-VP O
36 235 241 10539815 enzyme NN B-NP O
37 242 251 10539815 inhibitor NN I-NP O
38 252 259 10539815 therapy NN I-NP O
39 260 267 10539815 reduces VBZ B-VP O
40 268 277 10539815 mortality NN B-NP O
41 278 283 10539815 rates NNS I-NP O
42 284 286 10539815 in IN B-PP O
43 287 295 10539815 patients NNS B-NP O
44 296 300 10539815 with IN B-PP O
45 301 311 10539815 congestive JJ B-NP D006333
46 312 317 10539815 heart NN I-NP D006333
47 318 325 10539815 failure NN I-NP D006333
48 326 327 10539815 ( ( O O
49 327 330 10539815 CHF NN B-NP D006333
50 330 331 10539815 ) ) O O
51 331 332 10539815 , , O O
52 333 335 10539815 it PRP B-NP O
53 336 339 10539815 may MD B-VP O
54 340 344 10539815 also RB I-VP O
55 345 350 10539815 cause VB I-VP O
56 351 360 10539815 decreased VBN I-VP D051437
57 361 366 10539815 renal JJ B-NP D051437
58 367 375 10539815 function NN I-NP D051437
59 375 376 10539815 . . O O

1 377 383 10539815 Little JJ B-NP O
2 384 395 10539815 information NN I-NP O
3 396 398 10539815 is VBZ B-VP O
4 399 408 10539815 available JJ B-ADJP O
5 409 411 10539815 to TO B-VP O
6 412 419 10539815 predict VB I-VP O
7 420 425 10539815 which WDT B-NP O
8 426 434 10539815 patients NNS I-NP O
9 435 438 10539815 are VBP B-VP O
10 439 441 10539815 at IN B-PP O
11 442 449 10539815 highest JJS B-NP O
12 450 454 10539815 risk NN I-NP O
13 455 458 10539815 for IN B-PP O
14 459 463 10539815 this DT B-NP O
15 464 476 10539815 complication NN I-NP O
16 476 477 10539815 . . O O

1 478 487 10539815 OBJECTIVE NN B-NP O
2 487 488 10539815 : : O O
3 489 491 10539815 To TO B-VP O
4 492 500 10539815 quantify VB I-VP O
5 501 509 10539815 specific JJ B-NP O
6 510 518 10539815 clinical JJ I-NP O
7 519 529 10539815 predictors NNS I-NP O
8 530 532 10539815 of IN B-PP O
9 533 542 10539815 reduction NN B-NP D051437
10 543 545 10539815 in IN B-PP D051437
11 546 551 10539815 renal JJ B-NP D051437
12 552 560 10539815 function NN I-NP D051437
13 561 563 10539815 in IN B-PP O
14 564 572 10539815 patients NNS B-NP O
15 573 577 10539815 with IN B-PP O
16 578 581 10539815 CHF NN B-NP D006333
17 582 585 10539815 who WP B-NP O
18 586 589 10539815 are VBP B-VP O
19 590 600 10539815 prescribed VBN I-VP O
20 601 612 10539815 angiotensin NN B-NP D000809
21 612 613 10539815 - HYPH O O
22 613 623 10539815 converting VBG B-VP O
23 624 630 10539815 enzyme NN B-NP O
24 631 640 10539815 inhibitor NN I-NP O
25 641 648 10539815 therapy NN I-NP O
26 648 649 10539815 . . O O

1 650 656 10539815 METHOD NN B-NP O
2 656 657 10539815 : : O O
3 658 660 10539815 We PRP B-NP O
4 661 669 10539815 analyzed VBD B-VP O
5 670 674 10539815 data NNS B-NP O
6 675 679 10539815 from IN B-PP O
7 680 683 10539815 the DT B-NP O
8 684 691 10539815 Studies NNS I-NP O
9 692 694 10539815 of IN B-PP O
10 695 699 10539815 Left NNP B-NP D018487
11 700 711 10539815 Ventricular JJ I-NP D018487
12 712 723 10539815 Dysfunction NN I-NP D018487
13 724 725 10539815 ( ( O O
14 725 730 10539815 SOLVD NN B-NP O
15 730 731 10539815 ) ) O O
16 731 732 10539815 , , O O
17 733 734 10539815 a DT B-NP O
18 735 745 10539815 randomized VBN I-NP O
19 745 746 10539815 , , I-NP O
20 747 753 10539815 double JJ I-NP O
21 753 754 10539815 - HYPH I-NP O
22 754 759 10539815 blind JJ I-NP O
23 759 760 10539815 , , I-NP O
24 761 768 10539815 placebo NN I-NP O
25 768 769 10539815 - HYPH I-NP O
26 769 779 10539815 controlled VBN B-NP O
27 780 785 10539815 trial NN I-NP O
28 786 788 10539815 of IN B-PP O
29 789 798 10539815 enalapril NN B-NP D004656
30 799 802 10539815 for IN B-PP O
31 803 806 10539815 the DT B-NP O
32 807 816 10539815 treatment NN I-NP O
33 817 819 10539815 of IN B-PP O
34 820 823 10539815 CHF NN B-NP D006333
35 823 824 10539815 . . O O

1 825 830 10539815 There EX B-NP O
2 831 835 10539815 were VBD B-VP O
3 836 840 10539815 3379 CD B-NP O
4 841 849 10539815 patients NNS I-NP O
5 850 858 10539815 randomly RB B-VP O
6 859 867 10539815 assigned VBN I-VP O
7 868 870 10539815 to TO I-VP O
8 871 880 10539815 enalapril VB I-VP D004656
9 881 885 10539815 with IN B-PP O
10 886 887 10539815 a DT B-NP O
11 888 894 10539815 median JJ I-NP O
12 895 901 10539815 follow VB I-NP O
13 901 902 10539815 - HYPH B-VP O
14 902 904 10539815 up RP B-PRT O
15 905 907 10539815 of IN B-PP O
16 908 911 10539815 974 CD B-NP O
17 912 916 10539815 days NNS I-NP O
18 917 920 10539815 and CC O O
19 921 925 10539815 3379 CD B-NP O
20 926 934 10539815 patients NNS I-NP O
21 935 943 10539815 randomly RB B-VP O
22 944 952 10539815 assigned VBN I-VP O
23 953 955 10539815 to TO I-VP O
24 956 963 10539815 placebo VB I-VP O
25 964 968 10539815 with IN B-PP O
26 969 970 10539815 a DT B-NP O
27 971 975 10539815 mean JJ I-NP O
28 976 982 10539815 follow VB I-NP O
29 982 983 10539815 - HYPH B-VP O
30 983 985 10539815 up RP B-PRT O
31 986 988 10539815 of IN B-PP O
32 989 992 10539815 967 CD B-NP O
33 993 997 10539815 days NNS I-NP O
34 997 998 10539815 . . O O

1 999 1008 10539815 Decreased VBN B-NP D051437
2 1009 1014 10539815 renal JJ I-NP D051437
3 1015 1023 10539815 function NN I-NP D051437
4 1024 1027 10539815 was VBD B-VP O
5 1028 1035 10539815 defined VBN I-VP O
6 1036 1038 10539815 as IN B-PP O
7 1039 1040 10539815 a DT B-NP O
8 1041 1045 10539815 rise NN I-NP O
9 1046 1048 10539815 in IN B-PP O
10 1049 1054 10539815 serum NN B-NP O
11 1055 1065 10539815 creatinine NN I-NP D003404
12 1066 1067 10539815 > SYM B-VP O
13 1067 1068 10539815 / SYM B-NP O
14 1068 1069 10539815 = SYM B-VP O
15 1069 1072 10539815 0.5 CD B-NP O
16 1073 1075 10539815 mg NN I-NP O
17 1075 1076 10539815 / SYM B-NP O
18 1076 1078 10539815 dL NN B-NP O
19 1079 1080 10539815 ( ( O O
20 1080 1082 10539815 44 CD B-NP O
21 1083 1091 10539815 micromol NN I-NP O
22 1091 1092 10539815 / SYM B-NP O
23 1092 1093 10539815 L NN I-NP O
24 1093 1094 10539815 ) ) O O
25 1095 1099 10539815 from IN B-PP O
26 1100 1108 10539815 baseline NN B-NP O
27 1108 1109 10539815 . . O O

1 1110 1112 10539815 We PRP B-NP O
2 1113 1117 10539815 used VBD B-VP O
3 1118 1122 10539815 time NN B-NP O
4 1122 1123 10539815 - HYPH B-ADJP O
5 1123 1125 10539815 to TO B-PP O
6 1125 1126 10539815 - HYPH B-NP O
7 1126 1131 10539815 event NN I-NP O
8 1132 1140 10539815 analysis NN I-NP O
9 1141 1143 10539815 to TO B-VP O
10 1144 1152 10539815 identify VB I-VP O
11 1153 1162 10539815 potential JJ B-NP O
12 1163 1173 10539815 predictors NNS I-NP O
13 1174 1176 10539815 of IN B-PP O
14 1177 1185 10539815 decrease NN B-NP O
15 1186 1188 10539815 in IN B-PP O
16 1189 1194 10539815 renal JJ B-NP O
17 1195 1203 10539815 function NN I-NP O
18 1204 1213 10539815 including VBG B-PP O
19 1214 1217 10539815 age NN B-NP O
20 1217 1218 10539815 , , O O
21 1219 1227 10539815 baseline NN B-NP O
22 1228 1236 10539815 ejection NN I-NP O
23 1237 1245 10539815 fraction NN I-NP O
24 1245 1246 10539815 , , O O
25 1247 1255 10539815 baseline NN B-NP O
26 1256 1266 10539815 creatinine NN I-NP D003404
27 1266 1267 10539815 , , O O
28 1268 1271 10539815 low JJ B-NP O
29 1272 1280 10539815 systolic JJ I-NP O
30 1281 1286 10539815 blood NN I-NP O
31 1287 1295 10539815 pressure NN I-NP O
32 1296 1297 10539815 ( ( O O
33 1297 1298 10539815 < SYM B-NP O
34 1298 1301 10539815 100 CD I-NP O
35 1302 1304 10539815 mm NN I-NP O
36 1305 1307 10539815 Hg NN I-NP O
37 1307 1308 10539815 ) ) O O
38 1308 1309 10539815 , , O O
39 1310 1317 10539815 history NN B-NP O
40 1318 1320 10539815 of IN B-PP O
41 1321 1333 10539815 hypertension NN B-NP D006973
42 1333 1334 10539815 , , O O
43 1335 1343 10539815 diabetes NN B-NP D003920
44 1343 1344 10539815 , , O O
45 1345 1348 10539815 and CC O O
46 1349 1352 10539815 use NN B-NP O
47 1353 1355 10539815 of IN B-PP O
48 1356 1368 10539815 antiplatelet JJ B-NP O
49 1368 1369 10539815 , , I-NP O
50 1370 1378 10539815 diuretic JJ I-NP D004232
51 1378 1379 10539815 , , O O
52 1380 1383 10539815 and CC O O
53 1384 1388 10539815 beta SYM O O
54 1388 1389 10539815 - HYPH O O
55 1389 1396 10539815 blocker NN B-NP O
56 1397 1404 10539815 therapy NN I-NP O
57 1404 1405 10539815 . . O O

1 1406 1413 10539815 RESULTS NNS B-NP O
2 1413 1414 10539815 : : O O
3 1415 1423 10539815 Patients NNS B-NP O
4 1424 1432 10539815 randomly RB B-VP O
5 1433 1441 10539815 assigned VBN I-VP O
6 1442 1444 10539815 to TO I-VP O
7 1445 1454 10539815 enalapril VB I-VP D004656
8 1455 1458 10539815 had VBD B-VP O
9 1459 1460 10539815 a DT B-NP O
10 1461 1464 10539815 33% NN I-NP O
11 1465 1472 10539815 greater JJR B-NP O
12 1473 1483 10539815 likelihood NN I-NP O
13 1484 1486 10539815 of IN B-PP O
14 1487 1496 10539815 decreased VBN B-NP D051437
15 1497 1502 10539815 renal JJ I-NP D051437
16 1503 1511 10539815 function NN I-NP D051437
17 1512 1516 10539815 than IN B-PP O
18 1517 1525 10539815 controls NNS B-NP O
19 1526 1527 10539815 ( ( O O
20 1527 1528 10539815 P NN B-NP O
21 1529 1530 10539815 = SYM B-VP O
22 1530 1534 10539815 .003 CD B-NP O
23 1534 1535 10539815 ) ) O O
24 1535 1536 10539815 . . O O

1 1537 1539 10539815 By IN B-PP O
2 1540 1552 10539815 multivariate JJ B-NP O
3 1553 1561 10539815 analysis NN I-NP O
4 1561 1562 10539815 , , O O
5 1563 1565 10539815 in IN B-PP O
6 1566 1570 10539815 both CC B-NP O
7 1571 1574 10539815 the DT I-NP O
8 1575 1582 10539815 placebo NN I-NP O
9 1583 1586 10539815 and CC I-NP O
10 1587 1596 10539815 enalapril NN I-NP D004656
11 1597 1603 10539815 groups NNS I-NP O
12 1604 1609 10539815 older JJR B-NP O
13 1610 1613 10539815 age NN I-NP O
14 1613 1614 10539815 , , O O
15 1615 1623 10539815 diuretic JJ B-NP D004232
16 1624 1631 10539815 therapy NN I-NP O
17 1631 1632 10539815 , , O O
18 1633 1636 10539815 and CC O O
19 1637 1645 10539815 diabetes NNS B-NP D003920
20 1646 1650 10539815 were VBD B-VP O
21 1651 1661 10539815 associated VBN I-VP O
22 1662 1666 10539815 with IN B-PP O
23 1667 1676 10539815 decreased VBN B-NP D051437
24 1677 1682 10539815 renal JJ I-NP D051437
25 1683 1691 10539815 function NN I-NP D051437
26 1691 1692 10539815 , , O O
27 1693 1700 10539815 whereas IN O O
28 1701 1705 10539815 beta SYM O O
29 1705 1706 10539815 - HYPH B-NP O
30 1706 1713 10539815 blocker NN I-NP O
31 1714 1721 10539815 therapy NN I-NP O
32 1722 1725 10539815 and CC O O
33 1726 1732 10539815 higher JJR B-NP O
34 1733 1741 10539815 ejection NN I-NP O
35 1742 1750 10539815 fraction NN I-NP O
36 1751 1755 10539815 were VBD B-VP O
37 1756 1770 10539815 renoprotective JJ B-ADJP O
38 1770 1771 10539815 . . O O

1 1772 1777 10539815 Older JJR B-NP O
2 1778 1781 10539815 age NN I-NP O
3 1782 1785 10539815 was VBD B-VP O
4 1786 1796 10539815 associated VBN I-VP O
5 1797 1801 10539815 with IN B-PP O
6 1802 1803 10539815 a DT B-NP O
7 1804 1811 10539815 greater JJR I-NP O
8 1812 1816 10539815 risk NN I-NP O
9 1817 1819 10539815 of IN B-PP O
10 1820 1830 10539815 developing VBG B-VP O
11 1831 1840 10539815 decreased VBN B-NP D051437
12 1841 1846 10539815 renal JJ I-NP D051437
13 1847 1855 10539815 function NN I-NP D051437
14 1856 1858 10539815 in IN B-PP O
15 1859 1863 10539815 both DT B-NP O
16 1864 1870 10539815 groups NNS I-NP O
17 1870 1871 10539815 , , O O
18 1872 1875 10539815 but CC O O
19 1876 1889 10539815 significantly RB B-ADVP O
20 1890 1894 10539815 more RBR I-ADVP O
21 1895 1897 10539815 so RB I-ADVP O
22 1898 1900 10539815 in IN B-PP O
23 1901 1904 10539815 the DT B-NP O
24 1905 1914 10539815 enalapril NN I-NP D004656
25 1915 1920 10539815 group NN I-NP O
26 1921 1922 10539815 ( ( O O
27 1922 1931 10539815 enalapril NN B-NP D004656
28 1931 1932 10539815 : : O O
29 1933 1937 10539815 risk NN B-NP O
30 1938 1943 10539815 ratio NN I-NP O
31 1944 1945 10539815 [ ( O O
32 1945 1947 10539815 RR NN B-NP O
33 1947 1948 10539815 ] ) O O
34 1949 1953 10539815 1.42 CD B-NP O
35 1954 1957 10539815 per IN B-PP O
36 1958 1960 10539815 10 CD B-NP O
37 1961 1966 10539815 years NNS I-NP O
38 1966 1967 10539815 , , O O
39 1968 1971 10539815 95% CD B-NP O
40 1972 1982 10539815 confidence NN I-NP O
41 1983 1991 10539815 interval NN I-NP O
42 1992 1993 10539815 [ ( O O
43 1993 1995 10539815 CI NN B-NP O
44 1995 1996 10539815 ] ) O O
45 1997 2001 10539815 1.32 CD B-NP O
46 2001 2002 10539815 - : O O
47 2002 2006 10539815 1.52 CD B-NP O
48 2007 2011 10539815 with IN B-PP O
49 2012 2021 10539815 enalapril NN B-NP D004656
50 2021 2022 10539815 ; : O O
51 2023 2030 10539815 placebo NN B-NP O
52 2030 2031 10539815 : : O O
53 2032 2034 10539815 RR NN B-NP O
54 2035 2039 10539815 1.18 CD I-NP O
55 2039 2040 10539815 , , O O
56 2041 2044 10539815 95% CD B-NP O
57 2045 2047 10539815 CI NNP I-NP O
58 2048 2052 10539815 1.12 CD I-NP O
59 2052 2053 10539815 - HYPH I-NP O
60 2053 2057 10539815 1.25 CD I-NP O
61 2057 2058 10539815 ) ) O O
62 2058 2059 10539815 . . O O

1 2060 2068 10539815 Diuretic JJ B-NP D004232
2 2069 2076 10539815 therapy NN I-NP O
3 2077 2080 10539815 was VBD B-VP O
4 2081 2089 10539815 likewise RB I-VP O
5 2090 2100 10539815 associated VBN I-VP O
6 2101 2105 10539815 with IN B-PP O
7 2106 2107 10539815 a DT B-NP O
8 2108 2115 10539815 greater JJR I-NP O
9 2116 2120 10539815 risk NN I-NP O
10 2121 2123 10539815 of IN B-PP O
11 2124 2133 10539815 decreased VBN B-NP D051437
12 2134 2139 10539815 renal JJ I-NP D051437
13 2140 2148 10539815 function NN I-NP D051437
14 2149 2151 10539815 in IN B-PP O
15 2152 2155 10539815 the DT B-NP O
16 2156 2165 10539815 enalapril NN I-NP D004656
17 2166 2171 10539815 group NN I-NP O
18 2172 2173 10539815 ( ( O O
19 2173 2175 10539815 RR NN B-NP O
20 2176 2180 10539815 1.89 CD I-NP O
21 2180 2181 10539815 , , O O
22 2182 2185 10539815 95% CD B-NP O
23 2186 2188 10539815 CI NNP I-NP O
24 2189 2193 10539815 1.70 CD I-NP O
25 2193 2194 10539815 - HYPH I-NP O
26 2194 2198 10539815 2.08 CD I-NP O
27 2198 2199 10539815 ) ) O O
28 2200 2204 10539815 than IN B-PP O
29 2205 2207 10539815 in IN B-PP O
30 2208 2211 10539815 the DT B-NP O
31 2212 2219 10539815 placebo NN I-NP O
32 2220 2225 10539815 group NN I-NP O
33 2226 2227 10539815 ( ( O O
34 2227 2229 10539815 RR NN B-NP O
35 2230 2234 10539815 1.35 CD I-NP O
36 2234 2235 10539815 , , O O
37 2236 2239 10539815 95% CD B-NP O
38 2240 2242 10539815 CI NNP I-NP O
39 2243 2247 10539815 1.09 CD I-NP O
40 2247 2248 10539815 - HYPH I-NP O
41 2248 2252 10539815 1.66 CD I-NP O
42 2252 2253 10539815 ) ) O O
43 2253 2254 10539815 . . O O

1 2255 2265 10539815 Conversely RB B-ADVP O
2 2265 2266 10539815 , , O O
3 2267 2276 10539815 enalapril NN B-NP D004656
4 2277 2280 10539815 had VBD B-VP O
5 2281 2282 10539815 a DT B-NP O
6 2283 2291 10539815 relative JJ I-NP O
7 2292 2306 10539815 renoprotective JJ I-NP O
8 2307 2313 10539815 effect NN I-NP O
9 2314 2315 10539815 ( ( O O
10 2315 2317 10539815 RR NN B-NP O
11 2318 2322 10539815 1.33 CD I-NP O
12 2322 2323 10539815 , , O O
13 2324 2327 10539815 95% CD B-NP O
14 2328 2330 10539815 CI NNP I-NP O
15 2331 2335 10539815 1.13 CD I-NP O
16 2335 2336 10539815 - HYPH I-NP O
17 2336 2340 10539815 1.53 CD I-NP O
18 2340 2341 10539815 ) ) O O
19 2342 2350 10539815 compared VBN B-PP O
20 2351 2355 10539815 with IN B-PP O
21 2356 2363 10539815 placebo NN B-NP O
22 2364 2365 10539815 ( ( O O
23 2365 2367 10539815 RR NN B-NP O
24 2368 2372 10539815 1.96 CD I-NP O
25 2372 2373 10539815 , , O O
26 2374 2377 10539815 95% CD B-NP O
27 2378 2380 10539815 CI NNP I-NP O
28 2381 2385 10539815 1.57 CD I-NP O
29 2385 2386 10539815 - HYPH I-NP O
30 2386 2390 10539815 2.44 CD I-NP O
31 2390 2391 10539815 ) ) O O
32 2392 2394 10539815 in IN B-PP O
33 2395 2403 10539815 patients NNS B-NP O
34 2404 2408 10539815 with IN B-PP O
35 2409 2417 10539815 diabetes NN B-NP D003920
36 2417 2418 10539815 . . O O

1 2419 2420 10539815 A DT B-NP O
2 2421 2426 10539815 lower JJR I-NP O
3 2427 2431 10539815 risk NN I-NP O
4 2432 2434 10539815 of IN B-PP O
5 2435 2440 10539815 renal JJ B-NP D051437
6 2441 2451 10539815 impairment NN I-NP D051437
7 2452 2455 10539815 was VBD B-VP O
8 2456 2460 10539815 seen VBN I-VP O
9 2461 2463 10539815 in IN B-PP O
10 2464 2468 10539815 both DT B-NP O
11 2469 2475 10539815 groups NNS I-NP O
12 2476 2480 10539815 with IN B-PP O
13 2481 2485 10539815 beta SYM B-NP O
14 2485 2486 10539815 - HYPH O O
15 2486 2493 10539815 blocker NN B-NP O
16 2494 2501 10539815 therapy NN I-NP O
17 2502 2503 10539815 ( ( O O
18 2503 2505 10539815 RR NN B-NP O
19 2506 2510 10539815 0.70 CD I-NP O
20 2510 2511 10539815 , , O O
21 2512 2515 10539815 95% CD B-NP O
22 2516 2518 10539815 CI NNP I-NP O
23 2519 2523 10539815 0.57 CD I-NP O
24 2523 2524 10539815 - HYPH I-NP O
25 2524 2528 10539815 0.85 CD I-NP O
26 2528 2529 10539815 ) ) O O
27 2530 2533 10539815 and CC O O
28 2534 2540 10539815 higher JJR B-NP O
29 2541 2549 10539815 baseline NN I-NP O
30 2550 2558 10539815 ejection NN I-NP O
31 2559 2567 10539815 fraction NN I-NP O
32 2568 2569 10539815 ( ( O O
33 2569 2571 10539815 RR NN B-NP O
34 2572 2576 10539815 0.93 CD I-NP O
35 2577 2580 10539815 per IN B-PP O
36 2581 2583 10539815 5% CD B-NP O
37 2584 2593 10539815 increment NN I-NP O
38 2593 2594 10539815 , , O O
39 2595 2598 10539815 95% CD B-NP O
40 2599 2601 10539815 CI NNP I-NP O
41 2602 2606 10539815 0.91 CD I-NP O
42 2606 2607 10539815 - : O O
43 2607 2608 10539815 0 CD B-NP O
44 2608 2609 10539815 . . O O

1 2610 2612 10539815 96 CD B-NP O
2 2612 2613 10539815 ) ) O O
3 2613 2614 10539815 . . O O

1 2615 2626 10539815 CONCLUSIONS NNS B-NP O
2 2626 2627 10539815 : : O O
3 2628 2637 10539815 Enalapril NNP B-NP D004656
4 2638 2641 10539815 use NN I-NP O
5 2642 2648 10539815 caused VBD B-VP O
6 2649 2650 10539815 a DT B-NP O
7 2651 2654 10539815 33% NN I-NP O
8 2655 2663 10539815 increase NN I-NP O
9 2664 2666 10539815 in IN B-PP O
10 2667 2670 10539815 the DT B-NP O
11 2671 2675 10539815 risk NN I-NP O
12 2676 2678 10539815 of IN B-PP O
13 2679 2688 10539815 decreased VBN B-NP D051437
14 2689 2694 10539815 renal JJ I-NP D051437
15 2695 2703 10539815 function NN I-NP D051437
16 2704 2706 10539815 in IN B-PP O
17 2707 2715 10539815 patients NNS B-NP O
18 2716 2720 10539815 with IN B-PP O
19 2721 2724 10539815 CHF NN B-NP D006333
20 2724 2725 10539815 . . O O

1 2726 2734 10539815 Diuretic JJ B-NP D004232
2 2735 2738 10539815 use NN I-NP O
3 2739 2742 10539815 and CC O O
4 2743 2751 10539815 advanced JJ B-NP O
5 2752 2755 10539815 age NN I-NP O
6 2756 2765 10539815 increased VBD B-VP O
7 2766 2770 10539815 this DT B-NP O
8 2771 2775 10539815 risk NN I-NP O
9 2775 2776 10539815 . . O O

1 2777 2785 10539815 Diabetes NNS B-NP D003920
2 2786 2789 10539815 was VBD B-VP O
3 2790 2800 10539815 associated VBN I-VP O
4 2801 2805 10539815 with IN B-PP O
5 2806 2808 10539815 an DT B-NP O
6 2809 2818 10539815 increased VBN I-NP O
7 2819 2823 10539815 risk NN I-NP O
8 2824 2826 10539815 of IN B-PP O
9 2827 2832 10539815 renal JJ B-NP D051437
10 2833 2843 10539815 impairment NN I-NP D051437
11 2844 2846 10539815 in IN B-PP O
12 2847 2850 10539815 all DT B-NP O
13 2851 2859 10539815 patients NNS I-NP O
14 2860 2864 10539815 with IN B-PP O
15 2865 2868 10539815 CHF NN B-NP D006333
16 2868 2869 10539815 , , O O
17 2870 2873 10539815 but CC O O
18 2874 2878 10539815 this DT B-NP O
19 2879 2883 10539815 risk NN I-NP O
20 2884 2887 10539815 was VBD B-VP O
21 2888 2895 10539815 reduced VBN I-VP O
22 2896 2898 10539815 in IN B-PP O
23 2899 2902 10539815 the DT B-NP O
24 2903 2912 10539815 enalapril NN I-NP D004656
25 2913 2918 10539815 group NN I-NP O
26 2919 2927 10539815 compared VBN B-PP O
27 2928 2932 10539815 with IN B-PP O
28 2933 2936 10539815 the DT B-NP O
29 2937 2944 10539815 placebo NN I-NP O
30 2945 2950 10539815 group NN I-NP O
31 2950 2951 10539815 . . O O

1 2952 2956 10539815 beta SYM O O
2 2956 2957 10539815 - HYPH B-NP O
3 2957 2964 10539815 Blocker NN I-NP O
4 2965 2972 10539815 therapy NN I-NP O
5 2973 2976 10539815 and CC O O
6 2977 2983 10539815 higher JJR B-NP O
7 2984 2992 10539815 ejection NN I-NP O
8 2993 3001 10539815 fraction NN I-NP O
9 3002 3006 10539815 were VBD B-VP O
10 3007 3021 10539815 renoprotective JJ B-ADJP O
11 3022 3024 10539815 in IN B-PP O
12 3025 3028 10539815 all DT B-NP O
13 3029 3037 10539815 patients NNS I-NP O
14 3038 3048 10539815 regardless RB B-ADVP O
15 3049 3051 10539815 of IN B-PP O
16 3052 3059 10539815 therapy NN B-NP O
17 3059 3060 10539815 . . O O

1 0 0 9228650 -DOCSTART- -X- -X- O

1 0 7 9228650 Effects NNS B-NP O
2 8 10 9228650 of IN B-PP O
3 11 14 9228650 NIK NN B-NP C049860
4 14 15 9228650 - HYPH O C049860
5 15 18 9228650 247 CD B-NP C049860
6 19 21 9228650 on IN B-PP O
7 22 36 9228650 cholinesterase NN B-NP O
8 37 40 9228650 and CC I-NP O
9 41 52 9228650 scopolamine NN I-NP D012601
10 52 53 9228650 - HYPH B-NP O
11 53 60 9228650 induced VBN I-NP O
12 61 68 9228650 amnesia NN I-NP D000647
13 68 69 9228650 . . O O
14 70 73 9228650 The DT B-NP O
15 74 81 9228650 effects NNS I-NP O
16 82 84 9228650 of IN B-PP O
17 85 88 9228650 NIK NN B-NP C049860
18 88 89 9228650 - HYPH O C049860
19 89 92 9228650 247 CD B-NP C049860
20 93 95 9228650 on IN B-PP O
21 96 110 9228650 cholinesterase NN B-NP O
22 110 111 9228650 , , O O
23 112 123 9228650 scopolamine NN B-NP D012601
24 123 124 9228650 - HYPH B-VP O
25 124 131 9228650 induced VBN B-NP O
26 132 139 9228650 amnesia NN I-NP D000647
27 140 143 9228650 and CC O O
28 144 155 9228650 spontaneous JJ B-NP O
29 156 164 9228650 movement NN I-NP O
30 165 169 9228650 were VBD B-VP O
31 170 178 9228650 examined VBN I-VP O
32 179 182 9228650 and CC O O
33 183 191 9228650 compared VBN B-PP O
34 192 196 9228650 with IN B-PP O
35 197 202 9228650 those DT B-NP O
36 203 205 9228650 of IN B-PP O
37 206 209 9228650 the DT B-NP O
38 210 214 9228650 well RB I-NP O
39 214 215 9228650 - HYPH I-NP O
40 215 220 9228650 known VBN I-NP O
41 221 235 9228650 cholinesterase NN I-NP O
42 236 246 9228650 inhibitors NNS I-NP O
43 247 254 9228650 tacrine NN I-NP D013619
44 255 258 9228650 and CC I-NP O
45 259 260 9228650 E NN I-NP C076946
46 260 261 9228650 - SYM B-NP C076946
47 261 265 9228650 2020 CD B-NP C076946
48 265 266 9228650 . . O O

1 267 270 9228650 NIK NN B-NP C049860
2 270 271 9228650 - HYPH I-NP C049860
3 271 274 9228650 247 CD I-NP C049860
4 274 275 9228650 , , I-NP O
5 276 283 9228650 tacrine NN I-NP D013619
6 284 287 9228650 and CC I-NP O
7 288 289 9228650 E NN I-NP C076946
8 289 290 9228650 - HYPH B-NP C076946
9 290 294 9228650 2020 CD I-NP C076946
10 295 298 9228650 all DT B-NP O
11 299 307 9228650 strongly RB B-VP O
12 308 317 9228650 inhibited VBD I-VP O
13 318 338 9228650 acetylcholinesterase NN B-NP O
14 339 340 9228650 ( ( O O
15 340 344 9228650 AChE NN B-NP O
16 344 345 9228650 ) ) O O
17 346 348 9228650 in IN B-PP O
18 349 354 9228650 human JJ B-NP O
19 355 358 9228650 red JJ I-NP O
20 359 364 9228650 blood NN I-NP O
21 365 370 9228650 cells NNS I-NP O
22 371 372 9228650 ( ( O O
23 372 377 9228650 IC50s NN B-NP O
24 378 379 9228650 = SYM B-VP O
25 380 383 9228650 1.0 CD B-NP O
26 384 385 9228650 x SYM B-NP O
27 386 389 9228650 10( CD I-NP O
28 389 390 9228650 - HYPH I-NP O
29 390 392 9228650 6) CD I-NP O
30 392 393 9228650 , , I-NP O
31 394 397 9228650 2.9 CD I-NP O
32 398 399 9228650 x SYM I-NP O
33 400 403 9228650 10( CD I-NP O
34 403 404 9228650 - HYPH I-NP O
35 404 406 9228650 7) CD I-NP O
36 407 410 9228650 and CC I-NP O
37 411 414 9228650 3.7 CD I-NP O
38 415 416 9228650 x SYM I-NP O
39 417 420 9228650 10( CD I-NP O
40 420 421 9228650 - HYPH I-NP O
41 421 423 9228650 8) CD I-NP O
42 424 425 9228650 M NN I-NP O
43 425 426 9228650 , , O O
44 427 439 9228650 respectively RB B-ADVP O
45 439 440 9228650 ) ) O O
46 440 441 9228650 . . O O

1 442 444 9228650 In IN B-PP O
2 445 453 9228650 addition NN B-NP O
3 453 454 9228650 , , O O
4 455 458 9228650 NIK NN B-NP C049860
5 458 459 9228650 - HYPH B-NP C049860
6 459 462 9228650 247 CD I-NP C049860
7 463 466 9228650 and CC O O
8 467 474 9228650 tacrine NN B-NP D013619
9 474 475 9228650 , , O O
10 476 479 9228650 but CC O O
11 480 483 9228650 not RB O O
12 484 485 9228650 E NN B-NP C076946
13 485 486 9228650 - HYPH O C076946
14 486 490 9228650 2020 CD B-NP C076946
15 490 491 9228650 , , O O
16 492 500 9228650 strongly RB B-VP O
17 501 510 9228650 inhibited VBD I-VP O
18 511 531 9228650 butyrylcholinestrase NN B-NP O
19 532 533 9228650 ( ( O O
20 533 538 9228650 BuChE NN B-NP O
21 538 539 9228650 ) ) O O
22 540 542 9228650 in IN B-PP O
23 543 548 9228650 human JJ B-NP O
24 549 554 9228650 serum NN I-NP O
25 554 555 9228650 . . O O

1 556 559 9228650 All DT B-NP O
2 560 565 9228650 three CD I-NP O
3 566 571 9228650 drugs NNS I-NP O
4 572 580 9228650 produced VBD B-VP O
5 581 586 9228650 mixed JJ B-NP O
6 587 597 9228650 inhibition NN I-NP O
7 598 600 9228650 of IN B-PP O
8 601 605 9228650 AChE NN B-NP O
9 606 614 9228650 activity NN I-NP O
10 614 615 9228650 . . O O

1 616 624 9228650 Moreover RB B-ADVP O
2 624 625 9228650 , , O O
3 626 629 9228650 the DT B-NP O
4 630 640 9228650 inhibitory JJ I-NP O
5 641 647 9228650 effect NN I-NP O
6 648 650 9228650 of IN B-PP O
7 651 654 9228650 NIK NN B-NP C049860
8 654 655 9228650 - HYPH O C049860
9 655 658 9228650 247 CD B-NP C049860
10 659 661 9228650 on IN B-PP O
11 662 666 9228650 AChE NN B-NP O
12 667 670 9228650 was VBD B-VP O
13 671 681 9228650 reversible JJ B-ADJP O
14 681 682 9228650 . . O O

1 683 686 9228650 All DT B-NP O
2 687 696 9228650 compounds NNS I-NP O
3 697 699 9228650 at IN B-PP O
4 700 703 9228650 0.1 CD B-NP O
5 703 704 9228650 - HYPH I-NP O
6 704 705 9228650 1 CD I-NP O
7 706 708 9228650 mg NN I-NP O
8 708 709 9228650 / SYM B-NP O
9 709 711 9228650 kg NN I-NP O
10 712 715 9228650 p.o NN I-NP O
11 715 716 9228650 . . O O

1 717 730 9228650 significantly RB B-ADVP O
2 731 739 9228650 improved VBD B-VP O
3 740 743 9228650 the DT B-NP O
4 744 751 9228650 amnesia NN I-NP D000647
5 752 759 9228650 induced VBN B-VP O
6 760 762 9228650 by IN B-PP O
7 763 774 9228650 scopolamine NN B-NP D012601
8 775 776 9228650 ( ( O O
9 776 779 9228650 0.5 CD B-NP O
10 780 782 9228650 mg NN I-NP O
11 782 783 9228650 / SYM B-NP O
12 783 785 9228650 kg NN I-NP O
13 786 789 9228650 s.c NN I-NP O
14 789 790 9228650 . . O O
15 790 791 9228650 ) ) O O
16 792 794 9228650 in IN B-PP O
17 795 799 9228650 rats NNS B-NP O
18 800 810 9228650 performing VBG B-VP O
19 811 812 9228650 a DT B-NP O
20 813 820 9228650 passive JJ I-NP O
21 821 830 9228650 avoidance NN I-NP O
22 831 835 9228650 task NN I-NP O
23 835 836 9228650 . . O O

1 837 840 9228650 The DT B-NP O
2 841 846 9228650 three CD I-NP O
3 847 856 9228650 compounds NNS I-NP O
4 857 859 9228650 at IN B-PP O
5 860 861 9228650 1 CD B-NP O
6 862 865 9228650 and CC I-NP O
7 866 867 9228650 3 CD I-NP O
8 868 870 9228650 mg NN I-NP O
9 870 871 9228650 / SYM B-NP O
10 871 873 9228650 kg NN I-NP O
11 874 877 9228650 p.o NN I-NP O
12 877 878 9228650 . . O O

1 879 882 9228650 did VBD B-VP O
2 883 886 9228650 not RB I-VP O
3 887 900 9228650 significantly RB I-VP O
4 901 909 9228650 decrease VB I-VP O
5 910 921 9228650 spontaneous JJ B-NP O
6 922 930 9228650 movement NN I-NP O
7 931 933 9228650 by IN B-PP O
8 934 938 9228650 rats NNS B-NP O
9 938 939 9228650 . . O O

1 940 945 9228650 These DT B-NP O
2 946 954 9228650 findings NNS I-NP O
3 955 962 9228650 suggest VBP B-VP O
4 963 967 9228650 that IN B-SBAR O
5 968 971 9228650 NIK NN B-NP C049860
6 971 972 9228650 - HYPH B-NP C049860
7 972 975 9228650 247 CD I-NP C049860
8 976 978 9228650 at IN B-PP O
9 979 980 9228650 a DT B-NP O
10 981 984 9228650 low JJ I-NP O
11 985 989 9228650 dose NN I-NP O
12 990 991 9228650 ( ( O O
13 991 994 9228650 0.1 CD B-NP O
14 994 995 9228650 - HYPH I-NP O
15 995 996 9228650 1 CD I-NP O
16 997 999 9228650 mg NN I-NP O
17 999 1000 9228650 / SYM B-NP O
18 1000 1002 9228650 kg NN I-NP O
19 1003 1006 9228650 p.o NN I-NP O
20 1006 1007 9228650 . . O O
21 1007 1008 9228650 ) ) O O
22 1009 1017 9228650 improves VBZ B-VP O
23 1018 1029 9228650 scopolamine NN B-NP D012601
24 1029 1030 9228650 - HYPH B-NP O
25 1030 1037 9228650 induced VBN I-NP O
26 1038 1045 9228650 amnesia NN I-NP D000647
27 1046 1049 9228650 but CC O O
28 1050 1054 9228650 does VBZ B-VP O
29 1055 1058 9228650 not RB I-VP O
30 1059 1065 9228650 affect VB I-VP O
31 1066 1077 9228650 spontaneous JJ B-NP O
32 1078 1086 9228650 movement NN I-NP O
33 1086 1087 9228650 . . O O

1 1088 1091 9228650 The DT B-NP O
2 1092 1100 9228650 findings NNS I-NP O
3 1101 1108 9228650 suggest VBP B-VP O
4 1109 1113 9228650 that IN B-SBAR O
5 1114 1117 9228650 NIK NN B-NP C049860
6 1117 1118 9228650 - HYPH O C049860
7 1118 1121 9228650 247 CD B-NP C049860
8 1122 1125 9228650 may MD B-VP O
9 1126 1128 9228650 be VB I-VP O
10 1129 1130 9228650 a DT B-NP O
11 1131 1137 9228650 useful JJ I-NP O
12 1138 1142 9228650 drug NN I-NP O
13 1143 1146 9228650 for IN B-PP O
14 1147 1150 9228650 the DT B-NP O
15 1151 1160 9228650 treatment NN I-NP O
16 1161 1163 9228650 of IN B-PP O
17 1164 1175 9228650 Alzheimer's NNP B-NP D000544
18 1176 1183 9228650 disease NN I-NP D000544
19 1183 1184 9228650 . . O O

1 0 0 11752998 -DOCSTART- -X- -X- O

1 0 11 11752998 Preliminary JJ B-NP O
2 12 20 11752998 efficacy NN I-NP O
3 21 31 11752998 assessment NN I-NP O
4 32 34 11752998 of IN B-PP O
5 35 46 11752998 intrathecal JJ B-NP O
6 47 56 11752998 injection NN I-NP O
7 57 59 11752998 of IN B-PP O
8 60 62 11752998 an DT B-NP O
9 63 71 11752998 American JJ I-NP O
10 72 83 11752998 formulation NN I-NP O
11 84 86 11752998 of IN B-PP O
12 87 96 11752998 adenosine NN B-NP D000241
13 97 99 11752998 in IN B-PP O
14 100 106 11752998 humans NNS B-NP O
15 106 107 11752998 . . O O
16 108 118 11752998 BACKGROUND NN B-NP O
17 118 119 11752998 : : O O
18 120 131 11752998 Preclinical JJ B-NP O
19 132 139 11752998 studies NNS I-NP O
20 140 142 11752998 of IN B-PP O
21 143 154 11752998 intrathecal JJ B-NP O
22 155 164 11752998 adenosine NN I-NP D000241
23 165 172 11752998 suggest VBP B-VP O
24 173 175 11752998 it PRP B-NP O
25 176 179 11752998 may MD B-VP O
26 180 182 11752998 be VB I-VP O
27 183 192 11752998 effective JJ B-ADJP O
28 193 195 11752998 in IN B-PP O
29 196 199 11752998 the DT B-NP O
30 200 209 11752998 treatment NN I-NP O
31 210 212 11752998 of IN B-PP O
32 213 218 11752998 acute JJ B-NP D059787
33 219 222 11752998 and CC I-NP D059787
34 223 230 11752998 chronic JJ I-NP D059787
35 231 235 11752998 pain NN I-NP D059787
36 236 238 11752998 in IN B-PP O
37 239 245 11752998 humans NNS B-NP O
38 245 246 11752998 , , O O
39 247 250 11752998 and CC O O
40 251 262 11752998 preliminary JJ B-NP O
41 263 270 11752998 studies NNS I-NP O
42 271 273 11752998 in IN B-PP O
43 274 284 11752998 volunteers NNS B-NP O
44 285 288 11752998 and CC I-NP O
45 289 297 11752998 patients NNS I-NP O
46 298 302 11752998 with IN B-PP O
47 303 304 11752998 a DT B-NP O
48 305 312 11752998 Swedish JJ I-NP O
49 313 324 11752998 formulation NN I-NP O
50 325 327 11752998 of IN B-PP O
51 328 337 11752998 adenosine NN B-NP D000241
52 338 346 11752998 suggests VBZ B-VP O
53 347 349 11752998 it PRP B-NP O
54 350 353 11752998 may MD B-VP O
55 354 356 11752998 be VB I-VP O
56 357 366 11752998 effective JJ B-ADJP O
57 367 369 11752998 in IN B-PP O
58 370 386 11752998 hypersensitivity NN B-NP D004342
59 387 393 11752998 states NNS I-NP O
60 394 397 11752998 but CC B-PP O
61 398 401 11752998 not RB B-PP O
62 402 406 11752998 with IN I-PP O
63 407 412 11752998 acute JJ B-NP O
64 413 420 11752998 noxious JJ I-NP O
65 421 432 11752998 stimulation NN I-NP O
66 432 433 11752998 . . O O

1 434 437 11752998 The DT B-NP O
2 438 445 11752998 purpose NN I-NP O
3 446 448 11752998 of IN B-PP O
4 449 453 11752998 this DT B-NP O
5 454 459 11752998 study NN I-NP O
6 460 463 11752998 was VBD B-VP O
7 464 466 11752998 to TO B-VP O
8 467 473 11752998 screen VB I-VP O
9 474 477 11752998 for IN B-PP O
10 478 486 11752998 efficacy NN B-NP O
11 487 489 11752998 of IN B-PP O
12 490 491 11752998 a DT B-NP O
13 492 501 11752998 different JJ I-NP O
14 502 513 11752998 formulation NN I-NP O
15 514 516 11752998 of IN B-PP O
16 517 526 11752998 adenosine NN B-NP D000241
17 527 535 11752998 marketed VBN B-VP O
18 536 538 11752998 in IN B-PP O
19 539 542 11752998 the DT B-NP O
20 543 545 11752998 US NNP I-NP O
21 545 546 11752998 , , O O
22 547 552 11752998 using VBG B-VP O
23 553 557 11752998 both CC O O
24 558 563 11752998 acute JJ B-NP O
25 564 571 11752998 noxious JJ I-NP O
26 572 583 11752998 stimulation NN I-NP O
27 584 587 11752998 and CC I-NP O
28 588 597 11752998 capsaicin NN I-NP D002211
29 597 598 11752998 - HYPH O O
30 598 604 11752998 evoked VBN B-VP O
31 605 615 11752998 mechanical JJ B-NP O
32 616 632 11752998 hypersensitivity NN I-NP D004342
33 632 633 11752998 . . O O

1 634 641 11752998 METHODS NNS B-NP O
2 641 642 11752998 : : O O
3 643 652 11752998 Following VBG B-VP O
4 653 657 11752998 Food NNP B-NP O
5 658 661 11752998 and CC I-NP O
6 662 666 11752998 Drug NNP I-NP O
7 667 681 11752998 Administration NNP I-NP O
8 682 685 11752998 and CC O O
9 686 699 11752998 institutional JJ B-NP O
10 700 706 11752998 review NN I-NP O
11 707 712 11752998 board NN I-NP O
12 713 721 11752998 approval NN I-NP O
13 722 725 11752998 and CC O O
14 726 733 11752998 written VBN B-VP O
15 734 742 11752998 informed VBN B-NP O
16 743 750 11752998 consent NN I-NP O
17 750 751 11752998 , , O O
18 752 754 11752998 65 CD B-NP O
19 755 765 11752998 volunteers NNS I-NP O
20 766 770 11752998 were VBD B-VP O
21 771 778 11752998 studied VBN I-VP O
22 779 781 11752998 in IN B-PP O
23 782 785 11752998 two CD B-NP O
24 786 792 11752998 trials NNS I-NP O
25 792 793 11752998 : : O O
26 794 796 11752998 an DT B-NP O
27 797 801 11752998 open JJ I-NP O
28 801 802 11752998 - HYPH I-NP O
29 802 807 11752998 label NN I-NP O
30 807 808 11752998 , , O O
31 809 813 11752998 dose NN B-NP O
32 813 814 11752998 - HYPH O O
33 814 824 11752998 escalating VBG B-VP O
34 825 830 11752998 trial NN B-NP O
35 831 835 11752998 with IN B-PP O
36 836 847 11752998 intrathecal JJ B-NP O
37 848 857 11752998 adenosine NN I-NP D000241
38 858 863 11752998 doses NNS I-NP O
39 864 866 11752998 of IN B-PP O
40 867 871 11752998 0.25 CD B-NP O
41 871 872 11752998 - HYPH I-NP O
42 872 875 11752998 2.0 CD I-NP O
43 876 878 11752998 mg NN I-NP O
44 879 882 11752998 and CC O O
45 883 884 11752998 a DT B-NP O
46 885 891 11752998 double JJ I-NP O
47 891 892 11752998 - HYPH I-NP O
48 892 897 11752998 blind JJ I-NP O
49 897 898 11752998 , , I-NP O
50 899 906 11752998 placebo NN I-NP O
51 906 907 11752998 - HYPH I-NP O
52 907 917 11752998 controlled VBN B-NP O
53 918 923 11752998 trial NN I-NP O
54 924 926 11752998 of IN B-PP O
55 927 936 11752998 adenosine NN B-NP D000241
56 936 937 11752998 , , O O
57 938 939 11752998 2 CD B-NP O
58 940 942 11752998 mg NN I-NP O
59 942 943 11752998 . . O O

1 944 957 11752998 Cerebrospinal JJ B-NP O
2 958 963 11752998 fluid NN I-NP O
3 964 967 11752998 was VBD B-VP O
4 968 976 11752998 obtained VBN I-VP O
5 977 980 11752998 for IN B-PP O
6 981 996 11752998 pharmacokinetic JJ B-NP O
7 997 1005 11752998 analysis NN I-NP O
8 1005 1006 11752998 , , O O
9 1007 1010 11752998 and CC O O
10 1011 1015 11752998 pain NN B-NP D010146
11 1016 1023 11752998 ratings NNS I-NP O
12 1024 1026 11752998 in IN B-PP O
13 1027 1035 11752998 response NN B-NP O
14 1036 1038 11752998 to TO B-PP O
15 1039 1044 11752998 acute JJ B-NP O
16 1045 1049 11752998 heat NN I-NP O
17 1050 1057 11752998 stimuli NNS I-NP O
18 1058 1061 11752998 and CC I-NP O
19 1062 1067 11752998 areas NNS I-NP O
20 1068 1070 11752998 of IN B-PP O
21 1071 1081 11752998 mechanical JJ B-NP D006930
22 1082 1094 11752998 hyperalgesia NN I-NP D006930
23 1095 1098 11752998 and CC I-NP O
24 1099 1108 11752998 allodynia NN I-NP D006930
25 1109 1114 11752998 after IN B-PP O
26 1115 1126 11752998 intradermal JJ B-NP O
27 1127 1136 11752998 capsaicin NN I-NP D002211
28 1137 1146 11752998 injection NN I-NP O
29 1147 1151 11752998 were VBD B-VP O
30 1152 1162 11752998 determined VBN I-VP O
31 1162 1163 11752998 . . O O

1 1164 1171 11752998 RESULTS NNS B-NP O
2 1171 1172 11752998 : : O O
3 1173 1182 11752998 Adenosine NN B-NP D000241
4 1183 1191 11752998 produced VBD B-VP O
5 1192 1194 11752998 no DT B-NP O
6 1195 1201 11752998 effect NN I-NP O
7 1202 1204 11752998 on IN B-PP O
8 1205 1209 11752998 pain NN B-NP D010146
9 1210 1216 11752998 report NN I-NP O
10 1217 1219 11752998 to TO B-PP O
11 1220 1225 11752998 acute JJ B-NP O
12 1226 1233 11752998 noxious JJ I-NP O
13 1234 1241 11752998 thermal JJ I-NP O
14 1242 1244 11752998 or CC I-NP O
15 1245 1253 11752998 chemical JJ I-NP O
16 1254 1265 11752998 stimulation NN I-NP O
17 1266 1269 11752998 but CC O O
18 1270 1277 11752998 reduced VBD B-VP O
19 1278 1288 11752998 mechanical JJ B-NP D006930
20 1289 1301 11752998 hyperalgesia NN I-NP D006930
21 1302 1305 11752998 and CC I-NP O
22 1306 1315 11752998 allodynia NN I-NP D006930
23 1316 1320 11752998 from IN B-PP O
24 1321 1332 11752998 intradermal JJ B-NP O
25 1333 1342 11752998 capsaicin NN I-NP D002211
26 1343 1352 11752998 injection NN I-NP O
27 1353 1356 11752998 for IN B-PP O
28 1357 1359 11752998 at IN B-NP O
29 1360 1365 11752998 least JJS I-NP O
30 1366 1368 11752998 24 CD I-NP O
31 1369 1370 11752998 h NN I-NP O
32 1370 1371 11752998 . . O O

1 1372 1374 11752998 In IN B-PP O
2 1375 1383 11752998 contrast NN B-NP O
3 1383 1384 11752998 , , O O
4 1385 1394 11752998 residence NN B-NP O
5 1395 1399 11752998 time NN I-NP O
6 1400 1402 11752998 of IN B-PP O
7 1403 1412 11752998 adenosine NN B-NP D000241
8 1413 1415 11752998 in IN B-PP O
9 1416 1429 11752998 cerebrospinal JJ B-NP O
10 1430 1435 11752998 fluid NN I-NP O
11 1436 1439 11752998 was VBD B-VP O
12 1440 1445 11752998 short JJ B-ADJP O
13 1446 1447 11752998 ( ( O O
14 1447 1448 11752998 < SYM O O
15 1449 1450 11752998 4 CD B-NP O
16 1451 1452 11752998 h NN I-NP O
17 1452 1453 11752998 ) ) O O
18 1453 1454 11752998 . . O O

1 1455 1466 11752998 CONCLUSIONS NNS B-NP O
2 1466 1467 11752998 : : O O
3 1468 1473 11752998 These DT B-NP O
4 1474 1481 11752998 results NNS I-NP O
5 1482 1486 11752998 show VBP B-VP O
6 1487 1496 11752998 selective JJ B-NP O
7 1497 1507 11752998 inhibition NN I-NP O
8 1508 1510 11752998 by IN B-PP O
9 1511 1522 11752998 intrathecal JJ B-NP O
10 1523 1532 11752998 adenosine NN I-NP D000241
11 1533 1535 11752998 of IN B-PP O
12 1536 1552 11752998 hypersensitivity NN B-NP D004342
13 1552 1553 11752998 , , O O
14 1554 1562 11752998 presumed VBN B-VP O
15 1563 1565 11752998 to TO I-VP O
16 1566 1573 11752998 reflect VB I-VP O
17 1574 1581 11752998 central JJ B-NP O
18 1582 1595 11752998 sensitization NN I-NP O
19 1596 1598 11752998 in IN B-PP O
20 1599 1605 11752998 humans NNS B-NP O
21 1606 1611 11752998 after IN B-PP O
22 1612 1622 11752998 peripheral JJ B-NP O
23 1623 1632 11752998 capsaicin NN I-NP D002211
24 1633 1642 11752998 injection NN I-NP O
25 1642 1643 11752998 . . O O

1 1644 1647 11752998 The DT B-NP O
2 1648 1652 11752998 long JJ I-NP O
3 1652 1653 11752998 - HYPH I-NP O
4 1653 1660 11752998 lasting JJ I-NP O
5 1661 1667 11752998 effect NN I-NP O
6 1668 1670 11752998 is VBZ B-VP O
7 1671 1681 11752998 consistent JJ B-ADJP O
8 1682 1686 11752998 with IN B-PP O
9 1687 1691 11752998 that DT B-NP O
10 1692 1700 11752998 observed VBN B-VP O
11 1701 1703 11752998 in IN B-PP O
12 1704 1715 11752998 preliminary JJ B-NP O
13 1716 1723 11752998 reports NNS I-NP O
14 1724 1726 11752998 of IN B-PP O
15 1727 1735 11752998 patients NNS B-NP O
16 1736 1740 11752998 with IN B-PP O
17 1741 1748 11752998 chronic JJ B-NP O
18 1749 1760 11752998 neuropathic JJ I-NP D009437
19 1761 1765 11752998 pain NN I-NP D009437
20 1766 1769 11752998 and CC O O
21 1770 1772 11752998 is VBZ B-VP O
22 1773 1776 11752998 not RB O O
23 1777 1780 11752998 due JJ B-ADJP O
24 1781 1783 11752998 to TO B-PP O
25 1784 1793 11752998 prolonged VBN B-NP O
26 1794 1803 11752998 residence NN I-NP O
27 1804 1806 11752998 of IN B-PP O
28 1807 1816 11752998 adenosine NN B-NP D000241
29 1817 1819 11752998 in IN B-PP O
30 1820 1833 11752998 cerebrospinal JJ B-NP O
31 1834 1839 11752998 fluid NN I-NP O
32 1839 1840 11752998 . . O O

1 0 0 21294084 -DOCSTART- -X- -X- O

1 0 7 21294084 Effects NNS B-NP O
2 8 10 21294084 of IN B-PP O
3 11 14 21294084 the DT B-NP O
4 15 26 21294084 hippocampal JJ I-NP O
5 27 31 21294084 deep JJ I-NP O
6 32 37 21294084 brain NN I-NP O
7 38 49 21294084 stimulation NN I-NP O
8 50 52 21294084 on IN B-PP O
9 53 61 21294084 cortical JJ B-NP O
10 62 71 21294084 epileptic JJ I-NP D004827
11 72 82 21294084 discharges NNS I-NP O
12 83 85 21294084 in IN B-PP O
13 86 96 21294084 penicillin NN B-NP D010406
14 97 98 21294084 - HYPH B-NP O
15 99 106 21294084 induced VBN I-NP O
16 107 115 21294084 epilepsy NN I-NP D004827
17 116 121 21294084 model NN I-NP O
18 122 124 21294084 in IN B-PP O
19 125 129 21294084 rats NNS B-NP O
20 129 130 21294084 . . O O
21 131 134 21294084 AIM NN B-NP O
22 134 135 21294084 : : O O
23 136 148 21294084 Experimental JJ B-NP O
24 149 152 21294084 and CC I-NP O
25 153 161 21294084 clinical JJ I-NP O
26 162 169 21294084 studies NNS I-NP O
27 170 174 21294084 have VBP B-VP O
28 175 183 21294084 revealed VBN I-VP O
29 184 188 21294084 that IN B-SBAR O
30 189 200 21294084 hippocampal JJ B-NP O
31 201 204 21294084 DBS NNP I-NP O
32 205 208 21294084 can MD B-VP O
33 209 216 21294084 control VB I-VP O
34 217 226 21294084 epileptic JJ B-NP D004827
35 227 235 21294084 activity NN I-NP O
36 235 236 21294084 , , O O
37 237 240 21294084 but CC O O
38 241 244 21294084 the DT B-NP O
39 245 254 21294084 mechanism NN I-NP O
40 255 257 21294084 of IN B-PP O
41 258 264 21294084 action NN B-NP O
42 265 267 21294084 is VBZ B-VP O
43 268 275 21294084 obscure JJ B-NP O
44 276 279 21294084 and CC I-NP O
45 280 287 21294084 optimal JJ I-NP O
46 288 299 21294084 stimulation NN I-NP O
47 300 310 21294084 parameters NNS I-NP O
48 311 314 21294084 are VBP B-VP O
49 315 318 21294084 not RB O O
50 319 326 21294084 clearly RB B-VP O
51 327 334 21294084 defined VBN I-VP O
52 334 335 21294084 . . O O

1 336 339 21294084 The DT B-NP O
2 340 343 21294084 aim NN I-NP O
3 344 347 21294084 was VBD B-VP O
4 348 350 21294084 to TO B-VP O
5 351 359 21294084 evaluate VB I-VP O
6 360 363 21294084 the DT B-NP O
7 364 371 21294084 effects NNS I-NP O
8 372 374 21294084 of IN B-PP O
9 375 379 21294084 high JJ B-NP O
10 380 389 21294084 frequency NN I-NP O
11 390 401 21294084 hippocampal JJ I-NP O
12 402 413 21294084 stimulation NN I-NP O
13 414 416 21294084 on IN B-PP O
14 417 425 21294084 cortical JJ B-NP O
15 426 435 21294084 epileptic JJ I-NP D004827
16 436 444 21294084 activity NN I-NP O
17 445 447 21294084 in IN B-PP O
18 448 458 21294084 penicillin NN B-NP D010406
19 458 459 21294084 - HYPH B-NP O
20 459 466 21294084 induced VBN I-NP O
21 467 475 21294084 epilepsy NN I-NP D004827
22 476 481 21294084 model NN I-NP O
23 481 482 21294084 . . O O

1 483 491 21294084 MATERIAL NN B-NP O
2 492 495 21294084 AND CC I-NP O
3 496 503 21294084 METHODS NNS I-NP O
4 503 504 21294084 : : O O
5 505 511 21294084 Twenty CD B-NP O
6 511 512 21294084 - HYPH I-NP O
7 512 516 21294084 five CD I-NP O
8 517 524 21294084 Sprague NNP I-NP O
9 524 525 21294084 - HYPH I-NP O
10 525 531 21294084 Dawley NNP I-NP O
11 532 536 21294084 rats NNS I-NP O
12 537 541 21294084 were VBD B-VP O
13 542 551 21294084 implanted VBN I-VP O
14 552 555 21294084 DBS NNP B-NP O
15 556 566 21294084 electrodes NNS I-NP O
16 566 567 21294084 . . O O

1 568 570 21294084 In IN B-PP O
2 571 576 21294084 group NN B-NP O
3 576 577 21294084 - HYPH B-NP O
4 577 578 21294084 1 CD I-NP O
5 579 580 21294084 ( ( O O
6 580 581 21294084 n NN B-NP O
7 581 582 21294084 = SYM B-VP O
8 582 584 21294084 10 CD B-NP O
9 584 585 21294084 ) ) O O
10 586 597 21294084 hippocampal JJ B-NP O
11 598 601 21294084 DBS NN I-NP O
12 602 605 21294084 was VBD B-VP O
13 606 609 21294084 off RB B-ADVP O
14 610 613 21294084 and CC O O
15 614 616 21294084 in IN B-PP O
16 617 620 21294084 the DT B-NP O
17 621 626 21294084 group NN I-NP O
18 626 627 21294084 - HYPH O O
19 627 628 21294084 2 CD B-NP O
20 629 630 21294084 ( ( O O
21 630 631 21294084 n NN B-NP O
22 631 632 21294084 = SYM B-VP O
23 632 634 21294084 10 CD B-NP O
24 634 635 21294084 ) ) O O
25 636 647 21294084 hippocampal JJ B-NP O
26 648 651 21294084 DBS NN I-NP O
27 652 655 21294084 was VBD B-VP O
28 656 658 21294084 on IN B-PP O
29 659 660 21294084 ( ( O O
30 660 663 21294084 185 CD B-NP O
31 664 666 21294084 Hz NN I-NP O
32 666 667 21294084 , , O O
33 668 672 21294084 0.5V NN B-NP O
34 672 673 21294084 , , O O
35 674 676 21294084 1V NN B-NP O
36 676 677 21294084 , , O O
37 678 680 21294084 2V NN B-NP O
38 680 681 21294084 , , O O
39 682 685 21294084 and CC O O
40 686 688 21294084 5V NN B-NP O
41 689 692 21294084 for IN B-PP O
42 693 695 21294084 60 CD B-NP O
43 696 699 21294084 sec NN I-NP O
44 699 700 21294084 ) ) O O
45 701 710 21294084 following VBG B-PP O
46 711 721 21294084 penicillin NN B-NP D010400
47 722 723 21294084 G NN I-NP D010400
48 724 733 21294084 injection NN I-NP O
49 734 749 21294084 intracortically RB B-ADVP O
50 749 750 21294084 . . O O

1 751 753 21294084 In IN B-PP O
2 754 757 21294084 the DT B-NP O
3 758 765 21294084 control NN I-NP O
4 766 771 21294084 group NN I-NP O
5 772 783 21294084 hippocampal JJ I-NP O
6 784 787 21294084 DBS NN I-NP O
7 788 791 21294084 was VBD B-VP O
8 792 794 21294084 on IN B-PP O
9 795 804 21294084 following VBG B-VP O
10 805 806 21294084 8 CD B-NP O
11 808 809 21294084 l NN I-NP O
12 810 816 21294084 saline NN I-NP O
13 817 826 21294084 injection NN I-NP O
14 827 842 21294084 intracortically RB B-ADVP O
15 842 843 21294084 . . O O

1 844 847 21294084 EEG NN B-NP O
2 848 858 21294084 recordings NNS I-NP O
3 859 863 21294084 were VBD B-VP O
4 864 872 21294084 obtained VBN I-VP O
5 873 879 21294084 before IN B-PP O
6 880 883 21294084 and CC O O
7 884 886 21294084 15 CD B-NP O
8 887 894 21294084 minutes NNS I-NP O
9 895 904 21294084 following VBG B-PP O
10 905 915 21294084 penicillin NN B-NP D010400
11 915 916 21294084 - HYPH B-NP D010400
12 916 917 21294084 G NN I-NP D010400
13 918 927 21294084 injection NN I-NP O
14 927 928 21294084 , , B-PP O
15 929 932 21294084 and CC I-PP O
16 933 935 21294084 at IN B-PP O
17 936 940 21294084 10th JJ B-NP O
18 941 948 21294084 minutes NNS I-NP O
19 949 958 21294084 following VBG B-PP O
20 959 963 21294084 each DT B-NP O
21 964 972 21294084 stimulus NN I-NP O
22 973 976 21294084 for IN B-PP O
23 977 985 21294084 analysis NN B-NP O
24 986 988 21294084 in IN B-PP O
25 989 994 21294084 terms NNS B-NP O
26 995 997 21294084 of IN B-PP O
27 998 1007 21294084 frequency NN B-NP O
28 1007 1008 21294084 , , O O
29 1009 1018 21294084 amplitude NN B-NP O
30 1018 1019 21294084 , , O O
31 1020 1023 21294084 and CC O O
32 1024 1029 21294084 power NN B-NP O
33 1030 1038 21294084 spectrum NN I-NP O
34 1038 1039 21294084 . . O O

1 1040 1047 21294084 RESULTS NNS B-NP O
2 1047 1048 21294084 : : O O
3 1049 1053 21294084 High JJ B-NP O
4 1054 1063 21294084 frequency NN I-NP O
5 1064 1075 21294084 hippocampal JJ I-NP O
6 1076 1079 21294084 DBS NNP I-NP O
7 1080 1090 21294084 suppressed VBD B-VP O
8 1091 1094 21294084 the DT B-NP O
9 1095 1100 21294084 acute JJ I-NP O
10 1101 1111 21294084 penicillin NN I-NP D010406
11 1111 1112 21294084 - HYPH O O
12 1112 1119 21294084 induced VBN B-NP O
13 1120 1128 21294084 cortical JJ I-NP O
14 1129 1138 21294084 epileptic JJ I-NP D004827
15 1139 1147 21294084 activity NN I-NP O
16 1148 1159 21294084 independent JJ B-ADJP O
17 1160 1164 21294084 from IN B-PP O
18 1165 1173 21294084 stimulus NN B-NP O
19 1174 1183 21294084 intensity NN I-NP O
20 1183 1184 21294084 . . O O

1 1185 1187 21294084 In IN B-PP O
2 1188 1191 21294084 the DT B-NP O
3 1192 1199 21294084 control NN I-NP O
4 1200 1205 21294084 group NN I-NP O
5 1205 1206 21294084 , , O O
6 1207 1218 21294084 hippocampal JJ B-NP O
7 1219 1230 21294084 stimulation NN I-NP O
8 1231 1236 21294084 alone RB B-ADVP O
9 1237 1241 21294084 lead VBP B-VP O
10 1242 1246 21294084 only RB B-ADVP O
11 1247 1249 21294084 to TO B-VP O
12 1250 1257 21294084 diffuse VB I-VP O
13 1258 1265 21294084 slowing NN B-NP O
14 1266 1268 21294084 of IN B-PP O
15 1269 1277 21294084 cerebral JJ B-NP O
16 1278 1291 21294084 bioelectrical JJ I-NP O
17 1292 1300 21294084 activity NN I-NP O
18 1301 1303 21294084 at IN B-PP O
19 1304 1306 21294084 5V NN B-NP O
20 1307 1318 21294084 stimulation NN I-NP O
21 1318 1319 21294084 . . O O

1 1320 1330 21294084 CONCLUSION NN B-NP O
2 1330 1331 21294084 : : O O
3 1332 1335 21294084 Our PRP$ B-NP O
4 1336 1343 21294084 results NNS I-NP O
5 1344 1352 21294084 revealed VBD B-VP O
6 1353 1357 21294084 that IN B-SBAR O
7 1358 1368 21294084 continuous JJ B-NP O
8 1369 1373 21294084 high JJ I-NP O
9 1374 1383 21294084 frequency NN I-NP O
10 1384 1395 21294084 stimulation NN I-NP O
11 1396 1398 21294084 of IN B-PP O
12 1399 1402 21294084 the DT B-NP O
13 1403 1414 21294084 hippocampus NN I-NP O
14 1415 1425 21294084 suppressed VBD B-VP O
15 1426 1431 21294084 acute JJ B-NP O
16 1432 1440 21294084 cortical JJ I-NP O
17 1441 1450 21294084 epileptic JJ I-NP D004827
18 1451 1459 21294084 activity NN I-NP O
19 1460 1471 21294084 effectively RB B-ADVP O
20 1472 1479 21294084 without IN B-PP O
21 1480 1487 21294084 causing VBG B-VP O
22 1488 1497 21294084 secondary JJ B-NP O
23 1498 1507 21294084 epileptic JJ I-NP D004827
24 1508 1518 21294084 discharges NNS I-NP O
25 1518 1519 21294084 . . O O

1 1520 1525 21294084 These DT B-NP O
2 1526 1533 21294084 results NNS I-NP O
3 1534 1537 21294084 are VBP B-VP O
4 1538 1547 21294084 important JJ B-ADJP O
5 1548 1550 21294084 in IN B-PP O
6 1551 1556 21294084 terms NNS B-NP O
7 1557 1559 21294084 of IN B-PP O
8 1560 1568 21294084 defining VBG B-VP O
9 1569 1572 21294084 the DT B-NP O
10 1573 1580 21294084 optimal JJ I-NP O
11 1581 1591 21294084 parameters NNS I-NP O
12 1592 1594 21294084 of IN B-PP O
13 1595 1606 21294084 hippocampal JJ B-NP O
14 1607 1610 21294084 DBS NN I-NP O
15 1611 1613 21294084 in IN B-PP O
16 1614 1622 21294084 patients NNS B-NP O
17 1623 1627 21294084 with IN B-PP O
18 1628 1636 21294084 epilepsy NN B-NP D004827
19 1636 1637 21294084 . . O O

1 0 0 15814210 -DOCSTART- -X- -X- O

1 0 5 15814210 Minor JJ B-NP O
2 6 18 15814210 neurological JJ I-NP D009422
3 19 30 15814210 dysfunction NN I-NP D009422
4 30 31 15814210 , , O O
5 32 41 15814210 cognitive JJ B-NP O
6 42 53 15814210 development NN I-NP O
7 53 54 15814210 , , O O
8 55 58 15814210 and CC O O
9 59 66 15814210 somatic JJ B-NP O
10 67 78 15814210 development NN I-NP O
11 79 81 15814210 at IN B-PP O
12 82 85 15814210 the DT B-NP O
13 86 89 15814210 age NN I-NP O
14 90 92 15814210 of IN B-PP O
15 93 94 15814210 3 CD B-NP O
16 95 97 15814210 to TO I-NP O
17 98 99 15814210 7 CD I-NP O
18 100 105 15814210 years NNS I-NP O
19 106 111 15814210 after IN B-PP O
20 112 125 15814210 dexamethasone NN B-NP D003907
21 126 135 15814210 treatment NN I-NP O
22 136 138 15814210 in IN B-PP O
23 139 143 15814210 very RB B-NP O
24 143 144 15814210 - HYPH I-NP O
25 144 147 15814210 low JJ I-NP O
26 148 153 15814210 birth NN I-NP O
27 153 154 15814210 - HYPH I-NP O
28 154 160 15814210 weight NN B-NP O
29 161 168 15814210 infants NNS I-NP O
30 168 169 15814210 . . O O
31 170 173 15814210 The DT B-NP O
32 174 183 15814210 objective NN I-NP O
33 184 186 15814210 of IN B-PP O
34 187 191 15814210 this DT B-NP O
35 192 197 15814210 study NN I-NP O
36 198 201 15814210 was VBD B-VP O
37 202 204 15814210 to TO B-VP O
38 205 211 15814210 assess VB I-VP O
39 212 217 15814210 minor JJ B-NP O
40 218 230 15814210 neurological JJ I-NP D009422
41 231 242 15814210 dysfunction NN I-NP D009422
42 242 243 15814210 , , O O
43 244 253 15814210 cognitive JJ B-NP O
44 254 265 15814210 development NN I-NP O
45 265 266 15814210 , , O O
46 267 270 15814210 and CC O O
47 271 278 15814210 somatic JJ B-NP O
48 279 290 15814210 development NN I-NP O
49 291 296 15814210 after IN B-PP O
50 297 310 15814210 dexamethasone NN B-NP D003907
51 311 318 15814210 therapy NN I-NP O
52 319 321 15814210 in IN B-PP O
53 322 326 15814210 very RB B-NP O
54 326 327 15814210 - HYPH I-NP O
55 327 330 15814210 low JJ I-NP O
56 330 331 15814210 - HYPH I-NP O
57 331 342 15814210 birthweight NN I-NP O
58 343 350 15814210 infants NNS I-NP O
59 350 351 15814210 . . O O

1 352 358 15814210 Thirty CD B-NP O
2 358 359 15814210 - HYPH I-NP O
3 359 364 15814210 three CD I-NP O
4 365 373 15814210 children NNS I-NP O
5 374 379 15814210 after IN B-PP O
6 380 393 15814210 dexamethasone NN B-NP D003907
7 394 403 15814210 treatment NN I-NP O
8 404 408 15814210 were VBD B-VP O
9 409 416 15814210 matched VBN I-VP O
10 417 419 15814210 to TO B-PP O
11 420 422 15814210 33 CD B-NP O
12 423 431 15814210 children NNS I-NP O
13 432 439 15814210 without IN B-PP O
14 440 453 15814210 dexamethasone NN B-NP D003907
15 454 463 15814210 treatment NN I-NP O
16 463 464 15814210 . . O O

1 465 469 15814210 Data NNS B-NP O
2 470 474 15814210 were VBD B-VP O
3 475 483 15814210 assessed VBN I-VP O
4 484 486 15814210 at IN B-PP O
5 487 490 15814210 the DT B-NP O
6 491 494 15814210 age NN I-NP O
7 495 497 15814210 of IN B-PP O
8 498 499 15814210 3 CD B-NP O
9 499 500 15814210 - HYPH I-NP O
10 500 501 15814210 7 CD I-NP O
11 502 507 15814210 years NNS I-NP O
12 507 508 15814210 . . O O

1 509 522 15814210 Dexamethasone NN B-NP D003907
2 523 526 15814210 was VBD B-VP O
3 527 534 15814210 started VBN I-VP O
4 535 542 15814210 between IN B-PP O
5 543 546 15814210 the DT B-NP O
6 547 550 15814210 7th NN I-NP O
7 551 554 15814210 and CC O O
8 555 558 15814210 the DT B-NP O
9 559 563 15814210 28th JJ I-NP O
10 564 567 15814210 day NN I-NP O
11 568 570 15814210 of IN B-PP O
12 571 575 15814210 life NN B-NP O
13 576 580 15814210 over IN B-PP O
14 581 582 15814210 7 CD B-NP O
15 583 587 15814210 days NNS I-NP O
16 588 592 15814210 with IN B-PP O
17 593 594 15814210 a DT B-NP O
18 595 600 15814210 total JJ I-NP O
19 601 605 15814210 dose NN I-NP O
20 606 608 15814210 of IN B-PP O
21 609 613 15814210 2.35 CD B-NP O
22 614 616 15814210 mg NN I-NP O
23 616 617 15814210 / SYM B-NP O
24 617 619 15814210 kg NN I-NP O
25 619 620 15814210 / SYM B-NP O
26 620 623 15814210 day NN I-NP O
27 623 624 15814210 . . O O

1 625 634 15814210 Exclusion NN B-NP O
2 635 643 15814210 criteria NNS I-NP O
3 644 648 15814210 were VBD B-VP O
4 649 657 15814210 asphyxia NN B-NP D001237
5 657 658 15814210 , , O O
6 659 672 15814210 malformations NNS B-NP D000014
7 672 673 15814210 , , O O
8 674 679 15814210 major JJ B-NP O
9 680 688 15814210 surgical JJ I-NP O
10 689 702 15814210 interventions NNS I-NP O
11 702 703 15814210 , , O O
12 704 709 15814210 small JJ B-ADJP O
13 710 713 15814210 for IN B-PP O
14 714 725 15814210 gestational JJ B-NP O
15 726 729 15814210 age NN I-NP O
16 729 730 15814210 , , O O
17 731 747 15814210 intraventricular JJ B-NP O
18 748 759 15814210 haemorrhage NN I-NP D006470
19 760 766 15814210 grades NNS I-NP O
20 767 770 15814210 III CD B-NP O
21 771 774 15814210 and CC I-NP O
22 775 777 15814210 IV CD I-NP O
23 777 778 15814210 , , O O
24 779 794 15814210 periventricular JJ B-NP D007969
25 795 807 15814210 leukomalacia NN I-NP D007969
26 807 808 15814210 , , O O
27 809 812 15814210 and CC O O
28 813 819 15814210 severe JJ B-NP O
29 820 831 15814210 psychomotor NN I-NP D011596
30 832 843 15814210 retardation NN I-NP D011596
31 843 844 15814210 . . O O

1 845 849 15814210 Each DT B-NP O
2 850 855 15814210 child NN I-NP O
3 856 859 15814210 was VBD B-VP O
4 860 868 15814210 examined VBN I-VP O
5 869 871 15814210 by IN B-PP O
6 872 873 15814210 a DT B-NP O
7 874 891 15814210 neuropediatrician NN I-NP O
8 892 895 15814210 for IN B-PP O
9 896 901 15814210 minor JJ B-NP O
10 902 914 15814210 neurological JJ I-NP D009422
11 915 927 15814210 dysfunctions NNS I-NP D009422
12 928 931 15814210 and CC O O
13 932 938 15814210 tested VBN B-VP O
14 939 941 15814210 by IN B-PP O
15 942 943 15814210 a DT B-NP O
16 944 956 15814210 psychologist NN I-NP O
17 957 960 15814210 for IN B-PP O
18 961 970 15814210 cognitive JJ B-NP O
19 971 982 15814210 development NN I-NP O
20 983 987 15814210 with IN B-PP O
21 988 989 15814210 a DT B-NP O
22 990 997 15814210 Kaufman NNP I-NP O
23 998 1008 15814210 Assessment NNP I-NP O
24 1009 1016 15814210 Battery NNP I-NP O
25 1017 1020 15814210 for IN B-PP O
26 1021 1029 15814210 Children NNP B-NP O
27 1030 1033 15814210 and CC O O
28 1034 1035 15814210 a DT B-NP O
29 1036 1040 15814210 Draw NN I-NP O
30 1040 1041 15814210 - HYPH O O
31 1041 1042 15814210 a SYM B-NP O
32 1042 1043 15814210 - : O O
33 1043 1046 15814210 Man NNP B-NP O
34 1047 1051 15814210 Test NNP I-NP O
35 1051 1052 15814210 . . O O

1 1053 1058 15814210 There EX B-NP O
2 1059 1063 15814210 were VBD B-VP O
3 1064 1066 15814210 no DT B-NP O
4 1067 1078 15814210 differences NNS I-NP O
5 1079 1081 15814210 in IN B-PP O
6 1082 1093 15814210 demographic JJ B-NP O
7 1094 1098 15814210 data NNS I-NP O
8 1098 1099 15814210 , , O O
9 1100 1106 15814210 growth NN B-NP O
10 1106 1107 15814210 , , O O
11 1108 1111 15814210 and CC O O
12 1112 1117 15814210 socio AFX O O
13 1117 1118 15814210 - HYPH O O
14 1118 1126 15814210 economic JJ B-NP O
15 1127 1133 15814210 status NN I-NP O
16 1134 1141 15814210 between IN B-PP O
17 1142 1145 15814210 the DT B-NP O
18 1146 1149 15814210 two CD I-NP O
19 1150 1156 15814210 groups NNS I-NP O
20 1156 1157 15814210 . . O O

1 1158 1162 15814210 Fine JJ B-NP O
2 1163 1168 15814210 motor NN I-NP O
3 1169 1175 15814210 skills NNS I-NP O
4 1176 1179 15814210 and CC O O
5 1180 1185 15814210 gross JJ B-NP O
6 1186 1191 15814210 motor NN I-NP O
7 1192 1200 15814210 function NN I-NP O
8 1201 1205 15814210 were VBD B-VP O
9 1206 1219 15814210 significantly RB B-ADJP O
10 1220 1226 15814210 better JJR I-ADJP O
11 1227 1229 15814210 in IN B-PP O
12 1230 1233 15814210 the DT B-NP O
13 1234 1241 15814210 control NN I-NP O
14 1242 1247 15814210 group NN I-NP O
15 1248 1249 15814210 ( ( O O
16 1249 1250 15814210 p NN B-NP O
17 1250 1251 15814210 < SYM O O
18 1251 1255 15814210 0.01 CD B-NP O
19 1255 1256 15814210 ) ) O O
20 1256 1257 15814210 . . O O

1 1258 1260 15814210 In IN B-PP O
2 1261 1264 15814210 the DT B-NP O
3 1265 1269 15814210 Draw NNP I-NP O
4 1269 1270 15814210 - : O O
5 1270 1271 15814210 a DT B-NP O
6 1271 1272 15814210 - : O O
7 1272 1275 15814210 Man NNP B-NP O
8 1276 1280 15814210 Test NNP I-NP O
9 1280 1281 15814210 , , O O
10 1282 1285 15814210 the DT B-NP O
11 1286 1293 15814210 control NN I-NP O
12 1294 1299 15814210 group NN I-NP O
13 1300 1306 15814210 showed VBD B-VP O
14 1307 1313 15814210 better JJR B-NP O
15 1314 1321 15814210 results NNS I-NP O
16 1322 1323 15814210 ( ( O O
17 1323 1324 15814210 p NN B-NP O
18 1324 1325 15814210 < SYM O O
19 1325 1330 15814210 0.001 CD B-NP O
20 1330 1331 15814210 ) ) O O
21 1331 1332 15814210 . . O O

1 1333 1338 15814210 There EX B-NP O
2 1339 1343 15814210 were VBD B-VP O
3 1344 1346 15814210 no DT B-NP O
4 1347 1358 15814210 differences NNS I-NP O
5 1359 1361 15814210 in IN B-PP O
6 1362 1373 15814210 development NN B-NP O
7 1374 1376 15814210 of IN B-PP O
8 1377 1383 15814210 speech NN B-NP O
9 1383 1384 15814210 , , O O
10 1385 1391 15814210 social JJ B-NP O
11 1392 1403 15814210 development NN I-NP O
12 1403 1404 15814210 , , O O
13 1405 1408 15814210 and CC O O
14 1409 1412 15814210 the DT B-NP O
15 1413 1420 15814210 Kaufman NNP I-NP O
16 1421 1431 15814210 Assessment NNP I-NP O
17 1432 1439 15814210 Battery NNP I-NP O
18 1440 1443 15814210 for IN B-PP O
19 1444 1452 15814210 Children NNP B-NP O
20 1452 1453 15814210 . . O O

1 1454 1459 15814210 After IN B-PP O
2 1460 1473 15814210 dexamethasone NN B-NP D003907
3 1474 1483 15814210 treatment NN I-NP O
4 1483 1484 15814210 , , O O
5 1485 1493 15814210 children NNS B-NP O
6 1494 1500 15814210 showed VBD B-VP O
7 1501 1502 15814210 a DT B-NP O
8 1503 1509 15814210 higher JJR I-NP O
9 1510 1514 15814210 rate NN I-NP O
10 1515 1517 15814210 of IN B-PP O
11 1518 1523 15814210 minor JJ B-NP O
12 1524 1536 15814210 neurological JJ I-NP D009422
13 1537 1549 15814210 dysfunctions NNS I-NP D009422
14 1549 1550 15814210 . . O O

1 1551 1563 15814210 Neurological JJ B-NP O
2 1564 1575 15814210 development NN I-NP O
3 1576 1579 15814210 was VBD B-VP O
4 1580 1588 15814210 affected VBN I-VP O
5 1589 1593 15814210 even RB B-ADVP O
6 1594 1601 15814210 without IN B-PP O
7 1602 1614 15814210 neurological JJ B-NP O
8 1615 1624 15814210 diagnosis NN I-NP O
9 1624 1625 15814210 . . O O

1 1626 1633 15814210 Further RB B-NP O
2 1634 1638 15814210 long JJ I-NP O
3 1638 1639 15814210 - HYPH I-NP O
4 1639 1643 15814210 term NN B-NP O
5 1644 1650 15814210 follow VB B-VP O
6 1650 1651 15814210 - HYPH O O
7 1651 1653 15814210 up RP B-PRT O
8 1654 1661 15814210 studies NNS B-NP O
9 1662 1666 15814210 will MD B-VP O
10 1667 1669 15814210 be VB I-VP O
11 1670 1679 15814210 necessary JJ B-ADJP O
12 1680 1682 15814210 to TO B-VP O
13 1683 1688 15814210 fully RB I-VP O
14 1689 1697 15814210 evaluate VB I-VP O
15 1698 1701 15814210 the DT B-NP O
16 1702 1708 15814210 impact NN I-NP O
17 1709 1711 15814210 of IN B-PP O
18 1712 1725 15814210 dexamethasone NN B-NP D003907
19 1726 1728 15814210 on IN B-PP O
20 1729 1741 15814210 neurological JJ B-NP O
21 1742 1745 15814210 and CC I-NP O
22 1746 1755 15814210 cognitive JJ I-NP O
23 1756 1767 15814210 development NN I-NP O
24 1767 1768 15814210 . . O O

1 0 0 8600333 -DOCSTART- -X- -X- O

1 0 4 8600333 Late JJ B-NP O
2 5 19 8600333 cardiotoxicity NN I-NP D066126
3 20 25 8600333 after IN B-PP O
4 26 35 8600333 treatment NN B-NP O
5 36 39 8600333 for IN B-PP O
6 40 41 8600333 a DT B-NP O
7 42 51 8600333 malignant JJ I-NP O
8 52 56 8600333 bone NN I-NP D001859
9 57 62 8600333 tumor NN I-NP D001859
10 62 63 8600333 . . O O
11 64 71 8600333 Cardiac JJ B-NP O
12 72 80 8600333 function NN I-NP O
13 81 84 8600333 was VBD B-VP O
14 85 93 8600333 assessed VBN I-VP O
15 94 96 8600333 in IN B-PP O
16 97 101 8600333 long JJ B-NP O
17 101 102 8600333 - HYPH I-NP O
18 102 106 8600333 term NN I-NP O
19 107 116 8600333 survivors NNS I-NP O
20 117 119 8600333 of IN B-PP O
21 120 129 8600333 malignant JJ B-NP O
22 130 134 8600333 bone NN I-NP D001859
23 135 141 8600333 tumors NNS I-NP D001859
24 142 145 8600333 who WP B-NP O
25 146 150 8600333 were VBD B-VP O
26 151 158 8600333 treated VBN I-VP O
27 159 168 8600333 according VBG B-PP O
28 169 171 8600333 to TO B-PP O
29 172 179 8600333 Rosen's NNP B-NP C053519
30 180 182 8600333 T5 NN I-NP C053519
31 183 185 8600333 or CC I-NP C053519
32 186 189 8600333 T10 NN I-NP C053519
33 190 198 8600333 protocol NN I-NP C053519
34 198 199 8600333 , , O O
35 200 204 8600333 both DT B-NP O
36 205 214 8600333 including VBG I-NP O
37 215 226 8600333 doxorubicin NN I-NP D004317
38 226 227 8600333 . . O O

1 228 234 8600333 Thirty CD B-NP O
2 234 235 8600333 - HYPH I-NP O
3 235 238 8600333 one CD B-NP O
4 239 247 8600333 patients NNS I-NP O
5 247 248 8600333 , , O O
6 249 252 8600333 age NN B-NP O
7 253 255 8600333 10 CD I-NP O
8 255 256 8600333 - HYPH B-NP O
9 256 258 8600333 45 CD I-NP O
10 259 264 8600333 years NNS I-NP O
11 265 266 8600333 ( ( O O
12 266 272 8600333 median JJ B-NP O
13 273 276 8600333 age NN I-NP O
14 277 281 8600333 17.8 CD B-NP O
15 282 287 8600333 years NNS I-NP O
16 287 288 8600333 ) ) O O
17 289 293 8600333 were VBD B-VP O
18 294 303 8600333 evaluated VBN I-VP O
19 304 307 8600333 2.3 CD B-NP O
20 307 308 8600333 - HYPH I-NP O
21 308 312 8600333 14.1 CD I-NP O
22 313 318 8600333 years NNS I-NP O
23 319 320 8600333 ( ( O O
24 320 326 8600333 median NN B-NP O
25 327 330 8600333 8.9 CD B-NP O
26 331 336 8600333 years NNS I-NP O
27 336 337 8600333 ) ) O O
28 338 347 8600333 following VBG B-PP O
29 348 358 8600333 completion NN B-NP O
30 359 361 8600333 of IN B-PP O
31 362 371 8600333 treatment NN B-NP O
32 371 372 8600333 . . O O

1 373 383 8600333 Cumulative JJ B-NP O
2 384 389 8600333 doses NNS I-NP O
3 390 392 8600333 of IN B-PP O
4 393 404 8600333 doxorubicin NN B-NP D004317
5 405 409 8600333 were VBD B-VP O
6 410 413 8600333 225 CD B-NP O
7 413 414 8600333 - HYPH O O
8 414 417 8600333 550 CD B-NP O
9 418 420 8600333 mg NN I-NP O
10 420 421 8600333 / SYM B-NP O
11 421 423 8600333 m2 NN I-NP O
12 424 425 8600333 ( ( O O
13 425 431 8600333 median JJ B-NP O
14 432 436 8600333 dose NN I-NP O
15 437 440 8600333 360 CD I-NP O
16 440 441 8600333 ) ) O O
17 441 442 8600333 . . O O

1 443 446 8600333 The DT B-NP O
2 447 457 8600333 evaluation NN I-NP O
3 458 467 8600333 consisted VBD B-VP O
4 468 470 8600333 of IN B-PP O
5 471 472 8600333 a DT B-NP O
6 473 480 8600333 history NN I-NP O
7 480 481 8600333 , , O O
8 482 490 8600333 physical JJ B-NP O
9 491 502 8600333 examination NN I-NP O
10 502 503 8600333 , , O O
11 504 521 8600333 electrocardiogram NN B-NP O
12 522 523 8600333 ( ( O O
13 523 526 8600333 ECG NN B-NP O
14 526 527 8600333 ) ) O O
15 527 528 8600333 , , O O
16 529 535 8600333 signal NN B-NP O
17 536 544 8600333 averaged VBD B-VP O
18 545 548 8600333 ECG NN B-NP O
19 548 549 8600333 , , O O
20 550 552 8600333 24 CD B-NP O
21 552 553 8600333 - HYPH I-NP O
22 553 557 8600333 hour NN I-NP O
23 558 568 8600333 ambulatory JJ I-NP O
24 569 572 8600333 ECG NN I-NP O
25 572 573 8600333 , , O O
26 574 590 8600333 echocardiography NN B-NP O
27 591 594 8600333 and CC O O
28 595 607 8600333 radionuclide NN B-NP O
29 608 619 8600333 angiography NN I-NP O
30 619 620 8600333 . . O O

1 621 629 8600333 Eighteen CD B-NP O
2 630 632 8600333 of IN B-PP O
3 633 635 8600333 31 CD B-NP O
4 636 637 8600333 ( ( O O
5 637 640 8600333 58% CD B-NP O
6 640 641 8600333 ) ) O O
7 642 650 8600333 patients NNS B-NP O
8 651 657 8600333 showed VBD B-VP O
9 658 665 8600333 cardiac JJ B-NP D066126
10 666 674 8600333 toxicity NN I-NP D066126
11 674 675 8600333 , , O O
12 676 683 8600333 defined VBN B-VP O
13 684 686 8600333 as IN B-PP O
14 687 693 8600333 having VBG B-VP O
15 694 697 8600333 one CD B-NP O
16 698 700 8600333 or CC I-NP O
17 701 705 8600333 more JJR I-NP O
18 706 708 8600333 of IN B-PP O
19 709 712 8600333 the DT B-NP O
20 713 722 8600333 following VBG I-NP O
21 723 736 8600333 abnormalities NNS I-NP O
22 736 737 8600333 : : O O
23 738 742 8600333 late JJ B-NP O
24 743 753 8600333 potentials NNS I-NP O
25 753 754 8600333 , , O O
26 755 762 8600333 complex JJ B-NP O
27 763 774 8600333 ventricular JJ I-NP D001145
28 775 786 8600333 arrhythmias NNS I-NP D001145
29 786 787 8600333 , , O O
30 788 792 8600333 left VBD B-VP O
31 793 804 8600333 ventricular JJ B-NP D002311
32 805 813 8600333 dilation NN I-NP D002311
33 813 814 8600333 , , O O
34 815 824 8600333 decreased VBD B-VP O
35 825 835 8600333 shortening NN B-NP O
36 836 844 8600333 fraction NN I-NP O
37 844 845 8600333 , , O O
38 846 848 8600333 or CC O O
39 849 858 8600333 decreased VBN B-NP O
40 859 867 8600333 ejection NN I-NP O
41 868 876 8600333 fraction NN I-NP O
42 876 877 8600333 . . O O

1 878 881 8600333 The DT B-NP O
2 882 891 8600333 incidence NN I-NP O
3 892 894 8600333 of IN B-PP O
4 895 902 8600333 cardiac JJ B-NP D006331
5 903 916 8600333 abnormalities NNS I-NP D006331
6 917 926 8600333 increased VBD B-VP O
7 927 931 8600333 with IN B-PP O
8 932 938 8600333 length NN B-NP O
9 939 941 8600333 of IN B-PP O
10 942 948 8600333 follow VB B-VP O
11 948 949 8600333 - HYPH O O
12 949 951 8600333 up RP B-PRT O
13 952 953 8600333 ( ( O O
14 953 954 8600333 P NN B-NP O
15 954 955 8600333 < SYM B-VP O
16 956 958 8600333 or CC O O
17 959 960 8600333 = SYM B-VP O
18 961 964 8600333 .05 CD B-NP O
19 964 965 8600333 ) ) O O
20 965 966 8600333 . . O O

1 967 969 8600333 No DT B-NP O
2 970 981 8600333 correlation NN I-NP O
3 982 987 8600333 could MD B-VP O
4 988 990 8600333 be VB I-VP O
5 991 1003 8600333 demonstrated VBN I-VP O
6 1004 1011 8600333 between IN B-PP O
7 1012 1022 8600333 cumulative JJ B-NP O
8 1023 1027 8600333 dose NN I-NP O
9 1028 1030 8600333 of IN B-PP O
10 1031 1042 8600333 doxorubicin NN B-NP D004317
11 1043 1046 8600333 and CC O O
12 1047 1054 8600333 cardiac JJ B-NP O
13 1055 1061 8600333 status NN I-NP O
14 1061 1062 8600333 , , O O
15 1063 1069 8600333 except IN B-PP O
16 1070 1073 8600333 for IN B-PP O
17 1074 1079 8600333 heart NN B-NP O
18 1080 1084 8600333 rate NN I-NP O
19 1085 1096 8600333 variability NN I-NP O
20 1096 1097 8600333 . . O O

1 1098 1102 8600333 When WRB B-ADVP O
2 1103 1111 8600333 adjusted VBN B-VP O
3 1112 1114 8600333 to TO B-PP O
4 1115 1119 8600333 body NN B-NP O
5 1120 1127 8600333 surface NN I-NP O
6 1128 1132 8600333 area NN I-NP O
7 1132 1133 8600333 , , O O
8 1134 1137 8600333 the DT B-NP O
9 1138 1142 8600333 left JJ I-NP O
10 1143 1154 8600333 ventricular JJ I-NP O
11 1155 1164 8600333 posterior JJ I-NP O
12 1165 1169 8600333 wall NN I-NP O
13 1170 1179 8600333 thickness NN I-NP O
14 1180 1181 8600333 ( ( O O
15 1181 1185 8600333 LVPW NN B-NP O
16 1186 1191 8600333 index NN I-NP O
17 1191 1192 8600333 ) ) O O
18 1193 1196 8600333 was VBD B-VP O
19 1197 1206 8600333 decreased VBN I-VP O
20 1207 1209 8600333 in IN B-PP O
21 1210 1213 8600333 all DT B-NP O
22 1214 1222 8600333 patients NNS I-NP O
23 1222 1223 8600333 . . O O

1 1224 1227 8600333 The DT B-NP O
2 1228 1237 8600333 incidence NN I-NP O
3 1238 1240 8600333 of IN B-PP O
4 1241 1252 8600333 doxorubicin NN B-NP D004317
5 1252 1253 8600333 - HYPH B-NP O
6 1253 1260 8600333 induced VBN I-NP O
7 1261 1275 8600333 cardiotoxicity NN I-NP D066126
8 1276 1278 8600333 is VBZ B-VP O
9 1279 1283 8600333 high JJ B-ADJP O
10 1284 1287 8600333 and CC O O
11 1288 1297 8600333 increases VBZ B-VP O
12 1298 1302 8600333 with IN B-PP O
13 1303 1309 8600333 follow VB B-VP O
14 1309 1310 8600333 - HYPH O O
15 1310 1312 8600333 up RP B-PRT O
16 1312 1313 8600333 , , O O
17 1314 1326 8600333 irrespective JJ B-ADJP O
18 1327 1329 8600333 of IN B-PP O
19 1330 1340 8600333 cumulative JJ B-NP O
20 1341 1345 8600333 dose NN I-NP O
21 1345 1346 8600333 . . O O

1 1347 1351 8600333 Life NN B-NP O
2 1351 1352 8600333 - HYPH B-NP O
3 1352 1356 8600333 long JJ I-NP O
4 1357 1364 8600333 cardiac JJ I-NP O
5 1365 1371 8600333 follow VB B-VP O
6 1371 1372 8600333 - HYPH B-ADJP O
7 1372 1374 8600333 up RP B-PRT O
8 1375 1377 8600333 in IN B-PP O
9 1378 1383 8600333 these DT B-NP O
10 1384 1392 8600333 patients NNS I-NP O
11 1393 1395 8600333 is VBZ B-VP O
12 1396 1405 8600333 warranted VBN I-VP O
13 1405 1406 8600333 . . O O

1 1407 1410 8600333 The DT B-NP O
2 1411 1418 8600333 results NNS I-NP O
3 1419 1421 8600333 of IN B-PP O
4 1422 1425 8600333 our PRP$ B-NP O
5 1426 1431 8600333 study NN I-NP O
6 1432 1439 8600333 suggest VBP B-VP O
7 1440 1444 8600333 that IN B-SBAR O
8 1445 1450 8600333 heart NN B-NP O
9 1451 1455 8600333 rate NN I-NP O
10 1456 1467 8600333 variability NN I-NP O
11 1468 1471 8600333 and CC O O
12 1472 1476 8600333 LVPW NN B-NP O
13 1477 1482 8600333 index NN I-NP O
14 1483 1488 8600333 could MD B-VP O
15 1489 1491 8600333 be VB I-VP O
16 1492 1501 8600333 sensitive JJ B-NP O
17 1502 1512 8600333 indicators NNS I-NP O
18 1513 1516 8600333 for IN B-PP O
19 1517 1531 8600333 cardiotoxicity NN B-NP D066126
20 1531 1532 8600333 . . O O

1 0 0 17682013 -DOCSTART- -X- -X- O

1 0 7 17682013 Delayed VBN B-NP O
2 8 27 17682013 leukoencephalopathy NN I-NP D056784
3 28 32 17682013 with IN B-PP O
4 33 39 17682013 stroke NN B-NP D020521
5 39 40 17682013 - HYPH O O
6 40 44 17682013 like JJ B-NP O
7 45 57 17682013 presentation NN I-NP O
8 58 60 17682013 in IN B-PP O
9 61 73 17682013 chemotherapy NN B-NP O
10 74 84 17682013 recipients NNS I-NP O
11 84 85 17682013 . . O O
12 86 96 17682013 BACKGROUND NN B-NP O
13 96 97 17682013 : : O O
14 98 99 17682013 A DT B-NP O
15 100 109 17682013 transient JJ I-NP O
16 110 129 17682013 leukoencephalopathy NN I-NP D056784
17 130 139 17682013 mimicking VBG B-VP O
18 140 155 17682013 cerebrovascular JJ B-NP D002544
19 156 164 17682013 accident NN I-NP D002544
20 165 168 17682013 has VBZ B-VP O
21 169 173 17682013 been VBN I-VP O
22 174 183 17682013 described VBN I-VP O
23 184 186 17682013 as IN B-PP O
24 187 188 17682013 a DT B-NP O
25 189 201 17682013 complication NN I-NP O
26 202 204 17682013 of IN B-PP O
27 205 217 17682013 chemotherapy NN B-NP O
28 217 218 17682013 , , O O
29 219 223 17682013 most RBS B-ADVP O
30 224 232 17682013 commonly RB I-ADVP O
31 233 235 17682013 in IN B-PP O
32 236 246 17682013 recipients NNS B-NP O
33 247 249 17682013 of IN B-PP O
34 250 261 17682013 intrathecal JJ B-NP O
35 262 274 17682013 methotrexate NN I-NP D008727
36 275 278 17682013 for IN B-PP O
37 279 288 17682013 childhood NN B-NP O
38 289 298 17682013 leukaemia NN I-NP D007938
39 298 299 17682013 . . O O

1 300 308 17682013 Recently RB B-NP O
2 309 318 17682013 published VBN I-NP O
3 319 331 17682013 neuroimaging NN I-NP O
4 332 336 17682013 data NNS I-NP O
5 337 344 17682013 suggest VBP B-VP O
6 345 346 17682013 a DT B-NP O
7 347 353 17682013 common JJ I-NP O
8 354 369 17682013 pathophysiology NN I-NP O
9 370 380 17682013 associated VBN B-VP O
10 381 385 17682013 with IN B-PP O
11 386 387 17682013 a DT B-NP O
12 388 395 17682013 variety NN I-NP O
13 396 398 17682013 of IN B-PP O
14 399 411 17682013 chemotherapy NN B-NP O
15 412 418 17682013 agents NNS I-NP O
16 419 422 17682013 and CC O O
17 423 428 17682013 modes NNS B-NP O
18 429 431 17682013 of IN B-PP O
19 432 446 17682013 administration NN B-NP O
20 446 447 17682013 . . O O

1 448 455 17682013 METHODS NNS B-NP O
2 455 456 17682013 : : O O
3 457 459 17682013 We PRP B-NP O
4 460 468 17682013 reviewed VBD B-VP O
5 469 472 17682013 the DT B-NP O
6 473 480 17682013 medical JJ I-NP O
7 481 491 17682013 literature NN I-NP O
8 492 495 17682013 for IN B-PP O
9 496 502 17682013 single JJ B-NP O
10 503 510 17682013 reports NNS I-NP O
11 511 514 17682013 and CC O O
12 515 519 17682013 case NN O O
13 520 526 17682013 series NN B-NP O
14 527 529 17682013 of IN B-PP O
15 530 538 17682013 patients NNS B-NP O
16 539 549 17682013 presenting VBG B-VP O
17 550 554 17682013 with IN B-PP O
18 555 561 17682013 stroke NN B-NP D020521
19 561 562 17682013 - HYPH B-NP O
20 562 566 17682013 like JJ I-NP O
21 567 575 17682013 episodes NNS I-NP O
22 576 581 17682013 while IN B-SBAR O
23 582 591 17682013 receiving VBG B-VP O
24 592 600 17682013 systemic JJ B-NP O
25 601 603 17682013 or CC I-NP O
26 604 615 17682013 intrathecal JJ I-NP O
27 616 628 17682013 chemotherapy NN I-NP O
28 628 629 17682013 . . O O

1 630 632 17682013 We PRP B-NP O
2 633 637 17682013 only RB B-ADVP O
3 638 646 17682013 included VBD B-VP O
4 647 654 17682013 studies NNS B-NP O
5 655 664 17682013 providing VBG B-VP O
6 665 673 17682013 detailed JJ B-NP O
7 674 686 17682013 neuroimaging NN I-NP O
8 687 691 17682013 data NNS I-NP O
9 691 692 17682013 . . O O

1 693 701 17682013 Patients NNS B-NP O
2 702 706 17682013 with IN B-PP O
3 707 722 17682013 cerebrovascular JJ B-NP D002544
4 723 732 17682013 accidents NNS I-NP D002544
5 733 737 17682013 were VBD B-VP O
6 738 746 17682013 excluded VBN I-VP O
7 746 747 17682013 . . O O

1 748 755 17682013 RESULTS NNS B-NP O
2 755 756 17682013 : : O O
3 757 759 17682013 We PRP B-NP O
4 760 770 17682013 identified VBD B-VP O
5 771 773 17682013 27 CD B-NP O
6 774 781 17682013 reports NNS I-NP O
7 782 784 17682013 of IN B-PP O
8 785 790 17682013 toxic JJ B-NP O
9 791 810 17682013 leukoencephalopathy NN I-NP D056784
10 811 813 17682013 in IN B-PP O
11 814 822 17682013 patients NNS B-NP O
12 823 830 17682013 treated VBN B-VP O
13 831 835 17682013 with IN B-PP O
14 836 848 17682013 methotrexate NN B-NP D008727
15 849 850 17682013 ( ( O O
16 850 861 17682013 intrathecal JJ B-ADJP O
17 861 862 17682013 , , O O
18 863 871 17682013 systemic JJ B-ADVP O
19 871 872 17682013 ) ) O O
20 872 873 17682013 , , O O
21 874 875 17682013 5 CD B-NP D005472
22 875 876 17682013 - HYPH I-NP D005472
23 876 888 17682013 fluorouracil NN I-NP D005472
24 889 892 17682013 and CC O O
25 893 896 17682013 its PRP$ B-NP O
26 897 907 17682013 derivative JJ I-NP O
27 908 916 17682013 carmofur NN I-NP C017367
28 916 917 17682013 , , O O
29 918 921 17682013 and CC O O
30 922 934 17682013 capecitabine NN B-NP C110904
31 934 935 17682013 . . O O

1 936 945 17682013 Diffusion NN B-NP O
2 946 954 17682013 weighted VBD B-VP O
3 955 962 17682013 imaging NN B-NP O
4 963 964 17682013 ( ( O O
5 964 967 17682013 DWI NN B-NP O
6 967 968 17682013 ) ) O O
7 969 971 17682013 of IN B-PP O
8 972 975 17682013 all DT B-NP O
9 976 984 17682013 patients NNS I-NP O
10 985 993 17682013 revealed VBD B-VP O
11 994 998 17682013 well RB B-NP O
12 999 1009 17682013 demarcated VBN I-NP O
13 1010 1022 17682013 hyperintense JJ I-NP O
14 1023 1030 17682013 lesions NNS I-NP D056784
15 1031 1037 17682013 within IN B-PP D056784
16 1038 1041 17682013 the DT B-NP D056784
17 1042 1053 17682013 subcortical JJ I-NP D056784
18 1054 1059 17682013 white JJ I-NP D056784
19 1060 1066 17682013 matter NN I-NP D056784
20 1067 1069 17682013 of IN B-PP O
21 1070 1073 17682013 the DT B-NP O
22 1074 1082 17682013 cerebral JJ I-NP O
23 1083 1094 17682013 hemispheres NNS I-NP O
24 1095 1098 17682013 and CC O O
25 1099 1102 17682013 the DT B-NP O
26 1103 1109 17682013 corpus NN I-NP O
27 1110 1118 17682013 callosum NN I-NP O
28 1118 1119 17682013 , , O O
29 1120 1133 17682013 corresponding VBG B-VP O
30 1134 1136 17682013 to TO B-PP O
31 1137 1142 17682013 areas NNS B-NP O
32 1143 1145 17682013 of IN B-PP O
33 1146 1155 17682013 decreased VBN B-NP O
34 1156 1162 17682013 proton NN I-NP O
35 1163 1172 17682013 diffusion NN I-NP O
36 1173 1175 17682013 on IN B-PP O
37 1176 1184 17682013 apparent JJ B-NP O
38 1185 1194 17682013 diffusion NN I-NP O
39 1195 1206 17682013 coefficient NN I-NP O
40 1207 1208 17682013 ( ( O O
41 1208 1211 17682013 ADC NN B-NP O
42 1211 1212 17682013 ) ) O O
43 1213 1217 17682013 maps NNS B-NP O
44 1218 1219 17682013 ( ( O O
45 1219 1228 17682013 available JJ B-ADJP O
46 1229 1231 17682013 in IN B-PP O
47 1232 1234 17682013 21 CD B-NP O
48 1234 1235 17682013 / SYM O O
49 1235 1237 17682013 27 CD B-NP O
50 1238 1246 17682013 patients NNS I-NP O
51 1246 1247 17682013 ) ) O O
52 1247 1248 17682013 . . O O

1 1249 1256 17682013 Lesions NNS B-NP O
2 1257 1265 17682013 exceeded VBD B-VP O
3 1266 1269 17682013 the DT B-NP O
4 1270 1278 17682013 confines NNS I-NP O
5 1279 1281 17682013 of IN B-PP O
6 1282 1290 17682013 adjacent JJ B-NP O
7 1291 1299 17682013 vascular JJ I-NP O
8 1300 1311 17682013 territories NNS I-NP O
9 1311 1312 17682013 . . O O

1 1313 1321 17682013 Complete JJ B-NP O
2 1322 1332 17682013 resolution NN I-NP O
3 1333 1335 17682013 of IN B-PP O
4 1336 1344 17682013 symptoms NNS B-NP O
5 1345 1351 17682013 within IN B-PP O
6 1352 1353 17682013 1 CD B-NP O
7 1353 1354 17682013 - HYPH I-NP O
8 1354 1355 17682013 4 CD I-NP O
9 1356 1360 17682013 days NNS I-NP O
10 1361 1364 17682013 was VBD B-VP O
11 1365 1376 17682013 accompanied VBN I-VP O
12 1377 1379 17682013 by IN B-PP O
13 1380 1393 17682013 normalisation NN B-NP O
14 1394 1396 17682013 of IN B-PP O
15 1397 1400 17682013 ADC NN B-NP O
16 1401 1414 17682013 abnormalities NNS I-NP O
17 1414 1415 17682013 . . O O

1 1416 1423 17682013 However RB B-ADVP O
2 1423 1424 17682013 , , O O
3 1425 1430 17682013 fluid NN B-NP O
4 1431 1441 17682013 attenuated VBD B-VP O
5 1442 1451 17682013 inversion NN B-NP O
6 1452 1460 17682013 recovery NN I-NP O
7 1461 1462 17682013 ( ( O O
8 1462 1467 17682013 FLAIR NN B-NP O
9 1467 1468 17682013 ) ) O O
10 1469 1478 17682013 sequences NNS B-NP O
11 1479 1489 17682013 frequently RB B-ADVP O
12 1490 1498 17682013 revealed VBD B-VP O
13 1499 1509 17682013 persistent JJ B-NP O
14 1510 1515 17682013 white JJ I-NP D056784
15 1516 1522 17682013 matter NN I-NP D056784
16 1523 1536 17682013 abnormalities NNS I-NP D056784
17 1536 1537 17682013 . . O O

1 1538 1549 17682013 CONCLUSIONS NNS B-NP O
2 1549 1550 17682013 : : O O
3 1551 1558 17682013 Several JJ B-NP O
4 1559 1577 17682013 pathophysiological JJ I-NP O
5 1578 1584 17682013 models NNS I-NP O
6 1585 1587 17682013 of IN B-PP O
7 1588 1595 17682013 delayed VBN B-NP O
8 1596 1615 17682013 leukoencephalopathy NN I-NP D056784
9 1616 1621 17682013 after IN B-PP O
10 1622 1630 17682013 exposure NN B-NP O
11 1631 1633 17682013 to TO B-PP O
12 1634 1645 17682013 intrathecal JJ B-NP O
13 1646 1648 17682013 or CC I-NP O
14 1649 1657 17682013 systemic JJ I-NP O
15 1658 1670 17682013 chemotherapy NN I-NP O
16 1671 1675 17682013 have VBP B-VP O
17 1676 1680 17682013 been VBN I-VP O
18 1681 1689 17682013 proposed VBN I-VP O
19 1689 1690 17682013 . . O O

1 1691 1694 17682013 DWI NN B-NP O
2 1695 1703 17682013 findings NNS I-NP O
3 1704 1706 17682013 in IN B-PP O
4 1707 1711 17682013 this DT B-NP O
5 1712 1718 17682013 cohort NN I-NP O
6 1719 1722 17682013 are VBP B-VP O
7 1723 1733 17682013 indicative JJ B-ADJP O
8 1734 1736 17682013 of IN B-PP O
9 1737 1746 17682013 cytotoxic JJ B-NP D001929
10 1747 1753 17682013 oedema NN I-NP D001929
11 1754 1760 17682013 within IN B-PP D001929
12 1761 1769 17682013 cerebral JJ B-NP D001929
13 1770 1775 17682013 white JJ I-NP D001929
14 1776 1782 17682013 matter NN I-NP D001929
15 1783 1786 17682013 and CC O O
16 1787 1791 17682013 lend NN B-NP O
17 1792 1799 17682013 support NN I-NP O
18 1800 1802 17682013 to TO B-PP O
19 1803 1805 17682013 an DT B-NP O
20 1806 1808 17682013 at IN I-NP O
21 1809 1814 17682013 least JJS I-NP O
22 1815 1824 17682013 partially RB I-NP O
23 1825 1835 17682013 reversible JJ I-NP O
24 1836 1845 17682013 metabolic JJ I-NP O
25 1846 1857 17682013 derangement NN I-NP O
26 1858 1860 17682013 as IN B-PP O
27 1861 1864 17682013 the DT B-NP O
28 1865 1870 17682013 basis NN I-NP O
29 1871 1874 17682013 for IN B-PP O
30 1875 1879 17682013 this DT B-NP O
31 1880 1888 17682013 syndrome NN I-NP O
32 1888 1889 17682013 . . O O

1 0 0 11022397 -DOCSTART- -X- -X- O

1 0 7 11022397 Probing VBG B-VP O
2 8 18 11022397 peripheral JJ B-NP O
3 19 22 11022397 and CC I-NP O
4 23 30 11022397 central JJ I-NP O
5 31 42 11022397 cholinergic JJ I-NP O
6 43 49 11022397 system NN I-NP O
7 50 59 11022397 responses NNS I-NP O
8 59 60 11022397 . . O O
9 61 70 11022397 OBJECTIVE NN B-NP O
10 70 71 11022397 : : O O
11 72 75 11022397 The DT B-NP O
12 76 91 11022397 pharmacological JJ I-NP O
13 92 100 11022397 response NN I-NP O
14 101 103 11022397 to TO B-PP O
15 104 109 11022397 drugs NNS B-NP O
16 110 114 11022397 that WDT B-NP O
17 115 118 11022397 act VBP B-VP O
18 119 121 11022397 on IN B-PP O
19 122 125 11022397 the DT B-NP O
20 126 137 11022397 cholinergic JJ I-NP O
21 138 144 11022397 system NN I-NP O
22 145 147 11022397 of IN B-PP O
23 148 151 11022397 the DT B-NP O
24 152 156 11022397 iris NN I-NP O
25 157 160 11022397 has VBZ B-VP O
26 161 165 11022397 been VBN I-VP O
27 166 170 11022397 used VBN I-VP O
28 171 173 11022397 to TO I-VP O
29 174 181 11022397 predict VB I-VP O
30 182 190 11022397 deficits NNS B-NP O
31 191 193 11022397 in IN B-PP O
32 194 201 11022397 central JJ B-NP O
33 202 213 11022397 cholinergic JJ I-NP O
34 214 225 11022397 functioning NN I-NP O
35 226 229 11022397 due JJ B-ADJP O
36 230 232 11022397 to TO B-PP O
37 233 241 11022397 diseases NNS B-NP O
38 242 246 11022397 such JJ B-PP O
39 247 249 11022397 as IN I-PP O
40 250 261 11022397 Alzheimer's NNS B-NP D000544
41 262 269 11022397 disease NN I-NP D000544
42 269 270 11022397 , , O O
43 271 274 11022397 yet RB B-ADVP O
44 275 287 11022397 correlations NNS B-NP O
45 288 295 11022397 between IN B-PP O
46 296 303 11022397 central JJ B-NP O
47 304 307 11022397 and CC I-NP O
48 308 318 11022397 peripheral JJ I-NP O
49 319 328 11022397 responses NNS I-NP O
50 329 333 11022397 have VBP B-VP O
51 334 337 11022397 not RB I-VP O
52 338 342 11022397 been VBN I-VP O
53 343 351 11022397 properly RB I-VP O
54 352 359 11022397 studied VBN I-VP O
55 359 360 11022397 . . O O

1 361 365 11022397 This DT B-NP O
2 366 371 11022397 study NN I-NP O
3 372 380 11022397 assessed VBD B-VP O
4 381 384 11022397 the DT B-NP O
5 385 391 11022397 effect NN I-NP O
6 392 394 11022397 of IN B-PP O
7 395 401 11022397 normal JJ B-NP O
8 402 407 11022397 aging NN I-NP O
9 408 410 11022397 on IN B-PP O
10 411 412 11022397 ( ( B-LST O
11 412 413 11022397 1 LS I-LST O
12 413 414 11022397 ) ) O O
13 415 418 11022397 the DT B-NP O
14 419 430 11022397 tropicamide NN I-NP D014331
15 430 431 11022397 - HYPH B-VP O
16 431 438 11022397 induced VBN B-NP O
17 439 447 11022397 increase NN I-NP O
18 448 450 11022397 in IN B-PP O
19 451 456 11022397 pupil NN B-NP O
20 457 465 11022397 diameter NN I-NP O
21 465 466 11022397 , , O O
22 467 470 11022397 and CC O O
23 471 472 11022397 ( ( B-LST O
24 472 473 11022397 2 LS I-LST O
25 473 474 11022397 ) ) O O
26 475 478 11022397 the DT B-NP O
27 479 487 11022397 reversal NN I-NP O
28 488 490 11022397 of IN B-PP O
29 491 495 11022397 this DT B-NP O
30 496 502 11022397 effect NN I-NP O
31 503 507 11022397 with IN B-PP O
32 508 519 11022397 pilocarpine NN B-NP D010862
33 519 520 11022397 . . O O

1 521 532 11022397 Scopolamine NN B-NP D012601
2 533 536 11022397 was VBD B-VP O
3 537 541 11022397 used VBN I-VP O
4 542 544 11022397 as IN B-PP O
5 545 546 11022397 a DT B-NP O
6 547 555 11022397 positive JJ I-NP O
7 556 563 11022397 control NN I-NP O
8 564 566 11022397 to TO B-VP O
9 567 573 11022397 detect VB I-VP O
10 574 577 11022397 age NN B-NP O
11 577 578 11022397 - HYPH B-NP O
12 578 587 11022397 dependent JJ I-NP O
13 588 595 11022397 changes NNS I-NP O
14 596 598 11022397 in IN B-PP O
15 599 606 11022397 central JJ B-NP O
16 607 618 11022397 cholinergic JJ I-NP O
17 619 630 11022397 functioning NN I-NP O
18 631 633 11022397 in IN B-PP O
19 634 637 11022397 the DT B-NP O
20 638 645 11022397 elderly JJ I-NP O
21 645 646 11022397 . . O O

1 647 653 11022397 DESIGN NN B-NP O
2 653 654 11022397 : : O O
3 655 665 11022397 Randomized VBN B-NP O
4 666 672 11022397 double JJ I-NP O
5 672 673 11022397 - HYPH I-NP O
6 673 678 11022397 blind JJ I-NP O
7 679 689 11022397 controlled VBN I-NP O
8 690 695 11022397 trial NN I-NP O
9 695 696 11022397 . . O O

1 697 709 11022397 PARTICIPANTS NNS B-NP O
2 709 710 11022397 : : O O
3 711 714 11022397 Ten CD B-NP O
4 715 722 11022397 healthy JJ I-NP O
5 723 730 11022397 elderly JJ I-NP O
6 731 732 11022397 ( ( O O
7 732 736 11022397 mean JJ B-NP O
8 737 740 11022397 age NN I-NP O
9 741 743 11022397 70 CD I-NP O
10 743 744 11022397 ) ) O O
11 745 748 11022397 and CC O O
12 749 750 11022397 9 CD B-NP O
13 751 756 11022397 young JJ I-NP O
14 757 758 11022397 ( ( O O
15 758 762 11022397 mean JJ B-NP O
16 763 766 11022397 age NN I-NP O
17 767 769 11022397 33 CD I-NP O
18 769 770 11022397 ) ) O O
19 771 781 11022397 volunteers NNS B-NP O
20 781 782 11022397 . . O O

1 783 796 11022397 INTERVENTIONS NNS B-NP O
2 796 797 11022397 : : O O
3 798 803 11022397 Pupil NN B-NP O
4 804 812 11022397 diameter NN I-NP O
5 813 816 11022397 was VBD B-VP O
6 817 826 11022397 monitored VBN I-VP O
7 827 832 11022397 using VBG B-VP O
8 833 834 11022397 a DT B-NP O
9 835 847 11022397 computerized JJ I-NP O
10 848 856 11022397 infrared JJ I-NP O
11 857 869 11022397 pupillometer NN I-NP O
12 870 874 11022397 over IN B-PP O
13 875 876 11022397 4 CD B-NP O
14 877 882 11022397 hours NNS I-NP O
15 882 883 11022397 . . O O

1 884 887 11022397 The DT B-NP O
2 888 893 11022397 study NN I-NP O
3 894 902 11022397 involved VBD B-VP O
4 903 904 11022397 4 CD B-NP O
5 905 913 11022397 sessions NNS I-NP O
6 913 914 11022397 . . O O

1 915 917 11022397 In IN B-PP O
2 918 919 11022397 1 CD B-NP O
3 920 927 11022397 session NN I-NP O
4 927 928 11022397 , , O O
5 929 940 11022397 tropicamide NN B-NP D014331
6 941 942 11022397 ( ( O O
7 942 944 11022397 20 CD B-NP O
8 945 951 11022397 microL NN I-NP O
9 951 952 11022397 , , O O
10 953 958 11022397 0.01% CD B-NP O
11 958 959 11022397 ) ) O O
12 960 963 11022397 was VBD B-VP O
13 964 976 11022397 administered VBN I-VP O
14 977 979 11022397 to TO B-PP O
15 980 983 11022397 one CD B-NP O
16 984 987 11022397 eye NN I-NP O
17 988 991 11022397 and CC I-NP O
18 992 999 11022397 placebo NN I-NP O
19 1000 1002 11022397 to TO B-PP O
20 1003 1006 11022397 the DT B-NP O
21 1007 1012 11022397 other JJ I-NP O
22 1012 1013 11022397 . . O O

1 1014 1016 11022397 In IN B-PP O
2 1017 1024 11022397 another DT B-NP O
3 1025 1032 11022397 session NN I-NP O
4 1032 1033 11022397 , , O O
5 1034 1045 11022397 tropicamide NN B-NP D014331
6 1046 1047 11022397 ( ( O O
7 1047 1049 11022397 20 CD B-NP O
8 1050 1056 11022397 microL NN I-NP O
9 1056 1057 11022397 , , O O
10 1058 1063 11022397 0.01% CD B-NP O
11 1063 1064 11022397 ) ) O O
12 1065 1068 11022397 was VBD B-VP O
13 1069 1081 11022397 administered VBN I-VP O
14 1082 1084 11022397 to TO B-PP O
15 1085 1089 11022397 both DT B-NP O
16 1090 1094 11022397 eyes NNS I-NP O
17 1094 1095 11022397 , , O O
18 1096 1104 11022397 followed VBD B-VP O
19 1105 1107 11022397 23 CD B-NP O
20 1108 1115 11022397 minutes NNS I-NP O
21 1116 1121 11022397 later RB B-ADVP O
22 1122 1124 11022397 by IN B-PP O
23 1125 1128 11022397 the DT B-NP O
24 1129 1140 11022397 application NN I-NP O
25 1141 1143 11022397 of IN B-PP O
26 1144 1155 11022397 pilocarpine NN B-NP D010862
27 1156 1157 11022397 ( ( O O
28 1157 1159 11022397 20 CD B-NP O
29 1160 1166 11022397 microL NN I-NP O
30 1166 1167 11022397 , , O O
31 1168 1172 11022397 0.1% CD B-NP O
32 1172 1173 11022397 ) ) O O
33 1174 1176 11022397 to TO B-PP O
34 1177 1180 11022397 one CD B-NP O
35 1181 1184 11022397 eye NN I-NP O
36 1185 1188 11022397 and CC I-NP O
37 1189 1196 11022397 placebo NN I-NP O
38 1197 1199 11022397 to TO B-PP O
39 1200 1203 11022397 the DT B-NP O
40 1204 1209 11022397 other JJ I-NP O
41 1209 1210 11022397 . . O O

1 1211 1214 11022397 All DT B-NP O
2 1215 1218 11022397 eye NN I-NP O
3 1219 1224 11022397 drops NNS I-NP O
4 1225 1229 11022397 were VBD B-VP O
5 1230 1235 11022397 given VBN I-VP O
6 1236 1238 11022397 in IN B-PP O
7 1239 1240 11022397 a DT B-NP O
8 1241 1251 11022397 randomized VBN I-NP O
9 1252 1257 11022397 order NN I-NP O
10 1257 1258 11022397 . . O O

1 1259 1261 11022397 In IN B-PP O
2 1262 1263 11022397 2 CD B-NP O
3 1264 1272 11022397 separate JJ I-NP O
4 1273 1281 11022397 sessions NNS I-NP O
5 1281 1282 11022397 , , O O
6 1283 1284 11022397 a DT B-NP O
7 1285 1291 11022397 single JJ I-NP O
8 1292 1296 11022397 dose NN I-NP O
9 1297 1299 11022397 of IN B-PP O
10 1300 1311 11022397 scopolamine NN B-NP D012601
11 1312 1313 11022397 ( ( O O
12 1313 1316 11022397 0.5 CD B-NP O
13 1317 1319 11022397 mg NN I-NP O
14 1319 1320 11022397 , , O O
15 1321 1334 11022397 intravenously RB B-ADVP O
16 1334 1335 11022397 ) ) O O
17 1336 1338 11022397 or CC O O
18 1339 1346 11022397 placebo NN B-NP O
19 1347 1350 11022397 was VBD B-VP O
20 1351 1363 11022397 administered VBN I-VP O
21 1363 1364 11022397 , , O O
22 1365 1368 11022397 and CC O O
23 1369 1372 11022397 the DT B-NP O
24 1373 1380 11022397 effects NNS I-NP O
25 1381 1383 11022397 on IN B-PP O
26 1384 1388 11022397 word NN B-NP O
27 1389 1395 11022397 recall NN I-NP O
28 1396 1400 11022397 were VBD B-VP O
29 1401 1409 11022397 measured VBN I-VP O
30 1410 1415 11022397 using VBG B-VP O
31 1416 1419 11022397 the DT B-NP O
32 1420 1427 11022397 Buschke NNP I-NP O
33 1428 1437 11022397 Selective NNP I-NP O
34 1438 1447 11022397 Reminding NNP I-NP O
35 1448 1452 11022397 Test NNP I-NP O
36 1453 1457 11022397 over IN B-NP O
37 1458 1459 11022397 2 CD I-NP O
38 1460 1465 11022397 hours NNS I-NP O
39 1465 1466 11022397 . . O O

1 1467 1474 11022397 OUTCOME NN B-NP O
2 1475 1483 11022397 MEASURES NNS I-NP O
3 1483 1484 11022397 : : O O
4 1485 1490 11022397 Pupil NN B-NP O
5 1491 1495 11022397 size NN I-NP O
6 1496 1498 11022397 at IN B-PP O
7 1499 1503 11022397 time NN B-NP O
8 1504 1510 11022397 points NNS I-NP O
9 1511 1516 11022397 after IN B-PP O
10 1517 1531 11022397 administration NN B-NP O
11 1532 1534 11022397 of IN B-PP O
12 1535 1546 11022397 tropicamide NN B-NP D014331
13 1547 1550 11022397 and CC I-NP O
14 1551 1562 11022397 pilocarpine NN I-NP D010862
15 1562 1563 11022397 ; : O O
16 1564 1575 11022397 scopolamine NN B-NP D012601
17 1575 1576 11022397 - HYPH B-NP O
18 1576 1583 11022397 induced VBN I-NP O
19 1584 1594 11022397 impairment NN I-NP D008569
20 1595 1597 11022397 in IN B-PP D008569
21 1598 1602 11022397 word NN B-NP D008569
22 1603 1609 11022397 recall NN I-NP D008569
23 1609 1610 11022397 . . O O

1 1611 1618 11022397 RESULTS NNS B-NP O
2 1618 1619 11022397 : : O O
3 1620 1625 11022397 There EX B-NP O
4 1626 1629 11022397 was VBD B-VP O
5 1630 1632 11022397 no DT B-NP O
6 1633 1644 11022397 significant JJ I-NP O
7 1645 1655 11022397 difference NN I-NP O
8 1656 1663 11022397 between IN B-PP O
9 1664 1671 11022397 elderly JJ B-NP O
10 1672 1675 11022397 and CC I-NP O
11 1676 1681 11022397 young JJ I-NP O
12 1682 1692 11022397 volunteers NNS I-NP O
13 1693 1695 11022397 in IN B-PP O
14 1696 1705 11022397 pupillary JJ B-NP O
15 1706 1714 11022397 response NN I-NP O
16 1715 1717 11022397 to TO B-PP O
17 1718 1729 11022397 tropicamide NN B-NP D014331
18 1730 1732 11022397 at IN B-PP O
19 1733 1736 11022397 any DT B-NP O
20 1737 1741 11022397 time NN I-NP O
21 1742 1747 11022397 point NN I-NP O
22 1748 1749 11022397 ( ( O O
23 1749 1750 11022397 p NN B-NP O
24 1751 1752 11022397 > SYM O O
25 1753 1757 11022397 0.05 CD B-NP O
26 1757 1758 11022397 ) ) O O
27 1758 1759 11022397 . . O O

1 1760 1763 11022397 The DT B-NP O
2 1764 1771 11022397 elderly JJ I-NP O
3 1772 1777 11022397 group NN I-NP O
4 1778 1781 11022397 had VBD B-VP O
5 1782 1783 11022397 a DT B-NP O
6 1784 1797 11022397 significantly RB I-NP O
7 1798 1805 11022397 greater JJR I-NP O
8 1806 1817 11022397 pilocarpine NN I-NP D010862
9 1817 1818 11022397 - HYPH O O
10 1818 1825 11022397 induced VBN B-NP O
11 1826 1829 11022397 net JJ I-NP O
12 1830 1838 11022397 decrease NN I-NP O
13 1839 1841 11022397 in IN B-PP O
14 1842 1847 11022397 pupil NN B-NP O
15 1848 1852 11022397 size NN I-NP O
16 1853 1855 11022397 85 CD I-NP O
17 1855 1856 11022397 , , I-NP O
18 1857 1860 11022397 125 CD I-NP O
19 1860 1861 11022397 , , I-NP O
20 1862 1865 11022397 165 CD I-NP O
21 1866 1869 11022397 and CC I-NP O
22 1870 1873 11022397 215 CD I-NP O
23 1874 1881 11022397 minutes NNS I-NP O
24 1882 1887 11022397 after IN B-PP O
25 1888 1902 11022397 administration NN B-NP O
26 1902 1903 11022397 , , O O
27 1904 1912 11022397 compared VBN B-PP O
28 1913 1917 11022397 with IN B-PP O
29 1918 1921 11022397 the DT B-NP O
30 1922 1927 11022397 young JJ I-NP O
31 1928 1933 11022397 group NN I-NP O
32 1934 1935 11022397 ( ( O O
33 1935 1936 11022397 p NN B-NP O
34 1937 1938 11022397 < SYM O O
35 1939 1943 11022397 0.05 CD B-NP O
36 1943 1944 11022397 ) ) O O
37 1944 1945 11022397 . . O O

1 1946 1954 11022397 Compared VBN B-PP O
2 1955 1959 11022397 with IN B-PP O
3 1960 1963 11022397 the DT B-NP O
4 1964 1969 11022397 young JJ I-NP O
5 1970 1975 11022397 group NN I-NP O
6 1975 1976 11022397 , , O O
7 1977 1980 11022397 the DT B-NP O
8 1981 1988 11022397 elderly JJ I-NP O
9 1989 1994 11022397 group NN I-NP O
10 1995 1998 11022397 had VBD B-VP O
11 1999 2006 11022397 greater JJR B-NP O
12 2007 2018 11022397 scopolamine NN I-NP D012601
13 2018 2019 11022397 - HYPH O O
14 2019 2026 11022397 induced VBN B-NP O
15 2027 2037 11022397 impairment NN I-NP D008569
16 2038 2040 11022397 in IN B-PP D008569
17 2041 2045 11022397 word NN B-NP D008569
18 2046 2052 11022397 recall NN I-NP D008569
19 2053 2055 11022397 60 CD I-NP O
20 2055 2056 11022397 , , I-NP O
21 2057 2059 11022397 90 CD I-NP O
22 2060 2063 11022397 and CC I-NP O
23 2064 2067 11022397 120 CD I-NP O
24 2068 2075 11022397 minutes NNS I-NP O
25 2076 2081 11022397 after IN B-PP O
26 2082 2096 11022397 administration NN B-NP O
27 2097 2098 11022397 ( ( O O
28 2098 2099 11022397 p NN B-NP O
29 2100 2101 11022397 < SYM O O
30 2102 2106 11022397 0.05 CD B-NP O
31 2106 2107 11022397 ) ) O O
32 2107 2108 11022397 . . O O

1 2109 2119 11022397 CONCLUSION NN B-NP O
2 2119 2120 11022397 : : O O
3 2121 2126 11022397 There EX B-NP O
4 2127 2129 11022397 is VBZ B-VP O
5 2130 2132 11022397 an DT B-NP O
6 2133 2136 11022397 age NN I-NP O
7 2136 2137 11022397 - HYPH O O
8 2137 2144 11022397 related VBN B-NP O
9 2145 2154 11022397 pupillary JJ I-NP O
10 2155 2163 11022397 response NN I-NP O
11 2164 2166 11022397 to TO B-PP O
12 2167 2178 11022397 pilocarpine NN B-NP D010862
13 2179 2183 11022397 that WDT B-NP O
14 2184 2186 11022397 is VBZ B-VP O
15 2187 2190 11022397 not RB I-VP O
16 2191 2196 11022397 found VBN I-VP O
17 2197 2201 11022397 with IN B-PP O
18 2202 2213 11022397 tropicamide NN B-NP D014331
19 2213 2214 11022397 . . O O

1 2215 2219 11022397 Thus RB B-ADVP O
2 2219 2220 11022397 , , O O
3 2221 2232 11022397 pilocarpine NN B-NP D010862
4 2233 2236 11022397 may MD B-VP O
5 2237 2239 11022397 be VB I-VP O
6 2240 2246 11022397 useful JJ B-ADJP O
7 2247 2249 11022397 to TO B-VP O
8 2250 2256 11022397 assess VB I-VP O
9 2257 2267 11022397 variations NNS B-NP O
10 2268 2270 11022397 in IN B-PP O
11 2271 2278 11022397 central JJ B-NP O
12 2279 2290 11022397 cholinergic JJ I-NP O
13 2291 2299 11022397 function NN I-NP O
14 2300 2302 11022397 in IN B-PP O
15 2303 2310 11022397 elderly JJ B-NP O
16 2311 2319 11022397 patients NNS I-NP O
17 2319 2320 11022397 . . O O

1 0 0 6637851 -DOCSTART- -X- -X- O

1 0 4 6637851 Long JJ B-NP O
2 4 5 6637851 - HYPH I-NP O
3 5 9 6637851 term NN I-NP O
4 10 18 6637851 efficacy NN I-NP O
5 19 22 6637851 and CC I-NP O
6 23 31 6637851 toxicity NN I-NP D064420
7 32 34 6637851 of IN B-PP O
8 35 39 6637851 high JJ B-NP O
9 39 40 6637851 - HYPH I-NP O
10 40 44 6637851 dose NN I-NP O
11 45 55 6637851 amiodarone NN I-NP D000638
12 56 63 6637851 therapy NN I-NP O
13 64 67 6637851 for IN B-PP O
14 68 79 6637851 ventricular JJ B-NP D017180
15 80 91 6637851 tachycardia NN I-NP D017180
16 92 94 6637851 or CC I-NP O
17 95 106 6637851 ventricular JJ I-NP D014693
18 107 119 6637851 fibrillation NN I-NP D014693
19 119 120 6637851 . . I-NP O
20 121 131 6637851 Amiodarone NN I-NP D000638
21 132 135 6637851 was VBD B-VP O
22 136 148 6637851 administered VBN I-VP O
23 149 151 6637851 to TO B-PP O
24 152 155 6637851 154 CD B-NP O
25 156 164 6637851 patients NNS I-NP O
26 165 168 6637851 who WP B-NP O
27 169 172 6637851 had VBD B-VP O
28 173 182 6637851 sustained VBN I-VP O
29 182 183 6637851 , , O O
30 184 195 6637851 symptomatic JJ B-NP O
31 196 207 6637851 ventricular JJ I-NP D017180
32 208 219 6637851 tachycardia NN I-NP D017180
33 220 221 6637851 ( ( O O
34 221 223 6637851 VT NN B-NP D017180
35 223 224 6637851 ) ) O O
36 225 226 6637851 ( ( O O
37 226 227 6637851 n NN B-NP O
38 228 229 6637851 = SYM B-VP O
39 230 233 6637851 118 CD B-NP O
40 233 234 6637851 ) ) O O
41 235 237 6637851 or CC O O
42 238 239 6637851 a DT B-NP O
43 240 247 6637851 cardiac JJ I-NP D006323
44 248 254 6637851 arrest NN I-NP D006323
45 255 256 6637851 ( ( O O
46 256 257 6637851 n NN B-NP O
47 258 259 6637851 = SYM B-VP O
48 260 262 6637851 36 CD B-NP O
49 262 263 6637851 ) ) O O
50 264 267 6637851 and CC O O
51 268 271 6637851 who WP B-NP O
52 272 276 6637851 were VBD B-VP O
53 277 287 6637851 refractory JJ B-ADJP O
54 288 290 6637851 to TO B-PP O
55 291 303 6637851 conventional JJ B-NP O
56 304 318 6637851 antiarrhythmic JJ I-NP O
57 319 324 6637851 drugs NNS I-NP O
58 324 325 6637851 . . O O

1 326 329 6637851 The DT B-NP O
2 330 337 6637851 loading NN I-NP O
3 338 342 6637851 dose NN I-NP O
4 343 346 6637851 was VBD B-VP O
5 347 350 6637851 800 CD B-NP O
6 351 353 6637851 mg NN I-NP O
7 353 354 6637851 / SYM B-NP O
8 354 357 6637851 day NN I-NP O
9 358 361 6637851 for IN B-PP O
10 362 363 6637851 6 CD B-NP O
11 364 369 6637851 weeks NNS I-NP O
12 370 373 6637851 and CC O O
13 374 377 6637851 the DT B-NP O
14 378 389 6637851 maintenance NN I-NP O
15 390 394 6637851 dose NN I-NP O
16 395 398 6637851 was VBD B-VP O
17 399 402 6637851 600 CD B-NP O
18 403 405 6637851 mg NN I-NP O
19 405 406 6637851 / SYM B-NP O
20 406 409 6637851 day NN I-NP O
21 409 410 6637851 . . O O

1 411 416 6637851 Sixty CD B-NP O
2 416 417 6637851 - HYPH I-NP O
3 417 421 6637851 nine CD I-NP O
4 422 429 6637851 percent NN I-NP O
5 430 432 6637851 of IN B-PP O
6 433 441 6637851 patients NNS B-NP O
7 442 451 6637851 continued VBD B-VP O
8 452 461 6637851 treatment NN B-NP O
9 462 466 6637851 with IN B-PP O
10 467 477 6637851 amiodarone NN B-NP D000638
11 478 481 6637851 and CC O O
12 482 485 6637851 had VBD B-VP O
13 486 488 6637851 no DT B-NP O
14 489 499 6637851 recurrence NN I-NP O
15 500 502 6637851 of IN B-PP O
16 503 514 6637851 symptomatic JJ B-NP O
17 515 517 6637851 VT NN I-NP D017180
18 518 520 6637851 or CC O O
19 521 532 6637851 ventricular JJ B-NP D014693
20 533 545 6637851 fibrillation NN I-NP D014693
21 546 547 6637851 ( ( O O
22 547 549 6637851 VF NN B-NP D014693
23 549 550 6637851 ) ) O O
24 551 555 6637851 over IN B-PP O
25 556 557 6637851 a DT B-NP O
26 558 564 6637851 follow VB I-NP O
27 564 565 6637851 - HYPH I-NP O
28 565 567 6637851 up RP B-PRT O
29 568 570 6637851 of IN B-PP O
30 571 572 6637851 6 CD B-NP O
31 573 575 6637851 to TO I-NP O
32 576 578 6637851 52 CD I-NP O
33 579 585 6637851 months NNS I-NP O
34 586 587 6637851 ( ( O O
35 587 591 6637851 mean NN B-NP O
36 592 593 6637851 + SYM O O
37 593 594 6637851 / SYM B-NP O
38 594 595 6637851 - HYPH B-NP O
39 596 604 6637851 standard JJ I-NP O
40 605 614 6637851 deviation NN I-NP O
41 615 619 6637851 14.2 CD I-NP O
42 620 621 6637851 + SYM B-NP O
43 621 622 6637851 / SYM B-NP O
44 622 623 6637851 - SYM B-VP O
45 624 627 6637851 8.2 CD B-NP O
46 627 628 6637851 ) ) O O
47 628 629 6637851 . . O O

1 630 633 6637851 Six CD B-NP O
2 634 641 6637851 percent NN I-NP O
3 642 644 6637851 of IN B-PP O
4 645 648 6637851 the DT B-NP O
5 649 657 6637851 patients NNS I-NP O
6 658 661 6637851 had VBD B-VP O
7 662 663 6637851 a DT B-NP O
8 664 672 6637851 nonfatal JJ I-NP O
9 673 683 6637851 recurrence NN I-NP O
10 684 686 6637851 of IN B-PP O
11 687 689 6637851 VT NN B-NP D017180
12 690 693 6637851 and CC O O
13 694 698 6637851 were VBD B-VP O
14 699 711 6637851 successfully RB I-VP O
15 712 719 6637851 managed VBN I-VP O
16 720 722 6637851 by IN B-PP O
17 723 733 6637851 continuing VBG B-NP O
18 734 744 6637851 amiodarone NN I-NP D000638
19 745 747 6637851 at IN B-PP O
20 748 749 6637851 a DT B-NP O
21 750 756 6637851 higher JJR I-NP O
22 757 761 6637851 dose NN I-NP O
23 762 764 6637851 or CC B-PP O
24 765 767 6637851 by IN B-PP O
25 768 771 6637851 the DT B-NP O
26 772 780 6637851 addition NN I-NP O
27 781 783 6637851 of IN B-PP O
28 784 785 6637851 a DT B-NP O
29 786 798 6637851 conventional JJ I-NP O
30 799 813 6637851 antiarrhythmic JJ I-NP O
31 814 818 6637851 drug NN I-NP O
32 818 819 6637851 . . O O

1 820 823 6637851 One CD B-NP O
2 824 826 6637851 or CC I-NP O
3 827 831 6637851 more JJR I-NP O
4 832 839 6637851 adverse JJ I-NP O
5 840 844 6637851 drug NN I-NP O
6 845 854 6637851 reactions NNS I-NP O
7 855 863 6637851 occurred VBD B-VP O
8 864 866 6637851 in IN B-PP O
9 867 870 6637851 51% CD B-NP O
10 871 873 6637851 of IN B-PP O
11 874 882 6637851 patients NNS B-NP O
12 882 883 6637851 . . O O

1 884 891 6637851 Adverse JJ B-NP O
2 892 899 6637851 effects NNS I-NP O
3 900 906 6637851 forced VBD B-VP O
4 907 908 6637851 a DT B-NP O
5 909 918 6637851 reduction NN I-NP O
6 919 921 6637851 in IN B-PP O
7 922 925 6637851 the DT B-NP O
8 926 930 6637851 dose NN I-NP O
9 931 933 6637851 of IN B-PP O
10 934 944 6637851 amiodarone NN B-NP D000638
11 945 947 6637851 in IN B-PP O
12 948 951 6637851 41% NN B-NP O
13 952 955 6637851 and CC I-NP O
14 956 971 6637851 discontinuation NN I-NP O
15 972 974 6637851 of IN B-PP O
16 975 985 6637851 amiodarone NN B-NP D000638
17 986 988 6637851 in IN B-PP O
18 989 992 6637851 10% CD B-NP O
19 993 995 6637851 of IN B-PP O
20 996 1004 6637851 patients NNS B-NP O
21 1004 1005 6637851 . . O O

1 1006 1009 6637851 The DT B-NP O
2 1010 1014 6637851 most RBS I-NP O
3 1015 1021 6637851 common JJ I-NP O
4 1022 1033 6637851 symptomatic JJ I-NP O
5 1034 1041 6637851 adverse JJ I-NP O
6 1042 1051 6637851 reactions NNS I-NP O
7 1052 1056 6637851 were VBD B-VP O
8 1057 1063 6637851 tremor NN B-NP D014202
9 1064 1066 6637851 or CC O O
10 1067 1073 6637851 ataxia NN B-NP D001259
11 1074 1075 6637851 ( ( O O
12 1075 1078 6637851 35% CD B-NP O
13 1078 1079 6637851 ) ) O O
14 1079 1080 6637851 , , O O
15 1081 1087 6637851 nausea NN B-NP D009325
16 1088 1091 6637851 and CC O O
17 1092 1100 6637851 anorexia NN B-NP D000855
18 1101 1102 6637851 ( ( O O
19 1102 1104 6637851 8% NN B-NP O
20 1104 1105 6637851 ) ) O O
21 1105 1106 6637851 , , O O
22 1107 1113 6637851 visual JJ B-NP D014786
23 1114 1119 6637851 halos NNS I-NP D014786
24 1120 1122 6637851 or CC O D014786
25 1123 1131 6637851 blurring VBG B-VP D014786
26 1132 1133 6637851 ( ( O O
27 1133 1135 6637851 6% JJ B-ADJP O
28 1135 1136 6637851 ) ) O O
29 1136 1137 6637851 , , O O
30 1138 1145 6637851 thyroid JJ B-NP D013959
31 1146 1154 6637851 function NN I-NP D013959
32 1155 1168 6637851 abnormalities NNS I-NP D013959
33 1169 1170 6637851 ( ( O O
34 1170 1172 6637851 6% CD B-NP O
35 1172 1173 6637851 ) ) O O
36 1174 1177 6637851 and CC O O
37 1178 1187 6637851 pulmonary JJ B-NP -1
38 1188 1200 6637851 interstitial JJ I-NP -1
39 1201 1212 6637851 infiltrates NNS I-NP -1
40 1213 1214 6637851 ( ( O O
41 1214 1216 6637851 5% CD B-NP O
42 1216 1217 6637851 ) ) O O
43 1217 1218 6637851 . . O O

1 1219 1227 6637851 Although IN B-SBAR O
2 1228 1233 6637851 large JJ B-NP O
3 1233 1234 6637851 - HYPH I-NP O
4 1234 1238 6637851 dose NN I-NP O
5 1239 1249 6637851 amiodarone NN I-NP D000638
6 1250 1252 6637851 is VBZ B-VP O
7 1253 1259 6637851 highly RB B-ADJP O
8 1260 1269 6637851 effective JJ I-ADJP O
9 1270 1272 6637851 in IN B-PP O
10 1273 1276 6637851 the DT B-NP O
11 1277 1281 6637851 long JJ I-NP O
12 1281 1282 6637851 - HYPH I-NP O
13 1282 1286 6637851 term NN I-NP O
14 1287 1296 6637851 treatment NN I-NP O
15 1297 1299 6637851 of IN B-PP O
16 1300 1302 6637851 VT NN B-NP D017180
17 1303 1305 6637851 or CC I-NP O
18 1306 1308 6637851 VF NN I-NP D014693
19 1309 1319 6637851 refractory JJ B-ADJP O
20 1320 1322 6637851 to TO B-PP O
21 1323 1335 6637851 conventional JJ B-NP O
22 1336 1350 6637851 antiarrhythmic JJ I-NP O
23 1351 1356 6637851 drugs NNS I-NP O
24 1356 1357 6637851 , , O O
25 1358 1360 6637851 it PRP B-NP O
26 1361 1367 6637851 causes VBZ B-VP O
27 1368 1379 6637851 significant JJ B-NP O
28 1380 1388 6637851 toxicity NN I-NP D064420
29 1389 1391 6637851 in IN B-PP O
30 1392 1405 6637851 approximately RB B-NP O
31 1406 1409 6637851 50% CD I-NP O
32 1410 1412 6637851 of IN B-PP O
33 1413 1421 6637851 patients NNS B-NP O
34 1421 1422 6637851 . . O O

1 1423 1430 6637851 However RB B-ADVP O
2 1430 1431 6637851 , , O O
3 1432 1436 6637851 when WRB B-ADVP O
4 1437 1440 6637851 the DT B-NP O
5 1441 1445 6637851 dose NN I-NP O
6 1446 1448 6637851 is VBZ B-VP O
7 1449 1457 6637851 adjusted VBN I-VP O
8 1458 1463 6637851 based VBN B-PP O
9 1464 1466 6637851 on IN B-PP O
10 1467 1475 6637851 clinical JJ B-NP O
11 1476 1484 6637851 response NN I-NP O
12 1485 1487 6637851 or CC O O
13 1488 1491 6637851 the DT B-NP O
14 1492 1503 6637851 development NN I-NP O
15 1504 1506 6637851 of IN B-PP O
16 1507 1514 6637851 adverse JJ B-NP O
17 1515 1522 6637851 effects NNS I-NP O
18 1522 1523 6637851 , , O O
19 1524 1527 6637851 75% CD B-NP O
20 1528 1530 6637851 of IN B-PP O
21 1531 1539 6637851 patients NNS B-NP O
22 1540 1544 6637851 with IN B-PP O
23 1545 1547 6637851 VT NN B-NP D017180
24 1548 1550 6637851 or CC I-NP O
25 1551 1553 6637851 VF NN I-NP D014693
26 1554 1557 6637851 can MD B-VP O
27 1558 1560 6637851 be VB I-VP O
28 1561 1573 6637851 successfully RB I-VP O
29 1574 1581 6637851 managed VBN I-VP O
30 1582 1586 6637851 with IN B-PP O
31 1587 1597 6637851 amiodarone NN B-NP D000638
32 1597 1598 6637851 . . O O

1 0 0 10328196 -DOCSTART- -X- -X- O

1 0 8 10328196 Systemic JJ B-NP O
2 9 17 10328196 toxicity NN I-NP D064420
3 18 27 10328196 following VBG B-PP O
4 28 42 10328196 administration NN B-NP O
5 43 45 10328196 of IN B-PP O
6 46 55 10328196 sirolimus NN B-NP D020123
7 56 57 10328196 ( ( O O
8 57 65 10328196 formerly RB B-ADVP O
9 66 75 10328196 rapamycin NN B-NP D020123
10 75 76 10328196 ) ) O O
11 77 80 10328196 for IN B-PP O
12 81 90 10328196 psoriasis NN B-NP D011565
13 90 91 10328196 : : O O
14 92 103 10328196 association NN B-NP O
15 104 106 10328196 of IN B-PP O
16 107 116 10328196 capillary JJ B-NP D019559
17 117 121 10328196 leak NN I-NP D019559
18 122 130 10328196 syndrome NN I-NP D019559
19 131 135 10328196 with IN B-PP O
20 136 145 10328196 apoptosis NN B-NP O
21 146 148 10328196 of IN B-PP O
22 149 157 10328196 lesional JJ B-NP O
23 158 169 10328196 lymphocytes NNS I-NP O
24 169 170 10328196 . . O O
25 171 181 10328196 BACKGROUND NN B-NP O
26 181 182 10328196 : : O O
27 183 192 10328196 Sirolimus NN B-NP D020123
28 193 194 10328196 ( ( O O
29 194 202 10328196 formerly RB B-NP O
30 203 212 10328196 rapamycin NN I-NP D020123
31 212 213 10328196 ) ) O O
32 214 216 10328196 is VBZ B-VP O
33 217 219 10328196 an DT B-NP O
34 220 237 10328196 immunosuppressive JJ I-NP O
35 238 243 10328196 agent NN I-NP O
36 244 248 10328196 that WDT B-NP O
37 249 259 10328196 interferes VBZ B-VP O
38 260 264 10328196 with IN B-PP O
39 265 266 10328196 T NN B-NP O
40 266 267 10328196 - HYPH B-NP O
41 267 271 10328196 cell NN I-NP O
42 272 282 10328196 activation NN I-NP O
43 282 283 10328196 . . O O

1 284 289 10328196 After IN B-PP O
2 290 291 10328196 2 CD B-NP O
3 292 303 10328196 individuals NNS I-NP O
4 304 308 10328196 with IN B-PP O
5 309 318 10328196 psoriasis NN B-NP D011565
6 319 328 10328196 developed VBD B-VP O
7 329 330 10328196 a DT B-NP O
8 331 340 10328196 capillary JJ I-NP D019559
9 341 345 10328196 leak NN I-NP D019559
10 346 354 10328196 syndrome NN I-NP D019559
11 355 364 10328196 following VBG B-PP O
12 365 374 10328196 treatment NN B-NP O
13 375 379 10328196 with IN B-PP O
14 380 384 10328196 oral JJ B-NP O
15 385 394 10328196 sirolimus NN I-NP D020123
16 395 403 10328196 lesional JJ I-NP O
17 404 408 10328196 skin NN I-NP O
18 409 414 10328196 cells NNS I-NP O
19 415 418 10328196 and CC O O
20 419 428 10328196 activated VBN B-NP O
21 429 439 10328196 peripheral JJ I-NP O
22 440 445 10328196 blood NN I-NP O
23 446 451 10328196 cells NNS I-NP O
24 452 456 10328196 were VBD B-VP O
25 457 465 10328196 analyzed VBN I-VP O
26 466 469 10328196 for IN B-PP O
27 470 479 10328196 induction NN B-NP O
28 480 482 10328196 of IN B-PP O
29 483 492 10328196 apoptosis NN B-NP O
30 492 493 10328196 . . O O

1 494 506 10328196 OBSERVATIONS NNS B-NP O
2 506 507 10328196 : : O O
3 508 509 10328196 A DT B-NP O
4 510 518 10328196 keratome NN I-NP O
5 519 523 10328196 skin NN I-NP O
6 524 532 10328196 specimen NN I-NP O
7 533 537 10328196 from IN B-PP O
8 538 539 10328196 1 CD B-NP O
9 540 547 10328196 patient NN I-NP O
10 548 552 10328196 with IN B-PP O
11 553 562 10328196 sirolimus NN B-NP D020123
12 562 563 10328196 - HYPH B-NP O
13 563 570 10328196 induced VBN I-NP O
14 571 580 10328196 capillary JJ I-NP D019559
15 581 585 10328196 leak NN I-NP D019559
16 586 594 10328196 syndrome NN I-NP D019559
17 595 598 10328196 had VBD B-VP O
18 599 600 10328196 a DT B-NP O
19 601 604 10328196 2.3 CD I-NP O
20 604 605 10328196 - HYPH I-NP O
21 605 609 10328196 fold JJ I-NP O
22 610 618 10328196 increase NN I-NP O
23 619 621 10328196 in IN B-PP O
24 622 632 10328196 percentage NN B-NP O
25 633 635 10328196 of IN B-PP O
26 636 645 10328196 apoptotic JJ B-NP O
27 646 651 10328196 cells NNS I-NP O
28 652 653 10328196 ( ( O O
29 653 655 10328196 to TO B-PP O
30 656 659 10328196 48% CD B-NP O
31 659 660 10328196 ) ) O O
32 661 669 10328196 compared VBN B-PP O
33 670 674 10328196 with IN B-PP O
34 675 677 10328196 an DT B-NP O
35 678 688 10328196 unaffected JJ I-NP O
36 689 698 10328196 sirolimus NN I-NP D020123
37 698 699 10328196 - HYPH B-VP O
38 699 706 10328196 treated VBN B-NP O
39 707 714 10328196 patient NN I-NP O
40 715 719 10328196 with IN B-PP O
41 720 729 10328196 psoriasis NN B-NP D011565
42 730 731 10328196 ( ( O O
43 731 734 10328196 21% CD B-NP O
44 734 735 10328196 ) ) O O
45 735 736 10328196 . . O O

1 737 746 10328196 Activated VBN B-NP O
2 747 757 10328196 peripheral JJ I-NP O
3 758 763 10328196 blood NN I-NP O
4 764 765 10328196 T NN I-NP O
5 766 771 10328196 cells NNS I-NP O
6 772 776 10328196 from IN B-PP O
7 777 785 10328196 patients NNS B-NP O
8 786 790 10328196 with IN B-PP O
9 791 800 10328196 psoriasis NN B-NP D011565
10 801 807 10328196 tended VBD B-VP O
11 808 810 10328196 to TO I-VP O
12 811 818 10328196 exhibit VB I-VP O
13 819 826 10328196 greater JJR B-NP O
14 827 838 10328196 spontaneous JJ I-NP O
15 839 841 10328196 or CC I-NP O
16 842 855 10328196 dexamethasone NN I-NP D003907
17 855 856 10328196 - HYPH O O
18 856 863 10328196 induced VBN B-NP O
19 864 873 10328196 apoptosis NN I-NP O
20 874 878 10328196 than IN B-SBAR O
21 879 882 10328196 did VBD O O
22 883 889 10328196 normal JJ B-NP O
23 890 891 10328196 T NN I-NP O
24 892 897 10328196 cells NNS I-NP O
25 897 898 10328196 , , O O
26 899 911 10328196 particularly RB B-ADVP O
27 912 914 10328196 in IN B-PP O
28 915 918 10328196 the DT I-PP O
29 919 927 10328196 presence NN I-PP O
30 928 930 10328196 of IN I-PP O
31 931 940 10328196 sirolimus NN B-NP D020123
32 940 941 10328196 . . O O

1 942 953 10328196 CONCLUSIONS NNS B-NP O
2 953 954 10328196 : : O O
3 955 961 10328196 Severe JJ B-NP O
4 962 969 10328196 adverse JJ I-NP O
5 970 977 10328196 effects NNS I-NP O
6 978 980 10328196 of IN B-PP O
7 981 990 10328196 sirolimus NN B-NP D020123
8 991 998 10328196 include VBP B-VP O
9 999 1004 10328196 fever NN B-NP D005334
10 1004 1005 10328196 , , O O
11 1006 1012 10328196 anemia NN B-NP D000740
12 1012 1013 10328196 , , O O
13 1014 1017 10328196 and CC O O
14 1018 1027 10328196 capillary JJ B-NP D019559
15 1028 1032 10328196 leak NN I-NP D019559
16 1033 1041 10328196 syndrome NN I-NP D019559
17 1041 1042 10328196 . . O O

1 1043 1048 10328196 These DT B-NP O
2 1049 1057 10328196 symptoms NNS I-NP O
3 1058 1061 10328196 may MD B-VP O
4 1062 1064 10328196 be VB I-VP O
5 1065 1068 10328196 the DT B-NP O
6 1069 1075 10328196 result NN I-NP O
7 1076 1078 10328196 of IN B-PP O
8 1079 1083 10328196 drug NN B-NP O
9 1083 1084 10328196 - HYPH B-NP O
10 1084 1091 10328196 induced VBN I-NP O
11 1092 1101 10328196 apoptosis NN I-NP O
12 1102 1104 10328196 of IN B-PP O
13 1105 1113 10328196 lesional JJ B-NP O
14 1114 1124 10328196 leukocytes NNS I-NP O
15 1124 1125 10328196 , , O O
16 1126 1136 10328196 especially RB B-NP O
17 1137 1146 10328196 activated VBN I-NP O
18 1147 1148 10328196 T NN I-NP O
19 1149 1160 10328196 lymphocytes NNS I-NP O
20 1160 1161 10328196 , , O O
21 1162 1165 10328196 and CC O O
22 1166 1174 10328196 possibly RB B-ADVP O
23 1175 1182 10328196 release NN B-NP O
24 1183 1185 10328196 of IN B-PP O
25 1186 1198 10328196 inflammatory JJ B-NP O
26 1199 1208 10328196 mediators NNS I-NP O
27 1208 1209 10328196 . . O O

1 1210 1217 10328196 Because IN B-SBAR O
2 1218 1226 10328196 patients NNS B-NP O
3 1227 1231 10328196 with IN B-PP O
4 1232 1238 10328196 severe JJ B-NP O
5 1239 1248 10328196 psoriasis NN I-NP D011565
6 1249 1252 10328196 may MD B-VP O
7 1253 1260 10328196 develop VB I-VP O
8 1261 1270 10328196 capillary JJ B-NP D019559
9 1271 1275 10328196 leak NN I-NP D019559
10 1276 1280 10328196 from IN B-PP O
11 1281 1288 10328196 various JJ B-NP O
12 1289 1297 10328196 systemic JJ I-NP O
13 1298 1307 10328196 therapies NNS I-NP O
14 1307 1308 10328196 , , O O
15 1309 1317 10328196 clinical JJ B-NP O
16 1318 1328 10328196 monitoring NN I-NP O
17 1329 1331 10328196 is VBZ B-VP O
18 1332 1341 10328196 advisable JJ B-ADJP O
19 1342 1345 10328196 for IN B-PP O
20 1346 1354 10328196 patients NNS B-NP O
21 1355 1359 10328196 with IN B-PP O
22 1360 1372 10328196 inflammatory JJ B-NP D007249
23 1373 1381 10328196 diseases NNS I-NP D007249
24 1382 1385 10328196 who WP B-NP O
25 1386 1389 10328196 are VBP B-VP O
26 1390 1397 10328196 treated VBN I-VP O
27 1398 1402 10328196 with IN B-PP O
28 1403 1409 10328196 immune JJ B-NP O
29 1410 1420 10328196 modulators NNS I-NP O
30 1420 1421 10328196 . . O O

1 0 0 16006300 -DOCSTART- -X- -X- O

1 0 7 16006300 Calcium NN B-NP D002119
2 8 17 16006300 carbonate NN I-NP D002119
3 18 26 16006300 toxicity NN I-NP D064420
4 26 27 16006300 : : O O
5 28 31 16006300 the DT B-NP O
6 32 39 16006300 updated VBN I-NP O
7 40 44 16006300 milk NN I-NP D006934
8 44 45 16006300 - HYPH I-NP D006934
9 45 51 16006300 alkali JJ I-NP D006934
10 52 60 16006300 syndrome NN I-NP D006934
11 60 61 16006300 ; : O O
12 62 68 16006300 report NN B-NP O
13 69 71 16006300 of IN B-PP O
14 72 73 16006300 3 CD B-NP O
15 74 79 16006300 cases NNS I-NP O
16 80 83 16006300 and CC I-NP O
17 84 90 16006300 review NN I-NP O
18 91 93 16006300 of IN B-PP O
19 94 97 16006300 the DT B-NP O
20 98 108 16006300 literature NN I-NP O
21 108 109 16006300 . . I-NP O
22 110 119 16006300 OBJECTIVE NN I-NP O
23 119 120 16006300 : : O O
24 121 123 16006300 To TO B-VP O
25 124 132 16006300 describe VB I-VP O
26 133 134 16006300 3 CD B-NP O
27 135 143 16006300 patients NNS I-NP O
28 144 148 16006300 with IN B-PP O
29 149 156 16006300 calcium NN B-NP D002119
30 157 166 16006300 carbonate NN I-NP D002119
31 166 167 16006300 - HYPH B-NP O
32 167 174 16006300 induced VBN I-NP O
33 175 188 16006300 hypercalcemia NN I-NP D006934
34 189 192 16006300 and CC I-NP O
35 193 197 16006300 gain NN I-NP O
36 198 206 16006300 insights NNS I-NP O
37 207 211 16006300 into IN B-PP O
38 212 215 16006300 the DT B-NP O
39 216 221 16006300 cause NN I-NP O
40 222 225 16006300 and CC I-NP O
41 226 236 16006300 management NN I-NP O
42 237 239 16006300 of IN B-PP O
43 240 243 16006300 the DT B-NP O
44 244 248 16006300 milk NN I-NP D006934
45 248 249 16006300 - HYPH B-NP D006934
46 249 255 16006300 alkali JJ I-NP D006934
47 256 264 16006300 syndrome NN I-NP D006934
48 264 265 16006300 . . O O

1 266 273 16006300 METHODS NNS B-NP O
2 273 274 16006300 : : O O
3 275 277 16006300 We PRP B-NP O
4 278 284 16006300 report VBP B-VP O
5 285 288 16006300 the DT B-NP O
6 289 297 16006300 clinical JJ I-NP O
7 298 301 16006300 and CC I-NP O
8 302 312 16006300 laboratory JJ I-NP O
9 313 317 16006300 data NNS I-NP O
10 318 320 16006300 in IN B-PP O
11 321 322 16006300 3 CD B-NP O
12 323 331 16006300 patients NNS I-NP O
13 332 335 16006300 who WP B-NP O
14 336 345 16006300 presented VBD B-VP O
15 346 350 16006300 with IN B-PP O
16 351 357 16006300 severe JJ B-NP O
17 358 371 16006300 hypercalcemia NN I-NP D006934
18 372 373 16006300 ( ( O O
19 373 382 16006300 corrected VBN B-NP O
20 383 388 16006300 serum NN I-NP O
21 389 396 16006300 calcium NN I-NP D002118
22 397 398 16006300 > SYM B-VP O
23 399 401 16006300 or CC O O
24 402 403 16006300 = SYM B-VP O
25 404 406 16006300 14 CD B-NP O
26 407 409 16006300 mg NN I-NP O
27 409 410 16006300 / SYM B-NP O
28 410 412 16006300 dL NN I-NP O
29 412 413 16006300 ) ) O O
30 414 417 16006300 and CC O O
31 418 424 16006300 review VBP B-VP O
32 425 428 16006300 the DT B-NP O
33 429 438 16006300 pertinent JJ I-NP O
34 439 449 16006300 literature NN I-NP O
35 450 452 16006300 on IN B-PP O
36 453 457 16006300 milk NN B-NP D006934
37 457 458 16006300 - HYPH B-NP D006934
38 458 464 16006300 alkali JJ I-NP D006934
39 465 473 16006300 syndrome NN I-NP D006934
40 473 474 16006300 . . O O

1 475 482 16006300 RESULTS NNS B-NP O
2 482 483 16006300 : : O O
3 484 487 16006300 The DT B-NP O
4 488 489 16006300 3 CD I-NP O
5 490 498 16006300 patients NNS I-NP O
6 499 502 16006300 had VBD B-VP O
7 503 508 16006300 acute JJ B-NP D058186
8 509 514 16006300 renal JJ I-NP D058186
9 515 528 16006300 insufficiency NN I-NP D058186
10 528 529 16006300 , , O O
11 530 538 16006300 relative JJ B-NP O
12 539 548 16006300 metabolic JJ I-NP D000471
13 549 558 16006300 alkalosis NN I-NP D000471
14 558 559 16006300 , , O O
15 560 563 16006300 and CC O O
16 564 567 16006300 low JJ B-NP O
17 568 579 16006300 parathyroid NN I-NP O
18 580 587 16006300 hormone NN I-NP O
19 588 589 16006300 ( ( O O
20 589 592 16006300 PTH NN B-NP O
21 592 593 16006300 ) ) O O
22 593 594 16006300 , , O O
23 595 598 16006300 PTH NN B-NP O
24 598 599 16006300 - HYPH B-VP O
25 599 606 16006300 related VBN B-NP O
26 607 614 16006300 peptide NN I-NP O
27 614 615 16006300 , , O O
28 616 619 16006300 and CC O O
29 620 624 16006300 1,25 CD B-NP C097949
30 624 625 16006300 - HYPH I-NP C097949
31 625 641 16006300 dihydroxyvitamin NN I-NP C097949
32 642 643 16006300 D NN I-NP C097949
33 644 658 16006300 concentrations NNS I-NP O
34 658 659 16006300 . . O O

1 660 662 16006300 No DT B-NP O
2 663 672 16006300 malignant JJ I-NP O
3 673 679 16006300 lesion NN I-NP O
4 680 683 16006300 was VBD B-VP O
5 684 689 16006300 found VBN I-VP O
6 689 690 16006300 . . O O

1 691 700 16006300 Treatment NN B-NP O
2 701 709 16006300 included VBD B-VP O
3 710 720 16006300 aggressive JJ B-NP O
4 721 730 16006300 hydration NN I-NP O
5 731 734 16006300 and CC O O
6 735 741 16006300 varied VBD B-VP O
7 742 749 16006300 amounts NNS B-NP O
8 750 752 16006300 of IN B-PP O
9 753 763 16006300 furosemide NN B-NP D005665
10 763 764 16006300 . . O O

1 765 768 16006300 The DT B-NP O
2 769 770 16006300 2 CD I-NP O
3 771 779 16006300 patients NNS I-NP O
4 780 784 16006300 with IN B-PP O
5 785 788 16006300 the DT B-NP O
6 789 795 16006300 higher JJR I-NP O
7 796 801 16006300 serum NN I-NP O
8 802 809 16006300 calcium NN I-NP D002118
9 810 824 16006300 concentrations NNS I-NP O
10 825 833 16006300 received VBD B-VP O
11 834 845 16006300 pamidronate NN B-NP C019248
12 846 859 16006300 intravenously RB B-ADVP O
13 860 861 16006300 ( ( O O
14 861 863 16006300 60 CD B-NP O
15 864 867 16006300 and CC I-NP O
16 868 870 16006300 30 CD I-NP O
17 871 873 16006300 mg NN I-NP O
18 873 874 16006300 , , O O
19 875 887 16006300 respectively RB B-ADVP O
20 887 888 16006300 ) ) O O
21 888 889 16006300 , , O O
22 890 895 16006300 which WDT B-NP O
23 896 902 16006300 caused VBD B-VP O
24 903 909 16006300 severe JJ B-NP O
25 910 922 16006300 hypocalcemia NN I-NP D006996
26 922 923 16006300 . . O O

1 924 926 16006300 Of IN B-PP O
2 927 930 16006300 the DT B-NP O
3 931 932 16006300 3 CD I-NP O
4 933 941 16006300 patients NNS I-NP O
5 941 942 16006300 , , O O
6 943 944 16006300 2 CD B-NP O
7 945 949 16006300 were VBD B-VP O
8 950 959 16006300 ingesting VBG I-VP O
9 960 970 16006300 acceptable JJ B-NP O
10 971 976 16006300 doses NNS I-NP O
11 977 979 16006300 of IN B-PP O
12 980 989 16006300 elemental JJ B-NP O
13 990 997 16006300 calcium NN I-NP D002118
14 998 999 16006300 ( ( O O
15 999 1000 16006300 1 CD B-NP O
16 1001 1002 16006300 g NN I-NP O
17 1003 1006 16006300 and CC O O
18 1007 1008 16006300 2 CD B-NP O
19 1009 1010 16006300 g NN I-NP O
20 1011 1016 16006300 daily RB B-ADVP O
21 1016 1017 16006300 , , O O
22 1018 1030 16006300 respectively RB B-ADVP O
23 1030 1031 16006300 ) ) O O
24 1032 1034 16006300 in IN B-PP O
25 1035 1038 16006300 the DT B-NP O
26 1039 1043 16006300 form NN I-NP O
27 1044 1046 16006300 of IN B-PP O
28 1047 1054 16006300 calcium NN B-NP D002119
29 1055 1064 16006300 carbonate NN I-NP D002119
30 1064 1065 16006300 . . O O

1 1066 1068 16006300 In IN B-PP O
2 1069 1077 16006300 addition NN B-NP O
3 1078 1080 16006300 to TO B-PP O
4 1081 1084 16006300 our PRP$ B-NP O
5 1085 1096 16006300 highlighted JJ I-NP O
6 1097 1102 16006300 cases NNS I-NP O
7 1102 1103 16006300 , , O O
8 1104 1106 16006300 we PRP B-NP O
9 1107 1113 16006300 review VBP B-VP O
10 1114 1117 16006300 the DT B-NP O
11 1118 1125 16006300 history NN I-NP O
12 1125 1126 16006300 , , O O
13 1127 1141 16006300 classification NN B-NP O
14 1141 1142 16006300 , , O O
15 1143 1159 16006300 pathophysiologic JJ B-NP O
16 1160 1168 16006300 features NNS I-NP O
17 1168 1169 16006300 , , O O
18 1170 1173 16006300 and CC O O
19 1174 1183 16006300 treatment NN B-NP O
20 1184 1186 16006300 of IN B-PP O
21 1187 1191 16006300 milk NN B-NP D006934
22 1191 1192 16006300 - HYPH B-NP D006934
23 1192 1198 16006300 alkali NN I-NP D006934
24 1199 1207 16006300 syndrome NN I-NP D006934
25 1208 1211 16006300 and CC O O
26 1212 1221 16006300 summarize VB B-VP O
27 1222 1225 16006300 the DT B-NP O
28 1226 1231 16006300 cases NNS I-NP O
29 1232 1240 16006300 reported VBN B-VP O
30 1241 1245 16006300 from IN B-PP O
31 1246 1251 16006300 early RB B-NP O
32 1252 1256 16006300 1995 CD I-NP O
33 1257 1259 16006300 to TO B-PP O
34 1260 1268 16006300 November NNP B-NP O
35 1269 1273 16006300 2003 CD I-NP O
36 1273 1274 16006300 . . O O

1 1275 1285 16006300 CONCLUSION NN B-NP O
2 1285 1286 16006300 : : O O
3 1287 1291 16006300 Milk NN B-NP D006934
4 1291 1292 16006300 - HYPH B-NP D006934
5 1292 1298 16006300 alkali JJ I-NP D006934
6 1299 1307 16006300 syndrome NN I-NP D006934
7 1308 1311 16006300 may MD B-VP O
8 1312 1314 16006300 be VB I-VP O
9 1315 1316 16006300 a DT B-NP O
10 1317 1323 16006300 common JJ I-NP O
11 1324 1329 16006300 cause NN I-NP O
12 1330 1332 16006300 of IN B-PP O
13 1333 1344 16006300 unexplained JJ B-NP O
14 1345 1358 16006300 hypercalcemia NN I-NP D006934
15 1359 1362 16006300 and CC O O
16 1363 1366 16006300 can MD B-VP O
17 1367 1369 16006300 be VB I-VP O
18 1370 1382 16006300 precipitated VBN I-VP O
19 1383 1385 16006300 by IN B-PP O
20 1386 1391 16006300 small JJ B-NP O
21 1392 1399 16006300 amounts NNS I-NP O
22 1400 1402 16006300 of IN B-PP O
23 1403 1409 16006300 orally RB B-NP O
24 1410 1418 16006300 ingested VBN I-NP O
25 1419 1426 16006300 calcium NN I-NP D002119
26 1427 1436 16006300 carbonate NN I-NP D002119
27 1437 1439 16006300 in IN B-PP O
28 1440 1451 16006300 susceptible JJ B-NP O
29 1452 1459 16006300 persons NNS I-NP O
30 1459 1460 16006300 . . O O

1 1461 1470 16006300 Treatment NN B-NP O
2 1471 1475 16006300 with IN B-PP O
3 1476 1485 16006300 hydration NN B-NP O
4 1485 1486 16006300 , , O O
5 1487 1497 16006300 furosemide NN B-NP D005665
6 1497 1498 16006300 , , O O
7 1499 1502 16006300 and CC O O
8 1503 1518 16006300 discontinuation NN B-NP O
9 1519 1521 16006300 of IN B-PP O
10 1522 1525 16006300 the DT B-NP O
11 1526 1533 16006300 calcium NN I-NP D002118
12 1534 1537 16006300 and CC I-NP O
13 1538 1545 16006300 vitamin NN I-NP D014807
14 1546 1547 16006300 D NN I-NP D014807
15 1548 1554 16006300 source NN I-NP O
16 1555 1557 16006300 is VBZ B-VP O
17 1558 1566 16006300 adequate JJ B-ADJP O
18 1566 1567 16006300 . . O O

1 1568 1579 16006300 Pamidronate NN B-NP C019248
2 1580 1589 16006300 treatment NN I-NP O
3 1590 1592 16006300 is VBZ B-VP O
4 1593 1603 16006300 associated VBN I-VP O
5 1604 1608 16006300 with IN B-PP O
6 1609 1621 16006300 considerable JJ B-NP O
7 1622 1626 16006300 risk NN I-NP O
8 1627 1630 16006300 for IN B-PP O
9 1631 1643 16006300 hypocalcemia NN B-NP D006996
10 1643 1644 16006300 , , O O
11 1645 1649 16006300 even RB B-ADVP O
12 1650 1652 16006300 in IN B-PP O
13 1653 1658 16006300 cases NNS B-NP O
14 1659 1661 16006300 of IN B-PP O
15 1662 1671 16006300 initially RB B-NP O
16 1672 1678 16006300 severe JJ I-NP O
17 1679 1692 16006300 hypercalcemia NN I-NP D006934
18 1692 1693 16006300 . . O O

1 0 0 8514073 -DOCSTART- -X- -X- O

1 0 6 8514073 Venous JJ B-NP D014652
2 7 20 8514073 complications NNS I-NP D014652
3 21 23 8514073 of IN B-PP O
4 24 33 8514073 midazolam NN B-NP D008874
5 34 40 8514073 versus IN B-PP O
6 41 49 8514073 diazepam NN B-NP D003975
7 49 50 8514073 . . O O
8 51 59 8514073 Although IN B-SBAR O
9 60 64 8514073 some DT B-NP O
10 65 72 8514073 studies NNS I-NP O
11 73 77 8514073 have VBP B-VP O
12 78 87 8514073 suggested VBN I-VP O
13 88 93 8514073 fewer JJR B-NP O
14 94 100 8514073 venous JJ I-NP D014652
15 101 114 8514073 complications NNS I-NP D014652
16 115 118 8514073 are VBP B-VP O
17 119 129 8514073 associated VBN I-VP O
18 130 134 8514073 with IN B-PP O
19 135 144 8514073 midazolam NN B-NP D008874
20 145 149 8514073 than IN B-PP O
21 150 154 8514073 with IN B-PP O
22 155 163 8514073 diazepam NN B-NP D003975
23 164 167 8514073 for IN B-PP O
24 168 178 8514073 endoscopic JJ B-NP O
25 179 189 8514073 procedures NNS I-NP O
26 189 190 8514073 , , O O
27 191 195 8514073 this DT B-NP O
28 196 204 8514073 variable NN I-NP O
29 205 208 8514073 has VBZ B-VP O
30 209 212 8514073 not RB I-VP O
31 213 217 8514073 been VBN I-VP O
32 218 222 8514073 well RB B-ADJP O
33 223 233 8514073 documented VBN I-ADJP O
34 233 234 8514073 . . O O

1 235 237 8514073 We PRP B-NP O
2 238 251 8514073 prospectively RB B-ADVP O
3 252 261 8514073 evaluated VBD B-VP O
4 262 265 8514073 the DT B-NP O
5 266 275 8514073 incidence NN I-NP O
6 276 278 8514073 of IN B-PP O
7 279 285 8514073 venous JJ B-NP D014652
8 286 299 8514073 complications NNS I-NP D014652
9 300 305 8514073 after IN B-PP O
10 306 317 8514073 intravenous JJ B-NP O
11 318 327 8514073 injection NN I-NP O
12 328 330 8514073 of IN B-PP O
13 331 339 8514073 diazepam NN B-NP D003975
14 340 342 8514073 or CC I-NP O
15 343 352 8514073 midazolam NN I-NP D008874
16 353 355 8514073 in IN B-PP O
17 356 359 8514073 122 CD B-NP O
18 360 371 8514073 consecutive JJ I-NP O
19 372 380 8514073 patients NNS I-NP O
20 381 391 8514073 undergoing VBG B-VP O
21 392 403 8514073 colonoscopy NN B-NP O
22 404 407 8514073 and CC I-NP O
23 408 434 8514073 esophagogastroduodenoscopy NN I-NP O
24 434 435 8514073 . . O O

1 436 443 8514073 Overall RB B-ADVP O
2 443 444 8514073 , , O O
3 445 451 8514073 venous JJ B-NP D014652
4 452 465 8514073 complications NNS I-NP D014652
5 466 470 8514073 were VBD B-VP O
6 471 475 8514073 more RBR B-ADJP O
7 476 484 8514073 frequent JJ I-ADJP O
8 485 489 8514073 with IN B-PP O
9 490 498 8514073 diazepam NN B-NP D003975
10 499 500 8514073 ( ( O O
11 500 502 8514073 22 CD B-NP O
12 503 505 8514073 of IN B-PP O
13 506 508 8514073 62 CD B-NP O
14 509 517 8514073 patients NNS I-NP O
15 517 518 8514073 ) ) O O
16 519 523 8514073 than IN B-PP O
17 524 528 8514073 with IN B-PP O
18 529 538 8514073 midazolam NN B-NP D008874
19 539 540 8514073 ( ( O O
20 540 541 8514073 4 CD B-NP O
21 542 544 8514073 of IN B-PP O
22 545 547 8514073 60 CD B-NP O
23 548 556 8514073 patients NNS I-NP O
24 556 557 8514073 ) ) O O
25 558 559 8514073 ( ( O O
26 559 560 8514073 p NN B-NP O
27 561 562 8514073 < SYM O O
28 563 568 8514073 0.001 CD B-NP O
29 568 569 8514073 ) ) O O
30 569 570 8514073 . . O O

1 571 572 8514073 A DT B-NP O
2 573 581 8514073 palpable JJ I-NP O
3 582 588 8514073 venous JJ I-NP O
4 589 593 8514073 cord NN I-NP O
5 594 597 8514073 was VBD B-VP O
6 598 605 8514073 present JJ B-ADJP O
7 606 608 8514073 in IN B-PP O
8 609 612 8514073 23% CD B-NP O
9 613 614 8514073 ( ( O O
10 614 616 8514073 14 CD B-NP O
11 617 619 8514073 of IN B-PP O
12 620 622 8514073 62 CD B-NP O
13 622 623 8514073 ) ) O O
14 624 626 8514073 of IN B-PP O
15 627 635 8514073 patients NNS B-NP O
16 636 638 8514073 in IN B-PP O
17 639 642 8514073 the DT B-NP O
18 643 651 8514073 diazepam NN I-NP D003975
19 652 657 8514073 group NN I-NP O
20 657 658 8514073 , , O O
21 659 667 8514073 compared VBN B-PP O
22 668 672 8514073 with IN B-PP O
23 673 675 8514073 2% NN B-NP O
24 676 677 8514073 ( ( O O
25 677 678 8514073 1 CD B-NP O
26 679 681 8514073 of IN B-PP O
27 682 684 8514073 60 CD B-NP O
28 685 693 8514073 patients NNS I-NP O
29 693 694 8514073 ) ) O O
30 695 697 8514073 in IN B-PP O
31 698 701 8514073 the DT B-NP O
32 702 711 8514073 midazolam NN I-NP D008874
33 712 717 8514073 group NN I-NP O
34 718 719 8514073 ( ( O O
35 719 720 8514073 p NN B-NP O
36 721 722 8514073 < JJR B-NP O
37 723 728 8514073 0.002 CD I-NP O
38 728 729 8514073 ) ) O O
39 729 730 8514073 . . O O

1 731 735 8514073 Pain NN B-NP D010146
2 736 738 8514073 at IN B-PP O
3 739 742 8514073 the DT B-NP O
4 743 752 8514073 injection NN I-NP O
5 753 757 8514073 site NN I-NP O
6 758 766 8514073 occurred VBD B-VP O
7 767 769 8514073 in IN B-PP O
8 770 773 8514073 35% CD B-NP O
9 774 775 8514073 ( ( O O
10 775 777 8514073 22 CD B-NP O
11 778 780 8514073 of IN B-PP O
12 781 783 8514073 62 CD B-NP O
13 783 784 8514073 ) ) O O
14 785 787 8514073 of IN B-PP O
15 788 796 8514073 patients NNS B-NP O
16 797 799 8514073 in IN B-PP O
17 800 803 8514073 the DT B-NP O
18 804 812 8514073 diazepam NN I-NP D003975
19 813 818 8514073 group NN I-NP O
20 819 827 8514073 compared VBN B-PP O
21 828 832 8514073 with IN B-PP O
22 833 835 8514073 7% CD B-NP O
23 836 837 8514073 ( ( O O
24 837 838 8514073 4 CD B-NP O
25 839 841 8514073 of IN B-PP O
26 842 844 8514073 60 CD B-NP O
27 845 853 8514073 patients NNS I-NP O
28 853 854 8514073 ) ) O O
29 855 857 8514073 in IN B-PP O
30 858 861 8514073 the DT B-NP O
31 862 871 8514073 midazolam NN I-NP D008874
32 872 877 8514073 group NN I-NP O
33 878 879 8514073 ( ( O O
34 879 880 8514073 p NN B-NP O
35 881 882 8514073 < SYM O O
36 883 888 8514073 0.001 CD B-NP O
37 888 889 8514073 ) ) O O
38 889 890 8514073 . . O O

1 891 899 8514073 Swelling NN B-NP D004487
2 900 903 8514073 and CC I-NP O
3 904 910 8514073 warmth NN I-NP O
4 911 913 8514073 at IN B-PP O
5 914 917 8514073 the DT B-NP O
6 918 927 8514073 injection NN I-NP O
7 928 932 8514073 site NN I-NP O
8 933 937 8514073 were VBD B-VP O
9 938 941 8514073 not RB B-ADJP O
10 942 955 8514073 significantly RB I-ADJP O
11 956 965 8514073 different JJ I-ADJP O
12 966 973 8514073 between IN B-PP O
13 974 977 8514073 the DT B-NP O
14 978 981 8514073 two CD I-NP O
15 982 988 8514073 groups NNS I-NP O
16 988 989 8514073 . . O O

1 990 997 8514073 Smoking NN B-NP O
2 997 998 8514073 , , O O
3 999 1011 8514073 nonsteroidal JJ B-NP O
4 1012 1016 8514073 anti AFX I-NP O
5 1016 1017 8514073 - HYPH I-NP O
6 1017 1029 8514073 inflammatory JJ I-NP O
7 1030 1034 8514073 drug NN I-NP O
8 1035 1038 8514073 use NN I-NP O
9 1038 1039 8514073 , , O O
10 1040 1051 8514073 intravenous JJ B-NP O
11 1052 1060 8514073 catheter NN I-NP O
12 1061 1065 8514073 site NN I-NP O
13 1065 1066 8514073 , , O O
14 1067 1072 8514073 dwell NN B-NP O
15 1073 1077 8514073 time NN I-NP O
16 1078 1080 8514073 of IN B-PP O
17 1081 1084 8514073 the DT B-NP O
18 1085 1091 8514073 needle NN I-NP O
19 1091 1092 8514073 , , O O
20 1093 1100 8514073 alcohol NN B-NP D000431
21 1101 1104 8514073 use NN I-NP O
22 1104 1105 8514073 , , O O
23 1106 1109 8514073 and CC O O
24 1110 1114 8514073 pain NN B-NP D010146
25 1115 1121 8514073 during IN B-PP O
26 1122 1125 8514073 the DT B-NP O
27 1126 1135 8514073 injection NN I-NP O
28 1136 1139 8514073 had VBD B-VP O
29 1140 1142 8514073 no DT B-NP O
30 1143 1149 8514073 effect NN I-NP O
31 1150 1152 8514073 on IN B-PP O
32 1153 1156 8514073 the DT B-NP O
33 1157 1166 8514073 incidence NN I-NP O
34 1167 1169 8514073 of IN B-PP O
35 1170 1176 8514073 venous JJ B-NP D014652
36 1177 1190 8514073 complications NNS I-NP D014652
37 1190 1191 8514073 . . O O

1 0 0 12180796 -DOCSTART- -X- -X- O

1 0 19 12180796 Immunohistochemical JJ B-NP O
2 20 25 12180796 study NN I-NP O
3 26 28 12180796 on IN B-PP O
4 29 38 12180796 inducible JJ B-NP O
5 39 43 12180796 type NN I-NP O
6 44 46 12180796 of IN B-PP O
7 47 53 12180796 nitric JJ B-NP D009569
8 54 59 12180796 oxide NN I-NP D009569
9 60 61 12180796 ( ( O O
10 61 65 12180796 iNOS NN B-NP O
11 65 66 12180796 ) ) O O
12 66 67 12180796 , , O O
13 68 73 12180796 basic JJ B-NP O
14 74 84 12180796 fibroblast NN I-NP O
15 85 91 12180796 growth NN I-NP O
16 92 98 12180796 factor NN I-NP O
17 99 100 12180796 ( ( O O
18 100 104 12180796 bFGF NN B-NP O
19 104 105 12180796 ) ) O O
20 106 109 12180796 and CC O O
21 110 115 12180796 tumor NN B-NP D009369
22 116 122 12180796 growth NN I-NP O
23 123 129 12180796 factor NN I-NP O
24 129 130 12180796 - HYPH B-NP O
25 130 135 12180796 beta1 NN I-NP O
26 136 137 12180796 ( ( O O
27 137 140 12180796 TGF NN B-NP O
28 140 141 12180796 - HYPH B-NP O
29 141 146 12180796 beta1 NN I-NP O
30 146 147 12180796 ) ) O O
31 148 150 12180796 in IN B-PP O
32 151 160 12180796 arteritis NN B-NP D001167
33 161 168 12180796 induced VBN B-VP O
34 169 171 12180796 in IN B-PP O
35 172 176 12180796 rats NNS B-NP O
36 177 179 12180796 by IN B-PP O
37 180 190 12180796 fenoldopam NN B-NP D018818
38 191 194 12180796 and CC I-NP O
39 195 207 12180796 theophylline NN I-NP D013806
40 207 208 12180796 , , O O
41 209 221 12180796 vasodilators NNS B-NP O
42 221 222 12180796 . . I-NP O
43 223 232 12180796 Arteritis NN I-NP D001167
44 233 240 12180796 induced VBD B-VP O
45 241 243 12180796 in IN B-PP O
46 244 248 12180796 rats NNS B-NP O
47 249 251 12180796 by IN B-PP O
48 252 264 12180796 vasodilators NNS B-NP O
49 264 265 12180796 , , O O
50 266 276 12180796 fenoldopam NN B-NP D018818
51 277 280 12180796 and CC I-NP O
52 281 293 12180796 theophylline NN I-NP D013806
53 293 294 12180796 , , O O
54 295 298 12180796 was VBD B-VP O
55 299 307 12180796 examined VBN I-VP O
56 308 329 12180796 immunohistochemically RB B-ADVP O
57 330 333 12180796 for IN B-PP O
58 334 345 12180796 expressions NNS B-NP O
59 346 348 12180796 of IN B-PP O
60 349 358 12180796 inducible JJ B-NP O
61 359 363 12180796 type NN I-NP O
62 364 366 12180796 of IN B-PP O
63 367 373 12180796 nitric JJ B-NP D009569
64 374 379 12180796 oxide NN I-NP D009569
65 380 388 12180796 synthase NN I-NP O
66 389 390 12180796 ( ( O O
67 390 394 12180796 iNOS NN B-NP O
68 394 395 12180796 ) ) O O
69 395 396 12180796 , , O O
70 397 402 12180796 basic JJ B-NP O
71 403 413 12180796 fibroblast NN I-NP O
72 414 420 12180796 growth NN I-NP O
73 421 427 12180796 factor NN I-NP O
74 428 429 12180796 ( ( O O
75 429 433 12180796 bFGF NN B-NP O
76 433 434 12180796 ) ) O O
77 435 438 12180796 and CC O O
78 439 444 12180796 tumor NN B-NP D009369
79 445 451 12180796 growth NN I-NP O
80 452 458 12180796 factor NN I-NP O
81 458 459 12180796 - HYPH B-NP O
82 459 464 12180796 beta1 NN I-NP O
83 465 466 12180796 ( ( O O
84 466 469 12180796 TGF NN B-NP O
85 469 470 12180796 - HYPH B-NP O
86 470 475 12180796 beta1 NN I-NP O
87 475 476 12180796 ) ) O O
88 476 477 12180796 . . O O

1 478 482 12180796 Rats NNS B-NP O
2 483 487 12180796 were VBD B-VP O
3 488 500 12180796 administered VBN I-VP O
4 501 511 12180796 fenoldopam NN B-NP D018818
5 512 515 12180796 for IN B-PP O
6 516 518 12180796 24 CD B-NP O
7 519 524 12180796 hours NNS I-NP O
8 525 527 12180796 by IN B-PP O
9 528 539 12180796 intravenous JJ B-NP O
10 540 548 12180796 infusion NN I-NP O
11 549 553 12180796 with IN B-PP O
12 554 556 12180796 or CC B-PP O
13 557 564 12180796 without IN B-PP O
14 565 574 12180796 following VBG B-VP O
15 575 583 12180796 repeated VBN B-NP O
16 584 589 12180796 daily JJ I-NP O
17 590 594 12180796 oral JJ I-NP O
18 595 610 12180796 administrations NNS I-NP O
19 611 613 12180796 of IN B-PP O
20 614 626 12180796 theophylline NN B-NP D013806
21 626 627 12180796 . . O O

1 628 640 12180796 Irrespective JJ B-NP O
2 641 643 12180796 of IN B-PP O
3 644 656 12180796 theophylline NN B-NP D013806
4 657 671 12180796 administration NN I-NP O
5 671 672 12180796 , , O O
6 673 677 12180796 iNOS NN B-NP O
7 678 686 12180796 antigens NNS I-NP O
8 687 691 12180796 were VBD B-VP O
9 692 702 12180796 remarkably RB B-ADJP O
10 703 711 12180796 abundant JJ I-ADJP O
11 712 714 12180796 in IN B-PP O
12 715 717 12180796 ED VBN B-VP O
13 717 718 12180796 - HYPH B-NP O
14 718 719 12180796 1 CD I-NP O
15 719 720 12180796 - HYPH I-NP O
16 720 728 12180796 positive JJ I-NP O
17 729 734 12180796 cells NNS I-NP O
18 735 737 12180796 on IN B-PP O
19 738 741 12180796 day NN B-NP O
20 742 743 12180796 5 CD I-NP O
21 744 747 12180796 and CC I-NP O
22 748 749 12180796 8 CD I-NP O
23 750 754 12180796 post AFX I-NP O
24 754 755 12180796 - HYPH I-NP O
25 755 765 12180796 fenoldopam NN I-NP D018818
26 765 766 12180796 - HYPH O O
27 766 774 12180796 infusion NN B-NP O
28 775 776 12180796 ( ( O O
29 776 779 12180796 DPI NN B-NP O
30 779 780 12180796 ) ) O O
31 780 781 12180796 ; : O O
32 782 786 12180796 bFGF NN B-NP O
33 787 795 12180796 antigens NNS I-NP O
34 796 800 12180796 were VBD B-VP O
35 801 811 12180796 remarkably RB B-ADJP O
36 812 820 12180796 abundant JJ I-ADJP O
37 821 823 12180796 in IN B-PP O
38 824 826 12180796 ED VBN B-VP O
39 826 827 12180796 - HYPH B-NP O
40 827 828 12180796 1 CD I-NP O
41 828 829 12180796 - HYPH I-NP O
42 829 837 12180796 positive JJ I-NP O
43 838 843 12180796 cells NNS I-NP O
44 844 846 12180796 on IN B-PP O
45 847 848 12180796 1 CD B-NP O
46 849 852 12180796 and CC I-NP O
47 853 854 12180796 3 CD I-NP O
48 855 858 12180796 DPI NN I-NP O
49 858 859 12180796 ; : O O
50 860 863 12180796 TGF NN B-NP O
51 863 864 12180796 - HYPH I-NP O
52 864 869 12180796 beta1 NN I-NP O
53 870 878 12180796 antigens NNS I-NP O
54 879 883 12180796 were VBD B-VP O
55 884 892 12180796 observed VBN I-VP O
56 893 895 12180796 in IN B-PP O
57 896 898 12180796 ED NN B-NP O
58 898 899 12180796 - HYPH B-NP O
59 899 900 12180796 1 CD I-NP O
60 900 901 12180796 - HYPH I-NP O
61 901 909 12180796 positive JJ I-NP O
62 910 915 12180796 cells NNS I-NP O
63 916 918 12180796 on IN B-PP O
64 919 922 12180796 and CC I-PP O
65 923 928 12180796 after IN I-PP O
66 929 930 12180796 5 CD B-NP O
67 931 934 12180796 DPI NN I-NP O
68 934 935 12180796 . . O O

1 936 941 12180796 These DT B-NP O
2 942 949 12180796 results NNS I-NP O
3 950 957 12180796 suggest VBP B-VP O
4 958 962 12180796 that IN B-SBAR O
5 963 966 12180796 the DT B-NP O
6 967 971 12180796 peak JJ I-NP O
7 972 982 12180796 expression NN I-NP O
8 983 985 12180796 of IN B-PP O
9 986 990 12180796 iNOS NN B-NP O
10 991 998 12180796 antigen NN I-NP O
11 999 1002 12180796 was VBD B-VP O
12 1003 1011 12180796 followed VBN I-VP O
13 1012 1014 12180796 by IN B-PP O
14 1015 1019 12180796 that DT B-NP O
15 1020 1022 12180796 of IN B-PP O
16 1023 1027 12180796 bFGF NN B-NP O
17 1028 1035 12180796 antigen NN I-NP O
18 1035 1036 12180796 , , O O
19 1037 1040 12180796 and CC O O
20 1041 1045 12180796 bFGF NN B-NP O
21 1046 1049 12180796 may MD B-VP O
22 1050 1054 12180796 have VB I-VP O
23 1055 1056 12180796 a DT B-NP O
24 1057 1068 12180796 suppressive JJ I-NP O
25 1069 1075 12180796 effect NN I-NP O
26 1076 1078 12180796 on IN B-PP O
27 1079 1083 12180796 iNOS NN B-NP O
28 1084 1094 12180796 expression NN I-NP O
29 1095 1097 12180796 in IN B-PP O
30 1098 1103 12180796 these DT B-NP O
31 1104 1107 12180796 rat NN I-NP O
32 1108 1117 12180796 arteritis NN I-NP D001167
33 1118 1124 12180796 models NNS I-NP O
34 1124 1125 12180796 . . O O

1 1126 1128 12180796 On IN B-PP O
2 1129 1132 12180796 the DT B-NP O
3 1133 1138 12180796 other JJ I-NP O
4 1139 1143 12180796 hand NN I-NP O
5 1143 1144 12180796 , , O O
6 1145 1148 12180796 TGF NN B-NP O
7 1148 1149 12180796 - HYPH B-NP O
8 1149 1154 12180796 beta1 NN I-NP O
9 1155 1158 12180796 was VBD B-VP O
10 1159 1162 12180796 not RB I-VP O
11 1163 1173 12180796 considered VBN I-VP O
12 1174 1176 12180796 to TO I-VP O
13 1177 1181 12180796 have VB I-VP O
14 1182 1183 12180796 a DT B-NP O
15 1184 1195 12180796 suppressive JJ I-NP O
16 1196 1202 12180796 effect NN I-NP O
17 1203 1205 12180796 on IN B-PP O
18 1206 1210 12180796 iNOS NN B-NP O
19 1211 1221 12180796 expression NN I-NP O
20 1222 1224 12180796 in IN B-PP O
21 1225 1230 12180796 these DT B-NP O
22 1231 1237 12180796 models NNS I-NP O
23 1237 1238 12180796 . . O O

1 0 0 20103708 -DOCSTART- -X- -X- O

1 0 3 20103708 The DT B-NP O
2 4 14 20103708 protective JJ I-NP O
3 15 19 20103708 role NN I-NP O
4 20 22 20103708 of IN B-PP O
5 23 27 20103708 Nrf2 NN B-NP O
6 28 30 20103708 in IN B-PP O
7 31 45 20103708 streptozotocin NN B-NP D013311
8 45 46 20103708 - HYPH B-NP O
9 46 53 20103708 induced VBN I-NP O
10 54 62 20103708 diabetic JJ I-NP D003928
11 63 74 20103708 nephropathy NN I-NP D003928
12 74 75 20103708 . . I-NP O
13 76 85 20103708 OBJECTIVE NN I-NP O
14 85 86 20103708 : : O O
15 87 95 20103708 Diabetic JJ B-NP D003928
16 96 107 20103708 nephropathy NN I-NP D003928
17 108 110 20103708 is VBZ B-VP O
18 111 114 20103708 one CD B-NP O
19 115 117 20103708 of IN B-PP O
20 118 121 20103708 the DT B-NP O
21 122 127 20103708 major JJ I-NP O
22 128 134 20103708 causes NNS I-NP O
23 135 137 20103708 of IN B-PP O
24 138 143 20103708 renal JJ B-NP D051437
25 144 151 20103708 failure NN I-NP D051437
26 151 152 20103708 , , O O
27 153 158 20103708 which WDT B-NP O
28 159 161 20103708 is VBZ B-VP O
29 162 173 20103708 accompanied VBN I-VP O
30 174 176 20103708 by IN B-PP O
31 177 180 20103708 the DT B-NP O
32 181 191 20103708 production NN I-NP O
33 192 194 20103708 of IN B-PP O
34 195 203 20103708 reactive JJ B-NP O
35 204 210 20103708 oxygen NN I-NP D010100
36 211 218 20103708 species NNS I-NP O
37 219 220 20103708 ( ( O O
38 220 223 20103708 ROS NNS B-NP O
39 223 224 20103708 ) ) O O
40 224 225 20103708 . . O O

1 226 230 20103708 Nrf2 NN B-NP O
2 231 233 20103708 is VBZ B-VP O
3 234 237 20103708 the DT B-NP O
4 238 245 20103708 primary JJ I-NP O
5 246 259 20103708 transcription NN I-NP O
6 260 266 20103708 factor NN I-NP O
7 267 271 20103708 that WDT B-NP O
8 272 280 20103708 controls VBZ B-VP O
9 281 284 20103708 the DT B-NP O
10 285 296 20103708 antioxidant JJ I-NP O
11 297 305 20103708 response NN I-NP O
12 306 315 20103708 essential JJ B-ADJP O
13 316 319 20103708 for IN B-PP O
14 320 331 20103708 maintaining VBG B-VP O
15 332 340 20103708 cellular JJ B-NP O
16 341 346 20103708 redox NN I-NP O
17 347 358 20103708 homeostasis NN I-NP O
18 358 359 20103708 . . O O

1 360 364 20103708 Here RB B-ADVP O
2 364 365 20103708 , , O O
3 366 368 20103708 we PRP B-NP O
4 369 375 20103708 report VBP B-VP O
5 376 379 20103708 our PRP$ B-NP O
6 380 388 20103708 findings NNS I-NP O
7 389 402 20103708 demonstrating VBG B-VP O
8 403 404 20103708 a DT B-NP O
9 405 415 20103708 protective JJ I-NP O
10 416 420 20103708 role NN I-NP O
11 421 423 20103708 of IN B-PP O
12 424 428 20103708 Nrf2 NN B-NP O
13 429 436 20103708 against IN B-PP O
14 437 445 20103708 diabetic JJ B-NP D003928
15 446 457 20103708 nephropathy NN I-NP D003928
16 457 458 20103708 . . O O

1 459 467 20103708 RESEARCH NN B-NP O
2 468 474 20103708 DESIGN NN I-NP O
3 475 478 20103708 AND CC I-NP O
4 479 486 20103708 METHODS NNS I-NP O
5 486 487 20103708 : : O O
6 488 490 20103708 We PRP B-NP O
7 491 498 20103708 explore VBP B-VP O
8 499 502 20103708 the DT B-NP O
9 503 513 20103708 protective JJ I-NP O
10 514 518 20103708 role NN I-NP O
11 519 521 20103708 of IN B-PP O
12 522 526 20103708 Nrf2 NN B-NP O
13 527 534 20103708 against IN B-PP O
14 535 543 20103708 diabetic JJ B-NP D003928
15 544 555 20103708 nephropathy NN I-NP D003928
16 556 561 20103708 using VBG B-VP O
17 562 567 20103708 human JJ B-NP O
18 568 574 20103708 kidney NN I-NP O
19 575 581 20103708 biopsy NN I-NP O
20 582 589 20103708 tissues NNS I-NP O
21 590 594 20103708 from IN B-PP O
22 595 603 20103708 diabetic JJ B-NP D003928
23 604 615 20103708 nephropathy NN I-NP D003928
24 616 624 20103708 patients NNS I-NP O
25 624 625 20103708 , , O O
26 626 627 20103708 a DT B-NP O
27 628 642 20103708 streptozotocin NN I-NP D013311
28 642 643 20103708 - HYPH O O
29 643 650 20103708 induced VBN B-NP O
30 651 659 20103708 diabetic JJ I-NP D003928
31 660 671 20103708 nephropathy NN I-NP D003928
32 672 677 20103708 model NN I-NP O
33 678 680 20103708 in IN B-PP O
34 681 686 20103708 Nrf2( NN B-NP O
35 686 687 20103708 - HYPH O O
36 687 688 20103708 / SYM O O
37 688 689 20103708 - SYM O O
38 689 690 20103708 ) ) O O
39 691 695 20103708 mice NNS B-NP O
40 695 696 20103708 , , O O
41 697 700 20103708 and CC O O
42 701 709 20103708 cultured VBN B-VP O
43 710 715 20103708 human JJ B-NP O
44 716 725 20103708 mesangial JJ I-NP O
45 726 731 20103708 cells NNS I-NP O
46 731 732 20103708 . . O O

1 733 740 20103708 RESULTS NNS B-NP O
2 740 741 20103708 : : O O
3 742 745 20103708 The DT B-NP O
4 746 755 20103708 glomeruli NNS I-NP O
5 756 758 20103708 of IN B-PP O
6 759 764 20103708 human JJ B-NP O
7 765 773 20103708 diabetic JJ I-NP D003928
8 774 785 20103708 nephropathy NN I-NP D003928
9 786 794 20103708 patients NNS I-NP O
10 795 799 20103708 were VBD B-VP O
11 800 805 20103708 under IN B-PP O
12 806 815 20103708 oxidative JJ B-NP O
13 816 822 20103708 stress NN I-NP O
14 823 826 20103708 and CC O O
15 827 830 20103708 had VBD B-VP O
16 831 839 20103708 elevated VBN I-VP O
17 840 844 20103708 Nrf2 NN B-NP O
18 845 851 20103708 levels NNS I-NP O
19 851 852 20103708 . . O O

1 853 855 20103708 In IN B-PP O
2 856 859 20103708 the DT B-NP O
3 860 866 20103708 animal NN I-NP O
4 867 872 20103708 study NN I-NP O
5 872 873 20103708 , , O O
6 874 878 20103708 Nrf2 NN B-NP O
7 879 882 20103708 was VBD B-VP O
8 883 895 20103708 demonstrated VBN I-VP O
9 896 898 20103708 to TO I-VP O
10 899 901 20103708 be VB I-VP O
11 902 909 20103708 crucial JJ B-ADJP O
12 910 912 20103708 in IN B-PP O
13 913 925 20103708 ameliorating VBG B-VP O
14 926 940 20103708 streptozotocin NN B-NP D013311
15 940 941 20103708 - HYPH O O
16 941 948 20103708 induced VBN B-NP O
17 949 954 20103708 renal JJ I-NP D058186
18 955 961 20103708 damage NN I-NP D058186
19 961 962 20103708 . . O O

1 963 967 20103708 This DT B-NP O
2 968 970 20103708 is VBZ B-VP O
3 971 978 20103708 evident JJ B-ADJP O
4 979 981 20103708 by IN B-PP O
5 982 987 20103708 Nrf2( NN B-NP O
6 987 988 20103708 - HYPH O O
7 988 989 20103708 / SYM O O
8 989 990 20103708 - SYM O O
9 990 991 20103708 ) ) O O
10 992 996 20103708 mice NNS B-NP O
11 997 1003 20103708 having VBG B-VP O
12 1004 1010 20103708 higher JJR B-NP O
13 1011 1014 20103708 ROS NN I-NP O
14 1015 1025 20103708 production NN I-NP O
15 1026 1029 20103708 and CC O O
16 1030 1039 20103708 suffering VBG B-VP O
17 1040 1044 20103708 from IN B-PP O
18 1045 1052 20103708 greater JJR B-NP O
19 1053 1062 20103708 oxidative JJ I-NP O
20 1063 1066 20103708 DNA NN I-NP O
21 1067 1073 20103708 damage NN I-NP O
22 1074 1077 20103708 and CC O O
23 1078 1083 20103708 renal JJ B-NP D058186
24 1084 1090 20103708 injury NN I-NP D058186
25 1091 1099 20103708 compared VBN B-PP O
26 1100 1104 20103708 with IN B-PP O
27 1105 1111 20103708 Nrf2(+ NN B-NP O
28 1111 1112 20103708 / SYM O O
29 1112 1113 20103708 + SYM O O
30 1113 1114 20103708 ) ) O O
31 1115 1119 20103708 mice NNS B-NP O
32 1119 1120 20103708 . . O O

1 1121 1132 20103708 Mechanistic JJ B-NP O
2 1133 1140 20103708 studies NNS I-NP O
3 1141 1143 20103708 in IN B-PP O
4 1144 1148 20103708 both CC O O
5 1149 1151 20103708 in FW B-ADVP O
6 1152 1156 20103708 vivo FW I-ADVP O
7 1157 1160 20103708 and CC O O
8 1161 1163 20103708 in FW B-NP O
9 1164 1169 20103708 vitro FW I-NP O
10 1170 1177 20103708 systems NNS I-NP O
11 1178 1184 20103708 showed VBD B-VP O
12 1185 1189 20103708 that IN B-SBAR O
13 1190 1193 20103708 the DT B-NP O
14 1194 1198 20103708 Nrf2 NN I-NP O
15 1198 1199 20103708 - HYPH B-VP O
16 1199 1207 20103708 mediated VBN B-NP O
17 1208 1218 20103708 protection NN I-NP O
18 1219 1226 20103708 against IN B-PP O
19 1227 1235 20103708 diabetic JJ B-NP D003928
20 1236 1247 20103708 nephropathy NN I-NP D003928
21 1248 1250 20103708 is VBZ B-VP O
22 1250 1251 20103708 , , O O
23 1252 1254 20103708 at IN B-ADVP O
24 1255 1260 20103708 least JJS I-ADVP O
25 1260 1261 20103708 , , O O
26 1262 1271 20103708 partially RB B-ADVP O
27 1272 1279 20103708 through IN B-PP O
28 1280 1290 20103708 inhibition NN B-NP O
29 1291 1293 20103708 of IN B-PP O
30 1294 1306 20103708 transforming VBG B-VP O
31 1307 1313 20103708 growth NN B-NP O
32 1314 1320 20103708 factor NN I-NP O
33 1320 1321 20103708 - HYPH B-NP O
34 1321 1326 20103708 beta1 NN I-NP O
35 1327 1328 20103708 ( ( O O
36 1328 1331 20103708 TGF NN B-NP O
37 1331 1332 20103708 - HYPH B-NP O
38 1332 1337 20103708 beta1 NN I-NP O
39 1337 1338 20103708 ) ) O O
40 1339 1342 20103708 and CC O O
41 1343 1352 20103708 reduction NN B-NP O
42 1353 1355 20103708 of IN B-PP O
43 1356 1369 20103708 extracellular JJ B-NP O
44 1370 1376 20103708 matrix NN I-NP O
45 1377 1387 20103708 production NN I-NP O
46 1387 1388 20103708 . . O O

1 1389 1391 20103708 In IN B-PP O
2 1392 1397 20103708 human JJ B-NP O
3 1398 1403 20103708 renal JJ I-NP O
4 1404 1413 20103708 mesangial JJ I-NP O
5 1414 1419 20103708 cells NNS I-NP O
6 1419 1420 20103708 , , O O
7 1421 1425 20103708 high JJ B-NP O
8 1426 1433 20103708 glucose NN I-NP D005947
9 1434 1441 20103708 induced VBD B-VP O
10 1442 1445 20103708 ROS NN B-NP O
11 1446 1456 20103708 production NN I-NP O
12 1457 1460 20103708 and CC O O
13 1461 1470 20103708 activated VBN B-VP O
14 1471 1481 20103708 expression NN B-NP O
15 1482 1484 20103708 of IN B-PP O
16 1485 1489 20103708 Nrf2 NN B-NP O
17 1490 1493 20103708 and CC O O
18 1494 1497 20103708 its PRP$ B-NP O
19 1498 1508 20103708 downstream JJ I-NP O
20 1509 1514 20103708 genes NNS I-NP O
21 1514 1515 20103708 . . O O

1 1516 1527 20103708 Furthermore RB B-ADVP O
2 1527 1528 20103708 , , O O
3 1529 1539 20103708 activation NN B-NP O
4 1540 1542 20103708 or CC O O
5 1543 1557 20103708 overexpression NN B-NP O
6 1558 1560 20103708 of IN B-PP O
7 1561 1565 20103708 Nrf2 NN B-NP O
8 1566 1575 20103708 inhibited VBD B-VP O
9 1576 1579 20103708 the DT B-NP O
10 1580 1588 20103708 promoter NN I-NP O
11 1589 1597 20103708 activity NN I-NP O
12 1598 1600 20103708 of IN B-PP O
13 1601 1604 20103708 TGF NN B-NP O
14 1604 1605 20103708 - HYPH B-NP O
15 1605 1610 20103708 beta1 NN I-NP O
16 1611 1613 20103708 in IN B-PP O
17 1614 1615 20103708 a DT B-NP O
18 1616 1620 20103708 dose NN I-NP O
19 1620 1621 20103708 - HYPH B-NP O
20 1621 1630 20103708 dependent JJ I-NP O
21 1631 1637 20103708 manner NN I-NP O
22 1637 1638 20103708 , , O O
23 1639 1646 20103708 whereas IN O O
24 1647 1656 20103708 knockdown NN B-NP O
25 1657 1659 20103708 of IN B-PP O
26 1660 1664 20103708 Nrf2 NN B-NP O
27 1665 1667 20103708 by IN B-PP O
28 1668 1673 20103708 siRNA NN B-NP O
29 1674 1682 20103708 enhanced VBD B-VP O
30 1683 1686 20103708 TGF NN B-NP O
31 1686 1687 20103708 - HYPH B-NP O
32 1687 1692 20103708 beta1 NN I-NP O
33 1693 1706 20103708 transcription NN I-NP O
34 1707 1710 20103708 and CC O O
35 1711 1722 20103708 fibronectin NN B-NP O
36 1723 1733 20103708 production NN I-NP O
37 1733 1734 20103708 . . O O

1 1735 1746 20103708 CONCLUSIONS NNS B-NP O
2 1746 1747 20103708 : : O O
3 1748 1752 20103708 This DT B-NP O
4 1753 1757 20103708 work NN I-NP O
5 1758 1765 20103708 clearly RB B-ADVP O
6 1766 1775 20103708 indicates VBZ B-VP O
7 1776 1777 20103708 a DT B-NP O
8 1778 1788 20103708 protective JJ I-NP O
9 1789 1793 20103708 role NN I-NP O
10 1794 1796 20103708 of IN B-PP O
11 1797 1801 20103708 Nrf2 NN B-NP O
12 1802 1804 20103708 in IN B-PP O
13 1805 1813 20103708 diabetic JJ B-NP D003928
14 1814 1825 20103708 nephropathy NN I-NP D003928
15 1825 1826 20103708 , , O O
16 1827 1837 20103708 suggesting VBG B-VP O
17 1838 1842 20103708 that IN B-SBAR O
18 1843 1850 20103708 dietary JJ B-NP O
19 1851 1853 20103708 or CC I-NP O
20 1854 1865 20103708 therapeutic JJ I-NP O
21 1866 1876 20103708 activation NN I-NP O
22 1877 1879 20103708 of IN B-PP O
23 1880 1884 20103708 Nrf2 NN B-NP O
24 1885 1890 20103708 could MD B-VP O
25 1891 1893 20103708 be VB I-VP O
26 1894 1898 20103708 used VBN I-VP O
27 1899 1901 20103708 as IN B-PP O
28 1902 1903 20103708 a DT B-NP O
29 1904 1912 20103708 strategy NN I-NP O
30 1913 1915 20103708 to TO B-VP O
31 1916 1923 20103708 prevent VB I-VP O
32 1924 1926 20103708 or CC I-VP O
33 1927 1931 20103708 slow VB I-VP O
34 1932 1936 20103708 down RP B-PRT O
35 1937 1940 20103708 the DT B-NP O
36 1941 1952 20103708 progression NN I-NP O
37 1953 1955 20103708 of IN B-PP O
38 1956 1964 20103708 diabetic JJ B-NP D003928
39 1965 1976 20103708 nephropathy NN I-NP D003928
40 1976 1977 20103708 . . O O

1 0 0 20683499 -DOCSTART- -X- -X- O

1 0 7 20683499 Effects NNS B-NP O
2 8 10 20683499 of IN B-PP O
3 11 17 20683499 active JJ B-NP O
4 18 30 20683499 constituents NNS I-NP O
5 31 33 20683499 of IN B-PP O
6 34 40 20683499 Crocus NNP B-NP O
7 41 48 20683499 sativus NNP I-NP O
8 49 50 20683499 L NNP I-NP O
9 50 51 20683499 . NN I-NP O
10 51 52 20683499 , , O O
11 53 59 20683499 crocin NN B-NP C029036
12 60 62 20683499 on IN B-PP O
13 63 75 20683499 streptozocin NN B-NP D013311
14 75 76 20683499 - HYPH B-NP O
15 76 83 20683499 induced VBN I-NP O
16 84 89 20683499 model NN I-NP O
17 90 92 20683499 of IN B-PP O
18 93 101 20683499 sporadic JJ B-NP O
19 102 113 20683499 Alzheimer's NNP I-NP D000544
20 114 121 20683499 disease NN I-NP D000544
21 122 124 20683499 in IN B-PP O
22 125 129 20683499 male JJ B-NP O
23 130 134 20683499 rats NNS I-NP O
24 134 135 20683499 . . O O
25 136 146 20683499 BACKGROUND NN B-NP O
26 146 147 20683499 : : O O
27 148 151 20683499 The DT B-NP O
28 152 163 20683499 involvement NN I-NP O
29 164 166 20683499 of IN B-PP O
30 167 172 20683499 water NN B-NP O
31 172 173 20683499 - HYPH B-NP O
32 173 180 20683499 soluble JJ I-NP O
33 181 192 20683499 carotenoids NNS I-NP D002338
34 192 193 20683499 , , O O
35 194 201 20683499 crocins NNS B-NP C029036
36 201 202 20683499 , , O O
37 203 205 20683499 as IN B-SBAR O
38 206 209 20683499 the DT B-NP O
39 210 214 20683499 main JJ I-NP O
40 215 218 20683499 and CC I-NP O
41 219 225 20683499 active JJ I-NP O
42 226 236 20683499 components NNS I-NP O
43 237 239 20683499 of IN B-PP O
44 240 246 20683499 Crocus NNP B-NP O
45 247 254 20683499 sativus NNP I-NP O
46 255 256 20683499 L NNP I-NP O
47 256 257 20683499 . . I-NP O
48 258 265 20683499 extract NN I-NP O
49 266 268 20683499 in IN B-PP O
50 269 277 20683499 learning NN B-NP O
51 278 281 20683499 and CC I-NP O
52 282 288 20683499 memory NN I-NP O
53 289 298 20683499 processes NNS I-NP O
54 299 302 20683499 has VBZ B-VP O
55 303 307 20683499 been VBN I-VP O
56 308 316 20683499 proposed VBN I-VP O
57 316 317 20683499 . . O O

1 318 320 20683499 In IN B-PP O
2 321 324 20683499 the DT B-NP O
3 325 332 20683499 present JJ I-NP O
4 333 338 20683499 study NN I-NP O
5 338 339 20683499 , , O O
6 340 343 20683499 the DT B-NP O
7 344 350 20683499 effect NN I-NP O
8 351 353 20683499 of IN B-PP O
9 354 361 20683499 crocins NNS B-NP C029036
10 362 364 20683499 on IN B-PP O
11 365 373 20683499 sporadic JJ B-NP O
12 374 385 20683499 Alzheimer's NNS I-NP D000544
13 386 393 20683499 disease NN I-NP D000544
14 394 401 20683499 induced VBN B-VP O
15 402 404 20683499 by IN B-PP O
16 405 428 20683499 intracerebroventricular JJ B-NP O
17 429 430 20683499 ( ( O O
18 430 433 20683499 icv NN B-NP O
19 433 434 20683499 ) ) O O
20 435 447 20683499 streptozocin NN B-NP D013311
21 448 449 20683499 ( ( O O
22 449 452 20683499 STZ NN B-NP D013311
23 452 453 20683499 ) ) O O
24 454 456 20683499 in IN B-PP O
25 457 461 20683499 male JJ B-NP O
26 462 466 20683499 rats NNS I-NP O
27 467 470 20683499 was VBD B-VP O
28 471 483 20683499 investigated VBN I-VP O
29 483 484 20683499 . . O O

1 485 492 20683499 METHODS NNS B-NP O
2 492 493 20683499 : : O O
3 494 498 20683499 Male JJ B-NP O
4 499 504 20683499 adult JJ I-NP O
5 505 511 20683499 Wistar NNP I-NP O
6 512 516 20683499 rats NNS I-NP O
7 517 518 20683499 ( ( O O
8 518 519 20683499 n NN B-NP O
9 520 521 20683499 = SYM B-VP O
10 522 524 20683499 90 CD B-NP O
11 525 528 20683499 and CC I-NP O
12 529 532 20683499 260 CD I-NP O
13 532 533 20683499 - HYPH I-NP O
14 533 536 20683499 290 CD I-NP O
15 537 538 20683499 g NN I-NP O
16 538 539 20683499 ) ) O O
17 540 544 20683499 were VBD B-VP O
18 545 552 20683499 divided VBN I-VP O
19 553 557 20683499 into IN B-PP O
20 558 559 20683499 1 CD B-NP O
21 559 560 20683499 , , O O
22 561 568 20683499 control NN B-NP O
23 568 569 20683499 ; : O O
24 570 571 20683499 2 CD B-NP O
25 572 575 20683499 and CC I-NP O
26 576 577 20683499 3 CD I-NP O
27 577 578 20683499 , , O O
28 579 586 20683499 crocins NNS B-NP C029036
29 587 588 20683499 ( ( O O
30 588 590 20683499 15 CD B-NP O
31 591 594 20683499 and CC I-NP O
32 595 597 20683499 30 CD I-NP O
33 598 600 20683499 mg NN I-NP O
34 600 601 20683499 / SYM B-NP O
35 601 603 20683499 kg NN I-NP O
36 603 604 20683499 ) ) O O
37 604 605 20683499 ; : O O
38 606 607 20683499 4 CD B-NP O
39 607 608 20683499 , , O O
40 609 612 20683499 STZ NN B-NP D013311
41 612 613 20683499 ; : O O
42 614 615 20683499 5 CD B-NP O
43 616 619 20683499 and CC I-NP O
44 620 621 20683499 6 CD I-NP O
45 621 622 20683499 , , O O
46 623 626 20683499 STZ NN B-NP D013311
47 627 628 20683499 + SYM I-NP O
48 629 636 20683499 crocins NNS I-NP C029036
49 637 638 20683499 ( ( O O
50 638 640 20683499 15 CD B-NP O
51 641 644 20683499 and CC I-NP O
52 645 647 20683499 30 CD I-NP O
53 648 650 20683499 mg NN I-NP O
54 650 651 20683499 / SYM B-NP O
55 651 653 20683499 kg NN I-NP O
56 653 654 20683499 ) ) O O
57 655 661 20683499 groups NNS B-NP O
58 661 662 20683499 . . O O

1 663 665 20683499 In IN B-PP O
2 666 677 20683499 Alzheimer's NNS B-NP D000544
3 678 685 20683499 disease NN I-NP D000544
4 686 692 20683499 groups NNS I-NP O
5 692 693 20683499 , , O O
6 694 698 20683499 rats NNS B-NP O
7 699 703 20683499 were VBD B-VP O
8 704 712 20683499 injected VBN I-VP O
9 713 717 20683499 with IN B-PP O
10 718 721 20683499 STZ NN B-NP D013311
11 721 722 20683499 - HYPH B-NP O
12 722 725 20683499 icv NN I-NP O
13 726 737 20683499 bilaterally RB B-ADVP O
14 738 739 20683499 ( ( O O
15 739 740 20683499 3 CD B-NP O
16 741 743 20683499 mg NN I-NP O
17 743 744 20683499 / SYM B-NP O
18 744 746 20683499 kg NN I-NP O
19 746 747 20683499 ) ) O O
20 748 750 20683499 in IN B-PP O
21 751 756 20683499 first JJ B-NP O
22 757 760 20683499 day NN I-NP O
23 761 764 20683499 and CC O O
24 765 766 20683499 3 CD B-NP O
25 767 771 20683499 days NNS I-NP O
26 772 777 20683499 later RB B-ADVP O
27 777 778 20683499 , , O O
28 779 780 20683499 a DT B-NP O
29 781 788 20683499 similar JJ I-NP O
30 789 792 20683499 STZ NN I-NP D013311
31 792 793 20683499 - HYPH I-NP O
32 793 796 20683499 icv NN I-NP O
33 797 808 20683499 application NN I-NP O
34 809 812 20683499 was VBD B-VP O
35 813 821 20683499 repeated VBN I-VP O
36 821 822 20683499 . . O O

1 823 825 20683499 In IN B-PP O
2 826 829 20683499 STZ NN B-NP D013311
3 830 831 20683499 + CC B-NP O
4 832 838 20683499 crocin NN I-NP C029036
5 839 845 20683499 animal NN I-NP O
6 846 852 20683499 groups NNS I-NP O
7 852 853 20683499 , , O O
8 854 860 20683499 crocin NN B-NP C029036
9 861 864 20683499 was VBD B-VP O
10 865 872 20683499 applied VBN I-VP O
11 873 875 20683499 in IN B-PP O
12 876 881 20683499 doses NNS B-NP O
13 882 884 20683499 of IN B-PP O
14 885 887 20683499 15 CD B-NP O
15 888 891 20683499 and CC I-NP O
16 892 894 20683499 30 CD I-NP O
17 895 897 20683499 mg NN I-NP O
18 897 898 20683499 / SYM O O
19 898 900 20683499 kg NN B-NP O
20 900 901 20683499 , , O O
21 902 905 20683499 i.p NN B-NP O
22 905 906 20683499 . . O O
23 906 907 20683499 , , O O
24 908 911 20683499 one CD B-NP O
25 912 915 20683499 day NN I-NP O
26 916 919 20683499 pre AFX O O
27 919 920 20683499 - HYPH B-NP O
28 920 927 20683499 surgery NN I-NP O
29 928 931 20683499 and CC O O
30 932 941 20683499 continued VBN B-VP O
31 942 945 20683499 for IN B-PP O
32 946 951 20683499 three CD B-NP O
33 952 957 20683499 weeks NNS I-NP O
34 957 958 20683499 . . O O

1 959 971 20683499 Prescription NN B-NP O
2 972 974 20683499 of IN B-PP O
3 975 981 20683499 crocin NN B-NP C029036
4 982 984 20683499 in IN B-PP O
5 985 989 20683499 each DT B-NP O
6 990 994 20683499 dose NN I-NP O
7 995 998 20683499 was VBD B-VP O
8 999 1007 20683499 repeated VBN I-VP O
9 1008 1012 20683499 once RB B-ADVP O
10 1013 1016 20683499 for IN B-PP O
11 1017 1020 20683499 two CD B-NP O
12 1021 1025 20683499 days NNS I-NP O
13 1025 1026 20683499 . . O O

1 1027 1034 20683499 However RB B-ADVP O
2 1034 1035 20683499 , , O O
3 1036 1039 20683499 the DT B-NP O
4 1040 1048 20683499 learning NN I-NP O
5 1049 1052 20683499 and CC I-NP O
6 1053 1059 20683499 memory NN I-NP O
7 1060 1071 20683499 performance NN I-NP O
8 1072 1075 20683499 was VBD B-VP O
9 1076 1084 20683499 assessed VBN I-VP O
10 1085 1090 20683499 using VBG B-VP O
11 1091 1098 20683499 passive JJ B-NP O
12 1099 1108 20683499 avoidance NN I-NP O
13 1109 1117 20683499 paradigm NN I-NP O
14 1117 1118 20683499 , , O O
15 1119 1122 20683499 and CC O O
16 1123 1126 20683499 for IN B-PP O
17 1127 1134 20683499 spatial JJ B-NP O
18 1135 1144 20683499 cognition NN I-NP O
19 1145 1155 20683499 evaluation NN I-NP O
20 1155 1156 20683499 , , O O
21 1157 1158 20683499 Y NN B-NP O
22 1158 1159 20683499 - HYPH B-NP O
23 1159 1163 20683499 maze NN I-NP O
24 1164 1168 20683499 task NN I-NP O
25 1169 1172 20683499 was VBD B-VP O
26 1173 1177 20683499 used VBN I-VP O
27 1177 1178 20683499 . . O O

1 1179 1186 20683499 RESULTS NNS B-NP O
2 1186 1187 20683499 : : O O
3 1188 1190 20683499 It PRP B-NP O
4 1191 1194 20683499 was VBD B-VP O
5 1195 1200 20683499 found VBN I-VP O
6 1201 1204 20683499 out RP B-PRT O
7 1205 1209 20683499 that IN B-SBAR O
8 1210 1216 20683499 crocin NN B-NP C029036
9 1217 1218 20683499 ( ( O O
10 1218 1220 20683499 30 CD B-NP O
11 1221 1223 20683499 mg NN I-NP O
12 1223 1224 20683499 / SYM B-NP O
13 1224 1226 20683499 kg NN I-NP O
14 1226 1227 20683499 ) ) O O
15 1227 1228 20683499 - HYPH O O
16 1228 1235 20683499 treated VBN B-NP O
17 1236 1239 20683499 STZ NN I-NP D013311
18 1239 1240 20683499 - HYPH O O
19 1240 1248 20683499 injected VBN B-NP O
20 1249 1253 20683499 rats NNS I-NP O
21 1254 1258 20683499 show VBP B-VP O
22 1259 1265 20683499 higher JJR B-NP O
23 1266 1273 20683499 correct JJ I-NP O
24 1274 1281 20683499 choices NNS I-NP O
25 1282 1285 20683499 and CC O O
26 1286 1291 20683499 lower JJR B-NP O
27 1292 1298 20683499 errors NNS I-NP O
28 1299 1301 20683499 in IN B-PP O
29 1302 1303 20683499 Y NN B-NP O
30 1303 1304 20683499 - HYPH B-NP O
31 1304 1308 20683499 maze NN I-NP O
32 1309 1313 20683499 than IN B-PP O
33 1314 1321 20683499 vehicle NN B-NP O
34 1321 1322 20683499 - HYPH O O
35 1322 1329 20683499 treated VBN B-NP O
36 1330 1333 20683499 STZ NN I-NP D013311
37 1333 1334 20683499 - HYPH B-NP O
38 1334 1342 20683499 injected VBN I-NP O
39 1343 1347 20683499 rats NNS I-NP O
40 1347 1348 20683499 . . O O

1 1349 1351 20683499 In IN B-PP O
2 1352 1360 20683499 addition NN B-NP O
3 1360 1361 20683499 , , O O
4 1362 1368 20683499 crocin NN B-NP C029036
5 1369 1371 20683499 in IN B-PP O
6 1372 1375 20683499 the DT B-NP O
7 1376 1385 20683499 mentioned VBN I-NP O
8 1386 1390 20683499 dose NN I-NP O
9 1391 1396 20683499 could MD B-VP O
10 1397 1410 20683499 significantly RB I-VP O
11 1411 1421 20683499 attenuated VBD I-VP O
12 1422 1430 20683499 learning NN B-NP D007859
13 1431 1434 20683499 and CC I-NP D007859
14 1435 1441 20683499 memory NN I-NP D007859
15 1442 1452 20683499 impairment NN I-NP D007859
16 1453 1455 20683499 in IN B-PP O
17 1456 1463 20683499 treated VBN B-NP O
18 1464 1467 20683499 STZ NN I-NP D013311
19 1467 1468 20683499 - HYPH B-VP O
20 1468 1476 20683499 injected VBN B-NP O
21 1477 1482 20683499 group NN I-NP O
22 1483 1485 20683499 in IN B-PP O
23 1486 1493 20683499 passive JJ B-NP O
24 1494 1503 20683499 avoidance NN I-NP O
25 1504 1508 20683499 test NN I-NP O
26 1508 1509 20683499 . . O O

1 1510 1520 20683499 CONCLUSION NN B-NP O
2 1520 1521 20683499 : : O O
3 1522 1531 20683499 Therefore RB B-ADVP O
4 1531 1532 20683499 , , O O
5 1533 1538 20683499 these DT B-NP O
6 1539 1546 20683499 results NNS I-NP O
7 1547 1558 20683499 demonstrate VBP B-VP O
8 1559 1562 20683499 the DT B-NP O
9 1563 1576 20683499 effectiveness NN I-NP O
10 1577 1579 20683499 of IN B-PP O
11 1580 1586 20683499 crocin NN B-NP C029036
12 1587 1588 20683499 ( ( O O
13 1588 1590 20683499 30 CD B-NP O
14 1591 1593 20683499 mg NN I-NP O
15 1593 1594 20683499 / SYM B-NP O
16 1594 1596 20683499 kg NN I-NP O
17 1596 1597 20683499 ) ) O O
18 1598 1600 20683499 in IN B-PP O
19 1601 1613 20683499 antagonizing VBG B-VP O
20 1614 1617 20683499 the DT B-NP O
21 1618 1627 20683499 cognitive JJ I-NP D003072
22 1628 1636 20683499 deficits NNS I-NP D003072
23 1637 1643 20683499 caused VBN B-VP O
24 1644 1646 20683499 by IN B-PP O
25 1647 1650 20683499 STZ NN B-NP D013311
26 1650 1651 20683499 - HYPH B-NP O
27 1651 1654 20683499 icv NN I-NP O
28 1655 1657 20683499 in IN B-PP O
29 1658 1662 20683499 rats NNS B-NP O
30 1663 1666 20683499 and CC O O
31 1667 1670 20683499 its PRP$ B-NP O
32 1671 1680 20683499 potential NN I-NP O
33 1681 1683 20683499 in IN B-PP O
34 1684 1687 20683499 the DT B-NP O
35 1688 1697 20683499 treatment NN I-NP O
36 1698 1700 20683499 of IN B-PP O
37 1701 1718 20683499 neurodegenerative JJ B-NP D019636
38 1719 1727 20683499 diseases NNS I-NP D019636
39 1728 1732 20683499 such JJ B-PP O
40 1733 1735 20683499 as IN I-PP O
41 1736 1747 20683499 Alzheimer's NNS B-NP D000544
42 1748 1755 20683499 disease NN I-NP D000544
43 1755 1756 20683499 . . O O

1 0 0 2055425 -DOCSTART- -X- -X- O

1 0 3 2055425 The DT B-NP O
2 4 11 2055425 ability NN I-NP O
3 12 14 2055425 of IN B-PP O
4 15 22 2055425 insulin NN B-NP O
5 23 32 2055425 treatment NN I-NP O
6 33 35 2055425 to TO B-VP O
7 36 43 2055425 reverse VB I-VP O
8 44 46 2055425 or CC I-VP O
9 47 54 2055425 prevent VB I-VP O
10 55 58 2055425 the DT B-NP O
11 59 66 2055425 changes NNS I-NP O
12 67 69 2055425 in IN B-PP O
13 70 77 2055425 urinary JJ B-NP O
14 78 85 2055425 bladder NN I-NP O
15 86 94 2055425 function NN I-NP O
16 95 101 2055425 caused VBN B-VP O
17 102 104 2055425 by IN B-PP O
18 105 119 2055425 streptozotocin NN B-NP D013311
19 119 120 2055425 - HYPH B-NP O
20 120 127 2055425 induced VBN I-NP O
21 128 136 2055425 diabetes NN I-NP D003920
22 137 145 2055425 mellitus NN I-NP D003920
23 145 146 2055425 . . B-NP O
24 147 148 2055425 1 CD I-NP O
25 148 149 2055425 . . O O

1 150 153 2055425 The DT B-NP O
2 154 161 2055425 effects NNS I-NP O
3 162 164 2055425 of IN B-PP O
4 165 172 2055425 insulin NN B-NP O
5 173 182 2055425 treatment NN I-NP O
6 183 185 2055425 on IN B-PP O
7 186 188 2055425 in FW B-ADVP O
8 189 193 2055425 vivo FW I-ADVP O
9 194 197 2055425 and CC O O
10 198 200 2055425 in FW B-NP O
11 201 206 2055425 vitro FW I-NP O
12 207 214 2055425 urinary JJ I-NP O
13 215 222 2055425 bladder NN I-NP O
14 223 231 2055425 function NN I-NP O
15 232 234 2055425 in IN B-PP O
16 235 249 2055425 streptozotocin NN B-NP D013311
17 249 250 2055425 - HYPH B-NP O
18 250 258 2055425 diabetic JJ I-NP D003920
19 259 263 2055425 rats NNS I-NP O
20 264 268 2055425 were VBD B-VP O
21 269 281 2055425 investigated VBN I-VP O
22 281 282 2055425 . . O O

1 283 284 2055425 2 LS B-LST O
2 284 285 2055425 . . O O

1 286 294 2055425 Diabetes NNS B-NP D003920
2 295 297 2055425 of IN B-PP O
3 298 299 2055425 2 CD B-NP O
4 300 306 2055425 months NNS I-NP O
5 307 315 2055425 duration NN I-NP O
6 316 324 2055425 resulted VBD B-VP O
7 325 327 2055425 in IN B-PP O
8 328 337 2055425 decreases NNS B-NP O
9 338 340 2055425 in IN B-PP O
10 341 345 2055425 body NN B-NP O
11 346 352 2055425 weight NN I-NP O
12 353 356 2055425 and CC I-NP O
13 357 366 2055425 increases NNS I-NP O
14 367 369 2055425 in IN B-PP O
15 370 375 2055425 fluid NN B-NP O
16 376 387 2055425 consumption NN I-NP O
17 387 388 2055425 , , O O
18 389 394 2055425 urine NN B-NP O
19 395 401 2055425 volume NN I-NP O
20 401 402 2055425 , , O O
21 403 412 2055425 frequency NN B-NP O
22 413 415 2055425 of IN B-PP O
23 416 427 2055425 micturition NN B-NP O
24 427 428 2055425 , , O O
25 429 432 2055425 and CC O O
26 433 440 2055425 average JJ B-NP O
27 441 447 2055425 volume NN I-NP O
28 448 451 2055425 per IN B-PP O
29 452 463 2055425 micturition NN B-NP O
30 463 464 2055425 ; : O O
31 465 472 2055425 effects NNS B-NP O
32 473 478 2055425 which WDT B-NP O
33 479 483 2055425 were VBD B-VP O
34 484 493 2055425 prevented VBN I-VP O
35 494 496 2055425 by IN B-PP O
36 497 504 2055425 insulin NN B-NP O
37 505 514 2055425 treatment NN I-NP O
38 514 515 2055425 . . O O

1 516 517 2055425 3 LS B-LST O
2 517 518 2055425 . . O O

1 519 526 2055425 Insulin NN B-NP O
2 527 536 2055425 treatment NN I-NP O
3 537 541 2055425 also RB B-ADVP O
4 542 551 2055425 prevented VBD B-VP O
5 552 555 2055425 the DT B-NP O
6 556 565 2055425 increases NNS I-NP O
7 566 568 2055425 in IN B-PP O
8 569 580 2055425 contractile JJ B-NP O
9 581 590 2055425 responses NNS I-NP O
10 591 593 2055425 of IN B-PP O
11 594 601 2055425 bladder NN B-NP O
12 602 606 2055425 body NN I-NP O
13 607 613 2055425 strips NNS I-NP O
14 614 618 2055425 from IN B-PP O
15 619 627 2055425 diabetic JJ B-NP D003920
16 628 632 2055425 rats NNS I-NP O
17 633 635 2055425 to TO B-PP O
18 636 641 2055425 nerve NN B-NP O
19 642 653 2055425 stimulation NN I-NP O
20 653 654 2055425 , , O O
21 655 658 2055425 ATP NN B-NP D000255
22 658 659 2055425 , , O O
23 660 663 2055425 and CC O O
24 664 675 2055425 bethanechol NN B-NP D018723
25 675 676 2055425 . . O O

1 677 678 2055425 4 LS B-LST O
2 678 679 2055425 . . O O

1 680 688 2055425 Diabetes NNS B-NP D003920
2 689 691 2055425 of IN B-PP O
3 692 693 2055425 4 CD B-NP O
4 694 700 2055425 months NNS I-NP O
5 701 709 2055425 duration NN B-NP O
6 710 714 2055425 also RB B-ADVP O
7 715 723 2055425 resulted VBD B-VP O
8 724 726 2055425 in IN B-PP O
9 727 736 2055425 decreases NNS B-NP O
10 737 739 2055425 in IN B-PP O
11 740 744 2055425 body NN B-NP O
12 745 751 2055425 weight NN I-NP O
13 751 752 2055425 , , O O
14 753 756 2055425 and CC O O
15 757 766 2055425 increases NNS B-NP O
16 767 769 2055425 in IN B-PP O
17 770 775 2055425 fluid NN B-NP O
18 776 787 2055425 consumption NN I-NP O
19 787 788 2055425 , , O O
20 789 794 2055425 urine NN B-NP O
21 795 801 2055425 volume NN I-NP O
22 801 802 2055425 , , O O
23 803 812 2055425 frequency NN B-NP O
24 813 815 2055425 of IN B-PP O
25 816 827 2055425 micturition NN B-NP O
26 827 828 2055425 , , O O
27 829 832 2055425 and CC O O
28 833 840 2055425 average JJ B-NP O
29 841 847 2055425 volume NN I-NP O
30 848 851 2055425 per IN B-PP O
31 852 863 2055425 micturition NN B-NP O
32 863 864 2055425 , , O O
33 865 872 2055425 effects NNS B-NP O
34 873 878 2055425 which WDT B-NP O
35 879 883 2055425 were VBD B-VP O
36 884 892 2055425 reversed VBN I-VP O
37 893 895 2055425 by IN B-PP O
38 896 903 2055425 insulin NN B-NP O
39 904 913 2055425 treatment NN I-NP O
40 914 917 2055425 for IN B-PP O
41 918 921 2055425 the DT B-NP O
42 922 927 2055425 final JJ I-NP O
43 928 929 2055425 2 CD I-NP O
44 930 936 2055425 months NNS I-NP O
45 937 939 2055425 of IN B-PP O
46 940 943 2055425 the DT B-NP O
47 944 949 2055425 study NN I-NP O
48 949 950 2055425 . . O O

1 951 952 2055425 5 LS B-LST O
2 952 953 2055425 . . O O

1 954 961 2055425 Insulin NN B-NP O
2 962 971 2055425 treatment NN I-NP O
3 972 980 2055425 reversed VBD B-VP O
4 981 984 2055425 the DT B-NP O
5 985 994 2055425 increases NNS I-NP O
6 995 997 2055425 in IN B-PP O
7 998 1009 2055425 contractile JJ B-NP O
8 1010 1019 2055425 responses NNS I-NP O
9 1020 1022 2055425 of IN B-PP O
10 1023 1030 2055425 bladder NN B-NP O
11 1031 1035 2055425 body NN I-NP O
12 1036 1042 2055425 strips NNS I-NP O
13 1043 1047 2055425 from IN B-PP O
14 1048 1056 2055425 diabetic JJ B-NP D003920
15 1057 1061 2055425 rats NNS I-NP O
16 1062 1064 2055425 to TO B-PP O
17 1065 1070 2055425 nerve NN B-NP O
18 1071 1082 2055425 stimulation NN I-NP O
19 1082 1083 2055425 , , O O
20 1084 1087 2055425 ATP NN B-NP D000255
21 1087 1088 2055425 , , O O
22 1089 1092 2055425 and CC O O
23 1093 1104 2055425 bethanechol NN B-NP D018723
24 1104 1105 2055425 . . O O

1 1106 1107 2055425 6 CD B-NP O
2 1107 1108 2055425 . . O O

1 1109 1112 2055425 The DT B-NP O
2 1113 1117 2055425 data NNS I-NP O
3 1118 1126 2055425 indicate VBP B-VP O
4 1127 1131 2055425 that IN B-SBAR O
5 1132 1135 2055425 the DT B-NP O
6 1136 1143 2055425 effects NNS I-NP O
7 1144 1146 2055425 of IN B-PP O
8 1147 1161 2055425 streptozotocin NN B-NP D013311
9 1161 1162 2055425 - HYPH B-NP O
10 1162 1169 2055425 induced VBN I-NP O
11 1170 1178 2055425 diabetes NNS I-NP D003920
12 1179 1181 2055425 on IN B-PP O
13 1182 1189 2055425 urinary JJ B-NP O
14 1190 1197 2055425 bladder NN I-NP O
15 1198 1206 2055425 function NN I-NP O
16 1207 1210 2055425 are VBP B-VP O
17 1211 1215 2055425 both CC I-VP O
18 1216 1225 2055425 prevented VBN I-VP O
19 1226 1229 2055425 and CC O O
20 1230 1238 2055425 reversed VBN B-VP O
21 1239 1241 2055425 by IN B-PP O
22 1242 1249 2055425 insulin NN B-NP O
23 1250 1259 2055425 treatment NN I-NP O
24 1259 1260 2055425 . . O O

1 0 0 8988571 -DOCSTART- -X- -X- O

1 0 5 8988571 Fatal JJ B-NP O
2 6 13 8988571 excited JJ I-NP O
3 14 22 8988571 delirium NN I-NP D003693
4 23 32 8988571 following VBG B-PP O
5 33 40 8988571 cocaine NN B-NP D003042
6 41 44 8988571 use NN I-NP O
7 44 45 8988571 : : O O
8 46 59 8988571 epidemiologic JJ B-NP O
9 60 68 8988571 findings NNS I-NP O
10 69 76 8988571 provide VBP B-VP O
11 77 80 8988571 new JJ B-NP O
12 81 89 8988571 evidence NN I-NP O
13 90 93 8988571 for IN B-PP O
14 94 104 8988571 mechanisms NNS B-NP O
15 105 107 8988571 of IN B-PP O
16 108 115 8988571 cocaine NN B-NP D003042
17 116 124 8988571 toxicity NN I-NP D064420
18 124 125 8988571 . . O O
19 126 128 8988571 We PRP B-NP O
20 129 137 8988571 describe VBP B-VP O
21 138 140 8988571 an DT B-NP O
22 141 149 8988571 outbreak NN I-NP O
23 150 152 8988571 of IN B-PP O
24 153 159 8988571 deaths NNS B-NP O
25 160 164 8988571 from IN B-PP O
26 165 172 8988571 cocaine NN B-NP D003042
27 172 173 8988571 - HYPH B-NP O
28 173 180 8988571 induced VBN I-NP O
29 181 188 8988571 excited VBN I-NP O
30 189 197 8988571 delirium NN I-NP D003693
31 198 199 8988571 ( ( O O
32 199 203 8988571 EDDs NNS B-NP D003693
33 203 204 8988571 ) ) O O
34 205 207 8988571 in IN B-PP O
35 208 212 8988571 Dade NNP B-NP O
36 213 219 8988571 County NNP I-NP O
37 219 220 8988571 , , O O
38 221 228 8988571 Florida NNP B-NP O
39 229 236 8988571 between IN B-PP O
40 237 241 8988571 1979 CD B-NP O
41 242 245 8988571 and CC I-NP O
42 246 250 8988571 1990 CD I-NP O
43 250 251 8988571 . . O O

1 252 256 8988571 From IN B-PP O
2 257 258 8988571 a DT B-NP O
3 259 267 8988571 registry NN I-NP O
4 268 270 8988571 of IN B-PP O
5 271 274 8988571 all DT B-NP O
6 275 282 8988571 cocaine NN I-NP D003042
7 282 283 8988571 - HYPH B-NP O
8 283 290 8988571 related VBN I-NP O
9 291 297 8988571 deaths NNS I-NP O
10 298 300 8988571 in IN B-PP O
11 301 305 8988571 Dade NNP B-NP O
12 306 312 8988571 County NNP I-NP O
13 312 313 8988571 , , O O
14 314 321 8988571 Florida NNP B-NP O
15 321 322 8988571 , , O O
16 323 327 8988571 from IN B-PP O
17 328 332 8988571 1969 CD B-NP O
18 332 333 8988571 - HYPH I-NP O
19 333 337 8988571 1990 CD I-NP O
20 337 338 8988571 , , I-NP O
21 339 341 8988571 58 CD I-NP O
22 342 346 8988571 EDDs NNS I-NP D003693
23 347 351 8988571 were VBD B-VP O
24 352 360 8988571 compared VBN I-VP O
25 361 365 8988571 with IN B-PP O
26 366 369 8988571 125 CD B-NP O
27 370 377 8988571 victims NNS I-NP O
28 378 380 8988571 of IN B-PP O
29 381 391 8988571 accidental JJ B-NP O
30 392 399 8988571 cocaine NN I-NP D003042
31 400 408 8988571 overdose NN I-NP D062787
32 409 416 8988571 without IN B-PP O
33 417 424 8988571 excited JJ B-NP O
34 425 433 8988571 delirium NN I-NP D003693
35 433 434 8988571 . . O O

1 435 443 8988571 Compared VBN B-PP O
2 444 448 8988571 with IN B-PP O
3 449 457 8988571 controls NNS B-NP O
4 457 458 8988571 , , O O
5 459 463 8988571 EDDs NNS B-NP D003693
6 464 468 8988571 were VBD B-VP O
7 469 473 8988571 more RBR B-ADVP O
8 474 484 8988571 frequently RB I-ADVP O
9 485 490 8988571 black JJ B-NP O
10 490 491 8988571 , , I-NP O
11 492 496 8988571 male JJ I-NP O
12 496 497 8988571 , , I-NP O
13 498 501 8988571 and CC I-NP O
14 502 509 8988571 younger JJR I-NP O
15 509 510 8988571 . . O O

1 511 515 8988571 They PRP B-NP O
2 516 520 8988571 were VBD B-VP O
3 521 525 8988571 less RBR B-ADJP O
4 526 532 8988571 likely JJ I-ADJP O
5 533 535 8988571 to TO B-VP O
6 536 540 8988571 have VB I-VP O
7 541 542 8988571 a DT B-NP O
8 543 546 8988571 low JJ I-NP O
9 547 551 8988571 body NN I-NP O
10 552 556 8988571 mass NN I-NP O
11 557 562 8988571 index NN I-NP O
12 562 563 8988571 , , O O
13 564 567 8988571 and CC O O
14 568 572 8988571 more RBR B-ADJP O
15 573 579 8988571 likely JJ I-ADJP O
16 580 582 8988571 to TO B-VP O
17 583 587 8988571 have VB I-VP O
18 588 592 8988571 died VBN I-VP O
19 593 595 8988571 in IN B-PP O
20 596 602 8988571 police NN B-NP O
21 603 610 8988571 custody NN I-NP O
22 610 611 8988571 , , O O
23 612 614 8988571 to TO B-VP O
24 615 619 8988571 have VB I-VP O
25 620 628 8988571 received VBN I-VP O
26 629 636 8988571 medical JJ B-NP O
27 637 646 8988571 treatment NN I-NP O
28 647 658 8988571 immediately RB B-ADVP O
29 659 665 8988571 before IN B-PP O
30 666 671 8988571 death NN B-NP O
31 671 672 8988571 , , O O
32 673 675 8988571 to TO B-VP O
33 676 680 8988571 have VB I-VP O
34 681 689 8988571 survived VBN I-VP O
35 690 693 8988571 for IN B-PP O
36 694 695 8988571 a DT B-NP O
37 696 702 8988571 longer JJR I-NP O
38 703 709 8988571 period NN I-NP O
39 709 710 8988571 , , O O
40 711 713 8988571 to TO B-VP O
41 714 718 8988571 have VB I-VP O
42 719 728 8988571 developed VBN I-VP O
43 729 741 8988571 hyperthermia NN B-NP D005334
44 741 742 8988571 , , O O
45 743 746 8988571 and CC O O
46 747 749 8988571 to TO B-VP O
47 750 754 8988571 have VB I-VP O
48 755 759 8988571 died VBN I-VP O
49 760 762 8988571 in IN B-PP O
50 763 769 8988571 summer NN B-NP O
51 770 776 8988571 months NNS I-NP O
52 776 777 8988571 . . O O

1 778 782 8988571 EDDs NNS B-NP D003693
2 783 786 8988571 had VBD B-VP O
3 787 801 8988571 concentrations NNS B-NP O
4 802 804 8988571 of IN B-PP O
5 805 812 8988571 cocaine NN B-NP D003042
6 813 816 8988571 and CC I-NP O
7 817 832 8988571 benzoylecgonine NN I-NP C005618
8 833 835 8988571 in IN B-PP O
9 836 843 8988571 autopsy NN B-NP O
10 844 849 8988571 blood NN I-NP O
11 850 854 8988571 that WDT B-NP O
12 855 859 8988571 were VBD B-VP O
13 860 867 8988571 similar JJ B-ADJP O
14 868 870 8988571 to TO B-PP O
15 871 876 8988571 those DT B-NP O
16 877 880 8988571 for IN B-PP O
17 881 889 8988571 controls NNS B-NP O
18 889 890 8988571 . . O O

1 891 894 8988571 The DT B-NP O
2 895 908 8988571 epidemiologic JJ I-NP O
3 909 917 8988571 findings NNS I-NP O
4 918 921 8988571 are VBP B-VP O
5 922 926 8988571 most RBS B-ADJP O
6 927 937 8988571 consistent JJ I-ADJP O
7 938 942 8988571 with IN B-PP O
8 943 946 8988571 the DT B-NP O
9 947 957 8988571 hypothesis NN I-NP O
10 958 962 8988571 that IN B-SBAR O
11 963 970 8988571 chronic JJ B-NP O
12 971 978 8988571 cocaine NN I-NP D003042
13 979 982 8988571 use NN I-NP O
14 983 991 8988571 disrupts VBZ B-VP O
15 992 1004 8988571 dopaminergic JJ B-NP O
16 1005 1013 8988571 function NN I-NP O
17 1014 1017 8988571 and CC O O
18 1017 1018 8988571 , , O O
19 1019 1023 8988571 when WRB B-ADVP O
20 1024 1031 8988571 coupled VBN B-VP O
21 1032 1036 8988571 with IN B-PP O
22 1037 1043 8988571 recent JJ B-NP O
23 1044 1051 8988571 cocaine NN I-NP D003042
24 1052 1055 8988571 use NN I-NP O
25 1055 1056 8988571 , , O O
26 1057 1060 8988571 may MD B-VP O
27 1061 1072 8988571 precipitate VB I-VP O
28 1073 1082 8988571 agitation NN B-NP D011595
29 1082 1083 8988571 , , O O
30 1084 1092 8988571 delirium NN B-NP D003693
31 1092 1093 8988571 , , O O
32 1094 1102 8988571 aberrant JJ B-NP O
33 1103 1119 8988571 thermoregulation NN I-NP O
34 1119 1120 8988571 , , O O
35 1121 1135 8988571 rhabdomyolysis NN B-NP D012206
36 1135 1136 8988571 , , O O
37 1137 1140 8988571 and CC O O
38 1141 1147 8988571 sudden JJ B-NP D003645
39 1148 1153 8988571 death NN I-NP D003645
40 1153 1154 8988571 . . O O

1 0 0 2339463 -DOCSTART- -X- -X- O

1 0 8 2339463 Cerebral JJ B-NP D012851
2 9 14 2339463 sinus NN I-NP D012851
3 15 25 2339463 thrombosis NN I-NP D012851
4 26 28 2339463 as IN B-PP O
5 29 30 2339463 a DT B-NP O
6 31 40 2339463 potential JJ I-NP O
7 41 47 2339463 hazard NN I-NP O
8 48 50 2339463 of IN B-PP O
9 51 67 2339463 antifibrinolytic JJ B-NP O
10 68 77 2339463 treatment NN I-NP O
11 78 80 2339463 in IN B-PP O
12 81 92 2339463 menorrhagia NN B-NP D008595
13 92 93 2339463 . . O O
14 94 96 2339463 We PRP B-NP O
15 97 105 2339463 describe VBP B-VP O
16 106 107 2339463 a DT B-NP O
17 108 110 2339463 42 CD I-NP O
18 110 111 2339463 - HYPH I-NP O
19 111 115 2339463 year NN I-NP O
20 115 116 2339463 - HYPH B-NP O
21 116 119 2339463 old JJ I-NP O
22 120 125 2339463 woman NN I-NP O
23 126 129 2339463 who WP B-NP O
24 130 139 2339463 developed VBD B-VP O
25 140 148 2339463 superior JJ B-NP O
26 149 157 2339463 sagittal JJ I-NP D020225
27 158 161 2339463 and CC I-NP D020225
28 162 166 2339463 left JJ I-NP D020225
29 167 177 2339463 transverse JJ I-NP D020225
30 178 183 2339463 sinus NN I-NP D020225
31 184 194 2339463 thrombosis NN I-NP D020225
32 195 205 2339463 associated VBN B-VP O
33 206 210 2339463 with IN B-PP O
34 211 220 2339463 prolonged VBN B-NP O
35 221 228 2339463 epsilon NN I-NP D015119
36 228 229 2339463 - HYPH B-NP D015119
37 229 241 2339463 aminocaproic JJ I-NP D015119
38 242 246 2339463 acid NN I-NP D015119
39 247 254 2339463 therapy NN I-NP O
40 255 258 2339463 for IN B-PP O
41 259 270 2339463 menorrhagia NN B-NP D008595
42 270 271 2339463 . . O O

1 272 276 2339463 This DT B-NP O
2 277 293 2339463 antifibrinolytic JJ I-NP O
3 294 299 2339463 agent NN I-NP O
4 300 303 2339463 has VBZ B-VP O
5 304 308 2339463 been VBN I-VP O
6 309 313 2339463 used VBN I-VP O
7 314 316 2339463 in IN B-PP O
8 317 322 2339463 women NNS B-NP O
9 323 327 2339463 with IN B-PP O
10 328 339 2339463 menorrhagia NN B-NP D008595
11 340 342 2339463 to TO B-VP O
12 343 350 2339463 promote VB I-VP O
13 351 359 2339463 clotting NN B-NP O
14 360 363 2339463 and CC O O
15 364 370 2339463 reduce VB B-VP O
16 371 376 2339463 blood NN B-NP D006473
17 377 381 2339463 loss NN I-NP D006473
18 381 382 2339463 . . O O

1 383 391 2339463 Although IN B-SBAR O
2 392 401 2339463 increased VBN B-NP O
3 402 406 2339463 risk NN I-NP O
4 407 409 2339463 of IN B-PP O
5 410 424 2339463 thromboembolic JJ B-NP D013923
6 425 432 2339463 disease NN I-NP D013923
7 433 436 2339463 has VBZ B-VP O
8 437 441 2339463 been VBN I-VP O
9 442 450 2339463 reported VBN I-VP O
10 451 457 2339463 during IN B-PP O
11 458 467 2339463 treatment NN B-NP O
12 468 472 2339463 with IN B-PP O
13 473 480 2339463 epsilon NN B-NP D015119
14 480 481 2339463 - HYPH B-NP D015119
15 481 493 2339463 aminocaproic JJ I-NP D015119
16 494 498 2339463 acid NN I-NP D015119
17 498 499 2339463 , , O O
18 500 508 2339463 cerebral JJ B-NP D012851
19 509 514 2339463 sinus NN I-NP D012851
20 515 525 2339463 thrombosis NN I-NP D012851
21 526 529 2339463 has VBZ B-VP O
22 530 533 2339463 not RB I-VP O
23 534 538 2339463 been VBN I-VP O
24 539 549 2339463 previously RB I-VP O
25 550 559 2339463 described VBN I-VP O
26 559 560 2339463 . . O O

1 561 568 2339463 Careful JJ B-NP O
2 569 572 2339463 use NN I-NP O
3 573 575 2339463 of IN B-PP O
4 576 583 2339463 epsilon NN B-NP D015119
5 583 584 2339463 - HYPH B-NP D015119
6 584 596 2339463 aminocaproic JJ I-NP D015119
7 597 601 2339463 acid NN I-NP D015119
8 602 609 2339463 therapy NN I-NP O
9 610 612 2339463 is VBZ B-VP O
10 613 624 2339463 recommended VBN I-VP O
11 624 625 2339463 . . O O

1 0 0 16725121 -DOCSTART- -X- -X- O

1 0 4 16725121 Down RB B-ADVP O
2 4 5 16725121 - HYPH O O
3 5 15 16725121 regulation NN B-NP O
4 16 18 16725121 of IN B-PP O
5 19 33 16725121 norepinephrine NN B-NP D009638
6 34 45 16725121 transporter NN I-NP O
7 46 54 16725121 function NN I-NP O
8 55 62 16725121 induced VBN B-VP O
9 63 65 16725121 by IN B-PP O
10 66 73 16725121 chronic JJ B-NP O
11 74 88 16725121 administration NN I-NP O
12 89 91 16725121 of IN B-PP O
13 92 103 16725121 desipramine NN B-NP D003891
14 104 111 16725121 linking VBG B-VP O
15 112 114 16725121 to TO B-PP O
16 115 118 16725121 the DT B-NP O
17 119 129 16725121 alteration NN I-NP O
18 130 132 16725121 of IN B-PP O
19 133 144 16725121 sensitivity NN B-NP O
20 145 147 16725121 of IN B-PP O
21 148 153 16725121 local JJ B-NP O
22 153 154 16725121 - HYPH I-NP O
23 154 165 16725121 anesthetics NNS I-NP O
24 165 166 16725121 - HYPH B-NP O
25 166 173 16725121 induced VBN I-NP O
26 174 185 16725121 convulsions NNS I-NP D012640
27 186 189 16725121 and CC O O
28 190 193 16725121 the DT B-NP O
29 194 207 16725121 counteraction NN I-NP O
30 208 210 16725121 by IN B-PP O
31 211 213 16725121 co AFX B-NP O
32 213 214 16725121 - HYPH I-NP O
33 214 228 16725121 administration NN I-NP O
34 229 233 16725121 with IN B-PP O
35 234 239 16725121 local JJ B-NP O
36 240 251 16725121 anesthetics NNS I-NP O
37 251 252 16725121 . . O O
38 253 264 16725121 Alterations NNS B-NP O
39 265 267 16725121 of IN B-PP O
40 268 282 16725121 norepinephrine NN B-NP D009638
41 283 294 16725121 transporter NN I-NP O
42 295 296 16725121 ( ( O O
43 296 299 16725121 NET NN B-NP O
44 299 300 16725121 ) ) O O
45 301 309 16725121 function NN B-NP O
46 310 312 16725121 by IN B-PP O
47 313 320 16725121 chronic JJ B-NP O
48 321 331 16725121 inhibition NN I-NP O
49 332 334 16725121 of IN B-PP O
50 335 338 16725121 NET NN B-NP O
51 339 341 16725121 in IN B-PP O
52 342 350 16725121 relation NN B-NP O
53 351 353 16725121 to TO B-PP O
54 354 367 16725121 sensitization NN B-NP O
55 368 370 16725121 to TO B-PP O
56 371 379 16725121 seizures NNS B-NP D012640
57 380 386 16725121 induce VBP B-VP O
58 387 389 16725121 by IN B-PP O
59 390 397 16725121 cocaine NN B-NP D003042
60 398 401 16725121 and CC O O
61 402 407 16725121 local JJ B-NP O
62 408 419 16725121 anesthetics NNS I-NP O
63 420 424 16725121 were VBD B-VP O
64 425 432 16725121 studied VBN I-VP O
65 433 435 16725121 in IN B-PP O
66 436 440 16725121 mice NNS B-NP O
67 440 441 16725121 . . O O

1 442 447 16725121 Daily JJ B-NP O
2 448 462 16725121 administration NN I-NP O
3 463 465 16725121 of IN B-PP O
4 466 477 16725121 desipramine NN B-NP D003891
5 477 478 16725121 , , O O
6 479 481 16725121 an DT B-NP O
7 482 491 16725121 inhibitor NN I-NP O
8 492 494 16725121 of IN B-PP O
9 495 498 16725121 the DT B-NP O
10 499 502 16725121 NET NN I-NP O
11 502 503 16725121 , , O O
12 504 507 16725121 for IN B-PP O
13 508 509 16725121 5 CD B-NP O
14 510 514 16725121 days NNS I-NP O
15 515 524 16725121 decreased VBD B-VP O
16 525 545 16725121 [(3)H]norepinephrine NN B-NP D009638
17 546 552 16725121 uptake NN I-NP O
18 553 555 16725121 in IN B-PP O
19 556 559 16725121 the DT B-NP O
20 560 562 16725121 P2 NN I-NP O
21 563 572 16725121 fractions NNS I-NP O
22 573 575 16725121 of IN B-PP O
23 576 587 16725121 hippocampus NN B-NP O
24 588 591 16725121 but CC B-NP O
25 592 595 16725121 not RB I-NP O
26 596 602 16725121 cortex NN B-NP O
27 602 603 16725121 , , O O
28 604 612 16725121 striatum NN B-NP O
29 613 615 16725121 or CC I-NP O
30 616 625 16725121 amygdalae NN I-NP O
31 625 626 16725121 . . O O

1 627 629 16725121 Co AFX B-NP O
2 629 630 16725121 - HYPH I-NP O
3 630 644 16725121 administration NN B-NP O
4 645 647 16725121 of IN B-PP O
5 648 657 16725121 lidocaine NN B-NP D008012
6 657 658 16725121 , , O O
7 659 670 16725121 bupivacaine NN B-NP D002045
8 671 673 16725121 or CC O O
9 674 682 16725121 tricaine NN B-NP C003636
10 683 687 16725121 with IN B-PP O
11 688 699 16725121 desipramine NN B-NP D003891
12 700 708 16725121 reversed VBD B-VP O
13 709 713 16725121 this DT B-NP O
14 714 720 16725121 effect NN I-NP O
15 720 721 16725121 . . O O

1 722 727 16725121 Daily JJ B-NP O
2 728 737 16725121 treatment NN I-NP O
3 738 740 16725121 of IN B-PP O
4 741 748 16725121 cocaine NN B-NP D003042
5 749 758 16725121 increased VBD B-VP O
6 759 779 16725121 [(3)H]norepinephrine NN B-NP D009638
7 780 786 16725121 uptake NN I-NP O
8 787 791 16725121 into IN B-PP O
9 792 795 16725121 the DT B-NP O
10 796 807 16725121 hippocampus NN I-NP O
11 807 808 16725121 . . O O

1 809 814 16725121 Daily JJ B-NP O
2 815 829 16725121 administration NN I-NP O
3 830 832 16725121 of IN B-PP O
4 833 844 16725121 desipramine NN B-NP D003891
5 845 854 16725121 increased VBD B-VP O
6 855 858 16725121 the DT B-NP O
7 859 868 16725121 incidence NN I-NP O
8 869 871 16725121 of IN B-PP O
9 872 882 16725121 appearance NN B-NP O
10 883 885 16725121 of IN B-PP O
11 886 895 16725121 lidocaine NN B-NP D008012
12 895 896 16725121 - HYPH B-NP O
13 896 903 16725121 induced VBN I-NP O
14 904 915 16725121 convulsions NNS I-NP D012640
15 916 919 16725121 and CC O O
16 920 929 16725121 decreased VBD B-VP O
17 930 934 16725121 that DT B-NP O
18 935 937 16725121 of IN B-PP O
19 938 945 16725121 cocaine NN B-NP D003042
20 945 946 16725121 - HYPH B-NP O
21 946 953 16725121 induced VBN I-NP O
22 954 965 16725121 convulsions NNS I-NP D012640
23 965 966 16725121 . . O O

1 967 969 16725121 Co AFX B-NP O
2 969 970 16725121 - HYPH I-NP O
3 970 984 16725121 administration NN B-NP O
4 985 987 16725121 of IN B-PP O
5 988 997 16725121 lidocaine NN B-NP D008012
6 998 1002 16725121 with IN B-PP O
7 1003 1014 16725121 desipramine NN B-NP D003891
8 1015 1023 16725121 reversed VBD B-VP O
9 1024 1027 16725121 the DT B-NP O
10 1028 1035 16725121 changes NNS I-NP O
11 1036 1038 16725121 of IN B-PP O
12 1039 1049 16725121 convulsive JJ B-NP D012640
13 1050 1058 16725121 activity NN I-NP O
14 1059 1061 16725121 of IN B-PP O
15 1062 1071 16725121 lidocaine NN B-NP D008012
16 1072 1075 16725121 and CC I-NP O
17 1076 1083 16725121 cocaine NN I-NP D003042
18 1084 1091 16725121 induced VBN B-VP O
19 1092 1094 16725121 by IN B-PP O
20 1095 1103 16725121 repeated VBN B-NP O
21 1104 1118 16725121 administration NN I-NP O
22 1119 1121 16725121 of IN B-PP O
23 1122 1133 16725121 desipramine NN B-NP D003891
24 1133 1134 16725121 . . O O

1 1135 1140 16725121 These DT B-NP O
2 1141 1148 16725121 results NNS I-NP O
3 1149 1156 16725121 suggest VBP B-VP O
4 1157 1161 16725121 that IN B-ADVP O
5 1162 1166 16725121 down RB I-ADVP O
6 1166 1167 16725121 - HYPH O O
7 1167 1177 16725121 regulation NN B-NP O
8 1178 1180 16725121 of IN B-PP O
9 1181 1192 16725121 hippocampal JJ B-NP O
10 1193 1196 16725121 NET NN I-NP O
11 1197 1204 16725121 induced VBN B-VP O
12 1205 1207 16725121 by IN B-PP O
13 1208 1215 16725121 chronic JJ B-NP O
14 1216 1230 16725121 administration NN I-NP O
15 1231 1233 16725121 of IN B-PP O
16 1234 1245 16725121 desipramine NN B-NP D003891
17 1246 1249 16725121 may MD B-VP O
18 1250 1252 16725121 be VB I-VP O
19 1253 1261 16725121 relevant JJ B-ADJP O
20 1262 1264 16725121 to TO B-PP O
21 1265 1276 16725121 desipramine NN B-NP D003891
22 1276 1277 16725121 - HYPH B-NP O
23 1277 1284 16725121 induced VBN I-NP O
24 1285 1298 16725121 sensitization NN I-NP O
25 1299 1301 16725121 of IN B-PP O
26 1302 1311 16725121 lidocaine NN B-NP D008012
27 1312 1323 16725121 convulsions NNS I-NP D012640
28 1323 1324 16725121 . . O O

1 1325 1335 16725121 Inhibition NN B-NP O
2 1336 1338 16725121 of IN B-PP O
3 1339 1344 16725121 Na(+) NN B-NP D012964
4 1345 1353 16725121 channels NNS I-NP O
5 1354 1356 16725121 by IN B-PP O
6 1357 1362 16725121 local JJ B-NP O
7 1363 1374 16725121 anesthetics NNS I-NP O
8 1375 1378 16725121 may MD B-VP O
9 1379 1387 16725121 regulate VB I-VP O
10 1388 1399 16725121 desipramine NN B-NP D003891
11 1399 1400 16725121 - HYPH O O
12 1400 1407 16725121 induced VBN B-VP O
13 1408 1412 16725121 down RB B-ADVP O
14 1412 1413 16725121 - HYPH B-NP O
15 1413 1423 16725121 regulation NN I-NP O
16 1424 1426 16725121 of IN B-PP O
17 1427 1430 16725121 NET NN B-NP O
18 1431 1439 16725121 function NN I-NP O
19 1439 1440 16725121 . . O O

1 1441 1449 16725121 Repeated VBN B-NP O
2 1450 1464 16725121 administration NN I-NP O
3 1465 1467 16725121 of IN B-PP O
4 1468 1475 16725121 cocaine NN B-NP D003042
5 1476 1483 16725121 induces VBZ B-VP O
6 1484 1486 16725121 up RB B-ADVP O
7 1486 1487 16725121 - HYPH B-NP O
8 1487 1497 16725121 regulation NN I-NP O
9 1498 1500 16725121 of IN B-PP O
10 1501 1512 16725121 hippocampal JJ B-NP O
11 1513 1516 16725121 NET NN I-NP O
12 1517 1525 16725121 function NN I-NP O
13 1525 1526 16725121 . . O O

1 1527 1538 16725121 Desipramine NN B-NP D003891
2 1538 1539 16725121 - HYPH B-NP O
3 1539 1546 16725121 induced VBN I-NP O
4 1547 1560 16725121 sensitization NN I-NP O
5 1561 1563 16725121 of IN B-PP O
6 1564 1573 16725121 lidocaine NN B-NP D008012
7 1574 1582 16725121 seizures NNS I-NP D012640
8 1583 1586 16725121 may MD B-VP O
9 1587 1591 16725121 have VB I-VP O
10 1592 1593 16725121 a DT B-NP O
11 1594 1603 16725121 mechanism NN I-NP O
12 1604 1612 16725121 distinct JJ B-ADJP O
13 1613 1617 16725121 from IN B-PP O
14 1618 1626 16725121 kindling VBG B-VP O
15 1627 1636 16725121 resulting VBG B-VP O
16 1637 1641 16725121 from IN B-PP O
17 1642 1650 16725121 repeated VBN B-NP O
18 1651 1665 16725121 administration NN I-NP O
19 1666 1668 16725121 of IN B-PP O
20 1669 1676 16725121 cocaine NN B-NP D003042
21 1676 1677 16725121 . . O O

1 0 0 2840807 -DOCSTART- -X- -X- O

1 0 1 2840807 A DT B-NP O
2 2 10 2840807 dystonia NN I-NP D004421
3 10 11 2840807 - HYPH B-NP O
4 11 15 2840807 like JJ I-NP O
5 16 24 2840807 syndrome NN I-NP O
6 25 30 2840807 after IN B-PP O
7 31 43 2840807 neuropeptide NN B-NP O
8 44 45 2840807 ( ( O O
9 45 48 2840807 MSH NN B-NP D009074
10 48 49 2840807 / SYM O O
11 49 53 2840807 ACTH NN O D000324
12 53 54 2840807 ) ) O O
13 55 66 2840807 stimulation NN B-NP O
14 67 69 2840807 of IN B-PP O
15 70 73 2840807 the DT B-NP O
16 74 77 2840807 rat NN I-NP O
17 78 83 2840807 locus NN I-NP O
18 84 92 2840807 ceruleus NN I-NP O
19 92 93 2840807 . . O O
20 94 97 2840807 The DT B-NP O
21 98 106 2840807 movement NN I-NP D009069
22 107 115 2840807 disorder NN I-NP D009069
23 116 128 2840807 investigated VBN B-VP O
24 129 131 2840807 in IN B-PP O
25 132 137 2840807 these DT B-NP O
26 138 145 2840807 studies NNS I-NP O
27 146 149 2840807 has VBZ B-VP O
28 150 154 2840807 some DT B-NP O
29 155 163 2840807 features NNS I-NP O
30 164 166 2840807 in IN B-PP O
31 167 173 2840807 common JJ B-ADJP O
32 174 178 2840807 with IN B-PP O
33 179 184 2840807 human JJ B-NP O
34 185 195 2840807 idiopathic JJ I-NP O
35 196 204 2840807 dystonia NN I-NP D004421
36 204 205 2840807 , , O O
37 206 209 2840807 and CC O O
38 210 221 2840807 information NN B-NP O
39 222 230 2840807 obtained VBN B-VP O
40 231 233 2840807 in IN B-PP O
41 234 239 2840807 these DT B-NP O
42 240 247 2840807 studies NNS I-NP O
43 248 251 2840807 may MD B-VP O
44 252 254 2840807 be VB I-VP O
45 255 257 2840807 of IN B-PP O
46 258 267 2840807 potential JJ B-NP O
47 268 276 2840807 clinical JJ I-NP O
48 277 284 2840807 benefit NN I-NP O
49 284 285 2840807 . . O O

1 286 289 2840807 The DT B-NP O
2 290 297 2840807 present JJ I-NP O
3 298 310 2840807 experimental JJ I-NP O
4 311 318 2840807 results NNS I-NP O
5 319 328 2840807 indicated VBD B-VP O
6 329 333 2840807 that IN B-SBAR O
7 334 345 2840807 peptidergic JJ B-NP O
8 346 357 2840807 stimulation NN I-NP O
9 358 360 2840807 of IN B-PP O
10 361 364 2840807 the DT B-NP O
11 365 367 2840807 LC NN I-NP O
12 368 376 2840807 resulted VBD B-VP O
13 377 379 2840807 in IN B-PP O
14 380 381 2840807 a DT B-NP O
15 382 384 2840807 NE NN I-NP O
16 384 385 2840807 - HYPH O O
17 385 393 2840807 mediated VBN B-NP O
18 394 404 2840807 inhibition NN I-NP O
19 405 407 2840807 of IN B-PP O
20 408 418 2840807 cerebellar JJ B-NP O
21 419 427 2840807 Purkinje NN I-NP O
22 428 433 2840807 cells NNS I-NP O
23 434 441 2840807 located VBN B-VP O
24 442 444 2840807 at IN B-PP O
25 445 454 2840807 terminals NNS B-NP O
26 455 457 2840807 of IN B-PP O
27 458 461 2840807 the DT B-NP O
28 462 469 2840807 ceruleo AFX I-NP O
29 469 470 2840807 - HYPH I-NP O
30 470 480 2840807 cerebellar JJ I-NP O
31 481 488 2840807 pathway NN I-NP O
32 488 489 2840807 . . O O

1 490 497 2840807 However RB B-ADVP O
2 497 498 2840807 , , O O
3 499 501 2840807 it PRP B-NP O
4 502 504 2840807 is VBZ B-VP O
5 505 508 2840807 not RB B-ADJP O
6 509 516 2840807 certain JJ I-ADJP O
7 517 519 2840807 as IN B-PP O
8 520 522 2840807 to TO B-PP O
9 523 526 2840807 the DT B-NP O
10 527 536 2840807 following NN I-NP O
11 536 537 2840807 : : O O
12 538 539 2840807 ( ( B-LST O
13 539 540 2840807 a LS I-LST O
14 540 541 2840807 ) ) O O
15 542 546 2840807 what WP B-NP O
16 547 556 2840807 receptors NNS I-NP O
17 557 561 2840807 were VBD B-VP O
18 562 572 2840807 stimulated VBN I-VP O
19 573 575 2840807 by IN B-PP O
20 576 579 2840807 the DT B-NP O
21 580 584 2840807 ACTH NN I-NP D000324
22 585 586 2840807 N NN I-NP O
23 586 587 2840807 - HYPH B-NP O
24 587 595 2840807 terminal JJ I-NP O
25 596 605 2840807 fragments NNS I-NP O
26 606 608 2840807 at IN B-PP O
27 609 612 2840807 the DT B-NP O
28 613 615 2840807 LC NN I-NP O
29 616 620 2840807 that WDT B-NP O
30 621 629 2840807 resulted VBD B-VP O
31 630 632 2840807 in IN B-PP O
32 633 637 2840807 this DT B-NP O
33 638 646 2840807 disorder NN I-NP O
34 646 647 2840807 ; : O O
35 648 649 2840807 ( ( B-LST O
36 649 650 2840807 b LS I-LST O
37 650 651 2840807 ) ) O O
38 652 659 2840807 whether IN B-SBAR O
39 660 662 2840807 NE NN B-NP O
40 662 663 2840807 , , O O
41 664 672 2840807 released VBN B-VP O
42 673 677 2840807 onto IN B-PP O
43 678 686 2840807 Purkinje NN B-NP O
44 687 691 2840807 cell NN I-NP O
45 692 700 2840807 synapses NNS I-NP O
46 701 708 2840807 located VBN B-VP O
47 709 711 2840807 at IN B-PP O
48 712 721 2840807 terminals NNS B-NP O
49 722 724 2840807 of IN B-PP O
50 725 728 2840807 the DT B-NP O
51 729 736 2840807 ceruleo AFX I-NP O
52 736 737 2840807 - HYPH I-NP O
53 737 747 2840807 cerebellar JJ I-NP O
54 748 755 2840807 pathway NN I-NP O
55 755 756 2840807 , , O O
56 757 760 2840807 did VBD B-VP O
57 761 767 2840807 indeed RB I-VP O
58 768 773 2840807 cause VB I-VP O
59 774 777 2840807 the DT B-NP O
60 778 782 2840807 long JJ I-NP O
61 782 783 2840807 - HYPH I-NP O
62 783 787 2840807 term NN I-NP O
63 788 798 2840807 depression NN I-NP D003866
64 799 801 2840807 at IN B-PP O
65 802 810 2840807 Purkinje NNP B-NP O
66 811 815 2840807 cell NN I-NP O
67 816 824 2840807 synapses NNS I-NP O
68 825 826 2840807 ( ( O O
69 826 836 2840807 previously RB B-VP O
70 837 846 2840807 described VBN I-VP O
71 847 849 2840807 by IN B-PP O
72 850 856 2840807 others NNS B-NP O
73 856 857 2840807 ) ) O O
74 858 862 2840807 that WDT B-NP O
75 863 871 2840807 resulted VBD B-VP O
76 872 874 2840807 in IN B-PP O
77 875 878 2840807 the DT B-NP O
78 879 883 2840807 long JJ I-NP O
79 884 892 2840807 duration NN I-NP O
80 893 895 2840807 of IN B-PP O
81 896 899 2840807 the DT B-NP O
82 900 908 2840807 movement NN I-NP D009069
83 909 917 2840807 disorder NN I-NP D009069
84 917 918 2840807 ; : O O
85 919 920 2840807 ( ( B-LST O
86 920 921 2840807 c LS I-LST O
87 921 922 2840807 ) ) O O
88 923 930 2840807 whether IN B-SBAR O
89 931 934 2840807 the DT B-NP O
90 935 945 2840807 inhibition NN I-NP O
91 946 948 2840807 of IN B-PP O
92 949 959 2840807 inhibitory JJ B-NP O
93 960 968 2840807 Purkinje NN I-NP O
94 969 974 2840807 cells NNS I-NP O
95 975 983 2840807 resulted VBD B-VP O
96 984 986 2840807 in IN B-PP O
97 987 1000 2840807 disinhibition NN B-NP O
98 1001 1003 2840807 or CC O O
99 1004 1013 2840807 increased VBN B-NP O
100 1014 1026 2840807 excitability NN I-NP O
101 1027 1029 2840807 of IN B-PP O
102 1030 1033 2840807 the DT B-NP O
103 1034 1044 2840807 unilateral JJ I-NP O
104 1045 1055 2840807 cerebellar JJ I-NP O
105 1056 1065 2840807 fastigial JJ I-NP O
106 1066 1068 2840807 or CC I-NP O
107 1069 1081 2840807 interpositus NN I-NP O
108 1082 1088 2840807 nuclei NNS I-NP O
109 1088 1089 2840807 , , O O
110 1090 1093 2840807 the DT B-NP O
111 1094 1100 2840807 output NN I-NP O
112 1101 1108 2840807 targets NNS I-NP O
113 1109 1111 2840807 of IN B-PP O
114 1112 1115 2840807 the DT B-NP O
115 1116 1124 2840807 Purkinje NNP I-NP O
116 1125 1129 2840807 cell NN I-NP O
117 1130 1135 2840807 axons NNS I-NP O
118 1135 1136 2840807 , , O O
119 1137 1141 2840807 that WDT B-NP O
120 1142 1145 2840807 may MD B-VP O
121 1146 1150 2840807 have VB I-VP O
122 1151 1155 2840807 been VBN I-VP O
123 1156 1158 2840807 an DT B-NP O
124 1159 1168 2840807 important JJ I-NP O
125 1169 1181 2840807 contributing VBG I-NP O
126 1182 1188 2840807 factor NN I-NP O
127 1189 1191 2840807 to TO B-PP O
128 1192 1196 2840807 this DT B-NP O
129 1197 1205 2840807 disorder NN I-NP O
130 1205 1206 2840807 . . O O

1 1207 1212 2840807 These DT B-NP O
2 1213 1222 2840807 questions NNS I-NP O
3 1223 1226 2840807 are VBP B-VP O
4 1227 1236 2840807 currently RB I-VP O
5 1237 1242 2840807 being VBG I-VP O
6 1243 1255 2840807 investigated VBN I-VP O
7 1255 1256 2840807 . . O O

1 0 0 12452237 -DOCSTART- -X- -X- O

1 0 3 12452237 Can MD O O
2 4 13 12452237 lidocaine NN B-NP D008012
3 14 20 12452237 reduce VB B-VP O
4 21 36 12452237 succinylcholine NN B-NP D013390
5 37 44 12452237 induced JJ I-NP O
6 45 58 12452237 postoperative JJ I-NP D010149
7 59 66 12452237 myalgia NN I-NP D010149
8 66 67 12452237 ? . O O
9 68 72 12452237 This DT B-NP O
10 73 78 12452237 study NN I-NP O
11 79 82 12452237 was VBD B-VP O
12 83 93 12452237 undertaken VBN I-VP O
13 94 96 12452237 to TO B-VP O
14 97 106 12452237 determine VB I-VP O
15 107 110 12452237 the DT B-NP O
16 111 117 12452237 effect NN I-NP O
17 118 120 12452237 of IN B-PP O
18 121 130 12452237 lidocaine NN B-NP D008012
19 131 143 12452237 pretreatment NN I-NP O
20 144 146 12452237 on IN B-PP O
21 147 156 12452237 reduction NN B-NP O
22 157 159 12452237 of IN B-PP O
23 160 175 12452237 succinylcholine NN B-NP D013390
24 175 176 12452237 - HYPH B-NP O
25 176 183 12452237 induced VBN I-NP O
26 184 191 12452237 myalgia NN I-NP D063806
27 192 194 12452237 in IN B-PP O
28 195 203 12452237 patients NNS B-NP O
29 204 214 12452237 undergoing VBG B-VP O
30 215 222 12452237 general JJ B-NP O
31 223 233 12452237 anesthesia NN I-NP O
32 234 237 12452237 for IN B-PP O
33 238 251 12452237 gynecological JJ B-NP O
34 252 259 12452237 surgery NN I-NP O
35 259 260 12452237 . . O O

1 261 264 12452237 One CD B-NP O
2 265 272 12452237 hundred CD I-NP O
3 273 276 12452237 and CC I-NP O
4 277 283 12452237 thirty CD I-NP O
5 283 284 12452237 - HYPH I-NP O
6 284 288 12452237 five CD I-NP O
7 289 297 12452237 patients NNS I-NP O
8 298 302 12452237 were VBD B-VP O
9 303 311 12452237 assigned VBN I-VP O
10 312 314 12452237 to TO B-PP O
11 315 318 12452237 one CD B-NP O
12 319 321 12452237 of IN B-PP O
13 322 327 12452237 three CD B-NP O
14 328 334 12452237 groups NNS I-NP O
15 335 337 12452237 in IN B-PP O
16 338 339 12452237 a DT B-NP O
17 340 351 12452237 prospective JJ I-NP O
18 351 352 12452237 , , I-NP O
19 353 359 12452237 double JJ I-NP O
20 360 365 12452237 blind JJ I-NP O
21 365 366 12452237 , , I-NP O
22 367 377 12452237 randomized VBN I-NP O
23 378 384 12452237 manner NN I-NP O
24 384 385 12452237 . . O O

1 386 391 12452237 Group NNP B-NP O
2 392 394 12452237 PS NNP I-NP O
3 394 395 12452237 , , O O
4 396 399 12452237 the DT B-NP O
5 400 407 12452237 control NN I-NP O
6 408 413 12452237 group NN I-NP O
7 413 414 12452237 , , O O
8 415 423 12452237 received VBD B-VP O
9 424 430 12452237 normal JJ B-NP O
10 431 437 12452237 saline NN I-NP O
11 438 441 12452237 and CC I-NP O
12 442 457 12452237 succinylcholine NN I-NP D013390
13 458 461 12452237 1.5 CD I-NP O
14 462 464 12452237 mg NN I-NP O
15 465 466 12452237 x SYM B-NP O
16 467 470 12452237 kg( NN I-NP O
17 470 471 12452237 - HYPH B-NP O
18 471 473 12452237 1) NN I-NP O
19 473 474 12452237 ; : O O
20 475 480 12452237 Group NN B-NP O
21 481 483 12452237 LS NN I-NP O
22 483 484 12452237 , , O O
23 485 494 12452237 lidocaine NN B-NP D008012
24 495 498 12452237 1.5 CD I-NP O
25 499 501 12452237 mg NN I-NP O
26 502 503 12452237 x SYM B-NP O
27 504 507 12452237 kg( NN I-NP O
28 507 508 12452237 - HYPH B-NP O
29 508 510 12452237 1) NN I-NP O
30 511 514 12452237 and CC I-NP O
31 515 530 12452237 succinylcholine NN I-NP D013390
32 531 534 12452237 1.5 CD I-NP O
33 535 537 12452237 mg NN I-NP O
34 538 539 12452237 x SYM B-NP O
35 540 543 12452237 kg( NN I-NP O
36 543 544 12452237 - HYPH B-NP O
37 544 546 12452237 1) NN I-NP O
38 546 547 12452237 ; : O O
39 548 553 12452237 Group NN B-NP O
40 554 556 12452237 PR NN I-NP O
41 556 557 12452237 , , O O
42 558 564 12452237 normal JJ B-NP O
43 565 571 12452237 saline NN I-NP O
44 572 575 12452237 and CC O O
45 576 586 12452237 rocuronium NN B-NP C061870
46 587 590 12452237 0.6 CD I-NP O
47 591 593 12452237 mg NN I-NP O
48 594 595 12452237 x SYM B-NP O
49 596 599 12452237 kg( ( O O
50 599 600 12452237 - HYPH O O
51 600 602 12452237 1) LS B-LST O
52 602 603 12452237 . . O O

1 604 612 12452237 Morphine NN B-NP D009020
2 613 616 12452237 0.1 CD I-NP O
3 617 619 12452237 mg NN I-NP O
4 620 621 12452237 x SYM B-NP O
5 622 625 12452237 kg( NN I-NP O
6 625 626 12452237 - HYPH B-NP O
7 626 628 12452237 1) NN I-NP O
8 629 631 12452237 iv NN I-NP O
9 632 635 12452237 was VBD B-VP O
10 636 641 12452237 given VBN I-VP O
11 642 645 12452237 for IN B-PP O
12 646 659 12452237 premedication NN B-NP O
13 660 663 12452237 and CC O O
14 664 667 12452237 all DT B-NP O
15 668 676 12452237 patients NNS I-NP O
16 677 681 12452237 were VBD B-VP O
17 682 691 12452237 monitored VBN I-VP O
18 692 696 12452237 with IN B-PP O
19 697 698 12452237 a DT B-NP O
20 699 710 12452237 noninvasive JJ I-NP O
21 711 716 12452237 blood NN I-NP O
22 717 725 12452237 pressure NN I-NP O
23 726 733 12452237 monitor NN I-NP O
24 733 734 12452237 , , O O
25 735 738 12452237 ECG NN B-NP O
26 739 742 12452237 and CC O O
27 743 748 12452237 pulse NN B-NP O
28 749 757 12452237 oximetry NN I-NP O
29 757 758 12452237 . . O O

1 759 769 12452237 Anesthesia NNP B-NP O
2 770 773 12452237 was VBD B-VP O
3 774 781 12452237 induced VBN I-VP O
4 782 786 12452237 with IN B-PP O
5 787 788 12452237 5 CD B-NP O
6 789 795 12452237 mg.kg( NN I-NP O
7 795 796 12452237 - HYPH O O
8 796 798 12452237 1) LS B-NP O
9 799 809 12452237 thiopental JJ I-NP D013874
10 810 812 12452237 iv NN I-NP O
11 812 813 12452237 . . O O

1 814 822 12452237 followed VBN B-VP O
2 823 825 12452237 by IN B-PP O
3 826 841 12452237 succinylcholine NN B-NP D013390
4 842 843 12452237 ( ( O O
5 843 848 12452237 Group NN B-NP O
6 849 851 12452237 PS NN I-NP O
7 851 852 12452237 , , O O
8 853 855 12452237 LS NN B-NP O
9 855 856 12452237 ) ) O O
10 857 859 12452237 or CC O O
11 860 870 12452237 rocuronium NN B-NP C061870
12 871 872 12452237 ( ( O O
13 872 877 12452237 Group NN B-NP O
14 878 880 12452237 PR NN I-NP O
15 880 881 12452237 ) ) O O
16 882 885 12452237 for IN B-PP O
17 886 894 12452237 tracheal JJ B-NP O
18 895 905 12452237 intubation NN I-NP O
19 905 906 12452237 . . O O

1 907 916 12452237 Following VBG B-PP O
2 917 931 12452237 administration NN B-NP O
3 932 934 12452237 of IN B-PP O
4 935 940 12452237 these DT B-NP O
5 941 947 12452237 agents NNS I-NP O
6 947 948 12452237 , , O O
7 949 952 12452237 the DT B-NP O
8 953 961 12452237 presence NN I-NP O
9 961 962 12452237 , , O O
10 963 966 12452237 and CC O O
11 967 973 12452237 degree NN B-NP O
12 974 976 12452237 of IN B-PP O
13 977 990 12452237 fasciculation NN B-NP D005207
14 991 995 12452237 were VBD B-VP O
15 996 1004 12452237 assessed VBN I-VP O
16 1005 1013 12452237 visually RB B-ADVP O
17 1014 1016 12452237 on IN B-PP O
18 1017 1018 12452237 a DT B-NP O
19 1019 1023 12452237 four CD I-NP O
20 1024 1029 12452237 point NN I-NP O
21 1030 1035 12452237 scale NN I-NP O
22 1036 1038 12452237 by IN B-PP O
23 1039 1042 12452237 one CD B-NP O
24 1043 1055 12452237 investigator NN I-NP O
25 1056 1059 12452237 who WP B-NP O
26 1060 1063 12452237 was VBD B-VP O
27 1064 1071 12452237 blinded VBN I-VP O
28 1072 1074 12452237 to TO B-PP O
29 1075 1078 12452237 the DT B-NP O
30 1079 1083 12452237 drug NN I-NP O
31 1084 1096 12452237 administered VBN B-VP O
32 1096 1097 12452237 . . O O

1 1098 1101 12452237 The DT B-NP O
2 1102 1107 12452237 blood NN I-NP O
3 1108 1116 12452237 pressure NN I-NP O
4 1117 1120 12452237 and CC I-NP O
5 1121 1126 12452237 heart NN I-NP O
6 1127 1131 12452237 rate NN I-NP O
7 1132 1134 12452237 of IN B-PP O
8 1135 1139 12452237 each DT B-NP O
9 1140 1147 12452237 patient NN I-NP O
10 1148 1152 12452237 were VBD B-VP O
11 1153 1162 12452237 monitored VBN I-VP O
12 1163 1165 12452237 on IN B-PP O
13 1166 1170 12452237 nine CD B-NP O
14 1171 1180 12452237 occasions NNS I-NP O
15 1180 1181 12452237 . . O O

1 1182 1188 12452237 Twenty CD B-NP O
2 1188 1189 12452237 - HYPH I-NP O
3 1189 1193 12452237 four CD I-NP O
4 1194 1199 12452237 hours NNS I-NP O
5 1200 1205 12452237 later RB B-ADVP O
6 1205 1206 12452237 , , O O
7 1207 1210 12452237 any DT B-NP O
8 1211 1218 12452237 myalgia NN I-NP D063806
9 1219 1230 12452237 experienced VBN B-VP O
10 1231 1234 12452237 was VBD B-VP O
11 1235 1243 12452237 assessed VBN I-VP O
12 1244 1253 12452237 according VBG B-PP O
13 1254 1256 12452237 to TO B-PP O
14 1257 1258 12452237 a DT B-NP O
15 1259 1269 12452237 structured JJ I-NP O
16 1270 1282 12452237 questionaire NN I-NP O
17 1283 1286 12452237 and CC O O
18 1287 1293 12452237 graded VBN B-VP O
19 1294 1296 12452237 by IN B-PP O
20 1297 1298 12452237 a DT B-NP O
21 1299 1303 12452237 four CD I-NP O
22 1304 1309 12452237 point NN I-NP O
23 1310 1315 12452237 scale NN I-NP O
24 1316 1318 12452237 by IN B-PP O
25 1319 1322 12452237 one CD B-NP O
26 1323 1335 12452237 investigator NN I-NP O
27 1336 1343 12452237 blinded VBN B-VP O
28 1344 1346 12452237 to TO B-PP O
29 1347 1350 12452237 the DT B-NP O
30 1351 1365 12452237 intraoperative JJ I-NP O
31 1366 1376 12452237 management NN I-NP O
32 1376 1377 12452237 . . O O

1 1378 1381 12452237 The DT B-NP O
2 1382 1389 12452237 results NNS I-NP O
3 1390 1398 12452237 indicate VBP B-VP O
4 1399 1403 12452237 that IN B-SBAR O
5 1404 1410 12452237 muscle NN B-NP D005207
6 1411 1424 12452237 fasciculation NN I-NP D005207
7 1425 1428 12452237 was VBD B-VP O
8 1429 1432 12452237 not RB I-VP O
9 1433 1438 12452237 found VBN I-VP O
10 1439 1441 12452237 in IN B-PP O
11 1442 1447 12452237 Group NN B-NP O
12 1448 1450 12452237 PR NN I-NP O
13 1451 1456 12452237 while IN B-SBAR O
14 1457 1460 12452237 the DT B-NP O
15 1461 1469 12452237 patients NNS I-NP O
16 1470 1472 12452237 in IN B-PP O
17 1473 1478 12452237 Group NN B-NP O
18 1479 1481 12452237 LS NN I-NP O
19 1482 1485 12452237 had VBD B-VP O
20 1486 1487 12452237 a DT B-NP O
21 1488 1493 12452237 lower JJR I-NP O
22 1494 1503 12452237 incidence NN I-NP O
23 1504 1506 12452237 of IN B-PP O
24 1507 1513 12452237 muscle NN B-NP D005207
25 1514 1527 12452237 fasciculation NN I-NP D005207
26 1528 1532 12452237 than IN B-PP O
27 1533 1538 12452237 those DT B-NP O
28 1539 1541 12452237 in IN B-PP O
29 1542 1547 12452237 Group NN B-NP O
30 1548 1550 12452237 PS NN I-NP O
31 1551 1552 12452237 ( ( O O
32 1552 1553 12452237 p NN B-NP O
33 1554 1555 12452237 < SYM O O
34 1556 1561 12452237 0.001 CD B-NP O
35 1561 1562 12452237 ) ) O O
36 1562 1563 12452237 . . O O

1 1564 1566 12452237 At IN B-PP O
2 1567 1569 12452237 24 CD B-NP O
3 1570 1571 12452237 h NN I-NP O
4 1571 1572 12452237 , , O O
5 1573 1576 12452237 the DT B-NP O
6 1577 1586 12452237 incidence NN I-NP O
7 1587 1589 12452237 of IN B-PP O
8 1590 1597 12452237 myalgia NN B-NP D063806
9 1598 1601 12452237 was VBD B-VP O
10 1602 1608 12452237 higher JJR B-ADJP O
11 1609 1611 12452237 in IN B-PP O
12 1612 1617 12452237 Group NN B-NP O
13 1618 1620 12452237 PS NN I-NP O
14 1621 1625 12452237 than IN B-PP O
15 1626 1628 12452237 in IN B-PP O
16 1629 1634 12452237 Group NN B-NP O
17 1635 1637 12452237 LS NN I-NP O
18 1638 1641 12452237 and CC O O
19 1642 1644 12452237 PR NN B-NP O
20 1645 1646 12452237 ( ( O O
21 1646 1647 12452237 p NN B-NP O
22 1648 1649 12452237 < SYM O O
23 1650 1654 12452237 0.05 CD B-NP O
24 1654 1655 12452237 ) ) O O
25 1655 1656 12452237 . . O O

1 1657 1658 12452237 A DT B-NP O
2 1659 1670 12452237 correlation NN I-NP O
3 1671 1674 12452237 was VBD B-VP O
4 1675 1678 12452237 not RB I-VP O
5 1679 1684 12452237 found VBN I-VP O
6 1685 1692 12452237 between IN B-PP O
7 1693 1696 12452237 the DT B-NP O
8 1697 1706 12452237 incidence NN I-NP O
9 1707 1709 12452237 of IN B-PP O
10 1710 1717 12452237 myalgia NN B-NP D063806
11 1718 1721 12452237 and CC O O
12 1722 1725 12452237 the DT B-NP O
13 1726 1736 12452237 occurrence NN I-NP O
14 1737 1739 12452237 of IN B-PP O
15 1740 1746 12452237 muscle NN B-NP D005207
16 1747 1760 12452237 fasciculation NN I-NP D005207
17 1760 1761 12452237 . . O O

1 1762 1765 12452237 The DT B-NP O
2 1766 1773 12452237 changes NNS I-NP O
3 1774 1776 12452237 in IN B-PP O
4 1777 1785 12452237 systolic JJ B-NP O
5 1786 1789 12452237 and CC I-NP O
6 1790 1799 12452237 diastolic JJ I-NP O
7 1800 1805 12452237 blood NN I-NP O
8 1806 1814 12452237 pressure NN I-NP O
9 1815 1818 12452237 and CC I-NP O
10 1819 1824 12452237 heart NN I-NP O
11 1825 1829 12452237 rate NN I-NP O
12 1830 1834 12452237 were VBD B-VP O
13 1835 1838 12452237 not RB B-ADJP O
14 1839 1850 12452237 significant JJ I-ADJP O
15 1851 1856 12452237 among IN B-PP O
16 1857 1860 12452237 the DT B-NP O
17 1861 1866 12452237 three CD I-NP O
18 1867 1873 12452237 groups NNS I-NP O
19 1873 1874 12452237 . . O O

1 1875 1877 12452237 In IN B-PP O
2 1878 1888 12452237 conclusion NN B-NP O
3 1888 1889 12452237 , , O O
4 1890 1895 12452237 where WRB B-ADVP O
5 1896 1911 12452237 succinylcholine NN B-NP D013390
6 1912 1914 12452237 is VBZ B-VP O
7 1915 1919 12452237 used VBN I-VP O
8 1919 1920 12452237 , , O O
9 1921 1930 12452237 lidocaine NN B-NP D008012
10 1931 1933 12452237 is VBZ B-VP O
11 1934 1940 12452237 proven VBN I-VP O
12 1941 1943 12452237 to TO I-VP O
13 1944 1946 12452237 be VB I-VP O
14 1947 1950 12452237 the DT B-NP O
15 1951 1957 12452237 useful JJ I-NP O
16 1958 1970 12452237 pretreatment NN I-NP O
17 1971 1976 12452237 agent NN I-NP O
18 1977 1980 12452237 for IN B-PP O
19 1981 1984 12452237 the DT B-NP O
20 1985 1994 12452237 reduction NN I-NP O
21 1995 1997 12452237 of IN B-PP O
22 1998 2011 12452237 postoperative JJ B-NP D010149
23 2012 2019 12452237 myalgia NN I-NP D010149
24 2019 2020 12452237 . . O O

1 0 0 9041081 -DOCSTART- -X- -X- O

1 0 6 9041081 Effect NN B-NP O
2 7 9 9041081 of IN B-PP O
3 10 16 9041081 myopic JJ B-NP O
4 17 24 9041081 excimer NN I-NP O
5 25 30 9041081 laser NN I-NP O
6 31 46 9041081 photorefractive JJ I-NP O
7 47 58 9041081 keratectomy NN I-NP O
8 59 61 9041081 on IN B-PP O
9 62 65 9041081 the DT B-NP O
10 66 84 9041081 electrophysiologic JJ I-NP O
11 85 93 9041081 function NN I-NP O
12 94 96 9041081 of IN B-PP O
13 97 100 9041081 the DT B-NP O
14 101 107 9041081 retina NN I-NP O
15 108 111 9041081 and CC I-NP O
16 112 117 9041081 optic JJ I-NP O
17 118 123 9041081 nerve NN I-NP O
18 123 124 9041081 . . I-NP O
19 125 132 9041081 PURPOSE NN I-NP O
20 132 133 9041081 : : O O
21 134 136 9041081 To TO B-VP O
22 137 143 9041081 assess VB I-VP O
23 144 146 9041081 by IN B-PP O
24 147 165 9041081 electrophysiologic JJ B-NP O
25 166 173 9041081 testing NN I-NP O
26 174 177 9041081 the DT B-NP O
27 178 184 9041081 effect NN I-NP O
28 185 187 9041081 of IN B-PP O
29 188 203 9041081 photorefractive JJ B-NP O
30 204 215 9041081 keratectomy NN I-NP O
31 216 217 9041081 ( ( O O
32 217 220 9041081 PRK NN B-NP O
33 220 221 9041081 ) ) O O
34 222 224 9041081 on IN B-PP O
35 225 228 9041081 the DT B-NP O
36 229 235 9041081 retina NN I-NP O
37 236 239 9041081 and CC I-NP O
38 240 245 9041081 optic JJ I-NP O
39 246 251 9041081 nerve NN I-NP O
40 251 252 9041081 . . O O

1 253 260 9041081 SETTING NN B-NP O
2 260 261 9041081 : : O O
3 262 265 9041081 Eye NNP B-NP O
4 266 272 9041081 Clinic NNP I-NP O
5 272 273 9041081 , , O O
6 274 275 9041081 S NNP B-NP O
7 275 276 9041081 . . I-NP O
8 277 286 9041081 Salvatore NNP I-NP O
9 287 295 9041081 Hospital NNP I-NP O
10 295 296 9041081 , , O O
11 297 305 9041081 L'Aquila NNP B-NP O
12 306 316 9041081 University NNP I-NP O
13 316 317 9041081 , , O O
14 318 323 9041081 Italy NNP B-NP O
15 323 324 9041081 . . O O

1 325 332 9041081 METHODS NNS B-NP O
2 332 333 9041081 : : O O
3 334 342 9041081 Standard JJ B-NP O
4 343 350 9041081 pattern NN I-NP O
5 351 369 9041081 electroretinograms NNS I-NP O
6 370 371 9041081 ( ( O O
7 371 372 9041081 P NN B-NP O
8 372 373 9041081 - HYPH B-NP O
9 373 377 9041081 ERGs NNS I-NP O
10 377 378 9041081 ) ) O O
11 379 382 9041081 and CC O O
12 383 391 9041081 standard JJ B-NP O
13 392 399 9041081 pattern NN I-NP O
14 400 406 9041081 visual JJ I-NP O
15 407 413 9041081 evoked JJ I-NP O
16 414 424 9041081 potentials NNS I-NP O
17 425 426 9041081 ( ( O O
18 426 427 9041081 P NN B-NP O
19 427 428 9041081 - HYPH B-NP O
20 428 432 9041081 VEPs NNS I-NP O
21 432 433 9041081 ) ) O O
22 434 438 9041081 were VBD B-VP O
23 439 443 9041081 done VBN I-VP O
24 444 446 9041081 in IN B-PP O
25 447 449 9041081 25 CD B-NP O
26 450 454 9041081 eyes NNS I-NP O
27 455 457 9041081 of IN B-PP O
28 458 460 9041081 25 CD B-NP O
29 461 469 9041081 patients NNS I-NP O
30 470 473 9041081 who WP B-NP O
31 474 477 9041081 had VBD B-VP O
32 478 484 9041081 myopic JJ B-NP O
33 485 488 9041081 PRK NN I-NP O
34 489 492 9041081 for IN B-PP O
35 493 495 9041081 an DT B-NP O
36 496 505 9041081 attempted VBN I-NP O
37 506 516 9041081 correction NN I-NP O
38 517 524 9041081 between IN B-PP O
39 525 529 9041081 5.00 CD B-NP O
40 530 533 9041081 and CC I-NP O
41 534 539 9041081 15.00 CD I-NP O
42 540 548 9041081 diopters NNS I-NP O
43 549 550 9041081 ( ( O O
44 550 551 9041081 D NN B-NP O
45 551 552 9041081 ) ) O O
46 553 554 9041081 ( ( O O
47 554 558 9041081 mean NN B-NP O
48 559 563 9041081 8.00 CD I-NP O
49 564 565 9041081 D NN I-NP O
50 565 566 9041081 ) ) O O
51 566 567 9041081 . . O O

1 568 575 9041081 Testing NN B-NP O
2 576 579 9041081 was VBD B-VP O
3 580 584 9041081 done VBN I-VP O
4 585 599 9041081 preoperatively RB B-ADVP O
5 600 603 9041081 and CC O O
6 604 605 9041081 3 CD B-NP O
7 605 606 9041081 , , I-NP O
8 607 608 9041081 6 CD I-NP O
9 608 609 9041081 , , I-NP O
10 610 612 9041081 12 CD I-NP O
11 612 613 9041081 , , O O
12 614 617 9041081 and CC O O
13 618 620 9041081 18 CD B-NP O
14 621 627 9041081 months NNS I-NP O
15 628 643 9041081 postoperatively RB B-ADVP O
16 643 644 9041081 . . O O

1 645 648 9041081 The DT B-NP O
2 649 662 9041081 contralateral JJ I-NP O
3 663 667 9041081 eyes NNS I-NP O
4 668 674 9041081 served VBD B-VP O
5 675 677 9041081 as IN B-PP O
6 678 686 9041081 controls NNS B-NP O
7 686 687 9041081 . . O O

1 688 694 9041081 During IN B-PP O
2 695 698 9041081 the DT B-NP O
3 699 705 9041081 follow VB I-NP O
4 705 706 9041081 - HYPH B-VP O
5 706 708 9041081 up RP B-PRT O
6 708 709 9041081 , , O O
7 710 711 9041081 3 CD B-NP O
8 712 720 9041081 patients NNS I-NP O
9 721 722 9041081 ( ( O O
10 722 725 9041081 12% NN B-NP O
11 725 726 9041081 ) ) O O
12 727 736 9041081 developed VBD B-VP O
13 737 744 9041081 steroid NN B-NP D013256
14 744 745 9041081 - HYPH O O
15 745 752 9041081 induced VBN B-VP O
16 753 761 9041081 elevated VBN I-VP D009798
17 762 773 9041081 intraocular JJ B-NP D009798
18 774 782 9041081 pressure NN I-NP D009798
19 783 784 9041081 ( ( O O
20 784 787 9041081 IOP NN B-NP O
21 787 788 9041081 ) ) O O
22 789 793 9041081 that WDT B-NP O
23 794 802 9041081 resolved VBD B-VP O
24 803 808 9041081 after IN B-PP O
25 809 823 9041081 corticosteroid NN B-NP D000305
26 824 831 9041081 therapy NN I-NP O
27 832 835 9041081 was VBD B-VP O
28 836 848 9041081 discontinued VBN I-VP O
29 848 849 9041081 . . O O

1 850 857 9041081 RESULTS NNS B-NP O
2 857 858 9041081 : : O O
3 859 861 9041081 No DT B-NP O
4 862 875 9041081 statistically RB I-NP O
5 876 887 9041081 significant JJ I-NP O
6 888 899 9041081 differences NNS I-NP O
7 900 904 9041081 were VBD B-VP O
8 905 909 9041081 seen VBN I-VP O
9 910 917 9041081 between IN B-PP O
10 918 925 9041081 treated VBN B-NP O
11 926 929 9041081 and CC I-NP O
12 930 937 9041081 control NN I-NP O
13 938 942 9041081 eyes NNS I-NP O
14 943 946 9041081 nor CC B-PP O
15 947 954 9041081 between IN B-PP O
16 955 962 9041081 treated VBN B-NP O
17 963 967 9041081 eyes NNS I-NP O
18 968 982 9041081 preoperatively RB B-ADVP O
19 983 986 9041081 and CC I-ADVP O
20 987 1002 9041081 postoperatively RB I-ADVP O
21 1002 1003 9041081 . . O O

1 1004 1014 9041081 CONCLUSION NN B-NP O
2 1014 1015 9041081 : : O O
3 1016 1022 9041081 Myopic JJ B-NP O
4 1023 1030 9041081 excimer NN I-NP O
5 1031 1036 9041081 laser NN I-NP O
6 1037 1040 9041081 PRK NN I-NP O
7 1041 1044 9041081 did VBD B-VP O
8 1045 1048 9041081 not RB I-VP O
9 1049 1053 9041081 seem VB I-VP O
10 1054 1056 9041081 to TO I-VP O
11 1057 1063 9041081 affect VB I-VP O
12 1064 1067 9041081 the DT B-NP O
13 1068 1077 9041081 posterior JJ I-NP O
14 1078 1085 9041081 segment NN I-NP O
15 1085 1086 9041081 . . O O

1 1087 1090 9041081 The DT B-NP O
2 1091 1100 9041081 transient JJ I-NP O
3 1101 1108 9041081 steroid NN I-NP D013256
4 1108 1109 9041081 - HYPH B-NP O
5 1109 1116 9041081 induced VBN I-NP O
6 1117 1120 9041081 IOP NN I-NP D009798
7 1121 1125 9041081 rise NN I-NP D009798
8 1126 1129 9041081 did VBD B-VP O
9 1130 1133 9041081 not RB I-VP O
10 1134 1138 9041081 seem VB I-VP O
11 1139 1141 9041081 to TO I-VP O
12 1142 1147 9041081 cause VB I-VP O
13 1148 1158 9041081 functional JJ B-NP O
14 1159 1169 9041081 impairment NN I-NP O
15 1169 1170 9041081 . . O O

1 0 0 10225068 -DOCSTART- -X- -X- O

1 0 5 10225068 Cauda NNP B-NP D011128
2 6 12 10225068 equina NNP I-NP D011128
3 13 21 10225068 syndrome NN I-NP D011128
4 22 27 10225068 after IN B-PP O
5 28 34 10225068 spinal JJ B-NP O
6 35 46 10225068 anaesthesia NN I-NP O
7 47 51 10225068 with IN B-PP O
8 52 62 10225068 hyperbaric JJ B-NP O
9 63 65 10225068 5% NN I-NP O
10 66 76 10225068 lignocaine NN I-NP D008012
11 76 77 10225068 : : O O
12 78 79 10225068 a DT B-NP O
13 80 86 10225068 review NN I-NP O
14 87 89 10225068 of IN B-PP O
15 90 93 10225068 six CD B-NP O
16 94 99 10225068 cases NNS I-NP O
17 100 102 10225068 of IN B-PP O
18 103 108 10225068 cauda NN B-NP D011128
19 109 115 10225068 equina NN I-NP D011128
20 116 124 10225068 syndrome NN I-NP D011128
21 125 133 10225068 reported VBN B-VP O
22 134 136 10225068 to TO B-PP O
23 137 140 10225068 the DT B-NP O
24 141 148 10225068 Swedish NNP I-NP O
25 149 163 10225068 Pharmaceutical NNP I-NP O
26 164 173 10225068 Insurance NNP I-NP O
27 174 178 10225068 1993 CD I-NP O
28 178 179 10225068 - : O O
29 179 183 10225068 1997 CD B-NP O
30 183 184 10225068 . . O O
31 185 188 10225068 Six CD B-NP O
32 189 194 10225068 cases NNS I-NP O
33 195 197 10225068 of IN B-PP O
34 198 203 10225068 cauda NN B-NP D011128
35 204 210 10225068 equina NN I-NP D011128
36 211 219 10225068 syndrome NN I-NP D011128
37 220 224 10225068 with IN B-PP O
38 225 232 10225068 varying VBG B-NP O
39 233 241 10225068 severity NN I-NP O
40 242 246 10225068 were VBD B-VP O
41 247 255 10225068 reported VBN I-VP O
42 256 258 10225068 to TO B-PP O
43 259 262 10225068 the DT B-NP O
44 263 270 10225068 Swedish NNP I-NP O
45 271 285 10225068 Pharmaceutical NNP I-NP O
46 286 295 10225068 Insurance NNP I-NP O
47 296 302 10225068 during IN B-PP O
48 303 306 10225068 the DT B-NP O
49 307 313 10225068 period NN I-NP O
50 314 318 10225068 1993 CD I-NP O
51 318 319 10225068 - HYPH B-NP O
52 319 323 10225068 1997 CD I-NP O
53 323 324 10225068 . . O O

1 325 328 10225068 All DT B-NP O
2 329 333 10225068 were VBD B-VP O
3 334 344 10225068 associated VBN I-VP O
4 345 349 10225068 with IN B-PP O
5 350 356 10225068 spinal JJ B-NP O
6 357 368 10225068 anaesthesia NN I-NP O
7 369 374 10225068 using VBG B-VP O
8 375 385 10225068 hyperbaric JJ B-NP O
9 386 388 10225068 5% NN I-NP O
10 389 399 10225068 lignocaine NN I-NP D008012
11 399 400 10225068 . . O O

1 401 405 10225068 Five CD B-NP O
2 406 411 10225068 cases NNS I-NP O
3 412 415 10225068 had VBD B-VP O
4 416 422 10225068 single JJ B-NP O
5 422 423 10225068 - HYPH I-NP O
6 423 427 10225068 shot NN I-NP O
7 428 434 10225068 spinal JJ I-NP O
8 435 446 10225068 anaesthesia NN I-NP O
9 447 450 10225068 and CC O O
10 451 454 10225068 one CD B-NP O
11 455 458 10225068 had VBD B-VP O
12 459 460 10225068 a DT B-NP O
13 461 467 10225068 repeat NN I-NP O
14 468 474 10225068 spinal JJ I-NP O
15 475 486 10225068 anaesthetic NN I-NP O
16 487 490 10225068 due JJ B-PP O
17 491 493 10225068 to TO B-PP O
18 494 504 10225068 inadequate JJ B-NP O
19 505 510 10225068 block NN I-NP O
20 510 511 10225068 . . O O

1 512 515 10225068 The DT B-NP O
2 516 520 10225068 dose NN I-NP O
3 521 523 10225068 of IN B-PP O
4 524 534 10225068 hyperbaric JJ B-NP O
5 535 537 10225068 5% NN I-NP O
6 538 548 10225068 lignocaine NN I-NP D008012
7 549 561 10225068 administered VBN B-VP O
8 562 568 10225068 ranged VBD B-VP O
9 569 573 10225068 from IN B-PP O
10 574 576 10225068 60 CD B-NP O
11 577 579 10225068 to TO I-NP O
12 580 583 10225068 120 CD I-NP O
13 584 586 10225068 mg NN I-NP O
14 586 587 10225068 . . O O

1 588 593 10225068 Three CD B-NP O
2 594 596 10225068 of IN B-PP O
3 597 600 10225068 the DT B-NP O
4 601 606 10225068 cases NNS I-NP O
5 607 611 10225068 were VBD B-VP O
6 612 616 10225068 most RBS I-VP O
7 617 623 10225068 likely RB I-VP O
8 624 630 10225068 caused VBN I-VP O
9 631 633 10225068 by IN B-PP O
10 634 640 10225068 direct JJ B-NP O
11 641 654 10225068 neurotoxicity NN I-NP D020258
12 655 657 10225068 of IN B-PP O
13 658 668 10225068 hyperbaric JJ B-NP O
14 669 671 10225068 5% NN I-NP O
15 672 682 10225068 lignocaine NN I-NP D008012
16 682 683 10225068 . . O O

1 684 686 10225068 In IN B-PP O
2 687 690 10225068 the DT B-NP O
3 691 696 10225068 other JJ I-NP O
4 697 698 10225068 3 CD I-NP O
5 699 704 10225068 cases NNS I-NP O
6 704 705 10225068 , , O O
7 706 712 10225068 direct JJ B-NP O
8 713 726 10225068 neurotoxicity NN I-NP D020258
9 727 730 10225068 was VBD B-VP O
10 731 735 10225068 also RB B-ADVP O
11 736 744 10225068 probable JJ B-ADJP O
12 744 745 10225068 , , O O
13 746 749 10225068 but CC O O
14 750 763 10225068 unfortunately RB B-NP O
15 764 776 10225068 radiological JJ I-NP O
16 777 791 10225068 investigations NNS I-NP O
17 792 796 10225068 were VBD B-VP O
18 797 800 10225068 not RB I-VP O
19 801 805 10225068 done VBN I-VP O
20 806 808 10225068 to TO B-VP O
21 809 819 10225068 definitely RB I-VP O
22 820 827 10225068 exclude VB I-VP O
23 828 829 10225068 a DT B-NP O
24 830 841 10225068 compressive JJ I-NP O
25 842 851 10225068 aetiology NN I-NP O
26 851 852 10225068 . . O O

1 853 856 10225068 All DT B-NP O
2 857 862 10225068 cases NNS I-NP O
3 863 872 10225068 sustained VBD B-VP O
4 873 882 10225068 permanent JJ B-NP O
5 883 895 10225068 neurological JJ I-NP D009461
6 896 904 10225068 deficits NNS I-NP D009461
7 904 905 10225068 . . O O

1 906 908 10225068 We PRP B-NP O
2 909 918 10225068 recommend VBP B-VP O
3 919 923 10225068 that IN B-SBAR O
4 924 934 10225068 hyperbaric JJ B-NP O
5 935 945 10225068 lignocaine NN I-NP D008012
6 946 952 10225068 should MD B-VP O
7 953 955 10225068 be VB I-VP O
8 956 968 10225068 administered VBN I-VP O
9 969 971 10225068 in IN B-PP O
10 972 986 10225068 concentrations NNS B-NP O
11 987 990 10225068 not RB B-ADJP O
12 991 998 10225068 greater JJR I-ADJP O
13 999 1003 10225068 than IN B-PP O
14 1004 1006 10225068 2% NN B-NP O
15 1007 1010 10225068 and CC B-PP O
16 1011 1013 10225068 at IN B-PP O
17 1014 1015 10225068 a DT B-NP O
18 1016 1021 10225068 total JJ I-NP O
19 1022 1026 10225068 dose NN I-NP O
20 1027 1037 10225068 preferably RB B-VP O
21 1038 1041 10225068 not RB I-VP O
22 1042 1051 10225068 exceeding VBG I-VP O
23 1052 1054 10225068 60 CD B-NP O
24 1055 1057 10225068 mg NN I-NP O
25 1057 1058 10225068 . . O O

1 0 0 761833 -DOCSTART- -X- -X- O

1 0 8 761833 Reversal NN B-NP O
2 9 11 761833 of IN B-PP O
3 12 19 761833 ammonia NN B-NP D000641
4 20 24 761833 coma NN I-NP D003128
5 25 27 761833 in IN B-PP O
6 28 32 761833 rats NNS B-NP O
7 33 35 761833 by IN B-PP O
8 36 37 761833 L NN B-NP D007980
9 37 38 761833 - HYPH B-NP D007980
10 38 42 761833 dopa NN I-NP D007980
11 42 43 761833 : : O O
12 44 45 761833 a DT B-NP O
13 46 56 761833 peripheral JJ I-NP O
14 57 63 761833 effect NN I-NP O
15 63 64 761833 . . O O
16 65 72 761833 Ammonia NNP B-NP D000641
17 73 77 761833 coma NN I-NP D003128
18 78 81 761833 was VBD B-VP O
19 82 90 761833 produced VBN I-VP O
20 91 93 761833 in IN B-PP O
21 94 98 761833 rats NNS B-NP O
22 99 105 761833 within IN B-PP O
23 106 108 761833 10 CD B-NP O
24 109 111 761833 to TO I-NP O
25 112 114 761833 15 CD I-NP O
26 115 122 761833 minutes NNS I-NP O
27 123 125 761833 of IN B-PP O
28 126 128 761833 an DT B-NP O
29 129 153 761833 intraperitonealinjection NN I-NP O
30 154 156 761833 of IN B-PP O
31 157 160 761833 1.7 CD B-NP O
32 161 165 761833 mmol NN I-NP O
33 166 171 761833 NH4CL NN I-NP D000643
34 171 172 761833 . . O O

1 173 177 761833 This DT B-NP O
2 178 182 761833 coma NN I-NP D003128
3 183 186 761833 was VBD B-VP O
4 187 196 761833 prevented VBN I-VP O
5 197 201 761833 with IN B-PP O
6 202 206 761833 1.68 CD B-NP O
7 207 211 761833 mmol NN I-NP O
8 212 213 761833 L NN I-NP D007980
9 213 214 761833 - HYPH B-NP D007980
10 214 218 761833 dopa NN I-NP D007980
11 219 224 761833 given VBN B-VP O
12 225 227 761833 by IN B-PP O
13 228 235 761833 gastric JJ B-NP O
14 236 246 761833 intubation NN I-NP O
15 247 249 761833 15 CD B-NP O
16 250 257 761833 minutes NNS I-NP O
17 258 264 761833 before IN B-PP O
18 265 268 761833 the DT B-NP O
19 269 277 761833 ammonium NN I-NP D064751
20 278 282 761833 salt NN I-NP D064751
21 283 292 761833 injection NN I-NP O
22 292 293 761833 . . O O

1 294 297 761833 The DT B-NP O
2 298 304 761833 effect NN I-NP O
3 305 307 761833 of IN B-PP O
4 308 309 761833 L NN B-NP D007980
5 309 310 761833 - HYPH I-NP D007980
6 310 314 761833 dopa NN B-NP D007980
7 315 318 761833 was VBD B-VP O
8 319 329 761833 correlated VBN I-VP O
9 330 334 761833 with IN B-PP O
10 335 336 761833 a DT B-NP O
11 337 345 761833 decrease NN I-NP O
12 346 348 761833 in IN B-PP O
13 349 354 761833 blood NN B-NP O
14 355 358 761833 and CC I-NP O
15 359 364 761833 brain NN I-NP O
16 365 372 761833 ammonia NN I-NP D000641
17 372 373 761833 , , O O
18 374 376 761833 an DT B-NP O
19 377 385 761833 increase NN I-NP O
20 386 388 761833 in IN B-PP O
21 389 394 761833 brain NN B-NP O
22 395 403 761833 dopamine NN I-NP D004298
23 403 404 761833 , , O O
24 405 408 761833 and CC O O
25 409 411 761833 an DT B-NP O
26 412 420 761833 increase NN I-NP O
27 421 423 761833 in IN B-PP O
28 424 429 761833 renal JJ B-NP O
29 430 439 761833 excretion NN I-NP O
30 440 442 761833 of IN B-PP O
31 443 450 761833 ammonia NN B-NP D000641
32 451 454 761833 and CC I-NP O
33 455 459 761833 urea NN I-NP D014508
34 459 460 761833 . . O O

1 461 477 761833 Intraventricular JJ B-NP O
2 478 486 761833 infusion NN I-NP O
3 487 489 761833 of IN B-PP O
4 490 498 761833 dopamine NN B-NP D004298
5 499 509 761833 sufficient JJ B-ADJP O
6 510 512 761833 to TO B-VP O
7 513 518 761833 raise VB I-VP O
8 519 522 761833 the DT B-NP O
9 523 528 761833 brain NN I-NP O
10 529 537 761833 dopamine NN I-NP D004298
11 538 540 761833 to TO B-PP O
12 541 544 761833 the DT B-NP O
13 545 549 761833 same JJ I-NP O
14 550 556 761833 extent NN I-NP O
15 557 560 761833 did VBD B-VP O
16 561 564 761833 not RB I-VP O
17 565 572 761833 prevent VB I-VP O
18 573 576 761833 the DT B-NP O
19 577 584 761833 ammonia NN I-NP D000641
20 585 589 761833 coma NN I-NP D003128
21 590 593 761833 nor CC O O
22 594 600 761833 affect VB B-VP O
23 601 604 761833 the DT B-NP O
24 605 610 761833 blood NN I-NP O
25 611 614 761833 and CC I-NP O
26 615 620 761833 brain NN I-NP O
27 621 628 761833 ammonia NN I-NP D000641
28 629 643 761833 concentrations NNS I-NP O
29 643 644 761833 . . O O

1 645 654 761833 Bilateral JJ B-NP O
2 655 666 761833 nephrectomy NN I-NP O
3 667 677 761833 eliminated VBD B-VP O
4 678 681 761833 the DT B-NP O
5 682 692 761833 beneficial JJ I-NP O
6 693 699 761833 effect NN I-NP O
7 700 702 761833 of IN B-PP O
8 703 704 761833 L NN B-NP D007980
9 704 705 761833 - HYPH I-NP D007980
10 705 709 761833 dopa NN B-NP D007980
11 710 712 761833 on IN B-PP O
12 713 718 761833 blood NN B-NP O
13 719 722 761833 and CC I-NP O
14 723 728 761833 brain NN I-NP O
15 729 736 761833 ammonia NN I-NP D000641
16 737 740 761833 and CC O O
17 741 744 761833 the DT B-NP O
18 745 752 761833 ammonia NN I-NP D000641
19 753 757 761833 coma NN I-NP D003128
20 758 761 761833 was VBD B-VP O
21 762 765 761833 not RB I-VP O
22 766 775 761833 prevented VBN I-VP O
23 775 776 761833 . . O O

1 777 781 761833 Thus RB B-ADVP O
2 781 782 761833 , , O O
3 783 786 761833 the DT B-NP O
4 787 796 761833 reduction NN I-NP O
5 797 799 761833 in IN B-PP O
6 800 805 761833 blood NN B-NP O
7 806 809 761833 and CC I-NP O
8 810 815 761833 brain NN I-NP O
9 816 823 761833 ammonia NN I-NP D000641
10 824 827 761833 and CC O O
11 828 831 761833 the DT B-NP O
12 832 842 761833 prevention NN I-NP O
13 843 845 761833 of IN B-PP O
14 846 853 761833 ammonia NN B-NP D000641
15 854 858 761833 coma NN I-NP D003128
16 859 864 761833 after IN B-PP O
17 865 866 761833 L NN B-NP D007980
18 866 867 761833 - HYPH B-NP D007980
19 867 871 761833 dopa NN I-NP D007980
20 871 872 761833 , , O O
21 873 876 761833 can MD B-VP O
22 877 879 761833 be VB I-VP O
23 880 889 761833 accounted VBN I-VP O
24 890 893 761833 for IN B-PP O
25 894 896 761833 by IN B-PP O
26 897 900 761833 the DT B-NP O
27 901 911 761833 peripheral JJ I-NP O
28 912 918 761833 effect NN I-NP O
29 919 921 761833 of IN B-PP O
30 922 930 761833 dopamine NN B-NP D004298
31 931 933 761833 on IN B-PP O
32 934 939 761833 renal JJ B-NP O
33 940 948 761833 function NN I-NP O
34 949 955 761833 rather RB B-CONJP O
35 956 960 761833 than IN I-CONJP O
36 961 964 761833 its PRP$ B-NP O
37 965 972 761833 central JJ I-NP O
38 973 979 761833 action NN I-NP O
39 979 980 761833 . . O O

1 981 986 761833 These DT B-NP O
2 987 994 761833 results NNS I-NP O
3 995 1002 761833 provide VBP B-VP O
4 1003 1004 761833 a DT B-NP O
5 1005 1015 761833 reasonable JJ I-NP O
6 1016 1027 761833 explanation NN I-NP O
7 1028 1031 761833 for IN B-PP O
8 1032 1035 761833 the DT B-NP O
9 1036 1046 761833 beneficial JJ I-NP O
10 1047 1054 761833 effects NNS I-NP O
11 1055 1063 761833 observed VBN B-VP O
12 1064 1066 761833 in IN B-PP O
13 1067 1071 761833 some DT B-NP O
14 1072 1087 761833 encephalopathic JJ I-NP D001927
15 1088 1096 761833 patients NNS I-NP O
16 1097 1106 761833 receiving VBG B-VP O
17 1107 1108 761833 L NN B-NP D007980
18 1108 1109 761833 - HYPH B-VP D007980
19 1109 1113 761833 dopa NN B-NP D007980
20 1113 1114 761833 . . O O

1 0 0 11245434 -DOCSTART- -X- -X- O

1 0 14 11245434 Erythropoietin NN B-NP O
2 15 23 11245434 restores VBZ B-VP O
3 24 27 11245434 the DT B-NP O
4 28 34 11245434 anemia NN I-NP D000740
5 34 35 11245434 - HYPH B-VP O
6 35 42 11245434 induced VBN B-NP O
7 43 52 11245434 reduction NN I-NP O
8 53 55 11245434 in IN B-PP O
9 56 72 11245434 cyclophosphamide NN B-NP D003520
10 73 85 11245434 cytotoxicity NN I-NP D064420
11 86 88 11245434 in IN B-PP O
12 89 92 11245434 rat NN B-NP O
13 93 99 11245434 tumors NNS I-NP D009369
14 99 100 11245434 . . O O
15 101 104 11245434 The DT B-NP O
16 105 108 11245434 aim NN I-NP O
17 109 111 11245434 of IN B-PP O
18 112 116 11245434 this DT B-NP O
19 117 122 11245434 study NN I-NP O
20 123 126 11245434 was VBD B-VP O
21 127 129 11245434 to TO B-VP O
22 130 137 11245434 examine VB I-VP O
23 138 141 11245434 the DT B-NP O
24 142 148 11245434 impact NN I-NP O
25 149 151 11245434 of IN B-PP O
26 152 158 11245434 anemia NN B-NP D000740
27 159 169 11245434 prevention NN I-NP O
28 170 172 11245434 by IN B-PP O
29 173 184 11245434 recombinant JJ B-NP O
30 185 190 11245434 human JJ I-NP O
31 191 205 11245434 erythropoietin NN I-NP O
32 206 207 11245434 ( ( O O
33 207 213 11245434 rHuEPO NN B-NP O
34 213 214 11245434 ) ) O O
35 215 224 11245434 treatment NN B-NP O
36 225 227 11245434 on IN B-PP O
37 228 231 11245434 the DT B-NP O
38 232 244 11245434 cytotoxicity NN I-NP D064420
39 245 247 11245434 of IN B-PP O
40 248 264 11245434 cyclophosphamide NN B-NP D003520
41 265 267 11245434 in IN B-PP O
42 268 273 11245434 solid JJ B-NP O
43 274 286 11245434 experimental JJ I-NP O
44 287 293 11245434 tumors NNS I-NP D009369
45 293 294 11245434 . . O O

1 295 301 11245434 Anemia NN B-NP D000740
2 302 305 11245434 was VBD B-VP O
3 306 313 11245434 induced VBN I-VP O
4 314 319 11245434 using VBG I-VP O
5 320 321 11245434 a DT B-NP O
6 322 328 11245434 single JJ I-NP O
7 329 333 11245434 dose NN I-NP O
8 334 336 11245434 of IN B-PP O
9 337 348 11245434 carboplatin NN B-NP D016190
10 349 350 11245434 ( ( O O
11 350 352 11245434 50 CD B-NP O
12 353 355 11245434 mg NN I-NP O
13 355 356 11245434 / SYM B-NP O
14 356 358 11245434 kg NN I-NP O
15 359 362 11245434 i.v JJ B-ADJP O
16 362 363 11245434 . . O O
17 363 364 11245434 ) ) O O
18 365 374 11245434 resulting VBG B-VP O
19 375 377 11245434 in IN B-PP O
20 378 379 11245434 a DT B-NP O
21 380 384 11245434 long JJ I-NP O
22 384 385 11245434 - HYPH I-NP O
23 385 392 11245434 lasting VBG I-NP O
24 393 402 11245434 reduction NN I-NP O
25 403 404 11245434 ( ( O O
26 404 407 11245434 30% CD B-NP O
27 407 408 11245434 ) ) O O
28 409 411 11245434 of IN B-PP O
29 412 415 11245434 the DT B-NP O
30 416 426 11245434 hemoglobin NN I-NP O
31 427 440 11245434 concentration NN I-NP O
32 440 441 11245434 . . O O

1 442 444 11245434 In IN B-PP O
2 445 446 11245434 a DT B-NP O
3 447 453 11245434 second JJ I-NP O
4 454 459 11245434 group NN I-NP O
5 459 460 11245434 , , O O
6 461 464 11245434 the DT B-NP O
7 465 476 11245434 development NN I-NP O
8 477 479 11245434 of IN B-PP O
9 480 486 11245434 anemia NN B-NP D000740
10 487 490 11245434 was VBD B-VP O
11 491 500 11245434 prevented VBN I-VP O
12 501 503 11245434 by IN B-PP O
13 504 510 11245434 rHuEPO NN B-NP O
14 511 512 11245434 ( ( O O
15 512 516 11245434 1000 CD B-NP O
16 517 519 11245434 IU NN I-NP O
17 519 520 11245434 / SYM B-NP O
18 520 522 11245434 kg NN I-NP O
19 522 523 11245434 ) ) O O
20 524 536 11245434 administered VBN B-NP O
21 537 540 11245434 s.c NN I-NP O
22 540 541 11245434 . . O O

1 542 547 11245434 three CD B-NP O
2 548 553 11245434 times NNS I-NP O
3 553 554 11245434 / SYM I-NP O
4 554 558 11245434 week NN I-NP O
5 559 567 11245434 starting VBG B-VP O
6 568 569 11245434 7 CD B-NP O
7 570 574 11245434 days NNS I-NP O
8 575 581 11245434 before IN B-PP O
9 582 593 11245434 carboplatin NN B-NP D016190
10 594 605 11245434 application NN I-NP O
11 605 606 11245434 . . O O

1 607 611 11245434 Four CD B-NP O
2 612 616 11245434 days NNS I-NP O
3 617 622 11245434 after IN B-PP O
4 623 634 11245434 carboplatin NN B-NP D016190
5 635 644 11245434 treatment NN I-NP O
6 644 645 11245434 , , O O
7 646 652 11245434 tumors NNS B-NP D009369
8 653 654 11245434 ( ( O O
9 654 656 11245434 DS NN B-NP O
10 656 657 11245434 - HYPH O O
11 657 664 11245434 sarcoma NN B-NP D012509
12 665 667 11245434 of IN B-PP O
13 668 671 11245434 the DT B-NP O
14 672 675 11245434 rat NN I-NP O
15 675 676 11245434 ) ) O O
16 677 681 11245434 were VBD B-VP O
17 682 691 11245434 implanted VBN I-VP O
18 692 695 11245434 s.c NN B-NP O
19 695 696 11245434 . . O O

1 697 701 11245434 onto IN B-PP O
2 702 705 11245434 the DT B-NP O
3 706 710 11245434 hind NN I-NP O
4 711 715 11245434 food NN I-NP O
5 716 722 11245434 dorsum NN I-NP O
6 722 723 11245434 . . O O

1 724 731 11245434 Neither CC O O
2 732 743 11245434 carboplatin NN B-NP D016190
3 744 747 11245434 nor CC O O
4 748 754 11245434 rHuEPO NN B-NP O
5 755 764 11245434 treatment NN I-NP O
6 765 775 11245434 influenced VBD B-VP O
7 776 781 11245434 tumor NN B-NP D009369
8 782 788 11245434 growth NN I-NP O
9 789 793 11245434 rate NN I-NP O
10 794 797 11245434 per FW B-ADVP O
11 798 800 11245434 se FW I-ADVP O
12 800 801 11245434 . . O O

1 802 806 11245434 When WRB B-ADVP O
2 807 813 11245434 tumors NNS B-NP D009369
3 814 818 11245434 were VBD B-VP O
4 819 826 11245434 treated VBN I-VP O
5 827 831 11245434 with IN B-PP O
6 832 833 11245434 a DT B-NP O
7 834 840 11245434 single JJ I-NP O
8 841 845 11245434 dose NN I-NP O
9 846 848 11245434 of IN B-PP O
10 849 865 11245434 cyclophosphamide NN B-NP D003520
11 866 867 11245434 ( ( O O
12 867 869 11245434 60 CD B-NP O
13 870 872 11245434 mg NN I-NP O
14 872 873 11245434 / SYM B-NP O
15 873 875 11245434 kg NN I-NP O
16 876 879 11245434 i.p NN I-NP O
17 879 880 11245434 . . O O
18 880 881 11245434 ) ) O O
19 882 883 11245434 5 CD B-NP O
20 884 888 11245434 days NNS I-NP O
21 889 894 11245434 after IN B-PP O
22 895 907 11245434 implantation NN B-NP O
23 907 908 11245434 , , O O
24 909 910 11245434 a DT B-NP O
25 911 917 11245434 growth NN I-NP O
26 918 923 11245434 delay NN I-NP O
27 924 928 11245434 with IN B-PP O
28 929 930 11245434 a DT B-NP O
29 931 941 11245434 subsequent JJ I-NP O
30 942 950 11245434 regrowth NN I-NP O
31 951 953 11245434 of IN B-PP O
32 954 957 11245434 the DT B-NP O
33 958 964 11245434 tumors NNS I-NP D009369
34 965 968 11245434 was VBD B-VP O
35 969 977 11245434 observed VBN I-VP O
36 977 978 11245434 . . O O

1 979 981 11245434 In IN B-PP O
2 982 985 11245434 the DT B-NP O
3 986 992 11245434 anemia NN I-NP D000740
4 993 998 11245434 group NN I-NP O
5 998 999 11245434 , , O O
6 1000 1003 11245434 the DT B-NP O
7 1004 1010 11245434 growth NN I-NP O
8 1011 1016 11245434 delay NN I-NP O
9 1017 1020 11245434 was VBD B-VP O
10 1021 1034 11245434 significantly RB B-ADJP O
11 1035 1042 11245434 shorter JJR I-ADJP O
12 1043 1051 11245434 compared VBN B-PP O
13 1052 1056 11245434 with IN B-PP O
14 1057 1066 11245434 nonanemic JJ B-NP O
15 1067 1075 11245434 controls NNS I-NP O
16 1076 1077 11245434 ( ( O O
17 1077 1081 11245434 13.3 CD B-NP O
18 1082 1086 11245434 days NNS I-NP O
19 1087 1093 11245434 versus IN B-PP O
20 1094 1097 11245434 8.6 CD B-NP O
21 1098 1102 11245434 days NNS I-NP O
22 1102 1103 11245434 ) ) O O
23 1103 1104 11245434 . . O O

1 1105 1107 11245434 In IN B-PP O
2 1108 1111 11245434 the DT B-NP O
3 1112 1117 11245434 group NN I-NP O
4 1118 1123 11245434 where WRB B-ADVP O
5 1124 1130 11245434 anemia NN B-NP D000740
6 1131 1134 11245434 was VBD B-VP O
7 1135 1144 11245434 prevented VBN I-VP O
8 1145 1147 11245434 by IN B-PP O
9 1148 1154 11245434 rHuEPO NN B-NP O
10 1155 1164 11245434 treatment NN I-NP O
11 1164 1165 11245434 , , O O
12 1166 1172 11245434 growth NN B-NP O
13 1173 1178 11245434 delay NN I-NP O
14 1179 1182 11245434 was VBD B-VP O
15 1183 1193 11245434 comparable JJ B-ADJP O
16 1194 1198 11245434 with IN B-PP O
17 1199 1203 11245434 that DT B-NP O
18 1204 1206 11245434 of IN B-PP O
19 1207 1216 11245434 nonanemic JJ B-NP O
20 1217 1225 11245434 controls NNS I-NP O
21 1226 1227 11245434 ( ( O O
22 1227 1231 11245434 13.3 CD B-NP O
23 1232 1236 11245434 days NNS I-NP O
24 1236 1237 11245434 ) ) O O
25 1237 1238 11245434 . . O O

1 1239 1244 11245434 These DT B-NP O
2 1245 1252 11245434 results NNS I-NP O
3 1253 1260 11245434 suggest VBP B-VP O
4 1261 1265 11245434 that IN B-SBAR O
5 1266 1278 11245434 chemotherapy NN B-NP O
6 1278 1279 11245434 - HYPH B-NP O
7 1279 1286 11245434 induced VBN I-NP O
8 1287 1293 11245434 anemia NN I-NP D000740
9 1294 1301 11245434 reduces VBZ B-VP O
10 1302 1314 11245434 cytotoxicity NN B-NP D064420
11 1315 1317 11245434 of IN B-PP O
12 1318 1334 11245434 cyclophosphamide NN B-NP D003520
13 1335 1337 11245434 in IN B-PP O
14 1338 1344 11245434 tumors NNS B-NP D009369
15 1344 1345 11245434 , , O O
16 1346 1353 11245434 whereas IN O O
17 1354 1364 11245434 correction NN B-NP O
18 1365 1367 11245434 of IN B-PP O
19 1368 1374 11245434 anemia NN B-NP D000740
20 1375 1377 11245434 by IN B-PP O
21 1378 1384 11245434 rHuEPO NN B-NP O
22 1385 1394 11245434 treatment NN I-NP O
23 1395 1396 11245434 ( ( O O
24 1396 1403 11245434 epoetin NN B-NP O
25 1404 1409 11245434 alpha NN I-NP O
26 1409 1410 11245434 ) ) O O
27 1411 1420 11245434 increases VBZ B-VP O
28 1421 1424 11245434 the DT B-NP O
29 1425 1436 11245434 sensitivity NN I-NP O
30 1436 1437 11245434 , , O O
31 1438 1446 11245434 probably RB B-ADVP O
32 1447 1449 11245434 as IN B-PP O
33 1450 1451 11245434 a DT B-NP O
34 1452 1458 11245434 result NN I-NP O
35 1459 1461 11245434 of IN B-PP O
36 1462 1464 11245434 an DT B-NP O
37 1465 1473 11245434 improved VBN I-NP O
38 1474 1480 11245434 oxygen NN I-NP D010100
39 1481 1487 11245434 supply NN I-NP O
40 1488 1490 11245434 to TO B-PP O
41 1491 1496 11245434 tumor NN B-NP D009369
42 1497 1503 11245434 tissue NN I-NP O
43 1503 1504 11245434 . . O O

1 0 0 12093990 -DOCSTART- -X- -X- O

1 0 11 12093990 Intravenous JJ B-NP O
2 12 21 12093990 ribavirin NN I-NP D012254
3 22 31 12093990 treatment NN I-NP O
4 32 35 12093990 for IN B-PP O
5 36 42 12093990 severe JJ B-NP O
6 43 53 12093990 adenovirus NN I-NP D000257
7 54 61 12093990 disease NN I-NP D000257
8 62 64 12093990 in IN B-PP O
9 65 82 12093990 immunocompromised JJ B-NP O
10 83 91 12093990 children NNS I-NP O
11 91 92 12093990 . . O O
12 93 103 12093990 BACKGROUND NN B-NP O
13 103 104 12093990 : : O O
14 105 115 12093990 Adenovirus NN B-NP O
15 116 118 12093990 is VBZ B-VP O
16 119 121 12093990 an DT B-NP O
17 122 131 12093990 important JJ I-NP O
18 132 137 12093990 cause NN I-NP O
19 138 140 12093990 of IN B-PP O
20 141 150 12093990 morbidity NN B-NP O
21 151 154 12093990 and CC I-NP O
22 155 164 12093990 mortality NN I-NP O
23 165 167 12093990 in IN B-PP O
24 168 171 12093990 the DT B-NP O
25 172 189 12093990 immunocompromised JJ I-NP O
26 190 194 12093990 host NN I-NP O
27 194 195 12093990 . . O O

1 196 199 12093990 The DT B-NP O
2 200 209 12093990 incidence NN I-NP O
3 210 212 12093990 of IN B-PP O
4 213 219 12093990 severe JJ B-NP O
5 220 230 12093990 adenovirus NN I-NP D000257
6 231 238 12093990 disease NN I-NP D000257
7 239 241 12093990 in IN B-PP O
8 242 252 12093990 pediatrics NNS B-NP O
9 253 255 12093990 is VBZ B-VP O
10 256 266 12093990 increasing VBG I-VP O
11 267 269 12093990 in IN B-PP O
12 270 281 12093990 association NN B-NP O
13 282 286 12093990 with IN B-PP O
14 287 294 12093990 growing VBG B-NP O
15 295 302 12093990 numbers NNS I-NP O
16 303 305 12093990 of IN B-PP O
17 306 323 12093990 immunocompromised JJ B-NP O
18 324 332 12093990 children NNS I-NP O
19 332 333 12093990 , , O O
20 334 339 12093990 where WRB B-ADVP O
21 340 344 12093990 case NN B-NP O
22 345 353 12093990 fatality NN I-NP O
23 354 359 12093990 rates NNS I-NP O
24 360 362 12093990 as RB B-ADJP O
25 363 367 12093990 high JJ I-ADJP O
26 368 370 12093990 as IN B-PP O
27 371 374 12093990 50% CD B-NP O
28 375 377 12093990 to TO B-PP O
29 378 381 12093990 80% CD B-NP O
30 382 386 12093990 have VBP B-VP O
31 387 391 12093990 been VBN I-VP O
32 392 400 12093990 reported VBN I-VP O
33 400 401 12093990 . . O O

1 402 407 12093990 There EX B-NP O
2 408 411 12093990 are VBP B-VP O
3 412 414 12093990 no DT B-NP O
4 415 423 12093990 approved VBN I-NP O
5 424 433 12093990 antiviral JJ I-NP O
6 434 440 12093990 agents NNS I-NP O
7 441 445 12093990 with IN B-PP O
8 446 452 12093990 proven JJ B-NP O
9 453 461 12093990 efficacy NN I-NP O
10 462 465 12093990 for IN B-PP O
11 466 469 12093990 the DT B-NP O
12 470 479 12093990 treatment NN I-NP O
13 480 482 12093990 of IN B-PP O
14 483 489 12093990 severe JJ B-NP O
15 490 500 12093990 adenovirus NN I-NP D000257
16 501 508 12093990 disease NN I-NP D000257
17 508 509 12093990 , , O O
18 510 513 12093990 nor CC O O
19 514 517 12093990 are VBP B-VP O
20 518 523 12093990 there RB B-ADVP O
21 524 527 12093990 any DT B-NP O
22 528 539 12093990 prospective JJ I-NP O
23 540 550 12093990 randomized VBN I-NP O
24 550 551 12093990 , , I-NP O
25 552 562 12093990 controlled VBN I-NP O
26 563 569 12093990 trials NNS I-NP O
27 570 572 12093990 of IN B-PP O
28 573 584 12093990 potentially RB B-NP O
29 585 591 12093990 useful JJ I-NP O
30 592 596 12093990 anti AFX I-NP O
31 596 597 12093990 - HYPH I-NP O
32 597 607 12093990 adenovirus NN I-NP O
33 608 617 12093990 therapies NNS I-NP O
34 617 618 12093990 . . O O

1 619 627 12093990 Apparent JJ B-NP O
2 628 636 12093990 clinical JJ I-NP O
3 637 644 12093990 success NN I-NP O
4 645 647 12093990 in IN B-PP O
5 648 651 12093990 the DT B-NP O
6 652 661 12093990 treatment NN I-NP O
7 662 664 12093990 of IN B-PP O
8 665 671 12093990 severe JJ B-NP O
9 672 682 12093990 adenovirus NN I-NP D000257
10 683 690 12093990 disease NN I-NP D000257
11 691 693 12093990 is VBZ B-VP O
12 694 701 12093990 limited VBN I-VP O
13 702 704 12093990 to TO B-PP O
14 705 706 12093990 a DT B-NP O
15 707 710 12093990 few JJ I-NP O
16 711 715 12093990 case NN I-NP O
17 716 723 12093990 reports NNS I-NP O
18 724 727 12093990 and CC O O
19 728 733 12093990 small JJ B-NP O
20 734 740 12093990 series NN I-NP O
21 740 741 12093990 . . O O

1 742 752 12093990 Experience NN B-NP O
2 753 755 12093990 is VBZ B-VP O
3 756 764 12093990 greatest JJS B-ADJP O
4 765 769 12093990 with IN B-PP O
5 770 781 12093990 intravenous JJ B-NP O
6 782 791 12093990 ribavirin NN I-NP D012254
7 792 795 12093990 and CC I-NP O
8 796 805 12093990 cidofovir NN I-NP C059262
9 805 806 12093990 . . O O

1 807 816 12093990 Ribavirin NN B-NP D012254
2 816 817 12093990 , , O O
3 818 819 12093990 a DT B-NP O
4 820 829 12093990 guanosine NN I-NP D006151
5 830 838 12093990 analogue NN I-NP O
6 838 839 12093990 , , O O
7 840 843 12093990 has VBZ B-VP O
8 844 849 12093990 broad JJ B-NP O
9 850 859 12093990 antiviral JJ I-NP O
10 860 868 12093990 activity NN I-NP O
11 869 876 12093990 against IN B-PP O
12 877 881 12093990 both CC O O
13 882 885 12093990 RNA NN B-NP O
14 886 889 12093990 and CC I-NP O
15 890 893 12093990 DNA NN I-NP O
16 894 901 12093990 viruses NNS I-NP O
17 901 902 12093990 , , O O
18 903 912 12093990 including VBG B-PP O
19 913 923 12093990 documented VBN B-NP O
20 924 932 12093990 activity NN I-NP O
21 933 940 12093990 against IN B-PP O
22 941 951 12093990 adenovirus NN B-NP O
23 952 954 12093990 in FW B-ADVP O
24 955 960 12093990 vitro FW I-ADVP O
25 960 961 12093990 . . O O

1 962 971 12093990 Ribavirin NN B-NP D012254
2 972 974 12093990 is VBZ B-VP O
3 975 983 12093990 licensed VBN I-VP O
4 984 986 12093990 in IN B-PP O
5 987 994 12093990 aerosol NN B-NP O
6 995 999 12093990 form NN I-NP O
7 1000 1003 12093990 for IN B-PP O
8 1004 1007 12093990 the DT B-NP O
9 1008 1017 12093990 treatment NN I-NP O
10 1018 1020 12093990 of IN B-PP O
11 1021 1032 12093990 respiratory JJ B-NP D018357
12 1033 1042 12093990 syncytial JJ I-NP D018357
13 1043 1048 12093990 virus NN I-NP D018357
14 1049 1058 12093990 infection NN I-NP D018357
15 1058 1059 12093990 , , O O
16 1060 1063 12093990 and CC O O
17 1064 1070 12093990 orally RB B-ADVP O
18 1071 1073 12093990 in IN B-PP O
19 1074 1085 12093990 combination NN B-NP O
20 1086 1090 12093990 with IN B-PP O
21 1091 1101 12093990 interferon NN B-NP O
22 1102 1104 12093990 to TO B-VP O
23 1105 1110 12093990 treat VB I-VP O
24 1111 1120 12093990 hepatitis NN B-NP D006526
25 1121 1122 12093990 C NN I-NP D006526
26 1122 1123 12093990 . . O O

1 1124 1135 12093990 Intravenous JJ B-NP O
2 1136 1145 12093990 ribavirin NN I-NP D012254
3 1146 1148 12093990 is VBZ B-VP O
4 1149 1152 12093990 the DT B-NP O
5 1153 1162 12093990 treatment NN I-NP O
6 1163 1165 12093990 of IN B-PP O
7 1166 1172 12093990 choice NN B-NP O
8 1173 1176 12093990 for IN B-PP O
9 1177 1186 12093990 infection NN B-NP D006482
10 1187 1191 12093990 with IN B-PP D006482
11 1192 1203 12093990 hemorrhagic JJ B-NP D006482
12 1204 1209 12093990 fever NN I-NP D006482
13 1210 1217 12093990 viruses NNS I-NP D006482
14 1217 1218 12093990 . . O O

1 1219 1222 12093990 The DT B-NP O
2 1223 1227 12093990 most RBS I-NP O
3 1228 1234 12093990 common JJ I-NP O
4 1235 1242 12093990 adverse JJ I-NP O
5 1243 1249 12093990 effect NN I-NP O
6 1250 1252 12093990 of IN B-PP O
7 1253 1264 12093990 intravenous JJ B-NP O
8 1265 1274 12093990 ribavirin NN I-NP D012254
9 1275 1277 12093990 is VBZ B-VP O
10 1278 1288 12093990 reversible JJ B-NP O
11 1289 1293 12093990 mild JJ I-NP O
12 1294 1300 12093990 anemia NN I-NP D000740
13 1300 1301 12093990 . . O O

1 1302 1305 12093990 The DT B-NP O
2 1306 1309 12093990 use NN I-NP O
3 1310 1312 12093990 of IN B-PP O
4 1313 1322 12093990 cidofovir NN B-NP C059262
5 1323 1325 12093990 in IN B-PP O
6 1326 1332 12093990 severe JJ B-NP O
7 1333 1343 12093990 adenovirus NN I-NP D000257
8 1344 1353 12093990 infection NN I-NP D000257
9 1354 1357 12093990 has VBZ B-VP O
10 1358 1362 12093990 been VBN I-VP O
11 1363 1370 12093990 limited VBN I-VP O
12 1371 1373 12093990 by IN B-PP O
13 1374 1381 12093990 adverse JJ B-NP O
14 1382 1389 12093990 effects NNS I-NP O
15 1389 1390 12093990 , , O O
16 1391 1394 12093990 the DT B-NP O
17 1395 1399 12093990 most RBS I-NP O
18 1400 1411 12093990 significant JJ I-NP O
19 1412 1414 12093990 of IN B-PP O
20 1415 1420 12093990 which WDT B-NP O
21 1421 1423 12093990 is VBZ B-VP O
22 1424 1438 12093990 nephrotoxicity NN B-NP D007674
23 1438 1439 12093990 . . O O

1 1440 1449 12093990 OBJECTIVE NN B-NP O
2 1449 1450 12093990 : : O O
3 1451 1453 12093990 We PRP B-NP O
4 1454 1460 12093990 report VBP B-VP O
5 1461 1464 12093990 our PRP$ B-NP O
6 1465 1475 12093990 experience NN I-NP O
7 1476 1480 12093990 with IN B-PP O
8 1481 1492 12093990 intravenous JJ B-NP O
9 1493 1502 12093990 ribavirin NN I-NP D012254
10 1503 1510 12093990 therapy NN I-NP O
11 1511 1514 12093990 for IN B-PP O
12 1515 1521 12093990 severe JJ B-NP O
13 1522 1532 12093990 adenovirus NN I-NP D000257
14 1533 1540 12093990 disease NN I-NP D000257
15 1541 1543 12093990 in IN B-PP O
16 1544 1545 12093990 a DT B-NP O
17 1546 1552 12093990 series NN I-NP O
18 1553 1555 12093990 of IN B-PP O
19 1556 1573 12093990 immunocompromised JJ B-NP O
20 1574 1582 12093990 children NNS I-NP O
21 1583 1586 12093990 and CC O O
22 1587 1593 12093990 review VB B-VP O
23 1594 1597 12093990 the DT B-NP O
24 1598 1608 12093990 literature NN I-NP O
25 1608 1609 12093990 . . O O

1 1610 1616 12093990 DESIGN NN B-NP O
2 1616 1617 12093990 / SYM I-NP O
3 1617 1624 12093990 METHODS NN I-NP O
4 1624 1625 12093990 : : O O
5 1626 1628 12093990 We PRP B-NP O
6 1629 1644 12093990 retrospectively RB B-ADVP O
7 1645 1653 12093990 reviewed VBD B-VP O
8 1654 1657 12093990 the DT B-NP O
9 1658 1665 12093990 medical JJ I-NP O
10 1666 1673 12093990 records NNS I-NP O
11 1674 1676 12093990 of IN B-PP O
12 1677 1678 12093990 5 CD B-NP O
13 1679 1687 12093990 children NNS I-NP O
14 1688 1695 12093990 treated VBN B-VP O
15 1696 1700 12093990 with IN B-PP O
16 1701 1712 12093990 intravenous JJ B-NP O
17 1713 1722 12093990 ribavirin NN I-NP D012254
18 1723 1726 12093990 for IN B-PP O
19 1727 1737 12093990 documented VBN B-NP O
20 1738 1744 12093990 severe JJ I-NP O
21 1745 1755 12093990 adenovirus NN I-NP D000257
22 1756 1763 12093990 disease NN I-NP D000257
23 1763 1764 12093990 . . O O

1 1765 1768 12093990 Two CD B-NP O
2 1769 1777 12093990 patients NNS I-NP O
3 1778 1787 12093990 developed VBD B-VP O
4 1788 1798 12093990 adenovirus NN B-NP O
5 1799 1810 12093990 hemorrhagic JJ I-NP D006470
6 1811 1819 12093990 cystitis NN I-NP D006470
7 1820 1825 12093990 after IN B-PP O
8 1826 1833 12093990 cardiac JJ B-NP O
9 1834 1837 12093990 and CC I-NP O
10 1838 1842 12093990 bone NN I-NP O
11 1843 1849 12093990 marrow NN I-NP O
12 1850 1861 12093990 transplants NNS I-NP O
13 1861 1862 12093990 , , O O
14 1863 1875 12093990 respectively RB B-ADVP O
15 1875 1876 12093990 . . O O

1 1877 1880 12093990 The DT B-NP O
2 1881 1885 12093990 bone NN I-NP O
3 1886 1892 12093990 marrow NN I-NP O
4 1893 1903 12093990 transplant NN I-NP O
5 1904 1911 12093990 patient NN I-NP O
6 1912 1916 12093990 also RB B-ADVP O
7 1917 1925 12093990 received VBD B-VP O
8 1926 1937 12093990 intravenous JJ B-NP O
9 1938 1947 12093990 cidofovir NN I-NP C059262
10 1948 1951 12093990 for IN B-PP O
11 1952 1963 12093990 progressive JJ B-NP O
12 1964 1976 12093990 disseminated VBN I-NP O
13 1977 1984 12093990 disease NN I-NP O
14 1984 1985 12093990 . . O O

1 1986 1988 12093990 An DT B-NP O
2 1989 1999 12093990 additional JJ I-NP O
3 2000 2001 12093990 3 CD I-NP O
4 2002 2010 12093990 children NNS I-NP O
5 2011 2020 12093990 developed VBD B-VP O
6 2021 2031 12093990 adenovirus NN B-NP D000257
7 2032 2041 12093990 pneumonia NN I-NP D000257
8 2041 2042 12093990 ; : O O
9 2043 2044 12093990 2 CD B-NP O
10 2045 2049 12093990 were VBD B-VP O
11 2050 2058 12093990 neonates NNS B-NP O
12 2058 2059 12093990 , , O O
13 2060 2061 12093990 1 CD B-NP O
14 2062 2064 12093990 of IN B-PP O
15 2065 2069 12093990 whom WP B-NP O
16 2070 2073 12093990 had VBD B-VP O
17 2074 2081 12093990 partial JJ B-NP O
18 2082 2090 12093990 DiGeorge NNP I-NP D004062
19 2091 2099 12093990 syndrome NN I-NP D004062
20 2099 2100 12093990 . . O O

1 2101 2104 12093990 The DT B-NP O
2 2105 2114 12093990 remaining VBG I-NP O
3 2115 2121 12093990 infant NN I-NP O
4 2122 2125 12093990 had VBD B-VP O
5 2126 2134 12093990 recently RB I-VP O
6 2135 2144 12093990 undergone VBN I-VP O
7 2145 2146 12093990 a DT B-NP O
8 2147 2154 12093990 cardiac JJ I-NP O
9 2155 2165 12093990 transplant NN I-NP O
10 2165 2166 12093990 . . O O

1 2167 2178 12093990 Intravenous JJ B-NP O
2 2179 2188 12093990 ribavirin NN I-NP D012254
3 2189 2192 12093990 was VBD B-VP O
4 2193 2205 12093990 administered VBN I-VP O
5 2206 2208 12093990 on IN B-PP O
6 2209 2210 12093990 a DT B-NP O
7 2211 2224 12093990 compassionate JJ I-NP O
8 2224 2225 12093990 - HYPH I-NP O
9 2225 2228 12093990 use NN I-NP O
10 2229 2237 12093990 protocol NN I-NP O
11 2237 2238 12093990 . . O O

1 2239 2246 12093990 RESULTS NNS B-NP O
2 2246 2247 12093990 : : O O
3 2248 2256 12093990 Complete JJ B-NP O
4 2257 2265 12093990 clinical JJ I-NP O
5 2266 2274 12093990 recovery NN I-NP O
6 2275 2283 12093990 followed VBD B-VP O
7 2284 2289 12093990 later RB B-ADVP O
8 2290 2292 12093990 by IN B-PP O
9 2293 2298 12093990 viral JJ B-NP O
10 2299 2308 12093990 clearance NN I-NP O
11 2309 2312 12093990 was VBD B-VP O
12 2313 2321 12093990 observed VBN I-VP O
13 2322 2324 12093990 in IN B-PP O
14 2325 2326 12093990 2 CD B-NP O
15 2327 2335 12093990 children NNS I-NP O
16 2335 2336 12093990 : : O O
17 2337 2340 12093990 the DT B-NP O
18 2341 2348 12093990 cardiac JJ I-NP O
19 2349 2359 12093990 transplant NN I-NP O
20 2360 2369 12093990 recipient NN I-NP O
21 2370 2374 12093990 with IN B-PP O
22 2375 2385 12093990 adenovirus NN B-NP O
23 2386 2397 12093990 hemorrhagic JJ I-NP D006470
24 2398 2406 12093990 cystitis NN I-NP D006470
25 2407 2410 12093990 and CC O O
26 2411 2414 12093990 the DT B-NP O
27 2415 2430 12093990 immunocompetent JJ I-NP O
28 2431 2438 12093990 neonate NN I-NP O
29 2439 2443 12093990 with IN B-PP O
30 2444 2454 12093990 adenovirus NN B-NP D000257
31 2455 2464 12093990 pneumonia NN I-NP D000257
32 2464 2465 12093990 . . O O

1 2466 2469 12093990 The DT B-NP O
2 2470 2479 12093990 remaining VBG I-NP O
3 2480 2481 12093990 3 CD I-NP O
4 2482 2490 12093990 children NNS I-NP O
5 2491 2495 12093990 died VBD B-VP O
6 2496 2498 12093990 of IN B-PP O
7 2499 2509 12093990 adenovirus NN B-NP D000257
8 2510 2517 12093990 disease NN I-NP D000257
9 2517 2518 12093990 . . O O

1 2519 2530 12093990 Intravenous JJ B-NP O
2 2531 2540 12093990 ribavirin NN I-NP D012254
3 2541 2548 12093990 therapy NN I-NP O
4 2549 2552 12093990 was VBD B-VP O
5 2553 2557 12093990 well RB I-VP O
6 2558 2567 12093990 tolerated VBN I-VP O
7 2567 2568 12093990 . . O O

1 2569 2572 12093990 Use NN B-NP O
2 2573 2575 12093990 of IN B-PP O
3 2576 2585 12093990 cidofovir NN B-NP C059262
4 2586 2588 12093990 in IN B-PP O
5 2589 2590 12093990 1 CD B-NP O
6 2591 2596 12093990 child NN I-NP O
7 2597 2600 12093990 was VBD B-VP O
8 2601 2611 12093990 associated VBN I-VP O
9 2612 2616 12093990 with IN B-PP O
10 2617 2628 12093990 progressive JJ B-NP D058186
11 2629 2634 12093990 renal JJ I-NP D058186
12 2635 2642 12093990 failure NN I-NP D058186
13 2643 2646 12093990 and CC I-NP O
14 2647 2658 12093990 neutropenia NN I-NP D009503
15 2658 2659 12093990 . . O O

1 2660 2670 12093990 DISCUSSION NN B-NP O
2 2670 2671 12093990 : : O O
3 2672 2675 12093990 Our PRP$ B-NP O
4 2676 2682 12093990 series NN I-NP O
5 2683 2685 12093990 of IN B-PP O
6 2686 2694 12093990 patients NNS B-NP O
7 2695 2697 12093990 is VBZ B-VP O
8 2698 2712 12093990 representative JJ B-ADJP O
9 2713 2715 12093990 of IN B-PP O
10 2716 2719 12093990 the DT B-NP O
11 2720 2728 12093990 spectrum NN I-NP O
12 2729 2731 12093990 of IN B-PP O
13 2732 2749 12093990 immunocompromised JJ B-NP O
14 2750 2758 12093990 children NNS I-NP O
15 2759 2761 12093990 at IN B-PP O
16 2762 2770 12093990 greatest JJS B-NP O
17 2771 2775 12093990 risk NN I-NP O
18 2776 2779 12093990 for IN B-PP O
19 2780 2786 12093990 severe JJ B-NP O
20 2787 2797 12093990 adenovirus NN I-NP D000257
21 2798 2805 12093990 disease NN I-NP D000257
22 2805 2806 12093990 , , O O
23 2807 2813 12093990 namely RB B-NP O
24 2814 2819 12093990 solid JJ I-NP O
25 2819 2820 12093990 - HYPH I-NP O
26 2820 2825 12093990 organ NN I-NP O
27 2826 2829 12093990 and CC I-NP O
28 2830 2834 12093990 bone NN I-NP O
29 2835 2841 12093990 marrow NN I-NP O
30 2842 2852 12093990 transplant NN I-NP O
31 2853 2863 12093990 recipients NNS I-NP O
32 2863 2864 12093990 , , O O
33 2865 2873 12093990 neonates NNS B-NP O
34 2873 2874 12093990 , , O O
35 2875 2878 12093990 and CC O O
36 2879 2887 12093990 children NNS B-NP O
37 2888 2892 12093990 with IN B-PP O
38 2893 2909 12093990 immunodeficiency NN B-NP D007153
39 2909 2910 12093990 . . O O

1 2911 2919 12093990 Although IN B-SBAR O
2 2920 2931 12093990 intravenous JJ B-NP O
3 2932 2941 12093990 ribavirin NN I-NP D012254
4 2942 2945 12093990 was VBD B-VP O
5 2946 2949 12093990 not RB O O
6 2950 2959 12093990 effective JJ B-ADJP O
7 2960 2963 12093990 for IN B-PP O
8 2964 2967 12093990 all DT B-NP O
9 2968 2976 12093990 children NNS I-NP O
10 2977 2981 12093990 with IN B-PP O
11 2982 2988 12093990 severe JJ B-NP O
12 2989 2999 12093990 adenovirus NN I-NP D000257
13 3000 3007 12093990 disease NN I-NP D000257
14 3008 3010 12093990 in IN B-PP O
15 3011 3015 12093990 this DT B-NP O
16 3016 3022 12093990 series NN I-NP O
17 3023 3025 12093990 or CC B-PP O
18 3026 3028 12093990 in IN B-PP O
19 3029 3032 12093990 the DT B-NP O
20 3033 3043 12093990 literature NN I-NP O
21 3043 3044 12093990 , , O O
22 3045 3052 12093990 therapy NN B-NP O
23 3053 3055 12093990 is VBZ B-VP O
24 3056 3064 12093990 unlikely JJ B-ADJP O
25 3065 3067 12093990 to TO B-VP O
26 3068 3070 12093990 be VB I-VP O
27 3071 3073 12093990 of IN B-PP O
28 3074 3081 12093990 benefit NN B-NP O
29 3082 3084 12093990 if IN B-SBAR O
30 3085 3090 12093990 begun VBN B-VP O
31 3091 3095 12093990 late RB B-ADVP O
32 3096 3098 12093990 in IN B-PP O
33 3099 3102 12093990 the DT B-NP O
34 3103 3109 12093990 course NN I-NP O
35 3110 3112 12093990 of IN B-PP O
36 3113 3116 12093990 the DT B-NP O
37 3117 3126 12093990 infection NN I-NP D007239
38 3126 3127 12093990 . . O O

1 3128 3133 12093990 Early RB B-NP O
2 3134 3148 12093990 identification NN I-NP O
3 3148 3149 12093990 , , O O
4 3150 3152 12093990 eg NN B-NP O
5 3153 3155 12093990 by IN B-PP O
6 3156 3166 12093990 polymerase NN B-NP O
7 3167 3172 12093990 chain NN I-NP O
8 3173 3181 12093990 reaction NN I-NP O
9 3182 3184 12093990 of IN B-PP O
10 3185 3190 12093990 those DT B-NP O
11 3191 3199 12093990 patients NNS I-NP O
12 3200 3202 12093990 at IN B-PP O
13 3203 3207 12093990 risk NN B-NP O
14 3208 3210 12093990 of IN B-PP O
15 3211 3223 12093990 disseminated VBN B-NP O
16 3224 3234 12093990 adenovirus NN I-NP D000257
17 3235 3242 12093990 disease NN I-NP D000257
18 3243 3246 12093990 may MD B-VP O
19 3247 3253 12093990 permit VB I-VP O
20 3254 3261 12093990 earlier JJR B-NP O
21 3262 3271 12093990 antiviral JJ I-NP O
22 3272 3281 12093990 treatment NN I-NP O
23 3282 3285 12093990 and CC O O
24 3286 3292 12093990 better JJR B-NP O
25 3293 3303 12093990 evaluation NN I-NP O
26 3304 3306 12093990 of IN B-PP O
27 3307 3318 12093990 therapeutic JJ B-NP O
28 3319 3327 12093990 response NN I-NP O
29 3327 3328 12093990 . . O O

1 3329 3340 12093990 CONCLUSIONS NNS B-NP O
2 3340 3341 12093990 : : O O
3 3342 3345 12093990 Two CD B-NP O
4 3346 3348 12093990 of IN B-PP O
5 3349 3350 12093990 5 CD B-NP O
6 3351 3359 12093990 children NNS I-NP O
7 3360 3364 12093990 with IN B-PP O
8 3365 3371 12093990 severe JJ B-NP O
9 3372 3382 12093990 adenovirus NN I-NP D000257
10 3383 3390 12093990 disease NN I-NP D000257
11 3391 3398 12093990 treated VBN B-VP O
12 3399 3403 12093990 with IN B-PP O
13 3404 3415 12093990 intravenous JJ B-NP O
14 3416 3425 12093990 ribavirin NN I-NP D012254
15 3426 3435 12093990 recovered VBD B-VP O
16 3435 3436 12093990 . . O O

1 3437 3440 12093990 The DT B-NP O
2 3441 3453 12093990 availability NN I-NP O
3 3454 3456 12093990 of IN B-PP O
4 3457 3462 12093990 newer JJR B-NP O
5 3463 3468 12093990 rapid JJ I-NP O
6 3469 3479 12093990 diagnostic NN I-NP O
7 3480 3490 12093990 techniques NNS I-NP O
8 3490 3491 12093990 , , O O
9 3492 3496 12093990 such JJ B-PP O
10 3497 3499 12093990 as IN I-PP O
11 3500 3510 12093990 polymerase NN B-NP O
12 3511 3516 12093990 chain NN I-NP O
13 3517 3525 12093990 reaction NN I-NP O
14 3525 3526 12093990 , , O O
15 3527 3530 12093990 may MD B-VP O
16 3531 3535 12093990 make VB I-VP O
17 3536 3543 12093990 earlier RBR B-ADVP O
18 3543 3544 12093990 , , O O
19 3545 3549 12093990 more RBR B-NP O
20 3550 3559 12093990 effective JJ I-NP O
21 3560 3569 12093990 treatment NN I-NP O
22 3570 3572 12093990 of IN B-PP O
23 3573 3583 12093990 adenovirus NN B-NP D000257
24 3584 3593 12093990 infection NN I-NP D000257
25 3594 3602 12093990 possible JJ B-ADJP O
26 3602 3603 12093990 . . O O

1 3604 3609 12093990 Given VBN B-PP O
2 3610 3613 12093990 the DT B-NP O
3 3614 3625 12093990 seriousness NN I-NP O
4 3626 3629 12093990 and CC O O
5 3630 3640 12093990 increasing VBG B-NP O
6 3641 3651 12093990 prevalence NN I-NP O
7 3652 3654 12093990 of IN B-PP O
8 3655 3665 12093990 adenovirus NN B-NP D000257
9 3666 3673 12093990 disease NN I-NP D000257
10 3674 3676 12093990 in IN B-PP O
11 3677 3684 12093990 certain JJ B-NP O
12 3685 3690 12093990 hosts NNS I-NP O
13 3690 3691 12093990 , , O O
14 3692 3702 12093990 especially RB B-ADVP O
15 3703 3711 12093990 children NNS B-NP O
16 3711 3712 12093990 , , O O
17 3713 3714 12093990 a DT B-NP O
18 3715 3720 12093990 large JJ I-NP O
19 3720 3721 12093990 , , I-NP O
20 3722 3733 12093990 multicenter JJ I-NP O
21 3734 3742 12093990 clinical JJ I-NP O
22 3743 3748 12093990 trial NN I-NP O
23 3749 3751 12093990 of IN B-PP O
24 3752 3763 12093990 potentially RB B-NP O
25 3764 3770 12093990 useful JJ I-NP O
26 3771 3775 12093990 anti AFX I-NP O
27 3775 3776 12093990 - HYPH I-NP O
28 3776 3786 12093990 adenoviral JJ I-NP O
29 3787 3796 12093990 therapies NNS I-NP O
30 3796 3797 12093990 , , O O
31 3798 3802 12093990 such JJ B-PP O
32 3803 3805 12093990 as IN I-PP O
33 3806 3817 12093990 intravenous JJ B-NP O
34 3818 3827 12093990 ribavirin NN I-NP D012254
35 3827 3828 12093990 , , O O
36 3829 3831 12093990 is VBZ B-VP O
37 3832 3839 12093990 clearly RB I-VP O
38 3840 3848 12093990 required VBN I-VP O
39 3849 3851 12093990 to TO I-VP O
40 3852 3863 12093990 demonstrate VB I-VP O
41 3864 3867 12093990 the DT B-NP O
42 3868 3872 12093990 most RBS I-NP O
43 3873 3882 12093990 effective JJ I-NP O
44 3883 3886 12093990 and CC I-NP O
45 3887 3892 12093990 least JJS I-NP O
46 3893 3898 12093990 toxic JJ I-NP O
47 3899 3906 12093990 therapy NN I-NP O
48 3906 3907 12093990 . . O O

1 0 0 11900788 -DOCSTART- -X- -X- O

1 0 8 11900788 Nicotine NN B-NP D009538
2 9 21 11900788 potentiation NN I-NP O
3 22 24 11900788 of IN B-PP O
4 25 33 11900788 morphine NN B-NP D009020
5 33 34 11900788 - HYPH B-NP O
6 34 41 11900788 induced VBN I-NP O
7 42 51 11900788 catalepsy NN I-NP D002375
8 52 54 11900788 in IN B-PP O
9 55 59 11900788 mice NNS B-NP O
10 59 60 11900788 . . O O
11 61 63 11900788 In IN B-PP O
12 64 67 11900788 the DT B-NP O
13 68 75 11900788 present JJ I-NP O
14 76 81 11900788 study NN I-NP O
15 81 82 11900788 , , O O
16 83 90 11900788 effects NNS B-NP O
17 91 93 11900788 of IN B-PP O
18 94 102 11900788 nicotine NN B-NP D009538
19 103 105 11900788 on IN B-PP O
20 106 115 11900788 catalepsy NN B-NP D002375
21 116 123 11900788 induced VBN B-VP O
22 124 126 11900788 by IN B-PP O
23 127 135 11900788 morphine NN B-NP D009020
24 136 138 11900788 in IN B-PP O
25 139 143 11900788 mice NNS B-NP O
26 144 148 11900788 have VBP B-VP O
27 149 153 11900788 been VBN I-VP O
28 154 166 11900788 investigated VBN I-VP O
29 166 167 11900788 . . O O

1 168 176 11900788 Morphine NN B-NP D009020
2 177 180 11900788 but CC B-NP O
3 181 184 11900788 not RB I-NP O
4 185 193 11900788 nicotine NN B-NP D009538
5 194 201 11900788 induced VBD B-VP O
6 202 203 11900788 a DT B-NP O
7 204 208 11900788 dose NN I-NP O
8 208 209 11900788 - HYPH B-NP O
9 209 218 11900788 dependent JJ I-NP O
10 219 228 11900788 catalepsy NN I-NP D002375
11 228 229 11900788 . . O O

1 230 233 11900788 The DT B-NP O
2 234 242 11900788 response NN I-NP O
3 243 245 11900788 of IN B-PP O
4 246 254 11900788 morphine NN B-NP D009020
5 255 258 11900788 was VBD B-VP O
6 259 270 11900788 potentiated VBN I-VP O
7 271 273 11900788 by IN B-PP O
8 274 282 11900788 nicotine NN B-NP D009538
9 282 283 11900788 . . O O

1 284 299 11900788 Intraperitoneal JJ B-NP O
2 300 314 11900788 administration NN I-NP O
3 315 317 11900788 of IN B-PP O
4 318 326 11900788 atropine NN B-NP D001285
5 326 327 11900788 , , O O
6 328 336 11900788 naloxone NN B-NP D009270
7 336 337 11900788 , , O O
8 338 350 11900788 mecamylamine NN B-NP D008464
9 350 351 11900788 , , O O
10 352 355 11900788 and CC O O
11 356 369 11900788 hexamethonium NN B-NP D018738
12 370 372 11900788 to TO B-PP O
13 373 377 11900788 mice NNS B-NP O
14 378 385 11900788 reduced VBD B-VP O
15 386 395 11900788 catalepsy NN B-NP D002375
16 396 403 11900788 induced VBN B-VP O
17 404 406 11900788 by IN B-PP O
18 407 408 11900788 a DT B-NP O
19 409 420 11900788 combination NN I-NP O
20 421 423 11900788 of IN B-PP O
21 424 432 11900788 morphine NN B-NP D009020
22 433 437 11900788 with IN B-PP O
23 438 446 11900788 nicotine NN B-NP D009538
24 446 447 11900788 . . O O

1 448 471 11900788 Intracerebroventricular JJ B-NP O
2 472 481 11900788 injection NN I-NP O
3 482 484 11900788 of IN B-PP O
4 485 493 11900788 atropine NN B-NP D001285
5 493 494 11900788 , , O O
6 495 508 11900788 hexamethonium NN B-NP D018738
7 508 509 11900788 , , O O
8 510 513 11900788 and CC O O
9 514 522 11900788 naloxone NN B-NP D009270
10 523 527 11900788 also RB B-ADVP O
11 528 537 11900788 decreased VBD B-VP O
12 538 547 11900788 catalepsy NN B-NP D002375
13 548 555 11900788 induced VBN B-VP O
14 556 558 11900788 by IN B-PP O
15 559 567 11900788 morphine NN B-NP D009020
16 568 572 11900788 plus CC I-NP O
17 573 581 11900788 nicotine NN I-NP D009538
18 581 582 11900788 . . O O

1 583 598 11900788 Intraperitoneal JJ B-NP O
2 599 613 11900788 administration NN I-NP O
3 614 616 11900788 of IN B-PP O
4 617 625 11900788 atropine NN B-NP D001285
5 625 626 11900788 , , O O
6 627 630 11900788 but CC O O
7 631 634 11900788 not RB O O
8 635 650 11900788 intraperitoneal JJ B-NP O
9 651 653 11900788 or CC I-NP O
10 654 677 11900788 intracerebroventricular JJ I-NP O
11 678 687 11900788 injection NN I-NP O
12 688 690 11900788 of IN B-PP O
13 691 704 11900788 hexamethonium NN B-NP D018738
14 704 705 11900788 , , O O
15 706 715 11900788 decreased VBD B-VP O
16 716 719 11900788 the DT B-NP O
17 720 726 11900788 effect NN I-NP O
18 727 729 11900788 of IN B-PP O
19 730 731 11900788 a DT B-NP O
20 732 738 11900788 single JJ I-NP O
21 739 743 11900788 dose NN I-NP O
22 744 746 11900788 of IN B-PP O
23 747 755 11900788 morphine NN B-NP D009020
24 755 756 11900788 . . O O

1 757 759 11900788 It PRP B-NP O
2 760 763 11900788 was VBD B-VP O
3 764 773 11900788 concluded VBN I-VP O
4 774 778 11900788 that IN B-SBAR O
5 779 787 11900788 morphine NN B-NP D009020
6 788 797 11900788 catalepsy NN I-NP D002375
7 798 801 11900788 can MD B-VP O
8 802 804 11900788 be VB I-VP O
9 805 813 11900788 elicited VBN I-VP O
10 814 816 11900788 by IN B-PP O
11 817 823 11900788 opioid JJ B-NP O
12 824 827 11900788 and CC I-NP O
13 828 839 11900788 cholinergic JJ I-NP O
14 840 849 11900788 receptors NNS I-NP O
15 849 850 11900788 , , O O
16 851 854 11900788 and CC O O
17 855 858 11900788 the DT B-NP O
18 859 871 11900788 potentiation NN I-NP O
19 872 874 11900788 of IN B-PP O
20 875 883 11900788 morphine NN B-NP D009020
21 884 891 11900788 induced VBN B-VP O
22 892 894 11900788 by IN B-PP O
23 895 903 11900788 nicotine NN B-NP D009538
24 904 907 11900788 may MD B-VP O
25 908 912 11900788 also RB I-VP O
26 913 915 11900788 be VB I-VP O
27 916 924 11900788 mediated VBN I-VP O
28 925 932 11900788 through IN B-PP O
29 933 944 11900788 cholinergic JJ B-NP O
30 945 953 11900788 receptor NN I-NP O
31 954 964 11900788 mechanisms NNS I-NP O
32 964 965 11900788 . . O O

1 0 0 3461217 -DOCSTART- -X- -X- O

1 0 10 3461217 Production NN B-NP O
2 11 13 3461217 of IN B-PP O
3 14 27 3461217 autochthonous JJ B-NP O
4 28 36 3461217 prostate NN I-NP D011471
5 37 43 3461217 cancer NN I-NP D011471
6 44 46 3461217 in IN B-PP O
7 47 53 3461217 Lobund NNP B-NP O
8 53 54 3461217 - HYPH B-NP O
9 54 60 3461217 Wistar NNP I-NP O
10 61 65 3461217 rats NNS I-NP O
11 66 68 3461217 by IN B-PP O
12 69 79 3461217 treatments NNS B-NP O
13 80 84 3461217 with IN B-PP O
14 85 86 3461217 N NN B-NP D008770
15 86 87 3461217 - HYPH B-NP D008770
16 87 94 3461217 nitroso NN I-NP D008770
17 94 95 3461217 - HYPH B-NP D008770
18 95 96 3461217 N NN I-NP D008770
19 96 97 3461217 - HYPH B-NP D008770
20 97 107 3461217 methylurea NN I-NP D008770
21 108 111 3461217 and CC I-NP O
22 112 124 3461217 testosterone NN I-NP D013739
23 124 125 3461217 . . O O
24 126 130 3461217 More JJR B-NP O
25 131 135 3461217 than IN I-NP O
26 136 139 3461217 50% CD I-NP O
27 140 142 3461217 of IN B-PP O
28 143 149 3461217 Lobund NNP B-NP O
29 149 150 3461217 - HYPH O O
30 150 156 3461217 Wistar NNP B-NP O
31 157 158 3461217 ( ( O O
32 158 159 3461217 L NN B-NP O
33 159 160 3461217 - HYPH O O
34 160 161 3461217 W NN B-NP O
35 161 162 3461217 ) ) O O
36 163 169 3461217 strain NN B-NP O
37 170 174 3461217 rats NNS I-NP O
38 175 184 3461217 developed VBD B-VP O
39 185 190 3461217 large JJ B-NP O
40 190 191 3461217 , , I-NP O
41 192 200 3461217 palpable JJ I-NP O
42 201 209 3461217 prostate NN I-NP D011471
43 210 225 3461217 adenocarcinomas NNS I-NP D011471
44 226 227 3461217 ( ( O O
45 227 230 3461217 PAs NNS B-NP D011471
46 230 231 3461217 ) ) O O
47 232 241 3461217 following VBG B-PP O
48 242 252 3461217 treatments NNS B-NP O
49 253 257 3461217 with IN B-PP O
50 258 259 3461217 N NN B-NP D008770
51 259 260 3461217 - HYPH B-NP D008770
52 260 267 3461217 nitroso NN I-NP D008770
53 267 268 3461217 - HYPH B-NP D008770
54 268 269 3461217 N NN I-NP D008770
55 269 270 3461217 - HYPH O D008770
56 270 280 3461217 methylurea NN B-NP D008770
57 281 282 3461217 ( ( O O
58 282 285 3461217 CAS NN B-NP O
59 285 286 3461217 : : O O
60 287 290 3461217 684 CD B-NP O
61 290 291 3461217 - HYPH I-NP O
62 291 293 3461217 93 CD I-NP O
63 293 294 3461217 - HYPH I-NP O
64 294 295 3461217 5 CD I-NP O
65 295 296 3461217 ) ) O O
66 297 300 3461217 and CC O O
67 301 313 3461217 testosterone NN B-NP D043343
68 314 324 3461217 propionate NN I-NP D043343
69 325 326 3461217 [ ( O O
70 326 327 3461217 ( ( O O
71 327 329 3461217 TP NN B-NP D043343
72 329 330 3461217 ) ) O O
73 331 334 3461217 CAS NN B-NP O
74 334 335 3461217 : : O O
75 336 338 3461217 57 CD B-NP O
76 338 339 3461217 - HYPH I-NP O
77 339 341 3461217 85 CD I-NP O
78 341 342 3461217 - HYPH I-NP O
79 342 343 3461217 2 CD I-NP O
80 343 344 3461217 ] ) O O
81 344 345 3461217 , , O O
82 346 349 3461217 and CC O O
83 350 354 3461217 most JJS B-NP O
84 355 357 3461217 of IN B-PP O
85 358 361 3461217 the DT B-NP O
86 362 367 3461217 tumor NN I-NP D009369
87 367 368 3461217 - HYPH B-VP O
88 368 375 3461217 bearing VBG B-NP O
89 376 380 3461217 rats NNS I-NP O
90 381 391 3461217 manifested VBD B-VP O
91 392 402 3461217 metastatic JJ B-NP O
92 403 410 3461217 lesions NNS I-NP O
93 410 411 3461217 . . O O

1 412 415 3461217 The DT B-NP O
2 416 426 3461217 incubation NN I-NP O
3 427 434 3461217 periods NNS I-NP O
4 435 443 3461217 averaged VBD B-VP O
5 444 448 3461217 10.6 CD B-NP O
6 449 455 3461217 months NNS I-NP O
7 455 456 3461217 . . O O

1 457 463 3461217 Within IN B-PP O
2 464 467 3461217 the DT B-NP O
3 468 472 3461217 same JJ I-NP O
4 473 482 3461217 timeframe NN I-NP O
5 482 483 3461217 , , O O
6 484 486 3461217 no DT B-NP O
7 487 488 3461217 L NN I-NP O
8 488 489 3461217 - HYPH B-NP O
9 489 490 3461217 W NN I-NP O
10 491 494 3461217 rat NN I-NP O
11 495 504 3461217 developed VBD B-VP O
12 505 506 3461217 a DT B-NP O
13 507 514 3461217 similar JJ I-NP O
14 515 523 3461217 palpable JJ I-NP O
15 524 526 3461217 PA NN I-NP D011471
16 527 531 3461217 when WRB B-ADVP O
17 532 539 3461217 treated VBN B-VP O
18 540 544 3461217 only RB B-ADVP O
19 545 549 3461217 with IN B-PP O
20 550 552 3461217 TP NN B-NP D043343
21 552 553 3461217 . . O O

1 554 556 3461217 In IN B-PP O
2 557 558 3461217 L NN B-NP O
3 558 559 3461217 - HYPH B-NP O
4 559 560 3461217 W NN I-NP O
5 561 565 3461217 rats NNS I-NP O
6 565 566 3461217 , , O O
7 567 569 3461217 TP NN B-NP D043343
8 570 575 3461217 acted VBD B-VP O
9 576 578 3461217 as IN B-PP O
10 579 580 3461217 a DT B-NP O
11 581 586 3461217 tumor NN I-NP D009369
12 587 598 3461217 enhancement NN I-NP O
13 599 604 3461217 agent NN I-NP O
14 604 605 3461217 , , O O
15 606 610 3461217 with IN B-PP O
16 611 618 3461217 primary JJ B-NP O
17 619 627 3461217 emphasis NN I-NP O
18 628 630 3461217 on IN B-PP O
19 631 634 3461217 the DT B-NP O
20 635 646 3461217 development NN I-NP O
21 647 649 3461217 of IN B-PP O
22 650 658 3461217 prostate NN B-NP D011471
23 659 665 3461217 cancer NN I-NP D011471
24 665 666 3461217 . . O O

1 0 0 2569282 -DOCSTART- -X- -X- O

1 0 15 2569282 Dexmedetomidine NN B-NP D020927
2 15 16 2569282 , , O O
3 17 23 2569282 acting VBG B-VP O
4 24 31 2569282 through IN B-PP O
5 32 39 2569282 central JJ B-NP O
6 40 45 2569282 alpha SYM I-NP O
7 45 46 2569282 - HYPH I-NP O
8 46 47 2569282 2 CD I-NP O
9 48 61 2569282 adrenoceptors NNS I-NP O
10 61 62 2569282 , , O O
11 63 71 2569282 prevents VBZ B-VP O
12 72 78 2569282 opiate NN B-NP O
13 78 79 2569282 - HYPH B-NP O
14 79 86 2569282 induced VBN I-NP O
15 87 93 2569282 muscle NN I-NP D009127
16 94 102 2569282 rigidity NN I-NP D009127
17 103 105 2569282 in IN B-PP O
18 106 109 2569282 the DT B-NP O
19 110 113 2569282 rat NN I-NP O
20 113 114 2569282 . . O O
21 115 118 2569282 The DT B-NP O
22 119 125 2569282 highly RB I-NP O
23 125 126 2569282 - HYPH I-NP O
24 126 135 2569282 selective JJ I-NP O
25 136 141 2569282 alpha SYM I-NP O
26 141 142 2569282 - HYPH I-NP O
27 142 143 2569282 2 CD I-NP O
28 144 154 2569282 adrenergic JJ I-NP O
29 155 162 2569282 agonist NN I-NP O
30 163 178 2569282 dexmedetomidine NN I-NP D020927
31 179 180 2569282 ( ( O O
32 180 181 2569282 D NN B-NP D020927
33 181 182 2569282 - HYPH B-VP D020927
34 182 185 2569282 MED VBN I-VP D020927
35 185 186 2569282 ) ) O O
36 187 189 2569282 is VBZ B-VP O
37 190 197 2569282 capable JJ B-ADJP O
38 198 200 2569282 of IN B-PP O
39 201 209 2569282 inducing VBG B-VP O
40 210 216 2569282 muscle NN B-NP D009123
41 217 227 2569282 flaccidity NN I-NP D009123
42 228 231 2569282 and CC O O
43 232 242 2569282 anesthesia NN B-NP O
44 243 245 2569282 in IN B-PP O
45 246 250 2569282 rats NNS B-NP O
46 251 254 2569282 and CC I-NP O
47 255 259 2569282 dogs NNS I-NP O
48 259 260 2569282 . . O O

1 261 268 2569282 Intense JJ B-NP O
2 269 280 2569282 generalized VBN I-NP O
3 281 287 2569282 muscle NN I-NP D009127
4 288 296 2569282 rigidity NN I-NP D009127
5 297 299 2569282 is VBZ B-VP O
6 300 302 2569282 an DT B-NP O
7 303 314 2569282 undesirable JJ I-NP O
8 315 319 2569282 side NN I-NP O
9 320 326 2569282 effect NN I-NP O
10 327 329 2569282 of IN B-PP O
11 330 336 2569282 potent JJ B-NP O
12 337 343 2569282 opiate JJ I-NP O
13 344 352 2569282 agonists NNS I-NP O
14 352 353 2569282 . . O O

1 354 362 2569282 Although IN B-SBAR O
2 363 366 2569282 the DT B-NP O
3 367 381 2569282 neurochemistry NN I-NP O
4 382 384 2569282 of IN B-PP O
5 385 391 2569282 opiate NN B-NP O
6 391 392 2569282 - HYPH B-NP O
7 392 399 2569282 induced VBN I-NP O
8 400 408 2569282 rigidity NN I-NP D009127
9 409 412 2569282 has VBZ B-VP O
10 413 416 2569282 yet RB I-VP O
11 417 419 2569282 to TO I-VP O
12 420 422 2569282 be VB I-VP O
13 423 428 2569282 fully RB I-VP O
14 429 439 2569282 elucidated VBN I-VP O
15 439 440 2569282 , , O O
16 441 447 2569282 recent JJ B-NP O
17 448 452 2569282 work NN I-NP O
18 453 461 2569282 suggests VBZ B-VP O
19 462 463 2569282 a DT B-NP O
20 464 468 2569282 role NN I-NP O
21 469 472 2569282 for IN B-PP O
22 473 474 2569282 a DT B-NP O
23 475 482 2569282 central JJ I-NP O
24 483 493 2569282 adrenergic JJ I-NP O
25 494 503 2569282 mechanism NN I-NP O
26 503 504 2569282 . . O O

1 505 507 2569282 In IN B-PP O
2 508 511 2569282 the DT B-NP O
3 512 519 2569282 present JJ I-NP O
4 520 525 2569282 study NN I-NP O
5 525 526 2569282 , , O O
6 527 530 2569282 the DT B-NP O
7 531 538 2569282 authors NNS I-NP O
8 539 549 2569282 determined VBD B-VP O
9 550 552 2569282 if IN B-SBAR O
10 553 562 2569282 treatment NN B-NP O
11 563 567 2569282 with IN B-PP O
12 568 569 2569282 D NN B-NP D020927
13 569 570 2569282 - HYPH B-VP D020927
14 570 573 2569282 MED VBN I-VP D020927
15 574 582 2569282 prevents VBZ B-VP O
16 583 586 2569282 the DT B-NP O
17 587 593 2569282 muscle NN I-NP D009127
18 594 602 2569282 rigidity NN I-NP D009127
19 603 609 2569282 caused VBN B-VP O
20 610 612 2569282 by IN B-PP O
21 613 617 2569282 high JJ B-NP O
22 617 618 2569282 - HYPH I-NP O
23 618 622 2569282 dose NN I-NP O
24 623 633 2569282 alfentanil NN I-NP D015760
25 634 644 2569282 anesthesia NN I-NP O
26 645 647 2569282 in IN B-PP O
27 648 651 2569282 the DT B-NP O
28 652 655 2569282 rat NN I-NP O
29 655 656 2569282 . . O O

1 657 664 2569282 Animals NNS B-NP O
2 665 666 2569282 ( ( O O
3 666 667 2569282 n NN B-NP O
4 668 669 2569282 = SYM B-VP O
5 670 672 2569282 42 CD B-NP O
6 672 673 2569282 ) ) O O
7 674 678 2569282 were VBD B-VP O
8 679 686 2569282 treated VBN I-VP O
9 687 704 2569282 intraperitoneally RB B-ADVP O
10 705 709 2569282 with IN B-PP O
11 710 713 2569282 one CD B-NP O
12 714 716 2569282 of IN B-PP O
13 717 720 2569282 the DT B-NP O
14 721 730 2569282 following VBG I-NP O
15 731 734 2569282 six CD I-NP O
16 735 743 2569282 regimens NNS I-NP O
17 743 744 2569282 : : O O
18 745 746 2569282 1 LS B-LST O
19 746 747 2569282 ) ) O O
20 748 749 2569282 L NN B-NP O
21 749 750 2569282 - HYPH B-VP O
22 750 753 2569282 MED VBN I-VP O
23 754 755 2569282 ( ( O O
24 755 758 2569282 the DT B-NP O
25 759 767 2569282 inactive JJ I-NP O
26 768 769 2569282 L NN I-NP O
27 769 770 2569282 - HYPH O O
28 770 776 2569282 isomer NN B-NP O
29 777 779 2569282 of IN B-PP O
30 780 792 2569282 medetomidine NN B-NP D020926
31 792 793 2569282 ) ) O O
32 793 794 2569282 , , O O
33 795 797 2569282 30 CD B-NP O
34 798 808 2569282 micrograms NNS I-NP O
35 808 809 2569282 / SYM B-NP O
36 809 811 2569282 kg NN I-NP O
37 811 812 2569282 ; : O O
38 813 814 2569282 2 LS B-LST O
39 814 815 2569282 ) ) O O
40 816 817 2569282 D NN B-NP D020927
41 817 818 2569282 - HYPH O D020927
42 818 821 2569282 MED VBN B-VP D020927
43 821 822 2569282 , , O O
44 823 825 2569282 10 CD B-NP O
45 826 836 2569282 micrograms NNS I-NP O
46 836 837 2569282 / SYM B-NP O
47 837 839 2569282 kg NN I-NP O
48 839 840 2569282 ; : O O
49 841 842 2569282 3 LS B-LST O
50 842 843 2569282 ) ) O O
51 844 845 2569282 D NN B-NP D020927
52 845 846 2569282 - HYPH O D020927
53 846 849 2569282 MED VBN B-VP D020927
54 849 850 2569282 , , O O
55 851 853 2569282 30 CD B-NP O
56 854 864 2569282 micrograms NNS I-NP O
57 864 865 2569282 / SYM B-NP O
58 865 867 2569282 kg NN I-NP O
59 867 868 2569282 ; : O O
60 869 870 2569282 4 LS B-LST O
61 870 871 2569282 ) ) O O
62 872 873 2569282 D NN B-NP D020927
63 873 874 2569282 - HYPH O D020927
64 874 877 2569282 MED VBN B-VP D020927
65 878 879 2569282 [ ( O O
66 879 881 2569282 30 CD B-NP O
67 882 892 2569282 micrograms NNS I-NP O
68 892 893 2569282 / SYM B-NP O
69 893 895 2569282 kg NN I-NP O
70 895 896 2569282 ] ) O O
71 897 900 2569282 and CC O O
72 901 904 2569282 the DT B-NP O
73 905 912 2569282 central JJ I-NP O
74 912 913 2569282 - HYPH I-NP O
75 913 919 2569282 acting VBG B-VP O
76 920 925 2569282 alpha SYM B-NP O
77 925 926 2569282 - HYPH O O
78 926 927 2569282 2 CD B-NP O
79 928 938 2569282 antagonist NN I-NP O
80 938 939 2569282 , , O O
81 940 948 2569282 idazoxan NN B-NP D019329
82 949 950 2569282 [ ( O O
83 950 952 2569282 10 CD B-NP O
84 953 955 2569282 mg NN I-NP O
85 955 956 2569282 / SYM B-NP O
86 956 958 2569282 kg NN I-NP O
87 958 959 2569282 ] ) O O
88 959 960 2569282 ; : O O
89 961 962 2569282 5 CD B-NP O
90 962 963 2569282 ) ) O O
91 964 965 2569282 D NN B-NP D020927
92 965 966 2569282 - HYPH O D020927
93 966 969 2569282 MED VBN B-VP D020927
94 970 971 2569282 [ ( O O
95 971 973 2569282 30 CD B-NP O
96 974 984 2569282 micrograms NNS I-NP O
97 984 985 2569282 / SYM B-NP O
98 985 987 2569282 kg NN I-NP O
99 987 988 2569282 ] ) O O
100 989 992 2569282 and CC O O
101 993 996 2569282 the DT B-NP O
102 997 1007 2569282 peripheral JJ I-NP O
103 1007 1008 2569282 - HYPH I-NP O
104 1008 1014 2569282 acting VBG B-VP O
105 1015 1020 2569282 alpha SYM B-NP O
106 1020 1021 2569282 - HYPH B-NP O
107 1021 1022 2569282 2 CD I-NP O
108 1023 1033 2569282 antagonist NN I-NP O
109 1034 1036 2569282 DG NN I-NP C032368
110 1036 1037 2569282 - HYPH B-NP C032368
111 1037 1041 2569282 5128 CD I-NP C032368
112 1042 1043 2569282 [ ( O O
113 1043 1045 2569282 10 CD B-NP O
114 1046 1048 2569282 mg NN I-NP O
115 1048 1049 2569282 / SYM B-NP O
116 1049 1051 2569282 kg NN I-NP O
117 1051 1052 2569282 ] ) O O
118 1052 1053 2569282 , , O O
119 1054 1056 2569282 or CC O O
120 1056 1057 2569282 ; : O O
121 1058 1059 2569282 6 CD B-NP O
122 1059 1060 2569282 ) ) O O
123 1061 1067 2569282 saline NN B-NP O
124 1067 1068 2569282 . . O O

1 1069 1077 2569282 Baseline NN B-NP O
2 1078 1095 2569282 electromyographic JJ I-NP O
3 1096 1104 2569282 activity NN I-NP O
4 1105 1108 2569282 was VBD B-VP O
5 1109 1117 2569282 recorded VBN I-VP O
6 1118 1122 2569282 from IN B-PP O
7 1123 1126 2569282 the DT B-NP O
8 1127 1140 2569282 gastrocnemius NN I-NP O
9 1141 1147 2569282 muscle NN I-NP O
10 1148 1154 2569282 before IN B-PP O
11 1155 1158 2569282 and CC I-PP O
12 1159 1164 2569282 after IN I-PP O
13 1165 1169 2569282 drug NN B-NP O
14 1170 1179 2569282 treatment NN I-NP O
15 1179 1180 2569282 . . O O

1 1181 1185 2569282 Each DT B-NP O
2 1186 1189 2569282 rat NN I-NP O
3 1190 1193 2569282 was VBD B-VP O
4 1194 1198 2569282 then RB I-VP O
5 1199 1207 2569282 injected VBN I-VP O
6 1208 1212 2569282 with IN B-PP O
7 1213 1223 2569282 alfentanil NN B-NP D015760
8 1224 1225 2569282 ( ( O O
9 1225 1228 2569282 ALF NN B-NP D015760
10 1228 1229 2569282 , , O O
11 1230 1233 2569282 0.5 CD B-NP O
12 1234 1236 2569282 mg NN I-NP O
13 1236 1237 2569282 / SYM B-NP O
14 1237 1239 2569282 kg NN I-NP O
15 1240 1242 2569282 sc NN I-NP O
16 1242 1243 2569282 ) ) O O
17 1243 1244 2569282 . . O O

1 1245 1248 2569282 ALF NN B-NP D015760
2 1249 1258 2569282 injection NN I-NP O
3 1259 1267 2569282 resulted VBD B-VP O
4 1268 1270 2569282 in IN B-PP O
5 1271 1272 2569282 a DT B-NP O
6 1273 1279 2569282 marked JJ I-NP O
7 1280 1288 2569282 increase NN I-NP O
8 1289 1291 2569282 in IN B-PP O
9 1292 1300 2569282 hindlimb NN B-NP O
10 1301 1304 2569282 EMG NN I-NP O
11 1305 1313 2569282 activity NN I-NP O
12 1314 1316 2569282 in IN B-PP O
13 1317 1320 2569282 the DT B-NP O
14 1321 1322 2569282 L NN I-NP O
15 1322 1323 2569282 - HYPH B-VP O
16 1323 1326 2569282 MED VBN B-NP O
17 1327 1336 2569282 treatment NN I-NP O
18 1337 1342 2569282 group NN I-NP O
19 1343 1348 2569282 which WDT B-NP O
20 1349 1352 2569282 was VBD B-VP O
21 1353 1370 2569282 indistinguishable JJ B-ADJP O
22 1371 1375 2569282 from IN B-PP O
23 1376 1380 2569282 that DT B-NP O
24 1381 1385 2569282 seen VBN B-VP O
25 1386 1388 2569282 in IN B-PP O
26 1389 1396 2569282 animals NNS B-NP O
27 1397 1404 2569282 treated VBN B-VP O
28 1405 1409 2569282 with IN B-PP O
29 1410 1416 2569282 saline NN B-NP O
30 1416 1417 2569282 . . O O

1 1418 1420 2569282 In IN B-PP O
2 1421 1429 2569282 contrast NN B-NP O
3 1429 1430 2569282 , , O O
4 1431 1432 2569282 D NN B-NP D020927
5 1432 1433 2569282 - HYPH B-VP D020927
6 1433 1436 2569282 MED VBN I-VP D020927
7 1437 1446 2569282 prevented VBD B-VP O
8 1447 1457 2569282 alfentanil NN B-NP D015760
9 1457 1458 2569282 - HYPH B-NP O
10 1458 1465 2569282 induced VBN I-NP O
11 1466 1472 2569282 muscle NN I-NP D009127
12 1473 1481 2569282 rigidity NN I-NP D009127
13 1482 1484 2569282 in IN B-PP O
14 1485 1486 2569282 a DT B-NP O
15 1487 1491 2569282 dose NN I-NP O
16 1491 1492 2569282 - HYPH B-NP O
17 1492 1501 2569282 dependent JJ I-NP O
18 1502 1509 2569282 fashion NN I-NP O
19 1509 1510 2569282 . . O O

1 1511 1514 2569282 The DT B-NP O
2 1515 1520 2569282 small JJ I-NP O
3 1521 1524 2569282 EMG NN I-NP O
4 1525 1531 2569282 values NNS I-NP O
5 1532 1540 2569282 obtained VBN B-VP O
6 1541 1543 2569282 in IN B-PP O
7 1544 1547 2569282 the DT B-NP O
8 1548 1552 2569282 high JJ I-NP O
9 1552 1553 2569282 - HYPH I-NP O
10 1553 1557 2569282 dose NN I-NP O
11 1558 1559 2569282 D NN I-NP D020927
12 1559 1560 2569282 - HYPH B-NP D020927
13 1560 1563 2569282 MED VBN I-NP D020927
14 1564 1569 2569282 group NN I-NP O
15 1570 1574 2569282 were VBD B-VP O
16 1575 1585 2569282 comparable JJ B-ADJP O
17 1586 1590 2569282 with IN B-PP O
18 1591 1596 2569282 those DT B-NP O
19 1597 1605 2569282 recorded VBN B-VP O
20 1606 1608 2569282 in IN B-PP O
21 1609 1616 2569282 earlier JJR B-NP O
22 1617 1624 2569282 studies NNS I-NP O
23 1625 1629 2569282 from IN B-PP O
24 1630 1637 2569282 control NN B-NP O
25 1638 1645 2569282 animals NNS I-NP O
26 1646 1649 2569282 not RB B-VP O
27 1650 1655 2569282 given VBN I-VP O
28 1656 1659 2569282 any DT B-NP O
29 1660 1666 2569282 opiate NN I-NP O
30 1666 1667 2569282 . . O O

1 1668 1671 2569282 The DT B-NP O
2 1672 1676 2569282 high JJ I-NP O
3 1676 1677 2569282 - HYPH I-NP O
4 1677 1681 2569282 dose NN I-NP O
5 1682 1683 2569282 D NN I-NP D020927
6 1683 1684 2569282 - HYPH B-NP D020927
7 1684 1687 2569282 MED VBN I-NP D020927
8 1688 1695 2569282 animals NNS I-NP O
9 1696 1700 2569282 were VBD B-VP O
10 1701 1708 2569282 flaccid JJ B-ADJP O
11 1708 1709 2569282 , , O O
12 1710 1718 2569282 akinetic JJ B-ADJP D018476
13 1718 1719 2569282 , , O O
14 1720 1723 2569282 and CC O O
15 1724 1730 2569282 lacked VBD B-VP O
16 1731 1732 2569282 a DT B-NP O
17 1733 1740 2569282 startle JJ I-NP D012021
18 1741 1749 2569282 response NN I-NP O
19 1750 1756 2569282 during IN B-PP O
20 1757 1760 2569282 the DT B-NP O
21 1761 1767 2569282 entire JJ I-NP O
22 1768 1780 2569282 experimental JJ I-NP O
23 1781 1797 2569282 period.(ABSTRACT NN I-NP O
24 1798 1807 2569282 TRUNCATED VBN B-VP O
25 1808 1810 2569282 AT IN B-PP O
26 1811 1814 2569282 250 CD B-NP O
27 1815 1820 2569282 WORDS NNS I-NP O
28 1820 1821 2569282 ) ) O O

1 0 0 11009181 -DOCSTART- -X- -X- O

1 0 11 11009181 Apomorphine NN B-NP D001058
2 11 12 11009181 : : O O
3 13 15 11009181 an DT B-NP O
4 16 29 11009181 underutilized JJ I-NP O
5 30 37 11009181 therapy NN I-NP O
6 38 41 11009181 for IN B-PP O
7 42 53 11009181 Parkinson's NNP B-NP D010300
8 54 61 11009181 disease NN I-NP D010300
9 61 62 11009181 . . O O
10 63 74 11009181 Apomorphine NN B-NP D001058
11 75 78 11009181 was VBD B-VP O
12 79 82 11009181 the DT B-NP O
13 83 88 11009181 first JJ I-NP O
14 89 101 11009181 dopaminergic JJ I-NP O
15 102 106 11009181 drug NN I-NP O
16 107 111 11009181 ever RB B-VP O
17 112 116 11009181 used VBN I-VP O
18 117 119 11009181 to TO B-VP O
19 120 125 11009181 treat VB I-VP O
20 126 134 11009181 symptoms NNS B-NP O
21 135 137 11009181 of IN B-PP O
22 138 149 11009181 Parkinson's NNS B-NP D010300
23 150 157 11009181 disease NN I-NP D010300
24 157 158 11009181 . . O O

1 159 164 11009181 While IN B-SBAR O
2 165 173 11009181 powerful JJ B-NP O
3 174 190 11009181 antiparkinsonian JJ I-NP O
4 191 198 11009181 effects NNS I-NP O
5 199 202 11009181 had VBD B-VP O
6 203 207 11009181 been VBN I-VP O
7 208 216 11009181 observed VBN I-VP O
8 217 219 11009181 as RB B-ADVP O
9 220 225 11009181 early RB I-ADVP O
10 226 228 11009181 as IN B-PP O
11 229 233 11009181 1951 CD B-NP O
12 233 234 11009181 , , O O
13 235 238 11009181 the DT B-NP O
14 239 248 11009181 potential NN I-NP O
15 249 251 11009181 of IN B-PP O
16 252 260 11009181 treating VBG B-VP O
17 261 272 11009181 fluctuating VBG B-NP O
18 273 284 11009181 Parkinson's NNS I-NP D010300
19 285 292 11009181 disease NN I-NP D010300
20 293 295 11009181 by IN B-PP O
21 296 308 11009181 subcutaneous JJ B-NP O
22 309 323 11009181 administration NN I-NP O
23 324 326 11009181 of IN B-PP O
24 327 338 11009181 apomorphine NN B-NP D001058
25 339 342 11009181 has VBZ B-VP O
26 343 347 11009181 only RB I-VP O
27 348 356 11009181 recently RB I-VP O
28 357 363 11009181 become VB I-VP O
29 364 367 11009181 the DT B-NP O
30 368 375 11009181 subject NN I-NP O
31 376 378 11009181 of IN B-PP O
32 379 389 11009181 systematic JJ B-NP O
33 390 395 11009181 study NN I-NP O
34 395 396 11009181 . . O O

1 397 398 11009181 A DT B-NP O
2 399 405 11009181 number NN I-NP O
3 406 408 11009181 of IN B-PP O
4 409 414 11009181 small JJ B-NP O
5 415 420 11009181 scale NN I-NP O
6 421 429 11009181 clinical JJ I-NP O
7 430 436 11009181 trials NNS I-NP O
8 437 441 11009181 have VBP B-VP O
9 442 455 11009181 unequivocally RB I-VP O
10 456 461 11009181 shown VBN I-VP O
11 462 466 11009181 that IN B-SBAR O
12 467 479 11009181 intermittent JJ B-NP O
13 480 492 11009181 subcutaneous JJ I-NP O
14 493 504 11009181 apomorphine NN I-NP D001058
15 505 515 11009181 injections NNS I-NP O
16 516 523 11009181 produce VBP B-VP O
17 524 540 11009181 antiparkinsonian JJ B-NP O
18 541 548 11009181 benefit NN I-NP O
19 549 554 11009181 close NN I-NP O
20 555 557 11009181 if IN B-CONJP O
21 558 561 11009181 not RB I-CONJP O
22 562 571 11009181 identical JJ B-ADJP O
23 572 574 11009181 to TO B-PP O
24 575 579 11009181 that DT B-NP O
25 580 584 11009181 seen VBN B-VP O
26 585 589 11009181 with IN B-PP O
27 590 598 11009181 levodopa NN B-NP D007980
28 599 602 11009181 and CC O O
29 603 607 11009181 that IN B-SBAR O
30 608 619 11009181 apomorphine NN B-NP D001058
31 620 626 11009181 rescue NN I-NP O
32 627 637 11009181 injections NNS I-NP O
33 638 641 11009181 can MD B-VP O
34 642 650 11009181 reliably RB I-VP O
35 651 657 11009181 revert VB I-VP O
36 658 661 11009181 off RP B-PRT O
37 661 662 11009181 - HYPH B-NP O
38 662 669 11009181 periods NNS I-NP O
39 670 674 11009181 even RB B-ADVP O
40 675 677 11009181 in IN B-PP O
41 678 686 11009181 patients NNS B-NP O
42 687 691 11009181 with IN B-PP O
43 692 699 11009181 complex NN B-NP O
44 700 702 11009181 on IN B-PP O
45 702 703 11009181 - HYPH B-NP O
46 703 706 11009181 off RP I-NP O
47 707 712 11009181 motor NN B-NP O
48 713 719 11009181 swings NNS I-NP O
49 719 720 11009181 . . O O

1 721 731 11009181 Continuous JJ B-NP O
2 732 744 11009181 subcutaneous JJ I-NP O
3 745 756 11009181 apomorphine NN I-NP D001058
4 757 766 11009181 infusions NNS I-NP O
5 767 770 11009181 can MD B-VP O
6 771 777 11009181 reduce VB I-VP O
7 778 783 11009181 daily RB B-ADVP O
8 784 787 11009181 off RB B-ADVP O
9 787 788 11009181 - HYPH O O
10 788 792 11009181 time NN B-NP O
11 793 795 11009181 by IN B-PP O
12 796 800 11009181 more JJR B-NP O
13 801 805 11009181 than IN I-NP O
14 806 809 11009181 50% CD I-NP O
15 810 812 11009181 in IN B-PP O
16 813 817 11009181 this DT B-NP O
17 818 823 11009181 group NN I-NP O
18 824 826 11009181 of IN B-PP O
19 827 835 11009181 patients NNS B-NP O
20 835 836 11009181 , , O O
21 837 842 11009181 which WDT B-NP O
22 843 850 11009181 appears VBZ B-VP O
23 851 853 11009181 to TO I-VP O
24 854 856 11009181 be VB I-VP O
25 857 858 11009181 a DT B-NP O
26 859 867 11009181 stronger JJR I-NP O
27 868 874 11009181 effect NN I-NP O
28 875 879 11009181 than IN B-PP O
29 880 884 11009181 that DT B-NP O
30 885 894 11009181 generally RB B-VP O
31 895 899 11009181 seen VBN I-VP O
32 900 904 11009181 with IN B-PP O
33 905 908 11009181 add NN B-NP O
34 908 909 11009181 - HYPH B-ADVP O
35 909 911 11009181 on IN B-PP O
36 912 919 11009181 therapy NN B-NP O
37 920 924 11009181 with IN B-PP O
38 925 929 11009181 oral JJ B-NP O
39 930 938 11009181 dopamine NN I-NP D004298
40 939 947 11009181 agonists NNS I-NP O
41 948 950 11009181 or CC O O
42 951 955 11009181 COMT NN B-NP O
43 956 966 11009181 inhibitors NNS I-NP O
44 966 967 11009181 . . O O

1 968 976 11009181 Extended VBN B-VP O
2 977 983 11009181 follow VB B-VP O
3 983 984 11009181 - HYPH O O
4 984 986 11009181 up RP B-PRT O
5 987 994 11009181 studies NNS B-NP O
6 995 997 11009181 of IN B-PP O
7 998 1000 11009181 up IN B-NP O
8 1001 1003 11009181 to TO I-NP O
9 1004 1005 11009181 8 CD I-NP O
10 1006 1011 11009181 years NNS I-NP O
11 1012 1016 11009181 have VBP B-VP O
12 1017 1029 11009181 demonstrated VBN I-VP O
13 1030 1034 11009181 long JJ B-NP O
14 1034 1035 11009181 - HYPH I-NP O
15 1035 1039 11009181 term NN I-NP O
16 1040 1051 11009181 persistence NN I-NP O
17 1052 1054 11009181 of IN B-PP O
18 1055 1066 11009181 apomorphine NN B-NP D001058
19 1067 1075 11009181 efficacy NN I-NP O
20 1075 1076 11009181 . . O O

1 1077 1079 11009181 In IN B-PP O
2 1080 1088 11009181 addition NN B-NP O
3 1088 1089 11009181 , , O O
4 1090 1095 11009181 there EX B-NP O
5 1096 1098 11009181 is VBZ B-VP O
6 1099 1109 11009181 convincing VBG I-VP O
7 1110 1118 11009181 clinical JJ B-NP O
8 1119 1127 11009181 evidence NN I-NP O
9 1128 1132 11009181 that IN B-SBAR O
10 1133 1144 11009181 monotherapy NN B-NP O
11 1145 1149 11009181 with IN B-PP O
12 1150 1160 11009181 continuous JJ B-NP O
13 1161 1173 11009181 subcutaneous JJ I-NP O
14 1174 1185 11009181 apomorphine NN I-NP D001058
15 1186 1195 11009181 infusions NNS I-NP O
16 1196 1198 11009181 is VBZ B-VP O
17 1199 1209 11009181 associated VBN I-VP O
18 1210 1214 11009181 with IN B-PP O
19 1215 1221 11009181 marked JJ B-NP O
20 1222 1232 11009181 reductions NNS I-NP O
21 1233 1235 11009181 of IN B-PP O
22 1236 1247 11009181 preexisting VBG B-VP O
23 1248 1256 11009181 levodopa NN B-NP D007980
24 1256 1257 11009181 - HYPH B-NP O
25 1257 1264 11009181 induced VBN I-NP O
26 1265 1276 11009181 dyskinesias NNS I-NP D004409
27 1276 1277 11009181 . . O O

1 1278 1281 11009181 The DT B-NP O
2 1282 1286 11009181 main JJ I-NP O
3 1287 1291 11009181 side NN I-NP O
4 1292 1299 11009181 effects NNS I-NP O
5 1300 1302 11009181 of IN B-PP O
6 1303 1315 11009181 subcutaneous JJ B-NP O
7 1316 1327 11009181 apomorphine NN I-NP D001058
8 1328 1337 11009181 treatment NN I-NP O
9 1338 1341 11009181 are VBP B-VP O
10 1342 1349 11009181 related VBN I-VP O
11 1350 1352 11009181 to TO B-PP O
12 1353 1362 11009181 cutaneous JJ B-NP O
13 1363 1375 11009181 tolerability NN I-NP O
14 1376 1384 11009181 problems NNS I-NP O
15 1384 1385 11009181 , , O O
16 1386 1393 11009181 whereas IN O O
17 1394 1402 11009181 sedation NN B-NP O
18 1403 1406 11009181 and CC O O
19 1407 1418 11009181 psychiatric JJ B-NP D001523
20 1419 1432 11009181 complications NNS I-NP O
21 1433 1437 11009181 play VBP B-VP O
22 1438 1439 11009181 a DT B-NP O
23 1440 1446 11009181 lesser JJR I-NP O
24 1447 1451 11009181 role NN I-NP O
25 1451 1452 11009181 . . O O

1 1453 1458 11009181 Given VBN B-PP O
2 1459 1462 11009181 the DT B-NP O
3 1463 1469 11009181 marked JJ I-NP O
4 1470 1476 11009181 degree NN I-NP O
5 1477 1479 11009181 of IN B-PP O
6 1480 1488 11009181 efficacy NN B-NP O
7 1489 1491 11009181 of IN B-PP O
8 1492 1504 11009181 subcutaneous JJ B-NP O
9 1505 1516 11009181 apomorphine NN I-NP D001058
10 1517 1526 11009181 treatment NN I-NP O
11 1527 1529 11009181 in IN B-PP O
12 1530 1541 11009181 fluctuating VBG B-VP O
13 1542 1553 11009181 Parkinson's NNS B-NP D010300
14 1554 1561 11009181 disease NN I-NP D010300
15 1561 1562 11009181 , , O O
16 1563 1567 11009181 this DT B-NP O
17 1568 1576 11009181 approach NN I-NP O
18 1577 1582 11009181 seems VBZ B-VP O
19 1583 1585 11009181 to TO I-VP O
20 1586 1593 11009181 deserve VB I-VP O
21 1594 1598 11009181 more RBR B-NP O
22 1599 1609 11009181 widespread JJ I-NP O
23 1610 1618 11009181 clinical JJ I-NP O
24 1619 1622 11009181 use NN I-NP O
25 1622 1623 11009181 . . O O

1 0 0 7619765 -DOCSTART- -X- -X- O

1 0 9 7619765 Etoposide NN B-NP D005047
2 9 10 7619765 - HYPH O O
3 10 17 7619765 related VBN B-NP O
4 18 28 7619765 myocardial JJ I-NP D009203
5 29 39 7619765 infarction NN I-NP D009203
6 39 40 7619765 . . O O
7 41 44 7619765 The DT B-NP O
8 45 55 7619765 occurrence NN I-NP O
9 56 58 7619765 of IN B-PP O
10 59 60 7619765 a DT B-NP O
11 61 71 7619765 myocardial JJ I-NP D009203
12 72 82 7619765 infarction NN I-NP D009203
13 83 85 7619765 is VBZ B-VP O
14 86 94 7619765 reported VBN I-VP O
15 95 100 7619765 after IN B-PP O
16 101 113 7619765 chemotherapy NN B-NP O
17 114 124 7619765 containing VBG B-VP O
18 125 134 7619765 etoposide NN B-NP D005047
19 134 135 7619765 , , O O
20 136 138 7619765 in IN B-PP O
21 139 140 7619765 a DT B-NP O
22 141 144 7619765 man NN I-NP O
23 145 149 7619765 with IN B-PP O
24 150 152 7619765 no DT B-NP O
25 153 157 7619765 risk NN I-NP O
26 158 165 7619765 factors NNS I-NP O
27 166 169 7619765 for IN B-PP O
28 170 178 7619765 coronary JJ B-NP D003327
29 179 184 7619765 heart NN I-NP D003327
30 185 192 7619765 disease NN I-NP D003327
31 192 193 7619765 . . O O

1 194 202 7619765 Possible JJ B-NP O
2 203 209 7619765 causal JJ I-NP O
3 210 220 7619765 mechanisms NNS I-NP O
4 221 224 7619765 are VBP B-VP O
5 225 234 7619765 discussed VBN I-VP O
6 234 235 7619765 . . O O

1 0 0 3535719 -DOCSTART- -X- -X- O

1 0 8 3535719 Relative JJ B-NP O
2 9 17 3535719 efficacy NN I-NP O
3 18 21 3535719 and CC I-NP O
4 22 30 3535719 toxicity NN I-NP D064420
5 31 33 3535719 of IN B-PP O
6 34 44 3535719 netilmicin NN B-NP D009428
7 45 48 3535719 and CC I-NP O
8 49 59 3535719 tobramycin NN I-NP D014031
9 60 62 3535719 in IN B-PP O
10 63 71 3535719 oncology NN B-NP O
11 72 80 3535719 patients NNS I-NP O
12 80 81 3535719 . . O O
13 82 84 3535719 We PRP B-NP O
14 85 98 3535719 prospectively RB B-ADVP O
15 99 107 3535719 compared VBD B-VP O
16 108 111 3535719 the DT B-NP O
17 112 120 3535719 efficacy NN I-NP O
18 121 124 3535719 and CC I-NP O
19 125 131 3535719 safety NN I-NP O
20 132 134 3535719 of IN B-PP O
21 135 145 3535719 netilmicin NN B-NP D009428
22 146 153 3535719 sulfate NN I-NP D009428
23 154 156 3535719 or CC O O
24 157 167 3535719 tobramycin NN B-NP D014031
25 168 175 3535719 sulfate NN I-NP D014031
26 176 178 3535719 in IN B-PP O
27 179 190 3535719 conjunction NN B-NP O
28 191 195 3535719 with IN B-PP O
29 196 208 3535719 piperacillin NN B-NP D010878
30 209 215 3535719 sodium NN I-NP D010878
31 216 218 3535719 in IN B-PP O
32 219 222 3535719 118 CD B-NP O
33 223 240 3535719 immunocompromised JJ I-NP O
34 241 249 3535719 patients NNS I-NP O
35 250 254 3535719 with IN B-PP O
36 255 263 3535719 presumed VBN B-NP O
37 264 270 3535719 severe JJ I-NP O
38 271 281 3535719 infections NNS I-NP D007239
39 281 282 3535719 . . O O

1 283 286 3535719 The DT B-NP O
2 287 290 3535719 two CD I-NP O
3 291 300 3535719 treatment NN I-NP O
4 301 309 3535719 regimens NNS I-NP O
5 310 314 3535719 were VBD B-VP O
6 315 322 3535719 equally RB B-ADJP O
7 323 334 3535719 efficacious JJ I-ADJP O
8 334 335 3535719 . . O O

1 336 350 3535719 Nephrotoxicity NN B-NP D007674
2 351 359 3535719 occurred VBD B-VP O
3 360 362 3535719 in IN B-PP O
4 363 364 3535719 a DT B-NP O
5 365 372 3535719 similar JJ I-NP O
6 373 383 3535719 proportion NN I-NP O
7 384 386 3535719 in IN B-PP O
8 387 395 3535719 patients NNS B-NP O
9 396 403 3535719 treated VBN B-VP O
10 404 408 3535719 with IN B-PP O
11 409 419 3535719 netilmicin NN B-NP D009428
12 420 423 3535719 and CC I-NP O
13 424 434 3535719 tobramycin NN I-NP D014031
14 435 436 3535719 ( ( O O
15 436 439 3535719 17% CD B-NP O
16 440 442 3535719 vs CC I-NP O
17 443 446 3535719 11% CD I-NP O
18 446 447 3535719 ) ) O O
19 447 448 3535719 . . O O

1 449 460 3535719 Ototoxicity NN B-NP D006311
2 461 469 3535719 occurred VBD B-VP O
3 470 472 3535719 in IN B-PP O
4 473 477 3535719 four CD B-NP O
5 478 479 3535719 ( ( O O
6 479 483 3535719 9.5% CD B-NP O
7 483 484 3535719 ) ) O O
8 485 487 3535719 of IN B-PP O
9 488 490 3535719 42 CD B-NP O
10 491 501 3535719 netilmicin NN I-NP D009428
11 502 505 3535719 and CC I-NP O
12 506 518 3535719 piperacillin NN I-NP D010878
13 519 522 3535719 and CC O O
14 523 525 3535719 in IN B-PP O
15 526 528 3535719 12 CD B-NP O
16 529 530 3535719 ( ( O O
17 530 533 3535719 22% NN B-NP O
18 533 534 3535719 ) ) O O
19 535 537 3535719 of IN B-PP O
20 538 540 3535719 54 CD B-NP O
21 541 551 3535719 tobramycin NN I-NP D014031
22 552 555 3535719 and CC I-NP O
23 556 568 3535719 piperacillin NN I-NP D010878
24 568 569 3535719 - HYPH B-NP O
25 569 576 3535719 treated VBN I-NP O
26 577 585 3535719 patients NNS I-NP O
27 585 586 3535719 . . O O

1 587 589 3535719 Of IN B-PP O
2 590 595 3535719 those DT B-NP O
3 596 605 3535719 evaluated VBN B-VP O
4 606 610 3535719 with IN B-PP O
5 611 622 3535719 posttherapy NN B-NP O
6 623 633 3535719 audiograms NNS I-NP O
7 633 634 3535719 , , O O
8 635 640 3535719 three CD B-NP O
9 641 643 3535719 of IN I-NP O
10 644 648 3535719 four CD I-NP O
11 649 659 3535719 netilmicin NN I-NP D009428
12 660 663 3535719 and CC I-NP O
13 664 676 3535719 piperacillin NN I-NP D010878
14 676 677 3535719 - HYPH B-NP O
15 677 684 3535719 treated VBN I-NP O
16 685 693 3535719 patients NNS I-NP O
17 694 697 3535719 had VBD B-VP O
18 698 706 3535719 auditory JJ B-NP O
19 707 717 3535719 thresholds NNS I-NP O
20 718 724 3535719 return VBP B-VP O
21 725 727 3535719 to TO B-PP O
22 728 736 3535719 baseline NN B-NP O
23 737 745 3535719 compared VBN B-PP O
24 746 750 3535719 with IN B-PP O
25 751 754 3535719 one CD B-NP O
26 755 757 3535719 of IN B-PP O
27 758 762 3535719 nine CD B-NP O
28 763 773 3535719 tobramycin NN I-NP D014031
29 774 777 3535719 and CC I-NP O
30 778 790 3535719 piperacillin NN I-NP D010878
31 790 791 3535719 - HYPH B-NP O
32 791 798 3535719 treated VBN I-NP O
33 799 807 3535719 patients NNS I-NP O
34 807 808 3535719 . . O O

1 809 812 3535719 The DT B-NP O
2 813 819 3535719 number NN I-NP O
3 820 822 3535719 of IN B-PP O
4 823 830 3535719 greater JJR B-NP O
5 831 835 3535719 than IN B-PP O
6 836 838 3535719 or CC O O
7 839 844 3535719 equal JJ B-ADJP O
8 845 847 3535719 to TO B-PP O
9 848 850 3535719 15 CD B-NP O
10 850 851 3535719 - HYPH I-NP O
11 851 853 3535719 dB NN I-NP O
12 854 863 3535719 increases NNS I-NP O
13 864 866 3535719 in IN B-PP O
14 867 875 3535719 auditory JJ B-NP O
15 876 885 3535719 threshold NN I-NP O
16 886 888 3535719 as IN B-PP O
17 889 890 3535719 a DT B-NP O
18 891 901 3535719 proportion NN I-NP O
19 902 904 3535719 of IN B-PP O
20 905 910 3535719 total NN B-NP O
21 911 918 3535719 greater JJR B-ADJP O
22 919 923 3535719 than IN B-PP O
23 924 926 3535719 or CC O O
24 927 932 3535719 equal JJ B-ADJP O
25 933 935 3535719 to TO B-PP O
26 936 938 3535719 15 CD B-NP O
27 938 939 3535719 - HYPH I-NP O
28 939 941 3535719 dB NN I-NP O
29 942 949 3535719 changes NNS I-NP O
30 950 951 3535719 ( ( O O
31 951 960 3535719 increases NNS B-NP O
32 961 964 3535719 and CC I-NP O
33 965 974 3535719 decreases NNS I-NP O
34 974 975 3535719 ) ) O O
35 976 979 3535719 was VBD B-VP O
36 980 993 3535719 significantly RB B-ADJP O
37 994 999 3535719 lower JJR I-ADJP O
38 1000 1002 3535719 in IN B-PP O
39 1003 1013 3535719 netilmicin NN B-NP D009428
40 1014 1017 3535719 and CC I-NP O
41 1018 1030 3535719 piperacillin NN I-NP D010878
42 1030 1031 3535719 - HYPH O O
43 1032 1034 3535719 vs CC O O
44 1035 1045 3535719 tobramycin NN B-NP D014031
45 1046 1049 3535719 and CC I-NP O
46 1050 1062 3535719 piperacillin NN I-NP D010878
47 1062 1063 3535719 - HYPH B-NP O
48 1063 1070 3535719 treated VBN I-NP O
49 1071 1079 3535719 patients NNS I-NP O
50 1080 1081 3535719 ( ( O O
51 1081 1083 3535719 18 CD B-NP O
52 1084 1086 3535719 of IN B-PP O
53 1087 1089 3535719 78 CD B-NP O
54 1090 1092 3535719 vs IN I-NP O
55 1093 1095 3535719 67 CD I-NP O
56 1096 1098 3535719 of IN B-PP O
57 1099 1102 3535719 115 CD B-NP O
58 1102 1103 3535719 ) ) O O
59 1103 1104 3535719 . . O O

1 1105 1107 3535719 We PRP B-NP O
2 1108 1116 3535719 conclude VBP B-VP O
3 1117 1121 3535719 that IN B-SBAR O
4 1122 1136 3535719 aminoglycoside NN B-NP D000617
5 1136 1137 3535719 - HYPH B-VP O
6 1137 1147 3535719 associated VBN B-NP O
7 1148 1159 3535719 ototoxicity NN I-NP D006311
8 1160 1163 3535719 was VBD B-VP O
9 1164 1168 3535719 less RBR B-ADJP O
10 1169 1175 3535719 severe JJ I-ADJP O
11 1176 1179 3535719 and CC O O
12 1180 1184 3535719 more RBR B-ADVP O
13 1185 1190 3535719 often RB I-ADVP O
14 1191 1201 3535719 reversible JJ B-ADVP O
15 1202 1206 3535719 with IN B-PP O
16 1207 1217 3535719 netilmicin NN B-NP D009428
17 1218 1222 3535719 than IN B-PP O
18 1223 1227 3535719 with IN B-PP O
19 1228 1238 3535719 tobramycin NN B-NP D014031
20 1238 1239 3535719 . . O O

1 0 0 1969772 -DOCSTART- -X- -X- O

1 0 12 1969772 Preservation NN B-NP O
2 13 15 1969772 of IN B-PP O
3 16 21 1969772 renal JJ B-NP O
4 22 27 1969772 blood NN I-NP O
5 28 32 1969772 flow NN I-NP O
6 33 39 1969772 during IN B-PP O
7 40 51 1969772 hypotension NN B-NP D007022
8 52 59 1969772 induced VBN B-VP O
9 60 64 1969772 with IN B-PP O
10 65 75 1969772 fenoldopam NN B-NP D018818
11 76 78 1969772 in IN B-PP O
12 79 83 1969772 dogs NNS B-NP O
13 83 84 1969772 . . O O
14 85 88 1969772 The DT B-NP O
15 89 101 1969772 introduction NN I-NP O
16 102 104 1969772 of IN B-PP O
17 105 110 1969772 drugs NNS B-NP O
18 111 115 1969772 that WDT B-NP O
19 116 121 1969772 could MD B-VP O
20 122 128 1969772 induce VB I-VP O
21 129 140 1969772 hypotension NN B-NP D007022
22 141 145 1969772 with IN B-PP O
23 146 155 1969772 different JJ B-NP O
24 156 171 1969772 pharmacological JJ I-NP O
25 172 179 1969772 actions NNS I-NP O
26 180 185 1969772 would MD B-VP O
27 186 188 1969772 be VB I-VP O
28 189 201 1969772 advantageous JJ B-ADJP O
29 202 209 1969772 because IN B-SBAR O
30 210 214 1969772 side JJ B-NP O
31 215 222 1969772 effects NNS I-NP O
32 223 229 1969772 unique JJ B-ADVP O
33 230 232 1969772 to TO B-PP O
34 233 234 1969772 a DT B-NP O
35 235 243 1969772 specific JJ I-NP O
36 244 248 1969772 drug NN I-NP O
37 249 254 1969772 could MD B-VP O
38 255 257 1969772 be VB I-VP O
39 258 267 1969772 minimized VBN I-VP O
40 268 270 1969772 by IN B-PP O
41 271 280 1969772 selecting VBG B-VP O
42 281 292 1969772 appropriate JJ B-NP O
43 293 300 1969772 therapy NN I-NP O
44 300 301 1969772 . . O O

1 302 310 1969772 Specific JJ B-NP O
2 311 319 1969772 dopamine NN I-NP D004298
3 319 320 1969772 - HYPH B-NP O
4 320 321 1969772 1 CD I-NP O
5 321 322 1969772 , , O O
6 323 324 1969772 ( ( O O
7 324 327 1969772 DA1 NN B-NP D004298
8 327 328 1969772 ) ) O O
9 329 332 1969772 and CC O O
10 333 341 1969772 dopamine NN B-NP D004298
11 341 342 1969772 - HYPH O O
12 342 343 1969772 2 CD B-NP O
13 344 345 1969772 ( ( O O
14 345 348 1969772 DA2 NN B-NP D004298
15 348 349 1969772 ) ) O O
16 350 358 1969772 receptor NN B-NP O
17 359 367 1969772 agonists NNS I-NP O
18 368 371 1969772 are VBP B-VP O
19 372 375 1969772 now RB B-ADVP O
20 376 381 1969772 under IN B-PP O
21 382 390 1969772 clinical JJ B-NP O
22 391 404 1969772 investigation NN I-NP O
23 404 405 1969772 . . O O

1 406 416 1969772 Fenoldopam NN B-NP D018818
2 417 425 1969772 mesylate NN I-NP D018818
3 426 428 1969772 is VBZ B-VP O
4 429 430 1969772 a DT B-NP O
5 431 439 1969772 specific JJ I-NP O
6 440 443 1969772 DA1 NN I-NP O
7 444 452 1969772 receptor NN I-NP O
8 453 460 1969772 agonist NN I-NP O
9 461 465 1969772 that WDT B-NP O
10 466 472 1969772 lowers VBZ B-VP O
11 473 478 1969772 blood NN B-NP O
12 479 487 1969772 pressure NN I-NP O
13 488 490 1969772 by IN B-PP O
14 491 505 1969772 vasodilatation NN B-NP O
15 505 506 1969772 . . O O

1 507 510 1969772 The DT B-NP O
2 511 521 1969772 hypothesis NN I-NP O
3 522 526 1969772 that IN B-SBAR O
4 527 537 1969772 fenoldopam NN B-NP D018818
5 538 543 1969772 could MD B-VP O
6 544 546 1969772 be VB I-VP O
7 547 551 1969772 used VBN I-VP O
8 552 554 1969772 to TO B-VP O
9 555 561 1969772 induce VB I-VP O
10 562 573 1969772 hypotension NN B-NP D007022
11 574 577 1969772 and CC O O
12 578 586 1969772 preserve VB B-VP O
13 587 592 1969772 blood NN B-NP O
14 593 597 1969772 flow NN I-NP O
15 598 600 1969772 to TO B-PP O
16 601 604 1969772 the DT B-NP O
17 605 611 1969772 kidney NN I-NP O
18 612 615 1969772 was VBD B-VP O
19 616 622 1969772 tested VBN I-VP O
20 622 623 1969772 . . O O

1 624 632 1969772 Systemic JJ B-NP O
2 633 639 1969772 aortic JJ I-NP O
3 640 645 1969772 blood NN I-NP O
4 646 654 1969772 pressure NN I-NP O
5 655 658 1969772 and CC O O
6 659 664 1969772 renal JJ B-NP O
7 665 670 1969772 blood NN I-NP O
8 671 675 1969772 flow NN I-NP O
9 676 680 1969772 were VBD B-VP O
10 681 689 1969772 measured VBN I-VP O
11 690 702 1969772 continuously RB B-ADVP O
12 703 707 1969772 with IN B-PP O
13 708 709 1969772 a DT B-NP O
14 710 717 1969772 carotid JJ I-NP O
15 718 726 1969772 arterial JJ I-NP O
16 727 735 1969772 catheter NN I-NP O
17 736 739 1969772 and CC O O
18 740 742 1969772 an DT B-NP O
19 743 758 1969772 electromagnetic JJ I-NP O
20 759 763 1969772 flow NN I-NP O
21 764 769 1969772 probe NN I-NP O
22 770 782 1969772 respectively RB B-ADVP O
23 782 783 1969772 , , O O
24 784 786 1969772 in IN B-SBAR O
25 787 792 1969772 order NN O O
26 793 795 1969772 to TO B-VP O
27 796 803 1969772 compare VB I-VP O
28 804 807 1969772 the DT B-NP O
29 808 822 1969772 cardiovascular JJ I-NP O
30 823 826 1969772 and CC I-NP O
31 827 832 1969772 renal JJ I-NP O
32 833 841 1969772 vascular JJ I-NP O
33 842 849 1969772 effects NNS I-NP O
34 850 852 1969772 of IN B-PP O
35 853 863 1969772 fenoldopam NN B-NP D018818
36 864 867 1969772 and CC I-NP O
37 868 874 1969772 sodium NN I-NP D012964
38 875 888 1969772 nitroprusside NN I-NP D009599
39 889 891 1969772 in IN B-PP O
40 892 895 1969772 ten CD B-NP O
41 896 900 1969772 dogs NNS I-NP O
42 901 906 1969772 under IN B-PP O
43 907 916 1969772 halothane NN B-NP D006221
44 917 924 1969772 general JJ I-NP O
45 925 936 1969772 anaesthesia NN I-NP O
46 936 937 1969772 . . O O

1 938 942 1969772 Mean JJ B-NP O
2 943 951 1969772 arterial JJ I-NP O
3 952 960 1969772 pressure NN I-NP O
4 961 964 1969772 was VBD B-VP O
5 965 974 1969772 decreased VBN I-VP O
6 975 977 1969772 30 CD B-NP O
7 978 979 1969772 + SYM O O
8 979 980 1969772 / SYM O O
9 980 981 1969772 - SYM O O
10 982 983 1969772 8 CD B-NP O
11 984 987 1969772 per IN B-PP O
12 988 992 1969772 cent NN B-NP O
13 993 997 1969772 from IN B-PP O
14 998 1005 1969772 control NN B-NP O
15 1006 1010 1969772 with IN B-PP O
16 1011 1019 1969772 infusion NN B-NP O
17 1020 1022 1969772 of IN B-PP O
18 1023 1033 1969772 fenoldopam NN B-NP D018818
19 1034 1035 1969772 ( ( O O
20 1035 1038 1969772 3.4 CD B-NP O
21 1039 1040 1969772 + SYM O O
22 1040 1041 1969772 / SYM O O
23 1041 1042 1969772 - SYM O O
24 1043 1046 1969772 2.0 CD B-NP O
25 1047 1060 1969772 micrograms.kg NN I-NP O
26 1060 1061 1969772 - HYPH B-NP O
27 1061 1066 1969772 1.min NN I-NP O
28 1066 1067 1969772 - HYPH B-NP O
29 1067 1068 1969772 1 CD I-NP O
30 1068 1069 1969772 ) ) O O
31 1070 1073 1969772 and CC O O
32 1074 1076 1969772 34 CD B-NP O
33 1077 1078 1969772 + SYM O O
34 1078 1079 1969772 / SYM O O
35 1079 1080 1969772 - SYM O O
36 1081 1082 1969772 4 CD B-NP O
37 1083 1086 1969772 per IN B-PP O
38 1087 1091 1969772 cent NN B-NP O
39 1092 1096 1969772 with IN B-PP O
40 1097 1105 1969772 infusion NN B-NP O
41 1106 1108 1969772 of IN B-PP O
42 1109 1115 1969772 sodium NN B-NP D012964
43 1116 1129 1969772 nitroprusside NN I-NP D009599
44 1130 1131 1969772 ( ( O O
45 1131 1134 1969772 5.9 CD B-NP O
46 1135 1148 1969772 micrograms.kg NN I-NP O
47 1148 1149 1969772 - HYPH B-NP O
48 1149 1154 1969772 1.min NN I-NP O
49 1154 1155 1969772 - HYPH B-NP O
50 1155 1156 1969772 1 CD I-NP O
51 1156 1157 1969772 ) ) O O
52 1158 1159 1969772 ( ( O O
53 1159 1161 1969772 NS NN B-NP O
54 1161 1162 1969772 ) ) O O
55 1162 1163 1969772 . . O O

1 1164 1169 1969772 Renal JJ B-NP O
2 1170 1175 1969772 blood NN I-NP O
3 1176 1180 1969772 flow NN I-NP O
4 1181 1182 1969772 ( ( O O
5 1182 1185 1969772 RBF NN B-NP O
6 1185 1186 1969772 ) ) O O
7 1187 1196 1969772 increased VBD B-VP O
8 1197 1203 1969772 during IN B-PP O
9 1204 1214 1969772 fenoldopam NN B-NP D018818
10 1214 1215 1969772 - HYPH B-NP O
11 1215 1222 1969772 induced VBN I-NP O
12 1223 1234 1969772 hypotension NN I-NP D007022
13 1235 1237 1969772 11 CD I-NP O
14 1238 1239 1969772 + SYM B-VP O
15 1239 1240 1969772 / SYM B-NP O
16 1240 1241 1969772 - SYM B-VP O
17 1242 1243 1969772 7 CD B-NP O
18 1244 1247 1969772 per IN B-PP O
19 1248 1252 1969772 cent NN B-NP O
20 1253 1256 1969772 and CC O O
21 1257 1266 1969772 decreased VBD B-VP O
22 1267 1269 1969772 21 CD B-NP O
23 1270 1271 1969772 + SYM O O
24 1271 1272 1969772 / SYM O O
25 1272 1273 1969772 - SYM O O
26 1274 1275 1969772 8 CD B-NP O
27 1276 1279 1969772 per IN B-PP O
28 1280 1284 1969772 cent NN B-NP O
29 1285 1291 1969772 during IN B-PP O
30 1292 1298 1969772 sodium NN B-NP D012964
31 1299 1312 1969772 nitroprusside NN I-NP D009599
32 1312 1313 1969772 - HYPH B-VP O
33 1313 1320 1969772 induced VBN B-NP O
34 1321 1332 1969772 hypotension NN I-NP D007022
35 1333 1334 1969772 ( ( O O
36 1334 1335 1969772 P NN B-NP O
37 1336 1340 1969772 less JJR B-ADJP O
38 1341 1345 1969772 than IN B-PP O
39 1346 1350 1969772 0.01 CD B-NP O
40 1350 1351 1969772 ) ) O O
41 1351 1352 1969772 . . O O

1 1353 1359 1969772 Sodium NN B-NP O
2 1360 1373 1969772 nitroprusside NN I-NP D009599
3 1374 1376 1969772 is VBZ B-VP O
4 1377 1378 1969772 a DT B-NP O
5 1379 1382 1969772 non AFX I-NP O
6 1382 1383 1969772 - HYPH I-NP O
7 1383 1392 1969772 selective JJ I-NP O
8 1393 1403 1969772 arteriolar JJ I-NP O
9 1404 1407 1969772 and CC I-NP O
10 1408 1414 1969772 venous JJ I-NP O
11 1415 1426 1969772 vasodilator NN I-NP O
12 1427 1431 1969772 that WDT B-NP O
13 1432 1435 1969772 can MD B-VP O
14 1436 1443 1969772 produce VB I-VP O
15 1444 1458 1969772 redistribution NN B-NP O
16 1459 1461 1969772 of IN B-PP O
17 1462 1467 1969772 blood NN B-NP O
18 1468 1472 1969772 flow NN I-NP O
19 1473 1477 1969772 away RB B-ADVP O
20 1478 1482 1969772 from IN B-PP O
21 1483 1486 1969772 the DT B-NP O
22 1487 1493 1969772 kidney NN I-NP O
23 1494 1500 1969772 during IN B-PP O
24 1501 1508 1969772 induced VBN B-NP O
25 1509 1520 1969772 hypotension NN I-NP D007022
26 1520 1521 1969772 . . O O

1 1522 1532 1969772 Fenoldopam NN B-NP O
2 1533 1535 1969772 is VBZ B-VP O
3 1536 1537 1969772 a DT B-NP O
4 1538 1547 1969772 selective JJ I-NP O
5 1548 1556 1969772 dopamine NN I-NP D004298
6 1556 1557 1969772 - HYPH B-NP O
7 1557 1558 1969772 1 CD I-NP O
8 1559 1560 1969772 ( ( O O
9 1560 1563 1969772 DA1 NN B-NP O
10 1563 1564 1969772 ) ) O O
11 1565 1573 1969772 receptor NN B-NP O
12 1574 1581 1969772 agonist NN I-NP O
13 1582 1586 1969772 that WDT B-NP O
14 1587 1593 1969772 causes VBZ B-VP O
15 1594 1608 1969772 vasodilatation NN B-NP O
16 1609 1611 1969772 to TO B-PP O
17 1612 1615 1969772 the DT B-NP O
18 1616 1622 1969772 kidney NN I-NP O
19 1623 1626 1969772 and CC O O
20 1627 1632 1969772 other JJ B-NP O
21 1633 1639 1969772 organs NNS I-NP O
22 1640 1644 1969772 with IN B-PP O
23 1645 1648 1969772 DA1 NN B-NP O
24 1649 1658 1969772 receptors NNS I-NP O
25 1659 1662 1969772 and CC O O
26 1663 1672 1969772 preserves VBZ B-VP O
27 1673 1678 1969772 blood NN B-NP O
28 1679 1683 1969772 flow NN I-NP O
29 1684 1686 1969772 to TO B-PP O
30 1687 1690 1969772 the DT B-NP O
31 1691 1697 1969772 kidney NN I-NP O
32 1698 1704 1969772 during IN B-PP O
33 1705 1712 1969772 induced VBN B-NP O
34 1713 1724 1969772 hypotension NN I-NP D007022
35 1724 1725 1969772 . . O O

1 0 0 16586083 -DOCSTART- -X- -X- O

1 0 14 16586083 Cardiovascular JJ B-NP O
2 15 19 16586083 risk NN I-NP O
3 20 24 16586083 with IN B-PP O
4 25 39 16586083 cyclooxygenase NN B-NP D016861
5 40 50 16586083 inhibitors NNS I-NP D016861
6 50 51 16586083 : : O O
7 52 59 16586083 general JJ B-NP O
8 60 67 16586083 problem NN I-NP O
9 68 72 16586083 with IN B-PP O
10 73 82 16586083 substance NN B-NP O
11 83 91 16586083 specific JJ I-NP O
12 92 103 16586083 differences NNS I-NP O
13 103 104 16586083 ? . O O
14 105 115 16586083 Randomised VBN B-VP O
15 116 124 16586083 clinical JJ B-NP O
16 125 131 16586083 trials NNS I-NP O
17 132 135 16586083 and CC O O
18 136 149 16586083 observational JJ B-NP O
19 150 157 16586083 studies NNS I-NP O
20 158 162 16586083 have VBP B-VP O
21 163 168 16586083 shown VBN I-VP O
22 169 171 16586083 an DT B-NP O
23 172 181 16586083 increased VBN I-NP O
24 182 186 16586083 risk NN I-NP O
25 187 189 16586083 of IN B-PP O
26 190 200 16586083 myocardial JJ B-NP D009203
27 201 211 16586083 infarction NN I-NP D009203
28 211 212 16586083 , , O O
29 213 219 16586083 stroke NN B-NP D020521
30 219 220 16586083 , , O O
31 221 233 16586083 hypertension NN B-NP D006973
32 234 237 16586083 and CC I-NP O
33 238 243 16586083 heart NN I-NP D006333
34 244 251 16586083 failure NN I-NP D006333
35 252 258 16586083 during IN B-PP O
36 259 268 16586083 treatment NN B-NP O
37 269 273 16586083 with IN B-PP O
38 274 288 16586083 cyclooxygenase NN B-NP D016861
39 289 299 16586083 inhibitors NNS I-NP D016861
40 299 300 16586083 . . O O

1 301 308 16586083 Adverse JJ B-NP O
2 309 323 16586083 cardiovascular JJ I-NP O
3 324 331 16586083 effects NNS I-NP O
4 332 340 16586083 occurred VBD B-VP O
5 341 347 16586083 mainly RB B-ADVP O
6 347 348 16586083 , , O O
7 349 352 16586083 but CC O O
8 353 356 16586083 not RB B-ADVP O
9 357 368 16586083 exclusively RB I-ADVP O
10 368 369 16586083 , , O O
11 370 372 16586083 in IN B-PP O
12 373 381 16586083 patients NNS B-NP O
13 382 386 16586083 with IN B-PP O
14 387 398 16586083 concomitant JJ B-NP O
15 399 403 16586083 risk NN I-NP O
16 404 411 16586083 factors NNS I-NP O
17 411 412 16586083 . . O O

1 413 427 16586083 Cyclooxygenase NN B-NP D016861
2 428 438 16586083 inhibitors NNS I-NP D016861
3 439 444 16586083 cause VBP B-VP O
4 445 452 16586083 complex JJ B-NP O
5 453 460 16586083 changes NNS I-NP O
6 461 463 16586083 in IN B-PP O
7 464 469 16586083 renal JJ B-NP O
8 469 470 16586083 , , I-NP O
9 471 479 16586083 vascular JJ I-NP O
10 480 483 16586083 and CC I-NP O
11 484 491 16586083 cardiac JJ I-NP O
12 492 502 16586083 prostanoid NN I-NP O
13 503 511 16586083 profiles NNS I-NP O
14 512 519 16586083 thereby RB B-VP O
15 520 530 16586083 increasing VBG I-VP O
16 531 539 16586083 vascular JJ B-NP O
17 540 550 16586083 resistance NN I-NP O
18 551 554 16586083 and CC I-NP O
19 555 560 16586083 fluid NN I-NP O
20 561 570 16586083 retention NN I-NP O
21 570 571 16586083 . . O O

1 572 575 16586083 The DT B-NP O
2 576 585 16586083 incidence NN I-NP O
3 586 588 16586083 of IN B-PP O
4 589 603 16586083 cardiovascular JJ B-NP O
5 604 611 16586083 adverse JJ I-NP O
6 612 618 16586083 events NNS I-NP O
7 619 624 16586083 tends VBZ B-VP O
8 625 627 16586083 to TO I-VP O
9 628 636 16586083 increase VB I-VP O
10 637 641 16586083 with IN B-PP O
11 642 645 16586083 the DT B-NP O
12 646 651 16586083 daily JJ I-NP O
13 652 656 16586083 dose NN I-NP O
14 657 660 16586083 and CC O O
15 661 666 16586083 total JJ B-NP O
16 667 675 16586083 exposure NN I-NP O
17 676 680 16586083 time NN I-NP O
18 680 681 16586083 . . O O

1 682 683 16586083 A DT B-NP O
2 684 694 16586083 comparison NN I-NP O
3 695 697 16586083 of IN B-PP O
4 698 708 16586083 individual JJ B-NP O
5 709 718 16586083 selective JJ I-NP O
6 719 722 16586083 and CC I-NP O
7 723 734 16586083 unselective JJ I-NP O
8 735 749 16586083 cyclooxygenase NN I-NP D016861
9 750 760 16586083 inhibitors NNS I-NP D016861
10 761 769 16586083 suggests VBZ B-VP O
11 770 779 16586083 substance NN B-NP O
12 779 780 16586083 - HYPH B-NP O
13 780 788 16586083 specific JJ I-NP O
14 789 800 16586083 differences NNS I-NP O
15 800 801 16586083 , , O O
16 802 807 16586083 which WDT B-NP O
17 808 811 16586083 may MD B-VP O
18 812 818 16586083 depend VB I-VP O
19 819 821 16586083 on IN B-PP O
20 822 833 16586083 differences NNS B-NP O
21 834 836 16586083 in IN B-PP O
22 837 852 16586083 pharmacokinetic JJ B-NP O
23 853 863 16586083 parameters NNS I-NP O
24 864 866 16586083 or CC O O
25 867 877 16586083 inhibitory JJ B-NP O
26 878 885 16586083 potency NN I-NP O
27 886 889 16586083 and CC O O
28 890 893 16586083 may MD B-VP O
29 894 896 16586083 be VB I-VP O
30 897 908 16586083 contributed VBN I-VP O
31 909 911 16586083 by IN B-PP O
32 912 925 16586083 prostaglandin NN B-NP D011453
33 925 926 16586083 - HYPH B-NP O
34 926 937 16586083 independent JJ I-NP O
35 938 945 16586083 effects NNS I-NP O
36 945 946 16586083 . . O O

1 947 957 16586083 Diagnostic JJ B-NP O
2 958 965 16586083 markers NNS I-NP O
3 966 970 16586083 such JJ B-PP O
4 971 973 16586083 as IN I-PP O
5 974 975 16586083 N NN B-NP C109794
6 975 976 16586083 - HYPH B-NP C109794
7 976 984 16586083 terminal JJ I-NP C109794
8 985 988 16586083 pro JJ I-NP C109794
9 989 994 16586083 brain NN I-NP C109794
10 995 1006 16586083 natriuretic JJ I-NP C109794
11 1007 1014 16586083 peptide NN I-NP C109794
12 1015 1016 16586083 ( ( O O
13 1016 1018 16586083 NT NN B-NP C109794
14 1018 1019 16586083 - HYPH B-NP C109794
15 1019 1025 16586083 proBNP NN I-NP C109794
16 1025 1026 16586083 ) ) O O
17 1027 1029 16586083 or CC O O
18 1030 1034 16586083 high JJ B-NP O
19 1034 1035 16586083 - HYPH I-NP O
20 1035 1044 16586083 sensitive JJ I-NP O
21 1045 1046 16586083 C NN I-NP O
22 1046 1047 16586083 - HYPH B-NP O
23 1047 1055 16586083 reactive JJ I-NP O
24 1056 1063 16586083 protein NN I-NP O
25 1064 1069 16586083 might MD B-VP O
26 1070 1074 16586083 help VB I-VP O
27 1075 1077 16586083 in IN B-PP O
28 1078 1081 16586083 the DT B-NP O
29 1082 1087 16586083 early JJ I-NP O
30 1088 1102 16586083 identification NN I-NP O
31 1103 1105 16586083 of IN B-PP O
32 1106 1114 16586083 patients NNS B-NP O
33 1115 1117 16586083 at IN B-PP O
34 1118 1122 16586083 risk NN B-NP O
35 1122 1123 16586083 , , O O
36 1124 1128 16586083 thus RB B-ADVP O
37 1129 1137 16586083 avoiding VBG B-VP O
38 1138 1141 16586083 the DT B-NP O
39 1142 1152 16586083 occurrence NN I-NP O
40 1153 1155 16586083 of IN B-PP O
41 1156 1163 16586083 serious JJ B-NP O
42 1164 1178 16586083 cardiovascular JJ I-NP D002318
43 1179 1187 16586083 toxicity NN I-NP D002318
44 1187 1188 16586083 . . O O

1 0 0 8410199 -DOCSTART- -X- -X- O

1 0 4 8410199 Loss NN B-NP O
2 5 7 8410199 of IN B-PP O
3 8 17 8410199 glutamate NN B-NP D018698
4 18 31 8410199 decarboxylase NN I-NP O
5 32 36 8410199 mRNA NN I-NP O
6 36 37 8410199 - HYPH O O
7 37 47 8410199 containing VBG B-VP O
8 48 55 8410199 neurons NNS B-NP O
9 56 58 8410199 in IN B-PP O
10 59 62 8410199 the DT B-NP O
11 63 66 8410199 rat NN I-NP O
12 67 74 8410199 dentate NN I-NP O
13 75 80 8410199 gyrus NN I-NP O
14 81 90 8410199 following VBG B-NP O
15 91 102 8410199 pilocarpine NN I-NP D010862
16 102 103 8410199 - HYPH B-NP O
17 103 110 8410199 induced VBN I-NP O
18 111 119 8410199 seizures NNS I-NP D012640
19 119 120 8410199 . . O O
20 121 123 8410199 In FW B-NP O
21 124 128 8410199 situ FW I-NP O
22 129 142 8410199 hybridization NN I-NP O
23 143 150 8410199 methods NNS I-NP O
24 151 155 8410199 were VBD B-VP O
25 156 160 8410199 used VBN I-VP O
26 161 163 8410199 to TO B-VP O
27 164 173 8410199 determine VB I-VP O
28 174 176 8410199 if IN B-SBAR O
29 177 185 8410199 glutamic JJ B-NP D018698
30 186 190 8410199 acid NN I-NP D018698
31 191 204 8410199 decarboxylase NN I-NP O
32 205 206 8410199 ( ( O O
33 206 209 8410199 GAD NN B-NP O
34 209 210 8410199 ) ) O O
35 211 215 8410199 mRNA NN B-NP O
36 215 216 8410199 - HYPH O O
37 216 226 8410199 containing VBG B-VP O
38 227 234 8410199 neurons NNS B-NP O
39 235 241 8410199 within IN B-PP O
40 242 245 8410199 the DT B-NP O
41 246 251 8410199 hilus NN I-NP O
42 252 254 8410199 of IN B-PP O
43 255 258 8410199 the DT B-NP O
44 259 266 8410199 dentate NN I-NP O
45 267 272 8410199 gyrus NN I-NP O
46 273 276 8410199 are VBP B-VP O
47 277 287 8410199 vulnerable JJ B-ADJP O
48 288 290 8410199 to TO B-PP O
49 291 298 8410199 seizure NN B-NP D012640
50 298 299 8410199 - HYPH B-NP O
51 299 306 8410199 induced VBN I-NP O
52 307 313 8410199 damage NN I-NP O
53 314 316 8410199 in IN B-PP O
54 317 318 8410199 a DT B-NP O
55 319 324 8410199 model NN I-NP O
56 325 327 8410199 of IN B-PP O
57 328 335 8410199 chronic JJ B-NP O
58 336 344 8410199 seizures NNS I-NP D012640
59 344 345 8410199 . . O O

1 346 353 8410199 Sprague NNP B-NP O
2 353 354 8410199 - HYPH I-NP O
3 354 360 8410199 Dawley NNP I-NP O
4 361 365 8410199 rats NNS I-NP O
5 366 370 8410199 were VBD B-VP O
6 371 379 8410199 injected VBN I-VP O
7 380 397 8410199 intraperitoneally RB B-ADVP O
8 398 402 8410199 with IN B-PP O
9 403 414 8410199 pilocarpine NN B-NP D010862
10 414 415 8410199 , , O O
11 416 419 8410199 and CC O O
12 420 423 8410199 the DT B-NP O
13 424 435 8410199 hippocampal JJ I-NP O
14 436 445 8410199 formation NN I-NP O
15 446 449 8410199 was VBD B-VP O
16 450 457 8410199 studied VBN I-VP O
17 458 472 8410199 histologically RB B-ADVP O
18 473 475 8410199 at IN B-PP O
19 476 477 8410199 1 CD B-NP O
20 477 478 8410199 , , I-NP O
21 479 480 8410199 2 CD I-NP O
22 480 481 8410199 , , I-NP O
23 482 483 8410199 4 CD I-NP O
24 483 484 8410199 , , O O
25 485 488 8410199 and CC O O
26 489 490 8410199 8 CD B-NP O
27 491 495 8410199 week NN I-NP O
28 496 505 8410199 intervals NNS I-NP O
29 506 511 8410199 after IN B-PP O
30 512 523 8410199 pilocarpine NN B-NP D010862
31 523 524 8410199 - HYPH B-NP O
32 524 531 8410199 induced VBN I-NP O
33 532 540 8410199 seizures NNS I-NP D012640
34 540 541 8410199 . . O O

1 542 544 8410199 In FW B-NP O
2 545 549 8410199 situ FW I-NP O
3 550 563 8410199 hybridization NN I-NP O
4 564 578 8410199 histochemistry NN I-NP O
5 578 579 8410199 , , O O
6 580 585 8410199 using VBG B-VP O
7 586 587 8410199 a DT B-NP O
8 588 599 8410199 digoxigenin NN I-NP D004076
9 599 600 8410199 - HYPH O O
10 600 607 8410199 labeled VBN B-NP O
11 608 611 8410199 GAD NN I-NP O
12 612 616 8410199 cRNA NN I-NP O
13 617 622 8410199 probe NN I-NP O
14 622 623 8410199 , , O O
15 624 636 8410199 demonstrated VBD B-VP O
16 637 638 8410199 a DT B-NP O
17 639 650 8410199 substantial JJ I-NP O
18 651 659 8410199 decrease NN I-NP O
19 660 662 8410199 in IN B-PP O
20 663 666 8410199 the DT B-NP O
21 667 673 8410199 number NN I-NP O
22 674 676 8410199 of IN B-PP O
23 677 680 8410199 GAD NN B-NP O
24 681 685 8410199 mRNA NN I-NP O
25 685 686 8410199 - HYPH O O
26 686 696 8410199 containing VBG B-VP O
27 697 704 8410199 neurons NNS B-NP O
28 705 707 8410199 in IN B-PP O
29 708 711 8410199 the DT B-NP O
30 712 717 8410199 hilus NN I-NP O
31 718 720 8410199 of IN B-PP O
32 721 724 8410199 the DT B-NP O
33 725 732 8410199 dentate NN I-NP O
34 733 738 8410199 gyrus NN I-NP O
35 739 741 8410199 in IN B-PP O
36 742 745 8410199 the DT B-NP O
37 746 757 8410199 pilocarpine NN I-NP D010862
38 757 758 8410199 - HYPH B-NP O
39 758 765 8410199 treated VBN I-NP O
40 766 770 8410199 rats NNS I-NP O
41 771 773 8410199 as IN B-SBAR O
42 774 782 8410199 compared VBN B-VP O
43 783 785 8410199 to TO B-PP O
44 786 794 8410199 controls NNS B-NP O
45 795 797 8410199 at IN B-PP O
46 798 801 8410199 all DT B-NP O
47 802 806 8410199 time NN I-NP O
48 807 816 8410199 intervals NNS I-NP O
49 816 817 8410199 . . O O

1 818 828 8410199 Additional JJ B-NP O
2 829 845 8410199 neuronanatomical JJ I-NP O
3 846 853 8410199 studies NNS I-NP O
4 853 854 8410199 , , O O
5 855 864 8410199 including VBG B-PP O
6 865 871 8410199 cresyl NN B-NP C028911
7 872 878 8410199 violet NN I-NP C028911
8 879 887 8410199 staining NN I-NP O
9 887 888 8410199 , , O O
10 889 897 8410199 neuronal JJ B-NP D009410
11 898 910 8410199 degeneration NN I-NP D009410
12 911 918 8410199 methods NNS I-NP O
13 918 919 8410199 , , O O
14 920 923 8410199 and CC O O
15 924 937 8410199 histochemical JJ B-NP O
16 938 950 8410199 localization NN I-NP O
17 951 953 8410199 of IN B-PP O
18 954 959 8410199 glial JJ B-NP O
19 960 970 8410199 fibrillary JJ I-NP O
20 971 977 8410199 acidic JJ I-NP O
21 978 985 8410199 protein NN I-NP O
22 985 986 8410199 , , O O
23 987 996 8410199 suggested VBD B-VP O
24 997 1001 8410199 that IN B-SBAR O
25 1002 1005 8410199 the DT B-NP O
26 1006 1014 8410199 decrease NN I-NP O
27 1015 1017 8410199 in IN B-PP O
28 1018 1021 8410199 the DT B-NP O
29 1022 1028 8410199 number NN I-NP O
30 1029 1031 8410199 of IN B-PP O
31 1032 1035 8410199 GAD NN B-NP O
32 1036 1040 8410199 mRNA NN I-NP O
33 1040 1041 8410199 - HYPH B-VP O
34 1041 1051 8410199 containing VBG B-NP O
35 1052 1059 8410199 neurons NNS I-NP O
36 1060 1063 8410199 was VBD B-VP O
37 1064 1071 8410199 related JJ B-ADJP O
38 1072 1074 8410199 to TO B-PP O
39 1075 1083 8410199 neuronal JJ B-NP D009410
40 1084 1088 8410199 loss NN I-NP D009410
41 1089 1095 8410199 rather RB B-CONJP O
42 1096 1100 8410199 than IN I-CONJP O
43 1101 1103 8410199 to TO B-PP O
44 1104 1105 8410199 a DT B-NP O
45 1106 1114 8410199 decrease NN I-NP O
46 1115 1117 8410199 in IN B-PP O
47 1118 1121 8410199 GAD NN B-NP O
48 1122 1126 8410199 mRNA NN I-NP O
49 1127 1133 8410199 levels NNS I-NP O
50 1133 1134 8410199 . . O O

1 1135 1138 8410199 The DT B-NP O
2 1139 1143 8410199 loss NN I-NP O
3 1144 1146 8410199 of IN B-PP O
4 1147 1150 8410199 GAD NN B-NP O
5 1151 1155 8410199 mRNA NN I-NP O
6 1155 1156 8410199 - HYPH O O
7 1156 1166 8410199 containing VBG B-VP O
8 1167 1174 8410199 neurons NNS B-NP O
9 1175 1177 8410199 in IN B-PP O
10 1178 1181 8410199 the DT B-NP O
11 1182 1187 8410199 hilus NN I-NP O
12 1188 1198 8410199 contrasted VBN B-VP O
13 1199 1203 8410199 with IN B-PP O
14 1204 1207 8410199 the DT B-NP O
15 1208 1216 8410199 relative JJ I-NP O
16 1217 1229 8410199 preservation NN I-NP O
17 1230 1232 8410199 of IN B-PP O
18 1233 1240 8410199 labeled VBN B-NP O
19 1241 1249 8410199 putative JJ I-NP O
20 1250 1256 8410199 basket NN I-NP O
21 1257 1262 8410199 cells NNS I-NP O
22 1263 1268 8410199 along IN B-PP O
23 1269 1272 8410199 the DT B-NP O
24 1273 1278 8410199 inner JJ I-NP O
25 1279 1285 8410199 margin NN I-NP O
26 1286 1288 8410199 of IN B-PP O
27 1289 1292 8410199 the DT B-NP O
28 1293 1300 8410199 granule NN I-NP O
29 1301 1305 8410199 cell NN I-NP O
30 1306 1311 8410199 layer NN I-NP O
31 1311 1312 8410199 . . O O

1 1313 1325 8410199 Quantitative JJ B-NP O
2 1326 1334 8410199 analyses NNS I-NP O
3 1335 1337 8410199 of IN B-PP O
4 1338 1345 8410199 labeled VBN B-NP O
5 1346 1353 8410199 neurons NNS I-NP O
6 1354 1356 8410199 in IN B-PP O
7 1357 1362 8410199 three CD B-NP O
8 1363 1370 8410199 regions NNS I-NP O
9 1371 1373 8410199 of IN B-PP O
10 1374 1377 8410199 the DT B-NP O
11 1378 1385 8410199 dentate NN I-NP O
12 1386 1391 8410199 gyrus NN I-NP O
13 1392 1394 8410199 in IN B-PP O
14 1395 1398 8410199 the DT B-NP O
15 1399 1400 8410199 1 CD I-NP O
16 1401 1404 8410199 and CC I-NP O
17 1405 1406 8410199 2 CD I-NP O
18 1407 1411 8410199 week NN I-NP O
19 1412 1418 8410199 groups NNS I-NP O
20 1419 1425 8410199 showed VBD B-VP O
21 1426 1439 8410199 statistically RB B-NP O
22 1440 1451 8410199 significant JJ I-NP O
23 1452 1461 8410199 decreases NNS I-NP O
24 1462 1464 8410199 in IN B-PP O
25 1465 1468 8410199 the DT B-NP O
26 1469 1473 8410199 mean JJ I-NP O
27 1474 1480 8410199 number NN I-NP O
28 1481 1483 8410199 of IN B-PP O
29 1484 1487 8410199 GAD NN B-NP O
30 1488 1492 8410199 mRNA NN I-NP O
31 1492 1493 8410199 - HYPH O O
32 1493 1503 8410199 containing VBG B-VP O
33 1504 1511 8410199 neurons NNS B-NP O
34 1512 1514 8410199 in IN B-PP O
35 1515 1518 8410199 the DT B-NP O
36 1519 1524 8410199 hilus NN I-NP O
37 1525 1527 8410199 of IN B-PP O
38 1528 1532 8410199 both DT B-NP O
39 1533 1539 8410199 groups NNS I-NP O
40 1540 1542 8410199 of IN B-PP O
41 1543 1555 8410199 experimental JJ B-NP O
42 1556 1563 8410199 animals NNS I-NP O
43 1563 1564 8410199 . . O O

1 1565 1567 8410199 No DT B-NP O
2 1568 1579 8410199 significant JJ I-NP O
3 1580 1591 8410199 differences NNS I-NP O
4 1592 1596 8410199 were VBD B-VP O
5 1597 1602 8410199 found VBN I-VP O
6 1603 1605 8410199 in IN B-PP O
7 1606 1609 8410199 the DT B-NP O
8 1610 1619 8410199 molecular JJ I-NP O
9 1620 1625 8410199 layer NN I-NP O
10 1626 1628 8410199 or CC O O
11 1629 1632 8410199 the DT B-NP O
12 1633 1640 8410199 granule NN I-NP O
13 1641 1645 8410199 cell NN I-NP O
14 1646 1651 8410199 layer NN I-NP O
15 1651 1652 8410199 , , O O
16 1653 1658 8410199 which WDT B-NP O
17 1659 1667 8410199 included VBD B-VP O
18 1668 1675 8410199 labeled VBN B-NP O
19 1676 1683 8410199 neurons NNS I-NP O
20 1684 1689 8410199 along IN B-PP O
21 1690 1693 8410199 the DT B-NP O
22 1694 1699 8410199 lower JJR I-NP O
23 1700 1706 8410199 margin NN I-NP O
24 1707 1709 8410199 of IN B-PP O
25 1710 1713 8410199 the DT B-NP O
26 1714 1721 8410199 granule NN I-NP O
27 1722 1726 8410199 cell NN I-NP O
28 1727 1732 8410199 layer NN I-NP O
29 1732 1733 8410199 . . O O

1 1734 1737 8410199 The DT B-NP O
2 1738 1745 8410199 results NNS I-NP O
3 1746 1754 8410199 indicate VBP B-VP O
4 1755 1759 8410199 that IN B-SBAR O
5 1759 1760 8410199 , , O O
6 1761 1763 8410199 in IN B-PP O
7 1764 1768 8410199 this DT B-NP O
8 1769 1774 8410199 model NN I-NP O
9 1774 1775 8410199 , , O O
10 1776 1777 8410199 a DT B-NP O
11 1778 1791 8410199 subpopulation NN I-NP O
12 1792 1794 8410199 of IN B-PP O
13 1795 1798 8410199 GAD NN B-NP O
14 1799 1803 8410199 mRNA NN I-NP O
15 1803 1804 8410199 - HYPH O O
16 1804 1814 8410199 containing VBG B-VP O
17 1815 1822 8410199 neurons NNS B-NP O
18 1823 1829 8410199 within IN B-PP O
19 1830 1833 8410199 the DT B-NP O
20 1834 1841 8410199 dentate NN I-NP O
21 1842 1847 8410199 gyrus NN I-NP O
22 1848 1850 8410199 is VBZ B-VP O
23 1851 1862 8410199 selectively RB B-ADJP O
24 1863 1873 8410199 vulnerable JJ I-ADJP O
25 1874 1876 8410199 to TO B-PP O
26 1877 1884 8410199 seizure NN B-NP D012640
27 1884 1885 8410199 - HYPH B-NP O
28 1885 1892 8410199 induced VBN I-NP O
29 1893 1899 8410199 damage NN I-NP O
30 1899 1900 8410199 . . O O

1 1901 1905 8410199 Such JJ B-NP O
2 1906 1918 8410199 differential JJ I-NP O
3 1919 1932 8410199 vulnerability NN I-NP O
4 1933 1940 8410199 appears VBZ B-VP O
5 1941 1943 8410199 to TO I-VP O
6 1944 1946 8410199 be VB I-VP O
7 1947 1954 8410199 another DT B-NP O
8 1955 1965 8410199 indication NN I-NP O
9 1966 1968 8410199 of IN B-PP O
10 1969 1972 8410199 the DT B-NP O
11 1973 1986 8410199 heterogeneity NN I-NP O
12 1987 1989 8410199 of IN B-PP O
13 1990 1994 8410199 GABA NN B-NP D005680
14 1995 2002 8410199 neurons NNS I-NP O
15 2002 2003 8410199 . . O O

1 0 0 2435991 -DOCSTART- -X- -X- O

1 0 14 2435991 Antiarrhythmic JJ B-NP O
2 15 21 2435991 plasma NN I-NP O
3 22 36 2435991 concentrations NNS I-NP O
4 37 39 2435991 of IN B-PP O
5 40 51 2435991 cibenzoline NN B-NP C032151
6 52 54 2435991 on IN B-PP O
7 55 61 2435991 canine JJ B-NP O
8 62 73 2435991 ventricular JJ I-NP D001145
9 74 85 2435991 arrhythmias NNS I-NP D001145
10 85 86 2435991 . . O O
11 87 92 2435991 Using VBG B-VP O
12 93 96 2435991 two CD B-NP O
13 96 97 2435991 - HYPH I-NP O
14 97 102 2435991 stage NN I-NP O
15 103 111 2435991 coronary JJ I-NP O
16 112 120 2435991 ligation NN I-NP O
17 120 121 2435991 - HYPH B-ADJP O
18 121 122 2435991 , , O O
19 123 132 2435991 digitalis NN B-NP D004071
20 132 133 2435991 - HYPH B-ADJP O
21 133 134 2435991 , , O O
22 135 138 2435991 and CC O O
23 139 149 2435991 adrenaline NN B-NP D004837
24 149 150 2435991 - HYPH O O
25 150 157 2435991 induced VBN B-NP O
26 158 164 2435991 canine JJ I-NP O
27 165 176 2435991 ventricular JJ I-NP D001145
28 177 188 2435991 arrhythmias NNS I-NP D001145
29 188 189 2435991 , , O O
30 190 204 2435991 antiarrhythmic JJ B-NP O
31 205 212 2435991 effects NNS I-NP O
32 213 215 2435991 of IN B-PP O
33 216 227 2435991 cibenzoline NN B-NP C032151
34 228 232 2435991 were VBD B-VP O
35 233 241 2435991 examined VBN I-VP O
36 242 245 2435991 and CC O O
37 246 249 2435991 the DT B-NP O
38 250 257 2435991 minimum JJ I-NP O
39 258 267 2435991 effective JJ I-NP O
40 268 274 2435991 plasma NN I-NP O
41 275 288 2435991 concentration NN I-NP O
42 289 292 2435991 for IN B-PP O
43 293 297 2435991 each DT B-NP O
44 298 308 2435991 arrhythmia NN I-NP D001145
45 309 314 2435991 model NN I-NP O
46 315 318 2435991 was VBD B-VP O
47 319 329 2435991 determined VBN I-VP O
48 329 330 2435991 . . O O

1 331 342 2435991 Cibenzoline NN B-NP C032151
2 343 353 2435991 suppressed VBD B-VP O
3 354 357 2435991 all PDT B-NP O
4 358 361 2435991 the DT I-NP O
5 362 373 2435991 arrhythmias NNS I-NP D001145
6 373 374 2435991 , , O O
7 375 378 2435991 and CC O O
8 379 382 2435991 the DT B-NP O
9 383 390 2435991 minimum JJ I-NP O
10 391 400 2435991 effective JJ I-NP O
11 401 407 2435991 plasma NN I-NP O
12 408 422 2435991 concentrations NNS I-NP O
13 423 426 2435991 for IN B-PP O
14 427 438 2435991 arrhythmias NNS B-NP D001145
15 439 446 2435991 induced VBN B-VP O
16 447 449 2435991 by IN B-PP O
17 450 452 2435991 24 CD B-NP O
18 452 453 2435991 - HYPH I-NP O
19 453 454 2435991 h NN I-NP O
20 455 463 2435991 coronary JJ I-NP O
21 464 472 2435991 ligation NN I-NP O
22 472 473 2435991 , , O O
23 474 476 2435991 48 CD B-NP O
24 476 477 2435991 - HYPH I-NP O
25 477 478 2435991 h NN I-NP O
26 479 487 2435991 coronary JJ I-NP O
27 488 496 2435991 ligation NN I-NP O
28 496 497 2435991 , , O O
29 498 507 2435991 digitalis NN B-NP D004071
30 507 508 2435991 , , O O
31 509 512 2435991 and CC O O
32 513 523 2435991 adrenaline NN B-NP D004837
33 524 528 2435991 were VBD B-VP O
34 529 532 2435991 1.9 CD B-NP O
35 533 534 2435991 + SYM O O
36 534 535 2435991 / SYM B-NP O
37 535 536 2435991 - SYM B-NP O
38 537 540 2435991 0.9 CD I-NP O
39 541 542 2435991 ( ( O O
40 542 544 2435991 by IN B-PP O
41 545 546 2435991 8 CD B-NP O
42 547 549 2435991 mg NN I-NP O
43 549 550 2435991 / SYM B-NP O
44 550 552 2435991 kg NN I-NP O
45 553 556 2435991 i.v JJ B-ADJP O
46 556 557 2435991 . . O O
47 557 558 2435991 ) ) O O
48 558 559 2435991 , , O O
49 560 563 2435991 1.6 CD B-NP O
50 564 565 2435991 + SYM B-NP O
51 565 566 2435991 / SYM I-NP O
52 566 567 2435991 - SYM I-NP O
53 568 571 2435991 0.5 CD I-NP O
54 572 573 2435991 ( ( O O
55 573 575 2435991 by IN B-PP O
56 576 577 2435991 8 CD B-NP O
57 578 580 2435991 mg NN I-NP O
58 580 581 2435991 / SYM B-NP O
59 581 583 2435991 kg NN I-NP O
60 584 587 2435991 i.v JJ B-ADJP O
61 587 588 2435991 . . O O
62 588 589 2435991 ) ) O O
63 589 590 2435991 , , O O
64 591 594 2435991 0.6 CD B-NP O
65 595 596 2435991 + SYM O O
66 596 597 2435991 / SYM B-NP O
67 597 598 2435991 - SYM B-NP O
68 599 602 2435991 0.2 CD I-NP O
69 603 604 2435991 ( ( O O
70 604 606 2435991 by IN B-PP O
71 607 608 2435991 2 CD B-NP O
72 609 611 2435991 mg NN I-NP O
73 611 612 2435991 / SYM B-NP O
74 612 614 2435991 kg NN I-NP O
75 615 618 2435991 i.v JJ B-ADJP O
76 618 619 2435991 . . O O
77 619 620 2435991 ) ) O O
78 620 621 2435991 , , O O
79 622 625 2435991 and CC O O
80 626 629 2435991 3.5 CD B-NP O
81 630 631 2435991 + SYM B-NP O
82 631 632 2435991 / SYM I-NP O
83 632 633 2435991 - SYM I-NP O
84 634 637 2435991 1.3 CD I-NP O
85 638 639 2435991 ( ( O O
86 639 641 2435991 by IN B-PP O
87 642 643 2435991 5 CD B-NP O
88 644 646 2435991 mg NN I-NP O
89 646 647 2435991 / SYM B-NP O
90 647 649 2435991 kg NN I-NP O
91 650 653 2435991 i.v JJ B-ADJP O
92 653 654 2435991 . . O O
93 654 655 2435991 ) ) O O
94 656 666 2435991 micrograms NNS B-NP O
95 666 667 2435991 / SYM B-VP O
96 667 669 2435991 ml NN B-NP O
97 669 670 2435991 , , O O
98 671 683 2435991 respectively RB B-ADVP O
99 684 685 2435991 ( ( O O
100 685 689 2435991 mean NN B-NP O
101 690 691 2435991 + SYM O O
102 691 692 2435991 / SYM O O
103 692 693 2435991 - HYPH O O
104 694 697 2435991 SDM NN B-NP O
105 697 698 2435991 , , O O
106 699 700 2435991 n NN B-NP O
107 701 702 2435991 = SYM B-VP O
108 703 704 2435991 6 CD B-NP O
109 704 705 2435991 - HYPH I-NP O
110 705 706 2435991 7 CD I-NP O
111 706 707 2435991 ) ) O O
112 707 708 2435991 . . O O

1 709 712 2435991 The DT B-NP O
2 713 726 2435991 concentration NN I-NP O
3 727 730 2435991 for IN B-PP O
4 731 741 2435991 adrenaline NN B-NP D004837
5 741 742 2435991 - HYPH B-NP O
6 742 749 2435991 induced VBN I-NP O
7 750 760 2435991 arrhythmia NN I-NP D001145
8 761 764 2435991 was VBD B-VP O
9 765 778 2435991 significantly RB B-ADJP O
10 779 785 2435991 higher JJR I-ADJP O
11 786 790 2435991 than IN B-PP O
12 791 796 2435991 those DT B-NP O
13 797 800 2435991 for IN B-PP O
14 801 804 2435991 the DT B-NP O
15 805 810 2435991 other JJ I-NP O
16 811 816 2435991 types NNS I-NP O
17 817 819 2435991 of IN B-PP O
18 820 831 2435991 arrhythmias NNS B-NP D001145
19 831 832 2435991 . . O O

1 833 837 2435991 This DT B-NP O
2 838 853 2435991 pharmacological JJ I-NP O
3 854 861 2435991 profile NN I-NP O
4 862 864 2435991 is VBZ B-VP O
5 865 872 2435991 similar JJ B-ADJP O
6 873 875 2435991 to TO B-PP O
7 876 881 2435991 those DT B-NP O
8 882 884 2435991 of IN B-PP O
9 885 895 2435991 mexiletine NN B-NP D008801
10 896 899 2435991 and CC I-NP O
11 900 909 2435991 tocainide NN I-NP D016677
12 909 910 2435991 , , O O
13 911 914 2435991 and CC O O
14 915 918 2435991 all DT B-NP O
15 919 924 2435991 three CD I-NP O
16 925 930 2435991 drugs NNS I-NP O
17 931 935 2435991 have VBP B-VP O
18 936 943 2435991 central JJ B-NP O
19 944 951 2435991 nervous JJ I-NP O
20 952 958 2435991 system NN I-NP O
21 959 960 2435991 ( ( O O
22 960 963 2435991 CNS NN B-NP O
23 963 964 2435991 ) ) O O
24 965 974 2435991 stimulant JJ B-NP O
25 975 981 2435991 action NN I-NP O
26 981 982 2435991 . . O O

1 983 990 2435991 Because IN B-SBAR O
2 991 1002 2435991 cibenzoline NN B-NP C032151
3 1003 1006 2435991 had VBD B-VP O
4 1007 1011 2435991 only RB B-NP O
5 1012 1016 2435991 weak JJ I-NP O
6 1017 1028 2435991 hypotensive JJ I-NP D007022
7 1029 1032 2435991 and CC I-NP O
8 1033 1038 2435991 sinus NN I-NP O
9 1039 1043 2435991 node NN I-NP O
10 1044 1054 2435991 depressive JJ I-NP D003866
11 1055 1062 2435991 effects NNS I-NP O
12 1063 1066 2435991 and CC O O
13 1067 1070 2435991 was VBD B-VP O
14 1071 1076 2435991 found VBN I-VP O
15 1077 1079 2435991 to TO I-VP O
16 1080 1082 2435991 be VB I-VP O
17 1083 1089 2435991 orally RB B-ADJP O
18 1090 1096 2435991 active JJ I-ADJP O
19 1097 1101 2435991 when WRB B-ADVP O
20 1102 1107 2435991 given VBN B-PP O
21 1108 1110 2435991 to TO B-PP O
22 1111 1119 2435991 coronary JJ B-NP O
23 1120 1128 2435991 ligation NN I-NP O
24 1129 1139 2435991 arrhythmia NN I-NP D001145
25 1140 1144 2435991 dogs NNS I-NP O
26 1144 1145 2435991 , , O O
27 1146 1149 2435991 its PRP$ B-NP O
28 1150 1158 2435991 clinical JJ I-NP O
29 1159 1169 2435991 usefulness NN I-NP O
30 1170 1172 2435991 is VBZ B-VP O
31 1173 1181 2435991 expected VBN I-VP O
32 1181 1182 2435991 . . O O

1 0 0 9214597 -DOCSTART- -X- -X- O

1 0 4 9214597 Over IN B-PP O
2 5 15 9214597 expression NN B-NP O
3 16 18 9214597 of IN B-PP O
4 19 27 9214597 vascular JJ B-NP O
5 28 39 9214597 endothelial JJ I-NP O
6 40 46 9214597 growth NN I-NP O
7 47 53 9214597 factor NN I-NP O
8 54 57 9214597 and CC O O
9 58 61 9214597 its PRP$ B-NP O
10 62 70 9214597 receptor NN I-NP O
11 71 77 9214597 during IN B-PP O
12 78 81 9214597 the DT B-NP O
13 82 93 9214597 development NN I-NP O
14 94 96 9214597 of IN B-PP O
15 97 105 9214597 estrogen NN B-NP D004967
16 105 106 9214597 - HYPH B-NP O
17 106 113 9214597 induced VBN I-NP O
18 114 117 9214597 rat NN I-NP O
19 118 127 9214597 pituitary JJ I-NP D010911
20 128 134 9214597 tumors NNS I-NP D010911
21 135 138 9214597 may MD B-VP O
22 139 146 9214597 mediate VB I-VP O
23 147 155 9214597 estrogen NN B-NP D004967
24 155 156 9214597 - HYPH O O
25 156 165 9214597 initiated VBN B-NP O
26 166 171 9214597 tumor NN I-NP D009369
27 172 184 9214597 angiogenesis NN I-NP O
28 184 185 9214597 . . B-NP O
29 186 195 9214597 Estrogens NNS I-NP D004967
30 195 196 9214597 , , O O
31 197 202 9214597 which WDT B-NP O
32 203 207 9214597 have VBP B-VP O
33 208 212 9214597 been VBN I-VP O
34 213 223 9214597 associated VBN I-VP O
35 224 228 9214597 with IN B-PP O
36 229 236 9214597 several JJ B-NP O
37 237 242 9214597 types NNS I-NP O
38 243 245 9214597 of IN B-PP O
39 246 251 9214597 human JJ B-NP O
40 252 255 9214597 and CC I-NP O
41 256 262 9214597 animal JJ I-NP O
42 263 270 9214597 cancers NNS I-NP D009369
43 270 271 9214597 , , O O
44 272 275 9214597 can MD B-VP O
45 276 282 9214597 induce VB I-VP O
46 283 288 9214597 tumor NN B-NP D009369
47 289 301 9214597 angiogenesis NN I-NP O
48 302 304 9214597 in IN B-PP O
49 305 308 9214597 the DT B-NP O
50 309 318 9214597 pituitary NN I-NP O
51 319 321 9214597 of IN B-PP O
52 322 329 9214597 Fischer NNP B-NP O
53 330 333 9214597 344 CD I-NP O
54 334 338 9214597 rats NNS I-NP O
55 338 339 9214597 . . O O

1 340 343 9214597 The DT B-NP O
2 344 355 9214597 mechanistic JJ I-NP O
3 356 363 9214597 details NNS I-NP O
4 364 366 9214597 of IN B-PP O
5 367 372 9214597 tumor NN B-NP D009369
6 373 385 9214597 angiogenesis NN I-NP O
7 386 395 9214597 induction NN I-NP O
8 395 396 9214597 , , O O
9 397 403 9214597 during IN B-PP O
10 404 412 9214597 estrogen NN B-NP D004967
11 413 427 9214597 carcinogenesis NN I-NP D063646
12 427 428 9214597 , , O O
13 429 432 9214597 are VBP B-VP O
14 433 438 9214597 still RB B-ADVP O
15 439 446 9214597 unknown JJ B-ADJP O
16 446 447 9214597 . . O O

1 448 450 9214597 To TO B-VP O
2 451 460 9214597 elucidate VB I-VP O
3 461 464 9214597 the DT B-NP O
4 465 469 9214597 role NN I-NP O
5 470 472 9214597 of IN B-PP O
6 473 481 9214597 estrogen NN B-NP D004967
7 482 484 9214597 in IN B-PP O
8 485 488 9214597 the DT B-NP O
9 489 499 9214597 regulation NN I-NP O
10 500 502 9214597 of IN B-PP O
11 503 508 9214597 tumor NN B-NP D009369
12 509 521 9214597 angiogenesis NN I-NP O
13 522 524 9214597 in IN B-PP O
14 525 528 9214597 the DT B-NP O
15 529 538 9214597 pituitary NN I-NP O
16 539 541 9214597 of IN B-PP O
17 542 548 9214597 female JJ B-NP O
18 549 553 9214597 rats NNS I-NP O
19 553 554 9214597 , , O O
20 555 558 9214597 the DT B-NP O
21 559 566 9214597 density NN I-NP O
22 567 569 9214597 of IN B-PP O
23 570 575 9214597 blood NN B-NP O
24 576 583 9214597 vessels NNS I-NP O
25 584 587 9214597 was VBD B-VP O
26 588 596 9214597 analysed VBN I-VP O
27 597 602 9214597 using VBG B-VP O
28 603 609 9214597 factor NN B-NP O
29 610 614 9214597 VIII CD I-NP O
30 615 622 9214597 related JJ I-NP O
31 623 630 9214597 antigen NN I-NP O
32 631 632 9214597 ( ( O O
33 632 640 9214597 FVIIIRAg NN B-NP O
34 640 641 9214597 ) ) O O
35 642 662 9214597 immunohistochemistry NN B-NP O
36 663 666 9214597 and CC O O
37 667 670 9214597 the DT B-NP O
38 671 681 9214597 expression NN I-NP O
39 682 684 9214597 of IN B-PP O
40 685 693 9214597 vascular JJ B-NP O
41 694 705 9214597 endothelial JJ I-NP O
42 706 712 9214597 growth NN I-NP O
43 713 719 9214597 factor NN I-NP O
44 719 720 9214597 / SYM B-NP O
45 720 728 9214597 vascular JJ I-NP O
46 729 741 9214597 permeability NN I-NP O
47 742 748 9214597 factor NN I-NP O
48 749 750 9214597 ( ( O O
49 750 754 9214597 VEGF NN B-NP O
50 754 755 9214597 / SYM B-NP O
51 755 758 9214597 VPF NN I-NP O
52 758 759 9214597 ) ) O O
53 760 763 9214597 was VBD B-VP O
54 764 772 9214597 examined VBN I-VP O
55 773 775 9214597 by IN B-PP O
56 776 783 9214597 Western JJ B-NP O
57 784 788 9214597 blot NN I-NP O
58 789 792 9214597 and CC O O
59 793 812 9214597 immunohistochemical JJ B-NP O
60 813 821 9214597 analysis NN I-NP O
61 821 822 9214597 . . O O

1 823 826 9214597 The DT B-NP O
2 827 837 9214597 expression NN I-NP O
3 838 840 9214597 of IN B-PP O
4 841 845 9214597 VEGF NN B-NP O
5 846 854 9214597 receptor NN I-NP O
6 855 856 9214597 ( ( O O
7 856 861 9214597 VEGFR NN B-NP O
8 861 862 9214597 - HYPH B-NP O
9 862 863 9214597 2 CD I-NP O
10 863 864 9214597 / SYM I-NP O
11 864 867 9214597 Flk NN I-NP O
12 867 868 9214597 - SYM B-NP O
13 868 869 9214597 1 CD I-NP O
14 869 870 9214597 / SYM I-NP O
15 870 873 9214597 KDR NN I-NP O
16 873 874 9214597 ) ) O O
17 875 878 9214597 was VBD B-VP O
18 879 883 9214597 also RB I-VP O
19 884 892 9214597 examined VBN I-VP O
20 893 895 9214597 by IN B-PP O
21 896 916 9214597 immunohistochemistry NN B-NP O
22 916 917 9214597 . . O O

1 918 921 9214597 The DT B-NP O
2 922 929 9214597 results NNS I-NP O
3 930 942 9214597 demonstrated VBD B-VP O
4 943 947 9214597 that IN B-SBAR O
5 948 954 9214597 17beta NN B-NP D004958
6 954 955 9214597 - HYPH O D004958
7 955 964 9214597 estradiol NN B-NP D004958
8 965 966 9214597 ( ( O O
9 966 968 9214597 E2 NN B-NP D004958
10 968 969 9214597 ) ) O O
11 970 977 9214597 induces VBZ B-VP O
12 978 996 9214597 neovascularization NN B-NP O
13 996 997 9214597 , , O O
14 998 1000 9214597 as RB B-CONJP O
15 1001 1005 9214597 well RB I-CONJP O
16 1006 1008 9214597 as IN I-CONJP O
17 1009 1012 9214597 the DT B-NP O
18 1013 1019 9214597 growth NN I-NP O
19 1020 1023 9214597 and CC I-NP O
20 1024 1035 9214597 enlargement NN I-NP O
21 1036 1038 9214597 of IN B-PP O
22 1039 1044 9214597 blood NN B-NP O
23 1045 1052 9214597 vessels NNS I-NP O
24 1053 1058 9214597 after IN B-PP O
25 1059 1060 9214597 7 CD B-NP O
26 1061 1065 9214597 days NNS I-NP O
27 1066 1068 9214597 of IN B-PP O
28 1069 1077 9214597 exposure NN B-NP O
29 1077 1078 9214597 . . O O

1 1079 1082 9214597 The DT B-NP O
2 1083 1087 9214597 high JJ I-NP O
3 1088 1093 9214597 tumor NN I-NP D009369
4 1094 1104 9214597 angiogenic JJ I-NP O
5 1105 1114 9214597 potential NN I-NP O
6 1115 1118 9214597 was VBD B-VP O
7 1119 1129 9214597 associated VBN I-VP O
8 1130 1134 9214597 with IN B-PP O
9 1135 1137 9214597 an DT B-NP O
10 1138 1146 9214597 elevated VBN I-NP O
11 1147 1151 9214597 VEGF NN I-NP O
12 1151 1152 9214597 / SYM I-NP O
13 1152 1155 9214597 VPF NN I-NP O
14 1156 1163 9214597 protein NN I-NP O
15 1164 1174 9214597 expression NN I-NP O
16 1175 1177 9214597 in IN B-PP O
17 1178 1181 9214597 the DT B-NP O
18 1182 1184 9214597 E2 NN I-NP D004958
19 1185 1192 9214597 exposed VBN B-VP O
20 1193 1202 9214597 pituitary NN B-NP O
21 1203 1205 9214597 of IN B-PP O
22 1206 1220 9214597 ovariectomized VBN O O
23 1221 1222 9214597 ( ( O O
24 1222 1226 9214597 OVEX NN B-NP O
25 1226 1227 9214597 ) ) O O
26 1228 1232 9214597 rats NNS B-NP O
27 1232 1233 9214597 . . O O

1 1234 1238 9214597 VEGF NN B-NP O
2 1238 1239 9214597 / SYM I-NP O
3 1239 1242 9214597 VPF NN I-NP O
4 1243 1246 9214597 and CC I-NP O
5 1247 1255 9214597 FVIIIRAg NN I-NP O
6 1256 1276 9214597 immunohistochemistry NN I-NP O
7 1277 1280 9214597 and CC O O
8 1281 1292 9214597 endothelial JJ B-NP O
9 1293 1301 9214597 specific JJ I-NP O
10 1302 1308 9214597 lectin NN I-NP O
11 1309 1310 9214597 ( ( O O
12 1310 1314 9214597 UEA1 NN B-NP O
13 1314 1315 9214597 ) ) O O
14 1316 1323 9214597 binding NN B-NP O
15 1324 1331 9214597 studies NNS I-NP O
16 1331 1332 9214597 , , O O
17 1333 1341 9214597 indicate VBP B-VP O
18 1342 1346 9214597 that IN B-SBAR O
19 1347 1350 9214597 the DT B-NP O
20 1351 1360 9214597 elevation NN I-NP O
21 1361 1363 9214597 of IN B-PP O
22 1364 1368 9214597 VEGF NN B-NP O
23 1369 1376 9214597 protein NN I-NP O
24 1377 1387 9214597 expression NN I-NP O
25 1388 1397 9214597 initially RB B-ADVP O
26 1398 1406 9214597 occurred VBD B-VP O
27 1407 1409 9214597 in IN B-PP O
28 1410 1414 9214597 both DT B-NP O
29 1415 1420 9214597 blood NN I-NP O
30 1421 1428 9214597 vessels NNS I-NP O
31 1429 1432 9214597 and CC O O
32 1433 1436 9214597 non AFX B-NP O
33 1436 1437 9214597 - HYPH I-NP O
34 1437 1448 9214597 endothelial JJ I-NP O
35 1449 1454 9214597 cells NNS I-NP O
36 1454 1455 9214597 . . O O

1 1456 1461 9214597 After IN B-PP O
2 1462 1464 9214597 15 CD B-NP O
3 1465 1469 9214597 days NNS I-NP O
4 1470 1472 9214597 of IN B-PP O
5 1473 1475 9214597 E2 NN B-NP D004958
6 1476 1484 9214597 exposure NN I-NP O
7 1484 1485 9214597 , , O O
8 1486 1490 9214597 VEGF NN B-NP O
9 1490 1491 9214597 / SYM B-VP O
10 1491 1494 9214597 VPF NN B-NP O
11 1495 1502 9214597 protein NN I-NP O
12 1503 1513 9214597 expression NN I-NP O
13 1513 1514 9214597 , , O O
14 1515 1517 9214597 in IN B-PP O
15 1518 1521 9214597 the DT B-NP O
16 1522 1525 9214597 non AFX I-NP O
17 1525 1526 9214597 - HYPH I-NP O
18 1526 1537 9214597 endothelial JJ I-NP O
19 1538 1542 9214597 cell NN I-NP O
20 1543 1553 9214597 population NN I-NP O
21 1553 1554 9214597 , , O O
22 1555 1562 9214597 sharply RB B-VP O
23 1563 1571 9214597 declined VBD I-VP O
24 1572 1575 9214597 and CC I-VP O
25 1576 1579 9214597 was VBD I-VP O
26 1580 1590 9214597 restricted JJ B-ADJP O
27 1591 1593 9214597 to TO B-PP O
28 1594 1597 9214597 the DT B-NP O
29 1598 1603 9214597 blood NN I-NP O
30 1604 1611 9214597 vessels NNS I-NP O
31 1611 1612 9214597 . . O O

1 1613 1616 9214597 The DT B-NP O
2 1617 1625 9214597 function NN I-NP O
3 1626 1628 9214597 of IN B-PP O
4 1629 1632 9214597 non AFX B-NP O
5 1632 1633 9214597 - HYPH I-NP O
6 1633 1644 9214597 endothelial JJ I-NP O
7 1644 1645 9214597 - HYPH I-NP O
8 1645 1652 9214597 derived VBN I-NP O
9 1653 1657 9214597 VEGF NN I-NP O
10 1658 1660 9214597 is VBZ B-VP O
11 1661 1664 9214597 not RB O O
12 1665 1670 9214597 clear JJ B-ADJP O
13 1670 1671 9214597 . . O O

1 1672 1683 9214597 Furthermore RB B-ADVP O
2 1683 1684 9214597 , , O O
3 1685 1704 9214597 immunohistochemical JJ B-NP O
4 1705 1712 9214597 studies NNS I-NP O
5 1713 1725 9214597 demonstrated VBD B-VP O
6 1726 1730 9214597 that IN B-SBAR O
7 1731 1736 9214597 VEGFR NN B-NP O
8 1736 1737 9214597 - HYPH B-NP O
9 1737 1738 9214597 2 CD I-NP O
10 1739 1740 9214597 ( ( O O
11 1740 1743 9214597 flk NN B-NP O
12 1743 1744 9214597 - HYPH B-NP O
13 1744 1745 9214597 1 CD I-NP O
14 1745 1746 9214597 / SYM I-NP O
15 1746 1749 9214597 KDR NN I-NP O
16 1749 1750 9214597 ) ) O O
17 1750 1751 9214597 , , O O
18 1752 1762 9214597 expression NN B-NP O
19 1763 1766 9214597 was VBD B-VP O
20 1767 1775 9214597 elevated VBN I-VP O
21 1776 1789 9214597 significantly RB B-ADVP O
22 1790 1792 9214597 in IN B-PP O
23 1793 1796 9214597 the DT B-NP O
24 1797 1808 9214597 endothelial JJ I-NP O
25 1809 1814 9214597 cells NNS I-NP O
26 1815 1817 9214597 of IN B-PP O
27 1818 1828 9214597 microblood NN B-NP O
28 1829 1836 9214597 vessels NNS I-NP O
29 1837 1842 9214597 after IN B-PP O
30 1843 1844 9214597 7 CD B-NP O
31 1845 1849 9214597 days NNS I-NP O
32 1850 1852 9214597 of IN B-PP O
33 1853 1855 9214597 E2 NN B-NP D004958
34 1856 1864 9214597 exposure NN I-NP O
35 1864 1865 9214597 . . O O

1 1866 1871 9214597 These DT B-NP O
2 1872 1880 9214597 findings NNS I-NP O
3 1881 1888 9214597 suggest VBP B-VP O
4 1889 1893 9214597 that IN B-SBAR O
5 1894 1898 9214597 over IN B-PP O
6 1899 1909 9214597 expression NN B-NP O
7 1910 1912 9214597 of IN B-PP O
8 1913 1917 9214597 VEGF NN B-NP O
9 1918 1921 9214597 and CC O O
10 1922 1925 9214597 its PRP$ B-NP O
11 1926 1934 9214597 receptor NN I-NP O
12 1935 1936 9214597 ( ( O O
13 1936 1941 9214597 VEGFR NN O O
14 1941 1942 9214597 - HYPH O O
15 1942 1943 9214597 2 CD B-NP O
16 1943 1944 9214597 ) ) O O
17 1945 1948 9214597 may MD B-VP O
18 1949 1953 9214597 play VB I-VP O
19 1954 1956 9214597 an DT B-NP O
20 1957 1966 9214597 important JJ I-NP O
21 1967 1971 9214597 role NN I-NP O
22 1972 1974 9214597 in IN B-PP O
23 1975 1978 9214597 the DT B-NP O
24 1979 1986 9214597 initial JJ I-NP O
25 1987 1991 9214597 step NN I-NP O
26 1992 1994 9214597 of IN B-PP O
27 1995 1998 9214597 the DT B-NP O
28 1999 2009 9214597 regulation NN I-NP O
29 2010 2012 9214597 of IN B-PP O
30 2013 2021 9214597 estrogen NN B-NP D004967
31 2022 2029 9214597 induced VBD B-VP O
32 2030 2035 9214597 tumor NN B-NP D009369
33 2036 2048 9214597 angiogenesis NN I-NP O
34 2049 2051 9214597 in IN B-PP O
35 2052 2055 9214597 the DT B-NP O
36 2056 2059 9214597 rat NN I-NP O
37 2060 2069 9214597 pituitary NN I-NP O
38 2069 2070 9214597 . . O O

1 0 0 11860495 -DOCSTART- -X- -X- O

1 0 7 11860495 Steroid NN B-NP D013256
2 8 17 11860495 structure NN I-NP O
3 18 21 11860495 and CC O O
4 22 37 11860495 pharmacological JJ B-NP O
5 38 48 11860495 properties NNS I-NP O
6 49 58 11860495 determine VBP B-VP O
7 59 62 11860495 the DT B-NP O
8 63 67 11860495 anti AFX I-NP O
9 67 68 11860495 - HYPH I-NP O
10 68 75 11860495 amnesic JJ I-NP D000647
11 76 83 11860495 effects NNS I-NP O
12 84 86 11860495 of IN B-PP O
13 87 99 11860495 pregnenolone NN B-NP C018370
14 100 108 11860495 sulphate NN I-NP C018370
15 109 111 11860495 in IN B-PP O
16 112 115 11860495 the DT B-NP O
17 116 123 11860495 passive JJ I-NP O
18 124 133 11860495 avoidance NN I-NP O
19 134 138 11860495 task NN I-NP O
20 139 141 11860495 in IN B-PP O
21 142 146 11860495 rats NNS B-NP O
22 146 147 11860495 . . O O
23 148 160 11860495 Pregnenolone NN B-NP C018370
24 161 169 11860495 sulphate NN I-NP C018370
25 170 171 11860495 ( ( O O
26 171 176 11860495 PREGS NN B-NP C018370
27 176 177 11860495 ) ) O O
28 178 181 11860495 has VBZ B-VP O
29 182 191 11860495 generated VBN I-VP O
30 192 200 11860495 interest NN B-NP O
31 201 203 11860495 as IN B-PP O
32 204 207 11860495 one CD B-NP O
33 208 210 11860495 of IN B-PP O
34 211 214 11860495 the DT B-NP O
35 215 219 11860495 most RBS I-NP O
36 220 226 11860495 potent JJ I-NP O
37 227 233 11860495 memory NN I-NP O
38 233 234 11860495 - HYPH O O
39 234 243 11860495 enhancing VBG B-VP O
40 244 257 11860495 neurosteroids NNS B-NP O
41 258 260 11860495 to TO B-VP O
42 261 263 11860495 be VB I-VP O
43 264 272 11860495 examined VBN I-VP O
44 273 275 11860495 in IN B-PP O
45 276 282 11860495 rodent NN B-NP O
46 283 291 11860495 learning NN I-NP O
47 292 299 11860495 studies NNS I-NP O
48 299 300 11860495 , , O O
49 301 305 11860495 with IN B-PP O
50 306 316 11860495 particular JJ B-NP O
51 317 327 11860495 importance NN I-NP O
52 328 330 11860495 in IN B-PP O
53 331 334 11860495 the DT B-NP O
54 335 341 11860495 ageing VBG I-NP O
55 342 349 11860495 process NN I-NP O
56 349 350 11860495 . . O O

1 351 354 11860495 The DT B-NP O
2 355 364 11860495 mechanism NN I-NP O
3 365 367 11860495 by IN B-PP O
4 368 373 11860495 which WDT B-NP O
5 374 378 11860495 this DT B-NP O
6 379 389 11860495 endogenous JJ I-NP O
7 390 397 11860495 steroid NN I-NP D013256
8 398 406 11860495 enhances VBZ B-VP O
9 407 413 11860495 memory NN B-NP O
10 414 423 11860495 formation NN I-NP O
11 424 426 11860495 is VBZ B-VP O
12 427 439 11860495 hypothesized VBN I-VP O
13 440 442 11860495 to TO I-VP O
14 443 450 11860495 involve VB I-VP O
15 451 458 11860495 actions NNS B-NP O
16 459 461 11860495 on IN B-PP O
17 462 475 11860495 glutamatergic JJ B-NP O
18 476 479 11860495 and CC I-NP O
19 480 489 11860495 GABAergic JJ I-NP O
20 490 497 11860495 systems NNS I-NP O
21 497 498 11860495 . . O O

1 499 503 11860495 This DT B-NP O
2 504 514 11860495 hypothesis NN I-NP O
3 515 520 11860495 stems VBZ B-VP O
4 521 525 11860495 from IN B-PP O
5 526 534 11860495 findings NNS B-NP O
6 535 539 11860495 that IN B-SBAR O
7 540 545 11860495 PREGS NN B-NP C018370
8 546 548 11860495 is VBZ B-VP O
9 549 550 11860495 a DT B-NP O
10 551 557 11860495 potent JJ I-NP O
11 558 566 11860495 positive JJ I-NP O
12 567 576 11860495 modulator NN I-NP O
13 577 579 11860495 of IN B-PP O
14 580 581 11860495 N NN B-NP D016202
15 581 582 11860495 - HYPH B-NP D016202
16 582 588 11860495 methyl NN I-NP D016202
17 588 589 11860495 - HYPH B-NP D016202
18 589 590 11860495 d NN I-NP D016202
19 590 591 11860495 - HYPH B-NP D016202
20 591 600 11860495 aspartate NN I-NP D016202
21 601 610 11860495 receptors NNS I-NP O
22 611 612 11860495 ( ( O O
23 612 618 11860495 NMDARs NNS B-NP O
24 618 619 11860495 ) ) O O
25 620 623 11860495 and CC O O
26 624 625 11860495 a DT B-NP O
27 626 634 11860495 negative JJ I-NP O
28 635 644 11860495 modulator NN I-NP O
29 645 647 11860495 of IN B-PP O
30 648 653 11860495 gamma SYM B-NP D005680
31 653 654 11860495 - HYPH B-NP D005680
32 654 666 11860495 aminobutyric JJ I-NP D005680
33 667 674 11860495 acid(A) NN I-NP D005680
34 675 684 11860495 receptors NNS I-NP O
35 685 686 11860495 ( ( O O
36 686 695 11860495 GABA(A)Rs NNS B-NP D005680
37 695 696 11860495 ) ) O O
38 696 697 11860495 . . O O

1 698 706 11860495 Moreover RB B-ADVP O
2 706 707 11860495 , , O O
3 708 713 11860495 PREGS NN B-NP C018370
4 714 716 11860495 is VBZ B-VP O
5 717 721 11860495 able JJ B-ADJP O
6 722 724 11860495 to TO B-VP O
7 725 732 11860495 reverse VB I-VP O
8 733 736 11860495 the DT B-NP O
9 737 744 11860495 amnesic JJ I-NP D000647
10 744 745 11860495 - HYPH I-NP O
11 745 749 11860495 like JJ I-NP O
12 750 757 11860495 effects NNS I-NP O
13 758 760 11860495 of IN B-PP O
14 761 766 11860495 NMDAR NN B-NP O
15 767 770 11860495 and CC I-NP O
16 771 779 11860495 GABA(A)R NN I-NP D005680
17 780 787 11860495 ligands NNS I-NP O
18 787 788 11860495 . . O O

1 789 791 11860495 To TO B-VP O
2 792 803 11860495 investigate VB I-VP O
3 804 808 11860495 this DT B-NP O
4 809 819 11860495 hypothesis NN I-NP O
5 819 820 11860495 , , O O
6 821 824 11860495 the DT B-NP O
7 825 832 11860495 present JJ I-NP O
8 833 838 11860495 study NN I-NP O
9 839 841 11860495 in IN B-PP O
10 842 846 11860495 rats NNS B-NP O
11 847 855 11860495 examined VBN B-VP O
12 856 859 11860495 the DT B-NP O
13 860 866 11860495 memory NN I-NP O
14 866 867 11860495 - HYPH O O
15 867 875 11860495 altering VBG B-VP O
16 876 885 11860495 abilities NNS B-NP O
17 886 888 11860495 of IN B-PP O
18 889 899 11860495 structural JJ B-NP O
19 900 907 11860495 analogs NNS I-NP O
20 908 910 11860495 of IN B-PP O
21 911 916 11860495 PREGS NN B-NP C018370
22 916 917 11860495 , , O O
23 918 923 11860495 which WDT B-NP O
24 924 930 11860495 differ VBP B-VP O
25 931 933 11860495 in IN B-PP O
26 934 939 11860495 their PRP$ B-NP O
27 940 950 11860495 modulation NN I-NP O
28 951 953 11860495 of IN B-PP O
29 954 959 11860495 NMDAR NN B-NP O
30 960 963 11860495 and CC O O
31 963 964 11860495 / SYM B-NP O
32 964 966 11860495 or CC O O
33 967 975 11860495 GABA(A)R NN B-NP D005680
34 976 984 11860495 function NN I-NP O
35 984 985 11860495 . . O O

1 986 989 11860495 The DT B-NP O
2 990 997 11860495 analogs NNS I-NP O
3 998 1004 11860495 tested VBN B-VP O
4 1005 1009 11860495 were VBD B-VP O
5 1009 1010 11860495 : : O O
6 1011 1013 11860495 11 CD B-NP -1
7 1013 1014 11860495 - HYPH I-NP -1
8 1014 1030 11860495 ketopregnenolone NN I-NP -1
9 1031 1039 11860495 sulphate NN I-NP -1
10 1040 1041 11860495 ( ( O O
11 1041 1043 11860495 an DT B-NP O
12 1044 1049 11860495 agent NN I-NP O
13 1050 1054 11860495 that WDT B-NP O
14 1055 1057 11860495 is VBZ B-VP O
15 1058 1066 11860495 inactive JJ B-ADJP O
16 1067 1069 11860495 at IN B-PP O
17 1070 1079 11860495 GABA(A)Rs NNS B-NP D005680
18 1080 1083 11860495 and CC I-NP O
19 1084 1090 11860495 NMDARs NNS I-NP O
20 1090 1091 11860495 ) ) O O
21 1091 1092 11860495 , , O O
22 1093 1108 11860495 epipregnanolone NN B-NP C018370
23 1109 1110 11860495 ( ( O C018370
24 1110 1111 11860495 [ ( O C018370
25 1111 1116 11860495 3beta NN B-NP C018370
26 1116 1117 11860495 - HYPH B-NP C018370
27 1117 1124 11860495 hydroxy NN I-NP C018370
28 1124 1125 11860495 - HYPH B-NP C018370
29 1125 1130 11860495 5beta NN I-NP C018370
30 1130 1131 11860495 - HYPH B-NP C018370
31 1131 1138 11860495 pregnan NN I-NP C018370
32 1138 1139 11860495 - HYPH O C018370
33 1139 1141 11860495 20 CD B-NP C018370
34 1141 1142 11860495 - HYPH I-NP C018370
35 1142 1145 11860495 one CD I-NP C018370
36 1145 1146 11860495 ] ) I-NP C018370
37 1147 1155 11860495 sulphate NN I-NP C018370
38 1155 1156 11860495 , , O O
39 1157 1159 11860495 an DT B-NP O
40 1160 1169 11860495 inhibitor NN I-NP O
41 1170 1172 11860495 of IN B-PP O
42 1173 1177 11860495 both DT B-NP O
43 1178 1187 11860495 GABA(A)Rs NNS I-NP D005680
44 1188 1191 11860495 and CC I-NP O
45 1192 1198 11860495 NMDARs NNS I-NP O
46 1198 1199 11860495 ) ) O O
47 1199 1200 11860495 , , O O
48 1201 1204 11860495 and CC O O
49 1205 1206 11860495 a DT B-NP O
50 1207 1212 11860495 newly RB I-NP O
51 1213 1224 11860495 synthesized VBN I-NP O
52 1225 1226 11860495 ( ( O O
53 1226 1227 11860495 - SYM O O
54 1227 1228 11860495 ) ) O O
55 1229 1234 11860495 PREGS NN B-NP C018370
56 1235 1245 11860495 enantiomer NN I-NP O
57 1246 1247 11860495 ( ( O O
58 1247 1252 11860495 which WDT B-NP O
59 1253 1255 11860495 is VBZ B-VP O
60 1256 1265 11860495 identical JJ B-ADJP O
61 1266 1268 11860495 to TO B-PP O
62 1269 1274 11860495 PREGS NN B-NP C018370
63 1275 1277 11860495 in IN B-PP O
64 1278 1285 11860495 effects NNS B-NP O
65 1286 1288 11860495 on IN B-PP O
66 1289 1298 11860495 GABA(A)Rs NNS B-NP D005680
67 1299 1302 11860495 and CC I-NP O
68 1303 1309 11860495 NMDARs NNS I-NP O
69 1309 1310 11860495 ) ) O O
70 1310 1311 11860495 . . O O

1 1312 1315 11860495 The DT B-NP O
2 1316 1322 11860495 memory NN I-NP O
3 1322 1323 11860495 - HYPH O O
4 1323 1332 11860495 enhancing VBG B-VP O
5 1333 1340 11860495 effects NNS B-NP O
6 1341 1343 11860495 of IN B-PP O
7 1344 1349 11860495 PREGS NN B-NP C018370
8 1350 1353 11860495 and CC O O
9 1354 1357 11860495 its PRP$ B-NP O
10 1358 1365 11860495 analogs NNS I-NP O
11 1366 1370 11860495 were VBD B-VP O
12 1371 1377 11860495 tested VBN I-VP O
13 1378 1380 11860495 in IN B-PP O
14 1381 1384 11860495 the DT B-NP O
15 1385 1392 11860495 passive JJ I-NP O
16 1393 1402 11860495 avoidance NN I-NP O
17 1403 1407 11860495 task NN I-NP O
18 1408 1413 11860495 using VBG B-VP O
19 1414 1417 11860495 the DT B-NP O
20 1418 1423 11860495 model NN I-NP O
21 1424 1426 11860495 of IN B-PP O
22 1427 1438 11860495 scopolamine NN B-NP D012601
23 1438 1439 11860495 - HYPH B-NP O
24 1439 1446 11860495 induced VBN I-NP O
25 1447 1454 11860495 amnesia NN I-NP D000647
26 1454 1455 11860495 . . O O

1 1456 1460 11860495 Both CC O O
2 1461 1466 11860495 PREGS NN B-NP C018370
3 1467 1470 11860495 and CC O O
4 1471 1474 11860495 its PRP$ O O
5 1475 1476 11860495 ( ( O O
6 1476 1477 11860495 - SYM O O
7 1477 1478 11860495 ) ) O O
8 1479 1489 11860495 enantiomer NN B-NP O
9 1490 1497 11860495 blocked VBD B-VP O
10 1498 1501 11860495 the DT B-NP O
11 1502 1509 11860495 effects NNS I-NP O
12 1510 1512 11860495 of IN B-PP O
13 1513 1524 11860495 scopolamine NN B-NP D012601
14 1524 1525 11860495 . . O O

1 1526 1529 11860495 The DT B-NP O
2 1530 1537 11860495 results NNS I-NP O
3 1538 1542 11860495 show VBP B-VP O
4 1543 1547 11860495 that IN B-SBAR O
5 1547 1548 11860495 , , O O
6 1549 1555 11860495 unlike IN B-PP O
7 1556 1561 11860495 PREGS NN B-NP C018370
8 1561 1562 11860495 , , O O
9 1563 1565 11860495 11 CD B-NP -1
10 1565 1566 11860495 - HYPH I-NP -1
11 1566 1582 11860495 ketopregnenolone NN I-NP -1
12 1583 1591 11860495 sulphate NN I-NP -1
13 1592 1595 11860495 and CC O O
14 1596 1611 11860495 epipregnanolone NN B-NP C018370
15 1612 1620 11860495 sulphate NN I-NP C018370
16 1621 1627 11860495 failed VBD B-VP O
17 1628 1630 11860495 to TO I-VP O
18 1631 1636 11860495 block VB I-VP O
19 1637 1640 11860495 the DT B-NP O
20 1641 1647 11860495 effect NN I-NP O
21 1648 1650 11860495 of IN B-PP O
22 1651 1662 11860495 scopolamine NN B-NP D012601
23 1662 1663 11860495 , , O O
24 1664 1674 11860495 suggesting VBG B-VP O
25 1675 1679 11860495 that IN B-SBAR O
26 1680 1688 11860495 altering VBG B-VP O
27 1689 1692 11860495 the DT B-NP O
28 1693 1703 11860495 modulation NN I-NP O
29 1704 1706 11860495 of IN B-PP O
30 1707 1711 11860495 NMDA NN B-NP D016202
31 1712 1721 11860495 receptors NNS I-NP O
32 1722 1732 11860495 diminishes VBZ B-VP O
33 1733 1736 11860495 the DT B-NP O
34 1737 1743 11860495 memory NN I-NP O
35 1743 1744 11860495 - HYPH O O
36 1744 1753 11860495 enhancing VBG B-VP O
37 1754 1761 11860495 effects NNS B-NP O
38 1762 1764 11860495 of IN B-PP O
39 1765 1770 11860495 PREGS NN B-NP C018370
40 1770 1771 11860495 . . O O

1 1772 1780 11860495 Moreover RB B-ADVP O
2 1780 1781 11860495 , , O O
3 1782 1800 11860495 enantioselectivity NN B-NP O
4 1801 1804 11860495 was VBD B-VP O
5 1805 1817 11860495 demonstrated VBN I-VP O
6 1818 1820 11860495 by IN B-PP O
7 1821 1824 11860495 the DT B-NP O
8 1825 1832 11860495 ability NN I-NP O
9 1833 1835 11860495 of IN B-PP O
10 1836 1843 11860495 natural JJ B-NP O
11 1844 1849 11860495 PREGS NN I-NP C018370
12 1850 1852 11860495 to TO B-VP O
13 1853 1855 11860495 be VB I-VP O
14 1856 1858 11860495 an DT B-NP O
15 1859 1864 11860495 order NN I-NP O
16 1865 1867 11860495 of IN B-PP O
17 1868 1877 11860495 magnitude NN B-NP O
18 1878 1882 11860495 more RBR B-ADJP O
19 1883 1892 11860495 effective JJ I-ADJP O
20 1893 1897 11860495 than IN B-PP O
21 1898 1901 11860495 its PRP$ B-NP O
22 1902 1911 11860495 synthetic JJ I-NP O
23 1912 1922 11860495 enantiomer NN I-NP O
24 1923 1925 11860495 in IN B-PP O
25 1926 1935 11860495 reversing VBG B-VP O
26 1936 1947 11860495 scopolamine NN B-NP D012601
27 1947 1948 11860495 - HYPH B-NP O
28 1948 1955 11860495 induced VBN I-NP O
29 1956 1963 11860495 amnesia NN I-NP D000647
30 1963 1964 11860495 . . O O

1 1965 1970 11860495 These DT B-NP O
2 1971 1978 11860495 results NNS I-NP O
3 1979 1987 11860495 identify VBP B-VP O
4 1988 1989 11860495 a DT B-NP O
5 1990 1995 11860495 novel JJ I-NP O
6 1996 2016 11860495 neuropharmacological JJ I-NP O
7 2017 2021 11860495 site NN I-NP O
8 2022 2025 11860495 for IN B-PP O
9 2026 2029 11860495 the DT B-NP O
10 2030 2040 11860495 modulation NN I-NP O
11 2041 2043 11860495 of IN B-PP O
12 2044 2050 11860495 memory NN B-NP O
13 2051 2060 11860495 processes NNS I-NP O
14 2061 2063 11860495 by IN B-PP O
15 2064 2075 11860495 neuroactive JJ B-NP O
16 2076 2084 11860495 steroids NNS I-NP D013256
17 2084 2085 11860495 . . O O

1 0 0 9321531 -DOCSTART- -X- -X- O

1 0 14 9321531 Posteroventral JJ B-NP O
2 15 21 9321531 medial JJ I-NP O
3 22 33 9321531 pallidotomy NN I-NP O
4 34 36 9321531 in IN B-PP O
5 37 45 9321531 advanced VBN B-NP O
6 46 57 9321531 Parkinson's NNS I-NP D010300
7 58 65 9321531 disease NN I-NP D010300
8 65 66 9321531 . . O O
9 67 77 9321531 BACKGROUND NN B-NP O
10 77 78 9321531 : : O O
11 79 93 9321531 Posteroventral JJ B-NP O
12 94 100 9321531 medial JJ I-NP O
13 101 112 9321531 pallidotomy NN I-NP O
14 113 122 9321531 sometimes RB B-ADVP O
15 123 131 9321531 produces VBZ B-VP O
16 132 140 9321531 striking JJ B-NP O
17 141 152 9321531 improvement NN I-NP O
18 153 155 9321531 in IN B-PP O
19 156 164 9321531 patients NNS B-NP O
20 165 169 9321531 with IN B-PP O
21 170 178 9321531 advanced VBN B-NP O
22 179 190 9321531 Parkinson's NNS I-NP D010300
23 191 198 9321531 disease NN I-NP D010300
24 198 199 9321531 , , O O
25 200 203 9321531 but CC O O
26 204 207 9321531 the DT B-NP O
27 208 215 9321531 studies NNS I-NP O
28 216 218 9321531 to TO B-PP O
29 219 223 9321531 date NN B-NP O
30 224 228 9321531 have VBP B-VP O
31 229 237 9321531 involved VBN I-VP O
32 238 243 9321531 small JJ B-NP O
33 244 251 9321531 numbers NNS I-NP O
34 252 254 9321531 of IN B-PP O
35 255 263 9321531 patients NNS B-NP O
36 264 267 9321531 and CC O O
37 268 273 9321531 short JJ B-NP O
38 273 274 9321531 - HYPH I-NP O
39 274 278 9321531 term NN I-NP O
40 279 285 9321531 follow VB B-VP O
41 285 286 9321531 - HYPH B-ADJP O
42 286 288 9321531 up RP B-PRT O
43 288 289 9321531 . . O O

1 290 297 9321531 METHODS NNS B-NP O
2 297 298 9321531 : : O O
3 299 304 9321531 Forty CD B-NP O
4 305 313 9321531 patients NNS I-NP O
5 314 318 9321531 with IN B-PP O
6 319 330 9321531 Parkinson's NNS B-NP D010300
7 331 338 9321531 disease NN I-NP D010300
8 339 348 9321531 underwent VBD B-VP O
9 349 355 9321531 serial JJ B-NP O
10 355 356 9321531 , , I-NP O
11 357 365 9321531 detailed JJ I-NP O
12 366 377 9321531 assessments NNS I-NP O
13 378 382 9321531 both CC B-PP O
14 383 388 9321531 after IN B-PP O
15 389 393 9321531 drug NN B-NP O
16 394 404 9321531 withdrawal NN I-NP O
17 405 406 9321531 ( ( O O
18 406 407 9321531 " `` O O
19 407 410 9321531 off RP B-PRT O
20 410 411 9321531 " '' B-NP O
21 412 418 9321531 period NN I-NP O
22 418 419 9321531 ) ) O O
23 420 423 9321531 and CC O O
24 424 429 9321531 while IN B-SBAR O
25 430 436 9321531 taking VBG B-VP O
26 437 442 9321531 their PRP$ B-NP O
27 443 450 9321531 optimal JJ I-NP O
28 451 458 9321531 medical JJ I-NP O
29 459 467 9321531 regimens NNS I-NP O
30 468 469 9321531 ( ( O O
31 469 470 9321531 " '' O O
32 470 472 9321531 on IN B-PP O
33 472 473 9321531 " `` O O
34 474 480 9321531 period NN B-NP O
35 480 481 9321531 ) ) O O
36 481 482 9321531 . . O O

1 483 486 9321531 All DT B-NP O
2 487 495 9321531 patients NNS I-NP O
3 496 500 9321531 were VBD B-VP O
4 501 509 9321531 examined VBN I-VP O
5 510 524 9321531 preoperatively RB B-ADVP O
6 525 528 9321531 and CC O O
7 529 531 9321531 39 CD B-NP O
8 532 536 9321531 were VBD B-VP O
9 537 545 9321531 examined VBN I-VP O
10 546 548 9321531 at IN B-PP O
11 549 552 9321531 six CD B-NP O
12 553 559 9321531 months NNS I-NP O
13 559 560 9321531 ; : O O
14 561 563 9321531 27 CD B-NP O
15 564 566 9321531 of IN B-PP O
16 567 570 9321531 the DT B-NP O
17 571 579 9321531 patients NNS I-NP O
18 580 584 9321531 were VBD B-VP O
19 585 589 9321531 also RB I-VP O
20 590 598 9321531 examined VBN I-VP O
21 599 601 9321531 at IN B-PP O
22 602 605 9321531 one CD B-NP O
23 606 610 9321531 year NN I-NP O
24 610 611 9321531 , , O O
25 612 615 9321531 and CC O O
26 616 618 9321531 11 CD B-NP O
27 619 621 9321531 at IN B-PP O
28 622 625 9321531 two CD B-NP O
29 626 631 9321531 years NNS I-NP O
30 631 632 9321531 . . O O

1 633 640 9321531 RESULTS NNS B-NP O
2 640 641 9321531 : : O O
3 642 645 9321531 The DT B-NP O
4 646 653 9321531 percent NN I-NP O
5 654 666 9321531 improvements NNS I-NP O
6 667 669 9321531 at IN B-PP O
7 670 673 9321531 six CD B-NP O
8 674 680 9321531 months NNS I-NP O
9 681 685 9321531 were VBD B-VP O
10 686 688 9321531 as IN B-SBAR O
11 689 696 9321531 follows VBZ B-VP O
12 696 697 9321531 : : O O
13 698 701 9321531 off RP B-PRT O
14 701 702 9321531 - HYPH B-NP O
15 702 708 9321531 period NN I-NP O
16 709 714 9321531 score NN I-NP O
17 715 718 9321531 for IN B-PP O
18 719 726 9321531 overall JJ B-NP O
19 727 732 9321531 motor NN I-NP O
20 733 741 9321531 function NN I-NP O
21 741 742 9321531 , , O O
22 743 745 9321531 28 CD B-NP O
23 746 753 9321531 percent NN I-NP O
24 754 755 9321531 ( ( O O
25 755 757 9321531 95 CD B-NP O
26 758 765 9321531 percent NN I-NP O
27 766 776 9321531 confidence NN I-NP O
28 777 785 9321531 interval NN I-NP O
29 785 786 9321531 , , O O
30 787 789 9321531 19 CD B-NP O
31 790 792 9321531 to TO I-NP O
32 793 795 9321531 38 CD I-NP O
33 796 803 9321531 percent NN I-NP O
34 803 804 9321531 ) ) O O
35 804 805 9321531 , , O O
36 806 810 9321531 with IN B-PP O
37 811 815 9321531 most JJS B-NP O
38 816 818 9321531 of IN B-PP O
39 819 822 9321531 the DT B-NP O
40 823 834 9321531 improvement NN I-NP O
41 835 837 9321531 in IN B-PP O
42 838 841 9321531 the DT B-NP O
43 842 855 9321531 contralateral JJ I-NP O
44 856 861 9321531 limbs NNS I-NP O
45 861 862 9321531 ; : O O
46 863 866 9321531 off RB B-ADVP O
47 866 867 9321531 - HYPH B-NP O
48 867 873 9321531 period NN I-NP O
49 874 879 9321531 score NN I-NP O
50 880 883 9321531 for IN B-PP O
51 884 894 9321531 activities NNS B-NP O
52 895 897 9321531 of IN B-PP O
53 898 903 9321531 daily JJ B-NP O
54 904 910 9321531 living NN I-NP O
55 910 911 9321531 , , O O
56 912 914 9321531 29 CD B-NP O
57 915 922 9321531 percent NN I-NP O
58 923 924 9321531 ( ( O O
59 924 926 9321531 95 CD B-NP O
60 927 934 9321531 percent NN I-NP O
61 935 945 9321531 confidence NN I-NP O
62 946 954 9321531 interval NN I-NP O
63 954 955 9321531 , , O O
64 956 958 9321531 19 CD B-NP O
65 959 961 9321531 to TO I-NP O
66 962 964 9321531 39 CD I-NP O
67 965 972 9321531 percent NN I-NP O
68 972 973 9321531 ) ) O O
69 973 974 9321531 ; : O O
70 975 977 9321531 on IN B-PP O
71 977 978 9321531 - HYPH B-NP O
72 978 984 9321531 period NN I-NP O
73 985 990 9321531 score NN I-NP O
74 991 994 9321531 for IN B-PP O
75 995 1008 9321531 contralateral JJ B-NP O
76 1009 1020 9321531 dyskinesias NNS I-NP D004409
77 1020 1021 9321531 , , O O
78 1022 1024 9321531 82 CD B-NP O
79 1025 1032 9321531 percent NN I-NP O
80 1033 1034 9321531 ( ( O O
81 1034 1036 9321531 95 CD B-NP O
82 1037 1044 9321531 percent NN I-NP O
83 1045 1055 9321531 confidence NN I-NP O
84 1056 1064 9321531 interval NN I-NP O
85 1064 1065 9321531 , , O O
86 1066 1068 9321531 72 CD B-NP O
87 1069 1071 9321531 to TO I-NP O
88 1072 1074 9321531 91 CD I-NP O
89 1075 1082 9321531 percent NN I-NP O
90 1082 1083 9321531 ) ) O O
91 1083 1084 9321531 ; : O O
92 1085 1088 9321531 and CC O O
93 1089 1091 9321531 on IN B-PP O
94 1091 1092 9321531 - HYPH B-NP O
95 1092 1098 9321531 period NN I-NP O
96 1099 1104 9321531 score NN I-NP O
97 1105 1108 9321531 for IN B-PP O
98 1109 1120 9321531 ipsilateral JJ B-NP O
99 1121 1132 9321531 dyskinesias NNS I-NP D004409
100 1132 1133 9321531 , , O O
101 1134 1136 9321531 44 CD B-NP O
102 1137 1144 9321531 percent NN I-NP O
103 1145 1146 9321531 ( ( O O
104 1146 1148 9321531 95 CD B-NP O
105 1149 1156 9321531 percent NN I-NP O
106 1157 1167 9321531 confidence NN I-NP O
107 1168 1176 9321531 interval NN I-NP O
108 1176 1177 9321531 , , O O
109 1178 1180 9321531 29 CD B-NP O
110 1181 1183 9321531 to TO I-NP O
111 1184 1186 9321531 59 CD I-NP O
112 1187 1194 9321531 percent NN I-NP O
113 1194 1195 9321531 ) ) O O
114 1195 1196 9321531 . . O O

1 1197 1200 9321531 The DT B-NP O
2 1201 1213 9321531 improvements NNS I-NP O
3 1214 1216 9321531 in IN B-PP O
4 1217 1228 9321531 dyskinesias NNS B-NP D004409
5 1229 1232 9321531 and CC O O
6 1233 1236 9321531 the DT B-NP O
7 1237 1242 9321531 total JJ I-NP O
8 1243 1249 9321531 scores NNS I-NP O
9 1250 1253 9321531 for IN B-PP O
10 1254 1257 9321531 off RB B-NP O
11 1257 1258 9321531 - HYPH I-NP O
12 1258 1264 9321531 period NN I-NP O
13 1265 1277 9321531 parkinsonism NN I-NP D010300
14 1277 1278 9321531 , , O O
15 1279 1292 9321531 contralateral JJ B-NP O
16 1293 1305 9321531 bradykinesia NN I-NP D018476
17 1305 1306 9321531 , , O O
18 1307 1310 9321531 and CC O O
19 1311 1319 9321531 rigidity NN B-NP D009127
20 1320 1324 9321531 were VBD B-VP O
21 1325 1334 9321531 sustained VBN I-VP O
22 1335 1337 9321531 in IN B-PP O
23 1338 1341 9321531 the DT B-NP O
24 1342 1344 9321531 11 CD I-NP O
25 1345 1353 9321531 patients NNS I-NP O
26 1354 1362 9321531 examined VBN B-VP O
27 1363 1365 9321531 at IN B-PP O
28 1366 1369 9321531 two CD B-NP O
29 1370 1375 9321531 years NNS I-NP O
30 1375 1376 9321531 . . O O

1 1377 1380 9321531 The DT B-NP O
2 1381 1392 9321531 improvement NN I-NP O
3 1393 1395 9321531 in IN B-PP O
4 1396 1407 9321531 ipsilateral JJ B-NP O
5 1408 1419 9321531 dyskinesias NNS I-NP D004409
6 1420 1423 9321531 was VBD B-VP O
7 1424 1428 9321531 lost VBN I-VP O
8 1429 1434 9321531 after IN B-PP O
9 1435 1438 9321531 one CD B-NP O
10 1439 1443 9321531 year NN I-NP O
11 1443 1444 9321531 , , O O
12 1445 1448 9321531 and CC O O
13 1449 1452 9321531 the DT B-NP O
14 1453 1465 9321531 improvements NNS I-NP O
15 1466 1468 9321531 in IN B-PP O
16 1469 1477 9321531 postural JJ B-NP O
17 1478 1487 9321531 stability NN I-NP O
18 1488 1491 9321531 and CC I-NP O
19 1492 1496 9321531 gait NN I-NP O
20 1497 1503 9321531 lasted VBD B-VP O
21 1504 1508 9321531 only RB B-NP O
22 1509 1514 9321531 three CD I-NP O
23 1515 1517 9321531 to TO I-NP O
24 1518 1521 9321531 six CD I-NP O
25 1522 1528 9321531 months NNS I-NP O
26 1528 1529 9321531 . . O O

1 1530 1543 9321531 Approximately RB B-NP O
2 1544 1548 9321531 half PDT I-NP O
3 1549 1552 9321531 the DT I-NP O
4 1553 1561 9321531 patients NNS I-NP O
5 1562 1565 9321531 who WP B-NP O
6 1566 1569 9321531 had VBD B-VP O
7 1570 1574 9321531 been VBN I-VP O
8 1575 1584 9321531 dependent JJ B-ADJP O
9 1585 1587 9321531 on IN B-PP O
10 1588 1598 9321531 assistance NN B-NP O
11 1599 1601 9321531 in IN B-PP O
12 1602 1612 9321531 activities NNS B-NP O
13 1613 1615 9321531 of IN B-PP O
14 1616 1621 9321531 daily JJ B-NP O
15 1622 1628 9321531 living NN I-NP O
16 1629 1631 9321531 in IN B-PP O
17 1632 1635 9321531 the DT B-NP O
18 1636 1639 9321531 off JJ I-NP O
19 1640 1646 9321531 period NN I-NP O
20 1647 1653 9321531 before IN B-SBAR O
21 1654 1661 9321531 surgery NN B-NP O
22 1662 1668 9321531 became VBD B-VP O
23 1669 1680 9321531 independent JJ B-ADJP O
24 1681 1686 9321531 after IN B-PP O
25 1687 1694 9321531 surgery NN B-NP O
26 1694 1695 9321531 . . O O

1 1696 1699 9321531 The DT B-NP O
2 1700 1713 9321531 complications NNS I-NP O
3 1714 1716 9321531 of IN B-PP O
4 1717 1724 9321531 surgery NN B-NP O
5 1725 1729 9321531 were VBD B-VP O
6 1730 1739 9321531 generally RB I-VP O
7 1740 1744 9321531 well RB I-VP O
8 1745 1754 9321531 tolerated VBN I-VP O
9 1754 1755 9321531 , , O O
10 1756 1759 9321531 and CC O O
11 1760 1765 9321531 there EX B-NP O
12 1766 1770 9321531 were VBD B-VP O
13 1771 1773 9321531 no DT B-NP O
14 1774 1785 9321531 significant JJ I-NP O
15 1786 1793 9321531 changes NNS I-NP O
16 1794 1796 9321531 in IN B-PP O
17 1797 1800 9321531 the DT B-NP O
18 1801 1804 9321531 use NN I-NP O
19 1805 1807 9321531 of IN B-PP O
20 1808 1818 9321531 medication NN B-NP O
21 1818 1819 9321531 . . O O

1 1820 1831 9321531 CONCLUSIONS NNS B-NP O
2 1831 1832 9321531 : : O O
3 1833 1835 9321531 In IN B-PP O
4 1836 1840 9321531 late JJ B-NP O
5 1840 1841 9321531 - HYPH I-NP O
6 1841 1846 9321531 stage NN I-NP O
7 1847 1858 9321531 Parkinson's NNS I-NP D010300
8 1859 1866 9321531 disease NN I-NP D010300
9 1866 1867 9321531 , , O O
10 1868 1879 9321531 pallidotomy NN B-NP O
11 1880 1893 9321531 significantly RB B-ADVP O
12 1894 1901 9321531 reduces VBZ B-VP O
13 1902 1910 9321531 levodopa NN B-NP D007980
14 1910 1911 9321531 - HYPH B-NP O
15 1911 1918 9321531 induced VBN I-NP O
16 1919 1930 9321531 dyskinesias NNS I-NP D004409
17 1931 1934 9321531 and CC O O
18 1935 1938 9321531 off RB B-ADVP O
19 1938 1939 9321531 - HYPH B-NP O
20 1939 1945 9321531 period NN I-NP O
21 1946 1956 9321531 disability NN I-NP O
22 1956 1957 9321531 . . O O

1 1958 1962 9321531 Much JJ B-NP O
2 1963 1965 9321531 of IN B-PP O
3 1966 1969 9321531 the DT B-NP O
4 1970 1977 9321531 benefit NN I-NP O
5 1978 1980 9321531 is VBZ B-VP O
6 1981 1990 9321531 sustained VBN I-VP O
7 1991 1993 9321531 at IN B-PP O
8 1994 1997 9321531 two CD B-NP O
9 1998 2003 9321531 years NNS I-NP O
10 2003 2004 9321531 , , O O
11 2005 2013 9321531 although IN B-SBAR O
12 2014 2018 9321531 some DT B-NP O
13 2019 2031 9321531 improvements NNS I-NP O
14 2031 2032 9321531 , , O O
15 2033 2037 9321531 such JJ B-PP O
16 2038 2040 9321531 as IN I-PP O
17 2041 2046 9321531 those DT B-NP O
18 2047 2049 9321531 on IN B-PP O
19 2050 2053 9321531 the DT B-NP O
20 2054 2065 9321531 ipsilateral JJ I-NP O
21 2066 2070 9321531 side NN I-NP O
22 2071 2074 9321531 and CC B-PP O
23 2075 2077 9321531 in IN B-PP O
24 2078 2083 9321531 axial JJ B-NP O
25 2084 2092 9321531 symptoms NNS I-NP O
26 2092 2093 9321531 , , O O
27 2094 2098 9321531 wane VBP B-VP O
28 2099 2105 9321531 within IN B-PP O
29 2106 2109 9321531 the DT B-NP O
30 2110 2115 9321531 first JJ I-NP O
31 2116 2120 9321531 year NN I-NP O
32 2120 2121 9321531 . . O O

1 2122 2125 9321531 The DT B-NP O
2 2126 2128 9321531 on IN B-PP O
3 2128 2129 9321531 - HYPH B-NP O
4 2129 2135 9321531 period NN I-NP O
5 2136 2144 9321531 symptoms NNS I-NP O
6 2145 2149 9321531 that WDT B-NP O
7 2150 2153 9321531 are VBP B-VP O
8 2154 2163 9321531 resistant JJ B-ADJP O
9 2164 2166 9321531 to TO B-PP O
10 2167 2179 9321531 dopaminergic JJ B-NP O
11 2180 2187 9321531 therapy NN I-NP O
12 2188 2190 9321531 do VBP B-VP O
13 2191 2194 9321531 not RB I-VP O
14 2195 2202 9321531 respond VB I-VP O
15 2203 2205 9321531 to TO B-PP O
16 2206 2217 9321531 pallidotomy NN B-NP O
17 2217 2218 9321531 . . O O

1 0 0 17019386 -DOCSTART- -X- -X- O

1 0 7 17019386 Passage NN B-NP O
2 8 10 17019386 of IN B-PP O
3 11 19 17019386 mannitol NN B-NP D008353
4 20 24 17019386 into IN B-PP O
5 25 28 17019386 the DT B-NP O
6 29 34 17019386 brain NN I-NP O
7 35 41 17019386 around IN B-PP O
8 42 49 17019386 gliomas NNS B-NP D005910
9 49 50 17019386 : : O O
10 51 52 17019386 a DT B-NP O
11 53 62 17019386 potential JJ I-NP O
12 63 68 17019386 cause NN I-NP O
13 69 71 17019386 of IN B-PP O
14 72 79 17019386 rebound NN B-NP O
15 80 90 17019386 phenomenon NN I-NP O
16 90 91 17019386 . . O O

1 92 93 17019386 A DT B-NP O
2 94 99 17019386 study NN I-NP O
3 100 102 17019386 on IN B-PP O
4 103 105 17019386 21 CD B-NP O
5 106 114 17019386 patients NNS I-NP O
6 114 115 17019386 . . O O
7 116 119 17019386 AIM NN B-NP O
8 119 120 17019386 : : O O
9 121 131 17019386 Widespread JJ B-NP O
10 132 135 17019386 use NN I-NP O
11 136 138 17019386 of IN B-PP O
12 139 147 17019386 mannitol NN B-NP D008353
13 148 150 17019386 to TO B-VP O
14 151 157 17019386 reduce VB I-VP O
15 158 163 17019386 brain NN B-NP D001929
16 164 169 17019386 edema NN I-NP D001929
17 170 173 17019386 and CC O O
18 174 179 17019386 lower JJR B-NP O
19 180 188 17019386 elevated JJ I-NP D019586
20 189 192 17019386 ICP NN I-NP D019586
21 193 195 17019386 in IN B-PP O
22 196 201 17019386 brain NN B-NP D001932
23 202 207 17019386 tumor NN I-NP D001932
24 208 216 17019386 patients NNS I-NP O
25 217 226 17019386 continues VBZ B-VP O
26 227 229 17019386 to TO I-VP O
27 230 232 17019386 be VB I-VP O
28 233 242 17019386 afflicted VBN I-VP O
29 243 245 17019386 by IN B-PP O
30 246 249 17019386 the DT B-NP O
31 250 252 17019386 so RB I-NP O
32 252 253 17019386 - HYPH I-NP O
33 253 259 17019386 called VBN I-NP O
34 260 267 17019386 rebound NN I-NP O
35 268 278 17019386 phenomenon NN I-NP O
36 278 279 17019386 . . O O

1 280 287 17019386 Leakage NN B-NP O
2 288 290 17019386 of IN B-PP O
3 291 299 17019386 mannitol NN B-NP D008353
4 300 304 17019386 into IN B-PP O
5 305 308 17019386 the DT B-NP O
6 309 314 17019386 brain NN I-NP O
7 315 325 17019386 parenchyma NN I-NP O
8 326 333 17019386 through IN B-PP O
9 334 336 17019386 an DT B-NP O
10 337 344 17019386 altered JJ I-NP O
11 345 348 17019386 BBB NN I-NP O
12 349 352 17019386 and CC O O
13 353 362 17019386 secondary JJ B-NP O
14 363 371 17019386 reversal NN I-NP O
15 372 374 17019386 of IN B-PP O
16 375 382 17019386 osmotic JJ B-NP O
17 383 391 17019386 gradient NN I-NP O
18 392 394 17019386 is VBZ B-VP O
19 395 405 17019386 considered VBN I-VP O
20 406 409 17019386 the DT B-NP O
21 410 415 17019386 major JJ I-NP O
22 416 421 17019386 cause NN I-NP O
23 422 424 17019386 of IN B-PP O
24 425 432 17019386 rebound NN B-NP O
25 433 434 17019386 . . O O
26 435 439 17019386 This DT B-NP O
27 440 443 17019386 has VBZ B-VP O
28 444 448 17019386 only RB I-VP O
29 449 453 17019386 been VBN I-VP O
30 454 466 17019386 demonstrated VBN I-VP O
31 467 481 17019386 experimentally RB B-ADVP O
32 482 484 17019386 in IN B-PP O
33 485 492 17019386 animals NNS B-NP O
34 492 493 17019386 . . O O

1 494 496 17019386 As IN B-PP O
2 497 498 17019386 a DT B-NP O
3 499 511 17019386 contribution NN I-NP O
4 512 514 17019386 to TO B-PP O
5 515 519 17019386 this DT B-NP O
6 520 525 17019386 issue NN I-NP O
7 526 528 17019386 we PRP B-NP O
8 529 536 17019386 decided VBD B-VP O
9 537 539 17019386 to TO I-VP O
10 540 548 17019386 research VB I-VP O
11 549 552 17019386 the DT B-NP O
12 553 561 17019386 possible JJ I-NP O
13 562 569 17019386 passage NN I-NP O
14 570 572 17019386 of IN B-PP O
15 573 581 17019386 mannitol NN B-NP D008353
16 582 586 17019386 into IN B-PP O
17 587 590 17019386 the DT B-NP O
18 591 596 17019386 brain NN I-NP O
19 597 602 17019386 after IN B-PP O
20 603 617 17019386 administration NN B-NP O
21 618 620 17019386 to TO B-PP O
22 621 623 17019386 21 CD B-NP O
23 624 629 17019386 brain NN I-NP D001932
24 630 635 17019386 tumor NN B-NP D001932
25 636 644 17019386 patients NNS I-NP O
26 644 645 17019386 . . O O

1 646 653 17019386 METHODS NNS B-NP O
2 653 654 17019386 : : O O
3 655 663 17019386 Mannitol NN B-NP D008353
4 664 665 17019386 ( ( O O
5 665 668 17019386 18% CD B-NP O
6 669 677 17019386 solution NN I-NP O
7 677 678 17019386 ; : O O
8 679 680 17019386 1 CD B-NP O
9 681 682 17019386 g NN I-NP O
10 682 683 17019386 / SYM B-NP O
11 683 685 17019386 kg NN I-NP O
12 685 686 17019386 ) ) O O
13 687 690 17019386 was VBD B-VP O
14 691 703 17019386 administered VBN I-VP O
15 704 706 17019386 as IN B-PP O
16 707 708 17019386 a DT B-NP O
17 709 714 17019386 bolus NN I-NP O
18 715 717 17019386 to TO B-PP O
19 718 726 17019386 patients NNS B-NP O
20 727 728 17019386 ( ( O O
21 728 731 17019386 ten CD B-NP O
22 732 735 17019386 had VBD B-VP O
23 736 745 17019386 malignant JJ B-NP D005910
24 746 752 17019386 glioma NN I-NP D005910
25 752 753 17019386 , , O O
26 754 759 17019386 seven CD B-NP O
27 760 765 17019386 brain NN I-NP O
28 766 776 17019386 metastases NNS I-NP D009362
29 777 780 17019386 and CC O O
30 781 785 17019386 four CD B-NP O
31 786 796 17019386 meningioma NN I-NP D008579
32 796 797 17019386 ) ) O O
33 798 803 17019386 about IN B-NP O
34 804 806 17019386 30 CD I-NP O
35 807 814 17019386 minutes NNS I-NP O
36 815 821 17019386 before IN B-PP O
37 822 832 17019386 craniotomy NN B-NP O
38 832 833 17019386 . . O O

1 834 840 17019386 During IN B-PP O
2 841 850 17019386 resection NN B-NP O
3 850 851 17019386 , , O O
4 852 853 17019386 a DT B-NP O
5 854 860 17019386 sample NN I-NP O
6 861 863 17019386 of IN B-PP O
7 864 867 17019386 the DT B-NP O
8 868 879 17019386 surrounding VBG I-NP O
9 880 889 17019386 edematous JJ I-NP D004487
10 890 895 17019386 white JJ I-NP O
11 896 902 17019386 matter NN I-NP O
12 903 906 17019386 was VBD B-VP O
13 907 912 17019386 taken VBN I-VP O
14 913 915 17019386 at IN B-PP O
15 916 919 17019386 the DT B-NP O
16 920 924 17019386 same JJ I-NP O
17 925 929 17019386 time NN I-NP O
18 930 932 17019386 as IN B-PP O
19 933 934 17019386 a DT B-NP O
20 935 937 17019386 10 CD I-NP O
21 938 940 17019386 ml NN I-NP O
22 941 947 17019386 venous JJ I-NP O
23 948 953 17019386 blood NN I-NP O
24 954 960 17019386 sample NN I-NP O
25 960 961 17019386 . . O O

1 962 970 17019386 Mannitol NN B-NP D008353
2 971 985 17019386 concentrations NNS I-NP O
3 986 990 17019386 were VBD B-VP O
4 991 999 17019386 measured VBN I-VP O
5 1000 1002 17019386 in IN B-PP O
6 1003 1009 17019386 plasma NN B-NP O
7 1010 1013 17019386 and CC O O
8 1014 1019 17019386 white JJ B-NP O
9 1020 1026 17019386 matter NN I-NP O
10 1027 1029 17019386 by IN B-PP O
11 1030 1031 17019386 a DT B-NP O
12 1032 1040 17019386 modified VBN I-NP O
13 1041 1048 17019386 version NN I-NP O
14 1049 1051 17019386 of IN B-PP O
15 1052 1055 17019386 the DT B-NP O
16 1056 1062 17019386 enzyme NN I-NP O
17 1063 1068 17019386 assay NN I-NP O
18 1069 1071 17019386 of IN B-PP O
19 1072 1081 17019386 Blonquist NNP B-NP O
20 1082 1084 17019386 et FW I-NP O
21 1085 1088 17019386 al. FW I-NP O

1 1089 1096 17019386 RESULTS NNS B-NP O
2 1096 1097 17019386 : : O O
3 1098 1100 17019386 In IN B-PP O
4 1101 1105 17019386 most JJS B-NP O
5 1106 1112 17019386 glioma NN I-NP D005910
6 1113 1121 17019386 patients NNS I-NP O
7 1121 1122 17019386 , , O O
8 1123 1131 17019386 mannitol NN B-NP D008353
9 1132 1146 17019386 concentrations NNS I-NP O
10 1147 1149 17019386 in IN B-PP O
11 1150 1155 17019386 white JJ B-NP O
12 1156 1162 17019386 matter NN I-NP O
13 1163 1167 17019386 were VBD B-VP O
14 1168 1169 17019386 2 CD B-NP O
15 1170 1172 17019386 to TO B-PP O
16 1173 1174 17019386 6 CD B-ADJP O
17 1175 1180 17019386 times NNS I-ADJP O
18 1181 1187 17019386 higher JJR I-ADJP O
19 1188 1192 17019386 than IN B-PP O
20 1193 1195 17019386 in IN B-PP O
21 1196 1202 17019386 plasma NN B-NP O
22 1203 1204 17019386 ( ( O O
23 1204 1208 17019386 mean NN B-NP O
24 1209 1212 17019386 3.5 CD B-NP O
25 1213 1218 17019386 times NNS I-NP O
26 1218 1219 17019386 ) ) O O
27 1219 1220 17019386 . . O O

1 1221 1223 17019386 In IN B-PP O
2 1224 1234 17019386 meningioma NN B-NP D008579
3 1235 1238 17019386 and CC O O
4 1239 1249 17019386 metastases NNS B-NP D009362
5 1250 1258 17019386 patients NNS I-NP O
6 1259 1265 17019386 plasma NN I-NP O
7 1266 1280 17019386 concentrations NNS I-NP O
8 1281 1283 17019386 of IN B-PP O
9 1284 1292 17019386 mannitol NN B-NP D008353
10 1293 1297 17019386 were VBD B-VP O
11 1298 1304 17019386 higher JJR B-ADJP O
12 1305 1309 17019386 than IN B-PP O
13 1310 1315 17019386 white JJ B-NP O
14 1316 1322 17019386 matter NN I-NP O
15 1323 1337 17019386 concentrations NNS I-NP O
16 1338 1344 17019386 except IN B-PP O
17 1345 1347 17019386 in IN B-PP O
18 1348 1353 17019386 three CD B-NP O
19 1354 1359 17019386 cases NNS I-NP O
20 1360 1364 17019386 with IN B-PP O
21 1365 1377 17019386 infiltration NN B-NP O
22 1378 1380 17019386 by IN B-PP O
23 1381 1391 17019386 neoplastic JJ B-NP O
24 1392 1397 17019386 cells NNS I-NP O
25 1397 1398 17019386 . . O O

1 1399 1410 17019386 CONCLUSIONS NNS B-NP O
2 1410 1411 17019386 : : O O
3 1412 1415 17019386 The DT B-NP O
4 1416 1423 17019386 results NNS I-NP O
5 1424 1426 17019386 of IN B-PP O
6 1427 1430 17019386 our PRP$ B-NP O
7 1431 1436 17019386 study NN I-NP O
8 1437 1441 17019386 show VBP B-VP O
9 1442 1446 17019386 that IN B-SBAR O
10 1447 1451 17019386 even RB B-PP O
11 1452 1457 17019386 after IN I-PP O
12 1458 1459 17019386 a DT B-NP O
13 1460 1466 17019386 single JJ I-NP O
14 1467 1472 17019386 bolus NN I-NP O
15 1472 1473 17019386 , , O O
16 1474 1482 17019386 mannitol NN B-NP D008353
17 1483 1486 17019386 may MD B-VP O
18 1487 1491 17019386 leak VB I-VP O
19 1492 1499 17019386 through IN B-PP O
20 1500 1503 17019386 the DT B-NP O
21 1504 1511 17019386 altered JJ I-NP O
22 1512 1515 17019386 BBB NN I-NP O
23 1516 1520 17019386 near IN B-PP O
24 1521 1528 17019386 gliomas NNS B-NP D005910
25 1528 1529 17019386 , , O O
26 1530 1539 17019386 reversing VBG B-VP O
27 1540 1543 17019386 the DT B-NP O
28 1544 1551 17019386 initial JJ I-NP O
29 1552 1558 17019386 plasma NN I-NP O
30 1558 1559 17019386 - HYPH B-ADJP O
31 1559 1561 17019386 to TO B-PP O
32 1561 1562 17019386 - HYPH B-NP O
33 1562 1567 17019386 blood NN I-NP O
34 1568 1575 17019386 osmotic JJ I-NP O
35 1576 1584 17019386 gradient NN I-NP O
36 1584 1585 17019386 , , O O
37 1586 1597 17019386 aggravating VBG B-VP O
38 1598 1609 17019386 peritumoral JJ B-NP O
39 1610 1615 17019386 edema NN I-NP D004487
40 1616 1619 17019386 and CC O O
41 1620 1629 17019386 promoting VBG B-VP O
42 1630 1637 17019386 rebound NN B-NP O
43 1638 1640 17019386 of IN B-PP O
44 1641 1644 17019386 ICP NN B-NP O
45 1644 1645 17019386 . . O O

1 0 0 3311455 -DOCSTART- -X- -X- O

1 0 7 3311455 Cardiac JJ B-NP O
2 8 23 3311455 transplantation NN I-NP O
3 23 24 3311455 : : O O
4 25 33 3311455 improved VBN B-NP O
5 34 41 3311455 quality NN I-NP O
6 42 44 3311455 of IN B-PP O
7 45 53 3311455 survival NN B-NP O
8 54 58 3311455 with IN B-PP O
9 59 60 3311455 a DT B-NP O
10 61 69 3311455 modified VBN I-NP O
11 70 87 3311455 immunosuppressive JJ I-NP O
12 88 96 3311455 protocol NN I-NP O
13 96 97 3311455 . . O O
14 98 101 3311455 The DT B-NP O
15 102 109 3311455 effects NNS I-NP O
16 110 112 3311455 on IN B-PP O
17 113 118 3311455 renal JJ B-NP O
18 119 127 3311455 function NN I-NP O
19 128 130 3311455 on IN B-PP O
20 131 134 3311455 two CD B-NP O
21 135 144 3311455 different JJ I-NP O
22 145 162 3311455 immunosuppressive JJ I-NP O
23 163 172 3311455 protocols NNS I-NP O
24 173 177 3311455 were VBD B-VP O
25 178 187 3311455 evaluated VBN I-VP O
26 188 203 3311455 retrospectively RB B-ADVP O
27 204 206 3311455 in IN B-PP O
28 207 210 3311455 two CD B-NP O
29 211 221 3311455 subsequent JJ I-NP O
30 222 228 3311455 groups NNS I-NP O
31 229 231 3311455 of IN B-PP O
32 232 237 3311455 heart NN B-NP O
33 238 248 3311455 transplant NN I-NP O
34 249 259 3311455 recipients NNS I-NP O
35 259 260 3311455 . . O O

1 261 263 3311455 In IN B-PP O
2 264 269 3311455 group NN B-NP O
3 270 271 3311455 I NN I-NP O
4 271 272 3311455 , , O O
5 273 285 3311455 cyclosporine NN B-NP D016572
6 286 289 3311455 was VBD B-VP O
7 290 295 3311455 given VBN I-VP O
8 296 302 3311455 before IN B-PP O
9 303 306 3311455 the DT B-NP O
10 307 316 3311455 procedure NN I-NP O
11 317 319 3311455 at IN B-PP O
12 320 321 3311455 a DT B-NP O
13 322 329 3311455 loading NN I-NP O
14 330 334 3311455 dose NN I-NP O
15 335 337 3311455 of IN B-PP O
16 338 342 3311455 17.5 CD B-NP O
17 343 345 3311455 mg NN I-NP O
18 345 346 3311455 / SYM B-NP O
19 346 348 3311455 kg NN I-NP O
20 349 352 3311455 and CC O O
21 353 357 3311455 then RB B-ADVP O
22 358 367 3311455 continued VBN B-VP O
23 368 373 3311455 after IN B-PP O
24 374 377 3311455 the DT B-NP O
25 378 387 3311455 procedure NN I-NP O
26 388 390 3311455 to TO B-VP O
27 391 395 3311455 keep VB I-VP O
28 396 397 3311455 a DT B-NP O
29 398 403 3311455 whole JJ I-NP O
30 404 409 3311455 blood NN I-NP O
31 410 415 3311455 level NN I-NP O
32 416 421 3311455 about RB B-NP O
33 422 426 3311455 1000 CD I-NP O
34 427 429 3311455 ng NN I-NP O
35 429 430 3311455 / SYM B-NP O
36 430 432 3311455 ml NN I-NP O
37 432 433 3311455 . . O O

1 434 436 3311455 In IN B-PP O
2 437 442 3311455 group NN B-NP O
3 443 445 3311455 II CD I-NP O
4 445 446 3311455 , , O O
5 447 459 3311455 cyclosporine NN B-NP D016572
6 460 463 3311455 was VBD B-VP O
7 464 471 3311455 started VBN I-VP O
8 472 476 3311455 only RB B-ADVP O
9 477 482 3311455 after IN B-PP O
10 483 486 3311455 the DT B-NP O
11 487 496 3311455 procedure NN I-NP O
12 497 499 3311455 at IN B-PP O
13 500 501 3311455 a DT B-NP O
14 502 507 3311455 lower JJR I-NP O
15 508 514 3311455 dosage NN I-NP O
16 515 518 3311455 and CC O O
17 519 522 3311455 was VBD B-VP O
18 523 535 3311455 complemented VBN I-VP O
19 536 538 3311455 by IN B-PP O
20 539 551 3311455 azathioprine NN B-NP D001379
21 551 552 3311455 , , O O
22 553 558 3311455 which WDT B-NP O
23 559 562 3311455 was VBD B-VP O
24 563 567 3311455 used VBN I-VP O
25 568 571 3311455 for IN B-PP O
26 572 575 3311455 the DT B-NP O
27 576 581 3311455 first JJ I-NP O
28 582 595 3311455 postoperative JJ I-NP O
29 596 600 3311455 week NN I-NP O
30 600 601 3311455 . . O O

1 602 607 3311455 Group NN B-NP O
2 608 610 3311455 II CD I-NP O
3 611 617 3311455 showed VBD B-VP O
4 618 619 3311455 a DT B-NP O
5 620 626 3311455 better RBR I-NP O
6 627 640 3311455 perioperative JJ I-NP O
7 641 646 3311455 renal JJ I-NP O
8 647 655 3311455 function NN I-NP O
9 656 658 3311455 as IN B-SBAR O
10 659 669 3311455 determined VBN B-VP O
11 670 672 3311455 by IN B-PP O
12 673 678 3311455 serum NN B-NP O
13 679 684 3311455 blood NN I-NP O
14 685 689 3311455 urea NN I-NP D001806
15 690 698 3311455 nitrogen NN I-NP D001806
16 699 702 3311455 and CC I-NP O
17 703 708 3311455 serum NN I-NP O
18 709 719 3311455 creatinine NN I-NP D003404
19 720 726 3311455 levels NNS I-NP O
20 726 727 3311455 . . O O

1 728 733 3311455 Group NN B-NP O
2 734 736 3311455 II CD I-NP O
3 737 741 3311455 also RB B-ADVP O
4 742 748 3311455 showed VBD B-VP O
5 749 750 3311455 a DT B-NP O
6 751 762 3311455 significant JJ I-NP O
7 763 771 3311455 decrease NN I-NP O
8 772 774 3311455 of IN B-PP O
9 775 782 3311455 chronic JJ B-NP O
10 783 797 3311455 nephrotoxicity NN I-NP D007674
11 798 807 3311455 secondary JJ B-ADJP O
12 808 810 3311455 to TO B-PP O
13 811 815 3311455 long JJ B-NP O
14 815 816 3311455 - HYPH I-NP O
15 816 820 3311455 term NN I-NP O
16 821 828 3311455 therapy NN I-NP O
17 829 833 3311455 with IN B-PP O
18 834 846 3311455 cyclosporine NN B-NP D016572
19 846 847 3311455 . . O O

1 848 855 3311455 Despite IN B-PP O
2 856 860 3311455 this DT B-NP O
3 861 872 3311455 improvement NN I-NP O
4 873 875 3311455 in IN B-PP O
5 876 880 3311455 late JJ B-NP O
6 881 886 3311455 renal JJ I-NP O
7 887 895 3311455 function NN I-NP O
8 895 896 3311455 , , O O
9 897 902 3311455 group NN B-NP O
10 903 905 3311455 II CD I-NP O
11 906 911 3311455 still RB B-ADVP O
12 912 917 3311455 shows VBZ B-VP O
13 918 919 3311455 a DT B-NP O
14 920 924 3311455 slow JJ I-NP O
15 925 929 3311455 rise NN I-NP O
16 930 932 3311455 in IN B-PP O
17 933 938 3311455 serum NN B-NP O
18 939 949 3311455 creatinine NN I-NP D003404
19 949 950 3311455 . . O O

1 951 953 3311455 We PRP B-NP O
2 954 959 3311455 think VBP B-VP O
3 960 964 3311455 that IN B-SBAR O
4 965 969 3311455 even RB B-NP O
5 970 975 3311455 these DT I-NP O
6 976 981 3311455 lower JJR I-NP O
7 982 989 3311455 dosages NNS I-NP O
8 990 992 3311455 of IN B-PP O
9 993 1005 3311455 cyclosporine NN B-NP D016572
10 1006 1009 3311455 can MD B-VP O
11 1010 1015 3311455 cause VB I-VP O
12 1016 1023 3311455 chronic JJ B-NP O
13 1024 1038 3311455 nephrotoxicity NN I-NP D007674
14 1039 1042 3311455 and CC O O
15 1043 1047 3311455 that IN B-SBAR O
16 1048 1055 3311455 further JJ B-NP O
17 1056 1068 3311455 modification NN I-NP O
18 1069 1071 3311455 of IN B-PP O
19 1072 1075 3311455 the DT B-NP O
20 1076 1093 3311455 immunosuppressive JJ I-NP O
21 1094 1101 3311455 regimen NN I-NP O
22 1102 1104 3311455 is VBZ B-VP O
23 1105 1113 3311455 required VBN I-VP O
24 1114 1116 3311455 to TO B-VP O
25 1117 1127 3311455 completely RB I-VP O
26 1128 1135 3311455 abolish VB I-VP O
27 1136 1140 3311455 this DT B-NP O
28 1141 1146 3311455 toxic JJ I-NP O
29 1147 1151 3311455 side NN I-NP O
30 1152 1158 3311455 effect NN I-NP O
31 1158 1159 3311455 . . O O

1 0 0 8665051 -DOCSTART- -X- -X- O

1 0 7 8665051 Effects NNS B-NP O
2 8 10 8665051 of IN B-PP O
3 11 16 8665051 acute JJ B-NP O
4 17 24 8665051 steroid NN I-NP D013256
5 25 39 8665051 administration NN I-NP O
6 40 42 8665051 on IN B-PP O
7 43 54 8665051 ventilatory JJ B-NP O
8 55 58 8665051 and CC I-NP O
9 59 69 8665051 peripheral JJ I-NP O
10 70 77 8665051 muscles NNS I-NP O
11 78 80 8665051 in IN B-PP O
12 81 85 8665051 rats NNS B-NP O
13 85 86 8665051 . . O O
14 87 97 8665051 Occasional JJ B-NP O
15 98 102 8665051 case NN I-NP O
16 103 110 8665051 reports NNS I-NP O
17 111 115 8665051 have VBP B-VP O
18 116 121 8665051 shown VBN I-VP O
19 122 126 8665051 that IN B-SBAR O
20 127 132 8665051 acute JJ B-NP O
21 133 141 8665051 myopathy NN I-NP D009135
22 142 145 8665051 may MD B-VP O
23 146 151 8665051 occur VB I-VP O
24 152 154 8665051 in IN B-PP O
25 155 163 8665051 patients NNS B-NP O
26 164 171 8665051 treated VBN B-VP O
27 172 176 8665051 with IN B-PP O
28 177 184 8665051 massive JJ B-NP O
29 185 190 8665051 doses NNS I-NP O
30 191 193 8665051 of IN B-PP O
31 194 209 8665051 corticosteroids NNS B-NP D000305
32 209 210 8665051 . . O O

1 211 214 8665051 The DT B-NP O
2 215 224 8665051 mechanism NN I-NP O
3 225 227 8665051 of IN B-PP O
4 228 232 8665051 this DT B-NP O
5 233 241 8665051 myopathy NN I-NP D009135
6 242 244 8665051 is VBZ B-VP O
7 245 251 8665051 poorly RB I-VP O
8 252 262 8665051 understood VBN I-VP O
9 262 263 8665051 . . O O

1 264 273 8665051 Therefore RB B-ADVP O
2 273 274 8665051 , , O O
3 275 277 8665051 60 CD B-NP O
4 278 282 8665051 male JJ I-NP O
5 283 287 8665051 rats NNS I-NP O
6 288 292 8665051 were VBD B-VP O
7 293 301 8665051 randomly RB I-VP O
8 302 310 8665051 assigned VBN I-VP O
9 311 313 8665051 to TO I-VP O
10 314 321 8665051 receive VB I-VP O
11 322 327 8665051 daily JJ B-NP O
12 328 337 8665051 injection NN I-NP O
13 338 340 8665051 of IN B-PP O
14 341 347 8665051 saline NN B-NP O
15 348 349 8665051 ( ( O O
16 349 350 8665051 C NN B-NP O
17 350 351 8665051 ) ) O O
18 351 352 8665051 , , O O
19 353 371 8665051 methylprednisolone NN B-NP D008775
20 372 373 8665051 ( ( O O
21 373 374 8665051 M NN B-NP D008775
22 374 375 8665051 ) ) O O
23 375 376 8665051 , , O O
24 377 379 8665051 or CC O O
25 380 393 8665051 triamcinolone NN B-NP D014221
26 394 395 8665051 ( ( O O
27 395 396 8665051 T NN B-NP D014221
28 396 397 8665051 ) ) O O
29 398 400 8665051 80 CD B-NP O
30 401 403 8665051 mg NN I-NP O
31 403 404 8665051 / SYM B-NP O
32 404 406 8665051 kg NN I-NP O
33 406 407 8665051 / SYM B-NP O
34 407 408 8665051 d NN I-NP O
35 409 412 8665051 for IN B-PP O
36 413 414 8665051 5 CD B-NP O
37 415 416 8665051 d NN I-NP O
38 416 417 8665051 . . O O

1 418 429 8665051 Nutritional JJ B-NP O
2 430 436 8665051 intake NN I-NP O
3 436 437 8665051 , , O O
4 438 446 8665051 measured VBN B-VP O
5 447 452 8665051 daily RB B-ADVP O
6 453 455 8665051 in IN B-PP O
7 456 458 8665051 15 CD B-NP O
8 459 466 8665051 animals NNS I-NP O
9 466 467 8665051 , , O O
10 468 474 8665051 showed VBD B-VP O
11 475 476 8665051 a DT B-NP O
12 477 488 8665051 significant JJ I-NP O
13 489 498 8665051 reduction NN I-NP D000855
14 499 501 8665051 of IN B-PP D000855
15 502 506 8665051 food NN B-NP D000855
16 507 513 8665051 intake NN I-NP D000855
17 514 516 8665051 in IN B-PP O
18 517 520 8665051 the DT B-NP O
19 521 528 8665051 steroid NN I-NP D013256
20 528 529 8665051 - HYPH B-NP O
21 529 536 8665051 treated VBN I-NP O
22 537 543 8665051 groups NNS I-NP O
23 544 545 8665051 ( ( O O
24 545 546 8665051 - SYM B-NP O
25 546 548 8665051 50 CD I-NP O
26 549 552 8665051 and CC O O
27 553 554 8665051 - SYM B-NP O
28 554 557 8665051 79% NN I-NP O
29 558 560 8665051 in IN B-PP O
30 561 562 8665051 M NN B-NP D008775
31 563 566 8665051 and CC O O
32 567 568 8665051 T NN B-NP D014221
33 568 569 8665051 , , O O
34 570 582 8665051 respectively RB B-ADVP O
35 582 583 8665051 ) ) O O
36 583 584 8665051 . . O O

1 585 589 8665051 This DT B-NP O
2 590 593 8665051 was VBD B-VP O
3 594 604 8665051 associated VBN I-VP O
4 605 609 8665051 with IN B-PP O
5 610 611 8665051 a DT B-NP O
6 612 619 8665051 similar JJ I-NP O
7 620 624 8665051 loss NN I-NP D015431
8 625 627 8665051 in IN B-PP D015431
9 628 632 8665051 body NN B-NP D015431
10 633 639 8665051 weight NN I-NP D015431
11 639 640 8665051 . . O O

1 641 643 8665051 In IN B-PP O
2 644 647 8665051 the DT B-NP O
3 648 650 8665051 45 CD I-NP O
4 651 660 8665051 remaining VBG I-NP O
5 661 668 8665051 animals NNS I-NP O
6 668 669 8665051 , , O O
7 670 679 8665051 diaphragm NN B-NP O
8 680 693 8665051 contractility NN I-NP O
9 694 697 8665051 and CC O O
10 698 713 8665051 histopathologic JJ B-NP O
11 714 722 8665051 features NNS I-NP O
12 723 725 8665051 of IN B-PP O
13 726 733 8665051 several JJ B-NP O
14 734 741 8665051 muscles NNS I-NP O
15 742 746 8665051 were VBD B-VP O
16 747 754 8665051 studied VBN I-VP O
17 754 755 8665051 . . O O

1 756 763 8665051 Weights NNS B-NP O
2 764 766 8665051 of IN B-PP O
3 767 778 8665051 respiratory JJ B-NP O
4 779 782 8665051 and CC I-NP O
5 783 793 8665051 peripheral JJ I-NP O
6 794 801 8665051 muscles NNS I-NP O
7 802 806 8665051 were VBD B-VP O
8 807 816 8665051 similarly RB I-VP O
9 817 826 8665051 decreased VBN I-VP O
10 827 832 8665051 after IN B-PP O
11 833 840 8665051 steroid NN B-NP D013256
12 841 850 8665051 treatment NN I-NP O
13 850 851 8665051 . . O O

1 852 859 8665051 Maximal JJ B-NP O
2 860 868 8665051 twitches NNS I-NP O
3 869 871 8665051 of IN B-PP O
4 872 875 8665051 the DT B-NP O
5 876 885 8665051 diaphragm NN I-NP O
6 886 890 8665051 were VBD B-VP O
7 891 896 8665051 lower JJR B-ADJP O
8 897 899 8665051 in IN B-PP O
9 900 903 8665051 the DT B-NP O
10 904 905 8665051 C NN I-NP O
11 906 911 8665051 group NN I-NP O
12 912 913 8665051 ( ( O O
13 913 916 8665051 653 CD B-NP O
14 917 918 8665051 + SYM O O
15 918 919 8665051 / SYM O O
16 919 920 8665051 - SYM O O
17 921 924 8665051 174 CD B-NP O
18 925 926 8665051 g NN I-NP O
19 926 927 8665051 / SYM B-NP O
20 927 932 8665051 cm(2) NN I-NP O
21 932 933 8665051 ) ) O O
22 934 938 8665051 than IN B-PP O
23 939 941 8665051 in IN B-PP O
24 942 945 8665051 the DT B-NP O
25 946 947 8665051 M NN I-NP D008775
26 948 953 8665051 group NN I-NP O
27 954 955 8665051 ( ( O O
28 955 958 8665051 837 CD B-NP O
29 959 960 8665051 + SYM O O
30 960 961 8665051 / SYM O O
31 961 962 8665051 - SYM O O
32 963 966 8665051 171 CD B-NP O
33 967 968 8665051 g NN I-NP O
34 968 969 8665051 / SYM B-NP O
35 969 974 8665051 cm(2) NN I-NP O
36 974 975 8665051 ; : O O
37 976 977 8665051 p NN B-NP O
38 978 979 8665051 < SYM B-NP O
39 980 984 8665051 0.05 CD I-NP O
40 984 985 8665051 ) ) O O
41 986 989 8665051 and CC O O
42 990 993 8665051 the DT B-NP O
43 994 995 8665051 T NN I-NP D014221
44 996 1001 8665051 group NN I-NP O
45 1002 1003 8665051 ( ( O O
46 1003 1006 8665051 765 CD B-NP O
47 1007 1008 8665051 + SYM O O
48 1008 1009 8665051 / SYM O O
49 1009 1010 8665051 - SYM O O
50 1011 1014 8665051 145 CD B-NP O
51 1015 1016 8665051 g NN I-NP O
52 1016 1017 8665051 / SYM B-NP O
53 1017 1022 8665051 cm(2) NN I-NP O
54 1022 1023 8665051 , , O O
55 1024 1026 8665051 NS NN B-NP O
56 1026 1027 8665051 ) ) O O
57 1027 1028 8665051 . . O O

1 1029 1033 8665051 Half NN B-NP O
2 1033 1034 8665051 - HYPH I-NP O
3 1034 1044 8665051 relaxation NN I-NP O
4 1045 1049 8665051 time NN I-NP O
5 1050 1053 8665051 was VBD B-VP O
6 1054 1063 8665051 prolonged VBN I-VP O
7 1064 1066 8665051 in IN B-PP O
8 1067 1071 8665051 both CC O O
9 1072 1079 8665051 steroid NN B-NP D013256
10 1080 1086 8665051 groups NNS I-NP O
11 1086 1087 8665051 , , O O
12 1088 1091 8665051 and CC O O
13 1092 1096 8665051 time NN B-NP O
14 1097 1099 8665051 to TO B-PP O
15 1100 1104 8665051 peak JJ B-NP O
16 1105 1112 8665051 tension NN I-NP O
17 1113 1116 8665051 was VBD B-VP O
18 1117 1123 8665051 longer RBR B-ADVP O
19 1124 1128 8665051 with IN B-PP O
20 1129 1130 8665051 M NN B-NP D008775
21 1130 1131 8665051 , , O O
22 1132 1139 8665051 whereas IN O O
23 1140 1147 8665051 tetanic JJ B-NP D013746
24 1148 1156 8665051 tensions NNS I-NP O
25 1157 1161 8665051 were VBD B-VP O
26 1162 1169 8665051 similar JJ B-ADJP O
27 1169 1170 8665051 . . O O

1 1171 1178 8665051 Steroid NN B-NP D013256
2 1179 1188 8665051 treatment NN I-NP O
3 1189 1193 8665051 also RB B-ADVP O
4 1194 1201 8665051 induced VBD B-VP O
5 1202 1203 8665051 a DT B-NP O
6 1204 1212 8665051 leftward JJ I-NP O
7 1213 1218 8665051 shift NN I-NP O
8 1219 1221 8665051 of IN B-PP O
9 1222 1225 8665051 the DT B-NP O
10 1226 1231 8665051 force NN I-NP O
11 1231 1232 8665051 - HYPH B-NP O
12 1232 1241 8665051 frequency NN I-NP O
13 1242 1247 8665051 curve NN I-NP O
14 1248 1250 8665051 at IN B-PP O
15 1251 1253 8665051 25 CD B-NP O
16 1254 1257 8665051 and CC I-NP O
17 1258 1260 8665051 50 CD I-NP O
18 1261 1263 8665051 Hz NN I-NP O
19 1264 1268 8665051 when WRB B-ADVP O
20 1269 1277 8665051 compared VBN B-PP O
21 1278 1282 8665051 with IN B-PP O
22 1283 1289 8665051 saline NN B-NP O
23 1290 1299 8665051 treatment NN I-NP O
24 1300 1301 8665051 ( ( O O
25 1301 1302 8665051 p NN B-NP O
26 1303 1304 8665051 < SYM O O
27 1305 1309 8665051 0.05 CD B-NP O
28 1309 1310 8665051 ) ) O O
29 1310 1311 8665051 . . O O

1 1312 1318 8665051 ATPase NN B-NP O
2 1319 1327 8665051 staining NN I-NP O
3 1328 1330 8665051 of IN B-PP O
4 1331 1334 8665051 the DT B-NP O
5 1335 1344 8665051 diaphragm NN I-NP O
6 1344 1345 8665051 , , O O
7 1346 1354 8665051 scalenus NN B-NP O
8 1355 1361 8665051 medius NN I-NP O
9 1361 1362 8665051 , , O O
10 1363 1366 8665051 and CC O O
11 1367 1380 8665051 gastrocnemius NN B-NP O
12 1381 1387 8665051 showed VBD B-VP O
13 1388 1392 8665051 type NN B-NP O
14 1393 1396 8665051 IIb NN I-NP O
15 1397 1402 8665051 fiber NN I-NP O
16 1403 1410 8665051 atrophy NN I-NP D009133
17 1411 1413 8665051 in IN B-PP O
18 1414 1417 8665051 the DT B-NP O
19 1418 1425 8665051 steroid NN I-NP D013256
20 1426 1432 8665051 groups NNS I-NP O
21 1433 1436 8665051 and CC O O
22 1437 1441 8665051 also RB B-ADVP O
23 1442 1455 8665051 diaphragmatic JJ B-NP O
24 1456 1460 8665051 type NN I-NP O
25 1461 1464 8665051 IIa NN I-NP O
26 1465 1472 8665051 atrophy NN I-NP D009133
27 1473 1477 8665051 with IN B-PP O
28 1478 1479 8665051 T NN B-NP D014221
29 1479 1480 8665051 , , O O
30 1481 1488 8665051 whereas IN O O
31 1489 1499 8665051 histologic JJ B-NP O
32 1500 1512 8665051 examinations NNS I-NP O
33 1513 1521 8665051 revealed VBD B-VP O
34 1522 1523 8665051 a DT B-NP O
35 1524 1530 8665051 normal JJ I-NP O
36 1531 1539 8665051 muscular JJ I-NP O
37 1540 1547 8665051 pattern NN I-NP O
38 1548 1552 8665051 with IN B-PP O
39 1553 1560 8665051 absence NN B-NP O
40 1561 1563 8665051 of IN B-PP O
41 1564 1572 8665051 necrosis NN B-NP D009336
42 1572 1573 8665051 . . O O

1 1574 1581 8665051 Finally RB B-ADVP O
2 1581 1582 8665051 , , O O
3 1583 1584 8665051 a DT B-NP O
4 1585 1589 8665051 pair NN I-NP O
5 1589 1590 8665051 - HYPH B-VP O
6 1590 1593 8665051 fed VBN I-VP O
7 1594 1595 8665051 ( ( O O
8 1595 1597 8665051 PF NN B-NP O
9 1597 1598 8665051 ) ) O O
10 1599 1604 8665051 study NN B-NP O
11 1604 1605 8665051 , , O O
12 1606 1615 8665051 performed VBN B-VP O
13 1616 1618 8665051 in IN B-PP O
14 1619 1621 8665051 18 CD B-NP O
15 1622 1626 8665051 rats NNS I-NP O
16 1627 1628 8665051 ( ( O O
17 1628 1629 8665051 C NN B-NP O
18 1629 1630 8665051 , , O O
19 1631 1632 8665051 T NN B-NP D014221
20 1632 1633 8665051 , , O O
21 1634 1637 8665051 and CC O O
22 1638 1640 8665051 PF NN B-NP O
23 1640 1641 8665051 ) ) O O
24 1641 1642 8665051 , , O O
25 1643 1649 8665051 showed VBD B-VP O
26 1650 1654 8665051 that IN B-SBAR O
27 1655 1661 8665051 muscle NN B-NP D009133
28 1662 1669 8665051 atrophy NN I-NP D009133
29 1670 1673 8665051 was VBD B-VP O
30 1674 1686 8665051 considerably RB B-ADJP O
31 1687 1691 8665051 less RBR I-ADJP O
32 1692 1702 8665051 pronounced JJ I-ADJP O
33 1703 1705 8665051 in IN B-PP O
34 1706 1708 8665051 PF NN B-NP O
35 1709 1716 8665051 animals NNS I-NP O
36 1717 1721 8665051 than IN B-PP O
37 1722 1724 8665051 in IN B-PP O
38 1725 1726 8665051 T NN B-NP D014221
39 1726 1727 8665051 - HYPH B-NP O
40 1727 1734 8665051 treated VBN I-NP O
41 1735 1742 8665051 animals NNS I-NP O
42 1742 1743 8665051 . . O O

1 1744 1746 8665051 We PRP B-NP O
2 1747 1755 8665051 conclude VBP B-VP O
3 1756 1760 8665051 that IN B-SBAR O
4 1761 1762 8665051 ( ( B-LST O
5 1762 1763 8665051 1 LS I-LST O
6 1763 1764 8665051 ) ) O O
7 1765 1770 8665051 short JJ B-NP O
8 1770 1771 8665051 - HYPH I-NP O
9 1771 1775 8665051 term NN I-NP O
10 1776 1785 8665051 treatment NN I-NP O
11 1786 1790 8665051 with IN B-PP O
12 1791 1798 8665051 massive JJ B-NP O
13 1799 1804 8665051 doses NNS I-NP O
14 1805 1807 8665051 of IN B-PP O
15 1808 1816 8665051 steroids NNS B-NP D013256
16 1817 1824 8665051 induced VBD B-VP O
17 1825 1831 8665051 severe JJ B-NP O
18 1832 1843 8665051 respiratory NN I-NP O
19 1844 1847 8665051 and CC I-NP O
20 1848 1852 8665051 limb NN I-NP O
21 1853 1859 8665051 muscle NN I-NP O
22 1860 1867 8665051 wasting NN I-NP O
23 1867 1868 8665051 ; : O O
24 1869 1870 8665051 ( ( B-LST O
25 1870 1871 8665051 2 LS I-LST O
26 1871 1872 8665051 ) ) O O
27 1873 1877 8665051 both DT B-NP O
28 1878 1883 8665051 types NNS I-NP O
29 1884 1886 8665051 of IN B-PP O
30 1887 1895 8665051 steroids NNS B-NP D013256
31 1896 1903 8665051 induced VBD B-VP O
32 1904 1917 8665051 predominantly RB B-NP O
33 1918 1922 8665051 type NN I-NP O
34 1923 1926 8665051 IIb NN I-NP O
35 1927 1934 8665051 atrophy NN I-NP D001284
36 1934 1935 8665051 , , O O
37 1936 1945 8665051 resulting VBG B-VP O
38 1946 1948 8665051 in IN B-PP O
39 1949 1952 8665051 the DT B-NP O
40 1953 1961 8665051 expected JJ I-NP O
41 1962 1973 8665051 alterations NNS I-NP O
42 1974 1976 8665051 in IN B-PP O
43 1977 1986 8665051 diaphragm NN B-NP O
44 1987 1998 8665051 contractile JJ I-NP O
45 1999 2009 8665051 properties NNS I-NP O
46 2009 2010 8665051 ; : O O
47 2011 2012 8665051 ( ( B-LST O
48 2012 2013 8665051 3 LS I-LST O
49 2013 2014 8665051 ) ) O O
50 2015 2022 8665051 neither DT B-NP O
51 2023 2030 8665051 steroid NN I-NP D013256
52 2031 2037 8665051 caused VBD B-VP O
53 2038 2044 8665051 muscle NN B-NP O
54 2045 2053 8665051 necrosis NN I-NP D009336
55 2053 2054 8665051 ; : O O
56 2055 2056 8665051 ( ( B-LST O
57 2056 2057 8665051 4 LS I-LST O
58 2057 2058 8665051 ) ) O O
59 2059 2063 8665051 type NN B-NP O
60 2064 2067 8665051 IIb NN I-NP O
61 2068 2075 8665051 atrophy NN I-NP D009133
62 2076 2079 8665051 was VBD B-VP O
63 2080 2083 8665051 not RB I-VP O
64 2084 2090 8665051 caused VBN I-VP O
65 2091 2093 8665051 by IN B-PP O
66 2094 2099 8665051 acute JJ B-NP O
67 2100 2111 8665051 nutritional JJ I-NP O
68 2112 2123 8665051 deprivation NN I-NP O
69 2124 2129 8665051 alone RB B-ADVP O
70 2129 2130 8665051 . . O O

1 0 0 20558148 -DOCSTART- -X- -X- O

1 0 13 20558148 Glutamatergic JJ B-NP O
2 14 31 20558148 neurotransmission NN I-NP O
3 32 40 20558148 mediated VBN B-VP O
4 41 43 20558148 by IN B-PP O
5 44 48 20558148 NMDA NN B-NP D016202
6 49 58 20558148 receptors NNS I-NP O
7 59 61 20558148 in IN B-PP O
8 62 65 20558148 the DT B-NP O
9 66 74 20558148 inferior JJ I-NP O
10 75 85 20558148 colliculus NN I-NP O
11 86 89 20558148 can MD B-VP O
12 90 98 20558148 modulate VB I-VP O
13 99 110 20558148 haloperidol NN B-NP D006220
14 110 111 20558148 - HYPH B-NP O
15 111 118 20558148 induced VBN I-NP O
16 119 128 20558148 catalepsy NN I-NP D002375
17 128 129 20558148 . . O O
18 130 133 20558148 The DT B-NP O
19 134 142 20558148 inferior JJ I-NP O
20 143 153 20558148 colliculus NN I-NP O
21 154 155 20558148 ( ( O O
22 155 157 20558148 IC NN B-NP O
23 157 158 20558148 ) ) O O
24 159 161 20558148 is VBZ B-VP O
25 162 171 20558148 primarily RB I-VP O
26 172 180 20558148 involved VBN I-VP O
27 181 183 20558148 in IN B-PP O
28 184 187 20558148 the DT B-NP O
29 188 198 20558148 processing NN I-NP O
30 199 201 20558148 of IN B-PP O
31 202 210 20558148 auditory JJ B-NP O
32 211 222 20558148 information NN I-NP O
33 222 223 20558148 , , O O
34 224 227 20558148 but CC O O
35 228 230 20558148 it PRP B-NP O
36 231 233 20558148 is VBZ B-VP O
37 234 247 20558148 distinguished VBN I-VP O
38 248 252 20558148 from IN B-PP O
39 253 258 20558148 other JJ B-NP O
40 259 267 20558148 auditory JJ I-NP O
41 268 274 20558148 nuclei NNS I-NP O
42 275 277 20558148 in IN B-PP O
43 278 281 20558148 the DT B-NP O
44 282 291 20558148 brainstem NN I-NP O
45 292 294 20558148 by IN B-PP O
46 295 298 20558148 its PRP$ B-NP O
47 299 310 20558148 connections NNS I-NP O
48 311 315 20558148 with IN B-PP O
49 316 326 20558148 structures NNS B-NP O
50 327 329 20558148 of IN B-PP O
51 330 333 20558148 the DT B-NP O
52 334 339 20558148 motor NN I-NP O
53 340 346 20558148 system NN I-NP O
54 346 347 20558148 . . O O

1 348 358 20558148 Functional JJ B-NP O
2 359 367 20558148 evidence NN I-NP O
3 368 376 20558148 relating VBG B-VP O
4 377 380 20558148 the DT B-NP O
5 381 383 20558148 IC NN I-NP O
6 384 386 20558148 to TO B-PP O
7 387 392 20558148 motor NN B-NP O
8 393 401 20558148 behavior NN I-NP O
9 402 409 20558148 derives VBZ B-VP O
10 410 414 20558148 from IN B-PP O
11 415 426 20558148 experiments NNS B-NP O
12 427 434 20558148 showing VBG B-VP O
13 435 439 20558148 that IN B-SBAR O
14 440 450 20558148 activation NN B-NP O
15 451 453 20558148 of IN B-PP O
16 454 457 20558148 the DT B-NP O
17 458 460 20558148 IC NN I-NP O
18 461 463 20558148 by IN B-PP O
19 464 474 20558148 electrical JJ B-NP O
20 475 486 20558148 stimulation NN I-NP O
21 487 489 20558148 or CC O O
22 490 500 20558148 excitatory JJ B-NP O
23 501 506 20558148 amino JJ I-NP D000596
24 507 511 20558148 acid NN I-NP D000596
25 512 526 20558148 microinjection NN I-NP O
26 527 533 20558148 causes VBZ B-VP O
27 534 542 20558148 freezing NN B-NP O
28 542 543 20558148 , , O O
29 544 550 20558148 escape NN B-NP O
30 550 551 20558148 - HYPH B-NP O
31 551 555 20558148 like JJ I-NP O
32 556 564 20558148 behavior NN I-NP O
33 564 565 20558148 , , O O
34 566 569 20558148 and CC O O
35 570 580 20558148 immobility NN B-NP O
36 580 581 20558148 . . O O

1 582 589 20558148 However RB B-ADVP O
2 589 590 20558148 , , O O
3 591 594 20558148 the DT B-NP O
4 595 601 20558148 nature NN I-NP O
5 602 604 20558148 of IN B-PP O
6 605 609 20558148 this DT B-NP O
7 610 620 20558148 immobility NN I-NP O
8 621 623 20558148 is VBZ B-VP O
9 624 629 20558148 still RB B-ADVP O
10 630 637 20558148 unclear JJ B-ADJP O
11 637 638 20558148 . . O O

1 639 642 20558148 The DT B-NP O
2 643 650 20558148 present JJ I-NP O
3 651 656 20558148 study NN I-NP O
4 657 665 20558148 examined VBD B-VP O
5 666 669 20558148 the DT B-NP O
6 670 679 20558148 influence NN I-NP O
7 680 682 20558148 of IN B-PP O
8 683 693 20558148 excitatory JJ B-NP O
9 694 699 20558148 amino JJ I-NP D000596
10 700 704 20558148 acid NN I-NP D000596
11 704 705 20558148 - HYPH B-NP O
12 705 713 20558148 mediated VBN I-NP O
13 714 724 20558148 mechanisms NNS I-NP O
14 725 727 20558148 in IN B-PP O
15 728 731 20558148 the DT B-NP O
16 732 734 20558148 IC NN I-NP O
17 735 737 20558148 on IN B-PP O
18 738 741 20558148 the DT B-NP O
19 742 751 20558148 catalepsy NN I-NP D002375
20 752 759 20558148 induced VBN B-VP O
21 760 762 20558148 by IN B-PP O
22 763 766 20558148 the DT B-NP O
23 767 775 20558148 dopamine NN I-NP D004298
24 776 784 20558148 receptor NN I-NP O
25 785 792 20558148 blocker NN I-NP O
26 793 804 20558148 haloperidol NN I-NP D006220
27 805 817 20558148 administered VBN B-VP O
28 818 830 20558148 systemically RB B-ADVP O
29 831 832 20558148 ( ( O O
30 832 833 20558148 1 CD B-NP O
31 834 836 20558148 or CC I-NP O
32 837 840 20558148 0.5 CD I-NP O
33 841 843 20558148 mg NN I-NP O
34 843 844 20558148 / SYM B-NP O
35 844 846 20558148 kg NN I-NP O
36 846 847 20558148 ) ) O O
37 848 850 20558148 in IN B-PP O
38 851 855 20558148 rats NNS B-NP O
39 855 856 20558148 . . O O

1 857 868 20558148 Haloperidol NN B-NP D006220
2 868 869 20558148 - HYPH B-NP O
3 869 876 20558148 induced VBN I-NP O
4 877 886 20558148 catalepsy NN I-NP D002375
5 887 890 20558148 was VBD B-VP O
6 891 901 20558148 challenged VBN I-VP O
7 902 906 20558148 with IN B-PP O
8 907 912 20558148 prior JJ B-NP O
9 913 928 20558148 intracollicular JJ I-NP O
10 929 944 20558148 microinjections NNS I-NP O
11 945 947 20558148 of IN B-PP O
12 948 957 20558148 glutamate NN B-NP D018698
13 958 962 20558148 NMDA NN I-NP D016202
14 963 971 20558148 receptor NN I-NP O
15 972 983 20558148 antagonists NNS I-NP O
16 983 984 20558148 , , O O
17 985 987 20558148 MK NN B-NP D016291
18 987 988 20558148 - HYPH O D016291
19 988 991 20558148 801 CD B-NP D016291
20 992 993 20558148 ( ( O O
21 993 995 20558148 15 CD B-NP O
22 996 998 20558148 or CC I-NP O
23 999 1001 20558148 30 CD I-NP O
24 1002 1006 20558148 mmol NN I-NP O
25 1006 1007 20558148 / SYM B-NP O
26 1007 1010 20558148 0.5 CD B-NP O
27 1011 1017 20558148 microl NN I-NP O
28 1017 1018 20558148 ) ) O O
29 1019 1022 20558148 and CC O O
30 1023 1026 20558148 AP7 NN B-NP C031231
31 1027 1028 20558148 ( ( O O
32 1028 1030 20558148 10 CD B-NP O
33 1031 1033 20558148 or CC I-NP O
34 1034 1036 20558148 20 CD I-NP O
35 1037 1041 20558148 nmol NN I-NP O
36 1041 1042 20558148 / SYM I-NP O
37 1042 1045 20558148 0.5 CD I-NP O
38 1046 1052 20558148 microl NN I-NP O
39 1052 1053 20558148 ) ) O O
40 1053 1054 20558148 , , O O
41 1055 1057 20558148 or CC O O
42 1058 1060 20558148 of IN B-PP O
43 1061 1064 20558148 the DT B-NP O
44 1065 1069 20558148 NMDA NN I-NP D016202
45 1070 1078 20558148 receptor NN I-NP O
46 1079 1086 20558148 agonist NN I-NP O
47 1087 1088 20558148 N NN I-NP D016202
48 1088 1089 20558148 - HYPH B-NP D016202
49 1089 1095 20558148 methyl NN I-NP D016202
50 1095 1096 20558148 - HYPH B-NP D016202
51 1096 1097 20558148 d NN I-NP D016202
52 1097 1098 20558148 - HYPH O D016202
53 1098 1107 20558148 aspartate NN B-NP D016202
54 1108 1109 20558148 ( ( O O
55 1109 1113 20558148 NMDA NN B-NP D016202
56 1113 1114 20558148 , , O O
57 1115 1117 20558148 20 CD B-NP O
58 1118 1120 20558148 or CC I-NP O
59 1121 1123 20558148 30 CD I-NP O
60 1124 1128 20558148 nmol NN I-NP O
61 1128 1129 20558148 / SYM B-NP O
62 1129 1132 20558148 0.5 CD B-NP O
63 1133 1139 20558148 microl NN I-NP O
64 1139 1140 20558148 ) ) O O
65 1140 1141 20558148 . . O O

1 1142 1145 20558148 The DT B-NP O
2 1146 1153 20558148 results NNS I-NP O
3 1154 1160 20558148 showed VBD B-VP O
4 1161 1165 20558148 that IN B-SBAR O
5 1166 1181 20558148 intracollicular JJ B-NP O
6 1182 1196 20558148 microinjection NN I-NP O
7 1197 1199 20558148 of IN B-PP O
8 1200 1202 20558148 MK NN B-NP D016291
9 1202 1203 20558148 - HYPH B-NP D016291
10 1203 1206 20558148 801 CD I-NP D016291
11 1207 1210 20558148 and CC O O
12 1211 1214 20558148 AP7 NN B-NP C031231
13 1215 1223 20558148 previous JJ B-ADJP O
14 1224 1226 20558148 to TO B-PP O
15 1227 1235 20558148 systemic JJ B-NP O
16 1236 1246 20558148 injections NNS I-NP O
17 1247 1249 20558148 of IN B-PP O
18 1250 1261 20558148 haloperidol NN B-NP D006220
19 1262 1275 20558148 significantly RB B-ADVP O
20 1276 1286 20558148 attenuated VBD B-VP O
21 1287 1290 20558148 the DT B-NP O
22 1291 1300 20558148 catalepsy NN I-NP D002375
23 1300 1301 20558148 , , O O
24 1302 1304 20558148 as IN B-SBAR O
25 1305 1314 20558148 indicated VBN B-VP O
26 1315 1317 20558148 by IN B-PP O
27 1318 1319 20558148 a DT B-NP O
28 1320 1327 20558148 reduced VBN I-NP O
29 1328 1335 20558148 latency NN I-NP O
30 1336 1338 20558148 to TO B-VP O
31 1339 1343 20558148 step VB I-VP O
32 1344 1348 20558148 down RP B-PRT O
33 1349 1353 20558148 from IN B-PP O
34 1354 1355 20558148 a DT B-NP O
35 1356 1366 20558148 horizontal JJ I-NP O
36 1367 1370 20558148 bar NN I-NP O
37 1370 1371 20558148 . . O O

1 1372 1383 20558148 Accordingly RB B-ADVP O
2 1383 1384 20558148 , , O O
3 1385 1400 20558148 intracollicular JJ B-NP O
4 1401 1415 20558148 microinjection NN I-NP O
5 1416 1418 20558148 of IN B-PP O
6 1419 1423 20558148 NMDA NN B-NP D016202
7 1424 1433 20558148 increased VBD B-VP O
8 1434 1437 20558148 the DT B-NP O
9 1438 1445 20558148 latency NN I-NP O
10 1446 1448 20558148 to TO B-VP O
11 1449 1453 20558148 step VB I-VP O
12 1454 1458 20558148 down RP B-PRT O
13 1459 1462 20558148 the DT B-NP O
14 1463 1466 20558148 bar NN I-NP O
15 1466 1467 20558148 . . O O

1 1468 1473 20558148 These DT B-NP O
2 1474 1482 20558148 findings NNS I-NP O
3 1483 1490 20558148 suggest VBP B-VP O
4 1491 1495 20558148 that IN B-SBAR O
5 1496 1505 20558148 glutamate NN B-NP D018698
6 1505 1506 20558148 - HYPH B-NP O
7 1506 1514 20558148 mediated VBN I-NP O
8 1515 1525 20558148 mechanisms NNS I-NP O
9 1526 1528 20558148 in IN B-PP O
10 1529 1532 20558148 the DT B-NP O
11 1533 1539 20558148 neural JJ I-NP O
12 1540 1548 20558148 circuits NNS I-NP O
13 1549 1551 20558148 at IN B-PP O
14 1552 1555 20558148 the DT B-NP O
15 1556 1558 20558148 IC NN I-NP O
16 1559 1564 20558148 level NN I-NP O
17 1565 1574 20558148 influence NN I-NP O
18 1575 1586 20558148 haloperidol NN I-NP D006220
19 1586 1587 20558148 - HYPH B-VP O
20 1587 1594 20558148 induced VBN B-NP O
21 1595 1604 20558148 catalepsy NN I-NP D002375
22 1605 1608 20558148 and CC O O
23 1609 1620 20558148 participate VB B-VP O
24 1621 1623 20558148 in IN B-PP O
25 1624 1627 20558148 the DT B-NP O
26 1628 1638 20558148 regulation NN I-NP O
27 1639 1641 20558148 of IN B-PP O
28 1642 1647 20558148 motor NN B-NP O
29 1648 1656 20558148 activity NN I-NP O
30 1656 1657 20558148 . . O O

1 0 0 10692744 -DOCSTART- -X- -X- O

1 0 13 10692744 Acetazolamide NN B-NP D000086
2 13 14 10692744 - HYPH B-NP O
3 14 21 10692744 induced VBN I-NP O
4 22 31 10692744 Gerstmann NN I-NP D005862
5 32 40 10692744 syndrome NN I-NP D005862
6 40 41 10692744 . . O O
7 42 47 10692744 Acute JJ B-NP O
8 48 57 10692744 confusion NN I-NP D003221
9 58 65 10692744 induced VBN B-VP O
10 66 68 10692744 by IN B-PP O
11 69 82 10692744 acetazolamide NN B-NP D000086
12 83 85 10692744 is VBZ B-VP O
13 86 87 10692744 a DT B-NP O
14 88 92 10692744 well RB I-NP O
15 93 98 10692744 known VBN I-NP O
16 99 106 10692744 adverse JJ I-NP O
17 107 111 10692744 drug NN I-NP O
18 112 120 10692744 reaction NN I-NP O
19 121 123 10692744 in IN B-PP O
20 124 132 10692744 patients NNS B-NP O
21 133 137 10692744 with IN B-PP O
22 138 143 10692744 renal JJ B-NP D007674
23 144 154 10692744 impairment NN I-NP D007674
24 154 155 10692744 . . O O

1 156 158 10692744 We PRP B-NP O
2 159 165 10692744 report VBP B-VP O
3 166 167 10692744 a DT B-NP O
4 168 172 10692744 case NN I-NP O
5 173 175 10692744 of IN B-PP O
6 176 189 10692744 acetazolamide NN B-NP D000086
7 189 190 10692744 - HYPH B-NP O
8 190 197 10692744 induced VBN I-NP O
9 198 207 10692744 Gerstmann NN I-NP D005862
10 208 216 10692744 syndrome NN I-NP D005862
11 217 219 10692744 in IN B-PP O
12 220 221 10692744 a DT B-NP O
13 222 229 10692744 patient NN I-NP O
14 230 234 10692744 with IN B-PP O
15 235 241 10692744 normal JJ B-NP O
16 242 247 10692744 renal JJ I-NP O
17 248 256 10692744 function NN I-NP O
18 256 257 10692744 , , O O
19 258 260 10692744 to TO B-VP O
20 261 270 10692744 highlight VB I-VP O
21 271 283 10692744 predisposing VBG I-VP O
22 284 291 10692744 factors NNS B-NP O
23 292 296 10692744 that WDT B-NP O
24 297 300 10692744 are VBP B-VP O
25 301 311 10692744 frequently RB I-VP O
26 312 322 10692744 overlooked VBN I-VP O
27 322 323 10692744 . . O O

1 0 0 3123611 -DOCSTART- -X- -X- O

1 0 6 3123611 Chorea NN B-NP D002819
2 7 17 3123611 associated VBN B-VP O
3 18 22 3123611 with IN B-PP O
4 23 27 3123611 oral JJ B-NP D003276
5 28 41 3123611 contraception NN I-NP D003276
6 41 42 3123611 . . O O
7 43 48 3123611 Three CD B-NP O
8 49 57 3123611 patients NNS I-NP O
9 58 67 3123611 developed VBD B-VP O
10 68 74 3123611 chorea NN B-NP D002819
11 75 80 3123611 while IN B-SBAR O
12 81 90 3123611 receiving VBG B-VP O
13 91 95 3123611 oral JJ B-NP D003276
14 96 110 3123611 contraceptives NNS I-NP D003276
15 110 111 3123611 . . O O

1 112 115 3123611 Two CD B-NP O
2 116 120 3123611 were VBD B-VP O
3 121 126 3123611 young JJ B-NP O
4 127 135 3123611 patients NNS I-NP O
5 136 141 3123611 whose WP$ B-NP O
6 142 148 3123611 chorea NN I-NP D002819
7 149 158 3123611 developed VBD B-VP O
8 159 163 3123611 long RB B-ADVP O
9 164 169 3123611 after IN B-SBAR O
10 170 179 3123611 treatment NN B-NP O
11 180 183 3123611 had VBD B-VP O
12 184 188 3123611 been VBN I-VP O
13 189 196 3123611 started VBN I-VP O
14 197 200 3123611 and CC O O
15 201 212 3123611 disappeared VBD B-VP O
16 213 217 3123611 soon RB B-ADVP O
17 218 223 3123611 after IN B-SBAR O
18 224 226 3123611 it PRP B-NP O
19 227 230 3123611 had VBD B-VP O
20 231 235 3123611 been VBN I-VP O
21 236 248 3123611 discontinued VBN I-VP O
22 248 249 3123611 . . O O

1 250 253 3123611 The DT B-NP O
2 254 259 3123611 third JJ I-NP O
3 260 267 3123611 patient NN I-NP O
4 268 271 3123611 had VBD B-VP O
5 272 277 3123611 acute JJ B-NP O
6 278 289 3123611 amphetamine NN I-NP D000661
7 289 290 3123611 - HYPH B-NP O
8 290 297 3123611 induced VBN I-NP O
9 298 304 3123611 chorea NN I-NP D002819
10 305 310 3123611 after IN B-PP O
11 311 320 3123611 prolonged JJ B-NP O
12 321 325 3123611 oral JJ I-NP D003276
13 326 339 3123611 contraception NN I-NP D003276
14 339 340 3123611 . . O O

1 341 350 3123611 Prolonged JJ B-NP O
2 351 365 3123611 administration NN I-NP O
3 366 368 3123611 of IN B-PP O
4 369 375 3123611 female JJ B-NP O
5 376 379 3123611 sex NN I-NP O
6 380 388 3123611 hormones NNS I-NP O
7 389 391 3123611 is VBZ B-VP O
8 392 393 3123611 a DT B-NP O
9 394 402 3123611 possible JJ I-NP O
10 403 408 3123611 cause NN I-NP O
11 409 411 3123611 of IN B-PP O
12 412 418 3123611 chorea NN B-NP D002819
13 419 421 3123611 in IN B-PP O
14 422 427 3123611 women NNS B-NP O
15 428 431 3123611 who WP B-NP O
16 432 436 3123611 have VBP B-VP O
17 437 440 3123611 not RB I-VP O
18 441 451 3123611 previously RB I-VP O
19 452 455 3123611 had VBD I-VP O
20 456 462 3123611 chorea NN B-NP D002819
21 463 465 3123611 or CC O O
22 466 475 3123611 rheumatic JJ B-NP D012213
23 476 481 3123611 fever NN I-NP D012213
24 481 482 3123611 . . O O

1 0 0 15985056 -DOCSTART- -X- -X- O

1 0 8 15985056 Possible JJ B-NP O
2 9 21 15985056 azithromycin NN I-NP D017963
3 21 22 15985056 - HYPH B-NP O
4 22 32 15985056 associated VBN I-NP O
5 33 40 15985056 hiccups NNS I-NP D006606
6 40 41 15985056 . . I-NP O
7 42 51 15985056 OBJECTIVE NN I-NP O
8 51 52 15985056 : : O O
9 53 55 15985056 To TO B-VP O
10 56 62 15985056 report VB I-VP O
11 63 64 15985056 a DT B-NP O
12 65 69 15985056 case NN I-NP O
13 70 72 15985056 of IN B-PP O
14 73 83 15985056 persistent JJ B-NP O
15 84 91 15985056 hiccups NNS I-NP D006606
16 92 102 15985056 associated VBN B-VP O
17 103 105 15985056 by IN B-PP O
18 106 118 15985056 azithromycin NN B-NP D017963
19 119 126 15985056 therapy NN I-NP O
20 126 127 15985056 . . O O

1 128 132 15985056 CASE NN B-NP O
2 133 140 15985056 SUMMARY NN I-NP O
3 140 141 15985056 : : O O
4 142 143 15985056 A DT B-NP O
5 144 146 15985056 76 CD I-NP O
6 146 147 15985056 - HYPH I-NP O
7 147 151 15985056 year NN I-NP O
8 151 152 15985056 - HYPH O O
9 152 155 15985056 old JJ B-NP O
10 156 159 15985056 man NN I-NP O
11 160 169 15985056 presented VBN B-VP O
12 170 174 15985056 with IN B-PP O
13 175 185 15985056 persistent JJ B-NP O
14 186 193 15985056 hiccups NNS I-NP D006606
15 194 199 15985056 after IN B-PP O
16 200 209 15985056 beginning VBG B-VP O
17 210 222 15985056 azithromycin NN B-NP D017963
18 223 226 15985056 for IN B-PP O
19 227 230 15985056 the DT B-NP O
20 231 240 15985056 treatment NN I-NP O
21 241 243 15985056 of IN B-PP O
22 244 255 15985056 pharyngitis NN B-NP D010612
23 255 256 15985056 . . O O

1 257 264 15985056 Hiccups NNS B-NP D006606
2 265 269 15985056 were VBD B-VP O
3 270 280 15985056 persistent JJ B-ADJP O
4 281 284 15985056 and CC I-ADJP O
5 285 295 15985056 exhausting JJ I-ADJP O
6 295 296 15985056 . . O O

1 297 312 15985056 Discontinuation NN B-NP O
2 313 315 15985056 of IN B-PP O
3 316 328 15985056 azithromycin NN B-NP D017963
4 329 332 15985056 and CC I-NP O
5 333 340 15985056 therapy NN I-NP O
6 341 345 15985056 with IN B-PP O
7 346 354 15985056 baclofen NN B-NP D001418
8 355 362 15985056 finally RB B-NP O
9 363 371 15985056 resolved VBN I-NP O
10 372 379 15985056 hiccups NNS I-NP D006606
11 379 380 15985056 . . O O

1 381 383 15985056 No DT B-NP O
2 384 391 15985056 organic JJ I-NP O
3 392 397 15985056 cause NN I-NP O
4 398 400 15985056 of IN B-PP O
5 401 408 15985056 hiccups NNS B-NP D006606
6 409 412 15985056 was VBD B-VP O
7 413 423 15985056 identified VBN I-VP O
8 424 431 15985056 despite IN B-PP O
9 432 441 15985056 extensive JJ B-NP O
10 442 455 15985056 investigation NN I-NP O
11 455 456 15985056 . . O O

1 457 467 15985056 DISCUSSION NN B-NP O
2 467 468 15985056 : : O O
3 469 488 15985056 Pharmacotherapeutic JJ B-NP O
4 489 495 15985056 agents NNS I-NP O
5 496 500 15985056 have VBP B-VP O
6 501 505 15985056 been VBN I-VP O
7 506 516 15985056 uncommonly RB I-VP O
8 517 527 15985056 associated VBN I-VP O
9 528 532 15985056 with IN B-PP O
10 533 540 15985056 hiccups NNS B-NP D006606
11 540 541 15985056 . . O O

1 542 557 15985056 Corticosteroids NNS B-NP O
2 558 559 15985056 ( ( O O
3 559 572 15985056 dexamethasone NN B-NP D003907
4 573 576 15985056 and CC O O
5 577 595 15985056 methylprednisolone NN B-NP D008775
6 595 596 15985056 ) ) O O
7 596 597 15985056 , , O O
8 598 613 15985056 benzodiazepines NNS B-NP D001569
9 614 615 15985056 ( ( O O
10 615 624 15985056 midazolam NN B-NP D008874
11 624 625 15985056 ) ) O O
12 626 629 15985056 and CC O O
13 630 637 15985056 general JJ B-NP O
14 638 649 15985056 anaesthesia NN I-NP O
15 650 654 15985056 have VBP B-VP O
16 655 659 15985056 been VBN I-VP O
17 660 663 15985056 the DT B-NP O
18 664 672 15985056 specific JJ I-NP O
19 673 679 15985056 agents NNS I-NP O
20 680 689 15985056 mentioned VBD B-VP O
21 690 694 15985056 most RBS B-ADVP O
22 695 705 15985056 frequently RB I-ADVP O
23 706 708 15985056 in IN B-PP O
24 709 712 15985056 the DT B-NP O
25 713 723 15985056 literature NN I-NP O
26 724 726 15985056 as IN B-PP O
27 727 732 15985056 being VBG B-VP O
28 733 743 15985056 associated VBN I-VP O
29 744 748 15985056 with IN B-PP O
30 749 752 15985056 the DT B-NP O
31 753 764 15985056 development NN I-NP O
32 765 767 15985056 of IN B-PP O
33 768 775 15985056 hiccups NNS B-NP D006606
34 775 776 15985056 . . O O

1 777 780 15985056 Few JJ B-NP O
2 781 786 15985056 cases NNS I-NP O
3 787 789 15985056 of IN B-PP O
4 790 794 15985056 drug NN B-NP O
5 794 795 15985056 - HYPH B-NP O
6 795 802 15985056 induced VBN I-NP O
7 803 810 15985056 hiccups NNS I-NP D006606
8 811 815 15985056 have VBP B-VP O
9 816 820 15985056 been VBN I-VP O
10 821 829 15985056 reported VBN I-VP O
11 830 837 15985056 related VBN B-ADJP O
12 838 840 15985056 to TO B-PP O
13 841 850 15985056 macrolide NN B-NP D018942
14 851 865 15985056 antimicrobials NNS I-NP O
15 865 866 15985056 . . O O

1 867 872 15985056 Using VBG B-VP O
2 873 876 15985056 the DT B-NP O
3 877 884 15985056 Naranjo NNP I-NP O
4 885 892 15985056 adverse JJ I-NP O
5 893 899 15985056 effect NN I-NP O
6 900 908 15985056 reaction NN I-NP O
7 909 920 15985056 probability NN I-NP O
8 921 926 15985056 scale NN I-NP O
9 927 931 15985056 this DT B-NP O
10 932 937 15985056 event NN I-NP O
11 938 943 15985056 could MD B-VP O
12 944 946 15985056 be VB I-VP O
13 947 957 15985056 classified VBN I-VP O
14 958 960 15985056 as IN B-PP O
15 961 969 15985056 possible JJ B-ADJP O
16 970 971 15985056 ( ( O O
17 971 976 15985056 score NN B-NP O
18 977 978 15985056 5 CD B-NP O
19 979 985 15985056 points NNS I-NP O
20 985 986 15985056 ) ) O O
21 986 987 15985056 , , O O
22 988 994 15985056 mostly RB B-ADVP O
23 995 1002 15985056 because IN B-PP O
24 1003 1005 15985056 of IN I-PP O
25 1006 1009 15985056 the DT B-NP O
26 1010 1015 15985056 close JJ I-NP O
27 1016 1024 15985056 temporal JJ I-NP O
28 1025 1033 15985056 sequence NN I-NP O
29 1033 1034 15985056 , , O O
30 1035 1043 15985056 previous JJ B-NP O
31 1044 1051 15985056 reports NNS I-NP O
32 1052 1054 15985056 on IN B-PP O
33 1055 1059 15985056 this DT B-NP O
34 1060 1068 15985056 reaction NN I-NP O
35 1069 1073 15985056 with IN B-PP O
36 1074 1079 15985056 other JJ B-NP O
37 1080 1090 15985056 macrolides NNS I-NP D018942
38 1091 1094 15985056 and CC O O
39 1095 1098 15985056 the DT B-NP O
40 1099 1106 15985056 absence NN I-NP O
41 1107 1109 15985056 of IN B-PP O
42 1110 1113 15985056 any DT B-NP O
43 1114 1125 15985056 alternative JJ I-NP O
44 1126 1137 15985056 explanation NN I-NP O
45 1138 1141 15985056 for IN B-PP O
46 1142 1149 15985056 hiccups NNS B-NP D006606
47 1149 1150 15985056 . . O O

1 1151 1154 15985056 Our PRP$ B-NP O
2 1155 1165 15985056 hypothesis NN I-NP O
3 1166 1168 15985056 is VBZ B-VP O
4 1169 1173 15985056 that IN B-SBAR O
5 1174 1175 15985056 a DT B-NP O
6 1176 1181 15985056 vagal JJ I-NP O
7 1182 1191 15985056 mechanism NN I-NP O
8 1192 1200 15985056 mediated VBN B-VP O
9 1201 1203 15985056 by IN B-PP O
10 1204 1216 15985056 azithromycin NN B-NP D017963
11 1217 1222 15985056 could MD B-VP O
12 1223 1225 15985056 be VB I-VP O
13 1226 1229 15985056 the DT B-NP O
14 1230 1242 15985056 pathogenesis NN I-NP O
15 1243 1245 15985056 of IN B-PP O
16 1246 1253 15985056 hiccups NNS B-NP D006606
17 1254 1256 15985056 in IN B-PP O
18 1257 1260 15985056 our PRP$ B-NP O
19 1261 1268 15985056 patient NN I-NP O
20 1268 1269 15985056 . . O O

1 1270 1281 15985056 CONCLUSIONS NNS B-NP O
2 1281 1282 15985056 : : O O
3 1283 1292 15985056 Diagnosis NN B-NP O
4 1293 1295 15985056 of IN B-PP O
5 1296 1300 15985056 drug NN B-NP O
6 1300 1301 15985056 - HYPH B-NP O
7 1301 1308 15985056 induced VBN I-NP O
8 1309 1316 15985056 hiccups NNS I-NP D006606
9 1317 1319 15985056 is VBZ B-VP O
10 1320 1329 15985056 difficult JJ B-ADJP O
11 1330 1333 15985056 and CC O O
12 1334 1339 15985056 often RB B-VP O
13 1340 1348 15985056 achieved VBN I-VP O
14 1349 1353 15985056 only RB B-ADVP O
15 1354 1356 15985056 by IN B-PP O
16 1357 1358 15985056 a DT B-NP O
17 1359 1366 15985056 process NN I-NP O
18 1367 1369 15985056 of IN B-PP O
19 1370 1381 15985056 elimination NN B-NP O
20 1381 1382 15985056 . . O O

1 1383 1390 15985056 However RB B-ADVP O
2 1390 1391 15985056 , , O O
3 1392 1401 15985056 macrolide NN B-NP D018942
4 1402 1416 15985056 antimicrobials NNS I-NP O
5 1417 1421 15985056 have VBP B-VP O
6 1422 1426 15985056 been VBN I-VP O
7 1427 1435 15985056 reported VBN I-VP O
8 1436 1438 15985056 to TO I-VP O
9 1439 1441 15985056 be VB I-VP O
10 1442 1452 15985056 associated VBN I-VP O
11 1453 1457 15985056 with IN B-PP O
12 1458 1465 15985056 hiccups NNS B-NP D006606
13 1466 1469 15985056 and CC O O
14 1470 1475 15985056 vagal JJ B-NP O
15 1476 1485 15985056 mechanism NN I-NP O
16 1486 1491 15985056 could MD B-VP O
17 1492 1499 15985056 explain VB I-VP O
18 1500 1503 15985056 the DT B-NP O
19 1504 1515 15985056 development NN I-NP O
20 1516 1518 15985056 of IN B-PP O
21 1519 1523 15985056 this DT B-NP O
22 1524 1528 15985056 side NN I-NP O
23 1528 1529 15985056 - HYPH B-NP O
24 1529 1535 15985056 effect NN I-NP O
25 1535 1536 15985056 . . O O

1 0 0 20727411 -DOCSTART- -X- -X- O

1 0 6 20727411 Neural JJ B-NP O
2 7 17 20727411 correlates NNS I-NP O
3 18 20 20727411 of IN B-PP O
4 21 22 20727411 S NN B-NP -1
5 22 23 20727411 - HYPH B-NP -1
6 23 31 20727411 ketamine NN I-NP -1
7 32 39 20727411 induced VBD B-VP O
8 40 49 20727411 psychosis NN B-NP D011605
9 50 56 20727411 during IN B-PP O
10 57 62 20727411 overt JJ B-NP O
11 63 73 20727411 continuous JJ I-NP O
12 74 80 20727411 verbal JJ I-NP O
13 81 88 20727411 fluency NN I-NP O
14 88 89 20727411 . . O O
15 90 93 20727411 The DT B-NP O
16 94 107 20727411 glutamatergic JJ I-NP O
17 108 109 20727411 N NN I-NP D016202
18 109 110 20727411 - HYPH B-NP D016202
19 110 116 20727411 methyl NN I-NP D016202
20 116 117 20727411 - HYPH B-NP D016202
21 117 118 20727411 D NN I-NP D016202
22 118 119 20727411 - HYPH O D016202
23 119 128 20727411 aspartate NN B-NP D016202
24 129 130 20727411 ( ( O O
25 130 134 20727411 NMDA NN B-NP D016202
26 134 135 20727411 ) ) O O
27 136 144 20727411 receptor NN B-NP O
28 145 148 20727411 has VBZ B-VP O
29 149 153 20727411 been VBN I-VP O
30 154 164 20727411 implicated VBN I-VP O
31 165 167 20727411 in IN B-PP O
32 168 171 20727411 the DT B-NP O
33 172 187 20727411 pathophysiology NN I-NP O
34 188 190 20727411 of IN B-PP O
35 191 204 20727411 schizophrenia NN B-NP D012559
36 204 205 20727411 . . O O

1 206 218 20727411 Administered VBN B-VP O
2 219 221 20727411 to TO B-PP O
3 222 229 20727411 healthy JJ B-NP O
4 230 240 20727411 volunteers NNS I-NP O
5 240 241 20727411 , , O O
6 242 243 20727411 a DT B-NP O
7 244 257 20727411 subanesthetic JJ I-NP O
8 258 262 20727411 dose NN I-NP O
9 263 265 20727411 of IN B-PP O
10 266 269 20727411 the DT B-NP O
11 270 273 20727411 non AFX I-NP O
12 273 274 20727411 - HYPH I-NP O
13 274 285 20727411 competitive JJ I-NP O
14 286 290 20727411 NMDA NN I-NP D016202
15 291 299 20727411 receptor NN I-NP O
16 300 310 20727411 antagonist NN I-NP O
17 311 319 20727411 ketamine NN I-NP D007649
18 320 325 20727411 leads VBZ B-VP O
19 326 328 20727411 to TO B-PP O
20 329 347 20727411 psychopathological JJ B-NP O
21 348 356 20727411 symptoms NNS I-NP O
22 357 364 20727411 similar JJ B-ADJP O
23 365 367 20727411 to TO B-PP O
24 368 373 20727411 those DT B-NP O
25 374 382 20727411 observed VBN B-VP O
26 383 385 20727411 in IN B-PP O
27 386 399 20727411 schizophrenia NN B-NP D012559
28 399 400 20727411 . . O O

1 401 403 20727411 In IN B-PP O
2 404 412 20727411 patients NNS B-NP O
3 413 417 20727411 with IN B-PP O
4 418 431 20727411 schizophrenia NN B-NP D012559
5 431 432 20727411 , , O O
6 433 441 20727411 ketamine NN B-NP D007649
7 442 453 20727411 exacerbates VBZ B-VP O
8 454 457 20727411 the DT B-NP O
9 458 462 20727411 core NN I-NP O
10 463 471 20727411 symptoms NNS I-NP O
11 472 474 20727411 of IN B-PP O
12 475 482 20727411 illness NN B-NP O
13 482 483 20727411 , , O O
14 484 494 20727411 supporting VBG B-VP O
15 495 498 20727411 the DT B-NP O
16 499 509 20727411 hypothesis NN I-NP O
17 510 512 20727411 of IN B-PP O
18 513 514 20727411 a DT B-NP O
19 515 528 20727411 glutamatergic JJ I-NP D018754
20 529 540 20727411 dysfunction NN I-NP D018754
21 540 541 20727411 . . O O

1 542 544 20727411 In IN B-PP O
2 545 546 20727411 a DT B-NP O
3 547 562 20727411 counterbalanced JJ I-NP O
4 562 563 20727411 , , I-NP O
5 564 571 20727411 placebo NN I-NP O
6 571 572 20727411 - HYPH I-NP O
7 572 582 20727411 controlled VBN B-VP O
8 582 583 20727411 , , O O
9 584 590 20727411 double JJ B-NP O
10 590 591 20727411 - HYPH I-NP O
11 591 596 20727411 blind JJ I-NP O
12 597 602 20727411 study NN I-NP O
13 603 609 20727411 design NN I-NP O
14 609 610 20727411 , , O O
15 611 618 20727411 healthy JJ B-NP O
16 619 627 20727411 subjects NNS I-NP O
17 628 632 20727411 were VBD B-VP O
18 633 645 20727411 administered VBN I-VP O
19 646 647 20727411 a DT B-NP O
20 648 658 20727411 continuous JJ I-NP O
21 659 672 20727411 subanesthetic JJ I-NP O
22 673 674 20727411 S NN I-NP -1
23 674 675 20727411 - HYPH B-NP -1
24 675 683 20727411 ketamine NN I-NP -1
25 684 692 20727411 infusion NN I-NP O
26 693 698 20727411 while IN B-SBAR O
27 699 710 20727411 differences NNS B-NP O
28 711 713 20727411 in IN B-PP O
29 714 718 20727411 BOLD NN B-NP O
30 719 728 20727411 responses NNS I-NP O
31 729 737 20727411 measured VBN B-VP O
32 738 742 20727411 with IN B-PP O
33 743 747 20727411 fMRI NN B-NP O
34 748 752 20727411 were VBD B-VP O
35 753 761 20727411 detected VBN I-VP O
36 761 762 20727411 . . O O

1 763 769 20727411 During IN B-PP O
2 770 773 20727411 the DT B-NP O
3 774 782 20727411 scanning NN I-NP O
4 783 789 20727411 period NN I-NP O
5 789 790 20727411 , , O O
6 791 799 20727411 subjects NNS B-NP O
7 800 809 20727411 performed VBD B-VP O
8 810 820 20727411 continuous JJ B-NP O
9 821 826 20727411 overt JJ I-NP O
10 827 833 20727411 verbal JJ I-NP O
11 834 841 20727411 fluency NN I-NP O
12 842 847 20727411 tasks NNS I-NP O
13 848 849 20727411 ( ( O O
14 849 861 20727411 phonological JJ B-NP O
15 861 862 20727411 , , I-NP O
16 863 870 20727411 lexical JJ I-NP O
17 871 874 20727411 and CC I-NP O
18 875 883 20727411 semantic JJ I-NP O
19 883 884 20727411 ) ) O O
20 884 885 20727411 . . O O

1 886 894 20727411 Ketamine NN B-NP D007649
2 894 895 20727411 - HYPH O O
3 895 902 20727411 induced VBN B-NP O
4 903 921 20727411 psychopathological JJ I-NP O
5 922 930 20727411 symptoms NNS I-NP O
6 931 935 20727411 were VBD B-VP O
7 936 944 20727411 assessed VBN I-VP O
8 945 949 20727411 with IN B-PP O
9 950 953 20727411 the DT B-NP O
10 954 962 20727411 Positive JJ I-NP O
11 963 966 20727411 and CC I-NP O
12 967 975 20727411 Negative JJ I-NP O
13 976 984 20727411 Syndrome NN I-NP O
14 985 990 20727411 Scale NN I-NP O
15 991 992 20727411 ( ( O O
16 992 997 20727411 PANSS NN B-NP O
17 997 998 20727411 ) ) O O
18 998 999 20727411 . . O O

1 1000 1008 20727411 Ketamine NN B-NP D007649
2 1009 1017 20727411 elicited VBD B-VP O
3 1018 1027 20727411 psychosis NN B-NP D011605
4 1028 1032 20727411 like IN B-PP O
5 1033 1048 20727411 psychopathology NN B-NP O
6 1048 1049 20727411 . . O O

1 1050 1054 20727411 Post AFX B-NP O
2 1054 1055 20727411 - HYPH I-NP O
3 1055 1058 20727411 hoc NN I-NP O
4 1059 1060 20727411 t NN I-NP O
5 1060 1061 20727411 - HYPH I-NP O
6 1061 1066 20727411 tests NNS I-NP O
7 1067 1075 20727411 revealed VBD B-VP O
8 1076 1087 20727411 significant JJ B-NP O
9 1088 1099 20727411 differences NNS I-NP O
10 1100 1107 20727411 between IN B-PP O
11 1108 1115 20727411 placebo NN B-NP O
12 1116 1119 20727411 and CC I-NP O
13 1120 1128 20727411 ketamine NN I-NP D007649
14 1129 1132 20727411 for IN B-PP O
15 1133 1136 20727411 the DT B-NP O
16 1137 1144 20727411 amounts NNS I-NP O
17 1145 1147 20727411 of IN B-PP O
18 1148 1153 20727411 words NNS B-NP O
19 1154 1163 20727411 generated VBN B-VP O
20 1164 1170 20727411 during IN B-PP O
21 1171 1178 20727411 lexical JJ B-NP O
22 1179 1182 20727411 and CC I-NP O
23 1183 1191 20727411 semantic JJ I-NP O
24 1192 1198 20727411 verbal JJ I-NP O
25 1199 1206 20727411 fluency NN I-NP O
26 1206 1207 20727411 , , O O
27 1208 1213 20727411 while IN B-SBAR O
28 1214 1217 20727411 the DT B-NP O
29 1218 1230 20727411 phonological JJ I-NP O
30 1231 1237 20727411 domain NN I-NP O
31 1238 1246 20727411 remained VBD B-VP O
32 1247 1257 20727411 unaffected JJ B-ADJP O
33 1257 1258 20727411 . . O O

1 1259 1267 20727411 Ketamine NN B-NP D007649
2 1268 1271 20727411 led VBD B-VP O
3 1272 1274 20727411 to TO B-PP O
4 1275 1283 20727411 enhanced VBN B-NP O
5 1284 1292 20727411 cortical JJ I-NP O
6 1293 1304 20727411 activations NNS I-NP O
7 1305 1307 20727411 in IN B-PP O
8 1308 1321 20727411 supramarginal JJ B-NP O
9 1322 1325 20727411 and CC I-NP O
10 1326 1333 20727411 frontal JJ I-NP O
11 1334 1339 20727411 brain NN I-NP O
12 1340 1347 20727411 regions NNS I-NP O
13 1348 1351 20727411 for IN B-PP O
14 1352 1364 20727411 phonological JJ B-NP O
15 1365 1368 20727411 and CC I-NP O
16 1369 1376 20727411 lexical JJ I-NP O
17 1377 1383 20727411 verbal JJ I-NP O
18 1384 1391 20727411 fluency NN I-NP O
19 1391 1392 20727411 , , O O
20 1393 1396 20727411 but CC O O
21 1397 1400 20727411 not RB B-PP O
22 1401 1404 20727411 for IN I-PP O
23 1405 1413 20727411 semantic JJ B-NP O
24 1414 1420 20727411 verbal JJ I-NP O
25 1421 1428 20727411 fluency NN I-NP O
26 1428 1429 20727411 . . O O

1 1430 1438 20727411 Ketamine NN B-NP D007649
2 1439 1446 20727411 induces VBZ B-VP O
3 1447 1457 20727411 activation NN B-NP O
4 1458 1465 20727411 changes NNS I-NP O
5 1466 1468 20727411 in IN B-PP O
6 1469 1476 20727411 healthy JJ B-NP O
7 1477 1485 20727411 subjects NNS I-NP O
8 1486 1493 20727411 similar JJ B-ADJP O
9 1494 1496 20727411 to TO B-PP O
10 1497 1502 20727411 those DT B-NP O
11 1503 1511 20727411 observed VBN B-VP O
12 1512 1514 20727411 in IN B-PP O
13 1515 1523 20727411 patients NNS B-NP O
14 1524 1528 20727411 with IN B-PP O
15 1529 1542 20727411 schizophrenia NN B-NP D012559
16 1542 1543 20727411 , , O O
17 1544 1556 20727411 particularly RB B-ADVP O
18 1557 1559 20727411 in IN B-PP O
19 1560 1567 20727411 frontal JJ B-NP O
20 1568 1571 20727411 and CC I-NP O
21 1572 1580 20727411 temporal JJ I-NP O
22 1581 1586 20727411 brain NN I-NP O
23 1587 1594 20727411 regions NNS I-NP O
24 1594 1595 20727411 . . O O

1 1596 1599 20727411 Our PRP$ B-NP O
2 1600 1607 20727411 results NNS I-NP O
3 1608 1615 20727411 provide VBP B-VP O
4 1616 1623 20727411 further JJ B-NP O
5 1624 1631 20727411 support NN I-NP O
6 1632 1635 20727411 for IN B-PP O
7 1636 1639 20727411 the DT B-NP O
8 1640 1650 20727411 hypothesis NN I-NP O
9 1651 1653 20727411 of IN B-PP O
10 1654 1656 20727411 an DT B-NP O
11 1657 1661 20727411 NMDA NN I-NP D016202
12 1662 1670 20727411 receptor NN I-NP O
13 1671 1682 20727411 dysfunction NN I-NP O
14 1683 1685 20727411 in IN B-PP O
15 1686 1689 20727411 the DT B-NP O
16 1690 1705 20727411 pathophysiology NN I-NP O
17 1706 1708 20727411 of IN B-PP O
18 1709 1722 20727411 schizophrenia NN B-NP D012559
19 1722 1723 20727411 . . O O

1 0 0 2819587 -DOCSTART- -X- -X- O

1 0 8 2819587 Magnetic JJ B-NP O
2 9 18 2819587 resonance NN I-NP O
3 19 26 2819587 imaging NN I-NP O
4 27 29 2819587 of IN B-PP O
5 30 38 2819587 cerebral JJ B-NP O
6 39 45 2819587 venous JJ I-NP D020246
7 46 56 2819587 thrombosis NN I-NP D020246
8 57 66 2819587 secondary JJ B-ADJP O
9 67 69 2819587 to TO B-PP O
10 70 71 2819587 " `` O O
11 71 74 2819587 low JJ B-NP O
12 74 75 2819587 - HYPH I-NP O
13 75 79 2819587 dose NN I-NP O
14 79 80 2819587 " '' I-NP O
15 81 86 2819587 birth NN I-NP O
16 87 94 2819587 control NN I-NP O
17 95 100 2819587 pills NNS I-NP O
18 100 101 2819587 . . O O
19 102 105 2819587 The DT B-NP O
20 106 114 2819587 clinical JJ I-NP O
21 115 118 2819587 and CC I-NP O
22 119 131 2819587 radiographic JJ I-NP O
23 132 140 2819587 features NNS I-NP O
24 141 143 2819587 of IN B-PP O
25 144 152 2819587 cerebral JJ B-NP O
26 153 157 2819587 deep JJ I-NP D020246
27 158 164 2819587 venous JJ I-NP D020246
28 165 175 2819587 thrombosis NN I-NP D020246
29 176 178 2819587 in IN B-PP O
30 179 180 2819587 a DT B-NP O
31 181 183 2819587 21 CD I-NP O
32 183 184 2819587 - HYPH I-NP O
33 184 188 2819587 year NN I-NP O
34 188 189 2819587 - HYPH B-NP O
35 189 192 2819587 old JJ I-NP O
36 193 198 2819587 white JJ I-NP O
37 199 204 2819587 woman NN I-NP O
38 205 208 2819587 are VBP B-VP O
39 209 218 2819587 presented VBN I-VP O
40 218 219 2819587 . . O O

1 220 224 2819587 This DT B-NP O
2 225 236 2819587 nulliparous JJ I-NP O
3 237 244 2819587 patient NN I-NP O
4 245 254 2819587 presented VBD B-VP O
5 255 259 2819587 with IN B-PP O
6 260 270 2819587 relatively RB B-NP O
7 271 275 2819587 mild JJ I-NP O
8 276 284 2819587 clinical JJ I-NP O
9 285 293 2819587 symptoms NNS I-NP O
10 294 297 2819587 and CC O O
11 298 309 2819587 progressing VBG B-VP O
12 310 316 2819587 mental JJ B-NP O
13 317 323 2819587 status NN I-NP O
14 324 331 2819587 changes NNS I-NP O
15 331 332 2819587 . . O O

1 333 336 2819587 The DT B-NP O
2 337 341 2819587 only JJ I-NP O
3 342 347 2819587 known VBN I-NP O
4 348 352 2819587 risk NN I-NP O
5 353 359 2819587 factor NN I-NP O
6 360 363 2819587 was VBD B-VP O
7 364 365 2819587 " `` O O
8 365 368 2819587 low JJ B-NP O
9 368 369 2819587 - HYPH I-NP O
10 369 373 2819587 dose NN I-NP O
11 373 374 2819587 " '' O O
12 375 379 2819587 oral JJ B-NP D003276
13 380 393 2819587 contraceptive JJ I-NP D003276
14 394 399 2819587 pills NNS I-NP O
15 399 400 2819587 . . O O

1 401 404 2819587 The DT B-NP O
2 405 413 2819587 magnetic JJ I-NP O
3 414 423 2819587 resonance NN I-NP O
4 424 429 2819587 image NN I-NP O
5 430 431 2819587 ( ( O O
6 431 434 2819587 MRI NN B-NP O
7 434 435 2819587 ) ) O O
8 436 442 2819587 showed VBD B-VP O
9 443 452 2819587 increased VBN B-NP O
10 453 459 2819587 signal NN I-NP O
11 460 469 2819587 intensity NN I-NP O
12 470 474 2819587 from IN B-PP O
13 475 478 2819587 the DT B-NP O
14 479 487 2819587 internal JJ I-NP O
15 488 496 2819587 cerebral JJ I-NP O
16 497 502 2819587 veins NNS I-NP O
17 502 503 2819587 , , O O
18 504 508 2819587 vein NN B-NP O
19 509 511 2819587 of IN B-PP O
20 512 517 2819587 Galen NN B-NP O
21 517 518 2819587 , , O O
22 519 522 2819587 and CC O O
23 523 531 2819587 straight JJ B-NP O
24 532 537 2819587 sinus NN I-NP O
25 537 538 2819587 . . O O

1 539 542 2819587 The DT B-NP O
2 543 552 2819587 diagnosis NN I-NP O
3 553 556 2819587 was VBD B-VP O
4 557 566 2819587 confirmed VBN I-VP O
5 567 569 2819587 by IN B-PP O
6 570 578 2819587 arterial JJ B-NP O
7 579 590 2819587 angiography NN I-NP O
8 590 591 2819587 . . O O

1 0 0 15276120 -DOCSTART- -X- -X- O

1 0 4 15276120 Time NN B-NP O
2 5 11 15276120 trends NNS I-NP O
3 12 14 15276120 in IN B-PP O
4 15 23 15276120 warfarin NN B-NP D014859
5 23 24 15276120 - HYPH B-NP O
6 24 34 15276120 associated VBN I-NP O
7 35 45 15276120 hemorrhage NN I-NP D006470
8 45 46 15276120 . . O O
9 47 50 15276120 The DT B-NP O
10 51 57 15276120 annual JJ I-NP O
11 58 67 15276120 incidence NN I-NP O
12 68 70 15276120 of IN B-PP O
13 71 79 15276120 warfarin NN B-NP D014859
14 79 80 15276120 - HYPH O O
15 80 87 15276120 related VBN B-ADJP O
16 88 96 15276120 bleeding VBG B-VP D006470
17 97 99 15276120 at IN B-PP O
18 100 107 15276120 Brigham NNP B-NP O
19 108 111 15276120 and CC O O
20 112 119 15276120 Women's NNP B-NP O
21 120 128 15276120 Hospital NNP I-NP O
22 129 138 15276120 increased VBD B-VP O
23 139 143 15276120 from IN B-PP O
24 144 148 15276120 0.97 CD B-NP O
25 148 149 15276120 / SYM I-NP O
26 149 154 15276120 1,000 CD I-NP O
27 155 162 15276120 patient NN I-NP O
28 163 173 15276120 admissions NNS I-NP O
29 174 176 15276120 in IN B-PP O
30 177 180 15276120 the DT B-NP O
31 181 186 15276120 first JJ I-NP O
32 187 191 15276120 time NN I-NP O
33 192 198 15276120 period NN I-NP O
34 199 200 15276120 ( ( O O
35 200 207 15276120 January NNP B-NP O
36 208 212 15276120 1995 CD I-NP O
37 213 215 15276120 to TO B-PP O
38 216 223 15276120 October NNP B-NP O
39 224 228 15276120 1998 CD I-NP O
40 228 229 15276120 ) ) O O
41 230 232 15276120 to TO B-PP O
42 233 237 15276120 1.19 CD B-NP O
43 237 238 15276120 / SYM I-NP O
44 238 243 15276120 1,000 CD I-NP O
45 244 251 15276120 patient NN I-NP O
46 252 262 15276120 admissions NNS I-NP O
47 263 265 15276120 in IN B-PP O
48 266 269 15276120 the DT B-NP O
49 270 276 15276120 second JJ I-NP O
50 277 281 15276120 time NN I-NP O
51 282 288 15276120 period NN I-NP O
52 289 290 15276120 ( ( O O
53 290 298 15276120 November NNP B-NP O
54 299 303 15276120 1998 CD I-NP O
55 304 306 15276120 to TO B-PP O
56 307 313 15276120 August NNP B-NP O
57 314 318 15276120 2002 CD I-NP O
58 318 319 15276120 ) ) O O
59 320 322 15276120 of IN B-PP O
60 323 327 15276120 this DT B-NP O
61 328 333 15276120 study NN I-NP O
62 333 334 15276120 . . O O

1 335 338 15276120 The DT B-NP O
2 339 349 15276120 proportion NN I-NP O
3 350 352 15276120 of IN B-PP O
4 353 361 15276120 patients NNS B-NP O
5 362 366 15276120 with IN B-PP O
6 367 372 15276120 major JJ B-NP O
7 373 376 15276120 and CC I-NP O
8 377 389 15276120 intracranial JJ I-NP D020300
9 390 398 15276120 bleeding NN I-NP D020300
10 399 408 15276120 increased VBD B-VP O
11 409 413 15276120 from IN B-PP O
12 414 419 15276120 20.2% CD B-NP O
13 420 423 15276120 and CC I-NP O
14 424 428 15276120 1.9% CD I-NP O
15 428 429 15276120 , , O O
16 430 442 15276120 respectively RB B-ADVP O
17 442 443 15276120 , , O O
18 444 446 15276120 in IN B-PP O
19 447 450 15276120 the DT B-NP O
20 451 456 15276120 first JJ I-NP O
21 457 461 15276120 time NN I-NP O
22 462 468 15276120 period NN I-NP O
23 468 469 15276120 , , O O
24 470 472 15276120 to TO B-PP O
25 473 478 15276120 33.3% CD B-NP O
26 479 482 15276120 and CC I-NP O
27 483 487 15276120 7.8% CD I-NP O
28 487 488 15276120 , , O O
29 489 501 15276120 respectively RB B-ADVP O
30 501 502 15276120 , , O O
31 503 505 15276120 in IN B-PP O
32 506 509 15276120 the DT B-NP O
33 510 516 15276120 second NN I-NP O
34 516 517 15276120 . . O O

1 0 0 9630698 -DOCSTART- -X- -X- O

1 0 12 9630698 Contribution NN B-NP O
2 13 15 9630698 of IN B-PP O
3 16 19 9630698 the DT B-NP O
4 20 27 9630698 glycine NN I-NP D005998
5 28 32 9630698 site NN I-NP O
6 33 35 9630698 of IN B-PP O
7 36 40 9630698 NMDA NN B-NP D016202
8 41 50 9630698 receptors NNS I-NP O
9 51 53 9630698 in IN B-PP O
10 54 61 9630698 rostral JJ B-NP O
11 62 65 9630698 and CC I-NP O
12 66 78 9630698 intermediate JJ I-NP O
13 78 79 9630698 - HYPH I-NP O
14 79 85 9630698 caudal JJ I-NP O
15 86 91 9630698 parts NNS I-NP O
16 92 94 9630698 of IN B-PP O
17 95 98 9630698 the DT B-NP O
18 99 107 9630698 striatum NN I-NP O
19 108 110 9630698 to TO B-PP O
20 111 114 9630698 the DT B-NP O
21 115 125 9630698 regulation NN I-NP O
22 126 128 9630698 of IN B-PP O
23 129 135 9630698 muscle NN B-NP O
24 136 140 9630698 tone NN I-NP O
25 141 143 9630698 in IN B-PP O
26 144 148 9630698 rats NNS B-NP O
27 148 149 9630698 . . O O
28 150 153 9630698 The DT B-NP O
29 154 157 9630698 aim NN I-NP O
30 158 160 9630698 of IN B-PP O
31 161 164 9630698 the DT B-NP O
32 165 172 9630698 present JJ I-NP O
33 173 178 9630698 study NN I-NP O
34 179 182 9630698 was VBD B-VP O
35 183 185 9630698 to TO B-VP O
36 186 192 9630698 assess VB I-VP O
37 193 196 9630698 the DT B-NP O
38 197 209 9630698 contribution NN I-NP O
39 210 212 9630698 of IN B-PP O
40 213 216 9630698 the DT B-NP O
41 217 224 9630698 glycine NN I-NP D005998
42 225 229 9630698 site NN I-NP O
43 230 232 9630698 of IN B-PP O
44 233 237 9630698 NMDA NN B-NP D016202
45 238 247 9630698 receptors NNS I-NP O
46 248 250 9630698 in IN B-PP O
47 251 254 9630698 the DT B-NP O
48 255 263 9630698 striatum NN I-NP O
49 264 266 9630698 to TO B-PP O
50 267 270 9630698 the DT B-NP O
51 271 281 9630698 regulation NN I-NP O
52 282 284 9630698 of IN B-PP O
53 285 291 9630698 muscle NN B-NP O
54 292 296 9630698 tone NN I-NP O
55 296 297 9630698 . . O O

1 298 304 9630698 Muscle NN B-NP O
2 305 309 9630698 tone NN I-NP O
3 310 313 9630698 was VBD B-VP O
4 314 322 9630698 examined VBN I-VP O
5 323 328 9630698 using VBG B-VP O
6 329 330 9630698 a DT B-NP O
7 331 339 9630698 combined JJ I-NP O
8 340 350 9630698 mechanoand NN I-NP O
9 351 368 9630698 electromyographic JJ I-NP O
10 369 375 9630698 method NN I-NP O
11 375 376 9630698 , , O O
12 377 382 9630698 which WDT B-NP O
13 383 391 9630698 measured VBD B-VP O
14 392 406 9630698 simultaneously RB B-ADVP O
15 407 410 9630698 the DT B-NP O
16 411 417 9630698 muscle NN I-NP O
17 418 428 9630698 resistance NN I-NP O
18 429 430 9630698 ( ( O O
19 430 433 9630698 MMG NN B-NP O
20 433 434 9630698 ) ) O O
21 435 437 9630698 of IN B-PP O
22 438 441 9630698 the DT B-NP O
23 442 447 9630698 rat's NNS I-NP O
24 448 452 9630698 hind VBP B-VP O
25 453 457 9630698 foot NN B-NP O
26 458 460 9630698 to TO B-PP O
27 461 468 9630698 passive JJ B-NP O
28 469 478 9630698 extension NN I-NP O
29 479 482 9630698 and CC I-NP O
30 483 490 9630698 flexion NN I-NP O
31 491 493 9630698 in IN B-PP O
32 494 497 9630698 the DT B-NP O
33 498 503 9630698 ankle NN I-NP O
34 504 509 9630698 joint NN I-NP O
35 510 513 9630698 and CC O O
36 514 517 9630698 the DT B-NP O
37 518 535 9630698 electromyographic JJ I-NP O
38 536 544 9630698 activity NN I-NP O
39 545 546 9630698 ( ( O O
40 546 549 9630698 EMG NN B-NP O
41 549 550 9630698 ) ) O O
42 551 553 9630698 of IN B-PP O
43 554 557 9630698 the DT B-NP O
44 558 570 9630698 antagonistic JJ I-NP O
45 571 578 9630698 muscles NNS I-NP O
46 579 581 9630698 of IN B-PP O
47 582 586 9630698 that DT B-NP O
48 587 592 9630698 joint NN I-NP O
49 592 593 9630698 : : O O
50 594 607 9630698 gastrocnemius NN B-NP O
51 608 611 9630698 and CC I-NP O
52 612 620 9630698 tibialis NN I-NP O
53 621 629 9630698 anterior RB B-ADVP O
54 629 630 9630698 . . O O

1 631 637 9630698 Muscle NN B-NP D009127
2 638 646 9630698 rigidity NN I-NP D009127
3 647 650 9630698 was VBD B-VP O
4 651 658 9630698 induced VBN I-VP O
5 659 661 9630698 by IN B-PP O
6 662 673 9630698 haloperidol NN B-NP D006220
7 674 675 9630698 ( ( O O
8 675 678 9630698 2.5 CD B-NP O
9 679 681 9630698 mg NN I-NP O
10 681 682 9630698 / SYM B-NP O
11 682 684 9630698 kg NN I-NP O
12 685 688 9630698 i.p NN I-NP O
13 688 689 9630698 . . O O
14 689 690 9630698 ) ) O O
15 690 691 9630698 . . O O

1 692 695 9630698 5,7 CD B-NP C066192
2 695 696 9630698 - HYPH I-NP C066192
3 696 713 9630698 dichlorokynurenic JJ I-NP C066192
4 714 718 9630698 acid NN I-NP C066192
5 719 720 9630698 ( ( O O
6 720 723 9630698 5,7 CD B-NP C066192
7 723 724 9630698 - HYPH I-NP C066192
8 724 728 9630698 DCKA NN I-NP C066192
9 728 729 9630698 ) ) O O
10 729 730 9630698 , , O O
11 731 732 9630698 a DT B-NP O
12 733 742 9630698 selective JJ I-NP O
13 743 750 9630698 glycine NN I-NP D005998
14 751 755 9630698 site NN I-NP O
15 756 766 9630698 antagonist NN I-NP O
16 766 767 9630698 , , O O
17 768 776 9630698 injected VBN B-VP O
18 777 779 9630698 in IN B-PP O
19 780 785 9630698 doses NNS B-NP O
20 786 788 9630698 of IN B-PP O
21 789 792 9630698 2.5 CD B-NP O
22 793 796 9630698 and CC I-NP O
23 797 800 9630698 4.5 CD I-NP O
24 801 807 9630698 microg NN I-NP O
25 807 808 9630698 / SYM B-NP O
26 808 811 9630698 0.5 CD B-NP O
27 812 818 9630698 microl NN I-NP O
28 819 830 9630698 bilaterally RB B-ADVP O
29 830 831 9630698 , , O O
30 832 836 9630698 into IN B-PP O
31 837 840 9630698 the DT B-NP O
32 841 848 9630698 rostral JJ I-NP O
33 849 855 9630698 region NN I-NP O
34 856 858 9630698 of IN B-PP O
35 859 862 9630698 the DT B-NP O
36 863 871 9630698 striatum NN I-NP O
37 871 872 9630698 , , O O
38 873 882 9630698 decreased VBD B-VP O
39 883 887 9630698 both CC O O
40 888 891 9630698 the DT B-NP O
41 892 903 9630698 haloperidol NN I-NP D006220
42 903 904 9630698 - HYPH B-NP O
43 904 911 9630698 induced VBN I-NP O
44 912 918 9630698 muscle NN I-NP D009127
45 919 927 9630698 rigidity NN I-NP D009127
46 928 929 9630698 ( ( O O
47 929 932 9630698 MMG NN B-NP O
48 932 933 9630698 ) ) O O
49 934 937 9630698 and CC O O
50 938 941 9630698 the DT B-NP O
51 942 950 9630698 enhanced VBN I-NP O
52 951 968 9630698 electromyographic JJ I-NP O
53 969 977 9630698 activity NN I-NP O
54 978 979 9630698 ( ( O O
55 979 982 9630698 EMG NN B-NP O
56 982 983 9630698 ) ) O O
57 983 984 9630698 . . O O
58 985 988 9630698 5,7 CD B-NP C066192
59 988 989 9630698 - HYPH I-NP C066192
60 989 993 9630698 DCKA NN I-NP C066192
61 994 1002 9630698 injected VBN B-VP O
62 1003 1014 9630698 bilaterally RB B-ADVP O
63 1015 1017 9630698 in IN B-PP O
64 1018 1019 9630698 a DT B-NP O
65 1020 1024 9630698 dose NN I-NP O
66 1025 1027 9630698 of IN B-PP O
67 1028 1031 9630698 4.5 CD B-NP O
68 1032 1038 9630698 microg NN I-NP O
69 1038 1039 9630698 / SYM B-NP O
70 1039 1042 9630698 0.5 CD B-NP O
71 1043 1049 9630698 microl NN I-NP O
72 1050 1054 9630698 into IN B-PP O
73 1055 1058 9630698 the DT B-NP O
74 1059 1071 9630698 intermediate JJ I-NP O
75 1071 1072 9630698 - HYPH I-NP O
76 1072 1078 9630698 caudal JJ I-NP O
77 1079 1085 9630698 region NN I-NP O
78 1086 1088 9630698 of IN B-PP O
79 1089 1092 9630698 the DT B-NP O
80 1093 1101 9630698 striatum NN I-NP O
81 1102 1104 9630698 of IN B-PP O
82 1105 1109 9630698 rats NNS B-NP O
83 1110 1113 9630698 not RB B-VP O
84 1114 1124 9630698 pretreated VBN I-VP O
85 1125 1129 9630698 with IN B-PP O
86 1130 1141 9630698 haloperidol NN B-NP D006220
87 1142 1145 9630698 had VBD B-VP O
88 1146 1148 9630698 no DT B-NP O
89 1149 1155 9630698 effect NN I-NP O
90 1156 1158 9630698 on IN B-PP O
91 1159 1162 9630698 the DT B-NP O
92 1163 1169 9630698 muscle NN I-NP O
93 1170 1174 9630698 tone NN I-NP O
94 1174 1175 9630698 . . O O

1 1176 1179 9630698 The DT B-NP O
2 1180 1187 9630698 present JJ I-NP O
3 1188 1195 9630698 results NNS I-NP O
4 1196 1203 9630698 suggest VBP B-VP O
5 1204 1208 9630698 that IN B-SBAR O
6 1209 1217 9630698 blockade NN B-NP O
7 1218 1220 9630698 of IN B-PP O
8 1221 1224 9630698 the DT B-NP O
9 1225 1232 9630698 glycine NN I-NP D005998
10 1233 1237 9630698 site NN I-NP O
11 1238 1240 9630698 of IN B-PP O
12 1241 1245 9630698 NMDA NN B-NP D016202
13 1246 1255 9630698 receptors NNS I-NP O
14 1256 1258 9630698 in IN B-PP O
15 1259 1262 9630698 the DT B-NP O
16 1263 1270 9630698 rostral JJ I-NP O
17 1271 1275 9630698 part NN I-NP O
18 1276 1278 9630698 of IN B-PP O
19 1279 1282 9630698 the DT B-NP O
20 1283 1291 9630698 striatum NN I-NP O
21 1292 1295 9630698 may MD B-VP O
22 1296 1298 9630698 be VB I-VP O
23 1299 1305 9630698 mainly RB B-ADJP O
24 1306 1317 9630698 responsible JJ I-ADJP O
25 1318 1321 9630698 for IN B-PP O
26 1322 1325 9630698 the DT B-NP O
27 1326 1342 9630698 antiparkinsonian JJ I-NP O
28 1343 1349 9630698 action NN I-NP O
29 1350 1352 9630698 of IN B-PP O
30 1353 1357 9630698 this DT B-NP O
31 1358 1362 9630698 drug NN I-NP O
32 1362 1363 9630698 . . O O

1 0 0 8841157 -DOCSTART- -X- -X- O

1 0 9 8841157 Valsartan NNP B-NP C081489
2 9 10 8841157 , , O O
3 11 12 8841157 a DT B-NP O
4 13 16 8841157 new JJ I-NP O
5 17 28 8841157 angiotensin NN I-NP D000804
6 29 31 8841157 II CD I-NP D000804
7 32 42 8841157 antagonist NN I-NP O
8 43 46 8841157 for IN B-PP O
9 47 50 8841157 the DT B-NP O
10 51 60 8841157 treatment NN I-NP O
11 61 63 8841157 of IN B-PP O
12 64 73 8841157 essential JJ B-NP O
13 74 86 8841157 hypertension NN I-NP D006973
14 86 87 8841157 : : O O
15 88 89 8841157 a DT B-NP O
16 90 101 8841157 comparative JJ I-NP O
17 102 107 8841157 study NN I-NP O
18 108 110 8841157 of IN B-PP O
19 111 114 8841157 the DT B-NP O
20 115 123 8841157 efficacy NN I-NP O
21 124 127 8841157 and CC I-NP O
22 128 134 8841157 safety NN I-NP O
23 135 142 8841157 against IN B-PP O
24 143 153 8841157 amlodipine NN B-NP D017311
25 153 154 8841157 . . O O
26 155 164 8841157 OBJECTIVE NN B-NP O
27 164 165 8841157 : : O O
28 166 168 8841157 To TO B-VP O
29 169 176 8841157 compare VB I-VP O
30 177 180 8841157 the DT B-NP O
31 181 197 8841157 antihypertensive JJ I-NP O
32 198 206 8841157 efficacy NN I-NP O
33 207 209 8841157 of IN B-PP O
34 210 211 8841157 a DT B-NP O
35 212 215 8841157 new JJ I-NP O
36 216 227 8841157 angiotensin NN I-NP D000804
37 228 230 8841157 II CD I-NP D000804
38 231 241 8841157 antagonist NN I-NP O
39 241 242 8841157 , , O O
40 243 252 8841157 valsartan NN B-NP C081489
41 252 253 8841157 , , O O
42 254 258 8841157 with IN B-PP O
43 259 260 8841157 a DT B-NP O
44 261 270 8841157 reference NN I-NP O
45 271 278 8841157 therapy NN I-NP O
46 278 279 8841157 , , O O
47 280 290 8841157 amlodipine NN B-NP D017311
48 290 291 8841157 . . O O

1 292 299 8841157 METHODS NNS B-NP O
2 299 300 8841157 : : O O
3 301 304 8841157 One CD B-NP O
4 305 312 8841157 hundred CD I-NP O
5 313 318 8841157 sixty CD I-NP O
6 318 319 8841157 - HYPH B-NP O
7 319 324 8841157 eight CD I-NP O
8 325 330 8841157 adult JJ I-NP O
9 331 342 8841157 outpatients NNS I-NP O
10 343 347 8841157 with IN B-PP O
11 348 352 8841157 mild JJ B-ADJP O
12 353 355 8841157 to TO B-PP O
13 356 364 8841157 moderate JJ B-NP O
14 365 377 8841157 hypertension NN I-NP D006973
15 378 382 8841157 were VBD B-VP O
16 383 391 8841157 randomly RB I-VP O
17 392 401 8841157 allocated VBN I-VP O
18 402 404 8841157 in IN B-PP O
19 405 411 8841157 double JJ B-NP O
20 411 412 8841157 - HYPH I-NP O
21 412 417 8841157 blind JJ I-NP O
22 418 425 8841157 fashion NN I-NP O
23 426 429 8841157 and CC I-NP O
24 430 435 8841157 equal JJ I-NP O
25 436 442 8841157 number NN I-NP O
26 443 445 8841157 to TO B-VP O
27 446 453 8841157 receive VB I-VP O
28 454 456 8841157 80 CD B-NP O
29 457 459 8841157 mg NN I-NP O
30 460 469 8841157 valsartan NN I-NP C081489
31 470 472 8841157 or CC O O
32 473 474 8841157 5 CD B-NP O
33 475 477 8841157 mg NN I-NP O
34 478 488 8841157 amlodipine NN I-NP D017311
35 489 492 8841157 for IN B-PP O
36 493 495 8841157 12 CD B-NP O
37 496 501 8841157 weeks NNS I-NP O
38 501 502 8841157 . . O O

1 503 508 8841157 After IN B-PP O
2 509 510 8841157 8 CD B-NP O
3 511 516 8841157 weeks NNS I-NP O
4 517 519 8841157 of IN B-PP O
5 520 527 8841157 therapy NN B-NP O
6 527 528 8841157 , , O O
7 529 531 8841157 in IN B-PP O
8 532 540 8841157 patients NNS B-NP O
9 541 546 8841157 whose WP$ B-NP O
10 547 552 8841157 blood NN I-NP O
11 553 561 8841157 pressure NN I-NP O
12 562 570 8841157 remained VBD B-VP O
13 571 583 8841157 uncontrolled JJ B-ADJP O
14 583 584 8841157 , , O O
15 585 586 8841157 5 CD B-NP O
16 587 589 8841157 mg NN I-NP O
17 590 600 8841157 amlodipine NN I-NP D017311
18 601 604 8841157 was VBD B-VP O
19 605 610 8841157 added VBN I-VP O
20 611 613 8841157 to TO B-PP O
21 614 617 8841157 the DT B-NP O
22 618 625 8841157 initial JJ I-NP O
23 626 633 8841157 therapy NN I-NP O
24 633 634 8841157 . . O O

1 635 643 8841157 Patients NNS B-NP O
2 644 648 8841157 were VBD B-VP O
3 649 657 8841157 assessed VBN I-VP O
4 658 660 8841157 at IN B-PP O
5 661 662 8841157 4 CD B-NP O
6 662 663 8841157 , , I-NP O
7 664 665 8841157 8 CD I-NP O
8 665 666 8841157 , , O O
9 667 670 8841157 and CC O O
10 671 673 8841157 12 CD B-NP O
11 674 679 8841157 weeks NNS I-NP O
12 679 680 8841157 . . O O

1 681 684 8841157 The DT B-NP O
2 685 692 8841157 primary JJ I-NP O
3 693 701 8841157 efficacy NN I-NP O
4 702 710 8841157 variable NN I-NP O
5 711 714 8841157 was VBD B-VP O
6 715 721 8841157 change NN B-NP O
7 722 726 8841157 from IN B-PP O
8 727 735 8841157 baseline NN B-NP O
9 736 738 8841157 in IN B-PP O
10 739 743 8841157 mean JJ B-NP O
11 744 751 8841157 sitting VBG I-NP O
12 752 761 8841157 diastolic JJ I-NP O
13 762 767 8841157 blood NN I-NP O
14 768 776 8841157 pressure NN I-NP O
15 777 779 8841157 at IN B-PP O
16 780 781 8841157 8 CD B-NP O
17 782 787 8841157 weeks NNS I-NP O
18 787 788 8841157 . . O O

1 789 798 8841157 Secondary JJ B-NP O
2 799 808 8841157 variables NNS I-NP O
3 809 817 8841157 included VBD B-VP O
4 818 824 8841157 change NN B-NP O
5 825 827 8841157 in IN B-PP O
6 828 835 8841157 sitting VBG B-VP O
7 836 844 8841157 systolic JJ B-NP O
8 845 850 8841157 blood NN I-NP O
9 851 859 8841157 pressure NN I-NP O
10 860 863 8841157 and CC I-NP O
11 864 873 8841157 responder NN I-NP O
12 874 879 8841157 rates NNS I-NP O
13 879 880 8841157 . . O O

1 881 888 8841157 RESULTS NNS B-NP O
2 888 889 8841157 : : O O
3 890 894 8841157 Both CC O O
4 895 904 8841157 valsartan NN B-NP C081489
5 905 908 8841157 and CC I-NP O
6 909 919 8841157 amlodipine NN I-NP D017311
7 920 924 8841157 were VBD B-VP O
8 925 934 8841157 effective JJ B-ADJP O
9 935 937 8841157 at IN B-PP O
10 938 946 8841157 lowering VBG B-VP O
11 947 952 8841157 blood NN B-NP O
12 953 961 8841157 pressure NN I-NP O
13 962 964 8841157 at IN B-PP O
14 965 966 8841157 4 CD B-NP O
15 966 967 8841157 , , I-NP O
16 968 969 8841157 8 CD I-NP O
17 969 970 8841157 , , O O
18 971 974 8841157 and CC O O
19 975 977 8841157 12 CD B-NP O
20 978 983 8841157 weeks NNS I-NP O
21 983 984 8841157 . . O O

1 985 992 8841157 Similar JJ B-NP O
2 993 1002 8841157 decreases NNS I-NP O
3 1003 1007 8841157 were VBD B-VP O
4 1008 1016 8841157 observed VBN I-VP O
5 1017 1019 8841157 in IN B-PP O
6 1020 1024 8841157 both DT B-NP O
7 1025 1031 8841157 groups NNS I-NP O
8 1031 1032 8841157 , , O O
9 1033 1037 8841157 with IN B-PP O
10 1038 1040 8841157 no DT B-NP O
11 1041 1054 8841157 statistically RB I-NP O
12 1055 1066 8841157 significant JJ I-NP O
13 1067 1078 8841157 differences NNS I-NP O
14 1079 1086 8841157 between IN B-PP O
15 1087 1090 8841157 the DT B-NP O
16 1091 1097 8841157 groups NNS I-NP O
17 1098 1101 8841157 for IN B-PP O
18 1102 1105 8841157 any DT B-NP O
19 1106 1114 8841157 variable JJ I-NP O
20 1115 1123 8841157 analyzed VBN I-NP O
21 1123 1124 8841157 . . O O

1 1125 1128 8841157 For IN B-PP O
2 1129 1132 8841157 the DT B-NP O
3 1133 1140 8841157 primary JJ I-NP O
4 1141 1149 8841157 variable JJ I-NP O
5 1150 1153 8841157 the DT B-NP O
6 1154 1164 8841157 difference NN I-NP O
7 1165 1168 8841157 was VBD B-VP O
8 1169 1172 8841157 0.5 CD B-NP O
9 1173 1175 8841157 mm NN I-NP O
10 1176 1178 8841157 Hg NN I-NP O
11 1179 1181 8841157 in IN B-PP O
12 1182 1187 8841157 favor NN B-NP O
13 1188 1190 8841157 of IN B-PP O
14 1191 1200 8841157 valsartan NN B-NP C081489
15 1201 1202 8841157 ( ( O O
16 1202 1203 8841157 p NN B-NP O
17 1204 1205 8841157 = SYM B-VP O
18 1206 1210 8841157 0.68 CD B-NP O
19 1210 1211 8841157 ; : O O
20 1212 1215 8841157 95% CD B-NP O
21 1216 1226 8841157 confidence NN I-NP O
22 1227 1235 8841157 interval NN I-NP O
23 1235 1236 8841157 , , O O
24 1237 1238 8841157 - SYM B-NP O
25 1238 1241 8841157 2.7 CD B-NP O
26 1242 1244 8841157 to TO B-PP O
27 1245 1248 8841157 1.7 CD B-NP O
28 1248 1249 8841157 ) ) O O
29 1249 1250 8841157 . . O O

1 1251 1260 8841157 Responder NN B-NP O
2 1261 1266 8841157 rates NNS I-NP O
3 1267 1269 8841157 at IN B-PP O
4 1270 1271 8841157 8 CD B-NP O
5 1272 1277 8841157 weeks NNS I-NP O
6 1278 1282 8841157 were VBD B-VP O
7 1283 1288 8841157 66.7% CD B-NP O
8 1289 1292 8841157 for IN B-PP O
9 1293 1302 8841157 valsartan NN B-NP C081489
10 1303 1306 8841157 and CC I-NP O
11 1307 1312 8841157 60.2% NN I-NP O
12 1313 1316 8841157 for IN B-PP O
13 1317 1327 8841157 amlodipine NN B-NP D017311
14 1328 1329 8841157 ( ( O O
15 1329 1330 8841157 p NN B-NP O
16 1331 1332 8841157 = SYM B-VP O
17 1333 1337 8841157 0.39 CD B-NP O
18 1337 1338 8841157 ) ) O O
19 1338 1339 8841157 . . O O

1 1340 1344 8841157 Both DT B-NP O
2 1345 1355 8841157 treatments NNS I-NP O
3 1356 1360 8841157 were VBD B-VP O
4 1361 1365 8841157 well RB I-VP O
5 1366 1375 8841157 tolerated VBN I-VP O
6 1375 1376 8841157 . . O O

1 1377 1380 8841157 The DT B-NP O
2 1381 1390 8841157 incidence NN I-NP O
3 1391 1393 8841157 of IN B-PP O
4 1394 1398 8841157 drug NN B-NP O
5 1398 1399 8841157 - HYPH O O
6 1399 1406 8841157 related VBN B-NP O
7 1407 1416 8841157 dependent JJ I-NP O
8 1417 1422 8841157 edema NN I-NP D004487
9 1423 1426 8841157 was VBD B-VP O
10 1427 1435 8841157 somewhat RB B-ADJP O
11 1436 1442 8841157 higher JJR I-ADJP O
12 1443 1445 8841157 in IN B-PP O
13 1446 1449 8841157 the DT B-NP O
14 1450 1460 8841157 amlodipine NN I-NP D017311
15 1461 1466 8841157 group NN I-NP O
16 1466 1467 8841157 , , O O
17 1468 1480 8841157 particularly RB B-ADVP O
18 1481 1483 8841157 at IN B-PP O
19 1484 1485 8841157 a DT B-NP O
20 1486 1490 8841157 dose NN I-NP O
21 1491 1493 8841157 of IN B-PP O
22 1494 1496 8841157 10 CD B-NP O
23 1497 1499 8841157 mg NN I-NP O
24 1500 1503 8841157 per IN B-PP O
25 1504 1507 8841157 day NN B-NP O
26 1508 1509 8841157 ( ( O O
27 1509 1513 8841157 2.4% CD B-NP O
28 1514 1517 8841157 for IN B-PP O
29 1518 1520 8841157 80 CD B-NP O
30 1521 1523 8841157 mg NN I-NP O
31 1524 1533 8841157 valsartan NN I-NP C081489
32 1533 1534 8841157 ; : O O
33 1535 1539 8841157 3.6% CD B-NP O
34 1540 1543 8841157 for IN B-PP O
35 1544 1545 8841157 5 CD B-NP O
36 1546 1548 8841157 mg NN I-NP O
37 1549 1559 8841157 amlodipine NN I-NP D017311
38 1559 1560 8841157 ; : O O
39 1561 1563 8841157 0% NN B-NP O
40 1564 1567 8841157 for IN B-PP O
41 1568 1577 8841157 valsartan NN B-NP C081489
42 1578 1582 8841157 plus CC O O
43 1583 1584 8841157 5 CD B-NP O
44 1585 1587 8841157 mg NN I-NP O
45 1588 1598 8841157 amlodipine NN I-NP D017311
46 1598 1599 8841157 ; : O O
47 1600 1605 8841157 14.3% CD B-NP O
48 1606 1609 8841157 for IN B-PP O
49 1610 1612 8841157 10 CD B-NP O
50 1613 1615 8841157 mg NN I-NP O
51 1616 1626 8841157 amlodipine NN I-NP D017311
52 1626 1627 8841157 ) ) O O
53 1627 1628 8841157 . . O O

1 1629 1640 8841157 CONCLUSIONS NNS B-NP O
2 1640 1641 8841157 : : O O
3 1642 1645 8841157 The DT B-NP O
4 1646 1650 8841157 data NNS I-NP O
5 1651 1655 8841157 show VBP B-VP O
6 1656 1660 8841157 that IN B-SBAR O
7 1661 1670 8841157 valsartan NN B-NP C081489
8 1671 1673 8841157 is VBZ B-VP O
9 1674 1676 8841157 at IN B-ADVP O
10 1677 1682 8841157 least JJS I-ADVP O
11 1683 1685 8841157 as RB B-ADJP O
12 1686 1695 8841157 effective JJ I-ADJP O
13 1696 1698 8841157 as IN B-PP O
14 1699 1709 8841157 amlodipine NN B-NP D017311
15 1710 1712 8841157 in IN B-PP O
16 1713 1716 8841157 the DT B-NP O
17 1717 1726 8841157 treatment NN I-NP O
18 1727 1729 8841157 of IN B-PP O
19 1730 1734 8841157 mild JJ B-NP O
20 1735 1737 8841157 to TO B-PP O
21 1738 1746 8841157 moderate JJ B-NP O
22 1747 1759 8841157 hypertension NN I-NP D006973
23 1759 1760 8841157 . . O O

1 1761 1764 8841157 The DT B-NP O
2 1765 1772 8841157 results NNS I-NP O
3 1773 1777 8841157 also RB B-ADVP O
4 1778 1782 8841157 show VBP B-VP O
5 1783 1792 8841157 valsartan NN B-NP C081489
6 1793 1795 8841157 to TO B-VP O
7 1796 1798 8841157 be VB I-VP O
8 1799 1803 8841157 well RB I-VP O
9 1804 1813 8841157 tolerated VBN I-VP O
10 1814 1817 8841157 and CC O O
11 1818 1825 8841157 suggest VBP B-VP O
12 1826 1830 8841157 that IN B-SBAR O
13 1831 1833 8841157 it PRP B-NP O
14 1834 1836 8841157 is VBZ B-VP O
15 1837 1840 8841157 not RB I-VP O
16 1841 1851 8841157 associated VBN I-VP O
17 1852 1856 8841157 with IN B-PP O
18 1857 1861 8841157 side NN B-NP O
19 1862 1869 8841157 effects NNS I-NP O
20 1870 1884 8841157 characteristic JJ B-ADJP O
21 1885 1887 8841157 of IN B-PP O
22 1888 1892 8841157 this DT B-NP O
23 1893 1903 8841157 comparator NN I-NP O
24 1904 1909 8841157 class NN I-NP O
25 1909 1910 8841157 , , O O
26 1911 1926 8841157 dihydropyridine NN B-NP C038806
27 1927 1934 8841157 calcium NN I-NP D002118
28 1935 1946 8841157 antagonists NNS I-NP O
29 1946 1947 8841157 . . O O

1 0 0 9564988 -DOCSTART- -X- -X- O

1 0 4 9564988 Open JJ B-NP O
2 4 5 9564988 - HYPH I-NP O
3 5 10 9564988 label NN I-NP O
4 11 21 9564988 assessment NN I-NP O
5 22 24 9564988 of IN B-PP O
6 25 37 9564988 levofloxacin NN B-NP D064704
7 38 41 9564988 for IN B-PP O
8 42 45 9564988 the DT B-NP O
9 46 55 9564988 treatment NN I-NP O
10 56 58 9564988 of IN B-PP O
11 59 64 9564988 acute JJ B-NP O
12 65 74 9564988 bacterial JJ I-NP O
13 75 84 9564988 sinusitis NN I-NP D012852
14 85 87 9564988 in IN B-PP O
15 88 94 9564988 adults NNS B-NP O
16 94 95 9564988 . . O O
17 96 103 9564988 PURPOSE NN B-NP O
18 103 104 9564988 : : O O
19 105 107 9564988 To TO B-VP O
20 108 116 9564988 evaluate VB I-VP O
21 117 120 9564988 the DT B-NP O
22 121 129 9564988 efficacy NN I-NP O
23 130 133 9564988 and CC I-NP O
24 134 140 9564988 safety NN I-NP O
25 141 143 9564988 of IN B-PP O
26 144 156 9564988 levofloxacin NN B-NP D064704
27 157 158 9564988 ( ( O O
28 158 161 9564988 500 CD B-NP O
29 162 164 9564988 mg NN I-NP O
30 165 171 9564988 orally RB B-ADJP O
31 172 176 9564988 once RB I-ADJP O
32 177 182 9564988 daily JJ I-ADJP O
33 183 186 9564988 for IN B-PP O
34 187 189 9564988 10 CD B-NP O
35 190 192 9564988 to TO I-NP O
36 193 195 9564988 14 CD I-NP O
37 196 200 9564988 days NNS I-NP O
38 200 201 9564988 ) ) O O
39 202 204 9564988 in IN B-PP O
40 205 213 9564988 treating VBG B-VP O
41 214 219 9564988 adult JJ B-NP O
42 220 231 9564988 outpatients NNS I-NP O
43 232 236 9564988 with IN B-PP O
44 237 242 9564988 acute JJ B-NP O
45 243 252 9564988 bacterial JJ I-NP O
46 253 262 9564988 sinusitis NN I-NP D012852
47 262 263 9564988 . . O O

1 264 272 9564988 PATIENTS NNS B-NP O
2 273 276 9564988 AND CC I-NP O
3 277 284 9564988 METHODS NNS I-NP O
4 284 285 9564988 : : O O
5 286 287 9564988 A DT B-NP O
6 288 293 9564988 total NN I-NP O
7 294 296 9564988 of IN B-PP O
8 297 300 9564988 329 CD B-NP O
9 301 309 9564988 patients NNS I-NP O
10 310 318 9564988 enrolled VBN B-VP O
11 319 321 9564988 in IN B-PP O
12 322 325 9564988 the DT B-NP O
13 326 331 9564988 study NN I-NP O
14 332 334 9564988 at IN B-PP O
15 335 337 9564988 24 CD B-NP O
16 338 345 9564988 centers NNS I-NP O
17 345 346 9564988 . . O O

1 347 350 9564988 All DT B-NP O
2 351 359 9564988 patients NNS I-NP O
3 360 363 9564988 had VBD B-VP O
4 364 365 9564988 a DT B-NP O
5 366 369 9564988 pre AFX I-NP O
6 369 370 9564988 - HYPH I-NP O
7 370 377 9564988 therapy NN I-NP O
8 378 384 9564988 Gram's NNS I-NP O
9 385 390 9564988 stain NN I-NP O
10 391 394 9564988 and CC I-NP O
11 395 402 9564988 culture NN I-NP O
12 403 405 9564988 of IN B-PP O
13 406 411 9564988 sinus NN B-NP O
14 412 419 9564988 exudate NN I-NP O
15 420 428 9564988 obtained VBN B-VP O
16 429 431 9564988 by IN B-PP O
17 432 438 9564988 antral JJ B-NP O
18 439 447 9564988 puncture NN I-NP O
19 448 450 9564988 or CC O O
20 451 456 9564988 nasal JJ B-NP O
21 457 466 9564988 endoscopy NN I-NP O
22 466 467 9564988 . . O O

1 468 476 9564988 Clinical JJ B-NP O
2 477 485 9564988 response NN I-NP O
3 486 489 9564988 was VBD B-VP O
4 490 498 9564988 assessed VBN I-VP O
5 499 501 9564988 on IN B-PP O
6 502 505 9564988 the DT B-NP O
7 506 511 9564988 basis NN I-NP O
8 512 514 9564988 of IN B-PP O
9 515 520 9564988 signs NNS B-NP O
10 521 524 9564988 and CC I-NP O
11 525 533 9564988 symptoms NNS I-NP O
12 534 537 9564988 and CC O O
13 538 543 9564988 sinus NN B-NP O
14 544 554 9564988 radiograph NN I-NP O
15 555 557 9564988 or CC O O
16 558 566 9564988 computed VBN B-NP O
17 567 577 9564988 tomography NN I-NP O
18 578 585 9564988 results NNS I-NP O
19 585 586 9564988 . . O O

1 587 600 9564988 Microbiologic JJ B-NP O
2 601 605 9564988 cure NN I-NP O
3 606 611 9564988 rates NNS I-NP O
4 612 616 9564988 were VBD B-VP O
5 617 627 9564988 determined VBN I-VP O
6 628 630 9564988 on IN B-PP O
7 631 634 9564988 the DT B-NP O
8 635 640 9564988 basis NN I-NP O
9 641 643 9564988 of IN B-PP O
10 644 652 9564988 presumed VBN B-NP O
11 653 657 9564988 plus CC I-NP O
12 658 668 9564988 documented VBN I-NP O
13 669 680 9564988 eradication NN I-NP O
14 681 683 9564988 of IN B-PP O
15 684 687 9564988 the DT B-NP O
16 688 691 9564988 pre AFX I-NP O
17 691 692 9564988 - HYPH I-NP O
18 692 699 9564988 therapy NN I-NP O
19 700 708 9564988 pathogen NN I-NP O
20 708 709 9564988 ( ( I-NP O
21 709 710 9564988 s NNS I-NP O
22 710 711 9564988 ) ) O O
23 711 712 9564988 . . O O

1 713 720 9564988 RESULTS NNS B-NP O
2 720 721 9564988 : : O O
3 722 725 9564988 The DT B-NP O
4 726 730 9564988 most RBS I-NP O
5 731 737 9564988 common JJ I-NP O
6 738 747 9564988 pathogens NNS I-NP O
7 748 752 9564988 were VBD B-VP O
8 753 764 9564988 Haemophilus NNP B-NP O
9 765 775 9564988 influenzae NNP I-NP O
10 775 776 9564988 , , O O
11 777 790 9564988 Streptococcus NNP B-NP O
12 791 801 9564988 pneumoniae NNP I-NP O
13 801 802 9564988 , , O O
14 803 817 9564988 Staphylococcus NNP B-NP O
15 818 824 9564988 aureus NNP I-NP O
16 824 825 9564988 , , O O
17 826 829 9564988 and CC O O
18 830 839 9564988 Moraxella NNP B-NP O
19 840 851 9564988 catarrhalis NN I-NP O
20 851 852 9564988 . . O O

1 853 855 9564988 Of IN B-PP O
2 856 859 9564988 300 CD B-NP O
3 860 870 9564988 clinically RB I-NP O
4 871 880 9564988 evaluable JJ I-NP O
5 881 889 9564988 patients NNS I-NP O
6 889 890 9564988 , , O O
7 891 894 9564988 175 CD B-NP O
8 895 896 9564988 ( ( O O
9 896 899 9564988 58% NN B-NP O
10 899 900 9564988 ) ) O O
11 901 905 9564988 were VBD B-VP O
12 906 911 9564988 cured VBN I-VP O
13 912 915 9564988 and CC O O
14 916 918 9564988 90 CD B-NP O
15 919 920 9564988 ( ( O O
16 920 923 9564988 30% CD B-NP O
17 923 924 9564988 ) ) O O
18 925 929 9564988 were VBD B-VP O
19 930 938 9564988 improved VBN I-VP O
20 939 941 9564988 at IN B-PP O
21 942 945 9564988 the DT B-NP O
22 946 950 9564988 post AFX I-NP O
23 950 951 9564988 - HYPH I-NP O
24 951 958 9564988 therapy NN I-NP O
25 959 969 9564988 evaluation NN I-NP O
26 969 970 9564988 , , O O
27 971 980 9564988 resulting VBG B-VP O
28 981 983 9564988 in IN B-PP O
29 984 985 9564988 a DT B-NP O
30 986 994 9564988 clinical JJ I-NP O
31 995 1002 9564988 success NN I-NP O
32 1003 1007 9564988 rate NN I-NP O
33 1008 1010 9564988 of IN B-PP O
34 1011 1014 9564988 88% NN B-NP O
35 1014 1015 9564988 . . O O

1 1016 1022 9564988 Thirty CD B-NP O
2 1022 1023 9564988 - HYPH I-NP O
3 1023 1027 9564988 five CD B-NP O
4 1028 1036 9564988 patients NNS I-NP O
5 1037 1038 9564988 ( ( B-LST O
6 1038 1041 9564988 12% LS I-LST O
7 1041 1042 9564988 ) ) O O
8 1043 1053 9564988 clinically RB B-ADVP O
9 1054 1060 9564988 failed VBD B-VP O
10 1061 1070 9564988 treatment NN B-NP O
11 1070 1071 9564988 . . O O

1 1072 1075 9564988 The DT B-NP O
2 1076 1089 9564988 microbiologic JJ I-NP O
3 1090 1101 9564988 eradication NN I-NP O
4 1102 1106 9564988 rate NN I-NP O
5 1107 1108 9564988 ( ( O O
6 1108 1116 9564988 presumed VBN B-VP O
7 1117 1121 9564988 plus CC I-VP O
8 1122 1132 9564988 documented VBN I-VP O
9 1132 1133 9564988 ) ) O O
10 1134 1139 9564988 among IN B-PP O
11 1140 1143 9564988 138 CD B-NP O
12 1144 1161 9564988 microbiologically RB I-NP O
13 1162 1171 9564988 evaluable JJ I-NP O
14 1172 1180 9564988 patients NNS I-NP O
15 1181 1184 9564988 was VBD B-VP O
16 1185 1188 9564988 92% CD B-NP O
17 1188 1189 9564988 . . O O

1 1190 1203 9564988 Microbiologic JJ B-NP O
2 1204 1215 9564988 eradication NN I-NP O
3 1216 1221 9564988 rates NNS I-NP O
4 1222 1223 9564988 ( ( O O
5 1223 1231 9564988 presumed VBN B-VP O
6 1232 1236 9564988 plus CC I-VP O
7 1237 1247 9564988 documented VBN I-VP O
8 1247 1248 9564988 ) ) O O
9 1249 1251 9564988 of IN B-PP O
10 1252 1255 9564988 the DT B-NP O
11 1256 1260 9564988 most RBS I-NP O
12 1261 1267 9564988 common JJ I-NP O
13 1268 1277 9564988 pathogens NNS I-NP O
14 1278 1284 9564988 ranged VBD B-VP O
15 1285 1289 9564988 from IN B-PP O
16 1290 1293 9564988 93% CD B-NP O
17 1294 1295 9564988 ( ( O O
18 1295 1296 9564988 M NN B-NP O
19 1296 1297 9564988 . . O O
20 1298 1309 9564988 catarrhalis '' O O
21 1309 1310 9564988 ) ) O O
22 1311 1313 9564988 to TO B-PP O
23 1314 1318 9564988 100% CD B-NP O
24 1319 1320 9564988 ( ( O O
25 1320 1321 9564988 S NN B-NP O
26 1321 1322 9564988 . . O O
27 1323 1333 9564988 pneumoniae FW O O
28 1333 1334 9564988 ) ) O O
29 1335 1337 9564988 at IN B-PP O
30 1338 1341 9564988 the DT B-NP O
31 1342 1346 9564988 post AFX I-NP O
32 1346 1347 9564988 - HYPH I-NP O
33 1347 1354 9564988 therapy NN I-NP O
34 1355 1360 9564988 visit NN I-NP O
35 1360 1361 9564988 . . O O

1 1362 1365 9564988 All DT B-NP O
2 1366 1369 9564988 but IN B-PP O
3 1370 1373 9564988 one CD B-NP O
4 1374 1376 9564988 of IN B-PP O
5 1377 1380 9564988 the DT B-NP O
6 1381 1384 9564988 265 CD I-NP O
7 1385 1393 9564988 patients NNS I-NP O
8 1394 1397 9564988 who WP B-NP O
9 1398 1402 9564988 were VBD B-VP O
10 1403 1408 9564988 cured VBN I-VP O
11 1409 1411 9564988 or CC I-VP O
12 1412 1420 9564988 improved VBN I-VP O
13 1421 1423 9564988 at IN B-PP O
14 1424 1428 9564988 post AFX B-NP O
15 1428 1429 9564988 - HYPH I-NP O
16 1429 1436 9564988 therapy NN I-NP O
17 1437 1445 9564988 returned VBN B-VP O
18 1446 1449 9564988 for IN B-PP O
19 1450 1451 9564988 a DT B-NP O
20 1452 1456 9564988 long JJ I-NP O
21 1456 1457 9564988 - HYPH I-NP O
22 1457 1461 9564988 term NN I-NP O
23 1462 1468 9564988 follow VB B-VP O
24 1468 1469 9564988 - HYPH O O
25 1469 1471 9564988 up RP B-PRT O
26 1472 1477 9564988 visit NN B-NP O
27 1477 1478 9564988 ; : O O
28 1479 1482 9564988 243 CD B-NP O
29 1483 1484 9564988 ( ( O O
30 1484 1487 9564988 92% NN B-NP O
31 1487 1488 9564988 ) ) O O
32 1489 1497 9564988 remained VBD B-VP O
33 1498 1502 9564988 well RB B-NP O
34 1503 1504 9564988 4 CD I-NP O
35 1505 1507 9564988 to TO I-NP O
36 1508 1509 9564988 6 CD I-NP O
37 1510 1515 9564988 weeks NNS I-NP O
38 1516 1521 9564988 after IN B-PP O
39 1522 1529 9564988 therapy NN B-NP O
40 1529 1530 9564988 ; : O O
41 1531 1534 9564988 and CC O O
42 1535 1537 9564988 21 CD B-NP O
43 1538 1539 9564988 ( ( O O
44 1539 1541 9564988 8% NN B-NP O
45 1541 1542 9564988 ) ) O O
46 1543 1546 9564988 had VBD B-VP O
47 1547 1548 9564988 a DT B-NP O
48 1549 1556 9564988 relapse NN I-NP O
49 1557 1559 9564988 of IN B-PP O
50 1560 1568 9564988 symptoms NNS B-NP O
51 1568 1569 9564988 . . O O

1 1570 1577 9564988 Adverse JJ B-NP O
2 1578 1584 9564988 events NNS I-NP O
3 1585 1595 9564988 considered VBN B-VP O
4 1596 1598 9564988 to TO I-VP O
5 1599 1601 9564988 be VB I-VP O
6 1602 1609 9564988 related VBN I-VP O
7 1610 1612 9564988 to TO B-PP O
8 1613 1625 9564988 levofloxacin NN B-NP D064704
9 1626 1640 9564988 administration NN I-NP O
10 1641 1645 9564988 were VBD B-VP O
11 1646 1654 9564988 reported VBN I-VP O
12 1655 1657 9564988 by IN B-PP O
13 1658 1660 9564988 29 CD B-NP O
14 1661 1669 9564988 patients NNS I-NP O
15 1670 1671 9564988 ( ( O O
16 1671 1673 9564988 9% CD B-NP O
17 1673 1674 9564988 ) ) O O
18 1674 1675 9564988 . . O O

1 1676 1679 9564988 The DT B-NP O
2 1680 1684 9564988 most RBS I-NP O
3 1685 1691 9564988 common JJ I-NP O
4 1692 1696 9564988 drug NN I-NP O
5 1696 1697 9564988 - HYPH O O
6 1697 1704 9564988 related VBN B-NP O
7 1705 1712 9564988 adverse JJ I-NP O
8 1713 1719 9564988 events NNS I-NP O
9 1720 1724 9564988 were VBD B-VP O
10 1725 1733 9564988 diarrhea NN B-NP D003967
11 1733 1734 9564988 , , O O
12 1735 1745 9564988 flatulence NN B-NP D005414
13 1745 1746 9564988 , , O O
14 1747 1750 9564988 and CC O O
15 1751 1757 9564988 nausea NN B-NP D009325
16 1757 1758 9564988 ; : O O
17 1759 1763 9564988 most RBS B-NP O
18 1764 1771 9564988 adverse JJ I-NP O
19 1772 1778 9564988 events NNS I-NP O
20 1779 1783 9564988 were VBD B-VP O
21 1784 1788 9564988 mild JJ B-ADJP O
22 1789 1791 9564988 to TO B-VP O
23 1792 1800 9564988 moderate VB I-VP O
24 1801 1803 9564988 in IN B-PP O
25 1804 1812 9564988 severity NN B-NP O
26 1812 1813 9564988 . . O O

1 1814 1824 9564988 CONCLUSION NN B-NP O
2 1824 1825 9564988 : : O O
3 1826 1829 9564988 The DT B-NP O
4 1830 1837 9564988 results NNS I-NP O
5 1838 1840 9564988 of IN B-PP O
6 1841 1845 9564988 this DT B-NP O
7 1846 1851 9564988 study NN I-NP O
8 1852 1860 9564988 indicate VBP B-VP O
9 1861 1865 9564988 that IN B-SBAR O
10 1866 1878 9564988 levofloxacin NN B-NP D064704
11 1879 1882 9564988 500 CD I-NP O
12 1883 1885 9564988 mg NN I-NP O
13 1886 1890 9564988 once RB B-ADVP O
14 1891 1896 9564988 daily RB I-ADVP O
15 1897 1899 9564988 is VBZ B-VP O
16 1900 1902 9564988 an DT B-NP O
17 1903 1912 9564988 effective JJ I-NP O
18 1913 1916 9564988 and CC I-NP O
19 1917 1921 9564988 safe JJ I-NP O
20 1922 1931 9564988 treatment NN I-NP O
21 1932 1935 9564988 for IN B-PP O
22 1936 1941 9564988 acute JJ B-NP O
23 1942 1951 9564988 bacterial JJ I-NP O
24 1952 1961 9564988 sinusitis NN I-NP D012852
25 1961 1962 9564988 . . O O

1 0 0 7596955 -DOCSTART- -X- -X- O

1 0 8 7596955 Clinical JJ B-NP O
2 9 19 7596955 evaluation NN I-NP O
3 20 22 7596955 on IN B-PP O
4 23 31 7596955 combined VBN B-NP O
5 32 46 7596955 administration NN I-NP O
6 47 49 7596955 of IN B-PP O
7 50 54 7596955 oral JJ B-NP O
8 55 67 7596955 prostacyclin NN I-NP D011464
9 68 76 7596955 analogue NN I-NP O
10 77 86 7596955 beraprost NN I-NP C048081
11 87 90 7596955 and CC O O
12 91 108 7596955 phosphodiesterase NN B-NP O
13 109 118 7596955 inhibitor NN I-NP O
14 119 129 7596955 cilostazol NN I-NP C045645
15 129 130 7596955 . . O O
16 131 136 7596955 Among IN B-PP O
17 137 144 7596955 various JJ B-NP O
18 145 149 7596955 oral JJ I-NP O
19 150 163 7596955 antiplatelets NNS I-NP O
20 163 164 7596955 , , O O
21 165 166 7596955 a DT B-NP O
22 167 178 7596955 combination NN I-NP O
23 179 181 7596955 of IN B-PP O
24 182 183 7596955 a DT B-NP O
25 184 189 7596955 novel JJ I-NP O
26 190 202 7596955 prostacyclin NN I-NP D011464
27 203 211 7596955 analogue NN I-NP O
28 212 221 7596955 beraprost NN I-NP C048081
29 222 223 7596955 ( ( O O
30 223 226 7596955 BPT NN B-NP C048081
31 226 227 7596955 ) ) O O
32 228 231 7596955 and CC O O
33 232 233 7596955 a DT B-NP O
34 234 240 7596955 potent JJ I-NP O
35 241 258 7596955 phosphodiesterase NN I-NP O
36 259 268 7596955 inhibitor NN I-NP O
37 269 279 7596955 cilostazol NN I-NP C045645
38 280 281 7596955 ( ( O O
39 281 284 7596955 CLZ NN B-NP C045645
40 284 285 7596955 ) ) O O
41 286 289 7596955 may MD B-VP O
42 290 296 7596955 result VB I-VP O
43 297 299 7596955 in IN B-PP O
44 300 308 7596955 untoward JJ B-NP O
45 309 317 7596955 clinical JJ I-NP O
46 318 325 7596955 effects NNS I-NP O
47 326 329 7596955 due JJ B-PP O
48 330 332 7596955 to TO B-PP O
49 333 341 7596955 possible JJ B-NP O
50 342 353 7596955 synergistic JJ I-NP O
51 354 363 7596955 elevation NN I-NP O
52 364 366 7596955 of IN B-PP O
53 367 380 7596955 intracellular JJ B-NP O
54 381 385 7596955 cAMP NN I-NP D000242
55 386 387 7596955 ( ( O O
56 387 393 7596955 cyclic JJ B-NP D000242
57 394 403 7596955 adenosine NN I-NP D000242
58 404 409 7596955 3',5' NN I-NP D000242
59 409 410 7596955 - HYPH B-NP D000242
60 410 423 7596955 monophosphate NN I-NP D000242
61 423 424 7596955 ) ) O O
62 424 425 7596955 . . O O

1 426 433 7596955 Thereby RB B-ADVP O
2 433 434 7596955 , , O O
3 435 436 7596955 a DT B-NP O
4 437 445 7596955 clinical JJ I-NP O
5 446 451 7596955 study NN I-NP O
6 452 454 7596955 of IN B-PP O
7 455 458 7596955 the DT B-NP O
8 459 467 7596955 combined JJ I-NP O
9 468 482 7596955 administration NN I-NP O
10 483 485 7596955 of IN B-PP O
11 486 489 7596955 the DT B-NP O
12 490 493 7596955 two CD I-NP O
13 494 500 7596955 agents NNS I-NP O
14 501 504 7596955 was VBD B-VP O
15 505 514 7596955 attempted VBN I-VP O
16 514 515 7596955 . . O O

1 516 522 7596955 Twelve CD B-NP O
2 523 530 7596955 healthy JJ I-NP O
3 531 541 7596955 volunteers NNS I-NP O
4 542 546 7596955 were VBD B-VP O
5 547 555 7596955 assigned VBN I-VP O
6 556 558 7596955 to TO I-VP O
7 559 563 7596955 take VB I-VP O
8 564 567 7596955 BPT NN B-NP C048081
9 567 568 7596955 / SYM B-NP O
10 568 571 7596955 CLZ NN I-NP C045645
11 572 574 7596955 in IN B-PP O
12 575 578 7596955 the DT B-NP O
13 579 588 7596955 following VBG I-NP O
14 589 597 7596955 schedule NN I-NP O
15 597 598 7596955 ; : O O
16 599 602 7596955 BPT NN B-NP C048081
17 602 603 7596955 : : O O
18 604 606 7596955 40 CD B-NP O
19 607 617 7596955 micrograms NNS I-NP O
20 618 620 7596955 at IN B-PP O
21 621 624 7596955 day NN B-NP O
22 625 626 7596955 1 CD I-NP O
23 627 630 7596955 and CC I-NP O
24 631 634 7596955 120 CD I-NP O
25 635 645 7596955 micrograms NNS I-NP O
26 646 651 7596955 t.i.d NN I-NP O
27 651 652 7596955 . . O O

1 653 657 7596955 from IN B-PP O
2 658 661 7596955 day NN B-NP O
3 662 663 7596955 7 CD I-NP O
4 664 666 7596955 to TO B-PP O
5 667 669 7596955 14 CD B-NP O
6 669 670 7596955 , , O O
7 671 674 7596955 CLZ NN B-NP C045645
8 674 675 7596955 : : O O
9 676 679 7596955 200 CD B-NP O
10 680 682 7596955 mg NN I-NP O
11 683 688 7596955 t.i.d NN I-NP O
12 688 689 7596955 . . O O

1 690 694 7596955 from IN B-PP O
2 695 698 7596955 day NN B-NP O
3 699 700 7596955 3 CD I-NP O
4 701 703 7596955 to TO B-PP O
5 704 706 7596955 14 CD B-NP O
6 706 707 7596955 . . O O

1 708 710 7596955 At IN B-PP O
2 711 718 7596955 various JJ B-NP O
3 719 723 7596955 time NN I-NP O
4 724 733 7596955 intervals NNS I-NP O
5 733 734 7596955 , , O O
6 735 743 7596955 physical JJ B-NP O
7 744 755 7596955 examination NN I-NP O
8 756 759 7596955 and CC I-NP O
9 760 765 7596955 blood NN I-NP O
10 766 776 7596955 collection NN I-NP O
11 777 780 7596955 for IN B-PP O
12 781 783 7596955 ex FW B-NP O
13 784 788 7596955 vivo FW I-NP O
14 789 797 7596955 platelet NN I-NP D001791
15 798 809 7596955 aggregation NN I-NP D001791
16 810 813 7596955 and CC I-NP O
17 814 827 7596955 determination NN I-NP O
18 828 830 7596955 of IN B-PP O
19 831 844 7596955 intraplatelet JJ B-NP O
20 845 849 7596955 cAMP NN I-NP D000242
21 850 854 7596955 were VBD B-VP O
22 855 864 7596955 performed VBN I-VP O
23 864 865 7596955 . . O O

1 866 876 7596955 Throughout IN B-PP O
2 877 880 7596955 the DT B-NP O
3 881 892 7596955 observation NN I-NP O
4 893 899 7596955 period NN I-NP O
5 899 900 7596955 , , O O
6 901 903 7596955 no DT B-NP O
7 904 915 7596955 significant JJ I-NP O
8 916 926 7596955 alteration NN I-NP O
9 927 929 7596955 in IN B-PP O
10 930 935 7596955 vital JJ B-NP O
11 936 941 7596955 signs NNS I-NP O
12 942 945 7596955 was VBD B-VP O
13 946 954 7596955 observed VBN I-VP O
14 954 955 7596955 . . O O

1 956 961 7596955 Seven CD B-NP O
2 962 965 7596955 out IN I-NP O
3 966 968 7596955 of IN I-NP O
4 969 971 7596955 12 CD I-NP O
5 972 980 7596955 subjects NNS I-NP O
6 981 992 7596955 experienced VBD B-VP O
7 993 1001 7596955 headache NN B-NP D006261
8 1002 1004 7596955 of IN B-PP O
9 1005 1006 7596955 a DT B-NP O
10 1007 1012 7596955 short JJ I-NP O
11 1013 1021 7596955 duration NN I-NP O
12 1022 1034 7596955 accompanying VBG B-VP O
13 1035 1041 7596955 facial JJ B-NP D005483
14 1042 1047 7596955 flush NN I-NP D005483
15 1048 1050 7596955 in IN B-PP O
16 1051 1054 7596955 one CD B-NP O
17 1055 1058 7596955 and CC O O
18 1059 1065 7596955 nausea NN B-NP D009325
19 1066 1068 7596955 in IN B-PP O
20 1069 1072 7596955 one CD B-NP O
21 1072 1073 7596955 , , O O
22 1074 1084 7596955 especially RB B-ADVP O
23 1085 1090 7596955 after IN B-PP O
24 1091 1100 7596955 ingestion NN B-NP O
25 1101 1103 7596955 of IN B-PP O
26 1104 1107 7596955 CLZ NN B-NP C045645
27 1107 1108 7596955 . . O O

1 1109 1112 7596955 All DT B-NP O
2 1113 1115 7596955 of IN B-PP O
3 1116 1121 7596955 these DT B-NP O
4 1122 1130 7596955 symptoms NNS I-NP O
5 1130 1131 7596955 , , O O
6 1132 1140 7596955 probably RB B-VP O
7 1141 1147 7596955 caused VBN I-VP O
8 1148 1150 7596955 by IN B-PP O
9 1151 1154 7596955 the DT B-NP O
10 1155 1167 7596955 vasodilating VBG I-NP O
11 1168 1174 7596955 effect NN I-NP O
12 1175 1177 7596955 of IN B-PP O
13 1178 1181 7596955 the DT B-NP O
14 1182 1185 7596955 two CD I-NP O
15 1186 1192 7596955 agents NNS I-NP O
16 1192 1193 7596955 , , O O
17 1194 1198 7596955 were VBD B-VP O
18 1199 1201 7596955 of IN B-PP O
19 1202 1206 7596955 mild JJ B-NP O
20 1207 1213 7596955 degree NN I-NP O
21 1214 1217 7596955 and CC O O
22 1218 1220 7596955 no DT B-NP O
23 1221 1228 7596955 special JJ I-NP O
24 1229 1238 7596955 treatment NN I-NP O
25 1239 1242 7596955 was VBD B-VP O
26 1243 1251 7596955 required VBN I-VP O
27 1251 1252 7596955 . . O O

1 1253 1266 7596955 Intraplatelet JJ B-NP O
2 1267 1271 7596955 cAMP NN I-NP D000242
3 1272 1279 7596955 content NN I-NP O
4 1280 1283 7596955 was VBD B-VP O
5 1284 1293 7596955 gradually RB B-VP O
6 1294 1297 7596955 but CC I-VP O
7 1298 1311 7596955 significantly RB I-VP O
8 1312 1321 7596955 increased VBD I-VP O
9 1322 1324 7596955 to TO B-PP O
10 1325 1329 7596955 9.84 CD B-NP O
11 1330 1331 7596955 + SYM O O
12 1331 1332 7596955 / SYM O O
13 1332 1333 7596955 - SYM O O
14 1334 1338 7596955 4.59 CD B-NP O
15 1339 1343 7596955 pmol NN I-NP O
16 1344 1347 7596955 per IN B-PP O
17 1348 1353 7596955 10(9) CD B-NP O
18 1354 1363 7596955 platelets NNS I-NP O
19 1364 1366 7596955 at IN B-PP O
20 1367 1370 7596955 day NN B-NP O
21 1371 1373 7596955 14 CD I-NP O
22 1374 1376 7596955 in IN B-PP O
23 1377 1387 7596955 comparison NN B-NP O
24 1388 1392 7596955 with IN B-PP O
25 1393 1396 7596955 the DT B-NP O
26 1397 1404 7596955 initial JJ I-NP O
27 1405 1410 7596955 value NN I-NP O
28 1411 1412 7596955 ( ( O O
29 1412 1416 7596955 6.87 CD B-NP O
30 1417 1418 7596955 + SYM O O
31 1418 1419 7596955 / SYM O O
32 1419 1420 7596955 - SYM O O
33 1421 1425 7596955 2.25 CD B-NP O
34 1426 1430 7596955 pmol NN I-NP O
35 1430 1431 7596955 ) ) O O
36 1431 1432 7596955 . . O O

1 1433 1436 7596955 The DT B-NP O
2 1437 1445 7596955 platelet NN I-NP O
3 1446 1459 7596955 aggregability NN I-NP O
4 1460 1463 7596955 was VBD B-VP O
5 1464 1477 7596955 significantly RB I-VP O
6 1478 1488 7596955 suppressed VBN I-VP O
7 1489 1491 7596955 at IN B-PP O
8 1492 1499 7596955 various JJ B-NP O
9 1500 1504 7596955 time NN I-NP O
10 1505 1514 7596955 intervals NNS I-NP O
11 1515 1518 7596955 but CC O O
12 1519 1521 7596955 no DT B-NP O
13 1522 1530 7596955 additive JJ I-NP O
14 1531 1533 7596955 or CC I-NP O
15 1534 1545 7596955 synergistic JJ I-NP O
16 1546 1556 7596955 inhibitory JJ I-NP O
17 1557 1563 7596955 effect NN I-NP O
18 1564 1566 7596955 by IN B-PP O
19 1567 1570 7596955 the DT B-NP O
20 1571 1579 7596955 combined VBN I-NP O
21 1580 1594 7596955 administration NN I-NP O
22 1595 1598 7596955 was VBD B-VP O
23 1599 1604 7596955 noted VBN I-VP O
24 1604 1605 7596955 . . O O

1 1606 1608 7596955 In IN B-PP O
2 1609 1619 7596955 conclusion NN B-NP O
3 1619 1620 7596955 , , O O
4 1621 1624 7596955 the DT B-NP O
5 1625 1633 7596955 combined JJ I-NP O
6 1634 1648 7596955 administration NN I-NP O
7 1649 1651 7596955 of IN B-PP O
8 1652 1655 7596955 BPT NN B-NP C048081
9 1655 1656 7596955 / SYM B-NP O
10 1656 1659 7596955 CLZ NN I-NP C045645
11 1660 1662 7596955 is VBZ B-VP O
12 1663 1667 7596955 safe JJ B-ADJP O
13 1668 1670 7596955 at IN B-PP O
14 1671 1676 7596955 doses NNS B-NP O
15 1677 1681 7596955 used VBN B-VP O
16 1682 1684 7596955 in IN B-PP O
17 1685 1688 7596955 the DT B-NP O
18 1689 1694 7596955 study NN I-NP O
19 1694 1695 7596955 , , O O
20 1696 1702 7596955 though IN B-SBAR O
21 1703 1706 7596955 the DT B-NP O
22 1707 1717 7596955 beneficial JJ I-NP O
23 1718 1726 7596955 clinical JJ I-NP O
24 1727 1733 7596955 effect NN I-NP O
25 1734 1736 7596955 of IN B-PP O
26 1737 1740 7596955 the DT B-NP O
27 1741 1749 7596955 combined VBN I-NP O
28 1750 1764 7596955 administration NN I-NP O
29 1765 1768 7596955 has VBZ B-VP O
30 1769 1772 7596955 yet RB I-VP O
31 1773 1775 7596955 to TO I-VP O
32 1776 1778 7596955 be VB I-VP O
33 1779 1789 7596955 elucidated VBN I-VP O
34 1789 1790 7596955 . . O O

1 0 0 8677458 -DOCSTART- -X- -X- O

1 0 10 8677458 Continuous JJ B-NP O
2 11 23 8677458 subcutaneous JJ I-NP O
3 24 38 8677458 administration NN I-NP O
4 39 41 8677458 of IN B-PP O
5 42 47 8677458 mesna NN B-NP D015080
6 48 50 8677458 to TO B-VP O
7 51 58 8677458 prevent VB I-VP O
8 59 69 8677458 ifosfamide NN B-NP D007069
9 69 70 8677458 - HYPH O O
10 70 77 8677458 induced VBN B-NP O
11 78 89 8677458 hemorrhagic JJ I-NP D006470
12 90 98 8677458 cystitis NN I-NP D006470
13 98 99 8677458 . . I-NP O
14 100 111 8677458 Hemorrhagic JJ I-NP D006470
15 112 120 8677458 cystitis NN I-NP D006470
16 121 123 8677458 is VBZ B-VP O
17 124 125 8677458 a DT B-NP O
18 126 131 8677458 major JJ I-NP O
19 132 141 8677458 potential JJ I-NP O
20 142 150 8677458 toxicity NN I-NP D064420
21 151 153 8677458 of IN B-PP O
22 154 164 8677458 ifosfamide NN B-NP D007069
23 165 169 8677458 that WDT B-NP O
24 170 173 8677458 can MD B-VP O
25 174 176 8677458 be VB I-VP O
26 177 186 8677458 prevented VBN I-VP O
27 187 189 8677458 by IN B-PP O
28 190 203 8677458 administering VBG B-VP O
29 204 209 8677458 mesna NN B-NP D015080
30 210 215 8677458 along IN B-PP O
31 216 220 8677458 with IN B-PP O
32 221 224 8677458 the DT B-NP O
33 225 234 8677458 cytotoxic JJ I-NP O
34 235 240 8677458 agent NN I-NP O
35 240 241 8677458 . . O O

1 242 247 8677458 Mesna NNP B-NP D015080
2 248 250 8677458 is VBZ B-VP O
3 251 260 8677458 generally RB I-VP O
4 261 273 8677458 administered VBN I-VP O
5 274 276 8677458 by IN B-PP O
6 277 280 8677458 the DT B-NP O
7 281 292 8677458 intravenous JJ I-NP O
8 293 298 8677458 route NN I-NP O
9 298 299 8677458 , , O O
10 300 308 8677458 although IN B-SBAR O
11 309 319 8677458 experience NN B-NP O
12 320 324 8677458 with IN B-PP O
13 325 329 8677458 oral JJ B-NP O
14 330 338 8677458 delivery NN I-NP O
15 339 341 8677458 of IN B-PP O
16 342 345 8677458 the DT B-NP O
17 346 350 8677458 drug NN I-NP O
18 351 354 8677458 has VBZ B-VP O
19 355 364 8677458 increased VBN I-VP O
20 364 365 8677458 . . O O

1 366 369 8677458 The DT B-NP O
2 370 380 8677458 continuous JJ I-NP O
3 381 393 8677458 subcutaneous JJ I-NP O
4 394 408 8677458 administration NN I-NP O
5 409 411 8677458 of IN B-PP O
6 412 417 8677458 mesna NN B-NP D015080
7 418 421 8677458 has VBZ B-VP O
8 422 425 8677458 the DT B-NP O
9 426 435 8677458 advantage NN I-NP O
10 436 438 8677458 of IN B-PP O
11 439 442 8677458 not RB O O
12 443 452 8677458 requiring VBG B-VP O
13 453 464 8677458 intravenous JJ B-NP O
14 465 471 8677458 access NN I-NP O
15 471 472 8677458 . . O O

1 473 475 8677458 In IN B-PP O
2 476 484 8677458 addition NN B-NP O
3 484 485 8677458 , , O O
4 486 498 8677458 subcutaneous JJ B-NP O
5 499 507 8677458 delivery NN I-NP O
6 508 510 8677458 of IN B-PP O
7 511 514 8677458 the DT B-NP O
8 515 527 8677458 neutralizing VBG I-NP O
9 528 533 8677458 agent NN I-NP O
10 534 538 8677458 will MD B-VP O
11 539 542 8677458 not RB I-VP O
12 543 545 8677458 be VB I-VP O
13 546 556 8677458 associated VBN I-VP O
14 557 561 8677458 with IN B-PP O
15 562 565 8677458 the DT B-NP O
16 566 570 8677458 risk NN I-NP O
17 571 573 8677458 of IN B-PP O
18 574 584 8677458 inadequate JJ B-NP O
19 585 592 8677458 urinary JJ I-NP O
20 593 598 8677458 mesna NN I-NP D015080
21 599 613 8677458 concentrations NNS I-NP O
22 613 614 8677458 , , O O
23 615 619 8677458 such JJ B-PP O
24 620 622 8677458 as IN I-PP O
25 623 625 8677458 in IN B-PP O
26 626 627 8677458 a DT B-NP O
27 628 635 8677458 patient NN I-NP O
28 636 642 8677458 taking VBG B-VP O
29 643 647 8677458 oral JJ B-NP O
30 648 653 8677458 mesna NN I-NP D015080
31 654 657 8677458 who WP B-NP O
32 658 669 8677458 experiences VBZ B-VP O
33 670 676 8677458 severe JJ B-NP O
34 677 687 8677458 ifosfamide NN I-NP D007069
35 687 688 8677458 - HYPH B-VP O
36 688 695 8677458 induced VBN B-NP O
37 696 702 8677458 emesis NN I-NP D014839
38 703 706 8677458 and CC O O
39 707 709 8677458 is VBZ B-VP O
40 710 716 8677458 unable JJ B-ADJP O
41 717 719 8677458 to TO B-VP O
42 720 726 8677458 absorb VB I-VP O
43 727 730 8677458 the DT B-NP O
44 731 735 8677458 drug NN I-NP O
45 735 736 8677458 . . O O

1 737 744 8677458 Limited VBN B-VP O
2 745 753 8677458 clinical JJ B-NP O
3 754 764 8677458 experience NN I-NP O
4 765 769 8677458 with IN B-PP O
5 770 780 8677458 continuous JJ B-NP O
6 781 793 8677458 subcutaneous JJ I-NP O
7 794 799 8677458 mesna NN I-NP D015080
8 800 814 8677458 administration NN I-NP O
9 815 823 8677458 suggests VBZ B-VP O
10 824 826 8677458 it PRP B-NP O
11 827 829 8677458 is VBZ B-VP O
12 830 831 8677458 a DT B-NP O
13 832 836 8677458 safe JJ I-NP O
14 836 837 8677458 , , I-NP O
15 838 847 8677458 practical JJ I-NP O
16 847 848 8677458 , , O O
17 849 852 8677458 and CC O O
18 853 861 8677458 economic JJ B-NP O
19 862 868 8677458 method NN I-NP O
20 869 871 8677458 of IN B-PP O
21 872 876 8677458 drug NN B-NP O
22 877 885 8677458 delivery NN I-NP O
23 886 890 8677458 that WDT B-NP O
24 891 898 8677458 permits VBZ B-VP O
25 899 909 8677458 ifosfamide NN B-NP D007069
26 910 912 8677458 to TO B-VP O
27 913 915 8677458 be VB I-VP O
28 916 928 8677458 administered VBN I-VP O
29 929 941 8677458 successfully RB B-ADVP O
30 942 944 8677458 in IN B-PP O
31 945 948 8677458 the DT B-NP O
32 949 959 8677458 outpatient NN I-NP O
33 960 967 8677458 setting NN I-NP O
34 967 968 8677458 . . O O

1 0 0 19300240 -DOCSTART- -X- -X- O

1 0 1 19300240 5 CD B-NP D005472
2 2 14 19300240 flourouracil NN I-NP D005472
3 14 15 19300240 - HYPH O O
4 15 22 19300240 induced VBN B-NP O
5 23 29 19300240 apical JJ I-NP D054549
6 30 40 19300240 ballooning NN I-NP D054549
7 41 49 19300240 syndrome NN I-NP D054549
8 49 50 19300240 : : O O
9 51 52 19300240 a DT B-NP O
10 53 57 19300240 case NN I-NP O
11 58 64 19300240 report NN I-NP O
12 64 65 19300240 . . O O
13 66 69 19300240 The DT B-NP O
14 70 76 19300240 apical JJ I-NP D054549
15 77 87 19300240 ballooning NN I-NP D054549
16 88 96 19300240 syndrome NN I-NP D054549
17 97 98 19300240 ( ( O O
18 98 101 19300240 ABS NN B-NP D054549
19 101 102 19300240 ) ) O O
20 103 105 19300240 is VBZ B-VP O
21 106 107 19300240 a DT B-NP O
22 108 116 19300240 recently RB I-NP O
23 117 126 19300240 described VBN I-NP O
24 127 133 19300240 stress NN I-NP O
25 133 134 19300240 - HYPH O O
26 134 142 19300240 mediated VBN B-VP O
27 143 148 19300240 acute JJ B-NP D006331
28 149 156 19300240 cardiac JJ I-NP D006331
29 157 165 19300240 syndrome NN I-NP D006331
30 166 179 19300240 characterized VBN B-VP O
31 180 182 19300240 by IN B-PP O
32 183 192 19300240 transient JJ B-NP O
33 193 197 19300240 wall NN I-NP O
34 197 198 19300240 - HYPH B-NP O
35 198 204 19300240 motion NN I-NP O
36 205 218 19300240 abnormalities NNS I-NP O
37 219 228 19300240 involving VBG B-VP O
38 229 232 19300240 the DT B-NP O
39 233 237 19300240 apex NN I-NP O
40 238 241 19300240 and CC I-NP O
41 242 254 19300240 midventricle NN I-NP O
42 255 259 19300240 with IN B-PP O
43 260 272 19300240 hyperkinesis NN B-NP D006948
44 273 275 19300240 of IN B-PP O
45 276 279 19300240 the DT B-NP O
46 280 285 19300240 basal JJ I-NP O
47 286 290 19300240 left JJ I-NP O
48 291 302 19300240 ventricular JJ I-NP O
49 303 304 19300240 ( ( O O
50 304 306 19300240 LV NN B-NP O
51 306 307 19300240 ) ) O O
52 308 316 19300240 segments NNS B-NP O
53 317 324 19300240 without IN B-PP O
54 325 336 19300240 obstructive JJ B-NP O
55 337 347 19300240 epicardial JJ I-NP D003327
56 348 356 19300240 coronary JJ I-NP D003327
57 357 364 19300240 disease NN I-NP D003327
58 364 365 19300240 . . O O

1 366 380 19300240 Cardiotoxicity NN B-NP D066126
2 381 383 19300240 is VBZ B-VP O
3 384 387 19300240 not RB O O
4 388 390 19300240 an DT B-NP O
5 391 399 19300240 uncommon JJ I-NP O
6 400 407 19300240 adverse JJ I-NP O
7 408 414 19300240 effect NN I-NP O
8 415 417 19300240 of IN B-PP O
9 418 434 19300240 chemotherapeutic JJ B-NP O
10 435 441 19300240 agents NNS I-NP O
11 441 442 19300240 . . O O

1 443 450 19300240 However RB B-ADVP O
2 450 451 19300240 , , O O
3 452 457 19300240 there EX B-NP O
4 458 461 19300240 are VBP B-VP O
5 462 464 19300240 no DT B-NP O
6 465 472 19300240 reports NNS I-NP O
7 473 475 19300240 of IN B-PP O
8 476 479 19300240 ABS NNP B-NP D054549
9 480 489 19300240 secondary JJ B-ADJP O
10 490 492 19300240 to TO B-PP O
11 493 509 19300240 chemotherapeutic JJ B-NP O
12 510 516 19300240 agents NNS I-NP O
13 516 517 19300240 . . O O

1 518 520 19300240 We PRP B-NP O
2 521 529 19300240 describe VBP B-VP O
3 530 533 19300240 the DT B-NP O
4 534 538 19300240 case NN I-NP O
5 539 541 19300240 of IN B-PP O
6 542 543 19300240 a DT B-NP O
7 544 549 19300240 woman NN I-NP O
8 550 553 19300240 who WP B-NP O
9 554 563 19300240 developed VBD B-VP O
10 564 567 19300240 the DT B-NP O
11 568 576 19300240 syndrome NN I-NP O
12 577 582 19300240 after IN B-PP O
13 583 595 19300240 chemotherapy NN B-NP O
14 596 599 19300240 for IN B-PP O
15 600 610 19300240 metastatic JJ B-NP O
16 611 617 19300240 cancer NN I-NP D009369
17 617 618 19300240 . . O O

1 619 620 19300240 A DT B-NP O
2 621 623 19300240 79 CD I-NP O
3 623 624 19300240 - HYPH I-NP O
4 624 628 19300240 year NN I-NP O
5 628 629 19300240 - HYPH O O
6 629 632 19300240 old JJ B-NP O
7 633 638 19300240 woman NN I-NP O
8 639 648 19300240 presented VBD B-VP O
9 649 653 19300240 with IN B-PP O
10 654 661 19300240 typical JJ B-NP O
11 662 670 19300240 ischemic JJ I-NP D007511
12 671 676 19300240 chest NN I-NP D002637
13 677 681 19300240 pain NN I-NP D002637
14 681 682 19300240 , , O O
15 683 691 19300240 elevated VBD B-VP O
16 692 699 19300240 cardiac JJ B-NP O
17 700 707 19300240 enzymes NNS I-NP O
18 708 712 19300240 with IN B-PP O
19 713 724 19300240 significant JJ B-NP O
20 725 727 19300240 ST NN I-NP O
21 727 728 19300240 - HYPH I-NP O
22 728 735 19300240 segment NN I-NP O
23 736 749 19300240 abnormalities NNS I-NP O
24 750 752 19300240 on IN B-PP O
25 753 756 19300240 her PRP$ B-NP O
26 757 774 19300240 electrocardiogram NN I-NP O
27 774 775 19300240 . . O O

1 776 779 19300240 She PRP B-NP O
2 780 789 19300240 underwent VBD B-VP O
3 790 796 19300240 recent JJ B-NP O
4 797 809 19300240 chemotherapy NN I-NP O
5 810 814 19300240 with IN B-PP O
6 815 827 19300240 fluorouracil NN B-NP D005472
7 828 831 19300240 for IN B-PP O
8 832 842 19300240 metastatic JJ B-NP O
9 843 853 19300240 colorectal JJ I-NP D015179
10 854 860 19300240 cancer NN I-NP D015179
11 860 861 19300240 . . O O

1 862 878 19300240 Echocardiography NN B-NP O
2 879 887 19300240 revealed VBD B-VP O
3 888 889 19300240 a DT B-NP O
4 890 894 19300240 wall NN I-NP O
5 894 895 19300240 - HYPH B-NP O
6 895 901 19300240 motion NN I-NP O
7 902 913 19300240 abnormality NN I-NP O
8 914 923 19300240 involving VBG B-VP O
9 924 927 19300240 the DT B-NP O
10 928 934 19300240 apical JJ I-NP O
11 935 938 19300240 and CC I-NP O
12 939 949 19300240 periapical JJ I-NP O
13 950 958 19300240 segments NNS I-NP O
14 959 964 19300240 which WDT B-NP O
15 965 973 19300240 appeared VBD B-VP O
16 974 982 19300240 akinetic JJ B-ADJP D018476
17 982 983 19300240 . . O O

1 984 992 19300240 Coronary JJ B-NP O
2 993 1004 19300240 angiography NN I-NP O
3 1005 1013 19300240 revealed VBD B-VP O
4 1014 1016 19300240 no DT B-NP O
5 1017 1028 19300240 obstructive JJ I-NP O
6 1029 1037 19300240 coronary JJ I-NP O
7 1038 1045 19300240 lesions NNS I-NP O
8 1045 1046 19300240 . . O O

1 1047 1050 19300240 The DT B-NP O
2 1051 1058 19300240 patient NN I-NP O
3 1059 1062 19300240 was VBD B-VP O
4 1063 1073 19300240 stabilized VBN I-VP O
5 1074 1078 19300240 with IN B-PP O
6 1079 1086 19300240 medical JJ B-NP O
7 1087 1094 19300240 therapy NN I-NP O
8 1094 1095 19300240 . . O O

1 1096 1100 19300240 Four CD B-NP O
2 1101 1106 19300240 weeks NNS I-NP O
3 1107 1112 19300240 later RB B-ADVP O
4 1113 1116 19300240 she PRP B-NP O
5 1117 1125 19300240 remained VBD B-VP O
6 1126 1136 19300240 completely RB B-ADJP O
7 1137 1149 19300240 asymptomatic JJ I-ADJP O
8 1149 1150 19300240 . . O O

1 1151 1165 19300240 Echocardiogram NN B-NP O
2 1166 1174 19300240 revealed VBD B-VP O
3 1175 1176 19300240 a DT B-NP O
4 1177 1183 19300240 normal JJ I-NP O
5 1184 1192 19300240 ejection NN I-NP O
6 1193 1201 19300240 fraction NN I-NP O
7 1202 1205 19300240 and CC O O
8 1206 1207 19300240 a DT B-NP O
9 1208 1218 19300240 resolution NN I-NP O
10 1219 1221 19300240 of IN B-PP O
11 1222 1225 19300240 the DT B-NP O
12 1226 1232 19300240 apical JJ I-NP O
13 1233 1241 19300240 akinesis NN I-NP D018476
14 1241 1242 19300240 . . O O

1 1243 1255 19300240 Pathogenetic JJ B-NP O
2 1256 1266 19300240 mechanisms NNS I-NP O
3 1267 1269 19300240 of IN B-PP O
4 1270 1277 19300240 cardiac JJ B-NP D005117
5 1278 1291 19300240 complications NNS I-NP D005117
6 1292 1294 19300240 in IN B-PP O
7 1295 1301 19300240 cancer NN B-NP D009369
8 1302 1310 19300240 patients NNS I-NP O
9 1311 1321 19300240 undergoing VBG B-VP O
10 1322 1334 19300240 chemotherapy NN B-NP O
11 1335 1342 19300240 include VBP B-VP O
12 1343 1351 19300240 coronary JJ B-NP D003329
13 1352 1361 19300240 vasospasm NN I-NP D003329
14 1361 1362 19300240 , , O O
15 1363 1374 19300240 endothelial JJ B-NP O
16 1375 1381 19300240 damage NN I-NP O
17 1382 1385 19300240 and CC O O
18 1386 1396 19300240 consequent JJ B-NP O
19 1397 1405 19300240 thrombus NN I-NP D013927
20 1406 1415 19300240 formation NN I-NP O
21 1415 1416 19300240 . . O O

1 1417 1419 19300240 In IN B-PP O
2 1420 1423 19300240 our PRP$ B-NP O
3 1424 1431 19300240 patient NN I-NP O
4 1431 1432 19300240 , , O O
5 1433 1437 19300240 both DT B-NP O
6 1438 1454 19300240 supraphysiologic JJ I-NP O
7 1455 1461 19300240 levels NNS I-NP O
8 1462 1464 19300240 of IN B-PP O
9 1465 1471 19300240 plasma NN B-NP O
10 1472 1486 19300240 catecholamines NNS I-NP D002395
11 1487 1490 19300240 and CC O O
12 1491 1497 19300240 stress NN B-NP O
13 1498 1505 19300240 related VBN I-NP O
14 1506 1519 19300240 neuropeptides NNS I-NP O
15 1520 1526 19300240 caused VBN B-VP O
16 1527 1529 19300240 by IN B-PP O
17 1530 1536 19300240 cancer NN B-NP D009369
18 1537 1546 19300240 diagnosis NN I-NP O
19 1547 1549 19300240 as RB B-CONJP O
20 1550 1554 19300240 well RB I-CONJP O
21 1555 1557 19300240 as IN I-CONJP O
22 1558 1570 19300240 chemotherapy NN B-NP O
23 1571 1574 19300240 may MD B-VP O
24 1575 1579 19300240 have VB I-VP O
25 1580 1591 19300240 contributed VBN I-VP O
26 1592 1595 19300240 the DT B-NP O
27 1596 1607 19300240 development NN I-NP O
28 1608 1610 19300240 of IN B-PP O
29 1611 1614 19300240 ABS NNP B-NP D054549
30 1614 1615 19300240 . . O O

1 0 0 2564649 -DOCSTART- -X- -X- O

1 0 11 2564649 Involvement NN B-NP O
2 12 14 2564649 of IN B-PP O
3 15 20 2564649 locus NN B-NP O
4 21 30 2564649 coeruleus NN I-NP O
5 31 34 2564649 and CC O O
6 35 48 2564649 noradrenergic JJ B-NP O
7 49 66 2564649 neurotransmission NN I-NP O
8 67 69 2564649 in IN B-PP O
9 70 78 2564649 fentanyl NN B-NP D005283
10 78 79 2564649 - HYPH B-NP O
11 79 86 2564649 induced VBN I-NP O
12 87 95 2564649 muscular JJ I-NP D009127
13 96 104 2564649 rigidity NN I-NP D009127
14 105 107 2564649 in IN B-PP O
15 108 111 2564649 the DT B-NP O
16 112 115 2564649 rat NN I-NP O
17 115 116 2564649 . . O O
18 117 124 2564649 Whereas IN B-PP O
19 125 133 2564649 muscular JJ B-NP D009127
20 134 142 2564649 rigidity NN I-NP D009127
21 143 145 2564649 is VBZ B-VP O
22 146 147 2564649 a DT B-NP O
23 148 152 2564649 well RB I-NP O
24 152 153 2564649 - HYPH I-NP O
25 153 158 2564649 known VBN I-NP O
26 159 163 2564649 side NN I-NP O
27 164 170 2564649 effect NN I-NP O
28 171 175 2564649 that WDT B-NP O
29 176 178 2564649 is VBZ B-VP O
30 179 189 2564649 associated VBN I-VP O
31 190 194 2564649 with IN B-PP O
32 195 199 2564649 high JJ B-NP O
33 199 200 2564649 - HYPH I-NP O
34 200 204 2564649 dose NN I-NP O
35 205 213 2564649 fentanyl NN I-NP D005283
36 214 224 2564649 anesthesia NN I-NP O
37 224 225 2564649 , , O O
38 226 227 2564649 a DT B-NP O
39 228 235 2564649 paucity NN I-NP O
40 236 238 2564649 of IN B-PP O
41 239 250 2564649 information NN B-NP O
42 251 257 2564649 exists VBZ B-VP O
43 258 262 2564649 with IN B-PP O
44 263 269 2564649 regard NN B-NP O
45 270 272 2564649 to TO B-PP O
46 273 276 2564649 its PRP$ B-NP O
47 277 287 2564649 underlying VBG I-NP O
48 288 297 2564649 mechanism NN I-NP O
49 297 298 2564649 ( ( I-NP O
50 298 299 2564649 s NNS I-NP O
51 299 300 2564649 ) ) O O
52 300 301 2564649 . . O O

1 302 304 2564649 We PRP B-NP O
2 305 317 2564649 investigated VBD B-VP O
3 318 320 2564649 in IN B-PP O
4 321 325 2564649 this DT B-NP O
5 326 331 2564649 study NN I-NP O
6 332 335 2564649 the DT B-NP O
7 336 344 2564649 possible JJ I-NP O
8 345 355 2564649 engagement NN I-NP O
9 356 358 2564649 of IN B-PP O
10 359 364 2564649 locus NN B-NP O
11 365 374 2564649 coeruleus NN I-NP O
12 375 377 2564649 of IN B-PP O
13 378 381 2564649 the DT B-NP O
14 382 386 2564649 pons NNS I-NP O
15 387 389 2564649 in IN B-PP O
16 390 394 2564649 this DT B-NP O
17 395 405 2564649 phenomenon NN I-NP O
18 405 406 2564649 , , O O
19 407 412 2564649 using VBG B-VP O
20 413 417 2564649 male JJ B-NP O
21 418 425 2564649 Sprague NNP I-NP O
22 425 426 2564649 - HYPH I-NP O
23 426 432 2564649 Dawley NNP I-NP O
24 433 437 2564649 rats NNS I-NP O
25 438 450 2564649 anesthetized VBN B-VP O
26 451 455 2564649 with IN B-PP O
27 456 464 2564649 ketamine NN B-NP D007649
28 464 465 2564649 . . O O

1 466 471 2564649 Under IN B-PP O
2 472 478 2564649 proper JJ B-NP O
3 479 486 2564649 control NN I-NP O
4 487 489 2564649 of IN B-PP O
5 490 501 2564649 respiration NN B-NP O
6 501 502 2564649 , , O O
7 503 507 2564649 body NN B-NP O
8 508 519 2564649 temperature NN I-NP O
9 520 523 2564649 and CC I-NP O
10 524 527 2564649 end NN I-NP O
11 527 528 2564649 - HYPH B-NP O
12 528 533 2564649 tidal JJ I-NP O
13 534 537 2564649 CO2 NN I-NP D002245
14 537 538 2564649 , , O O
15 539 550 2564649 intravenous JJ B-NP O
16 551 565 2564649 administration NN I-NP O
17 566 568 2564649 of IN B-PP O
18 569 577 2564649 fentanyl NN B-NP D005283
19 578 579 2564649 ( ( O O
20 579 581 2564649 50 CD B-NP O
21 582 584 2564649 or CC I-NP O
22 585 588 2564649 100 CD I-NP O
23 589 599 2564649 micrograms NNS I-NP O
24 599 600 2564649 / SYM B-NP O
25 600 602 2564649 kg NN I-NP O
26 602 603 2564649 ) ) O O
27 604 616 2564649 consistently RB B-VP O
28 617 625 2564649 promoted VBD I-VP O
29 626 628 2564649 an DT B-NP O
30 629 637 2564649 increase NN I-NP O
31 638 640 2564649 in IN B-PP O
32 641 658 2564649 electromyographic JJ B-NP O
33 659 667 2564649 activity NN I-NP O
34 668 676 2564649 recorded VBN B-VP O
35 677 681 2564649 from IN B-PP O
36 682 685 2564649 the DT B-NP O
37 686 699 2564649 gastrocnemius NN I-NP O
38 700 703 2564649 and CC O O
39 704 713 2564649 abdominal JJ B-NP O
40 714 720 2564649 rectus NN I-NP O
41 721 728 2564649 muscles NNS I-NP O
42 728 729 2564649 . . O O

1 730 734 2564649 Such PDT B-NP O
2 735 737 2564649 an DT I-NP O
3 738 745 2564649 induced VBN I-NP O
4 746 754 2564649 muscular JJ I-NP D009127
5 755 763 2564649 rigidity NN I-NP D009127
6 764 766 2564649 by IN B-PP O
7 767 770 2564649 the DT B-NP O
8 771 779 2564649 narcotic JJ I-NP O
9 780 785 2564649 agent NN I-NP O
10 786 789 2564649 was VBD B-VP O
11 790 803 2564649 significantly RB I-VP O
12 804 815 2564649 antagonized VBN I-VP O
13 816 818 2564649 or CC O O
14 819 823 2564649 even RB B-VP O
15 824 831 2564649 reduced VBN I-VP O
16 832 834 2564649 by IN B-PP O
17 835 840 2564649 prior JJ B-NP O
18 841 853 2564649 electrolytic JJ I-NP O
19 854 861 2564649 lesions NNS I-NP O
20 862 864 2564649 of IN B-PP O
21 865 868 2564649 the DT B-NP O
22 869 874 2564649 locus NN I-NP O
23 875 884 2564649 coeruleus NN I-NP O
24 885 887 2564649 or CC I-NP O
25 888 900 2564649 pretreatment NN I-NP O
26 901 905 2564649 with IN B-PP O
27 906 909 2564649 the DT B-NP O
28 910 915 2564649 alpha SYM I-NP O
29 915 916 2564649 - HYPH I-NP O
30 916 928 2564649 adrenoceptor NN I-NP O
31 929 936 2564649 blocker NN I-NP O
32 936 937 2564649 , , O O
33 938 946 2564649 prazosin NN B-NP D011224
34 946 947 2564649 . . O O

1 948 962 2564649 Microinjection NN B-NP O
2 963 965 2564649 of IN B-PP O
3 966 974 2564649 fentanyl NN B-NP D005283
4 975 976 2564649 ( ( O O
5 976 979 2564649 2.5 CD B-NP O
6 980 990 2564649 micrograms NNS I-NP O
7 990 991 2564649 / SYM B-NP O
8 991 993 2564649 50 CD B-NP O
9 994 996 2564649 nl NN I-NP O
10 996 997 2564649 ) ) O O
11 998 1006 2564649 directly RB B-ADVP O
12 1007 1011 2564649 into IN B-PP O
13 1012 1016 2564649 this DT B-NP O
14 1017 1024 2564649 pontine JJ I-NP O
15 1025 1032 2564649 nucleus NN I-NP O
16 1032 1033 2564649 , , O O
17 1034 1036 2564649 on IN B-PP O
18 1037 1040 2564649 the DT B-NP O
19 1041 1046 2564649 other JJ I-NP O
20 1047 1051 2564649 hand NN I-NP O
21 1051 1052 2564649 , , O O
22 1053 1061 2564649 elicited VBD B-VP O
23 1062 1073 2564649 discernible JJ B-NP O
24 1074 1091 2564649 electromyographic JJ I-NP O
25 1092 1102 2564649 excitation NN I-NP O
26 1102 1103 2564649 . . O O

1 1104 1106 2564649 It PRP B-NP O
2 1107 1109 2564649 is VBZ B-VP O
3 1110 1120 2564649 speculated VBN I-VP O
4 1121 1125 2564649 that IN B-SBAR O
5 1126 1129 2564649 the DT B-NP O
6 1130 1139 2564649 induction NN I-NP O
7 1140 1142 2564649 of IN B-PP O
8 1143 1151 2564649 muscular JJ B-NP D009127
9 1152 1160 2564649 rigidity NN I-NP D009127
10 1161 1163 2564649 by IN B-PP O
11 1164 1172 2564649 fentanyl NN B-NP D005283
12 1173 1176 2564649 may MD B-VP O
13 1177 1184 2564649 involve VB I-VP O
14 1185 1188 2564649 the DT B-NP O
15 1189 1202 2564649 coerulospinal JJ I-NP O
16 1203 1216 2564649 noradrenergic JJ I-NP O
17 1217 1223 2564649 fibers NNS I-NP O
18 1224 1226 2564649 to TO B-PP O
19 1227 1230 2564649 the DT B-NP O
20 1231 1237 2564649 spinal JJ I-NP O
21 1238 1249 2564649 motoneurons NNS I-NP O
22 1249 1250 2564649 . . O O

1 0 0 12571256 -DOCSTART- -X- -X- O

1 0 11 12571256 Nephrotoxic JJ B-NP D007674
2 12 19 12571256 effects NNS I-NP O
3 20 22 12571256 in IN B-PP O
4 23 27 12571256 high JJ B-NP O
5 27 28 12571256 - HYPH I-NP O
6 28 32 12571256 risk NN B-NP O
7 33 41 12571256 patients NNS I-NP O
8 42 52 12571256 undergoing VBG B-VP O
9 53 64 12571256 angiography NN B-NP O
10 64 65 12571256 . . O O
11 66 76 12571256 BACKGROUND NN B-NP O
12 76 77 12571256 : : O O
13 78 81 12571256 The DT B-NP O
14 82 85 12571256 use NN I-NP O
15 86 88 12571256 of IN B-PP O
16 89 98 12571256 iodinated VBN B-NP O
17 99 107 12571256 contrast NN I-NP O
18 108 114 12571256 medium NN I-NP O
19 115 118 12571256 can MD B-VP O
20 119 125 12571256 result VB I-VP O
21 126 128 12571256 in IN B-PP O
22 129 140 12571256 nephropathy NN B-NP D007674
23 140 141 12571256 . . O O

1 142 149 12571256 Whether IN B-SBAR O
2 150 153 12571256 iso AFX B-NP O
3 153 154 12571256 - HYPH I-NP O
4 154 161 12571256 osmolar JJ I-NP O
5 162 170 12571256 contrast NN I-NP O
6 171 177 12571256 medium NN I-NP O
7 178 180 12571256 is VBZ B-VP O
8 181 185 12571256 less RBR B-ADJP O
9 186 197 12571256 nephrotoxic JJ I-ADJP D007674
10 198 202 12571256 than IN B-PP O
11 203 206 12571256 low JJ B-NP O
12 206 207 12571256 - HYPH I-NP O
13 207 214 12571256 osmolar JJ I-NP O
14 215 223 12571256 contrast NN I-NP O
15 224 230 12571256 medium NN I-NP O
16 231 233 12571256 in IN B-PP O
17 234 238 12571256 high JJ B-NP O
18 238 239 12571256 - HYPH I-NP O
19 239 243 12571256 risk NN B-NP O
20 244 252 12571256 patients NNS I-NP O
21 253 255 12571256 is VBZ B-VP O
22 256 265 12571256 uncertain JJ B-ADJP O
23 265 266 12571256 . . O O

1 267 274 12571256 METHODS NNS B-NP O
2 274 275 12571256 : : O O
3 276 278 12571256 We PRP B-NP O
4 279 288 12571256 conducted VBD B-VP O
5 289 290 12571256 a DT B-NP O
6 291 301 12571256 randomized VBN I-NP O
7 301 302 12571256 , , I-NP O
8 303 309 12571256 double JJ I-NP O
9 309 310 12571256 - HYPH I-NP O
10 310 315 12571256 blind JJ I-NP O
11 315 316 12571256 , , I-NP O
12 317 328 12571256 prospective JJ I-NP O
13 328 329 12571256 , , I-NP O
14 330 341 12571256 multicenter JJ I-NP O
15 342 347 12571256 study NN I-NP O
16 348 357 12571256 comparing VBG B-VP O
17 358 361 12571256 the DT B-NP O
18 362 373 12571256 nephrotoxic JJ I-NP D007674
19 374 381 12571256 effects NNS I-NP O
20 382 384 12571256 of IN B-PP O
21 385 387 12571256 an DT B-NP O
22 388 391 12571256 iso AFX I-NP O
23 391 392 12571256 - HYPH I-NP O
24 392 399 12571256 osmolar JJ I-NP O
25 399 400 12571256 , , I-NP O
26 401 408 12571256 dimeric JJ I-NP O
27 408 409 12571256 , , I-NP O
28 410 418 12571256 nonionic JJ I-NP O
29 419 427 12571256 contrast NN I-NP O
30 428 434 12571256 medium NN I-NP O
31 434 435 12571256 , , O O
32 436 445 12571256 iodixanol NN B-NP C044834
33 445 446 12571256 , , O O
34 447 451 12571256 with IN B-PP O
35 452 457 12571256 those DT B-NP O
36 458 460 12571256 of IN B-PP O
37 461 462 12571256 a DT B-NP O
38 463 466 12571256 low JJ I-NP O
39 466 467 12571256 - HYPH I-NP O
40 467 474 12571256 osmolar JJ I-NP O
41 474 475 12571256 , , I-NP O
42 476 484 12571256 nonionic JJ I-NP O
43 484 485 12571256 , , I-NP O
44 486 495 12571256 monomeric JJ I-NP O
45 496 504 12571256 contrast NN I-NP O
46 505 511 12571256 medium NN I-NP O
47 511 512 12571256 , , O O
48 513 520 12571256 iohexol NN B-NP D007472
49 520 521 12571256 . . O O

1 522 525 12571256 The DT B-NP O
2 526 531 12571256 study NN I-NP O
3 532 540 12571256 involved VBD B-VP O
4 541 544 12571256 129 CD B-NP O
5 545 553 12571256 patients NNS I-NP O
6 554 558 12571256 with IN B-PP O
7 559 567 12571256 diabetes NN B-NP D003920
8 568 572 12571256 with IN B-PP O
9 573 578 12571256 serum NN B-NP O
10 579 589 12571256 creatinine NN I-NP D003404
11 590 604 12571256 concentrations NNS I-NP O
12 605 607 12571256 of IN B-PP O
13 608 611 12571256 1.5 CD B-NP O
14 612 614 12571256 to TO I-NP O
15 615 618 12571256 3.5 CD I-NP O
16 619 621 12571256 mg NN I-NP O
17 622 625 12571256 per IN B-PP O
18 626 635 12571256 deciliter NN B-NP O
19 636 639 12571256 who WP B-NP O
20 640 649 12571256 underwent VBD B-VP O
21 650 658 12571256 coronary JJ B-NP O
22 659 661 12571256 or CC I-NP O
23 662 674 12571256 aortofemoral JJ I-NP O
24 675 686 12571256 angiography NN I-NP O
25 686 687 12571256 . . O O

1 688 691 12571256 The DT B-NP O
2 692 699 12571256 primary JJ I-NP O
3 700 703 12571256 end NN I-NP O
4 704 709 12571256 point NN I-NP O
5 710 713 12571256 was VBD B-VP O
6 714 717 12571256 the DT B-NP O
7 718 722 12571256 peak JJ I-NP O
8 723 731 12571256 increase NN I-NP O
9 732 736 12571256 from IN B-PP O
10 737 741 12571256 base NN B-NP O
11 742 746 12571256 line NN I-NP O
12 747 749 12571256 in IN B-PP O
13 750 753 12571256 the DT B-NP O
14 754 764 12571256 creatinine NN I-NP D003404
15 765 778 12571256 concentration NN I-NP O
16 779 785 12571256 during IN B-PP O
17 786 789 12571256 the DT B-NP O
18 790 795 12571256 three CD I-NP O
19 796 800 12571256 days NNS I-NP O
20 801 806 12571256 after IN B-PP O
21 807 818 12571256 angiography NN B-NP O
22 818 819 12571256 . . O O

1 820 825 12571256 Other JJ B-NP O
2 826 829 12571256 end NN I-NP O
3 830 836 12571256 points NNS I-NP O
4 837 841 12571256 were VBD B-VP O
5 842 844 12571256 an DT B-NP O
6 845 853 12571256 increase NN I-NP O
7 854 856 12571256 in IN B-PP O
8 857 860 12571256 the DT B-NP O
9 861 871 12571256 creatinine NN I-NP D003404
10 872 885 12571256 concentration NN I-NP O
11 886 888 12571256 of IN B-PP O
12 889 892 12571256 0.5 CD B-NP O
13 893 895 12571256 mg NN I-NP O
14 896 899 12571256 per IN B-PP O
15 900 909 12571256 deciliter NN B-NP O
16 910 912 12571256 or CC O O
17 913 917 12571256 more JJR B-NP O
18 917 918 12571256 , , O O
19 919 921 12571256 an DT B-NP O
20 922 930 12571256 increase NN I-NP O
21 931 933 12571256 of IN B-PP O
22 934 937 12571256 1.0 CD B-NP O
23 938 940 12571256 mg NN I-NP O
24 941 944 12571256 per IN B-PP O
25 945 954 12571256 deciliter NN B-NP O
26 955 957 12571256 or CC O O
27 958 962 12571256 more JJR B-NP O
28 962 963 12571256 , , O O
29 964 967 12571256 and CC O O
30 968 969 12571256 a DT B-NP O
31 970 976 12571256 change NN I-NP O
32 977 979 12571256 in IN B-PP O
33 980 983 12571256 the DT B-NP O
34 984 994 12571256 creatinine NN I-NP D003404
35 995 1008 12571256 concentration NN I-NP O
36 1009 1013 12571256 from IN B-PP O
37 1014 1017 12571256 day NN B-NP O
38 1018 1019 12571256 0 CD I-NP O
39 1020 1022 12571256 to TO B-PP O
40 1023 1026 12571256 day NN B-NP O
41 1027 1028 12571256 7 CD I-NP O
42 1028 1029 12571256 . . O O

1 1030 1037 12571256 RESULTS NNS B-NP O
2 1037 1038 12571256 : : O O
3 1039 1042 12571256 The DT B-NP O
4 1043 1053 12571256 creatinine NN I-NP D003404
5 1054 1067 12571256 concentration NN I-NP O
6 1068 1077 12571256 increased VBD B-VP O
7 1078 1091 12571256 significantly RB B-ADJP O
8 1092 1096 12571256 less JJR I-ADJP O
9 1097 1099 12571256 in IN B-PP O
10 1100 1108 12571256 patients NNS B-NP O
11 1109 1112 12571256 who WP B-NP O
12 1113 1121 12571256 received VBD B-VP O
13 1122 1131 12571256 iodixanol NN B-NP C044834
14 1131 1132 12571256 . . O O

1 1133 1137 12571256 From IN B-PP O
2 1138 1141 12571256 day NN B-NP O
3 1142 1143 12571256 0 CD I-NP O
4 1144 1146 12571256 to TO B-PP O
5 1147 1150 12571256 day NN B-NP O
6 1151 1152 12571256 3 CD I-NP O
7 1152 1153 12571256 , , O O
8 1154 1157 12571256 the DT B-NP O
9 1158 1162 12571256 mean JJ I-NP O
10 1163 1167 12571256 peak JJ I-NP O
11 1168 1176 12571256 increase NN I-NP O
12 1177 1179 12571256 in IN B-PP O
13 1180 1190 12571256 creatinine NN B-NP D003404
14 1191 1194 12571256 was VBD B-VP O
15 1195 1199 12571256 0.13 CD B-NP O
16 1200 1202 12571256 mg NN I-NP O
17 1203 1206 12571256 per IN B-PP O
18 1207 1216 12571256 deciliter NN B-NP O
19 1217 1219 12571256 in IN B-PP O
20 1220 1223 12571256 the DT B-NP O
21 1224 1233 12571256 iodixanol NN I-NP C044834
22 1234 1239 12571256 group NN I-NP O
23 1240 1243 12571256 and CC O O
24 1244 1248 12571256 0.55 CD B-NP O
25 1249 1251 12571256 mg NN I-NP O
26 1252 1255 12571256 per IN B-PP O
27 1256 1265 12571256 deciliter NN B-NP O
28 1266 1268 12571256 in IN B-PP O
29 1269 1272 12571256 the DT B-NP O
30 1273 1280 12571256 iohexol NN I-NP D007472
31 1281 1286 12571256 group NN I-NP O
32 1287 1288 12571256 ( ( O O
33 1288 1289 12571256 P NN B-NP O
34 1289 1290 12571256 = SYM B-VP O
35 1290 1295 12571256 0.001 CD B-NP O
36 1295 1296 12571256 ; : O O
37 1297 1300 12571256 the DT B-NP O
38 1301 1309 12571256 increase NN I-NP O
39 1310 1314 12571256 with IN B-PP O
40 1315 1324 12571256 iodixanol NN B-NP C044834
41 1325 1330 12571256 minus CC O O
42 1331 1334 12571256 the DT B-NP O
43 1335 1343 12571256 increase NN I-NP O
44 1344 1348 12571256 with IN B-PP O
45 1349 1356 12571256 iohexol NN B-NP D007472
46 1356 1357 12571256 , , O O
47 1358 1359 12571256 - SYM B-NP O
48 1359 1363 12571256 0.42 CD I-NP O
49 1364 1366 12571256 mg NN I-NP O
50 1367 1370 12571256 per IN B-PP O
51 1371 1380 12571256 deciliter NN B-NP O
52 1381 1382 12571256 [ ( O O
53 1382 1384 12571256 95 CD B-NP O
54 1385 1392 12571256 percent NN I-NP O
55 1393 1403 12571256 confidence NN I-NP O
56 1404 1412 12571256 interval NN I-NP O
57 1412 1413 12571256 , , O O
58 1414 1415 12571256 - SYM O O
59 1415 1419 12571256 0.73 CD B-NP O
60 1420 1422 12571256 to TO B-PP O
61 1423 1424 12571256 - SYM B-NP O
62 1424 1428 12571256 0.22 CD I-NP O
63 1428 1429 12571256 ] ) O O
64 1429 1430 12571256 ) ) O O
65 1430 1431 12571256 . . O O

1 1432 1435 12571256 Two CD B-NP O
2 1436 1438 12571256 of IN B-PP O
3 1439 1442 12571256 the DT B-NP O
4 1443 1445 12571256 64 CD I-NP O
5 1446 1454 12571256 patients NNS I-NP O
6 1455 1457 12571256 in IN B-PP O
7 1458 1461 12571256 the DT B-NP O
8 1462 1471 12571256 iodixanol NN I-NP C044834
9 1472 1477 12571256 group NN I-NP O
10 1478 1479 12571256 ( ( O O
11 1479 1480 12571256 3 CD B-NP O
12 1481 1488 12571256 percent NN I-NP O
13 1488 1489 12571256 ) ) O O
14 1490 1493 12571256 had VBD B-VP O
15 1494 1496 12571256 an DT B-NP O
16 1497 1505 12571256 increase NN I-NP O
17 1506 1508 12571256 in IN B-PP O
18 1509 1512 12571256 the DT B-NP O
19 1513 1523 12571256 creatinine NN I-NP D003404
20 1524 1537 12571256 concentration NN I-NP O
21 1538 1540 12571256 of IN B-PP O
22 1541 1544 12571256 0.5 CD B-NP O
23 1545 1547 12571256 mg NN I-NP O
24 1548 1551 12571256 per IN B-PP O
25 1552 1561 12571256 deciliter NN B-NP O
26 1562 1564 12571256 or CC O O
27 1565 1569 12571256 more JJR B-NP O
28 1569 1570 12571256 , , O O
29 1571 1573 12571256 as IN B-SBAR O
30 1574 1582 12571256 compared VBN B-PP O
31 1583 1587 12571256 with IN B-PP O
32 1588 1590 12571256 17 CD B-NP O
33 1591 1593 12571256 of IN B-PP O
34 1594 1597 12571256 the DT B-NP O
35 1598 1600 12571256 65 CD I-NP O
36 1601 1609 12571256 patients NNS I-NP O
37 1610 1612 12571256 in IN B-PP O
38 1613 1616 12571256 the DT B-NP O
39 1617 1624 12571256 iohexol NN I-NP D007472
40 1625 1630 12571256 group NN I-NP O
41 1631 1632 12571256 ( ( O O
42 1632 1634 12571256 26 CD B-NP O
43 1635 1642 12571256 percent NN I-NP O
44 1642 1643 12571256 ) ) O O
45 1644 1645 12571256 ( ( O O
46 1645 1646 12571256 P NN B-NP O
47 1646 1647 12571256 = SYM B-VP O
48 1647 1652 12571256 0.002 CD B-NP O
49 1652 1653 12571256 ; : O O
50 1654 1658 12571256 odds VBZ B-VP O
51 1659 1664 12571256 ratio NN B-NP O
52 1665 1668 12571256 for IN B-PP O
53 1669 1673 12571256 such JJ B-NP O
54 1674 1676 12571256 an DT I-NP O
55 1677 1685 12571256 increase NN I-NP O
56 1686 1688 12571256 in IN B-PP O
57 1689 1692 12571256 the DT B-NP O
58 1693 1702 12571256 iodixanol NN I-NP C044834
59 1703 1708 12571256 group NN I-NP O
60 1708 1709 12571256 , , O O
61 1710 1714 12571256 0.09 CD B-NP O
62 1715 1716 12571256 [ ( O O
63 1716 1718 12571256 95 CD B-NP O
64 1719 1726 12571256 percent NN I-NP O
65 1727 1737 12571256 confidence NN I-NP O
66 1738 1746 12571256 interval NN I-NP O
67 1746 1747 12571256 , , O O
68 1748 1752 12571256 0.02 CD B-NP O
69 1753 1755 12571256 to TO B-PP O
70 1756 1760 12571256 0.41 CD B-NP O
71 1760 1761 12571256 ] ) O O
72 1761 1762 12571256 ) ) O O
73 1762 1763 12571256 . . O O

1 1764 1766 12571256 No DT B-NP O
2 1767 1774 12571256 patient NN I-NP O
3 1775 1784 12571256 receiving VBG B-VP O
4 1785 1794 12571256 iodixanol NN B-NP C044834
5 1795 1798 12571256 had VBD B-VP O
6 1799 1801 12571256 an DT B-NP O
7 1802 1810 12571256 increase NN I-NP O
8 1811 1813 12571256 of IN B-PP O
9 1814 1817 12571256 1.0 CD B-NP O
10 1818 1820 12571256 mg NN I-NP O
11 1821 1824 12571256 per IN B-PP O
12 1825 1834 12571256 deciliter NN B-NP O
13 1835 1837 12571256 or CC O O
14 1838 1842 12571256 more JJR B-NP O
15 1842 1843 12571256 , , O O
16 1844 1847 12571256 but CC O O
17 1848 1850 12571256 10 CD B-NP O
18 1851 1859 12571256 patients NNS I-NP O
19 1860 1862 12571256 in IN B-PP O
20 1863 1866 12571256 the DT B-NP O
21 1867 1874 12571256 iohexol NN I-NP D007472
22 1875 1880 12571256 group NN I-NP O
23 1881 1882 12571256 ( ( O O
24 1882 1884 12571256 15 CD B-NP O
25 1885 1892 12571256 percent NN I-NP O
26 1892 1893 12571256 ) ) O O
27 1894 1897 12571256 did VBD B-VP O
28 1897 1898 12571256 . . O O

1 1899 1902 12571256 The DT B-NP O
2 1903 1907 12571256 mean JJ I-NP O
3 1908 1914 12571256 change NN I-NP O
4 1915 1917 12571256 in IN B-PP O
5 1918 1921 12571256 the DT B-NP O
6 1922 1932 12571256 creatinine NN I-NP D003404
7 1933 1946 12571256 concentration NN I-NP O
8 1947 1951 12571256 from IN B-PP O
9 1952 1955 12571256 day NN B-NP O
10 1956 1957 12571256 0 CD I-NP O
11 1958 1960 12571256 to TO B-PP O
12 1961 1964 12571256 day NN B-NP O
13 1965 1966 12571256 7 CD I-NP O
14 1967 1970 12571256 was VBD B-VP O
15 1971 1975 12571256 0.07 CD B-NP O
16 1976 1978 12571256 mg NN I-NP O
17 1979 1982 12571256 per IN B-PP O
18 1983 1992 12571256 deciliter NN B-NP O
19 1993 1995 12571256 in IN B-PP O
20 1996 1999 12571256 the DT B-NP O
21 2000 2009 12571256 iodixanol NN I-NP C044834
22 2010 2015 12571256 group NN I-NP O
23 2016 2019 12571256 and CC O O
24 2020 2024 12571256 0.24 CD B-NP O
25 2025 2027 12571256 mg NN I-NP O
26 2028 2031 12571256 per IN B-PP O
27 2032 2041 12571256 deciliter NN B-NP O
28 2042 2044 12571256 in IN B-PP O
29 2045 2048 12571256 the DT B-NP O
30 2049 2056 12571256 iohexol NN I-NP D007472
31 2057 2062 12571256 group NN I-NP O
32 2063 2064 12571256 ( ( O O
33 2064 2065 12571256 P NN B-NP O
34 2065 2066 12571256 = SYM B-VP O
35 2066 2071 12571256 0.003 CD B-NP O
36 2071 2072 12571256 ; : O O
37 2073 2078 12571256 value NN B-NP O
38 2079 2081 12571256 in IN B-PP O
39 2082 2085 12571256 the DT B-NP O
40 2086 2095 12571256 iodixanol NN I-NP C044834
41 2096 2101 12571256 group NN I-NP O
42 2102 2107 12571256 minus CC B-PP O
43 2108 2111 12571256 the DT B-NP O
44 2112 2117 12571256 value NN I-NP O
45 2118 2120 12571256 in IN B-PP O
46 2121 2124 12571256 the DT B-NP O
47 2125 2132 12571256 iohexol NN I-NP D007472
48 2133 2138 12571256 group NN I-NP O
49 2138 2139 12571256 , , O O
50 2140 2141 12571256 - SYM B-NP O
51 2141 2145 12571256 0.17 CD I-NP O
52 2146 2148 12571256 mg NN I-NP O
53 2149 2152 12571256 per IN B-PP O
54 2153 2162 12571256 deciliter NN B-NP O
55 2163 2164 12571256 [ ( O O
56 2164 2166 12571256 95 CD B-NP O
57 2167 2174 12571256 percent NN I-NP O
58 2175 2185 12571256 confidence NN I-NP O
59 2186 2194 12571256 interval NN I-NP O
60 2194 2195 12571256 , , O O
61 2196 2197 12571256 - SYM O O
62 2197 2201 12571256 0.34 CD B-NP O
63 2202 2204 12571256 to TO B-PP O
64 2205 2206 12571256 - SYM B-NP O
65 2206 2210 12571256 0.07 CD I-NP O
66 2210 2211 12571256 ] ) O O
67 2211 2212 12571256 ) ) O O
68 2212 2213 12571256 . . O O

1 2214 2225 12571256 CONCLUSIONS NNS B-NP O
2 2225 2226 12571256 : : O O
3 2227 2238 12571256 Nephropathy NN B-NP D007674
4 2239 2246 12571256 induced VBN B-VP O
5 2247 2249 12571256 by IN B-PP O
6 2250 2258 12571256 contrast NN B-NP O
7 2259 2265 12571256 medium NN I-NP O
8 2266 2269 12571256 may MD B-VP O
9 2270 2272 12571256 be VB I-VP O
10 2273 2277 12571256 less RBR B-ADJP O
11 2278 2284 12571256 likely JJ I-ADJP O
12 2285 2287 12571256 to TO B-VP O
13 2288 2295 12571256 develop VB I-VP O
14 2296 2298 12571256 in IN B-PP O
15 2299 2303 12571256 high JJ B-NP O
16 2303 2304 12571256 - HYPH I-NP O
17 2304 2308 12571256 risk NN B-NP O
18 2309 2317 12571256 patients NNS I-NP O
19 2318 2322 12571256 when WRB B-ADVP O
20 2323 2332 12571256 iodixanol NN B-NP C044834
21 2333 2335 12571256 is VBZ B-VP O
22 2336 2340 12571256 used VBN I-VP O
23 2341 2347 12571256 rather RB B-CONJP O
24 2348 2352 12571256 than IN I-CONJP O
25 2353 2354 12571256 a DT B-NP O
26 2355 2358 12571256 low JJ I-NP O
27 2358 2359 12571256 - HYPH I-NP O
28 2359 2366 12571256 osmolar JJ I-NP O
29 2366 2367 12571256 , , I-NP O
30 2368 2376 12571256 nonionic JJ I-NP O
31 2377 2385 12571256 contrast NN I-NP O
32 2386 2392 12571256 medium NN I-NP O
33 2392 2393 12571256 . . O O

1 0 0 18808529 -DOCSTART- -X- -X- O

1 0 13 18808529 Isoproterenol NN B-NP D007545
2 14 21 18808529 induces VBZ B-VP O
3 22 29 18808529 primary JJ B-NP O
4 30 34 18808529 loss NN I-NP O
5 35 37 18808529 of IN B-PP O
6 38 48 18808529 dystrophin NN B-NP O
7 49 51 18808529 in IN B-PP O
8 52 55 18808529 rat NN B-NP O
9 56 62 18808529 hearts NNS I-NP O
10 62 63 18808529 : : O O
11 64 75 18808529 correlation NN B-NP O
12 76 80 18808529 with IN B-PP O
13 81 91 18808529 myocardial JJ B-NP D009202
14 92 98 18808529 injury NN I-NP D009202
15 98 99 18808529 . . O O
16 100 103 18808529 The DT B-NP O
17 104 113 18808529 mechanism NN I-NP O
18 114 116 18808529 of IN B-PP O
19 117 130 18808529 isoproterenol NN B-NP D007545
20 130 131 18808529 - HYPH O O
21 131 138 18808529 induced VBN B-NP O
22 139 149 18808529 myocardial JJ I-NP D009202
23 150 156 18808529 damage NN I-NP D009202
24 157 159 18808529 is VBZ B-VP O
25 160 167 18808529 unknown JJ B-ADJP O
26 167 168 18808529 , , O O
27 169 172 18808529 but CC O O
28 173 174 18808529 a DT B-NP O
29 175 183 18808529 mismatch NN I-NP O
30 184 186 18808529 of IN B-PP O
31 187 193 18808529 oxygen NN B-NP D010100
32 194 200 18808529 supply NN I-NP O
33 201 203 18808529 vs NNS I-NP O
34 203 204 18808529 . . O O
35 205 211 18808529 demand NN B-NP O
36 212 221 18808529 following VBG B-PP O
37 222 230 18808529 coronary JJ B-NP O
38 231 242 18808529 hypotension NN I-NP D007022
39 243 246 18808529 and CC O O
40 247 257 18808529 myocardial JJ B-NP D009202
41 258 271 18808529 hyperactivity NN I-NP D009202
42 272 274 18808529 is VBZ B-VP O
43 275 278 18808529 the DT B-NP O
44 279 283 18808529 best JJS I-NP O
45 284 295 18808529 explanation NN I-NP O
46 296 299 18808529 for IN B-PP O
47 300 303 18808529 the DT B-NP O
48 304 311 18808529 complex JJ I-NP O
49 312 325 18808529 morphological JJ I-NP O
50 326 337 18808529 alterations NNS I-NP O
51 338 346 18808529 observed VBN B-VP O
52 346 347 18808529 . . O O

1 348 354 18808529 Severe JJ B-NP O
2 355 366 18808529 alterations NNS I-NP O
3 367 369 18808529 in IN B-PP O
4 370 373 18808529 the DT B-NP O
5 374 384 18808529 structural JJ I-NP O
6 385 394 18808529 integrity NN I-NP O
7 395 397 18808529 of IN B-PP O
8 398 401 18808529 the DT B-NP O
9 402 412 18808529 sarcolemma NN I-NP O
10 413 415 18808529 of IN B-PP O
11 416 430 18808529 cardiomyocytes NNS B-NP O
12 431 435 18808529 have VBP B-VP O
13 436 440 18808529 been VBN I-VP O
14 441 453 18808529 demonstrated VBN I-VP O
15 454 456 18808529 to TO I-VP O
16 457 459 18808529 be VB I-VP O
17 460 466 18808529 caused VBN I-VP O
18 467 469 18808529 by IN B-PP O
19 470 483 18808529 isoproterenol NN B-NP D007545
20 483 484 18808529 . . O O

1 485 491 18808529 Taking VBG B-VP O
2 492 496 18808529 into IN B-PP O
3 497 504 18808529 account NN B-NP O
4 505 509 18808529 that IN B-SBAR O
5 510 513 18808529 the DT B-NP O
6 514 525 18808529 sarcolemmal JJ I-NP O
7 526 535 18808529 integrity NN I-NP O
8 536 538 18808529 is VBZ B-VP O
9 539 549 18808529 stabilized VBN I-VP O
10 550 552 18808529 by IN B-PP O
11 553 556 18808529 the DT B-NP O
12 557 567 18808529 dystrophin NN I-NP O
13 567 568 18808529 - HYPH O O
14 568 580 18808529 glycoprotein NN B-NP O
15 581 588 18808529 complex NN I-NP O
16 589 590 18808529 ( ( O O
17 590 593 18808529 DGC NN B-NP O
18 593 594 18808529 ) ) O O
19 595 599 18808529 that WDT B-NP O
20 600 608 18808529 connects VBZ B-VP O
21 609 614 18808529 actin NN B-NP O
22 615 618 18808529 and CC I-NP O
23 619 626 18808529 laminin NN I-NP O
24 627 629 18808529 in IN B-PP O
25 630 641 18808529 contractile JJ B-NP O
26 642 651 18808529 machinery NN I-NP O
27 652 655 18808529 and CC O O
28 656 669 18808529 extracellular JJ B-NP O
29 670 676 18808529 matrix NN I-NP O
30 677 680 18808529 and CC B-PP O
31 681 683 18808529 by IN B-PP O
32 684 693 18808529 integrins NNS B-NP O
33 693 694 18808529 , , O O
34 695 699 18808529 this DT B-NP O
35 700 705 18808529 study NN I-NP O
36 706 711 18808529 tests VBZ B-VP O
37 712 715 18808529 the DT B-NP O
38 716 726 18808529 hypothesis NN I-NP O
39 727 731 18808529 that IN B-SBAR O
40 732 745 18808529 isoproterenol NN B-NP D007545
41 746 753 18808529 affects VBZ B-VP O
42 754 765 18808529 sarcolemmal JJ B-NP O
43 766 775 18808529 stability NN I-NP O
44 776 783 18808529 through IN B-PP O
45 784 791 18808529 changes NNS B-NP O
46 792 794 18808529 in IN B-PP O
47 795 798 18808529 the DT B-NP O
48 799 802 18808529 DGC NN I-NP O
49 803 806 18808529 and CC I-NP O
50 807 816 18808529 integrins NNS I-NP O
51 816 817 18808529 . . O O

1 818 820 18808529 We PRP B-NP O
2 821 826 18808529 found VBD B-VP O
3 827 836 18808529 different JJ B-NP O
4 837 848 18808529 sensitivity NN I-NP O
5 849 851 18808529 of IN B-PP O
6 852 855 18808529 the DT B-NP O
7 856 859 18808529 DGC NN I-NP O
8 860 863 18808529 and CC I-NP O
9 864 872 18808529 integrin NN I-NP O
10 873 875 18808529 to TO B-PP O
11 876 889 18808529 isoproterenol NN B-NP D007545
12 890 902 18808529 subcutaneous JJ I-NP O
13 903 917 18808529 administration NN I-NP O
14 917 918 18808529 . . O O

1 919 936 18808529 Immunofluorescent JJ B-NP O
2 937 945 18808529 staining NN I-NP O
3 946 954 18808529 revealed VBD B-VP O
4 955 959 18808529 that IN B-SBAR O
5 960 970 18808529 dystrophin NN B-NP O
6 971 973 18808529 is VBZ B-VP O
7 974 977 18808529 the DT B-NP O
8 978 982 18808529 most RBS I-NP O
9 983 992 18808529 sensitive JJ I-NP O
10 993 998 18808529 among IN B-PP O
11 999 1002 18808529 the DT B-NP O
12 1003 1013 18808529 structures NNS I-NP O
13 1014 1024 18808529 connecting VBG B-VP O
14 1025 1028 18808529 the DT B-NP O
15 1029 1034 18808529 actin NN I-NP O
16 1035 1037 18808529 in IN B-PP O
17 1038 1041 18808529 the DT B-NP O
18 1042 1055 18808529 cardiomyocyte NN I-NP O
19 1056 1068 18808529 cytoskeleton NN I-NP O
20 1069 1072 18808529 and CC O O
21 1073 1076 18808529 the DT B-NP O
22 1077 1090 18808529 extracellular JJ I-NP O
23 1091 1097 18808529 matrix NN I-NP O
24 1097 1098 18808529 . . O O

1 1099 1102 18808529 The DT B-NP O
2 1103 1113 18808529 sarcomeric JJ I-NP O
3 1114 1119 18808529 actin NN I-NP O
4 1120 1131 18808529 dissolution NN I-NP O
5 1132 1140 18808529 occurred VBD B-VP O
6 1141 1146 18808529 after IN B-SBAR O
7 1147 1150 18808529 the DT B-NP O
8 1151 1160 18808529 reduction NN I-NP O
9 1161 1163 18808529 or CC I-NP O
10 1164 1168 18808529 loss NN I-NP O
11 1169 1171 18808529 of IN B-PP O
12 1172 1182 18808529 dystrophin NN B-NP O
13 1182 1183 18808529 . . O O

1 1184 1196 18808529 Subsequently RB B-ADVP O
2 1196 1197 18808529 , , O O
3 1198 1203 18808529 after IN B-PP O
4 1204 1209 18808529 lysis NN B-NP O
5 1210 1212 18808529 of IN B-PP O
6 1213 1225 18808529 myofilaments NNS B-NP O
7 1225 1226 18808529 , , O O
8 1227 1232 18808529 gamma SYM O O
9 1232 1233 18808529 - HYPH O O
10 1233 1244 18808529 sarcoglycan NN B-NP O
11 1244 1245 18808529 , , O O
12 1246 1250 18808529 beta SYM O O
13 1250 1251 18808529 - HYPH O O
14 1251 1263 18808529 dystroglycan NN B-NP O
15 1263 1264 18808529 , , O O
16 1265 1270 18808529 beta1 NN B-NP O
17 1270 1271 18808529 - HYPH I-NP O
18 1271 1279 18808529 integrin NN I-NP O
19 1279 1280 18808529 , , O O
20 1281 1284 18808529 and CC O O
21 1285 1292 18808529 laminin NN B-NP O
22 1293 1298 18808529 alpha SYM O O
23 1298 1299 18808529 - HYPH B-NP O
24 1299 1300 18808529 2 CD I-NP O
25 1301 1312 18808529 expressions NNS I-NP O
26 1313 1317 18808529 were VBD B-VP O
27 1318 1325 18808529 reduced VBN I-VP O
28 1326 1334 18808529 followed VBN I-VP O
29 1335 1337 18808529 by IN B-PP O
30 1338 1343 18808529 their PRP$ B-NP O
31 1344 1353 18808529 breakdown NN I-NP O
32 1353 1354 18808529 , , O O
33 1355 1357 18808529 as IN B-PP O
34 1358 1370 18808529 epiphenomena NN B-NP O
35 1371 1373 18808529 of IN B-PP O
36 1374 1377 18808529 the DT B-NP O
37 1378 1390 18808529 myocytolytic JJ I-NP O
38 1391 1398 18808529 process NN I-NP O
39 1398 1399 18808529 . . O O

1 1400 1402 18808529 In IN B-PP O
2 1403 1413 18808529 conclusion NN B-NP O
3 1413 1414 18808529 , , O O
4 1415 1429 18808529 administration NN B-NP O
5 1430 1432 18808529 of IN B-PP O
6 1433 1446 18808529 isoproterenol NN B-NP D007545
7 1447 1449 18808529 to TO B-PP O
8 1450 1454 18808529 rats NNS B-NP O
9 1455 1462 18808529 results VBZ B-VP O
10 1463 1465 18808529 in IN B-PP O
11 1466 1473 18808529 primary JJ B-NP O
12 1474 1478 18808529 loss NN I-NP O
13 1479 1481 18808529 of IN B-PP O
14 1482 1492 18808529 dystrophin NN B-NP O
15 1492 1493 18808529 , , O O
16 1494 1497 18808529 the DT B-NP O
17 1498 1502 18808529 most RBS I-NP O
18 1503 1512 18808529 sensitive JJ I-NP O
19 1513 1518 18808529 among IN B-PP O
20 1519 1522 18808529 the DT B-NP O
21 1523 1533 18808529 structural JJ I-NP O
22 1534 1542 18808529 proteins NNS I-NP O
23 1543 1547 18808529 that WDT B-NP O
24 1548 1552 18808529 form VBP B-VP O
25 1553 1556 18808529 the DT B-NP O
26 1557 1560 18808529 DGC NN I-NP O
27 1561 1565 18808529 that WDT B-NP O
28 1566 1574 18808529 connects VBZ B-VP O
29 1575 1578 18808529 the DT B-NP O
30 1579 1592 18808529 extracellular JJ I-NP O
31 1593 1599 18808529 matrix NN I-NP O
32 1600 1603 18808529 and CC O O
33 1604 1607 18808529 the DT B-NP O
34 1608 1620 18808529 cytoskeleton NN I-NP O
35 1621 1623 18808529 in IN B-PP O
36 1624 1637 18808529 cardiomyocyte NN B-NP O
37 1637 1638 18808529 . . O O

1 1639 1644 18808529 These DT B-NP O
2 1645 1652 18808529 changes NNS I-NP O
3 1652 1653 18808529 , , O O
4 1654 1661 18808529 related VBN B-VP O
5 1662 1664 18808529 to TO B-PP O
6 1665 1674 18808529 ischaemic JJ B-NP D007511
7 1675 1681 18808529 injury NN I-NP D007511
8 1681 1682 18808529 , , O O
9 1683 1690 18808529 explain VBP B-VP O
10 1691 1694 18808529 the DT B-NP O
11 1695 1701 18808529 severe JJ I-NP O
12 1702 1713 18808529 alterations NNS I-NP O
13 1714 1716 18808529 in IN B-PP O
14 1717 1720 18808529 the DT B-NP O
15 1721 1731 18808529 structural JJ I-NP O
16 1732 1741 18808529 integrity NN I-NP O
17 1742 1744 18808529 of IN B-PP O
18 1745 1748 18808529 the DT B-NP O
19 1749 1759 18808529 sarcolemma NN I-NP O
20 1760 1762 18808529 of IN B-PP O
21 1763 1777 18808529 cardiomyocytes NNS B-NP O
22 1778 1781 18808529 and CC O O
23 1782 1787 18808529 hence RB B-NP O
24 1788 1794 18808529 severe JJ I-NP O
25 1795 1798 18808529 and CC I-NP O
26 1799 1811 18808529 irreversible JJ I-NP O
27 1812 1818 18808529 injury NN I-NP O
28 1819 1826 18808529 induced VBN B-VP O
29 1827 1829 18808529 by IN B-PP O
30 1830 1843 18808529 isoproterenol NN B-NP D007545
31 1843 1844 18808529 . . O O

1 0 0 17923537 -DOCSTART- -X- -X- O

1 0 11 17923537 Intraocular JJ B-NP O
2 12 20 17923537 pressure NN I-NP O
3 21 23 17923537 in IN B-PP O
4 24 32 17923537 patients NNS B-NP O
5 33 37 17923537 with IN B-PP O
6 38 45 17923537 uveitis NN B-NP D014605
7 46 53 17923537 treated VBN B-VP O
8 54 58 17923537 with IN B-PP O
9 59 71 17923537 fluocinolone NN B-NP D005446
10 72 81 17923537 acetonide NN I-NP D005446
11 82 90 17923537 implants NNS I-NP O
12 90 91 17923537 . . O O
13 92 101 17923537 OBJECTIVE NN B-NP O
14 101 102 17923537 : : O O
15 103 105 17923537 To TO B-VP O
16 106 112 17923537 report VB I-VP O
17 113 116 17923537 the DT B-NP O
18 117 126 17923537 incidence NN I-NP O
19 127 130 17923537 and CC I-NP O
20 131 141 17923537 management NN I-NP O
21 142 144 17923537 of IN B-PP O
22 145 153 17923537 elevated JJ B-NP D009798
23 154 165 17923537 intraocular JJ I-NP D009798
24 166 174 17923537 pressure NN I-NP D009798
25 175 176 17923537 ( ( O O
26 176 179 17923537 IOP NN B-NP O
27 179 180 17923537 ) ) O O
28 181 183 17923537 in IN B-PP O
29 184 192 17923537 patients NNS B-NP O
30 193 197 17923537 with IN B-PP O
31 198 205 17923537 uveitis NN B-NP D014605
32 206 213 17923537 treated VBN B-VP O
33 214 218 17923537 with IN B-PP O
34 219 222 17923537 the DT B-NP O
35 223 235 17923537 fluocinolone NN I-NP D005446
36 236 245 17923537 acetonide NN I-NP D005446
37 246 247 17923537 ( ( O O
38 247 249 17923537 FA NN B-NP D005446
39 249 250 17923537 ) ) O O
40 251 263 17923537 intravitreal JJ B-NP O
41 264 271 17923537 implant NN I-NP O
42 271 272 17923537 . . O O

1 273 279 17923537 DESIGN NN B-NP O
2 279 280 17923537 : : O O
3 281 287 17923537 Pooled VBN B-NP O
4 288 292 17923537 data NNS I-NP O
5 293 297 17923537 from IN B-PP O
6 298 299 17923537 3 CD B-NP O
7 300 311 17923537 multicenter JJ I-NP O
8 311 312 17923537 , , I-NP O
9 313 319 17923537 double JJ I-NP O
10 319 320 17923537 - HYPH I-NP O
11 320 326 17923537 masked VBN B-VP O
12 326 327 17923537 , , O O
13 328 338 17923537 randomized VBN B-VP O
14 338 339 17923537 , , O O
15 340 350 17923537 controlled VBN B-VP O
16 350 351 17923537 , , O O
17 352 357 17923537 phase NN B-NP O
18 358 360 17923537 2b NN I-NP O
19 360 361 17923537 / SYM B-VP O
20 361 362 17923537 3 CD B-NP O
21 363 371 17923537 clinical JJ I-NP O
22 372 378 17923537 trials NNS I-NP O
23 379 389 17923537 evaluating VBG B-VP O
24 390 393 17923537 the DT B-NP O
25 394 400 17923537 safety NN I-NP O
26 401 404 17923537 and CC I-NP O
27 405 413 17923537 efficacy NN I-NP O
28 414 416 17923537 of IN B-PP O
29 417 420 17923537 the DT B-NP O
30 421 425 17923537 0.59 CD I-NP O
31 425 426 17923537 - HYPH I-NP O
32 426 428 17923537 mg NN I-NP O
33 429 431 17923537 or CC I-NP O
34 432 435 17923537 2.1 CD I-NP O
35 435 436 17923537 - HYPH I-NP O
36 436 438 17923537 mg NN I-NP O
37 439 441 17923537 FA NN I-NP D005446
38 442 454 17923537 intravitreal JJ I-NP O
39 455 462 17923537 implant NN I-NP O
40 463 465 17923537 or CC O O
41 466 474 17923537 standard JJ B-NP O
42 475 482 17923537 therapy NN I-NP O
43 483 487 17923537 were VBD B-VP O
44 488 496 17923537 analyzed VBN I-VP O
45 496 497 17923537 . . O O

1 498 505 17923537 RESULTS NNS B-NP O
2 505 506 17923537 : : O O
3 507 513 17923537 During IN B-PP O
4 514 517 17923537 the DT B-NP O
5 518 519 17923537 3 CD I-NP O
6 519 520 17923537 - HYPH I-NP O
7 520 524 17923537 year NN I-NP O
8 525 531 17923537 follow VB B-VP O
9 531 532 17923537 - HYPH O O
10 532 534 17923537 up RP B-PRT O
11 534 535 17923537 , , O O
12 536 541 17923537 71.0% CD B-NP O
13 542 544 17923537 of IN B-PP O
14 545 554 17923537 implanted VBN B-NP O
15 555 559 17923537 eyes NNS I-NP O
16 560 563 17923537 had VBD B-VP O
17 564 566 17923537 an DT B-NP O
18 567 570 17923537 IOP NN I-NP O
19 571 579 17923537 increase NN I-NP O
20 580 582 17923537 of IN B-PP O
21 583 585 17923537 10 CD B-NP O
22 586 588 17923537 mm NN I-NP O
23 589 591 17923537 Hg NN I-NP O
24 592 594 17923537 or CC O O
25 595 599 17923537 more JJR B-ADJP O
26 600 604 17923537 than IN B-PP O
27 605 613 17923537 baseline NN B-NP O
28 614 617 17923537 and CC I-NP O
29 618 623 17923537 55.1% NN I-NP O
30 623 624 17923537 , , O O
31 625 630 17923537 24.7% NN B-NP O
32 630 631 17923537 , , O O
33 632 635 17923537 and CC O O
34 636 640 17923537 6.2% CD B-NP O
35 641 643 17923537 of IN B-PP O
36 644 648 17923537 eyes NNS B-NP O
37 649 656 17923537 reached VBD B-VP O
38 657 659 17923537 an DT B-NP O
39 660 663 17923537 IOP NN I-NP O
40 664 666 17923537 of IN B-PP O
41 667 669 17923537 30 CD B-NP O
42 670 672 17923537 mm NN I-NP O
43 673 675 17923537 Hg NN I-NP O
44 676 678 17923537 or CC I-NP O
45 679 683 17923537 more JJR I-NP O
46 683 684 17923537 , , O O
47 685 687 17923537 40 CD B-NP O
48 688 690 17923537 mm NN I-NP O
49 691 693 17923537 Hg NN I-NP O
50 694 696 17923537 or CC I-NP O
51 697 701 17923537 more JJR I-NP O
52 701 702 17923537 , , O O
53 703 706 17923537 and CC O O
54 707 709 17923537 50 CD B-NP O
55 710 712 17923537 mm NN I-NP O
56 713 715 17923537 Hg NN I-NP O
57 716 718 17923537 or CC I-NP O
58 719 723 17923537 more JJR I-NP O
59 723 724 17923537 , , O O
60 725 737 17923537 respectively RB B-ADVP O
61 737 738 17923537 . . O O

1 739 746 17923537 Topical JJ B-NP O
2 747 750 17923537 IOP NN I-NP O
3 750 751 17923537 - HYPH O O
4 751 759 17923537 lowering VBG B-VP O
5 760 770 17923537 medication NN B-NP O
6 771 774 17923537 was VBD B-VP O
7 775 787 17923537 administered VBN I-VP O
8 788 790 17923537 in IN B-PP O
9 791 796 17923537 74.8% NN B-NP O
10 797 799 17923537 of IN B-PP O
11 800 809 17923537 implanted VBN B-NP O
12 810 814 17923537 eyes NNS I-NP O
13 814 815 17923537 , , O O
14 816 819 17923537 and CC O O
15 820 823 17923537 IOP NN B-NP O
16 823 824 17923537 - HYPH O O
17 824 832 17923537 lowering VBG B-VP O
18 833 842 17923537 surgeries NNS B-NP O
19 842 843 17923537 , , O O
20 844 848 17923537 most JJS B-NP O
21 849 851 17923537 of IN B-PP O
22 852 857 17923537 which WDT B-NP O
23 858 862 17923537 were VBD B-VP O
24 863 879 17923537 trabeculectomies NNS B-NP O
25 880 881 17923537 ( ( O O
26 881 886 17923537 76.2% NN B-NP O
27 886 887 17923537 ) ) O O
28 887 888 17923537 , , O O
29 889 893 17923537 were VBD B-VP O
30 894 903 17923537 performed VBN I-VP O
31 904 906 17923537 on IN B-PP O
32 907 912 17923537 36.6% NN B-NP O
33 913 915 17923537 of IN B-PP O
34 916 925 17923537 implanted VBN B-NP O
35 926 930 17923537 eyes NNS I-NP O
36 930 931 17923537 . . O O

1 932 943 17923537 Intraocular JJ B-NP O
2 944 952 17923537 pressure NN I-NP O
3 952 953 17923537 - HYPH B-VP O
4 953 961 17923537 lowering VBG B-NP O
5 962 971 17923537 surgeries NNS I-NP O
6 972 976 17923537 were VBD B-VP O
7 977 987 17923537 considered VBN I-VP O
8 988 989 17923537 a DT B-NP O
9 990 997 17923537 success NN I-NP O
10 998 999 17923537 ( ( O O
11 999 1012 17923537 postoperative JJ B-NP O
12 1013 1016 17923537 IOP NN I-NP O
13 1017 1019 17923537 of IN B-PP O
14 1020 1021 17923537 6 CD B-NP O
15 1021 1022 17923537 - HYPH I-NP O
16 1022 1024 17923537 21 CD I-NP O
17 1025 1027 17923537 mm NN I-NP O
18 1028 1030 17923537 Hg NN I-NP O
19 1031 1035 17923537 with IN B-PP O
20 1036 1038 17923537 or CC B-PP O
21 1039 1046 17923537 without IN B-PP O
22 1047 1057 17923537 additional JJ B-NP O
23 1058 1061 17923537 IOP NN I-NP O
24 1061 1062 17923537 - HYPH O O
25 1062 1070 17923537 lowering VBG B-VP O
26 1071 1081 17923537 medication NN B-NP O
27 1081 1082 17923537 ) ) O O
28 1083 1085 17923537 in IN B-PP O
29 1086 1091 17923537 85.1% NN B-NP O
30 1092 1094 17923537 of IN B-PP O
31 1095 1099 17923537 eyes NNS B-NP O
32 1100 1102 17923537 at IN B-PP O
33 1103 1104 17923537 1 CD B-NP O
34 1105 1109 17923537 year NN I-NP O
35 1109 1110 17923537 . . O O

1 1111 1114 17923537 The DT B-NP O
2 1115 1119 17923537 rate NN I-NP O
3 1120 1122 17923537 of IN B-PP O
4 1123 1131 17923537 hypotony NN B-NP D015814
5 1132 1133 17923537 ( ( O O
6 1133 1136 17923537 IOP NN B-NP O
7 1137 1138 17923537 < SYM O O
8 1138 1139 17923537 / SYM B-NP O
9 1139 1140 17923537 = SYM B-VP O
10 1141 1142 17923537 5 CD B-NP O
11 1143 1145 17923537 mm NN I-NP O
12 1146 1148 17923537 Hg NN I-NP O
13 1148 1149 17923537 ) ) O O
14 1150 1159 17923537 following VBG B-PP O
15 1160 1163 17923537 IOP NN B-NP O
16 1163 1164 17923537 - HYPH O O
17 1164 1172 17923537 lowering VBG B-VP O
18 1173 1180 17923537 surgery NN B-NP O
19 1181 1182 17923537 ( ( O O
20 1182 1187 17923537 42.5% NN B-NP O
21 1187 1188 17923537 ) ) O O
22 1189 1192 17923537 was VBD B-VP O
23 1193 1196 17923537 not RB O O
24 1197 1206 17923537 different JJ B-ADJP O
25 1207 1211 17923537 from IN B-PP O
26 1212 1216 17923537 that DT B-NP O
27 1217 1219 17923537 of IN B-PP O
28 1220 1229 17923537 implanted VBN B-NP O
29 1230 1234 17923537 eyes NNS I-NP O
30 1235 1238 17923537 not RB B-VP O
31 1239 1248 17923537 subjected VBN I-VP O
32 1249 1251 17923537 to TO B-PP O
33 1252 1259 17923537 surgery NN B-NP O
34 1260 1261 17923537 ( ( O O
35 1261 1266 17923537 35.4% CD B-NP O
36 1266 1267 17923537 ) ) O O
37 1268 1269 17923537 ( ( O O
38 1269 1270 17923537 P NN B-NP O
39 1271 1272 17923537 = SYM B-VP O
40 1273 1276 17923537 .09 CD B-NP O
41 1276 1277 17923537 ) ) O O
42 1277 1278 17923537 . . O O

1 1279 1289 17923537 CONCLUSION NN B-NP O
2 1289 1290 17923537 : : O O
3 1291 1299 17923537 Elevated JJ B-NP O
4 1300 1303 17923537 IOP NN I-NP O
5 1304 1306 17923537 is VBZ B-VP O
6 1307 1308 17923537 a DT B-NP O
7 1309 1320 17923537 significant JJ I-NP O
8 1321 1333 17923537 complication NN I-NP O
9 1334 1338 17923537 with IN B-PP O
10 1339 1342 17923537 the DT B-NP O
11 1343 1345 17923537 FA NN I-NP O
12 1346 1358 17923537 intravitreal JJ I-NP O
13 1359 1366 17923537 implant NN I-NP O
14 1367 1370 17923537 but CC O O
15 1371 1374 17923537 may MD B-VP O
16 1375 1377 17923537 be VB I-VP O
17 1378 1388 17923537 controlled VBN I-VP O
18 1389 1393 17923537 with IN B-PP O
19 1394 1404 17923537 medication NN B-NP O
20 1405 1408 17923537 and CC I-NP O
21 1409 1416 17923537 surgery NN I-NP O
22 1416 1417 17923537 . . O O

1 0 0 8384253 -DOCSTART- -X- -X- O

1 0 4 8384253 Long JJ B-NP O
2 4 5 8384253 - HYPH I-NP O
3 5 9 8384253 term NN I-NP O
4 10 17 8384253 effects NNS I-NP O
5 18 20 8384253 of IN B-PP O
6 21 32 8384253 vincristine NN B-NP D014750
7 33 35 8384253 on IN B-PP O
8 36 39 8384253 the DT B-NP O
9 40 50 8384253 peripheral JJ I-NP O
10 51 58 8384253 nervous JJ I-NP O
11 59 65 8384253 system NN I-NP O
12 65 66 8384253 . . O O
13 67 72 8384253 Forty CD B-NP O
14 73 81 8384253 patients NNS I-NP O
15 82 86 8384253 with IN B-PP O
16 87 90 8384253 Non NNP B-NP D008228
17 90 91 8384253 - HYPH B-NP D008228
18 91 100 8384253 Hodgkin's NNP I-NP D008228
19 101 109 8384253 Lymphoma NN I-NP D008228
20 110 117 8384253 treated VBN B-VP O
21 118 122 8384253 with IN B-PP O
22 123 134 8384253 vincristine NN B-NP D014750
23 135 142 8384253 between IN B-PP O
24 143 147 8384253 1984 CD B-NP O
25 148 151 8384253 and CC I-NP O
26 152 156 8384253 1990 CD I-NP O
27 157 158 8384253 ( ( O O
28 158 168 8384253 cumulative JJ B-NP O
29 169 173 8384253 dose NN I-NP O
30 174 176 8384253 12 CD I-NP O
31 177 179 8384253 mg NN I-NP O
32 180 182 8384253 in IN B-PP O
33 183 185 8384253 18 CD B-NP O
34 185 186 8384253 - HYPH I-NP O
35 186 188 8384253 24 CD I-NP O
36 189 194 8384253 weeks NNS I-NP O
37 194 195 8384253 ) ) O O
38 196 200 8384253 were VBD B-VP O
39 201 213 8384253 investigated VBN I-VP O
40 214 216 8384253 in IN B-SBAR O
41 217 222 8384253 order NN O O
42 223 225 8384253 to TO B-VP O
43 226 234 8384253 evaluate VB I-VP O
44 235 238 8384253 the DT B-NP O
45 239 243 8384253 long JJ I-NP O
46 244 248 8384253 term NN I-NP O
47 249 256 8384253 effects NNS I-NP O
48 257 259 8384253 of IN B-PP O
49 260 271 8384253 vincristine NN B-NP D014750
50 272 274 8384253 on IN B-PP O
51 275 278 8384253 the DT B-NP O
52 279 289 8384253 peripheral JJ I-NP O
53 290 297 8384253 nervous JJ I-NP O
54 298 304 8384253 system NN I-NP O
55 304 305 8384253 . . O O

1 306 309 8384253 The DT B-NP O
2 310 318 8384253 patients NNS I-NP O
3 319 323 8384253 were VBD B-VP O
4 324 335 8384253 interviewed VBN I-VP O
5 336 340 8384253 with IN B-PP O
6 341 349 8384253 emphasis NN B-NP O
7 350 352 8384253 on IN B-PP O
8 353 364 8384253 neuropathic JJ B-NP D012678
9 365 373 8384253 symptoms NNS I-NP D012678
10 373 374 8384253 . . O O

1 375 383 8384253 Physical JJ B-NP O
2 384 387 8384253 and CC I-NP O
3 388 400 8384253 quantitative JJ I-NP O
4 401 408 8384253 sensory JJ I-NP O
5 409 420 8384253 examination NN I-NP O
6 421 425 8384253 with IN B-PP O
7 426 439 8384253 determination NN B-NP O
8 440 442 8384253 of IN B-PP O
9 443 452 8384253 vibratory JJ B-NP O
10 453 463 8384253 perception NN I-NP O
11 464 467 8384253 and CC O O
12 468 475 8384253 thermal JJ B-NP O
13 476 490 8384253 discrimination NN I-NP O
14 491 501 8384253 thresholds NNS I-NP O
15 502 506 8384253 were VBD B-VP O
16 507 516 8384253 performed VBN I-VP O
17 516 517 8384253 , , O O
18 518 522 8384253 four CD B-NP O
19 523 525 8384253 to TO I-NP O
20 526 528 8384253 77 CD I-NP O
21 529 535 8384253 months NNS I-NP O
22 536 537 8384253 ( ( O O
23 537 543 8384253 median NN B-NP O
24 544 546 8384253 34 CD I-NP O
25 547 553 8384253 months NNS I-NP O
26 553 554 8384253 ) ) O O
27 555 560 8384253 after IN B-PP O
28 561 572 8384253 vincristine NN B-NP D014750
29 573 582 8384253 treatment NN I-NP O
30 582 583 8384253 . . O O

1 584 590 8384253 Twenty CD B-NP O
2 590 591 8384253 - HYPH I-NP O
3 591 596 8384253 seven CD I-NP O
4 597 605 8384253 patients NNS I-NP O
5 606 614 8384253 reported VBD B-VP O
6 615 626 8384253 neuropathic JJ B-NP D012678
7 627 635 8384253 symptoms NNS I-NP D012678
8 635 636 8384253 . . O O

1 637 639 8384253 In IN B-PP O
2 640 642 8384253 13 CD B-NP O
3 643 645 8384253 of IN B-PP O
4 646 651 8384253 these DT B-NP O
5 652 654 8384253 27 CD I-NP O
6 655 663 8384253 patients NNS I-NP O
7 664 672 8384253 symptoms NNS I-NP O
8 673 677 8384253 were VBD B-VP O
9 678 683 8384253 still RB B-ADVP O
10 684 691 8384253 present JJ B-ADJP O
11 692 694 8384253 at IN B-PP O
12 695 698 8384253 the DT B-NP O
13 699 703 8384253 time NN I-NP O
14 704 706 8384253 of IN B-PP O
15 707 718 8384253 examination NN B-NP O
16 718 719 8384253 . . O O

1 720 722 8384253 In IN B-PP O
2 723 728 8384253 these DT B-NP O
3 729 737 8384253 patients NNS I-NP O
4 738 745 8384253 sensory VBP B-VP O
5 746 751 8384253 signs NNS B-NP O
6 752 755 8384253 and CC I-NP O
7 756 764 8384253 symptoms NNS I-NP O
8 765 777 8384253 predominated VBD B-VP O
9 777 778 8384253 . . O O

1 779 781 8384253 In IN B-PP O
2 782 785 8384253 the DT B-NP O
3 786 791 8384253 other JJ I-NP O
4 792 794 8384253 14 CD I-NP O
5 795 803 8384253 patients NNS I-NP O
6 804 812 8384253 symptoms NNS I-NP O
7 813 816 8384253 had VBD B-VP O
8 817 821 8384253 been VBN I-VP O
9 822 829 8384253 present JJ B-ADJP O
10 830 832 8384253 in IN B-PP O
11 833 836 8384253 the DT B-NP O
12 837 841 8384253 past NN I-NP O
13 841 842 8384253 . . O O

1 843 851 8384253 Symptoms NNS B-NP O
2 852 861 8384253 persisted VBD B-VP O
3 862 871 8384253 maximally RB B-NP O
4 872 874 8384253 40 CD I-NP O
5 875 881 8384253 months NNS I-NP O
6 882 887 8384253 since IN B-PP O
7 888 897 8384253 cessation NN B-NP O
8 898 900 8384253 of IN B-PP O
9 901 908 8384253 therapy NN B-NP O
10 908 909 8384253 . . O O

1 910 915 8384253 There EX B-NP O
2 916 919 8384253 was VBD B-VP O
3 920 922 8384253 no DT B-NP O
4 923 926 8384253 age NN I-NP O
5 927 937 8384253 difference NN I-NP O
6 938 945 8384253 between IN B-PP O
7 946 954 8384253 patients NNS B-NP O
8 955 959 8384253 with IN B-PP O
9 960 963 8384253 and CC B-PP O
10 964 971 8384253 without IN B-PP O
11 972 982 8384253 complaints NNS B-NP O
12 983 985 8384253 at IN B-PP O
13 986 989 8384253 the DT B-NP O
14 990 994 8384253 time NN I-NP O
15 995 997 8384253 of IN B-PP O
16 998 1009 8384253 examination NN B-NP O
17 1009 1010 8384253 . . O O

1 1011 1017 8384253 Normal JJ B-NP O
2 1018 1026 8384253 reflexes NNS I-NP O
3 1027 1031 8384253 were VBD B-VP O
4 1032 1037 8384253 found VBN I-VP O
5 1038 1040 8384253 in IN B-PP O
6 1041 1044 8384253 two CD B-NP O
7 1045 1050 8384253 third NN I-NP O
8 1051 1053 8384253 of IN B-PP O
9 1054 1062 8384253 patients NNS B-NP O
10 1062 1063 8384253 . . O O

1 1064 1075 8384253 Neuropathic JJ B-NP O
2 1076 1086 8384253 complaints NNS I-NP O
3 1087 1091 8384253 were VBD B-VP O
4 1092 1095 8384253 not RB O O
5 1096 1100 8384253 very RB B-ADJP O
6 1101 1112 8384253 troublesome JJ I-ADJP O
7 1113 1115 8384253 on IN B-PP O
8 1116 1119 8384253 the DT B-NP O
9 1120 1124 8384253 long JJ I-NP O
10 1125 1129 8384253 term NN I-NP O
11 1129 1130 8384253 . . O O

1 1131 1133 8384253 It PRP B-NP O
2 1134 1136 8384253 is VBZ B-VP O
3 1137 1146 8384253 concluded VBN I-VP O
4 1147 1151 8384253 that IN B-SBAR O
5 1152 1156 8384253 with IN B-PP O
6 1157 1160 8384253 the DT B-NP O
7 1161 1166 8384253 above RB I-NP O
8 1167 1176 8384253 mentioned VBN I-NP O
9 1177 1188 8384253 vincristine NN I-NP D014750
10 1189 1193 8384253 dose NN I-NP O
11 1194 1202 8384253 schedule NN I-NP O
12 1203 1208 8384253 signs NNS I-NP O
13 1209 1212 8384253 and CC I-NP O
14 1213 1221 8384253 symptoms NNS I-NP O
15 1222 1224 8384253 of IN B-PP O
16 1225 1236 8384253 vincristine NN B-NP D014750
17 1237 1247 8384253 neuropathy NN I-NP D009422
18 1248 1251 8384253 are VBP B-VP O
19 1252 1262 8384253 reversible JJ B-ADJP O
20 1263 1266 8384253 for IN B-PP O
21 1267 1268 8384253 a DT B-NP O
22 1269 1274 8384253 great JJ I-NP O
23 1275 1279 8384253 deal NN I-NP O
24 1280 1283 8384253 and CC I-NP O
25 1284 1293 8384253 prognosis NN I-NP O
26 1294 1296 8384253 is VBZ B-VP O
27 1297 1303 8384253 fairly RB B-ADJP O
28 1304 1308 8384253 good JJ I-ADJP O
29 1308 1309 8384253 . . O O

1 0 0 663266 -DOCSTART- -X- -X- O

1 0 11 663266 Ventricular JJ B-NP D014693
2 12 24 663266 fibrillation NN I-NP D014693
3 25 29 663266 from IN B-PP O
4 30 41 663266 diatrizoate NN B-NP D003973
5 42 46 663266 with IN B-PP O
6 47 50 663266 and CC B-PP O
7 51 58 663266 without IN B-PP O
8 59 68 663266 chelating VBG B-NP O
9 69 75 663266 agents NNS I-NP O
10 75 76 663266 . . O O
11 77 80 663266 The DT B-NP O
12 81 89 663266 toxicity NN I-NP D064420
13 90 92 663266 of IN B-PP O
14 93 103 663266 Renografin NN B-NP C027278
15 104 107 663266 76% NN I-NP C027278
16 108 111 663266 was VBD B-VP O
17 112 120 663266 compared VBN I-VP O
18 121 125 663266 with IN B-PP O
19 126 130 663266 that DT B-NP O
20 131 133 663266 of IN B-PP O
21 134 141 663266 Hypaque NNP B-NP C027278
22 142 145 663266 76% CD I-NP C027278
23 146 148 663266 by IN B-PP O
24 149 158 663266 selective JJ B-NP O
25 159 168 663266 injection NN I-NP O
26 169 171 663266 of IN B-PP O
27 172 176 663266 each DT B-NP O
28 177 181 663266 into IN B-PP O
29 182 185 663266 the DT B-NP O
30 186 191 663266 right JJ I-NP O
31 192 200 663266 coronary JJ I-NP O
32 201 207 663266 artery NN I-NP O
33 208 210 663266 of IN B-PP O
34 211 215 663266 dogs NNS B-NP O
35 215 216 663266 . . O O

1 217 227 663266 Renografin NN B-NP D003974
2 228 236 663266 contains VBZ B-VP O
3 237 240 663266 the DT B-NP O
4 241 250 663266 chelating VBG I-NP O
5 251 257 663266 agents NNS I-NP O
6 258 264 663266 sodium NN I-NP C102006
7 265 272 663266 citrate NN I-NP C102006
8 273 276 663266 and CC O O
9 277 285 663266 disodium NN B-NP D004492
10 286 293 663266 edetate NN I-NP D004492
11 293 294 663266 , , O O
12 295 300 663266 while IN B-SBAR O
13 301 308 663266 Hypaque NN B-NP D003973
14 309 317 663266 contains VBZ B-VP O
15 318 325 663266 calcium NN B-NP D004492
16 326 334 663266 disodium NN I-NP D004492
17 335 342 663266 edetate NN I-NP D004492
18 343 346 663266 and CC O O
19 347 349 663266 no DT B-NP O
20 350 356 663266 sodium NN I-NP C102006
21 357 364 663266 citrate NN I-NP C102006
22 364 365 663266 . . O O

1 366 377 663266 Ventricular JJ B-NP D014693
2 378 390 663266 fibrillation NN I-NP D014693
3 391 399 663266 occurred VBD B-VP O
4 400 413 663266 significantly RB B-ADVP O
5 414 418 663266 more RBR I-ADVP O
6 419 424 663266 often RB I-ADVP O
7 425 429 663266 with IN B-PP O
8 430 440 663266 Renografin NN B-NP D003974
9 440 441 663266 , , O O
10 442 452 663266 suggesting VBG B-VP O
11 453 457 663266 that IN B-SBAR O
12 458 467 663266 chelating VBG B-NP O
13 468 474 663266 agents NNS I-NP O
14 475 485 663266 contribute VBP B-VP O
15 486 488 663266 to TO B-PP O
16 489 497 663266 toxicity NN B-NP D064420
17 498 500 663266 in IN B-PP O
18 501 509 663266 coronary JJ B-NP O
19 510 521 663266 angiography NN I-NP O
20 521 522 663266 . . O O

1 0 0 9201797 -DOCSTART- -X- -X- O

1 0 3 9201797 The DT B-NP O
2 4 15 9201797 attenuating VBG I-NP O
3 16 22 9201797 effect NN I-NP O
4 23 25 9201797 of IN B-PP O
5 26 35 9201797 carteolol NN B-NP D002354
6 36 49 9201797 hydrochloride NN I-NP D002354
7 49 50 9201797 , , O O
8 51 52 9201797 a DT B-NP O
9 53 57 9201797 beta SYM I-NP O
10 57 58 9201797 - HYPH I-NP O
11 58 70 9201797 adrenoceptor NN I-NP O
12 71 81 9201797 antagonist NN I-NP O
13 81 82 9201797 , , O O
14 83 85 9201797 on IN B-PP O
15 86 97 9201797 neuroleptic JJ B-NP O
16 97 98 9201797 - HYPH I-NP O
17 98 105 9201797 induced VBN I-NP O
18 106 115 9201797 catalepsy NN I-NP D002375
19 116 118 9201797 in IN B-PP O
20 119 123 9201797 rats NNS B-NP O
21 123 124 9201797 . . O O
22 125 127 9201797 It PRP B-NP O
23 128 130 9201797 is VBZ B-VP O
24 131 136 9201797 known VBN I-VP O
25 137 141 9201797 that IN B-SBAR O
26 142 146 9201797 beta SYM B-NP O
27 146 147 9201797 - HYPH B-VP O
28 147 159 9201797 adrenoceptor NN B-NP O
29 160 171 9201797 antagonists NNS I-NP O
30 172 175 9201797 are VBP B-VP O
31 176 185 9201797 effective JJ B-ADJP O
32 186 188 9201797 in IN B-PP O
33 189 192 9201797 the DT B-NP O
34 193 202 9201797 treatment NN I-NP O
35 203 205 9201797 of IN B-PP O
36 206 215 9201797 akathisia NN B-NP D017109
37 215 216 9201797 , , O O
38 217 220 9201797 one CD B-NP O
39 221 223 9201797 of IN B-PP O
40 224 227 9201797 the DT B-NP O
41 228 242 9201797 extrapyramidal JJ I-NP O
42 243 247 9201797 side NN I-NP O
43 248 255 9201797 effects NNS I-NP O
44 256 260 9201797 that WDT B-NP O
45 261 266 9201797 occur VBP B-VP O
46 267 273 9201797 during IN B-PP O
47 274 285 9201797 neuroleptic JJ B-NP O
48 286 295 9201797 treatment NN I-NP O
49 295 296 9201797 . . O O

1 297 308 9201797 Neuroleptic JJ B-NP O
2 308 309 9201797 - HYPH I-NP O
3 309 316 9201797 induced VBN I-NP O
4 317 326 9201797 catalepsy NN I-NP D002375
5 326 327 9201797 , , O O
6 328 329 9201797 a DT B-NP O
7 330 335 9201797 model NN I-NP O
8 336 338 9201797 of IN B-PP O
9 339 350 9201797 neuroleptic JJ B-NP O
10 350 351 9201797 - HYPH I-NP O
11 351 358 9201797 induced VBN I-NP O
12 359 373 9201797 extrapyramidal JJ I-NP O
13 374 378 9201797 side NN I-NP O
14 379 386 9201797 effects NNS I-NP O
15 386 387 9201797 , , O O
16 388 391 9201797 was VBD B-VP O
17 392 402 9201797 considered VBN I-VP O
18 403 411 9201797 suitable JJ B-ADJP O
19 412 414 9201797 as IN B-PP O
20 415 416 9201797 a DT B-NP O
21 417 422 9201797 model NN I-NP O
22 423 426 9201797 for IN B-PP O
23 427 437 9201797 predicting VBG B-VP O
24 438 449 9201797 neuroleptic JJ B-NP O
25 449 450 9201797 - HYPH I-NP O
26 450 457 9201797 induced VBN I-NP O
27 458 467 9201797 akathisia NN I-NP D017109
28 468 470 9201797 in IN B-PP O
29 471 477 9201797 humans NNS B-NP O
30 477 478 9201797 , , O O
31 479 487 9201797 although IN B-SBAR O
32 488 499 9201797 neuroleptic JJ B-NP O
33 499 500 9201797 - HYPH I-NP O
34 500 507 9201797 induced VBN I-NP O
35 508 517 9201797 catalepsy NN I-NP D002375
36 518 521 9201797 was VBD B-VP O
37 522 525 9201797 not RB I-VP O
38 526 536 9201797 considered VBN I-VP O
39 537 538 9201797 a DT B-NP O
40 539 547 9201797 specific JJ I-NP O
41 548 552 9201797 test NN I-NP O
42 553 556 9201797 for IN B-PP O
43 557 568 9201797 neuroleptic JJ B-NP O
44 568 569 9201797 - HYPH I-NP O
45 569 576 9201797 induced VBN I-NP O
46 577 586 9201797 akathisia NN I-NP D017109
47 586 587 9201797 . . O O

1 588 597 9201797 Therefore RB B-ADVP O
2 597 598 9201797 , , O O
3 599 602 9201797 the DT B-NP O
4 603 610 9201797 effects NNS I-NP O
5 611 613 9201797 of IN B-PP O
6 614 623 9201797 carteolol NN B-NP D002354
7 623 624 9201797 , , O O
8 625 626 9201797 a DT B-NP O
9 627 631 9201797 beta SYM I-NP O
10 631 632 9201797 - HYPH I-NP O
11 632 644 9201797 adrenoceptor NN I-NP O
12 645 655 9201797 antagonist NN I-NP O
13 655 656 9201797 , , O O
14 657 659 9201797 on IN B-PP O
15 660 671 9201797 haloperidol NN B-NP D006220
16 671 672 9201797 - HYPH B-NP O
17 672 679 9201797 induced VBN I-NP O
18 680 689 9201797 catalepsy NN I-NP D002375
19 690 692 9201797 in IN B-PP O
20 693 697 9201797 rats NNS B-NP O
21 698 702 9201797 were VBD B-VP O
22 703 715 9201797 behaviorally RB I-VP O
23 716 723 9201797 studied VBN I-VP O
24 724 727 9201797 and CC O O
25 728 736 9201797 compared VBN B-PP O
26 737 741 9201797 with IN B-PP O
27 742 747 9201797 those DT B-NP O
28 748 750 9201797 of IN B-PP O
29 751 762 9201797 propranolol NN B-NP D011433
30 763 766 9201797 and CC I-NP O
31 767 776 9201797 biperiden NN I-NP D001712
32 776 777 9201797 , , O O
33 778 779 9201797 a DT B-NP O
34 780 790 9201797 muscarinic JJ I-NP O
35 791 799 9201797 receptor NN I-NP O
36 800 810 9201797 antagonist NN I-NP O
37 810 811 9201797 . . O O

1 812 821 9201797 Carteolol NN B-NP D002354
2 821 822 9201797 , , O O
3 823 825 9201797 as RB B-CONJP O
4 826 830 9201797 well RB I-CONJP O
5 831 833 9201797 as IN I-CONJP O
6 834 845 9201797 propranolol NN B-NP D011433
7 846 849 9201797 and CC I-NP O
8 850 859 9201797 biperiden NN I-NP D001712
9 859 860 9201797 , , O O
10 861 870 9201797 inhibited VBD B-VP O
11 871 874 9201797 the DT B-NP O
12 875 886 9201797 haloperidol NN I-NP D006220
13 886 887 9201797 - HYPH B-NP O
14 887 894 9201797 induced VBN I-NP O
15 895 904 9201797 catalepsy NN I-NP D002375
16 904 905 9201797 . . O O

1 906 909 9201797 The DT B-NP O
2 910 920 9201797 inhibitory JJ I-NP O
3 921 927 9201797 effect NN I-NP O
4 928 930 9201797 of IN B-PP O
5 931 940 9201797 carteolol NN B-NP D002354
6 941 944 9201797 was VBD B-VP O
7 945 951 9201797 almost RB B-ADJP O
8 952 962 9201797 comparable JJ I-ADJP O
9 963 965 9201797 to TO B-PP O
10 966 970 9201797 that DT B-NP O
11 971 973 9201797 of IN B-PP O
12 974 985 9201797 propranolol NN B-NP D011433
13 985 986 9201797 , , O O
14 987 990 9201797 but CC O O
15 991 994 9201797 was VBD B-VP O
16 995 1001 9201797 weaker JJR B-ADJP O
17 1002 1006 9201797 than IN B-PP O
18 1007 1011 9201797 that DT B-NP O
19 1012 1014 9201797 of IN B-PP O
20 1015 1024 9201797 biperiden NN B-NP D001712
21 1024 1025 9201797 . . O O

1 1026 1035 9201797 Carteolol NN B-NP D002354
2 1036 1039 9201797 did VBD B-VP O
3 1040 1043 9201797 not RB I-VP O
4 1044 1049 9201797 evoke VB I-VP O
5 1050 1062 9201797 postsynaptic JJ B-NP O
6 1063 1071 9201797 dopamine NN I-NP D004298
7 1072 1080 9201797 receptor NN I-NP O
8 1080 1081 9201797 - HYPH O O
9 1081 1092 9201797 stimulating VBG B-VP O
10 1093 1103 9201797 behavioral JJ B-NP O
11 1104 1109 9201797 signs NNS I-NP O
12 1110 1114 9201797 such JJ B-PP O
13 1115 1117 9201797 as IN I-PP O
14 1118 1128 9201797 stereotypy NN B-NP O
15 1129 1132 9201797 and CC I-NP O
16 1133 1148 9201797 hyperlocomotion NN I-NP D009069
17 1149 1151 9201797 in IN B-PP O
18 1152 1156 9201797 rats NNS B-NP O
19 1156 1157 9201797 . . O O

1 1158 1167 9201797 Carteolol NN B-NP D002354
2 1168 1171 9201797 did VBD B-VP O
3 1172 1175 9201797 not RB I-VP O
4 1176 1186 9201797 antagonize VB I-VP O
5 1187 1190 9201797 the DT B-NP O
6 1191 1201 9201797 inhibitory JJ I-NP O
7 1202 1209 9201797 effects NNS I-NP O
8 1210 1212 9201797 of IN B-PP O
9 1213 1224 9201797 haloperidol NN B-NP D006220
10 1225 1227 9201797 on IN B-PP O
11 1228 1239 9201797 apomorphine NN B-NP D001058
12 1239 1240 9201797 - HYPH B-NP O
13 1240 1247 9201797 induced VBN I-NP O
14 1248 1258 9201797 stereotypy NN I-NP O
15 1259 1262 9201797 and CC I-NP O
16 1263 1272 9201797 locomotor NN I-NP O
17 1273 1281 9201797 activity NN I-NP O
18 1282 1284 9201797 in IN B-PP O
19 1285 1289 9201797 rats NNS B-NP O
20 1289 1290 9201797 . . O O

1 1291 1293 9201797 In IN B-PP O
2 1294 1302 9201797 addition NN B-NP O
3 1302 1303 9201797 , , O O
4 1304 1313 9201797 carteolol NN B-NP D002354
5 1314 1317 9201797 did VBD B-VP O
6 1318 1321 9201797 not RB I-VP O
7 1322 1327 9201797 evoke VB I-VP O
8 1328 1329 9201797 5 CD B-NP O
9 1329 1330 9201797 - HYPH I-NP O
10 1330 1334 9201797 HT1A NN I-NP O
11 1335 1343 9201797 receptor NN I-NP O
12 1343 1344 9201797 - HYPH O O
13 1344 1355 9201797 stimulating VBG B-VP O
14 1356 1366 9201797 behavioral JJ B-NP O
15 1367 1372 9201797 signs NNS I-NP O
16 1373 1377 9201797 such JJ B-PP O
17 1378 1380 9201797 as IN I-PP O
18 1381 1385 9201797 flat JJ B-NP O
19 1386 1390 9201797 body NN I-NP O
20 1391 1398 9201797 posture NN I-NP O
21 1399 1402 9201797 and CC O O
22 1403 1410 9201797 forepaw NN B-NP O
23 1411 1419 9201797 treading NN I-NP O
24 1420 1423 9201797 and CC O O
25 1424 1427 9201797 did VBD B-VP O
26 1428 1431 9201797 not RB I-VP O
27 1432 1439 9201797 inhibit VB I-VP O
28 1440 1441 9201797 5 CD B-NP D006916
29 1441 1442 9201797 - HYPH I-NP D006916
30 1442 1459 9201797 hydroxytryptophan NN I-NP D006916
31 1459 1460 9201797 - HYPH B-NP O
32 1460 1467 9201797 induced VBN I-NP O
33 1468 1472 9201797 head NN I-NP O
34 1473 1479 9201797 twitch NN I-NP O
35 1480 1482 9201797 in IN B-PP O
36 1483 1487 9201797 rats NNS B-NP O
37 1487 1488 9201797 . . O O

1 1489 1496 9201797 Finally RB B-ADVP O
2 1496 1497 9201797 , , O O
3 1498 1507 9201797 carteolol NN B-NP D002354
4 1508 1511 9201797 did VBD B-VP O
5 1512 1515 9201797 not RB I-VP O
6 1516 1523 9201797 inhibit VB I-VP O
7 1524 1537 9201797 physostigmine NN B-NP D010830
8 1537 1538 9201797 - HYPH B-NP O
9 1538 1545 9201797 induced VBN I-NP O
10 1546 1555 9201797 lethality NN I-NP O
11 1556 1558 9201797 in IN B-PP O
12 1559 1563 9201797 rats NNS B-NP O
13 1563 1564 9201797 . . O O

1 1565 1570 9201797 These DT B-NP O
2 1571 1578 9201797 results NNS I-NP O
3 1579 1587 9201797 strongly RB B-VP O
4 1588 1595 9201797 suggest VBP I-VP O
5 1596 1600 9201797 that IN B-SBAR O
6 1601 1610 9201797 carteolol NN B-NP D002354
7 1611 1619 9201797 improves VBZ B-VP O
8 1620 1631 9201797 haloperidol NN B-NP D006220
9 1631 1632 9201797 - HYPH B-NP O
10 1632 1639 9201797 induced VBN I-NP O
11 1640 1649 9201797 catalepsy NN I-NP D002375
12 1650 1653 9201797 via IN B-PP O
13 1654 1657 9201797 its PRP$ B-NP O
14 1658 1662 9201797 beta SYM I-NP O
15 1662 1663 9201797 - HYPH I-NP O
16 1663 1675 9201797 adrenoceptor NN I-NP O
17 1676 1688 9201797 antagonistic JJ I-NP O
18 1689 1697 9201797 activity NN I-NP O
19 1698 1701 9201797 and CC O O
20 1702 1704 9201797 is VBZ B-VP O
21 1705 1713 9201797 expected VBN I-VP O
22 1714 1716 9201797 to TO I-VP O
23 1717 1719 9201797 be VB I-VP O
24 1720 1729 9201797 effective JJ B-ADJP O
25 1730 1732 9201797 in IN B-PP O
26 1733 1736 9201797 the DT B-NP O
27 1737 1746 9201797 treatment NN I-NP O
28 1747 1749 9201797 of IN B-PP O
29 1750 1759 9201797 akathisia NN B-NP D017109
30 1760 1767 9201797 without IN B-PP O
31 1768 1779 9201797 attenuating VBG B-VP O
32 1780 1791 9201797 neuroleptic JJ B-NP O
33 1791 1792 9201797 - HYPH I-NP O
34 1792 1799 9201797 induced VBN I-NP O
35 1800 1813 9201797 antipsychotic JJ I-NP O
36 1814 1821 9201797 effects NNS I-NP O
37 1822 1825 9201797 due JJ B-ADJP O
38 1826 1828 9201797 to TO B-PP O
39 1829 1832 9201797 its PRP$ B-NP O
40 1833 1845 9201797 postsynaptic JJ I-NP O
41 1846 1854 9201797 dopamine NN I-NP D004298
42 1855 1863 9201797 receptor NN I-NP O
43 1864 1876 9201797 antagonistic JJ I-NP O
44 1877 1885 9201797 activity NN I-NP O
45 1885 1886 9201797 . . O O

1 0 0 3961813 -DOCSTART- -X- -X- O

1 0 4 3961813 Dose NN B-NP O
2 4 5 3961813 - HYPH B-NP O
3 5 12 3961813 related VBN I-NP O
4 13 23 3961813 beneficial JJ I-NP O
5 24 27 3961813 and CC I-NP O
6 28 35 3961813 adverse JJ I-NP O
7 36 43 3961813 effects NNS I-NP O
8 44 46 3961813 of IN B-PP O
9 47 54 3961813 dietary JJ B-NP O
10 55 69 3961813 corticosterone NN I-NP D003345
11 70 72 3961813 on IN B-PP O
12 73 89 3961813 organophosphorus NN B-NP D010755
13 89 90 3961813 - HYPH B-NP O
14 90 97 3961813 induced VBN I-NP O
15 98 105 3961813 delayed VBN I-NP O
16 106 116 3961813 neuropathy NN I-NP D009422
17 117 119 3961813 in IN B-PP O
18 120 128 3961813 chickens NNS B-NP O
19 128 129 3961813 . . O O
20 130 133 3961813 Tri AFX O C025541
21 133 134 3961813 - HYPH B-NP C025541
22 134 139 3961813 ortho JJ I-NP C025541
23 139 140 3961813 - HYPH I-NP C025541
24 140 145 3961813 tolyl NN I-NP C025541
25 146 155 3961813 phosphate NN I-NP C025541
26 156 157 3961813 ( ( O O
27 157 161 3961813 TOTP NN B-NP C025541
28 161 162 3961813 ) ) O O
29 162 163 3961813 , , O O
30 164 167 3961813 360 CD B-NP O
31 168 170 3961813 mg NN I-NP O
32 170 171 3961813 / SYM O O
33 171 173 3961813 kg NN B-NP O
34 173 174 3961813 , , O O
35 175 177 3961813 po NN B-NP O
36 177 178 3961813 , , O O
37 179 182 3961813 and CC O O
38 183 187 3961813 0,0' NN B-NP D007531
39 187 188 3961813 - HYPH O D007531
40 188 199 3961813 diisopropyl NN B-NP D007531
41 200 219 3961813 phosphorofluoridate NN I-NP D007531
42 220 221 3961813 ( ( O O
43 221 224 3961813 DFP NN B-NP D007531
44 224 225 3961813 ) ) O O
45 225 226 3961813 , , O O
46 227 228 3961813 1 CD B-NP O
47 229 231 3961813 mg NN I-NP O
48 231 232 3961813 / SYM B-NP O
49 232 234 3961813 kg NN I-NP O
50 235 237 3961813 sc NN I-NP O
51 237 238 3961813 , , O O
52 239 243 3961813 were VBD B-VP O
53 244 256 3961813 administered VBN I-VP O
54 257 259 3961813 to TO B-PP O
55 260 265 3961813 adult JJ B-NP O
56 266 271 3961813 White NNP I-NP O
57 272 279 3961813 Leghorn NNP I-NP O
58 280 288 3961813 chickens VBZ B-VP O
59 289 291 3961813 24 CD B-NP O
60 292 294 3961813 hr NN I-NP O
61 295 300 3961813 after IN B-SBAR O
62 301 305 3961813 they PRP B-NP O
63 306 310 3961813 were VBD B-VP O
64 311 317 3961813 placed VBN I-VP O
65 318 320 3961813 on IN B-PP O
66 321 326 3961813 diets NNS B-NP O
67 327 337 3961813 containing VBG B-VP O
68 338 339 3961813 0 CD B-NP O
69 340 342 3961813 to TO I-NP O
70 343 346 3961813 300 CD I-NP O
71 347 350 3961813 ppm NN I-NP O
72 351 365 3961813 corticosterone NN I-NP D003345
73 365 366 3961813 . . O O

1 367 379 3961813 Supplemented VBN B-NP O
2 380 385 3961813 diets NNS I-NP O
3 386 390 3961813 were VBD B-VP O
4 391 400 3961813 continued VBN I-VP O
5 401 406 3961813 until IN B-PP O
6 407 415 3961813 clinical JJ B-NP O
7 416 421 3961813 signs NNS I-NP O
8 422 425 3961813 and CC I-NP O
9 426 433 3961813 lesions NNS I-NP O
10 434 436 3961813 of IN B-PP O
11 437 444 3961813 delayed VBN B-NP O
12 445 455 3961813 neuropathy NN I-NP D009422
13 456 464 3961813 appeared VBD B-VP O
14 464 465 3961813 . . O O

1 466 474 3961813 Although IN B-SBAR O
2 475 478 3961813 low JJ B-NP O
3 479 493 3961813 concentrations NNS I-NP O
4 494 495 3961813 ( ( O O
5 495 499 3961813 less JJR B-NP O
6 500 504 3961813 than IN B-PP O
7 505 507 3961813 or CC O O
8 508 513 3961813 equal JJ B-ADJP O
9 514 516 3961813 to TO B-PP O
10 517 519 3961813 50 CD B-NP O
11 520 523 3961813 ppm NN I-NP O
12 523 524 3961813 ) ) O O
13 525 527 3961813 of IN B-PP O
14 528 542 3961813 corticosterone NN B-NP D003345
15 543 546 3961813 had VBD B-VP O
16 547 557 3961813 beneficial JJ B-NP O
17 558 565 3961813 effects NNS I-NP O
18 566 568 3961813 on IN B-PP O
19 569 573 3961813 TOTP NN B-NP C025541
20 573 574 3961813 - HYPH B-NP O
21 574 581 3961813 induced VBN I-NP O
22 582 592 3961813 neuropathy NN I-NP D009422
23 592 593 3961813 , , O O
24 594 601 3961813 greater JJR B-ADJP O
25 602 606 3961813 than IN B-PP O
26 607 609 3961813 or CC O O
27 610 615 3961813 equal JJ B-ADJP O
28 616 618 3961813 to TO B-PP O
29 619 622 3961813 200 CD B-NP O
30 623 626 3961813 ppm NN I-NP O
31 627 638 3961813 exacerbated VBD B-VP O
32 639 647 3961813 clinical JJ B-NP O
33 648 653 3961813 signs NNS I-NP O
34 654 656 3961813 in IN B-PP O
35 657 665 3961813 chickens NNS B-NP O
36 666 671 3961813 given VBN B-VP O
37 672 678 3961813 either CC O O
38 679 683 3961813 TOTP NN B-NP C025541
39 684 686 3961813 or CC I-NP O
40 687 690 3961813 DFP NN I-NP D007531
41 690 691 3961813 . . O O

1 692 702 3961813 Neurotoxic JJ B-NP D020258
2 703 711 3961813 esterase NN I-NP O
3 712 722 3961813 activities NNS I-NP O
4 723 725 3961813 24 CD B-NP O
5 726 728 3961813 hr NN I-NP O
6 729 734 3961813 after IN B-PP O
7 735 739 3961813 TOTP NN B-NP C025541
8 740 742 3961813 or CC I-NP O
9 743 746 3961813 DFP NN I-NP D007531
10 747 751 3961813 were VBD B-VP O
11 752 756 3961813 less JJR B-NP O
12 757 761 3961813 than IN I-NP O
13 762 765 3961813 20% CD I-NP O
14 766 768 3961813 of IN B-PP O
15 769 775 3961813 values NNS B-NP O
16 776 784 3961813 measured VBN B-VP O
17 785 787 3961813 in IN B-PP O
18 788 796 3961813 chickens NNS B-NP O
19 797 800 3961813 not RB B-VP O
20 801 806 3961813 given VBN I-VP O
21 807 824 3961813 organophosphorous JJ B-NP D010755
22 825 834 3961813 compounds NNS I-NP O
23 834 835 3961813 . . O O

1 836 844 3961813 Chickens NNS B-NP O
2 845 850 3961813 given VBN B-PP O
3 851 854 3961813 200 CD B-NP O
4 855 858 3961813 ppm NN I-NP O
5 859 873 3961813 corticosterone NN I-NP D003345
6 874 881 3961813 without IN B-PP O
7 882 886 3961813 TOTP NN B-NP C025541
8 887 889 3961813 or CC I-NP O
9 890 893 3961813 DFP NN I-NP D007531
10 894 897 3961813 had VBD B-VP O
11 898 911 3961813 significantly RB B-NP O
12 912 920 3961813 elevated JJ I-NP O
13 921 929 3961813 activity NN I-NP O
14 930 932 3961813 of IN B-PP O
15 933 939 3961813 plasma NN B-NP O
16 940 954 3961813 cholinesterase NN I-NP O
17 955 958 3961813 and CC O O
18 959 972 3961813 significantly RB B-VP O
19 973 982 3961813 inhibited VBD I-VP O
20 983 991 3961813 activity NN B-NP O
21 992 994 3961813 of IN B-PP O
22 995 1000 3961813 liver NN B-NP O
23 1001 1017 3961813 carboxylesterase NN I-NP O
24 1017 1018 3961813 . . O O

1 1019 1031 3961813 Degenerating VBG B-VP D009410
2 1032 1042 3961813 myelinated VBN B-NP D009410
3 1043 1049 3961813 fibers NNS I-NP D009410
4 1050 1054 3961813 were VBD B-VP O
5 1055 1059 3961813 also RB B-ADVP O
6 1060 1067 3961813 evident JJ B-ADJP O
7 1068 1070 3961813 in IN B-PP O
8 1071 1077 3961813 distal JJ B-NP O
9 1078 1084 3961813 levels NNS I-NP O
10 1085 1087 3961813 of IN B-PP O
11 1088 1091 3961813 the DT B-NP O
12 1092 1102 3961813 peripheral JJ I-NP O
13 1103 1109 3961813 nerves NNS I-NP O
14 1110 1112 3961813 of IN B-PP O
15 1113 1121 3961813 chickens NNS B-NP O
16 1122 1127 3961813 given VBN B-VP O
17 1128 1132 3961813 TOTP NN B-NP C025541
18 1133 1135 3961813 or CC I-NP O
19 1136 1139 3961813 DFP NN I-NP D007531
20 1139 1140 3961813 . . O O

1 0 0 9067481 -DOCSTART- -X- -X- O

1 0 11 9067481 Cholesteryl NN B-NP C013440
2 12 25 9067481 hemisuccinate NN I-NP C013440
3 26 35 9067481 treatment NN I-NP O
4 36 44 9067481 protects VBZ B-VP O
5 45 52 9067481 rodents NNS B-NP O
6 53 57 9067481 from IN B-PP O
7 58 61 9067481 the DT B-NP O
8 62 67 9067481 toxic JJ I-NP O
9 68 75 9067481 effects NNS I-NP O
10 76 78 9067481 of IN B-PP O
11 79 92 9067481 acetaminophen NN B-NP D000082
12 92 93 9067481 , , O O
13 94 104 9067481 adriamycin NN B-NP D004317
14 104 105 9067481 , , O O
15 106 112 9067481 carbon NN B-NP D002251
16 113 126 9067481 tetrachloride NN I-NP D002251
17 126 127 9067481 , , O O
18 128 138 9067481 chloroform NN B-NP D002725
19 139 142 9067481 and CC I-NP O
20 143 156 9067481 galactosamine NN I-NP D005688
21 156 157 9067481 . . O O
22 158 160 9067481 In IN B-PP O
23 161 169 9067481 addition NN B-NP O
24 170 172 9067481 to TO B-PP O
25 173 176 9067481 its PRP$ B-NP O
26 177 180 9067481 use NN I-NP O
27 181 183 9067481 as IN B-PP O
28 184 185 9067481 a DT B-NP O
29 186 196 9067481 stabilizer NN I-NP O
30 196 197 9067481 / SYM B-NP O
31 197 207 9067481 rigidifier NN I-NP O
32 208 210 9067481 of IN B-PP O
33 211 220 9067481 membranes NNS B-NP O
34 220 221 9067481 , , O O
35 222 233 9067481 cholesteryl NN B-NP C013440
36 234 247 9067481 hemisuccinate NN I-NP C013440
37 247 248 9067481 , , O O
38 249 253 9067481 tris NN B-NP -1
39 254 258 9067481 salt NN I-NP -1
40 259 260 9067481 ( ( O O
41 260 262 9067481 CS NN B-NP -1
42 262 263 9067481 ) ) O O
43 264 278 9067481 administration NN B-NP O
44 279 282 9067481 has VBZ B-VP O
45 283 287 9067481 also RB I-VP O
46 288 292 9067481 been VBN I-VP O
47 293 298 9067481 shown VBN I-VP O
48 299 301 9067481 to TO I-VP O
49 302 309 9067481 protect VB I-VP O
50 310 314 9067481 rats NNS B-NP O
51 315 319 9067481 from IN B-PP O
52 320 323 9067481 the DT B-NP O
53 324 335 9067481 hepatotoxic JJ I-NP D056486
54 336 343 9067481 effects NNS I-NP O
55 344 346 9067481 of IN B-PP O
56 347 353 9067481 carbon NN B-NP D002251
57 354 367 9067481 tetrachloride NN I-NP D002251
58 368 369 9067481 ( ( O O
59 369 373 9067481 CCl4 NN B-NP D002251
60 373 374 9067481 ) ) O O
61 374 375 9067481 . . O O

1 376 378 9067481 To TO B-VP O
2 379 386 9067481 further VB I-VP O
3 387 390 9067481 our PRP$ B-NP O
4 391 404 9067481 understanding NN I-NP O
5 405 407 9067481 of IN B-PP O
6 408 411 9067481 the DT B-NP O
7 412 421 9067481 mechanism NN I-NP O
8 422 424 9067481 of IN B-PP O
9 425 427 9067481 CS NN B-NP -1
10 428 442 9067481 cytoprotection NN I-NP O
11 442 443 9067481 , , O O
12 444 446 9067481 we PRP B-NP O
13 447 455 9067481 examined VBD B-VP O
14 456 458 9067481 in IN B-PP O
15 459 463 9067481 rats NNS B-NP O
16 464 467 9067481 and CC I-NP O
17 468 472 9067481 mice NNS I-NP O
18 473 476 9067481 the DT B-NP O
19 477 487 9067481 protective JJ I-NP O
20 488 497 9067481 abilities NNS I-NP O
21 498 500 9067481 of IN B-PP O
22 501 503 9067481 CS NN B-NP -1
23 504 507 9067481 and CC O O
24 508 511 9067481 the DT B-NP O
25 512 515 9067481 non AFX I-NP O
26 515 516 9067481 - HYPH I-NP O
27 516 528 9067481 hydrolyzable JJ I-NP O
28 529 534 9067481 ether NN I-NP O
29 535 539 9067481 form NN I-NP O
30 540 542 9067481 of IN B-PP O
31 543 545 9067481 CS NN B-NP -1
32 545 546 9067481 , , O O
33 547 552 9067481 gamma SYM B-NP C103872
34 552 553 9067481 - HYPH B-VP C103872
35 553 574 9067481 cholesteryloxybutyric JJ B-NP C103872
36 575 579 9067481 acid NN I-NP C103872
37 579 580 9067481 , , O O
38 581 585 9067481 tris NN B-NP -1
39 586 590 9067481 salt NN I-NP -1
40 591 592 9067481 ( ( O O
41 592 595 9067481 CSE NN B-NP -1
42 595 596 9067481 ) ) O O
43 597 604 9067481 against IN B-PP O
44 605 618 9067481 acetaminophen NN B-NP D000082
45 618 619 9067481 - HYPH O O
46 619 620 9067481 , , O O
47 621 631 9067481 adriamycin NN B-NP D004317
48 631 632 9067481 - HYPH B-ADJP O
49 632 633 9067481 , , O O
50 634 640 9067481 carbon NN B-NP D002251
51 641 654 9067481 tetrachloride NN I-NP D002251
52 654 655 9067481 - HYPH B-ADJP O
53 655 656 9067481 , , O O
54 657 667 9067481 chloroform NN B-NP D002725
55 667 668 9067481 - HYPH B-NP O
56 669 672 9067481 and CC I-NP O
57 673 686 9067481 galactosamine NN I-NP D005688
58 686 687 9067481 - HYPH O O
59 687 694 9067481 induced VBN B-NP O
60 695 703 9067481 toxicity NN I-NP D064420
61 703 704 9067481 . . O O

1 705 708 9067481 The DT B-NP O
2 709 716 9067481 results NNS I-NP O
3 717 719 9067481 of IN B-PP O
4 720 725 9067481 these DT B-NP O
5 726 733 9067481 studies NNS I-NP O
6 734 746 9067481 demonstrated VBD B-VP O
7 747 751 9067481 that IN B-SBAR O
8 752 754 9067481 CS NN B-NP -1
9 754 755 9067481 - HYPH B-NP O
10 755 763 9067481 mediated VBN I-NP O
11 764 774 9067481 protection NN I-NP O
12 775 777 9067481 is VBZ B-VP O
13 778 781 9067481 not RB O O
14 782 791 9067481 selective JJ B-ADJP O
15 792 795 9067481 for IN B-PP O
16 796 797 9067481 a DT B-NP O
17 798 808 9067481 particular JJ I-NP O
18 809 816 9067481 species NNS I-NP O
19 816 817 9067481 , , O O
20 818 823 9067481 organ NN B-NP O
21 824 830 9067481 system NN I-NP O
22 831 833 9067481 or CC O O
23 834 839 9067481 toxic JJ B-NP O
24 840 848 9067481 chemical NN I-NP O
25 848 849 9067481 . . O O

1 850 851 9067481 A DT B-NP O
2 852 854 9067481 24 CD I-NP O
3 854 855 9067481 - HYPH I-NP O
4 855 856 9067481 h NN I-NP O
5 857 869 9067481 pretreatment NN I-NP O
6 870 872 9067481 of IN B-PP O
7 873 877 9067481 both DT B-NP O
8 878 882 9067481 rats NNS I-NP O
9 883 886 9067481 and CC I-NP O
10 887 891 9067481 mice NNS I-NP O
11 892 896 9067481 with IN B-PP O
12 897 898 9067481 a DT B-NP O
13 899 905 9067481 single JJ I-NP O
14 906 910 9067481 dose NN I-NP O
15 911 913 9067481 of IN B-PP O
16 914 916 9067481 CS NN B-NP -1
17 917 918 9067481 ( ( O O
18 918 923 9067481 100mg NN B-NP O
19 923 924 9067481 / SYM O O
20 924 926 9067481 kg NN B-NP O
21 926 927 9067481 , , O O
22 928 931 9067481 i.p NN B-NP O
23 931 932 9067481 . . O O
24 932 933 9067481 ) ) O O
25 933 934 9067481 , , O O
26 935 943 9067481 resulted VBD B-VP O
27 944 946 9067481 in IN B-PP O
28 947 958 9067481 significant JJ B-NP O
29 959 969 9067481 protection NN I-NP O
30 970 977 9067481 against IN B-PP O
31 978 981 9067481 the DT B-NP O
32 982 993 9067481 hepatotoxic JJ I-NP D056486
33 994 1001 9067481 effects NNS I-NP O
34 1002 1004 9067481 of IN B-PP O
35 1005 1009 9067481 CCl4 NN B-NP D002251
36 1009 1010 9067481 , , I-NP O
37 1011 1016 9067481 CHCl3 NN I-NP D002725
38 1016 1017 9067481 , , I-NP O
39 1018 1031 9067481 acetaminophen NN I-NP D000082
40 1032 1035 9067481 and CC I-NP O
41 1036 1049 9067481 galactosamine NN I-NP D005688
42 1050 1053 9067481 and CC O O
43 1054 1061 9067481 against IN B-PP O
44 1062 1065 9067481 the DT B-NP O
45 1066 1072 9067481 lethal JJ I-NP O
46 1073 1074 9067481 ( ( O O
47 1074 1077 9067481 and CC O O
48 1078 1088 9067481 presumably RB B-ADJP O
49 1089 1100 9067481 cardiotoxic JJ I-ADJP D066126
50 1100 1101 9067481 ) ) O O
51 1102 1108 9067481 effect NN B-NP O
52 1109 1111 9067481 of IN B-PP O
53 1112 1122 9067481 adriamycin NN B-NP D004317
54 1123 1137 9067481 administration NN I-NP O
55 1137 1138 9067481 . . O O

1 1139 1146 9067481 Maximal JJ B-NP O
2 1147 1149 9067481 CS NN I-NP -1
3 1149 1150 9067481 - HYPH B-VP O
4 1150 1158 9067481 mediated VBN B-NP O
5 1159 1169 9067481 protection NN I-NP O
6 1170 1173 9067481 was VBD B-VP O
7 1174 1182 9067481 observed VBN I-VP O
8 1183 1185 9067481 in IN B-PP O
9 1186 1198 9067481 experimental JJ B-NP O
10 1199 1206 9067481 animals NNS I-NP O
11 1207 1217 9067481 pretreated VBD B-VP O
12 1218 1220 9067481 24 CD B-NP O
13 1221 1222 9067481 h NN I-NP O
14 1223 1228 9067481 prior JJ B-ADJP O
15 1229 1231 9067481 to TO B-PP O
16 1232 1235 9067481 the DT B-NP O
17 1236 1241 9067481 toxic JJ I-NP O
18 1242 1248 9067481 insult NN I-NP O
19 1248 1249 9067481 . . O O

1 1250 1255 9067481 These DT B-NP O
2 1256 1260 9067481 data NNS I-NP O
3 1261 1268 9067481 suggest VBP B-VP O
4 1269 1273 9067481 that IN B-SBAR O
5 1274 1276 9067481 CS JJ B-NP -1
6 1277 1287 9067481 intervenes NNS I-NP O
7 1288 1290 9067481 in IN B-PP O
8 1291 1292 9067481 a DT B-NP O
9 1293 1301 9067481 critical JJ I-NP O
10 1302 1310 9067481 cellular JJ I-NP O
11 1311 1316 9067481 event NN I-NP O
12 1317 1321 9067481 that WDT B-NP O
13 1322 1324 9067481 is VBZ B-VP O
14 1325 1327 9067481 an DT B-NP O
15 1328 1337 9067481 important JJ I-NP O
16 1338 1344 9067481 common JJ I-NP O
17 1345 1352 9067481 pathway NN I-NP O
18 1353 1355 9067481 to TO B-PP O
19 1356 1361 9067481 toxic JJ B-NP O
20 1362 1366 9067481 cell NN I-NP O
21 1367 1372 9067481 death NN I-NP O
22 1372 1373 9067481 . . O O

1 1374 1377 9067481 The DT B-NP O
2 1378 1387 9067481 mechanism NN I-NP O
3 1388 1390 9067481 of IN B-PP O
4 1391 1393 9067481 CS NN B-NP -1
5 1394 1404 9067481 protection NN I-NP O
6 1405 1409 9067481 does VBZ B-VP O
7 1410 1413 9067481 not RB I-VP O
8 1414 1420 9067481 appear VB I-VP O
9 1421 1423 9067481 to TO I-VP O
10 1424 1426 9067481 be VB I-VP O
11 1427 1436 9067481 dependent JJ B-ADJP O
12 1437 1439 9067481 on IN B-PP O
13 1440 1443 9067481 the DT B-NP O
14 1444 1454 9067481 inhibition NN I-NP O
15 1455 1457 9067481 of IN B-PP O
16 1458 1466 9067481 chemical JJ B-NP O
17 1467 1480 9067481 bioactivation NN I-NP O
18 1481 1483 9067481 to TO B-PP O
19 1484 1485 9067481 a DT B-NP O
20 1486 1491 9067481 toxic JJ I-NP O
21 1492 1500 9067481 reactive JJ I-NP O
22 1501 1513 9067481 intermediate NN I-NP O
23 1514 1515 9067481 ( ( O O
24 1515 1517 9067481 in IN B-PP O
25 1518 1523 9067481 light NN B-NP O
26 1524 1526 9067481 of IN B-PP O
27 1527 1530 9067481 the DT B-NP O
28 1531 1541 9067481 protection NN I-NP O
29 1542 1550 9067481 observed VBN B-VP O
30 1551 1558 9067481 against IN B-PP O
31 1559 1572 9067481 galactosamine NN B-NP D005688
32 1573 1587 9067481 hepatotoxicity NN I-NP D056486
33 1587 1588 9067481 ) ) O O
34 1588 1589 9067481 . . O O

1 1590 1597 9067481 However RB B-ADVP O
2 1597 1598 9067481 , , O O
3 1599 1604 9067481 based VBN B-PP O
4 1605 1607 9067481 on IN B-PP O
5 1608 1611 9067481 the DT B-NP O
6 1612 1616 9067481 data NNS I-NP O
7 1617 1626 9067481 presented VBN B-VP O
8 1626 1627 9067481 , , O O
9 1628 1630 9067481 we PRP B-NP O
10 1631 1634 9067481 can MD B-VP O
11 1635 1638 9067481 not RB I-VP O
12 1639 1646 9067481 exclude VB I-VP O
13 1647 1650 9067481 the DT B-NP O
14 1651 1662 9067481 possibility NN I-NP O
15 1663 1667 9067481 that IN B-SBAR O
16 1668 1670 9067481 CS JJ B-NP -1
17 1671 1685 9067481 administration NN I-NP O
18 1686 1694 9067481 inhibits VBZ B-VP O
19 1695 1703 9067481 chemical JJ B-NP O
20 1704 1717 9067481 bioactivation NN I-NP O
21 1717 1718 9067481 . . O O

1 1719 1722 9067481 Our PRP$ B-NP O
2 1723 1731 9067481 findings NNS I-NP O
3 1732 1734 9067481 do VBP B-VP O
4 1735 1742 9067481 suggest VB I-VP O
5 1743 1747 9067481 that IN B-SBAR O
6 1748 1750 9067481 CS NN B-NP -1
7 1750 1751 9067481 - HYPH B-NP O
8 1751 1759 9067481 mediated VBN I-NP O
9 1760 1770 9067481 protection NN I-NP O
10 1771 1773 9067481 is VBZ B-VP O
11 1774 1783 9067481 dependent JJ B-ADJP O
12 1784 1786 9067481 on IN B-PP O
13 1787 1790 9067481 the DT B-NP O
14 1791 1797 9067481 action NN I-NP O
15 1798 1800 9067481 of IN B-PP O
16 1801 1804 9067481 the DT B-NP O
17 1805 1811 9067481 intact JJ I-NP O
18 1812 1819 9067481 anionic JJ I-NP O
19 1820 1822 9067481 CS NN I-NP -1
20 1823 1831 9067481 molecule NN I-NP O
21 1832 1833 9067481 ( ( O O
22 1833 1836 9067481 non AFX O O
23 1836 1837 9067481 - HYPH O O
24 1837 1849 9067481 hydrolyzable JJ B-NP O
25 1850 1853 9067481 CSE NN I-NP -1
26 1854 1857 9067481 was VBD B-VP O
27 1858 1860 9067481 as RB B-ADJP O
28 1861 1871 9067481 protective JJ I-ADJP O
29 1872 1874 9067481 as IN B-PP O
30 1875 1877 9067481 CS NN B-NP -1
31 1877 1878 9067481 ) ) O O
32 1878 1879 9067481 , , O O
33 1880 1885 9067481 whose WP$ B-NP O
34 1886 1895 9067481 mechanism NN I-NP O
35 1896 1899 9067481 has VBZ B-VP O
36 1900 1903 9067481 yet RB I-VP O
37 1904 1906 9067481 to TO I-VP O
38 1907 1909 9067481 be VB I-VP O
39 1910 1917 9067481 defined VBN I-VP O
40 1917 1918 9067481 . . O O

1 0 0 12600698 -DOCSTART- -X- -X- O

1 0 10 12600698 Protective JJ B-NP O
2 11 17 12600698 effect NN I-NP O
3 18 20 12600698 of IN B-PP O
4 21 30 12600698 edaravone NN B-NP C005435
5 31 38 12600698 against IN B-PP O
6 39 51 12600698 streptomycin NN B-NP D013307
7 51 52 12600698 - HYPH B-NP O
8 52 59 12600698 induced VBN I-NP O
9 60 77 12600698 vestibulotoxicity NN I-NP D015837
10 78 80 12600698 in IN B-PP O
11 81 84 12600698 the DT B-NP O
12 85 91 12600698 guinea NN I-NP O
13 92 95 12600698 pig NN I-NP O
14 95 96 12600698 . . O O
15 97 101 12600698 This DT B-NP O
16 102 107 12600698 study NN I-NP O
17 108 120 12600698 investigated VBD B-VP O
18 121 132 12600698 alleviation NN B-NP O
19 133 135 12600698 of IN B-PP O
20 136 148 12600698 streptomycin NN B-NP D013307
21 148 149 12600698 - HYPH B-NP O
22 149 156 12600698 induced VBN I-NP O
23 157 174 12600698 vestibulotoxicity NN I-NP D015837
24 175 177 12600698 by IN B-PP O
25 178 187 12600698 edaravone NN B-NP C005435
26 188 190 12600698 in IN B-PP O
27 191 197 12600698 guinea NN B-NP O
28 198 202 12600698 pigs NNS I-NP O
29 202 203 12600698 . . O O

1 204 213 12600698 Edaravone NN B-NP C005435
2 213 214 12600698 , , O O
3 215 216 12600698 a DT B-NP O
4 217 221 12600698 free JJ I-NP O
5 222 229 12600698 radical NN I-NP O
6 230 239 12600698 scavenger NN I-NP O
7 239 240 12600698 , , O O
8 241 244 12600698 has VBZ B-VP O
9 245 251 12600698 potent JJ B-NP O
10 252 256 12600698 free JJ I-NP O
11 257 264 12600698 radical NN I-NP O
12 265 274 12600698 quenching VBG B-VP O
13 275 281 12600698 action NN B-NP O
14 282 285 12600698 and CC O O
15 286 288 12600698 is VBZ B-VP O
16 289 293 12600698 used VBN I-VP O
17 294 296 12600698 in IN B-PP O
18 297 305 12600698 clinical JJ B-NP O
19 306 314 12600698 practice NN I-NP O
20 315 317 12600698 to TO B-VP O
21 318 323 12600698 treat VB I-VP O
22 324 332 12600698 cerebral JJ B-NP D002544
23 333 343 12600698 infarction NN I-NP D002544
24 343 344 12600698 . . O O

1 345 357 12600698 Streptomycin NN B-NP D013307
2 358 361 12600698 was VBD B-VP O
3 362 374 12600698 administered VBN I-VP O
4 375 377 12600698 to TO B-PP O
5 378 381 12600698 the DT B-NP O
6 382 387 12600698 inner JJ I-NP O
7 388 391 12600698 ear NN I-NP O
8 392 394 12600698 by IN B-PP O
9 395 402 12600698 osmotic JJ B-NP O
10 403 407 12600698 pump NN I-NP O
11 408 411 12600698 for IN B-PP O
12 412 414 12600698 24 CD B-NP O
13 415 416 12600698 h NN I-NP O
14 416 417 12600698 , , O O
15 418 421 12600698 and CC O O
16 422 431 12600698 edaravone NN B-NP C005435
17 432 433 12600698 ( ( O O
18 433 434 12600698 n NN B-NP O
19 434 435 12600698 = SYM B-VP O
20 435 436 12600698 8 CD B-NP O
21 436 437 12600698 ) ) O O
22 438 440 12600698 or CC O O
23 441 447 12600698 saline NN B-NP O
24 448 449 12600698 ( ( O O
25 449 450 12600698 n NN B-NP O
26 450 451 12600698 = SYM B-VP O
27 451 452 12600698 6 CD B-NP O
28 452 453 12600698 ) ) O O
29 454 457 12600698 was VBD B-VP O
30 458 475 12600698 intraperitoneally RB I-VP O
31 476 484 12600698 injected VBN I-VP O
32 485 489 12600698 once RB B-ADVP O
33 490 491 12600698 a DT B-NP O
34 492 495 12600698 day NN I-NP O
35 496 499 12600698 for IN B-PP O
36 500 501 12600698 7 CD B-NP O
37 502 506 12600698 days NNS I-NP O
38 506 507 12600698 . . O O

1 508 510 12600698 We PRP B-NP O
2 511 519 12600698 observed VBD B-VP O
3 520 530 12600698 horizontal JJ B-ADJP O
4 531 540 12600698 vestibulo AFX B-NP O
5 540 541 12600698 - HYPH I-NP O
6 541 547 12600698 ocular JJ I-NP O
7 548 554 12600698 reflex NN I-NP O
8 555 557 12600698 as IN B-PP O
9 558 559 12600698 a DT B-NP O
10 560 566 12600698 marker NN I-NP O
11 567 569 12600698 of IN B-PP O
12 570 583 12600698 postoperative JJ B-NP O
13 584 594 12600698 vestibular JJ I-NP O
14 595 603 12600698 function NN I-NP O
15 603 604 12600698 . . O O

1 605 612 12600698 Animals NNS B-NP O
2 613 621 12600698 injected VBN B-VP O
3 622 626 12600698 with IN B-PP O
4 627 633 12600698 saline NN B-NP O
5 634 640 12600698 showed VBD B-VP O
6 641 654 12600698 statistically RB B-NP O
7 655 662 12600698 smaller JJR I-NP O
8 663 668 12600698 gains NNS I-NP O
9 669 673 12600698 than IN B-PP O
10 674 679 12600698 those DT B-NP O
11 680 688 12600698 injected VBN B-VP O
12 689 693 12600698 with IN B-PP O
13 694 703 12600698 edaravone NN B-NP C005435
14 703 704 12600698 . . O O

1 705 710 12600698 These DT B-NP O
2 711 718 12600698 results NNS I-NP O
3 719 726 12600698 suggest VBP B-VP O
4 727 731 12600698 that IN B-SBAR O
5 732 741 12600698 edaravone NN B-NP C005435
6 742 752 12600698 suppresses VBZ B-VP O
7 753 765 12600698 streptomycin NN B-NP D013307
8 765 766 12600698 - HYPH B-NP O
9 766 773 12600698 induced VBN I-NP O
10 774 791 12600698 vestibulotoxicity NN I-NP D015837
11 791 792 12600698 . . O O

1 0 0 7791169 -DOCSTART- -X- -X- O

1 0 10 7791169 Protective JJ B-NP O
2 11 17 7791169 effect NN I-NP O
3 18 20 7791169 of IN B-PP O
4 21 32 7791169 misoprostol NN B-NP D016595
5 33 35 7791169 on IN B-PP O
6 36 48 7791169 indomethacin NN B-NP D007213
7 49 56 7791169 induced VBD B-VP O
8 57 62 7791169 renal JJ B-NP D007674
9 63 74 7791169 dysfunction NN I-NP D007674
10 75 77 7791169 in IN B-PP O
11 78 85 7791169 elderly JJ B-NP O
12 86 94 7791169 patients NNS I-NP O
13 94 95 7791169 . . O O
14 96 105 7791169 OBJECTIVE NN B-NP O
15 105 106 7791169 : : O O
16 107 109 7791169 To TO B-VP O
17 110 118 7791169 evaluate VB I-VP O
18 119 122 7791169 the DT B-NP O
19 123 131 7791169 possible JJ I-NP O
20 132 142 7791169 protective JJ I-NP O
21 143 150 7791169 effects NNS I-NP O
22 151 153 7791169 of IN B-PP O
23 154 165 7791169 misoprostol NN B-NP D016595
24 166 168 7791169 on IN B-PP O
25 169 174 7791169 renal JJ B-NP O
26 175 183 7791169 function NN I-NP O
27 184 186 7791169 in IN B-PP O
28 187 199 7791169 hospitalized VBN B-NP O
29 200 207 7791169 elderly JJ I-NP O
30 208 216 7791169 patients NNS I-NP O
31 217 224 7791169 treated VBN B-VP O
32 225 229 7791169 with IN B-PP O
33 230 242 7791169 indomethacin NN B-NP D007213
34 242 243 7791169 . . O O

1 244 251 7791169 METHODS NNS B-NP O
2 251 252 7791169 : : O O
3 253 258 7791169 Forty CD B-NP O
4 258 259 7791169 - : O O
5 259 263 7791169 five CD B-NP O
6 264 276 7791169 hospitalized VBD B-VP O
7 277 284 7791169 elderly JJ B-NP O
8 285 293 7791169 patients NNS I-NP O
9 294 295 7791169 ( ( O O
10 295 296 7791169 > SYM B-NP O
11 297 299 7791169 65 CD B-NP O
12 300 305 7791169 years NNS I-NP O
13 306 309 7791169 old JJ B-ADJP O
14 309 310 7791169 ) ) O O
15 311 314 7791169 who WP B-NP O
16 315 323 7791169 required VBD B-VP O
17 324 331 7791169 therapy NN B-NP O
18 332 336 7791169 with IN B-PP O
19 337 349 7791169 nonsteroidal JJ B-NP O
20 350 366 7791169 antiinflammatory JJ I-NP O
21 367 372 7791169 drugs NNS I-NP O
22 373 374 7791169 ( ( O O
23 374 379 7791169 NSAID NN B-NP O
24 379 380 7791169 ) ) O O
25 381 385 7791169 were VBD B-VP O
26 386 394 7791169 randomly RB I-VP O
27 395 403 7791169 assigned VBN I-VP O
28 404 406 7791169 to TO I-VP O
29 407 414 7791169 receive VB I-VP O
30 415 421 7791169 either CC O O
31 422 434 7791169 indomethacin NN B-NP D007213
32 434 435 7791169 , , O O
33 436 439 7791169 150 CD B-NP O
34 440 442 7791169 mg NN I-NP O
35 442 443 7791169 / SYM B-NP O
36 443 446 7791169 day NN I-NP O
37 447 448 7791169 ( ( O O
38 448 453 7791169 Group NN B-NP O
39 454 455 7791169 A NN I-NP O
40 455 456 7791169 ) ) O O
41 456 457 7791169 , , O O
42 458 460 7791169 or CC O O
43 461 473 7791169 indomethacin NN B-NP D007213
44 474 477 7791169 150 CD I-NP O
45 478 480 7791169 mg NN I-NP O
46 480 481 7791169 / SYM B-NP O
47 481 484 7791169 day NN I-NP O
48 485 489 7791169 plus CC O O
49 490 501 7791169 misoprostol NN B-NP D016595
50 502 504 7791169 at IN B-PP O
51 505 508 7791169 0.6 CD B-NP O
52 509 511 7791169 mg NN I-NP O
53 511 512 7791169 / SYM B-NP O
54 512 515 7791169 day NN I-NP O
55 516 517 7791169 ( ( O O
56 517 522 7791169 Group NN B-NP O
57 523 524 7791169 B NN I-NP O
58 524 525 7791169 ) ) O O
59 525 526 7791169 . . O O

1 527 537 7791169 Laboratory NN B-NP O
2 538 547 7791169 variables NNS I-NP O
3 548 550 7791169 of IN B-PP O
4 551 556 7791169 renal JJ B-NP O
5 557 565 7791169 function NN I-NP O
6 566 567 7791169 [ ( O O
7 567 572 7791169 serum NN B-NP O
8 573 583 7791169 creatinine NN I-NP D003404
9 583 584 7791169 , , O O
10 585 590 7791169 blood NN B-NP D001806
11 591 595 7791169 urea NN I-NP D001806
12 596 604 7791169 nitrogen NN I-NP D001806
13 605 606 7791169 ( ( O O
14 606 609 7791169 BUN NN B-NP D001806
15 609 610 7791169 ) ) O O
16 611 614 7791169 and CC O O
17 615 627 7791169 electrolytes NNS B-NP O
18 627 628 7791169 ] ) O O
19 629 633 7791169 were VBD B-VP O
20 634 643 7791169 evaluated VBN I-VP O
21 644 650 7791169 before IN B-PP O
22 651 661 7791169 initiation NN B-NP O
23 662 664 7791169 of IN B-PP O
24 665 672 7791169 therapy NN B-NP O
25 673 676 7791169 and CC O O
26 677 682 7791169 every DT B-NP O
27 683 684 7791169 2 CD I-NP O
28 685 689 7791169 days NNS I-NP O
29 689 690 7791169 , , O O
30 691 696 7791169 until IN B-PP O
31 697 708 7791169 termination NN B-NP O
32 709 711 7791169 of IN B-PP O
33 712 715 7791169 the DT B-NP O
34 716 721 7791169 study NN I-NP O
35 722 723 7791169 ( ( O O
36 723 724 7791169 a DT B-NP O
37 725 731 7791169 period NN I-NP O
38 732 734 7791169 of IN B-PP O
39 735 737 7791169 at IN B-NP O
40 738 743 7791169 least JJS I-NP O
41 744 745 7791169 6 CD I-NP O
42 746 750 7791169 days NNS I-NP O
43 750 751 7791169 ) ) O O
44 751 752 7791169 . . O O

1 753 761 7791169 Response NN B-NP O
2 762 764 7791169 to TO B-PP O
3 765 774 7791169 treatment NN B-NP O
4 775 778 7791169 was VBD B-VP O
5 779 788 7791169 estimated VBN I-VP O
6 789 791 7791169 by IN B-PP O
7 792 795 7791169 the DT B-NP O
8 796 802 7791169 visual JJ I-NP O
9 803 809 7791169 analog NN I-NP O
10 810 815 7791169 scale NN I-NP O
11 816 819 7791169 for IN B-PP O
12 820 828 7791169 severity NN B-NP O
13 829 831 7791169 of IN B-PP O
14 832 836 7791169 pain NN B-NP D010146
15 836 837 7791169 . . O O

1 838 845 7791169 RESULTS NNS B-NP O
2 845 846 7791169 : : O O
3 847 852 7791169 Forty CD B-NP O
4 852 853 7791169 - HYPH O O
5 853 856 7791169 two CD B-NP O
6 857 865 7791169 patients NNS I-NP O
7 866 875 7791169 completed VBD B-VP O
8 876 879 7791169 the DT B-NP O
9 880 885 7791169 study NN I-NP O
10 885 886 7791169 , , O O
11 887 889 7791169 22 CD B-NP O
12 890 892 7791169 in IN B-PP O
13 893 898 7791169 Group NN B-NP O
14 899 900 7791169 A NN I-NP O
15 901 904 7791169 and CC O O
16 905 907 7791169 20 CD B-NP O
17 908 910 7791169 in IN B-PP O
18 911 916 7791169 Group NN B-NP O
19 917 918 7791169 B NN I-NP O
20 918 919 7791169 . . O O

1 920 923 7791169 BUN NN B-NP D001806
2 924 927 7791169 and CC I-NP O
3 928 938 7791169 creatinine NN I-NP D003404
4 939 948 7791169 increased VBD B-VP O
5 949 951 7791169 by IN B-PP O
6 952 953 7791169 > JJR B-NP O
7 954 957 7791169 50% CD I-NP O
8 958 960 7791169 of IN B-PP O
9 961 969 7791169 baseline NN B-NP O
10 970 976 7791169 levels NNS I-NP O
11 977 979 7791169 in IN B-PP O
12 980 982 7791169 54 CD B-NP O
13 983 986 7791169 and CC I-NP O
14 987 990 7791169 45% CD I-NP O
15 991 993 7791169 of IN B-PP O
16 994 999 7791169 Group NN B-NP O
17 1000 1001 7791169 A NN I-NP O
18 1002 1010 7791169 patients NNS I-NP O
19 1010 1011 7791169 , , O O
20 1012 1024 7791169 respectively RB B-ADVP O
21 1024 1025 7791169 , , O O
22 1026 1034 7791169 compared VBN B-PP O
23 1035 1037 7791169 to TO B-PP O
24 1038 1042 7791169 only RB B-NP O
25 1043 1045 7791169 20 CD I-NP O
26 1046 1049 7791169 and CC I-NP O
27 1050 1053 7791169 10% CD I-NP O
28 1054 1056 7791169 of IN B-PP O
29 1057 1062 7791169 Group NN B-NP O
30 1063 1064 7791169 B NN I-NP O
31 1065 1073 7791169 patients NNS I-NP O
32 1074 1075 7791169 ( ( O O
33 1075 1076 7791169 p NN B-NP O
34 1077 1078 7791169 < SYM O O
35 1079 1083 7791169 0.05 CD B-NP O
36 1083 1084 7791169 ) ) O O
37 1084 1085 7791169 . . O O

1 1086 1095 7791169 Potassium NN B-NP D011188
2 1096 1097 7791169 ( ( O O
3 1097 1098 7791169 K NN B-NP D011188
4 1098 1099 7791169 ) ) O O
5 1100 1109 7791169 increment NN B-NP O
6 1110 1112 7791169 of IN B-PP O
7 1113 1116 7791169 0.6 CD B-NP O
8 1117 1120 7791169 mEq NN I-NP O
9 1120 1121 7791169 / SYM B-NP O
10 1121 1122 7791169 l NN B-NP O
11 1123 1125 7791169 or CC I-NP O
12 1126 1130 7791169 more JJR I-NP O
13 1131 1134 7791169 was VBD B-VP O
14 1135 1143 7791169 observed VBN I-VP O
15 1144 1146 7791169 in IN B-PP O
16 1147 1150 7791169 50% CD B-NP O
17 1151 1153 7791169 of IN B-PP O
18 1154 1159 7791169 Group NN B-NP O
19 1160 1161 7791169 A NN I-NP O
20 1161 1162 7791169 , , O O
21 1163 1166 7791169 but CC O O
22 1167 1169 7791169 in IN B-PP O
23 1170 1174 7791169 only RB B-NP O
24 1175 1178 7791169 15% CD I-NP O
25 1179 1181 7791169 of IN B-PP O
26 1182 1187 7791169 Group NN B-NP O
27 1188 1189 7791169 B NN I-NP O
28 1190 1198 7791169 patients NNS I-NP O
29 1199 1200 7791169 ( ( O O
30 1200 1201 7791169 p NN B-NP O
31 1202 1203 7791169 < SYM O O
32 1204 1208 7791169 0.05 CD B-NP O
33 1208 1209 7791169 ) ) O O
34 1209 1210 7791169 . . O O

1 1211 1214 7791169 The DT B-NP O
2 1215 1219 7791169 mean JJ I-NP O
3 1220 1230 7791169 increments NNS I-NP O
4 1231 1233 7791169 in IN B-PP O
5 1234 1237 7791169 BUN NN B-NP D001806
6 1237 1238 7791169 , , O O
7 1239 1249 7791169 creatinine NN B-NP D003404
8 1249 1250 7791169 , , O O
9 1251 1254 7791169 and CC O O
10 1255 1256 7791169 K NN B-NP D011188
11 1257 1261 7791169 were VBD B-VP O
12 1262 1269 7791169 reduced VBN I-VP O
13 1270 1272 7791169 by IN B-PP O
14 1273 1275 7791169 63 CD B-NP O
15 1275 1276 7791169 , , I-NP O
16 1277 1279 7791169 80 CD I-NP O
17 1279 1280 7791169 , , O O
18 1281 1284 7791169 and CC O O
19 1285 1288 7791169 42% CD B-NP O
20 1288 1289 7791169 , , O O
21 1290 1302 7791169 respectively RB B-ADVP O
22 1302 1303 7791169 , , O O
23 1304 1306 7791169 in IN B-PP O
24 1307 1312 7791169 Group NN B-NP O
25 1313 1314 7791169 B NN I-NP O
26 1315 1323 7791169 patients NNS I-NP O
27 1324 1332 7791169 compared VBN B-VP O
28 1333 1335 7791169 to TO B-PP O
29 1336 1341 7791169 Group NN B-NP O
30 1342 1343 7791169 A NN I-NP O
31 1343 1344 7791169 . . O O

1 1345 1353 7791169 Response NN B-NP O
2 1354 1356 7791169 to TO B-PP O
3 1357 1366 7791169 treatment NN B-NP O
4 1367 1370 7791169 did VBD B-VP O
5 1371 1374 7791169 not RB I-VP O
6 1375 1381 7791169 differ VB I-VP O
7 1382 1395 7791169 significantly RB B-ADVP O
8 1396 1403 7791169 between IN B-PP O
9 1404 1407 7791169 the DT B-NP O
10 1408 1409 7791169 2 CD I-NP O
11 1410 1416 7791169 groups NNS I-NP O
12 1416 1417 7791169 . . O O

1 1418 1428 7791169 CONCLUSION NN B-NP O
2 1428 1429 7791169 : : O O
3 1430 1442 7791169 Hospitalized VBN B-VP O
4 1443 1450 7791169 elderly JJ B-NP O
5 1451 1459 7791169 patients NNS I-NP O
6 1460 1463 7791169 are VBP B-VP O
7 1464 1466 7791169 at IN B-PP O
8 1467 1471 7791169 risk NN B-NP O
9 1472 1475 7791169 for IN B-PP O
10 1476 1486 7791169 developing VBG B-VP O
11 1487 1499 7791169 indomethacin NN B-NP D007213
12 1500 1507 7791169 related JJ I-NP O
13 1508 1513 7791169 renal JJ I-NP D007674
14 1514 1525 7791169 dysfunction NN I-NP D007674
15 1525 1526 7791169 . . O O

1 1527 1535 7791169 Addition NN B-NP O
2 1536 1538 7791169 of IN B-PP O
3 1539 1550 7791169 misoprostol NN B-NP D016595
4 1551 1554 7791169 can MD B-VP O
5 1555 1563 7791169 minimize VB I-VP O
6 1564 1568 7791169 this DT B-NP O
7 1569 1574 7791169 renal JJ I-NP D007674
8 1575 1585 7791169 impairment NN I-NP D007674
9 1586 1593 7791169 without IN B-PP O
10 1594 1603 7791169 affecting VBG B-VP O
11 1604 1608 7791169 pain NN B-NP D010146
12 1609 1616 7791169 control NN I-NP O
13 1616 1617 7791169 . . O O

1 0 0 3708922 -DOCSTART- -X- -X- O

1 0 12 3708922 Experimental JJ B-NP O
2 13 25 3708922 cyclosporine NN I-NP D016572
3 26 40 3708922 nephrotoxicity NN I-NP D007674
4 40 41 3708922 : : O O
5 42 46 3708922 risk NN B-NP O
6 47 49 3708922 of IN B-PP O
7 50 61 3708922 concomitant JJ B-NP O
8 62 74 3708922 chemotherapy NN I-NP O
9 74 75 3708922 . . O O
10 76 79 3708922 The DT B-NP O
11 80 84 3708922 role NN I-NP O
12 85 87 3708922 of IN B-PP O
13 88 100 3708922 cyclosporine NN B-NP D016572
14 101 102 3708922 ( ( O O
15 102 105 3708922 CSA NN B-NP D016572
16 105 106 3708922 ) ) O O
17 107 112 3708922 alone RB B-ADVP O
18 113 115 3708922 or CC O O
19 116 118 3708922 in IN B-PP O
20 119 130 3708922 combination NN B-NP O
21 131 135 3708922 with IN B-PP O
22 136 143 3708922 various JJ B-NP O
23 144 161 3708922 chemotherapeutics NNS I-NP O
24 162 164 3708922 in IN B-PP O
25 165 168 3708922 the DT B-NP O
26 169 180 3708922 development NN I-NP O
27 181 183 3708922 of IN B-PP O
28 184 189 3708922 renal JJ B-NP D007674
29 190 198 3708922 toxicity NN I-NP D007674
30 199 202 3708922 was VBD B-VP O
31 203 212 3708922 evaluated VBN I-VP O
32 213 215 3708922 in IN B-PP O
33 216 220 3708922 rats NNS B-NP O
34 220 221 3708922 . . O O

1 222 236 3708922 Administration NN B-NP O
2 237 239 3708922 of IN B-PP O
3 240 242 3708922 20 CD B-NP O
4 243 245 3708922 mg NN I-NP O
5 245 246 3708922 / SYM B-NP O
6 246 248 3708922 kg NN I-NP O
7 248 249 3708922 / SYM O O
8 249 252 3708922 day NN B-NP O
9 253 256 3708922 CSA NN I-NP D016572
10 257 260 3708922 for IN B-PP O
11 261 262 3708922 4 CD B-NP O
12 263 268 3708922 weeks NNS I-NP O
13 269 275 3708922 caused VBD B-VP O
14 276 281 3708922 renal JJ B-NP O
15 282 292 3708922 functional JJ I-NP O
16 293 296 3708922 and CC I-NP O
17 297 307 3708922 structural JJ I-NP O
18 308 315 3708922 changes NNS I-NP O
19 316 323 3708922 similar JJ B-ADJP O
20 324 326 3708922 to TO B-PP O
21 327 332 3708922 those DT B-NP O
22 333 341 3708922 reported VBN B-VP O
23 342 344 3708922 in IN B-PP O
24 345 348 3708922 man NN B-NP O
25 348 349 3708922 . . O O

1 350 353 3708922 The DT B-NP O
2 354 362 3708922 combined JJ I-NP O
3 363 377 3708922 administration NN I-NP O
4 378 380 3708922 of IN B-PP O
5 381 384 3708922 CSA NN B-NP D016572
6 385 388 3708922 and CC O O
7 389 396 3708922 various JJ B-NP O
8 397 413 3708922 chemotherapeutic JJ I-NP O
9 414 419 3708922 drugs NNS I-NP O
10 420 424 3708922 with IN B-PP O
11 425 426 3708922 a DT B-NP O
12 427 438 3708922 nephrotoxic JJ I-NP D007674
13 439 448 3708922 potential NN I-NP O
14 448 449 3708922 , , O O
15 450 454 3708922 such JJ B-PP O
16 455 457 3708922 as IN I-PP O
17 458 468 3708922 gentamicin NN B-NP D005839
18 469 470 3708922 ( ( O O
19 470 472 3708922 at IN B-PP O
20 473 484 3708922 therapeutic JJ B-NP O
21 485 490 3708922 doses NNS I-NP O
22 490 491 3708922 ) ) O O
23 491 492 3708922 , , O O
24 493 506 3708922 amphothericin NN B-NP D000666
25 507 508 3708922 B NN I-NP D000666
26 509 512 3708922 and CC O O
27 513 525 3708922 ketoconazole NN B-NP D007654
28 525 526 3708922 , , O O
29 527 532 3708922 which WDT B-NP O
30 533 536 3708922 are VBP B-VP O
31 537 547 3708922 frequently RB I-VP O
32 548 552 3708922 used VBN I-VP O
33 553 555 3708922 in IN B-PP O
34 556 572 3708922 immunosuppressed JJ B-NP O
35 573 581 3708922 patients NNS I-NP O
36 581 582 3708922 , , O O
37 583 586 3708922 did VBD B-VP O
38 587 590 3708922 not RB I-VP O
39 591 600 3708922 aggravate VB I-VP O
40 601 604 3708922 the DT B-NP O
41 605 608 3708922 CSA NN I-NP D016572
42 609 616 3708922 induced VBD B-VP O
43 617 625 3708922 toxicity NN B-NP D064420
44 626 628 3708922 in IN B-PP O
45 629 632 3708922 the DT B-NP O
46 633 636 3708922 rat NN I-NP O
47 637 642 3708922 model NN I-NP O
48 642 643 3708922 . . O O

1 644 654 3708922 Gentamicin NN B-NP D005839
2 655 657 3708922 at IN B-PP O
3 658 663 3708922 toxic JJ B-NP O
4 664 669 3708922 doses NNS I-NP O
5 669 670 3708922 , , O O
6 671 678 3708922 however RB B-ADVP O
7 678 679 3708922 , , O O
8 680 689 3708922 increased VBN B-NP O
9 690 693 3708922 CSA NN I-NP D016572
10 694 708 3708922 nephrotoxicity NN I-NP D007674
11 708 709 3708922 . . O O

1 710 714 3708922 Thus RB B-ADVP O
2 714 715 3708922 , , O O
3 716 719 3708922 the DT B-NP O
4 720 734 3708922 nephrotoxicity NN I-NP D007674
5 735 742 3708922 induced VBN B-VP O
6 743 745 3708922 by IN B-PP O
7 746 749 3708922 CSA NN B-NP D016572
8 750 753 3708922 has VBZ B-VP O
9 754 755 3708922 a DT B-NP O
10 756 765 3708922 different JJ I-NP O
11 766 778 3708922 pathogenetic JJ I-NP O
12 779 788 3708922 mechanism NN I-NP O
13 788 789 3708922 . . O O

1 0 0 458486 -DOCSTART- -X- -X- O

1 0 8 458486 Tiapride NN B-NP D063325
2 9 11 458486 in IN B-PP O
3 12 20 458486 levodopa NN B-NP D007980
4 20 21 458486 - HYPH B-NP O
5 21 28 458486 induced VBN I-NP O
6 29 40 458486 involuntary JJ I-NP D004409
7 41 50 458486 movements NNS I-NP D004409
8 50 51 458486 . . O O
9 52 60 458486 Tiapride NNP B-NP D063325
10 60 61 458486 , , O O
11 62 63 458486 a DT B-NP O
12 64 75 458486 substituted VBN I-NP O
13 76 85 458486 benzamide NN I-NP C037689
14 86 96 458486 derivative NN I-NP O
15 97 104 458486 closely RB B-ADJP O
16 105 112 458486 related JJ I-ADJP O
17 113 115 458486 to TO B-PP O
18 116 130 458486 metoclopramide NN B-NP D008787
19 130 131 458486 , , O O
20 132 139 458486 reduced VBD B-VP O
21 140 148 458486 levodopa NN B-NP D007980
22 148 149 458486 - HYPH B-NP O
23 149 156 458486 induced VBN I-NP O
24 157 161 458486 peak NN I-NP O
25 162 166 458486 dose NN I-NP O
26 167 178 458486 involuntary JJ I-NP D004409
27 179 188 458486 movements NNS I-NP D004409
28 189 191 458486 in IN B-PP O
29 192 194 458486 16 CD B-NP O
30 195 203 458486 patients NNS I-NP O
31 204 208 458486 with IN B-PP O
32 209 219 458486 idiopathic JJ B-NP D010300
33 220 231 458486 Parkinson's NNS I-NP D010300
34 232 239 458486 disease NN I-NP D010300
35 239 240 458486 . . O O

1 241 248 458486 However RB B-ADVP O
2 248 249 458486 , , O O
3 250 252 458486 an DT B-NP O
4 253 265 458486 unacceptable JJ I-NP O
5 266 274 458486 increase NN I-NP O
6 275 277 458486 in IN B-PP O
7 278 288 458486 disability NN B-NP O
8 289 293 458486 from IN B-PP O
9 294 306 458486 Parkinsonism NN B-NP D010300
10 307 311 458486 with IN B-PP O
11 312 323 458486 aggravation NN B-NP O
12 324 326 458486 of IN B-PP O
13 327 330 458486 end NN B-NP O
14 330 331 458486 - HYPH B-NP O
15 331 333 458486 of IN B-PP O
16 333 334 458486 - HYPH B-NP O
17 334 338 458486 dose NN I-NP O
18 339 347 458486 akinesia NN I-NP D004409
19 348 351 458486 led VBD B-VP O
20 352 354 458486 to TO B-PP O
21 355 358 458486 its PRP$ B-NP O
22 359 368 458486 cessation NN I-NP O
23 369 371 458486 in IN B-PP O
24 372 374 458486 14 CD B-NP O
25 375 383 458486 patients NNS I-NP O
26 383 384 458486 . . O O

1 385 393 458486 Tiapride NN B-NP D063325
2 394 397 458486 had VBD B-VP O
3 398 400 458486 no DT B-NP O
4 401 407 458486 effect NN I-NP O
5 408 410 458486 on IN B-PP O
6 411 419 458486 levodopa NN B-NP D007980
7 419 420 458486 - HYPH O O
8 420 427 458486 induced VBN B-VP O
9 428 433 458486 early JJ B-NP O
10 434 441 458486 morning NN I-NP O
11 442 444 458486 of IN B-PP O
12 445 446 458486 " `` O O
13 446 449 458486 off JJ B-NP O
14 449 450 458486 - HYPH I-NP O
15 450 456 458486 period NN I-NP O
16 456 457 458486 " '' O O
17 458 467 458486 segmental JJ B-NP O
18 468 476 458486 dystonia NN I-NP D004421
19 476 477 458486 . . O O

1 478 483 458486 These DT B-NP O
2 484 491 458486 results NNS I-NP O
3 492 496 458486 fail VBP B-VP O
4 497 499 458486 to TO I-VP O
5 500 507 458486 support VB I-VP O
6 508 511 458486 the DT B-NP O
7 512 518 458486 notion NN I-NP O
8 519 523 458486 that IN B-SBAR O
9 524 532 458486 levodopa NN B-NP D007980
10 532 533 458486 - HYPH B-NP O
11 533 540 458486 induced VBN I-NP O
12 541 552 458486 dyskinesias NNS I-NP D004409
13 553 556 458486 are VBP B-VP O
14 557 563 458486 caused VBN I-VP O
15 564 566 458486 by IN B-PP O
16 567 582 458486 overstimulation NN B-NP O
17 583 585 458486 of IN B-PP O
18 586 587 458486 a DT B-NP O
19 588 596 458486 separate JJ I-NP O
20 597 602 458486 group NN I-NP O
21 603 605 458486 of IN B-PP O
22 606 614 458486 dopamine NN B-NP D004298
23 615 624 458486 receptors NNS I-NP O
24 624 625 458486 . . O O

1 0 0 12852481 -DOCSTART- -X- -X- O

1 0 10 12852481 Comparison NN B-NP O
2 11 13 12852481 of IN B-PP O
3 14 27 12852481 developmental JJ B-NP O
4 28 38 12852481 toxicology NN I-NP O
5 39 41 12852481 of IN B-PP O
6 42 49 12852481 aspirin NN B-NP D001241
7 50 51 12852481 ( ( O O
8 51 66 12852481 acetylsalicylic JJ B-NP D001241
9 67 71 12852481 acid NN I-NP D001241
10 71 72 12852481 ) ) O O
11 73 75 12852481 in IN B-PP O
12 76 80 12852481 rats NNS B-NP O
13 81 86 12852481 using VBG B-VP O
14 87 95 12852481 selected VBN B-NP O
15 96 102 12852481 dosing NN I-NP O
16 103 112 12852481 paradigms NNS I-NP O
17 112 113 12852481 . . O O
18 114 124 12852481 BACKGROUND NN B-NP O
19 124 125 12852481 : : O O
20 126 134 12852481 Analysis NN B-NP O
21 135 137 12852481 of IN B-PP O
22 138 141 12852481 the DT B-NP O
23 142 152 12852481 literature NN I-NP O
24 153 156 12852481 for IN B-PP O
25 157 169 12852481 nonsteroidal JJ B-NP O
26 170 174 12852481 anti AFX I-NP O
27 174 175 12852481 - HYPH I-NP O
28 175 187 12852481 inflammatory JJ I-NP O
29 188 193 12852481 drugs NNS I-NP O
30 194 195 12852481 ( ( O O
31 195 201 12852481 NSAIDs NNS B-NP O
32 201 202 12852481 ) ) O O
33 203 211 12852481 suggests VBZ B-VP O
34 212 216 12852481 that IN B-SBAR O
35 217 218 12852481 a DT B-NP O
36 219 222 12852481 low JJ I-NP O
37 223 232 12852481 incidence NN I-NP O
38 233 235 12852481 of IN B-PP O
39 236 249 12852481 developmental JJ B-NP D000014
40 250 259 12852481 anomalies NNS I-NP D000014
41 260 266 12852481 occurs VBZ B-VP O
42 267 269 12852481 in IN B-PP O
43 270 274 12852481 rats NNS B-NP O
44 275 280 12852481 given VBN B-VP O
45 281 287 12852481 NSAIDs NNS B-NP O
46 288 290 12852481 on IN B-PP O
47 291 299 12852481 specific JJ B-NP O
48 300 304 12852481 days NNS I-NP O
49 305 311 12852481 during IN B-PP O
50 312 325 12852481 organogenesis NN B-NP O
51 325 326 12852481 . . O O

1 327 334 12852481 Aspirin NN B-NP D001241
2 335 336 12852481 ( ( O O
3 336 351 12852481 acetylsalicylic JJ B-NP D001241
4 352 356 12852481 acid NN I-NP D001241
5 357 358 12852481 [ ( O O
6 358 361 12852481 ASA NN B-NP D001241
7 361 362 12852481 ] ) O O
8 362 363 12852481 ) ) O O
9 363 364 12852481 , , O O
10 365 367 12852481 an DT B-NP O
11 368 380 12852481 irreversible JJ I-NP O
12 381 395 12852481 cyclooxygenase NN I-NP O
13 396 397 12852481 1 CD I-NP O
14 398 401 12852481 and CC I-NP O
15 402 403 12852481 2 CD I-NP O
16 404 413 12852481 inhibitor NN I-NP O
17 413 414 12852481 , , O O
18 415 422 12852481 induces VBZ B-VP O
19 423 436 12852481 developmental JJ B-NP D000014
20 437 446 12852481 anomalies NNS I-NP D000014
21 447 451 12852481 when WRB B-ADVP O
22 452 464 12852481 administered VBN B-VP O
23 465 467 12852481 to TO B-PP O
24 468 474 12852481 Wistar NNP B-NP O
25 475 479 12852481 rats NNS I-NP O
26 480 482 12852481 on IN B-PP O
27 483 494 12852481 gestational JJ B-NP O
28 495 498 12852481 day NN I-NP O
29 499 500 12852481 ( ( O O
30 500 502 12852481 GD NN B-NP O
31 502 503 12852481 ) ) O O
32 504 505 12852481 9 CD B-NP O
33 505 506 12852481 , , I-NP O
34 507 509 12852481 10 CD I-NP O
35 509 510 12852481 , , O O
36 511 513 12852481 or CC O O
37 514 516 12852481 11 CD B-NP O
38 517 518 12852481 ( ( O O
39 518 524 12852481 Kimmel NNP B-NP O
40 525 527 12852481 CA NNP I-NP O
41 527 528 12852481 , , O O
42 529 535 12852481 Wilson NNP B-NP O
43 536 538 12852481 JG NNP I-NP O
44 538 539 12852481 , , O O
45 540 550 12852481 Schumacher NNP B-NP O
46 551 553 12852481 HJ NNP I-NP O
47 553 554 12852481 . . O O

1 555 565 12852481 Teratology NN B-NP O
2 566 567 12852481 4 CD I-NP O
3 567 568 12852481 : : O O
4 568 570 12852481 15 CD B-NP O
5 570 571 12852481 - HYPH I-NP O
6 571 573 12852481 24 CD I-NP O
7 573 574 12852481 , , I-NP O
8 575 579 12852481 1971 CD I-NP O
9 579 580 12852481 ) ) O O
10 580 581 12852481 . . O O

1 582 587 12852481 There EX B-NP O
2 588 591 12852481 are VBP B-VP O
3 592 594 12852481 no DT B-NP O
4 595 604 12852481 published VBN I-NP O
5 605 608 12852481 ASA NN I-NP D001241
6 609 616 12852481 studies NNS I-NP O
7 617 622 12852481 using VBG B-VP O
8 623 626 12852481 the DT B-NP O
9 627 635 12852481 multiple JJ I-NP O
10 636 642 12852481 dosing NN I-NP O
11 643 651 12852481 paradigm NN I-NP O
12 652 654 12852481 of IN B-PP O
13 655 658 12852481 GDs NNS B-NP O
14 659 660 12852481 6 CD B-NP O
15 661 663 12852481 to TO B-PP O
16 664 666 12852481 17 CD B-NP O
17 666 667 12852481 . . O O

1 668 678 12852481 Objectives NNS B-NP O
2 679 681 12852481 of IN B-PP O
3 682 685 12852481 the DT B-NP O
4 686 693 12852481 current JJ I-NP O
5 694 699 12852481 study NN I-NP O
6 700 704 12852481 were VBD B-VP O
7 705 707 12852481 to TO I-VP O
8 708 715 12852481 compare VB I-VP O
9 716 723 12852481 results NNS B-NP O
10 724 731 12852481 between IN B-PP O
11 732 739 12852481 Sprague NNP B-NP O
12 739 740 12852481 - HYPH I-NP O
13 740 746 12852481 Dawley NNP I-NP O
14 747 748 12852481 ( ( O O
15 748 750 12852481 SD NNP B-NP O
16 750 751 12852481 ) ) O O
17 752 755 12852481 and CC O O
18 756 762 12852481 Wistar NNP B-NP O
19 763 770 12852481 strains NNS I-NP O
20 771 775 12852481 when WRB B-ADVP O
21 776 779 12852481 ASA NN B-NP D001241
22 780 782 12852481 is VBZ B-VP O
23 783 795 12852481 administered VBN I-VP O
24 796 798 12852481 on IN B-PP O
25 799 801 12852481 GD NN B-NP O
26 802 803 12852481 9 CD I-NP O
27 803 804 12852481 , , I-NP O
28 805 807 12852481 10 CD I-NP O
29 807 808 12852481 , , O O
30 809 811 12852481 or CC O O
31 812 814 12852481 11 CD B-NP O
32 814 815 12852481 ; : O O
33 816 818 12852481 to TO B-VP O
34 819 826 12852481 compare VB I-VP O
35 827 830 12852481 the DT B-NP O
36 831 843 12852481 malformation NN I-NP O
37 844 852 12852481 patterns NNS I-NP O
38 853 862 12852481 following VBG B-PP O
39 863 869 12852481 single JJ B-NP O
40 870 873 12852481 and CC I-NP O
41 874 882 12852481 multiple JJ I-NP O
42 883 890 12852481 dosings NNS I-NP O
43 891 897 12852481 during IN B-PP O
44 898 911 12852481 organogenesis NN B-NP O
45 912 914 12852481 in IN B-PP O
46 915 917 12852481 SD NNP B-NP O
47 918 922 12852481 rats NNS I-NP O
48 922 923 12852481 ; : O O
49 924 927 12852481 and CC O O
50 928 930 12852481 to TO B-VP O
51 931 935 12852481 test VB I-VP O
52 936 939 12852481 the DT B-NP O
53 940 950 12852481 hypothesis NN I-NP O
54 951 955 12852481 that IN B-SBAR O
55 956 964 12852481 maternal JJ B-NP O
56 965 981 12852481 gastrointestinal JJ I-NP D005767
57 982 990 12852481 toxicity NN I-NP D005767
58 991 1000 12852481 confounds VBZ B-VP O
59 1001 1004 12852481 the DT B-NP O
60 1005 1014 12852481 detection NN I-NP O
61 1015 1017 12852481 of IN B-PP O
62 1018 1021 12852481 low JJ B-NP O
63 1022 1031 12852481 incidence NN I-NP O
64 1032 1045 12852481 malformations NNS I-NP D000014
65 1046 1050 12852481 with IN B-PP O
66 1051 1054 12852481 ASA NN B-NP D001241
67 1055 1059 12852481 when WRB B-ADVP O
68 1060 1061 12852481 a DT B-NP O
69 1062 1070 12852481 multiple JJ I-NP O
70 1071 1077 12852481 dosing NN I-NP O
71 1078 1086 12852481 paradigm NN I-NP O
72 1087 1089 12852481 is VBZ B-VP O
73 1090 1094 12852481 used VBN I-VP O
74 1094 1095 12852481 . . O O

1 1096 1103 12852481 METHODS NNS B-NP O
2 1103 1104 12852481 : : O O
3 1105 1108 12852481 ASA NN B-NP D001241
4 1109 1112 12852481 was VBD B-VP O
5 1113 1125 12852481 administered VBN I-VP O
6 1126 1128 12852481 as IN B-PP O
7 1129 1130 12852481 a DT B-NP O
8 1131 1137 12852481 single JJ I-NP O
9 1138 1142 12852481 dose NN I-NP O
10 1143 1145 12852481 on IN B-PP O
11 1146 1148 12852481 GD NN B-NP O
12 1149 1150 12852481 9 CD I-NP O
13 1151 1152 12852481 ( ( O O
14 1152 1153 12852481 0 CD B-NP O
15 1153 1154 12852481 , , I-NP O
16 1155 1158 12852481 250 CD I-NP O
17 1158 1159 12852481 , , I-NP O
18 1160 1163 12852481 500 CD I-NP O
19 1163 1164 12852481 , , O O
20 1165 1167 12852481 or CC O O
21 1168 1171 12852481 625 CD B-NP O
22 1172 1174 12852481 mg NN I-NP O
23 1174 1175 12852481 / SYM B-NP O
24 1175 1177 12852481 kg NN I-NP O
25 1177 1178 12852481 ) ) O O
26 1178 1179 12852481 , , O O
27 1180 1182 12852481 10 CD B-NP O
28 1183 1184 12852481 ( ( O O
29 1184 1185 12852481 0 CD B-NP O
30 1185 1186 12852481 , , I-NP O
31 1187 1190 12852481 500 CD I-NP O
32 1190 1191 12852481 , , I-NP O
33 1192 1195 12852481 625 CD I-NP O
34 1195 1196 12852481 , , O O
35 1197 1199 12852481 or CC O O
36 1200 1203 12852481 750 CD B-NP O
37 1204 1206 12852481 mg NN I-NP O
38 1206 1207 12852481 / SYM B-NP O
39 1207 1209 12852481 kg NN I-NP O
40 1209 1210 12852481 ) ) O O
41 1210 1211 12852481 , , O O
42 1212 1214 12852481 or CC O O
43 1215 1217 12852481 11 CD B-NP O
44 1218 1219 12852481 ( ( O O
45 1219 1220 12852481 0 CD B-NP O
46 1220 1221 12852481 , , I-NP O
47 1222 1225 12852481 500 CD I-NP O
48 1225 1226 12852481 , , I-NP O
49 1227 1230 12852481 750 CD I-NP O
50 1230 1231 12852481 , , O O
51 1232 1234 12852481 or CC O O
52 1235 1239 12852481 1000 CD B-NP O
53 1240 1242 12852481 mg NN I-NP O
54 1242 1243 12852481 / SYM B-NP O
55 1243 1245 12852481 kg NN I-NP O
56 1245 1246 12852481 ) ) O O
57 1247 1250 12852481 and CC B-PP O
58 1251 1255 12852481 from IN B-PP O
59 1256 1258 12852481 GD NN B-NP O
60 1259 1260 12852481 6 CD I-NP O
61 1261 1263 12852481 to TO B-PP O
62 1264 1266 12852481 GD NN B-NP O
63 1267 1269 12852481 17 CD I-NP O
64 1270 1271 12852481 ( ( O O
65 1271 1272 12852481 0 CD B-NP O
66 1272 1273 12852481 , , I-NP O
67 1274 1276 12852481 50 CD I-NP O
68 1276 1277 12852481 , , I-NP O
69 1278 1281 12852481 125 CD I-NP O
70 1281 1282 12852481 , , O O
71 1283 1285 12852481 or CC O O
72 1286 1289 12852481 250 CD B-NP O
73 1290 1292 12852481 mg NN I-NP O
74 1292 1293 12852481 / SYM B-NP O
75 1293 1295 12852481 kg NN I-NP O
76 1296 1297 12852481 a DT B-NP O
77 1298 1301 12852481 day NN I-NP O
78 1301 1302 12852481 ) ) O O
79 1303 1305 12852481 in IN B-PP O
80 1306 1309 12852481 the DT B-NP O
81 1310 1318 12852481 multiple JJ I-NP O
82 1319 1323 12852481 dose NN I-NP O
83 1324 1329 12852481 study NN I-NP O
84 1330 1332 12852481 to TO B-PP O
85 1333 1335 12852481 SD NN B-NP O
86 1336 1340 12852481 rats NNS I-NP O
87 1340 1341 12852481 . . O O

1 1342 1349 12852481 Animals NNS B-NP O
2 1350 1354 12852481 were VBD B-VP O
3 1355 1361 12852481 killed VBN I-VP O
4 1362 1364 12852481 on IN B-PP O
5 1365 1367 12852481 GD NN B-NP O
6 1368 1370 12852481 21 CD I-NP O
7 1370 1371 12852481 , , O O
8 1372 1375 12852481 and CC O O
9 1376 1383 12852481 fetuses NNS B-NP O
10 1384 1388 12852481 were VBD B-VP O
11 1389 1397 12852481 examined VBN I-VP O
12 1398 1408 12852481 viscerally RB B-ADVP O
13 1408 1409 12852481 . . O O

1 1410 1417 12852481 RESULTS NNS B-NP O
2 1417 1418 12852481 : : O O
3 1419 1422 12852481 The DT B-NP O
4 1423 1433 12852481 literature NN I-NP O
5 1434 1444 12852481 evaluation NN I-NP O
6 1445 1454 12852481 suggested VBD B-VP O
7 1455 1459 12852481 that IN B-SBAR O
8 1460 1466 12852481 NSAIDs NNS B-NP O
9 1467 1473 12852481 induce VBP B-VP O
10 1474 1485 12852481 ventricular JJ B-NP D006345
11 1486 1492 12852481 septal JJ I-NP D006345
12 1493 1500 12852481 defects NNS I-NP D006345
13 1501 1502 12852481 ( ( O O
14 1502 1506 12852481 VSDs NNS B-NP D006345
15 1506 1507 12852481 ) ) O O
16 1508 1511 12852481 and CC O O
17 1512 1519 12852481 midline NN B-NP D009436
18 1520 1527 12852481 defects NNS I-NP D009436
19 1528 1529 12852481 ( ( O O
20 1529 1532 12852481 MDs NNS B-NP D009436
21 1532 1533 12852481 ) ) O O
22 1534 1536 12852481 in IN B-PP O
23 1537 1541 12852481 rats NNS B-NP O
24 1542 1545 12852481 and CC O O
25 1546 1559 12852481 diaphragmatic JJ B-NP D065630
26 1560 1566 12852481 hernia NN I-NP D065630
27 1567 1568 12852481 ( ( O O
28 1568 1570 12852481 DH NN B-NP D065630
29 1570 1571 12852481 ) ) O O
30 1571 1572 12852481 , , O O
31 1573 1576 12852481 MDs NNS B-NP D009436
32 1576 1577 12852481 , , O O
33 1578 1581 12852481 and CC O O
34 1582 1586 12852481 VSDs NNS B-NP D006345
35 1587 1589 12852481 in IN B-PP O
36 1590 1597 12852481 rabbits NNS B-NP O
37 1598 1599 12852481 ( ( O O
38 1599 1603 12852481 Cook NNP B-NP O
39 1604 1606 12852481 JC NNP I-NP O
40 1607 1609 12852481 et FW I-NP O
41 1610 1613 12852481 al. FW I-NP O
42 1613 1614 12852481 , , O O
43 1615 1619 12852481 2003 CD B-NP O
44 1619 1620 12852481 ) ) O O
45 1620 1621 12852481 ; : O O
46 1622 1627 12852481 hence RB B-ADVP O
47 1627 1628 12852481 , , O O
48 1629 1632 12852481 the DT B-NP O
49 1633 1640 12852481 present JJ I-NP O
50 1641 1646 12852481 study NN I-NP O
51 1647 1654 12852481 focused VBD B-VP O
52 1655 1657 12852481 on IN B-PP O
53 1658 1663 12852481 these DT B-NP O
54 1664 1677 12852481 malformations NNS I-NP D000014
55 1677 1678 12852481 , , O O
56 1679 1683 12852481 even RB B-SBAR O
57 1684 1690 12852481 though IN I-SBAR O
58 1691 1694 12852481 ASA NN B-NP D001241
59 1695 1702 12852481 induces VBZ B-VP O
60 1703 1710 12852481 several JJ B-NP O
61 1711 1716 12852481 other JJ I-NP O
62 1717 1720 12852481 low JJ I-NP O
63 1720 1721 12852481 - HYPH I-NP O
64 1721 1730 12852481 incidence NN I-NP O
65 1731 1744 12852481 malformations NNS I-NP D000014
66 1744 1745 12852481 . . O O

1 1746 1748 12852481 In IN B-PP O
2 1749 1755 12852481 single JJ B-NP O
3 1756 1760 12852481 dose NN I-NP O
4 1761 1768 12852481 studies NNS I-NP O
5 1768 1769 12852481 , , O O
6 1770 1772 12852481 DH NN B-NP D065630
7 1772 1773 12852481 , , O O
8 1774 1776 12852481 MD NN B-NP D009436
9 1776 1777 12852481 , , O O
10 1778 1781 12852481 and CC O O
11 1782 1785 12852481 VSD NN B-NP D006345
12 1786 1790 12852481 were VBD B-VP O
13 1791 1798 12852481 induced VBN I-VP O
14 1799 1801 12852481 on IN B-PP O
15 1802 1805 12852481 GDs NNS B-NP O
16 1806 1807 12852481 9 CD B-NP O
17 1808 1811 12852481 and CC I-NP O
18 1812 1814 12852481 10 CD I-NP O
19 1814 1815 12852481 . . O O

1 1816 1819 12852481 VSD NN B-NP D006345
2 1820 1824 12852481 also RB B-ADVP O
3 1825 1828 12852481 was VBD B-VP O
4 1829 1834 12852481 noted VBN I-VP O
5 1835 1844 12852481 following VBG B-PP O
6 1845 1854 12852481 treatment NN B-NP O
7 1855 1857 12852481 on IN B-PP O
8 1858 1860 12852481 GD NN B-NP O
9 1861 1863 12852481 11 CD I-NP O
10 1863 1864 12852481 . . O O

1 1865 1867 12852481 In IN B-PP O
2 1868 1876 12852481 contrast NN B-NP O
3 1876 1877 12852481 , , O O
4 1878 1880 12852481 DH NN B-NP D065630
5 1881 1884 12852481 and CC I-NP O
6 1885 1887 12852481 MD NN I-NP D009436
7 1888 1892 12852481 were VBD B-VP O
8 1893 1898 12852481 noted VBN I-VP O
9 1899 1901 12852481 in IN B-PP O
10 1902 1905 12852481 the DT B-NP O
11 1906 1914 12852481 multiple JJ I-NP O
12 1915 1919 12852481 dose NN I-NP O
13 1920 1925 12852481 study NN I-NP O
14 1926 1932 12852481 design NN I-NP O
15 1933 1937 12852481 only RB B-ADVP O
16 1938 1940 12852481 in IN B-PP O
17 1941 1944 12852481 the DT B-NP O
18 1945 1949 12852481 high JJ I-NP O
19 1949 1950 12852481 - HYPH I-NP O
20 1950 1954 12852481 dose NN I-NP O
21 1955 1960 12852481 group NN I-NP O
22 1960 1961 12852481 , , O O
23 1962 1965 12852481 and CC O O
24 1966 1969 12852481 VSD NN B-NP D006345
25 1970 1973 12852481 was VBD B-VP O
26 1974 1979 12852481 noted VBN I-VP O
27 1980 1986 12852481 across IN B-PP O
28 1987 1990 12852481 all DT B-NP O
29 1991 1995 12852481 dose NN I-NP O
30 1996 2002 12852481 groups NNS I-NP O
31 2002 2003 12852481 . . O O

1 2004 2015 12852481 CONCLUSIONS NNS B-NP O
2 2015 2016 12852481 : : O O
3 2017 2021 12852481 High JJ B-NP O
4 2022 2033 12852481 concordance NN I-NP O
5 2034 2036 12852481 in IN B-PP O
6 2037 2042 12852481 major JJ B-NP O
7 2043 2056 12852481 developmental JJ I-NP D000014
8 2057 2066 12852481 anomalies NNS I-NP D000014
9 2067 2074 12852481 between IN B-PP O
10 2075 2081 12852481 Wistar NNP B-NP O
11 2082 2085 12852481 and CC I-NP O
12 2086 2088 12852481 SD NNP I-NP O
13 2089 2093 12852481 rats NNS I-NP O
14 2094 2098 12852481 were VBD B-VP O
15 2099 2104 12852481 noted VBN I-VP O
16 2105 2109 12852481 with IN B-PP O
17 2110 2113 12852481 the DT B-NP O
18 2114 2123 12852481 exception NN I-NP O
19 2124 2126 12852481 of IN B-PP O
20 2127 2130 12852481 VSD NN B-NP D006345
21 2131 2133 12852481 in IN B-PP O
22 2134 2137 12852481 the DT B-NP O
23 2138 2140 12852481 SD NNP I-NP O
24 2141 2145 12852481 rats NNS I-NP O
25 2146 2149 12852481 and CC I-NP O
26 2150 2163 12852481 hydrocephalus NN I-NP D006849
27 2164 2166 12852481 in IN B-PP O
28 2167 2170 12852481 the DT B-NP O
29 2171 2177 12852481 Wistar NNP I-NP O
30 2178 2182 12852481 rats NNS I-NP O
31 2182 2183 12852481 . . O O

1 2184 2194 12852481 Variations NNS B-NP O
2 2195 2198 12852481 and CC I-NP O
3 2199 2212 12852481 malformations NNS I-NP D000014
4 2213 2217 12852481 were VBD B-VP O
5 2218 2225 12852481 similar JJ B-ADJP O
6 2226 2230 12852481 when WRB B-ADVP O
7 2231 2234 12852481 ASA NN B-NP D001241
8 2235 2238 12852481 was VBD B-VP O
9 2239 2251 12852481 administered VBN I-VP O
10 2252 2254 12852481 as IN B-PP O
11 2255 2256 12852481 a DT B-NP O
12 2257 2263 12852481 single JJ I-NP O
13 2264 2268 12852481 dose NN I-NP O
14 2269 2271 12852481 or CC B-PP O
15 2272 2278 12852481 during IN B-PP O
16 2279 2282 12852481 the DT B-NP O
17 2283 2289 12852481 period NN I-NP O
18 2290 2292 12852481 of IN B-PP O
19 2293 2306 12852481 organogenesis NN B-NP O
20 2307 2308 12852481 ( ( O O
21 2308 2311 12852481 GDs NNS B-NP O
22 2312 2313 12852481 6 CD B-NP O
23 2314 2316 12852481 to TO B-PP O
24 2317 2319 12852481 17 CD B-NP O
25 2319 2320 12852481 ) ) O O
26 2320 2321 12852481 . . O O

1 2322 2324 12852481 It PRP B-NP O
2 2325 2328 12852481 was VBD B-VP O
3 2329 2333 12852481 also RB B-ADVP O
4 2334 2341 12852481 evident JJ B-ADJP O
5 2342 2346 12852481 that IN B-SBAR O
6 2346 2347 12852481 , , O O
7 2348 2350 12852481 by IN B-PP O
8 2351 2360 12852481 titrating VBG B-VP O
9 2361 2364 12852481 the DT B-NP O
10 2365 2369 12852481 dose NN I-NP O
11 2370 2372 12852481 to TO B-VP O
12 2373 2380 12852481 achieve VB I-VP O
13 2381 2382 12852481 a DT B-NP O
14 2383 2390 12852481 maximum NN I-NP O
15 2391 2400 12852481 tolerated VBD B-VP O
16 2401 2405 12852481 dose NN B-NP O
17 2405 2406 12852481 , , O O
18 2407 2420 12852481 malformations NNS B-NP D000014
19 2421 2425 12852481 that WDT B-NP O
20 2426 2434 12852481 normally RB B-ADVP O
21 2435 2440 12852481 occur VBP B-VP O
22 2441 2443 12852481 at IN B-PP O
23 2444 2447 12852481 low JJ B-NP O
24 2448 2457 12852481 incidence NN I-NP O
25 2457 2458 12852481 , , O O
26 2459 2461 12852481 as IN B-SBAR O
27 2462 2470 12852481 reported VBN B-VP O
28 2471 2475 12852481 from IN B-PP O
29 2476 2484 12852481 previous JJ B-NP O
30 2485 2491 12852481 single JJ I-NP O
31 2492 2496 12852481 dose NN I-NP O
32 2497 2504 12852481 studies NNS I-NP O
33 2504 2505 12852481 , , O O
34 2506 2511 12852481 could MD B-VP O
35 2512 2516 12852481 also RB I-VP O
36 2517 2519 12852481 be VB I-VP O
37 2520 2527 12852481 induced VBN I-VP O
38 2528 2532 12852481 with IN B-PP O
39 2533 2536 12852481 ASA NN B-NP D001241
40 2537 2542 12852481 given VBN B-VP O
41 2543 2545 12852481 at IN B-PP O
42 2546 2554 12852481 multiple JJ B-NP O
43 2555 2560 12852481 doses NNS I-NP O
44 2560 2561 12852481 . . O O

1 0 0 7161250 -DOCSTART- -X- -X- O

1 0 14 7161250 Extrapyramidal JJ B-NP O
2 15 19 7161250 side NN I-NP O
3 20 27 7161250 effects NNS I-NP O
4 28 31 7161250 and CC O O
5 32 36 7161250 oral JJ B-NP O
6 37 48 7161250 haloperidol NN I-NP D006220
7 48 49 7161250 : : O O
8 50 52 7161250 an DT B-NP O
9 53 61 7161250 analysis NN I-NP O
10 62 64 7161250 of IN B-PP O
11 65 76 7161250 explanatory JJ B-NP O
12 77 84 7161250 patient NN I-NP O
13 85 88 7161250 and CC I-NP O
14 89 98 7161250 treatment NN I-NP O
15 99 114 7161250 characteristics NNS I-NP O
16 114 115 7161250 . . O O
17 116 119 7161250 The DT B-NP O
18 120 129 7161250 incidence NN I-NP O
19 130 132 7161250 of IN B-PP O
20 133 147 7161250 extrapyramidal JJ B-NP O
21 148 152 7161250 side NN I-NP O
22 153 160 7161250 effects NNS I-NP O
23 161 162 7161250 ( ( O O
24 162 165 7161250 EPS NNS B-NP O
25 165 166 7161250 ) ) O O
26 167 170 7161250 was VBD B-VP O
27 171 180 7161250 evaluated VBN I-VP O
28 181 183 7161250 in IN B-PP O
29 184 186 7161250 98 CD B-NP O
30 187 195 7161250 patients NNS I-NP O
31 196 203 7161250 treated VBN B-VP O
32 204 208 7161250 with IN B-PP O
33 209 220 7161250 haloperidol NN B-NP D006220
34 220 221 7161250 . . O O

1 222 225 7161250 The DT B-NP O
2 226 235 7161250 incidence NN I-NP O
3 236 238 7161250 of IN B-PP O
4 239 251 7161250 parkinsonism NN B-NP D010302
5 252 255 7161250 was VBD B-VP O
6 256 262 7161250 higher JJR B-ADJP O
7 263 265 7161250 at IN B-PP O
8 266 272 7161250 higher JJR B-NP O
9 273 278 7161250 doses NNS I-NP O
10 279 281 7161250 of IN B-PP O
11 282 293 7161250 haloperidol NN B-NP D006220
12 294 297 7161250 and CC O O
13 298 300 7161250 in IN B-PP O
14 301 308 7161250 younger JJR B-NP O
15 309 317 7161250 patients NNS I-NP O
16 317 318 7161250 . . O O

1 319 331 7161250 Prophylactic JJ B-NP O
2 332 348 7161250 antiparkinsonian JJ I-NP O
3 349 359 7161250 medication NN I-NP O
4 360 363 7161250 was VBD B-VP O
5 364 373 7161250 effective JJ B-ADJP O
6 374 376 7161250 in IN B-PP O
7 377 384 7161250 younger JJR B-ADJP O
8 385 388 7161250 but CC B-PP O
9 389 392 7161250 not RB B-PP O
10 393 395 7161250 in IN I-PP O
11 396 401 7161250 older JJR B-NP O
12 402 410 7161250 patients NNS I-NP O
13 410 411 7161250 . . O O

1 412 419 7161250 However RB B-ADVP O
2 419 420 7161250 , , O O
3 421 426 7161250 these DT B-NP O
4 427 438 7161250 medications NNS I-NP O
5 439 443 7161250 were VBD B-VP O
6 444 448 7161250 more RBR B-ADJP O
7 449 458 7161250 effective JJ I-ADJP O
8 459 461 7161250 in IN B-PP O
9 462 466 7161250 both CC B-NP O
10 467 472 7161250 young JJ I-NP O
11 473 476 7161250 and CC I-NP O
12 477 480 7161250 old JJ I-NP O
13 481 489 7161250 patients NNS I-NP O
14 490 494 7161250 when WRB B-ADVP O
15 495 500 7161250 given VBN B-VP O
16 501 506 7161250 after IN B-PP O
17 507 519 7161250 parkinsonism NN B-NP D010302
18 520 529 7161250 developed VBD B-VP O
19 529 530 7161250 . . O O

1 531 540 7161250 Akathisia NN B-NP D017109
2 541 544 7161250 was VBD B-VP O
3 545 555 7161250 controlled VBN I-VP O
4 556 558 7161250 by IN B-PP O
5 559 562 7161250 the DT B-NP O
6 563 577 7161250 benzodiazepine NN I-NP D001569
7 578 587 7161250 lorazepam NN I-NP D008140
8 588 590 7161250 in IN B-PP O
9 591 593 7161250 14 CD B-NP O
10 594 597 7161250 out IN I-NP O
11 598 600 7161250 of IN I-NP O
12 601 603 7161250 16 CD I-NP O
13 604 612 7161250 patients NNS I-NP O
14 612 613 7161250 , , O O
15 614 619 7161250 while IN B-SBAR O
16 620 632 7161250 prophylactic JJ B-NP O
17 633 650 7161250 antiparkinsonians NNS I-NP O
18 651 655 7161250 were VBD B-VP O
19 656 667 7161250 ineffective JJ B-ADJP O
20 667 668 7161250 . . O O

1 669 672 7161250 The DT B-NP O
2 673 680 7161250 present JJ I-NP O
3 681 686 7161250 study NN I-NP O
4 687 693 7161250 points VBZ B-VP O
5 694 696 7161250 to TO B-PP O
6 697 704 7161250 patient NN B-NP O
7 705 720 7161250 characteristics NNS I-NP O
8 721 725 7161250 that WDT B-NP O
9 726 729 7161250 may MD B-VP O
10 730 732 7161250 be VB I-VP O
11 733 735 7161250 of IN B-PP O
12 736 748 7161250 significance NN B-NP O
13 749 751 7161250 in IN B-PP O
14 752 755 7161250 the DT B-NP O
15 756 767 7161250 development NN I-NP O
16 768 770 7161250 of IN B-PP O
17 771 774 7161250 EPS NN B-NP O
18 775 778 7161250 due JJ B-ADJP O
19 779 781 7161250 to TO B-PP O
20 782 793 7161250 haloperidol NN B-NP D006220
21 793 794 7161250 . . O O

1 0 0 18363626 -DOCSTART- -X- -X- O

1 0 4 18363626 High JJ B-NP O
2 5 9 18363626 dose NN I-NP O
3 10 25 18363626 dexmedetomidine NN I-NP D020927
4 26 28 18363626 as IN B-PP O
5 29 32 18363626 the DT B-NP O
6 33 37 18363626 sole JJ I-NP O
7 38 46 18363626 sedative NN I-NP O
8 47 50 18363626 for IN B-PP O
9 51 60 18363626 pediatric JJ B-NP O
10 61 64 18363626 MRI NN I-NP O
11 64 65 18363626 . . I-NP O
12 66 75 18363626 OBJECTIVE NN I-NP O
13 75 76 18363626 : : O O
14 77 81 18363626 This DT B-NP O
15 82 87 18363626 large JJ I-NP O
16 87 88 18363626 - HYPH I-NP O
17 88 93 18363626 scale NN I-NP O
18 94 107 18363626 retrospective JJ I-NP O
19 108 114 18363626 review NN I-NP O
20 115 124 18363626 evaluates VBZ B-VP O
21 125 128 18363626 the DT B-NP O
22 129 137 18363626 sedation NN I-NP O
23 138 145 18363626 profile NN I-NP O
24 146 148 18363626 of IN B-PP O
25 149 164 18363626 dexmedetomidine NN B-NP D020927
26 164 165 18363626 . . O O

1 166 169 18363626 AIM NN B-NP O
2 169 170 18363626 : : O O
3 171 173 18363626 To TO B-VP O
4 174 183 18363626 determine VB I-VP O
5 184 187 18363626 the DT B-NP O
6 188 199 18363626 hemodynamic JJ I-NP O
7 200 209 18363626 responses NNS I-NP O
8 209 210 18363626 , , O O
9 211 219 18363626 efficacy NN B-NP O
10 220 223 18363626 and CC O O
11 224 231 18363626 adverse JJ B-NP O
12 232 238 18363626 events NNS I-NP O
13 239 249 18363626 associated VBN B-VP O
14 250 254 18363626 with IN B-PP O
15 255 258 18363626 the DT B-NP O
16 259 262 18363626 use NN I-NP O
17 263 265 18363626 of IN B-PP O
18 266 270 18363626 high JJ B-NP O
19 271 275 18363626 dose NN I-NP O
20 276 291 18363626 dexmedetomidine NN I-NP D020927
21 292 294 18363626 as IN B-PP O
22 295 298 18363626 the DT B-NP O
23 299 303 18363626 sole JJ I-NP O
24 304 312 18363626 sedative NN I-NP O
25 313 316 18363626 for IN B-PP O
26 317 325 18363626 magnetic JJ B-NP O
27 326 335 18363626 resonance NN I-NP O
28 336 343 18363626 imaging NN I-NP O
29 344 345 18363626 ( ( O O
30 345 348 18363626 MRI NN B-NP O
31 348 349 18363626 ) ) O O
32 350 357 18363626 studies NNS B-NP O
33 357 358 18363626 . . O O

1 359 369 18363626 BACKGROUND NN B-NP O
2 369 370 18363626 : : O O
3 371 386 18363626 Dexmedetomidine NN B-NP D020927
4 387 390 18363626 has VBZ B-VP O
5 391 395 18363626 been VBN I-VP O
6 396 400 18363626 used VBN I-VP O
7 401 403 18363626 at IN B-PP O
8 404 407 18363626 our PRP$ B-NP O
9 408 419 18363626 institution NN I-NP O
10 420 425 18363626 since IN B-PP O
11 426 430 18363626 2005 CD B-NP O
12 431 433 18363626 to TO B-VP O
13 434 441 18363626 provide VB I-VP O
14 442 450 18363626 sedation NN B-NP O
15 451 454 18363626 for IN B-PP O
16 455 464 18363626 pediatric JJ B-NP O
17 465 477 18363626 radiological JJ I-NP O
18 478 485 18363626 imaging NN I-NP O
19 486 493 18363626 studies NNS I-NP O
20 493 494 18363626 . . O O

1 495 499 18363626 Over IN B-PP O
2 500 504 18363626 time NN B-NP O
3 504 505 18363626 , , O O
4 506 508 18363626 an DT B-NP O
5 509 518 18363626 effective JJ I-NP O
6 519 527 18363626 protocol NN I-NP O
7 528 537 18363626 utilizing VBG B-VP O
8 538 542 18363626 high JJ B-NP O
9 543 547 18363626 dose NN I-NP O
10 548 563 18363626 dexmedetomidine NN I-NP D020927
11 564 566 18363626 as IN B-PP O
12 567 570 18363626 the DT B-NP O
13 571 575 18363626 sole JJ I-NP O
14 576 584 18363626 sedative JJ I-NP O
15 585 590 18363626 agent NN I-NP O
16 591 594 18363626 has VBZ B-VP O
17 595 602 18363626 evolved VBN I-VP O
18 602 603 18363626 . . O O

1 604 611 18363626 METHODS NNS B-NP O
2 611 612 18363626 / SYM B-NP O
3 612 621 18363626 MATERIALS NN I-NP O
4 621 622 18363626 : : O O
5 623 625 18363626 As IN B-PP O
6 626 630 18363626 part NN B-NP O
7 631 633 18363626 of IN B-PP O
8 634 637 18363626 the DT B-NP O
9 638 645 18363626 ongoing JJ I-NP O
10 646 653 18363626 Quality NNP I-NP O
11 654 663 18363626 Assurance NNP I-NP O
12 664 671 18363626 process NN I-NP O
13 671 672 18363626 , , O O
14 673 677 18363626 data NNS B-NP O
15 678 680 18363626 on IN B-PP O
16 681 684 18363626 all DT B-NP O
17 685 694 18363626 sedations NNS I-NP O
18 695 698 18363626 are VBP B-VP O
19 699 707 18363626 reviewed VBN I-VP O
20 708 715 18363626 monthly JJ B-ADJP O
21 716 719 18363626 and CC O O
22 720 729 18363626 protocols NNS B-NP O
23 730 738 18363626 modified VBN B-VP O
24 739 741 18363626 as IN B-PP O
25 742 748 18363626 needed VBN B-VP O
26 748 749 18363626 . . O O

1 750 754 18363626 Data NNS B-NP O
2 755 759 18363626 were VBD B-VP O
3 760 768 18363626 analyzed VBN I-VP O
4 769 773 18363626 from IN B-PP O
5 774 777 18363626 all DT B-NP O
6 778 781 18363626 747 CD I-NP O
7 782 793 18363626 consecutive JJ I-NP O
8 794 802 18363626 patients NNS I-NP O
9 803 806 18363626 who WP B-NP O
10 807 815 18363626 received VBD B-VP O
11 816 831 18363626 dexmedetomidine NN B-NP D020927
12 832 835 18363626 for IN B-PP O
13 836 839 18363626 MRI NN B-NP O
14 840 848 18363626 sedation NN I-NP O
15 849 853 18363626 from IN B-PP O
16 854 859 18363626 April NNP B-NP O
17 860 864 18363626 2005 CD I-NP O
18 865 867 18363626 to TO B-PP O
19 868 873 18363626 April NNP B-NP O
20 874 878 18363626 2007 CD I-NP O
21 878 879 18363626 . . O O

1 880 887 18363626 RESULTS NNS B-NP O
2 887 888 18363626 : : O O
3 889 894 18363626 Since IN B-PP O
4 895 899 18363626 2005 CD B-NP O
5 899 900 18363626 , , O O
6 901 904 18363626 the DT B-NP O
7 905 907 18363626 10 CD I-NP O
8 907 908 18363626 - HYPH I-NP O
9 908 911 18363626 min NN I-NP O
10 912 919 18363626 loading VBG I-NP O
11 920 924 18363626 dose NN I-NP O
12 925 927 18363626 of IN B-PP O
13 928 931 18363626 our PRP$ B-NP O
14 932 947 18363626 dexmedetomidine NN I-NP D020927
15 948 956 18363626 protocol NN I-NP O
16 957 966 18363626 increased VBD B-VP O
17 967 971 18363626 from IN B-PP O
18 972 973 18363626 2 CD B-NP O
19 974 976 18363626 to TO I-NP O
20 977 978 18363626 3 CD I-NP O
21 979 989 18363626 microg.kg( NN I-NP O
22 989 990 18363626 - HYPH B-NP O
23 990 992 18363626 1) NN I-NP O
24 992 993 18363626 , , O O
25 994 997 18363626 and CC O O
26 998 1001 18363626 the DT B-NP O
27 1002 1010 18363626 infusion NN I-NP O
28 1011 1015 18363626 rate NN I-NP O
29 1016 1025 18363626 increased VBD B-VP O
30 1026 1030 18363626 from IN B-PP O
31 1031 1032 18363626 1 CD B-NP O
32 1033 1035 18363626 to TO B-PP O
33 1036 1039 18363626 1.5 CD B-NP O
34 1040 1042 18363626 to TO I-NP O
35 1043 1044 18363626 2 CD I-NP O
36 1045 1055 18363626 microg.kg( NN I-NP O
37 1055 1056 18363626 - HYPH B-NP O
38 1056 1061 18363626 1).h( CD I-NP O
39 1061 1062 18363626 - HYPH I-NP O
40 1062 1064 18363626 1) CD I-NP O
41 1064 1065 18363626 . . O O

1 1066 1069 18363626 The DT B-NP O
2 1070 1077 18363626 current JJ I-NP O
3 1078 1086 18363626 sedation NN I-NP O
4 1087 1095 18363626 protocol NN I-NP O
5 1096 1109 18363626 progressively RB B-ADVP O
6 1110 1119 18363626 increased VBD B-VP O
7 1120 1123 18363626 the DT B-NP O
8 1124 1128 18363626 rate NN I-NP O
9 1129 1131 18363626 of IN B-PP O
10 1132 1142 18363626 successful JJ B-NP O
11 1143 1151 18363626 sedation NN I-NP O
12 1152 1153 18363626 ( ( O O
13 1153 1157 18363626 able JJ B-ADJP O
14 1158 1160 18363626 to TO B-VP O
15 1161 1169 18363626 complete VB I-VP O
16 1170 1173 18363626 the DT B-NP O
17 1174 1181 18363626 imaging NN I-NP O
18 1182 1187 18363626 study NN I-NP O
19 1187 1188 18363626 ) ) O O
20 1189 1193 18363626 when WRB B-ADVP O
21 1194 1199 18363626 using VBG B-VP O
22 1200 1215 18363626 dexmedetomidine NN B-NP D020927
23 1216 1221 18363626 alone RB B-ADVP O
24 1222 1226 18363626 from IN B-PP O
25 1227 1232 18363626 91.8% CD B-NP O
26 1233 1235 18363626 to TO B-PP O
27 1236 1241 18363626 97.6% CD B-NP O
28 1242 1243 18363626 ( ( O O
29 1243 1244 18363626 P NN B-NP O
30 1245 1246 18363626 = SYM B-VP O
31 1247 1252 18363626 0.009 CD B-NP O
32 1252 1253 18363626 ) ) O O
33 1253 1254 18363626 , , O O
34 1255 1263 18363626 reducing VBG B-VP O
35 1264 1267 18363626 the DT B-NP O
36 1268 1279 18363626 requirement NN I-NP O
37 1280 1283 18363626 for IN B-PP O
38 1284 1292 18363626 adjuvant JJ B-NP O
39 1293 1306 18363626 pentobarbital NN I-NP D010424
40 1307 1309 18363626 in IN B-PP O
41 1310 1313 18363626 the DT B-NP O
42 1314 1319 18363626 event NN I-NP O
43 1320 1322 18363626 of IN B-PP O
44 1323 1331 18363626 sedation NN B-NP O
45 1332 1339 18363626 failure NN I-NP O
46 1340 1344 18363626 with IN B-PP O
47 1345 1360 18363626 dexmedetomidine NN B-NP D020927
48 1361 1366 18363626 alone RB B-ADVP O
49 1367 1370 18363626 and CC O O
50 1371 1380 18363626 decreased VBD B-VP O
51 1381 1384 18363626 the DT B-NP O
52 1385 1389 18363626 mean JJ I-NP O
53 1390 1398 18363626 recovery NN I-NP O
54 1399 1403 18363626 time NN I-NP O
55 1404 1406 18363626 by IN B-PP O
56 1407 1409 18363626 10 CD B-NP O
57 1410 1413 18363626 min NN I-NP O
58 1414 1415 18363626 ( ( O O
59 1415 1416 18363626 P NN B-NP O
60 1417 1418 18363626 < SYM O O
61 1419 1424 18363626 0.001 CD B-NP O
62 1424 1425 18363626 ) ) O O
63 1425 1426 18363626 . . O O

1 1427 1435 18363626 Although IN B-SBAR O
2 1436 1451 18363626 dexmedetomidine NN B-NP D020927
3 1452 1460 18363626 sedation NN I-NP O
4 1461 1464 18363626 was VBD B-VP O
5 1465 1475 18363626 associated VBN I-VP O
6 1476 1480 18363626 with IN B-PP O
7 1481 1482 18363626 a DT B-NP O
8 1483 1486 18363626 16% NN I-NP O
9 1487 1496 18363626 incidence NN I-NP O
10 1497 1499 18363626 of IN B-PP O
11 1500 1511 18363626 bradycardia NN B-NP D001919
12 1511 1512 18363626 , , O O
13 1513 1516 18363626 all DT B-NP O
14 1517 1528 18363626 concomitant JJ I-NP O
15 1529 1533 18363626 mean JJ I-NP O
16 1534 1542 18363626 arterial JJ I-NP O
17 1543 1548 18363626 blood NN I-NP O
18 1549 1558 18363626 pressures NNS I-NP O
19 1559 1563 18363626 were VBD B-VP O
20 1564 1570 18363626 within IN B-PP O
21 1571 1574 18363626 20% CD B-NP O
22 1575 1577 18363626 of IN B-PP O
23 1578 1581 18363626 age NN B-NP O
24 1581 1582 18363626 - HYPH B-NP O
25 1582 1590 18363626 adjusted VBN I-NP O
26 1591 1597 18363626 normal JJ I-NP O
27 1598 1603 18363626 range NN I-NP O
28 1604 1607 18363626 and CC I-NP O
29 1608 1614 18363626 oxygen NN I-NP D010100
30 1615 1626 18363626 saturations NNS I-NP O
31 1627 1631 18363626 were VBD B-VP O
32 1632 1635 18363626 95% CD B-NP O
33 1636 1638 18363626 or CC I-NP O
34 1639 1645 18363626 higher JJR I-NP O
35 1645 1646 18363626 . . O O

1 1647 1657 18363626 CONCLUSION NN B-NP O
2 1657 1658 18363626 : : O O
3 1659 1674 18363626 Dexmedetomidine NN B-NP D020927
4 1675 1677 18363626 in IN B-PP O
5 1678 1682 18363626 high JJ B-NP O
6 1683 1688 18363626 doses NNS I-NP O
7 1689 1697 18363626 provides VBZ B-VP O
8 1698 1706 18363626 adequate JJ B-NP O
9 1707 1715 18363626 sedation NN I-NP O
10 1716 1719 18363626 for IN B-PP O
11 1720 1729 18363626 pediatric JJ B-NP O
12 1730 1733 18363626 MRI NN I-NP O
13 1734 1741 18363626 studies NNS I-NP O
14 1741 1742 18363626 . . O O

1 1743 1748 18363626 While IN B-SBAR O
2 1749 1752 18363626 use NN B-NP O
3 1753 1755 18363626 of IN B-PP O
4 1756 1760 18363626 high JJ B-NP O
5 1761 1765 18363626 dose NN I-NP O
6 1766 1781 18363626 dexmedetomidine NN I-NP D020927
7 1782 1784 18363626 is VBZ B-VP O
8 1785 1795 18363626 associated VBN I-VP O
9 1796 1800 18363626 with IN B-PP O
10 1801 1810 18363626 decreases NNS B-NP O
11 1811 1813 18363626 in IN B-PP O
12 1814 1819 18363626 heart NN B-NP O
13 1820 1824 18363626 rate NN I-NP O
14 1825 1828 18363626 and CC I-NP O
15 1829 1834 18363626 blood NN I-NP O
16 1835 1843 18363626 pressure NN I-NP O
17 1844 1851 18363626 outside IN B-PP O
18 1852 1855 18363626 the DT B-NP O
19 1856 1867 18363626 established VBN I-NP O
20 1868 1869 18363626 ' POS B-NP O
21 1869 1874 18363626 awake NN I-NP O
22 1874 1875 18363626 ' POS B-NP O
23 1876 1881 18363626 norms NNS I-NP O
24 1881 1882 18363626 , , O O
25 1883 1887 18363626 this DT B-NP O
26 1888 1897 18363626 deviation NN I-NP O
27 1898 1900 18363626 is VBZ B-VP O
28 1901 1910 18363626 generally RB B-ADVP O
29 1911 1917 18363626 within IN B-PP O
30 1918 1921 18363626 20% CD B-NP O
31 1922 1924 18363626 of IN B-PP O
32 1925 1930 18363626 norms NNS B-NP O
33 1930 1931 18363626 , , O O
34 1932 1935 18363626 and CC O O
35 1936 1938 18363626 is VBZ B-VP O
36 1939 1942 18363626 not RB I-VP O
37 1943 1953 18363626 associated VBN I-VP O
38 1954 1958 18363626 with IN B-PP O
39 1959 1966 18363626 adverse JJ B-NP O
40 1967 1975 18363626 sequelae NNS I-NP O
41 1975 1976 18363626 . . O O

1 1977 1992 18363626 Dexmedetomidine NN B-NP D020927
2 1993 1995 18363626 is VBZ B-VP O
3 1996 2002 18363626 useful JJ B-ADJP O
4 2003 2005 18363626 as IN B-SBAR O
5 2006 2009 18363626 the DT B-NP O
6 2010 2014 18363626 sole JJ I-NP O
7 2015 2023 18363626 sedative NN I-NP O
8 2024 2027 18363626 for IN B-PP O
9 2028 2037 18363626 pediatric JJ B-NP O
10 2038 2041 18363626 MRI NN I-NP O
11 2041 2042 18363626 . . O O

1 0 0 19139001 -DOCSTART- -X- -X- O

1 0 12 19139001 Longitudinal JJ B-NP O
2 13 23 19139001 assessment NN I-NP O
3 24 26 19139001 of IN B-PP O
4 27 30 19139001 air NN B-NP O
5 31 41 19139001 conduction NN I-NP O
6 42 52 19139001 audiograms NNS I-NP O
7 53 55 19139001 in IN B-PP O
8 56 57 19139001 a DT B-NP O
9 58 63 19139001 phase NN I-NP O
10 64 67 19139001 III CD I-NP O
11 68 76 19139001 clinical JJ I-NP O
12 77 82 19139001 trial NN I-NP O
13 83 85 19139001 of IN B-PP O
14 86 109 19139001 difluoromethylornithine NN B-NP D000518
15 110 113 19139001 and CC I-NP O
16 114 122 19139001 sulindac NN I-NP D013467
17 123 126 19139001 for IN B-PP O
18 127 137 19139001 prevention NN B-NP O
19 138 140 19139001 of IN B-PP O
20 141 149 19139001 sporadic JJ B-NP O
21 150 160 19139001 colorectal JJ I-NP D015179
22 161 169 19139001 adenomas NNS I-NP D015179
23 169 170 19139001 . . O O
24 171 172 19139001 A DT B-NP O
25 173 178 19139001 phase NN I-NP O
26 179 182 19139001 III CD I-NP O
27 183 191 19139001 clinical JJ I-NP O
28 192 197 19139001 trial NN I-NP O
29 198 206 19139001 assessed VBD B-VP O
30 207 210 19139001 the DT B-NP O
31 211 221 19139001 recurrence NN I-NP O
32 222 224 19139001 of IN B-PP O
33 225 236 19139001 adenomatous JJ B-NP D018256
34 237 243 19139001 polyps NNS I-NP D018256
35 244 249 19139001 after IN B-PP O
36 250 259 19139001 treatment NN B-NP O
37 260 263 19139001 for IN B-PP O
38 264 266 19139001 36 CD B-NP O
39 267 273 19139001 months NNS I-NP O
40 274 278 19139001 with IN B-PP O
41 279 302 19139001 difluoromethylornithine NN B-NP D000518
42 303 304 19139001 ( ( O O
43 304 308 19139001 DFMO NN B-NP D000518
44 308 309 19139001 ) ) O O
45 310 314 19139001 plus CC O O
46 315 323 19139001 sulindac NN B-NP D013467
47 324 326 19139001 or CC O O
48 327 334 19139001 matched VBN B-NP O
49 335 343 19139001 placebos NNS I-NP O
50 343 344 19139001 . . O O

1 345 354 19139001 Temporary JJ B-NP O
2 355 362 19139001 hearing NN I-NP D034381
3 363 367 19139001 loss NN I-NP D034381
4 368 370 19139001 is VBZ B-VP O
5 371 372 19139001 a DT B-NP O
6 373 378 19139001 known JJ I-NP O
7 379 387 19139001 toxicity NN I-NP D064420
8 388 390 19139001 of IN B-PP O
9 391 400 19139001 treatment NN B-NP O
10 401 405 19139001 with IN B-PP O
11 406 410 19139001 DFMO NN B-NP D000518
12 410 411 19139001 , , O O
13 412 416 19139001 thus RB B-ADVP O
14 417 418 19139001 a DT B-NP O
15 419 432 19139001 comprehensive JJ I-NP O
16 433 441 19139001 approach NN I-NP O
17 442 445 19139001 was VBD B-VP O
18 446 455 19139001 developed VBN I-VP O
19 456 458 19139001 to TO I-VP O
20 459 466 19139001 analyze VB I-VP O
21 467 473 19139001 serial JJ B-NP O
22 474 477 19139001 air NN I-NP O
23 478 488 19139001 conduction NN I-NP O
24 489 499 19139001 audiograms NNS I-NP O
25 499 500 19139001 . . O O

1 501 504 19139001 The DT B-NP O
2 505 516 19139001 generalized VBN I-NP O
3 517 527 19139001 estimating NN I-NP O
4 528 536 19139001 equation NN I-NP O
5 537 543 19139001 method NN I-NP O
6 544 553 19139001 estimated VBD B-VP O
7 554 557 19139001 the DT B-NP O
8 558 562 19139001 mean JJ I-NP O
9 563 573 19139001 difference NN I-NP O
10 574 581 19139001 between IN B-PP O
11 582 591 19139001 treatment NN B-NP O
12 592 596 19139001 arms NNS I-NP O
13 597 601 19139001 with IN B-PP O
14 602 608 19139001 regard NN B-NP O
15 609 611 19139001 to TO B-VP O
16 612 618 19139001 change VB I-VP O
17 619 621 19139001 in IN B-PP O
18 622 625 19139001 air NN B-NP O
19 626 636 19139001 conduction NN I-NP O
20 637 641 19139001 pure JJ I-NP O
21 642 646 19139001 tone NN I-NP O
22 647 657 19139001 thresholds NNS I-NP O
23 658 663 19139001 while IN B-SBAR O
24 664 674 19139001 accounting VBG B-VP O
25 675 678 19139001 for IN B-PP O
26 679 685 19139001 within IN B-PP O
27 685 686 19139001 - HYPH B-NP O
28 686 693 19139001 subject NN I-NP O
29 694 705 19139001 correlation NN I-NP O
30 706 709 19139001 due JJ B-ADJP O
31 710 712 19139001 to TO B-PP O
32 713 721 19139001 repeated VBN B-NP O
33 722 734 19139001 measurements NNS I-NP O
34 735 737 19139001 at IN B-PP O
35 738 749 19139001 frequencies NNS B-NP O
36 749 750 19139001 . . O O

1 751 756 19139001 Based VBN B-PP O
2 757 759 19139001 on IN B-PP O
3 760 763 19139001 290 CD B-NP O
4 764 772 19139001 subjects NNS I-NP O
5 772 773 19139001 , , O O
6 774 779 19139001 there EX B-NP O
7 780 783 19139001 was VBD B-VP O
8 784 786 19139001 an DT B-NP O
9 787 794 19139001 average JJ I-NP O
10 795 805 19139001 difference NN I-NP O
11 806 808 19139001 of IN B-PP O
12 809 813 19139001 0.50 CD B-NP O
13 814 816 19139001 dB NN I-NP O
14 817 824 19139001 between IN B-PP O
15 825 833 19139001 subjects NNS B-NP O
16 834 841 19139001 treated VBN B-VP O
17 842 846 19139001 with IN B-PP O
18 847 851 19139001 DFMO NN B-NP D000518
19 852 856 19139001 plus CC I-NP O
20 857 865 19139001 sulindac NN I-NP D013467
21 866 874 19139001 compared VBN B-PP O
22 875 879 19139001 with IN B-PP O
23 880 885 19139001 those DT B-NP O
24 886 893 19139001 treated VBN B-VP O
25 894 898 19139001 with IN B-PP O
26 899 906 19139001 placebo NN B-NP O
27 907 908 19139001 ( ( O O
28 908 911 19139001 95% CD B-NP O
29 912 922 19139001 confidence NN I-NP O
30 923 931 19139001 interval NN I-NP O
31 931 932 19139001 , , O O
32 933 934 19139001 - SYM B-NP O
33 934 938 19139001 0.64 CD B-NP O
34 939 941 19139001 to TO I-NP O
35 942 946 19139001 1.63 CD I-NP O
36 947 949 19139001 dB NN I-NP O
37 949 950 19139001 ; : O O
38 951 952 19139001 P NN B-NP O
39 953 954 19139001 = SYM B-VP O
40 955 959 19139001 0.39 CD B-NP O
41 959 960 19139001 ) ) O O
42 960 961 19139001 , , O O
43 962 970 19139001 adjusted VBN B-VP O
44 971 974 19139001 for IN B-PP O
45 975 983 19139001 baseline NN B-NP O
46 984 990 19139001 values NNS I-NP O
47 990 991 19139001 , , O O
48 992 995 19139001 age NN B-NP O
49 995 996 19139001 , , O O
50 997 1000 19139001 and CC O O
51 1001 1012 19139001 frequencies NNS B-NP O
52 1012 1013 19139001 . . O O

1 1014 1016 19139001 In IN B-PP O
2 1017 1020 19139001 the DT B-NP O
3 1021 1027 19139001 normal JJ I-NP O
4 1028 1034 19139001 speech NN I-NP O
5 1035 1040 19139001 range NN I-NP O
6 1041 1043 19139001 of IN B-PP O
7 1044 1047 19139001 500 CD B-NP O
8 1048 1050 19139001 to TO I-NP O
9 1051 1056 19139001 3,000 CD I-NP O
10 1057 1059 19139001 Hz NN I-NP O
11 1059 1060 19139001 , , O O
12 1061 1063 19139001 an DT B-NP O
13 1064 1073 19139001 estimated VBN I-NP O
14 1074 1084 19139001 difference NN I-NP O
15 1085 1087 19139001 of IN B-PP O
16 1088 1092 19139001 0.99 CD B-NP O
17 1093 1095 19139001 dB NN I-NP O
18 1096 1097 19139001 ( ( O O
19 1097 1098 19139001 - SYM B-NP O
20 1098 1102 19139001 0.17 CD B-NP O
21 1103 1105 19139001 to TO I-NP O
22 1106 1110 19139001 2.14 CD I-NP O
23 1111 1113 19139001 dB NN I-NP O
24 1113 1114 19139001 ; : O O
25 1115 1116 19139001 P NN B-NP O
26 1117 1118 19139001 = SYM B-VP O
27 1119 1123 19139001 0.09 CD B-NP O
28 1123 1124 19139001 ) ) O O
29 1125 1128 19139001 was VBD B-VP O
30 1129 1137 19139001 detected VBN I-VP O
31 1137 1138 19139001 . . O O

1 1139 1143 19139001 Dose NN B-NP O
2 1144 1153 19139001 intensity NN I-NP O
3 1154 1157 19139001 did VBD B-VP O
4 1158 1161 19139001 not RB I-VP O
5 1162 1165 19139001 add VB I-VP O
6 1166 1177 19139001 information NN B-NP O
7 1178 1180 19139001 to TO B-PP O
8 1181 1187 19139001 models NNS B-NP O
9 1187 1188 19139001 . . O O

1 1189 1194 19139001 There EX B-NP O
2 1195 1199 19139001 were VBD B-VP O
3 1200 1202 19139001 14 CD B-NP O
4 1203 1205 19139001 of IN B-PP O
5 1206 1209 19139001 151 CD B-NP O
6 1210 1211 19139001 ( ( O O
7 1211 1215 19139001 9.3% CD B-NP O
8 1215 1216 19139001 ) ) O O
9 1217 1219 19139001 in IN B-PP O
10 1220 1223 19139001 the DT B-NP O
11 1224 1228 19139001 DFMO NN I-NP D000518
12 1229 1233 19139001 plus CC I-NP O
13 1234 1242 19139001 sulindac NN I-NP D013467
14 1243 1248 19139001 group NN I-NP O
15 1249 1252 19139001 and CC O O
16 1253 1254 19139001 4 CD B-NP O
17 1255 1257 19139001 of IN B-PP O
18 1258 1261 19139001 139 CD B-NP O
19 1262 1263 19139001 ( ( O O
20 1263 1267 19139001 2.9% CD B-NP O
21 1267 1268 19139001 ) ) O O
22 1269 1271 19139001 in IN B-PP O
23 1272 1275 19139001 the DT B-NP O
24 1276 1283 19139001 placebo NN I-NP O
25 1284 1289 19139001 group NN I-NP O
26 1290 1293 19139001 who WP B-NP O
27 1294 1305 19139001 experienced VBD B-VP O
28 1306 1308 19139001 at IN B-NP O
29 1309 1314 19139001 least JJS I-NP O
30 1315 1317 19139001 15 CD I-NP O
31 1318 1320 19139001 dB NN I-NP O
32 1321 1328 19139001 hearing NN I-NP O
33 1329 1338 19139001 reduction NN I-NP O
34 1339 1343 19139001 from IN B-PP O
35 1344 1352 19139001 baseline NN B-NP O
36 1353 1355 19139001 in IN B-PP O
37 1356 1357 19139001 2 CD B-NP O
38 1358 1360 19139001 or CC I-NP O
39 1361 1365 19139001 more JJR I-NP O
40 1366 1377 19139001 consecutive JJ I-NP O
41 1378 1389 19139001 frequencies NNS I-NP O
42 1390 1396 19139001 across IN B-PP O
43 1397 1400 19139001 the DT B-NP O
44 1401 1407 19139001 entire JJ I-NP O
45 1408 1413 19139001 range NN I-NP O
46 1414 1420 19139001 tested VBN B-VP O
47 1421 1422 19139001 ( ( O O
48 1422 1423 19139001 P NN B-NP O
49 1424 1425 19139001 = SYM B-VP O
50 1426 1430 19139001 0.02 CD B-NP O
51 1430 1431 19139001 ) ) O O
52 1431 1432 19139001 . . O O

1 1433 1439 19139001 Follow VB B-VP O
2 1439 1440 19139001 - HYPH O O
3 1440 1442 19139001 up RP B-PRT O
4 1443 1446 19139001 air NN B-NP O
5 1447 1457 19139001 conduction NN I-NP O
6 1458 1462 19139001 done VBN B-VP O
7 1463 1465 19139001 at IN B-NP O
8 1466 1471 19139001 least JJS I-NP O
9 1472 1473 19139001 6 CD I-NP O
10 1474 1480 19139001 months NNS I-NP O
11 1481 1486 19139001 after IN B-PP O
12 1487 1490 19139001 end NN B-NP O
13 1491 1493 19139001 of IN B-PP O
14 1494 1503 19139001 treatment NN B-NP O
15 1504 1510 19139001 showed VBD B-VP O
16 1511 1513 19139001 an DT B-NP O
17 1514 1522 19139001 adjusted VBN I-NP O
18 1523 1527 19139001 mean JJ I-NP O
19 1528 1538 19139001 difference NN I-NP O
20 1539 1541 19139001 in IN B-PP O
21 1542 1549 19139001 hearing VBG B-VP O
22 1550 1560 19139001 thresholds NNS B-NP O
23 1561 1563 19139001 of IN B-PP O
24 1564 1568 19139001 1.08 CD B-NP O
25 1569 1571 19139001 dB NN I-NP O
26 1572 1573 19139001 ( ( O O
27 1573 1574 19139001 - SYM B-NP O
28 1574 1578 19139001 0.81 CD B-NP O
29 1579 1581 19139001 to TO I-NP O
30 1582 1586 19139001 2.96 CD I-NP O
31 1587 1589 19139001 dB NN I-NP O
32 1589 1590 19139001 ; : O O
33 1591 1592 19139001 P NN B-NP O
34 1593 1594 19139001 = SYM B-VP O
35 1595 1599 19139001 0.26 CD B-NP O
36 1599 1600 19139001 ) ) O O
37 1601 1608 19139001 between IN B-PP O
38 1609 1618 19139001 treatment NN B-NP O
39 1619 1623 19139001 arms NNS I-NP O
40 1623 1624 19139001 . . O O

1 1625 1630 19139001 There EX B-NP O
2 1631 1634 19139001 was VBD B-VP O
3 1635 1637 19139001 no DT B-NP O
4 1638 1649 19139001 significant JJ I-NP O
5 1650 1660 19139001 difference NN I-NP O
6 1661 1663 19139001 in IN B-PP O
7 1664 1667 19139001 the DT B-NP O
8 1668 1678 19139001 proportion NN I-NP O
9 1679 1681 19139001 of IN B-PP O
10 1682 1690 19139001 subjects NNS B-NP O
11 1691 1693 19139001 in IN B-PP O
12 1694 1697 19139001 the DT B-NP O
13 1698 1702 19139001 DFMO NN I-NP D000518
14 1703 1707 19139001 plus CC I-NP O
15 1708 1716 19139001 sulindac NN I-NP D013467
16 1717 1722 19139001 group NN I-NP O
17 1723 1726 19139001 who WP B-NP O
18 1727 1738 19139001 experienced VBD B-VP O
19 1739 1749 19139001 clinically RB B-NP O
20 1750 1761 19139001 significant JJ I-NP O
21 1762 1769 19139001 hearing NN I-NP D034381
22 1770 1774 19139001 loss NN I-NP D034381
23 1775 1783 19139001 compared VBN B-VP O
24 1784 1788 19139001 with IN B-PP O
25 1789 1792 19139001 the DT B-NP O
26 1793 1800 19139001 placebo NN I-NP O
27 1801 1806 19139001 group NN I-NP O
28 1806 1807 19139001 . . O O

1 1808 1811 19139001 The DT B-NP O
2 1812 1821 19139001 estimated VBN I-NP O
3 1822 1834 19139001 attributable JJ I-NP O
4 1835 1839 19139001 risk NN I-NP O
5 1840 1842 19139001 of IN B-PP O
6 1843 1854 19139001 ototoxicity NN B-NP D006311
7 1855 1859 19139001 from IN B-PP O
8 1860 1868 19139001 exposure NN B-NP O
9 1869 1871 19139001 to TO B-PP O
10 1872 1875 19139001 the DT B-NP O
11 1876 1880 19139001 drug NN I-NP O
12 1881 1883 19139001 is VBZ B-VP O
13 1884 1888 19139001 8.4% CD B-NP O
14 1889 1890 19139001 ( ( O O
15 1890 1893 19139001 95% CD B-NP O
16 1894 1904 19139001 confidence NN I-NP O
17 1905 1913 19139001 interval NN I-NP O
18 1913 1914 19139001 , , O O
19 1915 1916 19139001 - SYM O O
20 1916 1920 19139001 2.0% CD B-NP O
21 1921 1923 19139001 to TO B-PP O
22 1924 1929 19139001 18.8% CD B-NP O
23 1929 1930 19139001 ; : O O
24 1931 1932 19139001 P NN B-NP O
25 1933 1934 19139001 = SYM B-VP O
26 1935 1939 19139001 0.12 CD B-NP O
27 1939 1940 19139001 ) ) O O
28 1940 1941 19139001 . . O O

1 1942 1947 19139001 There EX B-NP O
2 1948 1950 19139001 is VBZ B-VP O
3 1951 1952 19139001 a DT B-NP O
4 1953 1954 19139001 < JJR I-NP O
5 1954 1955 19139001 2 CD I-NP O
6 1956 1958 19139001 dB NN I-NP O
7 1959 1969 19139001 difference NN I-NP O
8 1970 1972 19139001 in IN B-PP O
9 1973 1977 19139001 mean JJ B-NP O
10 1978 1987 19139001 threshold NN I-NP O
11 1988 1991 19139001 for IN B-PP O
12 1992 2000 19139001 patients NNS B-NP O
13 2001 2008 19139001 treated VBN B-VP O
14 2009 2013 19139001 with IN B-PP O
15 2014 2018 19139001 DFMO NN B-NP D000518
16 2019 2023 19139001 plus CC I-NP O
17 2024 2032 19139001 sulindac NN I-NP D013467
18 2033 2041 19139001 compared VBN B-PP O
19 2042 2046 19139001 with IN B-PP O
20 2047 2052 19139001 those DT B-NP O
21 2053 2060 19139001 treated VBN B-VP O
22 2061 2065 19139001 with IN B-PP O
23 2066 2073 19139001 placebo NN B-NP O
24 2073 2074 19139001 . . O O

1 0 0 839274 -DOCSTART- -X- -X- O

1 0 7 839274 Hepatic JJ B-NP O
2 8 16 839274 adenomas NNS I-NP D000236
3 17 20 839274 and CC O O
4 21 26 839274 focal JJ B-NP D020518
5 27 34 839274 nodular JJ I-NP D020518
6 35 46 839274 hyperplasia NN I-NP D020518
7 47 49 839274 of IN B-PP O
8 50 53 839274 the DT B-NP O
9 54 59 839274 liver NN I-NP O
10 60 62 839274 in IN B-PP O
11 63 68 839274 young JJ B-NP O
12 69 74 839274 women NNS I-NP O
13 75 77 839274 on IN B-PP O
14 78 82 839274 oral JJ B-NP D003276
15 83 97 839274 contraceptives NNS I-NP D003276
16 97 98 839274 : : O O
17 99 103 839274 case NN B-NP O
18 104 111 839274 reports NNS I-NP O
19 111 112 839274 . . O O
20 113 116 839274 Two CD B-NP O
21 117 122 839274 cases NNS I-NP O
22 123 125 839274 of IN B-PP O
23 126 133 839274 hepatic JJ B-NP O
24 134 141 839274 adenoma NN I-NP D000236
25 142 145 839274 and CC O O
26 146 149 839274 one CD B-NP O
27 150 152 839274 of IN B-PP O
28 153 158 839274 focal JJ B-NP D020518
29 159 166 839274 nodular JJ I-NP D020518
30 167 178 839274 hyperplasia NN I-NP D020518
31 179 189 839274 presumably RB B-VP O
32 190 200 839274 associated VBN I-VP O
33 201 205 839274 with IN B-PP O
34 206 209 839274 the DT B-NP O
35 210 213 839274 use NN I-NP O
36 214 216 839274 of IN B-PP O
37 217 221 839274 oral JJ B-NP D003276
38 222 236 839274 contraceptives NNS I-NP D003276
39 236 237 839274 , , O O
40 238 241 839274 are VBP B-VP O
41 242 250 839274 reported VBN I-VP O
42 250 251 839274 . . O O

1 252 259 839274 Special JJ B-NP O
2 260 269 839274 reference NN I-NP O
3 270 272 839274 is VBZ B-VP O
4 273 277 839274 made VBN I-VP O
5 278 280 839274 to TO B-PP O
6 281 286 839274 their PRP$ B-NP O
7 287 295 839274 clinical JJ I-NP O
8 296 308 839274 presentation NN I-NP O
9 308 309 839274 , , O O
10 310 315 839274 which WDT B-NP O
11 316 319 839274 may MD B-VP O
12 320 322 839274 be VB I-VP O
13 323 330 839274 totally RB B-ADJP O
14 331 343 839274 asymptomatic JJ I-ADJP O
15 343 344 839274 . . O O

1 345 350 839274 Liver NN B-NP O
2 350 351 839274 - HYPH I-NP O
3 351 359 839274 function NN I-NP O
4 360 365 839274 tests NNS I-NP O
5 366 369 839274 are VBP B-VP O
6 370 372 839274 of IN B-PP O
7 373 379 839274 little JJ B-NP O
8 380 390 839274 diagnostic JJ I-NP O
9 391 396 839274 value NN I-NP O
10 396 397 839274 , , O O
11 398 401 839274 but CC O O
12 402 410 839274 valuable JJ B-NP O
13 411 422 839274 information NN I-NP O
14 423 426 839274 may MD B-VP O
15 427 429 839274 be VB I-VP O
16 430 438 839274 obtained VBN I-VP O
17 439 443 839274 from IN B-PP O
18 444 448 839274 both CC O O
19 449 454 839274 liver NN B-NP O
20 455 463 839274 scanning NN I-NP O
21 464 467 839274 and CC O O
22 468 475 839274 hepatic JJ B-NP O
23 476 487 839274 angiography NN I-NP O
24 487 488 839274 . . O O

1 489 499 839274 Histologic JJ B-NP O
2 500 511 839274 differences NNS I-NP O
3 512 515 839274 and CC O O
4 516 524 839274 clinical JJ B-NP O
5 525 537 839274 similarities NNS I-NP O
6 538 545 839274 between IN B-PP O
7 546 553 839274 hepatic JJ B-NP O
8 554 561 839274 adenoma NN I-NP D000236
9 562 565 839274 and CC O O
10 566 571 839274 focal JJ B-NP D020518
11 572 579 839274 nodular JJ I-NP D020518
12 580 591 839274 hyperplasia NN I-NP D020518
13 592 594 839274 of IN B-PP O
14 595 598 839274 the DT B-NP O
15 599 604 839274 liver NN I-NP O
16 605 608 839274 are VBP B-VP O
17 609 618 839274 discussed VBN I-VP O
18 618 619 839274 . . O O

1 0 0 8045270 -DOCSTART- -X- -X- O

1 0 7 8045270 KF17837 NN B-NP C081198
2 7 8 8045270 : : O O
3 9 10 8045270 a DT B-NP O
4 11 16 8045270 novel JJ I-NP O
5 17 26 8045270 selective JJ I-NP O
6 27 36 8045270 adenosine NN I-NP D000241
7 37 40 8045270 A2A NN I-NP O
8 41 49 8045270 receptor NN I-NP O
9 50 60 8045270 antagonist NN I-NP O
10 61 65 8045270 with IN B-PP O
11 66 80 8045270 anticataleptic JJ B-NP O
12 81 89 8045270 activity NN I-NP O
13 89 90 8045270 . . I-NP O
14 91 98 8045270 KF17837 NN I-NP C081198
15 99 101 8045270 is VBZ B-VP O
16 102 103 8045270 a DT B-NP O
17 104 109 8045270 novel JJ I-NP O
18 110 119 8045270 selective JJ I-NP O
19 120 129 8045270 adenosine NN I-NP D000241
20 130 133 8045270 A2A NN I-NP O
21 134 142 8045270 receptor NN I-NP O
22 143 153 8045270 antagonist NN I-NP O
23 153 154 8045270 . . O O

1 155 159 8045270 Oral JJ B-NP O
2 160 174 8045270 administration NN I-NP O
3 175 177 8045270 of IN B-PP O
4 178 185 8045270 KF17837 NN B-NP C081198
5 186 187 8045270 ( ( O O
6 187 190 8045270 2.5 CD B-NP O
7 190 191 8045270 , , I-NP O
8 192 196 8045270 10.0 CD I-NP O
9 197 200 8045270 and CC I-NP O
10 201 205 8045270 30.0 CD I-NP O
11 206 208 8045270 mg NN I-NP O
12 208 209 8045270 / SYM B-NP O
13 209 211 8045270 kg NN I-NP O
14 211 212 8045270 ) ) O O
15 213 226 8045270 significantly RB B-VP O
16 227 238 8045270 ameliorated VBD I-VP O
17 239 242 8045270 the DT B-NP O
18 243 253 8045270 cataleptic JJ I-NP D002375
19 254 263 8045270 responses NNS I-NP O
20 264 271 8045270 induced VBN B-VP O
21 272 274 8045270 by IN B-PP O
22 275 298 8045270 intracerebroventricular JJ B-NP O
23 299 313 8045270 administration NN I-NP O
24 314 316 8045270 of IN B-PP O
25 317 319 8045270 an DT B-NP O
26 320 329 8045270 adenosine NN I-NP D000241
27 330 333 8045270 A2A NN I-NP O
28 334 342 8045270 receptor NN I-NP O
29 343 350 8045270 agonist NN I-NP O
30 350 351 8045270 , , O O
31 352 355 8045270 CGS NN B-NP C061282
32 356 361 8045270 21680 CD I-NP C061282
33 362 363 8045270 ( ( O O
34 363 365 8045270 10 CD B-NP O
35 366 376 8045270 micrograms NNS I-NP O
36 376 377 8045270 ) ) O O
37 377 378 8045270 , , O O
38 379 381 8045270 in IN B-PP O
39 382 383 8045270 a DT B-NP O
40 384 388 8045270 dose NN I-NP O
41 388 389 8045270 - HYPH B-NP O
42 389 398 8045270 dependent JJ I-NP O
43 399 405 8045270 manner NN I-NP O
44 405 406 8045270 . . O O

1 407 414 8045270 KF17837 NN B-NP C081198
2 415 419 8045270 also RB B-ADVP O
3 420 427 8045270 reduced VBD B-VP O
4 428 431 8045270 the DT B-NP O
5 432 441 8045270 catalepsy NN I-NP D002375
6 442 449 8045270 induced VBN B-VP O
7 450 452 8045270 by IN B-PP O
8 453 464 8045270 haloperidol NN B-NP D006220
9 465 466 8045270 ( ( O O
10 466 467 8045270 1 CD B-NP O
11 468 470 8045270 mg NN I-NP O
12 470 471 8045270 / SYM B-NP O
13 471 473 8045270 kg NN I-NP O
14 474 477 8045270 i.p NN I-NP O
15 477 478 8045270 . . O O
16 478 479 8045270 ) ) O O
17 480 483 8045270 and CC O O
18 484 486 8045270 by IN B-PP O
19 487 496 8045270 reserpine NN B-NP D012110
20 497 498 8045270 ( ( O O
21 498 499 8045270 5 CD B-NP O
22 500 502 8045270 mg NN I-NP O
23 502 503 8045270 / SYM B-NP O
24 503 505 8045270 kg NN I-NP O
25 506 509 8045270 i.p NN I-NP O
26 509 510 8045270 . . O O
27 510 511 8045270 ) ) O O
28 511 512 8045270 . . O O

1 513 518 8045270 These DT B-NP O
2 519 533 8045270 anticataleptic JJ I-NP O
3 534 541 8045270 effects NNS I-NP O
4 542 546 8045270 were VBD B-VP O
5 547 556 8045270 exhibited VBN I-VP O
6 557 561 8045270 dose NN B-NP O
7 562 573 8045270 dependently RB B-ADVP O
8 574 576 8045270 at IN B-PP O
9 577 582 8045270 doses NNS B-NP O
10 583 587 8045270 from IN B-PP O
11 588 593 8045270 0.625 CD B-NP O
12 594 597 8045270 and CC I-NP O
13 598 601 8045270 2.5 CD I-NP O
14 602 604 8045270 mg NN I-NP O
15 604 605 8045270 / SYM B-NP O
16 605 607 8045270 kg NN I-NP O
17 608 611 8045270 p.o NN I-NP O
18 611 612 8045270 . NN I-NP O
19 612 613 8045270 , , O O
20 614 626 8045270 respectively RB B-ADVP O
21 626 627 8045270 . . O O

1 628 636 8045270 Moreover RB B-ADVP O
2 636 637 8045270 , , O O
3 638 645 8045270 KF17837 NN B-NP C081198
4 646 647 8045270 ( ( O O
5 647 652 8045270 0.625 CD B-NP O
6 653 655 8045270 mg NN I-NP O
7 655 656 8045270 / SYM B-NP O
8 656 658 8045270 kg NN I-NP O
9 659 662 8045270 p.o NN I-NP O
10 662 663 8045270 . . O O
11 663 664 8045270 ) ) O O
12 665 676 8045270 potentiated VBD B-VP O
13 677 680 8045270 the DT B-NP O
14 681 695 8045270 anticataleptic JJ I-NP O
15 696 703 8045270 effects NNS I-NP O
16 704 706 8045270 of IN B-PP O
17 707 708 8045270 a DT B-NP O
18 709 721 8045270 subthreshold JJ I-NP O
19 722 726 8045270 dose NN I-NP O
20 727 729 8045270 of IN B-PP O
21 730 731 8045270 L NN B-NP D007980
22 731 732 8045270 - HYPH B-NP D007980
23 732 735 8045270 3,4 CD I-NP D007980
24 735 736 8045270 - HYPH I-NP D007980
25 736 758 8045270 dihydroxyphenylalanine NN I-NP D007980
26 759 760 8045270 ( ( O O
27 760 761 8045270 L NN B-NP D007980
28 761 762 8045270 - HYPH O D007980
29 762 766 8045270 DOPA NN B-NP D007980
30 766 767 8045270 ; : O O
31 768 770 8045270 25 CD B-NP O
32 771 773 8045270 mg NN I-NP O
33 773 774 8045270 / SYM B-NP O
34 774 776 8045270 kg NN I-NP O
35 777 780 8045270 i.p NN I-NP O
36 780 781 8045270 . . O O
37 781 782 8045270 ) ) O O
38 783 787 8045270 plus CC O O
39 788 799 8045270 benserazide NN B-NP D001545
40 800 801 8045270 ( ( O O
41 801 805 8045270 6.25 CD B-NP O
42 806 808 8045270 mg NN I-NP O
43 808 809 8045270 / SYM B-NP O
44 809 811 8045270 kg NN I-NP O
45 812 815 8045270 i.p NN I-NP O
46 815 816 8045270 . . O O
47 816 817 8045270 ) ) O O
48 817 818 8045270 . . O O

1 819 824 8045270 These DT B-NP O
2 825 832 8045270 results NNS I-NP O
3 833 842 8045270 suggested VBD B-VP O
4 843 847 8045270 that IN B-SBAR O
5 848 855 8045270 KF17837 NN B-NP C081198
6 856 858 8045270 is VBZ B-VP O
7 859 860 8045270 a DT B-NP O
8 861 870 8045270 centrally RB I-NP O
9 871 877 8045270 active JJ I-NP O
10 878 887 8045270 adenosine NN I-NP D000241
11 888 891 8045270 A2A NN I-NP O
12 892 900 8045270 receptor NN I-NP O
13 901 911 8045270 antagonist NN I-NP O
14 912 915 8045270 and CC O O
15 916 920 8045270 that IN B-SBAR O
16 921 924 8045270 the DT B-NP O
17 925 937 8045270 dopaminergic JJ I-NP O
18 938 946 8045270 function NN I-NP O
19 947 949 8045270 of IN B-PP O
20 950 953 8045270 the DT B-NP O
21 954 967 8045270 nigrostriatal JJ I-NP O
22 968 975 8045270 pathway NN I-NP O
23 976 978 8045270 is VBZ B-VP O
24 979 990 8045270 potentiated VBN I-VP O
25 991 993 8045270 by IN B-PP O
26 994 1003 8045270 adenosine NN B-NP D000241
27 1004 1007 8045270 A2A NN I-NP O
28 1008 1016 8045270 receptor NN I-NP O
29 1017 1028 8045270 antagonists NNS I-NP O
30 1028 1029 8045270 . . O O

1 1030 1041 8045270 Furthermore RB B-ADVP O
2 1041 1042 8045270 , , O O
3 1043 1050 8045270 KF17837 NN B-NP C081198
4 1051 1054 8045270 may MD B-VP O
5 1055 1057 8045270 be VB I-VP O
6 1058 1059 8045270 a DT B-NP O
7 1060 1066 8045270 useful JJ I-NP O
8 1067 1071 8045270 drug NN I-NP O
9 1072 1074 8045270 in IN B-PP O
10 1075 1078 8045270 the DT B-NP O
11 1079 1088 8045270 treatment NN I-NP O
12 1089 1091 8045270 of IN B-PP O
13 1092 1104 8045270 parkinsonism NN B-NP D010302
14 1104 1105 8045270 . . O O

1 0 0 2598570 -DOCSTART- -X- -X- O

1 0 3 2598570 The DT B-NP O
2 4 16 2598570 epidemiology NN I-NP O
3 17 19 2598570 of IN B-PP O
4 20 23 2598570 the DT B-NP O
5 24 29 2598570 acute JJ I-NP O
6 30 35 2598570 flank NN I-NP D021501
7 36 40 2598570 pain NN I-NP D021501
8 41 49 2598570 syndrome NN I-NP O
9 50 54 2598570 from IN B-PP O
10 55 63 2598570 suprofen NN B-NP D013496
11 63 64 2598570 . . O O
12 65 73 2598570 Suprofen NN B-NP D013496
13 73 74 2598570 , , O O
14 75 76 2598570 a DT B-NP O
15 77 80 2598570 new JJ I-NP O
16 81 93 2598570 nonsteroidal JJ I-NP O
17 94 98 2598570 anti AFX I-NP O
18 98 99 2598570 - HYPH I-NP O
19 99 111 2598570 inflammatory JJ I-NP O
20 112 116 2598570 drug NN I-NP O
21 116 117 2598570 , , O O
22 118 121 2598570 was VBD B-VP O
23 122 130 2598570 marketed VBN I-VP O
24 131 133 2598570 in IN B-PP O
25 134 139 2598570 early JJ B-NP O
26 140 144 2598570 1986 CD I-NP O
27 145 147 2598570 as IN B-PP O
28 148 150 2598570 an DT B-NP O
29 151 160 2598570 analgesic JJ I-NP O
30 161 166 2598570 agent NN I-NP O
31 166 167 2598570 . . O O

1 168 173 2598570 Until IN B-SBAR O
2 174 184 2598570 physicians NNS B-NP O
3 185 190 2598570 began VBD B-VP O
4 191 200 2598570 reporting VBG I-VP O
5 201 203 2598570 an DT B-NP O
6 204 211 2598570 unusual JJ I-NP O
7 212 217 2598570 acute JJ I-NP O
8 218 223 2598570 flank NN I-NP D021501
9 224 228 2598570 pain NN I-NP D021501
10 229 237 2598570 syndrome NN I-NP O
11 238 240 2598570 to TO B-PP O
12 241 244 2598570 the DT B-NP O
13 245 256 2598570 spontaneous JJ I-NP O
14 257 266 2598570 reporting NN I-NP O
15 267 273 2598570 system NN I-NP O
16 273 274 2598570 , , O O
17 275 282 2598570 700,000 CD B-NP O
18 283 290 2598570 persons NNS I-NP O
19 291 295 2598570 used VBD B-VP O
20 296 299 2598570 the DT B-NP O
21 300 304 2598570 drug NN I-NP O
22 305 307 2598570 in IN B-PP O
23 308 311 2598570 the DT B-NP O
24 312 318 2598570 United NNP I-NP O
25 319 325 2598570 States NNPS I-NP O
26 325 326 2598570 . . O O

1 327 334 2598570 Through IN B-PP O
2 335 341 2598570 August NNP B-NP O
3 342 346 2598570 1986 CD I-NP O
4 346 347 2598570 , , O O
5 348 349 2598570 a DT B-NP O
6 350 355 2598570 total NN I-NP O
7 356 358 2598570 of IN B-PP O
8 359 362 2598570 163 CD B-NP O
9 363 368 2598570 cases NNS I-NP O
10 369 371 2598570 of IN B-PP O
11 372 376 2598570 this DT B-NP O
12 377 385 2598570 syndrome NN I-NP O
13 386 390 2598570 were VBD B-VP O
14 391 399 2598570 reported VBN I-VP O
15 399 400 2598570 . . O O

1 401 403 2598570 To TO B-VP O
2 404 413 2598570 elucidate VB I-VP O
3 414 417 2598570 the DT B-NP O
4 418 430 2598570 epidemiology NN I-NP O
5 431 433 2598570 of IN B-PP O
6 434 437 2598570 the DT B-NP O
7 438 446 2598570 syndrome NN I-NP O
8 446 447 2598570 , , O O
9 448 449 2598570 a DT B-NP O
10 450 454 2598570 case NN I-NP O
11 454 455 2598570 - HYPH B-NP O
12 455 462 2598570 control NN I-NP O
13 463 468 2598570 study NN I-NP O
14 469 472 2598570 was VBD B-VP O
15 473 482 2598570 performed VBN I-VP O
16 482 483 2598570 , , O O
17 484 493 2598570 comparing VBG B-VP O
18 494 496 2598570 62 CD B-NP O
19 497 499 2598570 of IN B-PP O
20 500 503 2598570 the DT B-NP O
21 504 508 2598570 case NN I-NP O
22 509 517 2598570 patients NNS I-NP O
23 518 521 2598570 who WP B-NP O
24 522 525 2598570 had VBD B-VP O
25 526 530 2598570 been VBN I-VP O
26 531 539 2598570 reported VBN I-VP O
27 540 542 2598570 to TO B-PP O
28 543 546 2598570 the DT B-NP O
29 547 558 2598570 spontaneous JJ I-NP O
30 559 568 2598570 reporting VBG I-NP O
31 569 575 2598570 system NN I-NP O
32 576 578 2598570 to TO B-PP O
33 579 582 2598570 185 CD B-NP O
34 583 591 2598570 suprofen NN I-NP D013496
35 591 592 2598570 - HYPH O O
36 592 599 2598570 exposed VBN B-NP O
37 600 607 2598570 control NN I-NP O
38 608 616 2598570 subjects NNS I-NP O
39 617 620 2598570 who WP B-NP O
40 621 624 2598570 did VBD B-VP O
41 625 628 2598570 not RB I-VP O
42 629 633 2598570 have VB I-VP O
43 634 637 2598570 the DT B-NP O
44 638 646 2598570 syndrome NN I-NP O
45 646 647 2598570 . . O O

1 648 652 2598570 Case NN B-NP O
2 653 661 2598570 patients NNS I-NP O
3 662 666 2598570 were VBD B-VP O
4 667 671 2598570 more RBR B-ADJP O
5 672 678 2598570 likely JJ I-ADJP O
6 679 681 2598570 to TO B-VP O
7 682 684 2598570 be VB I-VP O
8 685 688 2598570 men NNS B-NP O
9 689 690 2598570 ( ( O O
10 690 694 2598570 odds NNS B-NP O
11 695 700 2598570 ratio NN I-NP O
12 700 701 2598570 , , O O
13 702 705 2598570 3.8 CD B-NP O
14 705 706 2598570 ; : O O
15 707 710 2598570 95% CD B-NP O
16 711 721 2598570 confidence NN I-NP O
17 722 730 2598570 interval NN I-NP O
18 730 731 2598570 , , O O
19 732 735 2598570 1.2 CD B-NP O
20 735 736 2598570 - HYPH I-NP O
21 736 740 2598570 12.1 CD I-NP O
22 740 741 2598570 ) ) O O
23 741 742 2598570 , , O O
24 743 749 2598570 suffer VBP B-VP O
25 750 754 2598570 from IN B-PP O
26 755 758 2598570 hay NN B-NP D006255
27 759 764 2598570 fever NN I-NP D006255
28 765 768 2598570 and CC O O
29 769 775 2598570 asthma NN B-NP D001249
30 776 777 2598570 ( ( O O
31 777 781 2598570 odds NNS B-NP O
32 782 787 2598570 ratio NN I-NP O
33 787 788 2598570 , , O O
34 789 792 2598570 3.4 CD B-NP O
35 792 793 2598570 ; : O O
36 794 797 2598570 95% CD B-NP O
37 798 808 2598570 confidence NN I-NP O
38 809 817 2598570 interval NN I-NP O
39 817 818 2598570 , , O O
40 819 822 2598570 1.0 CD B-NP O
41 822 823 2598570 - HYPH I-NP O
42 823 827 2598570 11.9 CD I-NP O
43 827 828 2598570 ) ) O O
44 828 829 2598570 ; : O O
45 830 832 2598570 to TO B-VP O
46 833 844 2598570 participate VB I-VP O
47 845 847 2598570 in IN B-PP O
48 848 855 2598570 regular JJ B-NP O
49 856 864 2598570 exercise NN I-NP O
50 865 866 2598570 ( ( O O
51 866 870 2598570 odds NNS B-NP O
52 871 876 2598570 ratio NN I-NP O
53 876 877 2598570 , , O O
54 878 881 2598570 5.9 CD B-NP O
55 881 882 2598570 ; : O O
56 883 886 2598570 95% CD B-NP O
57 887 897 2598570 confidence NN I-NP O
58 898 906 2598570 interval NN I-NP O
59 906 907 2598570 , , O O
60 908 911 2598570 1.1 CD B-NP O
61 911 912 2598570 - HYPH I-NP O
62 912 916 2598570 30.7 CD I-NP O
63 916 917 2598570 ) ) O O
64 917 918 2598570 , , O O
65 919 929 2598570 especially RB B-ADVP O
66 930 932 2598570 in IN B-PP O
67 933 936 2598570 the DT B-NP O
68 937 940 2598570 use NN I-NP O
69 941 943 2598570 of IN B-PP O
70 944 952 2598570 Nautilus NN B-NP O
71 953 962 2598570 equipment NN I-NP O
72 963 964 2598570 ( ( O O
73 964 965 2598570 p NN B-NP O
74 966 967 2598570 = SYM B-VP O
75 968 972 2598570 0.02 CD B-NP O
76 972 973 2598570 ) ) O O
77 973 974 2598570 ; : O O
78 975 978 2598570 and CC O O
79 979 981 2598570 to TO B-VP O
80 982 985 2598570 use VB I-VP O
81 986 993 2598570 alcohol NN B-NP D000431
82 994 995 2598570 ( ( O O
83 995 999 2598570 odds NNS B-NP O
84 1000 1005 2598570 ratio NN I-NP O
85 1005 1006 2598570 , , O O
86 1007 1010 2598570 4.4 CD B-NP O
87 1010 1011 2598570 ; : O O
88 1012 1015 2598570 95% CD B-NP O
89 1016 1026 2598570 confidence NN I-NP O
90 1027 1035 2598570 interval NN I-NP O
91 1035 1036 2598570 , , O O
92 1037 1040 2598570 1.1 CD B-NP O
93 1040 1041 2598570 - HYPH I-NP O
94 1041 1045 2598570 17.5 CD I-NP O
95 1045 1046 2598570 ) ) O O
96 1046 1047 2598570 . . O O

1 1048 1056 2598570 Possible JJ B-NP O
2 1057 1061 2598570 risk NN I-NP O
3 1062 1069 2598570 factors NNS I-NP O
4 1070 1078 2598570 included VBD B-VP O
5 1079 1084 2598570 young JJ B-NP O
6 1085 1088 2598570 age NN I-NP O
7 1088 1089 2598570 , , O O
8 1090 1100 2598570 concurrent JJ B-NP O
9 1101 1104 2598570 use NN I-NP O
10 1105 1107 2598570 of IN B-PP O
11 1108 1113 2598570 other JJ B-NP O
12 1114 1123 2598570 analgesic JJ I-NP O
13 1124 1130 2598570 agents NNS I-NP O
14 1131 1132 2598570 ( ( O O
15 1132 1142 2598570 especially RB B-NP O
16 1143 1152 2598570 ibuprofen NN I-NP D007052
17 1152 1153 2598570 ) ) O O
18 1153 1154 2598570 , , O O
19 1155 1166 2598570 preexisting VBG B-VP O
20 1167 1172 2598570 renal JJ B-NP D007674
21 1173 1180 2598570 disease NN I-NP D007674
22 1180 1181 2598570 , , O O
23 1182 1183 2598570 a DT B-NP O
24 1184 1191 2598570 history NN I-NP O
25 1192 1194 2598570 of IN B-PP O
26 1195 1201 2598570 kidney NN B-NP D007669
27 1202 1208 2598570 stones NNS I-NP D007669
28 1208 1209 2598570 , , O O
29 1210 1211 2598570 a DT B-NP O
30 1212 1219 2598570 history NN I-NP O
31 1220 1222 2598570 of IN B-PP O
32 1223 1227 2598570 gout NN B-NP D006073
33 1227 1228 2598570 , , O O
34 1229 1230 2598570 a DT B-NP O
35 1231 1237 2598570 recent JJ I-NP O
36 1238 1246 2598570 increase NN I-NP O
37 1247 1249 2598570 in IN B-PP O
38 1250 1258 2598570 activity NN B-NP O
39 1258 1259 2598570 , , O O
40 1260 1261 2598570 a DT B-NP O
41 1262 1268 2598570 recent JJ I-NP O
42 1269 1277 2598570 increase NN I-NP O
43 1278 1280 2598570 in IN B-PP O
44 1281 1284 2598570 sun NN B-NP O
45 1285 1293 2598570 exposure NN I-NP O
46 1293 1294 2598570 , , O O
47 1295 1298 2598570 and CC O O
48 1299 1308 2598570 residence NN B-NP O
49 1309 1311 2598570 in IN B-PP O
50 1312 1315 2598570 the DT B-NP O
51 1316 1323 2598570 Sunbelt NNP I-NP O
52 1323 1324 2598570 . . O O

1 1325 1330 2598570 These DT B-NP O
2 1331 1335 2598570 were VBD B-VP O
3 1336 1344 2598570 findings NNS B-NP O
4 1345 1349 2598570 that WDT B-NP O
5 1350 1354 2598570 were VBD B-VP O
6 1355 1365 2598570 suggestive JJ B-ADJP O
7 1366 1369 2598570 but CC O O
8 1370 1373 2598570 did VBD B-VP O
9 1374 1377 2598570 not RB I-VP O
10 1378 1383 2598570 reach VB I-VP O
11 1384 1396 2598570 conventional JJ B-NP O
12 1397 1408 2598570 statistical JJ I-NP O
13 1409 1421 2598570 significance NN I-NP O
14 1421 1422 2598570 . . O O

1 1423 1428 2598570 These DT B-NP O
2 1429 1437 2598570 findings NNS I-NP O
3 1438 1441 2598570 are VBP B-VP O
4 1442 1452 2598570 consistent JJ B-ADJP O
5 1453 1457 2598570 with IN B-PP O
6 1458 1461 2598570 the DT B-NP O
7 1462 1472 2598570 postulated VBN I-NP O
8 1473 1482 2598570 mechanism NN I-NP O
9 1483 1486 2598570 for IN B-PP O
10 1487 1491 2598570 this DT B-NP O
11 1492 1499 2598570 unusual JJ I-NP O
12 1500 1508 2598570 syndrome NN I-NP O
13 1508 1509 2598570 : : O O
14 1510 1515 2598570 acute JJ B-NP O
15 1516 1523 2598570 diffuse JJ I-NP O
16 1524 1539 2598570 crystallization NN I-NP O
17 1540 1542 2598570 of IN B-PP O
18 1543 1547 2598570 uric JJ B-NP D014527
19 1548 1552 2598570 acid NN I-NP D014527
20 1553 1555 2598570 in IN B-PP O
21 1556 1561 2598570 renal JJ B-NP O
22 1562 1569 2598570 tubules NNS I-NP O
23 1569 1570 2598570 . . O O

1 0 0 20705401 -DOCSTART- -X- -X- O

1 0 9 20705401 Serotonin NN B-NP D012701
2 10 11 20705401 6 CD I-NP O
3 12 20 20705401 receptor NN I-NP O
4 21 25 20705401 gene NN I-NP O
5 26 28 20705401 is VBZ B-VP O
6 29 39 20705401 associated VBN I-VP O
7 40 44 20705401 with IN B-PP O
8 45 60 20705401 methamphetamine NN B-NP D008694
9 60 61 20705401 - HYPH B-NP O
10 61 68 20705401 induced VBN I-NP O
11 69 78 20705401 psychosis NN I-NP D011605
12 79 81 20705401 in IN B-PP O
13 82 83 20705401 a DT B-NP O
14 84 92 20705401 Japanese JJ I-NP O
15 93 103 20705401 population NN I-NP O
16 103 104 20705401 . . I-NP O
17 105 115 20705401 BACKGROUND NN I-NP O
18 115 116 20705401 : : O O
19 117 124 20705401 Altered VBN B-VP O
20 125 137 20705401 serotonergic JJ B-NP O
21 138 144 20705401 neural JJ I-NP O
22 145 157 20705401 transmission NN I-NP O
23 158 160 20705401 is VBZ B-VP O
24 161 173 20705401 hypothesized VBN I-VP O
25 174 176 20705401 to TO I-VP O
26 177 179 20705401 be VB I-VP O
27 180 181 20705401 a DT B-NP O
28 182 196 20705401 susceptibility NN I-NP O
29 197 203 20705401 factor NN I-NP O
30 204 207 20705401 for IN B-PP O
31 208 217 20705401 psychotic JJ B-NP D011605
32 218 227 20705401 disorders NNS I-NP D011605
33 228 232 20705401 such JJ B-PP O
34 233 235 20705401 as IN I-PP O
35 236 249 20705401 schizophrenia NN B-NP D012559
36 249 250 20705401 . . O O

1 251 254 20705401 The DT B-NP O
2 255 264 20705401 serotonin NN I-NP D012701
3 265 266 20705401 6 CD I-NP O
4 267 268 20705401 ( ( O O
5 268 269 20705401 5 CD B-NP D012701
6 269 270 20705401 - HYPH I-NP D012701
7 270 273 20705401 HT6 NN I-NP D012701
8 273 274 20705401 ) ) O O
9 275 283 20705401 receptor NN B-NP O
10 284 286 20705401 is VBZ B-VP O
11 287 302 20705401 therapeutically RB I-VP O
12 303 311 20705401 targeted VBN I-VP O
13 312 314 20705401 by IN B-PP O
14 315 322 20705401 several JJ B-NP O
15 323 329 20705401 second JJ I-NP O
16 330 340 20705401 generation NN I-NP O
17 341 355 20705401 antipsychotics NNS I-NP O
18 355 356 20705401 , , O O
19 357 361 20705401 such JJ B-PP O
20 362 364 20705401 as IN I-PP O
21 365 374 20705401 clozapine NN B-NP D003024
22 375 378 20705401 and CC I-NP O
23 379 389 20705401 olanzapine NN I-NP C076029
24 389 390 20705401 , , O O
25 391 394 20705401 and CC O O
26 395 396 20705401 d NN B-NP D003913
27 396 397 20705401 - HYPH B-NP D003913
28 397 408 20705401 amphetamine NN I-NP D003913
29 408 409 20705401 - HYPH O O
30 409 416 20705401 induced VBN B-NP O
31 417 430 20705401 hyperactivity NN I-NP D006948
32 431 433 20705401 in IN B-PP O
33 434 438 20705401 rats NNS B-NP O
34 439 441 20705401 is VBZ B-VP O
35 442 451 20705401 corrected VBN I-VP O
36 452 456 20705401 with IN B-PP O
37 457 460 20705401 the DT B-NP O
38 461 464 20705401 use NN I-NP O
39 465 467 20705401 of IN B-PP O
40 468 469 20705401 a DT B-NP O
41 470 479 20705401 selective JJ I-NP O
42 480 481 20705401 5 CD I-NP D012701
43 481 482 20705401 - HYPH I-NP D012701
44 482 485 20705401 HT6 NN I-NP D012701
45 486 494 20705401 receptor NN I-NP O
46 495 505 20705401 antagonist NN I-NP O
47 505 506 20705401 . . O O

1 507 509 20705401 In IN B-PP O
2 510 518 20705401 addition NN B-NP O
3 518 519 20705401 , , O O
4 520 523 20705401 the DT B-NP O
5 524 533 20705401 disrupted VBN I-NP O
6 534 542 20705401 prepulse NN I-NP O
7 543 553 20705401 inhibition NN I-NP O
8 554 561 20705401 induced VBN B-VP O
9 562 564 20705401 by IN B-PP O
10 565 566 20705401 d NN B-NP D003913
11 566 567 20705401 - HYPH B-NP D003913
12 567 578 20705401 amphetamine NN I-NP D003913
13 579 581 20705401 or CC I-NP O
14 582 595 20705401 phencyclidine NN I-NP D010622
15 596 599 20705401 was VBD B-VP O
16 600 608 20705401 restored VBN I-VP O
17 609 611 20705401 by IN B-PP O
18 612 613 20705401 5 CD B-NP D012701
19 613 614 20705401 - HYPH I-NP D012701
20 614 617 20705401 HT6 NN I-NP D012701
21 618 626 20705401 receptor NN I-NP O
22 627 637 20705401 antagonist NN I-NP O
23 638 640 20705401 in IN B-PP O
24 641 643 20705401 an DT B-NP O
25 644 650 20705401 animal NN I-NP O
26 651 656 20705401 study NN I-NP O
27 657 662 20705401 using VBG B-VP O
28 663 667 20705401 rats NNS B-NP O
29 667 668 20705401 . . O O

1 669 674 20705401 These DT B-NP O
2 675 681 20705401 animal JJ I-NP O
3 682 688 20705401 models NNS I-NP O
4 689 693 20705401 were VBD B-VP O
5 694 704 20705401 considered VBN I-VP O
6 705 707 20705401 to TO B-VP O
7 708 715 20705401 reflect VB I-VP O
8 716 719 20705401 the DT B-NP O
9 720 728 20705401 positive JJ I-NP O
10 729 737 20705401 symptoms NNS I-NP O
11 738 740 20705401 of IN B-PP O
12 741 754 20705401 schizophrenia NN B-NP D012559
13 754 755 20705401 , , O O
14 756 759 20705401 and CC O O
15 760 763 20705401 the DT B-NP O
16 764 769 20705401 above JJ I-NP O
17 770 778 20705401 evidence NN I-NP O
18 779 787 20705401 suggests VBZ B-VP O
19 788 792 20705401 that IN B-SBAR O
20 793 800 20705401 altered VBN B-NP O
21 801 802 20705401 5 CD I-NP D012701
22 802 803 20705401 - HYPH I-NP D012701
23 803 806 20705401 HT6 NN I-NP D012701
24 807 816 20705401 receptors NNS I-NP O
25 817 820 20705401 are VBP B-VP O
26 821 829 20705401 involved VBN I-VP O
27 830 832 20705401 in IN B-PP O
28 833 836 20705401 the DT B-NP O
29 837 852 20705401 pathophysiology NN I-NP O
30 853 855 20705401 of IN B-PP O
31 856 865 20705401 psychotic JJ B-NP D011605
32 866 875 20705401 disorders NNS I-NP D011605
33 875 876 20705401 . . O O

1 877 880 20705401 The DT B-NP O
2 881 889 20705401 symptoms NNS I-NP O
3 890 892 20705401 of IN B-PP O
4 893 908 20705401 methamphetamine NN B-NP D008694
5 909 910 20705401 ( ( O O
6 910 914 20705401 METH NN B-NP D008694
7 914 915 20705401 ) ) O O
8 915 916 20705401 - HYPH B-NP O
9 916 923 20705401 induced VBN I-NP O
10 924 933 20705401 psychosis NN I-NP D011605
11 934 937 20705401 are VBP B-VP O
12 938 945 20705401 similar JJ B-ADJP O
13 946 948 20705401 to TO B-PP O
14 949 954 20705401 those DT B-NP O
15 955 957 20705401 of IN B-PP O
16 958 966 20705401 paranoid JJ B-NP D012563
17 967 971 20705401 type NN I-NP D012563
18 972 985 20705401 schizophrenia NN I-NP D012563
19 985 986 20705401 . . O O

1 987 996 20705401 Therefore RB B-ADVP O
2 996 997 20705401 , , O O
3 998 1000 20705401 we PRP B-NP O
4 1001 1010 20705401 conducted VBD B-VP O
5 1011 1013 20705401 an DT B-NP O
6 1014 1022 20705401 analysis NN I-NP O
7 1023 1025 20705401 of IN B-PP O
8 1026 1029 20705401 the DT B-NP O
9 1030 1041 20705401 association NN I-NP O
10 1042 1044 20705401 of IN B-PP O
11 1045 1048 20705401 the DT B-NP O
12 1049 1050 20705401 5 CD I-NP D012701
13 1050 1051 20705401 - HYPH I-NP D012701
14 1051 1054 20705401 HT6 NN I-NP D012701
15 1055 1059 20705401 gene NN I-NP O
16 1060 1061 20705401 ( ( O O
17 1061 1065 20705401 HTR6 NN B-NP O
18 1065 1066 20705401 ) ) O O
19 1067 1071 20705401 with IN B-PP O
20 1072 1076 20705401 METH NN B-NP D008694
21 1076 1077 20705401 - HYPH B-NP O
22 1077 1084 20705401 induced VBN I-NP O
23 1085 1094 20705401 psychosis NN I-NP D011605
24 1094 1095 20705401 . . O O

1 1096 1102 20705401 METHOD NN B-NP O
2 1102 1103 20705401 : : O O
3 1104 1109 20705401 Using VBG B-VP O
4 1110 1114 20705401 five CD B-NP O
5 1115 1122 20705401 tagging VBG I-NP O
6 1123 1127 20705401 SNPs NNS I-NP O
7 1128 1129 20705401 ( ( O O
8 1129 1138 20705401 rs6693503 NN B-NP O
9 1138 1139 20705401 , , O O
10 1140 1149 20705401 rs1805054 NN B-NP O
11 1149 1150 20705401 , , O O
12 1151 1160 20705401 rs4912138 NN B-NP O
13 1160 1161 20705401 , , O O
14 1162 1171 20705401 rs3790757 NN B-NP O
15 1172 1175 20705401 and CC O O
16 1176 1185 20705401 rs9659997 NN B-NP O
17 1185 1186 20705401 ) ) O O
18 1186 1187 20705401 , , O O
19 1188 1190 20705401 we PRP B-NP O
20 1191 1200 20705401 conducted VBD B-VP O
21 1201 1202 20705401 a DT B-NP O
22 1203 1210 20705401 genetic JJ I-NP O
23 1211 1222 20705401 association NN I-NP O
24 1223 1231 20705401 analysis NN I-NP O
25 1232 1234 20705401 of IN B-PP O
26 1235 1239 20705401 case NN O O
27 1239 1240 20705401 - HYPH O O
28 1240 1247 20705401 control NN B-NP O
29 1248 1255 20705401 samples NNS I-NP O
30 1256 1257 20705401 ( ( O O
31 1257 1260 20705401 197 CD B-NP O
32 1261 1265 20705401 METH NN I-NP D008694
33 1265 1266 20705401 - HYPH B-NP O
34 1266 1273 20705401 induced VBN I-NP O
35 1274 1283 20705401 psychosis NN I-NP D011605
36 1284 1292 20705401 patients NNS I-NP O
37 1293 1296 20705401 and CC O O
38 1297 1300 20705401 337 CD B-NP O
39 1301 1309 20705401 controls NNS I-NP O
40 1309 1310 20705401 ) ) O O
41 1311 1313 20705401 in IN B-PP O
42 1314 1317 20705401 the DT B-NP O
43 1318 1326 20705401 Japanese JJ I-NP O
44 1327 1337 20705401 population NN I-NP O
45 1337 1338 20705401 . . O O

1 1339 1342 20705401 The DT B-NP O
2 1343 1346 20705401 age NN I-NP O
3 1347 1350 20705401 and CC I-NP O
4 1351 1354 20705401 sex NN I-NP O
5 1355 1357 20705401 of IN B-PP O
6 1358 1361 20705401 the DT B-NP O
7 1362 1369 20705401 control NN I-NP O
8 1370 1378 20705401 subjects NNS I-NP O
9 1379 1382 20705401 did VBD B-VP O
10 1383 1386 20705401 not RB I-VP O
11 1387 1393 20705401 differ VB I-VP O
12 1394 1398 20705401 from IN B-PP O
13 1399 1404 20705401 those DT B-NP O
14 1405 1407 20705401 of IN B-PP O
15 1408 1411 20705401 the DT B-NP O
16 1412 1427 20705401 methamphetamine NN I-NP D008694
17 1428 1438 20705401 dependence NN I-NP O
18 1439 1447 20705401 patients NNS I-NP O
19 1447 1448 20705401 . . O O

1 1449 1456 20705401 RESULTS NNS B-NP O
2 1456 1457 20705401 : : O O
3 1458 1467 20705401 rs6693503 NN B-NP O
4 1468 1471 20705401 was VBD B-VP O
5 1472 1482 20705401 associated VBN I-VP O
6 1483 1487 20705401 with IN B-PP O
7 1488 1492 20705401 METH NN B-NP D008694
8 1492 1493 20705401 - HYPH B-NP O
9 1493 1500 20705401 induced VBN I-NP O
10 1501 1510 20705401 psychosis NN I-NP D011605
11 1511 1519 20705401 patients NNS I-NP O
12 1520 1522 20705401 in IN B-PP O
13 1523 1526 20705401 the DT B-NP O
14 1527 1533 20705401 allele NN I-NP O
15 1533 1534 20705401 / SYM B-NP O
16 1534 1542 20705401 genotype NN I-NP O
17 1542 1543 20705401 - HYPH B-NP O
18 1543 1547 20705401 wise JJ I-NP O
19 1548 1556 20705401 analysis NN I-NP O
20 1556 1557 20705401 . . O O

1 1558 1566 20705401 Moreover RB B-ADVP O
2 1566 1567 20705401 , , O O
3 1568 1572 20705401 this DT B-NP O
4 1573 1584 20705401 association NN I-NP O
5 1585 1593 20705401 remained VBD B-VP O
6 1594 1605 20705401 significant JJ B-ADJP O
7 1606 1611 20705401 after IN B-SBAR O
8 1612 1622 20705401 Bonferroni NNP B-NP O
9 1623 1633 20705401 correction NN I-NP O
10 1633 1634 20705401 . . O O

1 1635 1637 20705401 In IN B-PP O
2 1638 1641 20705401 the DT B-NP O
3 1642 1651 20705401 haplotype NN I-NP O
4 1651 1652 20705401 - HYPH B-NP O
5 1652 1656 20705401 wise JJ I-NP O
6 1657 1665 20705401 analysis NN I-NP O
7 1665 1666 20705401 , , O O
8 1667 1669 20705401 we PRP B-NP O
9 1670 1678 20705401 detected VBD B-VP O
10 1679 1681 20705401 an DT B-NP O
11 1682 1693 20705401 association NN I-NP O
12 1694 1701 20705401 between IN B-PP O
13 1702 1705 20705401 two CD B-NP O
14 1706 1713 20705401 markers NNS I-NP O
15 1714 1715 20705401 ( ( O O
16 1715 1724 20705401 rs6693503 NN B-NP O
17 1725 1728 20705401 and CC O O
18 1729 1738 20705401 rs1805054 NN B-NP O
19 1738 1739 20705401 ) ) O O
20 1740 1743 20705401 and CC O O
21 1744 1749 20705401 three CD B-NP O
22 1750 1757 20705401 markers NNS I-NP O
23 1758 1759 20705401 ( ( O O
24 1759 1768 20705401 rs6693503 NN B-NP O
25 1768 1769 20705401 , , O O
26 1770 1779 20705401 rs1805054 NN B-NP O
27 1780 1783 20705401 and CC O O
28 1784 1793 20705401 rs4912138 NN B-NP O
29 1793 1794 20705401 ) ) O O
30 1795 1797 20705401 in IN B-PP O
31 1798 1802 20705401 HTR6 NN B-NP O
32 1803 1806 20705401 and CC I-NP O
33 1807 1811 20705401 METH NN I-NP D008694
34 1811 1812 20705401 - HYPH B-NP O
35 1812 1819 20705401 induced VBN I-NP O
36 1820 1829 20705401 psychosis NN I-NP D011605
37 1830 1838 20705401 patients NNS I-NP O
38 1838 1839 20705401 , , O O
39 1840 1852 20705401 respectively RB B-ADVP O
40 1852 1853 20705401 . . O O

1 1854 1864 20705401 CONCLUSION NN B-NP O
2 1864 1865 20705401 : : O O
3 1866 1870 20705401 HTR6 NN B-NP O
4 1871 1874 20705401 may MD B-VP O
5 1875 1879 20705401 play VB I-VP O
6 1880 1882 20705401 an DT B-NP O
7 1883 1892 20705401 important JJ I-NP O
8 1893 1897 20705401 role NN I-NP O
9 1898 1900 20705401 in IN B-PP O
10 1901 1904 20705401 the DT B-NP O
11 1905 1920 20705401 pathophysiology NN I-NP O
12 1921 1923 20705401 of IN B-PP O
13 1924 1928 20705401 METH NN B-NP D008694
14 1928 1929 20705401 - HYPH B-NP O
15 1929 1936 20705401 induced VBN I-NP O
16 1937 1946 20705401 psychosis NN I-NP D011605
17 1947 1949 20705401 in IN B-PP O
18 1950 1953 20705401 the DT B-NP O
19 1954 1962 20705401 Japanese JJ I-NP O
20 1963 1973 20705401 population NN I-NP O
21 1973 1974 20705401 . . O O

1 0 0 921394 -DOCSTART- -X- -X- O

1 0 8 921394 Biphasic JJ B-NP O
2 9 17 921394 response NN I-NP O
3 18 20 921394 of IN B-PP O
4 21 24 921394 the DT B-NP O
5 25 27 921394 SA NN I-NP O
6 28 32 921394 node NN I-NP O
7 33 35 921394 of IN B-PP O
8 36 39 921394 the DT B-NP O
9 40 43 921394 dog NN I-NP O
10 44 49 921394 heart NN I-NP O
11 50 52 921394 in FW B-ADVP O
12 53 57 921394 vivo FW I-ADVP O
13 58 60 921394 to TO B-PP O
14 61 70 921394 selective JJ B-NP O
15 71 85 921394 administration NN I-NP O
16 86 88 921394 of IN B-PP O
17 89 97 921394 ketamine NN B-NP D007649
18 97 98 921394 . . O O
19 99 105 921394 Effect NN B-NP O
20 106 108 921394 of IN B-PP O
21 109 117 921394 ketamine NN B-NP D007649
22 118 120 921394 on IN B-PP O
23 121 124 921394 the DT B-NP O
24 125 127 921394 SA NN I-NP O
25 128 132 921394 node NN I-NP O
26 133 135 921394 of IN B-PP O
27 136 139 921394 the DT B-NP O
28 140 143 921394 dog NN I-NP O
29 144 149 921394 heart NN I-NP O
30 150 153 921394 was VBD B-VP O
31 154 161 921394 studied VBN I-VP O
32 162 164 921394 in FW B-ADVP O
33 165 169 921394 vivo FW I-ADVP O
34 170 175 921394 using VBG B-VP O
35 176 177 921394 a DT B-NP O
36 178 187 921394 selective JJ I-NP O
37 188 197 921394 perfusion NN I-NP O
38 198 207 921394 technique NN I-NP O
39 208 210 921394 of IN B-PP O
40 211 214 921394 the DT B-NP O
41 215 217 921394 SA NN I-NP O
42 218 222 921394 node NN I-NP O
43 223 229 921394 artery NN I-NP O
44 229 230 921394 . . O O

1 231 241 921394 Injections NNS B-NP O
2 242 244 921394 of IN B-PP O
3 245 253 921394 ketamine NN B-NP D007649
4 254 256 921394 in IN B-PP O
5 257 262 921394 doses NNS B-NP O
6 263 267 921394 from IN B-PP O
7 268 271 921394 100 CD B-NP O
8 272 281 921394 microgram NN I-NP O
9 282 284 921394 to TO B-PP O
10 285 286 921394 3 CD B-NP O
11 287 289 921394 mg NN I-NP O
12 290 294 921394 into IN B-PP O
13 295 298 921394 the DT B-NP O
14 299 305 921394 artery NN I-NP O
15 306 314 921394 produced VBD B-VP O
16 315 316 921394 a DT B-NP O
17 317 327 921394 depression NN I-NP D003866
18 328 330 921394 of IN B-PP O
19 331 334 921394 the DT B-NP O
20 335 337 921394 SA NN I-NP O
21 338 343 921394 nodal JJ I-NP O
22 344 352 921394 activity NN I-NP O
23 353 355 921394 by IN B-PP O
24 356 357 921394 a DT B-NP O
25 358 364 921394 direct JJ I-NP O
26 365 371 921394 action NN I-NP O
27 371 372 921394 . . O O

1 373 377 921394 This DT B-NP O
2 378 388 921394 depression NN I-NP D003866
3 389 392 921394 was VBD B-VP O
4 393 401 921394 followed VBN I-VP O
5 402 404 921394 by IN B-PP O
6 405 408 921394 the DT B-NP O
7 409 415 921394 sudden JJ I-NP O
8 416 426 921394 appearance NN I-NP O
9 427 429 921394 of IN B-PP O
10 430 431 921394 a DT B-NP O
11 432 443 921394 stimulatory JJ I-NP O
12 444 449 921394 phase NN I-NP O
13 449 450 921394 . . O O

1 451 460 921394 Bilateral JJ B-NP O
2 461 469 921394 vagotomy NN I-NP O
3 470 473 921394 and CC I-NP O
4 474 487 921394 sympathectomy NN I-NP O
5 488 490 921394 or CC O O
6 491 496 921394 prior JJ B-NP O
7 497 511 921394 administration NN I-NP O
8 512 514 921394 of IN B-PP O
9 515 516 921394 a DT B-NP O
10 517 525 921394 ganglion NN I-NP O
11 526 533 921394 blocker NN I-NP O
12 534 540 921394 failed VBD B-VP O
13 541 543 921394 to TO I-VP O
14 544 551 921394 inhibit VB I-VP O
15 552 555 921394 the DT B-NP O
16 556 566 921394 occurrence NN I-NP O
17 567 569 921394 of IN B-PP O
18 570 573 921394 the DT B-NP O
19 574 582 921394 ketamine NN I-NP D007649
20 582 583 921394 - HYPH B-NP O
21 583 590 921394 induced VBN I-NP O
22 591 602 921394 tachycardia NN I-NP D013610
23 602 603 921394 , , O O
24 604 609 921394 while IN B-SBAR O
25 610 612 921394 it PRP B-NP O
26 613 616 921394 was VBD B-VP O
27 617 627 921394 completely RB I-VP O
28 628 637 921394 abolished VBN I-VP O
29 638 640 921394 in IN B-PP O
30 641 644 921394 the DT B-NP O
31 645 657 921394 reserpinized VBN I-NP O
32 658 662 921394 dogs NNS I-NP O
33 663 665 921394 or CC B-PP O
34 666 668 921394 by IN B-PP O
35 669 670 921394 a DT B-NP O
36 671 676 921394 prior JJ I-NP O
37 677 686 921394 injection NN I-NP O
38 687 689 921394 of IN B-PP O
39 690 691 921394 a DT B-NP O
40 692 696 921394 beta SYM I-NP O
41 696 697 921394 - HYPH I-NP O
42 697 705 921394 blocking VBG B-VP O
43 706 711 921394 agent NN B-NP O
44 712 716 921394 into IN B-PP O
45 717 720 921394 the DT B-NP O
46 721 723 921394 SA NN I-NP O
47 724 728 921394 node NN I-NP O
48 729 735 921394 artery NN I-NP O
49 735 736 921394 . . O O

1 737 741 921394 This DT B-NP O
2 742 745 921394 may MD B-VP O
3 746 754 921394 indicate VB I-VP O
4 755 759 921394 that IN B-SBAR O
5 760 762 921394 an DT B-NP O
6 763 773 921394 activation NN I-NP O
7 774 776 921394 of IN B-PP O
8 777 780 921394 the DT B-NP O
9 781 791 921394 peripheral JJ I-NP O
10 792 802 921394 adrenergic JJ I-NP O
11 803 812 921394 mechanism NN I-NP O
12 813 818 921394 plays VBZ B-VP O
13 819 821 921394 an DT B-NP O
14 822 831 921394 important JJ I-NP O
15 832 836 921394 role NN I-NP O
16 837 839 921394 in IN B-PP O
17 840 843 921394 the DT B-NP O
18 844 853 921394 induction NN I-NP O
19 854 856 921394 of IN B-PP O
20 857 860 921394 the DT B-NP O
21 861 871 921394 excitatory JJ I-NP O
22 872 878 921394 effect NN I-NP O
23 879 881 921394 of IN B-PP O
24 882 890 921394 ketamine NN B-NP D007649
25 891 899 921394 injected VBN B-VP O
26 900 902 921394 in IN B-PP O
27 903 906 921394 the DT B-NP O
28 907 909 921394 SA NN I-NP O
29 910 914 921394 node NN I-NP O
30 915 921 921394 artery NN I-NP O
31 921 922 921394 . . O O

1 0 0 1687392 -DOCSTART- -X- -X- O

1 0 8 1687392 Blockade NN B-NP O
2 9 11 1687392 of IN B-PP O
3 12 16 1687392 both CC O O
4 17 18 1687392 D NN B-NP O
5 18 19 1687392 - HYPH B-NP O
6 19 20 1687392 1 CD I-NP O
7 21 24 1687392 and CC I-NP O
8 25 26 1687392 D NN I-NP O
9 26 27 1687392 - HYPH I-NP O
10 27 28 1687392 2 CD I-NP O
11 29 37 1687392 dopamine NN I-NP D004298
12 38 47 1687392 receptors NNS I-NP O
13 48 51 1687392 may MD B-VP O
14 52 58 1687392 induce VB I-VP O
15 59 68 1687392 catalepsy NN B-NP D002375
16 69 71 1687392 in IN B-PP O
17 72 76 1687392 mice NNS B-NP O
18 76 77 1687392 . . O O
19 78 79 1687392 1 CD B-NP O
20 79 80 1687392 . . O O

1 81 84 1687392 The DT B-NP O
2 85 94 1687392 catalepsy NN I-NP D002375
3 95 102 1687392 induced VBN B-VP O
4 103 105 1687392 by IN B-PP O
5 106 114 1687392 dopamine NN B-NP D004298
6 115 126 1687392 antagonists NNS I-NP O
7 127 130 1687392 has VBZ B-VP O
8 131 135 1687392 been VBN I-VP O
9 136 142 1687392 tested VBN I-VP O
10 143 146 1687392 and CC O O
11 147 150 1687392 the DT B-NP O
12 151 159 1687392 possible JJ I-NP O
13 160 168 1687392 dopamine NN I-NP D004298
14 169 177 1687392 subtypes NNS I-NP O
15 178 186 1687392 involved VBN B-VP O
16 187 189 1687392 in IN B-PP O
17 190 199 1687392 catalepsy NN B-NP D002375
18 200 203 1687392 was VBD B-VP O
19 204 214 1687392 determined VBN I-VP O
20 214 215 1687392 . . O O

1 216 217 1687392 2 LS B-LST O
2 217 218 1687392 . . O O

1 219 227 1687392 Dopamine NN B-NP D004298
2 228 238 1687392 antagonist NN I-NP O
3 239 251 1687392 fluphenazine NN I-NP D005476
4 251 252 1687392 , , O O
5 253 254 1687392 D NN B-NP O
6 254 255 1687392 - HYPH B-NP O
7 255 256 1687392 1 CD I-NP O
8 257 267 1687392 antagonist NN I-NP O
9 268 271 1687392 SCH NN I-NP C534628
10 272 277 1687392 23390 CD B-NP C534628
11 278 280 1687392 or CC I-NP O
12 281 282 1687392 D NN I-NP O
13 282 283 1687392 - HYPH B-NP O
14 283 284 1687392 2 CD I-NP O
15 285 295 1687392 antagonist NN I-NP O
16 296 305 1687392 sulpiride NN I-NP D013469
17 306 313 1687392 induced VBD B-VP O
18 314 323 1687392 catalepsy NN B-NP D002375
19 323 324 1687392 . . O O

1 325 328 1687392 The DT B-NP O
2 329 335 1687392 effect NN I-NP O
3 336 338 1687392 of IN B-PP O
4 339 351 1687392 fluphenazine NN B-NP D005476
5 352 355 1687392 and CC I-NP O
6 356 365 1687392 sulpiride NN I-NP D013469
7 366 369 1687392 was VBD B-VP O
8 370 374 1687392 dose NN B-NP O
9 374 375 1687392 - HYPH B-ADJP O
10 375 384 1687392 dependent JJ I-ADJP O
11 384 385 1687392 . . O O

1 386 397 1687392 Combination NN B-NP O
2 398 400 1687392 of IN B-PP O
3 401 404 1687392 SCH NN B-NP C534628
4 405 410 1687392 23390 CD I-NP C534628
5 411 415 1687392 with IN B-PP O
6 416 425 1687392 sulpiride NN B-NP D013469
7 426 429 1687392 did VBD B-VP O
8 430 433 1687392 not RB I-VP O
9 434 440 1687392 induce VB I-VP O
10 441 450 1687392 catalepsy NN B-NP D002375
11 451 463 1687392 potentiation NN I-NP O
12 463 464 1687392 . . O O

1 465 466 1687392 3 LS B-LST O
2 466 467 1687392 . . O O

1 468 469 1687392 D NN B-NP O
2 469 470 1687392 - HYPH B-NP O
3 470 471 1687392 1 CD I-NP O
4 472 479 1687392 agonist NN I-NP O
5 480 483 1687392 SKF NN I-NP D015647
6 484 489 1687392 38393 CD B-NP D015647
7 490 492 1687392 or CC I-NP O
8 493 494 1687392 D NN I-NP O
9 494 495 1687392 - HYPH B-NP O
10 495 496 1687392 2 CD I-NP O
11 497 504 1687392 agonist NN I-NP O
12 505 515 1687392 quinpirole NN I-NP D019257
13 516 525 1687392 decreased VBD B-VP O
14 526 529 1687392 the DT B-NP O
15 530 539 1687392 catalepsy NN I-NP D002375
16 540 547 1687392 induced VBN B-VP O
17 548 550 1687392 by IN B-PP O
18 551 563 1687392 fluphenazine NN B-NP D005476
19 563 564 1687392 , , O O
20 565 568 1687392 SCH NN B-NP C534628
21 569 574 1687392 23390 CD I-NP C534628
22 575 577 1687392 or CC O O
23 578 587 1687392 sulpiride NN B-NP D013469
24 587 588 1687392 . . O O

1 589 590 1687392 4 LS B-LST O
2 590 591 1687392 . . O O

1 592 603 1687392 Combination NN B-NP O
2 604 606 1687392 of IN B-PP O
3 607 610 1687392 SKF NN B-NP D015647
4 611 616 1687392 38393 CD I-NP D015647
5 617 621 1687392 with IN B-PP O
6 622 632 1687392 quinpirole NN B-NP D019257
7 633 636 1687392 did VBD B-VP O
8 637 640 1687392 not RB I-VP O
9 641 646 1687392 cause VB I-VP O
10 647 658 1687392 potentiated JJ B-NP O
11 659 669 1687392 inhibitory JJ I-NP O
12 670 676 1687392 effect NN I-NP O
13 677 679 1687392 on IN B-PP O
14 680 689 1687392 catalepsy NN B-NP D002375
15 690 697 1687392 induced VBN B-VP O
16 698 700 1687392 by IN B-PP O
17 701 709 1687392 dopamine NN B-NP D004298
18 710 721 1687392 antagonists NNS I-NP O
19 721 722 1687392 . . O O

1 723 724 1687392 5 LS B-LST O
2 724 725 1687392 . . O O

1 726 729 1687392 The DT B-NP O
2 730 734 1687392 data NNS I-NP O
3 735 738 1687392 may MD B-VP O
4 739 747 1687392 indicate VB I-VP O
5 748 752 1687392 that IN B-SBAR O
6 753 761 1687392 although IN B-SBAR O
7 762 763 1687392 D NN B-NP O
8 763 764 1687392 - HYPH B-NP O
9 764 765 1687392 2 CD I-NP O
10 766 774 1687392 receptor NN I-NP O
11 775 783 1687392 blockade NN I-NP O
12 784 786 1687392 is VBZ B-VP O
13 787 795 1687392 involved VBN I-VP O
14 796 798 1687392 in IN B-PP O
15 799 808 1687392 catalepsy NN B-NP D002375
16 808 809 1687392 , , O O
17 810 813 1687392 the DT B-NP O
18 814 815 1687392 D NN I-NP O
19 815 816 1687392 - HYPH B-NP O
20 816 817 1687392 1 CD I-NP O
21 818 826 1687392 receptor NN I-NP O
22 827 830 1687392 may MD B-VP O
23 831 835 1687392 plan VB I-VP O
24 836 837 1687392 a DT B-NP O
25 838 842 1687392 role NN I-NP O
26 842 843 1687392 . . O O

1 0 0 11847945 -DOCSTART- -X- -X- O

1 0 5 11847945 Acute JJ B-NP O
2 6 17 11847945 cholestatic JJ I-NP D002779
3 18 27 11847945 hepatitis NN I-NP D002779
4 28 33 11847945 after IN B-PP O
5 34 42 11847945 exposure NN B-NP O
6 43 45 11847945 to TO B-PP O
7 46 56 11847945 isoflurane NN B-NP D007530
8 56 57 11847945 . . I-NP O
9 58 67 11847945 OBJECTIVE NN I-NP O
10 67 68 11847945 : : O O
11 69 71 11847945 To TO B-VP O
12 72 78 11847945 report VB I-VP O
13 79 80 11847945 a DT B-NP O
14 81 85 11847945 case NN I-NP O
15 86 88 11847945 of IN B-PP O
16 89 94 11847945 acute JJ B-NP O
17 95 106 11847945 cholestatic JJ I-NP D002779
18 107 116 11847945 hepatitis NN I-NP D002779
19 117 126 11847945 following VBG B-PP O
20 127 135 11847945 exposure NN B-NP O
21 136 138 11847945 to TO B-PP O
22 139 142 11847945 the DT B-NP O
23 143 155 11847945 inhalational JJ I-NP O
24 156 166 11847945 anesthetic JJ I-NP O
25 167 177 11847945 isoflurane NN I-NP D007530
26 177 178 11847945 . . O O

1 179 183 11847945 CASE NN B-NP O
2 184 191 11847945 SUMMARY NN I-NP O
3 191 192 11847945 : : O O
4 193 194 11847945 A DT B-NP O
5 195 197 11847945 70 CD I-NP O
6 197 198 11847945 - HYPH I-NP O
7 198 202 11847945 year NN I-NP O
8 202 203 11847945 - HYPH O O
9 203 206 11847945 old JJ B-NP O
10 207 214 11847945 healthy JJ I-NP O
11 215 220 11847945 woman NN I-NP O
12 221 225 11847945 from IN B-PP O
13 226 230 11847945 Iraq NNP B-NP O
14 231 240 11847945 developed VBD B-VP O
15 241 246 11847945 acute JJ B-NP O
16 247 258 11847945 cholestatic JJ I-NP D002779
17 259 268 11847945 hepatitis NN I-NP D002779
18 269 270 11847945 3 CD B-NP O
19 271 276 11847945 weeks NNS I-NP O
20 277 286 11847945 following VBG B-PP O
21 287 293 11847945 repair NN B-NP O
22 294 296 11847945 of IN B-PP O
23 297 300 11847945 the DT B-NP O
24 301 306 11847945 right JJ I-NP O
25 307 314 11847945 rotator NN I-NP O
26 315 319 11847945 cuff NN I-NP O
27 320 325 11847945 under IN B-PP O
28 326 333 11847945 general JJ B-NP O
29 334 344 11847945 anesthesia NN I-NP O
30 344 345 11847945 . . O O

1 346 351 11847945 There EX B-NP O
2 352 355 11847945 was VBD B-VP O
3 356 358 11847945 no DT B-NP O
4 359 367 11847945 evidence NN I-NP O
5 368 371 11847945 for IN B-PP O
6 372 377 11847945 viral JJ B-NP O
7 377 378 11847945 , , I-NP O
8 379 389 11847945 autoimmune JJ I-NP O
9 389 390 11847945 , , I-NP O
10 391 393 11847945 or CC I-NP O
11 394 403 11847945 metabolic JJ I-NP O
12 404 410 11847945 causes NNS I-NP O
13 411 413 11847945 of IN B-PP O
14 414 423 11847945 hepatitis NN B-NP D056486
15 423 424 11847945 . . O O

1 425 427 11847945 No DT B-NP O
2 428 433 11847945 other JJ I-NP O
3 434 445 11847945 medications NNS I-NP O
4 446 450 11847945 were VBD B-VP O
5 451 459 11847945 involved VBN I-VP O
6 460 466 11847945 except IN B-PP O
7 467 470 11847945 for IN B-PP O
8 471 479 11847945 dipyrone NN B-NP D004177
9 480 483 11847945 for IN B-PP O
10 484 493 11847945 analgesia NN B-NP D000699
11 493 494 11847945 . . O O

1 495 498 11847945 The DT B-NP O
2 499 506 11847945 alanine NN I-NP D000409
3 507 523 11847945 aminotransferase NN I-NP O
4 524 527 11847945 was VBD B-VP O
5 528 536 11847945 elevated VBN I-VP O
6 537 539 11847945 to TO B-PP O
7 540 541 11847945 a DT B-NP O
8 542 546 11847945 peak JJ I-NP O
9 547 560 11847945 concentration NN I-NP O
10 561 563 11847945 of IN B-PP O
11 564 568 11847945 1533 CD B-NP O
12 569 570 11847945 U NN I-NP O
13 570 571 11847945 / SYM B-NP O
14 571 572 11847945 L NN I-NP O
15 573 576 11847945 and CC O O
16 577 580 11847945 the DT B-NP O
17 581 586 11847945 serum NN I-NP O
18 587 596 11847945 bilirubin NN I-NP D001663
19 597 604 11847945 reached VBD B-VP O
20 605 606 11847945 a DT B-NP O
21 607 611 11847945 peak NN I-NP O
22 612 614 11847945 of IN B-PP O
23 615 619 11847945 17.0 CD B-NP O
24 620 622 11847945 mg NN I-NP O
25 622 623 11847945 / SYM B-NP O
26 623 625 11847945 dL NN I-NP O
27 625 626 11847945 . . O O

1 627 632 11847945 There EX B-NP O
2 633 636 11847945 was VBD B-VP O
3 637 641 11847945 slow JJ B-NP O
4 642 653 11847945 improvement NN I-NP O
5 654 658 11847945 over IN B-PP O
6 659 660 11847945 4 CD B-NP O
7 661 667 11847945 months NNS I-NP O
8 667 668 11847945 . . O O

1 669 679 11847945 Accidental JJ B-NP O
2 680 690 11847945 reexposure NN I-NP O
3 691 693 11847945 by IN B-PP O
4 694 697 11847945 the DT B-NP O
5 698 705 11847945 patient NN I-NP O
6 706 708 11847945 to TO B-PP O
7 709 717 11847945 dipyrone NN B-NP D004177
8 718 721 11847945 was VBD B-VP O
9 722 732 11847945 uneventful JJ B-ADJP O
10 732 733 11847945 . . O O

1 734 744 11847945 DISCUSSION NN B-NP O
2 744 745 11847945 : : O O
3 746 749 11847945 The DT B-NP O
4 750 758 11847945 clinical JJ I-NP O
5 759 762 11847945 and CC I-NP O
6 763 773 11847945 histologic JJ I-NP O
7 774 781 11847945 picture NN I-NP O
8 782 784 11847945 of IN B-PP O
9 785 789 11847945 this DT B-NP O
10 790 794 11847945 case NN I-NP O
11 795 804 11847945 resembles VBZ B-VP O
12 805 814 11847945 halothane NN B-NP C562477
13 815 824 11847945 hepatitis NN I-NP C562477
14 824 825 11847945 , , O O
15 826 831 11847945 which WDT B-NP O
16 832 835 11847945 has VBZ B-VP O
17 836 837 11847945 a DT B-NP O
18 838 849 11847945 significant JJ I-NP O
19 850 859 11847945 mortality NN I-NP O
20 860 864 11847945 rate NN I-NP O
21 864 865 11847945 . . O O

1 866 877 11847945 CONCLUSIONS NNS B-NP O
2 877 878 11847945 : : O O
3 879 889 11847945 Isoflurane NN B-NP D007530
4 889 890 11847945 , , O O
5 891 892 11847945 a DT B-NP O
6 893 899 11847945 common JJ I-NP O
7 900 910 11847945 anesthetic JJ I-NP O
8 911 916 11847945 agent NN I-NP O
9 916 917 11847945 , , O O
10 918 921 11847945 can MD B-VP O
11 922 927 11847945 cause VB I-VP O
12 928 934 11847945 severe JJ B-NP O
13 935 946 11847945 cholestatic JJ I-NP D002779
14 947 956 11847945 hepatitis NN I-NP D002779
15 956 957 11847945 . . O O

1 0 0 11079278 -DOCSTART- -X- -X- O

1 0 6 11079278 Effect NN B-NP O
2 7 9 11079278 of IN B-PP O
3 10 21 11079278 intravenous JJ B-NP O
4 22 32 11079278 metoprolol NN I-NP D008790
5 33 35 11079278 or CC O O
6 36 47 11079278 intravenous JJ B-NP O
7 48 58 11079278 metoprolol NN I-NP D008790
8 59 63 11079278 plus CC O O
9 64 72 11079278 glucagon NN B-NP O
10 73 75 11079278 on IN B-PP O
11 76 86 11079278 dobutamine NN B-NP D004280
12 86 87 11079278 - HYPH B-NP O
13 87 94 11079278 induced VBN I-NP O
14 95 105 11079278 myocardial JJ I-NP D017202
15 106 114 11079278 ischemia NN I-NP D017202
16 114 115 11079278 . . I-NP O
17 116 121 11079278 STUDY NN I-NP O
18 122 131 11079278 OBJECTIVE NN I-NP O
19 131 132 11079278 : : O O
20 133 135 11079278 To TO B-VP O
21 136 145 11079278 determine VB I-VP O
22 146 149 11079278 the DT B-NP O
23 150 156 11079278 effect NN I-NP O
24 157 159 11079278 of IN B-PP O
25 160 170 11079278 metoprolol NN B-NP D008790
26 171 173 11079278 on IN B-PP O
27 174 184 11079278 dobutamine NN B-NP D004280
28 185 191 11079278 stress NN I-NP O
29 192 199 11079278 testing NN I-NP O
30 200 204 11079278 with IN B-PP O
31 205 215 11079278 technetium NN B-NP D017256
32 215 216 11079278 - HYPH O D017256
33 216 219 11079278 99m CD B-NP D017256
34 220 229 11079278 sestamibi NNS I-NP D017256
35 230 236 11079278 single JJ B-NP O
36 236 237 11079278 - HYPH I-NP O
37 237 243 11079278 photon NN I-NP O
38 244 252 11079278 emission NN I-NP O
39 253 261 11079278 computed VBD B-VP O
40 262 272 11079278 tomography NN B-NP O
41 273 280 11079278 imaging NN I-NP O
42 281 284 11079278 and CC I-NP O
43 285 287 11079278 ST NN I-NP O
44 287 288 11079278 - HYPH I-NP O
45 288 295 11079278 segment NN I-NP O
46 296 306 11079278 monitoring NN I-NP O
47 306 307 11079278 , , O O
48 308 311 11079278 and CC O O
49 312 314 11079278 to TO B-VP O
50 315 321 11079278 assess VB I-VP O
51 322 325 11079278 the DT B-NP O
52 326 332 11079278 impact NN I-NP O
53 333 335 11079278 of IN B-PP O
54 336 347 11079278 intravenous JJ B-NP O
55 348 356 11079278 glucagon NN I-NP O
56 357 359 11079278 on IN B-PP O
57 360 372 11079278 metoprolol's NNS B-NP D008790
58 373 380 11079278 effects NNS I-NP O
59 380 381 11079278 . . O O

1 382 388 11079278 DESIGN NN B-NP O
2 388 389 11079278 : : O O
3 390 400 11079278 Randomized VBN B-VP O
4 400 401 11079278 , , O O
5 402 408 11079278 double JJ B-NP O
6 408 409 11079278 - HYPH I-NP O
7 409 414 11079278 blind JJ I-NP O
8 414 415 11079278 , , I-NP O
9 416 423 11079278 placebo NN I-NP O
10 423 424 11079278 - HYPH I-NP O
11 424 434 11079278 controlled VBN B-NP O
12 435 440 11079278 trial NN I-NP O
13 440 441 11079278 . . O O

1 442 449 11079278 SETTING NN B-NP O
2 449 450 11079278 : : O O
3 451 460 11079278 Community NN B-NP O
4 461 469 11079278 hospital NN I-NP O
5 469 470 11079278 . . O O

1 471 479 11079278 PATIENTS NNS B-NP O
2 479 480 11079278 : : O O
3 481 487 11079278 Twenty CD B-NP O
4 487 488 11079278 - HYPH O O
5 488 491 11079278 two CD B-NP O
6 492 500 11079278 patients NNS I-NP O
7 501 505 11079278 with IN B-PP O
8 506 511 11079278 known JJ B-NP O
9 512 522 11079278 reversible JJ I-NP O
10 523 532 11079278 perfusion NN I-NP O
11 533 540 11079278 defects NNS I-NP O
12 540 541 11079278 . . O O

1 542 554 11079278 INTERVENTION NN B-NP O
2 554 555 11079278 : : O O
3 556 564 11079278 Patients NNS B-NP O
4 565 574 11079278 underwent VBD B-VP O
5 575 585 11079278 dobutamine NN B-NP D004280
6 586 592 11079278 stress NN I-NP O
7 593 598 11079278 tests NNS I-NP O
8 599 602 11079278 per IN B-PP O
9 603 611 11079278 standard JJ B-NP O
10 612 620 11079278 protocol NN I-NP O
11 620 621 11079278 . . O O

1 622 628 11079278 Before IN B-SBAR O
2 629 639 11079278 dobutamine NN B-NP D004280
3 640 643 11079278 was VBD B-VP O
4 644 649 11079278 begun VBN I-VP O
5 649 650 11079278 , , O O
6 651 653 11079278 no DT B-NP O
7 654 661 11079278 therapy NN I-NP O
8 662 665 11079278 was VBD B-VP O
9 666 671 11079278 given VBN I-VP O
10 672 678 11079278 during IN B-PP O
11 679 682 11079278 the DT B-NP O
12 683 688 11079278 first JJ I-NP O
13 689 694 11079278 visit NN I-NP O
14 694 695 11079278 , , O O
15 696 699 11079278 and CC O O
16 700 708 11079278 patients NNS B-NP O
17 709 713 11079278 were VBD B-VP O
18 714 724 11079278 randomized VBN I-VP O
19 725 727 11079278 on IN B-PP O
20 728 738 11079278 subsequent JJ B-NP O
21 739 745 11079278 visits NNS I-NP O
22 746 748 11079278 to TO B-VP O
23 749 756 11079278 receive VB I-VP O
24 757 767 11079278 metoprolol NN B-NP D008790
25 768 770 11079278 or CC I-NP O
26 771 781 11079278 metoprolol NN I-NP D008790
27 782 786 11079278 plus CC O O
28 787 795 11079278 glucagon NN B-NP O
29 796 797 11079278 1 CD I-NP O
30 798 800 11079278 mg NN I-NP O
31 800 801 11079278 . . O O

1 802 812 11079278 Metoprolol NN B-NP D008790
2 813 816 11079278 was VBD B-VP O
3 817 822 11079278 dosed VBN I-VP O
4 823 825 11079278 to TO I-VP O
5 826 833 11079278 achieve VB I-VP O
6 834 835 11079278 a DT B-NP O
7 836 843 11079278 resting JJ I-NP O
8 844 857 11079278 predobutamine NN I-NP -1
9 858 863 11079278 heart NN I-NP O
10 864 868 11079278 rate NN I-NP O
11 869 874 11079278 below IN B-PP O
12 875 877 11079278 65 CD B-NP O
13 878 883 11079278 beats NNS I-NP O
14 883 884 11079278 / SYM B-NP O
15 884 890 11079278 minute NN I-NP O
16 891 893 11079278 or CC O O
17 894 895 11079278 a DT B-NP O
18 896 901 11079278 total JJ I-NP O
19 902 913 11079278 intravenous JJ I-NP O
20 914 918 11079278 dose NN I-NP O
21 919 921 11079278 of IN B-PP O
22 922 924 11079278 20 CD B-NP O
23 925 927 11079278 mg NN I-NP O
24 927 928 11079278 . . O O

1 929 941 11079278 MEASUREMENTS NNS B-NP O
2 942 945 11079278 AND CC I-NP O
3 946 950 11079278 MAIN NN I-NP O
4 951 958 11079278 RESULTS NNS I-NP O
5 958 959 11079278 : : O O
6 960 970 11079278 Metoprolol NN B-NP D008790
7 971 978 11079278 reduced VBD B-VP O
8 979 986 11079278 maximum JJ B-NP O
9 987 992 11079278 heart NN I-NP O
10 993 997 11079278 rate NN I-NP O
11 998 1001 11079278 31% NN I-NP O
12 1001 1002 11079278 , , O O
13 1003 1009 11079278 summed VBD B-VP O
14 1010 1016 11079278 stress NN B-NP O
15 1017 1023 11079278 scores NNS I-NP O
16 1024 1027 11079278 29% CD B-NP O
17 1027 1028 11079278 , , O O
18 1029 1032 11079278 and CC O O
19 1033 1039 11079278 summed VBD B-VP O
20 1040 1050 11079278 difference NN B-NP O
21 1051 1057 11079278 scores NNS I-NP O
22 1058 1061 11079278 43% CD B-NP O
23 1062 1068 11079278 versus CC O O
24 1069 1076 11079278 control NN B-NP O
25 1076 1077 11079278 . . O O

1 1078 1088 11079278 Metoprolol NN B-NP D008790
2 1089 1093 11079278 plus CC I-NP O
3 1094 1102 11079278 glucagon NN I-NP O
4 1103 1107 11079278 also RB B-ADVP O
5 1108 1115 11079278 reduced VBD B-VP O
6 1116 1119 11079278 the DT B-NP O
7 1120 1127 11079278 maximum JJ I-NP O
8 1128 1133 11079278 heart NN I-NP O
9 1134 1138 11079278 rate NN I-NP O
10 1139 1142 11079278 29% CD B-NP O
11 1143 1149 11079278 versus CC B-PP O
12 1150 1157 11079278 control NN B-NP O
13 1157 1158 11079278 . . O O

1 1159 1165 11079278 Summed VBN B-NP O
2 1166 1172 11079278 stress NN I-NP O
3 1173 1176 11079278 and CC O O
4 1177 1183 11079278 summed VBD B-VP O
5 1184 1194 11079278 difference NN B-NP O
6 1195 1201 11079278 scores NNS I-NP O
7 1202 1206 11079278 were VBD B-VP O
8 1207 1210 11079278 not RB O O
9 1211 1224 11079278 significantly RB B-VP O
10 1225 1232 11079278 reduced VBN I-VP O
11 1232 1233 11079278 , , O O
12 1234 1242 11079278 although IN B-SBAR O
13 1243 1247 11079278 they PRP B-NP O
14 1248 1252 11079278 were VBD B-VP O
15 1253 1256 11079278 18% CD B-NP O
16 1257 1260 11079278 and CC I-NP O
17 1261 1264 11079278 30% CD I-NP O
18 1265 1270 11079278 lower JJR B-ADJP O
19 1270 1271 11079278 , , O O
20 1272 1284 11079278 respectively RB B-ADVP O
21 1284 1285 11079278 , , O O
22 1286 1290 11079278 than IN B-PP O
23 1291 1298 11079278 control NN B-NP O
24 1298 1299 11079278 . . O O

1 1300 1302 11079278 No DT B-NP O
2 1303 1314 11079278 significant JJ I-NP O
3 1315 1326 11079278 differences NNS I-NP O
4 1327 1331 11079278 were VBD B-VP O
5 1332 1337 11079278 found VBN I-VP O
6 1338 1340 11079278 in IN B-PP O
7 1341 1344 11079278 any DT B-NP O
8 1345 1354 11079278 parameter NN I-NP O
9 1355 1362 11079278 between IN B-PP O
10 1363 1373 11079278 metoprolol NN B-NP D008790
11 1374 1377 11079278 and CC I-NP O
12 1378 1388 11079278 metoprolol NN I-NP D008790
13 1388 1389 11079278 - HYPH B-NP O
14 1389 1397 11079278 glucagon NN I-NP O
15 1397 1398 11079278 . . O O

1 1399 1409 11079278 CONCLUSION NN B-NP O
2 1409 1410 11079278 : : O O
3 1411 1417 11079278 During IN B-PP O
4 1418 1428 11079278 dobutamine NN B-NP D004280
5 1429 1435 11079278 stress NN I-NP O
6 1436 1443 11079278 testing NN I-NP O
7 1443 1444 11079278 , , O O
8 1445 1455 11079278 metoprolol NN B-NP D008790
9 1456 1466 11079278 attenuates VBZ B-VP O
10 1467 1469 11079278 or CC I-VP O
11 1470 1480 11079278 eliminates VBZ I-VP O
12 1481 1489 11079278 evidence NN B-NP O
13 1490 1492 11079278 of IN B-PP O
14 1493 1503 11079278 myocardial JJ B-NP D017202
15 1504 1512 11079278 ischemia NN I-NP D017202
16 1512 1513 11079278 . . O O

1 1514 1522 11079278 Glucagon NN B-NP O
2 1523 1524 11079278 1 CD I-NP O
3 1525 1527 11079278 mg NN I-NP O
4 1527 1528 11079278 , , O O
5 1529 1537 11079278 although IN B-SBAR O
6 1538 1546 11079278 somewhat RB B-ADJP O
7 1547 1556 11079278 effective JJ I-ADJP O
8 1556 1557 11079278 , , O O
9 1558 1562 11079278 does VBZ B-VP O
10 1563 1566 11079278 not RB I-VP O
11 1567 1574 11079278 correct VB I-VP O
12 1575 1579 11079278 this DT B-NP O
13 1580 1586 11079278 effect NN I-NP O
14 1587 1589 11079278 to TO B-PP O
15 1590 1593 11079278 the DT B-NP O
16 1594 1600 11079278 extent NN I-NP O
17 1601 1605 11079278 that IN B-SBAR O
18 1606 1608 11079278 it PRP B-NP O
19 1609 1612 11079278 can MD B-VP O
20 1613 1615 11079278 be VB I-VP O
21 1616 1628 11079278 administered VBN I-VP O
22 1629 1639 11079278 clinically RB B-ADVP O
23 1639 1640 11079278 . . O O

1 0 0 19917396 -DOCSTART- -X- -X- O

1 0 10 19917396 Reversible JJ B-NP O
2 11 21 19917396 myocardial JJ I-NP D006332
3 22 33 19917396 hypertrophy NN I-NP D006332
4 34 41 19917396 induced VBN B-VP O
5 42 44 19917396 by IN B-PP O
6 45 55 19917396 tacrolimus NN B-NP D016559
7 56 58 19917396 in IN B-PP O
8 59 60 19917396 a DT B-NP O
9 61 70 19917396 pediatric JJ I-NP O
10 71 76 19917396 heart NN I-NP O
11 77 87 19917396 transplant NN I-NP O
12 88 97 19917396 recipient NN I-NP O
13 97 98 19917396 : : O O
14 99 103 19917396 case NN B-NP O
15 104 110 19917396 report NN I-NP O
16 110 111 19917396 . . B-NP O
17 112 122 19917396 Tacrolimus NN I-NP D016559
18 123 125 19917396 is VBZ B-VP O
19 126 127 19917396 a DT B-NP O
20 128 134 19917396 potent JJ I-NP O
21 135 152 19917396 immunosuppressant NN I-NP O
22 153 157 19917396 that WDT B-NP O
23 158 160 19917396 is VBZ B-VP O
24 161 171 19917396 frequently RB I-VP O
25 172 176 19917396 used VBN I-VP O
26 177 179 19917396 in IN B-PP O
27 180 185 19917396 organ NN B-NP O
28 186 201 19917396 transplantation NN I-NP O
29 201 202 19917396 . . O O

1 203 210 19917396 However RB B-ADVP O
2 210 211 19917396 , , O O
3 212 219 19917396 adverse JJ B-NP O
4 220 227 19917396 effects NNS I-NP O
5 228 235 19917396 include VBP B-VP O
6 236 243 19917396 cardiac JJ B-NP D066126
7 244 252 19917396 toxicity NN I-NP D066126
8 252 253 19917396 . . O O

1 254 260 19917396 Herein RB B-ADVP O
2 261 263 19917396 we PRP B-NP O
3 264 272 19917396 describe VBP B-VP O
4 273 282 19917396 transient JJ B-NP O
5 283 293 19917396 myocardial JJ I-NP D006332
6 294 305 19917396 hypertrophy NN I-NP D006332
7 306 313 19917396 induced VBN B-VP O
8 314 316 19917396 by IN B-PP O
9 317 327 19917396 tacrolimus NN B-NP D016559
10 328 333 19917396 after IN B-PP O
11 334 339 19917396 heart NN B-NP O
12 340 355 19917396 transplantation NN I-NP O
13 355 356 19917396 . . O O

1 357 360 19917396 The DT B-NP O
2 361 372 19917396 hypertrophy NN I-NP D006984
3 373 379 19917396 caused VBD B-VP O
4 380 382 19917396 no DT B-NP O
5 383 391 19917396 clinical JJ I-NP O
6 392 400 19917396 symptoms NNS I-NP O
7 401 404 19917396 but CC O O
8 405 408 19917396 was VBD B-VP O
9 409 414 19917396 noted VBN I-VP O
10 415 422 19917396 because IN B-PP O
11 423 425 19917396 of IN I-PP O
12 426 435 19917396 elevation NN B-NP O
13 436 438 19917396 of IN B-PP O
14 439 445 19917396 plasma NN B-NP O
15 446 451 19917396 brain NN I-NP O
16 452 463 19917396 natriuretic JJ I-NP O
17 464 471 19917396 peptide NN I-NP O
18 472 485 19917396 concentration NN I-NP O
19 486 489 19917396 and CC O O
20 490 499 19917396 confirmed VBN B-VP O
21 500 502 19917396 at IN B-PP O
22 503 519 19917396 echocardiography NN B-NP O
23 519 520 19917396 . . O O

1 521 530 19917396 Initially RB B-ADVP O
2 530 531 19917396 , , O O
3 532 541 19917396 allograft NN B-NP O
4 542 551 19917396 rejection NN I-NP O
5 552 555 19917396 was VBD B-VP O
6 556 562 19917396 feared VBN I-VP O
7 562 563 19917396 ; : O O
8 564 571 19917396 however RB B-ADVP O
9 571 572 19917396 , , O O
10 573 583 19917396 myocardial JJ B-NP O
11 584 590 19917396 biopsy NN I-NP O
12 591 598 19917396 samples NNS I-NP O
13 599 607 19917396 revealed VBD B-VP O
14 608 612 19917396 only RB B-NP O
15 613 625 19917396 interstitial JJ I-NP O
16 626 631 19917396 edema NN I-NP D004487
17 632 635 19917396 and CC O O
18 636 640 19917396 mild JJ B-NP O
19 641 651 19917396 myocardial JJ I-NP D006332
20 652 663 19917396 hypertrophy NN I-NP D006332
21 663 664 19917396 ; : O O
22 665 672 19917396 neither CC O O
23 673 681 19917396 cellular JJ B-NP O
24 682 685 19917396 nor CC I-NP O
25 686 693 19917396 humoral JJ I-NP O
26 694 703 19917396 rejection NN I-NP O
27 704 707 19917396 was VBD B-VP O
28 708 716 19917396 detected VBN I-VP O
29 716 717 19917396 . . O O

1 718 721 19917396 The DT B-NP O
2 722 727 19917396 blood NN I-NP O
3 728 738 19917396 tacrolimus NN I-NP D016559
4 739 752 19917396 concentration NN I-NP O
5 753 756 19917396 was VBD B-VP O
6 757 763 19917396 higher JJR B-ADJP O
7 764 768 19917396 than IN B-PP O
8 769 774 19917396 usual JJ B-ADJP O
9 775 777 19917396 at IN B-PP O
10 778 782 19917396 that DT B-NP O
11 783 787 19917396 time NN I-NP O
12 787 788 19917396 ; : O O
13 789 793 19917396 thus RB B-ADVP O
14 793 794 19917396 , , O O
15 795 805 19917396 tacrolimus NN B-NP D016559
16 806 812 19917396 dosage NN I-NP O
17 813 816 19917396 was VBD B-VP O
18 817 824 19917396 reduced VBN I-VP O
19 824 825 19917396 . . O O

1 826 836 19917396 Myocardial JJ B-NP D006332
2 837 848 19917396 hypertrophy NN I-NP D006332
3 849 859 19917396 completely RB B-VP O
4 860 868 19917396 resolved VBN I-VP O
5 869 873 19917396 upon IN B-PP O
6 874 882 19917396 reducing VBG B-VP O
7 883 886 19917396 the DT B-NP O
8 887 893 19917396 target NN I-NP O
9 894 907 19917396 concentration NN I-NP O
10 908 910 19917396 of IN B-PP O
11 911 921 19917396 tacrolimus NN B-NP D016559
12 922 925 19917396 and CC O O
13 926 929 19917396 did VBD B-VP O
14 930 933 19917396 not RB I-VP O
15 934 939 19917396 recur VB I-VP O
16 939 940 19917396 , , O O
17 941 943 19917396 as IN B-SBAR O
18 944 953 19917396 confirmed VBN B-VP O
19 954 956 19917396 at IN B-PP O
20 957 973 19917396 echocardiography NN B-NP O
21 974 977 19917396 and CC O O
22 978 988 19917396 myocardial JJ B-NP O
23 989 995 19917396 biopsy NN I-NP O
24 995 996 19917396 . . O O

1 997 1001 19917396 Thus RB B-ADVP O
2 1001 1002 19917396 , , O O
3 1003 1005 19917396 we PRP B-NP O
4 1006 1014 19917396 conclude VBP B-VP O
5 1015 1019 19917396 that IN B-SBAR O
6 1020 1030 19917396 tacrolimus NN B-NP D016559
7 1031 1038 19917396 induces VBZ B-VP O
8 1039 1049 19917396 reversible JJ B-NP O
9 1050 1060 19917396 myocardial JJ I-NP D006332
10 1061 1072 19917396 hypertrophy NN I-NP D006332
11 1072 1073 19917396 . . O O

1 1074 1076 19917396 In IN B-PP O
2 1077 1085 19917396 patients NNS B-NP O
3 1086 1095 19917396 receiving VBG B-VP O
4 1096 1106 19917396 tacrolimus NN B-NP D016559
5 1107 1114 19917396 therapy NN I-NP O
6 1114 1115 19917396 , , O O
7 1116 1121 19917396 blood NN B-NP O
8 1122 1135 19917396 concentration NN I-NP O
9 1136 1142 19917396 should MD B-VP O
10 1143 1145 19917396 be VB I-VP O
11 1146 1155 19917396 carefully RB B-ADJP O
12 1156 1166 19917396 controlled JJ B-NP O
13 1167 1170 19917396 and CC I-NP O
14 1171 1178 19917396 extreme JJ I-NP O
15 1179 1188 19917396 attention NN I-NP O
16 1189 1193 19917396 paid VBN B-VP O
17 1194 1196 19917396 to TO B-PP O
18 1197 1204 19917396 cardiac JJ B-NP O
19 1205 1216 19917396 involvement NN I-NP O
20 1216 1217 19917396 . . O O

1 0 0 8441146 -DOCSTART- -X- -X- O

1 0 8 8441146 Apparent JJ B-NP O
2 9 13 8441146 cure NN I-NP O
3 14 16 8441146 of IN B-PP O
4 17 27 8441146 rheumatoid JJ B-NP D001172
5 28 37 8441146 arthritis NN I-NP D001172
6 38 40 8441146 by IN B-PP O
7 41 45 8441146 bone NN B-NP O
8 46 52 8441146 marrow NN I-NP O
9 53 68 8441146 transplantation NN I-NP O
10 68 69 8441146 . . O O
11 70 72 8441146 We PRP B-NP O
12 73 81 8441146 describe VBP B-VP O
13 82 85 8441146 the DT B-NP O
14 86 95 8441146 induction NN I-NP O
15 96 98 8441146 of IN B-PP O
16 99 108 8441146 sustained JJ B-NP O
17 109 119 8441146 remissions NNS I-NP O
18 120 123 8441146 and CC O O
19 124 132 8441146 possible JJ B-NP O
20 133 137 8441146 cure NN I-NP O
21 138 140 8441146 of IN B-PP O
22 141 147 8441146 severe JJ B-NP O
23 148 155 8441146 erosive JJ I-NP O
24 156 166 8441146 rheumatoid JJ I-NP D001172
25 167 176 8441146 arthritis NN I-NP D001172
26 177 178 8441146 ( ( O O
27 178 180 8441146 RA NN B-NP D001172
28 180 181 8441146 ) ) O O
29 182 184 8441146 by IN B-PP O
30 185 189 8441146 bone NN B-NP O
31 190 196 8441146 marrow NN I-NP O
32 197 212 8441146 transplantation NN I-NP O
33 213 214 8441146 ( ( O O
34 214 217 8441146 BMT NN B-NP O
35 217 218 8441146 ) ) O O
36 219 221 8441146 in IN B-PP O
37 222 223 8441146 2 CD B-NP O
38 224 232 8441146 patients NNS I-NP O
39 232 233 8441146 . . O O

1 234 237 8441146 BMT NN B-NP O
2 238 241 8441146 was VBD B-VP O
3 242 246 8441146 used VBN I-VP O
4 247 249 8441146 to TO B-VP O
5 250 255 8441146 treat VB I-VP O
6 256 262 8441146 severe JJ B-NP O
7 263 271 8441146 aplastic JJ I-NP D000741
8 272 278 8441146 anemia NN I-NP D000741
9 279 284 8441146 which WDT B-NP O
10 285 288 8441146 was VBD B-VP O
11 289 295 8441146 caused VBN I-VP O
12 296 298 8441146 by IN B-PP O
13 299 303 8441146 gold NN B-NP D006046
14 304 306 8441146 in IN B-PP O
15 307 310 8441146 one CD B-NP O
16 311 315 8441146 case NN I-NP O
17 316 319 8441146 and CC I-NP O
18 320 321 8441146 D NN I-NP D010396
19 321 322 8441146 - HYPH B-NP D010396
20 322 335 8441146 penicillamine NN I-NP D010396
21 336 338 8441146 in IN B-PP O
22 339 342 8441146 the DT B-NP O
23 343 348 8441146 other JJ I-NP O
24 348 349 8441146 . . O O

1 350 352 8441146 In IN B-PP O
2 353 356 8441146 the DT B-NP O
3 357 358 8441146 8 CD I-NP O
4 359 362 8441146 and CC I-NP O
5 363 364 8441146 6 CD I-NP O
6 365 370 8441146 years NNS I-NP O
7 371 376 8441146 since IN B-SBAR O
8 377 380 8441146 the DT B-NP O
9 381 392 8441146 transplants NNS I-NP O
10 393 394 8441146 ( ( O O
11 394 406 8441146 representing VBG B-VP O
12 407 408 8441146 8 CD B-NP O
13 409 412 8441146 and CC I-NP O
14 413 414 8441146 4 CD I-NP O
15 415 420 8441146 years NNS I-NP O
16 421 426 8441146 since IN B-PP O
17 427 436 8441146 cessation NN B-NP O
18 437 439 8441146 of IN B-PP O
19 440 443 8441146 all DT B-NP O
20 444 461 8441146 immunosuppressive JJ I-NP O
21 462 469 8441146 therapy NN I-NP O
22 469 470 8441146 , , O O
23 471 483 8441146 respectively RB B-ADVP O
24 483 484 8441146 ) ) O O
25 484 485 8441146 , , O O
26 486 489 8441146 the DT B-NP O
27 490 492 8441146 RA NN I-NP D001172
28 493 495 8441146 in IN B-PP O
29 496 500 8441146 each DT B-NP O
30 501 505 8441146 case NN I-NP O
31 506 509 8441146 has VBZ B-VP O
32 510 514 8441146 been VBN I-VP O
33 515 525 8441146 completely RB B-ADJP O
34 526 535 8441146 quiescent JJ I-ADJP O
35 535 536 8441146 . . O O

1 537 545 8441146 Although IN B-SBAR O
2 546 551 8441146 short JJ B-NP O
3 552 556 8441146 term NN I-NP O
4 557 566 8441146 remission NN I-NP O
5 567 569 8441146 of IN B-PP O
6 570 576 8441146 severe JJ B-NP O
7 577 579 8441146 RA NN I-NP D001172
8 580 589 8441146 following VBG B-PP O
9 590 593 8441146 BMT NN B-NP O
10 594 597 8441146 has VBZ B-VP O
11 598 602 8441146 been VBN I-VP O
12 603 611 8441146 reported VBN I-VP O
13 611 612 8441146 , , O O
14 613 618 8441146 these DT B-NP O
15 619 622 8441146 are VBP B-VP O
16 623 626 8441146 the DT B-NP O
17 627 632 8441146 first JJ I-NP O
18 633 638 8441146 cases NNS I-NP O
19 639 642 8441146 for IN B-PP O
20 643 648 8441146 which WDT B-NP O
21 649 658 8441146 prolonged JJ B-NP O
22 659 667 8441146 followup NN I-NP O
23 668 671 8441146 has VBZ B-VP O
24 672 676 8441146 been VBN I-VP O
25 677 686 8441146 available JJ B-ADJP O
26 686 687 8441146 . . O O

1 688 692 8441146 This DT B-NP O
2 693 703 8441146 experience NN I-NP O
3 704 710 8441146 raises VBZ B-VP O
4 711 714 8441146 the DT B-NP O
5 715 723 8441146 question NN I-NP O
6 724 726 8441146 of IN B-PP O
7 727 730 8441146 the DT B-NP O
8 731 735 8441146 role NN I-NP O
9 736 738 8441146 of IN B-PP O
10 739 742 8441146 BMT NN B-NP O
11 743 749 8441146 itself PRP B-NP O
12 750 752 8441146 as IN B-PP O
13 753 754 8441146 a DT B-NP O
14 755 766 8441146 therapeutic JJ I-NP O
15 767 773 8441146 option NN I-NP O
16 774 777 8441146 for IN B-PP O
17 778 786 8441146 patients NNS B-NP O
18 787 791 8441146 with IN B-PP O
19 792 804 8441146 uncontrolled JJ B-NP O
20 805 816 8441146 destructive JJ I-NP O
21 817 826 8441146 synovitis NN I-NP D013585
22 826 827 8441146 . . O O

1 0 0 4038130 -DOCSTART- -X- -X- O

1 0 3 4038130 Rat NN B-NP O
2 4 15 4038130 extraocular JJ I-NP O
3 16 22 4038130 muscle NN I-NP O
4 23 35 4038130 regeneration NN I-NP O
5 35 36 4038130 . . O O

1 37 43 4038130 Repair NN B-NP O
2 44 46 4038130 of IN B-PP O
3 47 52 4038130 local JJ B-NP O
4 53 63 4038130 anesthetic NN I-NP O
5 63 64 4038130 - HYPH B-NP O
6 64 71 4038130 induced VBN I-NP O
7 72 78 4038130 damage NN I-NP O
8 78 79 4038130 . . I-NP O
9 80 85 4038130 Local JJ I-NP O
10 86 97 4038130 anesthetics NNS I-NP O
11 98 102 4038130 that WDT B-NP O
12 103 106 4038130 are VBP B-VP O
13 107 115 4038130 commonly RB I-VP O
14 116 120 4038130 used VBN I-VP O
15 121 123 4038130 in IN B-PP O
16 124 134 4038130 ophthalmic JJ B-NP O
17 135 142 4038130 surgery NN I-NP O
18 143 144 4038130 ( ( O O
19 144 149 4038130 0.75% CD B-NP O
20 150 161 4038130 bupivacaine NN I-NP D002045
21 162 175 4038130 hydrochloride NN I-NP D002045
22 175 176 4038130 , , O O
23 177 181 4038130 2.0% NN B-NP O
24 182 193 4038130 mepivacaine NN I-NP D008619
25 194 207 4038130 hydrochloride NN I-NP D008619
26 207 208 4038130 , , O O
27 209 212 4038130 and CC O O
28 213 217 4038130 2.0% CD B-NP O
29 218 227 4038130 lidocaine NN I-NP D008012
30 228 241 4038130 hydrochloride NN I-NP D008012
31 242 246 4038130 plus CC O O
32 247 248 4038130 1 CD B-NP O
33 248 249 4038130 : : O O
34 249 256 4038130 100,000 CD B-NP O
35 257 268 4038130 epinephrine NN I-NP D004837
36 268 269 4038130 ) ) O O
37 270 274 4038130 were VBD B-VP O
38 275 283 4038130 injected VBN I-VP O
39 284 288 4038130 into IN B-PP O
40 289 292 4038130 the DT B-NP O
41 293 304 4038130 retrobulbar JJ I-NP O
42 305 309 4038130 area NN I-NP O
43 310 312 4038130 of IN B-PP O
44 313 316 4038130 rat NN B-NP O
45 317 321 4038130 eyes NNS I-NP O
46 321 322 4038130 . . O O

1 323 331 4038130 Controls NNS B-NP O
2 332 336 4038130 were VBD B-VP O
3 337 345 4038130 injected VBN I-VP O
4 346 350 4038130 with IN B-PP O
5 351 364 4038130 physiological JJ B-NP O
6 365 371 4038130 saline NN I-NP O
7 371 372 4038130 . . O O

1 373 376 4038130 All DT B-NP O
2 377 382 4038130 three CD I-NP O
3 383 394 4038130 anesthetics NNS I-NP O
4 395 403 4038130 produced VBD B-VP O
5 404 411 4038130 massive JJ B-NP O
6 412 424 4038130 degeneration NN I-NP O
7 425 427 4038130 of IN B-PP O
8 428 431 4038130 the DT B-NP O
9 432 443 4038130 extraocular JJ I-NP O
10 444 451 4038130 muscles NNS I-NP O
11 451 452 4038130 . . O O

1 453 459 4038130 Muscle NN B-NP D009135
2 460 472 4038130 degeneration NN I-NP D009135
3 473 475 4038130 is VBZ B-VP O
4 476 484 4038130 followed VBN I-VP O
5 485 487 4038130 by IN B-PP O
6 488 500 4038130 regeneration NN B-NP O
7 501 503 4038130 of IN B-PP O
8 504 507 4038130 the DT B-NP O
9 508 515 4038130 damaged VBN I-NP O
10 516 522 4038130 muscle NN I-NP O
11 523 529 4038130 fibers NNS I-NP O
12 529 530 4038130 . . O O

1 531 533 4038130 In IN B-PP O
2 534 542 4038130 addition NN B-NP O
3 543 545 4038130 to TO B-PP O
4 546 552 4038130 muscle NN B-NP D009135
5 553 559 4038130 damage NN I-NP D009135
6 559 560 4038130 , , O O
7 561 567 4038130 severe JJ B-NP O
8 568 574 4038130 damage NN I-NP O
9 575 578 4038130 was VBD B-VP O
10 579 583 4038130 also RB I-VP O
11 584 588 4038130 seen VBN I-VP O
12 589 591 4038130 in IN B-PP O
13 592 601 4038130 harderian JJ B-NP O
14 602 608 4038130 glands NNS I-NP O
15 608 609 4038130 , , O O
16 610 620 4038130 especially RB B-ADVP O
17 621 626 4038130 after IN B-SBAR O
18 627 635 4038130 exposure NN B-NP O
19 636 638 4038130 to TO B-PP O
20 639 650 4038130 mepivacaine NN B-NP D008619
21 651 654 4038130 and CC I-NP O
22 655 664 4038130 lidocaine NN I-NP D008012
23 665 669 4038130 plus CC I-NP O
24 670 681 4038130 epinephrine NN I-NP D004837
25 681 682 4038130 . . O O

1 683 687 4038130 With IN B-PP O
2 688 693 4038130 these DT B-NP O
3 694 702 4038130 findings NNS I-NP O
4 703 705 4038130 in IN B-PP O
5 706 710 4038130 rats NNS B-NP O
6 710 711 4038130 , , O O
7 712 714 4038130 it PRP B-NP O
8 715 717 4038130 is VBZ B-VP O
9 718 730 4038130 hypothesized VBN I-VP O
10 731 735 4038130 that IN B-SBAR O
11 736 739 4038130 the DT B-NP O
12 740 749 4038130 temporary JJ I-NP O
13 750 758 4038130 diplopia NN I-NP D004172
14 759 768 4038130 sometimes RB B-VP O
15 769 773 4038130 seen VBN I-VP O
16 774 776 4038130 in IN B-PP O
17 777 785 4038130 patients NNS B-NP O
18 786 791 4038130 after IN B-PP O
19 792 802 4038130 ophthalmic JJ B-NP O
20 803 810 4038130 surgery NN I-NP O
21 811 816 4038130 might MD B-VP O
22 817 819 4038130 be VB I-VP O
23 820 823 4038130 due JJ B-ADVP O
24 824 826 4038130 to TO B-PP O
25 827 837 4038130 anesthetic JJ B-NP O
26 837 838 4038130 - HYPH I-NP O
27 838 845 4038130 induced VBN I-NP O
28 846 852 4038130 damage NN I-NP O
29 853 855 4038130 to TO B-PP O
30 856 859 4038130 the DT B-NP O
31 860 871 4038130 extraocular JJ I-NP O
32 872 879 4038130 muscles NNS I-NP O
33 879 880 4038130 . . O O

1 0 0 6794356 -DOCSTART- -X- -X- O

1 0 9 6794356 Tricuspid JJ B-NP D014262
2 10 15 6794356 valve NN I-NP D014262
3 16 29 6794356 regurgitation NN I-NP D014262
4 30 33 6794356 and CC O O
5 34 41 6794356 lithium NN B-NP D016651
6 42 51 6794356 carbonate NN I-NP D016651
7 52 60 6794356 toxicity NN I-NP D064420
8 61 63 6794356 in IN B-PP O
9 64 65 6794356 a DT B-NP O
10 66 73 6794356 newborn JJ I-NP O
11 74 80 6794356 infant NN I-NP O
12 80 81 6794356 . . O O
13 82 83 6794356 A DT B-NP O
14 84 91 6794356 newborn JJ I-NP O
15 92 96 6794356 with IN B-PP O
16 97 104 6794356 massive JJ B-NP O
17 105 114 6794356 tricuspid JJ I-NP D014262
18 115 128 6794356 regurgitation NN I-NP D014262
19 128 129 6794356 , , O O
20 130 136 6794356 atrial JJ B-NP D001282
21 137 144 6794356 flutter NN I-NP D001282
22 144 145 6794356 , , O O
23 146 156 6794356 congestive JJ B-NP D006333
24 157 162 6794356 heart NN I-NP D006333
25 163 170 6794356 failure NN I-NP D006333
26 170 171 6794356 , , O O
27 172 175 6794356 and CC O O
28 176 177 6794356 a DT B-NP O
29 178 182 6794356 high JJ I-NP O
30 183 188 6794356 serum NN I-NP O
31 189 196 6794356 lithium NN I-NP D008094
32 197 202 6794356 level NN I-NP O
33 203 205 6794356 is VBZ B-VP O
34 206 215 6794356 described VBN I-VP O
35 215 216 6794356 . . O O

1 217 221 6794356 This DT B-NP O
2 222 224 6794356 is VBZ B-VP O
3 225 228 6794356 the DT B-NP O
4 229 234 6794356 first JJ I-NP O
5 235 242 6794356 patient NN I-NP O
6 243 245 6794356 to TO B-VP O
7 246 255 6794356 initially RB I-VP O
8 256 264 6794356 manifest VB I-VP O
9 265 274 6794356 tricuspid JJ B-NP D014262
10 275 288 6794356 regurgitation NN I-NP D014262
11 289 292 6794356 and CC O O
12 293 299 6794356 atrial JJ B-NP D001282
13 300 307 6794356 flutter NN I-NP D001282
14 307 308 6794356 , , O O
15 309 312 6794356 and CC O O
16 313 316 6794356 the DT B-NP O
17 317 321 6794356 11th JJ I-NP O
18 322 331 6794356 described VBN I-NP O
19 332 339 6794356 patient NN I-NP O
20 340 344 6794356 with IN B-PP O
21 345 352 6794356 cardiac JJ B-NP D006331
22 353 360 6794356 disease NN I-NP D006331
23 361 366 6794356 among IN B-PP O
24 367 374 6794356 infants NNS B-NP O
25 375 382 6794356 exposed VBN B-VP O
26 383 385 6794356 to TO B-PP O
27 386 393 6794356 lithium NN B-NP D008094
28 394 403 6794356 compounds NNS I-NP O
29 404 406 6794356 in IN B-PP O
30 407 410 6794356 the DT B-NP O
31 411 416 6794356 first JJ I-NP O
32 417 426 6794356 trimester NN I-NP O
33 427 429 6794356 of IN B-PP O
34 430 439 6794356 pregnancy NN B-NP O
35 439 440 6794356 . . O O

1 441 446 6794356 Sixty CD B-NP O
2 446 447 6794356 - HYPH I-NP O
3 447 452 6794356 three CD I-NP O
4 453 460 6794356 percent NN I-NP O
5 461 463 6794356 of IN B-PP O
6 464 469 6794356 these DT B-NP O
7 470 477 6794356 infants NNS I-NP O
8 478 481 6794356 had VBD B-VP O
9 482 491 6794356 tricuspid JJ B-NP O
10 492 497 6794356 valve NN I-NP O
11 498 509 6794356 involvement NN I-NP O
12 509 510 6794356 . . O O

1 511 518 6794356 Lithium NN B-NP D016651
2 519 528 6794356 carbonate NN I-NP D016651
3 529 532 6794356 may MD B-VP O
4 533 535 6794356 be VB I-VP O
5 536 537 6794356 a DT B-NP O
6 538 544 6794356 factor NN I-NP O
7 545 547 6794356 in IN B-PP O
8 548 551 6794356 the DT B-NP O
9 552 562 6794356 increasing VBG I-NP O
10 563 572 6794356 incidence NN I-NP O
11 573 575 6794356 of IN B-PP O
12 576 586 6794356 congenital JJ B-NP D006331
13 587 592 6794356 heart NN I-NP D006331
14 593 600 6794356 disease NN I-NP D006331
15 601 605 6794356 when WRB B-ADVP O
16 606 611 6794356 taken VBN B-VP O
17 612 618 6794356 during IN B-PP O
18 619 624 6794356 early JJ B-NP O
19 625 634 6794356 pregnancy NN I-NP O
20 634 635 6794356 . . O O

1 636 638 6794356 It PRP B-NP O
2 639 643 6794356 also RB B-ADVP O
3 644 650 6794356 causes VBZ B-VP O
4 651 661 6794356 neurologic JJ B-NP D003866
5 662 672 6794356 depression NN I-NP D003866
6 672 673 6794356 , , O O
7 674 682 6794356 cyanosis NN B-NP D003490
8 682 683 6794356 , , O O
9 684 687 6794356 and CC O O
10 688 695 6794356 cardiac JJ B-NP D001145
11 696 706 6794356 arrhythmia NN I-NP D001145
12 707 711 6794356 when WRB B-ADVP O
13 712 720 6794356 consumed VBN B-VP O
14 721 726 6794356 prior RB B-ADVP O
15 727 729 6794356 to TO B-PP O
16 730 738 6794356 delivery NN B-NP O
17 738 739 6794356 . . O O

1 0 0 15266215 -DOCSTART- -X- -X- O

1 0 7 15266215 Effects NNS B-NP O
2 8 10 15266215 of IN B-PP O
3 11 14 15266215 the DT B-NP O
4 15 29 15266215 cyclooxygenase NN I-NP O
5 29 30 15266215 - HYPH B-NP O
6 30 31 15266215 2 CD I-NP O
7 32 40 15266215 specific JJ I-NP O
8 41 50 15266215 inhibitor NN I-NP O
9 51 61 15266215 valdecoxib NN I-NP C406224
10 62 68 15266215 versus IN B-PP O
11 69 81 15266215 nonsteroidal JJ B-NP O
12 82 98 15266215 antiinflammatory JJ I-NP O
13 99 105 15266215 agents NNS I-NP O
14 106 109 15266215 and CC O O
15 110 117 15266215 placebo NN B-NP O
16 118 120 15266215 on IN B-PP O
17 121 135 15266215 cardiovascular JJ B-NP O
18 136 146 15266215 thrombotic JJ I-NP D013927
19 147 153 15266215 events NNS I-NP O
20 154 156 15266215 in IN B-PP O
21 157 165 15266215 patients NNS B-NP O
22 166 170 15266215 with IN B-PP O
23 171 180 15266215 arthritis NN B-NP D001168
24 180 181 15266215 . . O O
25 182 187 15266215 There EX B-NP O
26 188 192 15266215 have VBP B-VP O
27 193 197 15266215 been VBN I-VP O
28 198 206 15266215 concerns NNS B-NP O
29 207 211 15266215 that IN B-SBAR O
30 212 215 15266215 the DT B-NP O
31 216 220 15266215 risk NN I-NP O
32 221 223 15266215 of IN B-PP O
33 224 238 15266215 cardiovascular JJ B-NP O
34 239 249 15266215 thrombotic JJ I-NP D013927
35 250 256 15266215 events NNS I-NP O
36 257 260 15266215 may MD B-VP O
37 261 263 15266215 be VB I-VP O
38 264 270 15266215 higher JJR B-ADJP O
39 271 275 15266215 with IN B-PP O
40 276 290 15266215 cyclooxygenase NN B-NP O
41 291 296 15266215 (COX) NN I-NP O
42 296 297 15266215 - HYPH B-NP O
43 297 298 15266215 2 CD I-NP O
44 298 299 15266215 - HYPH I-NP O
45 299 307 15266215 specific JJ I-NP O
46 308 318 15266215 inhibitors NNS I-NP O
47 319 323 15266215 than IN B-PP O
48 324 336 15266215 nonselective JJ B-NP O
49 337 349 15266215 nonsteroidal JJ I-NP O
50 350 366 15266215 antiinflammatory JJ I-NP O
51 367 372 15266215 drugs NNS I-NP O
52 373 374 15266215 ( ( O O
53 374 380 15266215 NSAIDs NNS B-NP O
54 380 381 15266215 ) ) O O
55 381 382 15266215 . . O O

1 383 385 15266215 We PRP B-NP O
2 386 395 15266215 evaluated VBD B-VP O
3 396 410 15266215 cardiovascular JJ B-NP O
4 411 416 15266215 event NN I-NP O
5 417 421 15266215 data NNS I-NP O
6 422 425 15266215 for IN B-PP O
7 426 436 15266215 valdecoxib NN B-NP C406224
8 436 437 15266215 , , O O
9 438 439 15266215 a DT B-NP O
10 440 443 15266215 new JJ I-NP O
11 444 447 15266215 COX NN I-NP O
12 447 448 15266215 - HYPH B-NP O
13 448 449 15266215 2 CD I-NP O
14 449 450 15266215 - HYPH I-NP O
15 450 458 15266215 specific JJ I-NP O
16 459 468 15266215 inhibitor NN I-NP O
17 469 471 15266215 in IN B-PP O
18 472 485 15266215 approximately RB B-NP O
19 486 490 15266215 8000 CD I-NP O
20 491 499 15266215 patients NNS I-NP O
21 500 504 15266215 with IN B-PP O
22 505 519 15266215 osteoarthritis NN B-NP D010003
23 520 523 15266215 and CC O O
24 524 534 15266215 rheumatoid JJ B-NP D001172
25 535 544 15266215 arthritis NN I-NP D001172
26 545 552 15266215 treated VBN B-VP O
27 553 557 15266215 with IN B-PP O
28 558 562 15266215 this DT B-NP O
29 563 568 15266215 agent NN I-NP O
30 569 571 15266215 in IN B-PP O
31 572 582 15266215 randomized VBN B-NP O
32 583 591 15266215 clinical JJ I-NP O
33 592 598 15266215 trials NNS I-NP O
34 598 599 15266215 . . O O

1 600 603 15266215 The DT B-NP O
2 604 613 15266215 incidence NN I-NP O
3 614 616 15266215 of IN B-PP O
4 617 631 15266215 cardiovascular JJ B-NP O
5 632 642 15266215 thrombotic JJ I-NP D013927
6 643 649 15266215 events NNS I-NP O
7 650 651 15266215 ( ( O O
8 651 658 15266215 cardiac JJ B-NP O
9 658 659 15266215 , , I-NP O
10 660 675 15266215 cerebrovascular JJ I-NP O
11 676 679 15266215 and CC I-NP O
12 680 690 15266215 peripheral JJ I-NP O
13 691 699 15266215 vascular JJ I-NP O
14 699 700 15266215 , , O O
15 701 703 15266215 or CC O O
16 704 712 15266215 arterial JJ B-NP O
17 713 723 15266215 thrombotic NN I-NP D013927
18 723 724 15266215 ) ) O O
19 725 728 15266215 was VBD B-VP O
20 729 739 15266215 determined VBN I-VP O
21 740 742 15266215 by IN B-PP O
22 743 752 15266215 analyzing VBG B-VP O
23 753 759 15266215 pooled VBN B-NP O
24 760 770 15266215 valdecoxib NN I-NP C406224
25 771 772 15266215 ( ( O O
26 772 774 15266215 10 CD B-NP O
27 774 775 15266215 - HYPH I-NP O
28 775 777 15266215 80 CD I-NP O
29 778 780 15266215 mg NN I-NP O
30 781 786 15266215 daily JJ I-NP O
31 786 787 15266215 ) ) O O
32 787 788 15266215 , , O O
33 789 801 15266215 nonselective JJ B-NP O
34 802 807 15266215 NSAID NN I-NP O
35 808 809 15266215 ( ( O O
36 809 819 15266215 diclofenac NN B-NP D004008
37 820 822 15266215 75 CD I-NP O
38 823 825 15266215 mg NN I-NP O
39 826 829 15266215 bid RB B-ADVP O
40 829 830 15266215 , , O O
41 831 840 15266215 ibuprofen NN B-NP D007052
42 841 844 15266215 800 CD I-NP O
43 845 847 15266215 mg NN I-NP O
44 848 851 15266215 tid NN I-NP O
45 851 852 15266215 , , O O
46 853 855 15266215 or CC O O
47 856 864 15266215 naproxen NN B-NP D009288
48 865 868 15266215 500 CD I-NP O
49 869 871 15266215 mg NN I-NP O
50 872 875 15266215 bid NN I-NP O
51 875 876 15266215 ) ) O O
52 877 880 15266215 and CC O O
53 881 888 15266215 placebo NN B-NP O
54 889 893 15266215 data NNS I-NP O
55 894 898 15266215 from IN B-PP O
56 899 901 15266215 10 CD B-NP O
57 902 912 15266215 randomized VBN I-NP O
58 913 927 15266215 osteoarthritis NN I-NP D010003
59 928 931 15266215 and CC I-NP O
60 932 942 15266215 rheumatoid JJ I-NP D001172
61 943 952 15266215 arthritis NN I-NP D001172
62 953 959 15266215 trials NNS I-NP O
63 960 964 15266215 that WDT B-NP O
64 965 969 15266215 were VBD B-VP O
65 970 971 15266215 6 CD B-NP O
66 971 972 15266215 - HYPH I-NP O
67 972 974 15266215 52 CD I-NP O
68 975 980 15266215 weeks NNS I-NP O
69 981 983 15266215 in IN B-PP O
70 984 992 15266215 duration NN B-NP O
71 992 993 15266215 . . O O

1 994 997 15266215 The DT B-NP O
2 998 1007 15266215 incidence NN I-NP O
3 1008 1013 15266215 rates NNS I-NP O
4 1014 1016 15266215 of IN B-PP O
5 1017 1023 15266215 events NNS B-NP O
6 1024 1028 15266215 were VBD B-VP O
7 1029 1039 15266215 determined VBN I-VP O
8 1040 1042 15266215 in IN B-PP O
9 1043 1046 15266215 all DT B-NP O
10 1047 1055 15266215 patients NNS I-NP O
11 1056 1057 15266215 ( ( O O
12 1057 1058 15266215 n NN B-NP O
13 1059 1060 15266215 = SYM B-VP O
14 1061 1065 15266215 7934 CD B-NP O
15 1065 1066 15266215 ) ) O O
16 1067 1070 15266215 and CC O O
17 1071 1073 15266215 in IN B-PP O
18 1074 1079 15266215 users NNS B-NP O
19 1080 1082 15266215 of IN B-PP O
20 1083 1086 15266215 low JJ B-NP O
21 1086 1087 15266215 - HYPH I-NP O
22 1087 1091 15266215 dose NN I-NP O
23 1092 1093 15266215 ( ( O O
24 1093 1094 15266215 < SYM B-NP O
25 1095 1097 15266215 or CC O O
26 1098 1099 15266215 = SYM B-VP O
27 1099 1102 15266215 325 CD B-NP O
28 1103 1105 15266215 mg NN I-NP O
29 1106 1111 15266215 daily JJ I-NP O
30 1111 1112 15266215 ) ) O O
31 1113 1120 15266215 aspirin NN B-NP D001241
32 1121 1122 15266215 ( ( O O
33 1122 1123 15266215 n NN B-NP O
34 1124 1125 15266215 = SYM B-VP O
35 1126 1130 15266215 1051 CD B-NP O
36 1130 1131 15266215 ) ) O O
37 1132 1135 15266215 and CC O O
38 1136 1144 15266215 nonusers NNS B-NP O
39 1145 1147 15266215 of IN B-PP O
40 1148 1155 15266215 aspirin NN B-NP D001241
41 1156 1157 15266215 ( ( O O
42 1157 1158 15266215 n NN B-NP O
43 1159 1160 15266215 = SYM B-VP O
44 1161 1165 15266215 6883 CD B-NP O
45 1165 1166 15266215 ) ) O O
46 1166 1167 15266215 . . O O

1 1168 1173 15266215 Crude NN B-NP O
2 1174 1177 15266215 and CC I-NP O
3 1178 1186 15266215 exposure NN I-NP O
4 1186 1187 15266215 - HYPH B-NP O
5 1187 1195 15266215 adjusted VBN I-NP O
6 1196 1206 15266215 incidences NNS I-NP O
7 1207 1209 15266215 of IN B-PP O
8 1210 1220 15266215 thrombotic JJ B-NP D013927
9 1221 1227 15266215 events NNS I-NP O
10 1228 1232 15266215 were VBD B-VP O
11 1233 1240 15266215 similar JJ B-ADJP O
12 1241 1244 15266215 for IN B-PP O
13 1245 1255 15266215 valdecoxib NN B-NP C406224
14 1255 1256 15266215 , , O O
15 1257 1263 15266215 NSAIDs NNS B-NP O
16 1263 1264 15266215 , , O O
17 1265 1268 15266215 and CC O O
18 1269 1276 15266215 placebo NN B-NP O
19 1276 1277 15266215 . . O O

1 1278 1281 15266215 The DT B-NP O
2 1282 1286 15266215 risk NN I-NP O
3 1287 1289 15266215 of IN B-PP O
4 1290 1297 15266215 serious JJ B-NP O
5 1298 1308 15266215 thrombotic JJ I-NP D013927
6 1309 1315 15266215 events NNS I-NP O
7 1316 1319 15266215 was VBD B-VP O
8 1320 1324 15266215 also RB B-ADVP O
9 1325 1332 15266215 similar JJ B-ADJP O
10 1333 1336 15266215 for IN B-PP O
11 1337 1341 15266215 each DT B-NP O
12 1342 1352 15266215 valdecoxib NN I-NP C406224
13 1353 1357 15266215 dose NN I-NP O
14 1357 1358 15266215 . . O O

1 1359 1369 15266215 Thrombotic JJ B-NP D013927
2 1370 1374 15266215 risk NN I-NP O
3 1375 1378 15266215 was VBD B-VP O
4 1379 1391 15266215 consistently RB B-ADJP O
5 1392 1398 15266215 higher JJR I-ADJP O
6 1399 1402 15266215 for IN B-PP O
7 1403 1408 15266215 users NNS B-NP O
8 1409 1411 15266215 of IN B-PP O
9 1412 1419 15266215 aspirin NN B-NP D001241
10 1420 1425 15266215 users NNS I-NP O
11 1426 1430 15266215 than IN B-PP O
12 1431 1439 15266215 nonusers NNS B-NP O
13 1440 1442 15266215 of IN B-PP O
14 1443 1450 15266215 aspirin NN B-NP D001241
15 1451 1452 15266215 ( ( O O
16 1452 1459 15266215 placebo NN B-NP O
17 1459 1460 15266215 , , O O
18 1461 1465 15266215 1.4% CD B-NP O
19 1466 1468 15266215 vs NNS I-NP O
20 1468 1469 15266215 . . O O
21 1470 1472 15266215 0% CD B-NP O
22 1472 1473 15266215 ; : O O
23 1474 1484 15266215 valdecoxib NN B-NP C406224
24 1484 1485 15266215 , , O O
25 1486 1490 15266215 1.7% CD B-NP O
26 1491 1493 15266215 vs NNS I-NP O
27 1493 1494 15266215 . . O O
28 1495 1499 15266215 0.2% CD B-NP O
29 1499 1500 15266215 ; : O O
30 1501 1507 15266215 NSAIDs NNS B-NP O
31 1507 1508 15266215 , , O O
32 1509 1513 15266215 1.9% CD B-NP O
33 1514 1516 15266215 vs NNS I-NP O
34 1516 1517 15266215 . . O O
35 1518 1522 15266215 0.5% CD B-NP O
36 1522 1523 15266215 ) ) O O
37 1523 1524 15266215 . . O O

1 1525 1528 15266215 The DT B-NP O
2 1529 1534 15266215 rates NNS I-NP O
3 1535 1537 15266215 of IN B-PP O
4 1538 1544 15266215 events NNS B-NP O
5 1545 1547 15266215 in IN B-PP O
6 1548 1553 15266215 users NNS B-NP O
7 1554 1556 15266215 of IN B-PP O
8 1557 1564 15266215 aspirin NN B-NP D001241
9 1565 1569 15266215 were VBD B-VP O
10 1570 1577 15266215 similar JJ B-ADJP O
11 1578 1581 15266215 for IN B-PP O
12 1582 1585 15266215 all DT B-NP O
13 1586 1587 15266215 3 CD I-NP O
14 1588 1597 15266215 treatment NN I-NP O
15 1598 1604 15266215 groups NNS I-NP O
16 1605 1608 15266215 and CC B-PP O
17 1609 1615 15266215 across IN B-PP O
18 1616 1626 15266215 valdecoxib NN B-NP C406224
19 1627 1632 15266215 doses NNS I-NP O
20 1632 1633 15266215 . . O O

1 1634 1639 15266215 Short JJ B-NP O
2 1639 1640 15266215 - HYPH I-NP O
3 1641 1644 15266215 and CC I-NP O
4 1645 1657 15266215 intermediate JJ I-NP O
5 1657 1658 15266215 - HYPH I-NP O
6 1658 1662 15266215 term NN I-NP O
7 1663 1672 15266215 treatment NN I-NP O
8 1673 1677 15266215 with IN B-PP O
9 1678 1689 15266215 therapeutic JJ B-NP O
10 1690 1691 15266215 ( ( O O
11 1691 1693 15266215 10 CD B-NP O
12 1694 1696 15266215 or CC I-NP O
13 1697 1699 15266215 20 CD I-NP O
14 1700 1702 15266215 mg NN I-NP O
15 1703 1708 15266215 daily JJ I-NP O
16 1708 1709 15266215 ) ) O O
17 1710 1713 15266215 and CC O O
18 1714 1730 15266215 supratherapeutic JJ B-ADJP O
19 1731 1732 15266215 ( ( O O
20 1732 1734 15266215 40 CD B-NP O
21 1735 1737 15266215 or CC I-NP O
22 1738 1740 15266215 80 CD I-NP O
23 1741 1743 15266215 mg NN I-NP O
24 1744 1749 15266215 daily JJ I-NP O
25 1749 1750 15266215 ) ) O O
26 1751 1761 15266215 valdecoxib NN B-NP C406224
27 1762 1767 15266215 doses NNS I-NP O
28 1768 1771 15266215 was VBD B-VP O
29 1772 1775 15266215 not RB I-VP O
30 1776 1786 15266215 associated VBN I-VP O
31 1787 1791 15266215 with IN B-PP O
32 1792 1794 15266215 an DT B-NP O
33 1795 1804 15266215 increased VBN I-NP O
34 1805 1814 15266215 incidence NN I-NP O
35 1815 1817 15266215 of IN B-PP O
36 1818 1828 15266215 thrombotic JJ B-NP D013927
37 1829 1835 15266215 events NNS I-NP O
38 1836 1844 15266215 relative JJ B-ADVP O
39 1845 1847 15266215 to TO B-PP O
40 1848 1860 15266215 nonselective JJ B-NP O
41 1861 1867 15266215 NSAIDs NNS I-NP O
42 1868 1870 15266215 or CC O O
43 1871 1878 15266215 placebo NN B-NP O
44 1879 1881 15266215 in IN B-PP O
45 1882 1896 15266215 osteoarthritis NN B-NP D010003
46 1897 1900 15266215 and CC O O
47 1901 1911 15266215 rheumatoid JJ B-NP D001172
48 1912 1921 15266215 arthritis NN I-NP D001172
49 1922 1930 15266215 patients NNS I-NP O
50 1931 1933 15266215 in IN B-PP O
51 1934 1944 15266215 controlled VBN B-NP O
52 1945 1953 15266215 clinical JJ I-NP O
53 1954 1960 15266215 trials NNS I-NP O
54 1960 1961 15266215 . . O O

1 0 0 1564236 -DOCSTART- -X- -X- O

1 0 8 1564236 Relation NN B-NP O
2 9 11 1564236 of IN B-PP O
3 12 21 1564236 perfusion NN B-NP O
4 22 29 1564236 defects NNS I-NP O
5 30 38 1564236 observed VBN B-VP O
6 39 43 1564236 with IN B-PP O
7 44 54 1564236 myocardial JJ B-NP O
8 55 63 1564236 contrast NN I-NP O
9 64 80 1564236 echocardiography NN I-NP O
10 81 83 1564236 to TO B-PP O
11 84 87 1564236 the DT B-NP O
12 88 96 1564236 severity NN I-NP O
13 97 99 1564236 of IN B-PP O
14 100 108 1564236 coronary JJ B-NP D023921
15 109 117 1564236 stenosis NN I-NP D023921
16 117 118 1564236 : : O O
17 119 130 1564236 correlation NN B-NP O
18 131 135 1564236 with IN B-PP O
19 136 144 1564236 thallium NN B-NP D013793
20 144 145 1564236 - HYPH O O
21 145 148 1564236 201 CD B-NP O
22 149 155 1564236 single JJ I-NP O
23 155 156 1564236 - HYPH I-NP O
24 156 162 1564236 photon NN I-NP O
25 163 171 1564236 emission NN I-NP O
26 172 182 1564236 tomography NN I-NP O
27 182 183 1564236 . . O O
28 184 186 1564236 It PRP B-NP O
29 187 190 1564236 has VBZ B-VP O
30 191 195 1564236 been VBN I-VP O
31 196 206 1564236 previously RB I-VP O
32 207 212 1564236 shown VBN I-VP O
33 213 217 1564236 that IN B-SBAR O
34 218 228 1564236 myocardial JJ B-NP O
35 229 237 1564236 contrast NN I-NP O
36 238 254 1564236 echocardiography NN I-NP O
37 255 257 1564236 is VBZ B-VP O
38 258 259 1564236 a DT B-NP O
39 260 268 1564236 valuable JJ I-NP O
40 269 278 1564236 technique NN I-NP O
41 279 282 1564236 for IN B-PP O
42 283 294 1564236 delineating VBG B-VP O
43 295 302 1564236 regions NNS B-NP O
44 303 305 1564236 of IN B-PP O
45 306 316 1564236 myocardial JJ B-NP O
46 317 331 1564236 underperfusion NN I-NP O
47 332 341 1564236 secondary JJ B-ADJP O
48 342 344 1564236 to TO B-PP O
49 345 353 1564236 coronary JJ B-NP D054059
50 354 363 1564236 occlusion NN I-NP D054059
51 364 367 1564236 and CC B-PP O
52 368 370 1564236 to TO B-PP O
53 371 379 1564236 critical JJ B-NP O
54 380 388 1564236 coronary JJ I-NP D023921
55 389 397 1564236 stenoses NNS I-NP D023921
56 398 400 1564236 in IN B-PP O
57 401 404 1564236 the DT B-NP O
58 405 413 1564236 presence NN I-NP O
59 414 416 1564236 of IN B-PP O
60 417 426 1564236 hyperemic JJ B-NP D006940
61 427 438 1564236 stimulation NN I-NP O
62 438 439 1564236 . . O O

1 440 443 1564236 The DT B-NP O
2 444 447 1564236 aim NN I-NP O
3 448 450 1564236 of IN B-PP O
4 451 455 1564236 this DT B-NP O
5 456 461 1564236 study NN I-NP O
6 462 465 1564236 was VBD B-VP O
7 466 468 1564236 to TO B-VP O
8 469 478 1564236 determine VB I-VP O
9 479 486 1564236 whether IN B-SBAR O
10 487 497 1564236 myocardial JJ B-NP O
11 498 506 1564236 contrast NN I-NP O
12 507 523 1564236 echocardiography NN I-NP O
13 524 533 1564236 performed VBN B-VP O
14 534 538 1564236 with IN B-PP O
15 539 540 1564236 a DT B-NP O
16 541 547 1564236 stable JJ I-NP O
17 548 556 1564236 solution NN I-NP O
18 557 559 1564236 of IN B-PP O
19 560 569 1564236 sonicated VBN B-NP O
20 570 577 1564236 albumin NN I-NP O
21 578 583 1564236 could MD B-VP O
22 584 590 1564236 detect VB I-VP O
23 591 598 1564236 regions NNS B-NP O
24 599 601 1564236 of IN B-PP O
25 602 612 1564236 myocardial JJ B-NP O
26 613 627 1564236 underperfusion NN I-NP O
27 628 637 1564236 resulting VBG B-VP O
28 638 642 1564236 from IN B-PP O
29 643 650 1564236 various JJ B-NP O
30 651 658 1564236 degrees NNS I-NP O
31 659 661 1564236 of IN B-PP O
32 662 670 1564236 coronary JJ B-NP D023921
33 671 679 1564236 stenosis NN I-NP D023921
34 679 680 1564236 . . O O

1 681 684 1564236 The DT B-NP O
2 685 694 1564236 perfusion NN I-NP O
3 695 701 1564236 defect NN I-NP O
4 702 710 1564236 produced VBN B-VP O
5 711 713 1564236 in IN B-PP O
6 714 716 1564236 16 CD B-NP O
7 717 721 1564236 open JJ I-NP O
8 722 727 1564236 chest NN I-NP O
9 728 732 1564236 dogs NNS I-NP O
10 733 736 1564236 was VBD B-VP O
11 737 745 1564236 compared VBN I-VP O
12 746 750 1564236 with IN B-PP O
13 751 754 1564236 the DT B-NP O
14 755 763 1564236 anatomic JJ I-NP O
15 764 768 1564236 area NN I-NP O
16 769 771 1564236 at IN B-PP O
17 772 776 1564236 risk NN B-NP O
18 777 785 1564236 measured VBN B-VP O
19 786 788 1564236 by IN B-PP O
20 789 792 1564236 the DT B-NP O
21 793 803 1564236 postmortem JJ I-NP O
22 804 808 1564236 dual JJ I-NP O
23 808 809 1564236 - HYPH I-NP O
24 809 818 1564236 perfusion NN I-NP O
25 819 828 1564236 technique NN I-NP O
26 829 832 1564236 and CC B-PP O
27 833 837 1564236 with IN B-PP O
28 838 846 1564236 thallium NN B-NP D013793
29 846 847 1564236 - HYPH O O
30 847 850 1564236 201 CD B-NP O
31 851 857 1564236 single JJ I-NP O
32 857 858 1564236 - HYPH I-NP O
33 858 864 1564236 photon NN I-NP O
34 865 873 1564236 emission NN I-NP O
35 874 884 1564236 tomography NN I-NP O
36 885 886 1564236 ( ( O O
37 886 891 1564236 SPECT NN B-NP O
38 891 892 1564236 ) ) O O
39 892 893 1564236 . . O O

1 894 900 1564236 During IN B-PP O
2 901 902 1564236 a DT B-NP O
3 903 912 1564236 transient JJ I-NP O
4 913 914 1564236 ( ( O O
5 914 916 1564236 20 CD B-NP O
6 916 917 1564236 - HYPH I-NP O
7 917 918 1564236 s NNS I-NP O
8 918 919 1564236 ) ) O O
9 920 928 1564236 coronary JJ B-NP D054059
10 929 938 1564236 occlusion NN I-NP D054059
11 938 939 1564236 , , O O
12 940 941 1564236 a DT B-NP O
13 942 951 1564236 perfusion NN I-NP O
14 952 958 1564236 defect NN I-NP O
15 959 962 1564236 was VBD B-VP O
16 963 971 1564236 observed VBN I-VP O
17 972 976 1564236 with IN B-PP O
18 977 985 1564236 contrast NN B-NP O
19 986 1002 1564236 echocardiography NN I-NP O
20 1003 1005 1564236 in IN B-PP O
21 1006 1008 1564236 14 CD B-NP O
22 1009 1011 1564236 of IN B-PP O
23 1012 1015 1564236 the DT B-NP O
24 1016 1018 1564236 15 CD I-NP O
25 1019 1023 1564236 dogs NNS I-NP O
26 1024 1026 1564236 in IN B-PP O
27 1027 1032 1564236 which WDT B-NP O
28 1033 1036 1564236 the DT B-NP O
29 1037 1046 1564236 occlusion NN I-NP O
30 1047 1050 1564236 was VBD B-VP O
31 1051 1059 1564236 produced VBN I-VP O
32 1059 1060 1564236 . . O O

1 1061 1064 1564236 The DT B-NP O
2 1065 1074 1564236 perfusion NN I-NP O
3 1075 1081 1564236 defect NN I-NP O
4 1082 1092 1564236 correlated VBD B-VP O
5 1093 1106 1564236 significantly RB B-ADVP O
6 1107 1111 1564236 with IN B-PP O
7 1112 1115 1564236 the DT B-NP O
8 1116 1124 1564236 anatomic JJ I-NP O
9 1125 1129 1564236 area NN I-NP O
10 1130 1132 1564236 at IN B-PP O
11 1133 1137 1564236 risk NN B-NP O
12 1138 1139 1564236 ( ( O O
13 1139 1140 1564236 r NN B-NP O
14 1141 1142 1564236 = SYM B-VP O
15 1143 1147 1564236 0.74 CD B-NP O
16 1147 1148 1564236 ; : O O
17 1149 1150 1564236 p NN B-NP O
18 1151 1155 1564236 less JJR B-ADJP O
19 1156 1160 1564236 than IN B-PP O
20 1161 1166 1564236 0.002 CD B-NP O
21 1166 1167 1564236 ) ) O O
22 1167 1168 1564236 . . O O

1 1169 1175 1564236 During IN B-PP O
2 1176 1188 1564236 dipyridamole NN B-NP D004176
3 1188 1189 1564236 - HYPH B-NP O
4 1189 1196 1564236 induced VBN I-NP O
5 1197 1206 1564236 hyperemia NN I-NP D006940
6 1206 1207 1564236 , , O O
7 1208 1210 1564236 12 CD B-NP O
8 1211 1213 1564236 of IN B-PP O
9 1214 1217 1564236 the DT B-NP O
10 1218 1220 1564236 16 CD I-NP O
11 1221 1225 1564236 dogs NNS I-NP O
12 1226 1230 1564236 with IN B-PP O
13 1231 1232 1564236 a DT B-NP O
14 1233 1240 1564236 partial JJ I-NP O
15 1241 1249 1564236 coronary JJ I-NP D023921
16 1250 1258 1564236 stenosis NN I-NP D023921
17 1259 1262 1564236 had VBD B-VP O
18 1263 1264 1564236 a DT B-NP O
19 1265 1272 1564236 visible JJ I-NP O
20 1273 1277 1564236 area NN I-NP O
21 1278 1280 1564236 of IN B-PP O
22 1281 1294 1564236 hypoperfusion NN B-NP O
23 1295 1297 1564236 by IN B-PP O
24 1298 1306 1564236 contrast NN B-NP O
25 1307 1323 1564236 echocardiography NN I-NP O
26 1323 1324 1564236 . . O O

1 1325 1328 1564236 The DT B-NP O
2 1329 1333 1564236 four CD I-NP O
3 1334 1338 1564236 dogs NNS I-NP O
4 1339 1346 1564236 without IN B-PP O
5 1347 1348 1564236 a DT B-NP O
6 1349 1358 1564236 perfusion NN I-NP O
7 1359 1365 1564236 defect NN I-NP O
8 1366 1369 1564236 had VBD B-VP O
9 1370 1371 1564236 a DT B-NP O
10 1372 1380 1564236 stenosis NN I-NP O
11 1381 1385 1564236 that WDT B-NP O
12 1386 1394 1564236 resulted VBD B-VP O
13 1395 1397 1564236 in IN B-PP O
14 1398 1399 1564236 a DT B-NP O
15 1400 1404 1564236 mild JJ I-NP O
16 1405 1406 1564236 ( ( O O
17 1406 1408 1564236 0% CD B-NP O
18 1409 1411 1564236 to TO O O
19 1412 1415 1564236 50% CD O O
20 1415 1416 1564236 ) ) O O
21 1417 1426 1564236 reduction NN B-NP O
22 1427 1429 1564236 in IN B-PP O
23 1430 1442 1564236 dipyridamole NN B-NP D004176
24 1442 1443 1564236 - HYPH B-NP O
25 1443 1450 1564236 induced VBN I-NP O
26 1451 1460 1564236 hyperemia NN I-NP D006940
27 1460 1461 1564236 . . O O

1 1462 1465 1564236 The DT B-NP O
2 1466 1470 1564236 size NN I-NP O
3 1471 1473 1564236 of IN B-PP O
4 1474 1477 1564236 the DT B-NP O
5 1478 1487 1564236 perfusion NN I-NP O
6 1488 1494 1564236 defect NN I-NP O
7 1495 1501 1564236 during IN B-PP O
8 1502 1510 1564236 stenosis NN B-NP O
9 1511 1521 1564236 correlated VBD B-VP O
10 1522 1535 1564236 significantly RB B-ADVP O
11 1536 1540 1564236 with IN B-PP O
12 1541 1544 1564236 the DT B-NP O
13 1545 1553 1564236 anatomic JJ I-NP O
14 1554 1558 1564236 area NN I-NP O
15 1559 1561 1564236 at IN B-PP O
16 1562 1566 1564236 risk NN B-NP O
17 1567 1568 1564236 ( ( O O
18 1568 1569 1564236 r NN B-NP O
19 1570 1571 1564236 = SYM B-VP O
20 1572 1576 1564236 0.61 CD B-NP O
21 1576 1577 1564236 ; : O O
22 1578 1579 1564236 p NN B-NP O
23 1580 1581 1564236 = SYM B-VP O
24 1582 1586 1564236 0.02 CD B-NP O
25 1586 1587 1564236 ) ) O O
26 1587 1588 1564236 . . O O

1 1589 1597 1564236 Thallium NN B-NP D013793
2 1597 1598 1564236 - HYPH I-NP O
3 1598 1601 1564236 201 CD I-NP O
4 1602 1607 1564236 SPECT NN I-NP O
5 1608 1620 1564236 demonstrated VBD B-VP O
6 1621 1622 1564236 a DT B-NP O
7 1623 1632 1564236 perfusion NN I-NP O
8 1633 1639 1564236 defect NN I-NP O
9 1640 1642 1564236 in IN B-PP O
10 1643 1646 1564236 all DT B-NP O
11 1647 1649 1564236 14 CD I-NP O
12 1650 1654 1564236 dogs NNS I-NP O
13 1655 1663 1564236 analyzed VBN B-VP O
14 1664 1670 1564236 during IN B-PP O
15 1671 1683 1564236 dipyridamole NN B-NP D004176
16 1683 1684 1564236 - HYPH B-NP O
17 1684 1691 1564236 induced VBN I-NP O
18 1692 1701 1564236 hyperemia NN I-NP D006940
19 1701 1702 1564236 ; : O O
20 1703 1706 1564236 the DT B-NP O
21 1707 1711 1564236 size NN I-NP O
22 1712 1714 1564236 of IN B-PP O
23 1715 1718 1564236 the DT B-NP O
24 1719 1728 1564236 perfusion NN I-NP O
25 1729 1735 1564236 defect NN I-NP O
26 1736 1746 1564236 correlated VBD B-VP O
27 1747 1751 1564236 with IN B-PP O
28 1752 1755 1564236 the DT B-NP O
29 1756 1764 1564236 anatomic JJ I-NP O
30 1765 1769 1564236 area NN I-NP O
31 1770 1772 1564236 at IN B-PP O
32 1773 1777 1564236 risk NN B-NP O
33 1778 1779 1564236 ( ( O O
34 1779 1780 1564236 r NN B-NP O
35 1781 1782 1564236 = SYM B-VP O
36 1783 1787 1564236 0.58 CD B-NP O
37 1787 1788 1564236 ; : O O
38 1789 1790 1564236 p NN B-NP O
39 1791 1795 1564236 less JJR B-ADJP O
40 1796 1800 1564236 than IN B-PP O
41 1801 1805 1564236 0.03 CD B-NP O
42 1805 1806 1564236 ) ) O O
43 1807 1810 1564236 and CC O O
44 1811 1815 1564236 with IN B-PP O
45 1816 1819 1564236 the DT B-NP O
46 1820 1829 1564236 perfusion NN I-NP O
47 1830 1836 1564236 defect NN I-NP O
48 1837 1839 1564236 by IN B-PP O
49 1840 1848 1564236 contrast NN B-NP O
50 1849 1865 1564236 echocardiography NN I-NP O
51 1866 1867 1564236 ( ( O O
52 1867 1868 1564236 r NN B-NP O
53 1869 1870 1564236 = SYM B-VP O
54 1871 1875 1564236 0.58 CD B-NP O
55 1875 1876 1564236 ; : O O
56 1877 1878 1564236 p NN B-NP O
57 1879 1883 1564236 less JJR B-ADJP O
58 1884 1888 1564236 than IN B-PP O
59 1889 1893 1564236 0.03 CD B-NP O
60 1893 1894 1564236 ) ) O O
61 1894 1895 1564236 . . O O

1 1896 1900 1564236 Thus RB B-ADVP O
2 1900 1901 1564236 , , O O
3 1902 1912 1564236 myocardial JJ B-NP O
4 1913 1921 1564236 contrast NN I-NP O
5 1922 1938 1564236 echocardiography NN I-NP O
6 1939 1942 1564236 can MD B-VP O
7 1943 1945 1564236 be VB I-VP O
8 1946 1950 1564236 used VBN I-VP O
9 1951 1953 1564236 to TO B-VP O
10 1954 1963 1564236 visualize VB I-VP O
11 1964 1967 1564236 and CC I-VP O
12 1968 1978 1564236 quantitate VB I-VP O
13 1979 1982 1564236 the DT B-NP O
14 1983 1989 1564236 amount NN I-NP O
15 1990 1992 1564236 of IN B-PP O
16 1993 2004 1564236 jeopardized JJ B-NP O
17 2005 2015 1564236 myocardium NN I-NP O
18 2016 2022 1564236 during IN B-PP O
19 2023 2031 1564236 moderate JJ B-ADJP O
20 2032 2034 1564236 to TO B-PP O
21 2035 2041 1564236 severe JJ B-NP O
22 2042 2049 1564236 degrees NNS I-NP O
23 2050 2052 1564236 of IN B-PP O
24 2053 2061 1564236 coronary JJ B-NP D023921
25 2062 2070 1564236 stenosis NN I-NP D023921
26 2070 2071 1564236 . . O O

1 2072 2075 1564236 The DT B-NP O
2 2076 2083 1564236 results NNS I-NP O
3 2084 2092 1564236 obtained VBN B-VP O
4 2093 2097 1564236 show VBP B-VP O
5 2098 2099 1564236 a DT B-NP O
6 2100 2111 1564236 correlation NN I-NP O
7 2112 2116 1564236 with IN B-PP O
8 2117 2120 1564236 the DT B-NP O
9 2121 2129 1564236 anatomic JJ I-NP O
10 2130 2134 1564236 area NN I-NP O
11 2135 2137 1564236 at IN B-PP O
12 2138 2142 1564236 risk NN B-NP O
13 2143 2150 1564236 similar JJ B-ADJP O
14 2151 2153 1564236 to TO B-PP O
15 2154 2158 1564236 that DT B-NP O
16 2159 2167 1564236 obtained VBN B-VP O
17 2168 2172 1564236 with IN B-PP O
18 2173 2181 1564236 thallium NN B-NP D013793
19 2181 2182 1564236 - HYPH O O
20 2182 2185 1564236 201 CD B-NP O
21 2186 2191 1564236 SPECT NN I-NP O
22 2191 2192 1564236 . . O O

1 0 0 3686155 -DOCSTART- -X- -X- O

1 0 10 3686155 Postpartum NNP B-NP O
2 11 20 3686155 psychosis NN I-NP D011605
3 21 28 3686155 induced VBN B-VP O
4 29 31 3686155 by IN B-PP O
5 32 45 3686155 bromocriptine NN B-NP D001971
6 45 46 3686155 . . O O
7 47 50 3686155 Two CD B-NP O
8 51 63 3686155 multigravida JJ I-NP O
9 64 72 3686155 patients NNS I-NP O
10 73 77 3686155 with IN B-PP O
11 78 80 3686155 no DT B-NP O
12 81 86 3686155 prior JJ I-NP O
13 87 98 3686155 psychiatric JJ I-NP D001523
14 99 106 3686155 history NN I-NP O
15 107 111 3686155 were VBD B-VP O
16 112 116 3686155 seen VBN I-VP O
17 117 121 3686155 with IN B-PP O
18 122 132 3686155 postpartum NN B-NP O
19 133 142 3686155 psychosis NN I-NP D011605
20 142 143 3686155 , , O O
21 144 150 3686155 having VBG B-VP O
22 151 159 3686155 received VBN I-VP O
23 160 173 3686155 bromocriptine NN B-NP D001971
24 174 177 3686155 for IN B-PP O
25 178 188 3686155 inhibition NN B-NP D007775
26 189 191 3686155 of IN B-PP D007775
27 192 201 3686155 lactation NN B-NP D007775
28 201 202 3686155 . . O O

1 203 216 3686155 Bromocriptine NN B-NP D001971
2 217 222 3686155 given VBN B-PP O
3 223 225 3686155 in IN B-PP O
4 226 230 3686155 high JJ B-NP O
5 231 236 3686155 doses NNS I-NP O
6 237 240 3686155 has VBZ B-VP O
7 241 245 3686155 been VBN I-VP O
8 246 256 3686155 associated VBN I-VP O
9 257 261 3686155 with IN B-PP O
10 262 271 3686155 psychosis NN B-NP D011605
11 272 274 3686155 in IN B-PP O
12 275 283 3686155 patients NNS B-NP O
13 284 293 3686155 receiving VBG B-VP O
14 294 297 3686155 the DT B-NP O
15 298 302 3686155 drug NN I-NP O
16 303 306 3686155 for IN B-PP O
17 307 318 3686155 Parkinson's NNP B-NP D010300
18 319 326 3686155 disease NN I-NP D010300
19 326 327 3686155 . . O O

1 328 333 3686155 These DT B-NP O
2 334 339 3686155 cases NNS I-NP O
3 340 351 3686155 demonstrate VBP B-VP O
4 352 356 3686155 that IN B-SBAR O
5 357 370 3686155 bromocriptine NN B-NP D001971
6 371 374 3686155 may MD B-VP O
7 375 380 3686155 cause VB I-VP O
8 381 390 3686155 psychosis NN B-NP D011605
9 391 395 3686155 even RB B-ADVP O
10 396 400 3686155 when WRB I-ADVP O
11 401 406 3686155 given VBN B-PP O
12 407 409 3686155 in IN B-PP O
13 410 413 3686155 low JJ B-NP O
14 414 419 3686155 doses NNS I-NP O
15 419 420 3686155 . . O O

1 0 0 11284996 -DOCSTART- -X- -X- O

1 0 10 11284996 Calcitonin NN B-NP O
2 11 15 11284996 gene NN I-NP O
3 15 16 11284996 - HYPH B-NP O
4 16 23 11284996 related VBN I-NP O
5 24 31 11284996 peptide NN I-NP O
6 32 38 11284996 levels NNS I-NP O
7 39 45 11284996 during IN B-PP O
8 46 52 11284996 nitric JJ B-NP D009569
9 53 58 11284996 oxide NN I-NP D009569
10 58 59 11284996 - HYPH B-NP O
11 59 66 11284996 induced VBN I-NP O
12 67 75 11284996 headache NN I-NP D006261
13 76 78 11284996 in IN B-PP O
14 79 87 11284996 patients NNS B-NP O
15 88 92 11284996 with IN B-PP O
16 93 100 11284996 chronic JJ B-NP O
17 101 108 11284996 tension NN I-NP D018781
18 108 109 11284996 - HYPH I-NP D018781
19 109 113 11284996 type NN I-NP D018781
20 114 122 11284996 headache NN I-NP D018781
21 122 123 11284996 . . O O
22 124 126 11284996 It PRP B-NP O
23 127 130 11284996 has VBZ B-VP O
24 131 135 11284996 been VBN I-VP O
25 136 144 11284996 proposed VBN I-VP O
26 145 149 11284996 that IN B-SBAR O
27 150 156 11284996 nitric JJ B-NP D009569
28 157 162 11284996 oxide NN I-NP D009569
29 163 164 11284996 ( ( O O
30 164 166 11284996 NO NN B-NP D009569
31 166 167 11284996 ) ) O O
32 168 175 11284996 induced VBD B-VP O
33 176 184 11284996 headache NN B-NP D006261
34 185 187 11284996 in IN B-PP O
35 188 195 11284996 primary JJ B-NP D051270
36 196 205 11284996 headaches NNS I-NP D051270
37 206 209 11284996 may MD B-VP O
38 210 212 11284996 be VB I-VP O
39 213 223 11284996 associated VBN I-VP O
40 224 228 11284996 with IN B-PP O
41 229 236 11284996 release NN B-NP O
42 237 239 11284996 of IN B-PP O
43 240 250 11284996 calcitonin NN B-NP O
44 251 255 11284996 gene NN I-NP O
45 255 256 11284996 - HYPH B-VP O
46 256 263 11284996 related VBN B-NP O
47 264 271 11284996 peptide NN I-NP O
48 272 273 11284996 ( ( O O
49 273 277 11284996 CGRP NN B-NP O
50 277 278 11284996 ) ) O O
51 278 279 11284996 . . O O

1 280 282 11284996 In IN B-PP O
2 283 286 11284996 the DT B-NP O
3 287 294 11284996 present JJ I-NP O
4 295 300 11284996 study NN I-NP O
5 301 303 11284996 we PRP B-NP O
6 304 309 11284996 aimed VBD B-VP O
7 310 312 11284996 to TO I-VP O
8 313 324 11284996 investigate VB I-VP O
9 325 331 11284996 plasma NN B-NP O
10 332 338 11284996 levels NNS I-NP O
11 339 341 11284996 of IN B-PP O
12 342 346 11284996 CGRP NN B-NP O
13 347 353 11284996 during IN B-PP O
14 354 362 11284996 headache NN B-NP D006261
15 363 370 11284996 induced VBN B-VP O
16 371 373 11284996 by IN B-PP O
17 374 377 11284996 the DT B-NP O
18 378 380 11284996 NO NN I-NP D009569
19 381 386 11284996 donor NN I-NP O
20 387 395 11284996 glyceryl NN I-NP D005996
21 396 406 11284996 trinitrate NN I-NP D005996
22 407 408 11284996 ( ( O O
23 408 411 11284996 GTN NN B-NP D005996
24 411 412 11284996 ) ) O O
25 413 415 11284996 in IN B-PP O
26 416 418 11284996 16 CD B-NP O
27 419 427 11284996 patients NNS I-NP O
28 428 432 11284996 with IN B-PP O
29 433 440 11284996 chronic JJ B-NP O
30 441 448 11284996 tension NN I-NP D018781
31 448 449 11284996 - HYPH I-NP D018781
32 449 453 11284996 type NN I-NP D018781
33 454 462 11284996 headache NN I-NP D018781
34 463 466 11284996 and CC O O
35 467 469 11284996 16 CD B-NP O
36 470 477 11284996 healthy JJ I-NP O
37 478 486 11284996 controls NNS I-NP O
38 486 487 11284996 . . O O

1 488 491 11284996 The DT B-NP O
2 492 500 11284996 subjects NNS I-NP O
3 501 505 11284996 were VBD B-VP O
4 506 514 11284996 randomly RB I-VP O
5 515 524 11284996 allocated VBN I-VP O
6 525 527 11284996 to TO I-VP O
7 528 535 11284996 receive VB I-VP O
8 536 539 11284996 0.5 CD B-NP O
9 540 546 11284996 microg NN I-NP O
10 546 547 11284996 / SYM B-NP O
11 547 549 11284996 kg NN I-NP O
12 549 550 11284996 / SYM O O
13 550 553 11284996 min NN B-NP O
14 554 557 11284996 GTN NN I-NP D005996
15 558 560 11284996 or CC O O
16 561 568 11284996 placebo NN B-NP O
17 569 573 11284996 over IN B-PP O
18 574 576 11284996 20 CD B-NP O
19 577 580 11284996 min NN I-NP O
20 581 583 11284996 on IN B-PP O
21 584 587 11284996 two CD B-NP O
22 588 596 11284996 headache NN I-NP D006261
23 596 597 11284996 - HYPH O O
24 597 601 11284996 free JJ B-NP O
25 602 606 11284996 days NNS I-NP O
26 606 607 11284996 . . O O

1 608 613 11284996 Blood NN B-NP O
2 614 621 11284996 samples NNS I-NP O
3 622 626 11284996 were VBD B-VP O
4 627 636 11284996 collected VBN I-VP O
5 637 639 11284996 at IN B-PP O
6 640 648 11284996 baseline NN B-NP O
7 648 649 11284996 , , O O
8 650 652 11284996 10 CD B-NP O
9 652 653 11284996 , , I-NP O
10 654 656 11284996 20 CD I-NP O
11 657 660 11284996 and CC I-NP O
12 661 663 11284996 60 CD I-NP O
13 664 667 11284996 min NN I-NP O
14 668 673 11284996 after IN B-PP O
15 674 679 11284996 start NN B-NP O
16 680 682 11284996 of IN B-PP O
17 683 691 11284996 infusion NN B-NP O
18 691 692 11284996 . . O O

1 693 697 11284996 Both DT B-NP O
2 698 706 11284996 patients NNS I-NP O
3 707 710 11284996 and CC I-NP O
4 711 719 11284996 controls NNS I-NP O
5 720 729 11284996 developed VBD B-VP O
6 730 743 11284996 significantly RB B-NP O
7 744 752 11284996 stronger JJR I-NP O
8 753 762 11284996 immediate JJ I-NP O
9 763 771 11284996 headache NN I-NP D006261
10 772 774 11284996 on IN B-PP O
11 775 778 11284996 the DT B-NP O
12 779 782 11284996 GTN NN I-NP D005996
13 783 786 11284996 day NN I-NP O
14 787 791 11284996 than IN B-PP O
15 792 794 11284996 on IN B-PP O
16 795 798 11284996 the DT B-NP O
17 799 806 11284996 placebo NN I-NP O
18 807 810 11284996 day NN I-NP O
19 811 814 11284996 and CC O O
20 815 818 11284996 the DT B-NP O
21 819 827 11284996 headache NN I-NP D006261
22 828 831 11284996 was VBD B-VP O
23 832 845 11284996 significantly RB B-ADJP O
24 846 850 11284996 more RBR I-ADJP O
25 851 861 11284996 pronounced JJ I-ADJP O
26 862 864 11284996 in IN B-PP O
27 865 873 11284996 patients NNS B-NP O
28 874 878 11284996 than IN B-PP O
29 879 881 11284996 in IN B-PP O
30 882 890 11284996 controls NNS B-NP O
31 890 891 11284996 . . O O

1 892 897 11284996 There EX B-NP O
2 898 901 11284996 was VBD B-VP O
3 902 904 11284996 no DT B-NP O
4 905 915 11284996 difference NN I-NP O
5 916 923 11284996 between IN B-PP O
6 924 927 11284996 the DT B-NP O
7 928 932 11284996 area NN I-NP O
8 933 938 11284996 under IN B-PP O
9 939 942 11284996 the DT B-NP O
10 943 947 11284996 CGRP NN I-NP O
11 948 953 11284996 curve NN I-NP O
12 954 955 11284996 ( ( O O
13 955 962 11284996 AUCCGRP NN B-NP O
14 962 963 11284996 ) ) O O
15 964 966 11284996 on IN B-PP O
16 967 970 11284996 GTN NN B-NP D005996
17 971 973 11284996 vs NNS I-NP O
18 973 974 11284996 . . O O
19 975 982 11284996 placebo NN B-NP O
20 983 986 11284996 day NN I-NP O
21 987 989 11284996 in IN B-PP O
22 990 996 11284996 either CC O O
23 997 1005 11284996 patients NNS B-NP O
24 1006 1007 11284996 ( ( O O
25 1007 1008 11284996 P NN B-NP O
26 1008 1009 11284996 = SYM B-VP O
27 1009 1013 11284996 0.65 CD B-NP O
28 1013 1014 11284996 ) ) O O
29 1015 1017 11284996 or CC O O
30 1018 1026 11284996 controls NNS B-NP O
31 1027 1028 11284996 ( ( O O
32 1028 1029 11284996 P NN B-NP O
33 1029 1030 11284996 = SYM B-VP O
34 1030 1034 11284996 0.48 CD B-NP O
35 1034 1035 11284996 ) ) O O
36 1035 1036 11284996 . . O O

1 1037 1040 11284996 The DT B-NP O
2 1041 1048 11284996 AUCCGRP NN I-NP O
3 1049 1057 11284996 recorded VBN B-VP O
4 1058 1060 11284996 on IN B-PP O
5 1061 1064 11284996 the DT B-NP O
6 1065 1068 11284996 GTN NN I-NP D005996
7 1069 1072 11284996 day NN I-NP O
8 1073 1076 11284996 did VBD B-VP O
9 1077 1080 11284996 not RB I-VP O
10 1081 1087 11284996 differ VB I-VP O
11 1088 1095 11284996 between IN B-PP O
12 1096 1104 11284996 patients NNS B-NP O
13 1105 1108 11284996 and CC I-NP O
14 1109 1117 11284996 controls NNS I-NP O
15 1118 1119 11284996 ( ( O O
16 1119 1120 11284996 P NN B-NP O
17 1120 1121 11284996 = SYM B-VP O
18 1121 1125 11284996 0.36 CD B-NP O
19 1125 1126 11284996 ) ) O O
20 1126 1127 11284996 . . O O

1 1128 1132 11284996 Both DT B-NP O
2 1133 1135 11284996 in IN B-PP O
3 1136 1144 11284996 patients NNS B-NP O
4 1145 1148 11284996 and CC I-NP O
5 1149 1157 11284996 controls NNS I-NP O
6 1157 1158 11284996 , , O O
7 1159 1163 11284996 CGRP NN B-NP O
8 1164 1170 11284996 levels NNS I-NP O
9 1171 1178 11284996 changed VBD B-VP O
10 1179 1192 11284996 significantly RB B-ADVP O
11 1193 1197 11284996 over IN B-PP O
12 1198 1202 11284996 time NN B-NP O
13 1202 1203 11284996 , , O O
14 1204 1206 11284996 on IN B-PP O
15 1207 1211 11284996 both CC O O
16 1212 1215 11284996 the DT B-NP O
17 1216 1219 11284996 GTN NN I-NP D005996
18 1220 1223 11284996 and CC I-NP O
19 1224 1231 11284996 placebo NN I-NP O
20 1232 1236 11284996 days NNS I-NP O
21 1237 1238 11284996 ( ( O O
22 1238 1239 11284996 P NN B-NP O
23 1240 1241 11284996 < SYM O O
24 1242 1246 11284996 0.05 CD B-NP O
25 1246 1247 11284996 ) ) O O
26 1247 1248 11284996 . . O O

1 1249 1252 11284996 The DT B-NP O
2 1253 1260 11284996 present JJ I-NP O
3 1261 1266 11284996 study NN I-NP O
4 1267 1276 11284996 indicates VBZ B-VP O
5 1277 1281 11284996 that IN B-SBAR O
6 1282 1284 11284996 NO NN B-NP D009569
7 1284 1285 11284996 - HYPH B-NP O
8 1285 1292 11284996 induced VBN I-NP O
9 1293 1302 11284996 immediate JJ I-NP O
10 1303 1311 11284996 headache NN I-NP D006261
11 1312 1314 11284996 is VBZ B-VP O
12 1315 1318 11284996 not RB I-VP O
13 1319 1329 11284996 associated VBN I-VP O
14 1330 1334 11284996 with IN B-PP O
15 1335 1342 11284996 release NN B-NP O
16 1343 1345 11284996 of IN B-PP O
17 1346 1350 11284996 CGRP NN B-NP O
18 1350 1351 11284996 . . O O

1 0 0 12691807 -DOCSTART- -X- -X- O

1 0 8 12691807 Levodopa NN B-NP D007980
2 8 9 12691807 - HYPH O O
3 9 16 12691807 induced VBN B-NP O
4 17 30 12691807 oromandibular JJ I-NP O
5 31 39 12691807 dystonia NN I-NP D004421
6 40 42 12691807 in IN B-PP O
7 43 54 12691807 progressive JJ B-NP D013494
8 55 67 12691807 supranuclear JJ I-NP D013494
9 68 73 12691807 palsy NN I-NP D013494
10 73 74 12691807 . . I-NP O
11 75 83 12691807 Levodopa NN I-NP D007980
12 83 84 12691807 - HYPH B-NP O
13 84 91 12691807 induced VBN I-NP O
14 92 103 12691807 dyskinesias NNS I-NP D004409
15 104 108 12691807 have VBP B-VP O
16 109 113 12691807 been VBN I-VP O
17 114 122 12691807 reported VBN I-VP O
18 123 125 12691807 in IN B-PP O
19 126 137 12691807 Parkinson's NNS B-NP D010300
20 138 145 12691807 disease NN I-NP D010300
21 146 149 12691807 and CC O O
22 150 158 12691807 multiple JJ B-NP D019578
23 159 165 12691807 system NN I-NP D019578
24 166 173 12691807 atrophy NN I-NP D019578
25 173 174 12691807 . . O O

1 175 182 12691807 Cranial JJ B-NP O
2 183 192 12691807 dystonias NNS I-NP D004421
3 193 196 12691807 are VBP B-VP O
4 197 201 12691807 rare JJ B-ADJP O
5 202 204 12691807 in IN B-PP O
6 205 213 12691807 patients NNS B-NP O
7 214 218 12691807 with IN B-PP O
8 219 230 12691807 progressive JJ B-NP D013494
9 231 243 12691807 supranuclear JJ I-NP D013494
10 244 249 12691807 palsy NN I-NP D013494
11 250 251 12691807 ( ( O O
12 251 254 12691807 PSP NN B-NP D013494
13 254 255 12691807 ) ) O O
14 255 256 12691807 . . O O

1 257 259 12691807 In IN B-PP O
2 260 264 12691807 this DT B-NP O
3 265 271 12691807 report NN I-NP O
4 272 274 12691807 we PRP B-NP O
5 275 283 12691807 describe VBP B-VP O
6 284 286 12691807 an DT B-NP O
7 287 294 12691807 unusual JJ I-NP O
8 295 299 12691807 case NN I-NP O
9 300 302 12691807 of IN B-PP O
10 303 313 12691807 reversible JJ B-NP O
11 314 322 12691807 levodopa NN I-NP D007980
12 322 323 12691807 - HYPH O O
13 323 330 12691807 induced VBN B-NP O
14 331 344 12691807 Oromandibular JJ I-NP D008538
15 345 353 12691807 dystonia NN I-NP D008538
16 354 355 12691807 ( ( O O
17 355 358 12691807 OMD NN B-NP D008538
18 358 359 12691807 ) ) O O
19 360 362 12691807 in IN B-PP O
20 363 364 12691807 a DT B-NP O
21 365 368 12691807 PSP NN I-NP D013494
22 369 376 12691807 patient NN I-NP O
23 377 379 12691807 to TO B-VP O
24 380 389 12691807 highlight VB I-VP O
25 390 393 12691807 the DT B-NP O
26 394 404 12691807 importance NN I-NP O
27 405 407 12691807 of IN B-PP O
28 408 419 12691807 recognizing VBG B-VP O
29 420 424 12691807 this DT B-NP O
30 425 429 12691807 drug NN I-NP O
31 430 437 12691807 related JJ I-NP O
32 438 450 12691807 complication NN I-NP O
33 451 453 12691807 in IN B-PP O
34 454 457 12691807 the DT B-NP O
35 458 468 12691807 management NN I-NP O
36 469 471 12691807 of IN B-PP O
37 472 475 12691807 PSP NN B-NP D013494
38 475 476 12691807 , , O O
39 477 480 12691807 and CC O O
40 481 488 12691807 discuss VBP B-VP O
41 489 492 12691807 the DT B-NP O
42 493 501 12691807 possible JJ I-NP O
43 502 512 12691807 underlying VBG I-NP O
44 513 528 12691807 pathophysiology NN I-NP O
45 528 529 12691807 . . O O

1 0 0 11195262 -DOCSTART- -X- -X- O

1 0 12 11195262 Contribution NN B-NP O
2 13 15 11195262 of IN B-PP O
3 16 22 11195262 sodium NN B-NP D014635
4 23 32 11195262 valproate NN I-NP D014635
5 33 35 11195262 to TO B-PP O
6 36 39 11195262 the DT B-NP O
7 40 48 11195262 syndrome NN I-NP D007177
8 49 51 11195262 of IN B-PP D007177
9 52 65 11195262 inappropriate JJ B-NP D007177
10 66 75 11195262 secretion NN I-NP D007177
11 76 78 11195262 of IN B-PP D007177
12 79 91 11195262 antidiuretic JJ B-NP D007177
13 92 99 11195262 hormone NN I-NP D007177
14 99 100 11195262 . . O O
15 101 103 11195262 We PRP B-NP O
16 104 110 11195262 report VBP B-VP O
17 111 114 11195262 the DT B-NP O
18 115 119 11195262 case NN I-NP O
19 120 122 11195262 of IN B-PP O
20 123 124 11195262 a DT B-NP O
21 125 127 11195262 62 CD I-NP O
22 127 128 11195262 - HYPH I-NP O
23 128 132 11195262 year NN I-NP O
24 132 133 11195262 - HYPH B-NP O
25 133 136 11195262 old JJ I-NP O
26 137 140 11195262 man NN I-NP O
27 141 144 11195262 who WP B-NP O
28 145 148 11195262 was VBD B-VP O
29 149 161 11195262 administered VBN I-VP O
30 162 168 11195262 sodium NN B-NP D014635
31 169 178 11195262 valproate NN I-NP D014635
32 179 180 11195262 ( ( O O
33 180 183 11195262 VPA NN B-NP D014635
34 183 184 11195262 ) ) O O
35 185 188 11195262 and CC O O
36 189 192 11195262 who WP B-NP O
37 193 205 11195262 subsequently RB B-ADVP O
38 206 215 11195262 developed VBD B-VP O
39 216 219 11195262 the DT B-NP O
40 220 228 11195262 syndrome NN I-NP D007177
41 229 231 11195262 of IN B-PP D007177
42 232 245 11195262 inappropriate JJ B-NP D007177
43 246 255 11195262 secretion NN I-NP D007177
44 256 258 11195262 of IN B-PP D007177
45 259 271 11195262 antidiuretic JJ B-NP D007177
46 272 279 11195262 hormone NN I-NP D007177
47 280 281 11195262 ( ( O O
48 281 286 11195262 SIADH NN B-NP D007177
49 286 287 11195262 ) ) O O
50 287 288 11195262 . . O O

1 289 291 11195262 He PRP B-NP O
2 292 295 11195262 had VBD B-VP O
3 296 300 11195262 been VBN I-VP O
4 301 307 11195262 taking VBG I-VP O
5 308 311 11195262 VPA NN B-NP D014635
6 312 315 11195262 for IN B-PP O
7 316 325 11195262 treatment NN B-NP O
8 326 328 11195262 of IN B-PP O
9 329 339 11195262 idiopathic JJ B-NP O
10 340 351 11195262 generalized VBN I-NP O
11 352 357 11195262 tonic JJ I-NP D004830
12 357 358 11195262 - HYPH I-NP D004830
13 358 364 11195262 clonic JJ I-NP D004830
14 365 376 11195262 convulsions NNS I-NP D004830
15 377 382 11195262 since IN B-SBAR O
16 383 385 11195262 he PRP B-NP O
17 386 389 11195262 was VBD B-VP O
18 390 392 11195262 56 CD B-NP O
19 393 398 11195262 years NNS I-NP O
20 399 402 11195262 old JJ B-ADJP O
21 402 403 11195262 . . O O

1 404 409 11195262 After IN B-PP O
2 410 422 11195262 substituting VBG B-VP O
3 423 426 11195262 VPA NN B-NP D014635
4 427 431 11195262 with IN B-PP O
5 432 442 11195262 zonisamide NN B-NP C022189
6 442 443 11195262 , , O O
7 444 447 11195262 the DT B-NP O
8 448 453 11195262 serum NN I-NP O
9 454 460 11195262 sodium NN I-NP D012964
10 461 466 11195262 level NN I-NP O
11 467 475 11195262 returned VBD B-VP O
12 476 478 11195262 to TO B-PP O
13 479 485 11195262 normal JJ B-NP O
14 485 486 11195262 . . O O

1 487 489 11195262 We PRP B-NP O
2 490 498 11195262 consider VBP B-VP O
3 499 503 11195262 this DT B-NP O
4 504 511 11195262 episode NN I-NP O
5 512 514 11195262 of IN B-PP O
6 515 520 11195262 SIADH NN B-NP D007177
7 521 523 11195262 to TO B-VP O
8 524 526 11195262 be VB I-VP O
9 527 530 11195262 the DT B-NP O
10 531 537 11195262 result NN I-NP O
11 538 540 11195262 of IN B-PP O
12 541 542 11195262 a DT B-NP O
13 543 554 11195262 combination NN I-NP O
14 555 557 11195262 of IN B-PP O
15 558 565 11195262 factors NNS B-NP O
16 566 575 11195262 including VBG B-PP O
17 576 577 11195262 a DT B-NP O
18 578 586 11195262 weakness NN I-NP D002493
19 587 589 11195262 of IN B-PP D002493
20 590 593 11195262 the DT B-NP D002493
21 594 601 11195262 central JJ I-NP D002493
22 602 609 11195262 nervous JJ I-NP D002493
23 610 616 11195262 system NN I-NP D002493
24 617 620 11195262 and CC O O
25 621 624 11195262 the DT B-NP O
26 625 629 11195262 long JJ I-NP O
27 629 630 11195262 - HYPH I-NP O
28 630 634 11195262 term NN I-NP O
29 635 649 11195262 administration NN I-NP O
30 650 652 11195262 of IN B-PP O
31 653 656 11195262 VPA NN B-NP D014635
32 656 657 11195262 . . O O

1 0 0 1300436 -DOCSTART- -X- -X- O

1 0 9 1300436 Potential JJ B-NP O
2 10 21 1300436 deleterious JJ I-NP O
3 22 28 1300436 effect NN I-NP O
4 29 31 1300436 of IN B-PP O
5 32 42 1300436 furosemide NN B-NP D005665
6 43 45 1300436 in IN B-PP O
7 46 59 1300436 radiocontrast NN B-NP O
8 60 71 1300436 nephropathy NN I-NP D007674
9 71 72 1300436 . . O O
10 73 76 1300436 The DT B-NP O
11 77 84 1300436 purpose NN I-NP O
12 85 87 1300436 of IN B-PP O
13 88 91 1300436 the DT B-NP O
14 92 97 1300436 study NN I-NP O
15 98 101 1300436 was VBD B-VP O
16 102 104 1300436 to TO B-VP O
17 105 114 1300436 determine VB I-VP O
18 115 118 1300436 the DT B-NP O
19 119 127 1300436 efficacy NN I-NP O
20 128 130 1300436 of IN B-PP O
21 131 141 1300436 furosemide NN B-NP D005665
22 142 144 1300436 in IN B-PP O
23 145 153 1300436 addition NN B-NP O
24 154 156 1300436 to TO B-PP O
25 157 168 1300436 intravenous JJ B-NP O
26 169 175 1300436 fluids NNS I-NP O
27 176 178 1300436 in IN B-PP O
28 179 182 1300436 the DT B-NP O
29 183 193 1300436 prevention NN I-NP O
30 194 196 1300436 of IN B-PP O
31 197 210 1300436 radiocontrast NN B-NP O
32 211 222 1300436 nephropathy NN I-NP D007674
33 222 223 1300436 . . O O

1 224 226 1300436 18 CD B-NP O
2 227 235 1300436 patients NNS I-NP O
3 235 236 1300436 , , O O
4 237 245 1300436 referred VBD B-VP O
5 246 248 1300436 to TO B-PP O
6 249 250 1300436 a DT B-NP O
7 251 264 1300436 radiocontrast NN I-NP O
8 265 270 1300436 study NN I-NP O
9 270 271 1300436 , , O O
10 272 282 1300436 considered VBN B-VP O
11 283 285 1300436 at IN B-PP O
12 286 290 1300436 risk NN B-NP O
13 291 298 1300436 because IN B-PP O
14 299 301 1300436 of IN I-PP O
15 302 313 1300436 preexisting VBG B-VP O
16 314 319 1300436 renal JJ B-NP D051437
17 320 333 1300436 insufficiency NN I-NP D051437
18 333 334 1300436 , , O O
19 335 339 1300436 were VBD B-VP O
20 340 348 1300436 enrolled VBN I-VP O
21 349 351 1300436 in IN B-PP O
22 352 353 1300436 a DT B-NP O
23 354 365 1300436 prospective JJ I-NP O
24 365 366 1300436 , , I-NP O
25 367 377 1300436 randomized VBN I-NP O
26 377 378 1300436 , , I-NP O
27 379 389 1300436 controlled VBN I-NP O
28 390 395 1300436 trial NN I-NP O
29 395 396 1300436 , , O O
30 397 406 1300436 performed VBN B-VP O
31 407 409 1300436 at IN B-PP O
32 410 413 1300436 the DT B-NP O
33 414 423 1300436 secondary JJ I-NP O
34 424 428 1300436 care NN I-NP O
35 429 435 1300436 center NN I-NP O
36 436 438 1300436 of IN B-PP O
37 439 440 1300436 a DT B-NP O
38 441 446 1300436 1,100 CD I-NP O
39 446 447 1300436 - HYPH I-NP O
40 447 450 1300436 bed NN I-NP O
41 451 458 1300436 private JJ I-NP O
42 459 469 1300436 university NN I-NP O
43 470 478 1300436 hospital NN I-NP O
44 478 479 1300436 . . O O

1 480 482 1300436 In IN B-PP O
2 483 491 1300436 addition NN B-NP O
3 492 494 1300436 to TO B-PP O
4 495 501 1300436 fluids NNS B-NP O
5 501 502 1300436 , , O O
6 503 506 1300436 the DT B-NP O
7 507 516 1300436 treatment NN I-NP O
8 517 522 1300436 group NN I-NP O
9 523 531 1300436 received VBD B-VP O
10 532 542 1300436 furosemide NN B-NP D005665
11 543 544 1300436 ( ( O O
12 544 548 1300436 mean JJ B-NP O
13 549 553 1300436 dose NN I-NP O
14 554 557 1300436 110 CD I-NP O
15 558 560 1300436 mg NN I-NP O
16 560 561 1300436 ) ) O O
17 562 575 1300436 intravenously RB B-NP O
18 576 578 1300436 30 CD I-NP O
19 579 582 1300436 min NN I-NP O
20 583 588 1300436 prior JJ B-ADJP O
21 589 591 1300436 to TO B-PP O
22 592 595 1300436 the DT B-NP O
23 596 605 1300436 injection NN I-NP O
24 606 608 1300436 of IN B-PP O
25 609 617 1300436 contrast NN B-NP O
26 618 626 1300436 material NN I-NP O
27 626 627 1300436 . . O O

1 628 631 1300436 The DT B-NP O
2 632 639 1300436 control NN I-NP O
3 640 645 1300436 group NN I-NP O
4 646 654 1300436 received VBD B-VP O
5 655 661 1300436 fluids NNS B-NP O
6 662 663 1300436 ( ( O O
7 663 667 1300436 mean NN B-NP O
8 668 669 1300436 3 CD I-NP O
9 670 676 1300436 liters NNS I-NP O
10 676 677 1300436 ) ) O O
11 677 678 1300436 . . O O

1 679 691 1300436 Radiological JJ B-NP O
2 692 699 1300436 studies NNS I-NP O
3 700 704 1300436 were VBD B-VP O
4 705 711 1300436 mostly RB B-ADVP O
5 712 725 1300436 angiographies NNS B-NP O
6 726 735 1300436 performed VBN B-VP O
7 736 740 1300436 with IN B-PP O
8 741 745 1300436 both CC O O
9 746 751 1300436 ionic JJ O O
10 752 755 1300436 and CC O O
11 756 759 1300436 non AFX B-NP O
12 759 760 1300436 - HYPH I-NP O
13 760 765 1300436 ionic JJ I-NP O
14 766 774 1300436 contrast NN I-NP O
15 775 783 1300436 material NN I-NP O
16 783 784 1300436 , , O O
17 785 787 1300436 at IN B-PP O
18 788 790 1300436 an DT B-NP O
19 791 798 1300436 average JJ I-NP O
20 799 803 1300436 dose NN I-NP O
21 804 806 1300436 of IN B-PP O
22 807 810 1300436 245 CD B-NP O
23 811 813 1300436 ml NN I-NP O
24 813 814 1300436 . . O O

1 815 820 1300436 Renal JJ B-NP D058186
2 821 829 1300436 function NN I-NP D058186
3 830 843 1300436 significantly RB B-VP D058186
4 844 856 1300436 deteriorated VBN I-VP D058186
5 857 859 1300436 in IN B-PP O
6 860 863 1300436 the DT B-NP O
7 864 869 1300436 group NN I-NP O
8 870 880 1300436 pretreated VBN B-VP O
9 881 885 1300436 with IN B-PP O
10 886 896 1300436 furosemide NN B-NP D005665
11 897 898 1300436 ( ( O O
12 898 899 1300436 p NN B-NP O
13 900 901 1300436 < JJR B-NP O
14 902 907 1300436 0.005 CD I-NP O
15 908 910 1300436 by IN B-PP O
16 911 916 1300436 ANOVA NN B-NP O
17 916 917 1300436 ) ) O O
18 917 918 1300436 , , O O
19 919 923 1300436 with IN B-PP O
20 924 925 1300436 a DT B-NP O
21 926 930 1300436 rise NN I-NP O
22 931 933 1300436 in IN B-PP O
23 934 939 1300436 serum NN B-NP O
24 940 950 1300436 creatinine NN I-NP D003404
25 951 955 1300436 from IN B-PP O
26 956 959 1300436 145 CD B-NP O
27 960 961 1300436 + SYM B-ADJP O
28 961 962 1300436 / SYM O O
29 962 963 1300436 - SYM O O
30 964 966 1300436 13 CD B-NP O
31 967 969 1300436 to TO B-PP O
32 970 973 1300436 182 CD B-NP O
33 974 975 1300436 + SYM O O
34 975 976 1300436 / SYM O O
35 976 977 1300436 - SYM O O
36 978 980 1300436 16 CD B-NP O
37 981 986 1300436 mumol NN I-NP O
38 986 987 1300436 / SYM B-NP O
39 987 988 1300436 l NN I-NP O
40 989 991 1300436 at IN B-PP O
41 992 994 1300436 24 CD B-NP O
42 995 996 1300436 h NN I-NP O
43 996 997 1300436 , , O O
44 998 1003 1300436 while IN B-SBAR O
45 1004 1006 1300436 no DT B-NP O
46 1007 1013 1300436 change NN I-NP O
47 1014 1022 1300436 occurred VBD B-VP O
48 1023 1025 1300436 in IN B-PP O
49 1026 1029 1300436 the DT B-NP O
50 1030 1037 1300436 control NN I-NP O
51 1038 1043 1300436 group NN I-NP O
52 1044 1045 1300436 ( ( O O
53 1045 1049 1300436 from IN B-PP O
54 1050 1053 1300436 141 CD B-NP O
55 1054 1055 1300436 + SYM B-ADJP O
56 1055 1056 1300436 / SYM O O
57 1056 1057 1300436 - SYM O O
58 1058 1059 1300436 6 CD B-NP O
59 1060 1062 1300436 to TO B-PP O
60 1063 1066 1300436 142 CD B-NP O
61 1067 1068 1300436 + SYM O O
62 1068 1069 1300436 / SYM O O
63 1069 1070 1300436 - SYM O O
64 1071 1072 1300436 7 CD B-NP O
65 1073 1078 1300436 mumol NN I-NP O
66 1078 1079 1300436 / SYM B-NP O
67 1079 1080 1300436 l NN I-NP O
68 1080 1081 1300436 ) ) O O
69 1081 1082 1300436 . . O O

1 1083 1088 1300436 Renal JJ B-NP D051437
2 1089 1096 1300436 failure NN I-NP D051437
3 1097 1100 1300436 was VBD B-VP O
4 1101 1111 1300436 associated VBN I-VP O
5 1112 1116 1300436 with IN B-PP O
6 1117 1123 1300436 weight NN B-NP D015431
7 1124 1128 1300436 loss NN I-NP D015431
8 1129 1131 1300436 in IN B-PP O
9 1132 1135 1300436 the DT B-NP O
10 1136 1146 1300436 furosemide NN I-NP D005665
11 1146 1147 1300436 - HYPH B-NP O
12 1147 1154 1300436 treated VBN I-NP O
13 1155 1160 1300436 group NN I-NP O
14 1160 1161 1300436 . . O O

1 1162 1172 1300436 Furosemide NN B-NP D005665
2 1173 1176 1300436 may MD B-VP O
3 1177 1179 1300436 be VB I-VP O
4 1180 1191 1300436 deleterious JJ B-ADJP O
5 1192 1194 1300436 in IN B-PP O
6 1195 1198 1300436 the DT B-NP O
7 1199 1209 1300436 prevention NN I-NP O
8 1210 1212 1300436 of IN B-PP O
9 1213 1226 1300436 radiocontrast NN B-NP O
10 1227 1238 1300436 nephropathy NN I-NP D007674
11 1238 1239 1300436 . . O O

1 0 0 9799166 -DOCSTART- -X- -X- O

1 0 6 9799166 Stroke NN B-NP D020521
2 7 10 9799166 and CC I-NP O
3 11 18 9799166 cocaine NN I-NP D003042
4 19 21 9799166 or CC I-NP O
5 22 33 9799166 amphetamine NN I-NP D000661
6 34 37 9799166 use NN I-NP O
7 37 38 9799166 . . O O
8 39 42 9799166 The DT B-NP O
9 43 54 9799166 association NN I-NP O
10 55 57 9799166 of IN B-PP O
11 58 65 9799166 cocaine NN B-NP D003042
12 66 69 9799166 and CC I-NP O
13 70 81 9799166 amphetamine NN I-NP D000661
14 82 85 9799166 use NN I-NP O
15 86 90 9799166 with IN B-PP O
16 91 102 9799166 hemorrhagic JJ B-NP O
17 103 106 9799166 and CC I-NP O
18 107 115 9799166 ischemic JJ I-NP D007511
19 116 122 9799166 stroke NN I-NP D020521
20 123 125 9799166 is VBZ B-VP O
21 126 131 9799166 based VBN I-VP O
22 132 138 9799166 almost RB B-ADVP O
23 139 145 9799166 solely RB I-ADVP O
24 146 148 9799166 on IN B-PP O
25 149 153 9799166 data NNS B-NP O
26 154 158 9799166 from IN B-PP O
27 159 163 9799166 case NN B-NP O
28 164 170 9799166 series NN I-NP O
29 170 171 9799166 . . O O

1 172 175 9799166 The DT B-NP O
2 176 183 9799166 limited JJ I-NP O
3 184 190 9799166 number NN I-NP O
4 191 193 9799166 of IN B-PP O
5 194 207 9799166 epidemiologic JJ B-NP O
6 208 215 9799166 studies NNS I-NP O
7 216 218 9799166 of IN B-PP O
8 219 225 9799166 stroke NN B-NP D020521
9 226 229 9799166 and CC I-NP O
10 230 233 9799166 use NN I-NP O
11 234 236 9799166 of IN B-PP O
12 237 244 9799166 cocaine NN B-NP D003042
13 245 248 9799166 and CC O O
14 248 249 9799166 / SYM B-NP O
15 249 251 9799166 or CC O O
16 252 263 9799166 amphetamine NN B-NP D000661
17 264 268 9799166 have VBP B-VP O
18 269 273 9799166 been VBN I-VP O
19 274 278 9799166 done VBN I-VP O
20 279 281 9799166 in IN B-PP O
21 282 290 9799166 settings NNS B-NP O
22 291 295 9799166 that WDT B-NP O
23 296 301 9799166 serve VBP B-VP O
24 302 308 9799166 mostly RB B-ADVP O
25 309 312 9799166 the DT B-NP O
26 313 317 9799166 poor JJ I-NP O
27 318 321 9799166 and CC O O
28 321 322 9799166 / SYM B-NP O
29 322 324 9799166 or CC O O
30 325 335 9799166 minorities NNS B-NP O
31 335 336 9799166 . . O O

1 337 341 9799166 This DT B-NP O
2 342 346 9799166 case NN I-NP O
3 346 347 9799166 - HYPH B-NP O
4 347 354 9799166 control NN I-NP O
5 355 360 9799166 study NN I-NP O
6 361 364 9799166 was VBD B-VP O
7 365 374 9799166 conducted VBN I-VP O
8 375 377 9799166 in IN B-PP O
9 378 381 9799166 the DT B-NP O
10 382 389 9799166 defined VBN I-NP O
11 390 400 9799166 population NN I-NP O
12 401 411 9799166 comprising VBG B-VP O
13 412 419 9799166 members NNS B-NP O
14 420 422 9799166 of IN B-PP O
15 423 429 9799166 Kaiser NNP B-NP O
16 430 440 9799166 Permanente NNP I-NP O
17 441 443 9799166 of IN B-PP O
18 444 452 9799166 Northern NNP B-NP O
19 453 456 9799166 and CC O O
20 457 465 9799166 Southern NNP B-NP O
21 466 476 9799166 California NNP I-NP O
22 476 477 9799166 . . O O

1 478 480 9799166 We PRP B-NP O
2 481 490 9799166 attempted VBD B-VP O
3 491 493 9799166 to TO I-VP O
4 494 502 9799166 identify VB I-VP O
5 503 506 9799166 all DT B-NP O
6 507 515 9799166 incident JJ I-NP O
7 516 523 9799166 strokes NNS I-NP D020521
8 524 526 9799166 in IN B-PP O
9 527 532 9799166 women NNS B-NP O
10 533 537 9799166 ages NNS I-NP O
11 538 540 9799166 15 CD B-NP O
12 540 541 9799166 - HYPH I-NP O
13 541 543 9799166 44 CD I-NP O
14 544 549 9799166 years NNS I-NP O
15 550 556 9799166 during IN B-PP O
16 557 558 9799166 a DT B-NP O
17 559 560 9799166 3 CD I-NP O
18 560 561 9799166 - HYPH I-NP O
19 561 565 9799166 year NN I-NP O
20 566 572 9799166 period NN I-NP O
21 573 578 9799166 using VBG B-VP O
22 579 587 9799166 hospital NN B-NP O
23 588 597 9799166 admission NN I-NP O
24 598 601 9799166 and CC I-NP O
25 602 611 9799166 discharge NN I-NP O
26 612 619 9799166 records NNS I-NP O
27 619 620 9799166 , , O O
28 621 630 9799166 emergency NN B-NP O
29 631 641 9799166 department NN I-NP O
30 642 646 9799166 logs NNS I-NP O
31 646 647 9799166 , , O O
32 648 651 9799166 and CC O O
33 652 659 9799166 payment NN B-NP O
34 660 668 9799166 requests NNS I-NP O
35 669 672 9799166 for IN B-PP O
36 673 676 9799166 out RB B-NP O
37 676 677 9799166 - HYPH I-NP O
38 677 679 9799166 of IN B-PP O
39 679 680 9799166 - HYPH B-NP O
40 680 684 9799166 plan NN I-NP O
41 685 701 9799166 hospitalizations NNS I-NP O
42 701 702 9799166 . . O O

1 703 705 9799166 We PRP B-NP O
2 706 714 9799166 selected VBD B-VP O
3 715 723 9799166 controls NNS B-NP O
4 723 724 9799166 , , O O
5 725 732 9799166 matched VBN B-VP O
6 733 735 9799166 on IN B-PP O
7 736 739 9799166 age NN B-NP O
8 740 743 9799166 and CC I-NP O
9 744 752 9799166 facility NN I-NP O
10 753 755 9799166 of IN B-PP O
11 756 761 9799166 usual JJ B-NP O
12 762 766 9799166 care NN I-NP O
13 766 767 9799166 , , O O
14 768 770 9799166 at IN B-PP O
15 771 777 9799166 random NN B-NP O
16 778 782 9799166 from IN B-PP O
17 783 790 9799166 healthy JJ B-NP O
18 791 798 9799166 members NNS I-NP O
19 799 801 9799166 of IN B-PP O
20 802 805 9799166 the DT B-NP O
21 806 812 9799166 health NN I-NP O
22 813 817 9799166 plan NN I-NP O
23 817 818 9799166 . . O O

1 819 821 9799166 We PRP B-NP O
2 822 830 9799166 obtained VBD B-VP O
3 831 842 9799166 information NN B-NP O
4 843 845 9799166 in IN B-PP O
5 846 850 9799166 face NN B-NP O
6 850 851 9799166 - HYPH B-ADVP O
7 851 853 9799166 to TO B-PP O
8 853 854 9799166 - HYPH B-NP O
9 854 858 9799166 face NN I-NP O
10 859 869 9799166 interviews NNS I-NP O
11 869 870 9799166 . . O O

1 871 876 9799166 There EX B-NP O
2 877 881 9799166 were VBD B-VP O
3 882 885 9799166 347 CD B-NP O
4 886 895 9799166 confirmed VBN I-NP O
5 896 902 9799166 stroke NN I-NP D020521
6 903 908 9799166 cases NNS I-NP O
7 909 912 9799166 and CC O O
8 913 918 9799166 1,021 CD B-NP O
9 919 927 9799166 controls NNS I-NP O
10 927 928 9799166 . . O O

1 929 932 9799166 The DT B-NP O
2 933 943 9799166 univariate JJ I-NP O
3 944 951 9799166 matched NN I-NP O
4 952 956 9799166 odds VBZ B-VP O
5 957 962 9799166 ratio NN B-NP O
6 963 966 9799166 for IN B-PP O
7 967 973 9799166 stroke NN B-NP D020521
8 974 976 9799166 in IN B-PP O
9 977 982 9799166 women NNS B-NP O
10 983 986 9799166 who WP B-NP O
11 987 995 9799166 admitted VBD B-VP O
12 996 998 9799166 to TO B-PP O
13 999 1004 9799166 using VBG B-VP O
14 1005 1012 9799166 cocaine NN B-NP D003042
15 1013 1016 9799166 and CC O O
16 1016 1017 9799166 / SYM B-NP O
17 1017 1019 9799166 or CC O O
18 1020 1031 9799166 amphetamine NN B-NP D000661
19 1032 1035 9799166 was VBD B-VP O
20 1036 1039 9799166 8.5 CD B-NP O
21 1040 1041 9799166 ( ( O O
22 1041 1044 9799166 95% CD B-NP O
23 1045 1055 9799166 confidence NN I-NP O
24 1056 1064 9799166 interval NN I-NP O
25 1065 1066 9799166 = SYM B-VP O
26 1067 1070 9799166 3.6 CD B-NP O
27 1070 1071 9799166 - HYPH I-NP O
28 1071 1075 9799166 20.0 CD I-NP O
29 1075 1076 9799166 ) ) O O
30 1076 1077 9799166 . . O O

1 1078 1083 9799166 After IN B-PP O
2 1084 1091 9799166 further JJR B-NP O
3 1092 1102 9799166 adjustment NN I-NP O
4 1103 1106 9799166 for IN B-PP O
5 1107 1116 9799166 potential JJ B-NP O
6 1117 1128 9799166 confounders NNS I-NP O
7 1128 1129 9799166 , , O O
8 1130 1133 9799166 the DT B-NP O
9 1134 1138 9799166 odds NNS I-NP O
10 1139 1144 9799166 ratio NN I-NP O
11 1145 1147 9799166 in IN B-PP O
12 1148 1153 9799166 women NNS B-NP O
13 1154 1157 9799166 who WP B-NP O
14 1158 1166 9799166 reported VBD B-VP O
15 1167 1172 9799166 using VBG I-VP O
16 1173 1180 9799166 cocaine NN B-NP D003042
17 1181 1184 9799166 and CC O O
18 1184 1185 9799166 / SYM B-NP O
19 1185 1187 9799166 or CC O O
20 1188 1199 9799166 amphetamine NN B-NP D000661
21 1200 1203 9799166 was VBD B-VP O
22 1204 1207 9799166 7.0 CD B-NP O
23 1208 1209 9799166 ( ( O O
24 1209 1212 9799166 95% CD B-NP O
25 1213 1223 9799166 confidence NN I-NP O
26 1224 1232 9799166 interval NN I-NP O
27 1233 1234 9799166 = SYM B-VP O
28 1235 1238 9799166 2.8 CD B-NP O
29 1238 1239 9799166 - HYPH I-NP O
30 1239 1243 9799166 17.9 CD I-NP O
31 1243 1244 9799166 ) ) O O
32 1244 1245 9799166 . . O O

1 1246 1249 9799166 The DT B-NP O
2 1250 1253 9799166 use NN I-NP O
3 1254 1256 9799166 of IN B-PP O
4 1257 1264 9799166 cocaine NN B-NP D003042
5 1265 1268 9799166 and CC O O
6 1268 1269 9799166 / SYM B-NP O
7 1269 1271 9799166 or CC O O
8 1272 1283 9799166 amphetamine NN B-NP D000661
9 1284 1286 9799166 is VBZ B-VP O
10 1287 1288 9799166 a DT B-NP O
11 1289 1295 9799166 strong JJ I-NP O
12 1296 1300 9799166 risk NN I-NP O
13 1301 1307 9799166 factor NN I-NP O
14 1308 1311 9799166 for IN B-PP O
15 1312 1318 9799166 stroke NN B-NP D020521
16 1319 1321 9799166 in IN B-PP O
17 1322 1326 9799166 this DT B-NP O
18 1327 1344 9799166 socioeconomically RB I-NP O
19 1345 1358 9799166 heterogeneous JJ I-NP O
20 1358 1359 9799166 , , I-NP O
21 1360 1367 9799166 insured JJ I-NP O
22 1368 1373 9799166 urban JJ I-NP O
23 1374 1384 9799166 population NN I-NP O
24 1384 1385 9799166 . . O O

1 0 0 19674115 -DOCSTART- -X- -X- O

1 0 9 19674115 Recurrent JJ B-NP O
2 10 18 19674115 dysosmia NN I-NP D000857
3 19 26 19674115 induced VBN B-VP O
4 27 29 19674115 by IN B-PP O
5 30 42 19674115 pyrazinamide NN B-NP D011718
6 42 43 19674115 . . O O
7 44 56 19674115 Pyrazinamide NN B-NP D011718
8 57 60 19674115 can MD B-VP O
9 61 65 19674115 have VB I-VP O
10 66 73 19674115 adverse JJ B-NP O
11 74 81 19674115 effects NNS I-NP O
12 82 86 19674115 such JJ B-PP O
13 87 89 19674115 as IN I-PP O
14 90 97 19674115 hepatic JJ B-NP D056486
15 98 106 19674115 toxicity NN I-NP D056486
16 106 107 19674115 , , O O
17 108 121 19674115 hyperuricemia NN B-NP D033461
18 122 124 19674115 or CC O O
19 125 134 19674115 digestive JJ B-NP O
20 135 144 19674115 disorders NNS I-NP O
21 144 145 19674115 . . O O

1 146 148 19674115 In IN B-PP O
2 149 153 19674115 rare JJ B-NP O
3 154 159 19674115 cases NNS I-NP O
4 159 160 19674115 , , O O
5 161 172 19674115 alterations NNS B-NP O
6 173 175 19674115 in IN B-PP O
7 176 181 19674115 taste NN B-NP O
8 182 185 19674115 and CC I-NP O
9 186 191 19674115 smell NN I-NP O
10 192 200 19674115 function NN I-NP O
11 201 205 19674115 have VBP B-VP O
12 206 210 19674115 been VBN I-VP O
13 211 219 19674115 reported VBN I-VP O
14 220 223 19674115 for IN B-PP O
15 224 236 19674115 pyrazinamide NN B-NP D011718
16 237 241 19674115 when WRB B-ADVP O
17 242 250 19674115 combined VBN B-VP O
18 251 255 19674115 with IN B-PP O
19 256 261 19674115 other JJ B-NP O
20 262 267 19674115 drugs NNS I-NP O
21 267 268 19674115 . . O O

1 269 271 19674115 We PRP B-NP O
2 272 278 19674115 report VBP B-VP O
3 279 280 19674115 a DT B-NP O
4 281 285 19674115 case NN I-NP O
5 286 288 19674115 of IN B-PP O
6 289 299 19674115 reversible JJ B-NP O
7 300 309 19674115 olfactory JJ I-NP D000857
8 310 318 19674115 disorder NN I-NP D000857
9 319 326 19674115 related VBN B-VP O
10 327 329 19674115 to TO B-PP O
11 330 342 19674115 pyrazinamide NN B-NP D011718
12 343 345 19674115 in IN B-PP O
13 346 347 19674115 a DT B-NP O
14 348 353 19674115 woman NN I-NP O
15 353 354 19674115 , , O O
16 355 359 19674115 with IN B-PP O
17 360 361 19674115 a DT B-NP O
18 362 370 19674115 positive JJ I-NP O
19 371 382 19674115 rechallenge NN I-NP O
20 382 383 19674115 . . O O

1 384 387 19674115 The DT B-NP O
2 388 395 19674115 patient NN I-NP O
3 396 405 19674115 presented VBD B-VP O
4 406 411 19674115 every DT B-NP O
5 412 415 19674115 day NN I-NP O
6 416 417 19674115 a DT B-NP O
7 418 427 19674115 sensation NN I-NP O
8 428 430 19674115 of IN B-PP O
9 431 439 19674115 smelling VBG B-VP O
10 440 449 19674115 something NN B-NP O
11 450 457 19674115 burning VBG B-VP O
12 458 460 19674115 15 CD B-NP O
13 461 464 19674115 min NN I-NP O
14 465 470 19674115 after IN B-PP O
15 471 475 19674115 drug NN B-NP O
16 476 482 19674115 intake NN I-NP O
17 482 483 19674115 . . O O

1 484 492 19674115 Dysosmia NN B-NP D000857
2 493 504 19674115 disappeared VBD B-VP O
3 505 515 19674115 completely RB B-ADVP O
4 516 521 19674115 after IN B-PP O
5 522 534 19674115 pyrazinamide NN B-NP D011718
6 535 545 19674115 withdrawal NN I-NP O
7 546 549 19674115 and CC O O
8 550 558 19674115 recurred VBD B-VP O
9 559 564 19674115 after IN B-PP O
10 565 568 19674115 its PRP$ B-NP O
11 569 580 19674115 rechallenge NN I-NP O
12 580 581 19674115 . . O O

1 582 585 19674115 The DT B-NP O
2 586 590 19674115 case NN I-NP O
3 591 594 19674115 was VBD B-VP O
4 595 603 19674115 reported VBN I-VP O
5 604 606 19674115 to TO B-PP O
6 607 610 19674115 the DT B-NP O
7 611 619 19674115 Tunisian NNP I-NP O
8 620 626 19674115 Centre NNP I-NP O
9 627 629 19674115 of IN B-PP O
10 630 647 19674115 Pharmacovigilance NNP B-NP O
11 647 648 19674115 . . O O

1 0 0 8480959 -DOCSTART- -X- -X- O

1 0 8 8480959 Efficacy NN B-NP O
2 9 12 8480959 and CC I-NP O
3 13 25 8480959 tolerability NN I-NP O
4 26 28 8480959 of IN B-PP O
5 29 39 8480959 lovastatin NN B-NP D008148
6 40 42 8480959 in IN B-PP O
7 43 47 8480959 3390 CD B-NP O
8 48 53 8480959 women NNS I-NP O
9 54 58 8480959 with IN B-PP O
10 59 67 8480959 moderate JJ B-NP O
11 68 88 8480959 hypercholesterolemia NN I-NP D006937
12 88 89 8480959 . . I-NP O
13 90 99 8480959 OBJECTIVE NN I-NP O
14 99 100 8480959 : : O O
15 101 103 8480959 To TO B-VP O
16 104 112 8480959 evaluate VB I-VP O
17 113 116 8480959 the DT B-NP O
18 117 125 8480959 efficacy NN I-NP O
19 126 129 8480959 and CC I-NP O
20 130 136 8480959 safety NN I-NP O
21 137 139 8480959 of IN B-PP O
22 140 150 8480959 lovastatin NN B-NP D008148
23 151 153 8480959 in IN B-PP O
24 154 159 8480959 women NNS B-NP O
25 160 164 8480959 with IN B-PP O
26 165 173 8480959 moderate JJ B-NP O
27 174 194 8480959 hypercholesterolemia NN I-NP D006937
28 194 195 8480959 . . O O

1 196 202 8480959 DESIGN NN B-NP O
2 202 203 8480959 : : O O
3 204 207 8480959 The DT B-NP O
4 208 216 8480959 Expanded NNP I-NP O
5 217 225 8480959 Clinical NNP I-NP O
6 226 236 8480959 Evaluation NNP I-NP O
7 237 239 8480959 of IN B-PP O
8 240 250 8480959 Lovastatin NN B-NP D008148
9 251 252 8480959 ( ( O O
10 252 257 8480959 EXCEL NN B-NP O
11 257 258 8480959 ) ) O O
12 259 264 8480959 Study NN B-NP O
13 264 265 8480959 , , O O
14 266 267 8480959 a DT B-NP O
15 268 279 8480959 multicenter JJ I-NP O
16 279 280 8480959 , , I-NP O
17 281 287 8480959 double JJ I-NP O
18 287 288 8480959 - HYPH I-NP O
19 288 293 8480959 blind JJ I-NP O
20 293 294 8480959 , , I-NP O
21 295 299 8480959 diet NN I-NP O
22 299 300 8480959 - HYPH I-NP O
23 301 304 8480959 and CC I-NP O
24 305 312 8480959 placebo NN I-NP O
25 312 313 8480959 - HYPH O O
26 313 323 8480959 controlled VBN B-NP O
27 324 329 8480959 trial NN I-NP O
28 329 330 8480959 , , O O
29 331 333 8480959 in IN B-PP O
30 334 339 8480959 which WDT B-NP O
31 340 352 8480959 participants NNS B-NP O
32 353 357 8480959 were VBD B-VP O
33 358 366 8480959 randomly RB I-VP O
34 367 375 8480959 assigned VBN I-VP O
35 376 378 8480959 to TO I-VP O
36 379 386 8480959 receive VB I-VP O
37 387 394 8480959 placebo NN B-NP O
38 395 397 8480959 or CC I-NP O
39 398 408 8480959 lovastatin NN I-NP D008148
40 409 411 8480959 at IN B-PP O
41 412 417 8480959 doses NNS B-NP O
42 418 420 8480959 of IN B-PP O
43 421 423 8480959 20 CD B-NP O
44 424 426 8480959 or CC I-NP O
45 427 429 8480959 40 CD I-NP O
46 430 432 8480959 mg NN I-NP O
47 433 437 8480959 once RB B-ADVP O
48 438 443 8480959 daily RB I-ADVP O
49 443 444 8480959 , , O O
50 445 447 8480959 or CC O O
51 448 450 8480959 20 CD B-NP O
52 451 453 8480959 or CC I-NP O
53 454 456 8480959 40 CD I-NP O
54 457 459 8480959 mg NN I-NP O
55 460 465 8480959 twice RB B-ADVP O
56 466 471 8480959 daily RB I-ADVP O
57 472 475 8480959 for IN B-PP O
58 476 478 8480959 48 CD B-NP O
59 479 484 8480959 weeks NNS I-NP O
60 484 485 8480959 . . O O

1 486 493 8480959 SETTING NN B-NP O
2 493 494 8480959 : : O O
3 495 505 8480959 Ambulatory JJ B-NP O
4 506 514 8480959 patients NNS I-NP O
5 515 524 8480959 recruited VBN B-VP O
6 525 527 8480959 by IN B-PP O
7 528 531 8480959 362 CD B-NP O
8 532 545 8480959 participating VBG I-NP O
9 546 553 8480959 centers NNS I-NP O
10 554 564 8480959 throughout IN B-PP O
11 565 568 8480959 the DT B-NP O
12 569 575 8480959 United NNP I-NP O
13 576 582 8480959 States NNPS I-NP O
14 582 583 8480959 . . O O

1 584 592 8480959 PATIENTS NNS B-NP O
2 592 593 8480959 : : O O
3 594 599 8480959 Women NNS B-NP O
4 600 601 8480959 ( ( O O
5 601 602 8480959 n NN B-NP O
6 603 604 8480959 = SYM B-VP O
7 605 609 8480959 3390 CD B-NP O
8 609 610 8480959 ) ) O O
9 611 615 8480959 from IN B-PP O
10 616 619 8480959 the DT B-NP O
11 620 625 8480959 total JJ I-NP O
12 626 632 8480959 cohort NN I-NP O
13 633 635 8480959 of IN B-PP O
14 636 640 8480959 8245 CD B-NP O
15 641 651 8480959 volunteers NNS I-NP O
16 651 652 8480959 . . O O

1 653 665 8480959 MEASUREMENTS NNS B-NP O
2 665 666 8480959 : : O O
3 667 673 8480959 Plasma NN B-NP O
4 674 679 8480959 total NN I-NP O
5 679 680 8480959 , , O O
6 681 684 8480959 low JJ B-NP O
7 684 685 8480959 - HYPH I-NP O
8 685 692 8480959 density NN I-NP O
9 693 704 8480959 lipoprotein NN I-NP O
10 705 706 8480959 ( ( O O
11 706 709 8480959 LDL NN B-NP O
12 709 710 8480959 ) ) O O
13 710 711 8480959 , , O O
14 712 715 8480959 and CC O O
15 716 720 8480959 high JJ B-NP O
16 720 721 8480959 - HYPH I-NP O
17 721 728 8480959 density NN I-NP O
18 729 740 8480959 lipoprotein NN I-NP O
19 741 742 8480959 ( ( O O
20 742 745 8480959 HDL NN B-NP O
21 745 746 8480959 ) ) O O
22 747 758 8480959 cholesterol NN B-NP D002784
23 758 759 8480959 , , O O
24 760 763 8480959 and CC O O
25 764 777 8480959 triglycerides NNS B-NP D014280
26 777 778 8480959 ; : O O
27 779 782 8480959 and CC O O
28 783 793 8480959 laboratory NN B-NP O
29 794 797 8480959 and CC O O
30 798 806 8480959 clinical JJ B-NP O
31 807 815 8480959 evidence NN I-NP O
32 816 818 8480959 of IN B-PP O
33 819 826 8480959 adverse JJ B-NP O
34 827 833 8480959 events NNS I-NP O
35 834 843 8480959 monitored VBN B-VP O
36 844 856 8480959 periodically RB B-ADVP O
37 857 867 8480959 throughout IN B-PP O
38 868 871 8480959 the DT B-NP O
39 872 877 8480959 study NN I-NP O
40 877 878 8480959 . . O O

1 879 886 8480959 RESULTS NNS B-NP O
2 886 887 8480959 : : O O
3 888 893 8480959 Among IN B-PP O
4 894 899 8480959 women NNS B-NP O
5 899 900 8480959 , , O O
6 901 911 8480959 lovastatin NN B-NP D008148
7 912 913 8480959 ( ( O O
8 913 915 8480959 20 CD B-NP O
9 916 918 8480959 to TO I-NP O
10 919 921 8480959 80 CD I-NP O
11 922 924 8480959 mg NN I-NP O
12 924 925 8480959 / SYM B-NP O
13 925 926 8480959 d NN I-NP O
14 926 927 8480959 ) ) O O
15 928 936 8480959 produced VBD B-VP O
16 937 946 8480959 sustained JJ B-ADJP O
17 947 948 8480959 ( ( O O
18 948 950 8480959 12 CD B-NP O
19 950 951 8480959 - HYPH B-ADJP O
20 952 954 8480959 to TO B-PP O
21 955 957 8480959 48 CD B-NP O
22 957 958 8480959 - HYPH B-NP O
23 958 962 8480959 week NN I-NP O
24 962 963 8480959 ) ) O O
25 963 964 8480959 , , O O
26 965 969 8480959 dose NN B-NP O
27 969 970 8480959 - HYPH B-NP O
28 970 977 8480959 related VBN I-NP O
29 978 985 8480959 changes NNS I-NP O
30 986 987 8480959 ( ( O O
31 987 988 8480959 P NN B-NP O
32 989 990 8480959 < SYM O O
33 991 996 8480959 0.001 CD B-NP O
34 996 997 8480959 ) ) O O
35 997 998 8480959 : : O O
36 999 1008 8480959 decreases VBZ B-VP O
37 1009 1011 8480959 in IN B-PP O
38 1012 1015 8480959 LDL NN B-NP O
39 1016 1027 8480959 cholesterol NN I-NP D002784
40 1028 1029 8480959 ( ( O O
41 1029 1032 8480959 24% CD B-NP O
42 1033 1035 8480959 to TO O O
43 1036 1039 8480959 40% CD B-NP O
44 1039 1040 8480959 ) ) O O
45 1041 1044 8480959 and CC O O
46 1045 1058 8480959 triglycerides NNS B-NP D014280
47 1059 1060 8480959 ( ( O O
48 1060 1062 8480959 9% CD B-NP O
49 1063 1065 8480959 to TO O O
50 1066 1069 8480959 18% CD B-NP O
51 1069 1070 8480959 ) ) O O
52 1070 1071 8480959 , , O O
53 1072 1075 8480959 and CC O O
54 1076 1085 8480959 increases NNS B-NP O
55 1086 1088 8480959 in IN B-PP O
56 1089 1092 8480959 HDL NN B-NP O
57 1093 1104 8480959 cholesterol NN I-NP D002784
58 1105 1106 8480959 ( ( O O
59 1106 1110 8480959 6.7% CD B-NP O
60 1111 1113 8480959 to TO O O
61 1114 1118 8480959 8.6% CD B-NP O
62 1118 1119 8480959 ) ) O O
63 1119 1120 8480959 . . O O

1 1121 1130 8480959 Depending VBG B-PP O
2 1131 1133 8480959 on IN B-PP O
3 1134 1137 8480959 the DT B-NP O
4 1138 1142 8480959 dose NN I-NP O
5 1142 1143 8480959 , , O O
6 1144 1148 8480959 from IN B-PP O
7 1149 1152 8480959 82% CD B-NP O
8 1153 1155 8480959 to TO B-PP O
9 1156 1159 8480959 95% CD B-NP O
10 1160 1162 8480959 of IN B-PP O
11 1163 1173 8480959 lovastatin NN B-NP D008148
12 1173 1174 8480959 - HYPH O O
13 1174 1181 8480959 treated VBN B-NP O
14 1182 1187 8480959 women NNS I-NP O
15 1188 1196 8480959 achieved VBD B-VP O
16 1197 1200 8480959 the DT B-NP O
17 1201 1209 8480959 National NNP I-NP O
18 1210 1221 8480959 Cholesterol NNP I-NP D002784
19 1222 1231 8480959 Education NNP I-NP O
20 1232 1239 8480959 Program NNP I-NP O
21 1240 1244 8480959 goal NN I-NP O
22 1245 1247 8480959 of IN B-PP O
23 1248 1251 8480959 LDL NN B-NP O
24 1252 1263 8480959 cholesterol NN I-NP D002784
25 1264 1270 8480959 levels NNS I-NP O
26 1271 1275 8480959 less JJR B-NP O
27 1276 1280 8480959 than IN I-NP O
28 1281 1285 8480959 4.14 CD I-NP O
29 1286 1290 8480959 mmol NN I-NP O
30 1290 1291 8480959 / SYM B-NP O
31 1291 1292 8480959 L NN B-NP O
32 1293 1294 8480959 ( ( O O
33 1294 1297 8480959 160 CD B-NP O
34 1298 1300 8480959 mg NN I-NP O
35 1300 1301 8480959 / SYM B-NP O
36 1301 1303 8480959 dL NN I-NP O
37 1303 1304 8480959 ) ) O O
38 1304 1305 8480959 , , O O
39 1306 1309 8480959 and CC O O
40 1310 1313 8480959 40% CD B-NP O
41 1314 1316 8480959 to TO B-PP O
42 1317 1320 8480959 87% CD B-NP O
43 1321 1329 8480959 achieved VBD B-VP O
44 1330 1333 8480959 the DT B-NP O
45 1334 1338 8480959 goal NN I-NP O
46 1339 1341 8480959 of IN B-PP O
47 1342 1346 8480959 3.36 CD B-NP O
48 1347 1351 8480959 mmol NN I-NP O
49 1351 1352 8480959 / SYM B-NP O
50 1352 1353 8480959 L NN B-NP O
51 1354 1355 8480959 ( ( O O
52 1355 1358 8480959 130 CD B-NP O
53 1359 1361 8480959 mg NN I-NP O
54 1361 1362 8480959 / SYM B-NP O
55 1362 1364 8480959 dL NN I-NP O
56 1364 1365 8480959 ) ) O O
57 1365 1366 8480959 . . O O

1 1367 1377 8480959 Successive JJ B-NP O
2 1378 1390 8480959 transaminase NN I-NP O
3 1391 1401 8480959 elevations NNS I-NP O
4 1402 1409 8480959 greater JJR B-ADJP O
5 1410 1414 8480959 than IN B-PP O
6 1415 1420 8480959 three CD B-NP O
7 1421 1426 8480959 times NNS I-NP O
8 1427 1430 8480959 the DT I-NP O
9 1431 1436 8480959 upper JJ I-NP O
10 1437 1442 8480959 limit NN I-NP O
11 1443 1445 8480959 of IN B-PP O
12 1446 1452 8480959 normal JJ B-NP O
13 1453 1461 8480959 occurred VBD B-VP O
14 1462 1464 8480959 in IN B-PP O
15 1465 1469 8480959 0.1% CD B-NP O
16 1470 1472 8480959 of IN B-PP O
17 1473 1478 8480959 women NNS B-NP O
18 1479 1482 8480959 and CC O O
19 1483 1487 8480959 were VBD B-VP O
20 1488 1492 8480959 dose NN B-NP O
21 1493 1502 8480959 dependent JJ B-ADJP O
22 1503 1508 8480959 above IN B-PP O
23 1509 1512 8480959 the DT B-NP O
24 1513 1515 8480959 20 CD I-NP O
25 1515 1516 8480959 - HYPH I-NP O
26 1516 1518 8480959 mg NN I-NP O
27 1519 1523 8480959 dose NN I-NP O
28 1523 1524 8480959 . . O O

1 1525 1533 8480959 Myopathy NN B-NP D009135
2 1533 1534 8480959 , , O O
3 1535 1542 8480959 defined VBN B-VP O
4 1543 1545 8480959 as IN B-PP O
5 1546 1552 8480959 muscle NN B-NP O
6 1553 1561 8480959 symptoms NNS I-NP O
7 1562 1566 8480959 with IN B-PP O
8 1567 1575 8480959 creatine NN B-NP D003401
9 1576 1582 8480959 kinase NN I-NP O
10 1583 1593 8480959 elevations NNS I-NP O
11 1594 1601 8480959 greater JJR B-NP O
12 1602 1606 8480959 than IN I-NP O
13 1607 1609 8480959 10 CD I-NP O
14 1610 1615 8480959 times NNS I-NP O
15 1616 1619 8480959 the DT I-NP O
16 1620 1625 8480959 upper JJ I-NP O
17 1626 1631 8480959 limit NN I-NP O
18 1632 1634 8480959 of IN B-PP O
19 1635 1641 8480959 normal JJ B-NP O
20 1641 1642 8480959 , , O O
21 1643 1646 8480959 was VBD B-VP O
22 1647 1651 8480959 rare JJ B-ADJP O
23 1652 1655 8480959 and CC O O
24 1656 1666 8480959 associated VBN B-VP O
25 1667 1671 8480959 with IN B-PP O
26 1672 1675 8480959 the DT B-NP O
27 1676 1683 8480959 highest JJS I-NP O
28 1684 1695 8480959 recommended VBN I-NP O
29 1696 1701 8480959 daily JJ I-NP O
30 1702 1706 8480959 dose NN I-NP O
31 1707 1709 8480959 of IN B-PP O
32 1710 1720 8480959 lovastatin NN B-NP D008148
33 1721 1722 8480959 ( ( O O
34 1722 1724 8480959 80 CD B-NP O
35 1725 1727 8480959 mg NN I-NP O
36 1727 1728 8480959 ) ) O O
37 1728 1729 8480959 . . O O

1 1730 1738 8480959 Estrogen NN B-NP O
2 1738 1739 8480959 - HYPH I-NP O
3 1739 1750 8480959 replacement NN I-NP O
4 1751 1758 8480959 therapy NN I-NP O
5 1759 1767 8480959 appeared VBD B-VP O
6 1768 1770 8480959 to TO I-VP O
7 1771 1775 8480959 have VB I-VP O
8 1776 1778 8480959 no DT B-NP O
9 1779 1785 8480959 effect NN I-NP O
10 1786 1788 8480959 on IN B-PP O
11 1789 1795 8480959 either CC O O
12 1796 1799 8480959 the DT B-NP O
13 1800 1808 8480959 efficacy NN I-NP O
14 1809 1811 8480959 or CC I-NP O
15 1812 1818 8480959 safety NN I-NP O
16 1819 1826 8480959 profile NN I-NP O
17 1827 1829 8480959 of IN B-PP O
18 1830 1840 8480959 lovastatin NN B-NP D008148
19 1840 1841 8480959 . . O O

1 1842 1852 8480959 CONCLUSION NN B-NP O
2 1852 1853 8480959 : : O O
3 1854 1864 8480959 Lovastatin NN B-NP D008148
4 1865 1867 8480959 is VBZ B-VP O
5 1868 1874 8480959 highly RB B-ADJP O
6 1875 1884 8480959 effective JJ I-ADJP O
7 1885 1888 8480959 and CC O O
8 1889 1898 8480959 generally RB B-VP O
9 1899 1903 8480959 well RB I-VP O
10 1904 1913 8480959 tolerated VBN I-VP O
11 1914 1916 8480959 as IN B-PP O
12 1917 1924 8480959 therapy NN B-NP O
13 1925 1928 8480959 for IN B-PP O
14 1929 1936 8480959 primary JJ B-NP O
15 1937 1957 8480959 hypercholesterolemia NN I-NP D006937
16 1958 1960 8480959 in IN B-PP O
17 1961 1966 8480959 women NNS B-NP O
18 1966 1967 8480959 . . O O

1 0 0 9270571 -DOCSTART- -X- -X- O

1 0 9 9270571 Potential JJ B-NP O
2 10 21 9270571 therapeutic JJ I-NP O
3 22 25 9270571 use NN I-NP O
4 26 28 9270571 of IN B-PP O
5 29 32 9270571 the DT B-NP O
6 33 42 9270571 selective JJ I-NP O
7 43 51 9270571 dopamine NN I-NP D004298
8 52 54 9270571 D1 NN I-NP O
9 55 63 9270571 receptor NN I-NP O
10 64 71 9270571 agonist NN I-NP O
11 71 72 9270571 , , O O
12 73 74 9270571 A NN B-NP C095427
13 74 75 9270571 - HYPH I-NP C095427
14 75 80 9270571 86929 CD I-NP C095427
15 80 81 9270571 : : O O
16 82 84 9270571 an DT B-NP O
17 85 90 9270571 acute JJ I-NP O
18 91 96 9270571 study NN I-NP O
19 97 99 9270571 in IN B-PP O
20 100 112 9270571 parkinsonian JJ B-NP D020734
21 113 121 9270571 levodopa NN I-NP D007980
22 121 122 9270571 - HYPH B-NP O
23 122 128 9270571 primed VBN I-NP O
24 129 136 9270571 monkeys NNS I-NP O
25 136 137 9270571 . . O O
26 138 141 9270571 The DT B-NP O
27 142 150 9270571 clinical JJ I-NP O
28 151 158 9270571 utility NN I-NP O
29 159 161 9270571 of IN B-PP O
30 162 170 9270571 dopamine NN B-NP D004298
31 171 172 9270571 ( ( O O
32 172 174 9270571 DA NN B-NP D004298
33 174 175 9270571 ) ) O O
34 176 178 9270571 D1 NN B-NP O
35 179 187 9270571 receptor NN I-NP O
36 188 196 9270571 agonists NNS I-NP O
37 197 199 9270571 in IN B-PP O
38 200 203 9270571 the DT B-NP O
39 204 213 9270571 treatment NN I-NP O
40 214 216 9270571 of IN B-PP O
41 217 228 9270571 Parkinson's NNS B-NP D010300
42 229 236 9270571 disease NN B-NP D010300
43 237 238 9270571 ( ( O O
44 238 240 9270571 PD NN B-NP D010300
45 240 241 9270571 ) ) O O
46 242 244 9270571 is VBZ B-VP O
47 245 250 9270571 still RB B-ADVP O
48 251 258 9270571 unclear JJ B-ADJP O
49 258 259 9270571 . . O O

1 260 263 9270571 The DT B-NP O
2 264 275 9270571 therapeutic JJ I-NP O
3 276 279 9270571 use NN I-NP O
4 280 282 9270571 of IN B-PP O
5 283 292 9270571 selective JJ B-NP O
6 293 295 9270571 DA NN I-NP D004298
7 296 298 9270571 D1 NN I-NP O
8 299 307 9270571 receptor NN I-NP O
9 308 316 9270571 agonists NNS I-NP O
10 317 321 9270571 such JJ B-PP O
11 322 324 9270571 as IN I-PP O
12 325 328 9270571 SKF NN B-NP C071262
13 328 329 9270571 - HYPH O C071262
14 329 334 9270571 82958 CD B-NP C071262
15 335 336 9270571 ( ( O O
16 336 337 9270571 6 CD B-NP C071262
17 337 338 9270571 - HYPH I-NP C071262
18 338 344 9270571 chloro NN I-NP C071262
19 344 345 9270571 - HYPH I-NP C071262
20 345 348 9270571 7,8 NN I-NP C071262
21 348 349 9270571 - HYPH B-NP C071262
22 349 358 9270571 dihydroxy NN I-NP C071262
23 358 359 9270571 - HYPH B-NP C071262
24 359 360 9270571 3 CD I-NP C071262
25 360 361 9270571 - HYPH I-NP C071262
26 361 366 9270571 allyl NN I-NP C071262
27 366 367 9270571 - HYPH B-NP C071262
28 367 368 9270571 1 CD I-NP C071262
29 368 369 9270571 - HYPH I-NP C071262
30 369 375 9270571 phenyl NN I-NP C071262
31 375 376 9270571 - HYPH B-NP C071262
32 376 383 9270571 2,3,4,5 CD I-NP C071262
33 383 384 9270571 - HYPH O C071262
34 384 394 9270571 tetrahydro AFX O C071262
35 394 395 9270571 - HYPH B-NP C071262
36 395 397 9270571 1H NN I-NP C071262
37 397 398 9270571 - HYPH B-NP C071262
38 398 399 9270571 3 CD I-NP C071262
39 399 400 9270571 - HYPH I-NP C071262
40 400 407 9270571 benzaze NN I-NP C071262
41 408 412 9270571 pine NN I-NP C071262
42 413 425 9270571 hydrobromide NN I-NP C071262
43 425 426 9270571 ) ) O O
44 427 430 9270571 and CC O O
45 431 432 9270571 A NN B-NP C079415
46 432 433 9270571 - HYPH I-NP C079415
47 433 438 9270571 77636 CD I-NP C079415
48 439 440 9270571 ( ( O O
49 440 441 9270571 [ ( O C079415
50 441 443 9270571 1R NN B-NP C079415
51 443 444 9270571 , , I-NP C079415
52 445 447 9270571 3S NN I-NP C079415
53 447 448 9270571 ] ) O C079415
54 449 450 9270571 3 CD B-NP C079415
55 450 451 9270571 - HYPH I-NP C079415
56 451 454 9270571 [1' NN I-NP C079415
57 454 455 9270571 - HYPH B-NP C079415
58 455 464 9270571 admantyl] NN I-NP C079415
59 464 465 9270571 - HYPH B-NP C079415
60 465 466 9270571 1 CD I-NP C079415
61 466 467 9270571 - HYPH I-NP C079415
62 467 478 9270571 aminomethyl NN I-NP C079415
63 478 479 9270571 - HYPH B-NP C079415
64 479 482 9270571 3,4 CD I-NP C079415
65 482 483 9270571 - HYPH O C079415
66 483 490 9270571 dihydro AFX O C079415
67 490 491 9270571 - HYPH B-NP C079415
68 491 494 9270571 5,6 CD I-NP C079415
69 494 495 9270571 - HYPH I-NP C079415
70 495 504 9270571 dihydroxy NN I-NP C079415
71 504 505 9270571 - HYPH B-NP C079415
72 505 507 9270571 1H NN I-NP C079415
73 507 508 9270571 - HYPH B-NP C079415
74 508 509 9270571 2 CD I-NP C079415
75 509 510 9270571 - HYPH I-NP C079415
76 510 515 9270571 benzo NN I-NP C079415
77 516 521 9270571 pyran NN I-NP C079415
78 522 535 9270571 hydrochloride NN I-NP C079415
79 535 536 9270571 ) ) O O
80 537 542 9270571 seems VBZ B-VP O
81 543 550 9270571 limited VBN B-ADJP O
82 551 558 9270571 because IN B-PP O
83 559 561 9270571 of IN I-PP O
84 562 567 9270571 their PRP$ B-NP O
85 568 576 9270571 duration NN I-NP O
86 577 579 9270571 of IN B-PP O
87 580 586 9270571 action NN B-NP O
88 586 587 9270571 , , O O
89 588 593 9270571 which WDT B-NP O
90 594 596 9270571 is VBZ B-VP O
91 597 600 9270571 too RB B-ADJP O
92 601 606 9270571 short JJ I-ADJP O
93 607 610 9270571 for IN B-PP O
94 611 614 9270571 SKF NN B-NP C071262
95 614 615 9270571 - HYPH B-NP C071262
96 615 620 9270571 82958 CD I-NP C071262
97 621 622 9270571 ( ( O O
98 622 623 9270571 < SYM O O
99 624 625 9270571 1 CD B-NP O
100 626 628 9270571 hr NN I-NP O
101 628 629 9270571 ) ) O O
102 630 633 9270571 and CC O O
103 634 637 9270571 too RB B-ADJP O
104 638 642 9270571 long JJ I-ADJP O
105 643 646 9270571 for IN B-PP O
106 647 648 9270571 A NN B-NP C079415
107 648 649 9270571 - HYPH I-NP C079415
108 649 654 9270571 77636 CD I-NP C079415
109 655 656 9270571 ( ( O O
110 656 657 9270571 > JJR B-NP O
111 658 660 9270571 20 CD I-NP O
112 661 663 9270571 hr NN I-NP O
113 663 664 9270571 , , O O
114 665 672 9270571 leading VBG B-VP O
115 673 675 9270571 to TO B-PP O
116 676 686 9270571 behavioral JJ B-NP O
117 687 696 9270571 tolerance NN I-NP O
118 696 697 9270571 ) ) O O
119 697 698 9270571 . . O O

1 699 701 9270571 We PRP B-NP O
2 702 711 9270571 therefore RB B-ADVP O
3 712 721 9270571 conducted VBD B-VP O
4 722 725 9270571 the DT B-NP O
5 726 733 9270571 present JJ I-NP O
6 734 739 9270571 acute JJ I-NP O
7 740 744 9270571 dose NN I-NP O
8 744 745 9270571 - HYPH B-NP O
9 745 753 9270571 response NN I-NP O
10 754 759 9270571 study NN I-NP O
11 760 762 9270571 in IN B-PP O
12 763 767 9270571 four CD B-NP O
13 768 769 9270571 1 CD I-NP D015632
14 769 770 9270571 - HYPH I-NP D015632
15 770 776 9270571 methyl NN I-NP D015632
16 776 777 9270571 - HYPH B-NP D015632
17 777 778 9270571 4 CD I-NP D015632
18 778 779 9270571 - HYPH I-NP D015632
19 779 785 9270571 phenyl NN I-NP D015632
20 785 786 9270571 - HYPH B-NP D015632
21 786 793 9270571 1,2,3,6 CD I-NP D015632
22 793 794 9270571 - HYPH I-NP D015632
23 794 812 9270571 tetrahydropyridine NN I-NP D015632
24 813 819 9270571 (MPTP) NN I-NP D015632
25 819 820 9270571 - HYPH B-VP O
26 820 827 9270571 exposed VBN B-NP O
27 828 838 9270571 cynomolgus NN I-NP O
28 839 846 9270571 monkeys NNS I-NP O
29 847 853 9270571 primed VBN B-VP O
30 854 856 9270571 to TO B-VP O
31 857 864 9270571 exhibit VB I-VP O
32 865 873 9270571 levodopa NN B-NP D007980
33 873 874 9270571 - HYPH B-NP O
34 874 881 9270571 induced VBN I-NP O
35 882 893 9270571 dyskinesias NNS I-NP D004409
36 894 896 9270571 to TO B-VP O
37 897 905 9270571 evaluate VB I-VP O
38 906 909 9270571 the DT B-NP O
39 910 919 9270571 locomotor NN I-NP O
40 920 923 9270571 and CC O O
41 924 934 9270571 dyskinetic JJ B-NP D004409
42 935 942 9270571 effects NNS I-NP O
43 943 945 9270571 on IN B-PP O
44 946 955 9270571 challenge NN B-NP O
45 956 960 9270571 with IN B-PP O
46 961 965 9270571 four CD B-NP O
47 966 971 9270571 doses NNS I-NP O
48 972 973 9270571 ( ( O O
49 973 977 9270571 from IN B-PP O
50 978 982 9270571 0.03 CD B-NP O
51 983 985 9270571 to TO I-NP O
52 986 989 9270571 1.0 CD I-NP O
53 990 992 9270571 mg NN I-NP O
54 992 993 9270571 / SYM B-NP O
55 993 995 9270571 kg NN I-NP O
56 995 996 9270571 ) ) O O
57 997 999 9270571 of IN B-PP O
58 1000 1001 9270571 A NN B-NP C095427
59 1001 1002 9270571 - HYPH I-NP C095427
60 1002 1007 9270571 86929 CD I-NP C095427
61 1008 1009 9270571 ( ( O O
62 1009 1010 9270571 [ ( O C095427
63 1010 1011 9270571 - HYPH O C095427
64 1011 1012 9270571 ] ) O C095427
65 1012 1013 9270571 - HYPH B-NP C095427
66 1013 1023 9270571 [5aR,11bS] NN I-NP C095427
67 1023 1024 9270571 - HYPH B-NP C095427
68 1024 1038 9270571 4,5,5a,6,7,11b NN I-NP C095427
69 1038 1039 9270571 - HYPH O C095427
70 1039 1048 9270571 hexahydro AFX O C095427
71 1048 1049 9270571 - HYPH B-NP C095427
72 1049 1050 9270571 2 CD I-NP C095427
73 1050 1051 9270571 - HYPH I-NP C095427
74 1051 1057 9270571 propyl NN I-NP C095427
75 1057 1058 9270571 - HYPH B-NP C095427
76 1058 1059 9270571 3 CD I-NP C095427
77 1059 1060 9270571 - HYPH O C095427
78 1060 1064 9270571 thia SYM B-NP C095427
79 1064 1065 9270571 - HYPH B-NP C095427
80 1065 1066 9270571 5 CD I-NP C095427
81 1066 1067 9270571 - HYPH O C095427
82 1067 1068 9270571 + SYM B-NP C095427
83 1069 1070 9270571 + SYM B-VP C095427
84 1070 1071 9270571 + SYM B-NP C095427
85 1071 1083 9270571 azacyclopent NN I-NP C095427
86 1083 1084 9270571 - HYPH B-NP C095427
87 1084 1085 9270571 1 CD I-NP C095427
88 1085 1086 9270571 - HYPH I-NP C095427
89 1087 1104 9270571 ena[c]phenathrene NN I-NP C095427
90 1104 1105 9270571 - HYPH B-NP C095427
91 1105 1106 9270571 9 CD I-NP C095427
92 1106 1107 9270571 - HYPH I-NP C095427
93 1107 1109 9270571 10 CD I-NP C095427
94 1109 1110 9270571 - HYPH I-NP C095427
95 1110 1114 9270571 diol NN I-NP C095427
96 1114 1115 9270571 ) ) O O
97 1115 1116 9270571 , , O O
98 1117 1118 9270571 a DT B-NP O
99 1119 1128 9270571 selective JJ I-NP O
100 1129 1132 9270571 and CC I-NP O
101 1133 1137 9270571 full JJ I-NP O
102 1138 1140 9270571 DA NN I-NP D004298
103 1141 1143 9270571 D1 NN I-NP O
104 1143 1144 9270571 - HYPH B-NP O
105 1144 1148 9270571 like JJ I-NP O
106 1149 1157 9270571 receptor NN I-NP O
107 1158 1165 9270571 agonist NN I-NP O
108 1166 1170 9270571 with IN B-PP O
109 1171 1173 9270571 an DT B-NP O
110 1174 1186 9270571 intermediate JJ I-NP O
111 1187 1195 9270571 duration NN I-NP O
112 1196 1198 9270571 of IN B-PP O
113 1199 1205 9270571 action NN B-NP O
114 1205 1206 9270571 . . O O

1 1207 1215 9270571 Levodopa NN B-NP D007980
2 1216 1219 9270571 and CC O O
3 1220 1223 9270571 the DT B-NP O
4 1224 1226 9270571 DA NN I-NP D004298
5 1227 1229 9270571 D2 NN I-NP O
6 1229 1230 9270571 - HYPH B-NP O
7 1230 1234 9270571 like JJ I-NP O
8 1235 1243 9270571 receptor NN I-NP O
9 1244 1251 9270571 agonist NN I-NP O
10 1251 1252 9270571 , , O O
11 1253 1255 9270571 LY NN B-NP C416545
12 1255 1256 9270571 - HYPH O C416545
13 1256 1262 9270571 171555 CD B-NP C416545
14 1263 1264 9270571 ( ( O O
15 1264 1268 9270571 [4aR NN B-NP C416545
16 1268 1269 9270571 - HYPH B-NP C416545
17 1269 1275 9270571 trans] NN I-NP C416545
18 1275 1276 9270571 - HYPH B-NP C416545
19 1276 1293 9270571 4,4a,5,6,7,8,8a,9 CD I-NP C416545
20 1293 1294 9270571 - HYPH O C416545
21 1294 1295 9270571 o AFX O C416545
22 1295 1296 9270571 - HYPH O C416545
23 1296 1303 9270571 dihydro AFX O C416545
24 1303 1304 9270571 - HYPH B-NP C416545
25 1304 1306 9270571 5n NN I-NP C416545
26 1306 1307 9270571 - HYPH B-NP C416545
27 1307 1313 9270571 propyl NN I-NP C416545
28 1313 1314 9270571 - HYPH B-NP C416545
29 1314 1316 9270571 2H NN I-NP C416545
30 1316 1317 9270571 - HYPH I-NP C416545
31 1317 1323 9270571 pyrazo NN I-NP C416545
32 1324 1326 9270571 lo AFX O C416545
33 1326 1327 9270571 - HYPH B-NP C416545
34 1327 1328 9270571 3 CD I-NP C416545
35 1328 1329 9270571 - HYPH I-NP C416545
36 1329 1330 9270571 4 CD I-NP C416545
37 1330 1331 9270571 - HYPH I-NP C416545
38 1331 1340 9270571 quinoline NN I-NP C416545
39 1341 1354 9270571 hydrochloride NN I-NP C416545
40 1354 1355 9270571 ) ) O O
41 1356 1360 9270571 were VBD B-VP O
42 1361 1365 9270571 also RB I-VP O
43 1366 1370 9270571 used VBN I-VP O
44 1371 1374 9270571 for IN B-PP O
45 1375 1385 9270571 comparison NN B-NP O
46 1385 1386 9270571 . . O O

1 1387 1392 9270571 Acute JJ B-NP O
2 1393 1407 9270571 administration NN I-NP O
3 1408 1410 9270571 of IN B-PP O
4 1411 1412 9270571 A NN B-NP C095427
5 1412 1413 9270571 - HYPH I-NP C095427
6 1413 1418 9270571 86929 CD I-NP C095427
7 1419 1422 9270571 was VBD B-VP O
8 1423 1425 9270571 as RB B-ADJP O
9 1426 1437 9270571 efficacious JJ I-ADJP O
10 1438 1440 9270571 in IN B-PP O
11 1441 1452 9270571 alleviating VBG B-VP O
12 1453 1457 9270571 MPTP NN B-NP D015632
13 1457 1458 9270571 - HYPH O O
14 1458 1465 9270571 induced VBN B-NP O
15 1466 1478 9270571 parkinsonism NN I-NP D020734
16 1479 1481 9270571 as IN B-PP O
17 1482 1490 9270571 levodopa NN B-NP D007980
18 1491 1494 9270571 and CC I-NP O
19 1495 1497 9270571 LY NN I-NP C416545
20 1497 1498 9270571 - HYPH O C416545
21 1498 1504 9270571 171555 CD B-NP C416545
22 1504 1505 9270571 , , O O
23 1506 1509 9270571 but CC O O
24 1510 1513 9270571 was VBD B-VP O
25 1514 1518 9270571 less RBR B-ADJP O
26 1519 1525 9270571 likely JJ I-ADJP O
27 1526 1528 9270571 to TO B-VP O
28 1529 1538 9270571 reproduce VB I-VP O
29 1539 1542 9270571 the DT B-NP O
30 1543 1551 9270571 levodopa NN I-NP D007980
31 1551 1552 9270571 - HYPH B-NP O
32 1552 1559 9270571 induced VBN I-NP O
33 1560 1571 9270571 dyskinesias NNS I-NP D004409
34 1572 1574 9270571 in IN B-PP O
35 1575 1580 9270571 these DT B-NP O
36 1581 1588 9270571 animals NNS I-NP O
37 1589 1593 9270571 than IN B-PP O
38 1594 1598 9270571 with IN B-PP O
39 1599 1605 9270571 either CC O O
40 1606 1608 9270571 LY NN B-NP C416545
41 1608 1609 9270571 - HYPH O C416545
42 1609 1615 9270571 171555 CD B-NP C416545
43 1616 1618 9270571 or CC O O
44 1619 1629 9270571 subsequent JJ B-NP O
45 1630 1639 9270571 challenge NN I-NP O
46 1640 1642 9270571 of IN B-PP O
47 1643 1651 9270571 levodopa NN B-NP D007980
48 1651 1652 9270571 . . O O

1 1653 1662 9270571 Selective JJ B-NP O
2 1663 1674 9270571 stimulation NN I-NP O
3 1675 1677 9270571 of IN B-PP O
4 1678 1681 9270571 the DT B-NP O
5 1682 1684 9270571 DA NN I-NP D004298
6 1685 1687 9270571 D1 NN I-NP O
7 1688 1696 9270571 receptor NN I-NP O
8 1697 1700 9270571 may MD B-VP O
9 1701 1708 9270571 provide VB I-VP O
10 1709 1715 9270571 better JJR B-NP O
11 1716 1727 9270571 integration NN I-NP O
12 1728 1730 9270571 of IN B-PP O
13 1731 1737 9270571 neural JJ B-NP O
14 1738 1744 9270571 inputs NNS I-NP O
15 1745 1756 9270571 transmitted VBN B-VP O
16 1757 1759 9270571 to TO B-PP O
17 1760 1763 9270571 the DT B-NP O
18 1764 1772 9270571 internal JJ I-NP O
19 1773 1780 9270571 segment NN I-NP O
20 1781 1783 9270571 of IN B-PP O
21 1784 1787 9270571 the DT B-NP O
22 1788 1794 9270571 globus NN I-NP O
23 1795 1803 9270571 pallidus NN I-NP O
24 1804 1805 9270571 ( ( O O
25 1805 1813 9270571 referred VBN B-VP O
26 1814 1816 9270571 to TO B-PP O
27 1817 1819 9270571 as IN B-PP O
28 1820 1823 9270571 the DT B-NP O
29 1824 1829 9270571 basal JJ I-NP O
30 1830 1837 9270571 ganglia NNS I-NP O
31 1838 1844 9270571 output NN I-NP O
32 1844 1845 9270571 ) ) O O
33 1846 1854 9270571 compared VBN B-PP O
34 1855 1859 9270571 with IN B-PP O
35 1860 1868 9270571 levodopa NN B-NP D007980
36 1869 1872 9270571 and CC O O
37 1873 1882 9270571 selective JJ B-NP O
38 1883 1885 9270571 DA NN I-NP D004298
39 1886 1888 9270571 D2 NN I-NP O
40 1889 1897 9270571 receptor NN I-NP O
41 1898 1905 9270571 agonist NN I-NP O
42 1905 1906 9270571 . . O O

1 1907 1913 9270571 Potent JJ B-NP O
2 1914 1916 9270571 DA NN I-NP D004298
3 1917 1919 9270571 D1 NN I-NP O
4 1920 1928 9270571 receptor NN I-NP O
5 1929 1935 9270571 agents NNS I-NP O
6 1936 1940 9270571 with IN B-PP O
7 1941 1943 9270571 an DT B-NP O
8 1944 1956 9270571 intermediate JJ I-NP O
9 1957 1965 9270571 duration NN I-NP O
10 1966 1968 9270571 of IN B-PP O
11 1969 1977 9270571 efficacy NN B-NP O
12 1978 1982 9270571 such JJ B-PP O
13 1983 1985 9270571 as IN I-PP O
14 1986 1987 9270571 A NN B-NP C095427
15 1987 1988 9270571 - HYPH I-NP C095427
16 1988 1993 9270571 86929 CD I-NP C095427
17 1994 1995 9270571 ( ( O O
18 1995 2008 9270571 approximately RB B-NP O
19 2009 2010 9270571 4 CD I-NP O
20 2011 2013 9270571 hr NN I-NP O
21 2014 2016 9270571 at IN B-PP O
22 2017 2023 9270571 higher JJR B-NP O
23 2024 2029 9270571 doses NNS I-NP O
24 2030 2036 9270571 tested VBN B-VP O
25 2036 2037 9270571 ) ) O O
26 2038 2041 9270571 are VBP B-VP O
27 2042 2051 9270571 potential JJ B-NP O
28 2052 2063 9270571 therapeutic JJ I-NP O
29 2064 2069 9270571 tools NNS I-NP O
30 2070 2072 9270571 in IN B-PP O
31 2073 2075 9270571 PD NN B-NP D010300
32 2076 2079 9270571 and CC O O
33 2080 2085 9270571 merit NN B-NP O
34 2086 2093 9270571 further JJ I-NP O
35 2094 2103 9270571 attention NN I-NP O
36 2103 2104 9270571 . . O O

1 0 0 17702969 -DOCSTART- -X- -X- O

1 0 8 17702969 Prenatal JJ B-NP O
2 9 17 17702969 exposure NN I-NP O
3 18 20 17702969 to TO B-PP O
4 21 31 17702969 fluoxetine NN B-NP D005473
5 32 39 17702969 induces VBZ B-VP O
6 40 45 17702969 fetal JJ B-NP D005315
7 46 55 17702969 pulmonary JJ I-NP D005315
8 56 68 17702969 hypertension NN I-NP D005315
9 69 71 17702969 in IN B-PP O
10 72 75 17702969 the DT B-NP O
11 76 79 17702969 rat NN I-NP O
12 79 80 17702969 . . I-NP O
13 81 90 17702969 RATIONALE NN I-NP O
14 90 91 17702969 : : O O
15 92 102 17702969 Fluoxetine NN B-NP D005473
16 103 105 17702969 is VBZ B-VP O
17 106 107 17702969 a DT B-NP O
18 108 117 17702969 selective JJ I-NP O
19 118 127 17702969 serotonin NN I-NP D012701
20 128 136 17702969 reuptake NN I-NP O
21 137 146 17702969 inhibitor NN I-NP O
22 147 161 17702969 antidepressant NN I-NP O
23 162 168 17702969 widely RB B-VP O
24 169 173 17702969 used VBN I-VP O
25 174 176 17702969 by IN B-PP O
26 177 185 17702969 pregnant JJ B-NP O
27 186 191 17702969 women NNS I-NP O
28 191 192 17702969 . . O O

1 193 208 17702969 Epidemiological JJ B-NP O
2 209 213 17702969 data NNS I-NP O
3 214 221 17702969 suggest VBP B-VP O
4 222 226 17702969 that IN B-SBAR O
5 227 237 17702969 fluoxetine NN B-NP D005473
6 238 246 17702969 exposure NN I-NP O
7 247 257 17702969 prenatally RB B-ADVP O
8 258 267 17702969 increases VBZ B-VP O
9 268 271 17702969 the DT B-NP O
10 272 282 17702969 prevalence NN I-NP O
11 283 285 17702969 of IN B-PP O
12 286 296 17702969 persistent JJ B-NP O
13 297 306 17702969 pulmonary JJ I-NP D006976
14 307 319 17702969 hypertension NN I-NP D006976
15 320 328 17702969 syndrome NN I-NP D006976
16 329 331 17702969 of IN B-PP O
17 332 335 17702969 the DT B-NP O
18 336 343 17702969 newborn NN I-NP O
19 343 344 17702969 . . O O

1 345 348 17702969 The DT B-NP O
2 349 358 17702969 mechanism NN I-NP O
3 359 370 17702969 responsible JJ B-ADJP O
4 371 374 17702969 for IN B-PP O
5 375 379 17702969 this DT B-NP O
6 380 386 17702969 effect NN I-NP O
7 387 389 17702969 is VBZ B-VP O
8 390 397 17702969 unclear JJ B-ADJP O
9 398 401 17702969 and CC I-ADJP O
10 402 413 17702969 paradoxical JJ I-ADJP O
11 413 414 17702969 , , O O
12 415 426 17702969 considering VBG B-VP O
13 427 430 17702969 the DT B-NP O
14 431 438 17702969 current JJ I-NP O
15 439 447 17702969 evidence NN I-NP O
16 448 450 17702969 of IN B-PP O
17 451 452 17702969 a DT B-NP O
18 453 462 17702969 pulmonary JJ I-NP D006976
19 463 475 17702969 hypertension NN I-NP D006976
20 476 486 17702969 protective JJ I-NP O
21 487 497 17702969 fluoxetine NN I-NP D005473
22 498 504 17702969 effect NN I-NP O
23 505 507 17702969 in IN B-PP O
24 508 513 17702969 adult JJ B-NP O
25 514 521 17702969 rodents NNS I-NP O
26 521 522 17702969 . . O O

1 523 533 17702969 OBJECTIVES NNS B-NP O
2 533 534 17702969 : : O O
3 535 537 17702969 To TO B-VP O
4 538 546 17702969 evaluate VB I-VP O
5 547 550 17702969 the DT B-NP O
6 551 561 17702969 fluoxetine NN I-NP D005473
7 562 568 17702969 effect NN I-NP O
8 569 571 17702969 on IN B-PP O
9 572 577 17702969 fetal JJ B-NP O
10 578 581 17702969 rat NN I-NP O
11 582 591 17702969 pulmonary JJ I-NP O
12 592 600 17702969 vascular JJ I-NP O
13 601 607 17702969 smooth JJ I-NP O
14 608 614 17702969 muscle NN I-NP O
15 615 625 17702969 mechanical JJ I-NP O
16 626 636 17702969 properties NNS I-NP O
17 637 640 17702969 and CC O O
18 641 645 17702969 cell NN B-NP O
19 646 659 17702969 proliferation NN I-NP O
20 660 664 17702969 rate NN I-NP O
21 664 665 17702969 . . O O

1 666 673 17702969 METHODS NNS B-NP O
2 673 674 17702969 : : O O
3 675 683 17702969 Pregnant JJ B-NP O
4 684 688 17702969 rats NNS I-NP O
5 689 693 17702969 were VBD B-VP O
6 694 701 17702969 treated VBN I-VP O
7 702 706 17702969 with IN B-PP O
8 707 717 17702969 fluoxetine NN B-NP D005473
9 718 719 17702969 ( ( O O
10 719 721 17702969 10 CD B-NP O
11 722 724 17702969 mg NN I-NP O
12 724 725 17702969 / SYM B-NP O
13 725 727 17702969 kg NN I-NP O
14 727 728 17702969 ) ) O O
15 729 733 17702969 from IN B-PP O
16 734 737 17702969 Day NN B-NP O
17 738 740 17702969 11 CD I-NP O
18 741 748 17702969 through IN B-PP O
19 749 752 17702969 Day NN B-NP O
20 753 755 17702969 21 CD I-NP O
21 756 758 17702969 of IN B-PP O
22 759 768 17702969 gestation NN B-NP O
23 768 769 17702969 . . O O

1 770 782 17702969 MEASUREMENTS NNS B-NP O
2 783 786 17702969 AND CC I-NP O
3 787 791 17702969 MAIN NN I-NP O
4 792 799 17702969 RESULTS NNS I-NP O
5 799 800 17702969 : : O O
6 801 808 17702969 Fetuses NNS B-NP O
7 809 813 17702969 were VBD B-VP O
8 814 823 17702969 delivered VBN I-VP O
9 824 826 17702969 by IN B-PP O
10 827 835 17702969 cesarean JJ B-NP O
11 836 843 17702969 section NN I-NP O
12 843 844 17702969 . . O O

1 845 847 17702969 As IN B-SBAR O
2 848 856 17702969 compared VBN B-PP O
3 857 861 17702969 with IN B-PP O
4 862 870 17702969 controls NNS B-NP O
5 870 871 17702969 , , O O
6 872 882 17702969 fluoxetine NN B-NP D005473
7 883 891 17702969 exposure NN I-NP O
8 892 900 17702969 resulted VBD B-VP O
9 901 903 17702969 in IN B-PP O
10 904 909 17702969 fetal JJ B-NP D005315
11 910 919 17702969 pulmonary JJ I-NP D005315
12 920 932 17702969 hypertension NN I-NP D005315
13 933 935 17702969 as IN B-SBAR O
14 936 945 17702969 evidenced VBN B-VP O
15 946 948 17702969 by IN B-PP O
16 949 951 17702969 an DT B-NP O
17 952 960 17702969 increase NN I-NP O
18 961 963 17702969 in IN B-PP O
19 964 967 17702969 the DT B-NP O
20 968 974 17702969 weight NN I-NP O
21 975 980 17702969 ratio NN I-NP O
22 981 983 17702969 of IN B-PP O
23 984 987 17702969 the DT B-NP O
24 988 993 17702969 right JJ I-NP O
25 994 1003 17702969 ventricle NN I-NP O
26 1004 1006 17702969 to TO B-PP O
27 1007 1010 17702969 the DT B-NP O
28 1011 1015 17702969 left JJ I-NP O
29 1016 1025 17702969 ventricle NN I-NP O
30 1026 1030 17702969 plus CC O O
31 1031 1037 17702969 septum NN B-NP O
32 1038 1039 17702969 ( ( O O
33 1039 1040 17702969 P NN B-NP O
34 1041 1042 17702969 = SYM B-VP O
35 1043 1047 17702969 0.02 CD B-NP O
36 1047 1048 17702969 ) ) O O
37 1049 1052 17702969 and CC O O
38 1053 1055 17702969 by IN B-PP O
39 1056 1058 17702969 an DT B-NP O
40 1059 1067 17702969 increase NN I-NP O
41 1068 1070 17702969 in IN B-PP O
42 1071 1080 17702969 pulmonary JJ B-NP O
43 1081 1089 17702969 arterial JJ I-NP O
44 1090 1096 17702969 medial JJ I-NP O
45 1097 1106 17702969 thickness NN I-NP O
46 1107 1108 17702969 ( ( O O
47 1108 1109 17702969 P NN B-NP O
48 1110 1111 17702969 < SYM O O
49 1112 1116 17702969 0.01 CD B-NP O
50 1116 1117 17702969 ) ) O O
51 1117 1118 17702969 . . O O

1 1119 1128 17702969 Postnatal JJ B-NP O
2 1129 1138 17702969 mortality NN I-NP O
3 1139 1142 17702969 was VBD B-VP O
4 1143 1152 17702969 increased VBN I-VP O
5 1153 1158 17702969 among IN B-PP O
6 1159 1171 17702969 experimental JJ B-NP O
7 1172 1179 17702969 animals NNS I-NP O
8 1179 1180 17702969 , , O O
9 1181 1184 17702969 and CC O O
10 1185 1193 17702969 arterial JJ B-NP O
11 1194 1200 17702969 oxygen NN I-NP D010100
12 1201 1211 17702969 saturation NN I-NP O
13 1212 1215 17702969 was VBD B-VP O
14 1216 1218 17702969 96 CD B-NP O
15 1219 1220 17702969 + SYM O O
16 1220 1221 17702969 / SYM O O
17 1221 1222 17702969 - SYM B-NP O
18 1223 1225 17702969 1% CD B-NP O
19 1226 1228 17702969 in IN B-PP O
20 1229 1230 17702969 1 CD B-NP O
21 1230 1231 17702969 - HYPH I-NP O
22 1231 1234 17702969 day NN I-NP O
23 1234 1235 17702969 - HYPH O O
24 1235 1238 17702969 old JJ B-NP O
25 1239 1246 17702969 control NN I-NP O
26 1247 1254 17702969 animals NNS I-NP O
27 1255 1258 17702969 and CC O O
28 1259 1272 17702969 significantly RB B-ADJP O
29 1273 1278 17702969 lower JJR I-ADJP O
30 1279 1280 17702969 ( ( O O
31 1280 1281 17702969 P NN B-NP O
32 1282 1283 17702969 < SYM O O
33 1284 1288 17702969 0.01 CD B-NP O
34 1288 1289 17702969 ) ) O O
35 1290 1292 17702969 in IN B-PP O
36 1293 1303 17702969 fluoxetine NN B-NP D005473
37 1303 1304 17702969 - HYPH B-NP O
38 1304 1311 17702969 exposed VBN I-NP O
39 1312 1316 17702969 pups NNS I-NP O
40 1317 1318 17702969 ( ( O O
41 1318 1320 17702969 79 CD B-NP O
42 1321 1322 17702969 + SYM O O
43 1322 1323 17702969 / SYM O O
44 1323 1324 17702969 - SYM O O
45 1325 1327 17702969 2% CD B-NP O
46 1327 1328 17702969 ) ) O O
47 1328 1329 17702969 . . O O

1 1330 1332 17702969 In FW B-ADVP O
2 1333 1338 17702969 vitro FW I-ADVP O
3 1338 1339 17702969 , , O O
4 1340 1350 17702969 fluoxetine NN B-NP D005473
5 1351 1358 17702969 induced VBD B-VP O
6 1359 1368 17702969 pulmonary JJ B-NP O
7 1369 1377 17702969 arterial JJ I-NP O
8 1378 1384 17702969 muscle NN I-NP O
9 1385 1396 17702969 contraction NN I-NP O
10 1397 1399 17702969 in IN B-PP O
11 1400 1405 17702969 fetal JJ B-NP O
12 1405 1406 17702969 , , I-NP O
13 1407 1410 17702969 but CC I-NP O
14 1411 1414 17702969 not RB I-NP O
15 1415 1420 17702969 adult JJ I-NP O
16 1420 1421 17702969 , , O O
17 1422 1429 17702969 animals NNS B-NP O
18 1430 1431 17702969 ( ( O O
19 1431 1432 17702969 P NN B-NP O
20 1433 1434 17702969 < SYM O O
21 1435 1439 17702969 0.01 CD B-NP O
22 1439 1440 17702969 ) ) O O
23 1441 1444 17702969 and CC O O
24 1445 1452 17702969 reduced VBD B-VP O
25 1453 1462 17702969 serotonin NN B-NP D012701
26 1462 1463 17702969 - HYPH B-NP O
27 1463 1470 17702969 induced VBN I-NP O
28 1471 1482 17702969 contraction NN I-NP O
29 1483 1485 17702969 at IN B-PP O
30 1486 1490 17702969 both DT B-NP O
31 1491 1495 17702969 ages NNS I-NP O
32 1496 1497 17702969 ( ( O O
33 1497 1498 17702969 P NN B-NP O
34 1499 1500 17702969 < SYM O O
35 1501 1505 17702969 0.01 CD B-NP O
36 1505 1506 17702969 ) ) O O
37 1506 1507 17702969 . . O O

1 1508 1513 17702969 After IN B-PP O
2 1514 1516 17702969 in IN B-PP O
3 1517 1522 17702969 utero NN B-NP O
4 1523 1531 17702969 exposure NN I-NP O
5 1532 1534 17702969 to TO B-PP O
6 1535 1536 17702969 a DT B-NP O
7 1537 1540 17702969 low JJ I-NP O
8 1541 1551 17702969 fluoxetine NN I-NP D005473
9 1552 1565 17702969 concentration NN I-NP O
10 1566 1569 17702969 the DT B-NP O
11 1570 1579 17702969 pulmonary JJ I-NP O
12 1580 1588 17702969 arterial JJ I-NP O
13 1589 1595 17702969 smooth JJ I-NP O
14 1596 1602 17702969 muscle NN I-NP O
15 1603 1607 17702969 cell NN I-NP O
16 1608 1621 17702969 proliferation NN I-NP O
17 1622 1626 17702969 rate NN I-NP O
18 1627 1630 17702969 was VBD B-VP O
19 1631 1644 17702969 significantly RB I-VP O
20 1645 1654 17702969 increased VBN I-VP O
21 1655 1657 17702969 in IN B-PP O
22 1658 1663 17702969 fetal JJ B-NP O
23 1663 1664 17702969 , , I-NP O
24 1665 1668 17702969 but CC I-NP O
25 1669 1672 17702969 not RB I-NP O
26 1673 1678 17702969 adult JJ I-NP O
27 1678 1679 17702969 , , O O
28 1680 1685 17702969 cells NNS B-NP O
29 1686 1687 17702969 ( ( O O
30 1687 1688 17702969 P NN B-NP O
31 1689 1690 17702969 < SYM O O
32 1691 1695 17702969 0.01 CD B-NP O
33 1695 1696 17702969 ) ) O O
34 1696 1697 17702969 . . O O

1 1698 1709 17702969 CONCLUSIONS NNS B-NP O
2 1709 1710 17702969 : : O O
3 1711 1713 17702969 In IN B-PP O
4 1714 1722 17702969 contrast NN B-NP O
5 1723 1725 17702969 to TO B-PP O
6 1726 1729 17702969 the DT B-NP O
7 1730 1735 17702969 adult NN I-NP O
8 1735 1736 17702969 , , O O
9 1737 1747 17702969 fluoxetine NN B-NP D005473
10 1748 1756 17702969 exposure NN I-NP O
11 1757 1759 17702969 in IN B-PP O
12 1760 1765 17702969 utero NN B-NP O
13 1766 1773 17702969 induces VBZ B-VP O
14 1774 1783 17702969 pulmonary JJ B-NP D006976
15 1784 1796 17702969 hypertension NN I-NP D006976
16 1797 1799 17702969 in IN B-PP O
17 1800 1803 17702969 the DT B-NP O
18 1804 1809 17702969 fetal JJ I-NP O
19 1810 1813 17702969 rat NN I-NP O
20 1814 1816 17702969 as IN B-PP O
21 1817 1818 17702969 a DT B-NP O
22 1819 1825 17702969 result NN I-NP O
23 1826 1828 17702969 of IN B-PP O
24 1829 1830 17702969 a DT B-NP O
25 1831 1846 17702969 developmentally RB I-NP O
26 1847 1856 17702969 regulated VBN I-NP O
27 1857 1865 17702969 increase NN I-NP O
28 1866 1868 17702969 in IN B-PP O
29 1869 1878 17702969 pulmonary JJ B-NP O
30 1879 1887 17702969 vascular JJ I-NP O
31 1888 1894 17702969 smooth JJ I-NP O
32 1895 1901 17702969 muscle NN I-NP O
33 1902 1915 17702969 proliferation NN I-NP O
34 1915 1916 17702969 . . O O

1 0 0 9514561 -DOCSTART- -X- -X- O

1 0 12 9514561 Experimental JJ B-NP O
2 13 20 9514561 cranial JJ I-NP O
3 21 25 9514561 pain NN I-NP D010146
4 26 34 9514561 elicited VBN B-VP O
5 35 37 9514561 by IN B-PP O
6 38 47 9514561 capsaicin NN B-NP D002211
7 47 48 9514561 : : O O
8 49 50 9514561 a DT B-NP O
9 51 54 9514561 PET NN I-NP O
10 55 60 9514561 study NN I-NP O
11 60 61 9514561 . . O O
12 62 67 9514561 Using VBG B-VP O
13 68 69 9514561 a DT B-NP O
14 70 78 9514561 positron NN I-NP O
15 79 87 9514561 emission NN I-NP O
16 88 98 9514561 tomography NN I-NP O
17 99 100 9514561 ( ( O O
18 100 103 9514561 PET NN B-NP O
19 103 104 9514561 ) ) O O
20 105 110 9514561 study NN B-NP O
21 111 113 9514561 it PRP B-NP O
22 114 117 9514561 was VBD B-VP O
23 118 123 9514561 shown VBN I-VP O
24 124 132 9514561 recently RB B-ADVP O
25 133 137 9514561 that IN B-SBAR O
26 138 140 9514561 in IN B-PP O
27 141 149 9514561 migraine NN B-NP D008881
28 150 157 9514561 without IN B-PP O
29 158 162 9514561 aura NN B-NP O
30 163 170 9514561 certain JJ I-NP O
31 171 176 9514561 areas NNS I-NP O
32 177 179 9514561 in IN B-PP O
33 180 183 9514561 the DT B-NP O
34 184 189 9514561 brain NN I-NP O
35 190 194 9514561 stem NN I-NP O
36 195 199 9514561 were VBD B-VP O
37 200 209 9514561 activated VBN I-VP O
38 210 216 9514561 during IN B-PP O
39 217 220 9514561 the DT B-NP O
40 221 229 9514561 headache NN I-NP D006261
41 230 235 9514561 state NN I-NP O
42 235 236 9514561 , , O O
43 237 240 9514561 but CC B-PP O
44 241 244 9514561 not RB B-PP O
45 245 247 9514561 in IN I-PP O
46 248 251 9514561 the DT B-NP O
47 252 260 9514561 headache NN I-NP D006261
48 261 265 9514561 free JJ I-NP O
49 266 274 9514561 interval NN I-NP O
50 274 275 9514561 . . O O

1 276 278 9514561 It PRP B-NP O
2 279 282 9514561 was VBD B-VP O
3 283 292 9514561 suggested VBN I-VP O
4 293 297 9514561 that IN B-SBAR O
5 298 302 9514561 this DT B-NP O
6 303 308 9514561 brain NN I-NP O
7 309 313 9514561 stem NN I-NP O
8 314 324 9514561 activation NN I-NP O
9 325 327 9514561 is VBZ B-VP O
10 328 336 9514561 inherent JJ B-ADJP O
11 337 339 9514561 to TO B-PP O
12 340 343 9514561 the DT B-NP O
13 344 352 9514561 migraine NN I-NP D008881
14 353 359 9514561 attack NN I-NP O
15 360 366 9514561 itself PRP B-NP O
16 367 370 9514561 and CC O O
17 371 381 9514561 represents VBZ B-VP O
18 382 385 9514561 the DT B-NP O
19 386 388 9514561 so RB I-NP O
20 389 395 9514561 called VBN I-NP O
21 396 397 9514561 ' `` I-NP O
22 397 405 9514561 migraine NN I-NP D008881
23 406 415 9514561 generator NN I-NP O
24 415 416 9514561 ' '' O O
25 416 417 9514561 . . O O

1 418 420 9514561 To TO B-VP O
2 421 425 9514561 test VB I-VP O
3 426 430 9514561 this DT B-NP O
4 431 441 9514561 hypothesis NN I-NP O
5 442 444 9514561 we PRP B-NP O
6 445 454 9514561 performed VBD B-VP O
7 455 457 9514561 an DT B-NP O
8 458 470 9514561 experimental JJ I-NP O
9 471 475 9514561 pain NN I-NP D010146
10 476 481 9514561 study NN I-NP O
11 482 484 9514561 in IN B-PP O
12 485 490 9514561 seven CD B-NP O
13 491 498 9514561 healthy JJ I-NP O
14 499 509 9514561 volunteers NNS I-NP O
15 509 510 9514561 , , O O
16 511 516 9514561 using VBG B-VP O
17 517 520 9514561 the DT B-NP O
18 521 525 9514561 same JJ I-NP O
19 526 537 9514561 positioning NN I-NP O
20 538 540 9514561 in IN B-PP O
21 541 544 9514561 the DT B-NP O
22 545 548 9514561 PET NN I-NP O
23 549 556 9514561 scanner NN I-NP O
24 557 559 9514561 as IN B-PP O
25 560 562 9514561 in IN B-PP O
26 563 566 9514561 the DT B-NP O
27 567 575 9514561 migraine NN I-NP D008881
28 576 584 9514561 patients NNS I-NP O
29 584 585 9514561 . . O O

1 586 587 9514561 A DT B-NP O
2 588 593 9514561 small JJ I-NP O
3 594 600 9514561 amount NN I-NP O
4 601 603 9514561 of IN B-PP O
5 604 613 9514561 capsaicin NN B-NP D002211
6 614 617 9514561 was VBD B-VP O
7 618 630 9514561 administered VBN I-VP O
8 631 645 9514561 subcutaneously RB B-ADVP O
9 646 648 9514561 in IN B-PP O
10 649 652 9514561 the DT B-NP O
11 653 658 9514561 right JJ I-NP O
12 659 667 9514561 forehead NN I-NP O
13 668 670 9514561 to TO B-VP O
14 671 676 9514561 evoke VB I-VP O
15 677 678 9514561 a DT B-NP O
16 679 686 9514561 burning VBG I-NP O
17 687 694 9514561 painful JJ I-NP D010146
18 695 704 9514561 sensation NN I-NP O
19 705 707 9514561 in IN B-PP O
20 708 711 9514561 the DT B-NP O
21 712 717 9514561 first JJ I-NP O
22 718 726 9514561 division NN I-NP O
23 727 729 9514561 of IN B-PP O
24 730 733 9514561 the DT B-NP O
25 734 744 9514561 trigeminal JJ I-NP O
26 745 750 9514561 nerve NN I-NP O
27 750 751 9514561 . . O O

1 752 761 9514561 Increases NNS B-NP O
2 762 764 9514561 of IN B-PP O
3 765 773 9514561 regional JJ B-NP O
4 774 782 9514561 cerebral JJ I-NP O
5 783 788 9514561 blood NN I-NP O
6 789 793 9514561 flow NN I-NP O
7 794 795 9514561 ( ( O O
8 795 799 9514561 rCBF NN B-NP O
9 799 800 9514561 ) ) O O
10 801 805 9514561 were VBD B-VP O
11 806 811 9514561 found VBN I-VP O
12 812 823 9514561 bilaterally RB B-ADVP O
13 824 826 9514561 in IN B-PP O
14 827 830 9514561 the DT B-NP O
15 831 837 9514561 insula NN I-NP O
16 837 838 9514561 , , O O
17 839 841 9514561 in IN B-PP O
18 842 845 9514561 the DT B-NP O
19 846 854 9514561 anterior JJ I-NP O
20 855 864 9514561 cingulate NN I-NP O
21 865 871 9514561 cortex NN I-NP O
22 871 872 9514561 , , O O
23 873 876 9514561 the DT B-NP O
24 877 886 9514561 cavernous JJ I-NP O
25 887 892 9514561 sinus NN I-NP O
26 893 896 9514561 and CC O O
27 897 900 9514561 the DT B-NP O
28 901 911 9514561 cerebellum NN I-NP O
29 911 912 9514561 . . O O

1 913 918 9514561 Using VBG B-VP O
2 919 922 9514561 the DT B-NP O
3 923 927 9514561 same JJ I-NP O
4 928 940 9514561 stereotactic JJ I-NP O
5 941 946 9514561 space NN I-NP O
6 947 953 9514561 limits NNS I-NP O
7 954 956 9514561 as IN B-PP O
8 957 959 9514561 in IN B-PP O
9 960 963 9514561 the DT B-NP O
10 964 969 9514561 above RB I-NP O
11 970 979 9514561 mentioned VBN I-NP O
12 980 988 9514561 migraine NN I-NP D008881
13 989 994 9514561 study NN I-NP O
14 995 997 9514561 no DT B-NP O
15 998 1003 9514561 brain NN I-NP O
16 1004 1008 9514561 stem NN I-NP O
17 1009 1019 9514561 activation NN I-NP O
18 1020 1023 9514561 was VBD B-VP O
19 1024 1029 9514561 found VBN I-VP O
20 1030 1032 9514561 in IN B-PP O
21 1033 1036 9514561 the DT B-NP O
22 1037 1042 9514561 acute JJ I-NP O
23 1043 1047 9514561 pain NN I-NP D010146
24 1048 1053 9514561 state NN I-NP O
25 1054 1062 9514561 compared VBN B-VP O
26 1063 1065 9514561 to TO B-PP O
27 1066 1069 9514561 the DT B-NP O
28 1070 1074 9514561 pain NN I-NP D010146
29 1075 1079 9514561 free JJ I-NP O
30 1080 1085 9514561 state NN I-NP O
31 1085 1086 9514561 . . O O

1 1087 1090 9514561 The DT B-NP O
2 1091 1099 9514561 increase NN I-NP O
3 1100 1102 9514561 of IN B-PP O
4 1103 1113 9514561 activation NN B-NP O
5 1114 1116 9514561 in IN B-PP O
6 1117 1120 9514561 the DT B-NP O
7 1121 1127 9514561 region NN I-NP O
8 1128 1130 9514561 of IN B-PP O
9 1131 1134 9514561 the DT B-NP O
10 1135 1144 9514561 cavernous JJ I-NP O
11 1145 1150 9514561 sinus NN I-NP O
12 1151 1158 9514561 however RB B-ADVP O
13 1158 1159 9514561 , , O O
14 1160 1168 9514561 suggests VBZ B-VP O
15 1169 1173 9514561 that IN B-SBAR O
16 1174 1178 9514561 this DT B-NP O
17 1179 1188 9514561 structure NN I-NP O
18 1189 1191 9514561 is VBZ B-VP O
19 1192 1196 9514561 more RBR B-ADJP O
20 1197 1203 9514561 likely JJ I-ADJP O
21 1204 1206 9514561 to TO B-VP O
22 1207 1209 9514561 be VB I-VP O
23 1210 1218 9514561 involved VBN I-VP O
24 1219 1221 9514561 in IN B-PP O
25 1222 1232 9514561 trigeminal JJ B-NP O
26 1233 1244 9514561 transmitted VBN I-NP O
27 1245 1249 9514561 pain NN I-NP D010146
28 1250 1252 9514561 as IN B-PP O
29 1253 1257 9514561 such JJ B-NP O
30 1257 1258 9514561 , , O O
31 1259 1265 9514561 rather RB B-PP O
32 1266 1270 9514561 than IN I-PP O
33 1271 1273 9514561 in IN B-PP O
34 1274 1275 9514561 a DT B-NP O
35 1276 1284 9514561 specific JJ I-NP O
36 1285 1289 9514561 type NN I-NP O
37 1290 1292 9514561 of IN B-PP O
38 1293 1301 9514561 headache NN B-NP D006261
39 1302 1304 9514561 as IN B-SBAR O
40 1305 1308 9514561 was VBD B-VP O
41 1309 1318 9514561 suggested VBN I-VP O
42 1319 1322 9514561 for IN B-PP O
43 1323 1330 9514561 cluster NN B-NP D003027
44 1331 1339 9514561 headache NN I-NP D003027
45 1339 1340 9514561 . . O O

1 0 0 10414674 -DOCSTART- -X- -X- O

1 0 7 10414674 Effects NNS B-NP O
2 8 10 10414674 of IN B-PP O
3 11 23 10414674 nonsteroidal JJ B-NP O
4 24 28 10414674 anti AFX I-NP O
5 28 29 10414674 - HYPH I-NP O
6 29 41 10414674 inflammatory JJ I-NP O
7 42 47 10414674 drugs NNS I-NP O
8 48 50 10414674 on IN B-PP O
9 51 61 10414674 hemostasis NN B-NP O
10 62 64 10414674 in IN B-PP O
11 65 73 10414674 patients NNS B-NP O
12 74 78 10414674 with IN B-PP O
13 79 89 10414674 aneurysmal JJ B-NP D013345
14 90 102 10414674 subarachnoid JJ I-NP D013345
15 103 113 10414674 hemorrhage NN I-NP D013345
16 113 114 10414674 . . O O
17 115 123 10414674 Platelet NN B-NP O
18 124 132 10414674 function NN I-NP O
19 133 135 10414674 is VBZ B-VP O
20 136 144 10414674 impaired VBN I-VP O
21 145 147 10414674 by IN B-PP O
22 148 160 10414674 nonsteroidal JJ B-NP O
23 161 165 10414674 anti AFX I-NP O
24 165 166 10414674 - HYPH I-NP O
25 166 178 10414674 inflammatory JJ I-NP O
26 179 184 10414674 drugs NNS I-NP O
27 185 186 10414674 ( ( O O
28 186 192 10414674 NSAIDs NNS B-NP O
29 192 193 10414674 ) ) O O
30 194 198 10414674 with IN B-PP O
31 199 208 10414674 prominent JJ B-NP O
32 209 213 10414674 anti AFX I-NP O
33 213 214 10414674 - HYPH I-NP O
34 214 226 10414674 inflammatory JJ I-NP O
35 227 237 10414674 properties NNS I-NP O
36 237 238 10414674 . . O O

1 239 244 10414674 Their PRP$ B-NP O
2 245 251 10414674 safety NN I-NP O
3 252 254 10414674 in IN B-PP O
4 255 263 10414674 patients NNS B-NP O
5 264 274 10414674 undergoing VBG B-VP O
6 275 287 10414674 intracranial JJ B-NP O
7 288 295 10414674 surgery NN I-NP O
8 296 298 10414674 is VBZ B-VP O
9 299 304 10414674 under IN B-PP O
10 305 311 10414674 debate NN B-NP O
11 311 312 10414674 . . O O

1 313 321 10414674 Patients NNS B-NP O
2 322 326 10414674 with IN B-PP O
3 327 337 10414674 aneurysmal JJ B-NP D013345
4 338 350 10414674 subarachnoid JJ I-NP D013345
5 351 361 10414674 hemorrhage NN I-NP D013345
6 362 363 10414674 ( ( O O
7 363 366 10414674 SAH NN B-NP D013345
8 366 367 10414674 ) ) O O
9 368 372 10414674 were VBD B-VP O
10 373 383 10414674 randomized VBN I-VP O
11 384 386 10414674 to TO B-VP O
12 387 394 10414674 receive VB I-VP O
13 395 401 10414674 either CC O O
14 402 412 10414674 ketoprofen NN B-NP D007660
15 412 413 10414674 , , O O
16 414 417 10414674 100 CD B-NP O
17 418 420 10414674 mg NN I-NP O
18 420 421 10414674 , , O O
19 422 427 10414674 three CD B-NP O
20 428 433 10414674 times NNS I-NP O
21 434 435 10414674 a DT B-NP O
22 436 439 10414674 day NN I-NP O
23 440 441 10414674 ( ( O O
24 441 451 10414674 ketoprofen NN B-NP D007660
25 452 457 10414674 group NN I-NP O
26 457 458 10414674 , , O O
27 459 460 10414674 n NN B-NP O
28 461 462 10414674 = SYM B-VP O
29 463 464 10414674 9 CD B-NP O
30 464 465 10414674 ) ) O O
31 466 468 10414674 or CC O O
32 469 470 10414674 a DT B-NP O
33 471 475 10414674 weak JJ I-NP O
34 476 481 10414674 NSAID NN I-NP O
35 481 482 10414674 , , O O
36 483 496 10414674 acetaminophen NN B-NP D000082
37 496 497 10414674 , , O O
38 498 499 10414674 1 CD B-NP O
39 500 501 10414674 g NN I-NP O
40 501 502 10414674 , , O O
41 503 508 10414674 three CD B-NP O
42 509 514 10414674 times NNS I-NP O
43 515 516 10414674 a DT B-NP O
44 517 520 10414674 day NN I-NP O
45 521 522 10414674 ( ( O O
46 522 535 10414674 acetaminophen NN B-NP D000082
47 536 541 10414674 group NN I-NP O
48 541 542 10414674 , , O O
49 543 544 10414674 n NN B-NP O
50 545 546 10414674 = SYM B-VP O
51 547 548 10414674 9 CD B-NP O
52 548 549 10414674 ) ) O O
53 550 558 10414674 starting VBG B-VP O
54 559 570 10414674 immediately RB B-ADVP O
55 571 576 10414674 after IN B-PP O
56 577 580 10414674 the DT B-NP O
57 581 590 10414674 diagnosis NN I-NP O
58 591 593 10414674 of IN B-PP O
59 594 604 10414674 aneurysmal JJ B-NP D017542
60 605 608 10414674 SAH NN I-NP D013345
61 608 609 10414674 . . O O

1 610 619 10414674 Treatment NN B-NP O
2 620 623 10414674 was VBD B-VP O
3 624 633 10414674 continued VBN I-VP O
4 634 637 10414674 for IN B-PP O
5 638 639 10414674 3 CD B-NP O
6 640 644 10414674 days NNS I-NP O
7 645 660 10414674 postoperatively RB B-ADVP O
8 660 661 10414674 . . O O

1 662 666 10414674 Test JJS B-NP O
2 667 672 10414674 blood NN I-NP O
3 673 680 10414674 samples NNS I-NP O
4 681 685 10414674 were VBD B-VP O
5 686 691 10414674 taken VBN I-VP O
6 692 698 10414674 before IN B-PP O
7 699 708 10414674 treatment NN B-NP O
8 709 712 10414674 and CC I-NP O
9 713 720 10414674 surgery NN I-NP O
10 721 723 10414674 as RB B-CONJP O
11 724 728 10414674 well RB I-CONJP O
12 729 731 10414674 as IN I-CONJP O
13 732 734 10414674 on IN B-PP O
14 735 738 10414674 the DT B-NP O
15 739 744 10414674 first JJ I-NP O
16 744 745 10414674 , , I-NP O
17 746 751 10414674 third JJ I-NP O
18 751 752 10414674 , , O O
19 753 756 10414674 and CC O O
20 757 762 10414674 fifth JJ B-NP O
21 763 776 10414674 postoperative JJ I-NP O
22 777 785 10414674 mornings NNS I-NP O
23 785 786 10414674 . . O O

1 787 794 10414674 Maximal JJ B-NP O
2 795 803 10414674 platelet NN I-NP D001791
3 804 815 10414674 aggregation NN I-NP D001791
4 816 823 10414674 induced VBN B-VP O
5 824 826 10414674 by IN B-PP O
6 827 828 10414674 6 CD B-NP O
7 829 835 10414674 microM NN I-NP O
8 836 838 10414674 of IN B-PP O
9 839 848 10414674 adenosine NN B-NP D000244
10 849 860 10414674 diphosphate NN I-NP D000244
11 861 870 10414674 decreased VBD B-VP O
12 871 876 10414674 after IN B-PP O
13 877 891 10414674 administration NN B-NP O
14 892 894 10414674 of IN B-PP O
15 895 905 10414674 ketoprofen NN B-NP D007660
16 905 906 10414674 . . O O

1 907 918 10414674 Aggregation NN B-NP O
2 919 922 10414674 was VBD B-VP O
3 923 928 10414674 lower JJR B-ADJP O
4 929 930 10414674 ( ( O O
5 930 931 10414674 P NN B-NP O
6 932 933 10414674 < JJR B-NP O
7 934 937 10414674 .05 CD I-NP O
8 937 938 10414674 ) ) O O
9 939 941 10414674 in IN B-PP O
10 942 945 10414674 the DT B-NP O
11 946 956 10414674 ketoprofen NN I-NP D007660
12 957 962 10414674 group NN I-NP O
13 963 967 10414674 than IN B-PP O
14 968 970 10414674 in IN B-PP O
15 971 974 10414674 the DT B-NP O
16 975 988 10414674 acetaminophen NN I-NP D000082
17 989 994 10414674 group NN I-NP O
18 995 999 10414674 just RB B-ADVP O
19 1000 1006 10414674 before IN B-PP O
20 1007 1014 10414674 surgery NN B-NP O
21 1015 1018 10414674 and CC B-PP O
22 1019 1021 10414674 on IN B-PP O
23 1022 1025 10414674 the DT B-NP O
24 1026 1031 10414674 third JJ I-NP O
25 1032 1045 10414674 postoperative JJ I-NP O
26 1046 1049 10414674 day NN I-NP O
27 1049 1050 10414674 . . O O

1 1051 1053 10414674 In IN B-PP O
2 1054 1062 10414674 contrast NN B-NP O
3 1062 1063 10414674 , , O O
4 1064 1071 10414674 maximal JJ B-NP O
5 1072 1080 10414674 platelet NN I-NP D001791
6 1081 1092 10414674 aggregation NN I-NP D001791
7 1093 1102 10414674 increased VBD B-VP O
8 1103 1105 10414674 in IN B-PP O
9 1106 1109 10414674 the DT B-NP O
10 1110 1123 10414674 acetaminophen NN I-NP D000082
11 1124 1129 10414674 group NN I-NP O
12 1130 1132 10414674 on IN B-PP O
13 1133 1136 10414674 the DT B-NP O
14 1137 1142 10414674 third JJ I-NP O
15 1143 1156 10414674 postoperative JJ I-NP O
16 1157 1160 10414674 day NN I-NP O
17 1161 1163 10414674 as IN B-PP O
18 1164 1172 10414674 compared VBN B-PP O
19 1173 1177 10414674 with IN B-PP O
20 1178 1181 10414674 the DT B-NP O
21 1182 1194 10414674 pretreatment NN I-NP O
22 1195 1203 10414674 platelet NN I-NP D001791
23 1204 1215 10414674 aggregation NN I-NP D001791
24 1216 1223 10414674 results NNS I-NP O
25 1224 1225 10414674 ( ( O O
26 1225 1226 10414674 P NN B-NP O
27 1227 1228 10414674 < JJR B-NP O
28 1229 1232 10414674 .05 CD I-NP O
29 1232 1233 10414674 ) ) O O
30 1233 1234 10414674 . . O O

1 1235 1238 10414674 One CD B-NP O
2 1239 1246 10414674 patient NN I-NP O
3 1247 1249 10414674 in IN B-PP O
4 1250 1253 10414674 the DT B-NP O
5 1254 1264 10414674 ketoprofen NN I-NP D007660
6 1265 1270 10414674 group NN I-NP O
7 1271 1280 10414674 developed VBD B-VP O
8 1281 1282 10414674 a DT B-NP O
9 1283 1296 10414674 postoperative JJ I-NP O
10 1297 1309 10414674 intracranial JJ I-NP O
11 1310 1318 10414674 hematoma NN I-NP D006406
12 1318 1319 10414674 . . O O

1 1320 1331 10414674 Coagulation NN B-NP O
2 1332 1333 10414674 ( ( O O
3 1333 1344 10414674 prothrombin NN B-NP O
4 1345 1349 10414674 time NN I-NP O
5 1350 1351 10414674 [ ( O O
6 1351 1353 10414674 PT NN B-NP O
7 1353 1354 10414674 ] ) O O
8 1354 1355 10414674 , , O O
9 1356 1365 10414674 activated VBN B-VP O
10 1366 1373 10414674 partial JJ B-NP O
11 1374 1388 10414674 thromboplastin NN I-NP O
12 1389 1393 10414674 time NN I-NP O
13 1394 1395 10414674 [ ( O O
14 1395 1399 10414674 APPT NN B-NP O
15 1399 1400 10414674 ] ) O O
16 1400 1401 10414674 , , O O
17 1402 1412 10414674 fibrinogen NN B-NP O
18 1413 1426 10414674 concentration NN I-NP O
19 1426 1427 10414674 , , O O
20 1428 1431 10414674 and CC O O
21 1432 1444 10414674 antithrombin NN B-NP O
22 1445 1448 10414674 III CD I-NP O
23 1449 1450 10414674 [ ( O O
24 1450 1452 10414674 AT NN B-NP O
25 1453 1456 10414674 III CD I-NP O
26 1456 1457 10414674 ] ) O O
27 1457 1458 10414674 ) ) O O
28 1459 1462 10414674 was VBD B-VP O
29 1463 1473 10414674 comparable JJ B-ADJP O
30 1474 1481 10414674 between IN B-PP O
31 1482 1485 10414674 the DT B-NP O
32 1486 1489 10414674 two CD I-NP O
33 1490 1496 10414674 groups NNS I-NP O
34 1496 1497 10414674 . . O O

1 1498 1508 10414674 Ketoprofen NN B-NP D007660
2 1509 1512 10414674 but CC O O
3 1513 1516 10414674 not RB O O
4 1517 1530 10414674 acetaminophen VB B-VP D000082
5 1531 1539 10414674 impaired JJ B-NP O
6 1540 1548 10414674 platelet NN I-NP O
7 1549 1557 10414674 function NN I-NP O
8 1558 1560 10414674 in IN B-PP O
9 1561 1569 10414674 patients NNS B-NP O
10 1570 1574 10414674 with IN B-PP O
11 1575 1578 10414674 SAH NN B-NP D013345
12 1578 1579 10414674 . . O O

1 1580 1582 10414674 If IN B-SBAR O
2 1583 1593 10414674 ketoprofen NN B-NP D007660
3 1594 1596 10414674 is VBZ B-VP O
4 1597 1601 10414674 used VBN I-VP O
5 1602 1608 10414674 before IN B-PP O
6 1609 1616 10414674 surgery NN B-NP O
7 1617 1619 10414674 on IN B-PP O
8 1620 1628 10414674 cerebral JJ B-NP O
9 1629 1635 10414674 artery NN I-NP D002532
10 1636 1645 10414674 aneurysms NNS I-NP D002532
11 1645 1646 10414674 , , O O
12 1647 1649 10414674 it PRP B-NP O
13 1650 1653 10414674 may MD B-VP O
14 1654 1658 10414674 pose VB I-VP O
15 1659 1661 10414674 an DT B-NP O
16 1662 1672 10414674 additional JJ I-NP O
17 1673 1677 10414674 risk NN I-NP O
18 1678 1684 10414674 factor NN I-NP O
19 1685 1688 10414674 for IN B-PP O
20 1689 1699 10414674 hemorrhage NN B-NP D006470
21 1699 1700 10414674 . . O O

1 0 0 11890511 -DOCSTART- -X- -X- O

1 0 8 11890511 Erectile JJ B-NP D007172
2 9 20 11890511 dysfunction NN I-NP D007172
3 21 27 11890511 occurs VBZ B-VP O
4 28 37 11890511 following VBG B-PP O
5 38 48 11890511 substantia NN B-NP O
6 49 54 11890511 nigra NN I-NP O
7 55 62 11890511 lesions NNS I-NP O
8 63 65 11890511 in IN B-PP O
9 66 69 11890511 the DT B-NP O
10 70 73 11890511 rat NN I-NP O
11 73 74 11890511 . . O O
12 75 83 11890511 Erectile JJ B-NP O
13 84 92 11890511 function NN I-NP O
14 93 96 11890511 was VBD B-VP O
15 97 105 11890511 assessed VBN I-VP O
16 106 107 11890511 6 CD B-NP O
17 108 113 11890511 weeks NNS I-NP O
18 114 123 11890511 following VBG B-PP O
19 124 127 11890511 uni AFX B-NP O
20 127 128 11890511 - HYPH I-NP O
21 129 132 11890511 and CC I-NP O
22 133 142 11890511 bilateral JJ I-NP O
23 143 153 11890511 injections NNS I-NP O
24 154 156 11890511 of IN B-PP O
25 157 158 11890511 6 CD B-NP D016627
26 158 159 11890511 - HYPH I-NP D016627
27 159 174 11890511 hydroxydopamine NN I-NP D016627
28 175 177 11890511 in IN B-PP O
29 178 181 11890511 the DT B-NP O
30 182 192 11890511 substantia NN I-NP O
31 193 198 11890511 nigra NN I-NP O
32 199 206 11890511 nucleus NN I-NP O
33 207 209 11890511 of IN B-PP O
34 210 213 11890511 the DT B-NP O
35 214 219 11890511 brain NN I-NP O
36 219 220 11890511 . . O O

1 221 231 11890511 Behavioral JJ B-NP O
2 232 243 11890511 apomorphine NN I-NP D001058
3 243 244 11890511 - HYPH O O
4 244 251 11890511 induced VBN B-NP O
5 252 258 11890511 penile JJ I-NP O
6 259 268 11890511 erections NNS I-NP O
7 269 273 11890511 were VBD B-VP O
8 274 281 11890511 reduced VBN I-VP O
9 282 283 11890511 ( ( O O
10 283 284 11890511 5 CD B-NP O
11 284 285 11890511 / SYM I-NP O
12 285 286 11890511 8 CD I-NP O
13 286 287 11890511 ) ) O O
14 288 291 11890511 and CC O O
15 292 301 11890511 increased VBN B-VP O
16 302 303 11890511 ( ( O O
17 303 304 11890511 3 CD B-NP O
18 304 305 11890511 / SYM I-NP O
19 305 306 11890511 8 CD I-NP O
20 306 307 11890511 ) ) O O
21 308 310 11890511 in IN B-PP O
22 311 314 11890511 uni AFX B-NP O
23 314 315 11890511 - HYPH I-NP O
24 316 319 11890511 and CC I-NP O
25 320 329 11890511 bilateral JJ I-NP O
26 330 338 11890511 lesioned VBN I-NP O
27 339 346 11890511 animals NNS I-NP O
28 346 347 11890511 . . O O

1 348 362 11890511 Intracavernous JJ B-NP O
2 363 372 11890511 pressures NNS I-NP O
3 372 373 11890511 , , O O
4 374 383 11890511 following VBG B-PP O
5 384 394 11890511 electrical JJ B-NP O
6 395 406 11890511 stimulation NN I-NP O
7 407 409 11890511 of IN B-PP O
8 410 413 11890511 the DT B-NP O
9 414 423 11890511 cavernous JJ I-NP O
10 424 429 11890511 nerve NN I-NP O
11 429 430 11890511 , , O O
12 431 440 11890511 decreased VBN B-VP O
13 441 443 11890511 in IN B-PP O
14 444 452 11890511 lesioned VBN B-NP O
15 453 460 11890511 animals NNS I-NP O
16 460 461 11890511 . . O O

1 462 469 11890511 Lesions NNS B-NP O
2 470 472 11890511 of IN B-PP O
3 473 476 11890511 the DT B-NP O
4 477 487 11890511 substantia NN I-NP O
5 488 493 11890511 nigra NN I-NP O
6 494 498 11890511 were VBD B-VP O
7 499 508 11890511 confirmed VBN I-VP O
8 509 511 11890511 by IN B-PP O
9 512 521 11890511 histology NN B-NP O
10 521 522 11890511 . . O O

1 523 536 11890511 Concentration NN B-NP O
2 537 539 11890511 of IN B-PP O
3 540 548 11890511 dopamine NN B-NP D004298
4 549 552 11890511 and CC O O
5 553 556 11890511 its PRP$ B-NP O
6 557 568 11890511 metabolites NNS I-NP O
7 569 573 11890511 were VBD B-VP O
8 574 583 11890511 decreased VBN I-VP O
9 584 586 11890511 in IN B-PP O
10 587 590 11890511 the DT B-NP O
11 591 599 11890511 striatum NN I-NP O
12 600 602 11890511 of IN B-PP O
13 603 613 11890511 substantia NN B-NP O
14 614 619 11890511 nigra NN I-NP O
15 620 628 11890511 lesioned VBD B-VP O
16 629 633 11890511 rats NNS B-NP O
17 633 634 11890511 . . O O

1 635 642 11890511 Lesions NNS B-NP O
2 643 645 11890511 of IN B-PP O
3 646 649 11890511 the DT B-NP O
4 650 660 11890511 substantia NN I-NP O
5 661 666 11890511 nigra NN I-NP O
6 667 670 11890511 are VBP B-VP O
7 671 680 11890511 therefore RB I-VP O
8 681 691 11890511 associated VBN I-VP O
9 692 696 11890511 with IN B-PP O
10 697 705 11890511 erectile JJ B-NP D007172
11 706 717 11890511 dysfunction NN I-NP D007172
12 718 720 11890511 in IN B-PP O
13 721 725 11890511 rats NNS B-NP O
14 726 729 11890511 and CC O O
15 730 733 11890511 may MD B-VP O
16 734 739 11890511 serve VB I-VP O
17 740 742 11890511 as IN B-PP O
18 743 744 11890511 a DT B-NP O
19 745 750 11890511 model NN I-NP O
20 751 753 11890511 to TO B-VP O
21 754 759 11890511 study VB I-VP O
22 760 768 11890511 erectile JJ B-NP D007172
23 769 780 11890511 dysfunction NN I-NP D007172
24 781 783 11890511 in IN B-PP O
25 784 795 11890511 Parkinson's NNP B-NP D010300
26 796 803 11890511 disease NN I-NP D010300
27 803 804 11890511 . . O O

1 0 0 9165568 -DOCSTART- -X- -X- O

1 0 11 9165568 Neuroleptic JJ B-NP D009459
2 12 21 9165568 malignant JJ I-NP D009459
3 22 30 9165568 syndrome NN I-NP D009459
4 31 35 9165568 with IN B-PP O
5 36 47 9165568 risperidone NN B-NP D018967
6 47 48 9165568 . . O O
7 49 60 9165568 Neuroleptic JJ B-NP D009459
8 61 70 9165568 malignant JJ I-NP D009459
9 71 79 9165568 syndrome NN I-NP D009459
10 80 82 9165568 is VBZ B-VP O
11 83 90 9165568 thought VBN I-VP O
12 91 93 9165568 to TO I-VP O
13 94 96 9165568 be VB I-VP O
14 97 98 9165568 a DT B-NP O
15 99 105 9165568 result NN I-NP O
16 106 108 9165568 of IN B-PP O
17 109 117 9165568 dopamine NN B-NP D004298
18 118 120 9165568 D2 NN I-NP O
19 121 129 9165568 receptor NN I-NP O
20 130 138 9165568 blockade NN I-NP O
21 139 141 9165568 in IN B-PP O
22 142 145 9165568 the DT B-NP O
23 146 154 9165568 striatum NN I-NP O
24 155 157 9165568 of IN B-PP O
25 158 161 9165568 the DT B-NP O
26 162 167 9165568 basal JJ I-NP O
27 168 175 9165568 ganglia NNS I-NP O
28 175 176 9165568 . . O O

1 177 188 9165568 Risperidone NN B-NP D018967
2 188 189 9165568 , , O O
3 190 191 9165568 a DT B-NP O
4 192 205 9165568 benzisoxazole NN I-NP C441200
5 206 216 9165568 derivative NN I-NP O
6 217 230 9165568 antipsychotic JJ B-ADJP O
7 230 231 9165568 , , O O
8 232 235 9165568 has VBZ B-VP O
9 236 240 9165568 high JJ B-NP O
10 241 250 9165568 serotonin NN I-NP D012701
11 251 252 9165568 5 CD I-NP O
12 252 253 9165568 - HYPH I-NP O
13 253 256 9165568 HT2 NN I-NP O
14 257 265 9165568 receptor NN I-NP O
15 266 274 9165568 blockade NN I-NP O
16 275 278 9165568 and CC I-NP O
17 279 283 9165568 dose NN I-NP O
18 283 284 9165568 - HYPH B-NP O
19 284 291 9165568 related VBN I-NP O
20 292 294 9165568 D2 NN I-NP O
21 295 303 9165568 receptor NN I-NP O
22 304 312 9165568 blockade NN I-NP O
23 312 313 9165568 . . O O

1 314 317 9165568 The DT B-NP O
2 318 322 9165568 high JJ I-NP O
3 323 328 9165568 ratio NN I-NP O
4 329 331 9165568 is VBZ B-VP O
5 332 340 9165568 believed VBN I-VP O
6 341 343 9165568 to TO I-VP O
7 344 350 9165568 impart VB I-VP O
8 351 354 9165568 the DT B-NP O
9 355 358 9165568 low JJ I-NP O
10 359 368 9165568 frequency NN I-NP O
11 369 371 9165568 of IN B-PP O
12 372 386 9165568 extrapyramidal JJ B-NP D001480
13 387 395 9165568 symptoms NNS I-NP D001480
14 396 400 9165568 with IN B-PP O
15 401 412 9165568 risperidone NN B-NP D018967
16 413 415 9165568 at IN B-PP O
17 416 419 9165568 low JJ B-NP O
18 420 427 9165568 dosages NNS I-NP O
19 427 428 9165568 . . O O

1 429 433 9165568 With IN B-PP O
2 434 438 9165568 this DT B-NP O
3 439 442 9165568 low JJ I-NP O
4 443 452 9165568 frequency NN I-NP O
5 453 455 9165568 of IN B-PP O
6 456 470 9165568 extrapyramidal JJ B-NP D001480
7 471 479 9165568 symptoms NNS I-NP D001480
8 479 480 9165568 , , O O
9 481 483 9165568 it PRP B-NP O
10 484 487 9165568 was VBD B-VP O
11 488 495 9165568 thought VBN I-VP O
12 496 499 9165568 the DT B-NP O
13 500 509 9165568 frequency NN I-NP O
14 510 512 9165568 of IN B-PP O
15 513 524 9165568 neuroleptic JJ B-NP D009459
16 525 534 9165568 malignant JJ I-NP D009459
17 535 543 9165568 syndrome NN I-NP D009459
18 544 549 9165568 might MD B-VP O
19 550 554 9165568 also RB I-VP O
20 555 557 9165568 be VB I-VP O
21 558 565 9165568 lowered VBN I-VP O
22 565 566 9165568 . . O O

1 567 568 9165568 A DT B-NP O
2 569 571 9165568 73 CD I-NP O
3 571 572 9165568 - HYPH I-NP O
4 572 576 9165568 year NN I-NP O
5 576 577 9165568 - HYPH O O
6 577 580 9165568 old JJ B-NP O
7 581 586 9165568 woman NN I-NP O
8 587 596 9165568 developed VBD B-VP O
9 597 608 9165568 neuroleptic JJ B-NP D009459
10 609 618 9165568 malignant JJ I-NP D009459
11 619 627 9165568 syndrome NN I-NP D009459
12 628 633 9165568 after IN B-PP O
13 634 645 9165568 monotherapy NN B-NP O
14 646 650 9165568 with IN B-PP O
15 651 662 9165568 risperidone NN B-NP D018967
16 662 663 9165568 . . O O

1 664 667 9165568 The DT B-NP O
2 668 676 9165568 syndrome NN I-NP O
3 677 685 9165568 reversed VBD B-VP O
4 686 691 9165568 after IN B-PP O
5 692 705 9165568 discontinuing VBG B-VP O
6 706 717 9165568 risperidone NN B-NP D018967
7 718 721 9165568 and CC O O
8 722 730 9165568 starting VBG B-VP O
9 731 740 9165568 treatment NN B-NP O
10 741 745 9165568 with IN B-PP O
11 746 756 9165568 dantrolene NN B-NP D003620
12 757 760 9165568 and CC I-NP O
13 761 774 9165568 bromocriptine NN I-NP D001971
14 774 775 9165568 . . O O

1 776 778 9165568 It PRP B-NP O
2 779 786 9165568 appears VBZ B-VP O
3 787 791 9165568 that IN B-SBAR O
4 792 795 9165568 the DT B-NP O
5 796 806 9165568 protection NN I-NP O
6 807 811 9165568 from IN B-PP O
7 812 826 9165568 extrapyramidal JJ B-NP O
8 827 831 9165568 side NN I-NP O
9 832 839 9165568 effects NNS I-NP O
10 840 848 9165568 observed VBN B-VP O
11 849 853 9165568 with IN B-PP O
12 854 865 9165568 risperidone NN B-NP D018967
13 866 870 9165568 does VBZ B-VP O
14 871 874 9165568 not RB I-VP O
15 875 881 9165568 ensure VB I-VP O
16 882 892 9165568 protection NN B-NP O
17 893 897 9165568 from IN B-PP O
18 898 909 9165568 neuroleptic JJ B-NP D009459
19 910 919 9165568 malignant JJ I-NP D009459
20 920 928 9165568 syndrome NN I-NP D009459
21 928 929 9165568 . . O O

1 0 0 3411101 -DOCSTART- -X- -X- O

1 0 9 3411101 Quinidine NN B-NP C033457
2 10 32 3411101 phenylethylbarbiturate NN I-NP C033457
3 32 33 3411101 - HYPH O O
4 33 40 3411101 induced VBN B-NP O
5 41 50 3411101 fulminant JJ I-NP O
6 51 60 3411101 hepatitis NN I-NP D056486
7 61 63 3411101 in IN B-PP O
8 64 65 3411101 a DT B-NP O
9 66 74 3411101 pregnant JJ I-NP O
10 75 80 3411101 woman NN I-NP O
11 80 81 3411101 . . O O

1 82 83 3411101 A DT B-NP O
2 84 88 3411101 case NN I-NP O
3 89 95 3411101 report NN I-NP O
4 95 96 3411101 . . O O
5 97 99 3411101 We PRP B-NP O
6 100 106 3411101 report VBP B-VP O
7 107 110 3411101 the DT B-NP O
8 111 115 3411101 case NN I-NP O
9 116 118 3411101 of IN B-PP O
10 119 120 3411101 a DT B-NP O
11 121 123 3411101 19 CD I-NP O
12 123 124 3411101 - HYPH I-NP O
13 124 128 3411101 year NN I-NP O
14 128 129 3411101 - HYPH O O
15 129 132 3411101 old JJ B-NP O
16 133 140 3411101 Laotian JJ I-NP O
17 141 148 3411101 patient NN I-NP O
18 149 157 3411101 affected VBN B-VP O
19 158 160 3411101 by IN B-PP O
20 161 170 3411101 fulminant JJ B-NP O
21 171 180 3411101 hepatitis NN I-NP D056486
22 181 187 3411101 during IN B-PP O
23 188 191 3411101 the DT B-NP O
24 192 197 3411101 third JJ I-NP O
25 198 207 3411101 trimester NN I-NP O
26 208 210 3411101 of IN B-PP O
27 211 214 3411101 her PRP$ B-NP O
28 215 224 3411101 pregnancy NN I-NP O
29 225 230 3411101 after IN B-PP O
30 231 232 3411101 a DT B-NP O
31 233 234 3411101 1 CD I-NP O
32 234 235 3411101 - HYPH I-NP O
33 235 240 3411101 month NN I-NP O
34 241 255 3411101 administration NN I-NP O
35 256 258 3411101 of IN B-PP O
36 259 268 3411101 quinidine NN B-NP C033457
37 269 291 3411101 phenylethylbarbiturate NN I-NP C033457
38 291 292 3411101 . . O O

1 293 298 3411101 After IN B-PP O
2 299 307 3411101 delivery NN B-NP O
3 307 308 3411101 , , O O
4 309 312 3411101 the DT B-NP O
5 313 320 3411101 patient NN I-NP O
6 321 330 3411101 underwent VBD B-VP O
7 331 341 3411101 orthotopic JJ B-NP O
8 342 347 3411101 liver NN I-NP O
9 348 363 3411101 transplantation NN I-NP O
10 363 364 3411101 . . O O

1 365 368 3411101 The DT B-NP O
2 369 376 3411101 patient NN I-NP O
3 377 380 3411101 was VBD B-VP O
4 381 383 3411101 in IN B-PP O
5 384 388 3411101 good JJ B-NP O
6 389 398 3411101 condition NN I-NP O
7 399 401 3411101 16 CD B-NP O
8 402 408 3411101 months NNS I-NP O
9 409 414 3411101 after IN B-SBAR O
10 415 420 3411101 liver NN B-NP O
11 421 436 3411101 transplantation NN I-NP O
12 436 437 3411101 . . O O

1 438 447 3411101 Quinidine NN B-NP D011802
2 448 454 3411101 itself PRP B-NP O
3 455 457 3411101 or CC O O
4 458 480 3411101 phenylethylbarbiturate VB B-VP C033457
5 481 484 3411101 may MD B-VP O
6 485 487 3411101 be VB I-VP O
7 488 499 3411101 responsible JJ B-ADJP O
8 500 503 3411101 for IN B-PP O
9 504 513 3411101 fulminant JJ B-NP O
10 514 523 3411101 hepatitis NN I-NP D056486
11 524 526 3411101 in IN B-PP O
12 527 531 3411101 this DT B-NP O
13 532 539 3411101 patient NN I-NP O
14 539 540 3411101 . . O O

1 0 0 12109865 -DOCSTART- -X- -X- O

1 0 3 12109865 Low JJ B-NP D006495
2 3 4 12109865 - HYPH I-NP D006495
3 4 13 12109865 molecular JJ I-NP D006495
4 13 14 12109865 - HYPH I-NP D006495
5 14 20 12109865 weight NN I-NP D006495
6 21 28 12109865 heparin NN I-NP D006495
7 29 32 12109865 for IN B-PP O
8 33 36 12109865 the DT B-NP O
9 37 46 12109865 treatment NN I-NP O
10 47 49 12109865 of IN B-PP O
11 50 58 12109865 patients NNS B-NP O
12 59 63 12109865 with IN B-PP O
13 64 74 12109865 mechanical JJ B-NP O
14 75 80 12109865 heart NN I-NP O
15 81 87 12109865 valves NNS I-NP O
16 87 88 12109865 . . O O
17 89 99 12109865 BACKGROUND NN B-NP O
18 99 100 12109865 : : O O
19 101 104 12109865 The DT B-NP O
20 105 117 12109865 interruption NN I-NP O
21 118 120 12109865 of IN B-PP O
22 121 125 12109865 oral JJ B-NP O
23 126 139 12109865 anticoagulant NN I-NP O
24 140 141 12109865 ( ( O O
25 141 144 12109865 OAC NN B-NP O
26 144 145 12109865 ) ) O O
27 146 160 12109865 administration NN B-NP O
28 161 163 12109865 is VBZ B-VP O
29 164 173 12109865 sometimes RB I-VP O
30 174 183 12109865 indicated VBN I-VP O
31 184 186 12109865 in IN B-PP O
32 187 195 12109865 patients NNS B-NP O
33 196 200 12109865 with IN B-PP O
34 201 211 12109865 mechanical JJ B-NP O
35 212 217 12109865 heart NN I-NP O
36 218 224 12109865 valves NNS I-NP O
37 224 225 12109865 , , O O
38 226 232 12109865 mainly RB B-ADVP O
39 233 239 12109865 before IN B-PP O
40 240 250 12109865 noncardiac JJ B-NP O
41 251 258 12109865 surgery NN I-NP O
42 258 259 12109865 , , O O
43 260 263 12109865 non AFX B-NP O
44 263 264 12109865 - HYPH I-NP O
45 264 272 12109865 surgical JJ B-NP O
46 273 286 12109865 interventions NNS I-NP O
47 286 287 12109865 , , O O
48 288 291 12109865 and CC O O
49 292 301 12109865 pregnancy NN B-NP O
50 301 302 12109865 . . O O

1 303 317 12109865 Unfractionated JJ B-NP D006493
2 318 325 12109865 heparin NN I-NP D006493
3 326 327 12109865 ( ( O O
4 327 329 12109865 UH NN B-NP D006493
5 329 330 12109865 ) ) O O
6 331 333 12109865 is VBZ B-VP O
7 334 343 12109865 currently RB B-ADVP O
8 344 347 12109865 the DT B-NP O
9 348 358 12109865 substitute NN I-NP O
10 359 362 12109865 for IN B-PP O
11 363 371 12109865 selected VBN B-NP O
12 372 380 12109865 patients NNS I-NP O
13 380 381 12109865 . . O O

1 382 385 12109865 Low JJ B-NP D006495
2 385 386 12109865 - HYPH I-NP D006495
3 386 395 12109865 molecular JJ I-NP D006495
4 395 396 12109865 - HYPH I-NP D006495
5 396 402 12109865 weight NN I-NP D006495
6 403 410 12109865 heparin NN I-NP D006495
7 411 412 12109865 ( ( O O
8 412 416 12109865 LMWH NN B-NP D006495
9 416 417 12109865 ) ) O O
10 418 424 12109865 offers VBZ B-VP O
11 425 436 12109865 theoretical JJ B-NP O
12 437 447 12109865 advantages NNS I-NP O
13 448 452 12109865 over IN B-PP O
14 453 455 12109865 UH NN B-NP D006493
15 455 456 12109865 , , O O
16 457 460 12109865 but CC O O
17 461 463 12109865 is VBZ B-VP O
18 464 467 12109865 not RB I-VP O
19 468 477 12109865 currently RB I-VP O
20 478 488 12109865 considered VBN I-VP O
21 489 491 12109865 in IN B-PP O
22 492 500 12109865 clinical JJ B-NP O
23 501 511 12109865 guidelines NNS I-NP O
24 512 514 12109865 as IN B-PP O
25 515 517 12109865 an DT B-NP O
26 518 529 12109865 alternative NN I-NP O
27 530 532 12109865 to TO B-PP O
28 533 535 12109865 UH NN B-NP D006493
29 536 538 12109865 in IN B-PP O
30 539 547 12109865 patients NNS B-NP O
31 548 552 12109865 with IN B-PP O
32 553 563 12109865 prosthetic JJ B-NP O
33 564 570 12109865 valves NNS I-NP O
34 570 571 12109865 . . O O

1 572 582 12109865 HYPOTHESIS NN B-NP O
2 582 583 12109865 : : O O
3 584 587 12109865 The DT B-NP O
4 588 591 12109865 aim NN I-NP O
5 592 594 12109865 of IN B-PP O
6 595 598 12109865 the DT B-NP O
7 599 606 12109865 present JJ I-NP O
8 607 612 12109865 study NN I-NP O
9 613 616 12109865 was VBD B-VP O
10 617 619 12109865 to TO B-VP O
11 620 626 12109865 review VB I-VP O
12 627 630 12109865 the DT B-NP O
13 631 635 12109865 data NNS I-NP O
14 636 647 12109865 accumulated VBN B-VP O
15 648 650 12109865 so RB B-ADVP O
16 651 654 12109865 far RB I-ADVP O
17 655 657 12109865 on IN B-PP O
18 658 661 12109865 the DT B-NP O
19 662 665 12109865 use NN I-NP O
20 666 668 12109865 of IN B-PP O
21 669 673 12109865 LMWH NN B-NP D006495
22 674 676 12109865 in IN B-PP O
23 677 681 12109865 this DT B-NP O
24 682 689 12109865 patient NN I-NP O
25 690 700 12109865 population NN I-NP O
26 701 704 12109865 and CC O O
27 705 707 12109865 to TO B-VP O
28 708 715 12109865 discuss VB I-VP O
29 716 719 12109865 its PRP$ B-NP O
30 720 733 12109865 applicability NN I-NP O
31 734 736 12109865 in IN B-PP O
32 737 743 12109865 common JJ B-NP O
33 744 752 12109865 practice NN I-NP O
34 752 753 12109865 . . O O

1 754 761 12109865 METHODS NNS B-NP O
2 761 762 12109865 : : O O
3 763 766 12109865 For IN B-PP O
4 767 771 12109865 this DT B-NP O
5 772 777 12109865 paper NN I-NP O
6 777 778 12109865 , , O O
7 779 782 12109865 the DT B-NP O
8 783 790 12109865 current JJ I-NP O
9 791 798 12109865 medical JJ I-NP O
10 799 809 12109865 literature NN I-NP O
11 810 812 12109865 on IN B-PP O
12 813 817 12109865 LMWH NN B-NP D006495
13 818 820 12109865 in IN B-PP O
14 821 829 12109865 patients NNS B-NP O
15 830 834 12109865 with IN B-PP O
16 835 845 12109865 mechanical JJ B-NP O
17 846 851 12109865 heart NN I-NP O
18 852 858 12109865 valves NNS I-NP O
19 859 862 12109865 was VBD B-VP O
20 863 874 12109865 extensively RB I-VP O
21 875 883 12109865 reviewed VBN I-VP O
22 883 884 12109865 . . O O

1 885 892 12109865 RESULTS NNS B-NP O
2 892 893 12109865 : : O O
3 894 899 12109865 There EX B-NP O
4 900 904 12109865 were VBD B-VP O
5 905 910 12109865 eight CD B-NP O
6 911 917 12109865 series NN I-NP O
7 918 921 12109865 and CC O O
8 922 925 12109865 six CD B-NP O
9 926 930 12109865 case NN I-NP O
10 931 938 12109865 reports NNS I-NP O
11 938 939 12109865 . . O O

1 940 944 12109865 None NN B-NP O
2 945 947 12109865 of IN B-PP O
3 948 951 12109865 the DT B-NP O
4 952 959 12109865 studies NNS I-NP O
5 960 963 12109865 was VBD B-VP O
6 964 974 12109865 randomized VBN I-VP O
7 974 975 12109865 , , O O
8 976 979 12109865 and CC O O
9 980 984 12109865 only RB B-NP O
10 985 988 12109865 one CD I-NP O
11 989 992 12109865 was VBD B-VP O
12 993 1004 12109865 prospective JJ B-ADJP O
13 1004 1005 12109865 . . O O

1 1006 1010 12109865 Data NNS B-NP O
2 1011 1013 12109865 to TO B-VP O
3 1014 1023 12109865 establish VB I-VP O
4 1024 1027 12109865 the DT B-NP O
5 1028 1042 12109865 thromboembolic JJ I-NP D013923
6 1043 1047 12109865 risk NN I-NP O
7 1048 1052 12109865 were VBD B-VP O
8 1053 1063 12109865 incomplete JJ B-ADJP O
9 1063 1064 12109865 . . O O

1 1065 1070 12109865 After IN B-PP O
2 1071 1080 12109865 excluding VBG B-VP O
3 1081 1085 12109865 case NN B-NP O
4 1086 1093 12109865 reports NNS I-NP O
5 1093 1094 12109865 , , O O
6 1095 1098 12109865 the DT B-NP O
7 1099 1108 12109865 following VBG I-NP O
8 1109 1115 12109865 groups NNS I-NP O
9 1116 1120 12109865 were VBD B-VP O
10 1121 1132 12109865 constructed VBN I-VP O
11 1132 1133 12109865 : : O O
12 1134 1135 12109865 ( ( B-LST O
13 1135 1136 12109865 a LS I-LST O
14 1136 1137 12109865 ) ) O O
15 1138 1143 12109865 short JJ B-NP O
16 1143 1144 12109865 - HYPH I-NP O
17 1144 1148 12109865 term NN I-NP O
18 1149 1163 12109865 administration NN I-NP O
19 1163 1164 12109865 , , O O
20 1165 1170 12109865 after IN B-PP O
21 1171 1176 12109865 valve NN B-NP O
22 1177 1186 12109865 insertion NN I-NP O
23 1187 1188 12109865 ( ( O O
24 1188 1189 12109865 n NN B-NP O
25 1190 1191 12109865 = SYM B-VP O
26 1192 1195 12109865 212 CD B-NP O
27 1195 1196 12109865 ) ) O O
28 1196 1197 12109865 ; : O O
29 1198 1199 12109865 ( ( B-LST O
30 1199 1200 12109865 b LS I-LST O
31 1200 1201 12109865 ) ) O O
32 1202 1207 12109865 short JJ B-NP O
33 1207 1208 12109865 - HYPH I-NP O
34 1208 1212 12109865 term NN I-NP O
35 1212 1213 12109865 , , O O
36 1214 1227 12109865 perioperative JJ O O
37 1228 1229 12109865 ( ( O O
38 1229 1239 12109865 noncardiac JJ B-ADJP O
39 1239 1240 12109865 ) ) O O
40 1240 1241 12109865 / SYM O O
41 1241 1255 12109865 periprocedural JJ O O
42 1256 1257 12109865 ( ( O O
43 1257 1258 12109865 n NN B-NP O
44 1259 1260 12109865 = SYM B-VP O
45 1261 1264 12109865 114 CD B-NP O
46 1264 1265 12109865 ) ) O O
47 1265 1266 12109865 ; : O O
48 1267 1268 12109865 ( ( B-LST O
49 1268 1269 12109865 c LS I-LST O
50 1269 1270 12109865 ) ) O O
51 1271 1275 12109865 long JJ B-NP O
52 1275 1276 12109865 - HYPH I-NP O
53 1276 1280 12109865 term NN I-NP O
54 1280 1281 12109865 , , O O
55 1282 1285 12109865 due IN B-PP O
56 1286 1288 12109865 to TO I-PP O
57 1289 1300 12109865 intolerance NN B-NP O
58 1301 1303 12109865 to TO B-PP O
59 1304 1307 12109865 OAC NN B-NP O
60 1308 1309 12109865 ( ( O O
61 1309 1310 12109865 n NN B-NP O
62 1311 1312 12109865 = SYM B-VP O
63 1313 1315 12109865 16 CD B-NP O
64 1315 1316 12109865 ) ) O O
65 1316 1317 12109865 ; : O O
66 1318 1319 12109865 ( ( B-LST O
67 1319 1320 12109865 d LS I-LST O
68 1320 1321 12109865 ) ) O O
69 1322 1326 12109865 long JJ O O
70 1326 1327 12109865 - HYPH O O
71 1327 1331 12109865 term NN B-NP O
72 1331 1332 12109865 , , O O
73 1333 1335 12109865 in IN B-PP O
74 1336 1345 12109865 pregnancy NN B-NP O
75 1346 1347 12109865 ( ( O O
76 1347 1348 12109865 n NN B-NP O
77 1349 1350 12109865 = SYM B-VP O
78 1351 1353 12109865 10 CD B-NP O
79 1353 1354 12109865 ) ) O O
80 1354 1355 12109865 . . O O

1 1356 1359 12109865 The DT B-NP O
2 1360 1369 12109865 incidence NN I-NP O
3 1370 1374 12109865 rate NN I-NP O
4 1375 1377 12109865 of IN B-PP O
5 1378 1393 12109865 thromboembolism NN B-NP D013923
6 1394 1397 12109865 was VBD B-VP O
7 1398 1402 12109865 0.9% CD B-NP O
8 1403 1406 12109865 for IN B-PP O
9 1407 1410 12109865 all PDT B-NP O
10 1411 1414 12109865 the DT I-NP O
11 1415 1422 12109865 studies NNS I-NP O
12 1423 1426 12109865 and CC I-NP O
13 1427 1430 12109865 0.5 CD I-NP O
14 1430 1431 12109865 , , I-NP O
15 1432 1433 12109865 0 CD I-NP O
16 1433 1434 12109865 , , I-NP O
17 1435 1437 12109865 20 CD I-NP O
18 1437 1438 12109865 , , O O
19 1439 1442 12109865 and CC O O
20 1443 1445 12109865 0% NN B-NP O
21 1446 1448 12109865 in IN B-PP O
22 1449 1455 12109865 groups NNS B-NP O
23 1456 1457 12109865 a NN I-NP O
24 1457 1458 12109865 , , O O
25 1459 1460 12109865 b NN B-NP O
26 1460 1461 12109865 , , O O
27 1462 1463 12109865 c NN B-NP O
28 1463 1464 12109865 , , O O
29 1465 1468 12109865 and CC O O
30 1469 1470 12109865 d NN B-NP O
31 1470 1471 12109865 , , O O
32 1472 1484 12109865 respectively RB B-ADVP O
33 1484 1485 12109865 ; : O O
34 1486 1489 12109865 for IN B-PP O
35 1490 1500 12109865 hemorrhage NN B-NP D006470
36 1500 1501 12109865 , , O O
37 1502 1505 12109865 the DT B-NP O
38 1506 1513 12109865 overall JJ I-NP O
39 1514 1518 12109865 rate NN I-NP O
40 1519 1522 12109865 was VBD B-VP O
41 1523 1527 12109865 3.4% CD B-NP O
42 1528 1529 12109865 ( ( O O
43 1529 1532 12109865 3.8 CD B-NP O
44 1532 1533 12109865 , , I-NP O
45 1534 1537 12109865 2.6 CD I-NP O
46 1537 1538 12109865 , , I-NP O
47 1539 1541 12109865 10 CD I-NP O
48 1541 1542 12109865 , , O O
49 1543 1546 12109865 and CC O O
50 1547 1549 12109865 0% CD B-NP O
51 1550 1553 12109865 for IN B-PP O
52 1554 1557 12109865 the DT B-NP O
53 1558 1568 12109865 respective JJ I-NP O
54 1569 1575 12109865 groups NNS I-NP O
55 1575 1576 12109865 ) ) O O
56 1576 1577 12109865 . . O O

1 1578 1589 12109865 CONCLUSIONS NNS B-NP O
2 1589 1590 12109865 : : O O
3 1591 1593 12109865 In IN B-PP O
4 1594 1602 12109865 patients NNS B-NP O
5 1603 1607 12109865 with IN B-PP O
6 1608 1618 12109865 mechanical JJ B-NP O
7 1619 1624 12109865 heart NN I-NP O
8 1625 1631 12109865 valves NNS I-NP O
9 1631 1632 12109865 , , O O
10 1633 1638 12109865 short JJ B-NP O
11 1638 1639 12109865 - HYPH I-NP O
12 1639 1643 12109865 term NN I-NP O
13 1644 1648 12109865 LMWH NN I-NP D006495
14 1649 1656 12109865 therapy NN I-NP O
15 1657 1665 12109865 compares VBZ B-VP O
16 1666 1675 12109865 favorably RB B-ADVP O
17 1676 1680 12109865 with IN B-PP O
18 1681 1683 12109865 UH NN B-NP D006493
19 1683 1684 12109865 . . O O

1 1685 1689 12109865 Data NNS B-NP O
2 1690 1692 12109865 on IN B-PP O
3 1693 1696 12109865 mid NN B-NP O
4 1696 1697 12109865 - HYPH I-NP O
5 1698 1701 12109865 and CC I-NP O
6 1702 1706 12109865 long JJ I-NP O
7 1706 1707 12109865 - HYPH I-NP O
8 1707 1711 12109865 term NN I-NP O
9 1712 1716 12109865 LMWH NN I-NP D006495
10 1717 1731 12109865 administration NN I-NP O
11 1732 1734 12109865 in IN B-PP O
12 1735 1740 12109865 these DT B-NP O
13 1741 1749 12109865 patients NNS I-NP O
14 1750 1753 12109865 are VBP B-VP O
15 1754 1760 12109865 sparse JJ B-ADJP O
16 1760 1761 12109865 . . O O

1 1762 1769 12109865 Further RB B-NP O
2 1770 1780 12109865 randomized VBN I-NP O
3 1781 1788 12109865 studies NNS I-NP O
4 1789 1792 12109865 are VBP B-VP O
5 1793 1799 12109865 needed VBN I-VP O
6 1800 1802 12109865 to TO B-VP O
7 1803 1810 12109865 confirm VB I-VP O
8 1811 1814 12109865 the DT B-NP O
9 1815 1821 12109865 safety NN I-NP O
10 1822 1825 12109865 and CC I-NP O
11 1826 1833 12109865 precise JJ I-NP O
12 1834 1845 12109865 indications NNS I-NP O
13 1846 1849 12109865 for IN B-PP O
14 1850 1853 12109865 the DT B-NP O
15 1854 1857 12109865 use NN I-NP O
16 1858 1860 12109865 of IN B-PP O
17 1861 1865 12109865 LMWH NN B-NP D006495
18 1866 1868 12109865 in IN B-PP O
19 1869 1877 12109865 patients NNS B-NP O
20 1878 1882 12109865 with IN B-PP O
21 1883 1893 12109865 mechanical JJ B-NP O
22 1894 1899 12109865 heart NN I-NP O
23 1900 1906 12109865 valves NNS I-NP O
24 1906 1907 12109865 . . O O

1 0 0 16826348 -DOCSTART- -X- -X- O

1 0 10 16826348 Peripheral JJ B-NP D010523
2 11 21 16826348 neuropathy NN I-NP D010523
3 22 28 16826348 caused VBN B-VP O
4 29 31 16826348 by IN B-PP O
5 32 36 16826348 high JJ B-NP O
6 36 37 16826348 - HYPH I-NP O
7 37 41 16826348 dose NN I-NP O
8 42 50 16826348 cytosine NN I-NP D003561
9 51 62 16826348 arabinoside NN I-NP D003561
10 63 72 16826348 treatment NN I-NP O
11 73 75 16826348 in IN B-PP O
12 76 77 16826348 a DT B-NP O
13 78 85 16826348 patient NN I-NP O
14 86 90 16826348 with IN B-PP O
15 91 96 16826348 acute JJ B-NP D015470
16 97 104 16826348 myeloid JJ I-NP D015470
17 105 113 16826348 leukemia NN I-NP D015470
18 113 114 16826348 . . O O
19 115 118 16826348 The DT B-NP O
20 119 126 16826348 central JJ I-NP O
21 127 134 16826348 nervous JJ I-NP O
22 135 141 16826348 system NN I-NP O
23 142 150 16826348 toxicity NN I-NP D064420
24 151 153 16826348 of IN B-PP O
25 154 158 16826348 high JJ B-NP O
26 158 159 16826348 - HYPH I-NP O
27 159 163 16826348 dose NN I-NP O
28 164 172 16826348 cytosine NN I-NP D003561
29 173 184 16826348 arabinoside NN I-NP D003561
30 185 187 16826348 is VBZ B-VP O
31 188 192 16826348 well RB I-VP O
32 193 203 16826348 recognized VBN I-VP O
33 203 204 16826348 , , O O
34 205 208 16826348 but CC O O
35 209 212 16826348 the DT B-NP O
36 213 221 16826348 toxicity NN I-NP D064420
37 222 224 16826348 of IN B-PP O
38 225 233 16826348 cytosine NN B-NP D003561
39 234 245 16826348 arabinoside NN I-NP D003561
40 246 248 16826348 in IN B-PP O
41 249 252 16826348 the DT B-NP O
42 253 263 16826348 peripheral JJ I-NP O
43 264 271 16826348 nervous JJ I-NP O
44 272 278 16826348 system NN I-NP O
45 279 282 16826348 has VBZ B-VP O
46 283 287 16826348 been VBN I-VP O
47 288 300 16826348 infrequently RB I-VP O
48 301 309 16826348 reported VBN I-VP O
49 309 310 16826348 . . O O

1 311 312 16826348 A DT B-NP O
2 313 315 16826348 49 CD I-NP O
3 315 316 16826348 - HYPH I-NP O
4 316 320 16826348 year NN I-NP O
5 320 321 16826348 - HYPH O O
6 321 324 16826348 old JJ B-NP O
7 325 333 16826348 Japanese JJ I-NP O
8 334 337 16826348 man NN I-NP O
9 338 341 16826348 was VBD B-VP O
10 342 351 16826348 diagnosed VBN I-VP O
11 352 356 16826348 with IN B-PP O
12 357 362 16826348 acute JJ B-NP D015470
13 363 370 16826348 myeloid JJ I-NP D015470
14 371 379 16826348 leukemia NN I-NP D015470
15 379 380 16826348 . . O O

1 381 386 16826348 After IN B-SBAR O
2 387 389 16826348 he PRP B-NP O
3 390 398 16826348 achieved VBD B-VP O
4 399 407 16826348 complete JJ B-NP O
5 408 417 16826348 remission NN I-NP O
6 417 418 16826348 , , O O
7 419 421 16826348 he PRP B-NP O
8 422 430 16826348 received VBD B-VP O
9 431 435 16826348 high JJ B-NP O
10 435 436 16826348 - HYPH I-NP O
11 436 440 16826348 dose NN I-NP O
12 441 449 16826348 cytosine NN I-NP D003561
13 450 461 16826348 arabinoside NN I-NP D003561
14 462 471 16826348 treatment NN I-NP O
15 472 473 16826348 ( ( O O
16 473 474 16826348 2 CD B-NP O
17 475 476 16826348 g NN I-NP O
18 476 477 16826348 / SYM B-NP O
19 477 479 16826348 m2 NN I-NP O
20 480 485 16826348 twice RB B-NP O
21 486 487 16826348 a DT I-NP O
22 488 491 16826348 day NN I-NP O
23 492 495 16826348 for IN B-PP O
24 496 497 16826348 5 CD B-NP O
25 498 502 16826348 days NNS I-NP O
26 502 503 16826348 ; : O O
27 504 509 16826348 total NN B-NP O
28 509 510 16826348 , , O O
29 511 513 16826348 20 CD B-NP O
30 514 515 16826348 g NN I-NP O
31 515 516 16826348 / SYM B-NP O
32 516 518 16826348 m2 NN I-NP O
33 518 519 16826348 ) ) O O
34 520 522 16826348 as IN B-PP O
35 523 536 16826348 consolidation NN B-NP O
36 537 544 16826348 therapy NN I-NP O
37 544 545 16826348 . . O O

1 546 549 16826348 The DT B-NP O
2 550 555 16826348 first JJ I-NP O
3 556 562 16826348 course NN I-NP O
4 563 565 16826348 of IN B-PP O
5 566 570 16826348 high JJ B-NP O
6 570 571 16826348 - HYPH I-NP O
7 571 575 16826348 dose NN I-NP O
8 576 584 16826348 cytosine NN I-NP D003561
9 585 596 16826348 arabinoside NN I-NP D003561
10 597 605 16826348 resulted VBD B-VP O
11 606 608 16826348 in IN B-PP O
12 609 611 16826348 no DT B-NP O
13 612 619 16826348 unusual JJ I-NP O
14 620 628 16826348 symptoms NNS I-NP O
15 628 629 16826348 , , B-PP O
16 630 633 16826348 but CC I-PP O
17 634 636 16826348 on IN B-PP O
18 637 640 16826348 day NN B-NP O
19 641 643 16826348 21 CD I-NP O
20 644 646 16826348 of IN B-PP O
21 647 650 16826348 the DT B-NP O
22 651 657 16826348 second JJ I-NP O
23 658 664 16826348 course NN I-NP O
24 665 667 16826348 of IN B-PP O
25 668 677 16826348 treatment NN B-NP O
26 677 678 16826348 , , O O
27 679 682 16826348 the DT B-NP O
28 683 690 16826348 patient NN I-NP O
29 691 701 16826348 complained VBD B-VP O
30 702 704 16826348 of IN B-PP O
31 705 713 16826348 numbness NN B-NP D006987
32 714 716 16826348 in IN B-PP O
33 717 720 16826348 his PRP$ B-NP O
34 721 726 16826348 right JJ I-NP O
35 727 731 16826348 foot NN I-NP O
36 731 732 16826348 . . O O

1 733 747 16826348 Electromyogram NN B-NP O
2 748 751 16826348 and CC I-NP O
3 752 757 16826348 nerve NN I-NP O
4 757 758 16826348 - HYPH B-NP O
5 758 768 16826348 conduction NN I-NP O
6 769 776 16826348 studies NNS I-NP O
7 777 783 16826348 showed VBD B-VP O
8 784 794 16826348 peripheral JJ B-NP D010523
9 795 805 16826348 neuropathy NN I-NP D010523
10 806 808 16826348 in IN B-PP O
11 809 813 16826348 both CC B-NP O
12 814 822 16826348 peroneal JJ I-NP O
13 823 829 16826348 nerves NNS I-NP O
14 829 830 16826348 . . O O

1 831 835 16826348 This DT B-NP O
2 836 846 16826348 neuropathy NN I-NP D009422
3 847 850 16826348 was VBD B-VP O
4 851 860 16826348 gradually RB I-VP O
5 861 870 16826348 resolving VBG I-VP O
6 870 871 16826348 ; : O O
7 872 879 16826348 however RB B-ADVP O
8 879 880 16826348 , , O O
9 881 886 16826348 after IN B-PP O
10 887 890 16826348 the DT B-NP O
11 891 898 16826348 patient NN I-NP O
12 899 907 16826348 received VBD B-VP O
13 908 918 16826348 allogeneic JJ B-NP O
14 919 923 16826348 bone NN I-NP O
15 924 930 16826348 marrow NN I-NP O
16 931 946 16826348 transplantation NN I-NP O
17 946 947 16826348 , , O O
18 948 951 16826348 the DT B-NP O
19 952 960 16826348 symptoms NNS I-NP O
20 961 969 16826348 worsened VBD B-VP O
21 969 970 16826348 , , O O
22 971 975 16826348 with IN B-PP O
23 976 979 16826348 the DT B-NP O
24 980 991 16826348 development NN I-NP O
25 992 994 16826348 of IN B-PP O
26 995 1000 16826348 graft NN B-NP D006086
27 1000 1001 16826348 - HYPH B-ADVP D006086
28 1001 1007 16826348 versus IN B-PP D006086
29 1007 1008 16826348 - HYPH B-NP D006086
30 1008 1012 16826348 host NN I-NP D006086
31 1013 1020 16826348 disease NN I-NP D006086
32 1020 1021 16826348 , , O O
33 1022 1025 16826348 and CC O O
34 1026 1029 16826348 the DT B-NP O
35 1030 1038 16826348 symptoms NNS I-NP O
36 1039 1051 16826348 subsequently RB B-ADVP O
37 1052 1061 16826348 responded VBD B-VP O
38 1062 1064 16826348 to TO B-PP O
39 1065 1083 16826348 methylprednisolone NN B-NP D008775
40 1083 1084 16826348 . . O O

1 1085 1093 16826348 Although IN B-SBAR O
2 1094 1097 16826348 the DT B-NP O
3 1098 1108 16826348 mechanisms NNS I-NP O
4 1109 1111 16826348 of IN B-PP O
5 1112 1122 16826348 peripheral JJ B-NP D010523
6 1123 1133 16826348 neuropathy NN I-NP D010523
7 1134 1137 16826348 are VBP B-VP O
8 1138 1143 16826348 still RB B-ADVP O
9 1144 1151 16826348 unclear JJ B-NP O
10 1151 1152 16826348 , , I-NP O
11 1153 1157 16826348 high JJ I-NP O
12 1157 1158 16826348 - HYPH I-NP O
13 1158 1162 16826348 dose NN I-NP O
14 1163 1171 16826348 cytosine NN I-NP D003561
15 1172 1183 16826348 arabinoside NN I-NP D003561
16 1184 1186 16826348 is VBZ B-VP O
17 1187 1188 16826348 a DT B-NP O
18 1189 1196 16826348 therapy NN I-NP O
19 1197 1201 16826348 that WDT B-NP O
20 1202 1204 16826348 is VBZ B-VP O
21 1205 1216 16826348 potentially RB B-ADJP O
22 1217 1222 16826348 toxic JJ I-ADJP O
23 1223 1225 16826348 to TO B-PP O
24 1226 1229 16826348 the DT B-NP O
25 1230 1240 16826348 peripheral JJ I-NP O
26 1241 1248 16826348 nervous JJ I-NP O
27 1249 1255 16826348 system NN I-NP O
28 1255 1256 16826348 , , O O
29 1257 1260 16826348 and CC O O
30 1261 1265 16826348 auto NN B-NP O
31 1265 1266 16826348 / SYM B-NP O
32 1266 1278 16826348 alloimmunity NN I-NP O
33 1279 1282 16826348 may MD B-VP O
34 1283 1287 16826348 play VB I-VP O
35 1288 1290 16826348 an DT B-NP O
36 1291 1300 16826348 important JJ I-NP O
37 1301 1305 16826348 role NN I-NP O
38 1306 1308 16826348 in IN B-PP O
39 1309 1314 16826348 these DT B-NP O
40 1315 1325 16826348 mechanisms NNS I-NP O
41 1325 1326 16826348 . . O O

1 0 0 19944333 -DOCSTART- -X- -X- O

1 0 9 19944333 Sorafenib NN B-NP C471405
2 9 10 19944333 - HYPH O O
3 10 17 19944333 induced VBN B-NP O
4 18 23 19944333 acute JJ I-NP O
5 24 34 19944333 myocardial JJ I-NP D009203
6 35 45 19944333 infarction NN I-NP D009203
7 46 49 19944333 due JJ B-PP O
8 50 52 19944333 to TO B-PP O
9 53 61 19944333 coronary JJ B-NP D003329
10 62 68 19944333 artery NN I-NP D003329
11 69 74 19944333 spasm NN I-NP D003329
12 74 75 19944333 . . O O
13 76 77 19944333 A NN B-NP O
14 78 80 19944333 65 CD I-NP O
15 80 81 19944333 - HYPH I-NP O
16 81 85 19944333 year NN I-NP O
17 85 86 19944333 - HYPH O O
18 86 89 19944333 old JJ B-NP O
19 90 93 19944333 man NN I-NP O
20 94 98 19944333 with IN B-PP O
21 99 107 19944333 advanced VBN B-NP O
22 108 113 19944333 renal JJ I-NP D002292
23 114 118 19944333 cell NN I-NP D002292
24 119 128 19944333 carcinoma NN I-NP D002292
25 129 132 19944333 was VBD B-VP O
26 133 141 19944333 admitted VBN I-VP O
27 142 145 19944333 due JJ B-ADJP O
28 146 148 19944333 to TO B-PP O
29 149 159 19944333 continuing VBG B-NP O
30 160 165 19944333 chest NN I-NP D002637
31 166 170 19944333 pain NN I-NP D002637
32 171 173 19944333 at IN B-PP O
33 174 178 19944333 rest NN B-NP O
34 178 179 19944333 . . O O

1 180 183 19944333 Two CD B-NP O
2 184 189 19944333 weeks NNS I-NP O
3 190 196 19944333 before IN B-PP O
4 197 200 19944333 his PRP$ B-NP O
5 201 210 19944333 admission NN I-NP O
6 210 211 19944333 , , O O
7 212 221 19944333 sorafenib NN B-NP C471405
8 222 225 19944333 had VBD B-VP O
9 226 230 19944333 been VBN I-VP O
10 231 238 19944333 started VBN I-VP O
11 238 239 19944333 . . O O

1 240 242 19944333 He PRP B-NP O
2 243 246 19944333 was VBD B-VP O
3 247 256 19944333 diagnosed VBN I-VP O
4 257 261 19944333 with IN B-PP O
5 262 265 19944333 non AFX B-NP O
6 265 266 19944333 - HYPH I-NP O
7 266 268 19944333 ST NN I-NP O
8 268 269 19944333 - HYPH I-NP O
9 269 278 19944333 elevation NN I-NP O
10 279 289 19944333 myocardial JJ I-NP D009203
11 290 300 19944333 infarction NN I-NP D009203
12 301 303 19944333 by IN B-PP O
13 304 314 19944333 laboratory NN B-NP O
14 315 319 19944333 data NNS I-NP O
15 320 323 19944333 and CC O O
16 324 341 19944333 electrocardiogram NN B-NP O
17 341 342 19944333 . . O O

1 343 351 19944333 Enhanced VBN B-NP O
2 352 357 19944333 heart NN I-NP O
3 358 366 19944333 magnetic JJ I-NP O
4 367 376 19944333 resonance NN I-NP O
5 377 384 19944333 imaging NN I-NP O
6 385 389 19944333 also RB B-ADVP O
7 390 396 19944333 showed VBD B-VP O
8 397 411 19944333 subendocardial JJ B-NP D009203
9 412 422 19944333 infarction NN I-NP D009203
10 422 423 19944333 . . O O

1 424 431 19944333 However RB B-ADVP O
2 431 432 19944333 , , O O
3 433 438 19944333 there EX B-NP O
4 439 442 19944333 was VBD B-VP O
5 443 445 19944333 no DT B-NP O
6 446 454 19944333 stenosis NN I-NP O
7 455 457 19944333 in IN B-PP O
8 458 466 19944333 coronary JJ B-NP O
9 467 475 19944333 arteries NNS I-NP O
10 476 478 19944333 on IN B-PP O
11 479 490 19944333 angiography NN B-NP O
12 490 491 19944333 . . O O

1 492 500 19944333 Coronary JJ B-NP D003329
2 501 507 19944333 artery NN I-NP D003329
3 508 513 19944333 spasm NN I-NP D003329
4 514 517 19944333 was VBD B-VP O
5 518 525 19944333 induced VBN I-VP O
6 526 528 19944333 by IN B-PP O
7 529 530 19944333 a DT B-NP O
8 531 542 19944333 provocative JJ I-NP O
9 543 547 19944333 test NN I-NP O
10 547 548 19944333 . . O O

1 549 558 19944333 Cessation NN B-NP O
2 559 561 19944333 of IN B-PP O
3 562 571 19944333 sorafenib NN B-NP C471405
4 572 575 19944333 and CC I-NP O
5 576 590 19944333 administration NN I-NP O
6 591 593 19944333 of IN B-PP O
7 594 596 19944333 Ca NN B-NP D002118
8 596 597 19944333 - HYPH B-NP O
9 597 604 19944333 channel NN I-NP O
10 605 612 19944333 blocker NN I-NP O
11 613 616 19944333 and CC I-NP O
12 617 625 19944333 nitrates NNS I-NP D009566
13 626 637 19944333 ameliorated VBD B-VP O
14 638 641 19944333 his PRP$ B-NP O
15 642 650 19944333 symptoms NNS I-NP O
16 650 651 19944333 , , O O
17 652 655 19944333 but CC O O
18 656 663 19944333 relapse NN B-NP O
19 664 672 19944333 occurred VBD B-VP O
20 673 678 19944333 after IN B-PP O
21 679 689 19944333 resumption NN B-NP O
22 690 692 19944333 of IN B-PP O
23 693 702 19944333 sorafenib NN B-NP C471405
24 702 703 19944333 . . O O

1 704 712 19944333 Addition NN B-NP O
2 713 715 19944333 of IN B-PP O
3 716 720 19944333 oral JJ B-NP O
4 721 731 19944333 nicorandil NN I-NP D020108
5 732 739 19944333 reduced VBD B-VP O
6 740 743 19944333 his PRP$ B-NP O
7 744 752 19944333 symptoms NNS I-NP O
8 753 756 19944333 and CC O O
9 757 767 19944333 maintained VBN B-VP O
10 768 774 19944333 stable JJ B-NP D060050
11 775 781 19944333 angina NN I-NP D060050
12 782 788 19944333 status NN I-NP O
13 788 789 19944333 . . O O

1 790 792 19944333 We PRP B-NP O
2 793 799 19944333 report VBP B-VP O
3 800 803 19944333 the DT B-NP O
4 804 809 19944333 first JJ I-NP O
5 810 814 19944333 case NN I-NP O
6 815 817 19944333 of IN B-PP O
7 818 827 19944333 sorafenib NN B-NP C471405
8 827 828 19944333 - HYPH B-NP O
9 828 835 19944333 induced VBN I-NP O
10 836 844 19944333 coronary JJ I-NP D003329
11 845 851 19944333 artery NN I-NP D003329
12 852 857 19944333 spasm NN I-NP D003329
13 857 858 19944333 . . O O

1 859 868 19944333 Sorafenib NN B-NP C471405
2 869 871 19944333 is VBZ B-VP O
3 872 873 19944333 a DT B-NP O
4 874 885 19944333 multikinase JJ I-NP O
5 886 895 19944333 inhibitor NN I-NP O
6 896 900 19944333 that WDT B-NP O
7 901 908 19944333 targets VBZ B-VP O
8 909 918 19944333 signaling NN B-NP O
9 919 927 19944333 pathways NNS I-NP O
10 928 937 19944333 necessary JJ B-ADJP O
11 938 941 19944333 for IN B-PP O
12 942 950 19944333 cellular JJ B-NP O
13 951 964 19944333 proliferation NN I-NP O
14 965 968 19944333 and CC I-NP O
15 969 977 19944333 survival NN I-NP O
16 977 978 19944333 . . O O

1 979 981 19944333 On IN B-PP O
2 982 985 19944333 the DT B-NP O
3 986 991 19944333 other JJ I-NP O
4 992 996 19944333 hand NN I-NP O
5 996 997 19944333 , , O O
6 998 1001 19944333 the DT B-NP O
7 1002 1005 19944333 Rho NN I-NP O
8 1005 1006 19944333 / SYM B-NP O
9 1006 1010 19944333 ROCK NN I-NP O
10 1011 1018 19944333 pathway NN I-NP O
11 1019 1022 19944333 has VBZ B-VP O
12 1023 1025 19944333 an DT B-NP O
13 1026 1035 19944333 important JJ I-NP O
14 1036 1040 19944333 role NN I-NP O
15 1041 1043 19944333 in IN B-PP O
16 1044 1047 19944333 the DT B-NP O
17 1048 1060 19944333 pathogenesis NN I-NP O
18 1061 1063 19944333 of IN B-PP O
19 1064 1072 19944333 coronary JJ B-NP D003329
20 1073 1079 19944333 artery NN I-NP D003329
21 1080 1085 19944333 spasm NN I-NP D003329
22 1085 1086 19944333 . . O O

1 1087 1090 19944333 Our PRP$ B-NP O
2 1091 1097 19944333 report NN I-NP O
3 1098 1101 19944333 may MD B-VP O
4 1102 1106 19944333 show VB I-VP O
5 1107 1109 19944333 an DT B-NP O
6 1110 1117 19944333 adverse JJ I-NP O
7 1118 1124 19944333 effect NN I-NP O
8 1125 1127 19944333 on IN B-PP O
9 1128 1131 19944333 the DT B-NP O
10 1132 1135 19944333 Rho NN I-NP O
11 1135 1136 19944333 / SYM B-NP O
12 1136 1140 19944333 ROCK NN I-NP O
13 1141 1148 19944333 pathway NN I-NP O
14 1149 1151 19944333 by IN B-PP O
15 1152 1161 19944333 sorafenib NN B-NP C471405
16 1162 1165 19944333 use NN I-NP O
17 1165 1166 19944333 . . O O

1 0 0 7337133 -DOCSTART- -X- -X- O

1 0 7 7337133 Massive JJ B-NP O
2 8 16 7337133 cerebral JJ I-NP D001929
3 17 22 7337133 edema NN I-NP D001929
4 23 33 7337133 associated VBN B-VP O
5 34 38 7337133 with IN B-PP O
6 39 48 7337133 fulminant JJ B-NP O
7 49 56 7337133 hepatic JJ I-NP D017093
8 57 64 7337133 failure NN I-NP D017093
9 65 67 7337133 in IN B-PP O
10 68 81 7337133 acetaminophen NN B-NP D000082
11 82 90 7337133 overdose NN I-NP D062787
12 90 91 7337133 : : O O
13 92 100 7337133 possible JJ B-NP O
14 101 105 7337133 role NN I-NP O
15 106 108 7337133 of IN B-PP O
16 109 116 7337133 cranial JJ B-NP O
17 117 130 7337133 decompression NN I-NP O
18 130 131 7337133 . . O O
19 132 140 7337133 Cerebral JJ B-NP D001929
20 141 146 7337133 edema NN I-NP D001929
21 147 150 7337133 may MD B-VP O
22 151 161 7337133 complicate VB I-VP O
23 162 165 7337133 the DT B-NP O
24 166 172 7337133 course NN I-NP O
25 173 175 7337133 of IN B-PP O
26 176 185 7337133 fulminant JJ B-NP D017093
27 186 193 7337133 hepatic JJ I-NP D017093
28 194 201 7337133 failure NN I-NP D017093
29 201 202 7337133 . . O O

1 203 211 7337133 Response NN B-NP O
2 212 214 7337133 to TO B-PP O
3 215 227 7337133 conventional JJ B-NP O
4 228 235 7337133 therapy NN I-NP O
5 236 239 7337133 has VBZ B-VP O
6 240 244 7337133 been VBN I-VP O
7 245 258 7337133 disappointing JJ B-ADJP O
8 258 259 7337133 . . O O

1 260 262 7337133 We PRP B-NP O
2 263 270 7337133 present VBP B-VP O
3 271 272 7337133 a DT B-NP O
4 273 280 7337133 patient NN I-NP O
5 281 285 7337133 with IN B-PP O
6 286 291 7337133 fatal JJ B-NP O
7 292 305 7337133 acetaminophen NN I-NP D000082
8 305 306 7337133 - HYPH O O
9 306 313 7337133 induced VBN B-NP O
10 314 323 7337133 fulminant JJ I-NP D017093
11 324 331 7337133 hepatic JJ I-NP D017093
12 332 339 7337133 failure NN I-NP D017093
13 339 340 7337133 , , O O
14 341 345 7337133 with IN B-PP O
15 346 351 7337133 signs NNS B-NP O
16 352 355 7337133 and CC I-NP O
17 356 364 7337133 symptoms NNS I-NP O
18 365 367 7337133 of IN B-PP O
19 368 376 7337133 cerebral JJ B-NP D001929
20 377 382 7337133 edema NN I-NP D001929
21 382 383 7337133 , , O O
22 384 396 7337133 unresponsive JJ B-ADJP O
23 397 399 7337133 to TO B-PP O
24 400 412 7337133 conventional JJ B-NP O
25 413 420 7337133 medical JJ I-NP O
26 421 428 7337133 therapy NN I-NP O
27 428 429 7337133 . . O O

1 430 437 7337133 Cranial JJ B-NP O
2 438 451 7337133 decompression NN I-NP O
3 452 455 7337133 was VBD B-VP O
4 456 463 7337133 carried VBN I-VP O
5 464 467 7337133 out RP B-PRT O
6 467 468 7337133 . . O O

1 469 470 7337133 A DT B-NP O
2 471 484 7337133 justification NN I-NP O
3 485 487 7337133 of IN B-PP O
4 488 491 7337133 the DT B-NP O
5 492 496 7337133 need NN I-NP O
6 497 500 7337133 for IN B-PP O
7 501 508 7337133 further JJ B-NP O
8 509 519 7337133 evaluation NN I-NP O
9 520 522 7337133 of IN B-PP O
10 523 530 7337133 cranial JJ B-NP O
11 531 544 7337133 decompression NN I-NP O
12 545 547 7337133 in IN B-PP O
13 548 552 7337133 such JJ B-NP O
14 553 561 7337133 patients NNS I-NP O
15 562 564 7337133 is VBZ B-VP O
16 565 574 7337133 presented VBN I-VP O
17 574 575 7337133 . . O O

1 0 0 9867728 -DOCSTART- -X- -X- O

1 0 4 9867728 Risk NN B-NP O
2 5 8 9867728 for IN B-PP O
3 9 17 9867728 valvular JJ B-NP D006349
4 18 23 9867728 heart NN I-NP D006349
5 24 31 9867728 disease NN I-NP D006349
6 32 37 9867728 among IN B-PP O
7 38 43 9867728 users NNS B-NP O
8 44 46 9867728 of IN B-PP O
9 47 59 9867728 fenfluramine NN B-NP D005277
10 60 63 9867728 and CC I-NP O
11 64 79 9867728 dexfenfluramine NN I-NP D020372
12 80 83 9867728 who WP B-NP O
13 84 93 9867728 underwent VBD B-VP O
14 94 110 9867728 echocardiography NN B-NP O
15 111 117 9867728 before IN B-PP O
16 118 121 9867728 use NN B-NP O
17 122 124 9867728 of IN B-PP O
18 125 135 9867728 medication NN B-NP O
19 135 136 9867728 . . O O
20 137 147 9867728 BACKGROUND NN B-NP O
21 147 148 9867728 : : O O
22 149 156 9867728 Because IN B-SBAR O
23 157 169 9867728 uncontrolled JJ B-NP O
24 170 187 9867728 echocardiographic JJ I-NP O
25 188 195 9867728 surveys NNS I-NP O
26 196 205 9867728 suggested VBD B-VP O
27 206 210 9867728 that IN B-SBAR O
28 211 213 9867728 up RB B-NP O
29 214 216 9867728 to TO I-NP O
30 217 220 9867728 30% CD I-NP O
31 221 223 9867728 to TO B-PP O
32 224 227 9867728 38% CD B-NP O
33 228 230 9867728 of IN B-PP O
34 231 236 9867728 users NNS B-NP O
35 237 239 9867728 of IN B-PP O
36 240 252 9867728 fenfluramine NN B-NP D005277
37 253 256 9867728 and CC I-NP O
38 257 272 9867728 dexfenfluramine NN I-NP D020372
39 273 276 9867728 had VBD B-VP O
40 277 285 9867728 valvular JJ B-NP D006349
41 286 293 9867728 disease NN I-NP D006349
42 293 294 9867728 , , O O
43 295 300 9867728 these DT B-NP O
44 301 306 9867728 drugs NNS I-NP O
45 307 311 9867728 were VBD B-VP O
46 312 321 9867728 withdrawn VBN I-VP O
47 322 326 9867728 from IN B-PP O
48 327 330 9867728 the DT B-NP O
49 331 337 9867728 market NN I-NP O
50 337 338 9867728 . . O O

1 339 348 9867728 OBJECTIVE NN B-NP O
2 348 349 9867728 : : O O
3 350 352 9867728 To TO B-VP O
4 353 362 9867728 determine VB I-VP O
5 363 366 9867728 the DT B-NP O
6 367 371 9867728 risk NN I-NP O
7 372 375 9867728 for IN B-PP O
8 376 379 9867728 new JJ B-ADJP O
9 380 382 9867728 or CC O O
10 383 392 9867728 worsening VBG B-VP O
11 393 401 9867728 valvular JJ B-NP D006349
12 402 415 9867728 abnormalities NNS I-NP D006349
13 416 421 9867728 among IN B-PP O
14 422 427 9867728 users NNS B-NP O
15 428 430 9867728 of IN B-PP O
16 431 443 9867728 fenfluramine NN B-NP D005277
17 444 446 9867728 or CC I-NP O
18 447 462 9867728 dexfenfluramine NN I-NP D020372
19 463 466 9867728 who WP B-NP O
20 467 476 9867728 underwent VBD B-VP O
21 477 493 9867728 echocardiography NN B-NP O
22 494 500 9867728 before IN B-SBAR O
23 501 505 9867728 they PRP B-NP O
24 506 511 9867728 began VBD B-VP O
25 512 514 9867728 to TO I-VP O
26 515 519 9867728 take VB I-VP O
27 520 525 9867728 these DT B-NP O
28 526 537 9867728 medications NNS I-NP O
29 537 538 9867728 . . O O

1 539 545 9867728 DESIGN NN B-NP O
2 545 546 9867728 : : O O
3 547 553 9867728 Cohort JJ B-NP O
4 554 559 9867728 study NN I-NP O
5 559 560 9867728 . . O O

1 561 568 9867728 SETTING NN B-NP O
2 568 569 9867728 : : O O
3 570 578 9867728 Academic JJ B-NP O
4 579 586 9867728 primary JJ I-NP O
5 587 591 9867728 care NN I-NP O
6 592 601 9867728 practices NNS I-NP O
7 601 602 9867728 . . O O

1 603 611 9867728 PATIENTS NNS B-NP O
2 611 612 9867728 : : O O
3 613 615 9867728 46 CD B-NP O
4 616 624 9867728 patients NNS I-NP O
5 625 628 9867728 who WP B-NP O
6 629 633 9867728 used VBD B-VP O
7 634 646 9867728 fenfluramine NN B-NP D005277
8 647 649 9867728 or CC I-NP O
9 650 665 9867728 dexfenfluramine NN I-NP D020372
10 666 669 9867728 for IN B-PP O
11 670 672 9867728 14 CD B-NP O
12 673 677 9867728 days NNS I-NP O
13 678 680 9867728 or CC I-NP O
14 681 685 9867728 more JJR I-NP O
15 686 689 9867728 and CC O O
16 690 693 9867728 had VBD B-VP O
17 694 709 9867728 echocardiograms NNS B-NP O
18 710 718 9867728 obtained VBN B-VP O
19 719 725 9867728 before IN B-PP O
20 726 733 9867728 therapy NN B-NP O
21 733 734 9867728 . . O O

1 735 747 9867728 MEASUREMENTS NNS B-NP O
2 747 748 9867728 : : O O
3 749 755 9867728 Follow VB B-VP O
4 755 756 9867728 - HYPH O O
5 756 758 9867728 up RP B-PRT O
6 759 775 9867728 echocardiography NN B-NP O
7 775 776 9867728 . . O O

1 777 780 9867728 The DT B-NP O
2 781 788 9867728 primary JJ I-NP O
3 789 796 9867728 outcome NN I-NP O
4 797 800 9867728 was VBD B-VP O
5 801 804 9867728 new JJ B-ADJP O
6 805 807 9867728 or CC O O
7 808 817 9867728 worsening VBG B-VP O
8 818 830 9867728 valvulopathy NN B-NP D006349
9 830 831 9867728 , , O O
10 832 839 9867728 defined VBN B-VP O
11 840 842 9867728 as IN B-PP O
12 843 854 9867728 progression NN B-NP O
13 855 857 9867728 of IN B-PP O
14 858 864 9867728 either CC B-NP O
15 865 871 9867728 aortic JJ I-NP D001022
16 872 874 9867728 or CC I-NP D001022
17 875 881 9867728 mitral JJ I-NP D001022
18 882 895 9867728 regurgitation NN I-NP D001022
19 896 898 9867728 by IN B-PP O
20 899 901 9867728 at IN B-NP O
21 902 907 9867728 least JJS I-NP O
22 908 911 9867728 one CD I-NP O
23 912 918 9867728 degree NN I-NP O
24 919 921 9867728 of IN B-PP O
25 922 930 9867728 severity NN B-NP O
26 931 934 9867728 and CC I-NP O
27 935 942 9867728 disease NN I-NP O
28 943 947 9867728 that WDT B-NP O
29 948 951 9867728 met VBD B-VP O
30 952 955 9867728 U.S NNP B-NP O
31 955 956 9867728 . . O O

1 957 961 9867728 Food NNP B-NP O
2 962 965 9867728 and CC I-NP O
3 966 970 9867728 Drug NNP I-NP O
4 971 985 9867728 Administration NNP I-NP O
5 986 994 9867728 criteria NNS I-NP O
6 995 996 9867728 ( ( O O
7 996 998 9867728 at IN B-NP O
8 999 1004 9867728 least JJS I-NP O
9 1005 1009 9867728 mild JJ I-NP O
10 1010 1016 9867728 aortic JJ I-NP D001022
11 1017 1030 9867728 regurgitation NN I-NP D001022
12 1031 1033 9867728 or CC O O
13 1034 1042 9867728 moderate JJ B-NP O
14 1043 1049 9867728 mitral JJ I-NP D008944
15 1050 1063 9867728 regurgitation NN I-NP D008944
16 1063 1064 9867728 ) ) O O
17 1064 1065 9867728 . . O O

1 1066 1073 9867728 RESULTS NNS B-NP O
2 1073 1074 9867728 : : O O
3 1075 1078 9867728 Two CD B-NP O
4 1079 1087 9867728 patients NNS I-NP O
5 1088 1089 9867728 ( ( O O
6 1089 1093 9867728 4.3% CD B-NP O
7 1094 1095 9867728 [ ( O O
8 1095 1098 9867728 95% CD B-NP O
9 1099 1101 9867728 CI NN I-NP O
10 1101 1102 9867728 , , O O
11 1103 1107 9867728 0.6% CD B-NP O
12 1108 1110 9867728 to TO B-PP O
13 1111 1116 9867728 14.8% CD B-NP O
14 1116 1117 9867728 ] ) O O
15 1117 1118 9867728 ) ) O O
16 1119 1128 9867728 receiving VBG B-VP O
17 1129 1141 9867728 fenfluramine NN B-NP D005277
18 1141 1142 9867728 - HYPH O O
19 1142 1153 9867728 phentermine NN B-NP D010645
20 1154 1163 9867728 developed VBD B-VP O
21 1164 1172 9867728 valvular JJ B-NP D006349
22 1173 1178 9867728 heart NN I-NP D006349
23 1179 1186 9867728 disease NN I-NP D006349
24 1186 1187 9867728 . . O O

1 1188 1191 9867728 One CD B-NP O
2 1192 1195 9867728 had VBD B-VP O
3 1196 1204 9867728 baseline NN B-NP O
4 1205 1213 9867728 bicuspid JJ I-NP C562388
5 1214 1220 9867728 aortic JJ I-NP C562388
6 1221 1226 9867728 valve NN I-NP C562388
7 1227 1230 9867728 and CC O O
8 1231 1235 9867728 mild JJ B-NP O
9 1236 1242 9867728 aortic JJ I-NP D001022
10 1243 1256 9867728 regurgitation NN I-NP D001022
11 1257 1261 9867728 that WDT B-NP O
12 1262 1272 9867728 progressed VBD B-VP O
13 1273 1275 9867728 to TO B-PP O
14 1276 1284 9867728 moderate JJ B-NP O
15 1285 1298 9867728 regurgitation NN I-NP O
16 1298 1299 9867728 . . O O

1 1300 1303 9867728 The DT B-NP O
2 1304 1310 9867728 second JJ I-NP O
3 1311 1318 9867728 patient NN I-NP O
4 1319 1328 9867728 developed VBD B-VP O
5 1329 1332 9867728 new JJ B-NP O
6 1333 1341 9867728 moderate JJ I-NP O
7 1342 1348 9867728 aortic JJ I-NP D001022
8 1349 1362 9867728 insufficiency NN I-NP D001022
9 1362 1363 9867728 . . O O

1 1364 1374 9867728 CONCLUSION NN B-NP O
2 1374 1375 9867728 : : O O
3 1376 1381 9867728 Users NNS B-NP O
4 1382 1384 9867728 of IN B-PP O
5 1385 1389 9867728 diet NN B-NP O
6 1390 1401 9867728 medications NNS I-NP O
7 1402 1405 9867728 are VBP B-VP O
8 1406 1408 9867728 at IN B-PP O
9 1409 1413 9867728 risk NN B-NP O
10 1414 1417 9867728 for IN B-PP O
11 1418 1426 9867728 valvular JJ B-NP D006349
12 1427 1432 9867728 heart NN I-NP D006349
13 1433 1440 9867728 disease NN I-NP D006349
14 1440 1441 9867728 . . O O

1 1442 1449 9867728 However RB B-ADVP O
2 1449 1450 9867728 , , O O
3 1451 1454 9867728 the DT B-NP O
4 1455 1464 9867728 incidence NN I-NP O
5 1465 1468 9867728 may MD B-VP O
6 1469 1471 9867728 be VB I-VP O
7 1472 1477 9867728 lower JJR B-ADJP O
8 1478 1482 9867728 than IN B-PP O
9 1483 1487 9867728 that DT B-NP O
10 1488 1496 9867728 reported VBN B-VP O
11 1497 1507 9867728 previously RB B-ADVP O
12 1507 1508 9867728 . . O O

1 0 0 8268147 -DOCSTART- -X- -X- O

1 0 1 8268147 A DT B-NP O
2 2 6 8268147 case NN I-NP O
3 7 9 8268147 of IN B-PP O
4 10 22 8268147 polymyositis NN B-NP D017285
5 23 25 8268147 in IN B-PP O
6 26 27 8268147 a DT B-NP O
7 28 35 8268147 patient NN I-NP O
8 36 40 8268147 with IN B-PP O
9 41 48 8268147 primary JJ B-NP D008105
10 49 56 8268147 biliary JJ I-NP D008105
11 57 66 8268147 cirrhosis NN I-NP D008105
12 67 74 8268147 treated VBN B-VP O
13 75 79 8268147 with IN B-PP O
14 80 81 8268147 D NN B-NP D010396
15 81 82 8268147 - HYPH I-NP D010396
16 82 95 8268147 penicillamine NN I-NP D010396
17 95 96 8268147 . . O O
18 97 105 8268147 Although IN B-SBAR O
19 106 107 8268147 D NN B-NP D010396
20 107 108 8268147 - HYPH O D010396
21 108 121 8268147 penicillamine NN B-NP D010396
22 122 125 8268147 has VBZ B-VP O
23 126 130 8268147 been VBN I-VP O
24 131 135 8268147 used VBN I-VP O
25 136 139 8268147 for IN B-PP O
26 140 144 8268147 many JJ B-NP O
27 145 158 8268147 rheumatologic JJ I-NP D012216
28 159 167 8268147 diseases NNS I-NP D012216
29 167 168 8268147 , , O O
30 169 177 8268147 toxicity NN B-NP D064420
31 178 184 8268147 limits VBZ B-VP O
32 185 188 8268147 its PRP$ B-NP O
33 189 199 8268147 usefulness NN I-NP O
34 200 202 8268147 in IN B-PP O
35 203 207 8268147 many JJ B-NP O
36 208 216 8268147 patients NNS I-NP O
37 216 217 8268147 . . O O

1 218 230 8268147 Polymyositis NN B-NP D017285
2 230 231 8268147 / SYM I-NP O
3 231 246 8268147 dermatomyositis NN I-NP D003882
4 247 250 8268147 can MD B-VP O
5 251 258 8268147 develop VB I-VP O
6 259 261 8268147 as IN B-PP O
7 262 265 8268147 one CD B-NP O
8 266 268 8268147 of IN B-PP O
9 269 272 8268147 the DT B-NP O
10 273 283 8268147 autoimmune JJ I-NP O
11 284 297 8268147 complications NNS I-NP O
12 298 300 8268147 of IN B-PP O
13 301 302 8268147 D NN B-NP D010396
14 302 303 8268147 - HYPH B-NP D010396
15 303 316 8268147 penicillamine NN I-NP D010396
16 317 326 8268147 treatment NN I-NP O
17 326 327 8268147 , , O O
18 328 331 8268147 but CC O O
19 332 335 8268147 its PRP$ B-NP O
20 336 341 8268147 exact JJ I-NP O
21 342 354 8268147 pathogenesis NN I-NP O
22 355 362 8268147 remains VBZ B-VP O
23 363 370 8268147 unclear JJ B-ADJP O
24 370 371 8268147 . . O O

1 372 374 8268147 We PRP B-NP O
2 375 381 8268147 report VBP B-VP O
3 382 383 8268147 a DT B-NP O
4 384 391 8268147 patient NN I-NP O
5 392 396 8268147 with IN B-PP O
6 397 404 8268147 primary JJ B-NP D008105
7 405 412 8268147 biliary JJ I-NP D008105
8 413 422 8268147 cirrhosis NN I-NP D008105
9 422 423 8268147 , , O O
10 424 427 8268147 who WP B-NP O
11 428 437 8268147 developed VBD B-VP O
12 438 450 8268147 polymyositis NN B-NP D017285
13 451 456 8268147 while IN B-SBAR O
14 457 466 8268147 receiving VBG B-VP O
15 467 468 8268147 D NN B-NP D010396
16 468 469 8268147 - HYPH B-NP D010396
17 469 482 8268147 penicillamine NN I-NP D010396
18 483 490 8268147 therapy NN I-NP O
19 490 491 8268147 . . O O

1 492 494 8268147 We PRP B-NP O
2 495 504 8268147 described VBD B-VP O
3 505 508 8268147 the DT B-NP O
4 509 516 8268147 special JJ I-NP O
5 517 525 8268147 clinical JJ I-NP O
6 526 532 8268147 course NN I-NP O
7 533 535 8268147 of IN B-PP O
8 536 539 8268147 the DT B-NP O
9 540 547 8268147 patient NN I-NP O
10 547 548 8268147 . . O O

1 549 557 8268147 Patients NNS B-NP O
2 558 567 8268147 receiving VBG B-VP O
3 568 569 8268147 D NN B-NP D010396
4 569 570 8268147 - HYPH B-NP D010396
5 570 583 8268147 penicillamine NN I-NP D010396
6 584 591 8268147 therapy NN I-NP O
7 592 598 8268147 should MD B-VP O
8 599 601 8268147 be VB I-VP O
9 602 610 8268147 followed VBN I-VP O
10 611 620 8268147 carefully RB B-ADVP O
11 621 624 8268147 for IN B-PP O
12 625 628 8268147 the DT B-NP O
13 629 640 8268147 development NN I-NP O
14 641 643 8268147 of IN B-PP O
15 644 654 8268147 autoimmune JJ B-NP O
16 655 668 8268147 complications NNS I-NP O
17 669 673 8268147 like IN B-PP O
18 674 686 8268147 polymyositis NN B-NP D017285
19 686 687 8268147 / SYM B-VP O
20 687 702 8268147 dermatomyositis NN B-NP D003882
21 702 703 8268147 . . O O

1 0 0 20552622 -DOCSTART- -X- -X- O

1 0 10 20552622 Swallowing VBG B-VP O
2 10 11 20552622 - HYPH B-NP O
3 11 18 20552622 induced VBN I-NP O
4 19 25 20552622 atrial JJ I-NP D013617
5 26 41 20552622 tachyarrhythmia NN I-NP D013617
6 42 51 20552622 triggered VBN B-VP O
7 52 54 20552622 by IN B-PP O
8 55 65 20552622 salbutamol NN B-NP D000420
9 65 66 20552622 : : O O
10 67 71 20552622 case NN B-NP O
11 72 78 20552622 report NN I-NP O
12 79 82 20552622 and CC O O
13 83 89 20552622 review NN B-NP O
14 90 92 20552622 of IN B-PP O
15 93 96 20552622 the DT B-NP O
16 97 107 20552622 literature NN I-NP O
17 107 108 20552622 . . I-NP O
18 109 113 20552622 CASE NN I-NP O
19 113 114 20552622 : : O O
20 115 116 20552622 A DT B-NP O
21 117 119 20552622 49 CD I-NP O
22 119 120 20552622 - HYPH I-NP O
23 120 124 20552622 year NN I-NP O
24 124 125 20552622 - HYPH O O
25 125 128 20552622 old JJ B-NP O
26 129 136 20552622 patient NN I-NP O
27 137 148 20552622 experienced VBD B-VP O
28 149 154 20552622 chest NN B-NP O
29 155 165 20552622 discomfort NN I-NP O
30 166 171 20552622 while IN B-SBAR O
31 172 182 20552622 swallowing VBG B-VP O
32 182 183 20552622 . . O O

1 184 186 20552622 On IN B-PP O
2 187 204 20552622 electrocardiogram NN B-NP O
3 204 205 20552622 , , O O
4 206 214 20552622 episodes NNS B-NP O
5 215 217 20552622 of IN B-PP O
6 218 224 20552622 atrial JJ B-NP D013617
7 225 240 20552622 tachyarrhythmia NN I-NP D013617
8 241 245 20552622 were VBD B-VP O
9 246 254 20552622 recorded VBN I-VP O
10 255 266 20552622 immediately RB B-ADVP O
11 267 272 20552622 after IN B-PP O
12 273 283 20552622 swallowing VBG B-VP O
13 283 284 20552622 ; : O O
14 285 287 20552622 24 CD B-NP O
15 287 288 20552622 - HYPH I-NP O
16 288 292 20552622 hour NN I-NP O
17 293 299 20552622 Holter NNP I-NP O
18 300 310 20552622 monitoring NN I-NP O
19 311 319 20552622 recorded VBD B-VP O
20 320 327 20552622 several JJ B-NP O
21 328 334 20552622 events NNS I-NP O
22 334 335 20552622 . . O O

1 336 339 20552622 The DT B-NP O
2 340 350 20552622 arrhythmia NN I-NP D001145
3 351 359 20552622 resolved VBN B-VP O
4 360 365 20552622 after IN B-PP O
5 366 373 20552622 therapy NN B-NP O
6 374 378 20552622 with IN B-PP O
7 379 387 20552622 atenolol NN B-NP D001262
8 387 388 20552622 , , O O
9 389 392 20552622 but CC O O
10 393 401 20552622 recurred VBD B-VP O
11 402 403 20552622 a DT B-NP O
12 404 408 20552622 year NN I-NP O
13 409 414 20552622 later RB B-ADVP O
14 414 415 20552622 . . O O

1 416 419 20552622 The DT B-NP O
2 420 427 20552622 patient NN I-NP O
3 428 435 20552622 noticed VBD B-VP O
4 436 440 20552622 that IN B-SBAR O
5 441 447 20552622 before IN B-SBAR O
6 448 453 20552622 these DT B-NP O
7 454 462 20552622 episodes NNS I-NP O
8 463 465 20552622 he PRP B-NP O
9 466 469 20552622 had VBD B-VP O
10 470 474 20552622 been VBN I-VP O
11 475 480 20552622 using VBG I-VP O
12 481 483 20552622 an DT B-NP O
13 484 493 20552622 inhalator NN I-NP O
14 494 496 20552622 of IN B-PP O
15 497 507 20552622 salbutamol NN B-NP D000420
16 507 508 20552622 . . O O

1 509 514 20552622 After IN B-PP O
2 515 523 20552622 stopping VBG B-VP O
3 524 527 20552622 the DT B-NP O
4 528 532 20552622 beta SYM I-NP O
5 532 533 20552622 - HYPH I-NP O
6 533 540 20552622 agonist NN I-NP O
7 540 541 20552622 , , O O
8 542 545 20552622 and CC O O
9 546 551 20552622 after IN B-PP O
10 552 553 20552622 a DT B-NP O
11 554 558 20552622 week NN I-NP O
12 559 563 20552622 with IN B-PP O
13 564 567 20552622 the DT B-NP O
14 568 576 20552622 atenolol NN I-NP D001262
15 576 577 20552622 , , O O
16 578 581 20552622 the DT B-NP O
17 582 592 20552622 arrhythmia NN I-NP D001145
18 593 604 20552622 disappeared VBD B-VP O
19 604 605 20552622 . . O O

1 606 616 20552622 DISCUSSION NN B-NP O
2 616 617 20552622 : : O O
3 618 628 20552622 Swallowing VBG B-VP O
4 628 629 20552622 - HYPH B-NP O
5 629 636 20552622 induced VBN I-NP O
6 637 643 20552622 atrial JJ I-NP D013617
7 644 659 20552622 tachyarrhythmia NN I-NP D013617
8 660 661 20552622 ( ( O O
9 661 665 20552622 SIAT NN B-NP D013617
10 665 666 20552622 ) ) O O
11 667 669 20552622 is VBZ B-VP O
12 670 671 20552622 a DT B-NP O
13 672 676 20552622 rare JJ I-NP O
14 677 687 20552622 phenomenon NN I-NP O
15 687 688 20552622 . . O O

1 689 694 20552622 Fewer JJR B-NP O
2 695 699 20552622 than IN I-NP O
3 700 702 20552622 50 CD I-NP O
4 703 708 20552622 cases NNS I-NP O
5 709 711 20552622 of IN B-PP O
6 712 716 20552622 SIAT NN B-NP D013617
7 717 721 20552622 have VBP B-VP O
8 722 726 20552622 been VBN I-VP O
9 727 736 20552622 described VBN I-VP O
10 737 739 20552622 in IN B-PP O
11 740 743 20552622 the DT B-NP O
12 744 754 20552622 literature NN I-NP O
13 754 755 20552622 . . O O

1 756 760 20552622 This DT B-NP O
2 761 768 20552622 article NN I-NP O
3 769 779 20552622 summarizes VBZ B-VP O
4 780 783 20552622 all PDT B-NP O
5 784 787 20552622 the DT I-NP O
6 788 793 20552622 cases NNS I-NP O
7 794 803 20552622 published VBN B-VP O
8 803 804 20552622 , , O O
9 805 813 20552622 creating VBG B-VP O
10 814 815 20552622 a DT B-NP O
11 816 829 20552622 comprehensive JJ I-NP O
12 830 836 20552622 review NN I-NP O
13 837 839 20552622 of IN B-PP O
14 840 843 20552622 the DT B-NP O
15 844 851 20552622 current JJ I-NP O
16 852 861 20552622 knowledge NN I-NP O
17 862 865 20552622 and CC I-NP O
18 866 874 20552622 approach NN I-NP O
19 875 877 20552622 to TO B-PP O
20 878 882 20552622 SIAT NN B-NP D013617
21 882 883 20552622 . . O O

1 884 886 20552622 It PRP B-NP O
2 887 896 20552622 discusses VBZ B-VP O
3 897 909 20552622 demographics NNS B-NP O
4 909 910 20552622 , , O O
5 911 919 20552622 clinical JJ B-NP O
6 920 935 20552622 characteristics NNS I-NP O
7 936 939 20552622 and CC I-NP O
8 940 945 20552622 types NNS I-NP O
9 946 948 20552622 of IN B-PP O
10 949 959 20552622 arrhythmia NN B-NP D001145
11 959 960 20552622 , , O O
12 961 971 20552622 postulated VBN B-VP O
13 972 982 20552622 mechanisms NNS B-NP O
14 983 985 20552622 of IN B-PP O
15 986 990 20552622 SIAT NN B-NP D013617
16 990 991 20552622 , , O O
17 992 995 20552622 and CC O O
18 996 1005 20552622 different JJ B-NP O
19 1006 1015 20552622 treatment NN I-NP O
20 1016 1029 20552622 possibilities NNS I-NP O
21 1030 1034 20552622 such JJ B-PP O
22 1035 1037 20552622 as IN I-PP O
23 1038 1049 20552622 medications NNS B-NP O
24 1049 1050 20552622 , , O O
25 1051 1058 20552622 surgery NN B-NP O
26 1058 1059 20552622 , , O O
27 1060 1063 20552622 and CC O O
28 1064 1078 20552622 radiofrequency NN B-NP O
29 1079 1087 20552622 catheter NN I-NP O
30 1088 1096 20552622 ablation NN I-NP O
31 1097 1098 20552622 ( ( O O
32 1098 1102 20552622 RFCA NN B-NP O
33 1102 1103 20552622 ) ) O O
34 1103 1104 20552622 . . O O

1 1105 1115 20552622 CONCLUSION NN B-NP O
2 1115 1116 20552622 : : O O
3 1117 1127 20552622 Salbutamol NN B-NP D000420
4 1128 1130 20552622 is VBZ B-VP O
5 1131 1140 20552622 presented VBN I-VP O
6 1141 1145 20552622 here RB B-ADVP O
7 1146 1148 20552622 as IN B-PP O
8 1149 1150 20552622 a DT B-NP O
9 1151 1159 20552622 possible JJ I-NP O
10 1160 1167 20552622 trigger NN I-NP O
11 1168 1171 20552622 for IN B-PP O
12 1172 1176 20552622 SIAT NN B-NP D013617
13 1176 1177 20552622 . . O O

1 1178 1186 20552622 Although IN B-SBAR O
2 1187 1189 20552622 it PRP B-NP O
3 1190 1192 20552622 is VBZ B-VP O
4 1193 1202 20552622 difficult JJ B-ADJP O
5 1203 1205 20552622 to TO B-VP O
6 1206 1212 20552622 define VB I-VP O
7 1213 1222 20552622 causality NN B-NP O
8 1223 1225 20552622 in IN B-PP O
9 1226 1227 20552622 a DT B-NP O
10 1228 1232 20552622 case NN I-NP O
11 1233 1239 20552622 report NN I-NP O
12 1239 1240 20552622 , , O O
13 1241 1243 20552622 it PRP B-NP O
14 1244 1246 20552622 is VBZ B-VP O
15 1247 1254 20552622 logical JJ B-ADJP O
16 1255 1257 20552622 to TO B-VP O
17 1258 1263 20552622 think VB I-VP O
18 1264 1268 20552622 that IN B-SBAR O
19 1269 1270 20552622 a DT B-NP O
20 1271 1275 20552622 beta SYM I-NP O
21 1275 1276 20552622 - HYPH I-NP O
22 1276 1283 20552622 agonist NN I-NP O
23 1284 1288 20552622 like JJ I-NP O
24 1289 1299 20552622 salbutamol NN I-NP D000420
25 1300 1301 20552622 ( ( O O
26 1301 1306 20552622 known VBN B-VP O
27 1307 1309 20552622 to TO B-VP O
28 1310 1316 20552622 induce VB I-VP O
29 1317 1328 20552622 tachycardia NN B-NP D013610
30 1328 1329 20552622 ) ) O O
31 1330 1333 20552622 may MD B-VP O
32 1334 1336 20552622 be VB I-VP O
33 1337 1340 20552622 the DT B-NP O
34 1341 1348 20552622 trigger NN I-NP O
35 1349 1351 20552622 of IN B-PP O
36 1352 1362 20552622 adrenergic JJ B-NP O
37 1363 1371 20552622 reflexes NNS I-NP O
38 1372 1383 20552622 originating VBG B-VP O
39 1384 1386 20552622 in IN B-PP O
40 1387 1390 20552622 the DT B-NP O
41 1391 1400 20552622 esophagus NN I-NP O
42 1401 1406 20552622 while IN B-SBAR O
43 1407 1417 20552622 swallowing VBG B-VP O
44 1418 1421 20552622 and CC O O
45 1422 1426 20552622 that IN B-SBAR O
46 1427 1428 20552622 a DT B-NP O
47 1429 1433 20552622 beta SYM I-NP O
48 1433 1434 20552622 - HYPH I-NP O
49 1434 1441 20552622 blocker NN I-NP O
50 1442 1446 20552622 such JJ B-PP O
51 1447 1449 20552622 as IN I-PP O
52 1450 1458 20552622 atenolol NN B-NP D001262
53 1459 1460 20552622 ( ( O O
54 1460 1464 20552622 that WDT B-NP O
55 1465 1471 20552622 blocks VBZ B-VP O
56 1472 1475 20552622 the DT B-NP O
57 1476 1486 20552622 adrenergic JJ I-NP O
58 1487 1495 20552622 activity NN I-NP O
59 1495 1496 20552622 ) ) O O
60 1497 1500 20552622 may MD B-VP O
61 1501 1508 20552622 relieve VB I-VP O
62 1509 1511 20552622 it PRP B-NP O
63 1511 1512 20552622 . . O O

1 0 0 16634859 -DOCSTART- -X- -X- O

1 0 6 16634859 Impact NN B-NP O
2 7 9 16634859 of IN B-PP O
3 10 17 16634859 alcohol NN B-NP D000431
4 18 26 16634859 exposure NN I-NP O
5 27 32 16634859 after IN B-PP O
6 33 42 16634859 pregnancy NN B-NP O
7 43 54 16634859 recognition NN I-NP O
8 55 57 16634859 on IN B-PP O
9 58 74 16634859 ultrasonographic JJ B-NP O
10 75 80 16634859 fetal JJ I-NP O
11 81 87 16634859 growth NN I-NP O
12 88 96 16634859 measures NNS I-NP O
13 96 97 16634859 . . B-NP O
14 98 108 16634859 BACKGROUND NN I-NP O
15 108 109 16634859 : : O O
16 110 114 16634859 More JJR B-NP O
17 115 119 16634859 than IN I-NP O
18 120 121 16634859 3 CD I-NP O
19 122 129 16634859 decades NNS I-NP O
20 130 135 16634859 after IN B-PP O
21 136 141 16634859 Jones NNP B-NP O
22 142 145 16634859 and CC I-NP O
23 146 151 16634859 Smith NNP I-NP O
24 152 153 16634859 ( ( O O
25 153 157 16634859 1973 CD B-NP O
26 157 158 16634859 ) ) O O
27 159 167 16634859 reported VBN B-VP O
28 168 170 16634859 on IN B-PP O
29 171 174 16634859 the DT B-NP O
30 175 186 16634859 devastation NN I-NP O
31 187 193 16634859 caused VBN B-VP O
32 194 196 16634859 by IN B-PP O
33 197 204 16634859 alcohol NN B-NP D000431
34 205 213 16634859 exposure NN I-NP O
35 214 216 16634859 on IN B-PP O
36 217 222 16634859 fetal JJ B-NP O
37 223 234 16634859 development NN I-NP O
38 234 235 16634859 , , O O
39 236 239 16634859 the DT B-NP O
40 240 245 16634859 rates NNS I-NP O
41 246 248 16634859 of IN B-PP O
42 249 254 16634859 heavy JJ B-NP O
43 255 263 16634859 drinking NN I-NP O
44 264 270 16634859 during IN B-PP O
45 271 280 16634859 pregnancy NN B-NP O
46 281 287 16634859 remain VBP B-VP O
47 288 298 16634859 relatively RB B-ADJP O
48 299 308 16634859 unchanged JJ I-ADJP O
49 308 309 16634859 . . O O

1 310 315 16634859 Early RB B-NP O
2 316 330 16634859 identification NN I-NP O
3 331 333 16634859 of IN B-PP O
4 334 339 16634859 fetal JJ B-NP O
5 340 347 16634859 alcohol NN I-NP D000431
6 348 356 16634859 exposure NN I-NP O
7 357 360 16634859 and CC O O
8 361 369 16634859 maternal JJ B-NP O
9 370 380 16634859 abstinence NN I-NP O
10 381 384 16634859 led VBD B-VP O
11 385 387 16634859 to TO B-PP O
12 388 394 16634859 better JJR B-NP O
13 395 401 16634859 infant NN I-NP O
14 402 410 16634859 outcomes NNS I-NP O
15 410 411 16634859 . . O O

1 412 416 16634859 This DT B-NP O
2 417 422 16634859 study NN I-NP O
3 423 431 16634859 examined VBD B-VP O
4 432 435 16634859 the DT B-NP O
5 436 443 16634859 utility NN I-NP O
6 444 446 16634859 of IN B-PP O
7 447 455 16634859 biometry NN B-NP O
8 456 459 16634859 for IN B-PP O
9 460 469 16634859 detecting VBG B-VP O
10 470 477 16634859 alcohol NN B-NP D000431
11 477 478 16634859 - HYPH O O
12 478 485 16634859 related VBN B-NP O
13 486 491 16634859 fetal JJ I-NP O
14 492 498 16634859 growth NN I-NP D006130
15 499 509 16634859 impairment NN I-NP D006130
16 509 510 16634859 . . O O

1 511 518 16634859 METHODS NNS B-NP O
2 518 519 16634859 : : O O
3 520 522 16634859 We PRP B-NP O
4 523 531 16634859 obtained VBD B-VP O
5 532 537 16634859 fetal JJ B-NP O
6 538 548 16634859 ultrasound JJ I-NP O
7 549 557 16634859 measures NNS I-NP O
8 558 562 16634859 from IN B-PP O
9 563 570 16634859 routine JJ B-NP O
10 571 581 16634859 ultrasound JJ I-NP O
11 582 594 16634859 examinations NNS I-NP O
12 595 598 16634859 for IN B-PP O
13 599 602 16634859 167 CD B-NP O
14 603 611 16634859 pregnant JJ I-NP O
15 612 621 16634859 hazardous JJ I-NP O
16 622 630 16634859 drinkers NNS I-NP O
17 631 634 16634859 who WP B-NP O
18 635 639 16634859 were VBD B-VP O
19 640 648 16634859 enrolled VBN I-VP O
20 649 651 16634859 in IN B-PP O
21 652 653 16634859 a DT B-NP O
22 654 659 16634859 brief JJ I-NP O
23 660 667 16634859 alcohol NN I-NP D000431
24 668 680 16634859 intervention NN I-NP O
25 681 686 16634859 study NN I-NP O
26 686 687 16634859 . . O O

1 688 691 16634859 The DT B-NP O
2 692 697 16634859 fetal JJ I-NP O
3 698 706 16634859 measures NNS I-NP O
4 707 710 16634859 for IN B-PP O
5 711 716 16634859 women NNS B-NP O
6 717 720 16634859 who WP B-NP O
7 721 725 16634859 quit VBP B-VP O
8 726 731 16634859 after IN B-PP O
9 732 740 16634859 learning VBG B-VP O
10 741 743 16634859 of IN B-PP O
11 744 749 16634859 their PRP$ B-NP O
12 750 761 16634859 pregnancies NNS I-NP O
13 762 766 16634859 were VBD B-VP O
14 767 775 16634859 compared VBN I-VP O
15 776 780 16634859 with IN B-PP O
16 781 789 16634859 measures NNS B-NP O
17 790 793 16634859 for IN B-PP O
18 794 799 16634859 women NNS B-NP O
19 800 803 16634859 who WP B-NP O
20 804 813 16634859 continued VBD B-VP O
21 814 818 16634859 some DT B-NP O
22 819 827 16634859 drinking NN I-NP O
23 828 838 16634859 throughout IN B-PP O
24 839 842 16634859 the DT B-NP O
25 843 849 16634859 course NN I-NP O
26 850 852 16634859 of IN B-PP O
27 853 858 16634859 their PRP$ B-NP O
28 859 870 16634859 pregnancies NNS I-NP O
29 870 871 16634859 . . O O

1 872 879 16634859 Because IN B-SBAR O
2 880 889 16634859 intensity NN B-NP O
3 890 892 16634859 of IN B-PP O
4 893 900 16634859 alcohol NN B-NP D000431
5 901 912 16634859 consumption NN I-NP O
6 913 915 16634859 is VBZ B-VP O
7 916 926 16634859 associated VBN I-VP O
8 927 931 16634859 with IN B-PP O
9 932 938 16634859 poorer JJR B-NP O
10 939 944 16634859 fetal JJ I-NP O
11 945 953 16634859 outcomes NNS I-NP O
12 953 954 16634859 , , O O
13 955 963 16634859 separate JJ B-NP O
14 964 972 16634859 analyses NNS I-NP O
15 973 977 16634859 were VBD B-VP O
16 978 987 16634859 conducted VBN I-VP O
17 988 991 16634859 for IN B-PP O
18 992 995 16634859 the DT B-NP O
19 996 1001 16634859 heavy NN I-NP O
20 1002 1003 16634859 ( ( O O
21 1003 1010 16634859 average NN B-NP O
22 1011 1013 16634859 of IN B-PP O
23 1014 1015 16634859 > SYM B-NP O
24 1015 1017 16634859 or CC O O
25 1017 1018 16634859 = SYM B-VP O
26 1018 1019 16634859 5 CD B-NP O
27 1020 1026 16634859 drinks NNS I-NP O
28 1027 1030 16634859 per IN B-PP O
29 1031 1039 16634859 drinking VBG B-VP O
30 1040 1043 16634859 day NN B-NP O
31 1043 1044 16634859 ) ) O O
32 1045 1052 16634859 alcohol NN B-NP D000431
33 1053 1062 16634859 consumers NNS I-NP O
34 1062 1063 16634859 . . O O

1 1064 1069 16634859 Fetal JJ B-NP O
2 1070 1078 16634859 measures NNS I-NP O
3 1079 1083 16634859 from IN B-PP O
4 1084 1087 16634859 the DT B-NP O
5 1088 1093 16634859 heavy NN I-NP O
6 1093 1094 16634859 - HYPH B-NP O
7 1094 1101 16634859 exposed VBN I-NP O
8 1102 1109 16634859 fetuses NNS I-NP O
9 1110 1114 16634859 were VBD B-VP O
10 1115 1119 16634859 also RB I-VP O
11 1120 1128 16634859 compared VBN I-VP O
12 1129 1133 16634859 with IN B-PP O
13 1134 1142 16634859 measures NNS B-NP O
14 1143 1147 16634859 from IN B-PP O
15 1148 1149 16634859 a DT B-NP O
16 1150 1161 16634859 nondrinking JJ I-NP O
17 1162 1167 16634859 group NN I-NP O
18 1168 1172 16634859 that WDT B-NP O
19 1173 1176 16634859 was VBD B-VP O
20 1177 1191 16634859 representative JJ B-ADJP O
21 1192 1194 16634859 of IN B-PP O
22 1195 1201 16634859 normal JJ B-NP O
23 1201 1202 16634859 , , I-NP O
24 1203 1216 16634859 uncomplicated JJ I-NP O
25 1217 1228 16634859 pregnancies NNS I-NP O
26 1229 1233 16634859 from IN B-PP O
27 1234 1237 16634859 our PRP$ B-NP O
28 1238 1245 16634859 clinics NNS I-NP O
29 1245 1246 16634859 . . O O

1 1247 1255 16634859 Analyses NNS B-NP O
2 1256 1258 16634859 of IN B-PP O
3 1259 1269 16634859 covariance NN B-NP O
4 1270 1274 16634859 were VBD B-VP O
5 1275 1279 16634859 used VBN I-VP O
6 1280 1282 16634859 to TO B-VP O
7 1283 1292 16634859 determine VB I-VP O
8 1293 1300 16634859 whether IN B-SBAR O
9 1301 1306 16634859 there EX B-NP O
10 1307 1311 16634859 were VBD B-VP O
11 1312 1323 16634859 differences NNS B-NP O
12 1324 1331 16634859 between IN B-PP O
13 1332 1338 16634859 groups NNS B-NP O
14 1339 1344 16634859 after IN B-PP O
15 1345 1356 16634859 controlling VBG B-VP O
16 1357 1360 16634859 for IN B-PP O
17 1361 1371 16634859 influences NNS B-NP O
18 1372 1374 16634859 of IN B-PP O
19 1375 1386 16634859 gestational JJ B-NP O
20 1387 1390 16634859 age NN I-NP O
21 1391 1394 16634859 and CC I-NP O
22 1395 1399 16634859 drug NN I-NP D019966
23 1400 1405 16634859 abuse NN I-NP D019966
24 1405 1406 16634859 . . O O

1 1407 1414 16634859 RESULTS NNS B-NP O
2 1414 1415 16634859 : : O O
3 1416 1422 16634859 Nearly RB B-NP O
4 1423 1427 16634859 half NN I-NP O
5 1428 1430 16634859 of IN B-PP O
6 1431 1434 16634859 the DT B-NP O
7 1435 1443 16634859 pregnant JJ I-NP O
8 1444 1452 16634859 drinkers NNS I-NP O
9 1453 1462 16634859 abstained VBN B-VP O
10 1463 1468 16634859 after IN B-PP O
11 1469 1477 16634859 learning VBG B-VP O
12 1478 1480 16634859 of IN B-PP O
13 1481 1486 16634859 their PRP$ B-NP O
14 1487 1498 16634859 pregnancies NNS I-NP O
15 1498 1499 16634859 . . O O

1 1500 1504 16634859 When WRB B-ADVP O
2 1505 1510 16634859 women NNS B-NP O
3 1511 1521 16634859 reportedly RB B-ADVP O
4 1522 1526 16634859 quit VBP B-VP O
5 1527 1535 16634859 drinking VBG I-VP O
6 1536 1541 16634859 early RB B-ADVP O
7 1542 1544 16634859 in IN B-PP O
8 1545 1550 16634859 their PRP$ B-NP O
9 1551 1562 16634859 pregnancies NNS I-NP O
10 1562 1563 16634859 , , O O
11 1564 1569 16634859 fetal JJ B-NP O
12 1570 1576 16634859 growth NN I-NP O
13 1577 1585 16634859 measures NNS I-NP O
14 1586 1590 16634859 were VBD B-VP O
15 1591 1594 16634859 not RB B-ADJP O
16 1595 1608 16634859 significantly RB I-ADJP O
17 1609 1618 16634859 different JJ I-ADJP O
18 1619 1623 16634859 from IN B-PP O
19 1624 1625 16634859 a DT B-NP O
20 1626 1629 16634859 non AFX I-NP O
21 1629 1630 16634859 - HYPH I-NP O
22 1630 1637 16634859 alcohol NN I-NP D000431
23 1637 1638 16634859 - HYPH B-NP O
24 1638 1645 16634859 exposed VBN I-NP O
25 1646 1651 16634859 group NN I-NP O
26 1651 1652 16634859 , , O O
27 1653 1663 16634859 regardless RB B-ADVP O
28 1664 1666 16634859 of IN B-PP O
29 1667 1672 16634859 prior JJ B-NP O
30 1673 1681 16634859 drinking NN I-NP O
31 1682 1690 16634859 patterns NNS I-NP O
32 1690 1691 16634859 . . O O

1 1692 1695 16634859 Any DT B-NP O
2 1696 1703 16634859 alcohol NN I-NP D000431
3 1704 1715 16634859 consumption NN I-NP O
4 1716 1729 16634859 postpregnancy NN I-NP O
5 1730 1741 16634859 recognition NN I-NP O
6 1742 1747 16634859 among IN B-PP O
7 1748 1751 16634859 the DT B-NP O
8 1752 1757 16634859 heavy JJ I-NP O
9 1758 1766 16634859 drinkers NNS I-NP O
10 1767 1775 16634859 resulted VBD B-VP O
11 1776 1778 16634859 in IN B-PP O
12 1779 1786 16634859 reduced VBN B-NP D006130
13 1787 1797 16634859 cerebellar JJ I-NP D006130
14 1798 1804 16634859 growth NN I-NP D006130
15 1805 1807 16634859 as RB B-CONJP O
16 1808 1812 16634859 well RB I-CONJP O
17 1813 1815 16634859 as IN I-CONJP O
18 1816 1825 16634859 decreased VBN B-NP D006130
19 1826 1833 16634859 cranial NN I-NP D006130
20 1834 1836 16634859 to TO B-PP D006130
21 1837 1841 16634859 body NN B-NP D006130
22 1842 1848 16634859 growth NN I-NP D006130
23 1849 1851 16634859 in IN B-PP O
24 1852 1862 16634859 comparison NN B-NP O
25 1863 1867 16634859 with IN B-PP O
26 1868 1873 16634859 women NNS B-NP O
27 1874 1877 16634859 who WP B-NP O
28 1878 1884 16634859 either CC O O
29 1885 1889 16634859 quit NN B-NP O
30 1890 1898 16634859 drinking NN I-NP O
31 1899 1901 16634859 or CC O O
32 1902 1905 16634859 who WP B-NP O
33 1906 1910 16634859 were VBD B-VP O
34 1911 1922 16634859 nondrinkers NNS B-NP O
35 1922 1923 16634859 . . O O

1 1924 1935 16634859 Amphetamine NN B-NP D000661
2 1936 1941 16634859 abuse NN I-NP O
3 1942 1945 16634859 was VBD B-VP O
4 1946 1956 16634859 predictive JJ B-ADJP O
5 1957 1959 16634859 of IN B-PP O
6 1960 1966 16634859 larger JJR B-NP O
7 1967 1974 16634859 cranial NN I-NP O
8 1975 1977 16634859 to TO B-PP O
9 1978 1982 16634859 body NN B-NP O
10 1983 1989 16634859 growth NN I-NP O
11 1990 1996 16634859 ratios NNS I-NP O
12 1996 1997 16634859 . . O O

1 1998 2009 16634859 CONCLUSIONS NNS B-NP O
2 2009 2010 16634859 : : O O
3 2011 2022 16634859 Alterations NNS B-NP O
4 2023 2025 16634859 in IN B-PP O
5 2026 2031 16634859 fetal JJ B-NP O
6 2032 2041 16634859 biometric JJ I-NP O
7 2042 2054 16634859 measurements NNS I-NP O
8 2055 2059 16634859 were VBD B-VP O
9 2060 2068 16634859 observed VBN I-VP O
10 2069 2074 16634859 among IN B-PP O
11 2075 2078 16634859 the DT B-NP O
12 2079 2084 16634859 heavy JJ I-NP O
13 2085 2093 16634859 drinkers NNS I-NP O
14 2094 2098 16634859 only RB B-ADVP O
15 2099 2103 16634859 when WRB B-ADVP O
16 2104 2108 16634859 they PRP B-NP O
17 2109 2118 16634859 continued VBD B-VP O
18 2119 2127 16634859 drinking VBG I-VP O
19 2128 2133 16634859 after IN B-PP O
20 2134 2142 16634859 becoming VBG B-VP O
21 2143 2148 16634859 aware JJ B-ADJP O
22 2149 2151 16634859 of IN B-PP O
23 2152 2157 16634859 their PRP$ B-NP O
24 2158 2169 16634859 pregnancies NNS I-NP O
25 2169 2170 16634859 . . O O

1 2171 2179 16634859 Although IN B-SBAR O
2 2180 2183 16634859 the DT B-NP O
3 2184 2192 16634859 reliance NN I-NP O
4 2193 2195 16634859 on IN B-PP O
5 2196 2200 16634859 self NN B-NP O
6 2200 2201 16634859 - HYPH O O
7 2201 2209 16634859 reported VBN B-NP O
8 2210 2218 16634859 drinking NN I-NP O
9 2219 2221 16634859 is VBZ B-VP O
10 2222 2223 16634859 a DT B-NP O
11 2224 2234 16634859 limitation NN I-NP O
12 2235 2237 16634859 in IN B-PP O
13 2238 2242 16634859 this DT B-NP O
14 2243 2248 16634859 study NN I-NP O
15 2248 2249 16634859 , , O O
16 2250 2255 16634859 these DT B-NP O
17 2256 2264 16634859 findings NNS I-NP O
18 2265 2272 16634859 support VBP B-VP O
19 2273 2276 16634859 the DT B-NP O
20 2277 2285 16634859 benefits NNS I-NP O
21 2286 2288 16634859 of IN B-PP O
22 2289 2294 16634859 early JJ B-NP O
23 2295 2305 16634859 abstinence NN I-NP O
24 2306 2309 16634859 and CC O O
25 2310 2313 16634859 the DT B-NP O
26 2314 2323 16634859 potential NN I-NP O
27 2324 2327 16634859 for IN B-PP O
28 2328 2338 16634859 ultrasound JJ B-NP O
29 2339 2351 16634859 examinations NNS I-NP O
30 2352 2354 16634859 in IN B-PP O
31 2355 2358 16634859 the DT B-NP O
32 2359 2368 16634859 detection NN I-NP O
33 2369 2371 16634859 of IN B-PP O
34 2372 2377 16634859 fetal JJ B-NP O
35 2378 2385 16634859 alcohol NN I-NP D000431
36 2386 2393 16634859 effects NNS I-NP O
37 2393 2394 16634859 . . O O

1 0 0 2343592 -DOCSTART- -X- -X- O

1 0 7 2343592 Seizure NN B-NP D012640
2 8 16 2343592 activity NN I-NP O
3 17 21 2343592 with IN B-PP O
4 22 30 2343592 imipenem NN B-NP D015378
5 31 38 2343592 therapy NN I-NP O
6 38 39 2343592 : : O O
7 40 49 2343592 incidence NN B-NP O
8 50 53 2343592 and CC I-NP O
9 54 58 2343592 risk NN I-NP O
10 59 66 2343592 factors NNS I-NP O
11 66 67 2343592 . . O O
12 68 71 2343592 Two CD B-NP O
13 72 79 2343592 elderly JJ I-NP O
14 80 88 2343592 patients NNS I-NP O
15 89 93 2343592 with IN B-PP O
16 94 95 2343592 a DT B-NP O
17 96 103 2343592 history NN I-NP O
18 104 106 2343592 of IN B-PP O
19 107 113 2343592 either CC B-NP O
20 114 122 2343592 cerebral JJ I-NP D020521
21 123 131 2343592 vascular JJ I-NP D020521
22 132 140 2343592 accident NN I-NP D020521
23 141 142 2343592 ( ( O O
24 142 145 2343592 CVA NN B-NP D020521
25 145 146 2343592 ) ) O O
26 147 149 2343592 or CC O O
27 150 154 2343592 head NN B-NP D006259
28 155 161 2343592 trauma NN I-NP D006259
29 162 165 2343592 and CC O O
30 166 168 2343592 no DT B-NP O
31 169 177 2343592 evidence NN I-NP O
32 178 180 2343592 of IN B-PP O
33 181 186 2343592 renal JJ B-NP D007674
34 187 194 2343592 disease NN I-NP D007674
35 195 204 2343592 developed VBD B-VP O
36 205 213 2343592 seizures NNS B-NP D012640
37 214 219 2343592 while IN B-SBAR O
38 220 229 2343592 receiving VBG B-VP O
39 230 237 2343592 maximum JJ B-NP O
40 238 243 2343592 doses NNS I-NP O
41 244 246 2343592 of IN B-PP O
42 247 255 2343592 imipenem NN B-NP C044650
43 255 256 2343592 / SYM B-NP C044650
44 256 266 2343592 cilastatin NN I-NP C044650
45 266 267 2343592 . . O O

1 268 275 2343592 Neither DT B-NP O
2 276 283 2343592 patient NN I-NP O
3 284 287 2343592 had VBD B-VP O
4 288 296 2343592 reported VBN I-VP O
5 297 305 2343592 previous JJ B-NP O
6 306 314 2343592 seizures NNS I-NP D012640
7 315 317 2343592 or CC O O
8 318 325 2343592 seizure NN B-NP D012640
9 325 326 2343592 - HYPH B-NP O
10 326 330 2343592 like JJ I-NP O
11 331 339 2343592 activity NN B-NP O
12 340 343 2343592 nor CC O O
13 344 347 2343592 was VBD B-VP O
14 348 357 2343592 receiving VBG I-VP O
15 358 372 2343592 anticonvulsant JJ B-NP O
16 373 379 2343592 agents NNS I-NP O
17 379 380 2343592 . . O O

1 381 384 2343592 All DT B-NP O
2 385 393 2343592 seizures NNS I-NP D012640
3 394 398 2343592 were VBD B-VP O
4 399 409 2343592 controlled VBN I-VP O
5 410 414 2343592 with IN B-PP O
6 415 426 2343592 therapeutic JJ B-NP O
7 427 432 2343592 doses NNS I-NP O
8 433 435 2343592 of IN B-PP O
9 436 445 2343592 phenytoin NN B-NP D010672
10 445 446 2343592 . . O O

1 447 451 2343592 Both DT B-NP O
2 452 460 2343592 patients NNS I-NP O
3 461 464 2343592 had VBD B-VP O
4 465 473 2343592 received VBN I-VP O
5 474 481 2343592 maximum JJ B-NP O
6 482 487 2343592 doses NNS I-NP O
7 488 490 2343592 of IN B-PP O
8 491 496 2343592 other JJ B-NP O
9 497 501 2343592 beta SYM I-NP D047090
10 501 502 2343592 - HYPH I-NP D047090
11 502 508 2343592 lactam NN I-NP D047090
12 509 520 2343592 antibiotics NNS I-NP O
13 521 528 2343592 without IN B-PP O
14 529 537 2343592 evidence NN B-NP O
15 538 540 2343592 of IN B-PP O
16 541 548 2343592 seizure NN B-NP D012640
17 549 557 2343592 activity NN I-NP O
18 557 558 2343592 . . O O

1 0 0 7416947 -DOCSTART- -X- -X- O

1 0 10 7416947 Subjective JJ B-NP O
2 11 21 7416947 assessment NN I-NP O
3 22 24 7416947 of IN B-PP O
4 25 31 7416947 sexual JJ B-NP D020018
5 32 43 7416947 dysfunction NN I-NP D020018
6 44 46 7416947 of IN B-PP O
7 47 55 7416947 patients NNS B-NP O
8 56 58 7416947 on IN B-PP O
9 59 63 7416947 long JJ B-NP O
10 63 64 7416947 - HYPH I-NP O
11 64 68 7416947 term NN I-NP O
12 69 83 7416947 administration NN I-NP O
13 84 86 7416947 of IN B-PP O
14 87 94 7416947 digoxin NN B-NP D004077
15 94 95 7416947 . . O O
16 96 103 7416947 Various JJ B-NP O
17 104 108 7416947 data NNS I-NP O
18 109 116 7416947 suggest VBP B-VP O
19 117 121 7416947 that IN B-SBAR O
20 122 126 7416947 male JJ B-NP O
21 127 135 7416947 patients NNS I-NP O
22 136 139 7416947 who WP B-NP O
23 140 144 7416947 have VBP B-VP O
24 145 153 7416947 received VBN I-VP O
25 154 161 7416947 digoxin NN B-NP D004077
26 162 164 7416947 on IN B-PP O
27 165 166 7416947 a DT B-NP O
28 167 175 7416947 longterm JJ I-NP O
29 176 181 7416947 basis NN I-NP O
30 182 186 7416947 have VBP B-VP O
31 187 196 7416947 increased VBN I-VP O
32 197 203 7416947 levels NNS B-NP O
33 204 206 7416947 of IN B-PP O
34 207 212 7416947 serum NN B-NP O
35 213 221 7416947 estrogen NN I-NP D004967
36 222 225 7416947 and CC O O
37 226 235 7416947 decreased VBD B-VP O
38 236 242 7416947 levels NNS B-NP O
39 243 245 7416947 of IN B-PP O
40 246 252 7416947 plasma NN B-NP O
41 253 265 7416947 testosterone NN I-NP D013739
42 266 269 7416947 and CC O O
43 270 281 7416947 luteinizing VBG B-VP O
44 282 289 7416947 hormone NN B-NP O
45 290 291 7416947 ( ( O O
46 291 293 7416947 LH NN B-NP O
47 293 294 7416947 ) ) O O
48 294 295 7416947 . . O O

1 296 300 7416947 This DT B-NP O
2 301 306 7416947 study NN I-NP O
3 307 310 7416947 was VBD B-VP O
4 311 321 7416947 undertaken VBN I-VP O
5 322 324 7416947 to TO I-VP O
6 325 336 7416947 investigate VB I-VP O
7 337 340 7416947 the DT B-NP O
8 341 346 7416947 links NNS I-NP O
9 347 354 7416947 between IN B-PP O
10 355 358 7416947 the DT B-NP O
11 359 363 7416947 long JJ I-NP O
12 363 364 7416947 - HYPH I-NP O
13 364 368 7416947 term NN I-NP O
14 369 383 7416947 administration NN I-NP O
15 384 386 7416947 of IN B-PP O
16 387 394 7416947 digoxin NN B-NP D004077
17 395 402 7416947 therapy NN I-NP O
18 403 406 7416947 and CC O O
19 407 413 7416947 sexual JJ B-NP O
20 414 422 7416947 behavior NN I-NP O
21 422 423 7416947 , , O O
22 424 427 7416947 and CC O O
23 428 431 7416947 the DT B-NP O
24 432 438 7416947 effect NN I-NP O
25 439 441 7416947 of IN B-PP O
26 442 449 7416947 digoxin NN B-NP D004077
27 450 452 7416947 on IN B-PP O
28 453 459 7416947 plasma NN B-NP O
29 460 466 7416947 levels NNS I-NP O
30 467 469 7416947 of IN B-PP O
31 470 479 7416947 estradiol NN B-NP D004958
32 479 480 7416947 , , O O
33 481 493 7416947 testosterone NN B-NP D013739
34 493 494 7416947 , , O O
35 495 498 7416947 and CC O O
36 499 501 7416947 LH NN B-NP O
37 501 502 7416947 . . O O

1 503 506 7416947 The DT B-NP O
2 507 515 7416947 patients NNS I-NP O
3 516 518 7416947 of IN B-PP O
4 519 522 7416947 the DT B-NP O
5 523 528 7416947 study NN I-NP O
6 529 532 7416947 and CC I-NP O
7 533 540 7416947 control NN I-NP O
8 541 546 7416947 group NN I-NP O
9 547 548 7416947 ( ( O O
10 548 555 7416947 without IN B-PP O
11 556 563 7416947 digoxin NN B-NP D004077
12 563 564 7416947 ) ) O O
13 565 569 7416947 were VBD B-VP O
14 570 572 7416947 of IN B-PP O
15 573 580 7416947 similar JJ B-NP O
16 581 588 7416947 cardiac JJ I-NP O
17 589 599 7416947 functional JJ I-NP O
18 600 608 7416947 capacity NN I-NP O
19 609 612 7416947 and CC O O
20 613 616 7416947 age NN B-NP O
21 617 618 7416947 ( ( O O
22 618 620 7416947 25 CD B-NP O
23 620 621 7416947 - HYPH I-NP O
24 621 623 7416947 40 CD I-NP O
25 624 629 7416947 years NNS I-NP O
26 629 630 7416947 ) ) O O
27 631 634 7416947 and CC O O
28 635 639 7416947 were VBD B-VP O
29 640 648 7416947 randomly RB I-VP O
30 649 657 7416947 selected VBN I-VP O
31 658 662 7416947 from IN B-PP O
32 663 666 7416947 the DT B-NP O
33 667 676 7416947 rheumatic JJ I-NP D012214
34 677 682 7416947 heart NN I-NP D012214
35 683 690 7416947 disease NN I-NP D012214
36 691 699 7416947 patients NNS B-NP O
37 699 700 7416947 . . O O

1 701 702 7416947 A DT B-NP O
2 703 713 7416947 subjective JJ I-NP O
3 714 724 7416947 assessment NN I-NP O
4 725 727 7416947 of IN B-PP O
5 728 734 7416947 sexual JJ B-NP O
6 735 743 7416947 behavior NN I-NP O
7 744 746 7416947 in IN B-PP O
8 747 750 7416947 the DT B-NP O
9 751 756 7416947 study NN I-NP O
10 757 760 7416947 and CC I-NP O
11 761 768 7416947 control NN I-NP O
12 769 775 7416947 groups NNS I-NP O
13 776 779 7416947 was VBD B-VP O
14 780 787 7416947 carried VBN I-VP O
15 788 791 7416947 out RP B-PRT O
16 791 792 7416947 , , O O
17 793 798 7416947 using VBG B-VP O
18 799 809 7416947 parameters NNS B-NP O
19 810 814 7416947 such JJ B-PP O
20 815 817 7416947 as IN I-PP O
21 818 824 7416947 sexual JJ B-NP O
22 825 831 7416947 desire NN I-NP O
23 831 832 7416947 , , O O
24 833 839 7416947 sexual JJ B-NP O
25 840 850 7416947 excitement NN I-NP O
26 850 851 7416947 , , O O
27 852 855 7416947 and CC O O
28 856 865 7416947 frequency NN B-NP O
29 866 868 7416947 of IN B-PP O
30 869 875 7416947 sexual JJ B-NP O
31 876 885 7416947 relations NNS I-NP O
32 885 886 7416947 . . O O

1 887 895 7416947 Personal JJ B-NP O
2 896 906 7416947 interviews NNS I-NP O
3 907 910 7416947 and CC O O
4 911 912 7416947 a DT B-NP O
5 913 926 7416947 questionnaire NN I-NP O
6 927 931 7416947 were VBD B-VP O
7 932 936 7416947 also RB I-VP O
8 937 941 7416947 used VBN I-VP O
9 942 945 7416947 for IN B-PP O
10 946 949 7416947 the DT B-NP O
11 950 960 7416947 evaluation NN I-NP O
12 961 963 7416947 of IN B-PP O
13 964 970 7416947 sexual JJ B-NP O
14 971 979 7416947 behavior NN I-NP O
15 979 980 7416947 . . O O

1 981 984 7416947 The DT B-NP O
2 985 993 7416947 findings NNS I-NP O
3 994 1001 7416947 support VBP B-VP O
4 1002 1005 7416947 the DT B-NP O
5 1006 1013 7416947 reports NNS I-NP O
6 1014 1024 7416947 concerning VBG B-VP O
7 1025 1032 7416947 digoxin NN B-NP D004077
8 1033 1039 7416947 effect NN I-NP O
9 1040 1042 7416947 on IN B-PP O
10 1043 1049 7416947 plasma NN B-NP O
11 1050 1059 7416947 estradiol NN I-NP D004958
12 1059 1060 7416947 , , O O
13 1061 1073 7416947 testosterone NN B-NP D013739
14 1073 1074 7416947 , , O O
15 1075 1078 7416947 and CC O O
16 1079 1081 7416947 LH NN B-NP O
17 1081 1082 7416947 . . O O

1 1083 1086 7416947 The DT B-NP O
2 1087 1098 7416947 differences NNS I-NP O
3 1099 1101 7416947 in IN B-PP O
4 1102 1105 7416947 the DT B-NP O
5 1106 1111 7416947 means NNS I-NP O
6 1112 1116 7416947 were VBD B-VP O
7 1117 1128 7416947 significant JJ B-ADJP O
8 1128 1129 7416947 . . O O

1 1130 1135 7416947 Tests NNS B-NP O
2 1136 1140 7416947 used VBN B-VP O
3 1141 1143 7416947 to TO B-VP O
4 1144 1152 7416947 evaluate VB I-VP O
5 1153 1156 7416947 the DT B-NP O
6 1157 1164 7416947 changes NNS I-NP O
7 1165 1167 7416947 in IN B-PP O
8 1168 1174 7416947 sexual JJ B-NP O
9 1175 1183 7416947 behavior NN I-NP O
10 1184 1190 7416947 showed VBD B-VP O
11 1191 1192 7416947 a DT B-NP O
12 1193 1204 7416947 significant JJ I-NP O
13 1205 1213 7416947 decrease NN I-NP D020018
14 1214 1216 7416947 in IN B-PP D020018
15 1217 1223 7416947 sexual JJ B-NP D020018
16 1224 1230 7416947 desire NN I-NP D020018
17 1230 1231 7416947 , , O O
18 1232 1238 7416947 sexual JJ B-NP O
19 1239 1249 7416947 excitement NN I-NP O
20 1250 1255 7416947 phase NN I-NP O
21 1256 1257 7416947 ( ( O O
22 1257 1265 7416947 erection NN B-NP O
23 1265 1266 7416947 ) ) O O
24 1266 1267 7416947 , , O O
25 1268 1271 7416947 and CC O O
26 1272 1281 7416947 frequency NN B-NP O
27 1282 1284 7416947 of IN B-PP O
28 1285 1291 7416947 sexual JJ B-NP O
29 1292 1301 7416947 relations NNS I-NP O
30 1302 1304 7416947 in IN B-PP O
31 1305 1308 7416947 the DT B-NP O
32 1309 1314 7416947 study NN I-NP O
33 1315 1320 7416947 group NN I-NP O
34 1320 1321 7416947 . . O O

1 0 0 188339 -DOCSTART- -X- -X- O

1 0 9 188339 Etiologic JJ B-NP O
2 10 17 188339 factors NNS I-NP O
3 18 20 188339 in IN B-PP O
4 21 24 188339 the DT B-NP O
5 25 37 188339 pathogenesis NN I-NP O
6 38 40 188339 of IN B-PP O
7 41 46 188339 liver NN B-NP D008113
8 47 53 188339 tumors NNS I-NP D008113
9 54 64 188339 associated VBN B-VP O
10 65 69 188339 with IN B-PP O
11 70 74 188339 oral JJ B-NP D003276
12 75 89 188339 contraceptives NNS I-NP D003276
13 89 90 188339 . . O O
14 91 97 188339 Within IN B-PP O
15 98 101 188339 the DT B-NP O
16 102 106 188339 last JJ I-NP O
17 107 114 188339 several JJ I-NP O
18 115 120 188339 years NNS I-NP O
19 120 121 188339 , , O O
20 122 132 188339 previously RB B-NP O
21 133 137 188339 rare JJ I-NP O
22 138 143 188339 liver NN I-NP D008113
23 144 150 188339 tumors NNS I-NP D008113
24 151 155 188339 have VBP B-VP O
25 156 160 188339 been VBN I-VP O
26 161 165 188339 seen VBN I-VP O
27 166 168 188339 in IN B-PP O
28 169 174 188339 young JJ B-NP O
29 175 180 188339 women NNS I-NP O
30 181 186 188339 using VBG B-VP O
31 187 191 188339 oral JJ B-NP D003276
32 192 205 188339 contraceptive JJ I-NP D003276
33 206 214 188339 steroids NNS I-NP D013256
34 214 215 188339 . . O O

1 216 219 188339 The DT B-NP O
2 220 228 188339 Registry NN I-NP O
3 229 232 188339 for IN B-PP O
4 233 238 188339 Liver NN B-NP D008113
5 239 245 188339 Tumors NNS I-NP D008113
6 246 256 188339 Associated VBN B-VP O
7 257 261 188339 with IN B-PP O
8 262 266 188339 Oral JJ B-NP D003276
9 267 281 188339 Contraceptives NNS I-NP D003276
10 282 284 188339 at IN B-PP O
11 285 288 188339 the DT B-NP O
12 289 299 188339 University NNP I-NP O
13 300 302 188339 of IN B-PP O
14 303 313 188339 California NNP B-NP O
15 313 314 188339 , , O O
16 315 321 188339 Irvine NNP B-NP O
17 321 322 188339 , , O O
18 323 326 188339 has VBZ B-VP O
19 327 334 188339 clearly RB I-VP O
20 335 345 188339 identified VBN I-VP O
21 346 348 188339 27 CD B-NP O
22 349 354 188339 cases NNS I-NP O
23 354 355 188339 . . O O

1 356 359 188339 The DT B-NP O
2 360 366 188339 recent JJ I-NP O
3 367 377 188339 literature NN I-NP O
4 378 386 188339 contains VBZ B-VP O
5 387 389 188339 44 CD B-NP O
6 390 394 188339 case NN I-NP O
7 395 402 188339 reports NNS I-NP O
8 402 403 188339 . . O O

1 404 410 188339 Common JJ B-ADJP O
2 411 413 188339 to TO B-PP O
3 414 419 188339 these DT B-NP O
4 420 422 188339 71 CD I-NP O
5 423 428 188339 cases NNS I-NP O
6 429 432 188339 has VBZ B-VP O
7 433 437 188339 been VBN I-VP O
8 438 439 188339 a DT B-NP O
9 440 455 188339 histopathologic JJ I-NP O
10 456 465 188339 diagnosis NN I-NP O
11 466 468 188339 of IN B-PP O
12 469 474 188339 focal JJ B-NP D020518
13 475 482 188339 nodular JJ I-NP D020518
14 483 494 188339 hyperplasia NN I-NP D020518
15 494 495 188339 , , O O
16 496 503 188339 adenoma NN B-NP D000236
17 503 504 188339 , , O O
18 505 514 188339 hamartoma NN B-NP D006222
19 514 515 188339 , , O O
20 516 519 188339 and CC O O
21 520 528 188339 hepatoma NN B-NP D006528
22 528 529 188339 . . O O

1 530 541 188339 Significant JJ B-NP O
2 542 553 188339 statistical JJ I-NP O
3 554 563 188339 etiologic JJ I-NP O
4 564 571 188339 factors NNS I-NP O
5 572 579 188339 include VBP B-VP O
6 580 589 188339 prolonged JJ B-NP O
7 590 603 188339 uninterrupted JJ I-NP O
8 604 609 188339 usage NN I-NP O
9 610 612 188339 of IN B-PP O
10 613 617 188339 oral JJ B-NP D003276
11 618 631 188339 contraceptive JJ I-NP D003276
12 632 640 188339 steroids NNS I-NP D013256
13 640 641 188339 . . O O

1 642 647 188339 Eight CD B-NP O
2 648 654 188339 deaths NNS I-NP O
3 655 658 188339 and CC O O
4 659 664 188339 liver NN B-NP O
5 665 672 188339 rupture NN I-NP D012421
6 673 675 188339 in IN B-PP O
7 676 678 188339 18 CD B-NP O
8 679 687 188339 patients NNS I-NP O
9 688 694 188339 attest NN I-NP O
10 695 697 188339 to TO B-PP O
11 698 701 188339 the DT B-NP O
12 702 713 188339 seriousness NN I-NP O
13 714 716 188339 of IN B-PP O
14 717 721 188339 this DT B-NP O
15 722 725 188339 new JJ I-NP O
16 726 737 188339 potentially RB I-NP O
17 738 744 188339 lethal JJ I-NP O
18 745 752 188339 adverse JJ I-NP O
19 753 763 188339 phenomenon NN I-NP O
20 763 764 188339 . . O O

1 0 0 18441470 -DOCSTART- -X- -X- O

1 0 8 18441470 Complete JJ B-NP O
2 9 25 18441470 atrioventricular JJ I-NP D054537
3 26 31 18441470 block NN I-NP D054537
4 32 41 18441470 secondary JJ B-ADJP O
5 42 44 18441470 to TO B-PP O
6 45 52 18441470 lithium NN B-NP D008094
7 53 60 18441470 therapy NN I-NP O
8 60 61 18441470 . . O O
9 62 67 18441470 Sinus NN B-NP D012804
10 68 72 18441470 node NN I-NP D012804
11 73 84 18441470 dysfunction NN I-NP D012804
12 85 88 18441470 has VBZ B-VP O
13 89 93 18441470 been VBN I-VP O
14 94 102 18441470 reported VBN I-VP O
15 103 107 18441470 most RBS B-ADVP O
16 108 118 18441470 frequently RB I-ADVP O
17 119 124 18441470 among IN B-PP O
18 125 128 18441470 the DT B-NP O
19 129 136 18441470 adverse JJ I-NP O
20 137 151 18441470 cardiovascular JJ I-NP O
21 152 159 18441470 effects NNS I-NP O
22 160 162 18441470 of IN B-PP O
23 163 170 18441470 lithium NN B-NP D008094
24 170 171 18441470 . . O O

1 172 174 18441470 In IN B-PP O
2 175 178 18441470 the DT B-NP O
3 179 186 18441470 present JJ I-NP O
4 187 191 18441470 case NN I-NP O
5 191 192 18441470 , , O O
6 193 201 18441470 complete JJ B-NP O
7 202 218 18441470 atrioventricular JJ I-NP D054537
8 219 220 18441470 ( ( O D054537
9 220 222 18441470 AV NN B-NP D054537
10 222 223 18441470 ) ) O D054537
11 224 229 18441470 block VBP B-VP D054537
12 230 234 18441470 with IN B-PP O
13 235 243 18441470 syncopal JJ B-NP D013575
14 244 251 18441470 attacks NNS I-NP D013575
15 252 261 18441470 developed VBD B-VP O
16 262 271 18441470 secondary JJ B-ADJP O
17 272 274 18441470 to TO B-PP O
18 275 282 18441470 lithium NN B-NP D008094
19 283 290 18441470 therapy NN I-NP O
20 290 291 18441470 , , O O
21 292 305 18441470 necessitating VBG B-VP O
22 306 315 18441470 permanent JJ B-NP O
23 316 325 18441470 pacemaker NN I-NP O
24 326 338 18441470 implantation NN I-NP O
25 338 339 18441470 . . O O

1 340 345 18441470 Serum NN B-NP O
2 346 353 18441470 lithium NN I-NP D008094
3 354 360 18441470 levels NNS I-NP O
4 361 369 18441470 remained VBD B-VP O
5 370 375 18441470 under IN B-PP O
6 376 378 18441470 or CC I-PP O
7 379 385 18441470 within IN I-PP O
8 386 389 18441470 the DT B-NP O
9 390 401 18441470 therapeutic JJ I-NP O
10 402 407 18441470 range NN I-NP O
11 408 414 18441470 during IN B-PP O
12 415 418 18441470 the DT B-NP O
13 419 427 18441470 syncopal JJ I-NP D013575
14 428 435 18441470 attacks NNS I-NP D013575
15 435 436 18441470 . . O O

1 437 444 18441470 Lithium NN B-NP D008094
2 445 451 18441470 should MD B-VP O
3 452 454 18441470 be VB I-VP O
4 455 459 18441470 used VBN I-VP O
5 460 464 18441470 with IN B-PP O
6 465 472 18441470 extreme JJ B-NP O
7 473 480 18441470 caution NN I-NP O
8 480 481 18441470 , , O O
9 482 492 18441470 especially RB B-ADVP O
10 493 495 18441470 in IN B-PP O
11 496 504 18441470 patients NNS B-NP O
12 505 509 18441470 with IN B-PP O
13 510 514 18441470 mild JJ B-NP O
14 515 526 18441470 disturbance NN I-NP O
15 527 529 18441470 of IN B-PP O
16 530 532 18441470 AV NN B-NP O
17 533 543 18441470 conduction NN I-NP O
18 543 544 18441470 . . O O

1 0 0 3934126 -DOCSTART- -X- -X- O

1 0 1 3934126 A DT B-NP O
2 2 13 3934126 prospective JJ I-NP O
3 14 19 3934126 study NN I-NP O
4 20 22 3934126 of IN B-PP O
5 23 30 3934126 adverse JJ B-NP O
6 31 40 3934126 reactions NNS I-NP O
7 41 51 3934126 associated VBN B-VP O
8 52 56 3934126 with IN B-PP O
9 57 67 3934126 vancomycin NN B-NP D014640
10 68 75 3934126 therapy NN I-NP O
11 75 76 3934126 . . O O
12 77 78 3934126 A DT B-NP O
13 79 90 3934126 prospective JJ I-NP O
14 91 101 3934126 evaluation NN I-NP O
15 102 104 3934126 of IN B-PP O
16 105 108 3934126 the DT B-NP O
17 109 117 3934126 efficacy NN I-NP O
18 118 121 3934126 and CC I-NP O
19 122 128 3934126 safety NN I-NP O
20 129 131 3934126 of IN B-PP O
21 132 142 3934126 vancomycin NN B-NP D014640
22 143 146 3934126 was VBD B-VP O
23 147 156 3934126 conducted VBN I-VP O
24 157 159 3934126 in IN B-PP O
25 160 162 3934126 54 CD B-NP O
26 163 174 3934126 consecutive JJ I-NP O
27 175 183 3934126 patients NNS I-NP O
28 184 188 3934126 over IN B-PP O
29 189 190 3934126 a DT B-NP O
30 191 193 3934126 16 CD I-NP O
31 193 194 3934126 - HYPH I-NP O
32 194 199 3934126 month NN I-NP O
33 200 206 3934126 period NN I-NP O
34 206 207 3934126 . . O O

1 208 218 3934126 Vancomycin NN B-NP D014640
2 219 222 3934126 was VBD B-VP O
3 223 231 3934126 curative JJ B-ADJP O
4 232 234 3934126 in IN B-PP O
5 235 238 3934126 95% CD B-NP O
6 239 241 3934126 of IN B-PP O
7 242 244 3934126 43 CD B-NP O
8 245 253 3934126 patients NNS I-NP O
9 254 258 3934126 with IN B-PP O
10 259 265 3934126 proven JJ B-NP O
11 266 275 3934126 infection NN I-NP D007239
12 275 276 3934126 . . O O

1 277 282 3934126 Drugs NNS B-NP O
2 283 287 3934126 were VBD B-VP O
3 288 294 3934126 ceased VBN I-VP O
4 295 297 3934126 in IN B-PP O
5 298 301 3934126 six CD B-NP O
6 302 310 3934126 patients NNS I-NP O
7 311 318 3934126 because IN B-PP O
8 319 321 3934126 of IN I-PP O
9 322 329 3934126 adverse JJ B-NP O
10 330 339 3934126 reactions NNS I-NP O
11 339 340 3934126 ; : O O
12 341 343 3934126 in IN B-PP O
13 344 349 3934126 three CD B-NP O
14 350 352 3934126 of IN B-PP O
15 353 358 3934126 these DT B-NP O
16 359 369 3934126 vancomycin NN I-NP D014640
17 370 373 3934126 was VBD B-VP O
18 374 384 3934126 considered VBN I-VP O
19 385 388 3934126 the DT B-NP O
20 389 395 3934126 likely JJ I-NP O
21 396 401 3934126 cause NN I-NP O
22 401 402 3934126 . . O O

1 403 412 3934126 Reactions NNS B-NP O
2 413 421 3934126 included VBD B-VP O
3 422 438 3934126 thrombophlebitis NN B-NP D013924
4 439 440 3934126 ( ( O O
5 440 442 3934126 20 CD B-NP O
6 443 445 3934126 of IN B-PP O
7 446 448 3934126 54 CD B-NP O
8 449 457 3934126 patients NNS I-NP O
9 457 458 3934126 ) ) O O
10 458 459 3934126 , , O O
11 460 464 3934126 rash NN B-NP D005076
12 465 466 3934126 ( ( O O
13 466 467 3934126 4 CD B-NP O
14 468 470 3934126 of IN B-PP O
15 471 473 3934126 54 CD B-NP O
16 473 474 3934126 ) ) O O
17 474 475 3934126 , , O O
18 476 490 3934126 nephrotoxicity NN B-NP D007674
19 491 492 3934126 ( ( O O
20 492 493 3934126 4 CD B-NP O
21 494 496 3934126 of IN B-PP O
22 497 499 3934126 50 CD B-NP O
23 499 500 3934126 ) ) O O
24 500 501 3934126 , , O O
25 502 513 3934126 proteinuria NN B-NP D011507
26 514 515 3934126 ( ( O O
27 515 516 3934126 1 CD B-NP O
28 517 519 3934126 of IN B-PP O
29 520 522 3934126 50 CD B-NP O
30 522 523 3934126 ) ) O O
31 524 527 3934126 and CC O O
32 528 539 3934126 ototoxicity NN B-NP D006311
33 540 541 3934126 ( ( O O
34 541 542 3934126 1 CD B-NP O
35 543 545 3934126 of IN B-PP O
36 546 548 3934126 11 CD B-NP O
37 549 557 3934126 patients NNS I-NP O
38 558 564 3934126 tested VBN B-VP O
39 565 567 3934126 by IN B-PP O
40 568 578 3934126 audiometry NN B-NP O
41 578 579 3934126 ) ) O O
42 579 580 3934126 . . O O

1 581 597 3934126 Thrombophlebitis NN B-NP D013924
2 598 606 3934126 occurred VBD B-VP O
3 607 611 3934126 only RB B-ADVP O
4 612 616 3934126 with IN B-PP O
5 617 625 3934126 infusion NN B-NP O
6 626 633 3934126 through IN B-PP O
7 634 644 3934126 peripheral JJ B-NP O
8 645 653 3934126 cannulae NNS I-NP O
9 653 654 3934126 ; : O O
10 655 669 3934126 nephrotoxicity NN B-NP D007674
11 670 673 3934126 and CC I-NP O
12 674 685 3934126 ototoxicity NN I-NP D006311
13 686 690 3934126 were VBD B-VP O
14 691 699 3934126 confined VBN I-VP O
15 700 702 3934126 to TO B-PP O
16 703 711 3934126 patients NNS B-NP O
17 712 721 3934126 receiving VBG B-VP O
18 722 724 3934126 an DT B-NP O
19 725 739 3934126 aminoglycoside NN I-NP D000617
20 740 744 3934126 plus CC I-NP O
21 745 755 3934126 vancomycin NN I-NP D014640
22 755 756 3934126 . . O O

1 757 759 3934126 We PRP B-NP O
2 760 768 3934126 conclude VBP B-VP O
3 769 773 3934126 that IN B-SBAR O
4 774 784 3934126 vancomycin NN B-NP D014640
5 784 785 3934126 , , O O
6 786 798 3934126 administered VBN B-VP O
7 799 812 3934126 appropriately RB B-ADVP O
8 812 813 3934126 , , O O
9 814 825 3934126 constitutes VBZ B-VP O
10 826 830 3934126 safe JJ B-NP O
11 830 831 3934126 , , I-NP O
12 832 841 3934126 effective JJ I-NP O
13 842 849 3934126 therapy NN I-NP O
14 850 853 3934126 for IN B-PP O
15 854 864 3934126 infections NNS B-NP D007239
16 865 871 3934126 caused VBN B-VP O
17 872 874 3934126 by IN B-PP O
18 875 886 3934126 susceptible JJ B-NP O
19 887 895 3934126 bacteria NNS I-NP O
20 895 896 3934126 . . O O

1 0 0 7053705 -DOCSTART- -X- -X- O

1 0 7 7053705 Hepatic JJ B-NP D006504
2 8 12 7053705 veno AFX I-NP D006504
3 12 13 7053705 - HYPH I-NP D006504
4 13 22 7053705 occlusive JJ I-NP D006504
5 23 30 7053705 disease NN I-NP D006504
6 31 37 7053705 caused VBN B-VP O
7 38 40 7053705 by IN B-PP O
8 41 42 7053705 6 CD B-NP D013866
9 42 43 7053705 - HYPH I-NP D013866
10 43 54 7053705 thioguanine NN I-NP D013866
11 54 55 7053705 . . O O
12 56 66 7053705 Clinically RB B-ADJP O
13 67 77 7053705 reversible JJ I-ADJP O
14 78 82 7053705 veno AFX B-NP D006504
15 82 83 7053705 - HYPH I-NP D006504
16 83 92 7053705 occlusive JJ I-NP D006504
17 93 100 7053705 disease NN I-NP D006504
18 101 103 7053705 of IN B-PP D006504
19 104 107 7053705 the DT B-NP D006504
20 108 113 7053705 liver NN I-NP D006504
21 114 123 7053705 developed VBN B-VP O
22 124 126 7053705 in IN B-PP O
23 127 128 7053705 a DT B-NP O
24 129 131 7053705 23 CD I-NP O
25 131 132 7053705 - HYPH I-NP O
26 132 136 7053705 year NN I-NP O
27 136 137 7053705 - HYPH O O
28 137 140 7053705 old JJ B-NP O
29 141 144 7053705 man NN I-NP O
30 145 149 7053705 with IN B-PP O
31 150 155 7053705 acute JJ B-NP D054198
32 156 167 7053705 lymphocytic JJ I-NP D054198
33 168 176 7053705 leukemia NN I-NP D054198
34 177 182 7053705 after IN B-PP O
35 183 185 7053705 10 CD B-NP O
36 186 192 7053705 months NNS I-NP O
37 193 195 7053705 of IN B-PP O
38 196 207 7053705 maintenance NN B-NP O
39 208 215 7053705 therapy NN I-NP O
40 216 220 7053705 with IN B-PP O
41 221 222 7053705 6 CD B-NP D013866
42 222 223 7053705 - HYPH I-NP D013866
43 223 234 7053705 thioguanine NN I-NP D013866
44 234 235 7053705 . . O O

1 236 242 7053705 Serial JJ B-NP O
2 243 248 7053705 liver NN I-NP O
3 249 257 7053705 biopsies NNS I-NP O
4 258 264 7053705 showed VBD B-VP O
5 265 268 7053705 the DT B-NP O
6 269 280 7053705 development NN I-NP O
7 281 284 7053705 and CC I-NP O
8 285 295 7053705 resolution NN I-NP O
9 296 298 7053705 of IN B-PP O
10 299 306 7053705 intense JJ B-NP O
11 307 317 7053705 sinusoidal JJ I-NP O
12 318 329 7053705 engorgement NN I-NP O
13 329 330 7053705 . . O O

1 331 339 7053705 Although IN B-SBAR O
2 340 344 7053705 this DT B-NP O
3 345 352 7053705 disease NN I-NP O
4 353 356 7053705 was VBD B-VP O
5 357 367 7053705 clinically RB B-ADJP O
6 368 378 7053705 reversible JJ I-ADJP O
7 378 379 7053705 , , O O
8 380 384 7053705 some DT B-NP O
9 385 395 7053705 subintimal JJ I-NP O
10 396 404 7053705 fibrosis NN I-NP D005355
11 405 410 7053705 about IN B-PP O
12 411 414 7053705 the DT B-NP O
13 415 423 7053705 terminal JJ I-NP O
14 424 431 7053705 hepatic JJ I-NP O
15 432 437 7053705 veins NNS I-NP O
16 438 447 7053705 persisted VBD B-VP O
17 447 448 7053705 . . O O

1 449 453 7053705 This DT B-NP O
2 454 458 7053705 case NN I-NP O
3 459 468 7053705 presented VBD B-VP O
4 469 470 7053705 a DT B-NP O
5 471 477 7053705 unique JJ I-NP O
6 478 489 7053705 opportunity NN I-NP O
7 490 492 7053705 to TO B-VP O
8 493 500 7053705 observe VB I-VP O
9 501 504 7053705 the DT B-NP O
10 505 515 7053705 histologic JJ I-NP O
11 516 524 7053705 features NNS I-NP O
12 525 527 7053705 of IN B-PP O
13 528 538 7053705 clinically RB B-NP O
14 539 549 7053705 reversible JJ I-NP O
15 550 557 7053705 hepatic JJ I-NP D006504
16 558 562 7053705 veno AFX I-NP D006504
17 562 563 7053705 - HYPH I-NP D006504
18 563 572 7053705 occlusive JJ I-NP D006504
19 573 580 7053705 disease NN I-NP D006504
20 581 585 7053705 over IN B-PP O
21 586 590 7053705 time NN B-NP O
22 590 591 7053705 , , O O
23 592 595 7053705 and CC O O
24 596 599 7053705 may MD B-VP O
25 600 602 7053705 be VB I-VP O
26 603 606 7053705 the DT B-NP O
27 607 612 7053705 first JJ I-NP O
28 613 617 7053705 case NN I-NP O
29 618 620 7053705 of IN B-PP O
30 621 625 7053705 veno AFX B-NP O
31 625 626 7053705 - HYPH I-NP O
32 626 635 7053705 occlusive JJ I-NP O
33 636 643 7053705 related VBN B-VP O
34 644 650 7053705 solely RB B-ADVP O
35 651 653 7053705 to TO B-PP O
36 654 655 7053705 6 CD B-NP D013866
37 655 656 7053705 - HYPH I-NP D013866
38 656 667 7053705 thioguanine NN I-NP D013866
39 667 668 7053705 . . O O

1 0 0 18589141 -DOCSTART- -X- -X- O

1 0 7 18589141 Heparin NN B-NP D006493
2 7 8 18589141 - HYPH B-NP O
3 8 15 18589141 induced VBN I-NP O
4 16 32 18589141 thrombocytopenia NN I-NP D013921
5 33 38 18589141 after IN B-PP O
6 39 44 18589141 liver NN B-NP O
7 45 60 18589141 transplantation NN I-NP O
8 60 61 18589141 . . I-NP O
9 62 72 18589141 BACKGROUND NN I-NP O
10 72 73 18589141 : : O O
11 74 88 18589141 Unfractionated JJ B-NP D006493
12 89 96 18589141 heparin NN I-NP D006493
13 97 103 18589141 sodium NN I-NP D006493
14 104 105 18589141 ( ( O O
15 105 108 18589141 UFH NN B-NP D006493
16 108 109 18589141 ) ) O O
17 110 112 18589141 or CC O O
18 113 116 18589141 low JJ B-NP D006495
19 116 117 18589141 - HYPH I-NP D006495
20 117 126 18589141 molecular JJ I-NP D006495
21 127 133 18589141 weight NN I-NP D006495
22 134 141 18589141 heparin NN I-NP D006495
23 142 143 18589141 ( ( O O
24 143 147 18589141 LMWH NN B-NP O
25 147 148 18589141 ) ) O O
26 149 151 18589141 is VBZ B-VP O
27 152 156 18589141 used VBN I-VP O
28 157 159 18589141 in IN B-PP O
29 160 173 18589141 anticoagulant JJ B-NP O
30 174 183 18589141 protocols NNS I-NP O
31 184 186 18589141 at IN B-PP O
32 187 194 18589141 several JJ B-NP O
33 195 207 18589141 institutions NNS I-NP O
34 208 210 18589141 to TO B-VP O
35 211 218 18589141 prevent VB I-VP O
36 219 229 18589141 thrombosis NN B-NP D013927
37 230 235 18589141 after IN B-PP O
38 236 241 18589141 liver NN B-NP O
39 242 257 18589141 transplantation NN I-NP O
40 257 258 18589141 . . O O

1 259 266 18589141 Heparin NN B-NP D006493
2 266 267 18589141 - HYPH B-PP O
3 267 274 18589141 induced VBN B-NP O
4 275 291 18589141 thrombocytopenia NN I-NP D013921
5 292 293 18589141 ( ( O O
6 293 296 18589141 HIT NN B-NP D013921
7 296 297 18589141 ) ) O O
8 298 300 18589141 is VBZ B-VP O
9 301 303 18589141 an DT B-NP O
10 304 311 18589141 adverse JJ I-NP O
11 312 318 18589141 immune JJ I-NP O
12 318 319 18589141 - HYPH I-NP O
13 319 327 18589141 mediated VBN I-NP O
14 328 336 18589141 reaction NN I-NP O
15 337 339 18589141 to TO B-PP O
16 340 347 18589141 heparin NN B-NP D006493
17 347 348 18589141 , , O O
18 349 358 18589141 resulting VBG B-VP O
19 359 361 18589141 in IN B-PP O
20 362 370 18589141 platelet NN B-NP O
21 371 376 18589141 count NN I-NP O
22 377 386 18589141 decreases VBZ B-VP O
23 387 389 18589141 of IN B-PP O
24 390 394 18589141 more JJR B-NP O
25 395 399 18589141 than IN I-NP O
26 400 403 18589141 50% CD I-NP O
27 403 404 18589141 . . O O

1 405 408 18589141 The DT B-NP O
2 409 420 18589141 frequencies NNS I-NP O
3 421 423 18589141 of IN B-PP O
4 424 427 18589141 HIT NN B-NP D013921
5 428 433 18589141 after IN B-PP O
6 434 439 18589141 liver NN B-NP O
7 440 455 18589141 transplantation NN I-NP O
8 456 459 18589141 and CC O O
9 460 468 18589141 platelet NN B-NP O
10 469 475 18589141 factor NN I-NP O
11 476 477 18589141 4 CD B-NP O
12 477 478 18589141 / SYM I-NP O
13 478 485 18589141 heparin NN I-NP D006493
14 485 486 18589141 - HYPH B-NP O
15 486 494 18589141 reactive JJ I-NP O
16 495 503 18589141 antibody NN I-NP O
17 504 505 18589141 ( ( O O
18 505 508 18589141 HIT NN B-NP D013921
19 509 517 18589141 antibody NN I-NP O
20 517 518 18589141 ) ) O O
21 519 529 18589141 positivity NN B-NP O
22 530 532 18589141 in IN B-PP O
23 533 538 18589141 liver NN B-NP O
24 539 554 18589141 transplantation NN I-NP O
25 555 563 18589141 patients NNS I-NP O
26 563 564 18589141 , , O O
27 565 572 18589141 however RB B-ADVP O
28 572 573 18589141 , , O O
29 574 577 18589141 are VBP B-VP O
30 578 585 18589141 unknown JJ B-ADJP O
31 585 586 18589141 . . O O

1 587 595 18589141 PATIENTS NNS B-NP O
2 596 599 18589141 AND CC I-NP O
3 600 607 18589141 METHODS NNS I-NP O
4 607 608 18589141 : : O O
5 609 612 18589141 The DT B-NP O
6 613 615 18589141 32 CD I-NP O
7 616 619 18589141 men NNS I-NP O
8 620 623 18589141 and CC O O
9 624 626 18589141 20 CD B-NP O
10 627 632 18589141 women NNS I-NP O
11 633 642 18589141 underwent VBD B-VP O
12 643 649 18589141 living VBG I-VP O
13 650 655 18589141 donor NN B-NP O
14 656 661 18589141 liver NN I-NP O
15 662 677 18589141 transplantation NN I-NP O
16 677 678 18589141 . . O O

1 679 681 18589141 We PRP B-NP O
2 682 689 18589141 started VBD B-VP O
3 690 694 18589141 LMWH NN B-NP O
4 695 696 18589141 ( ( O O
5 696 698 18589141 25 CD B-NP O
6 699 701 18589141 IU NN I-NP O
7 701 702 18589141 / SYM B-NP O
8 702 704 18589141 kg NN I-NP O
9 704 705 18589141 / SYM B-NP O
10 705 706 18589141 h NN I-NP O
11 706 707 18589141 ) ) O O
12 708 710 18589141 on IN B-PP O
13 711 724 18589141 postoperative JJ B-NP O
14 725 728 18589141 day NN I-NP O
15 729 730 18589141 ( ( O O
16 730 733 18589141 POD NN B-NP O
17 733 734 18589141 ) ) O O
18 735 736 18589141 1 CD B-NP O
19 736 737 18589141 , , O O
20 738 747 18589141 switching VBG B-VP O
21 748 750 18589141 to TO B-PP O
22 751 754 18589141 UFH NN B-NP D006493
23 755 756 18589141 ( ( O O
24 756 760 18589141 5000 CD B-NP O
25 761 762 18589141 U NN I-NP O
26 762 763 18589141 / SYM B-NP O
27 763 764 18589141 d NN I-NP O
28 764 765 18589141 ) ) O O
29 766 768 18589141 on IN B-PP O
30 769 772 18589141 POD NN B-NP O
31 773 774 18589141 2 CD I-NP O
32 775 777 18589141 or CC I-NP O
33 778 779 18589141 3 CD I-NP O
34 779 780 18589141 . . O O

1 781 784 18589141 The DT B-NP O
2 785 789 18589141 dose NN I-NP O
3 790 792 18589141 of IN B-PP O
4 793 796 18589141 UFH NN B-NP D006493
5 797 800 18589141 was VBD B-VP O
6 801 808 18589141 changed VBN I-VP O
7 809 818 18589141 according VBG B-PP O
8 819 821 18589141 to TO B-PP O
9 822 825 18589141 the DT B-NP O
10 826 835 18589141 activated VBN I-NP O
11 836 844 18589141 clotting NN I-NP O
12 845 849 18589141 time NN I-NP O
13 850 855 18589141 level NN I-NP O
14 855 856 18589141 . . O O

1 857 860 18589141 HIT NN B-NP D013921
2 861 869 18589141 antibody NN I-NP O
3 870 876 18589141 levels NNS I-NP O
4 877 881 18589141 were VBD B-VP O
5 882 890 18589141 measured VBN I-VP O
6 891 894 18589141 the DT B-NP O
7 895 898 18589141 day NN I-NP O
8 899 905 18589141 before IN B-PP O
9 906 913 18589141 surgery NN B-NP O
10 914 917 18589141 and CC B-PP O
11 918 920 18589141 on IN B-PP O
12 921 924 18589141 POD NN B-NP O
13 925 926 18589141 7 CD I-NP O
14 927 930 18589141 and CC I-NP O
15 931 933 18589141 14 CD I-NP O
16 933 934 18589141 . . O O

1 935 943 18589141 Platelet NN B-NP O
2 944 949 18589141 count NN I-NP O
3 950 953 18589141 was VBD B-VP O
4 954 962 18589141 measured VBN I-VP O
5 963 968 18589141 daily RB B-ADVP O
6 969 972 18589141 for IN B-PP O
7 973 974 18589141 3 CD B-NP O
8 975 980 18589141 weeks NNS I-NP O
9 980 981 18589141 . . O O

1 982 989 18589141 RESULTS NNS B-NP O
2 989 990 18589141 : : O O
3 991 994 18589141 The DT B-NP O
4 995 1002 18589141 average JJ I-NP O
5 1003 1011 18589141 platelet NN I-NP O
6 1012 1018 18589141 counts NNS I-NP O
7 1019 1033 18589141 preoperatively RB B-ADVP O
8 1033 1034 18589141 , , B-PP O
9 1035 1038 18589141 and CC I-PP O
10 1039 1041 18589141 on IN B-PP O
11 1042 1045 18589141 POD NN B-NP O
12 1046 1047 18589141 7 CD I-NP O
13 1047 1048 18589141 , , I-NP O
14 1049 1051 18589141 14 CD I-NP O
15 1051 1052 18589141 , , O O
16 1053 1056 18589141 and CC O O
17 1057 1059 18589141 21 CD B-NP O
18 1060 1064 18589141 were VBD B-VP O
19 1065 1067 18589141 65 CD B-NP O
20 1067 1068 18589141 , , I-NP O
21 1069 1071 18589141 88 CD I-NP O
22 1071 1072 18589141 , , I-NP O
23 1073 1076 18589141 149 CD I-NP O
24 1076 1077 18589141 , , O O
25 1078 1081 18589141 and CC O O
26 1082 1085 18589141 169 CD B-NP O
27 1086 1087 18589141 x SYM I-NP O
28 1088 1093 18589141 10(9) CD I-NP O
29 1093 1094 18589141 / SYM I-NP O
30 1094 1095 18589141 L NN I-NP O
31 1095 1096 18589141 , , O O
32 1097 1109 18589141 respectively RB B-ADVP O
33 1109 1110 18589141 . . O O

1 1111 1114 18589141 Two CD B-NP O
2 1115 1123 18589141 patients NNS I-NP O
3 1124 1133 18589141 developed VBD B-VP O
4 1134 1141 18589141 hepatic JJ B-NP O
5 1142 1148 18589141 artery NN I-NP O
6 1149 1159 18589141 thrombosis NN I-NP D013927
7 1160 1162 18589141 on IN B-PP O
8 1163 1166 18589141 POD NN B-NP O
9 1167 1169 18589141 11 CD I-NP O
10 1170 1173 18589141 and CC I-NP O
11 1174 1176 18589141 19 CD I-NP O
12 1176 1177 18589141 , , O O
13 1178 1190 18589141 respectively RB B-ADVP O
14 1190 1191 18589141 , , O O
15 1192 1200 18589141 although IN B-SBAR O
16 1201 1205 18589141 they PRP B-NP O
17 1206 1210 18589141 were VBD B-VP O
18 1211 1214 18589141 HIT NN B-NP D013921
19 1215 1223 18589141 antibody NN I-NP O
20 1223 1224 18589141 - HYPH B-VP O
21 1224 1232 18589141 negative JJ B-ADJP O
22 1233 1236 18589141 and CC O O
23 1237 1242 18589141 their PRP$ B-NP O
24 1243 1251 18589141 platelet NN I-NP O
25 1252 1258 18589141 counts NNS I-NP O
26 1259 1263 18589141 were VBD B-VP O
27 1264 1270 18589141 stable JJ B-ADJP O
28 1270 1271 18589141 . . O O

1 1272 1274 18589141 In IN B-PP O
2 1275 1276 18589141 2 CD B-NP O
3 1277 1282 18589141 other JJ I-NP O
4 1283 1291 18589141 patients NNS I-NP O
5 1291 1292 18589141 , , O O
6 1293 1296 18589141 the DT B-NP O
7 1297 1305 18589141 platelet NN I-NP O
8 1306 1311 18589141 count NN I-NP O
9 1312 1321 18589141 decreased VBD B-VP O
10 1322 1330 18589141 suddenly RB B-ADVP O
11 1331 1335 18589141 from IN B-PP O
12 1336 1339 18589141 107 CD B-NP O
13 1340 1341 18589141 x SYM I-NP O
14 1342 1347 18589141 10(9) CD I-NP O
15 1347 1348 18589141 / SYM I-NP O
16 1348 1349 18589141 L NN I-NP O
17 1350 1352 18589141 on IN B-PP O
18 1353 1356 18589141 POD NN B-NP O
19 1357 1358 18589141 4 CD I-NP O
20 1359 1361 18589141 to TO B-PP O
21 1362 1364 18589141 65 CD B-NP O
22 1365 1366 18589141 x SYM B-NP O
23 1367 1372 18589141 10(9) CD I-NP O
24 1372 1373 18589141 / SYM I-NP O
25 1373 1374 18589141 L NN I-NP O
26 1375 1377 18589141 on IN B-PP O
27 1378 1381 18589141 POD NN B-NP O
28 1382 1383 18589141 6 CD I-NP O
29 1384 1387 18589141 and CC B-PP O
30 1388 1392 18589141 from IN B-PP O
31 1393 1395 18589141 76 CD B-NP O
32 1396 1397 18589141 x SYM B-NP O
33 1398 1403 18589141 10(9) CD I-NP O
34 1403 1404 18589141 / SYM I-NP O
35 1404 1405 18589141 L NN I-NP O
36 1406 1408 18589141 on IN B-PP O
37 1409 1412 18589141 POD NN B-NP O
38 1413 1414 18589141 7 CD I-NP O
39 1415 1417 18589141 to TO I-NP O
40 1418 1420 18589141 33 CD I-NP O
41 1421 1422 18589141 x SYM I-NP O
42 1423 1428 18589141 10(9) CD I-NP O
43 1428 1429 18589141 / SYM I-NP O
44 1429 1430 18589141 L NN I-NP O
45 1431 1433 18589141 on IN B-PP O
46 1434 1437 18589141 POD NN B-NP O
47 1438 1439 18589141 9 CD I-NP O
48 1439 1440 18589141 , , O O
49 1441 1453 18589141 respectively RB B-ADVP O
50 1453 1454 18589141 . . O O

1 1455 1458 18589141 The DT B-NP O
2 1459 1466 18589141 heparin NN I-NP D006493
3 1466 1467 18589141 - HYPH B-VP O
4 1467 1474 18589141 induced VBN B-NP O
5 1475 1483 18589141 platelet NN I-NP D001791
6 1484 1495 18589141 aggregation NN I-NP D001791
7 1496 1500 18589141 test NN I-NP O
8 1501 1504 18589141 was VBD B-VP O
9 1505 1513 18589141 negative JJ B-ADJP O
10 1514 1516 18589141 in IN B-PP O
11 1517 1522 18589141 these DT B-NP O
12 1523 1531 18589141 patients NNS I-NP O
13 1531 1532 18589141 . . O O

1 1533 1536 18589141 The DT B-NP O
2 1537 1547 18589141 percentage NN I-NP O
3 1548 1550 18589141 of IN B-PP O
4 1551 1554 18589141 HIT NN B-NP D013921
5 1555 1563 18589141 antibody NN I-NP O
6 1563 1564 18589141 - HYPH O O
7 1564 1572 18589141 positive JJ B-NP O
8 1573 1581 18589141 patients NNS I-NP O
9 1582 1585 18589141 was VBD B-VP O
10 1586 1590 18589141 0.5% CD B-NP O
11 1591 1605 18589141 preoperatively RB B-ADVP O
12 1605 1606 18589141 , , O O
13 1607 1611 18589141 5.6% NN B-NP O
14 1612 1614 18589141 on IN B-PP O
15 1615 1618 18589141 POD NN B-NP O
16 1619 1620 18589141 7 CD I-NP O
17 1620 1621 18589141 , , O O
18 1622 1625 18589141 and CC O O
19 1626 1630 18589141 5.6% NN B-NP O
20 1631 1633 18589141 on IN B-PP O
21 1634 1637 18589141 POD NN B-NP O
22 1638 1640 18589141 14 CD I-NP O
23 1640 1641 18589141 . . O O

1 1642 1646 18589141 None NN B-NP O
2 1647 1649 18589141 of IN B-PP O
3 1650 1653 18589141 the DT B-NP O
4 1654 1662 18589141 subjects NNS I-NP O
5 1662 1663 18589141 / SYM B-NP O
6 1663 1671 18589141 patients NNS B-NP O
7 1672 1681 18589141 developed VBD B-VP O
8 1682 1685 18589141 UFH NN B-NP D006493
9 1685 1686 18589141 - HYPH B-NP O
10 1686 1693 18589141 related VBN I-NP O
11 1694 1697 18589141 HIT NN I-NP D013921
12 1697 1698 18589141 . . O O

1 1699 1710 18589141 CONCLUSIONS NNS B-NP O
2 1710 1711 18589141 : : O O
3 1712 1714 18589141 In IN B-PP O
4 1715 1718 18589141 our PRP$ B-NP O
5 1719 1725 18589141 series NN I-NP O
6 1725 1726 18589141 , , O O
7 1727 1730 18589141 the DT B-NP O
8 1731 1741 18589141 occurrence NN I-NP O
9 1742 1744 18589141 of IN B-PP O
10 1745 1748 18589141 HIT NN B-NP D013921
11 1749 1754 18589141 after IN B-PP O
12 1755 1760 18589141 liver NN B-NP O
13 1761 1776 18589141 transplantation NN I-NP O
14 1777 1780 18589141 was VBD B-VP O
15 1781 1789 18589141 uncommon JJ B-ADJP O
16 1789 1790 18589141 . . O O

1 0 0 15266362 -DOCSTART- -X- -X- O

1 0 16 15266362 Hypersensitivity NN B-NP D004342
2 17 28 15266362 myocarditis NN I-NP D009205
3 29 41 15266362 complicating VBG B-VP O
4 42 54 15266362 hypertrophic JJ B-NP D002312
5 55 69 15266362 cardiomyopathy NN I-NP D002312
6 70 75 15266362 heart NN I-NP O
7 75 76 15266362 . . O O
8 77 80 15266362 The DT B-NP O
9 81 88 15266362 present JJ I-NP O
10 89 95 15266362 report NN I-NP O
11 96 105 15266362 describes VBZ B-VP O
12 106 107 15266362 a DT B-NP O
13 108 112 15266362 case NN I-NP O
14 113 115 15266362 of IN B-PP O
15 116 128 15266362 eosinophilic JJ B-NP D004802
16 129 140 15266362 myocarditis NN I-NP D004802
17 141 153 15266362 complicating VBG B-VP O
18 154 166 15266362 hypertrophic JJ B-NP D002312
19 167 181 15266362 cardiomyopathy NN I-NP D002312
20 181 182 15266362 . . O O

1 183 186 15266362 The DT B-NP O
2 187 189 15266362 47 CD I-NP O
3 189 190 15266362 - HYPH I-NP O
4 190 194 15266362 year NN I-NP O
5 194 195 15266362 - HYPH O O
6 195 198 15266362 old JJ B-NP O
7 199 205 15266362 female JJ I-NP O
8 206 213 15266362 patient NN I-NP O
9 213 214 15266362 , , O O
10 215 220 15266362 known VBN B-VP O
11 221 223 15266362 to TO I-VP O
12 224 228 15266362 have VB I-VP O
13 229 241 15266362 hypertrophic JJ B-NP D002312
14 242 256 15266362 cardiomyopathy NN I-NP D002312
15 256 257 15266362 , , O O
16 258 261 15266362 was VBD B-VP O
17 262 270 15266362 admitted VBN I-VP O
18 271 275 15266362 with IN B-PP O
19 276 289 15266362 biventricular JJ B-NP D018754
20 290 297 15266362 failure NN I-NP D018754
21 298 301 15266362 and CC O O
22 302 309 15266362 managed VBD B-VP O
23 310 322 15266362 aggressively RB B-ADVP O
24 323 327 15266362 with IN B-PP O
25 328 338 15266362 dobutamine NN B-NP D004280
26 339 347 15266362 infusion NN I-NP O
27 348 351 15266362 and CC O O
28 352 357 15266362 other JJ B-NP O
29 358 363 15266362 drugs NNS I-NP O
30 364 369 15266362 while IN B-SBAR O
31 370 375 15266362 being VBG B-VP O
32 376 384 15266362 assessed VBN I-VP O
33 385 388 15266362 for IN B-PP O
34 389 394 15266362 heart NN B-NP O
35 395 410 15266362 transplantation NN I-NP O
36 410 411 15266362 . . O O

1 412 414 15266362 On IN B-PP O
2 415 428 15266362 transthoracic JJ B-NP O
3 429 443 15266362 echocardiogram NN I-NP O
4 443 444 15266362 , , O O
5 445 448 15266362 she PRP B-NP O
6 449 452 15266362 had VBD B-VP O
7 453 461 15266362 moderate JJ B-NP O
8 462 466 15266362 left JJ I-NP D018487
9 467 478 15266362 ventricular JJ I-NP D018487
10 479 490 15266362 dysfunction NN I-NP D018487
11 491 495 15266362 with IN B-PP O
12 496 504 15266362 regional JJ B-NP O
13 505 516 15266362 variability NN I-NP O
14 517 520 15266362 and CC O O
15 521 529 15266362 moderate JJ B-NP O
16 530 536 15266362 mitral JJ I-NP D008944
17 537 550 15266362 regurgitation NN I-NP D008944
18 550 551 15266362 . . O O

1 552 555 15266362 The DT B-NP O
2 556 567 15266362 recipient's NNS I-NP O
3 568 573 15266362 heart NN I-NP O
4 574 580 15266362 showed VBD B-VP O
5 581 584 15266362 the DT B-NP O
6 585 593 15266362 features NNS I-NP O
7 594 596 15266362 of IN B-PP O
8 597 603 15266362 apical JJ B-NP O
9 604 616 15266362 hypertrophic JJ I-NP D002312
10 617 631 15266362 cardiomyopathy NN I-NP D002312
11 632 635 15266362 and CC I-NP O
12 636 647 15266362 myocarditis NN I-NP D009205
13 648 652 15266362 with IN B-PP O
14 653 661 15266362 abundant JJ B-NP O
15 662 673 15266362 eosinophils NNS I-NP O
16 673 674 15266362 . . O O

1 675 686 15266362 Myocarditis NN B-NP D009205
2 687 689 15266362 is VBZ B-VP O
3 690 694 15266362 rare JJ B-NP O
4 695 698 15266362 and CC I-NP O
5 699 711 15266362 eosinophilic JJ I-NP D004802
6 712 723 15266362 myocarditis NN I-NP D004802
7 724 726 15266362 is VBZ B-VP O
8 727 732 15266362 rarer NN B-NP O
9 732 733 15266362 . . O O

1 734 736 15266362 It PRP B-NP O
2 737 739 15266362 is VBZ B-VP O
3 740 746 15266362 likely JJ B-ADJP O
4 747 751 15266362 that IN B-SBAR O
5 752 755 15266362 the DT B-NP O
6 756 772 15266362 hypersensitivity NN I-NP D004342
7 773 774 15266362 ( ( O O
8 774 786 15266362 eosinophilic JJ O D004802
9 786 787 15266362 ) ) O O
10 788 799 15266362 myocarditis NN B-NP D009205
11 800 803 15266362 was VBD B-VP O
12 804 811 15266362 related JJ B-ADJP O
13 812 814 15266362 to TO B-PP O
14 815 825 15266362 dobutamine NN B-NP D004280
15 826 834 15266362 infusion NN I-NP O
16 835 842 15266362 therapy NN I-NP O
17 842 843 15266362 . . O O

1 844 856 15266362 Eosinophilic JJ B-NP D004802
2 857 868 15266362 myocarditis NN I-NP D004802
3 869 872 15266362 has VBZ B-VP O
4 873 877 15266362 been VBN I-VP O
5 878 886 15266362 reported VBN I-VP O
6 887 891 15266362 with IN B-PP O
7 892 894 15266362 an DT B-NP O
8 895 904 15266362 incidence NN I-NP O
9 905 907 15266362 of IN B-PP O
10 908 912 15266362 2.4% CD B-NP O
11 913 915 15266362 to TO B-PP O
12 916 920 15266362 7.2% CD B-NP O
13 921 923 15266362 in IN B-PP O
14 924 933 15266362 explanted VBN B-NP O
15 934 940 15266362 hearts NNS I-NP O
16 941 944 15266362 and CC O O
17 945 948 15266362 may MD B-VP O
18 949 951 15266362 be VB I-VP O
19 952 959 15266362 related JJ B-ADJP O
20 960 962 15266362 to TO B-PP O
21 963 972 15266362 multidrug JJ B-NP O
22 973 980 15266362 therapy NN I-NP O
23 980 981 15266362 . . O O

1 0 0 15893386 -DOCSTART- -X- -X- O

1 0 15 15893386 Succinylcholine NN B-NP D013390
2 15 16 15893386 - HYPH B-NP O
3 16 23 15893386 induced VBN I-NP O
4 24 32 15893386 masseter NN I-NP D014313
5 33 39 15893386 muscle NN I-NP D014313
6 40 48 15893386 rigidity NN I-NP D014313
7 49 55 15893386 during IN B-PP O
8 56 69 15893386 bronchoscopic JJ B-NP O
9 70 77 15893386 removal NN I-NP O
10 78 80 15893386 of IN B-PP O
11 81 82 15893386 a DT B-NP O
12 83 91 15893386 tracheal JJ I-NP O
13 92 99 15893386 foreign JJ I-NP O
14 100 104 15893386 body NN I-NP O
15 104 105 15893386 . . O O
16 106 114 15893386 Masseter NNP B-NP D014313
17 115 121 15893386 muscle NN I-NP D014313
18 122 130 15893386 rigidity NN I-NP D014313
19 131 137 15893386 during IN B-PP O
20 138 145 15893386 general JJ B-NP O
21 146 156 15893386 anesthesia NN I-NP O
22 157 159 15893386 is VBZ B-VP O
23 160 170 15893386 considered VBN I-VP O
24 171 173 15893386 an DT B-NP O
25 174 179 15893386 early JJ I-NP O
26 180 187 15893386 warning NN I-NP O
27 188 192 15893386 sign NN I-NP O
28 193 195 15893386 of IN B-PP O
29 196 197 15893386 a DT B-NP O
30 198 206 15893386 possible JJ I-NP O
31 207 214 15893386 episode NN I-NP O
32 215 217 15893386 of IN B-PP O
33 218 227 15893386 malignant JJ B-NP D008305
34 228 240 15893386 hyperthermia NN I-NP D008305
35 240 241 15893386 . . O O

1 242 245 15893386 The DT B-NP O
2 246 254 15893386 decision NN I-NP O
3 255 262 15893386 whether IN B-SBAR O
4 263 265 15893386 to TO B-VP O
5 266 274 15893386 continue VB I-VP O
6 275 277 15893386 or CC I-VP O
7 278 289 15893386 discontinue VB I-VP O
8 290 293 15893386 the DT B-NP O
9 294 303 15893386 procedure NN I-NP O
10 304 311 15893386 depends VBZ B-VP O
11 312 314 15893386 on IN B-PP O
12 315 318 15893386 the DT B-NP O
13 319 326 15893386 urgency NN I-NP O
14 327 329 15893386 of IN B-PP O
15 330 333 15893386 the DT B-NP O
16 334 341 15893386 surgery NN I-NP O
17 342 345 15893386 and CC I-NP O
18 346 354 15893386 severity NN I-NP O
19 355 357 15893386 of IN B-PP O
20 358 366 15893386 masseter NN B-NP D014313
21 367 373 15893386 muscle NN I-NP D014313
22 374 382 15893386 rigidity NN I-NP D014313
23 382 383 15893386 . . O O

1 384 388 15893386 Here RB B-ADVP O
2 388 389 15893386 , , O O
3 390 392 15893386 we PRP B-NP O
4 393 401 15893386 describe VBP B-VP O
5 402 403 15893386 a DT B-NP O
6 404 408 15893386 case NN I-NP O
7 409 411 15893386 of IN B-PP O
8 412 418 15893386 severe JJ B-NP O
9 419 427 15893386 masseter NN I-NP D014313
10 428 434 15893386 muscle NN I-NP D014313
11 435 443 15893386 rigidity NN I-NP D014313
12 444 445 15893386 ( ( O O
13 445 448 15893386 jaw NN B-NP D014313
14 449 451 15893386 of IN B-PP D014313
15 452 457 15893386 steel NN B-NP D014313
16 457 458 15893386 ) ) O O
17 459 464 15893386 after IN B-PP O
18 465 480 15893386 succinylcholine NN B-NP D013390
19 481 482 15893386 ( ( O O
20 482 485 15893386 Sch NN B-NP D013390
21 485 486 15893386 ) ) O O
22 487 501 15893386 administration NN B-NP O
23 502 508 15893386 during IN B-PP O
24 509 516 15893386 general JJ B-NP O
25 517 527 15893386 anesthetic JJ I-NP O
26 528 538 15893386 management NN I-NP O
27 539 542 15893386 for IN B-PP O
28 543 548 15893386 rigid JJ B-NP O
29 549 562 15893386 bronchoscopic JJ I-NP O
30 563 570 15893386 removal NN I-NP O
31 571 573 15893386 of IN B-PP O
32 574 575 15893386 a DT B-NP O
33 576 584 15893386 tracheal JJ I-NP O
34 585 592 15893386 foreign JJ I-NP O
35 593 597 15893386 body NN I-NP O
36 597 598 15893386 . . O O

1 599 609 15893386 Anesthesia NNP B-NP O
2 610 613 15893386 was VBD B-VP O
3 614 623 15893386 continued VBN I-VP O
4 624 636 15893386 uneventfully RB B-ADVP O
5 637 641 15893386 with IN B-PP O
6 642 650 15893386 propofol NN B-NP D015742
7 651 659 15893386 infusion NN I-NP O
8 660 665 15893386 while IN B-SBAR O
9 666 669 15893386 all DT B-NP O
10 670 680 15893386 facilities NNS I-NP O
11 681 685 15893386 were VBD B-VP O
12 686 695 15893386 available JJ B-ADJP O
13 696 698 15893386 to TO B-VP O
14 699 705 15893386 detect VB I-VP O
15 706 709 15893386 and CC I-VP O
16 710 715 15893386 treat VB I-VP O
17 716 725 15893386 malignant JJ B-NP D008305
18 726 738 15893386 hyperthermia NN I-NP D008305
19 738 739 15893386 . . O O

1 0 0 3131282 -DOCSTART- -X- -X- O

1 0 2 3131282 Co AFX B-NP O
2 2 3 3131282 - HYPH I-NP O
3 3 15 3131282 carcinogenic JJ I-NP D063646
4 16 22 3131282 effect NN I-NP O
5 23 25 3131282 of IN B-PP O
6 26 33 3131282 retinyl NN B-NP C009166
7 34 41 3131282 acetate NN I-NP C009166
8 42 44 3131282 on IN B-PP O
9 45 56 3131282 forestomach NN B-NP D013274
10 57 71 3131282 carcinogenesis NN I-NP D013274
11 72 74 3131282 of IN B-PP O
12 75 79 3131282 male JJ B-NP O
13 80 84 3131282 F344 NN I-NP O
14 85 89 3131282 rats NNS I-NP O
15 90 97 3131282 induced VBN B-VP O
16 98 102 3131282 with IN B-PP O
17 103 112 3131282 butylated VBN B-NP D002083
18 113 127 3131282 hydroxyanisole NN I-NP D002083
19 127 128 3131282 . . O O
20 129 132 3131282 The DT B-NP O
21 133 142 3131282 potential JJ I-NP O
22 143 152 3131282 modifying NN I-NP O
23 153 159 3131282 effect NN I-NP O
24 160 162 3131282 of IN B-PP O
25 163 170 3131282 retinyl NN B-NP C009166
26 171 178 3131282 acetate NN I-NP C009166
27 179 180 3131282 ( ( O O
28 180 182 3131282 RA NN B-NP C009166
29 182 183 3131282 ) ) O O
30 184 186 3131282 on IN B-PP O
31 187 196 3131282 butylated VBN B-NP D002083
32 197 211 3131282 hydroxyanisole NN I-NP D002083
33 212 213 3131282 ( ( O O
34 213 216 3131282 BHA NN B-NP D002083
35 216 217 3131282 ) ) O O
36 217 218 3131282 - HYPH B-NP O
37 218 225 3131282 induced VBN I-NP O
38 226 229 3131282 rat NN I-NP O
39 230 241 3131282 forestomach NN I-NP D013274
40 242 255 3131282 tumorigenesis NN I-NP D013274
41 256 259 3131282 was VBD B-VP O
42 260 268 3131282 examined VBN I-VP O
43 268 269 3131282 . . O O

1 270 274 3131282 Male JJ B-NP O
2 275 279 3131282 F344 NN I-NP O
3 280 284 3131282 rats NNS I-NP O
4 284 285 3131282 , , O O
5 286 287 3131282 5 CD B-NP O
6 288 293 3131282 weeks NNS I-NP O
7 294 296 3131282 of IN B-PP O
8 297 300 3131282 age NN B-NP O
9 300 301 3131282 , , O O
10 302 306 3131282 were VBD B-VP O
11 307 317 3131282 maintained VBN I-VP O
12 318 320 3131282 on IN B-PP O
13 321 325 3131282 diet NN B-NP O
14 326 336 3131282 containing VBG B-VP O
15 337 339 3131282 1% CD B-NP O
16 340 342 3131282 or CC I-NP O
17 343 345 3131282 2% CD I-NP O
18 346 349 3131282 BHA NN I-NP D002083
19 350 352 3131282 by IN B-PP O
20 353 359 3131282 weight NN B-NP O
21 360 363 3131282 and CC O O
22 364 378 3131282 simultaneously RB B-ADVP O
23 379 381 3131282 on IN B-PP O
24 382 390 3131282 drinking NN B-NP O
25 391 396 3131282 water NN I-NP O
26 397 409 3131282 supplemented VBN B-VP O
27 410 414 3131282 with IN B-PP O
28 415 417 3131282 RA NN B-NP C009166
29 418 420 3131282 at IN B-PP O
30 421 428 3131282 various JJ B-NP O
31 429 443 3131282 concentrations NNS I-NP O
32 444 445 3131282 ( ( O O
33 445 446 3131282 w NN B-NP O
34 446 447 3131282 / SYM B-NP O
35 447 448 3131282 v NN I-NP O
36 448 449 3131282 ) ) O O
37 450 453 3131282 for IN B-PP O
38 454 456 3131282 52 CD B-NP O
39 457 462 3131282 weeks NNS I-NP O
40 462 463 3131282 . . O O

1 464 466 3131282 In IN B-PP O
2 467 473 3131282 groups NNS B-NP O
3 474 479 3131282 given VBN B-VP O
4 480 482 3131282 2% CD B-NP O
5 483 486 3131282 BHA NN I-NP D002083
6 486 487 3131282 , , O O
7 488 496 3131282 although IN B-SBAR O
8 497 503 3131282 marked JJ B-NP O
9 504 516 3131282 hyperplastic JJ I-NP O
10 517 524 3131282 changes NNS I-NP O
11 525 527 3131282 of IN B-PP O
12 528 531 3131282 the DT B-NP O
13 532 543 3131282 forestomach NN I-NP O
14 544 554 3131282 epithelium NN I-NP O
15 555 559 3131282 were VBD B-VP O
16 560 568 3131282 observed VBN I-VP O
17 569 571 3131282 in IN B-PP O
18 572 575 3131282 all DT B-NP O
19 576 583 3131282 animals NNS I-NP O
20 583 584 3131282 , , O O
21 585 587 3131282 co AFX O O
22 587 588 3131282 - HYPH O O
23 588 602 3131282 administration NN B-NP O
24 603 605 3131282 of IN B-PP O
25 606 611 3131282 0.25% CD B-NP O
26 612 614 3131282 RA NN I-NP C009166
27 615 628 3131282 significantly RB B-ADVP O
28 629 630 3131282 ( ( O O
29 630 631 3131282 P NN B-NP O
30 632 636 3131282 less JJR B-ADJP O
31 637 641 3131282 than IN B-PP O
32 642 646 3131282 0.05 CD B-NP O
33 646 647 3131282 ) ) O O
34 648 657 3131282 increased VBD B-VP O
35 658 661 3131282 the DT B-NP O
36 662 671 3131282 incidence NN I-NP O
37 672 674 3131282 of IN B-PP O
38 675 686 3131282 forestomach NN B-NP D013274
39 687 693 3131282 tumors NNS I-NP D013274
40 694 695 3131282 ( ( O O
41 695 703 3131282 squamous JJ B-NP D010212
42 704 708 3131282 cell NN I-NP D010212
43 709 718 3131282 papilloma NN I-NP D010212
44 719 722 3131282 and CC O O
45 723 732 3131282 carcinoma NN B-NP D002277
46 732 733 3131282 ) ) O O
47 734 736 3131282 to TO B-PP O
48 737 740 3131282 60% CD B-NP O
49 741 742 3131282 ( ( O O
50 742 743 3131282 9 CD B-NP O
51 743 744 3131282 / SYM B-NP O
52 744 746 3131282 15 CD I-NP O
53 746 747 3131282 , , O O
54 748 749 3131282 2 CD B-NP O
55 750 754 3131282 rats NNS I-NP O
56 755 759 3131282 with IN B-PP O
57 760 769 3131282 carcinoma NN B-NP D002277
58 769 770 3131282 ) ) O O
59 771 775 3131282 from IN B-PP O
60 776 779 3131282 15% CD B-NP O
61 780 781 3131282 ( ( O O
62 781 782 3131282 3 CD B-NP O
63 782 783 3131282 / SYM I-NP O
64 783 785 3131282 20 CD I-NP O
65 785 786 3131282 , , I-NP O
66 787 790 3131282 one CD I-NP O
67 791 794 3131282 rat NN I-NP O
68 795 799 3131282 with IN B-PP O
69 800 809 3131282 carcinoma NN B-NP D002277
70 809 810 3131282 ) ) O O
71 811 813 3131282 in IN B-PP O
72 814 817 3131282 the DT B-NP O
73 818 823 3131282 group NN I-NP O
74 824 829 3131282 given VBN B-NP O
75 830 832 3131282 RA NN I-NP C009166
76 832 833 3131282 - HYPH O O
77 833 837 3131282 free JJ B-NP O
78 838 843 3131282 water NN I-NP O
79 843 844 3131282 . . O O

1 845 847 3131282 In IN B-PP O
2 848 852 3131282 rats NNS B-NP O
3 853 858 3131282 given VBN B-VP O
4 859 861 3131282 1% CD B-NP O
5 862 865 3131282 BHA NN I-NP D002083
6 865 866 3131282 , , O O
7 867 869 3131282 RA NN B-NP C009166
8 870 872 3131282 co AFX O O
9 872 873 3131282 - HYPH O O
10 873 885 3131282 administered VBN B-VP O
11 886 888 3131282 at IN B-PP O
12 889 890 3131282 a DT B-NP O
13 891 895 3131282 dose NN I-NP O
14 896 898 3131282 of IN B-PP O
15 899 903 3131282 0.05 CD B-NP O
16 903 904 3131282 , , I-NP O
17 905 908 3131282 0.1 CD I-NP O
18 908 909 3131282 , , I-NP O
19 910 913 3131282 0.2 CD I-NP O
20 914 916 3131282 or CC I-NP O
21 917 922 3131282 0.25% CD I-NP O
22 923 929 3131282 showed VBD B-VP O
23 930 931 3131282 a DT B-NP O
24 932 936 3131282 dose NN I-NP O
25 936 937 3131282 - HYPH B-NP O
26 937 946 3131282 dependent JJ I-NP O
27 947 956 3131282 enhancing NN I-NP O
28 957 963 3131282 effect NN I-NP O
29 964 966 3131282 on IN B-PP O
30 967 970 3131282 the DT B-NP O
31 971 982 3131282 development NN I-NP O
32 983 985 3131282 of IN B-PP O
33 986 989 3131282 the DT B-NP O
34 990 993 3131282 BHA NN I-NP D002083
35 993 994 3131282 - HYPH O O
36 994 1001 3131282 induced VBN B-NP O
37 1002 1012 3131282 epithelial JJ I-NP D017573
38 1013 1024 3131282 hyperplasia NN I-NP D017573
39 1024 1025 3131282 . . O O

1 1026 1032 3131282 Tumors NNS B-NP D009369
2 1032 1033 3131282 , , O O
3 1034 1037 3131282 all DT B-NP O
4 1038 1048 3131282 papillomas NNS I-NP D010212
5 1048 1049 3131282 , , O O
6 1050 1054 3131282 were VBD B-VP O
7 1055 1062 3131282 induced VBN I-VP O
8 1063 1065 3131282 in IN B-PP O
9 1066 1067 3131282 3 CD B-NP O
10 1068 1072 3131282 rats NNS I-NP O
11 1073 1074 3131282 ( ( O O
12 1074 1077 3131282 17% NN B-NP O
13 1077 1078 3131282 ) ) O O
14 1079 1083 3131282 with IN B-PP O
15 1084 1089 3131282 0.25% CD B-NP O
16 1090 1092 3131282 RA NN I-NP C009166
17 1093 1096 3131282 and CC O O
18 1097 1099 3131282 in IN B-PP O
19 1100 1103 3131282 one CD B-NP O
20 1104 1107 3131282 rat NN I-NP O
21 1108 1109 3131282 ( ( O O
22 1109 1112 3131282 10% CD B-NP O
23 1112 1113 3131282 ) ) O O
24 1114 1118 3131282 with IN B-PP O
25 1119 1124 3131282 0.05% CD B-NP O
26 1125 1127 3131282 RA NN I-NP C009166
27 1128 1130 3131282 co AFX B-NP O
28 1130 1131 3131282 - HYPH I-NP O
29 1131 1145 3131282 administration NN B-NP O
30 1145 1146 3131282 . . O O

1 1147 1149 3131282 RA NN B-NP C009166
2 1150 1155 3131282 alone RB B-ADVP O
3 1156 1159 3131282 did VBD B-VP O
4 1160 1163 3131282 not RB I-VP O
5 1164 1170 3131282 induce VB I-VP O
6 1171 1183 3131282 hyperplastic JJ B-NP O
7 1184 1191 3131282 changes NNS I-NP O
8 1192 1194 3131282 in IN B-PP O
9 1195 1198 3131282 the DT B-NP O
10 1199 1210 3131282 forestomach NN I-NP O
11 1210 1211 3131282 . . O O

1 1212 1217 3131282 These DT B-NP O
2 1218 1226 3131282 findings NNS I-NP O
3 1227 1235 3131282 indicate VBP B-VP O
4 1236 1240 3131282 that IN B-SBAR O
5 1241 1243 3131282 RA NN B-NP C009166
6 1244 1249 3131282 acted VBD B-VP O
7 1250 1252 3131282 as IN B-PP O
8 1253 1254 3131282 a DT B-NP O
9 1255 1257 3131282 co AFX I-NP O
10 1257 1258 3131282 - HYPH I-NP O
11 1258 1268 3131282 carcinogen NN I-NP O
12 1269 1271 3131282 in IN B-PP O
13 1272 1275 3131282 the DT B-NP O
14 1276 1279 3131282 BHA NN I-NP D002083
15 1280 1291 3131282 forestomach NN I-NP D013274
16 1292 1306 3131282 carcinogenesis NN I-NP D013274
17 1307 1309 3131282 of IN B-PP O
18 1310 1313 3131282 the DT B-NP O
19 1314 1317 3131282 rat NN I-NP O
20 1317 1318 3131282 . . O O

1 0 0 8854309 -DOCSTART- -X- -X- O

1 0 1 8854309 A DT B-NP O
2 2 9 8854309 measure NN I-NP O
3 10 12 8854309 of IN B-PP O
4 13 22 8854309 pupillary JJ B-NP D011681
5 23 34 8854309 oscillation NN I-NP D011681
6 35 37 8854309 as IN B-PP O
7 38 39 8854309 a DT B-NP O
8 40 46 8854309 marker NN I-NP O
9 47 49 8854309 of IN B-PP O
10 50 57 8854309 cocaine NN B-NP D003042
11 57 58 8854309 - HYPH B-NP O
12 58 65 8854309 induced VBN I-NP O
13 66 74 8854309 paranoia NN I-NP D010259
14 74 75 8854309 . . I-NP O
15 76 83 8854309 Cocaine NN I-NP D003042
16 83 84 8854309 - HYPH O O
17 84 91 8854309 induced VBN B-NP O
18 92 100 8854309 paranoia NN I-NP D010259
19 101 102 8854309 ( ( O O
20 102 105 8854309 CIP NN B-NP D010259
21 105 106 8854309 ) ) O O
22 107 114 8854309 remains VBZ B-VP O
23 115 117 8854309 an DT B-NP O
24 118 127 8854309 important JJ I-NP O
25 128 132 8854309 drug NN I-NP O
26 132 133 8854309 - HYPH B-NP O
27 133 140 8854309 induced VBN I-NP O
28 141 146 8854309 model NN I-NP O
29 147 149 8854309 of IN B-PP O
30 150 160 8854309 idiopathic JJ B-NP O
31 161 169 8854309 paranoia NN I-NP D010259
32 170 173 8854309 for IN B-PP O
33 174 179 8854309 which WDT B-NP O
34 180 182 8854309 no DT B-NP O
35 183 200 8854309 psychophysiologic JJ I-NP O
36 201 207 8854309 marker NN I-NP O
37 208 211 8854309 has VBZ B-VP O
38 212 215 8854309 yet RB I-VP O
39 216 223 8854309 emerged VBN I-VP O
40 223 224 8854309 . . O O

1 225 233 8854309 Measures NNS B-NP O
2 234 236 8854309 of IN B-PP O
3 237 246 8854309 pupillary JJ B-NP D011681
4 247 258 8854309 oscillation NN I-NP D011681
5 259 263 8854309 were VBD B-VP O
6 264 268 8854309 able JJ B-ADJP O
7 269 271 8854309 to TO B-VP O
8 272 285 8854309 significantly RB I-VP O
9 286 297 8854309 distinguish VB I-VP O
10 298 299 8854309 a DT B-NP O
11 300 305 8854309 group NN I-NP O
12 306 308 8854309 of IN B-PP O
13 309 318 8854309 abstinent JJ B-NP O
14 319 324 8854309 crack NN I-NP D016578
15 325 332 8854309 cocaine NN I-NP D016578
16 333 340 8854309 abusers NNS I-NP O
17 341 350 8854309 endorsing VBG B-VP O
18 351 355 8854309 past JJ B-NP O
19 356 359 8854309 CIP NN I-NP D010259
20 360 361 8854309 ( ( O O
21 361 362 8854309 n NN B-NP O
22 363 364 8854309 = SYM B-VP O
23 365 367 8854309 32 CD B-NP O
24 367 368 8854309 ) ) O O
25 369 373 8854309 from IN B-PP O
26 374 381 8854309 another DT B-NP O
27 382 387 8854309 group NN I-NP O
28 388 390 8854309 of IN B-PP O
29 391 396 8854309 crack NN B-NP D016578
30 397 404 8854309 addicts NNS I-NP O
31 405 408 8854309 who WP B-NP O
32 409 415 8854309 denied VBD B-VP O
33 416 420 8854309 past JJ B-NP O
34 421 424 8854309 CIP NN I-NP D010259
35 425 426 8854309 ( ( O O
36 426 427 8854309 n NN B-NP O
37 428 429 8854309 = SYM B-VP O
38 430 432 8854309 29 CD B-NP O
39 432 433 8854309 ) ) O O
40 433 434 8854309 . . O O

1 0 0 15686794 -DOCSTART- -X- -X- O

1 0 5 15686794 Acute JJ B-NP O
2 6 9 15686794 low JJ I-NP D017116
3 10 14 15686794 back JJ I-NP D017116
4 15 19 15686794 pain NN I-NP D017116
5 20 26 15686794 during IN B-PP O
6 27 38 15686794 intravenous JJ B-NP O
7 39 53 15686794 administration NN I-NP O
8 54 56 15686794 of IN B-PP O
9 57 67 15686794 amiodarone NN B-NP D000638
10 67 68 15686794 : : O O
11 69 70 15686794 a DT B-NP O
12 71 77 15686794 report NN I-NP O
13 78 80 15686794 of IN B-PP O
14 81 84 15686794 two CD B-NP O
15 85 90 15686794 cases NNS I-NP O
16 90 91 15686794 . . O O
17 92 102 15686794 Amiodarone NN B-NP D000638
18 103 113 15686794 represents VBZ B-VP O
19 114 116 15686794 an DT B-NP O
20 117 126 15686794 effective JJ I-NP O
21 127 141 15686794 antiarrhythmic JJ I-NP O
22 142 146 15686794 drug NN I-NP O
23 147 150 15686794 for IN B-PP O
24 151 164 15686794 cardioversion NN B-NP O
25 165 167 15686794 of IN B-PP O
26 168 174 15686794 recent JJ B-NP O
27 174 175 15686794 - HYPH I-NP O
28 175 180 15686794 onset NN I-NP O
29 181 187 15686794 atrial JJ I-NP D001281
30 188 200 15686794 fibrillation NN I-NP D001281
31 201 202 15686794 ( ( O O
32 202 204 15686794 AF NN B-NP D001281
33 204 205 15686794 ) ) O O
34 206 209 15686794 and CC O O
35 210 221 15686794 maintenance NN B-NP O
36 222 224 15686794 of IN B-PP O
37 225 230 15686794 sinus NN B-NP O
38 231 237 15686794 rhythm NN I-NP O
39 237 238 15686794 . . O O

1 239 241 15686794 We PRP B-NP O
2 242 249 15686794 briefly RB B-ADVP O
3 250 258 15686794 describe VBP B-VP O
4 259 262 15686794 two CD B-NP O
5 263 271 15686794 patients NNS I-NP O
6 272 281 15686794 suffering VBG B-VP O
7 282 286 15686794 from IN B-PP O
8 287 293 15686794 recent JJ B-NP O
9 293 294 15686794 - HYPH I-NP O
10 294 299 15686794 onset NN I-NP O
11 300 306 15686794 atrial JJ I-NP D001281
12 307 319 15686794 fibrillation NN I-NP D001281
13 319 320 15686794 , , O O
14 321 324 15686794 who WP B-NP O
15 325 336 15686794 experienced VBD B-VP O
16 337 339 15686794 an DT B-NP O
17 340 345 15686794 acute JJ I-NP O
18 346 357 15686794 devastating VBG I-NP O
19 358 361 15686794 low JJ I-NP D017116
20 362 366 15686794 back NN I-NP D017116
21 367 371 15686794 pain VBP B-VP D017116
22 372 373 15686794 a DT B-NP O
23 374 377 15686794 few JJ I-NP O
24 378 385 15686794 minutes NNS I-NP O
25 386 391 15686794 after IN B-PP O
26 392 402 15686794 initiation NN B-NP O
27 403 405 15686794 of IN B-PP O
28 406 417 15686794 intravenous JJ B-NP O
29 418 428 15686794 amiodarone NN I-NP D000638
30 429 436 15686794 loading NN I-NP O
31 436 437 15686794 . . O O

1 438 445 15686794 Notably RB B-ADVP O
2 445 446 15686794 , , O O
3 447 451 15686794 this DT B-NP O
4 452 456 15686794 side NN I-NP O
5 457 463 15686794 effect NN I-NP O
6 464 467 15686794 has VBZ B-VP O
7 468 471 15686794 not RB I-VP O
8 472 476 15686794 been VBN I-VP O
9 477 481 15686794 ever RB I-VP O
10 482 490 15686794 reported VBN I-VP O
11 491 493 15686794 in IN B-PP O
12 494 497 15686794 the DT B-NP O
13 498 505 15686794 medical JJ I-NP O
14 506 516 15686794 literature NN I-NP O
15 516 517 15686794 . . O O

1 518 528 15686794 Clinicians NNS B-NP O
2 529 535 15686794 should MD B-VP O
3 536 538 15686794 be VB I-VP O
4 539 544 15686794 aware JJ B-ADJP O
5 545 547 15686794 of IN B-PP O
6 548 552 15686794 this DT B-NP O
7 553 561 15686794 reaction NN I-NP O
8 562 567 15686794 since IN B-PP O
9 568 574 15686794 prompt JJ B-NP O
10 575 586 15686794 termination NN I-NP O
11 587 589 15686794 of IN B-PP O
12 590 600 15686794 parenteral JJ B-NP O
13 601 615 15686794 administration NN I-NP O
14 616 621 15686794 leads VBZ B-VP O
15 622 624 15686794 to TO B-PP O
16 625 633 15686794 complete JJ B-NP O
17 634 644 15686794 resolution NN I-NP O
18 644 645 15686794 . . O O

1 0 0 8267029 -DOCSTART- -X- -X- O

1 0 13 8267029 Penicillamine NN B-NP D010396
2 13 14 8267029 - HYPH B-VP O
3 14 21 8267029 induced VBN B-NP O
4 22 29 8267029 rapidly RB I-NP O
5 30 41 8267029 progressive JJ I-NP O
6 42 60 8267029 glomerulonephritis NN I-NP D005921
7 61 63 8267029 in IN B-PP O
8 64 65 8267029 a DT B-NP O
9 66 73 8267029 patient NN I-NP O
10 74 78 8267029 with IN B-PP O
11 79 89 8267029 rheumatoid JJ B-NP D001172
12 90 99 8267029 arthritis NN I-NP D001172
13 99 100 8267029 . . O O
14 101 102 8267029 A DT B-NP O
15 103 105 8267029 67 CD I-NP O
16 105 106 8267029 - HYPH I-NP O
17 106 110 8267029 year NN I-NP O
18 110 111 8267029 - HYPH O O
19 111 114 8267029 old JJ B-NP O
20 115 120 8267029 woman NN I-NP O
21 121 125 8267029 with IN B-PP O
22 126 136 8267029 rheumatoid JJ B-NP D001172
23 137 146 8267029 arthritis NN I-NP D001172
24 147 156 8267029 presented VBD B-VP O
25 157 164 8267029 rapidly RB B-NP O
26 165 176 8267029 progressive JJ I-NP O
27 177 195 8267029 glomerulonephritis NN I-NP D005921
28 196 197 8267029 ( ( O O
29 197 201 8267029 RPGN NN B-NP D005921
30 201 202 8267029 ) ) O O
31 203 208 8267029 after IN B-PP O
32 209 210 8267029 5 CD B-NP O
33 211 217 8267029 months NNS I-NP O
34 218 220 8267029 of IN B-PP O
35 221 222 8267029 D NN B-NP D010396
36 222 223 8267029 - HYPH O D010396
37 223 236 8267029 penicillamine NN B-NP D010396
38 237 238 8267029 ( ( O O
39 238 241 8267029 250 CD B-NP O
40 242 244 8267029 mg NN I-NP O
41 244 245 8267029 / SYM B-NP O
42 245 248 8267029 day NN I-NP O
43 248 249 8267029 ) ) O O
44 250 259 8267029 treatment NN B-NP O
45 259 260 8267029 . . O O

1 261 266 8267029 Light NN B-NP O
2 267 277 8267029 microscopy NN I-NP O
3 278 283 8267029 study NN I-NP O
4 284 290 8267029 showed VBD B-VP O
5 291 297 8267029 severe JJ B-NP O
6 298 316 8267029 glomerulonephritis NN I-NP D005921
7 317 321 8267029 with IN B-PP O
8 322 330 8267029 crescent JJ B-NP O
9 331 340 8267029 formation NN I-NP O
10 341 343 8267029 in IN B-PP O
11 344 347 8267029 60% NN B-NP O
12 348 350 8267029 of IN B-PP O
13 351 354 8267029 the DT B-NP O
14 355 364 8267029 glomeruli NN I-NP O
15 365 368 8267029 and CC I-NP O
16 369 381 8267029 infiltration NN I-NP O
17 382 384 8267029 of IN B-PP O
18 385 397 8267029 inflammatory JJ B-NP O
19 398 403 8267029 cells NNS I-NP O
20 404 406 8267029 in IN B-PP O
21 407 410 8267029 the DT B-NP O
22 411 415 8267029 wall NN I-NP O
23 416 418 8267029 of IN B-PP O
24 419 421 8267029 an DT B-NP O
25 422 431 8267029 arteriole NN I-NP O
26 431 432 8267029 . . O O

1 433 451 8267029 Immunofluorescence NN B-NP O
2 452 460 8267029 revealed VBD B-VP O
3 461 467 8267029 scanty JJ B-NP O
4 468 476 8267029 granular JJ I-NP O
5 477 480 8267029 IgG NN I-NP O
6 480 481 8267029 , , O O
7 482 485 8267029 IgA NN B-NP O
8 486 489 8267029 and CC I-NP O
9 490 492 8267029 C3 NN I-NP O
10 493 501 8267029 deposits NNS I-NP O
11 502 507 8267029 along IN B-PP O
12 508 511 8267029 the DT B-NP O
13 512 521 8267029 capillary JJ I-NP O
14 522 527 8267029 walls NNS I-NP O
15 528 531 8267029 and CC I-NP O
16 532 541 8267029 mesangium NN I-NP O
17 541 542 8267029 . . O O

1 543 546 8267029 The DT B-NP O
2 547 554 8267029 patient NN I-NP O
3 555 558 8267029 was VBD B-VP O
4 559 566 8267029 treated VBN I-VP O
5 567 571 8267029 with IN B-PP O
6 572 579 8267029 steroid NN B-NP D013256
7 580 585 8267029 pulse NN I-NP O
8 585 586 8267029 , , O O
9 587 601 8267029 plasmapheresis NN B-NP O
10 601 602 8267029 , , O O
11 603 619 8267029 cyclophosphamide NN B-NP D003520
12 620 623 8267029 and CC O O
13 624 636 8267029 antiplatelet JJ B-NP D010975
14 637 643 8267029 agents NNS I-NP D010975
15 643 644 8267029 . . O O

1 645 646 8267029 A DT B-NP O
2 647 655 8267029 complete JJ I-NP O
3 656 664 8267029 recovery NN I-NP O
4 665 667 8267029 of IN B-PP O
5 668 673 8267029 renal JJ B-NP O
6 674 682 8267029 function NN I-NP O
7 683 686 8267029 was VBD B-VP O
8 687 695 8267029 achieved VBN I-VP O
9 696 698 8267029 in IN B-PP O
10 699 700 8267029 a DT B-NP O
11 701 704 8267029 few JJ I-NP O
12 705 710 8267029 weeks NNS I-NP O
13 710 711 8267029 . . O O

1 712 716 8267029 This DT B-NP O
2 717 720 8267029 new JJ I-NP O
3 721 725 8267029 case NN I-NP O
4 726 728 8267029 of IN B-PP O
5 729 733 8267029 RPGN NN B-NP D005921
6 734 736 8267029 in IN B-PP O
7 737 740 8267029 the DT B-NP O
8 741 747 8267029 course NN I-NP O
9 748 750 8267029 of IN B-PP O
10 751 752 8267029 D NN B-NP D010396
11 752 753 8267029 - HYPH B-NP D010396
12 753 766 8267029 penicillamine NN I-NP D010396
13 767 776 8267029 treatment NN I-NP O
14 777 787 8267029 emphasizes VBZ B-VP O
15 788 791 8267029 the DT B-NP O
16 792 796 8267029 need NN I-NP O
17 797 800 8267029 for IN B-PP O
18 801 809 8267029 frequent JJ B-NP O
19 810 820 8267029 monitoring NN I-NP O
20 821 823 8267029 of IN B-PP O
21 824 829 8267029 renal JJ B-NP O
22 830 838 8267029 function NN I-NP O
23 839 842 8267029 and CC I-NP O
24 843 853 8267029 evaluation NN I-NP O
25 854 856 8267029 of IN B-PP O
26 857 864 8267029 urinary JJ B-NP O
27 865 873 8267029 sediment NN I-NP O
28 874 877 8267029 and CC I-NP O
29 878 889 8267029 proteinuria NN I-NP D011507
30 890 892 8267029 in IN B-PP O
31 893 898 8267029 these DT B-NP O
32 899 907 8267029 patients NNS I-NP O
33 907 908 8267029 . . O O

1 909 912 8267029 The DT B-NP O
2 913 919 8267029 prompt JJ I-NP O
3 920 935 8267029 discontinuation NN I-NP O
4 936 938 8267029 of IN B-PP O
5 939 940 8267029 D NN B-NP D010396
6 940 941 8267029 - HYPH B-NP D010396
7 941 954 8267029 penicillamine NN I-NP D010396
8 955 958 8267029 and CC O O
9 959 967 8267029 vigorous JJ B-NP O
10 968 977 8267029 treatment NN I-NP O
11 978 986 8267029 measures NNS I-NP O
12 987 992 8267029 could MD B-VP O
13 993 998 8267029 allow VB I-VP O
14 999 1002 8267029 for IN B-PP O
15 1003 1004 8267029 a DT B-NP O
16 1005 1009 8267029 good JJ I-NP O
17 1010 1019 8267029 prognosis NN I-NP O
18 1020 1022 8267029 as IN B-PP O
19 1023 1025 8267029 in IN B-PP O
20 1026 1030 8267029 this DT B-NP O
21 1031 1035 8267029 case NN I-NP O
22 1035 1036 8267029 . . O O

1 0 0 3670965 -DOCSTART- -X- -X- O

1 0 1 3670965 A DT B-NP O
2 2 7 3670965 catch NN I-NP O
3 8 10 3670965 in IN B-PP O
4 11 14 3670965 the DT B-NP O
5 15 19 3670965 Reye NNP I-NP D012202
6 19 20 3670965 . . I-NP O
7 21 27 3670965 Twenty CD I-NP O
8 27 28 3670965 - HYPH I-NP O
9 28 31 3670965 six CD I-NP O
10 32 37 3670965 cases NNS I-NP O
11 38 40 3670965 of IN B-PP O
12 41 45 3670965 Reye NN B-NP D012202
13 46 54 3670965 syndrome NN I-NP D012202
14 55 59 3670965 from IN B-PP O
15 60 63 3670965 The DT B-NP O
16 64 74 3670965 Children's NNP I-NP O
17 75 83 3670965 Hospital NNP I-NP O
18 83 84 3670965 , , O O
19 85 95 3670965 Camperdown NNP B-NP O
20 95 96 3670965 , , O O
21 97 106 3670965 Australia NNP B-NP O
22 106 107 3670965 , , O O
23 108 117 3670965 occurring VBG B-VP O
24 118 125 3670965 between IN B-PP O
25 126 130 3670965 1973 CD B-NP O
26 131 134 3670965 and CC I-NP O
27 135 139 3670965 1982 CD I-NP O
28 140 144 3670965 were VBD B-VP O
29 145 153 3670965 reviewed VBN I-VP O
30 153 154 3670965 . . O O

1 155 157 3670965 Of IN B-PP O
2 158 163 3670965 these DT B-NP O
3 163 164 3670965 , , O O
4 165 167 3670965 20 CD B-NP O
5 168 173 3670965 cases NNS I-NP O
6 174 177 3670965 met VBD B-VP O
7 178 181 3670965 the DT B-NP O
8 182 184 3670965 US NNP I-NP O
9 185 191 3670965 Public NNP I-NP O
10 192 198 3670965 Health NNP I-NP O
11 199 206 3670965 Service NNP I-NP O
12 207 214 3670965 Centers NNP I-NP O
13 215 218 3670965 for IN B-PP O
14 219 226 3670965 Disease NNP B-NP O
15 227 234 3670965 Control NNP I-NP O
16 235 243 3670965 criteria NNS I-NP O
17 244 247 3670965 for IN B-PP O
18 248 251 3670965 the DT B-NP O
19 252 261 3670965 diagnosis NN I-NP O
20 262 264 3670965 of IN B-PP O
21 265 269 3670965 Reye NN B-NP D012202
22 270 278 3670965 syndrome NN I-NP D012202
23 278 279 3670965 . . O O

1 280 287 3670965 Aspirin NN B-NP D001241
2 288 290 3670965 or CC I-NP O
3 291 301 3670965 salicylate NN I-NP D012459
4 302 311 3670965 ingestion NN I-NP O
5 312 315 3670965 had VBD B-VP O
6 316 324 3670965 occurred VBN I-VP O
7 325 327 3670965 in IN B-PP O
8 328 332 3670965 only RB B-NP O
9 333 336 3670965 one CD I-NP O
10 337 339 3670965 of IN B-PP O
11 340 343 3670965 the DT B-NP O
12 344 346 3670965 20 CD I-NP O
13 347 352 3670965 cases NNS I-NP O
14 353 354 3670965 ( ( O O
15 354 356 3670965 5% NN B-NP O
16 356 357 3670965 ) ) O O
17 357 358 3670965 , , O O
18 359 362 3670965 and CC O O
19 363 374 3670965 paracetamol NN B-NP D000082
20 375 376 3670965 ( ( O O
21 376 389 3670965 acetaminophen NN B-NP D000082
22 389 390 3670965 ) ) O O
23 391 394 3670965 had VBD B-VP O
24 395 399 3670965 been VBN I-VP O
25 400 412 3670965 administered VBN I-VP O
26 413 415 3670965 in IN B-PP O
27 416 420 3670965 only RB B-NP O
28 421 424 3670965 six CD I-NP O
29 425 427 3670965 of IN B-PP O
30 428 431 3670965 the DT B-NP O
31 432 437 3670965 cases NNS I-NP O
32 438 439 3670965 ( ( O O
33 439 442 3670965 30% CD B-NP O
34 442 443 3670965 ) ) O O
35 443 444 3670965 . . O O

1 445 455 3670965 Pathologic JJ B-NP O
2 456 468 3670965 confirmation NN I-NP O
3 469 471 3670965 of IN B-PP O
4 472 475 3670965 the DT B-NP O
5 476 485 3670965 diagnosis NN I-NP O
6 486 488 3670965 of IN B-PP O
7 489 493 3670965 Reye NN B-NP D012202
8 494 502 3670965 syndrome NN I-NP D012202
9 503 506 3670965 was VBD B-VP O
10 507 519 3670965 accomplished VBN I-VP O
11 520 522 3670965 in IN B-PP O
12 523 526 3670965 90% CD B-NP O
13 527 529 3670965 of IN B-PP O
14 530 533 3670965 the DT B-NP O
15 534 539 3670965 cases NNS I-NP O
16 539 540 3670965 . . O O

1 541 544 3670965 The DT B-NP O
2 545 554 3670965 incidence NN I-NP O
3 555 557 3670965 of IN B-PP O
4 558 562 3670965 Reye NN B-NP D012202
5 563 571 3670965 syndrome NN I-NP D012202
6 572 574 3670965 in IN B-PP O
7 575 578 3670965 New NNP B-NP O
8 579 584 3670965 South NNP I-NP O
9 585 590 3670965 Wales NNP I-NP O
10 590 591 3670965 , , O O
11 592 601 3670965 Australia NNP B-NP O
12 601 602 3670965 , , O O
13 603 605 3670965 is VBZ B-VP O
14 606 615 3670965 estimated VBN I-VP O
15 616 620 3670965 from IN B-PP O
16 621 625 3670965 this DT B-NP O
17 626 631 3670965 study NN I-NP O
18 632 634 3670965 to TO B-VP O
19 635 637 3670965 be VB I-VP O
20 638 651 3670965 approximately RB B-NP O
21 652 656 3670965 nine CD I-NP O
22 657 662 3670965 cases NNS I-NP O
23 663 666 3670965 per IN B-PP O
24 667 668 3670965 1 CD B-NP O
25 669 676 3670965 million CD I-NP O
26 677 685 3670965 children NNS I-NP O
27 686 694 3670965 compared VBN B-PP O
28 695 699 3670965 with IN B-PP O
29 700 706 3670965 recent JJ B-NP O
30 707 709 3670965 US NNP I-NP O
31 710 714 3670965 data NNS I-NP O
32 715 717 3670965 of IN B-PP O
33 718 721 3670965 ten CD B-NP O
34 722 724 3670965 to TO I-NP O
35 725 727 3670965 20 CD I-NP O
36 728 733 3670965 cases NNS I-NP O
37 734 737 3670965 per IN B-PP O
38 738 739 3670965 1 CD B-NP O
39 740 747 3670965 million CD I-NP O
40 748 756 3670965 children NNS I-NP O
41 757 760 3670965 and CC O O
42 761 766 3670965 three CD B-NP O
43 767 769 3670965 to TO I-NP O
44 770 775 3670965 seven CD I-NP O
45 776 781 3670965 cases NNS I-NP O
46 782 785 3670965 per IN B-PP O
47 786 787 3670965 1 CD B-NP O
48 788 795 3670965 million CD I-NP O
49 796 804 3670965 children NNS I-NP O
50 805 807 3670965 in IN B-PP O
51 808 813 3670965 Great NNP B-NP O
52 814 821 3670965 Britain NNP I-NP O
53 821 822 3670965 . . O O

1 823 826 3670965 The DT B-NP O
2 827 836 3670965 mortality NN I-NP O
3 837 840 3670965 for IN B-PP O
4 841 846 3670965 these DT B-NP O
5 847 851 3670965 Reye NNP I-NP D012202
6 852 860 3670965 syndrome NN I-NP D012202
7 861 866 3670965 cases NNS I-NP O
8 867 869 3670965 in IN B-PP O
9 870 879 3670965 Australia NNP B-NP O
10 880 883 3670965 was VBD B-VP O
11 884 887 3670965 45% CD B-NP O
12 888 890 3670965 as IN B-PP O
13 891 899 3670965 compared VBN B-PP O
14 900 904 3670965 with IN B-PP O
15 905 906 3670965 a DT B-NP O
16 907 910 3670965 32% NN I-NP O
17 911 915 3670965 case NN I-NP O
18 915 916 3670965 - HYPH B-NP O
19 916 924 3670965 fatality NN I-NP O
20 925 929 3670965 rate NN I-NP O
21 930 932 3670965 in IN B-PP O
22 933 936 3670965 the DT B-NP O
23 937 943 3670965 United NNP I-NP O
24 944 950 3670965 States NNPS I-NP O
25 950 951 3670965 . . O O

1 952 954 3670965 In IN B-PP O
2 955 964 3670965 Australia NNP B-NP O
3 964 965 3670965 , , O O
4 966 969 3670965 the DT B-NP O
5 970 979 3670965 pediatric JJ I-NP O
6 980 985 3670965 usage NN I-NP O
7 986 988 3670965 of IN B-PP O
8 989 996 3670965 aspirin NN B-NP D001241
9 997 1000 3670965 has VBZ B-VP O
10 1001 1005 3670965 been VBN I-VP O
11 1006 1015 3670965 extremely RB B-ADJP O
12 1016 1019 3670965 low JJ I-ADJP O
13 1020 1023 3670965 for IN B-PP O
14 1024 1027 3670965 the DT B-NP O
15 1028 1032 3670965 past JJ I-NP O
16 1033 1035 3670965 25 CD I-NP O
17 1036 1041 3670965 years NNS I-NP O
18 1042 1043 3670965 ( ( O O
19 1043 1047 3670965 less JJR B-NP O
20 1048 1052 3670965 than IN I-NP O
21 1053 1055 3670965 1% CD I-NP O
22 1056 1058 3670965 of IN B-PP O
23 1059 1064 3670965 total JJ B-NP O
24 1065 1071 3670965 dosage NN I-NP O
25 1072 1077 3670965 units NNS I-NP O
26 1078 1082 3670965 sold VBN B-VP O
27 1082 1083 3670965 ) ) O O
28 1083 1084 3670965 , , O O
29 1085 1089 3670965 with IN B-PP O
30 1090 1101 3670965 paracetamol NN B-NP D000082
31 1102 1103 3670965 ( ( O O
32 1103 1116 3670965 acetaminophen NN B-NP D000082
33 1116 1117 3670965 ) ) O O
34 1118 1128 3670965 dominating VBG B-VP O
35 1129 1132 3670965 the DT B-NP O
36 1133 1142 3670965 pediatric JJ I-NP O
37 1143 1152 3670965 analgesic JJ I-NP O
38 1153 1156 3670965 and CC I-NP O
39 1157 1168 3670965 antipyretic JJ I-NP O
40 1169 1175 3670965 market NN I-NP O
41 1175 1176 3670965 . . O O

1 1177 1181 3670965 Reye NN B-NP D012202
2 1182 1190 3670965 syndrome NN I-NP D012202
3 1191 1194 3670965 may MD B-VP O
4 1195 1197 3670965 be VB I-VP O
5 1198 1210 3670965 disappearing VBG I-VP O
6 1211 1215 3670965 from IN B-PP O
7 1216 1225 3670965 Australia NNP B-NP O
8 1226 1233 3670965 despite IN B-PP O
9 1234 1235 3670965 a DT B-NP O
10 1236 1241 3670965 total JJ I-NP O
11 1242 1246 3670965 lack NN I-NP O
12 1247 1249 3670965 of IN B-PP O
13 1250 1261 3670965 association NN B-NP O
14 1262 1266 3670965 with IN B-PP O
15 1267 1278 3670965 salicylates NNS B-NP D012459
16 1279 1281 3670965 or CC O O
17 1282 1289 3670965 aspirin NN B-NP D001241
18 1290 1299 3670965 ingestion NN I-NP O
19 1299 1300 3670965 , , O O
20 1301 1306 3670965 since IN B-SBAR O
21 1307 1312 3670965 there EX B-NP O
22 1313 1317 3670965 were VBD B-VP O
23 1318 1320 3670965 no DT B-NP O
24 1321 1326 3670965 cases NNS I-NP O
25 1327 1332 3670965 found VBN B-VP O
26 1333 1335 3670965 at IN B-PP O
27 1336 1339 3670965 The DT B-NP O
28 1340 1350 3670965 Children's NNP I-NP O
29 1351 1359 3670965 Hospital NNP I-NP O
30 1360 1362 3670965 in IN B-PP O
31 1363 1367 3670965 1983 CD B-NP O
32 1367 1368 3670965 , , I-NP O
33 1369 1373 3670965 1984 CD I-NP O
34 1373 1374 3670965 , , O O
35 1375 1377 3670965 or CC O O
36 1378 1382 3670965 1985 CD B-NP O
37 1382 1383 3670965 . . O O

1 0 0 343678 -DOCSTART- -X- -X- O

1 0 4 343678 Type NN B-NP D006509
2 5 6 343678 B NN I-NP D006509
3 7 16 343678 hepatitis NN I-NP D006509
4 17 22 343678 after IN B-PP O
5 23 29 343678 needle NN B-NP O
6 29 30 343678 - HYPH B-NP O
7 30 35 343678 stick NN I-NP O
8 36 44 343678 exposure NN I-NP O
9 44 45 343678 : : O O
10 46 56 343678 prevention NN B-NP O
11 57 61 343678 with IN B-PP O
12 62 71 343678 hepatitis NN B-NP D006509
13 72 73 343678 B NN I-NP D006509
14 74 80 343678 immune JJ I-NP O
15 81 89 343678 globulin NN I-NP O
16 89 90 343678 . . O O

1 91 96 343678 Final JJ B-NP O
2 97 103 343678 report NN I-NP O
3 104 106 343678 of IN B-PP O
4 107 110 343678 the DT B-NP O
5 111 119 343678 Veterans NNP I-NP O
6 120 134 343678 Administration NNP I-NP O
7 135 146 343678 Cooperative NNP I-NP O
8 147 152 343678 Study NNP I-NP O
9 152 153 343678 . . I-NP O
10 154 163 343678 Hepatitis NNP I-NP D006509
11 164 165 343678 B NNP I-NP D006509
12 166 172 343678 immune JJ I-NP O
13 173 181 343678 globulin NN I-NP O
14 182 183 343678 ( ( O O
15 183 187 343678 HBIG NN B-NP O
16 187 188 343678 ) ) O O
17 189 192 343678 and CC O O
18 193 199 343678 immune JJ B-NP O
19 200 205 343678 serum NN I-NP O
20 206 214 343678 globulin NN I-NP O
21 215 216 343678 ( ( O O
22 216 219 343678 ISG NN B-NP O
23 219 220 343678 ) ) O O
24 221 225 343678 were VBD B-VP O
25 226 234 343678 examined VBN I-VP O
26 235 237 343678 in IN B-PP O
27 238 239 343678 a DT B-NP O
28 240 250 343678 randomized VBN I-NP O
29 250 251 343678 , , I-NP O
30 252 258 343678 double JJ I-NP O
31 258 259 343678 - HYPH I-NP O
32 259 264 343678 blind JJ I-NP O
33 265 270 343678 trial NN I-NP O
34 271 273 343678 to TO B-VP O
35 274 280 343678 assess VB I-VP O
36 281 286 343678 their PRP$ B-NP O
37 287 295 343678 relative JJ I-NP O
38 296 306 343678 efficacies NNS I-NP O
39 307 309 343678 in IN B-PP O
40 310 320 343678 preventing VBG B-VP O
41 321 325 343678 type NN B-NP D006509
42 326 327 343678 B NN I-NP D006509
43 328 337 343678 hepatitis NN I-NP D006509
44 338 343 343678 after IN B-PP O
45 344 350 343678 needle NN B-NP O
46 350 351 343678 - HYPH B-NP O
47 351 356 343678 stick NN I-NP O
48 357 365 343678 exposure NN I-NP O
49 366 368 343678 to TO B-PP O
50 369 378 343678 hepatitis NN B-NP D006514
51 379 380 343678 B NN I-NP D006514
52 381 388 343678 surface NN I-NP D006514
53 389 396 343678 antigen NN I-NP D006514
54 397 404 343678 (HBsAG) NN I-NP D006514
55 404 405 343678 - HYPH B-NP O
56 405 413 343678 positive JJ I-NP O
57 414 420 343678 donors NNS I-NP O
58 420 421 343678 . . O O

1 422 430 343678 Clinical JJ B-NP O
2 431 440 343678 hepatitis NN I-NP D056486
3 441 450 343678 developed VBN B-VP O
4 451 453 343678 in IN B-PP O
5 454 458 343678 1.4% NN B-NP O
6 459 461 343678 of IN B-PP O
7 462 466 343678 HBIG NN B-NP O
8 467 470 343678 and CC B-PP O
9 471 473 343678 in IN B-PP O
10 474 478 343678 5.9% NN B-NP O
11 479 481 343678 of IN B-PP O
12 482 485 343678 ISG NN B-NP O
13 486 496 343678 recipients NNS I-NP O
14 497 498 343678 ( ( O O
15 498 499 343678 P NN B-NP O
16 500 501 343678 = SYM B-VP O
17 502 507 343678 0.016 CD B-NP O
18 507 508 343678 ) ) O O
19 508 509 343678 , , O O
20 510 513 343678 and CC O O
21 514 528 343678 seroconversion NN B-NP O
22 529 530 343678 ( ( O O
23 530 534 343678 anti AFX O O
24 534 535 343678 - HYPH B-NP O
25 535 538 343678 HBs NNS I-NP O
26 538 539 343678 ) ) O O
27 540 548 343678 occurred VBD B-VP O
28 549 551 343678 in IN B-PP O
29 552 556 343678 5.6% CD B-NP O
30 557 560 343678 and CC I-NP O
31 561 566 343678 20.7% CD I-NP O
32 567 569 343678 of IN B-PP O
33 570 574 343678 them PRP B-NP O
34 575 587 343678 respectively RB B-ADVP O
35 588 589 343678 ( ( O O
36 589 590 343678 P NN B-NP O
37 591 595 343678 less JJR B-ADJP O
38 596 600 343678 than IN B-PP O
39 601 606 343678 0.001 CD B-NP O
40 606 607 343678 ) ) O O
41 607 608 343678 . . O O

1 609 613 343678 Mild JJ B-NP O
2 614 617 343678 and CC I-NP O
3 618 627 343678 transient JJ I-NP O
4 628 632 343678 side NN I-NP O
5 632 633 343678 - HYPH B-VP O
6 633 640 343678 effects NNS B-NP O
7 641 645 343678 were VBD B-VP O
8 646 651 343678 noted VBN I-VP O
9 652 654 343678 in IN B-PP O
10 655 659 343678 3.0% NN B-NP O
11 660 662 343678 of IN B-PP O
12 663 666 343678 ISG NN B-NP O
13 667 670 343678 and CC B-PP O
14 671 673 343678 in IN B-PP O
15 674 678 343678 3.2% NN B-NP O
16 679 681 343678 of IN B-PP O
17 682 686 343678 HBIG NN B-NP O
18 687 697 343678 recipients NNS I-NP O
19 697 698 343678 . . O O

1 699 708 343678 Available JJ B-NP O
2 709 714 343678 donor NN I-NP O
3 715 719 343678 sera NNS I-NP O
4 720 724 343678 were VBD B-VP O
5 725 733 343678 examined VBN I-VP O
6 734 737 343678 for IN B-PP O
7 738 741 343678 DNA NN B-NP O
8 742 752 343678 polymerase NN I-NP O
9 753 754 343678 ( ( O O
10 754 758 343678 DNAP NN B-NP O
11 758 759 343678 ) ) O O
12 760 763 343678 and CC O O
13 764 765 343678 e NN B-NP O
14 766 773 343678 antigen NN I-NP O
15 774 777 343678 and CC O O
16 778 786 343678 antibody NN B-NP O
17 787 788 343678 ( ( O O
18 788 793 343678 HBeAg NN B-NP D006513
19 793 794 343678 ; : O O
20 795 799 343678 anti AFX B-NP O
21 799 800 343678 - HYPH I-NP O
22 800 803 343678 HBE NN I-NP O
23 803 804 343678 ) ) O O
24 804 805 343678 . . O O

1 806 810 343678 Both CC O O
2 811 815 343678 DNAP NN B-NP O
3 816 819 343678 and CC I-NP O
4 820 825 343678 HBeAg NN I-NP D006513
5 826 832 343678 showed VBD B-VP O
6 833 834 343678 a DT B-NP O
7 835 841 343678 highly RB I-NP O
8 842 855 343678 statistically RB I-NP O
9 856 867 343678 significant JJ I-NP O
10 868 879 343678 correlation NN I-NP O
11 880 884 343678 with IN B-PP O
12 885 888 343678 the DT B-NP O
13 889 900 343678 infectivity NN I-NP O
14 901 903 343678 of IN B-PP O
15 904 909 343678 HBsAg NN B-NP D006514
16 909 910 343678 - HYPH B-NP O
17 910 918 343678 positive JJ I-NP O
18 919 925 343678 donors NNS I-NP O
19 925 926 343678 . . O O

1 927 936 343678 Hepatitis NN B-NP D006509
2 937 938 343678 B NN I-NP D006509
3 939 945 343678 immune JJ I-NP O
4 946 954 343678 globulin NN I-NP O
5 955 963 343678 remained VBD B-VP O
6 964 977 343678 significantly RB B-ADJP O
7 978 986 343678 superior JJ I-ADJP O
8 987 989 343678 to TO B-PP O
9 990 993 343678 ISG NN B-NP O
10 994 996 343678 in IN B-PP O
11 997 1007 343678 preventing VBG B-VP O
12 1008 1012 343678 type NN B-NP D006509
13 1013 1014 343678 B NN I-NP D006509
14 1015 1024 343678 hepatitis NN I-NP D006509
15 1025 1029 343678 even RB B-ADVP O
16 1030 1034 343678 when WRB I-ADVP O
17 1035 1038 343678 the DT B-NP O
18 1039 1047 343678 analysis NN I-NP O
19 1048 1051 343678 was VBD B-VP O
20 1052 1060 343678 confined VBN I-VP O
21 1061 1063 343678 to TO B-PP O
22 1064 1069 343678 these DT B-NP O
23 1070 1073 343678 two CD I-NP O
24 1074 1078 343678 high JJ I-NP O
25 1078 1079 343678 - HYPH I-NP O
26 1079 1083 343678 risk NN I-NP O
27 1084 1093 343678 subgroups NNS I-NP O
28 1093 1094 343678 . . O O

1 1095 1098 343678 The DT B-NP O
2 1099 1107 343678 efficacy NN I-NP O
3 1108 1110 343678 of IN B-PP O
4 1111 1114 343678 ISG NN B-NP O
5 1115 1117 343678 in IN B-PP O
6 1118 1128 343678 preventing VBG B-VP O
7 1129 1133 343678 type NN B-NP D006509
8 1134 1135 343678 B NN I-NP D006509
9 1136 1145 343678 hepatitis NN I-NP D006509
10 1146 1152 343678 cannot MD B-VP O
11 1153 1155 343678 be VB I-VP O
12 1156 1167 343678 ascertained VBN I-VP O
13 1168 1175 343678 because IN B-SBAR O
14 1176 1177 343678 a DT B-NP O
15 1178 1182 343678 true JJ I-NP O
16 1183 1190 343678 placebo NN I-NP O
17 1191 1196 343678 group NN I-NP O
18 1197 1200 343678 was VBD B-VP O
19 1201 1204 343678 not RB I-VP O
20 1205 1213 343678 included VBN I-VP O
21 1213 1214 343678 . . O O

1 0 0 19923525 -DOCSTART- -X- -X- O

1 0 10 19923525 Nimodipine NN B-NP D009553
2 11 19 19923525 prevents VBZ B-VP O
3 20 26 19923525 memory NN B-NP D008569
4 27 37 19923525 impairment NN I-NP D008569
5 38 44 19923525 caused VBN B-VP O
6 45 47 19923525 by IN B-PP O
7 48 61 19923525 nitroglycerin NN B-NP D005996
8 61 62 19923525 - HYPH B-NP O
9 62 69 19923525 induced VBN I-NP O
10 70 81 19923525 hypotension NN I-NP D007022
11 82 84 19923525 in IN B-PP O
12 85 90 19923525 adult JJ B-NP O
13 91 95 19923525 mice NNS I-NP O
14 95 96 19923525 . . O O
15 97 107 19923525 BACKGROUND NN B-NP O
16 107 108 19923525 : : O O
17 109 120 19923525 Hypotension NN B-NP D007022
18 121 124 19923525 and CC O O
19 125 126 19923525 a DT B-NP O
20 127 136 19923525 resultant JJ I-NP O
21 137 145 19923525 decrease NN I-NP O
22 146 148 19923525 in IN B-PP O
23 149 157 19923525 cerebral JJ B-NP O
24 158 163 19923525 blood NN I-NP O
25 164 168 19923525 flow NN I-NP O
26 169 173 19923525 have VBP B-VP O
27 174 178 19923525 been VBN I-VP O
28 179 189 19923525 implicated VBN I-VP O
29 190 192 19923525 in IN B-PP O
30 193 196 19923525 the DT B-NP O
31 197 208 19923525 development NN I-NP O
32 209 211 19923525 of IN B-PP O
33 212 221 19923525 cognitive JJ B-NP D003072
34 222 233 19923525 dysfunction NN I-NP D003072
35 233 234 19923525 . . O O

1 235 237 19923525 We PRP B-NP O
2 238 244 19923525 tested VBD B-VP O
3 245 248 19923525 the DT B-NP O
4 249 259 19923525 hypothesis NN I-NP O
5 260 264 19923525 that IN B-NP O
6 265 275 19923525 nimodipine NN B-NP D009553
7 276 277 19923525 ( ( O O
8 277 281 19923525 NIMO NN B-NP D009553
9 281 282 19923525 ) ) O O
10 283 295 19923525 administered VBN B-VP O
11 296 298 19923525 at IN B-PP O
12 299 302 19923525 the DT B-NP O
13 303 308 19923525 onset NN I-NP O
14 309 311 19923525 of IN B-PP O
15 312 325 19923525 nitroglycerin NN B-NP D005996
16 326 327 19923525 ( ( O O
17 327 330 19923525 NTG NN B-NP D005996
18 330 331 19923525 ) ) O O
19 331 332 19923525 - HYPH B-NP O
20 332 339 19923525 induced VBN I-NP O
21 340 351 19923525 hypotension NN I-NP D007022
22 352 357 19923525 would MD B-VP O
23 358 366 19923525 preserve VB I-VP O
24 367 371 19923525 long JJ B-NP O
25 371 372 19923525 - HYPH I-NP O
26 372 376 19923525 term NN I-NP O
27 377 388 19923525 associative JJ I-NP O
28 389 395 19923525 memory NN I-NP O
29 395 396 19923525 . . O O

1 397 404 19923525 METHODS NNS B-NP O
2 404 405 19923525 : : O O
3 406 409 19923525 The DT B-NP O
4 410 417 19923525 passive JJ I-NP O
5 418 427 19923525 avoidance NN I-NP O
6 428 429 19923525 ( ( O O
7 429 431 19923525 PA NN B-NP O
8 431 432 19923525 ) ) O O
9 433 441 19923525 paradigm NN B-NP O
10 442 445 19923525 was VBD B-VP O
11 446 450 19923525 used VBN I-VP O
12 451 453 19923525 to TO B-VP O
13 454 460 19923525 assess VB I-VP O
14 461 467 19923525 memory NN B-NP O
15 468 477 19923525 retention NN I-NP O
16 477 478 19923525 . . O O

1 479 482 19923525 For IN B-PP O
2 483 485 19923525 PA NN B-NP O
3 486 494 19923525 training NN I-NP O
4 494 495 19923525 , , O O
5 496 505 19923525 latencies NNS B-NP O
6 506 507 19923525 ( ( O O
7 507 514 19923525 seconds NNS B-NP O
8 514 515 19923525 ) ) O O
9 516 520 19923525 were VBD B-VP O
10 521 529 19923525 recorded VBN I-VP O
11 530 533 19923525 for IN B-PP O
12 534 539 19923525 entry NN B-NP O
13 540 544 19923525 from IN B-PP O
14 545 546 19923525 a DT B-NP O
15 547 556 19923525 suspended VBN I-NP O
16 557 565 19923525 platform NN I-NP O
17 566 570 19923525 into IN B-PP O
18 571 572 19923525 a DT B-NP O
19 573 582 19923525 Plexiglas NNP I-NP O
20 583 587 19923525 tube NN I-NP O
21 588 593 19923525 where WRB B-ADVP O
22 594 595 19923525 a DT B-NP O
23 596 601 19923525 shock NN I-NP O
24 602 605 19923525 was VBD B-VP O
25 606 619 19923525 automatically RB I-VP O
26 620 629 19923525 delivered VBN I-VP O
27 629 630 19923525 . . O O

1 631 640 19923525 Latencies NNS B-NP O
2 641 645 19923525 were VBD B-VP O
3 646 654 19923525 recorded VBN I-VP O
4 655 657 19923525 48 CD B-NP O
5 658 659 19923525 h NN I-NP O
6 660 665 19923525 later RB B-ADVP O
7 666 669 19923525 for IN B-PP O
8 670 671 19923525 a DT B-NP O
9 672 679 19923525 testing NN I-NP O
10 680 685 19923525 trial NN I-NP O
11 685 686 19923525 . . O O

1 687 693 19923525 Ninety CD B-NP O
2 693 694 19923525 - HYPH I-NP O
3 694 697 19923525 six CD I-NP O
4 698 703 19923525 Swiss JJ I-NP O
5 703 704 19923525 - HYPH I-NP O
6 704 711 19923525 Webster NN I-NP O
7 712 716 19923525 mice NNS I-NP O
8 717 718 19923525 ( ( O O
9 718 720 19923525 30 CD B-NP O
10 720 721 19923525 - HYPH I-NP O
11 721 723 19923525 35 CD I-NP O
12 724 725 19923525 g NN I-NP O
13 725 726 19923525 , , O O
14 727 728 19923525 6 CD B-NP O
15 728 729 19923525 - HYPH I-NP O
16 729 730 19923525 8 CD I-NP O
17 731 733 19923525 wk NN I-NP O
18 733 734 19923525 ) ) O O
19 734 735 19923525 , , O O
20 736 740 19923525 were VBD B-VP O
21 741 751 19923525 randomized VBN I-VP O
22 752 756 19923525 into IN B-PP O
23 757 758 19923525 6 CD B-NP O
24 759 765 19923525 groups NNS I-NP O
25 766 767 19923525 1 CD O O
26 767 768 19923525 ) ) O O
27 769 775 19923525 saline NN B-NP O
28 776 777 19923525 ( ( O O
29 777 784 19923525 control NN B-NP O
30 784 785 19923525 ) ) O O
31 785 786 19923525 , , O O
32 787 788 19923525 2 LS B-LST O
33 788 789 19923525 ) ) O O
34 790 793 19923525 NTG NN B-NP D005996
35 794 805 19923525 immediately RB B-ADVP O
36 806 811 19923525 after IN B-PP O
37 812 820 19923525 learning VBG B-VP O
38 820 821 19923525 , , O O
39 822 823 19923525 3 LS B-LST O
40 823 824 19923525 ) ) O O
41 825 828 19923525 NTG NN B-NP D005996
42 829 830 19923525 3 CD I-NP O
43 831 832 19923525 h NN I-NP O
44 833 838 19923525 after IN B-PP O
45 839 847 19923525 learning NN B-NP O
46 847 848 19923525 , , O O
47 849 850 19923525 4 CD B-NP O
48 850 851 19923525 ) ) O O
49 852 855 19923525 NTG NN B-NP D005996
50 856 859 19923525 and CC I-NP O
51 860 864 19923525 NIMO NN I-NP D009553
52 864 865 19923525 , , O O
53 866 867 19923525 5 CD B-NP O
54 867 868 19923525 ) ) O O
55 869 876 19923525 vehicle NN B-NP O
56 876 877 19923525 , , O O
57 878 881 19923525 and CC O O
58 882 883 19923525 6 CD B-NP O
59 883 884 19923525 ) ) O O
60 885 889 19923525 NIMO NN B-NP D009553
61 890 895 19923525 alone RB B-ADVP O
62 895 896 19923525 . . O O

1 897 900 19923525 The DT B-NP O
2 901 907 19923525 extent NN I-NP O
3 908 910 19923525 of IN B-PP O
4 911 922 19923525 hypotension NN B-NP D007022
5 923 926 19923525 and CC I-NP O
6 927 934 19923525 changes NNS I-NP O
7 935 937 19923525 in IN B-PP O
8 938 943 19923525 brain NN B-NP O
9 944 950 19923525 tissue NN I-NP O
10 951 962 19923525 oxygenation NN I-NP O
11 963 964 19923525 ( ( O O
12 964 971 19923525 PbtO(2) NN B-NP O
13 971 972 19923525 ) ) O O
14 973 976 19923525 and CC O O
15 977 979 19923525 in IN B-PP O
16 980 988 19923525 cerebral JJ B-NP O
17 989 994 19923525 blood NN I-NP O
18 995 999 19923525 flow NN I-NP O
19 1000 1004 19923525 were VBD B-VP O
20 1005 1012 19923525 studied VBN I-VP O
21 1013 1015 19923525 in IN B-PP O
22 1016 1017 19923525 a DT B-NP O
23 1018 1026 19923525 separate JJ I-NP O
24 1027 1032 19923525 group NN I-NP O
25 1033 1035 19923525 of IN B-PP O
26 1036 1043 19923525 animals NNS B-NP O
27 1043 1044 19923525 . . O O

1 1045 1052 19923525 RESULTS NNS B-NP O
2 1052 1053 19923525 : : O O
3 1054 1057 19923525 All DT B-NP O
4 1058 1064 19923525 groups NNS I-NP O
5 1065 1074 19923525 exhibited VBD B-VP O
6 1075 1082 19923525 similar JJ B-NP O
7 1083 1091 19923525 training NN I-NP O
8 1092 1101 19923525 latencies NNS I-NP O
9 1102 1103 19923525 ( ( O O
10 1103 1107 19923525 17.0 CD B-NP O
11 1108 1109 19923525 + SYM O O
12 1109 1110 19923525 / SYM B-NP O
13 1110 1111 19923525 - SYM I-NP O
14 1112 1115 19923525 4.6 CD I-NP O
15 1116 1117 19923525 s NN I-NP O
16 1117 1118 19923525 ) ) O O
17 1118 1119 19923525 . . O O

1 1120 1124 19923525 Mice NNS B-NP O
2 1125 1134 19923525 subjected VBN B-VP O
3 1135 1137 19923525 to TO B-PP O
4 1138 1149 19923525 hypotensive JJ B-NP D007022
5 1150 1158 19923525 episodes NNS I-NP O
6 1159 1165 19923525 showed VBD B-VP O
7 1166 1167 19923525 a DT B-NP O
8 1168 1179 19923525 significant JJ I-NP O
9 1180 1188 19923525 decrease NN I-NP O
10 1189 1191 19923525 in IN B-PP O
11 1192 1199 19923525 latency NN B-NP O
12 1200 1204 19923525 time NN I-NP O
13 1205 1206 19923525 ( ( O O
14 1206 1209 19923525 178 CD B-NP O
15 1210 1211 19923525 + SYM O O
16 1211 1212 19923525 / SYM B-NP O
17 1212 1213 19923525 - SYM I-NP O
18 1214 1217 19923525 156 CD I-NP O
19 1218 1219 19923525 s NN I-NP O
20 1219 1220 19923525 ) ) O O
21 1221 1229 19923525 compared VBN B-PP O
22 1230 1234 19923525 with IN B-PP O
23 1235 1240 19923525 those DT B-NP O
24 1241 1249 19923525 injected VBN B-VP O
25 1250 1254 19923525 with IN B-PP O
26 1255 1261 19923525 saline NN B-NP O
27 1261 1262 19923525 , , O O
28 1263 1266 19923525 NTG NN B-NP D005996
29 1267 1268 19923525 + SYM I-NP O
30 1269 1273 19923525 NIMO NN I-NP D009553
31 1273 1274 19923525 , , O O
32 1275 1277 19923525 or CC O O
33 1278 1285 19923525 delayed VBN B-NP O
34 1286 1289 19923525 NTG NN I-NP D005996
35 1290 1291 19923525 ( ( O O
36 1291 1294 19923525 580 CD B-NP O
37 1295 1296 19923525 + SYM O O
38 1296 1297 19923525 / SYM B-NP O
39 1297 1298 19923525 - SYM I-NP O
40 1299 1301 19923525 81 CD I-NP O
41 1302 1303 19923525 s NN I-NP O
42 1303 1304 19923525 , , O O
43 1305 1308 19923525 557 CD B-NP O
44 1309 1310 19923525 + SYM B-NP O
45 1310 1311 19923525 / SYM I-NP O
46 1311 1312 19923525 - SYM I-NP O
47 1313 1315 19923525 67 CD I-NP O
48 1316 1317 19923525 s NN I-NP O
49 1317 1318 19923525 , , O O
50 1319 1322 19923525 and CC O O
51 1323 1326 19923525 493 CD B-NP O
52 1327 1328 19923525 + SYM B-NP O
53 1328 1329 19923525 / SYM I-NP O
54 1329 1330 19923525 - SYM I-NP O
55 1331 1334 19923525 146 CD I-NP O
56 1335 1336 19923525 s NN I-NP O
57 1336 1337 19923525 , , O O
58 1338 1350 19923525 respectively RB B-ADVP O
59 1350 1351 19923525 ) ) O O
60 1351 1352 19923525 . . O O

1 1353 1354 19923525 A DT B-NP O
2 1355 1362 19923525 Kruskal NNP I-NP O
3 1362 1363 19923525 - HYPH I-NP O
4 1363 1369 19923525 Wallis NNP B-NP O
5 1370 1371 19923525 1 CD I-NP O
6 1371 1372 19923525 - HYPH I-NP O
7 1372 1375 19923525 way NN I-NP O
8 1376 1384 19923525 analysis NN I-NP O
9 1385 1387 19923525 of IN B-PP O
10 1388 1396 19923525 variance NN B-NP O
11 1397 1406 19923525 indicated VBD B-VP O
12 1407 1408 19923525 a DT B-NP O
13 1409 1420 19923525 significant JJ I-NP O
14 1421 1431 19923525 difference NN I-NP O
15 1432 1437 19923525 among IN B-PP O
16 1438 1441 19923525 the DT B-NP O
17 1442 1443 19923525 4 CD I-NP O
18 1444 1453 19923525 treatment NN I-NP O
19 1454 1460 19923525 groups NNS I-NP O
20 1461 1462 19923525 ( ( O O
21 1462 1463 19923525 H NN B-NP O
22 1464 1465 19923525 = SYM B-VP O
23 1466 1471 19923525 15.34 CD B-NP O
24 1471 1472 19923525 ; : O O
25 1473 1474 19923525 P NN B-NP O
26 1475 1476 19923525 < SYM B-NP O
27 1477 1482 19923525 0.001 CD I-NP O
28 1482 1483 19923525 ) ) O O
29 1483 1484 19923525 . . O O

1 1485 1487 19923525 In IN B-PP O
2 1488 1489 19923525 a DT B-NP O
3 1490 1498 19923525 separate JJ I-NP O
4 1499 1504 19923525 group NN I-NP O
5 1505 1507 19923525 of IN B-PP O
6 1508 1512 19923525 mice NNS B-NP O
7 1513 1516 19923525 not RB B-VP O
8 1517 1526 19923525 subjected VBN I-VP O
9 1527 1529 19923525 to TO B-PP O
10 1530 1540 19923525 behavioral JJ B-NP O
11 1541 1548 19923525 studies NNS I-NP O
12 1548 1549 19923525 , , O O
13 1550 1553 19923525 the DT B-NP O
14 1554 1558 19923525 same JJ I-NP O
15 1559 1563 19923525 dose NN I-NP O
16 1564 1566 19923525 of IN B-PP O
17 1567 1570 19923525 NTG NN B-NP D005996
18 1571 1572 19923525 ( ( O O
19 1572 1573 19923525 n NN B-NP O
20 1574 1575 19923525 = SYM B-VP O
21 1576 1577 19923525 3 CD B-NP O
22 1577 1578 19923525 ) ) O O
23 1579 1582 19923525 and CC O O
24 1583 1586 19923525 NTG NN B-NP D005996
25 1587 1588 19923525 + SYM O O
26 1589 1593 19923525 NIMO NN B-NP D009553
27 1594 1595 19923525 ( ( O O
28 1595 1596 19923525 n NN B-NP O
29 1597 1598 19923525 = SYM B-VP O
30 1599 1600 19923525 3 CD B-NP O
31 1600 1601 19923525 ) ) O O
32 1602 1608 19923525 caused VBD B-VP O
33 1609 1613 19923525 mean JJ B-NP O
34 1614 1622 19923525 arterial JJ I-NP O
35 1623 1628 19923525 blood NN I-NP O
36 1629 1637 19923525 pressure NN I-NP O
37 1638 1640 19923525 to TO B-VP O
38 1641 1649 19923525 decrease VB I-VP O
39 1650 1654 19923525 from IN B-PP O
40 1655 1659 19923525 85.9 CD B-NP O
41 1660 1661 19923525 + SYM B-ADJP O
42 1661 1662 19923525 / SYM O O
43 1662 1663 19923525 - SYM O O
44 1664 1667 19923525 3.8 CD B-NP O
45 1668 1670 19923525 mm NN I-NP O
46 1671 1673 19923525 Hg NN I-NP O
47 1674 1677 19923525 sem NN I-NP O
48 1678 1680 19923525 to TO B-PP O
49 1681 1685 19923525 31.6 CD B-NP O
50 1686 1687 19923525 + SYM O O
51 1687 1688 19923525 / SYM O O
52 1688 1689 19923525 - SYM O O
53 1690 1693 19923525 0.8 CD B-NP O
54 1694 1696 19923525 mm NN I-NP O
55 1697 1699 19923525 Hg NN I-NP O
56 1700 1703 19923525 sem NN I-NP O
57 1704 1707 19923525 and CC B-PP O
58 1708 1712 19923525 from IN B-PP O
59 1713 1717 19923525 86.2 CD B-NP O
60 1718 1719 19923525 + SYM B-ADJP O
61 1719 1720 19923525 / SYM O O
62 1720 1721 19923525 - SYM O O
63 1722 1725 19923525 3.7 CD B-NP O
64 1726 1728 19923525 mm NN I-NP O
65 1729 1731 19923525 Hg NN I-NP O
66 1732 1735 19923525 sem NN I-NP O
67 1736 1738 19923525 to TO B-PP O
68 1739 1743 19923525 32.6 CD B-NP O
69 1744 1745 19923525 + SYM O O
70 1745 1746 19923525 / SYM O O
71 1746 1747 19923525 - SYM O O
72 1748 1751 19923525 0.2 CD B-NP O
73 1752 1754 19923525 mm NN I-NP O
74 1755 1757 19923525 Hg NN I-NP O
75 1758 1761 19923525 sem NN I-NP O
76 1761 1762 19923525 , , O O
77 1763 1775 19923525 respectively RB B-ADVP O
78 1775 1776 19923525 . . O O

1 1777 1781 19923525 Mean JJ B-NP O
2 1782 1790 19923525 arterial JJ I-NP O
3 1791 1796 19923525 blood NN I-NP O
4 1797 1805 19923525 pressure NN I-NP O
5 1806 1808 19923525 in IN B-PP O
6 1809 1813 19923525 mice NNS B-NP O
7 1814 1821 19923525 treated VBN B-VP O
8 1822 1826 19923525 with IN B-PP O
9 1827 1831 19923525 NIMO NN B-NP D009553
10 1832 1837 19923525 alone RB B-ADVP O
11 1838 1847 19923525 decreased VBD B-VP O
12 1848 1852 19923525 from IN B-PP O
13 1853 1857 19923525 88.1 CD B-NP O
14 1858 1859 19923525 + SYM B-ADJP O
15 1859 1860 19923525 / SYM O O
16 1860 1861 19923525 - SYM O O
17 1862 1865 19923525 3.8 CD B-NP O
18 1866 1868 19923525 mm NN I-NP O
19 1869 1871 19923525 Hg NN I-NP O
20 1872 1874 19923525 to TO B-PP O
21 1875 1879 19923525 80.0 CD B-NP O
22 1880 1881 19923525 + SYM B-NP O
23 1881 1882 19923525 / SYM I-NP O
24 1882 1883 19923525 - SYM I-NP O
25 1884 1887 19923525 2.9 CD I-NP O
26 1888 1890 19923525 mm NN I-NP O
27 1891 1893 19923525 Hg NN I-NP O
28 1893 1894 19923525 . . O O

1 1895 1898 19923525 The DT B-NP O
2 1899 1909 19923525 intergroup NN I-NP O
3 1910 1920 19923525 difference NN I-NP O
4 1921 1924 19923525 was VBD B-VP O
5 1925 1938 19923525 statistically RB B-ADJP O
6 1939 1950 19923525 significant JJ I-ADJP O
7 1951 1952 19923525 ( ( O O
8 1952 1953 19923525 P NN B-NP O
9 1954 1955 19923525 < SYM O O
10 1956 1960 19923525 0.05 CD B-NP O
11 1960 1961 19923525 ) ) O O
12 1961 1962 19923525 . . O O

1 1963 1970 19923525 PbtO(2) NN B-NP O
2 1971 1980 19923525 decreased VBD B-VP O
3 1981 1985 19923525 from IN B-PP O
4 1986 1990 19923525 51.7 CD B-NP O
5 1991 1992 19923525 + SYM B-NP O
6 1992 1993 19923525 / SYM I-NP O
7 1993 1994 19923525 - SYM I-NP O
8 1995 1998 19923525 4.5 CD I-NP O
9 1999 2001 19923525 mm NN I-NP O
10 2002 2004 19923525 Hg NN I-NP O
11 2005 2008 19923525 sem NN I-NP O
12 2009 2011 19923525 to TO B-PP O
13 2012 2016 19923525 33.8 CD B-NP O
14 2017 2018 19923525 + SYM O O
15 2018 2019 19923525 / SYM O O
16 2019 2020 19923525 - SYM O O
17 2021 2024 19923525 5.2 CD B-NP O
18 2025 2027 19923525 mm NN I-NP O
19 2028 2030 19923525 Hg NN I-NP O
20 2031 2034 19923525 sem NN I-NP O
21 2035 2037 19923525 in IN B-PP O
22 2038 2041 19923525 the DT B-NP O
23 2042 2045 19923525 NTG NN I-NP D005996
24 2046 2051 19923525 group NN I-NP O
25 2052 2055 19923525 and CC B-PP O
26 2056 2060 19923525 from IN B-PP O
27 2061 2065 19923525 38.6 CD B-NP O
28 2066 2067 19923525 + SYM B-ADJP O
29 2067 2068 19923525 / SYM O O
30 2068 2069 19923525 - SYM O O
31 2070 2073 19923525 6.1 CD B-NP O
32 2074 2076 19923525 mm NN I-NP O
33 2077 2079 19923525 Hg NN I-NP O
34 2080 2083 19923525 sem NN I-NP O
35 2084 2086 19923525 to TO B-PP O
36 2087 2091 19923525 25.4 CD B-NP O
37 2092 2093 19923525 + SYM O O
38 2093 2094 19923525 / SYM O O
39 2094 2095 19923525 - SYM O O
40 2096 2099 19923525 2.0 CD B-NP O
41 2100 2102 19923525 mm NN I-NP O
42 2103 2105 19923525 Hg NN I-NP O
43 2106 2109 19923525 sem NN I-NP O
44 2110 2112 19923525 in IN B-PP O
45 2113 2116 19923525 the DT B-NP O
46 2117 2120 19923525 NTG NN I-NP D005996
47 2121 2122 19923525 + SYM B-NP O
48 2123 2127 19923525 NIMO NN I-NP D009553
49 2128 2134 19923525 groups NNS I-NP O
50 2134 2135 19923525 , , O O
51 2136 2148 19923525 respectively RB B-ADVP O
52 2148 2149 19923525 . . O O

1 2150 2155 19923525 There EX B-NP O
2 2156 2160 19923525 were VBD B-VP O
3 2161 2163 19923525 no DT B-NP O
4 2164 2175 19923525 significant JJ I-NP O
5 2176 2187 19923525 differences NNS I-NP O
6 2188 2193 19923525 among IN B-PP O
7 2194 2200 19923525 groups NNS B-NP O
8 2200 2201 19923525 . . O O

1 2202 2212 19923525 CONCLUSION NN B-NP O
2 2212 2213 19923525 : : O O
3 2214 2216 19923525 In IN B-PP O
4 2217 2218 19923525 a DT B-NP O
5 2219 2221 19923525 PA NN I-NP O
6 2222 2231 19923525 retention NN I-NP O
7 2232 2240 19923525 paradigm NN I-NP O
8 2240 2241 19923525 , , O O
9 2242 2245 19923525 the DT B-NP O
10 2246 2255 19923525 injection NN I-NP O
11 2256 2258 19923525 of IN B-PP O
12 2259 2262 19923525 NTG NN B-NP D005996
13 2263 2274 19923525 immediately RB B-ADVP O
14 2275 2280 19923525 after IN B-SBAR O
15 2281 2289 19923525 learning NN B-NP O
16 2290 2298 19923525 produced VBD B-VP O
17 2299 2300 19923525 a DT B-NP O
18 2301 2312 19923525 significant JJ I-NP O
19 2313 2323 19923525 impairment NN I-NP O
20 2324 2326 19923525 of IN B-PP O
21 2327 2331 19923525 long JJ B-NP O
22 2331 2332 19923525 - HYPH I-NP O
23 2332 2336 19923525 term NN I-NP O
24 2337 2348 19923525 associative JJ I-NP O
25 2349 2355 19923525 memory NN I-NP O
26 2356 2358 19923525 in IN B-PP O
27 2359 2363 19923525 mice NNS B-NP O
28 2363 2364 19923525 , , O O
29 2365 2372 19923525 whereas IN O O
30 2373 2380 19923525 delayed VBN B-NP O
31 2381 2388 19923525 induced VBN I-NP O
32 2389 2400 19923525 hypotension NN I-NP D007022
33 2401 2404 19923525 had VBD B-VP O
34 2405 2407 19923525 no DT B-NP O
35 2408 2414 19923525 effect NN I-NP O
36 2414 2415 19923525 . . O O

1 2416 2420 19923525 NIMO NN B-NP D009553
2 2421 2431 19923525 attenuated VBD B-VP O
3 2432 2435 19923525 the DT B-NP O
4 2436 2446 19923525 disruption NN I-NP O
5 2447 2449 19923525 in IN B-PP O
6 2450 2463 19923525 consolidation NN B-NP O
7 2464 2466 19923525 of IN B-PP O
8 2467 2471 19923525 long JJ B-NP O
9 2471 2472 19923525 - HYPH I-NP O
10 2472 2476 19923525 term NN I-NP O
11 2477 2483 19923525 memory NN I-NP O
12 2484 2490 19923525 caused VBN B-VP O
13 2491 2493 19923525 by IN B-PP O
14 2494 2497 19923525 NTG NN B-NP D005996
15 2498 2501 19923525 but CC O O
16 2502 2505 19923525 did VBD B-VP O
17 2506 2509 19923525 not RB I-VP O
18 2510 2517 19923525 improve VB I-VP O
19 2518 2525 19923525 latency NN B-NP O
20 2526 2528 19923525 in IN B-PP O
21 2529 2532 19923525 the DT B-NP O
22 2533 2540 19923525 absence NN I-NP O
23 2541 2543 19923525 of IN B-PP O
24 2544 2555 19923525 hypotension NN B-NP D007022
25 2555 2556 19923525 . . O O

1 2557 2560 19923525 The DT B-NP O
2 2561 2569 19923525 observed VBN I-NP O
3 2570 2576 19923525 effect NN I-NP O
4 2577 2579 19923525 of IN B-PP O
5 2580 2584 19923525 NIMO NN B-NP D009553
6 2585 2588 19923525 may MD B-VP O
7 2589 2593 19923525 have VB I-VP O
8 2594 2598 19923525 been VBN I-VP O
9 2599 2611 19923525 attributable JJ B-ADJP O
10 2612 2614 19923525 to TO B-PP O
11 2615 2618 19923525 the DT B-NP O
12 2619 2631 19923525 preservation NN I-NP O
13 2632 2634 19923525 of IN B-PP O
14 2635 2642 19923525 calcium NN B-NP D002118
15 2643 2654 19923525 homeostasis NN I-NP O
16 2655 2661 19923525 during IN B-PP O
17 2662 2673 19923525 hypotension NN B-NP D007022
18 2673 2674 19923525 , , O O
19 2675 2682 19923525 because IN B-SBAR O
20 2683 2688 19923525 there EX B-NP O
21 2689 2693 19923525 were VBD B-VP O
22 2694 2696 19923525 no DT B-NP O
23 2697 2708 19923525 differences NNS I-NP O
24 2709 2711 19923525 in IN B-PP O
25 2712 2715 19923525 the DT B-NP O
26 2716 2723 19923525 PbtO(2) NN I-NP O
27 2724 2731 19923525 indices NNS I-NP O
28 2732 2737 19923525 among IN B-PP O
29 2738 2744 19923525 groups NNS B-NP O
30 2744 2745 19923525 . . O O

1 0 0 9915601 -DOCSTART- -X- -X- O

1 0 8 9915601 Enhanced VBN B-NP O
2 9 20 9915601 bradycardia NN I-NP D001919
3 21 28 9915601 induced VBN B-VP O
4 29 31 9915601 by IN B-PP O
5 32 36 9915601 beta SYM B-NP O
6 36 37 9915601 - HYPH B-NP O
7 37 49 9915601 adrenoceptor NN I-NP O
8 50 61 9915601 antagonists NNS I-NP O
9 62 64 9915601 in IN B-PP O
10 65 69 9915601 rats NNS B-NP O
11 70 80 9915601 pretreated VBN B-VP O
12 81 85 9915601 with IN B-PP O
13 86 95 9915601 isoniazid NN B-NP D007538
14 95 96 9915601 . . O O
15 97 101 9915601 High JJ B-NP O
16 102 107 9915601 doses NNS I-NP O
17 108 110 9915601 of IN B-PP O
18 111 120 9915601 isoniazid NN B-NP D007538
19 121 129 9915601 increase NN I-NP O
20 130 141 9915601 hypotension NN I-NP D007022
21 142 149 9915601 induced VBN B-VP O
22 150 152 9915601 by IN B-PP O
23 153 165 9915601 vasodilators NNS B-NP O
24 166 169 9915601 and CC O O
25 170 176 9915601 change VB B-VP O
26 177 180 9915601 the DT B-NP O
27 181 193 9915601 accompanying VBG I-NP O
28 194 200 9915601 reflex NN I-NP O
29 201 212 9915601 tachycardia NN I-NP D013610
30 213 215 9915601 to TO B-PP O
31 216 227 9915601 bradycardia NN B-NP D001919
32 227 228 9915601 , , O O
33 229 231 9915601 an DT B-NP O
34 232 243 9915601 interaction NN I-NP O
35 244 254 9915601 attributed VBN B-VP O
36 255 257 9915601 to TO B-PP O
37 258 267 9915601 decreased VBN B-NP O
38 268 277 9915601 synthesis NN I-NP O
39 278 280 9915601 of IN B-PP O
40 281 286 9915601 brain NN B-NP O
41 287 292 9915601 gamma SYM B-NP D005680
42 292 293 9915601 - HYPH B-VP D005680
43 293 305 9915601 aminobutyric JJ B-NP D005680
44 306 310 9915601 acid NN I-NP D005680
45 311 312 9915601 ( ( O O
46 312 316 9915601 GABA NN B-NP D005680
47 316 317 9915601 ) ) O O
48 317 318 9915601 . . O O

1 319 321 9915601 In IN B-PP O
2 322 325 9915601 the DT B-NP O
3 326 333 9915601 present JJ I-NP O
4 334 339 9915601 study NN I-NP O
5 339 340 9915601 , , O O
6 341 344 9915601 the DT B-NP O
7 345 353 9915601 possible JJ I-NP O
8 354 365 9915601 enhancement NN I-NP O
9 366 368 9915601 by IN B-PP O
10 369 378 9915601 isoniazid NN B-NP D007538
11 379 381 9915601 of IN B-PP O
12 382 393 9915601 bradycardia NN B-NP D001919
13 394 401 9915601 induced VBN B-VP O
14 402 404 9915601 by IN B-PP O
15 405 409 9915601 beta SYM B-NP O
16 409 410 9915601 - HYPH B-NP O
17 410 422 9915601 adrenoceptor NN I-NP O
18 423 434 9915601 antagonists NNS I-NP O
19 435 438 9915601 was VBD B-VP O
20 439 449 9915601 determined VBN I-VP O
21 450 452 9915601 in IN B-PP O
22 453 457 9915601 rats NNS B-NP O
23 458 471 9915601 anaesthetised VBN B-VP O
24 472 476 9915601 with IN B-PP O
25 477 487 9915601 chloralose NN B-NP D002698
26 487 488 9915601 - HYPH I-NP O
27 488 496 9915601 urethane NN I-NP D014520
28 496 497 9915601 . . O O

1 498 507 9915601 Isoniazid NN B-NP D007538
2 508 521 9915601 significantly RB B-ADVP O
3 522 531 9915601 increased VBD B-VP O
4 532 543 9915601 bradycardia NN B-NP D001919
5 544 549 9915601 after IN B-PP O
6 550 561 9915601 propranolol NN B-NP D011433
7 561 562 9915601 , , O O
8 563 571 9915601 pindolol NN B-NP D010869
9 571 572 9915601 , , O O
10 573 582 9915601 labetalol NN B-NP D007741
11 583 586 9915601 and CC I-NP O
12 587 595 9915601 atenolol NN I-NP D001262
13 595 596 9915601 , , O O
14 597 599 9915601 as RB B-CONJP O
15 600 604 9915601 well RB I-CONJP O
16 605 607 9915601 as IN I-CONJP O
17 608 613 9915601 after IN B-PP O
18 614 623 9915601 clonidine NN B-NP D003000
19 623 624 9915601 , , O O
20 625 628 9915601 but CC O O
21 629 632 9915601 not RB B-PP O
22 633 638 9915601 after IN I-PP O
23 639 652 9915601 hexamethonium NN B-NP D018738
24 653 655 9915601 or CC I-NP O
25 656 665 9915601 carbachol NN I-NP D002217
26 665 666 9915601 . . O O

1 667 678 9915601 Enhancement NN B-NP O
2 679 682 9915601 was VBD B-VP O
3 683 686 9915601 not RB I-VP O
4 687 695 9915601 observed VBN I-VP O
5 696 698 9915601 in IN B-PP O
6 699 703 9915601 rats NNS B-NP O
7 704 714 9915601 pretreated VBN B-VP O
8 715 719 9915601 with IN B-PP O
9 720 734 9915601 methylatropine NN B-NP C006649
10 735 737 9915601 or CC O O
11 738 748 9915601 previously RB B-VP O
12 749 760 9915601 vagotomised VBN I-VP O
13 760 761 9915601 . . O O

1 762 767 9915601 These DT B-NP O
2 768 775 9915601 results NNS I-NP O
3 776 779 9915601 are VBP B-VP O
4 780 790 9915601 compatible JJ B-ADJP O
5 791 795 9915601 with IN B-PP O
6 796 808 9915601 interference NN B-NP O
7 809 811 9915601 by IN B-PP O
8 812 821 9915601 isoniazid NN B-NP D007538
9 822 826 9915601 with IN B-PP O
10 827 836 9915601 GABAergic JJ B-NP O
11 837 847 9915601 inhibition NN I-NP O
12 848 850 9915601 of IN B-PP O
13 851 858 9915601 cardiac JJ B-NP O
14 859 874 9915601 parasympathetic JJ I-NP O
15 875 879 9915601 tone NN I-NP O
16 879 880 9915601 . . O O

1 881 885 9915601 Such JJ B-NP O
2 886 898 9915601 interference NN I-NP O
3 899 904 9915601 could MD B-VP O
4 905 907 9915601 be VB I-VP O
5 908 915 9915601 exerted VBN I-VP O
6 916 925 9915601 centrally RB B-ADVP O
7 925 926 9915601 , , O O
8 927 935 9915601 possibly RB B-ADVP O
9 936 938 9915601 at IN B-PP O
10 939 942 9915601 the DT B-NP O
11 943 950 9915601 nucleus NN I-NP O
12 951 959 9915601 ambiguus NN I-NP O
13 959 960 9915601 , , O O
14 961 963 9915601 or CC O O
15 964 976 9915601 peripherally RB B-ADVP O
16 977 979 9915601 at IN B-PP O
17 980 983 9915601 the DT B-NP O
18 984 989 9915601 sinus NN I-NP O
19 990 994 9915601 node NN I-NP O
20 994 995 9915601 . . O O

1 0 0 6436733 -DOCSTART- -X- -X- O

1 0 5 6436733 Acute JJ B-NP O
2 6 13 6436733 changes NNS I-NP O
3 14 16 6436733 of IN B-PP O
4 17 22 6436733 blood NN B-NP O
5 23 30 6436733 ammonia NN I-NP D000641
6 31 34 6436733 may MD B-VP O
7 35 42 6436733 predict VB I-VP O
8 43 48 6436733 short JJ B-NP O
9 48 49 6436733 - HYPH I-NP O
10 49 53 6436733 term NN I-NP O
11 54 61 6436733 adverse JJ I-NP O
12 62 69 6436733 effects NNS I-NP O
13 70 72 6436733 of IN B-PP O
14 73 81 6436733 valproic JJ B-NP D014635
15 82 86 6436733 acid NN I-NP D014635
16 86 87 6436733 . . O O
17 88 96 6436733 Valproic JJ B-NP D014635
18 97 101 6436733 acid NN I-NP D014635
19 102 103 6436733 ( ( O O
20 103 106 6436733 VPA NN B-NP D014635
21 106 107 6436733 ) ) O O
22 108 111 6436733 was VBD B-VP O
23 112 117 6436733 given VBN I-VP O
24 118 120 6436733 to TO B-PP O
25 121 123 6436733 24 CD B-NP O
26 124 133 6436733 epileptic JJ I-NP D004827
27 134 142 6436733 patients NNS I-NP O
28 143 146 6436733 who WP B-NP O
29 147 151 6436733 were VBD B-VP O
30 152 159 6436733 already RB I-VP O
31 160 165 6436733 being VBG I-VP O
32 166 173 6436733 treated VBN I-VP O
33 174 178 6436733 with IN B-PP O
34 179 184 6436733 other JJ B-NP O
35 185 198 6436733 antiepileptic JJ I-NP O
36 199 204 6436733 drugs NNS I-NP O
37 204 205 6436733 . . O O

1 206 207 6436733 A DT B-NP O
2 208 220 6436733 standardized JJ I-NP O
3 221 228 6436733 loading NN I-NP O
4 229 233 6436733 dose NN I-NP O
5 234 236 6436733 of IN B-PP O
6 237 240 6436733 VPA NN B-NP D014635
7 241 244 6436733 was VBD B-VP O
8 245 257 6436733 administered VBN I-VP O
9 257 258 6436733 , , O O
10 259 262 6436733 and CC O O
11 263 269 6436733 venous JJ B-NP O
12 270 275 6436733 blood NN I-NP O
13 276 279 6436733 was VBD B-VP O
14 280 287 6436733 sampled VBN I-VP O
15 288 290 6436733 at IN B-PP O
16 291 292 6436733 0 CD B-NP O
17 292 293 6436733 , , I-NP O
18 294 295 6436733 1 CD I-NP O
19 295 296 6436733 , , I-NP O
20 297 298 6436733 2 CD I-NP O
21 298 299 6436733 , , I-NP O
22 300 301 6436733 3 CD I-NP O
23 301 302 6436733 , , O O
24 303 306 6436733 and CC O O
25 307 308 6436733 4 CD B-NP O
26 309 314 6436733 hours NNS I-NP O
27 314 315 6436733 . . O O

1 316 323 6436733 Ammonia NN B-NP D000641
2 324 325 6436733 ( ( O O
3 325 328 6436733 NH3 NN B-NP D000641
4 328 329 6436733 ) ) O O
5 330 333 6436733 was VBD B-VP O
6 334 340 6436733 higher JJR B-ADJP O
7 341 343 6436733 in IN B-PP O
8 344 352 6436733 patients NNS B-NP O
9 353 356 6436733 who WP B-NP O
10 356 357 6436733 , , O O
11 358 364 6436733 during IN B-PP O
12 365 375 6436733 continuous JJ B-NP O
13 376 383 6436733 therapy NN I-NP O
14 383 384 6436733 , , O O
15 385 395 6436733 complained VBD B-VP O
16 396 398 6436733 of IN B-PP O
17 399 409 6436733 drowsiness NN B-NP D006970
18 410 411 6436733 ( ( O O
19 411 412 6436733 7 CD B-NP O
20 413 421 6436733 patients NNS I-NP O
21 421 422 6436733 ) ) O O
22 423 427 6436733 than IN B-PP O
23 428 430 6436733 in IN B-PP O
24 431 436 6436733 those DT B-NP O
25 437 440 6436733 who WP B-NP O
26 441 445 6436733 were VBD B-VP O
27 446 453 6436733 symptom NN B-NP O
28 453 454 6436733 - HYPH O O
29 454 458 6436733 free JJ B-ADJP O
30 459 460 6436733 ( ( O O
31 460 462 6436733 17 CD B-NP O
32 463 471 6436733 patients NNS I-NP O
33 471 472 6436733 ) ) O O
34 472 473 6436733 , , O O
35 474 482 6436733 although IN B-SBAR O
36 483 486 6436733 VPA NN B-NP D014635
37 487 493 6436733 plasma NN I-NP O
38 494 500 6436733 levels NNS I-NP O
39 501 505 6436733 were VBD B-VP O
40 506 513 6436733 similar JJ B-ADJP O
41 514 516 6436733 in IN B-PP O
42 517 521 6436733 both DT B-NP O
43 522 528 6436733 groups NNS I-NP O
44 528 529 6436733 . . O O

1 530 532 6436733 By IN B-PP O
2 533 542 6436733 measuring VBG B-VP O
3 543 546 6436733 VPA NN B-NP D014635
4 546 547 6436733 - HYPH B-NP O
5 547 554 6436733 induced VBN I-NP O
6 555 562 6436733 changes NNS I-NP O
7 563 565 6436733 of IN B-PP O
8 566 571 6436733 blood NN B-NP O
9 572 575 6436733 NH3 NN I-NP D000641
10 576 583 6436733 content NN I-NP O
11 583 584 6436733 , , O O
12 585 587 6436733 it PRP B-NP O
13 588 591 6436733 may MD B-VP O
14 592 594 6436733 be VB I-VP O
15 595 603 6436733 possible JJ B-ADJP O
16 604 606 6436733 to TO B-VP O
17 607 615 6436733 identify VB I-VP O
18 616 624 6436733 patients NNS B-NP O
19 625 627 6436733 at IN B-PP O
20 628 634 6436733 higher JJR B-NP O
21 635 639 6436733 risk NN I-NP O
22 640 642 6436733 of IN B-PP O
23 643 654 6436733 obtundation NN B-NP O
24 655 659 6436733 when WRB B-ADVP O
25 660 663 6436733 VPA NN B-NP D014635
26 664 666 6436733 is VBZ B-VP O
27 667 672 6436733 given VBN I-VP O
28 673 684 6436733 chronically RB B-ADVP O
29 684 685 6436733 . . O O

1 0 0 9154656 -DOCSTART- -X- -X- O

1 0 7 9154656 Hepatic JJ B-NP O
2 8 11 9154656 and CC I-NP O
3 12 24 9154656 extrahepatic JJ I-NP O
4 25 40 9154656 angiotensinogen NN I-NP O
5 41 45 9154656 gene NN I-NP O
6 46 56 9154656 expression NN I-NP O
7 57 59 9154656 in IN B-PP O
8 60 64 9154656 rats NNS B-NP O
9 65 69 9154656 with IN B-PP O
10 70 75 9154656 acute JJ B-NP O
11 76 85 9154656 nephrotic JJ I-NP D009404
12 86 94 9154656 syndrome NN I-NP D009404
13 94 95 9154656 . . O O
14 96 102 9154656 Plasma NN B-NP O
15 103 116 9154656 concentration NN I-NP O
16 117 120 9154656 and CC O O
17 121 126 9154656 urine NN B-NP O
18 127 136 9154656 excretion NN I-NP O
19 137 139 9154656 of IN B-PP O
20 140 143 9154656 the DT B-NP O
21 144 149 9154656 renin NN I-NP O
22 149 150 9154656 - HYPH I-NP O
23 150 161 9154656 angiotensin NN I-NP D000809
24 162 168 9154656 system NN I-NP O
25 169 177 9154656 proteins NNS I-NP O
26 178 181 9154656 are VBP B-VP O
27 182 189 9154656 altered VBN I-VP O
28 190 192 9154656 in IN B-PP O
29 193 197 9154656 rats NNS B-NP O
30 198 202 9154656 with IN B-PP O
31 203 212 9154656 nephrotic JJ B-NP D009404
32 213 221 9154656 syndrome NN I-NP D009404
33 222 223 9154656 ( ( O O
34 223 225 9154656 NS NN B-NP D009404
35 225 226 9154656 ) ) O O
36 226 227 9154656 . . O O

1 228 230 9154656 In IN B-PP O
2 231 235 9154656 this DT B-NP O
3 236 240 9154656 work NN I-NP O
4 241 244 9154656 the DT B-NP O
5 245 254 9154656 messenger NN I-NP O
6 255 266 9154656 ribonucleic JJ I-NP O
7 267 271 9154656 acid NN I-NP O
8 272 273 9154656 ( ( O O
9 273 277 9154656 mRNA NN B-NP O
10 277 278 9154656 ) ) O O
11 279 285 9154656 levels NNS B-NP O
12 286 288 9154656 of IN B-PP O
13 289 304 9154656 angiotensinogen NN B-NP O
14 305 306 9154656 ( ( O O
15 306 308 9154656 Ao NN B-NP O
16 308 309 9154656 ) ) O O
17 310 314 9154656 were VBD B-VP O
18 315 323 9154656 analyzed VBN I-VP O
19 324 328 9154656 with IN B-PP O
20 329 332 9154656 the DT B-NP O
21 333 337 9154656 slot NN I-NP O
22 337 338 9154656 - HYPH B-NP O
23 338 342 9154656 blot NN I-NP O
24 343 356 9154656 hybridization NN I-NP O
25 357 366 9154656 technique NN I-NP O
26 367 369 9154656 in IN B-PP O
27 370 375 9154656 liver NN B-NP O
28 376 379 9154656 and CC O O
29 380 385 9154656 other JJ B-NP O
30 386 398 9154656 extrahepatic JJ I-NP O
31 399 406 9154656 tissues NNS I-NP O
32 406 407 9154656 : : O O
33 408 414 9154656 kidney NN B-NP O
34 414 415 9154656 , , O O
35 416 421 9154656 heart NN B-NP O
36 421 422 9154656 , , O O
37 423 428 9154656 brain NN B-NP O
38 428 429 9154656 , , O O
39 430 433 9154656 and CC O O
40 434 441 9154656 adrenal JJ B-NP O
41 442 447 9154656 gland NN I-NP O
42 448 452 9154656 from IN B-PP O
43 453 460 9154656 control NN B-NP O
44 460 461 9154656 , , O O
45 462 471 9154656 nephrotic JJ B-ADJP D009404
46 471 472 9154656 , , O O
47 473 476 9154656 and CC O O
48 477 481 9154656 pair NN B-NP O
49 481 482 9154656 - HYPH O O
50 482 485 9154656 fed VBN B-VP O
51 486 487 9154656 ( ( O O
52 487 489 9154656 PF NN B-NP O
53 489 490 9154656 ) ) O O
54 491 495 9154656 rats NNS B-NP O
55 495 496 9154656 . . O O

1 497 499 9154656 NS NN B-NP D009404
2 500 503 9154656 was VBD B-VP O
3 504 511 9154656 induced VBN I-VP O
4 512 514 9154656 by IN B-PP O
5 515 516 9154656 a DT B-NP O
6 517 523 9154656 single JJ I-NP O
7 524 533 9154656 injection NN I-NP O
8 534 536 9154656 of IN B-PP O
9 537 546 9154656 puromycin NN B-NP D011692
10 547 552 9154656 amino JJ O D011692
11 552 553 9154656 - HYPH O D011692
12 553 563 9154656 nucleoside NN B-NP D011692
13 564 565 9154656 ( ( O O
14 565 568 9154656 PAN NN B-NP D011692
15 568 569 9154656 ) ) O O
16 569 570 9154656 . . O O

1 571 579 9154656 Although IN B-SBAR O
2 580 581 9154656 a DT B-NP O
3 582 587 9154656 great JJ I-NP O
4 588 595 9154656 urinary JJ I-NP O
5 596 605 9154656 excretion NN I-NP O
6 606 609 9154656 and CC I-NP O
7 610 614 9154656 half NN I-NP O
8 614 615 9154656 - HYPH I-NP O
9 615 621 9154656 normal JJ I-NP O
10 622 628 9154656 plasma NN I-NP O
11 629 635 9154656 levels NNS I-NP O
12 636 638 9154656 of IN B-PP O
13 639 641 9154656 Ao NNP B-NP O
14 642 646 9154656 were VBD B-VP O
15 647 655 9154656 observed VBN I-VP O
16 656 658 9154656 on IN B-PP O
17 659 662 9154656 day NN B-NP O
18 663 664 9154656 6 CD I-NP O
19 665 670 9154656 after IN B-PP O
20 671 674 9154656 PAN NN B-NP D011692
21 675 684 9154656 injection NN I-NP O
22 684 685 9154656 , , O O
23 686 690 9154656 when WRB B-ADVP O
24 691 693 9154656 NS NN B-NP D009404
25 694 697 9154656 was VBD B-VP O
26 698 705 9154656 clearly RB I-VP O
27 706 717 9154656 established VBN I-VP O
28 717 718 9154656 , , O O
29 719 726 9154656 hepatic JJ B-NP O
30 727 729 9154656 Ao NN I-NP O
31 730 734 9154656 mRNA NN I-NP O
32 735 741 9154656 levels NNS I-NP O
33 742 745 9154656 did VBD B-VP O
34 746 749 9154656 not RB I-VP O
35 750 756 9154656 change VB I-VP O
36 756 757 9154656 . . O O

1 758 769 9154656 Furthermore RB B-ADVP O
2 769 770 9154656 , , O O
3 771 774 9154656 the DT B-NP O
4 775 777 9154656 Ao NNP I-NP O
5 778 782 9154656 mRNA NN I-NP O
6 783 789 9154656 levels NNS I-NP O
7 790 793 9154656 did VBD B-VP O
8 794 797 9154656 not RB I-VP O
9 798 804 9154656 change VB I-VP O
10 805 807 9154656 in IN B-PP O
11 808 811 9154656 any DT B-NP O
12 812 814 9154656 of IN B-PP O
13 815 818 9154656 the DT B-NP O
14 819 831 9154656 extrahepatic JJ I-NP O
15 832 839 9154656 tissues NNS I-NP O
16 840 847 9154656 studied VBN B-VP O
17 848 850 9154656 on IN B-PP O
18 851 854 9154656 day NN B-NP O
19 855 856 9154656 6 CD I-NP O
20 856 857 9154656 , , O O
21 858 861 9154656 nor CC O O
22 862 865 9154656 did VBD O O
23 866 869 9154656 its PRP$ B-NP O
24 870 877 9154656 hepatic JJ I-NP O
25 878 884 9154656 levels NNS I-NP O
26 885 887 9154656 at IN B-PP O
27 888 892 9154656 days NNS B-NP O
28 893 894 9154656 1 CD I-NP O
29 894 895 9154656 , , I-NP O
30 896 897 9154656 3 CD I-NP O
31 897 898 9154656 , , I-NP O
32 899 900 9154656 5 CD I-NP O
33 900 901 9154656 , , O O
34 902 904 9154656 or CC O O
35 905 906 9154656 7 CD B-NP O
36 907 912 9154656 after IN B-SBAR O
37 913 916 9154656 PAN NN B-NP D011692
38 917 926 9154656 injection NN I-NP O
39 926 927 9154656 . . O O

1 928 933 9154656 These DT B-NP O
2 934 938 9154656 data NNS I-NP O
3 939 946 9154656 suggest VBP B-VP O
4 947 951 9154656 that IN B-SBAR O
5 952 955 9154656 the DT B-NP O
6 956 963 9154656 hepatic JJ I-NP O
7 964 967 9154656 and CC I-NP O
8 968 980 9154656 extrahepatic JJ I-NP O
9 981 983 9154656 Ao NN I-NP O
10 984 988 9154656 mRNA NN I-NP O
11 989 995 9154656 levels NNS I-NP O
12 996 999 9154656 are VBP B-VP O
13 1000 1009 9154656 unaltered JJ B-ADJP O
14 1010 1016 9154656 during IN B-PP O
15 1017 1020 9154656 the DT B-NP O
16 1021 1032 9154656 development NN I-NP O
17 1033 1035 9154656 of IN B-PP O
18 1036 1039 9154656 the DT B-NP O
19 1040 1045 9154656 acute JJ I-NP O
20 1046 1048 9154656 NS NN I-NP D009404
21 1049 1056 9154656 induced VBN B-VP O
22 1057 1059 9154656 by IN B-PP O
23 1060 1063 9154656 PAN NN B-NP D011692
24 1063 1064 9154656 . . O O

1 0 0 6292680 -DOCSTART- -X- -X- O

1 0 11 6292680 Doxorubicin NN B-NP D004317
2 12 26 6292680 cardiomyopathy NN I-NP D009202
3 27 29 6292680 in IN B-PP O
4 30 38 6292680 children NNS B-NP O
5 39 43 6292680 with IN B-PP O
6 44 48 6292680 left JJ B-NP O
7 48 49 6292680 - HYPH I-NP O
8 49 54 6292680 sided JJ I-NP O
9 55 60 6292680 Wilms NNP I-NP D009396
10 61 66 6292680 tumor NN I-NP D009396
11 66 67 6292680 . . O O
12 68 71 6292680 Two CD B-NP O
13 72 80 6292680 children NNS I-NP O
14 81 85 6292680 with IN B-PP O
15 86 91 6292680 Wilms NNP B-NP D009396
16 92 97 6292680 tumor NN I-NP D009396
17 98 100 6292680 of IN B-PP O
18 101 104 6292680 the DT B-NP O
19 105 109 6292680 left JJ I-NP O
20 110 116 6292680 kidney NN I-NP O
21 117 128 6292680 experienced VBD B-VP O
22 129 135 6292680 severe JJ B-NP O
23 136 149 6292680 anthracycline NN I-NP D018943
24 150 164 6292680 cardiomyopathy NN I-NP D009202
25 165 170 6292680 after IN B-PP O
26 171 182 6292680 irradiation NN B-NP O
27 183 185 6292680 to TO B-PP O
28 186 189 6292680 the DT B-NP O
29 190 195 6292680 tumor NN I-NP D009369
30 196 199 6292680 bed NN I-NP O
31 200 203 6292680 and CC O O
32 204 216 6292680 conventional JJ B-NP O
33 217 223 6292680 dosage NN I-NP O
34 224 226 6292680 of IN B-PP O
35 227 238 6292680 doxorubicin NN B-NP D004317
36 238 239 6292680 . . O O

1 240 243 6292680 The DT B-NP O
2 244 258 6292680 cardiomyopathy NN I-NP D009202
3 259 261 6292680 is VBZ B-VP O
4 262 272 6292680 attributed VBN I-VP O
5 273 274 6292680 1 CD B-NP O
6 274 275 6292680 ) ) O O
7 276 278 6292680 to TO B-PP O
8 279 282 6292680 the DT B-NP O
9 283 287 6292680 fact NN I-NP O
10 288 292 6292680 that IN B-SBAR O
11 293 302 6292680 radiation NN B-NP O
12 303 309 6292680 fields NNS I-NP O
13 310 313 6292680 for IN B-PP O
14 314 318 6292680 left JJ B-NP O
15 319 324 6292680 Wilms NNP I-NP D009396
16 325 330 6292680 tumor NN I-NP D009396
17 331 338 6292680 include VBP B-VP O
18 339 342 6292680 the DT B-NP O
19 343 348 6292680 lower JJR I-NP O
20 349 356 6292680 portion NN I-NP O
21 357 359 6292680 of IN B-PP O
22 360 363 6292680 the DT B-NP O
23 364 369 6292680 heart NN I-NP O
24 370 373 6292680 and CC O O
25 374 375 6292680 2 LS B-LST O
26 375 376 6292680 ) ) O O
27 377 379 6292680 to TO B-PP O
28 380 383 6292680 the DT B-NP O
29 384 395 6292680 interaction NN I-NP O
30 396 398 6292680 of IN B-PP O
31 399 410 6292680 doxorubicin NN B-NP D004317
32 411 414 6292680 and CC I-NP O
33 415 426 6292680 irradiation NN I-NP O
34 427 429 6292680 on IN B-PP O
35 430 437 6292680 cardiac JJ B-NP O
36 438 444 6292680 muscle NN I-NP O
37 444 445 6292680 . . O O

1 446 448 6292680 It PRP B-NP O
2 449 451 6292680 is VBZ B-VP O
3 452 463 6292680 recommended VBN I-VP O
4 464 468 6292680 that IN B-SBAR O
5 469 480 6292680 doxorubicin NN B-NP D004317
6 481 487 6292680 dosage NN I-NP O
7 488 490 6292680 be VB B-VP O
8 491 498 6292680 sharply RB I-VP O
9 499 509 6292680 restricted VBN I-VP O
10 510 512 6292680 in IN B-PP O
11 513 521 6292680 children NNS B-NP O
12 522 526 6292680 with IN B-PP O
13 527 532 6292680 Wilms NNP B-NP D009396
14 533 538 6292680 tumor NN I-NP D009396
15 539 541 6292680 of IN B-PP O
16 542 545 6292680 the DT B-NP O
17 546 550 6292680 left JJ I-NP O
18 551 557 6292680 kidney NN I-NP O
19 558 561 6292680 who WP B-NP O
20 562 569 6292680 receive VBP B-VP O
21 570 583 6292680 postoperative JJ B-NP O
22 584 595 6292680 irradiation NN I-NP O
23 595 596 6292680 . . O O

1 0 0 9875685 -DOCSTART- -X- -X- O

1 0 11 9875685 Therapeutic JJ B-NP O
2 12 16 9875685 drug NN I-NP O
3 17 27 9875685 monitoring NN I-NP O
4 28 30 9875685 of IN B-PP O
5 31 41 9875685 tobramycin NN B-NP D014031
6 41 42 9875685 : : O O
7 43 47 9875685 once RB B-ADJP O
8 47 48 9875685 - HYPH I-ADJP O
9 48 53 9875685 daily JJ B-ADJP O
10 54 60 9875685 versus IN B-PP O
11 61 66 9875685 twice RB B-NP O
12 66 67 9875685 - HYPH I-NP O
13 67 72 9875685 daily JJ I-NP O
14 73 79 9875685 dosage NN I-NP O
15 80 89 9875685 schedules NNS I-NP O
16 89 90 9875685 . . O O
17 91 100 9875685 OBJECTIVE NN B-NP O
18 100 101 9875685 : : O O
19 102 104 9875685 To TO B-VP O
20 105 113 9875685 evaluate VB I-VP O
21 114 117 9875685 the DT B-NP O
22 118 124 9875685 effect NN I-NP O
23 125 127 9875685 of IN B-PP O
24 128 134 9875685 dosage NN B-NP O
25 135 142 9875685 regimen NN I-NP O
26 143 144 9875685 ( ( O O
27 144 148 9875685 once RB B-ADVP O
28 148 149 9875685 - HYPH B-NP O
29 149 154 9875685 daily JJ I-NP O
30 155 157 9875685 vs NNS I-NP O
31 157 158 9875685 . . O O
32 159 164 9875685 twice RB B-ADVP O
33 164 165 9875685 - HYPH B-ADVP O
34 165 170 9875685 daily RB B-ADVP O
35 170 171 9875685 ) ) O O
36 172 174 9875685 of IN B-PP O
37 175 185 9875685 tobramicyn NN B-NP D014031
38 186 188 9875685 on IN B-PP O
39 189 195 9875685 steady JJ B-NP O
40 195 196 9875685 - HYPH I-NP O
41 196 201 9875685 state NN I-NP O
42 202 207 9875685 serum NN I-NP O
43 208 222 9875685 concentrations NNS I-NP O
44 223 226 9875685 and CC O O
45 227 235 9875685 toxicity NN B-NP D064420
46 235 236 9875685 . . O O

1 237 246 9875685 MATERIALS NNS B-NP O
2 247 250 9875685 AND CC I-NP O
3 251 258 9875685 METHODS NNS I-NP O
4 258 259 9875685 : : O O
5 260 268 9875685 Patients NNS B-NP O
6 269 279 9875685 undergoing VBG B-VP O
7 280 289 9875685 treatment NN B-NP O
8 290 294 9875685 with IN B-PP O
9 295 298 9875685 i.v NN B-NP O
10 298 299 9875685 . . O O

1 300 310 9875685 tobramycin NN B-NP D014031
2 311 312 9875685 ( ( O O
3 312 313 9875685 4 CD B-NP O
4 314 316 9875685 mg NN I-NP O
5 316 317 9875685 / SYM B-NP O
6 317 319 9875685 kg NN I-NP O
7 319 320 9875685 / SYM B-NP O
8 320 323 9875685 day NN I-NP O
9 323 324 9875685 ) ) O O
10 325 329 9875685 were VBD B-VP O
11 330 340 9875685 randomised VBN I-VP O
12 341 343 9875685 to TO B-PP O
13 344 347 9875685 two CD B-NP O
14 348 354 9875685 groups NNS I-NP O
15 354 355 9875685 . . O O

1 356 361 9875685 Group NN B-NP O
2 362 364 9875685 OD NN I-NP O
3 365 366 9875685 ( ( O O
4 366 367 9875685 n NN B-NP O
5 368 369 9875685 = SYM B-VP O
6 370 372 9875685 22 CD B-NP O
7 372 373 9875685 ) ) O O
8 374 382 9875685 received VBD B-VP O
9 383 384 9875685 a DT B-NP O
10 385 389 9875685 once RB I-NP O
11 389 390 9875685 - HYPH I-NP O
12 390 395 9875685 daily JJ I-NP O
13 396 400 9875685 dose NN I-NP O
14 401 403 9875685 of IN B-PP O
15 404 414 9875685 tobramycin NN B-NP D014031
16 415 418 9875685 and CC I-NP O
17 419 424 9875685 group NN I-NP O
18 425 427 9875685 TD NN I-NP O
19 428 429 9875685 ( ( O O
20 429 430 9875685 n NN B-NP O
21 431 432 9875685 = SYM B-VP O
22 433 435 9875685 21 CD B-NP O
23 435 436 9875685 ) ) O O
24 437 445 9875685 received VBD B-VP O
25 446 449 9875685 the DT B-NP O
26 450 454 9875685 same JJ I-NP O
27 455 459 9875685 dose NN I-NP O
28 460 467 9875685 divided VBN B-VP O
29 468 472 9875685 into IN B-PP O
30 473 476 9875685 two CD B-NP O
31 477 482 9875685 doses NNS I-NP O
32 483 488 9875685 daily RB B-ADVP O
33 488 489 9875685 . . O O

1 490 500 9875685 Tobramycin NN B-NP D014031
2 501 506 9875685 serum NN I-NP O
3 507 521 9875685 concentrations NNS I-NP O
4 522 523 9875685 ( ( O O
5 523 527 9875685 peak NN B-NP O
6 528 531 9875685 and CC O O
7 532 538 9875685 trough NN B-NP O
8 538 539 9875685 ) ) O O
9 540 544 9875685 were VBD B-VP O
10 545 553 9875685 measured VBN I-VP O
11 554 556 9875685 by IN B-PP O
12 557 563 9875685 enzyme NN B-NP O
13 564 574 9875685 multiplied JJ I-NP O
14 575 586 9875685 immunoassay NN I-NP O
15 586 587 9875685 . . O O

1 588 591 9875685 The DT B-NP O
2 592 597 9875685 renal JJ I-NP O
3 598 601 9875685 and CC I-NP O
4 602 610 9875685 auditory JJ I-NP O
5 611 620 9875685 functions NNS I-NP O
6 621 623 9875685 of IN B-PP O
7 624 627 9875685 the DT B-NP O
8 628 636 9875685 patients NNS I-NP O
9 637 641 9875685 were VBD B-VP O
10 642 651 9875685 monitored VBN I-VP O
11 652 658 9875685 before IN B-ADVP O
12 658 659 9875685 , , O O
13 660 666 9875685 during IN B-PP O
14 667 670 9875685 and CC O O
15 671 682 9875685 immediately RB B-ADVP O
16 683 688 9875685 after IN B-PP O
17 689 698 9875685 treatment NN B-NP O
18 698 699 9875685 . . O O

1 700 707 9875685 RESULTS NNS B-NP O
2 707 708 9875685 : : O O
3 709 712 9875685 The DT B-NP O
4 713 716 9875685 two CD I-NP O
5 717 723 9875685 groups NNS I-NP O
6 724 728 9875685 were VBD B-VP O
7 729 739 9875685 comparable JJ B-ADJP O
8 740 744 9875685 with IN B-PP O
9 745 752 9875685 respect NN B-NP O
10 753 755 9875685 to TO B-PP O
11 756 759 9875685 sex NN B-NP O
12 759 760 9875685 , , O O
13 761 764 9875685 age NN B-NP O
14 764 765 9875685 , , O O
15 766 770 9875685 body NN B-NP O
16 771 777 9875685 weight NN I-NP O
17 778 781 9875685 and CC O O
18 782 787 9875685 renal JJ B-NP O
19 788 796 9875685 function NN I-NP O
20 796 797 9875685 . . O O

1 798 800 9875685 No DT B-NP O
2 801 814 9875685 statistically RB I-NP O
3 815 826 9875685 significant JJ I-NP O
4 827 838 9875685 differences NNS I-NP O
5 839 843 9875685 were VBD B-VP O
6 844 849 9875685 found VBN I-VP O
7 850 852 9875685 in IN B-PP O
8 853 857 9875685 mean JJ B-NP O
9 858 863 9875685 daily JJ I-NP O
10 864 868 9875685 dose NN I-NP O
11 868 869 9875685 , , O O
12 870 878 9875685 duration NN B-NP O
13 879 881 9875685 of IN B-PP O
14 882 891 9875685 treatment NN B-NP O
15 891 892 9875685 , , O O
16 893 895 9875685 or CC O O
17 896 906 9875685 cumulative JJ B-NP O
18 907 911 9875685 dose NN I-NP O
19 911 912 9875685 . . O O

1 913 919 9875685 Trough NN B-NP O
2 920 934 9875685 concentrations NNS I-NP O
3 935 939 9875685 were VBD B-VP O
4 940 941 9875685 < SYM B-ADJP O
5 942 943 9875685 2 CD B-NP O
6 944 945 9875685 g NN I-NP O
7 945 946 9875685 / SYM B-NP O
8 946 948 9875685 ml NN I-NP O
9 949 951 9875685 in IN B-PP O
10 952 955 9875685 the DT B-NP O
11 956 959 9875685 two CD I-NP O
12 960 966 9875685 groups NNS I-NP O
13 967 968 9875685 ( ( O O
14 968 972 9875685 100% CD B-NP O
15 972 973 9875685 ) ) O O
16 973 974 9875685 . . O O

1 975 979 9875685 Peak NN B-NP O
2 980 994 9875685 concentrations NNS I-NP O
3 995 999 9875685 were VBD B-VP O
4 1000 1001 9875685 > SYM B-ADJP O
5 1002 1003 9875685 6 CD B-NP O
6 1004 1010 9875685 microg NN I-NP O
7 1010 1011 9875685 / SYM B-NP O
8 1011 1013 9875685 ml NN I-NP O
9 1014 1016 9875685 in IN B-PP O
10 1017 1021 9875685 100% CD B-NP O
11 1022 1024 9875685 of IN B-PP O
12 1025 1028 9875685 the DT B-NP O
13 1029 1031 9875685 OD NN I-NP O
14 1032 1037 9875685 group NN I-NP O
15 1038 1041 9875685 and CC B-PP O
16 1042 1044 9875685 in IN B-PP O
17 1045 1048 9875685 67% CD B-NP O
18 1049 1051 9875685 of IN B-PP O
19 1052 1055 9875685 the DT B-NP O
20 1056 1058 9875685 TD NN I-NP O
21 1059 1064 9875685 group NN I-NP O
22 1065 1066 9875685 ( ( O O
23 1066 1067 9875685 P NN B-NP O
24 1067 1068 9875685 < SYM O O
25 1069 1073 9875685 0.01 CD B-NP O
26 1073 1074 9875685 ) ) O O
27 1074 1075 9875685 . . O O

1 1076 1080 9875685 Mean JJ B-NP O
2 1081 1085 9875685 peak NN I-NP O
3 1086 1100 9875685 concentrations NNS I-NP O
4 1101 1105 9875685 were VBD B-VP O
5 1106 1114 9875685 markedly RB B-ADJP O
6 1115 1124 9875685 different JJ I-ADJP O
7 1124 1125 9875685 : : O O
8 1126 1132 9875685 11.00+ JJ B-NP O
9 1132 1133 9875685 / SYM I-NP O
10 1133 1134 9875685 - SYM I-NP O
11 1134 1138 9875685 2.89 CD B-NP O
12 1139 1145 9875685 microg NN I-NP O
13 1145 1146 9875685 / SYM B-NP O
14 1146 1148 9875685 ml NN I-NP O
15 1149 1151 9875685 in IN B-PP O
16 1152 1154 9875685 OD NN B-NP O
17 1155 1157 9875685 vs NNS I-NP O
18 1157 1158 9875685 . . O O
19 1159 1164 9875685 6.53+ JJ B-NP O
20 1164 1165 9875685 / SYM I-NP O
21 1165 1166 9875685 - SYM I-NP O
22 1166 1170 9875685 1.45 CD B-NP O
23 1171 1177 9875685 microg NN I-NP O
24 1177 1178 9875685 / SYM B-NP O
25 1178 1180 9875685 ml NN I-NP O
26 1181 1183 9875685 in IN B-PP O
27 1184 1186 9875685 TD NN B-NP O
28 1187 1188 9875685 ( ( O O
29 1188 1189 9875685 P NN B-NP O
30 1189 1190 9875685 < SYM O O
31 1191 1195 9875685 0.01 CD B-NP O
32 1195 1196 9875685 ) ) O O
33 1196 1197 9875685 . . O O

1 1198 1201 9875685 The DT B-NP O
2 1202 1218 9875685 pharmacokinetics NNS I-NP O
3 1219 1229 9875685 parameters NNS I-NP O
4 1230 1234 9875685 were VBD B-VP O
5 1234 1235 9875685 : : O O
6 1236 1238 9875685 Ke NNP B-NP O
7 1238 1239 9875685 , , O O
8 1240 1241 9875685 ( ( O O
9 1241 1246 9875685 0.15+ SYM B-NP O
10 1246 1247 9875685 / SYM O O
11 1247 1248 9875685 - SYM O O
12 1248 1252 9875685 0.03 CD B-NP O
13 1252 1253 9875685 / SYM I-NP O
14 1253 1254 9875685 h NN I-NP O
15 1255 1257 9875685 in IN B-PP O
16 1258 1260 9875685 OD NN B-NP O
17 1261 1263 9875685 vs NNS I-NP O
18 1263 1264 9875685 . . O O
19 1265 1270 9875685 0.24+ CD B-NP O
20 1270 1271 9875685 / SYM O O
21 1271 1272 9875685 - SYM O O
22 1272 1276 9875685 0.06 CD B-NP O
23 1276 1277 9875685 / SYM I-NP O
24 1277 1278 9875685 h NN I-NP O
25 1279 1281 9875685 in IN B-PP O
26 1282 1284 9875685 TD NN B-NP O
27 1284 1285 9875685 ) ) O O
28 1285 1286 9875685 , , O O
29 1287 1289 9875685 t1 NN B-NP O
30 1289 1290 9875685 / SYM B-VP O
31 1290 1291 9875685 2 CD B-NP O
32 1291 1292 9875685 , , O O
33 1293 1294 9875685 ( ( O O
34 1294 1299 9875685 4.95+ SYM B-NP O
35 1299 1300 9875685 / SYM O O
36 1300 1301 9875685 - SYM O O
37 1301 1305 9875685 1.41 CD B-NP O
38 1306 1307 9875685 h NN I-NP O
39 1308 1310 9875685 in IN B-PP O
40 1311 1313 9875685 OD NN B-NP O
41 1314 1316 9875685 vs NNS I-NP O
42 1316 1317 9875685 . . O O
43 1318 1323 9875685 3.07+ SYM O O
44 1323 1324 9875685 / SYM O O
45 1324 1325 9875685 - SYM O O
46 1325 1329 9875685 0.71 CD B-NP O
47 1330 1331 9875685 h NN I-NP O
48 1332 1334 9875685 in IN B-PP O
49 1335 1337 9875685 TD NN B-NP O
50 1337 1338 9875685 ) ) O O
51 1338 1339 9875685 , , O O
52 1340 1342 9875685 Vd NN B-NP O
53 1343 1344 9875685 ( ( O O
54 1344 1349 9875685 0.35+ SYM B-NP O
55 1349 1350 9875685 / SYM O O
56 1350 1351 9875685 - SYM O O
57 1351 1355 9875685 0.11 CD B-NP O
58 1356 1357 9875685 l NN I-NP O
59 1357 1358 9875685 / SYM B-NP O
60 1358 1360 9875685 kg NN I-NP O
61 1361 1363 9875685 in IN B-PP O
62 1364 1366 9875685 OD NN B-NP O
63 1367 1369 9875685 vs NNS I-NP O
64 1369 1370 9875685 . . O O
65 1371 1376 9875685 0.33+ JJ B-NP O
66 1376 1377 9875685 / SYM I-NP O
67 1377 1378 9875685 - SYM I-NP O
68 1378 1382 9875685 0.09 CD B-NP O
69 1383 1384 9875685 l NN I-NP O
70 1384 1385 9875685 / SYM B-NP O
71 1385 1387 9875685 kg NN I-NP O
72 1388 1390 9875685 in IN B-PP O
73 1391 1393 9875685 TD NN B-NP O
74 1393 1394 9875685 ) ) O O
75 1394 1395 9875685 , , O O
76 1396 1398 9875685 Cl NN B-NP O
77 1399 1400 9875685 ( ( O O
78 1400 1405 9875685 0.86+ SYM B-NP O
79 1405 1406 9875685 / SYM O O
80 1406 1407 9875685 - SYM O O
81 1407 1411 9875685 0.29 CD B-NP O
82 1412 1414 9875685 ml NN I-NP O
83 1414 1415 9875685 / SYM B-NP O
84 1415 1418 9875685 min NN I-NP O
85 1418 1419 9875685 / SYM B-NP O
86 1419 1421 9875685 kg NN I-NP O
87 1422 1424 9875685 in IN B-PP O
88 1425 1427 9875685 OD NN B-NP O
89 1428 1430 9875685 vs NNS I-NP O
90 1430 1431 9875685 . . O O
91 1432 1437 9875685 1.28+ CD B-NP O
92 1437 1438 9875685 / SYM O O
93 1438 1439 9875685 - SYM O O
94 1439 1443 9875685 0.33 CD B-NP O
95 1444 1446 9875685 ml NN I-NP O
96 1446 1447 9875685 / SYM B-NP O
97 1447 1450 9875685 min NN I-NP O
98 1450 1451 9875685 / SYM B-NP O
99 1451 1453 9875685 kg NN I-NP O
100 1454 1456 9875685 in IN B-PP O
101 1457 1459 9875685 TD NN B-NP O
102 1459 1460 9875685 ) ) O O
103 1460 1461 9875685 . . O O

1 1462 1471 9875685 Increased VBN B-NP O
2 1472 1477 9875685 serum NN I-NP O
3 1478 1488 9875685 creatinine NN I-NP D003404
4 1489 1492 9875685 was VBD B-VP O
5 1493 1501 9875685 observed VBN I-VP O
6 1502 1504 9875685 in IN B-PP O
7 1505 1508 9875685 73% CD B-NP O
8 1509 1511 9875685 of IN B-PP O
9 1512 1520 9875685 patients NNS B-NP O
10 1521 1523 9875685 in IN B-PP O
11 1524 1526 9875685 OD NN B-NP O
12 1527 1533 9875685 versus IN B-PP O
13 1534 1537 9875685 57% NN B-NP O
14 1538 1540 9875685 of IN B-PP O
15 1541 1549 9875685 patients NNS B-NP O
16 1550 1552 9875685 in IN B-PP O
17 1553 1555 9875685 TD NN B-NP O
18 1555 1556 9875685 , , O O
19 1557 1564 9875685 without IN B-PP O
20 1565 1573 9875685 evidence NN B-NP O
21 1574 1576 9875685 of IN B-PP O
22 1577 1591 9875685 nephrotoxicity NN B-NP D007674
23 1591 1592 9875685 . . O O

1 1593 1595 9875685 In IN B-PP O
2 1596 1598 9875685 TD NN B-NP O
3 1599 1604 9875685 group NN I-NP O
4 1604 1605 9875685 , , O O
5 1606 1611 9875685 three CD B-NP O
6 1612 1620 9875685 patients NNS I-NP O
7 1621 1630 9875685 developed VBD B-VP O
8 1631 1640 9875685 decreased VBN I-VP D034381
9 1641 1649 9875685 auditory JJ B-NP D034381
10 1650 1658 9875685 function NN I-NP D034381
11 1658 1659 9875685 , , O O
12 1660 1662 9875685 of IN B-PP O
13 1663 1668 9875685 which WDT B-NP O
14 1669 1672 9875685 one CD B-NP O
15 1673 1682 9875685 presented VBD B-VP O
16 1683 1687 9875685 with IN B-PP O
17 1688 1690 9875685 an DT B-NP O
18 1691 1699 9875685 auditory JJ I-NP D034381
19 1700 1704 9875685 loss NN I-NP D034381
20 1705 1707 9875685 of IN B-PP O
21 1708 1709 9875685 - SYM B-NP O
22 1709 1711 9875685 30 CD I-NP O
23 1712 1714 9875685 dB NN I-NP O
24 1714 1715 9875685 , , O O
25 1716 1723 9875685 whereas IN O O
26 1724 1726 9875685 in IN B-PP O
27 1727 1730 9875685 the DT B-NP O
28 1731 1733 9875685 OD NN I-NP O
29 1734 1739 9875685 group NN I-NP O
30 1740 1744 9875685 only RB B-NP O
31 1745 1748 9875685 one CD I-NP O
32 1749 1756 9875685 patient NN I-NP O
33 1757 1766 9875685 presented VBN B-VP O
34 1767 1776 9875685 decreased VBD B-VP D034381
35 1777 1785 9875685 auditory JJ B-NP D034381
36 1786 1794 9875685 function NN I-NP D034381
37 1794 1795 9875685 . . O O

1 1796 1806 9875685 CONCLUSION NN B-NP O
2 1806 1807 9875685 : : O O
3 1808 1812 9875685 This DT B-NP O
4 1813 1818 9875685 small JJ I-NP O
5 1819 1824 9875685 study NN I-NP O
6 1825 1833 9875685 suggests VBZ B-VP O
7 1834 1838 9875685 that IN B-SBAR O
8 1839 1840 9875685 a DT B-NP O
9 1841 1845 9875685 once RB I-NP O
10 1845 1846 9875685 - HYPH I-NP O
11 1846 1851 9875685 daily JJ I-NP O
12 1852 1858 9875685 dosing NN I-NP O
13 1859 1866 9875685 regimen NN I-NP O
14 1867 1869 9875685 of IN B-PP O
15 1870 1880 9875685 tobramycin NN B-NP D014031
16 1881 1883 9875685 is VBZ B-VP O
17 1884 1886 9875685 at IN B-ADVP O
18 1887 1892 9875685 least JJS I-ADVP O
19 1893 1895 9875685 as RB B-ADJP O
20 1896 1905 9875685 effective JJ I-ADJP O
21 1906 1908 9875685 as IN B-PP O
22 1909 1912 9875685 and CC O O
23 1913 1915 9875685 is VBZ B-VP O
24 1916 1918 9875685 no RB B-NP O
25 1919 1923 9875685 more JJR I-NP O
26 1924 1927 9875685 and CC I-NP O
27 1928 1936 9875685 possibly RB I-NP O
28 1937 1941 9875685 less RBR I-NP O
29 1942 1947 9875685 toxic JJ I-NP O
30 1948 1952 9875685 than IN B-PP O
31 1953 1956 9875685 the DT B-NP O
32 1957 1962 9875685 twice RB I-NP O
33 1962 1963 9875685 - HYPH I-NP O
34 1963 1968 9875685 daily JJ I-NP O
35 1969 1976 9875685 regimen NN I-NP O
36 1976 1977 9875685 . . O O

1 1978 1983 9875685 Using VBG B-VP O
2 1984 1985 9875685 a DT B-NP O
3 1986 1992 9875685 single JJ I-NP O
4 1992 1993 9875685 - HYPH I-NP O
5 1993 1997 9875685 dose NN I-NP O
6 1998 2005 9875685 therapy NN I-NP O
7 2005 2006 9875685 , , O O
8 2007 2011 9875685 peak JJ B-NP O
9 2012 2025 9875685 concentration NN I-NP O
10 2026 2039 9875685 determination NN I-NP O
11 2040 2042 9875685 is VBZ B-VP O
12 2043 2046 9875685 not RB O O
13 2047 2056 9875685 necessary JJ B-ADJP O
14 2056 2057 9875685 , , O O
15 2058 2062 9875685 only RB B-NP O
16 2063 2069 9875685 trough NN I-NP O
17 2070 2077 9875685 samples NNS I-NP O
18 2078 2084 9875685 should MD B-VP O
19 2085 2087 9875685 be VB I-VP O
20 2088 2097 9875685 monitored VBN I-VP O
21 2098 2100 9875685 to TO B-VP O
22 2101 2107 9875685 ensure VB I-VP O
23 2108 2114 9875685 levels NNS B-NP O
24 2115 2120 9875685 below IN B-PP O
25 2121 2122 9875685 2 CD B-NP O
26 2123 2129 9875685 microg NN I-NP O
27 2129 2130 9875685 / SYM B-NP O
28 2130 2132 9875685 ml NN I-NP O
29 2132 2133 9875685 . . O O

1 0 0 10354657 -DOCSTART- -X- -X- O

1 0 6 10354657 Effect NN B-NP O
2 7 9 10354657 of IN B-PP O
3 10 17 10354657 lithium NN B-NP D008094
4 18 29 10354657 maintenance NN I-NP O
5 30 37 10354657 therapy NN I-NP O
6 38 40 10354657 on IN B-PP O
7 41 48 10354657 thyroid NN B-NP O
8 49 52 10354657 and CC I-NP O
9 53 64 10354657 parathyroid JJ I-NP O
10 65 73 10354657 function NN I-NP O
11 73 74 10354657 . . I-NP O
12 75 85 10354657 OBJECTIVES NNS I-NP O
13 85 86 10354657 : : O O
14 87 89 10354657 To TO B-VP O
15 90 96 10354657 assess VB I-VP O
16 97 104 10354657 changes NNS B-NP O
17 105 112 10354657 induced VBN B-VP O
18 113 115 10354657 by IN B-PP O
19 116 123 10354657 lithium NN B-NP D008094
20 124 135 10354657 maintenance NN I-NP O
21 136 143 10354657 therapy NN I-NP O
22 144 146 10354657 on IN B-PP O
23 147 150 10354657 the DT B-NP O
24 151 160 10354657 incidence NN I-NP O
25 161 163 10354657 of IN B-PP O
26 164 171 10354657 thyroid NN B-NP O
27 171 172 10354657 , , I-NP O
28 173 184 10354657 parathyroid NN I-NP O
29 185 188 10354657 and CC I-NP O
30 189 192 10354657 ion NN I-NP O
31 193 204 10354657 alterations NNS I-NP O
32 204 205 10354657 . . O O

1 206 211 10354657 These DT B-NP O
2 212 216 10354657 were VBD B-VP O
3 217 226 10354657 evaluated VBN I-VP O
4 227 231 10354657 with IN B-PP O
5 232 239 10354657 respect NN B-NP O
6 240 242 10354657 to TO B-PP O
7 243 246 10354657 the DT B-NP O
8 247 255 10354657 duration NN I-NP O
9 256 258 10354657 of IN B-PP O
10 259 266 10354657 lithium NN B-NP D008094
11 267 274 10354657 therapy NN I-NP O
12 274 275 10354657 , , O O
13 276 279 10354657 age NN B-NP O
14 279 280 10354657 , , O O
15 281 284 10354657 sex NN B-NP O
16 284 285 10354657 , , O O
17 286 289 10354657 and CC O O
18 290 296 10354657 family NN B-NP O
19 297 304 10354657 history NN I-NP O
20 305 306 10354657 ( ( O O
21 306 313 10354657 whether IN B-SBAR O
22 314 316 10354657 or CC O O
23 317 320 10354657 not RB O O
24 321 324 10354657 the DT B-NP O
25 325 332 10354657 patient NN I-NP O
26 333 336 10354657 had VBD B-VP O
27 337 338 10354657 a DT B-NP O
28 339 344 10354657 first JJ I-NP O
29 344 345 10354657 - HYPH I-NP O
30 345 351 10354657 degree NN I-NP O
31 352 360 10354657 relative JJ B-ADJP O
32 361 365 10354657 with IN B-PP O
33 366 373 10354657 thyroid JJ B-NP D013959
34 374 381 10354657 disease NN I-NP D013959
35 381 382 10354657 ) ) O O
36 382 383 10354657 . . O O

1 384 390 10354657 DESIGN NN B-NP O
2 390 391 10354657 : : O O
3 392 403 10354657 Prospective JJ B-NP O
4 404 409 10354657 study NN I-NP O
5 409 410 10354657 . . O O

1 411 418 10354657 SETTING NN B-NP O
2 418 419 10354657 : : O O
3 420 429 10354657 Affective JJ B-NP O
4 430 439 10354657 Disorders NNP I-NP O
5 440 446 10354657 Clinic NNP I-NP O
6 447 449 10354657 at IN B-PP O
7 450 452 10354657 St NNP B-NP O
8 452 453 10354657 . . O O

1 454 460 10354657 Mary's NNP B-NP O
2 461 469 10354657 Hospital NNP I-NP O
3 469 470 10354657 , , O O
4 471 479 10354657 Montreal NNP B-NP O
5 479 480 10354657 . . O O

1 481 489 10354657 PATIENTS NNS B-NP O
2 489 490 10354657 : : O O
3 491 494 10354657 One CD B-NP O
4 495 502 10354657 hundred CD I-NP O
5 503 506 10354657 and CC O O
6 507 510 10354657 one CD B-NP O
7 511 519 10354657 patients NNS I-NP O
8 520 521 10354657 ( ( O O
9 521 523 10354657 28 CD B-NP O
10 524 527 10354657 men NNS I-NP O
11 528 531 10354657 and CC O O
12 532 534 10354657 73 CD B-NP O
13 535 540 10354657 women NNS I-NP O
14 540 541 10354657 ) ) O O
15 542 546 10354657 with IN B-PP O
16 547 554 10354657 bipolar JJ B-NP D001714
17 555 563 10354657 disorder NN I-NP D001714
18 564 573 10354657 receiving VBG B-VP O
19 574 581 10354657 lithium NN B-NP D008094
20 582 593 10354657 maintenance NN I-NP O
21 594 601 10354657 therapy NN I-NP O
22 602 609 10354657 ranging VBG B-VP O
23 610 614 10354657 from IN B-PP O
24 615 616 10354657 1 CD B-NP O
25 617 623 10354657 year's NNS I-NP O
26 624 626 10354657 to TO B-PP O
27 627 629 10354657 32 CD B-NP O
28 630 635 10354657 years NNS I-NP O
29 635 636 10354657 ' POS B-NP O
30 637 645 10354657 duration NN I-NP O
31 645 646 10354657 . . O O

1 647 650 10354657 The DT B-NP O
2 651 658 10354657 control NN I-NP O
3 659 664 10354657 group NN I-NP O
4 665 674 10354657 consisted VBD B-VP O
5 675 677 10354657 of IN B-PP O
6 678 680 10354657 82 CD B-NP O
7 681 689 10354657 patients NNS I-NP O
8 690 694 10354657 with IN B-PP O
9 695 697 10354657 no DT B-NP O
10 698 709 10354657 psychiatric JJ I-NP D001523
11 710 712 10354657 or CC I-NP O
12 713 729 10354657 endocrinological JJ I-NP O
13 730 739 10354657 diagnoses NNS I-NP O
14 740 744 10354657 from IN B-PP O
15 745 748 10354657 the DT B-NP O
16 749 759 10354657 hospital's NNS I-NP O
17 760 763 10354657 out RP B-PRT O
18 763 764 10354657 - HYPH B-NP O
19 764 771 10354657 patient NN I-NP O
20 772 779 10354657 clinics NNS I-NP O
21 779 780 10354657 . . O O

1 781 788 10354657 OUTCOME NN B-NP O
2 789 797 10354657 MEASURES NNS I-NP O
3 797 798 10354657 : : O O
4 799 809 10354657 Laboratory NN B-NP O
5 810 818 10354657 analyses NNS I-NP O
6 819 821 10354657 of IN B-PP O
7 822 829 10354657 calcium NN B-NP D002118
8 829 830 10354657 , , I-NP O
9 831 840 10354657 magnesium NN I-NP D008274
10 841 844 10354657 and CC I-NP O
11 845 852 10354657 thyroid NN I-NP O
12 852 853 10354657 - HYPH O O
13 853 864 10354657 stimulating VBG B-VP O
14 865 872 10354657 hormone NN B-NP O
15 873 879 10354657 levels NNS I-NP O
16 880 889 10354657 performed VBN B-VP O
17 890 896 10354657 before IN B-PP O
18 897 906 10354657 beginning VBG B-VP O
19 907 914 10354657 lithium NN B-NP D008094
20 915 922 10354657 therapy NN I-NP O
21 923 926 10354657 and CC B-PP O
22 927 929 10354657 at IN B-PP O
23 930 938 10354657 biannual JJ B-NP O
24 939 945 10354657 follow VB I-NP O
25 945 946 10354657 - HYPH B-VP O
26 946 948 10354657 up RP B-PRT O
27 948 949 10354657 . . O O

1 950 957 10354657 RESULTS NNS B-NP O
2 957 958 10354657 : : O O
3 959 973 10354657 Hypothyroidism NN B-NP D007037
4 974 983 10354657 developed VBD B-VP O
5 984 986 10354657 in IN B-PP O
6 987 989 10354657 40 CD B-NP O
7 990 998 10354657 patients NNS I-NP O
8 998 999 10354657 , , O O
9 1000 1009 10354657 excluding VBG B-PP O
10 1010 1011 10354657 8 CD B-NP O
11 1012 1020 10354657 patients NNS I-NP O
12 1021 1024 10354657 who WP B-NP O
13 1025 1029 10354657 were VBD B-VP O
14 1030 1041 10354657 hypothyroid NN B-NP D007037
15 1042 1044 10354657 at IN B-PP O
16 1045 1053 10354657 baseline NN B-NP O
17 1053 1054 10354657 . . O O

1 1055 1058 10354657 All DT B-NP O
2 1059 1067 10354657 patients NNS I-NP O
3 1068 1074 10354657 having VBG B-VP O
4 1075 1080 10354657 first JJ B-NP O
5 1080 1081 10354657 - HYPH I-NP O
6 1081 1087 10354657 degree NN I-NP O
7 1088 1097 10354657 relatives NNS I-NP O
8 1098 1106 10354657 affected VBN B-VP O
9 1107 1109 10354657 by IN B-PP O
10 1110 1117 10354657 thyroid JJ B-NP D013959
11 1118 1125 10354657 illness NN I-NP D013959
12 1126 1129 10354657 had VBD B-VP O
13 1130 1141 10354657 accelerated VBN I-VP O
14 1142 1147 10354657 onset NN B-NP O
15 1148 1150 10354657 of IN B-PP O
16 1151 1165 10354657 hypothyroidism NN B-NP D007037
17 1166 1167 10354657 ( ( O O
18 1167 1170 10354657 3.7 CD B-NP O
19 1171 1176 10354657 years NNS I-NP O
20 1177 1182 10354657 after IN B-PP O
21 1183 1188 10354657 onset NN B-NP O
22 1189 1191 10354657 of IN B-PP O
23 1192 1199 10354657 lithium NN B-NP D008094
24 1200 1207 10354657 therapy NN I-NP O
25 1207 1208 10354657 ) ) O O
26 1209 1217 10354657 compared VBN B-PP O
27 1218 1222 10354657 with IN B-PP O
28 1223 1231 10354657 patients NNS B-NP O
29 1232 1239 10354657 without IN B-PP O
30 1240 1241 10354657 a DT B-NP O
31 1242 1248 10354657 family NN I-NP O
32 1249 1256 10354657 history NN I-NP O
33 1257 1258 10354657 ( ( O O
34 1258 1261 10354657 8.6 CD B-NP O
35 1262 1267 10354657 years NNS I-NP O
36 1268 1273 10354657 after IN B-PP O
37 1274 1279 10354657 onset NN B-NP O
38 1280 1282 10354657 of IN B-PP O
39 1283 1290 10354657 lithium NN B-NP D008094
40 1291 1298 10354657 therapy NN I-NP O
41 1298 1299 10354657 ) ) O O
42 1299 1300 10354657 . . O O

1 1301 1306 10354657 Women NNS B-NP O
2 1307 1311 10354657 over IN B-PP O
3 1312 1314 10354657 60 CD B-NP O
4 1315 1320 10354657 years NNS I-NP O
5 1321 1323 10354657 of IN B-PP O
6 1324 1327 10354657 age NN B-NP O
7 1328 1332 10354657 were VBD B-VP O
8 1333 1337 10354657 more RBR I-VP O
9 1338 1343 10354657 often RB I-VP O
10 1344 1352 10354657 affected VBN I-VP O
11 1353 1355 10354657 by IN B-PP O
12 1356 1370 10354657 hypothyroidism NN B-NP D007037
13 1371 1375 10354657 than IN B-PP O
14 1376 1381 10354657 women NNS B-NP O
15 1382 1387 10354657 under IN B-PP O
16 1388 1390 10354657 60 CD B-NP O
17 1391 1396 10354657 years NNS I-NP O
18 1397 1399 10354657 of IN B-PP O
19 1400 1403 10354657 age NN B-NP O
20 1404 1405 10354657 ( ( O O
21 1405 1410 10354657 34.6% CD B-NP O
22 1411 1417 10354657 versus CC I-NP O
23 1418 1423 10354657 31.9% CD I-NP O
24 1423 1424 10354657 ) ) O O
25 1424 1425 10354657 . . O O

1 1426 1435 10354657 Magnesium NN B-NP D008274
2 1436 1442 10354657 levels NNS I-NP O
3 1443 1445 10354657 in IN B-PP O
4 1446 1454 10354657 patients NNS B-NP O
5 1455 1457 10354657 on IN B-PP O
6 1458 1465 10354657 lithium NN B-NP D008094
7 1466 1475 10354657 treatment NN I-NP O
8 1476 1480 10354657 were VBD B-VP O
9 1481 1490 10354657 unchanged JJ B-ADJP O
10 1491 1495 10354657 from IN B-PP O
11 1496 1504 10354657 baseline NN B-NP O
12 1505 1511 10354657 levels NNS I-NP O
13 1511 1512 10354657 . . O O

1 1513 1518 10354657 After IN B-PP O
2 1519 1526 10354657 lithium NN B-NP D008094
3 1527 1536 10354657 treatment NN I-NP O
4 1536 1537 10354657 , , O O
5 1538 1545 10354657 calcium NN B-NP D002118
6 1546 1552 10354657 levels NNS I-NP O
7 1553 1557 10354657 were VBD B-VP O
8 1558 1564 10354657 higher JJR B-ADJP O
9 1565 1569 10354657 than IN B-PP O
10 1570 1576 10354657 either DT B-NP O
11 1577 1585 10354657 baseline NN I-NP O
12 1586 1592 10354657 levels NNS I-NP O
13 1593 1595 10354657 or CC O O
14 1596 1603 10354657 control NN B-NP O
15 1604 1610 10354657 levels NNS I-NP O
16 1610 1611 10354657 . . O O

1 1612 1616 10354657 Thus RB B-ADVP O
2 1616 1617 10354657 , , O O
3 1618 1625 10354657 lithium NN B-NP D008094
4 1626 1635 10354657 treatment NN I-NP O
5 1636 1648 10354657 counteracted VBD B-VP O
6 1649 1652 10354657 the DT B-NP O
7 1653 1661 10354657 decrease NN I-NP O
8 1662 1664 10354657 in IN B-PP O
9 1665 1671 10354657 plasma NN B-NP O
10 1672 1679 10354657 calcium NN I-NP D002118
11 1680 1686 10354657 levels NNS I-NP O
12 1687 1697 10354657 associated VBN B-VP O
13 1698 1702 10354657 with IN B-PP O
14 1703 1708 10354657 aging NN B-NP O
15 1708 1709 10354657 . . O O

1 1710 1721 10354657 CONCLUSIONS NNS B-NP O
2 1721 1722 10354657 : : O O
3 1723 1731 10354657 Familial JJ B-NP O
4 1732 1739 10354657 thyroid NN I-NP D013959
5 1740 1747 10354657 illness NN I-NP D013959
6 1748 1750 10354657 is VBZ B-VP O
7 1751 1752 10354657 a DT B-NP O
8 1753 1757 10354657 risk NN I-NP O
9 1758 1764 10354657 factor NN I-NP O
10 1765 1768 10354657 for IN B-PP O
11 1769 1783 10354657 hypothyroidism NN B-NP D007037
12 1784 1787 10354657 and CC I-NP O
13 1788 1801 10354657 hypercalcemia NN I-NP D006934
14 1802 1808 10354657 during IN B-PP O
15 1809 1816 10354657 lithium NN B-NP D008094
16 1817 1824 10354657 therapy NN I-NP O
17 1824 1825 10354657 . . O O

1 0 0 18627295 -DOCSTART- -X- -X- O

1 0 11 18627295 Doxorubicin NN B-NP D004317
2 12 26 18627295 cardiomyopathy NN I-NP D009202
3 26 27 18627295 - HYPH B-NP O
4 27 34 18627295 induced VBN I-NP O
5 35 47 18627295 inflammation NN I-NP D007249
6 48 51 18627295 and CC I-NP O
7 52 61 18627295 apoptosis NN I-NP O
8 62 65 18627295 are VBP B-VP O
9 66 76 18627295 attenuated VBN I-VP O
10 77 79 18627295 by IN B-PP O
11 80 84 18627295 gene NN B-NP O
12 85 93 18627295 deletion NN I-NP O
13 94 96 18627295 of IN B-PP O
14 97 100 18627295 the DT B-NP O
15 101 106 18627295 kinin NN I-NP O
16 107 109 18627295 B1 NN I-NP O
17 110 118 18627295 receptor NN I-NP O
18 118 119 18627295 . . O O
19 120 128 18627295 Clinical JJ B-NP O
20 129 132 18627295 use NN I-NP O
21 133 135 18627295 of IN B-PP O
22 136 139 18627295 the DT B-NP O
23 140 153 18627295 anthracycline NN I-NP D018943
24 154 165 18627295 doxorubicin NN I-NP D004317
25 166 167 18627295 ( ( O O
26 167 170 18627295 DOX NN B-NP D004317
27 170 171 18627295 ) ) O O
28 172 174 18627295 is VBZ B-VP O
29 175 182 18627295 limited VBN I-VP O
30 183 185 18627295 by IN B-PP O
31 186 189 18627295 its PRP$ B-NP O
32 190 201 18627295 cardiotoxic JJ I-NP D066126
33 202 209 18627295 effects NNS I-NP O
34 209 210 18627295 , , O O
35 211 216 18627295 which WDT B-NP O
36 217 220 18627295 are VBP B-VP O
37 221 231 18627295 attributed VBN I-VP O
38 232 234 18627295 to TO B-PP O
39 235 238 18627295 the DT B-NP O
40 239 248 18627295 induction NN I-NP O
41 249 251 18627295 of IN B-PP O
42 252 261 18627295 apoptosis NN B-NP O
43 261 262 18627295 . . O O

1 263 265 18627295 To TO B-VP O
2 266 275 18627295 elucidate VB I-VP O
3 276 279 18627295 the DT B-NP O
4 280 288 18627295 possible JJ I-NP O
5 289 293 18627295 role NN I-NP O
6 294 296 18627295 of IN B-PP O
7 297 300 18627295 the DT B-NP O
8 301 306 18627295 kinin NN I-NP O
9 307 309 18627295 B1 NN I-NP O
10 310 318 18627295 receptor NN I-NP O
11 319 320 18627295 ( ( O O
12 320 323 18627295 B1R NN B-NP O
13 323 324 18627295 ) ) O O
14 325 331 18627295 during IN B-PP O
15 332 335 18627295 the DT B-NP O
16 336 347 18627295 development NN I-NP O
17 348 350 18627295 of IN B-PP O
18 351 354 18627295 DOX NN B-NP D004317
19 355 369 18627295 cardiomyopathy NN I-NP D009202
20 369 370 18627295 , , O O
21 371 373 18627295 we PRP B-NP O
22 374 381 18627295 studied VBD B-VP O
23 382 385 18627295 B1R NN B-NP O
24 386 394 18627295 knockout NN I-NP O
25 395 399 18627295 mice NNS I-NP O
26 400 401 18627295 ( ( O O
27 401 405 18627295 B1R( NN B-NP O
28 405 406 18627295 - HYPH O O
29 406 407 18627295 / SYM O O
30 407 408 18627295 - SYM O O
31 408 409 18627295 ) ) O O
32 409 410 18627295 ) ) O O
33 411 413 18627295 by IN B-PP O
34 414 427 18627295 investigating VBG B-VP O
35 428 435 18627295 cardiac JJ B-NP O
36 436 448 18627295 inflammation NN I-NP D007249
37 449 452 18627295 and CC I-NP O
38 453 462 18627295 apoptosis NN I-NP O
39 463 468 18627295 after IN B-PP O
40 469 478 18627295 induction NN B-NP O
41 479 481 18627295 of IN B-PP O
42 482 485 18627295 DOX NN B-NP D004317
43 485 486 18627295 - HYPH B-NP O
44 486 493 18627295 induced VBN I-NP O
45 494 508 18627295 cardiomyopathy NN I-NP D009202
46 508 509 18627295 . . O O

1 510 513 18627295 DOX NN B-NP D004317
2 514 521 18627295 control NN I-NP O
3 522 526 18627295 mice NNS I-NP O
4 527 533 18627295 showed VBD B-VP O
5 534 541 18627295 cardiac JJ B-NP D006331
6 542 553 18627295 dysfunction NN I-NP D006331
7 554 562 18627295 measured VBN B-VP O
8 563 565 18627295 by IN B-PP O
9 566 574 18627295 pressure NN B-NP O
10 574 575 18627295 - HYPH O O
11 575 581 18627295 volume NN B-NP O
12 582 587 18627295 loops VBZ B-VP O
13 588 590 18627295 in FW B-ADVP O
14 591 595 18627295 vivo FW I-ADVP O
15 595 596 18627295 . . O O

1 597 601 18627295 This DT B-NP O
2 602 605 18627295 was VBD B-VP O
3 606 616 18627295 associated VBN I-VP O
4 617 621 18627295 with IN B-PP O
5 622 623 18627295 a DT B-NP O
6 624 631 18627295 reduced VBN I-NP O
7 632 642 18627295 activation NN I-NP O
8 643 648 18627295 state NN I-NP O
9 649 651 18627295 of IN B-PP O
10 652 655 18627295 AKT NN B-NP O
11 655 656 18627295 , , O O
12 657 659 18627295 as RB B-CONJP O
13 660 664 18627295 well RB I-CONJP O
14 665 667 18627295 as IN I-CONJP O
15 668 670 18627295 an DT B-NP O
16 671 680 18627295 increased VBN I-NP O
17 681 684 18627295 bax NN I-NP O
18 684 685 18627295 / SYM O O
19 685 689 18627295 bcl2 NN B-NP O
20 690 695 18627295 ratio NN I-NP O
21 696 698 18627295 in IN B-PP O
22 699 706 18627295 Western JJ B-NP O
23 707 712 18627295 blots NNS I-NP O
24 712 713 18627295 , , O O
25 714 724 18627295 indicating VBG B-VP O
26 725 732 18627295 cardiac JJ B-NP D006331
27 733 742 18627295 apoptosis NN I-NP D006331
28 742 743 18627295 . . O O

1 744 755 18627295 Furthermore RB B-ADVP O
2 755 756 18627295 , , O O
3 757 761 18627295 mRNA NN B-NP O
4 762 768 18627295 levels NNS I-NP O
5 769 771 18627295 of IN B-PP O
6 772 775 18627295 the DT B-NP O
7 776 791 18627295 proinflammatory JJ I-NP O
8 792 800 18627295 cytokine NN I-NP O
9 801 812 18627295 interleukin NN I-NP O
10 813 814 18627295 6 CD I-NP O
11 815 819 18627295 were VBD B-VP O
12 820 829 18627295 increased VBN I-VP O
13 830 832 18627295 in IN B-PP O
14 833 836 18627295 the DT B-NP O
15 837 844 18627295 cardiac JJ I-NP O
16 845 851 18627295 tissue NN I-NP O
17 851 852 18627295 . . O O

1 853 855 18627295 In IN B-PP O
2 856 859 18627295 DOX NN B-NP D004317
3 860 864 18627295 B1R( NN I-NP O
4 864 865 18627295 - HYPH O O
5 865 866 18627295 / SYM O O
6 866 867 18627295 - SYM O O
7 867 868 18627295 ) ) O O
8 869 873 18627295 mice NNS B-NP O
9 873 874 18627295 , , O O
10 875 882 18627295 cardiac JJ B-NP D006331
11 883 894 18627295 dysfunction NN I-NP D006331
12 895 898 18627295 was VBD B-VP O
13 899 907 18627295 improved VBN I-VP O
14 908 916 18627295 compared VBN B-PP O
15 917 919 18627295 to TO B-PP O
16 920 923 18627295 DOX NN B-NP D004317
17 924 931 18627295 control NN I-NP O
18 932 936 18627295 mice NNS I-NP O
19 936 937 18627295 , , O O
20 938 943 18627295 which WDT B-NP O
21 944 947 18627295 was VBD B-VP O
22 948 958 18627295 associated VBN I-VP O
23 959 963 18627295 with IN B-PP O
24 964 977 18627295 normalization NN B-NP O
25 978 980 18627295 of IN B-PP O
26 981 984 18627295 the DT B-NP O
27 985 988 18627295 bax NN I-NP O
28 988 989 18627295 / SYM B-NP O
29 989 992 18627295 bcl NN I-NP O
30 992 993 18627295 - HYPH O O
31 993 994 18627295 2 CD B-NP O
32 995 1000 18627295 ratio NN I-NP O
33 1001 1004 18627295 and CC O O
34 1005 1016 18627295 interleukin NN B-NP O
35 1017 1018 18627295 6 CD I-NP O
36 1018 1019 18627295 , , O O
37 1020 1022 18627295 as RB B-CONJP O
38 1023 1027 18627295 well RB I-CONJP O
39 1028 1030 18627295 as IN I-CONJP O
40 1031 1034 18627295 AKT NN B-NP O
41 1035 1045 18627295 activation NN I-NP O
42 1046 1051 18627295 state NN I-NP O
43 1051 1052 18627295 . . O O

1 1053 1058 18627295 These DT B-NP O
2 1059 1067 18627295 findings NNS I-NP O
3 1068 1075 18627295 suggest VBP B-VP O
4 1076 1080 18627295 that IN B-SBAR O
5 1081 1084 18627295 B1R NN B-NP O
6 1085 1087 18627295 is VBZ B-VP O
7 1088 1099 18627295 detrimental JJ B-ADJP O
8 1100 1102 18627295 in IN B-PP O
9 1103 1106 18627295 DOX NN B-NP D004317
10 1107 1121 18627295 cardiomyopathy NN I-NP D009202
11 1122 1124 18627295 in IN B-PP O
12 1125 1129 18627295 that IN B-NP O
13 1130 1132 18627295 it PRP B-NP O
14 1133 1141 18627295 mediates VBZ B-VP O
15 1142 1145 18627295 the DT B-NP O
16 1146 1158 18627295 inflammatory JJ I-NP O
17 1159 1167 18627295 response NN I-NP O
18 1168 1171 18627295 and CC I-NP O
19 1172 1181 18627295 apoptosis NN I-NP O
20 1181 1182 18627295 . . O O

1 1183 1188 18627295 These DT B-NP O
2 1189 1197 18627295 insights NNS I-NP O
3 1198 1203 18627295 might MD B-VP O
4 1204 1208 18627295 have VB I-VP O
5 1209 1215 18627295 useful JJ B-NP O
6 1216 1228 18627295 implications NNS I-NP O
7 1229 1232 18627295 for IN B-PP O
8 1233 1239 18627295 future JJ B-NP O
9 1240 1247 18627295 studies NNS I-NP O
10 1248 1257 18627295 utilizing VBG B-VP O
11 1258 1261 18627295 B1R NN B-NP O
12 1262 1273 18627295 antagonists NNS I-NP O
13 1274 1277 18627295 for IN B-PP O
14 1278 1287 18627295 treatment NN B-NP O
15 1288 1290 18627295 of IN B-PP O
16 1291 1296 18627295 human JJ B-NP O
17 1297 1300 18627295 DOX NN I-NP D004317
18 1301 1315 18627295 cardiomyopathy NN I-NP D009202
19 1315 1316 18627295 . . O O

1 0 0 14742097 -DOCSTART- -X- -X- O

1 0 1 14742097 A DT B-NP O
2 2 12 14742097 randomized VBN I-NP O
3 12 13 14742097 , , I-NP O
4 14 21 14742097 placebo NN I-NP O
5 21 22 14742097 - HYPH I-NP O
6 22 32 14742097 controlled VBN B-VP O
7 32 33 14742097 , , O O
8 34 43 14742097 crossover NN B-NP O
9 44 49 14742097 study NN I-NP O
10 50 52 14742097 of IN B-PP O
11 53 62 14742097 ephedrine NN B-NP D004809
12 63 66 14742097 for IN B-PP O
13 67 71 14742097 SSRI NN B-NP O
14 71 72 14742097 - HYPH B-NP O
15 72 79 14742097 induced VBN I-NP O
16 80 86 14742097 female JJ I-NP O
17 87 93 14742097 sexual JJ I-NP D020018
18 94 105 14742097 dysfunction NN I-NP D020018
19 105 106 14742097 . . O O
20 107 110 14742097 The DT B-NP O
21 111 120 14742097 objective NN I-NP O
22 121 123 14742097 of IN B-PP O
23 124 128 14742097 this DT B-NP O
24 129 134 14742097 study NN I-NP O
25 135 138 14742097 was VBD B-VP O
26 139 141 14742097 to TO B-VP O
27 142 151 14742097 determine VB I-VP O
28 152 159 14742097 whether IN B-SBAR O
29 160 169 14742097 ephedrine NN B-NP D004809
30 169 170 14742097 , , O O
31 171 173 14742097 an DT B-NP O
32 174 179 14742097 alpha SYM I-NP O
33 179 180 14742097 - HYPH I-NP O
34 181 184 14742097 and CC O O
35 185 189 14742097 beta SYM B-NP O
36 189 190 14742097 - HYPH B-NP O
37 190 200 14742097 adrenergic JJ I-NP O
38 201 208 14742097 agonist NN I-NP O
39 209 219 14742097 previously RB B-VP O
40 220 225 14742097 shown VBN I-VP O
41 226 228 14742097 to TO I-VP O
42 229 236 14742097 enhance VB I-VP O
43 237 244 14742097 genital JJ B-NP O
44 245 250 14742097 blood NN I-NP O
45 251 255 14742097 flow NN I-NP O
46 256 258 14742097 in IN B-PP O
47 259 264 14742097 women NNS B-NP O
48 264 265 14742097 , , O O
49 266 269 14742097 has VBZ B-VP O
50 270 280 14742097 beneficial JJ B-NP O
51 281 288 14742097 effects NNS I-NP O
52 289 291 14742097 in IN B-PP O
53 292 301 14742097 reversing VBG B-VP O
54 302 316 14742097 antidepressant NN B-NP O
55 316 317 14742097 - HYPH O O
56 317 324 14742097 induced VBN B-NP O
57 325 331 14742097 sexual JJ I-NP D020018
58 332 343 14742097 dysfunction NN I-NP D020018
59 343 344 14742097 . . O O

1 345 353 14742097 Nineteen CD B-NP O
2 354 362 14742097 sexually RB I-NP D020018
3 363 376 14742097 dysfunctional JJ I-NP D020018
4 377 382 14742097 women NNS I-NP O
5 383 392 14742097 receiving VBG B-VP O
6 393 399 14742097 either CC O O
7 400 410 14742097 fluoxetine NN B-NP D005473
8 410 411 14742097 , , O O
9 412 422 14742097 sertraline NN B-NP D020280
10 422 423 14742097 , , O O
11 424 426 14742097 or CC O O
12 427 437 14742097 paroxetine NN B-NP D017374
13 438 450 14742097 participated VBD B-VP O
14 451 453 14742097 in IN B-PP O
15 454 456 14742097 an DT B-NP O
16 457 462 14742097 eight CD I-NP O
17 462 463 14742097 - HYPH I-NP O
18 463 467 14742097 week NN I-NP O
19 467 468 14742097 , , O O
20 469 475 14742097 double JJ B-NP O
21 475 476 14742097 - HYPH I-NP O
22 476 481 14742097 blind JJ I-NP O
23 481 482 14742097 , , I-NP O
24 483 490 14742097 placebo NN I-NP O
25 490 491 14742097 - HYPH I-NP O
26 491 501 14742097 controlled VBN B-VP O
27 501 502 14742097 , , O O
28 503 508 14742097 cross AFX B-NP O
29 508 509 14742097 - HYPH I-NP O
30 509 513 14742097 over IN B-PP O
31 514 519 14742097 study NN B-NP O
32 520 522 14742097 of IN B-PP O
33 523 526 14742097 the DT B-NP O
34 527 534 14742097 effects NNS I-NP O
35 535 537 14742097 of IN B-PP O
36 538 547 14742097 ephedrine NN B-NP D004809
37 548 549 14742097 ( ( O O
38 549 551 14742097 50 CD B-NP O
39 552 554 14742097 mg NN I-NP O
40 554 555 14742097 ) ) O O
41 556 558 14742097 on IN B-PP O
42 559 563 14742097 self AFX B-NP O
43 563 564 14742097 - HYPH I-NP O
44 564 570 14742097 report NN I-NP O
45 571 579 14742097 measures NNS I-NP O
46 580 582 14742097 of IN B-PP O
47 583 589 14742097 sexual JJ B-NP O
48 590 596 14742097 desire NN I-NP O
49 596 597 14742097 , , O O
50 598 605 14742097 arousal NN B-NP O
51 605 606 14742097 , , O O
52 607 613 14742097 orgasm NN B-NP O
53 613 614 14742097 , , O O
54 615 618 14742097 and CC O O
55 619 625 14742097 sexual JJ B-NP O
56 626 638 14742097 satisfaction NN I-NP O
57 638 639 14742097 . . O O

1 640 648 14742097 Although IN B-SBAR O
2 649 654 14742097 there EX B-NP O
3 655 659 14742097 were VBD B-VP O
4 660 671 14742097 significant JJ B-NP O
5 672 684 14742097 improvements NNS I-NP O
6 685 693 14742097 relative JJ B-ADJP O
7 694 696 14742097 to TO B-PP O
8 697 705 14742097 baseline NN B-NP O
9 706 708 14742097 in IN B-PP O
10 709 715 14742097 sexual JJ B-NP O
11 716 722 14742097 desire NN I-NP O
12 723 726 14742097 and CC I-NP O
13 727 733 14742097 orgasm NN I-NP O
14 734 743 14742097 intensity NN I-NP O
15 743 744 14742097 / SYM B-NP O
16 744 752 14742097 pleasure NN I-NP O
17 753 755 14742097 on IN B-PP O
18 756 758 14742097 50 CD B-NP O
19 759 761 14742097 mg NN I-NP O
20 762 771 14742097 ephedrine NN I-NP D004809
21 772 773 14742097 1 CD I-NP O
22 773 774 14742097 - HYPH I-NP O
23 774 776 14742097 hr NN I-NP O
24 777 782 14742097 prior JJ B-ADJP O
25 783 785 14742097 to TO B-PP O
26 786 792 14742097 sexual JJ B-NP O
27 793 801 14742097 activity NN I-NP O
28 801 802 14742097 , , O O
29 803 814 14742097 significant JJ B-NP O
30 815 827 14742097 improvements NNS I-NP O
31 828 830 14742097 in IN B-PP O
32 831 836 14742097 these DT B-NP O
33 837 845 14742097 measures NNS I-NP O
34 845 846 14742097 , , O O
35 847 849 14742097 as RB B-CONJP O
36 850 854 14742097 well RB I-CONJP O
37 855 857 14742097 as IN I-CONJP O
38 858 860 14742097 in IN B-PP O
39 861 867 14742097 sexual JJ B-NP O
40 868 875 14742097 arousal JJ I-NP O
41 876 879 14742097 and CC I-NP O
42 880 888 14742097 orgasmic JJ I-NP O
43 889 896 14742097 ability NN I-NP O
44 897 901 14742097 also RB B-ADVP O
45 902 906 14742097 were VBD B-VP O
46 907 912 14742097 noted VBN I-VP O
47 913 917 14742097 with IN B-PP O
48 918 925 14742097 placebo NN B-NP O
49 925 926 14742097 . . O O

1 927 932 14742097 These DT B-NP O
2 933 941 14742097 findings NNS I-NP O
3 942 951 14742097 highlight VBP B-VP O
4 952 955 14742097 the DT B-NP O
5 956 966 14742097 importance NN I-NP O
6 967 969 14742097 of IN B-PP O
7 970 980 14742097 conducting VBG B-VP O
8 981 988 14742097 placebo NN B-NP O
9 988 989 14742097 - HYPH B-NP O
10 989 999 14742097 controlled VBN I-NP O
11 1000 1006 14742097 trials NNS I-NP O
12 1007 1010 14742097 for IN B-PP O
13 1011 1015 14742097 this DT B-NP O
14 1016 1025 14742097 condition NN I-NP O
15 1025 1026 14742097 . . O O

1 0 0 6118280 -DOCSTART- -X- -X- O

1 0 12 6118280 Serotonergic JJ B-NP O
2 13 18 6118280 drugs NNS I-NP O
3 18 19 6118280 , , O O
4 20 35 6118280 benzodiazepines NNS B-NP D001569
5 36 39 6118280 and CC O O
6 40 48 6118280 baclofen NN B-NP D001418
7 49 54 6118280 block VBP B-VP O
8 55 63 6118280 muscimol NN B-NP D009118
9 63 64 6118280 - HYPH O O
10 64 71 6118280 induced VBN B-NP O
11 72 81 6118280 myoclonic JJ I-NP D009207
12 82 87 6118280 jerks NNS I-NP D009207
13 88 90 6118280 in IN B-PP O
14 91 92 6118280 a DT B-NP O
15 93 99 6118280 strain NN I-NP O
16 100 102 6118280 of IN B-PP O
17 103 107 6118280 mice NNS B-NP O
18 107 108 6118280 . . O O
19 109 111 6118280 In IN B-PP O
20 112 116 6118280 male JJ B-NP O
21 117 122 6118280 Swiss JJ I-NP O
22 123 127 6118280 mice NNS I-NP O
23 127 128 6118280 , , O O
24 129 137 6118280 muscimol NN B-NP D009118
25 138 146 6118280 produced VBD B-VP O
26 147 156 6118280 myoclonic JJ B-NP D009207
27 157 162 6118280 jerks NNS I-NP D009207
28 162 163 6118280 . . O O

1 164 165 6118280 A DT B-NP O
2 166 167 6118280 3 CD I-NP O
3 168 170 6118280 mg NN I-NP O
4 170 171 6118280 / SYM B-NP O
5 171 173 6118280 kg NN I-NP O
6 174 175 6118280 ( ( O O
7 175 178 6118280 i.p JJ O O
8 178 179 6118280 . . O O
9 179 180 6118280 ) ) O O
10 181 185 6118280 dose NN B-NP O
11 186 193 6118280 induced VBD B-VP O
12 194 198 6118280 this DT B-NP O
13 199 207 6118280 response NN I-NP O
14 208 210 6118280 in IN B-PP O
15 211 214 6118280 all DT B-NP O
16 215 217 6118280 of IN B-PP O
17 218 221 6118280 the DT B-NP O
18 222 226 6118280 mice NNS I-NP O
19 227 233 6118280 tested VBN B-VP O
20 234 237 6118280 and CC O O
21 238 241 6118280 the DT B-NP O
22 242 246 6118280 peak JJ I-NP O
23 247 255 6118280 response NN I-NP O
24 256 258 6118280 of IN B-PP O
25 259 261 6118280 73 CD B-NP O
26 262 267 6118280 jerks NNS I-NP O
27 268 271 6118280 per IN B-PP O
28 272 275 6118280 min NN B-NP O
29 276 279 6118280 was VBD B-VP O
30 280 288 6118280 observed VBN I-VP O
31 289 296 6118280 between IN B-PP O
32 297 299 6118280 27 CD B-NP O
33 300 303 6118280 and CC I-NP O
34 304 306 6118280 45 CD I-NP O
35 307 310 6118280 min NN I-NP O
36 310 311 6118280 . . O O

1 312 322 6118280 Increasing VBG B-VP O
2 323 326 6118280 the DT B-NP O
3 327 332 6118280 brain NN I-NP O
4 333 342 6118280 serotonin NN I-NP D012701
5 343 349 6118280 levels NNS I-NP O
6 350 352 6118280 by IN B-PP O
7 353 356 6118280 the DT B-NP O
8 357 371 6118280 administration NN I-NP O
9 372 374 6118280 of IN B-PP O
10 375 376 6118280 5 CD B-NP D006916
11 376 377 6118280 - HYPH I-NP D006916
12 377 394 6118280 hydroxytryptophan NN I-NP D006916
13 395 396 6118280 ( ( O O
14 396 398 6118280 80 CD B-NP O
15 398 399 6118280 - HYPH I-NP O
16 399 402 6118280 160 CD I-NP O
17 403 405 6118280 mg NN I-NP O
18 405 406 6118280 / SYM B-NP O
19 406 408 6118280 kg NN I-NP O
20 408 409 6118280 ) ) O O
21 410 412 6118280 in IN B-PP O
22 413 424 6118280 combination NN B-NP O
23 425 429 6118280 with IN B-PP O
24 430 431 6118280 a DT B-NP O
25 432 442 6118280 peripheral JJ I-NP O
26 443 456 6118280 decarboxylase NN I-NP O
27 457 466 6118280 inhibitor NN I-NP O
28 467 475 6118280 resulted VBD B-VP O
29 476 478 6118280 in IN B-PP O
30 479 481 6118280 an DT B-NP O
31 482 492 6118280 inhibition NN I-NP O
32 493 495 6118280 of IN B-PP O
33 496 499 6118280 the DT B-NP O
34 500 508 6118280 muscimol NN I-NP D009118
35 509 515 6118280 effect NN I-NP O
36 515 516 6118280 . . O O

1 517 524 6118280 However RB B-ADVP O
2 524 525 6118280 , , O O
3 526 528 6118280 in IN B-PP O
4 529 530 6118280 a DT B-NP O
5 531 538 6118280 similar JJ I-NP O
6 539 549 6118280 experiment NN I-NP O
7 550 551 6118280 l NN I-NP D007980
8 551 552 6118280 - HYPH B-NP D007980
9 552 556 6118280 dopa NN I-NP D007980
10 557 558 6118280 ( ( O O
11 558 560 6118280 80 CD B-NP O
12 560 561 6118280 - HYPH I-NP O
13 561 564 6118280 160 CD I-NP O
14 565 567 6118280 mg NN I-NP O
15 567 568 6118280 / SYM B-NP O
16 568 570 6118280 kg NN I-NP O
17 570 571 6118280 ) ) O O
18 572 575 6118280 was VBD B-VP O
19 576 583 6118280 without IN B-PP O
20 584 590 6118280 effect NN B-NP O
21 590 591 6118280 . . O O

1 592 594 6118280 In IN B-PP O
2 595 600 6118280 doses NNS B-NP O
3 601 603 6118280 of IN B-PP O
4 604 605 6118280 3 CD B-NP O
5 605 606 6118280 - HYPH I-NP O
6 606 608 6118280 10 CD I-NP O
7 609 611 6118280 mg NN I-NP O
8 611 612 6118280 / SYM I-NP O
9 612 614 6118280 kg NN I-NP O
10 614 615 6118280 , , O O
11 616 619 6118280 the DT B-NP O
12 620 629 6118280 serotonin NN I-NP D012701
13 630 638 6118280 receptor NN I-NP O
14 639 646 6118280 agonist NN I-NP O
15 647 649 6118280 MK NN I-NP C014896
16 649 650 6118280 - HYPH B-NP C014896
17 650 653 6118280 212 CD I-NP C014896
18 654 660 6118280 caused VBD B-VP O
19 661 662 6118280 a DT B-NP O
20 663 667 6118280 dose NN I-NP O
21 667 668 6118280 - HYPH B-NP O
22 668 677 6118280 dependent JJ I-NP O
23 678 686 6118280 blockade NN I-NP O
24 687 689 6118280 of IN B-PP O
25 690 693 6118280 the DT B-NP O
26 694 702 6118280 response NN I-NP O
27 703 705 6118280 of IN B-PP O
28 706 714 6118280 muscimol NN B-NP D009118
29 714 715 6118280 . . O O

1 716 718 6118280 Of IN B-PP O
2 719 722 6118280 the DT B-NP O
3 723 738 6118280 benzodiazepines NNS I-NP D001569
4 738 739 6118280 , , O O
5 740 750 6118280 clonazepam NN B-NP D002998
6 751 752 6118280 ( ( O O
7 752 755 6118280 0.1 CD B-NP O
8 755 756 6118280 - HYPH I-NP O
9 756 759 6118280 0.3 CD I-NP O
10 760 762 6118280 mg NN I-NP O
11 762 763 6118280 / SYM B-NP O
12 763 765 6118280 kg NN I-NP O
13 765 766 6118280 ) ) O O
14 767 770 6118280 was VBD B-VP O
15 771 776 6118280 found VBN I-VP O
16 777 779 6118280 to TO I-VP O
17 780 782 6118280 be VB I-VP O
18 783 790 6118280 several JJ B-ADJP O
19 791 795 6118280 fold RB B-ADJP O
20 796 800 6118280 more RBR I-ADJP O
21 801 807 6118280 potent JJ I-ADJP O
22 808 812 6118280 than IN B-PP O
23 813 821 6118280 diazepam NN B-NP D003975
24 822 823 6118280 ( ( O O
25 823 826 6118280 0.3 CD B-NP O
26 826 827 6118280 - HYPH I-NP O
27 827 828 6118280 3 CD I-NP O
28 829 831 6118280 mg NN I-NP O
29 831 832 6118280 / SYM B-NP O
30 832 834 6118280 kg NN I-NP O
31 834 835 6118280 ) ) O O
32 836 838 6118280 in IN B-PP O
33 839 847 6118280 blocking VBG B-VP O
34 848 851 6118280 the DT B-NP O
35 852 861 6118280 myoclonic JJ I-NP D009207
36 862 867 6118280 jerks NNS I-NP D009207
37 867 868 6118280 . . O O

1 869 874 6118280 While IN B-SBAR O
2 875 876 6118280 ( ( O O
3 876 877 6118280 - SYM O O
4 877 878 6118280 ) ) O O
5 878 879 6118280 - HYPH B-NP O
6 879 887 6118280 baclofen NN I-NP D001418
7 888 889 6118280 ( ( O O
8 889 890 6118280 1 CD B-NP O
9 890 891 6118280 - HYPH I-NP O
10 891 892 6118280 3 CD I-NP O
11 893 895 6118280 mg NN I-NP O
12 895 896 6118280 / SYM B-NP O
13 896 898 6118280 kg NN I-NP O
14 898 899 6118280 ) ) O O
15 900 906 6118280 proved VBD B-VP O
16 907 909 6118280 to TO I-VP O
17 910 912 6118280 be VB I-VP O
18 913 915 6118280 an DT B-NP O
19 916 925 6118280 effective JJ I-NP O
20 926 936 6118280 antagonist NN I-NP O
21 937 939 6118280 of IN B-PP O
22 940 948 6118280 muscimol NN B-NP D009118
23 948 949 6118280 , , O O
24 950 953 6118280 its PRP$ O O
25 954 955 6118280 ( ( O O
26 955 956 6118280 + SYM O O
27 956 957 6118280 ) ) O O
28 957 958 6118280 - HYPH B-NP O
29 958 964 6118280 isomer NN I-NP O
30 965 966 6118280 ( ( O O
31 966 967 6118280 5 CD B-NP O
32 967 968 6118280 - HYPH I-NP O
33 968 970 6118280 20 CD I-NP O
34 971 973 6118280 mg NN I-NP O
35 973 974 6118280 / SYM B-NP O
36 974 976 6118280 kg NN I-NP O
37 976 977 6118280 ) ) O O
38 978 984 6118280 lacked VBD B-VP O
39 985 989 6118280 this DT B-NP O
40 990 998 6118280 property NN I-NP O
41 998 999 6118280 . . O O

1 1000 1011 6118280 Considering VBG B-VP O
2 1012 1015 6118280 the DT B-NP O
3 1016 1020 6118280 fact NN I-NP O
4 1021 1025 6118280 that IN B-SBAR O
5 1026 1027 6118280 5 CD B-NP D006916
6 1027 1028 6118280 - HYPH I-NP D006916
7 1028 1031 6118280 HTP NN I-NP D006916
8 1032 1035 6118280 and CC O O
9 1036 1039 6118280 the DT B-NP O
10 1040 1055 6118280 benzodiazepines NNS I-NP D001569
11 1056 1060 6118280 have VBP B-VP O
12 1061 1065 6118280 been VBN I-VP O
13 1066 1071 6118280 found VBN I-VP O
14 1072 1074 6118280 to TO I-VP O
15 1075 1077 6118280 be VB I-VP O
16 1078 1088 6118280 beneficial JJ B-ADJP O
17 1089 1091 6118280 in IN B-PP O
18 1092 1095 6118280 the DT B-NP O
19 1096 1106 6118280 management NN I-NP O
20 1107 1109 6118280 of IN B-PP O
21 1110 1118 6118280 clinical JJ B-NP O
22 1119 1128 6118280 myoclonus NN I-NP D009207
23 1128 1129 6118280 , , O O
24 1130 1133 6118280 the DT B-NP O
25 1134 1142 6118280 muscimol NN I-NP D009118
26 1142 1143 6118280 - HYPH B-NP O
27 1143 1150 6118280 induced VBN I-NP O
28 1151 1160 6118280 myoclonus NN I-NP D009207
29 1161 1166 6118280 seems VBZ B-VP O
30 1167 1169 6118280 to TO I-VP O
31 1170 1172 6118280 be VB I-VP O
32 1173 1174 6118280 a DT B-NP O
33 1175 1187 6118280 satisfactory JJ I-NP O
34 1188 1194 6118280 animal NN I-NP O
35 1195 1200 6118280 model NN I-NP O
36 1201 1205 6118280 that WDT B-NP O
37 1206 1209 6118280 may MD B-VP O
38 1210 1215 6118280 prove VB I-VP O
39 1216 1222 6118280 useful JJ B-ADJP O
40 1223 1226 6118280 for IN B-PP O
41 1227 1230 6118280 the DT B-NP O
42 1231 1242 6118280 development NN I-NP O
43 1243 1245 6118280 of IN B-PP O
44 1246 1249 6118280 new JJ B-NP O
45 1250 1254 6118280 drug NN I-NP O
46 1255 1265 6118280 treatments NNS I-NP O
47 1266 1269 6118280 for IN B-PP O
48 1270 1274 6118280 this DT B-NP O
49 1275 1284 6118280 condition NN I-NP O
50 1284 1285 6118280 . . O O

1 1286 1289 6118280 Our PRP$ B-NP O
2 1290 1297 6118280 present JJ I-NP O
3 1298 1303 6118280 study NN I-NP O
4 1304 1313 6118280 indicated VBD B-VP O
5 1314 1317 6118280 the DT B-NP O
6 1318 1326 6118280 possible JJ I-NP O
7 1327 1332 6118280 value NN I-NP O
8 1333 1335 6118280 of IN B-PP O
9 1336 1338 6118280 MK NN B-NP C014896
10 1338 1339 6118280 - HYPH B-NP C014896
11 1339 1342 6118280 212 CD I-NP C014896
12 1343 1346 6118280 and CC O O
13 1347 1348 6118280 ( ( O O
14 1348 1349 6118280 - SYM O O
15 1349 1350 6118280 ) ) O O
16 1350 1351 6118280 - HYPH B-NP O
17 1351 1359 6118280 baclofen NN I-NP D001418
18 1360 1362 6118280 in IN B-PP O
19 1363 1366 6118280 the DT B-NP O
20 1367 1377 6118280 management NN I-NP O
21 1378 1380 6118280 of IN B-PP O
22 1381 1389 6118280 clinical JJ B-NP O
23 1390 1399 6118280 myoclonus NN I-NP D009207
24 1399 1400 6118280 . . O O

1 0 0 16596970 -DOCSTART- -X- -X- O

1 0 11 16596970 Pilocarpine NN B-NP D010862
2 12 20 16596970 seizures NNS I-NP D012640
3 21 26 16596970 cause VBP B-VP O
4 27 30 16596970 age NN B-NP O
5 30 31 16596970 - HYPH B-NP O
6 31 40 16596970 dependent JJ I-NP O
7 41 51 16596970 impairment NN I-NP D001308
8 52 54 16596970 in IN B-PP D001308
9 55 63 16596970 auditory JJ B-NP D001308
10 64 72 16596970 location NN I-NP D001308
11 73 87 16596970 discrimination NN I-NP D001308
12 87 88 16596970 . . O O
13 89 97 16596970 Children NNP B-NP O
14 98 101 16596970 who WP B-NP O
15 102 106 16596970 have VBP B-VP O
16 107 113 16596970 status NN B-NP D013226
17 114 125 16596970 epilepticus NN I-NP D013226
18 126 130 16596970 have VBP B-VP O
19 131 141 16596970 continuous JJ B-ADJP O
20 142 144 16596970 or CC O O
21 145 152 16596970 rapidly RB B-VP O
22 153 162 16596970 repeating VBG I-VP O
23 163 171 16596970 seizures NNS B-NP D012640
24 172 176 16596970 that WDT B-NP O
25 177 180 16596970 may MD B-VP O
26 181 183 16596970 be VB I-VP O
27 184 188 16596970 life NN B-NP O
28 188 189 16596970 - HYPH O O
29 189 200 16596970 threatening VBG B-VP O
30 201 204 16596970 and CC O O
31 205 208 16596970 may MD B-VP O
32 209 214 16596970 cause VB I-VP O
33 215 219 16596970 life NN B-NP O
34 219 220 16596970 - HYPH B-NP O
35 220 224 16596970 long JJ I-NP O
36 225 232 16596970 changes NNS I-NP O
37 233 235 16596970 in IN B-PP O
38 236 241 16596970 brain NN B-NP O
39 242 245 16596970 and CC I-NP O
40 246 254 16596970 behavior NN I-NP O
41 254 255 16596970 . . O O

1 256 259 16596970 The DT B-NP O
2 260 266 16596970 extent NN I-NP O
3 267 269 16596970 to TO B-PP O
4 270 275 16596970 which WDT B-NP O
5 276 282 16596970 status NN B-NP D013226
6 283 294 16596970 epilepticus NN I-NP D013226
7 295 301 16596970 causes VBZ B-VP O
8 302 310 16596970 deficits NNS B-NP D001308
9 311 313 16596970 in IN B-PP D001308
10 314 322 16596970 auditory JJ B-NP D001308
11 323 337 16596970 discrimination NN I-NP D001308
12 338 340 16596970 is VBZ B-VP O
13 341 348 16596970 unknown JJ B-ADJP O
14 348 349 16596970 . . O O

1 350 351 16596970 A DT B-NP O
2 352 364 16596970 naturalistic JJ I-NP O
3 365 373 16596970 auditory JJ I-NP O
4 374 382 16596970 location NN I-NP O
5 383 397 16596970 discrimination NN I-NP O
6 398 404 16596970 method NN I-NP O
7 405 408 16596970 was VBD B-VP O
8 409 413 16596970 used VBN I-VP O
9 414 416 16596970 to TO B-VP O
10 417 425 16596970 evaluate VB I-VP O
11 426 430 16596970 this DT B-NP O
12 431 439 16596970 question NN I-NP O
13 440 445 16596970 using VBG B-VP O
14 446 448 16596970 an DT B-NP O
15 449 455 16596970 animal NN I-NP O
16 456 461 16596970 model NN I-NP O
17 462 464 16596970 of IN B-PP O
18 465 471 16596970 status NN B-NP D013226
19 472 483 16596970 epilepticus NN I-NP D013226
20 483 484 16596970 . . O O

1 485 489 16596970 Male JJ B-NP O
2 490 497 16596970 Sprague NNP I-NP O
3 497 498 16596970 - HYPH I-NP O
4 498 504 16596970 Dawley NNP I-NP O
5 505 509 16596970 rats NNS I-NP O
6 510 514 16596970 were VBD B-VP O
7 515 523 16596970 injected VBN I-VP O
8 524 528 16596970 with IN B-PP O
9 529 535 16596970 saline NN B-NP O
10 536 538 16596970 on IN B-PP O
11 539 548 16596970 postnatal JJ B-NP O
12 549 552 16596970 day NN I-NP O
13 553 554 16596970 ( ( O O
14 554 555 16596970 P NN B-NP O
15 555 556 16596970 ) ) O O
16 557 559 16596970 20 CD B-NP O
17 559 560 16596970 , , O O
18 561 563 16596970 or CC O O
19 564 565 16596970 a DT B-NP O
20 566 576 16596970 convulsant JJ I-NP O
21 577 581 16596970 dose NN I-NP O
22 582 584 16596970 of IN B-PP O
23 585 596 16596970 pilocarpine NN B-NP D010862
24 597 599 16596970 on IN B-PP O
25 600 603 16596970 P20 NN B-NP O
26 604 606 16596970 or CC I-NP O
27 607 610 16596970 P45 NN I-NP O
28 610 611 16596970 . . O O

1 612 623 16596970 Pilocarpine NN B-NP D010862
2 624 626 16596970 on IN B-PP O
3 627 633 16596970 either CC B-NP O
4 634 637 16596970 day NN I-NP O
5 638 645 16596970 induced VBD B-VP O
6 646 652 16596970 status NN B-NP D013226
7 653 664 16596970 epilepticus NN I-NP D013226
8 664 665 16596970 ; : O O
9 666 672 16596970 status NN B-NP D013226
10 673 684 16596970 epilepticus NN I-NP D013226
11 685 687 16596970 at IN B-PP O
12 688 691 16596970 P45 NN B-NP O
13 692 700 16596970 resulted VBD B-VP O
14 701 703 16596970 in IN B-PP O
15 704 707 16596970 CA3 NN B-NP O
16 708 712 16596970 cell NN I-NP O
17 713 717 16596970 loss NN I-NP O
18 718 721 16596970 and CC O O
19 722 733 16596970 spontaneous JJ B-NP O
20 734 742 16596970 seizures NNS I-NP D012640
21 742 743 16596970 , , O O
22 744 751 16596970 whereas IN O O
23 752 755 16596970 P20 NN B-NP O
24 756 760 16596970 rats NNS I-NP O
25 761 764 16596970 had VBD B-VP O
26 765 767 16596970 no DT B-NP O
27 768 772 16596970 cell NN I-NP O
28 773 777 16596970 loss NN I-NP O
29 778 780 16596970 or CC O O
30 781 792 16596970 spontaneous JJ B-NP O
31 793 801 16596970 seizures NNS I-NP D012640
32 801 802 16596970 . . O O

1 803 809 16596970 Mature JJ B-NP O
2 810 814 16596970 rats NNS I-NP O
3 815 819 16596970 were VBD B-VP O
4 820 827 16596970 trained VBN I-VP O
5 828 832 16596970 with IN B-PP O
6 833 838 16596970 sound JJ B-NP O
7 838 839 16596970 - HYPH I-NP O
8 839 845 16596970 source NN I-NP O
9 846 854 16596970 location NN I-NP O
10 855 858 16596970 and CC I-NP O
11 859 864 16596970 sound NN I-NP O
12 864 865 16596970 - HYPH B-NP O
13 865 872 16596970 silence NN I-NP O
14 873 888 16596970 discriminations NNS I-NP O
15 888 889 16596970 . . O O

1 890 897 16596970 Control NN B-NP O
2 898 899 16596970 ( ( O O
3 899 905 16596970 saline NN B-NP O
4 906 909 16596970 P20 NN I-NP O
5 909 910 16596970 ) ) O O
6 911 915 16596970 rats NNS B-NP O
7 916 924 16596970 acquired VBD B-VP O
8 925 929 16596970 both DT B-NP O
9 930 945 16596970 discriminations NNS I-NP O
10 946 957 16596970 immediately RB B-ADVP O
11 957 958 16596970 . . O O

1 959 961 16596970 In IN B-PP O
2 962 968 16596970 status NN B-NP D013226
3 969 980 16596970 epilepticus NN I-NP D013226
4 981 982 16596970 ( ( O O
5 982 985 16596970 P20 NN B-NP O
6 985 986 16596970 ) ) O O
7 987 991 16596970 rats NNS B-NP O
8 991 992 16596970 , , O O
9 993 1004 16596970 acquisition NN B-NP O
10 1005 1007 16596970 of IN B-PP O
11 1008 1011 16596970 the DT B-NP O
12 1012 1017 16596970 sound JJ I-NP O
13 1017 1018 16596970 - HYPH I-NP O
14 1018 1024 16596970 source NN I-NP O
15 1025 1033 16596970 location NN I-NP O
16 1034 1048 16596970 discrimination NN I-NP O
17 1049 1052 16596970 was VBD B-VP O
18 1053 1063 16596970 moderately RB B-ADJP O
19 1064 1072 16596970 impaired JJ I-ADJP O
20 1072 1073 16596970 . . O O

1 1074 1080 16596970 Status NN B-NP D013226
2 1081 1092 16596970 epilepticus NN I-NP D013226
3 1093 1094 16596970 ( ( O O
4 1094 1097 16596970 P45 NN B-NP O
5 1097 1098 16596970 ) ) O O
6 1099 1103 16596970 rats NNS B-NP O
7 1104 1110 16596970 failed VBD B-VP O
8 1111 1113 16596970 to TO I-VP O
9 1114 1121 16596970 acquire VB I-VP O
10 1122 1128 16596970 either CC I-VP O
11 1129 1134 16596970 sound VB I-VP O
12 1134 1135 16596970 - HYPH B-NP O
13 1135 1141 16596970 source NN I-NP O
14 1142 1150 16596970 location NN I-NP O
15 1151 1153 16596970 or CC I-NP O
16 1154 1159 16596970 sound NN I-NP O
17 1159 1160 16596970 - HYPH B-NP O
18 1160 1167 16596970 silence NN I-NP O
19 1168 1183 16596970 discriminations NNS I-NP O
20 1183 1184 16596970 . . O O

1 1185 1191 16596970 Status NN B-NP D013226
2 1192 1203 16596970 epilepticus NN I-NP D013226
3 1204 1206 16596970 in IN B-PP O
4 1207 1210 16596970 rat NN B-NP O
5 1211 1217 16596970 causes VBZ B-VP O
6 1218 1220 16596970 an DT B-NP O
7 1221 1224 16596970 age NN I-NP O
8 1224 1225 16596970 - HYPH B-NP O
9 1225 1234 16596970 dependent JJ I-NP O
10 1234 1235 16596970 , , I-NP O
11 1236 1240 16596970 long JJ I-NP O
12 1240 1241 16596970 - HYPH I-NP O
13 1241 1245 16596970 term NN I-NP O
14 1246 1256 16596970 impairment NN I-NP D001308
15 1257 1259 16596970 in IN B-PP D001308
16 1260 1268 16596970 auditory JJ B-NP D001308
17 1269 1283 16596970 discrimination NN I-NP D001308
18 1283 1284 16596970 . . O O

1 1285 1289 16596970 This DT B-NP O
2 1290 1300 16596970 impairment NN I-NP O
3 1301 1304 16596970 may MD B-VP O
4 1305 1312 16596970 explain VB I-VP O
5 1313 1316 16596970 one CD B-NP O
6 1317 1322 16596970 cause NN I-NP O
7 1323 1325 16596970 of IN B-PP O
8 1326 1334 16596970 impaired JJ B-NP D001308
9 1335 1343 16596970 auditory NN I-NP D001308
10 1344 1352 16596970 location NN I-NP D001308
11 1353 1367 16596970 discrimination NN I-NP D001308
12 1368 1370 16596970 in IN B-PP O
13 1371 1377 16596970 humans NNS B-NP O
14 1377 1378 16596970 . . O O

1 0 0 17049862 -DOCSTART- -X- -X- O

1 0 2 17049862 Is VBZ O O
2 3 12 17049862 phenytoin NN B-NP D010672
3 13 27 17049862 administration NN I-NP O
4 28 32 17049862 safe JJ B-ADJP O
5 33 35 17049862 in IN B-PP O
6 36 37 17049862 a DT B-NP O
7 38 49 17049862 hypothermic JJ I-NP D007035
8 50 55 17049862 child NN I-NP O
9 55 56 17049862 ? . O O
10 57 58 17049862 A DT B-NP O
11 59 63 17049862 male JJ I-NP O
12 64 71 17049862 neonate NN I-NP O
13 72 76 17049862 with IN B-PP O
14 77 78 17049862 a DT B-NP O
15 79 85 17049862 Chiari NNP I-NP D001139
16 86 98 17049862 malformation NN I-NP D001139
17 99 102 17049862 and CC O O
18 103 104 17049862 a DT B-NP O
19 105 112 17049862 leaking VBG I-NP O
20 113 130 17049862 myelomeningocoele NN I-NP O
21 131 140 17049862 underwent VBD B-VP O
22 141 161 17049862 ventriculoperitoneal JJ B-NP O
23 162 167 17049862 shunt NN I-NP O
24 168 177 17049862 insertion NN I-NP O
25 178 186 17049862 followed VBN B-VP O
26 187 189 17049862 by IN B-PP O
27 190 196 17049862 repair NN B-NP O
28 197 199 17049862 of IN B-PP O
29 200 217 17049862 myelomeningocoele NN B-NP O
30 217 218 17049862 . . O O

1 219 225 17049862 During IN B-PP O
2 226 237 17049862 anaesthesia NN B-NP O
3 238 241 17049862 and CC I-NP O
4 242 249 17049862 surgery NN I-NP O
5 249 250 17049862 , , O O
6 251 253 17049862 he PRP B-NP O
7 254 267 17049862 inadvertently RB B-ADVP O
8 268 274 17049862 became VBD B-VP O
9 275 285 17049862 moderately RB B-ADJP O
10 286 297 17049862 hypothermic JJ I-ADJP D007035
11 297 298 17049862 . . O O

1 299 310 17049862 Intravenous JJ B-NP O
2 311 320 17049862 phenytoin NN I-NP D010672
3 321 324 17049862 was VBD B-VP O
4 325 337 17049862 administered VBN I-VP O
5 338 344 17049862 during IN B-PP O
6 345 348 17049862 the DT B-NP O
7 349 354 17049862 later JJ I-NP O
8 355 359 17049862 part NN I-NP O
9 360 362 17049862 of IN B-PP O
10 363 366 17049862 the DT B-NP O
11 367 374 17049862 surgery NN I-NP O
12 375 378 17049862 for IN B-PP O
13 379 386 17049862 seizure NN B-NP D012640
14 387 398 17049862 prophylaxis NN I-NP O
15 398 399 17049862 . . O O

1 400 409 17049862 Following VBG B-PP O
2 410 419 17049862 phenytoin NN B-NP D010672
3 420 434 17049862 administration NN I-NP O
4 434 435 17049862 , , O O
5 436 439 17049862 the DT B-NP O
6 440 447 17049862 patient NN I-NP O
7 448 457 17049862 developed VBD B-VP O
8 458 463 17049862 acute JJ B-NP O
9 464 470 17049862 severe JJ I-NP O
10 471 482 17049862 bradycardia NN I-NP D001919
11 482 483 17049862 , , O O
12 484 494 17049862 refractory JJ B-ADJP O
13 495 497 17049862 to TO B-PP O
14 498 506 17049862 atropine NN B-NP D001285
15 507 510 17049862 and CC I-NP O
16 511 521 17049862 adrenaline NN I-NP D004837
17 521 522 17049862 . . O O

1 523 526 17049862 The DT B-NP O
2 527 534 17049862 cardiac JJ I-NP O
3 535 545 17049862 depressant JJ I-NP O
4 546 553 17049862 actions NNS I-NP O
5 554 556 17049862 of IN B-PP O
6 557 566 17049862 phenytoin NN B-NP D010672
7 567 570 17049862 and CC I-NP O
8 571 582 17049862 hypothermia NN I-NP D007035
9 583 586 17049862 can MD B-VP O
10 587 589 17049862 be VB I-VP O
11 590 598 17049862 additive JJ B-ADJP O
12 598 599 17049862 . . O O

1 600 614 17049862 Administration NN B-NP O
2 615 617 17049862 of IN B-PP O
3 618 627 17049862 phenytoin NN B-NP D010672
4 628 630 17049862 in IN B-PP O
5 631 634 17049862 the DT I-PP O
6 635 643 17049862 presence NN I-PP O
7 644 646 17049862 of IN I-PP O
8 647 658 17049862 hypothermia NN B-NP D007035
9 659 662 17049862 may MD B-VP O
10 663 667 17049862 lead VB I-VP O
11 668 670 17049862 to TO B-PP O
12 671 673 17049862 an DT B-NP O
13 674 681 17049862 adverse JJ I-NP O
14 682 689 17049862 cardiac JJ I-NP O
15 690 695 17049862 event NN I-NP O
16 696 698 17049862 in IN B-PP O
17 699 707 17049862 children NNS B-NP O
18 707 708 17049862 . . O O

1 709 711 17049862 As IN B-SBAR O
2 712 721 17049862 phenytoin NN B-NP D010672
3 722 724 17049862 is VBZ B-VP O
4 725 726 17049862 a DT B-NP O
5 727 735 17049862 commonly RB I-NP O
6 736 740 17049862 used VBN I-NP O
7 741 745 17049862 drug NN I-NP O
8 745 746 17049862 , , O O
9 747 757 17049862 clinicians NNS B-NP O
10 758 762 17049862 need VBP B-VP O
11 763 765 17049862 to TO I-VP O
12 766 768 17049862 be VB I-VP O
13 769 774 17049862 aware JJ B-ADJP O
14 775 777 17049862 of IN B-PP O
15 778 782 17049862 this DT B-NP O
16 783 794 17049862 interaction NN I-NP O
17 794 795 17049862 . . O O

1 0 0 18674790 -DOCSTART- -X- -X- O

1 0 4 18674790 High JJ B-NP O
2 5 8 18674790 fat NN I-NP D004041
3 9 13 18674790 diet NN I-NP O
4 13 14 18674790 - HYPH O O
5 14 17 18674790 fed VBN B-VP O
6 18 23 18674790 obese JJ B-NP D009765
7 24 28 18674790 rats NNS I-NP O
8 29 32 18674790 are VBP B-VP O
9 33 39 18674790 highly RB B-ADJP O
10 40 49 18674790 sensitive JJ I-ADJP O
11 50 52 18674790 to TO B-PP O
12 53 64 18674790 doxorubicin NN B-NP D004317
13 64 65 18674790 - HYPH B-NP O
14 65 72 18674790 induced VBN I-NP O
15 73 87 18674790 cardiotoxicity NN I-NP D066126
16 87 88 18674790 . . O O
17 89 94 18674790 Often RB B-ADVP O
18 94 95 18674790 , , O O
19 96 108 18674790 chemotherapy NN B-NP O
20 109 111 18674790 by IN B-PP O
21 112 123 18674790 doxorubicin NN B-NP D004317
22 124 125 18674790 ( ( O O
23 125 135 18674790 Adriamycin NN B-NP D004317
24 135 136 18674790 ) ) O O
25 137 139 18674790 is VBZ B-VP O
26 140 147 18674790 limited VBN I-VP O
27 148 151 18674790 due IN B-PP O
28 152 154 18674790 to TO B-PP O
29 155 159 18674790 life NN B-NP O
30 160 171 18674790 threatening JJ I-NP O
31 172 186 18674790 cardiotoxicity NN I-NP D066126
32 187 189 18674790 in IN B-PP O
33 190 198 18674790 patients NNS B-NP O
34 199 205 18674790 during IN B-PP O
35 206 209 18674790 and CC O O
36 210 221 18674790 posttherapy NN B-NP O
37 221 222 18674790 . . O O

1 223 231 18674790 Recently RB B-ADVP O
2 231 232 18674790 , , O O
3 233 235 18674790 we PRP B-NP O
4 236 240 18674790 have VBP B-VP O
5 241 246 18674790 shown VBN I-VP O
6 247 251 18674790 that IN B-SBAR O
7 252 260 18674790 moderate JJ B-NP O
8 261 265 18674790 diet NN I-NP O
9 266 277 18674790 restriction NN I-NP O
10 278 288 18674790 remarkably RB B-ADVP O
11 289 297 18674790 protects VBZ B-VP O
12 298 305 18674790 against IN B-PP O
13 306 317 18674790 doxorubicin NN B-NP D004317
14 317 318 18674790 - HYPH B-NP O
15 318 325 18674790 induced VBN I-NP O
16 326 340 18674790 cardiotoxicity NN I-NP D066126
17 340 341 18674790 . . O O

1 342 346 18674790 This DT B-NP O
2 347 363 18674790 cardioprotection NN I-NP O
3 364 366 18674790 is VBZ B-VP O
4 367 378 18674790 accompanied VBN I-VP O
5 379 381 18674790 by IN B-PP O
6 382 391 18674790 decreased VBN B-NP O
7 392 399 18674790 cardiac JJ I-NP O
8 400 409 18674790 oxidative JJ I-NP O
9 410 416 18674790 stress NN I-NP O
10 417 420 18674790 and CC I-NP O
11 421 434 18674790 triglycerides NNS I-NP D014280
12 435 438 18674790 and CC O O
13 439 448 18674790 increased VBD B-VP O
14 449 456 18674790 cardiac JJ B-NP O
15 457 462 18674790 fatty JJ I-NP O
16 462 463 18674790 - HYPH I-NP O
17 463 467 18674790 acid NN I-NP O
18 468 477 18674790 oxidation NN I-NP O
19 477 478 18674790 , , O O
20 479 482 18674790 ATP NN B-NP D000255
21 483 492 18674790 synthesis NN I-NP O
22 492 493 18674790 , , O O
23 494 497 18674790 and CC O O
24 498 509 18674790 upregulated VBN B-NP O
25 510 513 18674790 JAK NN I-NP O
26 513 514 18674790 / SYM I-NP O
27 514 519 18674790 STAT3 NN I-NP O
28 520 527 18674790 pathway NN I-NP O
29 527 528 18674790 . . O O

1 529 531 18674790 In IN B-PP O
2 532 535 18674790 the DT B-NP O
3 536 543 18674790 current JJ I-NP O
4 544 549 18674790 study NN I-NP O
5 549 550 18674790 , , O O
6 551 553 18674790 we PRP B-NP O
7 554 566 18674790 investigated VBD B-VP O
8 567 574 18674790 whether IN B-SBAR O
9 575 576 18674790 a DT B-NP O
10 577 590 18674790 physiological JJ I-NP O
11 591 603 18674790 intervention NN I-NP O
12 604 606 18674790 by IN B-PP O
13 607 614 18674790 feeding VBG B-VP O
14 615 618 18674790 40% JJ B-NP O
15 619 623 18674790 high JJ I-NP O
16 624 627 18674790 fat NN I-NP D004041
17 628 632 18674790 diet NN I-NP O
18 633 634 18674790 ( ( O O
19 634 637 18674790 HFD NN B-NP O
20 637 638 18674790 ) ) O O
21 638 639 18674790 , , O O
22 640 645 18674790 which WDT B-NP O
23 646 653 18674790 induces VBZ B-VP O
24 654 661 18674790 obesity NN B-NP D009765
25 662 664 18674790 in IN B-PP O
26 665 669 18674790 male JJ B-NP O
27 670 677 18674790 Sprague NNP I-NP O
28 677 678 18674790 - HYPH I-NP O
29 678 684 18674790 Dawley NNP I-NP O
30 685 689 18674790 rats NNS I-NP O
31 690 691 18674790 ( ( O O
32 691 694 18674790 250 CD B-NP O
33 694 695 18674790 - HYPH I-NP O
34 695 698 18674790 275 CD I-NP O
35 699 700 18674790 g NN I-NP O
36 700 701 18674790 ) ) O O
37 701 702 18674790 , , O O
38 703 713 18674790 sensitizes VBZ B-VP O
39 714 716 18674790 to TO B-PP O
40 717 728 18674790 doxorubicin NN B-NP D004317
41 728 729 18674790 - HYPH B-NP O
42 729 736 18674790 induced VBN I-NP O
43 737 751 18674790 cardiotoxicity NN I-NP D066126
44 751 752 18674790 . . O O

1 753 754 18674790 A DT B-NP O
2 755 761 18674790 LD(10) NN I-NP O
3 762 766 18674790 dose NN I-NP O
4 767 768 18674790 ( ( O O
5 768 769 18674790 8 CD B-NP O
6 770 772 18674790 mg NN I-NP O
7 773 784 18674790 doxorubicin NN I-NP D004317
8 784 785 18674790 / SYM B-NP O
9 785 787 18674790 kg NN I-NP O
10 787 788 18674790 , , O O
11 789 791 18674790 ip RB B-ADVP O
12 791 792 18674790 ) ) O O
13 793 805 18674790 administered VBN B-VP O
14 806 808 18674790 on IN B-PP O
15 809 812 18674790 day NN B-NP O
16 813 815 18674790 43 CD I-NP O
17 816 818 18674790 of IN B-PP O
18 819 822 18674790 the DT B-NP O
19 823 826 18674790 HFD NN I-NP O
20 827 834 18674790 feeding NN I-NP O
21 835 842 18674790 regimen NNS I-NP O
22 843 846 18674790 led VBD B-VP O
23 847 849 18674790 to TO B-PP O
24 850 856 18674790 higher JJR B-NP O
25 857 871 18674790 cardiotoxicity NN I-NP D066126
26 871 872 18674790 , , O O
27 873 880 18674790 cardiac JJ B-NP D006331
28 881 892 18674790 dysfunction NN I-NP D006331
29 892 893 18674790 , , O O
30 894 899 18674790 lipid NN B-NP O
31 900 912 18674790 peroxidation NN I-NP O
32 912 913 18674790 , , O O
33 914 917 18674790 and CC O O
34 918 921 18674790 80% CD B-NP O
35 922 931 18674790 mortality NN I-NP O
36 932 934 18674790 in IN B-PP O
37 935 938 18674790 the DT B-NP O
38 939 944 18674790 obese JJ I-NP D009765
39 945 946 18674790 ( ( O O
40 946 948 18674790 OB NN B-NP D009765
41 948 949 18674790 ) ) O O
42 950 954 18674790 rats NNS B-NP O
43 955 957 18674790 in IN B-PP O
44 958 961 18674790 the DT B-NP O
45 962 969 18674790 absence NN I-NP O
46 970 972 18674790 of IN B-PP O
47 973 976 18674790 any DT B-NP O
48 977 988 18674790 significant JJ I-NP O
49 989 994 18674790 renal JJ I-NP D007674
50 995 997 18674790 or CC I-NP D007674
51 998 1005 18674790 hepatic JJ I-NP D007674
52 1006 1014 18674790 toxicity NN I-NP D007674
53 1014 1015 18674790 . . O O

1 1016 1027 18674790 Doxorubicin NN B-NP D004317
2 1028 1042 18674790 toxicokinetics NNS I-NP O
3 1043 1050 18674790 studies NNS I-NP O
4 1051 1059 18674790 revealed VBD B-VP O
5 1060 1062 18674790 no DT B-NP O
6 1063 1069 18674790 change NN I-NP O
7 1070 1072 18674790 in IN B-PP O
8 1073 1085 18674790 accumulation NN B-NP O
9 1086 1088 18674790 of IN B-PP O
10 1089 1100 18674790 doxorubicin NN B-NP D004317
11 1101 1104 18674790 and CC I-NP O
12 1105 1118 18674790 doxorubicinol NN I-NP C010013
13 1119 1120 18674790 ( ( O O
14 1120 1125 18674790 toxic JJ B-NP O
15 1126 1136 18674790 metabolite NN I-NP O
16 1136 1137 18674790 ) ) O O
17 1138 1140 18674790 in IN B-PP O
18 1141 1144 18674790 the DT B-NP O
19 1145 1151 18674790 normal JJ I-NP O
20 1152 1156 18674790 diet NN I-NP O
21 1156 1157 18674790 - HYPH B-VP O
22 1157 1160 18674790 fed VBN I-VP O
23 1161 1162 18674790 ( ( O O
24 1162 1164 18674790 ND NN B-NP O
25 1164 1165 18674790 ) ) O O
26 1166 1169 18674790 and CC O O
27 1170 1172 18674790 OB NN B-NP D009765
28 1173 1179 18674790 hearts NNS I-NP O
29 1179 1180 18674790 . . O O

1 1181 1192 18674790 Mechanistic JJ B-NP O
2 1193 1200 18674790 studies NNS I-NP O
3 1201 1209 18674790 revealed VBD B-VP O
4 1210 1214 18674790 that IN B-SBAR O
5 1215 1217 18674790 OB NN B-NP D009765
6 1218 1222 18674790 rats NNS I-NP O
7 1223 1226 18674790 are VBP B-VP O
8 1227 1237 18674790 sensitized VBN I-VP O
9 1238 1241 18674790 due JJ B-ADJP O
10 1242 1244 18674790 to TO B-PP O
11 1244 1245 18674790 : : O O
12 1246 1247 18674790 ( ( B-LST O
13 1247 1248 18674790 1 LS I-LST O
14 1248 1249 18674790 ) ) O O
15 1250 1256 18674790 higher JJR B-NP O
16 1257 1267 18674790 oxyradical JJ I-NP O
17 1268 1274 18674790 stress NN I-NP O
18 1275 1282 18674790 leading VBG B-VP O
19 1283 1285 18674790 to TO B-PP O
20 1286 1298 18674790 upregulation NN B-NP O
21 1299 1301 18674790 of IN B-PP O
22 1302 1312 18674790 uncoupling VBG B-VP O
23 1313 1321 18674790 proteins NNS B-NP O
24 1322 1323 18674790 2 CD I-NP O
25 1324 1327 18674790 and CC I-NP O
26 1328 1329 18674790 3 CD I-NP O
27 1329 1330 18674790 , , O O
28 1331 1332 18674790 ( ( B-LST O
29 1332 1333 18674790 2 LS I-LST O
30 1333 1334 18674790 ) ) O O
31 1335 1349 18674790 downregulation NN B-NP O
32 1350 1352 18674790 of IN B-PP O
33 1353 1360 18674790 cardiac JJ B-NP O
34 1361 1371 18674790 peroxisome NN I-NP O
35 1372 1385 18674790 proliferators NNS I-NP O
36 1386 1395 18674790 activated VBD B-VP O
37 1396 1404 18674790 receptor NN B-NP O
38 1404 1405 18674790 - HYPH O O
39 1405 1410 18674790 alpha SYM B-NP O
40 1410 1411 18674790 , , O O
41 1412 1413 18674790 ( ( O O
42 1413 1414 18674790 3 CD B-NP O
43 1414 1415 18674790 ) ) O O
44 1416 1425 18674790 decreased VBD B-VP O
45 1426 1432 18674790 plasma NN B-NP O
46 1433 1444 18674790 adiponectin NN I-NP O
47 1445 1451 18674790 levels NNS I-NP O
48 1451 1452 18674790 , , O O
49 1453 1454 18674790 ( ( O O
50 1454 1455 18674790 4 CD B-NP O
51 1455 1456 18674790 ) ) O O
52 1457 1466 18674790 decreased VBD B-VP O
53 1467 1474 18674790 cardiac JJ B-NP O
54 1475 1480 18674790 fatty JJ I-NP O
55 1480 1481 18674790 - HYPH I-NP O
56 1481 1485 18674790 acid NN I-NP O
57 1486 1495 18674790 oxidation NN I-NP O
58 1496 1497 18674790 ( ( O O
59 1497 1503 18674790 666.9+ SYM B-NP O
60 1503 1504 18674790 / SYM O O
61 1504 1505 18674790 - SYM O O
62 1505 1509 18674790 14.0 CD B-NP O
63 1510 1514 18674790 nmol NN I-NP O
64 1514 1515 18674790 / SYM B-NP O
65 1515 1518 18674790 min NN I-NP O
66 1518 1519 18674790 / SYM I-NP O
67 1519 1520 18674790 g NN I-NP O
68 1521 1526 18674790 heart NN I-NP O
69 1527 1529 18674790 in IN B-PP O
70 1530 1532 18674790 ND NN B-NP O
71 1533 1539 18674790 versus IN B-PP O
72 1540 1546 18674790 400.2+ JJ B-NP O
73 1546 1547 18674790 / SYM I-NP O
74 1547 1548 18674790 - SYM I-NP O
75 1548 1552 18674790 11.8 CD B-NP O
76 1553 1557 18674790 nmol NN I-NP O
77 1557 1558 18674790 / SYM B-NP O
78 1558 1561 18674790 min NN I-NP O
79 1561 1562 18674790 / SYM I-NP O
80 1562 1563 18674790 g NN I-NP O
81 1564 1569 18674790 heart NN I-NP O
82 1570 1572 18674790 in IN B-PP O
83 1573 1575 18674790 OB NN B-NP D009765
84 1575 1576 18674790 ) ) O O
85 1576 1577 18674790 , , O O
86 1578 1579 18674790 ( ( O O
87 1579 1580 18674790 5 CD B-NP O
88 1580 1581 18674790 ) ) O O
89 1582 1591 18674790 decreased VBD B-VP O
90 1592 1605 18674790 mitochondrial JJ B-NP O
91 1606 1609 18674790 AMP NN I-NP D000249
92 1609 1610 18674790 - HYPH B-NP O
93 1610 1616 18674790 alpha2 NN I-NP O
94 1617 1624 18674790 protein NN I-NP O
95 1625 1631 18674790 kinase NN I-NP O
96 1631 1632 18674790 , , O O
97 1633 1636 18674790 and CC O O
98 1637 1638 18674790 ( ( O O
99 1638 1639 18674790 6 CD B-NP O
100 1639 1640 18674790 ) ) O O
101 1641 1644 18674790 86% CD B-NP O
102 1645 1649 18674790 drop NN I-NP O
103 1650 1652 18674790 in IN B-PP O
104 1653 1660 18674790 cardiac JJ B-NP O
105 1661 1664 18674790 ATP NN I-NP D000255
106 1665 1671 18674790 levels NNS I-NP O
107 1672 1683 18674790 accompanied VBN B-VP O
108 1684 1686 18674790 by IN B-PP O
109 1687 1696 18674790 decreased VBN B-NP O
110 1697 1700 18674790 ATP NN I-NP D000255
111 1700 1701 18674790 / SYM B-NP O
112 1701 1704 18674790 ADP NN I-NP D000244
113 1705 1710 18674790 ratio NN I-NP O
114 1711 1716 18674790 after IN B-PP O
115 1717 1728 18674790 doxorubicin NN B-NP D004317
116 1729 1743 18674790 administration NN I-NP O
117 1743 1744 18674790 . . O O

1 1745 1754 18674790 Decreased VBN B-NP O
2 1755 1762 18674790 cardiac JJ I-NP O
3 1763 1777 18674790 erythropoietin NN I-NP O
4 1778 1781 18674790 and CC O O
5 1782 1791 18674790 increased VBN B-NP O
6 1792 1797 18674790 SOCS3 NN I-NP O
7 1798 1805 18674790 further RBR B-ADVP O
8 1806 1819 18674790 downregulated VBD B-VP O
9 1820 1823 18674790 the DT B-NP O
10 1824 1840 18674790 cardioprotective JJ I-NP O
11 1841 1844 18674790 JAK NN I-NP O
12 1844 1845 18674790 / SYM B-VP O
13 1845 1850 18674790 STAT3 NN B-NP O
14 1851 1858 18674790 pathway NN I-NP O
15 1858 1859 18674790 . . O O

1 1860 1862 18674790 In IN B-PP O
2 1863 1873 18674790 conclusion NN B-NP O
3 1873 1874 18674790 , , O O
4 1875 1878 18674790 HFD NN B-NP O
5 1878 1879 18674790 - HYPH O O
6 1879 1886 18674790 induced VBN B-NP O
7 1887 1892 18674790 obese JJ I-NP D009765
8 1893 1897 18674790 rats NNS I-NP O
9 1898 1901 18674790 are VBP B-VP O
10 1902 1908 18674790 highly RB I-VP O
11 1909 1919 18674790 sensitized VBN I-VP O
12 1920 1922 18674790 to TO B-PP O
13 1923 1934 18674790 doxorubicin NN B-NP D004317
14 1934 1935 18674790 - HYPH B-NP O
15 1935 1942 18674790 induced VBN I-NP O
16 1943 1957 18674790 cardiotoxicity NN I-NP D066126
17 1958 1960 18674790 by IN B-PP O
18 1961 1974 18674790 substantially RB B-VP O
19 1975 1989 18674790 downregulating VBG I-VP O
20 1990 1997 18674790 cardiac JJ B-NP O
21 1998 2011 18674790 mitochondrial JJ I-NP O
22 2012 2015 18674790 ATP NN I-NP D000255
23 2016 2026 18674790 generation NN I-NP O
24 2026 2027 18674790 , , O O
25 2028 2038 18674790 increasing VBG B-VP O
26 2039 2048 18674790 oxidative JJ B-NP O
27 2049 2055 18674790 stress NN I-NP O
28 2056 2059 18674790 and CC O O
29 2060 2074 18674790 downregulating VBG B-VP O
30 2075 2078 18674790 the DT B-NP O
31 2079 2082 18674790 JAK NN I-NP O
32 2082 2083 18674790 / SYM B-NP O
33 2083 2088 18674790 STAT3 NN I-NP O
34 2089 2096 18674790 pathway NN I-NP O
35 2096 2097 18674790 . . O O

1 0 0 20331935 -DOCSTART- -X- -X- O

1 0 1 20331935 A DT B-NP O
2 2 7 20331935 cross AFX I-NP O
3 7 8 20331935 - HYPH I-NP O
4 8 17 20331935 sectional JJ I-NP O
5 18 28 20331935 evaluation NN I-NP O
6 29 31 20331935 of IN B-PP O
7 32 35 20331935 the DT B-NP O
8 36 42 20331935 effect NN I-NP O
9 43 45 20331935 of IN B-PP O
10 46 57 20331935 risperidone NN B-NP D018967
11 58 61 20331935 and CC I-NP O
12 62 71 20331935 selective JJ I-NP O
13 72 81 20331935 serotonin NN I-NP D012701
14 82 90 20331935 reuptake NN I-NP O
15 91 101 20331935 inhibitors NNS I-NP O
16 102 104 20331935 on IN B-PP O
17 105 109 20331935 bone NN B-NP O
18 110 117 20331935 mineral NN I-NP O
19 118 125 20331935 density NN I-NP O
20 126 128 20331935 in IN B-PP O
21 129 133 20331935 boys NNS B-NP O
22 133 134 20331935 . . O O
23 135 144 20331935 OBJECTIVE NN B-NP O
24 144 145 20331935 : : O O
25 146 149 20331935 The DT B-NP O
26 150 153 20331935 aim NN I-NP O
27 154 156 20331935 of IN B-PP O
28 157 160 20331935 the DT B-NP O
29 161 168 20331935 present JJ I-NP O
30 169 174 20331935 study NN I-NP O
31 175 178 20331935 was VBD B-VP O
32 179 181 20331935 to TO B-VP O
33 182 193 20331935 investigate VB I-VP O
34 194 197 20331935 the DT B-NP O
35 198 204 20331935 effect NN I-NP O
36 205 207 20331935 of IN B-PP O
37 208 219 20331935 risperidone NN B-NP D018967
38 219 220 20331935 - HYPH B-NP O
39 220 227 20331935 induced VBN I-NP O
40 228 246 20331935 hyperprolactinemia NN I-NP D006966
41 247 249 20331935 on IN B-PP O
42 250 260 20331935 trabecular JJ B-NP O
43 261 265 20331935 bone NN I-NP O
44 266 273 20331935 mineral NN I-NP O
45 274 281 20331935 density NN I-NP O
46 282 283 20331935 ( ( O O
47 283 286 20331935 BMD NN B-NP O
48 286 287 20331935 ) ) O O
49 288 290 20331935 in IN B-PP O
50 291 299 20331935 children NNS B-NP O
51 300 303 20331935 and CC I-NP O
52 304 315 20331935 adolescents NNS I-NP O
53 315 316 20331935 . . O O

1 317 323 20331935 METHOD NN B-NP O
2 323 324 20331935 : : O O
3 325 334 20331935 Medically RB B-NP O
4 335 342 20331935 healthy JJ I-NP O
5 343 344 20331935 7 CD I-NP O
6 344 345 20331935 - HYPH B-ADJP O
7 346 348 20331935 to TO B-PP O
8 349 351 20331935 17 CD B-NP O
9 351 352 20331935 - HYPH I-NP O
10 352 356 20331935 year NN I-NP O
11 356 357 20331935 - HYPH O O
12 357 360 20331935 old JJ B-NP O
13 361 366 20331935 males NNS I-NP O
14 367 378 20331935 chronically RB B-VP O
15 379 386 20331935 treated VBN I-VP O
16 386 387 20331935 , , O O
17 388 390 20331935 in IN B-PP O
18 391 392 20331935 a DT B-NP O
19 393 405 20331935 naturalistic JJ I-NP O
20 406 413 20331935 setting NN I-NP O
21 413 414 20331935 , , O O
22 415 419 20331935 with IN B-PP O
23 420 431 20331935 risperidone NN B-NP D018967
24 432 436 20331935 were VBD B-VP O
25 437 446 20331935 recruited VBN I-VP O
26 447 450 20331935 for IN B-PP O
27 451 455 20331935 this DT B-NP O
28 456 461 20331935 cross AFX B-NP O
29 461 462 20331935 - HYPH I-NP O
30 462 471 20331935 sectional JJ I-NP O
31 472 477 20331935 study NN I-NP O
32 478 485 20331935 through IN B-PP O
33 486 491 20331935 child NN B-NP O
34 492 502 20331935 psychiatry NN I-NP O
35 503 513 20331935 outpatient NN I-NP O
36 514 521 20331935 clinics NNS I-NP O
37 522 529 20331935 between IN B-PP O
38 530 538 20331935 November NNP B-NP O
39 539 543 20331935 2005 CD I-NP O
40 544 547 20331935 and CC O O
41 548 552 20331935 June NNP B-NP O
42 553 557 20331935 2007 CD I-NP O
43 557 558 20331935 . . O O

1 559 573 20331935 Anthropometric JJ B-NP O
2 574 586 20331935 measurements NNS I-NP O
3 587 590 20331935 and CC O O
4 591 601 20331935 laboratory NN B-NP O
5 602 609 20331935 testing NN I-NP O
6 610 614 20331935 were VBD B-VP O
7 615 624 20331935 conducted VBN I-VP O
8 624 625 20331935 . . O O

1 626 629 20331935 The DT B-NP O
2 630 638 20331935 clinical JJ I-NP O
3 639 648 20331935 diagnoses NNS I-NP O
4 649 653 20331935 were VBD B-VP O
5 654 659 20331935 based VBN I-VP O
6 660 662 20331935 on IN B-PP O
7 663 668 20331935 chart NN B-NP O
8 669 675 20331935 review NN I-NP O
9 675 676 20331935 , , O O
10 677 680 20331935 and CC O O
11 681 694 20331935 developmental JJ B-NP O
12 695 698 20331935 and CC I-NP O
13 699 708 20331935 treatment NN I-NP O
14 709 716 20331935 history NN I-NP O
15 717 720 20331935 was VBD B-VP O
16 721 729 20331935 obtained VBN I-VP O
17 730 734 20331935 from IN B-PP O
18 735 738 20331935 the DT B-NP O
19 739 746 20331935 medical JJ I-NP O
20 747 753 20331935 record NN I-NP O
21 753 754 20331935 . . O O

1 755 765 20331935 Volumetric JJ B-NP O
2 766 769 20331935 BMD NN I-NP O
3 770 772 20331935 of IN B-PP O
4 773 776 20331935 the DT B-NP O
5 777 788 20331935 ultradistal JJ I-NP O
6 789 795 20331935 radius NN I-NP O
7 796 799 20331935 was VBD B-VP O
8 800 808 20331935 measured VBN I-VP O
9 809 814 20331935 using VBG B-VP O
10 815 825 20331935 peripheral JJ B-NP O
11 826 838 20331935 quantitative JJ I-NP O
12 839 847 20331935 computed VBN I-NP O
13 848 858 20331935 tomography NN I-NP O
14 858 859 20331935 , , O O
15 860 863 20331935 and CC O O
16 864 869 20331935 areal VBP B-VP O
17 870 873 20331935 BMD NN B-NP O
18 874 876 20331935 of IN B-PP O
19 877 880 20331935 the DT B-NP O
20 881 887 20331935 lumbar NN I-NP O
21 888 893 20331935 spine NN I-NP O
22 894 897 20331935 was VBD B-VP O
23 898 907 20331935 estimated VBN I-VP O
24 908 913 20331935 using VBG B-VP O
25 914 918 20331935 dual JJ B-NP O
26 918 919 20331935 - HYPH I-NP O
27 919 925 20331935 energy NN I-NP O
28 926 927 20331935 x SYM O O
29 927 928 20331935 - HYPH O O
30 928 931 20331935 ray NN B-NP O
31 932 946 20331935 absorptiometry NN I-NP O
32 946 947 20331935 . . O O

1 948 955 20331935 RESULTS NNS B-NP O
2 955 956 20331935 : : O O
3 957 975 20331935 Hyperprolactinemia NN B-NP D006966
4 976 979 20331935 was VBD B-VP O
5 980 987 20331935 present JJ B-ADJP O
6 988 990 20331935 in IN B-PP O
7 991 994 20331935 49% CD B-NP O
8 995 997 20331935 of IN B-PP O
9 998 1000 20331935 83 CD B-NP O
10 1001 1005 20331935 boys NNS I-NP O
11 1006 1007 20331935 ( ( O O
12 1007 1008 20331935 n NN B-NP O
13 1009 1010 20331935 = SYM B-VP O
14 1011 1013 20331935 41 CD B-NP O
15 1013 1014 20331935 ) ) O O
16 1015 1022 20331935 treated VBN B-VP O
17 1023 1027 20331935 with IN B-PP O
18 1028 1039 20331935 risperidone NN B-NP D018967
19 1040 1043 20331935 for IN B-PP O
20 1044 1045 20331935 a DT B-NP O
21 1046 1050 20331935 mean NN I-NP O
22 1051 1053 20331935 of IN B-PP O
23 1054 1057 20331935 2.9 CD B-NP O
24 1058 1063 20331935 years NNS I-NP O
25 1063 1064 20331935 . . O O

1 1065 1070 20331935 Serum NN B-NP O
2 1071 1083 20331935 testosterone NN I-NP D013739
3 1084 1097 20331935 concentration NN I-NP O
4 1098 1107 20331935 increased VBD B-VP O
5 1108 1112 20331935 with IN B-PP O
6 1113 1121 20331935 pubertal JJ B-NP O
7 1122 1128 20331935 status NN I-NP O
8 1129 1132 20331935 but CC O O
9 1133 1136 20331935 was VBD B-VP O
10 1137 1140 20331935 not RB I-VP O
11 1141 1149 20331935 affected VBN I-VP O
12 1150 1152 20331935 by IN B-PP O
13 1153 1171 20331935 hyperprolactinemia NN B-NP D006966
14 1171 1172 20331935 . . O O

1 1173 1175 20331935 As IN B-SBAR O
2 1176 1184 20331935 expected VBN B-VP O
3 1184 1185 20331935 , , O O
4 1186 1190 20331935 bone NN B-NP O
5 1191 1198 20331935 mineral NN I-NP O
6 1199 1206 20331935 content NN I-NP O
7 1207 1210 20331935 and CC I-NP O
8 1211 1214 20331935 BMD NN I-NP O
9 1215 1224 20331935 increased VBD B-VP O
10 1225 1229 20331935 with IN B-PP O
11 1230 1236 20331935 sexual JJ B-NP O
12 1237 1245 20331935 maturity NN I-NP O
13 1245 1246 20331935 . . O O

1 1247 1252 20331935 After IN B-PP O
2 1253 1262 20331935 adjusting VBG B-VP O
3 1263 1266 20331935 for IN B-PP O
4 1267 1270 20331935 the DT B-NP O
5 1271 1276 20331935 stage NN I-NP O
6 1277 1279 20331935 of IN B-PP O
7 1280 1286 20331935 sexual JJ B-NP O
8 1287 1298 20331935 development NN I-NP O
9 1299 1302 20331935 and CC O O
10 1303 1309 20331935 height NN B-NP O
11 1310 1313 20331935 and CC I-NP O
12 1314 1317 20331935 BMI NN I-NP O
13 1318 1319 20331935 z NN I-NP O
14 1320 1326 20331935 scores NNS I-NP O
15 1326 1327 20331935 , , O O
16 1328 1333 20331935 serum NN B-NP O
17 1334 1343 20331935 prolactin NN I-NP O
18 1344 1347 20331935 was VBD B-VP O
19 1348 1358 20331935 negatively RB I-VP O
20 1359 1369 20331935 associated VBN I-VP O
21 1370 1374 20331935 with IN B-PP O
22 1375 1385 20331935 trabecular JJ B-NP O
23 1386 1396 20331935 volumetric JJ I-NP O
24 1397 1400 20331935 BMD NN I-NP O
25 1401 1403 20331935 at IN B-PP O
26 1404 1407 20331935 the DT B-NP O
27 1408 1419 20331935 ultradistal JJ I-NP O
28 1420 1426 20331935 radius NN I-NP O
29 1427 1428 20331935 ( ( O O
30 1428 1429 20331935 P NN B-NP O
31 1430 1431 20331935 < JJR B-NP O
32 1432 1435 20331935 .03 CD I-NP O
33 1435 1436 20331935 ) ) O O
34 1436 1437 20331935 . . O O

1 1438 1449 20331935 Controlling VBG B-VP O
2 1450 1453 20331935 for IN B-PP O
3 1454 1462 20331935 relevant JJ B-NP O
4 1463 1473 20331935 covariates NNS I-NP O
5 1473 1474 20331935 , , O O
6 1475 1477 20331935 we PRP B-NP O
7 1478 1482 20331935 also RB B-ADVP O
8 1483 1488 20331935 found VBD B-VP O
9 1489 1498 20331935 treatment NN B-NP O
10 1499 1503 20331935 with IN B-PP O
11 1504 1513 20331935 selective JJ B-NP O
12 1514 1523 20331935 serotonin NN I-NP D012701
13 1524 1532 20331935 reuptake NN I-NP O
14 1533 1543 20331935 inhibitors NNS I-NP O
15 1544 1545 20331935 ( ( O O
16 1545 1550 20331935 SSRIs NNS B-NP O
17 1550 1551 20331935 ) ) O O
18 1552 1554 20331935 to TO B-VP O
19 1555 1557 20331935 be VB I-VP O
20 1558 1568 20331935 associated VBN I-VP O
21 1569 1573 20331935 with IN B-PP O
22 1574 1579 20331935 lower JJR B-NP O
23 1580 1590 20331935 trabecular JJ I-NP O
24 1591 1594 20331935 BMD NN I-NP O
25 1595 1597 20331935 at IN B-PP O
26 1598 1601 20331935 the DT B-NP O
27 1602 1608 20331935 radius NN I-NP O
28 1609 1610 20331935 ( ( O O
29 1610 1611 20331935 P NN B-NP O
30 1612 1613 20331935 = SYM B-VP O
31 1614 1617 20331935 .03 CD B-NP O
32 1617 1618 20331935 ) ) O O
33 1619 1622 20331935 and CC O O
34 1623 1626 20331935 BMD NN B-NP O
35 1627 1628 20331935 z NN I-NP O
36 1629 1634 20331935 score NN I-NP O
37 1635 1637 20331935 at IN B-PP O
38 1638 1641 20331935 the DT B-NP O
39 1642 1648 20331935 lumbar NN I-NP O
40 1649 1654 20331935 spine NN I-NP O
41 1655 1656 20331935 ( ( O O
42 1656 1657 20331935 P NN B-NP O
43 1658 1659 20331935 < JJR B-NP O
44 1660 1663 20331935 .05 CD I-NP O
45 1663 1664 20331935 ) ) O O
46 1664 1665 20331935 . . O O

1 1666 1671 20331935 These DT B-NP O
2 1672 1680 20331935 findings NNS I-NP O
3 1681 1687 20331935 became VBD B-VP O
4 1688 1692 20331935 more RBR B-ADJP O
5 1693 1699 20331935 marked VBN I-ADJP O
6 1700 1704 20331935 when WRB B-ADVP O
7 1705 1708 20331935 the DT B-NP O
8 1709 1717 20331935 analysis NN I-NP O
9 1718 1721 20331935 was VBD B-VP O
10 1722 1732 20331935 restricted JJ B-ADJP O
11 1733 1735 20331935 to TO B-PP O
12 1736 1739 20331935 non AFX B-NP O
13 1739 1740 20331935 - HYPH I-NP O
14 1740 1748 20331935 Hispanic JJ I-NP O
15 1749 1754 20331935 white JJ I-NP O
16 1755 1763 20331935 patients NNS I-NP O
17 1763 1764 20331935 . . O O

1 1765 1767 20331935 Of IN B-PP O
2 1768 1770 20331935 13 CD B-NP O
3 1771 1781 20331935 documented VBN I-NP O
4 1782 1791 20331935 fractures NNS I-NP D050723
5 1791 1792 20331935 , , O O
6 1793 1794 20331935 3 CD B-NP O
7 1795 1803 20331935 occurred VBD B-VP O
8 1804 1809 20331935 after IN B-PP O
9 1810 1821 20331935 risperidone NN B-NP D018967
10 1822 1825 20331935 and CC I-NP O
11 1826 1831 20331935 SSRIs NNS I-NP O
12 1832 1836 20331935 were VBD B-VP O
13 1837 1844 20331935 started VBN I-VP O
14 1844 1845 20331935 , , O O
15 1846 1849 20331935 and CC O O
16 1850 1854 20331935 none NN B-NP O
17 1855 1863 20331935 occurred VBD B-VP O
18 1864 1866 20331935 in IN B-PP O
19 1867 1875 20331935 patients NNS B-NP O
20 1876 1880 20331935 with IN B-PP O
21 1881 1899 20331935 hyperprolactinemia NN B-NP D006966
22 1899 1900 20331935 . . O O

1 1901 1912 20331935 CONCLUSIONS NNS B-NP O
2 1912 1913 20331935 : : O O
3 1914 1918 20331935 This DT B-NP O
4 1919 1921 20331935 is VBZ B-VP O
5 1922 1925 20331935 the DT B-NP O
6 1926 1931 20331935 first JJ I-NP O
7 1932 1937 20331935 study NN I-NP O
8 1938 1940 20331935 to TO B-VP O
9 1941 1945 20331935 link VB I-VP O
10 1946 1957 20331935 risperidone NN B-NP D018967
11 1957 1958 20331935 - HYPH B-NP O
12 1958 1965 20331935 induced VBN I-NP O
13 1966 1984 20331935 hyperprolactinemia NN I-NP D006966
14 1985 1988 20331935 and CC I-NP O
15 1989 1993 20331935 SSRI NN I-NP O
16 1994 2003 20331935 treatment NN I-NP O
17 2004 2006 20331935 to TO B-PP O
18 2007 2012 20331935 lower JJR B-NP O
19 2013 2016 20331935 BMD NN I-NP O
20 2017 2019 20331935 in IN B-PP O
21 2020 2028 20331935 children NNS B-NP O
22 2029 2032 20331935 and CC I-NP O
23 2033 2044 20331935 adolescents NNS I-NP O
24 2044 2045 20331935 . . O O

1 2046 2052 20331935 Future JJ B-NP O
2 2053 2061 20331935 research NN I-NP O
3 2062 2068 20331935 should MD B-VP O
4 2069 2077 20331935 evaluate VB I-VP O
5 2078 2081 20331935 the DT B-NP O
6 2082 2094 20331935 longitudinal JJ I-NP O
7 2095 2101 20331935 course NN I-NP O
8 2102 2104 20331935 of IN B-PP O
9 2105 2109 20331935 this DT B-NP O
10 2110 2117 20331935 adverse JJ I-NP O
11 2118 2123 20331935 event NN I-NP O
12 2124 2126 20331935 to TO B-VP O
13 2127 2136 20331935 determine VB I-VP O
14 2137 2140 20331935 its PRP$ B-NP O
15 2141 2149 20331935 temporal JJ I-NP O
16 2150 2159 20331935 stability NN I-NP O
17 2160 2163 20331935 and CC O O
18 2164 2171 20331935 whether IN B-SBAR O
19 2172 2173 20331935 a DT B-NP O
20 2174 2180 20331935 higher JJR I-NP O
21 2181 2189 20331935 fracture NN I-NP O
22 2190 2194 20331935 rate NN I-NP O
23 2195 2201 20331935 ensues NNS I-NP O
24 2201 2202 20331935 . . O O

1 0 0 12091028 -DOCSTART- -X- -X- O

1 0 8 12091028 Ketamine NN B-NP D007649
2 9 11 12091028 in IN B-PP O
3 12 15 12091028 war NN B-NP O
4 15 16 12091028 / SYM B-NP O
5 16 24 12091028 tropical JJ I-NP O
6 25 32 12091028 surgery NN I-NP O
7 33 34 12091028 ( ( O O
8 34 35 12091028 a DT B-NP O
9 36 41 12091028 final JJ I-NP O
10 42 49 12091028 tribute NN I-NP O
11 50 52 12091028 to TO B-PP O
12 53 56 12091028 the DT B-NP O
13 57 64 12091028 racemic JJ I-NP O
14 65 72 12091028 mixture NN I-NP O
15 72 73 12091028 ) ) O O
16 73 74 12091028 . . O O
17 75 76 12091028 A DT B-NP O
18 77 86 12091028 technique NN I-NP O
19 87 89 12091028 of IN B-PP O
20 90 100 12091028 continuous JJ B-NP O
21 101 112 12091028 intravenous JJ I-NP O
22 113 124 12091028 anaesthesia NN I-NP O
23 125 129 12091028 with IN B-PP O
24 130 138 12091028 ketamine NN B-NP D007649
25 139 142 12091028 was VBD B-VP O
26 143 147 12091028 used VBN I-VP O
27 148 160 12091028 successfully RB B-ADVP O
28 161 167 12091028 during IN B-PP O
29 168 171 12091028 the DT B-NP O
30 172 179 12091028 Somalia NNP I-NP O
31 180 185 12091028 civil JJ I-NP O
32 186 189 12091028 war NN I-NP O
33 190 192 12091028 in IN B-PP O
34 193 197 12091028 1994 CD B-NP O
35 198 201 12091028 and CC O O
36 202 204 12091028 in IN B-PP O
37 205 210 12091028 north JJ B-NP O
38 211 217 12091028 Uganda NNP I-NP O
39 218 220 12091028 in IN B-PP O
40 221 225 12091028 1999 CD B-NP O
41 226 229 12091028 for IN B-PP O
42 230 232 12091028 64 CD B-NP O
43 233 243 12091028 operations NNS I-NP O
44 244 246 12091028 in IN B-PP O
45 247 249 12091028 62 CD B-NP O
46 250 258 12091028 patients NNS I-NP O
47 258 259 12091028 , , O O
48 260 264 12091028 aged VBN B-VP O
49 265 269 12091028 from IN B-PP O
50 270 271 12091028 6 CD B-NP O
51 272 277 12091028 weeks NNS I-NP O
52 278 280 12091028 to TO B-PP O
53 281 283 12091028 70 CD B-NP O
54 284 289 12091028 years NNS I-NP O
55 289 290 12091028 , , O O
56 291 301 12091028 undergoing VBG B-VP O
57 302 306 12091028 limb NN B-NP O
58 307 310 12091028 and CC O O
59 311 320 12091028 abdominal JJ B-NP O
60 321 328 12091028 surgery NN I-NP O
61 329 338 12091028 including VBG B-PP O
62 339 348 12091028 caesarian JJ B-NP O
63 349 357 12091028 sections NNS I-NP O
64 358 361 12091028 and CC I-NP O
65 362 375 12091028 interventions NNS I-NP O
66 376 378 12091028 in IN B-PP O
67 379 387 12091028 neonates NNS B-NP O
68 387 388 12091028 . . O O

1 389 399 12091028 Operations NNS B-NP O
2 400 407 12091028 lasting VBG B-VP O
3 408 410 12091028 up RB B-ADVP O
4 411 413 12091028 to TO B-PP O
5 414 416 12091028 2h NN B-NP O
6 417 422 12091028 could MD B-VP O
7 423 425 12091028 be VB I-VP O
8 426 435 12091028 performed VBN I-VP O
9 436 438 12091028 in IN B-PP O
10 439 442 12091028 the DT B-NP O
11 443 450 12091028 absence NN I-NP O
12 451 453 12091028 of IN B-PP O
13 454 467 12091028 sophisticated JJ B-NP O
14 468 477 12091028 equipment NN I-NP O
15 478 482 12091028 such JJ B-PP O
16 483 485 12091028 as IN I-PP O
17 486 491 12091028 pulse NN B-NP O
18 492 501 12091028 oximeters NNS I-NP O
19 502 504 12091028 or CC O O
20 505 516 12091028 ventilators NNS B-NP O
21 517 519 12091028 in IN B-PP O
22 520 528 12091028 patients NNS B-NP O
23 529 531 12091028 on IN B-PP O
24 532 543 12091028 spontaneous JJ B-NP O
25 544 555 12091028 ventilation NN I-NP O
26 556 565 12091028 breathing NN I-NP O
27 566 569 12091028 air NN I-NP O
28 569 570 12091028 / SYM B-NP O
29 570 576 12091028 oxygen NN I-NP D010100
30 577 581 12091028 only RB B-ADVP O
31 581 582 12091028 . . O O

1 583 588 12091028 After IN B-PP O
2 589 602 12091028 premedication NN B-NP O
3 603 607 12091028 with IN B-PP O
4 608 616 12091028 diazepam NN B-NP D003975
5 616 617 12091028 , , I-NP O
6 618 632 12091028 glycopyrrolate NN I-NP D006024
7 633 636 12091028 and CC I-NP O
8 637 642 12091028 local JJ I-NP O
9 643 654 12091028 anaesthesia NN I-NP O
10 654 655 12091028 , , O O
11 656 659 12091028 and CC O O
12 660 669 12091028 induction NN B-NP O
13 670 674 12091028 with IN B-PP O
14 675 683 12091028 standard JJ B-NP O
15 684 689 12091028 doses NNS I-NP O
16 690 692 12091028 of IN B-PP O
17 693 701 12091028 ketamine NN B-NP D007649
18 701 702 12091028 , , O O
19 703 704 12091028 a DT B-NP O
20 705 716 12091028 maintenance NN I-NP O
21 717 721 12091028 dose NN I-NP O
22 722 724 12091028 of IN B-PP O
23 725 727 12091028 10 CD B-NP O
24 727 728 12091028 - HYPH I-NP O
25 728 730 12091028 20 CD I-NP O
26 731 737 12091028 microg NN I-NP O
27 737 738 12091028 / SYM B-NP O
28 738 740 12091028 kg NN I-NP O
29 740 741 12091028 / SYM I-NP O
30 741 744 12091028 min NN I-NP O
31 745 747 12091028 of IN B-PP O
32 748 756 12091028 ketamine NN B-NP D007649
33 757 763 12091028 proved VBD B-VP O
34 764 768 12091028 safe JJ B-ADJP O
35 769 772 12091028 and CC I-ADJP O
36 773 782 12091028 effective JJ I-ADJP O
37 782 783 12091028 . . O O

1 784 792 12091028 Emphasis NN B-NP O
2 793 796 12091028 was VBD B-VP O
3 797 803 12091028 placed VBN I-VP O
4 804 806 12091028 on IN B-PP O
5 807 814 12091028 bedside NN B-NP O
6 815 823 12091028 clinical JJ I-NP O
7 824 834 12091028 monitoring NN I-NP O
8 834 835 12091028 , , O O
9 836 843 12091028 relying VBG B-VP O
10 844 851 12091028 heavily RB B-ADVP O
11 852 854 12091028 on IN B-PP O
12 855 858 12091028 the DT B-NP O
13 859 864 12091028 heart NN I-NP O
14 865 869 12091028 rate NN I-NP O
15 869 870 12091028 . . O O

1 871 879 12091028 Diazepam NN B-NP D003975
2 879 880 12091028 , , O O
3 881 887 12091028 unless IN B-SBAR O
4 888 903 12091028 contraindicated VBN B-NP O
5 904 906 12091028 or CC I-NP O
6 907 912 12091028 risky JJ I-NP O
7 912 913 12091028 , , O O
8 914 921 12091028 remains VBZ B-VP O
9 922 925 12091028 the DT B-NP O
10 926 930 12091028 only RB I-NP O
11 931 940 12091028 necessary JJ I-NP O
12 941 954 12091028 complementary JJ I-NP O
13 955 959 12091028 drug NN I-NP O
14 960 962 12091028 to TO B-PP O
15 963 971 12091028 ketamine NN B-NP D007649
16 972 974 12091028 as IN B-SBAR O
17 975 977 12091028 it PRP B-NP O
18 978 985 12091028 buffers VBZ B-VP O
19 986 989 12091028 its PRP$ B-NP O
20 990 1004 12091028 cardiovascular JJ I-NP O
21 1005 1013 12091028 response NN I-NP O
22 1014 1017 12091028 and CC O O
23 1018 1027 12091028 decreases VBZ B-VP O
24 1028 1031 12091028 the DT B-NP O
25 1032 1040 12091028 duration NN I-NP O
26 1041 1044 12091028 and CC I-NP O
27 1045 1054 12091028 intensity NN I-NP O
28 1055 1057 12091028 of IN B-PP O
29 1058 1067 12091028 operative JJ B-NP O
30 1068 1071 12091028 and CC I-NP O
31 1072 1085 12091028 postoperative JJ I-NP O
32 1086 1100 12091028 hallucinations NNS I-NP D006212
33 1100 1101 12091028 . . O O

1 1102 1107 12091028 Local JJ B-NP O
2 1108 1119 12091028 anaesthetic JJ I-NP O
3 1120 1126 12091028 blocks NNS I-NP O
4 1127 1131 12091028 were VBD B-VP O
5 1132 1138 12091028 useful JJ B-ADJP O
6 1139 1141 12091028 in IN B-PP O
7 1142 1152 12091028 decreasing VBG B-VP O
8 1153 1156 12091028 the DT B-NP O
9 1157 1168 12091028 requirement NN I-NP O
10 1169 1172 12091028 for IN B-PP O
11 1173 1186 12091028 postoperative JJ B-NP O
12 1187 1196 12091028 analgesia NN I-NP D000699
13 1196 1197 12091028 . . O O

1 1198 1200 12091028 An DT B-NP O
2 1201 1213 12091028 antisialogue NN I-NP O
3 1214 1217 12091028 was VBD B-VP O
4 1218 1225 12091028 usually RB B-ADJP O
5 1226 1237 12091028 unnecessary JJ I-ADJP O
6 1238 1240 12091028 in IN B-PP O
7 1241 1251 12091028 operations NNS B-NP O
8 1252 1259 12091028 lasting VBG B-VP O
9 1260 1262 12091028 up RB B-NP O
10 1263 1265 12091028 to TO I-NP O
11 1266 1267 12091028 2 CD I-NP O
12 1268 1269 12091028 h NN I-NP O
13 1269 1270 12091028 , , O O
14 1271 1285 12091028 glycopyrrolate NN B-NP D006024
15 1286 1291 12091028 being VBG B-VP O
16 1292 1295 12091028 the DT B-NP O
17 1296 1300 12091028 best JJS I-NP O
18 1301 1307 12091028 choice NN I-NP O
19 1308 1311 12091028 for IN B-PP O
20 1312 1315 12091028 its PRP$ B-NP O
21 1316 1322 12091028 lowest JJS I-NP O
22 1323 1335 12091028 psychotropic JJ I-NP O
23 1336 1339 12091028 and CC I-NP O
24 1340 1352 12091028 chronotropic JJ I-NP O
25 1353 1360 12091028 effects NNS I-NP O
26 1360 1361 12091028 , , O O
27 1362 1372 12091028 especially RB B-ADVP O
28 1373 1375 12091028 in IN B-PP O
29 1376 1377 12091028 a DT B-NP O
30 1378 1381 12091028 hot JJ I-NP O
31 1382 1389 12091028 climate NN I-NP O
32 1389 1390 12091028 . . O O

1 1391 1401 12091028 Experience NN B-NP O
2 1402 1404 12091028 in IN B-PP O
3 1405 1408 12091028 war NN B-NP O
4 1408 1409 12091028 / SYM B-NP O
5 1409 1417 12091028 tropical JJ I-NP O
6 1418 1426 12091028 settings NNS I-NP O
7 1427 1435 12091028 suggests VBZ B-VP O
8 1436 1440 12091028 this DT B-NP O
9 1441 1450 12091028 technique NN I-NP O
10 1451 1456 12091028 could MD B-VP O
11 1457 1459 12091028 be VB I-VP O
12 1460 1466 12091028 useful JJ B-ADJP O
13 1467 1469 12091028 in IN B-PP O
14 1470 1478 12091028 civilian JJ B-NP O
15 1479 1487 12091028 contexts NNS I-NP O
16 1488 1492 12091028 such JJ B-PP O
17 1493 1495 12091028 as IN I-PP O
18 1496 1503 12091028 outdoor JJ B-NP O
19 1504 1508 12091028 life NN I-NP O
20 1508 1509 12091028 - HYPH O O
21 1509 1515 12091028 saving VBG B-VP O
22 1516 1525 12091028 emergency NN B-NP O
23 1526 1533 12091028 surgery NN I-NP O
24 1534 1536 12091028 or CC B-PP O
25 1537 1539 12091028 in IN B-PP O
26 1540 1544 12091028 mass NN B-NP O
27 1545 1555 12091028 casualties NNS I-NP O
28 1556 1561 12091028 where WRB B-ADVP O
29 1561 1562 12091028 , , O O
30 1563 1567 12091028 e.g. FW B-NP O

1 1568 1578 12091028 amputation NN B-NP O
2 1579 1582 12091028 and CC O O
3 1583 1588 12091028 rapid JJ B-NP O
4 1589 1600 12091028 extrication NN I-NP O
5 1601 1605 12091028 were VBD B-VP O
6 1606 1614 12091028 required VBN I-VP O
7 1614 1615 12091028 . . O O

1 0 0 9121607 -DOCSTART- -X- -X- O

1 0 11 9121607 Neuroactive JJ B-NP O
2 12 20 9121607 steroids NNS I-NP D013256
3 21 28 9121607 protect VBP B-VP O
4 29 36 9121607 against IN B-PP O
5 37 48 9121607 pilocarpine NN B-NP D010862
6 48 49 9121607 - HYPH O O
7 50 53 9121607 and CC O O
8 54 60 9121607 kainic JJ B-NP D007608
9 61 65 9121607 acid NN I-NP D007608
10 65 66 9121607 - HYPH O O
11 66 73 9121607 induced VBN B-NP O
12 74 80 9121607 limbic JJ I-NP O
13 81 89 9121607 seizures NNS I-NP D012640
14 90 93 9121607 and CC O O
15 94 100 9121607 status NN B-NP D013226
16 101 112 9121607 epilepticus NN I-NP D013226
17 113 115 9121607 in IN B-PP O
18 116 120 9121607 mice NNS B-NP O
19 120 121 9121607 . . O O
20 122 129 9121607 Several JJ B-NP O
21 130 142 9121607 structurally RB I-NP O
22 143 150 9121607 related VBN I-NP O
23 151 162 9121607 metabolites NNS I-NP O
24 163 165 9121607 of IN B-PP O
25 166 178 9121607 progesterone NN B-NP D011374
26 179 180 9121607 ( ( O O
27 180 181 9121607 3 CD B-NP D011374
28 182 187 9121607 alpha SYM O D011374
29 187 188 9121607 - HYPH O D011374
30 188 195 9121607 hydroxy NN B-NP D011374
31 196 204 9121607 pregnane NN I-NP D011374
32 204 205 9121607 - HYPH B-NP D011374
33 205 207 9121607 20 CD I-NP D011374
34 207 208 9121607 - HYPH I-NP D011374
35 208 212 9121607 ones NNS I-NP D011374
36 212 213 9121607 ) ) O O
37 214 217 9121607 and CC O O
38 218 237 9121607 deoxycorticosterone NN B-NP D003900
39 238 239 9121607 ( ( O O
40 239 240 9121607 3 CD B-NP D003900
41 241 246 9121607 alpha SYM O D003900
42 246 247 9121607 - HYPH O D003900
43 247 254 9121607 hydroxy NN B-NP D003900
44 255 263 9121607 pregnane NN I-NP D003900
45 263 264 9121607 - HYPH B-NP D003900
46 264 266 9121607 21 CD I-NP D003900
47 266 267 9121607 - HYPH I-NP D003900
48 267 271 9121607 diol NN I-NP D003900
49 271 272 9121607 - HYPH B-NP D003900
50 272 274 9121607 20 CD I-NP D003900
51 274 275 9121607 - HYPH I-NP D003900
52 275 279 9121607 ones NNS I-NP D003900
53 279 280 9121607 ) ) O O
54 281 284 9121607 and CC O O
55 285 290 9121607 their PRP$ B-NP O
56 291 292 9121607 3 CD I-NP O
57 293 297 9121607 beta SYM I-NP O
58 297 298 9121607 - HYPH I-NP O
59 298 305 9121607 epimers NNS I-NP O
60 306 310 9121607 were VBD B-VP O
61 311 320 9121607 evaluated VBN I-VP O
62 321 324 9121607 for IN B-PP O
63 325 335 9121607 protective JJ B-NP O
64 336 344 9121607 activity NN I-NP O
65 345 352 9121607 against IN B-PP O
66 353 364 9121607 pilocarpine NN B-NP D010862
67 364 365 9121607 - HYPH O O
68 365 366 9121607 , , O O
69 367 373 9121607 kainic JJ B-NP D007608
70 374 378 9121607 acid NN I-NP D007608
71 378 379 9121607 - HYPH O O
72 380 383 9121607 and CC O O
73 384 385 9121607 N NN B-NP D016202
74 385 386 9121607 - HYPH B-NP D016202
75 386 392 9121607 methyl NN I-NP D016202
76 392 393 9121607 - HYPH B-NP D016202
77 393 394 9121607 D NN I-NP D016202
78 394 395 9121607 - HYPH O D016202
79 395 404 9121607 aspartate NN B-NP D016202
80 405 406 9121607 ( ( O O
81 406 410 9121607 NMDA NN B-NP D016202
82 410 411 9121607 ) ) O O
83 411 412 9121607 - HYPH B-NP O
84 412 419 9121607 induced VBN I-NP O
85 420 428 9121607 seizures NNS I-NP D012640
86 429 431 9121607 in IN B-PP O
87 432 436 9121607 mice NNS B-NP O
88 436 437 9121607 . . O O

1 438 446 9121607 Steroids NNS B-NP D013256
2 447 451 9121607 with IN B-PP O
3 452 455 9121607 the DT B-NP O
4 456 457 9121607 3 CD I-NP O
5 457 458 9121607 - HYPH I-NP O
6 458 465 9121607 hydroxy NN I-NP O
7 466 471 9121607 group NN I-NP O
8 472 474 9121607 in IN B-PP O
9 475 478 9121607 the DT B-NP O
10 479 484 9121607 alpha SYM I-NP O
11 484 485 9121607 - HYPH I-NP O
12 485 493 9121607 position NN I-NP O
13 494 497 9121607 and CC I-NP O
14 498 499 9121607 5 CD I-NP O
15 499 500 9121607 - HYPH I-NP O
16 500 501 9121607 H NN I-NP O
17 502 504 9121607 in IN B-PP O
18 505 508 9121607 the DT B-NP O
19 509 514 9121607 alpha SYM I-NP O
20 514 515 9121607 - HYPH I-NP O
21 516 518 9121607 or CC O O
22 519 523 9121607 beta SYM B-NP O
23 523 524 9121607 - HYPH B-VP O
24 524 538 9121607 configurations NNS B-NP O
25 539 543 9121607 were VBD B-VP O
26 544 550 9121607 highly RB B-ADJP O
27 551 560 9121607 effective JJ I-ADJP O
28 561 563 9121607 in IN B-PP O
29 564 574 9121607 protecting VBG B-VP O
30 575 582 9121607 against IN B-PP O
31 583 594 9121607 pilocarpine NN B-NP D010862
32 595 596 9121607 ( ( O O
33 596 599 9121607 416 CD B-NP O
34 600 602 9121607 mg NN I-NP O
35 602 603 9121607 / SYM B-NP O
36 603 605 9121607 kg NN I-NP O
37 605 606 9121607 , , O O
38 607 610 9121607 s.c NN B-NP O
39 610 611 9121607 . . O O
40 611 612 9121607 ) ) O O
41 612 613 9121607 - HYPH B-NP O
42 613 620 9121607 induced VBN I-NP O
43 621 627 9121607 limbic JJ I-NP O
44 628 633 9121607 motor NN I-NP O
45 634 642 9121607 seizures NNS I-NP D012640
46 643 646 9121607 and CC O O
47 647 653 9121607 status NN B-NP D013226
48 654 665 9121607 epilepticus NN I-NP D013226
49 666 667 9121607 ( ( O O
50 667 671 9121607 ED50 NN B-NP O
51 672 678 9121607 values NNS I-NP O
52 678 679 9121607 , , O O
53 680 683 9121607 7.0 CD B-NP O
54 683 684 9121607 - HYPH I-NP O
55 684 688 9121607 18.7 CD I-NP O
56 689 691 9121607 mg NN I-NP O
57 691 692 9121607 / SYM B-NP O
58 692 694 9121607 kg NN I-NP O
59 694 695 9121607 , , O O
60 696 699 9121607 i.p NN B-NP O
61 699 700 9121607 . . O O
62 700 701 9121607 ) ) O O
63 701 702 9121607 . . O O

1 703 706 9121607 The DT B-NP O
2 707 720 9121607 corresponding VBG I-NP O
3 721 728 9121607 epimers NNS I-NP O
4 729 733 9121607 with IN B-PP O
5 734 737 9121607 the DT B-NP O
6 738 739 9121607 3 CD I-NP O
7 739 740 9121607 - HYPH I-NP O
8 740 747 9121607 hydroxy NN I-NP O
9 748 753 9121607 group NN I-NP O
10 754 756 9121607 in IN B-PP O
11 757 760 9121607 the DT B-NP O
12 761 765 9121607 beta SYM I-NP O
13 765 766 9121607 - HYPH I-NP O
14 766 774 9121607 position NN I-NP O
15 775 779 9121607 were VBD B-VP O
16 780 784 9121607 also RB B-ADVP O
17 785 794 9121607 effective JJ B-ADJP O
18 795 798 9121607 but CC O O
19 799 803 9121607 less RBR B-ADJP O
20 804 810 9121607 potent JJ I-ADJP O
21 811 812 9121607 ( ( O O
22 812 816 9121607 ED50 NN B-NP O
23 817 823 9121607 values NNS I-NP O
24 823 824 9121607 , , O O
25 825 829 9121607 33.8 CD B-NP O
26 829 830 9121607 - HYPH I-NP O
27 830 834 9121607 63.5 CD I-NP O
28 834 835 9121607 , , O O
29 836 839 9121607 i.p JJ B-ADVP O
30 839 840 9121607 . . O O
31 840 841 9121607 ) ) O O
32 841 842 9121607 . . O O

1 843 851 9121607 Although IN B-SBAR O
2 852 855 9121607 the DT B-NP O
3 856 867 9121607 neuroactive JJ I-NP O
4 868 876 9121607 steroids NNS I-NP D013256
5 877 881 9121607 were VBD B-VP O
6 882 894 9121607 considerably RB B-ADJP O
7 895 899 9121607 less RBR I-ADJP O
8 900 906 9121607 potent JJ I-ADJP O
9 907 911 9121607 than IN B-PP O
10 912 915 9121607 the DT B-NP O
11 916 930 9121607 benzodiazepine NN I-NP D001569
12 931 941 9121607 clonazepam NN I-NP D002998
13 942 944 9121607 in IN B-PP O
14 945 955 9121607 protecting VBG B-VP O
15 956 963 9121607 against IN B-PP O
16 964 975 9121607 pilocarpine NN B-NP D010862
17 976 984 9121607 seizures NNS I-NP D012640
18 984 985 9121607 , , O O
19 986 994 9121607 steroids NNS B-NP D013256
20 995 999 9121607 with IN B-PP O
21 1000 1003 9121607 the DT B-NP O
22 1004 1005 9121607 5 CD I-NP O
23 1006 1013 9121607 alpha,3 NN I-NP O
24 1014 1019 9121607 alpha SYM O O
25 1019 1020 9121607 - HYPH O O
26 1020 1033 9121607 configuration NN B-NP O
27 1034 1037 9121607 had VBD B-VP O
28 1038 1048 9121607 comparable JJ B-NP O
29 1049 1051 9121607 or CC I-NP O
30 1052 1058 9121607 higher JJR I-NP O
31 1059 1069 9121607 protective JJ I-NP O
32 1070 1075 9121607 index NN I-NP O
33 1076 1082 9121607 values NNS I-NP O
34 1083 1084 9121607 ( ( O O
35 1084 1088 9121607 TD50 NN B-NP O
36 1089 1092 9121607 for IN B-PP O
37 1093 1098 9121607 motor NN B-NP O
38 1099 1109 9121607 impairment NN I-NP O
39 1110 1117 9121607 divided VBN B-VP O
40 1118 1120 9121607 by IN B-PP O
41 1121 1125 9121607 ED50 NN B-NP O
42 1126 1129 9121607 for IN B-PP O
43 1130 1137 9121607 seizure NN B-NP D012640
44 1138 1148 9121607 protection NN I-NP O
45 1148 1149 9121607 ) ) O O
46 1150 1154 9121607 than IN B-PP O
47 1155 1165 9121607 clonazepam NN B-NP D002998
48 1165 1166 9121607 , , O O
49 1167 1177 9121607 indicating VBG B-VP O
50 1178 1182 9121607 that IN B-SBAR O
51 1183 1187 9121607 some DT B-NP O
52 1188 1199 9121607 neuroactive JJ I-NP O
53 1200 1208 9121607 steroids NNS I-NP D013256
54 1209 1212 9121607 may MD B-VP O
55 1213 1217 9121607 have VB I-VP O
56 1218 1223 9121607 lower JJR B-NP O
57 1224 1232 9121607 relative JJ I-NP O
58 1233 1241 9121607 toxicity NN I-NP D064420
59 1241 1242 9121607 . . O O

1 1243 1251 9121607 Steroids NNS B-NP D013256
2 1252 1256 9121607 with IN B-PP O
3 1257 1260 9121607 the DT B-NP O
4 1261 1262 9121607 5 CD I-NP O
5 1263 1270 9121607 alpha,3 NN I-NP O
6 1271 1276 9121607 alpha SYM B-NP O
7 1276 1277 9121607 - HYPH B-VP O
8 1278 1280 9121607 or CC O O
9 1281 1282 9121607 5 CD B-NP O
10 1283 1289 9121607 beta,3 NN I-NP O
11 1290 1295 9121607 alpha SYM O O
12 1295 1296 9121607 - HYPH O O
13 1296 1310 9121607 configurations NNS B-NP O
14 1311 1315 9121607 also RB B-ADVP O
15 1316 1324 9121607 produced VBD B-VP O
16 1325 1326 9121607 a DT B-NP O
17 1327 1331 9121607 dose NN I-NP O
18 1331 1332 9121607 - HYPH B-NP O
19 1332 1341 9121607 dependent JJ I-NP O
20 1342 1347 9121607 delay NN I-NP O
21 1348 1350 9121607 in IN B-PP O
22 1351 1354 9121607 the DT B-NP O
23 1355 1360 9121607 onset NN I-NP O
24 1361 1363 9121607 of IN B-PP O
25 1364 1370 9121607 limbic JJ B-NP O
26 1371 1379 9121607 seizures NNS I-NP D012640
27 1380 1387 9121607 induced VBN B-VP O
28 1388 1390 9121607 by IN B-PP O
29 1391 1397 9121607 kainic JJ B-NP D007608
30 1398 1402 9121607 acid NN I-NP D007608
31 1403 1404 9121607 ( ( O O
32 1404 1406 9121607 32 CD B-NP O
33 1407 1409 9121607 mg NN I-NP O
34 1409 1410 9121607 / SYM B-NP O
35 1410 1412 9121607 kg NN I-NP O
36 1412 1413 9121607 , , O O
37 1414 1417 9121607 s.c NN B-NP O
38 1417 1418 9121607 . . O O
39 1418 1419 9121607 ) ) O O
40 1419 1420 9121607 , , O O
41 1421 1424 9121607 but CC O O
42 1425 1428 9121607 did VBD B-VP O
43 1429 1432 9121607 not RB I-VP O
44 1433 1443 9121607 completely RB I-VP O
45 1444 1451 9121607 protect VB I-VP O
46 1452 1459 9121607 against IN B-PP O
47 1460 1463 9121607 the DT B-NP O
48 1464 1472 9121607 seizures NNS I-NP D012640
49 1472 1473 9121607 . . O O

1 1474 1481 9121607 However RB B-ADVP O
2 1481 1482 9121607 , , O O
3 1483 1487 9121607 when WRB B-ADVP O
4 1488 1489 9121607 a DT B-NP O
5 1490 1496 9121607 second JJ I-NP O
6 1497 1501 9121607 dose NN I-NP O
7 1502 1504 9121607 of IN B-PP O
8 1505 1508 9121607 the DT B-NP O
9 1509 1516 9121607 steroid NN I-NP D013256
10 1517 1520 9121607 was VBD B-VP O
11 1521 1533 9121607 administered VBN I-VP O
12 1534 1535 9121607 1 CD B-NP O
13 1536 1538 9121607 hr NN I-NP O
14 1539 1544 9121607 after IN B-PP O
15 1545 1548 9121607 the DT B-NP O
16 1549 1554 9121607 first JJ I-NP O
17 1555 1559 9121607 dose NN I-NP O
18 1559 1560 9121607 , , O O
19 1561 1569 9121607 complete JJ B-NP O
20 1570 1580 9121607 protection NN I-NP O
21 1581 1585 9121607 from IN B-PP O
22 1586 1589 9121607 the DT B-NP O
23 1590 1596 9121607 kainic JJ I-NP D007608
24 1597 1601 9121607 acid NN I-NP D007608
25 1601 1602 9121607 - HYPH O O
26 1602 1609 9121607 induced VBN B-NP O
27 1610 1616 9121607 limbic JJ I-NP O
28 1617 1625 9121607 seizures NNS I-NP D012640
29 1626 1629 9121607 and CC O O
30 1630 1636 9121607 status NN B-NP D013226
31 1637 1648 9121607 epilepticus NN I-NP D013226
32 1649 1652 9121607 was VBD B-VP O
33 1653 1661 9121607 obtained VBN I-VP O
34 1661 1662 9121607 . . O O

1 1663 1666 9121607 The DT B-NP O
2 1667 1675 9121607 steroids NNS I-NP D013256
3 1676 1680 9121607 also RB B-ADVP O
4 1681 1687 9121607 caused VBD B-VP O
5 1688 1689 9121607 a DT B-NP O
6 1690 1694 9121607 dose NN I-NP O
7 1694 1695 9121607 - HYPH B-NP O
8 1695 1704 9121607 dependent JJ I-NP O
9 1705 1710 9121607 delay NN I-NP O
10 1711 1713 9121607 in IN B-PP O
11 1714 1718 9121607 NMDA NN B-NP D016202
12 1719 1720 9121607 ( ( O O
13 1720 1723 9121607 257 CD B-NP O
14 1724 1726 9121607 mg NN I-NP O
15 1726 1727 9121607 / SYM B-NP O
16 1727 1729 9121607 kg NN I-NP O
17 1729 1730 9121607 , , O O
18 1731 1734 9121607 s.c NN B-NP O
19 1734 1735 9121607 . . O O
20 1735 1736 9121607 ) ) O O
21 1736 1737 9121607 - HYPH B-NP O
22 1737 1744 9121607 induced VBN I-NP O
23 1745 1754 9121607 lethality NN I-NP O
24 1754 1755 9121607 , , O O
25 1756 1759 9121607 but CC O O
26 1760 1763 9121607 did VBD B-VP O
27 1764 1767 9121607 not RB I-VP O
28 1768 1778 9121607 completely RB I-VP O
29 1779 1786 9121607 protect VB I-VP O
30 1787 1794 9121607 against IN B-PP O
31 1795 1799 9121607 NMDA NN B-NP D016202
32 1800 1808 9121607 seizures NNS I-NP D012640
33 1809 1811 9121607 or CC O O
34 1812 1821 9121607 lethality NN B-NP O
35 1821 1822 9121607 . . O O

1 1823 1825 9121607 We PRP B-NP O
2 1826 1834 9121607 conclude VBP B-VP O
3 1835 1839 9121607 that IN B-SBAR O
4 1840 1851 9121607 neuroactive JJ B-NP O
5 1852 1860 9121607 steroids NNS I-NP D013256
6 1861 1864 9121607 are VBP B-VP O
7 1865 1871 9121607 highly RB B-ADJP O
8 1872 1881 9121607 effective JJ I-ADJP O
9 1882 1884 9121607 in IN B-PP O
10 1885 1895 9121607 protecting VBG B-VP O
11 1896 1903 9121607 against IN B-PP O
12 1904 1915 9121607 pilocarpine NN B-NP D010862
13 1915 1916 9121607 - HYPH O O
14 1917 1920 9121607 and CC O O
15 1921 1927 9121607 kainic JJ B-NP D007608
16 1928 1932 9121607 acid NN I-NP D007608
17 1932 1933 9121607 - HYPH B-NP O
18 1933 1940 9121607 induced VBN I-NP O
19 1941 1949 9121607 seizures NNS I-NP D012640
20 1950 1953 9121607 and CC O O
21 1954 1960 9121607 status NN B-NP D013226
22 1961 1972 9121607 epilepticus NN I-NP D013226
23 1973 1975 9121607 in IN B-PP O
24 1976 1980 9121607 mice NNS B-NP O
25 1980 1981 9121607 , , O O
26 1982 1985 9121607 and CC O O
27 1986 1989 9121607 may MD B-VP O
28 1990 1992 9121607 be VB I-VP O
29 1993 1995 9121607 of IN B-PP O
30 1996 2003 9121607 utility NN B-NP O
31 2004 2006 9121607 in IN B-PP O
32 2007 2010 9121607 the DT B-NP O
33 2011 2020 9121607 treatment NN I-NP O
34 2021 2023 9121607 of IN B-PP O
35 2024 2028 9121607 some DT B-NP O
36 2029 2034 9121607 forms NNS I-NP O
37 2035 2037 9121607 of IN B-PP O
38 2038 2044 9121607 status NN B-NP D013226
39 2045 2056 9121607 epilepticus NN I-NP D013226
40 2057 2059 9121607 in IN B-PP O
41 2060 2066 9121607 humans NNS B-NP O
42 2066 2067 9121607 . . O O

1 0 0 6293644 -DOCSTART- -X- -X- O

1 0 7 6293644 Effects NNS B-NP O
2 8 10 6293644 of IN B-PP O
3 11 21 6293644 calcitonin NN B-NP O
4 22 24 6293644 on IN B-PP O
5 25 28 6293644 rat NN B-NP O
6 29 43 6293644 extrapyramidal JJ I-NP O
7 44 49 6293644 motor NN I-NP O
8 50 56 6293644 system NN I-NP O
9 56 57 6293644 : : O O
10 58 68 6293644 behavioral JJ B-NP O
11 69 72 6293644 and CC I-NP O
12 73 84 6293644 biochemical JJ I-NP O
13 85 89 6293644 data NNS I-NP O
14 89 90 6293644 . . O O
15 91 94 6293644 The DT B-NP O
16 95 102 6293644 effects NNS I-NP O
17 103 105 6293644 of IN B-PP O
18 106 111 6293644 i.v.c NN B-NP O
19 111 112 6293644 . . O O

1 113 122 6293644 injection NN B-NP O
2 123 125 6293644 of IN B-PP O
3 126 131 6293644 human JJ B-NP O
4 132 135 6293644 and CC I-NP O
5 136 142 6293644 salmon NN I-NP O
6 143 153 6293644 calcitonin NN I-NP O
7 154 156 6293644 on IN B-PP O
8 157 168 6293644 biochemical JJ B-NP O
9 169 172 6293644 and CC I-NP O
10 173 183 6293644 behavioral JJ I-NP O
11 184 194 6293644 parameters NNS I-NP O
12 195 202 6293644 related VBN B-VP O
13 203 205 6293644 to TO B-PP O
14 206 209 6293644 the DT B-NP O
15 210 224 6293644 extrapyramidal JJ I-NP O
16 225 230 6293644 motor NN I-NP O
17 231 237 6293644 system NN I-NP O
18 237 238 6293644 , , O O
19 239 243 6293644 were VBD B-VP O
20 244 256 6293644 investigated VBN I-VP O
21 257 259 6293644 in IN B-PP O
22 260 264 6293644 male JJ B-NP O
23 265 269 6293644 rats NNS I-NP O
24 269 270 6293644 . . O O

1 271 281 6293644 Calcitonin NN B-NP O
2 282 291 6293644 injection NN I-NP O
3 292 300 6293644 resulted VBD B-VP O
4 301 303 6293644 in IN B-PP O
5 304 305 6293644 a DT B-NP O
6 306 318 6293644 potentiation NN I-NP O
7 319 321 6293644 of IN B-PP O
8 322 333 6293644 haloperidol NN B-NP D006220
9 333 334 6293644 - HYPH B-NP O
10 334 341 6293644 induced VBN I-NP O
11 342 351 6293644 catalepsy NN I-NP D002375
12 352 355 6293644 and CC O O
13 356 357 6293644 a DT B-NP O
14 358 365 6293644 partial JJ I-NP O
15 366 376 6293644 prevention NN I-NP O
16 377 379 6293644 of IN B-PP O
17 380 391 6293644 apomorphine NN B-NP D001058
18 391 392 6293644 - HYPH B-NP O
19 392 399 6293644 induced VBN I-NP O
20 400 413 6293644 hyperactivity NN I-NP D006948
21 413 414 6293644 . . O O

1 415 423 6293644 Moreover RB B-NP O
2 424 434 6293644 calcitonin NN I-NP O
3 435 442 6293644 induced VBD B-VP O
4 443 444 6293644 a DT B-NP O
5 445 456 6293644 significant JJ I-NP O
6 457 465 6293644 decrease NN I-NP O
7 466 468 6293644 in IN B-PP O
8 469 475 6293644 nigral JJ B-NP O
9 476 479 6293644 GAD NN I-NP O
10 480 488 6293644 activity NN I-NP O
11 489 492 6293644 but CC O O
12 493 495 6293644 no DT B-NP O
13 496 502 6293644 change NN I-NP O
14 503 505 6293644 in IN B-PP O
15 506 514 6293644 striatal JJ B-NP O
16 515 517 6293644 DA NN I-NP D004298
17 518 521 6293644 and CC I-NP O
18 522 527 6293644 DOPAC NN I-NP D015102
19 528 541 6293644 concentration NN I-NP O
20 542 544 6293644 or CC O O
21 545 548 6293644 GAD NN B-NP O
22 549 557 6293644 activity NN I-NP O
23 557 558 6293644 . . O O

1 559 562 6293644 The DT B-NP O
2 563 570 6293644 results NNS I-NP O
3 571 574 6293644 are VBP B-VP O
4 575 584 6293644 discussed VBN I-VP O
5 585 587 6293644 in IN B-PP O
6 588 592 6293644 view NN B-NP O
7 593 595 6293644 of IN B-PP O
8 596 597 6293644 a DT B-NP O
9 598 605 6293644 primary JJ I-NP O
10 606 612 6293644 action NN I-NP O
11 613 615 6293644 of IN B-PP O
12 616 626 6293644 calcitonin NN B-NP O
13 627 629 6293644 on IN B-PP O
14 630 633 6293644 the DT B-NP O
15 634 647 6293644 striatonigral JJ I-NP O
16 648 657 6293644 GABAergic JJ I-NP O
17 658 665 6293644 pathway NN I-NP O
18 666 675 6293644 mediating VBG B-VP O
19 676 679 6293644 the DT B-NP O
20 680 682 6293644 DA NN I-NP D004298
21 682 683 6293644 - HYPH O O
22 683 690 6293644 related VBN B-NP O
23 691 701 6293644 behavioral JJ I-NP O
24 702 710 6293644 messages NNS I-NP O
25 711 713 6293644 of IN B-PP O
26 714 722 6293644 striatal JJ B-NP O
27 723 729 6293644 origin NN I-NP O
28 729 730 6293644 . . O O

1 0 0 1255900 -DOCSTART- -X- -X- O

1 0 13 1255900 Pyeloureteral JJ B-NP O
2 14 21 1255900 filling NN I-NP O
3 22 29 1255900 defects NNS I-NP O
4 30 40 1255900 associated VBN B-VP O
5 41 45 1255900 with IN B-PP O
6 46 54 1255900 systemic JJ B-NP O
7 55 70 1255900 anticoagulation NN I-NP O
8 70 71 1255900 : : O O
9 72 73 1255900 a DT B-NP O
10 74 78 1255900 case NN I-NP O
11 79 85 1255900 report NN I-NP O
12 85 86 1255900 . . O O
13 87 90 1255900 The DT B-NP O
14 91 99 1255900 etiology NN I-NP O
15 100 102 1255900 of IN B-PP O
16 103 118 1255900 pyeloureteritis NN B-NP D011702
17 119 126 1255900 cystica NN I-NP D011702
18 127 130 1255900 has VBZ B-VP O
19 131 135 1255900 long RB I-VP O
20 136 140 1255900 been VBN I-VP O
21 141 151 1255900 attributed VBN I-VP O
22 152 154 1255900 to TO B-PP O
23 155 162 1255900 chronic JJ B-NP O
24 163 172 1255900 infection NN I-NP D007239
25 173 176 1255900 and CC I-NP O
26 177 189 1255900 inflammation NN I-NP D007249
27 189 190 1255900 . . O O

1 191 192 1255900 A DT B-NP O
2 193 197 1255900 case NN I-NP O
3 198 200 1255900 is VBZ B-VP O
4 201 210 1255900 presented VBN I-VP O
5 211 215 1255900 that WDT B-NP O
6 216 218 1255900 is VBZ B-VP O
7 219 225 1255900 unique JJ B-ADJP O
8 226 228 1255900 in IN B-PP O
9 229 233 1255900 that IN B-SBAR O
10 234 237 1255900 the DT B-NP O
11 238 243 1255900 acute JJ I-NP O
12 244 249 1255900 onset NN I-NP O
13 250 253 1255900 and CC O O
14 254 257 1255900 the DT B-NP O
15 258 263 1255900 rapid JJ I-NP O
16 264 274 1255900 resolution NN I-NP O
17 275 277 1255900 of IN B-PP O
18 278 291 1255900 pyeloureteral JJ B-NP O
19 292 299 1255900 filling NN I-NP O
20 300 307 1255900 defects NNS I-NP O
21 308 310 1255900 in IN B-PP O
22 311 315 1255900 this DT B-NP O
23 316 323 1255900 patient NN I-NP O
24 324 328 1255900 were VBD B-VP O
25 329 339 1255900 documented VBN I-VP O
26 340 342 1255900 by IN B-PP O
27 343 354 1255900 radiography NN B-NP O
28 354 355 1255900 . . O O

1 356 361 1255900 There EX B-NP O
2 362 364 1255900 is VBZ B-VP O
3 365 367 1255900 no DT B-NP O
4 368 376 1255900 evidence NN I-NP O
5 377 379 1255900 of IN B-PP O
6 380 390 1255900 antecedent JJ B-NP O
7 391 393 1255900 or CC I-NP O
8 394 404 1255900 concurrent JJ I-NP O
9 405 414 1255900 infection NN I-NP D007239
10 415 417 1255900 in IN B-PP O
11 418 422 1255900 this DT B-NP O
12 423 430 1255900 patient NN I-NP O
13 430 431 1255900 . . O O

1 432 435 1255900 The DT B-NP O
2 436 443 1255900 disease NN I-NP O
3 444 452 1255900 occurred VBD B-VP O
4 453 463 1255900 subsequent JJ B-ADJP O
5 464 466 1255900 to TO B-PP O
6 467 470 1255900 the DT B-NP O
7 471 481 1255900 initiation NN I-NP O
8 482 484 1255900 of IN B-PP O
9 485 492 1255900 heparin NN B-NP D006493
10 493 500 1255900 therapy NN I-NP O
11 501 504 1255900 for IN B-PP O
12 505 514 1255900 suspected VBN B-NP O
13 515 521 1255900 pelvic JJ I-NP O
14 522 538 1255900 thrombophlebitis NN I-NP D013924
15 539 542 1255900 and CC O O
16 543 550 1255900 cleared VBD B-VP O
17 551 558 1255900 rapidly RB B-ADJP O
18 559 569 1255900 subsequent JJ I-ADJP O
19 570 572 1255900 to TO B-PP O
20 573 576 1255900 its PRP$ B-NP O
21 577 592 1255900 discontinuation NN I-NP O
22 592 593 1255900 . . O O

1 594 597 1255900 The DT B-NP O
2 598 602 1255900 rate NN I-NP O
3 603 605 1255900 of IN B-PP O
4 606 616 1255900 resolution NN B-NP O
5 617 619 1255900 of IN B-PP O
6 620 623 1255900 the DT B-NP O
7 624 636 1255900 radiographic JJ I-NP O
8 637 645 1255900 findings NNS I-NP O
9 646 649 1255900 may MD B-VP O
10 650 652 1255900 be VB I-VP O
11 653 660 1255900 helpful JJ B-ADJP O
12 661 663 1255900 in IN B-PP O
13 664 678 1255900 distinguishing VBG B-VP O
14 679 686 1255900 between IN B-PP O
15 687 691 1255900 true JJ B-NP O
16 692 707 1255900 pyeloureteritis NN I-NP D011702
17 708 715 1255900 cystica NN I-NP D011702
18 716 719 1255900 and CC O O
19 720 730 1255900 submucosal JJ B-NP D006470
20 731 741 1255900 hemorrhage NN I-NP D006470
21 741 742 1255900 . . O O

1 0 0 11337188 -DOCSTART- -X- -X- O

1 0 9 11337188 Cutaneous JJ B-NP D018366
2 10 26 11337188 leucocytoclastic JJ I-NP D018366
3 27 37 11337188 vasculitis NN I-NP D018366
4 38 48 11337188 associated VBN B-VP O
5 49 53 11337188 with IN B-PP O
6 54 63 11337188 oxacillin NN B-NP D010068
7 63 64 11337188 . . O O
8 65 66 11337188 A DT B-NP O
9 67 69 11337188 67 CD I-NP O
10 69 70 11337188 - HYPH I-NP O
11 70 74 11337188 year NN I-NP O
12 74 75 11337188 - HYPH B-NP O
13 75 78 11337188 old JJ I-NP O
14 79 82 11337188 man NN I-NP O
15 83 86 11337188 who WP B-NP O
16 87 90 11337188 was VBD B-VP O
17 91 98 11337188 treated VBN I-VP O
18 99 103 11337188 with IN B-PP O
19 104 113 11337188 oxacillin NN B-NP D010068
20 114 117 11337188 for IN B-PP O
21 118 121 11337188 one CD B-NP O
22 122 126 11337188 week NN I-NP O
23 127 134 11337188 because IN B-PP O
24 135 137 11337188 of IN I-PP O
25 138 152 11337188 Staphylococcus FW B-NP D013203
26 153 159 11337188 aureus FW I-NP D013203
27 160 170 11337188 bacteremia NN I-NP D013203
28 170 171 11337188 , , O O
29 172 181 11337188 developed VBD B-VP O
30 182 187 11337188 renal JJ B-NP D051437
31 188 195 11337188 failure NN I-NP D051437
32 196 199 11337188 and CC O O
33 200 207 11337188 diffuse JJ B-NP O
34 207 208 11337188 , , I-NP O
35 209 218 11337188 symmetric JJ I-NP O
36 218 219 11337188 , , I-NP O
37 220 228 11337188 palpable JJ I-NP O
38 229 237 11337188 purpuric JJ I-NP D011693
39 238 245 11337188 lesions NNS I-NP D011693
40 246 248 11337188 on IN B-PP O
41 249 252 11337188 his PRP$ B-NP O
42 253 257 11337188 feet NNS I-NP O
43 257 258 11337188 . . O O

1 259 267 11337188 Necrotic JJ B-NP D009336
2 268 276 11337188 blisters NNS I-NP D009336
3 277 281 11337188 were VBD B-VP O
4 282 287 11337188 noted VBN I-VP O
5 288 290 11337188 on IN B-PP O
6 291 294 11337188 his PRP$ B-NP O
7 295 302 11337188 fingers NNS I-NP O
8 302 303 11337188 . . O O

1 304 308 11337188 Skin NN B-NP O
2 309 317 11337188 biopsies NNS I-NP O
3 318 324 11337188 showed VBD B-VP O
4 325 333 11337188 findings NNS B-NP O
5 334 344 11337188 diagnostic JJ B-ADJP O
6 345 347 11337188 of IN B-PP O
7 348 364 11337188 leucocytoclastic JJ B-NP D018366
8 365 375 11337188 vasculitis NN I-NP D018366
9 375 376 11337188 . . O O

1 377 386 11337188 Oxacillin NN B-NP D010068
2 387 390 11337188 was VBD B-VP O
3 391 403 11337188 discontinued VBN I-VP O
4 404 407 11337188 and CC O O
5 408 415 11337188 patient NN B-NP O
6 416 419 11337188 was VBD B-VP O
7 420 427 11337188 treated VBN I-VP O
8 428 432 11337188 with IN B-PP O
9 433 448 11337188 corticosteroids NNS B-NP D000305
10 448 449 11337188 . . O O

1 450 453 11337188 The DT B-NP O
2 454 458 11337188 rash NN I-NP D005076
3 459 470 11337188 disappeared VBD B-VP O
4 471 476 11337188 after IN B-PP O
5 477 482 11337188 three CD B-NP O
6 483 488 11337188 weeks NNS I-NP O
7 489 492 11337188 and CC O O
8 493 498 11337188 renal JJ B-NP O
9 499 507 11337188 function NN I-NP O
10 508 516 11337188 returned VBD B-VP O
11 517 519 11337188 to TO B-PP O
12 520 526 11337188 normal JJ B-NP O
13 526 527 11337188 . . O O

1 528 544 11337188 Leucocytoclastic JJ B-NP D018366
2 545 555 11337188 vasculitis NN I-NP D018366
3 556 564 11337188 presents VBZ B-VP O
4 565 567 11337188 as IN B-PP O
5 568 576 11337188 palpable JJ B-NP O
6 577 584 11337188 purpura NN I-NP D011693
7 585 587 11337188 of IN B-PP O
8 588 591 11337188 the DT B-NP O
9 592 597 11337188 lower JJR I-NP O
10 598 609 11337188 extremities NNS I-NP O
11 610 615 11337188 often RB B-VP O
12 616 627 11337188 accompanied VBN I-VP O
13 628 630 11337188 by IN B-PP O
14 631 640 11337188 abdominal JJ B-NP D015746
15 641 645 11337188 pain NN I-NP D015746
16 645 646 11337188 , , O O
17 647 657 11337188 arthralgia NN B-NP D018771
18 657 658 11337188 , , O O
19 659 662 11337188 and CC O O
20 663 668 11337188 renal JJ B-NP D007674
21 669 680 11337188 involvement NN I-NP D007674
22 680 681 11337188 . . O O

1 682 691 11337188 Etiologic JJ B-NP O
2 692 699 11337188 factors NNS I-NP O
3 700 702 11337188 or CC O O
4 703 713 11337188 associated VBN B-NP O
5 714 723 11337188 disorders NNS I-NP O
6 724 731 11337188 include VBP B-VP O
7 732 742 11337188 infections NNS B-NP D007239
8 742 743 11337188 , , O O
9 744 755 11337188 medications NNS B-NP O
10 755 756 11337188 , , O O
11 757 765 11337188 collagen NN B-NP D003095
12 766 774 11337188 vascular JJ I-NP D003095
13 775 782 11337188 disease NN I-NP D003095
14 783 786 11337188 and CC O O
15 787 796 11337188 neoplasia NN B-NP D009369
16 796 797 11337188 . . O O

1 798 805 11337188 However RB B-ADVP O
2 805 806 11337188 , , O O
3 807 809 11337188 in IN B-PP O
4 810 814 11337188 half NN B-NP O
5 815 817 11337188 of IN B-PP O
6 818 821 11337188 the DT B-NP O
7 822 827 11337188 cases NNS I-NP O
8 828 830 11337188 no DT B-NP O
9 831 840 11337188 etiologic JJ I-NP O
10 841 847 11337188 factor NN I-NP O
11 848 850 11337188 is VBZ B-VP O
12 851 861 11337188 identified VBN I-VP O
13 861 862 11337188 . . O O

1 863 870 11337188 Usually RB B-ADVP O
2 871 873 11337188 it PRP B-NP O
3 874 876 11337188 is VBZ B-VP O
4 877 878 11337188 a DT B-NP O
5 879 883 11337188 self NN I-NP O
6 883 884 11337188 - HYPH O O
7 884 891 11337188 limited VBN B-NP O
8 892 900 11337188 disorder NN I-NP O
9 900 901 11337188 , , O O
10 902 905 11337188 but CC O O
11 906 920 11337188 corticosteroid NN B-NP D000305
12 921 928 11337188 therapy NN I-NP O
13 929 932 11337188 may MD B-VP O
14 933 935 11337188 be VB I-VP O
15 936 942 11337188 needed VBN I-VP O
16 943 945 11337188 in IN B-PP O
17 946 950 11337188 life NN B-NP O
18 950 951 11337188 - HYPH O O
19 951 962 11337188 threatening VBG B-VP O
20 963 968 11337188 cases NNS B-NP O
21 969 974 11337188 since IN B-PP O
22 975 980 11337188 early JJ B-NP O
23 981 990 11337188 treatment NN I-NP O
24 991 995 11337188 with IN B-PP O
25 996 1011 11337188 corticosteroids NNS B-NP D000305
26 1012 1014 11337188 in IN B-PP O
27 1015 1021 11337188 severe JJ B-NP O
28 1022 1027 11337188 cases NNS I-NP O
29 1028 1031 11337188 can MD B-VP O
30 1032 1039 11337188 prevent VB I-VP O
31 1040 1053 11337188 complications NNS B-NP O
32 1053 1054 11337188 . . O O

1 1055 1064 11337188 Oxacillin NN B-NP D010068
2 1065 1071 11337188 should MD B-VP O
3 1072 1074 11337188 be VB I-VP O
4 1075 1083 11337188 included VBN I-VP O
5 1084 1089 11337188 among IN B-PP O
6 1090 1093 11337188 the DT B-NP O
7 1094 1099 11337188 drugs NNS I-NP O
8 1100 1104 11337188 that WDT B-NP O
9 1105 1108 11337188 can MD B-VP O
10 1109 1114 11337188 cause VB I-VP O
11 1115 1131 11337188 leucocytoclastic JJ B-NP D018366
12 1132 1142 11337188 vasculitis NN I-NP D018366
13 1142 1143 11337188 . . O O

1 0 0 7724492 -DOCSTART- -X- -X- O

1 0 5 7724492 Acute JJ B-NP O
2 6 11 7724492 renal JJ I-NP D007674
3 12 20 7724492 toxicity NN I-NP D007674
4 21 23 7724492 of IN B-PP O
5 24 35 7724492 doxorubicin NN B-NP D004317
6 36 37 7724492 ( ( O O
7 37 47 7724492 adriamycin NN B-NP D004317
8 47 48 7724492 ) ) O O
9 48 49 7724492 - HYPH O O
10 49 55 7724492 loaded VBN B-NP O
11 56 69 7724492 cyanoacrylate NN I-NP D003487
12 70 83 7724492 nanoparticles NNS I-NP O
13 83 84 7724492 . . O O
14 85 90 7724492 Acute JJ B-NP O
15 91 102 7724492 doxorubicin NN I-NP D004317
16 102 103 7724492 - HYPH O O
17 103 109 7724492 loaded VBN B-VP O
18 110 122 7724492 nanoparticle NN B-NP O
19 123 124 7724492 ( ( O O
20 124 128 7724492 DXNP NN B-NP O
21 128 129 7724492 ) ) O O
22 130 135 7724492 renal JJ B-NP D007674
23 136 144 7724492 toxicity NN I-NP D007674
24 145 148 7724492 was VBD B-VP O
25 149 157 7724492 explored VBN I-VP O
26 158 160 7724492 in IN B-PP O
27 161 165 7724492 both DT B-NP O
28 166 172 7724492 normal JJ I-NP O
29 173 177 7724492 rats NNS I-NP O
30 178 181 7724492 and CC I-NP O
31 182 186 7724492 rats NNS I-NP O
32 187 191 7724492 with IN B-PP O
33 192 204 7724492 experimental JJ B-NP O
34 205 223 7724492 glomerulonephritis NN I-NP D005921
35 223 224 7724492 . . O O

1 225 227 7724492 In IN B-PP O
2 228 234 7724492 normal JJ B-NP O
3 235 239 7724492 rats NNS I-NP O
4 239 240 7724492 , , O O
5 241 242 7724492 2 CD B-NP O
6 242 243 7724492 / SYM I-NP O
7 243 244 7724492 6 CD I-NP O
8 245 249 7724492 rats NNS I-NP O
9 250 255 7724492 given VBN B-PP O
10 256 260 7724492 free JJ B-NP O
11 261 272 7724492 doxorubicin NN I-NP D004317
12 273 274 7724492 ( ( O O
13 274 276 7724492 DX NN B-NP D004317
14 276 277 7724492 ) ) O O
15 278 279 7724492 ( ( O O
16 279 280 7724492 5 CD B-NP O
17 281 283 7724492 mg NN I-NP O
18 283 284 7724492 / SYM B-NP O
19 284 286 7724492 kg NN I-NP O
20 286 287 7724492 ) ) O O
21 288 292 7724492 died VBD B-VP O
22 293 299 7724492 within IN B-PP O
23 300 303 7724492 one CD B-NP O
24 304 308 7724492 week NN I-NP O
25 308 309 7724492 , , O O
26 310 317 7724492 whereas IN O O
27 318 321 7724492 all DT B-NP O
28 322 329 7724492 control NN I-NP O
29 330 337 7724492 animals NNS I-NP O
30 338 341 7724492 and CC O O
31 342 345 7724492 all DT B-NP O
32 346 350 7724492 rats NNS I-NP O
33 351 357 7724492 having VBG B-VP O
34 358 366 7724492 received VBN I-VP O
35 367 371 7724492 free JJ B-NP O
36 372 374 7724492 NP NN I-NP O
37 375 377 7724492 or CC I-NP O
38 378 382 7724492 DXNP NN I-NP O
39 383 391 7724492 survived VBD B-VP O
40 391 392 7724492 . . O O

1 393 394 7724492 A DT B-NP O
2 395 396 7724492 3 CD I-NP O
3 397 402 7724492 times NNS I-NP O
4 403 409 7724492 higher JJR I-NP O
5 410 421 7724492 proteinuria NN I-NP D011507
6 422 430 7724492 appeared VBD B-VP O
7 431 433 7724492 in IN B-PP O
8 434 441 7724492 animals NNS B-NP O
9 442 449 7724492 treated VBN B-VP O
10 450 454 7724492 with IN B-PP O
11 455 459 7724492 DXNP NN B-NP O
12 460 464 7724492 than IN B-PP O
13 465 467 7724492 in IN B-PP O
14 468 473 7724492 those DT B-NP O
15 474 481 7724492 treated VBN B-VP O
16 482 486 7724492 with IN B-PP O
17 487 489 7724492 DX NN B-NP D004317
18 489 490 7724492 . . O O

1 491 495 7724492 Free JJ B-NP O
2 496 498 7724492 NP NN I-NP O
3 499 502 7724492 did VBD B-VP O
4 503 506 7724492 not RB I-VP O
5 507 514 7724492 provoke VB I-VP O
6 515 518 7724492 any DT B-NP O
7 519 530 7724492 proteinuria NN I-NP D011507
8 530 531 7724492 . . O O

1 532 535 7724492 Two CD B-NP O
2 536 538 7724492 hr NN I-NP O
3 539 543 7724492 post AFX O O
4 543 544 7724492 - HYPH O O
5 544 553 7724492 injection NN B-NP O
6 553 554 7724492 , , O O
7 555 559 7724492 DXNP NN B-NP O
8 560 563 7724492 was VBD B-VP O
9 564 567 7724492 2.7 CD B-ADJP O
10 568 573 7724492 times NNS I-ADJP O
11 574 578 7724492 more JJR I-ADJP O
12 579 591 7724492 concentrated VBD B-VP O
13 592 594 7724492 in IN B-PP O
14 595 602 7724492 kidneys NNS B-NP O
15 603 607 7724492 than IN B-PP O
16 608 612 7724492 free JJ B-NP O
17 613 615 7724492 DX NN I-NP D004317
18 616 617 7724492 ( ( O O
19 617 618 7724492 p NN B-NP O
20 619 620 7724492 < JJR B-NP O
21 621 626 7724492 0.025 CD I-NP O
22 626 627 7724492 ) ) O O
23 627 628 7724492 . . O O

1 629 631 7724492 In IN B-PP O
2 632 636 7724492 rats NNS B-NP O
3 637 641 7724492 with IN B-PP O
4 642 648 7724492 immune JJ B-NP O
5 649 661 7724492 experimental JJ I-NP O
6 662 680 7724492 glomerulonephritis NN I-NP D005921
7 680 681 7724492 , , O O
8 682 683 7724492 5 CD B-NP O
9 683 684 7724492 / SYM I-NP O
10 684 685 7724492 6 CD I-NP O
11 686 690 7724492 rats NNS I-NP O
12 691 696 7724492 given VBN B-VP O
13 697 699 7724492 DX NN B-NP D004317
14 700 704 7724492 died VBD B-VP O
15 705 711 7724492 within IN B-PP O
16 712 713 7724492 7 CD B-NP O
17 714 718 7724492 days NNS I-NP O
18 718 719 7724492 , , O O
19 720 722 7724492 in IN B-PP O
20 723 731 7724492 contrast NN B-NP O
21 732 734 7724492 to TO B-PP O
22 735 742 7724492 animals NNS B-NP O
23 743 750 7724492 treated VBN B-VP O
24 751 753 7724492 by IN B-PP O
25 754 758 7724492 DXNP NN B-NP O
26 758 759 7724492 , , O O
27 760 762 7724492 NP NN B-NP O
28 762 763 7724492 , , O O
29 764 766 7724492 or CC O O
30 767 776 7724492 untreated JJ B-ADJP O
31 776 777 7724492 , , O O
32 778 783 7724492 which WDT B-NP O
33 784 787 7724492 all DT O O
34 788 796 7724492 survived VBD B-VP O
35 796 797 7724492 . . O O

1 798 809 7724492 Proteinuria NNP B-NP D011507
2 810 818 7724492 appeared VBD B-VP O
3 819 821 7724492 in IN B-PP O
4 822 825 7724492 all DT B-NP O
5 826 832 7724492 series NN I-NP O
6 832 833 7724492 , , O O
7 834 837 7724492 but CC O O
8 838 841 7724492 was VBD B-VP O
9 842 843 7724492 2 CD B-NP O
10 843 844 7724492 - HYPH O O
11 844 845 7724492 5 CD B-NP O
12 846 851 7724492 times NNS I-NP O
13 852 856 7724492 more RBR B-ADJP O
14 857 864 7724492 intense JJ I-ADJP O
15 865 866 7724492 ( ( O O
16 866 867 7724492 p NN B-NP O
17 868 869 7724492 > SYM O O
18 870 875 7724492 0.001 CD B-NP O
19 875 876 7724492 ) ) O O
20 877 880 7724492 and CC O O
21 881 890 7724492 prolonged VBD B-VP O
22 891 896 7724492 after IN B-PP O
23 897 908 7724492 doxorubicin NN B-NP D004317
24 909 918 7724492 treatment NN I-NP O
25 919 920 7724492 ( ( O O
26 920 923 7724492 400 CD B-NP O
27 923 924 7724492 - HYPH I-NP O
28 924 927 7724492 700 CD I-NP O
29 928 930 7724492 mg NN I-NP O
30 930 931 7724492 / SYM B-NP O
31 931 934 7724492 day NN I-NP O
32 934 935 7724492 ) ) O O
33 935 936 7724492 , , O O
34 937 944 7724492 without IN B-PP O
35 945 956 7724492 significant JJ B-NP O
36 957 967 7724492 difference NN I-NP O
37 968 975 7724492 between IN B-PP O
38 976 980 7724492 DXNP NN B-NP O
39 981 984 7724492 and CC I-NP O
40 985 987 7724492 DX NN I-NP D004317
41 987 988 7724492 . . O O

1 989 993 7724492 Rats NNS B-NP O
2 994 1001 7724492 treated VBN B-VP O
3 1002 1004 7724492 by IN B-PP O
4 1005 1013 7724492 unloaded JJ B-NP O
5 1014 1016 7724492 NP NN I-NP O
6 1017 1024 7724492 behaved VBD B-VP O
7 1025 1027 7724492 as IN B-PP O
8 1028 1036 7724492 controls NNS B-NP O
9 1036 1037 7724492 . . O O

1 1038 1043 7724492 These DT B-NP O
2 1044 1051 7724492 results NNS I-NP O
3 1052 1063 7724492 demonstrate VBP B-VP O
4 1064 1068 7724492 that IN B-SBAR O
5 1068 1069 7724492 , , O O
6 1070 1072 7724492 in IN B-PP O
7 1073 1078 7724492 these DT B-NP O
8 1079 1091 7724492 experimental JJ I-NP O
9 1092 1102 7724492 conditions NNS I-NP O
10 1102 1103 7724492 , , O O
11 1104 1108 7724492 DXNP NN B-NP O
12 1109 1115 7724492 killed VBD B-VP O
13 1116 1120 7724492 less JJR B-NP O
14 1121 1128 7724492 animals NNS I-NP O
15 1129 1133 7724492 than IN B-PP O
16 1134 1138 7724492 free JJ B-NP O
17 1139 1141 7724492 DX NN I-NP D004317
18 1141 1142 7724492 , , O O
19 1143 1150 7724492 despite IN B-PP O
20 1151 1153 7724492 of IN B-PP O
21 1154 1156 7724492 an DT B-NP O
22 1157 1165 7724492 enhanced VBN I-NP O
23 1166 1171 7724492 renal JJ I-NP D007674
24 1172 1180 7724492 toxicity NN I-NP D007674
25 1181 1183 7724492 of IN B-PP O
26 1184 1187 7724492 the DT B-NP O
27 1188 1194 7724492 former JJ I-NP O
28 1194 1195 7724492 . . O O

1 1196 1200 7724492 Both DT B-NP O
2 1201 1208 7724492 effects NNS I-NP O
3 1209 1210 7724492 ( ( O O
4 1210 1216 7724492 better JJR B-NP O
5 1217 1225 7724492 survival NN I-NP O
6 1226 1229 7724492 and CC I-NP O
7 1230 1239 7724492 nephrosis NN I-NP D009401
8 1239 1240 7724492 ) ) O O
9 1241 1244 7724492 are VBP B-VP O
10 1245 1249 7724492 most RBS I-VP O
11 1250 1258 7724492 probably RB I-VP O
12 1259 1266 7724492 related VBN I-VP O
13 1267 1269 7724492 to TO B-PP O
14 1270 1272 7724492 an DT B-NP O
15 1273 1281 7724492 enhanced VBN I-NP O
16 1282 1289 7724492 capture NN I-NP O
17 1290 1292 7724492 of IN B-PP O
18 1293 1297 7724492 DXNP NN B-NP O
19 1298 1300 7724492 by IN B-PP O
20 1301 1306 7724492 cells NNS B-NP O
21 1307 1309 7724492 of IN B-PP O
22 1310 1313 7724492 the DT B-NP O
23 1314 1325 7724492 mononuclear JJ I-NP O
24 1326 1335 7724492 phagocyte NN I-NP O
25 1336 1342 7724492 system NN I-NP O
26 1342 1343 7724492 , , O O
27 1344 1353 7724492 including VBG B-PP O
28 1354 1363 7724492 mesangial JJ B-NP O
29 1364 1369 7724492 cells NNS I-NP O
30 1369 1370 7724492 . . O O

1 0 0 6308526 -DOCSTART- -X- -X- O

1 0 10 6308526 Naloxazone NN B-NP C024224
2 11 23 6308526 pretreatment NN I-NP O
3 24 32 6308526 modifies VBZ B-VP O
4 33 50 6308526 cardiorespiratory JJ B-ADJP O
5 50 51 6308526 , , O O
6 52 63 6308526 temperature NN B-NP O
7 63 64 6308526 , , O O
8 65 68 6308526 and CC O O
9 69 79 6308526 behavioral JJ B-NP O
10 80 87 6308526 effects NNS I-NP O
11 88 90 6308526 of IN B-PP O
12 91 99 6308526 morphine NN B-NP D009020
13 99 100 6308526 . . O O
14 101 111 6308526 Behavioral JJ B-NP O
15 112 115 6308526 and CC I-NP O
16 116 133 6308526 cardiorespiratory JJ I-NP O
17 134 143 6308526 responses NNS I-NP O
18 144 146 6308526 to TO B-PP O
19 147 148 6308526 a DT B-NP O
20 149 155 6308526 lethal JJ I-NP O
21 156 160 6308526 dose NN I-NP O
22 161 163 6308526 of IN B-PP O
23 164 172 6308526 morphine NN B-NP D009020
24 173 177 6308526 were VBD B-VP O
25 178 187 6308526 evaluated VBN I-VP O
26 188 190 6308526 in IN B-PP O
27 191 195 6308526 rats NNS B-NP O
28 196 206 6308526 pretreated VBN B-VP O
29 207 211 6308526 with IN B-PP O
30 212 218 6308526 saline NN B-NP O
31 219 221 6308526 or CC I-NP O
32 222 232 6308526 naloxazone NN I-NP C024224
33 232 233 6308526 , , O O
34 234 236 6308526 an DT B-NP O
35 237 247 6308526 antagonist NN I-NP O
36 248 250 6308526 of IN B-PP O
37 251 255 6308526 high JJ B-NP O
38 255 256 6308526 - HYPH I-NP O
39 256 264 6308526 affinity NN I-NP O
40 265 267 6308526 mu SYM B-NP O
41 268 269 6308526 1 CD I-NP O
42 270 276 6308526 opioid JJ I-NP O
43 277 286 6308526 receptors NNS I-NP O
44 286 287 6308526 . . O O

1 288 300 6308526 Pretreatment NN B-NP O
2 301 305 6308526 with IN B-PP O
3 306 316 6308526 naloxazone NN B-NP C024224
4 317 330 6308526 significantly RB B-ADVP O
5 331 338 6308526 blocked VBD B-VP O
6 339 347 6308526 morphine NN B-NP D009020
7 348 357 6308526 analgesia NN I-NP D000699
8 357 358 6308526 , , O O
9 359 368 6308526 catalepsy NN B-NP D002375
10 369 372 6308526 and CC I-NP O
11 373 384 6308526 hypothermia NN I-NP D007035
12 385 387 6308526 at IN B-PP O
13 388 389 6308526 a DT B-NP O
14 390 394 6308526 dose NN I-NP O
15 395 400 6308526 which WDT B-NP O
16 401 411 6308526 completely RB B-ADVP O
17 412 422 6308526 eliminated VBD B-VP O
18 423 427 6308526 high JJ B-NP O
19 427 428 6308526 - HYPH I-NP O
20 428 436 6308526 affinity NN I-NP O
21 437 444 6308526 binding NN I-NP O
22 445 447 6308526 in IN B-PP O
23 448 453 6308526 brain NN B-NP O
24 454 463 6308526 membranes NNS I-NP O
25 463 464 6308526 . . O O

1 465 473 6308526 Moreover RB B-ADVP O
2 473 474 6308526 , , O O
3 475 485 6308526 naloxazone NN B-NP C024224
4 486 499 6308526 significantly RB B-ADVP O
5 500 510 6308526 attenuated VBD B-VP O
6 511 514 6308526 the DT B-NP O
7 515 523 6308526 morphine NN I-NP D009020
8 523 524 6308526 - HYPH B-NP O
9 524 531 6308526 induced VBN I-NP O
10 532 543 6308526 hypotension NN I-NP D007022
11 544 547 6308526 and CC I-NP O
12 548 559 6308526 respiratory JJ I-NP D012131
13 560 570 6308526 depression NN I-NP D012131
14 570 571 6308526 , , O O
15 572 579 6308526 whereas IN O O
16 580 588 6308526 morphine NN B-NP D009020
17 588 589 6308526 - HYPH O O
18 589 596 6308526 induced VBN B-NP O
19 597 608 6308526 bradycardia NN I-NP D001919
20 609 612 6308526 was VBD B-VP O
21 613 617 6308526 less RBR I-VP O
22 618 626 6308526 affected VBN I-VP O
23 626 627 6308526 . . O O

1 628 635 6308526 Results NNS B-NP O
2 636 644 6308526 indicate VBP B-VP O
3 645 649 6308526 that IN B-SBAR O
4 650 664 6308526 subpopulations NNS B-NP O
5 665 667 6308526 of IN B-PP O
6 668 670 6308526 mu SYM B-NP O
7 671 680 6308526 receptors NNS I-NP O
8 681 684 6308526 may MD B-VP O
9 685 692 6308526 mediate VB I-VP O
10 693 702 6308526 selective JJ B-NP O
11 703 713 6308526 behavioral JJ I-NP O
12 714 717 6308526 and CC I-NP O
13 718 735 6308526 cardiorespiratory JJ I-NP O
14 736 745 6308526 responses NNS I-NP O
15 746 748 6308526 to TO B-PP O
16 749 757 6308526 morphine NN B-NP D009020
17 757 758 6308526 . . O O

1 0 0 10074612 -DOCSTART- -X- -X- O

1 0 11 10074612 Hypotension NN B-NP D007022
2 11 12 10074612 , , O O
3 13 24 10074612 bradycardia NN B-NP D001919
4 24 25 10074612 , , O O
5 26 29 10074612 and CC O O
6 30 38 10074612 asystole NN B-NP D006323
7 39 44 10074612 after IN B-PP O
8 45 49 10074612 high JJ B-NP O
9 49 50 10074612 - HYPH I-NP O
10 50 54 10074612 dose NN I-NP O
11 55 66 10074612 intravenous JJ I-NP O
12 67 85 10074612 methylprednisolone NN I-NP D008775
13 86 88 10074612 in IN B-PP O
14 89 90 10074612 a DT B-NP O
15 91 100 10074612 monitored VBN I-NP O
16 101 108 10074612 patient NN I-NP O
17 108 109 10074612 . . O O
18 110 112 10074612 We PRP B-NP O
19 113 119 10074612 report VBP B-VP O
20 120 121 10074612 a DT B-NP O
21 122 126 10074612 case NN I-NP O
22 127 129 10074612 of IN B-PP O
23 130 141 10074612 hypotension NN B-NP D007022
24 141 142 10074612 , , O O
25 143 154 10074612 bradycardia NN B-NP D001919
26 154 155 10074612 , , O O
27 156 159 10074612 and CC O O
28 160 168 10074612 asystole NN B-NP D006323
29 169 174 10074612 after IN B-SBAR O
30 175 186 10074612 intravenous JJ B-NP O
31 187 201 10074612 administration NN I-NP O
32 202 204 10074612 of IN B-PP O
33 205 209 10074612 high JJ B-NP O
34 209 210 10074612 - HYPH I-NP O
35 210 214 10074612 dose NN I-NP O
36 215 233 10074612 methylprednisolone NN I-NP D008775
37 234 236 10074612 in IN B-PP O
38 237 238 10074612 a DT B-NP O
39 239 241 10074612 73 CD I-NP O
40 241 242 10074612 - HYPH I-NP O
41 242 246 10074612 year NN I-NP O
42 246 247 10074612 - HYPH B-NP O
43 247 250 10074612 old JJ I-NP O
44 251 258 10074612 patient NN I-NP O
45 259 262 10074612 who WP B-NP O
46 263 272 10074612 underwent VBD B-VP O
47 273 293 10074612 electrocardiographic JJ B-ADJP O
48 294 295 10074612 ( ( O O
49 295 298 10074612 ECG NN B-NP O
50 298 299 10074612 ) ) O O
51 300 310 10074612 monitoring NN B-NP O
52 311 321 10074612 throughout IN B-PP O
53 322 325 10074612 the DT B-NP O
54 326 333 10074612 episode NN I-NP O
55 333 334 10074612 . . O O

1 335 340 10074612 There EX B-NP O
2 341 344 10074612 was VBD B-VP O
3 345 346 10074612 a DT B-NP O
4 347 354 10074612 history NN I-NP O
5 355 357 10074612 of IN B-PP O
6 358 366 10074612 ischemic JJ B-NP D007511
7 367 374 10074612 cardiac JJ I-NP D006331
8 375 382 10074612 disease NN I-NP D006331
9 383 384 10074612 9 CD B-NP O
10 385 390 10074612 years NNS I-NP O
11 391 398 10074612 earlier RBR B-ADVP O
12 398 399 10074612 . . O O

1 400 403 10074612 The DT B-NP O
2 404 411 10074612 patient NN I-NP O
3 412 415 10074612 was VBD B-VP O
4 416 424 10074612 admitted VBN I-VP O
5 425 429 10074612 with IN B-PP O
6 430 431 10074612 a DT B-NP O
7 432 441 10074612 pulmonary JJ I-NP C538458
8 441 442 10074612 - HYPH I-NP C538458
9 442 447 10074612 renal JJ I-NP C538458
10 448 456 10074612 syndrome NN I-NP C538458
11 457 461 10074612 with IN B-PP O
12 462 472 10074612 hemoptysis NN B-NP D006469
13 472 473 10074612 , , O O
14 474 481 10074612 rapidly RB B-NP O
15 482 493 10074612 progressive JJ I-NP O
16 494 499 10074612 renal JJ I-NP D051437
17 500 507 10074612 failure NN I-NP D051437
18 507 508 10074612 , , O O
19 509 512 10074612 and CC O O
20 513 522 10074612 hypoxemia NN B-NP D000860
21 523 527 10074612 that WDT B-NP O
22 528 536 10074612 required VBD B-VP O
23 537 547 10074612 mechanical JJ B-NP O
24 548 559 10074612 ventilation NN I-NP O
25 560 562 10074612 in IN B-PP O
26 563 566 10074612 the DT B-NP O
27 567 576 10074612 intensive JJ I-NP O
28 577 581 10074612 care NN I-NP O
29 582 586 10074612 unit NN I-NP O
30 586 587 10074612 . . O O

1 588 593 10074612 After IN B-PP O
2 594 603 10074612 receiving VBG B-VP O
3 604 612 10074612 advanced JJ B-NP O
4 613 628 10074612 cardiopulmonary JJ I-NP O
5 629 642 10074612 resuscitation NN I-NP O
6 642 643 10074612 , , O O
7 644 647 10074612 the DT B-NP O
8 648 655 10074612 patient NN I-NP O
9 656 665 10074612 recovered VBD B-VP O
10 666 673 10074612 cardiac JJ B-NP O
11 674 680 10074612 rhythm NN I-NP O
12 680 681 10074612 . . O O

1 682 685 10074612 The DT B-NP O
2 686 689 10074612 ECG NN I-NP O
3 690 696 10074612 showed VBD B-VP O
4 697 698 10074612 a DT B-NP O
5 699 709 10074612 junctional JJ I-NP O
6 710 716 10074612 rhythm NN I-NP O
7 717 724 10074612 without IN B-PP O
8 725 736 10074612 ventricular JJ B-NP D001145
9 737 747 10074612 arrhythmia NN I-NP D001145
10 747 748 10074612 . . O O

1 749 753 10074612 This DT B-NP O
2 754 759 10074612 study NN I-NP O
3 760 767 10074612 reviews VBZ B-VP O
4 768 771 10074612 the DT B-NP O
5 772 779 10074612 current JJ I-NP O
6 780 788 10074612 proposed VBN I-NP O
7 789 799 10074612 mechanisms NNS I-NP O
8 800 802 10074612 of IN B-PP O
9 803 809 10074612 sudden JJ B-NP D003645
10 810 815 10074612 death NN I-NP D003645
11 816 821 10074612 after IN B-PP O
12 822 823 10074612 a DT B-NP O
13 824 828 10074612 high JJ I-NP O
14 829 833 10074612 dose NN I-NP O
15 834 836 10074612 of IN B-PP O
16 837 848 10074612 intravenous JJ B-NP O
17 849 867 10074612 methylprednisolone NN I-NP D008775
18 868 869 10074612 ( ( O O
19 869 873 10074612 IVMP NN B-NP D008775
20 873 874 10074612 ) ) O O
21 874 875 10074612 . . O O

1 876 881 10074612 These DT B-NP O
2 882 892 10074612 mechanisms NNS I-NP O
3 893 896 10074612 are VBP B-VP O
4 897 900 10074612 not RB I-VP O
5 901 905 10074612 well RB I-VP O
6 906 916 10074612 understood VBN I-VP O
7 917 924 10074612 because IN B-SBAR O
8 924 925 10074612 , , O O
9 926 928 10074612 in IN B-PP O
10 929 933 10074612 most JJS B-NP O
11 934 939 10074612 cases NNS I-NP O
12 939 940 10074612 , , O O
13 941 944 10074612 the DT B-NP O
14 945 953 10074612 patients NNS I-NP O
15 954 958 10074612 were VBD B-VP O
16 959 962 10074612 not RB I-VP O
17 963 972 10074612 monitored VBN I-VP O
18 973 975 10074612 at IN B-PP O
19 976 979 10074612 the DT B-NP O
20 980 986 10074612 moment NN I-NP O
21 987 989 10074612 of IN B-PP O
22 990 993 10074612 the DT B-NP O
23 994 999 10074612 event NN I-NP O
24 999 1000 10074612 . . O O

1 1001 1006 10074612 Rapid JJ B-NP O
2 1007 1015 10074612 infusion NN I-NP O
3 1016 1019 10074612 and CC O O
4 1020 1030 10074612 underlying VBG B-VP O
5 1031 1038 10074612 cardiac JJ B-NP D006331
6 1039 1046 10074612 disease NN I-NP D006331
7 1047 1051 10074612 were VBD B-VP O
8 1052 1061 10074612 important JJ B-NP O
9 1062 1066 10074612 risk NN I-NP O
10 1067 1074 10074612 factors NNS I-NP O
11 1075 1077 10074612 in IN B-PP O
12 1078 1081 10074612 the DT B-NP O
13 1082 1086 10074612 case NN I-NP O
14 1087 1095 10074612 reported VBN B-VP O
15 1096 1100 10074612 here RB B-ADVP O
16 1100 1101 10074612 , , O O
17 1102 1105 10074612 and CC O O
18 1106 1109 10074612 the DT B-NP O
19 1110 1117 10074612 authors NNS I-NP O
20 1118 1126 10074612 discount VBP B-VP O
21 1127 1138 10074612 ventricular JJ B-NP D001145
22 1139 1149 10074612 arrhythmia NN I-NP D001145
23 1150 1152 10074612 as IN B-PP O
24 1153 1156 10074612 the DT B-NP O
25 1157 1161 10074612 main JJ I-NP O
26 1162 1171 10074612 mechanism NN I-NP O
27 1171 1172 10074612 . . O O

1 0 0 3120485 -DOCSTART- -X- -X- O

1 0 10 3120485 Antagonism NN B-NP O
2 11 13 3120485 of IN B-PP O
3 14 22 3120485 diazepam NN B-NP D003975
4 22 23 3120485 - HYPH O O
5 23 30 3120485 induced VBN B-NP O
6 31 39 3120485 sedative JJ I-NP O
7 40 47 3120485 effects NNS I-NP O
8 48 50 3120485 by IN B-PP O
9 51 55 3120485 Ro15 NN B-NP D005442
10 55 56 3120485 - HYPH O D005442
11 56 60 3120485 1788 CD B-NP D005442
12 61 63 3120485 in IN B-PP O
13 64 72 3120485 patients NNS B-NP O
14 73 78 3120485 after IN B-PP O
15 79 86 3120485 surgery NN B-NP O
16 87 92 3120485 under IN B-PP O
17 93 99 3120485 lumbar JJ B-NP O
18 100 108 3120485 epidural JJ I-NP O
19 109 114 3120485 block NN I-NP O
20 114 115 3120485 . . O O

1 116 117 3120485 A DT B-NP O
2 118 124 3120485 double JJ I-NP O
3 124 125 3120485 - HYPH I-NP O
4 125 130 3120485 blind JJ I-NP O
5 131 138 3120485 placebo NN I-NP O
6 138 139 3120485 - HYPH B-VP O
7 139 149 3120485 controlled VBN B-NP O
8 150 163 3120485 investigation NN I-NP O
9 164 166 3120485 of IN B-PP O
10 167 175 3120485 efficacy NN B-NP O
11 176 179 3120485 and CC I-NP O
12 180 186 3120485 safety NN I-NP O
13 186 187 3120485 . . O O
14 188 191 3120485 The DT B-NP O
15 192 195 3120485 aim NN I-NP O
16 196 198 3120485 of IN B-PP O
17 199 203 3120485 this DT B-NP O
18 204 209 3120485 study NN I-NP O
19 210 213 3120485 was VBD B-VP O
20 214 216 3120485 to TO B-VP O
21 217 223 3120485 assess VB I-VP O
22 224 227 3120485 the DT B-NP O
23 228 236 3120485 efficacy NN I-NP O
24 237 239 3120485 of IN B-PP O
25 240 244 3120485 Ro15 NN B-NP D005442
26 244 245 3120485 - HYPH B-NP D005442
27 245 249 3120485 1788 CD I-NP D005442
28 250 253 3120485 and CC O O
29 254 255 3120485 a DT B-NP O
30 256 263 3120485 placebo NN I-NP O
31 264 266 3120485 in IN B-PP O
32 267 276 3120485 reversing VBG B-VP O
33 277 285 3120485 diazepam NN B-NP D003975
34 285 286 3120485 - HYPH B-NP O
35 286 293 3120485 induced VBN I-NP O
36 294 301 3120485 effects NNS I-NP O
37 302 307 3120485 after IN B-PP O
38 308 315 3120485 surgery NN B-NP O
39 316 321 3120485 under IN B-PP O
40 322 330 3120485 epidural JJ B-NP O
41 331 336 3120485 block NN I-NP O
42 336 337 3120485 , , O O
43 338 341 3120485 and CC O O
44 342 344 3120485 to TO B-VP O
45 345 353 3120485 evaluate VB I-VP O
46 354 357 3120485 the DT B-NP O
47 358 363 3120485 local JJ I-NP O
48 364 373 3120485 tolerance NN I-NP O
49 374 377 3120485 and CC O O
50 378 385 3120485 general JJ B-NP O
51 386 392 3120485 safety NN I-NP O
52 393 395 3120485 of IN B-PP O
53 396 400 3120485 Ro15 NN B-NP D005442
54 400 401 3120485 - HYPH B-NP D005442
55 401 405 3120485 1788 CD I-NP D005442
56 405 406 3120485 . . O O

1 407 412 3120485 Fifty CD B-NP O
2 412 413 3120485 - HYPH I-NP O
3 413 418 3120485 seven CD I-NP O
4 419 427 3120485 patients NNS I-NP O
5 428 432 3120485 were VBD B-VP O
6 433 440 3120485 sedated VBN I-VP O
7 441 445 3120485 with IN B-PP O
8 446 454 3120485 diazepam NN B-NP D003975
9 455 458 3120485 for IN B-PP O
10 459 466 3120485 surgery NN B-NP O
11 467 472 3120485 under IN B-PP O
12 473 481 3120485 epidural JJ B-NP O
13 482 493 3120485 anaesthesia NN I-NP O
14 493 494 3120485 . . O O

1 495 505 3120485 Antagonism NN B-NP O
2 506 508 3120485 of IN B-PP O
3 509 517 3120485 diazepam NN B-NP D003975
4 517 518 3120485 - HYPH B-NP O
5 518 525 3120485 induced VBN I-NP O
6 526 533 3120485 effects NNS I-NP O
7 534 536 3120485 by IN B-PP O
8 537 541 3120485 Ro15 NN B-NP D005442
9 541 542 3120485 - HYPH O D005442
10 542 546 3120485 1788 CD B-NP D005442
11 547 550 3120485 was VBD B-VP O
12 551 563 3120485 investigated VBN I-VP O
13 564 579 3120485 postoperatively RB B-ADVP O
14 580 582 3120485 in IN B-PP O
15 583 584 3120485 a DT B-NP O
16 585 591 3120485 double JJ I-NP O
17 591 592 3120485 - HYPH I-NP O
18 592 597 3120485 blind JJ I-NP O
19 598 605 3120485 placebo NN I-NP O
20 605 606 3120485 - HYPH B-VP O
21 606 616 3120485 controlled VBN B-NP O
22 617 622 3120485 trial NN I-NP O
23 622 623 3120485 . . O O

1 624 627 3120485 The DT B-NP O
2 628 637 3120485 patient's NNS I-NP O
3 638 648 3120485 subjective JJ I-NP O
4 649 659 3120485 assessment NN I-NP O
5 660 662 3120485 of IN B-PP O
6 663 667 3120485 mood NN B-NP O
7 668 674 3120485 rating NN I-NP O
8 674 675 3120485 , , O O
9 676 678 3120485 an DT B-NP O
10 679 688 3120485 objective JJ I-NP O
11 689 693 3120485 test NN I-NP O
12 694 696 3120485 of IN B-PP O
13 697 708 3120485 performance NN B-NP O
14 708 709 3120485 , , O O
15 710 711 3120485 a DT B-NP O
16 712 716 3120485 test NN I-NP O
17 717 720 3120485 for IN B-PP O
18 721 728 3120485 amnesia NN B-NP D000647
19 728 729 3120485 , , O O
20 730 733 3120485 and CC O O
21 734 739 3120485 vital JJ B-NP O
22 740 745 3120485 signs NNS I-NP O
23 746 750 3120485 were VBD B-VP O
24 751 759 3120485 recorded VBN I-VP O
25 760 763 3120485 for IN B-PP O
26 764 766 3120485 up RB B-NP O
27 767 769 3120485 to TO I-NP O
28 770 773 3120485 300 CD I-NP O
29 774 777 3120485 min NN I-NP O
30 778 783 3120485 after IN B-PP O
31 784 798 3120485 administration NN B-NP O
32 799 801 3120485 of IN B-PP O
33 802 805 3120485 the DT B-NP O
34 806 811 3120485 trial NN I-NP O
35 812 816 3120485 drug NN I-NP O
36 816 817 3120485 . . O O

1 818 820 3120485 No DT B-NP O
2 821 832 3120485 significant JJ I-NP O
3 833 844 3120485 differences NNS I-NP O
4 845 852 3120485 between IN B-PP O
5 853 856 3120485 the DT B-NP O
6 857 860 3120485 two CD I-NP O
7 861 867 3120485 groups NNS I-NP O
8 868 872 3120485 were VBD B-VP O
9 873 881 3120485 observed VBN I-VP O
10 882 885 3120485 for IN B-PP O
11 886 890 3120485 mood NN B-NP O
12 891 897 3120485 rating NN I-NP O
13 897 898 3120485 , , O O
14 899 906 3120485 amnesia NN B-NP D000647
15 906 907 3120485 , , O O
16 908 910 3120485 or CC O O
17 911 916 3120485 vital JJ B-NP O
18 917 922 3120485 signs NNS I-NP O
19 922 923 3120485 . . O O

1 924 927 3120485 The DT B-NP O
2 928 932 3120485 Ro15 NN I-NP D005442
3 932 933 3120485 - HYPH I-NP D005442
4 933 937 3120485 1788 CD I-NP D005442
5 938 943 3120485 group NN I-NP O
6 944 950 3120485 showed VBD B-VP O
7 951 952 3120485 a DT B-NP O
8 953 964 3120485 significant JJ I-NP O
9 965 976 3120485 improvement NN I-NP O
10 977 979 3120485 in IN B-PP O
11 980 983 3120485 the DT B-NP O
12 984 995 3120485 performance NN I-NP O
13 996 1000 3120485 test NN I-NP O
14 1001 1003 3120485 up IN B-NP O
15 1004 1006 3120485 to TO I-NP O
16 1007 1010 3120485 120 CD I-NP O
17 1011 1014 3120485 min NN I-NP O
18 1015 1020 3120485 after IN B-PP O
19 1021 1035 3120485 administration NN B-NP O
20 1036 1038 3120485 of IN B-PP O
21 1039 1042 3120485 the DT B-NP O
22 1043 1047 3120485 drug NN I-NP O
23 1047 1048 3120485 . . O O

1 1049 1054 3120485 There EX B-NP O
2 1055 1058 3120485 was VBD B-VP O
3 1059 1061 3120485 no DT B-NP O
4 1062 1070 3120485 evidence NN I-NP O
5 1071 1073 3120485 of IN B-PP O
6 1074 1082 3120485 reaction NN B-NP O
7 1083 1085 3120485 at IN B-PP O
8 1086 1089 3120485 the DT B-NP O
9 1090 1099 3120485 injection NN I-NP O
10 1100 1104 3120485 site NN I-NP O
11 1104 1105 3120485 . . O O

1 0 0 3962737 -DOCSTART- -X- -X- O

1 0 14 3962737 Hepatotoxicity NN B-NP D056486
2 15 17 3962737 of IN B-PP O
3 18 28 3962737 amiodarone NN B-NP D000638
4 28 29 3962737 . . O O
5 30 40 3962737 Amiodarone NN B-NP D000638
6 41 44 3962737 has VBZ B-VP O
7 45 51 3962737 proved VBN I-VP O
8 52 56 3962737 very RB B-ADJP O
9 57 66 3962737 effective JJ I-ADJP O
10 67 69 3962737 in IN B-PP O
11 70 73 3962737 the DT B-NP O
12 74 83 3962737 treatment NN I-NP O
13 84 86 3962737 of IN B-PP O
14 87 96 3962737 otherwise RB B-NP O
15 97 106 3962737 resistant JJ I-NP O
16 107 114 3962737 cardiac JJ I-NP O
17 115 131 3962737 tachyarrhythmias NNS I-NP D013610
18 131 132 3962737 . . O O

1 133 136 3962737 The DT B-NP O
2 137 140 3962737 use NN I-NP O
3 141 143 3962737 of IN B-PP O
4 144 154 3962737 amiodarone NN B-NP D000638
5 155 158 3962737 has VBZ B-VP O
6 158 159 3962737 , , O O
7 160 167 3962737 however RB B-ADVP O
8 167 168 3962737 , , O O
9 169 173 3962737 been VBN B-VP O
10 174 181 3962737 limited VBN I-VP O
11 182 185 3962737 due JJ B-ADJP O
12 186 188 3962737 to TO B-PP O
13 189 192 3962737 its PRP$ B-NP O
14 193 200 3962737 serious JJ I-NP O
15 201 205 3962737 side NN I-NP O
16 205 206 3962737 - HYPH B-NP O
17 206 213 3962737 effects NNS I-NP O
18 213 214 3962737 . . O O

1 215 216 3962737 A DT B-NP O
2 217 224 3962737 patient NN I-NP O
3 225 229 3962737 with IN B-PP O
4 230 241 3962737 cholestatic JJ B-NP D002779
5 242 251 3962737 hepatitis NN I-NP D002779
6 252 255 3962737 due JJ B-ADJP O
7 256 258 3962737 to TO B-PP O
8 259 269 3962737 amiodarone NN B-NP D000638
9 270 279 3962737 treatment NN I-NP O
10 280 282 3962737 is VBZ B-VP O
11 283 292 3962737 presented VBN I-VP O
12 293 298 3962737 below IN B-PP O
13 299 302 3962737 and CC O O
14 303 304 3962737 a DT B-NP O
15 305 311 3962737 review NN I-NP O
16 312 314 3962737 of IN B-PP O
17 315 318 3962737 the DT B-NP O
18 319 333 3962737 hepatotoxicity NN I-NP D056486
19 334 336 3962737 of IN B-PP O
20 337 347 3962737 amiodarone NN B-NP D000638
21 348 350 3962737 is VBZ B-VP O
22 351 356 3962737 given VBN I-VP O
23 356 357 3962737 . . O O

1 358 360 3962737 It PRP B-NP O
2 361 363 3962737 is VBZ B-VP O
3 364 373 3962737 concluded VBN I-VP O
4 374 378 3962737 that IN B-SBAR O
5 379 384 3962737 solid JJ B-NP O
6 385 393 3962737 evidence NN I-NP O
7 394 400 3962737 exists VBZ B-VP O
8 401 403 3962737 of IN B-PP O
9 404 411 3962737 hepatic JJ B-NP D056486
10 412 418 3962737 injury NN I-NP D056486
11 419 422 3962737 due JJ B-ADJP O
12 423 425 3962737 to TO B-PP O
13 426 436 3962737 amiodarone NN B-NP D000638
14 437 446 3962737 treatment NN I-NP O
15 446 447 3962737 , , O O
16 448 457 3962737 including VBG B-PP O
17 458 467 3962737 steatosis NN B-NP D005234
18 467 468 3962737 , , O O
19 469 480 3962737 alterations NNS B-NP O
20 481 491 3962737 resembling VBG B-VP O
21 492 501 3962737 alcoholic JJ B-NP D006519
22 502 511 3962737 hepatitis NN I-NP D006519
23 511 512 3962737 , , O O
24 513 524 3962737 cholestatic JJ B-NP D002779
25 525 534 3962737 hepatitis NN I-NP D002779
26 535 538 3962737 and CC O O
27 539 551 3962737 micronodular JJ B-NP O
28 552 561 3962737 cirrhosis NN I-NP D008103
29 562 564 3962737 of IN B-PP D008103
30 565 568 3962737 the DT B-NP D008103
31 569 574 3962737 liver NN I-NP D008103
32 574 575 3962737 . . O O

1 576 584 3962737 Patients NNS B-NP O
2 585 594 3962737 receiving VBG B-VP O
3 595 605 3962737 amiodarone NN B-NP D000638
4 606 612 3962737 should MD B-VP O
5 613 615 3962737 be VB I-VP O
6 616 625 3962737 regularly RB I-VP O
7 626 634 3962737 screened VBN I-VP O
8 635 639 3962737 with IN B-PP O
9 640 647 3962737 respect NN B-NP O
10 648 650 3962737 to TO B-PP O
11 651 658 3962737 hepatic JJ B-NP O
12 659 665 3962737 enzyme NN I-NP O
13 666 672 3962737 levels NNS I-NP O
14 672 673 3962737 . . O O

1 674 681 3962737 Therapy NN B-NP O
2 682 688 3962737 should MD B-VP O
3 689 691 3962737 be VB I-VP O
4 692 704 3962737 discontinued VBN I-VP O
5 705 707 3962737 on IN B-PP O
6 708 711 3962737 the DT B-NP O
7 712 721 3962737 suspicion NN I-NP O
8 722 724 3962737 of IN B-PP O
9 725 736 3962737 cholestatic JJ B-NP D002779
10 737 743 3962737 injury NN I-NP D002779
11 744 746 3962737 or CC I-NP O
12 747 759 3962737 hepatomegaly NN I-NP D006529
13 759 760 3962737 . . O O

1 0 0 16116131 -DOCSTART- -X- -X- O

1 0 4 16116131 rTMS NN B-NP O
2 5 7 16116131 of IN B-PP O
3 8 21 16116131 supplementary JJ B-NP O
4 22 27 16116131 motor NN I-NP O
5 28 32 16116131 area NN I-NP O
6 33 42 16116131 modulates VBZ B-VP O
7 43 50 16116131 therapy NN B-NP O
8 50 51 16116131 - HYPH B-NP O
9 51 58 16116131 induced VBN I-NP O
10 59 70 16116131 dyskinesias NNS I-NP D004409
11 71 73 16116131 in IN B-PP O
12 74 83 16116131 Parkinson NNP B-NP D010300
13 84 91 16116131 disease NN I-NP D010300
14 91 92 16116131 . . O O
15 93 96 16116131 The DT B-NP O
16 97 103 16116131 neural JJ I-NP O
17 104 114 16116131 mechanisms NNS I-NP O
18 115 118 16116131 and CC I-NP O
19 119 128 16116131 circuitry NN I-NP O
20 129 137 16116131 involved VBN B-VP O
21 138 140 16116131 in IN B-PP O
22 141 149 16116131 levodopa NN B-NP D007980
23 149 150 16116131 - HYPH B-NP O
24 150 157 16116131 induced VBN I-NP O
25 158 168 16116131 dyskinesia NN I-NP D004409
26 169 172 16116131 are VBP B-VP O
27 173 180 16116131 unclear JJ B-ADJP O
28 180 181 16116131 . . O O

1 182 187 16116131 Using VBG B-VP O
2 188 198 16116131 repetitive JJ B-NP O
3 199 211 16116131 transcranial JJ I-NP O
4 212 220 16116131 magnetic JJ I-NP O
5 221 232 16116131 stimulation NN I-NP O
6 233 234 16116131 ( ( O O
7 234 238 16116131 rTMS NN B-NP O
8 238 239 16116131 ) ) O O
9 240 244 16116131 over IN B-PP O
10 245 248 16116131 the DT B-NP O
11 249 262 16116131 supplementary JJ I-NP O
12 263 268 16116131 motor NN I-NP O
13 269 273 16116131 area NN I-NP O
14 274 275 16116131 ( ( O O
15 275 278 16116131 SMA NN B-NP O
16 278 279 16116131 ) ) O O
17 280 282 16116131 in IN B-PP O
18 283 284 16116131 a DT B-NP O
19 285 290 16116131 group NN I-NP O
20 291 293 16116131 of IN B-PP O
21 294 302 16116131 patients NNS B-NP O
22 303 307 16116131 with IN B-PP O
23 308 316 16116131 advanced VBN B-NP O
24 317 326 16116131 Parkinson NNP I-NP D010300
25 327 334 16116131 disease NN I-NP D010300
26 334 335 16116131 , , O O
27 336 339 16116131 the DT B-NP O
28 340 347 16116131 authors NNS I-NP O
29 348 360 16116131 investigated VBD B-VP O
30 361 368 16116131 whether IN B-SBAR O
31 369 379 16116131 modulation NN B-NP O
32 380 382 16116131 of IN B-PP O
33 383 386 16116131 SMA NN B-NP O
34 387 399 16116131 excitability NN I-NP O
35 400 403 16116131 may MD B-VP O
36 404 410 16116131 result VB I-VP O
37 411 413 16116131 in IN B-PP O
38 414 415 16116131 a DT B-NP O
39 416 428 16116131 modification NN I-NP O
40 429 431 16116131 of IN B-PP O
41 432 433 16116131 a DT B-NP O
42 434 444 16116131 dyskinetic JJ I-NP D004409
43 445 450 16116131 state NN I-NP O
44 451 458 16116131 induced VBN B-VP O
45 459 461 16116131 by IN B-PP O
46 462 472 16116131 continuous JJ B-NP O
47 473 484 16116131 apomorphine NN I-NP D001058
48 485 493 16116131 infusion NN I-NP O
49 493 494 16116131 . . O O

1 495 499 16116131 rTMS NN B-NP O
2 500 502 16116131 at IN B-PP O
3 503 504 16116131 1 CD B-NP O
4 505 507 16116131 Hz NN I-NP O
5 508 511 16116131 was VBD B-VP O
6 512 520 16116131 observed VBN I-VP O
7 521 523 16116131 to TO B-VP O
8 524 532 16116131 markedly RB I-VP O
9 533 539 16116131 reduce VB I-VP O
10 540 544 16116131 drug NN B-NP D004409
11 544 545 16116131 - HYPH B-NP D004409
12 545 552 16116131 induced VBN I-NP D004409
13 553 564 16116131 dyskinesias NNS I-NP D004409
14 564 565 16116131 , , O O
15 566 573 16116131 whereas IN O O
16 574 575 16116131 5 CD B-NP O
17 575 576 16116131 - HYPH I-NP O
18 576 578 16116131 Hz NN I-NP O
19 579 583 16116131 rTMS NN I-NP O
20 584 591 16116131 induced VBD B-VP O
21 592 593 16116131 a DT B-NP O
22 594 600 16116131 slight JJ I-NP O
23 601 604 16116131 but CC I-NP O
24 605 608 16116131 not RB I-NP O
25 609 620 16116131 significant JJ I-NP O
26 621 629 16116131 increase NN I-NP O
27 629 630 16116131 . . O O

1 0 0 2004015 -DOCSTART- -X- -X- O

1 0 11 2004015 Sensitivity NN B-NP O
2 12 14 2004015 of IN B-PP O
3 15 24 2004015 erythroid JJ B-NP O
4 25 35 2004015 progenitor NN I-NP O
5 36 44 2004015 colonies NNS I-NP O
6 45 47 2004015 to TO B-PP O
7 48 62 2004015 erythropoietin NN B-NP O
8 63 65 2004015 in IN B-PP O
9 66 80 2004015 azidothymidine NN B-NP D015215
10 81 88 2004015 treated VBN B-VP O
11 89 104 2004015 immunodeficient JJ B-NP C565469
12 105 109 2004015 mice NNS I-NP O
13 109 110 2004015 . . O O
14 111 114 2004015 The DT B-NP O
15 115 122 2004015 anaemia NN I-NP D000740
16 123 130 2004015 induced VBN B-VP O
17 131 133 2004015 by IN B-PP O
18 134 136 2004015 3' JJ O D015215
19 136 137 2004015 - HYPH O D015215
20 137 142 2004015 azido AFX O D015215
21 142 143 2004015 - HYPH O D015215
22 143 161 2004015 3'dideoxythymidine NN B-NP D015215
23 162 163 2004015 ( ( O O
24 163 166 2004015 AZT NN B-NP D015215
25 166 167 2004015 ) ) O O
26 168 170 2004015 is VBZ B-VP O
27 171 177 2004015 poorly RB I-VP O
28 178 188 2004015 understood VBN I-VP O
29 188 189 2004015 . . O O

1 190 192 2004015 We PRP B-NP O
2 193 197 2004015 have VBP B-VP O
3 198 202 2004015 used VBN I-VP O
4 203 204 2004015 a DT B-NP O
5 205 211 2004015 murine JJ I-NP O
6 212 217 2004015 model NN I-NP O
7 218 220 2004015 of IN B-PP O
8 221 225 2004015 AIDS NN B-NP D000163
9 225 226 2004015 , , O O
10 227 236 2004015 infection NN B-NP D007239
11 237 239 2004015 of IN B-PP O
12 240 246 2004015 female JJ B-NP O
13 247 252 2004015 C57BL NN I-NP O
14 252 253 2004015 / SYM B-NP O
15 253 254 2004015 6 CD B-NP O
16 255 259 2004015 mice NNS I-NP O
17 260 264 2004015 with IN B-PP O
18 265 267 2004015 LP NN B-NP O
19 267 268 2004015 - HYPH B-NP O
20 268 271 2004015 BM5 NN I-NP O
21 272 278 2004015 murine JJ I-NP O
22 279 288 2004015 leukaemia NN I-NP D007938
23 289 290 2004015 ( ( O O
24 290 294 2004015 MuLV NN B-NP O
25 294 295 2004015 ) ) O O
26 296 301 2004015 virus NN B-NP O
27 301 302 2004015 , , O O
28 303 305 2004015 to TO B-VP O
29 306 315 2004015 determine VB I-VP O
30 316 318 2004015 if IN B-SBAR O
31 319 322 2004015 AZT NN B-NP D015215
32 322 323 2004015 - HYPH B-NP O
33 323 330 2004015 induced VBN I-NP O
34 331 338 2004015 anaemia NN I-NP D000740
35 339 341 2004015 is VBZ B-VP O
36 342 345 2004015 due JJ B-ADJP O
37 345 346 2004015 , , O O
38 347 349 2004015 in IN B-PP O
39 350 354 2004015 part NN B-NP O
40 354 355 2004015 , , O O
41 356 358 2004015 to TO B-PP O
42 359 368 2004015 decreased VBN B-NP O
43 369 383 2004015 responsiveness NN I-NP O
44 384 386 2004015 of IN B-PP O
45 387 401 2004015 erythropoietic JJ B-NP O
46 402 412 2004015 precursors NNS I-NP O
47 413 414 2004015 ( ( O O
48 414 417 2004015 BFU NN B-NP O
49 417 418 2004015 - HYPH O O
50 418 419 2004015 e NN B-NP O
51 419 420 2004015 ) ) O O
52 421 423 2004015 to TO B-PP O
53 424 438 2004015 erythropoietin NN B-NP O
54 439 440 2004015 ( ( O O
55 440 443 2004015 EPO NN B-NP O
56 443 444 2004015 ) ) O O
57 444 445 2004015 . . O O

1 446 450 2004015 Mice NNS B-NP O
2 451 453 2004015 in IN B-PP O
3 454 457 2004015 the DT B-NP O
4 458 463 2004015 early JJ I-NP O
5 464 469 2004015 stage NN I-NP O
6 470 472 2004015 of IN B-PP O
7 473 475 2004015 LP NN B-NP O
8 475 476 2004015 - HYPH B-NP O
9 476 479 2004015 BM5 NN I-NP O
10 480 484 2004015 MuLV NN I-NP O
11 485 492 2004015 disease NN I-NP O
12 493 497 2004015 were VBD B-VP O
13 498 503 2004015 given VBN I-VP O
14 504 507 2004015 AZT NNP B-NP D015215
15 508 510 2004015 in IN B-PP O
16 511 516 2004015 their PRP$ B-NP O
17 517 525 2004015 drinking NN I-NP O
18 526 531 2004015 water NN I-NP O
19 532 534 2004015 at IN B-PP O
20 535 538 2004015 1.0 CD B-NP O
21 539 542 2004015 and CC I-NP O
22 543 546 2004015 2.5 CD I-NP O
23 547 549 2004015 mg NN I-NP O
24 549 550 2004015 / SYM B-NP O
25 550 552 2004015 ml NN I-NP O
26 552 553 2004015 . . O O

1 554 557 2004015 AZT NN B-NP D015215
2 558 566 2004015 produced VBD B-VP O
3 567 574 2004015 anaemia NN B-NP D000740
4 575 577 2004015 in IN B-PP O
5 578 582 2004015 both DT B-NP O
6 583 589 2004015 groups NNS I-NP O
7 589 590 2004015 , , O O
8 591 593 2004015 in IN B-PP O
9 594 595 2004015 a DT B-NP O
10 596 600 2004015 dose NN I-NP O
11 600 601 2004015 - HYPH B-NP O
12 601 610 2004015 dependent JJ I-NP O
13 611 618 2004015 fashion NN I-NP O
14 618 619 2004015 . . O O

1 620 627 2004015 Despite IN B-PP O
2 628 631 2004015 the DT B-NP O
3 632 639 2004015 anaemia NN I-NP D000740
4 639 640 2004015 , , O O
5 641 644 2004015 the DT B-NP O
6 645 651 2004015 number NN I-NP O
7 652 654 2004015 of IN B-PP O
8 655 662 2004015 splenic JJ B-NP O
9 663 666 2004015 and CC I-NP O
10 667 671 2004015 bone NN I-NP O
11 672 678 2004015 marrow NN I-NP O
12 679 682 2004015 BFU NN I-NP O
13 682 683 2004015 - HYPH B-NP O
14 683 684 2004015 e NN I-NP O
15 685 687 2004015 in IN B-PP O
16 688 691 2004015 AZT NNP B-NP D015215
17 692 699 2004015 treated VBN I-NP O
18 700 704 2004015 mice NNS I-NP O
19 705 714 2004015 increased VBD B-VP O
20 715 717 2004015 up RB B-NP O
21 718 720 2004015 to TO I-NP O
22 721 725 2004015 five CD I-NP O
23 725 726 2004015 - HYPH O O
24 726 730 2004015 fold RB B-ADVP O
25 731 735 2004015 over IN B-PP O
26 736 742 2004015 levels NNS B-NP O
27 743 751 2004015 observed VBN B-VP O
28 752 754 2004015 in IN B-PP O
29 755 763 2004015 infected JJ B-NP O
30 764 773 2004015 untreated JJ I-NP O
31 774 781 2004015 animals NNS I-NP O
32 782 787 2004015 after IN B-PP O
33 788 790 2004015 15 CD B-NP O
34 791 792 2004015 d NN I-NP O
35 793 795 2004015 of IN B-PP O
36 796 805 2004015 treatment NN B-NP O
37 805 806 2004015 . . O O

1 807 813 2004015 Colony NN B-NP O
2 814 823 2004015 formation NN I-NP O
3 824 826 2004015 by IN B-PP O
4 827 834 2004015 splenic JJ B-NP O
5 835 838 2004015 and CC I-NP O
6 839 843 2004015 bone NN I-NP O
7 844 850 2004015 marrow NN I-NP O
8 851 855 2004015 BFUe NN I-NP O
9 856 859 2004015 was VBD B-VP O
10 860 870 2004015 stimulated VBN I-VP O
11 871 873 2004015 at IN B-PP O
12 874 879 2004015 lower JJR B-NP O
13 880 894 2004015 concentrations NNS I-NP O
14 895 897 2004015 of IN B-PP O
15 898 901 2004015 EPO NN B-NP O
16 902 904 2004015 in IN B-PP O
17 905 909 2004015 mice NNS B-NP O
18 910 919 2004015 receiving VBG B-VP O
19 920 923 2004015 AZT NNP B-NP D015215
20 924 927 2004015 for IN B-PP O
21 928 930 2004015 15 CD B-NP O
22 931 932 2004015 d NN I-NP O
23 933 937 2004015 than IN B-PP O
24 938 941 2004015 for IN B-PP O
25 942 950 2004015 infected JJ B-NP O
26 950 951 2004015 , , I-NP O
27 952 961 2004015 untreated JJ I-NP O
28 962 966 2004015 mice NNS I-NP O
29 966 967 2004015 . . O O

1 968 970 2004015 By IN B-PP O
2 971 974 2004015 day NN B-NP O
3 975 977 2004015 30 CD I-NP O
4 977 978 2004015 , , O O
5 979 990 2004015 sensitivity NN B-NP O
6 991 993 2004015 of IN B-PP O
7 994 998 2004015 both CC B-NP O
8 999 1006 2004015 splenic JJ I-NP O
9 1007 1010 2004015 and CC I-NP O
10 1011 1015 2004015 bone NN I-NP O
11 1016 1022 2004015 marrow NN I-NP O
12 1023 1026 2004015 BFU NN I-NP O
13 1026 1027 2004015 - HYPH B-NP O
14 1027 1028 2004015 e NN I-NP O
15 1029 1031 2004015 of IN B-PP O
16 1032 1039 2004015 treated VBN B-NP O
17 1040 1047 2004015 animals NNS I-NP O
18 1048 1056 2004015 returned VBD B-VP O
19 1057 1059 2004015 to TO B-PP O
20 1060 1064 2004015 that DT B-NP O
21 1065 1073 2004015 observed VBN B-VP O
22 1074 1078 2004015 from IN B-PP O
23 1079 1084 2004015 cells NNS B-NP O
24 1085 1087 2004015 of IN B-PP O
25 1088 1096 2004015 infected JJ B-NP O
26 1097 1106 2004015 untreated JJ I-NP O
27 1107 1114 2004015 animals NNS I-NP O
28 1114 1115 2004015 . . O O

1 1116 1119 2004015 The DT B-NP O
2 1120 1124 2004015 mean JJ I-NP O
3 1125 1131 2004015 plasma NN I-NP O
4 1132 1138 2004015 levels NNS I-NP O
5 1139 1141 2004015 of IN B-PP O
6 1142 1145 2004015 EPO NN B-NP O
7 1146 1154 2004015 observed VBN B-VP O
8 1155 1157 2004015 in IN B-PP O
9 1158 1161 2004015 AZT NNP B-NP D015215
10 1162 1169 2004015 treated VBN I-NP O
11 1170 1174 2004015 mice NNS I-NP O
12 1175 1179 2004015 were VBD B-VP O
13 1180 1191 2004015 appropriate JJ B-ADJP O
14 1192 1195 2004015 for IN B-PP O
15 1196 1199 2004015 the DT B-NP O
16 1200 1206 2004015 degree NN I-NP O
17 1207 1209 2004015 of IN B-PP O
18 1210 1217 2004015 anaemia NN B-NP D000740
19 1218 1226 2004015 observed VBN B-VP O
20 1227 1231 2004015 when WRB B-ADVP O
21 1232 1240 2004015 compared VBN B-PP O
22 1241 1245 2004015 with IN B-PP O
23 1246 1261 2004015 phenylhydrazine NN B-NP C030299
24 1262 1263 2004015 ( ( O O
25 1263 1266 2004015 PHZ NN B-NP C030299
26 1266 1267 2004015 ) ) O O
27 1268 1275 2004015 treated VBN B-NP O
28 1276 1280 2004015 mice NNS I-NP O
29 1280 1281 2004015 . . O O

1 1282 1285 2004015 The DT B-NP O
2 1286 1293 2004015 numbers NNS I-NP O
3 1294 1296 2004015 of IN B-PP O
4 1297 1300 2004015 BFU NN B-NP O
5 1300 1301 2004015 - HYPH B-NP O
6 1301 1302 2004015 e NN I-NP O
7 1303 1306 2004015 and CC O O
8 1307 1310 2004015 the DT B-NP O
9 1311 1321 2004015 percentage NN I-NP O
10 1322 1324 2004015 of IN B-PP O
11 1325 1329 2004015 bone NN B-NP O
12 1330 1336 2004015 marrow NN I-NP O
13 1337 1350 2004015 erythroblasts NNS I-NP O
14 1351 1359 2004015 observed VBN B-VP O
15 1360 1364 2004015 were VBD B-VP O
16 1365 1375 2004015 comparable JJ B-ADJP O
17 1376 1378 2004015 in IN B-PP O
18 1379 1382 2004015 AZT NN B-NP D015215
19 1383 1386 2004015 and CC O O
20 1387 1390 2004015 PHZ NN B-NP C030299
21 1391 1398 2004015 treated VBN B-VP O
22 1399 1403 2004015 mice NNS B-NP O
23 1404 1408 2004015 with IN B-PP O
24 1409 1416 2004015 similar JJ B-NP O
25 1417 1424 2004015 degrees NNS I-NP O
26 1425 1427 2004015 of IN B-PP O
27 1428 1435 2004015 anaemia NN B-NP D000740
28 1435 1436 2004015 . . O O

1 1437 1444 2004015 However RB B-ADVP O
2 1444 1445 2004015 , , O O
3 1446 1461 2004015 reticulocytosis NN B-NP D045262
4 1462 1465 2004015 was VBD B-VP O
5 1466 1479 2004015 inappropriate JJ B-ADJP O
6 1480 1483 2004015 for IN B-PP O
7 1484 1487 2004015 the DT B-NP O
8 1488 1494 2004015 degree NN I-NP O
9 1495 1497 2004015 of IN B-PP O
10 1498 1505 2004015 anaemia NN B-NP D000740
11 1506 1514 2004015 observed VBN B-VP O
12 1515 1517 2004015 in IN B-PP O
13 1518 1521 2004015 AZT NNP B-NP D015215
14 1522 1529 2004015 treated VBN B-VP O
15 1530 1538 2004015 infected JJ B-NP O
16 1539 1543 2004015 mice NNS I-NP O
17 1543 1544 2004015 . . O O

1 1545 1548 2004015 AZT NN B-NP D015215
2 1548 1549 2004015 - HYPH O O
3 1549 1556 2004015 induced VBN B-NP O
4 1557 1567 2004015 peripheral JJ I-NP O
5 1568 1575 2004015 anaemia NN I-NP D000740
6 1576 1578 2004015 in IN B-PP O
7 1579 1582 2004015 the DT B-NP O
8 1583 1587 2004015 face NN I-NP O
9 1588 1590 2004015 of IN B-PP O
10 1591 1600 2004015 increased VBN B-NP O
11 1601 1608 2004015 numbers NNS I-NP O
12 1609 1611 2004015 of IN B-PP O
13 1612 1615 2004015 BFU NN B-NP O
14 1615 1616 2004015 - HYPH B-NP O
15 1616 1617 2004015 e NN I-NP O
16 1618 1621 2004015 and CC O O
17 1622 1631 2004015 increased VBN B-NP O
18 1632 1638 2004015 levels NNS I-NP O
19 1639 1641 2004015 of IN B-PP O
20 1642 1648 2004015 plasma NN B-NP O
21 1649 1652 2004015 EPO NN I-NP O
22 1653 1660 2004015 suggest VBP B-VP O
23 1661 1662 2004015 a DT B-NP O
24 1663 1669 2004015 lesion NN I-NP O
25 1670 1672 2004015 in IN B-PP O
26 1673 1681 2004015 terminal JJ B-NP O
27 1682 1697 2004015 differentiation NN I-NP O
28 1697 1698 2004015 . . O O

1 0 0 15811908 -DOCSTART- -X- -X- O

1 0 16 15811908 Pheochromocytoma NN B-NP D010673
2 17 25 15811908 unmasked JJ B-ADJP O
3 26 28 15811908 by IN B-PP O
4 29 40 15811908 amisulpride NN B-NP C012052
5 41 44 15811908 and CC I-NP O
6 45 53 15811908 tiapride NN I-NP D063325
7 53 54 15811908 . . I-NP O
8 55 64 15811908 OBJECTIVE NN I-NP O
9 64 65 15811908 : : O O
10 66 68 15811908 To TO B-VP O
11 69 77 15811908 describe VB I-VP O
12 78 81 15811908 the DT B-NP O
13 82 91 15811908 unmasking NN I-NP O
14 92 94 15811908 of IN B-PP O
15 95 111 15811908 pheochromocytoma NN B-NP D010673
16 112 114 15811908 in IN B-PP O
17 115 116 15811908 a DT B-NP O
18 117 124 15811908 patient NN I-NP O
19 125 132 15811908 treated VBN B-VP O
20 133 137 15811908 with IN B-PP O
21 138 149 15811908 amisulpride NN B-NP C012052
22 150 153 15811908 and CC I-NP O
23 154 162 15811908 tiapride NN I-NP D063325
24 162 163 15811908 . . O O

1 164 168 15811908 CASE NN B-NP O
2 169 176 15811908 SUMMARY NN I-NP O
3 176 177 15811908 : : O O
4 178 179 15811908 A DT B-NP O
5 180 182 15811908 42 CD I-NP O
6 182 183 15811908 - HYPH I-NP O
7 183 187 15811908 year NN I-NP O
8 187 188 15811908 - HYPH B-NP O
9 188 191 15811908 old JJ I-NP O
10 192 197 15811908 white JJ I-NP O
11 198 201 15811908 man NN I-NP O
12 202 211 15811908 developed VBD B-VP O
13 212 217 15811908 acute JJ B-NP O
14 218 230 15811908 hypertension NN I-NP D006973
15 231 235 15811908 with IN B-PP O
16 236 242 15811908 severe JJ B-NP O
17 243 251 15811908 headache NN I-NP D006261
18 252 255 15811908 and CC O O
19 256 264 15811908 vomiting VBG B-VP D014839
20 265 266 15811908 2 CD B-NP O
21 267 272 15811908 hours NNS I-NP O
22 273 278 15811908 after IN B-PP O
23 279 282 15811908 the DT B-NP O
24 283 288 15811908 first JJ I-NP O
25 289 294 15811908 doses NNS I-NP O
26 295 297 15811908 of IN B-PP O
27 298 309 15811908 amisulpride NN B-NP C012052
28 310 313 15811908 100 CD I-NP O
29 314 316 15811908 mg NN I-NP O
30 317 320 15811908 and CC I-NP O
31 321 329 15811908 tiapride NN I-NP D063325
32 330 333 15811908 100 CD I-NP O
33 334 336 15811908 mg NN I-NP O
34 336 337 15811908 . . O O

1 338 342 15811908 Both DT B-NP O
2 343 348 15811908 drugs NNS I-NP O
3 349 353 15811908 were VBD B-VP O
4 354 365 15811908 immediately RB I-VP O
5 366 378 15811908 discontinued VBN I-VP O
6 378 379 15811908 , , O O
7 380 383 15811908 and CC O O
8 384 387 15811908 the DT B-NP O
9 388 395 15811908 patient NN I-NP O
10 396 405 15811908 recovered VBD B-VP O
11 406 411 15811908 after IN B-PP O
12 412 422 15811908 subsequent JJ B-NP O
13 423 434 15811908 nicardipine NN I-NP D009529
14 435 438 15811908 and CC O O
15 439 448 15811908 verapamil NN B-NP D014700
16 449 458 15811908 treatment NN I-NP O
17 458 459 15811908 . . O O

1 460 469 15811908 Abdominal JJ B-NP O
2 470 480 15811908 ultrasound NN I-NP O
3 481 487 15811908 showed VBD B-VP O
4 488 490 15811908 an DT B-NP O
5 491 498 15811908 adrenal JJ I-NP O
6 499 503 15811908 mass NN I-NP O
7 503 504 15811908 , , O O
8 505 508 15811908 and CC O O
9 509 522 15811908 postoperative JJ B-NP O
10 523 533 15811908 histologic JJ I-NP O
11 534 545 15811908 examination NN I-NP O
12 546 555 15811908 confirmed VBD B-VP O
13 556 559 15811908 the DT B-NP O
14 560 569 15811908 diagnosis NN I-NP O
15 570 572 15811908 of IN B-PP O
16 573 589 15811908 pheochromocytoma NN B-NP D010673
17 589 590 15811908 . . O O

1 591 601 15811908 DISCUSSION NN B-NP O
2 601 602 15811908 : : O O
3 603 607 15811908 Drug NN B-NP O
4 607 608 15811908 - HYPH B-NP O
5 608 615 15811908 induced VBN I-NP O
6 616 624 15811908 symptoms NNS I-NP O
7 625 627 15811908 of IN B-PP O
8 628 644 15811908 pheochromocytoma NN B-NP D010673
9 645 648 15811908 are VBP B-VP O
10 649 654 15811908 often RB I-VP O
11 655 665 15811908 associated VBN I-VP O
12 666 670 15811908 with IN B-PP O
13 671 674 15811908 the DT B-NP O
14 675 678 15811908 use NN I-NP O
15 679 681 15811908 of IN B-PP O
16 682 693 15811908 substituted VBN B-NP O
17 694 703 15811908 benzamide NN I-NP C037689
18 704 709 15811908 drugs NNS I-NP O
19 709 710 15811908 , , O O
20 711 714 15811908 but CC O O
21 715 718 15811908 the DT B-NP O
22 719 729 15811908 underlying JJ I-NP O
23 730 739 15811908 mechanism NN I-NP O
24 740 742 15811908 is VBZ B-VP O
25 743 750 15811908 unknown JJ B-ADJP O
26 750 751 15811908 . . O O

1 752 754 15811908 In IN B-PP O
2 755 758 15811908 our PRP$ B-NP O
3 759 763 15811908 case NN I-NP O
4 763 764 15811908 , , O O
5 765 768 15811908 use NN B-NP O
6 769 771 15811908 of IN B-PP O
7 772 775 15811908 the DT B-NP O
8 776 783 15811908 Naranjo NNP I-NP O
9 784 795 15811908 probability NN I-NP O
10 796 801 15811908 scale NN I-NP O
11 802 811 15811908 indicated VBD B-VP O
12 812 813 15811908 a DT B-NP O
13 814 822 15811908 possible JJ I-NP O
14 823 835 15811908 relationship NN I-NP O
15 836 843 15811908 between IN B-PP O
16 844 847 15811908 the DT B-NP O
17 848 860 15811908 hypertensive JJ I-NP D006973
18 861 867 15811908 crisis NN I-NP O
19 868 871 15811908 and CC I-NP O
20 872 883 15811908 amisulpride NN I-NP C012052
21 884 887 15811908 and CC I-NP O
22 888 896 15811908 tiapride NN I-NP D063325
23 897 904 15811908 therapy NN I-NP O
24 904 905 15811908 . . O O

1 906 917 15811908 CONCLUSIONS NNS B-NP O
2 917 918 15811908 : : O O
3 919 921 15811908 As IN B-PP O
4 922 924 15811908 of IN B-PP O
5 925 930 15811908 March NNP B-NP O
6 931 933 15811908 24 CD I-NP O
7 933 934 15811908 , , I-NP O
8 935 939 15811908 2005 CD I-NP O
9 939 940 15811908 , , O O
10 941 945 15811908 this DT B-NP O
11 946 948 15811908 is VBZ B-VP O
12 949 952 15811908 the DT B-NP O
13 953 958 15811908 first JJ I-NP O
14 959 967 15811908 reported VBN I-NP O
15 968 972 15811908 case NN I-NP O
16 973 975 15811908 of IN B-PP O
17 976 987 15811908 amisulpride NN B-NP C012052
18 987 988 15811908 - HYPH B-NP O
19 989 992 15811908 and CC I-NP O
20 993 1001 15811908 tiapride NN I-NP D063325
21 1001 1002 15811908 - HYPH O O
22 1002 1009 15811908 induced VBN B-NP O
23 1010 1022 15811908 hypertensive JJ I-NP D006973
24 1023 1029 15811908 crisis NN I-NP O
25 1030 1032 15811908 in IN B-PP O
26 1033 1034 15811908 a DT B-NP O
27 1035 1042 15811908 patient NN I-NP O
28 1043 1047 15811908 with IN B-PP O
29 1048 1064 15811908 pheochromocytoma NN B-NP D010673
30 1064 1065 15811908 . . O O

1 1066 1076 15811908 Physicians NNS B-NP O
2 1077 1080 15811908 and CC O O
3 1081 1086 15811908 other JJ B-NP O
4 1087 1097 15811908 healthcare NN I-NP O
5 1098 1111 15811908 professionals NNS I-NP O
6 1112 1118 15811908 should MD B-VP O
7 1119 1121 15811908 be VB I-VP O
8 1122 1127 15811908 aware JJ B-ADJP O
9 1128 1130 15811908 of IN B-PP O
10 1131 1135 15811908 this DT B-NP O
11 1136 1145 15811908 potential JJ I-NP O
12 1146 1153 15811908 adverse JJ I-NP O
13 1154 1160 15811908 effect NN I-NP O
14 1161 1163 15811908 of IN B-PP O
15 1164 1172 15811908 tiapride NN B-NP D063325
16 1173 1176 15811908 and CC I-NP O
17 1177 1188 15811908 amisulpride NN I-NP C012052
18 1188 1189 15811908 . . O O

1 0 0 11226639 -DOCSTART- -X- -X- O

1 0 4 11226639 Dual JJ B-NP O
2 5 12 11226639 effects NNS I-NP O
3 13 15 11226639 of IN B-PP O
4 16 25 11226639 melatonin NN B-NP D008550
5 26 28 11226639 on IN B-PP O
6 29 40 11226639 barbiturate NN B-NP C032232
7 40 41 11226639 - HYPH B-NP O
8 41 48 11226639 induced VBN I-NP O
9 49 57 11226639 narcosis NN I-NP D053608
10 58 60 11226639 in IN B-PP O
11 61 65 11226639 rats NNS B-NP O
12 65 66 11226639 . . O O
13 67 76 11226639 Melatonin NN B-NP D008550
14 77 84 11226639 affects VBZ B-VP O
15 85 88 11226639 the DT B-NP O
16 89 98 11226639 circadian JJ I-NP O
17 99 104 11226639 sleep NN I-NP O
18 104 105 11226639 / SYM B-NP O
19 105 109 11226639 wake NN I-NP O
20 110 115 11226639 cycle NN I-NP O
21 115 116 11226639 , , O O
22 117 120 11226639 but CC O O
23 121 123 11226639 it PRP B-NP O
24 124 126 11226639 is VBZ B-VP O
25 127 130 11226639 not RB O O
26 131 136 11226639 clear JJ B-ADJP O
27 137 144 11226639 whether IN B-SBAR O
28 145 147 11226639 it PRP B-NP O
29 148 151 11226639 may MD B-VP O
30 152 161 11226639 influence VB I-VP O
31 162 166 11226639 drug NN B-NP O
32 166 167 11226639 - HYPH B-NP O
33 167 174 11226639 induced VBN I-NP O
34 175 183 11226639 narcosis NN I-NP D053608
35 183 184 11226639 . . O O

1 185 191 11226639 Sodium NN B-NP D013874
2 192 203 11226639 thiopenthal NN I-NP D013874
3 204 207 11226639 was VBD B-VP O
4 208 220 11226639 administered VBN I-VP O
5 221 238 11226639 intraperitoneally RB B-ADVP O
6 239 243 11226639 into IN B-PP O
7 244 248 11226639 male JJ B-NP O
8 249 253 11226639 rats NNS I-NP O
9 254 257 11226639 pre AFX O O
10 257 258 11226639 - HYPH O O
11 258 265 11226639 treated VBN B-VP O
12 266 270 11226639 with IN B-PP O
13 271 280 11226639 melatonin NN B-NP D008550
14 281 282 11226639 ( ( O O
15 282 286 11226639 0.05 CD B-NP O
16 286 287 11226639 , , I-NP O
17 288 291 11226639 0.5 CD I-NP O
18 291 292 11226639 , , I-NP O
19 293 294 11226639 5 CD I-NP O
20 295 298 11226639 and CC I-NP O
21 299 301 11226639 50 CD I-NP O
22 302 304 11226639 mg NN I-NP O
23 304 305 11226639 / SYM B-NP O
24 305 307 11226639 kg NN I-NP O
25 307 308 11226639 ) ) O O
26 308 309 11226639 . . O O

1 310 319 11226639 Melatonin NN B-NP D008550
2 320 323 11226639 pre AFX O O
3 323 324 11226639 - HYPH O O
4 324 333 11226639 treatment NN B-NP O
5 334 342 11226639 affected VBN B-VP O
6 343 345 11226639 in IN B-PP O
7 346 347 11226639 a DT B-NP O
8 348 352 11226639 dual JJ I-NP O
9 353 359 11226639 manner NN I-NP O
10 360 371 11226639 barbiturate NN I-NP C032232
11 372 380 11226639 narcosis NN I-NP D053608
12 380 381 11226639 , , O O
13 382 389 11226639 however RB B-ADVP O
14 389 390 11226639 , , O O
15 391 393 11226639 no DT B-NP O
16 394 398 11226639 dose NN I-NP O
17 398 399 11226639 - HYPH B-NP O
18 399 405 11226639 effect NN I-NP O
19 406 417 11226639 correlation NN I-NP O
20 418 421 11226639 was VBD B-VP O
21 422 427 11226639 found VBN I-VP O
22 427 428 11226639 . . O O

1 429 431 11226639 In IN B-PP O
2 432 442 11226639 particular JJ B-NP O
3 442 443 11226639 , , I-NP O
4 444 447 11226639 low JJ I-NP O
5 448 453 11226639 doses NNS I-NP O
6 454 461 11226639 reduced VBD B-VP O
7 462 465 11226639 the DT B-NP O
8 466 473 11226639 latency NN I-NP O
9 474 476 11226639 to TO B-PP O
10 477 480 11226639 and CC O O
11 481 490 11226639 prolonged VBD B-VP O
12 491 494 11226639 the DT B-NP O
13 495 503 11226639 duration NN I-NP O
14 504 506 11226639 of IN B-PP O
15 507 518 11226639 barbiturate NN B-NP C032232
16 519 527 11226639 narcosis NN I-NP D053608
17 527 528 11226639 . . O O

1 529 531 11226639 In IN B-PP O
2 532 540 11226639 contrast NN B-NP O
3 540 541 11226639 , , O O
4 542 545 11226639 the DT B-NP O
5 546 553 11226639 highest JJS I-NP O
6 554 558 11226639 dose NN I-NP O
7 559 561 11226639 of IN B-PP O
8 562 571 11226639 melatonin NN B-NP D008550
9 572 573 11226639 ( ( O O
10 573 575 11226639 50 CD B-NP O
11 576 578 11226639 mg NN I-NP O
12 578 579 11226639 / SYM B-NP O
13 579 581 11226639 kg NN I-NP O
14 581 582 11226639 ) ) O O
15 583 589 11226639 caused VBD B-VP O
16 590 591 11226639 a DT B-NP O
17 592 603 11226639 paradoxical JJ I-NP O
18 604 612 11226639 increase NN I-NP O
19 613 615 11226639 in IN B-PP O
20 616 619 11226639 the DT B-NP O
21 620 627 11226639 latency NN I-NP O
22 628 631 11226639 and CC O O
23 632 640 11226639 produced VBD B-VP O
24 641 642 11226639 a DT B-NP O
25 643 652 11226639 sustained JJ I-NP O
26 653 662 11226639 reduction NN I-NP O
27 663 665 11226639 of IN B-PP O
28 666 669 11226639 the DT B-NP O
29 670 678 11226639 duration NN I-NP O
30 679 681 11226639 of IN B-PP O
31 682 690 11226639 narcosis NN B-NP D053608
32 690 691 11226639 , , O O
33 692 695 11226639 and CC O O
34 696 697 11226639 a DT B-NP O
35 698 707 11226639 reduction NN I-NP O
36 708 710 11226639 in IN B-PP O
37 711 720 11226639 mortality NN B-NP O
38 721 725 11226639 rate NN I-NP O
39 725 726 11226639 . . O O

1 727 736 11226639 Melatonin NN B-NP D008550
2 737 740 11226639 0.5 CD I-NP O
3 741 744 11226639 and CC I-NP O
4 745 746 11226639 5 CD I-NP O
5 747 749 11226639 mg NN I-NP O
6 749 750 11226639 / SYM B-NP O
7 750 752 11226639 kg NN I-NP O
8 753 763 11226639 influenced VBD B-VP O
9 764 767 11226639 the DT B-NP O
10 768 776 11226639 duration NN I-NP O
11 777 780 11226639 but CC B-NP O
12 781 784 11226639 not RB I-NP O
13 785 788 11226639 the DT B-NP O
14 789 796 11226639 latency NN I-NP O
15 797 799 11226639 of IN B-PP O
16 800 808 11226639 ketamine NN B-NP D007649
17 808 809 11226639 - HYPH B-NP O
18 810 812 11226639 or CC I-NP O
19 813 821 11226639 diazepam NN I-NP D003975
20 821 822 11226639 - HYPH O O
21 822 829 11226639 induced VBN B-NP O
22 830 838 11226639 narcosis NN I-NP D053608
23 838 839 11226639 . . O O

1 840 844 11226639 Thus RB B-ADVP O
2 844 845 11226639 , , O O
3 846 849 11226639 the DT B-NP O
4 850 854 11226639 dual JJ I-NP O
5 855 861 11226639 action NN I-NP O
6 862 864 11226639 of IN B-PP O
7 865 874 11226639 melatonin NN B-NP D008550
8 875 877 11226639 on IN B-PP O
9 878 893 11226639 pharmacological JJ B-NP O
10 894 902 11226639 narcosis NN I-NP D053608
11 903 908 11226639 seems VBZ B-VP O
12 909 911 11226639 to TO I-VP O
13 912 914 11226639 be VB I-VP O
14 915 923 11226639 specific JJ B-ADJP O
15 924 927 11226639 for IN B-PP O
16 928 931 11226639 the DT B-NP O
17 932 943 11226639 barbiturate NN I-NP C032232
18 944 953 11226639 mechanism NN I-NP O
19 954 956 11226639 of IN B-PP O
20 957 963 11226639 action NN B-NP O
21 963 964 11226639 . . O O

1 0 0 17943461 -DOCSTART- -X- -X- O

1 0 10 17943461 Myocardial JJ B-NP O
2 11 14 17943461 Fas NN I-NP O
3 15 21 17943461 ligand NN I-NP O
4 22 32 17943461 expression NN I-NP O
5 33 42 17943461 increases VBZ B-VP O
6 43 57 17943461 susceptibility NN B-NP O
7 58 60 17943461 to TO B-PP O
8 61 64 17943461 AZT NN B-NP D015215
9 64 65 17943461 - HYPH B-NP O
10 65 72 17943461 induced VBN I-NP O
11 73 87 17943461 cardiomyopathy NN I-NP D009202
12 87 88 17943461 . . I-NP O
13 89 99 17943461 BACKGROUND NN I-NP O
14 99 100 17943461 : : O O
15 101 108 17943461 Dilated VBN B-NP D002311
16 109 123 17943461 cardiomyopathy NN I-NP D002311
17 124 125 17943461 ( ( O O
18 125 128 17943461 DCM NN B-NP D002311
19 128 129 17943461 ) ) O O
20 130 133 17943461 and CC O O
21 134 145 17943461 myocarditis NN B-NP D009205
22 146 151 17943461 occur VBP B-VP O
23 152 154 17943461 in IN B-PP O
24 155 159 17943461 many JJ B-NP O
25 160 163 17943461 HIV NN I-NP D015658
26 163 164 17943461 - HYPH I-NP D015658
27 164 172 17943461 infected VBN I-NP D015658
28 173 184 17943461 individuals NNS I-NP O
29 184 185 17943461 , , O O
30 186 195 17943461 resulting VBG B-VP O
31 196 198 17943461 in IN B-PP O
32 199 210 17943461 symptomatic JJ B-NP O
33 211 216 17943461 heart NN I-NP D006333
34 217 224 17943461 failure NN I-NP D006333
35 225 227 17943461 in IN B-PP O
36 228 230 17943461 up IN B-NP O
37 231 233 17943461 to TO I-NP O
38 234 236 17943461 5% CD B-NP O
39 237 239 17943461 of IN B-PP O
40 240 248 17943461 patients NNS B-NP O
41 248 249 17943461 . . O O

1 250 256 17943461 Highly RB B-NP O
2 257 263 17943461 active JJ I-NP O
3 264 278 17943461 antiretroviral JJ I-NP O
4 279 286 17943461 therapy NN I-NP O
5 287 288 17943461 ( ( O O
6 288 293 17943461 HAART NN B-NP O
7 293 294 17943461 ) ) O O
8 295 298 17943461 has VBZ B-VP O
9 299 312 17943461 significantly RB I-VP O
10 313 320 17943461 reduced VBN I-VP O
11 321 330 17943461 morbidity NN B-NP O
12 331 334 17943461 and CC I-NP O
13 335 344 17943461 mortality NN I-NP O
14 345 347 17943461 of IN B-PP O
15 348 356 17943461 acquired VBN B-NP D000163
16 357 373 17943461 immunodeficiency NN I-NP D000163
17 374 382 17943461 syndrome NN I-NP D000163
18 383 384 17943461 ( ( O O
19 384 388 17943461 AIDS NN B-NP D000163
20 388 389 17943461 ) ) O O
21 389 390 17943461 , , O O
22 391 394 17943461 but CC O O
23 395 398 17943461 has VBZ B-VP O
24 399 407 17943461 resulted VBN I-VP O
25 408 410 17943461 in IN B-PP O
26 411 413 17943461 an DT B-NP O
27 414 422 17943461 increase NN I-NP O
28 423 425 17943461 in IN B-PP O
29 426 433 17943461 cardiac JJ B-NP C538496
30 434 437 17943461 and CC I-NP C538496
31 438 446 17943461 skeletal JJ I-NP C538496
32 447 457 17943461 myopathies NNS I-NP C538496
33 457 458 17943461 . . O O

1 459 466 17943461 METHODS NNS B-NP O
2 467 470 17943461 AND CC I-NP O
3 471 478 17943461 RESULTS NNS I-NP O
4 478 479 17943461 : : O O
5 480 482 17943461 In IN B-SBAR O
6 483 488 17943461 order NN O O
7 489 491 17943461 to TO B-VP O
8 492 503 17943461 investigate VB I-VP O
9 504 511 17943461 whether IN B-SBAR O
10 512 515 17943461 the DT B-NP O
11 516 521 17943461 HAART NN I-NP O
12 522 531 17943461 component NN I-NP O
13 532 542 17943461 zidovudine NN I-NP D015215
14 543 544 17943461 ( ( O O
15 544 546 17943461 3' JJ O D015215
16 546 547 17943461 - HYPH O D015215
17 547 552 17943461 azido AFX O D015215
18 552 553 17943461 - HYPH B-NP D015215
19 553 558 17943461 2',3' NN I-NP D015215
20 558 559 17943461 - HYPH O D015215
21 559 573 17943461 deoxythymidine NN B-NP D015215
22 573 574 17943461 ; : O O
23 575 578 17943461 AZT NN B-NP D015215
24 578 579 17943461 ) ) O O
25 580 588 17943461 triggers VBZ B-VP O
26 589 592 17943461 the DT B-NP O
27 593 596 17943461 Fas NN I-NP O
28 596 597 17943461 - HYPH O O
29 597 606 17943461 dependent JJ B-NP O
30 607 611 17943461 cell NN I-NP O
31 611 612 17943461 - HYPH B-NP O
32 612 617 17943461 death NN I-NP O
33 618 625 17943461 pathway NN I-NP O
34 626 629 17943461 and CC O O
35 630 635 17943461 cause VBP B-VP O
36 636 648 17943461 cytoskeletal JJ B-NP O
37 649 659 17943461 disruption NN I-NP O
38 660 662 17943461 in IN B-PP O
39 663 664 17943461 a DT B-NP O
40 665 671 17943461 murine JJ I-NP O
41 672 677 17943461 model NN I-NP O
42 678 680 17943461 of IN B-PP O
43 681 684 17943461 DCM NN B-NP D002311
44 684 685 17943461 , , O O
45 686 687 17943461 8 CD B-NP O
46 687 688 17943461 - HYPH I-NP O
47 688 692 17943461 week NN I-NP O
48 692 693 17943461 - HYPH B-NP O
49 693 696 17943461 old JJ I-NP O
50 697 707 17943461 transgenic JJ I-NP O
51 708 709 17943461 ( ( O O
52 709 719 17943461 expressing VBG B-VP O
53 720 723 17943461 Fas NN B-NP O
54 724 730 17943461 ligand NN I-NP O
55 731 733 17943461 in IN B-PP O
56 734 737 17943461 the DT B-NP O
57 738 748 17943461 myocardium NN I-NP O
58 748 749 17943461 : : O O
59 750 754 17943461 FasL NN B-NP O
60 755 757 17943461 Tg NN I-NP O
61 757 758 17943461 ) ) O O
62 759 762 17943461 and CC O O
63 763 766 17943461 non AFX O O
64 766 767 17943461 - HYPH O O
65 767 777 17943461 transgenic JJ O O
66 778 779 17943461 ( ( O O
67 779 782 17943461 NTg NN B-NP O
68 782 783 17943461 ) ) O O
69 784 788 17943461 mice NNS B-NP O
70 789 797 17943461 received VBD B-VP O
71 798 803 17943461 water NN B-NP O
72 804 806 17943461 ad NN I-NP O
73 807 814 17943461 libitum NN I-NP O
74 815 825 17943461 containing VBG B-VP O
75 826 835 17943461 different JJ B-NP O
76 836 850 17943461 concentrations NNS I-NP O
77 851 853 17943461 of IN B-PP O
78 854 857 17943461 AZT NN B-NP D015215
79 858 859 17943461 ( ( O O
80 859 860 17943461 0 CD B-NP O
81 860 861 17943461 , , I-NP O
82 862 866 17943461 0.07 CD I-NP O
83 866 867 17943461 , , I-NP O
84 868 871 17943461 0.2 CD I-NP O
85 871 872 17943461 , , O O
86 873 876 17943461 and CC O O
87 877 880 17943461 0.7 CD B-NP O
88 881 883 17943461 mg NN I-NP O
89 883 884 17943461 / SYM B-NP O
90 884 886 17943461 ml NN I-NP O
91 886 887 17943461 ) ) O O
92 887 888 17943461 . . O O

1 889 894 17943461 After IN B-PP O
2 895 896 17943461 6 CD B-NP O
3 897 902 17943461 weeks NNS I-NP O
4 902 903 17943461 , , O O
5 904 911 17943461 cardiac JJ B-NP O
6 912 920 17943461 function NN I-NP O
7 921 924 17943461 was VBD B-VP O
8 925 933 17943461 assessed VBN I-VP O
9 934 936 17943461 by IN B-PP O
10 937 953 17943461 echocardiography NN B-NP O
11 954 957 17943461 and CC I-NP O
12 958 968 17943461 morphology NN I-NP O
13 969 972 17943461 was VBD B-VP O
14 973 981 17943461 assessed VBN I-VP O
15 982 984 17943461 by IN B-PP O
16 985 1000 17943461 histopathologic JJ B-NP O
17 1001 1004 17943461 and CC I-NP O
18 1005 1024 17943461 immunohistochemical JJ I-NP O
19 1025 1032 17943461 methods NNS I-NP O
20 1032 1033 17943461 . . O O

1 1034 1037 17943461 NTg NN B-NP O
2 1038 1041 17943461 and CC I-NP O
3 1042 1051 17943461 untreated JJ I-NP O
4 1052 1056 17943461 FasL NN I-NP O
5 1057 1059 17943461 Tg NN I-NP O
6 1060 1064 17943461 mice NNS I-NP O
7 1065 1071 17943461 showed VBD B-VP O
8 1072 1078 17943461 little JJ B-NP O
9 1079 1081 17943461 or CC I-NP O
10 1082 1084 17943461 no DT I-NP O
11 1085 1091 17943461 change NN I-NP O
12 1092 1094 17943461 in IN B-PP O
13 1095 1102 17943461 cardiac JJ B-NP O
14 1103 1112 17943461 structure NN I-NP O
15 1113 1115 17943461 or CC I-NP O
16 1116 1124 17943461 function NN I-NP O
17 1124 1125 17943461 . . O O

1 1126 1128 17943461 In IN B-PP O
2 1129 1137 17943461 contrast NN B-NP O
3 1137 1138 17943461 , , O O
4 1139 1142 17943461 AZT NN B-NP D015215
5 1142 1143 17943461 - HYPH B-VP O
6 1143 1150 17943461 treated VBN B-NP O
7 1151 1155 17943461 FasL NN I-NP O
8 1156 1158 17943461 Tg NN I-NP O
9 1159 1163 17943461 mice NNS I-NP O
10 1164 1173 17943461 developed VBD B-VP O
11 1174 1181 17943461 cardiac JJ B-NP D002311
12 1182 1190 17943461 dilation NN I-NP D002311
13 1191 1194 17943461 and CC O O
14 1195 1204 17943461 depressed VBD B-VP O
15 1205 1212 17943461 cardiac JJ B-NP O
16 1213 1221 17943461 function NN I-NP O
17 1222 1224 17943461 in IN B-PP O
18 1225 1226 17943461 a DT B-NP O
19 1227 1231 17943461 dose NN I-NP O
20 1231 1232 17943461 - HYPH B-NP O
21 1232 1241 17943461 dependent JJ I-NP O
22 1242 1248 17943461 manner NN I-NP O
23 1248 1249 17943461 , , O O
24 1250 1254 17943461 with IN B-PP O
25 1255 1266 17943461 concomitant JJ B-NP O
26 1267 1279 17943461 inflammatory JJ I-NP O
27 1280 1292 17943461 infiltration NN I-NP O
28 1293 1295 17943461 of IN B-PP O
29 1296 1300 17943461 both DT B-NP O
30 1301 1311 17943461 ventricles NNS I-NP O
31 1311 1312 17943461 . . O O

1 1313 1318 17943461 These DT B-NP O
2 1319 1326 17943461 changes NNS I-NP O
3 1327 1331 17943461 were VBD B-VP O
4 1332 1342 17943461 associated VBN I-VP O
5 1343 1347 17943461 with IN B-PP O
6 1348 1350 17943461 an DT B-NP O
7 1351 1360 17943461 increased VBN I-NP O
8 1361 1372 17943461 sarcolemmal JJ I-NP O
9 1373 1383 17943461 expression NN I-NP O
10 1384 1386 17943461 of IN B-PP O
11 1387 1390 17943461 Fas NN B-NP O
12 1391 1394 17943461 and CC I-NP O
13 1395 1399 17943461 FasL NN I-NP O
14 1399 1400 17943461 , , O O
15 1401 1403 17943461 as RB B-CONJP O
16 1404 1408 17943461 well RB I-CONJP O
17 1409 1411 17943461 as IN I-CONJP O
18 1412 1421 17943461 increased VBN B-NP O
19 1422 1432 17943461 activation NN I-NP O
20 1433 1435 17943461 of IN B-PP O
21 1436 1443 17943461 caspase NN B-NP O
22 1444 1445 17943461 3 CD I-NP O
23 1445 1446 17943461 , , O O
24 1447 1460 17943461 translocation NN B-NP O
25 1461 1463 17943461 of IN B-PP O
26 1464 1471 17943461 calpain NN B-NP O
27 1472 1473 17943461 1 CD I-NP O
28 1474 1476 17943461 to TO B-PP O
29 1477 1480 17943461 the DT B-NP O
30 1481 1491 17943461 sarcolemma NN I-NP O
31 1492 1495 17943461 and CC I-NP O
32 1496 1505 17943461 sarcomere NN I-NP O
33 1505 1506 17943461 , , O O
34 1507 1510 17943461 and CC O O
35 1511 1520 17943461 increased VBN B-NP O
36 1521 1528 17943461 numbers NNS I-NP O
37 1529 1531 17943461 of IN B-PP O
38 1532 1537 17943461 cells NNS B-NP O
39 1538 1548 17943461 undergoing VBG B-VP O
40 1549 1558 17943461 apoptosis NN B-NP O
41 1558 1559 17943461 . . O O

1 1560 1565 17943461 These DT B-NP O
2 1566 1570 17943461 were VBD B-VP O
3 1571 1581 17943461 associated VBN I-VP O
4 1582 1586 17943461 with IN B-PP O
5 1587 1594 17943461 changes NNS B-NP O
6 1595 1597 17943461 in IN B-PP O
7 1598 1608 17943461 dystrophin NN B-NP O
8 1609 1612 17943461 and CC O O
9 1613 1620 17943461 cardiac JJ B-NP O
10 1621 1629 17943461 troponin NN I-NP O
11 1630 1631 17943461 I CD I-NP O
12 1632 1644 17943461 localization NN I-NP O
13 1644 1645 17943461 , , O O
14 1646 1648 17943461 as RB B-CONJP O
15 1649 1653 17943461 well RB I-CONJP O
16 1654 1656 17943461 as IN I-CONJP O
17 1657 1661 17943461 loss NN B-NP O
18 1662 1664 17943461 of IN B-PP O
19 1665 1676 17943461 sarcolemmal JJ B-NP O
20 1677 1686 17943461 integrity NN I-NP O
21 1686 1687 17943461 . . O O

1 1688 1699 17943461 CONCLUSIONS NNS B-NP O
2 1699 1700 17943461 : : O O
3 1701 1704 17943461 The DT B-NP O
4 1705 1715 17943461 expression NN I-NP O
5 1716 1718 17943461 of IN B-PP O
6 1719 1722 17943461 Fas NN B-NP O
7 1723 1729 17943461 ligand NN I-NP O
8 1730 1732 17943461 in IN B-PP O
9 1733 1736 17943461 the DT B-NP O
10 1737 1747 17943461 myocardium NN I-NP O
11 1747 1748 17943461 , , O O
12 1749 1751 17943461 as IN B-SBAR O
13 1752 1762 17943461 identified VBN B-VP O
14 1763 1765 17943461 in IN B-PP O
15 1766 1769 17943461 HIV NN B-NP O
16 1769 1770 17943461 - HYPH B-NP O
17 1770 1778 17943461 positive JJ I-NP O
18 1779 1787 17943461 patients NNS I-NP O
19 1787 1788 17943461 , , O O
20 1789 1794 17943461 might MD B-VP O
21 1795 1803 17943461 increase VB I-VP O
22 1804 1807 17943461 the DT B-NP O
23 1808 1822 17943461 susceptibility NN I-NP O
24 1823 1825 17943461 to TO B-PP O
25 1826 1831 17943461 HAART NN B-NP O
26 1831 1832 17943461 - HYPH B-NP O
27 1832 1839 17943461 induced VBN I-NP O
28 1840 1854 17943461 cardiomyopathy NN I-NP D009202
29 1855 1858 17943461 due IN B-PP O
30 1859 1861 17943461 to TO I-PP O
31 1862 1872 17943461 activation NN B-NP O
32 1873 1875 17943461 of IN B-PP O
33 1876 1885 17943461 apoptotic JJ B-NP O
34 1886 1894 17943461 pathways NNS I-NP O
35 1894 1895 17943461 , , O O
36 1896 1905 17943461 resulting VBG B-VP O
37 1906 1908 17943461 in IN B-PP O
38 1909 1916 17943461 cardiac JJ B-NP D002311
39 1917 1925 17943461 dilation NN I-NP D002311
40 1926 1929 17943461 and CC I-NP D002311
41 1930 1941 17943461 dysfunction NN I-NP D002311
42 1941 1942 17943461 . . O O

1 0 0 17511042 -DOCSTART- -X- -X- O

1 0 2 17511042 An DT B-NP O
2 3 12 17511042 extremely RB I-NP O
3 13 17 17511042 rare JJ I-NP O
4 18 22 17511042 case NN I-NP O
5 23 25 17511042 of IN B-PP O
6 26 36 17511042 delusional JJ B-NP D063726
7 37 48 17511042 parasitosis NN I-NP D063726
8 49 51 17511042 in IN B-PP O
9 52 53 17511042 a DT B-NP O
10 54 61 17511042 chronic JJ I-NP D019698
11 62 71 17511042 hepatitis NN I-NP D019698
12 72 73 17511042 C NN I-NP D019698
13 74 81 17511042 patient NN I-NP O
14 82 88 17511042 during IN B-PP O
15 89 98 17511042 pegylated VBN B-NP C417083
16 99 109 17511042 interferon NN I-NP C417083
17 110 115 17511042 alpha SYM B-NP C417083
18 115 116 17511042 - HYPH I-NP C417083
19 116 118 17511042 2b NN I-NP C417083
20 119 122 17511042 and CC I-NP O
21 123 132 17511042 ribavirin NN I-NP D012254
22 133 142 17511042 treatment NN I-NP O
23 142 143 17511042 . . O O
24 144 150 17511042 During IN B-PP O
25 151 160 17511042 treatment NN B-NP O
26 161 163 17511042 of IN B-PP O
27 164 171 17511042 chronic JJ B-NP D019698
28 172 181 17511042 hepatitis NN I-NP D019698
29 182 183 17511042 C NN I-NP D019698
30 184 192 17511042 patients NNS I-NP O
31 193 197 17511042 with IN B-PP O
32 198 208 17511042 interferon NN B-NP O
33 209 212 17511042 and CC I-NP O
34 213 222 17511042 ribavirin NN I-NP D012254
35 222 223 17511042 , , O O
36 224 225 17511042 a DT B-NP O
37 226 229 17511042 lot NN I-NP O
38 230 232 17511042 of IN B-PP O
39 233 237 17511042 side JJ B-NP O
40 238 245 17511042 effects NNS I-NP O
41 246 249 17511042 are VBP B-VP O
42 250 259 17511042 described VBN I-VP O
43 259 260 17511042 . . O O

1 261 267 17511042 Twenty CD B-NP O
2 267 268 17511042 - HYPH I-NP O
3 268 273 17511042 three CD I-NP O
4 274 281 17511042 percent NN I-NP O
5 282 284 17511042 to TO B-PP O
6 285 288 17511042 44% CD B-NP O
7 289 291 17511042 of IN B-PP O
8 292 300 17511042 patients NNS B-NP O
9 301 308 17511042 develop VBP B-VP O
10 309 319 17511042 depression NN B-NP D003866
11 319 320 17511042 . . O O

1 321 322 17511042 A DT B-NP O
2 323 331 17511042 minority NN I-NP O
3 332 334 17511042 of IN B-PP O
4 335 343 17511042 patients NNS B-NP O
5 344 350 17511042 evolve VBP B-VP O
6 351 353 17511042 to TO B-PP O
7 354 363 17511042 psychosis NN B-NP D011605
8 363 364 17511042 . . O O

1 365 367 17511042 To TO B-PP O
2 368 371 17511042 the DT B-NP O
3 372 376 17511042 best JJS I-NP O
4 377 379 17511042 of IN B-PP O
5 380 383 17511042 our PRP$ B-NP O
6 384 393 17511042 knowledge NN I-NP O
7 393 394 17511042 , , O O
8 395 397 17511042 no DT B-NP O
9 398 403 17511042 cases NNS I-NP O
10 404 406 17511042 of IN B-PP O
11 407 418 17511042 psychogenic JJ B-NP D063726
12 419 430 17511042 parasitosis NN I-NP D063726
13 431 440 17511042 occurring VBG B-VP O
14 441 447 17511042 during IN B-PP O
15 448 458 17511042 interferon NN B-NP O
16 459 466 17511042 therapy NN I-NP O
17 467 471 17511042 have VBP B-VP O
18 472 476 17511042 been VBN I-VP O
19 477 486 17511042 described VBN I-VP O
20 487 489 17511042 in IN B-PP O
21 490 493 17511042 the DT B-NP O
22 494 504 17511042 literature NN I-NP O
23 504 505 17511042 . . O O

1 506 508 17511042 We PRP B-NP O
2 509 516 17511042 present VBP B-VP O
3 517 518 17511042 a DT B-NP O
4 519 521 17511042 49 CD I-NP O
5 521 522 17511042 - HYPH I-NP O
6 522 526 17511042 year NN I-NP O
7 526 527 17511042 - HYPH B-NP O
8 527 530 17511042 old JJ I-NP O
9 531 536 17511042 woman NN I-NP O
10 537 540 17511042 who WP B-NP O
11 541 550 17511042 developed VBD B-VP O
12 551 552 17511042 a DT B-NP O
13 553 563 17511042 delusional JJ I-NP D063726
14 564 575 17511042 parasitosis NN I-NP D063726
15 576 582 17511042 during IN B-PP O
16 583 592 17511042 treatment NN B-NP O
17 593 597 17511042 with IN B-PP O
18 598 607 17511042 pegylated VBN B-NP C417083
19 608 618 17511042 interferon NN I-NP C417083
20 619 624 17511042 alpha SYM B-NP C417083
21 624 625 17511042 - HYPH I-NP C417083
22 625 627 17511042 2b NN I-NP C417083
23 628 634 17511042 weekly JJ I-NP O
24 635 638 17511042 and CC I-NP O
25 639 648 17511042 ribavirin NN I-NP D012254
26 648 649 17511042 . . O O

1 650 653 17511042 She PRP B-NP O
2 654 664 17511042 complained VBD B-VP O
3 665 667 17511042 of IN B-PP O
4 668 674 17511042 seeing VBG B-NP O
5 675 684 17511042 parasites NNS I-NP O
6 685 688 17511042 and CC O O
7 689 692 17511042 the DT B-NP O
8 693 699 17511042 larvae NNS I-NP O
9 700 702 17511042 of IN B-PP O
10 703 708 17511042 fleas NNS B-NP O
11 709 711 17511042 in IN B-PP O
12 712 715 17511042 her PRP$ B-NP O
13 716 722 17511042 stools NNS I-NP O
14 722 723 17511042 . . O O

1 724 728 17511042 This DT B-NP O
2 729 734 17511042 could MD B-VP O
3 735 738 17511042 not RB I-VP O
4 739 741 17511042 be VB I-VP O
5 742 751 17511042 confirmed VBN I-VP O
6 752 754 17511042 by IN B-PP O
7 755 758 17511042 any DT B-NP O
8 759 768 17511042 technical JJ I-NP O
9 769 780 17511042 examination NN I-NP O
10 780 781 17511042 . . O O

1 782 785 17511042 All PDT B-NP O
2 786 789 17511042 the DT I-NP O
3 790 800 17511042 complaints NNS I-NP O
4 801 812 17511042 disappeared VBD B-VP O
5 813 818 17511042 after IN B-PP O
6 819 827 17511042 stopping VBG B-VP O
7 828 837 17511042 pegylated VBN B-NP C417083
8 838 848 17511042 interferon NN I-NP C417083
9 849 854 17511042 alpha SYM O C417083
10 854 855 17511042 - HYPH O C417083
11 855 857 17511042 2b NN B-NP C417083
12 858 861 17511042 and CC O O
13 862 872 17511042 reappeared VBD B-VP O
14 873 878 17511042 after IN B-PP O
15 879 889 17511042 restarting VBG B-VP O
16 890 892 17511042 it PRP B-NP O
17 892 893 17511042 . . O O

1 894 897 17511042 She PRP B-NP O
2 898 901 17511042 had VBD B-VP O
3 902 903 17511042 a DT B-NP O
4 904 912 17511042 complete JJ I-NP O
5 913 922 17511042 sustained JJ I-NP O
6 923 928 17511042 viral JJ I-NP O
7 929 937 17511042 response NN I-NP O
8 937 938 17511042 . . O O

1 0 0 8106150 -DOCSTART- -X- -X- O

1 0 6 8106150 Effect NN B-NP O
2 7 9 8106150 of IN B-PP O
3 10 25 8106150 nondopaminergic JJ B-NP O
4 26 31 8106150 drugs NNS I-NP O
5 32 34 8106150 on IN B-PP O
6 35 36 8106150 L NN B-NP D007980
7 36 37 8106150 - HYPH B-NP D007980
8 37 41 8106150 dopa NN I-NP D007980
9 41 42 8106150 - HYPH B-NP O
10 42 49 8106150 induced VBN I-NP O
11 50 61 8106150 dyskinesias NNS I-NP D004409
12 62 64 8106150 in IN B-PP O
13 65 69 8106150 MPTP NN B-NP D015632
14 69 70 8106150 - HYPH B-NP O
15 70 77 8106150 treated VBN I-NP O
16 78 85 8106150 monkeys NNS I-NP O
17 85 86 8106150 . . O O
18 87 88 8106150 A DT B-NP O
19 89 94 8106150 group NN I-NP O
20 95 97 8106150 of IN B-PP O
21 98 102 8106150 four CD B-NP O
22 103 110 8106150 monkeys NNS I-NP O
23 111 114 8106150 was VBD B-VP O
24 115 123 8106150 rendered VBN I-VP O
25 124 136 8106150 parkinsonian JJ B-ADJP D020734
26 137 141 8106150 with IN B-PP O
27 142 145 8106150 the DT B-NP O
28 146 151 8106150 toxin NN I-NP O
29 152 156 8106150 MPTP NN I-NP D015632
30 156 157 8106150 . . O O

1 158 162 8106150 They PRP B-NP O
2 163 167 8106150 were VBD B-VP O
3 168 172 8106150 then RB I-VP O
4 173 180 8106150 treated VBN I-VP O
5 181 192 8106150 chronically RB B-ADVP O
6 193 197 8106150 with IN B-PP O
7 198 199 8106150 L NN B-NP C005177
8 199 200 8106150 - HYPH I-NP C005177
9 200 204 8106150 DOPA NN I-NP C005177
10 204 205 8106150 / SYM B-VP C005177
11 205 216 8106150 benserazide NN B-NP C005177
12 217 219 8106150 50 CD I-NP O
13 219 220 8106150 / SYM I-NP O
14 220 224 8106150 12.5 CD I-NP O
15 225 227 8106150 mg NN I-NP O
16 227 228 8106150 / SYM B-NP O
17 228 230 8106150 kg NN I-NP O
18 231 236 8106150 given VBN B-VP O
19 237 243 8106150 orally RB B-ADVP O
20 244 249 8106150 daily RB I-ADVP O
21 250 253 8106150 for IN B-PP O
22 254 255 8106150 2 CD B-NP O
23 256 262 8106150 months NNS I-NP O
24 262 263 8106150 . . O O

1 264 268 8106150 This DT B-NP O
2 269 273 8106150 dose NN I-NP O
3 274 282 8106150 produced VBD B-VP O
4 283 284 8106150 a DT B-NP O
5 285 293 8106150 striking JJ I-NP O
6 294 310 8106150 antiparkinsonian JJ I-NP O
7 311 317 8106150 effect NN I-NP O
8 317 318 8106150 , , O O
9 319 322 8106150 but CC O O
10 323 326 8106150 all DT B-NP O
11 327 334 8106150 animals NNS I-NP O
12 335 345 8106150 manifested VBD B-VP O
13 346 356 8106150 dyskinesia NN B-NP D004409
14 356 357 8106150 . . O O

1 358 359 8106150 A DT B-NP O
2 360 366 8106150 series NN I-NP O
3 367 369 8106150 of IN B-PP O
4 370 376 8106150 agents NNS B-NP O
5 377 383 8106150 acting VBG B-VP O
6 384 393 8106150 primarily RB B-ADVP O
7 394 396 8106150 on IN B-PP O
8 397 414 8106150 neurotransmitters NNS B-NP O
9 415 420 8106150 other JJ B-ADJP O
10 421 425 8106150 than IN B-PP O
11 426 434 8106150 dopamine NN B-NP D004298
12 435 439 8106150 were VBD B-VP O
13 440 444 8106150 then RB I-VP O
14 445 451 8106150 tested VBN I-VP O
15 452 454 8106150 in IN B-PP O
16 455 466 8106150 combination NN B-NP O
17 467 471 8106150 with IN B-PP O
18 472 473 8106150 L NN B-NP D007980
19 473 474 8106150 - HYPH O D007980
20 474 478 8106150 DOPA NN B-NP D007980
21 479 481 8106150 to TO B-VP O
22 482 485 8106150 see VB I-VP O
23 486 488 8106150 if IN B-SBAR O
24 489 492 8106150 the DT B-NP O
25 493 503 8106150 dyskinetic JJ I-NP D004409
26 504 513 8106150 movements NNS I-NP O
27 514 519 8106150 would MD B-VP O
28 520 522 8106150 be VB I-VP O
29 523 531 8106150 modified VBN I-VP O
30 531 532 8106150 . . O O

1 533 540 8106150 Several JJ B-NP O
2 541 546 8106150 drugs NNS I-NP O
3 546 547 8106150 , , O O
4 548 557 8106150 including VBG B-PP O
5 558 567 8106150 clonidine NN B-NP D003000
6 567 568 8106150 , , O O
7 569 582 8106150 physostigmine NN B-NP D010830
8 582 583 8106150 , , O O
9 584 596 8106150 methysergide NN B-NP D008784
10 596 597 8106150 , , O O
11 598 599 8106150 5 CD B-NP -1
12 599 600 8106150 - HYPH I-NP -1
13 600 604 8106150 MDOT NN I-NP -1
14 604 605 8106150 , , O O
15 606 617 8106150 propranolol NN B-NP D011433
16 617 618 8106150 , , O O
17 619 622 8106150 and CC O O
18 623 625 8106150 MK NN B-NP D016291
19 625 626 8106150 - HYPH O D016291
20 626 629 8106150 801 CD B-NP D016291
21 629 630 8106150 , , O O
22 631 639 8106150 markedly RB B-ADVP O
23 640 647 8106150 reduced VBD B-VP O
24 648 651 8106150 the DT B-NP O
25 652 662 8106150 dyskinetic JJ I-NP D004409
26 663 672 8106150 movements NNS I-NP O
27 673 676 8106150 but CC B-PP O
28 677 679 8106150 at IN B-PP O
29 680 683 8106150 the DT B-NP O
30 684 688 8106150 cost NN I-NP O
31 689 691 8106150 of IN B-PP O
32 692 693 8106150 a DT B-NP O
33 694 700 8106150 return NN I-NP O
34 701 703 8106150 of IN B-PP O
35 704 716 8106150 parkinsonian JJ B-NP D020734
36 717 731 8106150 symptomatology NN I-NP O
37 731 732 8106150 . . O O

1 733 740 8106150 However RB B-ADVP O
2 740 741 8106150 , , O O
3 742 751 8106150 yohimbine NN B-NP D015016
4 752 755 8106150 and CC I-NP O
5 756 766 8106150 meperidine NN I-NP D008614
6 767 774 8106150 reduced VBD B-VP O
7 775 788 8106150 predominantly RB B-ADVP O
8 789 792 8106150 the DT B-NP O
9 793 803 8106150 dyskinetic JJ I-NP D004409
10 804 813 8106150 movements NNS I-NP O
11 813 814 8106150 . . O O

1 815 823 8106150 Baclofen NN B-NP D001418
2 824 827 8106150 was VBD B-VP O
3 828 832 8106150 also RB B-ADVP O
4 833 839 8106150 useful JJ B-ADJP O
5 840 842 8106150 in IN B-PP O
6 843 846 8106150 one CD B-NP O
7 847 853 8106150 monkey NN I-NP O
8 854 861 8106150 against IN B-PP O
9 862 863 8106150 a DT B-NP O
10 864 868 8106150 more RBR I-NP O
11 869 877 8106150 dystonic JJ I-NP D020821
12 878 882 8106150 form NN I-NP O
13 883 885 8106150 of IN B-PP O
14 886 896 8106150 dyskinesia NN B-NP D004409
15 896 897 8106150 . . O O

1 898 906 8106150 Atropine NN B-NP D001285
2 907 916 8106150 converted VBD B-VP O
3 917 920 8106150 the DT B-NP O
4 921 929 8106150 dystonic JJ I-NP D020821
5 930 939 8106150 movements NNS I-NP O
6 940 944 8106150 into IN B-PP O
7 945 951 8106150 chorea NN B-NP D002819
8 951 952 8106150 . . O O

1 0 0 16574713 -DOCSTART- -X- -X- O

1 0 6 16574713 Memory NN B-NP O
2 7 15 16574713 function NN I-NP O
3 16 19 16574713 and CC O O
4 20 29 16574713 serotonin NN B-NP D012701
5 30 41 16574713 transporter NN I-NP O
6 42 50 16574713 promoter NN I-NP O
7 51 55 16574713 gene NN I-NP O
8 56 68 16574713 polymorphism NN I-NP O
9 69 71 16574713 in IN B-PP O
10 72 79 16574713 ecstasy NN B-NP D018817
11 80 81 16574713 ( ( O O
12 81 85 16574713 MDMA NN B-NP D018817
13 85 86 16574713 ) ) O O
14 87 92 16574713 users NNS B-NP O
15 92 93 16574713 . . O O
16 94 102 16574713 Although IN B-SBAR O
17 103 106 16574713 3,4 CD B-NP D018817
18 106 107 16574713 - HYPH I-NP D018817
19 107 136 16574713 methylenedioxymethamphetamine NN I-NP D018817
20 137 138 16574713 ( ( O O
21 138 142 16574713 MDMA NN B-NP D018817
22 143 145 16574713 or CC O O
23 146 153 16574713 ecstasy NN B-NP D018817
24 153 154 16574713 ) ) O O
25 155 158 16574713 has VBZ B-VP O
26 159 163 16574713 been VBN I-VP O
27 164 169 16574713 shown VBN I-VP O
28 170 172 16574713 to TO I-VP O
29 173 179 16574713 damage VB I-VP O
30 180 185 16574713 brain NN B-NP O
31 186 195 16574713 serotonin NN I-NP D012701
32 196 197 16574713 ( ( O O
33 197 198 16574713 5 CD B-NP D012701
34 198 199 16574713 - HYPH I-NP D012701
35 199 201 16574713 HT NN I-NP D012701
36 201 202 16574713 ) ) O O
37 203 210 16574713 neurons NNS B-NP O
38 211 213 16574713 in IN B-PP O
39 214 221 16574713 animals NNS B-NP O
40 222 225 16574713 and CC O O
41 226 234 16574713 possibly RB B-NP O
42 235 241 16574713 humans NNS I-NP O
43 241 242 16574713 , , O O
44 243 249 16574713 little JJ B-NP O
45 250 252 16574713 is VBZ B-VP O
46 253 258 16574713 known VBN I-VP O
47 259 264 16574713 about IN B-PP O
48 265 268 16574713 the DT B-NP O
49 269 273 16574713 long JJ I-NP O
50 273 274 16574713 - HYPH I-NP O
51 274 278 16574713 term NN I-NP O
52 279 291 16574713 consequences NNS I-NP O
53 292 294 16574713 of IN B-PP O
54 295 299 16574713 MDMA NN B-NP D018817
55 299 300 16574713 - HYPH O O
56 300 307 16574713 induced VBN B-NP O
57 308 309 16574713 5 CD I-NP D012701
58 309 310 16574713 - HYPH I-NP D012701
59 310 312 16574713 HT NN I-NP D012701
60 313 323 16574713 neurotoxic JJ I-NP D020258
61 324 331 16574713 lesions NNS I-NP D020258
62 332 334 16574713 on IN B-PP O
63 335 344 16574713 functions NNS B-NP O
64 345 347 16574713 in IN B-PP O
65 348 353 16574713 which WDT B-NP O
66 354 355 16574713 5 CD B-NP D012701
67 355 356 16574713 - HYPH I-NP D012701
68 356 358 16574713 HT NN I-NP D012701
69 359 361 16574713 is VBZ B-VP O
70 362 370 16574713 involved VBN I-VP O
71 370 371 16574713 , , O O
72 372 376 16574713 such JJ B-PP O
73 377 379 16574713 as IN I-PP O
74 380 389 16574713 cognitive JJ B-NP O
75 390 398 16574713 function NN I-NP O
76 398 399 16574713 . . O O

1 400 407 16574713 Because IN B-SBAR O
2 408 409 16574713 5 CD B-NP D012701
3 409 410 16574713 - HYPH I-NP D012701
4 410 412 16574713 HT NN I-NP D012701
5 413 425 16574713 transporters NNS I-NP O
6 426 430 16574713 play VBP B-VP O
7 431 432 16574713 a DT B-NP O
8 433 436 16574713 key JJ I-NP O
9 437 444 16574713 element NN I-NP O
10 445 447 16574713 in IN B-PP O
11 448 451 16574713 the DT B-NP O
12 452 462 16574713 regulation NN I-NP O
13 463 465 16574713 of IN B-PP O
14 466 474 16574713 synaptic JJ B-NP O
15 475 476 16574713 5 CD I-NP D012701
16 476 477 16574713 - HYPH I-NP D012701
17 477 479 16574713 HT NN I-NP D012701
18 480 492 16574713 transmission NN I-NP O
19 493 495 16574713 it PRP B-NP O
20 496 499 16574713 may MD B-VP O
21 500 502 16574713 be VB I-VP O
22 503 512 16574713 important JJ B-ADJP O
23 513 515 16574713 to TO B-VP O
24 516 523 16574713 control VB I-VP O
25 524 527 16574713 for IN B-PP O
26 528 531 16574713 the DT B-NP O
27 532 541 16574713 potential JJ I-NP O
28 542 552 16574713 covariance NN I-NP O
29 553 559 16574713 effect NN I-NP O
30 560 562 16574713 of IN B-PP O
31 563 564 16574713 a DT B-NP O
32 565 577 16574713 polymorphism NN I-NP O
33 578 580 16574713 in IN B-PP O
34 581 584 16574713 the DT B-NP O
35 585 586 16574713 5 CD I-NP D012701
36 586 587 16574713 - HYPH I-NP D012701
37 587 589 16574713 HT NN I-NP D012701
38 590 601 16574713 transporter NN I-NP O
39 602 610 16574713 promoter NN I-NP O
40 611 615 16574713 gene NN I-NP O
41 616 622 16574713 region NN I-NP O
42 623 624 16574713 ( ( O O
43 624 625 16574713 5 CD B-NP O
44 625 626 16574713 - HYPH I-NP O
45 626 632 16574713 HTTLPR NN I-NP O
46 632 633 16574713 ) ) O O
47 634 638 16574713 when WRB B-ADVP O
48 639 647 16574713 studying VBG B-VP O
49 648 651 16574713 the DT B-NP O
50 652 659 16574713 effects NNS I-NP O
51 660 662 16574713 of IN B-PP O
52 663 667 16574713 MDMA NN B-NP D018817
53 668 670 16574713 as RB B-CONJP O
54 671 675 16574713 well RB I-CONJP O
55 676 678 16574713 as IN I-CONJP O
56 679 688 16574713 cognitive JJ B-NP O
57 689 700 16574713 functioning NN I-NP O
58 700 701 16574713 . . O O

1 702 705 16574713 The DT B-NP O
2 706 709 16574713 aim NN I-NP O
3 710 712 16574713 of IN B-PP O
4 713 716 16574713 the DT B-NP O
5 717 722 16574713 study NN I-NP O
6 723 726 16574713 was VBD B-VP O
7 727 729 16574713 to TO B-VP O
8 730 741 16574713 investigate VB I-VP O
9 742 745 16574713 the DT B-NP O
10 746 753 16574713 effects NNS I-NP O
11 754 756 16574713 of IN B-PP O
12 757 765 16574713 moderate JJ B-NP O
13 766 769 16574713 and CC I-NP O
14 770 775 16574713 heavy JJ I-NP O
15 776 780 16574713 MDMA NN I-NP D018817
16 781 784 16574713 use NN I-NP O
17 785 787 16574713 on IN B-PP O
18 788 797 16574713 cognitive JJ B-NP O
19 798 806 16574713 function NN I-NP O
20 806 807 16574713 , , O O
21 808 810 16574713 as RB B-CONJP O
22 811 815 16574713 well RB I-CONJP O
23 816 818 16574713 as IN I-CONJP O
24 819 822 16574713 the DT B-NP O
25 823 830 16574713 effects NNS I-NP O
26 831 833 16574713 of IN B-PP O
27 834 838 16574713 long JJ B-NP O
28 838 839 16574713 - HYPH I-NP O
29 839 843 16574713 term NN I-NP O
30 844 854 16574713 abstention NN I-NP O
31 855 859 16574713 from IN B-PP O
32 860 864 16574713 MDMA NN B-NP D018817
33 864 865 16574713 , , O O
34 866 868 16574713 in IN B-PP O
35 869 877 16574713 subjects NNS B-NP O
36 878 887 16574713 genotyped VBN B-VP O
37 888 891 16574713 for IN B-PP O
38 892 893 16574713 5 CD B-NP O
39 893 894 16574713 - HYPH I-NP O
40 894 900 16574713 HTTLPR NN I-NP O
41 900 901 16574713 . . O O

1 902 903 16574713 A DT B-NP O
2 904 910 16574713 second JJ I-NP O
3 911 914 16574713 aim NN I-NP O
4 915 917 16574713 of IN B-PP O
5 918 921 16574713 the DT B-NP O
6 922 927 16574713 study NN I-NP O
7 928 931 16574713 was VBD B-VP O
8 932 934 16574713 to TO B-VP O
9 935 944 16574713 determine VB I-VP O
10 945 952 16574713 whether IN B-SBAR O
11 953 958 16574713 these DT B-NP O
12 959 966 16574713 effects NNS I-NP O
13 967 973 16574713 differ VBP B-VP O
14 974 977 16574713 for IN B-PP O
15 978 985 16574713 females NNS B-NP O
16 986 989 16574713 and CC I-NP O
17 990 995 16574713 males NNS I-NP O
18 995 996 16574713 . . O O

1 997 1004 16574713 Fifteen CD B-NP O
2 1005 1013 16574713 moderate JJ I-NP O
3 1014 1018 16574713 MDMA NN I-NP D018817
4 1019 1024 16574713 users NNS I-NP O
5 1025 1026 16574713 ( ( O O
6 1026 1027 16574713 < SYM B-NP O
7 1027 1029 16574713 55 CD B-NP O
8 1030 1038 16574713 lifetime JJ I-NP O
9 1039 1046 16574713 tablets NNS I-NP O
10 1046 1047 16574713 ) ) O O
11 1047 1048 16574713 , , O O
12 1049 1051 16574713 22 CD B-NP O
13 1052 1057 16574713 heavy JJ I-NP O
14 1058 1063 16574713 MDMA+ JJ I-NP D018817
15 1064 1069 16574713 users NNS I-NP O
16 1070 1071 16574713 ( ( O O
17 1071 1072 16574713 > SYM B-NP O
18 1072 1074 16574713 55 CD B-NP O
19 1075 1083 16574713 lifetime JJ I-NP O
20 1084 1091 16574713 tablets NNS I-NP O
21 1091 1092 16574713 ) ) O O
22 1092 1093 16574713 , , O O
23 1094 1096 16574713 16 CD B-NP O
24 1097 1099 16574713 ex NN I-NP O
25 1099 1100 16574713 - HYPH B-NP O
26 1100 1105 16574713 MDMA+ JJ I-NP D018817
27 1106 1111 16574713 users NNS I-NP O
28 1112 1113 16574713 ( ( O O
29 1113 1117 16574713 last JJ B-NP O
30 1118 1124 16574713 tablet NN I-NP O
31 1125 1126 16574713 > SYM O O
32 1127 1128 16574713 1 CD B-NP O
33 1129 1133 16574713 year NN I-NP O
34 1134 1137 16574713 ago RB B-ADVP O
35 1137 1138 16574713 ) ) O O
36 1139 1142 16574713 and CC O O
37 1143 1145 16574713 13 CD B-NP O
38 1146 1154 16574713 controls NNS I-NP O
39 1155 1159 16574713 were VBD B-VP O
40 1160 1168 16574713 compared VBN I-VP O
41 1169 1171 16574713 on IN B-PP O
42 1172 1173 16574713 a DT B-NP O
43 1174 1181 16574713 battery NN I-NP O
44 1182 1184 16574713 of IN B-PP O
45 1185 1203 16574713 neuropsychological JJ B-NP O
46 1204 1209 16574713 tests NNS I-NP O
47 1209 1210 16574713 . . O O

1 1211 1214 16574713 DNA NN B-NP O
2 1215 1219 16574713 from IN B-PP O
3 1220 1230 16574713 peripheral JJ B-NP O
4 1231 1238 16574713 nuclear JJ I-NP O
5 1239 1244 16574713 blood NN I-NP O
6 1245 1250 16574713 cells NNS I-NP O
7 1251 1254 16574713 was VBD B-VP O
8 1255 1264 16574713 genotyped VBN I-VP O
9 1265 1268 16574713 for IN B-PP O
10 1269 1270 16574713 5 CD B-NP O
11 1270 1271 16574713 - HYPH I-NP O
12 1271 1277 16574713 HTTLPR NN I-NP O
13 1278 1283 16574713 using VBG B-VP O
14 1284 1292 16574713 standard JJ B-NP O
15 1293 1303 16574713 polymerase NN I-NP O
16 1304 1309 16574713 chain NN I-NP O
17 1310 1318 16574713 reaction NN I-NP O
18 1319 1328 16574713 methods.A NN I-NP O
19 1329 1340 16574713 significant JJ I-NP O
20 1341 1346 16574713 group NN I-NP O
21 1347 1353 16574713 effect NN I-NP O
22 1354 1357 16574713 was VBD B-VP O
23 1358 1366 16574713 observed VBN I-VP O
24 1367 1371 16574713 only RB B-ADVP O
25 1372 1374 16574713 on IN B-PP O
26 1375 1381 16574713 memory NN B-NP O
27 1382 1390 16574713 function NN I-NP O
28 1391 1396 16574713 tasks NNS I-NP O
29 1397 1398 16574713 ( ( O O
30 1398 1399 16574713 p NN B-NP O
31 1400 1401 16574713 = SYM B-VP O
32 1402 1406 16574713 0.04 CD B-NP O
33 1406 1407 16574713 ) ) O O
34 1408 1411 16574713 but CC B-PP O
35 1412 1415 16574713 not RB B-PP O
36 1416 1418 16574713 on IN I-PP O
37 1419 1427 16574713 reaction NN B-NP O
38 1428 1433 16574713 times NNS I-NP O
39 1434 1435 16574713 ( ( O O
40 1435 1436 16574713 p NN B-NP O
41 1437 1438 16574713 = SYM B-VP O
42 1439 1443 16574713 0.61 CD B-NP O
43 1443 1444 16574713 ) ) O O
44 1445 1447 16574713 or CC O O
45 1448 1457 16574713 attention NN B-NP O
46 1457 1458 16574713 / SYM O O
47 1458 1467 16574713 executive NN B-NP O
48 1468 1479 16574713 functioning NN I-NP O
49 1480 1481 16574713 ( ( O O
50 1481 1482 16574713 p NN B-NP O
51 1483 1484 16574713 = SYM B-VP O
52 1485 1489 16574713 0.59 CD B-NP O
53 1489 1490 16574713 ) ) O O
54 1490 1491 16574713 . . O O

1 1492 1497 16574713 Heavy NN B-NP O
2 1498 1501 16574713 and CC I-NP O
3 1502 1504 16574713 ex NN I-NP O
4 1504 1505 16574713 - HYPH B-NP O
5 1505 1510 16574713 MDMA+ NN I-NP D018817
6 1511 1516 16574713 users NNS I-NP O
7 1517 1526 16574713 performed VBD B-VP O
8 1527 1540 16574713 significantly RB B-ADJP O
9 1541 1547 16574713 poorer JJR I-ADJP O
10 1548 1550 16574713 on IN B-PP O
11 1551 1557 16574713 memory NN B-NP O
12 1558 1563 16574713 tasks NNS I-NP O
13 1564 1568 16574713 than IN B-PP O
14 1569 1577 16574713 controls NNS B-NP O
15 1577 1578 16574713 . . O O

1 1579 1581 16574713 In IN B-PP O
2 1582 1590 16574713 contrast NN B-NP O
3 1590 1591 16574713 , , O O
4 1592 1594 16574713 no DT B-NP O
5 1595 1603 16574713 evidence NN I-NP O
6 1604 1606 16574713 of IN B-PP O
7 1607 1613 16574713 memory NN B-NP D008569
8 1614 1624 16574713 impairment NN I-NP D008569
9 1625 1628 16574713 was VBD B-VP O
10 1629 1637 16574713 observed VBN I-VP O
11 1638 1640 16574713 in IN B-PP O
12 1641 1649 16574713 moderate JJ B-NP O
13 1650 1654 16574713 MDMA NN I-NP D018817
14 1655 1660 16574713 users NNS I-NP O
15 1660 1661 16574713 . . O O

1 1662 1664 16574713 No DT B-NP O
2 1665 1676 16574713 significant JJ I-NP O
3 1677 1683 16574713 effect NN I-NP O
4 1684 1686 16574713 of IN B-PP O
5 1687 1688 16574713 5 CD B-NP O
6 1688 1689 16574713 - HYPH I-NP O
7 1689 1695 16574713 HTTLPR NN I-NP O
8 1696 1698 16574713 or CC I-NP O
9 1699 1705 16574713 gender NN I-NP O
10 1706 1709 16574713 was VBD B-VP O
11 1710 1718 16574713 observed VBN I-VP O
12 1718 1719 16574713 . . O O

1 1720 1725 16574713 While IN B-SBAR O
2 1726 1729 16574713 the DT B-NP O
3 1730 1733 16574713 use NN I-NP O
4 1734 1736 16574713 of IN B-PP O
5 1737 1741 16574713 MDMA NN B-NP D018817
6 1742 1744 16574713 in IN B-PP O
7 1745 1755 16574713 quantities NNS B-NP O
8 1756 1760 16574713 that WDT B-NP O
9 1761 1764 16574713 may MD B-VP O
10 1765 1767 16574713 be VB I-VP O
11 1768 1778 16574713 considered VBN I-VP O
12 1779 1780 16574713 " `` B-ADJP O
13 1780 1788 16574713 moderate JJ I-ADJP O
14 1788 1789 16574713 " '' O O
15 1790 1792 16574713 is VBZ B-VP O
16 1793 1796 16574713 not RB I-VP O
17 1797 1807 16574713 associated VBN I-VP O
18 1808 1812 16574713 with IN B-PP O
19 1813 1821 16574713 impaired JJ B-NP D008569
20 1822 1828 16574713 memory NN I-NP D008569
21 1829 1840 16574713 functioning VBG B-VP D008569
22 1840 1841 16574713 , , O O
23 1842 1847 16574713 heavy JJ B-NP O
24 1848 1851 16574713 use NN I-NP O
25 1852 1854 16574713 of IN B-PP O
26 1855 1859 16574713 MDMA NN B-NP D018817
27 1860 1863 16574713 use NN I-NP O
28 1864 1867 16574713 may MD B-VP O
29 1868 1872 16574713 lead VB I-VP O
30 1873 1875 16574713 to TO B-PP O
31 1876 1880 16574713 long JJ B-NP O
32 1881 1888 16574713 lasting JJ I-NP O
33 1889 1895 16574713 memory NN I-NP D008569
34 1896 1907 16574713 impairments NNS I-NP D008569
35 1907 1908 16574713 . . O O

1 1909 1911 16574713 No DT B-NP O
2 1912 1918 16574713 effect NN I-NP O
3 1919 1921 16574713 of IN B-PP O
4 1922 1923 16574713 5 CD B-NP O
5 1923 1924 16574713 - HYPH I-NP O
6 1924 1930 16574713 HTTLPR NN I-NP O
7 1931 1933 16574713 or CC I-NP O
8 1934 1940 16574713 gender NN I-NP O
9 1941 1943 16574713 on IN B-PP O
10 1944 1950 16574713 memory NN B-NP O
11 1951 1959 16574713 function NN I-NP O
12 1960 1962 16574713 or CC O O
13 1963 1967 16574713 MDMA NN B-NP D018817
14 1968 1971 16574713 use NN I-NP O
15 1972 1975 16574713 was VBD B-VP O
16 1976 1984 16574713 observed VBN I-VP O
17 1984 1985 16574713 . . O O

1 0 0 3952818 -DOCSTART- -X- -X- O

1 0 7 3952818 Cardiac JJ B-NP D066126
2 8 16 3952818 toxicity NN I-NP D066126
3 17 19 3952818 of IN B-PP O
4 20 21 3952818 5 CD B-NP D005472
5 21 22 3952818 - HYPH I-NP D005472
6 22 34 3952818 fluorouracil NN I-NP D005472
7 34 35 3952818 . . O O

1 36 42 3952818 Report NN B-NP O
2 43 45 3952818 of IN B-PP O
3 46 47 3952818 a DT B-NP O
4 48 52 3952818 case NN I-NP O
5 53 55 3952818 of IN B-PP O
6 56 67 3952818 spontaneous JJ B-NP O
7 68 74 3952818 angina NN I-NP D000787
8 74 75 3952818 . . O O
9 76 78 3952818 We PRP B-NP O
10 79 85 3952818 report VBP B-VP O
11 86 87 3952818 a DT B-NP O
12 88 92 3952818 case NN I-NP O
13 93 95 3952818 of IN B-PP O
14 96 97 3952818 a DT B-NP O
15 98 105 3952818 patient NN I-NP O
16 106 110 3952818 with IN B-PP O
17 111 116 3952818 colon NN B-NP D003110
18 117 126 3952818 carcinoma NN I-NP D003110
19 127 130 3952818 and CC O O
20 131 136 3952818 liver NN B-NP O
21 137 147 3952818 metastasis NN I-NP D009362
22 148 151 3952818 who WP B-NP O
23 152 161 3952818 presented VBD B-VP O
24 162 167 3952818 chest NN B-NP D002637
25 168 172 3952818 pain NN I-NP D002637
26 173 178 3952818 after IN B-PP O
27 179 180 3952818 5 CD B-NP D005472
28 180 181 3952818 - HYPH I-NP D005472
29 181 193 3952818 fluorouracil NN I-NP D005472
30 194 195 3952818 ( ( O O
31 195 196 3952818 5 CD B-NP D005472
32 196 197 3952818 - HYPH I-NP D005472
33 197 199 3952818 FU NN I-NP D005472
34 199 200 3952818 ) ) O O
35 201 215 3952818 administration NN B-NP O
36 215 216 3952818 . . O O

1 217 225 3952818 Clinical JJ B-NP O
2 226 246 3952818 electrocardiographic JJ I-NP O
3 247 256 3952818 evolution NN I-NP O
4 257 260 3952818 was VBD B-VP O
5 261 268 3952818 similar JJ B-ADJP O
6 269 271 3952818 to TO B-PP O
7 272 276 3952818 that DT B-NP O
8 277 285 3952818 observed VBN B-VP O
9 286 288 3952818 in IN B-PP O
10 289 301 3952818 Prinzmetal's NNP B-NP D000788
11 302 308 3952818 angina NN I-NP D000788
12 308 309 3952818 , , O O
13 310 313 3952818 and CC O O
14 314 319 3952818 chest JJS B-NP D002637
15 320 324 3952818 pain NN I-NP D002637
16 325 333 3952818 promptly RB B-VP O
17 334 342 3952818 resolved VBN I-VP O
18 343 347 3952818 with IN B-PP O
19 348 358 3952818 nifedipine NN B-NP D009543
20 358 359 3952818 . . O O

1 360 365 3952818 These DT B-NP O
2 366 370 3952818 data NNS I-NP O
3 371 378 3952818 suggest VBP B-VP O
4 379 383 3952818 that IN B-SBAR O
5 384 392 3952818 coronary JJ B-NP D003329
6 393 398 3952818 spasm NN I-NP D003329
7 399 402 3952818 may MD B-VP O
8 403 405 3952818 be VB I-VP O
9 406 409 3952818 the DT B-NP O
10 410 415 3952818 cause NN I-NP O
11 416 418 3952818 of IN B-PP O
12 419 433 3952818 cardiotoxicity NN B-NP D066126
13 434 437 3952818 due JJ B-ADJP O
14 438 440 3952818 to TO B-PP O
15 441 442 3952818 5 CD B-NP D005472
16 442 443 3952818 - HYPH I-NP D005472
17 443 445 3952818 FU NN I-NP D005472
18 445 446 3952818 , , O O
19 447 450 3952818 and CC O O
20 451 455 3952818 that IN B-SBAR O
21 456 463 3952818 calcium NN B-NP D002118
22 464 475 3952818 antagonists NNS I-NP O
23 476 479 3952818 may MD B-VP O
24 480 488 3952818 probably RB I-VP O
25 489 491 3952818 be VB I-VP O
26 492 496 3952818 used VBN I-VP O
27 497 499 3952818 in IN B-PP O
28 500 503 3952818 the DT B-NP O
29 504 514 3952818 prevention NN I-NP O
30 515 517 3952818 or CC I-NP O
31 518 527 3952818 treatment NN I-NP O
32 528 530 3952818 of IN B-PP O
33 531 532 3952818 5 CD B-NP D005472
34 532 533 3952818 - HYPH I-NP D005472
35 533 535 3952818 FU NN I-NP D005472
36 536 550 3952818 cardiotoxicity NN I-NP D066126
37 550 551 3952818 . . O O

1 0 0 7189975 -DOCSTART- -X- -X- O

1 0 6 7189975 Deaths NNS B-NP O
2 7 11 7189975 from IN B-PP O
3 12 17 7189975 local JJ B-NP O
4 18 28 7189975 anesthetic NN I-NP O
5 28 29 7189975 - HYPH B-NP O
6 29 36 7189975 induced VBN I-NP O
7 37 48 7189975 convulsions NNS I-NP D012640
8 49 51 7189975 in IN B-PP O
9 52 56 7189975 mice NNS B-NP O
10 56 57 7189975 . . O O
11 58 64 7189975 Median JJ B-NP O
12 65 75 7189975 convulsant NN I-NP O
13 76 77 7189975 ( ( O O
14 77 81 7189975 CD50 NN B-NP O
15 81 82 7189975 ) ) O O
16 83 86 7189975 and CC O O
17 87 93 7189975 median JJ B-NP O
18 94 100 7189975 lethal JJ I-NP O
19 101 102 7189975 ( ( O O
20 102 106 7189975 LD50 NN B-NP O
21 106 107 7189975 ) ) O O
22 108 113 7189975 doses NNS B-NP O
23 114 116 7189975 of IN B-PP O
24 117 122 7189975 three CD B-NP O
25 123 137 7189975 representative JJ I-NP O
26 138 143 7189975 local JJ I-NP O
27 144 155 7189975 anesthetics NNS I-NP O
28 156 160 7189975 were VBD B-VP O
29 161 171 7189975 determined VBN I-VP O
30 172 174 7189975 in IN B-PP O
31 175 180 7189975 adult JJ B-NP O
32 181 185 7189975 mice NNS I-NP O
33 186 188 7189975 to TO B-VP O
34 189 197 7189975 evaluate VB I-VP O
35 198 201 7189975 the DT B-NP O
36 202 208 7189975 threat NN I-NP O
37 209 211 7189975 to TO B-PP O
38 212 216 7189975 life NN B-NP O
39 217 219 7189975 of IN B-PP O
40 220 225 7189975 local JJ B-NP O
41 226 236 7189975 anesthetic NN I-NP O
42 236 237 7189975 - HYPH B-NP O
43 237 244 7189975 induced VBN I-NP O
44 245 256 7189975 convulsions NNS I-NP D012640
45 256 257 7189975 . . O O

1 258 261 7189975 The DT B-NP O
2 262 266 7189975 CD50 NN I-NP O
3 267 270 7189975 and CC I-NP O
4 271 275 7189975 LD50 NN I-NP O
5 275 276 7189975 , , O O
6 277 289 7189975 respectively RB B-ADVP O
7 289 290 7189975 , , O O
8 291 295 7189975 were VBD B-VP O
9 296 300 7189975 57.7 CD B-NP O
10 301 304 7189975 and CC I-NP O
11 305 309 7189975 58.7 CD I-NP O
12 310 312 7189975 mg NN I-NP O
13 312 313 7189975 / SYM B-NP O
14 313 315 7189975 kg NN I-NP O
15 316 319 7189975 for IN B-PP O
16 320 331 7189975 bupivacaine NN B-NP D002045
17 331 332 7189975 , , O O
18 333 338 7189975 111.0 CD B-NP O
19 339 342 7189975 and CC I-NP O
20 343 348 7189975 133.1 CD I-NP O
21 349 351 7189975 mg NN I-NP O
22 351 352 7189975 / SYM B-NP O
23 352 354 7189975 kg NN I-NP O
24 355 358 7189975 for IN B-PP O
25 359 368 7189975 lidocaine NN B-NP D008012
26 368 369 7189975 , , O O
27 370 373 7189975 and CC O O
28 374 379 7189975 243.4 CD B-NP O
29 380 383 7189975 and CC I-NP O
30 384 389 7189975 266.5 CD I-NP O
31 390 392 7189975 mg NN I-NP O
32 392 393 7189975 / SYM B-NP O
33 393 395 7189975 kg NN I-NP O
34 396 399 7189975 for IN B-PP O
35 400 414 7189975 chloroprocaine NN B-NP C004616
36 414 415 7189975 . . O O

1 416 420 7189975 When WRB B-ADVP O
2 421 426 7189975 given VBN B-PP O
3 427 444 7189975 intraperitoneally RB B-ADVP O
4 444 445 7189975 , , O O
5 446 457 7189975 bupivacaine NN B-NP D002045
6 458 462 7189975 thus RB B-ADVP O
7 463 466 7189975 was VBD B-VP O
8 467 471 7189975 only RB B-NP O
9 472 477 7189975 about RB I-NP O
10 478 483 7189975 twice RB I-NP O
11 484 486 7189975 as RB I-NP O
12 487 492 7189975 toxic JJ I-NP O
13 493 495 7189975 as IN B-PP O
14 496 505 7189975 lidocaine NN B-NP D008012
15 506 509 7189975 and CC O O
16 510 514 7189975 four CD B-NP O
17 515 520 7189975 times NNS I-NP O
18 521 523 7189975 as RB I-NP O
19 524 529 7189975 toxic JJ I-NP O
20 530 532 7189975 as IN B-PP O
21 533 547 7189975 chloroprocaine NN B-NP C004616
22 547 548 7189975 . . O O

1 549 560 7189975 Convulsions NNS B-NP D012640
2 561 567 7189975 always RB B-ADVP O
3 568 576 7189975 preceded VBD B-VP O
4 577 582 7189975 death NN B-NP O
5 582 583 7189975 , , O O
6 584 590 7189975 except IN B-PP O
7 591 596 7189975 after IN B-PP O
8 597 608 7189975 precipitous JJ B-NP O
9 609 624 7189975 cardiopulmonary JJ I-NP D006323
10 625 631 7189975 arrest NN I-NP D006323
11 632 636 7189975 from IN B-PP O
12 637 644 7189975 extreme JJ B-NP O
13 645 650 7189975 doses NNS I-NP O
14 650 651 7189975 . . O O

1 652 653 7189975 A DT B-NP O
2 654 658 7189975 CD50 NN I-NP O
3 659 663 7189975 dose NN I-NP O
4 664 666 7189975 of IN B-PP O
5 667 672 7189975 local JJ B-NP O
6 673 683 7189975 anesthetic JJ I-NP O
7 684 685 7189975 ( ( O O
8 685 692 7189975 causing VBG B-VP O
9 693 704 7189975 convulsions NNS B-NP D012640
10 705 707 7189975 in IN B-PP O
11 708 711 7189975 50% CD B-NP O
12 712 714 7189975 of IN B-PP O
13 715 719 7189975 mice NNS B-NP O
14 719 720 7189975 ) ) O O
15 721 724 7189975 was VBD B-VP O
16 725 730 7189975 fatal JJ B-ADJP O
17 731 733 7189975 in IN B-PP O
18 734 737 7189975 90% NN B-NP O
19 738 740 7189975 of IN B-PP O
20 741 752 7189975 bupivacaine NN B-NP D002045
21 752 753 7189975 - HYPH B-NP O
22 753 760 7189975 induced VBN I-NP O
23 761 769 7189975 seizures NNS I-NP D012640
24 769 770 7189975 , , O O
25 771 773 7189975 in IN B-PP O
26 774 777 7189975 57% CD B-NP O
27 778 780 7189975 of IN B-PP O
28 781 784 7189975 the DT B-NP O
29 785 799 7189975 chloroprocaine NN I-NP C004616
30 800 805 7189975 group NN I-NP O
31 805 806 7189975 , , O O
32 807 810 7189975 and CC O O
33 811 813 7189975 in IN B-PP O
34 814 816 7189975 6% CD B-NP O
35 817 819 7189975 of IN B-PP O
36 820 823 7189975 the DT B-NP O
37 824 833 7189975 lidocaine NN I-NP D008012
38 834 839 7189975 group NN I-NP O
39 839 840 7189975 . . O O

1 841 844 7189975 The DT B-NP O
2 845 851 7189975 narrow JJ I-NP O
3 852 855 7189975 gap NN I-NP O
4 856 863 7189975 between IN B-PP O
5 864 874 7189975 convulsant JJ B-NP O
6 875 878 7189975 and CC I-NP O
7 879 885 7189975 lethal JJ I-NP O
8 886 891 7189975 doses NNS I-NP O
9 892 894 7189975 of IN B-PP O
10 895 900 7189975 local JJ B-NP O
11 901 912 7189975 anesthetics NNS I-NP O
12 913 922 7189975 indicates VBZ B-VP O
13 923 927 7189975 that IN B-SBAR O
14 928 937 7189975 untreated JJ B-NP O
15 938 949 7189975 convulsions NNS I-NP D012640
16 950 957 7189975 present VBP B-VP O
17 958 962 7189975 much RB B-NP O
18 963 967 7189975 more JJR I-NP O
19 968 970 7189975 of IN B-PP O
20 971 972 7189975 a DT B-NP O
21 973 979 7189975 threat NN I-NP O
22 980 982 7189975 to TO B-PP O
23 983 987 7189975 life NN B-NP O
24 988 992 7189975 than IN B-PP O
25 993 1003 7189975 heretofore RB B-NP O
26 1004 1015 7189975 appreciated VBN I-NP O
27 1015 1016 7189975 . . O O

1 0 0 3969369 -DOCSTART- -X- -X- O

1 0 11 3969369 Promotional JJ B-NP O
2 12 19 3969369 effects NNS I-NP O
3 20 22 3969369 of IN B-PP O
4 23 35 3969369 testosterone NN B-NP D013739
5 36 39 3969369 and CC O O
6 40 47 3969369 dietary JJ B-NP O
7 48 51 3969369 fat NN I-NP O
8 52 54 3969369 on IN B-PP O
9 55 63 3969369 prostate NN B-NP O
10 64 78 3969369 carcinogenesis NN I-NP D063646
11 79 81 3969369 in IN B-PP O
12 82 93 3969369 genetically RB B-NP O
13 94 105 3969369 susceptible JJ I-NP O
14 106 110 3969369 rats NNS I-NP O
15 110 111 3969369 . . O O
16 112 120 3969369 Germfree JJ O O
17 121 122 3969369 ( ( O O
18 122 124 3969369 GF NN B-NP O
19 124 125 3969369 ) ) O O
20 126 132 3969369 Lobund NN B-NP O
21 133 139 3969369 strain NN I-NP O
22 140 146 3969369 Wistar NNP I-NP O
23 147 148 3969369 ( ( O O
24 148 150 3969369 LW NNP B-NP O
25 150 151 3969369 ) ) O O
26 152 156 3969369 rats NNS B-NP O
27 156 157 3969369 , , O O
28 158 161 3969369 fed VBN B-VP O
29 162 171 3969369 vegetable JJ B-NP O
30 172 176 3969369 diet NN I-NP O
31 177 178 3969369 L NN I-NP O
32 178 179 3969369 - HYPH O O
33 179 182 3969369 485 CD B-NP O
34 182 183 3969369 , , O O
35 184 188 3969369 have VBP B-VP O
36 189 198 3969369 developed VBN I-VP O
37 199 207 3969369 prostate NN B-NP D011471
38 208 223 3969369 adenocarcinomas NNS I-NP D011471
39 224 237 3969369 spontaneously RB B-ADVP O
40 238 239 3969369 ( ( O O
41 239 242 3969369 10% CD B-NP O
42 243 252 3969369 incidence NN I-NP O
43 252 253 3969369 ) ) O O
44 254 256 3969369 at IN B-PP O
45 257 264 3969369 average JJ B-NP O
46 265 268 3969369 age NN I-NP O
47 269 271 3969369 34 CD B-NP O
48 272 278 3969369 months NNS I-NP O
49 278 279 3969369 . . O O

1 280 292 3969369 Conventional JJ B-NP O
2 293 295 3969369 LW NN I-NP O
3 296 300 3969369 rats NNS I-NP O
4 300 301 3969369 , , O O
5 302 311 3969369 implanted VBN B-VP O
6 312 316 3969369 with IN B-PP O
7 317 329 3969369 testosterone NN B-NP D013739
8 330 332 3969369 at IN B-PP O
9 333 336 3969369 age NN B-NP O
10 337 338 3969369 4 CD I-NP O
11 339 345 3969369 months NNS I-NP O
12 345 346 3969369 , , O O
13 347 356 3969369 developed VBD B-VP O
14 357 358 3969369 a DT B-NP O
15 359 365 3969369 higher JJR I-NP O
16 366 375 3969369 incidence NN I-NP O
17 376 378 3969369 of IN B-PP O
18 379 387 3969369 prostate NN B-NP D011471
19 388 394 3969369 cancer NN I-NP D011471
20 395 400 3969369 after IN B-PP O
21 401 403 3969369 an DT B-NP O
22 404 411 3969369 average JJ I-NP O
23 412 420 3969369 interval NN I-NP O
24 421 423 3969369 of IN B-PP O
25 424 426 3969369 14 CD B-NP O
26 427 433 3969369 months NNS I-NP O
27 433 434 3969369 : : O O
28 435 438 3969369 24% CD B-NP O
29 439 442 3969369 had VBD B-VP O
30 443 452 3969369 developed VBN I-VP O
31 453 458 3969369 gross JJ B-NP O
32 459 465 3969369 tumors NNS I-NP D009369
33 465 466 3969369 , , O O
34 467 470 3969369 and CC O O
35 471 474 3969369 40% LS B-LST O
36 475 479 3969369 when WRB B-ADVP O
37 480 482 3969369 it PRP B-NP O
38 483 491 3969369 included VBD B-VP O
39 492 503 3969369 microscopic JJ B-NP O
40 504 510 3969369 tumors NNS I-NP D009369
41 510 511 3969369 . . O O

1 512 523 3969369 Preliminary JJ B-NP O
2 524 531 3969369 results NNS I-NP O
3 532 540 3969369 indicate VBP B-VP O
4 541 545 3969369 that IN B-SBAR O
5 546 558 3969369 testosterone NN B-NP D013739
6 558 559 3969369 - HYPH B-VP O
7 559 566 3969369 treated VBN B-NP O
8 567 569 3969369 LW NN I-NP O
9 570 574 3969369 rats NNS I-NP O
10 575 579 3969369 that WDT B-NP O
11 580 584 3969369 were VBD B-VP O
12 585 588 3969369 fed VBN I-VP O
13 589 592 3969369 the DT B-NP O
14 593 597 3969369 same JJ I-NP O
15 598 602 3969369 diet NN I-NP O
16 602 603 3969369 , , O O
17 604 609 3969369 which WDT B-NP O
18 610 613 3969369 was VBD B-VP O
19 614 626 3969369 supplemented VBN I-VP O
20 627 631 3969369 with IN B-PP O
21 632 636 3969369 corn NN B-NP O
22 637 640 3969369 oil NN I-NP O
23 641 643 3969369 up IN B-NP O
24 644 646 3969369 to TO I-NP O
25 647 650 3969369 20% CD I-NP O
26 651 654 3969369 fat NN I-NP O
27 654 655 3969369 , , O O
28 656 665 3969369 developed VBD B-VP O
29 666 674 3969369 prostate NN B-NP D011471
30 675 681 3969369 cancer NN I-NP D011471
31 682 687 3969369 after IN B-PP O
32 688 697 3969369 intervals NNS B-NP O
33 698 700 3969369 of IN B-PP O
34 701 702 3969369 6 CD B-NP O
35 702 703 3969369 - HYPH I-NP O
36 703 705 3969369 12 CD I-NP O
37 706 712 3969369 months NNS I-NP O
38 712 713 3969369 . . O O

1 714 718 3969369 Aged NNP B-NP O
2 719 721 3969369 GF NNP I-NP O
3 722 729 3969369 Sprague NNP I-NP O
4 729 730 3969369 - HYPH I-NP O
5 730 736 3969369 Dawley NNP I-NP O
6 737 738 3969369 ( ( O O
7 738 740 3969369 SD NNP B-NP O
8 740 741 3969369 ) ) O O
9 742 746 3969369 rats NNS B-NP O
10 747 751 3969369 have VBP B-VP O
11 752 755 3969369 not RB I-VP O
12 756 765 3969369 developed VBN I-VP O
13 766 774 3969369 prostate NN B-NP D011471
14 775 781 3969369 cancer NN I-NP D011471
15 782 795 3969369 spontaneously RB B-ADVP O
16 795 796 3969369 . . O O

1 797 809 3969369 Conventional JJ B-NP O
2 810 812 3969369 SD NN I-NP O
3 813 817 3969369 rats NNS I-NP O
4 818 821 3969369 fed VBN B-VP O
5 822 826 3969369 diet NN B-NP O
6 827 828 3969369 L NN I-NP O
7 828 829 3969369 - HYPH O O
8 829 832 3969369 485 CD B-NP O
9 833 836 3969369 and CC O O
10 837 844 3969369 treated VBN B-VP O
11 845 849 3969369 with IN B-PP O
12 850 862 3969369 testosterone NN B-NP D013739
13 863 872 3969369 developed VBD B-VP O
14 873 877 3969369 only RB B-NP O
15 878 889 3969369 prostatitis NN I-NP D011472
16 889 890 3969369 . . O O

1 891 903 3969369 Experimental JJ B-NP O
2 904 911 3969369 designs NNS I-NP O
3 912 918 3969369 should MD B-VP O
4 919 927 3969369 consider VB I-VP O
5 928 935 3969369 genetic JJ B-NP O
6 936 950 3969369 susceptibility NN I-NP O
7 951 953 3969369 as IN B-PP O
8 954 955 3969369 a DT B-NP O
9 956 961 3969369 basic JJ I-NP O
10 962 974 3969369 prerequisite NN I-NP O
11 975 978 3969369 for IN B-PP O
12 979 986 3969369 studies NNS B-NP O
13 987 989 3969369 on IN B-PP O
14 990 1002 3969369 experimental JJ B-NP O
15 1003 1011 3969369 prostate NN I-NP D011471
16 1012 1018 3969369 cancer NN I-NP D011471
17 1018 1019 3969369 . . O O

1 0 0 16720068 -DOCSTART- -X- -X- O

1 0 8 16720068 Possible JJ B-NP O
2 9 20 16720068 neuroleptic JJ I-NP D009459
3 21 30 16720068 malignant JJ I-NP D009459
4 31 39 16720068 syndrome NN I-NP D009459
5 40 47 16720068 related VBN B-VP O
6 48 50 16720068 to TO B-PP O
7 51 62 16720068 concomitant JJ B-NP O
8 63 72 16720068 treatment NN I-NP O
9 73 77 16720068 with IN B-PP O
10 78 88 16720068 paroxetine NN B-NP D017374
11 89 92 16720068 and CC I-NP O
12 93 103 16720068 alprazolam NN I-NP D000525
13 103 104 16720068 . . O O
14 105 106 16720068 A DT B-NP O
15 107 109 16720068 74 CD I-NP O
16 109 110 16720068 - HYPH I-NP O
17 110 114 16720068 year NN I-NP O
18 114 115 16720068 - HYPH O O
19 115 118 16720068 old JJ B-NP O
20 119 122 16720068 man NN I-NP O
21 123 127 16720068 with IN B-PP O
22 128 138 16720068 depressive JJ B-NP D003866
23 139 147 16720068 symptoms NNS I-NP D003866
24 148 151 16720068 was VBD B-VP O
25 152 160 16720068 admitted VBN I-VP O
26 161 163 16720068 to TO B-PP O
27 164 165 16720068 a DT B-NP O
28 166 177 16720068 psychiatric JJ I-NP D001523
29 178 186 16720068 hospital NN I-NP O
30 187 190 16720068 due JJ B-ADJP O
31 191 193 16720068 to TO B-PP O
32 194 202 16720068 insomnia NN B-NP D007319
33 202 203 16720068 , , O O
34 204 208 16720068 loss NN B-NP D001068
35 209 211 16720068 of IN B-PP D001068
36 212 220 16720068 appetite NN B-NP D001068
37 220 221 16720068 , , O O
38 222 232 16720068 exhaustion NN B-NP O
39 232 233 16720068 , , O O
40 234 237 16720068 and CC O O
41 238 247 16720068 agitation NN B-NP D011595
42 247 248 16720068 . . O O

1 249 256 16720068 Medical JJ B-NP O
2 257 266 16720068 treatment NN I-NP O
3 267 270 16720068 was VBD B-VP O
4 271 280 16720068 initiated VBN I-VP O
5 281 283 16720068 at IN B-PP O
6 284 285 16720068 a DT B-NP O
7 286 291 16720068 daily JJ I-NP O
8 292 296 16720068 dose NN I-NP O
9 297 299 16720068 of IN B-PP O
10 300 302 16720068 20 CD B-NP O
11 303 305 16720068 mg NN I-NP O
12 306 316 16720068 paroxetine NN I-NP D017374
13 317 320 16720068 and CC O O
14 321 324 16720068 1.2 CD B-NP O
15 325 327 16720068 mg NN I-NP O
16 328 338 16720068 alprazolam NN I-NP D000525
17 338 339 16720068 . . O O

1 340 342 16720068 On IN B-PP O
2 343 346 16720068 the DT B-NP O
3 347 351 16720068 10th JJ I-NP O
4 352 355 16720068 day NN I-NP O
5 356 358 16720068 of IN B-PP O
6 359 369 16720068 paroxetine NN B-NP D017374
7 370 373 16720068 and CC I-NP O
8 374 384 16720068 alprazolam NN I-NP D000525
9 385 394 16720068 treatment NN I-NP O
10 394 395 16720068 , , O O
11 396 399 16720068 the DT B-NP O
12 400 407 16720068 patient NN I-NP O
13 408 417 16720068 exhibited VBD B-VP O
14 418 424 16720068 marked JJ B-NP O
15 425 436 16720068 psychomotor NN I-NP D011596
16 437 448 16720068 retardation NN I-NP D011596
17 448 449 16720068 , , O O
18 450 464 16720068 disorientation NN B-NP O
19 464 465 16720068 , , O O
20 466 469 16720068 and CC O O
21 470 476 16720068 severe JJ B-NP O
22 477 483 16720068 muscle NN I-NP D009127
23 484 492 16720068 rigidity NN I-NP D009127
24 493 497 16720068 with IN B-PP O
25 498 505 16720068 tremors NNS B-NP D014202
26 505 506 16720068 . . O O

1 507 510 16720068 The DT B-NP O
2 511 518 16720068 patient NN I-NP O
3 519 522 16720068 had VBD B-VP O
4 523 524 16720068 a DT B-NP O
5 525 530 16720068 fever NN I-NP D005334
6 531 532 16720068 ( ( O O
7 532 536 16720068 38.2 CD B-NP O
8 537 544 16720068 degrees NNS I-NP O
9 545 546 16720068 C NN I-NP O
10 546 547 16720068 ) ) O O
11 547 548 16720068 , , O O
12 549 560 16720068 fluctuating VBG B-VP O
13 561 566 16720068 blood NN B-NP O
14 567 575 16720068 pressure NN I-NP O
15 576 577 16720068 ( ( O O
16 577 584 16720068 between IN B-PP O
17 585 588 16720068 165 CD B-NP O
18 588 589 16720068 / SYM I-NP O
19 589 591 16720068 90 CD I-NP O
20 592 595 16720068 and CC I-NP O
21 596 599 16720068 130 CD I-NP O
22 599 600 16720068 / SYM I-NP O
23 600 602 16720068 70 CD I-NP O
24 603 605 16720068 mg NN I-NP O
25 606 608 16720068 mm NN I-NP O
26 609 611 16720068 Hg NN I-NP O
27 611 612 16720068 ) ) O O
28 612 613 16720068 , , O O
29 614 617 16720068 and CC O O
30 618 624 16720068 severe JJ B-NP O
31 625 639 16720068 extrapyramidal JJ I-NP D001480
32 640 648 16720068 symptoms NNS I-NP D001480
33 648 649 16720068 . . O O

1 650 660 16720068 Laboratory NN B-NP O
2 661 666 16720068 tests NNS I-NP O
3 667 673 16720068 showed VBD B-VP O
4 674 676 16720068 an DT B-NP O
5 677 686 16720068 elevation NN I-NP O
6 687 689 16720068 of IN B-PP O
7 690 698 16720068 creatine NN B-NP D003401
8 699 712 16720068 phosphokinase NN I-NP O
9 713 714 16720068 ( ( O O
10 714 718 16720068 2218 CD B-NP O
11 719 721 16720068 IU NN I-NP O
12 721 722 16720068 / SYM B-NP O
13 722 723 16720068 L NN I-NP O
14 723 724 16720068 ) ) O O
15 724 725 16720068 , , O O
16 726 735 16720068 aspartate NN B-NP D001224
17 736 752 16720068 aminotransferase NN I-NP O
18 753 754 16720068 ( ( O O
19 754 757 16720068 134 CD B-NP O
20 758 760 16720068 IU NN I-NP O
21 760 761 16720068 / SYM B-NP O
22 761 762 16720068 L NN I-NP O
23 762 763 16720068 ) ) O O
24 763 764 16720068 , , O O
25 765 772 16720068 alanine NN B-NP D000409
26 773 789 16720068 aminotransferase NN I-NP O
27 790 791 16720068 ( ( O O
28 791 793 16720068 78 CD B-NP O
29 794 796 16720068 IU NN I-NP O
30 796 797 16720068 / SYM B-NP O
31 797 798 16720068 L NN I-NP O
32 798 799 16720068 ) ) O O
33 799 800 16720068 , , O O
34 801 804 16720068 and CC O O
35 805 808 16720068 BUN NN B-NP O
36 809 810 16720068 ( ( O O
37 810 814 16720068 27.9 CD B-NP O
38 815 817 16720068 mg NN I-NP O
39 817 818 16720068 / SYM B-NP O
40 818 820 16720068 ml NN I-NP O
41 820 821 16720068 ) ) O O
42 822 828 16720068 levels NNS B-NP O
43 828 829 16720068 . . O O

1 830 833 16720068 The DT B-NP O
2 834 841 16720068 patient NN I-NP O
3 842 850 16720068 received VBD B-VP O
4 851 864 16720068 bromocriptine NN B-NP D001971
5 865 868 16720068 and CC I-NP O
6 869 877 16720068 diazepam NN I-NP D003975
7 878 880 16720068 to TO B-VP O
8 881 886 16720068 treat VB I-VP O
9 887 890 16720068 his PRP$ B-NP O
10 891 899 16720068 symptoms NNS I-NP O
11 899 900 16720068 . . O O

1 901 902 16720068 7 CD B-NP O
2 903 907 16720068 days NNS I-NP O
3 908 913 16720068 later RB B-ADVP O
4 913 914 16720068 , , O O
5 915 918 16720068 the DT B-NP O
6 919 924 16720068 fever NN I-NP D005334
7 925 936 16720068 disappeared VBD B-VP O
8 937 940 16720068 and CC O O
9 941 944 16720068 the DT B-NP O
10 945 954 16720068 patient's NNS I-NP O
11 955 960 16720068 serum NN I-NP O
12 961 964 16720068 CPK NN I-NP O
13 965 971 16720068 levels NNS I-NP O
14 972 976 16720068 were VBD B-VP O
15 977 987 16720068 normalized VBN I-VP O
16 988 989 16720068 ( ( O O
17 989 992 16720068 175 CD B-NP O
18 993 995 16720068 IU NN I-NP O
19 995 996 16720068 / SYM B-NP O
20 996 997 16720068 L NN I-NP O
21 997 998 16720068 ) ) O O
22 998 999 16720068 . . O O

1 1000 1004 16720068 This DT B-NP O
2 1005 1012 16720068 patient NN I-NP O
3 1013 1022 16720068 presented VBD B-VP O
4 1023 1027 16720068 with IN B-PP O
5 1028 1036 16720068 symptoms NNS B-NP O
6 1037 1039 16720068 of IN B-PP O
7 1040 1051 16720068 neuroleptic JJ B-NP D009459
8 1052 1061 16720068 malignant JJ I-NP D009459
9 1062 1070 16720068 syndrome NN I-NP D009459
10 1071 1072 16720068 ( ( O O
11 1072 1075 16720068 NMS NN B-NP D009459
12 1075 1076 16720068 ) ) O O
13 1076 1077 16720068 , , O O
14 1078 1082 16720068 thus RB B-ADVP O
15 1083 1096 16720068 demonstrating VBG B-VP O
16 1097 1101 16720068 that IN B-SBAR O
17 1102 1105 16720068 NMS NN B-NP D009459
18 1105 1106 16720068 - HYPH B-VP O
19 1106 1110 16720068 like JJ B-NP O
20 1111 1119 16720068 symptoms NNS I-NP O
21 1120 1123 16720068 can MD B-VP O
22 1124 1129 16720068 occur VB I-VP O
23 1130 1135 16720068 after IN B-PP O
24 1136 1144 16720068 combined VBN B-NP O
25 1145 1155 16720068 paroxetine NN I-NP D017374
26 1156 1159 16720068 and CC I-NP O
27 1160 1170 16720068 alprazolam NN I-NP D000525
28 1171 1180 16720068 treatment NN I-NP O
29 1180 1181 16720068 . . O O

1 1182 1185 16720068 The DT B-NP O
2 1186 1193 16720068 adverse JJ I-NP O
3 1194 1198 16720068 drug NN I-NP O
4 1199 1207 16720068 reaction NN I-NP O
5 1208 1213 16720068 score NN I-NP O
6 1214 1222 16720068 obtained VBN B-VP O
7 1223 1225 16720068 by IN B-PP O
8 1226 1229 16720068 the DT B-NP O
9 1230 1237 16720068 Naranjo NNP I-NP O
10 1238 1247 16720068 algorithm NN I-NP O
11 1248 1251 16720068 was VBD B-VP O
12 1252 1253 16720068 6 CD B-NP O
13 1254 1256 16720068 in IN B-PP O
14 1257 1260 16720068 our PRP$ B-NP O
15 1261 1265 16720068 case NN I-NP O
16 1265 1266 16720068 , , O O
17 1267 1277 16720068 indicating VBG B-VP O
18 1278 1279 16720068 a DT B-NP O
19 1280 1288 16720068 probable JJ I-NP O
20 1289 1301 16720068 relationship NN I-NP O
21 1302 1309 16720068 between IN B-PP O
22 1310 1313 16720068 the DT B-NP O
23 1314 1323 16720068 patient's NNS I-NP O
24 1324 1327 16720068 NMS NN I-NP D009459
25 1327 1328 16720068 - HYPH B-NP O
26 1328 1332 16720068 like JJ I-NP O
27 1333 1340 16720068 adverse JJ I-NP O
28 1341 1349 16720068 symptoms NNS I-NP O
29 1350 1353 16720068 and CC O O
30 1354 1357 16720068 the DT B-NP O
31 1358 1366 16720068 combined JJ I-NP O
32 1367 1376 16720068 treatment NN I-NP O
33 1377 1381 16720068 used VBN B-VP O
34 1382 1384 16720068 in IN B-PP O
35 1385 1389 16720068 this DT B-NP O
36 1390 1394 16720068 case NN I-NP O
37 1394 1395 16720068 . . O O

1 1396 1399 16720068 The DT B-NP O
2 1400 1411 16720068 involvement NN I-NP O
3 1412 1414 16720068 of IN B-PP O
4 1415 1426 16720068 physiologic JJ B-NP O
5 1427 1430 16720068 and CC I-NP O
6 1431 1444 16720068 environmental JJ I-NP O
7 1445 1452 16720068 aspects NNS I-NP O
8 1453 1461 16720068 specific JJ B-ADJP O
9 1462 1464 16720068 to TO B-PP O
10 1465 1469 16720068 this DT B-NP O
11 1470 1477 16720068 patient NN I-NP O
12 1478 1481 16720068 was VBD B-VP O
13 1482 1491 16720068 suspected VBN I-VP O
14 1491 1492 16720068 . . O O

1 1493 1500 16720068 Several JJ B-NP O
2 1501 1505 16720068 risk NN I-NP O
3 1506 1513 16720068 factors NNS I-NP O
4 1514 1517 16720068 for IN B-PP O
5 1518 1521 16720068 NMS NN B-NP D009459
6 1522 1528 16720068 should MD B-VP O
7 1529 1531 16720068 be VB I-VP O
8 1532 1537 16720068 noted VBN I-VP O
9 1538 1540 16720068 in IN B-PP O
10 1541 1548 16720068 elderly JJ B-NP O
11 1549 1559 16720068 depressive JJ I-NP D003866
12 1560 1568 16720068 patients NNS I-NP O
13 1569 1574 16720068 whose WP$ B-NP O
14 1575 1583 16720068 symptoms NNS I-NP O
15 1584 1589 16720068 often RB B-ADVP O
16 1590 1597 16720068 include VBP B-VP O
17 1598 1609 16720068 dehydration NN B-NP D003681
18 1609 1610 16720068 , , O O
19 1611 1620 16720068 agitation NN B-NP D011595
20 1620 1621 16720068 , , O O
21 1622 1634 16720068 malnutrition NN B-NP D044342
22 1634 1635 16720068 , , O O
23 1636 1639 16720068 and CC O O
24 1640 1650 16720068 exhaustion NN B-NP O
25 1650 1651 16720068 . . O O

1 1652 1659 16720068 Careful JJ B-NP O
2 1660 1671 16720068 therapeutic JJ I-NP O
3 1672 1684 16720068 intervention NN I-NP O
4 1685 1687 16720068 is VBZ B-VP O
5 1688 1697 16720068 necessary JJ B-ADJP O
6 1698 1700 16720068 in IN B-PP O
7 1701 1706 16720068 cases NNS B-NP O
8 1707 1716 16720068 involving VBG B-VP O
9 1717 1724 16720068 elderly JJ B-NP O
10 1725 1733 16720068 patients NNS I-NP O
11 1734 1737 16720068 who WP B-NP O
12 1738 1744 16720068 suffer VBP B-VP O
13 1745 1749 16720068 from IN B-PP O
14 1750 1760 16720068 depression NN B-NP D003866
15 1760 1761 16720068 . . O O

1 0 0 48362 -DOCSTART- -X- -X- O

1 0 9 48362 Quinidine NN B-NP D011802
2 10 19 48362 hepatitis NN I-NP D056486
3 19 20 48362 . . O O
4 21 25 48362 Long JJ B-NP O
5 25 26 48362 - HYPH I-NP O
6 26 30 48362 term NN I-NP O
7 31 45 48362 administration NN I-NP O
8 46 48 48362 of IN B-PP O
9 49 58 48362 quinidine NN B-NP D011802
10 59 62 48362 was VBD B-VP O
11 63 73 48362 associated VBN I-VP O
12 74 78 48362 with IN B-PP O
13 79 89 48362 persistent JJ B-NP O
14 90 99 48362 elevation NN I-NP O
15 100 102 48362 of IN B-PP O
16 103 108 48362 serum NN B-NP O
17 109 123 48362 concentrations NNS I-NP O
18 124 126 48362 of IN B-PP O
19 127 131 48362 SGOT NN B-NP O
20 131 132 48362 , , O O
21 133 139 48362 lactic JJ B-NP D019344
22 140 144 48362 acid NN I-NP D019344
23 145 158 48362 dehydrogenase NN I-NP O
24 158 159 48362 , , O O
25 160 163 48362 and CC O O
26 164 172 48362 alkaline NN B-NP O
27 173 184 48362 phosphatase NN I-NP O
28 184 185 48362 . . O O

1 186 191 48362 Liver NN B-NP O
2 192 198 48362 biopsy NN I-NP O
3 199 205 48362 showed VBD B-VP O
4 206 212 48362 active JJ B-NP O
5 213 222 48362 hepatitis NN I-NP D056486
6 222 223 48362 . . O O

1 224 238 48362 Discontinuance NN B-NP O
2 239 241 48362 of IN B-PP O
3 242 251 48362 quinidine NN B-NP D011802
4 252 259 48362 therapy NN I-NP O
5 260 263 48362 led VBD B-VP O
6 264 266 48362 to TO B-PP O
7 267 280 48362 normalization NN B-NP O
8 281 283 48362 of IN B-PP O
9 284 289 48362 liver NN B-NP O
10 290 298 48362 function NN I-NP O
11 299 304 48362 tests NNS I-NP O
12 304 305 48362 . . O O

1 306 307 48362 A DT B-NP O
2 308 317 48362 challenge NN I-NP O
3 318 322 48362 dose NN I-NP O
4 323 325 48362 of IN B-PP O
5 326 335 48362 quinidine NN B-NP D011802
6 336 342 48362 caused VBD B-VP O
7 343 351 48362 clinical JJ B-NP O
8 352 360 48362 symptoms NNS I-NP O
9 361 364 48362 and CC O O
10 365 371 48362 abrupt JJ B-NP O
11 372 381 48362 elevation NN I-NP O
12 382 384 48362 of IN B-PP O
13 385 389 48362 SGOT NN B-NP O
14 389 390 48362 , , O O
15 391 399 48362 alkaline NN B-NP O
16 400 411 48362 phosphatase NN I-NP O
17 411 412 48362 , , O O
18 413 416 48362 and CC O O
19 417 423 48362 lactic JJ B-NP D019344
20 424 428 48362 acid NN I-NP D019344
21 429 442 48362 dehydrogenase NN I-NP O
22 443 449 48362 values NNS I-NP O
23 449 450 48362 . . O O

1 451 453 48362 We PRP B-NP O
2 454 463 48362 concluded VBD B-VP O
3 464 468 48362 that IN B-SBAR O
4 469 473 48362 this DT B-NP O
5 474 481 48362 patient NN I-NP O
6 482 485 48362 had VBD B-VP O
7 486 495 48362 quinidine NN B-NP D011802
8 496 510 48362 hepatotoxicity NN I-NP D056486
9 511 514 48362 and CC O O
10 515 522 48362 believe VBP B-VP O
11 523 527 48362 that IN B-SBAR O
12 528 532 48362 this DT B-NP O
13 533 535 48362 is VBZ B-VP O
14 536 539 48362 the DT B-NP O
15 540 545 48362 first JJ I-NP O
16 546 550 48362 case NN I-NP O
17 551 559 48362 reported VBN B-VP O
18 560 564 48362 with IN B-PP O
19 565 570 48362 liver NN B-NP O
20 571 577 48362 biopsy NN I-NP O
21 578 591 48362 documentation NN I-NP O
22 591 592 48362 . . O O

1 593 597 48362 This DT B-NP O
2 598 604 48362 report NN I-NP O
3 605 609 48362 also RB B-ADVP O
4 610 618 48362 suggests VBZ B-VP O
5 619 623 48362 that IN B-SBAR O
6 623 624 48362 , , O O
7 625 629 48362 even RB B-PP O
8 630 635 48362 after IN I-PP O
9 636 640 48362 long JJ B-NP O
10 640 641 48362 - HYPH I-NP O
11 641 645 48362 term NN I-NP O
12 646 660 48362 administration NN I-NP O
13 660 661 48362 , , O O
14 662 665 48362 the DT B-NP O
15 666 673 48362 hepatic JJ I-NP D056486
16 674 682 48362 toxicity NN I-NP D056486
17 683 685 48362 is VBZ B-VP O
18 686 696 48362 reversible JJ B-ADJP O
19 696 697 48362 . . O O

1 0 0 6216862 -DOCSTART- -X- -X- O

1 0 8 6216862 Multiple JJ B-NP O
2 9 13 6216862 side NN I-NP O
3 14 21 6216862 effects NNS I-NP O
4 22 24 6216862 of IN B-PP O
5 25 38 6216862 penicillamine NN B-NP D010396
6 39 46 6216862 therapy NN I-NP O
7 47 49 6216862 in IN B-PP O
8 50 53 6216862 one CD B-NP O
9 54 61 6216862 patient NN I-NP O
10 62 66 6216862 with IN B-PP O
11 67 77 6216862 rheumatoid JJ B-NP D001172
12 78 87 6216862 arthritis NN I-NP D001172
13 87 88 6216862 . . O O
14 89 93 6216862 Skin NNP B-NP D005076
15 94 100 6216862 rashes NNS I-NP D005076
16 100 101 6216862 , , O O
17 102 113 6216862 proteinuria NN B-NP D011507
18 113 114 6216862 , , O O
19 115 123 6216862 systemic JJ B-NP D008180
20 124 129 6216862 lupus NN I-NP D008180
21 130 143 6216862 erythematosus NN I-NP D008180
22 143 144 6216862 , , O O
23 145 157 6216862 polymyositis NN B-NP D017285
24 158 161 6216862 and CC O O
25 162 172 6216862 myasthenia NN B-NP D009157
26 173 179 6216862 gravis NN I-NP D009157
27 180 184 6216862 have VBP B-VP O
28 185 188 6216862 all DT O O
29 189 193 6216862 been VBN B-VP O
30 194 202 6216862 recorded VBN I-VP O
31 203 205 6216862 as IN B-PP O
32 206 219 6216862 complications NNS B-NP O
33 220 222 6216862 of IN B-PP O
34 223 236 6216862 penicillamine NN B-NP D010396
35 237 244 6216862 therapy NN I-NP O
36 245 247 6216862 in IN B-PP O
37 248 256 6216862 patients NNS B-NP O
38 257 261 6216862 with IN B-PP O
39 262 272 6216862 rheumatoid JJ B-NP D001172
40 273 282 6216862 arthritis NN I-NP D001172
41 282 283 6216862 . . O O

1 284 285 6216862 A DT B-NP O
2 286 293 6216862 patient NN I-NP O
3 294 297 6216862 who WP B-NP O
4 298 301 6216862 had VBD B-VP O
5 302 311 6216862 developed VBN I-VP O
6 312 315 6216862 all DT B-NP O
7 316 317 6216862 5 CD I-NP O
8 318 320 6216862 is VBZ B-VP O
9 321 324 6216862 now RB I-VP O
10 325 334 6216862 described VBN I-VP O
11 334 335 6216862 . . O O

1 336 339 6216862 The DT B-NP O
2 340 344 6216862 skin NN I-NP D012871
3 345 351 6216862 lesion NN I-NP D012871
4 352 361 6216862 resembled VBD B-VP O
5 362 371 6216862 elastosis NN B-NP C536202
6 372 381 6216862 perforans NNS I-NP C536202
7 382 393 6216862 serpiginosa NN I-NP C536202
8 393 394 6216862 , , O O
9 395 400 6216862 which WDT B-NP O
10 401 404 6216862 has VBZ B-VP O
11 405 409 6216862 been VBN I-VP O
12 410 418 6216862 reported VBN I-VP O
13 419 421 6216862 as IN B-PP O
14 422 423 6216862 a DT B-NP O
15 424 428 6216862 rare JJ I-NP O
16 429 433 6216862 side NN I-NP O
17 434 440 6216862 effect NN I-NP O
18 441 443 6216862 in IN B-PP O
19 444 452 6216862 patients NNS B-NP O
20 453 457 6216862 with IN B-PP O
21 458 466 6216862 Wilson's NNS B-NP D006527
22 467 474 6216862 disease NN I-NP D006527
23 475 478 6216862 but CC B-PP O
24 479 482 6216862 not RB B-PP O
25 483 485 6216862 in IN I-PP O
26 486 494 6216862 patients NNS B-NP O
27 495 499 6216862 with IN B-PP O
28 500 510 6216862 rheumatoid JJ B-NP D001172
29 511 520 6216862 arthritis NN I-NP D001172
30 521 528 6216862 treated VBN B-VP O
31 529 533 6216862 with IN B-PP O
32 534 547 6216862 penicillamine NN B-NP D010396
33 547 548 6216862 . . O O

1 0 0 7072798 -DOCSTART- -X- -X- O

1 0 5 7072798 Fatal JJ B-NP O
2 6 14 7072798 aplastic JJ I-NP D000741
3 15 21 7072798 anemia NN I-NP D000741
4 22 31 7072798 following VBG B-PP O
5 32 39 7072798 topical JJ B-NP O
6 40 54 7072798 administration NN I-NP O
7 55 57 7072798 of IN B-PP O
8 58 68 7072798 ophthalmic JJ B-NP O
9 69 84 7072798 chloramphenicol NN I-NP D002701
10 84 85 7072798 . . O O
11 86 87 7072798 A DT B-NP O
12 88 90 7072798 73 CD I-NP O
13 90 91 7072798 - HYPH I-NP O
14 91 95 7072798 year NN I-NP O
15 95 96 7072798 - HYPH O O
16 96 99 7072798 old JJ B-NP O
17 100 105 7072798 woman NN I-NP O
18 106 110 7072798 died VBD B-VP O
19 111 113 7072798 of IN B-PP O
20 114 122 7072798 aplastic JJ B-NP D000741
21 123 129 7072798 anemia NN I-NP D000741
22 130 134 7072798 less JJR B-NP O
23 135 139 7072798 than IN I-NP O
24 140 143 7072798 two CD I-NP O
25 144 150 7072798 months NNS I-NP O
26 151 156 7072798 after IN B-SBAR O
27 157 167 7072798 undergoing VBG B-VP O
28 168 176 7072798 cataract NN B-NP D002386
29 177 187 7072798 extraction NN I-NP O
30 188 191 7072798 and CC O O
31 192 201 7072798 beginning VBG B-VP O
32 202 209 7072798 topical JJ B-NP O
33 210 217 7072798 therapy NN I-NP O
34 218 222 7072798 with IN B-PP O
35 223 238 7072798 chloramphenicol NN B-NP D002701
36 238 239 7072798 . . O O

1 240 243 7072798 The DT B-NP O
2 244 249 7072798 first JJ I-NP O
3 250 255 7072798 signs NNS I-NP O
4 256 258 7072798 of IN B-PP O
5 259 271 7072798 pancytopenia NN B-NP D010198
6 272 277 7072798 began VBD B-VP O
7 278 284 7072798 within IN B-PP O
8 285 288 7072798 one CD B-NP O
9 289 294 7072798 month NN I-NP O
10 295 297 7072798 of IN B-PP O
11 298 301 7072798 the DT B-NP O
12 302 309 7072798 surgery NN I-NP O
13 309 310 7072798 . . O O

1 311 314 7072798 The DT B-NP O
2 315 322 7072798 pattern NN I-NP O
3 323 325 7072798 of IN B-PP O
4 326 329 7072798 the DT B-NP O
5 330 338 7072798 aplastic JJ I-NP D000741
6 339 345 7072798 anemia NN I-NP D000741
7 346 349 7072798 was VBD B-VP O
8 350 360 7072798 associated VBN I-VP O
9 361 365 7072798 with IN B-PP O
10 366 368 7072798 an DT B-NP O
11 369 382 7072798 idiosyncratic JJ I-NP O
12 383 391 7072798 response NN I-NP O
13 392 394 7072798 to TO B-PP O
14 395 410 7072798 chloramphenicol NN B-NP D002701
15 410 411 7072798 . . O O

1 412 416 7072798 This DT B-NP O
2 417 420 7072798 was VBD B-VP O
3 421 424 7072798 the DT B-NP O
4 425 431 7072798 second JJ I-NP O
5 432 438 7072798 report NN I-NP O
6 439 441 7072798 of IN B-PP O
7 442 447 7072798 fatal JJ B-NP O
8 448 456 7072798 aplastic JJ I-NP D000741
9 457 463 7072798 anemia NN I-NP D000741
10 464 469 7072798 after IN B-PP O
11 470 477 7072798 topical JJ B-NP O
12 478 487 7072798 treatment NN I-NP O
13 488 492 7072798 with IN B-PP O
14 493 508 7072798 chloramphenicol NN B-NP D002701
15 509 512 7072798 for IN B-PP O
16 513 519 7072798 ocular JJ B-NP O
17 520 530 7072798 conditions NNS I-NP O
18 530 531 7072798 , , O O
19 532 540 7072798 although IN B-SBAR O
20 541 544 7072798 two CD B-NP O
21 545 550 7072798 cases NNS I-NP O
22 551 553 7072798 of IN B-PP O
23 554 564 7072798 reversible JJ B-NP O
24 565 569 7072798 bone NN I-NP D001855
25 570 576 7072798 marrow NN I-NP D001855
26 577 587 7072798 hypoplasia NN I-NP D001855
27 588 592 7072798 have VBP B-VP O
28 593 597 7072798 also RB I-VP O
29 598 602 7072798 been VBN I-VP O
30 603 611 7072798 reported VBN I-VP O
31 611 612 7072798 . . O O

1 613 616 7072798 Any DT B-NP O
2 617 622 7072798 other JJ I-NP O
3 623 632 7072798 suspected VBN I-NP O
4 633 638 7072798 cases NNS I-NP O
5 639 641 7072798 of IN B-PP O
6 642 648 7072798 ocular JJ B-NP D005128
7 649 657 7072798 toxicity NN I-NP D005128
8 658 668 7072798 associated VBN B-VP O
9 669 673 7072798 with IN B-PP O
10 674 683 7072798 topically RB B-NP O
11 684 691 7072798 applied VBN I-NP O
12 692 707 7072798 chloramphenicol NN I-NP D002701
13 708 714 7072798 should MD B-VP O
14 715 717 7072798 be VB I-VP O
15 718 726 7072798 reported VBN I-VP O
16 727 729 7072798 to TO B-PP O
17 730 733 7072798 the DT B-NP O
18 734 742 7072798 National NNP I-NP O
19 743 751 7072798 Registry NNP I-NP O
20 752 754 7072798 of IN B-PP O
21 755 759 7072798 Drug NNP B-NP O
22 759 760 7072798 - HYPH B-NP O
23 760 767 7072798 Induced NNP I-NP O
24 768 774 7072798 Ocular NNP I-NP O
25 775 779 7072798 Side NNP I-NP O
26 780 787 7072798 Effects NNS I-NP O
27 787 788 7072798 , , O O
28 789 795 7072798 Oregon NNP B-NP O
29 796 802 7072798 Health NNP I-NP O
30 803 811 7072798 Sciences NNP I-NP O
31 812 822 7072798 University NNP I-NP O
32 822 823 7072798 , , O O
33 824 832 7072798 Portland NNP B-NP O
34 832 833 7072798 , , O O
35 834 836 7072798 OR NNP B-NP O
36 837 842 7072798 97201 CD I-NP O
37 842 843 7072798 . . O O

1 0 0 8111719 -DOCSTART- -X- -X- O

1 0 14 8111719 Hallucinations NNS B-NP D006212
2 15 18 8111719 and CC I-NP O
3 19 29 8111719 ifosfamide NN I-NP D007069
4 29 30 8111719 - HYPH B-NP O
5 30 37 8111719 induced VBN I-NP O
6 38 51 8111719 neurotoxicity NN I-NP D020258
7 51 52 8111719 . . I-NP O
8 53 63 8111719 BACKGROUND NN I-NP O
9 63 64 8111719 : : O O
10 65 79 8111719 Hallucinations NNS B-NP D006212
11 80 82 8111719 as IN B-PP O
12 83 84 8111719 a DT B-NP O
13 85 92 8111719 symptom NN I-NP O
14 93 95 8111719 of IN B-PP O
15 96 103 8111719 central JJ B-NP O
16 104 117 8111719 neurotoxicity NN I-NP D020258
17 118 121 8111719 are VBP B-VP O
18 122 123 8111719 a DT B-NP O
19 124 129 8111719 known JJ I-NP O
20 130 133 8111719 but CC O O
21 134 140 8111719 poorly RB B-NP O
22 141 150 8111719 described VBN I-NP O
23 151 155 8111719 side NN I-NP O
24 156 162 8111719 effect NN I-NP O
25 163 165 8111719 of IN B-PP O
26 166 176 8111719 ifosfamide NN B-NP D007069
27 176 177 8111719 . . O O

1 178 182 8111719 Most JJS B-NP O
2 183 188 8111719 cases NNS I-NP O
3 189 191 8111719 of IN B-PP O
4 192 202 8111719 ifosfamide NN B-NP D007069
5 202 203 8111719 - HYPH B-NP O
6 203 210 8111719 induced VBN I-NP O
7 211 225 8111719 hallucinations NNS I-NP D006212
8 226 230 8111719 have VBP B-VP O
9 231 235 8111719 been VBN I-VP O
10 236 244 8111719 reported VBN I-VP O
11 245 249 8111719 with IN B-PP O
12 250 255 8111719 other JJ B-NP O
13 256 262 8111719 mental JJ I-NP O
14 263 269 8111719 status NN I-NP O
15 270 277 8111719 changes NNS I-NP O
16 277 278 8111719 . . O O

1 279 286 8111719 METHODS NNS B-NP O
2 286 287 8111719 : : O O
3 288 291 8111719 The DT B-NP O
4 292 299 8111719 authors NNS I-NP O
5 300 311 8111719 interviewed VBD B-VP O
6 312 315 8111719 six CD B-NP O
7 316 323 8111719 persons NNS I-NP O
8 324 328 8111719 with IN B-PP O
9 329 339 8111719 ifosfamide NN B-NP D007069
10 339 340 8111719 - HYPH B-NP O
11 340 347 8111719 induced VBN I-NP O
12 348 362 8111719 hallucinations NNS I-NP D006212
13 363 365 8111719 in IN B-PP O
14 366 369 8111719 the DT B-NP O
15 370 378 8111719 presence NN I-NP O
16 379 381 8111719 of IN B-PP O
17 382 383 8111719 a DT B-NP O
18 384 389 8111719 clear JJ I-NP O
19 390 399 8111719 sensorium NN I-NP O
20 399 400 8111719 . . O O

1 401 404 8111719 All DT B-NP O
2 405 413 8111719 patients NNS I-NP O
3 414 418 8111719 were VBD B-VP O
4 419 428 8111719 receiving VBG I-VP O
5 429 433 8111719 high JJ B-NP O
6 433 434 8111719 - HYPH I-NP O
7 434 438 8111719 dose NN I-NP O
8 439 449 8111719 ifosfamide NN I-NP D007069
9 450 452 8111719 as IN B-PP O
10 453 457 8111719 part NN B-NP O
11 458 460 8111719 of IN B-PP O
12 461 466 8111719 their PRP$ B-NP O
13 467 471 8111719 bone NN I-NP O
14 472 478 8111719 marrow NN I-NP O
15 479 489 8111719 transplant NN I-NP O
16 490 499 8111719 procedure NN I-NP O
17 499 500 8111719 . . O O

1 501 508 8111719 RESULTS NNS B-NP O
2 508 509 8111719 : : O O
3 510 524 8111719 Hallucinations NNS B-NP D006212
4 525 533 8111719 occurred VBD B-VP O
5 534 538 8111719 only RB B-ADVP O
6 539 543 8111719 when WRB I-ADVP O
7 544 547 8111719 the DT B-NP O
8 548 557 8111719 patient's NNS I-NP O
9 558 562 8111719 eyes NNS I-NP O
10 563 567 8111719 were VBD B-VP O
11 568 574 8111719 closed VBN B-ADJP O
12 575 578 8111719 and CC O O
13 578 579 8111719 , , O O
14 580 582 8111719 in IN B-PP O
15 583 586 8111719 all DT B-NP O
16 587 590 8111719 but IN B-PP O
17 591 594 8111719 one CD B-NP O
18 595 599 8111719 case NN I-NP O
19 599 600 8111719 , , O O
20 601 605 8111719 were VBD B-VP O
21 606 614 8111719 reported VBN I-VP O
22 615 617 8111719 as IN B-PP O
23 618 628 8111719 disturbing JJ B-NP O
24 629 631 8111719 or CC I-NP O
25 632 643 8111719 frightening NN I-NP O
26 643 644 8111719 . . O O

1 645 659 8111719 Underreporting VBG B-VP O
2 660 662 8111719 of IN B-PP O
3 663 668 8111719 these DT B-NP O
4 669 683 8111719 hallucinations NNS I-NP D006212
5 684 686 8111719 by IN B-PP O
6 687 695 8111719 patients NNS B-NP O
7 696 698 8111719 is VBZ B-VP O
8 699 705 8111719 likely JJ B-ADJP O
9 705 706 8111719 . . O O

1 707 718 8111719 CONCLUSIONS NNS B-NP O
2 718 719 8111719 : : O O
3 720 734 8111719 Hallucinations NNS B-NP D006212
4 735 738 8111719 may MD B-VP O
5 739 741 8111719 be VB I-VP O
6 742 745 8111719 the DT B-NP O
7 746 750 8111719 sole JJ I-NP O
8 751 753 8111719 or CC I-NP O
9 754 759 8111719 first JJ I-NP O
10 760 773 8111719 manifestation NN I-NP O
11 774 776 8111719 of IN B-PP O
12 777 790 8111719 neurotoxicity NN B-NP D020258
13 790 791 8111719 . . O O

1 792 795 8111719 The DT B-NP O
2 796 805 8111719 incidence NN I-NP O
3 806 809 8111719 may MD B-VP O
4 810 812 8111719 be VB I-VP O
5 813 817 8111719 dose NN B-NP O
6 818 821 8111719 and CC I-NP O
7 822 830 8111719 infusion NN I-NP O
8 830 831 8111719 - HYPH B-NP O
9 831 835 8111719 time NN I-NP O
10 836 843 8111719 related VBN B-VP O
11 843 844 8111719 . . O O

1 845 848 8111719 The DT B-NP O
2 849 858 8111719 clinician NN I-NP O
3 859 865 8111719 should MD B-VP O
4 866 868 8111719 be VB I-VP O
5 869 876 8111719 alerted VBN I-VP O
6 877 880 8111719 for IN B-PP O
7 881 889 8111719 possible JJ B-NP O
8 890 900 8111719 ifosfamide NN I-NP D007069
9 900 901 8111719 - HYPH B-NP O
10 901 908 8111719 induced VBN I-NP O
11 909 923 8111719 hallucinations NNS I-NP D006212
12 923 924 8111719 , , O O
13 925 930 8111719 which WDT B-NP O
14 931 934 8111719 may MD B-VP O
15 935 940 8111719 occur VB I-VP O
16 941 948 8111719 without IN B-PP O
17 949 954 8111719 other JJ B-NP O
18 955 960 8111719 signs NNS I-NP O
19 961 963 8111719 of IN B-PP O
20 964 977 8111719 neurotoxicity NN B-NP D020258
21 977 978 8111719 . . O O

1 979 980 8111719 " `` O O
2 980 984 8111719 Eyes NNS B-NP O
3 984 985 8111719 - HYPH O O
4 985 991 8111719 closed VBN B-VP O
5 991 992 8111719 " `` O O
6 993 1006 8111719 hallucinatory JJ B-NP D006212
7 1007 1018 8111719 experiences NNS I-NP O
8 1019 1025 8111719 appear VBP B-VP O
9 1026 1028 8111719 to TO I-VP O
10 1029 1031 8111719 be VB I-VP O
11 1032 1034 8111719 an DT B-NP O
12 1035 1042 8111719 unusual JJ I-NP O
13 1043 1050 8111719 feature NN I-NP O
14 1051 1053 8111719 of IN B-PP O
15 1054 1058 8111719 this DT B-NP O
16 1059 1071 8111719 presentation NN I-NP O
17 1071 1072 8111719 . . O O

1 1073 1081 8111719 Patients NNS B-NP O
2 1082 1089 8111719 anxious JJ B-ADJP O
3 1090 1095 8111719 about IN B-PP O
4 1096 1100 8111719 this DT B-NP O
5 1101 1111 8111719 experience NN I-NP O
6 1112 1119 8111719 respond VBP B-VP O
7 1120 1124 8111719 well RB B-ADVP O
8 1125 1127 8111719 to TO B-PP O
9 1128 1135 8111719 support NN B-NP O
10 1136 1139 8111719 and CC I-NP O
11 1140 1149 8111719 education NN I-NP O
12 1150 1155 8111719 about IN B-PP O
13 1156 1160 8111719 this DT B-NP O
14 1161 1171 8111719 occurrence NN I-NP O
15 1171 1172 8111719 . . O O

1 1173 1180 8111719 Optimal JJ B-NP O
2 1181 1194 8111719 pharmacologic JJ I-NP O
3 1195 1205 8111719 management NN I-NP O
4 1206 1208 8111719 of IN B-PP O
5 1209 1218 8111719 disturbed JJ B-NP O
6 1219 1227 8111719 patients NNS I-NP O
7 1228 1230 8111719 is VBZ B-VP O
8 1231 1238 8111719 unclear JJ B-ADJP O
9 1238 1239 8111719 . . O O

1 1240 1242 8111719 If IN B-SBAR O
2 1243 1252 8111719 agitation NN B-NP D011595
3 1253 1260 8111719 becomes VBZ B-VP O
4 1261 1267 8111719 marked JJ B-NP O
5 1267 1268 8111719 , , I-NP O
6 1269 1273 8111719 high JJ I-NP O
7 1273 1274 8111719 - HYPH I-NP O
8 1274 1281 8111719 potency NN I-NP O
9 1282 1294 8111719 neuroleptics NNS I-NP O
10 1295 1296 8111719 ( ( O O
11 1296 1300 8111719 i.e. FW B-NP O
12 1300 1301 8111719 , , I-NP O
13 1302 1313 8111719 haloperidol NN I-NP D006220
14 1313 1314 8111719 ) ) O O
15 1315 1318 8111719 may MD B-VP O
16 1319 1321 8111719 be VB I-VP O
17 1322 1331 8111719 effective JJ B-ADJP O
18 1331 1332 8111719 . . O O

1 0 0 6433367 -DOCSTART- -X- -X- O

1 0 6 6433367 Effect NN B-NP O
2 7 9 6433367 of IN B-PP O
3 10 23 6433367 prostaglandin NN B-NP D011453
4 24 34 6433367 synthetase NN I-NP O
5 35 45 6433367 inhibitors NNS I-NP O
6 46 48 6433367 on IN B-PP O
7 49 63 6433367 experimentally RB B-NP O
8 64 71 6433367 induced VBN I-NP O
9 72 83 6433367 convulsions NNS I-NP D012640
10 84 86 6433367 in IN B-PP O
11 87 91 6433367 rats NNS B-NP O
12 91 92 6433367 . . O O
13 93 95 6433367 To TO B-VP O
14 96 107 6433367 investigate VB I-VP O
15 108 111 6433367 the DT B-NP O
16 112 124 6433367 relationship NN I-NP O
17 125 127 6433367 of IN B-PP O
18 128 142 6433367 prostaglandins NNS B-NP D011453
19 143 144 6433367 ( ( O O
20 144 147 6433367 PGs NNS B-NP D011453
21 147 148 6433367 ) ) O O
22 149 151 6433367 to TO B-VP O
23 152 159 6433367 seizure VB I-VP D012640
24 160 169 6433367 induction NN B-NP O
25 169 170 6433367 , , O O
26 171 174 6433367 the DT B-NP O
27 175 182 6433367 effects NNS I-NP O
28 183 185 6433367 of IN B-PP O
29 186 189 6433367 six CD B-NP O
30 190 192 6433367 PG NN I-NP O
31 193 203 6433367 synthetase NN I-NP O
32 204 214 6433367 inhibitors NNS I-NP O
33 215 217 6433367 on IN B-PP O
34 218 229 6433367 convulsions NNS B-NP D012640
35 230 237 6433367 induced VBN B-VP O
36 238 240 6433367 by IN B-PP O
37 241 250 6433367 flurothyl NN B-NP D005481
38 250 251 6433367 , , O O
39 252 262 6433367 picrotoxin NN B-NP D010852
40 262 263 6433367 , , O O
41 264 275 6433367 pentetrazol NN B-NP D010433
42 276 277 6433367 ( ( O O
43 277 280 6433367 PTZ NN B-NP D010433
44 280 281 6433367 ) ) O O
45 281 282 6433367 , , O O
46 283 295 6433367 electroshock NN B-NP O
47 296 298 6433367 or CC I-NP O
48 299 310 6433367 bicuculline NN I-NP D001640
49 311 315 6433367 were VBD B-VP O
50 316 325 6433367 evaluated VBN I-VP O
51 325 326 6433367 . . O O

1 327 336 6433367 Ibuprofen NN B-NP D007052
2 336 337 6433367 , , O O
3 338 346 6433367 sulindac NN B-NP D013467
4 346 347 6433367 , , O O
5 348 357 6433367 mefenamic JJ B-NP D008528
6 358 362 6433367 acid NN I-NP D008528
7 362 363 6433367 , , O O
8 364 367 6433367 and CC O O
9 368 371 6433367 low JJ B-NP O
10 372 376 6433367 dose NN I-NP O
11 377 389 6433367 meclofenamic JJ I-NP D008469
12 390 394 6433367 acid NN I-NP D008469
13 395 404 6433367 increased VBD B-VP O
14 405 408 6433367 the DT B-NP O
15 409 416 6433367 latency NN I-NP O
16 416 417 6433367 - HYPH B-ADJP O
17 417 419 6433367 to TO B-PP O
18 419 420 6433367 - HYPH B-NP O
19 420 425 6433367 onset NN I-NP O
20 426 428 6433367 in IN B-PP O
21 429 432 6433367 the DT B-NP O
22 433 442 6433367 flurothyl NN I-NP D005481
23 443 446 6433367 and CC O O
24 446 447 6433367 / SYM B-NP O
25 447 449 6433367 or CC O O
26 450 453 6433367 PTZ NN B-NP D010433
27 454 460 6433367 models NNS I-NP O
28 460 461 6433367 ; : O O
29 462 465 6433367 the DT B-NP O
30 466 478 6433367 electroshock NN I-NP O
31 478 479 6433367 , , I-NP O
32 480 490 6433367 picrotoxin NN I-NP D010852
33 491 494 6433367 and CC I-NP O
34 495 506 6433367 bicuculline NN I-NP D001640
35 507 513 6433367 models NNS I-NP O
36 514 518 6433367 were VBD B-VP O
37 519 522 6433367 not RB I-VP O
38 523 536 6433367 significantly RB I-VP O
39 537 545 6433367 affected VBN I-VP O
40 546 548 6433367 by IN B-PP O
41 549 552 6433367 any DT B-NP O
42 553 555 6433367 of IN B-PP O
43 556 559 6433367 the DT B-NP O
44 560 572 6433367 pretreatment NN I-NP O
45 573 579 6433367 agents NNS I-NP O
46 579 580 6433367 . . O O

1 581 586 6433367 These DT B-NP O
2 587 594 6433367 results NNS I-NP O
3 595 602 6433367 suggest VBP B-VP O
4 603 607 6433367 that IN B-SBAR O
5 608 611 6433367 PGs NNS B-NP D011453
6 612 615 6433367 are VBP B-VP O
7 616 624 6433367 involved VBN I-VP O
8 625 627 6433367 in IN B-PP O
9 628 631 6433367 the DT B-NP O
10 632 641 6433367 mechanism NN I-NP O
11 641 642 6433367 ( ( I-NP O
12 642 643 6433367 s NNS I-NP O
13 643 644 6433367 ) ) O O
14 645 655 6433367 underlying VBG B-VP O
15 656 665 6433367 fluorthyl NN B-NP D005481
16 665 666 6433367 - HYPH B-NP O
17 667 670 6433367 and CC I-NP O
18 671 674 6433367 PTZ NN I-NP D010433
19 674 675 6433367 - HYPH O O
20 675 682 6433367 induced VBN B-NP O
21 683 694 6433367 convulsions NNS I-NP D012640
22 694 695 6433367 , , O O
23 696 699 6433367 but CC O O
24 700 703 6433367 not RB O O
25 704 714 6433367 picrotoxin NN B-NP D010852
26 714 715 6433367 - HYPH B-ADJP O
27 715 716 6433367 , , O O
28 717 729 6433367 electroshock NN B-NP O
29 729 730 6433367 - HYPH B-ADJP O
30 730 731 6433367 , , O O
31 732 734 6433367 or CC O O
32 735 746 6433367 bicuculline NN B-NP D001640
33 746 747 6433367 - HYPH B-NP O
34 747 754 6433367 induced VBN I-NP O
35 755 766 6433367 convulsions NNS I-NP D012640
36 766 767 6433367 . . O O

1 0 0 2257294 -DOCSTART- -X- -X- O

1 0 19 2257294 Benzylacyclouridine NN B-NP C034753
2 20 28 2257294 reverses VBZ B-VP O
3 29 43 2257294 azidothymidine NN B-NP D015215
4 43 44 2257294 - HYPH B-NP O
5 44 51 2257294 induced VBN I-NP O
6 52 58 2257294 marrow NN I-NP D001855
7 59 70 2257294 suppression NN I-NP D001855
8 71 78 2257294 without IN B-PP O
9 79 89 2257294 impairment NN B-NP O
10 90 92 2257294 of IN B-PP O
11 93 97 2257294 anti AFX B-NP O
12 97 98 2257294 - HYPH I-NP O
13 98 103 2257294 human JJ B-NP O
14 104 120 2257294 immunodeficiency NN I-NP D007153
15 121 126 2257294 virus NN I-NP O
16 127 135 2257294 activity NN I-NP O
17 135 136 2257294 . . O O
18 137 146 2257294 Increased VBD B-VP O
19 147 160 2257294 extracellular JJ B-NP O
20 161 175 2257294 concentrations NNS I-NP O
21 176 178 2257294 of IN B-PP O
22 179 186 2257294 uridine NN B-NP D014529
23 187 188 2257294 ( ( O O
24 188 191 2257294 Urd NN B-NP D014529
25 191 192 2257294 ) ) O O
26 193 197 2257294 have VBP B-VP O
27 198 202 2257294 been VBN I-VP O
28 203 211 2257294 reported VBN I-VP O
29 212 214 2257294 to TO I-VP O
30 215 221 2257294 reduce VB I-VP O
31 221 222 2257294 , , O O
32 223 225 2257294 in FW B-ADVP O
33 226 231 2257294 vitro FW I-ADVP O
34 231 232 2257294 , , O O
35 233 247 2257294 azidothymidine NN B-NP D015215
36 248 249 2257294 ( ( O O
37 249 252 2257294 AZT NN B-NP D015215
38 252 253 2257294 ) ) O O
39 253 254 2257294 - HYPH B-NP O
40 254 261 2257294 induced VBN I-NP O
41 262 272 2257294 inhibition NN I-NP O
42 273 275 2257294 of IN B-PP O
43 276 281 2257294 human JJ B-NP O
44 282 293 2257294 granulocyte NN I-NP O
45 293 294 2257294 - HYPH I-NP O
46 294 304 2257294 macrophage NN I-NP O
47 305 315 2257294 progenitor NN I-NP O
48 316 321 2257294 cells NNS I-NP O
49 322 329 2257294 without IN B-PP O
50 330 340 2257294 impairment NN B-NP O
51 341 343 2257294 of IN B-PP O
52 344 347 2257294 its PRP$ B-NP O
53 348 357 2257294 antihuman JJ I-NP O
54 358 374 2257294 immunodeficiency NN I-NP D007153
55 375 380 2257294 virus NN I-NP O
56 381 382 2257294 ( ( O O
57 382 385 2257294 HIV NN B-NP O
58 385 386 2257294 ) ) O O
59 387 395 2257294 activity NN B-NP O
60 395 396 2257294 . . O O

1 397 404 2257294 Because IN B-PP O
2 405 407 2257294 of IN I-PP O
3 408 411 2257294 the DT B-NP O
4 412 420 2257294 clinical JJ I-NP O
5 421 431 2257294 toxicities NNS I-NP D064420
6 432 442 2257294 associated VBN B-VP O
7 443 447 2257294 with IN B-PP O
8 448 455 2257294 chronic JJ B-NP O
9 456 459 2257294 Urd NNP I-NP D014529
10 460 474 2257294 administration NN I-NP O
11 474 475 2257294 , , O O
12 476 479 2257294 the DT B-NP O
13 480 487 2257294 ability NN I-NP O
14 488 490 2257294 of IN B-PP O
15 491 510 2257294 benzylacyclouridine NN B-NP C034753
16 511 512 2257294 ( ( O O
17 512 515 2257294 BAU NN B-NP C034753
18 515 516 2257294 ) ) O O
19 517 519 2257294 to TO B-PP O
20 520 526 2257294 effect NN B-NP O
21 526 527 2257294 , , O O
22 528 530 2257294 in FW B-ADVP O
23 531 535 2257294 vivo FW I-ADVP O
24 535 536 2257294 , , O O
25 537 540 2257294 AZT NN B-NP D015215
26 540 541 2257294 - HYPH B-NP O
27 541 548 2257294 induced VBN I-NP O
28 549 555 2257294 anemia NN I-NP D000740
29 556 559 2257294 and CC I-NP O
30 560 570 2257294 leukopenia NN I-NP D007970
31 571 574 2257294 was VBD B-VP O
32 575 583 2257294 assessed VBN I-VP O
33 583 584 2257294 . . O O

1 585 589 2257294 This DT B-NP O
2 590 595 2257294 agent NN I-NP O
3 596 604 2257294 inhibits VBZ B-VP O
4 605 608 2257294 Urd NNP B-NP D014529
5 609 619 2257294 catabolism NN I-NP O
6 620 623 2257294 and CC O O
7 623 624 2257294 , , O O
8 625 627 2257294 in FW B-ADVP O
9 628 632 2257294 vivo FW I-ADVP O
10 632 633 2257294 , , O O
11 634 643 2257294 increases VBZ B-VP O
12 644 647 2257294 the DT B-NP O
13 648 654 2257294 plasma NN I-NP O
14 655 668 2257294 concentration NN I-NP O
15 669 671 2257294 of IN B-PP O
16 672 675 2257294 Urd NNP B-NP D014529
17 676 678 2257294 in IN B-PP O
18 679 680 2257294 a DT B-NP O
19 681 685 2257294 dose NN I-NP O
20 685 686 2257294 - HYPH B-NP O
21 686 695 2257294 dependent JJ I-NP O
22 696 702 2257294 manner NN I-NP O
23 702 703 2257294 , , O O
24 704 711 2257294 without IN B-PP O
25 712 715 2257294 Urd NNP B-NP D014529
26 715 716 2257294 - HYPH B-NP O
27 716 723 2257294 related VBN I-NP O
28 724 732 2257294 toxicity NN I-NP D064420
29 732 733 2257294 . . O O

1 734 736 2257294 In IN B-PP O
2 737 741 2257294 mice NNS B-NP O
3 742 750 2257294 rendered VBD B-VP O
4 751 757 2257294 anemic JJ B-NP D000740
5 758 761 2257294 and CC I-NP O
6 762 772 2257294 leukopenic JJ I-NP D007970
7 773 775 2257294 by IN B-PP O
8 776 779 2257294 the DT B-NP O
9 780 794 2257294 administration NN I-NP O
10 795 797 2257294 of IN B-PP O
11 798 801 2257294 AZT NNP B-NP D015215
12 802 805 2257294 for IN B-PP O
13 806 808 2257294 28 CD B-NP O
14 809 813 2257294 days NNS I-NP O
15 814 816 2257294 in IN B-PP O
16 817 825 2257294 drinking NN B-NP O
17 826 831 2257294 water NN I-NP O
18 832 833 2257294 ( ( O O
19 833 836 2257294 1.5 CD B-NP O
20 837 839 2257294 mg NN I-NP O
21 839 840 2257294 / SYM B-NP O
22 840 842 2257294 mL NN I-NP O
23 842 843 2257294 ) ) O O
24 843 844 2257294 , , O O
25 845 848 2257294 the DT B-NP O
26 849 858 2257294 continued JJ I-NP O
27 859 873 2257294 administration NN I-NP O
28 874 876 2257294 of IN B-PP O
29 877 880 2257294 AZT NNP B-NP D015215
30 881 885 2257294 plus CC O O
31 886 891 2257294 daily JJ B-NP O
32 892 895 2257294 BAU NN I-NP C034753
33 896 897 2257294 ( ( O O
34 897 900 2257294 300 CD B-NP O
35 901 903 2257294 mg NN I-NP O
36 903 904 2257294 / SYM B-NP O
37 904 906 2257294 kg NN I-NP O
38 906 907 2257294 , , O O
39 908 914 2257294 orally RB B-ADVP O
40 914 915 2257294 ) ) O O
41 916 925 2257294 partially RB B-ADVP O
42 926 934 2257294 reversed VBD B-VP O
43 935 938 2257294 AZT NN B-NP D015215
44 938 939 2257294 - HYPH B-NP O
45 939 946 2257294 induced VBN I-NP O
46 947 953 2257294 anemia NN I-NP D000740
47 954 957 2257294 and CC I-NP O
48 958 968 2257294 leukopenia NN I-NP D007970
49 969 970 2257294 ( ( O O
50 970 971 2257294 P NN B-NP O
51 972 976 2257294 less JJR B-ADJP O
52 977 981 2257294 than IN B-PP O
53 982 985 2257294 .05 CD B-NP O
54 985 986 2257294 ) ) O O
55 986 987 2257294 , , O O
56 988 997 2257294 increased VBN B-NP O
57 998 1008 2257294 peripheral JJ I-NP O
58 1009 1022 2257294 reticulocytes NNS I-NP O
59 1023 1024 2257294 ( ( O O
60 1024 1026 2257294 to TO B-PP O
61 1027 1031 2257294 4.9% NN B-NP O
62 1031 1032 2257294 , , O O
63 1033 1034 2257294 P NN B-NP O
64 1035 1039 2257294 less JJR B-ADJP O
65 1040 1044 2257294 than IN B-PP O
66 1045 1048 2257294 .01 CD B-NP O
67 1048 1049 2257294 ) ) O O
68 1049 1050 2257294 , , O O
69 1051 1060 2257294 increased VBN B-NP O
70 1061 1072 2257294 cellularity NN I-NP O
71 1073 1075 2257294 in IN B-PP O
72 1076 1079 2257294 the DT B-NP O
73 1080 1086 2257294 marrow NN I-NP O
74 1086 1087 2257294 , , O O
75 1088 1091 2257294 and CC O O
76 1092 1100 2257294 improved VBN B-NP O
77 1101 1116 2257294 megaloblastosis NN I-NP -1
78 1116 1117 2257294 . . O O

1 1118 1122 2257294 When WRB B-ADVP O
2 1123 1137 2257294 coadministered VBN B-VP O
3 1138 1142 2257294 with IN B-PP O
4 1143 1146 2257294 AZT NN B-NP D015215
5 1147 1151 2257294 from IN B-PP O
6 1152 1155 2257294 the DT B-NP O
7 1156 1161 2257294 onset NN I-NP O
8 1162 1164 2257294 of IN B-PP O
9 1165 1169 2257294 drug NN B-NP O
10 1170 1184 2257294 administration NN I-NP O
11 1184 1185 2257294 , , O O
12 1186 1189 2257294 BAU NN B-NP C034753
13 1190 1197 2257294 reduced VBD B-VP O
14 1198 1201 2257294 AZT NN B-NP D015215
15 1201 1202 2257294 - HYPH B-NP O
16 1202 1209 2257294 induced VBN I-NP O
17 1210 1216 2257294 marrow NN I-NP D001855
18 1217 1225 2257294 toxicity NN I-NP D001855
19 1225 1226 2257294 . . O O

1 1227 1229 2257294 In FW B-ADVP O
2 1230 1235 2257294 vitro FW I-ADVP O
3 1235 1236 2257294 , , O O
4 1237 1239 2257294 at IN B-PP O
5 1240 1241 2257294 a DT B-NP O
6 1242 1255 2257294 concentration NN I-NP O
7 1256 1258 2257294 of IN B-PP O
8 1259 1262 2257294 100 CD B-NP O
9 1263 1268 2257294 mumol NN I-NP O
10 1268 1269 2257294 / SYM O O
11 1269 1270 2257294 L NN B-NP O
12 1270 1271 2257294 , , O O
13 1272 1275 2257294 BAU NN B-NP C034753
14 1276 1285 2257294 possesses VBZ B-VP O
15 1286 1293 2257294 minimal JJ B-NP O
16 1294 1298 2257294 anti AFX I-NP O
17 1298 1299 2257294 - HYPH I-NP O
18 1299 1302 2257294 HIV NN I-NP O
19 1303 1311 2257294 activity NN I-NP O
20 1312 1315 2257294 and CC O O
21 1316 1319 2257294 has VBZ B-VP O
22 1320 1322 2257294 no DT B-NP O
23 1323 1329 2257294 effect NN I-NP O
24 1330 1332 2257294 on IN B-PP O
25 1333 1336 2257294 the DT B-NP O
26 1337 1344 2257294 ability NN I-NP O
27 1345 1347 2257294 of IN B-PP O
28 1348 1351 2257294 AZT NNP B-NP D015215
29 1352 1354 2257294 to TO B-VP O
30 1355 1362 2257294 reverse VB I-VP O
31 1363 1366 2257294 the DT B-NP O
32 1367 1370 2257294 HIV NN I-NP O
33 1370 1371 2257294 - HYPH O O
34 1371 1378 2257294 induced VBN B-NP O
35 1379 1389 2257294 cytopathic JJ I-NP O
36 1390 1396 2257294 effect NN I-NP O
37 1397 1399 2257294 in IN B-PP O
38 1400 1403 2257294 MT4 NN B-NP O
39 1404 1409 2257294 cells NNS I-NP O
40 1409 1410 2257294 . . O O

1 1411 1414 2257294 The DT B-NP O
2 1415 1423 2257294 clinical JJ I-NP O
3 1424 1427 2257294 and CC I-NP O
4 1428 1439 2257294 biochemical JJ I-NP O
5 1440 1452 2257294 implications NNS I-NP O
6 1453 1455 2257294 of IN B-PP O
7 1456 1461 2257294 these DT B-NP O
8 1462 1470 2257294 findings NNS I-NP O
9 1471 1474 2257294 are VBP B-VP O
10 1475 1484 2257294 discussed VBN I-VP O
11 1484 1485 2257294 . . O O

1 0 0 11912119 -DOCSTART- -X- -X- O

1 0 5 11912119 Force NN B-NP O
2 6 14 11912119 overflow NN I-NP O
3 15 18 11912119 and CC I-NP O
4 19 27 11912119 levodopa NN I-NP D007980
5 27 28 11912119 - HYPH B-NP O
6 28 35 11912119 induced VBN I-NP O
7 36 47 11912119 dyskinesias NNS I-NP D004409
8 48 50 11912119 in IN B-PP O
9 51 62 11912119 Parkinson's NNS B-NP D010300
10 63 70 11912119 disease NN I-NP D010300
11 70 71 11912119 . . O O
12 72 74 11912119 We PRP B-NP O
13 75 83 11912119 assessed VBD B-VP O
14 84 89 11912119 force NN B-NP O
15 90 102 11912119 coordination NN I-NP O
16 103 105 11912119 of IN B-PP O
17 106 109 11912119 the DT B-NP O
18 110 114 11912119 hand NN I-NP O
19 115 117 11912119 in IN B-PP O
20 118 129 11912119 Parkinson's NNS B-NP D010300
21 130 137 11912119 disease NN I-NP D010300
22 138 141 11912119 and CC O O
23 142 145 11912119 its PRP$ B-NP O
24 146 158 11912119 relationship NN I-NP O
25 159 161 11912119 to TO B-PP O
26 162 167 11912119 motor NN B-NP O
27 168 181 11912119 complications NNS I-NP O
28 182 184 11912119 of IN B-PP O
29 185 193 11912119 levodopa NN B-NP D007980
30 194 201 11912119 therapy NN I-NP O
31 201 202 11912119 , , O O
32 203 215 11912119 particularly RB B-ADVP O
33 216 218 11912119 to TO B-PP O
34 219 227 11912119 levodopa NN B-NP D007980
35 227 228 11912119 - HYPH B-NP O
36 228 235 11912119 induced VBN I-NP O
37 236 247 11912119 dyskinesias NNS I-NP D004409
38 248 249 11912119 ( ( O O
39 249 252 11912119 LID NN B-NP D004409
40 252 253 11912119 ) ) O O
41 253 254 11912119 . . O O

1 255 257 11912119 We PRP B-NP O
2 258 265 11912119 studied VBD B-VP O
3 266 269 11912119 two CD B-NP O
4 270 276 11912119 groups NNS I-NP O
5 277 279 11912119 of IN B-PP O
6 280 291 11912119 Parkinson's NNS B-NP D010300
7 292 299 11912119 disease NN I-NP D010300
8 300 308 11912119 patients NNS I-NP O
9 309 313 11912119 with IN B-PP O
10 314 315 11912119 ( ( O O
11 315 326 11912119 Parkinson's NNS B-NP D010300
12 327 334 11912119 disease NN I-NP D010300
13 335 336 11912119 + SYM O O
14 337 340 11912119 LID NN B-NP D004409
15 340 341 11912119 , , O O
16 342 343 11912119 n NN B-NP O
17 344 345 11912119 = SYM B-VP O
18 346 348 11912119 23 CD B-NP O
19 348 349 11912119 ) ) O O
20 350 353 11912119 and CC O O
21 354 361 11912119 without IN B-PP O
22 362 370 11912119 levodopa NN B-NP D007980
23 370 371 11912119 - HYPH B-NP O
24 371 378 11912119 induced VBN I-NP O
25 379 390 11912119 dyskinesias NNS I-NP D004409
26 391 392 11912119 ( ( O O
27 392 403 11912119 Parkinson's NNS B-NP D010300
28 404 411 11912119 disease NN I-NP D010300
29 412 413 11912119 - HYPH O O
30 414 417 11912119 LID NN B-NP D004409
31 417 418 11912119 , , O O
32 419 420 11912119 n NN B-NP O
33 421 422 11912119 = SYM B-VP O
34 423 425 11912119 10 CD B-NP O
35 425 426 11912119 ) ) O O
36 426 427 11912119 , , O O
37 428 431 11912119 and CC O O
38 432 435 11912119 age NN B-NP O
39 435 436 11912119 - HYPH B-VP O
40 436 443 11912119 matched VBN B-NP O
41 444 451 11912119 healthy JJ I-NP O
42 452 460 11912119 controls NNS I-NP O
43 460 461 11912119 . . O O

1 462 465 11912119 The DT B-NP O
2 466 471 11912119 motor NN I-NP O
3 472 477 11912119 score NN I-NP O
4 478 480 11912119 of IN B-PP O
5 481 484 11912119 the DT B-NP O
6 485 492 11912119 Unified NNP I-NP O
7 493 504 11912119 Parkinson's NNP I-NP D010300
8 505 512 11912119 Disease NNP I-NP D010300
9 513 519 11912119 Rating NNP I-NP O
10 520 525 11912119 Scale NNP I-NP O
11 525 526 11912119 , , O O
12 527 528 11912119 a DT B-NP O
13 529 539 11912119 dyskinesia NN I-NP D004409
14 540 545 11912119 score NN I-NP O
15 546 549 11912119 and CC I-NP O
16 550 555 11912119 force NN I-NP O
17 556 558 11912119 in IN B-PP O
18 559 560 11912119 a DT B-NP O
19 561 565 11912119 grip NN I-NP O
20 565 566 11912119 - HYPH I-NP O
21 566 570 11912119 lift NN I-NP O
22 571 579 11912119 paradigm NN I-NP O
23 580 584 11912119 were VBD B-VP O
24 585 593 11912119 assessed VBN I-VP O
25 594 596 11912119 ON NN B-NP O
26 597 600 11912119 and CC I-NP O
27 601 604 11912119 OFF NN I-NP O
28 605 613 11912119 levodopa NN I-NP D007980
29 613 614 11912119 . . O O

1 615 616 11912119 A DT B-NP O
2 617 629 11912119 pathological JJ I-NP O
3 630 638 11912119 increase NN I-NP O
4 639 641 11912119 of IN B-PP O
5 642 648 11912119 forces NNS B-NP O
6 649 652 11912119 was VBD B-VP O
7 653 657 11912119 seen VBN I-VP O
8 658 660 11912119 in IN B-PP O
9 661 663 11912119 ON NN B-NP O
10 663 664 11912119 - HYPH I-NP O
11 664 669 11912119 state NN I-NP O
12 670 672 11912119 in IN B-PP O
13 673 684 11912119 Parkinson's NNS B-NP D010300
14 685 692 11912119 disease NN I-NP D010300
15 693 694 11912119 + SYM B-NP O
16 695 698 11912119 LID NN I-NP D004409
17 699 703 11912119 only RB B-ADVP O
18 703 704 11912119 . . O O

1 705 707 11912119 In IN B-PP O
2 708 719 11912119 Parkinson's NNS B-NP D010300
3 720 727 11912119 disease NN I-NP D010300
4 728 729 11912119 + SYM B-NP O
5 730 733 11912119 LID NN I-NP D004409
6 733 734 11912119 , , O O
7 735 738 11912119 the DT B-NP O
8 739 744 11912119 force NN I-NP O
9 745 753 11912119 involved VBN B-VP O
10 754 756 11912119 in IN B-PP O
11 757 765 11912119 pressing VBG B-VP O
12 766 770 11912119 down RP B-PRT O
13 771 774 11912119 the DT B-NP O
14 775 781 11912119 object NN I-NP O
15 782 788 11912119 before IN B-PP O
16 789 796 11912119 lifting NN B-NP O
17 797 800 11912119 was VBD B-VP O
18 801 814 11912119 significantly RB I-VP O
19 815 824 11912119 increased VBN I-VP O
20 825 827 11912119 by IN B-PP O
21 828 836 11912119 levodopa NN B-NP D007980
22 837 838 11912119 ( ( O O
23 838 840 11912119 by IN B-PP O
24 841 844 11912119 61% NN B-NP O
25 844 845 11912119 , , O O
26 846 847 11912119 P NN B-NP O
27 848 849 11912119 < SYM B-NP O
28 850 854 11912119 0.05 CD I-NP O
29 854 855 11912119 ) ) O O
30 855 856 11912119 . . O O

1 857 859 11912119 An DT B-NP O
2 860 872 11912119 overshooting NN I-NP O
3 873 875 11912119 of IN B-PP O
4 876 880 11912119 peak NN B-NP O
5 881 885 11912119 grip NN I-NP O
6 886 891 11912119 force NN I-NP O
7 892 894 11912119 by IN B-PP O
8 895 898 11912119 51% NN B-NP O
9 899 900 11912119 ( ( O O
10 900 901 11912119 P NN B-NP O
11 902 903 11912119 < SYM O O
12 904 908 11912119 0.05 CD B-NP O
13 908 909 11912119 ) ) O O
14 910 913 11912119 and CC O O
15 914 916 11912119 of IN B-PP O
16 917 923 11912119 static JJ B-NP O
17 924 928 11912119 grip NN I-NP O
18 929 934 11912119 force NN I-NP O
19 935 937 11912119 by IN B-PP O
20 938 941 11912119 45% NN B-NP O
21 942 943 11912119 ( ( O O
22 943 944 11912119 P NN B-NP O
23 945 946 11912119 < SYM B-NP O
24 947 951 11912119 0.01 CD I-NP O
25 951 952 11912119 ) ) O O
26 953 956 11912119 was VBD B-VP O
27 957 965 11912119 observed VBN I-VP O
28 966 968 11912119 in IN B-PP O
29 969 972 11912119 the DT B-NP O
30 973 975 11912119 ON NN I-NP O
31 975 976 11912119 - HYPH B-ADJP O
32 977 985 11912119 compared VBN B-PP O
33 986 990 11912119 with IN B-PP O
34 991 994 11912119 the DT B-NP O
35 995 998 11912119 OFF NN I-NP O
36 998 999 11912119 - HYPH I-NP O
37 999 1003 11912119 drug NN I-NP O
38 1004 1013 11912119 condition NN I-NP O
39 1013 1014 11912119 . . O O

1 1015 1017 11912119 In IN B-PP O
2 1018 1026 11912119 contrast NN B-NP O
3 1026 1027 11912119 , , O O
4 1028 1030 11912119 no DT B-NP O
5 1031 1040 11912119 excessive JJ I-NP O
6 1041 1046 11912119 force NN I-NP O
7 1047 1050 11912119 was VBD B-VP O
8 1051 1056 11912119 found VBN I-VP O
9 1057 1059 11912119 in IN B-PP O
10 1060 1071 11912119 Parkinson's NNP B-NP D010300
11 1072 1079 11912119 disease NN I-NP D010300
12 1080 1081 11912119 - HYPH B-NP O
13 1082 1085 11912119 LID NN I-NP D004409
14 1085 1086 11912119 . . O O

1 1087 1091 11912119 Peak JJ B-NP O
2 1092 1096 11912119 grip NN I-NP O
3 1097 1102 11912119 force NN I-NP O
4 1103 1105 11912119 in IN B-PP O
5 1106 1108 11912119 ON NN B-NP O
6 1108 1109 11912119 - HYPH B-NP O
7 1109 1114 11912119 state NN I-NP O
8 1115 1118 11912119 was VBD B-VP O
9 1119 1123 11912119 140% NN B-NP O
10 1124 1125 11912119 ( ( O O
11 1125 1126 11912119 P NN B-NP O
12 1127 1128 11912119 < SYM B-NP O
13 1129 1133 11912119 0.05 CD I-NP O
14 1133 1134 11912119 ) ) O O
15 1135 1141 11912119 higher JJR B-ADJP O
16 1142 1144 11912119 in IN B-PP O
17 1145 1156 11912119 Parkinson's NNS B-NP D010300
18 1157 1164 11912119 disease NN I-NP D010300
19 1165 1166 11912119 + SYM B-NP O
20 1167 1170 11912119 LID NN I-NP D004409
21 1171 1175 11912119 than IN B-PP O
22 1176 1178 11912119 in IN B-PP O
23 1179 1190 11912119 Parkinson's NNP B-NP D010300
24 1191 1198 11912119 disease NN I-NP D010300
25 1199 1200 11912119 - HYPH B-NP O
26 1201 1204 11912119 LID NN I-NP D004409
27 1204 1205 11912119 , , O O
28 1206 1211 11912119 while IN B-SBAR O
29 1212 1218 11912119 static JJ B-NP O
30 1219 1223 11912119 grip NN I-NP O
31 1224 1229 11912119 force NN I-NP O
32 1230 1233 11912119 was VBD B-VP O
33 1234 1243 11912119 increased VBN I-VP O
34 1244 1246 11912119 by IN B-PP O
35 1247 1251 11912119 138% NN B-NP O
36 1252 1253 11912119 ( ( O O
37 1253 1254 11912119 P NN B-NP O
38 1255 1256 11912119 < SYM O O
39 1257 1261 11912119 0.01 CD B-NP O
40 1261 1262 11912119 ) ) O O
41 1263 1270 11912119 between IN B-PP O
42 1271 1277 11912119 groups NNS B-NP O
43 1277 1278 11912119 . . O O

1 1279 1287 11912119 Severity NN B-NP O
2 1288 1290 11912119 of IN B-PP O
3 1291 1295 11912119 peak NN B-NP O
4 1295 1296 11912119 - HYPH B-NP O
5 1296 1300 11912119 dose NN I-NP O
6 1301 1312 11912119 dyskinesias NNS I-NP D004409
7 1313 1316 11912119 was VBD B-VP O
8 1317 1325 11912119 strongly RB I-VP O
9 1326 1336 11912119 correlated VBN I-VP O
10 1337 1341 11912119 with IN B-PP O
11 1342 1346 11912119 grip NN B-NP O
12 1347 1352 11912119 force NN I-NP O
13 1353 1355 11912119 in IN B-PP O
14 1356 1358 11912119 ON NN B-NP O
15 1358 1359 11912119 - HYPH O O
16 1359 1364 11912119 state NN B-NP O
17 1365 1366 11912119 ( ( O O
18 1366 1367 11912119 r NN B-NP O
19 1368 1369 11912119 = SYM B-VP O
20 1370 1374 11912119 0.79 CD B-NP O
21 1375 1379 11912119 with IN B-PP O
22 1380 1384 11912119 peak JJ B-NP O
23 1385 1390 11912119 force NN I-NP O
24 1390 1391 11912119 , , O O
25 1392 1393 11912119 P NN B-NP O
26 1394 1395 11912119 < SYM B-NP O
27 1396 1400 11912119 0.01 CD I-NP O
28 1400 1401 11912119 ) ) O O
29 1401 1402 11912119 . . O O

1 1403 1405 11912119 No DT B-NP O
2 1406 1417 11912119 correlation NN I-NP O
3 1418 1421 11912119 was VBD B-VP O
4 1422 1430 11912119 observed VBN I-VP O
5 1431 1438 11912119 between IN B-PP O
6 1439 1445 11912119 forces NNS B-NP O
7 1446 1449 11912119 and CC O O
8 1450 1453 11912119 the DT B-NP O
9 1454 1459 11912119 motor NN I-NP O
10 1460 1465 11912119 score NN I-NP O
11 1466 1468 11912119 as RB B-CONJP O
12 1469 1473 11912119 well RB I-CONJP O
13 1474 1476 11912119 as IN I-CONJP O
14 1477 1481 11912119 with IN B-PP O
15 1482 1485 11912119 the DT B-NP O
16 1486 1491 11912119 daily JJ I-NP O
17 1492 1496 11912119 dose NN I-NP O
18 1497 1499 11912119 of IN B-PP O
19 1500 1512 11912119 dopaminergic JJ B-NP O
20 1513 1523 11912119 medication NN I-NP O
21 1523 1524 11912119 . . O O

1 1525 1530 11912119 Force NN B-NP O
2 1531 1537 11912119 excess NN I-NP O
3 1538 1541 11912119 was VBD B-VP O
4 1542 1546 11912119 only RB I-VP O
5 1547 1555 11912119 observed VBN I-VP O
6 1556 1558 11912119 in IN B-PP O
7 1559 1567 11912119 patients NNS B-NP O
8 1568 1572 11912119 with IN B-PP O
9 1573 1576 11912119 LID NN B-NP D004409
10 1577 1580 11912119 and CC I-NP O
11 1581 1586 11912119 motor NN I-NP O
12 1587 1599 11912119 fluctuations NNS I-NP O
13 1599 1600 11912119 . . O O

1 1601 1602 11912119 A DT B-NP O
2 1603 1608 11912119 close JJ I-NP O
3 1609 1621 11912119 relationship NN I-NP O
4 1622 1625 11912119 was VBD B-VP O
5 1626 1630 11912119 seen VBN I-VP O
6 1631 1638 11912119 between IN B-PP O
7 1639 1642 11912119 the DT B-NP O
8 1643 1655 11912119 overshooting NN I-NP O
9 1656 1658 11912119 of IN B-PP O
10 1659 1665 11912119 forces NNS B-NP O
11 1666 1669 11912119 and CC I-NP O
12 1670 1681 11912119 dyskinesias NNS I-NP D004409
13 1682 1684 11912119 in IN B-PP O
14 1685 1688 11912119 the DT B-NP O
15 1689 1691 11912119 ON NN I-NP O
16 1691 1692 11912119 - HYPH B-NP O
17 1692 1696 11912119 drug NN I-NP O
18 1697 1706 11912119 condition NN I-NP O
19 1706 1707 11912119 . . O O

1 1708 1710 11912119 We PRP B-NP O
2 1711 1720 11912119 postulate VBP B-VP O
3 1721 1725 11912119 that IN B-SBAR O
4 1726 1730 11912119 both CC O O
5 1731 1734 11912119 LID NN B-NP D004409
6 1735 1738 11912119 and CC I-NP O
7 1739 1743 11912119 grip NN I-NP O
8 1744 1749 11912119 force NN I-NP O
9 1750 1756 11912119 excess JJ I-NP O
10 1757 1762 11912119 share NN I-NP O
11 1763 1769 11912119 common JJ I-NP O
12 1770 1788 11912119 pathophysiological JJ I-NP O
13 1789 1799 11912119 mechanisms NNS I-NP O
14 1800 1807 11912119 related VBN B-VP O
15 1808 1810 11912119 to TO B-PP O
16 1811 1816 11912119 motor NN B-NP O
17 1817 1829 11912119 fluctuations NNS I-NP O
18 1829 1830 11912119 . . O O

1 0 0 21418164 -DOCSTART- -X- -X- O

1 0 4 21418164 CCNU NN B-NP D008130
2 5 6 21418164 ( ( O O
3 6 15 21418164 lomustine NN B-NP D008130
4 15 16 21418164 ) ) O O
5 17 25 21418164 toxicity NN B-NP D064420
6 26 28 21418164 in IN B-PP O
7 29 33 21418164 dogs NNS B-NP O
8 33 34 21418164 : : O O
9 35 36 21418164 a DT B-NP O
10 37 50 21418164 retrospective JJ I-NP O
11 51 56 21418164 study NN I-NP O
12 57 58 21418164 ( ( O O
13 58 62 21418164 2002 CD B-NP O
14 62 63 21418164 - HYPH I-NP O
15 63 65 21418164 07 CD I-NP O
16 65 66 21418164 ) ) O O
17 66 67 21418164 . . O O
18 68 77 21418164 OBJECTIVE NN B-NP O
19 77 78 21418164 : : O O
20 79 81 21418164 To TO B-VP O
21 82 90 21418164 describe VB I-VP O
22 91 94 21418164 the DT B-NP O
23 95 104 21418164 incidence NN I-NP O
24 105 107 21418164 of IN B-PP O
25 108 122 21418164 haematological JJ B-NP D006402
26 122 123 21418164 , , I-NP D006402
27 124 129 21418164 renal JJ I-NP D006402
28 129 130 21418164 , , I-NP D006402
29 131 138 21418164 hepatic JJ I-NP D006402
30 139 142 21418164 and CC I-NP D006402
31 143 159 21418164 gastrointestinal JJ I-NP D006402
32 160 170 21418164 toxicities NNS I-NP D006402
33 171 173 21418164 in IN B-PP O
34 174 180 21418164 tumour NN B-NP O
35 180 181 21418164 - HYPH O O
36 181 188 21418164 bearing VBG B-VP O
37 189 193 21418164 dogs NNS B-NP O
38 194 203 21418164 receiving VBG B-VP O
39 204 205 21418164 1 CD B-NP D008130
40 205 206 21418164 - HYPH B-NP D008130
41 206 208 21418164 (2 CD I-NP D008130
42 208 209 21418164 - HYPH I-NP D008130
43 209 221 21418164 chloroethyl) NN I-NP D008130
44 221 222 21418164 - HYPH B-NP D008130
45 222 223 21418164 3 CD I-NP D008130
46 223 224 21418164 - HYPH I-NP D008130
47 224 234 21418164 cyclohexyl NN I-NP D008130
48 234 235 21418164 - HYPH B-NP D008130
49 235 236 21418164 1 CD I-NP D008130
50 236 237 21418164 - HYPH I-NP D008130
51 237 248 21418164 nitrosourea NN I-NP D008130
52 249 250 21418164 ( ( O O
53 250 254 21418164 CCNU NN B-NP D008130
54 254 255 21418164 ) ) O O
55 255 256 21418164 . . O O

1 257 263 21418164 DESIGN NN B-NP O
2 263 264 21418164 : : O O
3 265 268 21418164 The DT B-NP O
4 269 276 21418164 medical JJ I-NP O
5 277 284 21418164 records NNS I-NP O
6 285 287 21418164 of IN B-PP O
7 288 291 21418164 206 CD B-NP O
8 292 296 21418164 dogs NNS I-NP O
9 297 301 21418164 that WDT B-NP O
10 302 306 21418164 were VBD B-VP O
11 307 314 21418164 treated VBN I-VP O
12 315 319 21418164 with IN B-PP O
13 320 324 21418164 CCNU NN B-NP D008130
14 325 327 21418164 at IN B-PP O
15 328 331 21418164 the DT B-NP O
16 332 341 21418164 Melbourne NNP I-NP O
17 342 352 21418164 Veterinary NNP I-NP O
18 353 363 21418164 Specialist NNP I-NP O
19 364 370 21418164 Centre NNP I-NP O
20 371 378 21418164 between IN B-PP O
21 379 387 21418164 February NNP B-NP O
22 388 392 21418164 2002 CD I-NP O
23 393 396 21418164 and CC O O
24 397 405 21418164 December NNP B-NP O
25 406 410 21418164 2007 CD I-NP O
26 411 415 21418164 were VBD B-VP O
27 416 431 21418164 retrospectively RB I-VP O
28 432 441 21418164 evaluated VBN I-VP O
29 441 442 21418164 . . O O

1 443 450 21418164 RESULTS NNS B-NP O
2 450 451 21418164 : : O O
3 452 454 21418164 Of IN B-PP O
4 455 458 21418164 the DT B-NP O
5 459 462 21418164 206 CD I-NP O
6 463 467 21418164 dogs NNS I-NP O
7 468 475 21418164 treated VBN B-VP O
8 476 480 21418164 with IN B-PP O
9 481 485 21418164 CCNU NN B-NP D008130
10 485 486 21418164 , , O O
11 487 490 21418164 185 CD B-NP O
12 491 494 21418164 met VBD B-VP O
13 495 498 21418164 the DT B-NP O
14 499 508 21418164 inclusion NN I-NP O
15 509 517 21418164 criteria NNS I-NP O
16 518 521 21418164 for IN B-PP O
17 522 524 21418164 at IN B-NP O
18 525 530 21418164 least JJS I-NP O
19 531 534 21418164 one CD I-NP O
20 535 540 21418164 class NN I-NP O
21 541 543 21418164 of IN B-PP O
22 544 552 21418164 toxicity NN B-NP D064420
23 552 553 21418164 . . O O

1 554 558 21418164 CCNU NN B-NP D008130
2 559 562 21418164 was VBD B-VP O
3 563 567 21418164 used VBN I-VP O
4 568 572 21418164 most RBS B-ADVP O
5 573 581 21418164 commonly RB I-ADVP O
6 582 584 21418164 in IN B-PP O
7 585 588 21418164 the DT B-NP O
8 589 598 21418164 treatment NN I-NP O
9 599 601 21418164 of IN B-PP O
10 602 610 21418164 lymphoma NN B-NP D008223
11 610 611 21418164 , , O O
12 612 616 21418164 mast NN B-NP D034801
13 617 621 21418164 cell NN I-NP D034801
14 622 628 21418164 tumour NN I-NP D034801
15 628 629 21418164 , , O O
16 630 635 21418164 brain NN B-NP D001932
17 636 642 21418164 tumour NN I-NP D001932
18 642 643 21418164 , , O O
19 644 655 21418164 histiocytic JJ B-NP D015620
20 656 663 21418164 tumours NNS I-NP D015620
21 664 667 21418164 and CC O O
22 668 683 21418164 epitheliotropic JJ B-NP D008223
23 684 692 21418164 lymphoma NN I-NP D008223
24 692 693 21418164 . . O O

1 694 704 21418164 Throughout IN B-PP O
2 705 714 21418164 treatment NN B-NP O
3 714 715 21418164 , , O O
4 716 721 21418164 56.9% CD B-NP O
5 722 724 21418164 of IN B-PP O
6 725 729 21418164 dogs NNS B-NP O
7 730 741 21418164 experienced VBD B-VP O
8 742 753 21418164 neutropenia NN B-NP D009503
9 753 754 21418164 , , O O
10 755 760 21418164 34.2% NN B-NP O
11 761 772 21418164 experienced VBD B-VP O
12 773 780 21418164 anaemia NN B-NP D000740
13 781 784 21418164 and CC I-NP O
14 785 790 21418164 14.2% NN I-NP O
15 791 802 21418164 experienced VBD B-VP O
16 803 819 21418164 thrombocytopenia NN B-NP D013921
17 819 820 21418164 . . O O

1 821 837 21418164 Gastrointestinal JJ B-NP D005767
2 838 847 21418164 toxicosis NN I-NP D005767
3 848 851 21418164 was VBD B-VP O
4 852 860 21418164 detected VBN I-VP O
5 861 863 21418164 in IN B-PP O
6 864 869 21418164 37.8% NN B-NP O
7 870 872 21418164 of IN B-PP O
8 873 877 21418164 dogs NNS B-NP O
9 877 878 21418164 , , O O
10 879 882 21418164 the DT B-NP O
11 883 887 21418164 most RBS I-NP O
12 888 894 21418164 common JJ I-NP O
13 895 899 21418164 sign NN I-NP O
14 900 902 21418164 of IN B-PP O
15 903 908 21418164 which WDT B-NP O
16 909 912 21418164 was VBD B-VP O
17 913 921 21418164 vomiting VBG I-VP D014839
18 922 923 21418164 ( ( O O
19 923 928 21418164 24.3% CD B-NP O
20 928 929 21418164 ) ) O O
21 929 930 21418164 . . O O

1 931 940 21418164 Potential JJ B-NP O
2 941 946 21418164 renal JJ I-NP O
3 947 955 21418164 toxicity NN I-NP D064420
4 956 959 21418164 and CC O O
5 960 968 21418164 elevated JJ B-NP O
6 969 976 21418164 alanine NN I-NP D000409
7 977 989 21418164 transaminase NN I-NP O
8 990 991 21418164 ( ( O O
9 991 994 21418164 ALT NN B-NP O
10 994 995 21418164 ) ) O O
11 996 1009 21418164 concentration NN B-NP O
12 1010 1014 21418164 were VBD B-VP O
13 1015 1023 21418164 reported VBN I-VP O
14 1024 1026 21418164 in IN B-PP O
15 1027 1032 21418164 12.2% NN B-NP O
16 1033 1036 21418164 and CC I-NP O
17 1037 1042 21418164 48.8% NN I-NP O
18 1043 1045 21418164 of IN B-PP O
19 1046 1050 21418164 dogs NNS B-NP O
20 1050 1051 21418164 , , O O
21 1052 1064 21418164 respectively RB B-ADVP O
22 1064 1065 21418164 . . O O

1 1066 1069 21418164 The DT B-NP O
2 1070 1079 21418164 incidence NN I-NP O
3 1080 1082 21418164 of IN B-PP O
4 1083 1090 21418164 hepatic JJ B-NP D017093
5 1091 1098 21418164 failure NN I-NP D017093
6 1099 1102 21418164 was VBD B-VP O
7 1103 1107 21418164 1.2% CD B-NP O
8 1107 1108 21418164 . . O O

1 1109 1120 21418164 CONCLUSIONS NNS B-NP O
2 1120 1121 21418164 : : O O
3 1122 1126 21418164 CCNU NN B-NP D008130
4 1126 1127 21418164 - HYPH O O
5 1127 1137 21418164 associated VBN B-NP O
6 1138 1146 21418164 toxicity NN I-NP D064420
7 1147 1149 21418164 in IN B-PP O
8 1150 1154 21418164 dogs NNS B-NP O
9 1155 1157 21418164 is VBZ B-VP O
10 1158 1164 21418164 common JJ B-ADJP O
11 1164 1165 21418164 , , O O
12 1166 1169 21418164 but CC O O
13 1170 1172 21418164 is VBZ B-VP O
14 1173 1180 21418164 usually RB B-ADVP O
15 1181 1184 21418164 not RB O O
16 1185 1189 21418164 life NN B-NP O
17 1190 1201 21418164 threatening NN I-NP O
18 1201 1202 21418164 . . O O

1 0 0 16584858 -DOCSTART- -X- -X- O

1 0 4 16584858 Role NN B-NP O
2 5 7 16584858 of IN B-PP O
3 8 18 16584858 mangiferin NN B-NP C013592
4 19 21 16584858 on IN B-PP O
5 22 33 16584858 biochemical JJ B-NP O
6 34 45 16584858 alterations NNS I-NP O
7 46 49 16584858 and CC O O
8 50 61 16584858 antioxidant JJ B-NP O
9 62 68 16584858 status NN I-NP O
10 69 71 16584858 in IN B-PP O
11 72 85 16584858 isoproterenol NN B-NP D007545
12 85 86 16584858 - HYPH B-NP O
13 86 93 16584858 induced VBN I-NP O
14 94 104 16584858 myocardial JJ I-NP D009203
15 105 115 16584858 infarction NN I-NP D009203
16 116 118 16584858 in IN B-PP O
17 119 123 16584858 rats NNS B-NP O
18 123 124 16584858 . . O O
19 125 128 16584858 The DT B-NP O
20 129 136 16584858 current JJ I-NP O
21 137 142 16584858 study NN I-NP O
22 143 148 16584858 dealt NN I-NP O
23 149 153 16584858 with IN B-PP O
24 154 157 16584858 the DT B-NP O
25 158 168 16584858 protective JJ I-NP O
26 169 173 16584858 role NN I-NP O
27 174 176 16584858 of IN B-PP O
28 177 187 16584858 mangiferin NN B-NP C013592
29 187 188 16584858 , , O O
30 189 190 16584858 a DT B-NP O
31 191 201 16584858 polyphenol NN I-NP D059808
32 202 206 16584858 from IN B-PP O
33 207 216 16584858 Mangifera NNP B-NP O
34 217 223 16584858 indica NNP I-NP O
35 224 228 16584858 Linn NNP I-NP O
36 228 229 16584858 . . O O
37 230 231 16584858 ( ( O O
38 231 244 16584858 Anacardiaceae NNP B-NP O
39 244 245 16584858 ) ) O O
40 245 246 16584858 , , O O
41 247 249 16584858 on IN B-PP O
42 250 263 16584858 isoproterenol NN B-NP D007545
43 264 265 16584858 ( ( O O
44 265 269 16584858 ISPH NN B-NP D007545
45 269 270 16584858 ) ) O O
46 270 271 16584858 - HYPH O O
47 271 278 16584858 induced VBN B-NP O
48 279 289 16584858 myocardial JJ I-NP D009203
49 290 300 16584858 infarction NN I-NP D009203
50 301 302 16584858 ( ( O O
51 302 304 16584858 MI NN B-NP D009203
52 304 305 16584858 ) ) O O
53 306 308 16584858 in IN B-PP O
54 309 313 16584858 rats NNS B-NP O
55 314 321 16584858 through IN B-PP O
56 322 325 16584858 its PRP$ B-NP O
57 326 339 16584858 antioxidative JJ I-NP O
58 340 349 16584858 mechanism NN I-NP O
59 349 350 16584858 . . O O

1 351 363 16584858 Subcutaneous JJ B-NP O
2 364 373 16584858 injection NN I-NP O
3 374 376 16584858 of IN B-PP O
4 377 381 16584858 ISPH NN B-NP D007545
5 382 383 16584858 ( ( O O
6 383 386 16584858 200 CD B-NP O
7 387 389 16584858 mg NN I-NP O
8 389 390 16584858 / SYM B-NP O
9 390 392 16584858 kg NN I-NP O
10 393 397 16584858 body NN I-NP O
11 398 404 16584858 weight NN I-NP O
12 405 407 16584858 in IN B-PP O
13 408 409 16584858 1 CD B-NP O
14 410 412 16584858 ml NN I-NP O
15 413 419 16584858 saline NN I-NP O
16 419 420 16584858 ) ) O O
17 421 423 16584858 to TO B-PP O
18 424 428 16584858 rats NNS B-NP O
19 429 432 16584858 for IN B-PP O
20 433 434 16584858 2 CD B-NP O
21 435 446 16584858 consecutive JJ I-NP O
22 447 451 16584858 days NNS I-NP O
23 452 458 16584858 caused VBD B-VP O
24 459 469 16584858 myocardial JJ B-NP D009202
25 470 476 16584858 damage NN I-NP D009202
26 477 479 16584858 in IN B-PP O
27 480 483 16584858 rat NN B-NP O
28 484 489 16584858 heart NN I-NP O
29 489 490 16584858 , , O O
30 491 496 16584858 which WDT B-NP O
31 497 500 16584858 was VBD B-VP O
32 501 511 16584858 determined VBN I-VP O
33 512 514 16584858 by IN B-PP O
34 515 518 16584858 the DT B-NP O
35 519 528 16584858 increased VBN I-NP O
36 529 537 16584858 activity NN I-NP O
37 538 540 16584858 of IN B-PP O
38 541 546 16584858 serum NN B-NP O
39 547 554 16584858 lactate NN I-NP D019344
40 555 568 16584858 dehydrogenase NN I-NP O
41 569 570 16584858 ( ( O O
42 570 573 16584858 LDH NN B-NP O
43 573 574 16584858 ) ) O O
44 575 578 16584858 and CC O O
45 579 587 16584858 creatine NN B-NP D003401
46 588 601 16584858 phosphokinase NN I-NP O
47 602 612 16584858 isoenzymes NNS I-NP O
48 613 614 16584858 ( ( O O
49 614 616 16584858 CK NN B-NP O
50 616 617 16584858 - HYPH O O
51 617 619 16584858 MB NN B-NP O
52 619 620 16584858 ) ) O O
53 620 621 16584858 , , O O
54 622 631 16584858 increased VBN B-NP O
55 632 636 16584858 uric JJ I-NP D014527
56 637 641 16584858 acid NN I-NP D014527
57 642 647 16584858 level NN I-NP O
58 648 651 16584858 and CC O O
59 652 659 16584858 reduced VBN B-NP O
60 660 666 16584858 plasma NN I-NP O
61 667 671 16584858 iron NN I-NP D007501
62 672 679 16584858 binding NN I-NP O
63 680 688 16584858 capacity NN I-NP O
64 688 689 16584858 . . O O

1 690 693 16584858 The DT B-NP O
2 694 704 16584858 protective JJ I-NP O
3 705 709 16584858 role NN I-NP O
4 710 712 16584858 of IN B-PP O
5 713 723 16584858 mangiferin NN B-NP C013592
6 724 727 16584858 was VBD B-VP O
7 728 736 16584858 analyzed VBN I-VP O
8 737 739 16584858 by IN B-PP O
9 740 749 16584858 triphenyl NN B-NP C009591
10 750 761 16584858 tetrazolium NN I-NP C009591
11 762 770 16584858 chloride NN I-NP C009591
12 771 772 16584858 ( ( O O
13 772 775 16584858 TTC NN B-NP C009591
14 775 776 16584858 ) ) O O
15 777 781 16584858 test NN B-NP O
16 782 786 16584858 used VBN B-VP O
17 787 790 16584858 for IN B-PP O
18 791 802 16584858 macroscopic JJ B-NP O
19 803 809 16584858 enzyme NN I-NP O
20 810 817 16584858 mapping NN I-NP O
21 818 823 16584858 assay NN I-NP O
22 824 826 16584858 of IN B-PP O
23 827 830 16584858 the DT B-NP O
24 831 839 16584858 ischemic JJ I-NP D017202
25 840 850 16584858 myocardium NN I-NP D017202
26 850 851 16584858 . . O O

1 852 855 16584858 The DT B-NP O
2 856 861 16584858 heart NN I-NP O
3 862 868 16584858 tissue NN I-NP O
4 869 880 16584858 antioxidant JJ I-NP O
5 881 888 16584858 enzymes NNS I-NP O
6 889 893 16584858 such JJ B-PP O
7 894 896 16584858 as IN I-PP O
8 897 907 16584858 superoxide NN B-NP D013481
9 908 917 16584858 dismutase NN I-NP O
10 917 918 16584858 , , O O
11 919 927 16584858 catalase NN B-NP O
12 927 928 16584858 , , O O
13 929 940 16584858 glutathione NN B-NP D005978
14 941 951 16584858 peroxidase NN I-NP O
15 951 952 16584858 , , O O
16 953 964 16584858 glutathione NN B-NP D005978
17 965 976 16584858 transferase NN I-NP O
18 977 980 16584858 and CC O O
19 981 992 16584858 glutathione NN B-NP D005978
20 993 1002 16584858 reductase NN I-NP O
21 1003 1013 16584858 activities NNS I-NP O
22 1013 1014 16584858 , , O O
23 1015 1018 16584858 non AFX B-NP O
24 1018 1019 16584858 - HYPH I-NP O
25 1019 1026 16584858 enzymic JJ B-NP O
26 1027 1039 16584858 antioxidants NNS I-NP O
27 1040 1044 16584858 such JJ B-PP O
28 1045 1047 16584858 as IN I-PP O
29 1048 1062 16584858 cerruloplasmin NN B-NP O
30 1062 1063 16584858 , , O O
31 1064 1071 16584858 Vitamin NNP B-NP D001205
32 1072 1073 16584858 C NNP I-NP D001205
33 1073 1074 16584858 , , O O
34 1075 1082 16584858 Vitamin NN B-NP D014810
35 1083 1084 16584858 E NN I-NP D014810
36 1085 1088 16584858 and CC I-NP O
37 1089 1100 16584858 glutathione NN I-NP D005978
38 1101 1107 16584858 levels NNS I-NP O
39 1108 1112 16584858 were VBD B-VP O
40 1113 1120 16584858 altered VBN I-VP O
41 1121 1123 16584858 in IN B-PP O
42 1124 1126 16584858 MI NN B-NP D009203
43 1127 1131 16584858 rats NNS I-NP O
44 1131 1132 16584858 . . O O

1 1133 1137 16584858 Upon IN B-PP O
2 1138 1150 16584858 pretreatment NN B-NP O
3 1151 1155 16584858 with IN B-PP O
4 1156 1166 16584858 mangiferin NN B-NP C013592
5 1167 1168 16584858 ( ( O O
6 1168 1171 16584858 100 CD B-NP O
7 1172 1174 16584858 mg NN I-NP O
8 1174 1175 16584858 / SYM B-NP O
9 1175 1177 16584858 kg NN I-NP O
10 1178 1182 16584858 body NN I-NP O
11 1183 1189 16584858 weight NN I-NP O
12 1190 1199 16584858 suspended VBN B-VP O
13 1200 1202 16584858 in IN B-PP O
14 1203 1204 16584858 2 CD B-NP O
15 1205 1207 16584858 ml NN I-NP O
16 1208 1210 16584858 of IN B-PP O
17 1211 1219 16584858 dimethyl NN B-NP D004121
18 1220 1230 16584858 sulphoxide NN I-NP D004121
19 1230 1231 16584858 ) ) O O
20 1232 1237 16584858 given VBN B-VP O
21 1238 1255 16584858 intraperitoneally RB B-ADVP O
22 1256 1259 16584858 for IN B-PP O
23 1260 1262 16584858 28 CD B-NP O
24 1263 1267 16584858 days NNS I-NP O
25 1268 1270 16584858 to TO B-PP O
26 1271 1273 16584858 MI NN B-NP D009203
27 1274 1278 16584858 rats NNS I-NP O
28 1279 1288 16584858 protected VBD B-VP O
29 1289 1292 16584858 the DT B-NP O
30 1293 1298 16584858 above RB I-NP O
31 1298 1299 16584858 - HYPH I-NP O
32 1299 1308 16584858 mentioned VBN I-NP O
33 1309 1319 16584858 parameters NNS I-NP O
34 1320 1322 16584858 to TO B-VP O
35 1323 1327 16584858 fall VB I-VP O
36 1328 1332 16584858 from IN B-PP O
37 1333 1336 16584858 the DT B-NP O
38 1337 1343 16584858 normal JJ I-NP O
39 1344 1350 16584858 levels NNS I-NP O
40 1350 1351 16584858 . . O O

1 1352 1362 16584858 Activities NNS B-NP O
2 1363 1365 16584858 of IN B-PP O
3 1366 1371 16584858 heart NN B-NP O
4 1372 1378 16584858 tissue NN I-NP O
5 1379 1386 16584858 enzymic JJ I-NP O
6 1387 1399 16584858 antioxidants NNS I-NP O
7 1400 1403 16584858 and CC I-NP O
8 1404 1409 16584858 serum NN I-NP O
9 1410 1413 16584858 non AFX O O
10 1413 1414 16584858 - HYPH B-NP O
11 1414 1421 16584858 enzymic JJ I-NP O
12 1422 1434 16584858 antioxidants NNS I-NP O
13 1435 1441 16584858 levels NNS I-NP O
14 1442 1446 16584858 rose VBD B-VP O
15 1447 1460 16584858 significantly RB B-ADVP O
16 1461 1465 16584858 upon IN B-PP O
17 1466 1476 16584858 mangiferin NN B-NP C013592
18 1477 1491 16584858 administration NN I-NP O
19 1492 1494 16584858 as IN B-SBAR O
20 1495 1503 16584858 compared VBN B-PP O
21 1504 1506 16584858 to TO B-PP O
22 1507 1511 16584858 ISPH NN B-NP D007545
23 1511 1512 16584858 - HYPH B-NP O
24 1512 1519 16584858 induced VBN I-NP O
25 1520 1522 16584858 MI NN I-NP D009203
26 1523 1527 16584858 rats NNS I-NP O
27 1527 1528 16584858 . . O O

1 1529 1533 16584858 From IN B-PP O
2 1534 1537 16584858 the DT B-NP O
3 1538 1545 16584858 present JJ I-NP O
4 1546 1551 16584858 study NN I-NP O
5 1552 1554 16584858 it PRP B-NP O
6 1555 1557 16584858 is VBZ B-VP O
7 1558 1567 16584858 concluded VBN I-VP O
8 1568 1572 16584858 that IN B-SBAR O
9 1573 1583 16584858 mangiferin NN B-NP C013592
10 1584 1590 16584858 exerts VBZ B-VP O
11 1591 1592 16584858 a DT B-NP O
12 1593 1603 16584858 beneficial JJ I-NP O
13 1604 1610 16584858 effect NN I-NP O
14 1611 1618 16584858 against IN B-PP O
15 1619 1623 16584858 ISPH NN B-NP D007545
16 1623 1624 16584858 - HYPH B-NP O
17 1624 1631 16584858 induced VBN I-NP O
18 1632 1634 16584858 MI NN I-NP D009203
19 1635 1638 16584858 due IN B-PP O
20 1639 1641 16584858 to TO B-PP O
21 1642 1645 16584858 its PRP$ B-NP O
22 1646 1657 16584858 antioxidant JJ I-NP O
23 1658 1667 16584858 potential NN I-NP O
24 1667 1668 16584858 , , O O
25 1669 1674 16584858 which WDT B-NP O
26 1675 1684 16584858 regulated VBD B-VP O
27 1685 1688 16584858 the DT B-NP O
28 1689 1696 16584858 tissues NNS I-NP O
29 1697 1704 16584858 defense NN I-NP O
30 1705 1711 16584858 system NN I-NP O
31 1712 1719 16584858 against IN B-PP O
32 1720 1727 16584858 cardiac JJ B-NP D006331
33 1728 1734 16584858 damage NN I-NP D006331
34 1734 1735 16584858 . . O O

1 0 0 7197363 -DOCSTART- -X- -X- O

1 0 3 7197363 REM NN B-NP D012892
2 4 9 7197363 sleep NN I-NP D012892
3 10 21 7197363 deprivation NN I-NP D012892
4 22 29 7197363 changes VBZ B-VP O
5 30 40 7197363 behavioral JJ B-NP O
6 41 49 7197363 response NN I-NP O
7 50 52 7197363 to TO B-PP O
8 53 70 7197363 catecholaminergic JJ B-NP O
9 71 74 7197363 and CC I-NP O
10 75 87 7197363 serotonergic JJ I-NP O
11 88 96 7197363 receptor NN I-NP O
12 97 107 7197363 activation NN I-NP O
13 108 110 7197363 in IN B-PP O
14 111 115 7197363 rats NNS B-NP O
15 115 116 7197363 . . O O
16 117 120 7197363 The DT B-NP O
17 121 128 7197363 effects NNS I-NP O
18 129 131 7197363 of IN B-PP O
19 132 135 7197363 REM NN B-NP D012892
20 136 141 7197363 sleep NN I-NP D012892
21 142 153 7197363 deprivation NN I-NP D012892
22 154 155 7197363 ( ( O O
23 155 159 7197363 REMD NN B-NP D012892
24 159 160 7197363 ) ) O O
25 161 163 7197363 on IN B-PP O
26 164 175 7197363 apomorphine NN B-NP D001058
27 175 176 7197363 - HYPH B-NP O
28 176 183 7197363 induced VBN I-NP O
29 184 198 7197363 aggressiveness NN I-NP D001523
30 199 202 7197363 and CC I-NP O
31 203 212 7197363 quipazine NN I-NP D011814
32 212 213 7197363 - HYPH B-NP O
33 213 220 7197363 induced VBN I-NP O
34 221 225 7197363 head NN I-NP D009069
35 226 234 7197363 twitches NNS I-NP D009069
36 235 237 7197363 in IN B-PP O
37 238 242 7197363 rats NNS B-NP O
38 243 247 7197363 were VBD B-VP O
39 248 258 7197363 determined VBN I-VP O
40 258 259 7197363 . . O O

1 260 265 7197363 Forty CD B-NP O
2 265 266 7197363 - HYPH I-NP O
3 266 271 7197363 eight CD I-NP O
4 272 274 7197363 hr NN I-NP O
5 275 277 7197363 of IN B-PP O
6 278 282 7197363 REMD NN B-NP D012892
7 283 292 7197363 increased VBD B-VP O
8 293 304 7197363 apomorphine NN B-NP D001058
9 304 305 7197363 - HYPH B-NP O
10 305 312 7197363 induced VBN I-NP O
11 313 327 7197363 aggressiveness NN I-NP D001523
12 327 328 7197363 , , O O
13 329 332 7197363 and CC O O
14 333 340 7197363 reduced VBN B-VP O
15 341 342 7197363 ( ( O O
16 342 353 7197363 immediately RB B-PP O
17 354 359 7197363 after IN I-PP O
18 360 370 7197363 completing VBG B-VP O
19 371 373 7197363 of IN B-PP O
20 374 378 7197363 REMD NN B-NP D012892
21 378 379 7197363 ) ) O O
22 380 382 7197363 or CC O O
23 383 392 7197363 increased VBN B-VP O
24 393 394 7197363 ( ( O O
25 394 396 7197363 96 CD B-NP O
26 397 399 7197363 hr NN I-NP O
27 400 405 7197363 after IN B-PP O
28 406 416 7197363 completing VBG B-VP O
29 417 419 7197363 of IN B-PP O
30 420 424 7197363 REMD NN B-NP D012892
31 424 425 7197363 ) ) O O
32 426 435 7197363 quipazine NN B-NP D011814
33 435 436 7197363 - HYPH B-PP O
34 436 443 7197363 induced VBN B-NP O
35 444 448 7197363 head NN I-NP D009069
36 449 457 7197363 twitches NNS I-NP D009069
37 457 458 7197363 . . O O

1 459 466 7197363 Results NNS B-NP O
2 467 470 7197363 are VBP B-VP O
3 471 480 7197363 discussed VBN I-VP O
4 481 483 7197363 in IN B-PP O
5 484 489 7197363 terms NNS B-NP O
6 490 492 7197363 of IN B-PP O
7 493 503 7197363 similarity NN B-NP O
8 504 506 7197363 to TO B-PP O
9 507 522 7197363 pharmacological JJ B-NP O
10 523 530 7197363 effects NNS I-NP O
11 531 533 7197363 of IN B-PP O
12 534 539 7197363 other JJ B-NP O
13 540 554 7197363 antidepressive JJ I-NP O
14 555 565 7197363 treatments NNS I-NP O
15 565 566 7197363 . . O O

1 0 0 19370593 -DOCSTART- -X- -X- O

1 0 4 19370593 Long JJ B-NP O
2 5 9 19370593 term NN I-NP O
3 10 17 19370593 hormone NN I-NP O
4 18 25 19370593 therapy NN I-NP O
5 26 29 19370593 for IN B-PP O
6 30 44 19370593 perimenopausal JJ B-NP O
7 45 48 19370593 and CC I-NP O
8 49 63 19370593 postmenopausal JJ I-NP O
9 64 69 19370593 women NNS I-NP O
10 69 70 19370593 . . I-NP O
11 71 81 19370593 BACKGROUND NN I-NP O
12 81 82 19370593 : : O O
13 83 90 19370593 Hormone NN B-NP O
14 91 98 19370593 therapy NN I-NP O
15 99 100 19370593 ( ( O O
16 100 102 19370593 HT NN B-NP O
17 102 103 19370593 ) ) O O
18 104 106 19370593 is VBZ B-VP O
19 107 113 19370593 widely RB I-VP O
20 114 118 19370593 used VBN I-VP O
21 119 122 19370593 for IN B-PP O
22 123 134 19370593 controlling VBG B-VP O
23 135 145 19370593 menopausal JJ B-NP O
24 146 154 19370593 symptoms NNS I-NP O
25 155 158 19370593 and CC O O
26 159 162 19370593 has VBZ B-VP O
27 163 167 19370593 also RB I-VP O
28 168 172 19370593 been VBN I-VP O
29 173 177 19370593 used VBN I-VP O
30 178 181 19370593 for IN B-PP O
31 182 185 19370593 the DT B-NP O
32 186 196 19370593 management NN I-NP O
33 197 200 19370593 and CC I-NP O
34 201 211 19370593 prevention NN I-NP O
35 212 214 19370593 of IN B-PP O
36 215 229 19370593 cardiovascular JJ B-NP D002318
37 230 237 19370593 disease NN I-NP D002318
38 237 238 19370593 , , O O
39 239 251 19370593 osteoporosis NN B-NP D010024
40 252 255 19370593 and CC I-NP O
41 256 264 19370593 dementia NN I-NP D003704
42 265 267 19370593 in IN B-PP O
43 268 273 19370593 older JJR B-NP O
44 274 279 19370593 women NNS I-NP O
45 279 280 19370593 . . O O

1 281 285 19370593 This DT B-NP O
2 286 288 19370593 is VBZ B-VP O
3 289 291 19370593 an DT B-NP O
4 292 299 19370593 updated VBN I-NP O
5 300 307 19370593 version NN I-NP O
6 308 310 19370593 of IN B-PP O
7 311 314 19370593 the DT B-NP O
8 315 323 19370593 original JJ I-NP O
9 324 332 19370593 Cochrane NN I-NP O
10 333 339 19370593 review NN I-NP O
11 340 345 19370593 first RB B-VP O
12 346 355 19370593 published VBN I-VP O
13 356 358 19370593 in IN B-PP O
14 359 363 19370593 2005 CD B-NP O
15 363 364 19370593 . . O O

1 365 375 19370593 OBJECTIVES NNS B-NP O
2 375 376 19370593 : : O O
3 377 379 19370593 To TO B-VP O
4 380 386 19370593 assess VB I-VP O
5 387 390 19370593 the DT B-NP O
6 391 397 19370593 effect NN I-NP O
7 398 400 19370593 of IN B-PP O
8 401 405 19370593 long JJ B-NP O
9 405 406 19370593 - HYPH I-NP O
10 406 410 19370593 term NN I-NP O
11 411 413 19370593 HT NN I-NP O
12 414 416 19370593 on IN B-PP O
13 417 426 19370593 mortality NN B-NP O
14 426 427 19370593 , , O O
15 428 442 19370593 cardiovascular JJ B-NP O
16 443 451 19370593 outcomes NNS I-NP O
17 451 452 19370593 , , O O
18 453 459 19370593 cancer NN B-NP D009369
19 459 460 19370593 , , O O
20 461 472 19370593 gallbladder NN B-NP D005705
21 473 480 19370593 disease NN I-NP D005705
22 480 481 19370593 , , O O
23 482 491 19370593 cognition NN B-NP O
24 491 492 19370593 , , O O
25 493 502 19370593 fractures NNS B-NP D050723
26 503 506 19370593 and CC O O
27 507 514 19370593 quality NN B-NP O
28 515 517 19370593 of IN B-PP O
29 518 522 19370593 life NN B-NP O
30 522 523 19370593 . . O O

1 524 530 19370593 SEARCH NN B-NP O
2 531 539 19370593 STRATEGY NN I-NP O
3 539 540 19370593 : : O O
4 541 543 19370593 We PRP B-NP O
5 544 552 19370593 searched VBD B-VP O
6 553 556 19370593 the DT B-NP O
7 557 566 19370593 following VBG I-NP O
8 567 576 19370593 databases NNS I-NP O
9 577 579 19370593 to TO B-PP O
10 580 588 19370593 November NNP B-NP O
11 589 593 19370593 2007 CD I-NP O
12 593 594 19370593 : : O O
13 595 601 19370593 Trials NNS B-NP O
14 602 610 19370593 Register NN I-NP O
15 611 613 19370593 of IN B-PP O
16 614 617 19370593 the DT B-NP O
17 618 626 19370593 Cochrane NNP I-NP O
18 627 636 19370593 Menstrual NNP I-NP D008599
19 637 646 19370593 Disorders NNP I-NP D008599
20 647 650 19370593 and CC O O
21 651 663 19370593 Subfertility NNP B-NP O
22 664 669 19370593 Group NNP I-NP O
23 669 670 19370593 , , O O
24 671 679 19370593 Cochrane NNP B-NP O
25 680 687 19370593 Central NNP I-NP O
26 688 696 19370593 Register NNP I-NP O
27 697 699 19370593 of IN B-PP O
28 700 710 19370593 Controlled NNP B-NP O
29 711 717 19370593 Trials NNPS I-NP O
30 717 718 19370593 , , O O
31 719 726 19370593 MEDLINE NNP B-NP O
32 726 727 19370593 , , O O
33 728 734 19370593 EMBASE NNP B-NP O
34 734 735 19370593 , , O O
35 736 746 19370593 Biological NNP B-NP O
36 747 756 19370593 Abstracts NNPS I-NP O
37 756 757 19370593 . . O O

1 758 762 19370593 Also RB B-NP O
2 763 771 19370593 relevant JJ I-NP O
3 772 775 19370593 non AFX I-NP O
4 775 776 19370593 - HYPH I-NP O
5 776 783 19370593 indexed JJ I-NP O
6 784 792 19370593 journals NNS I-NP O
7 793 796 19370593 and CC O O
8 797 807 19370593 conference NN B-NP O
9 808 817 19370593 abstracts NNS I-NP O
10 817 818 19370593 . . O O

1 819 828 19370593 SELECTION NN B-NP O
2 829 837 19370593 CRITERIA NN I-NP O
3 837 838 19370593 : : O O
4 839 849 19370593 Randomised VBN B-NP O
5 850 856 19370593 double JJ I-NP O
6 856 857 19370593 - HYPH I-NP O
7 857 862 19370593 blind JJ I-NP O
8 863 869 19370593 trials NNS I-NP O
9 870 872 19370593 of IN B-PP O
10 873 875 19370593 HT NN B-NP O
11 876 882 19370593 versus IN B-PP O
12 883 890 19370593 placebo NN B-NP O
13 890 891 19370593 , , O O
14 892 897 19370593 taken VBN B-VP O
15 898 901 19370593 for IN B-PP O
16 902 904 19370593 at IN B-NP O
17 905 910 19370593 least JJS I-NP O
18 911 914 19370593 one CD I-NP O
19 915 919 19370593 year NN I-NP O
20 920 922 19370593 by IN B-PP O
21 923 937 19370593 perimenopausal JJ B-NP O
22 938 940 19370593 or CC I-NP O
23 941 955 19370593 postmenopausal JJ I-NP O
24 956 961 19370593 women NNS I-NP O
25 961 962 19370593 . . O O

1 963 965 19370593 HT NN B-NP O
2 966 974 19370593 included VBD B-VP O
3 975 985 19370593 oestrogens NNS B-NP D004967
4 985 986 19370593 , , O O
5 987 991 19370593 with IN B-PP O
6 992 994 19370593 or CC B-PP O
7 995 1002 19370593 without IN B-PP O
8 1003 1015 19370593 progestogens NNS B-NP D011374
9 1015 1016 19370593 , , O O
10 1017 1020 19370593 via IN B-PP O
11 1021 1025 19370593 oral JJ B-NP O
12 1025 1026 19370593 , , I-NP O
13 1027 1038 19370593 transdermal JJ I-NP O
14 1038 1039 19370593 , , I-NP O
15 1040 1052 19370593 subcutaneous JJ I-NP O
16 1053 1055 19370593 or CC I-NP O
17 1056 1066 19370593 transnasal JJ I-NP O
18 1067 1073 19370593 routes NNS I-NP O
19 1073 1074 19370593 . . O O

1 1075 1079 19370593 DATA NNP B-NP O
2 1080 1090 19370593 COLLECTION NNP I-NP O
3 1091 1094 19370593 AND CC O O
4 1095 1103 19370593 ANALYSIS NNP B-NP O
5 1103 1104 19370593 : : O O
6 1105 1108 19370593 Two CD B-NP O
7 1109 1116 19370593 authors NNS I-NP O
8 1117 1130 19370593 independently RB B-ADVP O
9 1131 1139 19370593 assessed VBD B-VP O
10 1140 1145 19370593 trial NN B-NP O
11 1146 1153 19370593 quality NN I-NP O
12 1154 1157 19370593 and CC O O
13 1158 1167 19370593 extracted VBN B-NP O
14 1168 1172 19370593 data NNS I-NP O
15 1172 1173 19370593 . . O O

1 1174 1178 19370593 MAIN NN B-NP O
2 1179 1186 19370593 RESULTS NNS I-NP O
3 1186 1187 19370593 : : O O
4 1188 1196 19370593 Nineteen CD B-NP O
5 1197 1203 19370593 trials NNS I-NP O
6 1204 1213 19370593 involving VBG B-VP O
7 1214 1220 19370593 41,904 CD B-NP O
8 1221 1226 19370593 women NNS I-NP O
9 1227 1231 19370593 were VBD B-VP O
10 1232 1240 19370593 included VBN I-VP O
11 1240 1241 19370593 . . O O

1 1242 1244 19370593 In IN B-PP O
2 1245 1255 19370593 relatively RB B-NP O
3 1256 1263 19370593 healthy JJ I-NP O
4 1264 1269 19370593 women NNS I-NP O
5 1269 1270 19370593 , , O O
6 1271 1279 19370593 combined JJ B-NP O
7 1280 1290 19370593 continuous JJ I-NP O
8 1291 1293 19370593 HT NN I-NP O
9 1294 1307 19370593 significantly RB B-ADVP O
10 1308 1317 19370593 increased VBD B-VP O
11 1318 1321 19370593 the DT B-NP O
12 1322 1326 19370593 risk NN I-NP O
13 1327 1329 19370593 of IN B-PP O
14 1330 1336 19370593 venous JJ B-NP D054556
15 1337 1344 19370593 thrombo AFX I-NP D054556
16 1344 1345 19370593 - HYPH I-NP D054556
17 1345 1353 19370593 embolism NN I-NP D054556
18 1354 1356 19370593 or CC I-NP O
19 1357 1365 19370593 coronary JJ I-NP O
20 1366 1371 19370593 event NN I-NP O
21 1372 1373 19370593 ( ( O O
22 1373 1378 19370593 after IN B-PP O
23 1379 1382 19370593 one CD B-NP O
24 1383 1389 19370593 year's NNS I-NP O
25 1390 1393 19370593 use NN I-NP O
26 1393 1394 19370593 ) ) O O
27 1394 1395 19370593 , , O O
28 1396 1402 19370593 stroke NN B-NP D020521
29 1403 1404 19370593 ( ( O O
30 1404 1409 19370593 after IN B-PP O
31 1410 1415 19370593 three CD B-NP O
32 1416 1421 19370593 years NNS I-NP O
33 1421 1422 19370593 ) ) O O
34 1422 1423 19370593 , , O O
35 1424 1430 19370593 breast NN B-NP D001943
36 1431 1437 19370593 cancer NN I-NP D001943
37 1438 1441 19370593 and CC O O
38 1442 1453 19370593 gallbladder NN B-NP D005705
39 1454 1461 19370593 disease NN I-NP D005705
40 1461 1462 19370593 . . O O

1 1463 1467 19370593 Long JJ B-NP O
2 1467 1468 19370593 - HYPH I-NP O
3 1468 1472 19370593 term NN I-NP O
4 1473 1482 19370593 oestrogen NN I-NP D004967
5 1482 1483 19370593 - HYPH B-VP O
6 1483 1487 19370593 only RB B-NP O
7 1488 1490 19370593 HT NN I-NP O
8 1491 1504 19370593 significantly RB B-ADVP O
9 1505 1514 19370593 increased VBD B-VP O
10 1515 1518 19370593 the DT B-NP O
11 1519 1523 19370593 risk NN I-NP O
12 1524 1526 19370593 of IN B-PP O
13 1527 1533 19370593 venous JJ B-NP D054556
14 1534 1541 19370593 thrombo AFX I-NP D054556
15 1541 1542 19370593 - HYPH I-NP D054556
16 1542 1550 19370593 embolism NN I-NP D054556
17 1550 1551 19370593 , , I-NP O
18 1552 1558 19370593 stroke NN I-NP D020521
19 1559 1562 19370593 and CC I-NP O
20 1563 1574 19370593 gallbladder NN I-NP D005705
21 1575 1582 19370593 disease NN I-NP D005705
22 1583 1584 19370593 ( ( O O
23 1584 1589 19370593 after IN B-PP O
24 1590 1593 19370593 one CD B-NP O
25 1594 1596 19370593 to TO B-PP O
26 1597 1600 19370593 two CD B-NP O
27 1601 1606 19370593 years NNS I-NP O
28 1606 1607 19370593 , , O O
29 1608 1613 19370593 three CD B-NP O
30 1614 1619 19370593 years NNS I-NP O
31 1620 1623 19370593 and CC O O
32 1624 1629 19370593 seven CD B-NP O
33 1630 1635 19370593 years NNS I-NP O
34 1635 1636 19370593 ' POS B-NP O
35 1637 1640 19370593 use NN I-NP O
36 1641 1653 19370593 respectively RB B-ADVP O
37 1653 1654 19370593 ) ) O O
38 1654 1655 19370593 , , O O
39 1656 1659 19370593 but CC O O
40 1660 1663 19370593 did VBD B-VP O
41 1664 1667 19370593 not RB I-VP O
42 1668 1681 19370593 significantly RB I-VP O
43 1682 1690 19370593 increase VB I-VP O
44 1691 1694 19370593 the DT B-NP O
45 1695 1699 19370593 risk NN I-NP O
46 1700 1702 19370593 of IN B-PP O
47 1703 1709 19370593 breast NN B-NP D001943
48 1710 1716 19370593 cancer NN I-NP D001943
49 1716 1717 19370593 . . O O

1 1718 1721 19370593 The DT B-NP O
2 1722 1726 19370593 only RB I-NP O
3 1727 1740 19370593 statistically RB I-NP O
4 1741 1752 19370593 significant JJ I-NP O
5 1753 1761 19370593 benefits NNS I-NP O
6 1762 1764 19370593 of IN B-PP O
7 1765 1767 19370593 HT NN B-NP O
8 1768 1772 19370593 were VBD B-VP O
9 1773 1774 19370593 a DT B-NP O
10 1775 1784 19370593 decreased VBN I-NP O
11 1785 1794 19370593 incidence NN I-NP O
12 1795 1797 19370593 of IN B-PP O
13 1798 1807 19370593 fractures NNS B-NP D050723
14 1808 1811 19370593 and CC O O
15 1812 1813 19370593 ( ( O O
16 1813 1816 19370593 for IN B-PP O
17 1817 1825 19370593 combined VBN B-NP O
18 1826 1828 19370593 HT NN I-NP O
19 1828 1829 19370593 ) ) O O
20 1830 1835 19370593 colon NN B-NP D003110
21 1836 1842 19370593 cancer NN I-NP D003110
22 1842 1843 19370593 , , O O
23 1844 1848 19370593 with IN B-PP O
24 1849 1853 19370593 long JJ B-NP O
25 1853 1854 19370593 - HYPH I-NP O
26 1854 1858 19370593 term NN I-NP O
27 1859 1862 19370593 use NN I-NP O
28 1862 1863 19370593 . . O O

1 1864 1869 19370593 Among IN B-PP O
2 1870 1875 19370593 women NNS B-NP O
3 1876 1880 19370593 aged VBN B-VP O
4 1881 1885 19370593 over IN B-PP O
5 1886 1888 19370593 65 CD B-NP O
6 1889 1892 19370593 who WP B-NP O
7 1893 1897 19370593 were VBD B-VP O
8 1898 1908 19370593 relatively RB B-ADJP O
9 1909 1916 19370593 healthy JJ I-ADJP O
10 1917 1918 19370593 ( ( O O
11 1918 1922 19370593 i.e. FW B-NP O
12 1923 1932 19370593 generally RB B-ADVP O
13 1933 1936 19370593 fit VBP B-VP O
14 1936 1937 19370593 , , O O
15 1938 1945 19370593 without IN B-PP O
16 1946 1951 19370593 overt JJ B-NP O
17 1952 1959 19370593 disease NN I-NP O
18 1959 1960 19370593 ) ) O O
19 1961 1964 19370593 and CC O O
20 1965 1971 19370593 taking VBG B-VP O
21 1972 1982 19370593 continuous JJ B-NP O
22 1983 1991 19370593 combined VBN I-NP O
23 1992 1994 19370593 HT NN I-NP O
24 1994 1995 19370593 , , O O
25 1996 2001 19370593 there EX B-NP O
26 2002 2005 19370593 was VBD B-VP O
27 2006 2007 19370593 a DT B-NP O
28 2008 2021 19370593 statistically RB I-NP O
29 2022 2033 19370593 significant JJ I-NP O
30 2034 2042 19370593 increase NN I-NP O
31 2043 2045 19370593 in IN B-PP O
32 2046 2049 19370593 the DT B-NP O
33 2050 2059 19370593 incidence NN I-NP O
34 2060 2062 19370593 of IN B-PP O
35 2063 2071 19370593 dementia NN B-NP D003704
36 2071 2072 19370593 . . O O

1 2073 2078 19370593 Among IN B-PP O
2 2079 2084 19370593 women NNS B-NP O
3 2085 2089 19370593 with IN B-PP O
4 2090 2104 19370593 cardiovascular JJ B-NP D002318
5 2105 2112 19370593 disease NN I-NP D002318
6 2112 2113 19370593 , , O O
7 2114 2118 19370593 long JJ B-NP O
8 2118 2119 19370593 - HYPH I-NP O
9 2119 2123 19370593 term NN I-NP O
10 2124 2127 19370593 use NN I-NP O
11 2128 2130 19370593 of IN B-PP O
12 2131 2139 19370593 combined JJ B-NP O
13 2140 2150 19370593 continuous JJ I-NP O
14 2151 2153 19370593 HT NN I-NP O
15 2154 2167 19370593 significantly RB B-ADVP O
16 2168 2177 19370593 increased VBD B-VP O
17 2178 2181 19370593 the DT B-NP O
18 2182 2186 19370593 risk NN I-NP O
19 2187 2189 19370593 of IN B-PP O
20 2190 2196 19370593 venous JJ B-NP D054556
21 2197 2204 19370593 thrombo AFX I-NP D054556
22 2204 2205 19370593 - HYPH I-NP D054556
23 2205 2217 19370593 embolism.One NN I-NP D054556
24 2218 2223 19370593 trial NN I-NP O
25 2224 2232 19370593 analysed VBD B-VP O
26 2233 2242 19370593 subgroups NNS B-NP O
27 2243 2245 19370593 of IN B-PP O
28 2246 2250 19370593 2839 CD B-NP O
29 2251 2261 19370593 relatively RB I-NP O
30 2262 2269 19370593 healthy JJ I-NP O
31 2270 2272 19370593 50 CD I-NP O
32 2273 2275 19370593 to TO I-NP O
33 2276 2278 19370593 59 CD I-NP O
34 2279 2283 19370593 year NN I-NP O
35 2284 2287 19370593 old JJ I-NP O
36 2288 2293 19370593 women NNS I-NP O
37 2294 2300 19370593 taking VBG B-VP O
38 2301 2309 19370593 combined JJ B-NP O
39 2310 2320 19370593 continuous JJ I-NP O
40 2321 2323 19370593 HT NN I-NP O
41 2324 2327 19370593 and CC O O
42 2328 2332 19370593 1637 CD B-NP O
43 2333 2339 19370593 taking VBG I-NP O
44 2340 2349 19370593 oestrogen NN I-NP D004967
45 2349 2350 19370593 - HYPH B-VP O
46 2350 2354 19370593 only RB B-NP O
47 2355 2357 19370593 HT NN I-NP O
48 2357 2358 19370593 , , O O
49 2359 2365 19370593 versus IN B-PP O
50 2366 2373 19370593 similar JJ B-NP O
51 2373 2374 19370593 - HYPH I-NP O
52 2374 2379 19370593 sized JJ I-NP O
53 2380 2387 19370593 placebo NN I-NP O
54 2388 2394 19370593 groups NNS I-NP O
55 2394 2395 19370593 . . O O

1 2396 2399 19370593 The DT B-NP O
2 2400 2404 19370593 only RB I-NP O
3 2405 2418 19370593 significantly RB I-NP O
4 2419 2428 19370593 increased VBD B-VP O
5 2429 2433 19370593 risk NN B-NP O
6 2434 2442 19370593 reported VBN B-VP O
7 2443 2446 19370593 was VBD B-VP O
8 2447 2450 19370593 for IN B-PP O
9 2451 2457 19370593 venous JJ B-NP D054556
10 2458 2465 19370593 thrombo AFX I-NP D054556
11 2465 2466 19370593 - HYPH I-NP D054556
12 2466 2474 19370593 embolism NN I-NP D054556
13 2475 2477 19370593 in IN B-PP O
14 2478 2483 19370593 women NNS B-NP O
15 2484 2490 19370593 taking VBG B-VP O
16 2491 2499 19370593 combined JJ B-NP O
17 2500 2510 19370593 continuous JJ I-NP O
18 2511 2513 19370593 HT NN I-NP O
19 2513 2514 19370593 : : O O
20 2515 2520 19370593 their PRP$ B-NP O
21 2521 2529 19370593 absolute JJ I-NP O
22 2530 2534 19370593 risk NN I-NP O
23 2535 2543 19370593 remained VBD B-VP O
24 2544 2547 19370593 low JJ B-ADJP O
25 2547 2548 19370593 , , O O
26 2549 2551 19370593 at IN B-PP O
27 2552 2556 19370593 less JJR B-NP O
28 2557 2561 19370593 than IN I-NP O
29 2562 2563 19370593 1 CD I-NP O
30 2563 2564 19370593 / SYM I-NP O
31 2564 2567 19370593 500 CD I-NP O
32 2567 2568 19370593 . . O O

1 2569 2576 19370593 However RB B-ADVP O
2 2576 2577 19370593 , , O O
3 2578 2582 19370593 this DT B-NP O
4 2583 2588 19370593 study NN I-NP O
5 2589 2592 19370593 was VBD B-VP O
6 2593 2596 19370593 not RB I-VP O
7 2597 2604 19370593 powered VBN I-VP O
8 2605 2607 19370593 to TO I-VP O
9 2608 2614 19370593 detect VB I-VP O
10 2615 2626 19370593 differences NNS B-NP O
11 2627 2634 19370593 between IN B-PP O
12 2635 2641 19370593 groups NNS B-NP O
13 2642 2644 19370593 of IN B-PP O
14 2645 2652 19370593 younger JJR B-NP O
15 2653 2658 19370593 women NNS I-NP O
16 2658 2659 19370593 . . O O

1 2660 2667 19370593 AUTHORS NNS B-NP O
2 2667 2668 19370593 ' POS B-NP O
3 2669 2680 19370593 CONCLUSIONS NNS I-NP O
4 2680 2681 19370593 : : O O
5 2682 2684 19370593 HT NN B-NP O
6 2685 2687 19370593 is VBZ B-VP O
7 2688 2691 19370593 not RB I-VP O
8 2692 2701 19370593 indicated VBN I-VP O
9 2702 2705 19370593 for IN B-PP O
10 2706 2709 19370593 the DT B-NP O
11 2710 2717 19370593 routine JJ I-NP O
12 2718 2728 19370593 management NN I-NP O
13 2729 2731 19370593 of IN B-PP O
14 2732 2739 19370593 chronic JJ B-NP O
15 2740 2747 19370593 disease NN I-NP O
16 2747 2748 19370593 . . O O

1 2749 2751 19370593 We PRP B-NP O
2 2752 2756 19370593 need VBP B-VP O
3 2757 2761 19370593 more JJR B-NP O
4 2762 2770 19370593 evidence NN I-NP O
5 2771 2773 19370593 on IN B-PP O
6 2774 2777 19370593 the DT B-NP O
7 2778 2784 19370593 safety NN I-NP O
8 2785 2787 19370593 of IN B-PP O
9 2788 2790 19370593 HT NN B-NP O
10 2791 2794 19370593 for IN B-PP O
11 2795 2805 19370593 menopausal JJ B-NP O
12 2806 2813 19370593 symptom NN I-NP O
13 2814 2821 19370593 control NN I-NP O
14 2821 2822 19370593 , , O O
15 2823 2829 19370593 though IN B-SBAR O
16 2830 2835 19370593 short JJ B-NP O
17 2835 2836 19370593 - HYPH I-NP O
18 2836 2840 19370593 term NN I-NP O
19 2841 2844 19370593 use NN I-NP O
20 2845 2852 19370593 appears VBZ B-VP O
21 2853 2855 19370593 to TO I-VP O
22 2856 2858 19370593 be VB I-VP O
23 2859 2869 19370593 relatively RB B-ADJP O
24 2870 2874 19370593 safe JJ I-ADJP O
25 2875 2878 19370593 for IN B-PP O
26 2879 2886 19370593 healthy JJ B-NP O
27 2887 2894 19370593 younger JJR I-NP O
28 2895 2900 19370593 women NNS I-NP O
29 2900 2901 19370593 . . O O

1 0 0 6540303 -DOCSTART- -X- -X- O

1 0 7 6540303 Effects NNS B-NP O
2 8 10 6540303 of IN B-PP O
3 11 16 6540303 amine NN B-NP D000588
4 17 29 6540303 pretreatment NN I-NP O
5 30 32 6540303 on IN B-PP O
6 33 41 6540303 ketamine NN B-NP D007649
7 42 51 6540303 catatonia NN I-NP D002389
8 52 54 6540303 in IN B-PP O
9 55 70 6540303 pinealectomized VBN B-NP O
10 71 73 6540303 or CC I-NP O
11 74 91 6540303 hypophysectomized VBN I-NP O
12 92 99 6540303 animals NNS I-NP O
13 99 100 6540303 . . O O
14 101 104 6540303 The DT B-NP O
15 105 112 6540303 present JJ I-NP O
16 113 120 6540303 studies NNS I-NP O
17 121 125 6540303 were VBD B-VP O
18 126 134 6540303 designed VBN I-VP O
19 135 137 6540303 to TO B-VP O
20 138 145 6540303 clarify VB I-VP O
21 146 149 6540303 the DT B-NP O
22 150 154 6540303 role NN I-NP O
23 155 157 6540303 of IN B-PP O
24 158 172 6540303 catecholamines NNS B-NP D002395
25 173 176 6540303 and CC O O
26 177 183 6540303 pineal JJ B-NP O
27 184 194 6540303 idolamines NNS I-NP O
28 195 197 6540303 on IN B-PP O
29 198 206 6540303 ketamine NN B-NP D007649
30 206 207 6540303 - HYPH B-NP O
31 207 214 6540303 induced VBN I-NP O
32 215 224 6540303 catatonia NN I-NP D002389
33 225 227 6540303 in IN B-PP O
34 228 231 6540303 the DT B-NP O
35 232 238 6540303 intact JJ I-NP O
36 238 239 6540303 , , I-NP O
37 240 255 6540303 pinealectomized VBN I-NP O
38 256 258 6540303 or CC I-NP O
39 259 276 6540303 hypophysectomized VBN I-NP O
40 277 282 6540303 chick NN I-NP O
41 283 286 6540303 and CC I-NP O
42 287 290 6540303 rat NN I-NP O
43 290 291 6540303 . . O O

1 292 294 6540303 In IN B-PP O
2 295 298 6540303 the DT B-NP O
3 299 314 6540303 pinealectomized VBN I-NP O
4 315 320 6540303 chick NN I-NP O
5 320 321 6540303 , , O O
6 322 334 6540303 pretreatment NN B-NP O
7 335 339 6540303 with IN B-PP O
8 340 348 6540303 dopamine NN B-NP D004298
9 349 358 6540303 increased VBD B-VP O
10 359 362 6540303 the DT B-NP O
11 363 371 6540303 duration NN I-NP O
12 372 374 6540303 of IN B-PP O
13 375 384 6540303 catatonia NN B-NP D002389
14 385 386 6540303 ( ( O O
15 386 389 6540303 DOC NN B-NP O
16 389 390 6540303 ) ) O O
17 391 396 6540303 after IN B-PP O
18 397 405 6540303 ketamine NN B-NP D007649
19 405 406 6540303 , , O O
20 407 410 6540303 but CC O O
21 411 423 6540303 pretreatment NN B-NP O
22 424 428 6540303 with IN B-PP O
23 429 443 6540303 norepinephrine NN B-NP D009638
24 444 447 6540303 did VBD B-VP O
25 448 451 6540303 not RB O O
26 451 452 6540303 . . O O

1 453 456 6540303 The DT B-NP O
2 457 463 6540303 pineal JJ I-NP O
3 464 475 6540303 indolamines NNS I-NP O
4 476 485 6540303 exhibited VBD B-VP O
5 486 491 6540303 mixed JJ B-NP O
6 492 499 6540303 actions NNS I-NP O
7 499 500 6540303 . . O O

1 501 510 6540303 Serotonin NN B-NP D012701
2 511 514 6540303 and CC I-NP O
3 515 516 6540303 N NN I-NP C006389
4 516 517 6540303 - HYPH B-NP C006389
5 517 523 6540303 acetyl NN I-NP C006389
6 524 533 6540303 serotonin NN I-NP C006389
7 534 539 6540303 which WDT B-NP O
8 540 549 6540303 augmented VBD B-VP O
9 550 558 6540303 ketamine NN B-NP D007649
10 559 562 6540303 DOC NN I-NP O
11 562 563 6540303 , , O O
12 564 567 6540303 did VBD B-VP O
13 568 571 6540303 not RB I-VP O
14 572 574 6540303 do VB I-VP O
15 575 577 6540303 so RB B-ADVP O
16 578 580 6540303 in IN B-PP O
17 581 584 6540303 the DT B-NP O
18 585 592 6540303 absence NN I-NP O
19 593 595 6540303 of IN B-PP O
20 596 599 6540303 the DT B-NP O
21 600 606 6540303 pineal JJ I-NP O
22 607 612 6540303 gland NN I-NP O
23 612 613 6540303 , , O O
24 614 621 6540303 whereas IN O O
25 622 631 6540303 melatonin NN B-NP D008550
26 632 643 6540303 potentiated VBD B-VP O
27 644 647 6540303 the DT B-NP O
28 648 656 6540303 ketamine NN I-NP D007649
29 657 660 6540303 DOC NN I-NP O
30 661 663 6540303 in IN B-PP O
31 664 668 6540303 both CC B-NP O
32 669 672 6540303 the DT I-NP O
33 673 679 6540303 intact JJ I-NP O
34 680 683 6540303 and CC I-NP O
35 684 699 6540303 pinealectomized VBN I-NP O
36 700 705 6540303 chick NN I-NP O
37 705 706 6540303 . . O O

1 707 715 6540303 Ketamine NN B-NP D007649
2 716 719 6540303 was VBD B-VP O
3 720 724 6540303 more RBR B-ADJP O
4 725 731 6540303 potent JJ I-ADJP O
5 732 734 6540303 in IN B-PP O
6 735 738 6540303 the DT B-NP O
7 739 756 6540303 hypophysectomized VBN I-NP O
8 757 762 6540303 chick NN I-NP O
9 763 766 6540303 and CC O O
10 767 770 6540303 the DT B-NP O
11 771 780 6540303 circadian JJ I-NP O
12 781 787 6540303 rhythm NN I-NP O
13 788 793 6540303 noted VBN B-VP O
14 794 796 6540303 in IN B-PP O
15 797 800 6540303 the DT B-NP O
16 801 807 6540303 intact JJ I-NP O
17 808 813 6540303 chick NN I-NP O
18 814 817 6540303 was VBD B-VP O
19 818 824 6540303 absent JJ B-ADJP O
20 824 825 6540303 ; : O O
21 826 837 6540303 furthermore RB B-ADVP O
22 837 838 6540303 , , O O
23 839 848 6540303 melatonin NN B-NP D008550
24 849 852 6540303 did VBD B-VP O
25 853 856 6540303 not RB I-VP O
26 857 864 6540303 augment VB I-VP O
27 865 868 6540303 the DT B-NP O
28 869 877 6540303 ketamine NN I-NP D007649
29 878 881 6540303 DOC NN I-NP O
30 882 889 6540303 whereas IN B-PP O
31 890 898 6540303 dopamine NN B-NP D004298
32 899 908 6540303 continued VBD B-VP O
33 909 911 6540303 to TO I-VP O
34 912 914 6540303 do VB I-VP O
35 915 917 6540303 so RB B-ADVP O
36 917 918 6540303 . . O O

1 919 923 6540303 This DT B-NP O
2 924 929 6540303 study NN I-NP O
3 930 933 6540303 did VBD B-VP O
4 934 937 6540303 not RB I-VP O
5 938 949 6540303 demonstrate VB I-VP O
6 950 951 6540303 a DT B-NP O
7 952 959 6540303 species NN I-NP O
8 960 970 6540303 difference NN I-NP O
9 971 980 6540303 regarding VBG B-VP O
10 981 984 6540303 the DT B-NP O
11 985 989 6540303 role NN I-NP O
12 990 992 6540303 of IN B-PP O
13 993 996 6540303 the DT B-NP O
14 997 1003 6540303 amines NNS I-NP D000588
15 1004 1006 6540303 on IN B-PP O
16 1007 1010 6540303 the DT B-NP O
17 1011 1017 6540303 pineal NN I-NP O
18 1018 1020 6540303 in IN B-PP O
19 1021 1026 6540303 spite NN B-NP O
20 1027 1029 6540303 of IN B-PP O
21 1030 1033 6540303 the DT B-NP O
22 1034 1042 6540303 immature JJ I-NP O
23 1043 1048 6540303 blood NN I-NP O
24 1048 1049 6540303 - HYPH I-NP O
25 1049 1054 6540303 brain NN I-NP O
26 1055 1062 6540303 barrier NN I-NP O
27 1063 1065 6540303 in IN B-PP O
28 1066 1069 6540303 the DT B-NP O
29 1070 1075 6540303 young JJ I-NP O
30 1076 1081 6540303 chick NN I-NP O
31 1082 1085 6540303 and CC O O
32 1086 1089 6540303 the DT B-NP O
33 1090 1096 6540303 intact JJ I-NP O
34 1097 1104 6540303 barrier NN I-NP O
35 1105 1107 6540303 in IN B-PP O
36 1108 1111 6540303 the DT B-NP O
37 1112 1115 6540303 rat NN I-NP O
38 1115 1116 6540303 . . O O

1 1117 1119 6540303 In IN B-PP O
2 1120 1128 6540303 addition NN B-NP O
3 1128 1129 6540303 , , O O
4 1130 1135 6540303 these DT B-NP O
5 1136 1140 6540303 data NNS I-NP O
6 1141 1149 6540303 indicate VBP B-VP O
7 1150 1151 6540303 a DT B-NP O
8 1152 1158 6540303 direct JJ I-NP O
9 1159 1163 6540303 role NN I-NP O
10 1164 1166 6540303 of IN B-PP O
11 1167 1170 6540303 the DT B-NP O
12 1171 1180 6540303 pituitary NN I-NP O
13 1181 1183 6540303 in IN B-PP O
14 1184 1187 6540303 the DT B-NP O
15 1188 1200 6540303 augmentation NN I-NP O
16 1201 1203 6540303 of IN B-PP O
17 1204 1212 6540303 ketamine NN B-NP D007649
18 1213 1216 6540303 DOC NN I-NP O
19 1217 1224 6540303 induced VBN B-VP O
20 1225 1227 6540303 by IN B-PP O
21 1228 1237 6540303 melatonin NN B-NP D008550
22 1237 1238 6540303 . . O O

1 1239 1250 6540303 Furthermore RB B-ADVP O
2 1250 1251 6540303 , , O O
3 1252 1260 6540303 dopamine NN B-NP D004298
4 1261 1269 6540303 appeared VBD B-VP O
5 1270 1272 6540303 to TO I-VP O
6 1273 1276 6540303 act VB I-VP O
7 1277 1279 6540303 on IN B-PP O
8 1280 1287 6540303 systems NNS B-NP O
9 1288 1292 6540303 more RBR B-VP O
10 1293 1300 6540303 closely RB I-VP O
11 1301 1309 6540303 involved VBN I-VP O
12 1310 1314 6540303 with IN B-PP O
13 1315 1318 6540303 the DT B-NP O
14 1319 1328 6540303 induction NN I-NP O
15 1329 1331 6540303 of IN B-PP O
16 1332 1340 6540303 ketamine NN B-NP D007649
17 1341 1350 6540303 catatonia NN I-NP D002389
18 1351 1357 6540303 rather RB B-PP O
19 1358 1362 6540303 than IN I-PP O
20 1363 1371 6540303 directly RB B-ADVP O
21 1372 1374 6540303 on IN B-PP O
22 1375 1378 6540303 the DT B-NP O
23 1379 1388 6540303 pituitary NN I-NP O
24 1388 1389 6540303 . . O O

1 0 0 6769133 -DOCSTART- -X- -X- O

1 0 11 6769133 Cardiotoxic JJ B-NP D066126
2 12 15 6769133 and CC I-NP O
3 16 24 6769133 possible JJ I-NP O
4 25 37 6769133 leukemogenic JJ I-NP O
5 38 45 6769133 effects NNS I-NP O
6 46 48 6769133 of IN B-PP O
7 49 59 6769133 adriamycin NN B-NP D004317
8 60 62 6769133 in IN B-PP O
9 63 71 6769133 nonhuman JJ B-NP O
10 72 80 6769133 primates NNS I-NP O
11 80 81 6769133 . . O O
12 82 84 6769133 10 CD B-NP O
13 85 92 6769133 monkeys NNS I-NP O
14 93 94 6769133 ( ( O O
15 94 102 6769133 macaques NNS B-NP O
16 102 103 6769133 ) ) O O
17 104 112 6769133 received VBD B-VP O
18 113 123 6769133 adriamycin NN B-NP D004317
19 124 126 6769133 by IN B-PP O
20 127 134 6769133 monthly JJ B-NP O
21 135 146 6769133 intravenous JJ I-NP O
22 147 157 6769133 injections NNS I-NP O
23 158 160 6769133 at IN B-PP O
24 161 163 6769133 12 CD B-NP O
25 164 166 6769133 mg NN I-NP O
26 166 167 6769133 / SYM B-NP O
27 167 169 6769133 m2 NN B-NP O
28 170 171 6769133 ( ( O O
29 171 172 6769133 1 CD B-NP O
30 173 175 6769133 mg NN I-NP O
31 175 176 6769133 / SYM B-NP O
32 176 178 6769133 kg NN I-NP O
33 178 179 6769133 ) ) O O
34 179 180 6769133 . . O O

1 181 182 6769133 8 CD B-NP O
2 183 185 6769133 of IN B-PP O
3 186 189 6769133 the DT B-NP O
4 190 192 6769133 10 CD I-NP O
5 193 200 6769133 monkeys NNS I-NP O
6 201 210 6769133 developed VBD B-VP O
7 211 221 6769133 congestive JJ B-NP D006333
8 222 227 6769133 heart NN I-NP D006333
9 228 235 6769133 failure NN I-NP D006333
10 236 238 6769133 at IN B-PP O
11 239 241 6769133 an DT B-NP O
12 242 249 6769133 average JJ I-NP O
13 250 260 6769133 cumulative JJ I-NP O
14 261 271 6769133 adriamycin NN I-NP D004317
15 272 276 6769133 dose NN I-NP O
16 277 278 6769133 ( ( O O
17 278 281 6769133 310 CD B-NP O
18 282 284 6769133 mg NN I-NP O
19 284 285 6769133 / SYM B-NP O
20 285 287 6769133 m2 NN I-NP O
21 287 288 6769133 ) ) O O
22 289 293 6769133 well RB B-PP O
23 294 299 6769133 below IN I-PP O
24 300 304 6769133 that DT B-NP O
25 305 315 6769133 considered VBN B-VP O
26 316 319 6769133 the DT B-NP O
27 320 324 6769133 safe JJ I-NP O
28 325 330 6769133 upper JJ I-NP O
29 331 336 6769133 limit NN I-NP O
30 337 338 6769133 ( ( O O
31 338 341 6769133 550 CD B-NP O
32 342 344 6769133 mg NN I-NP O
33 344 345 6769133 / SYM B-NP O
34 345 347 6769133 m2 NN I-NP O
35 347 348 6769133 ) ) O O
36 349 351 6769133 in IN B-PP O
37 352 355 6769133 man NN B-NP O
38 355 356 6769133 . . O O

1 357 371 6769133 Histologically RB B-ADVP O
2 371 372 6769133 , , O O
3 373 376 6769133 the DT B-NP O
4 377 387 6769133 myocardial JJ I-NP D001768
5 388 395 6769133 lesions NNS I-NP D001768
6 396 405 6769133 resembled VBD B-VP O
7 406 411 6769133 those DT B-NP O
8 412 417 6769133 found VBN B-VP O
9 418 420 6769133 in IN B-PP O
10 421 426 6769133 human JJ B-NP O
11 427 440 6769133 anthracycline NN I-NP D018943
12 440 441 6769133 - HYPH B-NP O
13 441 448 6769133 induced VBN I-NP O
14 449 463 6769133 cardiomyopathy NN I-NP D009202
15 463 464 6769133 . . O O

1 465 466 6769133 1 CD B-NP O
2 467 469 6769133 of IN B-PP O
3 470 473 6769133 the DT B-NP O
4 474 476 6769133 10 CD I-NP O
5 477 484 6769133 monkeys NNS I-NP O
6 485 494 6769133 developed VBD B-VP O
7 495 500 6769133 acute JJ B-NP D015470
8 501 513 6769133 myeloblastic JJ I-NP D015470
9 514 522 6769133 leukemia NN I-NP D015470
10 523 528 6769133 after IN B-PP O
11 529 538 6769133 receiving VBG B-VP O
12 539 542 6769133 324 CD B-NP O
13 543 545 6769133 mg NN I-NP O
14 545 546 6769133 / SYM B-NP O
15 546 548 6769133 m2 NN I-NP O
16 549 551 6769133 of IN B-PP O
17 552 562 6769133 adriamycin NN B-NP D004317
18 562 563 6769133 ; : O O
19 564 567 6769133 the DT B-NP O
20 568 572 6769133 10th JJ I-NP O
21 573 579 6769133 monkey NN I-NP O
22 580 582 6769133 is VBZ B-VP O
23 583 588 6769133 alive JJ B-ADJP O
24 589 592 6769133 and CC O O
25 593 597 6769133 well RB B-NP O
26 598 600 6769133 26 CD I-NP O
27 601 607 6769133 months NNS I-NP O
28 608 613 6769133 after IN B-PP O
29 614 617 6769133 the DT B-NP O
30 618 622 6769133 last JJ I-NP O
31 623 627 6769133 dose NN I-NP O
32 628 630 6769133 of IN B-PP O
33 631 635 6769133 drug NN B-NP O
34 635 636 6769133 . . O O

1 637 640 6769133 Our PRP$ B-NP O
2 641 648 6769133 results NNS I-NP O
3 649 656 6769133 suggest VBP B-VP O
4 657 661 6769133 that IN B-SBAR O
5 662 672 6769133 adriamycin NN B-NP D004317
6 673 675 6769133 is VBZ B-VP O
7 676 677 6769133 a DT B-NP O
8 678 682 6769133 more RBR I-NP O
9 683 689 6769133 potent JJ I-NP O
10 690 701 6769133 cardiotoxin NN I-NP O
11 702 704 6769133 in IN B-PP O
12 705 712 6769133 monkeys NNS B-NP O
13 713 717 6769133 than IN B-PP O
14 718 720 6769133 in IN B-PP O
15 721 724 6769133 man NN B-NP O
16 724 725 6769133 , , O O
17 726 729 6769133 and CC O O
18 730 734 6769133 that IN B-SBAR O
19 735 743 6769133 leukemia NN B-NP D007938
20 744 747 6769133 may MD B-VP O
21 748 750 6769133 be VB I-VP O
22 751 752 6769133 a DT B-NP O
23 753 764 6769133 consequence NN I-NP O
24 765 767 6769133 of IN B-PP O
25 768 777 6769133 prolonged JJ B-NP O
26 778 787 6769133 treatment NN I-NP O
27 788 792 6769133 with IN B-PP O
28 793 797 6769133 this DT B-NP O
29 798 802 6769133 drug NN I-NP O
30 802 803 6769133 . . O O

1 0 0 8305357 -DOCSTART- -X- -X- O

1 0 9 8305357 Liposomal JJ B-NP O
2 10 22 8305357 daunorubicin NN I-NP D003630
3 23 25 8305357 in IN B-PP O
4 26 34 8305357 advanced VBN B-NP O
5 35 43 8305357 Kaposi's NNP I-NP D012514
6 44 51 8305357 sarcoma NN I-NP D012514
7 51 52 8305357 : : O O
8 53 54 8305357 a DT B-NP O
9 55 60 8305357 phase NN I-NP O
10 61 63 8305357 II CD I-NP O
11 64 69 8305357 study NN I-NP O
12 69 70 8305357 . . O O
13 71 73 8305357 We PRP B-NP O
14 74 80 8305357 report VBP B-VP O
15 81 82 8305357 a DT B-NP O
16 83 86 8305357 non AFX I-NP O
17 86 87 8305357 - HYPH I-NP O
18 87 97 8305357 randomized VBN I-NP O
19 98 103 8305357 Phase NN I-NP O
20 104 106 8305357 II CD I-NP O
21 107 115 8305357 clinical JJ I-NP O
22 116 121 8305357 trial NN I-NP O
23 122 124 8305357 to TO B-VP O
24 125 131 8305357 assess VB I-VP O
25 132 135 8305357 the DT B-NP O
26 136 144 8305357 efficacy NN I-NP O
27 145 148 8305357 and CC I-NP O
28 149 155 8305357 safety NN I-NP O
29 156 158 8305357 of IN B-PP O
30 159 168 8305357 liposomal JJ B-NP O
31 169 181 8305357 daunorubicin NN I-NP D003630
32 182 183 8305357 ( ( O O
33 183 192 8305357 DaunoXome NN B-NP O
34 192 193 8305357 ) ) O O
35 194 196 8305357 in IN B-PP O
36 197 200 8305357 the DT B-NP O
37 201 210 8305357 treatment NN I-NP O
38 211 213 8305357 of IN B-PP O
39 214 218 8305357 AIDS NNP B-NP D000163
40 219 226 8305357 related JJ I-NP O
41 227 235 8305357 Kaposi's NNP I-NP D012514
42 236 243 8305357 sarcoma NN I-NP D012514
43 243 244 8305357 . . O O

1 245 251 8305357 Eleven CD B-NP O
2 252 262 8305357 homosexual JJ I-NP O
3 263 266 8305357 men NNS I-NP O
4 267 271 8305357 with IN B-PP O
5 272 280 8305357 advanced VBN B-NP O
6 281 289 8305357 Kaposi's NNP I-NP D012514
7 290 297 8305357 sarcoma NN I-NP D012514
8 298 302 8305357 were VBD B-VP O
9 303 310 8305357 entered VBN I-VP O
10 311 313 8305357 in IN B-PP O
11 314 317 8305357 the DT B-NP O
12 318 323 8305357 trial NN I-NP O
13 323 324 8305357 . . O O

1 325 332 8305357 Changes NNS B-NP O
2 333 335 8305357 in IN B-PP O
3 336 340 8305357 size NN B-NP O
4 340 341 8305357 , , O O
5 342 348 8305357 colour NN B-NP O
6 349 352 8305357 and CC O O
7 353 363 8305357 associated VBN B-NP O
8 364 370 8305357 oedema NN I-NP D004487
9 371 373 8305357 of IN B-PP O
10 374 382 8305357 selected VBN B-NP O
11 383 384 8305357 ' `` I-NP O
12 384 390 8305357 target NN I-NP O
13 390 391 8305357 ' '' I-NP O
14 392 399 8305357 lesions NNS I-NP O
15 400 404 8305357 were VBD B-VP O
16 405 413 8305357 measured VBN I-VP O
17 413 414 8305357 . . O O

1 415 423 8305357 Clinical JJ B-NP O
2 423 424 8305357 , , I-NP O
3 425 436 8305357 biochemical JJ I-NP O
4 437 440 8305357 and CC I-NP O
5 441 455 8305357 haematological JJ I-NP O
6 456 466 8305357 toxicities NNS I-NP D064420
7 467 471 8305357 were VBD B-VP O
8 472 480 8305357 assessed VBN I-VP O
9 480 481 8305357 . . O O

1 482 485 8305357 Ten CD B-NP O
2 486 494 8305357 subjects NNS I-NP O
3 495 499 8305357 were VBD B-VP O
4 500 509 8305357 evaluated VBN I-VP O
5 509 510 8305357 . . O O

1 511 512 8305357 A DT B-NP O
2 513 520 8305357 partial JJ I-NP O
3 521 529 8305357 response NN I-NP O
4 530 533 8305357 was VBD B-VP O
5 534 542 8305357 achieved VBN I-VP O
6 543 545 8305357 in IN B-PP O
7 546 550 8305357 four CD B-NP O
8 550 551 8305357 , , O O
9 552 554 8305357 of IN B-PP O
10 555 559 8305357 whom WP B-NP O
11 560 563 8305357 two CD B-NP O
12 564 576 8305357 subsequently RB I-NP O
13 577 585 8305357 relapsed VBN I-NP O
14 585 586 8305357 . . O O

1 587 600 8305357 Stabilization NN B-NP O
2 601 603 8305357 of IN B-PP O
3 604 612 8305357 Kaposi's NNP B-NP D012514
4 613 620 8305357 sarcoma NN I-NP D012514
5 621 629 8305357 occurred VBD B-VP O
6 630 632 8305357 in IN B-PP O
7 633 636 8305357 the DT B-NP O
8 637 646 8305357 remaining VBG I-NP O
9 647 650 8305357 six CD I-NP O
10 650 651 8305357 , , O O
11 652 662 8305357 maintained VBN B-VP O
12 663 668 8305357 until IN B-PP O
13 669 672 8305357 the DT B-NP O
14 673 676 8305357 end NN I-NP O
15 677 679 8305357 of IN B-PP O
16 680 683 8305357 the DT B-NP O
17 684 689 8305357 trial NN I-NP O
18 690 696 8305357 period NN I-NP O
19 697 699 8305357 in IN B-PP O
20 700 704 8305357 four CD B-NP O
21 704 705 8305357 . . O O

1 706 709 8305357 The DT B-NP O
2 710 714 8305357 drug NN I-NP O
3 715 718 8305357 was VBD B-VP O
4 719 728 8305357 generally RB I-VP O
5 729 733 8305357 well RB I-VP O
6 734 743 8305357 tolerated VBN I-VP O
7 743 744 8305357 , , O O
8 745 749 8305357 with IN B-PP O
9 750 753 8305357 few JJ B-NP O
10 754 758 8305357 mild JJ I-NP O
11 759 767 8305357 symptoms NNS I-NP O
12 768 770 8305357 of IN B-PP O
13 771 779 8305357 toxicity NN B-NP D064420
14 779 780 8305357 . . O O

1 781 784 8305357 The DT B-NP O
2 785 789 8305357 main JJ I-NP O
3 790 797 8305357 problem NN I-NP O
4 798 809 8305357 encountered VBN B-VP O
5 810 813 8305357 was VBD B-VP O
6 814 828 8305357 haematological JJ B-NP O
7 829 837 8305357 toxicity NN I-NP D064420
8 837 838 8305357 , , O O
9 839 843 8305357 with IN B-PP O
10 844 849 8305357 three CD B-NP O
11 850 858 8305357 subjects NNS I-NP O
12 859 871 8305357 experiencing VBG B-VP O
13 872 878 8305357 severe JJ B-NP O
14 879 890 8305357 neutropenia NN I-NP D009503
15 891 892 8305357 ( ( O O
16 892 902 8305357 neutrophil NN B-NP O
17 903 908 8305357 count NN I-NP O
18 909 910 8305357 < SYM B-NP O
19 911 914 8305357 0.5 CD B-NP O
20 915 916 8305357 x SYM I-NP O
21 917 922 8305357 10(9) CD I-NP O
22 922 923 8305357 / SYM I-NP O
23 923 924 8305357 l NN I-NP O
24 924 925 8305357 ) ) O O
25 925 926 8305357 . . O O

1 927 932 8305357 There EX B-NP O
2 933 936 8305357 was VBD B-VP O
3 937 939 8305357 no DT B-NP O
4 940 948 8305357 evidence NN I-NP O
5 949 951 8305357 of IN B-PP O
6 952 966 8305357 cardiotoxicity NN B-NP D066126
7 966 967 8305357 . . O O

1 968 970 8305357 In IN B-PP O
2 971 975 8305357 this DT B-NP O
3 976 981 8305357 small JJ I-NP O
4 982 989 8305357 patient NN I-NP O
5 990 996 8305357 sample NN I-NP O
6 996 997 8305357 , , O O
7 998 1007 8305357 liposomal JJ B-NP O
8 1008 1020 8305357 daunorubicin NN I-NP D003630
9 1021 1024 8305357 was VBD B-VP O
10 1025 1027 8305357 an DT B-NP O
11 1028 1037 8305357 effective JJ I-NP O
12 1038 1041 8305357 and CC I-NP O
13 1042 1046 8305357 well RB I-NP O
14 1047 1056 8305357 tolerated VBN I-NP O
15 1057 1062 8305357 agent NN I-NP O
16 1063 1065 8305357 in IN B-PP O
17 1066 1069 8305357 the DT B-NP O
18 1070 1079 8305357 treatment NN I-NP O
19 1080 1082 8305357 of IN B-PP O
20 1083 1091 8305357 Kaposi's NNP B-NP D012514
21 1092 1099 8305357 sarcoma NN I-NP D012514
22 1099 1100 8305357 . . O O

1 0 0 1899352 -DOCSTART- -X- -X- O

1 0 10 1899352 Ifosfamide NN B-NP D007069
2 11 21 1899352 continuous JJ I-NP O
3 22 30 1899352 infusion NN I-NP O
4 31 38 1899352 without IN B-PP O
5 39 44 1899352 mesna NN B-NP D015080
6 44 45 1899352 . . O O

1 46 47 1899352 A DT B-NP O
2 48 53 1899352 phase NN I-NP O
3 54 55 1899352 I CD I-NP O
4 56 61 1899352 trial NN I-NP O
5 62 64 1899352 of IN B-PP O
6 65 66 1899352 a DT B-NP O
7 67 69 1899352 14 CD I-NP O
8 69 70 1899352 - HYPH I-NP O
9 70 73 1899352 day NN I-NP O
10 74 79 1899352 cycle NN I-NP O
11 79 80 1899352 . . O O
12 81 87 1899352 Twenty CD B-NP O
13 88 96 1899352 patients NNS I-NP O
14 97 105 1899352 received VBD B-VP O
15 106 108 1899352 27 CD B-NP O
16 109 116 1899352 courses NNS I-NP O
17 117 119 1899352 of IN B-PP O
18 120 130 1899352 ifosfamide NN B-NP D007069
19 131 143 1899352 administered VBN B-VP O
20 144 146 1899352 as IN B-PP O
21 147 148 1899352 a DT B-NP O
22 149 151 1899352 24 CD I-NP O
23 151 152 1899352 - HYPH I-NP O
24 152 156 1899352 hour NN I-NP O
25 157 167 1899352 continuous JJ I-NP O
26 168 176 1899352 infusion NN I-NP O
27 177 180 1899352 for IN B-PP O
28 181 183 1899352 14 CD B-NP O
29 184 188 1899352 days NNS I-NP O
30 189 196 1899352 without IN B-PP O
31 197 202 1899352 Mesna NNP B-NP D015080
32 202 203 1899352 . . O O

1 204 207 1899352 The DT B-NP O
2 208 212 1899352 goal NN I-NP O
3 213 215 1899352 of IN B-PP O
4 216 219 1899352 the DT B-NP O
5 220 225 1899352 study NN I-NP O
6 226 229 1899352 was VBD B-VP O
7 230 232 1899352 to TO B-VP O
8 233 240 1899352 deliver VB I-VP O
9 241 242 1899352 a DT B-NP O
10 243 247 1899352 dose NN I-NP O
11 248 252 1899352 rate NN I-NP O
12 253 256 1899352 and CC O O
13 257 262 1899352 total JJ B-NP O
14 263 273 1899352 cumulative JJ I-NP O
15 274 278 1899352 dose NN I-NP O
16 279 281 1899352 of IN B-PP O
17 282 292 1899352 ifosfamide NN B-NP D007069
18 293 297 1899352 that WDT B-NP O
19 298 303 1899352 would MD B-VP O
20 304 306 1899352 be VB I-VP O
21 307 317 1899352 comparable JJ B-ADJP O
22 318 320 1899352 to TO B-PP O
23 321 329 1899352 standard JJ B-NP O
24 330 335 1899352 bolus NN I-NP O
25 336 338 1899352 or CC O O
26 339 344 1899352 short JJ B-NP O
27 344 345 1899352 - HYPH I-NP O
28 345 349 1899352 term NN I-NP O
29 350 359 1899352 infusions NNS I-NP O
30 360 372 1899352 administered VBN B-VP O
31 373 377 1899352 with IN B-PP O
32 378 383 1899352 Mesna NNP B-NP D015080
33 383 384 1899352 . . O O

1 385 389 1899352 Dose NN B-NP O
2 390 401 1899352 escalations NNS I-NP O
3 402 411 1899352 proceeded VBD B-VP O
4 412 416 1899352 from IN B-PP O
5 417 420 1899352 200 CD B-NP O
6 421 423 1899352 to TO I-NP O
7 424 427 1899352 300 CD I-NP O
8 427 428 1899352 , , I-NP O
9 429 432 1899352 400 CD I-NP O
10 432 433 1899352 , , I-NP O
11 434 437 1899352 450 CD I-NP O
12 437 438 1899352 , , I-NP O
13 439 442 1899352 500 CD I-NP O
14 442 443 1899352 , , O O
15 444 447 1899352 and CC O O
16 448 451 1899352 550 CD B-NP O
17 452 454 1899352 mg NN I-NP O
18 454 455 1899352 / SYM B-NP O
19 455 457 1899352 m2 NN I-NP O
20 457 458 1899352 / SYM I-NP O
21 458 459 1899352 d NN I-NP O
22 459 460 1899352 . . O O

1 461 465 1899352 Four CD B-NP O
2 466 474 1899352 patients NNS I-NP O
3 475 484 1899352 developed VBD B-VP O
4 485 494 1899352 transient JJ B-NP O
5 495 506 1899352 microscopic JJ I-NP O
6 507 516 1899352 hematuria NN I-NP D006417
7 517 519 1899352 at IN B-PP O
8 520 523 1899352 400 CD B-NP O
9 523 524 1899352 , , I-NP O
10 525 528 1899352 450 CD I-NP O
11 528 529 1899352 , , O O
12 530 533 1899352 and CC O O
13 534 537 1899352 500 CD B-NP O
14 538 540 1899352 mg NN I-NP O
15 540 541 1899352 / SYM B-NP O
16 541 543 1899352 m2 NN I-NP O
17 543 544 1899352 / SYM I-NP O
18 544 545 1899352 d NN I-NP O
19 545 546 1899352 . . O O

1 547 552 1899352 There EX B-NP O
2 553 557 1899352 were VBD B-VP O
3 558 560 1899352 no DT B-NP O
4 561 570 1899352 instances NNS I-NP O
5 571 573 1899352 of IN B-PP O
6 574 585 1899352 macroscopic JJ B-NP O
7 586 595 1899352 hematuria NN I-NP D006417
8 595 596 1899352 . . O O

1 597 599 1899352 At IN B-PP O
2 600 603 1899352 550 CD B-NP O
3 604 606 1899352 mg NN I-NP O
4 606 607 1899352 / SYM B-NP O
5 607 609 1899352 m2 NN I-NP O
6 609 610 1899352 / SYM I-NP O
7 610 611 1899352 d NN I-NP O
8 611 612 1899352 , , O O
9 613 618 1899352 three CD B-NP O
10 619 627 1899352 patients NNS I-NP O
11 628 639 1899352 experienced VBD B-VP O
12 640 651 1899352 nonurologic JJ B-NP O
13 652 660 1899352 toxicity NN I-NP D064420
14 660 661 1899352 ; : O O
15 662 671 1899352 confusion NN B-NP D003221
16 672 673 1899352 ( ( O O
17 673 674 1899352 1 CD B-NP O
18 674 675 1899352 ) ) O O
19 675 676 1899352 , , O O
20 677 683 1899352 nausea NN B-NP D009325
21 684 685 1899352 ( ( O O
22 685 686 1899352 1 CD B-NP O
23 686 687 1899352 ) ) O O
24 687 688 1899352 , , O O
25 689 692 1899352 and CC O O
26 693 698 1899352 Grade NN B-NP O
27 699 700 1899352 2 CD I-NP O
28 701 711 1899352 leukopenia NN I-NP D007970
29 712 713 1899352 ( ( O O
30 713 714 1899352 1 CD B-NP O
31 714 715 1899352 ) ) O O
32 715 716 1899352 . . O O

1 717 720 1899352 The DT B-NP O
2 721 732 1899352 recommended VBN I-NP O
3 733 737 1899352 dose NN I-NP O
4 738 740 1899352 of IN B-PP O
5 741 744 1899352 500 CD B-NP O
6 745 747 1899352 mg NN I-NP O
7 747 748 1899352 / SYM B-NP O
8 748 750 1899352 m2 NN I-NP O
9 750 751 1899352 / SYM B-NP O
10 751 752 1899352 d NN I-NP O
11 753 761 1899352 delivers VBZ B-VP O
12 762 763 1899352 a DT B-NP O
13 764 769 1899352 total JJ I-NP O
14 770 774 1899352 dose NN I-NP O
15 775 777 1899352 of IN B-PP O
16 778 779 1899352 7 CD B-NP O
17 780 781 1899352 g NN I-NP O
18 781 782 1899352 / SYM B-NP O
19 782 784 1899352 m2 NN I-NP O
20 785 788 1899352 per IN B-PP O
21 789 794 1899352 cycle NN B-NP O
22 794 795 1899352 , , O O
23 796 801 1899352 which WDT B-NP O
24 802 804 1899352 is VBZ B-VP O
25 805 815 1899352 comparable JJ B-ADJP O
26 816 818 1899352 to TO B-PP O
27 819 823 1899352 that DT B-NP O
28 824 833 1899352 delivered VBN B-VP O
29 834 836 1899352 in IN B-PP O
30 837 845 1899352 clinical JJ B-NP O
31 846 854 1899352 practice NN I-NP O
32 855 858 1899352 for IN B-PP O
33 859 864 1899352 bolus NN B-NP O
34 865 867 1899352 or CC O O
35 868 873 1899352 short JJ B-NP O
36 873 874 1899352 - HYPH I-NP O
37 874 878 1899352 term NN I-NP O
38 879 887 1899352 infusion NN I-NP O
39 887 888 1899352 . . O O

1 889 896 1899352 Because IN B-SBAR O
2 897 900 1899352 few JJ B-NP O
3 901 909 1899352 patients NNS I-NP O
4 910 918 1899352 received VBD B-VP O
5 919 927 1899352 multiple JJ B-NP O
6 928 935 1899352 courses NNS I-NP O
7 936 940 1899352 over IN B-PP O
8 941 945 1899352 time NN B-NP O
9 945 946 1899352 , , O O
10 947 950 1899352 the DT B-NP O
11 951 961 1899352 cumulative JJ I-NP O
12 962 969 1899352 effects NNS I-NP O
13 970 973 1899352 are VBP B-VP O
14 974 987 1899352 indeterminate JJ B-ADJP O
15 988 990 1899352 in IN B-PP O
16 991 994 1899352 the DT B-NP O
17 995 1002 1899352 present JJ I-NP O
18 1003 1008 1899352 trial NN I-NP O
19 1008 1009 1899352 . . O O

1 1010 1013 1899352 The DT B-NP O
2 1014 1023 1899352 frequency NN I-NP O
3 1024 1027 1899352 and CC I-NP O
4 1028 1042 1899352 predictability NN I-NP O
5 1043 1045 1899352 of IN B-PP O
6 1046 1055 1899352 hematuria NN B-NP D006417
7 1056 1059 1899352 are VBP B-VP O
8 1060 1063 1899352 not RB O O
9 1064 1071 1899352 precise JJ B-ADJP O
10 1071 1072 1899352 , , O O
11 1073 1076 1899352 and CC O O
12 1077 1079 1899352 at IN B-NP O
13 1080 1085 1899352 least JJS I-NP O
14 1086 1091 1899352 daily JJ I-NP O
15 1092 1102 1899352 monitoring NN I-NP O
16 1103 1105 1899352 by IN B-PP O
17 1106 1111 1899352 urine NN B-NP O
18 1112 1120 1899352 Hematest NN I-NP O
19 1121 1123 1899352 is VBZ B-VP O
20 1124 1133 1899352 essential JJ B-ADJP O
21 1133 1134 1899352 , , O O
22 1135 1141 1899352 adding VBG B-VP O
23 1142 1147 1899352 Mesna NNP B-NP D015080
24 1148 1150 1899352 to TO B-PP O
25 1151 1154 1899352 the DT B-NP O
26 1155 1163 1899352 infusate NN I-NP O
27 1164 1166 1899352 in IN B-PP O
28 1167 1175 1899352 patients NNS B-NP O
29 1176 1180 1899352 with IN B-PP O
30 1181 1191 1899352 persistent JJ B-NP O
31 1192 1201 1899352 hematuria NN I-NP D006417
32 1201 1202 1899352 . . O O

1 1203 1206 1899352 The DT B-NP O
2 1207 1217 1899352 protracted JJ I-NP O
3 1218 1226 1899352 infusion NN I-NP O
4 1227 1235 1899352 schedule NN I-NP O
5 1236 1239 1899352 for IN B-PP O
6 1240 1250 1899352 ifosfamide NN B-NP D007069
7 1251 1258 1899352 permits VBZ B-VP O
8 1259 1269 1899352 convenient JJ B-NP O
9 1270 1280 1899352 outpatient NN I-NP O
10 1281 1295 1899352 administration NN I-NP O
11 1296 1303 1899352 without IN B-PP O
12 1304 1309 1899352 Mesna NNP B-NP D015080
13 1310 1313 1899352 and CC O O
14 1314 1321 1899352 reduces VBZ B-VP O
15 1322 1325 1899352 the DT B-NP O
16 1326 1330 1899352 drug NN I-NP O
17 1331 1335 1899352 cost NN I-NP O
18 1336 1338 1899352 of IN B-PP O
19 1339 1347 1899352 clinical JJ B-NP O
20 1348 1353 1899352 usage NN I-NP O
21 1354 1356 1899352 of IN B-PP O
22 1357 1361 1899352 this DT B-NP O
23 1362 1367 1899352 agent NN I-NP O
24 1368 1370 1899352 by IN B-PP O
25 1371 1373 1899352 up RB B-NP O
26 1374 1376 1899352 to TO I-NP O
27 1378 1381 1899352 890 CD I-NP O
28 1382 1385 1899352 per IN B-PP O
29 1386 1391 1899352 cycle NN B-NP O
30 1391 1392 1899352 . . O O

1 1393 1401 1899352 Clinical JJ B-NP O
2 1402 1410 1899352 activity NN I-NP O
3 1411 1414 1899352 was VBD B-VP O
4 1415 1427 1899352 demonstrated VBN I-VP O
5 1428 1430 1899352 in IN B-PP O
6 1431 1432 1899352 a DT B-NP O
7 1433 1439 1899352 single JJ I-NP O
8 1440 1447 1899352 patient NN I-NP O
9 1447 1448 1899352 , , O O
10 1449 1452 1899352 but CC O O
11 1453 1454 1899352 a DT B-NP O
12 1455 1466 1899352 comparative JJ I-NP O
13 1467 1472 1899352 trial NN I-NP O
14 1473 1475 1899352 of IN B-PP O
15 1476 1484 1899352 standard JJ B-NP O
16 1485 1490 1899352 bolus NN I-NP O
17 1491 1500 1899352 schedules NNS I-NP O
18 1501 1505 1899352 with IN B-PP O
19 1506 1509 1899352 the DT B-NP O
20 1510 1520 1899352 protracted JJ I-NP O
21 1521 1529 1899352 infusion NN I-NP O
22 1530 1538 1899352 schedule NN I-NP O
23 1539 1543 1899352 will MD B-VP O
24 1544 1546 1899352 be VB I-VP O
25 1547 1556 1899352 necessary JJ B-ADJP O
26 1557 1559 1899352 to TO B-VP O
27 1560 1569 1899352 determine VB I-VP O
28 1570 1572 1899352 if IN B-SBAR O
29 1573 1576 1899352 the DT B-NP O
30 1577 1585 1899352 clinical JJ I-NP O
31 1586 1599 1899352 effectiveness NN I-NP O
32 1600 1602 1899352 of IN B-PP O
33 1603 1606 1899352 the DT B-NP O
34 1607 1611 1899352 drug NN I-NP O
35 1612 1614 1899352 is VBZ B-VP O
36 1615 1625 1899352 maintained VBN I-VP O
37 1625 1626 1899352 . . O O

1 0 0 17490864 -DOCSTART- -X- -X- O

1 0 10 17490864 Attenuated VBN B-NP O
2 11 21 17490864 disruption NN I-NP O
3 22 24 17490864 of IN B-PP O
4 25 33 17490864 prepulse NN B-NP O
5 34 44 17490864 inhibition NN I-NP O
6 45 47 17490864 by IN B-PP O
7 48 60 17490864 dopaminergic JJ B-NP O
8 61 72 17490864 stimulation NN I-NP O
9 73 78 17490864 after IN B-PP O
10 79 87 17490864 maternal JJ B-NP O
11 88 99 17490864 deprivation NN I-NP O
12 100 103 17490864 and CC O O
13 104 114 17490864 adolescent JJ B-NP O
14 115 129 17490864 corticosterone NN I-NP D003345
15 130 139 17490864 treatment NN I-NP O
16 140 142 17490864 in IN B-PP O
17 143 147 17490864 rats NNS B-NP O
18 147 148 17490864 . . O O
19 149 152 17490864 The DT B-NP O
20 153 164 17490864 development NN I-NP O
21 165 167 17490864 of IN B-PP O
22 168 181 17490864 schizophrenia NN B-NP D012559
23 182 185 17490864 may MD B-VP O
24 186 193 17490864 include VB I-VP O
25 194 196 17490864 an DT B-NP O
26 197 202 17490864 early JJ I-NP O
27 203 221 17490864 neurodevelopmental JJ I-NP O
28 222 228 17490864 stress NN I-NP O
29 229 238 17490864 component NN I-NP O
30 239 244 17490864 which WDT B-NP O
31 245 254 17490864 increases VBZ B-VP O
32 255 268 17490864 vulnerability NN B-NP O
33 269 271 17490864 to TO B-PP O
34 272 277 17490864 later JJ B-NP O
35 278 287 17490864 stressful JJ I-NP O
36 288 292 17490864 life NN I-NP O
37 293 299 17490864 events NNS I-NP O
38 299 300 17490864 , , O O
39 301 303 17490864 in IN B-PP O
40 304 315 17490864 combination NN B-NP O
41 316 323 17490864 leading VBG B-VP O
42 324 326 17490864 to TO B-PP O
43 327 332 17490864 overt JJ B-NP O
44 333 340 17490864 disease NN I-NP O
45 340 341 17490864 . . O O

1 342 344 17490864 We PRP B-NP O
2 345 357 17490864 investigated VBD B-VP O
3 358 361 17490864 the DT B-NP O
4 362 368 17490864 effect NN I-NP O
5 369 371 17490864 of IN B-PP O
6 372 374 17490864 an DT B-NP O
7 375 380 17490864 early JJ I-NP O
8 381 387 17490864 stress NN I-NP O
9 387 388 17490864 , , O O
10 389 391 17490864 in IN B-PP O
11 392 395 17490864 the DT B-NP O
12 396 400 17490864 form NN I-NP O
13 401 403 17490864 of IN B-PP O
14 404 412 17490864 maternal JJ B-NP O
15 413 424 17490864 deprivation NN I-NP O
16 424 425 17490864 , , O O
17 426 434 17490864 combined VBN B-VP O
18 435 439 17490864 with IN B-PP O
19 440 441 17490864 a DT B-NP O
20 442 447 17490864 later JJ I-NP O
21 448 454 17490864 stress NN I-NP O
22 454 455 17490864 , , O O
23 456 465 17490864 simulated VBN B-VP O
24 466 468 17490864 by IN B-PP O
25 469 476 17490864 chronic JJ B-NP O
26 477 491 17490864 periadolescent JJ I-NP O
27 492 506 17490864 corticosterone NN I-NP D003345
28 507 516 17490864 treatment NN I-NP O
29 516 517 17490864 , , O O
30 518 520 17490864 on IN B-PP O
31 521 530 17490864 behaviour NN B-NP O
32 531 533 17490864 in IN B-PP O
33 534 538 17490864 rats NNS B-NP O
34 538 539 17490864 . . O O

1 540 545 17490864 Acute JJ B-NP O
2 546 555 17490864 treatment NN I-NP O
3 556 560 17490864 with IN B-PP O
4 561 572 17490864 apomorphine NN B-NP D001058
5 573 579 17490864 caused VBD B-VP O
6 580 590 17490864 disruption NN B-NP O
7 591 593 17490864 of IN B-PP O
8 594 602 17490864 prepulse NN B-NP O
9 603 613 17490864 inhibition NN I-NP O
10 614 615 17490864 ( ( O O
11 615 618 17490864 PPI NN B-NP O
12 618 619 17490864 ) ) O O
13 620 622 17490864 in IN B-PP O
14 623 631 17490864 controls NNS B-NP O
15 632 635 17490864 and CC B-PP O
16 636 638 17490864 in IN B-PP O
17 639 643 17490864 rats NNS B-NP O
18 644 648 17490864 that WDT B-NP O
19 649 652 17490864 had VBD B-VP O
20 653 662 17490864 undergone VBN I-VP O
21 663 669 17490864 either CC O O
22 670 678 17490864 maternal JJ B-NP O
23 679 690 17490864 deprivation NN I-NP O
24 691 693 17490864 or CC O O
25 694 708 17490864 corticosterone NN B-NP D003345
26 709 718 17490864 treatment NN I-NP O
27 718 719 17490864 , , O O
28 720 723 17490864 but CC O O
29 724 727 17490864 was VBD B-VP O
30 728 740 17490864 surprisingly RB B-ADJP O
31 741 747 17490864 absent JJ I-ADJP O
32 748 750 17490864 in IN B-PP O
33 751 755 17490864 rats NNS B-NP O
34 756 760 17490864 that WDT B-NP O
35 761 764 17490864 had VBD B-VP O
36 765 774 17490864 undergone VBN I-VP O
37 775 778 17490864 the DT B-NP O
38 779 787 17490864 combined JJ I-NP O
39 788 793 17490864 early JJ I-NP O
40 794 797 17490864 and CC I-NP O
41 798 802 17490864 late JJ I-NP O
42 803 809 17490864 stress NN I-NP O
43 809 810 17490864 . . O O

1 811 822 17490864 Amphetamine NN B-NP D000661
2 823 832 17490864 treatment NN I-NP O
3 833 846 17490864 significantly RB B-ADVP O
4 847 856 17490864 disrupted VBD B-VP O
5 857 860 17490864 PPI NN B-NP O
6 861 863 17490864 in IN B-PP O
7 864 868 17490864 both CC O O
8 869 872 17490864 non AFX B-NP O
9 872 873 17490864 - HYPH I-NP O
10 873 881 17490864 deprived VBN I-NP O
11 882 888 17490864 groups NNS I-NP O
12 888 889 17490864 , , O O
13 890 893 17490864 but CC O O
14 894 897 17490864 was VBD B-VP O
15 898 904 17490864 absent JJ B-ADJP O
16 905 907 17490864 in IN B-PP O
17 908 912 17490864 both CC B-NP O
18 913 923 17490864 maternally RB I-NP O
19 924 932 17490864 deprived VBN I-NP O
20 933 939 17490864 groups NNS I-NP O
21 939 940 17490864 . . O O

1 941 944 17490864 The DT B-NP O
2 945 954 17490864 serotonin NN I-NP D012701
3 954 955 17490864 - HYPH I-NP O
4 955 957 17490864 1A NN I-NP O
5 958 966 17490864 receptor NN I-NP O
6 967 974 17490864 agonist NN I-NP O
7 974 975 17490864 , , O O
8 976 977 17490864 8 CD B-NP D017371
9 977 978 17490864 - HYPH I-NP D017371
10 978 980 17490864 OH NN I-NP D017371
11 980 981 17490864 - HYPH I-NP D017371
12 981 985 17490864 DPAT NN I-NP D017371
13 985 986 17490864 , , O O
14 987 994 17490864 induced VBD B-VP O
15 995 996 17490864 a DT B-NP O
16 997 1008 17490864 significant JJ I-NP O
17 1009 1019 17490864 disruption NN I-NP O
18 1020 1022 17490864 of IN B-PP O
19 1023 1026 17490864 PPI NN B-NP O
20 1027 1029 17490864 in IN B-PP O
21 1030 1033 17490864 all DT B-NP O
22 1034 1040 17490864 groups NNS I-NP O
23 1040 1041 17490864 . . O O

1 1042 1053 17490864 Amphetamine NN B-NP D000661
2 1053 1054 17490864 - HYPH B-NP O
3 1054 1061 17490864 induced VBN I-NP O
4 1062 1071 17490864 locomotor NN I-NP D006948
5 1072 1085 17490864 hyperactivity NN I-NP D006948
6 1086 1089 17490864 was VBD B-VP O
7 1090 1097 17490864 similar JJ B-ADJP O
8 1098 1100 17490864 in IN B-PP O
9 1101 1104 17490864 all DT B-NP O
10 1105 1111 17490864 groups NNS I-NP O
11 1111 1112 17490864 . . O O

1 1113 1118 17490864 These DT B-NP O
2 1119 1126 17490864 results NNS I-NP O
3 1127 1131 17490864 show VBP B-VP O
4 1132 1134 17490864 an DT B-NP O
5 1135 1145 17490864 inhibitory JJ I-NP O
6 1146 1157 17490864 interaction NN I-NP O
7 1158 1160 17490864 of IN B-PP O
8 1161 1166 17490864 early JJ B-NP O
9 1167 1173 17490864 stress NN I-NP O
10 1173 1174 17490864 , , O O
11 1175 1181 17490864 caused VBN B-VP O
12 1182 1184 17490864 by IN B-PP O
13 1185 1193 17490864 maternal JJ B-NP O
14 1194 1205 17490864 deprivation NN I-NP O
15 1205 1206 17490864 , , O O
16 1207 1215 17490864 combined VBN B-VP O
17 1216 1220 17490864 with IN B-PP O
18 1221 1222 17490864 ' `` B-NP O
19 1222 1232 17490864 adolescent JJ I-NP O
20 1232 1233 17490864 ' '' I-NP O
21 1234 1240 17490864 stress NN I-NP O
22 1240 1241 17490864 , , O O
23 1242 1251 17490864 simulated VBN B-VP O
24 1252 1254 17490864 by IN B-PP O
25 1255 1269 17490864 corticosterone NN B-NP D003345
26 1270 1279 17490864 treatment NN I-NP O
27 1279 1280 17490864 , , O O
28 1281 1283 17490864 on IN B-PP O
29 1284 1296 17490864 dopaminergic JJ B-NP O
30 1297 1307 17490864 regulation NN I-NP O
31 1308 1310 17490864 of IN B-PP O
32 1311 1314 17490864 PPI NN B-NP O
33 1314 1315 17490864 . . O O

1 1316 1319 17490864 The DT B-NP O
2 1320 1327 17490864 altered VBN I-NP O
3 1328 1335 17490864 effects NNS I-NP O
4 1336 1338 17490864 of IN B-PP O
5 1339 1350 17490864 apomorphine NN B-NP D001058
6 1351 1354 17490864 and CC I-NP O
7 1355 1366 17490864 amphetamine NN I-NP D000661
8 1367 1372 17490864 could MD B-VP O
9 1373 1381 17490864 indicate VB I-VP O
10 1382 1394 17490864 differential JJ B-NP O
11 1395 1402 17490864 changes NNS I-NP O
12 1403 1405 17490864 in IN B-PP O
13 1406 1414 17490864 dopamine NN B-NP D004298
14 1415 1423 17490864 receptor NN I-NP O
15 1424 1434 17490864 signalling NN I-NP O
16 1435 1442 17490864 leading VBG B-VP O
17 1443 1445 17490864 to TO B-PP O
18 1446 1456 17490864 functional JJ B-NP O
19 1457 1472 17490864 desensitisation NN I-NP O
20 1472 1473 17490864 , , O O
21 1474 1476 17490864 or CC O O
22 1477 1484 17490864 altered VBN B-NP O
23 1485 1495 17490864 modulation NN I-NP O
24 1496 1498 17490864 of IN B-PP O
25 1499 1506 17490864 sensory JJ B-NP O
26 1507 1513 17490864 gating NN I-NP O
27 1514 1516 17490864 in IN B-PP O
28 1517 1520 17490864 the DT B-NP O
29 1521 1528 17490864 nucleus NN I-NP O
30 1529 1538 17490864 accumbens VBZ B-VP O
31 1539 1541 17490864 by IN B-PP O
32 1542 1548 17490864 limbic JJ B-NP O
33 1549 1559 17490864 structures NNS I-NP O
34 1560 1564 17490864 such JJ B-PP O
35 1565 1567 17490864 as IN I-PP O
36 1568 1571 17490864 the DT B-NP O
37 1572 1583 17490864 hippocampus NN I-NP O
38 1583 1584 17490864 . . O O

1 0 0 8911359 -DOCSTART- -X- -X- O

1 0 16 8911359 Cyclophosphamide NN B-NP D003520
2 17 27 8911359 associated VBN I-NP O
3 28 35 8911359 bladder NN I-NP D001749
4 36 42 8911359 cancer NN I-NP D001749
5 42 43 8911359 - HYPH B-VP O
6 43 44 8911359 - : O O
7 44 45 8911359 a DT B-NP O
8 46 52 8911359 highly RB I-NP O
9 53 63 8911359 aggressive JJ I-NP O
10 64 71 8911359 disease NN I-NP O
11 71 72 8911359 : : O O
12 73 81 8911359 analysis NN B-NP O
13 82 84 8911359 of IN B-PP O
14 85 87 8911359 12 CD B-NP O
15 88 93 8911359 cases NNS I-NP O
16 93 94 8911359 . . B-NP O
17 95 102 8911359 PURPOSE NN I-NP O
18 102 103 8911359 : : O O
19 104 106 8911359 We PRP B-NP O
20 107 113 8911359 gained VBD B-VP O
21 114 123 8911359 knowledge NN B-NP O
22 124 126 8911359 of IN B-PP O
23 127 130 8911359 the DT B-NP O
24 131 139 8911359 etiology NN I-NP O
25 139 140 8911359 , , I-NP O
26 141 150 8911359 treatment NN I-NP O
27 151 154 8911359 and CC I-NP O
28 155 165 8911359 prevention NN I-NP O
29 166 168 8911359 of IN B-PP O
30 169 185 8911359 cyclophosphamide NN B-NP D003520
31 186 196 8911359 associated JJ I-NP O
32 197 207 8911359 urothelial JJ I-NP D014523
33 208 214 8911359 cancer NN I-NP D014523
34 214 215 8911359 . . O O

1 216 225 8911359 MATERIALS NNS B-NP O
2 226 229 8911359 AND CC I-NP O
3 230 237 8911359 METHODS NNS I-NP O
4 237 238 8911359 : : O O
5 239 242 8911359 The DT B-NP O
6 243 250 8911359 medical JJ I-NP O
7 251 258 8911359 records NNS I-NP O
8 259 261 8911359 of IN B-PP O
9 262 263 8911359 6 CD B-NP O
10 264 267 8911359 men NNS I-NP O
11 268 271 8911359 and CC O O
12 272 273 8911359 6 CD B-NP O
13 274 279 8911359 women NNS I-NP O
14 280 281 8911359 ( ( O O
15 281 285 8911359 mean JJ B-NP O
16 286 289 8911359 age NN I-NP O
17 290 292 8911359 55 CD B-NP O
18 293 298 8911359 years NNS I-NP O
19 298 299 8911359 ) ) O O
20 300 304 8911359 with IN B-PP O
21 305 321 8911359 cyclophosphamide NN B-NP D003520
22 322 332 8911359 associated VBN I-NP O
23 333 340 8911359 bladder NN I-NP D001749
24 341 347 8911359 cancer NN I-NP D001749
25 348 352 8911359 were VBD B-VP O
26 353 361 8911359 reviewed VBN I-VP O
27 361 362 8911359 . . O O

1 363 370 8911359 RESULTS NNS B-NP O
2 370 371 8911359 : : O O
3 372 375 8911359 All DT B-NP O
4 376 382 8911359 tumors NNS I-NP D009369
5 383 387 8911359 were VBD B-VP O
6 388 393 8911359 grade NN B-NP O
7 394 395 8911359 3 CD I-NP O
8 396 398 8911359 or CC I-NP O
9 399 400 8911359 4 CD I-NP O
10 401 413 8911359 transitional JJ I-NP O
11 414 418 8911359 cell NN I-NP O
12 419 428 8911359 carcinoma NN I-NP D002277
13 428 429 8911359 . . O O

1 430 432 8911359 Of IN B-PP O
2 433 436 8911359 the DT B-NP O
3 437 438 8911359 5 CD I-NP O
4 439 447 8911359 patients NNS I-NP O
5 448 457 8911359 initially RB B-VP O
6 458 465 8911359 treated VBN I-VP O
7 466 470 8911359 with IN B-PP O
8 471 481 8911359 endoscopic JJ B-NP O
9 482 491 8911359 resection NN I-NP O
10 492 497 8911359 alone RB B-ADVP O
11 498 502 8911359 only RB B-NP O
12 503 504 8911359 1 CD I-NP O
13 505 507 8911359 is VBZ B-VP O
14 508 513 8911359 alive JJ B-ADJP O
15 514 521 8911359 without IN B-PP O
16 522 529 8911359 disease NN B-NP O
17 529 530 8911359 . . O O

1 531 533 8911359 Of IN B-PP O
2 534 537 8911359 the DT B-NP O
3 538 539 8911359 6 CD I-NP O
4 540 548 8911359 patients NNS I-NP O
5 549 552 8911359 who WP B-NP O
6 553 562 8911359 underwent VBD B-VP O
7 563 568 8911359 early JJ B-NP O
8 569 579 8911359 cystectomy NN I-NP O
9 580 581 8911359 4 CD B-NP O
10 582 586 8911359 were VBD B-VP O
11 587 592 8911359 alive JJ B-ADJP O
12 593 595 8911359 at IN B-PP O
13 596 598 8911359 24 CD B-NP O
14 599 601 8911359 to TO I-NP O
15 602 605 8911359 111 CD I-NP O
16 606 612 8911359 months NNS I-NP O
17 612 613 8911359 . . O O

1 614 617 8911359 The DT B-NP O
2 618 627 8911359 remaining VBG I-NP O
3 628 635 8911359 patient NN I-NP O
4 636 640 8911359 with IN B-PP O
5 641 650 8911359 extensive JJ B-NP O
6 651 657 8911359 cancer NN I-NP D009369
7 658 667 8911359 underwent VBD B-VP O
8 668 675 8911359 partial JJ B-NP O
9 676 686 8911359 cystectomy NN I-NP O
10 687 690 8911359 for IN B-PP O
11 691 701 8911359 palliation NN B-NP O
12 702 705 8911359 and CC O O
13 706 710 8911359 died VBD B-VP O
14 711 712 8911359 3 CD B-NP O
15 713 719 8911359 months NNS I-NP O
16 720 725 8911359 later RB B-ADVP O
17 725 726 8911359 . . O O

1 727 738 8911359 CONCLUSIONS NNS B-NP O
2 738 739 8911359 : : O O
3 740 756 8911359 Cyclophosphamide NN B-NP D003520
4 757 767 8911359 associated VBN I-NP O
5 768 775 8911359 bladder NN I-NP D001749
6 776 781 8911359 tumor NN I-NP D001749
7 782 784 8911359 is VBZ B-VP O
8 785 787 8911359 an DT B-NP O
9 788 798 8911359 aggressive JJ I-NP O
10 799 806 8911359 disease NN I-NP O
11 806 807 8911359 . . O O

1 808 815 8911359 However RB B-ADVP O
2 815 816 8911359 , , O O
3 817 821 8911359 long JJ B-NP O
4 821 822 8911359 - HYPH I-NP O
5 822 826 8911359 term NN I-NP O
6 827 835 8911359 survival NN I-NP O
7 836 838 8911359 is VBZ B-VP O
8 839 847 8911359 possible JJ B-ADJP O
9 848 852 8911359 when WRB B-ADVP O
10 853 860 8911359 radical JJ B-NP O
11 861 871 8911359 cystectomy NN I-NP O
12 872 874 8911359 is VBZ B-VP O
13 875 884 8911359 performed VBN I-VP O
14 885 888 8911359 for IN B-PP O
15 889 896 8911359 bladder NN B-NP D001749
16 897 903 8911359 tumors NNS I-NP D001749
17 904 908 8911359 with IN B-PP O
18 909 912 8911359 any DT B-NP O
19 913 917 8911359 sign NN I-NP O
20 918 920 8911359 of IN B-PP O
21 921 929 8911359 invasion NN B-NP O
22 930 933 8911359 and CC B-PP O
23 934 937 8911359 for IN B-PP O
24 938 947 8911359 recurrent JJ B-NP O
25 948 952 8911359 high JJ I-NP O
26 953 958 8911359 grade NN I-NP O
27 959 966 8911359 disease NN I-NP O
28 966 967 8911359 , , O O
29 968 972 8911359 even RB B-ADVP O
30 973 977 8911359 when WRB I-ADVP O
31 978 989 8911359 noninvasive JJ B-ADVP O
32 989 990 8911359 . . O O

1 0 0 16225977 -DOCSTART- -X- -X- O

1 0 11 16225977 Amisulpride NN B-NP C012052
2 12 19 16225977 related VBN B-VP O
3 20 23 16225977 tic JJ B-NP D013981
4 23 24 16225977 - HYPH I-NP D013981
5 24 28 16225977 like JJ I-NP D013981
6 29 37 16225977 symptoms NNS I-NP D013981
7 38 40 16225977 in IN B-PP O
8 41 43 16225977 an DT B-NP O
9 44 54 16225977 adolescent JJ I-NP O
10 55 68 16225977 schizophrenic NN I-NP D012559
11 68 69 16225977 . . O O
12 70 73 16225977 Tic JJ B-NP D013981
13 74 83 16225977 disorders NNS I-NP D013981
14 84 87 16225977 can MD B-VP O
15 88 90 16225977 be VB I-VP O
16 91 102 16225977 effectively RB I-VP O
17 103 110 16225977 treated VBN I-VP O
18 111 113 16225977 by IN B-PP O
19 114 122 16225977 atypical JJ B-NP O
20 123 137 16225977 antipsychotics NNS I-NP O
21 138 142 16225977 such JJ B-PP O
22 143 145 16225977 as IN I-PP O
23 146 157 16225977 risperidone NN B-NP D018967
24 157 158 16225977 , , I-NP O
25 159 169 16225977 olanzapine NN I-NP C076029
26 170 173 16225977 and CC I-NP O
27 174 185 16225977 ziprasidone NN I-NP C092292
28 185 186 16225977 . . O O

1 187 194 16225977 However RB B-ADVP O
2 194 195 16225977 , , O O
3 196 201 16225977 there EX B-NP O
4 202 205 16225977 are VBP B-VP O
5 206 209 16225977 two CD B-NP O
6 210 214 16225977 case NN I-NP O
7 215 222 16225977 reports NNS I-NP O
8 223 227 16225977 that WDT B-NP O
9 228 232 16225977 show VBP B-VP O
10 233 236 16225977 tic JJ B-NP D013981
11 236 237 16225977 - HYPH I-NP D013981
12 237 241 16225977 like JJ I-NP D013981
13 242 250 16225977 symptoms NNS I-NP D013981
14 250 251 16225977 , , O O
15 252 261 16225977 including VBG B-PP O
16 262 267 16225977 motor NN B-NP O
17 268 271 16225977 and CC O O
18 272 278 16225977 phonic JJ B-NP O
19 279 287 16225977 variants NNS I-NP O
20 287 288 16225977 , , O O
21 289 298 16225977 occurring VBG B-VP O
22 299 305 16225977 during IN B-PP O
23 306 315 16225977 treatment NN B-NP O
24 316 320 16225977 with IN B-PP O
25 321 331 16225977 quetiapine NN B-NP C069541
26 332 334 16225977 or CC I-NP O
27 335 344 16225977 clozapine NN I-NP D003024
28 344 345 16225977 . . O O

1 346 348 16225977 We PRP B-NP O
2 349 356 16225977 present VBP B-VP O
3 357 358 16225977 a DT B-NP O
4 359 361 16225977 15 CD I-NP O
5 361 362 16225977 - HYPH I-NP O
6 362 366 16225977 year NN I-NP O
7 366 367 16225977 - HYPH B-NP O
8 367 370 16225977 old JJ I-NP O
9 371 375 16225977 girl NN I-NP O
10 376 389 16225977 schizophrenic NN I-NP D012559
11 390 393 16225977 who WP B-NP O
12 394 403 16225977 developed VBD B-VP O
13 404 412 16225977 frequent JJ B-NP O
14 413 424 16225977 involuntary JJ I-NP D020820
15 425 428 16225977 eye NN I-NP D020820
16 428 429 16225977 - HYPH O D020820
17 429 437 16225977 blinking VBG B-VP D020820
18 438 447 16225977 movements NNS B-NP D020820
19 448 453 16225977 after IN B-PP O
20 454 455 16225977 5 CD B-NP O
21 456 462 16225977 months NNS I-NP O
22 463 465 16225977 of IN B-PP O
23 466 477 16225977 amisulpride NN B-NP C012052
24 478 487 16225977 treatment NN I-NP O
25 488 489 16225977 ( ( O O
26 489 493 16225977 1000 CD B-NP O
27 494 496 16225977 mg NN I-NP O
28 497 500 16225977 per IN B-PP O
29 501 504 16225977 day NN B-NP O
30 504 505 16225977 ) ) O O
31 505 506 16225977 . . O O

1 507 510 16225977 The DT B-NP O
2 511 514 16225977 tic JJ I-NP D013981
3 514 515 16225977 - HYPH I-NP D013981
4 515 519 16225977 like JJ I-NP D013981
5 520 528 16225977 symptoms NNS I-NP D013981
6 529 537 16225977 resolved VBN B-VP O
7 538 548 16225977 completely RB B-ADVP O
8 549 554 16225977 after IN B-SBAR O
9 555 557 16225977 we PRP B-NP O
10 558 565 16225977 reduced VBD B-VP O
11 566 569 16225977 the DT B-NP O
12 570 574 16225977 dose NN I-NP O
13 575 577 16225977 of IN B-PP O
14 578 589 16225977 amisulpride NN B-NP C012052
15 590 594 16225977 down RB B-ADVP O
16 595 597 16225977 to TO B-PP O
17 598 601 16225977 800 CD B-NP O
18 602 604 16225977 mg NN I-NP O
19 605 608 16225977 per IN B-PP O
20 609 612 16225977 day NN B-NP O
21 612 613 16225977 . . O O

1 614 621 16225977 However RB B-ADVP O
2 621 622 16225977 , , O O
3 623 626 16225977 her PRP$ B-NP O
4 627 636 16225977 psychosis NN I-NP D011605
5 637 645 16225977 recurred VBD B-VP O
6 646 651 16225977 after IN B-SBAR O
7 652 655 16225977 the DT B-NP O
8 656 660 16225977 dose NN I-NP O
9 661 670 16225977 reduction NN I-NP O
10 670 671 16225977 . . O O

1 672 674 16225977 We PRP B-NP O
2 675 679 16225977 then RB B-ADVP O
3 680 686 16225977 placed VBD B-VP O
4 687 690 16225977 her PRP B-NP O
5 691 693 16225977 on IN B-PP O
6 694 696 16225977 an DT B-NP O
7 697 707 16225977 additional JJ I-NP O
8 708 711 16225977 100 CD I-NP O
9 712 714 16225977 mg NN I-NP O
10 715 718 16225977 per IN B-PP O
11 719 722 16225977 day NN B-NP O
12 723 725 16225977 of IN B-PP O
13 726 736 16225977 quetiapine NN B-NP C069541
14 736 737 16225977 . . O O

1 738 741 16225977 She PRP B-NP O
2 742 745 16225977 has VBZ B-VP O
3 746 750 16225977 been VBN I-VP O
4 751 753 16225977 in IN B-PP O
5 754 762 16225977 complete JJ B-NP O
6 763 772 16225977 remission NN I-NP O
7 773 778 16225977 under IN B-PP O
8 779 782 16225977 the DT B-NP O
9 783 791 16225977 combined VBN I-NP O
10 792 803 16225977 medications NNS I-NP O
11 804 807 16225977 for IN B-PP O
12 808 812 16225977 more JJR B-NP O
13 813 817 16225977 than IN I-NP O
14 818 821 16225977 one CD I-NP O
15 822 826 16225977 year NN I-NP O
16 827 830 16225977 and CC O O
17 831 840 16225977 maintains VBZ B-VP O
18 841 842 16225977 a DT B-NP O
19 843 847 16225977 fair JJ I-NP O
20 848 852 16225977 role NN I-NP O
21 853 861 16225977 function NN I-NP O
22 861 862 16225977 . . O O

1 863 865 16225977 No DT B-NP O
2 866 870 16225977 more RBR I-NP O
3 871 874 16225977 tic JJ I-NP D013981
4 874 875 16225977 - HYPH I-NP D013981
5 875 879 16225977 like JJ I-NP D013981
6 880 888 16225977 symptoms NNS I-NP D013981
7 889 891 16225977 or CC O O
8 892 897 16225977 other JJ B-NP O
9 898 902 16225977 side NN I-NP O
10 903 910 16225977 effects NNS I-NP O
11 911 915 16225977 have VBP B-VP O
12 916 920 16225977 been VBN I-VP O
13 921 929 16225977 reported VBN I-VP O
14 929 930 16225977 . . O O

1 931 939 16225977 Together RB B-ADVP O
2 940 944 16225977 with IN B-PP O
3 945 955 16225977 previously RB B-NP O
4 956 964 16225977 reported VBN I-NP O
5 965 970 16225977 cases NNS I-NP O
6 970 971 16225977 , , O O
7 972 975 16225977 our PRP$ B-NP O
8 976 983 16225977 patient NN I-NP O
9 984 992 16225977 suggests VBZ B-VP O
10 993 997 16225977 that IN B-SBAR O
11 998 1001 16225977 tic JJ B-NP D013981
12 1001 1002 16225977 - HYPH I-NP D013981
13 1002 1006 16225977 like JJ I-NP D013981
14 1007 1015 16225977 symptoms NNS I-NP D013981
15 1016 1021 16225977 might MD B-VP O
16 1022 1027 16225977 occur VB I-VP O
17 1028 1030 16225977 in IN B-PP O
18 1031 1038 16225977 certain JJ B-NP O
19 1039 1049 16225977 vulnerable JJ I-NP O
20 1050 1061 16225977 individuals NNS I-NP O
21 1062 1068 16225977 during IN B-PP O
22 1069 1078 16225977 treatment NN B-NP O
23 1079 1083 16225977 with IN B-PP O
24 1084 1092 16225977 atypical JJ B-NP O
25 1093 1107 16225977 antipsychotics NNS I-NP O
26 1108 1112 16225977 such JJ B-PP O
27 1113 1115 16225977 as IN I-PP O
28 1116 1126 16225977 quetiapine NN B-NP C069541
29 1126 1127 16225977 , , O O
30 1128 1137 16225977 clozapine NN B-NP D003024
31 1137 1138 16225977 , , O O
32 1139 1141 16225977 or CC O O
33 1142 1153 16225977 amisulpride NN B-NP C012052
34 1153 1154 16225977 . . O O

1 0 0 19719056 -DOCSTART- -X- -X- O

1 0 7 19719056 Dextran NN B-NP D003911
2 7 8 19719056 - HYPH I-NP O
3 8 16 19719056 etodolac NN I-NP D017308
4 17 27 19719056 conjugates NNS I-NP O
5 27 28 19719056 : : O O
6 29 38 19719056 synthesis NN B-NP O
7 38 39 19719056 , , O O
8 40 42 19719056 in FW B-ADVP O
9 43 48 19719056 vitro FW I-ADVP O
10 49 52 19719056 and CC O O
11 53 55 19719056 in FW B-NP O
12 56 60 19719056 vivo FW I-NP O
13 61 71 19719056 evaluation NN I-NP O
14 71 72 19719056 . . O O
15 73 81 19719056 Etodolac NN B-NP D017308
16 82 83 19719056 ( ( O O
17 83 84 19719056 E NN B-NP D017308
18 84 85 19719056 ) ) O O
19 85 86 19719056 , , O O
20 87 89 19719056 is VBZ B-VP O
21 90 91 19719056 a DT B-NP O
22 92 95 19719056 non AFX I-NP O
23 95 96 19719056 - HYPH I-NP O
24 96 104 19719056 narcotic JJ I-NP O
25 105 114 19719056 analgesic JJ I-NP O
26 115 118 19719056 and CC I-NP O
27 119 135 19719056 antiinflammatory JJ I-NP O
28 136 140 19719056 drug NN I-NP O
29 140 141 19719056 . . O O

1 142 143 19719056 A DT B-NP O
2 144 157 19719056 biodegradable JJ I-NP O
3 158 165 19719056 polymer NN I-NP O
4 166 173 19719056 dextran NN I-NP D003911
5 174 177 19719056 has VBZ B-VP O
6 178 182 19719056 been VBN I-VP O
7 183 191 19719056 utilized VBN I-VP O
8 192 194 19719056 as IN B-PP O
9 195 196 19719056 a DT B-NP O
10 197 204 19719056 carrier NN I-NP O
11 205 208 19719056 for IN B-PP O
12 209 218 19719056 synthesis NN B-NP O
13 219 221 19719056 of IN B-PP O
14 222 230 19719056 etodolac NN B-NP D017308
15 230 231 19719056 - HYPH B-NP O
16 231 238 19719056 dextran NN I-NP D003911
17 239 249 19719056 conjugates NNS I-NP O
18 250 251 19719056 ( ( O O
19 251 253 19719056 ED VBN B-VP O
20 253 254 19719056 ) ) O O
21 255 257 19719056 to TO B-VP O
22 258 265 19719056 improve VB I-VP O
23 266 269 19719056 its PRP$ B-NP O
24 270 277 19719056 aqueous JJ I-NP O
25 278 288 19719056 solubility NN I-NP O
26 289 292 19719056 and CC O O
27 293 299 19719056 reduce VB B-VP O
28 300 316 19719056 gastrointestinal JJ B-NP O
29 317 321 19719056 side NN I-NP O
30 322 329 19719056 effects NNS I-NP O
31 329 330 19719056 . . O O

1 331 333 19719056 An DT B-NP O
2 334 343 19719056 activated VBN I-NP O
3 344 350 19719056 moiety NN I-NP O
4 350 351 19719056 , , O O
5 352 356 19719056 i.e. FW B-NP O

1 357 358 19719056 N NN B-NP -1
2 358 359 19719056 - HYPH I-NP -1
3 359 372 19719056 acylimidazole NN I-NP -1
4 373 383 19719056 derivative NN I-NP O
5 384 386 19719056 of IN B-PP O
6 387 395 19719056 etodolac NN B-NP D017308
7 396 397 19719056 ( ( O O
8 397 400 19719056 EAI NN B-NP -1
9 400 401 19719056 ) ) O O
10 401 402 19719056 , , O O
11 403 406 19719056 was VBD B-VP O
12 407 416 19719056 condensed VBN I-VP O
13 417 421 19719056 with IN B-PP O
14 422 425 19719056 the DT B-NP O
15 426 440 19719056 polysaccharide NN I-NP O
16 441 448 19719056 polymer NN I-NP O
17 449 456 19719056 dextran NN I-NP D003911
18 457 459 19719056 of IN B-PP O
19 460 469 19719056 different JJ B-NP O
20 470 479 19719056 molecular JJ I-NP O
21 480 487 19719056 weights NNS I-NP O
22 488 489 19719056 ( ( O O
23 489 494 19719056 40000 CD B-NP O
24 494 495 19719056 , , I-NP O
25 496 501 19719056 60000 CD I-NP O
26 501 502 19719056 , , I-NP O
27 503 509 19719056 110000 CD I-NP O
28 510 513 19719056 and CC I-NP O
29 514 520 19719056 200000 CD I-NP O
30 520 521 19719056 ) ) O O
31 521 522 19719056 . . O O

1 523 525 19719056 IR NN B-NP O
2 526 534 19719056 spectral JJ I-NP O
3 535 539 19719056 data NNS I-NP O
4 540 549 19719056 confirmed VBD B-VP O
5 550 559 19719056 formation NN B-NP O
6 560 562 19719056 of IN B-PP O
7 563 568 19719056 ester NN B-NP O
8 569 576 19719056 bonding NN I-NP O
9 577 579 19719056 in IN B-PP O
10 580 583 19719056 the DT B-NP O
11 584 594 19719056 conjugates NNS I-NP O
12 594 595 19719056 . . O O

1 596 604 19719056 Etodolac NN B-NP D017308
2 605 613 19719056 contents NNS I-NP O
3 614 618 19719056 were VBD B-VP O
4 619 628 19719056 evaluated VBN I-VP O
5 629 631 19719056 by IN B-PP O
6 632 634 19719056 UV NN B-NP O
7 634 635 19719056 - HYPH B-NP O
8 635 653 19719056 spectrophotometric JJ I-NP O
9 654 662 19719056 analysis NN I-NP O
10 662 663 19719056 . . O O

1 664 667 19719056 The DT B-NP O
2 668 677 19719056 molecular JJ I-NP O
3 678 685 19719056 weights NNS I-NP O
4 686 690 19719056 were VBD B-VP O
5 691 701 19719056 determined VBN I-VP O
6 702 704 19719056 by IN B-PP O
7 705 714 19719056 measuring VBG B-VP O
8 715 724 19719056 viscosity NN B-NP O
9 725 730 19719056 using VBG B-VP O
10 731 734 19719056 the DT B-NP O
11 735 739 19719056 Mark NNP I-NP O
12 739 740 19719056 - HYPH I-NP O
13 740 746 19719056 Howink NNP I-NP O
14 746 747 19719056 - HYPH I-NP O
15 747 755 19719056 Sakurada NNP I-NP O
16 756 764 19719056 equation NN I-NP O
17 764 765 19719056 . . O O

1 766 768 19719056 In FW B-NP O
2 769 774 19719056 vitro FW I-NP O
3 775 785 19719056 hydrolysis NN I-NP O
4 786 788 19719056 of IN B-PP O
5 789 791 19719056 ED NN B-NP O
6 792 795 19719056 was VBD B-VP O
7 796 800 19719056 done VBN I-VP O
8 801 803 19719056 in IN B-PP O
9 804 811 19719056 aqueous JJ B-NP O
10 812 819 19719056 buffers NNS I-NP O
11 820 821 19719056 ( ( O O
12 821 823 19719056 pH NN B-NP O
13 824 827 19719056 1.2 CD I-NP O
14 827 828 19719056 , , I-NP O
15 829 832 19719056 7.4 CD I-NP O
16 832 833 19719056 , , I-NP O
17 834 835 19719056 9 CD I-NP O
18 835 836 19719056 ) ) O O
19 837 840 19719056 and CC O O
20 841 843 19719056 in IN B-PP O
21 844 847 19719056 80% CD B-NP O
22 848 849 19719056 ( ( O O
23 849 850 19719056 v NN B-NP O
24 850 851 19719056 / SYM B-NP O
25 851 852 19719056 v NN I-NP O
26 852 853 19719056 ) ) I-NP O
27 854 859 19719056 human JJ I-NP O
28 860 866 19719056 plasma NN I-NP O
29 867 868 19719056 ( ( O O
30 868 870 19719056 pH NN B-NP O
31 871 874 19719056 7.4 CD I-NP O
32 874 875 19719056 ) ) O O
33 875 876 19719056 . . O O

1 877 879 19719056 At IN B-PP O
2 880 882 19719056 pH NN B-NP O
3 883 884 19719056 9 CD I-NP O
4 884 885 19719056 , , O O
5 886 887 19719056 a DT B-NP O
6 888 894 19719056 higher JJR I-NP O
7 895 899 19719056 rate NN I-NP O
8 900 902 19719056 of IN B-PP O
9 903 911 19719056 etodolac NN B-NP D017308
10 912 919 19719056 release NN I-NP O
11 920 924 19719056 from IN B-PP O
12 925 927 19719056 ED NN B-NP O
13 928 931 19719056 was VBD B-VP O
14 932 940 19719056 observed VBN I-VP O
15 941 943 19719056 as IN B-SBAR O
16 944 952 19719056 compared VBN B-VP O
17 953 955 19719056 to TO B-PP O
18 956 963 19719056 aqueous JJ B-NP O
19 964 970 19719056 buffer NN I-NP O
20 971 973 19719056 of IN B-PP O
21 974 976 19719056 pH NN B-NP O
22 977 980 19719056 7.4 CD I-NP O
23 981 984 19719056 and CC I-NP O
24 985 988 19719056 80% CD I-NP O
25 989 994 19719056 human JJ I-NP O
26 995 1001 19719056 plasma NN I-NP O
27 1002 1003 19719056 ( ( O O
28 1003 1005 19719056 pH NN B-NP O
29 1006 1009 19719056 7.4 CD I-NP O
30 1009 1010 19719056 ) ) O O
31 1010 1011 19719056 , , O O
32 1012 1021 19719056 following VBG B-PP O
33 1022 1027 19719056 first JJ B-NP O
34 1027 1028 19719056 - HYPH I-NP O
35 1028 1033 19719056 order NN I-NP O
36 1034 1042 19719056 kinetics NNS I-NP O
37 1042 1043 19719056 . . O O

1 1044 1046 19719056 In FW B-NP O
2 1047 1051 19719056 vivo FW I-NP O
3 1052 1066 19719056 investigations NNS I-NP O
4 1067 1071 19719056 were VBD B-VP O
5 1072 1081 19719056 performed VBN I-VP O
6 1082 1084 19719056 in IN B-PP O
7 1085 1092 19719056 animals NNS B-NP O
8 1092 1093 19719056 . . O O

1 1094 1099 19719056 Acute JJ B-NP O
2 1100 1109 19719056 analgesic JJ I-NP O
3 1110 1113 19719056 and CC I-NP O
4 1114 1130 19719056 antiinflammatory JJ I-NP O
5 1131 1141 19719056 activities NNS I-NP O
6 1142 1146 19719056 were VBD B-VP O
7 1147 1158 19719056 ascertained VBN I-VP O
8 1159 1164 19719056 using VBG B-VP O
9 1165 1171 19719056 acetic JJ B-NP D019342
10 1172 1176 19719056 acid NN I-NP D019342
11 1177 1184 19719056 induced VBD B-VP O
12 1185 1193 19719056 writhing VBG I-VP D010146
13 1194 1199 19719056 model NN B-NP O
14 1200 1201 19719056 ( ( O O
15 1201 1205 19719056 mice NNS B-NP O
16 1205 1206 19719056 ) ) O O
17 1207 1210 19719056 and CC O O
18 1211 1222 19719056 carrageenan NN B-NP D002351
19 1222 1223 19719056 - HYPH B-NP O
20 1223 1230 19719056 induced VBN I-NP O
21 1231 1234 19719056 rat NN I-NP O
22 1235 1238 19719056 paw NN I-NP O
23 1239 1244 19719056 edema NN I-NP D004487
24 1245 1250 19719056 model NN I-NP O
25 1250 1251 19719056 , , O O
26 1252 1264 19719056 respectively RB B-ADVP O
27 1264 1265 19719056 . . O O

1 1266 1268 19719056 In IN B-PP O
2 1269 1279 19719056 comparison NN B-NP O
3 1280 1282 19719056 to TO B-PP O
4 1283 1290 19719056 control NN B-NP O
5 1290 1291 19719056 , , I-NP O
6 1292 1293 19719056 E NN I-NP D017308
7 1294 1297 19719056 and CC I-NP O
8 1298 1301 19719056 ED1 NN I-NP O
9 1301 1302 19719056 - HYPH B-NP O
10 1302 1305 19719056 ED4 NN I-NP O
11 1306 1312 19719056 showed VBD B-VP O
12 1313 1319 19719056 highly RB B-NP O
13 1320 1331 19719056 significant JJ I-NP O
14 1332 1341 19719056 analgesic JJ I-NP O
15 1342 1345 19719056 and CC I-NP O
16 1346 1362 19719056 antiinflammatory JJ I-NP O
17 1363 1373 19719056 activities NNS I-NP O
18 1374 1375 19719056 ( ( O O
19 1375 1376 19719056 p NN B-NP O
20 1377 1378 19719056 < SYM O O
21 1378 1383 19719056 0.001 CD B-NP O
22 1383 1384 19719056 ) ) O O
23 1384 1385 19719056 . . O O

1 1386 1396 19719056 Biological JJ B-NP O
2 1397 1407 19719056 evaluation NN I-NP O
3 1408 1417 19719056 suggested VBD B-VP O
4 1418 1422 19719056 that IN B-SBAR O
5 1423 1433 19719056 conjugates NNS B-NP O
6 1434 1435 19719056 ( ( O O
7 1435 1438 19719056 ED1 NN B-NP O
8 1438 1439 19719056 - HYPH B-NP O
9 1439 1442 19719056 ED4 NN I-NP O
10 1442 1443 19719056 ) ) O O
11 1444 1452 19719056 retained VBD B-VP O
12 1453 1463 19719056 comparable JJ B-NP O
13 1464 1473 19719056 analgesic JJ I-NP O
14 1474 1477 19719056 and CC I-NP O
15 1478 1494 19719056 antiinflammatory JJ I-NP O
16 1495 1505 19719056 activities NNS I-NP O
17 1506 1510 19719056 with IN B-PP O
18 1511 1521 19719056 remarkably RB B-NP O
19 1522 1529 19719056 reduced VBN I-NP O
20 1530 1544 19719056 ulcerogenicity NN I-NP O
21 1545 1547 19719056 as IN B-SBAR O
22 1548 1556 19719056 compared VBN B-VP O
23 1557 1559 19719056 to TO B-PP O
24 1560 1565 19719056 their PRP$ B-NP O
25 1566 1572 19719056 parent NN I-NP O
26 1573 1577 19719056 drug NN I-NP O
27 1577 1578 19719056 - HYPH B-NP O
28 1578 1579 19719056 - SYM I-NP O
29 1579 1587 19719056 etodolac NN B-NP D017308
30 1587 1588 19719056 . . O O

